FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Portella, ST
   Escudeiro, GP
   Mansilla, R
   Freitas, BS
   de Resende, MAC
   Fernandes, FC
   Salomao, R
   Lima, CR
   Landeiro, JA
   Acioly, MA
AF Portella, Stella Taylor
   Escudeiro, Gabriel Pereira
   Mansilla, Raissa
   Freitas, Bruno Spindola
   Cardoso de Resende, Marco Antonio
   Fernandes, Fatima Carneiro
   Salomao, Renan
   Lima, Carlos Roberto
   Landeiro, Jose Alberto
   Acioly, Marcus Andre
TI Predictive Factors for Muscle Injury After Posterior Lumbar Spinal
   Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Creatine phosphokinase; Microdiscectomy; Muscle injury; Posterior lumbar
   fusion; Rhabdomyolysis; Spinal surgery
ID SERUM CREATINE-PHOSPHOKINASE; LOW-BACK-PAIN; HISTOCHEMICAL ANALYSES;
   RHABDOMYOLYSIS; DISKECTOMY; STENOSIS; HEALTH; TRENDS; LEVEL; COST
AB OBJECTIVE: The aims of this study were to evaluate the risk factors for muscle injury in patients undergoing posterior lumbar spinal surgery and the clearance of postoperative biochemical changes following lumbar fusion and secondarily to evaluate the timing for monitoring postoperative biochemical serum levels and potential clinical correlation.
   METHODS: The study prospectively enrolled 39 patients with degenerative disease of the lumbar spine. Biochemical markers (creatine phosphokinase [CPK], creatinine, and hemoglobin) were analyzed in 5 predefined stages. All relevant clinical data were collected. Rhabdomyolysis (RML) was defined as a postoperative 5-fold increase of the baseline CPK value.
   RESULTS: Patients from the lumbar fusion group had the highest postoperative CPK ratio. Overall, the rate of RML was 43.6%. CPK and creatinine activity reached their maximum on the first postoperative day in 69.2% and 87.5% of patients, respectively. Lumbar fusion (P = 0.005), surgical time >270 minutes (P = 0.028), and fall in hemoglobin levels >3 g/dL (P = 0.034) were identified as independent factors associated with higher risk of RML.
   CONCLUSIONS: The risk of RML increases with prolonged and invasive surgery with higher bleeding potential. Knowing the clearance of postoperative biochemical changes permits a standardized strategy with measurements in precise intervals, thereby avoiding unnecessary costs. The clinical significance is still undetermined.
C1 [Portella, Stella Taylor; Acioly, Marcus Andre] Fed Univ State Rio de Janeiro, Postgrad Program Neurol, Rio De Janeiro, Brazil.
   [Portella, Stella Taylor] Armed Forces Hosp, Div Emergency, Brasilia, DF, Brazil.
   [Escudeiro, Gabriel Pereira; Mansilla, Raissa; Freitas, Bruno Spindola; Landeiro, Jose Alberto; Acioly, Marcus Andre] Fluminense Fed Univ, Div Neurosurg, Niteroi, RJ, Brazil.
   [Cardoso de Resende, Marco Antonio] Fluminense Fed Univ, Div Anesthesiol, Niteroi, RJ, Brazil.
   [Fernandes, Fatima Carneiro] Univ Fed Rio de Janeiro, Div Anesthesiol, Rio De Janeiro, Brazil.
   [Salomao, Renan; Lima, Carlos Roberto; Acioly, Marcus Andre] Univ Fed Rio de Janeiro, Div Neurosurg, Rio De Janeiro, Brazil.
RP Acioly, MA (reprint author), Fed Univ State Rio de Janeiro, Postgrad Program Neurol, Rio De Janeiro, Brazil.; Acioly, MA (reprint author), Fluminense Fed Univ, Div Neurosurg, Niteroi, RJ, Brazil.; Acioly, MA (reprint author), Univ Fed Rio de Janeiro, Div Neurosurg, Rio De Janeiro, Brazil.
EM marcusacioly@yahoo.com.br
OI Mansilla, Raissa/0000-0002-2519-0811
CR Adogwa Owoicho, 2012, Surg Neurol Int, V3, pS355, DOI 10.4103/2152-7806.103868
   Arts M, 2011, EUR SPINE J, V20, P51, DOI 10.1007/s00586-010-1482-y
   Arts MP, 2007, J NEUROSURG-SPINE, V7, P282, DOI 10.3171/SPI-07/09/282
   Cassidy JD, 1998, SPINE, V23, P1860, DOI 10.1097/00007632-199809010-00012
   Dakwar E, 2011, J NEUROSURG-SPINE, V14, P785, DOI 10.3171/2011.2.SPINE10369
   Deyo RA, 2010, JAMA-J AM MED ASSOC, V303, P1259, DOI 10.1001/jama.2010.338
   Dickerman RD, 2009, SPINE, V34, pE923, DOI 10.1097/BRS.0b013e3181af0523
   Duhon BS, 2012, SCHMIDEK SWEET OPERA, P1853
   Feng Y, 2016, GENES DIS, V3, P178, DOI 10.1016/j.gendis.2016.04.005
   Foster MR, 2003, SPINE, V28, pE276, DOI 10.1097/00007632-200307150-00030
   Gawri R, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4449
   Haefeli M, 2006, SPINE, V31, P1522, DOI 10.1097/01.brs.0000222032.52336.8e
   Jung Se Ho, 2014, Korean J Spine, V11, P238, DOI 10.14245/kjs.2014.11.4.238
   Katz JN, 2006, J BONE JOINT SURG AM, V88A, P21, DOI 10.2106/JBJS.E.01273
   KAWAGUCHI Y, 1994, SPINE, V19, P2590, DOI 10.1097/00007632-199411001-00017
   KAWAGUCHI Y, 1994, SPINE, V19, P2598, DOI 10.1097/00007632-199411001-00018
   Kawaguchi Y, 1996, SPINE, V21, P941, DOI 10.1097/00007632-199604150-00007
   Keltz Eran, 2013, Muscles Ligaments Tendons J, V3, P303
   Khan FY, 2009, NETH J MED, V67, P272
   Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group, 2012, KIDNEY INT S, V2, P19, DOI DOI 10.1038/KISUP.2011.32
   Kotil K, 2007, J NEUROSURG-SPINE, V6, P121, DOI 10.3171/spi.2007.6.2.121
   Kumbhare D, 2008, J SPINAL DISORD TECH, V21, P49, DOI 10.1097/BSD.0b013e31805777fb
   Kumbhare D, 2007, CLIN INVEST MED, V30, P12, DOI 10.25011/cim.v30i1.444
   Lagandre S, 2006, OBES SURG, V16, P1365, DOI 10.1381/096089206778663643
   Lurie JD, 2014, SPINE, V39, P3, DOI 10.1097/BRS.0000000000000088
   Motosuneya T, 2006, J SPINAL DISORD TECH, V19, P318, DOI 10.1097/01.bsd.0000211205.15997.06
   Papadakis M, 2008, J NEUROSURG-SPINE, V9, P387, DOI 10.3171/SPI.2008.9.10.387
   Parker SL, 2010, J NEUROSURG-SPINE, V12, P178, DOI 10.3171/2009.9.SPINE09410
   Patel AA, 2011, J BONE JOINT SURG AM, V93A, P225, DOI 10.2106/JBJS.J.00276
   Purvis TE, 2018, J NEUROSURG-SPINE, V28, P345, DOI 10.3171/2017.7.SPINE17301
   Purvis TE, 2017, SPINE J, V17, P1255, DOI 10.1016/j.spinee.2017.04.028
   Pye SR, 2007, ANN RHEUM DIS, V66, P426, DOI 10.1136/ard.2006.057166
   Rudolph T, 2011, EUR SPINE J, V20, pS180, DOI 10.1007/s00586-010-1499-2
   Shin DA, 2008, J NEUROSURG-SPINE, V8, P39, DOI 10.3171/SPI-08/01/039
   Shriver MF, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS15281
   Suwa H, 2000, NEUROL MED-CHIR, V40, P151, DOI 10.2176/nmc.40.151
   Vroomen PCAJ, 2002, BRIT J GEN PRACT, V52, P119
   Watanabe K, 2011, J NEUROSURG-SPINE, V14, P51, DOI 10.3171/2010.9.SPINE09933
   Weinstein JN, 2006, SPINE, V31, P2707, DOI 10.1097/01.brs.0000248132.15231.fe
   Ziser A, 1996, ANESTH ANALG, V82, P412, DOI 10.1097/00000539-199602000-00035
NR 40
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E514
EP E521
DI 10.1016/j.wneu.2019.05.197
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900065
PM 31152890
DA 2020-05-12
ER

PT J
AU Ramey, WL
   Altafulla, J
   Yilmaz, E
   Ishak, B
   Jack, A
   Litvack, ZN
   Oskouian, R
   Tubbs, RS
   Chapman, JR
AF Ramey, Wyatt L.
   Altafulla, Juan
   Yilmaz, Emre
   Ishak, Basem
   Jack, Andrew
   Litvack, Zachary N.
   Oskouian, Rod J.
   Tubbs, R. Shane
   Chapman, Jens R.
TI The ABC's of Spinal Decompression: Pearls and Technical Notes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bone cuts; Spinal decompression; Spine; Surgical technique
ID UNILATERAL LAMINOTOMY; STENOSIS
AB OBJECTIVE: The foundation of spine surgery centers on the proper identification, decompression, and stabilization of bony and neural elements. We describe easily reproducible and reliable methods for optimal decompression and release of neural structures to alleviate symptoms and improve patients' quality of life.
   METHODS: Multiple spinal decompression techniques were described in procedures for which the goal of surgery was decompression alone or decompression and fusion. Eight fundamental techniques were described: inverted U-cut, J-cut, T-cut, L-cut, Z-cut, I-track cuts, C-cut, and O-cut.
   RESULTS: These foundational cuts may be combined, as needed, to develop an individually tailored approach to the patient's pathology.
   CONCLUSIONS: After properly identifying the anatomic structures, each of these techniques provides a consistent, reproducible, and efficient means to decompress the spine under various circumstances. These techniques provide surgical trainees with a framework for approaching surgical decompression.
C1 [Altafulla, Juan; Yilmaz, Emre; Ishak, Basem; Litvack, Zachary N.; Oskouian, Rod J.; Tubbs, R. Shane] Swedish Med Ctr, Seattle Sci Fdn, Dept Neuroanat, Seattle, WA USA.
   [Ramey, Wyatt L.; Altafulla, Juan; Yilmaz, Emre; Ishak, Basem; Jack, Andrew; Litvack, Zachary N.; Oskouian, Rod J.; Chapman, Jens R.] Swedish Med Ctr, Swedish Neurosci Inst, Dept Neurosurg, Seattle, WA 98122 USA.
   [Tubbs, R. Shane] St Georges Univ, Dept Anat Sci, St Georges, Grenada.
RP Chapman, JR (reprint author), Swedish Med Ctr, Swedish Neurosci Inst, Dept Neurosurg, Seattle, WA 98122 USA.
EM jens.chapman@swedish.org
OI Altafulla, Juan/0000-0002-2110-8665
CR Babu JM, 2019, AM J MED, V132, P300, DOI 10.1016/j.amjmed.2018.09.022
   Baeesa S, 2019, WORLD NEUROSURG, V122, pE241, DOI 10.1016/j.wneu.2018.09.224
   Engel G, 2019, EUR RADIOL, V29, P1855, DOI 10.1007/s00330-018-5769-4
   He L, 2019, ORTHOPADE, V48, P170, DOI 10.1007/s00132-018-3633-5
   Montano N, 2018, NEUROL NEUROCHIR POL, V52, P448, DOI 10.1016/j.pjnns.2018.06.004
   Oertel MF, 2006, NEUROSURGERY, V59, P1264, DOI 10.1227/01.NEU.0000245616.32226.58
   POSTACCHINI F, 1993, J BONE JOINT SURG BR, V75, P386
   Schell A, 2017, GLOB SPINE J, V7, P266, DOI 10.1177/2192568217699190
   Shin WS, 2018, ASIAN SPINE J, V12, P734, DOI 10.31616/asj.2018.12.4.734
   Spector LR, 2006, SPINE, V31, P2827, DOI 10.1097/01.brs.0000245864.72372.8f
   Spetzger U, 1997, ACTA NEUROCHIR, V139, P397, DOI 10.1007/BF01808874
   Thome C, 2005, J NEUROSURG-SPINE, V3, P129, DOI 10.3171/spi.2005.3.2.0129
   Wang H, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891-018-2148-x
   Zigler J, 2018, GLOB SPINE J, V8, P413, DOI 10.1177/2192568217737317
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E146
EP E151
DI 10.1016/j.wneu.2019.05.064
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900019
PM 31102772
DA 2020-05-12
ER

PT J
AU Rao, SJB
   Konar, SK
   Shukla, D
   Bhat, DI
   Beniwal, M
   Rao, KVLN
   Nandeesh, BN
   Devi, BI
AF Rao, S. J. Balaparameswara
   Konar, Subhas K.
   Shukla, Dhaval
   Bhat, Dhananjaya, I
   Beniwal, Manish
   Rao, K. V. L. Narasinga
   Nandeesh, B. N.
   Devi, B. Indira
TI Factors Influencing Survival of Children with Atypical Teratoid/Rhabdoid
   Tumors: A Single-Institute Experience in a Developing Country
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adjuvant treatment; Atypical teratoid rhabdoid tumors; Embryonal tumor;
   Survival
ID CENTRAL-NERVOUS-SYSTEM; TERATOID RHABDOID TUMOR; HEALTH-ORGANIZATION
   CLASSIFICATION; CHILDHOOD; INFANCY; DEFINITION; THERAPY; BRAIN
AB BACKGROUND: We evaluated the factors influencing overall survival (OS) and event-free survival (EFS) in children with atypical teratoid/rhabdoid tumors (ATRTs).
   METHODS: We performed a retrospective study of children aged <16 years and tumor histological diagnosis of ATRT. Univariate and multivariate analyses were performed to determine the effect of individual and interdependent variables and survival.
   RESULTS: A total of 34 children had undergone surgery, with a male/female ratio of 1.8:1. On univariate analysis, the factors with statistically significant influence on OS and EFS were the extent of resection (P = 0.012 and P = 0.015, respectively), adjuvant therapy (P <= 0.001 and P = 0.001, respectively), and rhabdoid cell percentage (P = 0.004 and P = 0.005, respectively). On survival analysis, the median OS and EFS were better for those who had completed adjuvant therapy versus those who had not received adjuvant therapy (OS, 22.7 months vs. 3.5 months; EFS, 10.9 months vs. 3.5 months), those who had undergone gross total resection versus those who had undergone partial decompression (OS, 10.9 months vs. 2 months; EFS, 8.9 months vs. 2.5 months), and those with <50% rhabdoid cells in the biopsy specimen versus those with >50% rhabdoid cells (OS, 10.9 months vs. 3.7 months; EFS, 8.9 months vs. 3.5 months). On multivariate analysis, only the extent of resection and adjuvant therapy status had a significant influence on OS and EFS.
   CONCLUSION: Achieving gross total resection should be the aim of surgery, depending on the tumor location, and these children should undergo upfront adjuvant treatment.
C1 [Rao, S. J. Balaparameswara; Konar, Subhas K.; Shukla, Dhaval; Bhat, Dhananjaya, I; Beniwal, Manish; Rao, K. V. L. Narasinga; Devi, B. Indira] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India.
   [Nandeesh, B. N.] Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Bangalore, Karnataka, India.
RP Devi, BI (reprint author), Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India.
EM bidevidr@gmail.com
RI ; Beniwal, Manish/Q-1469-2016
OI Shukla, Dhaval/0000-0001-7613-1929; Beniwal, Manish/0000-0001-6037-3368
CR Al-Hussaini M, 2014, TURK J PATHOL, V30, P43, DOI 10.5146/tjpath.2013.01213
   Athale UH, 2009, J PEDIAT HEMATOL ONC, V31, P651, DOI 10.1097/MPH.0b013e3181b258a9
   Biegel JA, 2002, CLIN CANCER RES, V8, P3461
   Biswas A, 2016, CANCER MANAG RES, V8, P115, DOI 10.2147/CMAR.S83472
   Biswas A, 2015, ACTA NEUROCHIR, V157, P589, DOI 10.1007/s00701-015-2355-2
   Biswas A, 2009, CHILD NERV SYST, V25, P1495, DOI 10.1007/s00381-009-0903-x
   Chen Michael L, 2005, Neurosurg Focus, V18, pE8
   Chen YW, 2006, INT J RADIAT ONCOL, V64, P1038, DOI 10.1016/j.ijrobp.2005.10.001
   Chi SN, 2009, J CLIN ONCOL, V27, P385, DOI 10.1200/JCO.2008.18.7724
   Fruhwald MC, 2016, NEURO-ONCOLOGY, V18, P764, DOI 10.1093/neuonc/nov264
   Gardner SL, 2008, PEDIATR BLOOD CANCER, V51, P235, DOI 10.1002/pbc.21578
   Gonzales M, 2001, J CLIN NEUROSCI, V8, P1, DOI 10.1054/jocn.2000.0829
   Hasselblatt M, 2014, ACTA NEUROPATHOL, V128, P453, DOI 10.1007/s00401-014-1323-x
   Hilden JM, 2004, J CLIN ONCOL, V22, P2877, DOI 10.1200/jco.2004.07.073
   Kieran MW, 2012, PEDIATR BLOOD CANCER, V59, P1155, DOI 10.1002/pbc.24315
   Lafay-Cousin L, 2012, EUR J CANCER, V48, P353, DOI 10.1016/j.ejca.2011.09.005
   LEFKOWITZ IB, 1987, ANN NEUROL, V22, P448
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Meyers SP, 2006, AM J NEURORADIOL, V27, P962
   Ostrom QT, 2015, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou327
   Reddy AT, 2005, J NEURO-ONCOL, V75, P309, DOI 10.1007/s11060-005-6762-8
   Rorke LB, 1996, J NEUROSURG, V85, P56, DOI 10.3171/jns.1996.85.1.0056
   Souki C, 2014, CLIN NEUROPATHOL, V33, P245, DOI 10.5414/NP300683
   Tekautz TM, 2005, J CLIN ONCOL, V23, P1491, DOI 10.1200/JCO.2005.05.187
   Yang M, 2014, INT J CLIN EXP PATHO, V7, P2411
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E264
EP E272
DI 10.1016/j.wneu.2019.05.126
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900032
PM 31128308
DA 2020-05-12
ER

PT J
AU Rezaii, E
   Li, D
   Heiferman, DM
   Szujewski, CC
   Martin, B
   Cobb, A
   Malina, GEK
   Grahnke, KA
   Hofler, RC
   Leonetti, JP
   Anderson, DE
AF Rezaii, Elhaum
   Li, Daphne
   Heiferman, Daniel M.
   Szujewski, Caroline C.
   Martin, Brendan
   Cobb, Adrienne
   Malina, Giselle E. K.
   Grahnke, Kurt A.
   Hofler, Ryan C.
   Leonetti, John P.
   Anderson, Douglas E.
TI Effect of Institutional Volume on Acoustic Neuroma Surgical Outcomes:
   State Inpatient Database 2009-2013
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acoustic neuroma; Care delivery; Outcomes assessment; State inpatient
   database
ID VESTIBULAR SCHWANNOMA MANAGEMENT; EXTRACRANIAL-INTRACRANIAL BYPASS;
   HOSPITAL VOLUME; OPERATIVE MORTALITY; PATIENT OUTCOMES; UNITED-STATES;
   SURGERY; TRENDS; PROVIDER; CASELOAD
AB BACKGROUND: Evolving technologies and health care quality metrics have altered treatment algorithms for acoustic neuromas (ANs), increasing trends toward observation and radiosurgery, with proportionate declines in use of microsurgery. A correlation between increasing surgical volumes and superior outcomes has been investigated previously in numerous surgical diseases, including AN.
   OBJECTIVE: To re-evaluate the volume-outcome relationship of AN resection in a changing health care system, with evolving treatment strategies.
   METHODS: Patients who underwent AN resection between 2009 and 2013 were retrospectively identified in the State Inpatient Database subset of the Healthcare Cost and Utilization Project. Generalized linear mixed-effect models were used to assess odds of various outcome measures (length of stay [LOS], discharge disposition, and facial nerve or severe clinical complications). Institutions were grouped into low-volume centers (1-6 cases/year) and high-volume centers (HVC; >= 31 cases/year) for analysis.
   RESULTS: A total of 1873 patients underwent AN resection between 2009 and 2013 with a mean age of 50.1 +/- 14.1 years (+/- standard deviation). For each additional case treated annually, patients were 2% (odds ratio [OR], 0.98; 95% confidence interval, 0.96-0.99) less likely to experience a severe complication (P = 0.004). Each additional case also trended toward a decreased rate of facial nerve complications and nonroutine discharge. Inpatient LOS was also shorter for patients at HVCs (median, 4 vs. 5 days; P < 0.001).
   CONCLUSIONS: Despite a relative decline in microsurgery compared with previous eras, care at HVCs is still associated with superior short-term outcomes, such as decreased LOS, facial nerve or other severe complications, and nonroutine discharges.
C1 [Rezaii, Elhaum; Li, Daphne; Heiferman, Daniel M.; Malina, Giselle E. K.; Grahnke, Kurt A.; Hofler, Ryan C.; Anderson, Douglas E.] Loyola Univ, Stritch Sch Med, Dept Neurol Surg, 2160 S 1st Ave, Maywood, IL 60153 USA.
   [Cobb, Adrienne] Loyola Univ, Stritch Sch Med, Dept Gen Surg, 2160 S 1st Ave, Maywood, IL 60153 USA.
   [Leonetti, John P.] Loyola Univ, Stritch Sch Med, Dept Otolaryngol, 2160 S 1st Ave, Maywood, IL 60153 USA.
   [Szujewski, Caroline C.] Univ Chicago, Dept Neurobiol, Chicago, IL 60637 USA.
   [Martin, Brendan] Loyola Univ, Clincial Res Off, Chicago, IL 60611 USA.
RP Li, D (reprint author), Loyola Univ, Stritch Sch Med, Dept Neurol Surg, 2160 S 1st Ave, Maywood, IL 60153 USA.
EM daphne.li@lumc.edu
RI Martin, Brendan/AAG-6147-2020
OI li, daphne/0000-0001-9591-6406
CR Abou-Al-Shaar H, 2019, J NEUROSURG, V131, P561, DOI 10.3171/2018.4.JNS18365
   Ahmed OH, 2014, OTOLARYNG HEAD NECK, V150, P266, DOI 10.1177/0194599813507234
   Ahmed R, 2014, J NEUROSURG-PEDIATR, V13, P600, DOI [10.3171/2014.1.PEDS13317, 10.3171/2014.1.PEDS13316]
   Akbarian-Tefaghi H, 2017, WORLD NEUROSURG, V108, P716, DOI 10.1016/j.wneu.2017.09.082
   Amin-Hanjani S, 2005, J NEUROSURG, V103, P794, DOI 10.3171/jns.2005.103.5.0794
   Babadjouni R, 2019, NEUROSURGERY, V84, P726, DOI 10.1093/neuros/nyy187
   Babu R, 2013, J NEUROSURG, V119, P121, DOI 10.3171/2013.1.JNS121370
   Barker FG, 2003, LARYNGOSCOPE, V113, P1332, DOI 10.1097/00005537-200308000-00013
   Begg CB, 1998, JAMA-J AM MED ASSOC, V280, P1747, DOI 10.1001/jama.280.20.1747
   Birkmeyer JD, 2003, NEW ENGL J MED, V349, P2117, DOI 10.1056/NEJMsa035205
   Carlson ML, 2015, OTOLARYNG HEAD NECK, V153, P440, DOI 10.1177/0194599815590105
   Davies JM, 2015, NEUROSURG CLIN N AM, V26, P207, DOI 10.1016/j.nec.2014.11.015
   Dimick JB, 2008, J VASC SURG, V47, P1150, DOI 10.1016/j.jvs.2008.01.054
   Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004
   Hatch JL, 2018, OTOL NEUROTOL, V39, P481, DOI 10.1097/MAO.0000000000001718
   Haut ER, 2012, JAMA-J AM MED ASSOC, V307, P2589, DOI 10.1001/jama.2012.6626
   Hoh BL, 2010, STROKE, V41, P337, DOI 10.1161/STROKEAHA.109.569269
   Houchens R., 2014, HCUP METHODS SERIES
   Kizer KW, 2003, NEW ENGL J MED, V349, P2159, DOI 10.1056/NEJMe038166
   Mahboubi H, 2014, OTOLARYNG HEAD NECK, V150, P275, DOI 10.1177/0194599813512106
   Mattei TA, 2017, WORLD NEUROSURG, V98, P829, DOI 10.1016/j.wneu.2016.12.082
   Nuno M, 2015, J NEUROSURG, V123, P1247, DOI 10.3171/2014.10.JNS141516
   Patel J, 2014, BRIT J NEUROSURG, V28, P20, DOI 10.3109/02688697.2013.815323
   Patel S, 2013, WORLD NEUROSURG, V80, P142, DOI 10.1016/j.wneu.2012.06.029
   Pollock BE, 2006, NEUROSURGERY, V59, P77, DOI 10.1227/01.NEU.0000219217.14930.14
   Prasad SC, 2018, NEUROSURGERY, V83, P858, DOI 10.1093/neuros/nyx568
   Maria PLS, 2019, NEUROSURGERY, V85, P550, DOI 10.1093/neuros/nyy407
   Schwartz Marc S, 2005, Clin Neurosurg, V52, P359
   Smith TR, 2015, NEUROSURGERY, V77, P509, DOI 10.1227/NEU.0000000000000879
   Steiner Claudia, 2002, Eff Clin Pract, V5, P143
   Stulberg JJ, 2018, JAMA SURG, V153, P586, DOI 10.1001/jamasurg.2018.0542
   Trinh VT, 2015, J NEUROSURG, V122, P280, DOI 10.3171/2014.9.JNS131648
   von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010
   Ward BK, 2012, ARCH OTOLARYNGOL, V138, P577, DOI 10.1001/archoto.2012.877
   Zacharia BE, 2014, STROKE, V45, P1447, DOI 10.1161/STROKEAHA.113.004412
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E754
EP E760
DI 10.1016/j.wneu.2019.06.017
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900095
PM 31203081
DA 2020-05-12
ER

PT J
AU Ridwan, S
   Zur, B
   Kurscheid, J
   Esche, J
   Kristof, R
   Klingmuller, D
   Bostrom, A
AF Ridwan, Sami
   Zur, Bernd
   Kurscheid, Johanna
   Esche, Jonas
   Kristof, Rudolf
   Klingmueller, Dietrich
   Bostroem, Azize
TI Hyponatremia After Spontaneous Aneurysmal Subarachnoid Hemorrhage-A
   Prospective Observational Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Electrolyte; Hyponatremia; Outcome; Subarachnoid hemorrhage; Vasospasm
ID ANTIDIURETIC-HORMONE; CEREBRAL INFARCTION; IMPACT; COMPLICATIONS;
   SECRETION
AB OBJECTIVE: Hyponatremia has been frequently observed after aneurysmal subarachnoid hemorrhage (SAH), and some data have suggested a correlation with symptomatic cerebral vasospasm and poor outcomes. The present prospective study investigated sodium and water disturbances after aneurysmal SAH with regard to symptomatic vasospasm and patient outcomes. -
   METHODS: Data from all patients with aneurysmal SAH treated in our department during a 2-year period were collected. Daily natriuresis, sodium levels, water balance, and serum and urine osmolality were measured at 4 different points: day 1 of admission or bleeding, day 3, day 7, and day 14-21 or discharge. The clinical parameters (i.e., Hunt and Hess grade, aneurysm location and treatment, onset of vasospasm) were reviewed. The patients' outcome was assessed using the Glasgow outcome score and modified Rankin scale.
   RESULTS: A total of 101 patients (70 women; median age, 52 years) were enrolled in the present study. Of these 101 patients, 59.4% had a good grade SAH (Hunt and Hess grade 1-3). The most common aneurysm location was the anterior communicating artery (37%). The results from an electrolyte analysis were available for <= 91 patients at days 1 and 78 at discharge. In 33 patients (32.7%), hyponatremia had been diagnosed at any time point. Hyponatremia was most frequently observed at day 1 and later at days 7-10. A location in the anterior communicating artery resulted in hyponatremia more frequently only at day 1 (P = 0.007). The main causes of hyponatremia were cerebral salt-wasting syndrome (early onset) and syndrome of inappropriate antidiuretic hormone secretion (early and late onset).
   CONCLUSION: Distinguishing early-and late-onset hyponatremia is of major relevance, because different therapeutic approaches are required. Only hyponatremia at discharge resulted in less favorable outcomes.
C1 [Ridwan, Sami; Kurscheid, Johanna; Kristof, Rudolf; Bostroem, Azize] Univ Hosp, Dept Neurosurg, Bonn, Germany.
   [Zur, Bernd] Univ Hosp, Dept Clin Chem & Pharmacol, Bonn, Germany.
   [Klingmueller, Dietrich] Univ Hosp, Div Endocrinol & Diabet, Dept Med 1, Bonn, Germany.
   [Esche, Jonas] Univ Bonn, Dept & Nutr & Food Sci, Bonn, Germany.
   [Ridwan, Sami] Bethel Clin, Dept Neurosurg, Bielefeld, Germany.
   [Kristof, Rudolf] Helios Hosp Meiningen, Dept Neurosurg, Meiningen, Germany.
   [Bostroem, Azize] MEDICLIN Robert Janker Klin, Bonn, Germany.
RP Ridwan, S (reprint author), Univ Hosp, Dept Neurosurg, Bonn, Germany.; Ridwan, S (reprint author), Bethel Clin, Dept Neurosurg, Bielefeld, Germany.
EM sami.ridwan@yahoo.de
FU "Familie Mehdorn Stiftung" in Kiel, Germany
FX We are grateful for the partial funding of the prospective study from
   which our data had been extracted through the "Familie Mehdorn Stiftung"
   in Kiel, Germany.
CR Agha A, 2005, QJM-INT J MED, V98, P463, DOI 10.1093/qjmed/hci075
   Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058
   Bales J, 2016, WORLD NEUROSURG, V96, P340, DOI 10.1016/j.wneu.2016.09.005
   Betjes Michiel G.H., 2002, Eur J Intern Med, V13, P9, DOI 10.1016/S0953-6205(01)00192-3
   Burn JP, 1992, STROKE, V136, P831
   Chandy D, 2006, NEUROL INDIA, V54, P273, DOI 10.4103/0028-3886.27151
   DOCZI T, 1981, NEUROSURGERY, V9, P394, DOI 10.1227/00006123-198110000-00008
   Hannon MJ, 2014, J CLIN ENDOCR METAB, V99, P291, DOI 10.1210/jc.2013-3032
   Hoffman H, 2018, WORLD NEUROSURG, V110, pE621, DOI 10.1016/j.wneu.2017.11.058
   ISOTANI E, 1994, STROKE, V25, P2198, DOI 10.1161/01.STR.25.11.2198
   Janicic N, 2003, ENDOCRIN METAB CLIN, V32, P459, DOI 10.1016/S0889-8529(03)00004-5
   Kao L, 2009, PITUITARY, V12, P347, DOI 10.1007/s11102-009-0188-9
   KASSELL NF, 1985, STROKE, V16, P562, DOI 10.1161/01.STR.16.4.562
   Kaye AH, 2000, LANCET, V356, P1540, DOI 10.1016/S0140-6736(00)03121-4
   Kurokawa Y, 1996, SURG NEUROL, V46, P500, DOI 10.1016/S0090-3019(96)00034-1
   Maimaitili A, 2013, EXP THER MED, V5, P1657, DOI 10.3892/etm.2013.1068
   Mapa B, 2016, WORLD NEUROSURG, V85, P305, DOI 10.1016/j.wneu.2015.08.054
   Nakagawa I, 2010, ACTA NEUROCHIR, V152, P2147, DOI 10.1007/s00701-010-0735-1
   Palmer BF, 2000, NEPHROL DIAL TRANSPL, V15, P262, DOI 10.1093/ndt/15.2.262
   Qureshi AI, 2002, NEUROSURGERY, V50, P749, DOI 10.1097/00006123-200204000-00012
   Ridwan S, 2017, WORLD NEUROSURG, V97, P495, DOI 10.1016/j.wneu.2016.09.123
   Saramma PP, 2013, J NEUROSCI RURAL PRA, V4, P24, DOI 10.4103/0976-3147.105605
   Sayama T, 2000, NEUROL RES, V22, P151, DOI 10.1080/01616412.2000.11741052
   Sherlock M, 2006, CLIN ENDOCRINOL, V64, P250, DOI 10.1111/j.1365-2265.2006.02432.x
   Tsubokawa T, 2004, NEUROL RES, V26, P893, DOI 10.1179/016164104225017776
   Vrsajkov V, 2012, BALK MED J, V29, P243, DOI 10.5152/balkanmedj.2012.037
   Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35
   WIJDICKS EFM, 1985, ANN NEUROL, V17, P137, DOI 10.1002/ana.410170206
   Zheng B, 2011, J NEUROL NEUROSUR PS, V82, P213, DOI 10.1136/jnnp.2009.180349
NR 29
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E538
EP E544
DI 10.1016/j.wneu.2019.05.210
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900068
PM 31154098
DA 2020-05-12
ER

PT J
AU Roth, J
   Soleman, J
   Kozyrev, DA
   Jabang, JN
   Stein, M
   Grisaru-Soen, G
   Benvenisti, H
   Sadot, E
   Friedman, S
   Ayalon, I
   Goldiner, I
   Stark, M
   Hassoun, E
   Constantine, S
AF Roth, Jonathan
   Soleman, Jehuda
   Kozyrev, Danil A.
   Jabang, John N.
   Stein, Maya
   Grisaru-Soen, Galia
   Benvenisti, Haggai
   Sadot, Efraim
   Friedman, Shirley
   Ayalon, Itay
   Goldiner, Iiana
   Stark, Moshe
   Hassoun, Eyal
   Constantine, Shlomi
TI Value of Cerebrospinal Fluid Lactate Levels in Diagnosing Shunt
   Infections in Pediatric Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bacterial; Lactate; Meningitis; Pleocytosis; Shunt infection
ID ACID-BASE-BALANCE; BACTERIAL-MENINGITIS; CSF LACTATE; UNANESTHETIZED
   MAN; SEIZURES; PYRUVATE
AB OBJECTIVE: The diagnosis and timely treatment of shunt infections (SI) in children is of paramount importance. In some cases, the standard cerebrospinal fluid (CSF) variables will not be sufficient for an accurate diagnosis of SI. CSF lactate (LCSF) has been found to assist in differentiating bacterial from nonbacterial meningitis in non-neurosurgical patients. To the best of our knowledge, the use of lactate in diagnosing or confirming the presence of SI has not yet been discussed. The goal of the present study was to describe the role of LCSF levels in children with shunts and Ommaya reservoirs and to evaluate its role in the accurate diagnosis of shunt-related infection.
   METHODS: We retrospectively collected data for a consecutive series of pediatric patients treated at a large tertiary pediatric neurosurgical department, for whom CSF samples from shunts had been collected during a 2-year period (2016-2017). The lactate levels were correlated with the presence of SI.
   RESULTS: A total of 61 CSF samples were analyzed, with 6 SIs found. The LCSF levels and white blood cell count were both found to correlate with the presence of CSF infections. A cutoff value of >= 2.95 mmol/L reached a sensitivity of 83%, specificity of 83%, and positive predictive value of 50%. LCSF <2.95 mmol/L had a negative predictive value of 96%.
   CONCLUSIONS: LCSF levels can be used as an additional chemical marker for the diagnosis and confirmation of SIs. An LCSF value of <2.95 mmol/L had a high negative predictive value.
C1 [Roth, Jonathan; Soleman, Jehuda; Kozyrev, Danil A.; Jabang, John N.; Stein, Maya; Benvenisti, Haggai; Constantine, Shlomi] Tel Aviv Univ, Tel Aviv Med Ctr, Dept Pediat Neurosurg, Dana Childrens Hosp, Tel Aviv, Israel.
   [Grisaru-Soen, Galia] Tel Aviv Univ, Tel Aviv Med Ctr, Pediat Infect Dis Unit, Dana Childrens Hosp, Tel Aviv, Israel.
   [Sadot, Efraim; Friedman, Shirley; Ayalon, Itay] Tel Aviv Univ, Tel Aviv Med Ctr, Pediat Intens Care Unit, Dana Childrens Hosp, Tel Aviv, Israel.
   [Goldiner, Iiana; Stark, Moshe; Hassoun, Eyal] Tel Aviv Med Ctr & Sch Med, Clin Biochem & Pharmacol Lab, Tel Aviv, Israel.
RP Roth, J (reprint author), Tel Aviv Univ, Tel Aviv Med Ctr, Dept Pediat Neurosurg, Dana Childrens Hosp, Tel Aviv, Israel.
EM jonaroth@gmail.com
RI ; Kozyrev, Danil/B-6193-2017
OI Roth, Jonathan/0000-0002-4267-8835; Kozyrev, Danil/0000-0002-3211-7815
CR Begovac Josip, 1991, Acta Medica Croatica, V45, P341
   BROOK I, 1978, J INFECT DIS, V137, P384, DOI 10.1093/infdis/137.4.384
   BROOKS BR, 1975, NEUROLOGY, V25, P935, DOI 10.1212/WNL.25.10.935
   BROOKS BR, 1975, NEUROLOGY, V25, P943, DOI 10.1212/WNL.25.10.943
   BUSSE O, 1983, STROKE, V14, P960, DOI 10.1161/01.STR.14.6.960
   FROMAN C, 1967, LANCET, V1, P965
   FUJISHIMA M, 1975, STROKE, V6, P707, DOI 10.1161/01.STR.6.6.707
   Grille P, 2012, NEUROCIRUGIA, V23, P131, DOI 10.1016/j.neucir.2011.11.005
   Huy NT, 2010, CRIT CARE, V14, DOI [10.1186/cc9395, 10.1186/cc9268]
   JORDAN GW, 1983, ARCH INTERN MED, V143, P85, DOI 10.1001/archinte.143.1.85
   Leib SL, 1999, CLIN INFECT DIS, V29, P69, DOI 10.1086/520184
   Li YR, 2015, CLIN BIOCHEM, V48, P50, DOI 10.1016/j.clinbiochem.2014.10.007
   Maskin LP, 2013, CLIN NEUROL NEUROSUR, V115, P1820, DOI 10.1016/j.clineuro.2013.05.034
   Prusseit J, 2009, PEDIATR NEUROSURG, V45, P325, DOI 10.1159/000257520
   Sakushima K, 2011, J INFECTION, V62, P255, DOI 10.1016/j.jinf.2011.02.010
   Sarmey N, 2015, CHILD NERV SYST, V31, P541, DOI 10.1007/s00381-015-2637-2
   SHANNON DC, 1972, NEUROLOGY, V22, P585, DOI 10.1212/WNL.22.6.585
   Simon TD, 2019, J PEDIAT INF DIS SOC, V8, P235, DOI 10.1093/jpids/piy035
   SUGI T, 1975, STROKE, V6, P715, DOI 10.1161/01.STR.6.6.715
   Tavares WM, 2006, ARQ NEURO-PSIQUIAT, V64, P592, DOI 10.1590/S0004-282X2006000400012
   Viallon A, 2011, CRIT CARE, V15, DOI 10.1186/cc10254
   Vinchon M, 2012, FLUIDS BARRIERS CNS, V9, DOI 10.1186/2045-8118-9-18
   Xiao X, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1818-2
   YAO H, 1989, J NEUROL NEUROSUR PS, V52, P372, DOI 10.1136/jnnp.52.3.372
   Zhang Y, 2017, INT J INFECT DIS, V59, P50, DOI 10.1016/j.ijid.2017.03.026
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E207
EP E215
DI 10.1016/j.wneu.2019.05.111
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900026
PM 31125779
DA 2020-05-12
ER

PT J
AU Rothrock, RJ
   Morra, RP
   Deutsch, BC
   Neifert, SN
   Cho, SK
   Caridi, JM
AF Rothrock, Robert J.
   Morra, Rocco P., Jr.
   Deutsch, Brian C.
   Neifert, Sean N.
   Cho, Samuel K.
   Caridi, John M.
TI Effect of Psychiatric Comorbidities on In-Hospital Outcomes and Cost for
   Cervical Spondylotic Myelopathy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spondylotic myelopathy; Degenerative cervical myelopathy; Major
   psychiatric disorder; Mental illness in spine surgery; Outcomes of
   cervical myelopathy
ID OF-LIFE OUTCOMES; PREOPERATIVE DEPRESSION; DISORDERS; SURGERY; IMPACT;
   DECOMPRESSION; EPIDEMIOLOGY; CARE
AB OBJECTIVE: The present study examined the differences in outcomes of cervical spinal surgery for patients with and without a major psychiatric comorbidity using the Healthcare Cost and Utilization Project National Inpatient Sample database.
   METHODS: Data were queried from the Healthcare Cost and Utilization Project National Inpatient Sample database from 2013 to 2014 for hospitalizations with a major psychiatric comorbidity and a diagnosis of cervical spondylotic myelopathy treated by an appropriate surgical procedure. The included psychiatric comorbidities were schizophrenia, episodic mood disorders (bipolar I and II disorders), delusional disorders, and psychoses not otherwise specified. Univariate and multivariate regression analyses were performed to determine the differences in outcomes between patients with and without a major psychiatric comorbidity.
   RESULTS: A total of 18,335 hospitalizations met the inclusion criteria, of which 648 (3.5%) included a major psychiatric comorbidity. Multivariate regression analysis demonstrated that psychiatric comorbidity was an independent predictor of nonehome discharge (odds ratio [OR], 1.81; 95% confidence interval [CI], 1.43-2.30; P < 0.0001) and a longer hospital stay (+0.52 day; 95% CI, 0.43-0.61; P < 0.0001) but was not an independent predictor of overall complications (OR, 0.79; 95% CI, 0.58-1.07; P = 0.13) or total hospital charges ($1992; 95% CI, -$917-$4902; P = 0.18).
   CONCLUSIONS: Psychiatric comorbidity was associated with an increased risk of nonehome discharge and a longer length of stay for patients undergoing surgical intervention for cervical myelopathy. However, we did not find an associated increased risk of in-hospital mortality, complications, or total hospital charges. Psychiatric comorbidity should not be weighed against patients who require surgical treatment for cervical spondylotic myelopathy, and special attention should be given to postoperative care and discharge planning for this unique patient population.
C1 [Rothrock, Robert J.; Morra, Rocco P., Jr.; Deutsch, Brian C.; Neifert, Sean N.; Caridi, John M.] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
   [Cho, Samuel K.] Icahn Sch Med Mt Sinai, Dept Orthoped Surg, New York, NY 10029 USA.
RP Rothrock, RJ (reprint author), Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
EM RJRothrock@gmail.com
OI Deutsch, Brian/0000-0002-8622-9951
CR Alvin MD, 2015, SPINE J, V15, P79, DOI 10.1016/j.spinee.2014.07.001
   American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU
   Diebo BG, 2018, SPINE, V43, P1176, DOI 10.1097/BRS.0000000000002583
   Doody O, 2017, J PSYCHIATR MENT HLT, V24, P412, DOI 10.1111/jpm.12369
   Fehlings MG, 2017, GLOB SPINE J, V7, p21S, DOI 10.1177/2192568217703088
   Fehlings MG, 2013, J BONE JOINT SURG AM, V95A, P1651, DOI 10.2106/JBJS.L.00589
   Healthcare Cost and Utilization Project (HCUP), 2018, HCUP DAT HEALTHC COS
   Lebl DR, 2015, J AM ACAD ORTHOP SUR, V23, P648, DOI 10.5435/JAAOS-D-14-00250
   Mabire Cedric, 2016, JBI Database System Rev Implement Rep, V14, P217
   Mayr M, 2003, LANCET, V361, P531, DOI 10.1016/S0140-6736(03)12479-8
   Menendez ME, 2014, SPINE, V39, pE111, DOI 10.1097/BRS.0000000000000064
   Miller J, 2014, SPINE J, V14, pS27
   Miller JA, 2015, SPINE J, V15, P58, DOI 10.1016/j.spinee.2014.06.020
   Netto Martins Back, 2018, Rev. bras. ortop., V53, P38, DOI 10.1016/j.rboe.2017.01.009
   Nouri A, 2015, SPINE, V40, pE675, DOI 10.1097/BRS.0000000000000913
   Nurjannah I, 2014, J CLIN NURS, V23, P1175, DOI 10.1111/jocn.12297
   Osterweis M, 2014, PAIN DISABILITY CLIN
   Parkes J, 2000, COCHRANE DB SYST REV, V1
   Phan Kevin, 2017, J Spine Surg, V3, P133, DOI 10.21037/jss.2017.05.02
   Robinson JC, 2014, AM J MANAG CARE, V20, pE418
   Shepperd S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000313.pub4
   Tetreault L, 2017, SPINE, V42, P372, DOI 10.1097/BRS.0000000000001777
   Tetreault L, 2017, EUR SPINE J, V26, P78, DOI 10.1007/s00586-016-4660-8
   Tetreault L, 2015, NEUROSURGERY, V77, pS51, DOI 10.1227/NEU.0000000000000951
   Tracy JA, 2010, NEUROLOGIST, V16, P176, DOI 10.1097/NRL.0b013e3181da3a29
   Yarbrough CK, 2012, ADV ORTHOP, V2012, DOI 10.1155/2012/480643
   YOUSSEF FA, 1987, J ADV NURS, V12, P611
   Zhu QM, 2015, J CLIN NURS, V24, P2993, DOI 10.1111/jocn.12895
   Zong YQ, 2014, NEUROL SCI, V35, P1373, DOI 10.1007/s10072-014-1714-8
NR 29
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E718
EP E725
DI 10.1016/j.wneu.2019.05.258
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900090
PM 31181363
DA 2020-05-12
ER

PT J
AU Salzmann, SN
   Shirahata, T
   Okano, I
   Winter, F
   Sax, OC
   Yang, JY
   Shue, J
   Sama, AA
   Cammisa, FP
   Girard, FP
   Hughes, AP
AF Salzmann, Stephan N.
   Shirahata, Toshiyuki
   Okano, Ichiro
   Winter, Fabian
   Sax, Oliver C.
   Yang, Jingyan
   Shue, Jennifer
   Sama, Andrew A.
   Cammisa, Frank P.
   Girard, Federico P.
   Hughes, Alexander P.
TI Does L4-L5 Pose Additional Neurologic Risk in Lateral Lumbar Interbody
   Fusion?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complication; L4-L5; Lateral lumbar interbody fusion; LLIF; Motor
   deficit
ID TRANSPSOAS APPROACH; NERVE INJURY; PSOAS MUSCLE; PLEXUS; RESPECT;
   ELECTROMYOGRAPHY; COMPLICATIONS; OUTCOMES; ANATOMY; SAFE
AB OBJECTIVE: Lateral lumbar interbody fusion (LLIF) at the L4-L5 level is a controversial topic in the spine data. The aim of the present study was to compare the rate of nerve-related motor deficits in patients undergoing LLIF with and without L4-L5 involvement.
   METHODS: The clinical data from consecutive patients who had undergone LLIF from 2006 to 2016 at a single academic institution were retrospectively reviewed for new postoperative motor weakness of the quadriceps or tibialis anterior muscle. The patients were divided into 2 groups according to L4-L5 involvement. Regression analysis was performed to examine the association of LLIF at L4-L5 and the risk of new motor deficits.
   RESULTS: A total of 872 patients met inclusion criteria. The rate of new motor deficits at the 6-week postoperative visit in the L4-L5 group was 13.1%, which was significantly greater than that in the non-L4-L5 group at 5.5% (P < 0.001). After adjustment for potential confounders in multivariate logistic regression models, L4-L5 was still significantly associated with an increased risk of new motor deficit (odds ratio, 2.290; P = 0.008). Of the 686 patients with a minimum follow-up of 6 months, persistent nerve-related motor deficits at the last follow-up examination were recorded in 2.5% of the L4-L5 group and 0.4% of the none L4-L5 group (P = 0.065).
   CONCLUSIONS: The results from the present large study are in line with previous investigations reporting an initial increased risk of new motor deficits for LLIF performed at L4-L5. However, most new motor deficits were transient in nature and had resolved over time.
C1 [Salzmann, Stephan N.; Shirahata, Toshiyuki; Okano, Ichiro; Winter, Fabian; Sax, Oliver C.; Yang, Jingyan; Shue, Jennifer; Sama, Andrew A.; Cammisa, Frank P.; Girard, Federico P.; Hughes, Alexander P.] Weill Cornell Med, Dept Orthopaed Surg, Hosp Special Surg, New York, NY 10065 USA.
   [Shirahata, Toshiyuki; Yang, Jingyan] Showa Univ, Sch Med, Dept Orthopaed, Tokyo, Japan.
   [Yang, Jingyan] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA.
RP Hughes, AP (reprint author), Weill Cornell Med, Dept Orthopaed Surg, Hosp Special Surg, New York, NY 10065 USA.
EM hughesa@hss.edu
RI Okano, Ichiro/AAE-6747-2019
OI Okano, Ichiro/0000-0003-1741-5176; Winter, Fabian/0000-0003-0695-7877
CR Ahmadian A, 2013, J NEUROSURG-SPINE, V19, P314, DOI 10.3171/2013.6.SPINE1340
   Aichmair A, 2013, SPINE, V38, pE1483, DOI 10.1097/BRS.0b013e3182a3d1b4
   Banagan K, 2011, SPINE, V36, pE687, DOI 10.1097/BRS.0b013e3181ec5911
   Cahill KS, 2012, J NEUROSURG-SPINE, V17, P227, DOI 10.3171/2012.5.SPINE1288
   Davis TT, 2011, J BONE JOINT SURG AM, V93A, P1482, DOI 10.2106/JBJS.J.00962
   Guerin P, 2011, SURG RADIOL ANAT, V33, P665, DOI 10.1007/s00276-011-0798-6
   Kepler CK, 2011, EUR SPINE J, V20, P550, DOI 10.1007/s00586-010-1593-5
   Knight RQ, 2009, J SPINAL DISORD TECH, V22, P34, DOI 10.1097/BSD.0b013e3181679b8a
   Kotwal S, 2015, J SPINAL DISORD TECH, V28, P119, DOI 10.1097/BSD.0b013e3182706ce7
   Kueper J, 2015, EUR SPINE J, V24, P800, DOI 10.1007/s00586-015-3796-2
   Kwon B, 2016, J AM ACAD ORTHOP SUR, V24, P96, DOI 10.5435/JAAOS-D-14-00208
   Le TV, 2013, SPINE, V38, pE13, DOI 10.1097/BRS.0b013e318278417c
   Lee YP, 2013, SPINE J, V13, P1259, DOI 10.1016/j.spinee.2013.05.031
   Lehmen JA, 2015, EUR SPINE J, V24, pS287, DOI 10.1007/s00586-015-3886-1
   Lykissas MG, 2014, SPINE J, V14, P749, DOI 10.1016/j.spinee.2013.06.066
   Lykissas MG, 2014, SPINE J, V14, P217, DOI 10.1016/j.spinee.2013.06.109
   Moro T, 2003, SPINE, V28, P423, DOI 10.1097/00007632-200303010-00002
   Ozgur Burak M, 2006, Spine J, V6, P435, DOI 10.1016/j.spinee.2005.08.012
   Pumberger M, 2012, EUR SPINE J, V21, P1192, DOI 10.1007/s00586-011-2087-9
   Regev GJ, 2009, SPINE, V34, P1330, DOI 10.1097/BRS.0b013e3181a029e1
   Rodgers WB, 2011, SPINE, V36, P26, DOI 10.1097/BRS.0b013e3181e1040a
   Salzmann SN, 2017, CURR REV MUSCULOSKE, V10, P539, DOI 10.1007/s12178-017-9444-1
   Tohmeh AG, 2011, J NEUROSURG-SPINE, V14, P31, DOI 10.3171/2010.9.SPINE09871
   Uribe JS, 2015, EUR SPINE J, V24, pS378, DOI 10.1007/s00586-015-3871-8
   Uribe JS, 2010, J NEUROSURG-SPINE, V13, P260, DOI 10.3171/2010.3.SPINE09766
   Wagner SC, 2018, CLIN SPINE SURG, V31, P49, DOI 10.1097/BSD.0000000000000599
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E337
EP E342
DI 10.1016/j.wneu.2019.05.144
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900042
PM 31132495
DA 2020-05-12
ER

PT J
AU Satapathy, D
   Nadeem, M
   Shukla, DP
   Prabhuraj, AR
   Devi, BI
AF Satapathy, Diptiranjan
   Nadeem, Mohammed
   Shukla, Dhaval P.
   Prabhuraj, A. R.
   Devi, Bhagavatula Indira
TI Cosmetic Outcome of Cranioplasty After Decompressive Craniectomy-An
   Overlooked Aspect
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bone flap; Cosmetic outcome; Cranioplasty; Decompressive craniectomy
ID HEMICRANIECTOMY
AB BACKGROUND: Cranioplasty (CP) is an obligatory surgery after decompressive craniectomy (DC). The primary objective is to protect the brain from external injury and prevent syndrome of trephined. In a government hospital, such cases pose a significant burden to a trauma center. Because of this reason, cosmetic outcome is never taken into account for the CP. We present results of CP performed at our hospital.
   METHODS: This is a retrospective review of the cases of CP performed over the past 3 years at our hospital. The cosmetic outcome was divided into 3 grades: 1-good symmetrical, 2-irregularities, 2a-elevated and 2b depressed, and 3-bad cosmetic outcome requiring reoperation.
   RESULTS: A total of 133 patients with acute brain injury underwent CP during the study period. The outcome was good in 74 (55.6%) and bad, requiring reoperation, in 2 (1.5%) cases. Various types of the CP materials like autologous bone flap, titanium mesh, and customized titanium plates were used. Methods of fixation were threads or miniplates and screws. In univariate analysis, cerebral venous thrombosis as an indication for DC, use of autologous bone flap, and fixation with thread were associated with poor outcome. However, in multivariate analysis only the method of implant fixation was associated with poor outcome. It was found that if screws and plates are used for fixation of bone flap, the chances of bad outcome are reduced by 74.6%.
   CONCLUSIONS: The cosmetic outcome is overlooked for CP. The bone flap fixation has to be rigid for a good outcome.
C1 [Satapathy, Diptiranjan; Nadeem, Mohammed; Prabhuraj, A. R.] Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neurosurg, Bangalore, Karnataka, India.
   [Shukla, Dhaval P.; Devi, Bhagavatula Indira] Univ Cambridge, NIHR Global Hlth Res Grp Neurotrauma, Cambridge, England.
RP Shukla, DP (reprint author), Univ Cambridge, NIHR Global Hlth Res Grp Neurotrauma, Cambridge, England.
EM neurodhaval@rediffmail.com
CR Aydin S, 2011, J NEUROSCI RURAL PRA, V2, P162, DOI 10.4103/0976-3147.83584
   Barthelemy EJ, 2016, WORLD NEUROSURG, V88, P411, DOI 10.1016/j.wneu.2015.12.044
   Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2
   Brommeland T, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0155-6
   Chaturvedi J, 2016, BRIT J NEUROSURG, V30, P264, DOI 10.3109/02688697.2015.1054356
   Chun HJ, 2011, J CRANIOFAC SURG, V22, P203, DOI 10.1097/SCS.0b013e3181f753bd
   Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077
   Coulter IC, 2014, ACTA NEUROCHIR, V156, P1361, DOI 10.1007/s00701-014-2081-1
   Cushing H, 1908, ANN SURG, V47, P641, DOI 10.1097/00000658-190805000-00001
   Dujovny M, 1997, SURG NEUROL, V47, P238, DOI 10.1016/S0090-3019(96)00013-4
   Dujovny M, 1997, NEUROL RES, V19, P311, DOI 10.1080/01616412.1997.11740818
   Erdogan E, 2003, NEUROL INDIA, V51, P479
   Fischer CM, 2012, NEUROL RES, V34, P281, DOI 10.1179/1743132812Y.0000000007
   FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039
   Fodstad H, 1979, Acta Neurochir Suppl (Wien), V28, P514
   Giese H, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009273
   Henker C, 2018, J NEUROTRAUM, V35, P1030, DOI 10.1089/neu.2017.5512
   Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513
   Kolias AG, 2014, BRIT J NEUROSURG, V28, P310, DOI 10.3109/02688697.2013.859657
   Mrad MA, 2017, J CRANIOFAC SURG, V28, P1260, DOI 10.1097/SCS.0000000000003708
   Nievas MNCY, 2006, NEUROL RES, V28, P139, DOI 10.1179/016164106X98008
   Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018
   RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070
   Rocque BG, 2013, J NEUROSURG-PEDIATR, V12, P120, DOI 10.3171/2013.4.PEDS12605
   Wachter D, 2013, CLIN NEUROL NEUROSUR, V115, P1293, DOI 10.1016/j.clineuro.2012.12.002
   Waqas M, 2017, PEDIATR NEUROSURG, V52, P77, DOI 10.1159/000452808
   Zegers T, 2017, J CRANIO MAXILL SURG, V45, P82, DOI 10.1016/j.jcms.2016.10.016
NR 27
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E81
EP E86
DI 10.1016/j.wneu.2019.05.027
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900012
PM 31096024
DA 2020-05-12
ER

PT J
AU Sattur, MG
   Li, YC
   Almallouhi, E
   Lena, J
   Spiotta, AM
AF Sattur, Mithun G.
   Li, Yangchun
   Almallouhi, Eyad
   Lena, Jonathan
   Spiotta, Alejandro M.
TI Lessons Learned from Endovascular Coil Embolization of Pericallosal
   Artery Aneurysms and Adoption of Flow Diversion: A Retrospective Cohort
   Assessment of the Efficacy of Coiling and Flow Diversion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Coil embolization; Endovascular treatment; Flow diversion;
   LVIS Jr; Pericallosal artery aneurysm; Pipeline embolization device
ID ANTERIOR CEREBRAL-ARTERY; INTRACRANIAL ANEURYSMS; DEVICE; MANAGEMENT;
   FEATURES; COMPLEX; SAFETY; STENTS
AB BACKGROUND: The adoption of endovascular techniques for treatment of pericallosal artery aneurysms (PAAs) has been comparatively gradual due to anatomic and technological factors. We conducted a retrospective cohort study to evaluate the outcomes of PAA treatment with coiling and flow diversion at our institution.
   METHODS: This was a retrospective study of patients treated endovascularly for PAAs from December 2007 to January 2019.
   RESULTS: In total, 33 patients with 34 aneurysms were included (25 aneurysms ruptured, 9 unruptured or recurrent). Of the ruptured group, 22 were coiled (88%) and rest treated with flow diversion. Initial angiographic follow up rate was 72%, at median of 159 days. Overall recurrence rate was 40% (10/25) at median of 376 days, all among coiled aneurysms. 6 recurrent aneurysms were retreated with further coiling (2) and flow diversion (4). Of the unruptured/recurrent group, 5 were coiled (55%) and remainder treated with flow diversion. Angiographic follow-up rate was 100% at median of 267 days. Recurrence rate was 22% (2/9), both in coiled aneurysms. Overall, 27 aneurysms were coiled, 9 treated with flow diversion and 3 with "partial" flow diversion. All aneurysms treated with pipeline flow diversion achieved 100% occlusion. No re-rupture or new rupture was observed. Good clinical outcome (modified Rankin Scale 0-2) was seen in 79% of patients.
   CONCLUSIONS: Our study demonstrates that endovascular coiling for PAAs is associated with a definite rate of recurrence, which has to be monitored with timely angiography. We also demonstrate the excellent effectiveness of flow diversion for PAAs with either presentation.
C1 [Sattur, Mithun G.; Lena, Jonathan; Spiotta, Alejandro M.] Med Univ South Carolina, Dept Neurosurg, Charleston, SC 29425 USA.
   [Li, Yangchun] Med Univ South Carolina, Coll Med, Charleston, SC 29425 USA.
   [Almallouhi, Eyad] Med Univ South Carolina, Dept Neurol, Charleston, SC 29425 USA.
RP Spiotta, AM (reprint author), Med Univ South Carolina, Dept Neurosurg, Charleston, SC 29425 USA.
EM Spiotta@musc.edu
CR Aboukais R, 2015, NEUROCHIRURGIE, V61, P244, DOI 10.1016/j.neuchi.2015.03.010
   Clarencon F, 2017, CLIN NEURORADIOL, V27, P51, DOI 10.1007/s00062-015-0441-8
   Dabus G, 2017, J NEUROINTERV SURG, V9, P147, DOI 10.1136/neurintsurg-2016-012519
   Darkhabani ZM, 2012, J NEUROINTERV SURG, V4, P459, DOI 10.1136/neurintsurg-2011-010086
   de Sousa AA, 1999, SURG NEUROL, V52, P128, DOI 10.1016/S0090-3019(99)00066-X
   Gupta M, 2017, CUREUS, V9, DOI 10.7759/cureus.1037
   HERNESNIEMI J, 1992, NEUROSURGERY, V31, P994, DOI 10.1227/00006123-199212000-00002
   Hui FK, 2011, J NEUROINTERV SURG, V3, P319, DOI 10.1136/jnis.2011.004770
   Inci S, 1998, SURG NEUROL, V50, P130, DOI 10.1016/S0090-3019(97)00344-3
   Kwon TH, 2001, J KOREAN MED SCI, V16, P204, DOI 10.3346/jkms.2001.16.2.204
   Lee JY, 2007, J KOREAN NEUROSURG S, V42, P281, DOI 10.3340/jkns.2007.42.4.281
   Lehecka M, 2008, NEUROSURGERY, V63, P28
   Lehecka M, 2008, NEUROSURGERY, V63, P219, DOI 10.1227/01.NEU.0000310695.44670.32
   Lin N, 2016, NEUROSURGERY, V79, P14, DOI 10.1227/NEU.0000000000001117
   Martines F, 1996, J Neurosurg Sci, V40, P189
   Mascitelli JR, 2015, J NEUROINTERV SURG, V7, P496, DOI 10.1136/neurintsurg-2014-011258
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Navarro R, 2013, ACTA NEUROCHIR, V155, P2115, DOI 10.1007/s00701-013-1855-1
   Nelson PK, 2011, AM J NEURORADIOL, V32, P34, DOI 10.3174/ajnr.A2421
   Ng PY, 1998, BRIT J NEUROSURG, V12, P209
   Nossek E, 2017, J CLIN NEUROSCI, V35, P133, DOI 10.1016/j.jocn.2016.10.041
   Nyberg EM, 2013, J NEUROINTERV SURG, V5, DOI 10.1136/neurintsurg-2012-010387
   PERLMUTTER D, 1978, J NEUROSURG, V49, P204, DOI 10.3171/jns.1978.49.2.0204
   Primiani CT, 2019, J NEUROINTERV SURG, V11, P903, DOI 10.1136/neurintsurg-2018-014631
   Puri AS, 2016, NEURORADIOLOGY, V58, P267, DOI 10.1007/s00234-015-1630-5
   Rodrigues KD, 2018, OPER NEUROSURG, V14, P351, DOI 10.1093/ons/opx111
   Spetzler RF, 2015, J NEUROSURG, V123, P609, DOI 10.3171/2014.9.JNS141749
   Walsh KM, 2014, J NEUROINTERV SURG, V6, P184, DOI 10.1136/neurintsurg-2013-010648
   Wang C, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0959-9
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Yamazaki T, 2013, NEUROL MED-CHIR, V53, P409, DOI 10.2176/nmc.53.409
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E444
EP E451
DI 10.1016/j.wneu.2019.05.181
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900056
PM 31150866
DA 2020-05-12
ER

PT J
AU Scerrati, A
   Germano, A
   Trevisi, G
   Visani, J
   Lofrese, G
   D'Angelo, L
   Raffa, G
   Fazzari, E
   Mangiola, A
   Cavallo, MA
   De Bonis, P
AF Scerrati, Alba
   Germano, Antonino
   Trevisi, Gianluca
   Visani, Jacopo
   Lofrese, Giorgio
   D'Angelo, Luca
   Raffa, Giovanni
   Fazzari, Elena
   Mangiola, Annunziato
   Cavallo, Michele Alessandro
   De Bonis, Pasquale
TI Timing of Low-Dose Aspirin Discontinuation and the Influence on Clinical
   Outcome of Patients Undergoing Surgery for Chronic Subdural Hematoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE ASA discontinuation; Chronic subdural hematoma; Clinical outcome; CSDH;
   Low-dose ASA; Rebleeding
ID RISK-FACTORS; PERIOPERATIVE MANAGEMENT; INTRACRANIAL HEMORRHAGE;
   ANTIPLATELET AGENTS; COAGULATION
AB BACKGROUND: An appropriate time (5-7 days) of discontinuation of low-dose acetylsalicylic acid (ASA) in patients undergoing surgery for chronic subdural hematoma (CSDH) is recommended. However, patient clinical deterioration often does not allow to wait the recommended time for surgery. Clear guidelines regarding the perioperative management of patients with ASA therapy are still lacking. The aim of this study is to compare the surgical outcome, complications, and mortality of patients suffering from CSDHs who underwent urgent surgery or before and after 5 days of discontinuation of low-dose ASA.
   METHODS: A retrospective 3-center study included patients treated for CSDH taking low-dose ASA. Aspirin was discontinued on hospital admission. Based on the timing of discontinuation, we classified patients in 3 groups: urgent (surgery at admission), surgery within 5 days, and surgery 5 days after discontinuation. Surgery consisted of minicraniotomy or burr holes. Variables analyzed were age, comorbidities, modified Rankin Scale, complications, rebleedings, and mortality. Outcome measures were acute rebleeding requiring surgery, recurrence, mortality, complications, and clinical conditions. The chi(2) test and the Fisher exact test were used to compare variables. Logistic regression analysis was used for defining the impact on outcome measures.
   RESULTS: We enrolled 164 patients. After aspirin discontinuation, patients underwent surgery: on admission (69 cases [42.1%]), within 5 days (59 patients [36%]), and after 5 days (36 cases [22%]). No correlation was observed between time of discontinuation and outcome measures, including having a worse clinical outcome.
   CONCLUSIONS: Our data showed that the time of discontinuation of ASA does not influence outcome.
C1 [Scerrati, Alba; Visani, Jacopo; D'Angelo, Luca; Cavallo, Michele Alessandro; De Bonis, Pasquale] Ferrara Univ, Hosp S Anna, Neurosurg Div, Dept Morphol Surg & Expt Med, Ferrara, Italy.
   [Germano, Antonino; Raffa, Giovanni; Fazzari, Elena] Univ Messina, Dept Neurosci, Neurosurg Clin, Messina, Italy.
   [Trevisi, Gianluca; Mangiola, Annunziato] Chieti Univ G DAnnunzio, Santo Spirito Hosp, Dept Neurosurg, Pescara, Italy.
   [Lofrese, Giorgio] Osped Gen Provinciale M Bufalini, Neurosurg Div, Cesena, Italy.
RP Scerrati, A (reprint author), Ferrara Univ, Hosp S Anna, Neurosurg Div, Dept Morphol Surg & Expt Med, Ferrara, Italy.
EM a.scerrati@gmail.com
RI Raffa, Giovanni/K-7972-2016; Scerrati, Alba/Z-2079-2019
OI Raffa, Giovanni/0000-0001-8623-4964; Scerrati, Alba/0000-0002-8607-5323;
   Lofrese, Giorgio/0000-0001-5874-7340
CR Baechli H, 2004, NEUROSURG REV, V27, P263, DOI 10.1007/s10143-004-0337-6
   Campbell PG, 2010, WORLD NEUROSURG, V74, P279, DOI 10.1016/j.wneu.2010.05.030
   De Bonis P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068732
   Dobran M, 2017, G CHIR, V38, P66
   Forster MT, 2010, J CLIN NEUROSCI, V17, P975, DOI 10.1016/j.jocn.2009.11.023
   Guha D, 2016, J NEUROSURG, V124, P750, DOI 10.3171/2015.2.JNS141889
   Kamenova M, 2019, TRIALS, V20, DOI 10.1186/s13063-018-3064-y
   Kamenova M, 2017, WORLD NEUROSURG, V100, P594, DOI 10.1016/j.wneu.2017.01.065
   Korte W, 2011, THROMB HAEMOSTASIS, V105, P743, DOI 10.1160/TH10-04-0217
   Macdonald RL, 2018, NEUROSURG CLIN N AM, V29, P605, DOI 10.1016/j.nec.2018.06.013
   Mantz J, 2011, BRIT J ANAESTH, V107, P899, DOI 10.1093/bja/aer274
   Mehta V, 2018, J CLIN NEUROSCI, V50, P7, DOI 10.1016/j.jocn.2018.01.050
   Mizutani K, 2014, CLIN NEUROL NEUROSUR, V117, P100, DOI 10.1016/j.clineuro.2013.11.035
   Motoie R, 2018, WORLD NEUROSURG, V118, pE87, DOI 10.1016/j.wneu.2018.06.124
   Nathan S, 2017, NEUROLOGY, V88, P1889, DOI 10.1212/WNL.0000000000003918
   Okano A, 2014, BRIT J NEUROSURG, V28, P204, DOI 10.3109/02688697.2013.829563
   Poon Michael T C, 2019, J Neurotrauma, DOI 10.1089/neu.2018.6080
   Scerrati Alba, 2018, J Neurosurg Sci, DOI 10.23736/S0390-5616.18.04311-4
   Sim YW, 2012, J KOREAN NEUROSURG S, V52, P234, DOI 10.3340/jkns.2012.52.3.234
   Wang H, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000013972
NR 20
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E695
EP E699
DI 10.1016/j.wneu.2019.05.252
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900088
PM 31279757
DA 2020-05-12
ER

PT J
AU Shikata, E
   Tamura, T
   Shinno, K
   Okayama, Y
   Shinohara, N
   Shimoda, K
   Kanematsu, Y
   Kitazato, KT
   Nagahiro, S
   Takagi, Y
AF Shikata, Eiji
   Tamura, Tetsuya
   Shinno, Kiyohito
   Okayama, Yoshihiro
   Shinohara, Naoki
   Shimoda, Kenji
   Kanematsu, Yasuhisa
   Kitazato, Keiko T.
   Nagahiro, Shinji
   Takagi, Yasushi
TI Importance of Managing the Water-Electrolyte Balance by Delivering the
   Optimal Minimum Amount of Water and Sodium After Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysmal subarachnoid hemorrhage; Cerebral vasospasm;
   Water-electrolyte balance
ID CEREBRAL VASOSPASM; FLUID BALANCE; ASSOCIATION; MANAGEMENT; OUTCOMES;
   THERAPY; KIDNEY
AB BACKGROUND: After aneurysmal subarachnoid hemorrhage (aSAH), crystalloid fluids with a relatively high sodium concentration have been used to maintain the cerebral blood flow. However, the prophylactic delivery of water and sodium by intravenous (IV) infusion will not necessarily improve the prognosis of patients after aSAH, and the excessive supply of water and sodium can negatively affect the outcome. We hypothesized that the delivery of an optimal amount of water and sodium separately might improve the outcome after aSAH.
   METHODS: We recruited 55 consecutive patients who had undergone clipping or endovascular coil embolization after aSAH. Group 1 (n = 33) received conventional therapy (i.e., prophylactic IV sodium and water = protocol 1]). Group 2 (n = 22) received the optimal amount of water and sodium separately (protocol 2).
   RESULTS: The median total of water and sodium chloride supplied in group 1 was significantly greater than that supplied in group 2 (P < 0.01). The modified Rankin scale score at discharge was 0-2 in 15 patients (95%) in group 2 and 23 patients (55%) in group 1 (P < 0.001). On multivariate logistic regression analysis, the odds ratio for a discharge modified Rankin scale score of 0-2 or 3-6 was significantly associated with the treatment protocol (P < 0.05) and the net fluid balance on days 4-8 (P < 0.05).
   CONCLUSION: The separate delivery of optimal amounts of water and sodium could be a promising therapeutic strategy to improve the prognosis after aSAH.
C1 [Shikata, Eiji; Shimoda, Kenji; Kanematsu, Yasuhisa; Kitazato, Keiko T.; Nagahiro, Shinji; Takagi, Yasushi] Tokushima Univ Hosp, Dept Neurosurg, Tokushima, Japan.
   [Tamura, Tetsuya; Shinno, Kiyohito] Tokushima Prefectural Cent Hosp, Dept Neurosurg, Tokushima, Japan.
   [Okayama, Yoshihiro] Tokushima Univ Hosp, Clin Trial Ctr Dev Therapeut, Tokushima, Japan.
   [Shinohara, Naoki] HITO Med Ctr, Dept Neurosurg, Shikokuchuo, Ehime, Japan.
RP Shikata, E (reprint author), Tokushima Univ Hosp, Dept Neurosurg, Tokushima, Japan.
EM ninth4kata@yahoo.co.jp
OI Shikata, Eiji/0000-0002-5603-0255
CR Aggarwal A, 2018, NEUROSURG REV, V41, P241, DOI 10.1007/s10143-017-0843-y
   Chen S, 2017, BIOMED RES INT, DOI 10.1155/2017/8584753
   Chung DY, 2018, NEUROCRIT CARE, V28, P157, DOI 10.1007/s12028-017-0443-2
   Dankbaar JW, 2010, CRIT CARE, V14, DOI 10.1186/cc8886
   Francoeur CL, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1447-6
   Geraghty JR, 2017, CURR ATHEROSCLER REP, V19, DOI 10.1007/s11883-017-0690-x
   Ibrahim GM, 2013, NEUROCRIT CARE, V19, P140, DOI 10.1007/s12028-013-9860-z
   Igarashi T, 2007, NEUROL RES, V29, P835, DOI 10.1179/016164107X228624
   Joffe AM, 2015, NEUROCRIT CARE, V22, P82, DOI 10.1007/s12028-014-9993-8
   Kreiter KT, 2009, STROKE, V40, P2362, DOI 10.1161/STROKEAHA.109.547331
   Lee KH, 2006, NEUROCRIT CARE, V4, P68, DOI 10.1385/NCC:4:1:068
   Lennihan L, 2000, STROKE, V31, P383, DOI 10.1161/01.STR.31.2.383
   Malik AN, 2015, WORLD NEUROSURG, V83, P880, DOI 10.1016/j.wneu.2015.01.013
   Mapa B, 2016, WORLD NEUROSURG, V85, P305, DOI 10.1016/j.wneu.2015.08.054
   Martini RP, 2012, NEUROCRIT CARE, V17, P191, DOI 10.1007/s12028-011-9573-0
   McQuarrie EP, 2014, HYPERTENSION, V64, P111, DOI 10.1161/HYPERTENSIONAHA.113.03093
   Musso Carlos Guido, 2012, World J Nephrol, V1, P123, DOI 10.5527/wjn.v1.i5.123
   Mutoh T, 2007, STROKE, V38, P3218, DOI 10.1161/STROKEAHA.107.484634
   Nieuwkamp DJ, 2009, LANCET NEUROL, V8, P635, DOI 10.1016/S1474-4422(09)70126-7
   Okazaki T, 2017, SHOCK, V48, P558, DOI 10.1097/SHK.0000000000000897
   Oreskovic D, 2017, PEDIATR NEUROSURG, V52, P417, DOI 10.1159/000452169
   Pierrakos C, 2012, ANN INTENSIVE CARE, V2, DOI 10.1186/2110-5820-2-13
   Sakr Y, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0128-6
   Verbrugge FH, 2014, EUR J HEART FAIL, V16, P133, DOI 10.1002/ejhf.35
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E352
EP E360
DI 10.1016/j.wneu.2019.05.152
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900044
PM 31132492
DA 2020-05-12
ER

PT J
AU Shrivastava, A
   Mohammed, N
   Hung, YC
   Xu, ZY
   Schlesinger, D
   Heinrichs, T
   Kearns, K
   Li, CE
   Lavezzo, K
   Narayan, A
   Sheehan, JP
AF Shrivastava, Adesh
   Mohammed, Nasser
   Hung, Yi-Chieh
   Xu, Zhiyuan
   Schlesinger, David
   Heinrichs, Trevor
   Kearns, Kathryn
   Li, Chelsea E.
   Lavezzo, Karen
   Narayan, Aditya
   Sheehan, Jason P.
TI Impact of Integral Dose on the Maintenance of Pain Relief in Patients
   with Idiopathic Trigeminal Neuralgia Treated with Upfront Gamma Knife
   Radiosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Gamma knife radiosurgery; Integral dose; Stereotactic radiosurgery;
   Trigeminal neuralgia
ID STEREOTACTIC RADIOSURGERY
AB BACKGROUND: Integral dose (ID) defined as the product of mean dose and target volume, is a measure of the absorbed radiation energy.
   OBJECTIVE: To evaluate the effect of ID on the duration of pain relief after primary Gamma knife stereotactic radiosurgery (GKSRS) in trigeminal neuralgia.
   PATIENTS AND METHODS: A total of 78 patients who achieved initial pain response of I-III on the Barrow Neurological Institute Pain Scale (BNI-PS) following primary GKSRS for idiopathic trigeminal neuralgia were included in this study. A Cox regression model was used to compute the prognostic factor with respect to the ID within the 50% isodose line. Facial pain relief maintenance interval was defined as time interval between the day of improved BNI-PS grade and pain level back to the BNI-PS IV or V. The median duration of follow-up was 42 months (range 6-108 months).
   RESULTS: After the initial GKSRS, patients achieved pain relief at a median of 0.5 months (range, 7 days to 6 months); 28 patients developed recurrence of pain. There was a positive correlation between the pain relief maintenance and increasing ID within 50% isodose line (hazard ratio 1.85, P = 0.04) on multivariable Cox-regression analysis. Using logistic regression analysis, we found that ID was not predictive of developing post-stereotactic radiosurgery hypoesthesia (P = 0.64, hazard ratio 1.057).
   CONCLUSIONS: Stereotactic radiosurgery can be individualized based on trigeminal nerve morphology to achieve durable pain relief in patients with trigeminal neuralgia. ID calculation aids in planning an optimal radiation dose based on the nerve morphology to provide durable pain relief of idiopathic trigeminal neuralgia.
C1 [Shrivastava, Adesh; Mohammed, Nasser; Hung, Yi-Chieh; Xu, Zhiyuan; Schlesinger, David; Heinrichs, Trevor; Kearns, Kathryn; Li, Chelsea E.; Lavezzo, Karen; Narayan, Aditya; Sheehan, Jason P.] Univ Virginia, Dept Neurol Surg, Charlottesville, VA 22904 USA.
RP Mohammed, N (reprint author), Univ Virginia, Dept Neurol Surg, Charlottesville, VA 22904 USA.
EM Nasser30@gmail.com
RI mohammed, nasser/AAG-1525-2019
OI mohammed, nasser/0000-0002-3811-3559
CR Dimitriadis A, 2018, J NEUROSURG, V129, P118, DOI 10.3171/2018.7.GKS18694
   Eller Jorge L, 2005, Neurosurg Focus, V18, pE3
   Gellner V, 2008, J NEUROL NEUROSUR PS, V79, P1405, DOI 10.1136/jnnp.2007.142794
   Hung YC, 2014, J NEUROSURG, V121, P203, DOI 10.3171/2014.7.GKS141432
   Kakizawa Y, 2008, J NEUROSURG, V108, P483, DOI 10.3171/JNS/2008/108/3/0483
   Kondziolka D, 1996, J NEUROSURG, V84, P940, DOI 10.3171/jns.1996.84.6.0940
   Kotecha R, 2016, INT J RADIAT ONCOL, V96, P142, DOI 10.1016/j.ijrobp.2016.04.013
   Lee JYK, 2015, J NEUROSURG, V123, P961, DOI 10.3171/2014.12.JNS142013
   Marshall K, 2012, NEUROSURGERY, V70, P566, DOI 10.1227/NEU.0b013e3182320d36
   Mayneord WV, 1942, P PHYS SOC, V54, P405, DOI 10.1088/0959-5309/54/5/302
   Mohammed N, 2019, WORLD NEUROSURG, V125, pE1114, DOI 10.1016/j.wneu.2019.01.253
   Mousavi SH, 2018, J NEUROSURG, V128, P452, DOI 10.3171/2016.10.JNS16747
   Patra DP, 2019, J NEUROSURG, V131, P1197, DOI 10.3171/2018.5.JNS18583
   Regis J, 2006, J NEUROSURG, V104, P913, DOI 10.3171/jns.2006.104.6.913
   ROBERTS J E, 1954, Acta Radiol Suppl, V116, P510
   Shrivastava A, 2019, WORLD NEUROSURG, V125, pE1104, DOI 10.1016/j.wneu.2019.01.252
   Trifiletti DM, 2015, INT J RADIAT ONCOL, V93, P870, DOI 10.1016/j.ijrobp.2015.07.2280
   Wolf A, 2018, J NEUROSURG, V128, P891, DOI 10.3171/2016.12.JNS161862
NR 18
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E375
EP E380
DI 10.1016/j.wneu.2019.05.155
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900047
PM 31132503
DA 2020-05-12
ER

PT J
AU Sun, B
   Shi, CG
   Xu, Z
   Wu, HQ
   Zhang, Y
   Chen, Y
   Wu, XD
   Yuan, W
AF Sun, Bin
   Shi, Changgui
   Xu, Zeng
   Wu, Huiqiao
   Zhang, Ying
   Chen, Yu
   Wu, Xiao-Dong
   Yuan, Wen
TI Learning Curve for Percutaneous Endoscopic Lumbar Diskectomy in
   Bi-needle Technique Using Cumulative Summation Test for Learning Curve
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bi-needle technique; Cumulative summation; Learning curve; Lumbar disk
   herniation; Percutaneous endoscopic lumbar diskectomy
ID DISC HERNIATION; MICRODISCECTOMY; PROFICIENT; SURGERY; CUSUM
AB BACKGROUND: The purpose of this study was to determine the number of cases needed to achieve the level of competence for percutaneous endoscopic lumbar diskectomy (PELD) via the bi-needle technique using the cumulative summation test for learning curve (LC-CUSUM).
   METHODS:A retrospective design was used. We included 60 patients who underwent a single-level PELD via the bi-needle technique performed by a single surgeon. The surgeon had 5 years of experience in open surgery including the transforaminal endoscopic spine system and Yeung endoscopic spine system but no experience in the bi-needle technique. Surgery success was defined as an operative time <60 minutes, and the acceptable procedure was completed within 3 times of C-arm fluoroscopies. The LC-CUSUM was used to analyze the data.
   RESULTS: The average operative time for PELD via the bi-needle technique was 58.3 +/- 12.4 minutes. The mean operative time was 65.7 +/- 12.1 minutes in the early learning period (30 cases) and 51.0 +/- 7.5 minutes in the late learning period (30 cases) (P < 0.05). On the basis of the evaluation indexes of the operative time and radioactive exposure, the LC-CUSUM signaled proficiency for the bi-needle technique at the 50th-54th operation. Seven cases of complications were observed during the whole learning process, with 6 in the early period and 1 in the late period (P < 0.05).
   CONCLUSIONS: The novel bi-needle technique is safe and effective for PELD with appropriate patients, and the learning curve is acceptable. A substantial learning period (50-54 cases) is needed before a spine surgeon can master the bi-needle technique.
C1 [Sun, Bin; Shi, Changgui; Xu, Zeng; Wu, Huiqiao; Zhang, Ying; Chen, Yu; Wu, Xiao-Dong; Yuan, Wen] Second Mil Med Univ, Changzheng Hosp, Dept Orthopaed, Shanghai, Peoples R China.
RP Yuan, W (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Orthopaed, Shanghai, Peoples R China.
EM yuanwencspine@163.com
FU National Natural Science Foundation of China, ChinaNational Natural
   Science Foundation of China [31200718]; Shanghai Municipal Natural
   Science Foundation, China [19ZR1456700]
FX This work was supported by the National Natural Science Foundation of
   China, China [31200718] and Shanghai Municipal Natural Science
   Foundation, China [19ZR1456700].
CR Ao SX, 2019, BIOMED RES INT, DOI 10.1155/2019/6509409
   Ao SX, 2018, WORLD NEUROSURG, V115, pE263, DOI 10.1016/j.wneu.2018.04.032
   Biau DJ, 2008, BRIT J SURG, V95, P925, DOI 10.1002/bjs.6056
   Blau DJ, 2008, ULTRASOUND OBST GYN, V31, P252, DOI 10.1002/uog.5270
   Chen Y, 2019, WORLD NEUROSURG, V122, pE1449, DOI 10.1016/j.wneu.2018.11.083
   Cheng YH, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011089
   Cong L, 2016, EUR SPINE J, V25, P134, DOI 10.1007/s00586-015-3776-6
   Dagash H, 2003, J PEDIATR SURG, V38, P720, DOI 10.1016/jpsu.2003.50192
   Dessolle L, 2010, HUM REPROD, V25, P380, DOI 10.1093/humrep/dep391
   Dessolle L, 2009, FERTIL STERIL, V92, P943, DOI 10.1016/j.fertnstert.2009.01.133
   Durban M, 2016, J ASSIST REPROD GEN, V33, P1009, DOI 10.1007/s10815-016-0686-4
   Gu X, 2013, CLIN ANAT, V26, P728, DOI 10.1002/ca.22286
   Kapetanakis S, 2017, J BACK MUSCULOSKELET, V30, P1311, DOI 10.3233/BMR-169702
   Kim M, 2018, BIOMED RES INT, DOI 10.1155/2018/9073460
   Lee YK, 2014, J ARTHROPLASTY, V29, P586, DOI 10.1016/j.arth.2013.07.023
   Liu XY, 2018, J NEUROSURG-SPINE, V28, P317, DOI 10.3171/2017.6.SPINE172
   MACNAB I, 1971, J BONE JOINT SURG AM, VA 53, P891, DOI 10.2106/00004623-197153050-00004
   Nellensteijn J, 2010, EUR SPINE J, V19, P879, DOI 10.1007/s00586-009-1272-6
   Ng CLL, 2015, EUR SPINE J, V24, pS361, DOI 10.1007/s00586-015-3876-3
   Parikh K, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC/2008/25/8/E14
   Park SM, 2019, WORLD NEUROSURG, V122, pE1007, DOI 10.1016/j.wneu.2018.10.197
   Park SM, 2018, WORLD NEUROSURG, V118, pE550, DOI 10.1016/j.wneu.2018.06.236
   Ruetten S, 2007, J NEUROSURG-SPINE, V6, P521, DOI 10.3171/spi.2007.6.6.521
   Staartjes VE, 2017, WORLD NEUROSURG, V107, P28, DOI [10.1016/J.WNEU.2017.07.121, 10.1016/j.wneu.2017.07.121]
   Wang HW, 2013, CLIN NEUROL NEUROSUR, V115, P1987, DOI 10.1016/j.clineuro.2013.06.008
   Wu XD, 2018, WORLD NEUROSURG, V119, pE53, DOI 10.1016/j.wneu.2018.06.220
   Wu XB, 2016, J ZHEJIANG UNIV-SC B, V17, P553, DOI 10.1631/jzus.B1600002
   Yao Y, 2017, WORLD NEUROSURG, V100, P1, DOI 10.1016/j.wneu.2016.12.089
   Yeung AT, 2002, SPINE, V27, P722, DOI 10.1097/00007632-200204010-00009
   Zhang MB, 2019, EUR SPINE J, V28, P2543, DOI 10.1007/s00586-019-05980-9
NR 30
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E586
EP E593
DI 10.1016/j.wneu.2019.05.227
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900075
PM 31158541
DA 2020-05-12
ER

PT J
AU Sun, ZM
   Jiang, C
   Xu, JJ
   Chen, ZX
   Guo, Q
   Lin, Y
   Wu, YS
AF Sun, Ze-Ming
   Jiang, Chao
   Xu, Jia-Jing
   Chen, Ze-Xin
   Guo, Qiang
   Lin, Yan
   Wu, Yao-Sen
TI Vacuum Facet Phenomenon in Computed Tomography Imaging: A Sign of
   Instability in Degenerative Spondylolisthesis?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Degenerative spondylolisthesis; Lumbar facet joint; Lumbar instability;
   Vacuum phenomenon
AB OBJECTIVE: The aim of the present study was to investigate the relationship between vacuum facet phenomena and lumbar instability in patients with degenerative spondylolisthesis (DS) in L4-L5.
   METHODS: Patients with L4-L5 DS who had both lumbosacral flexion-extension radiographs and computed tomography (CT) scans available for review from January 2016 to December 2017 were eligible for the present study. The dynamic motion index (DMI) of each patient was used to represent the percentage of slippage of L-L4 on the L5 vertebral disks on the flexion radiographs minus the percentage on the extension radiographs. The facet vacuum index refers to the average width of the facet vacuum on the left and right sides.
   RESULTS: A total of 67 patients with L4-L5 DS were included in the present study. Of the 67 patients, 35 had a vacuum facet phenomenon on their CTscan and 32 patients did not. The incidence of lumbar instability in the patients with a vacuum facet phenomenon was significantly greater than that in the patients without a vacuum facet phenomenon (P = 0.015). The mean DMI for the patients with a vacuum facet phenomenon was significantly greater than that for the patients without a vacuum facet phenomenon (P < 0.001). A positive linear correlation was found between the facet vacuum index and DMI for patients with a vacuum facet phenomenon (Pearson correlation coefficient, 0.597; P < 0.001).
   CONCLUSIONS: A linear correlation was found between the degree of segmental motion and the width of the vacuum facet phenomenon in patients with DS at L4-L5. Our study has shown that vacuum facet phenomena detected on the CT images of patients with DS are highly predictive of segmental instability.
C1 [Sun, Ze-Ming; Jiang, Chao; Xu, Jia-Jing; Chen, Ze-Xin; Guo, Qiang; Lin, Yan; Wu, Yao-Sen] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Wenzhou, Peoples R China.
   [Sun, Ze-Ming; Jiang, Chao; Xu, Jia-Jing; Chen, Ze-Xin; Guo, Qiang; Lin, Yan; Wu, Yao-Sen] Wenzhou Med Univ, Yuying Childrens Hosp, Dept Orthopaed Surg, Wenzhou, Peoples R China.
   [Sun, Ze-Ming; Jiang, Chao; Xu, Jia-Jing; Chen, Ze-Xin; Guo, Qiang; Lin, Yan; Wu, Yao-Sen] Wenzhou Med Univ, Zhejiang Prov Key Lab Orthopaed, Wenzhou, Peoples R China.
   [Sun, Ze-Ming; Jiang, Chao; Xu, Jia-Jing; Chen, Ze-Xin; Guo, Qiang] Wenzhou Med Univ, Sch Med 2, Wenzhou, Peoples R China.
RP Wu, YS (reprint author), Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Wenzhou, Peoples R China.; Wu, YS (reprint author), Wenzhou Med Univ, Yuying Childrens Hosp, Dept Orthopaed Surg, Wenzhou, Peoples R China.; Wu, YS (reprint author), Wenzhou Med Univ, Zhejiang Prov Key Lab Orthopaed, Wenzhou, Peoples R China.
EM wys9453@126.com
FU Wenzhou Municipal Science and Technology Bureau [Y20150063]
FX This work was supported by the Wenzhou Municipal Science and Technology
   Bureau (Y20150063).
CR ADAMS MA, 1981, SPINE, V6, P241, DOI 10.1097/00007632-198105000-00006
   Bambakidis NC, 2005, SPINE, V30, pS2, DOI 10.1097/01.brs.0000174509.31291.26
   Beazell JR, 2010, J MAN MANIP THER, V18, P9, DOI 10.1179/106698110X12595770849443
   Bendo J A, 2001, Am J Orthop (Belle Mead NJ), V30, P247
   BODEN SD, 1990, SPINE, V15, P571, DOI 10.1097/00007632-199006000-00026
   BRIDWELL KH, 1993, J SPINAL DISORD, V6, P461, DOI 10.1097/00002517-199306060-00001
   Caterini R, 2011, J ORTHOP TRAUMATOL, V12, P87, DOI 10.1007/s10195-011-0141-3
   Chaput C, 2007, SPINE, V32, P1883, DOI 10.1097/BRS.0b013e318113271a
   Cho BY, 2009, J NEUROSURG-SPINE, V11, P614, DOI 10.3171/2009.6.SPINE08413
   DUPUIS PR, 1985, SPINE, V10, P262, DOI 10.1097/00007632-198504000-00015
   FREDRICKSON BE, 1984, J BONE JOINT SURG AM, V66A, P699, DOI 10.2106/00004623-198466050-00008
   FRYMOYER JW, 1985, SPINE, V10, P280, DOI 10.1097/00007632-198504000-00017
   Fujiwara A, 2000, SPINE, V25, P3036, DOI 10.1097/00007632-200012010-00011
   Gohil I, 2014, CLIN ANAT, V27, P455, DOI 10.1002/ca.22334
   Iguchi T, 2004, J SPINAL DISORD TECH, V17, P284, DOI 10.1097/01.bsd.0000102473.95064.9d
   Lattig F, 2012, CLIN SPINE SURG, V28, P95
   Lattig F, 2012, EUR SPINE J, V21, P276, DOI 10.1007/s00586-011-1993-1
   Pfirrmann CWA, 2001, SPINE, V26, P1873, DOI 10.1097/00007632-200109010-00011
   Simmonds AM, 2015, J NEUROSURG-SPINE, V23, P178, DOI 10.3171/2014.11.SPINE1426
   Stallenberg B, 2001, AM J ROENTGENOL, V176, P1161, DOI 10.2214/ajr.176.5.1761161
   Wagner H, 2005, Pathophysiology, V12, P257, DOI 10.1016/j.pathophys.2005.09.007
   YANG KH, 1984, SPINE, V9, P557, DOI 10.1097/00007632-198409000-00005
NR 22
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E393
EP E400
DI 10.1016/j.wneu.2019.05.163
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900050
PM 31150862
DA 2020-05-12
ER

PT J
AU Tan, CX
   Mu, HC
   Duan, R
   Shi, GC
   Zhao, YL
   Chen, XL
   Ye, X
   Wang, R
AF Tan, Cunxin
   Mu, Hongchuan
   Duan, Ran, I
   Shi, Guangchao
   Zhao, Yuanli
   Chen, Xiaolin
   Ye, Xun
   Wang, Rong
TI Abnormal Embryonic Development of Cerebral Arteries as a Potential Cause
   of Moyamoya Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral artery development; Embryology; Moyamoya disease
AB OBJECTIVE: Moyamoya disease (MMD) is a cerebrovascular disorder, currently defined as progressive stenosis of intracranial internal carotid artery and its main branches with secondary formation of netlike vessels. Its precise formation mechanism, however, is unknown. We propose that MMD is caused by abnormal embryonic development of the cerebral arteries and also propose a mechanism for MMD formation.
   METHODS: The anterior, middle, and posterior cerebral arteries, anterior choroidal arteries (AChoA) and posterior choroidal arteries, and posterior corpus callosum arteries were analyzed separately for each patient with MMD to determine whether the arteries exhibited the following characteristics, which we regarded as remnants of primitive vessels: 1) plexiform arteries rather than normal artery trunks; 2) clustered arteries converging at locations of normal artery trunks; and 3) dilated AChoA.
   RESULTS: We retrospectively analyzed 39 consecutive patients with MMD, of whom 30 had anterior cerebral arteries, 31 middle cerebral arteries, 10 posterior cerebral arteries, 30 AChoAs, 18 posterior choroidal arteries, and 20 posterior corpus callosum arteries and had the characteristics of primitive vessel remnants. Altogether, 82.05% of the patients had the remnants of primitive vessels.
   CONCLUSIONS: MMD is more likely to be caused by abnormalities of cerebral artery development, which mainly occur in the embryonic period or postnatally. The abnormality developing processes include sprouting angiogenesis, vessel fusion, and pruning, which primarily affect cranial ramus of primitive internal carotid artery, may occasionally affect the caudal ramus of the primitive internal carotid artery, and rarely affect the vertebrobasilar artery system. So-called moyamoya vessels comprise un-fused primitive small vessels; to compensate, enlarged AChoAs remain undegenerated but are not dilated.
C1 [Tan, Cunxin; Mu, Hongchuan; Duan, Ran, I; Zhao, Yuanli; Chen, Xiaolin; Ye, Xun; Wang, Rong] Peking Univ Int Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Shi, Guangchao; Zhao, Yuanli; Chen, Xiaolin; Ye, Xun; Wang, Rong] Beijing Tiantan Hosp Capital Med Univ, Dept Neurosurg, Beijing, Peoples R China.
RP Wang, R (reprint author), Peking Univ Int Hosp, Dept Neurosurg, Beijing, Peoples R China.; Wang, R (reprint author), Beijing Tiantan Hosp Capital Med Univ, Dept Neurosurg, Beijing, Peoples R China.
EM ronger090614@126.com
OI Duan, Ran/0000-0003-1475-2193
FU Training Plan of High-level Technical Talents in Beijing Health System
   [2015-3-041]
FX This work was supported by the Training Plan of High-level Technical
   Talents in Beijing Health System (2015-3-041).
CR Feinberg RN, 1991, DEV VASCULAR SYSTEM, P1
   JEANMART L, 1974, ANGIOLOGY, V25, P334, DOI 10.1177/000331977402500505
   Kamada F, 2011, J HUM GENET, V56, P34, DOI 10.1038/jhg.2010.132
   Kamata I, 2003, ACTA MED OKAYAMA, V57, P143
   Kimiwada T, 2018, J NEUROSURG-PEDIATR, V21, P632, DOI 10.3171/2018.1.PEDS17367
   Kuroda S, 2006, DIG WORLD CORE MED J, V36, P2148
   Kuroda S, 2008, LANCET NEUROL, V7, P1056, DOI 10.1016/S1474-4422(08)70240-0
   MOFFAT D B, 1962, Ann R Coll Surg Engl, V30, P368
   MOFFAT DB, 1961, J ANAT, V95, P485
   Ooi YC, 2016, AM J NEURORADIOL, V37, P1086, DOI 10.3174/ajnr.A4675
   Padget Dorcas Hager, 1948, CONTRIBUTIONS TO EMBRYOLOGY [CARNEGIE INST OF WASHINGTON PUBL], V32, P205
   Plate KH, 1999, J NEUROPATH EXP NEUR, V58, P313, DOI 10.1097/00005072-199904000-00001
   Research Committee on the Pathology Treatment of Spontaneous Occlusion of the Circle of Willis, 2012, NEUROL MED CHIR TOKY, V52, P245, DOI DOI 10.2176/NMC.52.245
   Scott RM, 2009, NEW ENGL J MED, V360, P1226, DOI 10.1056/NEJMra0804622
   Shusuke Y, 2019, WORLD NEUROSURG, V122, pe253
   SUZUKI J, 1969, ARCH NEUROL-CHICAGO, V20, P288, DOI 10.1001/archneur.1969.00480090076012
   Takeuchi K, 1957, BRAIN NERVE, V9, P37
   Tan CX, 2016, WORLD NEUROSURG, V96, P222, DOI 10.1016/j.wneu.2016.08.099
   Tanaka M, 2012, J STROKE CEREBROVASC, V21, P373, DOI 10.1016/j.jstrokecerebrovasdis.2010.10.001
NR 19
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E224
EP E232
DI 10.1016/j.wneu.2019.05.116
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900028
PM 31125778
DA 2020-05-12
ER

PT J
AU Tommiska, P
   Lonnrot, K
   Raj, R
   Luostarinen, T
   Kivisaari, R
AF Tommiska, Pihla
   Lonnrot, Kimmo
   Raj, Rahul
   Luostarinen, Teemu
   Kivisaari, Riku
TI Transition of a Clinical Practice to Use of Subdural Drains after Burr
   Hole Evacuation of Chronic Subdural Hematoma: The Helsinki Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Burr hole; Chronic subdural hematoma; Drain; Neurosurgery; Recurrence;
   Subdural drain; Surgery
ID CLOSED-SYSTEM DRAINAGE; INTERNATIONAL SURVEY; QUESTIONNAIRE SURVEY;
   RISK-FACTORS; MANAGEMENT; RECURRENCE; SUBACUTE; IRRIGATION; PREDICTORS;
   PLACEMENT
AB BACKGROUND: A number of randomized controlled trials have shown the benefit of drain placement in the operative treatment of chronic subdural hematoma (CSDH); however, few reports have described real-life results after adoption of drain placement into clinical practice. We report the results following a change in practice at Helsinki University Hospital from no drain to subdural drain (SD) placement after burr hole craniostomy for CSDH.
   METHODS: We conducted a retrospective observational study of consecutive patients undergoing burr hole craniostomy for CSDH. We compared outcomes between a 6-month period when SD placement was arbitrary (Julye December 2015) and a period when SD placement for 48 hours was routine (July-December 2017). Our primary outcome of interest was recurrence of CSDH necessitating reoperation within 6 months. Patient outcomes, infections, and other complications were assessed as well.
   RESULTS: A total of 161 patients were included, comprising 71 (44%) in the drain group and 90 (56%) in the non-drain group. There were no significant differences in age, comorbidities, history of trauma, or use of antithrombotic agents between the 2 groups (P > 0.05 for all). Recurrence within 6 months occurred in 18% of patients in the non-drain group, compared with 6% in the drain group (odds ratio, 0.28; 95% confidence interval, 0.09-0.87; P = 0.028). There were no differences in neurologic outcomes (P = 0.72), mortality (P = 0.55), infection rate (P = 0.96), or other complications (P = 0.20).
   CONCLUSIONS: The change in practice from no drain to use of an SD after burr hole craniostomy for CSDH effectively reduced the 6-month recurrence rate with no effect on patient outcomes, infections, or other complications.
C1 [Tommiska, Pihla; Lonnrot, Kimmo; Raj, Rahul; Kivisaari, Riku] Univ Helsinki, Dept Neurosurg, Helsinki, Finland.
   [Tommiska, Pihla; Lonnrot, Kimmo; Raj, Rahul; Luostarinen, Teemu; Kivisaari, Riku] Helsinki Univ Hosp, Helsinki, Finland.
   [Luostarinen, Teemu] Univ Helsinki, Dept Anesthesiol Intens Cate & Pain Med, Div Anesthesiol, Helsinki, Finland.
RP Tommiska, P (reprint author), Univ Helsinki, Dept Neurosurg, Helsinki, Finland.; Tommiska, P (reprint author), Helsinki Univ Hosp, Helsinki, Finland.
EM pihla.tommiska@helsinki.fi
RI Raj, Rahul/K-7693-2012
OI Raj, Rahul/0000-0003-4243-9591; Lonnrot, Kimmo/0000-0003-4361-1007;
   Tommiska, Pihla/0000-0002-7418-1946
CR Adeolu AA, 2012, BRIT J NEUROSURG, V26, P743, DOI 10.3109/02688697.2012.690912
   Ahmed S, 2011, INDIAN J NEUROTRAUM, V8, P17, DOI 10.1016/S0973-0508(11)80019-5
   Avanali R, 2016, WORLD NEUROSURG, V96, P355, DOI 10.1016/j.wneu.2016.09.010
   Baechli H, 2004, NEUROSURG REV, V27, P263, DOI 10.1007/s10143-004-0337-6
   Banks JL, 2007, STROKE, V38, P1091, DOI 10.1161/01.STR.0000258355.23810.c6
   Borger V, 2012, ACTA NEUROCHIR, V154, P1549, DOI 10.1007/s00701-012-1434-x
   Carlsen JG, 2011, BRIT J NEUROSURG, V25, P388, DOI 10.3109/02688697.2011.558945
   Cenic A, 2005, CAN J NEUROL SCI, V32, P501, DOI 10.1017/S0317167100004510
   Coleman MP, 2014, LANCET, V383, P564, DOI 10.1016/S0140-6736(13)62225-4
   Fomchenko EI, 2018, CURR TREAT OPTION NE, V20, DOI 10.1007/s11940-018-0518-1
   Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799
   Guilfoyle MR, 2017, ACTA NEUROCHIR, V159, P903, DOI 10.1007/s00701-017-3095-2
   Iftikhar M, 2016, J NEUROL SURG PART A, V77, P416, DOI 10.1055/s-0035-1564049
   Ivamoto HS, 2016, WORLD NEUROSURG, V86, P399, DOI 10.1016/j.wneu.2015.10.025
   Jablawi F, 2017, WORLD NEUROSURG, V100, P480, DOI 10.1016/j.wneu.2017.01.037
   JAMJOOM A, 1992, BRIT J NEUROSURG, V6, P27, DOI 10.3109/02688699209002898
   Leroy HA, 2015, J CLIN NEUROSCI, V22, P1895, DOI 10.1016/j.jocn.2015.03.064
   Lind CRP, 2003, J NEUROSURG, V99, P44, DOI 10.3171/jns.2003.99.1.0044
   Liu WM, 2014, J NEUROSURG, V121, P665, DOI 10.3171/2014.5.JNS132715
   Matsumoto H, 2018, J CLIN NEUROSCI, V49, P40, DOI 10.1016/j.jocn.2017.11.009
   Miranda LB, 2011, J NEUROSURG, V114, P72, DOI 10.3171/2010.8.JNS10298
   Oral S, 2015, NORTH CLIN ISTANB, V2, P115, DOI 10.14744/nci.2015.06977
   Roche N, 2013, LANCET RESP MED, V1, pE29, DOI 10.1016/S2213-2600(13)70199-1
   Santarius T, 2008, BRIT J NEUROSURG, V22, P529, DOI 10.1080/02688690802195381
   Santarius Thomas, 2010, Clin Neurosurg, V57, P112
   Santarius T, 2009, LANCET, V374, P1067, DOI 10.1016/S0140-6736(09)61115-6
   Schwarz F, 2015, CLIN NEUROL NEUROSUR, V138, P66, DOI 10.1016/j.clineuro.2015.08.002
   SCOTTI G, 1977, J NEUROSURG, V47, P311, DOI 10.3171/jns.1977.47.3.0311
   Singh AK, 2014, NEUROL INDIA, V62, P169, DOI 10.4103/0028-3886.132364
   Sivaraju L, 2018, NEUROSURG REV, V41, P165, DOI 10.1007/s10143-017-0831-2
   Sjavik K, 2017, J NEUROSURG, V23, P1, DOI DOI 10.3171/2016.12.JNS161713
   Smith MD, 2012, INT J SURG, V10, P450, DOI 10.1016/j.ijsu.2012.08.005
   Soleman J, 2017, WORLD NEUROSURG, V107, P778, DOI 10.1016/j.wneu.2017.08.065
   Soleman J, 2017, WORLD NEUROSURG, V104, P528, DOI 10.1016/j.wneu.2017.04.134
   Tailor J, 2017, ACTA NEUROCHIR, V159, P627, DOI 10.1007/s00701-016-3063-2
   Tsutsumi K, 1997, J NEUROSURG, V87, P870, DOI 10.3171/jns.1997.87.6.0870
   WAKAI S, 1990, NEUROSURGERY, V26, P771, DOI 10.1227/00006123-199005000-00006
   Wang H, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000013972
   Xu C, 2016, NEUROL MED-CHIR, V56, P62, DOI 10.2176/nmc.ra.2015-0013
   Yuan Y, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011827
NR 40
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E614
EP E626
DI 10.1016/j.wneu.2019.05.230
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900078
PM 31158547
DA 2020-05-12
ER

PT J
AU Udawatta, M
   Kwan, I
   Preet, K
   Nguyen, T
   Ong, V
   Sheppard, JP
   Duong, C
   Romiyo, P
   Lee, P
   Tenn, S
   Kaprealian, T
   Gopen, Q
   Yang, I
AF Udawatta, Methma
   Kwan, Isabelle
   Preet, Komal
   Thien Nguyen
   Ong, Vera
   Sheppard, John P.
   Duong, Courtney
   Romiyo, Prasanth
   Lee, Percy
   Tenn, Stephen
   Kaprealian, Tania
   Gopen, Quinton
   Yang, Isaac
TI Hearing Preservation for Vestibular Schwannomas Treated with
   Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Fractionated stereotactic radiotherapy; Hypofractionated stereotactic
   radiotherapy; Stereotactic radiosurgery; Vestibular schwannoma
ID QUALITY-OF-LIFE; GAMMA-KNIFE RADIOSURGERY; SINGLE-INSTITUTION
   EXPERIENCE; ACOUSTIC NEUROMAS; CONSERVATIVE MANAGEMENT; TUMOR-CONTROL;
   RADIATION-THERAPY; FOLLOW-UP; OUTCOMES; GROWTH
AB BACKGROUND: Vestibular schwannomas (VS) are benign intracranial neoplasms arising from the eighth cranial nerve for which targeted radiation therapy (RT) has proved increasingly successful. However, long-term hearing and related cranial nerve outcomes have been disputed for the 3 current RT modalities.
   OBJECTIVE: To determine differences in hearing preservation for patients treated with stereotactic radiosurgery (SRS), fractionated stereotactic radiotherapy (FSRT), or hypofractionated stereotactic radiotherapy (hypoFSRT) for VS.
   METHODS: A retrospective electronic chart review was conducted for all patients with unilateral VS treated with primary RT at a single academic medical center between 2000 and 2017. The primary outcome measure was preservation of serviceable hearing status in the affected ear at last follow-up. Secondary outcomes included tinnitus, vertigo, and imbalance.
   RESULTS: A total of 33 FSRT cases, 21 SRS cases, and 6 hypoFSRT cases were identified. Postoperative deterioration in serviceable hearing and tinnitus showed significant differences across cohorts. The SRS cohort had a higher baseline incidence of nonserviceable hearing and disequilibrium compared with other cohorts before RT (P = 0.001 and 0.022, respectively); no differences in baseline morbidity were observed for vertigo and tinnitus. The 5-year tumor control rate was 95.2%, 93.9%, and 100% with SRS, FSRT, and hypoFSRT, respectively.
   CONCLUSIONS: Our series indicated an excellent tumor control rate in all the modalities. Our SRS cohort showed increased incidence and shorter time to hearing deterioration compared with the FSRT and hypoFSRT cohorts. The FSRT and hypoFSRT cohorts have shown comparable overall outcomes. Onset of post-RT tinnitus was observed only with FSRT.
C1 [Udawatta, Methma; Kwan, Isabelle; Preet, Komal; Thien Nguyen; Ong, Vera; Sheppard, John P.; Duong, Courtney; Romiyo, Prasanth; Kaprealian, Tania; Yang, Isaac] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA 90095 USA.
   [Lee, Percy; Tenn, Stephen; Kaprealian, Tania; Yang, Isaac] Univ Calif Los Angeles, Dept Radiat Oncol, Los Angeles, CA 90024 USA.
   [Gopen, Quinton; Yang, Isaac] Univ Calif Los Angeles, Dept Head & Neck Surg, Los Angeles, CA 90095 USA.
   [Kaprealian, Tania; Yang, Isaac] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
   [Yang, Isaac] Univ Calif Los Angeles, Los Angeles Biomed Res Inst, Los Angeles, CA 90095 USA.
   [Yang, Isaac] Univ Calif Los Angeles, Harbor UCLA Med Ctr, Los Angeles, CA 90095 USA.
   [Udawatta, Methma; Preet, Komal; Thien Nguyen; Sheppard, John P.; Yang, Isaac] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Yang, I (reprint author), Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA 90095 USA.; Yang, I (reprint author), Univ Calif Los Angeles, Dept Radiat Oncol, Los Angeles, CA 90024 USA.; Yang, I (reprint author), Univ Calif Los Angeles, Dept Head & Neck Surg, Los Angeles, CA 90095 USA.; Yang, I (reprint author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.; Yang, I (reprint author), Univ Calif Los Angeles, Los Angeles Biomed Res Inst, Los Angeles, CA 90095 USA.; Yang, I (reprint author), Univ Calif Los Angeles, Harbor UCLA Med Ctr, Los Angeles, CA 90095 USA.; Yang, I (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
EM iyang@mednet.ucla.edu
RI Kwan, Isabelle/AAM-5526-2020; Duong, Courtney/AAD-4121-2019
OI Kwan, Isabelle/0000-0002-9957-755X; Ong, Vera/0000-0003-0522-7493;
   Udawatta, Methma/0000-0002-5225-7006
FU David Geffen Medical Scholarships; UCLA Visionary Ball Fund Grant; Eli
   and Edythe Broad Center of Regenerative Medicine and Stem Cell Research
   UCLA Scholars in Translational Medicine Program Award; Jason Dessel
   Memorial Seed Grant; UCLA Honberger Endowment Brain Tumor Research Seed
   Grant; Stryker Research Award; Stop Cancer (US) Research Career
   Development Award
FX M.U., T.N., and J.P.S. are supported by David Geffen Medical
   Scholarships. I.Y. is supported by the UCLA Visionary Ball Fund Grant,
   Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell
   Research UCLA Scholars in Translational Medicine Program Award, Jason
   Dessel Memorial Seed Grant, UCLA Honberger Endowment Brain Tumor
   Research Seed Grant, Stryker Research Award, and Stop Cancer (US)
   Research Career Development Award.
CR Agrawal Y, 2010, OTOL NEUROTOL, V31, P807, DOI 10.1097/MAO.0b013e3181de46ae
   Anderson BM, 2014, J NEURO-ONCOL, V116, P187, DOI 10.1007/s11060-013-1282-4
   [Anonymous], 1994, Arch Neurol, V51, P201
   Aoyama H, 2013, INT J RADIAT ONCOL, V85, P329, DOI 10.1016/j.ijrobp.2012.05.003
   Apicella G, 2016, REP PRACT ONCOL RADI, V21, P399, DOI 10.1016/j.rpor.2016.02.002
   Baguley D, 2013, LANCET, V382, P1600, DOI 10.1016/S0140-6736(13)60142-7
   Bhandare N, 2010, INT J RADIAT ONCOL, V76, pS50, DOI 10.1016/j.ijrobp.2009.04.096
   Boari N, 2014, J NEUROSURG, V121, P123, DOI 10.3171/2014.8.GKS141506
   Breivik CN, 2013, NEUROSURGERY, V73, P48, DOI 10.1227/01.neu.0000429862.50018.b9
   Carlson ML, 2015, J NEUROSURG, V122, P833, DOI 10.3171/2014.11.JNS14594
   Casentini L, 2015, J NEUROSURG, V122, P818, DOI 10.3171/2014.11.JNS131552
   Champ CE, 2013, NEUROSURGERY, V73, P489, DOI 10.1227/NEU.0000000000000019
   Combs SE, 2013, RADIOTHER ONCOL, V106, P175, DOI 10.1016/j.radonc.2012.12.004
   Evans DGR, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-16
   Foley RW, 2017, CUREUS, V9, DOI 10.7759/cureus.1846
   Gait C, 2014, CLIN OTOLARYNGOL, V39, P22, DOI 10.1111/coa.12205
   Godefroy WP, 2009, OTOL NEUROTOL, V30, P968, DOI 10.1097/MAO.0b013e3181b4e3c9
   Grauvogel J, 2010, NEUROSURGERY, V67, P601, DOI 10.1227/01.NEU.0000374725.19259.EA
   Hansasuta A, 2011, NEUROSURGERY, V69, P1200, DOI 10.1227/NEU.0b013e318222e451
   Hasegawa T, 2013, J NEUROSURG, V118, P557, DOI 10.3171/2012.10.JNS12523
   Hoistad DL, 2001, OTOL NEUROTOL, V22, P682, DOI 10.1097/00129492-200109000-00021
   Jethanamest D, 2015, LARYNGOSCOPE, V125, P2163, DOI 10.1002/lary.25159
   Kim YH, 2013, INT J RADIAT ONCOL, V85, P61, DOI 10.1016/j.ijrobp.2012.03.036
   Kshettry VR, 2015, J NEURO-ONCOL, V124, P223, DOI 10.1007/s11060-015-1827-9
   Leong SC, 2015, OTOL NEUROTOL, V36, P486, DOI 10.1097/MAO.0000000000000556
   Litre F, 2013, RADIOTHER ONCOL, V106, P169, DOI 10.1016/j.radonc.2012.10.013
   Liu WM, 2015, WORLD NEUROSURG, V84, P283, DOI 10.1016/j.wneu.2015.03.013
   Lustig LR, 1998, AM J OTOL, V19, P212
   Mahadevan A, 2011, COMPUT AIDED SURG, V16, P112, DOI 10.3109/10929088.2011.565160
   Matthies C, 1997, NEUROSURGERY, V40, P1
   McWilliams W, 2011, OTOL NEUROTOL, V32, P297, DOI 10.1097/MAO.0b013e318206fdde
   Meijer OWM, 2003, INT J RADIAT ONCOL, V56, P1390, DOI 10.1016/S0360-3016(03)00444-9
   Mindermann T, 2014, ACTA NEUROCHIR, V156, P1121, DOI 10.1007/s00701-014-2063-3
   Morrison D, 2010, LARYNGOSCOPE, V120, P783, DOI 10.1002/lary.20819
   Myrseth E, 2005, NEUROSURGERY, V56, P927, DOI 10.1227/01.NEU.0000158315.64079.0A
   Overdevest JB, 2016, LARYNGOSCOPE, V126, P1639, DOI 10.1002/lary.25672
   Paldor I, 2016, J CLIN NEUROSCI, V32, P1, DOI 10.1016/j.jocn.2016.05.003
   Patel MA, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00200
   Pawlik TM, 2004, INT J RADIAT ONCOL, V59, P928, DOI 10.1016/j.ijrobp.2004.03.005
   Peng KA, 2016, J LARYNGOL OTOL, V130, P606, DOI 10.1017/S0022215116007969
   Persson O, 2017, ACTA NEUROCHIR, V159, P1013, DOI 10.1007/s00701-017-3164-6
   Pollock BE, 2006, NEUROSURGERY, V59, P77, DOI 10.1227/01.NEU.0000219217.14930.14
   R Core Team, 2017, R LANG ENV STAT COMP
   Regis Jean, 2008, Prog Neurol Surg, V21, P142, DOI 10.1159/000156901
   Robinett ZN, 2014, OTOLARYNG HEAD NECK, V150, P1024, DOI 10.1177/0194599814524531
   Roche PH, 2012, OTOLARYNG CLIN N AM, V45, P367, DOI 10.1016/j.otc.2011.12.007
   Rosahl Steffen, 2017, GMS Curr Top Otorhinolaryngol Head Neck Surg, V16, pDoc03, DOI 10.3205/cto000142
   Song DY, 1999, STEREOT FUNCT NEUROS, V73, P45, DOI 10.1159/000029750
   Sughrue ME, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.9.FOCUS09198
   Teo M, 2016, WORLD NEUROSURG, V93, P398, DOI 10.1016/j.wneu.2016.06.080
   Therneau T. M., 2015, PACKAGE SURVIVAL ANA
   Therneau TM, 2000, STAT BIOL HEALTH
   Nguyen T, 2018, CLIN NEUROL NEUROSUR, V166, P116, DOI 10.1016/j.clineuro.2018.01.005
   Timmer FCA, 2011, ANN OTO RHINOL LARYN, V120, P807, DOI 10.1177/000348941112001206
   Torres-Russotto D, 2009, NEUROLOGY, V72, P1595, DOI 10.1212/WNL.0b013e3181a41280
   Tsai JT, 2013, BIOMED RES INT, DOI 10.1155/2013/297093
   Tveiten OV, 2015, NEUROSURGERY, V77, P218, DOI 10.1227/NEU.0000000000000760
   van de Langenberg R, 2011, OTOL NEUROTOL, V32, P338, DOI 10.1097/MAO.0b013e3182040d9f
   Varughese JK, 2012, J NEUROSURG, V116, P706, DOI 10.3171/2011.12.JNS111662
   Vernimmen FJAI, 2009, RADIOTHER ONCOL, V90, P208, DOI 10.1016/j.radonc.2008.11.004
   Vivas EX, 2014, OTOL NEUROTOL, V35, P162, DOI 10.1097/MAO.0b013e3182a435f5
   Wangerid T, 2014, ACTA NEUROCHIR, V156, P389, DOI 10.1007/s00701-013-1924-5
   Williams JA, 2002, INT J RADIAT ONCOL, V54, P500, DOI 10.1016/S0360-3016(02)02763-3
   Woolf DK, 2013, CLIN ONCOL-UK, V25, P734, DOI 10.1016/j.clon.2013.08.002
NR 64
TC 2
Z9 2
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E303
EP E310
DI 10.1016/j.wneu.2019.05.133
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900037
PM 31132496
DA 2020-05-12
ER

PT J
AU Wang, CH
   Niu, XD
   Ren, YM
   Lan, ZG
   Zhang, YK
AF Wang, Chenghong
   Niu, Xiaodong
   Ren, Yanming
   Lan, Zhigang
   Zhang, Yuekang
TI Risk Factors for Postoperative Intracranial Hemorrhage After Resection
   of Intracranial Tumor in 2259 Consecutive Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Age; International normalized ratio; Intracranial tumor; Postoperative
   hemorrhage; Tumor size
ID CHRONIC SUBDURAL-HEMATOMA; RECURRENCE; SURGERY; POSTURE
AB BACKGROUND: Postoperative hemorrhage (POH), an uncommon complication after cranial operation, may result in prolonged postoperative hospitalization, severe neurologic impairment, or even death. Most models in studies detecting risk factors for POH include all kinds of cranial lesions; however, factors associated with POH may vary among intracranial diseases. There is a paucity of large sample studies focusing solely on POH after intracranial tumor surgery. Therefore, this study was designed to investigate the preoperative risk factors for POH after surgery for intracranial tumor.
   METHODS: Medical records of 2259 adult patients who underwent primary surgical resection of single intracranial tumor between January 2017 and June 2018 at West China Hospital of Sichuan University were retrospectively studied. Univariate and multivariate analyses were performed to identify the risk factors for POH after resection of intracranial tumor.
   RESULTS: POH (defined as postoperative hematoma requiring surgical evacuation) occurred in 40 of 2259 patients (1.8%). Univariate analysis revealed that older age (P = 0.037, Wilcoxon-Mann-Whitney test), higher international normalized ratio (INR) (P = 0.037, Wilcoxon-Mann-Whitney test), and larger tumor size (P = 0.001, Wilcoxon-Mann-Whitney test) were significantly associated with POH. Then it was confirmed by multivariate analysis that all of the 3 factors (older age: P = 0.033, higher INR: P = 0.044, larger tumor size: P = 0.002) were independent risk factors for POH after removal of intracranial tumor.
   CONCLUSIONS: Older age, higher INR, and larger tumor size were identified as independent risk factors for POH after resection of intracranial tumor in adults.
C1 [Wang, Chenghong; Niu, Xiaodong; Ren, Yanming; Lan, Zhigang; Zhang, Yuekang] Sichuan Univ, Dept Neurosurg, West China Hosp, Chengdu, Sichuan, Peoples R China.
RP Zhang, YK (reprint author), Sichuan Univ, Dept Neurosurg, West China Hosp, Chengdu, Sichuan, Peoples R China.
EM zhangykneurosurg@sina.com
FU Department of Science and Technology of Sichuan Province [0040205302272]
FX This work was supported by Department of Science and Technology of
   Sichuan Province (grant number 0040205302272).
CR Abouzari M, 2007, NEUROSURGERY, V61, P794, DOI 10.1227/01.NEU.0000298908.94129.67
   Basali A, 2000, ANESTHESIOLOGY, V93, P48, DOI 10.1097/00000542-200007000-00012
   Brell M, 2000, ACTA NEUROCHIR, V142, P739, DOI 10.1007/s007010070088
   Burbury KL, 2011, BRIT J HAEMATOL, V154, P626, DOI 10.1111/j.1365-2141.2011.08787.x
   CHAN KH, 1989, J NEUROSURG, V71, P38, DOI 10.3171/jns.1989.71.1.0038
   Desai VR, 2016, CUREUS, V8, DOI 10.7759/cureus.616
   Douketis JD, 2012, CHEST, V141, pE326S, DOI 10.1378/chest.11-2298
   Gerlach R, 2003, NEUROSURGERY, V53, P1028, DOI 10.1227/01.NEU.0000088565.15719.22
   Gerlach R, 2002, STROKE, V33, P1618, DOI 10.1161/01.STR.0000017219.83330.FF
   Gerlach R, 2000, SURG NEUROL, V54, P260, DOI 10.1016/S0090-3019(00)00308-6
   Kageji T, 2017, OPER NEUROSURG, V13, P392, DOI 10.1093/ons/opw045
   KALFAS IH, 1988, NEUROSURGERY, V23, P343, DOI 10.1227/00006123-198809000-00010
   Lassen B, 2011, NEUROSURGERY, V68, P1259, DOI 10.1227/NEU.0b013e31820c0441
   Nakajima H, 2002, SURG NEUROL, V58, P385, DOI 10.1016/S0090-3019(02)00921-7
   PALMER JD, 1994, NEUROSURGERY, V35, P1061, DOI 10.1227/00006123-199412000-00007
   Raabe A, 2001, ACTA NEUROCHIR, V143, P1, DOI 10.1007/s007010170131
   Seifman MA, 2011, NEUROSURG REV, V34, P393, DOI 10.1007/s10143-010-0304-3
   Yamamoto H, 2003, J NEUROSURG, V98, P1217, DOI 10.3171/jns.2003.98.6.1217
   Zhang F, 2018, WORLD NEUROSURG, V119, pE703, DOI 10.1016/j.wneu.2018.07.251
   Zheng J, 2018, WORLD NEUROSURG, V114, pE756, DOI 10.1016/j.wneu.2018.03.077
NR 20
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E663
EP E668
DI 10.1016/j.wneu.2019.05.239
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900084
PM 31176060
DA 2020-05-12
ER

PT J
AU Waqas, M
   Rajabzadeh-Oghaz, H
   Tutino, VM
   Vakharia, K
   Poppenberg, KE
   Mowla, A
   Meng, H
   Siddiqui, AH
AF Waqas, Muhammad
   Rajabzadeh-Oghaz, Hamidreza
   Tutino, Vincent M.
   Vakharia, Kunal
   Poppenberg, Kerry E.
   Mowla, Ashkan
   Meng, Hui
   Siddiqui, Adnan H.
TI Morphologic Parameters and Location Associated with Rupture Status of
   Intracranial Aneurysms in Elderly Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aspect ratio; Elderly population; Intracranial aneurysms; Shape; Size
   ratio; Undulation index
ID ASPECT RATIO; CEREBRAL ANEURYSMS; SIZE RATIO; RISK; SHAPE
AB BACKGROUND: Treatment of unruptured intracranial aneurysms (IAs) in elderly patients is associated with a high risk of morbidity and mortality, necessitating a thorough understanding of the potential rupture risk. The aim of this study was to identify morphologic parameters and anatomic locations that could discriminate ruptured IAs in patients >= 70 years old.
   METHODS: Retrospective analysis was performed of three-dimensional angiograms and medical records of 344 patients with 411 saccular IAs. Patients >= 70 years old were defined as elderly. IAs were subdivided into ruptured and unruptured. Morphologic parameters and anatomic locations were compared in elderly and younger (<70 years old) patients with ruptured and unruptured IAs.
   RESULTS: The study included 266 patients <70 years old and 78 patients >= 70 years old with 411 aneurysms (102 ruptured and 309 unruptured). In the elderly group, 22 of 95 aneurysms were ruptured (23.15%) compared with 80 of 316 (25.3%) in the younger group. Size ratio and aspect ratio were higher in ruptured IAs, but only in the younger group. Undulation index, indicating IA shape irregularity, was significantly different between ruptured and unruptured IAs in younger and elderly groups. The only variables associated with rupture in the elderly group were undulation index (0.11 +/- 0.07 vs. 0.07 +/- 0.06, P = 0.02) and location (P = 0.001).
   CONCLUSIONS: Aneurysm size, size ratio, and aspect ratio may not be reliable discriminants of rupture in elderly patients. Unruptured IAs in elderly patients should be evaluated on the basis of shape irregularity and anatomic location.
C1 [Waqas, Muhammad; Tutino, Vincent M.; Vakharia, Kunal; Meng, Hui; Siddiqui, Adnan H.] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Neurosurg, Buffalo, NY 14260 USA.
   [Rajabzadeh-Oghaz, Hamidreza; Tutino, Vincent M.; Poppenberg, Kerry E.; Meng, Hui; Siddiqui, Adnan H.] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Canon Stroke & Vasc Res Ctr, Buffalo, NY 14260 USA.
   [Mowla, Ashkan] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Neurol, Buffalo, NY USA.
   [Siddiqui, Adnan H.] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Radiol, Buffalo, NY 14260 USA.
   [Waqas, Muhammad; Vakharia, Kunal; Siddiqui, Adnan H.] Kaleida Hlth, Dept Neurosurg, Gates Vasc Inst, Buffalo, NY 14203 USA.
   [Rajabzadeh-Oghaz, Hamidreza; Meng, Hui] Univ Buffalo, Dept Mech & Aerosp Engn, Buffalo, NY USA.
   [Tutino, Vincent M.] Univ Buffalo, Dept Pathol & Anat Sci, Buffalo, NY USA.
   [Poppenberg, Kerry E.] Univ Buffalo, Dept Biomed Engn, Buffalo, NY USA.
   [Siddiqui, Adnan H.] Jacobs Inst, Buffalo, NY 14203 USA.
   [Mowla, Ashkan] Ronald Reagan UCLA Med Ctr, Dept Radiol Sci, Santa Monica, CA USA.
RP Siddiqui, AH (reprint author), Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Neurosurg, Buffalo, NY 14260 USA.; Siddiqui, AH (reprint author), Univ Buffalo, Jacobs Sch Med & Biomed Sci, Canon Stroke & Vasc Res Ctr, Buffalo, NY 14260 USA.; Siddiqui, AH (reprint author), Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Radiol, Buffalo, NY 14260 USA.; Siddiqui, AH (reprint author), Kaleida Hlth, Dept Neurosurg, Gates Vasc Inst, Buffalo, NY 14203 USA.; Siddiqui, AH (reprint author), Jacobs Inst, Buffalo, NY 14203 USA.
EM asiddiqui@ubns.com
RI Siddiqui, Adnan H./AAG-9781-2019
OI Poppenberg, Kerry/0000-0002-1748-887X
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [1R03NS090193,
   1R01NS091075]; Canon Medical System Corporation
FX This work was supported by the National Institutes of Health Grants
   1R03NS090193 (Primary Investigator: H. Meng) and 1R01NS091075 (Primary
   Investigator: H. Meng; Co-investigator: A. H. Siddiqui) and Canon
   Medical System Corporation. H. Meng is founder of Neurovascular
   Diagnostics, Inc. V. M. Tutino is founder of Neurovascular Diagnostics,
   Inc. A. H. Siddiqui has financial interest in, is an investor in, has
   COMPASS, and INVEST. The remaining authors have no conflicts to report.
CR Brinjikji W, 2013, AM J NEURORADIOL, V34, P1022, DOI 10.3174/ajnr.A3321
   Chien A, 2018, AM J NEURORADIOL, V39, P500, DOI 10.3174/ajnr.A5531
   Dhar S, 2008, NEUROSURGERY, V63, P185, DOI 10.1227/01.NEU.0000316847.64140.81
   Duan ZH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24732-1
   Froelich JJ, 2016, WORLD NEUROSURG, V91, P260, DOI 10.1016/j.wneu.2016.04.044
   Greving JP, 2014, LANCET NEUROL, V13, P59, DOI 10.1016/S1474-4422(13)70263-1
   Kang HB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142330
   Kashiwazaki D, 2013, STROKE, V44, P2169, DOI 10.1161/STROKEAHA.113.001138
   Lasner TM, 1997, J NEUROSURG, V87, P381, DOI 10.3171/jns.1997.87.3.0381
   Lindgren AE, 2016, STROKE, V47, P1219, DOI 10.1161/STROKEAHA.115.012404
   Mahaney KB, 2014, J NEUROSURG, V121, P1024, DOI 10.3171/2014.6.JNS121179
   Morita A, 2012, NEW ENGL J MED, V366, P2474, DOI 10.1056/NEJMoa1113260
   Nader-Sepahi A, 2004, NEUROSURGERY, V54, P1343, DOI 10.1227/01.NEU.0000124482.03676.8B
   Nahed BV, 2005, NEUROSURGERY, V57, P676, DOI 10.1227/01.NEU.0000175549.96530.59
   Rahman M, 2010, STROKE, V41, P916, DOI 10.1161/STROKEAHA.109.574244
   Rajabzadeh-Oghaz H, 2018, WORLD NEUROSURG, V119, pE541, DOI 10.1016/j.wneu.2018.07.208
   Sedat J, 2002, STROKE, V33, P2620, DOI 10.1161/01.STR.0000034788.70971.14
   Ujiie H, 1999, NEUROSURGERY, V45, P119, DOI 10.1097/00006123-199907000-00028
   Varble N, 2018, STROKE, V49, P856, DOI 10.1161/STROKEAHA.117.019929
   Weir B, 2003, J NEUROSURG, V99, P447, DOI 10.3171/jns.2003.99.3.0447
   Xiang JP, 2016, J NEUROINTERV SURG, V8, P104, DOI 10.1136/neurintsurg-2014-011477
   Xiang JP, 2011, STROKE, V42, P144, DOI 10.1161/STROKEAHA.110.592923
   Zanaty M, 2014, NEUROL RES, V36, P308, DOI 10.1179/1743132814Y.0000000327
NR 23
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E831
EP E837
DI 10.1016/j.wneu.2019.06.045
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900104
PM 31207378
DA 2020-05-12
ER

PT J
AU Watanabe, K
   Zomorodi, AR
   Labidi, M
   Satoh, S
   Froelich, S
   Fukushima, T
AF Watanabe, Kentaro
   Zomorodi, Ali R.
   Labidi, Moujahed
   Satoh, Shunsuke
   Froelich, Sobastien
   Fukushima, Takanori
TI Visualization of Dark Side of Skull Base with Surgical Navigation and
   Endoscopic Assistance: Extended Petrous Rhomboid and Rhomboid with
   Maxillary Nerve-Mandibular Nerve Vidian Corridor
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clivus; Condyle; Endoscopic assistance; Extended anterior petrosal
   approach; Hypoglossal; Jugular foramen; Middle fossa approach
ID MIDDLE CRANIAL FOSSA; ANTERIOR TRANSPETROSAL APPROACH; POSTERIOR
   CAVERNOUS SINUS; ENDONASAL APPROACH; CLIVAL CHORDOMAS; PETROCLIVAL;
   SURGERY; MENINGIOMAS; RESECTION; ANATOMY
AB BACKGROUND: Lesions located at the petrous apex, cavernous sinus, clivus, medial aspect of the jugular foramen, or condylar regions are still difficult to fully expose using the operating microscope. Although approaches to this region through the middle cranial fossa have been previously described, these approaches afford only limited visualization. We have confirmed a transcranial infratemporal fossa combined microsurgical and endoscopic access to the petrous apex, clivus, medial aspect of the jugular foramen, and occipital condyle. We have presented the results of a micro-anatomical cadaver dissection study and its clinical application.
   METHODS: Ten latex-injected cadaveric specimens (20 twenty sides) underwent dissection with navigational guidance to achieve an extended anterior petrosal approach combined with a far vidian corridor approach (between the foramen rotundum and foramen ovale). We performed anatomical dissections to confirm the surgical anatomy and the feasibility and limitations of this approach. Anatomical dissections were performed in the skull base laboratory of Lariboisiere Hospital and Duke University Medical Center. This approach was then applied to some clinical cases.
   RESULTS: The combination of the microscope and endoscope, aided by surgical navigation, was extremely effective and provided a wide view of the petrous rhomboid, the entire clivus, and the medial condylar regions. The extended extradural anterior petrosal approach provided a large corridor to petrous and clival lesions. Endoscopic assistance allows for wide and deep exposure of the middle to lower clivus, epipharyngeal space, and bilateral condylar regions. This approach successfully provided adequate surgical access for resection of tumors located in these regions. The depth of the medial aspect of the jugular foramen was 16.3 +/- 1.2 mm deep from the geniculate ganglion. The emerging point of the inferior petrosal sinus in the jugular foramen was 16.5 +/- 1.8 mm deep from the geniculate ganglion. The hypoglossal canal was 21.6 +/- 2.2 mm deep from the geniculate ganglion. The foramen magnum was located 31.5 +/- 2.4 mm deep from the gasserian ganglion. The inferior petrosal sinus was found to be a reliable landmark to identify the medial portion of the jugular bulb. The introduction of the endoscope through the middle fossa rhomboid enabled visualization of the medial aspect of the jugular bulb, which otherwise would be hampered by the internal auditory canal under the microscope.
   CONCLUSION: After microscopic exposure of the middle fossa rhomboid, neuronavigational endoscopic assistance facilitated visualization of the ventral cavernous region, petrous apex, retropharyngeal space, and middle and inferior clivus down to the medial aspect of the jugular bulb and condyle regions. Additional maxillary nerve-mandibular nerve vidian corridor visualization provides a lateral transsphenoidal approach to upper clivus lesions.
C1 [Watanabe, Kentaro; Labidi, Moujahed; Froelich, Sobastien] Paris 7 Diderot Univ, Lariboisiere Hosp, Dept Neurosurg, Paris, France.
   [Watanabe, Kentaro; Fukushima, Takanori] Tokyo Jikei Univ, Sch Med, Dept Neurosurg, Tokyo, Japan.
   [Zomorodi, Ali R.; Satoh, Shunsuke] Duke Univ, Med Ctr, Dept Neurosurg, Durham, NC USA.
   [Satoh, Shunsuke] Southern Tohoku Gen Hosp, Dept Neurosurg, Koriyama, Fukushima, Japan.
RP Watanabe, K (reprint author), Paris 7 Diderot Univ, Lariboisiere Hosp, Dept Neurosurg, Paris, France.; Watanabe, K (reprint author), Tokyo Jikei Univ, Sch Med, Dept Neurosurg, Tokyo, Japan.
EM kentarow31@gmail.com
OI Labidi, Moujahed/0000-0002-7496-8327
CR ARISTEGUI M, 1994, SKULL BASE SURG, V4, P181, DOI 10.1055/s-2008-1058953
   Benet A, 2014, WORLD NEUROSURG, V81, P385, DOI 10.1016/j.wneu.2013.01.091
   Borghei-Razavi H, 2015, CLIN NEUROL NEUROSUR, V139, P282, DOI 10.1016/j.clineuro.2015.10.032
   DAY JD, 1994, NEUROSURGERY, V34, P1009, DOI 10.1227/00006123-199406000-00009
   Dehdashti AR, 2008, NEUROSURGERY, V63, P299, DOI 10.1227/01.NEU.0000316414.20247.32
   Fatemi N, 2008, SURG NEUROL, V69, P331, DOI 10.1016/j.surneu.2007.08.035
   Fraser JF, 2010, J NEUROSURG, V112, P1061, DOI 10.3171/2009.7.JNS081504
   Fukushima T, 1996, SKULL BASE SURG, V6, P95, DOI 10.1055/s-2008-1058650
   George B, 2014, NEUROCHIRURGIE, V60, P63, DOI 10.1016/j.neuchi.2014.02.003
   GOEL A, 1995, ACTA NEUROCHIR, V135, P78, DOI 10.1007/BF02307418
   GOEL A, 1995, ACTA NEUROCHIR, V136, P212, DOI 10.1007/BF01410628
   HARSH GR, 1992, J NEUROSURG, V77, P709, DOI 10.3171/jns.1992.77.5.0709
   Hasanbelliu Aurel, 2016, Neurosurgery, V63 Suppl 1, P186, DOI 10.1227/01.neu.0000489789.06793.0e
   House W F, 1968, Arch Otolaryngol, V88, P631
   HOUSE WF, 1986, AM J OTOL, V7, P1
   Jho HD, 1997, J NEUROSURG, V87, P44, DOI 10.3171/jns.1997.87.1.0044
   Jiang WH, 2009, ACTA OTO-LARYNGOL, V129, P71, DOI 10.1080/00016480801995404
   KAWASE T, 1994, ACTA NEUROCHIR, V129, P113, DOI 10.1007/BF01406489
   KAWASE T, 1991, NEUROSURGERY, V28, P869, DOI 10.1227/00006123-199106000-00014
   KAWASE T, 1985, J NEUROSURG, V63, P857, DOI 10.3171/jns.1985.63.6.0857
   Komatsu F, 2013, WORLD NEUROSURG, V80, P591, DOI 10.1016/j.wneu.2012.12.018
   Komatsu F, 2013, NEUROSURG REV, V36, P239, DOI 10.1007/s10143-012-0433-y
   Komotar RJ, 2011, WORLD NEUROSURG, V76, P318, DOI 10.1016/j.wneu.2011.02.026
   Kong F, 2012, J CLIN NEUROSCI, V19, P1695, DOI 10.1016/j.jocn.2011.09.042
   Maina R, 2007, SKULL BASE-INTERD AP, V17, P395, DOI 10.1055/s-2007-991117
   Maira G, 1996, J NEUROSURG, V85, P784, DOI 10.3171/jns.1996.85.5.0784
   Morera VA, 2010, NEUROSURGERY, V66, pONS211, DOI 10.1227/01.NEU.0000369926.01891.5D
   Mortini P, 2001, SKULL BASE-INTERD AP, V11, P177, DOI 10.1055/s-2001-16606
   Muto J, 2016, J NEUROSURG, V125, P1171, DOI 10.3171/2015.8.JNS15302
   PENSAK ML, 1994, LARYNGOSCOPE, V104, P814
   Pirris SM, 2007, CHILD NERV SYST, V23, P377, DOI 10.1007/s00381-006-0281-6
   Saito K, 2012, ACTA NEUROCHIR, V154, P879, DOI 10.1007/s00701-012-1317-1
   Simal-Julian JA, 2013, J NEUROSURG-PEDIATR, V11, P584, DOI 10.3171/2013.1.PEDS12462
   Stippler M, 2009, NEUROSURGERY, V64, P268, DOI 10.1227/01.NEU.0000338071.01241.E2
   Suslu HT, 2014, BRIT J NEUROSURG, V28, P503, DOI 10.3109/02688697.2014.889656
   Van Gompel JJ, 2014, J NEUROSURG, V120, P1321, DOI 10.3171/2014.2.JNS131773
   Wanibuchi M, 2009, PHOTOATLAS SKULL BAS
   Yasuda A, 2008, NEUROSURGERY, V62, P1240, DOI [10.1227/01.NEU.0000144208.42171.02, 10.1227/01.neu.0000333790.90972.59]
   Zanation AM, 2009, LARYNGOSCOPE, V119, P19, DOI 10.1002/lary.20027
NR 39
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E134
EP E145
DI 10.1016/j.wneu.2019.05.062
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900018
PM 31103769
DA 2020-05-12
ER

PT J
AU Wright, JM
   Wright, CH
   Cioffi, G
   Raghavan, A
   Hdeib, A
   Kasliwal, MK
   Kruchko, C
   Barnholtz-Sloan, JS
   Sloan, AE
AF Wright, James M.
   Wright, Christina Huang
   Cioffi, Gino
   Raghavan, Alankrita
   Hdeib, Alia
   Kasliwal, Manish K.
   Kruchko, Carol
   Barnholtz-Sloan, Jill S.
   Sloan, Andrew E.
TI Survival in Patients with High-Grade Spinal Meningioma: An Analysis of
   the National Cancer Database
SO WORLD NEUROSURGERY
LA English
DT Article
DE Meningioma; Race; Socioeconomic; Spine; Survival
ID EPIDEMIOLOGY; OUTCOMES; SURGERY; PROGRESSION
AB OBJECTIVE: To report baseline demographics and examine for differences in survival for patients with World Health Organization (WHO) grade II and III spinal meningioma.
   METHODS: The National Cancer Database was queried for patients diagnosed with WHO grade II or grade III spinal meningioma between 2004 and 2015. Cases with histopathological confirmation were included. Descriptive statistics were calculated and stratified by tumor type. Facility type, 30-day readmission, and 90-day mortality were also examined. Crude and adjusted Cox proportional hazards regression models were used to evaluate for differences in survival.
   RESULTS: A total of 287 patients with WHO grade II or grade III spinal meningioma (white, n = 237; black, n = 32; Asian and Pacific Islander, n = 11; unknown race, n = 7) were identified. The mean patient age was 56.4 years, and the majority were female (70%; n = 201). Almost one-half of the patients were treated in an academic/research program (45.3%; n = 130,). Those with WHO grade III lesions received the earliest treatment, at a mean of 10.8 days following diagnosis. The proportion of patients with unplanned 30-day readmission following surgery was 4.2% (n = 12). Two patients died within 90 days of surgery. Multivariable analysis demonstrated no differences in survival for patients with WHO grade II or grade III lesions (hazard ratio, 2.01; 95% confidence interval, 0.89-4.52; P = 0.09).
   CONCLUSIONS: No difference in overall survival was identified between patients with WHO grade II or III spinal meningioma, although a trend was seen toward worse survival for patients with WHO grade III lesions.
C1 [Wright, James M.; Wright, Christina Huang; Hdeib, Alia; Kasliwal, Manish K.; Sloan, Andrew E.] Case Western Reserve Univ, Dept Neurosurg, Univ Hosp, Cleveland Med Ctr, Cleveland, OH 44106 USA.
   [Raghavan, Alankrita] Case Western Reserve Univ, Sch Med, Cleveland, OH USA.
   [Sloan, Andrew E.] Case Western Reserve Univ, Seidman Canc Ctr, Sch Med, Cleveland, OH 44106 USA.
   [Sloan, Andrew E.] Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH USA.
   [Cioffi, Gino; Barnholtz-Sloan, Jill S.] Case Western Reserve Univ, Sch Med, Dept Populat & Quantitat Hlth Sci, Case Comprehens Canc Ctr, Cleveland, OH USA.
   [Kruchko, Carol; Barnholtz-Sloan, Jill S.] Cent Brain Tumor Registry US, Hinsdale, IL USA.
RP Wright, JM (reprint author), Case Western Reserve Univ, Dept Neurosurg, Univ Hosp, Cleveland Med Ctr, Cleveland, OH 44106 USA.
EM james.wright@uhhospitals.org
RI Sloan, Andrew/AAE-9842-2020; Barnholtz-Sloan, Jill/A-4817-2011
OI Barnholtz-Sloan, Jill/0000-0001-6190-9304
FU Junior Faculty Mentorship Program in the Department of Neurosurgery,
   University Hospitals Cleveland Medical Center; National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [CA217956]; Peter D. Cristal Chair;
   Center of Excellence for Translational Neuro-Oncology; Gerald Kaufman
   Fund for Glioma Research; Kimble Family Foundation; Ferry Family
   Foundation at University Hospitals of Cleveland
FX This project is supported by the Junior Faculty Mentorship Program in
   the Department of Neurosurgery, University Hospitals Cleveland Medical
   Center (Andrew E. Sloan). Andrew E. Sloan is supported by the National
   Institutes of Health (Grant CA217956), the Peter D. Cristal Chair, the
   Center of Excellence for Translational Neuro-Oncology, the Gerald
   Kaufman Fund for Glioma Research, the Kimble Family Foundation, and the
   Ferry Family Foundation at University Hospitals of Cleveland.
CR Barnholtz-Sloan JS, 2008, J NEUROSURG, V108, P642, DOI 10.3171/JNS/2008/108/4/0642
   Claus EB, 2005, NEUROSURGERY, V57, P1088, DOI 10.1227/01.NEU.0000188281.91351.B9
   Durand A, 2009, J NEURO-ONCOL, V95, P367, DOI 10.1007/s11060-009-9934-0
   Gezen F, 2000, SPINE, V25, P727, DOI 10.1097/00007632-200003150-00013
   Gottfried Oren N, 2003, Neurosurg Focus, V14, pe2, DOI 10.3171/foc.2003.14.6.2
   HELSETH A, 1989, J NEUROSURG, V71, P842, DOI 10.3171/jns.1989.71.6.0842
   King AT, 1998, BRIT J NEUROSURG, V12, P521, DOI 10.1080/02688699844367
   Kshettry VR, 2015, SPINE, V40, pE886, DOI 10.1097/BRS.0000000000000974
   Lerro CC, 2013, ANN SURG ONCOL, V20, P1759, DOI 10.1245/s10434-013-2901-1
   MIRIMANOFF RO, 1985, J NEUROSURG, V62, P18, DOI 10.3171/jns.1985.62.1.0018
   Nakamura M, 2012, SPINE, V37, pE617, DOI 10.1097/BRS.0b013e31824167f1
   Raco A, 2017, NEUROSURGERY, V80, P602, DOI 10.1093/neuros/nyw092
   Stessin AM, 2012, J NEUROSURG, V117, P669, DOI 10.3171/2012.7.JNS111439
   Sughrue ME, 2010, J NEUROSURG, V113, P202, DOI 10.3171/2010.1.JNS091114
   Sun SQ, 2014, NEUROSURGERY, V75, P356, DOI 10.1227/NEU.0000000000000462
   Vadivelu S, 2010, J NEUROSURG, V112, P920, DOI 10.3171/2009.8.JNS09201
   Westwick HJ, 2015, J NEUROSURG-SPINE, V23, P368, DOI 10.3171/2014.12.SPINE14974
   Wiemels J, 2010, J NEURO-ONCOL, V99, P307, DOI 10.1007/s11060-010-0386-3
   Yano S, 2006, J NEUROSURG, V105, P538, DOI 10.3171/jns.2006.105.4.538
   Ye JL, 2016, J NEURO-ONCOL, V128, P349, DOI 10.1007/s11060-016-2119-8
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E749
EP E753
DI 10.1016/j.wneu.2019.06.015
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900094
PM 31203074
DA 2020-05-12
ER

PT J
AU Wu, YS
   Ni, LH
   Fan, RM
   Yao, MY
AF Wu, Yi-Song
   Ni, Lin-Hui
   Fan, Ru-Meng
   Yao, Ming-Yang
TI Meta-Regression Analysis of the Long-Term Effects of Pallidal and
   Subthalamic Deep Brain Stimulation for the Treatment of Isolated
   Dystonia
SO WORLD NEUROSURGERY
LA English
DT Article
DE Deep brain stimulation; Globus pallidus internus; Isolated dystonia;
   Long-term effect; Meta-regression; Subthalamic nucleus
ID PRIMARY GENERALIZED DYSTONIA; 5-YEAR FOLLOW-UP; GLOBUS-PALLIDUS;
   SYNAPTIC PLASTICITY; SUSTAINED RELIEF; DYT1 DYSTONIA; INTERNUS;
   DISCONTINUATION; NUCLEUS; DBS
AB OBJECTIVE: The globus pallidus internus (GPi) and subthalamic nucleus (STN) are therapeutic targets for deep brain stimulation (DBS) in the treatment of isolated dystonia. We conducted a meta-regression analysis on long-term studies of bilateral DBS in the GPi and STN to compare the relative effects of the 2 approaches.
   METHODS: We systematically searched the PubMed, Embase, and Cochrane Controlled Register of Trials databases to identify studies reporting the treatment outcomes of GPi DBS and STN DBS for isolated dystonia. The primary outcome measure was the change in the Burke-Fahn-Marsden dystonia rating scale movement score between the baseline and follow-up evaluations. We performed a regression analysis using a random effects model.
   RESULTS: A total of 42 follow-up evaluations (30 for GPi and 12 for STN) nested in 19 studies (16 of GPi and 3 of STN) were included in our analysis. The results from univariate regression analysis suggested that shorter disease duration and STN stimulation were associated with a greater standardized change in the Burke-Fahn-Marsden dystonia rating scale movement score. On combining the factors into 1 model, only the disease duration remained significant. The regression analysis results of the GPi and STN subgroups revealed more persistent improvement after STN stimulation.
   CONCLUSIONS: A shorter disease duration correlated positively with better DBS outcomes. The STN appeared to be an optimized stimulation target for the treatment of isolated dystonia, although randomized controlled trials are needed to compare the treatment efficacy of GPi DBS and STN DBS.
C1 [Wu, Yi-Song; Ni, Lin-Hui; Fan, Ru-Meng] Xinyang Cent Hosp, Dept Neurol, Xinyang, Peoples R China.
   [Ni, Lin-Hui; Fan, Ru-Meng; Yao, Ming-Yang] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Neurol, Sch Med, Hangzhou, Zhejiang, Peoples R China.
   [Yao, Ming-Yang] Nanyang Cent Hosp, Dept Cardiol, Nanyang, Peoples R China.
RP Wu, YS (reprint author), Xinyang Cent Hosp, Dept Neurol, Xinyang, Peoples R China.
EM WuYS-neuro@outlook.com
OI Wu, Yi-Song/0000-0003-0912-5515
CR Albanese A, 2013, MOVEMENT DISORD, V28, P863, DOI 10.1002/mds.25475
   Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219
   Blahak C, 2010, STEREOT FUNCT NEUROS, V88, P311, DOI 10.1159/000319958
   BURKE RE, 1985, NEUROLOGY, V35, P73, DOI 10.1212/WNL.35.1.73
   Cao CY, 2013, MOVEMENT DISORD, V28, P1877, DOI 10.1002/mds.25586
   Cif L, 2012, J NEUROSURG, V116, P1144, DOI 10.3171/2012.1.JNS102045
   Cif L, 2010, MOVEMENT DISORD, V25, P289, DOI 10.1002/mds.22802
   Coenen VA, 2012, J NEUROL SURG PART A, V73, P178, DOI 10.1055/s-0032-1315569
   Deng ZD, 2018, PARKINSONISM RELAT D, V55, P103, DOI 10.1016/j.parkreldis.2018.05.024
   Detante O, 2004, BRAIN, V127, P1899, DOI 10.1093/brain/awh213
   Gagnier JJ, 2012, SYST REV-LONDON, V1, DOI 10.1186/2046-4053-1-18
   Goto S, 2004, J NEUROL NEUROSUR PS, V75, P1506, DOI 10.1136/jnnp.2003.031104
   Higgins JPT, 2004, STAT MED, V23, P1663, DOI 10.1002/sim.1752
   Higgins JPTGS, 2011, COCHRANE HDB SYSTEMA
   Isaias IU, 2008, BRAIN, V131, P1895, DOI 10.1093/brain/awn120
   Isaias IU, 2011, J NEUROL, V258, P1469, DOI 10.1007/s00415-011-5961-9
   Isaias IU, 2009, ARCH NEUROL-CHICAGO, V66, P465, DOI 10.1001/archneurol.2009.20
   Krause M, 2004, NEUROSURGERY, V55, P1361, DOI 10.1227/01.NEU.0000143331.86101.5E
   Kupsch A, 2006, NEW ENGL J MED, V355, P1978, DOI 10.1056/NEJMoa063618
   Liu YY, 2019, WORLD NEUROSURG, V123, pE211, DOI 10.1016/j.wneu.2018.11.137
   Loher TJ, 2008, J NEUROL, V255, P881, DOI 10.1007/s00415-008-0798-6
   Markun LC, 2012, NEUROSURGERY, V71, P325, DOI 10.1227/NEU.0b013e318258e21b
   Meoni S, 2017, J NEUROL NEUROSUR PS, V88, P960, DOI 10.1136/jnnp-2016-315504
   Moro E, 2017, EUR J NEUROL, V24, P552, DOI 10.1111/ene.13255
   Ostrem JL, 2017, NEUROLOGY, V88, P25, DOI 10.1212/WNL.0000000000003451
   Panov F, 2013, NEUROSURGERY, V73, P86, DOI 10.1227/01.neu.0000429841.84083.c8
   PARENT A, 1995, BRAIN RES REV, V20, P128, DOI 10.1016/0165-0173(94)00008-D
   Petrossian MT, 2013, J NEUROSURG-PEDIATR, V12, P582, DOI 10.3171/2013.8.PEDS13134
   Reese R, 2011, MOVEMENT DISORD, V26, P691, DOI 10.1002/mds.23549
   Sarubbo S, 2012, STEREOT FUNCT NEUROS, V90, P84, DOI 10.1159/000335706
   Schjerling L, 2013, J NEUROSURG, V119, P1537, DOI 10.3171/2013.8.JNS13844
   Sensi M, 2009, MOVEMENT DISORD, V24, P1829, DOI 10.1002/mds.22686
   Starr PA, 2006, J NEUROSURG, V104, P488, DOI 10.3171/jns.2006.104.4.488
   Stavrinou LC, 2012, J NEUROL SURG PART A, V73, P175, DOI 10.1055/s-0032-1313590
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tufanaru C, 2015, INT J EVID-BASED HEA, V13, P196, DOI 10.1097/XEB.0000000000000065
   Vasques X, 2009, MOVEMENT DISORD, V24, P846, DOI 10.1002/mds.22433
   Vayssiere N, 2004, J NEUROSURG, V101, P181, DOI 10.3171/jns.2004.101.2.0181
   Vidailhet M, 2005, NEW ENGL J MED, V352, P459, DOI 10.1056/NEJMoa042187
   Vidailhet M, 2007, LANCET NEUROL, V6, P223, DOI 10.1016/S1474-4422(07)70035-2
   Vitek JL, 2002, MOVEMENT DISORD, V17, pS49, DOI 10.1002/mds.10142
   Volkmann J, 2012, LANCET NEUROL, V11, P1029, DOI 10.1016/S1474-4422(12)70257-0
NR 42
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E409
EP E416
DI 10.1016/j.wneu.2019.05.165
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900052
PM 31146039
DA 2020-05-12
ER

PT J
AU Xie, E
   Garzon-Muvdi, T
   Bender, M
   Doshi, T
   Carson, B
   Lim, M
   Bettegowda, C
AF Xie, Eric
   Garzon-Muvdi, Tomas
   Bender, Matthew
   Doshi, Tina
   Carson, Benjamin
   Lim, Michael
   Bettegowda, Chetan
TI Association Between Radiofrequency Rhizotomy Parameters and Duration of
   Pain Relief in Trigeminal Neuralgia Patients with Recurrent Pain
SO WORLD NEUROSURGERY
LA English
DT Article
DE Pain relief; Radiofrequency rhizotomy; Temperature; Trigeminal neuralgia
ID MULTIPLE-SCLEROSIS; THERMOCOAGULATION; RADIOSURGERY; MANAGEMENT;
   DIAGNOSIS
AB BACKGROUND: Radiofrequency rhizotomy (RFR) is a commonly used, effective procedure for trigeminal neuralgia (TN), but a subset of patients experiences pain recurrence and requires subsequent surgeries. Currently, the rhizotomy temperature and duration of application are empirically determined, and there is no consensus on what settings are most beneficial. In this study, we analyzed patients who underwent trigeminal RFR and had subsequent surgeries to identify whether rhizotomy parameters were associated with the duration of pain relief.
   METHODS: Single-center, retrospective analysis of patients undergoing RFR for TN from 1995 to 2016. The primary endpoint was subsequent procedure. Associations with rhizotomy parameters and covariates were assessed using Cox regression analysis.
   RESULTS: The study included 338 patients, average age 65 years; 61% were women. Temperature was significantly associated with both the degree of immediate postoperative pain relief and the duration of pain relief, and in subgroup analyses by multiple sclerosis status and RFR procedural count. Ablation duration was also independently significant, though not when analyzed alongside age, sex, and race. Duration of pain relief was generally shorter in patients with multiple sclerosis and in repeated RFR.
   CONCLUSIONS: Higher temperatures may be necessary to achieve pain relief in some patients, given the progressive nature of the facial pain, but they are not associated with longer duration of pain relief in patients who have recurrent pain. Modulation of the ablation duration does not seem to affect the short-term or long-term outcomes.
C1 [Xie, Eric; Garzon-Muvdi, Tomas; Bender, Matthew; Doshi, Tina; Carson, Benjamin; Lim, Michael; Bettegowda, Chetan] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
RP Bettegowda, C (reprint author), Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
EM cbetteg1@jhmi.edu
OI Doshi, Tina/0000-0001-5011-3298
CR Bennetto L, 2007, BMJ-BRIT MED J, V334, P201, DOI 10.1136/bmj.39085.614792.BE
   Berk C, 2003, CAN J NEUROL SCI, V30, P220, DOI 10.1017/S0317167100002626
   Burchiel KJ, 2000, NEUROSURGERY, V46, P152
   Cheng Jason S, 2005, Neurosurg Focus, V18, pe13
   Cheng JS, 2014, OPER NEUROSURG, V10, P25, DOI 10.1227/NEU.00000000000001687
   Crayton HJ, 2006, CLIN THER, V28, P445, DOI 10.1016/j.clinthera.2006.04.005
   Cruccu G, 2008, EUR J NEUROL, V15, P1013, DOI 10.1111/j.1468-1331.2008.02185.x
   Emril Dessy R, 2010, J Pain Res, V3, P249, DOI 10.2147/JPR.S14455
   Harries AM, 2011, BRIT J NEUROSURG, V25, P268, DOI 10.3109/02688697.2011.558946
   Hasegawa T, 2002, NEUROSURGERY, V50, P494, DOI 10.1097/00006123-200203000-00012
   Kanpolat Y, 2001, NEUROSURGERY, V48, P524, DOI 10.1097/00006123-200103000-00013
   Kanpolat Y, 2000, ACTA NEUROCHIR, V142, P685, DOI 10.1007/s007010070113
   Koopman JSHA, 2009, PAIN, V147, P122, DOI 10.1016/j.pain.2009.08.023
   Kosugi S, 2015, PAIN PRACT, V15, P223, DOI 10.1111/papr.12163
   Mathews ES, 2000, MT SINAI J MED, V67, P288
   Montano N, 2015, THER CLIN RISK MANAG, V11, P289, DOI 10.2147/TCRM.S37592
   Northcutt BG, 2016, AM J NEURORADIOL, V37, P1920, DOI 10.3174/ajnr.A4868
   Pollock BE, 2000, J NEUROSURG, V93, P162, DOI 10.3171/jns.2000.93.supplement_3.0162
   Sabalys Gintautas, 2013, J Oral Maxillofac Res, V3, pe2, DOI 10.5037/jomr.2012.3402
   Sanchez-Mejia Rene O, 2005, Neurosurg Focus, V18, pe12
   Sindrup SH, 2002, CLIN J PAIN, V18, P22, DOI 10.1097/00002508-200201000-00004
   SWEET WH, 1986, NEW ENGL J MED, V315, P174, DOI 10.1056/NEJM198607173150307
   Taha JM, 1996, NEUROSURGERY, V38, P865, DOI 10.1097/00006123-199605000-00001
   Tang YZ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001994
   Tang YZ, 2014, EUR NEUROL, V72, P54, DOI 10.1159/000357868
   Tang YZ, 2016, MD MED, V95, P4103, DOI DOI 10.1097/MD.0000000000004103]
   Tatli M, 2008, ACTA NEUROCHIR, V150, P243, DOI 10.1007/s00701-007-1488-3
   Wang DD, 2018, J NEUROSURG, V128, P68, DOI 10.3171/2016.9.JNS16149
   Wray JK, 2019, RADIOFREQUENCY ABLAT
   Yao P, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004274
   Yao P, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004019
   Zakrzewska JM, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g474
   Zakrzewska JM, 2011, POSTGRAD MED J, V87, P410, DOI 10.1136/pgmj.2009.080473
NR 33
TC 0
Z9 0
U1 3
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E128
EP E133
DI 10.1016/j.wneu.2019.05.059
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900017
PM 31102773
DA 2020-05-12
ER

PT J
AU Xiong, JH
   Han, ZY
   Liu, BB
   Sun, J
   Yu, SP
   Tian, Y
   Wei, HJ
   Lin, Y
   Jiang, RC
   Yue, SY
   Yang, XJ
   Zhang, JN
AF Xiong Jianhua
   Han Zhenying
   Liu Bingbing
   Sun Jian
   Yu Shengping
   Tian Ye
   Wei Huijie
   Lin Yu
   Jiang Rongcai
   Yue Shuyuan
   Yang Xuejun
   Zhang Jianning
TI Comparison of Surgical Outcomes and Recovery of Neurologic and
   Linguistic Functions in the Dominant Hemisphere After Basal Ganglia
   Hematoma Evacuation by Craniotomy versus Endoscopy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Basal ganglia hematoma; Craniotomy; Endoscopy; Evacuation; Intracranial
   hemorrhage
ID INITIAL CONSERVATIVE TREATMENT; INTRACEREBRAL HEMORRHAGE; EARLY SURGERY;
   IMPROVE; STICH
AB OBJECTIVE: Hemorrhage in the basal ganglia is a common type of intracerebral hemorrhage and has high mortality and poor prognosis. In our study, we aimed to evaluate surgical outcomes and functional recovery after evacuation of hematoma using either craniotomy or endoscopy.
   METHODS: We analyzed retrospective data from 58 patients with basal ganglia hemorrhage who were treated with hematoma evacuation using either craniotomy or endoscopy. Magnetic resonance imaging and a navigation system were used for calculating hematoma volume and for navigation during surgery. Clinical information and surgical outcomes were recorded. At 6-month follow-up, the recovery of neurologic function and the results of the Aphasia Battery of Chinese test were assessed.
   RESULTS: The endoscopy group showed lower intraoperative blood loss (75.36 +/- 45.56 vs. 462.67 +/- 120.08 mL, P < 0.001), shorter operation time (1.59 +/- 0.30 vs. 4.17 +/- 0.86 hours, P < 0.001), and a higher hematoma clearance rate (0.93% +/- 0.05% vs. 0.88% +/- 0.13%, P = 0.04) than the craniotomy group, respectively. No significant differences in mortality were identified, but a trend toward lower mortality in the endoscopy group was apparent (7.14% in the endoscopy group vs. 16.67% in the craniotomy group, P = 0.43). Assessment of neurologic recovery indicated significant differences in the modified Rankin Scale grades between the 2 groups (chi(2) = 4.381, P = 0.036). Listening comprehension and speaking ability were also better in the endoscopy group than the craniotomy group (chi(2) = 4.693, P = 0.03).
   CONCLUSIONS: Evacuation by endoscopy had better surgical outcomes, recovery of neurologic function, and aphasia recovery than evacuation by craniotomy. It appears that endoscopy is the surgical treatment of choice for middle-aged and elderly patients with a basal ganglia hemorrhage volume of >35 mL.
C1 [Xiong Jianhua; Han Zhenying; Sun Jian; Yu Shengping; Tian Ye; Wei Huijie; Lin Yu; Jiang Rongcai; Yue Shuyuan; Yang Xuejun; Zhang Jianning] Tianjin Med Univ, Dept Neurosurg, Gen Hosp, Tianjin, Peoples R China.
   [Xiong Jianhua; Han Zhenying; Sun Jian; Yu Shengping; Tian Ye; Wei Huijie; Lin Yu; Jiang Rongcai; Yue Shuyuan; Yang Xuejun; Zhang Jianning] Minist Educ & Tianjin, Key Lab Postneuroinjury Neuro Repair & Regenerat, Tianjin, Peoples R China.
   [Liu Bingbing] Third Cent Hosp Tianjin, Dept Pathol, Tianjin, Peoples R China.
   [Liu Bingbing] Publ Hlth Minist, Tianjin Inst Hepatobiliary Dis, Tianjin Key Lab Artificial Cell, Artificial Cell Engn Technol Res Ctr, Tianjin, Peoples R China.
RP Zhang, JN (reprint author), Tianjin Med Univ, Dept Neurosurg, Gen Hosp, Tianjin, Peoples R China.; Zhang, JN (reprint author), Minist Educ & Tianjin, Key Lab Postneuroinjury Neuro Repair & Regenerat, Tianjin, Peoples R China.
EM jianningzhang@hotmail.com
FU National Natural Science Foundation International (Regional) Cooperation
   and Exchange Projects [81720108015]; National Natural Science Foundation
   of ChinaNational Natural Science Foundation of China [81502173]; Tian
   Jin Municipal Science and Technology Commission [15ZXLCSY00060]
FX This work was supported by grants from the National Natural Science
   Foundation International (Regional) Cooperation and Exchange Projects
   (81720108015), National Natural Science Foundation of China (81502173)
   and Tian Jin Municipal Science and Technology Commission
   (15ZXLCSY00060).
CR Andrews CM, 2012, NEUROCRIT CARE, V17, P37, DOI 10.1007/s12028-012-9757-2
   AUER LM, 1985, EUR NEUROL, V24, P254, DOI 10.1159/000115804
   Balami JS, 2012, LANCET NEUROL, V11, P101, DOI 10.1016/S1474-4422(11)70264-2
   Bosel J, 2015, CURR OPIN NEUROL, V28, P16, DOI 10.1097/WCO.0000000000000167
   Bonini MV, 2015, ARQ NEURO-PSIQUIAT, V73, P840, DOI 10.1590/0004-282X20150133
   Booth JR, 2007, BRAIN RES, V1133, P136, DOI 10.1016/j.brainres.2006.11.074
   Cho DY, 2006, SURG NEUROL, V65, P547, DOI 10.1016/j.surneu.2005.09.032
   Fernandes HM, 2000, STROKE, V31, P2511, DOI 10.1161/01.STR.31.10.2511
   Fu CH, 2019, WORLD NEUROSURG, V122, pE995, DOI 10.1016/j.wneu.2018.10.192
   Gao S. R., 1992, CHINESE MENTAL HLTH, V6, P125
   Hanley DF, 2013, STROKE, V44, pS65, DOI 10.1161/STROKEAHA.113.000856
   Hsieh PC, 2005, SURG NEUROL, V64, P147, DOI 10.1016/j.surneu.2004.11.028
   Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287
   Kuo LT, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.2.FOCUS10313
   Longatti P, 2005, NEUROSURGERY, V57, DOI 10.1227/01.NEU.0000176702.26810.B7
   Ma LC, 2017, WORLD NEUROSURG, V101, P57, DOI 10.1016/j.wneu.2017.01.072
   Mendelow AD, 2013, LANCET, V382, P397, DOI 10.1016/S0140-6736(13)60986-1
   Mendelow AD, 2005, LANCET, V365, P387
   Muiz AJ, 2003, NEUROEPIDEMIOLOGY, V22, P184, DOI 10.1159/000069894
   Nagasaka T, 2011, J STROKE CEREBROVASC, V20, P208, DOI 10.1016/j.jstrokecerebrovasdis.2009.11.021
   Nievas MC, 2005, NEUROL RES, V27, P755, DOI 10.1179/016164105X35620
   Ohwaki K, 2006, NEUROCRIT CARE, V5, P15, DOI 10.1385/NCC:5:1:15
   Rabinstein AA, 2002, NEUROLOGY, V58, P1367, DOI 10.1212/WNL.58.9.1367
   Radholm K, 2015, AGE AGEING, V44, P422, DOI 10.1093/ageing/afu198
   Ratre S, 2018, NEUROL INDIA, V66, P1694, DOI 10.4103/0028-3886.246288
   Ruiz-Sandoval JL, 2007, STROKE, V38, P1641, DOI 10.1161/STROKEAHA.106.478222
   van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0
   Wang S, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00374
   Wang XY, 2011, CHIN J CONT NEUROL N, V11, P230
   Weigel R, 2003, J NEUROL NEUROSUR PS, V74, P937, DOI 10.1136/jnnp.74.7.937
   Weimar C, 2017, CURR PHARM DESIGN, V23, P2193, DOI 10.2174/1381612822666161027152234
   Wu JB, 2017, CHINESE MED J-PEKING, V130, P2283, DOI 10.4103/0366-6999.215326
   Xu XH, 2018, J NEUROSURG, V128, P553, DOI 10.3171/2016.10.JNS161589
   Xu XH, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2041-1
   Yamashiro S, 2015, NEUROL MED-CHIR, V55, P819, DOI 10.2176/nmc.oa.2014-0136
   Yang G, 2016, PAK J MED SCI, V32, P677, DOI 10.12669/pjms.323.9533
   Ye ZPP, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007876
   You SJ, 2017, CEREBROVASC DIS, V44, P320, DOI 10.1159/000481443
   Zhang HZ, 2014, BIOMED RES INT, DOI 10.1155/2014/898762
   Zhou HG, 2011, J NEUROL, V258, P661, DOI 10.1007/s00415-011-5902-7
   Zhu HW, 2012, TURK NEUROSURG, V22, P294, DOI 10.5137/1019-5149.JTN.5136-11.1
NR 41
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E494
EP E501
DI 10.1016/j.wneu.2019.05.193
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900063
PM 31150853
DA 2020-05-12
ER

PT J
AU Yang, XY
   Donk, R
   Arts, MP
   Vleggeert-Lankamp, CLA
AF Yang, Xiaoyu
   Donk, Roland
   Arts, Mark P.
   Vleggeert-Lankamp, Carmen L. A.
TI Are Modic Vertebral End-Plate Signal Changes Associated with
   Degeneration or Clinical Outcomes in the Cervical Spine?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical discectomy; Modic changes; Neck pain; Radiologic degeneration;
   Vertebral end-plate signal changes
ID NECK DISABILITY INDEX; FOLLOW-UP; PAIN; RADICULOPATHY; EPIDEMIOLOGY;
   RELIABILITY; DISEASE; MARROW
AB OBJECTIVE: To report on the incidence of Modic changes (MCs) in patients with cervical radiculopathy due to a herniated disc. Presence of MCs was correlated to clinical outcomes and the presence of radiological degeneration.
   METHODS: Patients that underwent anterior discectomy for a cervical radiculopathy due to a herniating disc were analyzed for the presence of MCs at baseline and at 1-year follow-up after surgery. Neck Disability Index, physical component summary, mental component summary, and visual analog scale for neck pain and for arm pain were evaluated as clinical outcomes. The presence of radiological degeneration was defined by the method of Goffin.
   RESULTS: The prevalence of MCs was found at 18% at baseline and increased to 28% one year after surgery. Both at baseline and at 1-year follow-up, the percentage of patients with and without MCs reporting neck pain was comparable. Likewise, both at baseline and at 1-year follow-up, the percentage of patients with and without MCs reporting disabling arm pain was comparable. At baseline, the patients with MC demonstrated more radiologic degeneration than those without MC (OR 0.42), but this difference disappeared at 1 year after surgery.
   CONCLUSIONS: MCs were not associated with neck pain, nor with arm pain. Furthermore, there was a tendency for a correlation between the presence of MCs and radiological degeneration.
C1 [Yang, Xiaoyu; Vleggeert-Lankamp, Carmen L. A.] Leiden Univ, Dept Neurosurg, Med Ctr, Leiden, Netherlands.
   [Donk, Roland] Via Sana Clin, Dept Orthopaed Surg, Mill, Netherlands.
   [Arts, Mark P.] Haaglanden Med Ctr, Dept Neurosurg, The Hague, Netherlands.
RP Yang, XY (reprint author), Leiden Univ, Dept Neurosurg, Med Ctr, Leiden, Netherlands.
EM X.Yang@lumc.nl
FU China Scholarship CouncilChina Scholarship Council; Department of
   Neurosurgery, Leiden University Medical Centre, The
   NetherlandsNetherlands Government; B. Braun Medical; Department of
   Neurosurgery of the Leiden University Medical Center, the
   NetherlandsNetherlands Government
FX This work was supported by China Scholarship Council and the Department
   of Neurosurgery, Leiden University Medical Centre, The Netherlands.
   Xiaoyu Yang received support from both funding agencies. The NECK trial
   was sponsored by B. Braun Medical and the Department of Neurosurgery of
   the Leiden University Medical Center, the Netherlands.
CR Albert HB, 2008, BRIT J SPORT MED, V42, P969, DOI 10.1136/bjsm.2008.050369
   Albert HB, 2007, EUR SPINE J, V16, P977, DOI 10.1007/s00586-007-0336-8
   An YH, 2017, J PAIN RES, V10, P1657, DOI 10.2147/JPR.S138361
   Arts MP, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-122
   Bartels RHMA, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-85
   Donk RD, 2018, CLIN SPINE SURG, V31, pE50, DOI 10.1097/BSD.0000000000000551
   Donk RD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183603
   el Barzouhi A, 2014, SPINE J, V14, P225, DOI 10.1016/j.spinee.2013.08.058
   Eubanks JD, 2010, AM FAM PHYSICIAN, V81, P33
   Goffin J, 2004, J SPINAL DISORD TECH, V17, P79, DOI 10.1097/00024720-200404000-00001
   Jensen TS, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-81
   Kang Kyung Tag, 2017, Korean J Spine, V14, P41, DOI 10.14245/kjs.2017.14.2.41
   Kim YK, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15102094
   Kjaer P, 2006, EUR SPINE J, V15, P1312, DOI 10.1007/s00586-006-0185-x
   Kressig M, 2016, J MANIP PHYSIOL THER, V39, P565, DOI 10.1016/j.jmpt.2016.08.004
   Kuisma M, 2006, SPINE, V31, P1714, DOI 10.1097/01.brs.0000224167.18483.14
   Li J, 2017, J PAIN RES, V10, P2041, DOI 10.2147/JPR.S144814
   Mann E, 2014, EUR SPINE J, V23, P584, DOI 10.1007/s00586-013-2882-6
   Mann E, 2011, SPINE, V36, P1081, DOI 10.1097/BRS.0b013e3181ef6a1e
   Matsumoto M, 2012, J BONE JOINT SURG BR, V94B, P678, DOI 10.1302/0301-620X.94B5.28519
   MODIC MT, 1988, RADIOLOGY, V168, P177, DOI 10.1148/radiology.168.1.3289089
   MODIC MT, 1988, RADIOLOGY, V166, P193, DOI 10.1148/radiology.166.1.3336678
   Peters ML, 2007, ANN SURG, V245, P487, DOI 10.1097/01.sla.0000245495.79781.65
   Pietrobon B, 2002, SPINE, V27, P515, DOI 10.1097/00007632-200203010-00012
   RADHAKRISHNAN K, 1994, BRAIN, V117, P325, DOI 10.1093/brain/117.2.325
   Salemi G, 1996, ACTA NEUROL SCAND, V93, P184
   Schoenfeld AJ, 2012, J SPINAL DISORD TECH, V25, P17, DOI 10.1097/BSD.0b013e31820d77ea
   SHENGYUN L, 2014, PLOS ONE, V0009
   VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409
   Vleggeert-Lankamp CLA, 2019, SPINE J, V19, P965, DOI 10.1016/j.spinee.2018.12.013
   Vos CJ, 2006, EUR SPINE J, V15, P1729, DOI 10.1007/s00586-006-0119-7
   Yamashita K, 2006, SPINE, V31, P2602, DOI 10.1097/01.brs.0000240717.25787.7d
NR 32
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E881
EP E889
DI 10.1016/j.wneu.2019.06.067
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900110
PM 31226457
OA Other Gold
DA 2020-05-12
ER

PT J
AU Yoon, JS
   Tang, OY
   Lawton, MT
AF Yoon, James S.
   Tang, Oliver Y.
   Lawton, Michael T.
TI Volume-Cost Relationship in Neurosurgery: Analysis of 12,129,029
   Admissions from the National Inpatient Sample
SO WORLD NEUROSURGERY
LA English
DT Article
DE Centralization of surgery; Health care economics; Value-based health
   care; Volume-cost
ID HOSPITAL VOLUME; OUTCOMES; EXCELLENCE; ECONOMIES; SURGERY; CENTERS
AB BACKGROUND/OBJECTIVE: Several studies have documented improved outcomes at high-volume hospitals for neurosurgery. However, the relationship between neurosurgical volume and costs remains poorly understood.
   METHODS: Using neurosurgery-specific Diagnosis-Related Groups (DRG) codes, we identified adult neurosurgical admissions in the National Inpatient Sample from 2002 to 2014. We stratified hospitals by annual neurosurgical volume as high-volume (top 20%) or low-volume centers (bottom80%). We performed survey-weighted regression analyses to examine the impact of case volume on inpatient costs.
   RESULTS: A total of 12,129,029 admissions underwent neurosurgery from 2002 to 2014, with 59.6% treated at high-volume hospitals. Patients at high-volume centers were more likely to have private insurance, higher risk of mortality scores, and higher DRG weight procedures than those at low-volume centers (P < 0.001). High-volume hospital admissions were on average 9% or $1791 more expensive than their low-volume counterparts. However, after adjustment for patient, hospital, and case-mix differences, high-volume hospitals were 4.3% less expensive than low-volume centers ($21,825 vs. $22,924; P < 0.01). The southern United States, which had the biggest volume, showed the highest savings (6.5%).
   CONCLUSIONS: High-volume hospitals provide more cost-effective neurosurgical care. Centralization of care at high-volume neurosurgical institutions may be a promising strategy to delivering higher-value care, achieving better outcomes at lower costs.
C1 [Yoon, James S.; Lawton, Michael T.] St Josephs Hosp, Barrow Neurol Inst, Dept Neurol Surg, Phoenix, AZ 85013 USA.
   [Yoon, James S.] Yale Sch Med, New Haven, CT USA.
   [Tang, Oliver Y.] Brown Univ, Providence, RI 02912 USA.
RP Lawton, MT (reprint author), St Josephs Hosp, Barrow Neurol Inst, Dept Neurol Surg, Phoenix, AZ 85013 USA.
EM michael.lawton@barrowbrainandspine.com
CR Bardach NS, 2002, STROKE, V33, P1851, DOI 10.1161/01.STR.0000019126.43079.7B
   Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337
   Burket JC, 2016, 2016 ANN M AM AC ORT
   Cowan John A Jr, 2007, Clin Neurosurg, V54, P209
   Davies JM, 2017, J NEUROSURG, V127, P69, DOI 10.3171/2016.7.JNS15925
   Davies JM, 2015, NEUROSURG CLIN N AM, V26, P207, DOI 10.1016/j.nec.2014.11.015
   Gologorsky Y, 2014, J NEUROSURG-SPINE, V21, P984, DOI 10.3171/2014.8.SPINE131113
   Haeder SF, 2015, JAMA-J AM MED ASSOC, V314, P669, DOI 10.1001/jama.2015.6807
   Hartman M, 2018, HEALTH AFFAIR, V37, P150, DOI 10.1377/hlthaff.2017.1299
   Long DM, 2003, NEUROSURGERY, V52, P1056, DOI 10.1227/01.NEU.0000057745.48813.93
   Mehrotra A, 2013, MED CARE, V51, P748, DOI 10.1097/MLR.0b013e31829b091d
   Munoz E, 2010, ANN SURG, V251, P195, DOI 10.1097/SLA.0b013e3181cbcc9a
   Navathe AS, 2018, JAMA-J AM MED ASSOC, V319, P930, DOI 10.1001/jama.2018.0678
   Nouraei SAR, 2015, ANN SURG, V261, P1096, DOI 10.1097/SLA.0000000000000851
   Pieper D, 2013, J AM COLL SURGEONS, V216, P1015, DOI 10.1016/j.jamcollsurg.2012.12.049
   Ramkumar PN, 2017, J SHOULDER ELB SURG, V26, P1399, DOI 10.1016/j.jse.2017.05.019
   Schwartz TH, 2013, WORLD NEUROSURG, V80, P270, DOI 10.1016/j.wneu.2012.11.019
   Sharma M, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.8.FOCUS13295
   Svarts A, 2017, J HEALTH ORGAN MANAG, V31, P317, DOI 10.1108/JHOM-01-2017-0006
NR 19
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E791
EP E802
DI 10.1016/j.wneu.2019.06.034
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900100
PM 31203075
DA 2020-05-12
ER

PT J
AU Yu, HY
   Zhou, Z
   Lei, XF
   Liu, HQ
   Fan, GX
   He, SS
AF Yu, Haiyang
   Zhou, Zhi
   Lei, Xuefeng
   Liu, Huaqing
   Fan, Guoxin
   He, Shisheng
TI Mixed Reality-Based Preoperative Planning for Training of Percutaneous
   Transforaminal Endoscopic Discectomy: A Feasibility Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Mixed reality; Percutaneous transforaminal endoscopic discectomy;
   Preoperative planning; Surgical simulators; Training
ID OPEN LUMBAR MICRODISCECTOMY; AUGMENTED REALITY; LEARNING-CURVE;
   VIRTUAL-REALITY; INTERLAMINAR; SIMULATION; GUIDANCE
AB OBJECTIVE: To explore the effect of preoperative planning using mixed reality (MR) on training of percutaneous transforaminal endoscopic discectomy (PTED).
   METHODS: Before the training, we invited an experienced chief physician to plan the puncture path of PTED on the X-ray films of the lumbar spine model and the 3D Slicer platform, respectively, and used this as the standard to guide trainees. In the aggregate, 60 young residents were randomly divided into Group A (N = 30) and Group B (N = 30). Group A learned the 2-dimensional standard planning route, whereas Group B learned the standard route planning based on MR through the 3D Slicer platform. Then, trainees were asked to conduct PTED puncture on a lumbar spine model. Questionnaires were distributed to trainees before and after the training. During the training, puncture times, operating time (minutes), and fluoroscopy times were recorded.
   RESULTS: After the training, it was obvious that more trainees showed their recognition of MR, believing that MR could help preoperative planning and training of PTED. Their high satisfaction with the training indicated the success of our training. Moreover, puncture times, operating time (minutes), and fluoroscopy times of Group B were significantly lower than those of Group A.
   CONCLUSIONS: MR technology contributes to preoperative planning of PTED and is beneficial in the training of PTED. It significantly reduces puncture times and fluoroscopy times, providing a standardized method for the training of PTED.
C1 [Yu, Haiyang; Zhou, Zhi; Lei, Xuefeng; Fan, Guoxin; He, Shisheng] Tongji Univ, Sch Med, Orthoped Dept, Shanghai Tenth Peoples Hosp, Shanghai, Peoples R China.
   [Liu, Huaqing; Fan, Guoxin; He, Shisheng] Tongji Univ, Sch Med, Spinal Pain Res Inst, Shanghai, Peoples R China.
RP He, SS (reprint author), Tongji Univ, Sch Med, Orthoped Dept, Shanghai Tenth Peoples Hosp, Shanghai, Peoples R China.; He, SS (reprint author), Tongji Univ, Sch Med, Spinal Pain Res Inst, Shanghai, Peoples R China.
EM tjhss7414@tongji.edu.cn
CR Ahn SS, 2016, WORLD NEUROSURG, V86, P250, DOI [10.1016/J.WNEU.2015.09.047, 10.1016/j.wneu.2015.09.047]
   Ahn Y, 2014, EXPERT REV MED DEVIC, V11, P605, DOI 10.1586/17434440.2014.940314
   Ahn Y, 2013, SPINE, V38, P617, DOI 10.1097/BRS.0b013e318275ca58
   Barsom EZ, 2016, SURG ENDOSC, V30, P4174, DOI 10.1007/s00464-016-4800-6
   Bernhardt S, 2016, MED IMAGE ANAL, V30, P130, DOI 10.1016/j.media.2016.01.008
   Brun H, 2019, EUR HEART J-CARD IMG, V20, P883, DOI 10.1093/ehjci/jey184
   Choi G, 2013, J ORTHOP SURG RES, V8, DOI 10.1186/1749-799X-8-14
   Choi KC, 2016, PAIN PHYSICIAN, V19, pE291
   Coelho G, 2018, SPINE, V43, P1609, DOI 10.1097/BRS.0000000000002856
   Draelos M, 2018, BIOMED OPT EXPRESS, V9, P2825, DOI 10.1364/BOE.9.002825
   Fan GX, 2018, BIOMED RES INT, DOI 10.1155/2018/6740942
   Gaba DM, 2004, QUAL SAF HEALTH CARE, V13, pI2, DOI 10.1136/qshc.2004.009878
   Gasco J, 2014, NEUROL RES, V36, P968, DOI 10.1179/1743132814Y.0000000388
   Gu X, 2013, CLIN ANAT, V26, P728, DOI 10.1002/ca.22286
   GUAN X, 2015, J SPINAL DISORD TECH, V28, P78, DOI DOI 10.1097/BSD.0000000000000145
   Halic T, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-S6-S11
   Hirayama J, 2019, J NEUROL SURG PART A, V80, P88, DOI 10.1055/s-0038-1673399
   Hochman JB, 2014, J OTOLARYNGOL-HEAD N, V43, DOI 10.1186/s40463-014-0023-9
   Hsu HT, 2013, EUR SPINE J, V22, P727, DOI 10.1007/s00586-012-2540-4
   Hu ZY, 2017, INT J SURG, V41, P97, DOI 10.1016/j.ijsu.2017.03.059
   Javaux A, 2018, INT J COMPUT ASS RAD, V13, P1949, DOI 10.1007/s11548-018-1822-7
   Lee DY, 2008, NEUROL MED-CHIR, V48, P383, DOI 10.2176/nmc.48.383
   Lonner BS, 2005, SPINE, V30, P2835, DOI 10.1097/01.brs.0000192241.29644.6e
   Mahesha K, 2017, INDIAN J ORTHOP, V51, P36, DOI 10.4103/0019-5413.197520
   Rasouli MR, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010328.pub2
   Rosenthal M, 2002, MED IMAGE ANAL, V6, P313, DOI 10.1016/S1361-8415(02)00088-9
   Ruetten S, 2007, J NEUROSURG-SPINE, V6, P521, DOI 10.3171/spi.2007.6.6.521
   Ruetten S, 2008, SPINE, V33, P931, DOI 10.1097/BRS.0b013e31816c8af7
   Sanusi T, 2015, CLIN NEUROL NEUROSUR, V139, P324, DOI 10.1016/j.clineuro.2015.11.001
   Sauer IM, 2017, ANN SURG, V266, P706, DOI 10.1097/SLA.0000000000002448
   Sencer A, 2014, WORLD NEUROSURG, V82, P884, DOI 10.1016/j.wneu.2014.05.032
   Stefan R, 2018, UNFALLCHIRURG, V121, P271, DOI 10.1007/s00113-018-0467-x
   Tepper OM, 2017, PLAST RECONSTR SURG, V140, P1066, DOI 10.1097/PRS.0000000000003802
   Wei S, 2015, VIDEOSURGERY MINIINV, V10, P555, DOI 10.5114/wiitm.2015.55845
   Yari SS, 2018, ORTHOP J SPORTS MED, V6, DOI 10.1177/2325967118810176
   Yeung AT, 2002, SPINE, V27, P722, DOI 10.1097/00007632-200204010-00009
   Zheng CS, 2019, WORLD NEUROSURG, V123, pE1, DOI 10.1016/j.wneu.2018.08.082
NR 37
TC 1
Z9 1
U1 3
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E767
EP E775
DI 10.1016/j.wneu.2019.06.020
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900097
PM 31203062
DA 2020-05-12
ER

PT J
AU Zeng, Y
   Chen, RJ
   Ma, MM
   Liu, BQ
   Xia, J
   Xu, HW
   Liu, YH
   Du, XP
   Hu, ZP
   Yang, QD
   Zhang, L
AF Zeng, Yi
   Chen, RuiJuan
   Ma, MingMing
   Liu, BaoQiong
   Xia, Jian
   Xu, HongWei
   Liu, YunHai
   Du, XiaoPing
   Hu, ZhiPing
   Yang, QiDong
   Zhang, Le
TI Associations of EDNRA and EDNRB Polymorphisms with Intracerebral
   Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Blood pressure; EDNRA; EDNRB; Intracerebral hemorrhage; Polymorphism
ID ENDOTHELIN RECEPTOR-TYPE; BLOOD-PRESSURE; INTRACRANIAL ANEURYSM;
   CEREBRAL INFARCTION; VASCULAR ENDOTHELIN; GENETIC RISK; MIGRAINE;
   EXERCISE; OBESITY; VARIANT
AB OBJECTIVE: The most potent vasoconstrictor, endothelin-1 and its receptors, endothelin receptor A (EDNRA) and endothelin receptor B (EDNRB) are involved in hypertension. Hypertension is a major risk factor of intracerebral hemorrhage (ICH). Recent studies have demonstrated increased plasma endothelin-1 level in ICH patients and relationships between EDNRA and EDNRB genetic variants and ischemic stroke. The aim of the current study was to investigate whether EDNRA and EDNRB polymorphisms are associated with ICH by interacting with blood pressure levels.
   METHODS: Five EDNRA and EDNRB polymorphisms were genotyped in this case-control study.
   RESULTS: We identified that EDNRA rs5333 T allele might be a protective factor of ICH (adjusted odds ratio [OR] [0.638, 95% CI: 0.417-0.977, P = 0.038), while EDNRB rs5351 A allele could be a risk factor of ICH (adjusted OR = 1.476, 95% CI: 1.042-2.089, P = 0.028). Moreover, we only found that the GG genotype of EDNRA rs5335 had higher diastolic blood pressure than the GC D CC genotypes in ICH patients (91.69 +/- 18.77 vs. 84.71 +/- 21.48, P = 0.004).
   CONCLUSIONS: These findings support the important role of EDNRA and EDNRB polymorphisms in ICH, and suggest that they do not interact with blood pressure levels on altering ICH risk.
C1 [Zeng, Yi; Chen, RuiJuan] Cent S Univ, Xiangya Hosp 2, Dept Geriatr, Changsha, Hunan, Peoples R China.
   [Hu, ZhiPing] Cent S Univ, Xiangya Hosp 2, Dept Neurol, Changsha, Hunan, Peoples R China.
   [Ma, MingMing; Liu, BaoQiong; Xia, Jian; Xu, HongWei; Liu, YunHai; Du, XiaoPing; Yang, QiDong; Zhang, Le] Cent S Univ, Xiangya Hosp, Dept Neurol, Changsha, Hunan, Peoples R China.
RP Zhang, L (reprint author), Cent S Univ, Xiangya Hosp, Dept Neurol, Changsha, Hunan, Peoples R China.
EM zlzdzlzd@csu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81571151, 81641039]; Hunan Provincial Natural
   Science FoundationNatural Science Foundation of Hunan Province
   [2016JJ2164, 2017JJ2356]
FX The authors declare that the article content was composed in the absence
   of any commercial or financial relationships that could be construed as
   a potential conflict of interest. This study was supported by the
   National Natural Science Foundation of China (81571151, and 81641039)
   and Hunan Provincial Natural Science Foundation (2016JJ2164, and
   2017JJ2356).
CR Alg VS, 2013, NEUROLOGY, V80, P2154, DOI 10.1212/WNL.0b013e318295d751
   Benjafield AV, 2003, CLIN GENET, V64, P433, DOI 10.1034/j.1399-0004.2003.00148.x
   Coelho SC, 2018, HYPERTENSION, V71, P208, DOI 10.1161/HYPERTENSIONAHA.117.09925
   Czopek A, 2019, EUR HEART J, V40, P768, DOI 10.1093/eurheartj/ehy881
   Dubovyk YI, 2018, DIS MARKERS, DOI 10.1155/2018/1695782
   HASEGAWA K, 1994, HYPERTENSION, V23, P288, DOI 10.1161/01.HYP.23.3.288
   Iemitsu M, 2006, HYPERTENSION, V47, P928, DOI 10.1161/01.HYP.0000217520.44176.73
   Khalil Raouf A, 2011, Curr Mol Pharmacol, V4, P176
   Lemos C, 2011, EUR J NEUROL, V18, P649, DOI 10.1111/j.1468-1331.2010.03239.x
   Li TC, 2015, BIOMEDICINE-TAIWAN, V5, P8, DOI 10.7603/s40681-015-0008-7
   Li WJ, 2017, HYPERTENSION, V70, P508, DOI [10.1161/hypertensionaha.117.09479, 10.1161/HYPERTENSIONAHA.117.09479]
   Low SK, 2012, HUM MOL GENET, V21, P2102, DOI 10.1093/hmg/dds020
   Maguire JJ, 2015, SEMIN NEPHROL, V35, P125, DOI 10.1016/j.semnephrol.2015.02.002
   Martinez-Barquero V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118471
   Mazzuca MQ, 2012, BIOCHEM PHARMACOL, V84, P147, DOI 10.1016/j.bcp.2012.03.020
   McPherson A, 2019, ACTA CRYSTALLOGR F, V75, P47, DOI 10.1107/S2053230X18016011
   Nicaud V, 1999, AM J HYPERTENS, V12, P304, DOI 10.1016/S0895-7061(98)00255-6
   Ormezzano O, 2005, J HYPERTENS, V23, P2019, DOI 10.1097/01.hjh.0000184748.49189.36
   Ornello R, 2015, J HEADACHE PAIN, V16, DOI 10.1186/1129-2377-16-8
   Pezzini A, 2013, STROKE, V44, P1584, DOI 10.1161/STROKEAHA.111.000069
   Pollock DM, 2000, CURR OPIN NEPHROL HY, V9, P157, DOI 10.1097/00041552-200003000-00010
   Rahman T, 2008, J HUM HYPERTENS, V22, P282, DOI 10.1038/sj.jhh.1002322
   RUBANYI GM, 1994, PHARMACOL REV, V46, P325
   Sacco S, 2013, STROKE, V44, P3032, DOI 10.1161/STROKEAHA.113.002465
   Schiffrin EL, 2005, VASC PHARMACOL, V43, P19, DOI 10.1016/j.vph.2005.03.004
   Shihoya W, 2016, NATURE, V537, P363, DOI 10.1038/nature19319
   STEVENS PA, 1995, J CARDIOVASC PHARM, V26, pS9
   Stow LR, 2011, FASEB J, V25, P16, DOI 10.1096/fj.10-161612
   Tsai CL, 2016, J HEADACHE PAIN, V17, DOI 10.1186/s10194-016-0701-2
   Vercauteren M, 2017, J PHARMACOL EXP THER, V361, P322, DOI 10.1124/jpet.116.234930
   Xu YL, 2016, J CARDIOVASC MAGN R, V18, DOI 10.1186/s12968-016-0309-3
   Yamaguchi S, 2006, INT J MOL MED, V18, P871
   Yasuda H, 2007, J HUM HYPERTENS, V21, P883, DOI 10.1038/sj.jhh.1002234
   Yasuno K, 2011, P NATL ACAD SCI USA, V108, P19707, DOI 10.1073/pnas.1117137108
   Zeng Y, 2016, J INT MED RES, V44, P444, DOI 10.1177/0300060516635385
   Zeng Y, 2012, J CLIN NEUROSCI, V19, P753, DOI 10.1016/j.jocn.2011.09.019
   Zhang L, 2014, CELL BIOCHEM BIOPHYS, V70, P233, DOI 10.1007/s12013-014-9887-6
NR 37
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E472
EP E477
DI 10.1016/j.wneu.2019.05.186
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900060
PM 31150867
DA 2020-05-12
ER

PT J
AU Zhang, D
   Gong, HY
   Shen, M
   Wang, D
   Jiao, J
   Yang, XH
   Liu, TL
   Wei, HF
   Wu, ZP
   Xiao, JR
AF Zhang, Dan
   Gong, Haiyi
   Shen, Mao
   Wang, Da
   Jiao, Jian
   Yang, Xinghai
   Liu, Tielong
   Wei, Haifeng
   Wu, Zhipeng
   Xiao, Jianru
TI Surgical Management and Factors Affecting the Prognosis for Patients
   with Thyroid Cancer Spinal Metastases: A Retrospective Analysis of 52
   Consecutive Patients from a Single Center
SO WORLD NEUROSURGERY
LA English
DT Article
DE Multidisciplinary therapies; Prognostic factors; Spinal metastases;
   Surgery; Survival analysis; Thyroid cancer
ID BONE METASTASES; AMBULATORY STATUS; CORD COMPRESSION; CARCINOMA;
   SURGERY; SURVIVAL; IMPACT
AB BACKGROUND: Thyroid cancer, one of the most common endocrine malignancies in developed areas and China, is associated with favorable prognosis. However, the presence of spinal metastases will remarkably reduce the life expectancy for patients with thyroid cancer. In addition, limited information is available about such disease.
   METHODS: Various potential clinical factors were submitted to univariate and multivariate analyses to identify the independent variables that predicted the prognosis for patients. In addition, the survival rate was estimated according to the KaplaneMeier method, and statistic differences were calculated by the log-rank test. Moreover, factors with a P value of <= 0.1 were performed multivariate analysis using a multivariate Cox proportional hazards model, and factors with a P value of <0.05 were considered as statistically significant.
   RESULTS: Seven potential independent prognostic factors had been identified through univariate analysis, which were then subjected to multivariate analysis. Our results suggested that age of <= 50 years, single segment involved, and follicular thyroid cancer were the independent favorable prognostic factors.
   CONCLUSIONS: Findings in this study indicate that age of <= 50 years, single segment involved, and follicular thyroid cancer are favorable prognostic factors for patients with thyroid cancer spinal metastases.
C1 [Zhang, Dan; Gong, Haiyi; Shen, Mao; Jiao, Jian; Yang, Xinghai; Liu, Tielong; Wei, Haifeng; Wu, Zhipeng; Xiao, Jianru] Naval Med Univ, Changzheng Hosp, Dept Orthopaed Oncol, Shanghai, Peoples R China.
   [Wang, Da] Guizhou Med Univ, Dept Orthopaed, Affiliated Hosp, Guiyang, Guizhou, Peoples R China.
RP Xiao, JR (reprint author), Naval Med Univ, Changzheng Hosp, Dept Orthopaed Oncol, Shanghai, Peoples R China.
EM zdspine@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81702658]
FX This study was supported by the National Natural Science Foundation of
   China (Grant No. 81702658).
CR Alamanda Vignesh K, 2018, J Spine Surg, V4, P28, DOI 10.21037/jss.2018.03.12
   Bollen L, 2013, EUR SPINE J, V22, P1408, DOI 10.1007/s00586-013-2726-4
   Chaichana KL, 2008, NEUROSURGERY, V62, P683, DOI 10.1227/01.neu.0000317317.33365.15
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   de Geus-Oei LF, 2002, EUR J NUCL MED MOL I, V29, P768, DOI 10.1007/s00259-002-0781-x
   Demura S, 2011, J NEUROSURG-SPINE, V14, P172, DOI 10.3171/2010.9.SPINE09878
   Eustatia-Rutten CFA, 2003, J CLIN ENDOCR METAB, V88, P3184, DOI 10.1210/jc.2003-030231
   Farooki A, 2012, J CLIN ENDOCR METAB, V97, P2433, DOI 10.1210/jc.2012-1169
   Goel Manish Kumar, 2010, Int J Ayurveda Res, V1, P274, DOI 10.4103/0974-7788.76794
   Haigh PI, 2001, CANCER-AM CANCER SOC, V91, P2335, DOI 10.1002/1097-0142(20010615)91:12<2335::AID-CNCR1266>3.0.CO;2-1
   Horn SR, 2018, J CLIN NEUROSCI, V53, P183, DOI 10.1016/j.jocn.2018.04.022
   Jalai CM, 2016, SPINE, V41, pE139, DOI 10.1097/BRS.0000000000001181
   Kato S, 2016, CANCER MED-US, V5, P2343, DOI 10.1002/cam4.823
   Kawamura H, 2018, DIS COLON RECTUM, V61, P673, DOI 10.1097/DCR.0000000000001071
   Kim CH, 2011, SPINE J, V11, P1015, DOI 10.1016/j.spinee.2011.09.007
   Kim SK, 2017, SURGERY, V161, P485, DOI 10.1016/j.surg.2016.07.037
   Kushchayeva YS, 2014, THYROID, V24, P1488, DOI 10.1089/thy.2013.0633
   Kushchayeva YS, 2014, THYROID, V24, P1443, DOI 10.1089/thy.2013.0634
   Muresan MM, 2008, ENDOCR-RELAT CANCER, V15, P37, DOI 10.1677/ERC-07-0229
   Park JH, 2013, SPINE, V38, pE798, DOI 10.1097/BRS.0b013e3182927559
   Pittas AG, 2000, THYROID, V10, P261, DOI 10.1089/thy.2000.10.261
   Quan GMY, 2012, THYROID, V22, P125, DOI 10.1089/thy.2010.0248
   Ramadan Sami, 2012, Head Neck Oncol, V4, P39, DOI 10.1186/1758-3284-4-39
   Takayanagi A, 2017, CUREUS, V9, DOI 10.7759/cureus.1132
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Tsang TW, 1998, CANCER-AM CANCER SOC, V82, P375
   Yang L, 2017, Zhonghua Zhong Liu Za Zhi, V39, P862, DOI 10.3760/cma.j.issn.0253-3766.2017.11.010
   Yang Lei, 2014, Zhonghua Yu Fang Yi Xue Za Zhi, V48, P663
   Zettinig G, 2002, CLIN ENDOCRINOL, V56, P377, DOI 10.1046/j.1365-2265.2002.01482.x
   Zhang D, 2013, SPINE, V38, pE1090, DOI 10.1097/BRS.0b013e3182983bf8
   Zheng WP, 2018, EJSO-EUR J SURG ONC, V44, P1679, DOI 10.1016/j.ejso.2018.08.004
NR 31
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E330
EP E336
DI 10.1016/j.wneu.2019.05.143
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900041
PM 31132494
DA 2020-05-12
ER

PT J
AU Zhang, SH
   Bai, JW
   Li, MX
   Zhai, YX
   Wang, S
   Liu, Q
   Li, CZ
   Gui, SB
   Zhang, YZ
AF Zhang, Shuheng
   Bai, Jiwei
   Li, Mingxuan
   Zhai, Yixuan
   Wang, Shuai
   Liu, Qian
   Li, Chuzhong
   Gui, Songbai
   Zhang, Yazhuo
TI Predictive Value of Transforming Growth Factor-alpha and Ki-67 for the
   Prognosis of Skull Base Chordoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ki-67; Skull base chordoma; Survival analysis; TGF-alpha
ID TGF-ALPHA; OVARIAN-CANCER; EGF RECEPTOR; KI67; EXPRESSION; EPIDEMIOLOGY;
   METASTASIS; CARCINOMA; PROTEINS; ANTIGEN
AB OBJECTIVE: We aimed to characterize the expression of transforming growth factor-a (TGF-alpha) and Ki-67 and to assess the relationship between TGF-alpha and Ki-67 expression and prognostic factors in skull base chordoma.
   METHODS: We retrospectively analyzed the data from 46 patients with skull base chordoma. The follow-up duration ranged from 1 to 168 months (mean, 74.1). The survival data were statistically analyzed using the Kaplan-Meier method and multivariate Cox regression analysis. The expression of TGF-alpha and Ki-67 were detected by immunohistochemical staining of paraffin-embedded patient tissue specimens.
   RESULTS: The total resection (TR) group had longer overall survival compared with the non-TR group (P = 0.042). The TR group also had longer progression-free survival (PFS) than did the non-TR group (P = 0.046). The group with a high Ki-67 labeling index (Ki-67LI) had shorter overall survival than did the group with a low Ki-67LI (P = 0.039). Also, the group with a high Ki-67LI had significantly shorter PFS than did the group with a low Ki-67LI (P = 0.016). Moreover, the group with high TGF-alpha expression had significantly shorter PFS compared with the group with low TGF-alpha expression (P = 0.005).
   CONCLUSIONS: Our results have shown that high levels of TGF-alpha and Ki-67 are associated with shorter PFS in patients with chordoma. We have confirmed the role of Ki-67 as a functional molecular marker of poor prognosis. We also identified TGF-alpha as a potential novel biomarker for predicting prognosis for patients with skull base chordoma.
C1 [Zhang, Shuheng; Bai, Jiwei; Li, Mingxuan; Wang, Shuai; Liu, Qian; Li, Chuzhong; Zhang, Yazhuo] Capital Med Univ, Beijing Neurosurg Inst, Beijing, Peoples R China.
   [Zhang, Shuheng; Zhang, Yazhuo] Anshan Cent Hosp, Dept Neurosurg, Anshan, Peoples R China.
   [Bai, Jiwei; Gui, Songbai; Zhang, Yazhuo] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Zhai, Yixuan; Zhang, Yazhuo] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurosurg, Zhengzhou, Henan, Peoples R China.
RP Zhang, YZ (reprint author), Capital Med Univ, Beijing Neurosurg Inst, Beijing, Peoples R China.; Zhang, YZ (reprint author), Anshan Cent Hosp, Dept Neurosurg, Anshan, Peoples R China.; Zhang, YZ (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.; Zhang, YZ (reprint author), Zhengzhou Univ, Affiliated Hosp 1, Dept Neurosurg, Zhengzhou, Henan, Peoples R China.
EM zyz2004520@yeah.net
OI Zhai, Yixuan/0000-0002-4876-8487; KANG, JIE/0000-0002-2079-6742
FU National High Technology Research and Development Program of China (863
   Program)National High Technology Research and Development Program of
   China [2014AA020610]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China [30971005]
FX The present study was supported by the National High Technology Research
   and Development Program of China (863 Program; grant 2014AA020610) and
   the National Natural Science Foundation of China (grant 30971005).
CR AHMED SR, 1991, J STEROID BIOCHEM, V38, P687, DOI 10.1016/0960-0760(91)90079-K
   Awwad RA, 2003, CANCER RES, V63, P4731
   Baek JY, 2010, INT J CANCER, V127, P1060, DOI 10.1002/ijc.25127
   BUDWITNOVOTNY DA, 1986, CANCER RES, V46, P5419
   CLARK GM, 1992, J CLIN ONCOL, V10, P428, DOI 10.1200/JCO.1992.10.3.428
   Claudio PP, 2002, CLIN CANCER RES, V8, P1808
   DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6
   DIMARCO E, 1990, NAT IMMUN CELL GROW, V9, P209
   Fasching PA, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-486
   FERNANDEZ EB, 1994, J UROLOGY, V152, P1133, DOI 10.1016/S0022-5347(17)32522-3
   Fernandez-Miranda JC, 2014, HEAD NECK-J SCI SPEC, V36, P892, DOI 10.1002/hed.23415
   Flanagan AM, 2013, WHO CLASSIFICATION T, P328
   Genc CG, 2018, ANN SURG ONCOL, V25, P2467, DOI 10.1245/s10434-018-6518-2
   GRANDIS JR, 1993, J CELL BIOCHEM, P188
   Greten FR, 2001, PANCREATOLOGY, V1, P363, DOI 10.1159/000055835
   Gui SB, 2016, NEUROSURG REV, V39, P321, DOI 10.1007/s10143-015-0696-1
   Hanna SA, 2008, CLIN ORTHOP RELAT R, V466, P2217, DOI 10.1007/s11999-008-0356-7
   HEFFELFINGER MJ, 1973, CANCER-AM CANCER SOC, V32, P410, DOI 10.1002/1097-0142(197308)32:2<410::AID-CNCR2820320219>3.0.CO;2-S
   Holton JL, 2000, NEUROPATH APPL NEURO, V26, P497, DOI 10.1046/j.1365-2990.2000.00280.x
   Hu HY, 2012, HEPATO-GASTROENTEROL, V59, P2640, DOI 10.5754/hge12071
   Huang L, 1996, J ANAT, V189, P73
   Jones PS, 2014, J CLIN NEUROSCI, V21, P1490, DOI 10.1016/j.jocn.2014.02.008
   Kikuchi K, 2011, FEBS LETT, V585, P286, DOI 10.1016/j.febslet.2010.12.010
   Kullenberg B, 2000, INT J PANCREATOL, V28, P199, DOI 10.1385/IJGC:28:3:199
   Lau TS, 2017, ONCOGENE, V36, P3576, DOI 10.1038/onc.2016.509
   Li LT, 2015, MOL MED REP, V11, P1566, DOI 10.3892/mmr.2014.2914
   Lindsay CR, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2192-6
   LIU D, 1994, INT J CANCER, V56, P603, DOI 10.1002/ijc.2910560423
   MCCORMICK D, 1993, HISTOPATHOLOGY, V22, P355, DOI 10.1111/j.1365-2559.1993.tb00135.x
   MERKEL DE, 1987, J CLIN ONCOL, V5, P1690, DOI 10.1200/JCO.1987.5.10.1690
   Pelletier S, 2009, CANCER IMMUNOL IMMUN, V58, P1207, DOI 10.1007/s00262-008-0630-2
   Preusser M, 2012, HISTOPATHOLOGY, V60, P885, DOI 10.1111/j.1365-2559.2011.04134.x
   Raap M, 2017, VIRCHOWS ARCH, V471, P501, DOI 10.1007/s00428-017-2142-y
   SALISBURY JR, 1993, J PATHOL, V171, P253, DOI 10.1002/path.1711710404
   Sasaki T, 2008, AM J PATHOL, V173, P205, DOI 10.2353/ajpath.2008.071147
   Sasaki T, 2013, BIOMED RES INT, DOI 10.1155/2013/546318
   Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
   SCHULTZ G, 1991, J CELL BIOCHEM, V45, P346, DOI 10.1002/jcb.240450407
   Sciubba DM, 2009, J AM ACAD ORTHOP SUR, V17, P708, DOI 10.5435/00124635-200911000-00005
   Sewell JM, 2005, EXP CELL RES, V304, P305, DOI 10.1016/j.yexcr.2004.11.007
   Singh B, 2014, SEMIN CELL DEV BIOL, V28, P12, DOI 10.1016/j.semcdb.2014.03.003
   Stiller CA, 2013, EUR J CANCER, V49, P684, DOI 10.1016/j.ejca.2012.09.011
   Sun KX, 2016, ONCOTARGET, V7, P9236, DOI 10.18632/oncotarget.7061
   Takagi M, 2018, RADIAT ONCOL, V13, DOI 10.1186/s13014-018-1173-0
   TAKAHASHI N, 1986, J CLIN INVEST, V78, P894, DOI 10.1172/JCI112677
   TODARO GJ, 1976, NATURE, V264, P26, DOI 10.1038/264026a0
   Walcott BP, 2012, LANCET ONCOL, V13, pE69, DOI 10.1016/S1470-2045(11)70337-0
   WONG DTW, 1993, ORAL ONCOL, V29B, P3, DOI 10.1016/0964-1955(93)90003-W
   Yerushalmi R, 2010, LANCET ONCOL, V11, P174, DOI 10.1016/S1470-2045(09)70262-1
   YOSHIDA K, 1990, EXP PATHOL-JENA, V40, P291, DOI 10.1016/S0232-1513(11)80316-6
   Zenonos GA, 2019, J NEUROSURG, V130, P1528, DOI 10.3171/2018.3.JNS172321
   Zhai YX, 2018, WORLD NEUROSURG, V115, pE146, DOI 10.1016/j.wneu.2018.03.216
   Zhang HK, 2016, J CRANIOFAC SURG, V27, pE709, DOI 10.1097/SCS.0000000000003031
NR 53
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E199
EP E206
DI 10.1016/j.wneu.2019.05.110
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900025
PM 31125781
DA 2020-05-12
ER

PT J
AU Zhang, YQ
   Yu, F
   Zhao, ZY
   Men, XZ
AF Zhang, Yong-Qiang
   Yu, Feng
   Zhao, Zhen-Yu
   Men, Xue-Zhong
TI Combined Hyperactive Dysfunction Syndrome of the Cranial Nerves:
   Analysis of 37 Cases and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Bilateral trigeminal neuralgia; Glossopharyngeal neuralgia; Hemifacial
   spasm; Hyperactive dysfunction syndrome; Microvascular decompression
ID BILATERAL TRIGEMINAL NEURALGIA; MICROVASCULAR DECOMPRESSION SURGERY;
   HEMIFACIAL SPASM; GLOSSOPHARYNGEAL NEURALGIA; COMPLICATIONS;
   COMPRESSION; EXPERIENCE; MANAGEMENT; SAFETY
AB BACKGROUND: Hyperactive dysfunction syndrome (HDS) of the cranial nerves, such as trigeminal neuralgia (TN), hemifacial spasm (HFS), and glossopharyngeal neuralgia (GPN), is commonly managed by microsurgical treatment. However, certain patients may present a combination of these syndromes in the neurosurgery department. Here, we aimed to retrospectively assess patients with combined HDS from a single center.
   METHOD: Of 1275 consecutive patients with HDS treated at our center between 2007 and 2017, 37 patients with combined HDS were enrolled, and their medical and surgical records were analyzed.
   RESULTS: The patients with combined HDS, accounting for 2.9% of all patients with HDS, included 22 patients with bilateral TN, 5 patients with TN-HFS, 8 patients with TN-GPN, and 2 patients with GPN-HFS. A comparison of patients with single and combined HDS indicated a significant difference in the mean age at initial diagnosis (63.57 vs. 56.18 years, P = 0.000) but no such difference in the sex ratio (0.54 vs. 0.59, P = 0.865) or incidence of hypertension (32.43% vs. 24.56%, P = 0.274). In total, 32 microvascular decompression (MVD) procedures were performed in the 27 patients with combined HDS, and repeated MVD was required in 5 patients with bilateral TN. Of the 27 patients who underwent MVD, 25 (92.6%) experienced clinical cure or obvious alleviation.
   CONCLUSIONS: Combined HDS involves a group of functional disturbance disorders affecting specific cranial nerves, and it may include TN, HFS, and GPN. In addition to gender and incidence of hypertension, age appeared to be a vital indicator for the development of combined HDS, although this finding was inconsistent in previous studies. MVD appears to be a safe and effective treatment for combined HDS, with a high rate of long-term success.
C1 [Zhang, Yong-Qiang; Yu, Feng; Zhao, Zhen-Yu; Men, Xue-Zhong] PLA 960th Hosp, Dept Neurosurg, Jinan, Shandong, Peoples R China.
RP Yu, F (reprint author), PLA 960th Hosp, Dept Neurosurg, Jinan, Shandong, Peoples R China.
EM yufeng.yf@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81400919]; CAS Key Laboratory of Mental Health,
   Institute of Psychology [KLMH 2014G01]; research fund program of Jinan
   Military General Hospital [2015ZX03]
FX This work was funded by the National Natural Science Foundation of China
   (No. 81400919) to Z.-Y. Z., grants from the CAS Key Laboratory of Mental
   Health, Institute of Psychology (KLMH 2014G01), and research fund
   program of Jinan Military General Hospital (2015ZX03).
CR Barker FG, 1996, NEW ENGL J MED, V334, P1077, DOI 10.1056/NEJM199604253341701
   Bozkurt M, 2012, ACTA NEUROCHIR, V154, P785, DOI 10.1007/s00701-012-1311-7
   Cao JW, 2017, WORLD NEUROSURG, V104, P390, DOI 10.1016/j.wneu.2017.05.020
   Cruccu G, 2016, NEUROLOGY, V87, P220, DOI 10.1212/WNL.0000000000002840
   De Ridder D, 2002, NEUROSURGERY, V51, P427, DOI 10.1097/00006123-200208000-00023
   DeSouza DD, 2015, PAIN, V156, P1112, DOI 10.1097/j.pain.0000000000000156
   Dumot C, 2018, WORLD NEUROSURG, V117, P422, DOI 10.1016/j.wneu.2018.06.160
   Girard N, 1997, NEURORADIOLOGY, V39, P46, DOI 10.1007/s002340050366
   Huh R, 2008, SURG NEUROL, V69, P153, DOI 10.1016/j.surneu.2007.07.027
   Hyun SJ, 2010, NEUROSURG REV, V33, P325, DOI 10.1007/s10143-010-0254-9
   JANNETTA PJ, 1977, NEUROCHIRURGIA, V20, P145
   JANNETTA PJ, 1967, J NEUROSURG, V26, P159, DOI 10.3171/jns.1967.26.1part2.0159
   Kalkanis SN, 2003, NEUROSURGERY, V52, P1251, DOI 10.1227/01.NEU.0000065129.25359.EE
   KALKANIS SN, 2003, NEUROSURGERY, V52, P1261
   Kobata H, 1998, NEUROSURGERY, V43, P1351, DOI 10.1097/00006123-199812000-00052
   McLaughlin MR, 1999, J NEUROSURG, V90, P1, DOI 10.3171/jns.1999.90.1.0001
   Miller LE, 2012, BRIT J NEUROSURG, V26, P438, DOI 10.3109/02688697.2011.641613
   Mohyuddin A, 2009, J CLIN NEUROSCI, V16, P708, DOI 10.1016/j.jocn.2008.06.024
   Okada-Ogawa A, 2009, J NEUROSCI, V29, P11161, DOI 10.1523/JNEUROSCI.3365-09.2009
   POLLACK IF, 1988, J NEUROSURG, V68, P559, DOI 10.3171/jns.1988.68.4.0559
   Raval Ami B, 2014, Surg Neurol Int, V5, P160, DOI 10.4103/2152-7806.145201
   RESNICK DK, 1995, NEUROSURGERY, V36, P64, DOI 10.1227/00006123-199501000-00008
   Samii M, 2002, NEUROSURGERY, V50, P712, DOI 10.1097/00006123-200204000-00005
   Sampson JH, 2004, NEUROSURGERY, V54, P884, DOI 10.1227/01.NEU.0000114142.98655.CC
   TAARNHOJ P, 1952, J NEUROSURG, V9, P288, DOI 10.3171/jns.1952.9.3.0288
   Tacconi L, 2000, BRIT J NEUROSURG, V14, P33
   Wang YN, 2014, ACTA NEUROCHIR, V156, P1167, DOI 10.1007/s00701-014-2034-8
   WHITE JC, 1969, PAIN NEUROSURGEON 40
   Xia L, 2014, J CRANIOFAC SURG, V25, P1413, DOI 10.1097/SCS.0000000000000984
   Yang KH, 2009, J KOREAN NEUROSURG S, V46, P351, DOI 10.3340/jkns.2009.46.4.351
   Zhao H, 2018, WORLD NEUROSURG, V109, pE724, DOI 10.1016/j.wneu.2017.10.072
   Zhong J, 2015, ACTA NEUROCHIR, V157, P93, DOI 10.1007/s00701-014-2247-x
NR 32
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E650
EP E656
DI 10.1016/j.wneu.2019.05.237
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900082
PM 31158546
DA 2020-05-12
ER

PT J
AU Zhao, H
   Li, ST
   Zhu, J
   Hua, XM
   Wan, L
AF Zhao, Hua
   Li, Shi-ting
   Zhu, Jin
   Hua, Xu-Ming
   Wan, Liang
TI Analysis of Peripheral Blood Cells' Transcriptome in Patients With
   Subarachnoid Hemorrhage From Ruptured Aneurysm Reveals Potential
   Biomarkers
SO WORLD NEUROSURGERY
LA English
DT Article
DE Gene expression omnibus; Peripheral blood cells' transcriptome;
   Subarachnoid hemorrhage
ID INTRACRANIAL ANEURYSMS; INFLAMMATION
AB BACKGROUND: Subarachnoid hemorrhage (SAH) is an uncommon disease. Considering ruptured intracranial aneurysms as the main cause of this disease and only a minority of the intracranial aneurysms will rupture sooner or later, to understand the underlying pathology or a specific gene expression profile of an impending ruptured intracranial aneurysm is of great importance.
   METHODS: The transcriptome in peripheral blood cells of patients with SAH from ruptured aneurysm was compared with that of control patients suffering from headaches. The microarray dataset GSE36791 comprised 43 patients with SAH from ruptured aneurysms and 18 control patients. Differential expression analysis was performed with the R language packages to identify differentially expressed genes (DEGs). Gene Ontology enrichment analysis and Kyoto Encyclopedia of Genes and Genomes pathway database analysis were performed to identify significantly altered biological functions and pathways, respectively. The protein-protein interaction networks were constructed with information from the STRING database.
   RESULTS: A total of 528 DEGs were identified, of which 311 were upregulated and 217 downregulated. Clustering analysis confirmed that these genes can distinguish ruptured aneurysm SAH patients from the control patients. The DEGs were mainly enriched for immune/inflammation response and related pathways. Among the DEGs, 8 genes (ARG1, MAPK14, RPS2, SPI1, FYN, CEBPB, FLOT1, and CD4) were identified as the key regulators in the Protein-Protein Interaction network. MAPK14, CEBPB, FLOT1, and CD4 might be potential biomarkers of SAH.
   CONCLUSION: This study identified a range of DEGs SAH patients with ruptured aneurysms, which may enhance our current knowledge on this disease and may provide potential biomarkers of this disease.
C1 [Zhao, Hua; Li, Shi-ting; Zhu, Jin; Hua, Xu-Ming; Wan, Liang] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Neurosurg, Shanghai, Peoples R China.
RP Wan, L (reprint author), Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Neurosurg, Shanghai, Peoples R China.
EM wanliang15@126.com
CR Abraham MK, 2016, EMERG MED CLIN N AM, V34, P901, DOI 10.1016/j.emc.2016.06.011
   Achrol AS, 2016, FRONT SURG, V3, DOI 10.3389/fsurg.2016.00034
   Brisman JL, 2006, NEW ENGL J MED, V355, P928, DOI 10.1056/NEJMra052760
   Chalouhi N, 2012, J CEREBR BLOOD F MET, V32, P1659, DOI 10.1038/jcbfm.2012.84
   Chen S, 2014, BIOMED RES INT, DOI 10.1155/2014/858496
   Chyatte D, 1999, NEUROSURGERY, V45, P1137, DOI 10.1097/00006123-199911000-00024
   de Rooij NK, 2007, J NEUROL NEUROSUR PS, V78, P1365, DOI 10.1136/jnnp.2007.117655
   Dessau Ram Benny, 2008, Ugeskr Laeger, V170, P328
   Dority Jeremy S, 2016, Anesthesiol Clin, V34, P577, DOI 10.1016/j.anclin.2016.04.009
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0
   Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Kanehisa M, 2002, NOVART FDN SYMP, V247, P91
   Kataoka K, 1999, STROKE, V30, P1396, DOI 10.1161/01.STR.30.7.1396
   Kowalski RG, 2004, JAMA-J AM MED ASSOC, V291, P866, DOI 10.1001/jama.291.7.866
   Lanzino G, 2008, J NEUROSURG, V108, P1071, DOI 10.3171/JNS/2008/108/6/1071
   Lee CI, 2012, MOL MED REP, V5, P118, DOI 10.3892/mmr.2011.614
   Macdonald RL, 2017, LANCET, V389, P655, DOI 10.1016/S0140-6736(16)30668-7
   Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357
   Pera J, 2010, STROKE, V41, P224, DOI 10.1161/STROKEAHA.109.562009
   Perry JJ, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4277
   Provencio JJ, 2005, SEMIN NEUROL, V25, P435, DOI 10.1055/s-2005-923537
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   WIEBERS DO, 1987, J NEUROSURG, V66, P23, DOI 10.3171/jns.1987.66.1.0023
NR 25
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E16
EP E22
DI 10.1016/j.wneu.2019.04.125
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900004
PM 31026661
DA 2020-05-12
ER

PT J
AU Zhong, JL
   Cao, K
   Wang, B
   Zhou, XM
   Lin, N
   Lu, HD
AF Zhong, Junlong
   Cao, Kai
   Wang, Bin
   Zhou, Xuemei
   Lin, Nan
   Lu, Huading
TI The Perioperative Efficacy and Safety of Tranexamic Acid in Adolescent
   Idiopathic Scoliosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adolescent idiopathic scoliosis; Corrective surgery; Efficacy; Safety;
   Tranexamic acid
ID BLOOD-LOSS; SPINAL-FUSION; SURGERY; THERAPY
AB OBJECTIVE: To evaluate the efficacy and safety of tranexamic acid (TXA) in patients with adolescent idiopathic scoliosis undergoing corrective surgery.
   METHODS: A literature search of PubMed, Embase, and Cochrane Library was performed to identify studies published from inception to February 2019. After study selection and data extraction, statistical analysis was performed. Odds ratios and weighted mean differences (WMDs) with 95% confidence intervals (CIs) for all available clinical outcomes were analyzed using fixed-effects or random-effects models.
   RESULTS: Twelve studies comprising 2500 patients were included. Intravenous TXA use was associated with significantly fewer patients received blood transfusions (odds ratio, 0.12; 95% CI, 0.06 to 0.22; P < 0.001), less intraoperative estimated blood loss (WMD, -470.07; 95% CI, -645.23 to -294.90; P < 0.001), less intraoperative estimated blood loss per segment (WMD, -27.40; 95% CI, -32.80 to -22.00; P < 0.001), less cell salvage blood transfusion (WMD, -106.02; 95% CI, -170.84 to -41.20; P = 0.001), and shorter surgical time (WMD, -26.18; 95% CI, -46.91 to -5.46; P = 0.010). No significant difference was found in postoperative hemoglobin (WMD, 0.39; 95% CI, -0.07 to 0.86; P = 0.100) and hemoglobin change (WMD, -0.92; 95% CI, -2.90 to 1.07; P = 0.360) between TXA and control groups. No renal, thromboembolic, or other major complications associated with TXA were noted in included studies.
   CONCLUSIONS: TXA was effective in reducing surgical time, intraoperative estimated blood loss, and blood transfusion without increasing complications in patients undergoing corrective surgery for adolescent idiopathic scoliosis. TXA had no influence on postoperative hemoglobin and hemoglobin change.
C1 [Zhong, Junlong; Wang, Bin; Lin, Nan; Lu, Huading] Sun Yat Sen Univ, Dept Orthopaed, Affiliated Hosp 1, Zhuhai, Peoples R China.
   [Cao, Kai] Nanchang Univ, Dept Orthopaed, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China.
   [Zhou, Xuemei] Gannan Med Univ, Affiliated Hosp 2, 0Epartment Neurol, Ganzhou, Peoples R China.
RP Lu, HD (reprint author), Sun Yat Sen Univ, Dept Orthopaed, Affiliated Hosp 1, Zhuhai, Peoples R China.
EM johnniehuading@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81572174, 81772384]
FX This work was supported by the National Natural Science Foundation of
   China (Grant Nos. 81572174 and 81772384).
CR Alshryda S, 2014, BONE JOINT J, V96B, P1005, DOI 10.1302/0301-620X.96B8.33745
   Berney Mark J, 2015, Eur J Orthop Surg Traumatol, V25 Suppl 1, pS219, DOI 10.1007/s00590-015-1624-3
   Gong M, 2019, WORLD NEUROSURG, V122, P559, DOI 10.1016/j.wneu.2018.09.115
   Goobie SM, 2018, J BONE JOINT SURG AM, V100, P2024, DOI 10.2106/JBJS.18.00314
   GUAY J, 1994, CAN J ANAESTH, V41, P775, DOI 10.1007/BF03011583
   Johnston LR, 2018, JAMA SURG, V153, P169, DOI 10.1001/jamasurg.2017.3821
   Jones KE, 2017, INT J SPINE SURG, V11, DOI 10.14444/4027
   Lonner BS, 2018, BULL HOSP JT DIS, V76, P165
   Lu VM, 2018, SPINE, V43, pE949, DOI 10.1097/BRS.0000000000002580
   Lykissas MG, 2013, J CHILD ORTHOP, V7, P245, DOI 10.1007/s11832-013-0486-7
   McCormack PL, 2012, DRUGS, V72, P585, DOI 10.2165/11209070-000000000-00000
   Myers SP, 2019, J TRAUMA ACUTE CARE, V86, P20, DOI 10.1097/TA.0000000000002061
   Ng BKW, 2015, SCOLIOSIS SPINAL DIS, V10, DOI 10.1186/s13013-015-0052-9
   Ohashi N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173622
   Patil H, 2019, WORLD NEUROSURG, V124, pE779, DOI 10.1016/j.wneu.2019.01.023
   Saleh AN, 2018, OPEN ANESTHESIOL J, V12, P61
   Seki H, 2018, SCOLIOSIS SPINAL DIS, V13, DOI 10.1186/s13013-018-0165-z
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Sui WY, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1006-y
   Theroux J, 2017, J MANIP PHYSIOL THER, V40, P452, DOI 10.1016/j.jmpt.2017.03.009
   Verma Kushagra, 2014, J Bone Joint Surg Am, V96, pe80, DOI 10.2106/JBJS.L.00008
   Weinstein SL, 2008, LANCET, V371, P1527, DOI 10.1016/S0140-6736(08)60658-3
   Xu CS, 2012, ARCH ORTHOP TRAUM SU, V132, P25, DOI 10.1007/s00402-011-1390-6
   Yagi M, 2012, SPINE, V37, pE1336, DOI 10.1097/BRS.0b013e318266b6e5
NR 24
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E726
EP E732
DI 10.1016/j.wneu.2019.05.261
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900091
PM 31176837
DA 2020-05-12
ER

PT J
AU Liu, XY
   Fan, LH
   Yin, ST
   Chen, H
   Hu, HB
AF Liu, Xiaoyi
   Fan, Lihong
   Yin, Shutao
   Chen, Hui
   Hu, Hongbo
TI Molecular mechanisms of fumonisin B1-induced toxicities and its
   applications in the mechanism-based interventions
SO TOXICON
LA English
DT Review
DE Mycotoxins; Fumonisin B1; Toxicities; Mechanisms; Intervention
ID STRESS-MEDIATED AUTOPHAGY; SPRAGUE-DAWLEY RATS; HISTONE MODIFICATIONS;
   OXIDATIVE DAMAGE; PROTECTIVE ROLE; DNA-DAMAGE; B-1; LIVER; KIDNEY; B1
AB Fumonisin B1 (FB1), the most toxic member of fumonisins, is one of the most common mycotoxins contaminating feed and food. It has been shown to produce pleiotropic toxicities in animals including neurotoxicity, hepatotoxicity and nephrotoxicity, and with highly potential impact on human health. Proposed mechanisms include disruption of sphingolipid metabolism, induction of oxidative stress, activation of endoplasmic reticulum (ER) stress and MAPKs, modulation of autophagy and alteration of DNA methylation. These mechanistic findings provide the theoretical basis for effectively managing FB1-induced adverse health effects. In this review, we will summarize the present understanding of the molecular basis underlying FB1-mediated toxicities, discuss the feasibility of developing mechanism-based approach to prevent FB1-induced toxicities, and suggest the issues that need to be addressed in the future in the field of FB1 toxicity-related studies.
C1 [Liu, Xiaoyi; Yin, Shutao; Chen, Hui; Hu, Hongbo] China Agr Univ, Coll Food Sci & Nutr Engn, Dept Nutr & Food Safety, 17 Qinghua East Rd, Beijing 100083, Peoples R China.
   [Fan, Lihong] China Agr Univ, Coll Vet Med, 2 Yunamingyuan West, Beijing 100193, Peoples R China.
RP Fan, LH (reprint author), China Agr Univ, Coll Vet Med, 2 Yunamingyuan West, Beijing 100193, Peoples R China.
EM flh@cau.edu.cn
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China [31671945]
FX This work was funded by grants from National Natural Science Foundation
   of China (NSFC, 31671945).
CR Abbes S, 2016, J IMMUNOTOXICOL, V13, P46, DOI 10.3109/1547691X.2014.997905
   Abel S, 1998, TOXICOLOGY, V131, P121, DOI 10.1016/S0300-483X(98)00123-1
   Antonissen G, 2017, FOOD CHEM TOXICOL, V101, P75, DOI 10.1016/j.fct.2017.01.006
   Arumugam T, 2019, MYCOTOXIN RES, V35, P99, DOI 10.1007/s12550-018-0335-0
   Atroshi F, 1999, PHARMACOL RES, V40, P459, DOI 10.1006/phrs.1999.0529
   Bahna SG, 2018, BRIT J PHARMACOL, V175, P3209, DOI 10.1111/bph.14058
   Beerman I, 2015, CELL STEM CELL, V16, P613, DOI 10.1016/j.stem.2015.05.009
   Bennett JW, 2003, CLIN MICROBIOL REV, V16, P497, DOI 10.1128/CMR.16.3.497-516.2003
   Chuturgoon A, 2014, TOXICOLOGY, V315, P65, DOI 10.1016/j.tox.2013.11.004
   Demirel G, 2015, PHARM BIOL, V53, P1302, DOI 10.3109/13880209.2014.976714
   Denton D, 2015, IMMUNOL CELL BIOL, V93, P35, DOI 10.1038/icb.2014.85
   Dombrink-Kurtzman MA, 2000, IMMUNOPHARMACOLOGY, V49, P401, DOI 10.1016/S0162-3109(00)00262-9
   Domijan AM, 2012, ARH HIG RADA TOKSIKO, V63, P531, DOI 10.2478/10004-1254-63-2012-2239
   Domijan AM, 2011, INT J BIOCHEM CELL B, V43, P897, DOI 10.1016/j.biocel.2011.03.003
   Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458
   Gu Q, 2017, TOXINS, V9, DOI 10.3390/toxins9020043
   Hassa PO, 2005, BIOCHEM CELL BIOL, V83, P270, DOI 10.1139/o05-034
   He L, 2017, CELL PHYSIOL BIOCHEM, V44, P532, DOI 10.1159/000485089
   He Q, 2005, FOOD CHEM TOXICOL, V43, P969, DOI 10.1016/j.fct.2005.01.021
   He QR, 2002, PHARMACOL TOXICOL, V90, P268, DOI 10.1034/j.1600-0773.2002.900507.x
   Holthuis JCM, 2014, NATURE, V510, P48, DOI 10.1038/nature13474
   Huang DY, 2019, FOOD CHEM TOXICOL, V123, P595, DOI 10.1016/j.fct.2018.10.059
   IARC, 2002, IARC MON EV CARC RIS, V82, P301
   Kim DH, 2007, ARCH PHARM RES, V30, P962, DOI 10.1007/BF02993964
   Kim SH, 2018, J BIOCHEM MOL TOXIC, V32, DOI 10.1002/jbt.22161
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Kimura H, 2013, J HUM GENET, V58, P439, DOI 10.1038/jhg.2013.66
   Kovacic S, 2009, ARH HIG RADA TOKSIKO, V60, P419, DOI 10.2478/10004-1254-60-2009-1974
   Maatz H, 2017, METHODS MOL BIOL, V1488, P217, DOI 10.1007/978-1-4939-6427-7_9
   Mari M, 2009, ANTIOXID REDOX SIGN, V11, P2685, DOI [10.1089/ars.2009.2695, 10.1089/ARS.2009.2695]
   Marin S, 2013, FOOD CHEM TOXICOL, V60, P218, DOI 10.1016/j.fct.2013.07.047
   Mary VS, 2012, TOXICOLOGY, V302, P299, DOI 10.1016/j.tox.2012.08.012
   Mobio TA, 2000, ARCH TOXICOL, V74, P112, DOI 10.1007/s002040050661
   Moretti A, 2017, METHODS MOL BIOL, V1542, P3, DOI 10.1007/978-1-4939-6707-0_1
   Muller S, 2012, FOOD CHEM TOXICOL, V50, P3833, DOI 10.1016/j.fct.2012.06.053
   Ravegnini G, 2015, TOXICOL SCI, V148, P2, DOI 10.1093/toxsci/kfv165
   Riley RT, 2006, TOXICOL SCI, V92, P335, DOI 10.1093/toxsci/kfj198
   Riley RT, 2001, ENVIRON HEALTH PERSP, V109, P301, DOI 10.2307/3435022
   RILEY RT, 1994, J NUTR, V124, P594
   RILEY RT, 1993, TOXICOL APPL PHARM, V118, P105, DOI 10.1006/taap.1993.1015
   ROSS PF, 1990, APPL ENVIRON MICROB, V56, P3225, DOI 10.1128/AEM.56.10.3225-3226.1990
   Rumora L, 2007, TOXICOLOGY, V242, P31, DOI 10.1016/j.tox.2007.09.006
   Sancak D, 2015, TOXICOL IN VITRO, V29, P1809, DOI 10.1016/j.tiv.2015.07.019
   Sharma N, 2005, J BIOCHEM MOL TOXIC, V19, P359, DOI 10.1002/jbt.20102
   Sharp GC, 2017, EPIGENOMICS-UK, V9, P789, DOI 10.2217/epi-2017-0045
   Shin HJR, 2016, NATURE, V534, P553, DOI 10.1038/nature18014
   Singh MP, 2017, FOOD CHEM TOXICOL, V110, P371, DOI 10.1016/j.fct.2017.10.054
   Song SL, 2018, J CELL PHYSIOL, V233, P3867, DOI 10.1002/jcp.26137
   Soriano JM, 2005, PROG LIPID RES, V44, P345, DOI 10.1016/j.plipres.2005.09.001
   Stockmann-Juvala H, 2004, FREE RADICAL RES, V38, P933, DOI 10.1080/10715760412331273205
   Stockmann-Juvala H, 2008, HUM EXP TOXICOL, V27, P799, DOI 10.1177/0960327108099525
   THIEL PG, 1991, APPL ENVIRON MICROB, V57, P1089, DOI 10.1128/AEM.57.4.1089-1093.1991
   Tryphonas H, 1997, FUND APPL TOXICOL, V39, P53, DOI 10.1006/faat.1997.2348
   Turei D, 2015, AUTOPHAGY, V11, P155, DOI 10.4161/15548627.2014.994346
   Wang K, 2011, AUTOPHAGY, V7, P297, DOI 10.4161/auto.7.3.14502
   Wang X, 2016, ARCH TOXICOL, V90, P81, DOI 10.1007/s00204-015-1604-8
   Yeung JM, 1996, TOXICOL APPL PHARM, V141, P178, DOI 10.1016/S0041-008X(96)80023-8
   Yin ST, 2016, ARCH TOXICOL, V90, P985, DOI 10.1007/s00204-015-1514-9
   Yoo HS, 1996, TOXICOL APPL PHARM, V138, P211, DOI 10.1006/taap.1996.0119
   Zhang H, 2018, TOXICON, V146, P114, DOI 10.1016/j.toxicon.2018.02.052
   Zhang W, 2018, FOOD CHEM TOXICOL, V111, P27, DOI 10.1016/j.fct.2017.10.057
   Zlotorynski E, 2017, NAT REV MOL CELL BIO, V18, DOI 10.1038/nrm.2017.25
NR 62
TC 2
Z9 2
U1 6
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 1
EP 5
DI 10.1016/j.toxicon.2019.06.009
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000001
PM 31173793
DA 2020-05-12
ER

PT J
AU Nascimento, TL
   Conte, TC
   Rissato, TS
   Luna, MS
   Soares, AG
   Moriscot, AS
   Yamanouye, N
   Miyabara, EH
AF Nascimento, T. L.
   Conte, T. C.
   Rissato, T. S.
   Luna, M. S.
   Soares, A. G.
   Moriscot, A. S.
   Yamanouye, N.
   Miyabara, E. H.
TI Radicicol enhances the regeneration of skeletal muscle injured by
   crotoxin via decrease of NF-kB activation
SO TOXICON
LA English
DT Article
DE Heat shock proteins; Crotoxin; Muscle damage; Nuclear factor kappa B
ID KAPPA-B; SATELLITE CELLS; DIFFERENTIATION; COMPONENTS; RAT
AB This study evaluated cellular and molecular effects of radicicol, a heat shock protein (HSP) inducer, on the regeneration of skeletal muscle injured by crotoxin, the main toxin isolated from Crotalus durissus terrificus venom. Regenerating muscles treated with radicicol had decreased NF-kB activation. Differentiating myoblasts treated with radicicol showed reduced number of NF-kB positive nuclei and increased fusion index. The results suggest that radicicol enhances regeneration of muscle by attenuating NF-kB activation and increasing myogenic differentiation.
C1 [Nascimento, T. L.; Conte, T. C.; Rissato, T. S.; Moriscot, A. S.; Miyabara, E. H.] Univ Sao Paulo, Biomed Sci Inst, Dept Anat, Av Lineu Prestes 2415, BR-05508000 Sao Paulo, SP, Brazil.
   [Luna, M. S.; Yamanouye, N.] Butantan Inst, Pharmacol Lab, Av Vital Brazil 1500, BR-05503900 Sao Paulo, SP, Brazil.
   [Soares, A. G.] Univ Sao Paulo, Biomed Sci Inst, Dept Pharmacol, Av Lineu Prestes 1524, BR-05508900 Sao Paulo, SP, Brazil.
RP Miyabara, EH (reprint author), Univ Sao Paulo, Biomed Sci Inst, Dept Anat, Av Lineu Prestes 2415, BR-05508000 Sao Paulo, SP, Brazil.
EM elenm@usp.br
RI ; Soares Junior, Antonio Garcia/C-9179-2016; Yamanouye,
   Norma/I-3348-2013; Miyabara, Elen/E-8143-2012
OI Moriscot, Anselmo Sigari/0000-0003-3098-4613; Soares Junior, Antonio
   Garcia/0000-0001-5814-3475; Yamanouye, Norma/0000-0001-6007-0199;
   Miyabara, Elen/0000-0002-2325-9571
FU Foundation for Support to Research of the State of Sao Paulo (Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo FAPESP, Brazil)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [07/58758-5,
   09/53528-7, 12/21238-2]; National Council for Scientific and
   Technological Development (Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico CNPq, Brazil)National Council for Scientific
   and Technological Development (CNPq) [312142/2018-8]; FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [13/04783-0,
   07/56879-0, 08/58542-5]
FX The authors are grateful to Heloisa Selistre-de-Araujo for purifying CTX
   and Lygia S. G. Luchini for technical assistance. This study was funded
   by the Foundation for Support to Research of the State of Sao Paulo
   (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo FAPESP, Brazil)
   (Grants No. 07/58758-5, 09/53528-7, and 12/21238-2) and the National
   Council for Scientific and Technological Development (Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico CNPq, Brazil)
   (Fellowship/Grant No. 312142/2018-8). T.L.N., T.C.C., and L.S.G.L.
   received scholarships from FAPESP (Grants No. 13/04783-0; 07/56879-0,
   and 08/58542-5, respectively).
CR Bakkar N, 2008, J CELL BIOL, V180, P787, DOI 10.1083/jcb.200707179
   Brack AS, 2009, DEV BIOL, V335, P93, DOI 10.1016/j.ydbio.2009.08.014
   Conte TC, 2008, TOXICON, V52, P146, DOI 10.1016/j.toxicon.2008.04.177
   Conte TC, 2012, J GERONTOL A-BIOL, V67, P443, DOI 10.1093/gerona/glr195
   Dodd SL, 2009, FASEB J, V23, P3415, DOI 10.1096/fj.08-124602
   Frezzatti R, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001312
   GOPALAKRISHNAKONE P, 1984, TOXICON, V22, P85, DOI 10.1016/0041-0101(84)90141-7
   Gutierrez JM, 2003, TOXICON, V42, P915, DOI 10.1016/j.toxicon.2003.11.005
   Gutierrez JM, 2017, NAT REV DIS PRIMERS, V3, DOI [10.1038/nrdp.2017.79, 10.1038/nrdp.2017.63]
   Hawke TJ, 2001, J APPL PHYSIOL, V91, P534
   HENDON RA, 1971, P NATL ACAD SCI USA, V68, P1560, DOI 10.1073/pnas.68.7.1560
   Kasturiratne A, 2008, PLOS MED, V5, P1591, DOI 10.1371/journal.pmed.0050218
   LANDUCCI ECT, 1994, TOXICON, V32, P217, DOI 10.1016/0041-0101(94)90111-2
   Lu AP, 2012, MOL THER, V20, P661, DOI 10.1038/mt.2011.261
   MEBS D, 1990, PHARMACOL THERAPEUT, V48, P223, DOI 10.1016/0163-7258(90)90081-C
   Miyabara EH, 2004, TOXICON, V43, P425, DOI 10.1016/j.toxicon.2004.02.012
   Miyabara EH, 2010, MUSCLE NERVE, V42, P778, DOI 10.1002/mus.21754
   Mourkioti F, 2006, J CLIN INVEST, V116, P2945, DOI 10.1172/JCI28721
   Quach NL, 2006, DEV BIOL, V293, P38, DOI 10.1016/j.ydbio.2005.12.040
   Rong YQ, 1996, J NEUROCHEM, V67, P662
   Salvini TF, 2001, TOXICON, V39, P1141, DOI 10.1016/S0041-0101(00)00245-2
   Sampaio SC, 2010, TOXICON, V55, P1045, DOI 10.1016/j.toxicon.2010.01.011
   SCHAGGER H, 1988, ANAL BIOCHEM, V173, P201, DOI 10.1016/0003-2697(88)90179-0
   Senf SM, 2008, FASEB J, V22, P3836, DOI 10.1096/fj.08-110163
   Silva MT, 2014, ACTA PHYSIOL, V211, P617, DOI 10.1111/apha.12329
   Yin H, 2013, PHYSIOL REV, V93, P23, DOI 10.1152/physrev.00043.2011
NR 26
TC 0
Z9 0
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 6
EP 9
DI 10.1016/j.toxicon.2019.06.011
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000002
PM 31173791
DA 2020-05-12
ER

PT J
AU Souza, BBP
   Fh, JLC
   Murad, AM
   Prates, MV
   Coura, MMA
   Brand, GD
   Barbosa, EA
   Bloch, C
AF Souza, Beatriz Blenda P.
   Cardozo Fh, Jose L.
   Murad, Andre M.
   Prates, Maura, V
   Coura, Marcelo M. A.
   Brand, Guilherme D.
   Barbosa, Eder A.
   Bloch Jr, Carlos
TI Identification and characterization of phospholipases A(2) from the skin
   secretion of Pithecopus azureus anuran
SO TOXICON
LA English
DT Article
DE Phospholipase A2; Amino acid and cDNA sequencing; Pithecopus azureus;
   N-Glycosylation; Molecular modeling
ID AGKISTRODON-HALYS PALLAS; PANCREATIC PHOSPHOLIPASE-A2; BACTERICIDAL
   PROPERTIES; PROTEIN GLYCOSYLATION; TRYPSIN-INHIBITOR; SNAKE-VENOM;
   ACTIVE-SITE; GROUP-V; PEPTIDES; FROG
AB The present work reports the isolation, characterization and the complete sequence of a phospholipase A(2) (PLA(2)) present in the skin secretion of Pithecopus azureus. Among several peptides and small proteins previously described by our group from some species belonging to this amphibian genus (formerly named Phyllomedusa), a 15 kDa N-glycosylated protein showing PLA(2) activity was purified, assayed, sequenced and named Pa-PLA(2) . The Pithecopus azureus skin phospholipase A(2) polypeptide chain is composed by 125 amino acid residues linked by seven disulfide bonds and two N-glycosylated sites (N67 and N108). The Pa-PLA(2) enzymatic activity was qualitatively evaluated and compared to classical viperid PLA(2) showing that both, native and deglycosylated PaPLA(2) forms, are catalytically functional. The tridimensional molecular model of Pa-PLA(2) indicates that the observed glycan moieties are suggestively placed far from the active site of that enzyme and therefore having little or no significant role on the direct interaction of the Pa-PLA(2) catalytic pocket and its substrates.
C1 [Souza, Beatriz Blenda P.; Cardozo Fh, Jose L.; Murad, Andre M.; Prates, Maura, V; Coura, Marcelo M. A.; Bloch Jr, Carlos] Embrapa Recursos Genet & Biotecnol, Lab Espectrometria Massa, Estacao Parque Biol,Final W5,Asa Norte, BR-70770900 Brasilia, DF, Brazil.
   [Souza, Beatriz Blenda P.] Univ Brasilia, Inst Biol, Brasilia, DF, Brazil.
   [Coura, Marcelo M. A.] Univ Brasilia, Fac Ciencias Saude, Brasilia, DF, Brazil.
   [Brand, Guilherme D.; Barbosa, Eder A.] Univ Brasilia, Inst Quim, LSAB, Brasilia, DF, Brazil.
   [Cardozo Fh, Jose L.] Inst Mato Grossense Algodao, Cuiaba, MT, Brazil.
RP Bloch, C (reprint author), Embrapa Recursos Genet & Biotecnol, Lab Espectrometria Massa, Estacao Parque Biol,Final W5,Asa Norte, BR-70770900 Brasilia, DF, Brazil.
EM carlos.bloch@embrapa.br
RI Prates, Maura/S-8399-2019; , Andre/S-7486-2019; Bloch,
   Carlos/S-8375-2019; Brand, Guilherme/B-5603-2015; Murad, Andre
   M/C-4459-2017
OI Prates, Maura/0000-0002-0206-5890; , Andre/0000-0002-7055-9462; Brand,
   Guilherme/0000-0002-1615-0009; Murad, Andre M/0000-0002-7055-9462
FU Fundacao de Amparo a Pesquisa do Estado do Amazonas (FAPEAM); Conselho
   Nacional de Desenvolvimento Cientifico e Tencologico (CNPq)National
   Council for Scientific and Technological Development (CNPq)
   [303750/2015-4]; Serrapilheira Institute [Serra -1708-16056]
FX Fundacao de Amparo a Pesquisa do Estado do Amazonas (FAPEAM) directly
   supported the first author's research and PhD program. Other sources of
   funding: Serrapilheira Institute (Grant Number Serra -1708-16056) and
   Conselho Nacional de Desenvolvimento Cientifico e Tencologico (CNPq
   Grant Number: 303750/2015-4).
CR ACTIVITY, PEPTIDES
   ACTIVITY, PEPTIDES, V29, P1633
   Batista CVF, 1999, PEPTIDES, V20, P679, DOI 10.1016/S0196-9781(99)00050-9
   Brand GD, 2006, PEPTIDES, V27, P2137, DOI 10.1016/j.peptides.2006.04.020
   Brand GD, 2002, J BIOL CHEM, V277, P49332, DOI 10.1074/jbc.M209289200
   Burke JE, 2009, CARDIOVASC DRUG THER, V23, P49, DOI 10.1007/s10557-008-6132-9
   Conceicao K, 2007, TOXICON, V49, P1054, DOI 10.1016/j.toxicon.2006.12.010
   Conlon JM, 2009, BBA-BIOMEMBRANES, V1788, P1556, DOI 10.1016/j.bbamem.2008.09.018
   Darby N. J, 1991, ZAEVIS, V70, P65
   DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500
   DENNIS EA, 1994, J BIOL CHEM, V269, P13057
   Dennis EA, 2011, CHEM REV, V111, P6130, DOI 10.1021/cr200085w
   Duellman W. E., 1994, BIOLOGY OF AMPHIBIAN
   DUTTON MJ, 1983, EUR J BIOCHEM, V137, P545
   ERSPAMER V, 1951, NATURE, V167, P1033, DOI 10.1038/1671033a0
   Fenard D, 2001, MOL PHARMACOL, V60, P341
   GIOVANNINI MG, 1987, BIOCHEM J, V243, P113, DOI 10.1042/bj2430113
   Gronroos JO, 2001, J IMMUNOL, V166, P4029, DOI 10.4049/jimmunol.166.6.4029
   Han SK, 1997, J BIOL CHEM, V272, P3573, DOI 10.1074/jbc.272.26.16152
   Harris JB, 2013, TOXINS, V5, P2533, DOI 10.3390/toxins5122533
   HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704
   HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913
   Hiraoka M, 2013, J LIPID RES, V54, P3098, DOI 10.1194/jlr.M041640
   Hou SL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11219-8
   Jain MK, 2006, CURR OPIN CHEM BIOL, V10, P473, DOI 10.1016/j.cbpa.2006.08.015
   Kim JO, 2007, J VIROL, V81, P1444, DOI 10.1128/JVI.01790-06
   Konig E, 2015, PEPTIDES, V63, P96, DOI 10.1016/j.peptides.2014.11.003
   Konig E, 2013, ORG DIVERS EVOL, V13, P453, DOI 10.1007/s13127-013-0128-4
   Lai CC, 2000, RAPID COMMUN MASS SP, V14, P2012, DOI 10.1002/1097-0231(20001115)14:21<2012::AID-RCM126>3.3.CO;2-#
   Leite JRSA, 2005, PEPTIDES, V26, P565, DOI 10.1016/j.peptides.2004.11.002
   Liberio MD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096893
   Lomonte B, 2003, TOXICON, V42, P885, DOI 10.1016/j.toxicon.2003.11.008
   Magalhaes M. T. Q, 2013, PLOS ONE, V8, P1, DOI 10.1371/journal.pone.0059255
   Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959
   Martins M. J. P, 2007, J VENOM ANIM TOXINS, V13, P205
   Mitsuishi M, 2006, BIOCHEM J, V393, P97, DOI 10.1042/BJ20050781
   MIZUNO K, 1987, BIOCHEM BIOPH RES CO, V148, P546, DOI 10.1016/0006-291X(87)90911-9
   Morelle W, 2007, NAT PROTOC, V2, P1585, DOI 10.1038/nprot.2007.227
   Moremen KW, 2012, NAT REV MOL CELL BIO, V13, P448, DOI 10.1038/nrm3383
   Mukherjee AK, 2014, BIOCHIMIE, V99, P153, DOI 10.1016/j.biochi.2013.11.026
   Murakami MT, 2007, TOXICON, V49, P378, DOI 10.1016/j.toxicon.2006.10.011
   NCBI, 2016, PREDICTED XENOPUS TR
   OWEN MD, 1990, TOXICON, V28, P813, DOI 10.1016/S0041-0101(09)80004-4
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Prates MV, 2004, J BIOL CHEM, V279, P13018, DOI 10.1074/jbc.M310838200
   PRIGENTDACHARY J, 1980, J BIOL CHEM, V255, P7734
   Raaymakers C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01710-1
   RESENDE JM, 2008, NMR, P2, DOI DOI 10.1016/J.PEPTIDES.2008.06.022
   RESNICK NM, 1991, CELL, V66, P541, DOI 10.1016/0092-8674(81)90017-9
   ROLLINS S, 2005, DEV COMP IMMUNOL, V29, P589, DOI DOI 10.1016/J.TOXICON.2011.02.018
   Saikia D, 2011, TOXICON, V57, P841, DOI 10.1016/j.toxicon.2011.02.018
   Schaloske RH, 2006, BBA-MOL CELL BIOL L, V1761, P1246, DOI 10.1016/j.bbalip.2006.07.011
   SOBRINHO AJC, 2017, INT J BIOL MACROMOL, V49, pA2, DOI DOI 10.1002/JPS.21504
   Sola RJ, 2009, J PHARM SCI-US, V98, P1223, DOI 10.1002/jps.21504
   Stanley D, 2006, BBA-MOL CELL BIOL L, V1761, P1383, DOI 10.1016/j.bbalip.2006.05.011
   Taboada C, 2017, P NATL ACAD SCI USA, V114, P3672, DOI 10.1073/pnas.1701053114
   TOLEDO RC, 1995, COMP BIOCHEM PHYS A, V111, P1, DOI 10.1016/0300-9629(95)98515-I
   van Veen HA, 2004, EUR J BIOCHEM, V271, P678, DOI 10.1111/j.1432-1033.2003.03965.x
   VANDENBERGH CJ, 1988, EUR J BIOCHEM, V176, P353
   VERHEIJ HM, 1980, BIOCHEMISTRY-US, V19, P743, DOI 10.1021/bi00545a021
   Wegener KL, 1999, EUR J BIOCHEM, V265, P627, DOI 10.1046/j.1432-1327.1999.00750.x
   Weinrauch Y, 1996, J CLIN INVEST, V97, P250, DOI 10.1172/JCI118399
   Zhang YX, 2010, TOXICON, V56, P502, DOI 10.1016/j.toxicon.2010.05.006
   Zhao KH, 1998, ACTA CRYSTALLOGR D, V54, P510, DOI 10.1107/S0907444997013644
   Zhao KH, 2000, TOXICON, V38, P901, DOI 10.1016/S0041-0101(99)00193-2
   Zhao Y, 2005, TOXICON, V46, P635, DOI 10.1016/j.toxicon.2005.07.003
   DG
NR 67
TC 1
Z9 1
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 10
EP 19
DI 10.1016/j.toxicon.2019.06.002
PG 10
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000003
PM 31173792
DA 2020-05-12
ER

PT J
AU Moritz, MS
   Tepp, WH
   Inzalaco, HN
   Johnson, EA
   Pellett, S
AF Moritz, Molly S.
   Tepp, William H.
   Inzalaco, Heather N'te
   Johnson, Eric A.
   Pellett, Sabine
TI Comparative functional analysis of mice after local injection with
   botulinum neurotoxin A1, A2, A6, and B1 by catwalk analysis
SO TOXICON
LA English
DT Article
DE Botulinum neurotoxin; BoNT; A1; A2; A6; B1; Catwalk; Intramuscular
   injection
ID TOXIN TYPE-A; NEUROPATHIC PAIN; GAIT ANALYSIS; GENETIC DIVERSITY;
   AXONAL-TRANSPORT; SUBTYPES A1; PURIFICATION; INHIBITION; EXPRESSION;
   CLEAVAGE
AB Botulinum neurotoxins (BoNTs) are potent neurotoxins and are the causative agent of botulism, as well as valuable pharmaceuticals. BoNTs are divided into seven serotypes that comprise over 40 reported subtypes. BoNT/A1 and BoNT/B1 are currently the only subtypes approved for pharmaceutical use in the USA. While several other BoNT subtypes including BoNT/A2 and/A6 have been proposed as promising pharmaceuticals, detailed characterization using in vivo assays are essential to determine their pharmaceutical characteristics compared to the currently used BoNT/A1 and/B1. Several methods for studying BoNTs in mice are being used, but no objective and quantitative assay for assessment of functional outcomes after injection has been described. Here we describe the use of CatWalk XT as a new analytical tool for the objective and quantitative analysis of the paralytic effect after local intramuscular injection of BoNT subtypes Al, A2, A6, and B1. Catwalk is a sophisticated gait and locomotion analysis system that quantitatively analyzes a rodent's paw print dimensions and footfall patterns while traversing a glass plate during unforced walk. Significant changes were observed in several gait parameters in mice after local intramuscular injection of all tested BoNT subtypes, however, no changes were observed in mice injected intraperitoneally with the same BoNTs. While a clear difference in time to peak paralysis was observed between BoNT/A1 and/B1, injection of all four toxins resulted in a deficit in the injected limb with the other limbs functionally compensating and with no qualitative differences between the four BoNT subtypes. The presented data demonstrate the utility of CatWalk as a tool for functional outcomes after local BoNT injection through its ability to collect large amounts of quantitative data and objectively analyze sensitive changes in static and dynamic gait parameters.
C1 [Moritz, Molly S.; Tepp, William H.; Inzalaco, Heather N'te; Johnson, Eric A.; Pellett, Sabine] Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA.
RP Pellett, S (reprint author), 1550 Linden Dr, Madison, WI 53706 USA.
EM sabine.pellett@wisc.edu
OI Inzalaco, Heather N'te/0000-0001-9940-765X
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [RO1 AI095274, R56 AI095274]
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases RO1 AI095274, R56 AI095274. The authors would like
   to acknowledge the University of Wisconsin Madison Biosecurity Task
   Force for helping to ensure compliance with Select Agent Regulations.
CR Akaike N, 2013, J PHYSIOL-LONDON, V591, P1031, DOI 10.1113/jphysiol.2012.242131
   Alexiades-Armenakas M, 2008, J DRUGS DERMATOL, V7, P77
   Antonucci F, 2008, J NEUROSCI, V28, P3689, DOI 10.1523/JNEUROSCI.0375-08.2008
   Arndt JW, 2006, J MOL BIOL, V362, P733, DOI 10.1016/j.jmb.2006.07.040
   Bach-Rojecky L, 2010, EUR J PHARMACOL, V633, P10, DOI 10.1016/j.ejphar.2010.01.020
   Benoit RM, 2017, SCI REP-UK, V7, DOI 10.1038/srep43588
   Bentivoglio AR, 2015, TOXICON, V107, P77, DOI 10.1016/j.toxicon.2015.08.001
   Bozkurt A, 2008, J NEUROSCI METH, V173, P91, DOI 10.1016/j.jneumeth.2008.05.020
   Bradshaw M, 2014, APPL ENVIRON MICROB, V80, P7415, DOI 10.1128/AEM.01795-14
   Brashear A, 2010, DRUG TODAY, V46, P671, DOI 10.1358/dot.2010.46.9.1524356
   Broide RS, 2013, TOXICON, V71, P18, DOI 10.1016/j.toxicon.2013.05.004
   Brown EA, 2014, PAIN MANAG, V4, P129, DOI [10.2217/pmt.13.75, 10.2217/PMT.13.75]
   Caballero-Garrido E, 2017, BEHAV BRAIN RES, V331, P282, DOI 10.1016/j.bbr.2017.05.042
   Cai BB, 2017, NEUROSCIENCE, V352, P155, DOI 10.1016/j.neuroscience.2017.03.049
   Cameron MH, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-014-0463-7
   Cao Y, 2017, NEUROCHEM INT, V107, P198, DOI 10.1016/j.neuint.2016.10.014
   Chen YJ, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-62
   Dressler D, 2016, J NEURAL TRANSM, V123, P277, DOI 10.1007/s00702-015-1478-1
   Dressler D, 2018, J NEUROL, V265, P856, DOI 10.1007/s00415-018-8759-1
   Dressler D, 2012, CURR OPIN MICROBIOL, V15, P325, DOI 10.1016/j.mib.2012.05.012
   Duarte J, 2016, ACM T KNOWL DISCOV D, V10, DOI 10.1145/2829955
   Fabregat G, 2013, CLIN J PAIN, V29, P1006, DOI 10.1097/AJP.0b013e31827eafff
   Filipovic B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029803
   Frohlich H, 2018, IEEE T BIO-MED ENG, V65, P1133, DOI 10.1109/TBME.2017.2701204
   GIMENEZ DF, 1995, INT J FOOD MICROBIOL, V27, P1, DOI 10.1016/0168-1605(94)00144-U
   Hamers FPT, 2006, J NEUROTRAUM, V23, P537, DOI 10.1089/neu.2006.23.537
   Hatheway CL., 1988, LABORATORY DIAGNOSIS, V1, P111
   Herold S, 2016, BMC NEUROSCI, V17, DOI 10.1186/s12868-016-0317-0
   Hill KK, 2015, TOXICON, V107, P2, DOI 10.1016/j.toxicon.2015.09.011
   Hill KK, 2013, CURR TOP MICROBIOL, V364, P1, DOI 10.1007/978-3-642-33570-9_1
   Johnson Eric A, 2008, Handb Clin Neurol, V91, P333, DOI 10.1016/S0072-9752(07)01511-4
   Kalb SR, 2014, ANAL CHEM, V86, P3254, DOI 10.1021/ac5001509
   Kalb SR, 2012, FEBS LETT, V586, P109, DOI 10.1016/j.febslet.2011.11.033
   Kalb SR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005355
   Kappos EA, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.723
   Keller JE, 2006, NEUROSCIENCE, V139, P629, DOI 10.1016/j.neuroscience.2005.12.029
   Kim CS, 2013, HUM EXP TOXICOL, V32, P914, DOI 10.1177/0960327113479044
   Koizumi H, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00098
   Koopmans GC, 2007, PHYSIOL BEHAV, V92, P993, DOI 10.1016/j.physbeh.2007.07.018
   Kroken AR, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00795-16
   Kull S, 2015, PLOS ONE
   Lawrence GW, 2012, BIOCHEM J, V441, P443, DOI 10.1042/BJ20111117
   Lin GY, 2010, APPL ENVIRON MICROB, V76, P40, DOI 10.1128/AEM.01882-09
   Ma L, 2012, J PHARMACOL SCI, V119, P282, DOI 10.1254/jphs.12080SC
   Malizio CJ, 2000, METH MOL B, V145, P27
   Marchand-Pauvert V, 2013, J PHYSIOL-LONDON, V591, P1017, DOI 10.1113/jphysiol.2012.239178
   Masocha W, 2009, LIFE SCI, V85, P462, DOI 10.1016/j.lfs.2009.07.015
   Matak I, 2012, NEUROCHEM INT, V61, P236, DOI 10.1016/j.neuint.2012.05.001
   Mazzocchio R, 2015, NEUROSCIENTIST, V21, P44, DOI 10.1177/1073858414524633
   Montecucco C, 2015, MBIO, V6, DOI 10.1128/mBio.02131-14
   Moritz MS, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00466-18
   Mukai Y, 2014, TOXICON, V81, P32, DOI 10.1016/j.toxicon.2013.12.012
   Parvathy SS, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-14
   Peck MW, 2017, TOXINS, V9, DOI 10.3390/toxins9010038
   Pellete S, 2015, TOXICON, V107, P37, DOI 10.1016/j.toxicon.2015.06.021
   Pellett S, 2018, TOXICON, V147, P38, DOI 10.1016/j.toxicon.2017.12.048
   Pellett S, 2018, MBIO, V9, DOI 10.1128/mBio.00089-18
   Pellett S, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00100-15
   Pier CL, 2011, FEBS LETT, V585, P199, DOI 10.1016/j.febslet.2010.11.045
   Prabakaran S, 2001, TOXICON, V39, P1515, DOI 10.1016/S0041-0101(01)00124-6
   Przedpelski A, 2018, VACCINE, V36, P827, DOI 10.1016/j.vaccine.2017.12.064
   Ramachandran R, 2015, NEUROBIOL DIS, V79, P111, DOI 10.1016/j.nbd.2015.04.011
   Restani L, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003087
   Restani L, 2012, TRAFFIC, V13, P1083, DOI 10.1111/j.1600-0854.2012.01369.x
   Restani L, 2011, J NEUROSCI, V31, P15650, DOI 10.1523/JNEUROSCI.2618-11.2011
   SCHANTZ EJ, 1978, J ASSOC OFF ANA CHEM, V61, P96
   Schulz A, 2014, J VIS EXP, V86
   Shin MC, 2013, TOXICON, V64, P12, DOI 10.1016/j.toxicon.2012.12.011
   Simpson L, 2013, TOXICON, V68, P40, DOI 10.1016/j.toxicon.2013.02.014
   Singh JA, 2011, J RHEUMATOL, V38, P409, DOI 10.3899/jrheum.101081
   SUGIYAMA H, 1975, APPL MICROBIOL, V30, P420, DOI 10.1128/AEM.30.3.420-423.1975
   Tepp WH, 2012, APPL ENVIRON MICROB, V78, P3108, DOI 10.1128/AEM.07967-11
   Torii Y, 2015, BASIC CLIN PHARMACOL, V116, P524, DOI 10.1111/bcpt.12351
   Torii Y, 2011, J PHARMACOL SCI, V117, P275, DOI 10.1254/jphs.11121FP
   Torii Y, 2011, TOXICON, V57, P93, DOI 10.1016/j.toxicon.2010.10.009
   Tsai SW, 2013, J ORTHOP RES, V31, P125, DOI 10.1002/jor.22180
   Wang DX, 2013, BBA-PROTEINS PROTEOM, V1834, P2722, DOI 10.1016/j.bbapap.2013.09.007
   Whitemarsh RCM, 2013, INFECT IMMUN, V81, P3894, DOI 10.1128/IAI.00536-13
   Whitemarsh RCM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090252
   Wilder-Kofie TD, 2011, COMPARATIVE MED, V61, P235
NR 80
TC 1
Z9 1
U1 3
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 20
EP 28
DI 10.1016/j.toxicon.2019.06.004
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000004
PM 31181297
DA 2020-05-12
ER

PT J
AU Querobino, SM
   Costa, MS
   Alberto-Silva, C
AF Querobino, Samyr Machado
   Costa, Maricilia Silva
   Alberto-Silva, Carlos
TI Protective effects of distinct proline-rich oligopeptides from B.
   jararaca snake venom against oxidative stress-induced neurotoxicity
SO TOXICON
LA English
DT Article
DE Proline-rich peptides; Bradykinin-potentiating peptides;
   Argininosuccinate synthase; Neuroprotective; Oxidative stress; Bothrops
   jararaca
ID BRADYKININ-POTENTIATING PEPTIDES; NITRIC-OXIDE; THERAPEUTIC TARGET;
   LIPID-PEROXIDATION; CELL-LINE; AGMATINE; SH-SY5Y; BRAIN; POLYAMINES;
   RECEPTORS
AB The low molecular mass fraction from Bothrops jararaca snake venom contains proline-rich peptides (Bj-PROs), also known as bradykinin-potentiating peptides (BPPs), which were described as neuroprotective against H2O2 induced oxidative stress. Recently, we reported that the neuroprotective action of Bj-PRO-10c (< ENWPHPQ-IPP) is a result of an increase in the expression and activity of argininosuccinate synthase (AsS), thereby improving increase L-arginine synthesis. It is proposed that formation agmatine and polyamines from L-arginine metabolism are neuroprotective, reducing lipid peroxidation, oxidative stress, and maintenance of the mitochondrial membrane. In the present study, Bj-PRO-5a (< EKWAP), Bj-PRO-7a (< EDGPIPP), Bj-PRO-11e (< EARPPHPPIPP), and Bj-PRO-AP (< EARPPHPPIPPAP) - with different structure-activities, in particular on AsS expression and activity - were selected to study their protective properties on H2O2-induced oxidative stress in SH-SY5Y cells. Bj-PROs tested were neuroprotective, but Bj-PRO-5a and Bj-PRO-7a increased cell viability by more than 85% in the presence of H2O2 (450 mu M) and reduced the oxidative stress markers. AsS, iNOS, and NF-KB expressions were not involved in the neuroprotective mechanism for both peptides, in contrast to Bj-PRO-10c, as reported in the literature. Bj-PRO-5a is a neuroprotector peptide that decreases ROS production, NO levels lipid peroxidation, and changes in mitochondrial membrane permeability caused by H2O2 exposition. The neuroprotective property of Bj-PRO-7a against H2O2 is also related to decreased ROS production and lipid peroxidation but without altering NO levels. These results show that the protective effects of different Bj-PROs against oxidative stress can be explained by distinct mechanisms independent of an increase in L-arginine bioavailability arising from AsS activity. Further studies are now needed to reveal the details of the neuroprotective mechanisms exerted by Bj-PROs.
C1 [Querobino, Samyr Machado; Alberto-Silva, Carlos] Fed Univ ABC UFABC, Expt Morphophysiol Lab, Nat & Humanities Sci Ctr, Rua Arcturus 03,Bloco Delta, BR-09606070 Bernardo Do Campo, SP, Brazil.
   [Querobino, Samyr Machado] Univ Estado Minas Gerais, Av Juca Stockler 1130, BR-37900106 Passos, MG, Brazil.
   [Costa, Maricilia Silva] Univ Vale Paraiba UNIVAP, IP&D, Av Shishima Hifumi 2911, Sao Jose Dos Campos, SP, Brazil.
RP Alberto-Silva, C (reprint author), Fed Univ ABC UFABC, Nat & Humanities Sci Ctr CCNH, R Arcturus 03,Bloco Delta, BR-09606070 Sao Bernardo Do Campo, SP, Brazil.
EM carlos.asilva@ufabc.edu.br
RI /E-5852-2012; Alberto-Silva, Carlos/F-2972-2012
OI Alberto-Silva, Carlos/0000-0003-4519-8930
FU FAPESP (Sao Paulo Research Foundation)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP); CAPES (Coordination for the Improvement of
   Higher Education Personnel)CAPES [001]
FX The authors would like to thank FAPESP (Sao Paulo Research Foundation)
   and CAPES (Coordination for the Improvement of Higher Education
   Personnel) for their financial support (Finance Code 001).
CR Ahn SK, 2012, LIFE SCI, V91, P1345, DOI 10.1016/j.lfs.2012.10.010
   Amoroso S, 1999, BBA-MOL CELL RES, V1452, P151, DOI 10.1016/S0167-4889(99)00110-X
   Arias-Salvatierra D, 2011, CELL SIGNAL, V23, P425, DOI 10.1016/j.cellsig.2010.10.017
   Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25
   Browne R W, 1998, Methods Mol Biol, V108, P347
   Cai L, 2016, MOLECULES, V21, DOI 10.3390/molecules21081071
   Che YG, 2016, 2016 INTERNATIONAL CONFERENCE ON SOFTWARE ANALYSIS, TESTING AND EVOLUTION (SATE 2016), P1, DOI 10.1109/SATE.2016.7
   Chen WY, 2007, CHANNELS, V1, P281, DOI 10.4161/chan.4988
   CHEUNG HS, 1973, BIOCHIM BIOPHYS ACTA, V293, P451, DOI 10.1016/0005-2744(73)90352-5
   Cunha AS, 2016, BEHAV BRAIN RES, V312, P64, DOI 10.1016/j.bbr.2016.06.014
   de Oliveira EF, 2010, BRAIN RES, V1363, P11, DOI 10.1016/j.brainres.2010.09.067
   Ding WQ, 1998, ALCOHOL CLIN EXP RES, V22, P225, DOI 10.1097/00000374-199802000-00031
   Feng CS, 2016, MOL MED REP, V13, P4205, DOI 10.3892/mmr.2016.5056
   FERREIRA SH, 1970, BIOCHEMISTRY-US, V9, P2583, DOI 10.1021/bi00815a005
   Ferreira-Vieira TH, 2016, CURR NEUROPHARMACOL, V14, P101, DOI 10.2174/1570159X13666150716165726
   Freitas AE, 2016, MOL NEUROBIOL, V53, P3030, DOI 10.1007/s12035-015-9182-6
   Garcimartin A, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-384
   Guerreiro JR, 2009, J BIOL CHEM, V284, P20022, DOI 10.1074/jbc.M109.021089
   Haines Ricci J, 2011, Int J Biochem Mol Biol, V2, P8
   HALLIWELL B, 1993, AM J CLIN NUTR, V57, P715
   Han N, 2015, MOL MED REP, V12, P1098, DOI 10.3892/mmr.2015.3540
   Hayashi MAF, 2003, J NEUROCHEM, V85, P969, DOI 10.1046/j.1471-4159.2003.01743.x
   Higuchi S, 1999, IMMUNOPHARMACOLOGY, V44, P129, DOI 10.1016/S0162-3109(99)00119-8
   Horton JW, 2003, TOXICOLOGY, V189, P75, DOI 10.1016/S0300-483X(03)00154-9
   Ianzer D, 2004, PEPTIDES, V25, P1085, DOI 10.1016/j.peptides.2004.04.006
   Jamwal S, 2016, PHYSIOL BEHAV, V155, P180, DOI 10.1016/j.physbeh.2015.12.015
   Javadov S, 2009, J PHARMACOL EXP THER, V330, P670, DOI 10.1124/jpet.109.153213
   Joshi DC, 2011, JOVE-J VIS EXP, DOI 10.3791/2704
   KOH DS, 1995, J PHYSIOL-LONDON, V486, P305, DOI 10.1113/jphysiol.1995.sp020813
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LAMBERT DG, 1990, BIOCHEM J, V265, P555, DOI 10.1042/bj2650555
   Lameu C, 2010, CYTOM PART A, V77A, P220, DOI 10.1002/cyto.a.20860
   LARSSON C, 1994, EUR J PHARM-MOLEC PH, V268, P19
   Ling APK, 2017, J FUNDAM APPL SCI, V9, P637, DOI 10.4314/jfas.v9i7s.60
   Lu JM, 2010, J CELL MOL MED, V14, P840, DOI 10.1111/j.1582-4934.2009.00897.x
   Martins NM, 2015, CHEM-BIOL INTERACT, V235, P10, DOI 10.1016/j.cbi.2015.04.004
   Martins NM, 2010, TOXICON, V56, P86, DOI 10.1016/j.toxicon.2010.03.014
   Morais KLP, 2011, BIOCHEM PHARMACOL, V81, P736, DOI 10.1016/j.bcp.2010.12.016
   Morais KLP, 2013, PEPTIDES, V48, P124, DOI 10.1016/j.peptides.2013.07.016
   Morris SM, 2016, J NUTR, V146, P2579, DOI 10.3945/jn.115.226621
   Mott DD, 2003, J NEUROSCI, V23, P1179
   Moyano P, 2018, TOXICOLOGY, V394, P54, DOI 10.1016/j.tox.2017.12.006
   Nciri R, 2013, INT J NEUROPSYCHOPH, V16, P365, DOI 10.1017/S1461145712000132
   Negraes PD, 2011, CYTOM PART A, V79A, P77, DOI 10.1002/cyto.a.20963
   Neis VB, 2017, NEUROCHEM INT, V108, P318, DOI 10.1016/j.neuint.2017.05.006
   Niedzielska E, 2016, MOL NEUROBIOL, V53, P4094, DOI 10.1007/s12035-015-9337-5
   Querobino SM, 2018, PEPTIDES, V103, P90, DOI 10.1016/j.peptides.2018.03.017
   Querobino SM, 2017, TOXICON, V129, P134, DOI 10.1016/j.toxicon.2017.02.015
   Roe ND, 2012, VASC PHARMACOL, V57, P168, DOI 10.1016/j.vph.2012.02.004
   Rosseti IB, 2015, J TRACE ELEM MED BIO, V29, P289, DOI 10.1016/j.jtemb.2014.08.001
   Seo YJ, 2004, FREE RADICAL BIO MED, V37, P1272, DOI 10.1016/j.freeradbiomed.2004.07.012
   Silva CA, 2008, TOXICON, V52, P501, DOI 10.1016/j.toxicon.2008.06.024
   Skatchkov SN, 2014, PSYCHIAT CLIN N AM, V37, P653, DOI 10.1016/j.psc.2014.08.008
   Szczepanowicz K, 2016, NANOTECHNOLOGY, V27, DOI 10.1088/0957-4484/27/35/355101
   Wang J, 2015, INDIAN J PHARM SCI, V77, P163
   YAGI K, 1976, BIOCHEM MED METAB B, V15, P212, DOI 10.1016/0006-2944(76)90049-1
   Zitka O, 2012, ONCOL LETT, V4, P1247, DOI 10.3892/ol.2012.931
NR 59
TC 0
Z9 0
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 29
EP 37
DI 10.1016/j.toxicon.2019.06.012
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000005
PM 31181294
DA 2020-05-12
ER

PT J
AU Leon, C
   Penuela, GA
AF Leon, C.
   Penuela, G. A.
TI Detected cyanotoxins by UHPLC MS/MS technique in tropical reservoirs of
   northeastern Colombia
SO TOXICON
LA English
DT Article
DE Cyanotoxins; Natural water reservoir; Tropical reservoir; UHPLC MS/MS;
   Validation
ID SOLID-PHASE EXTRACTION; MASS-SPECTROMETRY METHOD; MICROCYSTIN-LR;
   SURFACE-WATER; CYANOBACTERIAL; BLOOMS; CYLINDROSPERMOPSIN; NODULARIN;
   EXPOSURE
AB This study focused on the detection and quantification of eight cyanotoxins in water samples in three reservoirs located in the eastern department of Antioquia, Colombia. The reservoirs are a source of water supply and hydroelectricity, and also generate economic activities in fishing and recreation. Between May 2015 and October 2016, 8 samplings were carried out at times of high temperatures, which ranged from 20 to 29 degrees C. This period was selected because of a significant or strong El Nino phenomenon, according to the World Meteorological Organization. For the study, 270 integrated samples were taken from the photic zone (PZ) and the surface of the reservoirs, at each of the three sampling points. The samples were analyzed by the analytical technique of ultrahigh-performance liquid chromatography coupled to triple quadrupole mass spectrometry (UHPLC MS/MS). The quantification performed for six microcystins (MCs), a nodularin (NOD) and a cylindrospermopsin (CYN), showed positive results well above 1 mu g L-1. In the water of the Abreo Malpaso and Penol reservoirs, microcystin-LR (MC-LR), microcystin-YR (MC-YR) and [D-Asp(3),(E)-Dhb(7)]- microcystin-RR toxins were detected at levels of considerable concentration, especially between May and September 2015, when there was no rainfall in this region. In the Playas reservoir, positive results for [D-Asp(3),(E)-Dhb(7)]-MC-RR were detected from May to November 2015, with the highest concentrations being reached in dry season. The temperatures reached and the changes in climatic conditions witnessed during the monitoring period of this study were important factors in the production of cyanotoxins. This was evidenced in this work by the high concentrations of detected cyanotoxins and their absence in periods of rain, as happened from the second quarter of 2016 until the end of the study in October. This is the first study of the detection and quantification of cyanotoxins in tropical reservoirs of northeastern Colombia using the UHPLC MS/MS analytical technique, which allowed the toxins to be unequivocally detected and confirmed. A method was developed and validated, proving to be sensitive, reproducible and accurate. For each of the toxins (microcystin-LR (MC-LR), microcystin-RR (MC-RR), microcystin-YR (MCYR), [13-Asp(3),(E)-Dhb(7)]- microcystin-RR, microcystin-LW (MC-LW), microcystin-LF (MC-LF), nodularin (NOD) and cylindrospermopsina (CYN)) the correlation coefficients (R-2) were in a range between 0.9907 and 0.9999. Verification of the accuracy of the method was performed through a calibration curve in solvent. The recovery percentages of the accuracy and precision tests of the method for low level, medium level and high level were in a range between 64% and 115% for all the cyanotoxins. The validation of the cyanotoxin method shows that it is possible to detect them individually in natural water with a quantification limit (LOQ) of approximately 0.05 mu g L-1.
C1 [Leon, C.; Penuela, G. A.] Univ Antioquia, SIU, Fac Ingn, Grp GDCON, Medellin, Colombia.
RP Leon, C (reprint author), Univ Antioquia, SIU, Fac Ingn, Grp GDCON, Medellin, Colombia.
EM melba.leon@udea.edu.co
FU University of Antioquia (CODI) [258]
FX The authors thank the Colombian Administrative Department of Science,
   Technology and Innovation (COLCIENCIAS) and Vice-Chancellor of Research
   of the University of Antioquia (CODI) [grant number 258].
CR Antoniou MG, 2008, TOXICON, V51, P1103, DOI 10.1016/j.toxicon.2008.01.018
   Balest L, 2016, ANAL BIOANAL CHEM, V408, P4063, DOI 10.1007/s00216-016-9495-y
   Beltran E, 2012, J CHROMATOGR A, V1266, P61, DOI 10.1016/j.chroma.2012.10.017
   Blahova L, 2009, TOXICON, V53, P519, DOI 10.1016/j.toxicon.2009.01.014
   Buratti FM, 2017, ARCH TOXICOL, V91, P1049, DOI 10.1007/s00204-016-1913-6
   Carmichael WW, 2016, HARMFUL ALGAE, V54, P194, DOI 10.1016/j.hal.2016.02.002
   Codd G. A, 2017, CYANOBACTERIAL CYANO, P3, DOI [10.1002/9781119068761, DOI 10.1002/9781119068761]
   Cong LM, 2006, ANAL CHIM ACTA, V569, P157, DOI 10.1016/j.aca.2006.03.052
   Douma M, 2017, ENVIRON MONIT ASSESS, V189, DOI 10.1007/s10661-016-5753-x
   Gaget V, 2017, WATER RES, V118, P227, DOI 10.1016/j.watres.2017.04.025
   Gonzalez-Piana M, 2017, B ENVIRON CONTAM TOX, V99, P488, DOI 10.1007/s00128-017-2158-7
   Greer B, 2017, ANAL BIOANAL CHEM, V409, P4057, DOI 10.1007/s00216-017-0352-4
   IPCC, 2007, CLIM CHANG 2007 IMP, V1, P976, DOI DOI 10.2134/JEQ2008.0015BR
   Kaebernick M, 2001, FEMS MICROBIOL ECOL, V35, P1, DOI 10.1111/j.1574-6941.2001.tb00782.x
   Kohoutek J, 2010, ANAL BIOANAL CHEM, V398, P1231, DOI 10.1007/s00216-010-3860-z
   Li W, 2011, J CHROMATOGR SCI, V49, P665, DOI 10.1093/chrsci/49.9.665
   Li YW, 2014, J AGR FOOD CHEM, V62, P11831, DOI 10.1021/jf5033075
   Manubolu M, 2014, INT J ENVIRON RES, V8, P733
   Merel S, 2010, SCI TOTAL ENVIRON, V408, P3433, DOI 10.1016/j.scitotenv.2010.04.033
   Miller MA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012576
   Moreno IM, 2004, J AGR FOOD CHEM, V52, P5933, DOI 10.1021/jf0489668
   Nyakairu GWA, 2010, TOXICON, V55, P939, DOI 10.1016/j.toxicon.2009.07.024
   O'Neil JM, 2012, HARMFUL ALGAE, V14, P313, DOI 10.1016/j.hal.2011.10.027
   Oehrle SA, 2010, TOXICON, V55, P965, DOI 10.1016/j.toxicon.2009.10.001
   Paerl HW, 2016, HARMFUL ALGAE, V54, P213, DOI 10.1016/j.hal.2015.09.009
   Pekar H, 2016, J CHROMATOGR A, V1429, P265, DOI 10.1016/j.chroma.2015.12.049
   Rodrigues MA, 2013, TOXICON, V74, P8, DOI 10.1016/j.toxicon.2013.07.013
   Severiano JD, 2018, HARMFUL ALGAE, V71, P10, DOI 10.1016/j.hal.2017.11.003
   Shin C, 2017, FOOD CONTROL, V77, P171, DOI 10.1016/j.foodcont.2017.02.034
   Shoemaker J, 2015, 544 USEPA
   Triantis T, 2010, TOXICON, V55, P979, DOI 10.1016/j.toxicon.2009.07.012
   Umehara A, 2017, CHEMOSPHERE, V167, P492, DOI 10.1016/j.chemosphere.2016.10.029
   Ame MV, 2010, HARMFUL ALGAE, V9, P66, DOI 10.1016/j.hal.2009.08.001
   Wang J, 2007, TOXICON, V49, P1120, DOI 10.1016/j.toxicon.2007.02.004
   Wood R, 2016, ENVIRON INT, V91, P276, DOI 10.1016/j.envint.2016.02.026
   Wood SA, 2007, TOXICON, V50, P292, DOI 10.1016/j.toxicon.2007.03.025
   Xu W, 2008, ANAL CHIM ACTA, V626, P28, DOI 10.1016/j.aca.2008.07.040
   Yen HK, 2011, TOXICON, V58, P209, DOI 10.1016/j.toxicon.2011.06.003
   Zervou SK, 2017, J HAZARD MATER, V323, P56, DOI 10.1016/j.jhazmat.2016.07.020
   Zhang YS, 2016, CHEM ENG J, V287, P189, DOI 10.1016/j.cej.2015.10.111
NR 40
TC 3
Z9 3
U1 11
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 38
EP 48
DI 10.1016/j.toxicon.2019.06.010
PG 11
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000006
PM 31185239
DA 2020-05-12
ER

PT J
AU Phatak, P
   Nagar, DP
   Saxena, N
AF Phatak, Pooja
   Nagar, Durga Prasad
   Saxena, Nandita
TI Dose dependent acute toxicity of abrin in Balb/c mice after
   intraperitoneal administration
SO TOXICON
LA English
DT Article
DE Abrin; Acute toxicity; Hepatotoxicity; Inflammation; Oxidative stress;
   Ricin
ID INACTIVATING PROTEINS; SIGNAL-TRANSDUCTION; REACTIVE OXYGEN; LECTINS
   ABRIN; IFN-GAMMA; RICIN; CELL; MECHANISM; TOXIN; LIPOPOLYSACCHARIDE
AB Abrin toxin is one of the most potent and deadly plant toxin obtained from the seeds of Abrus precatorious. It is more toxic than ricin which is classified as Schedule 1 agent by OPCW and Category B bioterrorism agent by Centre for Disease Control (CDC). Dose dependent acute toxicity of abrin is still a matter of investigation. The present study was carried out to assess the toxicity of abrin from sub lethal to supralethal doses (0.5X, 1X, 2X and 5XLD(50)) after intraperitoneal administration. After 8 and 24h of abrin exposure, hematological, biochemical, inflammatory and oxidative stress associated parameters were analyzed. Liver histology was also done to analyze the effect of abrin. Abrin exerts its toxicity in a dose and time dependent manner. Increases in neutrophil counts, lipid peroxidation with decreased lymphocyte counts, are the initiating factor irrespective of time and dose. At higher doses of abrin there was a decrease in hemoglobin level and RBC count which is reflected by increased levels of serum ammonia and bilirubin. Neutrophil infiltration in the liver and lipid peroxidation cause liver toxicity (increased production of ALT and ALP); oxidative stress (depletion of GSH and total antioxidant status); inflammation (increased production of TNF-alpha and IFN-gamma). Further, at higher doses of abrin, intensity of oxidative stress, inflammation and liver toxicity are more pronounced which may have been maintained by the self-sustaining loop of toxicity leading to death of the animals.
C1 [Phatak, Pooja; Nagar, Durga Prasad; Saxena, Nandita] Def Res Dev & Estab, Div Pharmacol & Toxicol, Gwalior 474002, India.
RP Saxena, N (reprint author), Def Res Dev Org, Def Res Dev & Estab, Gwalior 474002, India.
EM nanditasaxena@drde.drdo.in
FU Defence Research and Development Organization, Ministry of Defence, Govt
   of IndiaDefence Research & Development Organisation (DRDO); Defence
   Research and Development Establishment, Gwalior
FX The authors are thankful to Dr D K Dubey, Director, Defence Research and
   Development Establishment, Gwalior for providing all necessary
   facilities and financial support during this project. Ms Pooja Phatak is
   thankful to Defence Research and Development Organization, Ministry of
   Defence, Govt of India for the award of Senior Research Fellowship.
   Institutional accession no. for this manuscript is DRDE/P& T/017/2018.
CR Alipour M, 2013, DRUG CHEM TOXICOL, V36, P224, DOI 10.3109/01480545.2012.710624
   ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527
   Biswas SK, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5698931
   Bolognesi A, 1996, INT J CANCER, V68, P349, DOI 10.1002/(SICI)1097-0215(19961104)68:3<349::AID-IJC13>3.0.CO;2-3
   Chaturvedi K, 2015, CELL MOL BIOL, V61, P36
   Chen XY, 1998, BIOCHEMISTRY-US, V37, P11605, DOI 10.1021/bi980990p
   Christian F, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5010012
   DAVIS JH, 1978, J FLA MED ASSOC, V65, P189
   Dickers Kirsten J., 2003, Toxicological Reviews, V22, P137, DOI 10.2165/00139709-200322030-00002
   Fialkow L, 2007, FREE RADICAL BIO MED, V42, P153, DOI 10.1016/j.freeradbiomed.2006.09.030
   FODSTAD O, 1976, BRIT J CANCER, V34, P418, DOI 10.1038/bjc.1976.187
   Ghiselli A, 2000, FREE RADICAL BIO MED, V29, P1106, DOI 10.1016/S0891-5849(00)00394-4
   Glantzounis GK, 2006, CURR PHARM DESIGN, V12, P2891, DOI 10.2174/138161206777947641
   Guessous F, 2005, THROMB HAEMOSTASIS, V94, P1019, DOI 10.1160/TH05-02-0115
   HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2
   Hughes JN, 1996, HUM EXP TOXICOL, V15, P443, DOI 10.1177/096032719601500513
   IM SY, 1989, INFLAMMATION, V13, P707, DOI 10.1007/BF00914314
   Jaeschke Hartmut, 2005, Expert Opin Drug Metab Toxicol, V1, P389, DOI 10.1517/17425255.1.3.389
   Karpman D, 2001, BLOOD, V97, P3100, DOI 10.1182/blood.V97.10.3100
   KAUFMAN SJ, 1975, CELL, V4, P263, DOI 10.1016/0092-8674(75)90174-9
   KUMAR, 2008, J CELL TISSUE RES, V8, P1243
   Kumar O, 2004, DEFENCE SCI J, V54, P493
   LIN JY, 1981, TOXICON, V19, P41
   LIN JY, 1970, TOXICON, V8, P197, DOI 10.1016/0041-0101(70)90202-3
   LORD JM, 1994, FASEB J, V8, P201
   Lord Michael J., 2003, Toxicological Reviews, V22, P53, DOI 10.2165/00139709-200322010-00006
   Lushchak Volodymyr I, 2012, J Amino Acids, V2012, P736837, DOI 10.1155/2012/736837
   MCMANNUS JFA, 1960, METHODS, P73, DOI DOI 10.1089/ARS.2012.5149
   Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149
   Narayanan S, 2005, FEBS LETT, V579, P1324, DOI 10.1016/j.febslet.2005.01.038
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
   OLSNES S, 1974, NATURE, V249, P627, DOI 10.1038/249627a0
   Ossetrova NI, 2014, HEALTH PHYS, V106, P772, DOI 10.1097/HP.0000000000000094
   Qi XF, 2009, J CELL PHYSIOL, V220, P690, DOI 10.1002/jcp.21815
   Ramaiah SK, 2007, TOXICOL PATHOL, V35, P757, DOI 10.1080/01926230701584163
   Roberts RA, 2007, TOXICOL SCI, V96, P2, DOI 10.1093/toxsci/kfl173
   Rosales C, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00113
   Rotz LD, 2002, EMERG INFECT DIS, V8, P225, DOI 10.3201/eid0802.010164
   Saxena N, 2013, TOXICOL SCI, V135, P103, DOI 10.1093/toxsci/kft139
   Shih SF, 2001, J BIOL CHEM, V276, P21870, DOI 10.1074/jbc.M100571200
   SUNTRES ZE, 2005, J MED CHEM BIOL RADI, V3, P1
   Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8
   Uchida K, 2007, CHEM RES TOXICOL, V20, P3, DOI 10.1021/tx600304n
   Vaziri ND, 2006, NAT CLIN PRACT NEPHR, V2, P582, DOI 10.1038/ncpneph0283
   Wu YZ, 2013, J IMMUNOL, V190, P1859, DOI 10.4049/jimmunol.1201725
   Yu Q, 2019, INT IMMUNOPHARMACOL, V70, P435, DOI 10.1016/j.intimp.2019.02.024
   2013, IJC, V3, P2
NR 47
TC 0
Z9 0
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 49
EP 59
DI 10.1016/j.toxicon.2019.06.008
PG 11
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000007
PM 31185238
DA 2020-05-12
ER

PT J
AU Stegelmeier, BL
   Colegate, SM
   Knoppel, EL
   Rood, KA
   Collett, MG
AF Stegelmeier, Bryan L.
   Colegate, Steven M.
   Knoppel, Edward L.
   Rood, Kerry A.
   Collett, Mark G.
TI Wild parsnip (Pastinaca sativa)-induced photosensitization
SO TOXICON
LA English
DT Article
DE Wild parsnip; Pastinaca sativa; Photosensitization; Phyto-photo-contact
   dermatitis; Furanocoumarin; Xanthotoxin
ID C-14 XANTHOTOXIN 8-METHOXYPSORALEN; CONTACT-DERMATITIS;
   PASTINACA-SATIVA; SEEDS; FATE
AB Wild parsnip (Pastinaca saliva) has been associated with livestock and human photosensitization. An investigation of a natural occurrence of photosensitization of grazing horses identified wild parsnip as a possible cause. HPLC-MS and MS/MS analysis of this plant identified five furanocoumarins i.e., xanthotoxin, bergapten, isopimpinellin, imperatorin and a putative methoxyimperatorin. Goats fed this wild parsnip were largely unaffected. Xanthotoxin was not detected in the serum of parsnip-fed goats or in the serum of goats dosed orally or intravenous with purified xanthotoxin. Cutaneous application produced severe photodermatitis in goats and a horse consistent with topical exposure as the likely route to produce wild parsnip-induced photosensitivity. Wild parsnip-induced superficial necrotizing dermatitis was consistent with photodermatitis with no evidence of other allergic or inflammatory components.
C1 [Stegelmeier, Bryan L.; Colegate, Steven M.; Knoppel, Edward L.] ARS, USDA, Poisonous Plant Res Lab, Logan, UT USA.
   [Colegate, Steven M.; Rood, Kerry A.] Utah State Univ, Anim Dairy & Vet Sci Dept, Logan, UT 84322 USA.
   [Collett, Mark G.] Massey Univ, Sch Vet Sci, Palmerston North, New Zealand.
RP Stegelmeier, BL (reprint author), 1150 East 1400 North, Logan, UT 84341 USA.
EM Bryan.stegelmeier@ars.usda.gov
OI Collett, Mark/0000-0002-6686-4595; Rood, Kerry/0000-0001-6655-5381
FU USDA CRISUnited States Department of Agriculture (USDA)
   [2080-32630-012-00-D]
FX This work was previously presented and the abstract and summary included
   in the proceedings of the International Symposium of Poisonous Plants in
   Hohhot, Inner Mongolia, China, July 2013. It was funded by USDA CRIS
   2080-32630-012-00-D.
CR BERENBAUM MR, 1981, OECOLOGIA, V49, P236, DOI 10.1007/BF00349195
   BERENBAUM MR, 1984, PHYTOCHEMISTRY, V23, P1809, DOI 10.1016/S0031-9422(00)83503-7
   Bonamonte D, 2010, CONTACT DERMATITIS, V62, P343, DOI 10.1111/j.1600-0536.2010.01713.x
   Bowers A G, 1999, Am J Contact Dermat, V10, P89, DOI 10.1016/S1046-199X(99)90006-4
   IVIE GW, 1986, AM J VET RES, V47, P799
   Kriazheva S S, 1991, Pediatriia, P88
   MCMILLAN EM, 1985, J INVEST DERMATOL, V84, P229, DOI 10.1111/1523-1747.ep12265244
   MONTGOMERY JF, 1987, NEW ZEAL VET J, V35, P21, DOI 10.1080/00480169.1987.35369
   PANGILINAN NC, 1992, J CHEM ECOL, V18, P253, DOI 10.1007/BF00993757
   PICARDO M, 1986, CONTACT DERMATITIS, V15, P98, DOI 10.1111/j.1600-0536.1986.tb01291.x
   Renner J. E., 1991, VET ARGENT, V8, P452
   Waksmundzka-Hajnos M, 2004, J CHROMATOGR B, V800, P181, DOI 10.1016/j.jchromb.2003.07.006
   Walling A. L., 2018, DERMATOL ONLINE J, V24
   Zangerl AR, 2004, J CHEM ECOL, V30, P1985, DOI 10.1023/B:JOEC.0000045590.28631.00
   ZOBEL AM, 1991, CAN J BOT, V69, P485, DOI 10.1139/b91-065
NR 15
TC 0
Z9 0
U1 3
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 60
EP 66
DI 10.1016/j.toxicon.2019.06.007
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000008
PM 31173794
DA 2020-05-12
ER

PT J
AU Knudsen, C
   Ledsgaard, L
   Dehli, RI
   Ahmadi, S
   Sorensen, CV
   Laustsen, AH
AF Knudsen, Cecilie
   Ledsgaard, Line
   Dehli, Rasmus Ibsen
   Ahmadi, Shirin
   Sorensen, Christoffer Vinther
   Laustsen, Andreas Hougaard
TI Engineering and design considerations for next-generation snakebite
   antivenoms
SO TOXICON
LA English
DT Review
DE Next-generation antivenoms; Recombinant antivenoms; Small molecule toxin
   inhibitors; Toxin-neutralization; Monoclonal antibodies; Snakebite
   envenoming; Antivenom development; Antivenom manufacture
ID ADVERSE-REACTIONS; IMMUNOGLOBULIN THERAPY; ANTIBODY; METALLOPROTEINASE;
   PURIFICATION; SAFETY; TRIAL; INHIBITORS; POLYVALENT; STRATEGY
AB Snakebite envenoming is a devastating Neglected Tropical Disease, the treatment of which has seen relatively little innovation since the invention of antivenom serotherapy in 1894. Current antivenoms have been and continue to be invaluable in saving thousands of lives. However, these medicines are associated with a number of drawbacks pertaining to availability, safety, and efficacy. Fortunately, with the advent of novel methodologies, such as antibody discovery technologies, high-throughput drug discovery approaches, and improved methods for protein engineering, we are starting to see scientific advances in the field. This review presents relevant engineering and design considerations for exploiting these methodologies to develop next-generation antivenoms with improved safety, efficacy, and affordability. The pros and cons of different treatment modalities are discussed with regards to immunogenicity, the suitability of preclinical efficacy assays, availability of discovery methods, economic viability of production schemes, and possible regulatory approval paths.
C1 [Knudsen, Cecilie; Ledsgaard, Line; Dehli, Rasmus Ibsen; Ahmadi, Shirin; Sorensen, Christoffer Vinther; Laustsen, Andreas Hougaard] Tech Univ Denmark, Dept Biotechnol & Biomed, DK-2800 Lyngby, Denmark.
   [Ahmadi, Shirin] Eskisehir Osmangazi Univ, Dept Biotechnol & Biosafety, Eskisehir, Turkey.
RP Knudsen, C; Laustsen, AH (reprint author), Tech Univ Denmark, Dept Biotechnol & Biomed, DK-2800 Lyngby, Denmark.
EM cecknu@dtu.dk; liljen@dtu.dk; rasdeh@dtu.dk; shiahm@dtu.dk;
   s190279@student.dtu.dk; ahola@bio.dtu.dk
RI Jensen, Line/AAH-5951-2019
OI Ahmadi, Shirin/0000-0002-4131-583X; Knudsen,
   Cecilie/0000-0002-6399-3009; Laustsen, Andreas
   Hougaard/0000-0001-6918-5574
CR Ainsworth S, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0039-1
   Alirol E, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005612
   Anderson VE, 2019, CLIN TOXICOL, V57, P25, DOI 10.1080/15563650.2018.1491982
   [Anonymous], 2011, AM J CARDIOVASC DRUG, V11, P137, DOI 10.2165/11533650-000000000-00000
   Bawaskar HS, 2017, LANCET, V390, P1947, DOI 10.1016/S0140-6736(17)32175-X
   Bermudez-Mendez E, 2018, TOXINS, V10, DOI 10.3390/toxins10110452
   Bobo D, 2016, PHARM RES-DORDR, V33, P2373, DOI 10.1007/s11095-016-1958-5
   Boyer LV, 2013, TOXICON, V74, P101, DOI 10.1016/j.toxicon.2013.07.018
   Brvar M, 2017, CLIN TOXICOL, V55, P241, DOI 10.1080/15563650.2016.1277235
   Bryan-Quiros W, 2019, TOXICON, V157, P1, DOI 10.1016/j.toxicon.2018.11.292
   Burnouf T, 2004, BIOLOGICALS, V32, P115, DOI 10.1016/j.biologicals.2004.07.001
   Castro JMA, 2014, TOXICON, V87, P81, DOI 10.1016/j.toxicon.2014.05.017
   Chippaux JP, 2017, TOXINOLOGY, P475, DOI 10.1007/978-94-007-6410-1_25
   Chippaux JP, 1998, T ROY SOC TROP MED H, V92, P657, DOI 10.1016/S0035-9203(98)90802-1
   de Silva HA, 2016, BRIT J CLIN PHARMACO, V81, P446, DOI 10.1111/bcp.12739
   Descotes J, 2009, MABS, V1, P104, DOI 10.4161/mabs.1.2.7909
   El-Aziz TMA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07554-5
   Chaves LF, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500249
   Fry BG, 2018, TOXINS, V10, DOI 10.3390/toxins10040170
   Grilo AL, 2019, TRENDS BIOTECHNOL, V37, P9, DOI 10.1016/j.tibtech.2018.05.014
   Gutierrez JM, 2003, CLIN PHARMACOKINET, V42, P721, DOI 10.2165/00003088-200342080-00002
   Gutierrez JM, 2017, NAT REV DIS PRIMERS, V3, DOI [10.1038/nrdp.2017.79, 10.1038/nrdp.2017.63]
   Hammerschmidt N, 2014, BIOTECHNOL J, V9, P766, DOI 10.1002/biot.201300480
   Hansel TT, 2010, NAT REV DRUG DISCOV, V9, P325, DOI 10.1038/nrd3003
   Harding FA, 2010, MABS-AUSTIN, V2, P256, DOI 10.4161/mabs.2.3.11641
   Harrison RA, 2016, TOXINS, V8, DOI 10.3390/toxins8120351
   Harrison RA, 2011, J PROTEOMICS, V74, P1768, DOI 10.1016/j.jprot.2011.06.019
   He HT, 2016, 2016 7TH INTERNATIONAL CONFERENCE ON COMPUTER AIDED DESIGN FOR THIN-FILM TRANSISTOR TECHNOLOGIES (CAD-TFT), P8
   Herrera M, 2005, TOXICON, V46, P775, DOI 10.1016/j.toxicon.2005.08.004
   Howes JM, 2007, TOXICON, V49, P734, DOI 10.1016/j.toxicon.2006.11.020
   Jager V, 2013, BMC BIOTECHNOL, V13, DOI 10.1186/1472-6750-13-52
   Jenkins TP, 2019, TOXINS, V11, DOI 10.3390/toxins11010053
   Johnston CI, 2017, CLIN TOXICOL, V55, P115, DOI 10.1080/15563650.2016.1250903
   Parreno JMJ, 2018, PLANT BIOTECHNOL J, V16, P727, DOI 10.1111/pbi.12823
   Kannt A, 2016, N-S ARCH PHARMACOL, V389, P353, DOI 10.1007/s00210-016-1216-8
   Karain BD, 2016, J NANOSCI NANOTECHNO, V16, P7764, DOI 10.1166/jnn.2016.12851
   Keefe AD, 2010, NAT REV DRUG DISCOV, V9, P537, DOI 10.1038/nrd3141
   Kerpedjiev P, 2015, BIOINFORMATICS, V31, P3374, DOI 10.1093/bioinformatics/btv372
   King C, 2014, P NATL ACAD SCI USA, V111, P8577, DOI 10.1073/pnas.1321126111
   Kini RM, 2018, TOXINS, V10, DOI 10.3390/toxins10120534
   Knudsen Cecilie, 2018, Trop Med Infect Dis, V3, DOI 10.3390/tropicalmed3020042
   Laustsen AH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06086-4
   Laustsen AH, 2018, NEW BIOTECHNOL, V45, P19, DOI 10.1016/j.nbt.2017.05.005
   Laustsen AH, 2018, TOXICON, V146, P151, DOI 10.1016/j.toxicon.2018.03.004
   Laustsen AH, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005361
   Laustsen AH, 2016, CURR PHARM DESIGN, V22, P5270, DOI 10.2174/1381612822666160623073438
   Laustsen AH, 2016, NATURE, V538, P41, DOI 10.1038/538041e
   Laustsen AH, 2015, TOXICON, V104, P43, DOI 10.1016/j.toxicon.2015.07.334
   Laustsen AH, 2018, TOXINS, V10, DOI 10.3390/toxins10080309
   Laustsen AH, 2016, TOXIN REV, V35, P165, DOI 10.1080/15569543.2016.1220397
   Laustsen AH, 2016, TOXINS, V8, DOI 10.3390/toxins8080226
   Leon G, 2008, T ROY SOC TROP MED H, V102, P1115, DOI 10.1016/j.trstmh.2008.04.038
   Leon G, 2018, TOXICON, V151, P63, DOI 10.1016/j.toxicon.2018.06.084
   Leon G, 2013, TOXICON, V76, P63, DOI 10.1016/j.toxicon.2013.09.010
   Lewin M, 2016, TOXINS, V8, DOI 10.3390/toxins8090248
   Lewin MR, 2018, TOXINS, V10, DOI 10.3390/toxins10110479
   Lewin MR, 2018, TOXINS, V10, DOI 10.3390/toxins10100380
   Liu HF, 2010, MABS-AUSTIN, V2, P480, DOI 10.4161/mabs.2.5.12645
   Lojewska E, 2016, PROTEIN EXPRES PURIF, V120, P110, DOI 10.1016/j.pep.2015.12.018
   LoVecchio F, 2003, WILD ENVIRON MED, V14, P220, DOI 10.1580/1080-6032(2003)14[220:SSFAOA]2.0.CO;2
   MALASIT P, 1986, BRIT MED J, V292, P17, DOI 10.1136/bmj.292.6512.17
   Gutierrez JM, 2017, TOXINS, V9, DOI 10.3390/toxins9050163
   Gutierrez JM, 2014, B WORLD HEALTH ORGAN, V92, P526, DOI 10.2471/BLT.13.132431
   Gutierrez JM, 2013, TOXICON, V69, P168, DOI 10.1016/j.toxicon.2012.11.016
   Mazor R, 2017, CELL MOL IMMUNOL, V14, P432, DOI 10.1038/cmi.2015.91
   MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0
   Morais V, 2014, METHODS MOL BIOL, V1129, P137, DOI [10.1007/978-1-52703-977-2_13, 10.1007/978-1-62703-977-2_13]
   Moran NF, 1998, T ROY SOC TROP MED H, V92, P69, DOI 10.1016/S0035-9203(98)90959-2
   Nagata S, 2009, ADV DRUG DELIVER REV, V61, P977, DOI 10.1016/j.addr.2009.07.014
   Nelson AL, 2010, NAT REV DRUG DISCOV, V9, P767, DOI 10.1038/nrd3229
   O'Brien J, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006736
   Parsons SL, 1997, EUR J SURG ONCOL, V23, P526, DOI 10.1016/S0748-7983(97)93077-8
   Prado NDR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151363
   Rasmussen HS, 1997, PHARMACOL THERAPEUT, V75, P69, DOI 10.1016/S0163-7258(97)00023-5
   Rasmussen SK, 2012, ARCH BIOCHEM BIOPHYS, V526, P139, DOI 10.1016/j.abb.2012.07.001
   RAWAT S, 1994, TOXICON, V32, P185, DOI 10.1016/0041-0101(94)90107-4
   Reichert JM, 2010, MABS-AUSTIN, V2, P695, DOI 10.4161/mabs.2.6.13603
   Richard G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069495
   Rojas A, 2013, TOXICON, V70, P9, DOI 10.1016/j.toxicon.2013.03.013
   Rucavado A, 2000, AM J TROP MED HYG, V63, P313, DOI 10.4269/ajtmh.2000.63.313
   Sanhajariya S, 2018, TOXINS, V10, DOI 10.3390/toxins10020073
   Seifert SA, 2001, ANN EMERG MED, V37, P189, DOI 10.1067/mem.2001.113135
   Silva LC, 2018, ACTA TROP, V177, P66, DOI 10.1016/j.actatropica.2017.09.001
   Arias AS, 2017, TOXICON, V132, P40, DOI 10.1016/j.toxicon.2017.04.001
   SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944
   Sparano JA, 2004, J CLIN ONCOL, V22, P4683, DOI 10.1200/JCO.2004.08.054
   Steward WP, 1999, CANCER CHEMOTH PHARM, V43, pS56, DOI 10.1007/s002800051099
   Stone SF, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002326
   SUTHERLAND SK, 1977, MED J AUSTRALIA, V2, P841
   Taylor IJ, 2009, COMPUT COMMUN NETW S, P3
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   U.S. National Library of Medicine, VIST 16 TRIAL EV SAF
   Vargas M, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001144
   Vazquez-Lombardi R, 2015, DRUG DISCOV TODAY, V20, P1271, DOI 10.1016/j.drudis.2015.09.004
   Walsh G, 2014, NAT BIOTECHNOL, V32, P992, DOI 10.1038/nbt.3040
   Wang YD, 2018, MOLECULES, V23, DOI 10.3390/molecules23020391
   WHO, 2016, WORLD MALARIA REPORT, P1, DOI DOI 10.1017/CBO9781107415324.004
   Wiberg FC, 2006, BIOTECHNOL BIOENG, V94, P396, DOI 10.1002/bit.20865
   Wilken LR, 2012, BIOTECHNOL ADV, V30, P419, DOI 10.1016/j.biotechadv.2011.07.020
   Williams DJ, 2018, TOXICON, V150, P1, DOI 10.1016/j.toxicon.2018.05.001
   World Health Organization, 2010, WHO GUID PROD CONTR, DOI [10.1051/jbio/2009043, DOI 10.1051/JBIO/2009043]
   World Health Organization, 2018, GUIDELINES FOR THE P
NR 102
TC 3
Z9 3
U1 4
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 67
EP 75
DI 10.1016/j.toxicon.2019.06.005
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000009
PM 31173790
DA 2020-05-12
ER

PT J
AU Gao, CL
   Lin, SY
   Chen, M
   Hong, JJ
   Liu, CL
AF Gao, Chunlei
   Lin, Shuya
   Chen, Meng
   Hong, Jiajun
   Liu, Chenlin
TI Prevalence of phycotoxin contamination in shellfish from the Northern
   Bering Sea and the Chukchi Sea
SO TOXICON
LA English
DT Article
DE Shellfish; Northern Bering Sea; Chukchi Sea; Lipophilic toxins;
   Hydrophilic toxins; LC-MS/MS analysis
ID HARMFUL ALGAL BLOOMS; PROTOCERATIUM-RETICULATUM;
   LINGULODINIUM-POLYEDRUM; LIQUID-CHROMATOGRAPHY; SPECIES BOUNDARIES;
   MASS-SPECTROMETRY; TOXIN PROFILES; PECTENOTOXIN-6; DINOPHYCEAE;
   SEDIMENTS
AB To understand phycotoxin contamination in shellfish in the sub-Arctic and Arctic areas, scanning for the presence of 13 hydrophilic and lipophilic toxin components each was by liquid chromatography tandem quadrupole mass spectrometry analysis in shellfish samples collected from the Northern Bering Sea and the Chukchi Sea in 2014. The results showed that shellfish collected in both areas werecontaminated to different extents. Saxitoxin (STX), decarbamoylsaxitoxin (dcSTX) and decarbamoylneosaxitoxin (dcNEO) were the most frequently detected hydrophilic components, with maximum concentrations of 90.1 mu g/kg, 112.25 mu g/kg and 23.09 mu g/kg, respectively. Although gonyautoxins (GTXs) were only detected in 3 samples, they were the main contributors to overall toxicity of high-latitude samples, especially GTX1. For lipophilic toxins, spirolide-1 (SPX1) and yessotoxin (YTX) were present in all samples at low levels (< 7 mu g/kg and < 50 mu g/kg, respectively). Only 5 samples showed evidence of okadaic acid (OA) and dinophysistoxin-2 (DTX-2) at low concentrations, ranging from 0.42 mu g/kg to 7.23 mu g/kg and 3.03 mu g/kg to 30.59 mu g/kg, respectively. Notably, a high level of pectenotoxin-1 (PTX-1) at 467.40 mu g/kg was found in the shellfish collected at the northernmost station, exceeding the safety regulation standard by nearly 3 times. For both lipophilic and hydrophilic toxins, contamination in shellfish in the sub-Arctic and the Arctic area may be much more widespread and severe than was previously thought. This study highlighted the need to monitor toxins in a wider variety of shellfish, especially economic or commercial species, and across a wider range of sub-Arctic and Arctic waters, as well as the potential sources of these toxins.
C1 [Gao, Chunlei; Liu, Chenlin] Minist Nat Resources, Inst Oceanog 1, Qingdao 266061, Shandong, Peoples R China.
   [Gao, Chunlei; Liu, Chenlin] Pilot Natl Lab Marine Sci & Technol Qingdao, Lab Marine Ecol & Environm Sci, Qingdao 266237, Shandong, Peoples R China.
   [Lin, Shuya; Chen, Meng; Hong, Jiajun] Xiamen Univ, Coll Environm & Ecol, Xiamen 361005, Fujian, Peoples R China.
RP Gao, CL (reprint author), Minist Nat Resources, Inst Oceanog 1, Qingdao 266061, Shandong, Peoples R China.
EM gaochunlei@fio.org.cn
FU National Key RD Plan [2017YFC1404601]; Ministry of Science and
   Technology (MOST), ChinaMinistry of Science and Technology, China;
   Public Science and Technology Research Funds Project of Ocean
   [201305010]; State Oceanic Administration, China
FX This study was supported by the National Key R&D Plan (2017YFC1404601)
   from the Ministry of Science and Technology (MOST), China; and the
   Public Science and Technology Research Funds Project of Ocean
   (201305010) from the State Oceanic Administration, China. We thank
   Elaine Monaghan, BSc (Econ), from Liwen Bianji, Edanz Editing China
   (www.liwenbianji.cn/ac), for editing the English text of a draft of this
   manuscript.
CR Anderson D. M., 2018, HARMFUL ALGAL BLOOMS
   Anderson DM, 2012, HARMFUL ALGAE, V14, P10, DOI 10.1016/j.hal.2011.10.012
   Armstrong M, 2006, AFR J MAR SCI, V28, P399, DOI 10.2989/18142320609504186
   Baggesen C, 2012, HARMFUL ALGAE, V19, P108, DOI 10.1016/j.hal.2012.06.005
   Burrell S, 2013, FOOD CONTROL, V31, P295, DOI 10.1016/j.foodcont.2012.10.002
   CEMBELLA AD, 1994, J EXP MAR BIOL ECOL, V180, P1, DOI 10.1016/0022-0981(94)90075-2
   Grebmeier JM, 2012, ANNU REV MAR SCI, V4, P63, DOI 10.1146/annurev-marine-120710-100926
   Grebmeier JM, 2006, SCIENCE, V311, P1461, DOI 10.1126/science.1121365
   Gu HF, 2013, POLAR BIOL, V36, P427, DOI 10.1007/s00300-012-1273-5
   HALLEGRAEFF GM, 1993, PHYCOLOGIA, V32, P79, DOI 10.2216/i0031-8884-32-2-79.1
   Hallegraeff GM, 2010, J PHYCOL, V46, P220, DOI 10.1111/j.1529-8817.2010.00815.x
   Hunt GL, 2011, ICES J MAR SCI, V68, P1230, DOI 10.1093/icesjms/fsr036
   Ito E, 2008, TOXICON, V51, P707, DOI 10.1016/j.toxicon.2007.12.006
   Kremp A, 2014, J PHYCOL, V50, P81, DOI 10.1111/jpy.12134
   Krock B, 2008, TOXICON, V52, P927, DOI 10.1016/j.toxicon.2008.09.006
   Lefebvre KA, 2016, HARMFUL ALGAE, V55, P13, DOI 10.1016/j.hal.2016.01.007
   Li AF, 2016, TOXICON, V109, P84, DOI 10.1016/j.toxicon.2015.11.016
   Lilly EL, 2007, J PHYCOL, V43, P1329, DOI 10.1111/j.1529-8817.2007.00420.x
   Markus T, 2009, J GEOPHYS RES-OCEANS, V114, DOI 10.1029/2009JC005436
   Natsuike M, 2017, HARMFUL ALGAE, V63, P13, DOI 10.1016/j.hal.2017.01.001
   Natsuike M, 2017, HARMFUL ALGAE, V61, P80, DOI 10.1016/j.hal.2016.11.019
   Natsuike M, 2013, HARMFUL ALGAE, V27, P52, DOI 10.1016/j.hal.2013.04.006
   Ohashi R, 2013, DEEP-SEA RES PT II, V94, P44, DOI 10.1016/j.dsr2.2013.03.018
   Orlova TY, 2013, RUSS J MAR BIOL+, V39, P15, DOI 10.1134/S1063074013010069
   Paz B, 2004, TOXICON, V44, P251, DOI 10.1016/j.toxicon.2004.05.021
   Poulin Michel, 2011, Marine Biodiversity, V41, P13, DOI 10.1007/s12526-010-0058-8
   Rhodes L, 2006, HARMFUL ALGAE, V5, P148, DOI 10.1016/j.hal.2005.06.008
   Riccardi M, 2009, HARMFUL ALGAE, V8, P279, DOI 10.1016/j.hal.2008.06.008
   Sala-Perez M, 2016, HARMFUL ALGAE, V55, P85, DOI 10.1016/j.hal.2016.02.004
   Satake Masayuki, 1997, Natural Toxins, V5, P164
   Sayfritz SJ, 2008, TOXICON, V52, P330, DOI 10.1016/j.toxicon.2008.06.001
   Selina M.S., 2006, RUSS J MAR BIOL, V32, P321
   Stabeno P.J., 2007, DEEP SEA RES 2, VII, P5931
   Suzuki T, 1998, J CHROMATOGR A, V815, P155, DOI 10.1016/S0021-9673(98)00010-7
   Suzuki T., 2014, TOXINS BIOL ACTIVE C, V1, P104
   Tubaro A., 1998, HARMFUL ALGAE, P470
   YASUMOTO T, 1995, J AOAC INT, V78, P574
   YASUMOTO T, 1989, MYCOTOXINS PHYCOTOXI, V88, P375
NR 38
TC 0
Z9 0
U1 5
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 76
EP 81
DI 10.1016/j.toxicon.2019.06.001
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000010
PM 31170406
DA 2020-05-12
ER

PT J
AU Glatstein, M
   Lerman, L
   Friedman, S
   Carbell, G
   Munchak, I
   Valla, U
   Scolnik, D
   Hoyte, C
AF Glatstein, Miguel
   Lerman, Liat
   Friedman, Shirley
   Carbell, Gary
   Munchak, Itamar
   Valla, Uri
   Scolnik, Dennis
   Hoyte, Christopher
TI Severe disseminated intravascular coagulation in a child envenomated by
   Echis coloratus and successful treatment with monovalent equine
   immunoglobulin G antivenom
SO TOXICON
LA English
DT Review
DE Echis coloratus; Envenomation; Antivenom; Children; Israel
ID SAW-SCALED VIPER; EAST
AB Background Echis coloratus (Burton Carpet viper), a highly venomous snake belonging to the family Viperidae, is responsible for a large proportion of the venomous snakebites in Israel and Palestinian Authority. Procoagulant enzymes are present in Echis coloratus venom and significant coagulopathy is typical after envenomation. Here we report a case of envenomation by Echis coloratus that involved severe coagulopathy as the main systemic manifestation with severe bleeding after fasciotomy.
   Case details: A 3-year-old boy was admitted to our pediatric critical care unit after a snakebite to his left hand, 2-3 hours post-bite. Based on the possibility of compartment syndrome, a fasciotomy was performed before administration of antivenom. At our hospital, he had altered prothrombin time (PT) and activated partial thromboplastin time (aPTT), with low fibrinogen levels. The snake responsible for the bite was later identified as a 38-cm long Echis coloratus. Five vials of Israeli monovalent antivenom were subsequently administered with step-wise improvement in hematological abnormalities. Other treatments included massive blood products transfusion (packed RBC, FFP, cryoprecipitate, PLT), inotropes and ventilatory support. After a prolonged hospital course the patient had a positive outcome.
C1 [Glatstein, Miguel; Lerman, Liat; Carbell, Gary] Tel Aviv Univ, Sackler Sch Med, Dana Dwek Childrens Hosp, Div Pediat Emergency Med, 6 Weizman St, IL-64239 Tel Aviv, Israel.
   [Friedman, Shirley] Tel Aviv Univ, Sackler Sch Med, Dana Dwek Childrens Hosp, Dept Pediat Crit Care, Tel Aviv, Israel.
   [Munchak, Itamar] Galilee Med Ctr, Div Pediat Emergency Med, Nahariyya, Israel.
   [Valla, Uri] Hebrew Univ Jerusalem, Kaplan Med Ctr, Dept Pediat, Div Pediat Emergency Med, Jerusalem, Israel.
   [Scolnik, Dennis] Univ Toronto, Hosp Sick Children, Dept Pediat, Div Pediat Emergency Med, Toronto, ON, Canada.
   [Scolnik, Dennis] Univ Toronto, Hosp Sick Children, Dept Pediat, Div Pediat Clin Pharmacol, Toronto, ON, Canada.
   [Scolnik, Dennis] Univ Toronto, Hosp Sick Children, Dept Pediat, Div Toxicol, Toronto, ON, Canada.
   [Glatstein, Miguel; Hoyte, Christopher] Tel Aviv Univ, Sourasky Med Ctr, Div Clin Pharmacol & Toxicol, Tel Aviv, Israel.
   [Hoyte, Christopher] Univ Colorado, Sch Med, Dept Emergency Med, Boulder, CO 80309 USA.
   [Hoyte, Christopher] Univ Colorado, Sch Med, Sect Med Toxicol, Boulder, CO 80309 USA.
   [Hoyte, Christopher] Denver Hlth & Hosp Author, Rocky Mt Poison & Drug Ctr, Denver, CO USA.
RP Glatstein, M (reprint author), Tel Aviv Univ, Sackler Sch Med, Dana Dwek Childrens Hosp, Div Pediat Emergency Med, 6 Weizman St, IL-64239 Tel Aviv, Israel.
EM Nopasara73@hotmail.com
OI balla, uri/0000-0003-1109-3364
CR Al-Sadoon MK, 2012, SAUDI J BIOL SCI, V19, P221, DOI 10.1016/j.sjbs.2012.01.007
   Ben Abraham R, 2001, Eur J Emerg Med, V8, P189
   BENBASSAT J, 1993, ISRAEL J MED SCI, V29, P239
   Bentur Y, 2019, ISR MED ASSOC J, V21, P175
   Casewell NR, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-564
   Geron M, 2017, BBA-GEN SUBJECTS, V1861, P615, DOI 10.1016/j.bbagen.2017.01.004
   GILON D, 1989, TOXICON, V27, P1105, DOI 10.1016/0041-0101(89)90004-4
   Ismail M, 2003, INT J ANTIMICROB AG, V21, P164, DOI 10.1016/S0924-8579(02)00292-3
   Kochva E, 1998, Public Health Rev, V26, P209
   Leonardi A, 2014, TOXICON, V77, P141, DOI 10.1016/j.toxicon.2013.11.009
   Pivko-Levy D, 2017, CLIN TOXICOL, V55, P235, DOI 10.1080/15563650.2016.1277233
   PORATH A, 1992, TOXICON, V30, P25, DOI 10.1016/0041-0101(92)90498-T
   Swenson S., 2004, Current Drug Targets - Cardiovascular & Haematological Disorders, V4, P417, DOI 10.2174/1568006043335754
   Toschlog EA, 2013, J AM COLL SURGEONS, V217, P726, DOI 10.1016/j.jamcollsurg.2013.05.004
   WHO, 2010, SCREENING DONATED BLOOD FOR TRANSFUSION: TRANSMISSIBLE INFECTIONS, P1
   Yosef R, 2015, BEHAV PROCESS, V120, P50, DOI 10.1016/j.beproc.2015.08.009
NR 16
TC 0
Z9 0
U1 1
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 82
EP 86
DI 10.1016/j.toxicon.2019.05.012
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000011
PM 31150660
DA 2020-05-12
ER

PT J
AU Yilmaz, M
   Foss, AJ
   Miles, CO
   Ozen, M
   Demir, N
   Balci, M
   Beach, DG
AF Yilmaz, Mete
   Foss, Amanda J.
   Miles, Christopher O.
   Ozen, Mihriban
   Demir, Nilsun
   Balci, Muharrem
   Beach, Daniel G.
TI Comprehensive multi-technique approach reveals the high diversity of
   microcystins in field collections and an associated isolate of
   Microcystis aeruginosa from a Turkish lake
SO TOXICON
LA English
DT Article
DE [DMAdda(5)] MC-RR; Lake uluabat; MC-(H2)YR; [Mser(7)]MC-RR; Microcystin;
   Untargeted LC-HAMS
ID CYANOBACTERIAL GENUS ANABAENA; LC-MS ANALYSIS; FRESH-WATER; SUBG.
   DOLICHOSPERMUM; THIOL DERIVATIZATION; TOXIC CYANOBACTERIUM; SPECIES
   COMPOSITION; GENETIC DIVERSITY; BIOSYNTHESIS; PLANKTOTHRIX
AB Microcystins (MCs) are hepatotoxic and potentially carcinogenic cyanotoxins. They exhibit high structural variability, with nearly 250 variants described to date. This variability can result in incomplete detection of MC variants during lake surveys due to the frequent use of targeted analytical methods and a lack of standards available for identification and quantitation. In this study, Lake Uluabat in Turkey was sampled during the summer of 2015. Phylogenetic analysis of the environmental mcyA sequences suggested Microcystis spp. were the major MC contributors. A combination of liquid chromatography-tandem mass spectrometry (LC-MS/MS), liquid chromatography with UV detection and mass spectrometry (LC-UV-MS), and a novel liquid chromatography-high resolution mass spectrometry (LC-HRMS) method, together with thiol and periodate reactivity, revealed more than 36 MC variants in the lake samples and a strain of M. aeruginosa (AQUAMEB-24) isolated from Lake Uluabat. Only MCs containing arginine at position-4 were detected in the culture, while MC-LA, -LY, -LW and -LF were also detected in the lake samples, suggesting the presence of other MC producers in the lake. The previously unreported MCs MC-(H2)YR (dihydrotyrosine at position-2) (17), [epoxyAdda(5)]MC-LR, [DMAdda(5)]MC-RR (1) and [Mser(7)]MC-RR (8) were detected in the culture and/or field samples. This study is a good example of how commonly used targeted LC-MS methods can underestimate the diversity of MCs in freshwater lakes and cyanobacteria cultures and how untargeted LC-MS methods can be used to comprehensively assess MC diversity present in a new system.
C1 [Yilmaz, Mete; Ozen, Mihriban; Balci, Muharrem] Bursa Tech Univ, Dept Bioengn, TR-16310 Bursa, Turkey.
   [Foss, Amanda J.] CyanoLab, Green Water Labs, 205 Zeagler Dr, Palatka, FL 32177 USA.
   [Miles, Christopher O.; Beach, Daniel G.] Natl Res Council Canada, Biotoxin Metrol, Halifax, NS B3H 3Z1, Canada.
   [Ozen, Mihriban] Bursa Uludag Univ, Dept Biol, TR-16059 Bursa, Turkey.
   [Demir, Nilsun] Ankara Univ, Dept Fisheries & Aquaculture Engn, TR-06110 Ankara, Turkey.
   [Balci, Muharrem] Istanbul Univ, Dept Biol, TR-34134 Istanbul, Turkey.
RP Yilmaz, M (reprint author), Bursa Tech Univ, Dept Bioengn, TR-16310 Bursa, Turkey.
EM mete.yilmaz@btu.edu.tr; amandafoss@greenwaterlab.com;
   Christopher.Miles@nrc-cnrc.gc.ca; mihribanozen@uludag.edu.tr;
   ndemir@agri.ankara.edu.tr; muharrem.balci@istanbul.edu.tr;
   daniel.beach@nrc-cnrc.gc.ca
RI Demir, Nilsun/H-7762-2012
OI Demir, Nilsun/0000-0002-3895-7655; Miles, Chris/0000-0001-8537-4439;
   Yilmaz, Mete/0000-0002-0982-727X; Foss, Amanda/0000-0003-0412-3879;
   Beach, Daniel/0000-0002-5680-2112
FU Scientific and Technological Research Council of Turkey (TUBITAK)Turkiye
   Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [114Y641]
FX This study was supported by a grant from The Scientific and
   Technological Research Council of Turkey (TUBITAK) (Project no:
   114Y641). MY, MO and MB performed the field work. MO and MB prepared the
   samples for analyses. MB isolated the strain AQUAMEB24. MO performed
   ELISA and molecular analyses. ND performed cyanobacterial
   identifications and counts. AJF, COM, and DGB performed the LC-MS/MS
   analyses. MY planned the study, performed the phylogenetic analyses and
   wrote the paper with AJF, DGB and COM. The authors thank Cem Dirlik,
   Tolga Coskun and Gizem Seren Karatay for help during sampling and sample
   preparations, and K. Sivonen (Helsinki University, Helsinki, Finland)
   for providing Nostoc sp. strain 152.
CR Albay M, 2003, HYDROBIOLOGIA, V505, P89, DOI 10.1023/B:HYDR.0000007297.29998.5f
   Ballot A, 2014, MAR FRESHWATER RES, V65, P175, DOI 10.1071/MF13153
   Bernard C, 2017, HDB CYANOBACTERIAL M, P501, DOI DOI 10.1002/9781119068761.APP2
   Bortoli S, 2014, EUR J MASS SPECTROM, V20, P1, DOI 10.1255/ejms.1250
   Carmichael WW, 2016, HARMFUL ALGAE, V54, P194, DOI 10.1016/j.hal.2016.02.002
   Cerasino L, 2016, CHEM ECOL, V32, P492, DOI 10.1080/02757540.2016.1157175
   Christiansen G, 2003, J BACTERIOL, V185, P564, DOI 10.1128/JB.185.2.564-572.2003
   Cinar Sakir, 2013, Journal of FisheriesSciences.com, V7, P309
   Corbel S, 2014, CHEMOSPHERE, V96, P1, DOI 10.1016/j.chemosphere.2013.07.056
   Dalkiran Nurhayat, 2016, Journal of Limnology and Freshwater Fisheries Research, V2, P121, DOI 10.17216/LimnoFish.279720
   Dittmann E, 2013, FEMS MICROBIOL REV, V37, P23, DOI 10.1111/j.1574-6976.2012.12000.x
   Dorr FA, 2011, RAPID COMMUN MASS SP, V25, P1981, DOI 10.1002/rcm.5083
   Dyble J, 2008, ENVIRON TOXICOL, V23, P507, DOI 10.1002/tox.20370
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   FALCONER IR, 1981, AUST J BIOL SCI, V34, P179
   Fewer DP, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-183
   Fewer DP, 2008, MICROBIOL-SGM, V154, P1007, DOI 10.1099/mic.0.2007/016097-0
   Fischer WJ, 2005, TOXICOL APPL PHARM, V203, P257, DOI 10.1016/j.taap.2004.08.012
   Fischer WJ, 2001, ENVIRON SCI TECHNOL, V35, P4849, DOI 10.1021/es011182f
   Fontanillo M, 2018, BIOORGAN MED CHEM, V26, P1118, DOI 10.1016/j.bmc.2017.08.040
   Foss AJ, 2018, HARMFUL ALGAE, V80, P117, DOI 10.1016/j.hal.2018.10.006
   Foss AJ, 2017, TOXICON, V140, P45, DOI 10.1016/j.toxicon.2017.10.023
   Foss AJ, 2015, TOXICON, V104, P91, DOI 10.1016/j.toxicon.2015.07.332
   Gkelis S, 2005, ENVIRON TOXICOL, V20, P249, DOI 10.1002/tox.20105
   Grosse Y, 2006, LANCET ONCOL, V7, P628, DOI 10.1016/S1470-2045(06)70789-6
   Gurbuz F, 2016, SCI TOTAL ENVIRON, V562, P860, DOI 10.1016/j.scitotenv.2016.04.027
   Harke MJ, 2016, HARMFUL ALGAE, V54, P4, DOI 10.1016/j.hal.2015.12.007
   Hillebrand H, 1999, J PHYCOL, V35, P403, DOI 10.1046/j.1529-8817.1999.3520403.x
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Koker L, 2017, J ENVIRON PROT ECOL, V18, P425
   KOMAREK J, 1991, ARCH HYDROBIOL, P21
   Komarek J., 1999, SUSSWASSERFLORA MITT, P548
   KOMAREK J, 2005, CYANOPROKARYOTA, V2, P759
   Komarek J, 2013, SUSSWASSERFLORA MITT, V19, P1130, DOI 10.1007/978-3-8274-2737-3
   Komarek J, 2007, FOTTEA, V7, P1, DOI 10.5507/fot.2007.001
   Komarek J, 2008, FOTTEA, V8, P1, DOI 10.5507/fot.2008.001
   LEONARD NJ, 1962, J ORG CHEM, V27, P282, DOI 10.1021/jo01048a504
   Mantzouki E, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.226
   Mantzouki E, 2018, TOXINS, V10, DOI 10.3390/toxins10040156
   Mayumi T, 2006, J ANTIBIOT, V59, P710, DOI 10.1038/ja.2006.95
   Meriluoto J, 1997, ANAL CHIM ACTA, V352, P277, DOI 10.1016/S0003-2670(97)00131-1
   Metcalf JS, 2000, FEMS MICROBIOL LETT, V184, P241, DOI 10.1016/S0378-1097(00)00057-4
   Miles CO, 2014, ENVIRON SCI TECHNOL, V48, P13307, DOI 10.1021/es5029102
   Miles CO, 2013, TOXICON, V70, P21, DOI 10.1016/j.toxicon.2013.03.016
   Miles CO, 2013, ENVIRON SCI TECHNOL, V47, P4080, DOI 10.1021/es305202p
   Miles CO, 2012, ENVIRON SCI TECHNOL, V46, P8937, DOI 10.1021/es301808h
   NISHIWAKIMATSUSHIMA R, 1991, JPN J CANCER RES, V82, P993, DOI 10.1111/j.1349-7006.1991.tb01933.x
   Puddick J, 2014, MAR DRUGS, V12, P5372, DOI 10.3390/md12115372
   Rantala A, 2004, P NATL ACAD SCI USA, V101, P568, DOI 10.1073/pnas.0304489101
   Rantala A, 2006, APPL ENVIRON MICROB, V72, P6101, DOI 10.1128/AEM.01058-06
   Rantala-Ylinen A, 2011, APPL ENVIRON MICROB, V77, P7271, DOI 10.1128/AEM.06022-11
   Reed JM, 2008, BIOL CONSERV, V141, P2765, DOI 10.1016/j.biocon.2008.08.012
   Rubio F, 2014, TOXICON, V91, P45, DOI 10.1016/j.toxicon.2014.08.073
   SCHEFFER M, 1993, TRENDS ECOL EVOL, V8, P275, DOI 10.1016/0169-5347(93)90254-M
   Spoof L, 2017, HDB CYANOBACTERIAL M, P526, DOI DOI 10.1002/9781119068761.APP3
   Stal LJ, 1997, FEMS MICROBIOL REV, V21, P179, DOI 10.1111/j.1574-6976.1997.tb00350.x
   STANIER RY, 1971, BACTERIOL REV, V35, P171, DOI 10.1128/MMBR.35.2.171-205.1971
   Stewart AK, 2018, TOXICON, V144, P91, DOI 10.1016/j.toxicon.2018.01.021
   Sun J, 2003, J PLANKTON RES, V25, P1331, DOI 10.1093/plankt/fbg096
   Svircev Z, 2017, ARCH TOXICOL, V91, P621, DOI 10.1007/s00204-016-1921-6
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   Tillett D, 2000, CHEM BIOL, V7, P753, DOI 10.1016/S1074-5521(00)00021-1
   ULCAY S, 2010, BIYOLOJIBILIM, V3, P117
   Utermohl H., 1958, MITT INT VER LIMNOL, V9, P1, DOI DOI 10.1080/05384680.1958.11904091
   Vaitomaa J, 2003, APPL ENVIRON MICROB, V69, P7289, DOI 10.1128/AEM.69.12.7289-7297.2003
   Via-Ordorika L, 2004, SYST APPL MICROBIOL, V27, P592, DOI 10.1078/0723202041748163
   Xing Y, 2006, CELL, V127, P341, DOI 10.1016/j.cell.2006.09.025
   Yilmaz M, 2008, TOXICON, V51, P130, DOI 10.1016/j.toxicon.2007.08.013
   Yilmaz M, 2018, TOXICON, V148, P132, DOI 10.1016/j.toxicon.2018.04.028
   Yilmaz M, 2011, LAKE RESERV MANAGE, V27, P235, DOI 10.1080/07438141.2011.602203
   Zegura B, 2011, MUTAT RES-REV MUTAT, V727, P16, DOI 10.1016/j.mrrev.2011.01.002
NR 71
TC 7
Z9 7
U1 16
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 87
EP 100
DI 10.1016/j.toxicon.2019.06.006
PG 14
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000012
PM 31181296
HC N
HP Y
DA 2020-05-12
ER

PT J
AU Costa, LDF
   De Souza, MS
   Werlane, CC
   Madureira, LAS
   Weigert, SC
   Colett, JL
   de Pinho, MP
   Yunes, JS
AF Fonseca Costa, Luiza Dy
   De Souza, Marcio Silva
   Werlane, Chariane Camila
   Saint Pastous Madureira, Lauro Antonio
   Weigert, Stefan Cruz
   Colett, Juliano Lauser
   de Pinho, Marcelo Peres
   Yunes, Joao Sarkis
TI Domoic acid in the tropical South Atlantic Ocean - An environment case
   study
SO TOXICON
LA English
DT Article
DE Harmful algal blooms; Pseudo-nitzschia spp.; Domoic acid; Skipjack tuna;
   Brazilian coast/environment
ID DE-FUCA EDDY; PSEUDO-NITZSCHIA; COMPLEX BACILLARIOPHYCEAE; DIATOM;
   PSEUDODELICATISSIMA; VARIABILITY; MORTALITY; SHELLFISH; PUNGENS; BLOOMS
AB Domoic acid (DA) or Amnesic Shellfish Poisoning (ASP) produced by the genus Pseudo-nitzschia diatom was investigated in two seasonal periods in fishing areas of Katsuwonus pelamis in the South Atlantic Ocean. Higher DA concentrations were found in spring compared to winter. Pseudo-nitzschia spp. more quantified in winter than in spring, while P. pungens, a species among the most reported for an AD toxic potential, was only found in spring.
C1 [Fonseca Costa, Luiza Dy; De Souza, Marcio Silva; Werlane, Chariane Camila; Yunes, Joao Sarkis] Fed Univ Rio Grande, Inst Oceanog, Lab Cyanobacteria & Phycotoxins, Av Italia,Km 8, BR-96203900 Rio Grande, RS, Brazil.
   [Werlane, Chariane Camila; Yunes, Joao Sarkis] Fed Univ Rio Grande, Inst Oceanog, Postgrad Program Oceanol, Av Italia,Km 8, BR-96203900 Rio Grande, RS, Brazil.
   [De Souza, Marcio Silva; Saint Pastous Madureira, Lauro Antonio; Colett, Juliano Lauser] Fed Univ Rio Grande, Inst Oceanog, Postgrad Program Biol Oceanog, Av Italia,Km 8, BR-96203900 Rio Grande, RS, Brazil.
   [Saint Pastous Madureira, Lauro Antonio; Weigert, Stefan Cruz; Colett, Juliano Lauser; de Pinho, Marcelo Peres] Fed Univ Rio Grande, Inst Oceanog, Fisheries Technol & Hidroacoust Lab, Av Italia,Km 8, BR-96203900 Rio Grande, RS, Brazil.
RP Costa, LDF (reprint author), Fed Univ Rio Grande, Inst Oceanog, Av Italia,Km 8, BR-96203900 Rio Grande, RS, Brazil.
EM luiza_dy@hotmail.com
FU PNPD/CAPES (Brazil) fellowship; CAPES (Brazil)CAPES; Chevron Brazil;
   Federal Public Ministry
FX The authors would like to thank the staff of "Bonito" Project for the
   environmental data, the logistical support and samples and Murillo
   Cespedes and Caroline Varela by the field work. Bonito Project has
   financial support from the Term of Adjustment of Conduct signed by
   Chevron Brazil and Federal Public Ministry, with implementation of the
   Brazilian Biodiversity Fund - Funbio. LDFCosta and MsDeSouza are both
   granted by PNPD/CAPES (Brazil) fellowship and CWerlang is granted by an
   MSc fellowship from CAPES (Brazil); while J.S.Yunes is a research fellow
   in productivity of CNPq, Brazil. At last but not least, we thank the
   endorsement of the GlobalHAB/IOC-SCOR to this work.
CR Alves TP, 2018, ENVIRON MONIT ASSESS, V190, DOI 10.1007/s10661-018-6699-y
   Amato A, 2007, PROTIST, V158, P193, DOI 10.1016/j.protis.2006.10.001
   Andrade HA, 2003, FISH OCEANOGR, V12, P10, DOI 10.1046/j.1365-2419.2003.00220.x
   ANVISA, 2003, RES, V899
   Bates SS, 2006, ECOL STU AN, V189, P81, DOI 10.1007/978-3-540-32210-8_7
   BATES SS, 1989, CAN J FISH AQUAT SCI, V46, P1203, DOI 10.1139/f89-156
   BATES SS, 1998, PHYSL ECOLOGY HARMFU, P405
   Beltran AS, 1997, TOXICON, V35, P447, DOI 10.1016/S0041-0101(96)00140-7
   BRAGA ES, 1999, REV BRAS OCEANOGR, V47, P47, DOI DOI 10.1590/S1413-
   BRAGA ES, 2006, [No title captured], P161
   BRITTON G, 1985, METHOD ENZYMOL, V111, P113, DOI 10.1016/S0076-6879(85)11007-4
   Britton George, 2008, V4, P189, DOI 10.1007/978-3-7643-7499-0_10
   Dey S, 2013, ULTRASON SONOCHEM, V20, P271, DOI 10.1016/j.ultsonch.2012.05.010
   Dursun F, 2018, B ENVIRON CONTAM TOX, V100, P457, DOI 10.1007/s00128-018-2275-y
   FAO, 2018, IMPACTS CLIMATE CHAN, P654
   Fehling J, 2004, J PHYCOL, V40, P674, DOI 10.1111/j.1529-8817.2004.03213.x
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Godinho L, 2018, TOXICON, V155, P27, DOI 10.1016/j.toxicon.2018.10.003
   Hagstrom JA, 2011, J PLANKTON RES, V33, P297, DOI 10.1093/plankt/fbq102
   Hallegraeff G.M., 2003, Monographs on Oceanographic Methodology, V11, P25
   Hasle GR, 2005, PHYCOLOGIA, V44, P608, DOI 10.2216/0031-8884(2005)44[608:PSFOBR]2.0.CO;2
   HASLE GR, 1995, J PHYCOL, V31, P428, DOI 10.1111/j.0022-3646.1995.00428.x
   Hasle Grethe R., 2002, Harmful Algae, V1, P137, DOI 10.1016/S1568-9883(02)00014-8
   Horner RA, 1997, LIMNOL OCEANOGR, V42, P1076, DOI 10.4319/lo.1997.42.5_part_2.1076
   Hutchins DA, 1998, NATURE, V393, P561, DOI 10.1038/31203
   Kantha L, 2003, BOUNDARY LAYERS, P281
   Kara AB, 2000, J GEOPHYS RES-OCEANS, V105, P16803, DOI 10.1029/2000JC900072
   Karlson B, 2010, MICROSCOPIC MOL METH, V55, P110
   Landsberg JH, 2002, REV FISH SCI, V10, P113, DOI 10.1080/20026491051695
   Lelong A, 2012, PHYCOLOGIA, V51, P168, DOI 10.2216/11-37
   Lundholm N, 2006, J PHYCOL, V42, P464, DOI 10.1111/j.1529-8817.2006.00211.x
   Lundholm N, 2003, J PHYCOL, V39, P797, DOI 10.1046/j.1529-8817.2003.02031.x
   Maeno Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18651-w
   MARTIN JL, 1990, MAR ECOL PROG SER, V67, P177, DOI 10.3354/meps067177
   MIGUEZ A, 1996, HARMFUL TOXIC ALGAL, P143
   Moller OO, 2008, CONT SHELF RES, V28, P1607, DOI 10.1016/j.csr.2008.03.012
   Orsini L, 2004, MAR ECOL PROG SER, V271, P87, DOI 10.3354/meps271087
   Pan YL, 2001, MAR ECOL PROG SER, V220, P83, DOI 10.3354/meps220083
   Pan Youlian, 1998, Natural Toxins, V6, P127, DOI 10.1002/(SICI)1522-7189(199805/08)6:3/4<127::AID-NT9>3.3.CO;2-U
   Proenca L.A.O, 2005, SERIE LIVORS MUSEU N, V10, P57
   Proenca L.A.O, 1999, NOTAS TEC FACIMAR, V3, P27
   Pulido OM, 2008, MAR DRUGS, V6, P180, DOI 10.3390/md20080010
   Reguera B, 2012, HARMFUL ALGAE, V14, P87, DOI 10.1016/j.hal.2011.10.016
   Ribani M, 2004, QUIM NOVA, V27, P771, DOI 10.1590/S0100-40422004000500017
   Saldanha-Corrêa Flávia Marisa Prado, 2004, Braz. j. oceanogr., V52, P167, DOI 10.1590/S1679-87592004000300001
   Schnetzer A, 2017, HARMFUL ALGAE, V61, P23, DOI 10.1016/j.hal.2016.11.008
   Scholin CA, 2000, NATURE, V403, P80, DOI 10.1038/47481
   Silva M, 2018, TOXINS, V10, DOI 10.3390/toxins10090362
   Takanohashi R. A, 2015, BRAZ J AQUAT SCI TEC, V19, P3, DOI 10.14210/bjast.v19n3
   TAKEMOTO T, 1958, CHEM PHARM BULL, V6, P578, DOI DOI 10.1248/CPB.6.578B]
   Trainer V.L., 2008, OCEANS HUMAN HLTH RI, P219
   Trainer VL, 2009, LIMNOL OCEANOGR, V54, P289, DOI 10.4319/lo.2009.54.1.0289
   Trick CG, 2018, HARMFUL ALGAE, V79, P105, DOI 10.1016/j.hal.2018.08.007
   Utermohl H, 1958, MITT INT VER THEOR, V9, P1, DOI DOI 10.1080/05384680.1958.11904091
   Wiese M, 2010, MAR DRUGS, V8, P2185, DOI 10.3390/md8072185
   WRIGHT JLC, 1989, CAN J CHEM, V67, P481, DOI 10.1139/v89-075
NR 56
TC 0
Z9 0
U1 5
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 101
EP 105
DI 10.1016/j.toxicon.2019.05.009
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000013
PM 31125620
DA 2020-05-12
ER

PT J
AU Hew, BE
   Fritzinger, DC
   Pangburn, MK
   Vogel, CW
AF Hew, Brian E.
   Fritzinger, David C.
   Pangburn, Michael K.
   Vogel, Carl-Wilhelm
TI Identification of functionally important amino acid sequences in cobra
   venom factor using human C3/Cobra venom factor hybrid proteins
SO TOXICON
LA English
DT Article
DE Cobra venom factor; Complement; Complement component C3; C3 convertase;
   Hybrid proteins; Cobra (naja sp.)
ID ALTERNATIVE COMPLEMENT PATHWAY; FACTOR-B; ACTIVATING PROTEIN; C3-C5
   CONVERTASE; C3B INACTIVATOR; 3RD COMPONENT; C-3; BETA-1H; SERUM; NAJA
AB Cobra venom factor (CVF) is the complement-activating protein in cobra venom. CVF is a structural and functional analog of complement component C3. CVF, like C3b, forms a convertase with factor B. This bimolecular complex CVF,Bb is an enzyme that cleaves C3 and C5. However, CVF,Bb exhibits significantly different functional properties from C3b,Bb. The CVF,Bb convertase is physico-chemically very stable, and completely resistant to an activation by Factors H and I. These two properties, in contrast to C3b,Bb, allow continuous activation of C3 and C5, and complement depletion in serum. In order to understand the structural basis for the functional differences between CVF and C3, we have created several hybrid proteins of CVF and human C3. Here we report that replacing the C-terminal 168 amino acid residues of human C3 with the corresponding residues from CVF results in a hybrid protein (HC3-1496) which is essentially a human C3 derivative exhibiting the functional properties of CVF. This result demonstrates that the important structures for the CVF-specific functions reside within the C-terminal 168 amino acid residues of CVF. We further demonstrate that reverting the 46 C-terminal CVF residues of HC3-1496 to human C3 sequence results in a hybrid protein (HC3-1496/1617) that exhibits a physico-chemically unstable convertase with only residual complement depleting activity. This result demonstrates that most, but not all, structural requirements for CVF activity reside within the 46 C-terminal amino acid residues. We also investigated the potential role of position 1633, which is an acidic residue in human C3 (glutamic acid) but a basic amino acid residue (histidine) in CVF. However, the charge at position 1633 appears to be of no functional relevance. Exchanging the neutral amino acids present in CVF at positions 1499 and 1501 with the two charged amino acids at these positions in human C3 (aspartic acid and lysine) resulted in a hybrid protein that exhibited significantly slower convertase formation although both binding to Factor B and C3 cleavage was not affected, demonstrating that the charged amino acid residues at these two positions interfere with the formation of the convertase. In conclusion, our work demonstrates that hybrid proteins of human C3 and CVF present valuable tools to identify functionally important amino acid residues in CVF.
C1 [Hew, Brian E.; Fritzinger, David C.; Vogel, Carl-Wilhelm] Univ Hawaii Manoa, Univ Hawaii Canc Ctr, 701 Ilalo St, Honolulu, HI 96813 USA.
   [Pangburn, Michael K.] Univ Texas Hlth Sci Ctr, Biomed Res Dept, Tyler, TX 75708 USA.
   [Vogel, Carl-Wilhelm] Univ Hawaii Manoa, John A Burns Sch Med, Dept Pathol, 651 Ilalo St, Honolulu, HI 96813 USA.
RP Vogel, CW (reprint author), Univ Hawaii, Canc Ctr, 701 Ilalo St, Honolulu, HI 96813 USA.
EM cvogel@cc.hawaii.edu
FU Incode Biopharmaceutics, Inc., San Diego, CA
FX The author would like to thank Ms. June Lee and Ms. Katina Wong for
   expert technical assistance. Part of this work was supported by a
   research grant from Incode Biopharmaceutics, Inc., San Diego, CA.
CR ALPER CA, 1976, SCIENCE, V191, P1275, DOI 10.1126/science.56780
   Bammert H., 2002, INT IMMUNOPHARMACOL, V2, P1275
   COCHRANE CG, 1970, J IMMUNOL, V105, P55
   DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708
   DISCIPIO RG, 1983, J BIOL CHEM, V258, P629
   EGGERTSEN G, 1983, J IMMUNOL, V131, P1920
   EGGERTSEN G, 1981, MOL IMMUNOL, V18, P125, DOI 10.1016/0161-5890(81)90078-X
   Forneris F, 2010, SCIENCE, V330, P1816, DOI 10.1126/science.1195821
   Fritzinger DC, 2009, DEV COMP IMMUNOL, V33, P105, DOI 10.1016/j.dci.2008.07.006
   FRITZINGER DC, 1994, P NATL ACAD SCI USA, V91, P12775, DOI 10.1073/pnas.91.26.12775
   FRITZINGER DC, 1992, J IMMUNOL, V149, P3554
   GOTZE O, 1971, J EXP MED, V134, pS90
   Gowda DC, 2001, GLYCOBIOLOGY, V11, P195, DOI 10.1093/glycob/11.3.195
   GOWDA DC, 1994, J IMMUNOL, V152, P2977
   Grunwald Thomas, 1993, Molecular Immunology, V30, P13, DOI 10.1016/0161-5890(93)90211-S
   HENSLEY P, 1986, J BIOL CHEM, V261, P1038
   Hew BE, 2012, TOXICON, V60, P632, DOI 10.1016/j.toxicon.2012.05.004
   HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2
   Ing M, 2018, MOL IMMUNOL, V97, P1, DOI 10.1016/j.molimm.2018.02.018
   Janssen BJC, 2006, NATURE, V444, P213, DOI 10.1038/nature05172
   Janssen BJC, 2009, EMBO J, V28, P2469, DOI 10.1038/emboj.2009.184
   Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005
   Jokiranta TS, 2001, INT IMMUNOPHARMACOL, V1, P495, DOI 10.1016/S1567-5769(00)00042-4
   Kock MA, 2004, J BIOL CHEM, V279, P30836, DOI 10.1074/jbc.M403196200
   Krishnan V, 2009, STRUCTURE, V17, P611, DOI 10.1016/j.str.2009.01.015
   LACHMANN PJ, 1975, CLIN EXP IMMUNOL, V21, P109
   LESAVRE PH, 1979, J IMMUNOL, V123, P529
   MEDICUS RG, 1976, J EXP MED, V144, P1076, DOI 10.1084/jem.144.4.1076
   MULLEREBERHARD HJ, 1971, J IMMUNOL, V107, P1666
   NAGAKI K, 1978, INT ARCH ALLER A IMM, V57, P221, DOI 10.1159/000232106
   OKEEFE MC, 1988, J BIOL CHEM, V263, P12690
   PANGBURN MK, 1986, BIOCHEM J, V235, P723, DOI 10.1042/bj2350723
   PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257
   PETRELLA EC, 1987, J IMMUNOL METHODS, V104, P159, DOI 10.1016/0022-1759(87)90500-X
   Rawal N, 1998, J BIOL CHEM, V273, P16828, DOI 10.1074/jbc.273.27.16828
   Rawal N, 2001, INT IMMUNOPHARMACOL, V1, P415, DOI 10.1016/S1567-5769(00)00039-4
   Rawal N, 2000, J IMMUNOL, V164, P1379, DOI 10.4049/jimmunol.164.3.1379
   Rayes J, 2018, HAEMATOLOGICA, V103, P351, DOI 10.3324/haematol.2017.165720
   Rooijakkers SHM, 2009, NAT IMMUNOL, V10, P721, DOI 10.1038/ni.1756
   SMITH CA, 1984, J EXP MED, V159, P324, DOI 10.1084/jem.159.1.324
   SMITH CA, 1982, J BIOL CHEM, V257, P9879
   Vogel C.-W., 1991, HDB NATURAL TOXINS, P147
   Vogel CW, 2017, TOXINOLOGY, P345, DOI 10.1007/978-94-007-6410-1_4
   Vogel CW, 2015, THROMB HAEMOSTASIS, V113, P548, DOI 10.1160/TH14-04-0300
   Vogel CW, 2014, MOL IMMUNOL, V61, P191, DOI 10.1016/j.molimm.2014.06.035
   Vogel CW, 2010, TOXICON, V56, P1198, DOI 10.1016/j.toxicon.2010.04.007
   Vogel CW, 2004, MOL IMMUNOL, V41, P191, DOI 10.1016/j.molimm.2004.03.011
   VOGEL CW, 1984, J IMMUNOL METHODS, V73, P203, DOI 10.1016/0022-1759(84)90045-0
   Vogel CW, 1996, ADV EXP MED BIOL, V391, P97
   VOGEL CW, 1982, J BIOL CHEM, V257, P8292
   VOGEL CW, 1984, J IMMUNOL, V133, P3235
   VOGT W, 1974, H-S Z PHYSIOL CHEM, V355, P171, DOI 10.1515/bchm2.1974.355.1.171
   VONZABERN I, 1980, IMMUNOBIOLOGY, V157, P499
   WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147
NR 54
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 106
EP 116
DI 10.1016/j.toxicon.2019.06.017
PG 11
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000014
PM 31207349
DA 2020-05-12
ER

PT J
AU Guppy, R
   Ackbarali, C
   Ibrahim, D
AF Guppy, Reia
   Ackbarali, Christopher
   Ibrahim, Damien
TI Toxicity of crude organic extracts from the zoanthid Palythoa
   caribaeorum: A biogeography approach
SO TOXICON
LA English
DT Article
DE Palythoa caribaeorum; Zoanthid; Toxicity test; Organic extracts;
   Palytoxin
ID ARTEMIA-SALINA; PALYTOXIN; MECHANISMS; TOXINS; COAST; ASSAY; PUMP
AB Marine isolates such as palytoxin (PTX) are of concern within the Caribbean region due to their toxicity. PTX for example has been described as a one of the most known potent marine toxins, known to prevent predation from larger species (e.g. vertebrates) as well as the prevention of being overgrown from other coral species. PTX is a polyhydroxylated polyether toxin with a very large and complex chemical structure that possesses both hydrophilic and lipophilic properties. Previous acute toxicity tests using brine shrimp (Artemia salina) and PTX extract had shown it to be moderately toxic. In humans, PTX has been credited to be responsible for extreme symptoms such anaphylactic shock, rapid cardiac failure and eventual death occurring within minutes. Extrapolation for human dose ranges has therefore been suggested to be between 2.3 and 31.5 mu g. This study isolates a potentially PTX-enriched extract from Palythoa caribaeorum and examines its organic extract toxicity from a biogeography perspective from a within-colony to a variety of reef sites around Trinidad and Tobago that are popular for marine visitors. This research represents an acute study with a high level of crude organic extract toxicity on A. sauna whilst postulating potential factors which may contribute to its extreme toxicity and the risk posed to users of these environments.
C1 [Guppy, Reia; Ackbarali, Christopher; Ibrahim, Damien] Univ Trinidad & Tobago, Ctr Maritime & Ocean Studies, Marine Sci, 2nd Ave N,Western Main Rd, Chaguaramas, Trinid & Tobago.
RP Guppy, R (reprint author), Univ Trinidad & Tobago, Ctr Maritime & Ocean Studies, Marine Sci, 2nd Ave N,Western Main Rd, Chaguaramas, Trinid & Tobago.
EM Reia.Guppy@utt.edu.tt
OI Guppy, Reia/0000-0002-4281-2029
CR Aligizaki K, 2011, TOXICON, V57, P390, DOI 10.1016/j.toxicon.2010.11.014
   Aratake S, 2016, TOXICON, V111, P86, DOI 10.1016/j.toxicon.2015.12.004
   Artigas P, 2004, J GEN PHYSIOL, V123, P357, DOI 10.1085/jgp.200308964
   Bire R, 2013, HARMFUL ALGAE, V28, P10, DOI 10.1016/j.hal.2013.04.007
   Brovedani V, 2016, TOXICON, V119, P225, DOI 10.1016/j.toxicon.2016.06.013
   Costantino V, 2004, CURR MED CHEM, V11, P1671, DOI 10.2174/0929867043364973
   Deeds JR, 2010, TOXICON, V56, P150, DOI 10.1016/j.toxicon.2009.05.035
   Del Favero G, 2013, TOXICON, V75, P3, DOI 10.1016/j.toxicon.2013.06.003
   Dolabela M. F, 1997, THESIS U FEDERAL MIN, P128
   EFSA, 2009, EFSA J, V7, DOI 10.2903/j.efsa.2009.335r
   FRELIN C, 1995, GEN PHARMACOL, V26, P33, DOI 10.1016/0306-3623(94)00133-8
   Fusetani N, 2010, PURE APPL CHEM, V82, P17, DOI 10.1351/PAC-CON-09-01-11
   Gerssen A, 2010, TOXINS, V2, P878, DOI 10.3390/toxins2040878
   Gleibs S, 1999, TOXICON, V37, P1521, DOI 10.1016/S0041-0101(99)00093-8
   GLEIBS S, 1995, TOXICON, V33, P1531, DOI 10.1016/0041-0101(95)00079-2
   Harmel N, 2006, J GEN PHYSIOL, V128, P103, DOI 10.1085/jgp.200609505
   Hay ME, 1996, J EXP MAR BIOL ECOL, V200, P103, DOI 10.1016/S0022-0981(96)02659-7
   Hilgemann DW, 2003, P NATL ACAD SCI USA, V100, P386, DOI 10.1073/pnas.0437775100
   Hoffmann K, 2008, TOXICON, V51, P1535, DOI 10.1016/j.toxicon.2008.03.009
   Klijnstra MD, 2018, TOXINS, V10, DOI 10.3390/toxins10120537
   MELO LFD, 2012, BIOTEMAS, V25, P145, DOI DOI 10.5007/2175-7925.2012v25n3p145
   Miloslavich P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011916
   Munday R, 2011, TOXICON, V57, P470, DOI 10.1016/j.toxicon.2010.10.003
   Nordt SP, 2011, J EMERG MED, V40, P397, DOI 10.1016/j.jemermed.2009.05.004
   OLSEN DA, 1984, MAR FISH REV, V46, P13
   Patocka J, 2018, ARCH TOXICOL, V92, P143, DOI 10.1007/s00204-017-2105-8
   Patocka J, 2015, J HUAZHONG U SCI-MED, V35, P773, DOI 10.1007/s11596-015-1506-3
   Paul VJ, 2004, NAT PROD REP, V21, P189, DOI 10.1039/b302334f
   Ramos V, 2010, MAR DRUGS, V8, P2021, DOI 10.3390/md8072021
   Rhodes L, 2008, P 12 INT C HARMF ALG, P326
   Riobo P, 2006, ANAL CHIM ACTA, V566, P217, DOI 10.1016/j.aca.2006.03.013
   Riobo P, 2011, TOXICON, V57, P368, DOI 10.1016/j.toxicon.2010.09.012
   Rodrigues AM, 2009, PHYS BIOL, V6, DOI 10.1088/1478-3975/6/3/036010
   Rossini GP, 2011, TOXICON, V57, P429, DOI 10.1016/j.toxicon.2010.09.011
   Rumore MM, 2014, INT J CASE REP IMAGE, V5, P501, DOI DOI 10.5348/IJCRI-201488-CR-10399
   Soares Carolina L.S., 2006, Rev. bras. farmacogn., V16, P463, DOI 10.1590/S0102-695X2006000400004
   SOLIS PN, 1993, PLANTA MED, V59, P250, DOI 10.1055/s-2006-959661
   Tubaro A, 2012, VETERINARY TOXICOLOGY: BASIC AND CLINICAL PRINCIPLES, 2ND EDITION, P896, DOI 10.1016/B978-0-12-385926-6.00080-6
   Uemura D., 1991, BIOORGANIC MARINE CH, V4, P1
   Visciano P, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01051
   Whittle K, 2000, BRIT MED BULL, V56, P236, DOI 10.1258/0007142001902914
   WILES JS, 1974, TOXICON, V12, P427, DOI 10.1016/0041-0101(74)90011-7
   Wu CH, 2009, TOXICON, V54, P1183, DOI 10.1016/j.toxicon.2009.02.030
NR 43
TC 0
Z9 0
U1 6
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 117
EP 122
DI 10.1016/j.toxicon.2019.06.020
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000015
PM 31211958
DA 2020-05-12
ER

PT J
AU Domanska, B
   Fortea, E
   West, MJ
   Schwartz, JL
   Crickmore, N
AF Domanska, Barbara
   Fortea, Eva
   West, Michelle J.
   Schwartz, Jean-Louis
   Crickmore, Neil
TI The role of membrane-bound metal ions in toxicity of a human cancer
   cell-active pore-forming toxin Cry41Aa from Bacillus thuringiensis
SO TOXICON
LA English
DT Article
DE EGTA; Parasporin; Pore-forming toxin; HepG2; Cry toxin; Planar lipid
   bilayers; Patch-clamping
ID PLANAR LIPID-BILAYERS; EPITHELIAL-CELLS; CRYSTAL TOXIN; CALCIUM;
   PROTEIN; CHANNELS; ZINC; CA2+; PARASPORIN-2; CHELATION
AB Bacillus thuringiensis crystal (Cry) proteins, used for decades as insecticidal toxins, are well known to be toxic to certain insects, but not to mammals. A novel group of Cry toxins called parasporins possess a strong cytocidal activity against some human cancer cells. Cry41Aa, or parasporin3, closely resembles commercially used insecticidal toxins and yet is toxic to the human hepatic cancer cell line HepG2, disrupting membranes of susceptible cells, similar to its insecticidal counterparts. In this study, we explore the protective effect that the common divalent metal chelator EGTA exerts on Cry41Aa's activity on HepG2 cells. Our results indicate that rather than interfering with a signalling pathway as a result of chelating cations in the medium, the chelator prevented the toxin's interaction with the membrane, and thus the subsequent steps of membrane damage and p38 phosphorylation, by removing cations bound to plasma membrane components. BAPTA and DTPA also inhibited Cry41Aa toxicity but at higher concentrations. We also show for the first time that Cry41Aa induces pore formation in planar lipid bilayers. This activity is not altered by EGTA, consistent with a biological context of chelation. Salt supplementation assays identified Ca2+, Mn2+ and Zn2+ as being able to reinstate Cry41Aa activity. Our data suggest the existence of one or more metal cation-dependent receptors in the Cry41Aa mechanism of action.
C1 [Domanska, Barbara; West, Michelle J.; Crickmore, Neil] Univ Sussex, Sch Life Sci, Brighton BN1 9QG, E Sussex, England.
   [Fortea, Eva; Schwartz, Jean-Louis] Univ Montreal, Dept Pharmacol & Physiol, Montreal, PQ H3C 3J7, Canada.
   [Fortea, Eva] Cornea Grad Sch Med Sci, 1300 York Ave, New York, NY 10065 USA.
RP Domanska, B (reprint author), Univ Sussex, Sch Life Sci, Brighton BN1 9QG, E Sussex, England.
EM B.Domanska@sussex.ac.uk
OI West, Michelle/0000-0002-9497-9365
FU Biotechnology and Biological Sciences Research CouncilBiotechnology and
   Biological Sciences Research Council (BBSRC); University of Sussex;
   Research Opportunity Fund - University of Sussex; Medical Research
   CouncilMedical Research Council UK (MRC) [MR/K01952X/1]; Bloodwise
   [12035, 15024]; Natural Sciences and Engineering Council of
   CanadaNatural Sciences and Engineering Research Council of Canada [CRDPJ
   44052-12]; Universite de Montreal
FX BD would like to thank the Biotechnology and Biological Sciences
   Research Council and the University of Sussex for funding her PhD
   studentship. The electrophysiology work was supported by the Research
   Opportunity Fund funded by the University of Sussex. MJW is funded by
   grants from the Medical Research Council (MR/K01952X/1) and Bloodwise
   (12035 and 15024). JLS was supported by a grant from the Natural
   Sciences and Engineering Council of Canada (CRDPJ 44052-12) and EF by a
   Universite de Montreal graduate student scholarship.
CR Abe Y, 2008, J BIOCHEM, V143, P269, DOI 10.1093/jb/mvm220
   Adang MJ, 2014, ADV INSECT PHYSIOL, V47, P39, DOI 10.1016/B978-0-12-800197-4.00002-6
   Babor M, 2005, PROTEINS, V59, P221, DOI 10.1002/prot.20431
   BEAR CE, 1990, AM J PHYSIOL, V258, pC421
   Bolsover S, 1994, TRENDS CELL BIOL, V4, P443
   Breit S, 1997, PFLUGERS ARCH, V435, P203
   Brini Marisa, 2013, Met Ions Life Sci, V13, P81, DOI 10.1007/978-94-007-7500-8_4
   Bulcke Felix, 2017, Adv Neurobiol, V18, P313, DOI 10.1007/978-3-319-60189-2_16
   Byegard J, 1999, J RADIOANAL NUCL CH, V241, P281, DOI 10.1007/BF02347463
   Candas M, 2002, BIOCHEMISTRY-US, V41, P13717, DOI 10.1021/bi026323k
   CAPIOD T, 1989, J PHYSIOL-LONDON, V409, P285, DOI 10.1113/jphysiol.1989.sp017497
   Chen WH, 1997, J FORMOS MED ASSOC, V96, P503
   CHENG KL, 1982, CRC HDB ORGANIC ANAL
   Cho Young-Eun, 2007, Nutr Res Pract, V1, P29, DOI 10.4162/nrp.2007.1.1.29
   Fortea E, 2017, J BIOL CHEM, V292, P13122, DOI 10.1074/jbc.M116.765941
   Fortier M, 2005, J MEMBRANE BIOL, V208, P77, DOI 10.1007/s00232-005-0820-1
   Gabriel Narvaez V. V, 2014, 47 ANN M SOC INV PAT
   Hashemi M, 2007, EUR J PHARMACOL, V557, P9, DOI 10.1016/j.ejphar.2006.11.010
   HILLE B, 2001, ION CHANNELS EXCITAB
   Husmann M, 2006, BIOCHEM BIOPH RES CO, V344, P1128, DOI 10.1016/j.bbrc.2006.03.241
   Kao CY, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001314
   Katayama H, 2007, J BIOL CHEM, V282, P7742, DOI 10.1074/jbc.M611382200
   Kirouac M, 2006, APPL ENVIRON MICROB, V72, P506, DOI 10.1128/AEM.72.1.506-515.2006
   Kitada S, 2006, J BIOL CHEM, V281, P26350, DOI 10.1074/jbc.M602589200
   Kloft N, 2009, BIOCHEM BIOPH RES CO, V385, P503, DOI 10.1016/j.bbrc.2009.05.121
   KNOWLES BH, 1987, BIOCHIM BIOPHYS ACTA, V924, P509, DOI 10.1016/0304-4165(87)90167-X
   Koch MS, 2015, FRONT PLANT SCI, V6, DOI 10.3389/fpls.2015.00283
   KOUMI SI, 1994, J GEN PHYSIOL, V104, P357, DOI 10.1085/jgp.104.2.357
   Krishnan V, 2017, BIOCHEM J, V474, P1591, DOI 10.1042/BCJ20170122
   LEBERMAN R, 1959, T FARADAY SOC, V55, P1660, DOI 10.1039/tf9595501660
   Liu YB, 1997, J ECON ENTOMOL, V90, P287, DOI 10.1093/jee/90.2.287
   Malhi H, 2000, J BIOL CHEM, V275, P26050, DOI 10.1074/jbc.M001576200
   Mermelstein CS, 2003, BRAZ J MED BIOL RES, V36, P1111, DOI 10.1590/S0100-879X2003000800018
   Monette R, 1997, APPL ENVIRON MICROB, V63, P440, DOI 10.1128/AEM.63.2.440-447.1997
   Ohba M, 2009, ANTICANCER RES, V29, P427
   Okumura S., PARASPORIN CLASSIFIC
   Pacheco S, 2009, J BIOL CHEM, V284, P32750, DOI 10.1074/jbc.M109.024968
   Pigott CR, 2007, MICROBIOL MOL BIOL R, V71, P255, DOI 10.1128/MMBR.00034-06
   PITELKA DR, 1983, J CELL BIOL, V96, P613, DOI 10.1083/jcb.96.3.613
   Plum LM, 2010, INT J ENV RES PUB HE, V7, P1342, DOI 10.3390/ijerph7041342
   POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x
   Porta H, 2011, PEPTIDES, V32, P601, DOI 10.1016/j.peptides.2010.06.012
   QUASTEL MR, 1981, J CELL PHYSIOL, V107, P165, DOI 10.1002/jcp.1041070202
   Ratner AJ, 2006, J BIOL CHEM, V281, P12994, DOI 10.1074/jbc.M511431200
   SALAMA HS, 1985, Z ANGEW ENTOMOL, V100, P425
   SCHWARTZ JL, 1991, BIOCHIM BIOPHYS ACTA, V1065, P250, DOI 10.1016/0005-2736(91)90237-3
   Schwartz JL, 1997, FEBS LETT, V412, P270, DOI 10.1016/S0014-5793(97)00801-6
   SEGEL GB, 1981, J BIOL CHEM, V256, P6629
   SPENCER CP, 1958, J MAR BIOL ASSOC UK, V37, P127, DOI 10.1017/S0025315400014880
   Vachon V, 2012, J INVERTEBR PATHOL, V111, P1, DOI 10.1016/j.jip.2012.05.001
   Wittung-Stafshede P, 2002, ACCOUNTS CHEM RES, V35, P201, DOI 10.1021/ar010106e
   Yamashita S, 2005, J BIOCHEM, V138, P663, DOI 10.1093/jb/mvi177
NR 52
TC 0
Z9 2
U1 15
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 123
EP 133
DI 10.1016/j.toxicon.2019.06.003
PG 11
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000016
PM 31181295
DA 2020-05-12
ER

PT J
AU Guerra-Duarte, C
   Horta, CCR
   Oliveira-Mende, BBR
   Magalhaes, BD
   Costal-Oliveira, F
   Stransky, S
   de Freitas, CF
   Campolina, D
   Pardal, PPD
   Lira-da-Silva, R
   de Avila, RAM
   Kalapothakis, E
   Chavez-Olortegui, C
AF Guerra-Duarte, Clara
   Rebello Horta, Carolina Campolina
   Ribeiro Oliveira-Mende, Barbara Bruna
   Magalhaes, Barbara de Freitas
   Costal-Oliveira, Fernanda
   Stransky, Stephanie
   de Freitas, Claudio Fonseca
   Campolina, Deilo
   de Oliveira Pardal, Pedro Pereira
   Lira-da-Silva, Rejane
   Machado de Avila, Ricardo Andres
   Kalapothakis, Evanguedes
   Chavez-Olortegui, Carlos
TI Determination of hyaluronidase activity in Tityus spp. Scorpion venoms
   and its inhibition by Brazilian antivenoms
SO TOXICON
LA English
DT Article
DE Hyaluronidase; Scorpion venom; Tityus; Antivenom; Hyaluronidase
   inhibition; Epitope mapping
ID IN-VITRO; PROTEINS; PURIFICATION; BAHIENSIS; TIME
AB Hyaluronidases (HYALs) are enzymes ubiquitously found in venoms from diverse animals and seem to be related to venom spreading. HYAL activity might be important to Tityus spp. envenoming, since anti-Tityus serrulatus HYAL (TsHYAL) rabbit antibodies neutralize T. serrulatus venom (TsV) lethality. The present work aimed to verify and compare HYAL activity of venoms from other Brazilian Tityus spp. (Tityus bahiensis, Tityus stigmurus and Tityus obscurus) and to test whether anti-TsHYAL antibodies and Brazilian horse therapeutic scorpion antivenom (produced by Fundacao Ezequiel Dias (FUNED), Butantan and Vital Brazil Institutes) can recognize and inhibit HYAL activity from these venoms. In ELISA assays, anti-TsHYAL and scorpion antivenoms recognized T. serrulatus, T. bahiensis and T. stigmurus venoms, however, they demonstrated weaker reaction with T. obscurus, which was also observed in Western blotting assay. Epitope mapping by SPOT assay revealed different binding patterns for each antivenom. The assay showed a weaker binding of scorpion antivenom produced by FUNED to peptides recognized by anti-TsHYAL antibodies. Anti-TsHYAL antibodies and antivenoms produced by Butantan and Vital Brazil institutes inhibited HYAL activity of all tested venoms in vitro, whereas FUNED antivenom did not show the same property. These results call attention to the importance of hyaluronidase inhibition, that can aid the improvement of antivenom production.
C1 [Guerra-Duarte, Clara; de Freitas, Claudio Fonseca] Fundacao Ezequiel Dias, Ctr Pesquisa & Desenvolvimento, BR-30510010 Belo Horizonte, MG, Brazil.
   [Rebello Horta, Carolina Campolina; Kalapothakis, Evanguedes] Ctr Univ Sete Lagoas, Biotecnol & Gestao Inovacao, BR-35701242 Sete Lagoas, MG, Brazil.
   [Ribeiro Oliveira-Mende, Barbara Bruna; Chavez-Olortegui, Carlos] Dept Biol Geral Brazil, Belo Horizonte, MG, Brazil.
   [Costal-Oliveira, Fernanda; Stransky, Stephanie] Univ Fed Minas Gerais, Inst Ciencias Biol, Bioquim & Imunol, BR-31270901 Belo Horizonte, MG, Brazil.
   [Magalhaes, Barbara de Freitas] Rice Univ, Dept BioSci, Houston, TX 77005 USA.
   [Campolina, Deilo] Hosp Pronto Socorro Joao XXIII HPS, BR-30130100 Belo Horizonte, MG, Brazil.
   [de Oliveira Pardal, Pedro Pereira] Univ Fed Para, BR-66075110 Belem, Para, Brazil.
   [Lira-da-Silva, Rejane] Univ Fed Bahia, BR-40170115 Salvador, BA, Brazil.
   [Machado de Avila, Ricardo Andres] Univ Extremo Sul Catarinense, BR-88806000 Criciuma, SC, Brazil.
RP Guerra-Duarte, C (reprint author), Fundacao Ezequiel Dias, Ctr Pesquisa & Desenvolvimento, BR-30510010 Belo Horizonte, MG, Brazil.; Chavez-Olortegui, C (reprint author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, CP 486, BR-30161970 Belo Horizonte, MG, Brazil.
EM clara.duarte@funed.mg.gov.br; olortegi@icb.ufmg.br
RI Chavez Olortegui, Carlos Delfin/F-9227-2019
OI Chavez Olortegui, Carlos Delfin/0000-0001-9390-7207; Machado de Avila,
   Ricardo Andrez/0000-0002-1303-0490
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil -
   CAPESCAPES [TOXINOLOGIA 23038000825/2011-63]; CAPES-COFECUBCAPES
   [88881.191812/2018-01]; Fundacao de Amparo a Pesquisa do Estado de Minas
   Gerais, BrazilMinas Gerais State Research Foundation (FAPEMIG); Conselho
   Nacional de Desenvolvimento Cientifico e TecnolOgico, Brazil
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [406163/2018-9]; INCTTOX PROGRAM
FX This research was supported by Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior, Brazil - CAPES (TOXINOLOGIA 23038000825/2011-63) and
   CAPES-COFECUB (No 88881.191812/2018-01), Fundacao de Amparo a Pesquisa
   do Estado de Minas Gerais, Brazil and by funds of the INCTTOX PROGRAM
   and Universal Ed. (No 406163/2018-9) of Conselho Nacional de
   Desenvolvimento Cientifico e TecnolOgico, Brazil (CNPq).
CR Alvarenga E.R., 2012, OPEN J GENET, V2, P210, DOI [10.4236/ojgen.2012.24027, DOI 10.4236/OJGEN.2012.24027]
   ANVISA A. N., 2010, FARMACOPEIA BRASILEI
   Batista CVF, 2007, COMP BIOCHEM PHYS C, V146, P147, DOI 10.1016/j.cbpc.2006.12.004
   Biner O, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143963
   Bordon KCF, 2012, BIOCHIMIE, V94, P2740, DOI 10.1016/j.biochi.2012.08.014
   Brown N, 2010, TOXICON, V55, P1405, DOI 10.1016/j.toxicon.2010.02.012
   Bucaretchi F, 2014, TOXICON, V89, P17, DOI 10.1016/j.toxicon.2014.06.022
   Costal-Oliveira F, 2012, TOXICON, V60, P934, DOI 10.1016/j.toxicon.2012.06.013
   Cupo P, 2015, REV SOC BRAS MED TRO, V48, P642, DOI 10.1590/0037-8682-0237-2015
   de Oliveira UC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193739
   de Oliveira UC, 2015, TOXICON, V95, P52, DOI 10.1016/j.toxicon.2014.12.013
   de Rezende N A, 1995, Rev Inst Med Trop Sao Paulo, V37, P71, DOI 10.1590/S0036-46651995000100011
   de Souza LL, 2015, TOXICOL SCI, V147, P458, DOI 10.1093/toxsci/kfv140
   Fan HW, 2018, TOXICON, V151, P15, DOI 10.1016/j.toxicon.2018.06.070
   Ferrer VP, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002206
   Fox JW, 2013, TOXICON, V62, P75, DOI 10.1016/j.toxicon.2012.09.009
   Girish KS, 2006, LIFE SCI, V78, P1433, DOI 10.1016/j.lfs.2005.07.015
   Guerra-Duarte C, 2015, TOXICON, V108, P84, DOI 10.1016/j.toxicon.2015.09.007
   Harrison R. A., 2017, PRECLINICAL ANTIVENO, P1
   HECHTER O, 1947, J EXP MED, V85, P77, DOI 10.1084/jem.85.1.77
   Kemparaju K, 2006, CELL BIOCHEM FUNCT, V24, P7, DOI 10.1002/cbf.1261
   KREIL G, 1995, PROTEIN SCI, V4, P1666, DOI 10.1002/pro.5560040902
   Krifi MN, 2005, TOXICON, V45, P187, DOI 10.1016/j.toxicon.2004.10.007
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Mahadeswaraswamy YH, 2011, CURR TOP MED CHEM, V11, P2556
   Gutierrez JM, 2019, TOXINS, V11, DOI 10.3390/toxins11010005
   Maria WS, 2005, TOXICON, V46, P210, DOI 10.1016/j.toxicon.2005.03.024
   Ministerio da Saude do Brasil, 2018, SINAN SIST INF AGR N
   Mohamad IL, 2014, EUR J PEDIATR, V173, P815, DOI 10.1007/s00431-013-2244-8
   Pessini AC, 2001, TOXICON, V39, P1495, DOI 10.1016/S0041-0101(01)00122-2
   Pucca MB, 2014, TOXICON, V90, P326, DOI 10.1016/j.toxicon.2014.08.064
   Pucca MB, 2015, SCORPION VENOMS, P299, DOI DOI 10.1007/978-94-007-6404-0_20
   Horta CCR, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002693
   de Oliveira-Mendes BBR, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007048
   Squaiella-Baptistao CC, 2018, TOXICON, V150, P86, DOI 10.1016/j.toxicon.2018.05.008
   Sutti R, 2014, J VENOM ANIM TOXINS, V20, DOI 10.1186/1678-9199-20-2
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   Venancio EJ, 2013, TOXICON, V69, P180, DOI 10.1016/j.toxicon.2013.02.012
   Vivas-Ruiz DE, 2019, BIOCHIMIE, V162, P33, DOI 10.1016/j.biochi.2019.03.022
   Wahby AF, 2012, TOXICON, V60, P1380, DOI 10.1016/j.toxicon.2012.08.016
   *WHO, 2007, RAB ENV NEGL PUBL HL
   Williams DJ, 2018, TOXICON, V150, P1, DOI 10.1016/j.toxicon.2018.05.001
   Yingprasertchai S, 2003, TOXICON, V42, P635, DOI 10.1016/j.toxicon.2003.09.001
NR 44
TC 1
Z9 1
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 134
EP 143
DI 10.1016/j.toxicon.2019.06.019
PG 10
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000017
PM 31207348
DA 2020-05-12
ER

PT J
AU Lomonte, B
   Camacho, E
   Fernandez, J
   Salas, M
   Zavaleta, A
AF Lomonte, Bruno
   Camacho, Erika
   Fernandez, Julian
   Salas, Maria
   Zavaleta, Alfonso
TI Three-finger toxins from the venom of Micrurus tschudii tschudii (desert
   coral snake): Isolation and characterization of tschuditoxin-I
SO TOXICON
LA English
DT Article
DE Snake venom; Coral snake; Micrurus t. tschudii; Three-finger toxins
ID PHOSPHOLIPASES A(2); CROSS-REACTIVITY; COMPOSITIONAL PATTERNS;
   FEEDING-BEHAVIOR; SWISS-PDBVIEWER; ELAPIDAE; NIGROCINCTUS; MIPARTITUS;
   TOXICITY; FULVIUS
AB Venoms from Micrurus (New World coral snakes) display potent peripheral neurotoxicity which may cause death by respiratory paralysis, yet many are poorly or not characterized. The major venom components of coral snakes are three-finger toxins (3FTxs) and phospholipases A(2), whose proportions vary among species. As a trend, venoms of Micrurus from South America contain high proportions of 3FTxs, in contrast to most North and Central American species. Micrurus tschudii tschudii, the 'Desert coral snake' from Peril, displays an extreme 3FTx-predominant venom phenotype, with similar to 95% of its proteome belonging to this protein family. This study evaluated the toxicity of its major 3FTxs in mice. A lethal 3FTx, here named tschuditoxin-I, was purified and sequenced by MALDI-TOF-TOF and N-terminal degradation. Tschuditoxin-I showed highest similarity to MS-1, a short-chain alpha-neurotoxin from the aquatic, fish-eating coral snake M. surinamensis. The single amino acid substitution between these two toxins maps at the tip of the first beta-stranded 'finger' in the modeled structure of tschuditoxin-I, suggesting it may have a role in interaction with its target, which remains to be investigated. Owing to its lethal action, tschuditoxin-I is likely to be medically relevant in envenomings. In spite of its 74% sequence identity with an a-neurotoxin of M. nigrocinctus, an equine antivenom raised against venom of the latter did not immunorecognize tschuditoxin-I or M. t. tschudii venom by ELISA. This underscores the need of characterizing the biochemical and immunological properties of the main toxic components of Micrurus venoms, aiming to improve the limited para-specific coverage of current antivenoms.
C1 [Lomonte, Bruno; Camacho, Erika; Fernandez, Julian] Univ Costa Rica, Fac Microbiol, Inst Clodomiro Picado, San Jose 11501, Costa Rica.
   [Salas, Maria; Zavaleta, Alfonso] Univ Peruana Cayetano Heredia, Fac Ciencias & Filosofia, Dept Acad Ciencias Celulares & Mol, Lima 31, Peru.
RP Lomonte, B (reprint author), Univ Costa Rica, Fac Microbiol, Inst Clodomiro Picado, San Jose 11501, Costa Rica.
EM bruno.lomonte@ucr.ac.cr
RI Lomonte, Bruno/B-8862-2019
OI Lomonte, Bruno/0000-0003-2419-6469
FU Vicerrectoria de Investigacion, Universidad de Costa Rica [VI-B7608]
FX This study was conducted as part of an agreement signed between
   Instituto Nacional de Salud (Peru) and Universidad Peruana Cayetano
   Heredia. The partial financial support to this work by Vicerrectoria de
   Investigacion, Universidad de Costa Rica (VI-B7608) is gratefully
   acknowledged.
CR Aird SD, 2017, TOXINS, V9, DOI 10.3390/toxins9060187
   Alape-Giron A, 1999, EUR J BIOCHEM, V259, P225, DOI 10.1046/j.1432-1327.1999.00021.x
   AlapeGiron A, 1996, TOXICON, V34, P369, DOI 10.1016/0041-0101(95)00126-3
   ALAPEGIRON A, 1994, TOXICON, V32, P713, DOI 10.1016/0041-0101(94)90340-9
   Arce-Bejarano R, 2014, TOXICON, V90, P26, DOI 10.1016/j.toxicon.2014.07.010
   Benard-Valle M, 2014, TOXICON, V77, P6, DOI 10.1016/j.toxicon.2013.10.005
   Benkert P, 2011, BIOINFORMATICS, V27, P343, DOI 10.1093/bioinformatics/btq662
   BOLANOS R, 1975, TOXICON, V13, P139, DOI 10.1016/0041-0101(75)90123-3
   Bucaretchi Fábio, 2006, Rev. Inst. Med. trop. S. Paulo, V48, P141, DOI 10.1590/S0036-46652006000300005
   Bucaretchi F, 2016, CLIN TOXICOL, V54, P222, DOI 10.3109/15563650.2015.1135337
   Carrillo de Espinoza N, 1983, PUBLICACIONES MUSEO, V30, P1
   Casais-e-Silva LL, 2016, TOXICOL LETT, V257, P60, DOI 10.1016/j.toxlet.2016.06.005
   Castoe TA, 2007, ZOOL J LINN SOC-LOND, V151, P809, DOI 10.1111/j.1096-3642.2007.00350.x
   Correa-Netto C, 2011, J PROTEOMICS, V74, P1795, DOI 10.1016/j.jprot.2011.04.003
   da Silva ARDP, 2001, TOXICON, V39, P949
   da Silva MP, 2016, COMP MED SY, P169, DOI 10.1109/CBMS.2016.15
   da Silva NJ, 2001, COMP BIOCHEM PHYS C, V128, P425, DOI 10.1016/S1532-0456(00)00215-5
   Dashevsky D, 2018, J MOL EVOL, V86, P58, DOI 10.1007/s00239-017-9825-5
   de Almeida P. C. R, 2016, BIOL HIST NATURAL CO, P47
   de la Rosa G, 2018, AMINO ACIDS, V50, P885, DOI 10.1007/s00726-018-2556-0
   de Roodt AR, 2004, J TOXICOL-CLIN TOXIC, V42, P171, DOI 10.1081/CLT-120030943
   Fernandez J, 2015, TOXICON, V107, P217, DOI 10.1016/j.toxicon.2015.08.016
   Fernandez J, 2011, J PROTEOME RES, V10, P1816, DOI 10.1021/pr101091a
   Fernandez ML, 2018, TOXICOL LETT, V286, P39, DOI 10.1016/j.toxlet.2017.11.037
   Greene H.W., 1984, HERPETOLOGICA, V37, P213
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Guex N, 2009, ELECTROPHORESIS, V30, pS162, DOI 10.1002/elps.200900140
   Gutierrez J. M, 2016, MECANISMO ACAO VENEN, P295
   GUTIERREZ JM, 1992, TOXICON, V30, P1299, DOI 10.1016/0041-0101(92)90446-C
   GUTIERREZ JM, 1983, TOXICON, V21, P777, DOI 10.1016/0041-0101(83)90066-1
   HIGASHI HG, 1995, BRAZ J MED BIOL RES, V28, P767
   Kini RM, 2011, ACTA CHIM SLOV, V58, P693
   Lippa E, 2019, J PROTEOMICS
   Lomonte B, 2017, J VENOM ANIM TOXINS, V23, DOI 10.1186/s40409-017-0117-8
   Lomonte B, 2016, TOXICON, V122, P7, DOI 10.1016/j.toxicon.2016.09.008
   Lomonte B, 2016, TOXINS, V8, DOI 10.3390/toxins8050138
   Olamendi-Portugal T, 2008, PROTEOMICS, V8, P1919, DOI 10.1002/pmic.200700668
   Peterson ME, 2006, CLIN TECH SMALL AN P, V21, P183, DOI 10.1053/j.ctsap.2006.10.005
   de Roodt AR, 2012, TOXICON, V59, P356, DOI 10.1016/j.toxicon.2011.11.009
   Rey-Suarez P, 2017, BIOCHIMIE, V137, P88, DOI 10.1016/j.biochi.2017.03.008
   Rey-Suarez P, 2012, TOXICON, V60, P851, DOI 10.1016/j.toxicon.2012.05.023
   Rey-Suarez P, 2011, J PROTEOMICS, V75, P655, DOI 10.1016/j.jprot.2011.09.003
   Rossetto O, 2004, TOXICOL LETT, V149, P91, DOI 10.1016/j.toxlet.2003.12.023
   Rosso JP, 1996, EUR J BIOCHEM, V238, P231, DOI 10.1111/j.1432-1033.1996.0231q.x
   Roze J.A., 1983, MEM I BUTANTAN, V46, P305
   Sanz L, 2016, TOXINS, V8, DOI 10.3390/toxins8060178
   Silva Jr N.J., 2009, ANIMAIS PECONHENTOS, P116
   Solorzano A, 2005, REV BIOL TROP, V53, P227
   Souza Sergio Marques, 2011, Herpetology Notes, V4, P369
   Sribar J, 2014, TOXICON, V89, P9, DOI 10.1016/j.toxicon.2014.06.019
   Tanaka GD, 2016, TOXICON, V117, P59, DOI 10.1016/j.toxicon.2016.03.020
   Tanaka GD, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000622
   Urdaneta AH, 2004, COMP BIOCHEM PHYS C, V138, P485, DOI 10.1016/j.cca.2004.08.018
   Utkin Y., 2015, VENOMOUS REPTILES TH, P215
   Vergara I, 2014, J PROTEOMICS, V105, P295, DOI 10.1016/j.jprot.2014.02.027
NR 55
TC 1
Z9 1
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 144
EP 151
DI 10.1016/j.toxicon.2019.06.023
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000018
PM 31211957
DA 2020-05-12
ER

PT J
AU Macheskya, NJ
   Rusnak, JM
   Moore, EH
   Dorsey, CB
   Ward, LA
AF Macheskya, Nicholas J.
   Rusnak, Janice M.
   Moore, Evan H.
   Dorsey, Christopher B.
   Ward, Lucy A.
TI Development of a highly sensitive in vitro endothelial cell toxicity
   assay for evaluating ricin toxin A chain-based vaccines or therapeutics
SO TOXICON
LA English
DT Article
DE Ricin; Ricin toxin A chain; Vaccine; Vascular leak; Endothelial cell
   toxicity assay; Transendothelial electrical resistance
ID VASCULAR LEAK SYNDROME; CLINICAL-TRIAL; A-CHAIN; IMMUNOTOXIN; APOPTOSIS;
   BINDING; RIVAX; MODEL; MOTIF
AB The ricin toxin A chain (RTA) is responsible for ricin intoxication due to inhibition of protein synthesis. RTA is also known to cause endothelial toxicity [via a 3 amino acid sequence (x)D(y) motif that acts as a natural disintegrin] resulting in vascular leak syndrome (VLS) in humans. An in vitro endothelial cell toxicity (ECT) assay was developed to evaluate if the ricin vaccine candidate (RVEc) exhibited endothelial toxicity, determined by altered transendothelial electrical resistance (TEER) across human umbilical vein endothelial cell (HUVEC) monolayers. Timepoints at 2 and 4 h were included to evaluate HUVEC monolayers before the effects of RTA ribotoxic activity are observed. Both the 3 mu M and 6 mu M RTA positive controls consistently demonstrated significantly reduced TEER values, compared to their corresponding vehicle control, in a time- and concentration-dependent manner at 2, 4, and 24 h. Fluorescent imaging of HUVECs exposed to 3 mu M RTA showed cell rounding at 2 and 4 h and gap formation at 24 h. No changes in TEER or fluorescent imaging were observed after exposure to endothelial cell growth medium-2 (EGM-2) exchange (mock control). The negative controls, which included 2 mutant RTA vaccine derivatives [RVEc with an (x)D(y) VLS sequence modification to V76M or D75N] and bovine serum albumin (BSA), demonstrated no evidence of HUVEC toxicity at 3 mu M and 6 mu M concentrations. Overall, the performance of the ECT assay was consistent, allowing for the development of acceptance criteria that were related to time- and concentration-dependent decreases in TEER between 2 and 24 h.
C1 [Macheskya, Nicholas J.; Moore, Evan H.] Battelle Biomed Res Ctr, 1425 Plain City Georgesville Rd, West Jefferson, OH 43162 USA.
   [Rusnak, Janice M.; Dorsey, Christopher B.; Ward, Lucy A.] Med Countermeasure Syst MCS Joint Vaccine Acquisi, 1564 Freedman Dr, Ft Detrick, MD 21702 USA.
RP Rusnak, JM (reprint author), Joint Vaccine Acquisit Program, 1564 Freedman Dr, Ft Detrick, MD 21702 USA.
EM Janice.m.rusnak.ctr@mail.mil
FU U.S. Department of Defense (DOD) Joint Program Executive Office for
   Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)
   Joint Project Manager Medical Countermeasure Systems (JPM-MCS) - Joint
   Vaccine Acquisition Program (JVAP)
FX This work was funded and supported by the U.S. Department of Defense
   (DOD) Joint Program Executive Office for Chemical, Biological,
   Radiological and Nuclear Defense (JPEO-CBRND) Joint Project Manager
   Medical Countermeasure Systems (JPM-MCS) - Joint Vaccine Acquisition
   Program (JVAP).
CR Audi J, 2005, JAMA-J AM MED ASSOC, V294, P2342, DOI 10.1001/jama.294.18.2342
   Baluna R, 1997, IMMUNOPHARMACOLOGY, V37, P117, DOI 10.1016/S0162-3109(97)00041-6
   Baluna R, 1999, J IMMUNOTHER, V22, P41, DOI 10.1097/00002371-199901000-00006
   Baluna R, 1999, P NATL ACAD SCI USA, V96, P3957, DOI 10.1073/pnas.96.7.3957
   Baluna R, 1996, INT J IMMUNOPHARMACO, V18, P355, DOI 10.1016/S0192-0561(96)00043-4
   Baluna R, 2000, EXP CELL RES, V258, P417, DOI 10.1006/excr.2000.4954
   Hoyt DG, 1996, AM J PHYSIOL-LUNG C, V270, pL689
   HOYT DG, 1995, AM J PHYSIOL-LUNG C, V269, pL171
   Janosi L, 2013, TOXINS, V5, P224, DOI 10.3390/toxins5020224
   Legler PM, 2011, ACTA CRYSTALLOGR D, V67, P826, DOI 10.1107/S0907444911026771
   Lindstrom AL, 1997, BLOOD, V90, P2323
   McLane Mary Ann, 2004, Current Drug Targets - Cardiovascular & Haematological Disorders, V4, P327, DOI 10.2174/1568006043335880
   Pittman PR, 2015, VACCINE, V33, P7299, DOI 10.1016/j.vaccine.2015.10.094
   Porter A, 2011, TOXICON, V58, P68, DOI 10.1016/j.toxicon.2011.05.005
   SHAH SA, 1993, INT J IMMUNOPHARMACO, V15, P723, DOI 10.1016/0192-0561(93)90145-O
   Smallshaw JE, 2005, VACCINE, V23, P4775, DOI 10.1016/j.vaccine.2005.04.037
   Smallshaw JE, 2003, NAT BIOTECHNOL, V21, P387, DOI 10.1038/nbt800
   Smallshaw JE, 2002, VACCINE, V20, P3422, DOI 10.1016/S0264-410X(02)00312-2
   Smallshaw JE, 2012, CURR TOP MICROBIOL, V357, P259, DOI 10.1007/82_2011_156
   SOLERRODRIGUEZ AM, 1993, EXP CELL RES, V206, P227, DOI 10.1006/excr.1993.1142
   SOLERRODRIGUEZ AM, 1992, INT J IMMUNOPHARMACO, V14, P281, DOI 10.1016/0192-0561(92)90041-I
   Tselepis VH, 1997, J BIOL CHEM, V272, P21341, DOI 10.1074/jbc.272.34.21341
   Vitetta ES, 2012, CLIN VACCINE IMMUNOL, V19, P1697, DOI 10.1128/CVI.00381-12
   Vitetta ES, 2006, P NATL ACAD SCI USA, V103, P2268, DOI 10.1073/pnas.0510893103
   VITETTA ES, 1991, CANCER RES, V51, P4052
   Vitetta ES, 2000, CANCER J, V6, pS218
   Wu WB, 2003, EXP CELL RES, V286, P115, DOI 10.1016/S0014-4827(03)00105-8
NR 27
TC 1
Z9 1
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 152
EP 161
DI 10.1016/j.toxicon.2019.06.015
PG 10
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000019
PM 31207351
DA 2020-05-12
ER

PT J
AU Botha, CJ
   Venter, EA
   Ferreira, GCH
   Phaswane, RM
   Clift, SJ
AF Botha, Christo J.
   Venter, E. Annette
   Ferreira, Gezina C. H.
   Phaswane, Rephima M.
   Clift, Sarah J.
TI Geigerin-induced disorganization of desmin, an intermediate filament of
   the cytoskeleton, in a murine myoblast cell line (C2C12)
SO TOXICON
LA English
DT Article
DE alpha B-crystallin; Cytoskeleton; Desmin; F-actin; Sesquiterpene
   lactones; Synemin; Tubulin
ID SESQUITERPENE LACTONES; SYNEMIN; EXPRESSION
AB Ingestion of large quantities of Geigeria species by sheep causes "vermeersiekte", an economically important poisoning in southern Africa. The toxic principles are several sesquiterpene lactones, such as vermeerin, geigerin and ivalin. These sesquitepene lactones are myotoxic and the disease is characterized by microscopic and ultrastructural lesions in skeletal and cardiac muscle. Murine myoblast cells (C2C12) were exposed to 2.0, 2.5 and 5.0 mM geigerin for 24, 48 and 72 h to evaluate its effect on cytoskeletal proteins and filaments using immunocytochemistry and immunofluorescence staining. A concentration-dependent cytotoxic response was observed in desmin-expressing murine myoblasts under the light microscope, evidenced by disorganization and dot-like perinuclear aggregation of desmin filaments in the cells. beta-Tubulin, other desmin-associated proteins (alpha B-crystallin and synemin) as well as the microfilament F-actin were unaffected. The disorganization and aggregation of desmin following exposure to increasing geigerin concentrations is significant and can explain some of the striated muscle lesions observed in "vermeersiekte".
C1 [Botha, Christo J.; Venter, E. Annette; Ferreira, Gezina C. H.; Phaswane, Rephima M.; Clift, Sarah J.] Univ Pretoria, Fac Vet Sci, Dept Paraclin Sci, Private Bag X 04, ZA-0110 Onderstepoort, South Africa.
RP Botha, CJ (reprint author), Univ Pretoria, Fac Vet Sci, Dept Paraclin Sci, Private Bag X 04, ZA-0110 Onderstepoort, South Africa.
EM christo.botha@up.ac.za
OI Botha, Christo/0000-0003-1535-9270
CR Botha CJ, 2017, ONDERSTEPOORT J VET, V84, DOI 10.4102/ojvr.v84i1.1465
   Botha CJ, 1997, J S AFR VET ASSOC, V68, P97
   Capetanaki Y, 2002, TRENDS CARDIOVAS MED, V12, P339, DOI 10.1016/S1050-1738(02)00184-6
   Carlsson L, 2000, HISTOCHEM CELL BIOL, V114, P39
   Chourbagi O, 2011, EXP CELL RES, V317, P886, DOI 10.1016/j.yexcr.2011.01.013
   Costa ML, 2004, BRAZ J MED BIOL RES, V37, P1819, DOI 10.1590/S0100-879X2004001200007
   Costa ML, 2014, ISRN DEV BIOL, V2014, DOI [10.1155/2014/713631, DOI 10.1155/2014/713631]
   Dubinska-Magiera M, 2014, FEBS LETT, V588, P517, DOI 10.1016/j.febslet.2014.01.005
   Ellis CE, 2010, TOXICON, V55, P1071, DOI 10.1016/j.toxicon.2009.12.006
   Fittipaldi S, 2015, FREE RADICAL BIO MED, V86, P331, DOI 10.1016/j.freeradbiomed.2015.05.035
   Fletcher DA, 2010, NATURE, V463, P485, DOI 10.1038/nature08908
   Grosskopf J. F. W., 1964, TECHNICAL COMMUNICAT, V21
   Kellerman TS, 1996, ONDERSTEPOORT J VET, V63, P65
   KELLERMAN TS, 2005, PLANT POISONINGS MYC
   Launay N, 2006, EXP CELL RES, V312, P3570, DOI 10.1016/j.yexcr.2006.07.025
   Mermelstein CS, 2005, BRAZ J MED BIOL RES, V38, P1025, DOI 10.1590/S0100-879X2005000700005
   Milner DJ, 2000, J CELL BIOL, V150, P1283, DOI 10.1083/jcb.150.6.1283
   Mizuno Y, 2004, MUSCLE NERVE, V30, P337, DOI 10.1002/mus.20111
   Mizuno Y, 2001, P NATL ACAD SCI USA, V98, P6156, DOI 10.1073/pnas.111153298
   NARASIMHAN TR, 1989, GEN PHARMACOL, V20, P681, DOI 10.1016/0306-3623(89)90107-9
   Olive M, 2003, ACTA NEUROPATHOL, V106, P1, DOI 10.1007/s00401-003-0695-0
   Paul M, 2016, METHOD ENZYMOL, V568, P537, DOI 10.1016/bs.mie.2015.08.005
   Paulin D, 2004, J PATHOL, V204, P418, DOI 10.1002/path.1639
   Paulin D, 2004, EXP CELL RES, V301, P1, DOI 10.1016/j.yexcr.2004.08.004
   PIENAAR J G, 1973, Onderstepoort Journal of Veterinary Research, V40, P127
   VANASWEGEN CH, 1979, S AFR J SCI, V75, P84
   VANDERLUGT JJ, 1993, J S AFR VET ASSOC, V64, P82
NR 27
TC 0
Z9 0
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 162
EP 167
DI 10.1016/j.toxicon.2019.06.014
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000020
PM 31207352
DA 2020-05-12
ER

PT J
AU Silva, LM
   Nacif-Pimenta, R
   Ortolani, PL
   Moura, LM
   Cordeiro, MD
   Chavez-Olortegui, C
   Pimenta, PFP
   Fortes-Dias, CL
AF Silva, Luciana Maria
   Nacif-Pimenta, Rafael
   Ortolani, Paula Ladeira
   Moura, Layla Mosqueira
   Cordeiro, Marta do Nascimento
   Chavez-Olortegui, Carlos
   Paolucci Pimenta, Paulo Filemon
   Fortes-Dias, Consuelo Latorre
TI Immunodetection of toxins in historesin-embedded sections of Phoneutria
   nigriventer venom glands using laser confocal scanning microscopy
SO TOXICON
LA English
DT Article
DE Phoneutria nigriventer; Armed spider; Venom gland; Venom toxin
   secretion; Toxin immunodetection
ID AMINO-ACID-SEQUENCES; PURIFICATION; NEUROTOXINS; SPIDERS
AB In the last decades, main advances were achieved in the identification, structural and pharmacological characterization of Phoneutria nigriventer toxins. However, studies on the venom-producing apparatus are rare. Presently, we applied immunolabeling to historesin-embedded cross-sections of P. nigriventer venom glands. Toxins and toxin-secreting cells were successfully located in situ, using laser confocal scanning microscopy. The methodological strategy was successful and may be applied in future studies on venom glands and other secreting tissues, in general.
C1 [Silva, Luciana Maria; Ortolani, Paula Ladeira; Moura, Layla Mosqueira; Cordeiro, Marta do Nascimento; Fortes-Dias, Consuelo Latorre] Fundacao Ezequiel Dias FUNED, Diretoria Pesquisa & Desenvolvimento, Belo Horizonte, MG, Brazil.
   [Nacif-Pimenta, Rafael; Paolucci Pimenta, Paulo Filemon] Inst Rene Rachou Fiocruz Minas, Lab Med Entomol, Belo Horizonte, MG, Brazil.
   [Chavez-Olortegui, Carlos] Univ Fed Minas Gerais, Dept Bioquim & Imunol, Belo Horizonte, MG, Brazil.
RP Fortes-Dias, CL (reprint author), Fundacao Ezequiel Dias FUNED, Diretoria Pesquisa & Desenvolvimento, Belo Horizonte, MG, Brazil.
EM consuelo.latorre@funed.mg.gov.br
RI Silva, Luciana M/I-4353-2014; Fortes-Dias, Consuelo Latorre/U-9962-2019;
   Fortes-Dias, Consuelo/AAK-6897-2020; Pimenta, Paulo/AAH-1502-2020;
   Chavez Olortegui, Carlos Delfin/F-9227-2019
OI Silva, Luciana M/0000-0002-2038-0405; Fortes-Dias, Consuelo
   Latorre/0000-0002-4494-5108; Chavez Olortegui, Carlos
   Delfin/0000-0001-9390-7207
FU Fundacao de Amparo Pesquisa de Minas Gerais (FAPEMIG)Minas Gerais State
   Research Foundation (FAPEMIG); Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq)National Council for Scientific and
   Technological Development (CNPq); Fundacao do Instituto Oswaldo Cruz
   (FIOCRUZ); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES
FX Thanks are due to A. C. Valentim, T. Aguiar and M. N. A. Pereira for
   technical help. The Brazilian funding agencies: Fundacao de Amparo
   Pesquisa de Minas Gerais (FAPEMIG), Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq) and Fundacao do Instituto Oswaldo Cruz
   (FIOCRUZ) partially supported this study. RNP is a post-doc supported by
   the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES),
   PFPP is a researcher fellow held by CNPq and CLFD is a productivity
   fellow from FAPEMIG.
CR [Anonymous], 2010, DOENCAS NEGLIGENCIAD, V2010
   Brazil V., 1925, MEM I BUTANTAN, V2, P5
   Bucherl W., 1972, INVERTEBRADOS ARANHA
   BUCHERL WOLFGANG, 1964, MEMORIAS INST BUTANTAN, V31, P77
   CORDEIRO MD, 1993, TOXICON, V31, P35, DOI 10.1016/0041-0101(93)90354-L
   CORDEIRO MD, 1992, FEBS LETT, V310, P153, DOI 10.1016/0014-5793(92)81318-G
   EICKSTEDT VRD, 1994, VENENOS ANIMAIS VISA, P151
   Hell RCR, 2009, CLIN IMMUNOL, V131, P129, DOI 10.1016/j.clim.2008.10.012
   KARALLIEDDE L, 1995, BRIT J ANAESTH, V74, P319, DOI 10.1093/bja/74.3.319
   LUCAS S, 1988, TOXICON, V26, P759, DOI 10.1016/0041-0101(88)90317-0
   Martins R, 2007, ZOOTAXA, P1
   Peigneur S, 2018, TOXICON, V151, P96, DOI 10.1016/j.toxicon.2018.07.008
   REZENDE L, 1991, TOXICON, V29, P1225, DOI 10.1016/0041-0101(91)90195-W
   Richardson M, 2006, COMP BIOCHEM PHYS C, V142, P173, DOI 10.1016/j.cbpc.2005.09.010
   Schenberg S., 1978, HDB EXPT PHARM, V48, P149
   Silva LM, 2008, TOXICON, V51, P693, DOI 10.1016/j.toxicon.2007.12.009
   Simo Miguel, 2001, Bulletin of the British Arachnological Society, V12, P67
NR 17
TC 0
Z9 0
U1 1
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 168
EP 171
DI 10.1016/j.toxicon.2019.06.018
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000021
PM 31207353
DA 2020-05-12
ER

PT J
AU Collett, MG
   Taylor, SM
AF Collett, M. G.
   Taylor, S. M.
TI Photosensitising toxins in alligator weed (Alternanthera philoxeroides)
   likely to be anthraquinones
SO TOXICON
LA English
DT Letter
C1 [Collett, M. G.] Massey Univ, Sch Vet Sci, Private Bag 11222, Palmerston North 4442, New Zealand.
   [Taylor, S. M.] Dargaville Vet Ctr Ltd, 97 Normanby St, Dargaville 0310, New Zealand.
RP Collett, MG (reprint author), Massey Univ, Sch Vet Sci, Private Bag 11222, Palmerston North 4442, New Zealand.
EM m.g.collett@massey.ac.nz
OI Collett, Mark/0000-0002-6686-4595
CR [Anonymous], 1989, NZ DAIRY EXPORTER, V37
   Bourke CA, 2003, AUST VET J, V81, P361, DOI 10.1111/j.1751-0813.2003.tb11515.x
   Collett M. G, 2006, NZ VET J, V54, P50
   Fan Wen-Qian, 2008, Chinese Journal of Natural Medicines, V6, P112, DOI 10.3724/SP.J.1009.2008.00112
   Montoya SC, 2008, TOXICON, V51, P1409, DOI 10.1016/j.toxicon.2008.03.011
   Montoya SCN, 2006, J NAT PROD, V69, P801, DOI 10.1021/np050181o
   Popay I., 2010, ILLUSTRATED GUIDE CO
NR 7
TC 0
Z9 0
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 172
EP 173
DI 10.1016/j.toxicon.2019.06.218
PG 2
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000022
PM 31226258
DA 2020-05-12
ER

PT J
AU Reis, MB
   Zoccal, KF
   Gardinassi, LG
   Faccioli, LH
AF Reis, Mouzarllem Barros
   Zoccal, Karina Furlani
   Gardinassi, Luiz Gustavo
   Faccioli, Lucia Helena
TI Scorpion envenomation and inflammation: Beyond neurotoxic effects
SO TOXICON
LA English
DT Review
DE Inflammation; Scorpion venom; Eicosanoids; TLRs; VAMPs
ID TITYUS-SERRULATUS VENOM; COMPLEMENT-SYSTEM; TNF-ALPHA; MACROPHAGE
   ACTIVATION; BODY DISTRIBUTION; TSTX-I; TOXINS; TS6; IMMUNOMODULATION;
   RECRUITMENT
AB Scorpion envenomation results in a wide range of clinical manifestations that are mostly attributed to the activation of the autonomic nervous system by venom toxins. In fact, sympathetic and parasympathetic disturbances play important roles during poisoning. However, scorpion venom also induces a complex hyperin-flammatory state that occurs parallel to systemic inflammatory response syndrome and acute sepsis. After a scorpion sting, innate immune cells are exposed to the venom molecules, which bind to pattern recognition receptors and activate pro-inflammatory pathways that contribute toward the promotion of severe symptoms, such as pulmonary edema, and eventually lead to death. In this review, we highlight studies that pointed out inflammation as a major pathological facet of scorpion envenomation, so as to provide novel targets to improve therapeutics for scorpionism.
C1 [Reis, Mouzarllem Barros; Faccioli, Lucia Helena] Univ Sao Paulo, Fac Med Ribeirao Preto, Programa Posgrad Imunol Bas & Aplicada, Ribeirao Preto, SP, Brazil.
   [Zoccal, Karina Furlani] Ctr Univ Barao Maud, Ribeirao Preto, SP, Brazil.
   [Reis, Mouzarllem Barros; Gardinassi, Luiz Gustavo; Faccioli, Lucia Helena] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Anal Clin Toxicol & Bromatol, Ribeirao Preto, SP, Brazil.
RP Faccioli, LH (reprint author), Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Anal Clin Toxicol & Bromatol, Ribeirao Preto, SP, Brazil.
EM faccioli@fcfrp.usp.br
RI Gardinassi, Luiz Gustavo/V-2225-2019; Reis, Mouzarllem
   Barros/O-7635-2017; Faccioli, Lucia Helena/G-8976-2015
OI Gardinassi, Luiz Gustavo/0000-0002-9027-2688; Reis, Mouzarllem
   Barros/0000-0002-7074-6532; Faccioli, Lucia Helena/0000-0002-4999-8305
FU Fundacao de Apoio a Pesquisa do Estado de sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2017/02314-3,
   2014/07125-6]; CNPqNational Council for Scientific and Technological
   Development (CNPq); CAPESCAPES; Universidade of Sao Paulo, Faculdade de
   Ciencias Farmaceuticas de Ribeirao Preto (FCFRP-USP)
FX This work was supported by Fundacao de Apoio a Pesquisa do Estado de sao
   Paulo (FAPESP) grants #2017/02314-3 and #2014/07125-6; CNPq; CAPES and
   Universidade of Sao Paulo, Faculdade de Ciencias Farmaceuticas de
   Ribeirao Preto (FCFRP-USP).
CR Abdoon NA, 2009, TOXICON, V54, P471, DOI 10.1016/j.toxicon.2009.05.009
   Abourazzak S, 2009, J VENOM ANIM TOXINS, V15, P255, DOI 10.1590/S1678-91992009000200008
   Adi-Bessalem S, 2008, EXP TOXICOL PATHOL, V60, P373, DOI 10.1016/j.etp.2008.03.006
   Adi-Bessalem S, 2012, INFLAMMATION, V35, P501, DOI 10.1007/s10753-011-9338-0
   Ait-Lounis A, 2015, INFLAMM RES, V64, P929, DOI 10.1007/s00011-015-0876-z
   Ait-Lounis A, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001740
   Alvarez Y, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/201929
   Bai ZT, 2006, EUR J PHARMACOL, V552, P67, DOI 10.1016/j.ejphar.2006.09.018
   Bekkari N, 2015, EXP TOXICOL PATHOL, V67, P389, DOI 10.1016/j.etp.2015.04.002
   Bertazzi DT, 2005, INT IMMUNOPHARMACOL, V5, P1077, DOI 10.1016/j.intimp.2005.02.007
   Bertazzi DT, 2003, TOXICON, V41, P501, DOI 10.1016/S0041-0101(02)00391-4
   Casella-Martins A, 2015, J VENOM ANIM TOXINS, V21, DOI 10.1186/s40409-015-0046-3
   Chen B, 2002, TOXICON, V40, P527, DOI 10.1016/S0041-0101(01)00248-3
   Chippaux JP, 2008, ACTA TROP, V107, P71, DOI 10.1016/j.actatropica.2008.05.021
   Cupo Palmira, 1994, Revista do Instituto de Medicina Tropical de Sao Paulo, V36, P67, DOI 10.1590/S0036-46651994000100011
   Cupo P, 2015, REV SOC BRAS MED TRO, V48, P642, DOI 10.1590/0037-8682-0237-2015
   D'Suze G, 2004, TOXICON, V44, P851, DOI 10.1016/j.toxicon.2004.08.021
   Daar S, 1997, IPM SCH MANUAL AUTHO
   Daniele-Silva A, 2016, TOXICON, V121, P10, DOI 10.1016/j.toxicon.2016.08.016
   DEMAIN JG, 1995, J ALLERGY CLIN IMMUN, V95, P135, DOI 10.1016/S0091-6749(95)70163-X
   Fialho EMS, 2011, TOXICON, V58, P480, DOI 10.1016/j.toxicon.2011.08.006
   Fukuhara YDM, 2003, TOXICON, V41, P49, DOI 10.1016/S0041-0101(02)00208-8
   FUNASA, 2001, AC LEP MAN DIAGN TRA
   Goudet C, 2002, TOXICON, V40, P1239, DOI 10.1016/S0041-0101(02)00142-3
   Haddad-Ishak-boushaki W, 2017, INFLAMMATION, V40, P1131, DOI 10.1007/s10753-017-0557-x
   Isbister GK, 2014, NEW ENGL J MED, V371, P457, DOI 10.1056/NEJMra1401108
   Khattabi A, 2011, T ROY SOC TROP MED H, V105, P364, DOI 10.1016/j.trstmh.2011.03.007
   Kumar L, 2012, J FORENSIC LEG MED, V19, P494, DOI 10.1016/j.jflm.2012.02.028
   Liu T, 2007, EUR J PHARMACOL, V575, P46, DOI 10.1016/j.ejphar.2007.07.057
   Magalhaes MM, 1999, TOXICON, V37, P1155, DOI 10.1016/S0041-0101(98)00251-7
   Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529
   Neto EB, 2018, TOXINS, V10, DOI 10.3390/toxins10060250
   Nunan EA, 2003, LIFE SCI, V73, P319, DOI 10.1016/S0024-3205(03)00264-9
   Peres ACP, 2009, TOXICON, V53, P779, DOI 10.1016/j.toxicon.2009.02.002
   Pessini AC, 2003, INT IMMUNOPHARMACOL, V3, P765, DOI 10.1016/S1567-5769(03)00078-X
   Petricevich VL, 2008, CLIN EXP IMMUNOL, V154, P415, DOI 10.1111/j.1365-2249.2008.03754.x
   Petricevich VL, 2007, TOXICON, V50, P666, DOI 10.1016/j.toxicon.2007.06.001
   Petricevich VL, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/54273
   Petricevich VL, 2005, MEDIAT INFLAMM, P39, DOI 10.1155/MI.2005.39
   Petricevich VL, 2002, MEDIAT INFLAMM, V11, P23, DOI 10.1080/09629350210308
   Pucca MB, 2016, IMMUNOLOGY, V147, P240, DOI 10.1111/imm.12559
   Pucca MB, 2015, BIOCHIMIE, V115, P8, DOI 10.1016/j.biochi.2015.04.010
   Pucca MB, 2015, TOXICON, V108, P272, DOI 10.1016/j.toxicon.2015.10.015
   Qi J.-X, 2003, REV IBERICA ARACNOL, V10, P137
   Rahmani AH, 2012, J VENOM ANIM TOXINS, V18, P427, DOI 10.1590/S1678-91992012000400011
   Raouraoua-Boukari R, 2012, NEUROIMMUNOMODULAT, V19, P103, DOI 10.1159/000330241
   Reckziegel GC, 2014, J VENOM ANIM TOXINS, V20, DOI 10.1186/1678-9199-20-46
   Revelo MP, 1996, TOXICON, V34, P1119, DOI 10.1016/0041-0101(96)00074-8
   Saidi H, 2018, INFLAMMATION, V41, P773, DOI 10.1007/s10753-018-0731-9
   Saidi H, 2013, J VENOM ANIM TOXINS, V19, DOI 10.1186/1678-9199-19-8
   Santa T, 2008, BIOMED CHROMATOGR, V22, P343, DOI 10.1002/bmc.945
   Santana GC, 1996, TOXICON, V34, P1063, DOI 10.1016/0041-0101(96)00050-5
   Shao JH, 2007, ASIAN J TRADIT MED, V2, P45
   Van Fraga IT, 2015, NEUROSCI LETT, V588, P24, DOI 10.1016/j.neulet.2014.12.044
   Zoccal KF, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00171
   Zoccal KF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00890
   Zoccal KF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10760
   Zoccal KF, 2015, TOXICON, V93, P90, DOI 10.1016/j.toxicon.2014.11.226
   Zoccal KF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088174
   Zoccal KF, 2013, TOXICON, V61, P1, DOI 10.1016/j.toxicon.2012.10.002
   Zoccal KF, 2011, TOXICON, V57, P1101, DOI 10.1016/j.toxicon.2011.04.017
NR 61
TC 2
Z9 2
U1 5
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 174
EP 179
DI 10.1016/j.toxicon.2019.06.219
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000023
PM 31228480
DA 2020-05-12
ER

PT J
AU Tongpoo, A
   Trakulsrichai, S
   Putichote, K
   Sriapha, C
   Wananukul, W
AF Tongpoo, Achara
   Trakulsrichai, Satariya
   Putichote, Kessirin
   Sriapha, Charuwan
   Wananukul, Winai
TI Recurrent neurotoxic envenoming of cobra bite
SO TOXICON
LA English
DT Review
DE Recurrent; Envenomation; Snakebite; Neurotoxic snakes; Cobra
ID IMMUNOGLOBULIN THERAPY; COAGULOPATHY
AB Recurrent systemic envenomation in patients who sustained viper bites, and who previously responded to antivenom, is well described in the literature. However, cases of recurrent neurotoxic envenoming after antivenom treatment are rarely reported. We present three patients who were envenomed by a cobra (Naja kaouthia or N. siamensis) and experienced recurrent neurotoxic envenomation after they initially responded to antivenom treatments. These three patients, aged 13, 35 and 65 years, were consulted to the Ramathibodi Poison Centre. All were bitten by cobra snakes and developed neurotoxic signs and symptoms including ptosis, muscle weakness, and respiratory failure. All were treated with, and responded to, Fragment Affinity-Purified Secondary Antibody [F(ab')(2)] antivenom. Two cases underwent debridement and fasciotomy. One case required extensive wound dressing with bleb aspiration, in addition to usual wound care. Approximately 6-14 hours after these procedures, all three patients developed recurrent signs and symptoms of neurotoxicity. All received second doses of antivenom, after which their symptoms improved, and all were ultimately discharged. Each of these cases exhibited recurrent systemic envenomation that resulted from cobra bites after they exhibited antivenom responses. We believe that non-neutralized venom that remained at the bite site, was released, and re-entered the circulation after the wound was manipulated or the patient underwent surgery. This may explain these instances of recurrent envenomation. Future investigations should examine other potential mechanisms of recurrent envenomation, especially in patients without histories of aggressive wound manipulation. If neurological effects recur, prompt re-treatment with antivenom should be considered.
C1 [Tongpoo, Achara; Trakulsrichai, Satariya; Sriapha, Charuwan; Wananukul, Winai] Mahidol Univ, Ramathibodi Hosp, Fac Med, Ramathibodi Poison Ctr, Bangkok 10400, Thailand.
   [Trakulsrichai, Satariya] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Emergency Med, Bangkok 10400, Thailand.
   [Putichote, Kessirin] Bhumibol Adulyadej Hosp, Outpatient Deparanent, Emergency Med, Bangkok 10220, Thailand.
   [Wananukul, Winai] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Med, Bangkok 10400, Thailand.
RP Trakulsrichai, S (reprint author), Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Emergency Med, Bangkok 10400, Thailand.
EM Satariya.tra@mahidol.ac.th
CR Bogdan GM, 2000, SOUTHERN MED J, V93, P562, DOI 10.1097/00007611-200006000-00003
   Boyer LV, 2001, ANN EMERG MED, V37, P196, DOI 10.1067/mem.2001.113134
   Fazela J, 2008, CLIN TOXICOL, V46, P823, DOI 10.1080/15563650701753849
   Gutierrez JM, 2003, CLIN PHARMACOKINET, V42, P721, DOI 10.2165/00003088-200342080-00002
   Hwang Charles W, 2015, Case Rep Emerg Med, V2015, P719302, DOI 10.1155/2015/719302
   Naqvi U, 2019, STATPEARLS
   Otero-Patino R, 1998, AM J TROP MED HYG, V58, P183, DOI 10.4269/ajtmh.1998.58.183
   Queen Saovabha Memorial Institute (QSMI), 2008, PROD SER ANT
   THEAKSTON RDG, 1990, T ROY SOC TROP MED H, V84, P301, DOI 10.1016/0035-9203(90)90297-R
   Witham WR, 2015, WILD ENVIRON MED, V26, P211, DOI 10.1016/j.wem.2014.11.019
   World Health Organization, 2016, GUID MAN SNAK
NR 11
TC 0
Z9 0
U1 1
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 180
EP 183
DI 10.1016/j.toxicon.2019.05.011
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000024
PM 31129162
DA 2020-05-12
ER

PT J
AU Gurrola, GB
   Guijarro, JI
   Delepierre, M
   Mendoza, RLL
   Cid-Uribe, JI
   Coronas, FV
   Possani, LD
AF Gurrola, G. B.
   Guijarro, J., I
   Delepierre, M.
   Mendoza, R. L. L.
   Cid-Uribe, J., I
   Coronas, F., V
   Possani, L. D.
TI Cn29, a novel orphan peptide found in the venom of the scorpion
   Centruroides noxius: Structure and function
SO TOXICON
LA English
DT Article
DE Centruroides noxius; NMR; 3D-structure; Peptide synthesis; Scorpion
   peptide
ID PROTEIN-STRUCTURE ALIGNMENT; NMR SOLUTION STRUCTURE;
   SECONDARY-STRUCTURE; K+ CHANNELS; TOXIN; HOFFMANN; BLOCKER; SYSTEM;
   ALPHA; SPECTROSCOPY
AB A peptide (Cn29) from the venom of the scorpion Centruroides noxius (about 2% of the soluble venom) was purified and its primary and three-dimensional structures were determined. The peptide contains 27 amino acids with primary sequence: LCLSCRGGDYDCRVKGTCENGKCVCGS. The peptide is tightly packed by three disulfide linkages formed between C2-C23, C5-C18 and C12-C25. Since the native peptide was obtained in limited amounts, the full synthetic peptide was prepared using the standard F-moc-based solid phase synthesis method of Merrifield. The native and synthetic peptides were shown to be identical by sequencing, HPLC separation and mass spectrometry. The solution structure of the peptide solved from NMR data shows that it consists of a well-defined N-terminal region without regular secondary structure extending from Leu 1 to Asp 9, followed by a short helical fragment from Tyr10 to Val14 and two short beta strands (Thr17-Glu19 and Lys22-Val24). The primary and tertiary structures of Cn29 are different from all other scorpion peptides described in the literature. Transcriptome analysis of RNA obtained from C. noxius confirmed the expression of a gene coding for Cn29 in its venom gland. Initial experiments were conducted to identify its possible function: lethality tests in mice and insects as well as ion-channel binding using in vitro electrophysiological assays. None of the physiological or biological tests displayed any activity for this peptide, which at present is considered to be another orphan peptide found in scorpion venoms. The peptide is thus the first example of a novel structural component present in scorpion venoms.
C1 [Gurrola, G. B.; Mendoza, R. L. L.; Cid-Uribe, J., I; Coronas, F., V; Possani, L. D.] Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Mol Med & Bioproc, Av Univ 2001, Cuernavaca 62210, Morelos, Mexico.
   [Guijarro, J., I] CNRS UMR3528, Inst Pasteur, Biol NMR Technol Platform, Paris, France.
   [Delepierre, M.] Inst Pasteur, CNRS UMR3528, Paris, France.
RP Possani, LD (reprint author), Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Mol Med & Bioproc, Av Univ 2001, Cuernavaca 62210, Morelos, Mexico.
EM possani@ibt.unam.mx
RI Guijarro, J. Inaki/E-6438-2019
OI Guijarro, J. Inaki/0000-0002-3826-5245
FU Region Ile de France (SESAME 2014 NMRCHR grant) [4014526]
FX The authors acknowledge the experiments run by Dr. Froylan Gomez Laguna,
   Dr. Estuardo Lopez Vera and Dr. Rita Restano-Cassulini aimed at
   identifying a pharmacological function for Cn29 and Catherine Simenel
   (Biological NMR Technological Platform) for her help with the use of the
   800 MHz spectrometer. The 800 MHz NMR spectrometer of the Institut
   Pasteur was partially funded by the Region Ile de France (SESAME 2014
   NMRCHR grant no 4014526).
CR Batista CVF, 2004, J CHROMATOGR B, V803, P55, DOI 10.1016/j.jchromb.2003.09.002
   BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6
   BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   CARBONE E, 1982, NATURE, V296, P90, DOI 10.1038/296090a0
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Chuang RSI, 1998, NAT NEUROSCI, V1, P668
   Uribe JIC, 2017, TOXICON, V125, P91, DOI 10.1016/j.toxicon.2016.11.256
   Cid-Uribe JI, 2019, TOXINS, V11, DOI 10.3390/toxins11050247
   Cid-Uribe JI, 2018, TOXICON, V151, P47, DOI 10.1016/j.toxicon.2018.06.085
   Corzo G., 2009, ACTA PROTEINS PROTEO, V1591-1598, P1794
   Dalvit C, 1999, MAGN RESON CHEM, V37, P7, DOI 10.1002/(SICI)1097-458X(199901)37:1<7::AID-MRC398>3.0.CO;2-F
   de la Vega RCR, 2004, TOXICON, V43, P865, DOI 10.1016/j.toxicon.2004.03.022
   DEBIN JA, 1993, AM J PHYSIOL, V264, pC361
   del Rio-Portilla F, 2004, EUR J BIOCHEM, V271, P2504, DOI 10.1111/j.1432-1033.2004.04181.x
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809
   Garcia-Valdes J, 2001, FEBS LETT, V505, P369, DOI 10.1016/S0014-5793(01)02791-0
   GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044
   Guijarro JI, 2003, PROTEIN SCI, V12, P1844, DOI 10.1110/ps.03186703
   Gurrola GB, 1999, FASEB J, V13, P953
   Habeck M, 2006, P NATL ACAD SCI USA, V103, P1756, DOI 10.1073/pnas.0506412103
   Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0
   HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047
   JOVER E, 1980, BIOCHEM BIOPH RES CO, V95, P1607, DOI 10.1016/S0006-291X(80)80082-9
   KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211
   Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4
   Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460
   Kuzmenkov AI., 2016, KALIUM DATABASE POTA, DOI [10.1093/database/baw056, DOI 10.1093/DATABASE/BAW056]
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Lecchi M, 2002, J NEUROSCI, V22, P3414
   LEVITT MH, 1982, J MAGN RESON, V47, P328, DOI 10.1016/0022-2364(82)90124-X
   Linge JP, 2003, PROTEINS, V50, P496, DOI 10.1002/prot.10299
   Lopez-Vera E, 2008, BIOCHEMISTRY-US, V47, P1741, DOI 10.1021/bi701934m
   MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025
   Nieto AR, 1996, TOXICON, V34, P913, DOI 10.1016/0041-0101(96)00029-3
   Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044
   Olamendi-Portugal T, 1998, TOXICON, V36, P759, DOI 10.1016/S0041-0101(97)00163-3
   Olamendi-Portugal T, 2016, TOXICON, V115, P1, DOI 10.1016/j.toxicon.2016.02.017
   PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062
   Pintar A, 1999, J MOL BIOL, V287, P359, DOI 10.1006/jmbi.1999.2611
   Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x
   Ramirez-Dominguez ME, 2002, J EXP BIOL, V205, P869
   RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1
   Rendon-Anaya M., 2012, PLOS ONE, V8, P12
   Restano-Cassulini R, 2017, TOXINS, V9, DOI 10.3390/toxins9030074
   Rieping W, 2007, BIOINFORMATICS, V23, P381, DOI 10.1093/bioinformatics/btl589
   Romero-Gutierrez T, 2017, TOXINS, V9, DOI 10.3390/toxins9120399
   Santibanez-Lopez CE, 2017, TOXICON, V133, P95, DOI 10.1016/j.toxicon.2017.05.002
   Santibanez-Lopez CE, 2016, TOXINS, V8, DOI 10.3390/toxins8120367
   Schiavon E, 2006, J BIOL CHEM, V281, P20326, DOI 10.1074/jbc.M600565200
   Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5
   Selisko B, 1998, EUR J BIOCHEM, V254, P468, DOI 10.1046/j.1432-1327.1998.2540468.x
   Selisko B, 1996, EUR J BIOCHEM, V242, P235, DOI 10.1111/j.1432-1033.1996.0235r.x
   Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739
   SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404
   Srinivasan KN, 2002, J BIOL CHEM, V277, P30040, DOI 10.1074/jbc.M111258200
   STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7
   Romero-Gutierrez MT, 2018, TOXINS, V10, DOI 10.3390/toxins10090359
   Tytgat J, 1999, TRENDS PHARMACOL SCI, V20, P444, DOI 10.1016/S0165-6147(99)01398-X
   VAZQUEZ A, 1995, TOXICON, V33, P1161, DOI 10.1016/0041-0101(95)00058-T
   Vranken WF, 2005, PROTEINS, V59, P687, DOI 10.1002/prot.20449
   WAGNER G, 1983, BIOCHEM BIOPH RES CO, V113, P854, DOI 10.1016/0006-291X(83)91077-X
   WHEELER KP, 1983, PFLUG ARCH EUR J PHY, V397, P164, DOI 10.1007/BF00582058
   Wuthrich K., 1986, NMR PROTEINS NUCL AC
   Xiao L, 2016, J GEN PHYSIOL, V147, P375, DOI 10.1085/jgp.201511499
   ZAMUDIO F, 1992, EUR J BIOCHEM, V204, P281, DOI 10.1111/j.1432-1033.1992.tb16635.x
NR 66
TC 0
Z9 0
U1 1
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 184
EP 191
DI 10.1016/j.toxicon.2019.06.013
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000025
PM 31226259
DA 2020-05-12
ER

PT J
AU Zewde, TW
   Johansen, JA
   Kifle, D
   Demissie, TB
   Hansen, JH
   Tadesse, Z
AF Zewde, Tigist W.
   Johansen, Jostein A.
   Kifle, Demeke
   Demissie, Taye B.
   Hansen, Jorn H.
   Tadesse, Zenebe
TI Concentrations of microcystins in the muscle and liver tissues of fish
   species from Koka reservoir, Ethiopia: A potential threat to public
   health (vol 153, pg 85, 2018)
SO TOXICON
LA English
DT Correction
C1 [Zewde, Tigist W.] Addis Ababa Univ, Ethiopian Inst Water Resources, POB 1176, Addis Ababa, Ethiopia.
   [Johansen, Jostein A.; Demissie, Taye B.; Hansen, Jorn H.] UiT Arct Univ Norway, Dept Chem, Organ Chem Grp, N-9037 Tromso, Norway.
   [Kifle, Demeke] Addis Ababa Univ, Dept Zool Sci, Aquat Sci Fisheries & Aquaculture Stream, POB 1176, Addis Ababa, Ethiopia.
   [Demissie, Taye B.] Addis Ababa Univ, Dept Chem, Mat Sci Program, POB 1176, Addis Ababa, Ethiopia.
   [Tadesse, Zenebe] Ethiopian Inst Agr Res, Fishery Dept, Addis Ababa, Ethiopia.
RP Zewde, TW (reprint author), Addis Ababa Univ, Ethiopian Inst Water Resources, POB 1176, Addis Ababa, Ethiopia.
EM tgstw8@gmail.com
CR Zewde TW, 2018, TOXICON, V153, P85, DOI 10.1016/j.toxicon.2018.08.013
NR 1
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 192
EP 192
DI 10.1016/j.toxicon.2019.07.003
PG 1
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000026
PM 31331710
OA Bronze
DA 2020-05-12
ER

PT J
AU Tsutsui, K
   Shimada, E
   Nishi, S
   Sato, T
   Tsuruwaka, Y
AF Tsutsui, Kenta
   Shimada, Eriko
   Nishi, Shinro
   Sato, Tomomi
   Tsuruwaka, Yusuke
TI Identification of the two new, functional actinoporins, CJTOX I and
   CJTOX II, from the deep-sea anemone Cribrinopsis japonica (vol 148, pg
   40, 2018)
SO TOXICON
LA English
DT Correction
C1 [Tsutsui, Kenta; Sato, Tomomi] Yokohama City Univ, Grad Sch Nanobiosci, Kanazawa Ku, 22-2 Seto, Yokohama, Kanagawa 2360027, Japan.
   [Shimada, Eriko; Nishi, Shinro; Tsuruwaka, Yusuke] Japan Agcy Marine Earth Sci & Technol JAMSTEC, Marine Bioresource Explorat Res Grp, 2-15 Natsushima Cho, Yokosuka, Kanagawa 2370061, Japan.
   [Shimada, Eriko] Kyoto Univ, Grad Sch Agr, Div Appl Biosci, Sakyo Ku, Oiwake Cho, Kyoto 6068502, Japan.
   [Tsuruwaka, Yusuke] Keio Univ, Inst Adv Biosci, 403-1 Nipponkoku, Tsuruoka, Yamagata 9970017, Japan.
RP Sato, T (reprint author), Yokohama City Univ, Grad Sch Nanobiosci, Kanazawa Ku, 22-2 Seto, Yokohama, Kanagawa 2360027, Japan.; Tsuruwaka, Y (reprint author), Japan Agcy Marine Earth Sci & Technol JAMSTEC, Marine Bioresource Explorat Res Grp, 2-15 Natsushima Cho, Yokosuka, Kanagawa 2370061, Japan.
EM tomomi@yokohama-cu.ac.jp
RI Song, Eun Joo/Z-5130-2019
OI Tsuruwaka, Yusuke/0000-0003-3488-0731
FU Bluetale technologies U.S. award; JSPS KAKENHIMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)
   [16J11939]; Cytoclone
FX We would like to thank Nyuzen Town Office for helping us obtain the
   specimens. We are grateful to Dr. Raphael Guzman, Department of
   Molecular Cell Biology and Cancer Research Laboratory of University of
   California at Berkeley, for his critical reading of this manuscript and
   Dr. Taisen Iguchi for constantly giving us helpful suggestions and
   comments throughout this study. We also would like to thank Professor
   Hitoshi Miyakawa and Mr. Tomohisa Ogawa for helping us to analyze the
   genetic data. This work was supported by Bluetale technologies U.S.
   award (Y.T., E.S.), Cytoclone via crowdfunding (Y.T.), and JSPS KAKENHI
   Grant Number 16J11939 (K.T.). A special thanks goes to anonymous
   industrial sponsors.
CR Tsutsui K, 2018, TOXICON, V148, P40, DOI 10.1016/j.toxicon.2018.04.008
NR 1
TC 0
Z9 0
U1 2
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD SEP
PY 2019
VL 167
BP 193
EP 193
DI 10.1016/j.toxicon.2019.05.015
PG 1
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IS6FP
UT WOS:000482248000027
PM 31176456
OA Bronze
DA 2020-05-12
ER

PT J
AU Falcon-Cordon, Y
   Montoya-Alonsoa, JA
   Caro-Vadillo, A
   Matos-Riveroa, JI
   Carreton, E
AF Falcon-Cordon, Y.
   Montoya-Alonsoa, J. A.
   Caro-Vadillo, A.
   Matos-Riveroa, J., I
   Carreton, E.
TI Persistence of pulmonary endarteritis in canine heartworm infection 10
   months after the eradication of adult parasites of Dirofilaria immitis
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Heartworm; Dirofilaria immitis; Pulmonary hypertension; Proliferative
   endarteritis; Echocardiographic exam; Pulmonary thromboembolism
ID ARTERY DISTENSIBILITY INDEX; MYOINTIMAL PROLIFERATION; ENDOTHELIAL
   DYSFUNCTION; DOGS; HYPERTENSION; DISEASE; LESIONS; PROTEIN; IMPACT
AB Pulmonary endarteritis caused by Dirofilaria immitis and pulmonary hypertension (PH) are closely linked and the determination of PH could be validated to assess the severity and chronicity of the vascular damage, i.e. by the use of the Right Pulmonary Artery Distensibility (RPAD) Index. The aim was to evaluate the RPAD Index in dogs 10 months after the last dose of adulticide. The study included 23 clientowned dogs with heartworm brought for adulticide treatment. Echocardiographic exam was carried out to estimate worm burden, RPAD Index as well as other routine echocardiographic values on day 0 (diagnosis), day 120 (discharge), and 10 months after the last dose of adulticide. No significant differences were observed in the RPAD Index over time, neither when microfilaremic status and parasite burden were evaluated. An RPAD Index < 29% was found in 52.2% of the dogs on day 0, day 120, and 10 months after the last dose of adulticide. Regarding other echocardiographic parameters, only significant differences were observed on tricuspid annular plane systolic excursion (TAPSE) values between day 0:day 120 (p = 0.008), and day 0:end of the study (p = 0.037). There was not significant improvement in pulmonary damage 10 months after the elimination of the parasites (p = 0.296), suggesting that, once the endarteritis has developed, the vascular changes are chronic and may not be reversible. The modifications of the TAPSE value suggest an improvement in the systolic function of the right ventricle, after the disappearance of the worms, independently of the presence of PH. The endarteritis causes a decrease in the elasticity in the pulmonary vasculature and an increase in the resistance that, chronically, and depending on the severity, will cause the development of PH and later right heart failure. This complication of the disease is one of the most damaging and frequent, so it is necessary to adequately monitor PH in dogs undergoing adulticide treatment. Furthermore, knowing the pulmonary status could provide valuable information to help provide an objective prognosis and help assess the need to add additional treatments, once the worms have been eliminated.
C1 [Falcon-Cordon, Y.; Montoya-Alonsoa, J. A.; Matos-Riveroa, J., I; Carreton, E.] Univ Las Palmas Gran Canaria, Res Inst Biomed & Hlth Sci IUIBS, Fac Vet Med, Internal Med, Las Palmas Gran Canaria, Spain.
   [Caro-Vadillo, A.] Univ Complutense Madrid, Vet Fac, Dept Anim Med & Surg, Madrid, Spain.
RP Montoya-Alonsoa, JA (reprint author), Univ Las Palmas Gran Canaria, Res Inst Biomed & Hlth Sci IUIBS, Fac Vet Med, Internal Med, Las Palmas Gran Canaria, Spain.
EM alberto.montoya@ulpgc.es
RI Montoya-Alonso, Jose Alberto/M-2567-2014; Carreton, Elena/F-5722-2010
OI Montoya-Alonso, Jose Alberto/0000-0002-2683-7592; Carreton,
   Elena/0000-0001-6509-910X
CR American Heartworm Society, 2018, CURR CAN GUID PREV D
   ATWELL RB, 1985, VET REC, V116, P539, DOI 10.1136/vr.116.20.539
   ATWELL RB, 1988, J COMP PATHOL, V98, P349, DOI 10.1016/0021-9975(88)90043-6
   Bowman DD, 2009, VET CLIN N AM-SMALL, V39, P1127, DOI 10.1016/j.cvsm.2009.06.003
   Dillon AR, 1995, PROCEEDINGS OF THE HEARTWORM SYMPOSIUM '95, P113
   European Society of Dirofilariosis and Angiostrongylosis, 2017, GUID CLIN MAN CAN HE
   Genchi C., 2007, Mappe Parassitologiche, V8, P137
   Ghio S, 2016, OPEN HEART, V3, DOI 10.1136/openhrt-2016-000408
   Gonzalez-Miguel J, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0799-0
   Hsiao SH, 2006, J AM SOC ECHOCARDIOG, V19, P902, DOI 10.1016/j.echo.2006.01.014
   KEITH JC, 1983, AM J VET RES, V44, P181
   Martini F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07948-7
   McCall JW, 2008, ADV PARASIT, V66, P193, DOI 10.1016/S0065-308X(08)00204-2
   Mendez JC, 2015, VET PARASITOL, V209, P197, DOI 10.1016/j.vetpar.2015.02.036
   Montoya-Alonso JA, 2016, VET PARASITOL, V216, P66, DOI 10.1016/j.vetpar.2015.12.005
   Mordi I, 2016, J HYPERTENS, V34, P1464, DOI 10.1097/HJH.0000000000000965
   Mordi I, 2014, WORLD J CARDIOL, V6, P824, DOI 10.4330/wjc.v6.i8.824
   MUNNELL JF, 1980, AM J VET RES, V41, P1108
   RAWLINGS CA, 1981, J AM ANIM HOSP ASSOC, V17, P711
   SASAKI Y, 1992, J VET MED SCI, V54, P739, DOI 10.1292/jvms.54.739
   SCHAUB RG, 1981, AM J PATHOL, V104, P13
   Serrano-Parreno B, 2017, VET PARASITOL, V236, P34, DOI 10.1016/j.vetpar.2017.02.001
   Serrano-Parreno B, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2047-2
   Simon F, 2012, CLIN MICROBIOL REV, V25, P507, DOI 10.1128/CMR.00012-12
   Uchide T, 2005, J VET MED SCI, V67, P1155, DOI 10.1292/jvms.67.1155
   Venco L, 2003, RECENT ADV HEARTWORM, P111
   Venco L, 2014, VET PARASITOL, V206, P60, DOI 10.1016/j.vetpar.2014.08.016
   Venco L, 2014, VET PARASITOL, V206, P48, DOI 10.1016/j.vetpar.2014.08.018
   Visser LC, 2016, J VET INTERN MED, V30, P543, DOI 10.1111/jvim.13911
NR 29
TC 0
Z9 0
U1 2
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP
PY 2019
VL 273
BP 1
EP 4
DI 10.1016/j.vetpar.2019.07.008
PG 4
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JA1IK
UT WOS:000487570500001
PM 31442886
DA 2020-05-12
ER

PT J
AU Bahrami, S
   Mousavi, SS
   Alborzi, AR
   Mohammadi, G
   Namavari, M
AF Bahrami, Somayeh
   Mousavi, Seyyede Sedighe
   Alborzi, Ali Reza
   Mohammadi, Godratollah
   Namavari, Mehdi
TI Sperm quality and hormonal levels in C57BL/6 mice infected with Neospora
   caninum
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Neospora caninumm; Testis; Sperm; C57BL/6 mice
ID NATURAL NEOSPOROSIS; OXIDATIVE STRESS; HYPOTHYROIDISM; CAPACITATION;
   SEMEN; PHOSPHORYLATION; ANTIBODY; DNA
AB Neospora caninum is a major pathogen of cattle and dogs, and neosporosis is widespread in five continents. In this study effect of experimental neosporosis on sperm quality of C57BL/6 mice in different days was investigated. Based on the results sperm concentration was not changed in infected groups but neosporosis induced a significant decrease in epididymis sperm motility at 60 days post infection. A significant increase in the number of abnormal sperms at five, 15, 30 and 60 days post infection was found. At days 15, 30 and 60 post infection testosterone concentrations were significantly low in infected groups and FSH level was significantly high in infected groups at five and 30 days post infection. LH level was decreased in infected groups, but the difference was significant at five, 15 and 30 days post infection. Comparison of TSH and T4 levels between groups revealed a significant decrease in infected groups at five, 15, 30 and 60 days post infection. Except 15 days post infection T3 levels decreased significantly in infected groups. GPX activity, MDA and TAC level was significantly increased in infected mice at five days post infection. In this study neosporosis is associated with hypogonadotrophic gonadal insufficiency in infected C57BL/6 male mice.
C1 [Bahrami, Somayeh; Mousavi, Seyyede Sedighe; Alborzi, Ali Reza] Shahid Chamran Univ Ahvaz, Fac Vet Med, Dept Parasitol, Ahwaz, Iran.
   [Mohammadi, Godratollah] Shahid Chamran Univ Ahvaz, Fac Vet Med, Dept Clin Sci, Ahwaz, Iran.
   [Namavari, Mehdi] AREEO, Shiraz Branch, Razi Vaccine & Serum Res Inst, Tehran, Iran.
RP Bahrami, S (reprint author), Shahid Chamran Univ Ahvaz, Fac Vet Med, Dept Parasitol, Ahwaz, Iran.
EM s.bahrami@scu.ac.ir
FU Shahid Chamran University of Ahvaz
FX This study was supported by the research grant provided by the Shahid
   Chamran University of Ahvaz.
CR Agarwal A, 2003, FERTIL STERIL, V79, P829, DOI 10.1016/S0015-0282(02)04948-8
   Bahrami S, 2018, J HELL VET MED SOC, V69, P984, DOI 10.12681/jhvms.18028
   Bahrami S, 2018, TROP ANIM HEALTH PRO, V50, P85, DOI 10.1007/s11250-017-1403-8
   Bahrami S, 2017, LAB ANIM-UK, V51, P191, DOI 10.1177/0023677216652373
   Barragan A, 2003, TRENDS MICROBIOL, V11, P426, DOI 10.1016/S0966-842X(03)00205-1
   Benzie IFF, 1999, METHOD ENZYMOL, V299, P15
   Boczon K, 1996, ACTA PARASITOL, V41, P136
   Caetano-da-Silva A, 2004, THERIOGENOLOGY, V62, P1329, DOI 10.1016/j.theriogenology.2004.01.010
   DESMONTS G, 1980, J CLIN MICROBIOL, V11, P562, DOI 10.1128/JCM.11.6.562-568.1980
   du Plessis SS, 2010, ANDROLOGIA, V42, P206, DOI 10.1111/j.1439-0272.2009.00980.x
   Ford WCL, 2004, HUM REPROD UPDATE, V10, P387, DOI 10.1093/humupd/dmh034
   Herrero MB, 1999, BIOL REPROD, V61, P575, DOI 10.1095/biolreprod61.3.575
   Jannin A, 2019, CLIN CHEM LAB MED, V57, pE218, DOI 10.1515/cclm-2019-0090
   Kang SW, 2009, PARASITOL RES, V104, P1261, DOI 10.1007/s00436-008-1322-8
   Krassas GE, 2002, J CLIN ENDOCR METAB, V87, P3667, DOI 10.1210/jc.87.8.3667
   Krassas GE, 2008, THYROID, V18, P1255, DOI 10.1089/thy.2008.0257
   Laposata M, 2010, LAB MED DIAGNOSIS DI, P394
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   O'Flaherty CM, 1999, THERIOGENOLOGY, V52, P289, DOI 10.1016/S0093-691X(99)00129-6
   Ortega-Mora LM, 2003, VET PARASITOL, V117, P301, DOI 10.1016/j.vetpar.2003.09.015
   Pant N, 2003, J APPL TOXICOL, V23, P271, DOI 10.1002/jat.919
   PLACER ZA, 1966, ANAL BIOCHEM, V16, P359, DOI 10.1016/0003-2697(66)90167-9
   Sanchez-Campos S, 1999, PARASITOL RES, V85, P468, DOI 10.1007/s004360050579
   Serrano-Martinez E, 2007, THERIOGENOLOGY, V67, P1175, DOI 10.1016/j.theriogenology.2007.01.010
   Sharma RK, 1999, HUM REPROD, V14, P2801, DOI 10.1093/humrep/14.11.2801
   Shen HM, 2000, FREE RADICAL BIO MED, V28, P529, DOI 10.1016/S0891-5849(99)00234-8
   Singh R., 2011, OPEN REPROD SCI J, V3, P98
   Stahl W, 1998, PARASITOLOGY, V117, P223, DOI 10.1017/S0031182098003035
   THORNTON RN, 1991, NEW ZEAL VET J, V39, P129, DOI 10.1080/00480169.1991.35679
   Veldhuis JD, 2009, MOL CELL ENDOCRINOL, V299, P14, DOI 10.1016/j.mce.2008.09.005
   Wagner MS, 2008, J ENDOCRINOL, V199, P351, DOI 10.1677/JOE-08-0218
   Yokoi K, 2003, BIOL TRACE ELEM RES, V93, P141, DOI 10.1385/BTER:93:1-3:141
   Zamoner A, 2008, J MOL ENDOCRINOL, V40, P125, DOI 10.1677/JME-07-0089
   Zemjanis R, 1970, DIANOSTIC THERAPEUTI, P231
   ZINI A, 1995, J ANDROL, V16, P424
NR 35
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP
PY 2019
VL 273
BP 5
EP 10
DI 10.1016/j.vetpar.2019.07.010
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JA1IK
UT WOS:000487570500002
PM 31442893
DA 2020-05-12
ER

PT J
AU Genchi, M
   Vismarra, A
   Lucchetti, C
   Viglietti, A
   Crosara, S
   Gnudi, G
   Quintavalla, C
   Schaper, R
   Kramer, L
AF Genchi, Marco
   Vismarra, Alice
   Lucchetti, Chiara
   Viglietti, Antonio
   Crosara, Serena
   Gnudi, Giacomo
   Quintavalla, Cecilia
   Schaper, Roland
   Kramer, Laura
TI Efficacy of imidacloprid 10%/moxidectin 2.5% spot on (Advocate (R),
   Advantage Multi (R)) and doxycycline for the treatment of natural
   Dirofilaria immitis infections in dogs
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Dirofilaria immitis; Dog; Moxidectin; Doxycycline; Melarsomine
   dihydrochloride
ID MACROCYCLIC LACTONES; P-GLYCOPROTEIN; IVERMECTIN; COMBINATION;
   MOXIDECTIN; REPENS
AB Heartworm infection (also known as dirofilariosis due to Dirofilaria immitis) in dogs causes chronic pulmonary disease that, if left untreated, can lead to right-side congestive heart failure. Currently, the only registered drug for adulticide therapy in dogs with heartworm disease (HWD) is melarsomine dihydrochloride. The recent targeting of the bacterial endosymbiont Wolbachia, through antibiotic therapy of the infected host, has offered an interesting alternative for the treatment of HWD. Recent reports of the adulticide activity of an ivermectin/doxycycline combination protocol has lead the American Heartworm Society (AHS) to include in its guidelines that, in cases where arsenical therapy is not possible or is contraindicated, a monthly heartworm preventive along with doxycycline for a 4-week period might be considered. In the present study, 20 dogs with confirmed natural D. immitis infection were included following owner consent. Fourteen dogs were treated with a topical formulation containing 10% w/v imidacloprid and 2.5% w/v moxidectin (Advocate (R), Advantage Multi (R), Bayer), monthly for nine months, associated to doxycycline (10 mg/kg/BID) for the first 30 days. Six dogs were treated with melarsomine (Immiticide (R), Medal) (2.5 mg/kg) at enrollment, followed one month later by two injections 24 h apart.
   The presence of circulating antigens and the number of microfilariae (mf) were evaluated at the moment of enrollment and then at 1, 2, 3, 4, 5, 6, 7, 8, 12, 18, 24 months post enrollment. Echocardiogram and radiographs were performed at month 0, 6, 12, 18, 24.
   Monthly moxidectin combined with 30 days of doxycycline eliminated circulating microfilariae within one month, thus breaking the transmission cycle very quickly. Furthermore, dogs treated with the combination protocol started to become negative for circulating antigens at 4 months from the beginning of treatment and all except one were antigen negative at 9 months. All dogs treated with melarsomine were antigen negative by 5 months from the beginning of the treatment. No dogs showed worsening of pulmonary patterns or criteria indicative of pulmonary hypertension 12 to 24 months after. For the criteria mf concentration, antigen concentration, radiography and echocardiography at 12, 18 and 24 months the non-inferiority for the moxidectin group could be proven for a non-inferiority margin of 15% for the rate difference. Dogs treated with moxidectin and doxycycline became negative for microfilariae and antigens sooner when compared to melarsomine in the present study and to dogs treated with doxycycline combined with ivermectin in studies previously published.
C1 [Genchi, Marco; Vismarra, Alice; Lucchetti, Chiara; Crosara, Serena; Gnudi, Giacomo; Quintavalla, Cecilia; Kramer, Laura] Univ Parma, Dept Vet Sci, Via Taglio 10, I-43126 Parma, Italy.
   [Viglietti, Antonio] Ambulatorio Vet Dr Viglietti DR Ss Piazza, Carloforte, Italy.
   [Schaper, Roland] Bayer Anim Hlth GmbH, Leverkusen, Germany.
RP Vismarra, A (reprint author), Univ Parma, Dept Vet Sci, Via Taglio 10, I-43126 Parma, Italy.
EM alice.vismarra@unipr.it
OI Lucchetti, Chiara/0000-0002-6158-2150; Genchi, Marco/0000-0003-3768-2482
FU Bayer Animal Health GmbH, Leverkusen, Germany
FX The present study has been funded by Bayer Animal Health GmbH,
   Leverkusen, Germany.
CR American Heartworm Society, 2018, AHS GUID UPD
   American Heartworm Society, 2016, HEARTW INC MAPS
   Balbo T, 1968, NUOVA VET, V44, P18
   BAUER P, 1994, BIOMETRICS, V50, P1029, DOI 10.2307/2533441
   Bazzocchi C, 2008, INT J PARASITOL, V38, P1401, DOI 10.1016/j.ijpara.2008.03.002
   Bowman D. D, 2016, PARASITES VECTORS, V9
   Ciuca L, 2016, VET PARASITOL, V225, P81, DOI 10.1016/j.vetpar.2016.05.032
   Drake J, 2018, PARASITES VECTORS, V11
   European Society of Dirofilariosis and Angiostrongylosis (ESDA), 2017, GUID CLIN MAN CAN HE
   Genchi C, 2009, VET PARASITOL, V163, P286, DOI 10.1016/j.vetpar.2009.03.026
   Genchi M, 2019, VET PARASITOL, V267, P26, DOI 10.1016/j.vetpar.2019.01.014
   Grandi G, 2010, VET PARASITOL, V169, P347, DOI 10.1016/j.vetpar.2010.01.025
   Keister D. M., 1992, Proceedings of the heartworm symposium '92, Austin, Texas, USA, 27-29 March, 1992., P225
   Kiki-Mvouaka S, 2010, DRUG METAB DISPOS, V38, P573, DOI 10.1124/dmd.109.030700
   Kramer L, 2018, VET PARASITOL, V254, P95, DOI 10.1016/j.vetpar.2018.03.005
   Kramer L, 2011, VET PARASITOL, V176, P357, DOI 10.1016/j.vetpar.2011.01.021
   Kramer L, 2007, ISSUES INFECT DIS, V5, P124
   Lespine A, 2007, EUR J PHARM SCI, V30, P84, DOI 10.1016/j.ejps.2006.10.004
   Mavropoulou A, 2014, VET PARASITOL, V205, P211, DOI 10.1016/j.vetpar.2014.06.014
   Penezic A, 2014, PARASITOL RES, V113, P3281, DOI 10.1007/s00436-014-3991-9
   Prichard R, 2012, INT J PARASITOL-DRUG, V2, P134, DOI 10.1016/j.ijpddr.2012.04.001
   Bendas AJR, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2189-2
   Savadelis M. D, 2017, PARASITES VECTORS, V10
   Savadelis MD, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2685-z
   Venco L, 2004, VET PARASITOL, V124, P259, DOI 10.1016/j.vetpar.2004.06.024
   Venco L, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2444-6
   Vezzoni A., 1992, Proceedings of the heartworm symposium '92, Austin, Texas, USA, 27-29 March, 1992., P231
NR 27
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP
PY 2019
VL 273
BP 11
EP 16
DI 10.1016/j.vetpar.2019.07.011
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JA1IK
UT WOS:000487570500003
PM 31442887
DA 2020-05-12
ER

PT J
AU Dabrowska, J
   Karamon, J
   Kochanowski, M
   Gottstein, B
   Cencek, T
   Frey, CF
   Muller, N
AF Dabrowska, Joanna
   Karamon, Jacek
   Kochanowski, Maciej
   Gottstein, Bruno
   Cencek, Tomasz
   Frey, Caroline F.
   Mueller, Norbert
TI Development and comparative evaluation of different LAMP and PCR assays
   for coprological diagnosis of feline tritrichomonosis
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Tritrichomonas foetus; Tritrichomonosis; Coprology; LAMP; Conventional
   PCR; Real-time PCR
ID MEDIATED ISOTHERMAL AMPLIFICATION; REAL-TIME PCR; BETA-TUBULIN GENE;
   BENZIMIDAZOLE RESISTANCE; FETUS; DNA; PREVALENCE; CATTLE;
   TRICHOMONIASIS; INFECTION
AB The protozoan parasite Tritrichomonas foetus may cause severe diarrhea in cats all over the world. In order to evaluate the methodology in coprological molecular diagnosis of feline tritrichomonosis, we compared previously published ("old") and newly developed ("novel") loop-mediated isothermal amplification (LAMP) (targeted to the T. foetus beta-tubulin and the elf1 alpha 1 gene, respectively) as well as an old conventional and an old and novel real-time PCR (all targeted to overlapping regions of T. foetus rDNA) assays regarding their diagnostic sensitivities and specificities. Here, the novel real-time PCR yielded the best methodical performance in that a sensitivity with a detection limit of <= 0.1 trophozoites (corresponding to ca. <= 0.13 trophozoites per mg feces) and a maximal specificity for diagnosis of Tritrichomonas spp. was achieved. The other test systems exhibited either an approximately 10-times lower sensitivity (<= 1 trophozoite corresponding to ca. <= 1.3 trophozoites per mg feces) (conventional PCR and both LAMP assays) or a lower specificity (old real-time PCR). Conversely, the diagnostic performance assessed with clinical fecal samples from cats demonstrated identical sensitivities (8 of 20 samples tested were positive) for the novel PCR and both LAMP assays. Diagnostic sensitivities were significantly higher than those found for the old real-time (5 positive samples) and conventional PCR (6 positive samples), respectively. Accordingly, our data suggested the novel PCR and both LAMP assays to be well suited molecular tools for direct (i.e. without including an in vitro cultivation step) coprological diagnosis of tritrichomonosis in cats. Interestingly, relative high (novel LAMP, 7 positive samples) to at least moderate (old LAMP, 6 positive samples and 1 sample with equivocal score) diagnostic sensitivities were also achieved by testing clinical samples upon simple visual inspection of colorimetric changes during the LAMP amplification reactions. Accordingly, both LAMP assays may serve as practical molecular tools to perform epidemiological studies on feline (and bovine as well as porcine) tritrichomonosis under simple laboratory conditions.
C1 [Dabrowska, Joanna; Karamon, Jacek; Kochanowski, Maciej; Cencek, Tomasz] Natl Vet Res Inst, Dept Parasitol & Invas Dis, Partyzantow Ave 57, PL-24100 Pulawy, Poland.
   [Gottstein, Bruno; Frey, Caroline F.; Mueller, Norbert] Univ Bern, Vetsuisse Fac, Inst Parasitol, Langgassstr 122, CH-3012 Bern, Switzerland.
RP Muller, N (reprint author), Univ Bern, Vetsuisse Fac, Inst Parasitol, Langgassstr 122, CH-3012 Bern, Switzerland.
EM norbert.mueller@vetsuisse.unibe.ch
RI Karamon, Jacek/H-1824-2011
OI Karamon, Jacek/0000-0002-5830-167X
FU Swiss Government Excellence Scholarship for Foreign Students
FX This study was supported by Swiss Government Excellence Scholarship for
   Foreign Students. This paper is part of Joanna Nbrowska's Ph.D.
   dissertation (National Veterinary Research Institute, Pulawy, Poland).
CR Casteriano A, 2016, PARASITOLOGY, V143, P1954, DOI 10.1017/S003118201600158X
   CLARK BL, 1983, AUST VET J, V60, P71, DOI 10.1111/j.1751-0813.1983.tb05873.x
   DIAMOND LS, 1957, J PARASITOL, V43, P488, DOI 10.2307/3274682
   Elard L, 1999, PARASITOL RES, V85, P452, DOI 10.1007/s004360050577
   Felleisen RSJ, 1998, J CLIN MICROBIOL, V36, P513, DOI 10.1128/JCM.36.2.513-519.1998
   Francois P, 2011, FEMS IMMUNOL MED MIC, V62, P41, DOI 10.1111/j.1574-695X.2011.00785.x
   Frey CF, 2017, VET PARASITOL, V237, P30, DOI 10.1016/j.vetpar.2017.02.024
   Frey CF, 2012, MOL CELL PROBE, V26, P132, DOI 10.1016/j.mcp.2012.02.002
   Gookin JL, 2017, J FELINE MED SURG, V19, P261, DOI 10.1177/1098612X17693499
   Grant WN, 1996, INT J PARASITOL, V26, P71, DOI 10.1016/0020-7519(95)00092-5
   Kemleu S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165506
   KIMSEY PB, 1980, J AM VET MED ASSOC, V177, P616
   Kuboki N, 2003, J CLIN MICROBIOL, V41, P5517, DOI 10.1128/JCM.41.12.5517-5524.2003
   Lass A, 2017, PARASITOLOGY, V144, P1791, DOI [10.1017/S0031182017001172, 10.1017/s0031182017001172]
   Li WZ, 2015, VET PARASITOL, V211, P12, DOI 10.1016/j.vetpar.2015.04.028
   Lim S, 2010, KOREAN J PARASITOL, V48, P247, DOI 10.3347/kjp.2010.48.3.247
   LONGO MC, 1990, GENE, V93, P125, DOI 10.1016/0378-1119(90)90145-H
   Madico G, 1998, J CLIN MICROBIOL, V36, P3205, DOI 10.1128/JCM.36.11.3205-3210.1998
   McMillen L, 2006, VET PARASITOL, V141, P204, DOI 10.1016/j.vetpar.2006.06.012
   Meggiolaro MN, 2019, VET PARASITOL, V266, P12, DOI 10.1016/j.vetpar.2018.12.009
   Mueller K, 2015, VET PARASITOL, V212, P105, DOI 10.1016/j.vetpar.2015.08.010
   Njiru ZK, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000147
   OIE, 2018, OIE TERR MAN CHAPT 3, P1217
   Oyhenart J, 2018, VET PARASITOL, V261, P67, DOI 10.1016/j.vetpar.2018.08.011
   Oyhenart J, 2013, VET PARASITOL, V193, P59, DOI 10.1016/j.vetpar.2012.11.034
   PAKANDL M, 1994, VET MED-CZECH, V39, P377
   Plutzer J, 2009, PARASITOL RES, V104, P1527, DOI 10.1007/s00436-009-1391-3
   Reinmann K, 2012, VET PARASITOL, V185, P138, DOI 10.1016/j.vetpar.2011.09.032
   Schirm J, 2007, J MICROBIOL METH, V68, P243, DOI 10.1016/j.mimet.2006.08.002
   Simpson P, 2007, J MED MICROBIOL, V56, P772, DOI 10.1099/jmm.0.47163-0
   Stauffer SH, 2008, J VET DIAGN INVEST, V20, P639, DOI 10.1177/104063870802000518
   TAYLOR MA, 1994, BRIT VET J, V150, P73, DOI 10.1016/S0007-1935(05)80098-3
   Wozniakowski G, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-110
   Yao CQ, 2015, VET RES, V46, DOI 10.1186/s13567-015-0169-0
   YULE A, 1989, PARASITOL TODAY, V5, P373, DOI 10.1016/0169-4758(89)90298-6
NR 35
TC 2
Z9 2
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP
PY 2019
VL 273
BP 17
EP 23
DI 10.1016/j.vetpar.2019.07.014
PG 7
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JA1IK
UT WOS:000487570500004
PM 31442888
DA 2020-05-12
ER

PT J
AU Kellerova, P
   Matouskova, P
   Lamka, J
   Vokral, I
   Szotakova, B
   Zajickova, M
   Pasak, M
   Skalova, L
AF Kellerova, Pavlina
   Matouskova, Petra
   Lamka, Jiri
   Vokral, Ivan
   Szotakova, Barbora
   Zajickova, Marketa
   Pasak, Michael
   Skalova, Lenka
TI Ivermectin-induced changes in the expression of cytochromes P450 and
   efflux transporters in Haemonchus contortus female and male adults
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Drug resistance; Sex-differences; Anthelmintics; Macrocyclic lactones;
   Nematode
ID XENOBIOTIC-METABOLIZING ENZYMES; IN-VITRO EXPOSURE; P-GLYCOPROTEIN; ABC
   TRANSPORTERS; GENE-EXPRESSION; CAENORHABDITIS-ELEGANS; SEX-DIFFERENCES;
   ANTHELMINTIC RESISTANCE; COOPERIA-ONCOPHORA; CONSTITUTIVE EXPRESSION
AB Haemonchus contortus, one of the most pathogenic of all small ruminant parasites, have developed resistance to all used anthelmintics. Detoxification enzymes, e.g. cytochromes P450 (CYPs) and efflux transporters P-glycoproteins (P-gps), which represent the main defense system against harmful xenobiotics, have been suggested to contribute to drug resistance development. The present study was designed to compare the constitutive expression of individual CYPs and P-gps in females and males of H. contortus adults and to follow up on the changes in expression of these genes in nematodes exposed to sub-lethal concentrations of ivermectin (IVM), which might occur during inaccurate treatment. The adults of inbred susceptible-Edinburgh strain (ISE, MHco3) of H. contortus were used for this purpose. The nematodes were incubated ex vivo with or without 1VM (1, 10 and 100 nM) in culture medium for 4, 12 and 24 h. After incubation, total RNA was isolated and expression levels of individual CYPs and P-gps were analyzed using qPCR. Our results showed a great variability in the constitutive expression of individual CYPs and P-gps in H. contortus adults. The constitutive expression as well as the inducibility of CYPs and P-gps significantly differed in males and females. Contact of adult nematodes with sublethal IVM concentrations led to only minor changes in expression of CYPs, while expression of several P-gps, particularly pgp-9.2 in males and pgp-10, pgp-11 in females was increased significantly in IVM-exposed nematodes. In conclusion, inaccurate treatment of sheep with IVM might contribute to drug resistance development via increased expression of efflux transporters in H. contortus adults.
C1 [Kellerova, Pavlina; Matouskova, Petra; Szotakova, Barbora; Zajickova, Marketa; Pasak, Michael; Skalova, Lenka] Charles Univ Prague, Fac Pharm, Dept Biochem Sci, Heyrovskeho 1203, CZ-50005 Hradec Kralove, Czech Republic.
   [Lamka, Jiri; Vokral, Ivan] Charles Univ Prague, Fac Pharm, Dept Pharmacol & Toxicol, Heyrovskeho 1203, Hradec Kralove, Czech Republic.
RP Skalova, L (reprint author), Charles Univ Prague, Fac Pharm, Dept Biochem Sci, Heyrovskeho 1203, CZ-50005 Hradec Kralove, Czech Republic.
EM lenka.skalova@faf.cuni.cz
RI Matouskova, Petra/S-5687-2017; Vokral, Ivan/S-5861-2017
OI Matouskova, Petra/0000-0002-9421-5744; Vokral, Ivan/0000-0002-1348-0395
FU Czech Science FoundationGrant Agency of the Czech Republic [18-07724S];
   Charles University in Prague [PRIMUS/17/SCI/4, UNCE/18/SCI/012, SVV 260
   416]; ERDFEuropean Union (EU); project EFSA-CDN
   [CZ.02.1.01/0.0/0.0/16_019/0000841]
FX This work was supported by the Czech Science Foundation, grant No.
   18-07724S and by Charles University in Prague, projects PRIMUS/17/SCI/4,
   UNCE/18/SCI/012 and SVV 260 416. Lenka Skalova was partly supported by
   the project EFSA-CDN [CZ.02.1.01/0.0/0.0/16_019/0000841], co-funded by
   ERDF.
CR AlGusbi S, 2014, INT J PARASITOL, V44, P647, DOI 10.1016/j.ijpara.2014.04.007
   Ardelli BF, 2013, PARASITOL INT, V62, P639, DOI 10.1016/j.parint.2013.02.008
   Ardelli BF, 2008, J NEMATOL, V40, P290
   Areskog M, 2013, PARASITOL RES, V112, P3005, DOI 10.1007/s00436-013-3473-5
   Benenati G, 2009, MECH DEVELOP, V126, P382, DOI 10.1016/j.mod.2009.02.001
   Besier RB, 2016, ADV PARASIT, V93, P95, DOI 10.1016/bs.apar.2016.02.022
   David JP, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0429
   David M, 2018, INT J PARASITOL-DRUG, V8, P145, DOI 10.1016/j.ijpddr.2018.02.001
   De Graef J, 2013, PARASITOLOGY, V140, P499, DOI 10.1017/S0031182012001849
   Deneke C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035044
   Dicker AJ, 2011, INT J PARASITOL, V41, P935, DOI 10.1016/j.ijpara.2011.03.015
   Eckford PDW, 2009, CHEM REV, V109, P2989, DOI 10.1021/cr9000226
   Getachew T, 2007, PARASITE, V14, P3, DOI 10.1051/parasite/2007141003
   Glover-Cutter KM, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003701
   Godoy P, 2015, MOL BIOCHEM PARASIT, V204, P11, DOI 10.1016/j.molbiopara.2015.12.001
   Godoy P, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1317-8
   Godoy P, 2015, INT J PARASITOL, V45, P85, DOI 10.1016/j.ijpara.2014.09.008
   Gokbulut C, 2016, J VET PHARMACOL THER, V39, P584, DOI 10.1111/jvp.12308
   Canga AG, 2009, VET J, V179, P25, DOI 10.1016/j.tvjl.2007.07.011
   Howard JT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137830
   Igboeli OO, 2014, PEST MANAG SCI, V70, P905, DOI 10.1002/ps.3620
   Issouf M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087802
   James CE, 2009, TRENDS PARASITOL, V25, P328, DOI 10.1016/j.pt.2009.04.004
   James CE, 2009, INT J PARASITOL, V39, P213, DOI 10.1016/j.ijpara.2008.06.009
   Janssen IJI, 2015, INT J PARASITOL-DRUG, V5, P44, DOI 10.1016/j.ijpddr.2015.03.003
   Janssen IJI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061635
   Janssen IJI, 2013, EXP PARASITOL, V134, P171, DOI 10.1016/j.exppara.2013.03.005
   Kaplan RM, 2012, VET PARASITOL, V186, P70, DOI 10.1016/j.vetpar.2011.11.048
   Kotze AC, 2016, ADV PARASIT, V93, P397, DOI 10.1016/bs.apar.2016.02.012
   Kotze AC, 2006, VET PARASITOL, V136, P275, DOI 10.1016/j.vetpar.2005.11.001
   Laing R, 2015, INT J PARASITOL, V45, P243, DOI 10.1016/j.ijpara.2014.12.001
   Laing R, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-8-r88
   Laing R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023216
   Laing ST, 2010, BIOCHEM J, V432, P505, DOI 10.1042/BJ20101346
   Lanusse CE, 2016, ADV PARASIT, V93, P465, DOI 10.1016/bs.apar.2016.02.014
   Leathwick DM, 2014, VET PARASITOL, V204, P44, DOI 10.1016/j.vetpar.2013.12.022
   Lecova L, 2015, MOL BIOCHEM PARASIT, V201, P123, DOI 10.1016/j.molbiopara.2015.08.001
   Leonard GD, 2003, ONCOLOGIST, V8, P411, DOI 10.1634/theoncologist.8-5-411
   Lespine A, 2007, EUR J PHARM SCI, V30, P84, DOI 10.1016/j.ejps.2006.10.004
   Lespine A, 2012, INT J PARASITOL-DRUG, V2, P58, DOI 10.1016/j.ijpddr.2011.10.001
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lloberas M, 2013, INT J PARASITOL-DRUG, V3, P20, DOI 10.1016/j.ijpddr.2012.11.001
   Lnenickova K, 2018, ACTA PHARMACEUT, V68, P75, DOI 10.2478/acph-2018-0005
   Matouskova P, 2018, INT J PARASITOL-DRUG, V8, P420, DOI 10.1016/j.ijpddr.2018.09.005
   Matouskova P, 2016, TRENDS PARASITOL, V32, P481, DOI 10.1016/j.pt.2016.02.004
   Menez C, 2016, ANTIMICROB AGENTS CH, V60, P4809, DOI 10.1128/AAC.00713-16
   Menzel R, 2005, ARCH BIOCHEM BIOPHYS, V438, P93, DOI 10.1016/j.abb.2005.03.020
   Menzel R, 2001, ARCH BIOCHEM BIOPHYS, V395, P158, DOI 10.1006/abbi.2001.2568
   Omura S, 2008, INT J ANTIMICROB AG, V31, P91, DOI 10.1016/j.ijantimicag.2007.08.023
   Prichard RK, 2007, PARASITOLOGY, V134, P1123, DOI 10.1017/S0031182007000091
   Raza A, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1806-9
   Raza A, 2016, INT J PARASITOL-DRUG, V6, P103, DOI 10.1016/j.ijpddr.2016.03.001
   Rochat B, 2005, CLIN PHARMACOKINET, V44, P349, DOI 10.2165/00003088-200544040-00002
   Roos MH, 2004, INT J PARASITOL, V34, P109, DOI 10.1016/j.ijpara.2003.10.002
   Roulet A, 2003, EUR J PHARMACOL, V460, P85, DOI 10.1016/S0014-2999(02)02955-2
   Sarai RS, 2013, INT J PARASITOL-DRUG, V3, P51, DOI 10.1016/j.ijpddr.2013.01.002
   Stuchlikova L, 2014, DRUG TEST ANAL, V6, P1055, DOI 10.1002/dta.1630
   Stuchlikova LR, 2018, INT J PARASITOL-DRUG, V8, P50, DOI 10.1016/j.ijpddr.2018.01.005
   Tang LL, 2015, MECH AGEING DEV, V149, P88, DOI 10.1016/j.mad.2015.06.001
   Tyden E, 2014, MOL BIOCHEM PARASIT, V198, P66, DOI 10.1016/j.molbiopara.2015.01.002
   Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596
   VANWYK JA, 1980, ONDERSTEPOORT J VET, V47, P147
   Vokral I, 2013, VET PARASITOL, V196, P373, DOI 10.1016/j.vetpar.2013.03.018
   Vokral I, 2013, PARASITOLOGY, V140, P361, DOI 10.1017/S0031182012001680
   Waxman DJ, 2009, MOL PHARMACOL, V76, P215, DOI 10.1124/mol.109.056705
   Wolstenholme AJ, 2004, TRENDS PARASITOL, V20, P469, DOI 10.1016/j.pt.2004.07.010
   Yilmaz E, 2017, INT J PARASITOL-DRUG, V7, P362, DOI 10.1016/j.ijpddr.2017.10.001
   Zhao ZY, 2004, J MOL BIOL, V344, P409, DOI 10.1016/j.jmb.2004.09.052
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 69
TC 0
Z9 0
U1 10
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP
PY 2019
VL 273
BP 24
EP 31
DI 10.1016/j.vetpar.2019.07.006
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JA1IK
UT WOS:000487570500005
PM 31442889
OA Bronze
DA 2020-05-12
ER

PT J
AU Seale, J
   Swain, J
   Booth, R
   Blake, DP
AF Seale, Jessica
   Swain, Josh
   Booth, Richard
   Blake, Damer P.
TI A Cryptosporidium parvum genotype shift between week old and two week
   old calves following administration of a prophylactic antiprotozoal
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Cryptosporidium parvum; Halofuginone lactate; Calves; Genotype; gp60
ID HALOFUGINONE LACTATE; PREVENTION; CATTLE
AB This study looked to assess the stability of Cryptosporidium parvum genotypes in calves between the final day of treatment with the antiprotozoal halofuginone lactate and seven days post-treatment. Paired faecal samples were collected on the final day of treatment and seven days later from 54 calves across seven farms in South-west England. The presence of Cryptosporidium species was detected using polymerase chain reaction targeting the 18 s rDNA. The presence and genotype of C. parvum was determined by PCR and amplicon sequencing targeting the gp60 locus. On farms where C. parvum was detected at both sampling times there was a distinct genotype shift. Detection of gp60 genotype IlaA15G2R1 decreased from 40% to 7% while IlaA17G1R1 increased from 0% to 41%, supplemented by IlaA16G3R1 in one sample. A shift in C. parvum genotypes present in calves within a one week sampling timeframe has not been described prior to this study, indicating that the timeframe is likely suitable for observing variation in C. parvum populations and interactions with antiprotozoal control strategies.
C1 [Seale, Jessica; Booth, Richard; Blake, Damer P.] Univ London, Royal Vet Coll, Pathobiol & Populat Sci, Hawkshead Lane, N Mymms AL9 7TA, England.
   [Swain, Josh] Synergy Farm Hlth Ltd, West Hill Barn, Evershot DT2 0LD, Dorset, England.
RP Seale, J (reprint author), Univ London, Royal Vet Coll, Pathobiol & Populat Sci, Hawkshead Lane, N Mymms AL9 7TA, England.
EM js14717@bristol.ac.uk
OI Blake, Damer/0000-0003-1077-2306
FU Royal Veterinary College as part of a Masters One Health student project
FX The authors would like to acknowledge the assistance of Dr Yu-Mei Chang
   in the statistical analyses included here. This work was supported by
   funding provided by the Royal Veterinary College as part of a Masters
   One Health student project, supplemented by a Student Research Bursary
   from MSD Animal Health.
CR Abe N, 2002, VET PARASITOL, V108, P185, DOI 10.1016/S0304-4017(02)00204-2
   Almawly J, 2013, VET PARASITOL, V197, P59, DOI 10.1016/j.vetpar.2013.04.029
   Brook EJ, 2009, VET J, V179, P378, DOI 10.1016/j.tvjl.2007.10.023
   Chako CZ, 2010, J VET INTERN MED, V24, P37, DOI 10.1111/j.1939-1676.2009.0431.x
   de Graaf DC, 1999, INT J PARASITOL, V29, P1269, DOI 10.1016/S0020-7519(99)00076-4
   De Waele V, 2010, PREV VET MED, V96, P143, DOI 10.1016/j.prevetmed.2010.06.017
   European Medicines Agency, 2003, SCI DISC HAL
   European Medicines Agency, 2016, ANN 1 SUMM PROD CHAR
   Jarvie BD, 2005, J DAIRY SCI, V88, P1801, DOI 10.3168/jds.S0022-0302(05)72854-X
   Lefay D, 2001, VET REC, V148, P108, DOI 10.1136/vr.148.4.108
   Nolan M.J., 2017, VECTORS, V10, P1
   Olson ME, 1999, J ENVIRON QUAL, V28, P1991, DOI 10.2134/jeq1999.00472425002800060040x
   Rahal-Arabi T, 2007, 2007 IEEE WORKSHOP ON SIGNAL PROPAGATION ON INTERCONNECTS, P3, DOI 10.1109/SPI.2007.4512192
   Smith RP, 2014, VET PARASITOL, V204, P111, DOI 10.1016/j.vetpar.2014.05.022
   Thomson S, 2015, CRYPTOSPORIDIOSIS FA
   Trotz-Williams LA, 2011, VET REC, V168, DOI 10.1136/vr.d1492
   Xiao LH, 1999, APPL ENVIRON MICROB, V65, P1578
   Xiao LH, 2010, EXP PARASITOL, V124, P80, DOI 10.1016/j.exppara.2009.03.018
   Zambriski JA, 2013, PARASITOL RES, V112, P1247, DOI 10.1007/s00436-012-3258-2
NR 19
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP
PY 2019
VL 273
BP 32
EP 35
DI 10.1016/j.vetpar.2019.07.009
PG 4
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JA1IK
UT WOS:000487570500006
PM 31442890
DA 2020-05-12
ER

PT J
AU de Araujo, FF
   Ronda, JB
   Bittar, ER
   Venturini, GC
   Garcia, GC
   Martins, OA
   Araujo, MSS
   Bittar, JFF
AF de Araujo, Fernanda Fortes
   Ronda, Juliano Bergamo
   Bittar, Eustaquio Resende
   Venturini, Guilherme Costa
   Garcia, Guilherrne Caetano
   Martins-Filho, Olindo Assis
   Silva Araujo, Marcie Sobreira
   Figueiredo Bittar, Joely Ferreira
TI Distinct immune response profile during rhipicephalus (boophilus)
   microplus infestations of guzerat dairy herd according to the maternal
   lineage ancestry (mitochondrial DNA)
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Immune response; Rhipicephalus microplus; Guzerat dairy herd
ID CATTLE TICK; BOS-TAURUS; HOST-RESISTANCE; INDICUS; LARVAE; LYMPHOCYTES;
   CELLS; SHEEP
AB Rhipicephalus (Boophilus) microplus ticks cause major constraints to public and livestock health, and serious economic losses. It is well known that the immune response to infestations with cattle ticks is influenced by the host genetic background leading to distinct immunological profiles between bovine hosts genetically susceptible and resistant. The influence of Bos indicus (Bi) and Bos taurus (Bt) maternal lineage ancestry of mitochondrial DNA in the profile of the immune response of Zebu cattle to ticks remains unknown. The present work evaluated the hematological parameters and the immune response profile in the peripheral blood of a Guzerat dairy herd, further categorized into two maternal lineage ancestry subgroups (Bi-mtDNA and Bt-mtDNA) after experimental infestation with larvae of R. microplus. Our data demonstrated that although hematological and erythrogram analysis showed a similar profile throughout, some cell populations present a distinct profile between the groups. Especially MON, CD335(+) and CD8(+) T-cells are predominant in Bi-mtDNA. Moreover, an overall picture of R. microplus infestation demonstrated that Bi-mtDNA presented a more efficient and earlier innate immune response. Bi-mtDNA showed a greater number of connections with R. microplus counts and also with the CD25(+) activation marker of the immune response. Bi-mtDNA showed greater number of connections, with an important participation of the innate immune while Bt-mtDNA showed a delay in the immune response. Elucidating the mechanisms by which resistant animals prevent heavy tick infestation is a crucial step in the development of predictive biomarkers for tick resistance for use in selective breeding programs, and is also potentially useful for the development of anti-tick vaccines.
C1 [de Araujo, Fernanda Fortes; Ronda, Juliano Bergamo; Bittar, Eustaquio Resende; Venturini, Guilherme Costa; Garcia, Guilherrne Caetano; Figueiredo Bittar, Joely Ferreira] Univ Uberaba UNIUBE, Med Vet, Mestrado Sanidade & Prod Anim Trop, Ave Nene Sabino 1697-1698, BR-38055500 Uberaba, MG, Brazil.
   [de Araujo, Fernanda Fortes; Martins-Filho, Olindo Assis; Silva Araujo, Marcie Sobreira] Fundacao Oswaldo Cruz, Inst Rene Rachou, Grp Integrad Pesquisa Biomarcadores, Ave Augusto Lima 1715, BR-30190009 Belo Horizonte, MG, Brazil.
RP Araujo, MSS (reprint author), Fundacao Oswaldo Cruz, Inst Rene Rachou, Grp Integrad Pesquisa Biomarcadores, Ave Augusto Lima 1715, BR-30190009 Belo Horizonte, MG, Brazil.
EM sobreira@cpqrr.fiocruz.br
OI Sobreira, Marcio/0000-0002-7532-3360; Martins-Filho, Olindo
   Assis/0000-0002-5494-4889
FU Coordenadoria de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico, Brazil (CNPq)National Council for Scientific and
   Technological Development (CNPq); Fundacao de Amparo a Pesquisa do
   Estado de Minas Gerais, Brazil (FAPEMIG)Minas Gerais State Research
   Foundation (FAPEMIG); Programa de Apoio a Pesquisa da Universidade de
   Uberaba, Minas Gerais, Brazil (PAPE-UNIUBE); CNPqNational Council for
   Scientific and Technological Development (CNPq); PNPD/CAPES fellowship
   program
FX This work was financially supported by Coordenadoria de Aperfeicoamento
   de Pessoal de Nivel Superior (CAPES), Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico, Brazil (CNPq), Fundacao de
   Amparo a Pesquisa do Estado de Minas Gerais, Brazil (FAPEMIG) and
   Programa de Apoio a Pesquisa da Universidade de Uberaba, Minas Gerais,
   Brazil (PAPE-UNIUBE). OAMF and MSSA are thankful to CNPq for the PQ
   fellowship program. FFA thanks PNPD/CAPES fellowship program. The
   authors thank the Program for Technological Development in Tools for
   Health - PDTIS - FIOCRUZ for use of its facilities.
CR Andreotti R, 2002, INT IMMUNOPHARMACOL, V2, P557, DOI 10.1016/S1567-5769(01)00203-X
   Belkaid Y, 2007, NAT REV IMMUNOL, V7, P875, DOI 10.1038/nri2189
   Bittar JFF, 2004, ARQ BRAS MED VET ZOO, V56, P107, DOI 10.1590/S0102-09352004000100016
   Carvalho WA, 2008, EXP PARASITOL, V118, P587, DOI 10.1016/j.exppara.2007.10.006
   Constantinoiu CC, 2010, INT J PARASITOL, V40, P865, DOI 10.1016/j.ijpara.2010.01.004
   Engracia JR, 2017, EXP APPL ACAROL, V72, P171, DOI 10.1007/s10493-017-0143-9
   Franzin AM, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-016-1945-z
   Greer AW, 2018, VET PARASITOL, V250, P60, DOI 10.1016/j.vetpar.2017.12.013
   Greer AW, 2016, PARASITE IMMUNOL, V38, P263, DOI 10.1111/pim.12313
   Gutierrez M, 1999, VET IMMUNOL IMMUNOP, V71, P321, DOI 10.1016/S0165-2427(99)00106-3
   Hamie JC, 2019, VET PARASITOL, V270, P49, DOI 10.1016/j.vetpar.2019.04.014
   Jonsson NN, 2014, PARASITE IMMUNOL, V36, P551, DOI 10.1111/pim.12140
   KEMP DH, 1983, EXPERIENTIA, V39, P725, DOI 10.1007/BF01990293
   KEMP DH, 1976, PARASITOLOGY, V73, P123, DOI 10.1017/S0031182000051386
   KOUDSTAAL D, 1978, PARASITOLOGY, V76, P379, DOI 10.1017/S0031182000048241
   Lew-Tabor AE, 2016, TICKS TICK-BORNE DIS, V7, P573, DOI 10.1016/j.ttbdis.2015.12.012
   Luo SY, 2018, P NATL ACAD SCI USA, V115, P13039, DOI 10.1073/pnas.1810946115
   Macedo AA, 2014, BMC VET RES, V10, DOI 10.1186/1746-6148-10-79
   Marcondes CR, 2007, ARQ BRAS MED VET ZOO, V59, P977, DOI 10.1590/S0102-09352007000400025
   Meirelles FV, 1999, GENET MOL BIOL, V22, P543, DOI 10.1590/S1415-47571999000400013
   Paneto JCC, 2008, GENET MOL RES, V7, P592, DOI 10.4238/vol7-3gmr449
   Piper EK, 2010, INT J PARASITOL, V40, P431, DOI 10.1016/j.ijpara.2009.09.009
   Piper EK, 2009, CLIN VACCINE IMMUNOL, V16, P1074, DOI 10.1128/CVI.00157-09
   Ribeiro SHA, 2009, ARQ BRAS MED VET ZOO, V61, P232, DOI 10.1590/S0102-09352009000100033
   Rodriguez V, 2013, J RAMAN SPECTROSC, V44, P739, DOI 10.1002/jrs.4251
   SCHLEGER AV, 1976, AUST J BIOL SCI, V29, P499, DOI 10.1071/BI9760499
   SCHLEGER AV, 1981, EXPERIENTIA, V37, P49, DOI 10.1007/BF01965562
   SEIFERT GW, 1971, AUST J AGR RES, V22, P159, DOI 10.1071/AR9710159
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shyma K P, 2015, J Parasit Dis, V39, P1, DOI 10.1007/s12639-013-0294-5
   Tabor AE, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00506
   TATCHELL RJ, 1968, PARASITOLOGY, V58, P441, DOI 10.1017/S0031182000069468
   TAYLOR R, 1990, J DIAGN MED SONOG, V6, P35, DOI 10.1177/875647939000600106
   Villares J. Barisson, 1941, BOL INDUST ANIMAL, V4, P60
NR 34
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP
PY 2019
VL 273
BP 36
EP 44
DI 10.1016/j.vetpar.2019.07.005
PG 9
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JA1IK
UT WOS:000487570500007
PM 31442891
DA 2020-05-12
ER

PT J
AU Loeurng, V
   Ichikawa-Seki, M
   Wannasan, A
   Sothyra, T
   Chaisowwong, W
   Tiwananthagorn, S
AF Loeurng, Vandara
   Ichikawa-Seki, Madoka
   Wannasan, Anchalee
   Sothyra, Tum
   Chaisowwong, Warangkhana
   Tiwananthagorn, Saruda
TI Genetic Characterization of Cambodian Fasciola gigantica and Dispersal
   Direction of the Species in Asia
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Fasciola gigantica; Cattle; Phosphoenolpyruvate carboxykinase gene; NADH
   dehydrogenase subunit 1 gene; Population diversity; Gene flow
ID MOLECULAR CHARACTERIZATION; EVOLUTIONARY GENETICS; PHYLOGENETIC
   ANALYSIS; PHENOTYPIC ANALYSIS; MITOCHONDRIAL; DNA; NUCLEAR; HEPATICA;
   FLUKES; SPERMATOGENESIS
AB Fasciola gigantica and hybrid Fasciola are distributed throughout Asia. Herein, we investigated the species of the Fasciola fluke distributed in three hotspots of fascioliasis in Cambodia. A total of 92 flukes collected from 21 slaughtered cattle from Kandal (44), Battambang (41), and Kratie (7) Provinces were identified as F. gigantica using multiplex PCR for a nuclear phosphoenolpyruvate carboxykinase (PEPCK) gene. The overall prevalence of F. gigantica infestation was 7.14% (21/294). Phylogenetic as well as population genetics analyses were performed using the mitochondrial NADH dehydrogenase subunit 1 (ND1). The 19 ND1 haplotypes were identified from Cambodian F. gigantica (haplotype diversity, 0.83). All of the haplotypes were classified into F. gigantica haplogroup C, which includes ND1 haplotypes detected from Thailand, Vietnam, Indonesia, Myanmar, and China. Among haplogroup C, novel and unique haplotypes of Cambodia were found in the Battambang and Kandal Provinces, and the nucleotide diversity of the Cambodian population (0.00532) was the highest. Pairwise fixation indices among the F. gigantica populations from these countries indicated that the Cambodian and Thailand populations were related to each other. The highest genetic diversity in the Cambodian population suggests that F. gigantica in Cambodia may be the ancestor of the populations in Southeast Asian countries. Most likely, livestock movement, including Zebu cattle, played an important role in the transmission of F. gigantica. In this study, the hybrid Fasciola flukes that are commonly found in neighboring countries, were not found in Cambodia. Further comprehensive investigations of Fasciola prevalence should be conducted by analyzing a wider range of hosts throughout Cambodia to reach a more solid conclusion about the absence of hybrid flukes.
C1 [Loeurng, Vandara] Chiang Mai Univ, Fac Vet Med, Vet Publ Hlth Ctr Asia Pacific, Chiang Mai 50100, Thailand.
   [Loeurng, Vandara; Chaisowwong, Warangkhana] Chiang Mai Univ, Fac Vet Med, Excellent Ctr Vet Publ Hlth, Chiang Mai 50100, Thailand.
   [Ichikawa-Seki, Madoka] Iwate Univ, Fac Agr, Lab Vet Parasitol, Ueda 3-18-8, Morioka, Nagano 0208550, Japan.
   [Wannasan, Anchalee] Chiang Mai Univ, Fac Med, Dept Parasitol, Chiang Mai, Thailand.
   [Sothyra, Tum] Gen Directorate Anim Hlth & Prod, Natl Anim Hlth & Prod Res Inst, Phnom Penh 12350, Cambodia.
   [Chaisowwong, Warangkhana; Tiwananthagorn, Saruda] Chiang Mai Univ, Fac Vet Med, Dept Vet Biosci & Vet Publ Hlth, Chiang Mai 50100, Thailand.
   [Tiwananthagorn, Saruda] Chiang Mai Univ, Fac Vet Med, Excellent Ctr Vet Biosci, Chiang Mai 50100, Thailand.
RP Tiwananthagorn, S (reprint author), Chiang Mai Univ, Fac Vet Med, Dept Vet Biosci & Vet Publ Hlth, Chiang Mai 50100, Thailand.
EM vandara_loueng@yahoo.com; madoka@iwate-u.ac.jp; anchalee.wa@cmu.ac.th;
   sothyratum@gmail.com; warangkhana.chai@cmu.ac.th; saruda.t@cmu.ac.th
OI Chaisowwong, Warangkhana/0000-0002-9609-1087
FU Chiang Mai University via the Veterinary Public Health Centre for Asia
   Pacific; Excellence Center for Veterinary Public Health; Excellent
   Center in Veterinary Bioscience, Faculty of Veterinary Medicine, Chiang
   Mai University
FX This research project is supported by Chiang Mai University, in part via
   the Veterinary Public Health Centre for Asia Pacific, Excellence Center
   for Veterinary Public Health, and Excellent Center in Veterinary
   Bioscience, Faculty of Veterinary Medicine, Chiang Mai University.
   Laboratory support of National Veterinary Research Institution,
   Cambodia, and veterinarians of Kandal, Battambang, and Kratie Provinces
   are greatly appreciated.
CR Agatsuma T, 2000, PARASITOL INT, V49, P231, DOI 10.1016/S1383-5769(00)00051-9
   Ashrafi K, 2006, PARASITOL INT, V55, P249, DOI 10.1016/j.parint.2006.06.003
   Bandelt HJ, 1999, MOL BIOL EVOL, V16, P37, DOI 10.1093/oxfordjournals.molbev.a026036
   Bless PJ, 2015, ACTA TROP, V141, P295, DOI 10.1016/j.actatropica.2014.09.007
   Chaichanasak P, 2012, PARASITOL INT, V61, P545, DOI 10.1016/j.parint.2012.03.009
   Excoffier L, 2010, MOL ECOL RESOUR, V10, P564, DOI 10.1111/j.1755-0998.2010.02847.x
   Ghavami MB, 2009, IRAN J PARASITOL, V4, P61
   Gray G. D., 2008, ACIAR MONOGRAPH, V133
   Hayashi K, 2018, J VET MED SCI, V80, P98, DOI 10.1292/jvms.17-0406
   Hayashi K, 2016, J VET MED SCI, V78, P1529, DOI 10.1292/jvms.16-0126
   Hayashi K, 2016, PARASITOL INT, V65, P424, DOI 10.1016/j.parint.2016.06.004
   Hayashi K, 2015, PARASITOL INT, V64, P334, DOI 10.1016/j.parint.2015.04.004
   Ichikawa M, 2011, PARASITOL INT, V60, P474, DOI 10.1016/j.parint.2011.08.007
   Ichikawa M, 2010, J VET MED SCI, V72, P1371, DOI 10.1292/jvms.10-0104
   Ichikawa-Seki M, 2017, PARASITOLOGY, V144, P206, DOI 10.1017/S003118201600161X
   Itagaki T, 2005, PARASITOLOGY, V131, P679, DOI 10.1017/S0031182005008292
   Itagaki T, 2005, J VET MED SCI, V67, P1115, DOI 10.1292/jvms.67.1115
   Itagaki T, 2009, PARASITOL INT, V58, P81, DOI 10.1016/j.parint.2008.11.003
   Keiser J, 2009, CLIN MICROBIOL REV, V22, P466, DOI 10.1128/CMR.00012-09
   Kendall S. B., 1965, Advances in Parasitology, V3, P59, DOI 10.1016/S0065-308X(08)60363-2
   Le TH, 2008, INT J PARASITOL, V38, P725, DOI 10.1016/j.ijpara.2007.10.003
   Mas-Coma S, 2009, ADV PARASIT, V69, P41, DOI 10.1016/S0065-308X(09)69002-3
   Mohanta UK, 2014, PARASITOL RES, V113, P2493, DOI 10.1007/s00436-014-3898-5
   Peng M, 2009, PARASITOL RES, V105, P809, DOI 10.1007/s00436-009-1459-0
   Periago MV, 2006, PARASITOL RES, V99, P368, DOI 10.1007/s00436-006-0174-3
   Pham L., 2015, REG WORKSH BEEF MARK, P1
   Rozas J, 2017, MOL BIOL EVOL, V34, P3299, DOI 10.1093/molbev/msx248
   Shoriki T, 2016, PARASITOL INT, V65, P180, DOI 10.1016/j.parint.2015.12.002
   Shoriki T, 2014, PARASITOL INT, V63, P758, DOI 10.1016/j.parint.2014.07.001
   Sothoeun S, 2006, TROP ANIM HEALTH PRO, V38, P113, DOI 10.1007/s11250-006-4302-y
   Spithill TW, 1999, FASCIOLOSIS, P465
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   Torgerson P, 1999, FASCIOLOSIS, P113
   Tum S, 2004, VET PARASITOL, V122, P141, DOI 10.1016/j.vetpar.2004.03.016
   Wannasan A, 2014, EXP PARASITOL, V146, P64, DOI 10.1016/j.exppara.2014.09.006
   WHO, 2012, ACCL WORK OV GLOB IM
NR 36
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP
PY 2019
VL 273
BP 45
EP 51
DI 10.1016/j.vetpar.2019.07.013
PG 7
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JA1IK
UT WOS:000487570500008
PM 31442892
DA 2020-05-12
ER

PT J
AU Hautala, K
   Nareaho, A
   Kauppinen, O
   Nielsen, MK
   Sukura, A
   Rajala-Schultz, PJ
AF Hautala, Katja
   Nareaho, Anu
   Kauppinen, Oili
   Nielsen, Martin K.
   Sukura, Antti
   Rajala-Schultz, Paivi J.
TI Risk factors for equine intestinal parasite infections and reduced
   efficacy of pyrantel embonate against Parascaris sp.
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Anthelmintic resistance; Parascaris; Strongyle; Risk factor; Pyrantel;
   Efficacy; Egg count
ID HELMINTH CONTROL PRACTICES; ANTHELMINTIC RESISTANCE; GASTROINTESTINAL
   PARASITES; EQUORUM INFECTION; STRONGYLE INFECTIONS; CENTRAL KENTUCKY;
   HORSE FOALS; IN-FIELD; FARMS; FENBENDAZOLE
AB Gastrointestinal parasites, Parascaris sp. and strongyles, are common in young horses worldwide and control of these parasites is challenged by increasing anthelmintic resistance. Our aim was to identify risk factors for these infections as well as to assess the efficacy of fenbendazole (dose 7.5 mg/kg) and pyrantel embonate (dose 19 mg/kg) against Parascaris sp. We also evaluated association between owner observed symptoms and patent infections with these parasites. Fecal samples were collected from 367 young horses in Finland and a questionnaire study was conducted. Fecal egg counts were performed by Mini-FLOTAC (R) method. Univariable logistic regression models using patent infection status (Yes/No), separately for Parascaris sp. and strongyle infections as an outcome were run initially to screen potential risk factors collected by the questionnaire. After the initial screening, multiple logistic regression models were constructed and run to account for correlated data structure, risk factors and potential confounders simultaneously. Two significant risk factors for a patent Parascaris sp. infection were found: breeding farm size (p = 0.028) and frequency of horse movements (p = 0.010). Horses originating from large breeding farms were more likely (OR = 2.47, 95% confidence interval (CI) 1.10-5.51) to shed Parascaris sp. eggs upon relocation to training stables compared to horses originating from small breeding farms. Horses living in farms with frequent horse movements to other premises had higher odds (OR = 3.56, 95% CI: 1.35-9.39) of a patent Parascaris sp. infection compared to farms with less frequent horse movements. Risk factors for patent strongyle infection included age (p < 0.001) and season (p = 0.017). Horses were less likely (OR = 0.27, 95% CI: 0.10-0.66) to shed strongylid eggs during the spring compared to the winter. Horses excreting over 200 ascarid eggs per gram were included in the anthelmintic efficacy trial. A mean FECR less than 90% was interpreted as presence of anthelmintic resistance. The mean FECR was 98.5% (95% CI: 95.8-100) and 68.0% (95% CI: 52.7-83.3) in the fenbendazole (n = 31) and pyrantel (n = 26) treatment groups, respectively. In conclusion, we identified two new risk factors for patent Parascaris sp. infection; breeding farm size and frequency of horse movements. Reduced efficacy of pyrantel against Parascaris sp. was observed for the second time in Europe. A relatively high Parascaris sp. prevalence in yearlings (34%) and two-year-olds (20%) was observed, which has not been reported earlier. An association between symptoms and a patent Parascaris sp. infection was observed in foals.
C1 [Hautala, Katja; Nareaho, Anu; Kauppinen, Oili; Sukura, Antti; Rajala-Schultz, Paivi J.] Univ Helsinki, Fac Vet Med, POB 66, FIN-00014 Helsinki, Finland.
   [Nielsen, Martin K.] Univ Kentucky, MH Gluck Equine Res Ctr, 1400 Nicholasville Rd, Lexington, KY 40546 USA.
RP Hautala, K (reprint author), Univ Helsinki, Fac Vet Med, POB 66, FIN-00014 Helsinki, Finland.
EM katja.hautala@helsinki.fi
OI Nielsen, Martin/0000-0002-8942-6803; Rajala-Schultz,
   Paivi/0000-0003-4813-5097
FU Niemi Foundation; Erkki Rajakoski Foundation; MSD Animal Health (Axilur
   vet(R)); Zoetis (Strongid-P vet(R))
FX This study was partly supported by two grants provided by Niemi
   Foundation and Erkki Rajakoski Foundation. The pharmacological products
   used in the anthelmintic efficacy trial were sponsored by MSD Animal
   Health (Axilur vet (R)) and Zoetis (Strongid-P vet (R)).
CR Alanazi AD, 2017, VET QUART, V37, P200, DOI 10.1080/01652176.2017.1334981
   Armstrong SK, 2014, VET PARASITOL, V205, P575, DOI 10.1016/j.vetpar.2014.08.028
   Aromaa Maria, 2018, Vet Parasitol Reg Stud Reports, V12, P35, DOI 10.1016/j.vprsr.2018.01.006
   Becher AM, 2018, VET PARASITOL, V259, P6, DOI 10.1016/j.vetpar.2018.07.001
   Bellaw JL, 2016, VET PARASITOL, V221, P69, DOI 10.1016/j.vetpar.2016.03.018
   Boersema JH, 2002, VET REC, V150, P279, DOI 10.1136/vr.150.9.279
   Bolwell CF, 2015, VET PARASITOL, V209, P62, DOI 10.1016/j.vetpar.2015.02.011
   BUCKNELL DG, 1995, INT J PARASITOL, V25, P711, DOI 10.1016/0020-7519(94)00214-9
   CLAYTON HM, 1978, VET PARASITOL, V4, P69, DOI 10.1016/0304-4017(78)90037-7
   CLAYTON HM, 1979, INT J PARASITOL, V9, P285, DOI 10.1016/0020-7519(79)90076-6
   CLAYTON HM, 1979, RES VET SCI, V26, P383, DOI 10.1016/S0034-5288(18)32899-6
   Comer KC, 2006, VET REC, V158, P596, DOI 10.1136/vr.158.17.596
   Cringoli G, 2017, NAT PROTOC, V12, P1723, DOI 10.1038/nprot.2017.067
   Donoghue EM, 2015, VET PARASITOL, V214, P114, DOI 10.1016/j.vetpar.2015.09.003
   Fabiani JV, 2016, VET PARASITOL, V230, P62, DOI 10.1016/j.vetpar.2016.11.002
   Francisco I, 2009, J Parasitol Res, V2009, DOI 10.1155/2009/616173
   Fritzen B, 2010, EQUINE VET J, V42, P79, DOI 10.2746/042516409X471485
   Hinney B, 2011, PARASITOL RES, V108, P1083, DOI 10.1007/s00436-011-2362-z
   Kaplan RM, 2004, TRENDS PARASITOL, V20, P477, DOI 10.1016/j.pt.2004.08.001
   Kornas S, 2010, VET PARASITOL, V174, P285, DOI 10.1016/j.vetpar.2010.09.007
   Kornas S, 2015, INT J PARASITOL, V45, P237, DOI 10.1016/j.ijpara.2014.11.003
   Kuzmina TA, 2016, VET PARASITOL, V227, P56, DOI 10.1016/j.vetpar.2016.07.024
   Levy ST, 2015, ISR J VET MED, V70, P32
   Lind EO, 1999, EQUINE VET J, V31, P68, DOI 10.1111/j.2042-3306.1999.tb03793.x
   Lind EO, 2007, ACTA VET SCAND, V49, DOI 10.1186/1751-0147-49-25
   Lloyd S, 2000, VET REC, V146, P487, DOI 10.1136/vr.146.17.487
   Love S, 1999, VET PARASITOL, V85, P113, DOI 10.1016/S0304-4017(99)00092-8
   Lyons ET, 2008, PARASITOL RES, V103, P287, DOI 10.1007/s00436-008-0966-8
   Lyons ET, 2011, PARASITOL RES, V109, P1193, DOI 10.1007/s00436-011-2379-3
   Martin F, 2018, VET PARASITOL, V264, P69, DOI 10.1016/j.vetpar.2018.11.003
   Matthee S, 2002, J S AFR VET ASSOC, V73, P195
   Matthews JB, 2014, INT J PARASITOL-DRUG, V4, P310, DOI 10.1016/j.ijpddr.2014.10.003
   Mellor DJ, 2001, VET REC, V149, P417, DOI 10.1136/vr.149.14.417
   Morris LH, 2019, VET PARASITOL, V268, P46, DOI 10.1016/j.vetpar.2019.02.006
   Nareaho A, 2011, VET PARASITOL, V182, P372, DOI 10.1016/j.vetpar.2011.05.045
   Nielsen MK, 2018, VET PARASITOL, V257, P58, DOI 10.1016/j.vetpar.2018.05.006
   Nielsen MK, 2016, EQUINE VET EDUC, V28, P224, DOI 10.1111/eve.12536
   Nielsen MK, 2007, VET J, V174, P23, DOI 10.1016/j.tvjl.2006.05.009
   O'Meara B, 2002, VET PARASITOL, V109, P101, DOI 10.1016/S0304-4017(02)00249-2
   OGBOURNE CP, 1975, INT J PARASITOL, V5, P667, DOI 10.1016/0020-7519(75)90067-3
   Peregrine AS, 2014, VET PARASITOL, V201, P1, DOI 10.1016/j.vetpar.2014.01.004
   Peregrine AS, 2006, CAN VET J, V47, P80
   POYNTER D., 1954, Veterinary Record, V66, P74
   Rehbein S, 2013, PARASITOL RES, V112, P407, DOI 10.1007/s00436-012-3150-0
   Relf VE, 2013, PARASITOLOGY, V140, P641, DOI 10.1017/S0031182012001941
   Relf VE, 2014, INT J PARASITOL, V44, P507, DOI 10.1016/j.ijpara.2014.03.006
   Robert M, 2015, EQUINE VET J, V47, P694, DOI 10.1111/evj.12344
   Saville WJA, 2001, VET PARASITOL, V95, P211, DOI 10.1016/S0304-4017(00)00421-0
   Scheuerle MC, 2016, VET PARASITOL, V228, P103, DOI 10.1016/j.vetpar.2016.08.021
   Traversa D, 2010, VET PARASITOL, V168, P84, DOI 10.1016/j.vetpar.2009.10.006
   Tzelos T, 2017, VET PARASITOL, V237, P70, DOI 10.1016/j.vetpar.2017.02.018
   von Samson-Himmelstjerna G, 2012, VET PARASITOL, V185, P2, DOI 10.1016/j.vetpar.2011.10.010
NR 52
TC 0
Z9 0
U1 9
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP
PY 2019
VL 273
BP 52
EP 59
DI 10.1016/j.vetpar.2019.08.004
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JA1IK
UT WOS:000487570500009
PM 31442894
DA 2020-05-12
ER

PT J
AU Chu, KB
   Lee, HA
   Moon, EK
   Quan, FS
AF Chu, Ki-Back
   Lee, Hae-Ahm
   Moon, Eun-Kyung
   Quan, Fu-Shi
TI Resistance against Trichinella spiralis infection in pups delivered by
   T. spiralis-infected dam
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Trichinella spiralis; Resistance; Antibody response; Maternal immunity
ID NEONATAL TRANSMISSION; RAPID EXPULSION; NEWBORN LARVAE; IMMUNITY;
   MOTHER; EOSINOPHILIA; EXPRESSION; MOUSE; CELLS
AB Maternal antibody transmission via placenta and breastmilk are known to confer protection in infants. In this study, we investigated the maternal immunity transmission in pups delivered by rats infected with Trichinella spiralis and assessed the resulting resistance against subsequent parasitic infection. Our results revealed that parasite-specific IgG, IgG1 and IgG2a antibodies were present in pups prior to breastmilk ingestion (pre-milk), in which IgG and IgG1 antibodies persisted until week 8 after birth while parasite-specific IgG2a antibodies only lasted until week 4. After weaning on week 3, pups delivered by T. spiralis-infected dam and subsequently challenge-infected (immune-challenge) were found to possess higher mucosal IgG antibodies than control groups, whereas mucosal IgA levels were not significantly different across all groups. T. spiralis excretory-secretory antigen was discovered to react with pup sera until week 8, correlating with the resistance against parasitic infection which is represented by lessened worm burden. Upon T. spiralis infection at weeks 3 and 8, lower levels of eosinophil responses were detected in immune-challenge pups compared to naive-challenge pups, indicating correlates of resistances in which ADCC may be involved. Findings from the present study demonstrate that resistances against T. spiralis infection in pups can be acquired by maternally-derived IgG, IgG1 and IgG2a antibody transmission through the placenta and breastmilk from T. spiralis-infected dam, which lasts until week 8.
C1 [Chu, Ki-Back] Kyung Hee Univ, Grad Sch, Dept Biomed Sci, Seoul 02447, South Korea.
   [Lee, Hae-Ahm; Quan, Fu-Shi] Kyung Hee Univ, Sch Med, Grad Sch, Med Res Ctr Bioreact React Oxygen Species, Seoul 02447, South Korea.
   [Lee, Hae-Ahm; Quan, Fu-Shi] Kyung Hee Univ, Sch Med, Grad Sch, Biomed Sci Inst, Seoul 02447, South Korea.
   [Moon, Eun-Kyung; Quan, Fu-Shi] Kyung Hee Univ, Dept Med Zool, Sch Med, Seoul 02447, South Korea.
RP Quan, FS (reprint author), 26 Kyungheedae Ro, Seoul 02447, South Korea.
EM fsquan@khu.ac.kr
FU National Research Foundation of Korea (NRF)National Research Foundation
   of Korea [2018R1A2B6003535, 2018R1A6A1A03025124]; Cooperative Research
   Program for Agriculture Science & Technology Development, Rural
   Development Administration, Republic of KoreaRural Development
   Administration (RDA) [PJ01320501]
FX The authors would like to thank the National Research Foundation of
   Korea (NRF) (2018R1A2B6003535, 2018R1A6A1A03025124) and a grant from
   Cooperative Research Program for Agriculture Science & Technology
   Development, Rural Development Administration, Republic of Korea
   (Project No. PJ01320501) for providing financial support.
CR Alianmoghaddam N, 2018, J PEDIATR NURS, V39, P37, DOI 10.1016/j.pedn.2018.01.007
   APPLETON JA, 1988, IMMUNOLOGY, V65, P487
   APPLETON JA, 1984, SCIENCE, V226, P70, DOI 10.1126/science.6474191
   Black RE, 2013, LANCET, V382, P427, DOI 10.1016/S0140-6736(13)60937-X
   Cetre C, 1999, INFECT IMMUN, V67, P2713
   DESPOMMIER DD, 1977, IMMUNOLOGY, V33, P797
   DEVOS T, 1992, EXP PARASITOL, V75, P99, DOI 10.1016/0014-4894(92)90125-T
   DUCKETT MG, 1972, J PARASITOL, V58, P550, DOI 10.2307/3278203
   DUCKETT MG, 1971, T ROY SOC TROP MED H, V65, P432, DOI 10.1016/0035-9203(71)90138-6
   Dvoroznakova E, 2011, PARASITOL RES, V108, P169, DOI 10.1007/s00436-010-2049-x
   Einarsdottir HK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108319
   Fabre V, 2009, J IMMUNOL, V182, P1577, DOI 10.4049/jimmunol.182.3.1577
   Franssen FFJ, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-113
   Gebreselassie NG, 2012, J IMMUNOL, V188, P417, DOI 10.4049/jimmunol.1101980
   Gracie JA, 1996, EUR J IMMUNOL, V26, P1217, DOI 10.1002/eji.1830260605
   Grindstaff JL, 2003, P ROY SOC B-BIOL SCI, V270, P2309, DOI 10.1098/rspb.2003.2485
   Hasselquist D, 2009, PHILOS T R SOC B, V364, P51, DOI 10.1098/rstb.2008.0137
   Huang CC, 1999, DEV COMP IMMUNOL, V23, P545, DOI 10.1016/S0145-305X(99)00038-5
   KAZURA JW, 1978, NATURE, V274, P588, DOI 10.1038/274588a0
   KUMAR SN, 1990, J REPROD IMMUNOL, V17, P69, DOI 10.1016/0165-0378(90)90040-D
   KUMAR SN, 1989, IMMUNOLOGY, V68, P87
   LEE CM, 1983, J NATL MED ASSOC, V75, P1205
   Meedya Shahla, 2010, Women Birth, V23, P135, DOI 10.1016/j.wombi.2010.02.002
   MOLONEY A, 1979, Parasite Immunology (Oxford), V1, P3, DOI 10.1111/j.1365-3024.1979.tb00691.x
   Moret Y, 2001, NATURE, V414, P506, DOI 10.1038/35107138
   Murrell KD, 2016, VET PARASITOL, V231, P92, DOI 10.1016/j.vetpar.2016.03.020
   Murrell KD, 2011, EMERG INFECT DIS, V17, P2194, DOI 10.3201/eid1712.110896
   MURRELL KD, 1985, EXP PARASITOL, V59, P347, DOI 10.1016/0014-4894(85)90090-6
   Niewiesk S, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00446
   Nunez GG, 2002, PARASITOL RES, V88, P661, DOI 10.1007/s00436-002-0599-2
   Nunez GG, 2008, T ROY SOC TROP MED H, V102, P662, DOI 10.1016/j.trstmh.2008.03.009
   PERRY RH, 1974, J PARASITOL, V60, P460, DOI 10.2307/3278364
   Saracino MP, 2016, VET PARASITOL, V231, P2, DOI 10.1016/j.vetpar.2016.06.019
   Satoh T, 2000, CLIN EXP IMMUNOL, V122, P300, DOI 10.1046/j.1365-2249.2000.01355.x
   WAKELIN D, 1977, PARASITOLOGY, V74, P225, DOI 10.1017/S0031182000047855
   WAKELIN D, 1976, PARASITOLOGY, V72, P307, DOI 10.1017/S0031182000049507
   WAKELIN D, 1977, PARASITOLOGY, V74, P215, DOI 10.1017/S0031182000047843
   WAKELIN D, 1983, CLIN EXP IMMUNOL, V51, P239
   WANG CH, 1988, PARASITE IMMUNOL, V10, P293, DOI 10.1111/j.1365-3024.1988.tb00222.x
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP
PY 2019
VL 273
BP 60
EP 66
DI 10.1016/j.vetpar.2019.08.002
PG 7
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JA1IK
UT WOS:000487570500010
PM 31442895
DA 2020-05-12
ER

PT J
AU Holzhausen, I
   Lendner, M
   Daugschies, A
AF Holzhausen, I
   Lendner, M.
   Daugschies, A.
TI Bovine Cryptosporidium parvum field isolates differ in cytopathogenicity
   in HCT-8 monolayers
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Cryptosporidium parvum; HCT-8 cells; Cytopathogcnicity; MTT assay
ID VIRULENCE; VIABILITY; ETIOLOGY; ASSAYS
AB Suckling calves are prone to Cryptosporidium infection. The variable degree of clinical disease is influenced by keeping conditions and immune status of the host, but diversity of isolate virulence may also contribute. The aim of the current study was to evaluate the cytopathogenic effects of 26 C. parvum field isolates by using a MU assay in HCT-8 cell monolayers. Cell viability of monolayers inoculated with oocysts of the field isolates varied considerably with values of 17.7% (+/- 5.1%) to 99.5% (+/- 7.1%). A standard deviation of 18.6% was detected for cell viability of the in house reference strain, which were tested alongside in every assay. Field isolates were grouped in three categories of cytopathogenicity. Probably the length of storage has an effect on the level of the cell destruction category detected post infection in vitro. The applied tool may help to better understand the variable course of cryptosporidiosis in the field.
C1 [Holzhausen, I; Lendner, M.; Daugschies, A.] Univ Leipzig, Ctr Infect Dis, Inst Parasitol, Tierkliniken 35, D-04103 Leipzig, Germany.
   [Holzhausen, I; Daugschies, A.] Univ Leipzig, Albrecht Daniel Thaer Inst Agr Sci eV, Tierkliniken 29, D-04103 Leipzig, Germany.
RP Holzhausen, I (reprint author), Univ Leipzig, Ctr Infect Dis, Inst Parasitol, Tierkliniken 35, D-04103 Leipzig, Germany.
EM ivette.holzhausen@vetmed.uni-leipzig.de
CR Bouzid M, 2013, CLIN MICROBIOL REV, V26, P115, DOI 10.1128/CMR.00076-12
   Cho YI, 2013, VET MICROBIOL, V166, P375, DOI 10.1016/j.vetmic.2013.07.001
   Collinet-Adler S, 2010, EUR J CLIN MICROBIOL, V29, P927, DOI 10.1007/s10096-010-0960-9
   Delling C, 2017, VET PARASITOL, V245, P5, DOI 10.1016/j.vetpar.2017.07.018
   Delling C, 2016, PARASITOL RES, V115, P863, DOI 10.1007/s00436-015-4813-4
   FAYER R, 1986, MICROBIOL REV, V50, P458, DOI 10.1128/MMBR.50.4.458-483.1986
   Hijjawi NS, 2001, INT J PARASITOL, V31, P1048, DOI 10.1016/S0020-7519(01)00212-0
   Holzhausen I., 2019, PARASITOL RES
   Jenkins M, 2003, PARASITOL RES, V89, P1, DOI [10.1007/s00436-002-0720-6, 10.1645/0022-3395(2003)089[0001:ROESIN]2.0.CO;2]
   Joachim A, 2003, VET PARASITOL, V111, P47, DOI 10.1016/S0304-4017(02)00329-1
   Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2
   Mele R, 2004, INFECT IMMUN, V72, P6061, DOI 10.1128/IAI.72.10.6061-6067.2004
   Okhuysen PC, 1999, J INFECT DIS, V180, P1275, DOI 10.1086/315033
   POZIO E, 1992, T ROY SOC TROP MED H, V86, P636, DOI 10.1016/0035-9203(92)90165-9
   Rochelle PA, 2002, APPL ENVIRON MICROB, V68, P3809, DOI 10.1128/AEM.68.8.3809-3817.2002
   Ryan U, 2015, INT J PARASITOL, V45, P367, DOI 10.1016/j.ijpara.2015.01.009
   Sayed Fatma G., 2016, Annals of Parasitology, V62, P221, DOI 10.17420/ap6203.56
   Shahiduzzaman M, 2010, VET PARASITOL, V167, P43, DOI 10.1016/j.vetpar.2009.09.042
   VISTICA DT, 1991, CANCER RES, V51, P2515
NR 19
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP
PY 2019
VL 273
BP 67
EP 70
DI 10.1016/j.vetpar.2019.08.006
PG 4
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JA1IK
UT WOS:000487570500011
PM 31442896
DA 2020-05-12
ER

PT J
AU Valente, JDM
   Mongruel, ACB
   Machado, CAL
   Chiyo, L
   Leandro, AS
   Britto, AS
   Martins, TF
   Barros, IR
   Biondo, AW
   Perotta, JH
   Campos, ANS
   Vidotto, O
   Labruna, MB
   Aguiar, DM
   Vieira, TSWJ
   Vieira, RFC
AF Valente, Jessica D. M.
   Mongruel, Anna C. B.
   Machado, Carolina A. L.
   Chiyo, Luciana
   Leandro, Andre S.
   Britto, Andre S.
   Martins, Thiago F.
   Barros-Filho, Ivan R.
   Biondo, Alexander W.
   Perotta, Joao H.
   Campos, Amanda N. S.
   Vidotto, Odilon
   Labruna, Marcelo B.
   Aguiar, Daniel M.
   Vieira, Thallitha S. W. J.
   Vieira, Rafael F. C.
TI Tick-borne pathogens in carthorses from Foz do Iguacu City, Parana
   State, southern Brazil: A tri-border area of Brazil, Paraguay and
   Argentina
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Theileria equi; Babesia caballi; Ehrlichia spp.; Hemoplasmas; Ticks
ID THEILERIA-EQUI; BABESIA-CABALLI; HEMOTROPIC MYCOPLASMAS; SAO-PAULO;
   MOLECULAR-DETECTION; RURAL SETTLEMENT; RISK-FACTORS; HORSES; EHRLICHIA;
   PREVALENCE
AB Tick-borne diseases(TBD) constitute an important group of illness affecting animals and humans worldwide. In Brazil, carthorses are frequently exposed to ticks and tick-borne pathogens, leading to impairment of horse performance and imposing restrictions by the international veterinary authorities for the importation of horses. Accordingly, this study has aimed to i) determine the prevalence of the TBD agents Theileria equi, Babesia caballi, Ehrlichia spp., and hemotropic mycoplasmas in carthorses, ii) identify the tick species parasitizing the animals, and iii) determine factors associated with exposure/infection in Foz do Iguacu City, Parana state, southern Brazil. A total of 103 carthorses were screened for anti-T. equi and anti-Ehrlichia spp. antibodies by indirect fluorescent antibody assays (IFA). Samples were also tested by PCR assays targeting the 18S rRNA gene of T. equi and B. caballi, and 16S rRNA gene of hemoplasmas. Additionally, PCR assays targeting the 16S rRNA, disulfide bond formation protein (dsb) and tandem repeat proteins 36 (trp36) genes of Ehrlichia spp. were also performed. Antibodies to T. equi and Ehrlichia spp. were detected in 43/103 (41.75%; 95% CI: 32.10-51.88%) and 5/103 (4.85%; 95% CI: 1.59-10.97%) horses by IFA, respectively. DNA of T. equi and B. caballi were found in 25/103 (24.27%; 95% CI: 16.36-33.71%) and 10/103 (9.71%; 95% CI: 4.75-17.13%) carthorses, respectively, and all tested negative for Ehrlichia spp. and hemoplasmas. All sequences showed >= 99% identity with multiple T. equi and B. caballi 18S rRNA gene sequences deposited in GenBank. Overall, 191 Dermacentor nitens ticks were collected from 25/103 (24.27%) animals. Carthorses older than 5 years were more likely to be positive for T. equi (p < 0.05). In conclusion, equine piroplasmosis agents are highly prevalent in carthorses from Foz do Iguacu City. The low prevalence of Ehrlichia spp. found may be due to the absence of Amblyomma ticks infesting animals, which should be further investigated.
C1 [Valente, Jessica D. M.; Mongruel, Anna C. B.; Machado, Carolina A. L.; Barros-Filho, Ivan R.; Biondo, Alexander W.; Perotta, Joao H.; Vieira, Thallitha S. W. J.; Vieira, Rafael F. C.] Univ Fed Parana UFPR, Dept Med Vet, Curitiba, Parana, Brazil.
   [Chiyo, Luciana; Leandro, Andre S.; Britto, Andre S.] Secretaria Municipal Saude, Unidade Vigilancia Zoonoses, Foz Do Iguacu, Parana, Brazil.
   [Martins, Thiago F.; Labruna, Marcelo B.] Univ Sao Paulo, Fac Med Vet, Dept Med Vet Prevent & Saude Anim, Sao Paulo, SP, Brazil.
   [Vidotto, Odilon] Univ Estadual Londrina, Dept Med Vet Prevent, Londrina, Parana, Brazil.
   [Campos, Amanda N. S.; Aguiar, Daniel M.] Univ Fed Mato Grosso, Lab Virol & Rickettsioses, Cuiaba, Mato Grosso, Brazil.
   [Vieira, Rafael F. C.] Ohio State Univ, Global One Hlth Initiat, Columbus, OH 43210 USA.
RP Vieira, RFC (reprint author), Univ Fed Parana, Dept Med Vet, Campus Agr,R Funcionarios 1540, BR-80035050 Curitiba, Parana, Brazil.
EM rvieira@ufpr.br
RI Martins, Thiago/H-9971-2014; Perotta, Joao Henrique H/G-6321-2015;
   Mongruel, Anna Claudia Baumel/AAC-9332-2019; BIONDO, ALEXANDER WELKER
   W/E-8823-2018
OI Mongruel, Anna Claudia Baumel/0000-0002-9349-266X; BIONDO, ALEXANDER
   WELKER W/0000-0002-4182-5821; Valente, Jessica/0000-0002-9374-1419;
   Chiyo, Luciana/0000-0001-8751-8387; Roque de Barros Filho,
   Ivan/0000-0002-0056-9358
FU Brazilian National Council of Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; CNPqNational Council for Scientific and Technological
   Development (CNPq)
FX This study is part of a Master's degree for Jessica Valente at the
   Universidade Federal do Parana. Dr. Valente and Dr. Mongruel were
   sponsored by a fellowship from the Brazilian National Council of
   Scientific and Technological Development (CNPq), and Dr. Machado was
   sponsored by a fellowship from the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES) at the time of research. CNPq also
   provided a fellowship of research productivity (PQ) to Dr. Rafael Vieira
   and Dr. Daniel Aguiar. Authors would like to thank the technicians of
   the Center for Zoonosis Control of Foz do Iguacu City, Universidade
   Dinamica das Cataratas, and Colegio Agricola for all help during the
   study.
CR Afridi MJK, 2017, IRAN J PARASITOL, V12, P597
   Aguiar DM, 2007, J MED ENTOMOL, V44, P126, DOI 10.1603/0022-2585(2007)44[126:POECRA]2.0.CO;2
   Aguiar DM, 2014, TICKS TICK-BORNE DIS, V5, P537, DOI 10.1016/j.ttbdis.2014.03.010
   Alhassan A, 2005, VET PARASITOL, V129, P43, DOI 10.1016/j.vetpar.2004.12.018
   Almeida AP, 2013, J MED ENTOMOL, V50, P640, DOI 10.1603/ME12272
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Ambawat HK, 1999, VET PARASITOL, V85, P319, DOI 10.1016/S0304-4017(99)00110-7
   Ayala-Valdovinos MA, 2017, PARASITOL INT, V66, P821, DOI 10.1016/j.parint.2016.09.011
   [Anonymous], 2018, CAR DIM TUR INT BRAS
   Baldani CD, 2010, REV BRAS PARASITOL V, V19, P228, DOI 10.1590/S1984-29612010000400007
   Baneth G, 2014, INT J PARASITOL, V44, P591, DOI 10.1016/j.ijpara.2014.03.011
   Barros-Battesti D.M., 2006, CARRAPATOS IMPORTANC
   Bhoora R, 2009, VET PARASITOL, V159, P112, DOI 10.1016/j.vetpar.2008.10.004
   Birkenheuer AJ, 2003, J CLIN MICROBIOL, V41, P4172, DOI 10.1128/JCM.41.9.4172-4177.2003
   Carmichael RC, 2014, VECTOR-BORNE ZOONOT, V14, P552, DOI 10.1089/vbz.2013.1570
   Colwell DD, 2011, VET PARASITOL, V182, P14, DOI 10.1016/j.vetpar.2011.07.012
   Braga MDCD, 2017, REV BRAS PARASITOL V, V26, P331, DOI [10.1590/S1984-29612017046, 10.1590/s1984-29612017046]
   Cubilla MP, 2017, COMP IMMUNOL MICROB, V53, P19, DOI 10.1016/j.cimid.2017.06.004
   Cubilla MP, 2017, COMP IMMUNOL MICROB, V52, P6, DOI 10.1016/j.cimid.2017.05.002
   Vieira RFD, 2015, REV INST MED TROP SP, V57, P353, DOI 10.1590/S0036-46652015000400014
   Vieira RFD, 2013, REV INST MED TROP SP, V55, P335, DOI 10.1590/S0036-46652013000500007
   Vieira RFD, 2011, REV BRAS PARASITOL V, V20, P1, DOI 10.1590/S1984-29612011000100002
   Dantas-Torres F, 2015, INT J PARASITOL-PAR, V4, P452, DOI 10.1016/j.ijppaw.2015.07.001
   Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109
   Davitkov D, 2016, ACTA PARASITOL, V61, P337, DOI 10.1515/ap-2016-0044
   Dieckmann SM, 2012, VET MICROBIOL, V160, P43, DOI 10.1016/j.vetmic.2012.05.016
   Dieckmann SM, 2010, VET MICROBIOL, V145, P351, DOI 10.1016/j.vetmic.2010.04.009
   dos Santos Leonilda Correia, 2018, BMC Research Notes, V11, P536, DOI 10.1186/s13104-018-3638-5
   Duell JR, 2013, J MED ENTOMOL, V50, P1330, DOI 10.1603/ME13117
   Dumler JS, 2001, INT J SYST EVOL MICR, V51, P2145, DOI 10.1099/00207713-51-6-2145
   Dziegiel B, 2013, RES VET SCI, V95, P316, DOI 10.1016/j.rvsc.2013.05.010
   Ferreira EP, 2016, COMP IMMUNOL MICROB, V47, P72, DOI 10.1016/j.cimid.2016.06.004
   Friedhoff K T, 1990, Rev Sci Tech, V9, P1187
   Hall CM, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-35
   Hegarty BC, 2009, J AM ANIM HOSP ASSOC, V45, P118, DOI 10.5326/0450118
   Hoelzle K, 2011, VET J, V187, P408, DOI 10.1016/j.tvjl.2010.01.016
   HOLBROOK AA, 1969, J AM VET MED ASSOC, V155, P453
   HOLLAND CJ, 1985, SCIENCE, V227, P522, DOI 10.1126/science.3880925
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Kerber CE, 2009, REV BRAS PARASITOL V, V18, P1, DOI 10.4322/rbpv.01804001
   Labruna MB, 2014, J CLIN MICROBIOL, V52, P3788, DOI 10.1128/JCM.01914-14
   Labruna MB, 2001, VET PARASITOL, V97, P1, DOI 10.1016/S0304-4017(01)00387-9
   Liu Q, 2016, VET PARASITOL, V221, P24, DOI 10.1016/j.vetpar.2016.03.003
   Manna G, 2018, TICKS TICK-BORNE DIS, V9, P1212, DOI 10.1016/j.ttbdis.2018.05.005
   Martins TF, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1460-2
   Cortes MGM, 2017, PARASITE, V24, DOI 10.1051/parasite/2017015
   Moraes Marcela Figueredo Duarte, 2017, Vet Parasitol Reg Stud Reports, V8, P1, DOI [10.1016/j.vp, 10.1016/j.vprsr.2017.01.003]
   Nava S, 2007, ANN TROP MED PARASIT, V101, P255, DOI 10.1179/136485907X176319
   Nava S, 2017, TICKS SO CONE AM DIA
   Neimark H, 2004, INT J SYST EVOL MICR, V54, P365, DOI 10.1099/ijs.0.02858-0
   O'Connor TP, 2006, AM J VET RES, V67, P206, DOI 10.2460/ajvr.67.2.206
   O'Nion VL, 2015, EMERG INFECT DIS, V21, P335, DOI 10.3201/eid2102.140290
   Souza BMPD, 2010, REV BRAS PARASITOL V, V19, P89, DOI 10.1590/S1984-29612010000200004
   Rambaut A, 2014, FIGTREE V1 4 2 GRAPH
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   Rothschild CM, 2013, J EQUINE VET SCI, V33, P497, DOI 10.1016/j.jevs.2013.03.189
   Salim B, 2010, PARASITOL RES, V106, P493, DOI 10.1007/s00436-009-1691-7
   Sant C, 2019, PARASITOL RES, V118, P1171, DOI 10.1007/s00436-019-06240-x
   Satue K, 2014, J HEMATOL RES, V1, P1, DOI DOI 10.12974/2312-5411.2014.01.01.1
   Scoles GA, 2015, ANNU REV ENTOMOL, V60, P561, DOI 10.1146/annurev-ento-010814-021110
   Nogueira RDS, 2017, PESQUI VET BRASIL, V37, P1416, DOI [10.1590/S0100-736X2017001200010, 10.1590/s0100-736x2017001200010]
   Sela I, 2015, NUCLEIC ACIDS RES, V43, pW7, DOI 10.1093/nar/gkv318
   SENEVIRATNA P, 1973, RES VET SCI, V14, P112, DOI 10.1016/S0034-5288(18)33950-X
   Souza CE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153303
   Souza E. B. C, 2017, CUAD GEOGR REV COLOM, V26, P355
   Thomaz-Soccol V, 2017, PLOS ONE, V12
   Vieira TS, 2016, COMP IMMUNOL MICROB, V48, P1, DOI 10.1016/j.cimid.2016.07.002
   Vieira TSWJ, 2018, EMERG INFECT DIS, V24, P953, DOI 10.3201/eid2405.172076
   Vieira TSWJ, 2013, TICKS TICK-BORNE DIS, V4, P537, DOI 10.1016/j.ttbdis.2013.07.005
   Vitari GLV, 2019, J PARASITOL, V105, P186, DOI 10.1645/18-34
   Wang JM, 2019, TICKS TICK-BORNE DIS, V10, P528, DOI 10.1016/j.ttbdis.2019.01.003
   Weiss DJ, 2011, SCHALMS VET HEMATOLO
   Vieira TSWJ, 2015, SEMIN-CIENC AGRAR, V36, P4361, DOI 10.5433/1679-0359.2015v36n6Supl2p4361
   Vieira TSWJ, 2015, SEMIN-CIENC AGRAR, V36, P291, DOI 10.5433/1679-0359.2015v36n1p291
   Zanet S, 2017, VET PARASITOL, V236, P38, DOI 10.1016/j.vetpar.2017.01.003
   Zhang Y, 2017, VET PARASITOL, V244, P111, DOI 10.1016/j.vetpar.2017.07.014
NR 76
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP
PY 2019
VL 273
BP 71
EP 79
DI 10.1016/j.vetpar.2019.08.008
PG 9
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JA1IK
UT WOS:000487570500012
PM 31446256
DA 2020-05-12
ER

PT J
AU Rocha, AVVO
   Moreno, BFS
   Cabral, AD
   Louzeiro, NM
   Miranda, LM
   dos Santos, VMB
   Costa, FB
   Nogueira, RDS
   Marcili, A
   Speranca, MA
   da Costa, AP
AF Verde Oliveira Rocha, Ana Vitoria
   Sodre Moreno, Brenda Fernanda
   Cabral, Aline Diniz
   Louzeiro, Nayara Mendes
   Miranda, Leandro Macedo
   Brandao dos Santos, Vivian Magalhaes
   Costa, Francisco Borges
   Seabra Nogueira, Rita de Maria
   Marcili, Arlei
   Speranca, Marcia Aparecida
   da Costa, Andrea Pereira
TI Diagnosis and epidemiology of Leishmania infantum in domestic cats in an
   endemic area of the Amazon region, Brazil
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Leishmania; Feline leishmaniasis; Cat; Conjunctival swabs; Diagnosis;
   Brazil
ID AMERICAN VISCERAL LEISHMANIASIS; FELINE LEISHMANIASIS;
   LUTZOMYIA-LONGIPALPIS; TOXOPLASMA-GONDII; INFECTION; CHAGASI; STATE;
   ANTIBODIES; IRAN; SOUTH
AB Visceral leishmaniasis is a zoonotic disease caused by Leishmania infantum for which dogs are the main reservoir. In South America, presence of this disease is expanding along with increasing dispersion of its principal vector, the sand-fly Lutzomyia longipalpis. Feline leishmaniasis is an emerging disease in domestic cats, but epidemiological studies in endemic areas of the Amazon region of Brazil are scarce and the role of cats as reservoirs of L. infantum has been debated. The aim of this study was to investigate L. infantum infection in cats living in the Amazon biome region, using serological and molecular methods. A total of 105 cats were subjected to clinical examination and blood samples were taken for immunofluorescent-antibody (1FAT) serological evaluation, to determine anti-Leishmania antibody titers. Conventional PCR and Sanger's sequencing targeting L. infantum chitinase and Leishmania species ribosomal internal transcribed spacer (ITS-1) encoding genes were performed on conjunctival swabs from these cats. Seropositivity was detected in 32 animals (30.48%), thus confirming that contact between these cats and the parasite was occurring. PCR followed by amplicon sequencing showed that three samples (2.86%) were positive for a chitinase gene and six (5.71%) were positive for the ITS-1 gene. Parasite-positive diagnoses presented a statistically significant association with free access to the streets (p = 0.0111), cohabitation with dogs affected previously by VL (p = 0.0006) and absence of backyard cleaning and garbage collection (p = 0.00003). These results emphasize that cats should be included in epidemiological surveys of leishmaniasis, especially in endemic areas, if not as the reservoir host (unproven), at least as a "sentinel host" that is useful for revealing situations of endemic circulation of L. infantum. Moreover, in these areas, feline leishmaniasis needs to be considered in the differential diagnosis among domestic cats presenting alopecia, rarefied hair, lacerations and ulcerative dermatitis.
C1 [Verde Oliveira Rocha, Ana Vitoria; Sodre Moreno, Brenda Fernanda; Louzeiro, Nayara Mendes; Miranda, Leandro Macedo; Costa, Francisco Borges; Seabra Nogueira, Rita de Maria; da Costa, Andrea Pereira] Univ Estadual Maranhao, Sao Luis, Maranhao, Brazil.
   [Cabral, Aline Diniz; Speranca, Marcia Aparecida] Fed Univ ABC, Ctr Nat & Human Sci, Sao Bernardo Do Campo, SP, Brazil.
   [Brandao dos Santos, Vivian Magalhaes] Univ Estadual Ceara, Biotechnol & Mol Biol Lab, Itaperi Campus, Fortaleza, Ceara, Brazil.
   [Marcili, Arlei] Univ Sao Paulo, Sch Vet Med, Dept Prevent Vet Med & Anim Hlth, Sao Paulo, SP, Brazil.
   [Marcili, Arlei] Univ Santo Amaro, Sao Paulo, SP, Brazil.
RP da Costa, AP (reprint author), Univ Estadual Maranhao, Sao Luis, Maranhao, Brazil.
EM andrea.costa@professor.uema.br
RI Cabral, Aline Diniz/Q-8650-2019; Cabral, Aline Diniz/M-5779-2018;
   Marcili, Arlei/E-2888-2013; Aparecida Speranca, Marcia/D-2310-2012
OI Cabral, Aline Diniz/0000-0002-9439-4463; Cabral, Aline
   Diniz/0000-0002-9439-4463; Marcili, Arlei/0000-0002-0478-6771; Aparecida
   Speranca, Marcia/0000-0002-1178-3747
FU Scientific and Technological Development Support Foundation of Maranhao
   [FAPEMA] [2011/00147-6]; Research Support Foundation of the State of Sao
   Paulo [FAPESP]Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2013/26096-4, 2016/14514-4, 2010/50886-7]; Coordination Office
   for Technical Improvement of Higher-Education Personnel (CAPES)CAPES
FX This work was supported by the Scientific and Technological Development
   Support Foundation of Maranhao [FAPEMA grant number 2011/00147-6]; by
   the Research Support Foundation of the State of Sao Paulo [FAPESP
   postdoctoral fellowship for ADC, number 2013/26096-4, grant number
   2016/14514-4 for MAS and grant number 2010/50886-7 for AM] and the
   Coordination Office for Technical Improvement of Higher-Education
   Personnel (CAPES).
CR Akhtardanesh B, 2017, J VECTOR DIS, V54, P96
   Alemu A, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-382
   Borges BKA, 2008, CAD SAUDE PUBLICA, V24, P777, DOI 10.1590/S0102-311X2008000400007
   Asfaram S, 2019, J VENOM ANIM TOXINS, V25, DOI [10.1590/1678-9199-JVATITD-2019-0012, 10.1590/1678-9199-jvatitd-2019-0012]
   Ayllon T, 2008, ANN NY ACAD SCI, V1149, P361, DOI 10.1196/annals.1428.019
   Benassi JC, 2017, EXP PARASITOL, V177, P93, DOI 10.1016/j.exppara.2017.04.004
   Braga A. R. C., 2014, REV SOC BRAS MED TRO, V49, P2
   Chatzis MK, 2014, VET PARASITOL, V202, P217, DOI 10.1016/j.vetpar.2014.02.044
   Costa PL, 2013, ACTA TROP, V126, P99, DOI 10.1016/j.actatropica.2013.01.011
   Coura FM, 2018, REV BRAS PARASITOL V, V27, P570, DOI [10.1590/S1984-296120180052, 10.1590/s1984-296120180052]
   da Costa AP, 2015, VECTOR-BORNE ZOONOT, V15, P656, DOI 10.1089/vbz.2015.1771
   da Silva SM, 2010, VET PARASITOL, V174, P150, DOI 10.1016/j.vetpar.2010.08.005
   Costa KFD, 2014, REV SOC BRAS MED TRO, V47, P607, DOI 10.1590/0037-8682-0167-2014
   Oliveira TMFD, 2008, REV BRAS PARASITOL V, V17, P7, DOI 10.1590/S1984-29612008000100002
   Dedola C., 2018, VET PARASITOL REG ST, V13, P4
   Afonso MMD, 2012, J TROP MED, DOI 10.1155/2012/858657
   Coelho WMD, 2010, REV BRAS PARASITOL V, V19, P256, DOI 10.1590/S1984-29612010000400013
   Esch KJ, 2012, AM J TROP MED HYG, V87, P822, DOI 10.4269/ajtmh.2012.12-0251
   Espinosa OA, 2018, PARASITOLOGY, V145, P430, DOI [10.1017/S0031182016002092, 10.1017/s0031182016002092]
   Fatollahzadeh Mohammad, 2016, J Parasit Dis, V40, P683, DOI 10.1007/s12639-014-0559-7
   Feliciangeli MD, 2004, MED VET ENTOMOL, V18, P71, DOI 10.1111/j.0269-283X.2004.0487.x
   Oliveira TMFD, 2015, REV BRAS PARASITOL V, V24, P220, DOI 10.1590/S1984-29612015016
   Figueiredo FB, 2009, REV SOC BRAS MED TRO, V42, P141, DOI 10.1590/S0037-86822009000200009
   Franca V. H., 2013, ENSAIO-AVAL POLIT PU, V15, P17
   Freitas VC, 2012, AM J TROP MED HYG, V86, P606, DOI 10.4269/ajtmh.2012.11-0386
   Georgiadou SP, 2015, J TRANSL INTERN MED, V3, P43, DOI 10.1515/jtim-2015-0002
   Iatta R, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007594
   IBGE, 2015, CID
   KILLICKKENDRICK R, 1990, MED VET ENTOMOL, V4, P1, DOI 10.1111/j.1365-2915.1990.tb00255.x
   Koirala S., 1998, B WORLD HEALTH ORGAN, V76, P6
   Lainson R, 2005, MEM I OSWALDO CRUZ, V100, P811, DOI 10.1590/S0074-02762005000800001
   Lobo K. S., 2013, CIENCIA SAUDE COLETI, V18, P6
   da Silva AVM, 2008, ACTA TROP, V105, P92, DOI 10.1016/j.actatropica.2007.09.001
   Maia C, 2010, VET PARASITOL, V174, P336, DOI 10.1016/j.vetpar.2010.08.030
   Maia C, 2008, VECTOR-BORNE ZOONOT, V8, P555, DOI 10.1089/vbz.2007.0247
   Maia C, 2015, VET PARASITOL, V213, P2, DOI 10.1016/j.vetpar.2015.05.003
   Maia C, 2011, TRENDS PARASITOL, V27, P341, DOI 10.1016/j.pt.2011.03.008
   Maia-Elkhoury ANS, 2008, CAD SAUDE PUBLICA, V24, P2941, DOI 10.1590/S0102-311X2008001200024
   Mancianti F., 2004, Parassitologia (Rome), V46, P203
   Marcili A, 2014, INFECT GENET EVOL, V25, P44, DOI 10.1016/j.meegid.2014.04.001
   Maroli M, 2007, VET PARASITOL, V145, P357, DOI 10.1016/j.vetpar.2006.11.009
   de Sousa KCM, 2014, REV BRAS PARASITOL V, V23, P449, DOI 10.1590/S1984-29612014078
   Martin-Sanchez J, 2007, VET PARASITOL, V145, P267, DOI 10.1016/j.vetpar.2006.11.005
   Mendonca I. L. de, 2017, Parasitology Open, V3, pe1, DOI 10.1017/pao.2017.1
   Mendonca IL., 2017, PARASITOL OPEN, V3, P8
   Metzdorf IP, 2017, ACTA TROP, V166, P121, DOI 10.1016/j.actatropica.2016.11.013
   Silva RDN, 2014, REV SOC BRAS MED TRO, V47, P108, DOI 10.1590/0037-8682-0005-2012
   Nasereddin A, 2008, VET PARASITOL, V158, P364, DOI 10.1016/j.vetpar.2008.09.022
   Oliveira GC, 2015, REV BRAS PARASITOL V, V24, P464, DOI 10.1590/S1984-29612015071
   Pennisi MG, 2018, VET PARASITOL, V251, P131, DOI 10.1016/j.vetpar.2018.01.012
   Pennisi MG, 2013, J FELINE MED SURG, V15, P638, DOI 10.1177/1098612X13489229
   Pennisi MG, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0909-z
   Persichetti MF, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2046-3
   Pocholle E, 2012, PARASITE, V19, P77, DOI 10.1051/parasite/2012191077
   Quinnell RJ, 2003, VET IMMUNOL IMMUNOP, V91, P161, DOI 10.1016/S0165-2427(02)00311-2
   Rebelo J M, 1999, Cad Saude Publica, V15, P623, DOI 10.1590/S0102-311X1999000300020
   de Matos AMRN, 2018, REV BRAS PARASITOL V, V27, P232, DOI [10.1590/S1984-296120180033, 10.1590/s1984-296120180033]
   Bresciani KDS, 2010, REV BRAS PARASITOL V, V19, P127, DOI 10.1590/S1984-29612010000200012
   Sarkari B, 2009, ANN TROP MED PARASIT, V103, P275, DOI 10.1179/136485909X398276
   Schonian G, 2003, DIAGN MICR INFEC DIS, V47, P349, DOI 10.1016/S0732-8893(03)00093-2
   Shaw S E, 2001, J Feline Med Surg, V3, P193, DOI 10.1053/jfms.2001.0149
   Solano-Gallego L, 2007, AM J TROP MED HYG, V76, P676, DOI 10.4269/ajtmh.2007.76.676
   Sousa K. C. M., 2014, REV BRAS PARASITOL V, V23, P7
   Suzuki R. B., 2015, J MOL BIOMARK DIAGN, V7, P4
   Sobrinho LSV, 2012, VET PARASITOL, V187, P302, DOI 10.1016/j.vetpar.2012.01.010
   Vides JP, 2011, VET PARASITOL, V178, P22, DOI 10.1016/j.vetpar.2010.12.042
   Vita S, 2005, VET RES COMMUN, V29, P319, DOI 10.1007/s11259-005-0071-8
   WHO, 2017, 38 WHO, P16
NR 68
TC 0
Z9 0
U1 3
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP
PY 2019
VL 273
BP 80
EP 85
DI 10.1016/j.vetpar.2019.08.007
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JA1IK
UT WOS:000487570500013
PM 31446257
DA 2020-05-12
ER

PT J
AU Zynda, HM
   Scare, JA
   Steuer, AE
   Anderson, HP
   Nielsen, MK
AF Zynda, Haley M.
   Scare, Jessica A.
   Steuer, Ashley E.
   Anderson, Haley P.
   Nielsen, Martin K.
TI Encysted cyathostomin larval counts: Mucosal digestion revisited
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Cyathostomins; Mucosal digestion; Spatial variation
ID PONIES
AB Cyathostomins are pervasive equine parasites in horses across the world, and larval stages are known to cause the deadly disease larval cyathostominosis. The mucosal digestion technique is widely used for enumeration of encysted larval stages. Previous studies have investigated the spatial variation of encysted larvae, however current protocols lack a description of a standardized area from which to take the tissue sample. This study sought to evaluate spatial variation in encysted cyathostomin larval counts among the large intestinal organs and their subsections. Following humane euthanasia, ceca, ventral, and dorsal colons were harvested from 8 foals (aged 4-8 months) raised in an anthelmintic naive parasitology research herd. Each organ was weighed and separated into 3 equal sections by length: the orad, intermediate, and aborad portions. From each of those sections, two 5% weight tissue samples were collected and digested to quantify the early third stage larvae (EL3) and late third stage larvae/fourth stage larvae (LL3/L4). A mixed model statistical analysis was carried out to evaluate for differences of larval counts among the different organs, sections, and the interaction term between the organs and sections. There were significant differences among organs (P < 0.0001), with the ceca having higher counts than the ventral and dorsal colons. However, there were no significant differences among the three defined organ sections (P = 0.1076). Coefficients of variation (CV) were all calculated to be greater than 1, suggesting a high level of variability among the samples; the least amount of variation can be found in the cecal data with a CV of 1.4024 compared with the ventral colon's 1.529845 and dorsal colon's 3.339135 within the respective organ. The following sections had the highest mean counts of encysted larvae: intermediate cecum, orad ventral colon, and aborad dorsal colon. Though only a portion of the results were significant, trends were observed and these should be investigated further in future studies and potentially employed in larvicidal efficacy evaluations.
C1 [Zynda, Haley M.; Scare, Jessica A.; Steuer, Ashley E.; Anderson, Haley P.; Nielsen, Martin K.] Univ Kentucky, MH Gluck Equine Res Ctr, Dept Vet Sci, Lexington, KY USA.
RP Zynda, HM (reprint author), 56825 Oliver Ct, Shelby Twp, MI 48316 USA.
EM hmzy222@g.uky.edu
OI Nielsen, Martin/0000-0002-8942-6803
CR Chapman MR, 2003, J PARASITOL, V89, P309, DOI 10.1645/0022-3395(2003)089[0309:POSNIN]2.0.CO;2
   Chapman MR, 1999, VET PARASITOL, V86, P191, DOI 10.1016/S0304-4017(99)00144-2
   EYSKER M, 1984, RES VET SCI, V37, P355, DOI 10.1016/S0034-5288(18)31879-4
   Gibson T. E., 1953, Journal of Helminthology, V27, P29, DOI 10.1017/S0022149X00023488
   GILES CJ, 1985, EQUINE VET J, V17, P196, DOI 10.1111/j.2042-3306.1985.tb02469.x
   Leathwick DM, 2019, VET PARASITOL, V268, P53, DOI 10.1016/j.vetpar.2019.03.004
   Leathwick DM, 2015, VET PARASITOL, V209, P210, DOI 10.1016/j.vetpar.2015.02.031
   Love S, 1999, VET PARASITOL, V85, P113, DOI 10.1016/S0304-4017(99)00092-8
   Nielsen M. K, 2018, HDB EQUINE PARASITE
   Nielsen MK, 2017, VET PARASITOL, V236, P108, DOI 10.1016/j.vetpar.2017.02.013
   REID SWJ, 1995, EQUINE VET J, V27, P127, DOI 10.1111/j.2042-3306.1995.tb03048.x
   REINEMEYER CR, 1986, AM J VET RES, V47, P510
   REINEMEYER CR, 1986, AM J VET RES, V47, P507
   SMITH HJ, 1976, CAN J COMP MED, V40, P334
NR 14
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP
PY 2019
VL 273
BP 86
EP 89
DI 10.1016/j.vetpar.2019.08.009
PG 4
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JA1IK
UT WOS:000487570500014
PM 31449972
DA 2020-05-12
ER

PT J
AU Dickson, R
   Vose, J
   Bemis, D
   Daves, M
   Cecere, T
   Gookin, JL
   Steiner, J
   Tolbert, MK
AF Dickson, Rachel
   Vose, Julie
   Bemis, David
   Daves, Maggie
   Cecere, Thomas
   Gookin, Jody L.
   Steiner, Joerg
   Tolbert, M. Katherine
TI The effect of enterococci on feline Tritrichomonas foetus infection in
   vitro
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Cats; Enterococcus faecium; Enterococcus hirae; Probiotics
ID FAECIUM SF68; CATS; DIARRHEA; GIARDIA; DOGS
AB Tritrichomonas foetus is a common cause of large bowel diarrhea in cats. Probiotics have been suggested to be effective for many intestinal pathogens; however, there are a lack of studies evaluating the effect of probiotics in T. foetus infection. In vitro studies were performed to evaluate the effect of a probiotic containing Enterococcus faecium (Efm) SF68 and a novel probiotic, Enterococcus hirae, on the inhibition of T. foetus growth, adhesion to, and cytotoxicity towards the intestinal epithelium. The effect of enterococci on T. foetus proliferation during co-culture was evaluated throughout log phase T. foetus growth. The previously validated in vitro co-culture model system using porcine intestinal epithelial cells (IPEC-J2) was used to evaluate the effect of enterococci on T. foetus adhesion and cytotoxicity towards intestinal epithelial cells. Cytotoxicity was assessed using fluorescent microscopy and spectrophotometry. Interactions of T. foetus, enterococci, and intestinal epithelial cells were assessed using scanning electron microscopy and immunofluorescence assays (IFA). Enterococcus-induced inhibition of T. foetus growth was demonstrated at concentrations as low as 104 enterococci colony forming units (CFU)/mL and was dependent, in part, on environmental pH and the presence of viable enterococci organisms. T. foetus adhesion, including with a ronidazole-resistant strain, was reduced with pretreatment of intestinal epithelial cells with enterococci but was not significantly affected when enterococci were introduced simultaneously or following T. foetus infection. Compared to Efm, E. hirae more effectively decreased T. foetus adhesion, suggesting its superior potential as a novel probiotic for T. foetus infection. There was no effect of enterococci treatment on T. foetus-induced intestinal epithelial cell cytotoxicity. Our results support further study into the investigation of a possible benefit of enterococci-containing probiotic treatment for prevention of T. foetus infection in at-risk uninfected cats.
C1 [Dickson, Rachel; Vose, Julie; Bemis, David; Daves, Maggie] Univ Tennessee, Coll Vet Med, Dept Small Anim Clin Sci & Biomed & Diagnost Sci, Knoxville, TN USA.
   [Cecere, Thomas] Virginia Maryland Coll Vet Med, Dept Biomed Sci & Pathobiol, Blacksburg, VA USA.
   [Gookin, Jody L.] North Carolina State Univ, Dept Clin Sci, Raleigh, NC USA.
   [Steiner, Joerg; Tolbert, M. Katherine] Texas A&M Univ, Gastrointestinal Lab, College Stn, TX 77843 USA.
RP Tolbert, MK (reprint author), Texas A&M Univ, Gastrointestinal Lab, College Stn, TX 77843 USA.
EM ktolbert@cvm.tamu.edu
OI Gookin, Jody/0000-0002-2911-0874; Tolbert, M.
   Katherine/0000-0001-8725-9530
FU Winn Feline Foundation [W17-018]
FX This project was supported by the Winn Feline Foundation (Tolbert
   W17-018). The contents of this publication are solely the responsibility
   of the authors and do not necessarily represent the views of the Winn
   Foundation. This work was presented at the 2018 ACVIM Forum, Seattle,
   Washington. The authors thank Dr. Emily Gould for her technical
   assistance.
CR Antonio MAD, 1999, J INFECT DIS, V180, P1950, DOI 10.1086/315109
   Barman S, 2013, MICROBIOL IMMUNOL, V57, P762, DOI 10.1111/1348-0421.12095
   Benyacoub J, 2005, J NUTR, V135, P1171
   BOVARNICK MR, 1950, J BACTERIOL, V59, P509, DOI 10.1128/JB.59.4.509-522.1950
   Bybee SN, 2011, J VET INTERN MED, V25, P856, DOI 10.1111/j.1939-1676.2011.0738.x
   Carlin EP, 2006, VET THER, V7, P199
   Ekmekci H, 2009, MICROBIOL IMMUNOL, V53, P59, DOI 10.1111/j.1348-0421.2009.00115.x
   Foster DM, 2004, JAVMA-J AM VET MED A, V225, P888, DOI 10.2460/javma.2004.225.888
   Ghosh A, 2013, J CLIN MICROBIOL, V51, P3567, DOI 10.1128/JCM.00481-13
   Ghosh A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00062
   Gookin JL, 2010, J VET INTERN MED, V24, P1003, DOI 10.1111/j.1939-1676.2010.0534.x
   Gookin JL, 2006, J VET INTERN MED, V20, P536, DOI 10.1892/0891-6640(2006)20[536:EORFTO]2.0.CO;2
   Gould EN, 2017, VET PARASITOL, V244, P144, DOI 10.1016/j.vetpar.2017.08.001
   Lalor SL, 2012, J FELINE MED SURG, V14, P650
   Lippi I, 2018, CAN VET J, V58, P1301
   Litster A, 2009, VET MICROBIOL, V136, P130, DOI 10.1016/j.vetmic.2008.10.019
   Morin-Adeline V, 2015, EXP PARASITOL, V157, P68, DOI 10.1016/j.exppara.2015.06.017
   Phukan N, 2013, SEX TRANSM INFECT, V89, P455, DOI 10.1136/sextrans-2013-051039
   Ritchie LE, 2008, FEMS MICROBIOL ECOL, V66, P590, DOI 10.1111/j.1574-6941.2008.00609.x
   Rossi L, 2014, ARCH BUDO, V10
   Tang YR, 2014, CURR MICROBIOL, V69, P467, DOI 10.1007/s00284-014-0610-z
   Tolbert MK, 2014, INFECT IMMUN, V82, P2851, DOI 10.1128/IAI.01671-14
   Tolbert MK, 2013, VET PARASITOL, V192, P75, DOI 10.1016/j.vetpar.2012.10.019
NR 23
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP
PY 2019
VL 273
BP 90
EP 96
DI 10.1016/j.vetpar.2019.08.012
PG 7
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JA1IK
UT WOS:000487570500015
PM 31454711
DA 2020-05-12
ER

PT J
AU Orkun, O
AF Orkun, Omer
TI Molecular investigation of the natural transovarial transmission of
   tick-borne pathogens in Turkey
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Transovarial transmission; Tick-borne pathogens; Babesia occultans;
   Hyalomma excavatum; Rickettsia slovaca; Dermacentor marginatus
ID FEVER GROUP RICKETTSIAE; GENUS HYALOMMA KOCH; PHYLOGENETIC ANALYSIS;
   BABESIA-OVIS; BORRELIA-BURGDORFERI; IXODES-RICINUS; MARGINATUM; ACARI;
   AESCHLIMANNII; INFECTION
AB This study aimed to investigate the presence of the natural transovarial transmission of tick-borne pathogens in unfed larvae obtained from engorged female ticks from domestic animals in Turkey. Larvae (n = 4530, 151 pools) obtained from 75 engorged female ticks and female carcasses were screened for the presence of certain tick-borne pathogens by PCR. The presence of transovarial transmission of Babesia occultans was detected in Hyalomma marginatum and Hy. excavatum, while Ba. ovis in Rhipicephalus bursa. Theileria annulata was detected only in Hy. excavatum and Rh. turanicus female carcasses, but not in their examined progenies. Additionally, Rickettsia aeschlimannii and Rickettsia raoultii were detected in Hy. marginatum and Dermacentor marginatus females, respectively, and all their examined larvae. Besides, Ri. slovaca was detected in a De. marginatus female carcass and its one of two examined larvae pools. The presence of mixed Ba. occultans and RL aeschlimannii infection was also determined in an Hy. marginatum female and its larvae. This is the first demonstration of transovarial transmission of Ba. occultans in naturally infected Hy. excavatum. These data suggested that Hy. excavatum may act as vector in the natural cycle of Ba. occultans.
C1 [Orkun, Omer] Ankara Univ, Fac Vet Med, Dept Parasitol, TR-06110 Ankara, Turkey.
RP Orkun, O (reprint author), Ankara Univ, Fac Vet Med, Dept Parasitol, TR-06110 Ankara, Turkey.
EM omerorkun@yahoo.com.tr
RI Orkun, Omer/T-1900-2018
OI Orkun, Omer/0000-0002-4478-2521
CR Aktas M, 2014, VET PARASITOL, V204, P369, DOI 10.1016/j.vetpar.2014.05.037
   Altay K, 2008, RES VET SCI, V85, P116, DOI 10.1016/j.rvsc.2007.08.002
   Apanaskevich D. A., 2005, Acarina, V13, P181
   Apanaskevich DA, 2008, INT J ACAROL, V34, P13, DOI 10.1080/01647950808683704
   Apanaskevich Dmitry A., 2014, P59
   Beati L, 1997, INT J SYST BACTERIOL, V47, P548, DOI 10.1099/00207713-47-2-548
   BLACK WC, 1994, P NATL ACAD SCI USA, V91, P10034, DOI 10.1073/pnas.91.21.10034
   BURGDORFER W, 1975, ANN NY ACAD SCI, V266, P61, DOI 10.1111/j.1749-6632.1975.tb35088.x
   BURGDORFER W, 1967, ANNU REV ENTOMOL, V12, P347, DOI 10.1146/annurev.en.12.010167.002023
   BUSCHER G, 1988, PARASITOL RES, V74, P331, DOI 10.1007/BF00539454
   Casati S, 2006, ANN AGR ENV MED, V13, P65
   Chauvin A, 2009, VET RES, V40, DOI 10.1051/vetres/2009020
   Dantas-Torres F, 2012, TRENDS PARASITOL, V28, P437, DOI 10.1016/j.pt.2012.07.003
   de la Fuente J, 2007, VET MICROBIOL, V119, P375, DOI 10.1016/j.vetmic.2006.09.011
   Filippova NA, 1997, ARACHNOIDEA, P436
   Fournier PE, 1998, INT J SYST BACTERIOL, V48, P839, DOI 10.1099/00207713-48-3-839
   Gargili A, 2012, VECTOR-BORNE ZOONOT, V12, P938, DOI 10.1089/vbz.2012.0996
   GRAY JS, 1981, ONDERSTEPOORT J VET, V48, P215
   Hall AT, 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   Jongejan F, 2004, PARASITOLOGY, V129, pS3, DOI 10.1017/S0031182004005967
   JONGEJAN F, 1983, VET PARASITOL, V13, P121, DOI 10.1016/0304-4017(83)90071-7
   Kahl Olaf, 2002, P29, DOI 10.1079/9780851996325.0029
   Matsumoto K, 2004, EUR J CLIN MICROBIOL, V23, P732, DOI 10.1007/s10096-004-1190-9
   MEHLHORN H, 1984, ADV PARASIT, V23, P37, DOI 10.1016/S0065-308X(08)60285-7
   Midilli K, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-90
   Orkun O, 2015, THESIS, P336
   Orkun O, 2019, COMP IMMUNOL MICROB, V63, P58, DOI 10.1016/j.cimid.2018.12.007
   Orkun O, 2019, INFECT GENET EVOL, V69, P190, DOI 10.1016/j.meegid.2019.01.028
   Orkun O, 2016, VET PARASITOL, V228, P77, DOI 10.1016/j.vetpar.2016.08.013
   Orkun O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003067
   Orkun O, 2014, TICKS TICK-BORNE DIS, V5, P213, DOI 10.1016/j.ttbdis.2012.11.018
   Parola P, 2001, CLIN INFECT DIS, V32, P897, DOI 10.1086/319347
   Parola P, 2013, CLIN MICROBIOL REV, V26, P657, DOI 10.1128/CMR.00032-13
   Pfaffle M, 2013, INT J PARASITOL, V43, P1059, DOI 10.1016/j.ijpara.2013.06.009
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   POSTIC D, 1994, INT J SYST BACTERIOL, V44, P743, DOI 10.1099/00207713-44-4-743
   Rehaek J, 1984, ACTA SC NAT BRNO, V18, P1
   Rollend L, 2013, TICKS TICK-BORNE DIS, V4, P46, DOI 10.1016/j.ttbdis.2012.06.008
   Roux V, 1997, INT J SYST BACTERIOL, V47, P252, DOI 10.1099/00207713-47-2-252
   Salman M, 2013, TICKS AND TICK-BORNE DISEASES: GEOGRAPHICAL DISTRIBUTION AND CONTROL STRATEGIES IN THE EURO-ASIA REGION, pXVII
   Samoilenko IE, 2003, ANN NY ACAD SCI, V990, P612, DOI 10.1111/j.1749-6632.2003.tb07435.x
   Samoylenko I, 2009, CLIN MICROBIOL INFEC, V15, P305, DOI 10.1111/j.1469-0691.2008.02249.x
   Schnittger L, 2012, INFECT GENET EVOL, V12, P1788, DOI 10.1016/j.meegid.2012.07.004
   Sen E, 2011, TICKS TICK-BORNE DIS, V2, P94, DOI 10.1016/j.ttbdis.2011.03.004
   Sevinc F, 2013, VET PARASITOL, V191, P35, DOI 10.1016/j.vetpar.2012.07.025
   Silvestro D, 2012, ORG DIVERS EVOL, V12, P335, DOI 10.1007/s13127-011-0056-0
   Socolovschi C, 2009, VET RES, V40, DOI 10.1051/vetres/2009017
   Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033
   Turell Michael J., 2007, P143, DOI 10.1007/978-1-4020-6106-6_12
   Uilenberg G, 2006, VET PARASITOL, V138, P3, DOI 10.1016/j.vetpar.2006.01.035
   Walker B.J., 2000, GENUS RHIPICEPHALUS
NR 51
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP
PY 2019
VL 273
BP 97
EP 104
DI 10.1016/j.vetpar.2019.08.013
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JA1IK
UT WOS:000487570500016
PM 31473450
DA 2020-05-12
ER

PT J
AU El-Ashram, S
   Aboelhadid, SM
   Arafa, WM
   Gadelhaq, SM
   Abdel-Razik, ARH
AF El-Ashram, Saeed
   Aboelhadid, Shawky M.
   Arafa, Waleed M.
   Gadelhaq, Sahar M.
   Abdel-Razik, Abdel-Razik H.
TI Protective potential of diclazuril-treated oocysts against coccidiosis
   in layer chicks
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Eimeria spp.; Chickens; Diclazuril; Cytokines
ID INTESTINAL IMMUNE-RESPONSES; EIMERIA-TENELLA INFECTION; DEVELOPMENT
   IN-VITRO; ANTIGEN VACCINATION; ANTICOCCIDIAL DRUGS; MAXIMA INFECTION;
   INTERFERON-GAMMA; GENE-EXPRESSION; ACERVULINA; INHIBITION
AB Diclazuril, which is widely used for the prevention of coccidiosis in chickens, has a lethal effect on asexual and sexual stages of Eimeria spp. However, little is known about its effect on the exogenous stages of Eimeria spp. In this study, we evaluated the effect of in vitro treatment with 0.2% diclazuril on unsporulated and sporulated oocysts of Eimeria spp. For this purpose, a total of 180 male layer chicks aged one day were randomly divided into 5 experimental groups. Each group was divided into 3 replicates of 12 chicks each. Group 1 (G1) and Group 2 (G2) were negative (non-immunized and non-challenged) and positive (non-immunized and challenged) controls, respectively. Group 3 (G3) was immunized per os with 1.0 x 10(4) non-diclazuril treated-sporulated oocysts. Groups 4 (G4) was immunized per os with 0.2% diclazuril treated-unsporulated oocysts (1.0 x 10(4)) in which diclazzuril didn't affect sporulation. Group 5 (G5) was immunized per os with 0.2% diclazuril treated-sporulated oocysts (1.0 x 10(4)). Chicks of G2, G3, G4, and G5 were challenged with 7.5 x 10(4) untreated sporulated oocysts at the age of 21 days, while the group 1 chicks remained unchallenged. G4 and G5 animals immunized with 0.2% diclazuril-treated oocysts showed a significant decrease in bloody diarrhea severity, lesion scores, and oocyst counts in comparison to those immunized with untreated oocysts. Furthermore, histopathologic findings showed a low number of parasitic stages in cecal tissues in G4 and G5. A significant increased body weight gain was observed in Gs 4 and 5 in comparison to G2. In addition, expression levels of IL-2, IL-12, and IFN-gamma were significantly increased in G4 and G5. In conclusion, diclazuril is effective in attenuating Eimeria oocysts and thus provides an alternative approach for using diclazuril-treated oocysts to protect chicks against Eimeria challenge.
C1 [El-Ashram, Saeed] Foshan Univ, Coll Life Sci & Engn, 18 Jiangwan St, Foshan 528231, Guangdong, Peoples R China.
   [Aboelhadid, Shawky M.; Arafa, Waleed M.] Beni Suef Univ, Fac Vet Med, Dept Parasitol, Bani Suwayf 62511, Egypt.
   [Gadelhaq, Sahar M.] Menia Univ, Fac Vet Med, Dept Parasitol, El Minia, Egypt.
   [Abdel-Razik, Abdel-Razik H.] Beni Suef Univ, Fac Vet Med, Dept Histol, Bani Suwayf 62511, Egypt.
   [El-Ashram, Saeed] Kafrelsheikh Univ, Fac Sci, Kafr Al Sheikh 33516, Egypt.
RP El-Ashram, S (reprint author), Foshan Univ, Coll Life Sci & Engn, 18 Jiangwan St, Foshan 528231, Guangdong, Peoples R China.; Aboelhadid, SM (reprint author), Beni Suef Univ, Fac Vet Med, Dept Parasitol, Bani Suwayf 62511, Egypt.; El-Ashram, S (reprint author), Kafrelsheikh Univ, Fac Sci, Kafr Al Sheikh 33516, Egypt.
EM saeed_elashram@yahoo.com; drshawky2001@yahoo.com
OI Arafa, Waleed/0000-0002-9420-1764
FU Foshan University, Foshan city, Guangdong province [KLPREAD201801-02];
   School of Life Science and Engineering fund [KLPREAD201801-02];
   Guangdong Science and Technology Plan Project
FX This research was supported by the Start-up Research Grant Program
   provided by Foshan University, Foshan city, Guangdong provincefor
   distinguished researchers (Grant No: <GN1> KLPREAD201801-02), G </GN1>
   uangdong Science and Technology Plan Project and School of Life Science
   and Engineering fund (Grant No: KLPREAD201801-02). The authors
   appreciate the comments of Dr. Xianyong Liu, China Agricultural
   University.
CR Allen PC, 2002, CLIN MICROBIOL REV, V15, P58, DOI 10.1128/CMR.15.1.58-65.2002
   Balu S, 2011, VET IMMUNOL IMMUNOP, V140, P140, DOI 10.1016/j.vetimm.2010.11.009
   Bancroft JD, 2012, THEORY PRACTICE HIST
   Chapman HD, 2005, AVIAN PATHOL, V34, P279, DOI 10.1080/03079450500178378
   Chapman HD, 1997, AVIAN PATHOL, V26, P221, DOI 10.1080/03079459708419208
   Conway D. P., 2007, POULTRY COCCIDIOSIS, P164
   Conway DP, 2001, POULTRY SCI, V80, P426, DOI 10.1093/ps/80.4.426
   Dalloul RA, 2006, EXPERT REV VACCINES, V5, P143, DOI 10.1586/14760584.5.1.143
   Dimier IH, 1998, AVIAN DIS, V42, P239, DOI 10.2307/1592473
   Du A, 2004, J VET MED B, V51, P194, DOI 10.1111/j.1439-0450.2004.00749.x
   Dumetre A, 2013, P NATL ACAD SCI USA, V110, P11535, DOI 10.1073/pnas.1308425110
   Fetterer RH, 2014, AVIAN DIS, V58, P391, DOI 10.1637/10679-092613-Reg.1
   Gadelhaq Sahar M, 2017, VET PARASITOL, V15, P12, DOI [10.1016/j.vetpar.2017.12.020, DOI 10.1016/J.VETPAR.2017.12.020]
   Heriveau C, 2000, VET PARASITOL, V92, P37, DOI 10.1016/S0304-4017(00)00275-2
   Hong YH, 2006, VET IMMUNOL IMMUNOP, V114, P259, DOI 10.1016/j.vetimm.2006.08.006
   Hong YH, 2006, VET IMMUNOL IMMUNOP, V114, P209, DOI 10.1016/j.vetimm.2006.07.007
   Hong YH, 2006, DEV COMP IMMUNOL, V30, P919, DOI 10.1016/j.dci.2005.12.007
   Jang SI, 2010, VET PARASITOL, V172, P221, DOI 10.1016/j.vetpar.2010.04.042
   JOHNSON J, 1970, EXP PARASITOL, V28, P30, DOI 10.1016/0014-4894(70)90063-9
   Kaiser P, 2000, MICROBIOL-UK, V146, P3217, DOI 10.1099/00221287-146-12-3217
   KLASING KC, 1987, J NUTR, V117, P1629
   Laurent F, 2001, INFECT IMMUN, V69, P2527, DOI 10.1128/IAI.69.4.2527-2534.2001
   Li GQ, 2004, VET PARASITOL, V119, P261, DOI 10.1016/j.vetpar.2003.12.009
   Lillehoj HS, 1998, AVIAN DIS, V42, P307, DOI 10.2307/1592481
   Lillehoj HS, 2005, AVIAN DIS, V49, P112, DOI 10.1637/7249-073004R
   Lillehoj HS, 2004, POULTRY SCI, V83, P611, DOI 10.1093/ps/83.4.611
   LILLEHOJ HS, 1987, AVIAN DIS, V31, P112, DOI 10.2307/1590782
   Lin ZW, 2015, PARASITOL RES, V114, P3229, DOI 10.1007/s00436-015-4539-3
   Lowenthal JW, 1997, J INTERF CYTOK RES, V17, P551, DOI 10.1089/jir.1997.17.551
   Ma DX, 2011, EXP PARASITOL, V127, P208, DOI 10.1016/j.exppara.2010.07.015
   MAES L, 1991, POULTRY SCI, V70, P504, DOI 10.3382/ps.0700504
   McDougald L. R, 2003, COCCIDIOSIS DIS POUL, P1076
   McDougald LR, 1998, VET PARASITOL, V74, P91, DOI 10.1016/S0304-4017(97)00172-6
   Mortier L, 2005, J AGR FOOD CHEM, V53, P905, DOI 10.1021/jf048468z
   Ruff MD, 1996, P 20 WORLDS POULTR C, P427
   Ryley J F, 1980, Adv Vet Sci Comp Med, V24, P99
   Shirley MW, 2012, AVIAN PATHOL, V41, P111, DOI 10.1080/03079457.2012.666338
   Shirley MW, 2005, ADV PARASIT, V60, P285, DOI 10.1016/S0065-308X(05)60005-X
   VANPARIJS O, 1989, POULTRY SCI, V68, P489, DOI 10.3382/ps.0680489
   VERHEYEN A, 1988, J PARASITOL, V74, P939, DOI 10.2307/3282213
   VERHEYEN A, 1989, PARASITOL RES, V75, P604, DOI 10.1007/BF00930956
   Vermeulen A, 2001, VET PARASITOL, V100, P13, DOI 10.1016/S0304-4017(01)00479-4
   Vervelde L, 1996, PARASITE IMMUNOL, V18, P247, DOI 10.1046/j.1365-3024.1996.d01-94.x
   Yun CH, 2000, DEV COMP IMMUNOL, V24, P303, DOI 10.1016/S0145-305X(99)00080-4
   Zhang L, 2012, VET PARASITOL, V188, P239, DOI 10.1016/j.vetpar.2012.03.025
   Zhou BH, 2010, EXP PARASITOL, V125, P264, DOI 10.1016/j.exppara.2010.01.022
NR 46
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP
PY 2019
VL 273
BP 105
EP 111
DI 10.1016/j.vetpar.2019.08.010
PG 7
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JA1IK
UT WOS:000487570500017
PM 31473449
DA 2020-05-12
ER

PT J
AU Simon, JA
   Chancel, E
   Hubert, P
   Aubert, D
   Villena, I
   Gilot-Fromont, E
   Poulle, ML
AF Simon, Julie Alice
   Chancel, Eva
   Hubert, Pauline
   Aubert, Dominique
   Villena, Isabelle
   Gilot-Fromont, Emmanuelle
   Poulle, Marie-Lazarine
TI Pattern of latrine use by domestic cats on dairy farms and the
   implications for Toxoplasma gondii transmission
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Felis silvestris cams; Video trap; Cat faeces; Toxoplasmosis;
   Intermediate hosts
ID SPATIAL-DISTRIBUTION; PARASITIC ZOONOSES; DEFECATION SITES; CAMERA
   TRAPS; SWINE FARMS; HOME-RANGE; OOCYSTS; SEROPREVALENCE; WILDLIFE; SOIL
AB Toxoplasma gondii is the parasite responsible for toxoplasmosis, a highly prevalent zoonosis that affects humans and warm-blooded animals. Faeces of infected cats can contain millions of T. gondii oocysts, which remain infectious in the environment for months. Sites repeatedly used by cats for defecation (latrines') are recognised as hotspots of T. gondii soil contamination, but this contamination varies from one latrine to another. To understand this spatial heterogeneity, camera traps were deployed in 39 cat latrines on three dairy farms with high density cat populations and programmed to record visits during sixteen 10-day sessions, rotating between three farms over a period of a year. Generalized Linear Mixed Models were used to test the effects of cat sexual maturity, latrine location and season on the number of cat faeces deposited and on the number of cats defecating per latrine, as determined from the analysis of 41,282 video recordings. Sexually immature cats defecated 6.60 fold (95% CI = [2.87-15.25]) more often in latrines located close to a feeding site than in other latrines. This pattern was also observed for mature males (odds ratio [OR] = 9.42, 95% CI = [3.29-26.91]), especially during winter, but not for mature females (OR = 1.77, 95% CI = [0.80-3.94]). The number of defecating cats was also 2.67-fold (95% Cl = [1.66-4.30], P < 0.001) higher in latrines located close to a feeding point than in those located far from it, regardless of cat category and season. Visits by intermediate T. gondii hosts (micromammals, birds and others) were also recorded. Out of the 39 latrines, 30 (76.92%) were visited by at least one intermediate host during the study period, and some latrines were highly frequented (up to 8.74 visits/day on average). These results provide evidence that the location of food resources in dairy farms influences the latrine use pattern by cats. Highly frequented latrines can be of high risk of T. gondii infection for definitive and intermediate hosts.
C1 [Simon, Julie Alice; Aubert, Dominique; Villena, Isabelle; Poulle, Marie-Lazarine] Univ Reims, UFR Med, SFR Cap Sante, Lab Parasitol Mycol EA Escape 7510, 51 Rue Cognacg Jay, F-51095 Reims, France.
   [Simon, Julie Alice; Hubert, Pauline; Poulle, Marie-Lazarine] Univ Reims, CERFE, 5 Rue Heronniere, F-08240 Boult Aux Bois, France.
   [Chancel, Eva; Gilot-Fromont, Emmanuelle] VetAgro Sup, Campus Vet Lyon,1 Ave Bourgelat, F-69280 Marcy Letoile, France.
   [Hubert, Pauline] Faune Act, 6 Rue Jardin Gascon, F-08240 Boult Aux Bois, France.
   [Gilot-Fromont, Emmanuelle] Univ Claude Bernard Lyon 1, UMR CNRS Lab Biometrie & Biol Evolut 5558, 43 Bd 11 Novembre 1918, F-69622 Villeurbanne, France.
RP Simon, JA (reprint author), Univ Reims, UFR Med, SFR Cap Sante, Lab Parasitol Mycol EA Escape 7510, 51 Rue Cognacg Jay, F-51095 Reims, France.
EM julie.rabeisensimon@gmail.com; chancel_eva@hotmail.fr;
   pauline_hubert@hotmail.fr; daubert@chu-reims.fr; ivillena@chu-reims.fr;
   emmanuelle.gilotfromont@vetagro-sup.fr;
   marie-lazarine.poulle@univ-reims.fr
RI Aubert, dominique/AAH-5854-2019
OI Gilot-Fromont, Emmanuelle/0000-0003-0011-7519
FU Agence de l'Environnement et de la Maitrise de l'Energie (ADEME);
   Ministry of Higher Education, Research and Innovation, France
FX Part of this work was financially supported by the Agence de
   l'Environnement et de la Maitrise de l'Energie (ADEME) in the framework
   of the "L'animal, le Sol, l'Eau: Dynamique de la Contamination
   Environnementale par la toxoplasmose" project (AFSSET-ADEME, 2010-2014).
   Julie Alice Simon was also supported by a grant from the Ministry of
   Higher Education, Research and Innovation, France.
CR Afonso E, 2008, INT J PARASITOL, V38, P1017, DOI 10.1016/j.ijpara.2008.01.004
   Afonso Eve, 2013, International Journal for Parasitology Parasites and Wildlife, V2, P278, DOI 10.1016/j.ijppaw.2013.09.006
   Baneth G, 2016, J COMP PATHOL, V155, P54, DOI DOI 10.1016/J.JCPA.2015.10.179
   Barratt DG, 1997, ECOGRAPHY, V20, P271, DOI 10.1111/j.1600-0587.1997.tb00371.x
   Bastien M, 2018, FOLIA PARASIT, V65, DOI 10.14411/fp.2018.002
   Boyer K, 2011, CLIN INFECT DIS, V53, P1081, DOI 10.1093/cid/cir667
   Bradshaw J.W.S., 2012, BEHAV DOMESTIC CAT
   Buesching CD, 2016, ECOSPHERE, V7, DOI 10.1002/ecs2.1328
   Burnham KP, 2002, MODEL SELECTION MULT
   Conrad PA, 2005, INT J PARASITOL, V35, P1155, DOI 10.1016/j.ijpara.2005.07.002
   Courchamp F, 2000, WILDLIFE RES, V27, P603, DOI 10.1071/WR99049
   Dabritz HA, 2010, ZOONOSES PUBLIC HLTH, V57, P34, DOI 10.1111/j.1863-2378.2009.01273.x
   del Hoyo J., 1992, HDB BIRDS WORLD, V1-17
   Di Cerbo AR, 2008, HELMINTHOLOGIA, V45, P13, DOI 10.2478/s11687-008-0002-7
   Dubey JP, 2006, VET PARASITOL, V140, P69, DOI 10.1016/j.vetpar.2006.03.018
   Dubey J.P., 2010, TOXOPLASMOSIS ANIMAL
   DUBEY JP, 1995, J PARASITOL, V81, P723, DOI 10.2307/3283961
   Elizondo EC, 2016, WILDLIFE BIOL, V22, P246, DOI 10.2981/wlb.00237
   Ferreira JP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025970
   Forin-Wiart MA, 2014, EUR J WILDLIFE RES, V60, P665, DOI 10.1007/s10344-014-0833-0
   Gauss CBL, 2003, J PARASITOL, V89, P1067, DOI 10.1645/GE-114
   Germain E, 2008, J ZOOL, V276, P195, DOI 10.1111/j.1469-7998.2008.00479.x
   Gilot-Fromont E, 2009, VET PARASITOL, V161, P36, DOI 10.1016/j.vetpar.2008.12.004
   Gilot-Fromont E, 2012, TOXOPLASMOSIS RECENT, P1
   Glen AS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067940
   Goszczynski J, 2009, FOLIA ZOOL, V58, P363
   Gotteland C, 2014, INT J HEALTH GEOGR, P13
   Gotteland C, 2014, VET PARASITOL, V205, P629, DOI 10.1016/j.vetpar.2014.08.003
   Guislain MH, 2007, PARASITE, V14, P299, DOI 10.1051/parasite/2007144299
   Herrmann DC, 2010, INT J PARASITOL, V40, P285, DOI 10.1016/j.ijpara.2009.08.001
   Hill D, 2002, CLIN MICROBIOL INFEC, V8, P634, DOI 10.1046/j.1469-0691.2002.00485.x
   Horn JA, 2011, J WILDLIFE MANAGE, V75, P1177, DOI 10.1002/jwmg.145
   Ishida Y, 1998, J ETHOL, V16, P15, DOI 10.1007/BF02896349
   IZAWA M, 1982, Japanese Journal of Ecology, V32, P373
   Jordan NR, 2007, ANIM BEHAV, V73, P613, DOI 10.1016/j.anbehav.2006.06.010
   Kitts-Morgan SE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120513
   Knapp J, 2018, INT J PARASITOL, V48, P937, DOI [10.1016/j.ijpara.2018.05.007, 10.1016/j.ijpara.2018.]
   Krauze-Gryz D, 2017, URBAN ECOSYST, V20, P945, DOI 10.1007/s11252-016-0634-1
   Kukielka E, 2013, PREV VET MED, V112, P213, DOI 10.1016/j.prevetmed.2013.08.008
   Lehmann T, 2003, INFECT GENET EVOL, V3, P135, DOI 10.1016/S1567-1348(03)00067-4
   Lelu M, 2012, APPL ENVIRON MICROB, V78, P5127, DOI 10.1128/AEM.00246-12
   LIBERG O, 1982, ACTA THERIOL, V27, P115, DOI 10.4098/AT.arch.82-9
   Liberg Olof, 2000, P119
   Lindsay DS, 2009, J PARASITOL, V95, P1019, DOI 10.1645/GE-1919.1
   Macdonald D.W., 1985, P619
   Macdonald David W., 2000, P95
   Meek P, 2016, ECOL EVOL, V6, P3216, DOI 10.1002/ece3.2111
   Milkovic M, 2009, AREA, V41, P310, DOI 10.1111/j.1475-4762.2008.00865.x
   Munoz-Zanzi CA, 2010, EMERG INFECT DIS, V16, P1591, DOI 10.3201/eid1610.091674
   Page LK, 2009, EMERG INFECT DIS, V15, P1530, DOI 10.3201/eid1509.090128
   Page LK, 1998, AM MIDL NAT, V140, P180, DOI 10.1674/0003-0031(1998)140[0180:RLSAIP]2.0.CO;2
   Polley L, 2005, INT J PARASITOL, V35, P1279, DOI 10.1016/j.ijpara.2005.07.003
   [R-Core-Team Computing R.F. f.S], 2014, R LANG ENV STAT COMP
   Raoul F, 2015, VET PARASITOL, V213, P162, DOI 10.1016/j.vetpar.2015.07.034
   Richomme C, 2010, EPIDEMIOL INFECT, V138, P1257, DOI 10.1017/S0950268810000117
   Robertson ID, 2002, MICROBES INFECT, V4, P867, DOI 10.1016/S1286-4579(02)01607-6
   Rodgers TW, 2015, MAMM BIOL, V80, P380, DOI 10.1016/j.mambio.2015.05.004
   Rovero Francesco, 2010, Abc Taxa, V8, P100
   Say L, 1999, P ROY SOC B-BIOL SCI, V266, P2071, DOI 10.1098/rspb.1999.0889
   Schares G, 2016, INT J PARASITOL, V46, P263, DOI 10.1016/j.ijpara.2015.12.006
   Simon JA, 2017, INT J PARASITOL, V47, P357, DOI 10.1016/j.ijpara.2017.01.004
   Simon JA, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2834-4
   Soler Lucía, 2009, Mastozool. neotrop., V16, P485
   Tenter AM, 2000, INT J PARASITOL, V30, P1217, DOI 10.1016/S0020-7519(00)00124-7
   Traversa D, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-67
   Trolliet F, 2014, BIOTECHNOL AGRON SOC, V18, P446
   Turner DC, 2013, DOMESTIC CAT BIOL IT
   VanWormer E, 2013, COMP IMMUNOL MICROB, V36, P217, DOI 10.1016/j.cimid.2012.10.006
   WEIGEL RM, 1995, J PARASITOL, V81, P736, DOI 10.2307/3283964
   Zuur Alain F., 2009, P1
NR 70
TC 0
Z9 0
U1 4
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD SEP
PY 2019
VL 273
BP 112
EP 121
DI 10.1016/j.vetpar.2019.08.001
PG 10
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JA1IK
UT WOS:000487570500018
PM 31476666
DA 2020-05-12
ER

PT J
AU Thysen, SM
   Byberg, S
   Martins, JSD
   Kallestrup, P
   Griffiths, UK
   Fisker, AB
AF Thysen, Sanne M.
   Byberg, Stine
   Martins, Justiniano S. D.
   Kallestrup, Per
   Griffiths, Ulla K.
   Fisker, Ane B.
TI Household costs of seeking BCG vaccination in rural Guinea-Bissau
SO VACCINE
LA English
DT Article
DE BCG vaccination; Household cost; Vaccination cost
AB In Guinea-Bissau, a vial of BCG vaccine is often not opened unless 10 infants are present for vaccination, with the aim of reducing vaccine wastage. This causes delays in vaccination, as previously demonstrated in Guinea-Bissau and other low-income countries. Reducing wastage of BCG vaccine to save money may deprive infants of important health benefits and transfer costs from the vaccination programme to mothers.
   Using the Bandim Health Project's rural Health and Demographic Surveillance System, we interviewed mothers of infants aged 1-11 months about household costs of seeking BCG vaccination.
   On average mothers took their infant for BCG vaccination 1.26 times before obtaining the vaccine. For mothers who had sought BCG vaccine for their infants the average cost was 1.89 USD for each BCG-vaccinated infant. Among BCG-unvaccinated infants at the time of interview, 42% had brought their infant for BCG vaccination in vain at an average cost of 2.83 USD. (C) 2019 Published by Elsevier Ltd.
C1 [Thysen, Sanne M.; Fisker, Ane B.] Univ Southern Denmark, Inst Clin Res, OPEN, Odense, Denmark.
   [Thysen, Sanne M.; Byberg, Stine; Martins, Justiniano S. D.; Fisker, Ane B.] Bandim Hlth Project, Bissau, Guinea Bissau.
   [Thysen, Sanne M.; Byberg, Stine; Fisker, Ane B.] Statens Serum Inst, Bandim Hlth Project, Res Ctr Vitamins & Vaccines, Copenhagen, Denmark.
   [Kallestrup, Per] Aarhus Univ, Ctr Global Hlth GIoHAU, Aarhus, Denmark.
   [Griffiths, Ulla K.] UNICEF, Hlth Sect, Programme Div, New York, NY USA.
RP Thysen, SM (reprint author), Univ Southern Denmark, Inst Clin Res, OPEN, Odense, Denmark.
EM s.thysen@bandim.org
RI ; Fisker, Ane/E-9283-2019
OI Thysen, Sanne Marie/0000-0003-4541-3901; Fisker,
   Ane/0000-0002-8521-0992; Kallestrup, Per/0000-0001-6041-4510; Byberg,
   Stine/0000-0002-3626-3609
FU European UnionEuropean Union (EU) [Health-F3-2011-261375]; Augustinus
   Foundation; Danish National Research Foundation via Research Center for
   Vitamins and Vaccines [DNRF108]
FX This work was supported by European Union FP7 support for OPTIMUNISE
   [Health-F3-2011-261375], and by the Augustinus Foundation. The Bandim
   Health Project received support from the Danish National Research
   Foundation via Research Center for Vitamins and Vaccines [DNRF108]. The
   sponsors had no role in designing the study, the data collection, data
   analysis, data interpretation or writing the paper.
CR [Anonymous], 2018, Wkly Epidemiol Rec, V93, P73
   Biering-Sorensen S, 2017, CLIN INFECT DIS, V65, P1183, DOI 10.1093/cid/cix525
   Byberg S, 2017, TROP MED INT HEALTH, V22, P12, DOI 10.1111/tmi.12793
   Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170
   Kagone M, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5244-9
   Kagone M, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1399749
   Knight GM, 2014, P NATL ACAD SCI USA, V111, P15520, DOI 10.1073/pnas.1404386111
   Ministere de la sante publique Republique la Guinee-Bissau, 2013, PLAN PLUR COMPL PROG
   Scott S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107280
   Thysen SM, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1037
   Unicef, SUPPL LOG VACC PRIC
   VanderEnde K, 2018, MMWR-MORBID MORTAL W, V67, P1261, DOI 10.15585/mmwr.mm6745a2
   World Bank, 2018, WORLD BANK DAT CONS
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 3
PY 2019
VL 37
IS 37
BP 5505
EP 5508
DI 10.1016/j.vaccine.2019.08.004
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IW7ZL
UT WOS:000485212400001
PM 31405635
DA 2020-05-12
ER

PT J
AU Guo, A
   Lindley, MC
   Hurley, LP
   Allen, JA
   Allison, MA
   O'Leary, ST
   Crane, LA
   Brtnikova, M
   Beaty, BL
   Kempe, A
   Dooling, KL
AF Guo, Angela
   Lindley, Megan C.
   Hurley, Laura P.
   Allen, Jessica A.
   Allison, Mandy A.
   O'Leary, Sean T.
   Crane, Lori A.
   Brtnikova, Michaela
   Beaty, Brenda L.
   Kempe, Allison
   Dooling, Kathleen L.
TI Ten years of experience with herpes zoster vaccine in primary care- how
   attitudes and practices have changed and what it may mean for a new
   zoster vaccine
SO VACCINE
LA English
DT Article
DE Herpes zoster; Vaccination; Primary care
ID IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; SUBUNIT VACCINE;
   RECOMMENDATIONS; PHYSICIANS; EFFICACY
AB Zoster vaccine live (ZVL [Zostavax]) has been recommended for the prevention of herpes zoster (HZ) among immunocompetent adults >= 60 years in the United States since 2008. To examine changes in healthcare providers' perceptions and practices related to HZ disease and vaccination, we administered surveys to national networks of primary care physicians in 2005, 2008, and 2016. Ten years after ZVL was first licensed, physicians were more likely to respond that they perceived HZ as a serious disease and more strongly recommended ZVL, and were less likely to report less likely to report several major barriers to HZ vaccination such as patient cost, vaccine effectiveness and competing medical concerns. Overall, physician attitudes appear to be more favorable towards zoster vaccination after a decade of availability of a HZ vaccine. The new recombinant zoster vaccine (RZV [Shingrix]) may benefit from physician's increased perception of the importance of HZ and HZ vaccination. Published by Elsevier Ltd.
C1 [Guo, Angela; Lindley, Megan C.; Dooling, Kathleen L.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd, Atlanta, GA 30333 USA.
   [Hurley, Laura P.; Allison, Mandy A.; Crane, Lori A.; Brtnikova, Michaela; Beaty, Brenda L.; Kempe, Allison] Univ Colorado, Adult & Child Consortium Hlth Outcomes Res & Deli, Anschutz Med Campus,13001 E 17th Pl, Aurora, CO USA.
   [Hurley, Laura P.; Allison, Mandy A.; Crane, Lori A.; Brtnikova, Michaela; Beaty, Brenda L.; Kempe, Allison] Childrens Hosp Colorado, 13001 E 17th Pl, Aurora, CO USA.
   [Hurley, Laura P.] Div Gen Internal Med, 777 Bannock St, Denver, CO 80204 USA.
   [Allen, Jessica A.] Ctr Dis Control & Prevent, Off Associate Director Commun, 1600 Clifton Rd, Atlanta, GA 30333 USA.
   [Allison, Mandy A.; O'Leary, Sean T.; Brtnikova, Michaela; Kempe, Allison] Univ Colorado, Colorado Sch Publ Hlth, Dept Pediat, Anschutz Med Campus,13001 E 17th Pl, Aurora, CO USA.
   [Crane, Lori A.] Univ Colorado, Colorado Sch Publ Hlth, Dept Community & Behav Hlth, Anschutz Med Campus,13001 E 17th Pl, Aurora, CO USA.
RP Guo, A (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop H24-5,Bldg 24, Atlanta, GA 30333 USA.
EM ndv1@cdc.gov
FU Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA [1
   U01 IP000849-02]
FX This publication was supported by Cooperative Agreement Number 1 U01
   IP000849-02, funded by the Centers for Disease Control and Prevention.
   Its contents are solely the responsibility of the authors and do not
   necessarily represent the official views of the Centers for Disease
   Control and Prevention or the Department of Health and Human Services.
CR Advisory Committee on Immunization Practices, 2017, GRAD REC ASS DEV EV
   Cunningham AL, 2016, NEW ENGL J MED, V375, P1019, DOI 10.1056/NEJMoa1603800
   Dooling KL, 2018, MMWR-MORBID MORTAL W, V67, P103, DOI 10.15585/mmwr.mm6703a5
   Glanz K, 2008, HLTH BEHAV HLTH ED T
   Harpaz R, 2015, OPEN FORUM INFECT S1, V2, P1052
   Harpaz Rafael, 2007, Morbidity and Mortality Weekly Report, V57, P1
   Hung MC, 2016, VACCINATION COVERAGE
   Hurley LP, 2008, J INFECT DIS, V197, pS216, DOI 10.1086/522153
   Hurley LP, 2018, VACCINE, V36, P7408, DOI 10.1016/j.vaccine.2018.09.018
   Hurley LP, 2010, ANN INTERN MED, V152, P555, DOI 10.7326/0003-4819-152-9-201005040-00005
   Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184
   Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016
   Umansky D, CONSUMER REPORTS
   Weaver KK, PHARMACIST ADM IMMUN
NR 14
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 3
PY 2019
VL 37
IS 37
BP 5509
EP 5512
DI 10.1016/j.vaccine.2019.08.002
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IW7ZL
UT WOS:000485212400002
PM 31400911
OA Bronze
DA 2020-05-12
ER

PT J
AU Pollock, KG
   Wallace, LA
   Wrigglesworth, S
   McMaster, D
   Steedman, N
AF Pollock, K. G.
   Wallace, L. A.
   Wrigglesworth, S.
   McMaster, D.
   Steedman, N.
TI HPV vaccine uptake in men who have sex with men in Scotland
SO VACCINE
LA English
DT Article
DE MSM; HPV; Vaccine; Sexual health
ID CANCER
AB Human papillomavirus (HPV) vaccines are currently utilised globally in national immunisation programmes. In July 2017, a national HPV vaccine programme for men who have sex with men (MSM) was initiated across Scotland with vaccine being offered in the sexual health clinic setting. During the first year of this targeted vaccination programme, there were 5905 individuals who received at least one dose of HPV vaccine, representing 63.7% of eligible MSM attendees in this period. Vaccine uptake was relatively stable across all age groups (range 49.8-55.5%). The vaccination programme appears to have dovetailed well with pre-existing sexual health services and appears to be popular with MSM attending the service. The MSM HPV vaccine programme is a robust adjunct to the national girls programme but gender-neutral immunisation will reduce stigma and inequality in HPV-driven disease. Crown Copyright (C) 2018 Published by Elsevier Ltd. All rights reserved.
C1 [Pollock, K. G.; Wallace, L. A.] Glasgow Caledonian Univ, Sch Hlth & Life Sci, Cowcaddens Rd, Glasgow, Lanark, Scotland.
   [Wrigglesworth, S.; McMaster, D.; Steedman, N.] Informat Serv Div, Gyle Sq, Edinburgh, Midlothian, Scotland.
   [Steedman, N.] Scottish Govt, Edinburgh, Midlothian, Scotland.
   [Pollock, K. G.] Meridian Court, Hlth Protect Scotland, Cadogan St, Glasgow, Lanark, Scotland.
RP Pollock, KG (reprint author), Glasgow Caledonian Univ, Sch Hlth & Life Sci, Cowcaddens Rd, Glasgow, Lanark, Scotland.
EM Kevin.pollock@gcu.ac.uk
CR [Anonymous], 2017, CHIEF MED OFFER DIRE
   [Anonymous], 2015, JOINT COMMITTEE VACC
   Cameron RL, 2018, STD
   Chaturvedi AK, 2013, J CLIN ONCOL, V31, P4550, DOI 10.1200/JCO.2013.50.3870
   Kavanagh K, 2017, LANCET INFECT DIS, V17, P1293, DOI 10.1016/S1473-3099(17)30468-1
   Knapper C, 2018, INT J STD AIDS, V29, P1106, DOI 10.1177/0956462418775510
   Lin CQ, 2018, LANCET INFECT DIS, V18, P198, DOI [10.1016/S1473-3099(17)30653-9, 10.1016/s1473-3099(17)30653-9]
   Piketty C, 2012, J CLIN ONCOL, V30, P4360, DOI 10.1200/JCO.2012.44.5486
   Sinka K, 2014, J EPIDEMIOL COMMUN H, V68, P57, DOI 10.1136/jech-2013-202620
NR 9
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 3
PY 2019
VL 37
IS 37
BP 5513
EP 5514
DI 10.1016/j.vaccine.2018.11.081
PG 2
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IW7ZL
UT WOS:000485212400003
PM 30545714
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Paton, DJ
   Reeve, R
   Capozzo, AV
   Ludi, A
AF Paton, D. J.
   Reeve, R.
   Capozzo, A. V.
   Ludi, A.
TI Estimating the protection afforded by foot-and-mouth disease vaccines in
   the laboratory
SO VACCINE
LA English
DT Review
DE FMD; Vaccine; Selection; Serology; Protection; Quality control
ID IMMUNE-RESPONSE; VIRUS SEROTYPE; HETEROLOGOUS CHALLENGE;
   ANTIBODY-RESPONSE; ANTIGENIC SITES; INFORMAL CONSULTATION;
   HERD-IMMUNITY; LIQUID-PHASE; FIELD VIRUS; POTENCY
AB Foot-and-mouth disease (FMD) vaccines must be carefully selected and their application closely monitored to optimise their effectiveness. This review covers serological techniques for FMD vaccine quality control, including potency testing, vaccine matching and post-vaccination monitoring. It also discusses alternative laboratory procedures, such as antigen quantification and nucleotide sequencing, and briefly compares the approaches for FMD with those for measuring protection against influenza virus, where humoral immunity is also important. Serology is widely used to predict the protection afforded by vaccines and has great practical utility but also limitations. Animals differ in their responses to vaccines and in the protective mechanisms that they develop. Antibodies have a variety of properties and tests differ in what they measure. Antibody-virus interactions may vary between virus serotypes and strains and protection may be affected by the vaccination regime and the nature and timing of field virus challenge. Finally, tests employing biological reagents are difficult to standardise, whilst cross-protection data needed for test calibration and validation are scarce. All of this is difficult to reconcile with the desire for simple and universal criteria and thresholds for evaluating vaccines and vaccination responses and means that oversimplification of test procedures and their interpretation can lead to poor predictions. A holistic approach is therefore recommended, considering multiple sources of field, experimental and laboratory data. New antibody avidity and isotype tests seem promising alternatives to evaluate cross-protective, post-vaccination serological responses, taking account of vaccine potency as well as match. After choosing appropriate serological tests or test combinations and cut-offs, results should be interpreted cautiously and in context. Since opportunities for experimental challenge studies of cross-protection are limited and the approaches incompletely reflect real life, more field studies are needed to quantify cross-protection and its correlation to in vitro measurements. (C) 2019 Published by Elsevier Ltd.
C1 [Paton, D. J.; Ludi, A.] Pirbright Inst, Ash Rd, Surrey GU24 0NF, England.
   [Reeve, R.] Univ Glasgow, Boyd Orr Ctr Populat & Ecosystem Hlth, Inst Biodivers Anim Hlth & Comparat Med, Coll Med Vet & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.
   [Capozzo, A. V.] INTA, CICVyA, Inst Virol, N Repetto & Reseros S-N, RA-1686 Hurlingham, Buenos Aires, Argentina.
   [Capozzo, A. V.] Consejo Nacl Invest Cient & Tecn, Consejo Nacl Invest Cient & Tecn, Godoy Cruz 2290,C1454FQB, Buenos Aires, DF, Argentina.
RP Paton, DJ (reprint author), Pirbright Inst, Ash Rd, Surrey GU24 0NF, England.
EM david.paton@pirbright.ac.uk
RI Reeve, Richard/K-9918-2015; , Alejandra/C-2848-2019
OI Reeve, Richard/0000-0003-2589-8091; , Alejandra/0000-0002-7117-9955
FU European Commission for the Control of FMD (EuFMD); UK Department of
   food and rural affairs [5E1129]; Biotechnology and Biological Sciences
   Research CouncilBiotechnology and Biological Sciences Research Council
   (BBSRC) [BBS/E/I/00007035, BB/R012679/1]; National Research Council of
   Argentina (CONICET, AC)
FX This review was a deliverable of a fund for applied research (FAR) from
   the European Commission for the Control of FMD (EuFMD). Work at the
   Pirbright Institute was supported by the UK Department of food and rural
   affairs (Grant 5E1129) and the Biotechnology and Biological Sciences
   Research Council (Grant BBS/E/I/00007035). Richard Reeve was funded by
   the Biotechnology and Biological Sciences Research Council (Grant
   BB/R012679/1) and Alejandra Capozzo by the National Research Council of
   Argentina (CONICET, AC).
CR Alan H, 2017, VACCINE, V35, P1104, DOI 10.1016/j.vaccine.2017.01.018
   Ampofo WK, 2015, VACCINE, V33, P4368, DOI 10.1016/j.vaccine.2015.06.090
   Lavoria MA, 2012, VACCINE, V30, P6845, DOI 10.1016/j.vaccine.2012.09.011
   [Anonymous], 2007, Wkly Epidemiol Rec, V82, P425
   ARROWSMITH AEM, 1975, J HYG-CAMBRIDGE, V75, P387, DOI 10.1017/S0022172400024451
   Bachanek-Bankowska K, 2018, EMERG INFECT DIS, V24, P1073, DOI 10.3201/eid2406.170715
   Bari FD, 2015, J GEN VIROL, V96, P1033, DOI 10.1099/vir.0.000051
   Barnett PV, 2003, VACCINE, V21, P3240, DOI 10.1016/S0264-410X(03)00219-6
   Barrionuevo F, 2018, VIROLOGY, V518, P143, DOI 10.1016/j.virol.2018.02.012
   BARTELING SJ, 1974, ARCH GES VIRUSFORSCH, V45, P362, DOI 10.1007/BF01242879
   Borley DW, 2012, THESIS
   Brehm KE, 2008, VACCINE, V26, P1681, DOI 10.1016/j.vaccine.2008.01.038
   Brito BP, 2017, TRANSBOUND EMERG DIS, V64, P316, DOI 10.1111/tbed.12373
   BROOKSBY JB, 1982, INTERVIROLOGY, V18, P1, DOI 10.1159/000149299
   Capozzo AVE, 1997, VACCINE, V15, P624, DOI 10.1016/S0264-410X(96)00284-8
   Casey-Bryars M, 2018, NAT ECOL EVOL, V2, P1449, DOI 10.1038/s41559-018-0636-x
   Chabaud-Riou M, 2017, BIOLOGICALS, V46, P124, DOI 10.1016/j.biologicals.2017.02.002
   Clavijo A, 2004, VET J, V167, P9, DOI 10.1016/S1090-0233(03)00087-X
   Cox SJ, 2003, VACCINE, V21, P1336, DOI 10.1016/S0264-410X(02)00691-6
   CUNLIFFE HR, 1964, CORNELL VET, V54, P501
   Davies V, 2019, J R STAT SOC C-APPL, V68, P859, DOI 10.1111/rssc.12338
   Davies V, 2017, COMPUTATION STAT, V32, P803, DOI 10.1007/s00180-017-0730-6
   Di Giacomo S, 2015, TRANSBOUND EMERG DIS, V62, P280, DOI 10.1111/tbed.12130
   Diaz-San Segundo F, 2017, VET MICROBIOL, V206, P102, DOI 10.1016/j.vetmic.2016.12.018
   Doel TR, 2005, CURR TOP MICROBIOL, V288, P103
   Doel TR, 1999, VACCINE, V17, P1767, DOI 10.1016/S0264-410X(98)00444-7
   Duque H, 2016, VACCINE, V34, P4140, DOI 10.1016/j.vaccine.2016.06.073
   Feng X, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149569
   Ferrari G, FOOT MOUTH DIS VACCI
   Fry EE, 1999, EMBO J, V18, P543, DOI 10.1093/emboj/18.3.543
   Goris N, 2008, VACCINE, V26, P3432, DOI 10.1016/j.vaccine.2008.04.034
   Harvey WT, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005526
   Jamala SM, 2008, VACCINE, V26, P6317, DOI 10.1016/j.vaccine.2008.09.021
   Kang YL, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1686-7
   Kim T, 2019, VACCINE, V37, P1702, DOI 10.1016/j.vaccine.2018.11.080
   Knight-Jones TJD, 2014, VACCINE, V32, P1848, DOI 10.1016/j.vaccine.2014.01.071
   Kotecha A, 2016, J GEN VIROL, V97, P1557, DOI 10.1099/jgv.0.000462
   Lombard M, 2007, REV SCI TECH OIE, V26, P117, DOI 10.20506/rst.26.1.1733
   Ludi AB, 2014, J GEN VIROL, V95, P384, DOI 10.1099/vir.0.057521-0
   Luksza M, 2014, NATURE, V507, P57, DOI 10.1038/nature13087
   Lyons NA, 2016, FRONT VET SCI, V3, DOI 10.3389/fvets.2016.00102
   Mahapatra M, 2012, J GEN VIROL, V93, P488, DOI 10.1099/vir.0.037952-0
   Mahapatra M, 2018, EXPERT REV VACCINES, V17, P577, DOI 10.1080/14760584.2018.1492378
   Maradei E, 2014, VACCINE, V32, P2446, DOI 10.1016/j.vaccine.2014.02.092
   Maradei E, 2008, VACCINE, V26, P6577, DOI 10.1016/j.vaccine.2008.09.033
   Maree FF, 2011, J GEN VIROL, V92, P2297, DOI 10.1099/vir.0.032839-0
   Mattion N, 2004, VACCINE, V22, P4149, DOI 10.1016/j.vaccine.2004.06.040
   Mattion N, 2009, VACCINE, V27, P741, DOI 10.1016/j.vaccine.2008.11.026
   MCCULLOUGH KC, 1992, J VIROL, V66, P1835, DOI 10.1128/JVI.66.4.1835-1840.1992
   Mohapatra JK, 2018, VACCINE, V36, P3191, DOI 10.1016/j.vaccine.2018.04.090
   Moore SM, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000595
   Nagendrakumar SB, 2011, VACCINE, V29, P1906, DOI 10.1016/j.vaccine.2010.12.127
   Oh Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044365
   OIE, 2018, MAN DIAGN TESTS VACC, P433
   Paton DJ, 2009, PHILOS T R SOC B, V364, P2657, DOI 10.1098/rstb.2009.0100
   Paton DJ, 2005, REV SCI TECH OIE, V24, P981, DOI 10.20506/rst.24.3.1632
   Brito BP, 2014, VACCINE, V32, P433, DOI 10.1016/j.vaccine.2013.12.007
   PAY TWF, 1992, VACCINE, V10, P699, DOI 10.1016/0264-410X(92)90092-X
   Pay TWF, 1977, DEV BIOL STAND, V35, P369
   PAY TWF, 1984, APPL VIROLOGY, P73
   Reeve R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159360
   Reeve R, 2011, VACCINE, V29, P5467, DOI 10.1016/j.vaccine.2011.05.056
   Reeve R, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1001027
   Robinson L, 2016, TRANSBOUND EMERG DIS, V63, P56, DOI 10.1111/tbed.12518
   Robiolo B, 2006, VACCINE, V24, P997, DOI 10.1016/j.vaccine.2005.08.071
   Robiolo B, 2010, VACCINE, V28, P6235, DOI 10.1016/j.vaccine.2010.07.012
   RWEYEMAMU MM, 1984, J BIOL STAND, V12, P323, DOI 10.1016/S0092-1157(84)80013-X
   Schiffelers MJ, 2014, BIOLOGICALS, V42, P205, DOI 10.1016/j.biologicals.2014.04.001
   Sharma GK, 2017, TRANSBOUND EMERG DIS, V64, P1133, DOI 10.1111/tbed.12478
   Smith DJ, 2004, SCIENCE, V305, P371, DOI 10.1126/science.1097211
   Smitsaart EN, 1998, PREV VET MED, V33, P283, DOI 10.1016/S0167-5877(97)00014-7
   Spitteler MA, 2011, VACCINE, V29, P7182, DOI 10.1016/j.vaccine.2011.05.078
   Stenfeldt C, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00493-18
   Sucafusco D, 2014, VACCINE, V32, P6576, DOI 10.1016/j.vaccine.2014.06.056
   Szczepanek SM, 2012, CLIN VACCINE IMMUNOL, V19, P461, DOI 10.1128/CVI.00035-12
   Tekleghiorghis T, 2014, CLIN VACCINE IMMUNOL, V21, P674, DOI 10.1128/CVI.00034-14
   TERPSTRA C, 1990, RES VET SCI, V49, P236, DOI 10.1016/S0034-5288(18)31084-1
   Tosh PK, 2010, MAYO CLIN PROC, V85, P257, DOI 10.4065/mcp.2009.0615
   Valarcher JF, 2009, EMERG INFECT DIS, V15, P1046, DOI 10.3201/eid1507.081621
   VANMAANEN C, 1990, BIOLOGICALS, V18, P315, DOI 10.1016/1045-1056(90)90036-Y
   Wang P, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02500
   Ward BJ, 2018, HUM VACC IMMUNOTHER, V14, P647, DOI 10.1080/21645515.2017.1413518
   Waters R, 2018, VACCINE, V36, P1901, DOI 10.1016/j.vaccine.2018.02.016
   Willems T, 2012, VACCINE, V30, P5849, DOI 10.1016/j.vaccine.2012.07.015
NR 84
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 3
PY 2019
VL 37
IS 37
BP 5515
EP 5524
DI 10.1016/j.vaccine.2019.07.102
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IW7ZL
UT WOS:000485212400004
PM 31405637
OA Other Gold, Green Accepted
DA 2020-05-12
ER

PT J
AU Ozawa, S
   Yemeke, TT
   Evans, DR
   Pallas, SE
   Wallace, AS
   Lee, BY
AF Ozawa, Sachiko
   Yemeke, Tatenda T.
   Evans, Daniel R.
   Pallas, Sarah E.
   Wallace, Aaron S.
   Lee, Bruce Y.
TI Defining hard-to-reach populations for vaccination
SO VACCINE
LA English
DT Review
DE Hard-to-reach; Definition; Vaccination; Immunization; Unvaccinated
ID HUMAN-PAPILLOMAVIRUS VACCINATION; ROUTINE IMMUNIZATION COVERAGE;
   MIDDLE-INCOME COUNTRIES; HEALTH-CARE; INFLUENZA VACCINATION; CHILDREN;
   BARRIERS; RECOMMENDATIONS; INCREASE; SERVICES
AB Extending the benefits of vaccination to everyone who is eligible requires an understanding of which populations current vaccination efforts have struggled to reach. A clear definition of "hard-to-reach" populations - also known as high-risk or marginalized populations, or reaching the last mile - is essential for estimating the size of target groups, sharing lessons learned based on consistent definitions, and allocating resources appropriately. A literature review was conducted to determine what formal definitions of hard-to-reach populations exist and how they are being used, and to propose definitions to consider for future use. Overall, we found that (1) there is a need to distinguish populations that are hard to reach versus hard to vaccinate, and (2) the existing literature poorly defined these populations and clear criteria or thresholds for classifying them were missing. Based on this review, we propose that hard-to-reach populations be defined as those facing supply-side barriers to vaccination due to geography by distance or terrain, transient or nomadic movement, healthcare provider discrimination, lack of healthcare provider recommendations, inadequate vaccination systems, war and conflict, home births or other homebound mobility limitations, or legal restrictions. Although multiple mechanisms may apply to the same population, supply-side barriers should be distinguished from demand-side barriers. Hard-to-vaccinate populations are defined as those who are reachable but difficult to vaccinate due to distrust, religious beliefs, lack of awareness of vaccine benefits and recommendations, poverty or low socioeconomic status, lack of time to access available vaccination services, or gender-based discrimination. Further work is needed to better define hard-to-reach populations and delineate them from populations that may be hard to vaccinate due to complex refusal reasons, improve measurement of the size and importance of their impact, and examine interventions related to overcoming barriers for each mechanism. This will enable policy makers, governments, donors, and the vaccine community to better plan interventions and allocate necessary resources to remove existing barriers to vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ozawa, Sachiko; Yemeke, Tatenda T.] Univ N Carolina, UNC Eshelman Sch Pharm, Div Practice Adv & Clin Educ, Chapel Hill, NC 27515 USA.
   [Ozawa, Sachiko] Univ N Carolina, UNC Eshelman Sch Pharm, Dept Maternal & Child Hlth, Chapel Hill, NC 27515 USA.
   [Evans, Daniel R.] Duke Univ, Sch Med, Durham, NC USA.
   [Pallas, Sarah E.; Wallace, Aaron S.] CDC, US Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA.
   [Lee, Bruce Y.] Johns Hopkins Bloomberg Sch Publ Hlth, Publ Hlth Computat & Operat Res PHICOR, Baltimore, MD USA.
   [Lee, Bruce Y.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
   [Lee, Bruce Y.] Johns Hopkins Univ, GOPC, Baltimore, MD USA.
RP Ozawa, S (reprint author), UNC Eshelman Sch Pharm, CB 7574,Beard Hall 115H, Chapel Hill, NC 27599 USA.
EM ozawa@unc.edu
RI Ozawa, Sachiko/Z-4944-2019
OI Ozawa, Sachiko/0000-0001-7608-9038; Pallas, Sarah/0000-0002-9719-6278
FU Centers for Disease Control and Prevention (CDC)United States Department
   of Health & Human ServicesCenters for Disease Control & Prevention - USA
   [NU2GGH002000-02-00]; International Society for Infectious Diseases
   (ISID) via the SIGMA grant; Pfizer via the SIGMA grant; Agency for
   Healthcare Research and Quality (AHRQ)United States Department of Health
   & Human ServicesAgency for Healthcare Research & Quality [R01HS023317];
   Eunice Kennedy Shriver National Institute of Child Health and Human
   Development (NICHD) Office of Behavioral and Social Sciences Research
   (OBSSR) [U54HD070725]; Global Obesity Prevention Center (GOPC)
   [U54HD070725]; NICHDUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [U01HD086861]; National Institute for General Medical Science (NIGMS)
   [MIDAS 5U24GM110707]
FX Research reported in this publication was supported by the Centers for
   Disease Control and Prevention (CDC) via contract NU2GGH002000-02-00,
   the International Society for Infectious Diseases (ISID) and Pfizer via
   the SIGMA grant and the Agency for Healthcare Research and Quality
   (AHRQ) via grant R01HS023317, the Eunice Kennedy Shriver National
   Institute of Child Health and Human Development (NICHD) Office of
   Behavioral and Social Sciences Research (OBSSR) and the Global Obesity
   Prevention Center (GOPC) via grant U54HD070725, NICHD via grant
   U01HD086861, and the National Institute for General Medical Science
   (NIGMS) via the MIDAS 5U24GM110707 grant. The funder had no role in the
   design and conduct of the study; collection, management, analysis, and
   interpretation of the data; and preparation, review, or approval of the
   manuscript.
CR Anderson Edwin L, 2014, Mo Med, V111, P344
   [Anonymous], 2018, EST STRENGTH IMM 2 Y
   [Anonymous], 2013, REV OUTBR BARR MMR V
   Aragones A, 2016, J IMMIGR MINOR HEALT, V18, P1060, DOI 10.1007/s10903-015-0225-x
   Ashok A, 2017, VACCINE, V35, P2217, DOI 10.1016/j.vaccine.2016.08.045
   Balasingam M, 2017, INT J CLIN PRACT, V71, DOI 10.1111/ijcp.12989
   Baumgaertner B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191728
   Bednarczyk RA, 2017, PAPILLOMAVIRUS RES, V3, P121, DOI 10.1016/j.pvr.2017.04.002
   Benoit C, 2005, QUAL HEALTH RES, V15, P263, DOI 10.1177/1049732304267752
   Blanford JI, 2012, INT J HEALTH GEOGR, V11, DOI 10.1186/1476-072X-11-24
   Bonner K, 2018, VACCINE, V36, P191, DOI 10.1016/j.vaccine.2017.11.038
   Bruno DM, 2014, VACCINE, V32, P4149, DOI 10.1016/j.vaccine.2014.05.058
   Bryant WK, 2006, PREV MED, V43, P60, DOI 10.1016/j.ypmed.2006.03.018
   Cassady D, 2012, J HEALTH CARE POOR U, V23, P1106, DOI 10.1353/hpu.2012.0086
   Castro-Sanchez E, 2016, INT J INFECT DIS, V43, P103, DOI 10.1016/j.ijid.2015.12.019
   Coady MH, 2008, AM J PUBLIC HEALTH, V98, P1314, DOI 10.2105/AJPH.2007.119586
   Corsi DJ, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-S1-S3
   Creati M, 2007, VACCINE, V25, P5985, DOI 10.1016/j.vaccine.2007.05.055
   Cushon JA, 2012, CAN J PUBLIC HEALTH, V103, pS37, DOI 10.1007/BF03404458
   Cutts FT, 2013, EXPERT REV VACCINES, V12, P917, DOI 10.1586/14760584.2013.814847
   Devasenapathy N, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-013015
   Devine A, 2007, AUST NZ J PUBL HEAL, V31, P127, DOI 10.1111/j.1753-6405.2007.00029.x
   Doroshenko A, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-338
   Dube E, 2014, VACCINE, V32, P6649, DOI 10.1016/j.vaccine.2014.09.039
   Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657
   Duttine A, 2013, B WORLD HEALTH ORGAN, V91, P160, DOI 10.2471/BLT.13.118885
   Egondi T, 2015, INT J EQUITY HEALTH, V14, DOI 10.1186/s12939-015-0154-2
   Esposito S, 2014, CLIN MICROBIOL INFEC, V20, P25, DOI 10.1111/1469-0691.12447
   Favin M, 2012, INT HEALTH, V4, P229, DOI 10.1016/j.inhe.2012.07.004
   Ferreira FHG, 2015, INT POVERTY LINE HAS
   Fiscella K, 2014, J GEN INTERN MED, V29, P1579, DOI 10.1007/s11606-014-2999-2
   Froehlich Hervey, 2001, Ethnicity and Disease, V11, P548
   Gavi (The Vaccine Alliance), 2018, GEND IMM
   Gerede R, 2017, J RELIG HEALTH, V56, P1692, DOI 10.1007/s10943-017-0435-8
   Grabenstein JD, 2013, VACCINE, V31, P2011, DOI 10.1016/j.vaccine.2013.02.026
   Greenfield LS, 2015, J ADOLESCENT HEALTH, V56, P547
   Guthmann JP, 2014, ARCH PEDIATRIE, V21, P584, DOI 10.1016/j.arcped.2014.03.012
   Hacker K, 2015, RISK MANAG HEALTHC P, V8, P175, DOI 10.2147/RMHP.S70173
   Haq Z, 2019, HEALTH RES POLICY SY, V17, DOI 10.1186/s12961-019-0452-z
   Holzmann H, 2016, MED MICROBIOL IMMUN, V205, P201, DOI 10.1007/s00430-016-0451-4
   Jacob V, 2016, AM J PREV MED, V50, P797, DOI 10.1016/j.amepre.2015.11.003
   Jacobs B, 2012, REPROD HEALTH MATTER, V20, P112, DOI 10.1016/S0968-8080(12)40649-8
   Kaewkungwal J, 2015, JMIR MHEALTH UHEALTH, V3, DOI 10.2196/mhealth.3704
   Kaji A, 2016, J IMMIGR MINOR HEALT, V18, P1038, DOI 10.1007/s10903-015-0294-x
   Kpozehouen E, 2017, AUST NZ J PUBL HEAL, V41, P118, DOI 10.1111/1753-6405.12602
   Krakow M, 2017, J ADOLESCENT HEALTH, V60, P619, DOI 10.1016/j.jadohealth.2016.11.028
   Kriss JL, 2016, PAN AFR MED J, V24, DOI 10.11604/pamj.2016.24.47.8663
   LaFond A, 2015, HEALTH POLICY PLANN, V30, P298, DOI 10.1093/heapol/czu011
   Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063
   Lee BY, 2019, VACCINE, V37, P2377, DOI 10.1016/j.vaccine.2019.03.007
   McArthur-Lloyd A, 2016, ISSN GLOB HEAL COMMU, V2, P1, DOI [DOI 10.HTTPS://D0I.0RG/10.1080/23762004.2016.1205887, DOI 10.1080/23762004.2016.1205887]
   McKnight J, 2014, GLOB PUBLIC HEALTH, V9, P1152, DOI 10.1080/17441692.2014.972967
   Metcalfe SE, 2014, PUBLIC HEALTH NURS, V31, P175, DOI 10.1111/phn.12088
   Mipatrini D, 2017, PATHOG GLOB HEALTH, V111, P59, DOI 10.1080/20477724.2017.1281374
   Moyer CA, 2013, INT J GYNECOL OBSTET, V123, P217, DOI 10.1016/j.ijgo.2013.06.030
   Mrozek-Budzyn D, 2010, PEDIATR INFECT DIS J, V29, P397, DOI 10.1097/INF.0b013e3181c40a8a
   Muranjan M, 2011, INDIAN PEDIATR, V48, P633, DOI 10.1007/s13312-011-0102-1
   Nasiru SG, 2012, PATHOG GLOB HEALTH, V106, P166, DOI 10.1179/2047773212Y.0000000018
   Nelson KN, 2016, VACCINE, V34, P5495, DOI 10.1016/j.vaccine.2016.09.038
   Niveau G, 2006, PUBLIC HEALTH, V120, P33, DOI 10.1016/j.puhe.2005.03.017
   Nnadi C, 2017, J INFECT DIS, V216, pS368, DOI 10.1093/infdis/jix175
   Obradovic Zarema, 2014, Mater Sociomed, V26, P382, DOI 10.5455/msm.2014.26.382-384
   Olive JK, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002578
   Olorunsaiye Comfort Zuyeali, 2017, Pan Afr Med J, V27, P6, DOI 10.11604/pamj.supp.2017.27.3.12083
   Oyo-Ita A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008145.pub3
   Ozawa S, 2013, HUM VACC IMMUNOTHER, V9, P1774, DOI 10.4161/hv.24961
   Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042
   Pelcic G, 2016, CROAT MED J, V57, P516, DOI 10.3325/cmj.2016.57.516
   Phillips DE, 2018, VACCINE, V36, P4236, DOI 10.1016/j.vaccine.2018.05.116
   Phillips DE, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2626-0
   Print F, 2013, HUM VACC IMMUNOTHER, V9, P1372, DOI 10.4161/hv.24693
   Quinn K, 2016, TRANSNATL LIT, V8
   Rainey JJ, 2011, VACCINE, V29, P8215, DOI 10.1016/j.vaccine.2011.08.096
   Raslan R, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00283
   Redzwan Habib K, 2017, INT J IMMUNOLOGY, V5, P5
   Reiter PL, 2015, AM J PUBLIC HEALTH, V105, P96, DOI 10.2105/AJPH.2014.302095
   Renne E, 2006, SOC SCI MED, V63, P1857, DOI 10.1016/j.socscimed.2006.04.025
   Rose A, 2004, J GEN INTERN MED, V19, P57, DOI 10.1111/j.1525-1497.2004.21146.x
   Ruijs WLM, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-408
   SAGE Vaccine Hesitancy Working Group, 2014, REP SAG WORK GROUP V
   Sally ET, 2017, PAN AFR MED J, V28, DOI 10.11604/pamj.2017.28.238.11538
   Sarathchandra D, 2018, PREV MED, V109, P1, DOI 10.1016/j.ypmed.2018.01.006
   Scorgie F, 2013, CULT HEALTH SEX, V15, P450, DOI 10.1080/13691058.2012.763187
   Sequera VG, 2015, HUM VACC IMMUNOTHER, V11, P2615, DOI 10.1080/21645515.2015.1051269
   Silwal RC, 2006, PUBLIC HEALTH, V120, P805, DOI 10.1016/j.puhe.2006.05.019
   Sodha SV, 2015, BRIT MED BULL, V113, P5, DOI 10.1093/bmb/ldv001
   Spaan DH, 2017, EUR J PUBLIC HEALTH, V27, P524, DOI [10.1093/eurpub/ckw248, 10.1093/eurpub/ckx017]
   Stein-Zamir C, 2008, EPIDEMIOL INFECT, V136, P207, DOI 10.1017/S095026880700845X
   Stockwell MS, 2013, HUM VACC IMMUNOTHER, V9, P1802, DOI 10.4161/hv.25031
   Thompson KM, 2017, J INFECT DIS, V216, pS176, DOI 10.1093/infdis/jix108
   Thompson VLS, 2012, J HEALTH CARE POOR U, V23, P290, DOI 10.1353/hpu.2012.0007
   Toikilik S, 2010, VACCINE, V28, P4673, DOI 10.1016/j.vaccine.2010.04.063
   Topuzoglu A, 2007, EUR J PUBLIC HEALTH, V17, P348, DOI 10.1093/eurpub/ckl250
   Uddin MJ, 2016, VACCINE, V34, P276, DOI 10.1016/j.vaccine.2015.11.024
   Uddin MJ, 2010, VACCINE, V28, P1221, DOI 10.1016/j.vaccine.2009.11.028
   Vadaparampil ST, 2016, CANCER EPIDEM BIOMAR, V25, P1435, DOI 10.1158/1055-9965.EPI-15-1294
   Watson-Jones D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123701
   Whitehead J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146139
   WHO, 2015, IMM PRACT PRACT GUID
   Williams D R, 1997, J Health Psychol, V2, P335, DOI 10.1177/135910539700200305
   Woodward A, 2014, HEALTH POLICY PLANN, V29, P818, DOI 10.1093/heapol/czt061
   World Health Organisation, 2013, GUID TAIL IMM PROGR
   World Health Organization, 2017, REACHING EVERY DISTR
   World Health Organization, 2013, GLOB VACC ACT PLAN 2
   World Health Organization & UNICEF, 2009, MICR IMM SERV DEL US
   Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018
NR 106
TC 2
Z9 2
U1 4
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 3
PY 2019
VL 37
IS 37
BP 5525
EP 5534
DI 10.1016/j.vaccine.2019.06.081
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IW7ZL
UT WOS:000485212400005
PM 31400910
DA 2020-05-12
ER

PT J
AU Keitel, WA
   Voronca, DC
   Atmar, RL
   Paust, S
   Hill, H
   Wolff, MC
   Bellamy, AR
   Belshe, RB
   Bernstein, DB
   Spearman, PW
   Campbell, JD
   Dekker, CL
   Edwards, KM
   El Sahly, HM
   Patel, SM
   Jackson, LA
   Mink, CM
   Mulligan, MJ
   Poland, GA
   Treanor, JJ
   Wald, A
   Walter, EB
   Zangwill, KM
AF Keitel, W. A.
   Voronca, D. C.
   Atmar, R. L.
   Paust, S.
   Hill, H.
   Wolff, M. C.
   Bellamy, A. R.
   Belshe, R. B.
   Bernstein, D. B.
   Spearman, P. W.
   Campbell, J. D.
   Dekker, C. L.
   Edwards, K. M.
   El Sahly, H. M.
   Patel, S. M.
   Jackson, L. A.
   Mink, C. M.
   Mulligan, M. J.
   Poland, G. A.
   Treanor, J. J.
   Wald, A.
   Walter, E. B.
   Zangwill, K. M.
CA VTEU H5N1 Vaccine Working Grp
TI Effect of recent seasonal influenza vaccination on serum antibody
   responses to candidate pandemic influenza A/H5N1 vaccines: A
   meta-analysis
SO VACCINE
LA English
DT Review
DE Influenza; Vaccines; H5N1; Repeated vaccination; Meta-analysis; Antibody
   responses
ID PROPENSITY SCORE; IMMUNOLOGICAL REACTIVITY; HEALTHY-ADULTS; H5N1
   VACCINE; IMMUNOGENICITY; SAFETY; ADJUVANTS; EFFICACY; AS03
AB Recent studies have suggested that among those receiving seasonal influenza vaccine (Sly), reduced immunogenicity is observed in recently vaccinated (RV; within the past season or 2) persons when compared with those not recently vaccinated (NRV). We performed a meta-analysis to assess the effect of recent immunization with SIV on serum H5 hemagglutination inhibition (HAI) antibody responses after influenza A/H5N1 vaccination using data from a series of randomized controlled trials. The primary outcome was seroconversion measured by HAI assays following receipt of 2 doses of H5N1 vaccine. The geometric mean titer (GMT) of serum HAI antibody after vaccination was the secondary outcome. Analyses were performed using propensity score (PS) matching. The PS for each individual in the meta-analysis cohort was calculated using logistic regression and covariates included age, gender, race, antigen dose, adjuvant, statin use and vaccine manufacturer. 2015 subjects enrolled in 7 clinical trials were eligible for inclusion in the meta-analysis cohort; among these, 915 (45%) were RV. 901 RV subjects were matched (1:1) with replacement to a subject who was NRV. Subjects who received SIV within the previous season were significantly less likely to seroconvert following H5N1 vaccination (adjusted odds ratio 0.76; 95%CI 0.60-0.96; p = 0.024), and the GMT was 18% higher among NRV subjects (GM ratio of HAI antibody 1.18; 95%CI 1.04-1.33; p = 0.008). Further work is needed to better define the effects of, and mechanisms contributing to, reduced immune responses to H5N1 vaccine among RV subjects. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Keitel, W. A.; Atmar, R. L.; Paust, S.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.
   [Keitel, W. A.; Atmar, R. L.; Paust, S.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   [Voronca, D. C.; Hill, H.; Wolff, M. C.; Bellamy, A. R.] Emmes, Rockville, MD USA.
   [Paust, S.] Texas Childrens Hosp, Dept Pediat, Ctr Human Immunobiol, Houston, TX 77030 USA.
   [Belshe, R. B.] St Louis Univ, Sch Med, St Louis, MO USA.
   [Bernstein, D. B.; Spearman, P. W.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
   [Campbell, J. D.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
   [Dekker, C. L.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
   [Edwards, K. M.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
   [El Sahly, H. M.; Patel, S. M.] Baylor Coll Med, Houston, TX 77030 USA.
   [Jackson, L. A.] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA.
   [Mink, C. M.; Zangwill, K. M.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA.
   [Mulligan, M. J.] Emory Univ, Sch Med, Atlanta, GA USA.
   [Mulligan, M. J.] NYU, Sch Med, New York, NY USA.
   [Poland, G. A.] Mayo Clin, Rochester, MN USA.
   [Treanor, J. J.] Univ Rochester, Sch Med, Rochester, NY USA.
   [Treanor, J. J.] Biomed Adv Res & Dev Author, Washington, DC USA.
   [Wald, A.] Univ Washington, Seattle, WA 98195 USA.
   [Walter, E. B.] Duke Univ, Sch Med, Durham, NC USA.
   [Paust, S.] Scripps Res, La Jolla, CA USA.
RP Keitel, WA (reprint author), BCM MS 280,One Baylor Plaza, Houston, TX 77030 USA.
EM wkeitel@bcm.edu
FU NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID); National Institute of Allergy and
   Infectious DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [HHSN272201300015I,
   HHSN272201500002C, HHSN272200800003C, NIH-NIAID-DMID-02-01,
   HHSN2722013000171, HHSN272200800006C, HHSN272200800005C,
   HHSN272200800004C, HHSN272201300022I, HHSN272201300018I,
   HHSN272201300019I, N01-AI-25461, DMID-02-01, N01-AI-25462C];  [N01-AI
   -30039];  [N01-AI-25462];  [N01-AI-25465];  [N01-AI-25460]; 
   [N01-AI-300390];  [N01-AI-25464];  [5-20040-S1];  [N01-AI-25463]
FX The analyses for this meta -analysis utilized data generated by the
   NIAID-funded VTEUs. The authors gratefully acknowledge the study
   participants, personnel at the participating VTEU sites, and our
   colleagues Robert Johnson, PhD (currently affiliated with Biomedical
   Advanced Research Development Authority), Chris Roberts, PhD and Melinda
   Tibbals at DMID for their contributions. This work was supported by the
   National Institute of Allergy and Infectious Diseases (contract numbers
   HHSN272201300015I, HHSN272201500002C, HHSN272200800003C,
   NIH-NIAID-DMID-02-01, HHSN2722013000171, HHSN272200800006C,
   HHSN272200800005C, HHSN272200800004C, HHSN272201300022I,
   HHSN272201300018I, HHSN272201300019I, N01-AI-25461, DMID-02-01,
   N01-AI-25462C, N01-AI -30039, N01-AI-25462, N01-AI-25465, N01-AI-25460,
   N01-AI-300390, N01-AI-25460, N01-AI-25464, 5-20040-S1 and N01-AI-25463).
CR Alam S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176407
   [Anonymous], 2017, MMWR RECOMM REP, V66, P1
   Austin PC, 2007, STAT MED, V26, P734, DOI 10.1002/sim.2580
   Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480
   Bartoszko JJ, 2018, VACCINE, V36, P3434, DOI 10.1016/j.vaccine.2018.04.049
   Baxter R, 2011, VACCINE, V29, P2272, DOI 10.1016/j.vaccine.2011.01.039
   Belongia EA, 2017, EXPERT REV VACCINES, V16, P723, DOI 10.1080/14760584.2017.1334554
   Belshe RB, 2011, J INFECT DIS, V203, P666, DOI 10.1093/infdis/jiq093
   Bernstein DI, 2008, J INFECT DIS, V197, P667, DOI 10.1086/527489
   Black S, 2016, J INFECT DIS, V213, P1224, DOI 10.1093/infdis/jiv456
   Bodewes R, 2011, J VIROL, V85, P2695, DOI 10.1128/JVI.02371-10
   Bodewes R, 2011, J VIROL, V85, P11995, DOI 10.1128/JVI.05213-11
   Brookhart MA, 2006, AM J EPIDEMIOL, V163, P1149, DOI 10.1093/aje/kwj149
   Caliendo M, 2008, J ECON SURV, V22, P31, DOI 10.1111/j.1467-6419.2007.00527.x
   Fox GJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151724
   Irving SA, 2009, VACCINE, V27, P6546, DOI 10.1016/j.vaccine.2009.08.050
   Jackson LA, 2015, JAMA-J AM MED ASSOC, V314, P237, DOI 10.1001/jama.2015.7916
   Jackson LA, 2012, J INFECT DIS, V206, P811, DOI 10.1093/infdis/jis427
   Kedl RM, 2000, J EXP MED, V192, P1105, DOI 10.1084/jem.192.8.1105
   Keitel WA, 1997, VACCINE, V15, P1114, DOI 10.1016/S0264-410X(97)00003-0
   Keitel WA, 2008, J INFECT DIS, V198, P1309, DOI 10.1086/592172
   Keitel WA, 2009, VACCINE, V27, P6642, DOI 10.1016/j.vaccine.2009.03.015
   King JP, 2018, INFLUENZA OTHER RESP, V12, P808, DOI 10.1111/irv.12593
   Lanehart RE, 2012, SAS GLOBAL FORUM STA
   Li F, 2013, STAT MED, V32, P3373, DOI 10.1002/sim.5786
   McLean HQ, 2014, CLIN INFECT DIS, V59, P1375, DOI 10.1093/cid/ciu680
   Mulligan MJ, 2014, JAMA-J AM MED ASSOC, V312, P1409, DOI 10.1001/jama.2014.12854
   Nayak JL, 2013, J IMMUNOL, V191, P1001, DOI 10.4049/jimmunol.1203520
   Noah DL, 2009, CLIN VACCINE IMMUNOL, V16, P558, DOI 10.1128/CVI.00368-08
   Nolan T, 2008, VACCINE, V26, P6383, DOI 10.1016/j.vaccine.2008.08.046
   Patel SM, 2012, J INFECT DIS, V206, P1069, DOI 10.1093/infdis/jis402
   Patel SM, 2010, VACCINE, V28, P3025, DOI 10.1016/j.vaccine.2009.10.152
   Ramsay LC, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0919-0
   Richards KA, 2012, VACCINE, V31, P219, DOI 10.1016/j.vaccine.2012.10.039
   ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41
   Roy-Ghanta S, 2014, J INFECT DIS, V210, P1419, DOI 10.1093/infdis/jiu284
   Skull SA, 2007, VACCINE, V25, P4775, DOI 10.1016/j.vaccine.2007.04.015
   Smith DJ, 1999, P NATL ACAD SCI USA, V96, P14001, DOI 10.1073/pnas.96.24.14001
   Thomas D, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-79
   Treanor JJ, 2006, NEW ENGL J MED, V354, P1343, DOI 10.1056/NEJMoa055778
   Uno S, 2011, MICROBIOL IMMUNOL, V55, P783, DOI 10.1111/j.1348-0421.2011.00381.x
   Willis RA, 2006, P NATL ACAD SCI USA, V103, P12063, DOI 10.1073/pnas.0605130103
   Xu ZZ, 2010, BIOMETRICS, V66, P813, DOI 10.1111/j.1541-0420.2009.01364.x
NR 43
TC 0
Z9 0
U1 2
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 3
PY 2019
VL 37
IS 37
BP 5535
EP 5543
DI 10.1016/j.vaccine.2019.04.066
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IW7ZL
UT WOS:000485212400006
PM 31160101
DA 2020-05-12
ER

PT J
AU Principi, N
   Esposito, S
AF Principi, Nicola
   Esposito, Susanna
TI Vaccine-preventable diseases, vaccines and Guillain-Barre' syndrome
SO VACCINE
LA English
DT Review
DE Guillain-Barre syndrome; Human papillomavirus vaccine; Influenza;
   Measles/mumps/rubella vaccine; Safety; Tetravalent conjugated
   meningococcal vaccine
ID HUMAN-PAPILLOMAVIRUS VACCINATION; REAL-TIME SURVEILLANCE; INFLUENZA
   VACCINATION; UNITED-STATES; AUTOIMMUNE-DISEASES; ADVISORY-COMMITTEE;
   RISK; MEASLES; ASSOCIATION; IMMUNIZATION
AB Guillain-Barre syndrome (GBS) is an acute, immune-mediated polyradiculoneuropathy. Infections and vaccines have been hypothesized to play a role in triggering GBS development. These beliefs can play a role in reducing vaccination coverage. In this report, data concerning this hypothesis are discussed. It is shown that an association between vaccine administration and GBS has never been proven for most of debated vaccines, although it cannot be definitively excluded. The only exception is the influenza vaccine, at least for the preparation used in 1976. For some vaccines, such as measles/mumps/rubella, human papillomavirus, tetravalent conjugated meningococcal vaccine, and influenza, the debate between supporters and opponents of vaccination remains robust and perception of vaccines' low safety remains a barrier to achieving adequate vaccination coverage. Less than 1 case of GBS per million immunized persons might occur for these vaccines. However, in some casesimmunization actually reduces the risk of GBS development. In addition, the benefits of vaccination are clearly demonstrated by the eradication or enormous decline in the incidence of many vaccine-preventable diseases. These data highlight that the hypothesized risks of adverse events, such as GBS, cannot be considered a valid reason to avoid the administration of currently recommended vaccines. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Principi, Nicola] Univ Milan, Pediat, Milan, Italy.
   [Esposito, Susanna] Univ Perugia, Dept Surg & Biomed Sci, Piazza Menghini 1, I-06129 Perugia, Italy.
RP Esposito, S (reprint author), Univ Perugia, Dept Surg & Biomed Sci, Piazza Menghini 1, I-06129 Perugia, Italy.
EM susanna.esposito@unimi.it
RI Esposito, Susanna/K-3475-2016
OI Esposito, Susanna/0000-0003-4103-2837
FU World Association of Infectious Diseases and Immunological Disorders
   (WAidid)
FX This review was supported by a grant from the World Association of
   Infectious Diseases and Immunological Disorders (WAidid). The funding
   source had no impact on the literature search or preparation of the
   manuscript.
CR Allen D, 2005, J PERIPHER NERV SYST, V10, P174, DOI 10.1111/j.1085-9489.2005.0010207.x
   AMIT R, 1992, CHILD NERV SYST, V8, P354, DOI 10.1007/BF00296569
   Andrews N, 2017, VACCINE, V35, P1729, DOI 10.1016/j.vaccine.2017.01.076
   Angelo MG, 2014, PHARMACOEPIDEM DR S, V23, P466, DOI 10.1002/pds.3554
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P393
   [Anonymous], 2015, VACC ANT HPV RISQ MA
   [Anonymous], 2010, MMWR-MORBID MORTAL W, V59, P1
   Arnheim-Dahlstom L, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5906
   Asahina M, 2002, ACTA NEUROL SCAND, V105, P44, DOI 10.1034/j.1600-0404.2002.00099.x
   ASBURY AK, 1969, MEDICINE, V48, P173, DOI 10.1097/00005792-196905000-00001
   Baxter R, 2013, CLIN INFECT DIS, V57, P197, DOI 10.1093/cid/cit222
   BOTTIGER M, 1987, BRIT MED J, V295, P1264, DOI 10.1136/bmj.295.6608.1264
   Burwen DR, 2010, AM J PREV MED, V39, P296, DOI 10.1016/j.amepre.2010.05.022
   CABRERA J, 1987, J NEUROL SCI, V81, P239, DOI 10.1016/0022-510X(87)90099-2
   Caporale CM, 2006, J NEUROIMMUNOL, V174, P12, DOI 10.1016/j.jneuroim.2005.12.005
   Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P1023
   Centers for Disease Control and Prevention (CDC), 2006, MMWR Morb Mortal Wkly Rep, V55, P364
   Cho BH, 2010, VACCINE, V28, P817, DOI 10.1016/j.vaccine.2009.10.050
   Cohn AC, 2013, MMWR RECOMM REP, V62, P1
   daSilveira CM, 1997, LANCET, V349, P14, DOI 10.1016/S0140-6736(96)07408-9
   De Wals P, 2012, JAMA-J AM MED ASSOC, V308, P175, DOI 10.1001/jama.2012.7342
   Dieleman J, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3908
   Dodd CN, 2013, VACCINE, V31, P4448, DOI 10.1016/j.vaccine.2013.06.032
   Esposito S, 2014, CLIN MICROBIOL INFEC, V20, P25, DOI 10.1111/1469-0691.12447
   Esteghamati A, 2008, VACCINE, V26, P5058, DOI 10.1016/j.vaccine.2008.07.014
   FESCHAREK R, 1990, VACCINE, V8, P446, DOI 10.1016/0264-410X(90)90245-H
   Filia A, 2014, NEUROL SCI, V35, P2017, DOI 10.1007/s10072-014-1841-2
   Gee J, 2011, VACCINE, V29, P8279, DOI 10.1016/j.vaccine.2011.08.106
   Ghaderi S, 2016, EUR J EPIDEMIOL, V31, P67, DOI 10.1007/s10654-015-0047-0
   Greene SK, 2010, AM J EPIDEMIOL, V171, P177, DOI 10.1093/aje/kwp345
   Grimaldi-Bensouda L, 2017, J AUTOIMMUN, V79, P84, DOI 10.1016/j.jaut.2017.01.005
   GROSE C, 1976, AM J MED, V60, P441, DOI 10.1016/0002-9343(76)90762-2
   Haber P, 2009, DRUG SAFETY, V32, P309, DOI 10.2165/00002018-200932040-00005
   Hadden RDM, 2001, NEUROLOGY, V56, P758, DOI 10.1212/WNL.56.6.758
   Hughes R, 1996, BRIT MED J, V312, P1475
   Hughes RAC, 2006, LANCET, V367, P473, DOI 10.1016/S0140-6736(06)68176-2
   Institute of Medicine, 2012, ADV EFF VACC EV CAUS
   Institute of Medicine, 2011, ADV EV ASS CHILDH VA
   Institute of Medicine, 2003, IMM SAF REV INFL VAC
   Irie S, 1996, J NEUROIMMUNOL, V68, P19, DOI 10.1016/0165-5728(96)00059-8
   Jacobs BC, 1998, NEUROLOGY, V51, P1110, DOI 10.1212/WNL.51.4.1110
   Jonse II R, 1984, LAKARTIDNINGEN, V81, P1636
   Juurlink DN, 2006, ARCH INTERN MED, V166, P2217, DOI 10.1001/archinte.166.20.2217
   KAPLAN JE, 1982, JAMA-J AM MED ASSOC, V248, P698, DOI 10.1001/jama.248.6.698
   KUSUNOKI S, 1995, MUSCLE NERVE, V18, P409, DOI 10.1002/mus.880180407
   Kuwabara S, 2013, LANCET NEUROL, V12, P1180, DOI 10.1016/S1474-4422(13)70215-1
   Kwong JC, 2013, LANCET INFECT DIS, V13, P769, DOI 10.1016/S1473-3099(13)70104-X
   LANGMUIR AD, 1984, AM J EPIDEMIOL, V119, P841, DOI 10.1093/oxfordjournals.aje.a113809
   Lasky T, 1998, NEW ENGL J MED, V339, P1797, DOI 10.1056/NEJM199812173392501
   Lehmann HC, 2010, LANCET INFECT DIS, V10, P643, DOI 10.1016/S1473-3099(10)70140-7
   Lopez Adaros H, 1971, Res Publ Assoc Res Nerv Ment Dis, V49, P178
   Markowitz LE, 2014, MMWR RECOMM REP, V63, P1
   McGrogan A, 2009, NEUROEPIDEMIOLOGY, V32, P150, DOI 10.1159/000184748
   Miranda S, 2017, VACCINE, V35, P4761, DOI 10.1016/j.vaccine.2017.06.030
   Mori M, 2000, BRAIN, V123, P2171, DOI 10.1093/brain/123.10.2171
   MORRIS K, 1994, LANCET, V343, P60, DOI 10.1016/S0140-6736(94)90917-2
   Moyano AL, 2008, J NEUROL SCI, V272, P110, DOI 10.1016/j.jns.2008.05.006
   Nishimoto Y, 2004, J NEUROIMMUNOL, V148, P200, DOI 10.1016/j.jneuroim.2003.11.017
   Patja A, 2001, J PEDIATR-US, V138, P250, DOI 10.1067/mpd.2001.111165
   PLESNER AM, 1995, LANCET, V345, P316, DOI 10.1016/S0140-6736(95)90302-X
   Poropatich KO, 2010, J HEALTH POPUL NUTR, V28, P545, DOI 10.3329/jhpn.v28i6.6602
   Salisbury DM, 1998, LANCET, V351, P79, DOI 10.1016/S0140-6736(05)78156-3
   Salmon DA, 2013, LANCET, V381, P1461, DOI 10.1016/S0140-6736(12)62189-8
   Sandhu SK, 2017, VACCINE, V35, P2986, DOI 10.1016/j.vaccine.2017.03.087
   SCHONBERGER LB, 1979, AM J EPIDEMIOL, V110, P105, DOI 10.1093/oxfordjournals.aje.a112795
   Sejvar JJ, 2011, NEUROEPIDEMIOLOGY, V36, P123, DOI 10.1159/000324710
   Sekiguchi Y, 2012, J NEUROL NEUROSUR PS, V83, P23, DOI 10.1136/jnnp-2011-300309
   Shui IM, 2012, NEUROEPIDEMIOLOGY, V39, P109, DOI 10.1159/000339248
   Sivadon-Tardy V, 2009, CLIN INFECT DIS, V48, P48, DOI 10.1086/594124
   Skufca J, 2017, PAPILLOMAVIRUS RES, V3, P91, DOI 10.1016/j.pvr.2017.03.001
   Stowe J, 2009, AM J EPIDEMIOL, V169, P382, DOI 10.1093/aje/kwn310
   Tam CC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000344
   Tatarelli P, 2016, INT J NEUROSCI, V126, P478, DOI 10.3109/00207454.2015.1033621
   Tuttle J, 1997, AM J PUBLIC HEALTH, V87, P2045, DOI 10.2105/AJPH.87.12.2045
   Velentgas P, 2012, PHARMACOEPIDEM DR S, V21, P1350, DOI 10.1002/pds.3321
   Vellozzi C, 2014, AM J PUBLIC HEALTH, V104, P696, DOI 10.2105/AJPH.2013.301651
   Verity C, 2011, LANCET, V378, P1545, DOI 10.1016/S0140-6736(11)61665-6
   Vucic S, 2009, J CLIN NEUROSCI, V16, P733, DOI 10.1016/j.jocn.2008.08.033
   Winer JB, 2008, BMJ-BRIT MED J, V337, P227
   World Health Organization, SAF HPV VACC
   Yih WK, 2012, PHARMACOEPIDEM DR S, V21, P1359, DOI 10.1002/pds.3353
   Yu RK, 2006, INFECT IMMUN, V74, P6517, DOI 10.1128/IAI.00967-06
   Yuki N, 2001, ANN NEUROL, V49, P712, DOI 10.1002/ana.1012
   Yuki N, 2012, NEW ENGL J MED, V366, P2294, DOI 10.1056/NEJMra1114525
NR 84
TC 3
Z9 3
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 3
PY 2019
VL 37
IS 37
BP 5544
EP 5550
DI 10.1016/j.vaccine.2018.05.119
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IW7ZL
UT WOS:000485212400007
PM 29880241
DA 2020-05-12
ER

PT J
AU Perez, AC
   Murphy, TF
AF Perez, Antonia C.
   Murphy, Timothy F.
TI Potential impact of a Moraxella catarrhalis vaccine in COPD
SO VACCINE
LA English
DT Review
DE Moraxella catarrhalis; COPD; Vaccine; Chronic lung disease; Airway
   pathogen
ID MEMBRANE PROTEIN-CD; OBSTRUCTIVE PULMONARY-DISEASE; NONTYPABLE
   HAEMOPHILUS-INFLUENZAE; HUMAN EPITHELIAL-CELLS; HUMAN IMMUNE-RESPONSE;
   ACUTE OTITIS-MEDIA; BINDING-PROTEIN; MIDDLE-EAR;
   STREPTOCOCCUS-PNEUMONIAE; ACUTE EXACERBATIONS
AB Moraxella catarrhalis is the second most common cause of exacerbations in adults with COPD, resulting in enormous morbidity and mortality in this clinical setting. Vaccine development for M. catarrhalis has lagged behind the other two important causes of exacerbations in COPD, nontypeable Haemophilus influenzae and Streptococcus pneumoniae. While no licensed vaccine is currently available for M. catarrhalis, several promising candidate vaccine antigens have been identified and characterized and are close to entering clinical trials. Key steps that are required to advance vaccines for M. catarrhalis along the translational pipeline include standardization of assay systems to assess candidate antigens, identification of a reliable correlate of protection and expansion of partnerships between industry, academia and government to overcome regulatory hurdles. A vaccine to prevent M. catarrhalis infections in COPD would have a major impact in reducing morbidity, mortality and healthcare costs in COPD. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Perez, Antonia C.; Murphy, Timothy F.] SUNY Buffalo, Clin & Translat Res Ctr, 875 Ellicott St, Buffalo, NY 14203 USA.
   [Perez, Antonia C.; Murphy, Timothy F.] SUNY Buffalo, Dept Med, Div Infect Dis, 875 Ellicott St, Buffalo, NY 14203 USA.
   [Murphy, Timothy F.] SUNY Buffalo, Dept Microbiol, 875 Ellicott St, Buffalo, NY 14203 USA.
RP Murphy, TF (reprint author), SUNY Buffalo, Clin & Translat Res Ctr, 875 Ellicott St, Buffalo, NY 14203 USA.
EM murphyt@buffalo.edu
OI Murphy, Timothy/0000-0002-3496-2641
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR001412]; NIAID NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01 AI019641]; NIDCD NIH HHSUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Deafness & Other Communication Disorders (NIDCD)
   [R01 DC012200, F32 DC015393]
CR Adlowitz DG, 2006, FEMS IMMUNOL MED MIC, V46, P139, DOI 10.1111/j.1574-695X.2005.00020.x
   Adlowitz DG, 2005, INFECT IMMUN, V73, P6601, DOI 10.1128/IAI.73.10.6601-6607.2005
   Adlowitz DG, 2004, VACCINE, V22, P2533, DOI 10.1016/j.vaccine.2003.12.016
   Armbruster CE, 2011, MOL MICROBIOL, V82, P836, DOI 10.1111/j.1365-2958.2011.07831.x
   Armbruster CE, 2010, MBIO, V1, DOI 10.1128/mBio.00102-10
   Attia AS, 2006, J BACTERIOL, V188, P7840, DOI 10.1128/JB.01204-06
   Balder R, 2011, AM SOC MICR GEN M NE, P129
   Barker BL, 2015, CHEST, V147, P46, DOI 10.1378/chest.14-0764
   Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407
   Becker PD, 2007, INFECT IMMUN, V75, P1778, DOI 10.1128/IAI.01081-06
   Bernhard S, 2014, J INFECT DIS, V210, P1306, DOI 10.1093/infdis/jiu241
   Bosch AATM, 2016, VACCINE, V34, P531, DOI 10.1016/j.vaccine.2015.11.060
   Brockson ME, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040088
   Brooks MJ, 2007, J BACTERIOL, V189, P76, DOI 10.1128/JB.00788-06
   Bullard B, 2005, INFECT IMMUN, V73, P5127, DOI 10.1128/IAI.73.8.5127-5136.2005
   Celli BR, 2007, EUR RESPIR J, V29, P1224, DOI 10.1183/09031936.00109906
   Celli BR, 2015, AM J RESP CRIT CARE, V191, P831, DOI 10.1164/rccm.201501-0044ST
   Chen DX, 1999, INFECT IMMUN, V67, P1310, DOI 10.1128/IAI.67.3.1310-1316.1999
   Chonmaitree T, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3555
   Cox AD, 2011, GLYCOCONJ J
   Decramer M, 2012, LANCET, V379, P1341, DOI 10.1016/S0140-6736(11)60968-9
   Doring G, 2011, FEMS MICROBIOL REV, V35, P124, DOI 10.1111/j.1574-6976.2010.00237.x
   Doll H, 2005, PHARMACOECONOMICS, V23, P345, DOI 10.2165/00019053-200523040-00005
   Domenech A, 2013, J INFECTION, V67, P516, DOI 10.1016/j.jinf.2013.09.003
   Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847
   Donaldson GC, 1999, EUR RESPIR J, V13, P844, DOI 10.1034/j.1399-3003.1999.13d25.x
   Dowell SF, 2004, LANCET INFECT DIS, V4, P704, DOI 10.1016/S1473-3099(04)01177-6
   Easton DM, 2005, J BACTERIOL, V187, P6528, DOI 10.1128/JB.187.18.6528-6535.2005
   Easton DM, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00013
   Easton DM, 2008, J BACTERIOL, V190, P7994, DOI 10.1128/JB.01039-08
   FADEN H, 1989, J INFECT DIS, V160, P999, DOI 10.1093/infdis/160.6.999
   Forsgren A, 2004, J INFECT DIS, V190, P352, DOI 10.1086/422155
   Forsgren A, 2001, J IMMUNOL, V167, P2112, DOI 10.4049/jimmunol.167.4.2112
   Forsgren A, 2008, CLIN INFECT DIS, V46, P726, DOI 10.1086/527396
   Garcia-Rodriguez JA, 2002, J ANTIMICROB CHEMOTH, V50, P59, DOI 10.1093/jac/dkf506
   George SN, 2014, EUR RESPIR J, V44, P87, DOI 10.1183/09031936.00223113
   Gisselsson-Solen M, 2014, ACTA OTO-LARYNGOL, V134, P684, DOI 10.3109/00016489.2014.890291
   Gitiban N, 2005, J VIROL, V79, P6035, DOI 10.1128/JVI.79.10.6035-6042.2005
   Green LR, 2016, METHODS MOL BIOL, V1403, P445, DOI 10.1007/978-1-4939-3387-7_25
   Groenewegen KH, 2003, CHEST, V124, P459, DOI 10.1378/chest.124.2.459
   Hall-Stoodley L, 2006, JAMA-J AM MED ASSOC, V296, P202, DOI 10.1001/jama.296.2.202
   Heiniger N, 2005, INFECT IMMUN, V73, P8247, DOI 10.1128/IAI.73.12.8247-8255.2005
   Heinrich A, 2016, FASEB J, V30, P2426, DOI 10.1096/fj.201500172R
   Hoogendoorn Martine, 2010, Int J Chron Obstruct Pulmon Dis, V5, P435, DOI 10.2147/COPD.S13826
   HSIAO CB, 1995, MICROB PATHOGENESIS, V19, P215, DOI 10.1016/S0882-4010(95)90272-4
   Hu WG, 2004, FEMS IMMUNOL MED MIC, V41, P109, DOI 10.1016/j.femsim.2004.02.001
   Jemal A, 2005, JAMA-J AM MED ASSOC, V294, P1255, DOI 10.1001/jama.294.10.1255
   Jenkins CR, 2012, EUR RESPIR J, V39, P38, DOI 10.1183/09031936.00194610
   Johnson SE, 1999, J INFECT DIS, V180, P133, DOI 10.1086/314845
   Jones MM, 2015, INFECT IMMUN, V83, P3497, DOI 10.1128/IAI.00597-15
   Jones MM, 2014, INFECT IMMUN, V82, P4758, DOI 10.1128/IAI.02185-14
   Kanner RE, 2001, AM J RESP CRIT CARE, V164, P358, DOI 10.1164/ajrccm.164.3.2010017
   Kessler R, 2006, CHEST, V130, P133, DOI 10.1378/chest.130.1.133
   Kurai D, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00293
   Lafontaine ER, 2000, J BACTERIOL, V182, P1364, DOI 10.1128/JB.182.5.1364-1373.2000
   LaFontaine ER, 2009, CLIN VACCINE IMMUNOL, V16, P653, DOI 10.1128/CVI.00460-08
   Lipski SL, 2007, FEMS MICROBIOL LETT, V267, P207, DOI 10.1111/j.1574-6968.2006.00549.x
   Lipski SL, 2007, INFECT IMMUN, V75, P314, DOI 10.1128/IAI.01330-06
   Liu DF, 2007, INFECT IMMUN, V75, P2818, DOI 10.1128/IAI.00074-07
   Locht C, 1999, Int Microbiol, V2, P137
   Luke NR, 2007, INFECT IMMUN, V75, P5559, DOI 10.1128/IAI.00946-07
   Luke-Marshall NR, 2011, GENE, V477, P19, DOI 10.1016/j.gene.2011.01.010
   Madhi SA, 2015, PEDIATR INFECT DIS J, V34, P753, DOI 10.1097/INF.0000000000000733
   Mason KW, 2004, VACCINE, V22, P3449, DOI 10.1016/j.vaccine.2004.02.027
   Mawas F, 2007, VACCINE, V25, P4801, DOI 10.1016/j.vaccine.2007.04.026
   MAY JR, 1953, LANCET, V265, P534
   McGillivary G, 2009, CELL MICROBIOL, V11, P1399, DOI 10.1111/j.1462-5822.2009.01339.x
   McMichael JC, 2000, VACCINE, V19, pS101, DOI 10.1016/S0264-410X(00)00287-5
   McShane PJ, 2013, AM J RESP CRIT CARE, V188, P647, DOI 10.1164/rccm.201303-0411CI
   Murphy TF, 2000, INFECT IMMUN, V68, P6250, DOI 10.1128/IAI.68.11.6250-6256.2000
   Murphy TF, 2005, INFECT IMMUN, V73, P8161, DOI 10.1128/IAI.73.12.8161-8166.2005
   Murphy TF, 2005, AM J RESP CRIT CARE, V172, P195, DOI 10.1164/rccm.200412-1747OC
   Murphy TF, 2005, INFECT IMMUN, V73, P3471, DOI 10.1128/IAI.73.6.3471-3478.2005
   MURPHY TF, 1993, MOL MICROBIOL, V10, P87, DOI 10.1111/j.1365-2958.1993.tb00906.x
   Murphy TF, 1999, INFECT IMMUN, V67, P4578, DOI 10.1128/IAI.67.9.4578-4585.1999
   Murphy TF, 2003, INFECT IMMUN, V71, P1288, DOI 10.1128/IAI.71.3.1288-1294.2003
   Murphy TF, 1998, J INFECT DIS, V178, P1667, DOI 10.1086/314501
   Murphy TF, 2001, INFECT IMMUN, V69, P3576, DOI 10.1128/IAI.69.6.3576-3580.2001
   Murphy TF, 2015, PRINCIPLES PRACTICE
   Murphy TF, 2012, HARRISONS PRINCIPLES, P1228
   Murphy TF, 2008, AM J RESP CRIT CARE, V177, P853, DOI 10.1164/rccm.200709-1413OC
   Murphy TF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158689
   Murphy TF, 2016, VACCINE, V34, P3855, DOI 10.1016/j.vaccine.2016.05.045
   Murphy TF, 2009, CLIN INFECT DIS, V49, P124, DOI 10.1086/599375
   Murrah KA, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftu011
   Murrah KA, 2015, PATHOG DIS, V73, DOI 10.1111/2049-632X.12216
   Nakamura S, 2011, J CLIN INVEST, V121, P3657, DOI 10.1172/JCI57762
   Novotny LA, 2006, VACCINE, V24, P4804, DOI 10.1016/j.vaccine.2006.03.021
   Otsuka T, 2016, INFECT IMMUN, V84, P432, DOI 10.1128/IAI.00799-15
   Otsuka T, 2014, INFECT IMMUN, V82, P3503, DOI 10.1128/IAI.01832-14
   Perez AC, 2014, PATHOG DIS, V70, P280, DOI 10.1111/2049-632X.12129
   Plamondon P, 2007, INFECT IMMUN, V75, P2929, DOI 10.1128/IAI.00396-07
   Rabe KF, 2013, CHEST, V143, P711, DOI 10.1378/chest.12-1277
   Ren D, 2015, VACCINE, V33, P5809, DOI 10.1016/j.vaccine.2015.09.023
   Ren DB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029553
   Ren DB, 2011, VACCINE, V29, P4210, DOI 10.1016/j.vaccine.2011.03.102
   Riesbeck K, 2006, ACTA BIOCHIM POL, V53, P445
   Ruckdeschel EA, 2008, INFECT IMMUN, V76, P1599, DOI 10.1128/IAI.01253-07
   Ruckdeschel EA, 2009, VACCINE, V27, P7065, DOI 10.1016/j.vaccine.2009.09.062
   Ruohola A, 2013, J INFECTION, V66, P247, DOI 10.1016/j.jinf.2012.12.002
   Schaar V, 2011, ANTIMICROB AGENTS CH, V55, P3845, DOI 10.1128/AAC.01772-10
   Seemungal T, 2001, AM J RESP CRIT CARE, V164, P1618, DOI 10.1164/ajrccm.164.9.2105011
   Seemungal TAR, 2015, AM J RESP CRIT CARE, V192, P1036, DOI 10.1164/rccm.201503-0534UP
   Sethi S, 2002, NEW ENGL J MED, V347, P465, DOI 10.1056/NEJMoa012561
   Sethi S, 2008, NEW ENGL J MED, V359, P2355, DOI 10.1056/NEJMra0800353
   Shaffer TL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067881
   SHURIN PA, 1980, J PEDIATR-US, V97, P364, DOI 10.1016/S0022-3476(80)80182-X
   Siegel SJ, 2014, CELL HOST MICROBE, V16, P55, DOI 10.1016/j.chom.2014.06.005
   Singh B, 2015, INFECT IMMUN, V83, P3458, DOI 10.1128/IAI.00310-15
   Singh B, 2010, MOL MICROBIOL, V75, P1426, DOI 10.1111/j.1365-2958.2010.07066.x
   Singh R, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0114-1
   Smidt M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064422
   Soler-Cataluna JJ, 2005, THORAX, V60, P925, DOI 10.1136/thx.2005.040527
   Song JY, 2013, J INFECT CHEMOTHER, V19, P412, DOI 10.1007/s10156-013-0601-1
   Spencer S, 2004, EUR RESPIR J, V23, P698, DOI 10.1183/09031936.04.00121404
   Su YC, 2013, MICROBES INFECT, V15, P375, DOI 10.1016/j.micinf.2013.02.004
   Suarez-Arrabal MC, 2015, J INFECTION, V71, P458, DOI 10.1016/j.jinf.2015.06.010
   Tan TT, 2007, J INFECT DIS, V195, P1661, DOI 10.1086/517611
   Tan TT, 2006, J INFECT DIS, V194, P493, DOI 10.1086/505581
   Timpe JM, 2003, INFECT IMMUN, V71, P4341, DOI 10.1128/IAI.71.8.4341-4350.2003
   Torretta S, 2013, ANN OTO RHINOL LARYN, V122, P109, DOI 10.1177/000348941312200206
   Uitti JM, 2015, PEDIATR INFECT DIS J, V34, P1056, DOI 10.1097/INF.0000000000000800
   UNHANAND M, 1992, J INFECT DIS, V165, P644, DOI 10.1093/infdis/165.4.644
   Verhaegh SJC, 2011, VACCINE, V29, P5603, DOI 10.1016/j.vaccine.2011.06.019
   Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP
   Wark PAB, 2013, RESPIROLOGY, V18, P996, DOI 10.1111/resp.12099
   Wiertsema SP, 2011, J MED VIROL, V83, P2008, DOI 10.1002/jmv.22221
   Williams NP, 2017, INT J CHRONIC OBSTR, V12, P313, DOI 10.2147/COPD.S121389
   World Health Organisation, 2016, CHRON RESP DIS
   Wren JT, 2014, INFECT IMMUN, V82, P4802, DOI 10.1128/IAI.01856-14
   Yang M, 2011, INFECT IMMUN, V79, P846, DOI 10.1128/IAI.00314-10
   Yassin GM, 2016, J INFECT DIS, V213, P1938, DOI 10.1093/infdis/jiw062
   Yu SQ, 2007, INFECT IMMUN, V75, P2974, DOI 10.1128/IAI.01915-06
   Yu SQ, 2005, INFECT IMMUN, V73, P2790, DOI 10.1128/IAI.73.5.2790-2796.2005
NR 134
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 3
PY 2019
VL 37
IS 37
BP 5551
EP 5558
DI 10.1016/j.vaccine.2016.12.066
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IW7ZL
UT WOS:000485212400008
PM 28185742
DA 2020-05-12
ER

PT J
AU Hung, MC
   Cho, CY
   Chen, CJ
   Lai, CC
   Wu, KG
AF Hung, Miao-Chiu
   Cho, Ching-Yi
   Chen, Chun-Jen
   Lai, Chou-Cheng
   Wu, Keh-Gong
TI Immunogenicity and safety of an inactivated enterovirus A71 vaccine in
   children 3-6 years and 2-35 months of age- an open-label, randomized
   phase IIb clinical trial
SO VACCINE
LA English
DT Article
DE Enterovirus A71 vaccine; A randomized clinical trial; B4 subgenotype;
   Bioreactor
ID 71 INFECTION; OUTBREAKS; SELECTION; EFFICACY; FEATURES; DISEASE; VP1
AB Background: Enterovirus A71 (EV-A71) infection can cause severe debilitating complications and even death in young children. The immunogenicity and safety of an inactivated whole EV-A71 virus vaccine were assessed in children 2 months to 6 years of age.
   Methods: This was an open-label, multi-center and randomized phase IIb study, which divided into part A and B. In part A, children 36 months to 6 years of age were enrolled and randomized into 3 groups, receiving 0.5 mu g total viral protein (TP) with adjuvant Al(OH)3, 1.0 mu g TP with Al(OH)3 or 1.0 mu g TP only. Two doses of vaccines were administered at a 28-day interval and blood was taken before immunization, at week 4, 8, 28 and 52 (optional) for virus neutralization assay. Safety profiles were also monitored. After safety profiles had shown no concerns, children 2 months to 35 months of age (part B) were subsequently enrolled following the same protocol.
   Results: A total of 135 children completed two doses of immunization, including 58 in part A and 77 in part B. Both adjuvanted 0.5 mu g and 1.0 mu g TP elicited significant raise of neutralizing antibody titers and seroconversion rate was up to 93.75-100.0% after 2 doses of immunization. Adjuvanted 1.0 mu g TP induced higher titers of neutralizing antibodies than adjuvanted 0.5 mu g TP. By contrast, non-adjuvanted 1.0 mu g TP was not immunogenic. No major adverse events were reported.
   Conclusions: This EV-A71 vaccine containing adjuvant is immunogenic and safe in children 2 months to 6 years of age. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wu, Keh-Gong] Taipei Vet Gen Hosp, Div Infect Dis, Dept Pediat, 201,Sect 2,Shih Pai Rd, Taipei 11217, Taiwan.
   Natl Yang Ming Univ, Taipei, Taiwan.
RP Wu, KG (reprint author), Taipei Vet Gen Hosp, Div Infect Dis, Dept Pediat, 201,Sect 2,Shih Pai Rd, Taipei 11217, Taiwan.
EM mchung@vghtpe.gov.tw; kgwu@vghtpe.gov.tw
FU Enimmune Corporation
FX This work was supported by Enimmune Corporation, which also provided
   serological tests for the study.
CR Bessaud M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090624
   Cardosa MJ, 2003, EMERG INFECT DIS, V9, P461
   Chang JY, 2012, VACCINE, V30, P703, DOI 10.1016/j.vaccine.2011.11.087
   Chang L, 2007, NEW ENGL J MED, V356, P1226, DOI 10.1056/NEJMoa065954
   Chen SC, 2007, AM J TROP MED HYG, V77, P188, DOI 10.4269/ajtmh.2007.77.188
   Cheng A, 2013, VACCINE, V31, P2471, DOI 10.1016/j.vaccine.2013.03.015
   Chong P, 2015, CLIN INFECT DIS, V60, P797, DOI 10.1093/cid/ciu852
   Chou AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079783
   Chou AH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034834
   Fang CY, 2018, EXPERT REV VACCINES, V17, P819, DOI 10.1080/14760584.2018.1510326
   Ho MT, 1999, NEW ENGL J MED, V341, P929, DOI 10.1056/NEJM199909233411301
   Huang LM, 2019, VACCINE, V37, P1827, DOI 10.1016/j.vaccine.2019.02.023
   Li RC, 2014, NEW ENGL J MED, V370, P829, DOI 10.1056/NEJMoa1303224
   Liu CC, 2018, VACCINE, V36, P3134, DOI 10.1016/j.vaccine.2017.02.042
   Lu CY, 2002, J MED VIROL, V67, P217, DOI 10.1002/jmv.2210
   Luo ST, 2009, EMERG INFECT DIS, V15, P581, DOI 10.3201/eid1504.081550
   McMinn PC, 2002, FEMS MICROBIOL REV, V26, P91, DOI 10.1111/j.1574-6976.2002.tb00601.x
   Ooi MH, 2010, LANCET NEUROL, V9, P1097, DOI 10.1016/S1474-4422(10)70209-X
   SCHMIDT NJ, 1974, J INFECT DIS, V129, P304, DOI 10.1093/infdis/129.3.304
   Solomon T, 2010, LANCET INFECT DIS, V10, P778, DOI 10.1016/S1473-3099(10)70194-8
   Tambyah PA, 2019, VACCINE, V37, P4344, DOI 10.1016/j.vaccine.2019.06.023
   Tee KK, 2010, J VIROL, V84, P3339, DOI 10.1128/JVI.01019-09
   Wang JR, 2002, J CLIN MICROBIOL, V40, P10, DOI 10.1128/JCM.40.1.10-15.2002
   Wu CY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136420
   Yee PTI, 2017, VIROLOGY, V506, P121, DOI 10.1016/j.virol.2017.03.017
   Yi EJ, 2017, CLIN EXP VACCINE RES, V6, P4, DOI [10.7774/cevr.2017.6.1.4., 10.7774/cevr.2017.6.1.4]
   Zhu FC, 2013, LANCET, V381, P2024, DOI 10.1016/S0140-6736(13)61049-1
   Zhu FC, 2014, NEW ENGL J MED, V370, P818, DOI 10.1056/NEJMoa1304923
NR 28
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 3
PY 2019
VL 37
IS 37
BP 5559
EP 5566
DI 10.1016/j.vaccine.2019.07.096
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IW7ZL
UT WOS:000485212400009
PM 31399275
DA 2020-05-12
ER

PT J
AU Arunkumar, GA
   McMahon, M
   Pavot, V
   Aramouni, M
   Ioannou, A
   Lambe, T
   Gilbert, S
   Krammer, F
AF Arunkumar, Guha Asthagiri
   McMahon, Meagan
   Pavot, Vincent
   Aramouni, Mario
   Ioannou, Andriani
   Lambe, Teresa
   Gilbert, Sarah
   Krammer, Florian
TI Vaccination with viral vectors expressing NP, M1 and chimeric
   hemagglutinin induces broad protection against influenza virus challenge
   in mice
SO VACCINE
LA English
DT Article
DE Influenza; Stalk; NP; M1; T-cell immunity; Universal influenza virus
   vaccine
ID T-CELL IMMUNITY; SEASONAL INFLUENZA; CONSTRUCTS PROTECT; CD4(+);
   MVA-NP+M1; INFECTION; VACCINES; IMMUNOGENICITY; GENERATION; ANTIBODIES
AB Seasonal influenza virus infections cause significant morbidity and mortality every year. Annual influenza virus vaccines are effective but only when well matched with circulating strains. Therefore, there is an urgent need for better vaccines that induce broad protection against drifted seasonal and emerging pandemic influenza viruses. One approach to design such vaccines is based on targeting conserved regions of the influenza virus hemagglutinin. Sequential vaccination with chimeric hemagglutinin constructs can refocus antibody responses towards the conserved immunosubdominant stalk domain of the hemagglutinin, rather than the variable immunodominant head. A complementary approach for a universal influenza A virus vaccine is to induce T-cell responses to conserved internal influenza virus antigens. For this purpose, replication deficient recombinant viral vectors based on Chimpanzee Adenovirus Oxford 1 and Modified Vaccinia Ankara virus are used to express the viral nucleoprotein and the matrix protein 1. In this study, we combined these two strategies and evaluated the efficacy of viral vectors expressing both chimeric hemagglutinin and nucleoprotein plus matrix protein 1 in a mouse model against challenge with group 2 influenza viruses including H3N2, H7N9 and H10N8. We found that vectored vaccines expressing both sets of antigens provided enhanced protection against H3N2 virus challenge when compared to vaccination with viral vectors expressing only one set of antigens. Vaccine induced antibody responses against divergent group 2 hemagglutinins, nucleoprotein and matrix protein 1 as well as robust T-cell responses to the nucleoprotein and matrix protein 1 were detected. Of note, it was observed that while antibodies to the H3 stalk were already boosted to high levels after two vaccinations with chimeric hemagglutinins (cHAs), three exposures were required to induce strong reactivity across subtypes. Overall, these results show that a combinations of different universal influenza virus vaccine strategies can induce broad antibody and T-cell responses and can provide increased protection against influenza. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Arunkumar, Guha Asthagiri; McMahon, Meagan; Ioannou, Andriani; Krammer, Florian] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.
   [Arunkumar, Guha Asthagiri] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, New York, NY 10029 USA.
   [Pavot, Vincent; Aramouni, Mario; Lambe, Teresa; Gilbert, Sarah] Univ Oxford, Jenner Inst, Oxford, England.
RP Krammer, F (reprint author), Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.; Gilbert, S (reprint author), Univ Oxford, Jenner Inst, Oxford, England.
EM sarah.gilbert@ndm.ox.ac.uk; florian.kram-mer@mssm.edu
RI Krammer, Florian/H-3237-2019; Arunkumar, Guha Asthagiri/J-6238-2019
OI Krammer, Florian/0000-0003-4121-776X; Arunkumar, Guha
   Asthagiri/0000-0003-3665-2708; Gilbert, Sarah/0000-0002-6823-9750
FU MRC Biomedical Catalyst DPFS_DCS award [MR/N006372/1]; NIAID Centers of
   Excellence for Influenza Research and Surveillance contract (CEIRS)
   [HHSN272201400008C]; NIAID T32 Virus-Host Interactions training grant
   [5T32AI007647-17]
FX We thank Shirin Strohmeier and Fatima Amanat for purification of
   recombinant proteins used in this study. The study was funded by an MRC
   Biomedical Catalyst DPFS_DCS award (MR/N006372/1). In addition, this
   study was partially funded by the NIAID Centers of Excellence for
   Influenza Research and Surveillance contract (CEIRS, HHSN272201400008C).
   Andriani loannou was supported by an NIAID T32 Virus-Host Interactions
   training grant (5T32AI007647-17).
CR Antrobus RD, 2014, MOL THER, V22, P668, DOI 10.1038/mt.2013.284
   Antrobus RD, 2014, MOL THER, V22, P233, DOI 10.1038/mt.2013.162
   Antrobus RD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048322
   Babon JAB, 2009, HUM IMMUNOL, V70, P711, DOI 10.1016/j.humimm.2009.06.004
   Berthoud TK, 2011, CLIN INFECT DIS, V52, P1, DOI 10.1093/cid/ciq015
   Choi Angela, 2019, Immunohorizons, V3, P133, DOI 10.4049/immunohorizons.1900022
   Clemens EB, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020018
   Corbett KS, 2019, MBIO, V10, DOI 10.1128/mBio.02810-18
   Coughlan L, 2018, EBIOMEDICINE, V29, P146, DOI 10.1016/j.ebiom.2018.02.011
   de Jong JC, 2000, J MED VIROL, V61, P94, DOI 10.1002/(SICI)1096-9071(200005)61:1&lt;94::AID-JMV15&gt;3.0.CO;2-C
   Ermler ME, 2017, J VIROL, V91, DOI 10.1128/JVI.00286-17
   Forbes EK, 2011, J IMMUNOL, V187, P3738, DOI 10.4049/jimmunol.1003783
   Goff PH, 2013, J VIROL, V87, P8235, DOI [10.1128/JVI.01085-13, 10.1128/JVI.03183-13]
   Hayward AC, 2015, AM J RESP CRIT CARE, V191, P1422, DOI 10.1164/rccm.201411-1988OC
   Himly M, 1998, VIROLOGY, V248, P295, DOI 10.1006/viro.1998.9290
   Impagliazzo A, 2015, SCIENCE
   Isakova-Sivak I, 2018, VIROLOGY, V518, P313, DOI 10.1016/j.virol.2018.03.013
   Krammer F, 2019, NAT REV IMMUNOL
   Krammer F, 2015, CELL HOST MICROBE, V18, P395, DOI 10.1016/j.chom.2015.10.003
   Krammer F, 2014, J VIROL, V88, P3432, DOI 10.1128/JVI.03004-13
   Krammer F, 2013, J VIROL, V87, P6542, DOI 10.1128/JVI.00641-13
   Krammer F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043603
   Kreijtz JHCM, 2007, VACCINE, V25, P612, DOI 10.1016/j.vaccine.2006.08.036
   Lambe T, 2013, SCI REP-UK, V3, DOI 10.1038/srep01443
   LaMere MW, 2011, J VIROL, V85, P5027, DOI 10.1128/JVI.00150-11
   LaMere MW, 2011, J IMMUNOL, V186, P4331, DOI 10.4049/jimmunol.1003057
   Lillie PJ, 2012, CLIN INFECT DIS, V55, P19, DOI 10.1093/cid/cis327
   Margine I, 2013, J VIROL, V87, P10435, DOI 10.1128/JVI.01715-13
   Margine I, 2013, JOVE-J VIS EXP, DOI 10.3791/51112
   McElhaney JE, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00041
   MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103
   Mullarkey CE, 2013, EUR J IMMUNOL, V43, P1940, DOI 10.1002/eji.201242922
   Nachbagauer R, 2017, CLIN MICROBIOL INFEC, V23, P222, DOI 10.1016/j.cmi.2017.02.009
   Nachbagauer R, 2017, NAT IMMUNOL
   Nachbagauer R, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030047
   Nachbagauer R, 2018, CURR OPIN IMMUNOL, V53, P51, DOI 10.1016/j.coi.2018.04.001
   Nachbagauer R, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0026-4
   Nachbagauer R, 2016, NPJ VACCINES, V1, DOI 10.1038/npjvaccines.2016.15
   Nachbagauer R, 2016, MBIO, V7, DOI 10.1128/mBio.01996-15
   Nachbagauer R, 2016, J VIROL, V90, P3268, DOI 10.1128/JVI.02481-15
   Nayak JL, 2015, J INFECT DIS, V211, P1408, DOI 10.1093/infdis/jiu616
   Orubu T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040167
   Pavot V, 2017, METHODS MOL BIOL, V1581, P97, DOI 10.1007/978-1-4939-6869-5_6
   Powell TJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062778
   Richards KA, 2015, J INFECT DIS, V212, P86, DOI 10.1093/infdis/jiu662
   Ryder AB, 2016, J VIROL, V90, P2544, DOI 10.1128/JVI.02598-15
   Sant AJ, 2018, IMMUNOL REV, V284, P91, DOI 10.1111/imr.12662
   SCHULMAN JL, 1965, J BACTERIOL, V89, P170, DOI 10.1128/JB.89.1.170-174.1965
   Sebastian S, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020029
   Tully CM, 2017, J IMMUNOL
   Ulmer JB, 1998, J VIROL, V72, P5648, DOI 10.1128/JVI.72.7.5648-5653.1998
   Vanderven HA, 2016, EBIOMEDICINE, V8, P277, DOI 10.1016/j.ebiom.2016.04.029
   Wang ZD, 2010, VACCINE, V28, P1547, DOI 10.1016/j.vaccine.2009.11.056
   Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612
   Xie H, 2015, SCI REP-UK, V5, DOI 10.1038/srep15279
   Yassine HM, 2015, NAT MED, V21, P1065, DOI 10.1038/nm.3927
NR 56
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 3
PY 2019
VL 37
IS 37
BP 5567
EP 5577
DI 10.1016/j.vaccine.2019.07.095
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IW7ZL
UT WOS:000485212400010
PM 31399277
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Gebauer, M
   Hurlimann, HC
   Behrens, M
   Wolff, T
   Behrens, SE
AF Gebauer, Mandy
   Huerlimann, Hans C.
   Behrens, Martina
   Wolff, Thorsten
   Behrens, Sven-Erik
TI Subunit vaccines based on recombinant yeast protect against influenza A
   virus in a one-shot vaccination scheme
SO VACCINE
LA English
DT Article
DE Kluveromyces lactis; Yeast vaccine; Influenza; HA; M1; Subunit vaccine;
   DIVA
ID MATRIX PROTEIN; HEMAGGLUTININ; FORMULATION; PARTICLE; RECOGNITION
AB Here we report on new subunit vaccines based on recombinant yeast of the type Kluyveromyces lactis (K. lactis), which protect mice from a lethal influenza A virus infection. Applying a genetic system that enables the rapid generation of transgenic yeast, we have developed K. lactis strains that express the influenza A virus hemagglutinin, HA, either individually or in combination with the viral M1 matrix protein. Subcutaneous application of the inactivated, but otherwise non-processed yeast material shows a complete protection of BALB/c mice in prime/boost and even one-shot/single dose vaccination schemes against a subsequent, lethal challenge with the cognate influenza virus. The yeast vaccines induce titers of neutralizing antibodies that are readily comparable to those induced by an inactivated virus vaccine. These data suggest that HA and M1 are produced with a high antigenicity in the yeast cells. Based on these findings, multivalent, DIVA-capable, yeast-based subunit vaccines may be developed as promising alternatives to conventional virus-based anti-flu vaccines for veterinary applications. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Gebauer, Mandy; Behrens, Martina; Behrens, Sven-Erik] Martin Luther Univ Halle Wittenberg, Fac Life Sci NFl, Inst Biochem & Biotechnol, Kurt Mothes Str 3, D-06120 Halle, Saale, Germany.
   [Huerlimann, Hans C.] Martin Luther Univ Halle Wittenberg, Fac Life Sci NFl, Inst Biol, Weinbergweg 10, D-06120 Halle, Saale, Germany.
   [Wolff, Thorsten] Robert Koch Inst, Unit Influenza & Other Resp Viruses 17, Seestr 10, D-13353 Berlin, Germany.
RP Behrens, SE (reprint author), Martin Luther Univ Halle Wittenberg, Fac Life Sci NFl, Inst Biochem & Biotechnol, Kurt Mothes Str 3, D-06120 Halle, Saale, Germany.
EM sven.behrens@biochemtech.uni-halle.de
FU GO-Bio funding program (VER-OVACCiNES) of the Bundesministerium fur
   Bildung and Forschung (BMBF, PTJ), GermanyFederal Ministry of Education
   & Research (BMBF) [Fkz. 031A144]
FX This study was supported by the GO-Bio funding program (VER-OVACCiNES,
   Fkz. 031A144) of the Bundesministerium fur Bildung and Forschung (BMBF,
   PTJ), Germany. We thank Hanjo Hennemann, Karin Breunig, Karsten Mader,
   Christian Grund and Stefan Bennewitz for valuable discussions, and we
   are grateful to Gary Sawers for critical reading of the manuscript.
   Katja Rostowski, Marie-Luise Hoffmann, Mandy Koller and Jenny Wieszcorek
   are acknowledged for excellent technical assistance.
CR Ardiani A, 2010, FEMS YEAST RES, V10, P1060, DOI 10.1111/j.1567-1364.2010.00665.x
   Arnold M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042870
   Athmaram TN, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-524
   Bayne ACV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061790
   BRACIALE TJ, 1977, J EXP MED, V146, P673, DOI 10.1084/jem.146.3.673
   Breunig KD, 2000, ENZYME MICROB TECH, V26, P771, DOI 10.1016/S0141-0229(00)00170-8
   Calabro S, 2013, VACCINE, V31, P3363, DOI 10.1016/j.vaccine.2013.05.007
   Cao S, 2012, J VIROL, V86, P4883, DOI 10.1128/JVI.06586-11
   Chen J, 1998, CELL, V95, P409, DOI 10.1016/S0092-8674(00)81771-7
   Chianese-Bullock KA, 1998, J IMMUNOL, V161, P1599
   Cornelissen LAHM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010645
   Donnini C, 2004, APPL ENVIRON MICROB, V70, P2632, DOI 10.1128/AEM.70.5.2632-2638.2004
   Eggink D, 2014, J VIROL, V88, P699, DOI 10.1128/JVI.02608-13
   Galarza JM, 2005, VIRAL IMMUNOL, V18, P244, DOI 10.1089/vim.2005.18.244
   Hasan NH, 2016, VIRAL IMMUNOL, V29, P198, DOI 10.1089/vim.2015.0127
   Hernandez LA, 2016, VET MICROBIOL, V191, P35, DOI 10.1016/j.vetmic.2016.05.011
   Kang SM, 2012, EXPERT REV VACCINES, V11, P995, DOI 10.1586/ERV.12.70
   Krijger JJ, 2012, MICROB CELL FACT, V11, DOI 10.1186/1475-2859-11-112
   Kumru OS, 2014, BIOLOGICALS, V42, P237, DOI 10.1016/j.biologicals.2014.05.007
   Lin SC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092822
   Liu GL, 2013, VACCINE, V31, P5398, DOI 10.1016/j.vaccine.2013.09.009
   Lopez-Macias Constantino, 2012, Hum Vaccin Immunother, V8, P411, DOI 10.4161/hv.18757
   Luo Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22874-w
   Maciola AK, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00444
   Mallajosyula JK, 2014, HUM VACC IMMUNOTHER, V10, P586, DOI 10.4161/hv.27567
   Matrosovich M, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-63
   Milian E, 2015, BIOMED RES INT, DOI 10.1155/2015/504831
   MORTON DB, 1985, VET REC, V116, P431, DOI 10.1136/vr.116.16.431
   MULDER W, 1995, CURR GENET, V28, P267, DOI 10.1007/BF00309786
   Neumann G, 2015, VIROLOGY, V479, P234, DOI 10.1016/j.virol.2015.03.009
   Nogales A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010020
   Ozawa M, 2013, ANNU REV ANIM BIOSCI, V1, P21, DOI 10.1146/annurev-animal-031412-103733
   Palese P, 2006, EMERG INFECT DIS, V12, P61, DOI 10.3201/eid1201.051043
   Quan FS, 2016, EXPERT REV VACCINES, V15, P1281, DOI 10.1080/14760584.2016.1175942
   Rahn J, 2015, VACCINE, V33, P2414, DOI 10.1016/j.vaccine.2015.03.052
   Rajao DS, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00123
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Rey FA, 2018, CELL, V172, P1319, DOI 10.1016/j.cell.2018.02.054
   Rodicio R, 2013, YEAST, V30, P165, DOI 10.1002/yea.2954
   Rodriguez-Limas WA, 2011, MICROB CELL FACT, V10, DOI 10.1186/1475-2859-10-33
   SCHULZE IT, 1997, J INFECT DIS S1, V176, P24
   Scorza FB, 2016, VACCINE, V34, P2926, DOI 10.1016/j.vaccine.2016.03.085
   Shaw ML, 2013, FIELDS VIROLOGY, V1, P1151
   Short KR, 2015, ONE HEALTH, V1, P1, DOI [10.1016/j.onehlt.2015.03.001, 10.1016/j.onehit.2015.03.001]
   Soema PC, 2015, EUR J PHARM BIOPHARM, V94, P251, DOI 10.1016/j.ejpb.2015.05.023
   Spohner SC, 2016, J BIOTECHNOL, V222, P104, DOI 10.1016/j.jbiotec.2016.02.023
   Stelzner JJ, 2018, VACCINE, V36, P2314, DOI 10.1016/j.vaccine.2018.03.019
   Thompson CM, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-141
   Tsai SM, 2011, J VIROL METHODS, V175, P175, DOI 10.1016/j.jviromet.2011.05.006
   van Ooyen AJJ, 2006, FEMS YEAST RES, V6, P381, DOI 10.1111/j.1567-1364.2006.00049.x
   Van Reeth K, 2013, CURR TOP MICROBIOL, V370, P173, DOI 10.1007/82_2012_266
   VanderWaal K, 2018, P NATL ACAD SCI USA, V115, P11495, DOI 10.1073/pnas.1806068115
   Vincent AL, 2017, VET MICROBIOL, V206, P35, DOI 10.1016/j.vetmic.2016.11.026
   Wang M, 2016, BIOENGINEERED, V7, P155, DOI 10.1080/21655979.2016.1191707
   Wood JM, 2004, NAT REV MICROBIOL, V2, P842, DOI 10.1038/nrmicro979
   World Health Organization, 2018, INFL SEAS
NR 56
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 3
PY 2019
VL 37
IS 37
BP 5578
EP 5587
DI 10.1016/j.vaccine.2019.07.094
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IW7ZL
UT WOS:000485212400011
PM 31399274
DA 2020-05-12
ER

PT J
AU Zhao, FF
   Zhai, YZ
   Zhu, JY
   Xiao, PP
   Feng, GH
AF Zhao, Fangfang
   Zhai, Yongzhen
   Zhu, Junyao
   Xiao, Pengpeng
   Feng, Guohe
TI Enhancement of autophagy as a strategy for development of new DNA
   vaccine candidates against Japanese encephalitis
SO VACCINE
LA English
DT Article
DE Japanese encephalitis virus; DNA vaccine; Autophagy; LC3; Immune
   response; Long-term immune memory
ID VIRUS; ANTIGENS; SUBSETS; PROTEIN
AB For decades, an on-going concerted effort has been made to develop a universal DNA vaccine to combat the looming threat of a potential outbreak of the emerging Japanese encephalitis virus (JEV) infection. However, effective strategies are urgently required to counter poor immunogenicity and insufficient long-term protection. Recent reports have confirmed the critical role of autophagy in antigen presentation, long-term immune memory and immune responses against JEV. In this study, JEV prM and E protein with strong immunogenicity were fused with microtubule-associated protein 1 light chain 3 (LC3) encoding gene to construct an autophagy-mediated pJME-LC3 DNA vaccine. Researches indicated significant increase of autophagosomes or LC3 II expression in pJME-LC3 transfected cells. Furthermore, prME-LC3 fused protein was observed co-localized with GFP-LC3 to autophagosomes, which means it was successfully targeted to autophagosomes. After immunizing with pJME-LC3, mice were detected highest proportion of CD3(+)CD8(+) T lymphocytes, CD8(+) effector memory T cells (TEMs) and JEV specific cytotoxic T lymphocyte (CTL) activity to eliminate JEV. pJME-LC3 also enhanced IgG2a antibody in serum and cytokines IFN-gamma, IL-12 produced by splenocytes, thus skew toward Th1 type immune response by activating the JAK2/STAT1 signaling pathway and upregulating expression of transcription factor T-bet. Notably, mice immunized with pJME-LC3 showed highest survival rate and long-lasting neutralizing antibody when challenged with virulent JEV, which were consistent with augment in percentage of CD4(+) central memory T cells (TCMs). In brief, our studies suggested that autophagy can be used as a optimization strategy to enhance JEV specific immune response and long-term immune memory. Our attempt will contribute towards future efforts to develop an efficacious JEV vaccine. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhao, Fangfang; Zhai, Yongzhen; Zhu, Junyao; Feng, Guohe] China Med Univ, Shengjing Hosp, Dept Infect Dis, Shenyang 110004, Liaoning, Peoples R China.
   [Xiao, Pengpeng] Wenzhou Univ, Inst Virol, Wenzhou 325035, Peoples R China.
RP Feng, GH (reprint author), China Med Univ, Shengjing Hosp, Dept Infect Dis, Shenyang 110004, Liaoning, Peoples R China.
EM zhaiyz@sj-hospital.org; fenggh@sj-hospital.org
FU National Natural Science Foundation Youth Fund Project of China
   [81501428]
FX We would like to thank Pro. Huijun Lu for providing JEV-YN2016-1 strain.
   This work was supported by the National Natural Science Foundation Youth
   Fund Project of China (Grant No. 81501428).
CR Anthony MB, 2003, J IMMUNOL, V171, P17
   Burleson GR, 2018, METHODS MOL BIOL, V1803, P199, DOI 10.1007/978-1-4939-8549-4_13
   Busch DH, 2016, SEMIN IMMUNOL, V28, P28, DOI 10.1016/j.smim.2016.02.001
   Campbell GL, 2011, B WORLD HEALTH ORGAN, V89, P766, DOI 10.2471/BLT.10.085233
   Chinese Centers for Disease Control and Prevention, 2018, MORB MORT STAT COMM
   Das M, 2015, ONCOTARGET, V6, P28527, DOI 10.18632/oncotarget.5268
   English L, 2009, AUTOPHAGY, V5, P1026, DOI 10.4161/auto.5.7.9163
   Feng GH, 2007, INTERVIROLOGY, V50, P93, DOI 10.1159/000097395
   Jensen KDC, 2016, TRENDS PARASITOL, V32, P88, DOI 10.1016/j.pt.2015.12.011
   Kuma A, 2017, AUTOPHAGY, V13, P1619, DOI 10.1080/15548627.2017.1343770
   Leidal AM, 2018, NAT CELL BIOL, V20, P1338, DOI 10.1038/s41556-018-0235-8
   Li GY, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6040073
   Munz C, 2016, IMMUNOL REV, V272, P17, DOI 10.1111/imr.12422
   Murera D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23993-0
   Nickols B, 2017, VIROLOGY, V512, P66, DOI 10.1016/j.virol.2017.09.005
   Puleston DJ, 2014, ELIFE, V3, DOI 10.7554/eLife.03706
   Qi QC, 2018, MOLECULES, V23, DOI 10.3390/molecules23102668
   Sharma M, 2017, J GEN VIROL, V98, P1027, DOI 10.1099/jgv.0.000792
   Singh A, 2015, J INFECT DIS, V212, P715, DOI 10.1093/infdis/jiv023
   Tian Y, 2016, J IMMUNOL, V197, P1308, DOI 10.4049/jimmunol.1502481
   Walker WL, 2018, VACCINE, V36, P4369, DOI 10.1016/j.vaccine.2018.04.038
   Wijesinghe PR, 2016, VACCINE, V34, P5923, DOI 10.1016/j.vaccine.2016.10.028
   Wodarz D, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006461
   Wu H, 2018, EXP THER MED, V15, P1914, DOI 10.3892/etm.2017.5633
   Xu XJ, 2014, NAT IMMUNOL, V15, P1152, DOI 10.1038/ni.3025
   Yang L, 2018, RES VET SCI, V119, P79, DOI 10.1016/j.rvsc.2018.05.017
   Yuan BQ, 2017, MOL NEUROBIOL, V54, P115, DOI 10.1007/s12035-015-9642-z
   Yun SI, 2014, HUM VACC IMMUNOTHER, V10, P263, DOI 10.4161/hv.26902
   Zhai YZ, 2015, MOL MED REP, V12, P199, DOI 10.3892/mmr.2015.3419
NR 29
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 3
PY 2019
VL 37
IS 37
BP 5588
EP 5595
DI 10.1016/j.vaccine.2019.07.093
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IW7ZL
UT WOS:000485212400012
PM 31399273
DA 2020-05-12
ER

PT J
AU Hassan, WS
   Giaretta, PR
   Rech, R
   Ollivault-Shiflett, M
   Esteve-Gasent, MD
AF Hassan, Wisam Salim
   Giaretta, Paula R.
   Rech, Raquel
   Ollivault-Shiflett, Morgane
   Esteve-Gasent, Maria D.
TI Enhanced protective efficacy of Borrelia burgdorferi BB0172
   derived-peptide based vaccine to control Lyme disease
SO VACCINE
LA English
DT Article
DE Lyme disease vaccine; CRM197; TTHc; Conjugated vaccines; Tick challenge
ID CONJUGATE VACCINES; TETANUS TOXIN; MURINE MODEL; MONOCLONAL-ANTIBODIES;
   PROTEIN CARRIERS; SURFACE PROTEIN; EPITOPE DENSITY; OSPC; INFECTIVITY;
   EXPRESSION
AB Lyme disease (LD) accounts for over 70% of tick-borne disease reported in the United States. The disease in humans is characterized by skin rash, arthritis, cardiac and neurological signs. Vaccination is the most efficient preventive measure that could be taken to reduce the incidence of the LD worldwide; however, at present no vaccine is available. In this study, evaluation of the Borrelia burgdorferi BB0172-derived peptide (PepB) in conjugated formulations was investigated as a vaccine candidate in murine model of LD. In brief, PepB was conjugated to the Cross-Reacting Material 197 (CRM197) and to Tetanus Toxoid heavy chain (1THc) molecules, and subsequently used to immunize C3H/HeN mice. Following the challenge with 10(5) spirochetes/mouse via subcutaneous inoculation, TTHc:PepB construct showed protection in 66% of the immunized animals. Hence, to further evaluate the efficacy of TTHc:PepB, immunized mice were challenged with B. burgdorferi using the tick model of infection. The outcome of this experiment revealed that serum from TTHc:PepB immunized mice was borrelicidal. After tick infection, bacterial burden was significantly reduced (over 70%) in vaccinated animals when compared with the control groups regardless of whether the mice were infested 8 or 12-weeks post-priming. Therefore, we conclude that PepB conjugated antigens can serve as an alternative to prevent LD; nevertheless, further studies will be needed to dissect the mechanisms by which anti-PepB IgG antibodies are able to kill B. burgdorferi in vitro and in vivo to further advance in the development of formulations and delivery alternative to generate a safe anti-LD vaccine. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hassan, Wisam Salim; Giaretta, Paula R.; Rech, Raquel; Esteve-Gasent, Maria D.] Texas A&M Univ, Dept Vet Pathol, College Stn, TX 77843 USA.
   [Hassan, Wisam Salim] Univ Mosul, Dept Internal & Prevent Vet Med, Mosul, Iraq.
   [Ollivault-Shiflett, Morgane] Fina Biosolut LLC, 9430 Key West, Rockville, MD 20850 USA.
RP Esteve-Gasent, MD (reprint author), Texas A&M Univ, Dept Vet Pathol, College Stn, TX 77843 USA.
EM rrech@cvm.tamu.edu; legassent@gmail.com
RI Esteve-Gassent, Maria/AAF-2597-2020
OI Rech, Raquel/0000-0003-3768-0743; Esteve-Gasent,
   Maria/0000-0001-5921-2794
CR Anguita J, 2002, IMMUNITY, V16, P849, DOI 10.1016/S1074-7613(02)00325-4
   BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784
   Ball EC, 2015, DISEASE
   BARBOUR AG, 1984, INFECT IMMUN, V45, P94, DOI 10.1128/IAI.45.1.94-100.1984
   BARBOUR AG, 1993, SCIENCE, V260, P1610, DOI 10.1126/science.8503006
   BARBOUR AG, 1983, INFECT IMMUN, V41, P795, DOI 10.1128/IAI.41.2.795-804.1983
   Beresford NJ, 2017, VACCINE, V35, P3598, DOI 10.1016/j.vaccine.2017.03.066
   Borchers AT, 2015, J AUTOIMMUN, V57, P82, DOI 10.1016/j.jaut.2014.09.004
   Borrow R, 2005, VACCINE, V23, P2222, DOI 10.1016/j.vaccine.2005.01.051
   Broker M, 2017, VACCINE, V35, P3286, DOI 10.1016/j.vaccine.2017.04.078
   Brooks CS, 2003, INFECT IMMUN, V71, P3371, DOI 10.1128/IAI.71.6.3371-3383.2003
   Caimano MJ., 2005, CURRENT PROTOCOLS MI
   Cassatt DR, 1998, INFECT IMMUN, V66, P5379, DOI 10.1128/IAI.66.11.5379-5387.1998
   CHARLES IG, 1991, INFECT IMMUN, V59, P1627, DOI 10.1128/IAI.59.5.1627-1632.1991
   Conlon J A, 2000, Vet Ther, V1, P96
   DEMOTZ S, 1993, EUR J IMMUNOL, V23, P425, DOI 10.1002/eji.1830230219
   DESAYMARD C, 1975, EUR J IMMUNOL, V5, P541, DOI 10.1002/eji.1830050807
   DESILVA AM, 1995, AM J TROP MED HYG, V53, P397, DOI 10.4269/ajtmh.1995.53.397
   Diethelm-Okita BM, 2000, J INFECT DIS, V181, P1001, DOI 10.1086/315324
   Dunshea FR, 2001, J ANIM SCI, V79, P2524
   Earnhart CG, 2014, HUMAN VAC, V3, P281
   Earnhart CG, 2007, HUM VACCINES, V3, P281, DOI 10.4161/hv.4661
   Earnhart CG, 2007, CLIN VACCINE IMMUNOL, V14, P628, DOI 10.1128/CVI.00409-06
   Esteve-Gassent MD, 2009, MOL MICROBIOL, V71, P594, DOI 10.1111/j.1365-2958.2008.06549.x
   Feng SL, 1998, INFECT IMMUN, V66, P2827, DOI 10.1128/IAI.66.6.2827-2835.1998
   Gilmore RD, 2003, J MED MICROBIOL, V52, P551, DOI 10.1099/jmm.0.05068-0
   Heath PT, 1998, PEDIATR INFECT DIS J, V17, pS117, DOI 10.1097/00006454-199809001-00005
   HOWE TR, 1985, SCIENCE, V227, P645, DOI 10.1126/science.3969554
   Jegerlehner A, 2002, EUR J IMMUNOL, V32, P3305, DOI 10.1002/1521-4141(200211)32:11<3305::AID-IMMU3305>3.0.CO;2-J
   JOHNSON RC, 1986, INFECT IMMUN, V53, P713, DOI 10.1128/IAI.53.3.713-714.1986
   Jones C, 2005, AN ACAD BRAS CIENC, V77, P293, DOI 10.1590/S0001-37652005000200009
   Kang IS, 1997, INFECT IMMUN, V65, P3107, DOI 10.1128/IAI.65.8.3107-3111.1997
   Kasumba IN, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1380-1
   KEANEMYERS A, 1995, J IMMUNOL, V154, P1770
   Kumar M, 2011, VACCINE, V29, P9012, DOI 10.1016/j.vaccine.2011.09.035
   Labandeira-Rey M, 2001, INFECT IMMUN, V69, P446, DOI 10.1128/IAI.69.1.446-455.2001
   LaFleur RL, 2009, CLIN VACCINE IMMUNOL, V16, P253, DOI 10.1128/CVI.00373-08
   Lee Y, 2015, ADV PROTEIN CHEM STR, V99, P75, DOI 10.1016/bs.apcsb.2015.03.004
   Lefebure T, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r71
   Li QA, 2010, CHEMBIOCHEM, V11, P1686, DOI 10.1002/cbic.201000235
   Liang FT, 2004, INFECT IMMUN, V72, P5759, DOI 10.1128/IAI.72.10.5759-5767.2004
   Lockyer K, 2015, VACCINE, V33, P1345, DOI 10.1016/j.vaccine.2015.01.046
   Maruskova M, 2008, INFECT IMMUN, V76, P391, DOI 10.1128/IAI.01118-07
   Michaelsen TE, 2004, SCAND J IMMUNOL, V59, P34, DOI 10.1111/j.0300-9475.2004.01362.x
   Pal U, 2004, CELL, V119, P457, DOI 10.1016/j.cell.2004.10.027
   Papaevangelou V, 2012, EXPERT REV VACCINES, V11, P523, DOI [10.1586/erv.12.32, 10.1586/ERV.12.32]
   PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538
   Pechova J, 2002, FOLIA PARASIT, V49, P153, DOI 10.14411/fp.2002.027
   Pichichero ME, 2013, HUM VACC IMMUNOTHER, V9, P2505, DOI 10.4161/hv.26109
   Piesman J, 2001, J CLIN MICROBIOL, V39, P4145, DOI 10.1128/JCM.39.11.4145-4148.2001
   Poellabauer EM, 2005, HUM VACCINES, V1, P131, DOI 10.4161/hv.1.4.2018
   Puffer EB, 2007, ACS CHEM BIOL, V2, P252, DOI 10.1021/cb600489g
   Qazi O, 2007, J MOL BIOL, V365, P123, DOI 10.1016/j.jmb.2006.09.050
   Ramamoorthi N, 2005, NATURE, V436, P573, DOI 10.1038/nature03812
   Richer LM, 2011, CLIN VACCINE IMMUNOL, V18, P1809, DOI 10.1128/CVI.05226-11
   Richmond P, 2001, J INFECT DIS, V183, P160, DOI 10.1086/317646
   Richter D, 2010, APPL ENVIRON MICROB, V76, P7650, DOI 10.1128/AEM.01649-10
   Seib KL, 2012, CLIN MICROBIOL INFEC, V18, P109, DOI 10.1111/j.1469-0691.2012.03939.x
   Seshu J, 2006, MOL MICROBIOL, V59, P1591, DOI 10.1111/j.1365-2958.2005.05042.x
   Sette A, 2010, IMMUNITY, V33, P530, DOI 10.1016/j.immuni.2010.09.017
   SHEPPARD AJ, 1984, INFECT IMMUN, V43, P710, DOI 10.1128/IAI.43.2.710-714.1984
   Sjowall J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018220
   Skwarczynski M, 2014, NANOMEDICINE-UK, V9, P2657, DOI [10.2217/NNM.14.187, 10.2217/nnm.14.187]
   Small CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088245
   Srivastava SY, 2008, J BACTERIOL, V190, P3429, DOI 10.1128/JB.00085-08
   Tettelin H, 2005, P NATL ACAD SCI USA, V102, P13950, DOI 10.1073/pnas.0506758102
   Vipond C, 2012, VACCINE, V30, pB10, DOI 10.1016/j.vaccine.2011.12.060
   VOLK WA, 1984, INFECT IMMUN, V45, P604, DOI 10.1128/IAI.45.3.604-609.1984
   Weis JJ, 1999, J IMMUNOL, V162, P948
   Widhe M, 2004, J INFECT DIS, V189, P1881, DOI 10.1086/382893
   Wood E, 2013, J BACTERIOL, V195, P3320, DOI 10.1128/JB.00187-13
   Zeidner NS, 2002, J PARASITOL, V88, P1276, DOI 10.2307/3285513
NR 72
TC 0
Z9 0
U1 6
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 3
PY 2019
VL 37
IS 37
BP 5596
EP 5606
DI 10.1016/j.vaccine.2019.07.092
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IW7ZL
UT WOS:000485212400013
PM 31387750
DA 2020-05-12
ER

PT J
AU Souza, IEL
   Fernandes, FF
   Schiavoni, MCL
   Silva, CL
   Panunto-Castelo, A
AF Souza, Igor Emiliano L.
   Fernandes, Fabricio F.
   Schiavoni, Maria Cristina L.
   Silva, Celio L.
   Panunto-Castelo, Ademilson
TI Therapeutic effect of DNA vaccine encoding the 60-kDa-heat shock protein
   from Paracoccidoides brasiliensis on experimental paracoccidioidomycosis
   in mice
SO VACCINE
LA English
DT Article
DE Paracoccidioides; DNA vaccine; Heat-shock protein;
   Paracoccidioidomycosis
ID IMMUNE-RESPONSE; GAMMA; INTERFERON; RESISTANCE; INFECTION; CYTOKINES
AB Paracoccidioidomycosis (PCM) is a systemic mycosis autochthonous to Latin America and endemic to Brazil, which has the majority of the PCM cases. PCM is acquired through the inhalation of propagules of fungi from genus Paracoccidioides spp. and mainly affects the lungs. We have previously shown that P. brasiliensis-infected mice treated with single-dose of recombinant 60-kDa-heat shock protein from P. brasiliensis (rPbHsp60) had a worsening infection in comparison to animals only infected. In this study, we investigate whether the treatment of infected mice with PB_HSP60 gene cloned into a plasmid (pVAX1-PB_HSP60) would result in efficient immune response and better control of the disease. The harmful impact of single-dose therapy with protein was not seen with plasmid preparations. Most importantly, three doses of pVAX1-PB_HSP60 and protein induced a beneficial effect in experimental PCM with a reduction in fungal load and lung injury when compared with infected mice treated with pVAX1 or PBS. The increase of the cytokines IFN-gamma, TNF, and IL-17 and the decrease of IL-10 observed after treatment with three doses of pVAX1-PB_HSP60 appears to be responsible for the control of infection. These results open perspectives of the therapeutic use of Hsp60 in PCM. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Souza, Igor Emiliano L.; Schiavoni, Maria Cristina L.; Silva, Celio L.] Univ Sao Paulo, Ribeirao Preto Med Sch, BR-14049900 Ribeirao Preto, SP, Brazil.
   [Fernandes, Fabricio F.] Univ Paulista, BR-14024270 Ribeirao Preto, SP, Brazil.
   [Panunto-Castelo, Ademilson] Univ Sao Paulo, Fac Philosophy Sci & Letters Ribeirao Preto, Dept Biol, Av Bandeirantes 3900, BR-14040901 Ribeirao Preto, SP, Brazil.
RP Panunto-Castelo, A (reprint author), Univ Sao Paulo, Fac Philosophy Sci & Letters Ribeirao Preto, Dept Biol, Av Bandeirantes 3900, BR-14040901 Ribeirao Preto, SP, Brazil.
EM apcastelo@usp.br
RI Castelo, Ademilson Panunto/C-8501-2012
OI Castelo, Ademilson Panunto/0000-0003-0148-0133
FU Sao Paulo Research Foundation FAPESPFundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2017/01390-8, 2013/012278-3]; National
   Council for Scientific and Technological Development (CNPq)National
   Council for Scientific and Technological Development (CNPq)
   [830699/1999-6, 144190/2015-0]
FX This work was supported by the Sao Paulo Research Foundation FAPESP
   [grant numbers 2017/01390-8 and 2013/012278-3] and National Council for
   Scientific and Technological Development (CNPq) [grant number
   830699/1999-6 - fellowship 144190/2015-0].
CR Soares RDA, 2008, INFECT IMMUN, V76, P4214, DOI 10.1128/IAI.00753-07
   BRUMMER E, 1993, CLIN MICROBIOL REV, V6, P89, DOI 10.1128/CMR.6.2.89-117.1993
   Calvi SA, 2003, MICROBES INFECT, V5, P107, DOI 10.1016/S1286-4579(02)00078-3
   Cano LE, 1998, INFECT IMMUN, V66, P800, DOI 10.1128/IAI.66.2.800-806.1998
   Costa TA, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002512
   Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771
   Coutinho Ziadir Francisco, 2002, Cad. Saúde Pública, V18, P1441, DOI 10.1590/S0102-311X2002000500037
   da Silva Thiago Aparecido, 2017, Methods Mol Biol, V1625, P159, DOI 10.1007/978-1-4939-7104-6_12
   de Oliveira LL, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000183
   Felonato M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051071
   Feriotti C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00786
   Fernandes FF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162486
   Fernandes VC, 2011, MICROBES INFECT, V13, P1062, DOI 10.1016/j.micinf.2011.06.004
   Hickey MJ, 1997, J IMMUNOL, V158, P3391
   Kashino SS, 2000, J INTERF CYTOK RES, V20, P89, DOI 10.1089/107999000312766
   Loures FV, 2011, INFECT IMMUN, V79, P2470, DOI 10.1128/IAI.00375-10
   Loures FV, 2015, FRONT MICROBIOL, P6
   Magalhaes A, 2012, CLIN VACCINE IMMUNOL, V19, P23, DOI 10.1128/CVI.05414-11
   Mamoni RL, 2002, MED MYCOL, V40, P153, DOI 10.1080/714031098
   Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683
   Neworal EPM, 2003, CYTOKINE, V21, P234, DOI 10.1016/S1043-4666(03)00051-6
   Fortes MRP, 2011, AN BRAS DERMATOL, V86, P516, DOI 10.1590/S0365-05962011000300014
   Restrepo A, 2012, CURR FUNGAL INFECT R, V6, P303, DOI 10.1007/s12281-012-0114-x
   Ribeiro AM, 2010, VACCINE, V28, P1528, DOI 10.1016/j.vaccine.2009.11.062
   Rittner GMG, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001519
   SANBLAS G, 1993, J MED VET MYCOL, V31, P99
   Schenborn E T, 2000, Methods Mol Biol, V130, P135
   Shikanai-Yasuda MA, 2017, REV SOC BRAS MED TRO, V50, P715, DOI 10.1590/0037-8682-0230-2017
   Silva-Vergara ML, 1998, MED MYCOL, V36, P37, DOI 10.1080/02681219880000061
   Souto JT, 2000, AM J PATHOL, V156, P1811, DOI 10.1016/S0002-9440(10)65053-5
   Travassos LR, 2008, EXPERT REV ANTI-INFE, V6, P251, DOI 10.1586/14787210.6.2.251
   Tristao FS, 2017, FRONT IMMUNOL, V8, P1
   Verma A, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a019612
NR 33
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 3
PY 2019
VL 37
IS 37
BP 5607
EP 5613
DI 10.1016/j.vaccine.2019.07.090
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IW7ZL
UT WOS:000485212400014
PM 31399276
DA 2020-05-12
ER

PT J
AU Haider, EA
   Willocks, LJ
   Anderson, N
AF Haider, Eram A.
   Willocks, Lorna J.
   Anderson, Niall
TI Identifying inequalities in childhood immunisation uptake and timeliness
   in southeast Scotland, 2008-2018: A retrospective cohort study
SO VACCINE
LA English
DT Article
DE Vaccination; Uptake; Timeliness; Child; Deprivation; Inequalities
ID MMR VACCINE UPTAKE; CHILDREN; AGE; COVERAGE; RECORDS; CARE
AB Background: In 2018, there was a record incidence of measles and other vaccine-preventable diseases across developed countries. Declining childhood immunisation uptake in southeast Scotland-an area with a large, highly mobile, and socioeconomically diverse population-threatens regional herd immunity and warrants investigation of suboptimal coverage. As deprivation of social and material resources increases risk of non-vaccination, we examined here the relationship between deprivation, uptake, and timeliness for four routine childhood vaccines and identified trends over the past decade.
   Methods: This retrospective cohort study analysed immunisation data from the Scottish Immunisation Recall System (SIRS) for four routine childhood vaccines in the UK: the third dose of the primary vaccine (TPV), both doses of measles, mumps, rubella (MMR 1 and MMR 2), and the preschool booster (PSB). Immunisations (N = 329,897) were administered between 2008 and 2018. Deprivation was measured via the Scottish Index of Multiple Deprivation (SIMD), ranking postcodes by deprivation decile. Chi-squared tests and cox proportional hazards models assessed the relationship between uptake, timeliness, and deprivation.
   Results: There is strong evidence for an association between deprivation, uptake, and timeliness. Uptake for all childhood immunisations are very high, especially for TPV and MMR 1 (>98.0%), though certain deprivation deciles exhibit increased risks of non-vaccination for all vaccines. Delay was pronounced for the 40% most deprived population and for immunisations scheduled at later ages. Absolute PSB and MMR 2 uptake has improved since 2008; however, disparities in uptake have increased for all vaccines since the 2006 birth cohort.
   Conclusion: Both timeliness and uptake are strongly associated with deprivation. While absolute uptake was high for all vaccines, relative uptake and timeliness has been worsening for most groups; the reason for this decline is unclear. Here we identified subgroups that may require targeted interventions to facilitate uptake and timeliness for essential childhood vaccines. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Haider, Eram A.; Anderson, Niall] Univ Edinburgh, Old Med Sch, Usher Inst Populat Hlth Sci & Informat, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.
   [Willocks, Lorna J.] Natl Hlth Serv Scotland, Directorate Publ Hlth & Hlth Policy, NHS Lothian, 2-4 Waterloo Pl, Edinburgh EH1 3EG, Midlothian, Scotland.
RP Haider, EA (reprint author), Univ Edinburgh, Old Med Sch, Usher Inst Populat Hlth Sci & Informat, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.
EM Eram.Haider@glasgow.ac.uk
CR Bedford H, 2013, J HLTH VISIT, V1, P8
   Busby C, 2015, COMMEN CD HOWE I, V421, P3
   Cameron JC, 2007, VACCINE, V25, P6078, DOI 10.1016/j.vaccine.2007.05.047
   Carlsen B, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-26
   Crowcroft NS, 2009, ARCH DIS CHILD, V94, P829, DOI 10.1136/adc.2008.138776
   Dhami S, 2008, J NURSES GEN PRACTIC, V36, P21
   Dummer TJB, 2012, CAN J PUBLIC HEALTH, V103, pE363, DOI 10.1007/BF03404442
   European Centre for Disease Prevention and Control (ECDC), 2017, IMM INF SYST EU EEA, P13
   Friederichs V, 2006, ARCH DIS CHILD, V91, P465, DOI 10.1136/adc.2005.085944
   Grant CC, 2010, BRIT J GEN PRACT, V60, DOI 10.3399/bjgp10X483535
   Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433
   Hull BP, 2006, VACCINE, V24, P4403, DOI 10.1016/j.vaccine.2006.02.049
   Information Services Division (ISD), 2018, CHILDH IMM STAT SCOT
   Information Services Division (ISD), 2016, SCOTT IMM REC SYST S
   Kirolos A, 2018, EPIDEMIOL INFECT, V146, P741, DOI 10.1017/S0950268818000602
   Lamden KH, 2008, J PUBLIC HEALTH-UK, V30, P251, DOI 10.1093/pubmed/fdn036
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Lawrence GL, 2004, VACCINE, V22, P2345, DOI 10.1016/j.vaccine.2003.10.038
   Lernout T, 2014, VACCINE, V32, P284, DOI 10.1016/j.vaccine.2013.10.084
   National Health Services (NHS), 2013, CONS TREATM
   NHS Health Scotland, 2018, MEAS HLTH IN
   NHS Health Scotland, 2018, IMM CHILD TEEN IMM N
   NHS Lothian, 2014, OUR HLTH OUR CAR OUR
   Pearce A, 2015, VACCINE, V33, P3377, DOI 10.1016/j.vaccine.2015.04.089
   PrabhuDas M, 2011, NAT IMMUNOL, V12, P189, DOI 10.1038/ni0311-189
   Public Health England (PHE), 2016, UK IMM SCHED
   Rao T S Sathyanarayana, 2011, Indian J Psychiatry, V53, P95, DOI 10.4103/0019-5545.82529
   Roland Damian, 2013, Community Pract, V86, P28
   Rumball-Smith J, 2016, NEW ZEAL MED J, V129, P15
   Sandford H, 2015, VACCINE, V33, P1218, DOI 10.1016/j.vaccine.2014.12.006
   Scottish Government, 2013, GUID PERF AN TIM
   Scottish Public Health Observatory (SPHO), 2008, DEPR INTR
   Smith PJ, 2004, PEDIATRICS, V114, P187, DOI 10.1542/peds.114.1.187
   Stupart R, 2003, CHILDHOOD IMMUNISATI
   Tickner S, 2006, VACCINE, V24, P7030, DOI 10.1016/j.vaccine.2006.06.060
   Tiley KS, 2018, VACCINE, V36, P6726, DOI 10.1016/j.vaccine.2018.09.032
   Vasudevan L, 2014, VACCINE, V32, P5514, DOI 10.1016/j.vaccine.2014.06.092
   Walton S, 2017, VACCINE, V35, P7166, DOI 10.1016/j.vaccine.2017.10.085
   World Health Organization, 2019, MEASL EUR REC NUMB B
NR 39
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 3
PY 2019
VL 37
IS 37
BP 5614
EP 5624
DI 10.1016/j.vaccine.2019.07.080
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IW7ZL
UT WOS:000485212400015
PM 31402236
OA Bronze
DA 2020-05-12
ER

PT J
AU Wagner, BG
   Althouse, BM
   Givon-Lavi, N
   Hu, H
   Dagan, R
AF Wagner, Bradley G.
   Althouse, Benjamin M.
   Givon-Lavi, Noga
   Hu, Hao
   Dagan, Ron
TI Stable dynamics of pneumococcal carriage over a decade in the pre-PCV
   era
SO VACCINE
LA English
DT Article
DE Streptococcus pneumoniae; Pneumococcal carriage; Pneumococcal conjugate
   vaccine
ID STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL CARRIAGE; VACCINE; CHILDREN;
   IMMUNOGENICITY; REDUCTION; HEALTHY
AB Streptococcus pneumoniae (SP) nasopharyngeal carriage studies are important to understand SP circulation prior to implementation of vaccination programs. It is generally not known how stable these carriage rates are over time.
   Carriage studies were conducted in Southern Israel during a decade preceding Pneumococcal Conjugate Vaccine (PCV) introduction. We estimated total and vaccine-type SP carriage at 6 months of age to be stable at 35% (95% CI: 26, 44) and 19% (95% CI: 15, 24), respectively in Jewish and 70% (95% Cl, 62, 77) and 41% (95% CI: 38, 45) in Bedouin populations.
   The stability of carriage rates in two disparate populations over 10 years suggests a single survey may be sufficient to characterize pneumococcal carriage pre-PCV. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Wagner, Bradley G.; Althouse, Benjamin M.; Hu, Hao] Inst Dis Modeling, Bellevue, WA 98005 USA.
   [Althouse, Benjamin M.] Univ Washington, Informat Sch, Seattle, WA 98195 USA.
   [Althouse, Benjamin M.] New Mexico State Univ, Dept Biol, Las Cruces, NM 88003 USA.
   [Givon-Lavi, Noga] Soroka Univ, Med Ctr, Pediat Infect Dis Unit, Beer Sheva, Israel.
   [Givon-Lavi, Noga; Dagan, Ron] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel.
RP Wagner, BG (reprint author), Inst Dis Modeling, Bellevue, WA 98005 USA.
EM bwagner@idmod.org
FU Pasteur-Merieux, France; GSK, Berna; Wyeth/PfizerWyethPfizer; Global
   Good Fund
FX The various studies from which the carriage data were obtained were
   supported by Pasteur-Merieux, France, GSK, Berna, Wyeth/Pfizer. None of
   these companies participated or contributed to the current analysis.
   BGW, BMA and HH were supported by Bill and Melinda Gates through the
   Global Good Fund.
CR Althouse BM, 2017, EPIDEMIOL INFECT, V145, P2750, DOI 10.1017/S095026881700125X
   [Anonymous], 2004, STAT YB NEG BED
   [Anonymous], 1998, STAT ABSTR ISR
   Bates D, 2013, J STAT SOFTW, V52, P1, DOI 10.18637/jss.v052.i05
   *CENTR BUR STAT, 2005, STAT ABSTR ISR
   Dagan R, 2004, INFECT IMMUN, V72, P5383, DOI 10.1128/IAI.72.9.5383-5391.2004
   Dagan R, 2007, PEDIATR INFECT DIS J, V26, P787, DOI 10.1097/INF.0b013e318060acbd
   Dagan R, 2013, CLIN INFECT DIS, V57, P952, DOI 10.1093/cid/cit428
   Fisher LD, 1999, ANNU REV PUBL HEALTH, V20, P145, DOI 10.1146/annurev.publhealth.20.1.145
   Givon-Lavi N, 2010, PEDIATR INFECT DIS J, V29, P756, DOI 10.1097/INF.0b013e3181d99345
   Greenberg D, 2004, J CLIN MICROBIOL, V42, P4604, DOI 10.1128/JCM.42.10.4604-4609.2004
   Izurieta P, 2018, EXPERT REV VACCINES, V17, P479, DOI 10.1080/14760584.2018.1413354
   Knowles J. E., 2016, MERTOOLS TOOLS ANAL
   Kuprys PV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058661
   Levy A, 1998, EUR J EPIDEMIOL, V14, P179, DOI 10.1023/A:1007439908351
   Lindstrand A, 2016, PLOS ONE, V11, DOI [1, 10.1371/journal.pone.0166018]
   Mackenzie GA, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-304
   Ojal J, 2017, VACCINE, V35, P4561, DOI 10.1016/j.vaccine.2017.07.019
   Ueno M, 2013, JPN J INFECT DIS, V66, P22, DOI 10.7883/yoken.66.22
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 3
PY 2019
VL 37
IS 37
BP 5625
EP 5629
DI 10.1016/j.vaccine.2019.07.077
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IW7ZL
UT WOS:000485212400016
PM 31383489
OA Other Gold
DA 2020-05-12
ER

PT J
AU MacIntyre, CR
   Shaw, PJ
   Mackie, FE
   Boros, C
   Marshall, H
   Seale, H
   Kennedy, SE
   Moa, A
   Chughtai, AA
   Trent, M
   O'Loughlin, EV
   Stormon, M
AF MacIntyre, C. Raina
   Shaw, Peter J.
   Mackie, Fiona E.
   Boros, Christina
   Marshall, Helen
   Seale, Holly
   Kennedy, Sean E.
   Moa, Aye
   Chughtai, Abrar Ahmad
   Trent, Mallory
   O'Loughlin, Edward V.
   Stormon, Michael
TI Long term follow up of persistence of immunity following quadrivalent
   Human Papillomavirus (HPV) vaccine in immunocompromised children
SO VACCINE
LA English
DT Article
DE Human papillomavirus; Warts; Vaccine; Cancer; Immunisation;
   Immunodeficiency; Adolescents
ID HPV-16/18 AS04-ADJUVANTED VACCINE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; GRADE
   CERVICAL DYSPLASIA; INTRAEPITHELIAL NEOPLASIA; HPV-6/11/16/18 VACCINE;
   NEUTRALIZING EPITOPES; 2-DOSE SCHEDULE; IMMUNOGENICITY; SAFETY; WOMEN
AB Background: Human Papillomavirus (HPV) causes significant burden of HPV-related diseases, which are more prevalent in immunosuppressed compared to immunocompetent people. We conducted a multi-centre clinical trial to determine the immunogenicity and reactogenicity of HPV vaccine in immunocompromised children. Here we present the immunogenicity results 5 years post vaccination.
   Methods: We followed up immunocompromised children (5-18 years) with a range of specified underlying conditions who were previously recruited from three Australian paediatric hospitals. Participants received three doses of quadrivalent HPV vaccine (Gardasil Quadrivalent HPV Types 6, 11, 16, 18) and were followed up between 2007 and 2016 (60 months post-vaccination). The immunogenicity primary outcome was seroconversion and geometric mean titres (GMT) of the quadrivalent HPV vaccine serotypes in the study.
   Results: Of the 59 original participants, 37 were followed up at 60 months. The proportion of participants who seroconverted were: 86.5%, 89.2%, 89.2%, 91.9% by competitive Luminex immunoassay (cLIA) and 83.8%, 83.8%, 94.6%, 78.4% by total immunoglobulin G assays (IgG) for serotypes 6, 11, 16 and 18 respectively. GMT values ranged from 118 (95%CI: 79-177) for serotype 11, to 373 (95%CI: 215-649) for serotype 16 by cLIA. For IgG, serotype 16 had the highest GMT of 261 (95%CI: 143-477) and serotype 18 had the lowest value of 37 (95%CI: 21-68). All antibody titres were lower in females compared to males but the difference was not statistically significant except for serotype 16. No serious adverse event was reported during this follow-up period.
   Conclusion: Our evidence, although limited by small numbers, is reassuring that a three dose schedule of HPV vaccine remains immunogenic in immunocompromised children to five years post vaccination. Large scale studies are required to determine long term protection in immunocompromised children. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [MacIntyre, C. Raina; Moa, Aye; Trent, Mallory] Univ New South Wales, Kirby Inst, Biosecur Program, Fac Med, Kensington, NSW 2052, Australia.
   [Shaw, Peter J.] Childrens Hosp Westmead, BMT Serv, Hawkesbury Rd, Westmead, NSW 2145, Australia.
   [Mackie, Fiona E.; Kennedy, Sean E.] Sydney Childrens Hosp, Nephrol, High St, Randwick, NSW 2031, Australia.
   [Mackie, Fiona E.; Kennedy, Sean E.] Univ New South Wales, Fac Med, Sch Womens & Childrens Hlth, Kensington, NSW 2052, Australia.
   [Boros, Christina; Marshall, Helen] Univ Adelaide, Womens & Childrens Hosp, 55 King William Rd, Adelaide, SA 5006, Australia.
   [Boros, Christina; Marshall, Helen] Univ Adelaide, Robinson Res Inst, 55 King William Rd, Adelaide, SA 5006, Australia.
   [Boros, Christina; Marshall, Helen] Univ Adelaide, Adelaide Med Sch, 55 King William Rd, Adelaide, SA 5006, Australia.
   [Seale, Holly; Chughtai, Abrar Ahmad] Univ New South Wales, Sch Publ Hlth & Community Med, Fac Med, Kensington, NSW 2052, Australia.
   [O'Loughlin, Edward V.; Stormon, Michael] Childrens Hosp Westmead, Dept Gastroenterol, Hawkesbury Rd, Westmead, NSW 2145, Australia.
RP Trent, M (reprint author), Univ New South Wales, Fac Med, Biosecur Program, Kirby Inst, Wallace Wurth Bldg,Room 644, Sydney, NSW 2052, Australia.
EM mallory.trent@unsw.edu.au
OI Seale, Holly/0000-0002-1877-5395
FU CARG grant (Roche, 2008); NHMRC Principal Research FellowshipNational
   Health and Medical Research Council of Australia [1137582]; National
   Health and Medical Research CouncilNational Health and Medical Research
   Council of Australia [1084951]; MerckMerck & Company
FX The study was in part supported by a CARG grant (Roche, 2008) received
   by Fiona Mackie, Sean Kennedy and Raina Maclntyre. Raina Maclntyre is
   supported by a NHMRC Principal Research Fellowship (1137582). Helen
   Marshall acknowledges support from the National Health and Medical
   Research Council (1084951). Laboratory testing was done by Merck and
   supported by a Merck Investigator Sponsored Proposal.
CR [Anonymous], 2017, Wkly Epidemiol Rec, V92, P241
   Australian Technical Advisory Group on Immunisation (ATAGI), 2018, AUSTR IMM HDB
   Baseman JG, 2005, J CLIN VIROL, V32, pS16, DOI 10.1016/j.jcv.2004.12.008
   Brown DR, 2011, HUM VACCINES, V7, P230, DOI 10.4161/hv.7.2.13948
   Conley LJ, 2002, LANCET, V359, P108, DOI 10.1016/S0140-6736(02)07368-3
   De Vincenzo R, 2014, IN J WOMENS HEALTH, V6, P999, DOI 10.2147/IJWH.S50365
   Dias D, 2005, CLIN DIAGN LAB IMMUN, V12, P959, DOI 10.1128/CDLI.12.8.959-969.2005
   Einstein MH, 2014, HUM VACC IMMUNOTHER, V10, P3435, DOI 10.4161/hv.36121
   Feldman CH, 2017, LUPUS, V26, P682, DOI 10.1177/0961203316672928
   Ferris D, 2014, PEDIATRICS, V134, pE657, DOI 10.1542/peds.2013-4144
   Ferris DG, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2016-3947
   Flanagan KL, 2017, ANNU REV CELL DEV BI, V33, P577, DOI 10.1146/annurev-cellbio-100616-060718
   Frisch M, 2000, J NATL CANCER I, V92, P1500, DOI 10.1093/jnci/92.18.1500
   Garland SM, 2017, PAPILLOMAVIRUS RES, V4, P35, DOI 10.1016/j.pvr.2017.06.002
   Garland SM, 2016, CLIN INFECT DIS, V63, P519, DOI 10.1093/cid/ciw354
   Harder T, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1098-3
   Harper A, 2018, CURR OPIN PHARMACOL, V41, P122, DOI 10.1016/j.coph.2018.05.009
   Harper DM, 2017, GYNECOL ONCOL, V146, P196, DOI 10.1016/j.ygyno.2017.04.004
   Heijstek MW, 2013, J RHEUMATOL, V40, P1626, DOI 10.3899/jrheum.130246
   Iversen OE, 2016, JAMA-J AM MED ASSOC, V316, P2411, DOI 10.1001/jama.2016.17615
   Jacobson DL, 2013, INFLAMM BOWEL DIS, V19, P1441, DOI 10.1097/MIB.0b013e318281341b
   Kim SC, 2015, ANN RHEUM DIS, V74, P1360, DOI 10.1136/annrheumdis-2013-204993
   Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9
   Klumb EM, 2010, JCR-J CLIN RHEUMATOL, V16, P153, DOI 10.1097/RHU.0b013e3181df5261
   LATSUZBAIA A, 2018, COCHRANE DB SYST REV, V6, DOI DOI 10.1128/GENOMEA.00114-18
   Leung TF, 2015, HUM VACC IMMUNOTHER, V11, P1689, DOI 10.1080/21645515.2015.1050570
   Levin MJ, 2010, JAIDS-J ACQ IMM DEF, V55, P197, DOI 10.1097/QAI.0b013e3181de8d26
   MacIntyre CR, 2016, VACCINE, V34, P4343, DOI 10.1016/j.vaccine.2016.06.049
   Mok CC, 2013, ANN RHEUM DIS, V72, P659, DOI 10.1136/annrheumdis-2012-201393
   Morris EA, 2016, TRANSPORT RES REC, P16, DOI 10.3141/2552-03
   National Centre for Immunisation Research & Surveillance, 2018, SIGN EV HUM PAP HPV
   Naud PS, 2014, HUM VACC IMMUNOTHER, V10, P2147, DOI 10.4161/hv.29532
   Opalka D, 2003, CLIN DIAGN LAB IMMUN, V10, P108, DOI 10.1128/CDLI.10.1.108-115.2003
   Opalka D, 2010, CLIN VACCINE IMMUNOL, V17, P818, DOI 10.1128/CVI.00348-09
   Pedersen C, 2007, J ADOLESCENT HEALTH, V40, P564, DOI 10.1016/j.jadohealth.2007.02.015
   Petaja T, 2009, J ADOLESCENT HEALTH, V44, P33, DOI 10.1016/j.jadohealth.2008.10.002
   Romanowski B, 2016, HUM VACC IMMUNOTHER, V12, P20, DOI 10.1080/21645515.2015.1065363
   Romanowski B, 2011, HUM VACCINES, V7, P1374, DOI 10.4161/hv.7.12.18322
   Scepanovic P, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0568-8
   Schwarz TF, 2017, CANCER MED-US, V6, P2723, DOI 10.1002/cam4.1155
   Steben M, 2018, J OBSTET GYN CAN JOG
   Wang J, 2014, J AM ACAD DERMATOL, V70, P621, DOI 10.1016/j.jaad.2014.01.857
   Wei LH, 2019, VACCINE, V37, P3617, DOI 10.1016/j.vaccine.2018.08.009
   Weinberg A, 2018, AIDS, V32, P851, DOI [10.1097/QAD.0000000000001773, 10.1097/qad.0000000000001773]
   Weinberg A, 2012, J INFECT DIS, V206, P1309, DOI 10.1093/infdis/jis489
NR 45
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 3
PY 2019
VL 37
IS 37
BP 5630
EP 5636
DI 10.1016/j.vaccine.2019.07.072
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IW7ZL
UT WOS:000485212400017
PM 31402238
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Romijnders, KAGJ
   van Seventer, SL
   Scheltema, M
   van Osch, L
   de Vries, H
   Mollema, L
AF Romijnders, Kim A. G. J.
   van Seventer, Stephne L.
   Scheltema, Manon
   van Osch, Liesbeth
   de Vries, Hein
   Mollema, Liesbeth
TI A deliberate choice? Exploring factors related to informed
   decision-making about childhood vaccination among acceptors, refusers,
   and partial acceptors
SO VACCINE
LA English
DT Article
DE Childhood vaccination; Decision-making; Focus groups; Qualitative
   research; Vaccine hesitancy; Alternative vaccination schedule
ID PARENTS; INFORMATION; CONTEXT; PERCEPTION; BEHAVIOR; IMPACT; BIAS
AB Objective: In light of the decline in childhood vaccination coverage, the question rises concerning what factors play a role in informed decision-making about childhood vaccination. Insight into factors related to this decision helps us to support parents' informed decision-making about childhood vaccination.
   Method: We conducted 12 semi-structured focus group interviews across the Netherlands based on a definition of informed decision-making: three with acceptors, three with refusers, and six with partial acceptors to ask about knowledge, attitudes, deliberation, and information needs. We performed a thematic analysis of the transcripts.
   Results: Acceptors viewed the decision to participate in the National Immunization Program (NIP) as self-evident. Refusers and partial acceptors, however, reported to extensively deliberate the pros and cons of accepting or refusing the NIP in much detail. Their answers indicated that their knowledge was not always evidence-based. In addition, refusers and partial acceptors perceived fewer risks of vaccine preventable diseases (VPDs), more risks of side-effects of vaccines, less social support from their environment, less trust in child welfare centers (CWCs), and information provided than acceptors.
   Conclusion: We observed distinct differences in factors related to decision-making about childhood vaccination between acceptors, refusers, and partial acceptors. Acceptors in the current study perceived accepting childhood vaccinations as self-evident, refusers relied mostly on anecdotal information rather than evidence-based information to weigh up the pros and cons vaccines and the VPDs, and partial acceptors elaborately deliberated the pros and cons of each vaccine and VPD individually, which was time-consuming and difficult. To strengthen and support decision-making among parents, more elaborate dialogues are needed between Child Vaccine Providers (CVPs) and parents. These discussions could build trust between parents and CVPs, be used to discuss the evidence-based advantages of childhood vaccinations, and to decrease parents' susceptibility to anecdotal information and misperceptions about childhood vaccinations shared by other parents. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Romijnders, Kim A. G. J.] Natl Inst Publ Hlth & Environm RIVM, Ctr Hlth Protect GZB, Antonie van Leeuwenhoeklaan 9, NL-3721 MA Bilthoven, Netherlands.
   [Romijnders, Kim A. G. J.; van Seventer, Stephne L.; Scheltema, Manon; van Osch, Liesbeth; de Vries, Hein] Maastricht Univ, Dept Hlth Promot, Sch Publ Hlth & Primary Care CAPHRI, POB 616, NL-6200 MD Maastricht, Netherlands.
   [Mollema, Liesbeth] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis CIB, Antonie van Leeuwenhoeklaan 9, NL-3721 MA Bilthoven, Netherlands.
RP Romijnders, KAGJ (reprint author), Natl Inst Publ Hlth & Environm RIVM, Ctr Hlth Protect GZB, Antonie van Leeuwenhoeklaan 9, NL-3721 MA Bilthoven, Netherlands.
EM kim.romijnders@rivm.nl; stephne@live.nl; m.b.scheltema@student.vu.nl;
   liesbeth.vanosch@maaschtrichtuniversity.nl;
   hein.devries@maastrichtuniver-sity.nl; liesbeth.mollema@rivm.nl
FU Dutch National Institute for Public Health and the Environment (RIVM)
   [S132006]
FX This work was supported by the Dutch National Institute for Public
   Health and the Environment (RIVM) (grant number S132006).
CR Audiotranskription, 2017, F4TRANSKRIPT
   Baron J., 2007, THINKING DECIDING
   Bedford H, 2018, VACCINE, V36, P6556, DOI 10.1016/j.vaccine.2017.08.004
   Benin AL, 2006, PEDIATRICS, V117, P1532, DOI 10.1542/peds.2005-1728
   Betsch C, 2016, MED DECIS MAKING, V36, P811, DOI 10.1177/0272989X15600434
   Betsch C, 2013, MED DECIS MAKING, V33, P14, DOI 10.1177/0272989X12452342
   Betsch C, 2013, HEALTH PSYCHOL, V32, P146, DOI 10.1037/a0027387
   Betsch C, 2012, VACCINE, V30, P3723, DOI 10.1016/j.vaccine.2012.03.078
   Betsch C, 2010, J HEALTH PSYCHOL, V15, P446, DOI 10.1177/1359105309353647
   Brewer NT, 2007, HEALTH PSYCHOL, V26, P136, DOI 10.1037/0278-6133.26.2.136
   Brunson EK, 2013, VACCINE, V31, P5466, DOI 10.1016/j.vaccine.2013.08.104
   Brunson EK, 2013, PEDIATRICS, V131, pE1397, DOI 10.1542/peds.2012-2452
   Centraal Bureau voor Statistiek (CBS), 2018, INT STAND CLASS ED I, P39
   Centraal Bureau voor Statistiek (CBS). Society: numbers of level of education, 2018, TRENDS NETH 2018
   Compton J, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00122
   Corben P, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5389-6
   DiCicco-Bloom B, 2006, MED EDUC, V40, P314, DOI 10.1111/j.1365-2929.2006.02418.x
   Downs JS, 2008, VACCINE, V26, P1595, DOI 10.1016/j.vaccine.2008.01.011
   Evers J, 2012, QUALITIVE INTERVIEW
   Geelen E, 2016, SOC SCI MED, V153, P12, DOI 10.1016/j.socscimed.2016.01.051
   Geraedts JLE, 2017, VACCINE COVERAGE NIP
   Geraedts JLE, 2018, VACCINE COVERAGE NIP
   Glick M, 2017, J AM DENT ASSOC, V148, P131, DOI 10.1016/j.adaj.2017.01.009
   Haase N, 2015, J HEALTH COMMUN, V20, P920, DOI 10.1080/10810730.2015.1018605
   Haase N, 2012, MED DECIS MAKING, V32, P645, DOI 10.1177/0272989X12445286
   Harmsen IA, 2012, ADV PREVENT MED, V2012
   Harmsen IA, 2014, CHILD VACCINE PROVID
   Lehmann BA, 2017, PATIENT EDUC COUNS, V100, P2339, DOI 10.1016/j.pec.2017.06.015
   MacDonald N, 2019, VACCINE, V37, P3947, DOI 10.1016/j.vaccine.2017.11.060
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Marteau TM, 2005, ARCH DIS CHILD, V90, P546
   Michie S, 2003, PATIENT EDUC COUNS, V50, P247, DOI 10.1016/S0738-3991(03)00044-2
   Michie S, 2002, PATIENT EDUC COUNS, V48, P87, DOI 10.1016/S0738-3991(02)00089-7
   Mollema L, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-128
   Montano DE, 2008, HLTH BEHAV HLTH ED T
   National Institute for Public Health and the Environment (RIVM), 2017, E LEARN BACKGR NIP
   National Institute for Public Health and the Environment (RIVM). National Immunization Program, 2018, HISTORY
   Neale J, 2014, ADDICTION, V109, P175, DOI 10.1111/add.12408
   Oomen PJ, 2016, VACCINE COVERAGE NIP
   Pot M, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.7449
   Powell RA, 1996, INT J QUAL HEALTH C, V8, P499, DOI 10.1093/intqhc/8.5.499
   QSR International Pty Ltd, 2010, NVIVO QUAL DAT AN SO
   Schmidt AL, 2018, VACCINE, V36, P3606, DOI 10.1016/j.vaccine.2018.05.040
   Serpell L, 2006, VACCINE, V24, P4041, DOI 10.1016/j.vaccine.2006.02.037
   Siegrist M, 2001, RISK ANAL, V21, P199, DOI 10.1111/0272-4332.211102
   Tickner S, 2007, VACCINE, V25, P7399, DOI 10.1016/j.vaccine.2007.08.008
   Vaismoradi M, 2013, NURS HEALTH SCI, V15, P398, DOI 10.1111/nhs.12048
   van den Berg M, 2006, PATIENT EDUC COUNS, V63, P110, DOI 10.1016/j.pec.2005.09.007
   WEINSTEIN ND, 1984, HEALTH PSYCHOL, V3, P431, DOI 10.1037/0278-6133.3.5.431
   WHO, 2018, IMM VACC BIOL
   Wolfe RM, 2005, J HEALTH COMMUN, V10, P537, DOI 10.1080/10810730500228847
NR 51
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 3
PY 2019
VL 37
IS 37
BP 5637
EP 5644
DI 10.1016/j.vaccine.2019.07.060
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IW7ZL
UT WOS:000485212400018
PM 31383488
OA Other Gold
DA 2020-05-12
ER

PT J
AU Akhtar, M
   Chowdhury, MI
   Bhuiyan, TR
   Kaim, J
   Ahmed, T
   Rafique, TA
   Khan, A
   Rahman, SIA
   Khanam, F
   Begum, YA
   Sharif, MZ
   Islam, LN
   Carlin, N
   Maier, N
   Fix, A
   Wierzba, TF
   Walker, RI
   Bourgeois, AL
   Svennerholm, AM
   Qadri, F
   Lundgren, A
AF Akhtar, Marjahan
   Chowdhury, Mohiul I.
   Bhuiyan, Taufiqur R.
   Kaim, Joanna
   Ahmed, Tasnuva
   Rafique, Tanzeem A.
   Khan, Arifuzzaman
   Rahman, Sadia I. A.
   Khanam, Farhana
   Begum, Yasmin A.
   Sharif, Mir Z.
   Islam, Laila N.
   Carlin, Nils
   Maier, Nicole
   Fix, Alan
   Wierzba, Thomas F.
   Walker, Richard I.
   Bourgeois, A. Louis
   Svennerholm, Ann-Mari
   Qadri, Firdausi
   Lundgren, Anna
TI Evaluation of the safety and immunogenicity of the oral inactivated
   multivalent enterotoxigenic Escherichia coli vaccine ETVAX in
   Bangladeshi adults in a double-blind, randomized, placebo-controlled
   Phase I trial using electrochemiluminescence and ELISA assays for
   immunogenicity analyses
SO VACCINE
LA English
DT Article
DE ETEC; Vaccine; Antibodies in lymphocyte supernatant; Antibody-secreting
   cell; IgA; Adult; ELISA; Electrochemiluminescence
ID ANTIBODY-SECRETING CELL; B-SUBUNIT VACCINE; INTESTINAL IMMUNE-RESPONSES;
   DEVELOPING-COUNTRIES; CHOLERA VACCINATION; ETEC VACCINE; COLONIZATION
   FACTORS; INFANTS; MUCOSAL; HUMANS
AB The safety and immunogenicity of the second generation oral enterotoxigenic Escherichia coli (ETEC) vaccine ETVAX, consisting of inactivated recombinant E. coli strains over-expressing the colonization factors (CFs) CFA/I, CS3, CS5 and CS6 and the heat labile toxoid LCTBA, were evaluated in Bangladeshi volunteers. To enable analysis of antibody responses against multiple vaccine antigens for subsequent use in small sample volumes from children, a sensitive electrochemiluminescence (ECL) assay for analysis of intestine-derived antibody-secreting cell responses using the antibodies in lymphocyte secretions (ALS) assay was established using Meso Scale Discovery technology.
   Three groups of Bangladeshi adults (n = 15 per group) received two oral doses of ETVAX with or without double mutant LT (dmLT) adjuvant or placebo in the initial part of a randomized, double-blind, placebo-controlled, age-descending, dose-escalation trial. CF- and LTB-specific ALS and plasma IgA responses were analyzed by ECL and/or ELISA.
   ETVAX was safe and well tolerated in the adults. Magnitudes of IgA ALS responses determined by ECL and ELISA correlated well (r = 0.85 to 0.98 for the five primary antigens, P < 0.001) and ECL was selected as the ALS readout method. ALS IgA responses against each of the primary antigens were detected in 87-100% of vaccinees after the first and in 100% after the second vaccine dose. Plasma IgA responses against different CFs and LTB were observed in 62-93% and 100% of vaccinees, respectively. No statistically significant adjuvant effect of dmLT on antibody responses to any antigen was detected, but the overall anti-genic breadth of the plasma IgA response tended to favor the adjuvanted vaccine when responses to 4 or more or 5 vaccine antigens were considered. Responses in placebo recipients were infrequent and mainly detected against single antigens.
   The promising results in adults supported testing ETVAX in descending age groups of children. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Akhtar, Marjahan; Chowdhury, Mohiul I.; Bhuiyan, Taufiqur R.; Ahmed, Tasnuva; Rafique, Tanzeem A.; Khan, Arifuzzaman; Rahman, Sadia I. A.; Khanam, Farhana; Begum, Yasmin A.; Sharif, Mir Z.; Qadri, Firdausi] Icddr B, Dhaka, Bangladesh.
   [Kaim, Joanna; Svennerholm, Ann-Mari; Lundgren, Anna] Univ Gothenburg, Inst Biomed, Dept Microbiol & Immunol, GUVAX Gothenburg Univ Vaccine Res Inst, Gothenburg, Sweden.
   [Carlin, Nils] Scandinavian Biopharma, Solna, Sweden.
   [Maier, Nicole; Fix, Alan; Wierzba, Thomas F.; Walker, Richard I.; Bourgeois, A. Louis] PATH, Washington, DC USA.
   [Islam, Laila N.] Univ Dhaka, Dept Biochem & Mol Biol, Dhaka, Bangladesh.
RP Lundgren, A (reprint author), Univ Gothenburg, Sahlgrenska Acad, Inst Biomed, Dept Microbiol & Immunol, Box 435, S-40530 Gothenburg, Sweden.
EM anna.lundgren@microbio.gu.se
RI Al, Mamun M./AAF-5850-2019; Qadri, Firdausi/AAF-4583-2019; Khan,
   Arifuzzaman/C-1117-2019
OI Khan, Arifuzzaman/0000-0003-4770-8308
FU icddr,b; PATH through its enteric vaccine project from the Bill and
   Melinda Gates Foundation [GR01263]; Swedish Research CouncilSwedish
   Research Council [VR 348-2013-6615]; British Department of International
   Development [300341-107]; Swedish Foundation for Strategic
   ResearchSwedish Foundation for Strategic Research [SB12-0072]
FX We acknowledge the support of the study participants as well as the
   dedicated field and laboratory workers in this study at icddr,b. The
   work was supported by icddr,b with funding from PATH through its enteric
   vaccine project (grant no. GR01263) from the Bill and Melinda Gates
   Foundation, the Swedish Research Council (grant number VR
   348-2013-6615), the British Department of International Development
   (program number 300341-107) and the Swedish Foundation for Strategic
   Research (grant number SB12-0072). icddr,b is thankful to the
   institutional donors for their support to its research efforts. icddr,b
   is also grateful to the governments of Bangladesh, Canada, Sweden and
   the UK for providing core/unrestricted support.
CR Ahren C, 1995, VACCINE, V13, P1754
   Ahren C, 1998, INFECT IMMUN, V66, P3311
   Akhtar M, 2017, VACCINE, V35, P321, DOI 10.1016/j.vaccine.2016.11.055
   Alam MM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002822
   Begum YA, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003031
   Bergquist C, 2000, J IMMUNOL METHODS, V234, P51, DOI 10.1016/S0022-1759(99)00213-6
   BLACKBURN GF, 1991, CLIN CHEM, V37, P1534
   Bourgeois AL, 2016, VACCINE, V34, P2880, DOI 10.1016/j.vaccine.2016.02.076
   Carpenter CM, 2006, VACCINE, V24, P3709, DOI 10.1016/j.vaccine.2005.07.022
   Chowdhury F, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000999
   DEAVER DR, 1995, NATURE, V377, P758, DOI 10.1038/377758a0
   Goldblatt D, 2011, CLIN VACCINE IMMUNOL, V18, P1744, DOI 10.1128/CVI.05158-11
   Holmgren J, 2013, VACCINE, V31, P2457, DOI 10.1016/j.vaccine.2013.03.027
   Jertborn M, 2001, CLIN DIAGN LAB IMMUN, V8, P424, DOI 10.1128/CDLI.8.2.424-428.2001
   Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2
   Leach S, 2017, VACCINE, V35, P3966, DOI 10.1016/j.vaccine.2017.06.006
   Leach S, 2013, VACCINE, V31, P3035, DOI 10.1016/j.vaccine.2013.04.066
   Lebens M, 1996, INFECT IMMUN, V64, P2144, DOI 10.1128/IAI.64.6.2144-2150.1996
   Lundgren A, 2013, VACCINE, V31, P1163, DOI 10.1016/j.vaccine.2012.12.063
   Lundgren A, 2016, VACCINE, V34, P3132, DOI 10.1016/j.vaccine.2016.04.055
   Lundgren A, 2014, VACCINE, V32, P7077, DOI 10.1016/j.vaccine.2014.10.069
   Lundgren A, 2009, VACCINE, V27, P4529, DOI 10.1016/j.vaccine.2009.05.005
   Ma XY, 2012, VACCINE, V30, P5358, DOI 10.1016/j.vaccine.2012.06.037
   Malkin E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077104
   Marchese RD, 2009, CLIN VACCINE IMMUNOL, V16, P387, DOI 10.1128/CVI.00415-08
   Nataro JP, 1998, CLIN MICROBIOL REV, V11, P142
   Norton EB, 2011, CLIN VACCINE IMMUNOL, V18, P546, DOI 10.1128/CVI.00538-10
   Panicker G, 2015, J IMMUNOL METHODS, V417, P107, DOI 10.1016/j.jim.2014.12.013
   Qadri F, 2006, VACCINE, V24, P1726, DOI 10.1016/j.vaccine.2005.08.110
   Qadri F, 2003, VACCINE, V21, P2394, DOI 10.1016/S0264-410X(03)00077-X
   Qadri F, 2003, INFECT IMMUN, V71, P4808, DOI 10.1128/IAI.71.8.4808-4814.2003
   Qadri F, 2000, VACCINE, V18, P2704, DOI 10.1016/S0264-410X(00)00056-6
   Qadri F, 2005, CLIN MICROBIOL REV, V18, P465, DOI 10.1128/CMR.18.3.465-483.2005
   Qadri F, 2007, INFECT IMMUN, V75, P3961, DOI 10.1128/IAI.00459-07
   Qadri F, 2006, INFECT IMMUN, V74, P4512, DOI 10.1128/IAI.00474-06
   QUIDING M, 1991, J CLIN INVEST, V88, P143, DOI 10.1172/JCI115270
   QuidingJarbrink M, 1997, J CLIN INVEST, V99, P1281, DOI 10.1172/JCI119286
   Rahman A, 2013, CLIN VACCINE IMMUNOL, V20, P1592, DOI 10.1128/CVI.00347-13
   Sack DA, 2007, VACCINE, V25, P4392, DOI 10.1016/j.vaccine.2007.03.034
   Sanchez J, 2005, CURR OPIN IMMUNOL, V17, P388, DOI 10.1016/j.coi.2005.06.007
   Savarino SJ, 1999, J INFECT DIS, V179, P107, DOI 10.1086/314543
   Shamsuzzaman S, 2009, VACCINE, V27, P1386, DOI 10.1016/j.vaccine.2008.12.041
   Svennerholm AM, 2012, EXPERT REV VACCINES, V11, P495, DOI [10.1586/erv.12.12, 10.1586/ERV.12.12]
   Swanson S J, 1999, Dev Biol Stand, V97, P135
   Walker RI, 2007, VACCINE, V25, P2545, DOI 10.1016/j.vaccine.2006.12.028
   WENNERAS C, 1992, INFECT IMMUN, V60, P2605
   Zegeye ED, 2019, HUM VACC IMMUNOTHER, V15, P1379, DOI 10.1080/21645515.2018.1496768
NR 47
TC 7
Z9 7
U1 4
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 3
PY 2019
VL 37
IS 37
BP 5645
EP 5656
DI 10.1016/j.vaccine.2018.11.040
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IW7ZL
UT WOS:000485212400019
PM 30473185
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Cooper, LV
   Stuart, JM
   Okot, C
   Asiedu-Bekoe, F
   Afreh, OK
   Fernandez, K
   Ronveaux, O
   Trotter, CL
AF Cooper, Laura V.
   Stuart, James M.
   Okot, Charles
   Asiedu-Bekoe, Franklin
   Afreh, Osei Kuffour
   Fernandez, Katya
   Ronveaux, Olivier
   Trotter, Caroline L.
TI Reactive vaccination as a control strategy for pneumococcal meningitis
   outbreaks in the African meningitis belt: Analysis of outbreak data from
   Ghana
SO VACCINE
LA English
DT Article
DE Streptococcus pneumoniae; Immunization; Meningitis; Mathematical models;
   African meningitis belt; Outbreak response
ID EPIDEMIC; CHILDREN
AB Streptococcus pneumoniae is increasingly recognised as an important cause of bacterial meningitis in the African meningitis belt. The World Health Organization sets guidelines for response to outbreaks of meningococcal meningitis, but there are no current guidelines for outbreaks where S. pneumoniae is implicated. We aimed to evaluate the impact of using a similar response to target outbreaks of vaccine-preventable pneumococcal meningitis in the meningitis belt. Here, we adapt a previous model of reactive vaccination for meningococcal outbreaks to estimate the potential impact of reactive vaccination in a recent pneumococcal meningitis outbreak in the Brong-Ahafo region of central Ghana using weekly line list data on all suspected cases over a period of five months. We determine the sensitivity and specificity of various epidemic thresholds and model the cases and deaths averted by reactive vaccination. An epidemic threshold of 10 suspected cases per 100,000 population per week performed the best, predicting large outbreaks with 100% sensitivity and more than 85% specificity. In this outbreak, reactive vaccination would have prevented a lower number of cases per individual vaccinated (approximately 15,300 doses per case averted) than previously estimated for meningococcal outbreaks. Since the burden of death and disability from pneumococcal meningitis is higher than that from meningococcal meningitis, there may still be merit in considering reactive vaccination for outbreaks of pneumococcal meningitis. More outbreak data are needed to refine our model estimates. Whatever policy is followed, we emphasize the importance of timely laboratory confirmation of suspected cases to enable appropriate decisions about outbreak response. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Cooper, Laura V.; Trotter, Caroline L.] Univ Cambridge, Dept Vet Med, Dis Dynam Unit, Madingley Rd, Cambridge CB3 0ES, England.
   [Stuart, James M.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London, England.
   [Okot, Charles] WHO Country Off Ghana, Accra, Ghana.
   [Asiedu-Bekoe, Franklin] Ghana Hlth Serv, Accra, Ghana.
   [Afreh, Osei Kuffour] Brong Ahafo Reg Hlth Directorate, Sunyani, Brong Ahafo, Ghana.
   [Fernandez, Katya; Ronveaux, Olivier] WHO, Hlth Emergencies Programme, Geneva, Switzerland.
RP Cooper, LV (reprint author), Univ Cambridge, Dept Vet Med, Dis Dynam Unit, Madingley Rd, Cambridge CB3 0ES, England.
EM lvc32@cam.ac.uk
OI Cooper, Laura/0000-0002-2942-3627
FU Trinity Hall College
FX LVC is supported by a studentship from Trinity Hall College.
CR Adokiya MN, 2017, ARCH PUBLIC HEALTH, V75, DOI 10.1186/s13690-017-0196-6
   [Anonymous], 2016, Wkly Epidemiol Rec, V91, P298
   [Anonymous], 2015, WORLD POP PROSP
   Campbell JD, 2004, PEDIATR INFECT DIS J, V23, P642, DOI 10.1097/01.inf.0000130951.85974.79
   Collard J-M, DETERMINATION PNEUMO
   Frenck R, 2014, PEDIATR INFECT DIS J, V33, P183, DOI 10.1097/INF.0000000000000056
   Gessner BD, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-22
   Greenwood B, 2006, CLIN INFECT DIS, V43, P701, DOI 10.1086/506943
   Kambire D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166384
   Kwambana-Adams BA, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1914-3
   Leimkugel J, 2005, J INFECT DIS, V192, P192, DOI 10.1086/431151
   Lingani C, 2015, CLIN INFECT DIS, V61, pS410, DOI 10.1093/cid/civ597
   Mackenzie GA, 2016, LANCET INFECT DIS, V16, P703, DOI 10.1016/S1473-3099(16)00054-2
   Moisi JC, BURDEN PNEUMOCOCCAL
   Stuart JM, CAN INFANT VACCINATI
   Traore Y, 2009, CLIN INFECT DIS, V48, pS181, DOI 10.1086/596498
   Trotter CL, 2015, VACCINE, V33, P6212, DOI 10.1016/j.vaccine.2015.09.107
   Tsaban G, 2017, VACCINE, V35, P2882, DOI 10.1016/j.vaccine.2017.04.032
   von Gottberg A, 2014, NEW ENGL J MED, V371, P1889, DOI 10.1056/NEJMoa1401914
   WHO, 2016, MAN MEN EP AFR
   World Health Organization, REV GUID MEN OUTBR R
   Yaro S, 2006, CLIN INFECT DIS, V43, P693, DOI 10.1086/506940
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 3
PY 2019
VL 37
IS 37
BP 5657
EP 5663
DI 10.1016/j.vaccine.2017.12.069
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IW7ZL
UT WOS:000485212400020
PM 29371015
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Laupeze, B
   Herve, C
   Di Pasquale, A
   Da Silva, FT
AF Laupeze, Beatrice
   Herve, Caroline
   Di Pasquale, Alberta
   Da Silva, Fernanda Tavares
TI Adjuvant Systems for vaccines: 13 years of post-licensure experience in
   diverse populations have progressed the way adjuvanted vaccine safety is
   investigated and understood
SO VACCINE
LA English
DT Review
DE Vaccine; Safety; Adjuvant; Adjuvant System; AS01; AS03; AS04
ID PAPILLOMAVIRUS-16/18 AS04-ADJUVANTED VACCINE; RTS,S/AS01 MALARIA
   VACCINE; ZOSTER SUBUNIT VACCINE; H1N1 2009 VACCINE; INFLUENZA
   VACCINATION; DOUBLE-BLIND; RISK; IMMUNOGENICITY; NARCOLEPSY; EFFICACY
AB Adjuvant Systems (AS) are combinations of immune stimulants that enhance the immune response to vaccine antigens. The first vaccine containing an AS (AS04) was licensed in 2005. As of 2018, several vaccines containing AS04, AS03 or AS01 have been licensed or approved by regulatory authorities in some countries, and included in vaccination programs. These vaccines target diverse viral and parasitic diseases (hepatitis B, human papillomavirus, malaria, herpes zoster, and (pre)pandemic influenza), and were developed for widely different target populations (e.g. individuals with renal impairment, girls and young women, infants and children living in Africa, adults 50 years of age and older, and the general population). Clearly, the safety profile of one vaccine in one target population cannot be extrapolated to another vaccine or to another target population, even for vaccines containing the same adjuvant. Therefore, the assessment of adjuvant safety poses specific challenges. In this review we provide a historical perspective on how AS were developed from the angle of the challenges encountered on safety evaluation during clinical development and after licensure, and illustrate how these challenges have been met to date. Methods to evaluate safety of adjuvants have evolved based on the availability of new technologies allowing a better understanding of their mode of action, and new ways of collecting and assessing safety information. Since 2005, safety experience with AS has accumulated with their use in diverse vaccines and in markedly different populations, in national immunization programs, and in a pandemic setting. Thirteen years of experience using antigens combined with AS attest to their acceptable safety profile. Methods developed to assess the safety of vaccines containing AS have progressed the way we understand and investigate vaccine safety, and have helped set new standards that will guide and support new candidate vaccine development, particularly those using new adjuvants.
   Focus on the patient: What is the context? Adjuvants are immunostimulants used to modulate and enhance the immune response induced by vaccination. Since the 1990s, adjuvantation has moved toward combining several immunostimulants in the form of Adjuvant System(s) (AS), rather than relying on a single immunostimulant. AS have enabled the development of new vaccines targeting diseases and/or populations with special challenges that were previously not feasible using classical vaccine technology.
   What is new? In the last 13 years, several AS-containing vaccines have been studied targeting different diseases and populations. Over this period, overall vaccine safety has been monitored and real-life safety profiles have been assessed following routine use in the general population in many countries. Moreover, new methods for safety assessment, such as a better determination of the mode of action, have been implemented in order to help understand the safety characteristics of AS-containing vaccines.
   What is the impact? New standards and safety experience accumulated over the last decade can guide and help support the safety assessment of new candidate vaccines during development. (C) 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.
C1 [Laupeze, Beatrice; Herve, Caroline; Di Pasquale, Alberta; Da Silva, Fernanda Tavares] GSK, 20 Ave Fleming, B-1300 Wavre, Belgium.
RP Laupeze, B (reprint author), GSK, 20 Ave Fleming, B-1300 Wavre, Belgium.
EM beatrice.n.laupeze@gsk.com; caroline.c.herve@gsk.com;
   alberta.di-pasquale@gsk.com; fernanda.tavares@gsk.com
FU GlaxoSmithKline Biologicals SA, BelgiumGlaxoSmithKline
FX GlaxoSmithKline Biologicals SA, Belgium was the funding source and was
   involved in all stages of the study conduct and analysis.
   GlaxoSmithKline Biologicals SA also took responsibility for all costs
   associated with the development and publishing of the present
   manuscript.
CR Aaby P, 2015, LANCET, V386, P1735, DOI 10.1016/S0140-6736(15)00693-5
   Minsoko PA, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001685
   Agnandji ST, 2011, NEW ENGL J MED, V365, P1863, DOI 10.1056/NEJMoa1102287
   Andrews N, 2011, J INFECT DIS, V203, P32, DOI 10.1093/infdis/jiq014
   Angelo MG, 2014, PHARMACOEPIDEM DR S, V23, P456, DOI 10.1002/pds.3593
   [Anonymous], 2016, Wkly Epidemiol Rec, V91, P33
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P13
   Baril L, 2016, MAL VACC WORLD 2 4 M
   Baril L, 2015, VACCINE, V33, P6884, DOI 10.1016/j.vaccine.2015.07.024
   Beck CR, 2012, J INFECT DIS, V206, P1250, DOI 10.1093/infdis/jis487
   Beran J, 2008, EXPERT OPIN BIOL TH, V8, P235, DOI 10.1517/14712598.8.2.235 
   Burny W, 2014, KEYST S SEATTL US OC
   Burny W, 2017, FRONT IMMUNOL, V8, P14, DOI 10.3389/fimmu.2017.00943
   Canelle Q, 2016, HUM VACC IMMUNOTHER, V12, P2289, DOI 10.1080/21645515.2016.1168954
   Cherif H, 2013, EUR J HAEMATOL, V90, P413, DOI 10.1111/ejh.12094
   Coccia M, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0027-3
   Cohet C, 2019, VACCINE, V37, P3006, DOI 10.1016/j.vaccine.2019.04.048
   Cohet C, 2017, VACCINE, V35, P3041, DOI 10.1016/j.vaccine.2017.04.058
   Cohet C, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009264
   Cunningham AL, 2016, NEW ENGL J MED, V375, P1019, DOI 10.1056/NEJMoa1603800
   Da Silva FT, 2015, HUM VACC IMMUNOTHER, V11, P1814, DOI 10.1080/21645515.2015.1043501
   Da Silva FT, 2013, VACCINE, V31, P1870, DOI 10.1016/j.vaccine.2013.01.042
   de la Serna J, 2018, BMT TAND M SALT LAK
   De Wals P, 2012, JAMA-J AM MED ASSOC, V308, P175, DOI 10.1001/jama.2012.7342
   Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001
   Denny L, 2013, INT J GYNECOL OBSTET, V123, P187, DOI 10.1016/j.ijgo.2013.09.009
   Di Pasquale A, 2016, VACCINE, V34, P6672, DOI 10.1016/j.vaccine.2016.10.039
   Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320
   Didierlaurent AM, 2017, EXPERT REV VACCINES, V16, P55, DOI 10.1080/14760584.2016.1213632
   Didierlaurent AM, 2014, J IMMUNOL, V193, P1920, DOI 10.4049/jimmunol.1400948
   Didierlaurent AM, 2009, J IMMUNOL, V183, P6186, DOI 10.4049/jimmunol.0901474
   Dodd CN, 2013, VACCINE, V31, P4448, DOI 10.1016/j.vaccine.2013.06.032
   European Medicines Agency, EMEA 359381 2009
   European Medicines Agency, ADJUPANRIX PREVIOUSL
   European Medicines Agency, 2009, EMEA 608259 2009REV
   European Medicines Agency, MOSQ H W 2300 PROD I
   European Medicines Agency, 2016, EMACHMP5663592015
   European Medicines Agency. Human medicines, HPV VACCINES EMA CON
   European Medicines Agency Pandemrix, EMA3881822016
   Farizo K., 2015, VSQ, V3, P5
   Galson JD, 2016, SCI REP-UK, V6, DOI 10.1038/srep37229
   Garcon N, 2011, PERSPECT VACCINOL, P89, DOI DOI 10.1016/J.PERVAC.2011.05.004
   Garcon Nathalie, 2006, P161, DOI 10.1016/B978-012088403-2/50011-3
   Garcon N, 2017, HUM VACC IMMUNOTHER, V13, P19, DOI 10.1080/21645515.2016.1225635
   Garcon N, 2012, EXPERT REV VACCINES, V11, P349, DOI [10.1586/ERV.11.192, 10.1586/erv.11.192]
   Garcon N, 2011, VACCINE, V29, P4453, DOI 10.1016/j.vaccine.2011.04.046
   Garcon N, 2011, EXPERT OPIN BIOL TH, V11, P667, DOI 10.1517/14712598.2011.573624
   Gessner BD, 2017, VACCINE, V35, P716, DOI 10.1016/j.vaccine.2016.12.067
   Givord C, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0058-4
   Han F, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003880
   Han F, 2013, ANN NEUROL, V73, P560, DOI 10.1002/ana.23799
   Han F, 2011, ANN NEUROL, V70, P410, DOI 10.1002/ana.22587
   Huygen F, 2015, EBIOMEDICINE, V2, P1114, DOI 10.1016/j.ebiom.2015.07.003
   Isai A, 2012, VACCINE, V30, P7123, DOI 10.1016/j.vaccine.2012.09.032
   Kazmin D, 2017, P NATL ACAD SCI USA, V114, P2425, DOI 10.1073/pnas.1621489114
   Kester KE, 2009, J INFECT DIS, V200, P337, DOI 10.1086/600120
   Klein SL, 2016, MBIO, V7, DOI 10.1128/mBio.00514-16
   Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184
   Larson HJ, 2017, CLIN INFECT DIS, V64, P533, DOI 10.1093/cid/ciw796
   Lecrenier N, 2018, EXPERT REV VACCINES, V17, P619, DOI 10.1080/14760584.2018.1495565
   Leroux-Roels G, 2016, CLIN IMMUNOL, V169, P16, DOI 10.1016/j.clim.2016.05.007
   Lewis DJM, 2015, J IMMUNOL RES, DOI 10.1155/2015/909406
   Lopez-Fauqued M, 2017, VACCINE, V35, P5325, DOI 10.1016/j.vaccine.2017.08.042
   Luo G, 2018, P NATL ACAD SCI USA, V115, pE12323, DOI 10.1073/pnas.1818150116
   Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510
   Marty-Roix R, 2016, J BIOL CHEM, V291, P1123, DOI 10.1074/jbc.M115.683011
   Mastelic B, 2013, BIOLOGICALS, V41, P458, DOI 10.1016/j.biologicals.2013.08.006
   McElhaney JE, 2016, EFFICACY IMMUNOGENIC
   Mendoza YG, 2019, HUM VACC IMMUNOTHER, V15, P2386, DOI 10.1080/21645515.2019.1586040
   Mian-McCarthy S, 2012, NEW ENGL J MED, V367, P2284, DOI 10.1056/NEJMoa1208394
   Montplaisir J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108489
   Morel S, 2011, VACCINE, V29, P2461, DOI 10.1016/j.vaccine.2011.01.011
   Muller O, 2015, LANCET, V386, P1736, DOI 10.1016/S0140-6736(15)00694-7
   Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2
   National Centre for Immunisation Research & Surveillance, NCIRS POSITION STATE
   Oberle D, 2015, SLEEP, V38, P1619, DOI 10.5665/sleep.5060
   Ozawa S, 2017, B WORLD HEALTH ORGAN, V95, P629, DOI 10.2471/BLT.16.178475
   Palmer T., 2019, BMJ-BRIT MED J, V365, P11161, DOI [10.1136/bmj.11161, DOI 10.1136/BMJ.I1161]
   Pollock KGJ, 2014, BRIT J CANCER, V111, P1824, DOI 10.1038/bjc.2014.479
   Romio S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082222
   Sarkanen TO, 2018, SLEEP MED REV, V38, P177, DOI 10.1016/j.smrv.2017.06.006
   SCHONBERGER LB, 1979, AM J EPIDEMIOL, V110, P105, DOI 10.1093/oxfordjournals.aje.a112795
   Stassijns J, 2016, VACCINE, V34, P714, DOI 10.1016/j.vaccine.2015.12.024
   Steffens B, 2011, EUR J MED RES, V16, P289, DOI 10.1186/2047-783X-16-7-289
   Sullivan K, 2018, 44 ANN M EUR SOC BLO
   Tavares F, 2011, VACCINE, V29, P6358, DOI 10.1016/j.vaccine.2011.04.114
   Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8
   US Food and Drug Administration, INFLUENZA A H5N1 VIR
   Verstraeten T, 2016, HUM VACC IMMUNOTHER, V12, P187, DOI 10.1080/21645515.2015.1068486
   Verstraeten T, 2008, VACCINE, V26, P6630, DOI 10.1016/j.vaccine.2008.09.049
   Wacholder S, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c712
   Weibel D, 2018, VACCINE, V36, P6202, DOI 10.1016/j.vaccine.2018.08.008
   Wheeler CM, 2012, LANCET ONCOL, V13, P100, DOI 10.1016/S1470-2045(11)70287-X
   Wilkins AL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01760
   Willame C, 2016, HUM VACC IMMUNOTHER, V12, P2862, DOI 10.1080/21645515.2016.1199308
   World Health Organisation, 2006, WHO ACTIVITIES IN AV
NR 96
TC 2
Z9 3
U1 2
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 10
PY 2019
VL 37
IS 38
BP 5660
EP 5680
DI 10.1016/j.vaccine.2019.07.098
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IY4JV
UT WOS:000486358200004
PM 31420171
OA Other Gold
DA 2020-05-12
ER

PT J
AU Zhang, W
   Wang, Q
AF Zhang, Wen
   Wang, Qi
TI The failure of news coverage supportive of human papillomavirus
   vaccination: The investigation of the effects of online comments on
   female college students' vaccination intention
SO VACCINE
LA English
DT Article
DE Human papillomavirus; Narrative; Online comment; Valence; Risk
   perception; HPV vaccination intention
ID PERCEPTION; KNOWLEDGE
AB Background: News coverage supportive of human papillomavirus (HPV) vaccination is widespread on the Internet. Meanwhile, large numbers of online comments questioning HPV vaccine safety, attacking vaccine manufacturers or providing personal experience of side effects may reduce the persuasion effect. This study explored how and under what conditions such comments influence the behavioral intention of subsequent youth female viewers or readers.
   Methods: We recruited a random sample of 239 Chinese undergraduate female students from different, non-medicine-related disciplines and conducted a 2 (valence of online comments: positive vs. negative) x 2 (presentation of comments: narrative vs. descriptive) between-subjects factorial design study. After carrying two ANOVAs to examine the effects of experimental conditions, we established a simple mediation and a moderated mediation analysis to test hypothesis.
   Results: Perceived risk of HPV emerged as a significant mediator in the moderated mediation model. Particularly under the negative condition, the narrative (vs. descriptive) comments increased behavioral intention to receive the vaccine (B = -0.20, SE = 0.10, 95% CI = -0.40 to -0.01) while they increased participants' perceived risk of HPV (B = -0.14, SE = -0.05, 95% CI = -0.27 to -0.06). However, under the positive condition, there was no significant difference in either risk perception or behavioral intention between the effects of narrative and descriptive comments on participants.
   Conclusions: Online comments do influence participants' perceived risk of HPV and vaccination intention. Perceived risk of HPV fully mediates the effect of comments on vaccination intention. More importantly, the indirect effect of narrative (vs. descriptive) comments on behavioral intention through risk perception is moderated by the valence of comments, and significant only under the negative comments condition. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhang, Wen] Zhongnan Univ Econ & Law, Sch Journalism & Culture Commun, 182 Nanhu Ave, Wuhan 430073, Hubei, Peoples R China.
   [Wang, Qi] Hubei Univ Technol, Shool Ind Design, 28 Nanli Rd, Wuhan 430068, Hubei, Peoples R China.
   [Wang, Qi] Wuhan Railway Vocat Coll Technol, 1 Canglong Rd, Wuhan 430000, Hubei, Peoples R China.
RP Wang, Q (reprint author), Hubei Univ Technol, Shool Ind Design, 28 Nanli Rd, Wuhan 430068, Hubei, Peoples R China.
EM Z0004810@zuel.edu.cn; 24250@whut.edu.cn
OI Wang, Qi/0000-0002-2171-9183; zhang, wen/0000-0001-7209-2731
FU "Fundamental Research Funds for the Central University", Zhongnan
   University of Economics and Law [2722019JCG043, 2722019JCT022];
   Humanities and Social Science Foundation for Youth of Hubei Provincial
   Department of Education [19Q196]
FX This research received financial support from "the Fundamental Research
   Funds for the Central University", Zhongnan University of Economics and
   Law (2722019JCG043, 2722019JCT022); the Humanities and Social Science
   Foundation for Youth of Hubei Provincial Department of Education
   (19Q196). We would like to thank Dr. Jing Zhang for providing helpful
   methodological suggestions.
CR Administration CNMP, INT HUM PAP HPV VACC
   [Anonymous], 2018, HPV VACCINATION RATE
   Ball LK, 1998, PEDIATRICS, DOI [10.1547/peds.1013.453, DOI 10.1547/PEDS.1013.453]
   Baranowski T., 2013, NUTR EPIDEMIOL, DOI [10.1093/acprof:oso19780199754038.003.0004, DOI 10.1093/ACPROF:OSO19780199754038.003.0004]
   BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173
   Betsch C, 2011, MED DECIS MAKING, V31, P742, DOI 10.1177/0272989X11400419
   Chakraborty P., 2017, Cogent Medicine, V4, P1390853, DOI 10.1080/2331205x.2017.1390853
   Cialdini RB, 2004, ANNU REV PSYCHOL, V55, P591, DOI 10.1146/annurev.psych.55.090902.142015
   Cody R, 1990, J BEHAV MED, DOI [10.1007/BFOOR44885, DOI 10.1007/BFOOR44885]
   Cohen J., 1988, STAT POWER ANAL BEHA, DOI [10.1016/8978-0-12-179060-8.50008-6, DOI 10.1016/8978-0-12-179060-8.50008-6]
   Davies P, 2002, ARCH DIS CHILD, V87, P22, DOI 10.1136/adc.87.1.22
   Dillard JP, 2011, J AM COLL HEALTH, V59, P186, DOI 10.1080/07448481.2010.493189
   Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149
   Feinberg Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129587
   Fischhoff B, 1978, POLICY SCI, DOI [10.1007/RF00143739, DOI 10.1007/RF00143739]
   Gerend MA, 2008, ANN BEHAV MED, DOI [10.1007/s12160-008-9074-0, DOI 10.1007/S12160-008-9074-0]
   Gu C, 2015, J CLIN NURS, V24, P2765, DOI 10.1111/jocn.12871
   Hayes AF, 2009, COMMUN MONOGR, V76, P408, DOI 10.1080/03637750903310360
   Hilverda F, 2018, FRONT COMMUN, DOI [10.3389/fcamm.2018.00030, DOI 10.3389/FCAMM.2018.00030]
   Hoffman BL, 2019, VACCINE, V37, P2216, DOI 10.1016/j.vaccine.2019.03.003
   Hu TJ, 2018, CHINESE J VIRAL DIS, V8, P60
   Kasperson RE, 1996, ANN AM ACAD POLIT SS, V545, P95, DOI 10.1177/0002716296545001010
   Kause A, 2014, 23 SRA E C IST
   Leventhal H, 1970, ADV EXPT SOCIAL PSYC, V5, P119, DOI DOI 10.1016/S0065-2601(08)60091-X
   LORD CG, 1979, J PERS SOC PSYCHOL, V37, P2098, DOI 10.1037/0022-3514.37.11.2098
   Meijnders AL, 2001, RISK ANAL, V21, P955, DOI 10.1111/0272-4332.215164
   Miyagi E, 2014, INT J GYNECOL CANCER, V24, P1347, DOI 10.1097/IGC.0000000000000220
   Morman MT, 2000, J APPL COMMUN RES, DOI [10.1080/00909880009364558, DOI 10.1080/00909880009364558]
   Nabi AL, 2003, COMMUN RES, DOI [10.1177/0093650202250881, DOI 10.1177/0093650202250881]
   Oatley K., 1999, REV GEN PSYCHOL, V3, P101, DOI DOI 10.1037/1089-2680.3.2.101
   Okuhara T, 2018, ASIAN PAC J CANCER P, DOI [10.22034/APJCP.2018.19.10.2691, DOI 10.22034/APJCP.2018.19.10.2691]
   Prematunge C, 2012, VACCINE, V30, P4733, DOI 10.1016/j.vaccine.2012.05.018
   Qin A., 2014, J MASS COMMUN MONTHL, V17, P49
   Reich Z., 2011, PARTICIPATORY J GUAR, DOI [10.1002/9781444340747.rh6, DOI 10.1002/9781444340747.RH6]
   Rogers RW, 1975, J PSYCHOL, DOI [10.1089/00223980.1975.9915803, DOI 10.1089/00223980.1975.9915803]
   Rosenstock IM, 1974, HEALTH EDUC BEHAV, DOI [10.1172/109019817400200403, DOI 10.1172/109019817400200403]
   Ruiz C, 2011, INT J PRESS/POLIT, V16, P463, DOI 10.1177/1940161211415849
   Shi R, 2014, J COMPUT-MEDIAT COMM, V19, P975, DOI 10.1111/jcc4.12057
   SLOVIC P, 1979, ENVIRONMENT, V21, P14, DOI 10.1080/00139157.1979.9933091
   SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507
   Steinhardt J, 2015, RISK ANAL, V35, P1423, DOI 10.1111/risa.12368
   Wikfors Gary H., 2013, International Journal of Ecology, P1
   Wilson K, 2005, VACCINE, V23, P3010, DOI 10.1016/j.vaccine.2004.12.002
   WITTE K, 1992, COMMUN MONOGR, V59, P329, DOI 10.1080/03637759209376276
   Wroe AL, 2005, VACCINE, V23, P1428, DOI 10.1016/j.vaccine.2004.10.004
   Xie XF, 2011, RISK ANAL, V31, P450, DOI 10.1111/j.1539-6924.2010.01530.x
   Yu Zhaojia, 2017, CHINESE J HLTH STAT, V4, P578
   Zhang Q, 2017, TOPICAL DIFFERENCES, DOI [10.1145/2872518.2890562, DOI 10.1145/2872518.2890562]
NR 48
TC 1
Z9 1
U1 2
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 10
PY 2019
VL 37
IS 38
BP 5681
EP 5687
DI 10.1016/j.vaccine.2019.08.007
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IY4JV
UT WOS:000486358200005
PM 31421931
DA 2020-05-12
ER

PT J
AU Cataldi, JR
   Sevick, C
   Pyrzanowski, J
   Wagner, N
   Brewer, SE
   Narwaney, KJ
   Shoup, JA
   Resnicow, K
   Glanz, J
   Dempsey, A
   Kwan, BM
AF Cataldi, Jessica R.
   Sevick, Carter
   Pyrzanowski, Jennifer
   Wagner, Nicole
   Brewer, Sarah E.
   Narwaney, Komal J.
   Shoup, Jo Ann
   Resnicow, Ken
   Glanz, Jason
   Dempsey, Amanda
   Kwan, Bethany M.
TI Addressing personal parental values in decisions about childhood
   vaccination: Measure development
SO VACCINE
LA English
DT Article
DE Values; Immunization; Vaccine hesitancy; Parents
ID SELF-AFFIRMATION; HEALTH MESSAGES; UNITED-STATES; SAFETY CONCERNS;
   HESITANCY; ATTITUDES; VACCINES; IMMUNIZATIONS; ASSOCIATION; ACCEPTANCE
AB Objective: Evidence-based strategies to address vaccine hesitancy are lacking. Personal values are a measurable psychological construct that could be used to deliver personalized messages to influence vaccine hesitancy and behavior. Our objectives were to develop a valid, reliable self-report survey instrument to measure vaccine values based on the Schwartz theory of basic human values, and to test the hypothesis that vaccine values are distinct from vaccine attitudes and are related to vaccine hesitancy and behavior.
   Methods: Parental Vaccine Values (PVV) scale items were generated using formative qualitative research and expert input, yielding 24 items for testing. 295 parents of children aged 14-30 months completed a self-report survey with measures of Schwartz's global values, the PVV, vaccine attitudes, and vaccine hesitancy. Factor analysis was used to determine vaccine values factor structure. Associations between vaccine values, vaccine attitudes, vaccine hesitancy, and vaccination behavior were assessed using linear and logistic regression models. Late vaccination was assessed from electronic medical records.
   Results: A six-factor structure for vaccine values was determined with good fit (RMSEA = 0.07, Bentler's CFI = 0.91) with subscales for Conformity, Universalism, Tradition, Self-Direction, Security-Disease Prevention, and Security-Vaccine Risk Vaccine values were moderately associated with Schwartz global values and vaccine attitudes, indicating discriminant validity from these constructs. Multivariable linear regression showed vaccine hesitancy was associated with vaccine values Conformity (partial R-2 = 0.10) and Universalism (0.04) and vaccine attitudes Vaccine Safety (0.52) and Vaccine Benefit (0.16). Multivariable logistic regression showed that late vaccination was associated with vaccine value Self direction (OR = 1.80, 95% CI: 1.26-2.65) and vaccine attitude of Vaccine Benefit (OR = 0.44, 95% CI: 032-0.60).
   Conclusions: The PVV scale had good psychometric properties and appears related to but distinct from Schwartz global values and vaccine attitudes. Vaccine values are associated with vaccine hesitancy and late vaccination and may be useful in tailoring future interventions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Cataldi, Jessica R.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA.
   [Cataldi, Jessica R.; Sevick, Carter; Pyrzanowski, Jennifer; Brewer, Sarah E.; Dempsey, Amanda; Kwan, Bethany M.] Univ Colorado, Adult & Child Consortium Hlth Outcomes Res & Deli, Aurora, CO USA.
   [Wagner, Nicole; Narwaney, Komal J.; Shoup, Jo Ann; Glanz, Jason] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA.
   [Resnicow, Ken] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA.
   [Glanz, Jason] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA.
   [Kwan, Bethany M.] Univ Colorado, Sch Med, Dept Family Med, Aurora, CO USA.
RP Cataldi, JR (reprint author), 13123 East 16th Ave, Aurora, CO 80045 USA.
EM Jessica.Cataldi@ucdenver.edu
RI Brewer, Sarah/AAG-7535-2019; Cataldi, Jessica/Y-6544-2019
OI Cataldi, Jessica/0000-0002-4480-0304; Brewer, Sarah
   E./0000-0003-0063-6626
FU Department of Health and Human Services, National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [1R01HD079457-01]
FX This project was supported by a grant from the Department of Health and
   Human Services, National Institutes of Health, Grant Number:
   1R01HD079457-01 (PIs: Amanda Dempsey and Jason Glanz).
CR AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Allred NJ, 2005, AM J PREV MED, V28, P221, DOI 10.1016/j.amepre.2004.10.014
   Amin AB, 2017, NAT HUM BEHAV, V1, P873, DOI 10.1038/s41562-017-0256-5
   Attwell K, 2015, VACCINE, V33, P6235, DOI 10.1016/j.vaccine.2015.09.092
   Bednarczyk R, 2017, OP FOR INF DIS
   Boer D, 2013, PSYCHOL BULL, V139, P1113, DOI 10.1037/a0031347
   Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P243
   Cohen GL, 2014, ANNU REV PSYCHOL, V65, P333, DOI 10.1146/annurev-psych-010213-115137
   Connolly T, 2003, ORGAN BEHAV HUM DEC, V91, P186, DOI 10.1016/S0749-5978(03)00057-8
   CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297
   de Vaus D., 2014, SURVEYS SOCIAL RES
   Dempsey AF, 2014, VACCINE, V32, P2463, DOI 10.1016/j.vaccine.2014.02.089
   DeVellis R., 2016, SCALE DEV THEORY APP
   Dube E, 2015, VACCINE, V33, P4191, DOI 10.1016/j.vaccine.2015.04.041
   Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657
   Fagerlin A, 2010, HDB HLTH PSYCHOL BEH, V1, P49
   Falk EB, 2015, P NATL ACAD SCI USA, V112, P1977, DOI 10.1073/pnas.1500247112
   Finley AJ, 2018, SOC COGN AFFECT NEUR, V13, P569, DOI 10.1093/scan/nsy036
   Fiske ST, 2010, HDB SOCIAL PSYCHOL
   Foxcroft DR, 2015, COCHRANE DB SYST REV, V12
   Freed GL, 2010, PEDIATRICS, V125, P654, DOI 10.1542/peds.2009-1962
   Gellin BG, 2000, PEDIATRICS, V106, P1097, DOI 10.1542/peds.106.5.1097
   Glanz JM, 2013, ACAD PEDIATR, V13, P481, DOI 10.1016/j.acap.2013.05.030
   Glanz JM, 2013, JAMA PEDIATR, V167, P274, DOI 10.1001/jamapediatrics.2013.502
   Gowda C, 2013, HUM VACC IMMUNOTHER, V9, P1755, DOI 10.4161/hv.25085
   Gust DA, 2005, AM J PREV MED, V29, P105, DOI 10.1016/j.amepre.2005.04.010
   Hamborsky J, 2015, EPIDEMIOLOGY PREVENT
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Hill HA, 2015, MMWR-MORBID MORTAL W, V64, P889, DOI 10.15585/mmwr.mm6433a1
   HOMER PM, 1988, J PERS SOC PSYCHOL, V54, P638, DOI 10.1037/0022-3514.54.4.638
   Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040
   Kahan D, 2010, NATURE, V463, P296, DOI 10.1038/463296a
   Kahan DM, 2010, LAW HUMAN BEHAV, V34, P501, DOI 10.1007/s10979-009-9201-0
   Kang Y, 2017, PSYCHOSOM MED, V79, P379, DOI 10.1097/PSY.0000000000000445
   Kaufman J, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010038.pub2
   Kelly MP, 2015, BMC MED ETHICS, V16, DOI 10.1186/s12910-015-0063-3
   Kempe A, 2015, PEDIATRICS, V135, P666, DOI 10.1542/peds.2014-3474
   Kennedy A, 2011, HEALTH AFFAIR, V30, P1151, DOI 10.1377/hlthaff.2011.0396
   Kline R. B., 2016, PRINCIPLES PRACTICE
   Leask J, 2008, J PAEDIATR CHILD H, V44, P534, DOI 10.1111/j.1440-1754.2008.01381.x
   MacCallum RC, 1996, PSYCHOL METHODS, V1, P130, DOI 10.1037/1082-989X.1.2.130
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Meszaros JR, 1996, J CLIN EPIDEMIOL, V49, P697, DOI 10.1016/0895-4356(96)00007-8
   Oberski D, 2014, J STAT SOFTW, V57, P1
   Odone A, 2015, HUM VACC IMMUNOTHER, V11, P72, DOI 10.4161/hv.34313
   Oladejo O, 2016, VACCINE, V34, P4964, DOI 10.1016/j.vaccine.2016.08.046
   Omer SB, 2006, JAMA-J AM MED ASSOC, V296, P1757, DOI 10.1001/jama.296.14.1757
   Opel DJ, 2017, JAMA PEDIAT
   Opel DJ, 2011, VACCINE, V29, P6598, DOI 10.1016/j.vaccine.2011.06.115
   Opel DJ, 2011, HUM VACCINES, V7, P419, DOI 10.4161/hv.7.4.14120
   Roush SW, 2007, JAMA-J AM MED ASSOC, V298, P2155, DOI 10.1001/jama.298.18.2155
   Ryan RM, 2000, AM PSYCHOL, V55, P68, DOI 10.1037/0003-066X.55.1.68
   Salmon DA, 2005, ARCH PEDIAT ADOL MED, V159, P470, DOI 10.1001/archpedi.159.5.470
   Salmon DA, 2015, AM J PREV MED, V49, pS391, DOI 10.1016/j.amepre.2015.06.009
   Salmon Daniel A, 2009, WMJ, V108, P17
   Schultz PW, 2007, PSYCHOL SCI, V18, P429, DOI 10.1111/j.1467-9280.2007.01917.x
   Schwartz S. H., 2012, ONLINE READINGS PSYC, V2, P1, DOI [10.9707/2307-0919.1116, DOI 10.9707/2307-0919.1116]
   Schwartz SH, 2001, J CROSS CULT PSYCHOL, V32
   Schwartz SH, 2006, REV FR SOCIOL, V47, P929, DOI 10.3917/rfs.474.0929
   Sherman DAK, 2000, PERS SOC PSYCHOL B, V26, P1046, DOI 10.1177/01461672002611003
   Shim S, 2005, PSYCHOL MARKET, V22, P649, DOI 10.1002/mar.20078
   Shoup JA., 2015, ATTITUDES BELIEFS IN
   Strikas RA, 2015, MMWR-MORBID MORTAL W, V64, P93
   Sweeney AM, 2015, HEALTH PSYCHOL, V34, P149, DOI 10.1037/hea0000110
   Tavakol M, 2011, INT J MED EDUC, V2, P53, DOI 10.5116/ijme.4dfb.8dfd
   Team RC, 2014, R LANG ENV STAT COMP, P2017
   Thompson B., 2004, EXPLORATORY CONFIRMA
   Williams GC, 1998, HEALTH PSYCHOL, V17, P269, DOI 10.1037/0278-6133.17.3.269
   Williams GC, 2002, HEALTH PSYCHOL, V21, P40, DOI 10.1037//0278-6133.21.1.40
   Witteman HO, 2015, PEDIATRICS, V136, P215, DOI 10.1542/peds.2015-0949
   Wroe AL, 2005, VACCINE, V23, P1428, DOI 10.1016/j.vaccine.2004.10.004
NR 71
TC 1
Z9 1
U1 3
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 10
PY 2019
VL 37
IS 38
BP 5688
EP 5697
DI 10.1016/j.vaccine.2019.08.009
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IY4JV
UT WOS:000486358200006
PM 31421930
DA 2020-05-12
ER

PT J
AU van Wijhe, M
   de Boer, PT
   de Jong, HJ
   van Vliet, H
   Wallinga, J
   Postma, MJ
AF van Wijhe, Maarten
   de Boer, Pieter T.
   de Jong, Herman J.
   van Vliet, Hans
   Wallinga, Jacco
   Postma, Maarten J.
TI Trends in governmental expenditure on vaccination programmes in the
   Netherlands, a historical analysis
SO VACCINE
LA English
DT Article
DE Vaccination; Finance; History; Expenditure; Netherlands; Prevention
ID INFLUENZA VACCINATION; CONJUGATE VACCINATION; ECONOMIC-EVALUATION;
   COST-EFFECTIVENESS; UNITED-STATES; VACCINES; HEALTH; IMPACT; MORTALITY;
   DISEASES
AB Background: Health economic evaluations are often required before implementing a vaccination programme. Such evaluations rarely consider the historical context of a vaccination programme. We review the financial history of vaccination programmes in the Netherlands, and compare these to demographic and macroeconomic developments as well as avoided mortality burden.
   Methods: Previously uncatalogued historical expenditures on the Dutch National Immunisation Programme (NIP) and influenza vaccination were obtained from official reports. Costs were adjusted for inflation using Consumer Price Indices and expressed in Euro of 2016. Estimates on mortality burden averted were obtained from previous research and used to calculate the ratio of expenses to averted mortality burden for vaccinations against diphtheria, tetanus, pertussis, polio, measles, mumps and rubella for birth cohorts 1953-1992.
   Results: Developments towards a uniform government funded NIP started early 1950s with vaccinations against diphtheria, pertussis and tetanus, culminating in its official launch in 1957 together with polio vaccinations. Since the 1980s, expenditure increased nearly five-fold mostly due to the addition of new vaccines, while spending on already implemented vaccinations tended to decline. Overall, expenditure increased from (sic) 5 million in 1957 to (sic) 93 million in 2014. Relative to total healthcare expenditure, the NIP contributed little, ranging between 0.05% and 0.14%. Spending on influenza vaccination increased from (sic) 37 million in 1996 to (sic) 52 million in 2014, while relative to total healthcare expenditure it decreased from 0.069% to 0.055%. In 2014, 0.15% of healthcare expenditure and (sic) 533 per birth was spent on vaccination programmes. Overall, for birth cohorts 1953-1992, (sic) 5.4 thousand (95% confidence interval: 4.0-7.3) was expended per year-of-life-lost averted.
   Conclusion: The actual costs per year-of-life gained are more favorable than estimated here since averted medical costs were not included. Although expenditure on vaccination programmes increased substantially, the contribution to overall healthcare expenditure remained small. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [van Wijhe, Maarten; de Boer, Pieter T.; van Vliet, Hans; Wallinga, Jacco] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, Bilthoven, Netherlands.
   [van Wijhe, Maarten; Postma, Maarten J.] Univ Groningen, Groningen Res Inst Pharm, Unit PharmacoTherapy Epidemiol & Econ, Groningen, Netherlands.
   [van Wijhe, Maarten] Roskilde Univ, Dept Sci & Environm, Univ Vej 1, DK-4000 Roskilde, Denmark.
   [de Jong, Herman J.; Postma, Maarten J.] Univ Groningen, Fac Econ & Business, Groningen, Netherlands.
   [Wallinga, Jacco] Leiden Univ, Med Ctr, Dept Biomed Data Sci, Leiden, Netherlands.
   [Postma, Maarten J.] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Groningen, Netherlands.
RP van Wijhe, M (reprint author), Roskilde Univ, Dept Sci & Environm, Univ Vej 1, DK-4000 Roskilde, Denmark.
EM wijhe@ruc.dk
OI van Wijhe, Maarten/0000-0001-9216-8393
FU Dutch Ministry of Health, Welfare and Sport
FX This work was supported by the Dutch Ministry of Health, Welfare and
   Sport. The funding source had no involvement in any aspect of the
   research or the preparation of this manuscript.
CR Anderson GF, 2003, HEALTH AFFAIR, V22, P89, DOI 10.1377/hlthaff.22.3.89
   Beutels P, 2007, VACCINE, V25, P1355, DOI 10.1016/j.vaccine.2006.10.034
   Beyer W E, 1983, Ned Tijdschr Geneeskd, V127, P1779
   Black S, 2013, VACCINE, V31, P6046, DOI 10.1016/j.vaccine.2013.08.008
   Bloom DE, 2015, VACCINE, V33, pB29, DOI 10.1016/j.vaccine.2015.03.023
   Bos JM, 2003, CLIN THER, V25, P2614, DOI 10.1016/S0149-2918(03)80322-3
   Chabot I, 2004, VACCINE, V22, P1992, DOI 10.1016/j.vaccine.2003.10.027
   Davidse W., 1994, INFLUENZAVACCINATIE
   Davis MM, 2010, HUM VACCINES, V6, P689, DOI 10.4161/hv.6.9.13496
   de Bekker-Grob EW, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-252
   Ethgen O, 2018, HUM VACC IMMUNOTHER, V30, P1
   Ethgen O, 2016, HUM VACC IMMUNOTHER, V12, P2038, DOI 10.1080/21645515.2016.1155013
   Hannoun C, 2013, EXPERT REV VACCINES, V12, P1085, DOI 10.1586/14760584.2013.824709
   Health Council of the Netherlands, 2017, VACC ROT
   Health Council of the Netherlands, 2018, VACC ELD PNEUM
   Heins M, 2017, MONITOR VACCINATIEGR
   Hinman Alan R, 2011, MMWR Suppl, V60, P49
   Hinman AR, 2004, CLIN INFECT DIS, V38, P1445, DOI 10.1086/420748
   HOOGENDOORN D, 1954, Ned Tijdschr Geneeskd, V98, P1806
   Houweling H, 2010, VACCINE, V28, P2924, DOI 10.1016/j.vaccine.2010.02.021
   Jit M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0446-9
   Mangen MJJ, 2015, EUR RESPIR J, V46, P1407, DOI 10.1183/13993003.00325-2015
   McIntosh E David G, 2004, Expert Rev Vaccines, V3, P433, DOI 10.1586/14760584.3.4.433
   Meltzer MI, 2008, LANCET, V372, P612, DOI 10.1016/S0140-6736(08)61257-X
   MEYNAAR IA, 1991, BRIT MED J, V303, P508, DOI 10.1136/bmj.303.6801.508
   Netherlands Bureau for Economic Policy Analysis (CPB), 2017, LANG TIJDR OV
   Perenboom RJM, 1996, J PUBLIC HEALTH MED, V18, P183, DOI 10.1093/oxfordjournals.pubmed.a024478
   Porchia BR, 2017, EXPERT REV VACCINES, V16, P93, DOI 10.1080/14760584.2017.1242419
   Postma MJ, 1999, PHARMACOECONOMICS, V16, P33, DOI 10.2165/00019053-199916001-00005
   Rappuoli R, 2014, P NATL ACAD SCI USA, V111, P12282, DOI 10.1073/pnas.1413559111
   Roush SW, 2007, JAMA-J AM MED ASSOC, V298, P2155, DOI 10.1001/jama.298.18.2155
   Rozenbaum MH, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2509
   Rozenbaum MH, 2010, VACCINE, V28, P2367, DOI 10.1016/j.vaccine.2010.01.005
   Sprenger M J, 1992, Ned Tijdschr Geneeskd, V136, P1968
   Statistics Netherlands (CBS), 2017, CONS PRIC PRIC PRIC
   Statistics Netherlands (CBS), 2017, POP KEY FIG
   Statistics Netherlands (CBS), 2017, HEALTHC SPEND FIN SI
   Strutton DR, 2012, J INFECTION, V64, P54, DOI 10.1016/j.jinf.2011.10.015
   Tacken MAJB, 2015, VACCINE, V33, P4886, DOI 10.1016/j.vaccine.2015.07.052
   van Lier EA, 2018, 20180008 RIVM
   van Panhuis WG, 2013, NEW ENGL J MED, V369, P2152, DOI 10.1056/NEJMms1215400
   van Wijhe M, 2018, EPIDEMIOL INFECT, V146, P716, DOI 10.1017/S0950268818000481
   van Wijhe M, 2016, LANCET INFECT DIS, V16, P592, DOI 10.1016/S1473-3099(16)00027-X
   Verweij MF, 2014, VACCINE, V32, P7163, DOI 10.1016/j.vaccine.2014.10.008
   Vos D, 2004, INFECT B, V15, P13
   Vos D, 2004, INFECT B, V15, P49
   Wagenvoort GHJ, 2016, VACCINE, V34, P1077, DOI 10.1016/j.vaccine.2015.12.066
   Welte R, 2004, VACCINE, V23, P470, DOI 10.1016/j.vaccine.2004.06.019
   WHO, 2017, WHO GLOB HLTH EXP DA
   Wu DBC, 2015, VACCINE, V33, P1633, DOI 10.1016/j.vaccine.2015.01.081
NR 50
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 10
PY 2019
VL 37
IS 38
BP 5698
EP 5707
DI 10.1016/j.vaccine.2019.07.097
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IY4JV
UT WOS:000486358200007
PM 31420172
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Bowen, W
   Batra, L
   Pulsifer, AR
   Yolcu, ES
   Lawrenz, MB
   Shirwan, H
AF Bowen, William
   Batra, Lalit
   Pulsifer, Amanda R.
   Yolcu, Esma S.
   Lawrenz, Matthew B.
   Shirwan, Haval
TI Robust Th1 cellular and humoral responses generated by the Yersinia
   pestis rF1-V subunit vaccine formulated to contain an agonist of the
   CD137 pathway do not translate into increased protection against
   pneumonic plague
SO VACCINE
LA English
DT Article
DE Yersinia pestis; Plague; Subunit vaccine; SA-4-1BBL; Th1-mediated
   immunity
ID MEDIATED IMMUNE-RESPONSE; B-T CONSTRUCTS; V ANTIGENS; GAMMA-INTERFERON;
   4-1BB LIGAND; F1 ANTIGEN; IFN-GAMMA; MOUSE; SA-4-1BBL; INFECTION
AB Yersinia pestis is the causative agent of plague and is a re-emerging pathogen that also has the potential as a biological weapon, necessitating the development of a preventive vaccine. Despite intense efforts for the last several decades, there is currently not a vaccine approved by the FDA. The rF1-V vaccine adjuvanted with Alhydrogel is a lead candidate subunit vaccine for plague and generates a strong Th2-mediate humoral response with a modest Th1 cellular response. As immune protection against Y. pestis requires both humoral and Th1 cellular responses, modifying the rF1-V subunit vaccine formulation to include a robust inducer of Th1 responses may improve efficacy. Thus, we reformulated the subunit vaccine to include SA-4-1BBL, an agonist of the CD137 costimulatory pathway and a potent inducer of Th1 response, and assessed its protective efficacy against pneumonic plague. We herein show for the first time a sex bias in the prophylactic efficacy of the Alhydrogel adjuvanted rF1-V vaccine, with female mice showing better protection against pneumonic plague than male. The sex bias for protection was irrespective of the generation of comparable levels of rF1-V-specific antibody titers and Th1 cellular responses in both sexes. The subunit vaccine reformulated with SA-4-1BBL generated robust Th1 cellular and humoral responses. A prime-boost vaccination scheme involving prime with rF1-V + Alhydrogel and boost with the rF1-V + SA-4-1BBL provided protection in male mice against pneumonic plague. In marked contrast, prime and boost with rF1-V reformulated with both adjuvants resulted in the loss of protection against pneumonic plague, despite generating high levels of humoral and Th1 cellular responses. While unexpected, these findings demonstrate the complexity of immune mechanisms required for protection. Elucidating mechanisms responsible for these differences in protection will help to guide the development of better prophylactic subunit vaccines effective against pneumonic plague. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bowen, William; Batra, Lalit; Yolcu, Esma S.; Shirwan, Haval] Univ Louisville, Inst Cellular Therapeut, 570 S Preston St,Donald Baxter Biomed Bldg, Louisville, KY 40202 USA.
   [Pulsifer, Amanda R.; Yolcu, Esma S.; Lawrenz, Matthew B.; Shirwan, Haval] Univ Louisville, Dept Microbiol & Immunol, Louisville, KY 40202 USA.
   [Lawrenz, Matthew B.] Univ Louisville, Ctr Predict Med Biodef & Emerging Infect Dis, 505 S Hancock St,CTRB,Rm 618, Louisville, KY 40202 USA.
   [Bowen, William] FasCure Therapeut LLC, Louisville, KY 40202 USA.
RP Shirwan, H (reprint author), Univ Louisville, Inst Cellular Therapeut, 570 S Preston St,Donald Baxter Biomed Bldg, Louisville, KY 40202 USA.; Lawrenz, MB (reprint author), Univ Louisville, Ctr Predict Med Biodef & Emerging Infect Dis, 505 S Hancock St,CTRB,Rm 618, Louisville, KY 40202 USA.
EM matt.lawrenz@louisville.edu; haval.shirwan@louisville.edu
OI BATRA, LALIT/0000-0002-4375-9004; Lawrenz, Matthew/0000-0003-1505-5429
FU National Institutes of Health NIAIDUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [AI112618, AI120353];
   NIGMSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [GM125504]
FX We would like to acknowledge the University of Louisville Center for
   Predictive Medicine Shared Resources Staff for technical support for
   these studies. This work was supported by funding support from the
   National Institutes of Health NIAID (AI112618 to MBL and HS; AI120353 to
   WB, MBL, and HS) and NIGMS (GM125504 to MBL).
CR Ali R, 2013, SCAND J IMMUNOL, V77, P361, DOI 10.1111/sji.12042
   Amemiya K, 2009, VACCINE, V27, P2220, DOI 10.1016/j.vaccine.2009.02.016
   Bashaw J, 2007, CLIN VACCINE IMMUNOL, V14, P605, DOI 10.1128/CVI.00398-06
   Brewer JM, 1999, J IMMUNOL, V163, P6448
   Chu K, 2016, HUM VACC IMMUNOTHER, V12, P2334, DOI 10.1080/21645515.2016.1175261
   Croft M, 2009, NAT REV IMMUNOL, V9, P271, DOI 10.1038/nri2526
   Dawicki W, 2004, EUR J IMMUNOL, V34, P743, DOI 10.1002/eji.200324278
   Dennis DT, 2004, PEDIATR INFECT DIS J, V23, P69, DOI 10.1097/01.inf.0000106918.18570.dd
   Dinc G, 2014, VACCINE, V32, P5035, DOI 10.1016/j.vaccine.2014.07.015
   Eisen RJ, 2015, J MED ENTOMOL, V52, P1183, DOI 10.1093/jme/tjv128
   Elpek KG, 2007, J IMMUNOL, V179, P7295, DOI 10.4049/jimmunol.179.11.7295
   Green M, 1999, FEMS IMMUNOL MED MIC, V23, P107, DOI 10.1111/j.1574-695X.1999.tb01229.x
   Gupta G, 2010, SCAND J IMMUNOL, V71, P186, DOI 10.1111/j.1365-3083.2009.02365.x
   Gupta G, 2012, INT IMMUNOPHARMACOL, V12, P64, DOI 10.1016/j.intimp.2011.10.012
   Hart Mary Kate, 2012, Adv Prev Med, V2012, P731604, DOI 10.1155/2012/731604
   Heath DG, 1998, VACCINE, V16, P1131, DOI 10.1016/S0264-410X(98)80110-2
   Koster F, 2010, INFECT IMMUN, V78, P2946, DOI 10.1128/IAI.01296-09
   Kummer LW, 2008, VACCINE, V26, P6901, DOI 10.1016/j.vaccine.2008.09.063
   Lin JS, 2011, J IMMUNOL, V187, P897, DOI 10.4049/jimmunol.1100174
   Lin JS, 2011, J IMMUNOL, V186, P1675, DOI 10.4049/jimmunol.1003303
   Lin JS, 2010, VACCINE, V29, P357, DOI 10.1016/j.vaccine.2010.08.099
   MEYER KF, 1974, J INFECT DIS, V129, pS13, DOI 10.1093/infdis/129.Supplement_1.S13
   Mittler RS, 1999, J EXP MED, V190, P1535, DOI 10.1084/jem.190.10.1535
   Morris SR, 2007, VACCINE, V25, P3115, DOI 10.1016/j.vaccine.2007.01.071
   NAKAJIMA R, 1993, INFECT IMMUN, V61, P23, DOI 10.1128/IAI.61.1.23-31.1993
   Parent MA, 2005, INFECT IMMUN, V73, P7304, DOI 10.1128/IAI.73.11.7304-7310.2005
   Parent MA, 2006, INFECT IMMUN, V74, P3381, DOI 10.1128/IAI.00185-06
   Pechous RD, 2016, TRENDS MICROBIOL, V24, P190, DOI 10.1016/j.tim.2015.11.008
   Philipovskiy AV, 2007, INFECT IMMUN, V75, P878, DOI 10.1128/IAI.01529-06
   Prentice MB, 2007, LANCET, V369, P1196, DOI 10.1016/S0140-6736(07)60566-2
   Price JL, 2013, INT J TOXICOL, V32, P327, DOI 10.1177/1091581813497405
   Price PA, 2012, P NATL ACAD SCI USA, V109, P3083, DOI 10.1073/pnas.1112729109
   Rai R, 2015, MICROB PATHOGENESIS, V87, P13, DOI 10.1016/j.micpath.2015.07.012
   Reilly LAO, 2009, NATURE, V461, P659, DOI 10.1038/nature08402
   RUSSELL P, 1995, VACCINE, V13, P1551, DOI 10.1016/0264-410X(95)00090-N
   Sabhnani L, 2003, FEMS IMMUNOL MED MIC, V38, P215, DOI 10.1016/S0928-8244(03)00170-6
   Schabowsky RH, 2009, VACCINE, V28, P512, DOI 10.1016/j.vaccine.2009.09.127
   Sharma RK, 2014, EXPERT REV VACCINES, V13, P387, DOI 10.1586/14760584.2014.880340
   Sharma RK, 2010, CANCER RES, V70, P3945, DOI 10.1158/0008-5472.CAN-09-4480
   Sharma RK, 2009, CANCER RES, V69, P4319, DOI 10.1158/0008-5472.CAN-08-3141
   Shreewastav RK, 2012, CELL IMMUNOL, V278, P55, DOI 10.1016/j.cellimm.2012.07.002
   Smiley ST, 2008, EXPERT REV VACCINES, V7, P209, DOI 10.1586/14760584.7.2.209
   Srivastava AK, 2014, CANCER RES, V74, P6441, DOI 10.1158/0008-5472.CAN-14-1768-A
   Sun YW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047123
   Titball RW, 2004, EXPERT OPIN BIOL TH, V4, P965, DOI 10.1517/14712598.4.6.965
   Verma SK, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00602
   Wang SX, 2011, VACCINE, V29, P6802, DOI 10.1016/j.vaccine.2010.12.062
   Wang XY, 2013, EXPERT REV VACCINES, V12, P677, DOI [10.1586/erv.13.42, 10.1586/ERV.13.42]
   Welch TJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000309
   Williamson ED, 2007, MICROB PATHOGENESIS, V42, P11, DOI 10.1016/j.micpath.2006.09.003
   Williamson ED, 2011, VACCINE, V29, P4771, DOI 10.1016/j.vaccine.2011.04.084
   Williamson ED, 1999, CLIN EXP IMMUNOL, V116, P107
   Williamson ED, 2000, VACCINE, V19, P566, DOI 10.1016/S0264-410X(00)00159-6
   Williamson ED, 2005, INFECT IMMUN, V73, P3598, DOI 10.1128/IAI.73.6.3598-3608.2005
   Williamson ED, 1997, VACCINE, V15, P1079, DOI 10.1016/S0264-410X(96)00303-9
   Zhang BY, 2007, J CLIN INVEST, V117, P3029, DOI 10.1172/JCI32426
   Zilinskas RA, 2017, REV SCI TECH OIE, V36, P415, DOI 10.20506/rst.36.2.2662
   Zvi A, 2017, VACCINE, V35, P5995, DOI 10.1016/j.vaccine.2017.05.092
NR 58
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 10
PY 2019
VL 37
IS 38
BP 5708
EP 5716
DI 10.1016/j.vaccine.2019.07.103
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IY4JV
UT WOS:000486358200008
PM 31416643
DA 2020-05-12
ER

PT J
AU Bruun, T
   Watle, SSV
   Tveteraas, IH
   Flem, E
AF Bruun, Tone
   Watle, Sara Sofie Viksmoen
   Tveteraas, Ingun Heiene
   Flem, Elmira
TI Intussusception among Norwegian children: What to expect after
   introduction of rotavirus vaccination?
SO VACCINE
LA English
DT Article
DE Rotavirus vaccines; Intussusception; Vaccine safety
ID CASE-DEFINITION; RISK; INFANTS; BENEFITS; VACCINES; IMMUNIZATION;
   SURVEILLANCE; DISEASE; NORWAY; EUROPE
AB Background: To reduce the risk of vaccine-associated intussusception, rotavirus vaccination in Norway was implemented under strict age limits (the first dose given by 12 weeks of age and the second dose by 16 weeks of age) in 2014. We estimated the incidence of intussusception in children <2 years old before vaccine introduction and the number of vaccine-associated cases under current and extended age limits for vaccine administration in Norway.
   Methods: To estimate the baseline incidence, we validated all diagnoses in children <2 years old registered in the national hospital registry during the pre-vaccine period of 2008-2013. Using national vaccine coverage data and international estimates of intussusception risk after rotavirus vaccination, we calculated the numbers of expected vaccine-associated intussusception cases to compare with the estimated numbers of averted rotavirus cases. Uncertainty was accounted for by several scenario analyses using current and extended age limits for vaccine administration.
   Results: The pre-vaccine incidence of intussusception was 26.7 (95% CI 23.1-30.6) cases/year per 100,000 children <2 years old and 37.1 (95% CI 31.2-43.8) cases/year per 100,000 children <1 year old. In the 2016 birth cohort (approx. 60,000) vaccinated under the current age limits, 1.3 (95% CI 0.7-2.0) vaccine associated intussusception cases were expected to occur. If age limits were extended to 16 weeks for the first vaccine dose and 24 weeks for the second dose, leading to more children vaccinated at an older age, 2.2 (95% CI 1.2-3.5) excess cases would be expected in the same cohort. Simultaneously, an estimated 1768 rotavirus hospitalizations/year in children <5 years old would be averted under current age limits, with 98 additional rotavirus hospitalizations averted under extended age limits.
   Conclusions: Administering rotavirus vaccines beyond current age limits in Norway would lead to a marginal increase in the number of intussusception cases, which would be offset by the benefits of vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bruun, Tone; Watle, Sara Sofie Viksmoen; Tveteraas, Ingun Heiene; Flem, Elmira] Norwegian Inst Publ Hlth, POB 222 Skoyen, N-0213 Oslo, Norway.
RP Bruun, T (reprint author), Norwegian Inst Publ Hlth, Dept Vaccine Preventable Dis, POB 222 Skoyen, N-0213 Oslo, Norway.
EM tone.bruun@fhi.no
FU Norwegian Institute of Public Health
FX The study was fully funded by the Norwegian Institute of Public Health.
CR Bines JE, 2004, J PEDIATR GASTR NUTR, V39, P511, DOI 10.1097/00005176-200411000-00012
   Bines JE, 2004, VACCINE, V22, P569, DOI 10.1016/j.vaccine.2003.09.016
   Bruun T, 2016, PEDIATR INFECT DIS J, V35, P396, DOI 10.1097/INF.0000000000001055
   Buettcher M, 2007, PEDIATRICS, V120, P473, DOI 10.1542/peds.2007-0035
   Buttery JP, 2011, VACCINE, V29, P3061, DOI 10.1016/j.vaccine.2011.01.088
   Carlin JB, 2013, CLIN INFECT DIS, V57, P1427, DOI 10.1093/cid/cit520
   Clark A, 2014, VACCINE, V32, P3604, DOI 10.1016/j.vaccine.2014.04.082
   Cortese MM, 2009, J INFECT DIS, V200, pS264, DOI 10.1086/605055
   de Blasio BF, 2014, EMERG INFECT DIS, V20, P29, DOI 10.3201/eid2001.130019
   Desai R, 2013, PEDIATR INFECT DIS J, V32, P1, DOI 10.1097/INF.0b013e318270362c
   Edwards CH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183306
   Fischer TK, 2004, PEDIATRICS, V114, P782, DOI 10.1542/peds.2004-0390
   Gadroen K, 2017, EUR COMMUN DIS B, V22, P22
   Glass RI, 2004, LANCET, V363, P1547, DOI 10.1016/S0140-6736(04)16155-2
   Hawken S, 2017, HUM VACC IMMUNOTHER, V13, P703, DOI 10.1080/21645515.2016.1240846
   Hoffman V, 2018, HUM VACC IMMUNOTHER, V14, P1782, DOI 10.1080/21645515.2018.1450123
   Huppertz HI, 2006, PEDIATR INFECT DIS J, V25, pS22, DOI 10.1097/01.inf.0000197713.32880.46
   Jiang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068482
   Justice FA, 2006, J GASTROEN HEPATOL, V21, P842, DOI 10.1111/j.1440-1746.2005.04031.x
   Kramarz P, 2001, PEDIATR INFECT DIS J, V20, P410, DOI 10.1097/00006454-200104000-00008
   Layton JB, 2018, PAEDIATR PERINAT EP, V32, P448, DOI 10.1111/ppe.12496
   Ledent E, 2018, BIODRUGS, V32, P139, DOI 10.1007/s40259-018-0273-6
   Leino T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0144812
   Lloyd-Johnsen C, 2012, VACCINE, V30, pA190, DOI 10.1016/j.vaccine.2011.11.015
   Murphy TV, 2001, NEW ENGL J MED, V344, P564, DOI 10.1056/NEJM200102223440804
   Parez N, 2014, LANCET INFECT DIS, V14, P416, DOI 10.1016/S1473-3099(14)70035-0
   Patel MM, 2011, NEW ENGL J MED, V364, P2283, DOI 10.1056/NEJMoa1012952
   Peter G, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.6.e67
   Saez-Llorens X, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-95
   Salamanca BV, 2016, VACCINE, V34, P4684, DOI 10.1016/j.vaccine.2016.08.017
   Samad L, 2013, VACCINE, V31, P4098, DOI 10.1016/j.vaccine.2013.06.084
   Simonsen L, 2001, LANCET, V358, P1224, DOI 10.1016/S0140-6736(01)06346-2
   Stowe J, 2016, VACCINE, V34, P3684, DOI 10.1016/j.vaccine.2016.04.050
   Tate JE, 2016, PEDIATRICS, P138
   Vesikari T, 2008, J PEDIATR GASTR NUTR, V46, P615, DOI 10.1097/MPG.0b013e31816e213a
   Weintraub ES, 2014, NEW ENGL J MED, V370, P513, DOI 10.1056/NEJMoa1311738
   World Health Organization. Dept. of Immunization VaB, 2009, POSTM SURV ROT VACC
   Yih WK, 2014, NEW ENGL J MED, V370, P503, DOI 10.1056/NEJMoa1303164
   Yung CF, 2016, DRUG SAFETY, V39, P745, DOI 10.1007/s40264-016-0424-y
NR 39
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 10
PY 2019
VL 37
IS 38
BP 5717
EP 5723
DI 10.1016/j.vaccine.2019.06.058
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IY4JV
UT WOS:000486358200009
PM 31255303
DA 2020-05-12
ER

PT J
AU Kleynhans, J
   Cohen, C
   McMorrow, M
   Tempia, S
   Crowther-Gibson, P
   Quan, V
   de Gouveia, L
   von Gottberg, A
AF Kleynhans, Jackie
   Cohen, Cheryl
   McMorrow, Meredith
   Tempia, Stefano
   Crowther-Gibson, Penny
   Quan, Vanessa
   de Gouveia, Linda
   von Gottberg, Anne
CA GERMS-SA
TI Can pneumococcal meningitis surveillance be used to assess the impact of
   pneumococcal conjugate vaccine on total invasive pneumococcal disease? A
   case-study from South Africa, 2005-2016
SO VACCINE
LA English
DT Article
DE Streptococcus pneumoniae; Invasive disease; Meningitis; Conjugate
   vaccine
AB Introduction: South Africa introduced seven-valent pneumococcal conjugate vaccine (PCV7) in 2009 and PCV13 in 2011. We aimed to compare the estimated impact of PCV on pneumococcal meningitis (PM) to impact of PCV on total invasive pneumococcal disease (tIPD) based on risk reduction after PCV introduction.
   Methods: We conducted national, laboratory-based surveillance for tIPD during 2005-2016. We estimated and compared rates of PCV13 and non-PCV13 serotype disease among tIPD and PM in individuals aged <5 years and >= 5 years, and compared these rates between the 2005-2008 pre-PCV introduction period and two time points after PCV introduction, 2012 and 2016.
   Results: We enrolled 45,853 tIPD cases; 17,251 (38%) were PM. By 2016, IPD caused by all serotypes decreased 55% (95%Cl -57% to -53%) for tIPD, and 54% for PM (95%CI -58% to -51%), 0.7% difference between estimates (p = 0.7). No significant differences were observed between PCV7-serotype disease reduction in tIPD and PM in both age groups or the additional 6 serotypes included in PCV13 in <5 year olds in 2012 and 2016. In 2012 there was a significant difference between increases in non-PCV13 serotype disease in those >= 5 years for tIPD and PM (32% greater increase in PM, p < 0.001), but this difference was absent by 2016. There was a significant difference between the estimated decrease in additional PCV13 type disease in 2016 between tIPD and PM for those aged >= 5 years (28% greater reduction in PM, p = 0.008).
   Conclusion: PM showed similar reductions to tIPD seven years after PCV introduction in vaccine serotype disease in those <5 years, and increases in non-vaccine serotype disease in all ages. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kleynhans, Jackie; Cohen, Cheryl; Tempia, Stefano; de Gouveia, Linda; von Gottberg, Anne] NICD, NHLS, Ctr Resp Dis & Meningitis, 1 Modderfontein Rd, Johannesburg, South Africa.
   [Kleynhans, Jackie] NICD, NHIS, South African Field Epidemiol Training Programme, Johannesburg, South Africa.
   [Kleynhans, Jackie] Univ Pretoria, Fac Hlth Sci, Sch Hlth Syst & Publ Hlth, Pretoria, South Africa.
   [Cohen, Cheryl] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Johannesburg, South Africa.
   [McMorrow, Meredith; Tempia, Stefano] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
   [McMorrow, Meredith; Tempia, Stefano] Ctr Dis Control & Prevent, Influenza Program, Pretoria, South Africa.
   [Crowther-Gibson, Penny; Quan, Vanessa] NICD, NHLS, Div Publ Hlth Surveillance & Response, Johannesburg, South Africa.
   [von Gottberg, Anne] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Johannesburg, South Africa.
RP Kleynhans, J (reprint author), NICD, NHLS, Ctr Resp Dis & Meningitis, 1 Modderfontein Rd, Johannesburg, South Africa.
EM jackiekleyn@gmail.com
OI Tempia, Stefano/0000-0003-4395-347X; Kleynhans,
   Jackie/0000-0001-7081-6273; McMorrow, Meredith/0000-0001-6363-4033;
   Cohen, Cheryl/0000-0003-0376-2302
FU National Institute for Communicable Diseases a division of the National
   Health Laboratory Service, South Africa; United States Agency for
   International Development's Antimicrobial Resistance Initiative, United
   States of America [U60/CCU022088]; United States Centers for Disease
   Control and Prevention, United States if AmerivaUnited States Department
   of Health & Human ServicesCenters for Disease Control & Prevention -
   USA; United States Centers for Disease Control and Prevention, United
   States of AmericaUnited States Department of Health & Human
   ServicesCenters for Disease Control & Prevention - USA [U62/CCU022901]
FX This work was supported by the National Institute for Communicable
   Diseases a division of the National Health Laboratory Service, South
   Africa; the United States Agency for International Development's
   Antimicrobial Resistance Initiative, United States of America,
   transferred via a cooperative agreement [U60/CCU022088] from the United
   States Centers for Disease Control and Prevention, United States if
   Ameriva; and the United States Centers for Disease Control and
   Prevention [U62/CCU022901], United States of America. The findings and
   conclusions in this report are those of the author(s) and do not
   necessarily represent the official position of the funding agencies.
CR Alari A, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0755-7
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P129
   Bamford C, 2011, SAMJ S AFR MED J, V101, P579
   Ben-Shimol S, 2016, VACCINE, V34, P4543, DOI 10.1016/j.vaccine.2016.07.038
   Econex, 2013, S AFR PRIV HEALTHC S
   GERMS-SA, 2015, ANN REPORT
   Meiring S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149104
   Mhlanga B., 2009, Morbidity and Mortality Weekly Report, V58, P493
   Murray J, 2014, MMWR-MORBID MORTAL W, V63, P1159
   National Institute for Communicable Diseases, 2016, VACC INF PAR CAR
   von Gottberg A, 2014, NEW ENGL J MED, V371, P1889, DOI 10.1056/NEJMoa1401914
   von Gottberg A, 2013, VACCINE, V31, P4200, DOI 10.1016/j.vaccine.2013.04.077
   World Health Organization, 2017, WHO UNICEF EST PCV3
   World Health Organization, 2001, RES PNEUM INF
   Wouters E, 2010, HEALTH POLICY PLANN, V25, P171, DOI 10.1093/heapol/czp057
NR 15
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 10
PY 2019
VL 37
IS 38
BP 5724
EP 5730
DI 10.1016/j.vaccine.2019.04.090
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IY4JV
UT WOS:000486358200010
PM 31076159
DA 2020-05-12
ER

PT J
AU Moreno-Mendieta, S
   Barrera-Rosales, A
   Mata-Espinosa, D
   Barrios-Payan, J
   Sanchez, S
   Hernandez-Pando, R
   Rodriguez-Sanoja, R
AF Moreno-Mendieta, Silvia
   Barrera-Rosales, Alejandra
   Mata-Espinosa, Dulce
   Barrios-Payan, Jorge
   Sanchez, Sergio
   Hernandez-Pando, Rogelio
   Rodriguez-Sanoja, Romina
TI Raw starch microparticles as BCG adjuvant: Their efficacy depends on the
   virulence of the infection strains
SO VACCINE
LA English
DT Article
DE Starch microparticles; Bacille Calmette-Guerin; Adjuvant; Tuberculosis
ID MYCOBACTERIUM-TUBERCULOSIS; CATIONIC LIPOSOMES; IMMUNE-RESPONSE;
   VACCINE; IMMUNOGENICITY; DELIVERY; ANTIGEN
AB The persistence of tuberculosis (TB) as one of the top 10 causes of death worldwide, the growing incidence of multidrug-resistant tuberculosis and the controversial efficacy of the Bacille Calmette-Guerin (BCG) vaccine drives the development of new generation multistage vaccines against this disease that can boost BCG-primed immunity. The use of polymeric microparticles for this purpose increases due to their advantages, especially their good safety levels and intrinsic immunostimulant properties. We recently explored and demonstrated the reinforcing and adjuvant potential of starch microparticles (SMPs) that administered intranasally to BCG-primed BALB/c mice, alone or in combination with a recombinant antigen, increased survival rates and induced a reduction of bacterial load in the lungs of mice infected with tuberculosis. Here, we tested the effect of SMPs added to the BCG vaccine as adjuvant to the wholecell vaccine and investigated their contribution to the improvement of the protective efficacy of subcutaneous vaccination in mice challenged with virulent strains of Mycobacterium tuberculosis. As expected, our results were dependent on the infection strains, showing that virulence is a crucial factor that affects the adjuvant activity of SMPs. Our results also confirm the adjuvant activity of this carbohydrate and its usefulness in diverse vaccination strategies not only for mucosal but also for parenteral administration. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Moreno-Mendieta, Silvia] Univ Nacl Autonoma Mexico, CONACYT, Inst Invest Biomed, AP 70228,Ciudad Univ, Mexico City 04510, DF, Mexico.
   [Moreno-Mendieta, Silvia; Sanchez, Sergio; Rodriguez-Sanoja, Romina] Univ Nacl Autonoma Mexico, Inst Invest Biomed, AP 70228,Ciudad Univ, Mexico City 04510, DF, Mexico.
   [Barrera-Rosales, Alejandra] Univ Nacl Autonoma Mexico, Posgrad Ciencias Bioquim, AP 70228,Ciudad Univ, Mexico City 04510, DF, Mexico.
   [Mata-Espinosa, Dulce; Barrios-Payan, Jorge; Hernandez-Pando, Rogelio] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Secc Patol Expt, Vasco Quiroga 15, Mexico City, DF, Mexico.
RP Rodriguez-Sanoja, R (reprint author), Univ Nacl Autonoma Mexico, Inst Invest Biomed, AP 70228,Ciudad Univ, Mexico City 04510, DF, Mexico.; Hernandez-Pando, R (reprint author), Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Secc Patol Expt, Vasco Quiroga 15, Mexico City, DF, Mexico.
EM rhdezpando@hotmail.com; romina@biomedicas.unam.mx
RI Rodriguez-Sanoja, Romina/C-5333-2009
OI Rodriguez-Sanoja, Romina/0000-0002-2722-5432; Moreno, Silvia
   A./0000-0001-7981-0492
FU UNAM-DGAPAUniversidad Nacional Autonoma de Mexico [IN209316, IN216419];
   CONACYTConsejo Nacional de Ciencia y Tecnologia (CONACyT) [FC
   2015-1/115, Fons Inst./58/2016]
FX This work was supported by grants: UNAM-DGAPA IN209316, IN216419 and
   CONACYT Fons Inst./58/2016 and FC 2015-1/115.
CR Abdelaziz HM, 2018, J CONTROL RELEASE, V269, P374, DOI 10.1016/j.jconrel.2017.11.036
   Aboutorabian S, 2015, HUM VACC IMMUNOTHER, V11, P1449, DOI 10.1080/21645515.2015.1023970
   Agger EM, 2016, ADV DRUG DELIVER REV, V102, P73, DOI 10.1016/j.addr.2015.11.012
   Aguilar D, 2010, TUBERCULOSIS, V90, P319, DOI 10.1016/j.tube.2010.08.004
   Ahmed M, 2017, J LEUKOCYTE BIOL, V101, P1373, DOI 10.1189/jlb.4A0616-270R
   [Anonymous], 2017, GLOBAL TUBERCULOSIS, DOI [10.1001/jama.2014.11450, DOI 10.1001/JAMA.2014.11450]
   Azad AK, 2012, INFECT IMMUN, V80, P3343, DOI 10.1128/IAI.00443-12
   Bifani P, 2000, J CLIN MICROBIOL, V38, P3200, DOI 10.1128/JCM.38.9.3200-3204.2000
   Castillo-Rodal AI, 2006, INFECT IMMUN, V74, P1718, DOI 10.1128/IAI.74.3.1718-1724.2006
   Counoupas C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09119-y
   Derrick SC, 2015, VACCINE, V33, P126, DOI 10.1016/j.vaccine.2014.11.004
   Ginsberg AM, 2016, TUBERCULOSIS, V99, pS16, DOI 10.1016/j.tube.2016.05.013
   Glynn JR, 2002, EMERG INFECT DIS, V8, P843
   Guillen D, 2014, CARBOHYD POLYM, V112, P210, DOI 10.1016/j.carbpol.2014.05.089
   Khademi F, 2018, APMIS, V126, P509, DOI 10.1111/apm.12851
   Khademi F, 2018, MICROB PATHOGENESIS, V121, P218, DOI 10.1016/j.micpath.2018.05.035
   Khademi F, 2018, EXPERT REV VACCINES, V17, P31, DOI 10.1080/14760584.2018.1406309
   Kumar NP, 2015, TUBERCULOSIS, V95, P707, DOI 10.1016/j.tube.2015.06.004
   Lopez B, 2003, CLIN EXP IMMUNOL, V133, P30, DOI 10.1046/j.1365-2249.2003.02171.x
   Luabeya AKK, 2015, VACCINE, V33, P4130, DOI 10.1016/j.vaccine.2015.06.051
   Marais BJ, 2016, ADV DRUG DELIVER REV, V102, P3, DOI 10.1016/j.addr.2016.01.021
   Marquina-Castillo B, 2009, IMMUNOLOGY, V128, P123, DOI 10.1111/j.1365-2567.2008.03004.x
   Moliva Juan I, 2017, Front Immunol, V8, P407, DOI 10.3389/fimmu.2017.00407
   Moreno-Mendieta S, 2017, VACCINE, V35, P5123, DOI 10.1016/j.vaccine.2017.08.012
   Moreno-Mendieta SA, 2010, FEMS IMMUNOL MED MIC, V58, P75, DOI 10.1111/j.1574-695X.2009.00629.x
   Pellegrino P, 2015, AUTOIMMUN REV, V14, P880, DOI 10.1016/j.autrev.2015.05.014
   Penn-Nicholson A, 2015, VACCINE, V33, P4025, DOI 10.1016/j.vaccine.2015.05.088
   Portevin D, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001307
   Slutter B, 2011, J CONTROL RELEASE, V154, P123, DOI 10.1016/j.jconrel.2011.02.007
   Tientcheu LD, 2017, EUR J IMMUNOL, V47, P432, DOI 10.1002/eji.201646562
   VANSOOLINGEN D, 1995, J CLIN MICROBIOL, V33, P3234, DOI 10.1128/JCM.33.12.3234-3238.1995
   Wani AA, 2012, COMPR REV FOOD SCI F, V11, P417, DOI 10.1111/j.1541-4337.2012.00193.x
   Woodworth JS, 2017, MUCOSAL IMMUNOL, V10, P555, DOI 10.1038/mi.2016.70
   Yadav AB, 2010, TUBERCULOSIS, V90, P188, DOI 10.1016/j.tube.2010.03.001
   Yu WL, 2016, MOL PHARMACEUT, V13, P3626, DOI 10.1021/acs.molpharmaceut.6b00138
NR 35
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 10
PY 2019
VL 37
IS 38
BP 5731
EP 5737
DI 10.1016/j.vaccine.2019.04.027
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IY4JV
UT WOS:000486358200011
PM 31000412
DA 2020-05-12
ER

PT J
AU Oster, NV
   Williams, EC
   Unger, JM
   Newcomb, PA
   Jacobson, EN
   deHart, MP
   Englund, JA
   Hofstetter, AM
AF Oster, Natalia V.
   Williams, Emily C.
   Unger, Joseph M.
   Newcomb, Polly A.
   Jacobson, Elizabeth N.
   deHart, M. Patricia
   Englund, Janet A.
   Hofstetter, Annika M.
TI Sociodemographic, clinical and birth hospitalization characteristics and
   infant Hepatitis B vaccination in Washington State
SO VACCINE
LA English
DT Article
DE Newborn; Hepatitis B; Immunization practices
ID UNITED-STATES; HEALTH-CARE; VIRUS-INFECTIONS; NEWBORN-INFANTS;
   IMMUNIZATION; CHILDREN; ASSOCIATION; COVERAGE; PREVENTION; REFUSAL
AB Objective: Hepatitis B (HepB) vaccine is recommended at birth; however, national coverage estimates fall far below target levels. Studies describing the factors associated with infant HepB vaccination are lacking. This study aimed to identify the sociodemographic, clinical and birth hospitalization factors associated with timely receipt of the first HepB vaccine dose.
   Study Design: This retrospective cohort study included Washington State infants born weighing >= 2000 g who received birth hospitalization care at an urban academic medical center between January 2008 December 2013. Multivariable logistic regression was used to estimate adjusted odds ratios (AOR) and 95% confidence intervals (CI) for associations between maternal and infant characteristics and HepB vaccine receipt during the birth hospitalization.
   Results: Of the 9080 study infants, 75.5% received HepB vaccine during the birth hospitalization. Infants had higher odds of being vaccinated during the birth hospitalization if they were Hispanic (AOR 2.08; CI: 1.63, 2.65), non-Hispanic black (AOR 2.34; CI: 1.93, 2.84) or Asian (AOR 2.70; CI: 2.22, 3.28) compared to non-Hispanic white. Infants with a Spanish- vs. English-speaking mother (AOR 1.97; CI: 1.46, 2.68), public vs. private insurance (AOR 2.01; CI: 1.78, 2.29), and those hospitalized >= 96 h vs. 24 to <48 h (AOR 1.67; CI: 1.34, 2.09) also had higher odds of vaccination.
   Conclusions: Populations that are typically underserved (e.g., publicly insured, racial/ethnic minorities) had higher odds of receiving HepB vaccine during the birth hospitalization. These findings may aid in identifying high-risk infants who could benefit from targeted interventions to increase initial HepB vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Oster, Natalia V.; Williams, Emily C.; Unger, Joseph M.] Univ Washington, Dept Hlth Serv, 1959 NE Pacific St, Seattle, WA 98195 USA.
   [Williams, Emily C.] Vet Hlth Adm, VA Puget Sound, Hlth Serv Res & Dev Ctr Innovat Vet Ctr & Value D, 1660 S Columbian Way, Seattle, WA 98108 USA.
   [Unger, Joseph M.; Newcomb, Polly A.] Fred Hutchinson Canc Res Ctr, Publ Hlth Sci Div, 1100 Fairview Ave N, Seattle, WA 98109 USA.
   [Newcomb, Polly A.] Univ Washington, Dept Epidemiol, 1959 NE Pacific St, Seattle, WA 98195 USA.
   [Jacobson, Elizabeth N.; Englund, Janet A.; Hofstetter, Annika M.] Univ Washington, Dept Pediat, 1959 NE Pacific St, Seattle, WA 98195 USA.
   [deHart, M. Patricia] Washington State Dept Hlth, 111 Israel Rd SE, Tumwater, WA 98501 USA.
   [Englund, Janet A.; Hofstetter, Annika M.] Seattle Childrens Res Inst, 1900 9th Ave, Seattle, WA 98101 USA.
RP Oster, NV (reprint author), Univ Washington, Sch Publ Hlth, Dept Hlth Serv, 1959 NE Pacific St, Seattle, WA 98195 USA.
EM nvoster@uw.edu
OI Williams, Emily/0000-0002-8210-6137
FU National Center for Advancing Translational SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1 TR002319]
FX Data collection was supported in part by the National Center for
   Advancing Translational Sciences (Award UL1 TR002319). The fun der was
   not involved in the study design, data collection, analysis or
   interpretation, the writing of the report or the decision to submit the
   manuscript for publication.
CR American Academy of Pediatrics. Committee on Infectious Diseases, 2017, PEDIATRICS, V140
   Anderson TA, 2003, IMMUNIZATION ACTION
   BEASLEY RP, 1983, LANCET, V2, P1099
   Berdahl TA, 2013, ACAD PEDIATR, V13, P191, DOI 10.1016/j.acap.2013.02.003
   Centers for Disease Control and Prevention, 2018, MMWR MORB MORTAL WKL, V67
   Centers for Disease Control and Prevention, 2010, VIR HEP SURV US
   Centers for Disease Control and Prevention, 2013, PERC CHILDR AG 6 YEA
   Gust D A, 2003, Semin Pediatr Infect Dis, V14, P207, DOI 10.1016/S1045-1870(03)00035-9
   Hill HA, 2017, MMWR-MORBID MORTAL W, V66, P1171, DOI 10.15585/mmwr.mm6643a3
   Jackson ML, 2014, ACAD PEDIATR, V14, P71, DOI 10.1016/j.acap.2013.10.002
   Ko SC, 2016, J PEDIAT INF DIS SOC, V5, P114, DOI 10.1093/jpids/piu115
   Kogan MD, 1998, PEDIATRICS, V102, P25, DOI 10.1542/peds.102.1.25
   Lauderdale DS, 1999, JAMA-J AM MED ASSOC, V282, P1725, DOI 10.1001/jama.282.18.1725
   Lee CF, 2006, BMJ-BRIT MED J, V332, P328, DOI 10.1136/bmj.38719.435833.7C
   Leininger L, 2015, FUTURE CHILD, V25, P65, DOI 10.1353/foc.2015.0003
   Mast Eric E., 2005, Morbidity and Mortality Weekly Report, V54, P1
   McClure CC, 2017, CLIN THER, V39, P1550, DOI 10.1016/j.clinthera.2017.07.003
   Murthy N, 2017, MMWR-MORBID MORTAL W, V66, P1178, DOI 10.15585/mmwr.mm6643a4
   Myers HI, 2015, VACCINE, V33, P2316, DOI 10.1016/j.vaccine.2015.03.053
   New York State Department of Health, PER HEP B PREV PROGR
   Newacheck PW, 1996, PEDIATRICS, V97, P26
   O'Leary ST, 2012, PEDIATR INFECT DIS J, V31, P1, DOI 10.1097/INF.0b013e3182345995
   Ocama Ponsiano, 2005, Am J Med, V118, P1413
   Opel DJ, 2013, PEDIATRICS, V132, P1037, DOI 10.1542/peds.2013-2037
   Quinn JA, 2016, VACCINE, V34, P6047, DOI 10.1016/j.vaccine.2016.03.045
   Rural Health Research Center, RUR URB COMM AR
   Schillie S, 2015, PEDIATRICS, V135, pE1141, DOI 10.1542/peds.2014-3213
   Seither R, 2013, MMWR-MORBID MORTAL W, V62, P607
   Smith EA, 2012, PEDIATRICS, V129, P609, DOI 10.1542/peds.2011-2866
   Smith PJ, 2006, PEDIATRICS, V118, pE1287, DOI 10.1542/peds.2006-0923
   Smith PJ, 2011, PUBLIC HEALTH REP, V126, P135, DOI 10.1177/00333549111260S215
   Smith PJ, 2004, PEDIATRICS, V114, P187, DOI 10.1542/peds.114.1.187
   U.S. Census Bureau, 2010, OVERVIEW RACE HISPAN
   University of Michigan Institute for Social Research., 2006, MED HOUS INC
   Vasireddy D, 2014, J PEDIATR INFECT, V8, P159, DOI 10.5152/ced.2014.1920
   Walker TY, 2016, PUBLIC HEALTH REP, V131, P685, DOI 10.1177/0033354916663183
   Washington State Department of Health, EV BIRTH HOSP PER HE
   Washington State Office of Financial Management, WASH STAT COUNT MED
   Wheeler M, 2013, HUM VACC IMMUNOTHER, V9, P1782, DOI 10.4161/hv.25959
   Yang S, 2006, J HEALTH CARE POOR U, V17, P928, DOI 10.1353/hpu.2006.0137
   Yusuf HR, 2000, JAMA-J AM MED ASSOC, V284, P978, DOI 10.1001/jama.284.8.978
NR 41
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 10
PY 2019
VL 37
IS 38
BP 5738
EP 5744
DI 10.1016/j.vaccine.2019.03.050
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IY4JV
UT WOS:000486358200012
PM 30930007
DA 2020-05-12
ER

PT J
AU Kriss, JL
   Grant, GB
   Moss, WJ
   Durrheim, DN
   Shefer, A
   Rota, PA
   Omer, SB
   Masresha, BG
   Mulders, MN
   Hanson, M
   Linkins, RW
   Goodson, JL
AF Kriss, Jennifer L.
   Grant, Gavin B.
   Moss, William J.
   Durrheim, David N.
   Shefer, Abigail
   Rota, Paul A.
   Omer, Saad B.
   Masresha, Balcha G.
   Mulders, Mick N.
   Hanson, Matt
   Linkins, Robert W.
   Goodson, James L.
TI Research priorities for accelerating progress toward measles and rubella
   elimination identified by a cross-sectional web-based survey
SO VACCINE
LA English
DT Article
DE Measles; Rubella; Elimination; Research; Priorities
ID WORLDWIDE
AB Background: In 2012, the World Health Assembly endorsed the Global Vaccine Action Plan (GVAP) that set a target to eliminate measles and rubella in five of the six World Health Organization (WHO) regions by 2020. Significant progress has been made toward achieving this goal through intensive efforts by countries and Measles & Rubella Initiative (M&RI) partners. Accelerating progress will require evidence-based approaches to improve implementation of the core strategies in the Global Measles and Rubella Strategic Plan. The M&RI Research and Innovation Working Group (R&IWG) conducted a web-based survey as part of a process to identify measles and rubella research priorities. Survey findings were used to inform discussions during a meeting of experts convened by the M&RI at the Pan American Health Organization in November 2016.
   Methods: The cross-sectional web-based survey of scientific and programmatic experts included questions in four main topic areas: (1) epidemiology and economics (epidemiology); (2) new tools for surveillance, vaccine delivery, and laboratory testing (new tools); (3) immunization strategies and outbreak response (strategies); and (4) vaccine demand and communications (demand). Analyses were stratified by the six WHO regions and by global, regional, or national/sub-national level of respondents.
   Results: The six highest priority research questions selected by survey respondents from the four topic areas were the following: (1) What are the causes of outbreaks in settings with high reported vaccination coverage? (epidemiology); (2) Can affordable diagnostic tests be developed to confirm measles and rubella cases rapidly and accurately at the point of care? (new tools); (3) What are effective strategies for increasing coverage of the routine first dose of measles vaccine administered at 9 or 12 months? (strategies); (4) What are effective strategies for increasing coverage of the second dose given after the first year of life? (strategies); (5) How can communities best be engaged in planning, implementing and monitoring health services including vaccinations? (demand); (6) What capacity building is needed for health workers to be able to identify and work more effectively with community leaders? (demand). Research priorities varied by region and by global/regional/national levels for all topic areas.
   Conclusions: Research and innovation will be critical to make further progress toward achieving the GVAP measles and rubella elimination goals. The results of this survey can be used to inform decision-making for investments in research activities at the global, regional, and national levels. (C) 2019 Published by Elsevier Ltd.
C1 [Kriss, Jennifer L.; Grant, Gavin B.; Linkins, Robert W.; Goodson, James L.] Ctr Dis Control & Prevent, Accelerated Dis Control & Surveillance Branch, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA.
   [Moss, William J.] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Durrheim, David N.] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW, Australia.
   [Shefer, Abigail] Ctr Dis Control & Prevent, Immunizat Syst Branch, Global Immunizat Div, Atlanta, GA USA.
   [Rota, Paul A.] Ctr Dis Control & Prevent, Viral Vaccine Preventable Dis Branch, Div Viral Dis, Atlanta, GA USA.
   [Omer, Saad B.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA.
   [Omer, Saad B.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
   [Masresha, Balcha G.] WHO, Immunisat & Vaccine Dev Program, Reg Off Africa, Brazzaville, Rep Congo.
   [Mulders, Mick N.] WHO, Dept Immunizat Vaccines & Biol, Expanded Programme Immunizat, Geneva, Switzerland.
   [Hanson, Matt] Bill & Melinda Gates Fdn, Seattle, WA USA.
   [Kriss, Jennifer L.] Ctr Global Hlth, Global Immunizat Div, Accelerated Dis Control & Surveillance Branch, Atlanta, GA 30333 USA.
   [Kriss, Jennifer L.] Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Assessment Branch, Atlanta, GA 30333 USA.
RP Kriss, JL (reprint author), Ctr Dis Control & Prevent, MS A-19,1600 Clifton Rd NE, Atlanta, GA 30329 USA.; Kriss, JL (reprint author), Ctr Global Hlth, Global Immunizat Div, Accelerated Dis Control & Surveillance Branch, Atlanta, GA 30333 USA.; Kriss, JL (reprint author), Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Assessment Branch, Atlanta, GA 30333 USA.
EM JKriss@cdc.gov
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR001863]; World Health
   OrganizationWorld Health Organization [001]; Intramural CDC HHS
   [CC999999]
CR [Anonymous], 2016, Wkly Epidemiol Rec, V91, P525
   Dabbagh A, 2018, MMWR-MORBID MORTAL W, V67, P1323, DOI 10.15585/mmwr.mm6747a6
   Feldstein LR, 2017, MMWR-MORBID MORTAL W, V66, P1252, DOI 10.15585/mmwr.mm6645a3
   Goodson JL, 2012, VACCINE, V30, P4709, DOI 10.1016/j.vaccine.2012.04.058
   Grant GB, 2019, VACCINE, V37, P5754, DOI 10.1016/j.vaccine.2019.01.081
   Grant GB, 2017, MMWR-MORBID MORTAL W, V66, P1256, DOI 10.15585/mmwr.mm6645a4
   Moss WJ, 2013, SAGE WORK GROUP MEAS
   Orenstein WA, 2018, VACCINE, V36, pA1, DOI 10.1016/j.vaccine.2017.09.026
   Orenstein WA, 2018, VACCINE, V36, pA35, DOI 10.1016/j.vaccine.2017.10.065
   Pan American Health Organization (PAHO), 2015, IMM NEWSL, V37
   The Measles & Rubella Initiative, 2016, SURV ID RES PRIOR AC
   The Measles & Rubella Initiative, 2016, ACC MEASL RUB EL RES
   VanderEnde K, 2018, MMWR-MORBID MORTAL W, V67, P1261, DOI 10.15585/mmwr.mm6745a2
   World Health Organization, 2013, GLOB VACC ACT PLAN 2
   World Health Organization, 2012, GLOB MEASL RUB START
NR 15
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 10
PY 2019
VL 37
IS 38
BP 5745
EP 5753
DI 10.1016/j.vaccine.2019.02.058
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IY4JV
UT WOS:000486358200013
PM 30898393
DA 2020-05-12
ER

PT J
AU Grant, GB
   Masresha, BG
   Moss, WJ
   Mulders, MN
   Rota, PA
   Omer, SB
   Shefer, A
   Kriss, JL
   Hanson, M
   Durrheim, DN
   Linkins, R
   Goodson, JL
AF Grant, Gavin B.
   Masresha, Balcha G.
   Moss, William J.
   Mulders, Mick N.
   Rota, Paul A.
   Omer, Saad B.
   Shefer, Abigail
   Kriss, Jennifer L.
   Hanson, Matt
   Durrheim, David N.
   Linkins, Robert
   Goodson, James L.
TI Accelerating measles and rubella elimination through research and
   innovation - Findings from the Measles & Rubella Initiative research
   prioritization process, 2016
SO VACCINE
LA English
DT Article
DE Measles; Rubella; Eradication; Research; Immunization; Vaccines
ID MIDDLE-INCOME COUNTRIES; GLOBAL MEASLES; POLIO ERADICATION; LABORATORY
   NETWORK; COST-EFFECTIVENESS; MICRONEEDLE PATCH; VACCINE REFUSAL;
   IMMUNIZATION; SURVEILLANCE; WORLDWIDE
AB The Measles & Rubella Initiative (M&RI) identified five key strategies to achieve measles and rubella elimination, including research and innovation to support cost-effective operations and improve vaccination and diagnostic tools. In 2016, the M&RI Research and Innovation Working Group (R&IWG) completed a research prioritization process to identify key research questions and update the global research agenda. The R&IWG reviewed meeting reports and strategic planning documents and solicited programmatic inputs from vaccination experts at the program operational level through a web survey, to identify previous research priorities and new research questions. The R&IWG then convened a meeting of experts to prioritize the identified research questions in four strategic areas: (1) epidemiology and economics, (2) surveillance and laboratory, (3) immunization strategies, and (4) demand creation and communications. The experts identified 19 priority research questions in the four strategic areas to address key areas of work necessary to further progress toward elimination. Future commitments from partners will be needed to develop a platform for improved coordination with adequate and predictable resources for research implementation and innovation to address these identified priorities. (C) 2019 Published by Elsevier Ltd.
C1 [Grant, Gavin B.; Kriss, Jennifer L.; Linkins, Robert; Goodson, James L.] Ctr Dis Control & Prevent, Accelerated Dis Control & Surveillance Branch, Global Immunizat Div, Atlanta, GA USA.
   [Masresha, Balcha G.] WHO, Immunisat & Vaccine Dev Program, Reg Off Africa, Brazzaville, Rep Congo.
   [Moss, William J.] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Mulders, Mick N.] WHO, Dept Immunizat Vaccines & Biol, Geneva, Switzerland.
   [Rota, Paul A.] Ctr Dis Control & Prevent, Viral Vaccine Preventable Dis Branch, Div Viral Dis, Atlanta, GA USA.
   [Omer, Saad B.] Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
   [Shefer, Abigail] Ctr Dis Control & Prevent, Immunizat Syst Branch, Global Immunizat Div, Atlanta, GA USA.
   [Hanson, Matt] Bill & Melinda Gates Fdn, Seattle, WA USA.
   [Durrheim, David N.] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW, Australia.
RP Grant, GB (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd,NE MS-E05, Atlanta, GA 30333 USA.
EM gbgrant@cdc.gov
FU World Health OrganizationWorld Health Organization [001]
CR Adhikari BB, 2016, DRUGS R&D, V16, P327, DOI 10.1007/s40268-016-0144-x
   Alonso PL, 2013, VACCINE, V31, pB3, DOI 10.1016/j.vaccine.2013.02.035
   [Anonymous], 2018, Wkly Epidemiol Rec, V93, P55
   [Anonymous], 2012, UPS DOWNS MEAS
   [Anonymous], 2016, GLOB ROUT IMM STRAT
   [Anonymous], 2017, LANCET
   Arya J, 2017, BIOMATERIALS, V128, P1, DOI 10.1016/j.biomaterials.2017.02.040
   Bharti N, 2016, SCI REP-UK, V6, DOI 10.1038/srep34541
   Breman JG, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000405
   Bryant KA, 2009, VACCINE, V27, P3616, DOI 10.1016/j.vaccine.2009.03.048
   Buttenheim AM, 2015, VACCINE, V33, P6250, DOI 10.1016/j.vaccine.2015.09.075
   Casey RM, 2016, MMWR-MORBID MORTAL W, V65, P1270, DOI 10.15585/mmwr.mm6545a5
   Chalmers I, 2016, LANCET, V387, P122, DOI 10.1016/S0140-6736(15)01353-7
   Chatterjee A, 2010, EXPERT REV VACCINES, V9, P497, DOI [10.1586/erv.10.36, 10.1586/ERV.10.36]
   Cochi SL, 2014, J INFECT DIS, V210, pS540, DOI 10.1093/infdis/jiu345
   Cochi SL, 2011, J INFECT DIS, V204, pS4, DOI 10.1093/infdis/jir100
   Dabbagh A, 2017, MMWR-MORBID MORTAL W, V66, P1148, DOI 10.15585/mmwr.mm6642a6
   Durrheim DN, 2017, T ROY SOC TROP MED H, V111, P41, DOI 10.1093/trstmh/trx018
   Durrheim DN, 2017, LANCET PUBLIC HEALTH, V2, pE130, DOI 10.1016/S2468-2667(17)30026-9
   Edens C, 2015, VACCINE, V33, P4712, DOI 10.1016/j.vaccine.2015.02.074
   Fonnesbeck CJ, 2018, J R SOC INTERFACE, V15, DOI 10.1098/rsif.2017.0575
   Ford AQ, 2016, VACCINE, V34, P1489, DOI 10.1016/j.vaccine.2015.11.038
   Gastanaduy PA, 2018, AM J EPIDEMIOL
   Godlee Fiona, 2011, BMJ, V342, pc7452, DOI 10.1136/bmj.c7452
   Goel K, 2016, RISK ANALYSIS AN OFF
   Goodson JL, 2017, EXPERT REV VACCINES, V16, P1203, DOI 10.1080/14760584.2017.1393337
   Goodson JL, 2012, VACCINE, V30, P4709, DOI 10.1016/j.vaccine.2012.04.058
   Grant GB, 2017, MMWR-MORBID MORTAL W, V66, P1256, DOI 10.15585/mmwr.mm6645a4
   Hagan JE, 2017, EMERG INFECT DIS, V23, pS77, DOI 10.3201/eid2313.170594
   Henderson DA, 2011, VACCINE, V29, pD7, DOI 10.1016/j.vaccine.2011.06.080
   Joyce JC, 2018, J INFECT DIS, V218, P124, DOI 10.1093/infdis/jiy139
   Kriss JL, 2019, VACCINE, V37, P5745, DOI 10.1016/j.vaccine.2019.02.058
   Kriss JL, 2016, RISK ANALYSIS AN OFF
   Kriss JL, 2016, RISK ANAL OFFICIAL P
   Lam E, 2015, DEV DISTRICT LEVEL P
   Lee LA, 2013, VACCINE, V31, pB61, DOI 10.1016/j.vaccine.2012.11.035
   Manakongtreecheep Kasidet, 2017, Pan Afr Med J, V27, P23, DOI 10.11604/pamj.supp.2017.27.3.12115
   Mulders MN, 2017, J INFECT DIS, V216, pS324, DOI 10.1093/infdis/jix077
   Mulders MN, 2016, MMWR-MORBID MORTAL W, V65, P438, DOI 10.15585/mmwr.mm6517a3
   Muller CP, 2007, VACCINE, V25, P1, DOI 10.1016/j.vaccine.2006.07.039
   National Center for Immunization and Respiratory Disease CfDCaP, 2009, GLOB MEASL RUB RES E
   Omer SB, 2013, NEW ENGL J MED, V368, P1374, DOI 10.1056/NEJMp1300765
   Opel DJ, 2015, JAMA PEDIATR, V169, P303, DOI 10.1001/jamapediatrics.2015.0291
   Orenstein WA, 2018, VACCINE, V36, pA1, DOI 10.1016/j.vaccine.2017.09.026
   Orenstein WA, 2018, VACCINE, V36, pA35, DOI 10.1016/j.vaccine.2017.10.065
   Ozawa S, 2016, HEALTH AFFAIR, V35, P199, DOI 10.1377/hlthaff.2015.1086
   Ozawa S, 2012, VACCINE, V31, P96, DOI 10.1016/j.vaccine.2012.10.103
   Paterson RRM, 2017, INT J ENV RES PUB HE, V14, DOI [10.3390/ijerph14020199, :10.3390/ijerph14020199]
   Rota PA, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.49
   Rota PA, 2015, J INFECT DIS, V212, P1529, DOI 10.1093/infdis/jiv272
   Rouphael NG, LANCET
   Rutter PD, 2014, J INFECT DIS, V210, pS16, DOI 10.1093/infdis/jiu181
   Saint-Victor DS, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0148
   Shonhai A, 2015, EPIDEMIOL INFECT, V143, P3442, DOI 10.1017/S0950268815000540
   Simons E, 2012, LANCET, V379, P2173, DOI 10.1016/S0140-6736(12)60522-4
   Strebel PM, 2011, J INFECT DIS, V204, pS1, DOI 10.1093/infdis/jir111
   Takahashi S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15585
   Thompson KM, 2016, RISK ANAL, V36, P1427, DOI 10.1111/risa.12454
   Thompson KM, 2016, RISK ANAL, V36, P1297, DOI 10.1111/risa.12331
   UNICEF, COMM DEV 2016
   Wallace AS, 2014, VACCINE, V32, P4505, DOI 10.1016/j.vaccine.2014.06.035
   World Health Organization, 2016, PLANN IMPL HIGH QUAL
   World Health Organization, 2012, GLOB MEASL RUB STRAT, P42
   World Health Organization (WHO), 2009, RESP MEASL OUTBR MEA
   World Health Organization (WHO), 2012, GLOB MEASL RUB STRAT
   Yoshida S, 2016, J GLOB HEALTH, V6, DOI 10.7189/jogh.06.010507
NR 66
TC 2
Z9 2
U1 3
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 10
PY 2019
VL 37
IS 38
BP 5754
EP 5761
DI 10.1016/j.vaccine.2019.01.081
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IY4JV
UT WOS:000486358200014
PM 30904317
DA 2020-05-12
ER

PT J
AU Burkhardt, M
   Reiter, K
   Nguyen, V
   Suzuki, M
   Herrera, R
   Duffy, PE
   Shimp, R
   MacDonald, NJ
   Olano, LR
   Narum, DL
AF Burkhardt, Martin
   Reiter, Karine
   Vu Nguyen
   Suzuki, Motoshi
   Herrera, Raul
   Duffy, Patrick E.
   Shimp, Richard, Jr.
   MacDonald, Nicholas J.
   Olano, L. Renee
   Narum, David L.
TI Assessment of the impact of manufacturing changes on the physicochemical
   properties of the recombinant vaccine carrier ExoProtein A
SO VACCINE
LA English
DT Article
DE Vaccine; Vaccine carrier; Malaria; Host cell protein; Mass spectrometry;
   ExoProtein A; Purification; Mixed-mode chromatography
ID INFLUENZAE TYPE-B; IGG ANTI-VI; MALARIA VACCINE; PROTEINS;
   IMMUNOGENICITY; CHILDREN; EFFICACY
AB Efforts to develop a vaccine for the elimination of malaria include the use of carrier proteins to assemble monomeric antigens into nanoparticles to maximize immunogenicity. Recombinant ExoProtein A (EPA) is a detoxified form of Pseudomonas aeruginosa Exotoxin A which has been used as a carrier in the conjugate vaccine field. A pilot-scale process developed for purification of EPA yielded product that consistently approached a preset upper limit for host cell protein (HCP) content per human dose. To minimize the risk of bulk material exceeding the specification, the purification process was redeveloped using mixed-mode chromatography resins. Purified EPA derived from the primary and redeveloped processes were comparable following full biochemical and biophysical characterization. However, using a process specific immunoassay, the HCP content was shown to decrease from a range of 0.14-0.24% w/w of total protein to below the level of detection with the revised process. The improved process reproducibly yields EPA with highly similar quality characteristics as the original process but with an improved profile for the HCP content. Published by Elsevier Ltd.
C1 [Burkhardt, Martin; Reiter, Karine; Vu Nguyen; Herrera, Raul; Duffy, Patrick E.; Shimp, Richard, Jr.; MacDonald, Nicholas J.; Narum, David L.] NIAID, Lab Malaria Immunol & Vaccinol, NIH, 5640 Fishers Lane, Rockville, MD 20852 USA.
   [Suzuki, Motoshi; Olano, L. Renee] NIAID, Res Technol Branch, NIH, 5640 Fishers Lane, Rockville, MD 20852 USA.
RP Narum, DL (reprint author), NIAID, Lab Malaria Immunol & Vaccinol, NIH, 5640 Fishers Lane, Rockville, MD 20852 USA.
EM dnarum@niaid.nih.gov
FU Intramural Research Program of the National Institute for Allergy and
   Infectious Diseases, National Institutes of Health; RTB
FX We appreciate the technical assistance for formulating EPA by Kelly
   Rausch, and Emma Barnafo, and performance of the small animal
   immunizations by Brandi Butler, and Lynn Lambert. Weili Dai provided
   technical support for performance of HCP assays. We also thank Drs.
   Duck-Yeon Lee, Glenn Nardone, and Brian Martin from RTB for support in
   the biophysical characterization of EPA. Finally, we appreciated Drs.
   David Fitzgerald and Ira Pastan for their assistance in the
   clarification of the unreported mutation in EPA. This work was supported
   by the Intramural Research Program of the National Institute for Allergy
   and Infectious Diseases, National Institutes of Health.
CR Aon JC, 2008, APPL ENVIRON MICROB, V74, P950, DOI 10.1128/AEM.01790-07
   Avery O T, 1932, J Exp Med, V55, P769, DOI 10.1084/jem.55.5.769
   Burton SC, 1998, J CHROMATOGR A, V814, P71, DOI 10.1016/S0021-9673(98)00436-1
   Chambers MC, 2012, NAT BIOTECHNOL, V30, P918, DOI 10.1038/nbt.2377
   DONNELLY JJ, 1990, J IMMUNOL, V145, P3071
   FASS R, 1991, APPL MICROBIOL BIOT, V36, P65, DOI 10.1007/BF00164700
   FATTOM A, 1992, INFECT IMMUN, V60, P584, DOI 10.1128/IAI.60.2.584-589.1992
   FU J, 1995, BIO-TECHNOL, V13, P170, DOI 10.1038/nbt0295-170
   Hoogsteder PHJ, 2014, ADDICTION, V109, P1252, DOI 10.1111/add.12573
   Jones DS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0138761
   Kaslow DC, 2015, VACCINE, V33, P7425, DOI 10.1016/j.vaccine.2015.09.061
   Le Merdy S, 2015, BIOPROCESS J, V14, P50
   Li XJ, 2008, J AM SOC MASS SPECTR, V19, P855, DOI 10.1016/j.jasms.2008.02.011
   Lin DQ, 2012, J CHROMATOGR A, V1260, P143, DOI 10.1016/j.chroma.2012.08.080
   LUKAC M, 1988, INFECT IMMUN, V56, P3095, DOI 10.1128/IAI.56.12.3095-3098.1988
   Masforrol Y, 2017, HUM VACC IMMUNOTHER, V13, P2548, DOI 10.1080/21645515.2017.1356961
   Narum DL, 2000, INFECT IMMUN, V68, P2899, DOI 10.1128/IAI.68.5.2899-2906.2000
   Pluskal T, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-395
   Qian F, 2007, VACCINE, V25, P3923, DOI 10.1016/j.vaccine.2007.02.073
   Qian F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036996
   Radtke AJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep40312
   Ritz C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0146021
   SCHNEERSON R, 1986, INFECT IMMUN, V52, P519, DOI 10.1128/IAI.52.2.519-528.1986
   Shimp RL, 2013, VACCINE, V31, P2954, DOI 10.1016/j.vaccine.2013.04.034
   Suckau D, 2003, ANAL CHEM, V75, P5817, DOI 10.1021/ac034362b
   Szu SC, 2013, VACCINE, V31, P1970, DOI 10.1016/j.vaccine.2013.02.006
   Talaat KR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163144
   Team RC, 2017, LANG ENV STAT COMP
   Team RS, 2015, RSTUDIO INT DEV R
   Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8
   Tregnaghi MW, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001657
   Uchime O, 2012, EUKARYOT CELL, V11, P615, DOI 10.1128/EC.00039-12
   Thiem VD, 2011, CLIN VACCINE IMMUNOL, V18, P730, DOI 10.1128/CVI.00532-10
   WENGER JD, 1991, LANCET, V338, P395
   Zhu DM, 2017, VACCINE, V35, P3232, DOI 10.1016/j.vaccine.2017.04.067
   Zhu DM, 2005, J IMMUNOL METHODS, V306, P40, DOI 10.1016/j.jim.2005.07.021
   Zuercher AW, 2006, FEMS IMMUNOL MED MIC, V47, P302, DOI 10.1111/j.1574-695X.2006.00103.x
NR 37
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 10
PY 2019
VL 37
IS 38
BP 5762
EP 5769
DI 10.1016/j.vaccine.2018.09.037
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IY4JV
UT WOS:000486358200015
PM 30262247
DA 2020-05-12
ER

PT J
AU McCoy, JD
   Painter, JE
   Jacobsen, KH
AF McCoy, Jeremiah D.
   Painter, Julia E.
   Jacobsen, Kathryn H.
TI Perceptions of vaccination within a Christian homeschooling community in
   Pennsylvania
SO VACCINE
LA English
DT Article
DE Adolescent; Child; Parent; Health knowledge, Attitudes, Practice; Health
   attitudes; Health behaviors; Immunization; Vaccination
ID UNITED-STATES; VACCINES; CHILDREN; PARENTS; REFUSAL; ASSOCIATION;
   BELIEFS
AB Background: More than 1.8 million American children ages 5-17 are being educated at home. The percentage of school-aged children in the United States who are homeschooled increased from 1.7% in 1999 to 3.4% in 2012. Every state has established school-entry vaccination requirements for kindergarten students, but most states exempt homeschoolers from these regulations. The goal of this study was to use qualitative methods to examine the vaccination perceptions and practices of Christian homeschooling families in Pennsylvania.
   Methods: A qualitative study (focus groups) of Christian homeschooling parents representing a diversity of vaccination practices (full, partial/delayed, and no vaccination) was conducted in south-central Pennsylvania in 2017. An analysis using a grounded theory approach identified themes that strongly aligned with constructs from the Health Belief Model.
   Results: Many of the perspectives expressed by the study population aligned with those of the general American population, including uncertainty about the risk from vaccine-preventable diseases, concerns about the efficacy and safety of vaccines, and confusion about conflicting vaccine information. The Christian homeschooling parents expressed two especially prominent perceptions: a belief that they had a very low risk of contracting infectious diseases because God has provided them with the natural tools necessary for health and a stronger-than-typical sense of empowerment related to parental decision-making and autonomy. Participants expressed that they were generally open to honest communication about vaccination with physicians who respect parental authority.
   Conclusions: Homeschooling families have diverse vaccination practices. Pediatricians and other health-care practitioners should not make assumptions about health beliefs in this community, and should instead engage parents in conversations about their risk perceptions and vaccine decisions. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [McCoy, Jeremiah D.; Painter, Julia E.; Jacobsen, Kathryn H.] George Mason Univ, Dept Global & Community Hlth, 4400 Univ Dr 5B7, Fairfax, VA 22030 USA.
RP Jacobsen, KH (reprint author), George Mason Univ, Dept Global & Community Hlth, 4400 Univ Dr 5B7, Fairfax, VA 22030 USA.
EM kjacobse@gmu.edu
RI Jacobsen, Kathryn/B-5857-2008
OI Jacobsen, Kathryn/0000-0002-4198-6246
CR Amin AB, 2017, NAT HUM BEHAV, V1, P873, DOI 10.1038/s41562-017-0256-5
   BECKER MH, 1974, HLTH BELIEF MODEL PE
   Cordner A, 2012, SOC SCI MED, V75, P269, DOI 10.1016/j.socscimed.2012.02.002
   Diekema DS, 2014, ANNU REV PUBL HEALTH, V35, P275, DOI 10.1146/annurev-publhealth-032013-182452
   Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212
   Glanz JM, 2013, ACAD PEDIATR, V13, P481, DOI 10.1016/j.acap.2013.05.030
   Gofen A, 2015, POLICY SCI, V48, P3, DOI 10.1007/s11077-014-9202-9
   Hausman Bernice L., 2014, Yale Journal of Biology and Medicine, V87, P403
   Isenberg J. E., 2007, PEABODY J EDUC, V82, P387, DOI [10.1080/01619560701312996, DOI 10.1080/01619560701312996]
   Kennedy A, 2011, HEALTH AFFAIR, V30, P1151, DOI 10.1377/hlthaff.2011.0396
   Kennedy AM, 2005, J SCHOOL HEALTH, V75, P276, DOI 10.1111/j.1746-1561.2005.00037.x
   Khalili D, 2007, J LAW MED ETHICS, V35, P471, DOI 10.1111/j.1748-720X.2007.00169.x
   KUNZMAN R, 2010, INT ELECT J ELEMENTA, V3, P17
   Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   McQuiggan M, 2017, 2017102 NCES
   Offit PA, 2009, PEDIATRICS, V123, pE164, DOI 10.1542/peds.2008-2189
   Olive Jacqueline K, 2018, PLoS Med, V15, pe1002616, DOI 10.1371/journal.pmed.1002616
   Omer SB, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofx244
   Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353
   Redford J, 2017, 2016096REV NCES
   ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P328, DOI 10.1177/109019817400200403
   Salmon DA, 2005, ARCH PEDIAT ADOL MED, V159, P470, DOI 10.1001/archpedi.159.5.470
   Sandelowski M., 2008, SAGE ENCY QUALITATIV, V2, P875
   Seither R, 2017, MMWR-MORBID MORTAL W, V66, P1073, DOI 10.15585/mmwr.mm6640a3
   Smith G., 2015, AM CHANGING RELIG LA
   Thorpe EL, 2012, VACCINE, V30, P1149, DOI 10.1016/j.vaccine.2011.12.019
   Troupe D., 2017, Californian Journal of Health Promotion, V15, P46
   Vieux A, 2014, SOC SCI J, V51, P556, DOI 10.1016/j.soscij.2014.06.004
NR 29
TC 2
Z9 2
U1 4
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 10
PY 2019
VL 37
IS 38
BP 5770
EP 5776
DI 10.1016/j.vaccine.2018.09.036
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IY4JV
UT WOS:000486358200016
PM 30253888
DA 2020-05-12
ER

PT J
AU Gessner, BD
   Jiang, Q
   Van Werkhoven, CH
   Sings, HL
   Webber, C
   Scott, D
   Neuzil, KM
   O'Brien, KL
   Wunderink, RG
   Grobbee, DE
   Bonten, MJM
   Jodar, L
AF Gessner, Bradford D.
   Jiang, Qin
   Van Werkhoven, Cornelis H.
   Sings, Heather L.
   Webber, Chris
   Scott, Daniel
   Neuzil, Kathleen M.
   O'Brien, Katherine L.
   Wunderink, Richard G.
   Grobbee, Diederick E.
   Bonten, Marc J. M.
   Jodar, Luis
TI A public health evaluation of 13-valent pneumococcal conjugate vaccine
   impact on adult disease outcomes from a randomized clinical trial in the
   Netherlands
SO VACCINE
LA English
DT Article
ID COMMUNITY-ACQUIRED PNEUMONIA; STANDARDIZED INTERPRETATION; HOSPITAL
   STAY; EFFICACY; CHILDREN; POPULATION; PREVENTION; REDUCTION; EPISODES
AB Background: We conducted a post-hoc analysis of a double blind, randomized, placebo-controlled trial of 13-valent pneumococcal conjugate vaccine (PCV13) among adults aged 65 years or older to assess public health impact.
   Methods: For all outcomes, we included all randomized subjects, using a modified intention-to-treat (mITT) approach to determine vaccine efficacy (VE), vaccine preventable disease incidence (VPDI) defined as control minus vaccinated group incidence, and numbers needed to vaccinate (NNV) (based on a five-year duration of protection).
   Results: Results are reported for, in order, clinical, adjudicated (clinical plus radiologic infiltrate determined by committee), pneumococcal, and vaccine-type pneumococcal (VT-Sp) community-acquired pneumonia; invasive pneumococcal disease (IPD) and VT-IPD. VEs (95% CI) for all hospital episodes were 8.1% (-0.6%, 16.1%), 6.7% (-4.1%, 16.3%), 22.2% (2.0%, 38.3%), 37.5% (143%, 54.5%), 49.3% (23.2%, 66.5%), and 75.8% (47.6%, 88.8%). VPDIs per 100,000 person-years of observation (PYOs) were 72, 37, 25, 25, 20, and 15 with NNVs of 277, 535, 816, 798, 1016, and 1342. For clinical CAP, PCV13 was associated with a reduction of 909 (-115, 2013) hospital days per 100,000 PYOs translating to a reduction over 5 years of one hospital day for every 22 people vaccinated. When comparing at-risk persons (defined by self-report of diabetes, chronic lung disease, or other underlying conditions) to not at-risk persons, VEs were similar or lower, but because baseline incidences were higher the VPDIs were approximately 2-10 times higher and NNVs 50-90% lower.
   Conclusion: A public health analysis of pneumonia and IPD outcomes in a randomized controlled trial found substantial burden reduction following adult PCV13 immunization implemented in a setting with an ongoing infant PCV7-PCV10 program. VPDIs were higher among at-risk adults. Funding: The original study and the current analysis were funded by Pfizer. (C) 2018 The Author(s). Published by Elsevier Ltd.
C1 [Gessner, Bradford D.; Jiang, Qin; Sings, Heather L.; Webber, Chris; Scott, Daniel; Jodar, Luis] Pfizer Vaccines, 500 Arcola Rd, Collegeville, PA 19426 USA.
   [Van Werkhoven, Cornelis H.; Grobbee, Diederick E.] Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
   [Neuzil, Kathleen M.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA.
   [O'Brien, Katherine L.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Wunderink, Richard G.] Northwestern Univ, Feinberg Sch Med, Dept Med Pulm & Crit Care, Chicago, IL 60611 USA.
   [Grobbee, Diederick E.] Acad Contract Res Org, Julius Clin, Zeist, Netherlands.
   [Bonten, Marc J. M.] Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands.
RP Gessner, BD (reprint author), Pfizer Vaccines, 500 Arcola Rd, Collegeville, PA 19426 USA.
EM Bradford.gessner@Pfizer.com
FU Pfizer Inc.Pfizer
FX This study was sponsored by Pfizer Inc. The sponsor was involved with
   study concept and design, conduct, analysis and interpretation of the
   data, drafting of the manuscript, and the decision to submit the
   manuscript for publication. The corresponding author had full access to
   the study data and had final responsibility for the decision to submit
   for publication.
CR Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544
   Chan ISF, 1998, COMMUN STAT-THEOR M, V27, P1305, DOI 10.1080/03610929808832160
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Dagan R, 2016, LANCET INFECT DIS, V16, P480, DOI 10.1016/S1473-3099(15)00549-6
   Feikin DR, 2014, LANCET, V383, P1762, DOI 10.1016/S0140-6736(13)61682-7
   Feikin DR, 2012, VACCINE, V30, pA52, DOI 10.1016/j.vaccine.2011.08.043
   Gessner BD, 2005, LANCET, V365, P43, DOI 10.1016/S0140-6736(04)17664-2
   Gessner BD, 2016, VACCINE, V34, P2397, DOI 10.1016/j.vaccine.2016.03.017
   Gessner BD, 2014, VACCINE, V32, P3133, DOI 10.1016/j.vaccine.2014.04.019
   Hak E, 2008, NETH J MED, V66, P378
   Hanquet G, INDIRECT EFFECT INFA
   Hansen J, 2006, PEDIATR INFECT DIS J, V25, P779, DOI 10.1097/01.inf.0000232706.35674.2f
   Huijts SM, 2013, EUR RESPIR J, V42, P1283, DOI 10.1183/09031936.00137412
   Kozma C M, 2010, J Med Econ, V13, P719, DOI 10.3111/13696998.2010.536350
   Madhi SA, 2007, VACCINE, V25, P2413, DOI 10.1016/j.vaccine.2006.09.010
   Mangen MJJ, 2015, EUR RESPIR J, V46, P1407, DOI 10.1183/13993003.00325-2015
   Palmu AA, 2018, VACCINE, V36, P1816, DOI 10.1016/j.vaccine.2018.02.088
   Patterson S., 2016, Trials in Vaccinology, V5, P92, DOI 10.1016/j.trivac.2016.04.004
   Qadri F, 2015, LANCET, V386, P1362, DOI 10.1016/S0140-6736(15)61140-0
   Raut M, 2009, CURR MED RES OPIN, V25, P2151, DOI 10.1185/03007990903102743
   Sur D, 2009, LANCET, V374, P1694, DOI 10.1016/S0140-6736(09)61297-6
   Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8
   Tregnaghi MW, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001657
   van Werkhoven CH, 2016, J CLIN EPIDEMIOL, V69, P185, DOI 10.1016/j.jclinepi.2015.07.004
   Vissink CE, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1783-9
   Webber C, 2017, VACCINE, V35, P1266, DOI 10.1016/j.vaccine.2017.01.032
   Wilder-Smith A, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0911-8
   Zhou H, 2012, EMERG INFECT DIS, V18, P294, DOI 10.3201/eid1802.102025
NR 29
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 10
PY 2019
VL 37
IS 38
BP 5777
EP 5787
DI 10.1016/j.vaccine.2018.05.097
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IY4JV
UT WOS:000486358200017
PM 29861177
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Reisinger, KS
   Richardson, E
   Malacaman, EA
   Levin, MJ
   Gardner, JL
   Wang, W
   Stek, JE
   Kuter, B
AF Reisinger, Keith S.
   Richardson, Elizabeth
   Malacaman, Edgardo A.
   Levin, Myron J.
   Gardner, Julie L.
   Wang, William
   Stek, Jon E.
   Kuter, Barbara
TI A double-blind, randomized, controlled, multi-center safety and
   immunogenicity study of a refrigerator-stable formulation of VARIVAX (R)
SO VACCINE
LA English
DT Article
DE Varicella; Vaccine; Immunogenicity; Safety; Refrigerator-stable
ID ANTIBODY; MEASLES; VACCINE; RUBELLA; MUMPS
AB Objective: VARIVAX (R) (varicella virus vaccine, live Oka/Merck, Merck & Co., Inc., Kenilworth, NJ, USA) was originally licensed as a frozen formulation. A refrigerator-stable formulation of VARIVAX was subsequently developed to allow for increased availability of the product around the world. The objective of this study (V210-051) was to demonstrate that the safety, tolerability and immunogenicity profile of the refrigerator-stable formulation of VARIVAX was similar to the frozen formulation.
   Methods: In this double-blind, randomized, multicenter study, healthy 12- to 23-month-old children with negative vaccination and clinical histories for measles, mumps, rubella, varicella, and zoster were vaccinated with either a refrigerator-stable formulation of VARIVAX (at two dosage levels; 8000 PFU [N = 320] or 25,000 PFU [N = 315]) or the frozen formulation of VARIVAX (10,000 PFU, N = 323) given concomitantly with M-M-RII (R) (measles, mumps, and rubella virus vaccine live, Merck & Co., Inc., Kenilworth, NJ, USA). Children were followed for 42 days after vaccination for adverse experiences. Immunogenicity was evaluated 6 weeks after vaccination.
   Results: The refrigerator-stable formulation of VARIVAX was generally well tolerated. The incidence of adverse experiences was similar between all three groups. No vaccine-related serious adverse experiences were reported with any of the vaccine formulations. The immune response (percentage of subjects with varicella antibody titers >= 5 gpELISA units) for both refrigerator-stable formulations of VARIVAX at 6 weeks postvaccination was similar to that of the frozen formulation. Administration of either refrigerator-stable formulation of VARIVAX with M-M-RII yielded seroconversion rates and GMTs for measles, mumps and rubella that were comparable to those achieved after administration of the frozen formulation of VARIVAX with M-M-RII.
   Conclusion: The safety, tolerability, and immunogenicity profile of the refrigerator-stable varicella vaccine was similar to that of the frozen formulation. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Reisinger, Keith S.] Primary Phys Res, Pittsburgh, PA USA.
   [Malacaman, Edgardo A.] MD Res, North Canton, MD USA.
   [Levin, Myron J.] Univ Colorado Anschutz Med Campus, Aurora, CO USA.
   [Richardson, Elizabeth; Gardner, Julie L.; Wang, William; Stek, Jon E.; Kuter, Barbara] Merck & Co Inc, Kenilworth, NJ USA.
RP Kuter, B (reprint author), Merck & Co Inc, 351 North Sumneytown Pike,UG-B35, N Wales, PA 19454 USA.
EM barbara_kuter@merck.com
FU Merck & Co., Inc., Kenilworth, NJ, USA (Sponsor)
FX This study was funded by Merck & Co., Inc., Kenilworth, NJ, USA
   (Sponsor). In conjunction with the external investigators, this study
   was designed, executed, and analyzed by the Sponsor. Although the
   Sponsor formally reviewed a penultimate draft, the opinions expressed
   are those of the authorship and may not necessarily reflect those of the
   Sponsor. All co-authors approved the final version of the manuscript.
CR Bernstein HH, 2007, PEDIATRICS, V120, P924, DOI 10.1542/peds.2007-2013
   Bernstein HH, 2007, PEDIATRICS, V119, pE1299, DOI 10.1542/peds.2006-2283
   FARRINGTON CP, 1990, STAT MED, V9, P1447, DOI 10.1002/sim.4780091208
   Galazka A, 1998, THERMOSTABILITY VACC
   HEYMANN DL, 1982, BRIT MED J, V285, P531, DOI 10.1136/bmj.285.6341.531
   Johnson CE, 1996, PEDIATR INFECT DIS J, V15, P687, DOI 10.1097/00006454-199608000-00010
   KELLER PM, 1986, J VIROL METHODS, V14, P177, DOI 10.1016/0166-0934(86)90048-0
   Paul William E, 2013, FUNDAMENTAL IMMUNOLO
   PROVOST PJ, 1991, VACCINE, V9, P111, DOI 10.1016/0264-410X(91)90266-9
   SHEHAB ZM, 1984, J INFECT DIS, V149, P810, DOI 10.1093/infdis/149.5.810
   WASMUTH EH, 1990, J MED VIROL, V32, P189, DOI 10.1002/jmv.1890320310
NR 11
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 10
PY 2019
VL 37
IS 38
BP 5788
EP 5795
DI 10.1016/j.vaccine.2018.01.089
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IY4JV
UT WOS:000486358200018
PM 30146405
DA 2020-05-12
ER

PT J
AU Kochhar, S
   Excler, JL
   Bok, K
   Gurwith, M
   McNeil, MM
   Seligman, SJ
   Khuri-Bulos, N
   Klug, B
   Laderoute, M
   Robertson, JS
   Singh, V
   Chen, RT
   Mac, L
   Chapman, L
   Condit, R
   Hendry, M
   Williamson, AL
AF Kochhar, Sonali
   Excler, Jean-Louis
   Bok, Karin
   Gurwith, Marc
   McNeil, Michael M.
   Seligman, Stephen J.
   Khuri-Bulos, Najwa
   Klug, Bettina
   Laderoute, Marian
   Robertson, James S.
   Singh, Vidisha
   Chen, Robert T.
   Mac, Lisa
   Chapman, Louisa
   Condit, Richard
   Hendry, Michael
   Williamson, Anna-Lise
CA Brighton Collaboration Viral Vecto
TI Defining the interval for monitoring potential adverse events following
   immunization (AEFIs) after receipt of live viral vectored vaccines
SO VACCINE
LA English
DT Article
DE Viral vector; Vaccines; Safety; Surveillance; Duration; Adverse events
   following immunization (AEFI); Adverse event of special interest (AESI);
   Treescan
ID MIDDLE-INCOME COUNTRIES; SAFETY SURVEILLANCE; INFLUENZA; VIRUS;
   PHARMACOVIGILANCE; VACCINATION; RISK
AB Live viral vectors that express heterologous antigens of the target pathogen are being investigated in the development of novel vaccines against serious infectious agents like HIV and Ebola. As some live recombinant vectored vaccines may be replication-competent, a key challenge is defining the length of time for monitoring potential adverse events following immunization (AEFI) in clinical trials and epidemiologic studies. This time period must be chosen with care and based on considerations of pre-clinical and clinical trials data, biological plausibility and practical feasibility. The available options include: (1) adapting from the current relevant regulatory guidelines; (2) convening a panel of experts to review the evidence from a systematic literature search to narrow down a list of likely potential or known AEFI and establish the optimal risk window(s); and (3) conducting "near real-time" prospective monitoring for unknown clustering's of AEFI in validated large linked vaccine safety databases using Rapid Cycle Analysis for pre-specified adverse events of special interest (AESI) and Treescan to identify previously unsuspected outcomes. The risk window established by any of these options could be used along with (4) establishing a registry of clinically validated pre-specified AESI to include in case-control studies. Depending on the infrastructure, human resources and databases available in different countries, the appropriate option or combination of options can be determined by regulatory agencies and investigators. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Kochhar, Sonali] Global Healthcare Consulting, New Delhi, India.
   [Kochhar, Sonali] Univ Med Ctr, Erasmus MC, Rotterdam, Netherlands.
   [Kochhar, Sonali] Univ Washington, Seattle, WA 98195 USA.
   [Excler, Jean-Louis] Int Vaccine Inst, Seoul, South Korea.
   [Bok, Karin] US Dept HHS, Natl Vaccine Program Off, Off Assistant Secretary Hlth, Washington, DC 20201 USA.
   [Gurwith, Marc] PaxVax Inc, San Diego, CA USA.
   [McNeil, Michael M.] Ctr Dis Control & Prevent, Immunizat Safety Off, CDC, Atlanta, GA USA.
   [Seligman, Stephen J.] New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA.
   [Seligman, Stephen J.] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, 1230 York Ave, New York, NY 10021 USA.
   [Khuri-Bulos, Najwa] Jordan Univ Hosp, Div Infect Dis, Amman, Jordan.
   [Klug, Bettina] Paul Ehrlich Inst, Div Immunol, Langen, Germany.
   [Laderoute, Marian] Immune Syst Management Clin & Lab, Ottawa, ON, Canada.
   [Singh, Vidisha; Chen, Robert T.] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.
   [Chen, Robert T.] Ctr Dis Control & Prevent, CDC, Atlanta, GA 30333 USA.
RP Chen, RT (reprint author), Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.; Chen, RT (reprint author), Ctr Dis Control & Prevent, CDC, Atlanta, GA 30333 USA.
EM brightoncollaborationv3swg@gmail.com
OI Seligman, Stephen/0000-0001-7036-3323; Kochhar,
   Sonali/0000-0002-1150-5691
FU Intramural CDC HHS [CC999999]
CR Altenburg AF, 2014, VIRUSES-BASEL, V6, P2735, DOI 10.3390/v6072735
   [Anonymous], 2013, WHO INFORMAL CONSULT
   [Anonymous], 2010, GUID QUAL NONCL CLIN
   [Anonymous], 2013, WHO REPORT 2 M GLOBA
   [Anonymous], 2011, STAT NARC VACC
   [Anonymous], 2003, WHO INFORMAL CONSULT
   [Anonymous], 2006, FDA GUIDANCE IND GEN
   Baker MA, 2013, VACCINE, V31, pK98, DOI 10.1016/j.vaccine.2013.04.088
   Borg JJ, 2011, DRUG SAFETY, V34, P187, DOI 10.2165/11586620-000000000-00000
   Casanova JL, 2014, J EXP MED, V211, P2137, DOI 10.1084/jem.20140520
   Centlivre M, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0075-2
   Chappell KJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006037
   Chattopadhyay A, 2018, VACCINE, V36, P3894, DOI 10.1016/j.vaccine.2018.05.095
   Chen RT, 2005, PHARMACOEPIDEMIOLOGY, 4TH EDITION, P455
   Chen RT, 2015, VACCINE, V33, P73, DOI 10.1016/j.vaccine.2014.09.035
   Cho H, 2018, HUM VACC IMMUNOTHER, V14, P304, DOI 10.1080/21645515.2017.1389362
   Choi Y, 2013, CLIN EXP VACCINE RES, V2, P97, DOI 10.7774/cevr.2013.2.2.97
   Condit RC, 2016, VACCINE, V34, P6610, DOI 10.1016/j.vaccine.2016.04.060
   Crosby CM, 2017, J VIROL, V91, DOI 10.1128/JVI.00720-16
   Davis Robert L, 2013, Pharmaceutics, V5, P168, DOI 10.3390/pharmaceutics5010168
   de Vries RD, 2016, HUM VACC IMMUNOTHER, V12, P2881, DOI 10.1080/21645515.2016.1210729
   Ewer K, 2017, HUM VACC IMMUNOTHER, V13, P3020, DOI 10.1080/21645515.2017.1383575
   Glanz Jason M, 2016, Vaccine, V34 Suppl 1, pA1, DOI 10.1016/j.vaccine.2015.10.082
   Guvenel AK, 2014, EXPERT REV VACCINES, V13, P333, DOI 10.1586/14760584.2014.878653
   Halliday J, 2011, EXPERT REV VACCINES, V10, P659, DOI [10.1586/ERV.11.55, 10.1586/erv.11.55]
   Harpaz R, 2013, CLIN PHARMACOL THER, V93, P539, DOI 10.1038/clpt.2013.24
   Hawken S, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0225-0
   Hsu C. C., 2007, RES EVALUAT, V12, P1, DOI DOI 10.1016/S0169-2070(99)00018-7
   Huang YL, 2014, DRUG SAFETY, V37, P581, DOI 10.1007/s40264-014-0194-3
   Jones CE, 2016, VACCINE, V34, P5998, DOI 10.1016/j.vaccine.2016.07.032
   Kapadia SU, 2008, VIROLOGY, V376, P165, DOI 10.1016/j.virol.2008.03.002
   Kaufmann SHE, 2017, INT J INFECT DIS, V56, P263, DOI 10.1016/j.ijid.2016.10.018
   Kochhar S, 2017, VACCINE, V35, P6469, DOI 10.1016/j.vaccine.2017.09.033
   Kochhar S, 2017, VACCINE, V35, P6575, DOI 10.1016/j.vaccine.2017.03.103
   Kochhar S, 2015, CURR DRUG SAF, V10, P55, DOI 10.2174/157488631001150407110435
   Kules J, 2016, MOL BIOSYST, V12, P2680, DOI 10.1039/c6mb00268d
   Kulldorff M, 2003, BIOMETRICS, V59, P323, DOI 10.1111/1541-0420.00039
   Kulldorff M, 2013, PHARMACOEPIDEM DR S, V22, P517, DOI 10.1002/pds.3423
   Lauer KB, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00298-16
   Lauer KB, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/j.CVI.00298-16, DOI 10.1128/J.CVI.00298-16]
   Lei JY, 2018, VACCINE, V36, P1577, DOI 10.1016/j.vaccine.2018.02.012
   Limbach KJ, 2009, PARASITE IMMUNOL, V31, P501, DOI 10.1111/j.1365-3024.2009.01141.x
   Nascimento IP, 2012, BRAZ J MED BIOL RES, V45, P1102, DOI 10.1590/S0100-879X2012007500142
   Ozawa S, 2012, VACCINE, V31, P96, DOI 10.1016/j.vaccine.2012.10.103
   Parks CL, 2013, CURR OPIN HIV AIDS, V8, P402, DOI 10.1097/COH.0b013e328363d389
   Penina Haber, 2011, MANUAL SURVEILLANCE
   Prestel J, 2014, PHARMACOEPIDEM DR S, V23, P1192, DOI 10.1002/pds.3638
   Rayner JO, 2002, REV MED VIROL, V12, P279, DOI 10.1002/rmv.360
   Remy Vanessa, 2015, J Mark Access Health Policy, V3, DOI 10.3402/jmahp.v3.27041
   Rowhani-Rahbar A, 2012, VACCINE, V31, P271, DOI 10.1016/j.vaccine.2012.07.024
   Shi M, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2838-2
   Shimabukuro TT, 2015, VACCINE, V33, P4398, DOI 10.1016/j.vaccine.2015.07.035
   Silva I, 1999, CANC EPIDEMIOLOGY PR
   Souza APD, 2005, BRAZ J MED BIOL RES, V38, P509, DOI 10.1590/S0100-879X2005000400004
   Varricchio F, 2004, PEDIATR INFECT DIS J, V23, P287, DOI 10.1097/00006454-200404000-00002
   Weli SC, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-49
   Wu NC, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006682
   Yih WK, 2018, AM J EPIDEMIOL, V187, P1269, DOI 10.1093/aje/kwy023
   Yih WK, 2011, PEDIATRICS, V127, pS54, DOI 10.1542/peds.2010-1722I
   Yih WK, 2016, PHARMACOEPIDEM DR S, V25, P481, DOI 10.1002/pds.3908
NR 60
TC 3
Z9 3
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 10
PY 2019
VL 37
IS 38
BP 5796
EP 5802
DI 10.1016/j.vaccine.2018.08.085
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IY4JV
UT WOS:000486358200019
PM 30497831
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Bruxvoort, KJ
   Luo, Y
   Ackerson, B
   Tanenbaum, HC
   Sy, LS
   Gandhi, A
   Tseng, HF
AF Bruxvoort, Katia J.
   Luo, Yi
   Ackerson, Bradley
   Tanenbaum, Hilary C.
   Sy, Lina S.
   Gandhi, Ashesh
   Tseng, Hung Fu
TI Comparison of vaccine effectiveness against influenza hospitalization of
   cell-based and egg-based influenza vaccines, 2017-2018
SO VACCINE
LA English
DT Article
DE Influenza; Influenza vaccine; Vaccine effectiveness
ID TEST-NEGATIVE DESIGN; SEASON
AB Egg-based influenza vaccines could be less effective than cell-based vaccine due to adaptive mutations acquired for growth. We conducted a test-negative case-control study at Kaiser Permanente Southern California to assess vaccine effectiveness (VE) against hospitalization for laboratory-confirmed influenza during 2017-2018. Among the 1186 cases and 6946 controls, 74% and 59%, respectively, were ages >= 65-years. For any influenza, the adjusted relative VE of cell-based vaccine versus egg-based vaccines was 43% (95% CI: -45% to 77%) for patients ages < 65 years and 6% (95% CI: -46% to 39%) for patients ages >= 65-years. For influenza A(H3N2), the adjusted relative VE was 61% (95% CI: -63% to 91%) for patients ages < 65 years and -4% (95% CI: -70% to 37%) for patients ages >= 65 years. Statistically significant protection against influenza hospitalization of cell-based vaccine compared to egg-based vaccines was not observed, but further studies in additional influenza seasons are warranted. (C) 2019 Published by Elsevier Ltd.
C1 [Bruxvoort, Katia J.; Luo, Yi; Ackerson, Bradley; Tanenbaum, Hilary C.; Sy, Lina S.; Tseng, Hung Fu] Kaiser Permanente Southern Calif, Dept Res & Evaluat, 100 S Los Robles Ave, Pasadena, CA 91101 USA.
   [Gandhi, Ashesh] Seqirus, Summit, NJ USA.
RP Bruxvoort, KJ (reprint author), Kaiser Permanente Southern Calif, Dept Res & Evaluat, 100 S Los Robles Ave, Pasadena, CA 91101 USA.
EM katia.bruxvoort@kp.org; Yi.X.Luo@kp.org; Bradley.K.Ackerson@kp.org;
   Hilary.Tanenbaum@kp.org; Lina.S.Sy@kp.org; Ashesh.Gandhi@Seqirus.com;
   Hung-Fu.X.Tseng@kp.org
OI Bruxvoort, Katia/0000-0001-8277-2431; Tanenbaum,
   Hilary/0000-0003-2282-1662
FU Seqirus
FX This work was supported by Seqirus.
CR Andrew MK, 2017, J INFECT DIS, V216, P405, DOI 10.1093/infdis/jix282
   Belongia Edward A, 2017, Expert Rev Vaccines, V16, P1, DOI 10.1080/14760584.2017.1334554
   Flannery B, 2018, M ADV COMM IMM PRACT
   Flannery B, 2018, J INFECT DIS
   Fukushima W, 2017, VACCINE, V35, P4796, DOI 10.1016/j.vaccine.2017.07.003
   Garten R, 2018, MMWR-MORBID MORTAL W, V67, P634, DOI 10.15585/mmwr.mm6722a4
   Ip DKM, 2016, CLIN INFECT DIS, V62, P431, DOI 10.1093/cid/civ909
   Izurieta HS, 2018, J INFECT DIS
   Jackson ML, 2013, VACCINE, V31, P2165, DOI 10.1016/j.vaccine.2013.02.053
   Leekha S, 2007, INFECT CONT HOSP EP, V28, P1071, DOI 10.1086/520101
   McElhaney JE, 2017, J INFECT DIS, V216, P399, DOI 10.1093/infdis/jix269
   Rolfes MA, 2019, CLIN INFECT DIS
   Skowronski DM, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.5.18-00035
   Sullivan SG, 2017, EURO SURVEILL, V22
   Wu NC, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006682
   Xie H, 2017, CLIN INFECT DIS, V65, P259, DOI 10.1093/cid/cix269
   Zost SJ, 2017, P NATL ACAD SCI USA, V114, P12578, DOI 10.1073/pnas.1712377114
NR 17
TC 0
Z9 1
U1 2
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 16
PY 2019
VL 37
IS 39
BP 5807
EP 5811
DI 10.1016/j.vaccine.2019.08.024
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IZ6EX
UT WOS:000487175700001
PM 31445771
DA 2020-05-12
ER

PT J
AU Costantino, C
   Restivo, V
   Amodio, E
   Colomba, GME
   Vitale, F
   Tramuto, F
AF Costantino, Claudio
   Restivo, Vincenzo
   Amodio, Emanuele
   Colomba, Giuseppina Maria Elena
   Vitale, Francesco
   Tramuto, Fabio
TI A mid-term estimate of 2018/2019 vaccine effectiveness to prevent
   laboratory confirmed A(H1N1)pdm09 and A(H3N2) influenza cases in Sicily
   (Italy)
SO VACCINE
LA English
DT Article
DE Influenza vaccine effectiveness; Surveillance network; Laboratory
   confirmed cases; Influenza epidemic; Influenza viruses; Test-negative
   design
AB Influenza season started in Italy during the month of October 2018, approaching the epidemic peak in January 2019. This report aim to explore the mid-term virologic surveillance data of the 2018-2019 influenza season in Sicily and to estimate the effectiveness of seasonal influenza vaccine (VE) against A(H1N1) pdm09 and A(H3N2) influenza viruses. A test-negative design was used to evaluate influenza VE.
   In Sicily, almost all influenza infections were sustained by influenza type A viruses, of which 62.3% were A(H3N2) and 36.3% A(H1N1)pdm09. A reduction of laboratory confirmed influenza cases in Sicilian population immunized against influenza were observed. In particular, an overall significant protective values were observed for any influenza A viruses (Adj-VE = 44.0%; 95%CI: 11.2-64.7%), especially among 15-64 years old age group (Adj-VE = 59.5%; 95%CI: 0.03-83.1) and among the elderly (Adj-VE = 73.6%; 95% CI: 29.4-90.2). (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Costantino, Claudio; Restivo, Vincenzo; Amodio, Emanuele; Vitale, Francesco; Tramuto, Fabio] Univ Palermo, Dept Hlth Promot Sci Maternal & Infant Care, Internal Med & Med Specialties G DAlessandro, Via Vespro 133, I-90127 Palermo, Italy.
   [Colomba, Giuseppina Maria Elena; Vitale, Francesco; Tramuto, Fabio] Univ Hosp Paolo Giaccone, Reg Reference Lab Mol Surveillance Influenza, Clin Epidemiol Unit, Via Vespro 133, I-90127 Palermo, Italy.
RP Costantino, C (reprint author), Via Vespro 133, I-90127 Palermo, Italy.
EM claudio.costantino01@unipa.it
RI Costantino, Claudio/F-4742-2018
OI Costantino, Claudio/0000-0002-3397-7331
CR [Anonymous], 2019, LNFLUNET REPORT INTE
   Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8
   Doyle JD, 2019, MMWR-MORBID MORTAL W, V68, P135, DOI 10.15585/mmwr.mm6806a2
   European Center for Disease Control and Prevention, 2019, WEEKL INFL UPD WEEK
   Italian Health Department, REC PREV CONTR INFL
   Jackson ML, 2013, VACCINE, V31, P2165, DOI 10.1016/j.vaccine.2013.02.053
   Kissling E, 2019, EURO SURVEILL, V24
   Lau LLH, 2010, J INFECT DIS, V201, P1509, DOI 10.1086/652241
   Maldonado YA, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-2367
   National Health Department, INFL VACC COV IT
   Orsi Andrea, 2018, Hum Vaccin Immunother, V14, P523, DOI 10.1080/21645515.2017.1342907
   Restivo V, 2018, HUM VACC IMMUNOTHER, V14, P724, DOI 10.1080/21645515.2017.1321722
   Skowronski DM, 2017, J INFECT DIS, V216, P1487, DOI 10.1093/infdis/jix526
   Skowronski DM, 2019, EUROSURVEILLANCE, V24, DOI [10.2807/1560-7917.E5.2019.24.4.1900055, DOI 10.2807/1560-7917.E5.2019.24.4.1900055]
   Tramuto F, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040549
   WHO, GLOB INFL SURV RESP
   World Health Organization, EV INFL VACC EFF GUI
NR 17
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 16
PY 2019
VL 37
IS 39
BP 5812
EP 5816
DI 10.1016/j.vaccine.2019.08.014
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IZ6EX
UT WOS:000487175700002
PM 31427134
OA Other Gold
DA 2020-05-12
ER

PT J
AU Malik, A
   Haldar, P
   Ray, A
   Shet, A
   Kapuria, B
   Bhadana, S
   Santosham, M
   Ghos, RS
   Steinglass, R
   Kumar, R
AF Malik, Akash
   Haldar, Pradeep
   Ray, Arindam
   Shet, Anita
   Kapuria, Bhrigu
   Bhadana, Sheenu
   Santosham, Mathuram
   Ghos, Raj Shankar
   Steinglass, Robert
   Kumar, Rakesh
TI Introducing rotavirus vaccine in the Universal Immunization Programme in
   India: From evidence to policy to implementation
SO VACCINE
LA English
DT Review
DE Rotavirus vaccine; Diarrhea; Immunization
ID COST-EFFECTIVENESS; SURVEILLANCE; EFFICACY; INTUSSUSCEPTION;
   GASTROENTERITIS; DISEASE; IMPACT
AB Background: In 2016, India became one of the first countries in Asia to introduce an indigenously manufactured rotavirus vaccine. However, any new vaccine introduction needs to be meticulously planned to allow for strengthening of the existing immunization systems instead of burdening them.
   Methods: The process of rotavirus vaccine introduction in India started with the establishment of National Rotavirus Surveillance Network in 2005 which generated relevant evidence to inform policy level decisions to introduce the vaccine. The preparatory activities started with assessment of health systems and closing any gaps. This was followed by development of vaccine specific training packages and cascade training for programme managers and health workers. The introduction was complemented with strong communications systems and media involvement to allow for good acceptability of the vaccine on the ground. Each step of introduction was led by the government and technically supported by development partners.
   Results: India introduced rotavirus vaccine in a phased wise manner. In the first two phases the vaccine has been introduced in nine states of the country accounting for nearly 35% of the annual birth cohort of the country. From March 2016 to November 2017, approximately 13,260,000 rotavirus vaccine doses were administered in the country. The vaccine was well accepted by both the health workers and parents/caregivers.
   Conclusion: Rotavirus vaccine introduction in India is an excellent example of how government stewardship with well-defined roles for development partners can allow a new vaccine introduction to be used as a system strengthening activity. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Malik, Akash; Kumar, Rakesh] United Nat Dev Programme, New Delhi, India.
   [Haldar, Pradeep] Govt India, Minist Hlth & Family Welf, New Delhi, India.
   [Ray, Arindam; Ghos, Raj Shankar] Bill & Melinda Gates Fdn, New Delhi, India.
   [Shet, Anita; Santosham, Mathuram] Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Baltimore, MD USA.
   [Kapuria, Bhrigu] UNICEF, New Delhi, India.
   [Bhadana, Sheenu] Govt India, Minist Hlth & Family Welf, Immunizat Tech Support Unit, New Delhi, India.
   [Steinglass, Robert] John Snow Inc, Arlington, VA USA.
RP Malik, A (reprint author), GC 16, New Delhi 110027, India.
EM drakashmalik28@gmail.com; Arindam.ray@gatesfoundation.org;
   aseth1@jhu.org; bkapuria@unicef.org; msantosham@jhu.org;
   raj.ghosh@gatesfoundation.org; robert@steinglass.com;
   rakesh.kumar@undp.org
RI Ray, Arindam/AAN-1525-2020
OI Ray, Arindam/0000-0002-5955-0352; Malik, Akash/0000-0003-0745-5908
CR [Anonymous], 2017, NAT HLTH POL
   [Anonymous], 2011, NAT VACC POL
   Chatterjee S, 2016, INDIAN J MED RES, V143, P801, DOI 10.4103/0971-5916.192073
   Government of India. Ministry of Health and Family Welfare. Department of Family Welfare. Child Health Division, 2006, VIT A IFA SUPPL
   Government of India. Ministry of Health and Family Welfare. Department of Family Welfare. Child Health Division, 2006, US ZINC ALT THER TRE
   Isanaka S, 2017, NEW ENGL J MED, V376, P1121, DOI [10.1056/nejmoa1609462, 10.1056/NEJMoa1609462]
   John J, 2014, VACCINE, V32, pA104, DOI 10.1016/j.vaccine.2014.03.036
   John J, 2014, VACCINE, V32, pA5, DOI 10.1016/j.vaccine.2014.03.004
   Kumar CPG, 2016, INDIAN PEDIATR, V53, P619, DOI 10.1007/s13312-016-0897-x
   Mehendale S, 2016, INDIAN PEDIATR, V53, P575, DOI 10.1007/s13312-016-0891-3
   Ministry of Health and Family Welfare, NAT RUR HLTH MISS FR
   Ministry of Health and Family Welfare Government of India, 2014, M NAT TECHN ADV GROU
   Ministry of Health and Family Welfare. Government of India, LIST CAS SEL CAUS AS
   Murphy TV, 2001, NEW ENGL J MED, V344, P564, DOI 10.1056/NEJM200102223440804
   Ozawa S, 2016, HEALTH AFFAIR, V35, P199, DOI 10.1377/hlthaff.2015.1086
   Parashar UD, 2003, EMERG INFECT DIS, V9, P565, DOI 10.3201/eid0905.020562
   Registrar General India, 2011, SAMPL REG SYST, V46
   Registrar General India, 2019, SAMPL REG SYST, V52
   Rheingans R, 2014, VACCINE, V32, pA140, DOI 10.1016/j.vaccine.2014.05.073
   Troeger C, 2017, LANCET INFECT DIS, V17, P909, DOI 10.1016/S1473-3099(17)30276-1
   UNICEF, 2017, UNICEF DAT MON SIT C
   Verguet S, 2013, VACCINE, V31, P4902, DOI 10.1016/j.vaccine.2013.07.014
   Vesikari T, 2006, NEW ENGL J MED, V354, P23, DOI 10.1056/NEJMoa052664
   WHO, 2013, WEEKLY EPIDEMIOLOGIC
   World Health Organization, 2014, INF B VACC VIAL MON
   World Health Organization (WHO)/United Nations Children's Fund (UNICEF), 2014, END PREV DEATHS GLOB
NR 26
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 16
PY 2019
VL 37
IS 39
BP 5817
EP 5824
DI 10.1016/j.vaccine.2019.07.104
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IZ6EX
UT WOS:000487175700003
PM 31474519
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Chang, LJ
   Meng, Y
   Janosczyk, H
   Landolfi, V
   Talbot, HK
   Boone, G
   Briskin, T
   Cannon, K
   Christensen, S
   Davis, M
   Miel, E
   Eck, J
   Essink, B
   Finn, D
   Fried, D
   Gorse, G
   Griffin, C
   Hollister, R
   Jacqmein, J
   Johnson, M
   Julien, K
   Kay, J
   Kirstein, J
   Koehler, T
   Levin, M
   Martin, E
   Matherne, P
   Peterson, J
   Poling, T
   Saleh, J
   Segall, N
   Seiden, D
   Strout, C
   Turner, M
   Varano, S
   Wilson, J
   Winkle, P
   Wombolt, D
   Abel, K
   Babyak, J
   Bethuel, K
   Boyle, J
   Broudic, K
   De Bruijn, I
   De Sousa, J
   Drago, E
   Flores, A
   Francis, D
   Hicks, B
   Fontvieille, AI
   Hollingsworth, R
   Khoury, R
   Lopez, D
   Lupinsky, N
   Marshall, E
   Menard, L
   Pandey, A
   Patskan, V
   Pekala, D
   Quinn, T
   Salamand, C
   Samson, S
   Seprish, M
   Setty, R
   Urso, M
   Wang, R
AF Chang, Lee-Jah
   Meng, Ya
   Janosczyk, Helene
   Landolfi, Victoria
   Talbot, H. Keipp
   Boone, Gary
   Briskin, Toby
   Cannon, Kevin
   Christensen, Shane
   Davis, Matthew
   Miel, Emmanuel
   Eck, John
   Essink, Brandon
   Finn, Daniel
   Fried, David
   Gorse, Geoffrey
   Griffin, Carl
   Hollister, Ripley
   Jacqmein, Jeffry
   Johnson, Mark
   Julien, Katie
   Kay, Jennifer
   Kirstein, Judith
   Koehler, Timothy
   Levin, Michael
   Martin, Earl
   Matherne, Paul
   Peterson, James
   Poling, Terry
   Saleh, Jamshid
   Segall, Nathan
   Seiden, David
   Strout, Cynthia
   Turner, Mark
   Varano, Susann
   Wilson, Jonathan
   Winkle, Peter
   Wombolt, Duane
   Abel, Keshia
   Babyak, Jennifer
   Bethuel, Karine
   Boyle, Jacqueline
   Broudic, Karine
   De Bruijn, Iris
   De Sousa, Jennifer
   Drago, Erica
   Flores, Alma
   Francis, Deborah
   Hicks, Bryony
   Fontvieille, Anne-Isabelle
   Hollingsworth, Rosalind
   Khoury, Rawia
   Lopez, Denise
   Lupinsky, Nicole
   Marshall, Erik
   Menard, Lisa
   Pandey, Aseem
   Patskan, Viktor
   Pekala, David
   Quinn, Therese
   Salamand, Camille
   Samson, Sandrine
   Seprish, Mike
   Setty, Ramana
   Urso, Maxime
   Wang, Rose
CA QHD00013 Study Grp
TI Safety and immunogenicity of high-dose quadrivalent influenza vaccine in
   adults >= 65 years of age: A phase 3 randomized clinical trial
SO VACCINE
LA English
DT Article
DE High-dose influenza vaccine; Quadrivalent influenza vaccine; Elderly
   adults; Immunogenicity; Safety; Clinical trial
ID EFFICACY; ANTIBODY; OLDER; CHILDREN
AB Background: A high-dose, split-virion inactivated trivalent influenza vaccine (IIV3-HD; Fluzone (R) High-Dose, Sanofi Pasteur) is available for adults >= 65 years of age. This study examined the safety and immunogenicity of a quadrivalent high-dose split-virion inactivated influenza vaccine (IIV4-HD).
   Methods: This was a randomized, modified double-blind, active-controlled, multi-center trial in healthy adults >= 65 years of age. Subjects were randomized in a 4:1:1 ratio to receive a single intramuscular injection of IIV4-HD, the licensed IIV3-HD, or an IIV3-HD containing the alternate B-lineage strain. Hemagglutination inhibition (HAI), seroneutralisation, and anti-neuraminidase antibody titers were measured at baseline and day 28. Solicited reactions were collected for up to 7 days, unsolicited adverse events up to 28 days, and serious adverse events up to 180 days. The primary immunogenicity objective was to demonstrate that IIV4-HD induces HAI geometric mean titers (GMTs) and seroconversion rates that are non-inferior to those induced by IIV3-HD. Secondary objectives were to describe the safety of IIV4-HD and IIV3-HD and to demonstrate that IIV4-HD induces HAI GMTs and seroconversion rates that are superior to those induced by IIV3-HD not containing the same B-lineage strain.
   Results: The study included 2670 adults >= 65 years of age. For all four strains, HAI GMTs and seroconversion rates induced by IIV4-HD were non-inferior to those induced by IIV3-HDs containing the same strains. For both B strains, HAI GMTs and seroconversion rates induced by IIV4-HD were superior to those induced by IIV3-HD not containing the same B-lineage strain. Seroneutralisation and anti-neuraminidase antibody responses, measured in a subset of subjects, were similar. No new safety concerns were identified, and the safety profiles of IIV4-HD and IIV3-HD were similar.
   Conclusions: Adding a second B strain in IIV4-HD resulted in improved immunogenicity against the added strain without compromising the immunogenicity of the other strains or the vaccine's tolerability. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Chang, Lee-Jah; Meng, Ya; Janosczyk, Helene; Landolfi, Victoria] Sanofi Pasteur, 1 Discovery Dr, Swiftwater, PA 18370 USA.
   [Talbot, H. Keipp] Vanderbilt Univ, Med Ctr, 1761 21st Ave South, Nashville, TN 37232 USA.
RP Chang, LJ (reprint author), Sanofi Pasteur, 1 Discovery Dr, Swiftwater, PA 18370 USA.
EM Lee-Jah.Chang@sanofi.com
OI Chang, Lee-Jah/0000-0003-1766-3153
FU Sanofi Pasteur
FX This work was supported by Sanofi Pasteur.
CR Becker DL, 2016, HUM VACC IMMUNOTHER, V12, P3036, DOI 10.1080/21645515.2016.1215395
   Cadorna-Carlos JB, 2015, VACCINE, V33, P2485, DOI 10.1016/j.vaccine.2015.03.065
   Caini S, 2015, INFLUENZA OTHER RESP, V9, P3, DOI 10.1111/irv.12319
   Couch Robert B., 1997, Journal of Infectious Diseases, V176, pS38, DOI 10.1086/514173
   Couzens L, 2014, J VIROL METHODS, V210, P7, DOI 10.1016/j.jviromet.2014.09.003
   DiazGranados CA, 2015, VACCINE, V33, P4988, DOI 10.1016/j.vaccine.2015.07.006
   DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727
   Gorse GJ, 2015, VACCINE, V33, P1151, DOI 10.1016/j.vaccine.2015.01.025
   Gravenstein S, 2017, LANCET RESP MED, V5, P738, DOI 10.1016/S2213-2600(17)30235-7
   Greenberg DP, 2017, HUM VACC IMMUNOTHER, V13, P2058, DOI 10.1080/21645515.2017.1344375
   Greenberg DP, 2013, VACCINE, V31, P770, DOI 10.1016/j.vaccine.2012.11.074
   Haq K, 2014, CURR OPIN IMMUNOL, V29, P38, DOI 10.1016/j.coi.2014.03.008
   International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), 1994, CLIN SAF DAT MAN DEF
   Izurieta HS, 2018, J INFECT DIS, DOI [10.1093/infdis/jiy716, DOI 10.1093/INFDIS/JIJY716]
   Keitel WA, 1997, VACCINE, V15, P1114, DOI 10.1016/S0264-410X(97)00003-0
   LAMBRE CR, 1990, J IMMUNOL METHODS, V135, P49, DOI 10.1016/0022-1759(90)90255-T
   Lee JKH, 2018, EXPERT REV VACCINES, V17, P435, DOI 10.1080/14760584.2018.1471989
   LEVANDOWSKI RA, 1991, PEDIATRICS, V88, P1031
   Montomoli E, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6010014
   Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I
   Robertson CA, 2016, EXPERT REV VACCINES, V15, P1495, DOI 10.1080/14760584.2016.1254044
   Robison SG, 2018, VACCINE, V36, P6683, DOI 10.1016/j.vaccine.2018.09.050
   Samson SI, 2019, EXPERT REV VACCINES, V18, P295, DOI 10.1080/14760584.2019.1575734
   Sanofi Pasteur, 2019, DAT FIL SAN PAST FLU
   Sasaki S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002975
   Seidman JC, 2012, INFLUENZA OTHER RESP, V6, P52, DOI 10.1111/j.1750-2659.2011.00268.x
   Shay DK, 2017, J INFECT DIS, V215, P510, DOI 10.1093/infdis/jiw641
   Skowronski DM, 2011, PEDIATR INFECT DIS J, V30, P833, DOI 10.1097/INF.0b013e31822db4dc
   Smetana J, 2018, HUM VACC IMMUNOTHER, V14, P540, DOI 10.1080/21645515.2017.1343226
   Sopacua M, 2019, J PERIPHER NERV SYST, V24, P19, DOI 10.1111/jns.12298
   Souayah N, 2009, VACCINE, V27, P7322, DOI 10.1016/j.vaccine.2009.09.077
   Tisa V, 2016, J Prev Med Hyg, V57, pE28
   US Centers for Disease Control and Prevention (CDC), 2018, SEAS INFL FLU HLTH P
   Wilkinson K, 2017, VACCINE, V35, P2775, DOI 10.1016/j.vaccine.2017.03.092
   Yinong YX, 2019, VACCINE, V37, P1484, DOI 10.1016/j.vaccine.2019.01.063
   Young-Xu YN, 2018, J INFECT DIS, V217, P1718, DOI 10.1093/infdis/jiy088
NR 36
TC 2
Z9 2
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 16
PY 2019
VL 37
IS 39
BP 5825
EP 5834
DI 10.1016/j.vaccine.2019.08.016
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IZ6EX
UT WOS:000487175700004
PM 31431411
OA Other Gold
DA 2020-05-12
ER

PT J
AU Fathima, P
   Gidding, HF
   Snelling, TL
   McIntyre, PB
   Blyth, CC
   Sheridan, S
   Liu, B
   de Klerk, N
   Moore, HC
AF Fathima, Parveen
   Gidding, Heather F.
   Snelling, Thomas L.
   McIntyre, Peter B.
   Blyth, Christopher C.
   Sheridan, Sarah
   Liu, Bette
   de Klerk, Nicholas
   Moore, Hannah C.
TI Timeliness and factors associated with rotavirus vaccine uptake among
   Australian Aboriginal and non-Aboriginal children: A record linkage
   cohort study
SO VACCINE
LA English
DT Article
DE Rotavirus vaccine; Vaccine coverage; Record-linkage; Timeliness; DTPa
   vaccine
ID INTUSSUSCEPTION; COUNTRIES; COVERAGE; INFANTS; DISEASE; HOSPITALIZATION;
   RECOMMENDATIONS; GASTROENTERITIS; VACCINATIONS; PREVENTION
AB Objectives: Rotavirus vaccines (RV), included in Australia's National Immunisation Program from mid-July 2007, are unique in strict time limits for administration. Here, we report on timeliness of RV uptake, compare cumulative RV coverage to age 12 months with DTPa, and assess factors associated with receipt of RV among Aboriginal and non-Aboriginal children.
   Methods: Birth records for 681,456 children born in two Australian states in 2007-2012 were probabilistically linked to national immunisation records. We assessed on-time coverage (defined as receipt of vaccine dose between 4 days prior to scheduled date and the recommended upper limit) for RV and compared this to diphtheria-tetanus-pertussis (DTPa) vaccine. Logistic regression modelling was used to assess independent determinants of receipt of RV.
   Results: Compared to non-Aboriginal infants, on-time RV coverage was lower for all doses among Aboriginal infants. Post the upper age limit of RV dose2, DTPa dose2 coverage increased by 9-16% to >= 90%, whereas RV coverage remained around 77% (Aboriginal) and 85% (non-Aboriginal). Compared to first-born children, the adjusted odds of receiving >= 1 RV dose if born to a mother with >= 3 previous births was 0.30 (95%CI: 0.27-0.34) among Aboriginal, and 0.53 (95%CI: 0.51-0.55) among non-Aboriginal children. Prematurity (<33 weeks), low birthweight (<1500 g), maternal age <20 years, maternal smoking during pregnancy and living in a disadvantaged area were independently associated with decreased vaccine uptake.
   Conclusions: Aboriginal children are at greater risk of rotavirus disease than non-Aboriginal children and delayed vaccine receipt is substantially higher. Although specific programs targeting groups at risk of delayed vaccination might improve RV coverage, relaxation of upper age restrictions is most readily implementable, and its overall risk-benefit should be evaluated. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fathima, Parveen; Snelling, Thomas L.; Blyth, Christopher C.; de Klerk, Nicholas; Moore, Hannah C.] Univ Western Australia, Wesfarmers Ctr Vaccines & Infect Dis, Telethon Kids Inst, Perth, WA, Australia.
   [Gidding, Heather F.] Northern Sydney Local Hlth Dist, Kolling Inst, Clin & Populat Perinatal Hlth Res, St Leonards, NSW 2065, Australia.
   [Gidding, Heather F.] Univ Sydney, Northern Clin Sch, Sydney, NSW, Australia.
   [Gidding, Heather F.; McIntyre, Peter B.; Sheridan, Sarah; Liu, Bette] Univ New South Wales, Sch Publ Hlth & Community Med, UNSW Med, Sydney, NSW, Australia.
   [Gidding, Heather F.] Natl Ctr Immunisat Res & Surveillance Vaccine Pre, Sydney, NSW, Australia.
   [Snelling, Thomas L.; Blyth, Christopher C.] Perth Childrens Hosp, Dept Infect Dis, Perth, WA, Australia.
   [Snelling, Thomas L.] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT, Australia.
   [Snelling, Thomas L.] Curtin Univ, Sch Publ Hlth, Perth, WA, Australia.
   [Blyth, Christopher C.] Univ Western Australia, Sch Med, Perth, WA, Australia.
   [Blyth, Christopher C.] Princess Margaret Hosp, Dept Microbiol, PathWest Lab Med WA, Perth, WA, Australia.
RP Fathima, P (reprint author), Univ Western Australia, Wesfarmers Ctr Vaccines & Infect Dis, Telethon Kids Inst, POB 855, Perth, WA 6872, Australia.
EM parveen.fathima@telethonkids.org.au; heather.gidding@sydney.edu.au;
   tom.snelling@telethonkids.org.au; peter.mcintyre@health.nsw.gov.au;
   christopher.blyth@telethonkids.org.au; sarah.sheridan@unsw.edu.au;
   bette.liu@unsw.edu.au; nick.deKlerk@telethonkids.org.au;
   hannah.moore@telethonkids.org.au
RI ; Moore, Hannah/W-4727-2018; de Klerk, Nicholas/D-8388-2016
OI Gidding, Heather/0000-0001-7595-9281; Liu, Bette/0000-0002-0787-5825;
   Moore, Hannah/0000-0001-6434-8290; de Klerk,
   Nicholas/0000-0001-9223-0767; Snelling, Thomas/0000-0003-4670-0638;
   McIntyre, Peter/0000-0001-5808-7450
FU Population Health Research Network (PHRN), a capability of the
   Commonwealth Government Collaborative Research Infrastructure Strategy
   and Education Investment Fund Super Science Initiative; National Health
   and Medical Research Council (NHMRC)National Health and Medical Research
   Council of Australia [APP1082342]; NHMRCNational Health and Medical
   Research Council of Australia
FX This project was funded by the Population Health Research Network
   (PHRN), a capability of the Commonwealth Government Collaborative
   Research Infrastructure Strategy and Education Investment Fund Super
   Science Initiative; and a National Health and Medical Research Council
   (NHMRC) project grant (APP1082342). HM, TS, CB and HG are supported by
   NHMRC Fellowships.
CR Akmatov MK, 2012, J EPIDEMIOL COMMUN H, V66, DOI 10.1136/jech.2010.124651
   Aliabadi N, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-1824
   Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P201
   Australian Technical Advisory Group on Immunisation (ATAGI), 2017, AUSTR IMM HDB
   Carlin JB, 2013, CLIN INFECT DIS, V57, P1427, DOI 10.1093/cid/cit520
   Centers for Disease Control and Prevention (CDC), 2017, VACC REC GUID ADV CO
   Chhabra P, 2013, J INFECT DIS
   Christensen D, 2014, AUST J SOC ISSUES, V49, P423, DOI 10.1002/j.1839-4655.2014.tb00322.x
   Cortese Margaret M., 2009, Morbidity and Mortality Weekly Report, V58, P1
   Dennehy PH, 2006, PEDIATR INFECT DIS J, V25, P1123, DOI 10.1097/01.inf.0000243777.01375.5b
   Falagas ME, 2008, CURR MED RES OPIN, V24, P1719, DOI 10.1185/03007990802085692
   Fathima P, 2018, PEDIAT INFECT DIS J
   Ferson MJ, 2015, MED J AUSTRALIA, V203, DOI 10.5694/mja15.00478
   Gidding HF, 2017, INT J POPULAT DATA S, V2
   Glatman-Freedman Aharona, 2012, Hum Vaccin Immunother, V8, P293, DOI 10.4161/hv.19003
   Hull Brynley P, 2003, Commun Dis Intell Q Rep, V27, P357
   Hull BP, 2014, COMMUN DIS INTELL, V38, pE208
   Hull BP, 2009, VACCINE, V27, P5054, DOI 10.1016/j.vaccine.2009.06.056
   Kolos V, 2007, VACCINE, V25, P588, DOI 10.1016/j.vaccine.2006.08.022
   Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2
   Kurosky SK, 2016, VACCINE, V34, P387, DOI 10.1016/j.vaccine.2015.11.011
   MacDonald SE, 2016, PEDIATR INFECT DIS J, V35, pE177, DOI 10.1097/INF.0000000000001125
   Moore HC, 2018, VACCINE, V36, P4062, DOI 10.1016/j.vaccine.2018.05.084
   Naidu L, 2013, COMMUN DIS INTELL, V37, pS1
   Palupi-Baroto R, 2015, AUST NZ J PUBL HEAL, V39, P11, DOI 10.1111/1753-6405.12297
   Panozzo CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073825
   Payne DC, 2013, CLIN INFECT DIS, V57, P13, DOI 10.1093/cid/cit164
   Poelaert D, 2018, VACCINE, V36, P2243, DOI 10.1016/j.vaccine.2018.02.080
   Quinn HE, 2014, PEDIATR INFECT DIS J, V33, P959, DOI 10.1097/INF.0000000000000362
   Sax Institute, 2017, SURE SEC UN RES ENV
   Stumpf KA, 2013, PEDIATRICS
   Tauil MD, 2016, VACCINE, V34, P2635, DOI 10.1016/j.vaccine.2016.04.016
   Yen C, 2016, HUM VACC IMMUNOTHER, V12, P2580, DOI 10.1080/21645515.2016.1197452
NR 34
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 16
PY 2019
VL 37
IS 39
BP 5835
EP 5843
DI 10.1016/j.vaccine.2019.08.013
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IZ6EX
UT WOS:000487175700005
PM 31443995
DA 2020-05-12
ER

PT J
AU Hilke, J
   Strobel, H
   Woelke, S
   Stoeter, M
   Voigt, K
   Grimm, L
   Meilwes, J
   Punsmann, T
   Blaha, I
   Salditt, A
   Rohn, K
   Bastian, M
   Ganter, M
AF Hilke, Johanna
   Strobel, Heinz
   Woelke, Soeren
   Stoeter, Melanie
   Voigt, Katja
   Grimm, Lucie
   Meilwes, Johanna
   Punsmann, Teresa
   Blaha, Irena
   Salditt, Andreas
   Rohn, Karl
   Bastian, Max
   Ganter, Martin
TI A comparison of different vaccination schemes used in sheep combining
   inactivated bluetongue vaccines against serotypes 4 and 8
SO VACCINE
LA English
DT Article
DE Bluetongue virus; Sheep; Vaccination; Inactivated vaccines; BTV-4; BTV-8
ID IMMUNE-RESPONSE; PROTECTIVE EFFICACY; VIRUS SEROTYPE-8; HUMORAL
   RESPONSE; CATTLE; IMMUNOGENICITY; PATHOGENESIS; PARAMETERS; INFECTION
AB Eight different vaccination schemes using four commercially available inactivated Bluetongue vaccines against serotypes 4 and 8 in three different combinations (setting 1-3) were tested under field conditions for their ability to generate a measurable immune response in sheep.
   Animals of setting 1 (groups A-D) were simultaneously vaccinated using either individual injections at different locations (groups A & D) or double injection by a twin-syringe (groups B & C). For both application methods, a one-shot vaccination (groups C & D) was compared to a boosted vaccination (groups A & B). Sheep of setting 2 (groups E-G) were vaccinated in an alternating, boosted pattern at fortnightly intervals starting with serotype 4 (groups E & F) or vice versa (group G). Group H of setting 3 was vaccinated simultaneously and vaccines were injected individually as a one-shot application. Each group consisted of 30 sheep. The immunogenic response was tested in all sheep (n = 240) by ELISA (IDScreen (R) Bluetongue Competition), while serum neutralisation tests were performed in five to six sheep from each group (n=45).
   All vaccine combinations were well tolerated by all sheep. Of all vaccines and schemes described, the simultaneous double injected boosted vaccination of setting 1 (group B) yielded the highest median serotype-specific titres 26 weeks after the first vaccination (afv) and 100% seropositive animals (ELISA) one year afv. In setting 1, there were no relevant significant differences in the immunogenic response between simultaneously applied vaccines at different sites or at the same injection site. Importantly, a one-shot vaccination induced comparable immunogenicity to a boosted injection half a year afv. Low serotype-specific neutralising antibody levels were detected in settings 2 and 3 and are attributed to diverse factors which may have influenced the measured immunogenicity. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hilke, Johanna; Strobel, Heinz] Sheep Vet Practice Strobel, Hopfenberg 8, D-89352 Stoffenried, Germany.
   [Hilke, Johanna; Stoeter, Melanie; Grimm, Lucie; Meilwes, Johanna; Punsmann, Teresa; Ganter, Martin] Univ Vet Med Hannover, Clin Swine & Small Ruminants, Forens Med & Ambulatory Serv, Bischofsholer Damm 15, D-30173 Hannover, Germany.
   [Woelke, Soeren; Bastian, Max] Friedrich Loeffler Inst, Fed Res Inst Anim Hlth, Suedufer 10, D-17493 Greifswald, Germany.
   [Voigt, Katja] Ludwig Maximilians Univ Munchen, Clin Ruminants Ambulatory & Herd Hlth Serv, Sonnenstr 16, D-85764 Oberschleissheim, Germany.
   [Blaha, Irena; Salditt, Andreas] State Vet Invest Ctr Aulendorf, Loewenbreitestr 20, D-88326 Aulendorf, Germany.
   [Rohn, Karl] Univ Vet Med Hannover, Inst Biometry Epidemiol & Informat Proc, Buenteweg 2, D-30559 Hannover, Germany.
RP Hilke, J (reprint author), Hopfenberg 8, D-89352 Stoffenried, Germany.
EM johanna.hilke@tiho-hannover.de
CR Asin J, 2019, VET PATHOL, V56, P418, DOI 10.1177/0300985818809142
   Ayrle H, 2018, VACCINE, V36, P5807, DOI 10.1016/j.vaccine.2018.08.015
   Baetza HJ, 2014, VET IMMUNOL IMMUNOP, V158, P116, DOI 10.1016/j.vetimm.2013.09.001
   Bastian M, 2016, EMPFEHLUNGEN BTV IMP
   Batten CA, 2013, VACCINE, V31, P3783, DOI 10.1016/j.vaccine.2013.06.033
   Behrens R, 2009, J INSTRUM, V4, DOI 10.1088/1748-0221/4/03/P03027
   Belbis G, 2017, ADV VIRUS RES, V99, P161, DOI 10.1016/bs.aivir.2017.08.003
   Bournez L, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1388-1
   Breard E, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.00163-16
   Conraths FJ, 2009, EMERG INFECT DIS, V15, P433, DOI 10.3201/eid1503.081210
   Darpel KE, 2007, VET REC, V161, P253, DOI 10.1136/vr.161.8.253
   Darpel KE, 2009, BIOL ANIM INFECT, P265, DOI 10.1016/B978-012369368-6.50016-2
   Du Toit R. M., 1944, ONDERSTEPOORT JOUR VET SCI AND ANIMAL INDUST, V19, P7
   Emidio BD, 2004, VET ITALIANA, V6
   Eschbaumer M, 2009, VACCINE, V27, P4169, DOI 10.1016/j.vaccine.2009.04.056
   FRANCIS T, 1947, AM J PUBLIC HEALTH, V37, P1013, DOI 10.2105/AJPH.37.8.1013
   Ganter M, 2001, TIERARZTL PRAX G N, V29, P37
   Gethmann J, 2009, VACCINE, V27, P4118, DOI 10.1016/j.vaccine.2009.04.072
   Gonzalez JM, 2010, VET REC, V166, P757, DOI 10.1136/vr.b4849
   Hemati B, 2009, J VIROL, V83, P8789, DOI 10.1128/JVI.00626-09
   Ingram JR, 2002, ANIM WELF, V10
   Jeggo M H, 1985, Prog Clin Biol Res, V178, P477
   Jeggo MH, STUDY ROLE CELL MEDI, P8
   MACLACHLAN NJ, 1994, COMP IMMUNOL MICROB, V17, P197, DOI 10.1016/0147-9571(94)90043-4
   Mayr A., 1974, VIROLOGISCHE ARBEITS, VI, P35
   MENDEL VE, 1964, J PHYSIOL-LONDON, V174, P206, DOI 10.1113/jphysiol.1964.sp007482
   Mettenleiter TC, 2015, QUALITATIVE RISIKOBE
   Oura CAL, 2012, VACCINE, V30, P112, DOI 10.1016/j.vaccine.2011.10.100
   Oura CAL, 2009, VACCINE, V27, P7326, DOI 10.1016/j.vaccine.2009.09.070
   Painter SD, 2015, VACCINE, V33, P4422, DOI 10.1016/j.vaccine.2015.06.101
   Parrott RF, 1999, ANIM WELF, V8
   Pedernera-Romano C, 2010, PHARMACOL BIOCHEM BE, V94, P329, DOI 10.1016/j.pbb.2009.09.013
   Poirer MK, 1996, VACCINE, V14, P25, DOI 10.1016/0264-410X(95)00170-6
   Rendi-Wagner P, 2006, VACCINE, V24, P2781, DOI 10.1016/j.vaccine.2006.01.007
   Sailleau C, 2017, TRANSBOUND EMERG DIS, V64, P998, DOI 10.1111/tbed.12453
   Savini G, 2007, VET MICROBIOL, V124, P140, DOI 10.1016/j.vetmic.2007.04.017
   Schwartz-Cornil I, 2008, VET RES, V39, DOI 10.1051/vetres:2008023
   SHAW FE, 1989, VACCINE, V7, P425, DOI 10.1016/0264-410X(89)90157-6
   Spedicato M, 2017, PREV VET MED, V136, P49, DOI 10.1016/j.prevetmed.2016.11.016
   Speiser KL, 2016, JAVMA-J AM VET MED A, V248, P1043, DOI 10.2460/javma.248.9.1043
   Stoop CL, 2016, J DAIRY SCI, V99, P4870, DOI 10.3168/jds.2015-10145
   Tizard IR, 2013, VET IMMUNOLOGY
   Umeshappa CS, 2010, VACCINE, V28, P2522, DOI 10.1016/j.vaccine.2010.01.039
   Vandenbussche F, 2008, VET MICROBIOL, V129, P15, DOI 10.1016/j.vetmic.2007.10.029
   VERWOERD DW, 1970, J VIROL, V5, P1
   Wackerlin R, 2010, VACCINE, V28, P4348, DOI 10.1016/j.vaccine.2010.04.055
   Wilson AJ, 2009, PHILOS T R SOC B, V364, P2669, DOI 10.1098/rstb.2009.0091
   Zientara S, 2013, VET MICROBIOL, V165, P33, DOI 10.1016/j.vetmic.2013.01.010
NR 48
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 16
PY 2019
VL 37
IS 39
BP 5844
EP 5853
DI 10.1016/j.vaccine.2019.08.011
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IZ6EX
UT WOS:000487175700006
PM 31431410
DA 2020-05-12
ER

PT J
AU Hyer, RN
   Janssen, RS
AF Hyer, Randall N.
   Janssen, Robert S.
TI Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG
   1018, in persons with diabetes mellitus aged 60-70 years
SO VACCINE
LA English
DT Article
DE Diabetes mellitus; Health services for the aged; Hepatitis B; Hepatitis
   B vaccines; Vaccination; Advisory Committee on Immunization; Practices
ID IMMUNOSTIMULATORY PHOSPHOROTHIOATE OLIGODEOXYRIBONUCLEOTIDE;
   UNITED-STATES; ADULTS; VIRUS; HBSAG-1018; INFECTION
AB Background: Hepatitis B virus (HBV) remains a major public health issue, although it is a vaccine preventable disease. Adults with diabetes are at greater risk of contracting HBV than the general population. Commonly used 3-dose HBV vaccines have reduced immunogenicity in older individuals and in those with diabetes mellitus.
   Methods: In this post hoc analysis of a phase 3 clinical trial, participants with type 2 diabetes mellitus aged 60-70 years received either 2-dose HBsAg/CpG 1018 (HEPLISAV-B (R), n = 327) at 0 and 4 weeks and placebo at 24 weeks or 3-dose HBsAg/alum (Engerix-B (R), n = 153) at 0, 4, and 24 weeks. Immunogenicity, including seroprotection rate (SPR) at week 28, and safety were assessed by subgroup (sex, body mass index, and smoking status). SPR was defined as antibody against hepatitis B surface antigen serum concentration >= 10 mIU/mL.
   Results: The SPR at week 28 was significantly higher with HBsAg/CpG 1018 (85.8% [235/274]) than with HBsAg/alum (58.5% [76/1301) in the per-protocol analysis, for an overall difference of 27.3% (95% CI, 18.0-36.8). SPRs with HBsAg/CpG 1018 were consistently markedly higher compared with HBsAg/alum, regardless of sex, body mass index, or smoking status. Adverse events and deaths were comparable between groups.
   Conclusions: Two-dose HBsAg/CpG 1018 provides a higher level of seroprotection against HBV than does a 3-dose vaccine (HBsAg/alum) with a similar safety profile in patients aged 60-70 years with type 2 diabetes mellitus. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Hyer, Randall N.; Janssen, Robert S.] Dynavax Technol Corp, 2929 Seventh St,Suite 100, Berkeley, CA 94710 USA.
RP Hyer, RN (reprint author), Dynavax Technol Corp, 2929 Seventh St,Suite 100, Berkeley, CA 94710 USA.
EM rhyer@dynavax.com; rjanssen@dynavax.com
FU Dynavax Technologies Corporation, Berkeley, California
FX The design, study conduct, analysis, and financial support for this
   study were provided by Dynavax Technologies Corporation, Berkeley,
   California.
CR Alcusky Matthew J, 2015, Clin Diabetes, V33, P116, DOI 10.2337/diaclin.33.3.116
   American Diabetes Association, 2015, HEP B
   ANDRE FE, 1989, AM J MED, V87, pS14, DOI 10.1016/0002-9343(89)90525-1
   CDC's Division of Diabetes Translation, 2017, US DIAB SURV SYST LO
   Centers for Disease Control, 2017, NAT DIAB STAT REP 20
   Centers for Disease Control and Prevention (CDC), 2011, MMWR Morb Mortal Wkly Rep, V60, P1709
   Daley MF, 2009, AM J PREV MED, V36, P491, DOI 10.1016/j.amepre.2009.01.037
   Division of Viral Hepatitis and National Center for HIV/AIDS VH STD and TB Prevention, 2015, VIR HEP SURV US
   Duffell EF, 2011, EPIDEMIOL INFECT, V139, P327, DOI 10.1017/S0950268810001007
   Duffell EF, 2017, EURO SURVEILL, V22
   Ferreira GLC, 2017, J VIRAL HEPAT
   Fisman DN, 2002, CLIN INFECT DIS, V35, P1368, DOI 10.1086/344271
   Ghaswalla PK, 2018, HUM VACC IMMUNOTHER, V14, P2780, DOI 10.1080/21645515.2018.1489189
   Halperin SA, 2013, HUM VACC IMMUNOTHER, V9, P1438, DOI 10.4161/hv.24256
   Halperin SA, 2012, VACCINE, V30, P2556, DOI 10.1016/j.vaccine.2012.01.087
   Harris AM, 2016, MMWR-MORBID MORTAL W, V65, P47, DOI 10.15585/mmwr.mm6503a2
   Heineman TC, 1999, VACCINE, V17, P2769, DOI 10.1016/S0264-410X(99)00088-2
   Heyward WL, 2013, VACCINE, V31, P5300, DOI 10.1016/j.vaccine.2013.05.068
   Hyer R, 2018, VACCINE, V36, P2604, DOI 10.1016/j.vaccine.2018.03.067
   Jackson S, 2018, VACCINE, V36, P668, DOI 10.1016/j.vaccine.2017.12.038
   Janssen JM, 2015, VACCINE, V33, P3614, DOI 10.1016/j.vaccine.2015.05.070
   Janssen JM, 2015, VACCINE, V33, P833, DOI 10.1016/j.vaccine.2014.12.060
   Kowa Paul, 2016, AGING WORLD 2015 INT
   Ladak F, 2012, INFECTION, V40, P405, DOI 10.1007/s15010-011-0241-2
   OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78
   Ozisik L, 2015, HUM VACC IMMUNOTHER, V11, P2806, DOI 10.1080/21645515.2015.1070999
   REED GF, 1995, PEDIATRICS, V96, P600
   Reilly Meredith L, 2012, J Diabetes Sci Technol, V6, P858
   Schillie SF, 2012, J VIRAL HEPATITIS, V19, P674, DOI 10.1111/j.1365-2893.2012.01616.x
   Schillie SF, 2012, DIABETES CARE, V35, P2690, DOI 10.2337/dc12-0312
   Strom BL, 2017, NATL STRATEGY ELIMIN
   Van der Meeren O, 2016, HUM VACC IMMUNOTHER, V12, P2197, DOI 10.1080/21645515.2016.1164362
   W.H Organization, 2017, GLOB HEP REP
   WHO, 2017, HEP B FACT SHEET
   WHO, 2017, DIAB FACT SHEET
   Williams WW, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6611a1
   Wolters B, 2003, VACCINE, V21, P3623, DOI 10.1016/S0264-410X(03)00399-2
   Yang SG, 2016, SCI REP-UK, V6, DOI 10.1038/srep27251
   Younossi Z, 2017, HUM VACC IMMUNOTHER, V13, P2695, DOI 10.1080/21645515.2017.1353850
   Zhu HJ, 2016, J INFECT DEV COUNTR, V10, P837, DOI 10.3855/jidc.7656
NR 40
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 16
PY 2019
VL 37
IS 39
BP 5854
EP 5861
DI 10.1016/j.vaccine.2019.08.005
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IZ6EX
UT WOS:000487175700007
PM 31431412
OA Other Gold
DA 2020-05-12
ER

PT J
AU Rouers, EDM
   Berbers, GAM
   van Dongen, JAP
   Sanders, EAM
   Bruijning-Verhagen, P
   van Houten, M
   van Kempen, A
   Norbuis, O
   Pajkrt, D
   van der Sluijs, J
   Vlieger, A
   van Well, G
AF Rouers, Elsbeth D. M.
   Berbers, Guy A. M.
   van Dongen, Josephine A. P.
   Sanders, Elisabeth A. M.
   Bruijning-Verhagen, Patricia
   van Houten, Marlies
   van Kempen, Anne
   Norbuis, Obbe
   Pajkrt, Dasja
   van der Sluijs, Jacqueline
   Vlieger, Arine
   van Well, Gijs
CA PRIEMA Study Grp
TI Timeliness of immunisations in preterm infants in the Netherlands
SO VACCINE
LA English
DT Article
DE Preterm infants; Timeliness; Vaccination; National immunisation
   programme
ID BIRTH-WEIGHT INFANTS; ROUTINE IMMUNIZATION; ACELLULAR PERTUSSIS;
   PREMATURE; VACCINATION; DIPHTHERIA; TETANUS; TRANSPORT; EVENTS; RISK
AB Background: In the Netherlands, preterm infants receive the immunisations at the same chronological age as recommended for term infants without correction for gestational age (GA). The aim of this paper was to describe the timeliness of the routine Dutch national immunisation schedule in preterm infants in their first year of life and to evaluate possible determinants of delay.
   Methods: Preterm infants were prospectively recruited between October 2015 and October 2017 and stratified according to GA (<28, 28-32 and 32-36 weeks). Data from the baseline parental questionnaire, monthly parental questionnaires and medical records were used to determine the immunisation age and proportion of infants timely receiving the first immunisations (between 42 and 63 days). Results were compared between the GA and birth weight (BW) groups. Determinants associated with timeliness of immunisation were studied by multivariate logistic regression analysis.
   Results: Timely start of immunisation occurs in 60.5% of preterm infants in the Netherlands. The proportion of infants receiving the first immunisation on time was lowest for the group with GA <28 weeks (37%). The mean age of the first immunisation across all GA groups was 62.7 days (range 33-118) and differed significantly between GA group <28 weeks and the other two GA groups of 28-32 and 3236 weeks (p < 0.001). Similar results were seen when stratified by BW. Multivariate analysis showed that low socioeconomic status (SES) and prolonged hospitalisation beyond 37 weeks each negatively influenced timeliness of the first immunisation.
   Conclusion: These findings indicate that start of immunisations was often delayed in prematures and differs for different GA groups, being lowest (37%) in infants <28 weeks GA. Lower SES and prolonged hospital stay beyond 37 weeks GA are important determinants of timeliness. Efforts to improve timeliness should focus most on counselling parents in lower SES. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Rouers, Elsbeth D. M.; Berbers, Guy A. M.; Sanders, Elisabeth A. M.; Bruijning-Verhagen, Patricia] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, POB 1, NL-3720 BA Bilthoven, Netherlands.
   [Rouers, Elsbeth D. M.; van Dongen, Josephine A. P.; Bruijning-Verhagen, Patricia] Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
   [Sanders, Elisabeth A. M.] Wilhelmina Childrens Hosp, Dept Paediat Immunol & Infect Dis, Utrecht, Netherlands.
   [van Houten, Marlies] Spaarne Gasthuis Hosp, Dept Paediat, Hoofddorp, Netherlands.
   [van Kempen, Anne] Onze Lieve Vrouw Hosp, Dept Paediat, Amsterdam, Netherlands.
   [Norbuis, Obbe] Isala Clin, Dept Paediat, Zwolle, Netherlands.
   [Pajkrt, Dasja] Amsterdam Med Ctr, Dept Paediat, Amsterdam, Netherlands.
   [van der Sluijs, Jacqueline] Maxima Med Ctr, Dept Paediat & Neonatol, Veldhoven, Netherlands.
   [Vlieger, Arine] St Antonius Hosp, Dept Paediat, Nieuwegein, Netherlands.
   [van Well, Gijs] Maastricht Univ, Med Ctr, Dept Paediat, Maastricht, Netherlands.
RP Rouers, EDM (reprint author), Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, POB 1, NL-3720 BA Bilthoven, Netherlands.
EM Elsbeth.rouers@rivm.nl
RI Bruijning-Verhagen, Patricia C.J.L./E-4134-2015
OI Bruijning-Verhagen, Patricia C.J.L./0000-0003-4105-9669
FU Dutch Ministry of Health, Welfare and Sport
FX This work was funded by the Dutch Ministry of Health, Welfare and Sport.
CR [Anonymous], 2018, ACT PASS IMM, P1
   Batra JS, 2009, PEDIATRICS, V123, P951, DOI 10.1542/peds.2008-0231
   Bonhoeffer J, 2006, ARCH DIS CHILD, V91, P929, DOI 10.1136/adc.2005.086306
   Buijs Stephanie C, 2012, Ned Tijdschr Geneeskd, V156, pA3797
   Carbone T, 2008, PEDIATRICS, V121, pE1085, DOI 10.1542/peds.2007-2059
   CBS, 2018, TRENDS NED 2018 MAAT
   Davis RL, 1999, JAMA-J AM MED ASSOC, V282, P547, DOI 10.1001/jama.282.6.547
   de Greeff SC, 2009, EPIDEMIOL INFECT, V137, P1388, DOI 10.1017/S0950268809002489
   de Greeff SC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014183
   Demeo SD, 2015, JAMA PEDIATR, V169, P740, DOI 10.1001/jamapediatrics.2015.0418
   Esposito S, 2012, EXPERT REV VACCINES, V11, P1199, DOI [10.1586/ERV.12.93, 10.1586/erv.12.93]
   Gagneur A, 2015, HUM VACC IMMUNOTHER, V11, P2556, DOI 10.1080/21645515.2015.1074358
   Hacking DF, 2010, J PAEDIATR CHILD H, V46, P742, DOI 10.1111/j.1440-1754.2010.01832.x
   Jauniaux E, 1995, HUM REPROD, V10, P3297, DOI 10.1093/oxfordjournals.humrep.a135906
   Kent A, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-3945
   Langkamp DL, 1996, J PEDIATR-US, V128, P654, DOI 10.1016/S0022-3476(96)80131-4
   Langkamp DL, 2001, ARCH PEDIAT ADOL MED, V155, P167, DOI 10.1001/archpedi.155.2.167
   Offit PA, 2002, PEDIATRICS, V109, P124, DOI 10.1542/peds.109.1.124
   Palmeira P, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/985646
   RIVM, 2019, RICHTL UITV RVP
   Saari TN, 2003, PEDIATRICS, V112, P193, DOI 10.1542/peds.112.1.193
   Scheepers ED, 2017, EUR J PEDIATR, V176, P769, DOI 10.1007/s00431-017-2904-1
   Schulzke S, 2005, EUR J PEDIATR, V164, P432, DOI 10.1007/s00431-005-1674-3
   Simister NE, 2003, VACCINE, V21, P3365, DOI 10.1016/S0264-410X(03)00334-7
   Tillmann BU, 2001, ACTA PAEDIATR, V90, P1421, DOI 10.1080/08035250152708842
   Tozzi AE, 2014, VACCINE, V32, P793, DOI 10.1016/j.vaccine.2013.12.044
   van den Berg JP, 2010, PEDIATR INFECT DIS J, V29, P801, DOI 10.1097/INF.0b013e3181dc4f77
   van Lier A, 2014, EUR J PUBLIC HEALTH, V24, P304, DOI 10.1093/eurpub/ckt042
   Van Lier E.A., 2018, VACCINATIEGRAAD JAAR
   Volksgezondheid. info, 2018, VROEGG LAAG GEB RIVM
   Voysey M, 2017, JAMA PEDIATR, V171, P637, DOI 10.1001/jamapediatrics.2017.0638
   Woestenberg PJ, 2014, PEDIATR INFECT DIS J, V33, P190, DOI 10.1097/INF.0000000000000106
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 16
PY 2019
VL 37
IS 39
BP 5862
EP 5867
DI 10.1016/j.vaccine.2019.08.006
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IZ6EX
UT WOS:000487175700008
PM 31443994
DA 2020-05-12
ER

PT J
AU Xia, RY
   Sun, SL
   Shen, MW
   Zhang, L
   Zhuang, GH
AF Xia, Ruyi
   Sun, Shuliu
   Shen, Mingwang
   Zhang, Lei
   Zhuang, Guihua
TI Targeted hepatitis E vaccination for women of childbearing age is
   cost-effective in China
SO VACCINE
LA English
DT Article
DE HEV 239; Cost-effectiveness; Women of childbearing age; China
ID VIRUS-RELATED DISEASES; ACUTE VIRAL-HEPATITIS; LIFE YEARS DALYS;
   PREGNANT-WOMEN; GLOBAL BURDEN; ECONOMIC BURDEN; FETAL OUTCOMES; HEALTH;
   SEROPREVALENCE; PERFORMANCE
AB Background: Hepatitis E virus (HEV) infection is hyper-endemic in China, it is characterized with a high morbidity of fulminant hepatitis and mortality in pregnant women. The first hepatitis E vaccine, HEV 239, was licensed in China in 2011 which provides an effective preventive measure.
   Objective: To evaluate the cost-effectiveness of vaccination with HEV 239 in women of childbearing age in China and whether HEV antibody screening should be considered before vaccination.
   Methods: A decision tree-Markov model was constructed to simulate HEV infection in a closed female cohort with an average first-marriage age of 25 years and evaluate health and economic outcomes of two potential vaccination strategies, direct vaccination and combined screening and vaccination, from a societal perspective. An incremental cost-effectiveness ratio (ICER, additional costs per disability adjusted life-year (DALY) averted) was calculated for each vaccination strategy versus no vaccination and between two vaccination strategies. Univariate and probabilistic sensitivity analyses were conducted to assess the robustness of the model findings.
   Results: ICERs of direct vaccination and combined screening and vaccination versus no vaccination were $4040 and $3114 per DALY averted, respectively, much lower than 1-time Chinese per-capita GDP ($8127). Direct vaccination would need additional $45,455 for each DALY averted compared with combined screening and vaccination, far more than the 3-time per-capita GDP. Probabilistic sensitivity analyses confirmed our findings that two vaccination strategies would be cost-effective if the willingness-to-pay reached the 1-time per-capita GDP, and that combined screening and vaccination would be more cost-effective than direct vaccination strategy.
   Conclusion: Vaccinating women of childbearing age with HEV 239 would cost less than the 1-time per-capita GDP for each DALY averted in China, and the vaccination with a prior screening would be the optimal option. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Xia, Ruyi; Shen, Mingwang; Zhang, Lei; Zhuang, Guihua] Xi An Jiao Tong Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Hlth Sci Ctr, 76 West Yanta Rd, Xian 710061, Shaanxi, Peoples R China.
   [Sun, Shuliu] Northwest Womens & Childrens Hosp, Dept Obstet, Xian 710061, Shaanxi, Peoples R China.
   [Zhang, Lei] Alfred Hlth, Melbourne Sexual Hlth Ctr, Melbourne, Vic, Australia.
   [Zhang, Lei] Monash Univ, Fac Med, Cent Clin Sch, Melbourne, Vic, Australia.
   [Zhang, Lei] Monash Univ, Fac Med, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia.
RP Zhuang, GH (reprint author), Xi An Jiao Tong Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Hlth Sci Ctr, 76 West Yanta Rd, Xian 710061, Shaanxi, Peoples R China.
EM xiaruyi0820@163.com; shuliu0823@outlook.com;
   mingwangshen521@xjtu.edu.cn; lei.zhang1@xjtu.edu.cn;
   zhuanggh@mail.xjtu.edu.cn
CR Abravanel F, 2013, J CLIN VIROL, V58, P624, DOI 10.1016/j.jcv.2013.10.003
   Aggarwal R, 2011, VIRUS RES, V161, P15, DOI 10.1016/j.virusres.2011.03.017
   Bertram MY, 2016, B WORLD HEALTH ORGAN, V94, P925, DOI 10.2471/BLT.15.164418
   Boccia D, 2006, CLIN INFECT DIS, V42, P1679, DOI 10.1086/504322
   Che YH, 2016, PUBLIC HEALTH, V130, P13, DOI 10.1016/j.puhe.2015.03.015
   Chen S, 2015, VACCINE, V33, P4124, DOI 10.1016/j.vaccine.2015.06.050
   Chionne P, 2016, J CLIN VIROL, V78, P4, DOI 10.1016/j.jcv.2016.02.005
   Cong W, 2015, J MED VIROL, V87, P446, DOI 10.1002/jmv.24058
   Genders TSS, 2009, RADIOLOGY, V253, P734, DOI 10.1148/radiol.2533090507
   Haffar S, 2015, LIVER INT, V35, P311, DOI 10.1111/liv.12590
   Havelaar AH, 2012, INT J FOOD MICROBIOL, V156, P231, DOI 10.1016/j.ijfoodmicro.2012.03.029
   He Z, 2016, BIOMED RES INT, V2016, P1, DOI DOI 10.1038/SREP29621
   Hu Y, 2016, GESUNDHEITSWESEN, V78, pE1, DOI 10.1055/s-0035-1549937
   Jacobsen KH, 2010, GLOBAL PREVALENCE HE
   Jia ZY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110837
   Jilani N, 2007, J GASTROEN HEPATOL, V22, P676, DOI 10.1111/j.1440-1746.2007.04913.x
   Jin H, 2016, EPIDEMIOL INFECT, V144, P2098, DOI 10.1017/S0950268816000418
   Kamar N, 2012, LANCET, V379, P2477, DOI 10.1016/S0140-6736(11)61849-7
   Khuroo MS, 2011, VIRUS RES, V161, P3, DOI 10.1016/j.virusres.2011.02.007
   Khuroo MS, 2003, J VIRAL HEPATITIS, V10, P61, DOI 10.1046/j.1365-2893.2003.00398.x
   Krain LJ, 2014, AM J TROP MED HYG, V90, P365, DOI 10.4269/ajtmh.13-0265
   [刘海平 Liu Haiping], 2012, [中国公共卫生, China Public Health], V28, P135
   Lu JJ, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-37
   Lu JunLong, 2012, Chinese Preventive Medicine, V13, P326
   Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4
   Nelson KE, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu098
   Pas SD, 2013, J CLIN VIROL, V58, P629, DOI 10.1016/j.jcv.2013.10.010
   Patra S, 2007, ANN INTERN MED, V147, P28, DOI 10.7326/0003-4819-147-1-200707030-00005
   Rein DB, 2012, HEPATOLOGY, V55, P988, DOI 10.1002/hep.25505
   Rein DB, 2011, HEPATOLOGY, V54, p1176A
   Ren FR, 2014, TRANSFUSION, V54, P910, DOI 10.1111/trf.12530
   Rushby JF, 2001, HEALTH POLICY PLANN, V16, P326, DOI 10.1093/heapol/16.3.326
   Shinde NR, 2014, ANN MED HEALTH SCI R, V4, P133, DOI 10.4103/2141-9248.138033
   Teshale EH, 2010, EMERG INFECT DIS, V16, P126, DOI 10.3201/eid1601.090764
   The Lancet, 2010, LANCET, V376, P845
   Thomson K, 2013, MMWR-MORBID MORTAL W, V62, P581
   Tremeaux P, 2016, J CLIN VIROL, V79, P1, DOI 10.1016/j.jcv.2016.03.019
   Walker DG, 2010, VACCINE, V28, P2356, DOI 10.1016/j.vaccine.2009.06.035
   Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253
   WHO, 2016, VACCINE, V34, P304, DOI 10.1016/j.vaccine.2015.07.056
   World Health Organization, 2017, GLOB HEP REP 2017
   Wu T, 2012, HEPATOLOGY, V55, DOI 10.1002/hep.25522
   Zhang H, 2015, ASIA-PAC J PUBLIC HE, V27, p41S, DOI 10.1177/1010539514560057
   Zhang J, 2014, CLIN MICROBIOL INFEC, V20, pO397, DOI 10.1111/1469-0691.12419
   Zhang J, 2015, NEW ENGL J MED, V372, P914, DOI 10.1056/NEJMoa1406011
   Zhang J, 2009, VACCINE, V27, P1869, DOI 10.1016/j.vaccine.2008.12.061
   Zhang S, 2016, J VIRAL HEPATITIS, V23, P202, DOI 10.1111/jvh.12482
   Zhao YY, 2016, HUM VACC IMMUNOTHER, V12, P2003, DOI 10.1080/21645515.2016.1141844
   Zhu FC, 2010, LANCET, V376, P895, DOI 10.1016/S0140-6736(10)61030-6
   Zhuang GH, 2008, VACCINE, V26, P4608, DOI 10.1016/j.vaccine.2008.05.086
NR 50
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 16
PY 2019
VL 37
IS 39
BP 5868
EP 5876
DI 10.1016/j.vaccine.2019.08.003
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IZ6EX
UT WOS:000487175700009
PM 31443991
DA 2020-05-12
ER

PT J
AU Strezova, A
   Lal, H
   Enweonye, I
   Campora, L
   Beukelaers, P
   Segall, N
   Heineman, TC
   Schuin, AE
   Oostvogels, L
AF Strezova, Ana
   Lal, Himal
   Enweonye, Igwebuike
   Campora, Laura
   Beukelaers, Pierre
   Segall, Nathan
   Heineman, Thomas C.
   Schuin, Anne E.
   Oostvogels, Lidia
TI The adjuvanted recombinant zoster vaccine co-administered with a
   tetanus, diphtheria and pertussis vaccine in adults aged >= 50 years: A
   randomized trial
SO VACCINE
LA English
DT Article
DE Herpes zoster; Adjuvanted recombinant zoster vaccine;
   Reduced-antigen-content diphtheriatetanus-acellular pertussis vaccine;
   Co-administration; Immune response; Safety
ID SUBUNIT CANDIDATE VACCINE; HERPES-ZOSTER; IMMUNIZATION PRACTICES;
   ADVISORY-COMMITTEE; INFLUENZA VACCINE; IMMUNOGENICITY; SAFETY;
   RECOMMENDATIONS; EFFICACY; PREVENTION
AB Background: This study evaluated immunogenicity and safety of the adjuvanted recombinant zoster vaccine (RZV) and the reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine (Tdap) when co-administered in adults aged >= 50 years.
   Methods: In this open label, multi-center study (NCT02052596), participants were randomized 1:1 to the Co-Administration group (RZV dose 1 and Tdap at Day 0 [DO], RZV dose 2 at Month 2 [M2]) or Control group (Tdap at DO, RZV dose 1 at M2, RZV dose 2 at M4). Co-primary objectives were evaluation of the vaccine response rate (VRR) to RZV in the Co-Administration group, and demonstration of non inferiority of the humoral responses to RZV and Tdap in the Co-Administration compared to Control group. Reactogenicity and safety of RZV and Tdap were also assessed.
   Results: VRR to RZV was 97.8% in the Co-Administration group. The non-inferiority criterion was met for the humoral response to RZV and for 4 Tdap antigens, but was not met for the Tdap antigen pertactin. Occurrences of solicited, unsolicited and serious adverse events, and potential immune-mediated diseases were similar between groups.
   Conclusions: Co-administration of RZV and Tdap did not interfere with the humoral immune response to RZV or 4 of the 5 Tdap antigens. No safety concerns were identified. (C) 2019 GSK. Published by Elsevier Ltd.
C1 [Strezova, Ana; Campora, Laura; Beukelaers, Pierre; Oostvogels, Lidia] GSK, 20 Ave Fleming, B-1300 Wavre, Belgium.
   [Lal, Himal; Heineman, Thomas C.] GSK, 2301 Renaissance Blvd, King Of Prussia, PA 19406 USA.
   [Enweonye, Igwebuike] GSK, 81-87 Hullenberweg, NL-1101 CL Amsterdam, Netherlands.
   [Segall, Nathan] Clin Res Atlanta, 175 Country Club Dr Ste A, Stockbridge, GA 30281 USA.
   [Schuin, Anne E.] GSK, 14200 Shady Grove Rd, Rockville, MD 20850 USA.
   [Lal, Himal] Pfizer Inc, 500 Arcola Rd, Collegeville, PA 19426 USA.
   [Heineman, Thomas C.] Halozyme Therapeut, 11388 Sorrento Valley Rd, San Diego, CA 92121 USA.
   [Oostvogels, Lidia] CureVac AG, Paul Ehrlich Str 15, D-72076 Tubingen, Germany.
RP Schuin, AE (reprint author), GSK, 14200 Shady Grove Rd, Rockville, MD 20850 USA.
EM ana.x.strezova@gsk.com; himallal@pfizer.com;
   igwebuike.x.enweonye@gsk.com; laura.e.campora@gsk.com;
   pierre.x.beukelaers@gsk.com; nsegall@clinicalresearchatlanta.com;
   tch3768@gmail.com; Anne.E.Schuind@gsk.com; cornelia.oostvogels@orange.fr
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline
FX This work was supported by GlaxoSmithKline Biologicals SA in all stages
   of the study conduct and analysis. GlaxoSmithKline Biologicals SA also
   took responsibility for all costs associated with the development and
   publishing of the present manuscript.
CR CAMARGO ME, 1984, J CLIN MICROBIOL, V20, P772, DOI 10.1128/JCM.20.4.772-774.1984
   CDC, EP PREV VACC PREV DI
   Chlibek R, 2014, VACCINE, V32, P1745, DOI 10.1016/j.vaccine.2014.01.019
   Chlibek R, 2013, J INFECT DIS, V208, P1953, DOI 10.1093/infdis/jit365
   Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.1093/biomet/26.4.404
   Cunningham AL, 2016, NEW ENGL J MED, V375, P1019, DOI 10.1056/NEJMoa1603800
   Cunningham AL, 2018, J INFECT DIS, V217, P1750, DOI 10.1093/infdis/jiy095
   Dooling KL, 2018, MMWR-MORBID MORTAL W, V67, P103, DOI 10.15585/mmwr.mm6703a5
   Dworkin RH, 2007, CLIN INFECT DIS, V44, pS1, DOI 10.1086/510206
   EMA, SUMMARY PRODUCT CHAR
   FDA, SHINGR PRESCR INF
   Gershon AA, 2010, J CLIN VIROL, V48, P52, DOI DOI 10.1016/51386-6532(10)70002-0
   Ghebrehewet S, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i6258
   Gnann JW, 2002, NEW ENGL J MED, V347, P340, DOI 10.1056/NEJMcp1302674
   GSK, CLIN STUD REG STUD I
   Halperin SA, 2006, PEDIATR INFECT DIS J, V25, P195, DOI 10.1097/01.inf.0000202082.56403.c4
   Harpaz Rafael, 2007, Morbidity and Mortality Weekly Report, V57, P1
   Health Canada, SUMM BAS DEC
   Johnson BH, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1262-8
   Johnson RW, 2010, EXPERT REV VACCINES, V9, P21, DOI 10.1586/ERV.10.30
   Kawai K, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004833
   Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184
   Lecrenier N, 2018, EXPERT REV VACCINES, V17, P619, DOI 10.1080/14760584.2018.1495565
   Lee HJ, 2017, CLIN EXP VACCINE RES, V6, P22, DOI [10.7774/cevr.2017.6.1.22., 10.7774/cevr.2017.6.1.22]
   Leonardi M, 2015, VACCINE, V33, P924, DOI 10.1016/j.vaccine.2014.09.064
   Liang JL, 2018, MMWR RECOMM REP, V67, P1, DOI 10.15585/mmwr.rr6702a1
   Marechal C, 2018, VACCINE, V36, P4278, DOI 10.1016/j.vaccine.2018.05.110
   Masseria C, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1269-1
   McElhaney JE, 2016, OPEN FORUM INFECT S1, V3, P127, DOI [10.1093/ofid/ofw194.40, DOI 10.1093/OFID/OFW194.40]
   McGuiness CB, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-32
   McQuillan GM, 2002, ANN INTERN MED, V136, P660, DOI 10.7326/0003-4819-136-9-200205070-00008
   MELVILLESMITH ME, 1983, J BIOL STAND, V11, P137, DOI 10.1016/S0092-1157(83)80038-9
   Mullooly JP, 2007, VACCINE, V25, P846, DOI 10.1016/j.vaccine.2006.09.041
   Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I
   Oxman MN, 2009, J AM OSTEOPATH ASSOC, V109, pS13
   Schmitt HJ, 1996, JAMA-J AM MED ASSOC, V275, P37, DOI 10.1001/jama.275.1.37
   Schmitt HJ, 1996, J PEDIATR-US, V129, P695, DOI 10.1016/S0022-3476(96)70152-X
   Schwarz TF, 2017, J INFECT DIS, V216, P1352, DOI 10.1093/infdis/jix481
   Stupka John E, 2009, Aging health, V5, P763, DOI 10.2217/ahe.09.74
   Weinberg A, 2009, J INFECT DIS, V200, P1068, DOI 10.1086/605611
   Weston WM, 2011, VACCINE, V29, P1017, DOI 10.1016/j.vaccine.2010.11.057
   Weston WM, 2009, HUM VACCINES, V5, P858, DOI 10.4161/hv.9961
   WHO, AC PERT VACC
   Yawn BP, 2013, NEUROLOGY, V81, P928, DOI 10.1212/WNL.0b013e3182a3516e
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 16
PY 2019
VL 37
IS 39
BP 5877
EP 5885
DI 10.1016/j.vaccine.2019.08.001
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IZ6EX
UT WOS:000487175700010
PM 31443993
OA Other Gold
DA 2020-05-12
ER

PT J
AU Hoque, SA
   Iizuka, I
   Kobayashi, M
   Takanashi, S
   Anwar, KS
   Islam, MT
   Hoque, SA
   Khamrin, P
   Okitsu, S
   Hayakawa, S
   Ushijima, H
AF Hoque, Sheikh Ariful
   Iizuka, Itoe
   Kobayashi, Masaaki
   Takanashi, Sayaka
   Anwar, Kazi Selim
   Islam, Mohammad Tajul
   Hoque, Sk Azimul
   Khamrin, Pattara
   Okitsu, Shoko
   Hayakawa, Satoshi
   Ushijima, Hiroshi
TI Determining effectiveness of rotavirus vaccine by immunochromatography
   and reverse transcriptase polymerase chain reaction: A comparison
SO VACCINE
LA English
DT Article
DE Rotavirus (RV) diagnosis; Vaccine effectiveness; Immunochromatography
   (IC); Reverse transcription polymerase chain; reaction (RT-PCR);
   Sensitivity; Specificity
ID LINKED-IMMUNOSORBENT-ASSAY; CHILDREN; GASTROENTERITIS; NOROVIRUS;
   MORTALITY
AB Introduction: Because of the large animal reservoirs and reassortment capacity of rotaviruses (RVs) that pose the possibilities of waning the effectiveness of RV-vaccines, it remains essential to monitor vaccine effectiveness (VE) regularly. Although reverse transcription polymerase chain reaction (RT-PCR) remains sensitive for RV detection, physicians, especially in Japan, frequently use immunochromatography (IC)-based kits for RV diagnosis. Recently, IC is being used to calculate VE also. Herein, we investigated the validity of VEs determined by IC compared to that by RT-PCR during an outbreak in Shizuoka Prefecture, Japan.
   Methods: RVs in the stool or rectal swabs from children with acute gastroenteritis (AGE) were tested first by IC in the clinic and then by RT-PCR in the laboratory. A test-negative study design was used to examine VE.
   Results: Although the specificity of IC assay revealed 100%, its sensitivity remained weaker (67%) than that of RT-PCR that increased up to 88% depending on disease severity. VE assessed by IC remained stronger than that by RT-PCR: 79% (95% CI: 39-93%) by IC, and 58% (95% CI: -20% to 90%) by RT-PCR. However, VEs by IC and RT-PCR appeared almost similar in higher disease severity: 81.5% (95% CI: 40-94%) by IC and 72% (95% CI: 7-92%) by RT-PCR at severity >= 7, while 97.5% (95% CI: 77-99.7%) by IC and 92% (95% Cl: 58-98%) by RT-PCR at severity >= 11. We showed that RV-vaccinated children had 80% [OR = 0.192 (95% CI: 0.052-0.709) less chance to be detected by IC.
   Conclusion: Although the sensitivity and specificity of IC differ by brand type, generally, IC is not as sensitive as RT-PCR. Despite the VEs remain higher by IC, it looks comparable with that of RT-PCR in severe cases implying that VEs evaluated by IC against severe illness remain useful for VE-monitoring. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hoque, Sheikh Ariful; Iizuka, Itoe; Khamrin, Pattara; Okitsu, Shoko; Hayakawa, Satoshi; Ushijima, Hiroshi] Nihon Univ, Dept Pathol & Microbiol, Div Microbiol, Sch Med, Tokyo, Japan.
   [Hoque, Sheikh Ariful] Univ Dhaka, Ctr Adv Res Sci, Cell & Tissue Culture Lab, Dhaka, Bangladesh.
   [Kobayashi, Masaaki] Kobayashi Pediat Clin, Shizuoka, Japan.
   [Takanashi, Sayaka] Univ Tokyo, Sch Int Hlth, Grad Sch Med, Dept Dev Med Sci, Tokyo, Japan.
   [Anwar, Kazi Selim] Int Univ Hlth & Welf, Sch Med, Dept Infect Dis, Narita Campus, Chiba, Japan.
   [Islam, Mohammad Tajul] Save Children, Dhaka, Bangladesh.
   [Hoque, Sk Azimul] Natl Inst Neurosci & Hosp, Dhaka, Bangladesh.
   [Khamrin, Pattara] Chiang Mai Univ, Fac Med, Dept Microbiol, Chiang Mai, Thailand.
RP Ushijima, H (reprint author), Nihon Univ, Dept Pathol & Microbiol, Div Microbiol, Sch Med,Itabashi Ku, 30-1 OyaguchiKamicho, Tokyo 1738610, Japan.
EM ushijima-hiroshi@jcom.home.ne.jp
FU Kurozumi Medical Foundation, Japan; Public Foundation of the Vaccination
   Research Center, Japan [2018-38];  [16H05360]
FX We are grateful to all parents and children who willingly participated
   in this study. This work was supported by Grant-in-Aid for Scientific
   Research, Japan (16H05360), Kurozumi Medical Foundation, Japan and
   Public Foundation of the Vaccination Research Center, Japan (2018-38).
   I, personally, like to express my utmost gratitude to Prof. Dr. Golam
   Mohammed Bhuiyan, Director, Centre for Advanced Research in Sciences
   (CARS), University of Dhaka, Bangladesh for allowing me for this
   collaborative study between University of Dhaka, Bangladesh and Nihon
   University School of Medicine, Japan. We gratefully acknowledge all
   members of Division of Microbiology, Department of Pathology and
   Microbiology, Nihon University School of Medicine, for their generous
   cooperation throughout this work.
CR Abou-Nader AJ, 2018, HUM VACC IMMUNOTHER, V14, P2281, DOI 10.1080/21645515.2018.1470725
   Araki K, 2018, J EPIDEMIOL
   Araki K, 2018, VACCINE, V36, P5187, DOI 10.1016/j.vaccine.2018.07.007
   Desselberger U, 2017, PATHOGENS, V6, DOI 10.3390/pathogens6040065
   Dhiman S, 2015, J CLIN DIAGN RES, V9, pDC6, DOI 10.7860/JCDR/2015/14049.6425
   Fujii Y, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0916-7
   Gonzalez-Ochoa G, 2017, ARCH MICROBIOL, V199, P953, DOI 10.1007/s00203-017-1400-3
   Hoque SA, 2019, FOOD ENVIRON VIROL, V11, P65, DOI 10.1007/s12560-018-09363-z
   Hoque SA, 2018, VACCINE, V36, P5110, DOI 10.1016/j.vaccine.2018.05.004
   Hoque SA, 2018, VACCINE, V36, P43, DOI 10.1016/j.vaccine.2017.11.056
   Iyoha O, 2015, NIGER J CLIN PRACT, V18, P48, DOI 10.4103/1119-3077.146978
   Khamrin P, 2008, J VIROL METHODS, V147, P360, DOI 10.1016/j.jviromet.2007.09.007
   Khamrin P, 2018, CLIN LAB, V64, P793, DOI 10.7754/Clin.Lab.2017.171201
   Kim J, 2014, ANN LAB MED, V34, P216, DOI 10.3343/alm.2014.34.3.216
   Leshem E, 2014, LANCET INFECT DIS, V14, P847, DOI 10.1016/S1473-3099(14)70832-1
   Lewis K., 2011, VESIKARI CLIN SEVERI
   Lopez-Lacort M, 2016, VACCINE, V34, P5912, DOI 10.1016/j.vaccine.2016.10.032
   Mino S, 2015, J VIROL METHODS, V222, P1, DOI 10.1016/j.jviromet.2015.05.002
   Moyo SJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097562
   Muhsen K, 2018, CLIN MICROBIOL INFEC, V24, P53, DOI 10.1016/j.cmi.2017.04.018
   Nguyen TA, 2007, J TROP PEDIATRICS, V53, P264, DOI 10.1093/tropej/fmm021
   Rovida F, 2013, DIAGN MICR INFEC DIS, V75, P110, DOI 10.1016/j.diagmicrobio.2012.09.016
   Soheibi N, 2017, EUR PHYS J B, V90, DOI 10.1140/epjb/e2017-80468-9
   Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013
   Tate JE, 2013, EMERG INFECT DIS, V19, P1245, DOI 10.3201/eid1908.130461
   Tate JE, 2012, LANCET INFECT DIS, V12, P136, DOI 10.1016/S1473-3099(11)70253-5
NR 26
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 16
PY 2019
VL 37
IS 39
BP 5886
EP 5890
DI 10.1016/j.vaccine.2019.07.091
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IZ6EX
UT WOS:000487175700011
PM 31451325
DA 2020-05-12
ER

PT J
AU Nealon, J
   Lim, WY
   Moureau, A
   Lojikip, SL
   Junus, S
   Kumar, S
   Nachiappan, JP
   Sekaran, SD
   Radigue, C
   Cowling, BJ
   Ochiai, RL
   Amar-Singh, HSS
AF Nealon, Joshua
   Lim, Wei-Yin
   Moureau, Annick
   Lojikip, Sharon Linus
   Junus, Suria
   Kumar, Suresh
   Nachiappan, Jeyaseelan P.
   Sekaran, Shamala Devi
   Radigue, Cedric
   Cowling, Benjamin J.
   Ochiai, R. Leon
   Amar-Singh, H. S. S.
TI Feasibility of case-control and test-negative designs to evaluate dengue
   vaccine effectiveness in Malaysia
SO VACCINE
LA English
DT Article
DE Dengue; Vaccine effectiveness; Malaysia; Case-control
ID INFECTION; DISEASE; BURDEN; VIRUS
AB Background: The world's first dengue vaccine [Dengvaxia; Sanofi Pasteur] was licensed in 2015 and others are in development. Real-world evaluations of dengue vaccines will therefore soon be needed. We assessed feasibility of case control (CC) and test-negative (TN) design studies for dengue vaccine effectiveness by measuring associations between socio-demographic risk factors, and hospitalized dengue outcomes, in Malaysia.
   Methods: Following ethical approval, we conducted hospital-based dengue surveillance for one year in three referral hospitals. Suspected cases aged 9-25 years underwent dengue virological confirmation by RT-PCR and/or NS1 Ag ELISA at a central laboratory. Two age- and geography-matched hospitalized non dengue case-controls were recruited for a traditional CC study. Suspected cases testing negative were test-negative controls. Socio-demographic, risk factor and routine laboratory data were collected. Logistic regression models were used to estimate associations between confirmed dengue and risk factors.
   Results: We recruited 327 subjects; 155 were suspected of dengue. The planned sample size was not met. 124 (80%) of suspected cases were dengue-confirmed; seven were assessed as severe. Three had missing RT-PCR results; the study recruited 28 test-negative controls. Only 172 matched controls could be recruited; 90 cases were matched with >= 1 controls. Characteristics of cases and controls were mostly similar. By CC design, two variables were significant risk factors for hospitalized dengue: recent household dengue contact (OR: 54, 95% CI: 7.3-397) and recent neighbourhood insecticidal fogging (OR: 2.1; 95% CI: 1.3-3.6). In the TN design, no risk factors were identified. In comparison with gold-standard diagnostics, routine tests performed poorly.
   Conclusions: The CC design may be more appropriate than the TN design for hospitalized dengue vaccine effectiveness studies. Selection bias in case control selection could be minimized by protocol changes more easily than increasing TN design control numbers, because early-stage dengue diagnosis in endemic countries is highly specific. MREC study approval: (39)KKM/NIHSEC/P16-1334. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Nealon, Joshua; Radigue, Cedric] Sanofi Pasteur Asia & JPAC Reg, 38 Beach Rd 18-11, Singapore, Singapore.
   [Lim, Wei-Yin; Lojikip, Sharon Linus; Junus, Suria; Amar-Singh, H. S. S.] Minist Hlth Malaysia, Clin Res Ctr Perak, Hosp Raja Permaisuri Bainun, Raja Ashman Shah Rd, Ipoh 30450, Perak, Malaysia.
   [Moureau, Annick; Ochiai, R. Leon] Sanofi Pasteur, Lyon, France.
   [Kumar, Suresh] Minist Hlth Malaysia, Dept Gen Med, Hosp Sungai Buloh, Hosp Rd, Sungai Buloh 47000, Selangor, Malaysia.
   [Nachiappan, Jeyaseelan P.] Minist Hlth Malaysia, Dept Paediat, Hosp Raja Permaisuri Bainun, Raja Ashman Shah Rd, Ipoh 30450, Perak, Malaysia.
   [Sekaran, Shamala Devi] MAHSA Univ, Fac Med, Dept Microbiol, Jenjarom 42610, Selangor, Malaysia.
   [Cowling, Benjamin J.] Univ Hong Kong, Sch Publ Hlth, Hong Kong, Peoples R China.
   [Lim, Wei-Yin] Minist Hlth Malaysia, Inst Clin Res, Natl Inst Hlth, Ctr Clin Epidemiol, Ipoh, Perak, Malaysia.
RP Nealon, J (reprint author), Sanofi Pasteur Asia & JPAC Reg, 38 Beach Rd 18-11, Singapore, Singapore.
EM Joshua.nealon@sanofi.com
OI Linus Lojikip, Sharon/0000-0001-8824-5464; Lim, Wei
   Yin/0000-0002-2612-0604
FU Sanofi Pasteur
FX Dr Azmillah Rosman was the site PI, responsible for subject recruitment,
   at Hospital Selayang. Study sub-investigators: Ker Hong Bee, Cheng Joo
   Thye, Arvinder Singh HS, Haema Shunmugarajo, Wan Jazilah Wan Ismail,
   Marina Md Sham, Lau Ing Soo, Lee Yoong Wah, Annie Liau Fui Vun,
   Jamaluddin Hj. Mohamed, Amita Vivehanantham, Nor Arisah Misnan,
   Sharimila a/p Shanmugam, Mohd Aizuddin Abdul Rahman. Study coordinators:
   Lina Hashim, Nur Fatin Zulaikha Kharudin, Hasni Adha Ibrahim, Nur Azwin
   Ismail, Anusha d/o T Ganesapillai, Citra d/o Palanisamy. Laboratory
   staff from the Department of Medical Microbiology, UMMC. The following
   team contributed to data collection, management and coordination: Karina
   Abalos, Emily De Jesus, Yong-Ho Oh, Saranyaporn Phrutisunakon, Celine
   Zocchetti. Jean-Sebastien Persico coordinated the publication process.
   The study was funded by Sanofi Pasteur.
CR [Anonymous], 2012, GLOB STRAT DENG PREV
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Chiu SS, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.8.18
   Diaz J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153141
   Economic Planning Unit of the Malaysian Prime Minister's office, 2016, 11 MAL PLAN 2016 202, P4
   Franke MF, 2017, VACCINE, V35, P5819, DOI 10.1016/j.vaccine.2017.09.025
   Fujii Y, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0916-7
   Fukushima W, 2017, VACCINE, V35, P4796, DOI 10.1016/j.vaccine.2017.07.003
   Gibson Gerusa, 2014, Infection Ecology & Epidemiology, V4, P22110, DOI 10.3402/iee.v4.22110
   Grimes DA, 2005, LANCET, V365, P1429, DOI 10.1016/S0140-6736(05)66379-9
   Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0
   Guzman MG, 2013, ARCH VIROL, V158, P1445, DOI 10.1007/s00705-013-1645-3
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   Hennessy S, 1996, LANCET, V347, P1583, DOI 10.1016/S0140-6736(96)91075-2
   International epidemiological association, 2007, GUID GOOD COND EP PR
   Jackson ML, 2017, NEW ENGL J MED, V377, P534, DOI [10.1056/NEJMoa1700153, 10.1056/nejmoa1700153]
   Kimiya T, 2018, EUR J PEDIATR, V177, P1009, DOI 10.1007/s00431-018-3145-7
   Mammen MP, 2008, PLOS MED, V5, P1605, DOI 10.1371/journal.pmed.0050205
   McLaughlin JM, 2018, CLIN INFECT DIS, V67, P1498, DOI 10.1093/cid/ciy312
   Mohd-Zaki AH, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003159
   NPRA Malaysia, 2017, COND REG DENG VACC U
   Pal S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113411
   Pang JX, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001641
   Plennevaux E, 2016, VACCINE, V34, P2707, DOI 10.1016/j.vaccine.2016.04.028
   Puig-Barbera J, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3378-1
   RODRIGUES L, 1990, INT J EPIDEMIOL, V19, P205, DOI 10.1093/ije/19.1.205
   Sabin vaccine institute, 2014, PRINC EV EFF DENG VA
   Saul N, 2018, VACCINE, V36, P1887, DOI 10.1016/j.vaccine.2018.02.047
   Shepard DS, 2016, LANCET INFECT DIS, V16, P935, DOI 10.1016/S1473-3099(16)00146-8
   Sullivan SG, 2016, AM J EPIDEMIOL, V184, P345, DOI 10.1093/aje/kww064
   Vannice KS, 2016, VACCINE, V34, P2934, DOI 10.1016/j.vaccine.2015.12.073
   Verani JR, 2017, VACCINE, V35, P3295, DOI 10.1016/j.vaccine.2017.04.037
   WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1019, DOI 10.1093/oxfordjournals.aje.a116396
   WHO western Pacific regional office, WPRO DENG SIT UPD 20
   Wichmann O, 2017, VACCINE, V35, P5535, DOI 10.1016/j.vaccine.2017.08.066
   World Health Organization, 2008, GUID CLIN EV DENG VA
   World Health Organization Special Programme for Research Training in Tropical Diseases World Health Organization. Department of Control of Neglected Tropical Diseases World Health Organization, 2009, DENG GUID DIAGN TREA
   World Medical Association, 2013, DECL HELS ETH PRINC
   Yong Y. K., 2007, SMJ Singapore Medical Journal, V48, P662
   Yung CF, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1662-4
NR 40
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 16
PY 2019
VL 37
IS 39
BP 5891
EP 5898
DI 10.1016/j.vaccine.2019.07.083
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IZ6EX
UT WOS:000487175700012
PM 31445770
OA Other Gold
DA 2020-05-12
ER

PT J
AU Packnet, E
   Irwin, DE
   Novy, P
   Watson, PS
   Whelan, J
   Moore-Schiltz, L
   Lucci, M
   Hogea, C
AF Packnet, Elizabeth
   Irwin, Debra E.
   Novy, Patricia
   Watson, Philip S.
   Whelan, Jane
   Moore-Schiltz, Laura
   Lucci, Matthew
   Hogea, Cosmina
TI Meningococcal-group B (MenB) vaccine series completion and adherence to
   dosing schedule in the United States: A retrospective analysis by
   vaccine and payer type
SO VACCINE
LA English
DT Article
DE Meningitis B; Completion; Compliance; Adherence; Vaccine; Retrospective
ID IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; RECOMMENDATIONS;
   ADOLESCENTS; DISEASE
AB Background: Two MenB vaccines with different dosing schedules are approved in the US: MenB-4C (2 doses) and MenB-FHbp (2-3 doses). Both vaccines were licensed on the basis of immunogenicity demonstrated after vaccine series completion. We evaluated vaccination completion and adherence to dosing schedules.
   Methods: This retrospective analysis used data from MarketScan Commercial Claims and Encounters Database (Commercial) January 1, 2015 - February 28, 2018 and Multi-State Medicaid Database (Medicaid) January 1, 2015 - December 31, 2017 to examine vaccine series completion and adherence to dosing schedule in individuals who initiated a MenB series at ages 16-23 years. Vaccine series completion and dose schedule adherence were assessed during a 15-month follow-up period after the first dose. Completion was defined as individual receipt of the recommended number of doses, with current recommendations applied retroactively to allow individuals who initiated the MenB-FHbp series to be complete with either the 2- or the 3-dose schedule.
   Results: The study population comprised 65,205 commercially-insured individuals (36,118 initiated MenB-4C; 29,087 initiated MenB-FHbp) and 13,535 Medicaid-covered individuals (10,153 initiated MenB-4C; 3382 initiated MenB-FHbp). In Commercial, 63% of individuals who initiated MenB-4C and 52% of individuals who initiated MenB-FHbp completed vaccination within 15 months; dosing schedule adherence was 62% for MenB-4C initiators and 18% for MenB-FHbp initiators. In Medicaid, 15-month completion rates for MenB-4C and MenB-FHbp initiators were 49% and 31%, respectively, with corresponding dosing schedule adherence of 48% and 8%. Among individuals who completed the series, median time to completion was 68 days for MenB-4C versus 258 days for MenB-FHbp in Commercial and 88 days for MenB-4C versus 309 days for MenB-FHbp in Medicaid.
   Conclusion: During the study period, MenB vaccine series completion was suboptimal. However, completion was significantly higher for MenB-4C, with notably shorter time to completion. This may reflect the flexible dosing schedule of MenB-4C. (C) 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.
C1 [Packnet, Elizabeth; Irwin, Debra E.; Moore-Schiltz, Laura; Lucci, Matthew] IBM Watson Hlth, 7700 Old Georgetown Rd,Suite 650, Bethesda, MD 20814 USA.
   [Novy, Patricia; Watson, Philip S.; Hogea, Cosmina] GSK, 5 Crescent Dr, Philadelphia, PA 19112 USA.
   [Whelan, Jane] GSK, Hullenbergweg 83-85, NL-1101 CL Amsterdam, Netherlands.
RP Packnet, E (reprint author), IBM Watson Hlth, 7700 Old Georgetown Rd,Suite 650, Bethesda, MD 20814 USA.
EM packnett@us.ibm.com; debirwin@us.ibm.com; patricia.l.novy@gsk.com;
   philip.s.watson@gsk.com; jane.x.whelan@gsk.com; schiltz@us.ibm.com;
   matthew.lucci@ibm.com; cosmina.s.hogea@gsk.com
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline
FX GlaxoSmithKline Biologicals SA was the funding source (GSK study
   identifier: HO -17-18203) and was involved in all stages of the study
   conduct and analysis. GlaxoSmithKline Biologicals SA also funded all
   costs associated with the development and the publishing of the present
   manuscript. All authors had full access to the data and agreed with the
   submission of the publication.
CR Baccarini C, 2013, HUM VACC IMMUNOTHER, V9, P162, DOI 10.4161/hv.22302
   Santolaya ME, 2012, LANCET, V379, P617, DOI 10.1016/S0140-6736(11)61713-3
   Folaranmi T, 2015, MMWR-MORBID MORTAL W, V64, P608
   Gallagher KE, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2845-z
   Kroger AT, 2017, GEN BEST PRACTICE GU
   Macdonald V, 2007, SEX HEALTH, V4, P27, DOI 10.1071/SH06008
   MacNeil J, 2017, CONSIDERATIONS SEROG
   MacNeil JR, 2015, MMWR-MORBID MORTAL W, V64, P1171, DOI 10.15585/mmwr.mm6441a3
   Patton ME, 2017, MMWR-MORBID MORTAL W, V66, P509, DOI 10.15585/mmwr.mm6619a6
   Viner RM, 2012, LANCET NEUROL, V11, P774, DOI 10.1016/S1474-4422(12)70180-1
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 16
PY 2019
VL 37
IS 39
BP 5899
EP 5908
DI 10.1016/j.vaccine.2019.06.065
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IZ6EX
UT WOS:000487175700013
PM 31443990
OA Other Gold
DA 2020-05-12
ER

PT J
AU Pagliusi, S
   Che, YC
   Dong, SZ
AF Pagliusi, Sonia
   Che, Yanchun
   Dong, Shaozhong
TI The art of partnerships for vaccines
SO VACCINE
LA English
DT Article
DE Public-private partnerships; Immunization; Vaccine market trends;
   Technology innovation; Developing countries
ID ROTAVIRUS VACCINE; IMMUNOGENICITY; AFRICA
AB The Developing Countries Vaccine Manufacturers Network (DCVMN) convened vaccine manufacturing experts and leaders from local and global public health organizations for its 19th Annual General Meeting. Lectures and panel discussions centered on international cooperation for better access to vaccines, and partnerships in areas ranging from vaccine research and process development, to clinical studies, regulatory, supply chain and emergency preparedness and response.
   Global vaccine market trends and changes that will impact vaccine financing and procurement methods were discussed as well as capital sources, including funding, for the development of new or improved vaccines.
   DCVMN members presented their progress in developing novel Hexavalent, Meningitis, Pneumococcal Conjugate Vaccine, Shigella, Mumps, Rotavirus, Yellow Fever, Polio, Hepatitis E and Dengue vaccines, and a novel monoclonal antibody cocktail for post-bite prophylaxis against rabies infections.
   Access to and availability of vaccines is enhanced through sharing of best practices for vaccine quality control, reducing redundant testing and promoting development of harmonized common standards. Eligible stakeholders were encouraged to join the WHO-National Control Laboratory Network for Biologicals which serves as a platform for collaboration and technical exchange in this area.
   Increasing regulatory convergence at the regional and global levels through mechanisms such as joint dossier review and the WHO Collaborative Registration Procedure can help to accelerate vaccine access globally. Additionally, four proposals for streamlining procedures and alignment of dossiers were discussed.
   Successful partnerships between a broad range of stakeholders, including international organizations, manufacturers, academic research institutes and regulators have provided support for, and in some cases accelerated, vaccine innovation, clinical trials and registration, WHO prequalification, vaccine introduction and access. Strong partnerships, based on experience and trust, help leverage opportunities and are critically important to advancing the shared goal of providing quality vaccines for all people. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Pagliusi, Sonia] DCVMN Int, Route Crassier 7, CH-1262 Eysins Nyon, Switzerland.
   [Che, Yanchun; Dong, Shaozhong] Chinese Acad Med Sci, Inst Med Biotechnol, Beijing, Peoples R China.
RP Pagliusi, S (reprint author), DCVMN Int, Route Crassier 7, CH-1262 Eysins Nyon, Switzerland.
EM s.pagliusi@dcvmn.net; cheyanchun@imbcams.com.cn; dsz@imbcams.com.cn
FU Alfa Wasserman; Applikon Biotechnology; Bausch Stroebel; Bioengineering;
   Biozeen; Bosch; GEA; GE HealthcareGE Healthcare; Gihon; IQVIA; Merck
   GroupMerck & Company; Munters; OMPI (Stevanato Group); Rommelag;
   Temptime Corporation; Univercells; Bill & Melinda Gates FoundationGates
   Foundation [OPP1153279]
FX We are grateful to all speakers and moderators whose contributions made
   the meeting possible and contributed to its success. We are particularly
   thankful to the experts who graciously served as session rapporteurs: W.
   Bakker (Intravacc), K. Balaji (PATH), Clarke Cole (CHAI), J. Li
   (IMBCAMS) and A. Ottonsen (UNICEF). We thank Ms. S. Ramirez for
   editorial assistance. We thank corporate partners for supporting DCVMN
   with unrestricted educational grants: Alfa Wasserman, Applikon
   Biotechnology, Bausch & Stroebel, Bioengineering, Biozeen, Bosch, GEA,
   GE Healthcare, Gihon, IQVIA, Merck Group, Munters, OMPI (Stevanato
   Group), Rommelag, Temptime Corporation and Univercells. This meeting was
   partly supported by a grant from the Bill & Melinda Gates Foundation,
   Grant no. OPP1153279.
CR [Anonymous], 2016, 996 WHO TRS
   [Anonymous], 2014, ANNEX 5 WHO TECHNICA, V927
   [Anonymous], 2012, WHO STANDARD OPERATI
   [Anonymous], 2014, WHO TECHN REP SER, V980
   [Anonymous], 2014, REPLACEMENT ANNEX 2, V800
   Bines JE, 2018, NEW ENGL J MED, V378, P719, DOI 10.1056/NEJMoa1706804
   Cernuschi T, 2018, VACCINE, V36, P6858, DOI 10.1016/j.vaccine.2018.06.012
   Chen WH, 2018, LANCET INFECT DIS, V18, P1088, DOI 10.1016/S1473-3099(18)30400-6
   Chilukuri SR, 2014, BIOLOGICALS, V42, P160, DOI 10.1016/j.biologicals.2013.12.001
   Cooper BS, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006807
   Dellepiane N, 2018, VACCINE, V36, P3389, DOI 10.1016/j.vaccine.2018.03.049
   European Commission, EU B
   Groome MJ, 2017, LANCET INFECT DIS, V17, P843, DOI [10.1016/S1473-3099(17)30242-6, 10.1016/s1473-3099(17)30242-6]
   Isbrucker R, 2016, Pharmeur Bio Sci Notes, V2015, P97
   Katzelnick LC, 2017, VACCINE, V35, P4659, DOI 10.1016/j.vaccine.2017.07.045
   Langar H, 2018, E MEDITERR HEALTH J, V24, P588, DOI 10.26719/2018.24.6.588
   Mohanty L, 2018, VACCINE, V36, P2378, DOI 10.1016/j.vaccine.2017.09.029
   Mustapha MM, 2018, HUM VACC IMMUNOTHER, V14, P1107, DOI 10.1080/21645515.2017.1412020
   NIBSC & WHO International Standard-Sabin Inactivated Polio Vaccine (sIPV), SAB IN POL VACC SIPV
   Precioso AR, 2015, VACCINE, V33, P7121, DOI 10.1016/j.vaccine.2015.09.105
   Sanofi Pasteur, PROD MON IMOGAM RAB
   Troeger C, 2018, LANCET INFECT DIS, V18, P1211, DOI 10.1016/S1473-3099(18)30362-1
   WHO Regulatory networks, 2018, WHO DRUG INF, V32, P189
   World Health Organization, 2017, WHO DRUG INFORM, V31, P3
NR 24
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 20
PY 2019
VL 37
IS 40
BP 5909
EP 5919
DI 10.1016/j.vaccine.2019.07.088
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA8YK
UT WOS:000488137000001
PM 31447125
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Chen, PC
   Ding, LL
   Jiang, YP
   Zeng, XY
   Deng, GH
   Shi, JZ
   Li, YB
   Liu, LL
   Zhao, YH
   Hu, YZ
   Liu, JX
   Chen, HL
AF Chen, Pucheng
   Ding, Leilei
   Jiang, Yongping
   Zeng, Xianying
   Deng, Guohua
   Shi, Jianzhong
   Li, Yanbing
   Liu, Liling
   Zhao, Yuhui
   Hu, Yuzhen
   Liu, Jinxiong
   Chen, Hualan
TI Protective efficacy in farmed ducks of a duck enteritis virus-vectored
   vaccine against H5N1, H5N6, and H5N8 avian influenza viruses
SO VACCINE
LA English
DT Article
DE Duck enteritis virus-vectored vaccine; H5 avian influenza viruses;
   Farmed ducks; Clinical trial
ID CLADE 2.3.4.4; INFECTION; NOMENCLATURE
AB Ducks play a key role in the maintenance and spread of avian influenza viruses (AIVs) in nature, and control of AIVs in ducks has important implications for AIV eradication from poultry. We previously constructed a recombinant duck enteritis virus (DEV), rDEVus78HA, that expresses the HA gene of an H5N1 AIV and showed that rDEVus78HA immunization provides complete protection against both DEV and H5N1 AIV challenge in specific-pathogen-free ducks. In this study, we performed a 60-week clinical trial and found that this rDEVus78HA vaccine can function as a bivalent vaccine in farmed ducks against lethal challenge with DEV and H5N1 virus. Moreover, we found that rDEVus78HA-vaccinated ducks were efficiently protected against challenges with recently isolated heterologous H5N6 and H5N8 viruses. Our results demonstrate that rDEVus78HA could be extremely valuable for the control of DEV and H5 AlVs in ducks. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chen, Pucheng; Ding, Leilei; Jiang, Yongping; Zeng, Xianying; Deng, Guohua; Shi, Jianzhong; Li, Yanbing; Liu, Liling; Zhao, Yuhui; Hu, Yuzhen; Liu, Jinxiong; Chen, Hualan] Chinese Acad Agr Sci, State Key Lab Vet Biotechnol, Harbin Vet Res Inst, Harbin 150069, Heilongjiang, Peoples R China.
RP Liu, JX; Chen, HL (reprint author), Harbin Vet Res Inst, 678 Haping Rd, Harbin 150069, Heilongjiang, Peoples R China.
EM liujinxiong@caas.cn; chenhualan@caas.cn
FU National Key Research and Development Program of China [2017YFD0500805];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31302064]; Harbin Applied Technology Research and
   Development Project [2013AA6BN001]
FX This work was supported by the National Key Research and Development
   Program of China (2017YFD0500805), by the National Natural Science
   Foundation of China (No. 31302064), and by the Harbin Applied Technology
   Research and Development Project (2013AA6BN001).
CR Abdel-Ghafar AN, 2008, NEW ENGL J MED, V358, P261, DOI 10.1056/NEJMra0707279
   Brown IH, 2009, INFLUENZA OTHER RESP, V3, P59, DOI 10.1111/j.1750-2659.2009.00078.x
   Chen HL, 2009, CURR TOP MICROBIOL, V333, P153, DOI 10.1007/978-3-540-92165-3_7
   Guan Y, 2009, REV SCI TECH OIE, V28, P39, DOI 10.20506/rst.28.1.1868
   HUANG Y, 1980, J S CHINA AGR COLL, V1, P21
   Li CJ, 2014, TRENDS BIOTECHNOL, V32, P147, DOI 10.1016/j.tibtech.2014.01.001
   Li M, 2019, SCI CHINA LIFE SCI, V62, P854, DOI 10.1007/s11427-019-9522-7
   Li YB, 2010, J VIROL, V84, P8389, DOI 10.1128/JVI.00413-10
   Liu JX, 2011, J VIROL, V85, P10989, DOI 10.1128/JVI.05420-11
   Nunez A, 2016, TRANSBOUND EMERG DIS, V63, P5, DOI 10.1111/tbed.12442
   Saito T, 2015, REV MED VIROL, V25, P388, DOI 10.1002/rmv.1857
   Smith GJD, 2014, INFLUENZA OTHER RESP, V8, P384, DOI 10.1111/irv.12230
   Sun HL, 2016, VET MICROBIOL, V182, P116, DOI 10.1016/j.vetmic.2015.11.001
   Tian GB, 2005, VIROLOGY, V341, P153, DOI 10.1016/j.virol.2005.07.011
   Zeng XY, 2016, AVIAN DIS, V60, P253, DOI 10.1637/11179-052015-ResNoteR
NR 15
TC 0
Z9 0
U1 3
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 20
PY 2019
VL 37
IS 40
BP 5925
EP 5929
DI 10.1016/j.vaccine.2019.08.026
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA8YK
UT WOS:000488137000004
PM 31471151
DA 2020-05-12
ER

PT J
AU Beun, AJ
   Grammens, T
   Hainaut, M
   Barlow, P
   Van den Wijngaert, S
   Delforge, M
   De Wit, S
   Dauby, N
AF Beun, Abraham J.
   Grammens, Tine
   Hainaut, Marc
   Barlow, Patricia
   Van den Wijngaert, Sigi
   Delforge, Marc
   De Wit, Stephane
   Dauby, Nicolas
TI High rate of rubella seronegativity in perinatally-infected HIV women of
   childbearing age: A case-control study
SO VACCINE
LA English
DT Article
DE Rubella vaccine; Vertical transmission; Seroprevalence; Vaccine; HIV
ID ANTIRETROVIRAL THERAPY; CHILDREN; MEASLES; VACCINATION; MUMPS;
   REVACCINATION; ADOLESCENTS; RESPONSES
AB Rubella infection is a vaccine preventable disease. Maternal infection during pregnancy may lead to congenital infection and severe foetal malformations. Thanks to antiretroviral therapy, perinatally HIV-infected women have better prognosis and are now experiencing pregnancy. We evaluated the rate of rubella seronegativity in a cohort of HIV perinatally-infected women of childbearing age. A high rate of seronegativity was found in this group as compared to age-matched non-perinatally infected HIV infected women (34.5% vs 6.90%, p < 0.01). MMR administration before rubella testing was identified in 75.8% of perinatally-infected women (22/29) with a mean of 2 doses (range: 1-3 doses). HIV perinatally-infected women of childbearing age should be screened repeatedly for rubella immunity. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Beun, Abraham J.; Delforge, Marc; De Wit, Stephane; Dauby, Nicolas] ULB, Ctr Hosp Univ St Pierre, Dept Infect Dis, Brussels, Belgium.
   [Grammens, Tine] Sciensano, Epidemiol Infect Dis, Brussels, Belgium.
   [Hainaut, Marc] ULB, Ctr Hosp Univ St Pierre, Dept Paediat, Brussels, Belgium.
   [Barlow, Patricia] ULB, Ctr Hosp Univ St Pierre, Dept Obstet Gynecol, Brussels, Belgium.
   [Van den Wijngaert, Sigi] ULB, LHUB, Microbiol, Brussels, Belgium.
   [Dauby, Nicolas] ULB, Ctr Environm Hlth & Occupat Hlth, Sch Publ Hlth, Brussels, Belgium.
   [Dauby, Nicolas] ULB, Inst Med Immunol, Brussels, Belgium.
RP Dauby, N (reprint author), ULB, Ctr Hosp Univ St Pierre, Dept Infect Dis, Brussels, Belgium.; Dauby, N (reprint author), ULB, Ctr Environm Hlth & Occupat Hlth, Sch Publ Hlth, Brussels, Belgium.; Dauby, N (reprint author), ULB, Inst Med Immunol, Brussels, Belgium.
RI Dauby, Nicolas/F-1235-2011
OI Dauby, Nicolas/0000-0002-7697-6849
CR Adland E, 2018, AIDS, V32, P1413, DOI [10.1097/QAD.0000000000001844, 10.1097/qad.0000000000001844]
   Aurpibul L, 2010, CLIN INFECT DIS, V50, P1415, DOI 10.1086/652150
   Cruz MLS, 2010, AIDS, V24, P2727, DOI 10.1097/QAD.0b013e32833e50d4
   Dauby N, 2018, HIV MED, V19, P426, DOI 10.1111/hiv.12610
   Geretti AM, 2016, HIV MED, V17, pS2, DOI 10.1111/hiv.12424
   Grahmeier-Pfistershammer K, 2014, VACCINE, V32, P6020, DOI 10.1016/j.vaccine.2014.07.114
   Kerneis S, 2014, CLIN INFECT DIS, V58, P1130, DOI 10.1093/cid/cit937
   Menson EN, 2012, HIV MED, V13, P333, DOI 10.1111/j.1468-1293.2011.00982.x
   Mirambo MM, 2015, BMC RES NOTES, V8, DOI [10.1186/S13104-015-1711-x, DOI 10.1186/S13104-0151711-X]
   Newman LP, 2017, PEDIATR INFECT DIS J, V36, P1148, DOI 10.1097/INF.0000000000001572
   Pandolfi E, 2017, EUR J PUBLIC HEALTH, V27, P530, DOI 10.1093/eurpub/ckw259
   Rakhmanina N, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20936
   Reef SE, 2018, PLOTKINS VACCINES, P970
   Sadlier C, 2016, J INFECTION, V73, P84, DOI 10.1016/j.jinf.2016.04.013
   Schwarze-Zander C, 2017, EPIDEMIOL INFECT, V145, P236, DOI 10.1017/S095026881600217X
   Scott P, 2011, J INFECT DIS, V204, pS164, DOI 10.1093/infdis/jir071
   Slogrove AL, 2018, CURR OPIN HIV AIDS, V13, P170, DOI [10.1097/COH.0000000000000449, 10.1097/coh.0000000000000449]
   Succi RCM, 2018, PEDIATR INFECT DIS J, V37, P304, DOI 10.1097/INF.0000000000001831
   WHO, 2014, EL MEASL RUB FRAM VE
   Xu HB, 2018, J IMMUNOL, V201, P1994, DOI 10.4049/jimmunol.1800235
NR 20
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 20
PY 2019
VL 37
IS 40
BP 5930
EP 5933
DI 10.1016/j.vaccine.2019.08.034
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA8YK
UT WOS:000488137000005
PM 31451323
OA Green Published
DA 2020-05-12
ER

PT J
AU Niccolai, LM
   Yakely, AE
   Hansen, CE
AF Niccolai, Linda M.
   Yakely, Anthony E.
   Hansen, Caitlin E.
TI Up-to-date coverage with meningococcal vaccine among adolescents age 17
   years: Patterns and correlates in the United States, 2017
SO VACCINE
LA English
DT Article
DE Vaccination; Adolescent; Meningococcal vaccine; National Immunization
   Survey - Teen
ID HUMAN-PAPILLOMAVIRUS VACCINATION; BARRIERS
AB Limited research has explored reasons for low up-to-date coverage with meningococcal vaccine (UTD MenACWY) among adolescents at age 17 years. This analysis used National Immunization Survey-Teen data from 2017 to examine patterns of UTD MenACWY coverage. Correlates of higher UTD MenACWY coverage included black race and Hispanic ethnicity, residing in Northeast census region, recent health care visits, and receipt of recommendation for HPV vaccine. Median UTD MenACWY coverage was significantly higher in states with 1 and 2-dose requirements for school entry compared to no requirement; exemption policies were not associated. Approximately 13% of adolescents had a missed opportunity for UTD MenACWY. Future research should examine barriers to coverage at the patient, parent, provider and structural (clinic, social, policy) levels so that programs and interventions can be designed and implemented to increase coverage. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Niccolai, Linda M.; Yakely, Anthony E.] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, 60 Coll St, New Haven, CT 06520 USA.
   [Hansen, Caitlin E.] Yale Sch Med, Dept Pediat, POB 208064, New Haven, CT 06520 USA.
RP Niccolai, LM (reprint author), Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, 60 Coll St, New Haven, CT 06520 USA.
EM linda.niccolai@yale.edu
CR Adams SH, 2015, AM J PREV MED, V49, P238, DOI 10.1016/j.amepre.2015.02.022
   Bednarczyk RA, 2019, J INFECT DIS
   Brewer NT, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-1764
   Centers for disease control and prevention, 2013, MORB MORT WEEKLY REV, pRR62
   Centers for Disease Control and Prevention, 2018, NAT IMM SURV TEEN US
   Centers for Disease Control and Prevention Office for State Tribal Local and Territorial Support, STAT SCH IMM REQ VAC
   Cohn A, 2015, INFECT DIS CLIN N AM, V29, P667, DOI 10.1016/j.idc.2015.08.002
   Ferrer HB, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-700
   Holman DM, 2014, JAMA PEDIATR, V168, P76, DOI 10.1001/jamapediatrics.2013.2752
   Immunization Action Coalition, STAT INF STAT MAND I
   Kharbanda EO, 2010, AM J PUBLIC HEALTH, V100, P1635, DOI 10.2105/AJPH.2009.179341
   MacNeil JR, 2018, CLIN INFECT DIS, V66, P1276, DOI 10.1093/cid/cix993
   Moss JL, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-1414
   Newman PA, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019206
   Niccolai LM, 2015, JAMA PEDIATR, V169, P686, DOI 10.1001/jamapediatrics.2015.0310
   Omer SB, 2006, JAMA-J AM MED ASSOC, V296, P1757, DOI 10.1001/jama.296.14.1757
   Omer SB, 2018, OPEN FORUM INFECT DI, DOI [10.1093/ofid/oxf244, DOI 10.1093/OFID/OXF244]
   Rambout L, 2014, PREV MED, V58, P22, DOI 10.1016/j.ypmed.2013.10.009
   Walker TY, 2018, MMWR-MORBID MORTAL W, V67, P909, DOI 10.15585/mmwr.mm6733a1
   Webb NS, 2018, PUBLIC HEALTH REP, V133, P667, DOI 10.1177/0033354918805720
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 20
PY 2019
VL 37
IS 40
BP 5934
EP 5938
DI 10.1016/j.vaccine.2019.08.015
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA8YK
UT WOS:000488137000006
PM 31473004
DA 2020-05-12
ER

PT J
AU Poudel, A
   Lau, ETL
   Deldot, M
   Campbell, C
   Waite, NM
   Nissen, LM
AF Poudel, Arjun
   Lau, Esther T. L.
   Deldot, Megan
   Campbell, Chris
   Waite, Nancy M.
   Nissen, Lisa M.
TI Pharmacist role in vaccination: Evidence and challenges
SO VACCINE
LA English
DT Review
DE Barriers; Challenges; Vaccination; Pharmacist; Uptake; Vaccination
ID INFLUENZA VACCINE; COMMUNITY PHARMACY; IMMUNIZATION; IMPACT; HESITANCY;
   IMMUNIZERS; CHILDREN; REFUSAL; PROGRAM; ACCESS
AB Vaccines prevent an estimated 2.5 million deaths worldwide each year and are amongst the most cost-effective preventive measures against infectious diseases. Despite the effectiveness and availability of vaccines in many parts of the world, vaccination rates and service uptake remains suboptimal among both healthcare providers and the public. Pharmacists as established advocates, educators as well as qualified providers of vaccinations have a significant role to play in promoting and supporting the uptake of vaccination. Challenges and barriers to pharmacist vaccination are multifactorial, which needs effective strategies to address. Overcoming these barriers will increase the role of pharmacists as vaccinators that ultimately increases public access to vaccination and accurate and reliable information about vaccines. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Poudel, Arjun; Lau, Esther T. L.; Nissen, Lisa M.] Queensland Univ Technol, Sch Clin Sci, Fac Hlth, Q Block Level 9, Brisbane, Qld 4000, Australia.
   [Deldot, Megan] Queensland Univ Technol, Fac Hlth, Brisbane, Qld 4000, Australia.
   [Campbell, Chris] Terry White Chemmart Grp, Brisbane, Qld, Australia.
   [Waite, Nancy M.] Univ Waterloo, Sch Pharm, Kitchener, ON N2G 1C5, Canada.
RP Poudel, A (reprint author), Queensland Univ Technol, Sch Clin Sci, Fac Hlth, Q Block Level 9, Brisbane, Qld 4000, Australia.
EM a3.poudel@qut.edu.au; et.lau@qut.edu.au; m.deldot@qut.edu.au;
   chris.campbell@twcmhealth.com.au; nmwaite@uwaterloo.ca;
   l.nissen@qut.edu.au
RI Nissen, Lisa/N-9476-2019; Poudel, Arjun/B-9883-2014
OI Nissen, Lisa/0000-0001-5826-4605; Poudel, Arjun/0000-0003-3601-4650;
   Waite, Nancy/0000-0003-3440-9843
CR A. P. A. American Pharmacist Association, 2013, ANN PHARM BAS INFL A
   Anderson C, 2016, INT J CLIN PHARM-NET, V38, P218, DOI 10.1007/s11096-016-0255-z
   Anderson C, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-35
   [Anonymous], 2016, NHS ENGL REC FLU VAC
   [Anonymous], PHARM VACC
   Atkins K, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009739
   Bach AT, 2015, INTEGR PHARM RES PRA, V4, P67, DOI 10.2147/IPRP.S63822
   Buchan SA, 2017, CAN MED ASSOC J, V189, pE146, DOI 10.1503/cmaj.151027
   Burson RC, 2016, HUM VACC IMMUNOTHER, V12, P3146, DOI 10.1080/21645515.2016.1215393
   Burt S, 2018, INT J CLIN PHARM-NET, V40, P1519, DOI 10.1007/s11096-018-0738-1
   Camilleri SA, 2018, MULTIDISCIP RESP MED, V13, DOI 10.1186/s40248-018-0135-6
   Clements CJ, 2000, LANCET, V355, P1279, DOI 10.1016/S0140-6736(05)74714-0
   Clift K, 2014, JAAPA-J AM ACAD PHYS, V27, P21, DOI 10.1097/01.JAA.0000451873.94189.56
   Deshpande M, 2003, J AM PHARM ASSOC, V2013, P488
   Doherty M, 2016, VACCINE, V34, P6707, DOI 10.1016/j.vaccine.2016.10.025
   Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212
   Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657
   Esposito S, 2014, CLIN MICROBIOL INFEC, V20, P25, DOI 10.1111/1469-0691.12447
   Favin M, 2012, INT HEALTH, V4, P229, DOI 10.1016/j.inhe.2012.07.004
   Fitzgerald TJ, 2016, VACCINE, V34, P5643, DOI 10.1016/j.vaccine.2016.09.020
   Francis MHA, 2010, VACCINATION SERVICES
   Glanz JM, 2010, ARCH PEDIAT ADOL MED, V164, P66, DOI 10.1001/archpediatrics.2009.244
   Glatman-Freedman Aharona, 2012, Hum Vaccin Immunother, V8, P293, DOI 10.4161/hv.19003
   Goodyear-Smith F, 2009, HUM VACCINES, V5, P403, DOI 10.4161/hv.5.6.8356
   GRABENSTEIN JD, 1992, MED CARE, V30, P503, DOI 10.1097/00005650-199206000-00004
   Grabenstein JD, 2003, J AM PHARM ASSOC, V2009, P628
   Haggan M., 2018, AUST J PHARM
   Hartzell V., 2017, PHARM TIMES
   Hattingh HL, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011948
   Hava C., 2019, AUSTR PHARM     0528
   Henderson KC, 2011, AIDS PATIENT CARE ST, V25, P221, DOI 10.1089/apc.2010.0324
   Hendriksz T., 2013, ADA HLTH WATCH NEW E, V8, P9
   Hogue MD, 2006, J AM PHARM ASSOC, V46, P168, DOI 10.1331/154434506776180621
   Houle SKD, 2019, CAN PHARM J, V152, P92, DOI 10.1177/1715163518811065
   Houle SKD, 2018, TRAVEL MED INFECT DI, V23, P21, DOI 10.1016/j.tmaid.2018.02.011
   Houle SKD, 2017, CAN J PUBLIC HEALTH, V108, pE418, DOI [10.17269/cjph.108.6119, 10.17269/CJPH.108.6119]
   Hussain A, 2018, CUREUS, V10
   International Pharmaceutical Federation (FIP), 2016, OV CURR PHARM IMP IM
   Isenor JE, 2016, VACCINE, V34, P5708, DOI 10.1016/j.vaccine.2016.08.085
   Isenor JE, 2018, HUM VACC IMMUNOTHER, V14, P706, DOI 10.1080/21645515.2018.1423930
   Isenor Jennifer E, 2016, J Pharm Policy Pract, V9, P32
   Jones L, 2010, PREV MED, V50, P148, DOI 10.1016/j.ypmed.2009.12.001
   Kennedy A, 2011, PEDIATRICS
   Koppaka Ram, 2011, Morbidity and Mortality Weekly Report, V60, P814
   Lai E, 2013, UNIVERS J PUBLIC HLT, V1, P79
   Lau ETL, 2017, CAN J HOSP PHARM, V70, P281
   Lee C, 2018, NEW ZEAL MED J, V131, P60
   MacDougall D, 2016, HUM VACC IMMUNOTHER, V12, P623, DOI 10.1080/21645515.2015.1093714
   Marra Fawziah, 2014, Can Pharm J (Ott), V147, P33, DOI 10.1177/1715163513514020
   Morgado M, 2011, INT J CLIN PHARM-NET, V33, P132, DOI 10.1007/s11096-010-9474-x
   Nissen L, 2015, QUEENSLAND PHARM IMM
   NISSEN LM, 2016, J PHARM PRACT RES, V46, P310, DOI DOI 10.1002/jppr.1295
   O'Reilly DJ, 2018, CLINICOECONOMIC OUTC, V10, P655, DOI 10.2147/CEOR.S167500
   Ontario College of Pharmacists, 2012, PHARM CONNECTION, V19, P12
   Papastergiou John, 2014, Can Pharm J (Ott), V147, P359, DOI 10.1177/1715163514552557
   Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042
   Poulose S, 2015, CAN PHARM J, V148, P64, DOI 10.1177/1715163515569344
   Rhodes LA, 2017, INT J HEALTH GOV, V22, P167, DOI 10.1108/IJHG-05-2017-0020
   Rothholz MC., 2003, J AM PHARM ASSOC, V2011, P704
   Schwerzmann J, 2017, DISASTER MED PUBLIC, V11, P587, DOI 10.1017/dmp.2017.1
   Shah PD, 2018, CANCER EPIDEM BIOMAR, V27, P970, DOI 10.1158/1055-9965.EPI-18-0380
   Smith J, 2011, LANCET, V378, P428, DOI 10.1016/S0140-6736(11)60478-9
   Steyer TE, 2004, VACCINE, V22, P1001, DOI 10.1016/j.vaccine.2003.08.045
   Taitel M, 2011, VACCINE, V29, P8073, DOI 10.1016/j.vaccine.2011.08.051
   Terrie Y., 2010, PHARM TIMES, V15
   Vaccination services, PHARM GUILD AUSTR
   Wakefield AJ, 1998, RETRACTED ILEAL LYMP
   Wong CA, 2013, J ADOLESCENT HEALTH, V53, P492, DOI 10.1016/j.jadohealth.2013.05.009
   World Health Organization, 2013, GLOB VACC ACT PLAN 2
NR 69
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 20
PY 2019
VL 37
IS 40
BP 5939
EP 5945
DI 10.1016/j.vaccine.2019.08.060
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA8YK
UT WOS:000488137000007
PM 31474520
DA 2020-05-12
ER

PT J
AU Cook, E
   Russell, G
   Grant, D
   Mutisya, C
   Omoto, L
   Dobson, E
   Lankester, F
   Nene, V
AF Cook, Elizabeth
   Russell, George
   Grant, Dawn
   Mutisya, Christine
   Omoto, Lazarus
   Dobson, Elizabeth
   Lankester, Felix
   Nene, Vishvanath
TI A randomised vaccine field trial in Kenya demonstrates protection
   against wildebeest-associated malignant catarrhal fever in cattle
SO VACCINE
LA English
DT Article
DE Alcelaphine herpesvirus I; Malignant catarrhal fever; Wildebeest;
   Vaccine field trial; Vaccine efficacy
ID DAIRY-CATTLE; IMMUNIZATION; HERPESVIRUS; VIRUS; PERSPECTIVES;
   INFECTIONS; EFFICACY; ASSAY
AB Wildebeest-associated malignant catarrhal fever (WA-MCF), a fatal disease of cattle caused by alcelaphine herpesvirus 1 (AIHV-1), is one of the most important seasonal diseases of cattle in wildebeest endemic areas, with annual incidence reaching 10%. Here we report efficacy of over 80% for a vaccine based on the attenuated AIHV-1 C500 strain, in preventing fatal WA-MCF in cattle exposed to natural wildebeest challenge. The study was conducted at Kapiti Plains Ranch Ltd, south-east of Nairobi, Kenya. In 2016, 146 cattle were selected for a randomised placebo-controlled trial. Cattle were stratified according to breed and age and randomly assigned to groups given vaccine or culture medium mixed with Emulsigee (R). Cattle received prime and boost inoculations one month apart and few adverse reactions (n = 4) were observed. Indirect ELISA demonstrated that all cattle in the vaccine group developed a serological response to AIHV-1. The study herd was grazed with wildebeest from one month after booster vaccination. Three cattle, two that received vaccine and one control, succumbed to conditions unrelated to WA-MCF before the study ended. Twenty-five cattle succumbed to WA-MCF; four of the remaining 71 cattle in the vaccine group (5.6%) and 21 of the remaining 72 control cattle (29.2%; chi(2) =13.6, df = 1, p < 0.001). All of the WA-MCF affected cattle were confirmed by PCR to be infected with AlHV-1 and in 23 cases exhibited histopathology typical of WA-MCF. Vaccine efficacy was determined to be 80.6% (95% CI 46.5-93.0%). Hence, the AlHV-1 C500 vaccine is a safe and potentially effective novel method for controlling WA-MCF in cattle. The implementation of this vaccine may have significant impacts on marginalised cattle keeping communities. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Cook, Elizabeth; Mutisya, Christine; Omoto, Lazarus; Nene, Vishvanath] Int Livestock Res Inst, POB 30709, Nairobi 00100, Kenya.
   [Russell, George; Grant, Dawn] Moredun Res Inst, Edinburgh EH26 0PZ, Midlothian, Scotland.
   [Dobson, Elizabeth] Dobson Pathol, Elsternwick 3185, Australia.
   [Lankester, Felix] Washington State Univ, Paul G Allen Sch Global Anim Hlth, Pullman, WA 99164 USA.
   [Lankester, Felix] Global Anim Hlth Tanzania, Arusha, Tanzania.
RP Cook, E (reprint author), Int Livestock Res Inst, POB 30709, Nairobi 00100, Kenya.
EM e.cook@cgiar.org
RI Cook, Elizabeth/L-1479-2019
OI Cook, Elizabeth/0000-0001-6081-8363
FU Directorate of the International Livestock Research Institute (ILRI);
   Global Alliance for Livestock Veterinary Medicines (GALVmed); Scottish
   Government Rural and Environment Science and Analytical Services
   Division (RESAS); CGIAR Trust Fund
FX The research was carried out under the CGIAR Research Program on
   Livestock, which is supported by CGIAR Trust Fund Donors
   https://www.cgiar.org/funders/.Additional financial support was received
   from the Directorate of the International Livestock Research Institute
   (ILRI) and the Global Alliance for Livestock Veterinary Medicines
   (GALVmed); and the Scottish Government Rural and Environment Science and
   Analytical Services Division (RESAS) through their Strategic Research
   Programme.
CR Bedelian C, 2007, PREV VET MED, V78, P296, DOI 10.1016/j.prevetmed.2006.10.012
   Carpenter TE, 2001, AM J VET RES, V62, P1582, DOI 10.2460/ajvr.2001.62.1582
   Cleaveland S, 2001, ASSESSING IMPACT MAL
   Collins JK, 2000, J VET DIAGN INVEST, V12, P406, DOI 10.1177/104063870001200503
   Haig DM, 2008, VACCINE, V26, P4461, DOI 10.1016/j.vaccine.2008.06.056
   HIGHTOWER AW, 1988, B WORLD HEALTH ORGAN, V66, P99
   IUCN, 2016, IUCN RED LIST THREAT, V2016, DOI [10.2305/IUCN.UK.2016-2.RLTS.T5229A50185086.en, DOI 10.2305/IUCN.UK.2016-2.RLTS.T5229A50185086.EN]
   Lankester F, 2016, REV SCI TECH OIE, V35, P473, DOI 10.20506/rst.35.2.2536
   Lankester F, 2016, VACCINE, V34, P831, DOI 10.1016/j.vaccine.2015.12.009
   Lankester F, 2016, VET MICROBIOL, V195, P144, DOI 10.1016/j.vetmic.2016.09.019
   Lankester F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116059
   Li H, 1996, J WILDLIFE DIS, V32, P437, DOI 10.7589/0090-3558-32.3.437
   Li H, 2011, INT J MOL SCI, V12, P6881, DOI 10.3390/ijms12106881
   LIGGITT HD, 1980, VET PATHOL, V17, P58, DOI 10.1177/030098588001700107
   MUSHI EZ, 1980, RES VET SCI, V29, P168, DOI 10.1016/S0034-5288(18)32659-6
   Orono SA, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-1818-8
   OTOOLE D, 1995, J VET DIAGN INVEST, V7, P108, DOI 10.1177/104063879500700118
   Parameswaran N, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-59
   PLOWRIGHT W, 1960, NATURE, V188, P1167, DOI 10.1038/1881167a0
   PLOWRIGHT W, 1975, RES VET SCI, V19, P159, DOI 10.1016/S0034-5288(18)33526-4
   Powers JG, 2005, JAVMA-J AM VET MED A, V227, P606, DOI 10.2460/javma.2005.227.606
   Quinn PJ, 2011, VET MICROBIOLOGY MIC, P1479
   Russell GC, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-51
   Russell GC, 2009, VET J, V179, P324, DOI 10.1016/j.tvjl.2007.11.007
   Taus NS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145073
   Traul DL, 2007, ANIM GENET, V38, P141, DOI 10.1111/j.1365-2052.2007.01575.x
   Traul DL, 2005, J VIROL METHODS, V129, P186, DOI 10.1016/j.jviromet.2005.05.021
   Wambua L, 2016, ARCH VIROL, V161, P1, DOI 10.1007/s00705-015-2617-6
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 20
PY 2019
VL 37
IS 40
BP 5946
EP 5953
DI 10.1016/j.vaccine.2019.08.040
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA8YK
UT WOS:000488137000008
PM 31473000
OA Other Gold
DA 2020-05-12
ER

PT J
AU Nguyen, TT
   Choi, JA
   Kim, JS
   Park, H
   Yang, E
   Lee, WJ
   Baek, SK
   Song, M
   Park, JH
AF Thuy Trang Nguyen
   Choi, Jung-ah
   Kim, Ji Seok
   Park, Hayan
   Yang, Eunji
   Lee, Won Jun
   Baek, Seung-Ki
   Song, Manki
   Park, Jung-Hwan
TI Skin immunization with third-generation hepatitis B surface antigen
   using microneedles
SO VACCINE
LA English
DT Article
DE Skin immunization; Third-generation hepatitis B surface antigen;
   (L-HBsAg); Microneedles; Adjuvant
ID INFLUENZA VACCINE; IMMUNE-RESPONSE; PROTECTIVE EFFICACY; VIRUS;
   STABILITY; DNA; IMMUNOGENICITY; STABILIZATION; FORMULATION; MECHANISMS
AB L-HBsAg is a third-generation hepatitis vaccine capable of inducing antibodies in non-responders and thus providing potentially therapeutic treatment. In this study, L-HBsAg was administered using micro needles (MN) without an adjuvant to induce intradermal (ID) immunization, and the efficacy of ID immunization was compared with that of intramuscular (IM) immunization that uses a conventional formulation with an adjuvant of aluminum hydroxide (L-HBsAg-AL-IM).
   The L-HBsAg was dip-coated onto 800-mu m-long microneedles made of polylactic acid (PLA). Delivery efficiency and administration time were determined through in vitro experiments using porcine skin. The denaturation of the formulation against sterilization by gamma rays was observed. A storage test and a freeze-thaw cycle test of the microneedles with trehalose as a stabilizer (L-HBsAg-MN-Tre) were observed. An antibody titer of L-HBsAg-MN-Tre was compared with that of the conventional IM immunization of the L-HBsAg solution with aluminum hydroxide (L-HBsAg-AL-IM).
   The formulation containing L-HBsAg was located on the upper third of the microneedle tips. The formulation on the MN was dissolved and delivered within 30 min of insertion into porcine skin in vitro. Trehalose was selected as a stabilizer, and the stabilizing effect increased with the increase of trehalose content in the solidified formulation. L-HBsAg-MN with 15% of trehalose was stable for 7 days at 40 degrees C and showed increased stability compared to the conventional liquid formulations. L-HBsAg-MN-Tre showed improved stability during the freeze-thaw cycle. The antibody titer of L-HBsAg-MN-Tre at 28 days was higher than that of L-HBsAg-AL-IM.
   ID administration of L-HBsAg-MN-Tre showed better efficacy and improved thermal and freeze thaw stability compared to L-HBsAg-AL-IM. Therefore, L-HBsAg-MN-Tre administration showed the possibility of ID delivery of L-HBsAg without the use of an adjuvant for the efficacy, convenience, and safety of pediatric vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Thuy Trang Nguyen; Kim, Ji Seok; Lee, Won Jun; Park, Jung-Hwan] Gachon Univ, Dept BioNano Technol, Gachon BioNano Res Inst, Seongnam, South Korea.
   [Choi, Jung-ah; Park, Hayan; Yang, Eunji; Song, Manki] Int Vaccine Inst, Dept Sci, Seoul, South Korea.
   [Baek, Seung-Ki] QuadMed Co Ltd, QuadMed R&D Ctr, Seongnam, South Korea.
RP Park, JH (reprint author), Gachon Univ, Dept BioNano Technol, Gachon BioNano Res Inst, Seongnam, South Korea.; Song, M (reprint author), Int Vaccine Inst, Dept Sci, Seoul, South Korea.
EM mksong@ivi.int; pa90201@gachon.ac.kr
FU Korea Ministry of Trade, Industry & Energy, South Korea (MOTIE)
   [10067809]; Korea Ministry of Health and Welfare, South Korea (MoHW)
   [HI15C2971]
FX This work was funded by grants from Korea Ministry of Trade, Industry &
   Energy, South Korea (MOTIE, 10067809 (Industrial Strategic Technology
   Development Program)) and Korea Ministry of Health and Welfare, South
   Korea (MoHW, HI15C2971 (Technology Development Program of Responding to
   Infectious Disease)). We appreciate CHA Vaccine Institute to provide
   L-HBsAg.
CR ALPER CA, 1989, NEW ENGL J MED, V321, P708, DOI 10.1056/NEJM198909143211103
   Boros CA, 2001, VACCINE, V19, P3537, DOI 10.1016/S0264-410X(01)00063-9
   Chen DS, 2009, J HEPATOL, V50, P805, DOI 10.1016/j.jhep.2009.01.002
   Choi HJ, 2012, BIOMATERIALS, V33, P3756, DOI 10.1016/j.biomaterials.2012.01.054
   Chu LY, 2016, PHARM RES-DORDR, V33, P868, DOI 10.1007/s11095-015-1833-9
   Clayton K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01676
   COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2
   CROWE JH, 1987, BIOCHEM J, V242, P1, DOI 10.1042/bj2420001
   Cuevas MBP, 2018, BIOENG TRANSL MED, V3, P186, DOI 10.1002/btm2.10098
   Dhillon S, 2012, DIGEST DIS SCI, V57, P215, DOI 10.1007/s10620-011-1996-0
   Dimayuga R, 1995, Can Commun Dis Rep, V21, P101
   Diminsky D, 1999, VACCINE, V18, P3, DOI 10.1016/S0264-410X(99)00149-8
   Fabrizi F, 2011, J VIRAL HEPATITIS, V18, P730, DOI 10.1111/j.1365-2893.2010.01354.x
   Fernando GJP, 2016, J CONTROL RELEASE, V237, P35, DOI 10.1016/j.jconrel.2016.06.045
   Gilliet M, 2008, NAT REV IMMUNOL, V8, P594, DOI 10.1038/nri2358
   Guo L, 2013, BIOMED MICRODEVICES, V15, P1077, DOI 10.1007/s10544-013-9799-z
   Henderson EA, 2000, INFECT CONT HOSP EP, V21, P264, DOI 10.1086/501756
   Hirschberg HJHB, 2010, J CONTROL RELEASE, V147, P211, DOI 10.1016/j.jconrel.2010.06.028
   ITOH Y, 1986, P NATL ACAD SCI USA, V83, P9174, DOI 10.1073/pnas.83.23.9174
   Kamath GR, 2014, VACCINE, V32, P2265, DOI 10.1016/j.vaccine.2014.02.072
   Kim B, 2018, KOREAN J INTERN MED, V33, P483, DOI 10.3904/kjim.2016.227
   Kim YC, 2010, AAPS PHARMSCITECH, V11, P1193, DOI 10.1208/s12249-010-9471-3
   Kim YC, 2010, J CONTROL RELEASE, V142, P187, DOI 10.1016/j.jconrel.2009.10.013
   Koutsonanos DG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004773
   Kubba A K, 2003, Commun Dis Public Health, V6, P106
   Kupper TS, 2004, NAT REV IMMUNOL, V4, P211, DOI 10.1038/nri1310
   Lee HS, 2017, PHARM RES-DORDR, V34, P101, DOI 10.1007/s11095-016-2042-x
   Leonardi S, 2012, WORLD J GASTROENTERO, V18, P5729, DOI 10.3748/wjg.v18.i40.5729
   Levin C, 2015, HUM VACC IMMUNOTHER, V11, P27, DOI 10.4161/hv.34299
   MCALEER WJ, 1984, NATURE, V307, P178, DOI 10.1038/307178a0
   McCrudden MTC, 2015, DRUG DELIV TRANSL RE, V5, P3, DOI 10.1007/s13346-014-0211-1
   Mistilis MJ, 2017, DRUG DELIV TRANSL RE, V7, P195, DOI 10.1007/s13346-016-0282-2
   Ono A, 2017, INT J PHARMACEUT, V532, P374, DOI 10.1016/j.ijpharm.2017.08.110
   Pasparakis M, 2014, NAT REV IMMUNOL, V14, P289, DOI 10.1038/nri3646
   Pearton M, 2013, ADV HEALTHC MATER, V2, P1401, DOI 10.1002/adhm.201300006
   Poirier D, 2017, BIOMATERIALS, V145, P256, DOI 10.1016/j.biomaterials.2017.08.038
   Pollicino T, 2014, J HEPATOL, V61, P408, DOI 10.1016/j.jhep.2014.04.041
   Quan FS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007152
   Rodgers AM, 2018, INT J PHARMACEUT, V549, P87, DOI 10.1016/j.ijpharm.2018.07.049
   Schipper P, 2017, J CONTROL RELEASE, V262, P28, DOI 10.1016/j.jconrel.2017.07.017
   Seok H, 2017, J CONTROL RELEASE, V265, P66, DOI 10.1016/j.jconrel.2017.04.027
   SHOUVAL D, 1994, VACCINE, V12, P1453, DOI 10.1016/0264-410X(94)90155-4
   Shouval D, 2015, MED MICROBIOL IMMUN, V204, P57, DOI 10.1007/s00430-014-0374-x
   SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127
   SZMUNESS W, 1980, NEW ENGL J MED, V303, P833, DOI 10.1056/NEJM198010093031501
   Yang HW, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201600750
   Yum JS, 2012, CLIN VACCINE IMMUNOL, V19, P120, DOI 10.1128/CVI.05355-11
   Zanetti AR, 2008, VACCINE, V26, P6266, DOI 10.1016/j.vaccine.2008.09.056
   Zuckerman JN, 2006, J MED VIROL, V78, P169, DOI 10.1002/jmv.20524
NR 49
TC 0
Z9 0
U1 2
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 20
PY 2019
VL 37
IS 40
BP 5954
EP 5961
DI 10.1016/j.vaccine.2019.08.036
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA8YK
UT WOS:000488137000009
PM 31466705
DA 2020-05-12
ER

PT J
AU Hankaniemi, MM
   Stone, VM
   Sioofy-Khojine, AB
   Heinimaki, S
   Marjomaki, V
   Hyoty, H
   Blazevic, V
   Laitinen, IH
   Flodstrom-Tullberg, M
   Hytonen, VP
AF Hankaniemi, Minna M.
   Stone, Virginia M.
   Sioofy-Khojine, Amir-Babak
   Heinimaki, Suvi
   Marjomaki, Varpu
   Hyoty, Heikki
   Blazevic, Vesna
   Laitinen, I. H.
   Flodstrom-Tullberg, Malin
   Hytonen, Vesa P.
TI A comparative study of the effect of UV and formalin inactivation on the
   stability and immunogenicity of a Coxsackievirus B1 vaccine
SO VACCINE
LA English
DT Article
DE Coxsackievirus B; Inactivated vaccine; Formalin; UV
ID INDUCED CROSS-LINKING; ENTEROVIRUS 71; POLIOVIRUS; INFECTIONS;
   MYOCARDITIS; RESPONSES
AB Type B Coxsackieviruses (CVBs) belong to the enterovirus genus, and they cause both acute and chronic diseases in humans. CVB infections usually lead to flu-like symptoms but can also result in more serious diseases such as myocarditis, aseptic meningitis and life-threatening multi-organ infections in young infants. Thus, CVBs have long been considered as important targets of future vaccines.
   We have previously observed CVB1 capsid disintegration and virus concentration decrease with 12-day long formalin inactivation protocol. Here a scalable ion exchange chromatography purification method was developed, and purified CVB1 was inactivated with UV-C or formalin. Virus morphology and concentration remained unchanged, when the UV (2 min) or formalin (5 days) inactivation were performed in the presence of tween80 detergent. The concentration of the native and UV inactivated CVB1 remained constant at 4 degrees C during a six months stability study, whereas the concentration of the formalin inactivated vaccine decreased 29% during this time. UV treatment decreased, whereas formalin treatment increased the thermal stability of the capsid.
   The formalin inactivated CVB1 vaccine was more immunogenic than the UV inactivated vaccine; the protective neutralizing antibody levels were higher in mice immunized with formalin inactivated vaccine. High levels of CVB1 neutralizing antibodies as well as IgG1 antibodies were detected in mice that were protected against viremia induced by experimental CVB1 infection.
   In conclusion, this study describes a scalable ion exchange chromatography purification method and optimized 5-day long formalin inactivation method that preserves CVB1 capsid structure and immunogenicity. Formalin treatment stabilizes the virus particle at elevated temperatures, and the formalin inactivated vaccine induces high levels of serum IgG1 antibodies (Th2 type response) and protective levels of neutralizing antibodies. Formalin inactivated CVB vaccines are promising candidates for human clinical trials. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Hankaniemi, Minna M.; Stone, Virginia M.; Sioofy-Khojine, Amir-Babak; Hyoty, Heikki; Laitinen, I. H.; Flodstrom-Tullberg, Malin; Hytonen, Vesa P.] Tampere Univ, Fac Med & Hlth Technol, FI-33014 Tampere, Finland.
   [Stone, Virginia M.; Flodstrom-Tullberg, Malin] Karolinska Inst, Ctr Infect Med, Dept Med Huddinge, Karolinska Univ Hosp, Alfred Nobels Alle 8, SE-14152 Stockholm, Sweden.
   [Heinimaki, Suvi; Blazevic, Vesna] Tampere Univ, Vaccine Res Ctr, Fac Med & Hlth Technol, FI-33014 Tampere, Finland.
   [Marjomaki, Varpu] Univ Jyvaskyla, Dept Biol & Environm Sci, Nanosci Ctr, POB 35, FI-40014 Jyvaskyla, Finland.
   [Hyoty, Heikki; Hytonen, Vesa P.] Pirkanmaa Hosp Dist, Fimlab Labs, FI-33520 Tampere, Finland.
RP Hytonen, VP (reprint author), Tampere Univ, Fac Med & Hlth Technol, FI-33014 Tampere, Finland.; Hytonen, VP (reprint author), Pirkanmaa Hosp Dist, Fimlab Labs, FI-33520 Tampere, Finland.
EM vesa.hytonen@tuni.fi
RI Hytonen, Vesa/E-8855-2013
OI Hytonen, Vesa/0000-0002-9357-1480; Heinimaki, Suvi/0000-0001-9374-4583;
   Hankaniemi, Minna/0000-0001-6463-1248; Flodstrom Tullberg,
   Malin/0000-0003-2685-2052; Sioofy-Khojine,
   Amir-Babak/0000-0001-5538-5153
FU Academy of FinlandAcademy of Finland [1309455, 288671]; Business Finland
   [THERDIAB: 1843/31/2014]; Swedish Child Diabetes Foundation; Karolinska
   InstitutetKarolinska Institutet; Jane and Aatos Erkko Foundation;
   Strategic Research Program in Diabetes
FX The research was funded by the Academy of Finland (projects 1309455 and
   288671), Business Finland (project THERDIAB: 1843/31/2014), the Swedish
   Child Diabetes Foundation, Karolinska Institutet including the Strategic
   Research Program in Diabetes and Jane and Aatos Erkko Foundation.
CR Adeyemi OO, 2017, J VIROL, V91, DOI 10.1128/JVI.01586-16
   Bopegamage S, 2016, VIRULENCE, V7, P495, DOI 10.1080/21505594.2016.1175701
   Cao RY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064024
   Chang JY, 2012, VACCINE, V30, P703, DOI 10.1016/j.vaccine.2011.11.087
   Chang PC, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13090890
   Chong P, 2012, HUM VACC IMMUNOTHER, V8, P1775, DOI 10.4161/hv.21739
   Delrue I, 2012, EXPERT REV VACCINES, V11, P695, DOI [10.1586/erv.12.38, 10.1586/ERV.12.38]
   DORRIES R, 1983, J GEN VIROL, V64, P159, DOI 10.1099/0022-1317-64-1-159
   Dunne JL, 2019, DIABETOLOGIA
   FERGUSON M, 1993, J GEN VIROL, V74, P685, DOI 10.1099/0022-1317-74-4-685
   Furuya Y, 2010, J GEN VIROL, V91, P1450, DOI 10.1099/vir.0.018168-0
   Hankaniemi MM, 2017, VACCINE, V35, P3718, DOI 10.1016/j.vaccine.2017.05.057
   Heinimaki S, 2018, ANTIVIR RES, V157, P1, DOI 10.1016/j.antiviral.2018.06.012
   Huber S, 2004, VIRAL IMMUNOL, V17, P358, DOI 10.1089/0882824041857030
   Hyoty H, 2018, EXPERT REV VACCINES, V17, P1071, DOI 10.1080/14760584.2018.1548281
   Hyoty H, 2018, EXPERT REV VACC
   Khetsuriani N, 2006, MMWR SURVEILL SUMM, V55, P1
   Koho T, 2014, ANTIVIR RES, V104, P93, DOI 10.1016/j.antiviral.2014.01.013
   Laitinen OH, 2014, DIABETES, V63, P446, DOI 10.2337/db13-0619
   Leo G, 2013, RAPID COMMUN MASS SP, V27, P1660, DOI 10.1002/rcm.6610
   Lien G, 2013, INFECT DIS THER, V2, P167, DOI 10.1007/s40121-013-0014-6
   Lim H, 2018, VACCINE, V36, P3445, DOI 10.1016/j.vaccine.2018.05.005
   Lin SY, 2014, J BIOSCI BIOENG, V117, P366, DOI 10.1016/j.jbiosc.2013.08.015
   LODGE PA, 1987, AM J PATHOL, V128, P455
   Martin J, 2003, J GEN VIROL, V84, P1781, DOI 10.1099/vir.0.19088-0
   Niesen FH, 2007, NAT PROTOC, V2, P2212, DOI 10.1038/nprot.2007.321
   Niespodziana K, 2012, FASEB J, V26, P1001, DOI 10.1096/fj.11-193557
   OFORIANYINAM O, 1995, VACCINE, V13, P983, DOI 10.1016/0264-410X(95)00036-Z
   Richardson SJ, 2018, CURR OPIN PHARMACOL, V43, P11, DOI 10.1016/j.coph.2018.07.006
   Romero JR, 2008, CURR TOP MICROBIOL, V323, P223
   SAITO I, 1985, ACCOUNTS CHEM RES, V18, P134, DOI 10.1021/ar00113a002
   Shiomi H, 2004, J MED VIROL, V74, P484, DOI 10.1002/jmv.20202
   Sin J, 2015, VIROLOGY, V484, P288, DOI 10.1016/j.virol.2015.06.006
   Sioofy-Khojine AB, 2018, DIABETOLOGIA
   Stone VM, 2018, DIABETOLOGIA, V61, P476, DOI 10.1007/s00125-017-4492-z
   Sun SY, 2014, HUM VACC IMMUNOTHER, V10, P2885, DOI 10.4161/hv.29823
   Tano Y, 2007, VACCINE, V25, P7041, DOI 10.1016/j.vaccine.2007.07.060
   TORFASON EG, 1987, J CLIN MICROBIOL, V25, P1376, DOI 10.1128/JCM.25.8.1376-1379.1987
   Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520
   White JA, 2018, BIOLOGICALS, V53, P30, DOI 10.1016/j.biologicals.2018.03.002
   Wong AH, 2011, J MED VIROL, V83, P483, DOI 10.1002/jmv.21998
   Yajima T, 2011, FUTURE MICROBIOL, V6, P551, DOI [10.2217/fmb.11.40, 10.2217/FMB.11.40]
NR 42
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 20
PY 2019
VL 37
IS 40
BP 5962
EP 5971
DI 10.1016/j.vaccine.2019.08.037
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA8YK
UT WOS:000488137000010
PM 31471148
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Park, BJ
   Ahn, HS
   Han, SH
   Go, HJ
   Lee, JB
   Park, SY
   Song, CS
   Lee, SW
   Paik, HJ
   Choi, YK
   Choi, IS
AF Park, Byung-Joo
   Ahn, Hee-Seop
   Han, Sang-Hoon
   Go, Hyeon-Jeong
   Lee, Joong-Bok
   Park, Seung-Yong
   Song, Chang-Seon
   Lee, Sang-Won
   Paik, Hyun-Jong
   Choi, Yang-Kyu
   Choi, In-Soo
TI Evaluation of the protective effects of a nanogel-based vaccine against
   rabbit hepatitis E virus
SO VACCINE
LA English
DT Article
DE Rabbit; HEV; Nanogel; Subunit; Vaccine
ID PIG-LIVER; INTERLEUKIN-12; CLEARANCE; INFECTION; GENOTYPE; CAMELS
AB Infection with hepatitis E virus (HEV) has raised serious public health concerns worldwide. In this study, a nanogel-based vaccine encapsulating the capsid protein of rabbit HEV was developed and its protective efficacy was compared with a subunit vaccine. A total of 23 rabbits were divided into 5 groups: (1) negative control (n = 4), (2) positive control (n = 4), (3) nanogel control (n = 5), (4) nanogel vaccine (n = 5), and (5) subunit vaccine (n = 5). Rabbits were vaccinated two times, at weeks 0 and 1, with nanogel and subunit vaccines, respectively, and challenged with rabbit HEV at week 4. By week 11, rabbits vaccinated with the nanogel vaccine produced higher antibodies than those vaccinated with the subunit vaccine. Fecal viral shedding and viremia were identified in rabbits of the positive and nanogel control groups at weeks 6-10. However, there was no viral shedding and viremia in rabbits immunized with both the nanogel and subunit vaccines. Alanine aminotransferase and aspartate aminotransferase levels were not elevated in any rabbit. However, histopathological examination revealed much less hepatic inflammation in rabbits of the nanogel vaccine group compared to the positive and nanogel control groups. Significant increases in IL-12 and IFN-gamma levels were identified from rabbits immunized with the nanogel vaccine. Collectively, these results indicate that the newly developed nanogel vaccine induced sufficient immunity leading to complete protection from HEV infection in rabbits. Application of this vaccine should be considered as a preventive measure against HEV infection in other animal species and humans. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Park, Byung-Joo; Ahn, Hee-Seop; Han, Sang-Hoon; Go, Hyeon-Jeong; Lee, Joong-Bok; Park, Seung-Yong; Song, Chang-Seon; Lee, Sang-Won; Choi, In-Soo] Konkuk Univ, Coll Vet Med, Dept Infect Dis, 120 Neungdong Ro, Seoul 05029, South Korea.
   [Paik, Hyun-Jong] Pusan Natl Univ, Dept Polymer Sci & Engn, San 30 Jangjeon 2 Dong, Busan 609735, South Korea.
   [Choi, Yang-Kyu] Konkuk Univ, Dept Lab Anim Med, Coll Vet Med, 120 Neungdong Ro, Seoul 05029, South Korea.
RP Choi, IS (reprint author), Konkuk Univ, Coll Vet Med, Dept Infect Dis, 120 Neungdong Ro, Seoul 05029, South Korea.
EM ischoi@konkuk.ac.kr
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI) - Ministry of Health & Welfare, Republic
   of Korea [HI18C1836]
FX This study was supported by a grant from the Korea Health Technology R&D
   Project through the Korea Health Industry Development Institute (KHIDI),
   funded by the Ministry of Health & Welfare, Republic of Korea (grant
   number: HI18C1836).
CR Abravanel F, 2017, EMERG INFECT DIS, V23, P1191, DOI 10.3201/eid2307.170318
   Ahn HS, 2017, VIROLOGY, V512, P187, DOI 10.1016/j.virol.2017.09.020
   Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1016/S0002-9270(99)00433-5
   Cheng XS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048968
   Colson P, 2010, J INFECT DIS, V202, P825, DOI 10.1086/655898
   Dalton HR, 2009, NEW ENGL J MED, V361, P1025, DOI 10.1056/NEJMc0903778
   De Coen R, 2016, BIOMACROMOLECULES, V17, P2479, DOI 10.1021/acs.biomac.6b00685
   Han SH, 2018, VIRUS GENES, V54, P587, DOI 10.1007/s11262-018-1562-3
   Ikuta Y, 2002, BLOOD, V99, P3717, DOI 10.1182/blood.V99.10.3717
   Jothikumar N, 2006, J VIROL METHODS, V131, P65, DOI 10.1016/j.jviromet.2005.07.004
   Kaiser M, 2018, GENOME ANNOUNC, V6
   Kamar N, 2008, NEW ENGL J MED, V358, P811, DOI 10.1056/NEJMoa0706992
   Kamar N, 2014, CLIN MICROBIOL REV, V27, P116, DOI 10.1128/CMR.00057-13
   Kitano S, 2006, CLIN CANCER RES, V12, P7397, DOI 10.1158/1078-0432.CCR-06-1546
   Lee GH, 2016, GASTROENTEROLOGY, V150, P355, DOI 10.1053/j.gastro.2015.10.048
   Li DD, 2015, ADV FUNCT MATER, V25, P2993, DOI 10.1002/adfm.201500894
   Li SW, 2015, HUM VACC IMMUNOTHER, V11, P908, DOI 10.1080/21645515.2015.1008870
   Lim YT, 2011, SMALL, V7, P3281, DOI 10.1002/smll.201101836
   Meng XJ, 1997, P NATL ACAD SCI USA, V94, P9860, DOI 10.1073/pnas.94.18.9860
   Murali AR, 2015, WORLD J HEPATOL, V7, P2194, DOI 10.4254/wjh.v7.i19.2194
   Nimgaonkar I, 2018, NAT REV GASTRO HEPAT, V15, P96, DOI 10.1038/nrgastro.2017.150
   Okamura H, 1998, CURR OPIN IMMUNOL, V10, P259, DOI 10.1016/S0952-7915(98)80163-5
   Ollier L, 2009, ANN INTERN MED, V150, P430, DOI 10.7326/0003-4819-150-6-200903170-00026
   Pape GR, 1999, J VIRAL HEPATITIS, V6, P36, DOI 10.1046/j.1365-2893.1999.00006.x
   Pavio N, 2015, CURR OPIN VIROL, V10, P34, DOI 10.1016/j.coviro.2014.12.006
   Pavio N, 2010, VET RES, V41, DOI 10.1051/vetres/2010018
   Purdy MA, 2017, J GEN VIROL, V98, P2645, DOI 10.1099/jgv.0.000940
   Ragelle H, 2017, EXPERT OPIN DRUG DEL, V14, P851, DOI 10.1080/17425247.2016.1244187
   Rossol S, 1997, J CLIN INVEST, V99, P3025, DOI 10.1172/JCI119498
   Smith DB, 2014, J GEN VIROL, V95, P2223, DOI 10.1099/vir.0.068429-0
   Spahr C, 2018, ZOONOSES PUBLIC HLTH, V65, P11, DOI 10.1111/zph.12405
   Takahashi M, 2011, J GEN VIROL, V92, P902, DOI 10.1099/vir.0.029470-0
   Thomann-Harwood LJ, 2013, J CONTROL RELEASE, V166, P95, DOI 10.1016/j.jconrel.2012.11.015
   TRINCHIERI G, 1993, IMMUNOL TODAY, V14, P335, DOI 10.1016/0167-5699(93)90230-I
   TSAREV SA, 1994, P NATL ACAD SCI USA, V91, P10198, DOI 10.1073/pnas.91.21.10198
   Woo PCY, 2016, EMERG INFECT DIS, V22, P2219, DOI 10.3201/eid2212.160979
   Woo PCY, 2014, EMERG INFECT DIS, V20, P1044, DOI 10.3201/eid2006.140140
   Xia J, 2015, J VIRAL HEPATITIS, V22, P850, DOI 10.1111/jvh.12406
   Yazaki Y, 2003, J GEN VIROL, V84, P2351, DOI 10.1099/vir.0.19242-0
NR 39
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 20
PY 2019
VL 37
IS 40
BP 5972
EP 5978
DI 10.1016/j.vaccine.2019.08.029
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA8YK
UT WOS:000488137000011
PM 31455586
DA 2020-05-12
ER

PT J
AU Raj, SM
   Chughtai, AA
   Sharma, A
   Tan, TC
   Maclntyre, CR
AF Raj, Suresh Mahendra
   Chughtai, Abrar Ahmad
   Sharma, Anurag
   Tan, Timothy C.
   Maclntyre, C. Raina
TI Cost-benefit analysis of a national influenza vaccination program in
   preventing hospitalisation costs in Australian adults aged 50-64 years
   old
SO VACCINE
LA English
DT Article
DE Influenza; Vaccination; Economic evaluation; Cost-benefit analysis
ID ACUTE MYOCARDIAL-INFARCTION; ACUTE CORONARY SYNDROMES; CARDIOVASCULAR
   EVENTS; INFECTION; DISEASE; IMPACT
AB Introduction: Influenza causes a significant burden among Australian adults aged 50-64, however, vaccine coverage rates remain suboptimal. The National Immunisation Program (NIP) currently funds influenza vaccinations in this age group only for those at high risk of influenza complications.
   Aims: The main aim of this study was to determine whether a strategy of expanding the government-funded vaccination program to all adults 50-64 in preventing influenza-related hospitalisations will be cost beneficial to the government.
   Methods: A cost-benefit analysis from a governmental perspective was performed using parameters informed by publicly available databases and published literature. Costs included cost of vaccinations and general practitioner consultation while benefits included the savings from averted respiratory and acute myocardial infarction (AMI) hospitalisations.
   Results: In the base-case scenario, the proposed policy would prevent 314 influenza/pneumonia, 388 other respiratory and 1482 AMI hospitalisations in a year. The government would save $8.03 million with an incremental benefit-cost ratio of 1.40. Most savings were due to averted AMI hospitalisations. In alternative scenarios cost savings ranged from saving of $31.4 million to additional cost to the government of $15.4 million, with sensitive variation in vaccine administration practices (through general practitioner or pharmacists) and vaccine effectiveness estimates.
   Discussion: Extension of the NIP to include adults 50-64 years of age is likely to be cost beneficial to the government, although this finding is sensitive to vaccine administration cost, which varies if provided through general practitioners or pharmacists; and to variation in vaccine effectiveness. An increased role of pharmacists in immunisation programs would likely result in cost savings in an expanded adult immunisation program. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Raj, Suresh Mahendra; Tan, Timothy C.] Univ New South Wales, Fac Med, Sydney, NSW 2052, Australia.
   [Chughtai, Abrar Ahmad; Sharma, Anurag] Univ New South Wales, Sch Publ Hlth & Community Med, Fac Med, Samuels Bldg, Sydney, NSW 2052, Australia.
   [Tan, Timothy C.] Blacktown Hosp, Dept Cardiol, Blacktown, NSW 2148, Australia.
   [Tan, Timothy C.] Western Sydney Univ, Sch Med, Sydney, NSW 2751, Australia.
   [Tan, Timothy C.] Univ Sydney, Fac Med & Hlth, Sydney, NSW 2006, Australia.
   [Maclntyre, C. Raina] Univ New South Wales, Biosecur Program, Kirby Inst, Fac Med, Sydney, NSW 2052, Australia.
   [Maclntyre, C. Raina] Arizona State Univ, Coll Publ Affairs & Community Solut, Phoenix, AZ 85004 USA.
RP Raj, SM (reprint author), Univ New South Wales, Fac Med, Sydney, NSW 2052, Australia.
EM s.mahendraraj@unsw.edu.au
RI Sharma, Anurag/B-4769-2008
OI Sharma, Anurag/0000-0001-7570-852X
FU National Health and Medical Research Council (NHMRC) Centre for Research
   Excellence in Integrated Systems for Epidemic Response (ISER)National
   Health and Medical Research Council of Australia [1107393]; NHMRC
   Principal Research FellowshipNational Health and Medical Research
   Council of Australia [1137582]
FX This work was supported by a grant from the National Health and Medical
   Research Council (NHMRC) Centre for Research Excellence in Integrated
   Systems for Epidemic Response (ISER) (grant number 1107393). Raina
   Maclntyre is supported by a NHMRC Principal Research Fellowship (grant
   number 1137582).
CR Aballea S, 2007, VACCINE, V25, P6900, DOI 10.1016/j.vaccine.2007.07.033
   Aballea S, 2007, VALUE HEALTH, V10, P98, DOI 10.1111/j.1524-4733.2006.00157.x
   [Anonymous], 2018, AUSTR REFINED DIAGNO
   Australian Bureau of Statistics, 2017, 3101031010DO00120170
   Australian Institute of Health and Welfare, 2016, AUSTR BURD DIS STUD, V3
   Australian Technical Advisory Group on Immunisation (ATAGI), 2018, AUSTR IMM HDB
   Barnes M, 2015, HEART, DOI [10.1136/hearjnl-2015-307691, DOI 10.1136/HEARJNL-2015-307691]
   Cheng AC, 2017, COMMUN DIS INTELL, V41, pE337
   Ciszewski A, 2008, EUR HEART J, V29, P1350, DOI 10.1093/eurheartj/ehm581
   Ciszewski A, 2018, VACCINE, V36, P202, DOI 10.1016/j.vaccine.2017.11.078
   Corrales-Medina VF, 2010, LANCET INFECT DIS, V10, P83, DOI 10.1016/S1473-3099(09)70331-7
   Department of Health, 2018, MED BEN SCHED BOOK
   Department of Health Australia, 2014, NEWSP OMN SURV AD FL
   Duncan Ian G, 2012, Cost Eff Resour Alloc, V10, P10
   Dyda A, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1820-8
   Estabragh ZR, 2013, INT J CARDIOL, V167, P2397, DOI 10.1016/j.ijcard.2013.01.274
   Frobert O, 2017, AM HEART J, V189, P94, DOI 10.1016/j.ahj.2017.04.003
   Gurfinkel EP, 2004, EUR HEART J, V25, P25, DOI 10.1016/j.ehj.2003.10.018
   Heart Foundation, 2018, EC COST AC COR SYNDR
   Independent Hospital Pricing Authority, 2017, NAT EFF PRIC DET 201
   Jimenez-Garcia Rodrigo, 2012, Hum Vaccin Immunother, V8, P228, DOI 10.4161/hv.18433
   Jit M, 2013, HUM VACC IMMUNOTHER, V9, P834, DOI 10.4161/hv.23637
   Kieninger D, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-343
   Kwong Jeff C, 2007, Health Rep, V18, P9
   Kwong JC, 2008, PLOS MED, V5, P1440, DOI 10.1371/journal.pmed.0050211
   Kwong JC, 2018, NEW ENGL J MED, V378, P345, DOI 10.1056/NEJMoa1702090
   MacIntyre CR, 2013, HEART, V99, P1843, DOI 10.1136/heartjnl-2013-304320
   Moa AM, ESTIMATED HOSP UNPUB
   Mogasale V, 2011, AUST NZ J PUBL HEAL, V35, P180, DOI 10.1111/j.1753-6405.2010.00639.x
   National Hospital Morbidity Database, 2018, PRINC DIAGN DAT CUB
   Newall AT, 2008, VACCINE, V26, P2142, DOI 10.1016/j.vaccine.2008.01.050
   Newall AT, 2008, VACCINE, V26, P2135, DOI 10.1016/j.vaccine.2008.01.051
   Newall AT, 2008, VACCINE, V26, P6818, DOI 10.1016/j.vaccine.2008.09.086
   Nichol KL, 2001, ARCH INTERN MED, V161, P749, DOI 10.1001/archinte.161.5.749
   Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X
   Phrommintikul A, 2011, EUR HEART J, V32, P1730, DOI 10.1093/eurheartj/ehr004
   Pothineni NVK, 2017, EUR HEART J, V38, P3195, DOI 10.1093/eurheartj/ehx362
   Prosser LA, 2008, PHARMACOECONOMICS, V26, P163, DOI 10.2165/00019053-200826020-00006
   Reed C, 2012, VACCINE, V30, P1993, DOI 10.1016/j.vaccine.2011.12.098
   Sribhutorn A, 2018, J GERIATR CARDIOL, V15, P413, DOI 10.11909/j.issn.1671-5411.2018.06.008
   Suh J, 2017, VACCINE, V35, P2811, DOI 10.1016/j.vaccine.2017.04.016
   The Pharmacy Guild of Australia, 2018, VACC SERV
   Turner DA, 2006, VACCINE, V24, P1035, DOI 10.1016/j.vaccine.2004.12.033
   Warren-Gash C, 2012, J INFECT DIS, V206, P1652, DOI 10.1093/infdis/jis597
   World Health Organization, 2018, INFL SEAS
NR 45
TC 0
Z9 0
U1 4
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 20
PY 2019
VL 37
IS 40
BP 5979
EP 5985
DI 10.1016/j.vaccine.2019.08.028
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA8YK
UT WOS:000488137000012
PM 31473001
DA 2020-05-12
ER

PT J
AU Rozbroj, T
   Lyons, A
   Lucke, J
AF Rozbroj, T.
   Lyons, A.
   Lucke, J.
TI The mad leading the blind: Perceptions of the vaccine-refusal movement
   among Australians who support vaccination
SO VACCINE
LA English
DT Article
DE Vaccine hesitancy; Attitude; Australia; Qualitative; Public perceptions;
   Stigma
ID WEB 2.0; PARENTAL ATTITUDES; MORAL REGULATION; ONLINE; MEASLES;
   DISCOURSE; COVERAGE; PROJECT; HEALTH; DEBATE
AB Background: Vaccine refusal is shaped by the social ecology in which it occurs. How people who refuse vaccines are communicated to and treated may affect the nature and strength of their negative vaccine beliefs, and their responsiveness to health promotion messages. Yet little is known about how people who refuse vaccines are perceived by the public. Our research examined perceptions among pro vaccine Australians of the vaccine-refusal movement.
   Methods: Descriptions of the vaccine-refusal movement by 2666 pro-vaccine Australians were analysed using thematic discourse analysis. Descriptive themes were identified via inductive, iterative coding. Discourse analysis techniques were then used to interpret latent beliefs about the vaccine-refusal movement.
   Results: Participants had negative and stigmatising perceptions of the vaccine-refusal movement. They believed the movement is dangerous, misinformed, and comprised of charlatans and fools who are unintelligent, selfish, overly emotional, conspiratorial and scientifically illiterate. Discursive analysis showed that these perceptions were underpinned by beliefs that people would have to be defective in some way to believe anti-vaccine rhetoric. Furthermore, perceptions were underpinned by beliefs that the movement spreads not only disease, but also dangerous ideas that were seen to attack the social order, institutions, values and reason. Participants' intensely-negative views related to their inability to imagine why someone would refuse vaccines.
   Conclusions: This research provides a focused, qualitative account of public perceptions of the vaccine-refusal movement. The findings are concerning: stigma towards vaccine-refusing people may adversely affect their wellbeing and entrench their negative vaccine beliefs. The research suggests that more compassionate, nuanced discussion of vaccine refusal in the public sphere is needed. It also supports the need to systematically examine public attitudes towards vaccine refusal as a determinant of vaccine confidence. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Rozbroj, T.; Lyons, A.; Lucke, J.] La Trobe Univ, Australian Res Ctr Sex Hlth & Soc, Bundoora, Vic 3086, Australia.
   [Lucke, J.] Univ Queensland, Sch Publ Hlth, St Lucia, Qld 4072, Australia.
RP Rozbroj, T (reprint author), La Trobe Univ, Australian Res Ctr Sex Hlth & Soc, Bundoora, Vic 3086, Australia.
EM t.rozbroj@latrobe.edu.au
OI Rozbroj, Tomas/0000-0002-3084-746X
FU La Trobe University Postgraduate Research Scholarship
FX The study was undertaken as part of a PhD. The PhD was supported by a La
   Trobe University Postgraduate Research Scholarship awarded to TR.
CR Alvesson M, 2000, HUM RELAT, V53, P1125, DOI 10.1177/0018726700539002
   Attwell K, 2018, VACCINE, V36, P7377, DOI 10.1016/j.vaccine.2018.10.019
   Bester JC, 2015, J BIOETHIC INQ, V12, P555, DOI 10.1007/s11673-015-9673-1
   Betsch C, 2012, VACCINE, V30, P3727, DOI 10.1016/j.vaccine.2012.02.025
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI DOI 10.1191/1478088706QP0630A
   Broniatowski DA, 2018, AM J PUBLIC HEALTH, V108, P1378, DOI 10.2105/AJPH.2018.304567
   Brunson EK, 2013, PEDIATRICS, V131, pE1397, DOI 10.1542/peds.2012-2452
   Capurro G, 2018, CAN J SOCIOL, V43, P25, DOI 10.29173/cjs29301
   Carpiano RM, 2017, SOC SCI MED, V185, P127, DOI 10.1016/j.socscimed.2017.05.014
   Cassell JA, 2006, PUBLIC HEALTH, V120, P783, DOI 10.1016/j.puhe.2006.03.011
   Chow MYK, 2017, AUST FAM PHYSICIAN, V46, P145
   Costa-Pinto J, 2016, J PAEDIATR CHILD H, V52, P7, DOI [10.1111/jpc.13245_9, DOI 10.1111/JPC.13245_9]
   Department of Health, 2018, IMM COV RAT ALL CHIL
   Dijk TAV, 2015, HDB DISCOURSE ANAL
   Dixon GN, 2013, SCI COMMUN, V35, P358, DOI 10.1177/1075547012458290
   Enkel SL, 2018, VACCINE, V36, P6459, DOI 10.1016/j.vaccine.2017.09.088
   Ernst E, 2001, VACCINE, V20, pS90, DOI 10.1016/S0264-410X(01)00290-0
   Ford AJ, 2018, VACCINE, V36, P5294, DOI 10.1016/j.vaccine.2018.07.022
   Harmsen IA, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1183
   Johnson Joy L, 2004, Health Commun, V16, P255
   Kaplan JT, 2016, SCI REP-UK, V6, DOI 10.1038/srep39589
   Kata A, 2012, VACCINE, V30, P3778, DOI 10.1016/j.vaccine.2011.11.112
   Keelan J, 2010, VACCINE, V28, P1535, DOI 10.1016/j.vaccine.2009.11.060
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Macdonald L, 2010, CAN J SOCIOL, V35, P627, DOI 10.29173/cjs8977
   Maclntyre CR, 2015, COMMUNICATION
   Mak WWS, 2007, SOC SCI MED, V65, P245, DOI 10.1016/j.socscimed.2007.03.015
   McKee M, 2017, LANCET, V389, P748, DOI 10.1016/S0140-6736(17)30122-8
   Muscat M, 2011, J INFECT DIS, V204, pS353, DOI 10.1093/infdis/jir067
   Navin M., 2015, VALUES VACCINE REFUS
   Nicholson MS, 2012, VACCINE, V30, P3806, DOI 10.1016/j.vaccine.2011.10.072
   Ozawa S, 2016, HEALTH AFFAIR, V35, P2124, DOI 10.1377/hlthaff.2016.0462
   Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353
   Ramsay S, 2002, LANCET, V359, P590, DOI 10.1016/S0140-6736(02)07771-1
   Reich JA., 2019, COMMUNICATION
   Reich Jennifer A, 2018, Soc Sci Med, P112015, DOI 10.1016/j.socscimed.2018.10.027
   Rozbroj T, 2019, PATIENT EDUC COUNS, V102, P172, DOI 10.1016/j.pec.2018.08.027
   Salmon DA, 2005, ARCH PEDIAT ADOL MED, V159, P470, DOI 10.1001/archpedi.159.5.470
   Salmon DA, 2006, EMERG THEMES EPIDEMI, V3, DOI 10.1186/1742-7622-3-13
   Scavone C, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00574
   Schmidt AL, 2018, VACCINE, V36, P3606, DOI 10.1016/j.vaccine.2018.05.040
   Shaw SE, 2009, FAM PRACT, V26, P413, DOI 10.1093/fampra/cmp038
   Smith PJ, 2011, PUBLIC HEALTH REP, V126, P135, DOI 10.1177/00333549111260S215
   Smith TC, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx146
   Stefanoff P, 2010, VACCINE, V28, P5731, DOI 10.1016/j.vaccine.2010.06.009
   Tchuenche JM, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S1-S5
   Vanderslott S, 2019, SOC SCI MED, V222, P59, DOI 10.1016/j.socscimed.2018.12.033
   WHO, 2014, STRATEGIES ADDRESSIN
   Wigginton B, 2017, WOMEN HEALTH ISS, V27, P93, DOI 10.1016/j.whi.2016.09.008
   Wigginton B, 2014, QUAL RES PSYCHOL, V11, P265, DOI 10.1080/14780887.2014.902523
   Witteman HO, 2012, VACCINE, V30, P3734, DOI 10.1016/j.vaccine.2011.12.039
NR 51
TC 0
Z9 0
U1 3
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 20
PY 2019
VL 37
IS 40
BP 5986
EP 5993
DI 10.1016/j.vaccine.2019.08.023
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA8YK
UT WOS:000488137000013
PM 31451326
DA 2020-05-12
ER

PT J
AU Carlson, SJ
   Scanlan, C
   Marshall, HS
   Blyth, CC
   Macartney, K
   Leask, J
AF Carlson, Samantha J.
   Scanlan, Camilla
   Marshall, Helen S.
   Blyth, Christopher C.
   Macartney, Kristine
   Leask, Julie
TI Attitudes about and access to influenza vaccination experienced by
   parents of children hospitalised for influenza in Australia
SO VACCINE
LA English
DT Article
DE Influenza; Vaccination; Hospital; Vaccine Uptake; Attitude to Health;
   Health Behavior; Parent
ID PREGNANT-WOMEN; IMMUNIZATION; COVERAGE; DETERMINANTS
AB Introduction: In Australia, influenza hospitalises more children than any other vaccine preventable disease does. Children aged six months or older are recommended to receive annual influenza vaccines, and pregnant women are recommended vaccination to protect infants aged up to six months. However, vaccine uptake is low. This study explored influenza vaccination knowledge and behaviours of parents of children who were hospitalised for influenza, in order to inform strategies that target barriers to uptake.
   Methods: We conducted 27 semi-structured interviews with parents caregivers during or shortly after their child's hospitalisation for laboratory-confirmed influenza in 2017. Questions were guided by the Social Ecological Model exploring all levels of influence on vaccination uptake from the intrapersonal through to policy, via the parents' perspective. Transcripts were inductively analysed. Themes were categorised into the components of the Capability-Opportunity-Motivation-Behaviour (COM-B) model.
   Results: 20/27 children were aged six months or older; 16/20 had not received an influenza vaccine in 2017. Mothers of 4/7 infants aged less than six months were not vaccinated in pregnancy. The themes regarding barriers to influenza vaccination were: (1) Limited Capability - misinterpretations and knowledge gaps, (2) Lack of Opportunity - inconvenient vaccination pathway, missing recommendations, absence of promotion to all, and the social norm, and (3) Missing Motivation - hierarchy of perceived seriousness, safety concerns, a preference for 'natural' ways. Though most parents, now aware of the severity of influenza, intended to vaccinate their child in future seasons, some harboured reservations about necessity and safety. When parents were asked how to help them vaccinate their children, SMS reminders and information campaigns delivered through social media, schools and childcare were suggested.
   Conclusion: Improving parents' and providers' knowledge and confidence in influenza vaccination safety, efficacy, and benefits should be prioritised. This, together with making influenza vaccination more convenient for parents, would likely raise vaccine coverage. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Carlson, Samantha J.] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia.
   [Scanlan, Camilla; Macartney, Kristine] Natl Ctr Immunisat Res & Surveillance, Westmead, NSW 2145, Australia.
   [Marshall, Helen S.] Univ Adelaide, Robinson Res Inst, Adelaide, SA 5006, Australia.
   [Marshall, Helen S.] Univ Adelaide, Adelaide Med Sch, Adelaide, SA 5006, Australia.
   [Marshall, Helen S.] Womens & Childrens Hlth Network, Adelaide, SA 5006, Australia.
   [Blyth, Christopher C.] Univ Western Australia, Sch Med, Discipline Paediat, GPO Box D184, Perth, WA 6840, Australia.
   [Blyth, Christopher C.] Univ Western Australia, Telethon Kids Inst, Wesfarmers Ctr Vaccines & Infect Dis, GPO Box D184, Perth, WA 6840, Australia.
   [Blyth, Christopher C.] Perth Childrens Hosp, Hosp Ave, Nedlands, WA 6009, Australia.
   [Macartney, Kristine] Univ Sydney, Discipline Child & Adolescent Hlth, Sydney, NSW 2006, Australia.
   [Leask, Julie] Univ Sydney, Susan Wakil Sch Nursing & Midwifery, 88 Mallett St, Camperdown, NSW 2006, Australia.
   Univ Sydney, Sydney Hlth Eth, Sydney, NSW 2006, Australia.
RP Carlson, SJ (reprint author), Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia.
EM samantha.carlson@sydney.edu.au; camilla.scan-lan@sydney.edu.au;
   helen.marshall@adelaide.edu.au; christopher.blyth@uwa.edu.au;
   kristine.macartney@health.nsw.gov.au; julie.leask@sydney.edu.au
OI Scanlan, Camilla/0000-0002-9764-0367; Macartney,
   Kristine/0000-0002-4675-0232; Carlson, Samantha/0000-0002-4362-7730;
   Leask, Julie/0000-0001-5095-1443
FU National Health and Medical Research Council (NHMRC) AustraliaNational
   Health and Medical Research Council of Australia [1113851]; Australian
   Government Department of HealthAustralian GovernmentDepartment of Health
   & Ageing; NSW Health; South Australia Department for Health and
   Wellbeing; NSW Ministry of Health under NSW Health PhD Scholarship
   Program
FX This research was supported by a National Health and Medical Research
   Council (NHMRC) Partnership Project Grant (1113851) Australia, the
   Australian Government Department of Health, NSW Health and South
   Australia Department for Health and Wellbeing. SC was supported by the
   NSW Ministry of Health under the NSW Health PhD Scholarship Program.
CR Australian Bureau of Statistics, 2018, SOC IND AR SEIFA 201
   Australian Government Department of Health, 2017, 2017 INLF SEAS AUSTR
   Australian Government Department of Health, 2018, NAT IMM PROGR SCHED
   Australian Government Department of Health, 2018, AUSTRALIAN IMMUNISAT
   Beard FH, 2019, MED J AUST
   Biezen R, 2018, VACCINE, V36, P859, DOI 10.1016/j.vaccine.2017.12.066
   Blyth CC, 2014, EUROSURVEILLANCE, V2016, P21, DOI DOI 10.2807/1560-7917
   Blyth CC, 2019, CLIN INFECT DIS, V68, P940, DOI 10.1093/cid/ciy597
   Blyth CC, 2014, VACCINE, V32, P4075, DOI 10.1016/j.vaccine.2014.05.055
   Bohm R, 2017, HEALTH ECON, V26, P66, DOI 10.1002/hec.3584
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI DOI 10.1191/1478088706QP0630A
   Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521
   Britton PN, 2017, CLIN INFECT DIS, V65, P653, DOI [10.1093/cid/cix412, 10.1093/clinid/cix412]
   Carlson S, 2019, PUBLIC HLTH RES PRAC
   Chow MYK, 2012, J PEDIAT INF DIS-GER, V7, P89, DOI 10.3233/JPI-120344
   Crawford NW, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-87
   Dalton L, 2018, AUSTR IMMUNISATION R
   Danchin MH, 2018, VACCINE, V36, P6473, DOI 10.1016/j.vaccine.2017.08.003
   Dey A, 2016, COMMUN DIS INTELL, V40, pS1
   Ellingson MK, 2019, EXPERT REV VACCINES, V18, P191, DOI 10.1080/14760584.2019.1562907
   Hale K, 2006, J PAEDIATR CHILD H, V42, P321, DOI 10.1111/j.1440-1754.2006.00865.x
   Hull B, 2018, ANN IMMUNISATION COV
   King C, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4032-2
   Kumar S, 2012, HEALTH EDUC BEHAV, V39, P229, DOI 10.1177/1090198111415105
   Lakhan N, 2016, INFLUENZA OTHER RESP, V10, P479, DOI 10.1111/irv.12403
   Li-Kim-Moy J, 2016, COMMUN DIS INTELL, V40, pE482
   Maher L, 2014, BMC FAM PRACT, V15, DOI 10.1186/1471-2296-15-102
   Maher L, 2013, VACCINE, V31, P5557, DOI 10.1016/j.vaccine.2013.08.081
   Mak DB, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-2051-3
   Mak DB, 2015, AUST NZ J OBSTET GYN, V55, P131, DOI 10.1111/ajo.12292
   MCCARTHY EA, 2015, BMC PREGNANCY CHILDB, V15, P1
   McCarthy EA, 2012, AUST NZ J OBSTET GYN, V52, P334, DOI 10.1111/j.1479-828X.2012.01428.x
   MCLEROY KR, 1988, HEALTH EDUC QUART, V15, P351, DOI 10.1177/109019818801500401
   McRae J, 2017, COMMUN DIS INTELL, V41, pE275
   Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-10
   Mohammed H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197867
   National Centre for Immunisation Research and Surveillance, 2019, SIGN EV INFL VACC PR
   Newcombe J, 2014, VACCINE, V32, P6364, DOI 10.1016/j.vaccine.2014.06.044
   Newcombe JP, 2017, J PAEDIATR CHILD H, V53, P711, DOI 10.1111/jpc.13406
   Pearce A, 2015, VACCINE, V33, P3377, DOI 10.1016/j.vaccine.2015.04.089
   Phillips A, 2018, J PAEDIATR CHILD H, V54, P356, DOI 10.1111/jpc.13835
   Regan AK, 2016, WOMEN BIRTH, V29, P423, DOI 10.1016/j.wombi.2016.01.009
   Taksdal SE, 2013, AUST FAM PHYSICIAN, V42, P582
   Van Buynder PG, 2011, INFLUENZA OTHER RESP, V5, P33, DOI 10.1111/j.1750-2659.2010.00167.x
   Wiley KE, 2013, MED J AUSTRALIA, V198, P373, DOI 10.5694/mja12.11849
   Wong CY, 2015, HUM VACC IMMUNOTHER, V11, P1165, DOI 10.1080/21645515.2015.1019188
   Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630
NR 47
TC 1
Z9 1
U1 3
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 20
PY 2019
VL 37
IS 40
BP 5994
EP 6001
DI 10.1016/j.vaccine.2019.08.021
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA8YK
UT WOS:000488137000014
PM 31471153
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Pindyck, T
   Tate, JE
   Bonkoungou, IJO
   Armah, G
   Mujuru, HA
   Rugambwa, C
   Mwenda, JM
   Parashar, U
AF Pindyck, Talia
   Tate, Jacqueline E.
   Bonkoungou, Isidore Juste O.
   Armah, George
   Mujuru, Hilda Angela
   Rugambwa, Celse
   Mwenda, Jason M.
   Parashar, Umesh
TI Timeliness of rotavirus vaccination at sentinel sites in four
   early-adopter African countries
SO VACCINE
LA English
DT Article
DE Surveillance; Validation; Acute gastroenteritis; Methods
ID CHILDREN LESS-THAN-5 YEARS; DIARRHEA; AGE
AB Background: The majority of countries with the highest rotavirus-associated death rates are in sub-Saharan Africa. In 2009, the World Health Organization (WHO) recommended routine vaccination against rotavirus worldwide, with unique age recommendations to administer the first dose before 15 weeks of age and last dose by 32 weeks of age. These age restrictions were relaxed in January 2013, but they may still lead to lower rotavirus vaccine coverage.
   Methods: Children age-eligible to have received rotavirus vaccine that were enrolled in Ghana, Zimbabwe, Rwanda or Burkina Faso's active rotavirus surveillance platforms from 2013 to 2017 and had a stool specimen that tested rotavirus-negative were included in the analysis. Proportion vaccinated and timeliness of rotavirus vaccine versus DTPw-HepB-Hib (pentavalent) first dose and last dose were compared at weeks 15 and 32, respectively, using Chi-square analyses. Odds ratios were calculated using logistic regression.
   Results: Among children who received rotavirus vaccine dose 1, 96-99% received this dose by 15 weeks of age and among children who received the last dose, 98-99% received it by 32 weeks of age. In all four countries, there was no significant difference in the proportion of children who received first dose rotavirus versus pentavalent vaccine by week 15, or last dose rotavirus versus concordant pentavalent vaccine by week 32. Delayed administration of first dose pentavalent vaccine was significantly associated with missing first dose of rotavirus vaccine in 3 of the 4 countries studied, although delays in administration were rare (1-4%).
   Conclusions: Rotavirus vaccination was timely among sentinel sites in these four early rotavirus vaccine-introducing countries in Africa. Late presentation for vaccination may have resulted in some children with access to care missing first dose of rotavirus vaccine; however, vaccination delays were infrequent and therefore the potential impact of the age restrictions on overall proportion vaccinated was minimal. Published by Elsevier Ltd.
C1 [Pindyck, Talia] Ctr Dis Control & Prevent CDC, EIS, Atlanta, GA 30333 USA.
   [Pindyck, Talia; Tate, Jacqueline E.; Parashar, Umesh] CDC, Div Viral Dis, Atlanta, GA 30333 USA.
   [Bonkoungou, Isidore Juste O.] Univ Ouaga, UFR SVT, Pr Joseph KI ZERBO, Ouagadougou, Burkina Faso.
   [Bonkoungou, Isidore Juste O.] Natl Publ Hlth Lab, Ouagadougou, Burkina Faso.
   [Armah, George] Univ Ghana, Coll Hlth Sci, Noguchi Mem Inst Med Res, Accra, Ghana.
   [Mujuru, Hilda Angela] Univ Zimbabwe, Coll Hlth Sci, Dept Pediat & Child Hlth, Harare, Zimbabwe.
   [Rugambwa, Celse] WHO Country Off, Kigali, Rwanda.
   [Mwenda, Jason M.] WHO AFRO, WHO Reg Off Africa, Brazzaville, Rep Congo.
RP Pindyck, T (reprint author), Ctr Dis Control & Prevent CDC, EIS, Atlanta, GA 30333 USA.
EM nrb1@cdc.gov
RI Mujuru, Hilda Angela/AAF-2511-2020
FU Gavi, the Vaccine Alliance, through the CDC Foundation; World Health
   OrganizationWorld Health Organization
FX All authors attest they meet the ICMJE criteria for authorship.
   Financial support for this evaluation was provided by Gavi, the Vaccine
   Alliance, through the CDC Foundation and the World Health Organization.
CR [Anonymous], 2013, Wkly Epidemiol Rec, V88, P49
   [Anonymous], 2009, Wkly Epidemiol Rec, V84, P533
   [Anonymous], 2016, ZIMB DEM HLTH SURV 2
   Armah G, 2016, CLIN INFECT DIS, V62, pS200, DOI 10.1093/cid/ciw014
   Bonkoungou IJO, 2017, VACCINE
   GSS, 2015, GHAN DEM HLTH SURV 2, DOI 10.15171/ijhpm.2016.42
   Institut National de la Statistique et de la Demographie; Ministere de l'Economie et des Finances, ENQ DEM SANT IND MUL
   Mujuru HA, 2017, PEDIATR INFECT DIS J, V36, P995, DOI [10.1097/INF.0000000000001648, 10.1097/inf.0000000000001648]
   National Institute of Statistics of Rwanda Ministry of Health and ICF International, 2015, RWAND DEM HLTH SURV
   Schwartz LM, 2017, VACCINE, V35, P184, DOI 10.1016/j.vaccine.2016.10.077
   Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013
   Tate JE, 2016, CLIN INFECT DIS, V62, pS208, DOI 10.1093/cid/civ1016
   World Health Organization, 2002, GEN PROT I HOSP BAS
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 20
PY 2019
VL 37
IS 40
BP 6002
EP 6007
DI 10.1016/j.vaccine.2019.08.008
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA8YK
UT WOS:000488137000015
PM 31455587
DA 2020-05-12
ER

PT J
AU Evans, DR
   Yemeke, TT
   Kiracho, EE
   Mutebi, A
   Apolot, RR
   Ssebagereka, A
   Ozawa, S
AF Evans, Daniel R.
   Yemeke, Tatenda T.
   Kiracho, Elizabeth E.
   Mutebi, Aloysius
   Apolot, Rebecca R.
   Ssebagereka, Anthony
   Ozawa, Sachiko
TI Trust in vaccines and medicines in Uganda
SO VACCINE
LA English
DT Article
DE Trust; Confidence; Hesitancy; Vaccine; Medicine; Uganda
ID PRIMARY-CARE; HESITANCY; IMMUNIZATION; PHYSICIANS; ADHERENCE; DISEASE;
   SYSTEMS; DEMAND; IMPACT
AB Trust underlies numerous decisions in health care, affecting vaccine uptake as well as care seeking rates, treatment adherence, and health outcomes. Although trust in the doctor-patient relationship has garnered much attention, trust in health care commodities such as vaccines and medicines has rarely been examined. We report findings from a cross-sectional survey to assess trust in vaccines vis-vis their trust in conventional medicines and traditional medicines in Uganda. Trust in vaccines, conventional and traditional medicines were assessed by adapting the vaccine hesitancy scale developed by the SAGE Working Group on Vaccine Hesitancy. Reported trust in vaccines and conventional medicines was much higher than trust in traditional medicines. Significant associations were observed between trust in vaccines and trust in conventional medicines. Of the trust components explored, respondents were most concerned about access to and safety of vaccines and medicines. Further, respondents' previous health care experiences, primary source of health information, and trust in providers' skills were significantly associated with reported trust in vaccines and medicines. Although strong levels of trust in vaccines and conventional medicines were observed overall, the findings identify areas where policies and communication efforts can focus to strengthen trust. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Evans, Daniel R.] Duke Univ, Sch Med, Durham, NC USA.
   [Yemeke, Tatenda T.; Ozawa, Sachiko] Univ N Carolina, UNC Eshelman Sch Pharm, Div Practice Adv & Clin Educ, Chapel Hill, NC 27515 USA.
   [Kiracho, Elizabeth E.; Mutebi, Aloysius; Apolot, Rebecca R.; Ssebagereka, Anthony] Makerere Univ, Sch Publ Hlth, Dept Hlth Policy Planning & Management, Kampala, Uganda.
   [Ozawa, Sachiko] Univ N Carolina, UNC Gillings Sch Global Publ Hlth, Dept Maternal & Child Hlth, Chapel Hill, NC 27515 USA.
RP Ozawa, S (reprint author), UNC Eshelman Sch Pharm, CB 7574,Beard Hall 11511, Chapel Hill, NC 27599 USA.
EM ozawa@unc.edu
CR Abel Willie M, 2013, Front Public Health, V1, P66, DOI 10.3389/fpubh.2013.00066
   Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089
   Bbaale E, 2013, J HEALTH POPUL NUTR, V31, P118
   Birkhauer J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170988
   Braka F, 2012, MATERN CHILD HLTH J, V16, P1045, DOI 10.1007/s10995-011-0826-5
   Canavan ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095709
   Casiday R, 2006, VACCINE, V24, P177, DOI 10.1016/j.vaccine.2005.07.063
   Cassell JA, 2006, HEALTH POLICY PLANN, V21, P373, DOI 10.1093/heapol/czl020
   Cooper S, 2018, HUM VACC IMMUNOTHER, V14, P2355, DOI 10.1080/21645515.2018.1460987
   Domek GJ, 2018, VACCINE, V36, P5273, DOI 10.1016/j.vaccine.2018.07.046
   Dube E, 2015, VACCINE, V33, P4191, DOI 10.1016/j.vaccine.2015.04.041
   Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212
   Glaeser EL, 2000, Q J ECON, V115, P811, DOI 10.1162/003355300554926
   Graham JL, 2015, AIDS PATIENT CARE ST, V29, P661, DOI 10.1089/apc.2015.0156
   Gunnala R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167835
   Gureje O, 2015, LANCET PSYCHIAT, V2, P168, DOI 10.1016/S2215-0366(15)00013-9
   Hall MA, 2001, MILBANK Q, V79, P613, DOI 10.1111/1468-0009.00223
   Hall MA, 2002, HEALTH SERV RES, V37, P1419, DOI 10.1111/1475-6773.01070
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Haywood C, 2014, J GEN INTERN MED, V29, P1657, DOI 10.1007/s11606-014-2986-7
   Hickler B, 2017, VACCINE, V35, P3515, DOI 10.1016/j.vaccine.2017.04.056
   Kerse N, 2004, ANN FAM MED, V2, P455, DOI 10.1370/afm.139
   Kestenbaum LA, 2015, PEDIATR ANN, V44, pE71, DOI 10.3928/00904481-20150410-07
   Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037
   Linsky A, 2018, J AM PHARM ASSOC, V58, P13, DOI 10.1016/j.japh.2017.10.012
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Marti M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172310
   McClure CC, 2017, CLIN THER, V39, P1550, DOI 10.1016/j.clinthera.2017.07.003
   McKinstry B, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-56
   Meyer SB, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001389
   Mutua MK, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-6
   Nasir UN, 2016, HUM VACC IMMUNOTHER, V12, P658, DOI 10.1080/21645515.2015.1088617
   Nuwaha F, 2000, TROP MED INT HEALTH, V5, P364, DOI 10.1046/j.1365-3156.2000.00560.x
   Oyo-Ita A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008145.pub3
   Ozawa S, 2018, HEALTH POLICY PLANN, V33, P1009, DOI 10.1093/heapol/czy080
   Ozawa S, 2017, VACCINE, V35, P6429, DOI 10.1016/j.vaccine.2017.09.079
   Ozawa S, 2017, B WORLD HEALTH ORGAN, V95, P629, DOI 10.2471/BLT.16.178475
   Ozawa S, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1867-7
   Ozawa S, 2013, HUM VACC IMMUNOTHER, V9, P1774, DOI 10.4161/hv.24961
   Ozawa S, 2013, SOC SCI MED, V91, P10, DOI 10.1016/j.socscimed.2013.05.005
   Ozawa S, 2011, HEALTH POLICY PLANN, V26, pi20, DOI 10.1093/heapol/czr045
   Polinski JM, 2014, HEALTH EDUC RES, V29, P755, DOI 10.1093/her/cyu023
   Roberts L, 2007, SCIENCE, V317, P1842, DOI 10.1126/science.317.5846.1842
   Rolfe A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004134.pub3
   Sansgiry SS, 2017, J PHARM HEALTH SERV, V8, P123, DOI 10.1111/jphs.12172
   Semali IA, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-299
   Shapiro GK, 2018, VACCINE, V36, P660, DOI 10.1016/j.vaccine.2017.12.043
   Sodha SV, 2015, BRIT MED BULL, V113, P5, DOI 10.1093/bmb/ldv001
   Stuttaford M, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.24121
   UBOS, 2017, NAT POP HOUS CENS 20
   Uganda Bureau of Statistics (UBOS) and ICF, 2018, UG DEM HLTH SURV 201
   Uganda Bureau of Statistics (UBOS) and ICF International Inc, 2012, UG DEM HLTH SURV 201
   Vonasek BJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150131
   World Health Organization, 2016, UG IMPR ACC IMM SERV
   World Health Organization, 2018, VACCINES
   World Health Organization, 2013, WHO TRAD MED STRAT 2
NR 56
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 20
PY 2019
VL 37
IS 40
BP 6008
EP 6015
DI 10.1016/j.vaccine.2019.07.022
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA8YK
UT WOS:000488137000016
PM 31447127
DA 2020-05-12
ER

PT J
AU Klenov, OP
   Chumakova, NA
   Pokrovskaya, SA
   Noskov, AS
AF Klenov, Oleg P.
   Chumakova, Nataliya A.
   Pokrovskaya, Svetlana A.
   Noskov, Alexander S.
TI Impact of heat and mass transfer in porous catalytic monolith: CFD
   modeling of exothermic reaction
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Honeycomb catalyst; Porous structure; Exothermic reaction; Conversion
   rate; Computational fluid dynamics
ID PARTIAL OXIDATION; REACTORS; TEMPERATURE; TRANSIENT; PROFILES; BEHAVIOR;
   METHANE; SYNGAS; CH4; RH
AB Impact of mass and heat transfer on exothermic reaction performance in porous catalytic monolith with triangular channels is investigated by CFD modeling. Detailed analysis of spatial distributions of process characteristics for methane oxidation shows that in the initial part of catalyst volume there is the active subsurface layer. The domain of sharp gradients of the reaction rate is revealed that includes the parts of external surface and thin subsurface layers near the monolith inlet, which results in sharp rearrangement of 3D-field of temperature and reagent concentrations. It is shown that the formation of such conditions is strongly influenced by complex gaseous flow reconstruction with gas penetration into the catalyst volume, significant heat release, and heat transfer between channel wall and gas flow. Though the region with high reaction rate is rather short this could be of high importance for reactor design and selection of optimal operation conditions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Klenov, Oleg P.; Chumakova, Nataliya A.; Pokrovskaya, Svetlana A.; Noskov, Alexander S.] Boreskov Inst Catalysis, Pr Akad Lavrentieva 5, Novosibirsk 630090, Russia.
   [Chumakova, Nataliya A.; Pokrovskaya, Svetlana A.] Novosibirsk State Univ, Ul Pirogova 2, Novosibirsk 630090, Russia.
RP Chumakova, NA (reprint author), Boreskov Inst Catalysis, Pr Akad Lavrentieva 5, Novosibirsk 630090, Russia.
EM chum@catalysis.ru
RI Chumakova, Nataliya/D-2000-2014
OI Chumakova, Nataliya/0000-0002-6874-8731
FU  [AAAA-A17-117041710077-4];  [AAAA-A17-117041710076-7]
FX This work was conducted for Boreskov Institute of Catalysis within the
   framework of the budget projects nos. AAAA-A17-117041710077-4 and
   AAAA-A17-117041710076-7.
CR Beretta A, 2011, CATAL TODAY, V171, P79, DOI 10.1016/j.cattod.2011.03.081
   Beretta A, 2009, IND ENG CHEM RES, V48, P3825, DOI 10.1021/ie8017143
   Chen JW, 2008, APPL CATAL A-GEN, V345, P1, DOI 10.1016/j.apcata.2008.04.010
   CYBULSKI A, 2006, STRUCTURED CATALYSTS
   Farrauto RJ, 2014, CHEM ENG J, V238, P172, DOI 10.1016/j.cej.2013.07.004
   Forzatti P., 2008, HDB HETEROGENEOUS CA, P2411
   Gu T, 2016, CHEM ENG J, V284, P513, DOI 10.1016/j.cej.2015.09.005
   Heck R.M., 2009, CATALYTIC AIR POLLUT
   Hettel M, 2015, CATAL TODAY, V258, P230, DOI 10.1016/j.cattod.2015.02.011
   Hettel M, 2013, CATAL TODAY, V216, P2, DOI 10.1016/j.cattod.2013.05.005
   Horn R, 2006, CATAL LETT, V110, P169, DOI 10.1007/s10562-006-0117-8
   Khanaev V. M., 2007, CHEM ENG RES TRENDS, P127
   Klenov OP, 2011, CATAL IND, V3, P331, DOI 10.1134/S2070050411040039
   Klenov OP, 2009, CATAL TODAY, V144, P258, DOI 10.1016/j.cattod.2008.11.014
   Klenov OP, 2016, IND ENG CHEM RES, V55, P3879, DOI 10.1021/acs.iecr.5b04804
   Livio D, 2013, APPL CATAL A-GEN, V467, P530, DOI 10.1016/j.apcata.2013.07.054
   Maestri M, 2005, CATAL TODAY, V105, P709, DOI 10.1016/j.cattod.2005.06.045
   Michael BC, 2010, CHEM ENG SCI, V65, P3893, DOI 10.1016/j.ces.2010.03.033
   Moulijn JA, 2011, ADV CATAL, V54, P249, DOI 10.1016/B978-0-12-387772-7.00005-8
   Sadykov V, 2012, SYNGAS GENERATION HY
   Schlichting H, 2004, BOUNDARY LAYER THEOR
   Schmidt LD, 2003, CHEM ENG SCI, V58, P1037, DOI 10.1016/S0009-2509(02)00645-0
   Schwiedernoch R, 2003, CHEM ENG SCI, V58, P633, DOI 10.1016/S0009-2509(02)00589-4
   Tischer S, 2005, CATAL TODAY, V105, P407, DOI 10.1016/j.cattod.2005.06.061
   Twigg MV, 2007, APPL CATAL B-ENVIRON, V70, P2, DOI 10.1016/j.apcatb.2006.02.029
NR 25
TC 0
Z9 0
U1 2
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 1
EP 13
DI 10.1016/j.ces.2019.04.010
PG 13
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000001
DA 2020-05-12
ER

PT J
AU Hu, SW
   Liu, XH
AF Hu, Shanwei
   Liu, Xinhua
TI A general EMMS drag model applicable for gas-solid turbulent beds and
   cocurrent downers
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE EMMS drag; Simulation; Mesoscale; Cluster; Turbulent bed; Cocurrent
   downer
ID FLUIDIZED-BEDS; NUMERICAL-SIMULATION; MESOSCALE STRUCTURES; CFD
   SIMULATION; 2-PHASE FLOW; HYDRODYNAMICS; RISER; BEHAVIOR; HETEROGENEITY;
   GELDART
AB Eulerian-Eulerian models incorporated with the kinetic theory of granular flow were widely used in the simulation of gas-solid two-phase flow, while the effects of mesoscale structures such as particle clusters and gas bubbles could not be considered adequately if traditional homogeneous drag models were adopted in the coarse grid simulations. The energy minimization multiscale (EMMS) model has been proved to facilitate calculating a structure-dependent drag coefficient by considering particle clustering phenomena, which can be coupled with the two-fluid model (TFM) to improve the accuracy of coarse-grid simulation of gas-solid circulating fluidized beds. However, the original EMMS drag model cannot be further applied to the simulation of gas-solid fluidized beds with solids flow rate smaller than zero, e.g., turbulent fluidized beds and cocurrent downward flow, because the original cluster diameter correlation gives rise to a value smaller than single particle diameter or even negative value at extremely low solids fluxes or downward gas-solid flow. In this study, a new proposed cluster evolution equation is proposed by quantifying local clustering dynamics to replace the original cluster diameter correlation. The newly formulated EMMS drag model can be used to avoid a negative cluster diameter to be involved in calculating interphase drag force in the overall fluidization regime. The improved EMMS drag law is incorporated into the Eulerian-Eulerian model to simulate gas-solid turbulent fluidized beds and cocurrent downer reactors, since they both were widely used in many industrial processes. By analyzing local hydrodynamics as well as the axial and radial heterogeneous distributions in the two kinds of fluidized beds, it is clarified that the simulation using the improved EMMS drag model shows a better agreement with the experimental data than the computation using the homogeneous drag law. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hu, Shanwei; Liu, Xinhua] Chinese Acad Sci, Inst Proc Engn, State Key Lab Multiphase Complex Syst, Beijing 100190, Peoples R China.
RP Liu, XH (reprint author), Chinese Acad Sci, Inst Proc Engn, State Key Lab Multiphase Complex Syst, Beijing 100190, Peoples R China.
EM xhliu@ipe.ac.cn
FU Strategic Priority Research Program of the Chinese Academy of
   SciencesChinese Academy of Sciences [XDA21040400, XDA07080400]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [21376244, 91334107]
FX We would like to thank financial supports from the Strategic Priority
   Research Program of the Chinese Academy of Sciences (Nos. XDA21040400
   and XDA07080400) and the National Natural Science Foundation of China
   (Nos. 21376244 and 91334107).
CR Agrawal K, 2001, J FLUID MECH, V445, P151, DOI 10.1017/S0022112001005663
   Benzarti S, 2014, ADV POWDER TECHNOL, V25, P1737, DOI 10.1016/j.apt.2014.06.024
   Bi HT, 2000, CHEM ENG SCI, V55, P4789, DOI 10.1016/S0009-2509(00)00107-X
   Bolkan Y, 2003, POWDER TECHNOL, V132, P85, DOI 10.1016/S0032-5910(03)00059-7
   Chalermsinsuwan B, 2012, CHEM ENG J, V189, P314, DOI 10.1016/j.cej.2012.02.020
   Chen S, 2016, POWDER TECHNOL, V287, P29, DOI 10.1016/j.powtec.2015.09.005
   Du B, 2003, AICHE J, V49, P1109, DOI 10.1002/aic.690490506
   Gao JS, 2009, AICHE J, V55, P1680, DOI 10.1002/aic.11824
   Gao X, 2012, POWDER TECHNOL, V228, P1, DOI 10.1016/j.powtec.2012.04.025
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   Hong K, 2016, POWDER TECHNOL, V296, P2, DOI 10.1016/j.powtec.2015.07.003
   HORIO M, 1994, CHEM ENG SCI, V49, P2413, DOI 10.1016/0009-2509(94)E0071-W
   Hu SW, 2017, CHEM ENG J, V307, P326, DOI 10.1016/j.cej.2016.08.084
   Hu SW, 2013, CHEM ENG SCI, V96, P165, DOI 10.1016/j.ces.2013.04.004
   Jian H, 2003, POWDER TECHNOL, V138, P73, DOI 10.1016/j.powtec.2003.07.001
   JOHNSON PC, 1987, J FLUID MECH, V176, P67, DOI 10.1017/S0022112087000570
   Karimipour S, 2006, IND ENG CHEM RES, V45, P7204, DOI 10.1021/ie060026k
   KMIEC A, 1980, CHEM ENG J BIOCH ENG, V19, P189, DOI 10.1016/0300-9467(80)80029-3
   Kwauk M., 1963, SCI SINICA, V12, P587
   Lanza A, 2012, CHEM ENG J, V200, P439, DOI 10.1016/j.cej.2012.06.027
   Lehner P, 1999, CHEM ENG SCI, V54, P5471, DOI 10.1016/S0009-2509(99)00286-9
   Lettieri P, 2003, INT J CHEM REACT ENG, V1
   Li J, 1990, CIRCULATING FLUIDIZE, P105
   Li Y., 1980, FLUIDIZATION, P537
   Lim KS, 1995, INT J MULTIPHAS FLOW, V21, P141, DOI 10.1016/0301-9322(95)00038-Y
   Luo H, 2017, CHEM ENG J, V326, P47, DOI 10.1016/j.cej.2017.04.145
   Milioli CC, 2013, AICHE J, V59, P3265, DOI 10.1002/aic.14130
   Nikolopoulos A, 2013, CHEM ENG SCI, V90, P137, DOI 10.1016/j.ces.2012.12.007
   Nikolopoulos A, 2010, CHEM ENG SCI, V65, P4080, DOI 10.1016/j.ces.2010.03.054
   Nikolopoulos A, 2012, PARTICUOLOGY, V10, P699, DOI 10.1016/j.partic.2012.09.001
   Shah MT, 2011, CHEM ENG J, V168, P812, DOI 10.1016/j.cej.2011.01.076
   Shu Z, 2015, POWDER TECHNOL, V281, P34, DOI 10.1016/j.powtec.2015.04.055
   TSUO YP, 1990, AICHE J, V36, P885, DOI 10.1002/aic.690360610
   Ullah A, 2018, PARTICUOLOGY, V38, P165, DOI 10.1016/j.partic.2017.06.007
   Ullah A, 2013, CHEM ENG SCI, V92, P89, DOI 10.1016/j.ces.2013.01.019
   Vaishali S, 2008, CHEM ENG SCI, V63, P5107, DOI 10.1016/j.ces.2008.06.014
   Wang W, 2007, CHEM ENG SCI, V62, P208, DOI 10.1016/j.ces.2006.08.017
   WANG Z, 1992, POWDER TECHNOL, V70, P271, DOI 10.1016/0032-5910(92)80062-2
   WILHELM RH, 1948, CHEM ENG PROG, V44, P201
   Xie N, 2008, POWDER TECHNOL, V182, P1, DOI 10.1016/j.powtec.2007.07.005
   Yang N, 2003, CHEM ENG J, V96, P71, DOI 10.1016/j.cej.2003.08.006
   YERUSHALMI J, 1976, IND ENG CHEM PROC DD, V15, P47, DOI 10.1021/i260057a010
   Yuu S, 2001, POWDER TECHNOL, V118, P32, DOI 10.1016/S0032-5910(01)00292-3
   Zeneli M, 2015, CHEM ENG SCI, V138, P482, DOI 10.1016/j.ces.2015.08.008
   Zhang DZ, 2002, INT J MULTIPHAS FLOW, V28, P805, DOI 10.1016/S0301-9322(02)00005-8
   Zhang H, 1999, CHEM ENG SCI, V54, P5461, DOI 10.1016/S0009-2509(99)00284-5
   Zhang H, 2000, CHEM ENG SCI, V55, P4367, DOI 10.1016/S0009-2509(00)00087-7
   Zhang MH, 2008, POWDER TECHNOL, V184, P151, DOI 10.1016/j.powtec.2007.11.036
   ZHANG YF, 1995, POWDER TECHNOL, V84, P221, DOI 10.1016/0032-5910(95)02991-A
   Zhang ZX, 2016, PARTICUOLOGY, V29, P110, DOI 10.1016/j.partic.2016.01.011
   Zhao YZ, 2010, POWDER TECHNOL, V199, P2, DOI 10.1016/j.powtec.2009.04.014
   Zhu LT, 2018, CHEM ENG SCI, V192, P759, DOI 10.1016/j.ces.2018.08.026
NR 52
TC 6
Z9 6
U1 12
U2 29
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 14
EP 24
DI 10.1016/j.ces.2019.04.033
PG 11
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000002
DA 2020-05-12
ER

PT J
AU Zhang, F
   Erriguible, A
   Marre, S
AF Zhang, Fan
   Erriguible, Arnaud
   Marre, Samuel
TI Investigating laminar mixing in high pressure microfluidic systems
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Supercritical antisolvent process (SAS); Micro particle image
   velocimetry (mu PIV); High pressure microfluidic mixing; Computational
   fluid dynamics (CFD); Mixing time constant
ID MICRONIZATION; PRECIPITATION; TEMPERATURE; MECHANISMS
AB In this study, the hydrodynamic behavior of coflowing fluids CO2 and ethanol has been investigated in a high-pressure microfluidic reactor working at supercritical conditions, in which the two fluids are completely miscible. The velocity field has been measured by Micro Particle Image Velocimetry (mu PIV) for different temperatures between 20 and 50 degrees C at a fixed pressure of 100 bar. Meanwhile, we have developed a model to investigate numerically the mixing. By comparing the experimental results to a three-dimensional numerical simulation, the mixing model has been validated for the laminar coflow in the micromixer. In order to understand the mixing condition effects, several parameters have been investigated, namely: the Reynolds number, the temperature and the CO2/ethanol ratio. A mixing time constant is defined by using the segregation intensity curve and later used to characterize the mixing quality. The characteristic mixing time has been related to the laminar energy dissipation rate epsilon, similarly to the stretching efficiency model in previous studies. The mixing quality is eventually analyzed in term of segregation index and mixing time. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhang, Fan; Erriguible, Arnaud; Marre, Samuel] Univ Bordeaux, CNRS, Bordeaux INP, ICMCB,UMR 5026, F-33600 Pessac, France.
   [Erriguible, Arnaud] Univ Bordeaux, CNRS, Bordeaux INP, I2M,UMR 5295, F-33600 Pessac, France.
RP Zhang, F (reprint author), Univ Bordeaux, CNRS, Bordeaux INP, ICMCB,UMR 5026, F-33600 Pessac, France.
OI MARRE, Samuel/0000-0001-8889-187X
FU French National Research AgencyFrench National Research Agency (ANR)
   [ANR-17-CE07-0029]; University of Bordeaux
FX This study was supported by the French National Research Agency
   (ANR-17-CE07-0029 -SUPERFON) and the University of Bordeaux (Ph.D.
   funding of Fan Zhang).
CR Aubin J, 2010, CHEM ENG SCI, V65, P2065, DOI 10.1016/j.ces.2009.12.001
   Bahrami M, 2005, 3 INT C MICR MIN
   Baldyga J, 1984, CHEM ENG COMMUN, V28, P259, DOI 10.1080/00986448408940137
   Baldyga J., 1986, ENCY FLUID MECH FLOW, V1
   Baldyga J, 2010, CHEM ENG RES DES, V88, P331, DOI 10.1016/j.cherd.2010.01.019
   Boutin O, 2012, J CRYST GROWTH, V342, P13, DOI 10.1016/j.jcrysgro.2010.11.099
   Campardelli R, 2017, J SUPERCRIT FLUID, V130, P273, DOI 10.1016/j.supflu.2017.06.014
   Chang SC, 2008, CHEM ENG J, V139, P416, DOI 10.1016/j.cej.2007.12.008
   Couto R, 2015, CHEM COMMUN, V51, P1008, DOI 10.1039/c4cc07878k
   DANCKWERTS PV, 1958, CHEM ENG SCI, V8, P93, DOI 10.1016/0009-2509(58)80040-8
   De Marco I, 2011, J SUPERCRIT FLUID, V58, P295, DOI 10.1016/j.supflu.2011.06.005
   Erriguible A, 2013, COMPUT CHEM ENG, V52, P1, DOI 10.1016/j.compchemeng.2012.12.002
   Fadli T, 2010, J SUPERCRIT FLUID, V52, P193, DOI 10.1016/j.supflu.2010.01.008
   Falgout RD, 2002, LECT NOTES COMPUT SC, V2331, P632
   Falk L, 2010, CHEM ENG SCI, V65, P405, DOI 10.1016/j.ces.2009.05.045
   Ghanem A, 2014, CHEM ENG RES DES, V92, P205, DOI 10.1016/j.cherd.2013.07.013
   Hayduk W, 1982, CANAD J CHEM ENG, V60
   Jiang GS, 1996, J COMPUT PHYS, V126, P202, DOI 10.1006/jcph.1996.0130
   Maeta Y, 2015, FLUID PHASE EQUILIBR, V405, P96, DOI 10.1016/j.fluid.2015.07.025
   Marre S, 2010, IND ENG CHEM RES, V49, P11310, DOI 10.1021/ie101346u
   Metzger L., 2017, THESIS
   Miguel F, 2008, CHEM ENG PROCESS, V47, P1594, DOI 10.1016/j.cep.2007.07.008
   Rossmann M, 2014, J SUPERCRIT FLUID, V89, P16, DOI 10.1016/j.supflu.2014.02.010
   Zhang F, 2018, PHYS REV FLUIDS, V3, DOI 10.1103/PhysRevFluids.3.092201
NR 24
TC 1
Z9 1
U1 9
U2 48
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 25
EP 35
DI 10.1016/j.ces.2019.03.063
PG 11
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000003
DA 2020-05-12
ER

PT J
AU Harkat, MF
   Mansouri, M
   Nounou, M
   Nounou, H
AF Harkat, M. -F.
   Mansouri, M.
   Nounou, M.
   Nounou, H.
TI Fault detection of uncertain nonlinear process using interval-valued
   data-driven approach
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Kernel PCA; Interval-valued data; Fault detection; Tennessee Eastman
   process
ID PRINCIPAL COMPONENT ANALYSIS; LINEAR-REGRESSION; SENSOR FDI; PCA;
   STRATEGY; NUMBER; SCHEME
AB This paper introduces a new structure kernel principal component analysis (KPCA) that can successfully model symbolic interval-valued data for fault detection. In the proposed structure, interval KPCA (IKPCA) method is proposed to deal with interval-valued data. Two IKPCA models are proposed. The first model is based on the centers and ranges of intervals IKPCA(CR) and the second model is based the upper and lower bounds of intervals IKPCA(UL). Residuals are generated and fault detection indices are computed. The aim of using IKPCA is to ensure robustness to false alarm without affecting the fault detection performance. The proposed fault detection approach is carried out using simulation example and Tennessee Eastman Process (TEP). The obtained results demonstrate the effectiveness of the proposed technique. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Harkat, M. -F.; Nounou, M.] Texas A&M Univ Qatar, Chem Engn Program, Doha, Qatar.
   [Mansouri, M.; Nounou, H.] Texas A&M Univ Qatar, Elect & Comp Engn Program, Doha, Qatar.
RP Harkat, MF (reprint author), Texas A&M Univ Qatar, Chem Engn Program, Doha, Qatar.
EM mohamed.harkat@qatar.tamu.edu
RI HARKAT, Mohamed-Faouzi/I-2692-2019
OI HARKAT, Mohamed-Faouzi/0000-0003-2093-0902; Mansouri,
   Majdi/0000-0001-6390-4304
CR Ait-Izem T, 2017, QUAL ENG, V11, P1
   Ait-Izem T, 2018, J PROCESS CONTR, V63, P29, DOI 10.1016/j.jprocont.2018.01.006
   Alcala CF, 2010, IND ENG CHEM RES, V49, P7849, DOI 10.1021/ie9018947
   Ammiche M, 2018, CHEM ENG SCI, V187, P269, DOI 10.1016/j.ces.2018.05.001
   Billard L., 2007, SELECTED CONTRIBUTIO, P3
   Bock H.-H., 2012, ANAL SYMBOLIC DATA E
   CAZES P, 1997, REV STAT APPL, V45, P5
   Choi SW, 2005, CHEMOMETR INTELL LAB, V75, P55, DOI 10.1016/j.chemolab.2004.05.001
   Chouakria A, 1998, THESIS
   Costa A, 2010, PROC INT C TOOLS ART, P375, DOI 10.1109/ICTAI.2010.133
   Cui PL, 2008, EXPERT SYST APPL, V34, P1210, DOI 10.1016/j.eswa.2006.12.010
   D'Urso P, 2004, CHEMOMETR INTELL LAB, V70, P179, DOI 10.1016/j.chemolab.2003.11.005
   da Costa AFBF, 2013, J INTELL INF SYST, V40, P109, DOI 10.1007/s10844-012-0219-2
   Domingues MAO, 2010, PATTERN RECOGN LETT, V31, P1991, DOI 10.1016/j.patrec.2010.06.008
   Dong D, 1996, COMPUT CHEM ENG, V20, P65, DOI 10.1016/0098-1354(95)00003-K
   DOWNS JJ, 1993, COMPUT CHEM ENG, V17, P245, DOI 10.1016/0098-1354(93)80018-I
   Ge ZQ, 2009, CHEM ENG SCI, V64, P2245, DOI 10.1016/j.ces.2009.01.050
   Gertler J., 1997, IFAC P, V30, P833
   Harkat MF, 2006, J PROCESS CONTR, V16, P625, DOI 10.1016/j.jprocont.2005.09.007
   Harkat MF, 2018, ENVIRON RES, V160, P183, DOI 10.1016/j.envres.2017.09.023
   JACKSON JE, 1979, TECHNOMETRICS, V21, P341, DOI 10.2307/1267757
   Kano M, 2002, AICHE J, V48, P1231, DOI 10.1002/aic.690480610
   KOURTI T, 1995, CHEMOMETR INTELL LAB, V28, P3, DOI 10.1016/0169-7439(94)00079-X
   KRAMER MA, 1991, AICHE J, V37, P233, DOI 10.1002/aic.690370209
   KRESTA JV, 1991, CAN J CHEM ENG, V69, P35, DOI 10.1002/cjce.5450690105
   Le-Rademacher J, 2012, J COMPUT GRAPH STAT, V21, P413, DOI 10.1080/10618600.2012.679895
   Lee JM, 2004, CHEM ENG SCI, V59, P223, DOI 10.1016/j.ces.2003.09.012
   Li G, 2011, IEEE T CONTR SYST T, V19, P1114, DOI 10.1109/TCST.2010.2071415
   Lima ED, 2008, COMPUT STAT DATA AN, V52, P1500, DOI 10.1016/j.csda.2007.04.014
   LYMAN PR, 1995, COMPUT CHEM ENG, V19, P321, DOI 10.1016/0098-1354(94)00057-U
   MACGREGOR JF, 1995, CONTROL ENG PRACT, V3, P403, DOI 10.1016/0967-0661(95)00014-L
   Mansouri M., 2018, CHEMOMET INTELL LAB
   Mansouri M, 2016, J LOSS PREVENT PROC, V40, P334, DOI 10.1016/j.jlp.2016.01.011
   Mika S., 1991, ADV NEURAL INFORM PR, P536
   Palumbo F, 2003, NEW DEVELOPMENTS IN PSYCHOMETRICS, P641, DOI 10.1007/978-4-431-66996-8_74
   Pimentel B., 2013, P 20 ACM INT C INF K, P2189
   Qin SJ, 2012, ANNU REV CONTROL, V36, P220, DOI 10.1016/j.arcontrol.2012.09.004
   Qin SJ, 2003, J CHEMOMETR, V17, P480, DOI 10.1002/cem.800
   Rathi Y., 2006, IMAGE PROCESSING ALG, V6064
   Rato T, 2016, AICHE J, V62, P1478, DOI 10.1002/aic.15062
   RUSSELL E, 2000, ADV IND CON, P3
   Russell E.L., 2012, DATA DRIVEN METHODS
   Russell EL, 2000, CHEMOMETR INTELL LAB, V51, P81, DOI 10.1016/S0169-7439(00)00058-7
   Scholkopf B, 1998, NEURAL COMPUT, V10, P1299, DOI 10.1162/089976698300017467
   Scholkopf B., 1997, KERNEL PRINCIPAL COM, DOI [DOI 10.1007/BFB0020217, 10.1007/bfb0020217]
   Sumana C, 2012, INT J ADV ENG SCI AP, V4, P52, DOI 10.1007/s12572-012-0060-4
   Tamura M, 2007, COMPUT CHEM ENG, V31, P1035, DOI 10.1016/j.compchemeng.2006.09.004
   TAN SF, 1995, AICHE J, V41, P1471, DOI 10.1002/aic.690410612
   Valle S, 1999, IND ENG CHEM RES, V38, P4389, DOI 10.1021/ie990110i
   Wang HQ, 2002, IND ENG CHEM RES, V41, P2455, DOI 10.1021/ie0007567
   Yu HY, 2017, CHEM ENG SCI, V168, P325, DOI 10.1016/j.ces.2017.04.048
NR 51
TC 4
Z9 4
U1 7
U2 33
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 36
EP 45
DI 10.1016/j.ces.2018.11.063
PG 10
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000004
DA 2020-05-12
ER

PT J
AU Santana, ER
   Pozzetti, G
   Peters, B
AF Santana, Edder Rabadan
   Pozzetti, Gabriele
   Peters, Bernhard
TI Application of a dual-grid multiscale CFD-DEM coupling method to model
   the raceway dynamics in packed bed reactors
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CFD-DEM coupling; Multiscale simulation; Dual-grid approach; Blast
   injection; Raceway; Packed bed reactors
ID DISCRETE ELEMENT METHOD; GAS-SOLID FLOW; COMPUTATIONAL FLUID-DYNAMICS;
   NUMERICAL-SIMULATION; BLAST-FURNACE; COAL/COKE COMBUSTION; BEHAVIOR
AB A CFD-DEM coupling model with dual-grid multiscale approach is used to model high-speed injection into a packed bed reactor. The present CFD-DEM coupling uses a separate coarse grid for the discrete phase (DEM model) and a fine grid for the continuum phase (CFD model). This CFD-DEM approach allows high grid resolution for solving the gas phase and preserving the accuracy of the CFD solution at higher Reynolds numbers. The dual-grid multiscale approach is used to model high-speed lateral gas injection in a two-dimensional blast furnace reactor. Blast velocities up to u = 230 m s(-1), as in real blast furnace operation, are used to investigate the formation and dynamics of the raceway inside the reactor. The effect of the blast velocity on the size and shape of the raceway was investigated using different jet velocities. It is shown how the use of an adequate grid resolution for the continuum phase is needed in order to achieve a grid independent solution and how it influenced on the discrete solution. It was observed that the variation of the blast velocity directly influenced on the size and shape of the cavity. However, the particles and the flow showed the same pattern and behavior at the different investigated blast velocities, with a proportional scaling according to the gas velocity. At the investigated blast velocities the raceway formed very rapidly showing a transition period with lateral periodic oscillations before stabilization was observed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Santana, Edder Rabadan; Pozzetti, Gabriele; Peters, Bernhard] Univ Luxembourg, 6 Ave Fonte, L-4364 Esch Sur Alzette, Luxembourg.
RP Santana, ER (reprint author), Univ Luxembourg, 6 Ave Fonte, L-4364 Esch Sur Alzette, Luxembourg.
EM edder.rabadan@uni.lu
FU Luxembourg National Research Fund (FNR)Luxembourg National Research Fund
FX The authors would like to thank to the Luxembourg National Research Fund
   (FNR) for the financial support of this project and to the HPC Cluster
   facilities of the University of Luxembourg.
CR Adema A., 2014, THESIS
   Adema AT, 2010, ISIJ INT, V50, P954, DOI 10.2355/isijinternational.50.954
   ELLIOTT JF, 1952, JOM-J MIN MET MAT S, V4, P709
   ERGUN S, 1949, IND ENG CHEM, V41, P1179, DOI 10.1021/ie50474a011
   FLINT PJ, 1992, METALL TRANS B, V23, P267, DOI 10.1007/BF02656282
   Geerdes M, 2009, MODERN BLAST FURNACE IRONMAKING: AN INTRODUCTION, SECOND EDITION, P1
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   Hertz H. J., 1881, REINE ANGEW MATH, V92, P156
   Hilton JE, 2012, CHEM ENG SCI, V80, P306, DOI 10.1016/j.ces.2012.06.044
   HO CK, 1990, POWDER TECHNOL, V63, P13, DOI 10.1016/0032-5910(90)80003-H
   Kuipers JAM, 1997, REV CHEM ENG, V13, P1
   Launder B. E., 1974, Computer Methods in Applied Mechanics and Engineering, V3, P269, DOI 10.1016/0045-7825(74)90029-2
   Li YQ, 2014, APPL THERM ENG, V67, P72, DOI 10.1016/j.applthermaleng.2014.02.062
   Mathieson JG, 2005, FUEL, V84, P1229, DOI 10.1016/j.fuel.2004.06.036
   Matsui Y, 2005, ISIJ INT, V45, P1439, DOI 10.2355/isijinternational.45.1439
   MINDLIN RD, 1949, J APPL MECH-T ASME, V16, P259
   Natsui S, 2011, ISIJ INT, V51, P41, DOI 10.2355/isijinternational.51.41
   Nogami H, 2004, ISIJ INT, V44, P2150, DOI 10.2355/isijinternational.44.2150
   Peters Bernhard, 2017, EPJ Web of Conferences, V140, DOI 10.1051/epjconf/201714013001
   Peters B, 2012, MECHANIKA, P177, DOI 10.5755/j01.mech.18.2.1564
   Peters B., 2013, SCHOLARLY J ENG RES, V2, P1
   Peters B, 2019, PARTICUOLOGY, V44, P176, DOI 10.1016/j.partic.2018.04.005
   PILCHER KA, 1990, CHEM ENG SCI, V45, P2535, DOI 10.1016/0009-2509(90)80139-6
   Pozzetti G, 2019, J COMPUT PHYS, V378, P708, DOI 10.1016/j.jcp.2018.11.030
   Pozzetti G, 2018, ADV POWDER TECHNOL, V29, P3220, DOI 10.1016/j.apt.2018.08.025
   Pozzetti G, 2018, POWDER TECHNOL, V333, P229, DOI 10.1016/j.powtec.2018.04.006
   Pozzetti G, 2018, INT J MULTIPHAS FLOW, V99, P186, DOI 10.1016/j.ijmultiphaseflow.2017.10.008
   Pozzetti G, 2017, AIP CONF PROC, V1863, DOI 10.1063/1.4992362
   Rabadan-Santana E, 2016, P INT C COMP METH, V3, P294
   Samiei K, 2013, COMPUT CHEM ENG, V49, P183, DOI 10.1016/j.compchemeng.2012.10.009
   Shen YS, 2011, FUEL, V90, P728, DOI 10.1016/j.fuel.2010.08.030
   Shen YS, 2012, MINER ENG, V33, P54, DOI 10.1016/j.mineng.2011.10.014
   TAKAHASHI H, 1993, ISIJ INT, V33, P655, DOI 10.2355/isijinternational.33.655
   Tang HQ, 2015, PROCEDIA ENGINEER, V102, P1583, DOI 10.1016/j.proeng.2015.01.294
   Umekage T, 2005, ISIJ INT, V45, P1416, DOI 10.2355/isijinternational.45.1416
   Umekage T, 2007, ISIJ INT, V47, P659, DOI 10.2355/isijinternational.47.659
   Wright B, 2011, POWDER TECHNOL, V208, P86, DOI 10.1016/j.powtec.2010.12.006
   Xiao H, 2011, COMMUN COMPUT PHYS, V9, P297, DOI 10.4208/cicp.260509.230210a
   Xu BH, 2000, POWDER TECHNOL, V109, P13, DOI 10.1016/S0032-5910(99)00223-5
   Xu BH, 1998, CHEM ENG SCI, V53, P2646
   Yang WJ, 2015, CHEM ENG J, V278, P339, DOI 10.1016/j.cej.2014.11.144
   Yang WJ, 2014, IND ENG CHEM RES, V53, P8245, DOI 10.1021/ie404158e
NR 42
TC 1
Z9 1
U1 5
U2 39
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 46
EP 57
DI 10.1016/j.ces.2019.04.025
PG 12
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000005
DA 2020-05-12
ER

PT J
AU Maghami, S
   Mehrabani-Zeinabad, A
   Sadeghi, M
   Sanchez-Lainez, J
   Zornoza, B
   Tellez, C
   Coronas, J
AF Maghami, Saeid
   Mehrabani-Zeinabad, Arjomand
   Sadeghi, Morteza
   Sanchez-Lainez, Javier
   Zornoza, Beatriz
   Tellez, Carlos
   Coronas, Joaquin
TI Mathematical modeling of temperature and pressure effects on
   permeability, diffusivity and solubility in polymeric and mixed matrix
   membranes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Polymeric membrane; Mixed matrix membrane; Permeability; Diffusivity;
   Solubility; Temperature; Pressure; Mathematical modeling
ID GAS SEPARATION PROPERTIES; POLYURETHANE MEMBRANE; PERMEATION;
   PERFORMANCE; CO2; DEPENDENCE; TRANSPORT; SORPTION; CH4;
   POLY(DIMETHYLSILOXANE)
AB Due to the temperature and pressure dependency of gas transport through polymeric and mixed matrix membranes, probing of their separation performance at different operational conditions seems crucial to determine an optimal operational condition. To minimize the number of costly and time consuming experiments, a modified form of van't Hoff-Arrhenius model was developed to consider the simultaneous effects of temperature and pressure on the separation performance of polymeric and mixed matrix membranes. Moreover, the proposed model is capable to consider pressure dependency of energetic parameters of Arrhenius model including activation energies of permeability and diffusivity, heat of sorption and the corresponding pre-exponential factors. The validity of the proposed model was investigated by using permeation coefficients of CO2 and N-2 in a binary mixture through 6FDA-DAM at different temperatures in the range of 35-55 degrees C and in the feed pressure range from 2 to 5 atm. Besides, from data taken from the literature, the proposed model was validated by the prediction of temperature and pressure dependency of transport properties of glassy and rubbery polymers as well as mixed matrix membranes (MMMs) for different gas molecules including He, H-2, CO2, O-2, N-2, CH4 and C4H10. Predictions corresponding to 300 data points revealed that the maximum average absolute relative error was 5.1%. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Maghami, Saeid; Mehrabani-Zeinabad, Arjomand; Sadeghi, Morteza] Isfahan Univ Technol, Dept Chem Engn, Esfahan 8415683111, Iran.
   [Maghami, Saeid; Sanchez-Lainez, Javier; Zornoza, Beatriz; Tellez, Carlos; Coronas, Joaquin] Univ Zaragoza, CSIC, Inst Mat Aragon ICMA, Chem & Environm Engn Dept,INA, Zaragoza 50018, Spain.
RP Sadeghi, M (reprint author), Isfahan Univ Technol, Dept Chem Engn, Esfahan 8415683111, Iran.; Coronas, J (reprint author), Univ Zaragoza, CSIC, Inst Mat Aragon ICMA, Chem & Environm Engn Dept,INA, Zaragoza 50018, Spain.
EM m-sadeghi@cc.iut.ac.ir; coronas@unizar.es
RI Tellez, Carlos/L-8832-2013; Zornoza, Beatriz/C-3283-2017
OI Tellez, Carlos/0000-0002-4954-1188; Sanchez-Lainez,
   Javier/0000-0001-6627-0079; Zornoza Encabo, Beatriz/0000-0002-9934-1707;
   Sadeghi, Morteza/0000-0002-0075-1520; Coronas,
   Joaquin/0000-0003-1512-4500
FU Spanish MINECO; FEDEREuropean Union (EU) [MAT2016-77290-R]; Aragon
   GovernmentGobierno de Aragon [T43-17R]; ESF; Spanish Ministry of
   Economy, Industry and Competitiveness Program FPI2014; Spanish Education
   Ministry Program FPU2014
FX Financial support from the Spanish MINECO and FEDER (MAT2016-77290-R),
   the Aragon Government (T43-17R) and the ESF is gratefully acknowledged.
   L.P. thanks the Spanish Ministry of Economy, Industry and
   Competitiveness Program FPI2014 for her PhD grant. J.S.-L. thanks the
   Spanish Education Ministry Program FPU2014 for his PhD grant.
CR Adatoz E, 2015, SEP PURIF TECHNOL, V152, P207, DOI 10.1016/j.seppur.2015.08.020
   Ahmad MZ, 2018, J MEMBRANE SCI, V558, P64, DOI 10.1016/j.memsci.2018.04.040
   Ahmadpour E, 2016, J NAT GAS SCI ENG, V35, P33, DOI 10.1016/j.jngse.2016.08.042
   Bachman JE, 2016, NAT MATER, V15, P845, DOI [10.1038/NMAT4621, 10.1038/nmat4621]
   Bakonyi P, 2013, INT J HYDROGEN ENERG, V38, P9673, DOI 10.1016/j.ijhydene.2013.05.158
   BARBARI TA, 1989, J MEMBRANE SCI, V42, P69, DOI 10.1016/S0376-7388(00)82366-2
   Castarlenas S, 2017, J MEMBRANE SCI, V526, P205, DOI 10.1016/j.memsci.2016.12.041
   Cong HL, 2007, SEP PURIF TECHNOL, V55, P281, DOI 10.1016/j.seppur.2006.12.017
   COSTELLO LM, 1994, J POLYM SCI POL PHYS, V32, P701, DOI 10.1002/polb.1994.090320412
   Duthie X, 2007, J MEMBRANE SCI, V294, P40, DOI 10.1016/j.memsci.2007.02.004
   Ebadi A, 2015, J MEMBRANE SCI, V490, P364, DOI [10.1016/j.memsci.2015.04.070, DOI 10.1016/J.MEMSCI.2015.04.070]
   Erucar I, 2011, IND ENG CHEM RES, V50, P12606, DOI 10.1021/ie201885s
   Flory P.J., 1953, PRINCIPLES POLYM CHE
   Guo XY, 2018, CHEM ENG SCI, V189, P277, DOI 10.1016/j.ces.2018.06.008
   Isfahani AP, 2018, ACS APPL MATER INTER, V10, P17366, DOI 10.1021/acsami.7b18475
   Isfahani AP, 2016, J IND ENG CHEM, V44, P67, DOI 10.1016/j.jiec.2016.08.012
   Jha P, 2006, J MEMBRANE SCI, V272, P125, DOI 10.1016/j.memsci.2005.07.039
   KUMAZAWA H, 1994, J MEMBRANE SCI, V97, P7, DOI 10.1016/0376-7388(94)00143-M
   Laghaei M, 2016, J MEMBRANE SCI, V513, P20, DOI 10.1016/j.memsci.2016.04.039
   Li P, 2014, J MEMBRANE SCI, V450, P380, DOI 10.1016/j.memsci.2013.09.030
   Liu L, 2006, CHEM ENG SCI, V61, P6142, DOI 10.1016/j.ces.2006.05.045
   Maghami S, 2017, POLYM TEST, V63, P25, DOI 10.1016/j.polymertesting.2017.07.021
   Merkel TC, 2002, SCIENCE, V296, P519, DOI 10.1126/science.1069580
   Merkel TC, 2001, J MEMBRANE SCI, V191, P85, DOI 10.1016/S0376-7388(01)00452-5
   Moghadam F, 2011, SEP PURIF TECHNOL, V77, P128, DOI 10.1016/j.seppur.2010.11.032
   Prabhakar RS, 2005, IND ENG CHEM RES, V44, P1547, DOI 10.1021/ie0492909
   Rabiee H, 2014, J MEMBRANE SCI, V469, P43, DOI 10.1016/j.memsci.2014.06.026
   Raharjo RD, 2007, J MEMBRANE SCI, V306, P75, DOI 10.1016/j.memsci.2007.08.014
   Rezakazemi M, 2012, INT J HYDROGEN ENERG, V37, P14576, DOI 10.1016/j.ijhydene.2012.06.104
   Rungta M, 2012, CARBON, V50, P1488, DOI 10.1016/j.carbon.2011.11.019
   Sabzevari SA, 2013, MACROMOL CHEM PHYS, V214, P2367, DOI 10.1002/macp.201300280
   Sadeghi M, 2018, CHEM ENG SCI, V192, P688, DOI 10.1016/j.ces.2018.08.030
   Sadeghi M, 2018, CHEMISTRYSELECT, V3, P3302, DOI 10.1002/slct.201703170
   Sadeghi M, 2011, J MEMBRANE SCI, V376, P188, DOI 10.1016/j.memsci.2011.04.021
   Sadrzadeh M, 2009, J MEMBRANE SCI, V342, P327, DOI 10.1016/j.memsci.2009.07.015
   Safari M, 2009, INT J GREENH GAS CON, V3, P3, DOI 10.1016/j.ijggc.2008.05.001
   Scholes CA, 2012, AICHE J, V58, P967, DOI 10.1002/aic.12610
   Semsarzadeh MA, 2013, J MEMBRANE SCI, V432, P115, DOI 10.1016/j.memsci.2013.01.005
   Seoane B, 2015, CHEM SOC REV, V44, P2421, DOI 10.1039/c4cs00437j
   Shahrooz M, 2016, MACROMOLECULES, V49, P4220, DOI 10.1021/acs.macromol.6b00617
   Tavasoli E, 2018, FIBER POLYM, V19, P2049, DOI 10.1007/s12221-018-8424-4
   Topuz B, 2012, J MEMBRANE SCI, V415, P725, DOI 10.1016/j.memsci.2012.05.060
   Wu FW, 2006, CHINESE J CHEM ENG, V14, P700, DOI 10.1016/S1004-9541(06)60138-9
   Yilmaz G, 2012, IND ENG CHEM RES, V51, P14218, DOI 10.1021/ie302290a
   Zornoza B, 2015, AICHE J, V61, P4481, DOI 10.1002/aic.15011
   Zornoza B, 2011, CHEM COMMUN, V47, P9522, DOI 10.1039/c1cc13431k
NR 46
TC 7
Z9 7
U1 9
U2 43
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 58
EP 73
DI 10.1016/j.ces.2019.04.037
PG 16
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000006
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Moura-Nickel, CD
   Tachinski, CG
   Landers, R
   De Noni, A
   Virmond, E
   Peterson, M
   Moreira, RDPM
   Jose, HJ
AF Moura-Nickel, Camilla Daniela
   Tachinski, Camila Gaspodini
   Landers, Richard
   De Noni Junior, Agenor
   Virmond, Elaine
   Peterson, Michael
   Peralta Muniz Moreira, Regina de Fatima
   Jose, Humberto Jorge
TI Syngas production by dry reforming of methane using lyophilized nickel
   catalysts
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Hydrogen production; CO2 utilization; Coke; Alumina; Epoxide-initiated
   gelation method
ID SUPPORTED COBALT CATALYST; CO-RICH HYDROGEN; CARBON-DIOXIDE; NI; CH4;
   PERFORMANCE; ALPHA-AL2O3; PROMOTERS; ETHANOL; IMPACT
AB In this work, lyophilized nickel catalysts were synthesized and compared with a commercial catalyst (CCom) in the process of dry reforming of methane. Ni-Al2O3 catalysts were prepared by epoxide-initiated gelation method and lyophilized with different percentage of active phase: 5 wt% (LNi5), 10 wt% (LNi10), 15 wt% (LNi15) and 20 wt% (LNi20). The catalysts were characterized by physical nitrogen adsorption, infrared spectroscopy, X-ray diffractometry, scanning electron microscopy and X-ray photoelectron spectroscopy. The catalytic tests were performed at 600 degrees C, 700 degrees C and 800 degrees C. All catalysts were active in the reforming reactions except the LNi5 and CCom catalysts at temperatures of 600 degrees C and 700 degrees C. The LNi10 catalyst at 800 degrees C has presented the highest syngas production. The CCom showed the highest carbon deposition at 600 degrees C with 2.26 mg which represents 4.52% of the initial weight of the catalyst. Increasing the nickel content from 5 wt% to 10 wt% resulted in a syngas gain of 1.31 mu mol/min, 0.86 mu mol/min and 1.25 mu mol/min at 600 degrees C, 700 degrees C and 800 degrees C, respectively. The increase of the active phase from 10 wt% to 15 wt% and 20 wt% did not present significant effects in the syngas production. The lyophilization process in the drying stage of the catalyst has proved to be quite satisfactory in the dry reforming of methane. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Moura-Nickel, Camilla Daniela; Tachinski, Camila Gaspodini; De Noni Junior, Agenor; Peralta Muniz Moreira, Regina de Fatima; Jose, Humberto Jorge] Fed Univ Santa Catarina UFSC, Dept Chem & Food Engn, BR-88040900 Florianopolis, SC, Brazil.
   [Landers, Richard] Univ Campinas UNICAMP, Gleb Wataghin Inst Phys, BR-13083859 Campinas, SP, Brazil.
   [Virmond, Elaine] Fed Univ Santa Catarina UFSC, Dept Energy & Sustainabil, BR-88906072 Ararangua, SC, Brazil.
   [Peterson, Michael] Univ Extremo Sul Catarinense UNESC, Postgrad Program Sci & Mat Engn, BR-88806000 Criciuma, SC, Brazil.
RP Moura-Nickel, CD (reprint author), Fed Univ Santa Catarina UFSC, Dept Chem & Food Engn, BR-88040900 Florianopolis, SC, Brazil.
EM camilla.nickel@gmail.com
RI Peterson, Michael/G-5190-2012; Moura-Nickel, Camilla/P-9572-2019
OI Virmond, Elaine/0000-0001-5372-1184; Jose, Humberto
   Jorge/0000-0002-9219-0942; Peterson, Michael/0000-0002-5002-1294
FU National Council for Scientific and Technological Development
   (CNPq/Brazil)National Council for Scientific and Technological
   Development (CNPq) [140698/2015-9, 153813/2018-0]; Coordination for the
   Improvement of Higher Level Personnel (CAPES/Brazil)CAPES
FX The authors would like to thank the National Council for Scientific and
   Technological Development (CNPq/Brazil, Processes No. 140698/2015-9 and
   No. 153813/2018-0) and the Coordination for the Improvement of Higher
   Level Personnel (CAPES/Brazil) for their financial support. They also
   acknowledge the Central Laboratory of Electronic Microscopy
   (LCME-UFSC/Brazil) for technical support.
CR Al-Fatesh ASA, 2011, CHINESE J CATAL, V32, P1604, DOI 10.1016/S1872-2067(10)60267-7
   Alipour Z, 2014, J IND ENG CHEM, V20, P2858, DOI 10.1016/j.jiec.2013.11.018
   Alipour Z, 2014, FUEL, V129, P197, DOI 10.1016/j.fuel.2014.03.045
   Alpaydin CY, 2020, INT J HYDROGEN ENERG, V45, P3414, DOI 10.1016/j.ijhydene.2019.02.181
   Aramouni NAK, 2018, RENEW SUST ENERG REV, V82, P2570, DOI 10.1016/j.rser.2017.09.076
   Ayodele BV, 2016, J NAT GAS SCI ENG, V34, P873, DOI 10.1016/j.jngse.2016.07.059
   Ayodele BV, 2016, INT J HYDROGEN ENERG, V41, P4603, DOI 10.1016/j.ijhydene.2016.01.091
   Ayodele BV, 2016, INT J HYDROGEN ENERG, V41, P198, DOI 10.1016/j.ijhydene.2015.10.049
   Bahari MB, 2016, J ENVIRON CHEM ENG, V4, P4830, DOI 10.1016/j.jece.2016.01.038
   Bang Y, 2012, INT J HYDROGEN ENERG, V37, P1436, DOI 10.1016/j.ijhydene.2011.10.008
   Bradford MCJ, 1996, APPL CATAL A-GEN, V142, P73, DOI 10.1016/0926-860X(96)00065-8
   Cao P, 2017, DEV NI BASED CATALYS
   Carrier X, 2003, J MOL STRUCT, V656, P231, DOI 10.1016/S0022-2860(03)00328-4
   Charisiou ND, 2018, INT J HYDROGEN ENERG, V43, P18955, DOI 10.1016/j.ijhydene.2018.08.074
   Charisiou ND, 2019, APPL SURF SCI, V474, P42, DOI 10.1016/j.apsusc.2018.05.177
   Coates J., 2000, ENCY ANAL CHEM, P1, DOI DOI 10.1002/9780470027318.A5606
   Courson C, 2002, CATAL TODAY, V76, P75, DOI 10.1016/S0920-5861(02)00202-X
   Danghyan V, 2018, APPL CATAL B-ENVIRON, V234, P178, DOI 10.1016/j.apcatb.2018.04.033
   Debek R, 2017, CATALYSTS, V7, DOI 10.3390/catal7010032
   Domenico MD, 2019, CHEM ENG RES DES, V141, P529, DOI 10.1016/j.cherd.2018.11.011
   Fogler H. S., 2016, ELEMENTS CHEM REACTI
   Gangadharan P, 2012, CHEM ENG RES DES, V90, P1956, DOI 10.1016/j.cherd.2012.04.008
   Ghelamallah M, 2012, FUEL, V97, P269, DOI 10.1016/j.fuel.2012.02.068
   Gill SK, 2010, J SOL-GEL SCI TECHN, V53, P635, DOI 10.1007/s10971-009-2142-8
   Goula MA, 1996, J CATAL, V161, P626, DOI 10.1006/jcat.1996.0225
   Goula MA, 2015, INT J HYDROGEN ENERG, V40, P9183, DOI 10.1016/j.ijhydene.2015.05.129
   Gurav HR, 2017, J CO2 UTIL, V20, P357, DOI 10.1016/j.jcou.2017.06.014
   Kim HJ, 2009, APPL CATAL A-GEN, V352, P145, DOI 10.1016/j.apcata.2008.10.014
   Kraiwattanawong K, 2011, CARBON, V49, P3404, DOI 10.1016/j.carbon.2011.04.018
   Lau CS, 2011, INT J HYDROGEN ENERG, V36, P397, DOI 10.1016/j.ijhydene.2010.09.086
   Moura-Nickel CD, 2019, INT J HYDROGEN ENERG, V44, P11861, DOI 10.1016/j.ijhydene.2019.03.022
   Nair MM, 2016, NEW J CHEM, V40, P4049, DOI 10.1039/c5nj03268g
   NAKAMURA J, 1994, CATAL LETT, V25, P265, DOI 10.1007/BF00816306
   Nieva MA, 2014, CHEM ENG J, V235, P158, DOI 10.1016/j.cej.2013.09.030
   Noor ZZ, 2013, RENEW SUST ENERG REV, V20, P378, DOI 10.1016/j.rser.2012.11.050
   Pacioni TR, 2016, WASTE MANAGE, V58, P221, DOI 10.1016/j.wasman.2016.08.021
   Park N, 2014, FUEL, V115, P357, DOI 10.1016/j.fuel.2013.07.035
   Pompeo F, 2007, APPL CATAL A-GEN, V316, P175, DOI 10.1016/j.apcata.2006.09.007
   Rathod V, 2014, ENRGY PROCED, V54, P236, DOI 10.1016/j.egypro.2014.07.267
   San-Jose-Alonso D, 2009, APPL CATAL A-GEN, V371, P54, DOI 10.1016/j.apcata.2009.09.026
   Selvarajah K, 2016, RES CHEM INTERMEDIAT, V42, P269, DOI 10.1007/s11164-015-2395-5
   Song JH, 2016, J MOL CATAL A-CHEM, V424, P342, DOI 10.1016/j.molcata.2016.09.013
   Souza MD, 2004, APPL CATAL A-GEN, V272, P133, DOI 10.1016/j.apcata.2004.05.026
   Usman M, 2015, RENEW SUST ENERG REV, V45, P710, DOI 10.1016/j.rser.2015.02.026
   Vergunst T, 2001, APPL CATAL A-GEN, V213, P179, DOI 10.1016/S0926-860X(00)00896-6
   Wang Y, 2014, INT J HYDROGEN ENERG, V39, P10971, DOI 10.1016/j.ijhydene.2014.05.074
   Wehinger GD, 2015, CHEM ENG SCI, V122, P197, DOI 10.1016/j.ces.2014.09.007
   Wurzel T, 2000, CHEM ENG SCI, V55, P3955, DOI 10.1016/S0009-2509(99)00444-3
   Xi XL, 2009, POWDER TECHNOL, V191, P107, DOI 10.1016/j.powtec.2008.09.017
   Xu LL, 2014, INT J HYDROGEN ENERG, V39, P3253, DOI 10.1016/j.ijhydene.2013.12.077
   Xu Z, 2001, APPL CATAL A-GEN, V210, P45, DOI 10.1016/S0926-860X(00)00798-5
   Yang TZ, 2016, J CO2 UTIL, V16, P130, DOI 10.1016/j.jcou.2016.07.005
   Yoo J, 2015, J MOL CATAL A-CHEM, V410, P74, DOI 10.1016/j.molcata.2015.09.008
   Zhang JG, 2007, J CATAL, V249, P300, DOI 10.1016/j.jcat.2007.05.004
NR 54
TC 0
Z9 0
U1 5
U2 38
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 74
EP 82
DI 10.1016/j.ces.2019.04.035
PG 9
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000007
DA 2020-05-12
ER

PT J
AU Majumdar, A
   Das, PK
AF Majumdar, Arijit
   Das, P. K.
TI Rise of Taylor bubbles through power law fluids - Analytical modelling
   and numerical simulation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Taylor bubble; Power law fluid; VOF; Rise velocity; Semi-analytical
   theory
ID VERTICAL COLUMNS; LONG BUBBLES; GAS-BUBBLES; MOTION; VELOCITY; FLOW;
   LIQUIDS; INCLINATION; TUBES; FILM
AB An attempt has been made to explore the dynamics of Taylor bubbles rising through circular tubes filled with stagnant power law fluids using CFD and a semi-analytical technique. While the freeware OpenFOAM was used for CFD simulation, the semi-analytical model was developed considering viscous film drainage around the axisymmetric bubble and was closed using a single tuning coefficient from experimental data. Bubble rise velocity derived from both the techniques exhibit good agreement with experiments. Though the velocity field around a bubble rising through a power law fluid does not show any remarkable difference with that observed for bubbles through Newtonian liquids, the rise velocity is noted to depend strongly on both K and n of the power law relationship. Nevertheless, the influence of n is much greater as is evident from the change of nose shape with its variation. Effect of such variation in nose shape is also reflected in the predicted rise velocity. However, as observed in case of Newtonian fluids, for a given n and K, the rise velocity of Taylor bubble asymptotically reaches a constant value as the bubble volume is increased. It is also seen that surface tension does not have any significant effect on the nose shape and rise velocity while it modifies the tail shape. Finally, it has been noted that the increase in rise velocity with tube diameter depicts a non linear trend for non-Newtonian fluids while it is linear for their Newtonian counterpart. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Majumdar, Arijit; Das, P. K.] Indian Inst Technol, Dept Mech Engn, Kharagpur 721302, W Bengal, India.
RP Das, PK (reprint author), Indian Inst Technol, Dept Mech Engn, Kharagpur 721302, W Bengal, India.
EM pkd@mech.iitkgp.ac.in
CR Araujo JDP, 2017, J NON-NEWTON FLUID, V245, P49, DOI 10.1016/j.jnnfm.2017.04.009
   Batchelor G. K., 2000, INTRO FLUID DYNAMICS
   BATCHELOR GK, 1987, J FLUID MECH, V184, P399, DOI 10.1017/S0022112087002945
   BENDIKSEN KH, 1985, INT J MULTIPHAS FLOW, V11, P797, DOI 10.1016/0301-9322(85)90025-4
   BRACKBILL JU, 1992, J COMPUT PHYS, V100, P335, DOI 10.1016/0021-9991(92)90240-Y
   BROWN RAS, 1965, CAN J CHEM ENG, V43, P217, DOI 10.1002/cjce.5450430501
   Bugg JD, 1998, INT J MULTIPHAS FLOW, V24, P271, DOI 10.1016/S0301-9322(97)00047-5
   CAMPOS JBLM, 1988, J FLUID MECH, V196, P27, DOI 10.1017/S0022112088002599
   CAREW PS, 1995, INT J MULTIPHAS FLOW, V21, P1091, DOI 10.1016/0301-9322(95)00047-2
   COLLINS R, 1978, J FLUID MECH, V89, P497, DOI 10.1017/S0022112078002700
   Davies R. M., 1988, DYNAMICS CURVED FRON, V200, P377
   Dumitrescu DT, 1943, Z ANGEW MATH MECH, V23, P139, DOI 10.1002/zamm.19430230303
   Figueroa-Espinoza B, 2011, J FLUID MECH, V679, P432, DOI 10.1017/jfm.2011.159
   Funada T, 2005, INT J MULTIPHAS FLOW, V31, P473, DOI 10.1016/j.ijmultiphaseflow.2004.11.010
   GOLDSMITH HL, 1962, J FLUID MECH, V14, P42, DOI 10.1017/S0022112062001068
   HIRT CW, 1981, J COMPUT PHYS, V39, P201, DOI 10.1016/0021-9991(81)90145-5
   Kamisli F, 2003, CHEM ENG PROCESS, V42, P569, DOI 10.1016/S0255-2701(02)00077-6
   Kang CW, 2010, PHYS REV E, V81, DOI 10.1103/PhysRevE.81.066308
   Llewellin EW, 2012, P ROY SOC A-MATH PHY, V468, P1041, DOI 10.1098/rspa.2011.0476
   Lu XZ, 2009, IND ENG CHEM RES, V48, P242, DOI 10.1021/ie800201x
   Mandal T. K., 2008, J FLUIDS ENG, V131
   MAO ZS, 1990, J COMPUT PHYS, V91, P132, DOI 10.1016/0021-9991(90)90008-O
   Mukundakrishnan K, 2009, ANN NY ACAD SCI, V1161, P256, DOI 10.1111/j.1749-6632.2009.04089.x
   Nogueira S, 2006, CHEM ENG SCI, V61, P7199, DOI 10.1016/j.ces.2006.08.002
   Nogueira S, 2006, CHEM ENG SCI, V61, P845, DOI 10.1016/j.ces.2005.07.038
   REINELT DA, 1987, J FLUID MECH, V175, P557, DOI 10.1017/S0022112087000521
   Rusche H., 2002, THESIS
   Sousa RG, 2006, INT J MULTIPHAS FLOW, V32, P1182, DOI 10.1016/j.ijmultiphaseflow.2006.06.002
   Sousa RG, 2005, CHEM ENG SCI, V60, P1859, DOI 10.1016/j.ces.2004.11.035
   Viana F, 2003, J FLUID MECH, V494, P379, DOI 10.1017/S0022112003006165
   Wallis G., GEN CORRELATIONS RIS
   WHITE ET, 1962, CHEM ENG SCI, V17, P351, DOI 10.1016/0009-2509(62)80036-0
   Zudin YB, 2013, PHYS FLUIDS, V25, DOI 10.1063/1.4803878
   ZUKOSKI EE, 1966, J FLUID MECH, V25, P821, DOI 10.1017/S0022112066000442
NR 34
TC 2
Z9 2
U1 4
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 83
EP 93
DI 10.1016/j.ces.2019.04.028
PG 11
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000008
DA 2020-05-12
ER

PT J
AU Martinez, I
   Grasa, G
   Meyer, J
   Di Felice, L
   Kazi, S
   Sanz, C
   Maury, D
   Voisin, C
AF Martinez, Isabel
   Grasa, Gemma
   Meyer, Julien
   Di Felice, Luca
   Kazi, Saima
   Sanz, Cristina
   Maury, Delphine
   Voisin, Christophe
TI Performance and operating limits of a sorbent-catalyst system for
   sorption-enhanced reforming (SER) in a fluidized bed reactor
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Sorption enhanced reforming; Hydrogen production; CO2 sorbent;
   Functional combined materials; Fluidized bed reactor
ID HYDROGEN-PRODUCTION; CO2 CAPTURE; H-2 PRODUCTION; THERMODYNAMIC
   ANALYSIS; METHANE; CAO; TEMPERATURE; SIMULATION; DOLOMITE
AB The combined performance of a synthetic CaO-Ca12Al14O33 sorbent and an Ni-MgAl2O4 reforming catalyst was tested in a fluidized bed reactor under relevant operating conditions for the sorption-enhanced reforming (SER) process. The effect of CH4 space velocity (i.e. kg(CH4)/h.kg(cat)), steam-to-carbon (S/C) ratio and superficial gas velocity on product gas composition was assessed, as well as the effect of regeneration conditions on material performance. Moreover, a bi-functional material prepared by mechanical mixing of the separate materials was also tested in the reactor under consecutive SER/regeneration cycles. H-2 contents as high as 96 vol% (N-2 free, dry basis) were achieved under SER operation, using the separate materials working with an Ni content of 3.75 wt% in the solid bed at 650 degrees C with S/C ratios of 3 and 4. This solid system is able to process up to 0.63 kg(CH4)/h.kg(cat) at 0.1 m/s superficial gas velocity and with an S/C ratio of 4, although the CH4 input has to be reduced to 0.33 kg(CH4)/h.kg(cat) when working with a lower S/C ratio. Similar H-2 contents to those found with the separate materials were obtained with the combined sorbent-catalyst material working with 0.33 kg(CH4)/h.kg(cat) at 0.1 m/s superficial gas velocity and S/C ratios of 3 and 4. The CO2 sorption capacity of the combined material produced the same as that of the separate sorbent particles (i.e. around 0.25 g(CO2)/g calcined sorbent), while remaining stable throughout the SER/regeneration cycles. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Martinez, Isabel; Grasa, Gemma] Spanish Res Council ICB CSIC, Inst Carboquim, Miguel Luesma Castan 4, Zaragoza 50018, Spain.
   [Meyer, Julien; Di Felice, Luca; Kazi, Saima; Sanz, Cristina] Inst Energy Technol IFE, POB 40, N-2027 Kjeller, Norway.
   [Maury, Delphine; Voisin, Christophe] Marion Technol, 55 Rue Louis Pasteur, F-09340 Verniolle, France.
RP Martinez, I (reprint author), Spanish Res Council ICB CSIC, Inst Carboquim, Miguel Luesma Castan 4, Zaragoza 50018, Spain.
EM imartinez@icb.csic.es
RI ; Martinez, Isabel/M-6624-2017
OI Di Felice, Luca/0000-0002-4378-6408; Martinez,
   Isabel/0000-0002-2364-463X
FU European UnionEuropean Union (EU) [608512]; Regional Government of
   Aragon (DGA)Gobierno de Aragon
FX This work was supported by the European Union (Grant agreement No.
   608512) and the Regional Government of Aragon (DGA) under its research
   groups support programme.
CR Abanades JC, 2010, ENVIRON SCI TECHNOL, V44, P6901, DOI 10.1021/es101707t
   Aloisi I, 2017, CHEM ENG J, V314, P570, DOI 10.1016/j.cej.2016.12.014
   Antzara A, 2015, INT J GREENH GAS CON, V32, P115, DOI 10.1016/j.ijggc.2014.11.010
   Arstad B, 2012, CHEM ENG J, V189, P413, DOI 10.1016/j.cej.2012.02.057
   Arstad B, 2009, ENRGY PROCED, V1, P715, DOI 10.1016/j.egypro.2009.01.094
   BAKER EH, 1962, J CHEM SOC, P464, DOI 10.1039/jr9620000464
   Cesario MR, 2015, FUEL PROCESS TECHNOL, V131, P247, DOI 10.1016/j.fuproc.2014.11.028
   Chanburanasiri N, 2011, IND ENG CHEM RES, V50, P13662, DOI 10.1021/ie201226j
   Di Felice L, 2019, FUEL PROCESS TECHNOL, V183, P35, DOI 10.1016/j.fuproc.2018.10.012
   Di Giuliano A, 2018, CHEM ENG PROCESS, V130, P240, DOI 10.1016/j.cep.2018.06.021
   Di Giuliano A, 2017, INT J HYDROGEN ENERG, V42, P13661, DOI 10.1016/j.ijhydene.2016.11.198
   Edenhofer O., 2014, IPCC 2014 CLIMATE CH
   Edenhofer O, 2014, CLIMATE CHANGE 2014: MITIGATION OF CLIMATE CHANGE, P1
   Erans M, 2016, APPL ENERG, V180, P722, DOI 10.1016/j.apenergy.2016.07.074
   Fernandez JR, 2012, CHEM ENG SCI, V84, P12, DOI 10.1016/j.ces.2012.07.050
   Garcia-Lario AL, 2015, CHEM ENG J, V264, P697, DOI 10.1016/j.cej.2014.11.116
   Garcia-Lario AL, 2015, INT J HYDROGEN ENERG, V40, P219, DOI 10.1016/j.ijhydene.2014.10.033
   Grasa GS, 2006, IND ENG CHEM RES, V45, P8846, DOI 10.1021/ie0606946
   Han C, 1994, CHEM ENG SCI, V49, P5875, DOI 10.1016/0009-2509(94)00266-5
   Harrison DP, 2008, IND ENG CHEM RES, V47, P6486, DOI 10.1021/ie800298z
   Hildenbrand N, 2006, APPL CATAL A-GEN, V303, P131, DOI 10.1016/j.apcata.2006.02.015
   IEA, 2006, HYDR PROD STOR R D P, DOI [10.1016/0360-3199(88)90106-1, DOI 10.1016/0360-3199(88)90106-1]
   Johnsen K, 2006, CHEM ENG SCI, V61, P1195, DOI 10.1016/j.ces.2005.08.022
   Kalantzopoulos G., 2015, P EN MAT RES EMR C
   Kazi SS, 2014, ENRGY PROCED, V63, P2207, DOI 10.1016/j.egypro.2014.11.240
   Li ZS, 2006, IND ENG CHEM RES, V45, P8788, DOI 10.1021/ie061010x
   Li ZS, 2006, IND ENG CHEM RES, V45, P1911, DOI 10.1021/ie051211l
   Garcia-Lario AL, 2015, J POWER SOURCES, V285, P90, DOI 10.1016/j.jpowsour.2015.03.075
   Lopez JM, 2018, CHEM ENG J, V350, P559, DOI 10.1016/j.cej.2018.05.014
   Martavaltzi CS, 2011, IND ENG CHEM RES, V50, P539, DOI 10.1021/ie1002284
   Martavaltzi CS, 2010, CHEM ENG SCI, V65, P4134, DOI 10.1016/j.ces.2010.04.038
   Martinez I, 2013, INT J HYDROGEN ENERG, V38, P15180, DOI 10.1016/j.ijhydene.2013.09.062
   Mastin J, 2011, ENRGY PROCED, V4, P1184, DOI 10.1016/j.egypro.2011.01.172
   Meyer J, 2011, ENRGY PROCED, V4, P1949, DOI 10.1016/j.egypro.2011.02.075
   Ochoa-Fernandez E, 2007, GREEN CHEM, V9, P654, DOI 10.1039/b614270b
   Ortiz AL, 2001, IND ENG CHEM RES, V40, P5102
   Romano MC, 2011, ENRGY PROCED, V4, P1125, DOI 10.1016/j.egypro.2011.01.164
   Waldron WE, 2001, AICHE J, V47, P1477, DOI 10.1002/aic.690470623
   WEN CY, 1966, AICHE J, V12, P610, DOI 10.1002/aic.690120343
   Yancheshmeh MS, 2016, CHEM ENG J, V283, P420, DOI 10.1016/j.cej.2015.06.060
   Yi KB, 2005, IND ENG CHEM RES, V44, P1665, DOI 10.1021/ie048883g
   Yin JJ, 2012, ENERG FUEL, V26, P169, DOI 10.1021/ef201142w
   Zamboni I, 2015, INT J HYDROGEN ENERG, V40, P5297, DOI 10.1016/j.ijhydene.2015.01.065
   Zhu L, 2015, INT J ENERG RES, V39, P356, DOI 10.1002/er.3248
NR 44
TC 0
Z9 0
U1 9
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 94
EP 105
DI 10.1016/j.ces.2019.04.029
PG 12
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000009
DA 2020-05-12
ER

PT J
AU Hofgen, E
   Collini, D
   Batterham, RJ
   Scales, PJ
   Stickland, AD
AF Hofgen, Eric
   Collini, Davide
   Batterham, Robin J.
   Scales, Peter J.
   Stickland, Anthony D.
TI High pressure dewatering rolls: Comparison of a novel prototype to
   existing industrial technology
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Dewatering; Solid-liquid separation; Shear enhanced compression;
   Industrial comparison; High pressure dewatering rolls
ID FILTRATION; RHEOLOGY; SUSPENSIONS; YIELD; SHEAR; TOOL; GAS
AB The optimisation of solid-liquid separation or dewatering processes for more efficient operation and reuse of material streams is of high importance. Suspension dewatering aims to increase the solids concentration and exhibits two limitations: the dewatering extent and the rate.
   A novel dewatering device, called High Pressure Dewatering Rolls (HPDR), has been developed. It combines shear and compression while maintaining a short filtration length between the rollers. The HPDR challenges the limitations of dewatering processes through the application of high pressures and induced shear to aid the extent of dewatering, and a short filtration length to allow fast dewatering. A prototype HPDR is described along with a performance assessment for different operating conditions as well as a comparison against state-of-the-art technology for a variety of industrial suspensions. The results demonstrate that the HPDR prototype, without any optimisation, outperforms or achieves comparable cake solids concentrations to existing equipment in a continuous mode of operation. Analysis of energy consumption and throughput remain outstanding and require further prototype development. (C) 2019 Published by Elsevier Ltd.
C1 [Hofgen, Eric; Batterham, Robin J.; Scales, Peter J.; Stickland, Anthony D.] Univ Melbourne, Dept Chem Engn, Particulate Fluids Proc Ctr, Parkville, Vic 3010, Australia.
   [Collini, Davide] Aqseptence Grp Srl, Via Gessi 16, I-48022 Lugo, RA, Italy.
RP Stickland, AD (reprint author), Univ Melbourne, Dept Chem Engn, Particulate Fluids Proc Ctr, Parkville, Vic 3010, Australia.
EM stad@unimelb.edu.au
RI ; SCALES, PETER/I-8103-2013
OI Hofgen, Eric/0000-0002-9702-6789; SCALES, PETER/0000-0002-8033-3686
FU University of MelbourneUniversity of Melbourne; Particulate Fluids
   Processing Centre (PFPC) in Melbourne; Carlton Connect Initiative Fund;
   Visy Industries; Victorian Government DSDBI Technology Voucher
   [TVP-TDev131A.1]; MDB Energy; Aqseptence Group Srl, Italy
FX The authors would like to acknowledge the funding of the project through
   the University of Melbourne and the Particulate Fluids Processing Centre
   (PFPC) in Melbourne who provided access to facilities and supply of
   equipment. The prototype development and initial studies were funded by
   the Carlton Connect Initiative Fund together with Visy Industries and
   the Victorian Government DSDBI Technology Voucher (TVP-TDev131A.1) in
   collaboration with MDB Energy. Further, the industrial partners are
   thanked for their collaboration in providing samples, namely Australian
   Paper and Melbourne Water for the HPDR testing of industrial
   suspensions. The benchmarking study has been funded by the Aqseptence
   Group Srl, Italy.
CR Aydogan NA, 2006, MINER ENG, V19, P130, DOI 10.1016/j.mineng.2005.08.011
   Barnes H.A., 2000, HDB ELEMENTARY RHEOL
   Batterham R, 2011, ADV POWDER TECHNOL, V22, P138, DOI 10.1016/j.apt.2010.11.007
   Bird MI, 2011, BIORESOURCE TECHNOL, V102, P1886, DOI 10.1016/j.biortech.2010.07.106
   Buchner E, 1888, CHEM ZEITUNG, V12, P1277
   BUSCALL R, 1987, J CHEM SOC FARAD T 1, V83, P873, DOI 10.1039/f19878300873
   BUSCALL R, 1988, J CHEM SOC FARAD T 1, V84, P4249, DOI 10.1039/f19888404249
   Buscall R, 2009, ARXIV09030970CONDMAT
   Buscall R, 2015, J NON-NEWTON FLUID, V222, P112, DOI 10.1016/j.jnnfm.2014.09.010
   Channel G. M, 1999, THESIS
   Channell GM, 1997, AICHE J, V43, P1700, DOI 10.1002/aic.690430707
   de Kretser RG, 2001, AICHE J, V47, P1758, DOI 10.1002/aic.690470808
   Doucha J, 2005, J APPL PHYCOL, V17, P403, DOI 10.1007/s10811-005-8701-7
   DZUY NQ, 1985, J RHEOL, V29, P335, DOI 10.1122/1.549794
   DZUY NQ, 1983, J RHEOL, V27, P321, DOI 10.1122/1.549709
   Erk A., 2006, THESIS
   Green MD, 1997, IND ENG CHEM RES, V36, P4984, DOI 10.1021/ie970141i
   Green Melanie, 1997, THESIS
   Illies S, 2017, DRY TECHNOL, V35, P66, DOI 10.1080/07373937.2016.1159576
   JOHANSON JR, 1965, J APPL MECH, V32, P842, DOI 10.1115/1.3627325
   KYNCH GJ, 1952, T FARADAY SOC, V48, P166, DOI 10.1039/tf9524800166
   LANDMAN KA, 1994, ADV COLLOID INTERFAC, V51, P175, DOI 10.1016/0001-8686(94)80036-7
   LANDMAN KA, 1991, PHYS FLUIDS A-FLUID, V3, P1495, DOI 10.1063/1.857986
   Landman KA, 1999, AICHE J, V45, P1875, DOI 10.1002/aic.690450905
   Landman KA, 1997, AICHE J, V43, P3147, DOI 10.1002/aic.690431204
   Lester DR, 2014, J RHEOL, V58, P1247, DOI 10.1122/1.4891873
   Lester D. R, 2002, THESIS
   Lester DR, 2005, AICHE J, V51, P1158, DOI 10.1002/aic.10333
   MEETEN GH, 1994, COLLOID SURFACE A, V82, P77, DOI 10.1016/0927-7757(93)02613-J
   Mladenchev T., 2007, THESIS
   NGUYEN QD, 1987, RHEOL ACTA, V26, P508, DOI 10.1007/BF01333734
   Packer M, 2009, ENERG POLICY, V37, P3428, DOI 10.1016/j.enpol.2008.12.025
   Qi Y, 2011, CHEM ENG J, V171, P373, DOI 10.1016/j.cej.2011.04.060
   Ragnar M, 2010, ULLMANNS ENCY IND CH
   SCHWECHTEN D, 1990, MINER ENG, V3, P23, DOI 10.1016/0892-6875(90)90078-P
   Silva PHD, 2008, AQUACULTURE, V284, P74, DOI 10.1016/j.aquaculture.2008.07.035
   Sofra F, 2002, CHEM ENG J, V86, P319, DOI 10.1016/S1385-8947(01)00225-X
   Stickland A. D, 2005, THESIS
   Stickland AD, 2008, CHEM ENG SCI, V63, P5283, DOI 10.1016/j.ces.2008.07.016
   Stickland AD, 2006, CHEM ENG SCI, V61, P3818, DOI 10.1016/j.ces.2006.01.020
   Stickland AD, 2015, WATER RES, V82, P37, DOI 10.1016/j.watres.2015.04.004
   Stickland AD, 2015, RHEOL ACTA, V54, P337, DOI 10.1007/s00397-015-0847-x
   Svarovsky L, 1981, SOLID LIQUID SEPARAT
   Tavares LM, 2005, MINER ENG, V18, P651, DOI 10.1016/j.mineng.2004.10.012
   Uduman N, 2010, J RENEW SUSTAIN ENER, V2, DOI 10.1063/1.3294480
   Usher S.P, 2002, THESIS
   Usher SP, 2013, CHEM ENG SCI, V93, P277, DOI 10.1016/j.ces.2013.02.026
   Wakeman R.J., 2005, SOLID LIQUID SEPARAT
   Yap BHJ, 2016, ALGAL RES, V14, P1, DOI 10.1016/j.algal.2015.12.007
NR 49
TC 1
Z9 1
U1 1
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 106
EP 120
DI 10.1016/j.ces.2019.03.080
PG 15
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000010
DA 2020-05-12
ER

PT J
AU Yue, YH
   Wang, TY
   Sakai, M
   Shen, YS
AF Yue, Yuanhe
   Wang, Tianyu
   Sakai, Mikio
   Shen, Yansong
TI Particle-scale study of spout deflection in a flat-bottomed spout
   fluidized bed
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Instability; Spout deflection; Spout fluidized bed; Particles; CFD-DEM;
   Modelling
ID DISCRETE-ELEMENT METHOD; CFD-DEM SIMULATION; DRAFT PLATES;
   OPERATING-CONDITIONS; ROLLING FRICTION; FLOW REGIMES; STABILITY;
   BEHAVIOR; HYDRODYNAMICS; SPHERE
AB Spout deflection is a common instability phenomenon in spout fluidized beds. However, spout deflection was not well characterized and quantified in the past. In this work, spout deflection in a flat-bottomed spout fluidized bed is investigated at the particle scale by means of Computer Fluid Dynamic-Discrete Element Method (CFD-DEM) coupling approach. Two types of spout deflections - alternating and non-alternating spout deflections are captured by the CFD-DEM simulations and qualitatively analyzed in terms of voidage distributions and particle momentum profiles. The spout deflection angle is defined and used to characterize the intensity of spout deflection quantitatively. Then, the effects of spouting velocity on alternating spout deflection are investigated quantitatively using the spout deflection angle. The simulation results indicate that spouting velocity has a limited effect on the amplitude and frequency of alternating spout deflection. The relation between solid flow pattern and spout behaviour are also investigated with the help of spout deflection angle. The results indicate that spout deflection angle is highly relevant to particle distribution non-uniformity at the upper region of the bed. The study offers a cost-effective tool to characterize and quantify spout deflection in a spout fluidized bed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yue, Yuanhe; Wang, Tianyu; Shen, Yansong] Univ New South Wales, Sch Chem Engn, Sydney, NSW 2052, Australia.
   [Wang, Tianyu] Harbin Inst Technol, Sch Energy Sci & Engn, Harbin 150001, Heilongjiang, Peoples R China.
   [Sakai, Mikio] Univ Tokyo, Sch Engn, Resilience Engn Res Ctr, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.
RP Shen, YS (reprint author), Univ New South Wales, Sch Chem Engn, Sydney, NSW 2052, Australia.
EM ys.shen@unsw.edu.au
RI Shen, Yansong/A-9037-2010
OI Shen, Yansong/0000-0001-8472-8805
FU Australian Research CouncilAustralian Research Council [DP180101232];
   China Scholarship CouncilChina Scholarship Council
FX This work is financially supported by the Australian Research Council
   (DP180101232). The first author wishes to acknowledge the financial
   support from the China Scholarship Council.
CR Bertuol DA, 2015, J POWER SOURCES, V275, P627, DOI 10.1016/j.jpowsour.2014.11.036
   Braga MB, 2015, DRY TECHNOL, V33, P216, DOI 10.1080/07373937.2014.947511
   Brilliantov NV, 1998, EUROPHYS LETT, V42, P511, DOI 10.1209/epl/i1998-00281-7
   Chen Z, 2011, CAN J CHEM ENG, V89, P1401, DOI 10.1002/cjce.20511
   Chen Z., 2008, HYDRODYNAMICS STABIL, DOI [10.14288/1.0058503, DOI 10.14288/1.0058503]
   da Cunha RL, 2006, DRY TECHNOL, V24, P423, DOI 10.1080/07373930600611869
   Di Renzo A, 2004, CHEM ENG SCI, V59, P525, DOI 10.1016/j.ces.2003.09.037
   DIFELICE R, 1994, INT J MULTIPHAS FLOW, V20, P153, DOI 10.1016/0301-9322(94)90011-6
   Dogan OM, 2000, CHEM ENG COMMUN, V181, P225, DOI 10.1080/00986440008912822
   Feng YQ, 2004, AICHE J, V50, P1713, DOI 10.1002/aic.10169
   Gryczka O, 2008, CHEM ENG SCI, V63, P791, DOI 10.1016/j.ces.2007.10.023
   He Y, 2018, POWDER TECHNOL, V325, P620, DOI 10.1016/j.powtec.2017.11.045
   Hertz H.R., 1882, BERUHRUNG FESTER ELA, P449
   Hoomans BPB, 1996, CHEM ENG SCI, V51, P99, DOI 10.1016/0009-2509(95)00271-5
   Hosseini SH, 2017, BRAZ J CHEM ENG, V34, P997, DOI 10.1590/0104-6632.20170344s20150588
   Hosseini SH, 2014, J TAIWAN INST CHEM E, V45, P2140, DOI 10.1016/j.jtice.2014.05.027
   Hou QF, 2013, AIP CONF PROC, V1542, P1106, DOI 10.1063/1.4812129
   Hou QF, 2012, AICHE J, V58, P1422, DOI 10.1002/aic.12700
   Jiang ZC, 2018, CHEM ENG SCI, V179, P115, DOI 10.1016/j.ces.2018.01.013
   Kloss C, 2012, PROG COMPUT FLUID DY, V12, P140, DOI 10.1504/PCFD.2012.047457
   Kuang SB, 2011, AICHE J, V57, P2708, DOI 10.1002/aic.12480
   LANGSTON PA, 1994, CHEM ENG SCI, V49, P1259, DOI 10.1016/0009-2509(94)85095-X
   Li LM, 2017, POWDER TECHNOL, V305, P364, DOI 10.1016/j.powtec.2016.10.005
   Li SQ, 2011, PROG ENERG COMBUST, V37, P633, DOI 10.1016/j.pecs.2011.02.001
   Link JM, 2005, CHEM ENG SCI, V60, P3425, DOI 10.1016/j.ces.2005.01.027
   Littman H., 2010, SPOUTED SPOUT FLUID, P128, DOI [10.1017/CBO9780511777936.008, DOI 10.1017/CBO9780511777936.008]
   Luo K, 2016, AICHE J, V62, P1917, DOI 10.1002/aic.15186
   MINDLIN RD, 1953, J APPL MECH-T ASME, V20, P327
   PASSOS ML, 1993, POWDER TECHNOL, V74, P97, DOI 10.1016/0032-5910(93)87002-6
   Perazzini MTB, 2018, DRY TECHNOL, V36, P341, DOI 10.1080/07373937.2017.1331240
   Reza Z, 2016, COUPLED CFD DEM MODE, P257, DOI 10.1002/9781119005315.ch6
   Saidi M, 2015, POWDER TECHNOL, V284, P355, DOI 10.1016/j.powtec.2015.07.005
   Salam PA, 2006, CHEM ENG SCI, V61, P1946, DOI 10.1016/j.ces.2005.10.044
   Salikov V, 2015, ADV POWDER TECHNOL, V26, P718, DOI 10.1016/j.apt.2015.02.011
   Shrestha S, 2018, POWDER TECHNOL, V339, P70, DOI 10.1016/j.powtec.2018.08.001
   Sun XS, 2018, CHEM ENG SCI, V182, P28, DOI 10.1016/j.ces.2018.02.034
   Sutkar VS, 2013, CHEM ENG SCI, V104, P790, DOI 10.1016/j.ces.2013.10.005
   Sutkar VS, 2013, CHEM ENG SCI, V86, P124, DOI 10.1016/j.ces.2012.06.022
   Takabatake K, 2018, CHEM ENG J, V346, P416, DOI 10.1016/j.cej.2018.04.015
   Tang TQ, 2017, CHEM ENG SCI, V172, P79, DOI 10.1016/j.ces.2017.06.025
   Tang Y, 2016, CHEM ENG SCI, V143, P166, DOI 10.1016/j.ces.2015.12.026
   Tsuji T, 2013, ADV POWDER TECHNOL, V24, P565, DOI 10.1016/j.apt.2012.11.006
   TSUJI Y, 1993, POWDER TECHNOL, V77, P79, DOI 10.1016/0032-5910(93)85010-7
   van Buijtenen MS, 2011, CHEM ENG SCI, V66, P2368, DOI 10.1016/j.ces.2011.02.055
   Wang TY, 2016, POWDER TECHNOL, V301, P927, DOI 10.1016/j.powtec.2016.07.005
   Wang TY, 2016, CHEM ENG J, V283, P127, DOI 10.1016/j.cej.2015.07.038
   Wang TY, 2015, POWDER TECHNOL, V271, P35, DOI 10.1016/j.powtec.2014.11.005
   Wu F, 2018, CHEM ENG TECHNOL, V41, P1716, DOI 10.1002/ceat.201800048
   Wu ZH, 2008, POWDER TECHNOL, V183, P260, DOI 10.1016/j.powtec.2007.07.040
   Yang JS, 2018, CHEM ENG SCI, V188, P238, DOI 10.1016/j.ces.2018.05.057
   Yang SL, 2016, CHEM ENG SCI, V148, P108, DOI 10.1016/j.ces.2016.03.010
   Yang SL, 2014, AICHE J, V60, P2788, DOI 10.1002/aic.14494
   Yang SL, 2014, CHEM ENG J, V247, P161, DOI 10.1016/j.cej.2014.03.003
   Yang SL, 2014, CAN J CHEM ENG, V92, P1130, DOI 10.1002/cjce.21958
   Yang SL, 2013, POWDER TECHNOL, V243, P85, DOI 10.1016/j.powtec.2013.03.041
   Zhang BQ, 2019, POWDER TECHNOL, V343, P309, DOI 10.1016/j.powtec.2018.11.044
   Zhao XL, 2008, POWDER TECHNOL, V183, P79, DOI 10.1016/j.powtec.2007.11.021
   Zhong WQ, 2006, CHEM ENG PROCESS, V45, P734, DOI 10.1016/j.cep.2006.03.005
   Zhou YC, 1999, PHYSICA A, V269, P536, DOI 10.1016/S0378-4371(99)00183-1
   Zhou ZY, 2010, J FLUID MECH, V661, P482, DOI 10.1017/S002211201000306X
   Zhu HP, 2008, CHEM ENG SCI, V63, P5728, DOI 10.1016/j.ces.2008.08.006
   Zielinska M, 2007, DRY TECHNOL, V25, P261, DOI 10.1080/07373930601161138
NR 62
TC 5
Z9 5
U1 7
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 121
EP 133
DI 10.1016/j.ces.2019.04.031
PG 13
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000011
DA 2020-05-12
ER

PT J
AU Wang, SN
   Wu, JH
   Liu, JZ
   Li, N
   Zeng, XQ
   Cen, KF
AF Wang, Shuangni
   Wu, Junhong
   Liu, Jianzhong
   Li, Ning
   Zeng, Xianqing
   Cen, Kefa
TI Effect of ammonia nitrogen and low-molecular-weight organics on the
   adsorption of additives on coal surface: A combination of experiments
   and molecular dynamics simulations
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Coal water slurry; Additives; Wastewater treatment; Adsorption;
   Molecular dynamics
ID WATER; BEHAVIOR; ACID; CORROSION; REMOVAL; RANK; SDS; PH
AB Experiments and molecular dynamics (MD) simulations were conducted to investigate the effect of ammonia nitrogen and low-molecular-weight organics on the adsorption of sodium lignosulfonate (SL) on Shenhua coal. Results of adsorption and adsorption film thickness experiments showed that ammonia nitrogen and low-molecular-weight organics have different effects on the adsorption of SL on coal surface, thus resulting in different adsorption configurations of SL. A ternary system that was composed of water-SL-Shenhua coal was established through MD simulation. The adsorption mechanism of SL on Shenhua coal in different solutions was explored, and the influencing factors were analyzed using a microscopic mechanism. Results showed that the adsorption conformations of SL molecules on coal surface in aqueous and low-molecular-weight organics solutions are single-layer and multi-point adsorption, whereas the adsorption conformations in ammonia nitrogen solutions are double-layer adsorption. The mechanism of the adsorption of SL molecule on Shenhua coal surface by ammonia nitrogen and low-molecular-weight organics was studied in detail. The calculation results of adsorption energy are consistent with the experimental results in thermodynamics. This result demonstrates the feasibility and accuracy of the MD simulation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Shuangni; Liu, Jianzhong; Cen, Kefa] Zhejiang Univ, State Key Lab Clean Energy Utilizat, Hangzhou 310027, Zhejiang, Peoples R China.
   [Wu, Junhong] Zhejiang Dev & Planning Inst, Hangzhou 310012, Zhejiang, Peoples R China.
   [Li, Ning] Zhejiang Univ, Dept Chem, Hangzhou 310027, Zhejiang, Peoples R China.
   [Zeng, Xianqing] Zhejiang Univ, Coll Chem & Biol Engn, Hangzhou 310027, Zhejiang, Peoples R China.
RP Liu, JZ (reprint author), Zhejiang Univ, State Key Lab Clean Energy Utilizat, Hangzhou 310027, Zhejiang, Peoples R China.
EM jzliu@zju.edu.cn
FU National Key Research and Development Program of China [2016YFB0600505]
FX The authors would like to acknowledge the financial support provided by
   the National Key Research and Development Program of China (Grant No.
   2016YFB0600505).; We are grateful for the support of the Research
   Computing Center in College of Chemical and Biological Engineering at
   Zhejiang University for assistance with the calculations carried out in
   this work.
CR Aslam R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21175-6
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Boylu F, 2004, FUEL PROCESS TECHNOL, V85, P241, DOI 10.1016/S0378-3820(03)00198-X
   CANNON CG, 1953, ANAL CHEM, V25, P168, DOI 10.1021/ac60073a033
   Chen YY, 2016, INT J PATTERN RECOGN, V30, DOI 10.1142/S0218001416500075
   Crawford RJ, 2001, FUEL, V80, P313, DOI 10.1016/S0016-2361(00)00110-1
   Dominguez H, 2007, J PHYS CHEM B, V111, P4054, DOI 10.1021/jp067768b
   Fan SS, 2017, J ENVIRON CHEM ENG, V5, P601, DOI 10.1016/j.jece.2016.12.019
   Filius JD, 2000, GEOCHIM COSMOCHIM AC, V64, P51, DOI 10.1016/S0016-7037(99)00176-3
   Gundersen SA, 1999, COLLOID POLYM SCI, V277, P462, DOI 10.1007/s003960050409
   HATCHER PG, 1990, ORG GEOCHEM, V16, P959, DOI 10.1016/0146-6380(90)90132-J
   Ji QH, 2015, ENVIRON TECHNOL, V36, P2815, DOI 10.1080/09593330.2015.1049215
   Li DD, 2018, ASIA-PAC J CHEM ENG, V13, DOI 10.1002/apj.2162
   Li HQ, 2011, BIORESOURCE TECHNOL, V102, P4667, DOI 10.1016/j.biortech.2011.01.029
   Liu JZ, 2012, CHEM ENG SCI, V76, P1, DOI 10.1016/j.ces.2012.04.010
   Liu Y, 2009, J CHEM ENG DATA, V54, P1981, DOI 10.1021/je800661q
   Mobin M, 2017, CARBOHYD POLYM, V156, P202, DOI 10.1016/j.carbpol.2016.08.066
   Nose S, 2002, MOL PHYS, V100, P191, DOI 10.1080/00268970110089108
   Nunez-Rojas E, 2011, J COLLOID INTERF SCI, V364, P417, DOI 10.1016/j.jcis.2011.08.069
   Oguzie EE, 2006, MATER CHEM PHYS, V99, P441, DOI 10.1016/j.matchemphys.2005.11.018
   Papachristodoulou G., 2010, CAN J CHEM ENG, V65, P177
   Peng CL, 2017, APPL SURF SCI, V425, P996, DOI 10.1016/j.apsusc.2017.07.085
   Rai B, 2011, J COLLOID INTERF SCI, V362, P510, DOI 10.1016/j.jcis.2011.06.069
   Silva JP, 2004, SEP PURIF TECHNOL, V40, P163, DOI 10.1016/j.seppur.2004.02.006
   Sun H., 1988, J PHYS CHEM B, V102
   Wang JQ, 2018, ENERG FUEL, V32, P4833, DOI 10.1021/acs.energyfuels.8b00107
   Wang L, 2015, APPL SURF SCI, V327, P364, DOI 10.1016/j.apsusc.2014.11.160
   Wang S, 2017, ASIA-PAC J CHEM ENG, V12, P268, DOI 10.1002/apj.2070
   Xu Y, 2013, MINER ENG, V53, P101, DOI 10.1016/j.mineng.2013.07.006
   Yan MF, 2010, COLLOID SURFACE A, V371, P50, DOI 10.1016/j.colsurfa.2010.08.062
   Yin Q., 2017, ENVIRON SCI POLLUT R, V25, P4320
   Zhang M, 1998, WATER RES, V32, P519, DOI 10.1016/S0043-1354(97)00231-5
   Zhao HX, 2017, APPL SURF SCI, V407, P8, DOI 10.1016/j.apsusc.2017.02.132
   Zhou Q, 2015, FUEL PROCESS TECHNOL, V134, P325, DOI 10.1016/j.fuproc.2014.12.052
   Zhu JF, 2015, COLLOID POLYM SCI, V293, P1093, DOI 10.1007/s00396-014-3488-1
NR 35
TC 2
Z9 2
U1 10
U2 60
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 134
EP 142
DI 10.1016/j.ces.2019.04.042
PG 9
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000012
DA 2020-05-12
ER

PT J
AU Ding, D
   Yu, TF
   Du, BW
   Huang, YQ
AF Ding, Ding
   Yu, Tengfei
   Du, Bowei
   Huang, Yaqin
TI Collagen hydrolysate from Thunnus orientalis bone induces osteoblast
   proliferation and differentiation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Collagen hydrolysate; Proliferation; Differentiation; MC3T3-E1 cells;
   Thunnus orientalis bone
ID MESENCHYMAL STEM-CELLS; FISH COLLAGEN; SKIN GELATIN; AMINO-ACID;
   PEPTIDES; HYDROXYPROLINE; HYDROXYAPATITE; NANOCOMPOSITES; EXPRESSION;
   PROTEINS
AB A Thunnus orientalis bone-based collagen hydrolysate (TBCH) was prepared with alcalase, and its osteogenic effect was examined using MC3T3-E1 cells. The mechanism by which TBCH promotes osteogenesis was also investigated. The results showed that TBCH, even at an extremely low concentration (2 mu g/mL), significantly stimulated the proliferation and promoted osteogenic differentiation of MC3T3-E1 cells. This suggests that TBCH is biocompatible and potentially useful for promoting bone formation. Moreover, TBCH significantly upregulated the mRNA levels of osteogenic markers, such as runt-related transcription factor 2, alkaline phosphatase, osteopontin, and osteocalcin. Western blot results showed that the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway in MC3T3-E1 cells was activated by treatment with TBCH. Based on these results, we speculate that TBCH could provide a promising way for inducing bone regeneration. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ding, Ding; Du, Bowei; Huang, Yaqin] Beijing Univ Chem Technol, Beijing Lab Biomed Mat, Beijing Key Lab Electrochem Proc & Technol Mat, Beijing 100029, Peoples R China.
   [Yu, Tengfei] Chinese Peoples Liberat Army Gen Hosp, Dept Ultrasound, Beijing 100853, Peoples R China.
RP Huang, YQ (reprint author), Beijing Univ Chem Technol, Beijing Lab Biomed Mat, Beijing Key Lab Electrochem Proc & Technol Mat, Beijing 100029, Peoples R China.
EM huangyq@mail.buct.edu.cn
FU Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [PYBZ1805]
FX Financial support received from the Fundamental Research Funds for the
   Central Universities (no. PYBZ1805) is gratefully appreciated. The
   authors also thank the Protein Chemistry Facility at the Center for
   Biomedical Analysis of Tsinghua University for sample analysis.
CR Abdollahi M, 2018, FOOD CHEM, V242, P568, DOI 10.1016/j.foodchem.2017.09.045
   Ahmed R, 2018, J SUPERCRIT FLUID, V141, P88, DOI 10.1016/j.supflu.2018.03.006
   Aubin JE, 2002, PRINCIPLES BONE BIOL, V1, P59
   Boanini E, 2008, BIOMATERIALS, V29, P790, DOI 10.1016/j.biomaterials.2007.10.040
   Boanini E, 2006, BIOMATERIALS, V27, P4428, DOI 10.1016/j.biomaterials.2006.04.019
   Ceylan H, 2014, BIOMACROMOLECULES, V15, P2407, DOI 10.1021/bm500248r
   Chahal S, 2016, CHEM ENG SCI, V144, P17, DOI 10.1016/j.ces.2015.12.030
   Du LH, 2016, J AGR FOOD CHEM, V64, P5232, DOI 10.1021/acs.jafc.6b01911
   Hoemann CD, 2009, PATHOL BIOL, V57, P318, DOI 10.1016/j.patbio.2008.06.004
   Hsu HH, 2016, J BIOSCI BIOENG, V122, P219, DOI 10.1016/j.jbiosc.2016.01.001
   Karim AA, 2009, FOOD HYDROCOLLOID, V23, P563, DOI 10.1016/j.foodhyd.2008.07.002
   Kim HK, 2014, FOOD FUNCT, V5, P573, DOI 10.1039/c3fo60509d
   Kodama H., 1981, JPN J ORAL BIOL, V23, P899, DOI DOI 10.2330/JORALBIOSCI1965.23.899
   Langer R, 1995, CHEM ENG SCI, V50, P4109, DOI 10.1016/0009-2509(95)00226-X
   Lassoued I, 2014, FOOD HYDROCOLLOID, V41, P309, DOI 10.1016/j.foodhyd.2014.04.029
   Lee P, 2015, SOFT MATTER, V11, P7648, DOI 10.1039/c5sm01909e
   Li YA, 2011, J MATER SCI, V46, P1396, DOI 10.1007/s10853-010-4933-2
   Li-Chan ECY, 2012, J AGR FOOD CHEM, V60, P973, DOI 10.1021/jf204720q
   Liu C, 2014, BIOMACROMOLECULES, V15, P436, DOI 10.1021/bm401780v
   Liu JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099920
   Mangang KCS, 2017, J FOOD PROCESS PRES, V41, DOI 10.1111/jfpp.12990
   Mason Deborah J, 2004, Eur Cell Mater, V7, P12
   Matoz-Fernandez DA, 2017, SOFT MATTER, V13, P3205, DOI 10.1039/c6sm02580c
   Nikoo M, 2015, FOOD CHEM, V181, P295, DOI 10.1016/j.foodchem.2015.02.095
   Ohara H, 2010, J DERMATOL, V37, P330, DOI 10.1111/j.1346-8138.2010.00827.x
   Raabe O, 2010, HISTOCHEM CELL BIOL, V134, P545, DOI 10.1007/s00418-010-0760-4
   Schadow S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053955
   Sengupta S, 2010, TISSUE ENG PT A, V16, P3623, DOI [10.1089/ten.tea.2010.0302, 10.1089/ten.TEA.2010.0302]
   Taga Y, 2014, J AGR FOOD CHEM, V62, P12096, DOI 10.1021/jf5039597
   Washington JM, 2010, AM J PHYSIOL-CELL PH, V298, pC982, DOI 10.1152/ajpcell.00498.2009
   Willems WF, 2015, MICROSURG, V35, P45, DOI 10.1002/micr.22300
   Yamada S, 2013, DENT MATER J, V32, P233, DOI 10.4012/dmj.2012-188
   Yeh CT, 2005, CARCINOGENESIS, V26, P2138, DOI 10.1093/carcin/bgi185
NR 33
TC 0
Z9 0
U1 9
U2 34
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 143
EP 150
DI 10.1016/j.ces.2019.04.040
PG 8
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000013
DA 2020-05-12
ER

PT J
AU Moreno, J
   Casado, C
   Marugan, J
AF Moreno, Jose
   Casado, Cintia
   Marugan, Javier
TI Improved discrete ordinate method for accurate simulation radiation
   transport using solar and LED light sources
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE OpenFOAM; Radiation; Photoactivated; Quadrature; Simulation; CFD
ID PHOTOCATALYTIC REACTOR; DESIGN; TIO2
AB This work describes adaptive quadrature, a new feature designed to improve the Discrete Ordinate Method (DOM) in parallel and cone-shaped radiation sources. OpenFOAM was chosen as the simulation framework to implement the new feature. It already included a Discrete Ordinate Method (fvDOM), but it focuses on thermal radiation and is limited to isotropic emission, diffuse phenomena, and non-scattering media. The model was completed to cover volumetric and superficial absorption, isotropic and anisotropic scattering (with user-defined phase functions), diffuse and specular reflection, diffuse and parallel transmission, and three types of superficial emission sources, i.e., isotropic, cone-shaped, and parallel. Additionally, the model is prepared to work in grey mode or with wavelength bands. Multiple regions with different optical properties are also allowed. Most of the model has been validated by individual simulations of every feature in simple geometries that permit an analytical solution, with errors between 0% and 6.08%. These simulations were also verified in a comparison with an established version of the standard DOM, with differences between model implementations below 2.5%. Some advantages of the developed adaptive quadrature are also analysed using simulation results for different radiative sources and angular discretization. The main conclusion is that adaptive quadrature better defines view angle and light direction of emission sources compared to the established DOM, improving significantly the accuracy of the simulation of non-isotropic sources. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Moreno, Jose; Casado, Cintia; Marugan, Javier] Univ Rey Juan Carlos, ESCET, Dept Chem & Environm Technol, C Tulipan S-N, Mostoles 28933, Madrid, Spain.
RP Marugan, J (reprint author), Univ Rey Juan Carlos, ESCET, Dept Chem & Environm Technol, C Tulipan S-N, Mostoles 28933, Madrid, Spain.
EM javier.marugan@urjc.es
RI Marugan, Javier/A-7370-2008
OI Marugan, Javier/0000-0003-1195-462X
FU Spanish State Research Agency (AEI); Spanish Ministry of Economy and
   Competitiveness (MINECO) [WATER4FOOD project] [CTQ2014-54563-C3];
   Comunidad de MadridComunidad de MadridInstituto de Salud Carlos III;
   European Structural Funds [FOTOCAOS project] [Y2018/EMT-5062]
FX This work was supported by the Spanish State Research Agency (AEI) and
   the Spanish Ministry of Economy and Competitiveness (MINECO) [WATER4FOOD
   project, CTQ2014-54563-C3] and Comunidad de Madrid and European
   Structural Funds [FOTOCAOS project, Y2018/EMT-5062].
CR ACHDOU Y, 1993, COMPUT METHOD APPL M, V102, P89, DOI 10.1016/0045-7825(93)90142-K
   ANSYS I, 2012, ANSYS US THEOR GUID
   Avila M, 2011, COMPUT METHOD APPL M, V200, P425, DOI 10.1016/j.cma.2010.11.003
   Casado C, 2017, CHEM ENG J, V327, P1043, DOI 10.1016/j.cej.2017.06.167
   CASSANO AE, 1995, IND ENG CHEM RES, V34, P2155, DOI 10.1021/ie00046a001
   CHAI JC, 1993, NUMER HEAT TR B-FUND, V24, P373, DOI 10.1080/10407799308955899
   Cid K., 2016, AN C BRAS FLUID COMP
   DRAKE DJ, 1990, J COMPUT PHYS, V87, P73, DOI 10.1016/0021-9991(90)90226-Q
   Eskandarian MR, 2016, CHEM ENG J, V300, P414, DOI 10.1016/j.cej.2016.05.049
   Ge WJ, 2015, J HEAT TRANS-T ASME, V137, DOI 10.1115/1.4029546
   Habibi A, 2007, COMPUT CHEM ENG, V31, P1389, DOI 10.1016/j.compchemeng.2006.11.009
   Heimsath A, 2014, ENRGY PROCED, V49, P386, DOI 10.1016/j.egypro.2014.03.042
   Hettel M, 2018, COMPUT CHEM ENG, V109, P166, DOI 10.1016/j.compchemeng.2017.11.005
   Kong B, 2014, BIORESOURCE TECHNOL, V158, P141, DOI 10.1016/j.biortech.2014.01.052
   Kong R, 2008, J COMPUT PHYS, V227, P9463, DOI 10.1016/j.jcp.2008.06.037
   Kuczynski P, 2014, ARCH THERMODYN, V35, P65, DOI 10.2478/aoter-2014-0014
   Martin CA, 1999, CATAL TODAY, V48, P307, DOI 10.1016/S0920-5861(98)00386-1
   Marugan J, 2008, APPL CATAL B-ENVIRON, V85, P48, DOI 10.1016/j.apcatb.2008.06.026
   Moreno I, 2008, OPT EXPRESS, V16, P1808, DOI 10.1364/OE.16.001808
   Paixao De Almeida Y., 2013, 22 INT C MECH ENG CO
   Pareek VK, 2004, AICHE J, V50, P1273, DOI 10.1002/aic.10107
   Radice D, 2013, J COMPUT PHYS, V242, P648, DOI 10.1016/j.jcp.2013.01.048
   Sergejevs A, 2017, PHOTOCH PHOTOBIO SCI, V16, P1690, DOI 10.1039/c7pp00269f
   Uhl A, 2004, DENT MATER, V20, P80, DOI 10.1016/S0109-5641(03)00095-2
   Vikas V, 2013, J COMPUT PHYS, V246, P221, DOI 10.1016/j.jcp.2013.03.028
   Wang ZM, 2012, J HAZARD MATER, V215, P25, DOI 10.1016/j.jhazmat.2012.02.021
NR 26
TC 1
Z9 1
U1 4
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 151
EP 164
DI 10.1016/j.ces.2019.04.034
PG 14
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000014
DA 2020-05-12
ER

PT J
AU Yablonsky, GS
   Branco, D
   Marin, GB
   Constales, D
AF Yablonsky, Gregory S.
   Branco, Daniel
   Marin, Guy B.
   Constales, Denis
TI Swapping the equilibrium
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Swapped equilibrium; Conservatively Perturbed Equilibrium;
   Intersections; Invariants; Two-step mechanism; Linear reaction
ID CHEMICAL-REACTIONS; COINCIDENCES; INTERSECTIONS; SYSTEMS; BALANCE;
   EVENTS
AB A "swapped equilibrium" (SE) occurs when the initial concentrations of two chemical species are taken as their equilibrium concentrations, but swapped. In complex mechanisms, this implies that the initial concentrations of the other chemical species remain equal to their corresponding equilibrium concentrations; a phenomenon called Conservatively Perturbed Equilibrium (CPE), described in a previous paper (Chem. Eng. Sci. 196, 2019, 384-390). The SE-phenomenon is illustrated for both a single-step and a two-step mechanism with first-order reactions. For the two-step mechanism, invariant expressions are obtained based on the corrected ratios of CPE concentration profiles, while the other two chemical species are under swapped equilibrium conditions. For the related CPE case, invariant expressions are also obtained considering the same two-step mechanism. The CPE-properties described previously (Chem. Eng. Sci. 196, 2019, 384-390) are now completed with the invariant expressions presented now, specific for the two-step linear mechanism. (C) 2019 Published by Elsevier Ltd.
C1 [Yablonsky, Gregory S.] Washington Univ, Dept Energy Environm & Chem Engn, St Louis, MO 63130 USA.
   [Branco, Daniel; Constales, Denis] Univ Ghent, Dept Math Anal, Bldg S-8,Krijgslaan 281, B-9000 Ghent, Belgium.
   [Marin, Guy B.] Univ Ghent, Chem Technol Lab, Technol Pk 914, B-9052 Ghent, Belgium.
RP Yablonsky, GS (reprint author), Washington Univ, Dept Energy Environm & Chem Engn, St Louis, MO 63130 USA.
EM gy@wustl.edu; Daniel.BrancoPinto@UGent.be; Guy.Marin@UGent.be;
   Denis.Constales@UGent.be
FU Long Term Structural Methusalem Funding by the Flemish government; Ghent
   University's Special Research Fund [BOF-STA 2014-0002]
FX The authors are grateful for the financial support from the Long Term
   Structural Methusalem Funding by the Flemish government. D. Branco and
   D. Constales acknowledge support from Ghent University's Special
   Research Fund, grant BOF-STA 2014-0002.
CR ARIS R, 1968, ARCH RATION MECH AN, V27, P356
   Aris Rutherford, 1965, ARCH RATIONAL MECH A, V19, P81, DOI DOI 10.1007/BF00282276
   Branco PD, 2017, CHEM ENG SCI, V158, P370, DOI 10.1016/j.ces.2016.10.032
   Branco PD, 2018, CHEM ENG SCI, V184, P25, DOI 10.1016/j.ces.2018.02.020
   Branco RD, 2019, COMPUT CHEM ENG, V125, P606, DOI 10.1016/j.compchemeng.2016.06.022
   Constales D, 2013, COMPUT MATH APPL, V65, P1614, DOI 10.1016/j.camwa.2012.11.005
   Constales D, 2015, CHEM ENG SCI, V123, P328, DOI 10.1016/j.ces.2014.11.030
   Gorban AN, 2013, PHYSICA A, V392, P1318, DOI 10.1016/j.physa.2012.10.009
   Gorban AN, 2011, CHEM ENG SCI, V66, P5388, DOI 10.1016/j.ces.2011.07.054
   GORBANY AN, 1980, REACT KINET CATAL L, V15, P315
   Hankins MJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173786
   HORN F, 1972, ARCH RATION MECH AN, V47, P81
   Khudyaev S. I., ANAL CLASSES DISCONT
   Marin G., 2011, KINETICS CHEM REACTI
   Peng BX, 2018, CHEM ENG SCI, V191, P262, DOI 10.1016/j.ces.2018.06.065
   Pinto DB, 2015, ENTROPY-SWITZ, V17, P6783, DOI 10.3390/e17106783
   SHAPIRO NZ, 1965, J SOC IND APPL MATH, V13, P353, DOI 10.1137/0113020
   Vol'pert A. I., 1972, MATH USSR SB, V17, P571, DOI DOI 10.1070/SM1972V017N04ABEH001603
   Yablonskii G. S., 1991, COMPREHENSIVE CHEM K
   Yablonsky GS, 2011, EPL-EUROPHYS LETT, V93, DOI 10.1209/0295-5075/93/20004
   Yablonsky GS, 2011, CHEM ENG SCI, V66, P111, DOI 10.1016/j.ces.2010.10.014
   Yablonsky GS, 2010, CHEM ENG SCI, V65, P6065, DOI 10.1016/j.ces.2010.04.007
   Yablonsky GS, 2019, CHEM ENG SCI, V196, P384, DOI 10.1016/j.ces.2018.11.010
   Zeldovich Y. B., CHEM PHYS HYDRODYNAM, V204, P44
NR 24
TC 2
Z9 2
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 165
EP 173
DI 10.1016/j.ces.2019.04.048
PG 9
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000015
DA 2020-05-12
ER

PT J
AU Crundwell, FK
AF Crundwell, Frank K.
TI The impact of surface charge on the ionic dissociation of common salt
   (NaCl)
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Ionic dissociation; Salt; NaCl; Dissolution; Crystallization;
   Potential-determining ions
ID DISSOLUTION; MECHANISM; MINERALS; SIMULATIONS; NACL(001); WATER
AB The ionic dissociation of NaCl has long been thought to be fully understood in terms of the simultaneous removal and hydration of the constituent ions from the surface. However, there are two observations that trouble the current model of ionic dissociation. The first of these observations is that the surface is charged. This has been established by several of studies using laser doppler electrophoresis and membrane electrochemistry. This has not been accounted for in descriptions of ionic dissociation, dissolution or crystallization of salt. The second observation is that the current model, which envisages sodium and chloride ions hydrating and departing the surface, does not yield a rate law consistent with experimental data. These two observations are resolved in this work. It is proposed that the removal of ions form ionic vacancies while deposition forms excess ions on the surface. Vacancies and excess ions are the source of surface charge. The effect of this surface charge affects the rate of removal of ions from the surface, resulting in a feedback mechanism: ionic vacancies are formed by the removal of ions, which affects the rate at which ions are removed. From this model, expressions are derived for the establishment of the charge on the surface and for the kinetics of ionic dissociation, dissolution and crystallization of NaCl. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Crundwell, Frank K.] Univ Witwatersrand, Sch Chem & Met Engn, Johannesburg, South Africa.
   [Crundwell, Frank K.] Crundwell Met Ltd, 71-75 Shelton St, London WC2H 9JQ, England.
RP Crundwell, FK (reprint author), Univ Witwatersrand, Sch Chem & Met Engn, Johannesburg, South Africa.; Crundwell, FK (reprint author), Crundwell Met Ltd, 71-75 Shelton St, London WC2H 9JQ, England.
OI Crundwell, Frank/0000-0002-5669-9522
CR Alkattan M, 1997, CHEM GEOL, V137, P201, DOI 10.1016/S0009-2541(96)00164-7
   Bahadur R, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2185091
   Ballard AJ, 2012, J PHYS CHEM B, V116, P13490, DOI 10.1021/jp309300b
   Bard A. J., 1980, ELECTROCHEMICAL METH
   Crundwell FK, 2016, MINER ENG, V95, P185, DOI 10.1016/j.mineng.2016.06.017
   Crundwell FK, 2015, HYDROMETALLURGY, V151, P163, DOI 10.1016/j.hydromet.2014.10.004
   Crundwell FK, 2015, HYDROMETALLURGY, V151, P151, DOI 10.1016/j.hydromet.2014.10.006
   Crundwell FK, 2014, HYDROMETALLURGY, V149, P265, DOI 10.1016/j.hydromet.2014.07.003
   Crundwell FK, 2014, HYDROMETALLURGY, V149, P252, DOI 10.1016/j.hydromet.2014.06.009
   Crundwell FK, 2014, HYDROMETALLURGY, V149, P71, DOI 10.1016/j.hydromet.2014.06.008
   Crundwell FK, 2017, ACS OMEGA, V2, P4845, DOI 10.1021/acsomega.7b00344
   Crundwell FK, 2017, ACS OMEGA, V2, P1116, DOI 10.1021/acsomega.7b00019
   Crundwell FK, 2016, CRYST GROWTH DES, V16, P5877, DOI 10.1021/acs.cgd.6b00939
   Engkvist O, 2000, J CHEM PHYS, V112, P6827, DOI 10.1063/1.481257
   Geissler PL, 1999, J PHYS CHEM B, V103, P3706, DOI 10.1021/jp984837g
   Holmberg N, 2014, PHYS CHEM CHEM PHYS, V16, P17437, DOI 10.1039/c4cp00635f
   Hunter R. J., 1988, ZETA POTENTIAL COLLO, P385
   IBL N, 1975, Z PHYS CHEM NEUE FOL, V98, P123, DOI 10.1524/zpch.1975.98.1-6.123
   Klimes J, 2013, J CHEM PHYS, V139, DOI 10.1063/1.4840675
   Lanaro G, 2015, J PHYS CHEM B, V119, P4275, DOI 10.1021/jp512358s
   MILLER JD, 1992, LANGMUIR, V8, P1464, DOI 10.1021/la00041a036
   MILLER JD, 1994, MINER ENG, V7, P305, DOI 10.1016/0892-6875(94)90072-8
   OHTAKI H, 1988, PURE APPL CHEM, V60, P1321, DOI 10.1351/pac198860081321
   RASTOGI RP, 1970, J APPL PHYS, V41, P2787, DOI 10.1063/1.1659316
   RASTOGI RP, 1983, J ELECTROCHEM SOC, V130, P1327, DOI 10.1149/1.2119947
   Roman R.J., 1968, T AIME, V241, P56
   Seidell A, 1965, AM CHEM SOC, V2
   Shinto H, 1998, J PHYS CHEM B, V102, P1974, DOI 10.1021/jp972795a
   SIMON B, 1981, J CRYST GROWTH, V52, P789, DOI 10.1016/0022-0248(81)90377-8
   Timko J, 2010, J CHEM PHYS, V132, DOI 10.1063/1.3360310
   1986, CRC HDB CHEM PHYS
NR 31
TC 0
Z9 0
U1 4
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 174
EP 180
DI 10.1016/j.ces.2019.04.050
PG 7
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000016
DA 2020-05-12
ER

PT J
AU Ma, S
   Wang, YX
   Liu, ZY
   Huang, MN
   Yang, H
   Xu, ZL
AF Ma, Shuai
   Wang, Yixing
   Liu, Zhenying
   Huang, Mengnan
   Yang, Hu
   Xu, Zhen-liang
TI Preparation of carbon nanofiber with multilevel gradient porous
   structure for supercapacitor and CO2 adsorption
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE PVDF; Carbon nanofiber; Pore structure; Supercapacitor; CO2 adsorption
ID ELECTROCHEMICAL PERFORMANCE; POLYVINYLIDENE FLUORIDE; ASSISTED
   SYNTHESIS; ACTIVATED CARBONS; OXIDE; ELECTRODE; NANOPARTICLES;
   MORPHOLOGY; POROSITY; CAPTURE
AB In this work, we demonstrate a simple method to prepare carbon nanofiber (CNF) with multilevel gradient porous structure derived from polyvinylidene fluoride (PVDF)-polyvinyl pyrrolidone (PVP) /PVP core-shell nanofiber. Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) have confirmed that the as-prepared CNF contains a hollow channel embraced by mesoporous and microporous structures. Its specific surface area reaches to 1084 m(2)/g with the mesoporous volume contribution of 59%. The as-prepared porous CNF shows a high capacitance of 331 F/g at 1 A/g and 99.6% capacitance retention after 10,000 cycles at 5 A/g, which is better than the corresponding CNF with irregularly arranged hierarchical pores. The all-solid-state symmetric supercapacitor assembled using the as-prepared porous CNF as electrodes exhibits an excellent high specific capacitance of 147.4F/g at 1 A/g with a high energy density of 13.1Wh/kg. The capacitance retention still maintains at 89.2% after 2000 cycles at a current density of 5 A/g. Meanwhile, the as-prepared porous CNF also shows a high CO2 adsorption uptake, 5.08 mmol/g at 0 degrees C and 1 bar. The possible reason and mechanism have been discussed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ma, Shuai; Wang, Yixing; Liu, Zhenying; Huang, Mengnan; Yang, Hu; Xu, Zhen-liang] East China Univ Sci & Technol, Chem Engn Res Ctr, State Key Lab Chem Engn, Membrane Sci & Engn R&D Lab, 130 Meilong Rd, Shanghai 200237, Peoples R China.
RP Yang, H (reprint author), East China Univ Sci & Technol, Chem Engn Res Ctr, State Key Lab Chem Engn, Membrane Sci & Engn R&D Lab, 130 Meilong Rd, Shanghai 200237, Peoples R China.
EM hyang@ecust.edu.cn
RI Wang, Yixing/S-4984-2019
OI yang, hu/0000-0001-9411-2553; Xu, Zhen-Liang/0000-0002-1436-4927
CR Aytug T, 2018, ACS APPL MATER INTER, V10, P11008, DOI 10.1021/acsami.8b01938
   Bai BC, 2015, APPL SURF SCI, V353, P158, DOI 10.1016/j.apsusc.2015.06.046
   Bing XF, 2017, J COLLOID INTERF SCI, V488, P207, DOI 10.1016/j.jcis.2016.10.076
   Bui HT, 2018, CARBON, V130, P94, DOI 10.1016/j.carbon.2017.12.111
   Chen T, 2014, SCI REP-UK, V4, DOI 10.1038/srep03612
   Chu P.K., 2016, MATER CHEM PHYS, V96, P253
   Drisko GL, 2013, ACS APPL MATER INTER, V5, P5009, DOI 10.1021/am4007929
   Estevez L, 2018, IND ENG CHEM RES, V57, P1262, DOI 10.1021/acs.iecr.7b03879
   Frey M, 2019, CHEM ENG SCI, V195, P271, DOI 10.1016/j.ces.2018.11.028
   Garcia-Bordeje E, 2017, CARBON, V123, P421, DOI 10.1016/j.carbon.2017.07.085
   Guan TT, 2017, J MATER CHEM A, V5, P15869, DOI 10.1039/c7ta02966g
   Guo ZY, 2016, J MATER CHEM A, V4, P6282, DOI 10.1039/c6ta02030e
   He G, 2014, CHEM MATER, V26, P3879, DOI 10.1021/cm403740r
   Heo YJ, 2019, COMPOS PART B-ENG, V156, P95, DOI 10.1016/j.compositesb.2018.08.057
   Hong SM, 2016, MICROPOR MESOPOR MAT, V219, P59, DOI 10.1016/j.micromeso.2015.07.034
   Huang MN, 2017, NEW J CHEM, V41, P7544, DOI 10.1039/c7nj01555k
   Huo SL, 2018, J POWER SOURCES, V387, P81, DOI 10.1016/j.jpowsour.2018.03.061
   Kim C, 2007, SMALL, V3, P91, DOI 10.1002/smll.200600243
   Kim M, 2018, J POWER SOURCES, V389, P20, DOI 10.1016/j.jpowsour.2018.03.080
   Kshetri T, 2018, CHEM ENG J, V345, P39, DOI 10.1016/j.cej.2018.03.143
   Lee GH, 2010, MACROMOL RES, V18, P571, DOI 10.1007/s13233-010-0607-9
   Li T, 2019, IND ENG CHEM RES, V58, P1601, DOI 10.1021/acs.iecr.8b06437
   Li XY, 2017, ELECTROCHIM ACTA, V240, P43, DOI 10.1016/j.electacta.2017.04.061
   Li Z, 2015, ANGEW CHEM INT EDIT, V54, P12886, DOI 10.1002/anie.201506972
   Ludwinowicz J, 2015, CARBON, V82, P297, DOI 10.1016/j.carbon.2014.10.074
   Ma C, 2016, CHEM ENG J, V304, P587, DOI 10.1016/j.cej.2016.07.002
   Malanoski AP, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.041603
   Miao FJ, 2016, J MATER CHEM A, V4, P4180, DOI 10.1039/c6ta00015k
   Miura K, 2001, CHEM ENG SCI, V56, P1623, DOI 10.1016/S0009-2509(00)00390-0
   Modi A, 2016, ELECTROCHIM ACTA, V190, P620, DOI 10.1016/j.electacta.2015.12.191
   Namsaeng J, 2019, CHEM ENG SCI, V193, P230, DOI 10.1016/j.ces.2018.09.019
   Nguyen PTM, 2013, COLLOID SURFACE A, V437, P56, DOI 10.1016/j.colsurfa.2013.03.028
   Ning J, 2016, MATER DESIGN, V109, P264, DOI 10.1016/j.matdes.2016.07.074
   Qasem NAA, 2018, APPL ENERG, V210, P317, DOI 10.1016/j.apenergy.2017.11.011
   Redondo E, 2015, ELECTROCHIM ACTA, V160, P178, DOI 10.1016/j.electacta.2015.02.006
   Taha AA, 2014, J COLLOID INTERF SCI, V417, P199, DOI 10.1016/j.jcis.2013.11.015
   Tan YT, 2018, J MATER RES, V33, P1120, DOI 10.1557/jmr.2017.373
   Ternero-Hidalgo JJ, 2016, CARBON, V101, P409, DOI 10.1016/j.carbon.2016.02.015
   Topuz F, 2017, MAT SCI ENG C-MATER, V80, P371, DOI 10.1016/j.msec.2017.06.001
   Wang G, 2016, NEW J CHEM, V40, P3786, DOI 10.1039/c5nj02963e
   Wang H, 2018, ACS APPL ENERG MATER, V1, P431, DOI 10.1021/acsaem.7b00083
   Wei HM, 2018, ELECTROCHIM ACTA, V266, P161, DOI 10.1016/j.electacta.2017.12.192
   Wei XJ, 2016, CHEM MATER, V28, P445, DOI 10.1021/acs.chemmater.5b02336
   Xing YL, 2014, ACS APPL MATER INTER, V6, P2561, DOI 10.1021/am404988b
   Xu ZL, 2014, NANO ENERGY, V6, P27, DOI 10.1016/j.nanoen.2014.03.003
   Xue CF, 2017, RSC ADV, V7, P24195, DOI 10.1039/c6ra26997d
   Xue GB, 2016, ELECTROCHIM ACTA, V215, P29, DOI 10.1016/j.electacta.2016.08.063
   Yang CM, 2015, J PHYS CHEM C, V119, P2935, DOI 10.1021/jp510630e
   Yang Y, 2011, CARBON, V49, P3395, DOI 10.1016/j.carbon.2011.04.015
   Yoo SH, 2017, APPL SURF SCI, V402, P456, DOI 10.1016/j.apsusc.2017.01.154
   Zhang LJ, 2016, ELECTROCHIM ACTA, V196, P189, DOI 10.1016/j.electacta.2016.02.050
   Zheng GY, 2011, NANO LETT, V11, P4462, DOI 10.1021/nl2027684
   Zhu XQ, 2018, CHEM ENG SCI, V181, P36, DOI 10.1016/j.ces.2018.02.004
   Zhuang XP, 2014, CHEM ENG J, V237, P308, DOI 10.1016/j.cej.2013.10.038
NR 54
TC 6
Z9 6
U1 34
U2 189
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 181
EP 189
DI 10.1016/j.ces.2019.05.001
PG 9
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000017
DA 2020-05-12
ER

PT J
AU Dong, C
   Li, ZY
   Liu, FX
   Wei, W
   Wang, XJ
   Liu, ZJ
AF Dong, Chao
   Li, Zhiyi
   Liu, Fengxia
   Wei, Wei
   Wang, Xiaojuan
   Liu, Zhijun
TI Effects of supercritical fluid parameters and emulsion formulation on
   the production of quercetin nanocapsules by supercritical fluid
   extraction of emulsion
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Supercritical extraction of emulsion; Quercetin nanoparticles; Emulsion
   stability; Pressure-composition diagram; Minimum density point
ID ETHYL-ACETATE; TRANSPORT PROPERTIES; ORGANIC-SOLVENT; CARBON-DIOXIDE;
   DIFFUSION; MICRONIZATION; ENCAPSULATION; NANOPARTICLES; PREVENTION;
   PRESSURE
AB Quercetin nanoparticles encapsulated by Polysorbate 80 were produced by supercritical fluid extraction of emulsion. To analyze the effect of supercritical fluid parameters on organic solvent extraction by scCO(2), Peng-Robinson equation of state was employed to obtain the pressure-composition diagram of the mixture system concerned. Also, Huang equation was adopted in combination with Peng-Robinson equation to calculate the density of the solvent/CO2 binary system. The effects of supercritical fluid parameters such as pressure and temperature on emulsion stability in the emulsion extraction stage and extraction efficiency in both emulsion and solution extraction stages were examined experimentally. The analytical and experimental results showed that phase separation could happen in the emulsion extraction stage because of the swelling and the rapid decrease in the density of ethyl acetate droplets in the emulsion to the minimum density point as the mole fraction of CO2 in ethyl acetate increased with the rise in pressure below the mixture critical point. To avoid the minimum density point, a lower pressure (<6 MPa) could be employed to guarantee the emulsion stability while the similar level of extraction efficiency in the emulsion extraction stage was retained. The supercritical fluid extraction was proven to be very efficient in reducing the content of residual organic solvent in the solution extraction stage with the minimum residual content as low as 5.3 ppm. (C) 2019 Published by Elsevier Ltd.
C1 [Dong, Chao; Li, Zhiyi; Liu, Fengxia; Wei, Wei; Wang, Xiaojuan; Liu, Zhijun] Dalian Univ Technol, R&D Inst Fluid & Powder Engn, Dalian 116024, Peoples R China.
RP Liu, ZJ (reprint author), Dalian Univ Technol, R&D Inst Fluid & Powder Engn, Dalian 116024, Peoples R China.
EM liuzj@dlut.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21606037]
FX This work was supported by the National Natural Science Foundation of
   China (No. 21606037).
CR ALTSHULLER AP, 1953, J AM CHEM SOC, V75, P1727, DOI 10.1021/ja01103a501
   Anton N, 2008, J CONTROL RELEASE, V128, P185, DOI 10.1016/j.jconrel.2008.02.007
   Boots AW, 2008, EUR J PHARMACOL, V585, P325, DOI 10.1016/j.ejphar.2008.03.008
   Byun HS, 2006, J SUPERCRIT FLUID, V37, P323, DOI 10.1016/j.supflu.2005.10.007
   Chakraborty S, 2012, BIOMATERIALS, V33, P2991, DOI 10.1016/j.biomaterials.2011.12.037
   Chattopadhyay P, 2006, J PHARM SCI-US, V95, P667, DOI 10.1002/jps.20555
   Cussler E.L., 1984, DIFFUSION MASS TRANS
   D'Andrea G, 2015, FITOTERAPIA, V106, P256, DOI 10.1016/j.fitote.2015.09.018
   Dajas F, 2012, J ETHNOPHARMACOL, V143, P383, DOI 10.1016/j.jep.2012.07.005
   Della Porta G, 2012, J SUPERCRIT FLUID, V63, P1, DOI 10.1016/j.supflu.2011.12.020
   Fraile M, 2014, IND ENG CHEM RES, V53, P4318, DOI 10.1021/ie5001136
   FULLER EN, 1969, J PHYS CHEM-US, V73, P3679, DOI 10.1021/j100845a020
   Garcia-Casas I, 2017, EUR J PHARM SCI, V100, P79, DOI 10.1016/j.ejps.2017.01.010
   Hari BNV, 2016, CHEM ENG SCI, V155, P366, DOI 10.1016/j.ces.2016.08.019
   HUANG FH, 1985, J CHEM ENG JPN, V18, P490, DOI 10.1252/jcej.18.490
   KENNEDY JT, 1961, AICHE J, V7, P625, DOI 10.1002/aic.690070419
   Levai G, 2017, J SUPERCRIT FLUID, V129, P36, DOI 10.1016/j.supflu.2017.01.015
   Levai G, 2017, POWDER TECHNOL, V317, P142, DOI 10.1016/j.powtec.2017.04.041
   Levai G, 2017, FOOD BIOPROD PROCESS, V103, P27, DOI 10.1016/j.fbp.2017.02.008
   Levai G, 2015, J SUPERCRIT FLUID, V100, P34, DOI 10.1016/j.supflu.2015.02.019
   Liu XW, 2005, CHINESE J CHEM ENG, V13, P128
   Mattea F, 2010, AICHE J, V56, P1184, DOI 10.1002/aic.12061
   Meng FT, 2003, J CONTROL RELEASE, V91, P407, DOI 10.1016/S0168-3659(03)00273-6
   Montes A, 2017, J CO2 UTIL, V21, P169, DOI 10.1016/j.jcou.2017.07.009
   Murakami Y, 2017, J SUPERCRIT FLUID, V128, P121, DOI 10.1016/j.supflu.2017.05.014
   PENG D, 1976, IND ENG CHEM FUND, V15, P59, DOI 10.1021/i160057a011
   Porta GD, 2008, BIOTECHNOL BIOENG, V100, P1020, DOI 10.1002/bit.21845
   Prieto C, 2017, J SUPERCRIT FLUID, V119, P274, DOI 10.1016/j.supflu.2016.10.004
   Reid RC, 1987, PROPERTIES GASES LIQ
   Reverchon E, 2010, CHEM ENG J, V156, P446, DOI 10.1016/j.cej.2009.10.052
   Russo M, 2012, BIOCHEM PHARMACOL, V83, P6, DOI 10.1016/j.bcp.2011.08.010
   Santos DT, 2013, J FOOD PROCESS ENG, V36, P36, DOI 10.1111/j.1745-4530.2011.00651.x
   Serban MC, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002713
   Tian YL, 2004, J CHEM ENG DATA, V49, P1554, DOI 10.1021/je034224j
   Tsivintzelis I, 2004, FLUID PHASE EQUILIBR, V224, P89, DOI 10.1016/j.fluid.2004.06.046
   TYN MT, 1975, J CHEM ENG DATA, V20, P106, DOI 10.1021/je60064a006
   Valente I, 2012, CHEM ENG SCI, V77, P217, DOI 10.1016/j.ces.2012.02.050
   VIGNES A, 1966, IND ENG CHEM FUND, V5, P189, DOI 10.1021/i160018a007
   Widjojokusumo E, 2013, J CO2 UTIL, V3-4, P30, DOI 10.1016/j.jcou.2013.09.001
NR 39
TC 1
Z9 1
U1 12
U2 31
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 190
EP 200
DI 10.1016/j.ces.2019.03.042
PG 11
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000018
DA 2020-05-12
ER

PT J
AU Torres, M
   Berrios, J
   Rigual, Y
   Latorre, Y
   Vergara, M
   Dickson, AJ
   Altamirano, C
AF Torres, Mauro
   Berrios, Julio
   Rigual, Yandi
   Latorre, Yesenia
   Vergara, Mauricio
   Dickson, Alan J.
   Altamirano, Claudia
TI Metabolic flux analysis during galactose and lactate co-consumption
   reveals enhanced energy metabolism in continuous CHO cell cultures
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bioprocessing; Biochemical engineering; Biopharmaceuticals; Metabolism
   modelling; Metabolic flux analysis; Lactate
ID FED-BATCH CULTIVATION; GLUCOSE; PRODUCTIVITY; PROTEIN; GROWTH;
   GLYCOSYLATION; SHIFT; SUBSTITUTION; GLUTAMINE; INSIGHT
AB Chinese Hamster Ovary (CHO) cells are the main expression system for production of therapeutic recombinant (r-) proteins. The increased demand for these therapeutics has boosted the development of more robust production processes. Use of optimised feed/media has dramatically improved the performance of CHO cells in culture. However, such progress in biomass synthesis and r-protein production often come with an increased accumulation of lactate. In this study, we present a combined feeding strategy that uses galactose and lactate to replace glucose in CHO cell cultures. Replacement of glucose by galactose and lactate sustained cell growth and r-protein production in CHO cells. This strategy supported a better-balanced and more efficient metabolism, observed by an overall decreased consumption of carbon sources and amino acids, associated with an increased ATP production per C-mol consumed. Our results provide new insights of CHO cell metabolism in glucose-free media based on galactose and lactate. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Torres, Mauro; Dickson, Alan J.] Univ Manchester, Manchester Inst Biotechnol, Fac Sci & Engn, Manchester, Lancs, England.
   [Berrios, Julio; Rigual, Yandi; Latorre, Yesenia; Vergara, Mauricio; Altamirano, Claudia] Pontificia Univ Catolica Valparaiso, Sch Biochem Engn, Brasil Ave 2085, Valparaiso, Chile.
   [Altamirano, Claudia] GORE Valparaiso, CONICYT REG, Reg Ctr Hlth Food Studies CREAS R17A10001, Valparaiso, Chile.
RP Altamirano, C (reprint author), Pontificia Univ Catolica Valparaiso, Sch Biochem Engn, Brasil Ave 2085, Valparaiso, Chile.
EM claudia.altamirano@pucv.cl
OI Berrios, Julio/0000-0002-6180-0023; Torres, Mauro/0000-0002-4054-4323;
   Altamirano, Claudia/0000-0002-6389-086X
FU Becas Chile scholarship [21160312, 21140857, 1161452]; Fondo Nacional de
   Desarrollo Cientifico y TecnologicoComision Nacional de Investigacion
   Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT [BB/N004000/1];
   Biotechnology and Biological Sciences Research Council of the
   UKBiotechnology and Biological Sciences Research Council (BBSRC)
FX This work was supported by Becas Chile scholarship to MT, YR (21160312)
   and YL (21140857), by 1161452 Fondo Nacional de Desarrollo Cientifico y
   Tecnologico to CA and by funding (BB/N004000/1) from the Biotechnology
   and Biological Sciences Research Council of the UK.
CR Ahn WS, 2011, METAB ENG, V13, P598, DOI 10.1016/j.ymben.2011.07.002
   Altamirano C, 2004, J BIOTECHNOL, V110, P171, DOI 10.1016/j.jbiotec.2004.02.004
   Altamirano C, 2001, BIOTECHNOL PROGR, V17, P1032, DOI 10.1021/bp0100981
   Altamirano C, 2000, BIOTECHNOL PROGR, V16, P69, DOI 10.1021/bp990124j
   Altamirano C, 2006, J BIOTECHNOL, V125, P547, DOI 10.1016/j.jbiotec.2006.03.023
   Anumula KR, 1999, ANAL BIOCHEM, V275, P236, DOI 10.1006/abio.1999.4323
   Berrios J, 2011, CHEM ENG SCI, V66, P2431, DOI 10.1016/j.ces.2011.03.011
   Buchsteiner M, 2018, BIOTECHNOL BIOENG, V115, P2315, DOI 10.1002/bit.26724
   Carinhas N, 2013, BIOTECHNOL BIOENG, V110, P3244, DOI 10.1002/bit.24983
   Charaniya S, 2010, J BIOTECHNOL, V147, P186, DOI 10.1016/j.jbiotec.2010.04.005
   Clark KJR, 2005, BIOTECHNOL BIOENG, V90, P568, DOI 10.1002/bit.20439
   Cruz HJ, 2000, ENZYME MICROB TECH, V27, P43, DOI 10.1016/S0141-0229(00)00151-4
   Dickson AJ, 2014, CURR OPIN BIOTECH, V30, P73, DOI 10.1016/j.copbio.2014.06.004
   Freund NW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020385
   FU DT, 1995, ANAL BIOCHEM, V227, P377, DOI 10.1006/abio.1995.1294
   Grainger RK, 2013, BIOTECHNOL BIOENG, V110, P2970, DOI 10.1002/bit.24959
   Gramer MJ, 2011, BIOTECHNOL BIOENG, V108, P1591, DOI 10.1002/bit.23075
   Hartley F, 2018, BIOTECHNOL BIOENG, V115, P1890, DOI 10.1002/bit.26603
   Heussen C., 1984, J BIOL CHEM, DOI [10.1002/J.1545-7249.2008.TB00161.X, DOI 10.1002/J.1545-7249.2008.TB00161.X]
   Ivarsson M, 2015, BIOTECHNOL PROGR, V31, P347, DOI 10.1002/btpr.2043
   Karst DJ, 2017, BIOTECHNOL BIOENG, V114, P1978, DOI 10.1002/bit.26315
   Le H, 2012, J BIOTECHNOL, V162, P210, DOI 10.1016/j.jbiotec.2012.08.021
   Li JC, 2012, BIOTECHNOL BIOENG, V109, P1173, DOI 10.1002/bit.24389
   Liste-Calleja L, 2015, APPL MICROBIOL BIOT, V99, P9951, DOI 10.1007/s00253-015-6855-z
   Liu JT, 2015, WORLD J MICROB BIOT, V31, P1147, DOI 10.1007/s11274-015-1864-8
   Lu SB, 2005, PROCESS BIOCHEM, V40, P1917, DOI 10.1016/j.procbio.2004.07.004
   Luo J, 2012, BIOTECHNOL BIOENG, V109, P146, DOI 10.1002/bit.23291
   Ma NN, 2009, BIOTECHNOL PROGR, V25, P1353, DOI 10.1002/btpr.238
   Martinez VS, 2013, BIOTECHNOL BIOENG, V110, P660, DOI 10.1002/bit.24728
   Mulukutla BC, 2017, BIOTECHNOL BIOENG, V114, P1779, DOI 10.1002/bit.26313
   Mulukutla BC, 2012, METAB ENG, V14, P138, DOI 10.1016/j.ymben.2011.12.006
   Narkewicz M. R., 1996, BIOCHEMISTRY-US, V996, P3, DOI [10.1074/JBC.271.28.16906, DOI 10.1074/JBC.271.28.16906]
   Quek LE, 2010, METAB ENG, V12, P161, DOI 10.1016/j.ymben.2009.09.002
   Quek LE, 2008, GENOME INFORM SER, V21, P89
   R Core Team, 2016, R LANG ENV STAT COMP, DOI [10.1017/CBO9781107415324.004, DOI 10.1017/CBO9781107415324.004]
   Roman R, 2018, J BIOTECHNOL, V287, P68, DOI 10.1016/j.jbiotec.2018.10.005
   Sha S, 2018, CURR OPIN CHEM ENG, V22, P54, DOI 10.1016/j.coche.2018.08.010
   Sou SN, 2015, BIOTECHNOL BIOENG, V112, P1165, DOI 10.1002/bit.25524
   Sun YT, 2013, BIOCHEM ENG J, V81, P126, DOI 10.1016/j.bej.2013.10.012
   Templeton N, 2017, METAB ENG, V44, P126, DOI 10.1016/j.ymben.2017.09.010
   Templeton N, 2017, METAB ENG, V43, P218, DOI 10.1016/j.ymben.2017.01.008
   Templeton N, 2013, BIOTECHNOL BIOENG, V110, P2013, DOI 10.1002/bit.24858
   Torres M, 2018, CURR OPIN CHEM ENG, V22, P184, DOI 10.1016/j.coche.2018.10.004
   VARMA A, 1995, BIOTECHNOL BIOENG, V45, P69, DOI 10.1002/bit.260450110
   Vergara M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202098
   Vergara M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144224
   Vergara M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093865
   Wahrheit J, 2014, APPL MICROBIOL BIOT, V98, P1771, DOI 10.1007/s00253-013-5452-2
   Wilkens CA, 2011, BIOTECHNOL BIOPROC E, V16, P714, DOI 10.1007/s12257-010-0409-0
   Wong NSC, 2010, BIOTECHNOL BIOENG, V107, P321, DOI 10.1002/bit.22812
   Wurm FM, 2004, NAT BIOTECHNOL, V22, P1393, DOI 10.1038/nbt1026
   Yuk IH, 2015, BIOTECHNOL PROGR, V31, P226, DOI 10.1002/btpr.2004
   Zagari F, 2013, NEW BIOTECHNOL, V30, P238, DOI 10.1016/j.nbt.2012.05.021
   Zhang L, 2019, J BIOTECHNOL, V289, P71, DOI 10.1016/j.jbiotec.2018.11.004
NR 54
TC 0
Z9 0
U1 4
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 201
EP 211
DI 10.1016/j.ces.2019.04.049
PG 11
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000019
DA 2020-05-12
ER

PT J
AU Yu, YS
   Wang, MC
   Zhu, YQ
   Zhou, JZ
   Zhou, A
AF Yu, Ying-Song
   Wang, Ming-Chao
   Zhu, Yi-Qi
   Zhou, Jin-Zhi
   Zhou, An
TI Evaporative deposition of mono- and bi-dispersed colloids on a
   polydimethylsiloxane (PDMS) surface
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Droplet; Evaporation; PDMS; Microparticle; Capillary force
ID CONTACT LINE; COFFEE-RING; SUBSTRATE-TEMPERATURE; DROPLET EVAPORATION;
   NANOFLUID DROPLETS; PATTERN-FORMATION; PARTICLE; WETTABILITY; DYNAMICS;
   FORCES
AB Evaporative deposition of mono-and bi-dispersed colloids on a polydimethylsiloxane (PDMS) surface was studied. At particle concentrations of 0.02 and 0.08 wt%, 1.58 mu m diameter polystyrene (PS) microparticles were uniformly distributed from mono-dispersed colloids. PS microparticles located at the edge of the deposition increased when the particle concentration increased to 0.32 and 1.28 wt%. Mono-dispersed colloids of 1.21 mu m silica microparticles produced a ring-like deposition at particle concentrations ranging from 0.02 to 0.32 wt%. The width of the ring increased with increasing concentration and a mountain-like structure was produced at 1.28 wt%. The settling speed of 1.21 mu m silica microparticles is 14 times greater than 1.58 mu m PS microparticles resulting in easier settling of silica compared with PS microparticles. Experimental investigations show PS microparticles are dragged inward with the depinning contact line, and the outmost silica microparticles are pinned. The edge of the depositions of bi-dispersed colloids were made up of smaller microparticles and larger microparticles were found far from the edge due to capillary force. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yu, Ying-Song; Wang, Ming-Chao; Zhu, Yi-Qi; Zhou, Jin-Zhi; Zhou, An] Hubei Univ Technol, Dept Mech, Sch Civil Engn Architecture & Environm, Wuhan 430068, Hubei, Peoples R China.
RP Yu, YS; Zhou, JZ (reprint author), Hubei Univ Technol, Dept Mech, Sch Civil Engn Architecture & Environm, Wuhan 430068, Hubei, Peoples R China.
EM yuys@hbut.edu.cn; zhoujz@hbut.edu.cn
RI Yu, Ying-Song/E-9772-2014
OI Yu, Ying-Song/0000-0002-3914-1121
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [11572114]; State Key Laboratory of Nonlinear
   Mechanics (LNM)
FX The work is financially supported by the National Natural Science
   Foundation of China (Grant No. 11572114), and the opening fund of State
   Key Laboratory of Nonlinear Mechanics (LNM). We also thank Prof. Quanzi
   Yuan from State Key Laboratory of Nonlinear Mechanics, Institute of
   Mechanics, Chinese Academy of Sciences and Prof. Fengchao Wang from
   University of Science and Technology of China for helpful discussions.
   Besides, we thank ScienceDocs Inc. (https://www.sciencedocs.com) for
   language editing.
CR Askounis A, 2015, ADV COLLOID INTERFAC, V222, P44, DOI 10.1016/j.cis.2014.05.003
   Bhardwaj R, 2010, LANGMUIR, V26, P7833, DOI 10.1021/la9047227
   Biswas S, 2010, J SOL ENERG-T ASME, V132, DOI 10.1115/1.4001470
   Brutin D, 2018, CHEM SOC REV, V47, P558, DOI 10.1039/c6cs00902f
   Butt HJ, 2003, PHYS CHEM INTERFACES
   Chhasatia VH, 2011, SOFT MATTER, V7, P10135, DOI 10.1039/c1sm06393f
   Deegan RD, 1997, NATURE, V389, P827, DOI 10.1038/39827
   Devlin NR, 2016, AICHE J, V62, P947, DOI 10.1002/aic.15120
   Drummond CJ, 1997, LANGMUIR, V13, P3890, DOI 10.1021/la962131c
   Dugas V, 2005, LANGMUIR, V21, P9130, DOI 10.1021/la050764y
   Gao MN, 2018, SCI CHINA TECHNOL SC, V61, P949, DOI 10.1007/s11431-017-9202-y
   Ghosh UU, 2016, LANGMUIR, V32, P12790, DOI 10.1021/acs.langmuir.6b03267
   Grosshans H, 2016, INT J HEAT MASS TRAN, V96, P97, DOI 10.1016/j.ijheatmasstransfer.2015.12.062
   HORN RG, 1989, CHEM PHYS LETT, V162, P404, DOI 10.1016/0009-2614(89)87066-6
   Hu H, 2006, J PHYS CHEM B, V110, P7090, DOI 10.1021/jp0609232
   Hu HL, 2018, APPL SURF SCI, V441, P295, DOI 10.1016/j.apsusc.2018.02.049
   Hu YC, 2018, APPL SURF SCI, V434, P626, DOI 10.1016/j.apsusc.2017.10.202
   Ihnen AC, 2011, APPL SURF SCI, V258, P827, DOI 10.1016/j.apsusc.2011.08.125
   Iqbal R, 2018, SOFT MATTER, V14, P9901, DOI 10.1039/c8sm01915k
   Jeong H, 2018, ACS APPL MATER INTER, V10, P22877, DOI 10.1021/acsami.8b05793
   Jung JY, 2007, ANAL CHEM, V79, P5087, DOI 10.1021/ac0702903
   Jung JY, 2010, ANAL CHEM, V82, P784, DOI 10.1021/ac902288z
   Jung JY, 2009, ANAL CHEM, V81, P8256, DOI 10.1021/ac901247c
   Kirby BJ, 2004, ELECTROPHORESIS, V25, P203, DOI 10.1002/elps.200305755
   Koh A, 2000, J COLLOID INTERF SCI, V227, P390, DOI 10.1006/jcis.2000.6909
   Landau L D, 1987, FLUID MECH
   Larson RG, 2017, NATURE, V550, P466, DOI 10.1038/550466a
   Lee HH, 2017, INT J HEAT MASS TRAN, V105, P230, DOI 10.1016/j.ijheatmasstransfer.2016.09.093
   Li YS, 2015, SOFT MATTER, V11, P4669, DOI 10.1039/c5sm00654f
   Li YQ, 2016, LANGMUIR, V32, P12676, DOI 10.1021/acs.langmuir.6b03595
   Lin Z., 2012, EVAPORATIVE SELF ASS
   Lopes MC, 2013, SOFT MATTER, V9, P7942, DOI 10.1039/c3sm51184g
   Majumder M, 2012, J PHYS CHEM B, V116, P6536, DOI 10.1021/jp3009628
   Mampallil D, 2012, SOFT MATTER, V8, P10614, DOI 10.1039/c2sm26103k
   Monteux C, 2011, LANGMUIR, V27, P2917, DOI 10.1021/la104055j
   Nakao A, 1998, J COLLOID INTERF SCI, V197, P257, DOI 10.1006/jcis.1997.5289
   Parsa M, 2018, ADV COLLOID INTERFAC, V254, P22, DOI 10.1016/j.cis.2018.03.007
   Parsa M, 2017, J PHYS CHEM B, V121, P11002, DOI 10.1021/acs.jpcb.7b09700
   Parsa M, 2015, LANGMUIR, V31, P3354, DOI 10.1021/acs.langmuir.5b00362
   Patil ND, 2018, LANGMUIR, V34, P12058, DOI 10.1021/acs.langmuir.8b00427
   Patil ND, 2016, LANGMUIR, V32, P11958, DOI 10.1021/acs.langmuir.6b02769
   Thiele U, 2014, ADV COLLOID INTERFAC, V206, P399, DOI 10.1016/j.cis.2013.11.002
   Weon BM, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.028303
   Weon BM, 2010, PHYS REV E, V82, DOI 10.1103/PhysRevE.82.015305
   Wong TS, 2011, ANAL CHEM, V83, P1871, DOI 10.1021/ac102963x
   Xie QG, 2018, LANGMUIR, V34, P5303, DOI 10.1021/acs.langmuir.8b00727
   Yu YS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14593-5
   Yu YS, 2017, SCI CHINA PHYS MECH, V60, DOI 10.1007/s11433-017-9060-3
   Yu YS, 2016, AIP ADV, V6, DOI 10.1063/1.4964315
   Yunker PJ, 2011, NATURE, V476, P308, DOI 10.1038/nature10344
   Zhao Y P, 2012, PHYS MECH SURFACES I
   Zhong X, 2017, APPL THERM ENG, V111, P1565, DOI 10.1016/j.applthermaleng.2016.08.040
   Zhong X, 2016, PHYS CHEM CHEM PHYS, V18, P20664, DOI 10.1039/c6cp03231a
NR 53
TC 0
Z9 0
U1 2
U2 33
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 212
EP 219
DI 10.1016/j.ces.2019.05.006
PG 8
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000020
DA 2020-05-12
ER

PT J
AU Huang, XP
   Huang, KH
   Jia, Y
   Wang, S
   Cao, ZF
   Zhong, H
AF Huang, Xiaoping
   Huang, Kaihua
   Jia, Yun
   Wang, Shuai
   Cao, Zhanfang
   Zhong, Hong
TI Investigating the selectivity of a xanthate derivative for the flotation
   separation of chalcopyrite from pyrite
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Chalcopyrite; Pyrite; Xanthate; Flotation; Separation
ID ADSORPTION MECHANISM; TOF-SIMS; SURFACTANTS; BEHAVIOR; DFT; XPS;
   COLLECTORS; REMOVAL; IRON; THIONOCARBAMATE
AB Separating chalcopyrite, an important copper-containing ore, from pyrite is an important mineral-processing objective. Herein, we report the synthesis of S-hydroxyethyl-O-isobutyl xanthate (HEIBX), a novel surfactant bearing both hydroxyl and thione groups, through the attachment of a hydroxyethyl group to sodium isobutyl xanthate (SIBX), and its first application as a flotation collector for the selective flotation-separation of chalcopyrite from pyrite. The flotation mechanism involving HEIBX and chalcopyrite or pyrite was investigated by DFT calculations, UV-vis spectroscopy, contact-angle and surface-tension measurements, flotation and zeta-potential experiments, as well as FTIR spectroscopy and XPS. Incorporation of the hydroxyethyl group was observed to increase the molecular properties of SIBX by increasing the number of active sites, arrangement density, selectivity and hydrophobicity, thereby improving its flotation performance. Chalcopyrite was separated from pyrite using 4 x 10(-5) mol.L-1 HEIBX at pH similar to 8.0. Furthermore, we found that the hydroxyl and thione functional groups adsorb onto the chalcopyrite surface though the formation of C-O-Cu and C-S-Cu bonds. (C) 2019 Published by Elsevier Ltd.
C1 [Huang, Xiaoping; Huang, Kaihua; Jia, Yun; Wang, Shuai; Cao, Zhanfang; Zhong, Hong] Cent S Univ, Coll Chem & Chem Engn, Changsha 410083, Hunan, Peoples R China.
RP Cao, ZF; Zhong, H (reprint author), Cent S Univ, Coll Chem & Chem Engn, Changsha 410083, Hunan, Peoples R China.
EM zfcao1980@163.com; zhongh@csu.edu.cn
RI Wang, Shuai/F-7613-2013
OI Wang, Shuai/0000-0002-1678-0211; Cao, Zhanfang/0000-0002-2257-2582
FU National High Technology Research and Development Program of China (863
   Program)National High Technology Research and Development Program of
   China [2013AA064101]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China [21776320]
FX The authors gratefully acknowledge the National High Technology Research
   and Development Program of China (863 Program, Grant No. 2013AA064101)
   and National Natural Science Foundation of China (Grant No. 21776320)
   for the financial support.
CR ALAMI E, 1993, LANGMUIR, V9, P1465, DOI 10.1021/la00030a006
   Balachandran V, 2013, SPECTROCHIM ACTA A, V104, P114, DOI 10.1016/j.saa.2012.11.052
   Basnayaka L, 2017, APPL CLAY SCI, V136, P230, DOI 10.1016/j.clay.2016.12.004
   Besada LN, 2018, J NANOPART RES, V20, DOI 10.1007/s11051-018-4169-7
   Budi S, 2010, APPL SURF SCI, V257, P1027, DOI 10.1016/j.apsusc.2010.07.103
   Carta F, 2013, J MED CHEM, V56, P4691, DOI 10.1021/jm400414j
   Chand P, 2015, INT BIODETER BIODEGR, V97, P60, DOI 10.1016/j.ibiod.2014.10.015
   CHANDER S, 1991, INT J MINER PROCESS, V33, P121, DOI 10.1016/0301-7516(91)90047-M
   Chen LJ, 2012, J PHYS CHEM C, V116, P8579, DOI 10.1021/jp2120862
   Deng LQ, 2016, J IND ENG CHEM, V33, P131, DOI 10.1016/j.jiec.2015.09.027
   Deng W, 2017, MINERALS-BASEL, V7, DOI 10.3390/min7030040
   Ejtemaei M, 2017, MINER ENG, V112, P36, DOI 10.1016/j.mineng.2017.07.005
   Ermis E, 2018, J MOL STRUCT, V1168, P115, DOI 10.1016/j.molstruc.2018.05.021
   Fairthorne G, 1997, INT J MINER PROCESS, V50, P227, DOI 10.1016/S0301-7516(97)00048-3
   Farquhar ML, 2003, APPL SURF SCI, V218, P34, DOI 10.1016/S0169-4332(03)00538-5
   Ghahremaninezhad A, 2013, ELECTROCHIM ACTA, V87, P97, DOI 10.1016/j.electacta.2012.07.119
   Ghosh S, 2007, J PHYS CHEM B, V111, P8080, DOI 10.1021/jp067761u
   He ZL, 2016, J IND ENG CHEM, V37, P107, DOI 10.1016/j.jiec.2016.03.013
   Hesabi M, 2018, PHYS CHEM RES, V6, P115, DOI 10.22036/pcr.2017.96386.1411
   Hirajima T, 2017, MINER ENG, V100, P83, DOI 10.1016/j.mineng.2016.10.007
   Huang XP, 2019, APPL SURF SCI, V476, P460, DOI 10.1016/j.apsusc.2019.01.053
   Huang XP, 2017, J ENVIRON MANAGE, V204, P264, DOI 10.1016/j.jenvman.2017.09.007
   Huang ZG, 2014, CHEM ENG J, V257, P218, DOI 10.1016/j.cej.2014.07.057
   Jia Y, 2019, APPL SURF SCI, V484, P864, DOI 10.1016/j.apsusc.2019.03.323
   Juncal LC, 2015, SPECTROCHIM ACTA A, V139, P346, DOI 10.1016/j.saa.2014.12.086
   Kaczor A, 2004, J MOL STRUCT, V704, P189, DOI 10.1016/j.molstruc.2004.01.067
   Kaltenhauser V, 2013, J MATER CHEM C, V1, P7825, DOI 10.1039/c3tc31684j
   Kato E, 1994, Japanese patent, Patent No. [JP 066003869 A, 066003869]
   Khusnun NF, 2018, POWDER TECHNOL, V327, P170, DOI 10.1016/j.powtec.2017.12.052
   Li SK, 2018, T NONFERR METAL SOC, V28, P1241, DOI 10.1016/S1003-6326(18)64762-4
   Liu GY, 2016, COLLOID SURFACE A, V511, P285, DOI 10.1016/j.colsurfa.2016.10.017
   Liu GY, 2016, COLLOID SURFACE A, V503, P34, DOI 10.1016/j.colsurfa.2016.05.028
   Liu GY, 2015, J COLLOID INTERF SCI, V437, P42, DOI 10.1016/j.jcis.2014.08.069
   Liu K, 2011, J APPL REMOTE SENS, V5, DOI 10.1117/1.3613946
   Liu S, 2017, J IND ENG CHEM, V52, P359, DOI 10.1016/j.jiec.2017.04.015
   Long XH, 2016, APPL SURF SCI, V370, P11, DOI 10.1016/j.apsusc.2016.02.094
   Lyu L, 2018, ENVIRON SCI TECHNOL, V52, P4294, DOI 10.1021/acs.est.7b06545
   Ma X, 2017, IND ENG CHEM RES, V56, P6307, DOI 10.1021/acs.iecr.6b04566
   Madec L, 2015, PHYS CHEM CHEM PHYS, V17, P27062, DOI 10.1039/c5cp04221f
   Menger FM, 2000, LANGMUIR, V16, P2062, DOI 10.1021/la9910576
   Mitchell TK, 2005, ADV COLLOID INTERFAC, V114, P227, DOI 10.1016/j.cis.2004.08.009
   Mustafa S, 2004, INT J MINER PROCESS, V74, P317, DOI 10.1016/j.minpro.2004.04.006
   Owusu C, 2014, MINER ENG, V55, P87, DOI 10.1016/j.mineng.2013.09.018
   Sewanthi S, 2018, J MOL STRUCT, V1173, P251, DOI 10.1016/j.molstruc.2018.07.001
   Sheridan MS, 2002, MINER ENG, V15, P333, DOI 10.1016/S0892-6875(02)00037-7
   Suyantara GPW, 2018, COLLOID SURFACE A, V554, P34, DOI 10.1016/j.colsurfa.2018.06.029
   TAN BJ, 1990, CHEM MATER, V2, P186, DOI 10.1021/cm00008a021
   Tian J, 2017, CHEM ENG SCI, V164, P99, DOI 10.1016/j.ces.2017.02.013
   Tobon YA, 2009, J PHYS ORG CHEM, V22, P815, DOI 10.1002/poc.1525
   Wang NN, 2017, BIORESOURCE TECHNOL, V233, P58, DOI 10.1016/j.biortech.2017.02.069
   Wang Y., 2015, Chinese patent, Patent No. [CN 104761579 A, 104761579]
   Xiao JJ, 2017, J TAIWAN INST CHEM E, V71, P38, DOI 10.1016/j.jtice.2016.12.022
   Yang XL, 2018, J TAIWAN INST CHEM E, V93, P109, DOI 10.1016/j.jtice.2018.09.022
   Yin WZ, 2018, MINER ENG, V115, P142, DOI 10.1016/j.mineng.2017.10.016
   Yin ZG, 2018, LANGMUIR, V34, P4071, DOI 10.1021/acs.langmuir.7b03975
   Yu DF, 2010, J PHYS CHEM B, V114, P14955, DOI 10.1021/jp106031d
   Zhao G, 2013, MINER ENG, V49, P54, DOI 10.1016/j.mineng.2013.04.025
NR 57
TC 6
Z9 6
U1 12
U2 66
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 220
EP 229
DI 10.1016/j.ces.2019.04.051
PG 10
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000021
DA 2020-05-12
ER

PT J
AU Zhang, QL
   Su, WK
   Ning, P
   Liu, X
   Wang, HM
   Hu, J
AF Zhang, Qiulin
   Su, Weikang
   Ning, Ping
   Liu, Xin
   Wang, Huimin
   Hu, Jia
TI Catalytic performance and mechanistic study of toluene combustion over
   the Pt-Pd-HMS catalyst
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Pt-Pd; HMS; Toluene; Catalytic combustion; In-situ DRIFTS
ID VOLATILE ORGANIC-COMPOUNDS; TOTAL OXIDATION; MESOPOROUS SILICAS;
   COMPOUNDS VOCS; SURFACE-AREA; NANOPARTICLES; V2O5/TIO2; REDUCTION;
   SYSTEMS; INSIGHT
AB Pt-Pd-HMS catalyst had been prepared by a one-pot approach and tested for toluene combustion. Comparing with conventional impregnated Pt-Pd/HMS (E-a = 111.41 kJ/mol, Pt-Pd particle size = 23.4 nm), the Pt-Pd-HMS exhibited lower activation energy (E-a = 80.23 kJ/mol) and smaller Pt-Pd particle size (6.3 nm). Moreover, surface Pt-0/Pt-total of the Pt-Pd-HMS (52.8%) was higher than that of the Pt-Pd/HMS (46.8%), and Pt-Pd-HMS obtained an optimal catalytic performance with T-90 = 179 degrees C at a GHSV = 26,000 mL/(g.h). In-situ DRIFTS indicated that simultaneous generation of benzoate species and aliphatic compounds as intermediates occurred on the active sites of Pt-Pd-HMS. In contrast, the intermediates of toluene combustion on the active sites of Pt-Pd/HMS were dominated by benzoates. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhang, Qiulin; Su, Weikang; Ning, Ping; Liu, Xin; Wang, Huimin; Hu, Jia] Kunming Univ Sci & Technol, Fac Environm Sci & Engn, Kunming 650500, Yunnan, Peoples R China.
RP Ning, P (reprint author), Kunming Univ Sci & Technol, Fac Environm Sci & Engn, Kunming 650500, Yunnan, Peoples R China.
EM ningping_58@126.com
FU National key R&D Program of China [2018YFC0213400]
FX This work is supported by the National key R&D Program of China
   (2018YFC0213400).
CR Barakat T, 2014, NEW J CHEM, V38, P2066, DOI 10.1039/c3nj01190a
   Bendahou K, 2008, APPL CATAL A-GEN, V351, P82, DOI 10.1016/j.apcata.2008.09.001
   Besselmann S, 2000, J MOL CATAL A-CHEM, V162, P401, DOI 10.1016/S1381-1169(00)00307-1
   Bharti A, 2018, INT J HYDROGEN ENERG, V43, P14729, DOI 10.1016/j.ijhydene.2018.06.009
   Calderon JC, 2018, INT J HYDROGEN ENERG, V43, P16881, DOI 10.1016/j.ijhydene.2017.12.182
   Chen CY, 2015, CATAL TODAY, V258, P190, DOI 10.1016/j.cattod.2015.02.006
   Chen L, 2018, APPL SURF SCI, V457, P821, DOI 10.1016/j.apsusc.2018.07.032
   Cheng TQ, 2017, APPL SURF SCI, V426, P745, DOI 10.1016/j.apsusc.2017.07.120
   Das DD, 2007, J CATAL, V246, P60, DOI 10.1016/j.jcat.2006.11.020
   Deng H, 2018, CHEM ENG J, V348, P361, DOI 10.1016/j.cej.2018.04.184
   Du JP, 2018, APPL SURF SCI, V433, P1025, DOI 10.1016/j.apsusc.2017.10.116
   Fu XR, 2016, CATAL COMMUN, V83, P22, DOI 10.1016/j.catcom.2016.05.001
   Guan WB, 2017, CATAL COMMUN, V98, P57, DOI 10.1016/j.catcom.2017.04.036
   Han DM, 2018, ATMOS RES, V209, P123, DOI 10.1016/j.atmosres.2018.04.002
   He YB, 2011, CATAL COMMUN, V14, P77, DOI 10.1016/j.catcom.2011.07.024
   Jiang ZY, 2018, APPL CATAL B-ENVIRON, V226, P220, DOI 10.1016/j.apcatb.2017.12.007
   Kamal MS, 2016, ATMOS ENVIRON, V140, P117, DOI 10.1016/j.atmosenv.2016.05.031
   Li W, 2018, CHINESE J CATAL, V39, P946, DOI 10.1016/S1872-2067(18)63015-3
   Liao FL, 2015, CHEMCATCHEM, V7, P1998, DOI 10.1002/cctc.201500245
   Lin HQ, 2016, J TAIWAN INST CHEM E, V67, P69, DOI 10.1016/j.jtice.2016.07.033
   Liu X, 2018, CATAL COMMUN, V115, P26, DOI 10.1016/j.catcom.2018.07.003
   Liu YX, 2012, J CATAL, V287, P149, DOI 10.1016/j.jcat.2011.12.015
   Luo YJ, 2018, J HAZARD MATER, V349, P119, DOI 10.1016/j.jhazmat.2018.01.053
   Matejova L, 2012, APPL CATAL A-GEN, V443, P40, DOI 10.1016/j.apcata.2012.07.018
   Parreira LA, 2011, APPL CATAL A-GEN, V397, P145, DOI 10.1016/j.apcata.2011.02.028
   Peng RS, 2016, CHEM ENG J, V306, P1234, DOI 10.1016/j.cej.2016.08.056
   Rui ZB, 2017, CATAL TODAY, V297, P159, DOI 10.1016/j.cattod.2017.04.055
   Rui ZB, 2014, IND ENG CHEM RES, V53, P15879, DOI 10.1021/ie5029107
   SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603
   SPIVEY JJ, 1987, IND ENG CHEM RES, V26, P2165, DOI 10.1021/ie00071a001
   Sun H, 2015, CHEM ENG J, V270, P58, DOI 10.1016/j.cej.2015.02.017
   Tantishaiyakul V, 1999, INT J PHARM, V181, P143, DOI 10.1016/S0378-5173(99)00070-8
   Tuel A, 1999, MICROPOR MESOPOR MAT, V27, P151, DOI 10.1016/S1387-1811(98)00250-9
   Wang GW, 2017, J CATAL, V351, P90, DOI 10.1016/j.jcat.2017.04.018
   Wang H, 2017, APPL CATAL A-GEN, V529, P60, DOI 10.1016/j.apcata.2016.10.016
   Williams T, 2006, MICROPOR MESOPOR MAT, V88, P91, DOI 10.1016/j.micromeso.2005.08.027
   Wong CT, 2008, J HAZARD MATER, V157, P480, DOI 10.1016/j.jhazmat.2008.01.012
   Wu ZX, 2016, MICROPOR MESOPOR MAT, V224, P311, DOI 10.1016/j.micromeso.2015.11.061
   Xu WC, 2016, CATAL COMMUN, V84, P61, DOI 10.1016/j.catcom.2016.06.004
   Yan FW, 2009, CATAL COMMUN, V10, P1689, DOI 10.1016/j.catcom.2009.05.008
   Zepeda TA, 2015, J MOL CATAL A-CHEM, V397, P26, DOI 10.1016/j.molcata.2014.09.002
   Zhang F, 2015, ACS CATAL, V5, P1381, DOI 10.1021/cs501763k
   Zhang H, 2012, CHEM SOC REV, V41, P8035, DOI 10.1039/c2cs35173k
   Zhang JY, 2018, CHEM ENG J, V334, P10, DOI 10.1016/j.cej.2017.10.017
   Zhang XD, 2012, POWDER TECHNOL, V230, P212, DOI 10.1016/j.powtec.2012.07.031
   Zhao S, 2016, APPL CATAL B-ENVIRON, V181, P236, DOI 10.1016/j.apcatb.2015.08.001
   Zhao W, 2005, MATER RES BULL, V40, P1775, DOI 10.1016/j.materresbull.2005.05.012
   Zulkepli S, 2018, ENERG CONVERS MANAGE, V165, P495, DOI 10.1016/j.enconman.2018.03.087
NR 48
TC 4
Z9 4
U1 21
U2 92
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 230
EP 237
DI 10.1016/j.ces.2019.04.047
PG 8
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000022
DA 2020-05-12
ER

PT J
AU Lu, F
   Wen, LY
   Chen, YX
   Zhong, H
   Xu, J
   Zhang, SF
   Yang, ZQ
AF Lu, Feng
   Wen, Liangying
   Chen, Yangxin
   Zhong, Hong
   Xu, Jian
   Zhang, Shengfu
   Yang, Zhongqing
TI Carbon formation on the surface during the reduction of iron oxide
   particles by CO and CO/H-2 mixtures
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Direct reduction; Carbon formation; DFT; Kinetic model; Adsorption
ID MONOXIDE-HYDROGEN MIXTURES; FLUIDIZED-BED; SELF-AGGLOMERATION; FE2O3
   PARTICLES; DEPOSITION; BEHAVIOR; STICKING; ORE; PREVENTION; MECHANISM
AB Carbon deposition on the iron surface is of great interest due to a good performance to prevent sticking during the direct reduction (DR) in the fluidized bed. The promising routes of carbon formation were investigated by the density function theory (DFT). An innovative kinetic model, which considers adsorption and decomposition of CO, is applied to control the carbon content of direct reduction iron in the two-stages reduction process. The results show that the C-O bond of CO is stretched due to the attractive force of surface iron atoms on the C and O atoms. The added H-2 can significantly improve this C-O bond stretch to decrease the barrier energy of CO decomposition. The formation of carbon is sensitive to the temperature and the added H-2 can extend the temperature range for carbon formation and reduce the temperature of the maximum rate of carbon formation. Besides, the proper concentration of H-2 added in the CO/H-2 mixtures can improve the formation of carbon shell. However, the carbon shell will not be formed under a condition of extremely high mole fraction of H-2 because H-2 increases the adsorption energy of CO on the iron surface. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lu, Feng; Wen, Liangying; Chen, Yangxin; Zhong, Hong; Xu, Jian; Zhang, Shengfu] Chongqing Univ, Sch Mat Sci & Engn, Chongqing 400044, Peoples R China.
   [Lu, Feng; Wen, Liangying; Chen, Yangxin; Xu, Jian; Zhang, Shengfu] Chongqing Univ, Chongqing Key Lab Vanadium Titanium Met & Adv Mat, Chongqing 400044, Peoples R China.
   [Zhong, Hong] Washington State Univ, Sch Mech & Mat Engn, Pullman, WA 99163 USA.
   [Yang, Zhongqing] Chongqing Univ, Key Lab Low Grade Energy Utilizat Technol & Syst, Minist Educ, Chongqing 400044, Peoples R China.
RP Wen, LY (reprint author), Chongqing Univ, Sch Mat Sci & Engn, Chongqing 400044, Peoples R China.
EM cquwen@cqu.edu.cn
RI Xu, Jian/Y-9405-2019
OI Xu, Jian/0000-0002-7565-9665
FU National Natural Science Foundation Project of ChinaNational Natural
   Science Foundation of China [51374263, 51674052]; Chongqing Research
   Program of Basic Research and Frontier Technology [cstc2018jcyjAX0003];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [91634106, 51704048]
FX This work is supported by the National Natural Science Foundation
   Project of China (51374263, 51674052). The authors are grateful for the
   Chongqing Research Program of Basic Research and Frontier Technology
   (cstc2018jcyjAX0003) and National Natural Science Foundation of China
   (91634106, 51704048) is also acknowledged.
CR Adham K, 2004, CAN METALL QUART, V43, P67
   Akbarzadeh H., 2017, J MOL LIQ, V248
   Argyle MD, 2015, CATALYSTS, V5, P145, DOI 10.3390/catal5010145
   BERRY TF, 1956, J AM CERAM SOC, V39, P308, DOI 10.1111/j.1151-2916.1956.tb15838.x
   ELKASABGY T, 1980, METALL TRANS B, V11, P409
   Feng F, 2019, FUEL, V235, P85, DOI 10.1016/j.fuel.2018.07.076
   Garnier C, 2011, INT J COAL GEOL, V87, P80, DOI 10.1016/j.coal.2011.05.001
   Gong XZ, 2014, METALL MATER TRANS B, V45, P2050, DOI 10.1007/s11663-014-0125-9
   Guo L, 2015, INT J MIN MET MATER, V22, P12, DOI 10.1007/s12613-015-1037-7
   Harada T, 2011, ISIJ INT, V51, P1301, DOI 10.2355/isijinternational.51.1301
   Jedli H, 2017, APPL CLAY SCI, V136, P199, DOI 10.1016/j.clay.2016.11.022
   Jess A, 1998, STEEL RES, V69, P77, DOI 10.1002/srin.199801454
   Kandagal VS, 2017, J CHEM PHYS, V147, DOI 10.1063/1.4993654
   Karimi F, 2018, ADV POWDER TECHNOL, V29, P3145, DOI 10.1016/j.apt.2018.08.017
   Komatina M., 2004, METALURGIJA, V10, P309, DOI DOI 10.30544/378
   Lei C, 2016, POWDER TECHNOL, V296, P79, DOI 10.1016/j.powtec.2015.12.024
   Lei C, 2014, CHEM ENG SCI, V118, P50, DOI 10.1016/j.ces.2014.07.034
   Li J, 2018, CHEM ENG SCI, V177, P455, DOI 10.1016/j.ces.2017.11.038
   Li J, 2017, AICHE J, V63, P459, DOI 10.1002/aic.15402
   Li LY., 2013, POWDER TECHNOL, V235, P1001
   Lin CL, 2009, POWDER TECHNOL, V189, P57, DOI 10.1016/j.powtec.2008.06.003
   Lu F, 2019, INT J HYDROGEN ENERG, V44, P6427, DOI 10.1016/j.ijhydene.2019.01.173
   Lu F, 2018, J APPL CRYSTALLOGR, V51, P1641, DOI 10.1107/S1600576718014747
   MISAK NZ, 1995, COLLOID SURFACE A, V97, P129, DOI 10.1016/0927-7757(94)03073-9
   NEUSCHUTZ D, 1989, STEEL RES, V60, P113, DOI 10.1002/srin.198900885
   NEUSCHUTZ D, 1991, STEEL RES, V62, P333, DOI 10.1002/srin.199101306
   Plaul EJ, 2009, J S AFR I MIN METALL, V109, P121
   Sasaki Y, 2005, ISIJ INT, V45, P1077, DOI 10.2355/isijinternational.45.1077
   Schenk JL, 2011, PARTICUOLOGY, V9, P14, DOI 10.1016/j.partic.2010.08.011
   SRINIVASAN NS, 1990, CHEM ENG SCI, V45, P1253, DOI 10.1016/0009-2509(90)87118-C
   TOWHIDI N, 1983, METALL TRANS B, V14, P359, DOI 10.1007/BF02654354
   TURKDOGAN ET, 1974, METALL TRANS, V5, P11
   WALKER PL, 1959, J PHYS CHEM-US, V63, P140, DOI 10.1021/j150572a003
   WALKER PL, 1959, J PHYS CHEM-US, V63, P133, DOI 10.1021/j150572a002
   Wang S, 2019, AICHE J, V65, P1035, DOI 10.1002/aic.16474
   Wang W, 2016, 2016 IEEE INNOVATIVE SMART GRID TECHNOLOGIES - ASIA (ISGT-ASIA), P1, DOI [10.1109/ISGT-Asia.2016.7796352, 10.1109/CPEM.2016.7540636]
   Yi LY, 2014, J CENT SOUTH UNIV, V21, P506, DOI 10.1007/s11771-014-1968-6
   Yi LY, 2015, POWDER TECHNOL, V269, P290, DOI 10.1016/j.powtec.2014.09.018
   Zhang B, 2013, ISIJ INT, V53, P411, DOI 10.2355/isijinternational.53.411
   Zhang B, 2011, ISIJ INT, V51, P1403, DOI 10.2355/isijinternational.51.1403
   Zhang T, 2014, POWDER TECHNOL, V254, P1, DOI 10.1016/j.powtec.2014.01.004
   Zhong H., 2015, METALL MAT T, V46, P1
   Zhong YW, 2013, POWDER TECHNOL, V249, P175, DOI 10.1016/j.powtec.2013.08.016
   Zhong YW, 2013, POWDER TECHNOL, V241, P142, DOI 10.1016/j.powtec.2013.03.030
   ZHU KS, 1989, J ANHUI U TECH NAT S, V6, P97
NR 45
TC 0
Z9 0
U1 9
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 238
EP 247
DI 10.1016/j.ces.2019.04.046
PG 10
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000023
DA 2020-05-12
ER

PT J
AU Leimann, VF
   Goncalves, OH
   Sorita, GD
   Rezende, S
   Bona, E
   Fernandes, IPM
   Ferreira, ICFR
   Barreiro, MF
AF Leimann, V. F.
   Goncalves, O. H.
   Sorita, G. D.
   Rezende, S.
   Bona, E.
   Fernandes, I. P. M.
   Ferreira, I. C. F. R.
   Barreiro, M. F.
TI Heat and pH stable curcumin-based hydrophilic colorants obtained by the
   solid dispersion technology assisted by spray-drying
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Curcuma longa; Solid dispersions; Natural food colorants; pH stability;
   Temperature stability; Chemometrics
ID PRINCIPAL COMPONENT ANALYSIS; GOLDEN SPICE; SOLUBILITY; BIOAVAILABILITY;
   STABILITY; STRATEGY; IMPROVE; MICRO
AB Natural food colorants are on demand due to food safety concerns related with some synthetic counterparts. Health-friendly alternatives can be available from plant sources, which include curcumin extracted from Curcuma longa L. However, its industrial use is difficult to achieve due to the low water affinity, pH and thermal instability, which is particularly challenging, e.g. for baked foods. In this work, the solid dispersion technique followed by spray-drying, an emergent approach in the context of colorants, was applied to curcumin using k-carrageenan, poly(vinyl alcohol) and polyvinylpyrrolidone, as the encapsulant materials. An orthogonal central composite design with dummy-variables was applied, and principal component analysis (PCA) and hierarchical cluster analysis (HCA) carried out to identify the experimental conditions leading to the most effective formulations. In general, particles with a wide range of pH and heat stability have been produced depending on the chosen encapsulant material, used formulation (curcumin, surfactant and polymer contents), and synthesis conditions (pH). Moreover, the used mathematical approach showed to be a valuable tool to support the development of tailor-made formulations directed to specific applications where pH and temperature are relevant processing parameters. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Leimann, V. F.; Goncalves, O. H.; Rezende, S.; Fernandes, I. P. M.; Ferreira, I. C. F. R.; Barreiro, M. F.] Inst Politecn Braganca, Ctr Invest Montanha CIMO, Campus Santa Apolonia, P-5300253 Braganca, Portugal.
   [Leimann, V. F.; Goncalves, O. H.; Sorita, G. D.; Bona, E.] Fed Univ Technol Parana UTFPR, Postgrad Program Food Technol PPGTA, Campus Campo Mourao,Via Rosalina Maria Santos, BR-87301899 Campo Mourao, PR, Brazil.
   [Leimann, V. F.; Goncalves, O. H.; Sorita, G. D.; Fernandes, I. P. M.; Barreiro, M. F.] Polytech Inst Braganca, Lab Separat & React Engn, Lab Catalysis & Mat LSRE LCM, P-5301857 Braganca, Portugal.
RP Goncalves, OH; Barreiro, MF (reprint author), Inst Politecn Braganca, Ctr Invest Montanha CIMO, Campus Santa Apolonia, P-5300253 Braganca, Portugal.
EM odinei@utfpr.edu.br; barreiro@ipb.pt
RI Bona, Evandro/F-8225-2012; Ferreira, Isabel C.F.R./E-8500-2013; Leimann,
   Fernanda V/O-5001-2016; Fernandes, Isabel Patricia/L-1552-2016;
   Barreiro, Filomena/L-9802-2014
OI Bona, Evandro/0000-0001-8557-7527; Ferreira, Isabel
   C.F.R./0000-0003-4910-4882; Leimann, Fernanda V/0000-0001-6230-9597;
   Cunha De Rezende, Stephany/0000-0002-9265-636X; Fernandes, Isabel
   Patricia/0000-0002-0069-4503; Barreiro, Filomena/0000-0002-6844-333X
FU Associate Laboratory LSRE-LCM - FCT/MCTES (PIDDAC) [UID/EQU/50020/2019];
   Foundation for Science and Technology (FCT, Portugal)Portuguese
   Foundation for Science and Technology; FEDER under Program PT2020
   [UID/AGR/00690/2019]; CAPES (Brazil)CAPES; CNPq (Brazil)National Council
   for Scientific and Technological Development (CNPq); Fundacao Araucaria
   (Brazil)Fundacao Araucaria
FX This work was financially supported by Associate Laboratory LSRE-LCM
   (UID/EQU/50020/2019) funded by national funds through FCT/MCTES
   (PIDDAC), and Foundation for Science and Technology (FCT, Portugal).
   CIMO (UID/AGR/00690/2019) through FEDER under Program PT2020. Authors
   thank CAPES (Brazil), CNPq (Brazil) and Fundacao Araucaria (Brazil) for
   the support.
CR Aggarwal BB, 2009, INT J BIOCHEM CELL B, V41, P40, DOI 10.1016/j.biocel.2008.06.010
   Ahmed T, 2009, PHARMACOL BIOCHEM BE, V91, P554, DOI 10.1016/j.pbb.2008.09.010
   Bajpai SK, 2015, INT J BIOL MACROMOL, V79, P440, DOI 10.1016/j.ijbiomac.2015.05.012
   Berrnejo-Prada A, 2016, J FOOD ENG, V169, P141, DOI 10.1016/j.jfoodeng.2015.08.030
   Bona Evandro, 2002, Acta Scientiarum Universidade Estadual de Maringa, V24, P1843
   Brereton R. G., 2018, CHEMOMETRICS DATA DR
   Chuah AM, 2014, FOOD CHEM, V156, P227, DOI 10.1016/j.foodchem.2014.01.108
   da Silva AC, 2017, FOOD FUNCT, V8, P1851, DOI 10.1039/c7fo00452d
   de Almeida M, 2018, FOOD FUNCT, V9, P440, DOI 10.1039/c7fo01616f
   Silva JTD, 2017, MAT SCI ENG C-MATER, V76, P1005, DOI 10.1016/j.msec.2017.03.212
   Gangurde AB, 2015, J DRUG DELIV SCI TEC, V29, P226, DOI 10.1016/j.jddst.2015.08.005
   Granato D, 2018, TRENDS FOOD SCI TECH, V72, P83, DOI 10.1016/j.tifs.2017.12.006
   HARDY MA, 1993, REGRESSION DUMMY VAR
   Hu LD, 2015, AAPS PHARMSCITECH, V16, P1327, DOI 10.1208/s12249-014-0254-0
   Jaiswal SK, 2016, BIOCHEM RES INT, DOI 10.1155/2016/7637931
   Li B, 2013, CARBOHYD POLYM, V98, P1108, DOI 10.1016/j.carbpol.2013.07.017
   MCGUIRE RG, 1992, HORTSCIENCE, V27, P1254, DOI 10.21273/HORTSCI.27.12.1254
   Meng F, 2015, EUR J PHARM SCI, V71, P12, DOI 10.1016/j.ejps.2015.02.003
   Obon JM, 2009, J FOOD ENG, V90, P471, DOI 10.1016/j.jfoodeng.2008.07.013
   Paradkar A, 2004, INT J PHARM, V271, P281, DOI 10.1016/j.ijpharm.2003.11.014
   Patel BB, 2015, SAUDI PHARM J, V23, P352, DOI 10.1016/j.jsps.2013.12.013
   Prasad S, 2014, BIOTECHNOL ADV, V32, P1053, DOI 10.1016/j.biotechadv.2014.04.004
   Ramachandraiah K, 2018, TRENDS FOOD SCI TECH, V71, P25, DOI 10.1016/j.tifs.2017.10.017
   Salvia-Trujillo L, 2017, FOOD CHEM, V229, P653, DOI 10.1016/j.foodchem.2017.02.146
   Sena MM, 2002, SOIL TILL RES, V67, P171, DOI 10.1016/S0167-1987(02)00063-6
   Seo SW, 2012, INT J PHARMACEUT, V424, P18, DOI 10.1016/j.ijpharm.2011.12.051
   Siviero A, 2015, J HERB MED, V5, P57, DOI 10.1016/j.hermed.2015.03.001
   Sousdaleff M, 2013, J AGR FOOD CHEM, V61, P955, DOI 10.1021/jf304047g
   Vasconcelos T, 2007, DRUG DISCOV TODAY, V12, P1068, DOI 10.1016/j.drudis.2007.09.005
   Yen FL, 2010, J AGR FOOD CHEM, V58, P7376, DOI 10.1021/jf100135h
NR 30
TC 1
Z9 1
U1 2
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 248
EP 258
DI 10.1016/j.ces.2019.04.044
PG 11
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000024
OA Green Published
DA 2020-05-12
ER

PT J
AU Lian, WH
   Pan, XE
   Zheng, S
   Zhang, W
   Zhang, H
   Fushimi, C
   Tsutsumi, A
   Hao, XG
   Huang, W
   Guan, GQ
AF Lian, Wenhao
   Pan, Xueer
   Zheng, Shuang
   Zhang, Wei
   Zhang, Hui
   Fushimi, Chihiro
   Tsutsumi, Atsushi
   Hao, Xiaogang
   Huang, Wei
   Guan, Guoqing
TI Mechanism analysis of the solids holdup variations in downer reactors
   based on volumetric flux
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Solids volumetric flux; Solids holdup; RSM; High-density operation;
   Extreme operation condition
ID HEAT-TRANSFER; GAS; FLOW; SIMULATION; PYROLYSIS; HYDRODYNAMICS;
   OPTIMIZATION; BEHAVIORS
AB Solids volumetric flux (V-s), which is expected to replace the solids mass flux (G(s)) as the key factor influencing solids holdup in circulating fluidized beds, was proposed to investigate the solids holdup variation and predict the extreme operation conditions in the downers. In this work, by using more than 400 sets of experimental data from different literature in Response Surface Methodology (RSM) analysis, it is found that the overestimation of particle density effect on the solids holdup can be avoided by converting the G(s) into V-s. Further studies indicated that the difference of solids holdup (Delta epsilon(s)) resulted from the different types of particles increased with the increase in V-s as well as the decrease in superficial gas velocity (U-g). Based on the normalized fitting results, the effects of different factors on the solids holdup were characterized. It is concluded that the effect extent was in the order of V-s > U-g >> particle size (d(p)) > particle density (rho(p)), which provided a guidance to control the solids holdup to satisfy the requirements in the downer by adjustment of various parameters, that is, V-s and U-g can adjust solids holdup roughly whereas d(p) and rho(p) can adjust solids holdup finely. Meanwhile, it is found that the upper limit of solids volumetric flux (V-s,V-max) can be increased by the increase of U-g, d(p) and/or rho(p). In addition, it is considered that using V-s to replace G(s) to define high-density operation in the downer could be more suitable in this study. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lian, Wenhao; Pan, Xueer; Zheng, Shuang; Zhang, Wei; Hao, Xiaogang] Taiyuan Univ Technol, Sch Chem & Chem Engn, Taiyuan 030024, Shanxi, Peoples R China.
   [Zhang, Hui] Univ Western Ontario, Dept Chem & Biochem Engn, London, ON N6A 5B9, Canada.
   [Fushimi, Chihiro] Tokyo Univ Agr & Technol, Dept Chem Engn, 2-24-16 Naka Cho, Koganei, Tokyo 1848588, Japan.
   [Tsutsumi, Atsushi] Univ Tokyo, Grad Sch Art & Sci, Komaba Org Educ Excellence, Meguro Ku, 3-8-1 Komaba, Tokyo 1538902, Japan.
   [Huang, Wei] Taiyuan Univ Technol, Key Lab Coal Sci & Technol, Minist Educ & Shanxi Prov, Taiyuan 030024, Shanxi, Peoples R China.
   [Guan, Guoqing] Hirosaki Univ, Inst Reg Innovat IRI, Lab Energy Convers Engn, 2-1-3 Matsubara, Aomori 0300813, Japan.
RP Hao, XG (reprint author), Taiyuan Univ Technol, Sch Chem & Chem Engn, Taiyuan 030024, Shanxi, Peoples R China.; Huang, W (reprint author), Taiyuan Univ Technol, Key Lab Coal Sci & Technol, Minist Educ & Shanxi Prov, Taiyuan 030024, Shanxi, Peoples R China.; Guan, GQ (reprint author), Hirosaki Univ, Inst Reg Innovat IRI, Lab Energy Convers Engn, 2-1-3 Matsubara, Aomori 0300813, Japan.
EM xghao@tyut.edu.cn; huangwei@tyut.edu.cn; guan@hirosaki-u.ac.jp
RI Guan, Guoqing/K-6555-2013; Fushimi, Chihiro/B-9979-2013
OI Guan, Guoqing/0000-0002-5875-3596; Fushimi, Chihiro/0000-0003-2219-3117
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [U1710101]; Special Talents Project of Shanxi
   Province [201605D211005]; JSPS KAKENHIMinistry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT)Japan Society for the
   Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)
   [17H03451]
FX This work was supported by the National Natural Science Foundation of
   China (No. U1710101), the Special Talents Project of Shanxi Province
   (No. 201605D211005), and the JSPS KAKENHI Grant-in-Aid for Scientific
   Research B (Kiban B, 17H03451), Japan.
CR BERG DA, 1989, CAN J CHEM ENG, V67, P96, DOI 10.1002/cjce.5450670113
   [陈恒志 Chen Hengzhi], 2005, [化工学报, Journal of Chemical Industry and Engineering (China)], V56, P1456
   [陈恒志 Chen Hengzhi], 2005, [化工学报, Journal of Chemical Industry and Engineering (China)], V56, P455
   Chen HZ, 2004, POWDER TECHNOL, V146, P84, DOI 10.1016/j.powtec.2004.07.008
   Cheng Y., 1998, J CHEM IND ENG, V49, P185
   Cheng Y., 2000, CIESC J, V51, P344
   Cheng Y, 2008, POWDER TECHNOL, V183, P364, DOI 10.1016/j.powtec.2008.01.022
   Deng R., 2001, CHINESE J PROCESS EN, V1, P337
   Ding TL, 2012, CHEM ENG TECHNOL, V35, P2170, DOI 10.1002/ceat.201200140
   Dong PF, 2012, ENERG FUEL, V26, P5193, DOI 10.1021/ef300652f
   Fushimi C, 2011, POWDER TECHNOL, V209, P1, DOI 10.1016/j.powtec.2011.01.018
   Guan GQ, 2011, CHEM ENG SCI, V66, P4212, DOI 10.1016/j.ces.2011.06.006
   Guan GQ, 2010, PARTICUOLOGY, V8, P602, DOI 10.1016/j.partic.2010.07.013
   Kim YJ, 1999, CAN J CHEM ENG, V77, P207, DOI 10.1002/cjce.5450770204
   Li DB, 2011, CHEM ENG SCI, V66, P4615, DOI 10.1016/j.ces.2011.06.027
   Li SG, 2004, CHINESE J CHEM ENG, V12, P342
   [李志强 LI Zhiqiang], 2005, [化工学报, Journal of Chemical Industry and Engineering (China)], V56, P816
   Liu W, 2001, POWDER TECHNOL, V115, P27, DOI 10.1016/S0032-5910(00)00276-X
   Luo KB, 2001, POWDER TECHNOL, V115, P36, DOI 10.1016/S0032-5910(00)00277-1
   Ma Y, 1999, CHEM ENG J, V72, P235, DOI 10.1016/S1385-8947(99)00009-1
   Ma Y, 1999, CHEM ENG SCI, V54, P41, DOI 10.1016/S0009-2509(98)00233-4
   Qi XB, 2008, CHEM ENG J, V142, P318, DOI 10.1016/j.cej.2008.03.009
   [钱震 Qian Zhen], 2004, [化工学报, Journal of Chemical Industry and Engineering (China)], V55, P1249
   Qiu TS, 2018, POWDER TECHNOL, V330, P330, DOI 10.1016/j.powtec.2018.02.044
   Senthilkumar T, 2017, CHEM ENG COMMUN, V204, P238, DOI 10.1080/00986445.2016.1262358
   Shaikh AA, 2008, IND ENG CHEM RES, V47, P9018, DOI 10.1021/ie800060y
   Song X., 2005, INT J CHEM REACT ENG, DOI [10.2202/1542-6580.1220, DOI 10.2202/1542-6580.1220]
   Sumic Z, 2016, FOOD CHEM, V203, P465, DOI 10.1016/j.foodchem.2016.02.109
   Talman JA, 1999, CHEM ENG SCI, V54, P2123, DOI 10.1016/S0009-2509(98)00378-9
   Vaishali S, 2008, CHEM ENG SCI, V63, P5107, DOI 10.1016/j.ces.2008.06.014
   [王成秀 Wang Chengxiu], 2015, [化工学报, CIESC Journal], V66, P2810
   Wei F., 1998, J CHEM IND ENG, V49, P28
   Wen C.Y., 1966, CHEM ENG PROGR S SER, V62, P100, DOI DOI 10.1016/S0032-0633(98)00014-2
   Zhang H, 1999, CAN J CHEM ENG, V77, P194, DOI 10.1002/cjce.5450770202
   Zhang H, 1999, CHEM ENG SCI, V54, P5461, DOI 10.1016/S0009-2509(99)00284-5
   Zhang H, 2000, CHEM ENG SCI, V55, P4367, DOI 10.1016/S0009-2509(00)00087-7
   Zhang H, 2001, AICHE J, V47, P2000, DOI 10.1002/aic.690470911
   Zhang H., 2006, CHINA PART, V4, P167
   Zhang MH, 2003, POWDER TECHNOL, V129, P46, DOI 10.1016/S0032-5910(02)00130-4
   Zhang YC, 2019, BIORESOURCE TECHNOL, V274, P207, DOI 10.1016/j.biortech.2018.11.093
   [朱丙田 ZHU Bingtian], 2006, [过程工程学报, The chinese journal of process engineering], V6, P173
   ZHU JX, 1995, CAN J CHEM ENG, V73, P662, DOI 10.1002/cjce.5450730510
NR 42
TC 0
Z9 0
U1 10
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 259
EP 268
DI 10.1016/j.ces.2019.04.045
PG 10
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000025
DA 2020-05-12
ER

PT J
AU Yang, XX
   Fu, K
   Mao, LC
   Peng, W
   Jin, JH
   Yang, SL
   Li, G
AF Yang, Xiaoxiao
   Fu, Kang
   Mao, Linchang
   Peng, Wei
   Jin, Junhong
   Yang, Shenglin
   Li, Guang
TI Bio-mediated synthesis of alpha-Ni(OH)(2) nanobristles on hollow porous
   carbon nanofibers for rechargeable alkaline batteries
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Eggshells; Eggshell membrane; alpha-Ni(OH)(2) nanobristles; HPCNFs;
   Alkaline batteries
ID ALPHA-NICKEL-HYDROXIDE; ATOMIC LAYER DEPOSITION; ELECTRODE MATERIAL;
   ACTIVATED CARBON; ENERGY-STORAGE; WASTE; SUPERCAPACITORS; NANOSHEETS;
   COMPOSITE; GRAPHENE
AB Nickel hydroxide nanobristles were fabricated on the surface of hollow carbon nanofibers (HPCNFs) through a low cost and effective bio-mediated technology, where the eggshells with eggshell membrane were selected as multifunctional reactors to separate the precursor solution to control OH ion diffusion in order to form alpha-Ni(OH)(2) instead of beta-Ni(OH)(2). The as prepared Ni(OH)(2)/HPCNFs displays high capacity (283 mAh/g) and a remarkable cycle life (82% specific capacity retained after 5000 cycle numbers) in 1M KOH aqueous solution. Compared with literature reports, in which Ni(OH)(2) are often considered for pseudocapacitors, we suggest our electrodes are good for rechargeable alkaline secondary batteries or as battery electrodes in hybrid supercapacitors, based on battery behavior observed in our electrochemical measurements. As battery electrodes in hybrid supercapacitors, an asymmetric supercapacitor was fabricated, in which Ni(OH)(2)/HPCNFs and activated carbon as positive and negative electrode, respectively (Ni(OH)(2)/HPCNFs//AC ASC), which displays intriguing electrochemical performances with a high energy density (31.3 Wh/kg at 300.5 W/kg). The results demonstrate that the bio-mediated method for achieving Ni(OH)(2)/HPCNFs nanomaterials is becoming a promising technology in alkaline batteries. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yang, Xiaoxiao; Fu, Kang; Mao, Linchang; Peng, Wei; Jin, Junhong; Yang, Shenglin; Li, Guang] Donghua Univ, Coll Mat Sci & Engn, State Key Lab Modificat Chem Fibers & Polymer Mat, Shanghai, Peoples R China.
RP Li, G (reprint author), Donghua Univ, Coll Mat Sci & Engn, State Key Lab Modificat Chem Fibers & Polymer Mat, Shanghai, Peoples R China.
EM lig@dhu.edu.cn
FU Fundamental Research Funds for the Central Universities,
   ChinaFundamental Research Funds for the Central Universities; Graduate
   Student Innovation Fund of Donghua University, China [CUSF-DH-D-2019011]
FX This work has been financially supported by the Fundamental Research
   Funds for the Central Universities, China and Graduate Student
   Innovation Fund of Donghua University, China (Item No.
   CUSF-DH-D-2019011).
CR Acharya R, 2002, J POWER SOURCES, V109, P494, DOI 10.1016/S0378-7753(02)00164-7
   Beleke AB, 2013, J POWER SOURCES, V225, P215, DOI 10.1016/j.jpowsour.2012.10.048
   Cai FS, 2004, ANGEW CHEM INT EDIT, V43, P4212, DOI 10.1002/anie.200460053
   Cakici M, 2017, CHEM ENG J, V309, P151, DOI 10.1016/j.cej.2016.10.012
   CORRIGAN DA, 1989, J ELECTROCHEM SOC, V136, P723, DOI 10.1149/1.2096717
   Dong ZX, 2011, J POWER SOURCES, V196, P4886, DOI 10.1016/j.jpowsour.2011.01.090
   Fang JH, 2012, ELECTROCHIM ACTA, V85, P248, DOI 10.1016/j.electacta.2012.08.078
   Gao MR, 2014, J AM CHEM SOC, V136, P7077, DOI 10.1021/ja502128j
   Godillot G, 2016, J POWER SOURCES, V331, P277, DOI 10.1016/j.jpowsour.2016.09.035
   Gogotsi Y, 2018, ACS NANO, V12, P2081, DOI 10.1021/acsnano.8b01914
   Gogotsi Y, 2014, ACS NANO, V8, P5369, DOI 10.1021/nn503164x
   Guan C, 2011, ENERG ENVIRON SCI, V4, P4496, DOI 10.1039/c1ee01685g
   Jeevanandam P, 2001, NANO LETT, V1, P263, DOI 10.1021/nl010003p
   Jiang H, 2012, CHEM COMMUN, V48, P4465, DOI 10.1039/c2cc31418e
   KAMATH PV, 1994, J ELECTROCHEM SOC, V141, P2956, DOI 10.1149/1.2059264
   Kim C, 2004, ELECTROCHEM SOLID ST, V7, pA397, DOI 10.1149/1.1801631
   Kim ND, 2012, ELECTROCHIM ACTA, V78, P340, DOI 10.1016/j.electacta.2012.06.025
   Lee BS, 2012, ACS APPL MATER INTER, V4, P6701, DOI 10.1021/am301873d
   Lee BS, 2012, MACROMOL RES, V20, P605, DOI 10.1007/s13233-012-0087-1
   Lee JW, 2011, CHEM COMMUN, V47, P6305, DOI 10.1039/c1cc11566a
   Liu JP, 2011, CHEM COMMUN, V47, P3436, DOI 10.1039/c0cc04906a
   Liu Y, 2018, MATER LETT, V214, P194, DOI 10.1016/j.matlet.2017.12.014
   Meng XH, 2017, CHEMNANOMAT, V3, P479, DOI 10.1002/cnma.201700035
   Meng XH, 2017, ACS APPL MATER INTER, V9, P5244, DOI 10.1021/acsami.6b14053
   Meng XH, 2016, J MATER CHEM A, V4, P6919, DOI 10.1039/c5ta09329e
   Park SH, 2013, J POWER SOURCES, V239, P122, DOI 10.1016/j.jpowsour.2013.03.079
   Patil UM, 2009, J POWER SOURCES, V188, P338, DOI 10.1016/j.jpowsour.2008.11.136
   Prasad KR, 2004, ELECTROCHEM COMMUN, V6, P1004, DOI 10.1016/j.elecom.2004.07.017
   Simon P, 2014, SCIENCE, V343, P1210, DOI 10.1126/science.1249625
   Soler-Illia GJDA, 1999, CHEM MATER, V11, P3140, DOI 10.1021/cm9902220
   Taibi M, 2002, J MATER CHEM, V12, P3238, DOI 10.1039/b204087e
   Topallar H, 1998, J SURFACTANTS DETERG, V1, P49
   Tsai WT, 2008, BIORESOURCE TECHNOL, V99, P1623, DOI 10.1016/j.biortech.2007.04.010
   Wang CY, 2014, J TAIWAN INST CHEM E, V45, P1, DOI 10.1016/j.jtice.2013.04.008
   Wang HL, 2010, J AM CHEM SOC, V132, P7472, DOI 10.1021/ja102267j
   Wang HJ, 2012, CRYSTENGCOMM, V14, P6843, DOI 10.1039/c2ce25553g
   Wang JG, 2011, ELECTROCHIM ACTA, V56, P9240, DOI 10.1016/j.electacta.2011.07.140
   Wang RT, 2015, NPG ASIA MATER, V7, DOI 10.1038/am.2015.42
   Wei ZK, 2009, BIORESOURCE TECHNOL, V100, P2883, DOI 10.1016/j.biortech.2008.12.039
   Wu QD, 2007, J PHYS CHEM C, V111, P17082, DOI 10.1021/jp0756045
   Xu B, 2014, J ELECTROANAL CHEM, V712, P146, DOI 10.1016/j.jelechem.2013.11.020
   Xu JM, 2015, J POWER SOURCES, V274, P816, DOI 10.1016/j.jpowsour.2014.10.106
   Xu LP, 2008, CHEM MATER, V20, P308, DOI 10.1021/cm702207w
   Yan H, 2008, POWDER TECHNOL, V188, P128, DOI 10.1016/j.powtec.2008.04.024
   Yang D, 2010, J AM CERAM SOC, V93, P2935, DOI 10.1111/j.1551-2916.2010.03905.x
   Yang XX, 2019, CERAM INT, V45, P759, DOI 10.1016/j.ceramint.2018.09.242
   Yoon S, 2011, J ELECTROANAL CHEM, V650, P187, DOI 10.1016/j.jelechem.2010.10.008
   Yu L, 2018, ELECTROCHIM ACTA, V268, P283, DOI 10.1016/j.electacta.2018.02.114
   Yu L, 2016, DALTON T, V45, P13779, DOI 10.1039/c6dt01927g
   Yu SH, 2015, J AM CHEM SOC, V137, P11954, DOI 10.1021/jacs.5b03673
   Zhang J, 2004, CHEM LETT, V33, P1054, DOI 10.1246/cl.2004.1054
   Zhang LL, 2009, CHEM SOC REV, V38, P2520, DOI 10.1039/b813846j
   Zhao L, 2013, NANOSCALE, V5, P4902, DOI 10.1039/c3nr33927k
   Zhu F. F, 2010, ADV POWDER TECHNOL, V22, P422
NR 54
TC 1
Z9 1
U1 15
U2 141
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 269
EP 277
DI 10.1016/j.ces.2019.04.039
PG 9
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000026
DA 2020-05-12
ER

PT J
AU Yu, HQ
   Zhang, T
   Jing, ZF
   Xu, JC
   Qiu, FX
   Yang, DY
   Yu, LB
AF Yu, Hanqiang
   Zhang, Tao
   Jing, Zefeng
   Xu, Jicheng
   Qiu, Fengxian
   Yang, Dongya
   Yu, Longbao
TI In situ fabrication of dynamic nano zero-valent iron/activated carbon
   nanotubes membranes for tellurium separation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Adsorption; Dynamic membrane; Tellurium; Carbon nanotube; Nanoscale
   zero-valent iron
ID SOLAR-CELLS; ANODE SLIME; CADMIUM; COMPOSITES; RECOVERY; SORPTION; CDTE
AB Recovery of valuable elements from (industrial process) photovoltaic wastes would be beneficial for both economical and sustainability reasons. In this work, nano zero-valent iron/activated carbon nanotubes (NZVI/ACNTs) hybrid membranes were fabricated by using NZVI as dynamic layer and CNTs as substrate for deep tellurium extraction, where the NZVI particles were formed by in situ reduction. Batch experiments were conducted to investigate the adsorption properties of NZVI/ACNTs hybrid membranes under different solution conditions such as pH, temperature, sorbent dosage, and competitive ions. Energy dispersive X-ray and X-ray photoelectron spectroscopy results confirmed good adsorption capacity of tellurium by NZVI/ACNTs through redox reactions. The tellurium adsorption capacities decreased in the presence of competitive ions and as the concentration of NO3 significantly increased, the adsorption quantity dropped from 331.6 to 286.5 mg/g. Extraction of tellurium under weakly acidic conditions had a positive effect and reached a maximum adsorption capacity about 800 mg/g at pH 4.7. Kinetic models and equilibrium isotherms fitted well to the adsorption experimental data indicating that chemical adsorption dominate during the adsorption process of NZVI/ACNTs-Te. As a reusable and high-efficient adsorbent, NZVI/ACNTs membrane has tremendous potential to handle and recycle toxic tellurium containing compounds. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yu, Hanqiang; Zhang, Tao; Jing, Zefeng; Qiu, Fengxian; Yang, Dongya; Yu, Longbao] Jiangsu Univ, Sch Chem & Chem Engn, Zhenjiang 212013, Jiangsu, Peoples R China.
   [Zhang, Tao] Jiangsu Univ, Inst Green Chem & Chem Technol, Zhenjiang 212013, Jiangsu, Peoples R China.
   [Xu, Jicheng] Zhenjiang Coll, Inst Med & Chem Engn, Zhenjiang Key Lab Funct Chem, Zhenjiang 212028, Jiangsu, Peoples R China.
RP Zhang, T; Qiu, FX (reprint author), Jiangsu Univ, Sch Chem & Chem Engn, Zhenjiang 212013, Jiangsu, Peoples R China.
EM zhangtaochem@163.com; fxqiu@ujs.edu.cn
OI Zhang, Tao/0000-0001-9255-9802
FU State Key Laboratory of Pollution Control and Resource Reuse Foundation
   [PCRRF18003]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [21706100, 21878132]; Natural
   Science Foundation of Jiangsu ProvinceJiangsu Planned Projects for
   Postdoctoral Research FundsNatural Science Foundation of Jiangsu
   Province [BK20160500, BK20161362, BK20160491]; China Postdoctoral
   Science FoundationChina Postdoctoral Science Foundation [2018 T110452];
   China Postdoctoral Science Foundation of Jiangsu ProvinceChina
   Postdoctoral Science Foundation [1701067C, 1701073C]; Qing Lan Project
   of Jiangsu Province (2018-2021); Youth Talent Cultivation Program of
   Jiangsu University; 333 High-Level Personnel Training Project of Jiangsu
   Province [BRA2016142]; Key Research and Development Program of Jiangxi
   Province [20171BBH80008]; Society Development Fund of Zhenjiang
   [SH2018009]
FX This work was financially supported by State Key Laboratory of Pollution
   Control and Resource Reuse Foundation (PCRRF18003), National Natural
   Science Foundation of China (21706100 and 21878132), Natural Science
   Foundation of Jiangsu Province (BK20160500, BK20161362 and BK20160491),
   the China Postdoctoral Science Foundation (2018 T110452), China
   Postdoctoral Science Foundation of Jiangsu Province (1701067C and
   1701073C), Qing Lan Project of Jiangsu Province (2018-2021), Youth
   Talent Cultivation Program of Jiangsu University, 333 High-Level
   Personnel Training Project of Jiangsu Province (BRA2016142), Key
   Research and Development Program of Jiangxi Province (20171BBH80008) and
   Society Development Fund of Zhenjiang (SH2018009).
CR Ajalkar BD, 2004, J MATER SCI, V39, P1659, DOI 10.1023/B:JMSC.0000016166.15326.41
   Bandal HA, 2016, ELECTROCHIM ACTA, V222, P1316, DOI 10.1016/j.electacta.2016.11.107
   Boparai HK, 2011, J HAZARD MATER, V186, P458, DOI 10.1016/j.jhazmat.2010.11.029
   CHAMBERLAIN GA, 1983, SOL CELLS, V8, P47, DOI 10.1016/0379-6787(83)90039-X
   Chen C, 2019, APPL CATAL B-ENVIRON, V250, P382, DOI 10.1016/j.apcatb.2019.03.048
   Dong HR, 2017, CHEM ENG J, V316, P410, DOI 10.1016/j.cej.2017.01.118
   Fthenakis VM, 2011, SOL ENERGY, V85, P1609, DOI 10.1016/j.solener.2009.10.002
   Fthenakis VM, 2006, PROG PHOTOVOLTAICS, V14, P363, DOI 10.1002/pip.676
   Hait J, 2002, IND ENG CHEM RES, V41, P6593, DOI 10.1021/ie020239j
   Ho YS, 2006, WATER RES, V40, P119, DOI 10.1016/j.watres.2005.10.040
   Khaleghi A, 2014, INT J MIN SCI TECHNO, V24, P251, DOI 10.1016/j.ijmst.2014.01.018
   LEVAN MD, 1981, J PHYS CHEM-US, V85, P3247, DOI 10.1021/j150622a009
   Liu JX, 2018, CHEM ENG J, V332, P517, DOI 10.1016/j.cej.2017.09.079
   Liu Y, 2018, FOOD BIOPROD PROCESS, V111, P93, DOI 10.1016/j.fbp.2018.07.004
   Luo JS, 2014, SCIENCE, V345, P1593, DOI 10.1126/science.1258307
   Matsukiyo H, 2009, RADIOL PHYS TECHNOL, V2, P46, DOI 10.1007/s12194-008-0042-1
   Mayers B, 2002, ADV MATER, V14, P279, DOI 10.1002/1521-4095(20020219)14:4<279::AID-ADMA279>3.0.CO;2-2
   Mi WL, 2007, J MEMBRANE SCI, V304, P1, DOI 10.1016/j.memsci.2007.07.021
   MROZ S, 1986, PHYS STATUS SOLIDI A, V95, P407, DOI 10.1002/pssa.2210950206
   OHTSUKA S, 1992, APPL PHYS LETT, V61, P2953, DOI 10.1063/1.108028
   OShannessy DJ, 1996, ANAL BIOCHEM, V236, P275, DOI 10.1006/abio.1996.0167
   RAI BP, 1988, SOL CELLS, V25, P265, DOI 10.1016/0379-6787(88)90065-8
   Scheiber C, 2001, NUCL INSTRUM METH A, V458, P12, DOI 10.1016/S0168-9002(00)01032-9
   Simon FG, 2013, WASTE MANAGE, V33, P942, DOI 10.1016/j.wasman.2012.12.025
   Wang WM, 2005, J HAZARD MATER, V125, P80, DOI 10.1016/j.jhazmat.2005.02.013
   Yarema MC, 2005, PEDIATRICS, V116, pE319, DOI 10.1542/peds.2005-0172
   Yu HQ, 2018, HYDROMETALLURGY, V177, P1, DOI 10.1016/j.hydromet.2018.02.009
   Yue XJ, 2018, IND ENG CHEM RES, V57, P10439, DOI 10.1021/acs.iecr.8b02577
   Zhang L, 2010, TALANTA, V83, P344, DOI 10.1016/j.talanta.2010.09.022
   Zhang T, 2018, FIBER POLYM, V19, P2195, DOI 10.1007/s12221-018-8399-1
   Zhang T, 2017, CHEM ENG J, V309, P7, DOI 10.1016/j.cej.2016.08.085
   Zhu KR, 2018, CHEM ENG J, V331, P395, DOI 10.1016/j.cej.2017.08.126
NR 32
TC 3
Z9 3
U1 12
U2 65
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 278
EP 286
DI 10.1016/j.ces.2019.05.012
PG 9
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000027
DA 2020-05-12
ER

PT J
AU Zheng, WZ
   Cao, P
   Sun, WZ
   Zhao, L
AF Zheng, Weizhong
   Cao, Piao
   Sun, Weizhen
   Zhao, Ling
TI Towards an understanding of the microstructure and interfacial
   properties of the ionic liquid/sulfuric acid catalyst in liquid-liquid
   reactions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Sulfonic-acid-functionalized ionic liquids; Microstructure and
   interfacial properties; Molecular dynamics simulation
ID MOLECULAR-FORCE FIELD; ISOBUTANE ALKYLATION; DYNAMICS SIMULATIONS;
   SURFACE-STRUCTURE; SULFURIC-ACID; IMIDAZOLIUM; BEHAVIORS; EFFICIENT;
   MIXTURES; SPECTRA
AB Sulfonic-acid-functionalized Bronsted acidic ionic liquids (SFILs) have been considered as a promising dual solvent-catalyst for numerous applications. The bulk microstructure and interfacial characteristics of different kinds of SFILs and the corresponding SFIL/H2SO4 systems were investigated in this work using molecular dynamics (MD) simulations in terms of the SFILs possessing three anions (e.g. bisulfate, triflate, and bis(trifluoromethylsulfonyl)imide), different alkyl chain lengths, and different introduced position of the sulfonic acid groups (-SO3H). The introduction of the sulfonic acid groups is found to provide a strong hydrogen-bonding interaction site with both the HSO4 and H2SO4, making almost two order of magnitudes larger for average numbers of hydrogen bonds between different pairs. The introduction of sulfonic acid groups onto the shorter side chains contributes to stronger hydrogen-bonding interactions with both the HSO4 and H2SO4 than when introduced onto the longer side chains. The coordination numbers of the equivalent terminal carbon atoms of octyl chain and equivalent sulfur atoms of sulfonic acid groups are more than 4.5 and 2.5, respectively, which suggests that obvious nanostructured aggregation of the polar sulfonic acid groups, as well as nonpolar longer alkyl chains, exists in the pure SFILs and SFIL/H2SO4 systems. In addition, it is found that the ordering preference and interfacial orientation of the side chains and imidazole rings at gas-liquid interfaces are sharply changed following the addition of the sulfonic acid groups. The insights into the bulk structural and interfacial characteristics of the SFIL/H2SO4 systems obtained in this work may inform the design and optimization of novel SFILs for specific catalytic applications. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zheng, Weizhong; Cao, Piao; Sun, Weizhen; Zhao, Ling] East China Univ Sci & Technol, State Key Lab Chem Engn, Shanghai 200237, Peoples R China.
RP Sun, WZ (reprint author), East China Univ Sci & Technol, State Key Lab Chem Engn, Shanghai 200237, Peoples R China.
EM sunwz@ecust.edu.cn
OI SUN, WEIZHEN/0000-0002-9957-3620
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [91434108]
FX The financial support by the National Natural Science Foundation of
   China (91434108) is gratefully acknowledged
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Amarasekara AS, 2016, CHEM REV, V116, P6133, DOI 10.1021/acs.chemrev.5b00763
   Armand M., 2011, MAT SUSTAINABLE ENER, P129
   Bhargava BL, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2772268
   Burrell GL, 2010, PHYS CHEM CHEM PHYS, V12, P1571, DOI 10.1039/b921432a
   Lopes JNC, 2006, J PHYS CHEM B, V110, P19586, DOI 10.1021/jp063901o
   Chaumont A, 2005, J PHYS CHEM B, V109, P18964, DOI 10.1021/jp052854h
   Chevrot G, 2006, PHYS CHEM CHEM PHYS, V8, P4166, DOI 10.1039/b608218a
   Crowhurst L, 2004, J AM CHEM SOC, V126, P11549, DOI 10.1021/ja046757y
   Cui YN, 2016, PHYS CHEM CHEM PHYS, V18, P19731, DOI 10.1039/c6cp03293a
   Dai CN, 2017, CHEM REV, V117, P6929, DOI 10.1021/acs.chemrev.7b00030
   Docampo-Alvarez B, 2014, J CHEM PHYS, V140, DOI 10.1063/1.4879660
   Dong K, 2012, CHEM-EUR J, V18, P2748, DOI 10.1002/chem.201101645
   Earle MJ, 2006, NATURE, V439, P831, DOI 10.1038/nature04451
   Feng S, 2010, FLUID PHASE EQUILIBR, V294, P148, DOI 10.1016/j.fluid.2010.02.034
   Frisch MJ, 2009, GAUSSIAN 09 REVISION
   Greaves TL, 2008, CHEM REV, V108, P206, DOI 10.1021/cr068040u
   Greaves TL, 2015, CHEM REV, V115, P11379, DOI 10.1021/acs.chemrev.5b00158
   Greaves TL, 2015, PHYS CHEM CHEM PHYS, V17, P2357, DOI 10.1039/c4cp04241g
   Gu YL, 2003, CATAL COMMUN, V4, P597, DOI 10.1016/j.catcom.2003.09.004
   Han XX, 2019, CHEM ENG J, V359, P733, DOI 10.1016/j.cej.2018.11.169
   Hapiot P, 2008, CHEM REV, V108, P2238, DOI 10.1021/cr0680686
   Hu JY, 2015, ANGEW CHEM INT EDIT, V54, P5399, DOI 10.1002/anie.201411969
   Huang Q, 2015, IND ENG CHEM RES, V54, P1464, DOI 10.1021/ie504163h
   Ishak ZI, 2017, CATAL REV, V59, P44, DOI 10.1080/01614940.2016.1268021
   Ishiyama T, 2011, J PHYS CHEM C, V115, P13704, DOI 10.1021/jp200269k
   Jiang HJ, 2018, CURR OPIN GREEN SUST, V12, P27, DOI 10.1016/j.cogsc.2018.05.003
   Kennedy DF, 2009, J PHYS CHEM B, V113, P5690, DOI 10.1021/jp900814y
   King AWT, 2011, ANGEW CHEM, V123, P6425, DOI [10.1002/ange.201100274, DOI 10.1002/ANGE.201100274]
   Koddermann T, 2007, CHEMPHYSCHEM, V8, P2464, DOI 10.1002/cphc.200700552
   Lisal M, 2012, PHYS CHEM CHEM PHYS, V14, P5164, DOI 10.1039/c2cp23572b
   Lopes JNC, 2004, J PHYS CHEM B, V108, P16893, DOI 10.1021/jp0476545
   Lopes JNC, 2004, J PHYS CHEM B, V108, P2038, DOI 10.1021/jp0362133
   Lopes JNC, 2008, J PHYS CHEM B, V112, P5039, DOI 10.1021/jp800281e
   Lynden-Bell RM, 2006, PHYS CHEM CHEM PHYS, V8, P949, DOI 10.1039/b514848k
   MacFarlane DR, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2015.5
   MacFarlane DR, 2014, ENERG ENVIRON SCI, V7, P232, DOI 10.1039/c3ee42099j
   Martinez L, 2009, J COMPUT CHEM, V30, P2157, DOI 10.1002/jcc.21224
   Niga P, 2010, LANGMUIR, V26, P8282, DOI 10.1021/la904697g
   Onsager L, 1934, J CHEM PHYS, V2, DOI 10.1063/1.1749522
   Palchowdhury S, 2016, J PHYS CHEM C, V120, P5430, DOI 10.1021/acs.jpcc.5b10868
   Palchowdhury S, 2015, PHYS CHEM CHEM PHYS, V17, P19919, DOI 10.1039/c5cp02932e
   Plechkova NV, 2008, CHEM SOC REV, V37, P123, DOI 10.1039/b006677j
   Reid JESJ, 2017, PHYS CHEM CHEM PHYS, V19, P28133, DOI 10.1039/c7cp05076c
   Ridings C, 2017, J PHYS CHEM LETT, V8, P4264, DOI 10.1021/acs.jpclett.7b01654
   Ridings C, 2012, PHYS CHEM CHEM PHYS, V14, P16088, DOI 10.1039/c2cp43035e
   Rogers RD, 2003, SCIENCE, V302, P792, DOI 10.1126/science.1090313
   Sepehri A, 2018, CHEM ENG PROCESS, V128, P10, DOI 10.1016/j.cep.2018.04.006
   Sha ML, 2014, ACS APPL MATER INTER, V6, P12556, DOI 10.1021/am502413m
   Shan WD, 2015, J PHYS CHEM C, V119, P20379, DOI 10.1021/acs.jpcc.5b02814
   Sun WZ, 2019, CHEM ENG J, V377, DOI 10.1016/j.cej.2018.08.130
   Sun WZ, 2018, IND ENG CHEM RES, V57, P15310, DOI 10.1021/acs.iecr.8b03923
   Tang SW, 2009, J CATAL, V268, P243, DOI 10.1016/j.jcat.2009.09.022
   Timperman L, 2015, ELECTROCHIM ACTA, V155, P164, DOI 10.1016/j.electacta.2014.12.130
   Ventura SPM, 2017, CHEM REV, V117, P6984, DOI 10.1021/acs.chemrev.6b00550
   Vogl T, 2016, J MATER CHEM A, V4, P10472, DOI 10.1039/c6ta02277d
   Wakeham D, 2012, PHYS CHEM CHEM PHYS, V14, P5106, DOI 10.1039/c2cp23694j
   Wakeham D, 2011, PHYS CHEM CHEM PHYS, V13, P20828, DOI 10.1039/c1cp22351h
   Wang AY, 2016, IND ENG CHEM RES, V55, P8271, DOI 10.1021/acs.iecr.6b00768
   Welton T, 1999, CHEM REV, V99, P2071, DOI 10.1021/cr980032t
   Wu BN, 2018, J CHEM PHYS, V148, DOI 10.1063/1.5010983
   Zhang SG, 2014, J AM CHEM SOC, V136, P1690, DOI 10.1021/ja411981c
   Zheng WZ, 2019, CHEM ENG J, V377, DOI 10.1016/j.cej.2018.07.180
   Zheng WZ, 2018, AICHE J, V64, P950, DOI 10.1002/aic.15984
   Zheng WZ, 2018, J PHYS CHEM B, V122, P1460, DOI 10.1021/acs.jpcb.7b09755
   Zheng WZ, 2017, CHEM ENG SCI, V166, P42, DOI 10.1016/j.ces.2017.02.049
NR 66
TC 1
Z9 1
U1 14
U2 62
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 287
EP 298
DI 10.1016/j.ces.2019.05.008
PG 12
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000028
DA 2020-05-12
ER

PT J
AU Voncken, RJW
   Roghair, I
   Annaland, MV
AF Voncken, R. J. W.
   Roghair, I.
   Annaland, M. van Sint
TI A numerical study on concentration polarization in 3D cylindrical
   fluidized beds with vertically immersed membranes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Concentration polarization; Mass transfer; Hydrodynamics; Fluidized bed;
   Membranes; Two-fluid model; CFD
ID DISCRETE PARTICLE SIMULATIONS; HEAT-TRANSFER; MASS-TRANSFER; FLOW
   MODELS; HYDRODYNAMICS; REACTORS; TUBE
AB Concentration polarization is a serious issue for systems in which high-flux, palladium-based, hydrogen perm-selective membranes are used to extract hydrogen, not only for packed-bed reactor systems, but also for fluidized bed membrane reactors. Two-Fluid Model simulations of 3D cylindrical lab-scale fluidized beds with single and multiple vertically immersed cylindrical membranes with state-of-the-art hydrogen permeability were performed to quantify concentration polarization, to study the interaction between concentration polarization zones of multiple vertically immersed membranes and to link these findings to the bed hydrodynamics. Simulations of a fluidized bed consisting of 500 mu m particles using a H-2/N-2 mixture as fluidization gas with a single immersed membrane, show that reduced hydrogen concentrations prevail mostly within 1 cm from the membrane surface, and have disappeared beyond about 2 cm distance from the membrane surface. A 3D simulation was compared to a Cartesian 2D simulation that represents a slice of the 3D system, to assess the accuracy of 2D simulations. The 2D simulation did not fully capture the hydrodynamics and radial mass transfer effects of 3D cylindrical fluidized bed membrane reactors and overestimated the severity of concentration polarization and the formation of densified zones near the membrane surface. In particular, the hydrogen fluxes were determined at 0.217 mol/(m(2) s Pa-0.5) for the 3D case, and 0.133 mol/(m(2) s Pa-0.5) for the 2D case. The severity of densified zones is also affected by the particle size, because for smaller particles (250 mu m) the emulsion phase density near the membrane surface is higher than for systems with larger particles (500 mu m), which results in increased concentration polarization and a reduced extractive hydrogen flux. Therefore, employing relatively large particles of at least 500 mu m in fluidized beds with modern high-flux membranes is advised. In fluidized beds with multiple membranes, interaction between concentration polarization zones of each membrane was observed. The interaction becomes more significant at smaller inter-membrane distances, especially below 2 cm, and decreasing the bed diameter decreases the system performance even more due to hydrogen depletion. Vertically immersed membranes also affect the fluidized bed hydrodynamics by reducing bubble size and increasing the number of small bubbles. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Voncken, R. J. W.; Roghair, I.; Annaland, M. van Sint] Eindhoven Univ Technol, Dept Chem Engn & Chem, Chem Proc Intensificat, POB 513, NL-5612 AZ Eindhoven, Netherlands.
RP Annaland, MV (reprint author), Eindhoven Univ Technol, Dept Chem Engn & Chem, Chem Proc Intensificat, POB 513, NL-5612 AZ Eindhoven, Netherlands.
EM m.v.sintannaland@tue.nl
OI Roghair, Ivo/0000-0002-7221-5567
FU NWO/STW through the VIDI project ClingCO2 [12365]; NWO Exacte en
   Natuurwetenschappen; Nederlandse Organisatie voor Wetenschappelijk
   Onderzoek (Netherlands Organisation for Scientific Research,
   NWO)Netherlands Organization for Scientific Research (NWO); SURF
   Cooperative
FX The authors are grateful to NWO/STW for the financial support through
   the VIDI project ClingCO<INF>2</INF> - project number 12365.; This work
   was sponsored by NWO Exacte en Natuurwetenschappen (Physical Sciences)
   for the use of supercomputer facilities, with financial support from the
   Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands
   Organisation for Scientific Research, NWO).; This work was carried out
   on the Dutch national e-infrastructure with the support of SURF
   Cooperative.
CR Bird RB, 2007, TRANSPORT PHENOMENA
   BOUILLARD JX, 1989, AICHE J, V35, P908, DOI 10.1002/aic.690350604
   Caravella A, 2009, SEP PURIF TECHNOL, V66, P613, DOI 10.1016/j.seppur.2009.01.008
   Coroneo M, 2009, J MEMBRANE SCI, V343, P34, DOI 10.1016/j.memsci.2009.07.008
   Dang NTY, 2014, CHEM ENG J, V239, P42, DOI 10.1016/j.cej.2013.11.001
   de Jong JF, 2011, CHEM ENG SCI, V66, P2398, DOI 10.1016/j.ces.2011.02.059
   ERGUN S, 1952, CHEM ENG PROG, V48, P89
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   Helmi A, 2017, CHEM ENG PROCESS, V122, P508, DOI 10.1016/j.cep.2017.05.006
   Helmi A, 2018, CHEM ENG J, V332, P464, DOI 10.1016/j.cej.2017.09.045
   Jakobsen HA, 2014, CHEM REACTOR MODELIN, DOI [10.1007/978-3-319-05092-8, DOI 10.1007/978-3-319-05092-8]
   Jaso S, 2011, CHEM ENG J, V171, P255, DOI 10.1016/j.cej.2011.03.077
   JOHNSON PC, 1987, J FLUID MECH, V176, P67, DOI 10.1017/S0022112087000570
   KUIPERS JAM, 1993, COMPUT CHEM ENG, V17, P839, DOI 10.1016/0098-1354(93)80067-W
   Liu YF, 2014, COMPUT CHEM ENG, V69, P75, DOI 10.1016/j.compchemeng.2014.07.002
   LUN CKK, 1984, J FLUID MECH, V140, P223, DOI 10.1017/S0022112084000586
   MATHUR A, 1986, IND ENG CHEM PROC DD, V25, P156, DOI 10.1021/i200032a024
   Medrano JA, 2015, CHEM ENG J, V282, P45, DOI 10.1016/j.cej.2015.04.007
   Medrano JA, 2014, INT J HYDROGEN ENERG, V39, P4725, DOI 10.1016/j.ijhydene.2013.11.126
   Nieuwland JJ, 1996, AICHE J, V42, P1569, DOI 10.1002/aic.690420608
   OGATA A, 1961, US GEOL SURV PROF PA, V411, pA1
   Ozawa M, 2002, EXP THERM FLUID SCI, V26, P643, DOI 10.1016/S0894-1777(02)00178-4
   Passalacqua A, 2011, POWDER TECHNOL, V213, P174, DOI 10.1016/j.powtec.2011.07.030
   Roghair I, 2019, MENDELEY DATA, V1, DOI [10.17632/NHYH3PB748.1, DOI 10.17632/NHYH3PB748.1]
   Rusche H., 2002, COMPUTATIONAL FLUID, DOI [10.1145/1806799.1806850, DOI 10.1145/1806799.1806850]
   Stefanova A, 2008, INT J HEAT MASS TRAN, V51, P2020, DOI 10.1016/j.ijheatmasstransfer.2007.06.005
   Stevens RJAM, 2016, WIND ENERGY, V19, P651, DOI 10.1002/we.1857
   Tan LH, 2017, PARTICUOLOGY, V33, P80, DOI 10.1016/j.partic.2016.09.008
   Tan LH, 2016, INT J HYDROGEN ENERG, V41, P8719, DOI 10.1016/j.ijhydene.2016.01.176
   Tan LH, 2014, APPL MATH MODEL, V38, P4291, DOI 10.1016/j.apm.2014.04.044
   Tiemersma TP, 2006, CHEM ENG SCI, V61, P1602, DOI 10.1016/j.ces.2005.10.004
   Troldborg N, 2014, WIND ENERGY, V17, P657, DOI 10.1002/we.1608
   TSOTSAS E, 1988, CHEM ENG PROCESS, V24, P15, DOI 10.1016/0255-2701(88)87002-8
   TSOTSIS TT, 1992, CHEM ENG SCI, V47, P2903, DOI 10.1016/0009-2509(92)87149-K
   Tukovic Z, 2018, COMPUT FLUIDS, V166, P78, DOI 10.1016/j.compfluid.2018.01.041
   van der Hoef M.A., 2006, ADV CHEM ENG, P65, DOI DOI 10.1016/S0065-2377(06)31002-2
   van Wachem B. G. M, 2000, DERIVATION IMPLEMENT
   Venier CM, 2018, CHEM ENG COMMUN, V205, P456, DOI 10.1080/00986445.2017.1403907
   Venier CM, 2016, COMPUT FLUIDS, V133, P151, DOI 10.1016/j.compfluid.2016.05.003
   Voncken R. J. W, 2017, PROG APPL CFD CFD201, P53
   WEN CY, 1966, AICHE J, V12, P610, DOI 10.1002/aic.690120343
   Yang XS, 2019, J MEMBRANE SCI, V581, P262, DOI 10.1016/j.memsci.2019.03.068
NR 42
TC 1
Z9 1
U1 3
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 299
EP 318
DI 10.1016/j.ces.2019.05.010
PG 20
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000029
DA 2020-05-12
ER

PT J
AU Jin, Y
   Lu, HF
   Guo, XL
   Gong, X
AF Jin, Yong
   Lu, Haifeng
   Guo, Xiaolei
   Gong, Xin
TI Characteristics and formation mechanism of plug flow in the industrial
   vertical pipeline of dense-phase pneumatic conveying of pulverized coal
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Dense-phase pneumatic conveying; Plug flow; Particle velocity; ECT;
   Jansen stress analysis
ID MINIMUM TRANSPORT BOUNDARY; PRESSURE-DROP PREDICTION; CAPACITANCE
   TOMOGRAPHY; SLUG; FLUCTUATIONS; VELOCITY; PARTICLES; SOLIDS
AB Plug flow, which affects the reliable feeding of pulverized coal, is one of flow patterns in dense-phase pneumatic conveying of pulverized coal. The control and formation mechanism of plug flow are very important for the industrial application and theoretical research. In this work, experiments were carried out on a pneumatic conveying test platform in the Key Lab of Coal Gasification and Energy Chemical Engineering of Ministry of Education, ECUST, to study on the plug flow in the industrial vertical pipe under a low superficial gas velocity. All the flow states and flow patterns of the dense-phase pneumatic conveying process were analyzed. The present study shows that five different particle velocity distributions were found in the plug flow. However, the time series of the pressure and solid concentration signal are almost the same. What's more, the power spectral density function analysis provides the relationship of the solid concentration signal of the cross-section by the electrical capacitance tomography (ECT) between all four operational cases and five different kinds of plug flows. From the point view of application, five different kinds of the plug flow were characterized by the plug length, fluctuation parameter of the plug flow (the Strouhal number) and the operational parameters (Lockhart-Martinelli parameter and the Froude number of the gas phase and the solid phase). Based on the phase diagram constructed using the Strouhal number and Lockhart-Martinelli parameter, five types of plug flow could be predicted. A larger Strouhal number indicates the poorer stability of the plug flow. Moreover, the formation mechanism of the plug flow was analyzed by the Janssen equation. Finally, we found that all types of the plug flow have the same unit friction force based on a statistical discussion. Through this work, we wish that our research will give a deeper understanding of the formation and control of the plug flow in the dense-phase pneumatic conveying of pulverized coal. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Jin, Yong; Lu, Haifeng; Guo, Xiaolei; Gong, Xin] East China Univ Sci & Technol, Shanghai Engn Res Ctr Coal Gasificat, Key Lab Coal Gasificat & Energy Chem Engn, Minist Educ, Shanghai 200237, Peoples R China.
RP Lu, HF; Gong, X (reprint author), East China Univ Sci & Technol, Shanghai Engn Res Ctr Coal Gasificat, Key Lab Coal Gasificat & Energy Chem Engn, Minist Educ, Shanghai 200237, Peoples R China.
EM luhf@ecust.edu.cn; gongxin@ecust.edu.cn
RI Jin, Yong/P-9904-2018
OI Jin, Yong/0000-0001-5472-2939
FU National Key R&D Program of China [2018YFC0808503]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [51876066]; Shanghai Engineering Research Center of Coal Gasification
   [18DZ2283900]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
FX This work was supported by the National Key R&D Program of China
   (2018YFC0808503), the National Natural Science Foundation of China
   (51876066), the Shanghai Engineering Research Center of Coal
   Gasification (18DZ2283900) and the Fundamental Research Funds for the
   Central Universities.
CR AZIZ ZB, 1988, POWDER TECHNOL, V55, P97, DOI 10.1016/0032-5910(88)80092-5
   Azzopardi BJ, 2008, CHEM ENG SCI, V63, P2548, DOI 10.1016/j.ces.2008.02.013
   BORZONE LA, 1987, POWDER TECHNOL, V53, P273, DOI 10.1016/0032-5910(87)80100-6
   Cong XL, 2011, POWDER TECHNOL, V208, P600, DOI 10.1016/j.powtec.2010.12.027
   DHODAPKAR SV, 1993, POWDER TECHNOL, V74, P179, DOI 10.1016/0032-5910(93)87010-L
   Dyakowski T, 1997, CHEM ENG SCI, V52, P2099, DOI 10.1016/S0009-2509(97)00037-7
   Jaworski AJ, 2002, POWDER TECHNOL, V125, P279, DOI 10.1016/S0032-5910(01)00516-2
   KONRAD K, 1989, CAN J CHEM ENG, V67, P245, DOI 10.1002/cjce.5450670211
   Kuang SB, 2009, IND ENG CHEM RES, V48, P6846, DOI 10.1021/ie900230s
   Lecreps I, 2014, POWDER TECHNOL, V262, P82, DOI 10.1016/j.powtec.2014.04.058
   Lecreps I, 2009, PARTICUL SCI TECHNOL, V27, P297, DOI 10.1080/02726350902990991
   Levy A, 2000, POWDER TECHNOL, V112, P263, DOI 10.1016/S0032-5910(00)00301-6
   Liu Y, 2015, POWDER TECHNOL, V284, P47, DOI 10.1016/j.powtec.2015.06.041
   Lu HF, 2017, IND ENG CHEM RES, V56, P9734, DOI 10.1021/acs.iecr.7b02020
   Makwana AB, 2015, PARTICUL SCI TECHNOL, V33, P59, DOI 10.1080/02726351.2014.936541
   MCKEE S, 1995, POWDER TECHNOL, V82, P105, DOI 10.1016/0032-5910(94)02894-T
   MI B, 1995, POWDER TECHNOL, V84, P91, DOI 10.1016/0032-5910(95)02974-7
   MI B, 1994, POWDER TECHNOL, V81, P125, DOI 10.1016/0032-5910(94)2875O-3
   Mills D., 2015, PNEUMATIC CONVEYING
   Mittal A, 2014, PARTICUOLOGY, V16, P187, DOI 10.1016/j.partic.2014.03.006
   Neiderreiter G., 2002, P 4 WORLD C PART TEC
   Ostrowski KL, 2000, CHEM ENG J, V77, P43, DOI 10.1016/S1385-8947(99)00140-0
   Pahk JB, 2012, POWDER TECHNOL, V222, P58, DOI 10.1016/j.powtec.2012.01.040
   Pan R, 1997, POWDER TECHNOL, V94, P123, DOI 10.1016/S0032-5910(97)03290-7
   Rabinovich E, 2011, POWDER TECHNOL, V207, P119, DOI 10.1016/j.powtec.2010.10.017
   Rao SM, 2001, IND ENG CHEM RES, V40, P4216, DOI 10.1021/ie0100028
   Sakai M, 2009, CHEM ENG SCI, V64, P533, DOI 10.1016/j.ces.2008.10.003
   Setia G, 2015, POWDER TECHNOL, V277, P244, DOI 10.1016/j.powtec.2015.02.050
   Shaul S, 2015, POWDER TECHNOL, V283, P579, DOI 10.1016/j.powtec.2015.05.047
   Shaul S, 2014, POWDER TECHNOL, V256, P310, DOI 10.1016/j.powtec.2014.02.036
   Strauss M, 2007, GRANUL MATTER, V9, P35, DOI 10.1007/s10035-006-0020-4
   Tan SM, 2008, PARTICUOLOGY, V6, P307, DOI 10.1016/j.partic.2008.05.001
   Tomas J, 2004, CHEM ENG TECHNOL, V27, P605, DOI 10.1002/ceat.200406134
   Tomas J, 2001, PARTICUL SCI TECHNOL, V19, P111, DOI 10.1080/02726350152772065
   TSUJI Y, 1992, POWDER TECHNOL, V71, P239, DOI 10.1016/0032-5910(92)88030-L
   Williams KC, 2008, PARTICUOLOGY, V6, P301, DOI 10.1016/j.partic.2008.03.007
   Wypych PW, 2003, POWDER TECHNOL, V129, P111, DOI 10.1016/S0032-5910(02)00224-3
   Yang WQ, 2003, MEAS SCI TECHNOL, V14, pR1, DOI 10.1088/0957-0233/14/1/201
   Yang W, 2006, IEEE SENSOR, P497
   Zhang H, 2018, POWDER TECHNOL, V332, P79, DOI 10.1016/j.powtec.2018.03.055
NR 40
TC 0
Z9 0
U1 6
U2 29
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 319
EP 331
DI 10.1016/j.ces.2019.05.002
PG 13
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000030
DA 2020-05-12
ER

PT J
AU Tamir, E
   Sidess, A
   Srebnik, S
AF Tamir, Erez
   Sidess, Arieh
   Srebnik, Simcha
TI Thermodynamic, structural, and mechanical properties of fluoropolymers
   from molecular dynamics simulation: Comparison of force fields
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fluoropolymer; Viton A; Molecular dynamics; Force fields; Mechanical
   properties
ID AB-INITIO; VISCOELASTIC PROPERTIES; SURFACE-TENSION; SELF-DIFFUSION;
   POTENTIALS; PREDICTION; ALKANE; PERFLUOROALKANES; COEFFICIENT;
   DIMENSIONS
AB Copolymers of vinylidene fluoride (VDF) and hexafluoropropylene (HFP) make up the largest volume of fluoroelastomers sales. Within this family, Viton A (VDF/HFP 60/40 wt%, 66% fluorine) is most important commercially. Determination of thermomechanical properties of such fluorinated polymers is still limited to experimentation or empirical models, while computational prediction of their physical properties is still at its infancy. Considerable efforts have been made to develop molecular force fields for the prediction of properties of various crystalline as well as amorphous fluorinated substances. These force fields were parametrized based on small molecules or oligomers, hence their transferability to longer and more complex (i.e. copolymer) chain architectures must be tested. In this work, thermodynamic, structural, and mechanical properties of the Viton A fluoroelastomer are evaluated using atomistic molecular dynamics (MD) simulations for several force fields and compared with available experimental data. Differences in molecular structure of the chains modeled by different force fields are shown to substantially influence thermodynamic and mechanical behavior. OPLS-derived force fields give rise to extended chains that are more mobile and result in softer material that lack in molecular structure. Other force fields rely on strong nonbonded interactions that interfere with chain dynamics and mechanics. PCFF is shown to most satisfactorily predict structural properties and thermal volumetric behavior around T-g, demonstrating relatively successful transferability to long linear polymer chains. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tamir, Erez; Srebnik, Simcha] Technion Israel Inst Technol, Dept Chem Engn, IL-32000 Haifa, Israel.
   [Tamir, Erez] RAFAEL Adv Def Syst Ltd, POB 2250, IL-3102102 Haifa, Israel.
   [Sidess, Arieh] Technion Israel Inst Technol, Dept Civil & Environm Engn, IL-32000 Haifa, Israel.
RP Srebnik, S (reprint author), Technion Israel Inst Technol, Dept Chem Engn, IL-32000 Haifa, Israel.; Sidess, A (reprint author), Technion Israel Inst Technol, Dept Civil & Environm Engn, IL-32000 Haifa, Israel.
EM sidess@technion.ac.il; simchas@technion.ac.il
OI Srebnik, Simcha/0000-0001-9843-1869
FU RAFAEL Advanced Defense Systems Ltd through the RSF [850030]
FX We gratefully acknowledge the support of RAFAEL Advanced Defense Systems
   Ltd through the RSF funding Grant No. 850030.
CR Agrawal V, 2016, J POLYM SCI POL PHYS, V54, P797, DOI 10.1002/polb.23976
   Borodin O, 2002, J PHYS CHEM B, V106, P9912, DOI 10.1021/jp026158i
   Brini E, 2013, SOFT MATTER, V9, P2108, DOI 10.1039/c2sm27201f
   BUECHE F, 1952, J CHEM PHYS, V20, P1956, DOI 10.1063/1.1700348
   Byutner OG, 2000, MACROMOLECULES, V33, P4264, DOI 10.1021/ma9918295
   Caleman C, 2012, J CHEM THEORY COMPUT, V8, P61, DOI 10.1021/ct200731v
   CARBECK JD, 1995, J CHEM PHYS, V103, P10347, DOI 10.1063/1.469872
   Chantawansri TL, 2012, J CHEM PHYS, V137, DOI 10.1063/1.4767394
   Chemours Company, 2017, VIT FLUOR SEL GUID
   Cui ST, 1998, FLUID PHASE EQUILIBR, V146, P51, DOI 10.1016/S0378-3812(98)00216-7
   DEE GT, 1994, MACROMOLECULES, V27, P6106, DOI 10.1021/ma00099a025
   Dlubek G, 2004, MACROMOLECULES, V37, P6606, DOI 10.1021/ma049067n
   Dobratz B. M., 1985, LLNL EXPLOSIVES HDB
   Doi M, 1988, THEORY POLYM DYNAMIC
   Drobny J.G., 2009, TECHNOLOGY FLUOROPOL
   Fetters L. J., 2007, PHYS PROPERTIES POLY, P447, DOI DOI 10.1007/978-0-387-69002-5_25
   Fetters LJ, 1999, J POLYM SCI POL PHYS, V37, P1023, DOI 10.1002/(SICI)1099-0488(19990515)37:10<1023::AID-POLB7>3.0.CO;2-T
   Gao PY, 2015, POLYMER, V69, P25, DOI 10.1016/j.polymer.2015.05.023
   Gee RH, 2007, MACROMOLECULES, V40, P3422, DOI 10.1021/ma0702501
   HARIHARAN A, 1994, J CHEM PHYS, V101, P4156, DOI 10.1063/1.467466
   Hoffman DM, 2003, POLYM ENG SCI, V43, P139
   Hsu DD, 2015, MACROMOLECULES, V48, P3057, DOI 10.1021/acs.macromol.5b00259
   In't Veld PJ, 2003, MACROMOLECULES, V36, P7358, DOI 10.1021/ma0346658
   JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001
   KARASAWA N, 1992, MACROMOLECULES, V25, P7268, DOI 10.1021/ma00052a031
   Kendall MJ, 2014, P ROY SOC A-MATH PHY, V470, DOI 10.1098/rspa.2014.0012
   KLEIN J, 1978, NATURE, V271, P143, DOI 10.1038/271143a0
   Lachet V, 2015, J PHYS CHEM A, V119, P140, DOI 10.1021/jp506895p
   Mahajan DK, 2010, INT J APPL MECH, V2, P515, DOI 10.1142/S1758825110000639
   Maurel G, 2012, J CHEM THEORY COMPUT, V8, P4570, DOI 10.1021/ct300582y
   Omar MF, 2012, MAT SCI ENG A-STRUCT, V538, P125, DOI 10.1016/j.msea.2011.12.111
   Padua AAH, 2002, J PHYS CHEM A, V106, P10116, DOI 10.1021/jp025732n
   Patil R. D, 1999, POLYM DATA HDB, P998
   Paulechka E, 2012, J PHYS CHEM B, V116, P14389, DOI 10.1021/jp309119h
   PEARSON DS, 1987, MACROMOLECULES, V20, P1133, DOI 10.1021/ma00171a044
   Pierce F, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2924120
   PLIMPTON S, 1995, J COMPUT PHYS, V117, P1, DOI 10.1006/jcph.1995.1039
   Rubinstein M., 2003, POLYM PHYS, P1492, DOI [10.1021/ma0491210, DOI 10.1021/MA0491210]
   SHIN S, 1992, J CHEM PHYS, V96, P1352, DOI 10.1063/1.462171
   Smith GD, 1999, MACROMOLECULES, V32, P8857, DOI 10.1021/ma991130z
   Song W, 2003, J CHEM PHYS, V119, P9145, DOI 10.1063/1.1610435
   SUN H, 1994, J AM CHEM SOC, V116, P2978, DOI 10.1021/ja00086a030
   Sun H, 1998, J PHYS CHEM B, V102, P7338, DOI 10.1021/jp980939v
   Tao J, 2017, J ADHES SCI TECHNOL, V31, P250, DOI 10.1080/01694243.2016.1209001
   Teng HX, 2012, APPL SCI-BASEL, V2, P496, DOI 10.3390/app2020496
   Tsige M, 2008, J PHYS CHEM C, V112, P5029, DOI 10.1021/jp710678w
   Tsolou G, 2005, MACROMOLECULES, V38, P1478, DOI 10.1021/ma0491210
   Utracki LA, 2002, J APPL POLYM SCI, V84, P1101, DOI 10.1002/app.10344
   Vattulainen I., 2005, J BIOL PHYS
   Wang QF, 2010, J PHYS CHEM B, V114, P786, DOI 10.1021/jp909762j
   Wang XB, 2017, ENERGIES, V10, DOI 10.3390/en10091377
   Watkins EK, 2001, J PHYS CHEM A, V105, P4118, DOI 10.1021/jp004071w
   WELCH GJ, 1974, POLYMER, V15, P429, DOI 10.1016/0032-3861(74)90106-2
   Wu C, 2018, MACROMOL THEOR SIMUL, V27, DOI 10.1002/mats.201700066
   Xiao J. J., 2004, CHINESE SCI BULL, V50, P21
   Xu MM, 2016, POLYMERS-BASEL, V8, DOI 10.3390/polym8040077
NR 56
TC 0
Z9 0
U1 4
U2 33
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 332
EP 340
DI 10.1016/j.ces.2019.05.007
PG 9
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000031
DA 2020-05-12
ER

PT J
AU Jiao, WH
   Wang, ZQ
   Zhou, X
   Mei, YG
   Feng, RT
   Liu, T
   Ding, L
   Huang, JJ
   Fang, YT
AF Jiao, Weihong
   Wang, Zhiqing
   Zhou, Xing
   Mei, Yangang
   Feng, Rongtao
   Liu, Tao
   Ding, Liang
   Huang, Jiejie
   Fang, Yitian
TI Catalytic steam gasification of sawdust char on K-based composite
   catalyst at high pressure and low temperature
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Composite catalysts; Pressure gasification; Steam gasification; Gas
   composition
ID RICH GAS-PRODUCTION; BIOMASS; PYROLYSIS; COAL; AIR; CONVERSION;
   HYDROGASIFICATION; PERFORMANCE; REACTIVITY; RESIDUES
AB The effects of temperature, pressure, steam ratio and K-based composite catalysts on the pressurized steam gasification of sawdust char were studied and the physicochemical structure of composite catalysts was characterized in detail. The results indicated that steam promoted the production of hydrogen but suppressed that of CH4. The generation of CH4 required high pressure, low temperature and suitable steam atmosphere. The composite catalysts reduced the reaction temperature and increased the carbon conversion, theirs catalytic performance ranked in descending order was KCe > KCo > KFe > KNi, where KCe showed perfect catalytic performance, which mainly determined by the ability to activate carbon during pressurized steam gasification of char. KFe and KCo were more conducive to water-gas-shift reaction, while KNi had the better performance on gasification reaction. The transformation paths of the composite catalysts were as follows: Ce(NO3)(3)center dot 6H(2)O -> CeO2, Co(NO3)(2)center dot 6H(2)O -> CoO/Co3O4 -> Co -> CoO, Fe (NO3)(3)center dot 9H(2)O -> Fe2O3 -> FeO -> Fe3O4 and Ni(NO3)(2)center dot 6H(2)O -> NiO -> Ni. (C) 2019 Published by Elsevier Ltd.
C1 [Jiao, Weihong; Wang, Zhiqing; Zhou, Xing; Mei, Yangang; Feng, Rongtao; Liu, Tao; Ding, Liang; Huang, Jiejie; Fang, Yitian] Chinese Acad Sci, Inst Coal Chem, State Key Lab Coal Convers, Taiyuan 030001, Shanxi, Peoples R China.
   [Jiao, Weihong; Zhou, Xing; Mei, Yangang; Feng, Rongtao; Liu, Tao; Ding, Liang] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
RP Wang, ZQ; Fang, YT (reprint author), Chinese Acad Sci, Inst Coal Chem, State Key Lab Coal Convers, Taiyuan 030001, Shanxi, Peoples R China.
EM qcumt@sxicc.ac.cn; fyt@sxicc.ac.cn
OI Mei, Yangang/0000-0002-9554-9500
FU National Science Foundation of ChinaNational Natural Science Foundation
   of China [21676289]; Youth Innovation Promotion Association [2014156];
   CAS/SAFEA International Partnership Program for Creative Research
   TeamsChinese Academy of Sciences
FX The work is financially supported by the National Science Foundation of
   China (21676289), Youth Innovation Promotion Association (2014156) and
   Research Supported by the CAS/SAFEA International Partnership Program
   for Creative Research Teams.
CR Abdelghany AM, 2018, J NON-CRYST SOLIDS, V499, P153, DOI 10.1016/j.jnoncrysol.2018.07.022
   Belaroui LS, 2018, APPL CLAY SCI, V164, P26, DOI 10.1016/j.clay.2018.03.021
   Chen TJ, 2016, BIORESOURCE TECHNOL, V211, P502, DOI 10.1016/j.biortech.2016.03.091
   Cheng F, 2016, APPL CATAL A-GEN, V527, P1, DOI 10.1016/j.apcata.2016.08.013
   Coetzee S, 2013, FUEL PROCESS TECHNOL, V114, P75, DOI 10.1016/j.fuproc.2013.03.041
   de Lasa H, 2011, CHEM REV, V111, P5404, DOI 10.1021/cr200024w
   Dias D, 2018, BIORESOURCE TECHNOL, V266, P139, DOI 10.1016/j.biortech.2018.06.054
   Dupont C, 2016, ENERGY, V109, P430, DOI 10.1016/j.energy.2016.04.094
   Enache DI, 2002, J CATAL, V205, P346, DOI 10.1006/jcat.2001.3462
   Fan S, 2016, FUEL, V165, P397, DOI 10.1016/j.fuel.2015.10.084
   Francis MF, 2017, J PHYS CHEM C, V121, P6113, DOI 10.1021/acs.jpcc.6b12329
   Galvagno A, 2017, ENRGY PROCED, V126, P485, DOI 10.1016/j.egypro.2017.08.233
   Hong RY, 2007, J MAGN MAGN MATER, V310, P37, DOI 10.1016/j.jmmm.2006.07.026
   Hong WZ, 2018, ACS SUSTAIN CHEM ENG, V6, P889, DOI 10.1021/acssuschemeng.7b03250
   Hu M, 2018, ENERGY, V145, P228, DOI 10.1016/j.energy.2017.12.096
   Huang Z, 2016, INT J HYDROGEN ENERG, V41, P17871, DOI 10.1016/j.ijhydene.2016.07.089
   Huang Z, 2013, BIORESOURCE TECHNOL, V140, P138, DOI 10.1016/j.biortech.2013.04.055
   Jia S, 2017, INT J HYDROGEN ENERG, V42, P18844, DOI 10.1016/j.ijhydene.2017.05.008
   Jiang MQ, 2012, FUEL, V99, P64, DOI 10.1016/j.fuel.2012.04.007
   Kaviyarasu K, 2015, MATER LETT, V160, P61, DOI 10.1016/j.matlet.2015.07.099
   Kim YK, 2014, J IND ENG CHEM, V20, P216, DOI 10.1016/j.jiec.2013.04.004
   Lin SSY, 2010, J CATAL, V273, P229, DOI 10.1016/j.jcat.2010.05.016
   Liu T., 2017, INT J HYDROGEN ENERG, V42
   Meng JG, 2018, BIORESOURCE TECHNOL, V268, P212, DOI 10.1016/j.biortech.2018.07.135
   Monterroso R, 2014, FUEL, V116, P341, DOI 10.1016/j.fuel.2013.08.003
   Ning SY, 2018, BIOMASS BIOENERG, V117, P131, DOI 10.1016/j.biombioe.2018.07.003
   Park JL, 2018, J COLLOID INTERF SCI, V525, P143, DOI 10.1016/j.jcis.2018.04.078
   Parparita E, 2015, J MATER CYCLES WASTE, V17, P756, DOI 10.1007/s10163-014-0308-0
   Prestipino M, 2018, ENERGY, V161, P1055, DOI 10.1016/j.energy.2018.07.205
   Prestipino M, 2017, INT J HYDROGEN ENERG, V42, P26816, DOI 10.1016/j.ijhydene.2017.05.173
   Ran X. -M., 2017, ABSTR PAP AM CHEM S, P253
   Sonia MML, 2018, J MAGN MAGN MATER, V466, P238, DOI 10.1016/j.jmmm.2018.07.017
   Wang SQ, 2018, BIORESOURCE TECHNOL, V268, P323, DOI 10.1016/j.biortech.2018.07.117
   Wang ZQ, 2016, FUEL, V186, P587, DOI 10.1016/j.fuel.2016.08.108
   Wang ZQ, 2015, FUEL, V150, P386, DOI 10.1016/j.fuel.2015.02.056
   Wu QM, 2015, BIORESOURCE TECHNOL, V179, P98, DOI 10.1016/j.biortech.2014.12.026
   Wu SY, 2018, FUEL PROCESS TECHNOL, V171, P293, DOI 10.1016/j.fuproc.2017.11.025
   Wu Y, 2017, FUEL PROCESS TECHNOL, V166, P115, DOI 10.1016/j.fuproc.2017.05.025
   Yan F, 2010, BIORESOURCE TECHNOL, V101, P5633, DOI 10.1016/j.biortech.2010.02.025
   Yan S, 2017, APPL ENERG, V206, P401, DOI 10.1016/j.apenergy.2017.08.189
   Yang HP, 2018, BIORESOURCE TECHNOL, V249, P744, DOI 10.1016/j.biortech.2017.10.083
   Yuan SF, 2015, FUEL, V147, P133, DOI 10.1016/j.fuel.2015.01.004
   Yuan XZ, 2017, APPL ENERG, V195, P850, DOI 10.1016/j.apenergy.2017.03.088
   Zhai M, 2017, ENERGY, V128, P509, DOI 10.1016/j.energy.2017.04.083
   Zhai M, 2015, FUEL, V158, P42, DOI 10.1016/j.fuel.2015.05.019
   Zhang H, 2018, BIORESOURCE TECHNOL, V270, P416, DOI 10.1016/j.biortech.2018.09.053
   Zhang SY, 2013, J REINF PLAST COMP, V32, P786, DOI 10.1177/0731684412470727
   Zhang S, 2016, FUEL, V183, P177, DOI 10.1016/j.fuel.2016.06.078
   Zhao XY, 2017, ENERG FUEL, V31, P4054, DOI 10.1021/acs.energyfuels.7b00005
   Zheng AQ, 2015, BIORESOURCE TECHNOL, V176, P15, DOI 10.1016/j.biortech.2014.10.157
   Zhu HL, 2015, ENERGY TECHNOL-GER, V3, P961, DOI 10.1002/ente.201500094
   Zubek K, 2018, ENERG FUEL, V32, P5684, DOI 10.1021/acs.energyfuels.7b03562
NR 52
TC 2
Z9 2
U1 9
U2 55
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 341
EP 349
DI 10.1016/j.ces.2019.05.009
PG 9
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000032
DA 2020-05-12
ER

PT J
AU Deshpande, SS
   Kar, K
   Pressler, J
   Tebeka, I
   Martins, B
   Rosenfeld, D
   Biggs, J
AF Deshpande, S. S.
   Kar, K.
   Pressler, J.
   Tebeka, I.
   Martins, B.
   Rosenfeld, D.
   Biggs, J.
TI Mass transfer estimation for bubble column scale up
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
ID TRANSFER COEFFICIENTS; OXYGEN-TRANSFER; AERATION
AB The productivity of a bubble column reactor (BCR) critically depends upon gas-liquid mass transfer coefficient, k(L)a. The prediction of k(L)a as function of design and operating conditions is central to BCR scale up. A large number of researchers have successfully characterized k(L)a experimentally in terms of superficial gas velocity, U-sg using the power law relation k(L)alpha = alpha U-sg(beta), with alpha, beta as fit parameters. We probe the applicability of such correlations to the design of a scaled up BCR, which differs from laboratory BCR in two important aspects: (i) the scale of operation, which can be O(10(2) - 10(3)) times larger, and (ii) the type of sparger used. To this end, experiments were performed with air and water in a pilot scale (D-C = 1.6 m diameter) BCR using a coarse bubble sparger. We found that the existing correlations do, indeed, describe k(L)a over a wide range of BCR sizes, suggesting that these correlations are fairly scale insensitive. However, the correlations provide no means to capture the role of sparger explicitly. We cast our experimental k(L)a values in terms of a mass transfer efficiency and independently recover the power law relation with beta = 1. We suggest that the role of sparger design can be incorporated in the definition of alpha through the well-documented sparger efficiency factors. The alpha and beta estimates thus obtained are in good agreement with the literature. (C) 2019 Published by Elsevier Ltd.
C1 [Deshpande, S. S.; Kar, K.; Pressler, J.] Dow Chem Co USA, Core R&D, Midland, MI 48674 USA.
   [Tebeka, I.; Rosenfeld, D.] Dow Chem Co USA, Hydrocarbons R&D, Freeport, TX 77541 USA.
   [Martins, B.; Biggs, J.] Dow Chem Co USA, Hydrocarbons R&D, BR-04794 Sao Paulo, Brazil.
RP Deshpande, SS (reprint author), Dow Chem Co USA, Core R&D, Midland, MI 48674 USA.
EM Suraj.Deshpande@DuPont.com
CR Besagni Giorgio, 2018, ChemEngineering, V2, DOI 10.3390/chemengineering2020013
   Besagni G, 2017, PETROLEUM
   Besagni G, 2017, CHEM ENG SCI, V158, P516, DOI 10.1016/j.ces.2016.11.003
   Bird R.B., 1960, TRANSPORT PHENOMENA
   Chern JM, 2003, IND ENG CHEM RES, V42, P6653, DOI 10.1021/ie030396y
   DECKWER WD, 1974, CHEM ENG SCI, V29, P2177, DOI 10.1016/0009-2509(74)80025-4
   ECKENFELDER WW, 1952, SEWAGE IND WASTES, V24, P1221
   Frossling N., 1938, Gerlands Beitrage zur Geophysik, V52, P170
   Garcia-Ochoa F, 2009, BIOTECHNOL ADV, V27, P153, DOI 10.1016/j.biotechadv.2008.10.006
   HIKITA H, 1981, CHEM ENG J BIOCH ENG, V22, P61, DOI 10.1016/0300-9467(81)85006-X
   JACKSON ML, 1978, AICHE J, V24, P63, DOI 10.1002/aic.690240108
   Joint Task Force of the Water Pollution Control Federation and ASCE, 1988, AER WAST TREATM PROC
   Mena PC, 2005, CHEM ENG SCI, V60, P6013, DOI 10.1016/j.ces.2005.04.020
   MORRISON TJ, 1952, J CHEM SOC, P3819, DOI 10.1039/jr9520003819
   Mounsef JR, 2015, J BIOTECHNOL, V210, P100, DOI 10.1016/j.jbiotec.2015.06.387
   Nedeltchev S, 2014, CHEM ENG SCI, V106, P119, DOI 10.1016/j.ces.2013.11.030
   Onsan Z. I., 2016, MULTIPHASE CATALYTIC
   Paul E.L., 2004, HDB IND MIXING SCI P
   POPEL HJ, 1994, WATER SCI TECHNOL, V30, P71
   Rollbusch P, 2015, CHEM ENG SCI, V126, P660, DOI 10.1016/j.ces.2014.11.061
   ROONEY TC, 1980, J WATER POLLUT CON F, V52, P2315
   Shah Y. T., 1979, GAS LIQUID SOLID REA, V327
   SHAH YT, 1982, AICHE J, V28, P353, DOI 10.1002/aic.690280302
   Shaikh A, 2013, IND ENG CHEM RES, V52, P8091, DOI 10.1021/ie302080m
   Sharaf S., 2016, CHEM ENG J
   Vandu CO, 2004, CHEM ENG PROCESS, V43, P575, DOI 10.1016/S0255-2701(03)00015-1
   Vasconcelos JMT, 2003, CHEM ENG SCI, V58, P1431, DOI 10.1016/S0009-2509(02)00675-9
   Wilkinson P., 1992, AICHE J, V38
   Xylem, 2018, AER PROD EN EFF BIOL
   YOSHIDA F, 1965, AICHE J, V11, P9, DOI 10.1002/aic.690110106
   Zednikova Maria, 2018, ChemEngineering, V2, DOI 10.3390/chemengineering2020019
NR 31
TC 1
Z9 1
U1 7
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 350
EP 357
DI 10.1016/j.ces.2019.05.011
PG 8
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000033
DA 2020-05-12
ER

PT J
AU Farooqui, A
   Bose, A
   Ferrero, D
   Llorca, J
   Santarelli, M
AF Farooqui, Azharuddin
   Bose, Archishman
   Ferrero, Domenico
   Llorca, Jordi
   Santarelli, Massimo
TI Simulation of two-step redox recycling of non-stoichiometric ceria with
   thermochemical dissociation of CO2/H2O in moving bed reactors - Part II:
   Techno-economic analysis and integration with 100 MW oxyfuel power plant
   with carbon capture
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Solar fuels; Reaction kinetics; Techno-economic; Carbon capture and
   utilization; Chemical looping
ID CHEMICAL-LOOPING COMBUSTION; CO2 CAPTURE; HYDROGEN-PRODUCTION; FUEL
   PRODUCTION; EXERGY ANALYSIS; COMBINED-CYCLE; SOLAR; SYSTEM;
   POLYGENERATION; TECHNOLOGY
AB This paper presents the model of a solar thermochemical looping CO2/H2O dissociation (CL) unit with commercial ceria as the redox oxygen carrier. The CL unit is integrated in an oxy-fuelled combined cycle power plant as an add-on unit to a 100 MW oxy-fuelled natural gas power plant with carbon capture. The efficiency benefit obtained was investigated. A moving bed counter-current reactor model, developed in ASPEN Plus (R), consisting of a series of rigorous continuous stirred reactors (RCSTRs) was used for the simulation of both reduction and oxidation reactors of the CL unit. A kinetic subroutine was developed in FORTRAN and linked with each RCSTR for both reduction and oxidation reactions. It is found that the efficiency of the CL unit varies widely with reduction reactor temperature and operating pressure. Considering three different compositions of the feed gas to the oxidation reactor, the CL unit efficiency is obtained as: 35.41% with CO2 only; 30.84% with H2O only; and 35.26% for a mixture of 86% CO2 and 14% H2O. The lower efficiency for H2O-only operation is due to the heat requirement for water vaporization and the higher compression work required for compressing H-2 than CO. The maximum solar to electrical efficiency for the whole add-on unit is found to be 25.44% with a reduction reactor operating at a temperature of 1600 degrees C and 10(-7) bar vacuum pressure. With 0.5 m(3) reduction reactor volume and 5 m(3) oxidation reactor volume, the maximum net electricity produced by the CL add-on unit is 12.85 MWe. Economic analysis revealed that the major contributors to total plant cost are the hydrogen compressor and solar field and tower, which are the 19% and 39% of the total equipment cost, giving a specific overnight capital cost of 12,136 $/kW with an LCOE of 1321 $/MWh with a capacity factor of 21%. The LCOE drops to 628 $/MWh with a carbon tax of 80 $/tonne of CO2 and increased capacity factor of 26%. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Farooqui, Azharuddin; Bose, Archishman; Ferrero, Domenico; Santarelli, Massimo] Politecn Torino, Energy Dept DENERG, Corso Duca Abruzzi 24, I-10129 Turin, Italy.
   [Farooqui, Azharuddin; Llorca, Jordi] Univ Politecn Cataluna, Dept Chem Engn, Inst Energy Technol, EEBE, Eduard Maristany 10-14, Barcelona 08019, Spain.
   [Farooqui, Azharuddin; Llorca, Jordi] Univ Politecn Cataluna, Barcelona Res Ctr Multiscale Sci & Engn, EEBE, Eduard Maristany 10-14, Barcelona 08019, Spain.
   [Bose, Archishman] Univ Coll Cork, Marine & Renewable Energy Res MaREI Ctr, Environm Res Inst, Lee Rd, Cork T23 XE10, Ireland.
RP Farooqui, A (reprint author), Politecn Torino, Energy Dept DENERG, Corso Duca Abruzzi 24, I-10129 Turin, Italy.
EM Azharuddin.xxx@polito.it
RI Farooqui, Azharuddin/K-1259-2017
OI Farooqui, Azharuddin/0000-0003-2689-261X
FU Education, Audiovisual, and Culture Executive Agency (EACEA) of the
   European Commission; InnoEnergy (E.I.T); UPC;  [GC 2017 SGR 128]
FX The research presented is performed within the framework of the SELECT+
   'Environomical Pathways for Sustainable Energy Systems' and funded with
   support from the Education, Audiovisual, and Culture Executive Agency
   (EACEA) of the European Commission. This publication reflects the views
   only of the author(s), and the Commission cannot be held responsible for
   any use, which may be made of the information contained therein. The
   financial support provided by InnoEnergy (E.I.T) and UPC are also highly
   appreciated. JL is a Serra Hunter Fellow and is grateful to the ICREA
   Academia program and grant GC 2017 SGR 128.
CR Abanades S, 2006, SOL ENERGY, V80, P1611, DOI 10.1016/j.solener.2005.12.005
   Abanades S, 2011, CHEM ENG J, V175, P368, DOI 10.1016/j.cej.2011.09.124
   [Anonymous], 2016, CAPITAL COST ESTIMAT
   Apt J, 2008, 143 US DEP EN NAT EN, P143
   Arifin D., 2013, STUDY REDOX REACTION
   Bejan A., 1996, THERMAL DESIGN OPTIM
   Ben-Mansour R, 2012, ENERG FUEL, V26, P4599, DOI 10.1021/ef300539c
   Berghout N, 2015, INT J GREENH GAS CON, V39, P256, DOI 10.1016/j.ijggc.2015.05.019
   Breault RW, 2015, APPL ENERG, V157, P174, DOI 10.1016/j.apenergy.2015.08.015
   Brendelberger S, 2018, SOL ENERGY, V170, P273, DOI 10.1016/j.solener.2018.05.063
   Brendelberger S, 2017, SOL ENERGY, V141, P91, DOI 10.1016/j.solener.2016.11.023
   Bulfin B, 2017, J MATER CHEM A, V5, P18951, DOI 10.1039/c7ta05025a
   Bulfin B, 2013, J PHYS CHEM C, V117, P24129, DOI 10.1021/jp406578z
   Cormos CC, 2012, ENERGY, V42, P434, DOI 10.1016/j.energy.2012.03.025
   Daza YA, 2014, IND ENG CHEM RES, V53, P5828, DOI 10.1021/ie5002185
   Diver RB, 2008, J SOL ENERG-T ASME, V130, DOI 10.1115/1.2969781
   Ehrhart BD, 2016, INT J HYDROGEN ENERG, V41, P19904, DOI 10.1016/j.ijhydene.2016.07.106
   Ermanoski I, 2013, J SOL ENERG-T ASME, V135, DOI 10.1115/1.4023356
   Ermanoski  Ivan, 2013, Patent No. [US 8.420,032 B1, 8420032]
   Falter C, 2016, ENVIRON SCI TECHNOL, V50, P470, DOI 10.1021/acs.est.5b03515
   Falter CP, 2018, APPL THERM ENG, V132, P613, DOI 10.1016/j.applthermaleng.2017.12.087
   Fan JM, 2016, J CLEAN PROD, V131, P247, DOI 10.1016/j.jclepro.2016.05.040
   Farooqui A, 2019, CHEM ENG SCI, DOI [10.1016/j.ces.2019.03.050, DOI 10.1016/J.CES.2019.03.050]
   Farooqui A, 2018, J CO2 UTIL
   Farooqui A, 2019, ENERG CONVERS MANAGE, V186, P200, DOI 10.1016/j.enconman.2019.02.043
   Furler P, 2012, ENERG ENVIRON SCI, V5, P6098, DOI 10.1039/c1ee02620h
   Hammond GP, 2004, INT J ENERG RES, V28, P613, DOI 10.1002/cr.988
   Hong H, 2006, J SOL ENERG-T ASME, V128, P275, DOI 10.1115/1.2212443
   Hossain MM, 2008, CHEM ENG SCI, V63, P4433, DOI 10.1016/j.ces.2008.05.028
   IEA, 2015, EX SUMM PROJ COSTS G
   IPCC, 2019, IPCC SPEC REP GLOB W
   IRENA, 2012, COMPR RENEW ENERGY, V3, P595, DOI [10.1016/B978-0-08-087872-0.00319-X, DOI 10.1016/B978-0-08-087872-0.00319-X]
   Jafarian M, 2013, APPL ENERG, V103, P671, DOI 10.1016/j.apenergy.2012.10.033
   Jana K, 2017, APPL ENERG, V202, P88, DOI 10.1016/j.apenergy.2017.05.129
   Kim J, 2011, ENERG ENVIRON SCI, V4, P3122, DOI 10.1039/c1ee01311d
   Kong H, 2018, APPL ENERG, V228, P301, DOI 10.1016/j.apenergy.2018.05.099
   Kong H, 2016, APPL THERM ENG, V108, P958, DOI 10.1016/j.applthermaleng.2016.03.170
   Lapp J, 2012, ENERGY, V37, P591, DOI 10.1016/j.energy.2011.10.045
   Lapp J, 2013, J SOL ENERG-T ASME, V135, DOI 10.1115/1.4023357
   Li S, 2018, ENERGY FUELS
   Li S, 2018, ENERG FUEL, V32, P10838, DOI 10.1021/acs.energyfuels.8b02081
   Mitsubishi Heavy Industries, GAS TURB
   Mletzko J, 2016, ENRGY PROCED, V86, P2, DOI 10.1016/j.egypro.2016.01.001
   Muhich CL, 2016, WIRES ENERGY ENVIRON, V5, P261, DOI 10.1002/wene.174
   Nazir SM, 2018, ENERGIES, V11, DOI 10.3390/en11010147
   Ogidiama OV, 2018, APPL ENERG, V228, P724, DOI 10.1016/j.apenergy.2018.06.091
   Politecnico di Milano - Alstom UK, 2011, CARBON FREE EL SEWGS
   Politecnico di Milano - Alstom UK (CAESAR project), 2011, EUR BEST PRACT GUID
   Politecnico di Milano - CAESER Project, 2011, EN ADV PREC CAPT TEC
   Sievers S, 2017, CHEM ENG SCI, V158, P395, DOI 10.1016/j.ces.2016.09.029
   Stanger R, 2015, INT J GREENH GAS CON, V40, P55, DOI 10.1016/j.ijggc.2015.06.010
   Steinfeld A, 2005, SOL ENERGY, V78, P603, DOI 10.1016/j.solener.2003.12.012
   Wartsila, 2018, GAS TURB POW GEN INT
   Wheeler VM, 2018, OPT EXPRESS, V26, pA360, DOI 10.1364/OE.26.00A360
   World Bank Group, 2015, STAT TRENDS CARB PRI, DOI [10.1596/978-1-4648-1292-7, DOI 10.1596/978-1-4648-1292-7, 10.1596/978-1-4648-1292-7.]
   Yadav D, 2016, RENEW SUST ENERG REV, V54, P497, DOI 10.1016/j.rser.2015.10.026
   Zhou C, 2016, ENERG FUEL, V30, P1741, DOI 10.1021/acs.energyfuels.5b02209
   Zhou C, 2015, ENERG FUEL, V29, P2074, DOI 10.1021/ef5022076
NR 58
TC 1
Z9 1
U1 5
U2 41
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 358
EP 373
DI 10.1016/j.ces.2019.05.013
PG 16
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000034
DA 2020-05-12
ER

PT J
AU Shirazi, AS
   Frigaard, IA
AF Shirazi, A. Sarraf
   Frigaard, I. A.
TI A three layer model for solids transport in pipes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Critical velocity; Triple layer model; Heterogeneous slurry
ID PARTICLE-SIZE DISTRIBUTION; NEWTONIAN SLURRIES; CRITICAL VELOCITY;
   PIPELINE FLOW; LIQUID FLOW; SUSPENSIONS; DEPOSITION; DIFFUSIVITY;
   PREDICTION; FRICTION
AB A modified three-layer model for solid-liquid flow in inclined pipes is developed, which overcomes the limitations of previous mechanistic models. The steady-state model predicts the pressure loss, critical velocity, concentration profile in the heterogeneous layer, mean heterogeneous layer and moving bed layer velocities, and bed layer heights for each set of parameters. We propose a new correlation for the turbulent solids diffusivity, and include appropriate closures for forces and stresses attributed to the solids and liquid phases in the different layers. The proposed turbulent solids diffusivity correlation and the steady-state model predictions show a good agreement with experimentally measured results in the literature: for concentration profiles in the heterogeneous layer, pressure losses and critical (deposition) velocity, both over a wide range of parameters and for different regimes. We also define a critical Peclet number based on which, a transition boundary between bed-load and heterogeneous regimes can be found. This boundary implicitly represents the critical velocity. In turbulent flow, the pressure loss vs mean velocity curve shows a characteristic minimum just before the critical velocity is attained, in agreement with published research. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Shirazi, A. Sarraf] Univ British Columbia, Dept Mech Engn, 2054-6250 Appl Sci Lane, Vancouver, BC V6T 1Z4, Canada.
   [Frigaard, I. A.] Univ British Columbia, Dept Math, 1984 Math Rd, Vancouver, BC V6T 1Z2, Canada.
   [Frigaard, I. A.] Univ British Columbia, Dept Mech Engn, 1984 Math Rd, Vancouver, BC V6T 1Z2, Canada.
RP Frigaard, IA (reprint author), Univ British Columbia, Dept Math, 1984 Math Rd, Vancouver, BC V6T 1Z2, Canada.; Frigaard, IA (reprint author), Univ British Columbia, Dept Mech Engn, 1984 Math Rd, Vancouver, BC V6T 1Z2, Canada.
EM frigaard@math.ubc.ca
FU NSERCNatural Sciences and Engineering Research Council of Canada;
   Schlumberger through CRD project [505549-16]; UBC through the 4YF
   programme
FX This research has been carried out at the University of British
   Columbia, supported financially by NSERC and Schlumberger through CRD
   project 505549-16, as well as by UBC through the 4YF programme.
CR Avci I., 1981, EXPT DETERMINATION C
   BAGNOLD RA, 1954, PROC R SOC LON SER-A, V225, P49, DOI 10.1098/rspa.1954.0186
   BAGNOLD RA, 1956, PHILOS TR R SOC S-A, V249, P235, DOI 10.1098/rsta.1956.0020
   Bartosik A, 2010, ARCH MECH ENG, V57, P45, DOI 10.2478/v10180-010-0003-1
   Condolios E., 1952, DEUX JOURN LHYDR SOC
   DORON P, 1993, INT J MULTIPHAS FLOW, V19, P1029, DOI 10.1016/0301-9322(93)90076-7
   Durand R., 1953, P MINN INT HYDR CONV, P89
   Durand R., 1952, P C HYDR TRANSP FRAN
   Eskin D, 2012, CHEM ENG SCI, V82, P84, DOI 10.1016/j.ces.2012.07.017
   Gillies RG, 2004, CAN J CHEM ENG, V82, P1060
   GILLIES RG, 1991, CAN J CHEM ENG, V69, P173, DOI 10.1002/cjce.5450690120
   GILLIES RG, 1994, PARTICUL SCI TECHNOL, V12, P45, DOI 10.1080/02726359408906641
   Gillies RG, 2000, CAN J CHEM ENG, V78, P709, DOI 10.1002/cjce.5450780413
   GILLIES RG, 1991, CAN J CHEM ENG, V69, P1225, DOI 10.1002/cjce.5450690525
   Gillies RG, 2000, CAN J CHEM ENG, V78, P704, DOI 10.1002/cjce.5450780412
   Graf W.H, 1970, FRITZ LAB REPORTS
   KARABELAS AJ, 1977, AICHE J, V23, P426, DOI 10.1002/aic.690230404
   Kaushal DR, 2007, POWDER TECHNOL, V172, P177, DOI 10.1016/j.powtec.2006.11.020
   Kaushal DR, 2002, APPL MATH MODEL, V26, P941, DOI 10.1016/S0307-904X(02)00054-9
   Kokpinar MA, 2001, J HYDRAUL ENG-ASCE, V127, P763
   Matousek V, 2018, POWDER TECHNOL, V333, P317, DOI 10.1016/j.powtec.2018.04.021
   Matousek V, 2002, EXP THERM FLUID SCI, V26, P693, DOI 10.1016/S0894-1777(02)00176-0
   Matousek V, 2009, J HYDRAUL ENG-ASCE, V135, P1101, DOI 10.1061/(ASCE)HY.1943-7900.0000113
   Mols B, 1998, INT J MULTIPHAS FLOW, V24, P55, DOI 10.1016/S0301-9322(97)00043-8
   NASRELDIN H, 1987, INT J MULTIPHAS FLOW, V13, P661, DOI 10.1016/0301-9322(87)90043-7
   OROSKAR AR, 1980, AICHE J, V26, P550, DOI 10.1002/aic.690260405
   Ramadan A, 2005, CHEM ENG SCI, V60, P2557, DOI 10.1016/j.ces.2004.12.011
   RICHARDSON JF, 1954, T I CHEM ENG-LOND, V32, P35, DOI DOI 10.1016/S0263-8762(97)80006-8
   ROCO MC, 1983, CAN J CHEM ENG, V61, P494, DOI 10.1002/cjce.5450610402
   Schaan J, 2000, CAN J CHEM ENG, V78, P717, DOI 10.1002/cjce.5450780414
   Seshadri V, 2006, PARTICUL SCI TECHNOL, V24, P239, DOI 10.1080/02726350500544265
   SHOOK CA, 1994, POWDER TECHNOL, V81, P117, DOI 10.1016/0032-5910(94)02877-X
   Sinclair C.G, 1962, S INT FLUIDS PART 3
   Sonnad JR, 2006, J HYDRAUL ENG-ASCE, V132, P863, DOI 10.1061/(ASCE)0733-9429(2006)132:8(863)
   TELEVANTOS Y, 1979, CAN J CHEM ENG, V57, P255, DOI 10.1002/cjce.5450570302
   THOMAS DG, 1962, AICHE J, V8, P373, DOI 10.1002/aic.690080323
   TURIAN RM, 1987, POWDER TECHNOL, V51, P35, DOI 10.1016/0032-5910(87)80038-4
   TURIAN RM, 1977, AICHE J, V23, P232, DOI 10.1002/aic.690230305
   VANONI VA, 1975, ASCE MANUALS REPORTS, V54
   WALTON IC, 1995, AICHE J, V41, P1815, DOI 10.1002/aic.690410716
   Wicks M., 1971, ADV SOLID LIQUID FLO, P101
   Yotsukura N., 1961, THESIS
   Zandi I., 1967, J HYDR DIV ASCE, V93, P145
NR 43
TC 0
Z9 0
U1 5
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 374
EP 390
DI 10.1016/j.ces.2019.04.038
PG 17
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000035
DA 2020-05-12
ER

PT J
AU Zhao, HY
   An, XZ
   Dong, KJ
   Yang, RY
   Xu, F
   Fu, HT
   Zhang, H
   Yang, XH
AF Zhao, Haiyang
   An, Xizhong
   Dong, Kejun
   Yang, Runyu
   Xu, Fan
   Fu, Haitao
   Zhang, Hao
   Yang, Xiaohong
TI Macro- and microscopic analyses of piles formed by Platonic solids
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Sandpile; Platonic solids; DEM simulation; Structure and property
   characterization; Stress/force behavior
ID STRESS-DISTRIBUTION; PARTICLE-SHAPE; REPOSE; ANGLE; SIMULATION; PACKING;
   SEGREGATION; PRESSURE; MODEL
AB Sandpiles are ubiquitous in nature and engineering applications but still not fully understood due to the complexity of structures and materials properties. This work presents a systematic study on the piles of Platonic solids using the discrete element method (DEM), mainly focusing on the effect of particle shape on the repose angles and bottom pressure distributions of the piles. Five Platonic particles (tetrahedron, cube, octahedron, dodecahedron, and icosahedron) were discharged to form wedge-shaped piles. It was found that the repose angle did not increase with the decrease of particle sphericity. The pile formed by the cubes had the maximum repose angle and its bottom stress dip phenomena were more significant in terms of dip width and depth than that of other particle piles. The pressure distributions at different heights of the piles were quite similar to those of the whole piles, while the shear stress distributions near the boundaries exhibited different characteristics for the cube piles. The analyses of packing structures in terms of coordination number, radial distribution function, as well as contact types inside the piles were discussed to understand the change of pressure dips. The influence of static friction on the repose angle was more significant and it enhanced the stress dip phenomenon. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhao, Haiyang; An, Xizhong; Xu, Fan; Fu, Haitao; Zhang, Hao; Yang, Xiaohong] Northeastern Univ, Sch Met, Key Lab Ecol Met Multimetall Mineral, Minist Educ, Shenyang 110004, Liaoning, Peoples R China.
   [Dong, Kejun] Western Sydney Univ, Ctr Infrastruct Engn, Penrith, NSW 2751, Australia.
   [Yang, Runyu] Univ New South Wales, Sch Mat Sci & Engn, Sydney, NSW 2052, Australia.
   [Yang, Xiaohong] Sechenov First Moscow State Med Univ, Inst Mol Med, Moscow 119991, Russia.
RP An, XZ (reprint author), Northeastern Univ, Sch Met, Key Lab Ecol Met Multimetall Mineral, Minist Educ, Shenyang 110004, Liaoning, Peoples R China.
EM anxz@mail.neu.edu.cn
RI An, Xizhong/AAG-2879-2020
OI Dong, Kejun/0000-0002-0520-1739
FU National Key R&D Program of China [2016YFB0600101-4]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [51374070]; Liaoning Revitalization Talents Program [XLYC1805007]
FX The authors are grateful to the National Key R&D Program of China
   (2016YFB0600101-4), National Natural Science Foundation of China
   (51374070), and Liaoning Revitalization Talents Program (XLYC1805007)
   for the financial support of current work.
CR Abreu CRA, 2003, POWDER TECHNOL, V134, P167, DOI 10.1016/S0032-5910(03)00151-7
   Ai J, 2013, MECH MATER, V66, P160, DOI 10.1016/j.mechmat.2013.08.005
   Ai J, 2013, INT J SOLIDS STRUCT, V50, P981, DOI 10.1016/j.ijsolstr.2012.12.006
   Athanassiadis AG, 2014, SOFT MATTER, V10, P48, DOI 10.1039/c3sm52047a
   Atman APF, 2005, EUR PHYS J E, V17, P93, DOI 10.1140/epje/i2005-10002-2
   Azema E, 2013, PHYS REV E, V87, DOI 10.1103/PhysRevE.87.062203
   Baker J, 2010, PHYS REV E, V82, DOI 10.1103/PhysRevE.82.061304
   Chaumet PC, 2009, INVERSE PROBL, V25, DOI 10.1088/0266-5611/25/2/024003
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   Cunha RN, 2016, POWDER TECHNOL, V303, P203, DOI 10.1016/j.powtec.2016.09.023
   de Gennes PG, 1999, REV MOD PHYS, V71, pS374, DOI 10.1103/RevModPhys.71.S374
   de Gennes PG, 1998, PHYSICA A, V261, P267, DOI 10.1016/S0378-4371(98)00438-5
   Friedman SP, 2002, WATER RESOUR RES, V38, DOI 10.1029/2001WR000746
   Geng JF, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.060301
   Guo Q, 2012, FUEL, V102, P453, DOI 10.1016/j.fuel.2012.05.025
   Guo ZG, 2014, FUEL, V116, P131, DOI 10.1016/j.fuel.2013.07.098
   Hge H., 2017, SOFT MATTER, V13, P29
   Horabik J, 2017, POWDER TECHNOL, V312, P194, DOI 10.1016/j.powtec.2017.02.048
   Jaeger HM, 1996, REV MOD PHYS, V68, P1259, DOI 10.1103/RevModPhys.68.1259
   Jin WW, 2015, SCI REP-UK, V5, DOI 10.1038/srep15640
   Li TQ, 2017, MATERIALS, V10, DOI 10.3390/ma10050520
   Liu LF, 2017, SOFT MATTER, V13, P748, DOI 10.1039/c6sm02065h
   Lu HF, 2009, ENERG FUEL, V23, P5529, DOI 10.1021/ef9005753
   Luding S, 1997, PHYS REV E, V55, P4720, DOI 10.1103/PhysRevE.55.4720
   Makse HA, 1999, EUR PHYS J B, V7, P271, DOI 10.1007/s100510050613
   Matuttis HG, 2000, POWDER TECHNOL, V109, P278, DOI 10.1016/S0032-5910(99)00243-0
   Poschel T., 2005, COMPUTATIONAL GRANUL, P55
   Ramos O, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.078701
   Shimokawa M, 2008, PHYS REV E, V77, DOI 10.1103/PhysRevE.77.011305
   Swartz AG, 2009, GRANUL MATTER, V11, P185, DOI 10.1007/s10035-009-0135-5
   Szalay A, 2015, CHEM ENG RES DES, V93, P349, DOI 10.1016/j.cherd.2014.05.008
   Torquato S, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.041104
   Wang W, 2010, PARTICUOLOGY, V8, P482, DOI 10.1016/j.partic.2010.07.008
   Wittmer JP, 1996, NATURE, V382, P336, DOI 10.1038/382336a0
   Wu YL, 2017, POWDER TECHNOL, V314, P89, DOI 10.1016/j.powtec.2016.09.029
   Zhao B, 2017, POWDER TECHNOL, V317, P171, DOI 10.1016/j.powtec.2017.04.048
   Zheng QJ, 2014, PHYS REV LETT, V113, DOI 10.1103/PhysRevLett.113.068001
   Zhou C, 2009, MECH MATER, V41, P707, DOI 10.1016/j.mechmat.2009.01.017
   Zhou YC, 2002, POWDER TECHNOL, V125, P45, DOI 10.1016/S0032-5910(01)00520-4
   Zhou ZY, 2014, GRANUL MATTER, V16, P695, DOI 10.1007/s10035-014-0522-4
   Zhu HP, 2008, CHEM ENG SCI, V63, P5728, DOI 10.1016/j.ces.2008.08.006
   Zhu JY, 2013, POWDER TECHNOL, V234, P37, DOI 10.1016/j.powtec.2012.09.032
   Zuriguel I, 2008, P ROY SOC A-MATH PHY, V464, P99, DOI 10.1098/rspa.2007.1899
   Zuriguel I, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.028001
NR 44
TC 2
Z9 2
U1 6
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 391
EP 400
DI 10.1016/j.ces.2019.05.018
PG 10
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000036
DA 2020-05-12
ER

PT J
AU Maruyama, RT
   Karnal, P
   Sainio, T
   Rajendran, A
AF Maruyama, Rafael Teruo
   Karnal, Preetika
   Sainio, Tuomo
   Rajendran, Arvind
TI Design of bypass-simulated moving bed chromatography for reduced purity
   requirements
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Simulated moving bed chromatography; Reduced purity; Equilibrium theory;
   Sugar separations; Triangle theory
ID BATCH CHROMATOGRAPHY; SEPARATION; OPERATION
AB Bypass-Simulated moving bed (BP-SMB) chromatography, a process characterized by the possibility of over-purifying the raffinate and/or the extract product followed by blending with the feed, is studied. The BP-SMB provides additional degrees of freedom; the opportunity to increase productivity; increased robustness and operational flexibility compared to obtaining reduced purities directly from the SMB. Based on the local-equilibrium theory, explicit equations to calculate productivity are derived for systems following a linear isotherm based on the minimum switch time. It is shown that the BP-SMB offers productivity advantage compared to a reduced-purity SMB specifically at low purity requirements, high selectivity and high efficiency conditions. The effect of column efficiency and feed concentration for systems following non-linear isotherms are studied using numerical simulations. The production of high-fructose corn syrup, an industrial application of BP-SMB, is analysed. For the HFCS separation, it is shown that a BP-SMB operation while not providing any advantages in terms of productivity, provides operational flexibility and robustness. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Maruyama, Rafael Teruo; Rajendran, Arvind] Univ Alberta, Dept Chem & Mat Engn, Donadeo Innovat Ctr Engn ICE, 12th Floor,9211-116 St, Edmonton, AB T6G 1H9, Canada.
   [Karnal, Preetika] Johns Hopkins Univ, Dept Chem & Biomol Engn, 3400 N Charles St, Baltimore, MD 21218 USA.
   [Sainio, Tuomo] LUT Univ, Sch Engn Sci, Yliopistonkatu 34, FI-53850 Lappeenranta, Finland.
RP Rajendran, A (reprint author), Univ Alberta, Dept Chem & Mat Engn, Donadeo Innovat Ctr Engn ICE, 12th Floor,9211-116 St, Edmonton, AB T6G 1H9, Canada.
EM arvind.rajendran@ualberta.ca
OI Sainio, Tuomo/0000-0002-4951-8711
CR Amanullah M, 2006, J CHROMATOGR A, V1107, P36, DOI 10.1016/j.chroma.2005.09.087
   Azevedo DCS, 2001, CHEM ENG J, V82, P95, DOI 10.1016/S1385-8947(00)00359-4
   Azevedo DCS, 2001, AICHE J, V47, P2042, DOI 10.1002/aic.690470915
   Futterer M, 2010, CHEM ENG TECHNOL, V33, P21, DOI 10.1002/ceat.200900319
   Jermann S, 2012, ORG PROCESS RES DEV, V16, P311, DOI 10.1021/op200239e
   Kaspereit M, 2007, J CHROMATOGR A, V1162, P2, DOI 10.1016/j.chroma.2007.02.063
   Katsuo S, 2010, J CHROMATOGR A, V1217, P1354, DOI 10.1016/j.chroma.2009.12.065
   Mazzotti M, 1997, J CHROMATOGR A, V769, P3, DOI 10.1016/S0021-9673(97)00048-4
   Mazzotti M, 2006, J CHROMATOGR A, V1126, P311, DOI 10.1016/j.chroma.2006.06.022
   Mazzotti M, 2013, ANNU REV CHEM BIOMOL, V4, P119, DOI 10.1146/annurev-chembioeng-061312-103318
   Nicoud R-M, 2015, CHROMATOGRAPHIC PROC
   Nicoud RM, 2014, IND ENG CHEM RES, V53, P3755, DOI 10.1021/ie5005866
   Rajendran A, 2008, J CHROMATOGR A, V1185, P216, DOI 10.1016/j.chroma.2008.01.054
   Rajendran A, 2013, CURR OPIN CHEM ENG, V2, P263, DOI 10.1016/j.coche.2013.04.001
   Rajendran A, 2009, J CHROMATOGR A, V1216, P709, DOI 10.1016/j.chroma.2008.10.075
   RHEE HK, 2001, 1 ORDER PARTIAL DIFF, V1
   RUTHVEN DM, 1989, CHEM ENG SCI, V44, P1011, DOI 10.1016/0009-2509(89)87002-2
   Siitonen J, 2013, J CHROMATOGR A, V1286, P55, DOI 10.1016/j.chroma.2013.02.051
   Siitonen J, 2012, J CHROMATOGR A, V1230, P77, DOI 10.1016/j.chroma.2012.01.071
NR 19
TC 1
Z9 1
U1 3
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 401
EP 413
DI 10.1016/j.ces.2019.05.003
PG 13
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000037
DA 2020-05-12
ER

PT J
AU Ma, SH
AF Ma, Shaohua
TI Engineering inverse opals with enclosed voids via Bottom-up assembly of
   double emulsions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Double emulsions; Bottom-up assembly; Inverse opals; Sol-gel transition;
   Microfluidics
ID MESOPOROUS SILICA; PARTICLES; MICROFLUIDICS; NANOPARTICLES; GENERATION;
   COLOR; SHAPE
AB Bottom-up assembly of monodisperse microfluidic droplets is an established route to engineer ordered structures with a periodicity of tens to hundreds of microns. When the microfluidic droplets are oil-in-water-in-oil (o/w/o) double emulsions, inverse opals with enclosed voids are derived by initiating the crosslinking within the shells and across the emulsion interfaces, accompanied by the gradual evaporation of the cores. The morphology and periodicity of the inverse opals are tailored by the emulsion size, the shell thickness, and the sol-gel transition and evaporation dynamics, etc. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Ma, Shaohua] Tsinghua Univ, Tsinghua Berkeley Shenzhen Inst, Shenzhen Engn Lab Precis Med & Healthcare, Shenzhen 518055, Peoples R China.
RP Ma, SH (reprint author), Tsinghua Univ, Tsinghua Berkeley Shenzhen Inst, Shenzhen Engn Lab Precis Med & Healthcare, Shenzhen 518055, Peoples R China.
EM ma.shaohua@sz.tsinghua.edu.cn
RI Ma, Shaohua/O-1097-2018
OI Ma, Shaohua/0000-0002-4995-2032
FU Shenzhen Municipal Development and Reform Commission, Shenzhen
   Engineering Laboratory for Precision Medicine and Healthcare [SDRC
   [2015] 1950]; Tsinghua-Berkeley Shenzhen Institute
FX The work is funded by Shenzhen Municipal Development and Reform
   Commission, Shenzhen Engineering Laboratory for Precision Medicine and
   Healthcare, Grant Number: SDRC [2015] 1950. The work is also funded by
   the scientific research start-up fund of Tsinghua-Berkeley Shenzhen
   Institute.
CR Adams LLA, 2012, SOFT MATTER, V8, P10719, DOI 10.1039/c2sm25953b
   Alsina C, 2015, DOLCIANI MATH EXPO, P27
   Bauer WAC, 2010, LAB CHIP, V10, P1814, DOI 10.1039/c004046k
   Chen Q, 2011, NATURE, V469, P381, DOI 10.1038/nature09713
   Colvin VL, 2001, MRS BULL, V26, P637, DOI 10.1557/mrs2001.159
   Costantini M, 2014, J MATER CHEM B, V2, P2290, DOI 10.1039/c3tb21227k
   Hatton B, 2010, P NATL ACAD SCI USA, V107, P10354, DOI 10.1073/pnas.1000954107
   Holland BT, 1998, SCIENCE, V281, P538, DOI 10.1126/science.281.5376.538
   Hu ZB, 2001, ADV MATER, V13, P1708, DOI 10.1002/1521-4095(200111)13:22<1708::AID-ADMA1708>3.0.CO;2-L
   Imhof A, 1997, NATURE, V389, P948
   Kim SW, 2015, ADV MATER INTERFACES, V2, DOI 10.1002/admi.201500152
   Ko WL, 1965, J CELL PLAST, V1, P45, DOI DOI 10.1177/0021955X6500100107
   Lash MH, 2015, SOFT MATTER, V11, P5597, DOI 10.1039/c5sm00764j
   Li Y, 2012, ADV FUNCT MATER, V22, P4634, DOI 10.1002/adfm.201200591
   Lu J, 2014, NANOSCALE, V6, P10650, DOI 10.1039/c4nr02626h
   Ma SH, 2014, LAB CHIP, V14, P3611, DOI 10.1039/c4lc00671b
   Ma SH, 2012, SMALL, V8, P2356, DOI 10.1002/smll.201102715
   Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0
   Nie ZH, 2005, J AM CHEM SOC, V127, P8058, DOI 10.1021/ja042494w
   Park SY, 2008, NATURE, V451, P553, DOI 10.1038/nature06508
   Pursiainen OLJ, 2008, ADV MATER, V20, P1484, DOI 10.1002/adma.200701363
   Shang LR, 2017, CHEM REV, V117, P7964, DOI 10.1021/acs.chemrev.6b00848
   Theberge AB, 2010, ANGEW CHEM INT EDIT, V49, P5846, DOI 10.1002/anie.200906653
   van Rijt SH, 2015, ACS NANO, V9, P2377, DOI 10.1021/nn5070343
   Vlasov YA, 2001, NATURE, V414, P289, DOI 10.1038/35104529
   Vogel N, 2015, P NATL ACAD SCI USA, V112, P10845, DOI 10.1073/pnas.1506272112
   Wan JD, 2012, LANGMUIR, V28, P37, DOI 10.1021/la203824f
   Wang CC, 2011, BIOMATERIALS, V32, P7118, DOI 10.1016/j.biomaterials.2011.06.018
   Wang W, 2013, ANGEW CHEM INT EDIT, V52, P8084, DOI 10.1002/anie.201301590
   Whitesides GM, 2002, SCIENCE, V295, P2418, DOI 10.1126/science.1070821
   Xia YN, 1998, ANNU REV MATER SCI, V28, P153, DOI 10.1146/annurev.matsci.28.1.153
   Xu SQ, 2005, ANGEW CHEM INT EDIT, V44, P724, DOI 10.1002/anie.200462226
   Xuan MJ, 2015, ADV HEALTHC MATER, V4, P1645, DOI 10.1002/adhm.201500129
   Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548
   Zhao DY, 2000, CHEM MATER, V12, P275, DOI 10.1021/cm9911363
   Zhao YJ, 2012, CHEM SOC REV, V41, P3297, DOI 10.1039/c2cs15267c
   Zhu PA, 2018, SMALL METHODS, V2, DOI 10.1002/smtd.201800017
NR 37
TC 1
Z9 1
U1 10
U2 39
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD SEP 21
PY 2019
VL 205
BP 414
EP 419
DI 10.1016/j.ces.2018.11.027
PG 6
WC Engineering, Chemical
SC Engineering
GA IB5HU
UT WOS:000470303000038
DA 2020-05-12
ER

PT J
AU Bar-Peled, Y
   Huang, JC
   Nunez, IA
   Pierce, SR
   Ecker, JW
   Ross, TM
   Mousa, JJ
AF Bar-Peled, Yael
   Huang, Jiachen
   Nunez, Ivette A.
   Pierce, Spencer R.
   Ecker, Jeffrey W.
   Ross, Ted M.
   Mousa, Jarrod J.
TI Structural and antigenic characterization of a computationally-optimized
   H5 hemagglutinin influenza vaccine
SO VACCINE
LA English
DT Article
DE Influenza; Vaccine; Antibody; Hemagglutinin
ID AVIAN INFLUENZA; ANTIBODY; VIRUS; ELICITS
AB Influenza A virus is a leading cause of death worldwide. Viruses of the H5 subtype have the potential to induce high mortality, and no vaccines are currently available to protect against H5 influenza viruses in the event of an outbreak. Experimental vaccination with one Glade 2 virus does not protect against other subclades. The computationally optimized broadly reactive (COBRA) methodology was previously used to generate a H5 hemagglutinin (HA) antigen (COBRA2) that elicited increased serological breadth against multiple clade 2 H5N1 influenza viruses. In this report, we structurally and antigenically characterized the COBRA2 HA antigen. We examined the biochemical characteristics of the COBRA2 protein and determined the protein is correctly cleaved, properly folded into a trimeric structure, and antigenically correct by probing with HA head- and stem-specific monoclonal antibodies (mAbs). We further probed the antigenicity by examining binding of a panel of H5 mouse mAbs to the COBRA2 antigen, as well as several other HA antigens. We determined the X-ray crystal structure of the COBRA2 HA antigen to 2.8 angstrom and the protein was observed to be in the expected trimeric form. The COBRA2 HA was structurally similar to the naturally occurring H5 HA antigens and suggests the protein folds similar to known HA structures. Overall, our data allow us to formulate a hypothesis on the mechanism of increased breadth due to vaccination with the COBRA2 HA antigen, which is that the protein incorporates antigenic sites from numerous HA antigens, and elicits mAbs with limited breadth, but with diversity in targeted antigenic sites. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bar-Peled, Yael; Huang, Jiachen; Nunez, Ivette A.; Pierce, Spencer R.; Ecker, Jeffrey W.; Ross, Ted M.; Mousa, Jarrod J.] Univ Georgia, Coll Vet Med, Ctr Vaccines & Immunol, Athens, GA 30602 USA.
   [Huang, Jiachen; Nunez, Ivette A.; Ross, Ted M.; Mousa, Jarrod J.] Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA 30602 USA.
RP Mousa, JJ (reprint author), Univ Georgia, Coll Vet Med, Ctr Vaccines & Immunol, Athens, GA 30602 USA.; Mousa, JJ (reprint author), Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA 30602 USA.
EM jarrod.mousa@uga.edu
OI Ross, Ted/0000-0003-1947-7469
FU University of Georgia Office of Vice President for Research; National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [S10_RR25528,
   S10_RR028976, 1K010D026569, 1R01AI14386501]; U.S. Department of Energy,
   Office of Science, Office of Basic Energy SciencesUnited States
   Department of Energy (DOE) [W-31-109-Eng-38]; University of Georgia
   Department of Infectious Diseases; University of Georgia Center for
   Vaccines and Immunology
FX These studies were supported by the University of Georgia Office of Vice
   President for Research, Department of Infectious Diseases, and Center
   for Vaccines and Immunology. X-ray data were collected at the Southeast
   Regional Collaborative Access Team (SER-CAT) 22-ID beamline at the
   Advanced Photon Source, Argonne National Laboratory. SER-CAT is
   supported by its member institutions (see www.ser-cat.org/members.html),
   and equipment grants (S10_RR25528 and S10_RR028976) from the National
   Institutes of Health. Use of the Advanced Photon Source was supported by
   the U.S. Department of Energy, Office of Science, Office of Basic Energy
   Sciences, under Contract No. W-31-109-Eng-38. We are grateful to the
   International Reagent Resource (IRR) for mAbs AT159.246.90,
   AT159.257.173, and AT159.134.119, and the A/Vietnam/1203/04,
   A/Anhui/1/05, and A/Indonesia/5/05 proteins, and to the Biodefense and
   Emerging Infections Research Resources Repository (BEI Resources) for
   the influenza antibody reagents DPJY02, 464E11, 6B4. We thank the CVI
   Antibody Core for use of the OctetRED384 system. The structure factors
   and structure coordinates were deposited to the Protein Data Bank under
   accession code 6NTF. TMR is supported, in part, from the Georgia
   Research Alliance as an Eminent Scholar. JJM is supported by the
   National Institutes of Health grant 1K010D026569 and 1R01AI14386501.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Adlhoch C, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.49.30419
   Allen JD, 2017, VACCINE, V35, P5209, DOI 10.1016/j.vaccine.2017.07.107
   [Anonymous], 2011, WKLY EPIDEMIOL REC, P93
   Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8
   Carter DM, 2016, J VIROL, V90, P4720, DOI 10.1128/JVI.03152-15
   Chen LM, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000072
   Crevar CJ, 2015, HUM VACC IMMUNOTHER, V11, P572, DOI 10.1080/21645515.2015.1012013
   Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Erbelding EJ, 2018, J INFECT DIS, V218, P347, DOI 10.1093/infdis/jiy103
   Evans PR, 2013, ACTA CRYSTALLOGR D, V69, P1204, DOI 10.1107/S0907444913000061
   Giles BM, 2012, CLIN VACCINE IMMUNOL, V19, P128, DOI 10.1128/CVI.05533-11
   Giles BM, 2011, VACCINE, V29, P3043, DOI 10.1016/j.vaccine.2011.01.100
   Girard MP, 2010, VACCINE, V28, P4895, DOI [10.1016/j.vaccine.2010.05.031, 10.1016/j.vaccine.2010.07.034]
   Herfst S, 2012, SCIENCE, V336, P1534, DOI 10.1126/science.1213362
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Kallewaard NL, 2016, CELL, V166, P596, DOI 10.1016/j.cell.2016.05.073
   Kirchenbaum GA, 2017, J IMMUNOL, V199, P3798, DOI 10.4049/jimmunol.1701174
   Koudstaal W, 2009, J INFECT DIS, V200, P1870, DOI 10.1086/648378
   Lee EK, 2017, INFECT GENET EVOL, V51, P21, DOI 10.1016/j.meegid.2017.03.005
   Maciola AK, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00444
   Mulatti P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36892-1
   Peiris JSM, 2016, LANCET INFECT DIS, V16, P252, DOI 10.1016/S1473-3099(15)00502-2
   Saunders-Hastings PR, 2016, PATHOGENS, V5, DOI 10.3390/pathogens5040066
   Sautto Giuseppe A, 2018, Immunohorizons, V2, P226, DOI 10.4049/immunohorizons.1800044
   Shore DA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075209
   Stevens J, 2006, SCIENCE, V312, P404, DOI 10.1126/science.1124513
   Takahashi K, 2017, J VET SCI, V18, P269, DOI [10.1252/jcej.13we358, DOI 10.1252/JCEJ.13WE358]
   Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979
   Wells SJ, 2017, AVIAN DIS, V61, P198, DOI 10.1637/11543-112816-Reg.1
   Whittle JRR, 2014, J VIROL, V88, P4047, DOI 10.1128/JVI.03422-13
   WHO, 2015, CUM NUMB CONF HUM CA, DOI [10.1016/j.archoralbio.2009.02.002, DOI 10.1016/J.ARCHORALBIO.2009.02.002]
   WHO, 2015, WKLY EPIDEMIOL REC, V90, P261, DOI [10.1111/irv.12324/epdf, DOI 10.1111/IRV.12324/EPDF]
   Winarski KL, 2015, P NATL ACAD SCI USA, V112, P9346, DOI 10.1073/pnas.1502762112
   Xiong XL, 2015, P NATL ACAD SCI USA, V112, P9430, DOI 10.1073/pnas.1510816112
   Xiong XL, 2013, NATURE, V497, P392, DOI 10.1038/nature12144
   Zhang W, 2013, SCIENCE, V340, P1463, DOI 10.1126/science.1236787
   Zuo T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9855
NR 39
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 24
PY 2019
VL 37
IS 41
BP 6022
EP 6029
DI 10.1016/j.vaccine.2019.08.062
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA1HT
UT WOS:000487568800002
PM 31481254
OA Bronze
DA 2020-05-12
ER

PT J
AU Lim, ASE
   Lim, RBT
AF Lim, Andrea Su En
   Lim, Raymond Boon Tar
TI Facilitators and barriers of human papillomavirus vaccine uptake in
   young females 18-26 years old in Singapore: A qualitative study
SO VACCINE
LA English
DT Article
DE Human papillomavirus; Vaccine; Barriers; Facilitators; Qualitative
   research
ID LONG-TERM; HPV 16/18; WOMEN; PREVALENCE; REDUCTION; KNOWLEDGE; SAFETY;
   ADOLESCENTS; ATTITUDES; COVERAGE
AB Background: Around 70% of cervical cancers are caused by Types 16 and 18 of human papillomavirus (HPV). Vaccines against HPV have been shown to be safe and effective in preventing HPV and cervical cancer.
   Objective: To explore the facilitators and barriers of HPV vaccination in young females aged 18-26 years in Singapore, and to describe their recommended strategies to improve the uptake of HPV vaccination.
   Design: Qualitative, descriptive design guided by the socio-ecological model.
   Participants: Young women studying in National University of Singapore (NUS), aged 18-26 (N = 40). Purposive sampling was used to recruit participants from various socio-economic levels and faculties, both vaccinated against HPV and unvaccinated.
   Methods: In-depth interviews (IDIs) and focus group discussions (FGDs) were conducted with the participants. IDIs and FGDs were transcribed and coded using NVIVO software. Thematic data analysis was performed using an inductive approach.
   Results: Barriers to HPV vaccination included lack of awareness, lack of perceived risk for cervical cancer, cost, lack of parental support, inconvenience of getting the vaccination, stigma associated with connection with sexual activity, and concern regarding safety. Facilitators include parental encouragement, protection of one's health, lack of logistical barriers, and perceived safety and efficacy of the vaccine. Participants recommended increasing awareness of HPV vaccination and cervical cancer, reducing cost of vaccination and making the vaccine compulsory to increase vaccine uptake.
   Conclusion: Barriers and facilitators exist at different levels to influence vaccine uptake. Public education on cervical cancer and the vaccine should be stepped up to increase public awareness. A school-based national vaccination programme was proposed by the target group to increase the rate of uptake of HPV vaccination in Singapore. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lim, Andrea Su En] Natl Univ Hlth Syst, Prevent Med Resident, 1E Kent Ridge Rd, Singapore 119228, Singapore.
   [Lim, Raymond Boon Tar] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, 12 Sci Dr 2,10-01, Singapore 117549, Singapore.
RP Lim, ASE (reprint author), Natl Univ Hlth Syst, Prevent Med Resident, 1E Kent Ridge Rd, Singapore 119228, Singapore.
EM andrea_lim@nuhs.edu.sg
FU Saw Swee Hock School of Public Health, National University of Singapore,
   Singapore
FX Participant reimbursement came from the Masters of Public Health course
   practicum project funding provided by the Saw Swee Hock School of Public
   Health, National University of Singapore, Singapore.
CR [Anonymous], 2016, TODAY ONLINE    1130
   Baker JA, 2019, CHANNEL NEWS ASIA
   BEAVIS A, 2017, GYNECOL ONCOL, V145, P4, DOI DOI 10.1016/J.YGYNO.2017.03.032
   Benard VB, JAMA ONCOL
   Bergquist S, 2016, PUBLIC HEALTH REP, V131, P17
   Bruni L, 2016, LANCET GLOB HEALTH, V4, pE453, DOI 10.1016/S2214-109X(16)30099-7
   Buang SN, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4602
   Chan ZCY, 2012, PUBLIC HEALTH NURS, V29, P481, DOI 10.1111/j.1525-1446.2012.01022.x
   de Martel C, 2017, INT J CANCER, V141, P664, DOI 10.1002/ijc.30716
   De Vincenzo R, 2014, IN J WOMENS HEALTH, V6, P999, DOI 10.2147/IJWH.S50365
   Department of Health, HUM PAP VACC
   Ferrer HB, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-700
   Ferris D, 2014, PEDIATRICS, V134, pE657, DOI 10.1542/peds.2013-4144
   Garland SM, 2016, CLIN INFECT DIS, V63, P519, DOI 10.1093/cid/ciw354
   Harder T, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1098-3
   Health Promotion Board Singapore, FACT SHEET NAT SCH B
   Holman DM, 2014, JAMA PEDIATR, V168, P76, DOI 10.1001/jamapediatrics.2013.2752
   Hong Kong Cancer Registry, OV HONG KONG CANC ST
   Hopfer S, 2011, QUAL HEALTH RES, V21, P262, DOI 10.1177/1049732310383868
   Kavanagh K, 2014, BRIT J CANCER, V110, P2804, DOI 10.1038/bjc.2014.198
   Klein NP, 2012, ARCH PEDIAT ADOL MED, V166, P1140, DOI 10.1001/archpediatrics.2012.1451
   Kmietowicz Z, 2018, BMJ-BRIT MED J, V24
   Lee VJ, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-203
   Loke AY, 2017, J PRIM CARE COMMUNIT, V8, P349, DOI 10.1177/2150131917742299
   Lu BB, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-13
   Macartney KK, 2013, DRUG SAFETY, V36, P393, DOI 10.1007/s40264-013-0039-5
   Markowitz LE, 2013, J INFECT DIS, V208, P385, DOI 10.1093/infdis/jit192
   MCLEROY KR, 1988, HEALTH EDUC QUART, V15, P351, DOI 10.1177/109019818801500401
   Mesher D, 2013, VACCINE, V32, P26, DOI 10.1016/j.vaccine.2013.10.085
   Ministry of Health Singapore, PARL Q A HPV 11 MAY
   Ministry of Health Singapore Health Promotion Board Singapore, HEALTHHUB FAQS HPV H
   Mortensen GL, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-68
   National Registry of Diseases Office, SING CANC REG ANN RE
   Patel C, 2018, EUROSURVEILLANCE, V23, P30, DOI 10.2807/1560-7917.ES.2018.23.41.1700737
   Public Health England, HUM PAP HPV VACC COV
   Rambout L, 2014, PREV MED, V58, P22, DOI 10.1016/j.ypmed.2013.10.009
   Santhanes D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21912-x
   Schiller JT, 2012, VACCINE, V30, pF123, DOI 10.1016/j.vaccine.2012.04.108
   Siu JYM, 2013, CULT HEALTH SEX, V15, P1071, DOI 10.1080/13691058.2013.807518
   Tan M, 2017, J DERMATOL SCI, V86, pe1
   Tay S K, 2015, Asian Pac J Cancer Prev, V16, P5119
   Tay SK, 2018, SINGAP MED J, V59, P370, DOI 10.11622/smedj.2017085
   Teitelman AM, 2011, JOGNN-J OBST GYN NEO, V40, P691, DOI 10.1111/j.1552-6909.2011.01297.x
   Ueda Y, 2015, AM J OBSTET GYNECOL, V212, P405, DOI 10.1016/j.ajog.2014.11.037
   Van Den Brink T, EFFECTS MODERNIZATIO
   Vichnin M, 2015, PEDIATR INFECT DIS J, V34, P983, DOI 10.1097/INF.0000000000000793
   Waller J, 2013, PREV MED, V56, P35, DOI 10.1016/j.ypmed.2012.10.028
   World Health Organization, HUM PAP HPV CERV CAN
   World Hlth Org, 2017, VACCINE, V35, P5753, DOI 10.1016/j.vaccine.2017.05.069
   Zhuang QY, 2016, SINGAP MED J, V57, P329, DOI 10.11622/smedj.2016108
NR 50
TC 0
Z9 0
U1 2
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 24
PY 2019
VL 37
IS 41
BP 6030
EP 6038
DI 10.1016/j.vaccine.2019.08.053
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA1HT
UT WOS:000487568800003
PM 31473002
DA 2020-05-12
ER

PT J
AU Zimmermann, M
   Frey, K
   Hagedorn, B
   Oteri, AJ
   Yahya, A
   Hamisu, M
   Mogekwu, F
   Shuaib, F
   McCarthy, KA
   Chabot-Couture, G
AF Zimmermann, Marita
   Frey, Kurt
   Hagedorn, Brittany
   Oteri, A. J.
   Yahya, Abdulazeez
   Hamisu, Maimuna
   Mogekwu, Fred
   Shuaib, Faisal
   McCarthy, Kevin A.
   Chabot-Couture, Guillaume
TI Optimization of frequency and targeting of measles supplemental
   immunization activities in Nigeria: A cost-effectiveness analysis
SO VACCINE
LA English
DT Article
DE Cost-effectiveness; Measles; Routine immunization; Sub-national;
   Supplemental immunization activities
ID PERFORMANCE; STRATEGIES; IMPACT
AB Background: Measles causes significant childhood morbidity in Nigeria. Routine immunization (RI) coverage is around 40% country-wide, with very high levels of spatial heterogeneity (3-86%), with supplemental immunization activities (SIAs) at 2-year or 3-year intervals. We investigated cost savings and burden reduction that could be achieved by adjusting the inter-campaign interval by region.
   Methods: We modeled 81 scenarios; permuting SIA calendars of every one, two, or three years in each of four regions of Nigeria (North-west, North-central, North-east, and South). We used an agent-based disease transmission model to estimate the number of measles cases and ingredients-based cost models to estimate RI and SIA costs for each scenario over a 10 year period.
   Results: Decreasing SIAs to every three years in the North-central and South (regions of above national average RI coverage) while increasing to every year in either the North-east or North-west (regions of below national-average RI coverage) would avert measles cases (0.4 or 1.4 million, respectively), and save vaccination costs (save $19.4 or $5.4 million, respectively), compared to a base-case of national SIAs every two years. Decreasing SIA frequency to every three years in the South while increasing to every year in the just the North-west, or in all Northern regions would prevent more cases (2.1 or 5.0 million, respectively), but would increase vaccination costs (add $3.5 million or $34.6 million, respectively), for $1.65 or $6.99 per case averted, respectively.
   Conclusions: Our modeling shows how increasing SIA frequency in Northern regions, where RI is low and birth rates are high, while decreasing frequency in the South of Nigeria would reduce the number of measles cases with relatively little or no increase in vaccination costs. A national vaccination strategy that incorporates regional SIA targeting in contexts with a high level of sub-national variation would lead to improved health outcomes and/or lower costs. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Zimmermann, Marita; Frey, Kurt; Hagedorn, Brittany; McCarthy, Kevin A.; Chabot-Couture, Guillaume] Inst Dis Modeling, 3150 139th Ave SE, Bellevue, WA 98005 USA.
   [Oteri, A. J.; Yahya, Abdulazeez; Hamisu, Maimuna; Mogekwu, Fred; Shuaib, Faisal] Natl Primary Hlth Care Dev Agcy, 681-682 Port Harcourt Cresent,Area 11 Garki, Abuja, Fct, Nigeria.
RP Zimmermann, M (reprint author), Inst Dis Modeling, 3150 139th Ave SE, Bellevue, WA 98005 USA.
EM mzimmermann@idmod.org
RI Frey, Kurt/G-6968-2014
OI Frey, Kurt/0000-0002-3383-2730; McCarthy, Kevin/0000-0002-9148-8448
FU Global Good Fund, Seattle, WA, USA
FX This work was funded by Bill and Melinda Gates through the Global Good
   Fund, Seattle, WA, USA.
CR Aisha Nnamani, 2017, FEDERAL CIVIL SERVIC
   Bershteyn A, 2018, PATHOG DIS, V76, P1, DOI [10.1093/femsod/fty059, DOI 10.1093/FEMSOD/FTY059]
   Centers for Disease Control and Prevention, 2015, EPIDEMIOLOGY PREVENT
   Das Gupta M, 2003, DECENTRALIZED DELIVE
   Dayan GH, 2004, VACCINE, V22, P475, DOI 10.1016/j.vaccine.2003.07.007
   Gandhi G, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-67
   Gberevbie DE, 2010, AFR J BUS MANAGE, V4, P1447
   Geng F, 2017, HEALTH POLICY PLANN, V32, P1174, DOI 10.1093/heapol/czx067
   Heaton A, 2017, VACCINE, V35, P2272, DOI 10.1016/j.vaccine.2016.11.066
   Institute for Health Metrics and Evaluation, GBD RES
   Kaucley L, 2015, COST EFFECT RESOUR A, V13, DOI 10.1186/s12962-015-0039-7
   Mckee A, 2018, EPIDEMIOL INFECT, V146, P468, DOI 10.1017/S0950268817003077
   Moss WJ, 2006, NAT REV MICROBIOL, V4, P900, DOI 10.1038/nrmicro1550
   Moss WJ, 2017, LANCET, V390, P2490, DOI 10.1016/S0140-6736(17)31463-0
   National Comprehensive Cancer Network, 2018, NCCN CLIN PRACT GUID, V2018, P1, DOI [DOI 10.1016/J.AMJMED.2006.02.031, 10.1016/j.amjmed.2006.02.031]
   National Population Commission (Nigeria) and ICF International, 2014, NIG DEM HLTH SURV 20
   National Salaries Incomes and Wages Commission-Office of the Executive Chairman, 2009, CONS HLTH SAL STRUCT
   Ojo K, 2011, CHECOD WORKING PAPER
   Oku A, 2017, PLOS ONE, V12, DOI [10.1371/journal.pone.0186733e0186733, DOI 10.1371/JOURNAL.PONE.0186733E0186733]
   Parmar D, 2010, HUM VACCINES, V6, P270, DOI 10.4161/hv.6.3.10397
   PayScale, SAL SURV SAL WAG COM
   Portnoy A, 2019, LANCET GLOB HEALTH, V7, pE472, DOI 10.1016/S2214-109X(18)30537-0
   Portnoy A, 2018, VACCINE, V36, P170, DOI 10.1016/j.vaccine.2017.10.080
   Ryman TK, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-134
   Saleh AJ, 2016, SAHEL MED J, V19, P5, DOI DOI 10.4103/1118-8561.181887
   Thorrington D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105153
   UNICEF, VACC PRIC DAT SUPPL
   UNICEF, AUT AD REUS PREV RUP
   Utazi CE, 2018, VACCINE, V36, P1583, DOI 10.1016/j.vaccine.2018.02.020
   Weldegebriel GG, 2011, J INFECT DIS S1, V204, P2005
   WHO, 2012, PREL DOS EST NUCL AC, P1
   Wolfson LJ, 2009, INT J EPIDEMIOL, V38, P192, DOI 10.1093/ije/dyn224
   World Health Organization, 2018, MEASL
   World Health Organization, 2017, WEEKL EP REC MEASL V
NR 34
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 24
PY 2019
VL 37
IS 41
BP 6039
EP 6047
DI 10.1016/j.vaccine.2019.08.050
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA1HT
UT WOS:000487568800004
PM 31471147
OA Other Gold
DA 2020-05-12
ER

PT J
AU Fathima, P
   Snelling, TL
   Gibbs, RA
AF Fathima, Parveen
   Snelling, Thomas L.
   Gibbs, Robyn A.
TI Effectiveness of rotavirus vaccines in an Australian population: A
   case-control study
SO VACCINE
LA English
DT Article
DE Rotavirus; Rotavirus vaccines; Vaccine effectiveness; Case-control;
   Notification data
ID ACUTE GASTROENTERITIS; YOUNG-CHILDREN; HOSPITALIZATIONS; PENTAVALENT;
   VACCINATION; MONOVALENT; EFFICACY; DIARRHEA; BURDEN; PREVENTION
AB Objective: Two rotavirus vaccines (RV1 and RV5) were included in the publicly funded National Immunisation Program in Australia from July 2007. The programme in Western Australia initially provided RV1 (at ages 2 and 4 months) and then switched to RV5 (at ages 2,4 and 6 months) from July 2009. This retrospective case-control study was conducted to assess the effectiveness of rotavirus vaccine against laboratory confirmed and notified cases of rotavirus infection among children aged <5 years.
   Methods: Case-subjects were identified as vaccine-eligible children (born from 1 May 2007) who were notified as having rotavirus infection during the period 2009-2011. The control group was vaccine eligible children notified as having Campylobacter or Salmonella infection during the same period. Individual rotavirus immunisation status was ascertained from a population-based immunisation register. Full-dose and partial-dose vaccine effectiveness (VE) were calculated for both vaccines using the adjusted odds ratio (OR) of vaccination for cases versus controls (VE = (1 - OR)*100%).
   Results: Overall, 282 cases and 883 controls were included. The adjusted VE for a full course of either rotavirus vaccine was 72% (95% CI: 56-82) and 71% (95% CI: 50-84) for partial vaccination (one dose of RV1 or one/two doses of RV5). The VE for a complete 3-dose course of RV5 was 82% (95% CI: 59-92) and for a full 2-dose course of RV1 was 73% (95% CI: 55-83).
   Conclusions: RV1 and RV5 were both effective in preventing laboratory confirmed and notified rotavirus infections among children aged <5 years. Even incomplete courses of vaccination conferred good protection. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fathima, Parveen] Univ Western Australia, Sch Populat & Global Hlth, Nedlands, WA 6009, Australia.
   [Fathima, Parveen; Snelling, Thomas L.] Univ Western Australia, Telethon Kids Inst, Wesfarmers Ctr Vaccines & Infect Dis, POB 855, Perth, WA 6872, Australia.
   [Snelling, Thomas L.] Perth Childrens Hosp, Dept Infect Dis, Locked Bag 2010, Nedlands, WA 6909, Australia.
   [Snelling, Thomas L.] Menzies Sch Hlth Res, POB 41096, Casuarina, NT 0811, Australia.
   [Snelling, Thomas L.] Charles Darwin Univ, POB 41096, Casuarina, NT 0811, Australia.
   [Snelling, Thomas L.] Curtin Univ, Sch Publ Hlth, GPO Box U1987, Perth, WA 6845, Australia.
   [Gibbs, Robyn A.] Dept Hlth, Perth Business Ctr, Communicable Dis Control Directorate, POB 8172, Perth, WA 6849, Australia.
RP Fathima, P (reprint author), Perth Childrens Hosp, Telethon Kids Inst, Wesfarmers Ctr Vaccines & Infect Dis, 15 Hosp Ave, Perth, WA 6008, Australia.
EM parveen.fathima@telethonkids.org.au; tom.snelling@telethonkids.org.au;
   robyn.gibbs@health.wa.gov.au
OI Snelling, Thomas/0000-0003-4670-0638
FU University of Western Australia International Postgraduate Award; NHMRC
   Career Development FellowshipNational Health and Medical Research
   Council of Australia [1111657]
FX PF was supported by a University of Western Australia International
   Postgraduate Award. TLS is supported by a NHMRC Career Development
   Fellowship (1111657). The funding bodies had no part in the design,
   conduct, analysis or interpretation of this study
CR ABS, 2006, POP DISTR AB TORR ST
   [Anonymous], 2013, AUSTR IMM HDB
   Armah GE, 2010, LANCET, V376, P606, DOI 10.1016/S0140-6736(10)60889-6
   Buttery JP, 2011, PEDIATR INFECT DIS J, V30, pS25, DOI 10.1097/INF.0b013e3181fefdee
   Carlin JB, 1998, MED J AUSTRALIA, V169, P252, DOI 10.5694/j.1326-5377.1998.tb140248.x
   Castilla J, 2012, VACCINE, V30, P539, DOI 10.1016/j.vaccine.2011.11.071
   CDCD, 2002, DIS WATCH W AUSTR CO
   Clarke MF, 2011, VACCINE, V29, P4663, DOI 10.1016/j.vaccine.2011.04.109
   Correia JB, 2010, J INFECT DIS, V201, P363, DOI 10.1086/649843
   Cortese MM, 2013, PEDIATRICS, V132, pE25, DOI 10.1542/peds.2012-3804
   Dennehy PH, 2008, CLIN MICROBIOL REV, V21, P198, DOI 10.1128/CMR.00029-07
   Dey A, 2012, MED J AUSTRALIA, V197, P453, DOI 10.5694/mja12.10062
   Field EJ, 2010, PEDIATRICS, V126, pE506, DOI 10.1542/peds.2010-0443
   Galati JC, 2006, AUST NZ J PUBL HEAL, V30, P416, DOI 10.1111/j.1467-842X.2006.tb00456.x
   Giaquinto C, 2011, HUM VACCINES, V7, P734, DOI 10.4161/hv.7.7.15511
   Hull B, 2011, COMMUN DIS INTELL, V37, P22
   Izzo MM, 2012, AUST VET J, V90, P122, DOI 10.1111/j.1751-0813.2011.00891.x
   Kirkwood CD, 2011, COMMUN DIS INTELL, V35, P281
   Kirkwood CD, 2011, PEDIATR INFECT DIS J, V30, pS48, DOI 10.1097/INF.0b013e3181fefd90
   Leshem E, 2014, LANCET INFECT DIS, V14, P847, DOI 10.1016/S1473-3099(14)70832-1
   Macartney KK, 2011, J PAEDIATR CHILD H, V47, P266, DOI 10.1111/j.1440-1754.2010.01953.x
   Muhsen K, 2010, HUM VACCINES, V6, P450, DOI 10.4161/hv.6.6.11759
   NCIRS, 2009, RES SURVEILL FACTSH
   Newall AT, 2006, J PAEDIATR CHILD H, V42, P521, DOI 10.1111/j.1440-1754.2006.00915.x
   O'Ryan M, 2011, EXPERT REV VACCINES, V10, P1645, DOI [10.1586/erv.11.152, 10.1586/ERV.11.152]
   ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055
   Parashar UD, 2003, EMERG INFECT DIS, V9, P565, DOI 10.3201/eid0905.020562
   Payne DC, 2013, CLIN INFECT DIS, V57, P13, DOI 10.1093/cid/cit164
   Pendleton A, 2013, HUM VACCIN IMMUNOTHE, V9
   Phua KB, 2012, VACCINE, V30, P4552, DOI 10.1016/j.vaccine.2012.03.030
   Ruiz-Palacios GM, 2006, NEW ENGL J MED, V354, P11, DOI 10.1056/NEJMoa052434
   Snelling TL, 2011, CLIN INFECT DIS, V52, P191, DOI 10.1093/cid/ciq101
   Tate JE, 2016, CLIN INFECT DIS, V62, pS106, DOI 10.1093/cid/civ1014
   Tate JE, 2012, LANCET INFECT DIS, V12, P136, DOI 10.1016/S1473-3099(11)70253-5
   Vesikari T, 2006, NEW ENGL J MED, V354, P23, DOI 10.1056/NEJMoa052664
   Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6
   Walker CLF, 2011, BMC PUBL HLTH, V11
   WHO, 2009, WKLY EPIDEMIOL REC, V2009, P213
   WHO, 2009, WKLY EPIDEMIOL REC, V84, P517
   Zeller M, 2010, VACCINE, V28, P7507, DOI 10.1016/j.vaccine.2010.09.004
NR 40
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 24
PY 2019
VL 37
IS 41
BP 6048
EP 6053
DI 10.1016/j.vaccine.2019.08.047
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA1HT
UT WOS:000487568800005
PM 31473003
DA 2020-05-12
ER

PT J
AU Doraivelu, K
   Boulet, SL
   Biswas, HH
   Adams, JC
   Haddad, LB
   Jamieson, DJ
AF Doraivelu, Kamini
   Boulet, Sheree L.
   Biswas, Hope H.
   Adams, Jenna C.
   Haddad, Lisa B.
   Jamieson, Denise J.
TI Predictors of tetanus, diphtheria, acellular pertussis and influenza
   vaccination during pregnancy among full-term deliveries in a medically
   underserved population
SO VACCINE
LA English
DT Article
DE Antenatal vaccination predictors; Tdap; Influenza vaccination
ID SEASONAL INFLUENZA; UNITED-STATES; PRENATAL-CARE; FLU VACCINE; WOMEN;
   DISPARITIES; ATTITUDES; COVERAGE; ACCESS; IMPACT
AB Objective: To evaluate predictors of vaccination among women who received tetanus, diphtheria, and acellular pertussis vaccination (Tdap), influenza vaccination, and Tdap and influenza vaccinations.
   Study Design: In a retrospective cohort study of all full-term (>= 37 weeks gestation) deliveries between July 1, 2016 and June 30, 2018 at a single, safety-net institution, we used multinomial logistic regression models to compare predictors of vaccination among women who received Tdap only, influenza only, and both Tdap and influenza vaccines.
   Results: Among 3132 full-term deliveries, women were primarily non-Hispanic black (67.5%), between the ages of 21-34 (65.3%), and multiparous (76.0%). The rates of only influenza or Tdap vaccination were 10.3% and 21.6%, respectively; 43.3% of women received both vaccines, and 24.9% of women did not receive either vaccine. In the adjusted models, Hispanic ethnicity was positively associated with receipt of all types of vaccination and non-Spanish language interpreter use was positively associated with receipt of Tdap vaccination and Tdap and influenza vaccination. A parity of greater than three and inadequate and unknown prenatal care adequacy were negative predictors of all types of vaccination. Pre-existing hypertension was negatively associated with Tdap vaccination, and HIV-positive status was negatively associated with influenza vaccination and Tdap and influenza vaccination.
   Conclusion: Compared to the national rate of both Tdap and influenza vaccination (32.8%), a higher proportion of women received both vaccines in our study population. Vaccine uptake may be affected by race/ethnicity, use of interpreter services, parity, pre-existing comorbidities, and prenatal care adequacy. The lower rate of influenza vaccination compared to Tdap vaccination suggests that other factors, such as vaccine hesitancy and mistrust, may be differentially impacting influenza vaccination uptake in our predominantly minority population. Future provider and public health approaches to vaccine promotion should incorporate culturally appropriate strategies that address vaccine-related beliefs and misconceptions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Doraivelu, Kamini] Emory Univ, Rollins Sch Publ Hlth, 1518 Clifton Rd, Atlanta, GA 30322 USA.
   [Boulet, Sheree L.; Biswas, Hope H.; Haddad, Lisa B.; Jamieson, Denise J.] Emory Univ, Sch Med, Dept Gynecol & Obstet, 69 Jesse Hill Jr Dr SE, Atlanta, GA 30303 USA.
   [Adams, Jenna C.] Emory Univ, Sch Med, 201 Dowman Dr, Atlanta, GA 30322 USA.
RP Jamieson, DJ (reprint author), Emory Univ, Sch Med, Dept Gynecol & Obstet, 69 Jesse Hill Jr Dr SE, Atlanta, GA 30303 USA.
EM djamieson@emory.edu
OI Jamieson, Denise/0000-0003-2597-1201
CR Barber A, 2017, MMWR-MORBID MORTAL W, V66, P56, DOI 10.15585/mmwr.mm6602a4
   Bethancourt CN, 2017, CURR OPIN PEDIATR, V29, P737, DOI 10.1097/MOP.0000000000000553
   Callaghan WM, 2010, OBSTET GYNECOL, V115, P919, DOI 10.1097/AOG.0b013e3181d99d85
   Carlisle N, 2019, MIDWIFERY, V72, P67, DOI 10.1016/j.midw.2019.02.008
   Centers for Disease Control and Prevention, 2016, MAT VACC COV PREGN V
   Chamberlain AT, 2015, PLOS CURR, P7
   Cook CAL, 1999, SOC WORK, V44, P129
   Ding H, 2017, PREGNANT WOMEN INFLU
   Dlugacz Y, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2011.12.027
   Dodds L, 2007, CAN MED ASSOC J, V176, P463, DOI 10.1503/cmaj.061435
   Fiore Anthony E., 2010, Morbidity and Mortality Weekly Report, V59, P1
   Freimuth VS, 2017, SOC SCI MED, V193, P70, DOI 10.1016/j.socscimed.2017.10.001
   Goldfarb IT, 2014, AM J OBSTET GYNECOL, V211, DOI 10.1016/j.ajog.2014.05.029
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Healy CM, 2016, HUM VACC IMMUNOTHER, V12, P1972, DOI 10.1080/21645515.2016.1171948
   Healy CM, 2015, VACCINE, V33, P4983, DOI 10.1016/j.vaccine.2015.07.018
   Heaman MI, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0431-5
   Henninger M, 2013, OBSTET GYNECOL, V121, P741, DOI 10.1097/AOG.0b013e3182878a5a
   Hofstetter AM, 2017, VACCINE, V35, P2709, DOI 10.1016/j.vaccine.2017.03.077
   Housey M, 2014, MMWR-MORBID MORTAL W, V63, P839
   Hutcheon JA, 2013, EPIDEMIOLOGY, V24, P787, DOI 10.1097/EDE.0b013e3182a6d9aa
   Influenza vaccination during pregnancy, 2014, OBSTET GYNECOL, V124, P648, DOI DOI 10.1097/01.AOG.0000453599.11566.11
   Jamieson DJ, 2006, EMERG INFECT DIS, V12, P1638, DOI 10.3201/eid1211.060152
   Jamieson DJ, 2018, OBSTET GYNECOL, V131, P1145, DOI 10.1097/AOG.0000000000002638
   Jamieson DJ, 2009, LANCET, V374, P451, DOI 10.1016/S0140-6736(09)61304-0
   Ju Mindy, 2017, Hosp Pediatr, V7, P1, DOI 10.1542/hpeds.2016-0069
   Kerr S, 2017, MMWR-MORBID MORTAL W, V66, P1105, DOI 10.15585/mmwr.mm6641a3
   Kim EJ, 2017, J GEN INTERN MED, V32, P632, DOI 10.1007/s11606-017-3999-9
   Koerner J, 2018, ANN PHARMACOTHER, V52, P655, DOI 10.1177/1060028018755454
   KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1486, DOI 10.2105/AJPH.84.9.1486
   Lindley MC, 2006, AM J PREV MED, V31, P281, DOI 10.1016/j.amepre.2006.06.025
   Lutz CS, 2018, VACCINE, V36, P7445, DOI 10.1016/j.vaccine.2018.10.046
   Meijer WJ, 2015, ACTA OBSTET GYN SCAN, V94, P797, DOI 10.1111/aogs.12680
   Morgan JL, 2015, OBSTET GYNECOL, V125, P1433, DOI 10.1097/AOG.0000000000000862
   Neuzil KM, 1998, AM J EPIDEMIOL, V148, P1094, DOI 10.1093/oxfordjournals.aje.a009587
   O'Halloran AC, 2016, AM J INFECT CONTROL, V44, P786, DOI 10.1016/j.ajic.2016.03.048
   O'Leary ST, 2019, OBSTET GYNECOL, V133, P40, DOI 10.1097/AOG.0000000000003005
   Payakachat N, 2016, VACCINE, V34, P179, DOI 10.1016/j.vaccine.2015.09.062
   Quinn SC, 2017, VACCINE, V35, P1167, DOI 10.1016/j.vaccine.2016.12.046
   Shi LY, 2009, ETHNIC HEALTH, V14, P625, DOI 10.1080/13557850903248639
   Wilcox CR, 2018, VACCINE, V36, P7625, DOI 10.1016/j.vaccine.2018.10.092
   Wong CY, 2015, HUM VACC IMMUNOTHER, V11, P1165, DOI 10.1080/21645515.2015.1019188
   Wong VWY, 2016, VACCINE, V34, P5243, DOI 10.1016/j.vaccine.2016.09.019
NR 43
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 24
PY 2019
VL 37
IS 41
BP 6054
EP 6059
DI 10.1016/j.vaccine.2019.08.044
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA1HT
UT WOS:000487568800006
PM 31471152
DA 2020-05-12
ER

PT J
AU Zhao, RQ
   Yu, PC
   Shan, Y
   Thirumeni, N
   Li, MH
   Lv, YL
   Li, JL
   Ren, WL
   Huang, LS
   Wei, JS
   Sun, YF
   Zhu, WY
   Sun, L
AF Zhao, Rongqing
   Yu, Pengcheng
   Shan, Yi
   Thirumeni, Nagarajan
   Li, Maohua
   Lv, Yanli
   Li, Jianli
   Ren, Wenlin
   Huang, Lisong
   Wei, Jingshuang
   Sun, Yufei
   Zhu, Wuyang
   Sun, Le
TI Rabies virus glycoprotein serology ELISA for measurement of neutralizing
   antibodies in sera of vaccinated human subjects
SO VACCINE
LA English
DT Article
DE Rabies Virus (RABV); Virus neutralizing antibody (VNA); Glycoprotein
   (GP); ELISA
ID HUMAN MONOCLONAL-ANTIBODIES; PUBLIC VETERINARY-MEDICINE; PROTECTION;
   HEALTH
AB Background: Vaccination provides protection against infection by inducing VNAs mainly against RABV surface GP. The measurement of VNAs to RABV is commonly used to assess the level of immunity in humans and animals after vaccination. A VNA titer of >= 0.5 IU/mL of sera indicates adequate response to vaccination. Here, we report the development and validation of a RABV GP serology ELISA kit for semi-quantitative measurement of VNA titers in sera of vaccinated human subjects.
   Methods: Using a recombinant RABV GP expressed in mammalian cells as the capture antigen, the ELISA method was established using HuMAb NM57 reference initially and HRIG reference subsequently. The limit of detection (LOD), linear range, reproducibility, and precision of the method were examined. Specificity and sensitivity were established to assess the diagnostic accuracy.
   Results: RABV GP for ELISA plate coating and optimal dilution of human serum sample was 1 mu g/mL and 1:20, respectively. Multiple assays were carried out by different technicians at different laboratories for assay standardization. Using the HRIG reference, the LOD was found to be 0.02-0.06 IU/mL and the linear range was 0.2-10.0 IU/mL. The inter-assay CVs were in the range of 6.60-10.79%, indicating the reproducibility. None of the 12 known negative human sera, tested positive by ELISA, highlighting the specificity. A total of 415 unknown positive human sera were double-blind tested by the RFFIT and ELISA. The VNA titer cut-off value of ELISA was set at 1.5 IU/mL to ensure no false-positive. The diagnostic specificity and sensitivity were 100% and 91.1%, respectively.
   Conclusions: The validation data characterize this ELISA as a suitable method for semi-quantitative measurement of VNA titers in human serum samples to assess vaccination status. The ELISA kit can offer simplicity, speed, low cost and high throughput, making it a practical tool for monitoring the immune response following vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhao, Rongqing; Sun, Yufei; Sun, Le] AnyGo Technol, D1117 New China Int Sq,89 Dayangfang Rd, Beijing, Peoples R China.
   [Yu, Pengcheng; Zhu, Wuyang] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, 155 Changbai Rd, Beijing, Peoples R China.
   [Shan, Yi; Huang, Lisong] Gen Hosp Peoples Liberat Army, Med Ctr 6, Dept Emergency, Beijing 100048, Peoples R China.
   [Thirumeni, Nagarajan; Li, Maohua; Li, Jianli; Ren, Wenlin; Sun, Le] AbMax Biotechnol Co LTD, 99 Kechuang 14th St,Bldg 18-2-201, Beijing, Peoples R China.
   [Lv, Yanli] China Agr Univ, Coll Vet Med, 2 Yuanmingyuan Xilu, Beijing, Peoples R China.
   [Wei, Jingshuang] North China Pharmaceut Corp, State Key Lab Antibody Res & Dev, New Drug R&D Ctr, 388 Heping East Rd, Shijiazhuang, Hebei, Peoples R China.
   [Zhao, Rongqing] Tsinghua Univ, Sch Life Sci, MOE Key Lab Prot Sci, Beijing 100084, Peoples R China.
RP Zhu, WY; Sun, L (reprint author), AnyGo Technol, D1117 New China Int Sq,89 Dayangfang Rd, Beijing, Peoples R China.
EM Zhuwuyang1971@sina.com; Lsun@antibodychina.com
FU Small Business Research from Innovation Zone of Quzhou City, Zhejiang,
   China
FX The study was supported by grants for Small Business Research from
   Innovation Zone of Quzhou City, Zhejiang, China (to L. Sun). We would
   like to thank the reviewers for their insightful comments which helped
   to improve the quality of our paper. We appreciate the support of all
   kinds extended by Rongxu Zhang, Meng Jin, Linqiang Ying, Yin Zou, Xiaoxu
   Lian, Xinkun Mao, Xiafei Hu, Ying Sun, Junchi Su, Jinmei He, Mingliang
   Zhang, Hunter Sun and Dee Hong throughout this study.
CR Armbruster David A, 2008, Clin Biochem Rev, V29 Suppl 1, pS49
   Aubert M F, 1992, Rev Sci Tech, V11, P735
   Brown D, 2011, ADV PREV MED
   Clark KA, 1996, J AM VET MED ASSOC, V208, P1827
   Cliquet F, 1998, J IMMUNOL METHODS, V212, P79, DOI 10.1016/S0022-1759(97)00212-3
   COX JH, 1977, INFECT IMMUN, V16, P754, DOI 10.1128/IAI.16.3.754-759.1977
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   DIETZSCHOLD B, 1990, J VIROL, V64, P3087, DOI 10.1128/JVI.64.6.3087-3090.1990
   Feyssaguet M, 2007, VACCINE, V25, P2244, DOI 10.1016/j.vaccine.2006.12.012
   Johnson N, 2010, VACCINE, V28, P3896, DOI 10.1016/j.vaccine.2010.03.039
   LAFON M, 1990, J GEN VIROL, V71, P1689, DOI 10.1099/0022-1317-71-8-1689
   Li Geng, 2009, Chinese Journal of Biologicals, V22, P891
   Moore SM, 2005, BIOLOGICALS, V33, P269, DOI 10.1016/j.biologicals.2005.06.005
   Oie AHS, 2015, B OFF INT EPIZOOT, P1092
   PERRIN P, 1986, J BIOL STAND, V14, P95, DOI 10.1016/0092-1157(86)90027-2
   Rotz LD, 1998, J AM VET MED ASSOC, V212, P1198
   Rupprecht CE, 2015, CURRENT LAB TECHNIQU, V2, P157
   Servat A, 2006, VIRUS RES, V120, P17, DOI 10.1016/j.virusres.2006.02.011
   SMITH JS, 1973, B WORLD HEALTH ORGAN, V48, P535
   Tarantola A., 2017, TROP MED INFECT DIS, V2, P1
   Wang HL, 2010, J VIROL METHODS, V170, P80, DOI 10.1016/j.jviromet.2010.09.002
   Wasniewski M, 2013, J VIROL METHODS, V187, P264, DOI 10.1016/j.jviromet.2012.11.022
   Webster LT, 1935, P SOC EXP BIOL MED, V32, P570
   World Health Organization, 2018, WHO EXP CONS RAB, P121
   Xiang ZQ, 1995, VIROLOGY, V214, P398, DOI 10.1006/viro.1995.0049
   Zhang SF, 2009, VACCINE, V27, P2108, DOI 10.1016/j.vaccine.2009.01.126
   ZWAHLEN RD, 1999, PHARMEUROPA BIO, V99, P10
NR 27
TC 0
Z9 0
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 24
PY 2019
VL 37
IS 41
BP 6060
EP 6067
DI 10.1016/j.vaccine.2019.08.043
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA1HT
UT WOS:000487568800007
PM 31471146
DA 2020-05-12
ER

PT J
AU Mokoena, NB
   Moetlhoa, B
   Rutkowska, DA
   Mamputha, S
   Dibakwane, VS
   Tsekoa, TL
   O'Kennedy, MM
AF Mokoena, Nobalanda B.
   Moetlhoa, Boitumelo
   Rutkowska, Dada A.
   Mamputha, Sipho
   Dibakwane, Vusi S.
   Tsekoa, Tsepo L.
   O'Kennedy, Martha M.
TI Plant-produced Bluetongue chimaeric VLP vaccine candidates elicit
   serotype-specific immunity in sheep
SO VACCINE
LA English
DT Article
DE Vaccine; Bluetongue virus (BTV); Bluetongue (BT) disease; Chimaeric 8T
   virus-like particles; Seroconversion; Sheep
ID VIRUS-LIKE PARTICLES; GENERATION; VP2
AB Bluetongue (BT) is a hemorrhagic non-contagious, biting midge-transmitted disease of wild and domestic ruminants that is caused by bluetongue virus (BTV). Annual vaccination plays a pivotal role in BT disease control in endemic regions. Due to safety concerns of the current BTV multivalent live attenuated vaccine (LAV), a safe efficacious new generation subunit vaccine such as a plant-produced BT virus-like particle (VLP) vaccine is imperative. Previously, homogenous BTV serotype 8 (BTV-8) VLPs were successfully produced in Nicotiana benthamiana plants and provided protective immunity in sheep. In this study, combinations of BTV capsid proteins from more than one serotype were expressed and assembled to form chimaeric BTV-3 and BTV-4 VLPs in N. benthamiana plants. The assembled homogenous BTV-8, as well as chimaeric BTV-3 and chimaeric BTV-4 VLP serotypes, were confirmed by SDS-PAGE, Transmission Electron microscopy (TEM) and protein confirmation using liquid chromatography-mass spectrometry (LC-MS/MS) based peptide sequencing. As VP2 is the major determinant eliciting protective immunity, the percentage coverage and number of unique VP2 peptides detected in assembled chimaeric BT VLP5 were used as a guide to assemble the most appropriate chimaeric combinations. Both plant-produced chimaeric BTV-3 and BTV-4 VLPs were able to induce long-lasting serotype-specific neutralizing antibodies equivalent to the monovalent LAV controls. Antibody levels remained high to the end of the trial. Combinations of homogenous and chimaeric BT VLPs have great potential as a safe, effective multivalent vaccine with the ability to distinguish between vaccinated and infected individuals (DIVA) due to the absence of non-structural proteins. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Rutkowska, Dada A.; Mamputha, Sipho; Tsekoa, Tsepo L.; O'Kennedy, Martha M.] Council Sci & Ind Res CSIR Biosci, Pretoria, South Africa.
   [Mokoena, Nobalanda B.; Moetlhoa, Boitumelo; Dibakwane, Vusi S.] Onderstepoort Biol Prod SOC Ltd, Onderstepoort, South Africa.
RP O'Kennedy, MM (reprint author), CSIR Biosci, POB 395, ZA-0001 Pretoria, South Africa.
EM mokennedy@csir.co.za
OI O'Kennedy, Martha M/0000-0003-3050-7008; Tsekoa,
   Tsepo/0000-0002-5561-5462
FU Technology Innovation Agency (TIA) Tshwane Animal Health Cluster
   [TAHC-1200013]
FX This work was supported by the Technology Innovation Agency (TIA)
   Tshwane Animal Health Cluster [Grant number TAHC-1200013] entitled:
   "Plant-expressed Orbivirus vaccines". Complementary research funds were
   invested by OBP and CSIR.
CR Anderson J, 2014, VACCINE, V32, P6614, DOI 10.1016/j.vaccine.2014.09.066
   Calvo-Pinilla E, 2014, VIRUS RES, V182, P78, DOI 10.1016/j.virusres.2013.11.013
   Chen Q, 2013, HUM VACC IMMUNOTHER, V9, P26, DOI 10.4161/hv.22218
   Crisci E, 2012, VET IMMUNOL IMMUNOP, V148, P211, DOI 10.1016/j.vetimm.2012.04.026
   Dennis SJ, 2018, VET RES, V49, DOI 10.1186/s13567-018-0600-4
   Dungu B, 2004, Vet Ital, V40, P616
   Dungu B, 2009, Patent No. [WO 2009/128043 Al, 2009128043]
   Dungu B. K., 2008, Open Veterinary Science Journal, V2, P130, DOI 10.2174/1874318808002010130
   Fay P, 2015, 12 INT DSRNA VIR S G
   Feenstra F, 2017, CRIT REV MICROBIOL, V43, P142, DOI 10.1080/1040841X.2016.1186005
   Feenstra F, 2015, VACCINE, V33, P812, DOI 10.1016/j.vaccine.2014.12.003
   HOWELL P. G., 1967, ONDERSTEPOORT J VET RES, V34, P317
   Jaafar FM, 2014, VACCINE, V32, P4059, DOI 10.1016/j.vaccine.2014.05.056
   MARTINELLE L, 2018, BMC VET RES, V49, DOI DOI 10.1186/S13567-018-0556-4
   Nason EL, 2004, J VIROL, V78, P8059, DOI 10.1128/JVI.78.15.8059-8067.2004
   PEARSON LD, 1993, IMMUNOL CELL BIOL, V71, P381, DOI 10.1038/icb.1993.44
   Rojas JM, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-30
   Sainsbury F, 2012, METHOD ENZYMOL, V517, P185, DOI 10.1016/B978-0-12-404634-4.00009-7
   Savini G, 2008, COMP IMMUNOL MICROB, V31, P101, DOI 10.1016/j.cimid.2007.07.006
   Shaw AE, 2013, J VIROL, V87, P543, DOI 10.1128/JVI.02266-12
   Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468
   Strasser R, 2008, PLANT BIOTECHNOL J, V6, P392, DOI 10.1111/j.1467-7652.2008.00330.x
   Thuenemann EC, 2013, PLANT BIOTECHNOL J, P1
   Van den Bergh C, 2016, AM SOC MICROBIOL, V4, P1
   van Zyl Albertha R, 2016, Biotechnol Rep (Amst), V9, P15, DOI 10.1016/j.btre.2015.12.001
   Zhugunissov K, 2015, VET RES COMMUN, V39, P203, DOI 10.1007/s11259-015-9643-4
   Zulu GB, 2014, J S AFR VET ASSOC, V85, DOI 10.4102/jsava.v85i1.1041
NR 27
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 24
PY 2019
VL 37
IS 41
BP 6068
EP 6075
DI 10.1016/j.vaccine.2019.08.042
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA1HT
UT WOS:000487568800008
PM 31471154
DA 2020-05-12
ER

PT J
AU Feng, JX
   Hu, XY
   Fu, MJ
   Dai, LP
   Yu, YH
   Luo, WB
   Zhao, ZM
   Lu, ZY
   Du, ZM
   Zhou, DS
   Wen, BH
   Jiao, J
   Xiong, XL
AF Feng, Junxia
   Hu, Xueyuan
   Fu, Mengjiao
   Dai, Lupeng
   Yu, Yonghui
   Luo, Wenbo
   Zhao, Zengming
   Lu, Zhiyu
   Du, Zongmin
   Zhou, Dongsheng
   Wen, Bohai
   Jiao, Jun
   Xiong, Xiaolu
TI Enhanced protection against Q fever in BALB/c mice elicited by
   immunization of chloroform-methanol residue of Coxiella burnetii via
   intratracheal inoculation
SO VACCINE
LA English
DT Article
DE Coxiella burnetii; Q fever; Intratracheal inoculation; Mucosal immunity
ID IMMUNE-RESPONSES; VACCINE; MUCOSAL; CELLS; NEUTROPHILS; GROWTH; MODEL
AB Human Q fever is recognized as a worldwide public health problem. It often occurs by inhalation of airborne aerosols contaminated with Coxiella burnetii, a gram-negative intracellular bacterium, mainly from domestic livestock. In this study, we analyzed the possibility to establish mucosal and systemic immunity against C burnetii infection using a pulmonary delivery of chloroform-methanol residue of C burnetii (CMR) vaccine. Mice were immunized by the intratracheal inoculation of CMR (IT-CMR) or the subcutaneous injection of CMR (SC-CMR), and the immunized mice were challenged with C. burnetii by the intratracheal route. The levels of IFN-gamma, IL-12p70, IL-5, and IL-4 in the IT-CMR group in splenic T cells stimulated ex vivo were significantly higher than in the SC-CMR group. Significantly elevated sIgA to C burnetii was detected in the bronchoalveolar lavage fluid of mice immunized by IT-CMR but not by SC-CMR, which might have contributed to the significant reduction in C burnetii load and pathological lesions in the lungs of the mice after the challenge of C burnetii. These results suggest that compared with SC-CMR in mice, IT-CMR was more efficient to elicit cellular and lung mucosal immune responses against aerosol infection of C burnetii. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Feng, Junxia; Hu, Xueyuan; Fu, Mengjiao; Dai, Lupeng; Yu, Yonghui; Lu, Zhiyu; Du, Zongmin; Zhou, Dongsheng; Wen, Bohai; Jiao, Jun; Xiong, Xiaolu] Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, 20 Dong Dia Jie St, Beijing 100071, Peoples R China.
   [Luo, Wenbo] Anhui Med Univ, Mei Shan Rd, Hefei 230032, Anhui, Peoples R China.
   [Zhao, Zengming] Ctr Dis Control & Prevent Chinese Peoples Liberat, 20 Dong Dia Jie St, Beijing 100071, Peoples R China.
RP Jiao, J; Xiong, XL (reprint author), Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, 20 Dong Dia Jie St, Beijing 100071, Peoples R China.
EM jiaojun51920@sina.com; xiongxiaolu624@sohu.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [SKLPBS1802]; Beijing Nova ProgramBeijing Municipal
   Science & Technology Commission [31970178];  [Z181100006218116]
FX This work was supported by grants from SKLPBS1802, National Natural
   Science Foundation of China (31970178) and the Beijing Nova Program
   (Z181100006218116).
CR Ashtekar AR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050460
   Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/erv.10.174, 10.1586/ERV.10.174]
   Camacho MT, 2000, VACCINE, V18, P1773, DOI 10.1016/S0264-410X(99)00484-3
   Camacho MT, 1998, CLIN IMMUNOL IMMUNOP, V88, P80, DOI 10.1006/clin.1998.4547
   Chiu C, 2015, NAT IMMUNOL, V16, P18, DOI 10.1038/ni.3056
   Elliott A, 2015, INFECT IMMUN, V83, P3104, DOI 10.1128/IAI.00042-15
   Elliott A, 2013, INFECT IMMUN, V81, P4604, DOI 10.1128/IAI.00973-13
   FISCHER W, 1983, EUR J BIOCHEM, V133, P523, DOI 10.1111/j.1432-1033.1983.tb07495.x
   Florido M, 2018, MUCOSAL IMMUNOL, V11, P1743, DOI 10.1038/s41385-018-0065-9
   FRIES LF, 1993, INFECT IMMUN, V61, P1251, DOI 10.1128/IAI.61.4.1251-1258.1993
   Fukuyama Y, 2015, IMMUNE NETW, V15, P9, DOI 10.4110/in.2015.15.1.9
   Gong WP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124664
   Hendrix LR, 2012, ADV EXP MED BIOL, V984, P299, DOI 10.1007/978-94-007-4315-1_16
   Hofherr SE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017076
   Iho S, 2015, HUM VACC IMMUNOTHER, V11, P755, DOI 10.1080/21645515.2014.1004033
   Lee J, 2012, REGUL PEPTIDES, V177, P68, DOI 10.1016/j.regpep.2012.04.010
   Maurin M, 1999, CLIN MICROBIOL REV, V12, P518, DOI 10.1128/CMR.12.4.518
   Melenotte C, 2016, INFECT IMMUN, V84, P2116, DOI 10.1128/IAI.00108-16
   Mueller SN, 2016, NAT REV IMMUNOL, V16, P79, DOI 10.1038/nri.2015.3
   Neuhaus V, 2014, VACCINE, V32, P3216, DOI 10.1016/j.vaccine.2014.04.011
   Omsland A, 2011, APPL ENVIRON MICROB, V77, P3720, DOI 10.1128/AEM.02826-10
   Omsland A, 2009, P NATL ACAD SCI USA, V106, P4430, DOI 10.1073/pnas.0812074106
   Park CO, 2015, NAT MED, V21, P688, DOI 10.1038/nm.3883
   Perdomo C, 2016, MBIO, V7, DOI 10.1128/mBio.01686-16
   Scheiermann J, 2014, VACCINE, V32, P6377, DOI 10.1016/j.vaccine.2014.06.065
   Peng Y, 2014, INFECT IMMUN, V82, P4530, DOI 10.1128/IAI.01695-14
   Stein A, 2005, INFECT IMMUN, V73, P2469, DOI 10.1128/IAI.73.4.2469-2477.2005
   Timothy AA, 2015, HUM VACC IMMUNOTHER, V11, P377, DOI 10.4161/21645515.2014.990859
   van Loenhout JAF, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-280
   Waag DM, 2008, CLIN VACCINE IMMUNOL, V15, P1505, DOI 10.1128/CVI.00119-08
   Waag DM, 1997, VACCINE, V15, P1779, DOI 10.1016/S0264-410X(97)00107-2
   Waag DM, 1999, LAB ANIM SCI, V49, P634
   Wei Y, 2011, J INFECT DIS, V203, P283, DOI 10.1093/infdis/jiq037
   WEN BH, 1991, ACTA VIROL, V35, P538
   WILLIAMS JC, 1986, INFECT IMMUN, V51, P851, DOI 10.1128/IAI.51.3.851-858.1986
   Wu ML, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00445
   Xiong XL, 2017, J INFECT DIS, V215, P1580, DOI 10.1093/infdis/jiw470
   Xiong XL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087206
   Xiong XL, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-35
   Zhang GQ, 2013, INFECT IMMUN, V81, P2112, DOI 10.1128/IAI.00297-13
NR 40
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 24
PY 2019
VL 37
IS 41
BP 6076
EP 6084
DI 10.1016/j.vaccine.2019.08.041
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA1HT
UT WOS:000487568800009
PM 31477436
DA 2020-05-12
ER

PT J
AU Parenky, AC
   Akalkotkar, A
   Mulla, NS
   D'Souza, MJ
AF Parenky, Ashwin C.
   Akalkotkar, Archana
   Mulla, Nihal S.
   D'Souza, Martin J.
TI Harnessing T-cell activity against prostate cancer: A therapeutic
   microparticulate oral cancer vaccine
SO VACCINE
LA English
DT Article
DE Cancer vaccine; Prostate cancer; Microparticles; Oral delivery;
   Cyclophosphamide; GM-CSF; Immunotherapy
ID LOW-DOSE CYCLOPHOSPHAMIDE; IN-VITRO; GM-CSF; IMMUNOTHERAPY; DELIVERY;
   STIMULATION; LYMPHOCYTES; FORMULATION; IPILIMUMAB; CARCINOMA
AB Prostate Cancer specific immunotherapy in combination with immune stimulating adjuvants may serve as a viable strategy for facilitating tumor regression and preventing recurrence. In this study, an oral microparticulate vaccine encapsulating tumor associated antigens (TAA) extracted from a murine prostate cancer cell line, TRAMP-C2, was formulated with the help of a spray dryer. Microparticles were characterized in vitro to determine their physicochemical properties and antigenicity. Formulated microparticles had an average size of 4.92 +/- 0.5 mu m with a zeta potential of 7.92 +/- 1.2 mV. In order to test our formulation for its ability to demonstrate adequate antigen presentation and co-stimulation, microparticles were tested in vitro on murine dendritic cells. In vitro biological characterization demonstrated the activation of specific immune system markers such as CD80/86, CD40, MHC-I and MHC-II. Following in vitro characterization, in vivo anti-tumor efficacy of the oral microparticulate vaccine was evaluated in C57BL/6 male mice. Combination therapy of vaccine microparticles with cyclophosphamide and granulocyte macrophage-colony stimulating factor (GM-CSF) demonstrated a five-fold reduction in tumor volume as compared to non-vaccinated mice. At the cellular level, cyclophosphamide and GMCSF augmented the vaccine response as indicated by the reduced tumor volume and significant elevation of cytotoxic T-cell (CTL) CD8+ and (T-helper) CD4+ T-cells compared to mice receiving vaccine microparticles alone. Furthermore, our studies indicate a significant reduction in T-regulatory cells (T-regs) in mice receiving vaccine along with GM-CSF and cyclophosphamide, one of the immune escape mechanisms linked to tumor growth and progression. Thus, oral microparticulate vaccines have the potential to trigger a robust anti-tumor cellular response, and in combination with clinically relevant agents, significantly resist tumor growth and progression. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Parenky, Ashwin C.; Akalkotkar, Archana; Mulla, Nihal S.; D'Souza, Martin J.] Mercer Univ, Vaccine Nanotechnol Lab, Ctr Drug Delivery Res, Atlanta, GA 30341 USA.
   [Akalkotkar, Archana] Charles River Labs, Ashland, OH 44805 USA.
   [Mulla, Nihal S.] Drake Univ, Coll Pharm & Hlth Sci, Dept Pharmaceut & Adm Sci, 2507 Univ Ave, Des Moines, IA 50311 USA.
RP Parenky, AC (reprint author), Mercer Univ, Vaccine Nanotechnol Lab, Ctr Drug Delivery Res, Atlanta, GA 30341 USA.
EM Ashwin.chandrashekar.parenky@live.mercer.edu;
   archana.akalkotkar@crl.com; Dsouza_MJ@mercer.edu
CR Agarwal N, 2014, ANN ONCOL, V25, P1700, DOI 10.1093/annonc/mdu038
   Akalkotkar A, 2012, J DRUG TARGET, V20, P338, DOI 10.3109/1061186X.2011.654122
   Antonarakis ES, 2010, EXPERT OPIN INV DRUG, V19, P311, DOI 10.1517/13543780903530678
   Aylward RB, 2014, B WORLD HEALTH ORGAN, V92, P466, DOI 10.2471/BLT.14.142273
   Barbon CM, 2010, CELL IMMUNOL, V262, P150, DOI 10.1016/j.cellimm.2010.02.007
   Casak SJ, 2011, ONCOLOGIST, V16, P97, DOI 10.1634/theoncologist.2010-0306
   Chablani L, 2012, J PHARM SCI-US, V101, P3661, DOI 10.1002/jps.23275
   D'Souza B, 2012, J DRUG TARGET, V20, P166, DOI 10.3109/1061186X.2011.622395
   De Jesus M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091002
   De Smet R, 2014, BIOMACROMOLECULES, V15, P2301, DOI 10.1021/bm5005367
   Demento SL, 2012, BIOMATERIALS, V33, P4957, DOI 10.1016/j.biomaterials.2012.03.041
   Dong BJ, 2014, EXPERT REV CLIN IMMU, V10, P1547, DOI 10.1586/1744666X.2014.962515
   Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x
   Fesnak AD, 2016, NAT REV CANCER, V16, P566, DOI 10.1038/nrc.2016.97
   Geary SM, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.24523
   Hanlon DJ, 2011, AM J REPROD IMMUNOL, V65, P597, DOI 10.1111/j.1600-0897.2010.00968.x
   Huang J, 2005, CANCER RES, V65, P8461, DOI 10.1158/0008-5472.CAN-05-0654
   Joshi VB, 2014, EXPERT REV VACCINES, V13, P9, DOI 10.1586/14760584.2014.851606
   Karan D, 2012, IMMUNOTHERAPY-UK, V4, P577, DOI [10.2217/IMT.12.53, 10.2217/imt.12.53]
   Kawashima H, 2014, BJU INT, V113, P320, DOI 10.1111/bju.12499
   Kilinc MO, 2009, J IMMUNOL, V182, P4217, DOI 10.4049/jimmunol.0802793
   Le DT, 2015, J CLIN ONCOL OFF J A, P12
   Le DT, 2012, CANCER RES, V72, P3439, DOI 10.1158/0008-5472.CAN-11-3912
   Liu JY, 2007, CANCER IMMUNOL IMMUN, V56, P1597, DOI 10.1007/s00262-007-0305-4
   Lopez-Gigosos RM, 2011, J GLOB INFECT DIS, V3, P56, DOI 10.4103/0974-777X.77297
   Pan K, 2014, CLIN CANCER RES, V20, P3003, DOI 10.1158/1078-0432.CCR-14-0082
   Pardoll D, 2002, P NATL ACAD SCI USA, V99, P15840, DOI 10.1073/PNAS.262669499
   Pastor M, 2014, J DRUG TARGET, V22, P478, DOI 10.3109/1061186X.2014.888071
   Pati R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02224
   Rutkowski R, 2003, ARCH IMMUNOL THER EX, V51, P421
   Schnurr M, 2001, CANCER RES, V61, P6445
   Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002
   Shi YF, 2006, CELL RES, V16, P126, DOI 10.1038/sj.cr.7310017
   Silva AL, 2016, HUM VACC IMMUNOTHER, V12, P1056, DOI 10.1080/21645515.2015.1117714
   Soriano JL, 2011, INT J BREAST CANC, V2011, P1
   Suksamran T, 2013, INT J PHARMACEUT, V448, P19, DOI 10.1016/j.ijpharm.2013.03.015
   Tabata Y, 1996, VACCINE, V14, P1677, DOI 10.1016/S0264-410X(96)00149-1
   Tawde SA, 2012, VACCINE, V30, P5675, DOI 10.1016/j.vaccine.2012.05.073
   van den Eertwegh AJM, 2012, LANCET ONCOL, V13, P509, DOI 10.1016/S1470-2045(12)70007-4
   Van der Lubben IM, 2002, J DRUG TARGET, V10, P449, DOI 10.1080/1061186021000038319
   Van Gool SW, 1999, EUR J IMMUNOL, V29, P2367, DOI 10.1002/(SICI)1521-4141(199908)29:08<2367::AID-IMMU2367>3.3.CO;2-V
   van Soest RJ, 2013, EUR J CANCER, V49, P3821, DOI 10.1016/j.ejca.2013.09.026
   van Soest RJ, 2014, EUR UROL
   Wada S, 2009, CANCER RES, V69, P4309, DOI 10.1158/0008-5472.CAN-08-4102
   Wright SE, 2014, ONCOL LETT, V7, P2113, DOI 10.3892/ol.2014.1969
   Zhao J, 2010, CANCER RES, V70, P4850, DOI 10.1158/0008-5472.CAN-10-0283
NR 46
TC 0
Z9 0
U1 2
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 24
PY 2019
VL 37
IS 41
BP 6085
EP 6092
DI 10.1016/j.vaccine.2019.08.033
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA1HT
UT WOS:000487568800010
PM 31477437
DA 2020-05-12
ER

PT J
AU Hagedorn, BL
   Dabbagh, A
   McCarthy, KA
AF Hagedorn, Brittany L.
   Dabbagh, Alya
   McCarthy, Kevin A.
TI The cost saving opportunity of introducing a card review into
   measles-containing vaccination campaigns
SO VACCINE
LA English
DT Review
DE Campaign; Selective vaccination; Card retention; Measles; Cost; Savings
ID OUTBREAK RESPONSE VACCINATION
AB Measles vaccination is a cost-effective way to prevent infection and reduce mortality and morbidity. However, in countries with fragile routine immunization infrastructure, coverage rates are still low and supplementary immunization campaigns (SIAs) are used to reach previously unvaccinated children. During campaigns, vaccine is generally administered to every child, regardless of their vaccination status and as a result, there is the possibility that a child that is already immune to measles (i.e. who has had 2 + vaccinations) would receive an unnecessary dose, resulting in excess cost. Selective vaccination has been proposed as one solution to this; children who were able to provide documentation of previous vaccination would not be vaccinated repeatedly. While this would result in reduced vaccine and supply cost, it would also require additional staff time and increased social mobilization investment, potentially outweighing the benefits. We utilize Monte Carlo simulation to assess under what conditions a selective vaccination policy would indeed result in net savings. We demonstrate that cost savings are possible in contexts with a high joint probability of an individual child having both 2+ previous measles doses and also an available record. We also find that the magnitude of net cost savings is highly dependent on whether a country is using measles-only or measles-rubella vaccine and on the required skill set of the individual who would review the previous vaccination records. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Hagedorn, Brittany L.; McCarthy, Kevin A.] Inst Dis Modeling, 3150 139th Ave SE, Bellevue, WA 98005 USA.
   [Dabbagh, Alya] WHO, Dept Immunizat Vaccines & Biol, Ave Appia 20, CH-1211 Geneva, Switzerland.
RP Hagedorn, BL (reprint author), Inst Dis Modeling, 3150 139th Ave SE, Bellevue, WA 98005 USA.
EM bhagedorn@idmod.org
OI McCarthy, Kevin/0000-0002-9148-8448
FU Bill and Melinda Gates through the Global Good Fund
FX This work was supported by Bill and Melinda Gates through the Global
   Good Fund. The funders had no role in study design, data collection,
   data analysis, the decision to publish, or preparation of the
   manuscript.
CR Asturias EJ, 2016, LANCET, V388, P158, DOI 10.1016/S0140-6736(16)00703-0
   Bhandari R, 2013, INT J CHILD HLTH NUT, DOI [10.6000/1929-4247.2013.0202E, DOI 10.6000/1929-4247.2013.0202E]
   Brown DW, 2018, HOME BASED RECORD HB, DOI [10.1371/journal.pone.0201538, DOI 10.1371/JOURNAL.PONE.0201538]
   Cairns KL, 2011, J INFECT DIS, V204, pS35, DOI 10.1093/infdis/jir072
   Centers for Disease Control and Prevention, 2015, MEASL EP PREV VACC P, P209
   Grais RF, 2008, J R SOC INTERFACE, V5, P67, DOI 10.1098/rsif.2007.1038
   Kamadjeu Raoul M, 2005, Inform Prim Care, V13, P179
   Kawakatsu Y, 2015, HEALTH EDUC RES, V30, P935, DOI 10.1093/her/cyv048
   King C, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25878
   Minetti A, 2014, AM J EPIDEMIOL, V179, P245, DOI 10.1093/aje/kwt236
   Oh DH, 2016, WKLY EPIDEMIOL REC, V92, P205
   Pahari D P, 2011, J Nepal Health Res Counc, V9, P154
   Portnoy A, 2018, VACCINE, V36, P170, DOI 10.1016/j.vaccine.2017.10.080
   Sheikh Sana Sadiq, 2014, Oman Med J, V29, P190, DOI 10.5001/omj.2014.47
   Simons E, 2011, J INFECT DIS, V204, pS28, DOI 10.1093/infdis/jir095
   Team RC, 2018, R LANG ENV STAT COMP
   The World Bank, IMM MEASL CHILDR AG
   UNICEF Supply Division, 2016, SUPPL LOGIST, P462
   UNICEF Supply Division, 2018, MR PRIC LIST UNICEF
   WHO, 2017, GLOB VACC ACT PLAN 2
   WHO, 2012, PREL DOS EST NUCL AC, P1
   World Bank, GDP DEFL
   World Health Organization, 2015, PRACT GUID DES US PR
NR 23
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 24
PY 2019
VL 37
IS 41
BP 6093
EP 6101
DI 10.1016/j.vaccine.2019.08.049
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA1HT
UT WOS:000487568800011
PM 31471145
OA Other Gold
DA 2020-05-12
ER

PT J
AU Wilkinson, TMA
   Schembri, S
   Brightling, C
   Bakerly, ND
   Lewis, K
   MacNee, W
   Rombo, L
   Hedner, J
   Allen, M
   Walker, PP
   De Ryck, I
   Tasciotti, A
   Casula, D
   Moris, P
   Testa, M
   Arora, AK
AF Wilkinson, Tom M. A.
   Schembri, Stuart
   Brightling, Christopher
   Bakerly, Nawar D.
   Lewis, Keir
   MacNee, William
   Rombo, Lars
   Hedner, Jan
   Allen, Martin
   Walker, Paul P.
   De Ryck, Iris
   Tasciotti, Annaelisa
   Casula, Daniela
   Moris, Philippe
   Testa, Marco
   Arora, Ashwani K.
TI Non-typeable Haemophilus influenzae protein vaccine in adults with COPD:
   A phase 2 clinical trial
SO VACCINE
LA English
DT Article
DE Non-typeable Haemophilus influenzae; COPD; Exacerbation; Vaccine;
   Safety; Immunogenicity
ID T-CELL RESPONSES; MICROBIOME DYNAMICS; LUNG MICROBIOME; EXACERBATIONS;
   SAFETY; IMMUNOGENICITY; ANTIGEN; VITRONECTIN; PATHOGENS; BACTERIAL
AB Loss of airway microbial diversity is associated with non-typeable Haemophilus influenzae (NTHi) infection and increased risk of exacerbation in chronic obstructive pulmonary disease (COPD). We assessed the safety and immunogenicity of an investigational vaccine containing NTHi antigens, recombinant protein D (PD) and combined protein E and Pilin A (PE-PilA), and AS01 adjuvant in adults with moderate/-severe COPD and prior exacerbations.
   In this phase 2, observer-blind, controlled trial (NCT02075541), 145 COPD patients aged 40-80 years randomly (1:1) received two doses of NTHi vaccine or placebo 60 days apart, on top of standard care.
   Reactogenicity in the 7-day post-vaccination period was higher following NTHi vaccine than placebo. Most solicited adverse events (AEs) were mild/moderate. At least one unsolicited AE was reported during the 30-day post-vaccination period by 54.8% of NTHi vaccine and 51.4% of placebo recipients. One serious AE (placebo group) was assessed by the investigator as vaccine-related. Anti-PD, anti-PE and anti-PiIA geometric mean antibody concentrations increased up to 30 days after each NTHi vaccine dose, waned thereafter, but remained higher than baseline (non-overlapping confidence intervals) up to 13 months post-dose 2. The frequency of specific CD4(+) T cells increased following two doses of NTHi vaccine and remained higher than baseline. Exploratory analysis showed a statistically non-significant lower yearly rate of moderate/severe exacerbations in the NTHi vaccine group than following placebo (1.49 versus 1.73) in the one-year period post-dose 2, with estimated vaccine efficacy of 13.3% (95% confidence interval -24.2 to 39.5; p = 0.44).
   The NTHi vaccine had an acceptable safety and reactogenicity profile and good immunogenicity in adults with COPD. (C) 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.
C1 [Wilkinson, Tom M. A.] Univ Southampton, Southampton Gen Hosp, Clin & Expt Sci, Fac Med, Southampton, Hants, England.
   [Wilkinson, Tom M. A.] Southampton Gen Hosp, Southampton NIHR Resp Biomed Res Unit, Southampton, Hants, England.
   [Wilkinson, Tom M. A.] Univ Southampton, Southampton Gen Hosp, Wessex Invest Sci Hub, Fac Med, Southampton, Hants, England.
   [Schembri, Stuart] Univ Dundee, Scottish Ctr Resp Res, Dundee, Scotland.
   [Brightling, Christopher] Univ Leicester, Inst Lung Hlth, Dept Infect Immun & Inflammat, Leicester, Leics, England.
   [Bakerly, Nawar D.] Salford Royal NHS Fdn Trust, Salford, Lancs, England.
   [Lewis, Keir] Univ Swansea, Sch Med, Swansea, W Glam, Wales.
   [MacNee, William] Univ Edinburgh, MRC Ctr Inflammat Res, Edinburgh, Midlothian, Scotland.
   [Rombo, Lars] Uppsala Univ, Sormland Cty Council, Clin Res Ctr, Uppsala, Sweden.
   [Hedner, Jan] Sahlgrens Univ Hosp, Dept Internal Med, Pulm Med, Gothenburg, Sweden.
   [Allen, Martin] Univ Hosp North Midlands, Royal Stoke Hosp, Dept Resp Med, Stoke On Trent, Staffs, England.
   [Walker, Paul P.] Aintree Univ Hosp NHS Fdn Trust, Dept Resp Med, Liverpool, Merseyside, England.
   [De Ryck, Iris; Tasciotti, Annaelisa; Casula, Daniela; Testa, Marco; Arora, Ashwani K.] GSK, Siena, Italy.
   [Moris, Philippe] GSK, Rixensart, Belgium.
RP Testa, M (reprint author), GSK, Clin Res & Dev, Via Fiorentina 1, I-53100 Siena, Italy.
EM marco.x.testa@gsk.com
OI Casula, Daniela/0000-0001-7111-5946
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline
FX The study funder, GlaxoSmithKline Biologicals SA, designed the study in
   collaboration with the investigators, and coordinated collection,
   analysis and interpretation of data. The investigators obtained data and
   cared for the study participants. The authors had full access to all
   data in the study, contributed to the writing of the report and had
   final responsibility for the decision to submit for publication.
CR ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196
   Awate S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00114
   Berglund J, 2014, CLIN VACCINE IMMUNOL, V21, P56, DOI 10.1128/CVI.00430-13
   Clancy RL, 2016, INTERN MED J, V46, P684, DOI 10.1111/imj.13072
   Da Silva FT, 2013, VACCINE, V31, P1870, DOI 10.1016/j.vaccine.2013.01.042
   Dickson RP, 2016, ANNU REV PHYSIOL, V78, P481, DOI 10.1146/annurev-physiol-021115-105238
   Didierlaurent AM, 2014, J IMMUNOL, V193, P1920, DOI 10.4049/jimmunol.1400948
   Food and drug administration guidance for industry, 2007, TOXICITY GRADING SCA
   Forsgren A, 2008, CLIN INFECT DIS, V46, P726, DOI 10.1086/527396
   Garcha DS, 2012, THORAX, V67, P1075, DOI 10.1136/thoraxjnl-2012-201924
   Global Initiative for Chronic Obstructive Lung Disease ( GOLD), 2019, GLOB STRAT DIAGN MAN
   Hallstrom T, 2009, J IMMUNOL, V183, P2593, DOI 10.4049/jimmunol.0803226
   Huang YJ, 2014, J CLIN MICROBIOL, V52, P2813, DOI 10.1128/JCM.00035-14
   Jurcisek JA, 2007, MOL MICROBIOL, V65, P1288, DOI 10.1111/j.1365-2958.2007.05864.x
   Kester KE, 2009, J INFECT DIS, V200, P337, DOI 10.1086/600120
   Leroux-Roels G, 2016, CLIN IMMUNOL, V169, P16, DOI 10.1016/j.clim.2016.05.007
   Leroux-Roels G, 2016, VACCINE, V34, P3156, DOI 10.1016/j.vaccine.2016.04.051
   Leroux-Roels I, 2015, VACCINE, V33, P577, DOI 10.1016/j.vaccine.2013.10.052
   Mackay AJ, 2013, IMMUNOL ALLERGY CLIN, V33, P95, DOI 10.1016/j.iac.2012.10.006
   Mayhew D, 2018, THORAX, V73, P422, DOI 10.1136/thoraxjnl-2017-210408
   Millares L, 2014, EUR J CLIN MICROBIOL, V33, P1101, DOI 10.1007/s10096-013-2044-0
   Moris P, 2011, J CLIN IMMUNOL, V31, P443, DOI 10.1007/s10875-010-9490-6
   Murphy TF, 2015, CLIN VACCINE IMMUNOL, V22, P459, DOI 10.1128/CVI.00089-15
   Pauksens K, 2014, CLIN VACCINE IMMUNOL, V21, P651, DOI 10.1128/CVI.00807-13
   Poolman JT, 2000, VACCINE, V19, pS108, DOI 10.1016/S0264-410X(00)00288-7
   Prymula R, 2009, EXPERT REV VACCINES, V8, P1479, DOI 10.1586/ERV.09.113
   Sethi S, 2002, NEW ENGL J MED, V347, P465, DOI 10.1056/NEJMoa012561
   Singh B, 2013, INFECT IMMUN, V81, P801, DOI 10.1128/IAI.01111-12
   Singh B, 2011, MOL MICROBIOL, V81, P80, DOI 10.1111/j.1365-2958.2011.07678.x
   Sze MA, 2014, INT J CHRONIC OBSTR, V9, P229, DOI 10.2147/COPD.S38932
   Teo E, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010010.pub3
   Van Braeckel E, 2011, CLIN INFECT DIS, V52, P522, DOI 10.1093/cid/ciq160
   Vandepapeliere P, 2008, VACCINE, V26, P1375, DOI 10.1016/j.vaccine.2007.12.038
   Wang HY, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0094-z
   Wang Z, 2016, EUR RESPIR J, V47, P1082, DOI 10.1183/13993003.01406-2015
   Wilkinson TMA, 2017, THORAX, V72, P919, DOI 10.1136/thoraxjnl-2016-209023
NR 36
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 24
PY 2019
VL 37
IS 41
BP 6102
EP 6111
DI 10.1016/j.vaccine.2019.07.100
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA1HT
UT WOS:000487568800012
PM 31447126
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Patel, N
   Massare, MJ
   Tian, JH
   Guebre-Xabier, M
   Lu, HX
   Zhou, HX
   Maynard, E
   Scott, D
   Ellingsworth, L
   Glenn, G
   Smith, G
AF Patel, Nita
   Massare, Mike J.
   Tian, Jing-Hui
   Guebre-Xabier, Mimi
   Lu, Hanxin
   Zhou, Haixia
   Maynard, Ernest
   Scott, Daniel
   Ellingsworth, Larry
   Glenn, Gregory
   Smith, Gale
TI Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle
   vaccine: Structure, antigenic profile, immunogenicity, and protection
SO VACCINE
LA English
DT Article
DE Respiratory syncytial virus; Prefusogenic fusion glycoprotein; Vaccine;
   Cotton rat
ID RSV F; MONOCLONAL-ANTIBODY; HEALTHY WOMEN; SITE II; GLYCOPROTEIN;
   PALIVIZUMAB; INFECTION; SAFETY
AB Respiratory syncytial virus (RSV) is a major cause of severe respiratory disease in the very young, elderly, and immunocompromised for which there is no vaccine. The surface exposed RSV fusion (F) glycoprotein is required for membrane fusion and infection and is a desirable vaccine candidate. RSV F glycoprotein structure is dynamic and undergoes significant rearrangements during virus assembly, fusion, and infection. We have previously described an RSV fusion-inactive prefusogenic F with a mutation of one of two furin cleavage sites resulting in the p27 region on the N-terminus of F1 with a truncated fusion peptide covalently linked to F2. A processing intermediate RSV prefusogenic F has been reported in infected cells, purified F, budded virus, and elicited a strong immune response against p27 in RSV infected young children. In this report, we demonstrate that prefusogenic F, when expressed on the cell surface of Sf9 insect and human 293T cells, binds monoclonal antibodies (mAbs) that target prefusion-specific antigenic sites empty set and VIII, and mAbs targeting epitopes common to pre- and postfusion F sites II and IV. Purified prefusogenic F bound prefusion F specific mAbs to antigenic sites empty set and VIII and mAbs targeting pre- and post fusion sites 11, IV, and p27. Mice immunized with prefusogenic F antigen produced significantly higher levels of anti-F IgG and RSV neutralizing antibodies than prefusion or postfusion F antigens and induced antibodies competitive with mAbs to sites empty set, VIII, II, and IV. RSV prefusogenic F neutralization antibody responses were enhanced with aluminum phosphate adjuvant and significantly higher than prefusion F. Prefusogenic F vaccine protected cotton rats against upper and lower respiratory tract infection by RSV/A. For the first time, we present the structure, antigenic profile, immunogenicity, and protective efficacy of RSV prefusogenic F nanoparticle vaccine. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Patel, Nita; Massare, Mike J.; Tian, Jing-Hui; Guebre-Xabier, Mimi; Lu, Hanxin; Zhou, Haixia; Maynard, Ernest; Scott, Daniel; Ellingsworth, Larry; Glenn, Gregory; Smith, Gale] Noyayax Inc, Gaithersburg, MD 20878 USA.
RP Smith, G (reprint author), Noyayax Inc, Gaithersburg, MD 20878 USA.
EM gsmith@novavax.com
FU Novavax, Inc.
FX Support of this work was provided by Novavax, Inc. The funder had no
   role in the study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR ARBIZA J, 1992, J GEN VIROL, V73, P2225, DOI 10.1099/0022-1317-73-9-2225
   August A, 2017, VACCINE, V35, P3749, DOI 10.1016/j.vaccine.2017.05.045
   Brady MT, 2014, PEDIATRICS, V134, P415, DOI 10.1542/peds.2014-1665
   Fries L, 2017, IMMUN AGEING, V14, DOI 10.1186/s12979-017-0090-7
   Fuentes S, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005554
   Gilbert BE, 2018, VACCINE, V36, P8069, DOI 10.1016/j.vaccine.2018.10.073
   Gilman MSA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09807-5
   Glenn GM, 2016, J INFECT DIS, V213, P411, DOI 10.1093/infdis/jiv406
   Glenn GM, 2013, VACCINE, V31, P524, DOI 10.1016/j.vaccine.2012.11.009
   Gonzalez-Reyes L, 2001, P NATL ACAD SCI USA, V98, P9859, DOI 10.1073/pnas.151098198
   Huang K, 2010, J VIROL, V84, P8132, DOI 10.1128/JVI.02699-09
   KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955
   Krarup A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9143
   Krzyzaniak MA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003309
   Kulkarni PS, 2018, VIRAL IMMUNOL, V31, P195, DOI 10.1089/vim.2017.0147
   Kwakkenbos MJ, 2010, NAT MED, V16, P123, DOI 10.1038/nm.2071
   Leemans A, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10080426
   Mazur NI, 2019, J INFECT DIS, V219, P59, DOI 10.1093/infdis/jiy477
   Mazur NI, 2018, LANCET INFECT DIS, V18, pE295, DOI 10.1016/S1473-3099(18)30292-5
   McLellan JS, 2015, CURR OPIN VIROL, V11, P70, DOI 10.1016/j.coviro.2015.03.002
   McLellan JS, 2013, CURR TOP MICROBIOL, V372, P83, DOI 10.1007/978-3-642-38919-1_4
   McLellan JS, 2011, J VIROL, V85, P7788, DOI 10.1128/JVI.00555-11
   McLellan JS, 2010, J VIROL, V84, P12236, DOI 10.1128/JVI.01579-10
   McLellan JS, 2010, NAT STRUCT MOL BIOL, V17, P248, DOI 10.1038/nsmb.1723
   Mejias A, 2008, BIOL-TARGETS THER, V2, P433
   Morton CJ, 2003, VIROLOGY, V311, P275, DOI 10.1016/S0042-6822(03)00115-6
   Mousa JJ, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2016.271
   Mousa JJ, 2016, P NATL ACAD SCI USA, V113, pE6849, DOI 10.1073/pnas.1609449113
   MUFSON MA, 1985, J GEN VIROL, V66, P2111, DOI 10.1099/0022-1317-66-10-2111
   Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531
   Patel NFD, 2017, PRESENTED AT RSV VAC
   Piedimonte G, 2014, PEDIATR REV, V35, P519, DOI 10.1542/pir.35-12-519
   Raghunandan R, 2014, VACCINE, V32, P6485, DOI 10.1016/j.vaccine.2014.09.030
   Rossey I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14158
   Ruiz-Arguello MB, 2004, J GEN VIROL, V85, P3677, DOI 10.1099/vir.0.80318-0
   Sandritter T, 1999, J Pediatr Health Care, V13, P191, DOI 10.1016/S0891-5245(99)90039-1
   Smith G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050852
   Swanson KA, 2011, P NATL ACAD SCI USA, V108, P9619, DOI 10.1073/pnas.1106536108
   Tapia LI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090786
   Turner TL, 2014, CLINICOECONOMIC OUTC, V6, P217, DOI 10.2147/CEOR.S60710
   Walsh EE, 2018, J INFECT DIS, V218, P208, DOI 10.1093/infdis/jiy106
   Zhao M, 2017, J VIROL, V91, DOI 10.1128/JVI.00176-17
NR 42
TC 4
Z9 4
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 24
PY 2019
VL 37
IS 41
BP 6112
EP 6124
DI 10.1016/j.vaccine.2019.07.089
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA1HT
UT WOS:000487568800013
PM 31416644
OA Other Gold
DA 2020-05-12
ER

PT J
AU Zuk, P
   Zuk, P
AF Zuk, Piotr
   Zuk, Pawel
TI One of the recent attacks of smallpox in Europe: A massive vaccination
   campaign during the epidemic in Wroclaw in 1963
SO VACCINE
LA English
DT Article
DE Smallpox; Vaccination campaign; Epidemic; Post-vaccination complications
ID ERADICATION; OUTBREAK; LESSONS; VIRUS
AB Based on archival materials, collected literature and archival articles analysing the clinical course of the disease, the article presents the medical and social course of one of the recent epidemics of smallpox in Europe, which took place in Wroclaw in 1963. During the epidemic, 99 people fell ill and seven of them died. The authors describe how a mass vaccination campaign was organised in the city and the entire surrounding region. This historical study shows not only the course of the epidemic itself, but also the ways to prevent and deal with infectious diseases and the organisation of vaccinations in communist Poland. The authors also discuss the issue of the relationship between the vaccination period and the course of smallpox in patients and show the scale of post-vaccination complications in the situation of mass vaccination against smallpox. Although the article refers to historical events, it draws attention to the topicality of challenges posed by the variola virus. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zuk, Piotr] Univ Wroclaw, Dept Sociol, Wroclaw, Poland.
   [Zuk, Pawel] Ctr Civil Rights & Democracy Res, Wroclaw, Poland.
RP Zuk, P; Zuk, P (reprint author), Inst Socjol, Ul Koszarowa 3, PL-51149 Wroclaw, Poland.
EM pzuk@uni.wroc.pl; zuk.paw@gmail.com
CR Arendzikowski B, 1964, PRZEGLAD EPIDEMIOLOG, V18
   de Quadros CA, 2011, VACCINE, V29, pD30, DOI 10.1016/j.vaccine.2011.10.001
   Dutta M, 2011, VACCINE, V29, pD19, DOI 10.1016/j.vaccine.2011.12.001
   Esparza J, 2017, VACCINE, V35, P7222, DOI 10.1016/j.vaccine.2017.11.003
   FENNER F, 1988, SMALLPOX ITS ERADICA
   Foster SO, 2011, VACCINE, V29, pD22, DOI 10.1016/j.vaccine.2011.06.081
   Hammarlund E, 2010, J VIROL, V84, P12754, DOI 10.1128/JVI.01763-10
   Hora Z., 1982, VARIOLA VERA
   IRONS JV, 1953, AM J PUBLIC HEALTH, V43, P25, DOI 10.2105/AJPH.43.1.25
   Kienzler I, 2015, KRONIKA PRL 1945 198, V3
   Komunikat Wydzialu Zdrowia, 1963, SLOWO POLSKIE
   Kos JB, 2017, ALARM DLA WROCLAWIA
   KOSTRZEWSKI J, 1964, Przegl Epidemiol, V18, P141
   Lasco G, 2019, SOC SCI MED, V221, P1, DOI 10.1016/j.socscimed.2018.12.006
   Litvinjenko S, 1973, EPIDEMIOLOGIC ASPECT
   MACK TM, 1972, J INFECT DIS, V125, P161, DOI 10.1093/infdis/125.2.161
   Muyembe-Tamfum JJ, 2011, VACCINE, V29, pD13, DOI 10.1016/j.vaccine.2011.10.049
   PENAR S, 1964, Przegl Epidemiol, V18, P189
   Poland GA, 2009, VACCINE, V27, pD23, DOI 10.1016/j.vaccine.2009.08.054
   Shchelkunov SN, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003756
   Shchelkunov SN, 2011, VACCINE, V29, pD49, DOI 10.1016/j.vaccine.2011.05.037
   Shchelkunova GA, 2017, ACTA NATURAE, V9, P4, DOI 10.32607/2075851-2017-9-4-4-12
   SKURSKA Z, 1964, Przegl Epidemiol, V18, P173
   Surowcowa-Swidzifiska A, 1964, PRZEGLAD EPIDEMIOLOG, V18
   Trzaskowska G, 2008, EPIDEMIA CZARNEJ OSP
   WEHRLE PF, 1970, B WORLD HEALTH ORGAN, V43, P669
   Wieckowska E, 1999, Przegl Epidemiol, V53, P395
   Zaraza Ambroziewicz J., 2016, WARSZAWA DOWODY ISTN
   Zelicoff AP, 2003, CRIT REV MICROBIOL, V29, P97, DOI 10.1080/713610418
   Zuk P, 2019, ECON LABOUR RELAT RE, V30, P307, DOI 10.1177/1035304619847335
   Zuk P, 2019, VACCINE, V37, P1491, DOI 10.1016/j.vaccine.2019.01.073
NR 31
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 24
PY 2019
VL 37
IS 41
BP 6125
EP 6131
DI 10.1016/j.vaccine.2019.08.038
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JA1HT
UT WOS:000487568800014
PM 31455585
DA 2020-05-12
ER

PT J
AU Rollenhagen, JE
   Woods, CM
   O'Dowd, A
   Poole, ST
   Tian, JH
   Guebre-Xabierc, M
   Ellingsworth, L
   Prouty, MG
   Glenn, G
   Savarino, SJ
AF Rollenhagen, Julianne E.
   Woods, Colleen M.
   O'Dowd, Aisling
   Poole, Steven T.
   Tian, Jing-Hui
   Guebre-Xabierc, Mimi
   Ellingsworth, Larry
   Prouty, Michael G.
   Glenn, Greg
   Savarino, Stephen J.
TI Evaluation of transcutaneous immunization as a delivery route for an
   enterotoxigenic E. coli adhesin-based vaccine with CfaE, the
   colonization factor antigen 1 (CFA/I) tip adhesin
SO VACCINE
LA English
DT Article
DE ETEC; TCI; CFA/I; CfaE; Transcutaneous; Adhesin
ID HEAT-LABILE TOXIN; ESCHERICHIA-COLI; PROTECTIVE IMMUNITY; DOUBLE-BLIND;
   IMMUNOGENICITY; TRAVELERS; FIMBRIAE; ETIOLOGY; EFFICACY; DIARRHEA
AB dscCfaE is a recombinant form of the CFA/I tip adhesin CfaE, expressed by a large proportion of enterotoxigenic E. coli (ETEC). It is highly immunogenic by the intranasal route in mice and Aotus nancymaae, protective against challenge with CFA/I+ ETEC in an A. nancymaae challenge model, and antibodies to dscCfaE passively protect against CFA/I+ ETEC challenge in human volunteers. Here, we show that transcutaneous immunization (TCI) with dscCfaE in mice resulted in strong anti-CfaE IgG serum responses, with a clear dose-response effect. Co-administration with heat-labile enterotoxin (LT) resulted in enhanced immune responses over those elicited by dscCfaE alone and strong anti-LT antibody responses. The highest dose of dscCfaE administered transcutaneously with LT elicited strong HAI titers, a surrogate for the neutralization of intestinal adhesion. Fecal anti-adhesin IgG and IgA antibody responses were also induced. These findings support the feasibility of TCI for the application of an adhesin-toxin based ETEC vaccine. Published by Elsevier Ltd.
C1 [Rollenhagen, Julianne E.; O'Dowd, Aisling; Poole, Steven T.] Henry M Jackson Fdn Adv Mil Med, 6720A Rockledge Dr, Bethesda, MD 20817 USA.
   [Woods, Colleen M.; Prouty, Michael G.; Savarino, Stephen J.] Naval Med Res Ctr, Enter Dis Dept, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.
   [Tian, Jing-Hui; Guebre-Xabierc, Mimi; Ellingsworth, Larry; Glenn, Greg] Iomai Corp, Firstfield Rd,Suite 250, Gaithersburg, MD 20878 USA.
   [Savarino, Stephen J.] Uniformed Serv Univ Hlth Sci, Dept Pediat, Bethesda, MD 20814 USA.
   [Woods, Colleen M.] PATH Malaria Vaccine Initiat, 2201 Westlake Ave,Suite 200, Seattle, WA 98121 USA.
   [O'Dowd, Aisling] Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England.
   [Tian, Jing-Hui; Guebre-Xabierc, Mimi; Ellingsworth, Larry; Glenn, Greg] Novavax, 20 Firstfield Rd, Gaithersburg, MD 20878 USA.
   [Savarino, Stephen J.] Sanofi Pasteur, 1 Discovery Dr, Swiftwater, PA 18370 USA.
RP Prouty, MG (reprint author), Naval Med Res Ctr, Enter Dis Dept, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.
EM michael.g.prouty2.mil@mail.mil
FU U.S. Army Military Infectious Diseases Research Program
   [6000.RAD1.DA2.A0307]; Henry M. Jackson Foundation for the Advancement
   of Military Medicine
FX The authors wish to thank Dr. Chad Porter and Dr. Milton Maciel for
   editorial input. This research was supported by U.S. Army Military
   Infectious Diseases Research Program Work Unit Number
   6000.RAD1.DA2.A0307 (to S.J.S) and by the Henry M. Jackson Foundation
   for the Advancement of Military Medicine. All animal study protocols
   were reviewed and approved by the Gene Logic, INC Institutional Animal
   Care and Use Committee in compliance with all applicable Federal
   regulations governing the protection of animals in research. The views
   expressed in this article are those of the authors and do not
   necessarily reflect the official policy or position of the Department of
   the Navy, Department of Defense, nor the U.S. Government. S.J.S.,
   C.M.W., and M.G.P. served as a military service members over the course
   of this work, which was prepared as part of their official duties. Title
   17 USC. 105 provides that 'Copyright protection under this title is not
   available for any work of the United States Government.' Title 17 U.S.C.
   101 defines a U.S. Government work as a work prepared by a military
   service member or employee of the U.S. Government as part of that
   person's official duties.
CR Anantha RP, 2004, INFECT IMMUN, V72, P7190, DOI 10.1128/IAI.72.12.7190-7201.2004
   Behrens RH, 2014, LANCET INFECT DIS, V14, P197, DOI 10.1016/S1473-3099(13)70297-4
   Glenn GM, 1998, J IMMUNOL, V161, P3211
   Glenn GM, 2000, NAT MED, V6, P1403, DOI 10.1038/82225
   Glenn GM, 1998, NATURE, V391, P851, DOI 10.1038/36014
   Gockel CM, 2000, MOL IMMUNOL, V37, P537, DOI 10.1016/S0161-5890(00)00074-2
   Guerena-Burgueno F, 2002, INFECT IMMUN, V70, P1874, DOI 10.1128/IAI.70.4.1874-1880.2002
   Isidean SD, 2011, VACCINE, V29, P6167, DOI 10.1016/j.vaccine.2011.06.084
   Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2
   Lewis DJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006999
   Mawas F, 2004, J INFECT DIS, V190, P1177, DOI 10.1086/423327
   McKenzie R, 2007, VACCINE, V25, P3684, DOI 10.1016/j.vaccine.2007.01.043
   Poole ST, 2007, MOL MICROBIOL, V63, P1372, DOI 10.1111/j.1365-2958.2007.05612.x
   Riddle MS, 2006, AM J TROP MED HYG, V74, P891, DOI 10.4269/ajtmh.2006.74.891
   Rollenhagen JE, ESTABLISHMENT VALIDA, DOI [10.1128/IA1.00634-18, DOI 10.1128/IA1.00634-18]
   Rollenhagen JE, 2006, INFECT IMMUN, V74, P5834, DOI 10.1128/IAI.00438-06
   Savarino Si.McKenzieR.TribbleDR, 2017, J INFECT DIS, P24
   Scharton-Kersten T, 2000, INFECT IMMUN, V68, P5306, DOI 10.1128/IAI.68.9.5306-5313.2000
   Sincock SA, 2016, VACCINE, V34, P284, DOI 10.1016/j.vaccine.2015.11.017
   Yu JM, 2002, INFECT IMMUN, V70, P1056, DOI 10.1128/IAI.70.3.1056-1068.2002
NR 20
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 30
PY 2019
VL 37
IS 42
BP 6134
EP 6138
DI 10.1016/j.vaccine.2019.08.057
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JB1JT
UT WOS:000488317400002
PM 31492474
OA Other Gold
DA 2020-05-12
ER

PT J
AU Nielsen, LE
   Kelly, DC
   Gyorffy, J
   Ager, EP
   Markelz, AE
AF Nielsen, Lindsey E.
   Kelly, Devin C.
   Gyorffy, Janelle
   Ager, Edward P.
   Markelz, Ana E.
TI Mumps outbreak and MMR IgG surveillance as a predictor for immunity in
   military trainees
SO VACCINE
LA English
DT Article
DE Mumps; MMR vaccine; Measles; Rubella; IgG Titer
ID RUBELLA VACCINE; VIRUS; MEASLES; PERSISTENCE; ANTIBODIES; IMMUNIZATION;
   PROTEIN; STRAIN
AB In 2017, a mumps outbreak occurred in a barrack holding 249 service members. Suspected cases were evaluated with a combination of mumps IgG, IgM, viral culture, PCR and sequencing. Seven cases were diagnosed in febrile patients presenting with parotitis or orchitis. Mumps infection was confirmed by IgM or positive PCR with 5/7 cases having notable IgG levels before infection. Sequencing confirmed mumps genotype G strain. Serum from all 249 service members collected prior to the outbreak was withdrawn from the Department of Defense (DoD) Serum Repository and the IgG values of measles, mumps and rubella determined with 20.2%, 12.3% and 9.7% service members being seronegative, respectively. No specific IgG seronegativity combination predicted IgG marker levels to another virus within the same vaccine. This paper provides additional evidence that mumps serology is not a reliable surrogate for mumps immunity and that we need better laboratory correlates to confirm immunity. Published by Elsevier Ltd.
C1 [Nielsen, Lindsey E.; Ager, Edward P.] Brooke Army Med Ctr, Dept Pathol & Area Lab Serv, San Antonio, TX USA.
   [Nielsen, Lindsey E.] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA.
   [Kelly, Devin C.; Gyorffy, Janelle; Markelz, Ana E.] Brooke Army Med Ctr, Dept Med, San Antonio, TX USA.
   [Kelly, Devin C.] Wright Patterson Med Ctr, Dept Med, Dayton, OH USA.
RP Nielsen, LE (reprint author), Univ Nebraska, Med Ctr, Omaha, NE 68182 USA.
EM lindsey.nielsen@unmc.edu
OI Nielsen, Lindsey/0000-0002-7468-9504
FU DoDUnited States Department of Defense
FX We would like to thank the DoD Public Health and DoD Serum Repository
   for their insights and assistance during the outbreak period and Dr.
   Winfred Stacey for biostatistician analysis. The authors have no
   financial or personal disclosures. This work was deemed exempt from IRB
   review based on support of public health outbreak initiative and funded
   exclusively through the DoD. The view(s) expressed herein are those of
   the author(s) and do not reflect the official policy or position of
   Brooke Army Medical Center, the U.S. Army Medical Department, the U.S.
   Army Office of the Surgeon General, the Department of the Air Force, the
   Department of the Army or the Department of Defense or the U.S.
   Government.
CR Abedi GR, 2012, VACCINE, V30, P7052, DOI 10.1016/j.vaccine.2012.09.053
   AFZAL MA, 1993, J GEN VIROL, V74, P917, DOI 10.1099/0022-1317-74-5-917
   Albertson JP, 2016, MMWR MORBIDITY MORTA, V65
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P217
   Barskey AE, 2012, NEW ENGL J MED, V367, P1704, DOI 10.1056/NEJMoa1202865
   Cardemil CV, 2017, NEW ENGL J MED, V377, P947, DOI 10.1056/NEJMoa1703309
   CDC, 2012, MUMPS 2012 CAS DEF
   DAVIDKIN I, 1995, VACCINE, V13, P1617, DOI 10.1016/0264-410X(95)00064-8
   Davidkin I, 2008, J INFECT DIS, V197, P950, DOI 10.1086/528993
   Dayan GH, 2008, CLIN INFECT DIS, V47, P1458, DOI 10.1086/591196
   Deeks SL, 2011, CAN MED ASSOC J, V183, P1014, DOI 10.1503/cmaj.101371
   HILLEMAN MR, 1968, NEW ENGL J MED, V278, P227, DOI 10.1056/NEJM196802012780501
   Hviid A, 2008, LANCET, V371, P932, DOI 10.1016/S0140-6736(08)60419-5
   Ivancic-Jelecki J, 2008, INFECT GENET EVOL, V8, P603, DOI 10.1016/j.meegid.2008.04.007
   Kutty PK, 2014, HUM VACC IMMUNOTHER, V10, P1373, DOI 10.4161/hv.28389
   LeBaron CW, 2009, J INFECT DIS, V199, P552, DOI 10.1086/596207
   Marin M, 2018, MMWR-MORBID MORTAL W, V67, P33, DOI 10.15585/mmwr.mm6701a7
   May M, 2018, INT J INFECT DIS, V66, P1, DOI 10.1016/j.ijid.2017.09.024
   Nojd J, 2001, VACCINE, V19, P1727, DOI 10.1016/S0264-410X(00)00392-3
   Ogbuanu IU, 2012, PEDIATRICS, V130, pE1567, DOI 10.1542/peds.2012-0177
   Orvell C, 2002, J GEN VIROL, V83, P2489, DOI 10.1099/0022-1317-83-10-2489
   Parker Fiebelkorn A, 2012, MANUAL SURVEILLANCE
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Rubin S, 2006, VACCINE, V24, P2662, DOI 10.1016/j.vaccine.2005.10.050
   Rubin SA, 2008, J INFECT DIS, V198, P508, DOI 10.1086/590115
   WEIBEL RE, 1980, P SOC EXP BIOL MED, V165, P260, DOI 10.3181/00379727-165-40967
   White Sarah J, 2012, Clin Obstet Gynecol, V55, P550, DOI 10.1097/GRF.0b013e31824df256
   2008, MMWR MORBID MORTAL W, V57, P1103
NR 28
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 30
PY 2019
VL 37
IS 42
BP 6139
EP 6143
DI 10.1016/j.vaccine.2019.08.054
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JB1JT
UT WOS:000488317400003
PM 31493948
DA 2020-05-12
ER

PT J
AU Kauffmann, F
   Van Damme, P
   Leroux-Roels, G
   Vandermeulen, C
   Berthels, N
   Beuneu, C
   Mali, S
AF Kauffmann, Florence
   Van Damme, Pierre
   Leroux-Roels, Geert
   Vandermeulen, Corinne
   Berthels, Nele
   Beuneu, Claire
   Mali, Stephanie
TI Clinical trials with GMO-containing vaccines in Europe: Status and
   regulatory framework
SO VACCINE
LA English
DT Review
DE Genetically modified organism; GMO; Vaccines; Vector-based vaccines;
   Regulation; Clinical trials contained use; Deliberate release
AB Recombinant technology has revolutionised the way novel vaccines are developed and manufactured. The possibility to genetically modify micro-organisms to bring immunogenic material (antigens/epitopes) to the human (or animal) immune system to provoke an immune response, provides new hope to producing prophylactic vaccines against HIV, malaria and tuberculosis and emerging diseases. Regulatory requirements associated with the development of genetically-modified organism (GMO)-containing vaccines in Europe add an additional burden to the clinical trial application procedure and to the preparation and initiation of a clinical trial of such vaccines. Moreover, the GMO regulatory framework is complex and only partially harmonised across Europe, which may hamper multi-country clinical trials with GMO-containing vaccines. This paper provides an overview of clinical trial applications with GMO-containing vaccines in Europe and reviews the regulatory framework in countries where GMO-containing vaccine clinical trial authorisation (CTA) applications were submitted between 2004 and 2017. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kauffmann, Florence] GlaxoSmithKline Biol SA, Rue Inst 89, B-1330 Rixensart, Belgium.
   [Van Damme, Pierre] Univ Antwerp, Ctr Evaluat Vaccinat, Vaccines & Infect Dis Inst, Antwerp, Belgium.
   [Leroux-Roels, Geert] Univ Ghent, Ctr Vaccinol CEVAC, Ghent, Belgium.
   [Leroux-Roels, Geert] Ghent Univ Hosp, Ghent, Belgium.
   [Vandermeulen, Corinne] Katholieke Univ Leuven, Leuven Univ, Vaccinol Ctr, Leuven, Belgium.
   [Berthels, Nele; Beuneu, Claire; Mali, Stephanie] FAMHP, Brussels, Belgium.
RP Mali, S (reprint author), FAMHP, Brussels, Belgium.
EM Stephanie.Mali@fagg-afmps.be
CR Aguiar M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005179
   [Anonymous], 2005, ARRETE ROYAL REGLEME
   Coleman MS, 2005, HEALTH AFFAIR, V24, P635, DOI 10.1377/hlthaff.24.3.635
   E. Commission, 2017, NAT PROC MUST BE FOL
   e. E. E. Alliance for Regenerative Medicine, 2017, POSS SOL IMPR EUR RE
   European Commission, ADV THER MAJ DEV
   Ginn SL, 2013, J GENE MED, V15, P65, DOI 10.1002/jgm.2698
   Guy B, 2010, VACCINE, V28, P632, DOI 10.1016/j.vaccine.2009.09.098
   Kreijtz J, 2014, GM VACCINES BENCH BE
   Liu MA, 2010, IMMUNITY, V33, P504, DOI 10.1016/j.immuni.2010.10.004
   Loomis RJ, 2015, VACCINES-BASEL, V3, P429, DOI 10.3390/vaccines3020429
   McConaghie A, 2017, CAN UK IMPROVE CLIN
   Nakayama Y, 2015, VACCINES-BASEL, V3, P186, DOI 10.3390/vaccines3010186
   Offit PA, 2005, HEALTH AFFAIR, V24, P622, DOI 10.1377/hlthaff.24.3.622
   P.I.R.A.S.S. PERSEUS, 2006, PERSEUS AN APPL CONT
   Plotkin SA, 2005, HEALTH AFFAIR, V24, P631, DOI 10.1377/hlthaff.24.3.631
   Plotkin S, 2014, P NATL ACAD SCI USA, V111, P12283, DOI 10.1073/pnas.1400472111
   Plotkin SA, 2017, HUM VACC IMMUNOTHER, V13, P2755, DOI 10.1080/21645515.2017.1306615
   Ramenzanpour B, 2015, INT J CLIN TRIALS, V2, P64
   Ramezanpour B, 2016, VACCINE, V34, P6436, DOI 10.1016/j.vaccine.2016.06.059
   Sun YS, 2012, J PHARMACOL TOX MET, V65, P49, DOI 10.1016/j.vascn.2012.01.002
NR 21
TC 0
Z9 0
U1 13
U2 20
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 30
PY 2019
VL 37
IS 42
BP 6144
EP 6153
DI 10.1016/j.vaccine.2019.08.018
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JB1JT
UT WOS:000488317400004
PM 31493949
DA 2020-05-12
ER

PT J
AU An, SH
   Lee, CY
   Hong, SM
   Choi, JG
   Lee, YJ
   Jeong, JH
   Kim, JB
   Song, CS
   Kim, JH
   Kwon, HJ
AF An, Se-Hee
   Lee, Chung-Young
   Hong, Seung-Min
   Choi, Jun-Gu
   Lee, Youn-Jeong
   Jeong, Jei-Hyun
   Kim, Jun-Beom
   Song, Chang-Seon
   Kim, Jae-Hong
   Kwon, Hyuk-Joon
TI Bioengineering a highly productive vaccine strain in embryonated chicken
   eggs and mammals from a non-pathogenic Glade 2.3.4.4 H5N8 strain
SO VACCINE
LA English
DT Article
DE Highly pathogenic avian influenza; Clade 2.3.4.4; H5N8; H103Y; Vaccine
ID PATHOGENIC AVIAN INFLUENZA; MANDARIN DUCK; SOUTH-KOREA;
   EXPERIMENTAL-INFECTION; PROTECTIVE EFFICACY; A(H5N6) VIRUS; WILD BIRDS;
   A VIRUS; HEMAGGLUTININ; TRANSMISSION
AB The Glade 2.3.4.4 H5Nx is a highly pathogenic avian influenza (HPAI) virus, which first appeared in China and has spread worldwide since then, including Korea. It is divided into subclades a - d, but the PR8-derived recombinant Glade 2.3.4.4 a viruses replicate inefficiently in embryonated chicken eggs (ECEs). High virus titer in ECEs and no mammalian pathogenicity are the most important prerequisites of efficacious and safer vaccine strains against HPAI. In this study, we have synthesized hemagglutinin (HA) and neuraminidase (NA) genes based on the consensus amino acid sequences of the Glade 2.3.4.4a and b H5N8 HPAIVs, using the GISAID database. We generated PR8-derived H5N8 recombinant viruses with single point mutations in HA and NA, which are related to efficient replication in ECEs. The H103Y mutation in HA increased mammalian pathogenicity as well as virus titer in ECEs, by 10-fold. We also successfully eradicated mammalian pathogenicity in H103Y-bearing H5N8 recombinant virus by exchanging PB2 genes of PR8 and 01310 (Korean H9N2 vaccine strain). The final optimized H5N8 vaccine strain completely protected against a heterologous Glade 2.344c H5N6 HPAIV in chickens, and induced hemagglutination inhibition (HI) antibody in ducks. However, the antibody titer of ducks showed age-dependent results. Thus, H103Y and 01310PB2 gene have been successfully applied to generate a highly productive, safe, and efficacious Glade 2.344 H5N8 vaccine strain in ECEs. (C) 2019 Published by Elsevier Ltd.
C1 [An, Se-Hee; Hong, Seung-Min; Kim, Jae-Hong] Seoul Natl Univ, Coll Vet Med, Lab Avian Dis, Seoul 08826, South Korea.
   [Kwon, Hyuk-Joon] Seoul Natl Univ, Coll Vet Med, Dept Farm Anim Med, Lab Poultry Med, Seoul 08826, South Korea.
   [Kim, Jae-Hong; Kwon, Hyuk-Joon] Seoul Natl Univ, Coll Vet Med, Res Inst Vet Sci, Seoul 08826, South Korea.
   [Lee, Chung-Young] Emory Univ, Dept Microbiol & Immunol, Sch Med, 1510 Clifton Rd, Atlanta, GA 30322 USA.
   [Choi, Jun-Gu; Lee, Youn-Jeong] Anim & Plant Quarantine Agcy, Avian Dis Div, 177,Hyeoksin 8 Ro, Gyeongsangbuk Do 39660, South Korea.
   [Jeong, Jei-Hyun; Kim, Jun-Beom; Song, Chang-Seon] Konkuk Univ, Coll Vet Med, Lab Avian Dis, Seoul 05029, South Korea.
   [Kwon, Hyuk-Joon] Seoul Natl Univ, GBST, FACTRC, Kangwon Do, South Korea.
RP Kwon, HJ (reprint author), Seoul Natl Univ, Dept Farm Anim Med, Coll Vet Med, 1 Gwanak Ro, Seoul 88026, South Korea.; Kwon, HJ (reprint author), Seoul Natl Univ, BK21 Plus Vet Sci, 1 Gwanak Ro, Seoul 88026, South Korea.
EM kwonhj01@snu.ac.kr
OI Choi, Jun-Gu/0000-0002-4859-1132
FU Ministry of Food, Agriculture, Forestry, and Fisheries, Republic of
   Korea [112102-2];  [A103001]
FX This work was supported by a grant (Grant No. 112102-2) from the
   Ministry of Food, Agriculture, Forestry, and Fisheries, Republic of
   Korea and a grant from the Korea Healthcare Technology R&D Project,
   Ministry of Health & Welfare, Republic of Korea (Grant No. A103001).
CR ALEXANDER DJ, 1986, AVIAN PATHOL, V15, P647, DOI 10.1080/03079458608436328
   An SH, 2019, VET MICROBIOL, V228, P213, DOI 10.1016/j.vetmic.2018.11.031
   Choi JG, 2008, J VET SCI, V9, P67, DOI 10.4142/jvs.2008.9.1.67
   Claes F, 2016, CURR OPIN VIROL, V16, P158, DOI 10.1016/j.coviro.2016.02.005
   de Vries RP, 2014, J VIROL, V88, P768, DOI 10.1128/JVI.02690-13
   Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491
   Giles BM, 2011, VACCINE, V29, P3043, DOI 10.1016/j.vaccine.2011.01.100
   HAMILTON MA, 1978, ENVIRON SCI TECHNOL, V12, P417, DOI 10.1021/es60140a017
   Herfst S, 2012, SCIENCE, V336, P1534, DOI 10.1126/science.1213362
   Hoffmann E, 2000, P NATL ACAD SCI USA, V97, P6108, DOI 10.1073/pnas.100133697
   Hoffmann E, 2001, ARCH VIROL, V146, P2275, DOI 10.1007/s007050170002
   Imai M, 2012, NATURE, V486, P420, DOI 10.1038/nature10831
   Jang JW, 2017, J VET SCI, V18, P299, DOI 10.4142/jvs.2017.18.S1.299
   Jin M, 2018, J VET RES, V62, P413, DOI 10.2478/jvetres-2018-0078
   Kandeil A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28057-x
   Kang HM, 2017, VET MICROBIOL, V198, P59, DOI 10.1016/j.vetmic.2016.12.005
   Kapczynski DR, 2017, VACCINE, V35, P6345, DOI 10.1016/j.vaccine.2017.04.042
   Kaverin NV, 2007, J VIROL, V81, P12911, DOI 10.1128/JVI.01522-07
   KIDA H, 1980, INFECT IMMUN, V30, P547
   Kim IH, 2015, VACCINE, V33, P6314, DOI 10.1016/j.vaccine.2015.09.048
   Kim IH, 2014, VET MICROBIOL, V168, P41, DOI 10.1016/j.vetmic.2013.10.011
   Kim IH, 2013, VET MICROBIOL, V162, P471, DOI 10.1016/j.vetmic.2012.10.034
   Kuchipudi SV, 2014, VET RES, V45, DOI 10.1186/s13567-014-0118-3
   Kwon HJ, 2014, METHOD PREPARING HA2
   Kwon HyukJoon, 2009, Open Veterinary Science Journal, V3, P9, DOI 10.2174/1874318800903010009
   Kwon JH, 2018, EMERG INFECT DIS, V24, P1953, DOI 10.3201/eid2410.180461
   Kwon JH, 2017, VET MICROBIOL, V203, P95, DOI 10.1016/j.vetmic.2017.03.003
   Kwon JN, 2017, EMERG INFECT DIS, V23, P823, DOI 10.3201/eid2305.161905
   Lee CR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04815-1
   Lee DH, 2016, AVIAN PATHOL, V45, P208, DOI 10.1080/03079457.2016.1142502
   Lee DH, 2015, J VIROL, V89, P6521, DOI 10.1128/JVI.00728-15
   Lee EK, 2017, INFECT GENET EVOL, V51, P21, DOI 10.1016/j.meegid.2017.03.005
   Lee MS, 2019, ARCH VIROL, V164, P127, DOI 10.1007/s00705-018-4062-9
   Lee YJ, 2014, EMERG INFECT DIS, V20, P1087, DOI 10.3201/eid2006.140233
   Linster M, 2014, CELL, V157, DOI 10.1016/j.cell.2014.02.040
   Lourens A, 2005, POULTRY SCI, V84, P914, DOI 10.1093/ps/84.6.914
   Lyons DM, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10080407
   MCLEAN IW, 1945, P SOC EXP BIOL MED, V59, P192
   Middleton D, 2007, VIROLOGY, V359, P66, DOI 10.1016/j.virol.2006.08.046
   Miller GL, 1944, J EXP MED, V79, P173, DOI 10.1084/jem.79.2.173
   Ohmit SE, 2011, J INFECT DIS, V204, P1879, DOI 10.1093/infdis/jir661
   Pantin-Jackwood MJ, 2013, VIRUS RES, V178, P21, DOI 10.1016/j.virusres.2013.07.012
   Poen MJ, 2019, VIRUS EVOL, V5, DOI 10.1093/ve/vez004
   POTTER CW, 1979, BRIT MED BULL, V35, P69, DOI 10.1093/oxfordjournals.bmb.a071545
   Richard M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07000-6
   Santos JJS, 2017, VACCINE, V35, P5637, DOI 10.1016/j.vaccine.2017.08.059
   Smith GJD, 2015, INFLUENZA OTHER RESP, V9, P271, DOI 10.1111/irv.12324
   Smith J, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1778-8
   Song BM, 2017, J VET SCI, V18, P89, DOI 10.4142/jvs.2017.18.1.89
   STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x
   SUBBARAO EK, 1993, J VIROL, V67, P1761, DOI 10.1128/JVI.67.4.1761-1764.1993
   Takahashi Y, 2009, J INFECT DIS, V199, P1629, DOI 10.1086/598954
   Taubenberger JK, 2005, NATURE, V437, P889, DOI 10.1038/nature04230
   van den Brand JMA, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0070-9
   Velkov T, 2013, MOL IMMUNOL, V56, P705, DOI 10.1016/j.molimm.2013.07.010
   Webster RG, 2006, VIROLOGY, V351, P303, DOI 10.1016/j.virol.2006.01.044
   Wen F, 2009, J VIROL, V2018, P92
   Xiong XL, 2013, NATURE, V497, P392, DOI 10.1038/nature12144
   Yang ZF, 2015, NEW ENGL J MED, V373, P487, DOI 10.1056/NEJMc1502983
   Zhang W, 2013, SCIENCE, V340, P1463, DOI 10.1126/science.1236787
NR 60
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 30
PY 2019
VL 37
IS 42
BP 6154
EP 6161
DI 10.1016/j.vaccine.2019.08.074
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JB1JT
UT WOS:000488317400005
PM 31495597
DA 2020-05-12
ER

PT J
AU Smith, D
   Streatfield, SJ
   Acosta, H
   Ganesan, S
   Fattom, A
AF Smith, Douglas
   Streatfield, Stephen J.
   Acosta, Hugo
   Ganesan, Shyamala
   Fattom, Ali
TI A nanoemulsion-adjuvanted intranasal H5N1 influenza vaccine protects
   ferrets against homologous and heterologous H5N1 lethal challenge
SO VACCINE
LA English
DT Article
DE Pandemic flu; Nanoemulsion; Intranasal immunization; Vaccine; Ferrets
   model
ID CELLULAR-IMMUNITY; HUMAN SERA; VIRUS; ANTIBODY; IMMUNOGENICITY;
   IMMUNIZATION; NEUTRALIZATION; RESPONSES; SAFETY
AB Background: Flu vaccines administered intramuscularly (IM) have shown seasonally fluctuating efficacy, 20-60%, throughout the last 15 years. We formulated a recombinant H5 (rH5) in our Nanovax (R) (NE01) (rH5/NE01) adjuvant for intranasal vaccination in ferrets. We evaluated the regimen, one vs two immunization, and cross Glade protection a ferret challenge model.
   Methods: Plant derived recombinant H5 (rH5) antigen was formulated with NE01 and administered intranasally to ferrets. Immunogenicity (IgG), hemagglutination inhibition (HI), and protection against lethal challenge, were measured following one or two immunizations. Protection against homologous (strain A/Indo) and heterologous (strain A/Vn) was evaluated in ferrets following two immunizations.
   Results: IN immunization with rH5/NE01 induced significant IgG levels after one and two immunizations. One vaccination did not induce any HI while low HI was measured after two immunizations. Homologous challenge with H5N1 A/ Indonesia showed 100% survival, with minimal weight loss in animals vaccinated twice compared to the unvaccinated controls. Analysis of nasal wash from these challenged ferrets vaccinated twice showed decreased viral shedding compared to unvaccinated controls. Interestingly, animals that received one vaccination showed 88% survival with moderate weight loss. Cross Glade protection was evaluated using an increased antigen dose (45 jig rH5). Vaccinated animals demonstrated increased IgG and HAI antibody responses. Both homologous (A/Indo) and heterologous challenge (A/ Vietnam) following two immunizations showed 100% survival with no loss of body weight. However viral clearance was more rapid against the homologous (day 3) compared to the heterologous (day 5) post challenge.
   Conclusion: Intranasal administration of NE01 adjuvant-formulated rH5 vaccine elicited systemic and probably mucosal immunity that conferred protection against lethal challenge with homologous or heterologous viral strains. It also enhanced viral clearance with decreased shedding. These outcomes strongly suggest that intranasal immunization using NE01 against flu infections warrants clinical testing. (C) 2019 Published by Elsevier Ltd.
C1 [Smith, Douglas; Acosta, Hugo; Ganesan, Shyamala; Fattom, Ali] BlueWillow Biol, Ann Arbor, MI USA.
   [Streatfield, Stephen J.] Fraunhofer USA Ctr Mol Biotechnol FhCMB, Newark, DE USA.
RP Fattom, A (reprint author), 2311 Green Rd,Suite A, Ann Arbor, MI 48105 USA.
EM ali.fattom@bluewillow.com
FU National Institute of Allergy and Infectious Diseases, part of The
   National Institutes of health, Bethesda, Maryland, USA
   [HHSN272201300028C]
FX This project was funded by The National Institute of Allergy and
   Infectious Diseases, part of The National Institutes of health,
   Bethesda, Maryland, USA under Adjuvant Development Program Contract #
   HHSN272201300028C.
CR Baz M, 2013, VIRUS RES, V178, P78, DOI 10.1016/j.virusres.2013.05.006
   Bielinska AU, 2008, AIDS RES HUM RETROV, V24, P271, DOI 10.1089/aid.2007.0148
   Bielinska AU, 2007, INFECT IMMUN, V75, P4020, DOI 10.1128/IAI.00070-07
   Bielinska AU, 2014, J IMMUNOL, V192, P2722, DOI 10.4049/jimmunol.1301424
   Bielinska AU, 2010, CRIT REV IMMUNOL, V30, P189, DOI 10.1615/CritRevImmunol.v30.i2.60
   Chichester JA, 2012, VIRUSES-BASEL, V4, P3227, DOI 10.3390/v4113227
   Coudeville L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-18
   de Jong J C, 2003, Dev Biol (Basel), V115, P63
   Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491
   Haaheim Lars R, 2011, Influenza Other Respir Viruses, V5, P288, DOI 10.1111/j.1750-2659.2011.00242.x
   Hamouda T, 2011, CLIN VACCINE IMMUNOL, V18, P1167, DOI 10.1128/CVI.00035-11
   Hamouda T, 2010, HUM VACCINES, V6, P585, DOI 10.4161/hv.6.7.11818
   Hellens RP, 2000, PLANT MOL BIOL, V42, P819, DOI 10.1023/A:1006496308160
   Holmgren J, 2012, CURR OPIN IMMUNOL, V24, P343, DOI 10.1016/j.coi.2012.03.014
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   Kayali G, 2008, J CLIN VIROL, V43, P73, DOI 10.1016/j.jcv.2008.04.013
   Knossow M, 2002, VIROLOGY, V302, P294, DOI 10.1006/viro.2002.1625
   Kolls JK, 2010, CYTOKINE GROWTH F R, V21, P443, DOI 10.1016/j.cytogfr.2010.11.002
   Krammer F, 2013, CURR OPIN VIROL, V3, P521, DOI 10.1016/j.coviro.2013.07.007
   Lindell DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021823
   Makidon PE, 2012, EUR J IMMUNOL, V42, P2073, DOI 10.1002/eji.201142346
   Makidon PE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002954
   Nimmerjahn F, 2005, SCIENCE, V310, P1510, DOI 10.1126/science.1118948
   Ohmit SE, 2011, J INFECT DIS, V204, P1879, DOI 10.1093/infdis/jir661
   REUMAN PD, 1989, J VIROL METHODS, V24, P27, DOI 10.1016/0166-0934(89)90004-9
   Rotrosen ET, 2017, PEDIATR CLIN N AM, V64, P911, DOI 10.1016/j.pcl.2017.03.007
   Shoji Y, 2009, VACCINE, V27, P1087, DOI 10.1016/j.vaccine.2008.11.108
   Shoji Y, 2011, HUM VACCINES, V7, P41, DOI 10.4161/hv.7.0.14561
   Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531
   SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127
   Spitaels J, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4040033
   Stanberry LR, 2012, VACCINE, V30, P307, DOI 10.1016/j.vaccine.2011.10.094
   Stary G, 2015, SCIENCE, V348, DOI 10.1126/science.aaa8205
   Stephenson I, 2003, J MED VIROL, V70, P391, DOI 10.1002/jmv.10408
   Stephenson I, 2004, VIRUS RES, V103, P91, DOI 10.1016/j.virusres.2004.02.019
   Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566
   Sun HY, 2019, CELL MOL IMMUNOL, V16, P205, DOI 10.1038/s41423-018-0192-y
   Throsby M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003942
   Tumpey TM, 2001, J VIROL, V75, P5141, DOI 10.1128/JVI.75.11.5141-5150.2001
   Wang SH, 2019, VACCINE, V37, P1591, DOI 10.1016/j.vaccine.2019.02.002
   Wang TT, 2011, SCIENCE, V333, P834, DOI 10.1126/science.1210724
   Webster R.G., 2002, WHO MAN AN INFL DIAG
   WHO, 2019, CUM NUMB CONF HUM CA
NR 43
TC 1
Z9 1
U1 7
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 30
PY 2019
VL 37
IS 42
BP 6162
EP 6170
DI 10.1016/j.vaccine.2019.08.071
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JB1JT
UT WOS:000488317400006
PM 31495593
DA 2020-05-12
ER

PT J
AU Tipton, M
   Daly, W
   Senders, S
   Block, SL
   Lattanzi, M
   Mzolo, T
   Barbi, S
   Pellegrini, M
   Keshavan, P
AF Tipton, Mary
   Daly, Wendy
   Senders, Shelly
   Block, Stanley L.
   Lattanzi, Maria
   Mzolo, Thembile
   Barbi, Silvia
   Pellegrini, Michele
   Keshavan, Pavitra
TI MenACWY-CRM conjugate vaccine booster dose given 4-6 years after
   priming: Results from a phase IIIb, multicenter, open label study in
   adolescents and adults
SO VACCINE
LA English
DT Article
DE Quadrivalent meningococcal conjugate vaccine; Booster response; Safety;
   Adolescents; Adults; Early immune response
ID MENINGOCOCCAL DISEASE; ANTIBODY PERSISTENCE; IMMUNOGENICITY; SAFETY;
   EPIDEMIOLOGY; CHILDREN; INFANTS; IMPACT
AB Background: Vaccination strategies against bacterial meningitis vary across countries. In the United States, a single dose of quadrivalent meningococcal conjugate vaccine (MenACWY) is recommended at 11-12 years of age, with a booster dose approximately 5 years later. We assessed immune responses to a booster dose of MenACWY-CRM vaccine after priming with MenACWY-CRM or MenACWY-D vaccines in adolescents and adults.
   Methods: In this phase Illb, multicenter, open-label study, healthy 15-55-year-olds, who received MenACWY-CRM (N = 301) or MenACWY-D (N = 300) 4-6 years earlier or were meningococcal vaccine naive (N = 100), received one MenACWY-CRM vaccine dose. Immunogenicity was evaluated pre vaccination, 3 or 5 days post-vaccination (sampling subgroups), and 28 days post-vaccination by serum bactericidal activity assay using human complement (hSBA). After vaccination, participants were monitored for 7 days for reactogenicity, 29 days for unsolicited adverse events (AEs), and 181 days for serious AEs and medically-attended AEs.
   Results: Sufficiency of the immune response to a MenACWY-CRM booster dose was demonstrated; the lower limit of the 1-sided 97.5% confidence interval for percentages of participants with hSBA serore-sponse at 28 days post-vaccination was >= 75% for each serogroup in those primed with either the MenACWY-CRM or MenACWY-D vaccine. Seroresponse was observed in >= 93.24% of primed participants and >= 35.87% of na ve participants 28 days post-vaccination. At 5 days post-booster, among primed participants, hSBA titers >= 1:8 were achieved in >= 47.14% of participants for MenA and in >= 85.52% of participants for MenC, MenW and MenY, and 3.25- to 8.59-fold increases in hSBA geometric mean titers against each vaccine serogroup were observed. No safety concerns were raised throughout the 6-month follow-up period.
   Conclusions: A booster dose of the MenACWY-CRM vaccine induced a robust and rapid anamnestic response in adolescents and adults, irrespectively of either MenACWY-CRM or MenACWY-D vaccine administered 4-6 years earlier, with an acceptable clinical safety profile. (C) 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.
C1 [Tipton, Mary] CopperView Med Ctr, South Jordan, UT USA.
   [Daly, Wendy] Brownsboro Pk Pediat, Louisville, KY USA.
   [Senders, Shelly] Senders Pediat, Cleveland, OH USA.
   [Block, Stanley L.] Kentucky Pediat Adult Res, Bardstown, KY USA.
   [Lattanzi, Maria; Pellegrini, Michele; Keshavan, Pavitra] GSK, Via Fiorentina 1, I-53100 Siena, SJ, Italy.
   [Mzolo, Thembile; Barbi, Silvia] GSK, Amsterdam, Netherlands.
RP Pellegrini, M (reprint author), GSK, Via Fiorentina 1, I-53100 Siena, SJ, Italy.
EM tipton@rx-research.com; ssenders@senderspediatrics.com;
   maria.x.lattanzi@gsk.com; thembile.x.mzolo@gsk.com;
   silvia.x.barbi@gsk.com; michele.x.pellegrini@gsk.com;
   pavitra.x.keshavan@gsk.com
FU GlaxoSmithKline Biologicals S.A.GlaxoSmithKline
FX This study and related publication were sponsored by GlaxoSmithKline
   Biologicals S.A.
CR Anonymous, 2011, Morbidity and Mortality Weekly Report, V60, P1018
   Baxter R, 2014, J PEDIAT, V164, DOI [10.1016/j.jpeds.2014.02.025e4, DOI 10.1016/J.JPEDS.2014.02.025E4]
   Baxter R, 2016, HUM VACC IMMUNOTHER, V12, P1300, DOI 10.1080/21645515.2015.1136040
   Baxter R, 2015, PEDIATR INFECT DIS J, V34, P1236, DOI 10.1097/INF.0000000000000866
   Baxter R, 2014, PEDIATR INFECT DIS J, V33, P1169, DOI 10.1097/INF.0000000000000438
   Borrow R, 2017, EXPERT REV VACCINES, V16, P313, DOI 10.1080/14760584.2017.1258308
   Christensen H, 2010, LANCET INFECT DIS, V10, P853, DOI 10.1016/S1473-3099(10)70251-6
   Cohn AC, 2013, MMWR RECOMM REP, V62, P1
   Cohn AC, 2010, CLIN INFECT DIS, V50, P184, DOI 10.1086/649209
   Dwilow R, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0524-6
   Halperin SA, 2012, VACCINE, V30, pB26, DOI 10.1016/j.vaccine.2011.12.032
   Halperin SA, 2010, VACCINE, V28, P7865, DOI 10.1016/j.vaccine.2010.09.092
   Harrison LH, 2009, VACCINE, V27, pB51, DOI 10.1016/j.vaccine.2009.04.063
   Hoffman Olaf, 2009, Ther Adv Neurol Disord, V2, P1, DOI 10.1177/1756285609337975
   Jacobson RM, 2013, PEDIATR INFECT DIS J, V32, pE170, DOI 10.1097/INF.0b013e318279ac38
   Jafri RZ, 2013, POPUL HEALTH METR, V11, DOI 10.1186/1478-7954-11-17
   Khatami A, 2010, EXPERT REV VACCINES, V9, P285, DOI 10.1586/ERV.10.3
   Klein NP, 2012, PEDIATR INFECT DIS J, V31, P64, DOI 10.1097/INF.0b013e31823dce5c
   MacNeil JR, 2018, CLIN INFECT DIS, V66, P1276, DOI 10.1093/cid/cix993
   McNamara LA, 2018, LANCET INFECT DIS, V18, pE272, DOI 10.1016/S1473-3099(18)30124-5
   Pelton SI, 2016, J ADOLESCENT HEALTH, V59, pS3, DOI 10.1016/j.jadohealth.2016.04.012
   Reisinger KS, 2009, CLIN VACCINE IMMUNOL, V16, P1810, DOI 10.1128/CVI.00207-09
   Robertson CA, 2016, VACCINE, V34, P5273, DOI 10.1016/j.vaccine.2016.09.003
   Snape MD, 2008, JAMA-J AM MED ASSOC, V299, P173, DOI 10.1001/jama.2007.29-c
   Tregnaghi M, 2014, INT J INFECT DIS, V26, P22, DOI 10.1016/j.ijid.2014.03.1390
   US Food and Drug administration, 2013, PACKAGE INSERT MENVE
   2011, MMWR MORBID MORTAL W, V60, P72
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 30
PY 2019
VL 37
IS 42
BP 6171
EP 6179
DI 10.1016/j.vaccine.2019.08.065
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JB1JT
UT WOS:000488317400007
PM 31495595
OA Other Gold
DA 2020-05-12
ER

PT J
AU Yarnoff, B
   Khavjou, O
   King, G
   Bates, L
   Zhou, FJ
   Leidner, AJ
   Shen, AK
AF Yarnoff, Benjamin
   Khavjou, Olga
   King, Grant
   Bates, Laurel
   Zhou, Fangjun
   Leidner, Andrew J.
   Shen, Angela K.
TI Analysis of the profitability of adult vaccination in 13 private
   provider practices in the United States
SO VACCINE
LA English
DT Article
DE Economic analysis; Adult vaccination; Financial analysis; Barriers to
   vaccination
ID IMMUNIZATION SCHEDULE; ERA
AB Vaccination coverage among adults remains low in the United States. Understanding the barriers to provision of adult vaccination is an important step to increasing vaccination coverage and improving public health. To better understand financial factors that may affect practice decisions about adult vaccination, this study sought to understand how costs compared with payments for adult vaccinations in a sample of U.S. physician practices. We recruited a convenience sample of 19 practices in nine states in 2017. We conducted a time-motion study to assess the time costs of vaccination activities and conducted a survey of practice managers to assess materials, management, and dose costs and payments for vaccination. We received complete cost and payment data from 13 of the 19 practices. We calculated annual income from vaccination services by comparing estimated costs with payments received for vaccine doses and vaccine administration. Median annual total income from vaccination services was $90,343 at family medicine practices (range: $3968-$249,628), $28,267 at internal medicine practices (-$32,659-$141,034) and $2886 at obstetrics and gynecology practices (-$73,451-$23,820). Adult vaccination was profitable at the median of our sample, but there is wide variation in profitability due to differences in costs and payment rates across practices. This study provides evidence on the financial viability of adult vaccination and supports actions for improving financial viability. These results can help inform practices' decisions whether to provide adult vaccines and contribute to keeping adults up-to-date with the recommended vaccination schedule. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yarnoff, Benjamin; Khavjou, Olga; King, Grant; Bates, Laurel] RTI Int, 3040 E Cornwallis Rd, Res Triangle Pk, NC 27709 USA.
   [Zhou, Fangjun] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Leidner, Andrew J.] Berry Technol Solut, Atlanta, GA USA.
   [Shen, Angela K.] US Dept Hlth & Human Serv, Natl Vaccine Program Off, Off Assistant Secretary Hlth, Washington, DC USA.
RP Yarnoff, B (reprint author), RTI Int, 3040 E Cornwallis Rd, Res Triangle Pk, NC 27709 USA.
EM byarnoff@rti.org
OI Shen, Angela/0000-0003-3761-0016; Bates, Laurel/0000-0003-0142-4975;
   Leidner, Andrew/0000-0001-8869-5561
FU RTI International [HHSP233201500391]
FX This report was prepared by RTI International, under contract
   HHSP233201500391 to the National Vaccine Program Office. The findings
   and conclusions of this article are those of the authors and do not
   necessarily represent the official position of National Vaccine Program
   Office or the Centers for Disease Control and Prevention.
CR AAP, 2012, BUS CAS PRIC VACC
   Berchick E. R., 2017, HLTH INSURANCE COVER
   BLS, 2016, MAY 2016 METR NONM A
   CDC ACIP, 2019, ACIP REC JUN 2019 M
   Cowan AE, 2016, VACCINE, V34, P5060, DOI 10.1016/j.vaccine.2016.08.080
   Gellin BG, 2016, AM J PREV MED, V51, P1079, DOI 10.1016/j.amepre.2016.04.014
   Hurley LP, 2017, VACCINE, V35, P647, DOI 10.1016/j.vaccine.2016.12.007
   Hurley LP, 2014, ANN INTERN MED, V160, P161, DOI 10.7326/M13-2332
   Kim DK, 2019, ANN INTERN MED, V170, P182, DOI 10.7326/M18-3600
   Kim DK, 2018, ANN INTERN MED, V168, P210, DOI 10.7326/M17-3439
   Leddy MA, 2009, OBSTET GYNECOL SURV, V64, P823, DOI 10.1097/OGX.0b013e3181c4bbb7
   Lindley MCHL, 2018, VACCINE
   O'Leary S, 2016, VACCINATION PRACTICE
   Ozawa S, 2016, HEALTH AFFAIR, V35, P2124, DOI 10.1377/hlthaff.2016.0462
   Shen A, 2019, VACCINE, V37, P792, DOI 10.1016/j.vaccine.2018.12.045
   Whitney CG, 2014, MMWR-MORBID MORTAL W, V63, P352
   Williams WW, 2017, MMWR SURVEILLANCE SU, V66
   2012, PUBLIC HEALTH REP S1, V127, P1
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 30
PY 2019
VL 37
IS 42
BP 6180
EP 6185
DI 10.1016/j.vaccine.2019.08.056
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JB1JT
UT WOS:000488317400008
PM 31495594
DA 2020-05-12
ER

PT J
AU Salama, M
   Kopel, E
   Jaffe, J
   Amitai, Z
   Sheffer, R
   Rahmani, S
   Yuabov, I
   Dardik, L
   Valinsky, L
AF Salama, Matanelle
   Kopel, Eran
   Jaffe, Joseph
   Amitai, Ziva
   Sheffer, Rivka
   Rahmani, Sarit
   Yuabov, Irina
   Dardik, Laura
   Valinsky, Lea
TI Surveillance of invasive meningococcal disease in the Tel Aviv District,
   Israel, 2007-2017
SO VACCINE
LA English
DT Article
DE Invasive meningococcal disease; Epidemiology
ID EPIDEMIOLOGY
AB Invasive meningococcal disease (IMD) is one of the leading causes of bacterial meningitis and septicemia in Israel. The purpose of the study was to describe the IMD in the Tel Aviv District and to identify specific populations who could benefit from vaccine introduction.
   In the Tel Aviv District, the incidence rates ranged from 0.4 to 1.4 cases per 100,000 population per year during 2007-2017.
   During the study period, seventy-nine patients (65%) occurred among children younger than four years of age. Eight deaths occurred (7%), most of them among children under the age of 1 year (5 deaths; 15%). A serogroup was identified in 82 isolates. Most of the isolates (69 cases - 84%) belonged to serogroup B (NmB).
   IMD clustered geographically in the city of Bnei Brak, with a predominantly Ultra-Orthodox Jewish population. It is the youngest and most densely populated city in the district. The overall incidence rates of IMD among children in Bnei Brak were more than seven times higher in children up to nine years, compared to the rest of the district. Specifically for NmB, disease rates were 9.08 times higher in children up to the age of four, and 7.74 times higher in children from five to nine years old in Bnei Brak, compared to the rest of the district.
   Our findings describe the burden of a vaccine-preventable disease and reinforce the need for routine 4CmenB introduction, especially in groups where the disease clusters. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Salama, Matanelle; Amitai, Ziva; Rahmani, Sarit; Yuabov, Irina; Dardik, Laura] Minist Hlth, Tel Aviv Dist Hlth Off, Tel Aviv, Israel.
   [Kopel, Eran] Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Tel Aviv, Israel.
   [Sheffer, Rivka] Israel Minist Hlth, Publ Hlth Serv, Jerusalem, Israel.
   [Jaffe, Joseph; Valinsky, Lea] Israel Minist Hlth, Cent Labs, Jerusalem, Israel.
RP Salama, M (reprint author), Tel Aviv Dist Hlth Off, 12 Ha Arbaa St,POB 20301, IL-61203 Tel Aviv, Israel.
EM Matanelle.salama@gmail.com
OI salama, matanelle/0000-0001-7486-8046
CR Ben-Shimol S, 2013, INFECTION, V41, P791, DOI 10.1007/s15010-013-0439-6
   Campbell G, 2018, J PAEDIAT CHILD HLTH
   DAGAN R, 1994, J INFECT DIS, V169, P912, DOI 10.1093/infdis/169.4.912
   De Serres G, 2018, VACCINE, V36, P8039, DOI 10.1016/j.vaccine.2018.10.095
   Doedee AMCM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098175
   Ginsberg GM, 2016, INT J PUBLIC HEALTH, V61, P683, DOI 10.1007/s00038-016-0821-0
   Parikh SR, 2018, VACCINE
   Parikh SR, 2016, LANCET, V388, P2775, DOI 10.1016/S0140-6736(16)31921-3
   Scheifele D, 2018, PAED CHILD HEALT-CAN, V23, P245, DOI 10.1093/pch/pxy011
   Stein-Zamir C, 2007, EPIDEMIOL INFECT, V136
   Stein-Zamir C, 2014, PEDIATR INFECT DIS J, V33, P777, DOI 10.1097/INF.0000000000000282
   Valinsky L, 2016, EPIDEMIOL INFECT, V144, P183, DOI 10.1017/S0950268815001296
   Whittaker R, 2017, VACCINE, V35, P2034, DOI 10.1016/j.vaccine.2017.03.007
   Wiringa AE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082048
NR 14
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 30
PY 2019
VL 37
IS 42
BP 6186
EP 6191
DI 10.1016/j.vaccine.2019.08.055
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JB1JT
UT WOS:000488317400009
PM 31495596
DA 2020-05-12
ER

PT J
AU Domek, GJ
   Contreras-Roldan, IL
   Bull, S
   O'Leary, ST
   Ventura, GAB
   Bronsert, M
   Kempe, A
   Asturias, EJ
AF Domek, Gretchen J.
   Contreras-Roldan, Ingrid L.
   Bull, Sheana
   O'Leary, Sean T.
   Ventura, Guillermo Antonio Bolanos
   Bronsert, Michael
   Kempe, Allison
   Asturias, Edwin J.
TI Text message reminders to improve infant immunization in Guatemala: A
   randomized clinical trial
SO VACCINE
LA English
DT Article
DE Childhood immunization; Vaccine coverage; SMS; Text messaging;
   Reminder-recall; Guatemala
ID AGE-APPROPRIATE VACCINATION; INFLUENZA VACCINATION; COVERAGE;
   INTERVENTIONS; TIMELINESS; PERTUSSIS; HEALTH; DELAY; FEASIBILITY;
   VACCINES
AB Objective: Millions of infants worldwide remain under-immunized and at risk for unnecessary morbidity and mortality. Text messaging may offer a low-cost solution. We aimed to evaluate text message reminders to improve infant immunization in Guatemala.
   Methods: A randomized clinical trial was conducted at four public health clinics in rural and urban Guatemala. Infants ages six weeks to six months presenting for the first visit of the primary immunization series were randomly and equally allocated to an intervention or usual care group. Intervention participants were sent three text reminders before the second and third vaccine visits. The main outcome was timeliness of the second and third visits of the primary immunization series.
   Results: Of 1088 families approached for enrollment between March to November 2016, 871 were eligible and 720 (82.7%) participated; only 54 families did not own a cell phone. Due to country-wide vaccine shortages, visit completion was used as a proxy for overall immunization coverage. In intention to treat analysis, both intervention and usual care groups had high rates of visit completion, but intervention participants presented on the scheduled date more often (151[42.2%] of 358 intervention vs. 111 [30.7%] of 362 usual care participants for visit 2, p = 0.001, and 112 [34.0%] of 329 intervention vs. 90 [27.0%] of 333 usual care participants for visit 3, p = 0.05). Intervention caregivers were significantly more likely to want to receive future text message reminders for vaccines and other appointments and were more willing to pay for these reminders.
   Conclusion: Caregivers who were sent text message reminders in urban and rural Guatemala were less delayed for their child's immunization visits and reported high user satisfaction. Text message reminders may be an effective tool to increase infant vaccination coverage in low-income settings by reminding parents to vaccinate. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Domek, Gretchen J.; O'Leary, Sean T.; Kempe, Allison; Asturias, Edwin J.] Univ Colorado, Dept Pediat, Anschutz Med Campus,B065,13123 E 16th Ave, Aurora, CO 80045 USA.
   [Domek, Gretchen J.; Bull, Sheana; Bronsert, Michael; Asturias, Edwin J.] Colorado Sch Publ Hlth, Ctr Global Hlth, A090,13199 E Montview Blvd,Suite 310, Aurora, CO 80045 USA.
   [Contreras-Roldan, Ingrid L.] Univ Valle Guatemala, Ctr Hlth Studies, 18 Av 11-95,Zona 15,Vista Hermosa III, Guatemala City, Guatemala.
   [Bull, Sheana] Colorado Sch Publ Hlth, Dept Community & Behav Hlth, B119,13001 E 17th Pl, Aurora, CO 80045 USA.
   [O'Leary, Sean T.; Bronsert, Michael; Kempe, Allison] Univ Colorado, Adult & Child Consortium Hlth Outcomes Res & Deli, Anschutz Med Campus,F443,13199 E Montview Blvd, Aurora, CO 80045 USA.
   [Ventura, Guillermo Antonio Bolanos] Ctr Human Dev Southwest Trifinio, Retalhuleu, Guatemala.
   [Asturias, Edwin J.] Colorado Sch Publ Hlth, Dept Epidemiol, B119,13001 E 17th Pl, Aurora, CO 80045 USA.
RP Domek, GJ (reprint author), Ctr Global Hlth, Mail Stop A090,13199 E Montview Blvd,Suite 310, Aurora, CO 80045 USA.
EM gretchen.domek@childrenscolorado.org
RI Asturias, Edwin/D-9842-2016
OI Asturias, Edwin/0000-0002-1275-0787
FU Eunice Kennedy Shriver National Institute of Child Health & Human
   Development at the National Institutes of Health [1R21HD084115-01];
   Thrasher Research Fund Early Career Award Program [12797]; National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; National Center for
   Research Resources Colorado CTSI [UL1 RR025780]
FX This work was supported by the Eunice Kennedy Shriver National Institute
   of Child Health & Human Development at the National Institutes of Health
   [grant number 1R21HD084115-01] and the Thrasher Research Fund Early
   Career Award Program [award number 12797]. REDCap was supported by the
   National Institutes of Health and National Center for Research Resources
   Colorado CTSI [grant number UL1 RR025780]. The funders had no
   involvement in the study design and conduct, data collection and
   analysis, interpretation of the data, decision to publish, or
   preparation of the manuscript.
CR Ahlers-Schmidt CR, 2012, VACCINE, V30, P5305, DOI 10.1016/j.vaccine.2012.06.058
   Akmatov MK, 2008, VACCINE, V26, P3805, DOI 10.1016/j.vaccine.2008.05.031
   Akmatov MK, 2012, J EPIDEMIOL COMMUN H, V66, DOI 10.1136/jech.2010.124651
   Bangure D, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1470-6
   BART KJ, 1991, JAMA-J AM MED ASSOC, V266, P1547
   Bolton P, 1998, PUBLIC HEALTH REP, V113, P527
   Chen L, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-262
   Clark A, 2009, LANCET, V373, P1543, DOI 10.1016/S0140-6736(09)60317-2
   Coates J, 2007, HOUSEHOLD FOOD INSEC
   Dayan GH, 2006, AM J EPIDEMIOL, V163, P561, DOI 10.1093/aje/kwj074
   Deglise C, 2012, J MED INTERNET RES, V14, DOI 10.2196/jmir.1823
   Dombkowski KJ, 2002, AM J PREV MED, V23, P36, DOI 10.1016/S0749-3797(02)00442-7
   Domek GJ, 2018, VACCINE, V36, P5273, DOI 10.1016/j.vaccine.2018.07.046
   Domek Gretchen J, 2018, Mhealth, V4, P9, DOI 10.21037/mhealth.2018.03.05
   Domek GJ, 2016, VACCINE, V34, P2437, DOI 10.1016/j.vaccine.2016.03.065
   Fadnes LT, 2011, VACCINE, V29, P3564, DOI 10.1016/j.vaccine.2011.02.093
   Gibson DG, 2017, LANCET GLOB HEALTH, V5, pE428, DOI [10.1016/S2214-109X(17)30072-4, 10.1016/s2214-109x(17)30072-4]
   Gibson DG, 2015, VACCINE, V33, P6778, DOI 10.1016/j.vaccine.2015.10.021
   Glanz JM, 2013, JAMA PEDIATR, V167, P1060, DOI 10.1001/jamapediatrics.2013.2353
   Grant CC, 2003, BRIT MED J, V326, P852, DOI 10.1136/bmj.326.7394.852
   Gurman TA, 2012, J HEALTH COMMUN, V17, P82, DOI 10.1080/10810730.2011.649160
   Haji A, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2823-5
   Hall AK, 2015, ANNU REV PUBL HEALTH, V36, P393, DOI 10.1146/annurev-publhealth-031914-122855
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Head KJ, 2013, SOC SCI MED, V97, P41, DOI 10.1016/j.socscimed.2013.08.003
   Hofstetter AM, 2015, VACCINE, V33, P5741, DOI 10.1016/j.vaccine.2015.09.042
   Hofstetter AM, 2015, AM J PREV MED, V48, P392, DOI 10.1016/j.amepre.2014.10.023
   Hu Y, 2014, HUM VACC IMMUNOTHER, V10, P1408, DOI 10.4161/hv.28054
   Kazi AM, 2018, JMIR PUBLIC HLTH SUR, V4, P333, DOI 10.2196/publichealth.7026
   Kharbanda EO, 2011, VACCINE, V29, P2537, DOI 10.1016/j.vaccine.2011.01.065
   Kolos V, 2007, VACCINE, V25, P588, DOI 10.1016/j.vaccine.2006.08.022
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037
   Luman ET, 2005, JAMA-J AM MED ASSOC, V293, P1204, DOI 10.1001/jama.293.10.1204
   Minesterio de Salud Publica y Asistencia Social Instituto Nacional de Estadistica Secretaria de Planificacion y Programacion de la Presidencia, 2015, VI ENCUESTA NACIONAL
   Nguyen Nga Tuyet, 2017, Mhealth, V3, P26, DOI 10.21037/mhealth.2017.06.03
   O'Leary ST, 2015, PEDIATRICS, V136, pE1220, DOI 10.1542/peds.2015-1089
   Oyo-Ita A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008145.pub3
   Seth R, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-3455
   Siedler A, 2002, PEDIATR INFECT DIS J, V21, P826, DOI 10.1097/00006454-200209000-00008
   Stockwell MS, 2015, PEDIATRICS, V135, pE83, DOI 10.1542/peds.2014-2475
   Stockwell MS, 2012, JAMA-J AM MED ASSOC, V307, P1702, DOI 10.1001/jama.2012.502
   Stockwell MS, 2012, AM J PUBLIC HEALTH, V102, pE15, DOI 10.2105/AJPH.2011.300331
   Tierney CD, 2003, PEDIATRICS, V112, P1076, DOI 10.1542/peds.112.5.1076
   Uddin MJ, 2016, VACCINE, V34, P276, DOI 10.1016/j.vaccine.2015.11.024
   Vann JCJ, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003941.pub3
   vonKries R, 1997, EUR J PEDIATR, V156, P282, DOI 10.1007/s004310050601
   Wakadha H, 2013, VACCINE, V31, P987, DOI 10.1016/j.vaccine.2012.11.093
   World Health Organization, 2017, ASS REP GLOB VACC AC
   World Health Organization, 2013, GLOB VACC ACT PLAN 2
NR 50
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 30
PY 2019
VL 37
IS 42
BP 6192
EP 6200
DI 10.1016/j.vaccine.2019.08.046
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JB1JT
UT WOS:000488317400010
PM 31492475
DA 2020-05-12
ER

PT J
AU Thompson, A
   Lamberth, E
   Severs, J
   Scully, I
   Tarabar, S
   Ginis, J
   Jansen, KU
   Gruber, WC
   Scott, DA
   Watson, W
AF Thompson, Allison
   Lamberth, Erik
   Severs, Joseph
   Scully, Ingrid
   Tarabar, Sanela
   Ginis, John
   Jansen, Kathrin U.
   Gruber, William C.
   Scott, Daniel A.
   Watson, Wendy
TI Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy
   adults
SO VACCINE
LA English
DT Article
DE PCV20; Pneumococcal conjugate vaccine
ID COMMUNITY-ACQUIRED PNEUMONIA; POLYSACCHARIDE VACCINE;
   STREPTOCOCCUS-PNEUMONIAE; PCV7/PCV13 INTRODUCTION; DISEASE; IMPACT;
   CHILDREN; SEROTYPES; IMMUNOGENICITY; IMPLEMENTATION
AB Introduction: Streptococcus pneumoniae is a leading cause of bacteremia, bacterial pneumonia, and meningitis, and is associated with substantial morbidity and mortality, particularly in those under 2 years of age and those over 65 years of age. While significant progress against S. pneumoniae-related disease has been made as a result of the introduction of pneumococcal conjugate vaccines (PCV7, PCV10 and PCV13), there remains value in further expanding pneumococcal vaccine serotype coverage. Here we present the first report of a 20-valent pneumococcal conjugate vaccine (PCV20) containing capsular polysaccharide conjugates present in PCV13 as well as 7 new serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) which are important contributors to pneumococcal disease.
   Methods: This Phase I first-in-human study was a randomized, controlled, observer-blinded study with a two-arm parallel design to assess the safety, tolerability, and immunogenicity of PCV20 in adults. A total of 66 healthy adults 18-49 years of age with no history of pneumococcal vaccination were enrolled and randomized to receive a single dose of PCV20 or a licensed tetanus, diphtheria, acellular pertussis combination vaccine (Tdap) control. Local injection site reactions, select systemic symptoms, laboratory studies, and adverse events were assessed. Opsonophagocytic activity (OPA) titers and IgG concentrations were measured in sera collected prior to, and approximately one month (28-35 days) after vaccination.
   Results: Vaccination with PCV20 elicited substantial IgG and functional bactericidal immune responses as demonstrated by increases in IgG geometric mean concentrations (GMCs) and OPA geometric mean titers (GMTs) to the 20 vaccine serotypes. The overall safety profile of PCV20 was similar to Tdap, and generally consistent with that observed after PCV13 administration.
   Conclusions: Vaccination with PCV20 was well tolerated and induced substantial functional (OPA) and IgG responses to all vaccine serotypes. There were no safety issues identified in this Phase 1 study, and the data supported further evaluation of PCV20. (C) 2019 Published by Elsevier Ltd.
C1 [Thompson, Allison; Severs, Joseph; Scully, Ingrid; Jansen, Kathrin U.; Gruber, William C.] Pfizer Inc, Vaccine Res & Dev, Pearl River, NY USA.
   [Lamberth, Erik; Ginis, John; Scott, Daniel A.; Watson, Wendy] Pfizer Inc, Vaccine Res & Dev, Collegeville, PA 19426 USA.
   [Tarabar, Sanela] Pfizer Inc, Pfizer Clin Res Unit, New Haven, CT USA.
RP Lamberth, E (reprint author), Pfizer Inc, 500 Arcola Rd, Collegeville, PA 19426 USA.
EM Erik.Lamberth@Pfizer.com
CR Andrews NJ, 2012, VACCINE, V30, P6802, DOI 10.1016/j.vaccine.2012.09.019
   Angoulvant F, 2014, CLIN INFECT DIS, V58, P918, DOI 10.1093/cid/ciu006
   [Anonymous], 2016, ACT BACT COR SURV RE
   Ben-Shimol S, 2016, VACCINE, V34, P4543, DOI 10.1016/j.vaccine.2016.07.038
   Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544
   Bryant KA, 2015, VACCINE, V33, P5854, DOI 10.1016/j.vaccine.2015.08.080
   Cohen R, 2016, HUM VACC IMMUNOTHER, V12, P277, DOI 10.1080/21645515.2015.1116654
   Cooper D, 2011, VACCINE, V29, P7207, DOI 10.1016/j.vaccine.2011.06.056
   Desai AP, 2015, PEDIATR INFECT DIS J, V34, P1168, DOI 10.1097/INF.0000000000000849
   Drijkoningen JJC, 2014, CLIN MICROBIOL INFEC, V20, P45, DOI 10.1111/1469-0691.12461
   Greenberg D, 2015, VACCINE, V33, P4623, DOI 10.1016/j.vaccine.2015.06.062
   Harboe ZB, 2014, CLIN INFECT DIS, V59, P1066, DOI 10.1093/cid/ciu524
   Hausdorff WP, 2005, LANCET INFECT DIS, V5, P83, DOI 10.1016/S1473-3099(05)01280-6
   Huang SS, 2011, VACCINE, V29, P3398, DOI 10.1016/j.vaccine.2011.02.088
   Iyer AS, 2015, EXPERT REV VACCINES, V14, P85, DOI 10.1586/14760584.2015.963058
   Jackson LA, 2008, CLIN INFECT DIS, V47, P1328, DOI 10.1086/592691
   Jackson LA, 2013, VACCINE, V31, P3594, DOI 10.1016/j.vaccine.2013.04.084
   Jackson LA, 2013, VACCINE, V31, P3577, DOI 10.1016/j.vaccine.2013.04.085
   McLaughlin JM, 2018, CLIN INFECT DIS, V67, P1498, DOI 10.1093/cid/ciy312
   Musher DM, 2013, J INFECTION, V67, P11, DOI 10.1016/j.jinf.2013.03.003
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Oordt-Speets AM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198772
   Pavliakova D, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00128-18
   Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593
   Ramirez JA, 2017, CLIN INFECT DIS, V65, P1806, DOI 10.1093/cid/cix647
   Restrepo MI, 2008, CHEST, V133, P610, DOI 10.1378/chest.07-1456
   Richter SS, 2014, ANTIMICROB AGENTS CH, V58, P6484, DOI 10.1128/AAC.03344-14
   SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101
   Sherwin RL, 2013, J INFECT DIS, V208, P1813, DOI 10.1093/infdis/jit506
   STEIN KE, 1992, J INFECT DIS, V165, pS49, DOI 10.1093/infdis/165-Supplement_1-S49
   Tomczyk S, 2016, CLIN INFECT DIS, V62, P1119, DOI 10.1093/cid/ciw067
   Tomczyk S, 2014, MMWR-MORBID MORTAL W, V63, P822
   Torling J, 2003, VACCINE, V22, P96, DOI 10.1016/S0264-410X(03)00521-8
   Torres A, 2015, EUR J CLIN MICROBIOL, V34, P19, DOI 10.1007/s10096-014-2208-6
   Troeger C, 2017, LANCET INFECT DIS, V17, P1133, DOI 10.1016/S1473-3099(17)30396-1
   United States Census Bureau, 2017, QUICK FACTS
   University of York Centre for Reviews and Dissemination, 2009, SYSTEMATIC REV CRDS, p[x, 281]
   van Hoek AJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039150
   Varon E, 2015, VACCINE, V33, P6178, DOI 10.1016/j.vaccine.2015.10.015
   Wahl B, 2016, 10 INT S PNEUM PNEUM
NR 40
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 30
PY 2019
VL 37
IS 42
BP 6201
EP 6207
DI 10.1016/j.vaccine.2019.08.048
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JB1JT
UT WOS:000488317400011
PM 31495592
DA 2020-05-12
ER

PT J
AU Rudicell, RS
   Garinot, M
   Kanekiyo, M
   Kamp, HD
   Swanson, K
   Chou, TH
   Dai, S
   Bedel, O
   Simard, D
   Gillespie, RA
   Yang, KW
   Reardon, M
   Avila, LZ
   Besev, M
   Dhal, PK
   Dharanipragada, R
   Zheng, LY
   Duan, XC
   Dinapoli, J
   Vogel, TU
   Kleanthous, H
   Mascola, JR
   Graham, BS
   Haensler, J
   Wei, CJ
   Nabel, GJ
AF Rudicell, Rebecca S.
   Garinot, Marie
   Kanekiyo, Masaru
   Kamp, Heather D.
   Swanson, Kurt
   Chou, Te-hui
   Dai, Shujia
   Bedel, Olivier
   Simard, Daniel
   Gillespie, Rebecca A.
   Yang, Kanwen
   Reardon, Michael
   Avila, Luis Z.
   Besev, Magnus
   Dhal, Pradeep K.
   Dharanipragada, Ram
   Zheng, Lingyi
   Duan, Xiaochu
   Dinapoli, Joshua
   Vogel, Thorsten U.
   Kleanthous, Harry
   Mascola, John R.
   Graham, Barney S.
   Haensler, Jean
   Wei, Chih-Jen
   Nabel, Gary J.
TI Comparison of adjuvants to optimize influenza neutralizing antibody
   responses
SO VACCINE
LA English
DT Article
DE Influenza vaccine; Nanoparticles; Adjuvants; TLR agonists; STING
   agonists; AF03
ID MONOPHOSPHORYL-LIPID-A; HEPATITIS-B-VACCINE; T-CELL RESPONSES; CYCLIC
   GMP-AMP; IMMUNE-RESPONSES; CPG MOTIFS; BACTERIAL LIPOPROTEINS;
   IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; MALARIA VACCINE
AB Seasonal influenza vaccines represent a positive intervention to limit the spread of the virus and protect public health. Yet continual influenza evolution and its ability to evade immunity pose a constant threat. For these reasons, vaccines with improved potency and breadth of protection remain an important need. We previously developed a next-generation influenza vaccine that displays the trimeric influenza hemagglutinin (HA) on a ferritin nanoparticle (NP) to optimize its presentation. Similar to other vaccines, HA-nanoparticle vaccine efficacy is increased by the inclusion of adjuvants during immunization. To identify the optimal adjuvants to enhance influenza immunity, we systematically analyzed TLR agonists for their ability to elicit immune responses. HA-NPs were compatible with nearly all adjuvants tested, including TLR2, TLR4, TLR7/8, and TLR9 agonists, squalene oil-in-water mixtures, and STING agonists. In addition, we chemically conjugated TLR7/8 and TLR9 ligands directly to the HA-ferritin nanoparticle. These TLR agonist-conjugated nanoparticles induced stronger antibody responses than nanoparticles alone, which allowed the use of a 5000-fold-lower dose of adjuvant than traditional admixtures. One candidate, the oil-in-water adjuvant AF03, was also tested in non-human primates and showed strong induction of neutralizing responses against both matched and heterologous H1N1 viruses. These data suggest that AF03, along with certain TLR agonists, enhance strong neutralizing antibody responses following influenza vaccination and may improve the breadth, potency, and ultimately vaccine protection in humans. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Rudicell, Rebecca S.; Kamp, Heather D.; Swanson, Kurt; Chou, Te-hui; Dai, Shujia; Bedel, Olivier; Simard, Daniel; Yang, Kanwen; Reardon, Michael; Avila, Luis Z.; Besev, Magnus; Dhal, Pradeep K.; Dharanipragada, Ram; Wei, Chih-Jen; Nabel, Gary J.] Sanofi, Cambridge, MA 02139 USA.
   [Garinot, Marie; Zheng, Lingyi; Duan, Xiaochu; Dinapoli, Joshua; Vogel, Thorsten U.; Kleanthous, Harry; Haensler, Jean] Sanofi Pastuer, Cambridge, MA USA.
   [Kanekiyo, Masaru; Gillespie, Rebecca A.; Mascola, John R.; Graham, Barney S.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Yang, Kanwen] Alex Pharmaceut, Boston, MA USA.
   [Reardon, Michael] Immunogen Inc, Waltham, MA USA.
   [Avila, Luis Z.] Aveta Biom Inc, Bedford, MA USA.
   [Besev, Magnus] Xleco Inc, Wakefield, MA USA.
RP Wei, CJ; Nabel, GJ (reprint author), Sanofi, Cambridge, MA 02139 USA.
EM Chih-Jen.Wei@sanofi.com; Gary.Nabel@sanofi.com
RI Graham, Barney S./AAC-5898-2019
OI Graham, Barney S./0000-0001-8112-0853; Kanekiyo,
   Masaru/0000-0001-5767-1532
FU Intramural NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [ZIA AI005003-17]
CR Adams S, 2009, IMMUNOTHERAPY-UK, V1, P949, DOI 10.2217/IMT.09.70
   Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736
   Bagnoli F, 2015, P NATL ACAD SCI USA, V112, P3680, DOI 10.1073/pnas.1424924112
   Berman Brian, 2012, Skin Therapy Lett, V17, P5
   Bertholet S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001094
   Burdette DL, 2011, NATURE, V478, P515, DOI 10.1038/nature10429
   Buwitt-Beckmann U, 2005, EUR J IMMUNOL, V35, P282, DOI 10.1002/eji.200424955
   Caillet C, 2010, VACCINE, V28, P3076, DOI 10.1016/j.vaccine.2010.02.050
   Caproni E, 2012, J IMMUNOL, V188, P3088, DOI 10.4049/jimmunol.1101764
   Cauwelaert ND, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146372
   Cheng WK, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00284
   Chlibek R, 2013, J INFECT DIS, V208, P1953, DOI 10.1093/infdis/jit365
   Coler RN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016333
   Coler RN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013677
   Cooper CL, 2004, J CLIN IMMUNOL, V24, P693, DOI 10.1007/s10875-004-6244-3
   Corrales L, 2015, CELL REP, V11, P1018, DOI 10.1016/j.celrep.2015.04.031
   Cui WG, 2014, J IMMUNOL, V192, P4221, DOI 10.4049/jimmunol.1302569
   Darricarrere N, 2018, J VIROL, V92, DOI 10.1128/JVI.01349-18
   Demento SL, 2010, J IMMUNOL, V185, P2989, DOI 10.4049/jimmunol.1000768
   Didierlaurent AM, 2017, EXPERT REV VACCINES, V16, P55, DOI 10.1080/14760584.2016.1213632
   Dong W, 2018, BIOTECHNOL J, V13, DOI 10.1002/biot.201700645
   Dooling KL, 2018, MMWR-MORBID MORTAL W, V67, P103, DOI 10.15585/mmwr.mm6703a5
   Dubensky Jr TW, 2014, COMPOSITIONS METHODS
   Dupont J, 2006, VACCINE, V24, P7167, DOI 10.1016/j.vaccine.2006.06.053
   Eidhin DBN, 2008, FEMS IMMUNOL MED MIC, V52, P207, DOI 10.1111/j.1574-695X.2007.00363.x
   Evans Jay T, 2003, Expert Rev Vaccines, V2, P219, DOI 10.1586/14760584.2.2.219
   Fang YA, 2010, J VIROL, V84, P8369, DOI 10.1128/JVI.02305-09
   Feng Y, 2013, VIROLOGY, V446, P56, DOI 10.1016/j.virol.2013.07.028
   Francica JR, 2016, BIOCONJUGATE CHEM, V27, P2372, DOI 10.1021/acs.bioconjchem.6b00370
   Freed DC, 2011, VACCINE, V29, P9385, DOI 10.1016/j.vaccine.2011.09.122
   Fu J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4306
   Gao P, 2014, CELL REP, V8, P1668, DOI 10.1016/j.celrep.2014.08.010
   Garten RJ, 2009, SCIENCE, V325, P197, DOI 10.1126/science.1176225
   Gavin AL, 2006, SCIENCE, V314, P1936, DOI 10.1126/science.1135299
   Haensler J, 2015, INT J PHARMACEUT, V486, P99, DOI 10.1016/j.ijpharm.2015.03.028
   Halperin SA, 2003, VACCINE, V21, P2461, DOI 10.1016/S0264-410X(03)00045-8
   Hanson MC, 2015, J CLIN INVEST, V125, P2532, DOI 10.1172/JCI79915
   Heeke DS, 2016, VACCINE, V34, P2562, DOI 10.1016/j.vaccine.2016.04.012
   Holbrook BC, 2017, VACCINE, V35, P6137, DOI 10.1016/j.vaccine.2017.09.054
   Huang L, 2018, CELL MOL IMMUNOL
   Hyer R, 2018, VACCINE, V36, P2604, DOI 10.1016/j.vaccine.2018.03.067
   Ishizaka ST, 2007, EXPERT REV VACCINES, V6, P773, DOI 10.1586/14760584.6.5.773
   Iurescia S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00711
   Jones TR, 1999, VACCINE, V17, P3065, DOI 10.1016/S0264-410X(99)00145-0
   Junkins RD, 2018, J CONTROL RELEASE, V270, P1, DOI 10.1016/j.jconrel.2017.11.030
   Kanekiyo M, 2015, CELL, V162, P1090, DOI 10.1016/j.cell.2015.07.043
   Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202
   Keller CD, 2005, AM FAM PHYSICIAN, V72, P41
   Klinman DA, 2004, VACCINE, V22, P2881, DOI 10.1016/j.vaccine.2003.12.020
   Klinman DM, 2009, ADV DRUG DELIVER REV, V61, P248, DOI 10.1016/j.addr.2008.12.012
   Klucker MF, 2012, J PHARM SCI-US, V101, P4490, DOI 10.1002/jps.23311
   Ko EJ, 2017, IMMUNE NETW, V17, P326, DOI 10.4110/in.2017.17.5.326
   Kong WP, 2006, P NATL ACAD SCI USA, V103, P15987, DOI 10.1073/pnas.0607564103
   Krammer F, 2016, CURR OPIN VIROL, V17, P95, DOI 10.1016/j.coviro.2016.02.002
   KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0
   Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842
   Landi A, 2017, VACCINE, V35, P6949, DOI 10.1016/j.vaccine.2017.10.072
   Levie K, 2008, J INFECT DIS, V198, P642, DOI 10.1086/590913
   Maisonneuve C, 2014, P NATL ACAD SCI USA, V111, P12294, DOI 10.1073/pnas.1400478111
   Margaroni M, 2017, INT J NANOMED, V12, P6169, DOI 10.2147/IJN.S141069
   Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510
   McKee AS, 2017, CURR OPIN IMMUNOL, V47, P44, DOI 10.1016/j.coi.2017.06.005
   Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246
   Misquith A, 2014, COLLOID SURFACE B, V113, P312, DOI 10.1016/j.colsurfb.2013.09.006
   Near KA, 2002, INFECT IMMUN, V70, P692, DOI 10.1128/IAI.70.2.692-701.2002
   Neu KE, 2016, CURR OPIN IMMUNOL, V42, P48, DOI 10.1016/j.coi.2016.05.012
   Nkolola JP, 2014, VACCINE, V32, P2109, DOI 10.1016/j.vaccine.2014.02.001
   Okusawa T, 2004, INFECT IMMUN, V72, P1657, DOI 10.1128/IAI.72.3.1657-1665.2004
   Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497
   Park H, 2013, J IMMUNOL, V190, P4103, DOI 10.4049/jimmunol.1202958
   Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017
   Polhemus ME, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006465
   Poteet E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136862
   Prantner D, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.382986
   Rhee EG, 2010, J VIROL, V84, P10413, DOI 10.1128/JVI.00928-10
   Sastry M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186854
   Schillie S, 2018, MMWR-MORBID MORTAL W, V67, P455, DOI 10.15585/mmwr.mm6715a5
   Shafique M, 2012, VACCINE, V30, P597, DOI 10.1016/j.vaccine.2011.11.054
   Sliepen K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10262-5
   Song PX, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2147-1
   Szarewski A, 2012, EXPERT REV VACCINES, V11, P645, DOI [10.1586/erv.12.42, 10.1586/ERV.12.42]
   Takaki H, 2017, MED SCI BASEL, V5
   Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933
   Tang CK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060038
   Tian MP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00310
   Tregoning JS, 2018, HUM VACC IMMUNOTHER, V14, P550, DOI 10.1080/21645515.2017.1415684
   Van Dis E, 2018, CELL REP, V23, P1435, DOI 10.1016/j.celrep.2018.04.003
   Van Hoeven N, 2017, SCI REP-UK, V7, DOI 10.1038/srep46426
   Vasilakos JP, 2013, EXPERT REV VACCINES, V12, P809, DOI 10.1586/14760584.2013.811208
   Vasou A, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9070186
   Visan L, 2016, HUM VACC IMMUNOTHER, V12, P2341, DOI 10.1080/21645515.2016.1168958
   Wang LS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8712
   Wang Q, 2018, J BIOMED MATER RES B, V106, P1587, DOI 10.1002/jbm.b.33965
   Wang Y, 2016, P NATL ACAD SCI USA, V113, pE884, DOI 10.1073/pnas.1525639113
   Wei CJ, 2008, J VIROL, V82, P6200, DOI 10.1128/JVI.00187-08
   Wei CJ, 2010, SCIENCE, V329, P1060, DOI 10.1126/science.1192517
   Wei CJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000799
   Weir JP, 2016, INFLUENZA OTHER RESP, V10, P354, DOI 10.1111/irv.12383
   Whittle JRR, 2014, J VIROL, V88, P4047, DOI 10.1128/JVI.03422-13
   Wille-Reece U, 2005, P NATL ACAD SCI USA, V102, P15190, DOI 10.1073/pnas.0507484102
   Wu JX, 2013, SCIENCE, V339, P826, DOI 10.1126/science.1229963
   Wu NC, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006682
   Xu L, 2017, SCIENCE, V358, P85, DOI 10.1126/science.aan8630
   Yang ZY, 2007, SCIENCE, V317, P825, DOI 10.1126/science.1135165
   Yassine HM, 2015, NAT MED, V21, P1065, DOI 10.1038/nm.3927
   Zhang X, 2013, MOL CELL, V51, P226, DOI 10.1016/j.molcel.2013.05.022
   Zhao L, 2014, VACCINE, V32, P327, DOI 10.1016/j.vaccine.2013.11.069
   Zost SJ, 2017, P NATL ACAD SCI USA, V114, P12578, DOI 10.1073/pnas.1712377114
NR 108
TC 0
Z9 0
U1 3
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 30
PY 2019
VL 37
IS 42
BP 6208
EP 6220
DI 10.1016/j.vaccine.2019.08.030
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JB1JT
UT WOS:000488317400012
PM 31493950
DA 2020-05-12
ER

PT J
AU Sitt, T
   Kenney, M
   Barrera, J
   Pandya, M
   Eckstrom, K
   Warner, M
   Pacheco, JM
   LaRocco, M
   Palarea-Albaladejo, J
   Brake, D
   Rieder, E
   Arzt, J
   Barlow, JW
   Golde, WT
AF Sitt, Tatjana
   Kenney, Mary
   Barrera, Jose
   Pandya, Mital
   Eckstrom, Korin
   Warner, Megan
   Pacheco, Juan M.
   LaRocco, Michael
   Palarea-Albaladejo, Javier
   Brake, David
   Rieder, Elizabeth
   Arzt, Jonathan
   Barlow, John W.
   Golde, William T.
TI Duration of protection and humoral immunity induced by an
   adenovirus-vectored subunit vaccine for foot-and-mouth disease (FMD) in
   Holstein steers
SO VACCINE
LA English
DT Article
DE Foot-and-mouth disease virus; Cattle; Replication-deficient human
   adenoviru vectored vaccine; FMDV A24/Cruzeiro/BRA/55; Duration of
   protection; Humoral immunity
ID VIRUS SEROTYPE; PROFILE; CATTLE
AB Foot-and-mouth disease (FMD) is a highly contagious viral infection of cloven hooved animals that continues to cause economic disruption in both endemic countries or when introduced into a formally FMD free country. Vaccines that protect against clinical disease and virus shedding are critical to control FMD. The replication deficient human adenovirus serotype 5 (Ad5) vaccine vector expressing empty FMD virus (FMDV) capsid, AdtFMD, is a promising new vaccine platform. With no shedding or spreading of viral vector detected in field trials, this vaccine is very safe to manufacture, as there is no requirement for high containment faciitites. Here, we describe three studies assessing the proportion of animals protected from clinical vesicular disease (foot lesions) following live-FMDV challenge by intradermolingual inoculation at 6 or 9 months following a single vaccination with the commercial AdtFMD vaccine, provisionally licensed for cattle in the United States. Further, we tested the effect of vaccination route (transdermal, intramuscular, subcutaneous) on clinical outcome and humoral immunity. Results demonstrate that a single dose vaccination in cattle with the commercial vaccine vector expressing capsid proteins of the FMDV strain A24 Cruzeiro (Adt.A24), induced protection against clinical FMD at 6 months (100% trans dermal, 80% intramuscular, and 60% subcutaneous) that waned by 9 months post-vaccination (33% trans dermal and 20% intramuscular). Post-vaccination serum from immunized cattle (all studies) generally contained FMDV specific neutralizing antibodies by day 14. Anti-FMDV antibody secreting cells are detected in peripheral blood early following vaccination, but are absent after 28 days post-vaccination. Thus, the decay in antibody mediated immunity over time is likely a function of FMDV-specific antibody half-life. These data reveal the short time span of anti-FMDV antibody secreting cells (ASCs) and important performance characteristics of needle-free vaccination with a recombinant vectored subunit vaccine for FMDV. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Sitt, Tatjana; Pandya, Mital; Eckstrom, Korin; Barlow, John W.] Univ Vermont, Dept Anim & Vet Sci, 201 Terrill Bldg,570 Main St, Burlington, VT USA.
   [Sitt, Tatjana; Kenney, Mary; Warner, Megan; Pacheco, Juan M.; LaRocco, Michael; Rieder, Elizabeth; Arzt, Jonathan; Golde, William T.] ARS, US DOE, Plum Isl Anim Dis Ctr, POB 848, Greenport, NY 11944 USA.
   [Barrera, Jose] Leidos Inc, Plum Isl Anim Dis Ctr, POB 848, Greenport, NY 11944 USA.
   [Palarea-Albaladejo, Javier] Themat & Stat Scotland, JCMB, Kings Bldg, Edinburgh EH9 3FD, Midlothian, Scotland.
   [Brake, David] BioQuest Associates LLC, Plum Isl Anim Dis Ctr, POB 848, Greenport, NY 11944 USA.
   [Golde, William T.] Moredun Res Inst, Pentlands Sci Pk, Penicuik EH26 0PZ, Midlothian, Scotland.
   [Sitt, Tatjana] Kansas State Univ, Coll Veternary Med, Dept Diagnost Med Pathobiol, Manhattan, KS 66506 USA.
RP Golde, WT (reprint author), Moredun Res Inst, Pentlands Sci Pk, Penicuik EH26 0PZ, Midlothian, Scotland.
EM william.golde@moredun.ac.uk
RI Sitt, Tatjana/L-7968-2015; Palarea-Albaladejo, Javier/J-5591-2013
OI Palarea-Albaladejo, Javier/0000-0003-0162-669X; Arzt,
   Jonathan/0000-0002-7517-7893; Sitt, Tatjana/0000-0001-7104-2345
FU United States Department of Agriculture (USDA) ARS-CRIS Project
   [1940-32000-057-00D]; USDA ARSUnited States Department of Agriculture
   (USDA) [HSHQPM-13-X-00110]; Science and Technology Directorate of the
   United States Department of Homeland Security [HSHQPM-13-X-00110];
   Livestock Vaccine Innovation Fund, International Development Research
   Centre, Canada [108705-002]
FX This work was supported by the United States Department of Agriculture
   (USDA) ARS-CRIS Project 1940-32000-057-00D (W.T. G). Additional funding
   was received from an interagency agreement between USDA ARS and the
   Science and Technology Directorate of the United States Department of
   Homeland Security (award number HSHQPM-13-X-00110) (J.W.B. and W.T.G).
   Funding was also received from the Livestock Vaccine Innovation Fund,
   International Development Research Centre, Canada, Project #108705-002
   (W.T.G.).
CR Barrera J, 2018, TRANSBOUND EMERG DIS, V65, P447, DOI 10.1111/tbed.12724
   Barrera J, 2018, VACCINE, V36, P1078, DOI 10.1016/j.vaccine.2018.01.026
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Brake DA, 2012, DEV BIOLOGICALS, V134, P123
   Carpenter TE, 2011, J VET DIAGN INVEST, V23, P26, DOI 10.1177/104063871102300104
   Chase-Topping ME, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-46
   Doel TR, 2003, VIRUS RES, V91, P81, DOI 10.1016/S0168-1702(02)00261-7
   Grubman MJ, 2010, FUTURE VIROL, V5, P51, DOI 10.2217/FVL.09.68
   Grubman MJ, 2005, BIOLOGICALS, V33, P227, DOI 10.1016/j.biologicals.2005.08.009
   Grubman MJ, 2004, CLIN MICROBIOL REV, V17, P465, DOI 10.1128/CMR.17.2.465-493.2004
   Kenney M, 2017, J IMMUNOL METHODS, V450, P1, DOI 10.1016/j.jim.2017.07.001
   Pacheco JM, 2005, VIROLOGY, V337, P205, DOI 10.1016/j.virol.2005.04.014
   Pandya M, 2012, VACCINE, V30, P3106, DOI 10.1016/j.vaccine.2012.02.049
   Paton DJ, 2009, PHILOS T R SOC B, V364, P2657, DOI 10.1098/rstb.2009.0100
   R Core Team, 2014, R LANG ENV STAT COMP
   Rodriguez LL, 2011, EXPERT REV VACCINES, V10, P377, DOI [10.1586/ERV.11.4, 10.1586/erv.11.4]
   Rodriguez LL, 2009, VACCINE, V27, pD90, DOI 10.1016/j.vaccine.2009.08.039
   Samuel AR, 2001, TRENDS GENET, V17, P421, DOI 10.1016/S0168-9525(01)02374-5
   Schutta C, 2016, VACCINE, V34, P3214, DOI 10.1016/j.vaccine.2015.12.018
   Sheehy SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031208
   Shimada M, 2009, GENE THER, V16, P218, DOI 10.1038/gt.2008.152
   Tekleghiorghis T, 2016, TRANSBOUND EMERG DIS, V63, P136, DOI 10.1111/tbed.12248
NR 22
TC 2
Z9 2
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 30
PY 2019
VL 37
IS 42
BP 6221
EP 6231
DI 10.1016/j.vaccine.2019.08.017
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JB1JT
UT WOS:000488317400013
PM 31493951
OA Other Gold
DA 2020-05-12
ER

PT J
AU Lan, HWX
   Hosomi, K
   Kunisawa, J
AF Lan, Huangwenxian
   Hosomi, Koji
   Kunisawa, Jun
TI Clostridium perfringens enterotoxin-based protein engineering for the
   vaccine design and delivery system
SO VACCINE
LA English
DT Article
DE C-CPE; Food poisoning vaccine; Vaccine delivery system
ID HEAT-LABILE ENTEROTOXIN; C-TERMINAL FRAGMENT; FACTOR SPI-B;
   CHOLERA-TOXIN; ESCHERICHIA-COLI; UNITED-STATES; PROTECTIVE IMMUNITY;
   MUCOSAL VACCINE; TIGHT JUNCTIONS; GM1 GANGLIOSIDE
AB Clostridium perfringens is a major cause of food poisoning worldwide, with its enterotoxin (CPE) being the major virulence factor. The C-terminus of CPE (C-CPE) is non-toxic and is the part of the toxin that binds to epithelial cells via the claudins in tight junctions; however, C-CPE has low antigenicity. To address this issue, we have used protein engineering technology to augment the antigenicity of C-CPE and have developed a C-CPE-based vaccine against C. perfringens-mediated food poisoning. Moreover, C-CPE has properties that make it potentially useful for the development of vaccines against other bacterial toxins that cause food poisoning. For example, we hypothesized that the ability of C-CPE to bind to claudins could be harnessed to deliver vaccine antigens directly to mucosa-associated lymphoid tissues, and we successfully developed a nasally administered C-CPE-based vaccine delivery system that promotes antigen specific mucosal and systemic immune responses. In addition, our group has revealed the roles that the nasal mucus plays in lowering the efficacy of C-CPE-based nasal vaccines. Here, we review recent advances in the development of C-CPE-based vaccines against the major bacterial toxins that cause food poisoning and discuss our C-CPE-based nasal vaccine delivery system. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Lan, Huangwenxian; Hosomi, Koji; Kunisawa, Jun] Natl Inst Biomed Innovat Hlth & Nutr NIBIOHN, Ctr Vaccine & Adjuvant Res, Lab Vaccine Mat, Osaka, Japan.
   [Lan, Huangwenxian; Hosomi, Koji; Kunisawa, Jun] Natl Inst Biomed Innovat Hlth & Nutr NIBIOHN, Lab Gut Environm Syst, Osaka, Japan.
   [Lan, Huangwenxian; Kunisawa, Jun] Osaka Univ, Grad Sch Pharmaceut Sci, Osaka, Japan.
   [Kunisawa, Jun] Univ Tokyo, Inst Med Sci, Div Mucosal Immunol, Dept Microbiol & Immunol, Tokyo, Japan.
   [Kunisawa, Jun] Univ Tokyo, Int Res & Dev Ctr Mucosal Vaccines, Inst Med Sci, Tokyo, Japan.
   [Kunisawa, Jun] Kobe Univ, Grad Sch Med, Kobe, Hyogo, Japan.
   [Kunisawa, Jun] Osaka Univ, Grad Sch Med, Osaka, Japan.
   [Kunisawa, Jun] Osaka Univ, Grad Sch Dent, Osaka, Japan.
   [Kunisawa, Jun] Natl Inst Biomed Innovat Hlth & Nutr, 7-6-8 Asagi, Ibaraki, Osaka 5670085, Japan.
RP Lan, HWX; Kunisawa, J (reprint author), Natl Inst Biomed Innovat Hlth & Nutr NIBIOHN, Ctr Vaccine & Adjuvant Res, Lab Vaccine Mat, Osaka, Japan.; Lan, HWX; Kunisawa, J (reprint author), Natl Inst Biomed Innovat Hlth & Nutr NIBIOHN, Lab Gut Environm Syst, Osaka, Japan.; Lan, HWX; Kunisawa, J (reprint author), Osaka Univ, Grad Sch Pharmaceut Sci, Osaka, Japan.; Kunisawa, J (reprint author), Univ Tokyo, Inst Med Sci, Div Mucosal Immunol, Dept Microbiol & Immunol, Tokyo, Japan.; Kunisawa, J (reprint author), Univ Tokyo, Int Res & Dev Ctr Mucosal Vaccines, Inst Med Sci, Tokyo, Japan.; Kunisawa, J (reprint author), Kobe Univ, Grad Sch Med, Kobe, Hyogo, Japan.; Kunisawa, J (reprint author), Osaka Univ, Grad Sch Med, Osaka, Japan.; Kunisawa, J (reprint author), Osaka Univ, Grad Sch Dent, Osaka, Japan.; Kunisawa, J (reprint author), Natl Inst Biomed Innovat Hlth & Nutr, 7-6-8 Asagi, Ibaraki, Osaka 5670085, Japan.
EM h-lan@nibiohn.go.jp; hosomi@nibiohn.go.jp; kunisawa@nibiohn.go.jp
FU Ministry of Education, Culture, Sports, Science, and Technology of
   JapanMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT) [18H02150, 18H02674, 17K09604, 18K17997]; Japan Society for
   the Promotion of ScienceMinistry of Education, Culture, Sports, Science
   and Technology, Japan (MEXT)Japan Society for the Promotion of Science
   [18H02150, 18H02674, 17K09604, 18K17997]; Japan Agency for Medical
   Research and Development (AMED)Japan Agency for Medical Research and
   Development (AMED) [17fk0108223h0002, 17ek0410032s0102,
   17fk0108207h0002, 17ek0210078h0002, 17ak0101068h0001, 17gm1010006s0101,
   18ck0106243h0003]; Ministry of Health, Labour, and Welfare of
   JapanMinistry of Health, Labour and Welfare, Japan; Science and
   Technology Research Promotion Program for Agriculture, Forestry,
   Fisheries, and Food Industry; Terumo Foundation for Life Sciences and
   Arts; ONO Medical Research Foundation; Canon FoundationCanon Foundation;
   Ministry of Health, Labour, and Welfare of JapanMinistry of Health,
   Labour and Welfare, Japan [JP19KA3001]
FX This work was supported by the Ministry of Education, Culture, Sports,
   Science, and Technology of Japan and the Japan Society for the Promotion
   of Science under grant numbers 18H02150 (J.K.), 18H02674 (J.K.),
   17K09604 (J.K.), and 18K17997 (K.H.); the Japan Agency for Medical
   Research and Development (AMED) under grant numbers 17fk0108223h0002
   (J.K.), 17ek0410032s0102 (J.K.), 17fk0108207h0002 (J.K.),
   17ek0210078h0002 (J.K.), 17ak0101068h0001 (J.K.), 17gm1010006s0101
   (J.K.), and 18ck0106243h0003 (J.K.); the Ministry of Health, Labour, and
   Welfare of Japan (J.K.); the Science and Technology Research Promotion
   Program for Agriculture, Forestry, Fisheries, and Food Industry (J.K.);
   the Terumo Foundation for Life Sciences and Arts (J.K.); the ONO Medical
   Research Foundation (J.K.); the Canon Foundation (J.K.); and the
   Ministry of Health, Labour, and Welfare of Japan under grant numbers
   JP19KA3001 (K.H.). None of these funding sources had a role in study
   design; in the collection, analysis, and interpretation of data; or in
   the writing of the report.
CR Almagro-Moreno S, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004787
   Apter FM, 1993, IN VITRO, V61, P8
   Arimitsu H, 2015, MICROBIOL IMMUNOL, V59, P71, DOI 10.1111/1348-0421.12221
   Bharati K, 2011, INDIAN J MED RES, V133, P179
   Bustamante-Marin XM, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a028241
   Calix JJ, 2010, J INFECT DIS, V202, P29, DOI 10.1086/653123
   Caprioli A, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.EHEC-0014-2013
   Caserta JA, 2011, INFECT IMMUN, V79, P3020, DOI 10.1128/IAI.01342-10
   Chakrabarti G, 2005, CELL MICROBIOL, V7, P129, DOI 10.1111/j.1462-5822.2004.00442.x
   Chatterjee S, 2007, J MED MICROBIOL, V56, P824, DOI 10.1099/jmm.0.46982-0
   Chemouny JM, 2016, NEPHROL DIAL TRANSPL, V31, P1235, DOI 10.1093/ndt/gfv335
   Chen JW, 2012, INFECT IMMUN, V80, P4078, DOI 10.1128/IAI.00069-12
   Clemens JD, 2017, LANCET, V390, P1539, DOI 10.1016/S0140-6736(17)30559-7
   CRAIN MJ, 1990, INFECT IMMUN, V58, P3293, DOI 10.1128/IAI.58.10.3293-3299.1990
   Daniels Calvin C, 2016, J Pediatr Pharmacol Ther, V21, P27, DOI 10.5863/1551-6776-21.1.27
   Deenick EK, 2005, EUR J IMMUNOL, V35, P2949, DOI 10.1002/eji.200425719
   English DP, 2013, INT J MOL SCI, V14, P10412, DOI 10.3390/ijms140510412
   Evans WH, 2002, MOL MEMBR BIOL, V19, P121, DOI 10.1080/09687680210139839
   Fazilleau N, 2009, IMMUNITY, V30, P324, DOI 10.1016/j.immuni.2009.03.003
   Fernandez-Miyakawa ME, 2007, INFECT IMMUN, V75, P1443, DOI 10.1128/IAI.01672-06
   FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.immunol.8.1.303
   Forster C, 2008, HISTOCHEM CELL BIOL, V130, P55, DOI 10.1007/s00418-008-0424-9
   Frank C, 2011, NEW ENGL J MED, V365, P1771, DOI 10.1056/NEJMoa1106483
   Fraser ME, 1994, CRYSTAL STRUCTURE HO, V1, P6
   Freedman JC, 2016, TOXINS, V8, DOI 10.3390/toxins8030073
   Friedrich AW, 2002, J INFECT DIS, V185, P74, DOI 10.1086/338115
   Fukuyama Y, 2010, J IMMUNOL, V185, P1755, DOI 10.4049/jimmunol.1000831
   Gao ZJ, 2012, J TOXICOL, DOI 10.1155/2012/981626
   Giepmans BNG, 2009, BBA-BIOMEMBRANES, V1788, P820, DOI 10.1016/j.bbamem.2008.07.015
   Grass JE, 2013, FOODBORNE PATHOG DIS, V10, P131, DOI 10.1089/fpd.2012.1316
   Grevers G, 2010, INT J PEDIATR OTORHI, V74, P572, DOI 10.1016/j.ijporl.2010.03.049
   Gunzel D, 2013, PHYSIOL REV, V93, P525, DOI 10.1152/physrev.00019.2012
   HANNA PC, 1992, INFECT IMMUN, V60, P2110, DOI 10.1128/IAI.60.5.2110-2114.1992
   Harada M, 2007, BIOCHEM PHARMACOL, V73, P206, DOI 10.1016/j.bcp.2006.10.002
   HOLMGREN J, 1973, INFECT IMMUN, V8, P208, DOI 10.1128/IAI.8.2.208-214.1973
   Hosomi K, 2019, INT IMMUNOL, V31, P91, DOI 10.1093/intimm/dxy071
   Hwang JK, 2015, MICROBIOL SPECTR, V3, DOI 10.1128/microbiolspec.MDNA3-0037-2014
   Ikegami K, 2010, P NATL ACAD SCI USA, V107, P10490, DOI 10.1073/pnas.1002128107
   Itoh M, 2003, J MAMMARY GLAND BIOL, V8, P449, DOI 10.1023/B:JOMG.0000017431.45314.07
   Johannes L, 2010, NAT REV MICROBIOL, V8, P105, DOI 10.1038/nrmicro2279
   Kakutani H, 2010, BIOMATERIALS, V31, P5463, DOI 10.1016/j.biomaterials.2010.03.047
   Kanaya T, 2012, NAT IMMUNOL, V13, P729, DOI 10.1038/ni.2352
   Karaman S, 2012, PLANT CELL REP, V31, P527, DOI 10.1007/s00299-011-1146-3
   Kelsall BL, 1996, J EXP MED, V183, P237, DOI 10.1084/jem.183.1.237
   Kiyono H, 2015, P JPN ACAD B-PHYS, V91, P423, DOI 10.2183/pjab.91.423
   Kokai-Kun JF, 1999, INFECT IMMUN, V67, P5634, DOI 10.1128/IAI.67.11.5634-5641.1999
   Kondoh M, 2005, MOL PHARMACOL, V67, P749, DOI 10.1124/mol.104.008375
   Konno A, 2012, INT REV CEL MOL BIO, V294, P133, DOI 10.1016/B978-0-12-394305-7.00003-3
   Kunisawa J, 2012, ADV DRUG DELIVER REV, V64, P523, DOI 10.1016/j.addr.2011.07.003
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P86, DOI 10.1016/j.addr.2008.09.012
   Lee J, 2015, PARASITOL RES, V114, P1377, DOI 10.1007/s00436-015-4316-3
   Li JH, 2013, MICROBIOL MOL BIOL R, V77, P208, DOI 10.1128/MMBR.00062-12
   Liang JL, 2018, MMWR RECOMM REP, V67, P1, DOI 10.15585/mmwr.rr6702a1
   Lutz C, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00375
   Lycke N, 1950, J IMMUNOL BALTIM MD, V1999, P913
   Mabbott NA, 2013, MUCOSAL IMMUNOL, V6, P666, DOI 10.1038/mi.2013.30
   MATSUDA M, 1986, BIOCHEM BIOPH RES CO, V141, P704, DOI 10.1016/S0006-291X(86)80229-7
   MCCLANE BA, 1994, TOXICOLOGY, V87, P43, DOI 10.1016/0300-483X(94)90154-6
   Melton-Celsa AR, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.EHEC-0024-2013
   MIETZNER TA, 1992, INFECT IMMUN, V60, P3947, DOI 10.1128/IAI.60.9.3947-3951.1992
   Miyaji EN, 2013, CELL MOL LIFE SCI, V70, P3303, DOI 10.1007/s00018-012-1234-8
   Mora JR, 2006, SCIENCE, V314, P1157, DOI 10.1126/science.1132742
   Moreno AT, 2010, CLIN VACCINE IMMUNOL, V17, P439, DOI 10.1128/CVI.00430-09
   Niessen CM, 2007, J INVEST DERMATOL, V127, P2525, DOI 10.1038/sj.jid.5700865
   Nochi T, 2007, P NATL ACAD SCI USA, V104, P10986, DOI 10.1073/pnas.0703766104
   Obata F, 2008, J INFECT DIS, V198, P1398, DOI 10.1086/591911
   Orata FD, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003967
   Park IH, 2007, J CLIN MICROBIOL, V45, P1225, DOI 10.1128/JCM.02199-06
   Rivas M, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.EHEC-0002-2013
   Robertson SL, 2007, CELL MICROBIOL, V9, P2734, DOI 10.1111/j.1462-5822.2007.00994.x
   Sanchez J, 2008, CELL MOL LIFE SCI, V65, P1347, DOI 10.1007/s00018-008-7496-5
   Sarker MR, 1999, MOL MICROBIOL, V33, P946, DOI 10.1046/j.1365-2958.1999.01534.x
   Sato S, 2013, MUCOSAL IMMUNOL, V6, P838, DOI 10.1038/mi.2012.122
   Scallan E, 2011, EMERG INFECT DIS, V17, P16, DOI [10.3201/eid1701.P21101, 10.3201/eid1701.091101p2]
   SCHNEEBERGER EE, 1992, AM J PHYSIOL, V262, pL647
   SIXMA TK, 1993, J MOL BIOL, V230, P890, DOI 10.1006/jmbi.1993.1209
   Smedley JG, 2007, INFECT IMMUN, V75, P2381, DOI 10.1128/IAI.01737-06
   SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127
   Sonoda N, 1999, J CELL BIOL, V147, P195, DOI 10.1083/jcb.147.1.195
   STEIN PE, 1992, NATURE, V355, P748, DOI 10.1038/355748a0
   Stratmann T, 2015, VACCINES-BASEL, V3, P579, DOI 10.3390/vaccines3030579
   SUGII S, 1994, J VET MED SCI, V56, P1047, DOI 10.1292/jvms.56.1047
   Suzuki H, 2010, PHARMAZIE, V65, P766, DOI 10.1691/ph.2010.0097
   Suzuki H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02320
   Suzuki H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21120-7
   Suzuki H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126352
   TAKEDA Y, 1993, MICROBIOL IMMUNOL, V37, P591, DOI 10.1111/j.1348-0421.1993.tb01681.x
   Tamagawa H, 2003, LAB INVEST, V83, P1045, DOI 10.1097/01.LAB.0000078741.55670.6E
   Terajima J, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.EHEC-0011-2013
   Tokuhara D, 2010, P NATL ACAD SCI USA, V107, P8794, DOI 10.1073/pnas.0914121107
   Troeger C, 2017, LANCET INFECT DIS, V17, P909, DOI 10.1016/S1473-3099(17)30276-1
   Tu AHT, 1999, INFECT IMMUN, V67, P4720, DOI 10.1128/IAI.67.9.4720-4724.1999
   Uchida H, 2010, BIOCHEM PHARMACOL, V79, P1437, DOI 10.1016/j.bcp.2010.01.010
   Uren TK, 2005, EUR J IMMUNOL, V35, P180, DOI 10.1002/eji.200425492
   Uzal FA, 2011, VET MICROBIOL, V153, P37, DOI 10.1016/j.vetmic.2011.02.048
   Uzal FA, 2012, MICROBES INFECT, V14, P1009, DOI 10.1016/j.micinf.2012.06.003
   Uzal FA, 2008, J VET DIAGN INVEST, V20, P253, DOI 10.1177/104063870802000301
   WADDELL T, 1990, P NATL ACAD SCI USA, V87, P7898, DOI 10.1073/pnas.87.20.7898
   Watari A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15108-y
   WELLING GW, 1985, FEBS LETT, V188, P215, DOI 10.1016/0014-5793(85)80374-4
   Williams OW, 2006, AM J RESP CELL MOL, V34, P527, DOI 10.1165/rcmb.2005-0436SF
   WNEK AP, 1985, INFECT IMMUN, V50, P442, DOI 10.1128/IAI.50.2.442-448.1985
   Yu RK, 2016, GLYCOBIOLOGY, V26, P63, DOI 10.1093/glycob/cwv080
NR 103
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 30
PY 2019
VL 37
IS 42
BP 6232
EP 6239
DI 10.1016/j.vaccine.2019.08.032
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JB1JT
UT WOS:000488317400014
PM 31466706
OA Other Gold
DA 2020-05-12
ER

PT J
AU Garcia-Garcia, G
   Rahimifard, S
AF Garcia-Garcia, Guillermo
   Rahimifard, Shahin
TI Life-cycle environmental impacts of barley straw valorisation
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Life-Cycle assessment; Waste management; Waste valorisation; Food waste;
   Barley straw
ID SOLID-WASTE MANAGEMENT; EXTRACTION; PART; LCA; WAX; ASSESSMENTS;
   SYSTEMS; SCOPE
AB Most food manufacturers in industrialised countries produce significant amounts of food wastes during their manufacturing activities. Due to the serious environmental consequences of managing these materials, environmental impact analyses have become popular to identify more sustainable practices for food waste management. Life-Cycle Assessment (LCA) is a useful methodology to assess such environmental impacts. This paper presents the main results obtained using the LCA methodology to analyse the potential environmental impacts of waste management for a brewery in the UK. Initially, the main waste types are identified for this industry: barley straw, malt waste and spent grain, and then barley straw is selected to study its environmental impact in detail. An alternative, more sustainable way to manage barley straw by extracting its wax with supercritical CO2 is discussed. SimaPro software is used to both quantify potential environmental impacts and evaluate the overall environmental performance of this valorisation opportunity, and to compare its modelled environmental impacts to the current impacts of managing barley straw. Results show that valorising barley straw by this method generates a high environmental impact due to the energy requirements of the processes involved, principally for human toxicity (cancer effects), human toxicity (non-cancer effects) and freshwater ecotoxicity impact categories. Using more energy-efficient processes or an alternative energy source would reduce this environmental impact. The analysis used in this paper allows an objective comparison between different scenarios with the final aim of supporting the use of sustainable solutions for waste management in the food industry.
C1 [Garcia-Garcia, Guillermo; Rahimifard, Shahin] Loughborough Univ, Ctr Sustainable Mfg & Recycling Technol, SMART, Loughborough, Leics, England.
RP Rahimifard, S (reprint author), Loughborough Univ, Ctr Sustainable Mfg & Recycling Technol, SMART, Loughborough, Leics, England.
EM G.Garcia-Garcia@lboro.ac.uk; S.Rahimifard@lboro.ac.uk
RI Garcia-Garcia, Guillermo/P-9975-2017
OI Garcia-Garcia, Guillermo/0000-0001-5562-9197
FU Engineering and Physical Sciences Research Council (EPSRC)Engineering &
   Physical Sciences Research Council (EPSRC) [EP/P008771/1]
FX The authors acknowledge the financial support of the Engineering and
   Physical Sciences Research Council (EPSRC) [grant reference
   EP/P008771/1]. The authors thank Thomas Dugmore from the University of
   York and Molson Coors for their support to define the initial stages of
   this work.; Engineering and Physical Sciences Research Council (EPSRC)
   [grant reference EP/P008771/1] is the funding source. University of York
   and Molson Coors participated in the project and provided some technical
   support, acknowledged in this section, but they did not provide
   financial support. The text in the article is correct.
CR Allesch A, 2014, WASTE MANAGE RES, V32, P461, DOI 10.1177/0734242X14535653
   Attard TM, 2018, J CLEAN PROD, V177, P684, DOI 10.1016/j.jclepro.2017.12.155
   Attard TM, 2015, INT J MOL SCI, V16, P17546, DOI 10.3390/ijms160817546
   Bisinella V, 2016, INT J LIFE CYCLE ASS, V21, P378, DOI 10.1007/s11367-015-1014-4
   Brancoli P, 2017, RESOUR CONSERV RECY, V118, P39, DOI 10.1016/j.resconrec.2016.11.024
   Brogaard LK, 2016, WASTE MANAGE, V56, P561, DOI 10.1016/j.wasman.2016.07.037
   Brunklaus B, 2018, J CLEAN PROD, V202, P1, DOI 10.1016/j.jclepro.2018.07.240
   Caduff M, 2011, ENVIRON SCI TECHNOL, V45, P751, DOI 10.1021/es103095k
   Moraes EDC, 2020, WASTE BIOMASS VALORI, V11, P1837, DOI 10.1007/s12649-018-0501-9
   Chen W., 2016, AGROCYCLE
   Colen L, 2016, J AGR ECON, V67, P186, DOI 10.1111/1477-9552.12128
   Davis J, 2017, GENERIC STRATEGY LCA
   De Luca AI, 2017, SCI TOTAL ENVIRON, V595, P352, DOI 10.1016/j.scitotenv.2017.03.284
   Department for Business Energy & Industrial Strategy (UK), 2019, NAT STAT EN TRENDS R
   Dri M., 2018, LEARNING FRONTRUNNER, DOI [10.2760/2115, DOI 10.2760/2115]
   European Commission Joint Research Centre-Institute for Environment and Sustainability, 2011, ILCD HDB INT REF LIF
   FAOSTAT, 2017, CROPS REG WORLD LIST
   Fortunati E, 2016, IND CROP PROD, V92, P201, DOI 10.1016/j.indcrop.2016.07.047
   Garcia-Garcia G, 2019, J CLEAN PROD, V211, P1339, DOI 10.1016/j.jclepro.2018.11.269
   Goedkoop M, 2016, INTRO LCA SIMAPRO
   Gonzalez-Garcia S, 2018, IND CROP PROD, V123, P331, DOI 10.1016/j.indcrop.2018.07.003
   Coelho LMG, 2018, RESOUR CONSERV RECY, V128, P438, DOI 10.1016/j.resconrec.2016.09.026
   Grand View Research, 2017, WAX MARK SIZ SHAR
   Hauschild MZ, 2015, LCA COMPEND, P1, DOI 10.1007/978-94-017-9744-3_1
   Hums ME, 2018, J AM OIL CHEM SOC, V95, P845, DOI 10.1002/aocs.12088
   International Organisation for Standardization, 2006, 140402006 ISO
   ISO, 2006, 140442006 ISO
   Khoo HH, 2010, SCI TOTAL ENVIRON, V408, P1367, DOI 10.1016/j.scitotenv.2009.10.072
   Kim MH, 2010, SCI TOTAL ENVIRON, V408, P3998, DOI 10.1016/j.scitotenv.2010.04.049
   Komilis D, 2017, WASTE MANAGE, V61, P1, DOI 10.1016/j.wasman.2017.03.016
   Krendlinger E., 2015, WAXES ULLMANNS ENCY, DOI [10.1002/14356007.a28_103.pub2, DOI 10.1002/14356007.A28_103.PUB2]
   Laborel-Preneron A, 2018, WASTE BIOMASS VALORI, V9, P1095, DOI 10.1007/s12649-017-9895-z
   Laurent A, 2014, WASTE MANAGE, V34, P573, DOI 10.1016/j.wasman.2013.10.045
   Lee SH, 2007, SCI TOTAL ENVIRON, V387, P42, DOI 10.1016/j.scitotenv.2007.06.037
   Liu GY, 2017, RESOUR CONSERV RECY, V120, P131, DOI 10.1016/j.resconrec.2016.12.003
   Lundie S, 2005, J CLEAN PROD, V13, P275, DOI 10.1016/j.jclepro.2004.02.020
   Nikkhah A, 2019, SCI TOTAL ENVIRON, V665, P538, DOI 10.1016/j.scitotenv.2019.02.170
   Palmer D, 2019, RENEW ENERG, V133, P1136, DOI 10.1016/j.renene.2018.08.109
   Pellerin P., 2003, P 6 INT S SUP FLUIDS
   Rebitzer G, 2004, ENVIRON INT, V30, P701, DOI 10.1016/j.envint.2003.11.005
   Research and Markets, 2018, WAX MARKET TYP APPL, P2017
   Salemdeeb R., 2018, International Journal of Recycling of Organic Waste in Agriculture, V7, P217, DOI 10.1007/s40093-018-0208-8
   Schott ABS, 2016, J CLEAN PROD, V119, P13, DOI 10.1016/j.jclepro.2016.01.079
   Sin E.H.K., 2012, EXTRACTION FRACTIONA
   Steinle JV, 1936, IND ENG CHEM, V28, P1004, DOI 10.1021/ie50321a003
   Sun RC, 2010, CEREAL STRAW AS A RESOURCE FOR SUSTAINABLE BIOMATERIALS AND BIOFUELS: CHEMISTRY, EXTRACTIVES, LIGNINS, HEMICELLULOSES AND CELLULOSE, P1
   Pham TCT, 2018, CAN J CHEM ENG, V96, P2273, DOI 10.1002/cjce.23260
   Thyberg KL, 2017, J CLEAN PROD, V158, P101, DOI 10.1016/j.jclepro.2017.04.169
   Vargas F, 2015, BIORESOURCE TECHNOL, V191, P263, DOI 10.1016/j.biortech.2015.05.035
   Winkler J, 2007, WASTE MANAGE, V27, P1021, DOI 10.1016/j.wasman.2007.02.023
   Wolf M.-A., 2012, JRC REFERENCES REPOR
   WRAP, RES EFF UK BREW SECT
NR 52
TC 1
Z9 1
U1 2
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 1
EP 11
DI 10.1016/j.resconrec.2019.05.026
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300001
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Nansai, K
   Kondo, Y
   Giurco, D
   Sussman, D
   Nakajima, K
   Kagawa, S
   Takayanagi, W
   Shigetomi, Y
   Tohno, S
AF Nansai, Keisuke
   Kondo, Yasushi
   Giurco, Damien
   Sussman, David
   Nakajima, Kenichi
   Kagawa, Shigemi
   Takayanagi, Wataru
   Shigetomi, Yosuke
   Tohno, Susumu
TI Nexus between economy-wide metal inputs and the deterioration of
   sustainable development goals
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Sustainable development; Social impact; Scarce metals; International
   trade; Mining; Material flow
ID LOW-CARBON TECHNOLOGIES; IMPACT ASSESSMENT; SOCIAL LICENSE; ENERGY;
   CONSUMPTION; PRODUCER; COBALT; FLOWS; RISK; REQUIREMENTS
AB This study investigates, at the country level, the adverse effects of changes in metal inputs on the achievement of sustainable development goals (SDGs). It also highlights the relationships between metals use and various socioeconomic consequences that urgently require decoupling in order to achieve the SDGs. We performed panel data analysis to evaluate, on a national scale and over a ten-year period (2004-2013), the impact of changes in the material flows of 11 metals on 96 SDG indicators corresponding to the 17 SDGs defined by the UN. On average, an increase in the material flow of the targeted metals was found to be correlated with a deterioration in approximately 10% of the 96 indicators. Among the affected SDGs, the adverse impact of metals on SDG 3 (Health), SDG 8 (Economic Growth), and SDG 16 (Peace, Justice, and Strong Institutions) was particularly noteworthy. More SDGs were negatively impacted in metal-mining countries than in metal-importing countries.
C1 [Nansai, Keisuke; Nakajima, Kenichi; Takayanagi, Wataru] Natl Inst Environm Studies, Ctr Mat Cycles & Waste Management Res, 16-2 Onogawa, Tsukuba, Ibaraki 3058506, Japan.
   [Nansai, Keisuke] Univ Sydney, Fac Sci, Sch Phys, ISA, Camperdown, NSW 2006, Australia.
   [Kondo, Yasushi] Waseda Univ, Fac Polit Sci & Econ, Shinjuku Ku, 1-6-1 Nishi Waseda, Tokyo 1698050, Japan.
   [Giurco, Damien] Univ Technol Sydney, Inst Sustainable Futures, 235 Jones St, Ultimo 2007, Australia.
   [Sussman, David] Tufts Univ, Global Dev & Environm Inst, 44 Teele Ave, Somerville, MA 02144 USA.
   [Kagawa, Shigemi] Kyushu Univ, Fac Econ, Nish Ku, 744 Motooka, Fukuoka, Fukuoka 8190395, Japan.
   [Shigetomi, Yosuke] Nagasaki Univ, Fac Environm Sci, 1-14 Bunkyo Machi, Nagasaki 8528521, Japan.
   [Tohno, Susumu] Kyoto Univ, Grad Sch Energy Sci, Sakyo Ku, Kyoto 6068501, Japan.
RP Nansai, K (reprint author), Natl Inst Environm Studies, Ctr Mat Cycles & Waste Management Res, 16-2 Onogawa, Tsukuba, Ibaraki 3058506, Japan.
EM nansai.keisuke@nies.go.jp
RI Kondo, Yasushi/B-9219-2013; Nansai, Keisuke/C-2516-2008; Shigetomi,
   Yosuke/H-4422-2018
OI Kondo, Yasushi/0000-0002-6855-2691; /0000-0002-2449-1874; Giurco,
   Damien/0000-0002-1707-9531; Shigetomi, Yosuke/0000-0003-1384-0992;
   Tohno, Susumu/0000-0002-3936-5600
FU Japanese Ministry of Education, Culture, Sports, Science and
   TechnologyMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT) [18KT0056]; Environment Research & Technology
   Development Fund of the Environmental Restoration and Conservation
   Agency, Japan [1-1601, 2-1801]
FX This research was supported in part by Grants-in-Aid for Research (No.
   18KT0056) from the Japanese Ministry of Education, Culture, Sports,
   Science and Technology and the Environment Research & Technology
   Development Fund (1-1601, 2-1801) of the Environmental Restoration and
   Conservation Agency, Japan.
CR Abela GJ, 2016, P NATL ACAD SCI USA, V113, P14294, DOI 10.1073/pnas.1611386113
   Adriaanse A., 1997, RESOURCE FLOWS MAT B
   Akizu-Gardoki O, 2018, J CLEAN PROD, V202, P1145, DOI 10.1016/j.jclepro.2018.08.235
   Ali SH, 2017, NATURE, V543, P367, DOI 10.1038/nature21359
   Alonso E, 2012, ENVIRON SCI TECHNOL, V46, P12986, DOI 10.1021/es301110e
   Alonso E, 2012, ENVIRON SCI TECHNOL, V46, P3406, DOI 10.1021/es203518d
   Alvarez IC, 2017, J STAT SOFTW, V76, P1, DOI 10.18637/jss.v076.i06
   Amirshenava S, 2019, J CLEAN PROD, V218, P823, DOI 10.1016/j.jclepro.2019.02.026
   Amirshenava S, 2018, J CLEAN PROD, V184, P389, DOI 10.1016/j.jclepro.2018.01.186
   [Anonymous], 2011, DEC NAT RES US ENV I
   Antwi EK, 2017, SUSTAIN SCI, V12, P747, DOI 10.1007/s11625-017-0474-9
   Arrobas D.L.P., 2017, GROWING ROLE MINERAL
   Ayogu M., 2011, CONFLICT MINERALS AS, P2011
   Ayre G., 2013, EARTHSCAN
   Bebbington A, 2018, SUSTAIN DEV, V26, P441, DOI 10.1002/sd.1888
   Bebbington A, 2008, DEV CHANGE, V39, P887, DOI 10.1111/j.1467-7660.2008.00517.x
   Brand-Correa LI, 2017, ECOL ECON, V141, P43, DOI 10.1016/j.ecolecon.2017.05.019
   Bruckner M., 2012, GLOB ENV CHANG, V22, P568
   Columbia Center on Sustainable Investment (CCSI)  UN Sustainable Development Solutions Network (SDSN)  United Nations Development Programme (UNDP)  and the World Economic Forum, 2016, MAPP MIN SUST DEV GO
   Daigo I, 2010, RESOUR CONSERV RECY, V54, P851, DOI 10.1016/j.resconrec.2010.01.004
   Dare M, 2014, IMPACT ASSESS PROJ A, V32, P188, DOI 10.1080/14615517.2014.927108
   de Koning A, 2018, RESOUR CONSERV RECY, V129, P202, DOI 10.1016/j.resconrec.2017.10.040
   Deetman S, 2018, ENVIRON SCI TECHNOL, V52, P4950, DOI 10.1021/acs.est.7b05549
   Demuijnck G, 2016, J BUS ETHICS, V136, P675, DOI 10.1007/s10551-015-2976-7
   Dialga I, 2018, J CLEAN PROD, V179, P278, DOI 10.1016/j.jclepro.2017.12.185
   EITI, 2017, STAT SUPP EITI FIN L
   El-Maghrabi M. H., 2018, SUSTAINABLE DEV GOAL
   *EUR, 2001, EC WID MAT FLOW ACC
   Fernandes de Mesquite R., 2017, GEO RESOUR ENV ENG, V2
   Fischer-Kowalski M, 2011, J IND ECOL, V15, P855, DOI 10.1111/j.1530-9290.2011.00366.x
   Franks DM, 2014, P NATL ACAD SCI USA, V111, P7576, DOI 10.1073/pnas.1405135111
   Giljum S, 2014, RESOURCES-BASEL, V3, P319, DOI 10.3390/resources3010319
   Giurco D, 2014, J CLEAN PROD, V84, P322, DOI 10.1016/j.jclepro.2014.05.102
   Grandell L, 2016, RENEW ENERG, V95, P53, DOI 10.1016/j.renene.2016.03.102
   Helbig C, 2018, J CLEAN PROD, V172, P274, DOI 10.1016/j.jclepro.2017.10.122
   Kanbur R., 2018, GOOD MEASURE ADV RES
   Keser A., 2018, J PUBLIC ADM GOV, V8
   Kleijn R, 2011, ENERGY, V36, P5640, DOI 10.1016/j.energy.2011.07.003
   Krausmann F, 2009, ECOL ECON, V68, P2696, DOI 10.1016/j.ecolecon.2009.05.007
   Lenzen M, 2007, ECOL ECON, V61, P27, DOI 10.1016/j.ecolecon.2006.05.018
   Manberger A, 2018, ENERG POLICY, V119, P226, DOI 10.1016/j.enpol.2018.04.056
   Mancini L, 2018, RESOUR POLICY, V57, P98, DOI 10.1016/j.resourpol.2018.02.002
   Munksgaard J, 2001, ENERG POLICY, V29, P327, DOI 10.1016/S0301-4215(00)00120-8
   Nakajima K, 2017, SCI TOTAL ENVIRON, V586, P730, DOI 10.1016/j.scitotenv.2017.02.049
   Nakajima K, 2013, ENVIRON SCI TECHNOL, V47, P4653, DOI 10.1021/es3043559
   Nansai K, 2015, ENVIRON SCI TECHNOL, V49, P2022, DOI 10.1021/es504255r
   Nansai K, 2014, ENVIRON SCI TECHNOL, V48, P1391, DOI 10.1021/es4033452
   O'Connell R., 2018, GFMS PLATINUM GROUP
   O'Rourke D, 2015, ANNU REV ENV RESOUR, V40, P233, DOI 10.1146/annurev-environ-102014-021224
   Peters GP, 2008, ECOL ECON, V65, P13, DOI 10.1016/j.ecolecon.2007.10.014
   Pradhan P, 2017, EARTHS FUTURE, V5, P1169, DOI 10.1002/2017EF000632
   Prno J, 2012, RESOUR POLICY, V37, P346, DOI 10.1016/j.resourpol.2012.04.002
   Ranis G, 2000, WORLD DEV, V28, P197, DOI 10.1016/S0305-750X(99)00131-X
   Schandl H., 2016, GLOBAL MAT FLOWS RES
   Simon B, 2015, RESOUR CONSERV RECY, V104, P300, DOI 10.1016/j.resconrec.2015.07.011
   Stevens B, 2010, FOUND REV, V2, P10, DOI 10.4087/FOUNDATIONREVIEW-D-09-00050
   Stiglitz J.E., 2018, GDP MEASURING WHAT C
   Sudmant A, 2018, J CLEAN PROD, V176, P654, DOI 10.1016/j.jclepro.2017.12.139
   Tokimatsu K, 2018, APPL ENERG, V225, P1158, DOI 10.1016/j.apenergy.2018.05.047
   Tost M, 2018, J CLEAN PROD, V182, P969, DOI 10.1016/j.jclepro.2018.02.051
   Tseng ML, 2019, RESOUR CONSERV RECY, V145, P419, DOI 10.1016/j.resconrec.2019.03.012
   Umicore, 2017, DUE DIL COMP REP COB
   UN, 2015, UN SUST DEV GOALS 17
   van den Brink S, 2019, RESOUR CONSERV RECY, V145, P389, DOI 10.1016/j.resconrec.2019.02.040
   Vidal O, 2013, NAT GEOSCI, V6, P894, DOI 10.1038/ngeo1993
   Wiedmann TO, 2013, P NATL ACAD SCI US
   World Bureau of Metal Statistics (WBMS), 2015, ANN STAINL STEEL STA
   World Economic Forum, 2016, UN DEV PROGR UN MEMB
   Yakovleva N, 2017, EXTRACT IND SOC, V4, P426, DOI 10.1016/j.exis.2017.06.010
   Zeng XL, 2015, RESOUR CONSERV RECY, V104, P12, DOI 10.1016/j.resconrec.2015.09.014
NR 70
TC 0
Z9 0
U1 3
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 12
EP 19
DI 10.1016/j.resconrec.2019.05.017
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300002
OA Other Gold
DA 2020-05-12
ER

PT J
AU Li, Z
   Diaz, LA
   Yang, ZY
   Jin, HY
   Lister, TE
   Vahidi, E
   Zhao, F
AF Li, Zhen
   Diaz, Luis A.
   Yang, Zhiyao
   Jin, Hongyue
   Lister, Tedd E.
   Vahidi, Ehsan
   Zhao, Fu
TI Comparative life cycle analysis for value recovery of precious metals
   and rare earth elements from electronic waste
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Electronic waste; Electrochemical recovery; Life cycle assessment;
   Precious metal recovery
ID MANAGEMENT; EXTRACTION; ENERGY; COPPER; BOARDS; WEEE
AB There is an ever-increasing concern regarding the electronic waste (e-waste), which is the fastest growing waste stream in the world. Incentivized by various legislations and the intrinsic value of critical metals inside, recycling of e-waste is becoming an attractive business opportunity that also benefits the environment. A novel electrochemical recovery (ER) process has been developed as a promising alternative to the existing pyrometallurgical and hydrometallurgical processes based technologies to recover base metals, precious metals, and rare earth elements (REEs) from e-waste. Experimental results indicate that the ER process has lower chemical consumption, enhanced control, and reduced energy demand compared to the pyrometallurgical and the hydro metallurgical processes. To quantify and compare the environmental performances of the three technologies, life cycle analysis has been conducted. Results show that the ER process outperforms the other two processes in almost all impact categories adopted in TRACI and ILCD while there is no clear winner between the hydro metallurgical and the pyrometallurgical processes. The highest impactful input for the ER method is hydrochloric acid, and for the pyrometallurgical method is copper scrap, while for the hydrometallurgical method, it is hydrogen peroxide, an oxidizer that accelerates base metal extraction process, that dominates the overall environmental footprint. The environmental viability of the ER process warrants the further development of ER process at industrial scale.
C1 [Li, Zhen; Zhao, Fu] Purdue Univ, Sch Mech Engn, 585 Purdue Mall, W Lafayette, IN 47907 USA.
   [Li, Zhen; Zhao, Fu] Purdue Univ, Ecol Sci & Engn Interdisciplinary Grad Program, W Lafayette, IN 47907 USA.
   [Diaz, Luis A.; Lister, Tedd E.] Idaho Natl Lab, Biol & Chem Proc Dept, Idaho Falls, ID 83402 USA.
   [Yang, Zhiyao] Purdue Univ, Lyles Sch Civil Engn, W Lafayette, IN 47907 USA.
   [Jin, Hongyue] Univ Arizona, Dept Syst & Ind Engn, Tucson, AZ 85721 USA.
   [Vahidi, Ehsan] MIT, Dept Civil & Environm Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Zhao, Fu] Purdue Univ, Div Environm & Ecol Engn, W Lafayette, IN 47907 USA.
RP Zhao, F (reprint author), Purdue Univ, Sch Mech Engn, 585 Purdue Mall, W Lafayette, IN 47907 USA.
EM fzhao@purdue.edu
RI Aldana, Luis A Diaz/A-1903-2016; Aldana, Luis Diaz/AAE-1115-2019
OI Aldana, Luis A Diaz/0000-0003-4895-464X; Aldana, Luis
   Diaz/0000-0003-4895-464X; Zhao, Fu/0000-0001-5195-868X; Jin,
   Hongyue/0000-0002-9531-340X
FU Critical Materials Institute, an Energy Innovation Hub - U.S. Department
   of Energy, Office of Energy Efficiency and Renewable Energy, Advanced
   Manufacturing OfficeUnited States Department of Energy (DOE)
FX This work is supported by the Critical Materials Institute, an Energy
   Innovation Hub funded by the U.S. Department of Energy, Office of Energy
   Efficiency and Renewable Energy, Advanced Manufacturing Office.
CR [Anonymous], 2018, WEEK COPPER PRICES C
   [Anonymous], 2019, SILV PRIC TOD
   [Anonymous], 2006140402006 ISO EN
   [Anonymous], 2019, TOD CURR SCR MET PRI
   [Anonymous], 2019, GOLD PRIC TOD
   Arcadi G, 2016, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2016/07/005
   Arshi PS, 2018, ACS SUSTAIN CHEM ENG, V6, P3311, DOI 10.1021/acssuschemeng.7b03484
   Awasthi AK, 2018, SCI TOTAL ENVIRON, V613, P46, DOI 10.1016/j.scitotenv.2017.08.288
   Bailey G, 2016, WORLD C EXP REC
   Behnamfard A, 2013, WASTE MANAGE, V33, P2354, DOI 10.1016/j.wasman.2013.07.017
   Belaissaoui B, 2014, ENRGY PROCED, V63, P497, DOI 10.1016/j.egypro.2014.11.054
   Bigum M, 2012, J HAZARD MATER, V207, P8, DOI 10.1016/j.jhazmat.2011.10.001
   Cheng Y, 2013, IND ENG CHEM RES, V52, P16622, DOI 10.1021/ie4026852
   Cui JR, 2008, J HAZARD MATER, V158, P228, DOI 10.1016/j.jhazmat.2008.02.001
   Diaz LA, 2018, WASTE MANAGE, V74, P384, DOI 10.1016/j.wasman.2017.11.050
   Diaz LA, 2017, IND ENG CHEM RES, V56, P7516, DOI 10.1021/acs.iecr.7b01009
   Diaz LA, 2016, J CLEAN PROD, V125, P236, DOI 10.1016/j.jclepro.2016.03.061
   Ghodrat M, 2016, J CLEAN PROD, V126, P178, DOI 10.1016/j.jclepro.2016.03.033
   Hageluken C., 2005, P EMC, V59, P152
   Hong JL, 2015, WASTE MANAGE, V38, P357, DOI 10.1016/j.wasman.2014.12.022
   Iannicelli-Zubiani EM, 2017, J CLEAN PROD, V140, P1204, DOI 10.1016/j.jclepro.2016.10.040
   Isildar A, 2018, RESOUR CONSERV RECY, V135, P296, DOI 10.1016/j.resconrec.2017.07.031
   Jelea S. G, 2010, STUD U VASILE GOL SV, V20, P27, DOI [10.1021/es071873x, DOI 10.1021/ES071873X]
   Kaya M, 2016, WASTE MANAGE, V57, P64, DOI 10.1016/j.wasman.2016.08.004
   Khaliq A, 2014, RESOURCES-BASEL, V3, P152, DOI 10.3390/resources3010152
   Kiddee P, 2013, WASTE MANAGE, V33, P1237, DOI 10.1016/j.wasman.2013.01.006
   Kumar A, 2017, RESOUR CONSERV RECY, V122, P32, DOI 10.1016/j.resconrec.2017.01.018
   Lister T. E, 2016, IMPC 2016 28 INT MIN
   Lister TE, 2014, HYDROMETALLURGY, V149, P228, DOI 10.1016/j.hydromet.2014.08.011
   Namias J., 2013, FUTURE ELECT WASTE R, P66, DOI [10.1021/acs.jpclett.8b00176, DOI 10.1021/ACS.JPCLETT.8B00176]
   Perkins DN, 2014, ANN GLOB HEALTH, V80, P286, DOI 10.1016/j.aogh.2014.10.001
   Rocchetti L, 2013, ENVIRON SCI TECHNOL, V47, P1581, DOI 10.1021/es302192t
   Rodriguez-Garcia G, 2016, WEEE RECYCLING: RESEARCH, DEVELOPMENT, AND POLICIES, P177, DOI 10.1016/B978-0-12-803363-0.00007-9
   Rubin RS, 2014, J CLEAN PROD, V64, P297, DOI 10.1016/j.jclepro.2013.07.051
   Santero N, 2016, INT J LIFE CYCLE ASS, V21, P1543, DOI 10.1007/s11367-015-1022-4
   Sprecher B, 2014, ENVIRON SCI TECHNOL, V48, P3951, DOI 10.1021/es404596q
   Vahidi E, 2016, RESOUR CONSERV RECY, V113, P1, DOI 10.1016/j.resconrec.2016.05.006
   Xue MQ, 2015, ENVIRON SCI TECHNOL, V49, P940, DOI 10.1021/es504750q
   Zaimes GG, 2015, ACS SUSTAIN CHEM ENG, V3, P237, DOI 10.1021/sc500573b
   Zeng XL, 2018, ENVIRON SCI TECHNOL, V52, P4835, DOI 10.1021/acs.est.7b04909
   Zhang K, 2012, ENVIRON SCI TECHNOL, V46, P10861, DOI 10.1021/es303166s
   Zhang WH, 2012, PEDOSPHERE, V22, P434, DOI 10.1016/S1002-0160(12)60030-7
NR 42
TC 2
Z9 2
U1 21
U2 32
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 20
EP 30
DI 10.1016/j.resconrec.2019.05.025
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300003
DA 2020-05-12
ER

PT J
AU Joseph, N
   Ryu, D
   Malano, HM
   George, B
   Sudheer, KP
   Anshuman
AF Joseph, Naveen
   Ryu, Dongryeol
   Malano, Hector M.
   George, Biju
   Sudheer, K. P.
   Anshuman
TI Estimation of industrial water demand in India using census-based
   statistical data
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Industrial water demand; Water consumption; Principal component
   analysis; Industrial production; Census-based statistical data
ID MODEL
AB Rising population and industrialisation aided by technological advancements have resulted in increased industrial water demand in India. Industrial water demand accounts for about 8-10 % of the total water demand in the country. Although some national and international organisations report industrial water demand, there is a wide variation in data due to the scarcity of the reliable data and inconsistencies in the methods adopted for quantification. Rather than using these estimates, the census-based statistical data could provide better figures. Therefore, the present study aims to quantify industrial water demand by compiling census-based statistical data collected from various Governmental agencies in India. Based on census datasets collected at National and State Governmental institutions, this study develops a new model to estimate industrial water demand. Industrial water demand is estimated in this study at State and monthly scale from 1991 to 2010. The study models industrial water demand as a function of industrial production data, industrial survey components, and economic/technological development indicators. Principal component analysis is employed to reduce these large number of input variables to a smaller number of latent variables, which account for the variance in the input variables. The model results are cross-validated with industrial water demand data obtained from National Commission on Integrated Water Resources Development (NCIWRD). Country-level estimates are disaggregated to State-level water demand estimates based on number of industrial units in each State. These State-level results are verified against an independent census dataset on industrial water demand collected from State Governmental organisations. It is found that industrial water demand increased at a rate of 2% per annum during the period of analysis, which exceeds the increase rate of agricultural and domestic water demands during the same period.
C1 [Joseph, Naveen; Ryu, Dongryeol; Malano, Hector M.; George, Biju] Univ Melbourne, Dept Infrastruct Engn, Parkville, Vic, Australia.
   [Sudheer, K. P.] IIT Madras, Dept Civil Engn, Chennai, Tamil Nadu, India.
   [Anshuman] Energy & Resources Inst, New Delhi, India.
RP Joseph, N (reprint author), Univ Melbourne, Dept Infrastruct Engn, Parkville, Vic, Australia.
EM naveenj@student.unimelb.edu.au
FU M.K.N. Johansen scholarship through the Department of Infrastructure
   Engineering, University of Melbourne
FX The M.K.N. Johansen scholarship financially supports the research
   through the Department of Infrastructure Engineering, University of
   Melbourne. We also thank the three anonymous reviewers and the Editor of
   the journal for their constructive feedback.
CR Abdi H, 2010, WIRES COMPUT STAT, V2, P433, DOI 10.1002/wics.101
   Aggarwal S. C, 2011, INDIA INFRASTRUCTURE
   Alcamo J, 2002, AQUAT SCI, V64, P352, DOI 10.1007/PL00012591
   Alcamo J, 2003, HYDROLOG SCI J, V48, P317, DOI 10.1623/hysj.48.3.317.45290
   Alcamo J, 2007, HYDROLOG SCI J, V52, P247, DOI 10.1623/hysj.52.2.247
   Amarasinghe Upali A., 2005, SPATIAL VARIATION WA
   [Anonymous], 2009, 3 UNESCO WORLD WAT A
   Batra R, 2012, ENHANCING WATER USE
   Bhat T. A., 2014, Journal of Environment and Earth Science, V4, P67
   Cagliarini A, 2011, RESERVE BANK AUSTR B, P15
   CEA (Central Electricity Authority), 2016, ALL IND EL STAT GEN
   Chandrakanth M, 2009, ITP RES SERIES, V3
   Chandramouli C, 2011, CENSUS INDIA 2011 PR
   Chaturvedi M.C, 2012, GANGA BRAHMAPUTRA ME
   Cohen R. A, 2002, ELECT GREEN J, V1, P2, DOI DOI 10.1016/S1040-6190(02)00334-2
   CSE (Centre for Science and Environment), 2004, EARTH S, P1
   CSO (Central Statistical Organisation), 1998, COMP ENV STAT
   CWC (Central Water Commission), 2010, WAT REL STAT
   EFRON B, 1983, AM STAT, V37, P36, DOI 10.2307/2685844
   GOW (Government of West Bengal), 2010, W BENG STAT ACT PLAN
   Hanasaki N, 2008, HYDROL EARTH SYST SC, V12, P1027, DOI 10.5194/hess-12-1027-2008
   Hoekstra AY, 2007, INTEGRATED ASSESSMENT OF WATER RESOURCES AND GLOBAL CHANGE, P35, DOI 10.1007/s11269-006-9039-x
   Hoekstra AY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032688
   Hoekstra AY, 2012, P NATL ACAD SCI USA, V109, P3232, DOI 10.1073/pnas.1109936109
   ICID (International Commission on Irrigation and Drainage), 2005, WAT POL ISSU IND STU
   Islam MS, 2007, INTEGRATED ASSESSMENT OF WATER RESOURCES AND GLOBAL CHANGE, P19, DOI 10.1007/s11269-006-9038-y
   Jolliffe IT, 2002, PRINCIPAL COMPONENT
   Kohli A, 2010, DISAMBIGUATION WATER
   Kummu M, 2010, ENVIRON RES LETT, V5, DOI 10.1088/1748-9326/5/3/034006
   Madhusudhan L, 2015, BUS EC J, V6, P1
   Mekonnen MM, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1500323
   MOEF (Ministry of Environment and Forests), 2007, UT CHAND ACT PLAN CL
   National Thermal Power Corporation (NTPC), 2008, 32 ANN REP 2007 2008
   National Thermal Power Corporation (NTPC), 2009, 33 ANN REP 2008 2009
   NCIWRD (National Commission of Integrated Water Resources Development), 1999, PLAN ACT REP COMM IN, V1
   Oki T, 2001, HYDROLOG SCI J, V46, P983, DOI 10.1080/02626660109492890
   Panandiker A. P, 2013, SECTORAL WATER DEMAN
   Planning-Commission, 1992, IND 85 YEAR PLAN 199
   QUENOUILLE MH, 1949, J ROY STAT SOC B, V11, P68
   Rencher A. C., 2002, METHODS MULTIVARIATE, P380, DOI DOI 10.1002/0471271357.CH12
   Shiklomanov IA, 2000, WATER INT, V25, P11, DOI 10.1080/02508060008686794
   SSC-MoWR (Standing Sub-Committee of Ministry of Water Resources), 2000, ASS AV REQ WAT DIV U
   Thukral R. K, 2011, INDIASTAT
   Wada Y, 2016, GEOSCI MODEL DEV, V9, P175, DOI 10.5194/gmd-9-175-2016
   Wada Y, 2011, HYDROL EARTH SYST SC, V15, P3785, DOI 10.5194/hess-15-3785-2011
   Wada Y., 2011, WATER RESOUR RES, V47
   Wilson S, 2014, 2 GOV HAR
NR 47
TC 1
Z9 1
U1 4
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 31
EP 44
DI 10.1016/j.resconrec.2019.05.036
PG 14
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300004
DA 2020-05-12
ER

PT J
AU Sun, X
   Hao, H
   Liu, ZW
   Zhao, FQ
   Song, JN
AF Sun, Xin
   Hao, Han
   Liu, Zongwei
   Zhao, Fuquan
   Song, Junnan
TI Tracing global cobalt flow: 1995-2015
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Cobalt; Material flow analysis; International trade; In-use stock
ID LITHIUM-ION BATTERIES; CRITICAL METALS; ALUMINUM; STOCKS
AB Cobalt is an essential metal for next-generation clean technologies. In this study, a long-term trade-linked material flow analysis model is established to analyze cobalt flows throughout the metal's anthropogenic life cycle and across national boundaries during the 1995-2015 period. The results indicate that driven by more cobalt applications discovered and developed, global cobalt supply and demand have experienced rapid growth in recent decades. Global cobalt in-use stock reached 220 kilotons in 2015, which is mainly embodied in laptop computers. The major opportunity for secondary cobalt recovery exists in the cobalt stock contained in battery applications. Cutting the excess productivity of batteries is essential to improving cobalt utilization efficiency. A globally-distributed cobalt trade network has been established. Democratic Republic of the Congo, the United States, China, and Japan are the major powers in the trade network. Countries with strong dependence on cobalt imports face a high risk of cobalt shortages. The establishment of domestic cobalt reserves and the development of cobalt substitutes are viable options for these countries. Besides, international coordination and governance through the whole value chain of cobalt should be under consideration. High attention need to be paid on harmonizing the extraction of cobalt and other companion metals, mostly copper and nickel.
C1 [Sun, Xin; Hao, Han; Liu, Zongwei; Zhao, Fuquan] Tsinghua Univ, State Key Lab Automot Safety & Energy, Beijing 100084, Peoples R China.
   [Hao, Han] Tsinghua Univ, China Automot Energy Res Ctr, Beijing 100084, Peoples R China.
   [Hao, Han; Liu, Zongwei; Zhao, Fuquan] Tsinghua Univ, Tsinghua Automot Strategy Res Inst, Beijing 100084, Peoples R China.
   [Song, Junnan] China Natl Petr Corp, Petrochem Res Inst, Beijing 102206, Peoples R China.
RP Hao, H (reprint author), Tsinghua Univ, State Key Lab Automot Safety & Energy, Beijing 100084, Peoples R China.
EM hao@tsinghua.edu.cn
OI Sun, Xin/0000-0003-1772-8623
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [71774100, 71690241, 71403142]; Young Elite
   Scientists Sponsorship Program by CAST [YESS20160140]; State Key
   Laboratory of Automotive Safety and Energy [ZZ2019-023]
FX This study is sponsored by the National Natural Science Foundation of
   China (71774100, 71690241, 71403142), Young Elite Scientists Sponsorship
   Program by CAST (YESS20160140), State Key Laboratory of Automotive
   Safety and Energy (ZZ2019-023).
CR AirInsight, 2017, BIG DAT CIV AV ENG M
   Ali SH, 2017, NATURE, V543, P367, DOI 10.1038/nature21359
   [安洪涛 An Hongtao], 2015, [矿冶工程, Mining and Metallurgical Engineering], V35, P149
   [Anonymous], 2013, AN MARK SIT NI MH BA
   [Anonymous], 2016, STUDY CATHODE MAT DE
   [Anonymous], 2016, WORLD COBALT METAL P
   [Anonymous], 2017, MARKET ANAL REPORT C
   [Anonymous], 2018, GLOBAL GIANT MAGNETI
   [Anonymous], 2017, AN GLOB COB RES SUPP
   Antaike, 2017, COB IND CHAIN REP
   Brunner P. H., 2004, INT J LIFE CYCLE ASS, V9, P337, DOI DOI 10.1007/BF02979426
   Cailu Technology, 2014, GLOB CAT MARK AN
   CECA, 2016, RES DEV MAGN MAT IND
   Che S., 2013, CURRENT SITUATION FU
   Chen Q., 2018, PROMOTE DEV POWER BA
   CHYXX, 2016, RES AN CURR SIT COB
   CHYXX, 2016, 2016 GLOB COB DEM ST
   CRN, 2017, PROD GROWTH RAT SUPP
   CRSL, 2017, IMP NICK CHIN
   Cullen JM, 2013, ENVIRON SCI TECHNOL, V47, P3057, DOI 10.1021/es304256s
   Cullen JM, 2012, ENVIRON SCI TECHNOL, V46, P13048, DOI 10.1021/es302433p
   CUPS, 2016, AN PRES SIT FUT DEV
   Deetman S, 2018, ENVIRON SCI TECHNOL, V52, P4950, DOI 10.1021/acs.est.7b05549
   Ding L, 2017, ACTA PHYSIOL PLANT, V39, DOI 10.1007/s11738-017-2575-6
   Fortune securities, 2017, NEW EN VAL CHAIN CAT
   Hang H., 2016, EXPLANATION NOUNS
   Hao H, 2017, ENERG POLICY, V108, P355, DOI 10.1016/j.enpol.2017.06.011
   Harper EM, 2012, ENVIRON SCI TECHNOL, V46, P1079, DOI 10.1021/es201874e
   Harvey LDD, 2018, APPL ENERG, V212, P663, DOI 10.1016/j.apenergy.2017.11.074
   Highpower International, 2014, DOM FOR NI MH BATT M
   Jian Q., 1999, NONFERROUS MET SCI E, V13, P34
   Kapusta JPT, 2006, JOM-US, V58, P33, DOI 10.1007/s11837-006-0198-2
   Kim H, 2018, FRONT ENV SCI ENG, V12, DOI 10.1007/s11783-018-1019-x
   Knobloch V, 2018, RESOUR CONSERV RECY, V138, P272, DOI 10.1016/j.resconrec.2018.05.027
   Lv W., 2017, ACS SUSTAIN CHEM ENG, V6, P1504
   Melo MT, 1999, RESOUR CONSERV RECY, V26, P91, DOI 10.1016/S0921-3449(98)00077-9
   Meng H., 2015, GUANGZHOU CHEM IND, V43, P14
   Muller E, 2014, ENVIRON SCI TECHNOL, V48, P2102, DOI 10.1021/es403506a
   Nansai K, 2014, ENVIRON SCI TECHNOL, V48, P1391, DOI 10.1021/es4033452
   Natalia L, 2017, LITHIUM ION BATTERY
   Olivetti EA, 2017, JOULE, V1, P229, DOI 10.1016/j.joule.2017.08.019
   Qu Y., 2005, PRESENT SITUATION DE
   Rare Earth Information Editorial Department, 2001, STAT DEV NI MH BATT
   Restrepo E, 2017, ENVIRON SCI TECHNOL, V51, P1129, DOI 10.1021/acs.est.6b05743
   Shedd K. B., 1993, MAT FLOW COBALT US
   Song JL, 2019, J CLEAN PROD, V215, P570, DOI 10.1016/j.jclepro.2019.01.081
   Sun X, 2019, ENVIRON SCI TECHNOL, V53, P743, DOI 10.1021/acs.est.8b04288
   Sun X, 2018, ENVIRON SCI TECHNOL, V52, P2827, DOI 10.1021/acs.est.7b06092
   Sun X, 2017, RESOUR CONSERV RECY, V124, P50, DOI 10.1016/j.resconrec.2017.04.012
   Tisserant A., 2016, J EC STRUCT, V5, P1
   Turcheniuk K, 2018, NATURE, V559, P467, DOI 10.1038/d41586-018-05752-3
   UN Comtrade, 2018, TRAD DAT
   USGS, 2015, COB STAT
   USGS, 2009, MAT US US SEL CAS ST
   USGS, 1996, 1995 MIN YB COB
   USGS, 2017, 2015 MIN YB COB
   USGS-United States Geological Survey, 2018, MINERAL COMMODITY SU
   Wang W, 2017, RESOUR CONSERV RECY, V127, P233, DOI 10.1016/j.resconrec.2017.08.019
   [项嘉义 Xiang Jiayi], 2014, [材料导报, Materials Review], V28, P100
   Yan Y., 2012, CONT CHEM IND, V41, P1076
   Yang H., 2005, WORLD NONFURROUS MET, V3, P29
   Yang X., 2016, PETROCHEM IND TECHNO, V23, P292
   Zeng XL, 2015, RESOUR CONSERV RECY, V104, P12, DOI 10.1016/j.resconrec.2015.09.014
   Zhang L, 2009, CEMENTED CARBIDE, V26, P122
   Zhao M., 2015, PRESENT SITUATION TR
   Zhao S., 2012, MIN METALL ENG, V32, P153
NR 66
TC 5
Z9 5
U1 19
U2 29
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 45
EP 55
DI 10.1016/j.resconrec.2019.05.009
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300005
DA 2020-05-12
ER

PT J
AU Casalo, LV
   Escario, JJ
   Rodriguez-Sanchez, C
AF Casalo, Luis, V
   Escario, Jose-Julian
   Rodriguez-Sanchez, Carla
TI Analyzing differences between different types of pro-environmental
   behaviors: Do attitude intensity and type of knowledge matter?
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Environmental attitudes; Pro-environmental behaviors; Curtailment;
   Efficiency; Knowledge; Mixed effects logistic regression
ID OBJECTIVE KNOWLEDGE; PLANNED BEHAVIOR; ENERGY; CONSERVATION;
   CONSUMPTION; DETERMINANTS; ASSOCIATION; PERCEPTIONS; MOTIVATIONS;
   EMOTIONS
AB This study explores whether the associations between general environmental attitudes and pro-environmental behaviors are heterogeneous and whether these associations depend on attitude intensity and the specific pro environmental behavior. The study also examines the association between objective and subjective knowledge and behavior and the relationship with socioeconomic and personal characteristics. Mixed effects logistic regressions were performed using data from a representative nationwide survey of Spanish citizens aged 18 to 90 years (N = 2495). The results revealed interesting patterns of heterogeneity. First, only curtailment behaviors (separating trash and using street trash cans) were significantly associated with general environmental attitudes. This result was observed only for the highest level of environmental attitudes. Second, whereas subjective knowledge was associated with all pro-environmental behaviors, objective knowledge was only associated with efficiency behavior (using energy-efficient light bulbs). Finally, men showed lower levels of reported behavior than women for all pro-environmental activities. The policy implications of these findings are discussed.
C1 [Casalo, Luis, V; Escario, Jose-Julian] Univ Zaragoza, Fac Business & Publ Management, Fac Empresa & Gest Publ, Plaza Constituc S-N, Huesca 22001, Spain.
   [Rodriguez-Sanchez, Carla] Univ Alicante, Fac Ciencias Econ & Empresariales, Carretera San Vicente del Raspeig S-N, San Vicente Del Raspeig 03690, Spain.
RP Escario, JJ (reprint author), Univ Zaragoza, Fac Business & Publ Management, Fac Empresa & Gest Publ, Plaza Constituc S-N, Huesca 22001, Spain.
EM jescario@unizar.es
RI Casalo, Luis V./T-7450-2019
OI Casalo, Luis V./0000-0002-9643-2814; Escario Gracia, Jose
   Julian/0000-0002-2940-6587
CR Aarts H, 1998, J APPL SOC PSYCHOL, V28, P1355, DOI 10.1111/j.1559-1816.1998.tb01681.x
   Abrahamse W, 2005, J ENVIRON PSYCHOL, V25, P273, DOI 10.1016/j.jenvp.2005.08.002
   Aertsens J, 2011, BRIT FOOD J, V113, P1353, DOI 10.1108/00070701111179988
   AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Ajzen I, 1980, UNDERSTANDING ATTITU
   Arnocky S, 2011, CURR RES SOC PSYCHOL, V16
   Vicente-Molina MA, 2013, J CLEAN PROD, V61, P130, DOI 10.1016/j.jclepro.2013.05.015
   Bamberg S, 2007, J ENVIRON PSYCHOL, V27, P14, DOI 10.1016/j.jenvp.2006.12.002
   Barr S, 2007, ENVIRON BEHAV, V39, P435, DOI 10.1177/0013916505283421
   Belanche D., 2013, J RELATSH MARK, V12, P79, DOI [10.1080/15332667.2013.794099, DOI 10.1080/15332667.2013.794099]
   Belanche D, 2012, INFORM RES, V17
   Benn J., 2004, INT J CONSUM STUD, V28, P108, DOI DOI 10.1111/J.1470-6431.2003.00364.X
   Bissing-Olson MJ, 2016, J ENVIRON PSYCHOL, V45, P145, DOI 10.1016/j.jenvp.2016.01.001
   Bissing-Olson MJ, 2013, J ORGAN BEHAV, V34, P156, DOI 10.1002/job.1788
   Boudet HS, 2016, ENERG POLICY, V92, P444, DOI 10.1016/j.enpol.2016.02.033
   Bouisson J, 2002, J AGING STUD, V16, P295, DOI 10.1016/S0890-4065(02)00051-8
   BRUCKS M, 1986, ADV CONSUM RES, V13, P58
   Carmi N, 2015, J ENVIRON EDUC, V46, P183, DOI 10.1080/00958964.2015.1028517
   Carrus G, 2008, J ENVIRON PSYCHOL, V28, P51, DOI 10.1016/j.jenvp.2007.09.003
   Casalo LV, 2018, J CLEAN PROD, V175, P155, DOI 10.1016/j.jclepro.2017.11.237
   Casalo LV, 2016, J ENVIRON PSYCHOL, V48, P65, DOI 10.1016/j.jenvp.2016.09.001
   Chi G., 2005, J REGIONAL ANAL POLI, V35, P11, DOI DOI 10.3109/09593985.2012.666632
   Collado S, 2017, J ENVIRON PSYCHOL, V54, P27, DOI 10.1016/j.jenvp.2017.09.007
   Collado S, 2017, INT HANDB QUALITY, P127, DOI 10.1007/978-3-319-31416-7_7
   De Nardo Matheus, 2017, Environment Systems & Decisions, V37, P184, DOI 10.1007/s10669-017-9624-y
   Diekmann A, 2003, RATION SOC, V15, P441, DOI 10.1177/1043463103154002
   Duarte R, 2017, ENVIRON EDUC RES, V23, P23, DOI 10.1080/13504622.2015.1074660
   Dunlap RE, 2000, J SOC ISSUES, V56, P425, DOI 10.1111/0022-4537.00176
   ELLEN PS, 1994, J BUS RES, V30, P43, DOI 10.1016/0148-2963(94)90067-1
   Fielding K. S., 2010, ENV SUSTAINABILITY U
   Fielding KS, 2012, ENVIRON EDUC RES, V18, P171, DOI 10.1080/13504622.2011.592936
   Frederiks ER, 2015, ENERGIES, V8, P573, DOI 10.3390/en8010573
   Frick J, 2004, PERS INDIV DIFFER, V37, P1597, DOI 10.1016/j.paid.2004.02.015
   Gao L, 2017, RESOUR CONSERV RECY, V127, P107, DOI 10.1016/j.resconrec.2017.08.030
   Gardner G. T., 2002, ENV PROBLEMS HUMAN B
   Gatersleben B, 2014, CONTEMP SOC SCI, V9, P374, DOI 10.1080/21582041.2012.682086
   Gifford R., 2010, MARTIN IAAP HDB APPL
   Gifford R., 2012, OXFORD HDB ENV CONSE
   Gifford R, 2014, INT J PSYCHOL, V49, P141, DOI 10.1002/ijop.12034
   Heimlich JE, 2008, ENVIRON EDUC RES, V14, P215, DOI 10.1080/13504620802148881
   Hini D., 1995, MARK B, V6, P22
   Kaiser FG, 2003, J APPL SOC PSYCHOL, V33, P586, DOI 10.1111/j.1559-1816.2003.tb01914.x
   Karlin B, 2014, ENVIRON BEHAV, V46, P423, DOI 10.1177/0013916512467532
   Karp DG, 1996, ENVIRON BEHAV, V28, P111, DOI 10.1177/0013916596281006
   Kollmuss A., 2002, ENVIRON EDUC RES, V8, P239, DOI DOI 10.1080/13504620220145401
   Li DW, 2019, SUSTAINABILITY-BASEL, V11, DOI 10.3390/su11020393
   Lu L, 2001, PERS INDIV DIFFER, V30, P1161, DOI 10.1016/S0191-8869(00)00100-8
   McFadden D., 1977, COWLES FOUNDATION DI
   Meinhold JL, 2005, ENVIRON BEHAV, V37, P511, DOI 10.1177/0013916504269665
   Paco A, 2017, J ENVIRON MANAGE, V197, P384, DOI 10.1016/j.jenvman.2017.03.100
   Pagiaslis A, 2014, PSYCHOL MARKET, V31, P335, DOI 10.1002/mar.20698
   Pieniak Z, 2010, FOOD QUAL PREFER, V21, P581, DOI 10.1016/j.foodqual.2010.03.004
   Pothitou M, 2016, APPL ENERG, V184, P1217, DOI 10.1016/j.apenergy.2016.06.017
   Prati G, 2017, ENVIRON EDUC RES, V23, P176, DOI 10.1080/13504622.2015.1118752
   Robelia B, 2012, ENVIRON EDUC RES, V18, P299, DOI 10.1080/13504622.2011.618288
   Rodriguez-Barreiro LM, 2013, J CLEAN PROD, V48, P116, DOI 10.1016/j.jclepro.2012.09.029
   Rodriguez-Sanchez C, 2018, BRIT J SOC PSYCHOL, V57, P610, DOI 10.1111/bjso.12242
   Sarabia-Sanchez FJ, 2016, J ENVIRON PSYCHOL, V47, P1, DOI 10.1016/j.jenvp.2016.04.011
   Shen JY, 2008, J ENVIRON PSYCHOL, V28, P42, DOI 10.1016/j.jenvp.2007.10.003
   Steg L, 2009, J ENVIRON PSYCHOL, V29, P309, DOI 10.1016/j.jenvp.2008.10.004
   Stern PC, 2011, AM PSYCHOL, V66, P303, DOI 10.1037/a0023235
   Sutterlin B, 2011, ENERG POLICY, V39, P8137, DOI 10.1016/j.enpol.2011.10.008
   Tam KP, 2018, GLOBAL ENVIRON CHANG, V48, P182, DOI 10.1016/j.gloenvcha.2017.12.001
   Thogersen J, 2004, J ENVIRON PSYCHOL, V24, P93, DOI 10.1016/S0272-4944(03)00039-2
   United Nations, 2004, MOR SEC WORLD OUR SH, DOI [10.2307/20034356, DOI 10.2307/20034356]
   Vicente-Molina MA, 2018, J CLEAN PROD, V176, P89, DOI 10.1016/j.jclepro.2017.12.079
   Vining J., 2002, HDB ENV PSYCHOL, P541
   von Borgstede C, 2013, ENERG POLICY, V57, P182, DOI 10.1016/j.enpol.2013.01.051
   Worldwatch Institute, 2013, STATE WORLD 2013 IS
   ZEITHAML VA, 1988, J MARKETING, V52, P2, DOI 10.2307/1251446
   Zelezny LC, 2000, J SOC ISSUES, V56, P443, DOI 10.1111/0022-4537.00177
NR 71
TC 0
Z9 0
U1 13
U2 29
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 56
EP 64
DI 10.1016/j.resconrec.2019.05.024
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300006
DA 2020-05-12
ER

PT J
AU Doyle, G
AF Doyle, Gerard
TI A new era for reuse social enterprises in Ireland? The capacities
   required for achieving sustainability
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Capacity; Community; Reuse; Social enterprise; Sustainability
ID WASTE MANAGEMENT; PARTNERSHIPS; LEADERSHIP; POLICY
AB The conventional linear relationship between production and consumption is no longer sustainable. A key component of the transition towards a more sustainable society is the continuation in use of products for longer and the development of a repair and reuse culture. Reuse social enterprises contribute to addressing a range of environmental, economic and social issues facing urban areas. This paper is concerned with, firstly, the motivations for citizens to establish reuse social enterprises in Ireland. Secondly, the paper examines the factors that contribute to reuse social enterprises in Ireland becoming sustainable.
   The research points to the necessity of reuse social enterprises possessing: individuals with both strategic and operational expertise, appropriate facilities and adequate funding to commence operations. The research highlights the crucial role that the manager of the enterprise performs in engaging with state agencies, the community and other stakeholders. The theoretical framework detailed in the paper needs to take into account the challenges associated with being located in urban areas which reuse social enterprises encounter.
   It is incumbent upon the Irish State to develop policies to assist individuals who are interested in establishing reuse social enterprises. These policy areas include procurement, the introduction of additional producer responsibility initiatives and the amendment of the tax system to encourage reuse.
C1 [Doyle, Gerard] Technol Univ Dublin, Dublin, Ireland.
RP Doyle, G (reprint author), Technol Univ Dublin, Dublin, Ireland.
FU ICOS Golden Jubilee Trust Fund
FX The author is grateful to the ICOS Golden Jubilee Trust Fund for
   sponsoring his PhD
CR ACKERMAN F, 2001, LOCAL ENVIRON, V6, P113, DOI DOI 10.1080/13549830120052764.AVAILABLE
   Ahmed SA, 2004, HABITAT INT, V28, P467, DOI 10.1016/S0197-3975(03)00044-4
   Aiken M, 2007, 4 ANN UK SOC ENT RES
   Amin A., 2009, SOCIAL EC INT PERSPE
   AMIN A, 2002, PLACING SOCIAL EC
   Aziz L, 2017, EUROPEAN J MULTIDISC, V2, P7
   Belk R, 2007, ANN AM ACAD POLIT SS, V611, P126, DOI 10.1177/0002716206298483
   Bichard E, 2006, BETTER WAY RECYCLE C
   Bocken NMP, 2017, J IND ECOL, V21, P476, DOI 10.1111/jiec.12606
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI DOI 10.1191/1478088706QP0630A
   Brennan S., 2004, LOCAL EC, V19, P175, DOI DOI 10.1080/0269094042000208266
   Brook Lyndhurst, 2007, PROJECT WR0501 WRT 2
   Brook Lyndhurst, 2009, HOUS WAST PREV EU LE
   Chan A, 2017, NONPROF VOLUNT SEC Q, V46, P261, DOI 10.1177/0899764016655620
   Collins J., 2001, GOOD GREAT
   Connett P, 2001, CITIZENS AGENDA ZERO
   CWIN, 2016, REUS UK IR STAT NAT
   Davies A, 2007, ENVIRON POLIT, V16, P52, DOI 10.1080/09644010601073564
   Davies AR, 2002, AREA, V34, P190, DOI 10.1111/1475-4762.00071
   Dedehouanou IH, 1998, ENVIRON URBAN, V10, P191, DOI 10.1177/095624789801000208
   Doyle G, 2009, THESIS
   Doyle G, 2019, VALUE CREATION SMALL
   Doyle R, 2013, J CLEAN PROD, V48, P260, DOI 10.1016/j.jclepro.2012.12.015
   EC, 2011, COM2011571 EC
   Ellen Macarthur Foundation, 2015, CIRCULAR EC BUSINESS
   Ellen MacArthur Foundation, 2011, RESOURCE REVOLUTION
   Forde C, 2017, CHANGING LANDSCAPE L
   Forfas, 2013, SOC ENT IR SECT OPP
   GHK, 2006, SOC ENT INT LIT REV
   Gutberlet, 2016, URB REC COOP BUILD R
   Gutberlet J., 2008, RECOVERING RESOURCES
   Harvey B, 2012, IR C TRAD UN COMM SE
   Hines F, 2008, MODEL SOCIAL ENTERPR
   Jackson B, 2018, SOC ENTERP J, V14, P71, DOI 10.1108/SEJ-03-2017-0016
   Jackson T., 2011, PROSPERITY GROWTH EC
   King MF, 2013, WASTE MANAGE, V33, P2771, DOI 10.1016/j.wasman.2013.07.031
   Luckin D., 2005, DEV J, V40, P62
   Luckin D., 2003, SUSTAINABLE DEV PRAC
   Mason C, 2008, J FINANCE MANAGEMENT, V6, P57
   Mazzei M, 2017, SOC ENTERP J, V13, P299, DOI 10.1108/SEJ-07-2016-0026
   Middlemiss L, 2010, ENERG POLICY, V38, P7559, DOI 10.1016/j.enpol.2009.07.003
   Miller S, 2017, MAT REUSE GOOD PRACT
   Molloy A, 2000, BUILDING SOCIAL EC N
   Moreau V, 2017, J IND ECOL, V21, P497, DOI 10.1111/jiec.12598
   Munro MM, 2017, SOC ENTERP J, V13, P38, DOI 10.1108/SEJ-06-2016-0021
   Nicholls A., 2006, SOCIAL ENTREPRENEURS
   Nicholls A, 2017, POLICY POLIT, V45, P323, DOI 10.1332/030557316X14775864546490
   Pongracz E, 2004, RESOUR CONSERV RECY, V40, P141, DOI 10.1016/S0921-3449(03)00057-0
   Price JL, 2000, SUSTAIN DEV, V8, P96, DOI 10.1002/(SICI)1099-1719(200005)8:2<96::AID-SD133>3.3.CO;2-A
   Pringle R, 2015, THESIS
   Resource Futures, 2009, UND WAST GROWTH LOC
   Ridley-Duff R., 2016, UNDERSTANDING SOCIAL
   Seanor P, 2013, INT J ENTREP BEHAV R, V19, P324, DOI 10.1108/13552551311330200
   Steel BS, 1996, J ENVIRON MANAGE, V47, P27, DOI 10.1006/jema.1996.0033
   Taylor E, 2008, THESIS
   van Dierendonck D, 2011, J MANAGE, V37, P1228, DOI 10.1177/0149206310380462
   Vickers I., 2010, 22 3 SECT RES CTR
   Yousefpour N., 2012, BASELINE STUDY AUSTR
NR 58
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 65
EP 74
DI 10.1016/j.resconrec.2019.05.012
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300007
DA 2020-05-12
ER

PT J
AU Hung, CCW
   Hsu, SC
   Cheng, KL
AF Hung, Cathy C. W.
   Hsu, Shu-Chien
   Cheng, Kuang-Ly
TI Quantifying city-scale carbon emissions of the construction sector based
   on multi-regional input-output analysis
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE CO2 emissions; Construction sector; Multi-regional input-output
   analysis; Urban area
ID GREENHOUSE-GAS EMISSIONS; INTERNATIONAL-TRADE; ENERGY-CONSUMPTION; CO2
   EMISSIONS; FOOTPRINT; CHINA; RESPONSIBILITY; ECONOMIES; INDUSTRY;
   ACCOUNTS
AB Cities are open systems that rely heavily on external trade and release carbon dioxide (CO2) as a predominant by-product. Quantification of trans-boundary emissions is essential, especially for the construction sector, which requires great intermediate inputs from upstream sectors locally and globally. This study investigates the global energy-related CO2 emissions induced by Hong Kong's construction consumption based on multi-regional input-output analysis for the years 2004, 2007, and 2011. The results showed that the consumption-based CO2 emissions emitted to sustain the local construction consumption are at least 32.37% higher than those estimated by the conventional approach. The consumption-based CO2 has slightly declined from 2004 to 2011. This trend was closely tied to decreasing emission intensities of upstream sectors, even with strong growth in construction final demand. 96.61-97.41% of the consumption-based CO2 were indirect emissions, and 73.50-78.58% were trans-boundary emissions. Utilities, Manufacturing, and Transport & Storage were the main source sectors contributing the most to total CO2 emissions. Based on the results, extended emission monitoring beyond municipal boundaries, diversification of import origins, implementation of import substitution, use of low carbon intensive materials, and enhancement in electricity generation towards low-carbon fuels are proposed to mitigate construction-related CO2 emissions.
C1 [Hung, Cathy C. W.; Hsu, Shu-Chien] Hong Kong Polytech Univ, Dept Civil & Environm Engn, Kowloon, 181 Chatham Rd South, Hong Kong 00000, Peoples R China.
   [Cheng, Kuang-Ly] Natl Taiwan Univ, Grad Inst Environm Engn, 71 Chou Shan Rd, Taipei 106, Taiwan.
RP Hsu, SC (reprint author), Hong Kong Polytech Univ, Dept Civil & Environm Engn, Kowloon, 181 Chatham Rd South, Hong Kong 00000, Peoples R China.
EM mark.hsu@polyu.edu.hk
OI Hung, Cathy Chang-Wei/0000-0002-0329-3326
CR Acquaye AA, 2010, BUILD ENVIRON, V45, P784, DOI 10.1016/j.buildenv.2009.08.022
   Aguiar A, 2016, J GLOB ECON ANAL, V1, P181, DOI 10.21642/JGEA.010103AF
   Andrew RM, 2013, ECON SYST RES, V25, P99, DOI 10.1080/09535314.2012.761953
   Arto I, 2014, ECON SYST RES, V26, P327, DOI 10.1080/09535314.2014.939949
   Athanassiadis A, 2018, J CLEAN PROD, V173, P112, DOI 10.1016/j.jclepro.2016.10.068
   Bai XM, 2007, J IND ECOL, V11, P1, DOI 10.1162/jie.2007.1296
   Baiocchi G, 2010, ENVIRON SCI TECHNOL, V44, P1177, DOI 10.1021/es902662h
   CCC, 2017, M CARB BUDG CLOS POL
   Census and Statistics Department, 2017, HONG KONG ANN DIG ST
   Census and Statistics Dept, 2018, TABL 104 GROSS VAL C
   Chang YA, 2010, ENERG POLICY, V38, P6597, DOI 10.1016/j.enpol.2010.06.030
   Chen GW, 2016, ENERGIES, V9, DOI 10.3390/en9080602
   Chen G, 2017, J CLEAN PROD, V163, P224, DOI 10.1016/j.jclepro.2016.04.046
   Chen JD, 2017, J CLEAN PROD, V168, P645, DOI 10.1016/j.jclepro.2017.09.072
   Chuai XW, 2015, ENVIRON SCI TECHNOL, V49, P13021, DOI 10.1021/acs.est.5b01732
   CIC (The Construction Industry Council, 2018, CONSTR EXP FOR
   Davis SJ, 2010, P NATL ACAD SCI USA, V107, P5687, DOI 10.1073/pnas.0906974107
   Du Q, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15061220
   Eggleston H.S., 2006, 2006 IPCC GUIDELINES
   Environment Bureau, 2017, HONG KONG CLIM CHANG
   Fan JL, 2016, APPL ENERG, V184, P790, DOI 10.1016/j.apenergy.2016.06.076
   Feng KS, 2014, ECOL INDIC, V47, P26, DOI 10.1016/j.ecolind.2014.04.045
   Franzen A, 2018, ENVIRON SCI POLICY, V84, P34, DOI 10.1016/j.envsci.2018.02.009
   Giesekam J, 2016, BUILD RES INF, V44, P423, DOI 10.1080/09613218.2016.1086872
   Harris PG, 2012, ENERG POLICY, V44, P416, DOI 10.1016/j.enpol.2012.02.012
   Hermannsson K, 2014, ECOL ECON, V104, P1, DOI 10.1016/j.ecolecon.2014.04.020
   Hertwich EG, 2009, ENVIRON SCI TECHNOL, V43, P6414, DOI 10.1021/es803496a
   Hong JK, 2016, RENEW SUST ENERG REV, V53, P1303, DOI 10.1016/j.rser.2015.09.068
   Hong T, 2014, J MANAGE ENG, V30, P226, DOI 10.1061/(ASCE)ME.1943-5479.0000199
   Hu YC, 2016, ENVIRON SCI TECHNOL, V50, P6154, DOI 10.1021/acs.est.6b00985
   Huang LZ, 2018, RENEW SUST ENERG REV, V81, P1906, DOI 10.1016/j.rser.2017.06.001
   Huang LZ, 2012, BUILD RES INF, V40, P581, DOI 10.1080/09613218.2012.711993
   Hung CCW, 2019, J MANAGE ENG, V35, DOI 10.1061/(ASCE)ME.1943-5479.0000653
   Huwart J. Y., 2013, WHAT IS IMPACT GLOBA, DOI [10.1787/9789264111905-8-en, DOI 10.1787/9789264111905-8-EN]
   IEA, 2019, GLOB EN CO2 STAT REP
   KANEMOTO K, 2009, J JAPAN SOC ENERGY R, V30, P15
   Kanemoto K, 2016, ENVIRON SCI TECHNOL, V50, P10512, DOI 10.1021/acs.est.6b03227
   Kanemoto K, 2012, ENVIRON SCI TECHNOL, V46, P172, DOI 10.1021/es202239t
   Lenzen M, 2013, ECON SYST RES, V25, P20, DOI 10.1080/09535314.2013.769938
   Lin JY, 2015, ENVIRON RES LETT, V10, DOI 10.1088/1748-9326/10/5/054001
   Liu HG, 2015, ENERG ECON, V50, P294, DOI 10.1016/j.eneco.2015.06.006
   Long Y, 2018, APPL ENERG, V218, P349, DOI 10.1016/j.apenergy.2018.02.167
   Lu YJ, 2016, BUILD ENVIRON, V95, P94, DOI 10.1016/j.buildenv.2015.09.011
   Mi ZF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01820-w
   Miller R.E., 2009, INPUT OUTPUT ANAL FD
   Minx J, 2013, ENVIRON RES LETT, V8, DOI 10.1088/1748-9326/8/3/035039
   Moran D, 2014, ECON SYST RES, V26, P245, DOI 10.1080/09535314.2014.935298
   Munksgaard J, 2001, ENERG POLICY, V29, P327, DOI 10.1016/S0301-4215(00)00120-8
   Munoz P, 2010, ECOL ECON, V69, P2003, DOI 10.1016/j.ecolecon.2010.05.017
   Narayanan BG, 2008, GLOBAL TRADE ASSISTA
   Nassen J, 2007, ENERGY, V32, P1593, DOI 10.1016/j.energy.2007.01.002
   Peters GP, 2012, BIOGEOSCIENCES, V9, P3247, DOI 10.5194/bg-9-3247-2012
   Peters GP, 2008, ECOL ECON, V65, P13, DOI 10.1016/j.ecolecon.2007.10.014
   Peters GP, 2008, ENVIRON SCI TECHNOL, V42, P1401, DOI 10.1021/es072023k
   Peters GP, 2006, J IND ECOL, V10, P89, DOI 10.1162/jiec.2006.10.3.89
   Peters GP, 2011, ECON SYST RES, V23, P131, DOI 10.1080/09535314.2011.563234
   Peters GP, 2011, P NATL ACAD SCI USA, V108, P8903, DOI 10.1073/pnas.1006388108
   Peters GP, 2009, CLIMATIC CHANGE, V97, P379, DOI 10.1007/s10584-009-9606-2
   Rao BB, 2010, APPL ECON, V42, P3693, DOI 10.1080/00036840802534468
   Sato M, 2014, J ECON SURV, V28, P831, DOI 10.1111/joes.12027
   Serrenho AC, 2019, RESOUR CONSERV RECY, V144, P267, DOI 10.1016/j.resconrec.2019.02.001
   Singapore Dept of Statistics, 2016, YB STAT SING 2015
   Steen-Olsen K, 2014, ECON SYST RES, V26, P284, DOI 10.1080/09535314.2014.934325
   Steininger KW, 2018, GLOBAL ENVIRON CHANG, V48, P226, DOI 10.1016/j.gloenvcha.2017.11.011
   Steininger KW, 2016, NAT CLIM CHANGE, V6, P35, DOI 10.1038/NCLIMATE2867
   Sudmant A, 2018, J CLEAN PROD, V176, P654, DOI 10.1016/j.jclepro.2017.12.139
   Tian X, 2014, ENVIRON SCI POLICY, V37, P243, DOI 10.1016/j.envsci.2013.10.001
   Tukker A, 2013, ECON SYST RES, V25, P1, DOI 10.1080/09535314.2012.761179
   Turner K, 2007, ECOL ECON, V62, P37, DOI 10.1016/j.ecolecon.2006.12.002
   UNEP GABC IEA, 2017, ZER EM EFF RES BUILD
   UNEP (United Nations Environment Programme), 2014, CLIM FIN CIT BUILD H
   Weber CL, 2007, ENVIRON SCI TECHNOL, V41, P4875, DOI 10.1021/es0629110
   Wiebe KS, 2012, ECON SYST RES, V24, P113, DOI 10.1080/09535314.2011.643293
   Wiedmann T, 2018, NAT GEOSCI, V11, P314, DOI 10.1038/s41561-018-0113-9
   Wiedmann T, 2010, ECON SYST RES, V22, P19, DOI 10.1080/09535311003612591
   Wiedmann T, 2009, ECON SYST RES, V21, P175, DOI 10.1080/09535310903541256
   Wilting HC, 2009, ECON SYST RES, V21, P291, DOI 10.1080/09535310903541736
   Yuan JH, 2018, RESOUR CONSERV RECY, V129, P443, DOI 10.1016/j.resconrec.2016.03.021
   Zhang XC, 2016, BUILD ENVIRON, V104, P188, DOI 10.1016/j.buildenv.2016.05.018
   Zhang ZH, 2017, RENEW SUST ENERG REV, V68, P492, DOI 10.1016/j.rser.2016.10.009
NR 80
TC 1
Z9 1
U1 20
U2 29
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 75
EP 85
DI 10.1016/j.resconrec.2019.05.013
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300008
DA 2020-05-12
ER

PT J
AU Maga, D
   Hiebel, M
   Thonemann, N
AF Maga, Daniel
   Hiebel, Markus
   Thonemann, Nils
TI Life cycle assessment of recycling options for polylactic acid
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Life cycle assessment; LCA; Polylactic acid; End-of-life; Recycling;
   Thermal treatment
ID POLY(LACTIC ACID); BIOPOLYMERS; END
AB This paper presents an attributional life cycle assessment for different recycling technologies for post-industrial and post-consumer polylactic acid (PLA) waste in Germany. The study investigates mechanical recycling of post-industrial and post-consumer PLA waste as well as solvent based recycling and chemical recycling of post consumer PLA waste. Recycling of PLA waste is exclusively compared to thermal treatment since a comparison of the different recycling options is not possible due to different qualities of the waste streams and of the products. The life cycle impact results show environmental benefits of all recycling technologies. Environmental benefits are achieved by replacing virgin PLA with PLA recyclates. The substitution of virgin PLA by recyclates leads to higher savings of greenhouse gas emissions compared to incineration. Depending on the recycling technology, savings are 0.3-1.2 times higher. The lower global warming impact goes along with higher savings in primary energy demand and less fossil resource depletion. Apart from benefits related to global warming impact and energy, the comparison between thermal treatment and the recycling shows benefits in the category agricultural land occupation since biomass cultivation is avoided. Further environmental benefits are achieved in the impact categories photochemical ozone formation, terrestrial and aquatic eutrophication, acidification, and particulate matter due to avoided biomass cultivation, harvesting, and transportation. The latter three impacts are mainly influenced by agricultural activities and transportation, whereas eutrophication is driven by fertilization. The results demonstrate that recycling of PLA products can contribute to a better environmental performance of PLA products in their life cycle.
C1 [Maga, Daniel; Hiebel, Markus; Thonemann, Nils] Fraunhofer Inst Environm Safety & Energy Technol, Business Unit Sustainabil & Resources Management, Osterfelder Str 3, D-46047 Oberhausen, Germany.
RP Maga, D (reprint author), Fraunhofer Inst Environm Safety & Energy Technol, Business Unit Sustainabil & Resources Management, Osterfelder Str 3, D-46047 Oberhausen, Germany.
EM daniel.maga@umsicht.fraunhofer.de
FU German Ministry of Food and Agriculture (BMEL) within the research
   alliance "Sustainable recycling for products and wastes from biobased
   plastics" [LCA 22031812]
FX The work was funded by the German Ministry of Food and Agriculture
   (BMEL) within the research alliance "Sustainable recycling for products
   and wastes from biobased plastics" (Funding code for the LCA 22031812).
   Several project reports were published which describe the recycling
   technologies in detail (Fraunhofer Society, 2017; IfBB, 2017; KNOTEN
   WEIMAR GmbH, 2017; TU Chemnitz, 2017). We thank the Agency of Renewable
   Resources (FNR) for the excellent supervision.
CR Auras R, 2004, MACROMOL BIOSCI, V4, P835, DOI 10.1002/mabi.200400043
   Castro-Aguirre E, 2016, ADV DRUG DELIVER REV, V107, P333, DOI 10.1016/j.addr.2016.03.010
   Consultic, 2016, PROD VER VERW KUNSTS
   de Andrade MFC, 2016, J POLYM ENVIRON, V24, P372, DOI 10.1007/s10924-016-0787-2
   Fell T., 2019, POLYM DEGRAD STABIL
   Fraunhofer Society, 2017, SCHL VORH VERB NACHH
   Goedkoop M., 2013, 1 CML RUN RIVM
   Groot WJ, 2010, INT J LIFE CYCLE ASS, V15, P970, DOI 10.1007/s11367-010-0225-y
   Harbec A., 2010, LACTIC ACID PRODUCTI
   Hauschild MZ, 2015, LCA COMPEND, P1, DOI 10.1007/978-94-017-9744-3
   Hottle TA, 2017, RESOUR CONSERV RECY, V122, P295, DOI 10.1016/j.resconrec.2017.03.002
   IfBB, 2017, SCHLUSSB VORH VERB N
   ISO Environmental Management, 2006, LIF CYCL ASS PRINC F
   JRC, 2010, ILCD HDB REC LIF CYC
   Karamanlioglu M, 2017, POLYM DEGRAD STABIL, V137, P122, DOI 10.1016/j.polymdegradstab.2017.01.009
   Klopffer W., 2009, OKOBILANZ LCA LEITFA
   KNOTEN WEIMAR GmbH, 2017, ABSCHL VORH VERB NAC
   KNOTEN WEIMAR GmbH, 2016, PROD BIOB KUNSTS LVP
   Malik MSI, 2020, ARTIF INTELL REV, V53, P407, DOI 10.1007/s10462-018-9662-y
   Myhre G., 2013, CLIMATE CHANGE 2013
   Rossi V, 2015, J CLEAN PROD, V86, P132, DOI 10.1016/j.jclepro.2014.08.049
   Shi B, 2010, J POLYM ENVIRON, V18, P122, DOI 10.1007/s10924-010-0190-3
   Siebert Tanja, 2013, Kunststoffe International, V103, P143
   Thinkstep, 2017, GABI SOFTW SYST DAT
   thinkstep, 2016, POL AC PLA WAST INC
   TU Chemnitz, 2017, ABSCHL VORH VERB NAC
   van der Harst E, 2016, WASTE MANAGE, V48, P565, DOI 10.1016/j.wasman.2015.09.027
   Vink E.T., 2015, IND BIOTECHNOL, V11, P167, DOI DOI 10.1089/IND.2015.0003
   Weiss M, 2012, J IND ECOL, V16, pS169, DOI 10.1111/j.1530-9290.2012.00468.x
   Wernet G, 2016, INT J LIFE CYCLE ASS, V21, P1218, DOI 10.1007/s11367-016-1087-8
   Yates MR, 2013, RESOUR CONSERV RECY, V78, P54, DOI 10.1016/j.resconrec.2013.06.010
NR 31
TC 2
Z9 2
U1 9
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 86
EP 96
DI 10.1016/j.resconrec.2019.05.018
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300009
OA Other Gold
DA 2020-05-12
ER

PT J
AU Barone, AM
   Grappi, S
   Romani, S
AF Barone, Ada Maria
   Grappi, Silvia
   Romani, Simona
TI "The road to food waste is paved with good intentions": When consumers'
   goals inhibit the minimization of household food waste
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Food waste; Goals; Theory of Planned Behavior
ID STRUCTURAL EQUATION MODELS; BEHAVIOR; POLICY; INTERVENTION; BARRIERS;
   EFFICACY; DRIVERS; REDUCE
AB Despite their generally negative attitude toward food waste, consumers often pursue goals that can inhibit their intention to reduce food waste. Identifying these goals that inhibit consumers' intention to reduce food waste is essential for the development of successful public policy and retail approaches designed to curb or reduce household food waste. First, we conducted semi-structured qualitative interviews (N = 110) aimed at identifying the consumers' main goals conflicting with their attitude toward food waste. Four main conflicts emerged as relevant in consumers' minds: being a good provider, concerns over possible health risks, healthy diet, and saving money. We then ran a quantitative study on adult consumers (N = 163), aimed at testing an extended Theory of Planned Behavior (TPB) model with the inclusion of such conflicting goals as additional predictors of the consumers' intention to reduce food waste. Both studies were conducted in Italy. Results show that three out of four conflicting goals - being a good provider, concerns over possible health risks, and healthy diet together with attitude and subjective norms, significantly affect the intention to reduce food waste. In turn, the intention to reduce food waste negatively affects food waste behavior. This study contributes to research on food waste by identifying additional and previously neglected predictors of the intention to reduce food waste. In turn, these results provide evidence of the existence of other valuable entry points to use for the design of successful interventions aimed at reducing household food waste.
C1 [Barone, Ada Maria; Romani, Simona] LUISS Guido Carli, Dept Business & ManagemenL, Viale Romania 32, I-00197 Rome, Italy.
   [Grappi, Silvia] Univ Modena & Reggio Emilia, Marco Biagi Dept Econ, Viale Berengario 51, I-41121 Modena, Italy.
RP Grappi, S (reprint author), Univ Modena & Reggio Emilia, Marco Biagi Dept Econ, Viale Berengario 51, I-41121 Modena, Italy.
EM abarone@luiss.it; silvia.grappi@unimore.it; sromani@luiss.it
CR Ajzen I, 2002, J APPL SOC PSYCHOL, V32, P665, DOI 10.1111/j.1559-1816.2002.tb00236.x
   AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Ajzen I, 2015, HEALTH PSYCHOL REV, V9, P131, DOI 10.1080/17437199.2014.883474
   Armitage CJ, 2001, SOC SCI MED, V52, P1517, DOI 10.1016/S0277-9536(00)00265-3
   Aschemann-Witzel J, 2017, APPETITE, V116, P246, DOI 10.1016/j.appet.2017.05.013
   Aschemann-Witzel J, 2015, CURR OPIN FOOD SCI, V3, P6, DOI 10.1016/j.cofs.2014.08.002
   Aschemann-Witzel J, 2015, SUSTAINABILITY-BASEL, V7, P6457, DOI 10.3390/su7066457
   Bagozzi RP, 2012, J ACAD MARKET SCI, V40, P8, DOI 10.1007/s11747-011-0278-x
   BENTLER PM, 1987, SOCIOL METHOD RES, V16, P78, DOI 10.1177/0049124187016001004
   Cappellini B., 2009, Journal of Consumer Behaviour, V8, P365, DOI 10.1002/cb.299
   Cappellini B, 2012, SOCIOL REV, V60, P121, DOI 10.1111/1467-954X.12041
   Conrad Z, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195405
   Eaicicco L., 2016, BEHOLD SAMSUNGS NEW
   Eisinga R, 2013, INT J PUBLIC HEALTH, V58, P637, DOI 10.1007/s00038-012-0416-3
   Evans D, 2012, SOCIOLOGY, V46, P41, DOI 10.1177/0038038511416150
   Farr-Wharton G, 2014, J CONSUM BEHAV, V13, P393, DOI 10.1002/cb.1488
   FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312
   Graham-Rowe E, 2015, RESOUR CONSERV RECY, V101, P194, DOI 10.1016/j.resconrec.2015.05.020
   Graham-Rowe E, 2014, RESOUR CONSERV RECY, V84, P15, DOI 10.1016/j.resconrec.2013.12.005
   Hair J., 2005, MULTIVARIATE DATA AN
   Hebrok M, 2019, J CLEAN PROD, V210, P1435, DOI 10.1016/j.jclepro.2018.11.141
   Hebrok M, 2017, J CLEAN PROD, V151, P380, DOI 10.1016/j.jclepro.2017.03.069
   Hoolohan C, 2018, ENERGY RES SOC SCI, V39, P93, DOI 10.1016/j.erss.2017.10.050
   ISTAT, 2016, TEMP VIT QUOT
   Lazell J, 2016, J CONSUM BEHAV, V15, P430, DOI 10.1002/cb.1581
   Maubach N, 2009, APPETITE, V53, P297, DOI 10.1016/j.appet.2009.07.005
   Parizeau K, 2015, WASTE MANAGE, V35, P207, DOI 10.1016/j.wasman.2014.09.019
   Richetin J, 2012, J ENVIRON PSYCHOL, V32, P112, DOI 10.1016/j.jenvp.2012.01.003
   Romani S, 2018, APPETITE, V121, P215, DOI 10.1016/j.appet.2017.11.093
   Russell SV, 2017, RESOUR CONSERV RECY, V125, P107, DOI 10.1016/j.resconrec.2017.06.007
   Schanes K, 2018, J CLEAN PROD, V182, P978, DOI 10.1016/j.jclepro.2018.02.030
   Schmidt K, 2018, RESOUR CONSERV RECY, V139, P1, DOI 10.1016/j.resconrec.2018.07.023
   Setti M, 2018, J CLEAN PROD, V185, P694, DOI 10.1016/j.jclepro.2018.03.024
   Sideridis G, 2014, EDUC PSYCHOL MEAS, V74, P733, DOI 10.1177/0013164414525397
   Smithers R, 2015, GUARDIAN
   Stancu V, 2016, APPETITE, V96, P7, DOI 10.1016/j.appet.2015.08.025
   Stanley Julian C., 1971, ED MEASUREMENT
   Stefan V, 2013, FOOD QUAL PREFER, V28, P375, DOI 10.1016/j.foodqual.2012.11.001
   Stenmarck A., 2016, ESTIMATES EUROPEAN F
   Stockli S, 2018, RESOUR CONSERV RECY, V136, P445, DOI 10.1016/j.resconrec.2018.03.029
   Thyberg KL, 2016, RESOUR CONSERV RECY, V106, P110, DOI 10.1016/j.resconrec.2015.11.016
   US Department of Health and Human Services US Department of Agriculture, 2017, DIET GUID AM 2015 20
   Vanham D, 2015, ENVIRON RES LETT, V10, DOI 10.1088/1748-9326/10/8/084008
   Visschers VHM, 2016, J ENVIRON PSYCHOL, V45, P66, DOI 10.1016/j.jenvp.2015.11.007
   Watson M, 2012, SOCIOL REV, V60, P102, DOI 10.1111/1467-954X.12040
   Williams H, 2012, J CLEAN PROD, V24, P141, DOI 10.1016/j.jclepro.2011.11.044
   Wolf EJ, 2013, EDUC PSYCHOL MEAS, V73, P913, DOI 10.1177/0013164413495237
   Xue L, 2017, ENVIRON SCI TECHNOL, V51, P6618, DOI 10.1021/acs.est.7b00401
NR 48
TC 1
Z9 1
U1 16
U2 22
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 97
EP 105
DI 10.1016/j.resconrec.2019.05.037
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300010
DA 2020-05-12
ER

PT J
AU Hu, MM
   Li, ZT
   Wang, YF
   Jiao, MY
   Li, M
   Xia, BC
AF Hu, Mengmeng
   Li, Zhaotian
   Wang, Yafei
   Jiao, Mengyu
   Li, Miao
   Xia, Beicheng
TI Spatio-temporal changes in ecosystem service value in response to
   land-use/cover changes in the Pearl River Delta
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE InVEST; Spatial differentiation; Hot spot; Local management; Urban
   agglomeration
ID COVER CHANGE; CHINA; IMPACTS; URBANIZATION; CONSERVATION; LEVEL
AB Urban development and human activities threaten ecosystem structures and ecological processes. Since 1995, the gross domestic product (GDP) of the Pearl River Delta (PRD) has increased by more than thirteen fold. However, our understanding of how the ecosystem service value (ESV) has responded to land-use/cover changes (LUCC) in the PRD remains limited. In this paper, we use a multi-source data approach to assess the patterns of ESV in the PRD from 1995 to 2015. The hot/cool-spot mapping method is used to analyse the spatial differences in ESV at a 1 km scale. The results revealed the following: (a) the proportion of increase in built-up land area is 6.3% in the PRD; this change occurred mainly through the occupation of farmland and forest land. (b) The area of hot spots increased from 37% in 1995 to 41% in 2015, while the area of cool spots increased from 34.6% to 36.3%. The ESV hot spots are mainly distributed in Zhaoqing and Huizhou. (c) The ESV has changed due to a combination of natural and anthropogenic factors in the PRD. Furthermore, corresponding management measures are identified according to the results of the exploratory spatial data analysis. The findings of this study have practical significance for establishing mathematical models to reveal the patterns of ESV in urban agglomerations.
C1 [Hu, Mengmeng; Li, Zhaotian; Wang, Yafei; Jiao, Mengyu; Li, Miao; Xia, Beicheng] Sun Yat Sen Univ, Sch Environm Sci & Engn, Guangzhou 510275, Guangdong, Peoples R China.
RP Xia, BC (reprint author), Sun Yat Sen Univ, Sch Environm Sci & Engn, Guangzhou 510275, Guangdong, Peoples R China.
EM xiabch@mail.sysu.edu.cn
RI Hu, Mengmeng/AAJ-3751-2020
OI Hu, Mengmeng/0000-0002-9625-0295
FU National Key R&D Program of China [2016YFC0502803]
FX This research was financially supported by the National Key R&D Program
   of China (2016YFC0502803). We are grateful to the anonymous reviewers
   for their constructive comments.
CR [Anonymous], 2005, ECOSYSTEMS HUMAN WEL
   Arowolo AO, 2018, SCI TOTAL ENVIRON, V636, P597, DOI 10.1016/j.scitotenv.2018.04.277
   Bhandari P, 2016, APPL GEOGR, V69, P25, DOI 10.1016/j.apgeog.2016.02.003
   Bockstael N. E, 2000, MEASURING EC VALUES
   Bryan BA, 2018, ECOSYST SERV, V32, P144, DOI 10.1016/j.ecoser.2018.07.002
   Costanza R, 1997, NATURE, V387, P253, DOI 10.1038/387253a0
   Daily G. C., 1997, NATURES SERVICES SOC
   Ehrlich P.R., 1981, EXTINCTION CAUSES CO
   EHRLICH PR, 1983, BIOSCIENCE, V33, P248, DOI 10.2307/1309037
   Farber SC, 2002, ECOL ECON, V41, P375, DOI 10.1016/S0921-8009(02)00088-5
   Fu BJ, 2013, CURR OPIN ENV SUST, V5, P4, DOI 10.1016/j.cosust.2012.12.002
   Guangdong Statistical Bureau (GSB), 2018, GUANGD STAT YB
   Hackbart VCS, 2017, ECOSYST SERV, V23, P218, DOI 10.1016/j.ecoser.2016.12.010
   Kumar P., 2010, EC ECOSYSTEMS BIODIV
   Li F, 2018, ECOSYST SERV, V31, P12, DOI 10.1016/j.ecoser.2018.03.009
   Li YF, 2018, RESOUR CONSERV RECY, V132, P291, DOI 10.1016/j.resconrec.2017.03.009
   Liu BJ, 2018, J CLEAN PROD, V177, P413, DOI 10.1016/j.jclepro.2017.12.203
   Liu JG, 2012, SCIENCE, V337, P649, DOI 10.1126/science.1219471
   Luo D, 2014, ECOSYST SERV, V7, P57, DOI 10.1016/j.ecoser.2013.11.001
   Polasky S, 2011, ENVIRON RESOUR ECON, V48, P219, DOI 10.1007/s10640-010-9407-0
   Schroter M, 2015, ECOSYST SERV, V13, P64, DOI 10.1016/j.ecoser.2014.07.003
   Sherrouse BC, 2011, APPL GEOGR, V31, P748, DOI 10.1016/j.apgeog.2010.08.002
   Silvestri S, 2013, ENVIRON SCI POLICY, V31, P23, DOI 10.1016/j.envsci.2013.03.008
   Su SL, 2012, APPL GEOGR, V34, P295, DOI 10.1016/j.apgeog.2011.12.001
   Sun X, 2017, SCI TOTAL ENVIRON, V609, P1569, DOI 10.1016/j.scitotenv.2017.07.221
   Sutton PC, 2002, ECOL ECON, V41, P509, DOI 10.1016/S0921-8009(02)00097-6
   Ter Braak CJF, 2002, POWER, DOI DOI 10.1038/ISMEJ.2011.139
   Terrado M, 2016, SCI TOTAL ENVIRON, V540, P63, DOI 10.1016/j.scitotenv.2015.03.064
   Tolessa T, 2017, ECOSYST SERV, V23, P47, DOI 10.1016/j.ecoser.2016.11.010
   Wang JY, 2018, LAND USE POLICY, V74, P204, DOI 10.1016/j.landusepol.2017.11.037
   Wang MX, 2018, J CLEAN PROD, V174, P315, DOI 10.1016/j.jclepro.2017.10.328
   Wang XC, 2017, ECOSYST SERV, V27, P113, DOI 10.1016/j.ecoser.2017.08.013
   WESTMAN WE, 1977, SCIENCE, V197, P960, DOI 10.1126/science.197.4307.960
   Wischmeier W. H., 1978, PREDICTING RAINFALL, V537
   [谢高地 XIE Gao-di], 2008, [自然资源学报, Journal of Natural Resources], V23, P911
   Xie GD, 2017, ECOSYST SERV, V26, P146, DOI 10.1016/j.ecoser.2017.06.010
   Yang W, 2018, ECOL INDIC, V92, P354, DOI 10.1016/j.ecolind.2017.05.005
   Yu WS, 2015, FOOD SECUR, V7, P405, DOI 10.1007/s12571-015-0432-2
   Zhang B, 2003, CHINESE GEOGR SCI, V13, P119, DOI 10.1007/s11769-003-0004-9
   Zhang C, 2016, FORESTS, V7, DOI 10.3390/f7120299
   Zhao MY, 2018, ECOL ECON, V152, P106, DOI 10.1016/j.ecolecon.2018.04.023
   Zhou DY, 2018, ECOL INDIC, V95, P152, DOI 10.1016/j.ecolind.2018.07.007
NR 42
TC 1
Z9 1
U1 42
U2 81
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 106
EP 114
DI 10.1016/j.resconrec.2019.05.032
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300011
DA 2020-05-12
ER

PT J
AU Tate, WL
   Bals, L
   Bals, C
   Foerstl, K
AF Tate, Wendy L.
   Bals, Lydia
   Bals, Cristof
   Foerstl, Kai
TI Seeing the forest and not the trees: Learning from nature's circular
   economy
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Biomimicry; Global challenges; Networks; Complex adaptive systems;
   Mycorrhiza; Fungi
ID INDUSTRIAL ECOSYSTEMS; SUPPLY NETWORKS; ECOLOGY; SYSTEMS; ORGANIZATION;
   SCAVENGERS; SUSTAINABILITY; PHOSPHORUS; COMPLEXITY; WATER
AB Managing for triple bottom line (TBL) by creating economic, ecological and social value is increasingly on the business agenda. However, it is challenging to address non-economic issues because businesses are designed to maximize profit and are less aligned with global ecological and social challenges. Shifting from linear supply chain thinking to interconnected, circular, ecosystem thinking could offer insights into addressing these challenges. Looking at time-tested patterns and strategies from natural ecosystems that operate using, reusing, and repurposing materials and components in a way that is sustainable, may allow for innovative and effective solutions for businesses to begin addressing these global challenges. Biomimicry, an approach to innovation that seeks solutions to human challenges by emulating nature, can inspire evolutionary and structural aspects of business ecosystems. Biomimetic insights related to mycorrhizal (root-fungus) networks are used as a foundation of this research. This research draws on network theory and complex adaptive systems (CAS) to translate the biomimetic language to the language of networked business systems. Based on literature and interview data gathered from five businesses, biomimetic principles were developed that can guide businesses as they transition from linear, wasteful chains to circular business value systems. In particular, business ecosystems require more participants in the roles of 'scavengers' and 'decomposers' and an underlying infrastructure, that helps to manage information and material flows in an integrated way.
C1 [Tate, Wendy L.] Univ Tennessee, Knoxville, TN 37996 USA.
   [Bals, Lydia] Mainz Univ Appl Sci Germany, Mainz, Germany.
   [Bals, Lydia] Copenhagen Business Sch, Copenhagen, Denmark.
   [Bals, Cristof] Tech Univ Dortmund, Dortmund, Germany.
   [Foerstl, Kai] German Grad Sch Management & Law, Heilbronn, Germany.
RP Tate, WL (reprint author), Univ Tennessee, Knoxville, TN 37996 USA.
EM wendy.tate@utk.edu
CR Allen DT, 2002, CHEM ENG PROG, V98, P40
   Allen MF, 2007, VADOSE ZONE J, V6, P291, DOI 10.2136/vzj2006.0068
   Allenby B.R., 1994, TOTAL QUALITY ENV MA, V3, P343
   Ashton W. S, 2017, SUSTAINABILITY, V9, P1
   Ashton W, 2008, J IND ECOL, V12, P34, DOI 10.1111/j.1530-9290.2008.00002.x
   Asim M, 2012, RESOUR CONSERV RECY, V58, P152, DOI 10.1016/j.resconrec.2011.10.013
   Babbitt CW, 2018, RESOUR CONSERV RECY, V135, P1, DOI 10.1016/j.resconrec.2018.04.012
   Bakshi BR, 2003, AICHE J, V49, P1350, DOI 10.1002/aic.690490602
   Balde C.P., 2017, GLOBAL E WASTE MONIT
   Bazeley P, 2013, QUALITATIVE DATA ANA
   Beiler KJ, 2010, NEW PHYTOL, V185, P543, DOI 10.1111/j.1469-8137.2009.03069.x
   Bellamy MA, 2014, J OPER MANAG, V32, P357, DOI 10.1016/j.jom.2014.06.004
   BENYUS JM, 1997, BIOMIMICRY INNOVATIO
   Besiou M, 2012, EUR J OPER RES, V218, P563, DOI 10.1016/j.ejor.2011.11.030
   Biomimicry Institute, 2017, WHAT IS BIOM
   BOCCARA N, 2004, MODELING COMPLEX SYS
   Braungart M., 2002, CRADLE CRADLE REMAKI
   Braungart M, 2007, J CLEAN PROD, V15, P1337, DOI 10.1016/j.jclepro.2006.08.003
   Choi TY, 2006, J OPER MANAG, V24, P637, DOI 10.1016/j.jom.2005.07.002
   Choi TY, 2002, J OPER MANAG, V20, P469, DOI 10.1016/S0272-6963(02)00025-6
   Choi TY, 2001, J OPER MANAG, V19, P351, DOI 10.1016/S0272-6963(00)00068-1
   Cote R. P., 2000, PRIMER IND ECOSYSTEM
   Dhungana D., 2010, P 4 EUR C SOFTW ARCH
   Domenech T, 2019, RESOUR CONSERV RECY, V141, P76, DOI 10.1016/j.resconrec.2018.09.016
   Dooley Kevin J., 1997, NONLINEAR DYNAMICS P, V1, p[69, 42], DOI DOI 10.1023/A:1022375910940
   Dooley KJ, 1999, ORGAN SCI, V10, P358, DOI 10.1287/orsc.10.3.358
   EASON WR, 1991, PLANT SOIL, V137, P267, DOI 10.1007/BF00011205
   EC, 2015, CIRC EC PACK QUEST A
   Eisenhardt KM, 2007, ACAD MANAGE J, V50, P25, DOI 10.5465/AMJ.2007.24160888
   EISENHARDT KM, 1989, ACAD MANAGE REV, V14, P532, DOI 10.2307/258557
   Filotas E, 2014, ECOSPHERE, V5, DOI 10.1890/ES13-00182.1
   Fisher A.G.B., 1939, ECON REC, V15, P24, DOI DOI 10.1111/J.1475-4932.1939.TB01015.X
   FROSCH RA, 1992, P NATL ACAD SCI USA, V89, P800, DOI 10.1073/pnas.89.3.800
   FROSCH RA, 1989, SCI AM, V261, P144, DOI 10.1038/scientificamerican0989-144
   Geng Y, 2002, INT J SUST DEV WORLD, V9, P333, DOI 10.1080/13504500209470128
   Gephart RP, 2004, ACAD MANAGE J, V47, P454, DOI 10.5465/AMJ.2004.14438580
   Glaser B. G., 1967, DISCOVERY GROUNDED T
   Gorzelak MA, 2015, AOB PLANTS, V7, DOI 10.1093/aobpla/plv050
   Graedel T. E., 1995, IND ECOLOGY AT T
   Gulati R, 1999, AM J SOCIOL, V104, P1439, DOI 10.1086/210179
   Haas W, 2015, J IND ECOL, V19, P765, DOI 10.1111/jiec.12244
   HOLLAND JH, 1995, HIDDEN ORDER
   Husar R., 1994, IND METABOLISM RESTR, P21
   Jacobi N, 2018, RESOUR CONSERV RECY, V137, P156, DOI 10.1016/j.resconrec.2018.05.022
   JELINSKI LW, 1992, P NATL ACAD SCI USA, V89, P793, DOI 10.1073/pnas.89.3.793
   Kalish Y, 2008, ASIAN J SOC PSYCHOL, V11, P53, DOI 10.1111/j.1467-839X.2007.00243.x
   KAST FE, 1972, ACAD MANAGE J, V15, P447, DOI 10.2307/255141
   Kim Y, 2011, J OPER MANAG, V29, P194, DOI 10.1016/j.jom.2010.11.001
   Kirchherr J, 2017, RESOUR CONSERV RECY, V127, P221, DOI 10.1016/j.resconrec.2017.09.005
   Korhonen J, 2005, ECOL ECON, V52, P169, DOI 10.1016/j.ecolecon.2004.07.016
   Korhonen J, 2001, INT J SUST DEV WORLD, V8, P29
   KORHONEN J, 2001, J CLEAN PROD, V9, P253, DOI DOI 10.1016/S0959-6526(00)00058-5
   Layton k, 2015, ASME 2015 INT DES EN
   Levin SA, 2005, BIOSCIENCE, V55, P1075, DOI 10.1641/0006-3568(2005)055[1075:SATEOC]2.0.CO;2
   Levin SA, 1998, ECOSYSTEMS, V1, P431, DOI 10.1007/s100219900037
   Lichtenstein BB, 2006, COMPLEXITY LEADERSHI
   Liwarska-Bizukojc E, 2009, J CLEAN PROD, V17, P732, DOI 10.1016/j.jclepro.2008.11.004
   Marshall NA, 2014, AGR ECOSYST ENVIRON, V186, P86, DOI 10.1016/j.agee.2014.01.004
   Gomez AMM, 2018, RESOUR CONSERV RECY, V135, P58, DOI 10.1016/j.resconrec.2017.08.007
   McDonough W., 2010, CRADLE CRADLE REMAKI
   Mitchell M., 2009, COMPLEXITY GUIDED TO
   Murray A, 2017, J BUS ETHICS, V140, P369, DOI 10.1007/s10551-015-2693-2
   Perry DA, 1994, FOREST ECOSYSTEMS
   Pratt MG, 2009, ACAD MANAGE J, V52, P856, DOI 10.5465/AMJ.2009.44632557
   Preston F., 2012, GLOBAL REDESIGN SHAP
   Rade L., 2015, BIOMIMICRY WHAT BUSI
   Rogers C. D., 2017, ROLE CONSUMER ECOSYS
   Ryen EG, 2018, RESOUR CONSERV RECY, V135, P48, DOI 10.1016/j.resconrec.2017.08.006
   Saberi S, 2018, RESOUR CONSERV RECY, V130, P80, DOI 10.1016/j.resconrec.2017.11.020
   Saunders LW, 2019, J BUS ETHICS, V154, P849, DOI 10.1007/s10551-017-3436-3
   Seigler T., 2018, PRODUCERS CONSUMERS
   Simard S, 2016, TREES TALK EACH OTHE
   Simard Suzanne W., 2012, Fungal Biology Reviews, V26, P39, DOI 10.1016/j.fbr.2012.01.001
   Simard SW, 2009, FOREST ECOL MANAG, V258, pS95, DOI 10.1016/j.foreco.2009.05.001
   Simard SW, 1997, NEW PHYTOL, V137, P529, DOI 10.1046/j.1469-8137.1997.00834.x
   Sivakumar N., 2012, IUP J SUPPLY CHAIN M, V9, P21
   SOLE RV, 2000, SIGNS LIFE COMPLEXIT
   Stahel WR, 2016, NATURE, V531, P435, DOI 10.1038/531435a
   Sternberg H, 2017, INT J PHYS DISTR LOG, V47, P736, DOI 10.1108/IJPDLM-12-2016-0353
   Strauss A., 1998, BASICS QUALITATIVE R
   Suding KN, 2004, TRENDS ECOL EVOL, V19, P46, DOI 10.1016/j.tree.2003.10.005
   Swan Melanie, 2015, BLOCKCHAIN BLUEPRINT
   The natural step, 2013, INT JOURN LIF
   TIBBS HBC, 1992, WHOLE EARTH REV  WIN, P4
   Treseder KK, 2004, NEW PHYTOL, V164, P347, DOI 10.1111/j.1469-8137.2004.01159.x
   van Buren N, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8070647
   Vanegas P, 2018, RESOUR CONSERV RECY, V135, P323, DOI 10.1016/j.resconrec.2017.06.022
   Vaughan D., 1992, WHAT IS CASE EXPLORI, P173
   von Bertalanffy K.L., 1972, ACAD MANAGE J, V15, P407, DOI DOI 10.2307/255139
   Von Bertalanffy L., 1934, MODERN THEORIES DEV
   Warren JM, 2008, NEW PHYTOL, V178, P382, DOI 10.1111/j.1469-8137.2008.02377.x
   Wilhelm MM, 2016, J OPER MANAG, V41, P42, DOI 10.1016/j.jom.2015.11.001
   Winn MI, 2013, ORGAN ENVIRON, V26, P203, DOI 10.1177/1086026613490173
   Yin R., 2009, CASE STUDY RES DESIG
NR 94
TC 3
Z9 3
U1 16
U2 34
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 115
EP 129
DI 10.1016/j.resconrec.2019.05.023
PG 15
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300012
DA 2020-05-12
ER

PT J
AU Papadaskalopoulou, C
   Sotiropoulos, A
   Novacovic, J
   Barabouti, E
   Mai, S
   Malamis, D
   Kekos, D
   Loizidou, M
AF Papadaskalopoulou, Christina
   Sotiropoulos, Aggelos
   Novacovic, Jelica
   Barabouti, Elli
   Mai, Sofia
   Malamis, Dimitris
   Kekos, Dimitris
   Loizidou, Maria
TI Comparative life cycle assessment of a waste to ethanol biorefinery
   system versus conventional waste management methods
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE life cycle assessment; Biowaste; Ethanol; Conventional waste management;
   Biorefinery; Enzyme dosage
ID MUNICIPAL SOLID-WASTE; HOUSEHOLD FOOD WASTE; ENVIRONMENTAL ASSESSMENT;
   PHYSICAL-PROPERTIES; AGRICULTURAL LAND; ENERGY; TECHNOLOGIES; IMPACTS;
   FERMENTATION; PERFORMANCE
AB Biowaste is a prominent source for second generation biofuels and other biobased products since it constitutes an abundant feedstock, the current treatment of which poses challenges to the environment. In the current paper, the environmental sustainability of a biorefinery system producing ethanol from biowaste is assessed by means of Life Cycle Assessment. It is shown that the biorefinery system presents very good environmental performance, as the net emissions are quite low for all the impact categories examined, while in many of the cases the emissions are negative. The total net global warming impact is estimated to be -15 kg CO(2)eq/ton biowaste. Following, the environmental impacts from biowaste treatment with the biorefinery system are compared to those from biowaste treatment with the conventional municipal waste management methods. It is shown that the biorefinery system presents very good performance compared to the current waste management methods. Furthermore, a sensitivity analysis is conducted for investigating the impact of increased enzyme dosage to the overall environmental performance of the system. It is found that, the increase in ethanol production due to increased enzyme dosage has a smaller impact to the system performance compared to the effect of increased enzyme dosage. Furthermore, it was shown that the range of enzyme contribution in the global warming impact of ethanol biorefineries is wide (11-62%) which is attributed to a number of parameters, such as the high variation of the reported global warming impact of enzymes, the different enzyme loadings and ethanol yields.
C1 [Papadaskalopoulou, Christina; Novacovic, Jelica; Barabouti, Elli; Mai, Sofia; Malamis, Dimitris; Kekos, Dimitris; Loizidou, Maria] Natl Tech Univ Athens, Sch Chem Engn, Unit Environm Sci & Technol, Zographou Campus,9 Heroon Polytechniou St, Athens 15780, Greece.
   [Sotiropoulos, Aggelos] Green Fund, 241 Leof Kifisias, Kifisia 14561, Greece.
RP Papadaskalopoulou, C (reprint author), Natl Tech Univ Athens, Sch Chem Engn, Unit Environm Sci & Technol, Zographou Campus,9 Heroon Polytechniou St, Athens 15780, Greece.
EM chpapad@chemeng.ntua.gr
OI Sotiropoulos, Aggelos/0000-0001-8685-6878
FU European CommissionEuropean Commission Joint Research Centre [LIFE 11
   ENV/GR/000949]
FX The authors would like to acknowledge the contribution of Ms Vasiliki
   Panaretou and of Ms Nikoleta Kontogianni from the National Technical
   University of Athens for the provision of data on the compositional
   analysis of waste and for the provision of results from the operation of
   the pilot bioreactor unit, respectively. This work has been elaborated
   in the framework of the LIFE + project entitled: Development and
   demonstration of an innovative method of converting waste into
   bioethanol, Waste2Bio, (LIFE 11 ENV/GR/000949, 2012-2016), which is
   co-financed by the European Commission.
CR Ahamed A, 2016, J CLEAN PROD, V131, P607, DOI 10.1016/j.jclepro.2016.04.127
   Ahlgren S, 2014, BIOTECHNOL BIOFUELS, V7, DOI 10.1186/1754-6834-7-35
   Alamanou DG, 2015, WASTE BIOMASS VALORI, V6, P353, DOI 10.1007/s12649-015-9355-6
   Angelidaki I., 2010, SOLID WASTE TECHNOLO, V1, P583, DOI [10.1002/9780470666883.ch37, DOI 10.1002/9780470666883.CH37]
   Bernstad A, 2011, WASTE MANAGE, V31, P1879, DOI 10.1016/j.wasman.2011.02.026
   Blok K, 2013, NOVEL METHODOLOGY SU
   Bruun S, 2006, ENVIRON MODEL ASSESS, V11, P251, DOI 10.1007/s10666-005-9028-0
   Buratti C, 2015, J CLEAN PROD, V89, P125, DOI 10.1016/j.jclepro.2014.11.012
   Chester M, 2009, CELLULOSIC ETHANOL M
   Clavreul J, 2014, ENVIRON MODELL SOFTW, V60, P18, DOI 10.1016/j.envsoft.2014.06.007
   Colon J, 2015, RESOUR CONSERV RECY, V95, P143, DOI 10.1016/j.resconrec.2014.12.012
   Dunn JB, 2012, BIOTECHNOL LETT, V34, P2259, DOI 10.1007/s10529-012-1057-6
   Ebner J, 2014, APPL ENERG, V130, P86, DOI 10.1016/j.apenergy.2014.04.099
   Ecoinvent. Swiss Centre for Life Cycle Inventories, 2016, EC DAT V 3
   Edwards J, 2018, BIORESOURCE TECHNOL, V248, P156, DOI 10.1016/j.biortech.2017.06.070
   Eggleston H. S, 2006, WASTE PREPARED NATL, V5
   European Commission, 2011, INT REF LIF CYCL DAT
   European Commission, 2010, 24708 EUR EN
   Fargione J, 2008, SCIENCE, V319, P1235, DOI 10.1126/science.1152747
   Hansen TL, 2006, WASTE MANAGE RES, V24, P153, DOI 10.1177/0734242X06063053
   Hong Y, 2013, BIOFUEL BIOPROD BIOR, V7, P303, DOI 10.1002/bbb.1393
   Hsu DD, 2010, ENVIRON SCI TECHNOL, V44, P5289, DOI 10.1021/es100186h
   International Organisation for Standardization, 2006, 140402006 ISO
   Jensen MB, 2016, WASTE MANAGE, V49, P491, DOI 10.1016/j.wasman.2016.01.035
   Kalogo Y, 2007, ENVIRON SCI TECHNOL, V41, P35, DOI 10.1021/es061117b
   Karlsson H, 2014, J CLEAN PROD, V83, P420, DOI [10.1016/j.jclepro.2014.07.029, 10.1016/]
   Larsen AW, 2009, WASTE MANAGE RES, V27, P652, DOI 10.1177/0734242X08097636
   MacLean HL, 2009, ENVIRON RES LETT, V4, DOI 10.1088/1748-9326/4/1/014001
   Madson P. W, 2005, MONT S EN FUT W
   Manfredi S, 2015, IMPROVING SUSTAINABI
   Manfredi S, 2009, ENV ASSESSMENT SOLID
   Manfredi S, 2009, WASTE MANAGE, V29, P32, DOI 10.1016/j.wasman.2008.02.021
   Mani S, 2004, BIOMASS BIOENERG, V27, P339, DOI 10.1016/j.biombioe.2004.03.007
   Miao Z, 2011, IND CROP PROD, V33, P504, DOI 10.1016/j.indcrop.2010.12.016
   Moller J, 2010, SOLID WASTE MANAGEME
   Nielsen M, 2010, 071882 AARH U NAT EN
   Nielsen PH, 2007, INT J LIFE CYCLE ASS, V12, P432, DOI 10.1065/lca2006.08.265.1
   Olofsson J, 2017, BIOTECHNOL BIOFUELS, V10, DOI 10.1186/s13068-017-0733-0
   Patterson T, 2008, ENERG FUEL, V22, P3506, DOI 10.1021/ef800237q
   Popp J, 2014, RENEW SUST ENERG REV, V32, P559, DOI 10.1016/j.rser.2014.01.056
   Saffy HA, 2015, ENERG CONVERS MANAGE, V105, P900, DOI 10.1016/j.enconman.2015.08.039
   Smith RL, 2015, RESOUR CONSERV RECY, V104, P317, DOI 10.1016/j.resconrec.2015.05.016
   Sotiropoulos A, 2016, WASTE MANAGE, V52, P353, DOI 10.1016/j.wasman.2016.03.047
   Stichnothe H, 2009, RESOUR CONSERV RECY, V53, P624, DOI 10.1016/j.resconrec.2009.04.012
   Tonini D, 2016, GCB BIOENERGY, V8, P690, DOI 10.1111/gcbb.12290
   Tumuluru JS, 2014, BIOMASS BIOENERG, V60, P58, DOI 10.1016/j.biombioe.2013.10.011
   Vane LM, 2008, BIOFUEL BIOPROD BIOR, V2, P553, DOI 10.1002/bbb.108
   Yoshida H, 2012, RESOUR CONSERV RECY, V60, P1, DOI 10.1016/j.resconrec.2011.11.011
NR 48
TC 2
Z9 2
U1 10
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 130
EP 139
DI 10.1016/j.resconrec.2019.05.006
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300013
DA 2020-05-12
ER

PT J
AU Long, J
   Zhang, SX
   Luo, KL
AF Long, Jie
   Zhang, Shixi
   Luo, Kunli
TI Selenium in Chinese coal gangue: Distribution, availability, and
   recommendations
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Resource-exhausted cites; Trace elements; Se-enriched fertilizer;
   Environmental sustainability
ID FLY-ASH PARTICLES; HAZARDOUS ELEMENTS; CLEANING REJECTS; SPONTANEOUS
   COMBUSTION; SELENOSIS AREA; ULTRA-FINE; NANOMINERALS; PATTERNS;
   PROVINCE; GENOTOXICITY
AB Coal gangue accounts for a large proportion of the solid waste in China, and greater attention has been focused on the concentrations of potentially hazardous trace elements (PHEs) than on the potentially useful trace elements (PUEs), such as selenium (Se). Chinese coal gangue is enriched in Se, and the arithmetic mean value is 2.87 mg/kg (0.06-17 mg/kg), which is 97 times higher than the average Se concentration in the upper continental crust. For coal gangue deposited during different periods, the arithmetic mean Se values are 4.25 mg/kg (C-1) > 4.15 mg/kg (C-2-P-1) > 3.95 mg/kg (P-2) > 2.65 mg/kg (T-3) > 1.73 mg/kg (J(1)-J(2)) > 1.47 mg/kg (J(3)-K-1) > 0.66 mg/kg (E-N). The Se content in lignite coal gangue is 0.88 mg/kg (0.06-4.90 mg/kg), which is 0.26 and 0.21 times lower than that in bituminite and anthracite gangue. Pearson correlation results indicate that carbonates and aluminosilicates are the dominant carriers of selenium in J(3)-K-1 and J(1)-J(2) coal gangue, respectively. Selenium in late Carboniferous and early Permian coal gangue probably are likely primarily associated with sulfide minerals. In addition, crushed Se-enriched coal gangue powder is considered to be a potential resource for Se-enriched fertilizer, although As (avg = 90 mg/kg) and Cr (1.07 mg/kg) are enriched in early Carboniferous and late Triassic coal gangue. The findings suggest that a comprehensive system for managing resources (e.g., coal gangue) should be developed to improve the recovery and utilization of these resources and promote a more eco-friendly society and resource conservation in China.
C1 [Long, Jie; Zhang, Shixi; Luo, Kunli] Chinese Acad Sci, Inst Geog Sci & Nat Resources Res, Beijing 100101, Peoples R China.
   [Long, Jie] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
RP Luo, KL (reprint author), Chinese Acad Sci, Inst Geog Sci & Nat Resources Res, Beijing 100101, Peoples R China.
EM luokl@igsnrr.ac.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [41877299, 41172310, 41472322]; Science and
   Technology major project of Guangxi [AA17202026-1]; National Basic
   Research Program of ChinaNational Basic Research Program of China
   [2014CB238906]
FX This study is supported by the National Natural Science Foundation of
   China (Grant Nos. 41877299, 41172310, and 41472322), Science and
   Technology major project of Guangxi (AA17202026-1), and the National
   Basic Research Program of China (2014CB238906). We gratefully
   acknowledge the editor and four anonymous reviewers for their
   constructive comments and suggestions. The authors acknowledge the
   assistance of Huijie Li and Ling Li in the collection of coal mine data
   and analysis of coal samples.
CR Agricultural Strategy Research Group of China Academy of Sciences(ASRCAS), 2009, AGR SCI TECHN DEV RO, P2
   Agudelo-Castaneda DM, 2017, ENVIRON POLLUT, V224, P158, DOI 10.1016/j.envpol.2017.01.075
   [Anonymous], 1973, Nutr Rev, V31, P289
   [Anonymous], 2014, DZT02142002 MIN LAND
   [Anonymous], 2002, DZT02032002 MIN LAND
   Bock A., 2013, SELENOPROTEINS
   Bureau C. C. G., 1996, ATL COAL RES MAJ COA
   Chen YN, 2015, ENVIRON EARTH SCI, V73, P547, DOI 10.1007/s12665-013-3002-y
   China National Environment Monitoring Center (CNEMC), 1990, BACKGR VAL CHIN SOIL, P87
   Civeira MS, 2016, CHEMOSPHERE, V145, P142, DOI 10.1016/j.chemosphere.2015.11.059
   Cutruneo CMNL, 2014, INT J COAL GEOL, V130, P33, DOI 10.1016/j.coal.2014.05.009
   Dai SF, 2012, INT J COAL GEOL, V94, P3, DOI 10.1016/j.coal.2011.02.003
   Dal S, 2011, CHEM GEOL, V282, P29
   Dalmora AC, 2016, CHEMOSPHERE, V144, P2013, DOI 10.1016/j.chemosphere.2015.10.047
   Dias CL, 2014, INT J COAL GEOL, V122, P50, DOI 10.1016/j.coal.2013.12.011
   Doblin MA, 1999, J PLANKTON RES, V21, P1153, DOI 10.1093/plankt/21.6.1153
   Doyle W, 1976, DEEP COAL MINING WAS
   Duarte Ana L., 2018, GEOSCI FRONT, V1
   Dutta M, 2017, GEOSCI FRONT, V8, P1285, DOI 10.1016/j.gsf.2016.11.014
   Eftekhari A, 2017, SUSTAIN ENERG FUELS, V1, P14, DOI 10.1039/c6se00094k
   Fadeeva VP, 2014, J ANAL CHEM+, V69, P432, DOI 10.1134/S1061934814030034
   Fang WX, 2002, ENVIRON GEOCHEM HLTH, V24, P35, DOI 10.1023/A:1013981016542
   de Vallejuelo SFO, 2017, CHEMOSPHERE, V169, P725, DOI 10.1016/j.chemosphere.2016.09.125
   Finkelman R. B, 1982, NEUV C INT STRAT GEO, V4, P407
   FINKELMAN RB, 1982, ATOMIC NUCL METHODS, P141
   Gasparotto J, 2018, ECOTOX ENVIRON SAFE, V165, P44, DOI 10.1016/j.ecoenv.2018.08.097
   Ge H. Q., 2005, SICHUAN NONFERROUS M, V3, P7
   GOLDSHTEIN YE, 1979, MET SCI HEAT TREAT+, V21, P741, DOI 10.1007/BF00708374
   Gredilla A, 2017, ENVIRON SCI POLLUT R, V24, P24333, DOI 10.1007/s11356-017-9831-6
   Guo S, 2018, TRACE ELEMENTS COAL, DOI [10.1039/C6SE00094K, DOI 10.1039/C6SE00094K]
   Han D.X., 1996, COAL PETROLOGY CHINA
   Hao Q., 2008, COAL GEOLOGY CHINA, V20, P23
   Ketris MP, 2009, INT J COAL GEOL, V78, P135, DOI 10.1016/j.coal.2009.01.002
   Kronbauer MA, 2013, SCI TOTAL ENVIRON, V456, P95, DOI 10.1016/j.scitotenv.2013.02.066
   Leon-Mejia G, 2018, SCI TOTAL ENVIRON, V625, P589, DOI 10.1016/j.scitotenv.2017.12.283
   Leon-Mejia G, 2016, ENVIRON SCI POLLUT R, V23, P24019, DOI 10.1007/s11356-016-7623-z
   LI Dong, 2015, NONFERROUS METALS SC, V6, P18
   Liu G. J., 2017, J GEOCHEM EXPLOR, V186
   Liu Guijian, 2001, GEOLOGICAL J CHINA U, V7, P449
   Liu H, 2016, ANHUI AGR SCI B, V22, P61
   Liu HB, 2010, RESOUR CONSERV RECY, V54, P1331, DOI 10.1016/j.resconrec.2010.05.005
   Liu YJ, 1984, ELEMENT GEOCHEMISTRY
   Long J, 2018, ENERG FUEL, V32, P12091, DOI 10.1021/acs.energyfuels.8b02354
   Long J, 2017, J GEOCHEM EXPLOR, V172, P211, DOI 10.1016/j.gexplo.2016.11.010
   Luo KL, 2004, ENVIRON GEOL, V45, P426, DOI 10.1007/s00254-003-0893-z
   Luo KL, 2011, ENERG FUEL, V25, P4479, DOI 10.1021/ef200737s
   Mao D., 1993, SOILENVIORNMENT SCI, V3, P62
   Martinello K, 2014, SCI TOTAL ENVIRON, V470, P444, DOI 10.1016/j.scitotenv.2013.10.007
   Ni RX, 2016, ENVIRON GEOCHEM HLTH, V38, P927, DOI 10.1007/s10653-015-9772-2
   Nordin AP, 2018, J HAZARD MATER, V346, P263, DOI 10.1016/j.jhazmat.2017.12.026
   Oliveira MLS, 2018, J CLEAN PROD, V188, P662, DOI 10.1016/j.jclepro.2018.04.050
   Oliveira MLS, 2018, ENVIRON RES, V160, P562, DOI 10.1016/j.envres.2017.08.009
   Oliveira MLS, 2014, SCI TOTAL ENVIRON, V468, P1128, DOI 10.1016/j.scitotenv.2013.09.040
   Plant J. A., 2014, TREATISE GEOCHEMISTR, V9, P17
   Querol X, 2008, INT J COAL GEOL, V75, P93, DOI 10.1016/j.coal.2008.04.003
   Rahib H, 2018, ENV GEOCHEMISTRY HLT
   Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9
   Ren D., 2006, TRACE ELEMENT GEOCHE
   Rodriguez-Iruretagoiena A, 2015, SCI TOTAL ENVIRON, V508, P374, DOI 10.1016/j.scitotenv.2014.12.015
   Romero A, 2006, APPL GEOCHEM, V21, P1093, DOI 10.1016/j.apgeochem.2006.03.002
   Rotruck J. T., 1973, SCIENCE, V38, P280, DOI DOI 10.1111/J.1753-4887.1980.TB05961.X
   Saha K., 2014, INT J ENVIRON STUD, V71, P380
   Saikia BK, 2018, GEOSCI FRONT, V9, P863, DOI 10.1016/j.gsf.2017.11.013
   Sheng M. L, 2016, COAL ENG, V48, P502
   Silva LFO, 2013, ENERG FUEL, V27, P1194, DOI 10.1021/ef4000038
   Skidmore D. R., 1986, COMBUST FLAME, V65, P251
   Su H., 2016, Patent, REF, Patent No. 105460907
   Sun S. X., 2013, APPL MECH MAT, V340, P1045
   Tan J. A., 1989, THE ATLAS OF ENDEMIC, V36, P379
   Taylor SR, 1985, CONTINENTAL CRUST IT, p312p
   Thomson CD, 2004, EUR J CLIN NUTR, V58, P391, DOI 10.1038/sj.ejcn.1601800
   THORNTON I, 1983, APPL ENV GEOCHEMISTR
   [僮祥英 Tong Xiangying], 2013, [安全与环境学报, Journal of Safety and Environment], V13, P148
   TUREKIAN KK, 1961, GEOL SOC AM BULL, V72, P175, DOI 10.1130/0016-7606(1961)72[175:DOTEIS]2.0.CO;2
   Wang J, 2008, FUEL, V87, P2211, DOI 10.1016/j.fuel.2007.10.012
   [温汉捷 Wen Hanjie], 2003, [沉积学报, Acta Sedimentologica Sinica], V21, P619
   Wilcox J, 2015, ENERG FUEL, V29, P7168, DOI 10.1021/acs.energyfuels.5b02033
   Xu ZC, 2012, PAK J BOT, V44, P1563
   [杨娅 Yang Ya], 2016, [地球与环境, Earth and Environment], V44, P36
   Ye J.W., 2010, CHINA RESOUR COMPR U, V28, P32
   Yu JL, 2012, ADV MATER RES-SWITZ, V550-553, P443, DOI 10.4028/www.scientific.net/AMR.550-553.443
   Zhang CS, 2005, APPL GEOCHEM, V20, P1857, DOI 10.1016/j.apgeochem.2005.06.006
   Zhang HM, 2018, J CLEAN PROD, V196, P1418, DOI 10.1016/j.jclepro.2018.06.093
   Zhao YC, 2008, INT J COAL GEOL, V73, P52, DOI 10.1016/j.coal.2007.07.007
   Zhou CC, 2014, FUEL, V135, P1, DOI 10.1016/j.fuel.2014.06.034
   Zhou CC, 2014, SCI REP-UK, V4, DOI 10.1038/srep06221
   Zhou CC, 2014, BIORESOURCE TECHNOL, V166, P243, DOI 10.1016/j.biortech.2014.05.076
   Zhou CC, 2014, CHEMOSPHERE, V95, P274, DOI 10.1016/j.chemosphere.2013.09.004
NR 88
TC 1
Z9 1
U1 19
U2 26
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 140
EP 150
DI 10.1016/j.resconrec.2019.05.039
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300014
DA 2020-05-12
ER

PT J
AU Wu, YL
   Tian, X
   Li, XR
   Yuan, HM
   Liu, G
AF Wu, Yinglei
   Tian, Xin
   Li, Xinran
   Yuan, Haoming
   Liu, Gang
TI Characteristics, influencing factors, and environmental effects of plate
   waste at university canteens in Beijing, China
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Food waste; Plate waste; University students; Beijing; Environmental
   impacts
ID FOOD WASTE; RHODES UNIVERSITY; IMPACTS; BEHAVIOR; WATER; RESOURCES;
   LOSSES; ENERGY
AB Food waste in China has gained increased attention in recent years due to its rising quantity and adverse environmental, economic, and societal impacts. As university students are an indispensable part of Chinese society and will become the backbone of China's future sustainable development, their dietary habits and food-wasting behaviors are of both societal and scientific relevance. In this study, we combined direct weighing, questionnaire surveys, and regression analysis to quantify the plate waste of university students in Beijing and identified key influencing factors, based on 551 observations from 6 sample universities. We also evaluated the environmental impacts of university plate waste from the perspective of nitrogen, phosphorus, carbon, and ecological footprints. The results showed that the average plate waste generated by university students in Beijing was 73.7 g/cap/meal in 2018, with staple foods and vegetables contributing the most. There were apparent correlations between plate waste and both grade level and financial condition: lower educational levels and higher disposable incomes both led to more food waste. Male students wasted significantly less staple food than female students. Students' self-report difficulty of avoiding waste significantly related to plate waste. Dietary preference and personal appetite were prominent considerations when students ordered food, corresponding to problems in food quality and quantity at university canteens. Attitudes most likely to reduce plate waste included a sense of guilt and considering saving food a positive lifestyle. The estimated annual environmental footprints caused by plate waste were considerable, mainly deriving from staple foods and meats.
C1 [Wu, Yinglei; Tian, Xin] Beijing Normal Univ, Sch Environ, Beijing 100875, Peoples R China.
   [Tian, Xin] Beijing Normal Univ, State Key Lab Water Environm Simulat, Beijing 100875, Peoples R China.
   [Li, Xinran] Beijing Normal Univ, High Sch 2, Beijing 100088, Peoples R China.
   [Yuan, Haoming] Beijing Normal Univ, Business Sch, Beijing 100875, Peoples R China.
   [Liu, Gang] Chinese Acad Sci, Inst Geog Sci & Nat Resources Res, Beijing 100101, Peoples R China.
   [Liu, Gang] Univ Southern Denmark, SDU Life Cycle Engn, Dept Chem Engn Biotechnol & Environm Technol, DK-5230 Odense, Denmark.
RP Tian, X (reprint author), Beijing Normal Univ, Sch Environ, Beijing 100875, Peoples R China.
EM tianx@bnu.edu.cn
OI Liu, Gang/0000-0002-7613-1985
FU foundation for Innovative Research Groups of the National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [51721093]; International Cooperation and Exchanges of the national
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [51661125010]; National Key Research and Development Plan of
   China [2016YFE0113100]
FX This work was jointly supported by the foundation for Innovative
   Research Groups of the National Natural Science Foundation of China (No.
   51721093), International Cooperation and Exchanges of the national
   Natural Science Foundation of China(No. 51661125010), and National Key
   Research and Development Plan of China (No. 2016YFE0113100). We
   gratefully acknowledge the help of student volunteers in our field
   survey, including Yuewen Jia, Siqi You, Yiling Xiong, Jie Wang, Fuli
   Bai, Shaoying Zhang, Minzi Li, Haoxin Li, Yifei Wang, Ruyan Wang and
   Shuya Xiao.
CR AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Ajzen I, 1985, ACTION CONTROL COGNI, P11, DOI DOI 10.1007/978-3-642-69746-3_2
   [Anonymous], 2017, CHINA STAT YB 2016
   Aschemann-Witzel J, 2015, SUSTAINABILITY-BASEL, V7, P6457, DOI 10.3390/su7066457
   Buzby J. C, 2002, PLATE WASTE SCH NUTR, P20
   Cheon J, 2012, COMPUT EDUC, V59, P1054, DOI 10.1016/j.compedu.2012.04.015
   China statistics press, 2018, BEIJING STAT YB 2017
   Chinese Statistics Press, 2007, CHINA STAT YB 2006
   Cuellar AD, 2010, ENVIRON SCI TECHNOL, V44, P6464, DOI 10.1021/es100310d
   Davis LE, 2002, J EDUC PSYCHOL, V94, P810, DOI 10.1037//0022-0663.94.4.810
   Derqui B, 2018, APPETITE, V129, P1, DOI 10.1016/j.appet.2018.06.022
   Ellison B, 2019, RESOUR CONSERV RECY, V144, P276, DOI 10.1016/j.resconrec.2019.01.046
   FAO, 2013, FOOD WAST FOOTPR IMP
   Ferreira M, 2013, BRIT FOOD J, V115, P1628, DOI 10.1108/BFJ-03-2012-0051
   Forster-Carneiro T, 2008, BIORESOURCE TECHNOL, V99, P6994, DOI 10.1016/j.biortech.2008.01.018
   Gobel C, 2015, SUSTAINABILITY-BASEL, V7, P1429, DOI 10.3390/su7021429
   Hall KD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007940
   He P, 2018, NAT SUSTAIN, V1, P122, DOI 10.1038/s41893-018-0035-y
   Hic C, 2016, ENVIRON SCI TECHNOL, V50, P4269, DOI 10.1021/acs.est.5b05088
   Kummu M, 2012, SCI TOTAL ENVIRON, V438, P477, DOI 10.1016/j.scitotenv.2012.08.092
   Lee H, 2015, LOW CARBON EC, V6, P30, DOI [10.4236/Ice.2015.62005, DOI 10.4236/ICE.2015.62005]
   Liu JG, 2013, ENVIRON SCI TECHNOL, V47, P10137, DOI 10.1021/es401426b
   LIU Y, 2016, SUSTAINABILITY-BASEL, V8, DOI DOI 10.3390/SU8121288
   Martins ML, 2014, WASTE MANAGE, V34, P1362, DOI 10.1016/j.wasman.2014.03.020
   Melbye EL, 2017, J FOOD PROD MARK, V23, P416, DOI 10.1080/10454446.2015.1048017
   Mtutu P, 2016, HABITAT INT, V53, P142, DOI 10.1016/j.habitatint.2015.11.031
   Neff RA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127881
   Nikolaus CJ, 2018, APPETITE, V130, P70, DOI 10.1016/j.appet.2018.07.026
   Oldfield TL, 2018, J CLEAN PROD, V170, P1554, DOI 10.1016/j.jclepro.2017.09.239
   Painter K, 2016, WASTE MANAGE, V56, P491, DOI 10.1016/j.wasman.2016.07.013
   Piao SL, 2010, NATURE, V467, P43, DOI 10.1038/nature09364
   Qi X, 2019, APPETITE, V133, P414, DOI 10.1016/j.appet.2018.12.004
   Quested TE, 2013, RESOUR CONSERV RECY, V79, P43, DOI 10.1016/j.resconrec.2013.04.011
   Russell SV, 2017, RESOUR CONSERV RECY, V125, P107, DOI 10.1016/j.resconrec.2017.06.007
   Scherhaufer S, 2018, WASTE MANAGE, V77, P98, DOI 10.1016/j.wasman.2018.04.038
   Song GB, 2018, J CLEAN PROD, V202, P916, DOI 10.1016/j.jclepro.2018.08.233
   Vittuari M, 2016, ENERGIES, V9, DOI 10.3390/en9080660
   Wang LE, 2017, WASTE MANAGE, V66, P3, DOI 10.1016/j.wasman.2017.04.007
   Wang LG, 2018, RESOUR CONSERV RECY, V136, P1, DOI 10.1016/j.resconrec.2018.04.001
   Wilkie AC, 2015, SUSTAINABILITY-BASEL, V7, P1370, DOI 10.3390/su7021370
   Wooldridge J. M, 2015, INTRO ECONOMETRICS, DOI [10.1016/j.jconhyd.2010.08.009, DOI 10.1016/J.JCONHYD.2010.08.009]
   Yazdanpanah M, 2015, J CLEAN PROD, V107, P342, DOI 10.1016/j.jclepro.2015.02.071
   Zhang D, 2017, ACTA ECOL SIN, P37, DOI [10.5846/stxb201510162088, DOI 10.5846/STM201510162088]
   Zhang D, 2016, RESOUR SCI, V38, P11, DOI [10.18402/resci.2016.01.02, DOI 10.18402/RESCI.2016.01.02]
   [张丹 Zhang Dan], 2016, [生态学报, Acta Ecologica Sinica], V36, P5937
   [张丹 Zhang Dan], 2016, [自然资源学报, Journal of Natural Resources], V31, P812
   Zhao HH, 2014, J CLEAN PROD, V63, P143, DOI 10.1016/j.jclepro.2013.05.021
NR 47
TC 0
Z9 0
U1 13
U2 35
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 151
EP 159
DI 10.1016/j.resconrec.2019.05.022
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300015
DA 2020-05-12
ER

PT J
AU Jiahuey, Y
   Liu, Y
   Yu, YN
AF Jiahuey, Yeh
   Liu, Yi
   Yu, Yanni
TI Measuring green growth performance of China's chemical industry
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Green energy efficiency; Green growth; Carbon shadow price; China;
   chemical industry
ID CO2 EMISSION PERFORMANCE; CARBON-DIOXIDE EMISSIONS; ENERGY EFFICIENCY;
   SHADOW PRICE; ENVIRONMENTAL-REGULATIONS; PRODUCTIVITY GROWTH;
   EMPIRICAL-ANALYSIS; IRON; GENERATION; REDUCTION
AB The chemical industry is a key energy-consuming sector in China. This paper aims to examine total-factor green growth performance, including energy efficiency and carbon shadow price of China's chemical sector from 1980 to 2013. On the basis of no-radial directional distance function, this paper takes into account both desirable and undesirable outputs. To investigate policy effects, we check the Granger causality test between shadow prices of emission and total-factor green energy efficiency. The results demonstrate that increased environmental regulation costs have substantial effect on total-factor green energy efficiency of the chemical industry in the last decade. The latter also causes significant improvement of the former.
C1 [Jiahuey, Yeh] Jiangxi Univ Finance & Econ, Sch Tourism & Urban Management, Nanchang 330013, Jiangxi, Peoples R China.
   [Liu, Yi] Jiangxi Univ Finance & Econ, Sch Int Trade & Econ, Nanchang 330013, Jiangxi, Peoples R China.
   [Yu, Yanni] Shandong Univ, Inst Blue & Green Dev, Weihai 264209, Peoples R China.
   [Yu, Yanni] Shandong Univ, Acad Adv Interdisciplinary Studies, Weihai 264209, Peoples R China.
RP Yu, YN (reprint author), Shandong Univ, Inst Blue & Green Dev, Weihai 264209, Peoples R China.
EM yayabaobei@naver.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [71711540308, 71603102]; Philosophy and Social
   Sciences Research of Ministry of Education of China [17JZD013]; National
   Social Science Foundation of China [15ZDA054]
FX The study is supported by the National Natural Science Foundation of
   China (71711540308, 71603102), Philosophy and Social Sciences Research
   of Ministry of Education of China (17JZD013) and National Social Science
   Foundation of China (15ZDA054).
CR Atkinson SE, 2005, J ECONOMETRICS, V126, P445, DOI 10.1016/j.jeconom.2004.05.009
   Chambers RG, 1996, J ECON THEORY, V70, P407, DOI 10.1006/jeth.1996.0096
   Chang YT, 2013, ENERG POLICY, V58, P277, DOI 10.1016/j.enpol.2013.03.011
   Chen SY, 2014, ENERG ECON, V44, P89, DOI 10.1016/j.eneco.2014.04.002
   Choi Y, 2012, APPL ENERG, V98, P198, DOI 10.1016/j.apenergy.2012.03.024
   Clark JH, 2007, J CHEM TECHNOL BIOT, V82, P603, DOI 10.1002/jctb.1710
   CNPC, 2017, CHIN MAK BLUEPR HIGH
   Diaz Lopez F. J., 2012, GREEN CHEM ENV REMED
   Lopez FJD, 2015, J CLEAN PROD, V102, P30, DOI 10.1016/j.jclepro.2015.04.007
   Fare R, 2012, APPL ECON, V44, P39, DOI 10.1080/00036846.2010.498368
   Fare R, 2005, J ECONOMETRICS, V126, P469, DOI 10.1016/j.jeconom.2004.05.010
   Galinato GI, 2018, RESOUR ENERGY ECON, V53, P114, DOI 10.1016/j.reseneeco.2018.04.001
   GOLLOP FM, 1983, J POLIT ECON, V91, P654, DOI 10.1086/261170
   Graedel T.E., 2005, GREENING IND FACILIT
   Granger C. W. J., 1974, J ECONOMETRICS, V35, P143
   GRANGER CWJ, 1988, J ECONOMETRICS, V39, P199, DOI 10.1016/0304-4076(88)90045-0
   He F, 2013, ENERG POLICY, V54, P204, DOI 10.1016/j.enpol.2012.11.020
   Hikino T., 2007, GLOBAL CHEM IND AGE
   Hoffman AJ, 1999, ACAD MANAGE J, V42, P351, DOI 10.2307/257008
   KPMG, 2013, CHIN CHEM IND EM LOC
   Lee M, 2012, ENERG ECON, V34, P1492, DOI 10.1016/j.eneco.2012.06.023
   Li Dong, 2013, China Environmental Science, V33, P56
   Li JL, 2019, RESOUR CONSERV RECY, V145, P349, DOI 10.1016/j.resconrec.2019.01.036
   Lin BQ, 2015, ENERG POLICY, V86, P483, DOI 10.1016/j.enpol.2015.07.030
   Managi S, 2005, LAND ECON, V81, P303, DOI 10.3368/le.81.2.303
   Matsushita K, 2012, ENERG ECON, V34, P1124, DOI 10.1016/j.eneco.2011.09.011
   Murty S., 2002, WORKING PAPER
   Peng LH, 2015, ENERG POLICY, V80, P65, DOI 10.1016/j.enpol.2015.01.028
   PITTMAN RW, 1983, ECON J, V93, P883, DOI 10.2307/2232753
   Porter M, 1995, J ECON PERSPECT, V9, P120
   Shao YM, 2017, RESOUR CONSERV RECY, V117, P25, DOI 10.1016/j.resconrec.2015.09.015
   Shephard R.W., 1970, THEORY COST PRODUCTI
   Song ML, 2018, RESOUR CONSERV RECY, V128, P197, DOI 10.1016/j.resconrec.2016.08.015
   Song ML, 2012, RENEW SUST ENERG REV, V16, P4465, DOI 10.1016/j.rser.2012.04.052
   Spitz P., 2005, CHEM IND MILLENNIUM
   Tian YH, 2013, ENERG POLICY, V56, P352, DOI 10.1016/j.enpol.2012.12.068
   Turner R.K., 1993, ENV EC ELEMENTARY IN
   van Soest DP, 2006, EUR ECON REV, V50, P1151, DOI 10.1016/j.euroecorev.2005.02.002
   Wang CH, 2007, ENERGY, V32, P1326, DOI 10.1016/j.energy.2006.10.001
   Wang QW, 2011, ENRGY PROCED, V5, P2316, DOI 10.1016/j.egypro.2011.03.398
   Wang W, 2018, RESOUR CONSERV RECY, V128, P489, DOI 10.1016/j.resconrec.2016.09.005
   Wei C, 2013, ENERG ECON, V40, P22, DOI 10.1016/j.eneco.2013.05.018
   Wei N, 2014, ENRGY PROCED, V63, P7307, DOI 10.1016/j.egypro.2014.11.767
   Wei YM, 2007, ENERGY, V32, P2262, DOI 10.1016/j.energy.2007.07.007
   Xia XH, 2011, ENERG POLICY, V39, P3520, DOI 10.1016/j.enpol.2011.03.051
   Xie BC, 2012, APPL ENERG, V96, P261, DOI 10.1016/j.apenergy.2011.11.011
   Zeng SY, 2017, RESOUR CONSERV RECY, V120, P157, DOI 10.1016/j.resconrec.2016.12.005
   Zhang JX, 2018, RESOUR CONSERV RECY, V132, P269, DOI 10.1016/j.resconrec.2017.02.015
   Zhang N, 2017, SCIENCE, V357, P1107, DOI 10.1126/science.aao6621
   Zhang N, 2015, COMPUT ECON, V46, P389, DOI 10.1007/s10614-014-9467-2
   Zhang N, 2015, TECHNOL FORECAST SOC, V96, P62, DOI 10.1016/j.techfore.2014.10.011
   Zhang N, 2013, ENERG POLICY, V62, P324, DOI 10.1016/j.enpol.2013.07.060
   Zhao XL, 2013, ENERG POLICY, V57, P89, DOI 10.1016/j.enpol.2012.11.037
   Zhou GH, 2013, ENERGY, V50, P302, DOI 10.1016/j.energy.2012.11.045
   Zhou P, 2012, EUR J OPER RES, V221, P625, DOI 10.1016/j.ejor.2012.04.022
   Ziek, 2011, GUARDIAN
NR 56
TC 2
Z9 2
U1 14
U2 27
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 160
EP 167
DI 10.1016/j.resconrec.2019.03.025
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300016
DA 2020-05-12
ER

PT J
AU Rajapaksa, D
   Gifford, R
   Torgler, B
   Garcia-Valinas, M
   Athukorala, W
   Managi, S
   Wilson, C
AF Rajapaksa, Darshana
   Gifford, Robert
   Torgler, Benno
   Garcia-Valinas, Marian
   Athukorala, Wasantha
   Managi, Shunsuke
   Wilson, Clevo
TI Do monetary and non-monetary incentives influence environmental
   attitudes and behavior? Evidence from an experimental analysis
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Pro-environmental behavior; Environmental attitudes; Water consumption
ID RESIDENTIAL WATER DEMAND; CLIMATE-CHANGE; CONSERVATION; PRICE;
   PERCEPTIONS; ELASTICITIES; CONSUMPTION; STRATEGIES; HOUSEHOLDS; SUPPORT
AB There is a wide array of empirical work on the use of monetary and non-monetary measures to manage residential water consumption. However, there has been little focus on exploring the ability to change human attitudes and behavior through offering consumers sustainable resource management. This research helps bridge this gap, through an experimental trial in Brisbane, Australia. Choices of different monetary and non-monetary incentives for managing water demand are offered to survey participants. A structural behavioral model is then developed to identify direct and indirect impacts of attitudes and behavior and which can be compared between separate groups drawn from the survey's participants. Our results suggest that both monetary and non-monetary incentives offered to households significantly reduce water consumption, which is especially so for those holding pro-environmental attitudes/behavior. Importantly, the impact is higher for non-monetary incentives. The results therefore provide valuable insight for the development of long-term sustainable resource management policies.
C1 [Rajapaksa, Darshana; Gifford, Robert; Torgler, Benno; Garcia-Valinas, Marian; Athukorala, Wasantha; Managi, Shunsuke; Wilson, Clevo] Univ Sri Jayewardenepura, Dept Forestry & Environm Sci, Nugegoda, Sri Lanka.
RP Rajapaksa, D (reprint author), Univ Sri Jayewardenepura, Dept Forestry & Environm Sci, Nugegoda, Sri Lanka.
EM darshanarajapaksa@gmail.com
RI Managi, Shunsuke/G-1740-2013; Torgler, Benno/J-1140-2012
OI Managi, Shunsuke/0000-0001-7883-1427; Wilson, Clevo/0000-0002-3885-0495;
   Torgler, Benno/0000-0002-9809-963X; Rajapaksa,
   Darshana/0000-0002-8161-7963
FU Australian Research Council (ARC)Australian Research Council [DP0776795]
FX This work was supported by the Australian Research Council (ARC)
   Discovery Project DP0776795 entitled 'Determining urban water
   conservation and management strategies: a novel approach using field and
   survey data'. Any opinions, findings, and conclusions expressed in this
   material are those of the authors and do not necessarily reflect the
   views of the ARC. Authors also acknowledge the editor and three
   anonymous reviewers for their valuable comments.
CR Arbues F, 2016, URBAN WATER J, V13, P511, DOI 10.1080/1573062X.2014.994004
   Attari SZ, 2014, P NATL ACAD SCI USA, V111, P5129, DOI 10.1073/pnas.1316402111
   Baki S, 2018, SCI TOTAL ENVIRON, V622, P1590, DOI 10.1016/j.scitotenv.2017.10.041
   Beal CD, 2013, J CLEAN PROD, V60, P116, DOI 10.1016/j.jclepro.2011.09.007
   BIRRELL B, 2005, IMPACT DEMOGRAPHIC C
   Botetzagias I, 2015, RESOUR CONSERV RECY, V95, P58, DOI 10.1016/j.resconrec.2014.12.004
   Brown BB, 2016, J ENVIRON PSYCHOL, V46, P188, DOI 10.1016/j.jenvp.2016.04.010
   Carter DW, 2005, LAND ECON, V81, P265, DOI 10.3368/le.81.2.265
   Chenoweth J, 2016, ECOL ECON, V130, P186, DOI 10.1016/j.ecolecon.2016.07.006
   Comerford E, 2014, J ENVIRON MANAGE, V141, P169, DOI 10.1016/j.jenvman.2014.01.049
   Dalhuisen JM, 2003, LAND ECON, V79, P292, DOI 10.2307/3146872
   Dean AJ, 2016, ENVIRON SCI POLICY, V55, P238, DOI 10.1016/j.envsci.2015.10.016
   Distefano T, 2017, ECOL ECON, V142, P130, DOI 10.1016/j.ecolecon.2017.06.019
   Duflo Esther, 2007, HDB DEV EC, V4, P3895, DOI DOI 10.1016/S1573-4471(07)04061-2
   Eluwa SE, 2013, ARPN J EARTH SCI, V2, P81
   Fielding KS, 2013, J ENVIRON MANAGE, V114, P343, DOI 10.1016/j.jenvman.2012.10.027
   Fox C, 2009, LAND USE POLICY, V26, P558, DOI 10.1016/j.landusepol.2008.08.004
   Garcia-Cuerva L, 2016, RESOUR CONSERV RECY, V113, P106, DOI 10.1016/j.resconrec.2016.06.006
   Ghimire M, 2016, J WATER RES PLAN MAN, V142, DOI 10.1061/(ASCE)WR.1943-5452.0000580
   Gilg A, 2006, ECOL ECON, V57, P400, DOI 10.1016/j.ecolecon.2005.04.010
   Goonetilleke A, 2017, ECON ANAL POLICY, V56, P14, DOI 10.1016/j.eap.2017.08.001
   Haque MM, 2014, WATER RESOUR MANAG, V28, P1959, DOI 10.1007/s11269-014-0587-1
   Hayes AF, 2014, BRIT J MATH STAT PSY, V67, P451, DOI 10.1111/bmsp.12028
   Howarth D, 2004, WA SCI TECHNOL, V4, P33
   Hung MF, 2017, ENVIRON ECON POLICY, V19, P249, DOI 10.1007/s10018-016-0154-5
   Jayarathna L, 2017, SUSTAIN CITIES SOC, V32, P67, DOI 10.1016/j.scs.2017.03.012
   Jorgensen BS, 2013, J ENVIRON MANAGE, V115, P124, DOI 10.1016/j.jenvman.2012.11.008
   Kisakye V, 2018, RESOUR CONSERV RECY, V138, P49, DOI 10.1016/j.resconrec.2018.07.009
   Klaiber HA, 2014, LAND ECON, V90, P100, DOI 10.3368/le.90.1.100
   Lanzini P, 2014, J ENVIRON PSYCHOL, V40, P381, DOI 10.1016/j.jenvp.2014.09.006
   Linden A, 2013, HEALTH SERV OUTCOME, V13, P86, DOI 10.1007/s10742-013-0106-5
   Locio M, 2018, WATER RESOUR MANAG, V32, P4123, DOI 10.1007/s11269-018-2049-7
   Maas A, 2017, J ENVIRON MANAGE, V196, P394, DOI 10.1016/j.jenvman.2017.03.008
   Mintz KK, 2019, RESOUR CONSERV RECY, V145, P11, DOI 10.1016/j.resconrec.2019.01.045
   Newton P, 2012, ENVIRON BEHAV, V44, P107, DOI 10.1177/0013916510390494
   Olmstead SM, 2009, WATER RESOUR RES, V45, DOI 10.1029/2008WR007227
   Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879
   Randolph B, 2008, ENVIRON SCI POLICY, V11, P441, DOI 10.1016/j.envsci.2008.03.003
   Ratnasiri S, 2018, ENVIRON ECON POLICY, V20, P547, DOI 10.1007/s10018-017-0205-6
   Steg L, 2014, J ENVIRON PSYCHOL, V38, P104, DOI 10.1016/j.jenvp.2014.01.002
   Steg L, 2009, J ENVIRON PSYCHOL, V29, P309, DOI 10.1016/j.jenvp.2008.10.004
   Tiefenbeck V, 2013, ENERG POLICY, V57, P160, DOI 10.1016/j.enpol.2013.01.021
   von Borgstede C, 2013, ENERG POLICY, V57, P182, DOI 10.1016/j.enpol.2013.01.051
   Vorfismarty C. J., 2010, NATURE, V467, P555
   Wichman CJ, 2014, J ECON BEHAV ORGAN, V107, P308, DOI 10.1016/j.jebo.2014.02.017
   Willis RM, 2013, J CLEAN PROD, V60, P107, DOI 10.1016/j.jclepro.2011.08.006
   Woodridge J, 2007, WHATS NEW ECONOMETRI
   Worthington AC, 2008, J ECON SURV, V22, P842, DOI 10.1111/j.1467-6419.2008.00551.x
   Yan LP, 2018, GEOGR RES-AUST, V56, P54, DOI 10.1111/1745-5871.12244
   Yoshida Y, 2017, J EC STRUCT, V6, P4
   Zhao J, 2016, ECON ANAL POLICY, V51, P90, DOI 10.1016/j.eap.2016.06.003
NR 51
TC 0
Z9 0
U1 13
U2 20
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 168
EP 176
DI 10.1016/j.resconrec.2019.05.034
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300017
DA 2020-05-12
ER

PT J
AU Hu, JY
   Liu, YL
   Yuen, TWW
   Lim, MK
   Hu, JL
AF Hu, Jiayao
   Liu, Yu-Lun
   Yuen, Tsun Wai Wesley
   Lim, Ming Kim
   Hu, Jialun
TI Do green practices really attract customers? The sharing economy from
   the sustainable supply chain management perspective
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Sharing economy; Sustainable supply chain management; Customer
   intention; Mixed methods research
ID CONSUMER ENVIRONMENTAL AWARENESS; SOCIAL SUSTAINABILITY; CONSUMPTION;
   PERFORMANCE; FRAMEWORK; ATTITUDES; QUALITY; ANTECEDENTS; BENEFITS;
   LOYALTY
AB The notion of the sharing economy has been introduced in many sectors and provided significant benefits to consumers and asset owners. Despite the remarkable improvement of the sharing economy in recent years, its relationship with sustainability remains insufficiently researched. This study adopts a sustainable supply chain management (SSCM) perspective. A large-scale survey with 420 participants showed that investment recovery (IR) practices and corporate social responsibility (CSR) conducted by sharing economy platforms significantly and positively affect customers' intention to use sharing economy-based services/products, whereas internal green management (IGM), supplier green management (SGM), eco-design (ECD) and customer green management (CGM) practices do not. A follow-up qualitative study with ten participants provided further explanations and supported the findings of the survey. This study links the sharing economy and sustainability by testing the effectiveness of sharing economy platforms' sustainable practices and proposes the best practices for sharing economy platforms to maintain a long-term sustainable marketplace.
C1 [Hu, Jiayao] Coventry Univ, Sch Strategy & Leadership, Ctr Business Soc, 117 William Morris Bldg,Priory St, Coventry, W Midlands, England.
   [Liu, Yu-Lun] Univ Kent, Natl Taipei Univ Technol, Giles Lane, Canterbury, Kent, England.
   [Yuen, Tsun Wai Wesley] Univ Manchester, Oxford Rd, Manchester, Lancs, England.
   [Lim, Ming Kim] ChongQing Univ, Coll Mech Engn, Bldg 7,174 Shazheng St, Chongqing, Peoples R China.
   [Hu, Jialun] Coventry Univ, Sch Strategy & Leadership, 116 William Morris Bldg,Priory St, Coventry, W Midlands, England.
RP Liu, YL (reprint author), Univ Kent, Natl Taipei Univ Technol, Giles Lane, Canterbury, Kent, England.
EM ac5218@coventry.ac.uk; y.l.liu@kent.ac.uk;
   tsunwai.yuen@manchester.ac.uk; ming.lim@cqu.edu.cn;
   ac0047@coventry.ac.uk
RI Lim, Ming K/D-1476-2017
OI Lim, Ming K/0000-0003-0809-9431; Yuen, Tsun Wai/0000-0003-3732-7317; HU,
   JIAYAO/0000-0002-5970-0154
CR Ahmad S, 2018, RESOUR CONSERV RECY, V132, P49, DOI 10.1016/j.resconrec.2018.01.020
   Ahmadi HB, 2017, RESOUR CONSERV RECY, V126, P99, DOI 10.1016/j.resconrec.2017.07.020
   Albino V, 2004, RESOUR CONSERV RECY, V41, P165, DOI 10.1016/j.resconrec.2003.09.006
   Baird Carolyn Heller, 2011, Strategy & Leadership, V39, P30, DOI 10.1108/10878571111161507
   Belk R, 2007, ANN AM ACAD POLIT SS, V611, P126, DOI 10.1177/0002716206298483
   Belk R, 2014, J BUS RES, V67, P1595, DOI 10.1016/j.jbusres.2013.10.001
   Bocker L, 2017, ENVIRON INNOV SOC TR, V23, P28, DOI 10.1016/j.eist,2016.09,004
   Buhrmester M, 2011, PERSPECT PSYCHOL SCI, V6, P3, DOI 10.1177/1745691610393980
   Campbell J, 2014, INT J HOSP MANAG, V42, P39, DOI 10.1016/j.ijhm.2014.05.014
   Carter CR, 2011, INT J PHYS DISTR LOG, V41, P46, DOI 10.1108/09600031111101420
   Carter CR, 2008, INT J PHYS DISTR LOG, V38, P360, DOI 10.1108/09600030810882816
   Chen IJ, 2004, J OPER MANAG, V22, P119, DOI 10.1016/j.jom.2003.12.007
   Chi CG, 2009, INT J HOSP MANAG, V28, P245, DOI 10.1016/j.ijhm.2008.08.003
   Christopher M., 1998, LOGISTICS SUPPLY CHA
   Costa AIA, 2004, TRENDS FOOD SCI TECH, V15, P403, DOI 10.1016/j.tifs.2004.02.005
   De Giovanni P, 2012, INT J OPER PROD MAN, V32, P265, DOI 10.1108/01443571211212574
   Demailly D., 2014, SHARING EC MAKE IT S
   Eckhard G. M., 2015, HARV BUS REV
   Eisenhardt KM, 2007, ACAD MANAGE J, V50, P25, DOI 10.5465/AMJ.2007.24160888
   Flynn BB, 2010, J OPER MANAG, V28, P58, DOI 10.1016/j.jom.2009.06.001
   FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312
   de Leaniz PMG, 2015, J HOSP MARKET MANAG, V24, P1, DOI 10.1080/19368623.2014.891961
   GUTMAN J, 1982, J MARKETING, V46, P60, DOI 10.2307/3203341
   Guttentag D, 2015, CURR ISSUES TOUR, V18, P1192, DOI 10.1080/13683500.2013.827159
   Hair J.F., 2006, MULTIVARIATE DATA AN
   Hamari J, 2016, J ASSOC INF SCI TECH, V67, P2047, DOI 10.1002/asi.23552
   Han H, 2011, INT J HOSP MANAG, V30, P345, DOI 10.1016/j.ijhm.2010.07.008
   Hartmann P, 2006, MARK INTELL PLAN, V24, P673, DOI 10.1108/02634500610711842
   Hassini E, 2012, INT J PROD ECON, V140, P69, DOI 10.1016/j.ijpe.2012.01.042
   Heinrichs H, 2013, GAIA, V22, P228, DOI 10.14512/gaia.22.4.5
   Holmes TJ, 2012, J FOOD PROD MARK, V18, P369, DOI 10.1080/10454446.2012.685029
   Howard J, 1977, CONSUMER BEHAV APPL
   Hsu CC, 2016, INT J OPER PROD MAN, V36, P86, DOI 10.1108/IJOPM-06-2014-0252
   Hutcheson GD, 1999, MULTIVARIATE SOCIAL
   Jamali D, 2007, J BUS ETHICS, V72, P243, DOI 10.1007/s10551-006-9168-4
   Jung HS, 2013, INT J HOSP MANAG, V34, P1, DOI 10.1016/j.ijhm.2013.02.003
   Kang KH, 2012, INT J HOSP MANAG, V31, P564, DOI 10.1016/j.ijhm.2011.08.001
   Keating B, 2008, SUPPLY CHAIN MANAG, V13, P175, DOI 10.1108/13598540810871217
   Kuo TC, 2019, RESOUR CONSERV RECY, V146, P384, DOI 10.1016/j.resconrec.2019.04.007
   Lai K., 2008, INT J PROD ECON, V111, P261
   Liu SQ, 2017, INT J HOSP MANAG, V60, P33, DOI 10.1016/j.ijhm.2016.09.012
   Lo A, 2015, J HOSP MARKET MANAG, V24, P155, DOI 10.1080/19368623.2014.885872
   Lyons G, 2018, RESOUR CONSERV RECY, V132, P246, DOI 10.1016/j.resconrec.2017.07.032
   Manaktola K., 2007, INT J CONT HOSPITALI, V19, P364, DOI DOI 10.1108/09596110710757534
   Mani V, 2016, RESOUR CONSERV RECY, V111, P42, DOI 10.1016/j.resconrec.2016.04.003
   Marchi A., 2016, MCKINSEY Q, V2016, P112
   Martha C C, 1993, INT J LOGIST MANAG, V4, P13, DOI DOI 10.1108/09574099310804957
   Martin CJ, 2016, ECOL ECON, V121, P149, DOI 10.1016/j.ecolecon.2015.11.027
   Martinez P, 2013, INT J HOSP MANAG, V35, P89, DOI 10.1016/j.ijhm.2013.05.009
   Mathivathanan D, 2018, RESOUR CONSERV RECY, V128, P284, DOI 10.1016/j.resconrec.2017.01.003
   Milanova V, 2017, J BUS RES, V75, P159, DOI 10.1016/j.jbusres.2017.02.002
   Miles MB, 2016, QUALITATIVE DATA ANA
   Miles MP, 2000, J BUS ETHICS, V23, P299, DOI 10.1023/A:1006214509281
   Mintel, 2018, EUR CONS TREND
   Narasimhan C, 2018, CUST NEEDS SOLUT, V5, P93, DOI DOI 10.1007/S40547-017-0079-6
   Nikolaeva R, 2011, J ACAD MARKET SCI, V39, P136, DOI 10.1007/s11747-010-0214-5
   Oyedele A, 2018, J SERV MARK, V32, P161, DOI 10.1108/JSM-09-2016-0344
   Ozanne LK, 2010, J CONSUM BEHAV, V9, P485, DOI 10.1002/cb.334
   Prokesch S., 2010, HARVARD BUS REV, V88, P70
   PwC, 2015, SHARING EC SIZING RE
   Roos D, 2017, J BUS RES, V77, P113, DOI 10.1016/j.jbusres.2017.04.011
   Samu S, 2009, J BUS RES, V62, P432, DOI 10.1016/j.jbusres.2008.01.039
   Sanchez-Fernandez R, 2009, J RETAIL CONSUM SERV, V16, P425, DOI 10.1016/j.jretconser.2009.06.003
   Scaggs A., 2017, FINANCIAL TIMES ALPH
   Scavarda A, 2019, RESOUR CONSERV RECY, V141, P418, DOI 10.1016/j.resconrec.2018.10.027
   Seuring S, 2008, J CLEAN PROD, V16, P1699, DOI 10.1016/j.jclepro.2008.04.020
   Shah R, 2006, J OPER MANAG, V24, P148, DOI 10.1016/j.jom.2005.05.001
   Shah R, 2007, J OPER MANAG, V25, P785, DOI 10.1016/j.jom.2007.01.019
   Shi L, 2017, RESOUR CONSERV RECY, V119, P24, DOI 10.1016/j.resconrec.2016.08.014
   Tarfasa S, 2013, APPL ECON, V45, P1099, DOI 10.1080/00036846.2011.613793
   Tussyadiah I.P., 2016, INFORM COMMUNICATION, P695
   Vachon S, 2008, INT J PROD ECON, V111, P299, DOI 10.1016/j.ijpe.2006.11.030
   Vachon S, 2006, INT J OPER PROD MAN, V26, P795, DOI 10.1108/01443570610672248
   Wagner T, 2009, J MARKETING, V73, P77, DOI 10.1509/jmkg.73.6.77
   Worthington RL, 2006, COUNS PSYCHOL, V34, P806, DOI 10.1177/0011000006288127
   Xu X, 2015, INT J HOSP MANAG, V49, P105, DOI 10.1016/j.ijhm.2015.06.003
   Yang S, 2017, J SERV MARK, V31, P48, DOI 10.1108/JSM-01-2016-0042
   Yang XS, 2019, RESOUR CONSERV RECY, V146, P55, DOI 10.1016/j.resconrec.2019.03.005
   Yin R. K., 2017, CASE STUDY RES APPL
   YOUNG S, 1975, J MARKETING, V39, P72, DOI 10.2307/1250907
   Zhang LH, 2019, J CLEAN PROD, V213, P1063, DOI 10.1016/j.jclepro.2018.12.187
   Zhang LH, 2015, EUR J OPER RES, V241, P63, DOI 10.1016/j.ejor.2014.07.043
   Zhang MH, 2018, RESOUR CONSERV RECY, V128, P206, DOI 10.1016/j.resconrec.2016.06.015
   Zhang Tiehua, 2020, Crit Rev Food Sci Nutr, V60, P94, DOI 10.1080/10408398.2018.1514580
   Zhu QH, 2013, J PURCH SUPPLY MANAG, V19, P106, DOI 10.1016/j.pursup.2012.12.001
   Zhu QH, 2012, INT J PROD RES, V50, P1377, DOI 10.1080/00207543.2011.571937
   Zhu QY, 2018, RESOUR CONSERV RECY, V132, P1, DOI 10.1016/j.resconrec.2018.01.010
NR 87
TC 7
Z9 7
U1 15
U2 43
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 177
EP 187
DI 10.1016/j.resconrec.2019.05.042
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300018
DA 2020-05-12
ER

PT J
AU Wu, JN
   Lv, JW
   Shang, JW
   Guo, Y
   Pu, GY
AF Wu Junnian
   Lv Jingwen
   Shang Jiangwei
   Guo Yan
   Pu Guangying
TI Evaluating chromium coupled with carbon metabolism and environmental
   performance in the chromate industrial symbiosis network in China
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Industrial symbiosis (IS); Ecological network analysis (ENA); Chromium
   metabolism; Carbon metabolism; Chromate industrial symbiosis network
ID INPUT-OUTPUT-ANALYSIS; PARK; FOOTPRINT; URBAN; PERSPECTIVE; CONSUMPTION;
   EFFICIENCY; ECONOMY; SYSTEM
AB The pollution of toxic and carcinogenic chromium slags of the chromate industry has been a public concern and industrial symbiosis is proved to be feasible and efficient in recycling chromium slags. How to appraise and improve sustainability of chromate industrial symbiosis networks is still an open problem where functional and structural performance are key approaches to solve. This paper aims to explore chromium and carbon metabolic behavior of a chromate industrial symbiosis network with ecological network analysis at infra-firm level. Results show that industrial symbiosis reduces chromium slags emissions and improves resource utilization efficiency. Influenced by flow type and quantity, the chromium metabolism realizes mutualism but the carbon metabolism fails due to intense competition for carbon resource among the recycling processes (the aluminum hydroxide, sodium sulfide and alloy steel processes). The sodium dichromate process is the largest controller on the chromium and carbon metabolism and the sodium sulfide and alloy steel processes both rely on carbon resource support of the sodium dichromate process even to 100% which may explain the intense competition. Under disharmonious connection pattern of metabolic processes, structural defects both occur to the chromium and carbon metabolism. Even though, the chromium metabolism is closed to the stable condition while the carbon metabolism still requires more network efficiency. Overall, the combination of chromium and carbon metabolism provide more details in exploring metabolic behavior of the chromate industrial symbiosis network. The applied method may be helpful to refine management and optimization in developing industrial symbiosis.
C1 [Wu Junnian; Lv Jingwen; Shang Jiangwei; Guo Yan; Pu Guangying] Lanzhou Univ, Coll Earth & Environm Sci, Gansu Key, Lab Environm Pollut Predict & Control, Lanzhou 730000, Gansu, Peoples R China.
RP Wu, JN (reprint author), Lanzhou Univ, Coll Earth & Environm Scientes, Lanzhou, Gansu, Peoples R China.
EM wu_jn@lzu.edu.cn
CR Bansal P, 2009, J SUPPLY CHAIN MANAG, V45, P26, DOI 10.1111/j.1745-493X.2009.03174.x
   Borrett SR, 2003, ECOL MODEL, V170, P173, DOI 10.1016/S0304-3800(03)00224-2
   Chen B, 2014, ECOL INDIC, V47, P5, DOI 10.1016/j.ecolind.2014.09.021
   Chen SQ, 2015, RENEW SUST ENERG REV, V42, P78, DOI 10.1016/j.rser.2014.10.017
   Fan YP, 2017, J CLEAN PROD, V142, P1552, DOI 10.1016/j.jclepro.2016.11.149
   Fath BD, 2006, ENVIRON MODELL SOFTW, V21, P375, DOI 10.1016/j.envsoft.2004.11.007
   Fath BD, 2004, ECOL MODEL, V179, P235, DOI 10.1016/j.ecolmodel.2004.06.007
   Fath BD, 1999, ECOL MODEL, V123, P193, DOI 10.1016/S0304-3800(99)00130-1
   Fath BD, 1999, ECOSYSTEMS, V2, P167, DOI 10.1007/s100219900067
   Fath B, 2007, ECOL MODEL, V208, P56, DOI 10.1016/j.ecolmodel.2007.04.021
   Gao TM, 2016, J CLEAN PROD, V112, P553, DOI 10.1016/j.jclepro.2015.08.054
   Han F, 2016, J CLEAN PROD, V133, P459, DOI 10.1016/j.jclepro.2016.05.184
   He H, 2019, APPL ENERG, V240, P766, DOI 10.1016/j.apenergy.2019.02.081
   Heihsel M, 2019, DESALINATION, V454, P71, DOI 10.1016/j.desal.2018.12.008
   Herczeg G, 2018, J CLEAN PROD, V171, P1058, DOI 10.1016/j.jclepro.2017.10.046
   Huang SH, 2009, T NONFERR METAL SOC, V19, P756, DOI 10.1016/S1003-6326(08)60346-5
   Kazanci C, 2012, ECOL MODEL, V242, P180, DOI 10.1016/j.ecolmodel.2012.05.021
   Kazanci C, 2007, ECOL MODEL, V208, P3, DOI 10.1016/j.ecolmodel.2007.04.031
   Lane J. L, 2019, J CLEAN PROD
   Lenzen M, 2007, ECOL MODEL, V200, P334, DOI 10.1016/j.ecolmodel.2006.07.041
   Leontief W, 1951, INPUT OUTPUT EC
   Leontief W. W, 1936, REV ECON STAT, V18, P21
   Li XM, 2017, ECOL INDIC, V74, P403, DOI 10.1016/j.ecolind.2016.11.031
   Li Y, 2011, ECOL MODEL, V222, P1771, DOI 10.1016/j.ecolmodel.2011.03.001
   Liu CH, 2015, WASTE MANAGE RES, V33, P363, DOI 10.1177/0734242X15574562
   Lobanova G, 2007, EXPLORING SIMPLE STR
   Long Y, 2019, APPL ENERG, V236, P379, DOI 10.1016/j.apenergy.2018.12.002
   Lu Y, 2015, ENVIRON SCI TECHNOL, V49, P7254, DOI 10.1021/es5056758
   Ma SJ, 2015, J CLEAN PROD, V87, P839, DOI 10.1016/j.jclepro.2014.10.059
   Makarichi L, 2018, RESOUR CONSERV RECY, V139, P351, DOI 10.1016/j.resconrec.2018.07.024
   Morris JT, 2005, AQUATIC FOOD WEBS: AN ECOSYSTEM APPROACH, P73
   Na HM, 2017, ECOL MODEL, V365, P45, DOI 10.1016/j.ecolmodel.2017.09.023
   PAINE RT, 1969, AM NAT, V103, P91, DOI 10.1086/282586
   Patten B.C., 1991, THEORETICAL STUDIES, P288
   PATTEN BC, 1981, AM NAT, V117, P893, DOI 10.1086/283777
   Rostas L., 1941, REV EC, V4, P124
   Tian ZZ, 2019, ENRGY PROCED, V158, P4049, DOI 10.1016/j.egypro.2019.01.833
   Ulanowicz R. E, 2015, Q REV BIOL, V22
   Ulanowicz RE, 2004, COMPUT BIOL CHEM, V28, P321, DOI 10.1016/j.compbiolchem.2004.09.001
   Ulanowicz RE, 2000, ENVIRONM & ECOL MODE, P303
   Wu JN, 2015, J CLEAN PROD, V95, P156, DOI 10.1016/j.jclepro.2015.02.041
   Wu XD, 2019, SCI TOTAL ENVIRON, V662, P65, DOI 10.1016/j.scitotenv.2019.01.108
   Zhang H, 2013, ENERG POLICY, V61, P1400, DOI 10.1016/j.enpol.2013.05.066
   Zhang Q, 2018, J CLEAN PROD, V172
   Zhang Y, 2015, ECOL MODEL, V306, P174, DOI 10.1016/j.ecolmodel.2014.05.005
   Zhang Y, 2015, J CLEAN PROD, V96, P126, DOI 10.1016/j.jclepro.2014.01.096
   Zhang Y, 2009, ECOL MODEL, V220, P1431, DOI 10.1016/j.ecolmodel.2009.02.001
NR 47
TC 1
Z9 1
U1 9
U2 22
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 188
EP 196
DI 10.1016/j.resconrec.2019.05.016
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300019
DA 2020-05-12
ER

PT J
AU Guo, HW
   Zhao, Y
   Damgaard, A
   Wang, Q
   Lu, WJ
   Wang, HT
   Christensen, TH
AF Guo, Hanwen
   Zhao, Yan
   Damgaard, Anders
   Wang, Qian
   Lu, Wenjing
   Wang, Hongtao
   Christensen, Thomas H.
TI Material flow analysis of alternative biorefinery systems for managing
   Chinese food waste
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Food waste; Biorefinery; Material flow analysis; Substance flow
   analysis; Scenario inventory
ID ANAEROBIC CO-DIGESTION; FUEL ETHANOL; BIODIESEL PRODUCTION; KITCHEN
   WASTE; BIOGAS; ENERGY; EFFICIENCY; PERFORMANCES; FERMENTATION;
   PRETREATMENT
AB Consistent material and substance flow diagrams for five alternative biorefinery scenarios for treating Chinese food waste were obtained by combining reported experimental research data and material flow analysis. The biorefinery alternatives produced biogas, biomethane, bioethanol and biodiesel in various combinations. The compiled statistical data compiled showed that 100 t of Chinese food waste could produce 16 +/- 1.1 t of biogas as a single technology and that other advanced biorefinery concepts could produce 5 +/- 0.4 t of biomethane, 4 +/- 1.6 t of bioethanol and/or 3 +/- 0.2 t of biodiesel. In terms of substance flow, biorefinery scenarios transfer up to 75% of the total initial carbon in the food waste into bioproducts, while 22% of carbon is emitted, primarily as carbon dioxide. The compost obtained by composting the dewatered digestate contained about 75% of input P, 27% of input K and 6% of input N. About 15% of input N was lost to the air during composting. The remaining C, N, P and K were in the wastewater. Introducing biorefinery concepts to the management of Chinese food waste can facilitate the generation of high-value bioproducts. However, biorefinery concepts are technologically complicated and the energy consumption may triple relative to that of only biogas production, The issue of a considerably large liquid fraction in all cases still needs to be addressed. The material flow diagrams in this work constitute a consistent platform for assessing future scenarios for treating Chinese food waste from a technical, economical as well environmental perspective.
C1 [Guo, Hanwen; Wang, Qian; Lu, Wenjing; Wang, Hongtao] Tsinghua Univ, Sch Environm, Beijing 100084, Peoples R China.
   [Zhao, Yan] Beijing Normal Univ, Sch Environm, Beijing 100875, Peoples R China.
   [Damgaard, Anders; Christensen, Thomas H.] Tech Univ Denmark, Dept Environm Engn, DK-2800 Lyngby, Denmark.
RP Lu, WJ (reprint author), Tsinghua Univ, Sch Environm, Beijing 100084, Peoples R China.; Christensen, TH (reprint author), Tech Univ Denmark, Dept Environm Engn, DK-2800 Lyngby, Denmark.
EM luwenjing@tsinghua.edu.cn; thho@env.dtu.dk
RI Damgaard, Anders/H-9234-2012
OI Damgaard, Anders/0000-0002-0452-1220
FU National Key R&D Program of China [2018YFD1100605]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [51578071]; China Scholarship Council (CSC)China Scholarship Council
   [201606210401]; Tsinghua University Initiative Scientific Research
   Program
FX The present study was supported by the National Key R&D Program of China
   (Grant No. 2018YFD1100605), the National Natural Science Foundation of
   China (Grant No.51578071), the China Scholarship Council (CSC:
   No.201606210401) and Tsinghua University Initiative Scientific Research
   Program.
CR Balat M, 2011, ENERG CONVERS MANAGE, V52, P858, DOI 10.1016/j.enconman.2010.08.013
   Bernstad A, 2011, WASTE MANAGE, V31, P1879, DOI 10.1016/j.wasman.2011.02.026
   Cencic O, 2008, J ENV ENG MANAG, V18, P3
   Cesaro A, 2015, ENERGIES, V8, P8121, DOI 10.3390/en8088121
   Cherubini F, 2010, ENERG CONVERS MANAGE, V51, P1412, DOI 10.1016/j.enconman.2010.01.015
   Christensen T. H., 2015, SARD 2015 15 INT WAS, P5
   Clavreul J, 2014, ENVIRON MODELL SOFTW, V60, P18, DOI 10.1016/j.envsoft.2014.06.007
   Coma M, 2017, FARADAY DISCUSS, V202, P175, DOI 10.1039/c7fd00070g
   Design P., 2006, DESIGN, P1
   Ebner J, 2014, APPL ENERG, V130, P86, DOI 10.1016/j.apenergy.2014.04.099
   Esposite E., 2019, SIMULTANEOUS PRODUCT, P281, DOI [10.1039/c8ee02897d, DOI 10.1039/C8EE02897D]
   Fuldauer LI, 2018, J CLEAN PROD, V185, P929, DOI 10.1016/j.jclepro.2018.03.045
   Gaudino EC, 2019, GREEN CHEM, V21, P1202, DOI 10.1039/c8gc03908a
   Hahn H, 2014, RENEW SUST ENERG REV, V29, P383, DOI 10.1016/j.rser.2013.08.085
   Hayes AC, 2016, WASTE MANAGE, V58, P70, DOI 10.1016/j.wasman.2016.09.043
   He MN, 2012, PROCEDIA ENVIRON SCI, V16, P85, DOI 10.1016/j.proenv.2012.10.012
   Heimann K., 2016, SPRINGER NATURE, DOI [10.1007/978-981-10-0150-5, DOI 10.1007/978-981-10-0150-5]
   Hao HTN, 2015, ENERGIES, V8, P6350, DOI 10.3390/en8076350
   IEA, 2012, IEA BIOENERGY
   Jensen MB, 2017, WASTE MANAGE, V66, P23, DOI 10.1016/j.wasman.2017.03.029
   Jian H., 2010, RES ENV SCI, V23, P521
   Jin YY, 2015, APPL ENERG, V151, P227, DOI 10.1016/j.apenergy.2015.04.058
   Karmee S.K., 2014, SUSTAIN CHEM PROCESS, V2, P22, DOI DOI 10.1186/S40508-014-0022-1
   Karmee SK, 2016, RENEW SUST ENERG REV, V53, P945, DOI 10.1016/j.rser.2015.09.041
   Karmee SK, 2015, WASTE MANAGE, V41, P169, DOI 10.1016/j.wasman.2015.03.025
   Kiran EU, 2015, J CHEM TECHNOL BIOT, V90, P1364, DOI 10.1002/jctb.4551
   Koike Y, 2009, J BIOSCI BIOENG, V108, P508, DOI 10.1016/j.jbiosc.2009.06.007
   Lavelli V, 2018, FOOD FUNCT, V9, P1353, DOI 10.1039/c7fo01747b
   Li YY, 2016, APPL ENERG, V172, P47, DOI 10.1016/j.apenergy.2016.03.080
   Lin CSK, 2013, ENERG ENVIRON SCI, V6, P426, DOI 10.1039/c2ee23440h
   Lopez VM, 2016, WASTE MANAGE, V56, P477, DOI 10.1016/j.wasman.2016.07.024
   Lv F., 2017, ENV SANIT ENG
   Ma HZ, 2008, INT J GREEN ENERGY, V5, P480, DOI 10.1080/15435070802498176
   Ma KD, 2016, BIORESOURCE TECHNOL, V203, P295, DOI 10.1016/j.biortech.2015.12.054
   Ma K, 2009, BIORESOURCE TECHNOL, V100, P2289, DOI 10.1016/j.biortech.2008.11.010
   Miezah K, 2017, WASTE BIOMASS VALORI, V8, P115, DOI 10.1007/s12649-016-9566-5
   Moller K., 2016, ASSESSMENT ALTERATIV
   Patterson T, 2011, ENERG POLICY, V39, P1806, DOI 10.1016/j.enpol.2011.01.017
   Poschl M, 2010, APPL ENERG, V87, P3305, DOI 10.1016/j.apenergy.2010.05.011
   Quiroz-Arita C, 2017, ALGAL RES, V26, P445, DOI 10.1016/j.algal.2017.06.021
   Rudroff S. F., 2017, GREEN CHEM, V19, P367, DOI [10.1039/c6gc01138a, DOI 10.1039/C6GC01138A]
   Ryckebosch E, 2011, BIOMASS BIOENERG, V35, P1633, DOI 10.1016/j.biombioe.2011.02.033
   Sakuragi K, 2016, ENERGIES, V9, DOI 10.3390/en9020106
   Sawatdeenarunat C, 2016, BIORESOURCE TECHNOL, V215, P304, DOI 10.1016/j.biortech.2016.03.074
   Shen F, 2013, BIORESOURCE TECHNOL, V144, P80, DOI 10.1016/j.biortech.2013.06.099
   Sherwood J., 2018, GREEN CHEM, V20, P2064, DOI [10.1039/c8gc00358k, DOI 10.1039/C8GC00358K]
   Stoknes K, 2016, WASTE MANAGE, V56, P466, DOI 10.1016/j.wasman.2016.06.027
   Sun YF, 2013, J ENVIRON SCI-CHINA, V25, P2112, DOI 10.1016/S1001-0742(12)60236-8
   Tampio E, 2016, J CLEAN PROD, V125, P22, DOI 10.1016/j.jclepro.2016.03.127
   Tan L, 2014, BIOPROC BIOSYST ENG, V37, P2031, DOI 10.1007/s00449-014-1178-5
   Tang YQ, 2008, BIOMASS BIOENERG, V32, P1037, DOI 10.1016/j.biombioe.2008.01.027
   Tao F, 2005, PROCESS BIOCHEM, V40, P183, DOI 10.1016/j.procbio.2003.11.054
   Torres EA, 2013, WASTE MANAGE, V33, P2670, DOI 10.1016/j.wasman.2013.07.030
   Uncu ON, 2011, WASTE MANAGE, V31, P636, DOI 10.1016/j.wasman.2010.12.007
   Wang CM, 2017, WASTE BIOMASS VALORI, V8, P369, DOI 10.1007/s12649-016-9606-1
   Wang L, 2018, SCI TOTAL ENVIRON, V631-632, P1321, DOI 10.1016/j.scitotenv.2018.03.103
   Wen ZG, 2016, J CLEAN PROD, V118, P88, DOI 10.1016/j.jclepro.2015.12.087
   Woon KS, 2016, WASTE MANAGE, V50, P290, DOI 10.1016/j.wasman.2016.02.022
   Wu CF, 2015, ENERG FUEL, V29, P6494, DOI 10.1021/acs.energyfuels.5b01507
   Wu LJ, 2015, ENERG CONVERS MANAGE, V106, P1174, DOI 10.1016/j.enconman.2015.10.059
   Yan SB, 2013, BIOPROC BIOSYST ENG, V36, P937, DOI 10.1007/s00449-012-0827-9
   Yang SG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029652
   Yong ZH, 2015, RENEW ENERG, V78, P527, DOI 10.1016/j.renene.2015.01.033
   Yu IKM, 2017, BIORESOURCE TECHNOL, V237, P222, DOI 10.1016/j.biortech.2017.01.017
   Zhang CS, 2013, BIORESOURCE TECHNOL, V129, P170, DOI 10.1016/j.biortech.2012.10.138
   Zhang L, 2011, BIORESOURCE TECHNOL, V102, P5048, DOI 10.1016/j.biortech.2011.01.082
   Zhang Y, 2012, J ENVIRON MANAGE, V104, P166, DOI 10.1016/j.jenvman.2012.03.043
   Zhang ZY, 2016, CURR OPIN BIOTECH, V38, P97, DOI 10.1016/j.copbio.2016.01.010
   Zhao Y, 2015, WASTE MANAGE, V42, P55, DOI 10.1016/j.wasman.2015.04.021
   Zhou Q, 2014, BIORESOURCE TECHNOL, V166, P31, DOI 10.1016/j.biortech.2014.04.074
NR 70
TC 1
Z9 1
U1 18
U2 30
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 197
EP 209
DI 10.1016/j.resconrec.2019.05.010
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300020
DA 2020-05-12
ER

PT J
AU Ribeiro, AP
   Rok, J
   Harmsen, R
   Carreon, JR
   Worrell, E
AF Ribeiro, Ana Pocas
   Rok, Jakub
   Harmsen, Robert
   Carreon, Jesus Rosales
   Worrell, Ernst
TI Food waste in an alternative food network - A case-study
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Food waste; Alternative food networks; Food waste management; Food waste
   prevention; Retail
ID RETAIL; PREVENTION; PRODUCTS; LOSSES
AB This paper investigates food waste dynamics in a retail alternative food network (AFN). We provide a first contribution to assess food waste in an AFN in terms of 1) food waste levels, 2) food waste causes, and 3) food waste management practices (i.e. food waste reduction and handling). We use an exploratory case-study to investigate food waste in a Polish AFN. We place the results of this case-study in the context of conventional retail, by reviewing retail food waste literature. Quantitative results show that food waste levels at the AFN are very low compared to conventional retail literature. Qualitative results show that food waste causes at the AFN are partly shared with conventional retail, and partly specific to the AFN. Possible explanations for low food waste are provided by the food waste management strategies, in which food waste prevention is a key component of the AFN practices.
   Two other possible explanations are the degree of flexibility and the main drivers of the organization. Conventional retail is ruled by top-down policies, focusing on profit-maximization. The AFN we studied is small-scale, independently organized, and non-profit. Its main driver is to balance financial viability, accessibility and ethical guidelines. Looking beyond profit allows for a high concern with food waste, while the autonomy of the organization gives its members flexibility to develop ways to prevent and handle food waste. Future research can build on our approach of combining food waste estimations with qualitative investigation of food waste causes and management practices. Food waste dynamics should be further investigated in other (retail) AFNs, in small-scale conventional and organic food retail, and in small and large-scale cooperative supermarkets.
C1 [Ribeiro, Ana Pocas; Harmsen, Robert; Carreon, Jesus Rosales; Worrell, Ernst] Copernicus Inst Sustainable Dev, NL-3508 TC Utrecht, Netherlands.
   [Rok, Jakub] Univ Warsaw, Ctr European Reg & Local Studies EUROREG, Warsaw, Poland.
RP Ribeiro, AP (reprint author), Copernicus Inst Sustainable Dev, NL-3508 TC Utrecht, Netherlands.
EM a.s.pocasribeiro@uu.nl
RI Worrell, Ernst/L-5455-2013
OI Worrell, Ernst/0000-0002-0199-9755; Pocas Ribeiro,
   Ana/0000-0001-7611-1055
FU Netherlands Organisation for Scientific Research (NWO) in the project
   Transitioning to Sustainable Energy SystemsNetherlands Organization for
   Scientific Research (NWO) [22.004.023]
FX This work was supported by the Netherlands Organisation for Scientific
   Research (NWO) in the project Transitioning to Sustainable Energy
   Systems [22.004.023].
CR Alexander C, 2008, RESOUR CONSERV RECY, V52, P1290, DOI 10.1016/j.resconrec.2008.07.009
   Aschemann-Witzel J, 2015, SUSTAINABILITY-BASEL, V7, P6457, DOI 10.3390/su7066457
   Beretta C, 2013, WASTE MANAGE, V33, P764, DOI 10.1016/j.wasman.2012.11.007
   Born B, 2006, J PLAN EDUC RES, V26, P195, DOI 10.1177/0739456X06291389
   Brautigam KR, 2014, WASTE MANAGE RES, V32, P683, DOI 10.1177/0734242X14545374
   Cicatiello C, 2017, RESOUR CONSERV RECY, V125, P273, DOI 10.1016/j.resconrec.2017.06.010
   Douthwaite R., 1996, SHORT CIRCUIT STRENG
   Eriksson M, 2012, RESOUR CONSERV RECY, V68, P14, DOI 10.1016/j.resconrec.2012.08.001
   Filimonau V, 2017, J CLEAN PROD, V167, P1184, DOI 10.1016/j.jclepro.2017.07.229
   Forssell S, 2015, AGR HUM VALUES, V32, P63, DOI 10.1007/s10460-014-9516-4
   FSIN, 2018, GLOB REP FOOD CRIS 2, P202
   Gjerris M, 2013, ETIKK PRAKSIS, V7, P6
   Gruber V, 2016, J PUBLIC POLICY MARK, V35, P3, DOI 10.1509/jppm.14.095
   Gustavsson J, 2011, RESOUR CONSERV RECY, V55, P554, DOI 10.1016/j.resconrec.2011.01.007
   Holweg C, 2016, INT J PHYS DISTR LOG, V46, P634, DOI 10.1108/IJPDLM-11-2014-0285
   ICA, 2018, COOP ID VAL PRINC
   Kantor L. S., 1997, FoodReview, V20, P2
   Katajajuuri JM, 2014, J CLEAN PROD, V73, P322, DOI 10.1016/j.jclepro.2013.12.057
   Kotzab H, 2005, BRIT FOOD J, V107, P594, DOI 10.1108/00070700510610995
   Lebersorger S, 2014, WASTE MANAGE, V34, P1911, DOI 10.1016/j.wasman.2014.06.013
   Mena C, 2011, RESOUR CONSERV RECY, V55, P648, DOI 10.1016/j.resconrec.2010.09.006
   Parfitt J, 2010, PHILOS T R SOC B, V365, P3065, DOI 10.1098/rstb.2010.0126
   Patel R., 2007, STUFFED AND STARVED
   Priefer C, 2016, RESOUR CONSERV RECY, V109, P155, DOI 10.1016/j.resconrec.2016.03.004
   Principato L, 2018, SPRINGERBR ENV SCI, P1, DOI 10.1007/978-3-319-78887-6
   Ribeiro AP, 2019, J CLEAN PROD, V209, P200, DOI 10.1016/j.jclepro.2018.10.103
   Roland Berger, 2016, POLSK RYN HANDL SPOZ
   Scherhaufer S, 2018, WASTE MANAGE, V77, P98, DOI 10.1016/j.wasman.2018.04.038
   Stancu V, 2016, APPETITE, V96, P7, DOI 10.1016/j.appet.2015.08.025
   Stenmarck A., 2000, ESTIMATES EUROPEAN F, DOI [10.13140/rg.2.1.4658.4721, DOI 10.13140/RG.2.1.4658.4721, 10.13140/RG.2.1.4658.4721]
   Teller C, 2018, J CLEAN PROD, V185, P981, DOI 10.1016/j.jclepro.2018.02.280
   TESCO, 2018, DAN DOT MARN ZYWN PO
   Tregear A, 2011, J RURAL STUD, V27, P419, DOI 10.1016/j.jrurstud.2011.06.003
   Turner BJ, 2019, PSYCHOL MED, V49, P1470, DOI 10.1017/S0033291718002015
NR 34
TC 1
Z9 1
U1 5
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 210
EP 219
DI 10.1016/j.resconrec.2019.05.029
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300021
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Kamdar, I
   Ali, S
   Bennui, A
   Techato, K
   Jutidamrongphan, W
AF Kamdar, Ismail
   Ali, Shahid
   Bennui, Adul
   Techato, Kuaanan
   Jutidamrongphan, Warangkana
TI Municipal solid waste landfill siting using an integrated GIS-AHP
   approach: A case study from Songkhla, Thailand
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Landfill siting; Municipal solid waste; Geographic; Information; System;
   Multi-criteria decision making; Thailand
ID ANALYTICAL HIERARCHY PROCESS; GEOGRAPHIC INFORMATION-SYSTEMS; WEIGHTED
   LINEAR COMBINATION; SITE SELECTION; COMBINING AHP; DECISION-SUPPORT; MSW
   LANDFILLS; METHODOLOGY; SUITABILITY; ENVIRONMENT
AB The determination of suitable landfill sites has become indispensable in recent years as the global generation of waste has increased and the use of unsuitable landfill sites results in negative impacts on the ecosystem. This study demonstrates a scientific approach in identifying appropriate landfill sites. The study includes morphological, environmental and socio-economic factors to achieve its objective. Geographic Information System (GIS) and Analytic Hierarchy Process (AHP) were combined in order to analyze data obtained from online portals and government institutions, with a recent study of waste production centres being provided by the Regional Environmental Office. To illustrate the method, a case study from Thailand was used. Expert judgement was solicited over 13 landfill site selection criteria. This study identified an area of 560.59 ha as very highly suitable for landfill sites, 993.19 ha as highly suitable and 180.72 ha as moderately suitable, with the remaining parts of the study area being unsuitable for landfill sites. This research has the potential to influence future waste management policies by assisting stakeholders in landfill siting in a manner that reduces negative impacts on the environment.
C1 [Kamdar, Ismail] Prince Songkla Univ, IGES, Hat Yai 90110, Songkhla, Thailand.
   [Ali, Shahid] Prince Songkla Univ, Program Sustainable Energy Management SEM, Fac Environm Management, Hat Yai 90110, Songkhla, Thailand.
   [Bennui, Adul] Prince Songkla Univ, Southern Reg Ctr Geoinformat & Space Technol, Fac Environm Management, Hat Yai 90110, Songkhla, Thailand.
   [Techato, Kuaanan; Jutidamrongphan, Warangkana] Prince Songkla Univ, Environm Assessment & Technol Hazardous Waste Man, Fac Environm Management, Hat Yai 90110, Songkhla, Thailand.
   [Techato, Kuaanan; Jutidamrongphan, Warangkana] Ctr Excellence Hazardous Subst Management HSM, Res Program Municipal Solid Waste & Hazardous Was, Bangkok 10330, Thailand.
RP Jutidamrongphan, W (reprint author), Prince Songkla Univ, Fac Environm Management, Hat Yai 90110, Songkhla, Thailand.
EM ismailkamdar1014@gmail.com; shahid_maidi@hotmail.com;
   adul1445@gmail.com; kuaanan.t@psu.ac.th; warangkana.j@psu.ac.th
OI Ali, Shahid/0000-0003-0260-488X; Kamdar, Ismail/0000-0002-6552-6981
FU Prince of Songkla University Hat Yai, Songkhla, Thailand [90112]; grant
   of an Interdisciplinary Graduate School (IGS); research program,
   'Municipal Solid Waste and Hazardous Waste Management' from the Center
   of Excellence on Hazardous Substance Management (HSM), Thailand;
   Thailand Research Fund TRFThailand Research Fund (TRF) [TRG 5880268]
FX The authors acknowledge the help of the government organizations,
   researchers and experts who were involved at various stages in this
   project. This work was supported by Prince of Songkla University Hat
   Yai, Songkhla 90112, Thailand, by the grant of an Interdisciplinary
   Graduate School (IGS), and partially supported by the research program,
   'Municipal Solid Waste and Hazardous Waste Management' from the Center
   of Excellence on Hazardous Substance Management (HSM), Thailand and
   Thailand Research Fund TRF (TRG 5880268).
CR Akinjare O.A, 2011, J SUSTAIN DEV, V4, P48, DOI DOI 10.5539/jsd.v4n2p48
   Al-Hanbali A., 2011, Journal of Geographic Information System, V3, P267, DOI 10.4236/jgis.2011.34023
   Alavi N, 2013, WASTE MANAGE RES, V31, P98, DOI 10.1177/0734242X12456092
   Ali S, 2019, RENEW ENERG, V132, P1360, DOI 10.1016/j.renene.2018.09.035
   Augusto PA, 2019, SCI TOTAL ENVIRON, V648, P636, DOI 10.1016/j.scitotenv.2018.08.056
   Aydi A, 2013, ENVIRON EARTH SCI, V68, P1375, DOI 10.1007/s12665-012-1836-3
   Baban S. M. J., 1998, PLANNING PRACTICE RE, V13, P139, DOI DOI 10.1080/02697459816157
   Bagchi A, 2004, DESIGN LANDFILLS INT
   BAGCHI A, 1994, DESIGN CONSTRUCTION
   BAHRANI S, 2016, ENVIRON EARTH SCI, V75, P1, DOI DOI 10.1007/S12665-015-5146-4
   Barakat A, 2017, ENVIRON EARTH SCI, V76, DOI 10.1007/s12665-017-6757-8
   Bosompem C, 2016, WASTE MANAGE RES, V34, P1054, DOI 10.1177/0734242X16658363
   Delgado OB, 2008, WASTE MANAGE, V28, P1137, DOI 10.1016/j.wasman.2007.07.002
   Buranasing N, 2015, SOLID WASTE MANAGEME
   Chabuk A, 2016, WASTE MANAGE RES, V34, P427, DOI 10.1177/0734242X16633778
   Chabuk AJ, 2017, ENVIRON EARTH SCI, V76, DOI 10.1007/s12665-017-6524-x
   Challcharoenwattana A, 2016, HABITAT INT, V51, P23, DOI 10.1016/j.habitatint.2015.10.008
   Chang NB, 2008, J ENVIRON MANAGE, V87, P139, DOI 10.1016/j.jenvman.2007.01.011
   Chanhthamixay B, 2017, APPL ENV RES J, V39, P49, DOI DOI 10.35762/AER.2017.39.3.6
   Charusiri P, 2008, INT J GEOINFORMATICS, V4, P29
   Chen Y, 2010, ENVIRON MODELL SOFTW, V25, P1582, DOI 10.1016/j.envsoft.2010.06.001
   Colvero DA, 2018, WASTE MANAGE, V77, P500, DOI 10.1016/j.wasman.2018.04.036
   De Feo G, 2014, WASTE MANAGE, V34, P2225, DOI 10.1016/j.wasman.2014.05.028
   Demesouka OE, 2013, WASTE MANAGE, V33, P1190, DOI 10.1016/j.wasman.2013.01.030
   Demesouka OE, 2019, EUR J OPER RES, V272, P574, DOI 10.1016/j.ejor.2018.07.005
   Dijkstra JJ, 2018, WASTE MANAGE, V75, P407, DOI 10.1016/j.wasman.2018.02.002
   DONEGAN HA, 1991, MATH COMPUT MODEL, V15, P135, DOI 10.1016/0895-7177(91)90098-R
   Effat HA, 2012, EGYPT J REMOTE SENS, V15, P125, DOI 10.1016/j.ejrs.2012.09.002
   Ersoy H, 2013, ENG GEOL, V154, P20, DOI 10.1016/j.enggeo.2012.12.005
   Ersoy H, 2009, WASTE MANAGE RES, V27, P489, DOI 10.1177/0734242X08098430
   Eskandari M, 2015, ENVIRON SCI POLLUT R, V22, P7754, DOI 10.1007/s11356-015-4182-7
   Eskandari M, 2012, WASTE MANAGE, V32, P1528, DOI 10.1016/j.wasman.2012.03.014
   Gbanie SP, 2013, APPL GEOGR, V36, P3, DOI 10.1016/j.apgeog.2012.06.013
   Gorsevski PV, 2012, WASTE MANAGE, V32, P287, DOI 10.1016/j.wasman.2011.09.023
   Kahraman C, 2018, ENG APPL ARTIF INTEL, V67, P157, DOI 10.1016/j.engappai.2017.09.009
   Khan MMU, 2018, SCI TOTAL ENVIRON, V610, P1065, DOI 10.1016/j.scitotenv.2017.08.169
   Khan S, 2008, WASTE MANAGE, V28, P1500, DOI 10.1016/j.wasman.2007.06.015
   Khodaparast M, 2018, ENVIRON EARTH SCI, V77, DOI 10.1007/s12665-017-7215-3
   Kontos TD, 2005, WASTE MANAGE, V25, P818, DOI 10.1016/j.wasman.2005.04.002
   Krcmar D, 2018, SCI TOTAL ENVIRON, V615, P1341, DOI 10.1016/j.scitotenv.2017.09.283
   Lee S, 2003, ENVIRON GEOL, V44, P654, DOI 10.1007/s00254-003-0803-4
   Lima RM, 2018, WASTE MANAGE, V74, P323, DOI 10.1016/j.wasman.2017.12.011
   Lin HY, 2005, J COMPUT CIVIL ENG, V19, P369, DOI 10.1061/(ASCE)0887-3801(2005)19:4(369)
   Makarichi L, 2018, RESOUR CONSERV RECY, V139, P351, DOI 10.1016/j.resconrec.2018.07.024
   Moeinaddini M, 2010, WASTE MANAGE, V30, P912, DOI 10.1016/j.wasman.2010.01.015
   Motlagh ZK, 2015, WASTE MANAGE, V46, P322, DOI 10.1016/j.wasman.2015.08.013
   Nas B, 2010, ENVIRON MONIT ASSESS, V160, P215, DOI 10.1007/s10661-008-0689-4
   PCD, 2017, THAIL STAT POLL CONT
   PCD, 1998, REG GUIDL MUN SOL WA
   Perotto E, 2008, J CLEAN PROD, V16, P517, DOI 10.1016/j.jclepro.2007.01.004
   Ramjeawon T, 2008, WASTE MANAGE RES, V26, P439, DOI 10.1177/0734242X07080758
   Ready RC, 2010, J REAL ESTATE RES, V32, P321
   REO, 2016, MON EV REP DOM WAST
   Saaty T.L., 2001, MODELS METHODS CONCE, V175, DOI [10.1007/978-1-4614-3597-6, DOI 10.1007/978-1-4614-3597-6]
   SAATY TL, 1990, EUR J OPER RES, V48, P9, DOI 10.1016/0377-2217(90)90057-I
   Saaty TL, 1993, CENT EUR J OPER RES, V2, P119
   Samadder SR, 2017, SCI TOTAL ENVIRON, V580, P593, DOI 10.1016/j.scitotenv.2016.12.003
   Sener S, 2011, ENVIRON MONIT ASSESS, V173, P533, DOI 10.1007/s10661-010-1403-x
   Sener S, 2010, WASTE MANAGE, V30, P2037, DOI 10.1016/j.wasman.2010.05.024
   Seshadri B., 2016, BIOREMEDIATION BIOEC, P99, DOI [DOI 10.1016/B978-0-12-802830-8.00005-8, 10.1016/B978-0-12-802830-8.00005-8]
   Shahabi H, 2014, ENVIRON EARTH SCI, V71, P4221, DOI 10.1007/s12665-013-2816-y
   Sharifi M.A., 2004, J TELECOMMUN INF TEC, V3, P28, DOI DOI 10.1016/J.WASMAN.2011.09.023
   Simoes P, 2012, WASTE MANAGE, V32, P1266, DOI 10.1016/j.wasman.2012.02.004
   Simoes P, 2010, WASTE MANAGE, V30, P1130, DOI 10.1016/j.wasman.2009.12.015
   Simsek C, 2014, LANDSCAPE URBAN PLAN, V132, P1, DOI 10.1016/j.landurbplan.2014.08.007
   Spigolon LMG, 2018, WASTE MANAGE RES, V36, P606, DOI 10.1177/0734242X18773538
   Sukholthaman P, 2015, TECHNOL SOC, V43, P231, DOI 10.1016/j.techsoc.2015.05.003
   Sumathi VR, 2008, WASTE MANAGE, V28, P2146, DOI 10.1016/j.wasman.2007.09.032
   Cervantes DET, 2018, WASTE MANAGE, V80, P51, DOI 10.1016/j.wasman.2018.08.046
   Uyan M, 2014, ENVIRON EARTH SCI, V71, P1629, DOI 10.1007/s12665-013-2567-9
   Wang GQ, 2009, J ENVIRON MANAGE, V90, P2414, DOI 10.1016/j.jenvman.2008.12.008
   Wang Y, 2018, RESOUR CONSERV RECY, V138, P40, DOI 10.1016/j.resconrec.2018.07.008
   Xiong Y, 2007, ECOL MODEL, V209, P97, DOI 10.1016/j.ecolmodel.2007.06.007
   Yal GP, 2014, B ENG GEOL ENVIRON, V73, P369, DOI 10.1007/s10064-013-0562-8
   Yildirim V, 2012, WASTE MANAGE RES, V30, P949, DOI 10.1177/0734242X12445656
NR 75
TC 6
Z9 6
U1 18
U2 32
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 220
EP 235
DI 10.1016/j.resconrec.2019.05.027
PG 16
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300022
DA 2020-05-12
ER

PT J
AU Sehnem, S
   Jabbour, CJC
   Pereira, SCF
   Jabbour, ABLD
AF Sehnem, Simone
   Chiappetta Jabbour, Charbel Jose
   Farias Pereira, Susana Carla
   Lopes de Sousa Jabbour, Ana Beatriz
TI Improving sustainable supply chains performance through operational
   excellence: circular economy approach
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Sustainability; Circular economy; Exploratory case study; Operational
   excellence approaches; Upper echelons theory
ID CRITICAL SUCCESS FACTORS; UPPER ECHELONS THEORY; MANAGEMENT; FOOD;
   ADOPTION; WASTE; INITIATIVES; CONSUMPTION; FRAMEWORK; INDUSTRY
AB This work is framed by the search for sustainable supply chain success through new approaches of operational excellence. By applying certain characteristics of Upper Echelons Theory in the context of the circular economy, this study analyzes critical success factors for the adoption of the circular economy using focal companies selected from both emerging (Brazil) and mature (Scotland) economies. Thus, this study relates to the maturity level of circular economy adoption, how well companies manage critical success factors, and the influence of selected characteristics of firms' upper echelons in promoting the circular economy. After conducting two exploratory case studies in Brazil and Scotland, as well as exploring the suitability of four research propositions, this work suggests that: (i) among the firms studied, companies that are more proactive towards the circular economy also demonstrate better management of critical success factors; (ii) based on these cases, companies that are less proactive in terms of the circular economy tend to face greater challenges and tensions due to unmanaged critical success factors; (iii) among the companies studied, those that are most proactive in terms of the circular economy tend to have top management who are more supportive of sustainability; (iv) certain top management characteristics in the companies studied, such as formal sustainability education and understanding of national sustainability strategy, are revealed to be relevant to the adoption of circular economy initiatives; and finally, (v) while our study shows that the theory behind the circular economy and critical success factors for promoting circular production systems have been developing separately, the integration of these important topical issues currently remains scarce.
C1 [Sehnem, Simone] Univ Oeste Santa Catarina, Univ Sul Santa Catarina, Ave Nereu Ramos,Neighborhood Seminario 3777D, BR-89813000 Chapeco, SC, Brazil.
   [Sehnem, Simone; Farias Pereira, Susana Carla] Fundacao Getulio Vargas FGV EAESP, Ave Nereu Ramos,Neighborhood Seminario 3777D, BR-89813000 Chapeco, SC, Brazil.
   [Chiappetta Jabbour, Charbel Jose; Lopes de Sousa Jabbour, Ana Beatriz] Montpellier Business Sch, Montpellier, France.
RP Sehnem, S (reprint author), Univ Oeste Santa Catarina, Univ Sul Santa Catarina, Ave Nereu Ramos,Neighborhood Seminario 3777D, BR-89813000 Chapeco, SC, Brazil.; Sehnem, S (reprint author), Fundacao Getulio Vargas FGV EAESP, Ave Nereu Ramos,Neighborhood Seminario 3777D, BR-89813000 Chapeco, SC, Brazil.
EM simonesehnem_adm@yahoo.com.br; cjcjabbour@gmail.com;
   susana.pereira@fgv.br; ablsjabbour@gmail.com
RI de Sousa Jabbour, Ana Beatriz Lopes/B-8966-2012; Sehnem,
   Simone/L-7842-2018; Jabbour, Charbel Jose Chiappetta/F-3505-2010;
   Sehnem, Simone/AAA-5623-2019
OI de Sousa Jabbour, Ana Beatriz Lopes/0000-0002-8472-9784; Jabbour,
   Charbel Jose Chiappetta/0000-0002-6143-4924; Lopes de Sousa Jabbour, Ana
   Beatriz/0000-0001-6423-8868; Sehnem, Simone/0000-0002-2416-4881
CR Aqlan F, 2018, INT J PROD ECON, V196, P261, DOI 10.1016/j.ijpe.2017.12.004
   Babbitt CW, 2018, RESOUR CONSERV RECY, V135, P1, DOI 10.1016/j.resconrec.2018.04.012
   Barratt M, 2011, J OPER MANAG, V29, P329, DOI 10.1016/j.jom.2010.06.002
   Blomsma F, 2017, J IND ECOL, V21, P603, DOI 10.1111/jiec.12603
   Bocken NMP, 2017, J IND ECOL, V21, P476, DOI 10.1111/jiec.12606
   Butterworth J, 2013, J IND ECOL, V1, P4, DOI [10.1162/108819806775545321, DOI 10.1162/108819806775545321]
   Campos LMS, 2016, SUPPLY CHAIN MANAG, V21, P627, DOI 10.1108/SCM-03-2016-0101
   Chertow M, 2012, J IND ECOL, V16, P13, DOI 10.1111/j.1530-9290.2011.00450.x
   Jabbour CJC, 2015, INT J PROD ECON, V164, P245, DOI 10.1016/j.ijpe.2014.11.015
   Chinese National People's Congress, 2008, REG PROM CIRC EC REG
   Choudhari SC, 2012, INT J OPER PROD MAN, V32, P1337, DOI 10.1108/01443571211274576
   Circular Economy, 2015, EUR CIRC EC STAK PLA
   Cucchiella F, 2015, RENEW SUST ENERG REV, V51, P263, DOI 10.1016/j.rser.2015.06.010
   Domenech T, 2019, RESOUR CONSERV RECY, V141, P76, DOI 10.1016/j.resconrec.2018.09.016
   EC. European Commission, 2011, ROADM RES EFF EUR, P571
   Ellen MacArthur Foundation, 2015, GROW CIRC EC VIS COM
   European Comission, 2014, COM2014398 COMM EU, P398, DOI DOI 10.1017/CB09781107415324.004
   European Commision, 2015, EU ACT PLAN CIRC EC, V614, P21, DOI DOI 10.1017/CB09781107415324.004
   European Commission, 2015, THRESH TOX IN PRESS, P1, DOI DOI 10.1017/CB09781107415324.004
   European Commission, 2010, EUR 2020 STRAT SMART
   Gaustad G, 2018, RESOUR CONSERV RECY, V135, P24, DOI 10.1016/j.resconrec.2017.08.002
   Ghisellini P, 2016, J CLEAN PROD, V114, P11, DOI 10.1016/j.jclepro.2015.09.007
   Govindan K, 2018, INT J PROD ECON, V195, P419, DOI 10.1016/j.ijpe.2017.03.003
   Haddadsisakht A, 2018, INT J PROD ECON, V195, P118, DOI 10.1016/j.ijpe.2017.09.009
   HAMBRICK DC, 1984, ACAD MANAGE REV, V9, P193, DOI 10.2307/258434
   Hambrick DC, 2007, ACAD MANAGE REV, V32, P334, DOI 10.5465/amr.2007.24345254
   Huang K, 2009, J HAZARD MATER, V164, P399, DOI 10.1016/j.jhazmat.2008.08.051
   Iacondini A, 2015, WASTE BIOMASS VALORI, V6, P865, DOI 10.1007/s12649-015-9380-5
   Jabbour CJC, 2017, PROD PLAN CONTROL, V28, P671, DOI 10.1080/09537287.2017.1309705
   Jacobi N, 2018, RESOUR CONSERV RECY, V137, P156, DOI 10.1016/j.resconrec.2018.05.022
   Jakhar SK, 2018, RESOUR CONSERV RECY, V139, P262, DOI 10.1016/j.resconrec.2018.08.019
   Kalmykova Y, 2018, RESOUR CONSERV RECY, V135, P190, DOI 10.1016/j.resconrec.2017.10.034
   Kirchherr J, 2017, RESOUR CONSERV RECY, V127, P221, DOI 10.1016/j.resconrec.2017.09.005
   Knight D, 1999, STRATEGIC MANAGE J, V20, P445, DOI 10.1002/(SICI)1097-0266(199905)20:5<445::AID-SMJ27>3.0.CO;2-V
   Korhonen J, 2018, ECOL ECON, V143, P37, DOI 10.1016/j.ecolecon.2017.06.041
   Liu Z, 2018, RESOUR CONSERV RECY, V128, P417, DOI 10.1016/j.resconrec.2016.06.012
   Long TB, 2018, J CLEAN PROD, V175, P82, DOI 10.1016/j.jclepro.2017.11.067
   Luthra S, 2018, RESOUR CONSERV RECY, V138, P194, DOI 10.1016/j.resconrec.2018.07.005
   Luthra S, 2017, RESOUR CONSERV RECY, V125, P198, DOI 10.1016/j.resconrec.2017.02.018
   Manfrin Pâmela Mocelin, 2013, Prod., P0, DOI [10.1590/S0103-65132013000400008, 10.1590/S0103-65132013005000029]
   Mangla S. K., 2019, CALL PAPERS SPECIAL
   Mangla SK, 2018, INT J PROD ECON, V203, P379, DOI 10.1016/j.ijpe.2018.07.012
   Mangla SK, 2018, PROD PLAN CONTROL, V29, P551, DOI 10.1080/09537287.2018.1449265
   Mangla SK, 2015, RESOUR CONSERV RECY, V104, P375, DOI 10.1016/j.resconrec.2015.01.001
   Mani V, 2018, INT J PROD ECON, V199, P150, DOI 10.1016/j.ijpe.2018.02.015
   Masi D, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9091602
   Merli R, 2018, J CLEAN PROD, V178, P703, DOI 10.1016/j.jclepro.2017.12.112
   Mills A. J., 2010, SAGE ENCY CASE STUDY
   Mirabella N, 2014, J CLEAN PROD, V65, P28, DOI 10.1016/j.jclepro.2013.10.051
   Moreno M, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8090937
   Murray A, 2017, J BUS ETHICS, V140, P369, DOI 10.1007/s10551-015-2693-2
   Pauliuk S, 2018, RESOUR CONSERV RECY, V129, P81, DOI 10.1016/j.resconrec.2017.10.019
   Pitkanen K, 2016, J CLEAN PROD, V139, P666, DOI 10.1016/j.jclepro.2016.08.071
   Raut RD, 2019, J CLEAN PROD, V215, P926, DOI 10.1016/j.jclepro.2019.01.139
   Reike D, 2018, RESOUR CONSERV RECY, V135, P246, DOI 10.1016/j.resconrec.2017.08.027
   ROCKART JF, 1979, HARVARD BUS REV, V57, P81
   Rowshannahad M, 2018, INT J PROD ECON, V198, P25, DOI 10.1016/j.ijpe.2018.01.014
   Ryen EG, 2018, RESOUR CONSERV RECY, V135, P48, DOI 10.1016/j.resconrec.2017.08.006
   Schroeder P, 2018, RESOUR CONSERV RECY, V136, P77, DOI 10.1016/j.resconrec.2018.04.003
   Sehnem S., 2016, 42 ANN C EUR INT BUS
   Sehnem S., 2019, MANAGE
   Simon B, 2019, RESOUR CONSERV RECY, V141, P299, DOI 10.1016/j.resconrec.2018.10.044
   Sousa-Zomer TT, 2018, J CLEAN PROD, V185, P740, DOI 10.1016/j.jclepro.2018.03.006
   Su B, 2013, J CLEAN PROD, V42, P215, DOI 10.1016/j.jclepro.2012.11.020
   Sudarsan Rachuri, 2010, 2010 IEEE International Conference on Automation Science and Engineering (CASE 2010), P144, DOI 10.1109/COASE.2010.5584472
   Teixeira AA, 2012, INT J PROD ECON, V140, P318, DOI 10.1016/j.ijpe.2012.01.009
   Tseng ML, 2018, RESOUR CONSERV RECY, V131, P146, DOI 10.1016/j.resconrec.2017.12.028
   Tukker A, 2015, J CLEAN PROD, V97, P76, DOI 10.1016/j.jclepro.2013.11.049
   Unctad, 2017, STAT DISP
   Voss C, 2002, INT J OPER PROD MAN, V22, P195, DOI 10.1108/01443570210414329
   Wen Z., 2015, RESOUR CONSERV RECY, V55, P703, DOI [10.1016/j.resconrec.2011.02.003, DOI 10.1016/J.RESCONREC.2011.02.003]
   Yamak S, 2014, GROUP ORGAN MANAGE, V39, P69, DOI 10.1177/1059601113511663
   Yin R.K., 2010, ESTUDO CASO PLANEJAM
   YIN RK, 1981, ADMIN SCI QUART, V26, P58, DOI 10.2307/2392599
   Zeng HX, 2017, J CLEAN PROD, V155, P54, DOI 10.1016/j.jclepro.2016.10.093
   Zhong S, 2018, RESOUR CONSERV RECY, V128, P48, DOI 10.1016/j.resconrec.2017.09.023
NR 76
TC 6
Z9 6
U1 10
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 236
EP 248
DI 10.1016/j.resconrec.2019.05.021
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300023
DA 2020-05-12
ER

PT J
AU Diaz-Ruiz, R
   Costa-Font, M
   Lopez-i-Gelats, F
   Gil, JM
AF Diaz-Ruiz, Raquel
   Costa-Font, Montserrat
   Lopez-i-Gelats, Feliu
   Gil, Jose M.
TI Food waste prevention along the food supply chain: A multi-actor
   approach to identify effective solutions
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Barcelona; Food losses; Delphi; Food waste prevention; Food
   redistribution; Reduction
ID LEVERAGE POINTS; DELPHI; LOSSES; FRAMEWORK; MANAGEMENT; REDUCTION;
   QUALITY; FUTURE
AB There is a large consensus highlighting the need to prevent the food waste volume along the food supply chain. However, there is currently a lack of understanding as to what the most effective anti-food waste measures to be implemented in fact are. The food waste puzzle can be considered from diverse perspectives depending on the stakeholder position on the chain. In view of this, the objective of this paper is to conduct a multi-actor approach to identify the most effective measures to prevent food waste. To do so, we combined in-depth interviews and the Delphi method and applied this to key agents along the food supply chain. The study was conducted in the Barcelona metropolitan region, and a total of 24 key stakeholders participated in the process. We identified 48 measures from the in-depth interviews. The Delphi method was used to evaluate stakeholders' perception of the effectiveness of each measure to prevent food waste and, the consensus and dissensus among the panel. In particular, we found different strong prevention measures, such as the increasing of diet valuation, weak prevention measures, such as building consumer awareness about food waste, and a set of redistribution measures. Finally, we discussed the importance of engaging as diverse a panel of stakeholders as possible when addressing food waste. The paper contributes to the incipient debate on how to examine the impact of multiple and diverse alternatives to food waste prevention.
C1 [Diaz-Ruiz, Raquel; Lopez-i-Gelats, Feliu; Gil, Jose M.] Ctr Agrofood Econ & Dev CREDA UPC IRTA, C Esteve Terrades 8, Barcelona 08860, Spain.
   [Costa-Font, Montserrat] Scotlands Rural Coll SRUC, Land Econ Environm & Soc Res Grp, West Mains Rd, Edinburgh EH9 3JG, Midlothian, Scotland.
   [Lopez-i-Gelats, Feliu] Cent Univ Catalonia, Univ Vic, Chair Agroecol & Food Syst, Vic 08500, Spain.
RP Diaz-Ruiz, R (reprint author), Ctr Agrofood Econ & Dev CREDA UPC IRTA, C Esteve Terrades 8, Barcelona 08860, Spain.
EM raquel.diaz.ruiz@upc.edu; Montse.CostaFont@sruc.ac.uk;
   feliu.lopez@uvic.cat; chema.gil@upc.edu
RI Lopez-i-Gelats, Feliu/M-3801-2014; Diaz-Ruiz, Raquel/AAA-7571-2020;
   Gelats, feliu/AAI-7248-2020
OI Lopez-i-Gelats, Feliu/0000-0003-4908-4017; Diaz-Ruiz,
   Raquel/0000-0001-6452-8283; 
FU Waste Prevention department of the Metropolitan Area of Barcelona; Pre
   Doctoral teaching fellowship - Spanish Ministry of Education, Culture
   and Sport [FPU 13/06077]
FX This work was partially funded the Waste Prevention department of the
   Metropolitan Area of Barcelona. Raquel Diaz -Ruiz was funded by Pre
   Doctoral teaching fellowship awarded by the Spanish Ministry of
   Education, Culture and Sport (FPU 13/06077).
CR Beretta C, 2013, WASTE MANAGE, V33, P764, DOI 10.1016/j.wasman.2012.11.007
   Betz A, 2015, WASTE MANAGE, V35, P218, DOI 10.1016/j.wasman.2014.09.015
   Blay-Palmer A, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10051680
   Brancoli P, 2017, RESOUR CONSERV RECY, V118, P39, DOI 10.1016/j.resconrec.2016.11.024
   Buzby JC, 2012, FOOD POLICY, V37, P561, DOI 10.1016/j.foodpol.2012.06.002
   Callejo Gallego J, 2009, INTRO TECNICAS INVES, P336
   Campoy-Munoz P, 2017, RESOUR CONSERV RECY, V122, P202, DOI 10.1016/j.resconrec.2017.02.010
   Canali M, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9010037
   Chaboud G, 2017, RESOUR CONSERV RECY, V125, P188, DOI 10.1016/j.resconrec.2017.06.008
   Clibbens Nicola, 2012, Nurse Res, V19, P37
   Cristobal J, 2018, WASTE MANAGE, V72, P3, DOI 10.1016/j.wasman.2017.11.007
   De Schutter O, 2017, GREEN EUR J
   Del-Val-Cid Del-Val-Cid, 2009, INTRO TECNICAS INVES, P336
   Diaz-Ruiz R, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10103730
   European Union, 2016, 34 EN EUR UN, DOI [10.2865/8374, DOI 10.2865/8374]
   FAO, 2015, FOOD URB WORLD
   FAO, 2013, CLIM SMART AGR SOURC
   Faysse N, 2014, REG ENVIRON CHANGE, V14, pS57, DOI 10.1007/s10113-012-0362-x
   Food and Agriculture Agency of the United Nations (FAO), 2017, STAT FOOD SEC NUTR W
   Food and Agriculture Organisation (FAO) International Fund for Agricultural Development (IFAD) World Food Program (WFP), 2015, STAT FOOD INS WORLD
   Gamboa G, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8060515
   Gary JE, 2015, FUTURES, V71, P132, DOI 10.1016/j.futures.2015.03.005
   GIZ FAO RUAF, 2016, CITY REGION FOOD SYS
   Gobel C, 2015, SUSTAINABILITY-BASEL, V7, P1429, DOI 10.3390/su7021429
   Gustaysson J., 2011, GLOBAL FOOD LOSSES F
   Hasson F, 2000, J ADV NURS, V32, P1008, DOI 10.1046/j.1365-2648.2000.01567.x
   HLPE, 2014, FOOD LOSS WAST CONT, P2014
   Ju M, 2017, WASTE MANAGE, V61, P443, DOI 10.1016/j.wasman.2017.01.021
   Kennedy HP, 2004, J ADV NURS, V45, P504, DOI 10.1046/j.1365-2648.2003.02933.x
   Kummu M, 2012, SCI TOTAL ENVIRON, V438, P477, DOI 10.1016/j.scitotenv.2012.08.092
   Li LZ, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9091565
   Mattsson L, 2018, RESOUR CONSERV RECY, V130, P118, DOI 10.1016/j.resconrec.2017.10.037
   Midgley JL, 2014, J ENVIRON PLANN MAN, V57, P1872, DOI 10.1080/09640568.2013.848192
   Mourad M, 2016, J CLEAN PROD, V126, P461, DOI 10.1016/j.jclepro.2016.03.084
   MUFPP, 2017, MIL URB FOOD POL PAC
   Neumayer E., 2003, WEAK VERSUS STRONG S, DOI DOI 10.4337/9781849805438
   Papargyropoulou E, 2016, WASTE MANAGE, V49, P326, DOI 10.1016/j.wasman.2016.01.017
   Papargyropoulou E, 2014, J CLEAN PROD, V76, P106, DOI 10.1016/j.jclepro.2014.04.020
   Parizeau K, 2015, WASTE MANAGE, V35, P207, DOI 10.1016/j.wasman.2014.09.019
   Perveen S, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9101787
   Phillips C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075530
   PILL J, 1971, SOCIO ECON PLAN SCI, V5, P57, DOI 10.1016/0038-0121(71)90041-3
   Powell C, 2003, J ADV NURS, V41, P376, DOI 10.1046/j.1365-2648.2003.02537.x
   Priefer C, 2016, RESOUR CONSERV RECY, V109, P155, DOI 10.1016/j.resconrec.2016.03.004
   Reed MS, 2008, BIOL CONSERV, V141, P2417, DOI 10.1016/j.biocon.2008.07.014
   Reed MS, 2009, J ENVIRON MANAGE, V90, P1933, DOI 10.1016/j.jenvman.2009.01.001
   Reynolds CJ, 2015, SUSTAINABILITY-BASEL, V7, P4707, DOI 10.3390/su7044707
   Rowe G, 2011, TECHNOL FORECAST SOC, V78, P1487, DOI 10.1016/j.techfore.2011.09.002
   STROTMANN C, 2017, SUSTAINABILITY-BASEL, V9, DOI DOI 10.3390/SU9010066
   Thyberg KL, 2016, RESOUR CONSERV RECY, V106, P110, DOI 10.1016/j.resconrec.2015.11.016
   Vila M, 2016, EUR, V28422, DOI [10.2760/256208, DOI 10.2760/256208]
   Vinet L, 2011, J PHYS A-MATH THEOR, V44, DOI 10.1088/1751-8113/44/8/085201
   Vittuari M, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9101817
   Vittuari M, 2016, ENERGIES, V9, DOI 10.3390/en9080660
   Vivero-Pol JL, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9030442
   von der Gracht HA, 2012, TECHNOL FORECAST SOC, V79, P1525, DOI 10.1016/j.techfore.2012.04.013
   West PC, 2014, SCIENCE, V345, P325, DOI 10.1126/science.1246067
   Willersinn C, 2015, WASTE MANAGE, V46, P120, DOI 10.1016/j.wasman.2015.08.033
   Wunder S, 2018, FOOD WASTE PREVENTIO
NR 59
TC 4
Z9 4
U1 15
U2 19
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 249
EP 260
DI 10.1016/j.resconrec.2019.05.031
PG 12
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300024
DA 2020-05-12
ER

PT J
AU Zuo, L
   Wang, C
   Corder, GD
   Sun, Q
AF Zuo, Lyushui
   Wang, Chang
   Corder, Glen David
   Sun, Qiao
TI Future trends and strategies of recycling high-tech metals from urban
   mines in China: 2015-2050
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE High-tech metals; Urban mines; Future trend; Development strategies
ID CRITICALITY; WEEE; VULNERABILITY; COBALT
AB High-tech metals are necessary materials for strategic emerging industries but their primary ores are generally difficult to be extracted because of economic and technical limitations. Urban mines have become a potential pool of secondary high-tech metals, called high-tech urban mines (HUMs). It is important and urgent to make a dynamic evaluation to understand the potential and technical feasibility for HUMs development. In this study, we construct the strategic development index (SDI) from three aspects - resource, technology, and environmental (R-T-E) to assess HUMs in China from 2015 to 2050. Furthermore, development strategies are proposed based on the dynamic evaluation results. Here we show that, there are four patterns of future trends of HUMs in China sustainable growth, first increase and then decrease, continuous decline, and fading out. The distribution of HUMs in "R-T-E" shows a trend of polarization with continuously shrinks of the range along all the three indexes. According to the evaluation results, different strategies - key development strategy, digestion strategy, reserve strategy and transfer strategy - should be adopted to develop HUMs. Wind turbines, fluorescence lamps, smartphones, EVs, Li-ion batteries and computers will be main reservoirs of secondary high-tech metals for a long time, they should be the focus of technology, funds and policy from both the government and enterprises.
C1 [Zuo, Lyushui] Cent S Univ, Inst Local Governance, Changsha 410083, Hunan, Peoples R China.
   [Zuo, Lyushui] Cent S Univ, Inst Met Resources Strategy, Changsha 410083, Hunan, Peoples R China.
   [Wang, Chang; Sun, Qiao] Cent S Univ, Sch Business, Management Bldg,932 Lushan South Rd, Changsha 410083, Hunan, Peoples R China.
   [Wang, Chang] Minist Land & Resources, Key Lab Strateg Studies, Beijing 100812, Peoples R China.
   [Corder, Glen David] Univ Queensland, Sustainable Minerals Inst, St Lucia, Qld 4072, Australia.
RP Wang, C; Sun, Q (reprint author), Cent S Univ, Sch Business, Management Bldg,932 Lushan South Rd, Changsha 410083, Hunan, Peoples R China.
EM zuo.lvshui@csu.edu.au; changwang@csu.edu.cn; g.corder@smi.uq.edu.au;
   sunqiao@csu.edu.cn
RI ; Corder, Glen/K-3133-2014
OI Zuo, Lyushui/0000-0003-4216-1139; Corder, Glen/0000-0001-8733-1248
FU Key Program of National Science Foundation of ChinaNational Natural
   Science Foundation of China [71633006]; Major Program of National Social
   Science Foundation of ChinaNational Natural Science Foundation of China
   [14ZDB136, 18ZDA061]; National Social Science Foundation of China
   [15BGL147, 14BGL196]; Chinese Scholarship CouncilChina Scholarship
   Council
FX This work is supported by the Key Program of National Science Foundation
   of China (71633006), Major Program of National Social Science Foundation
   of China (14ZDB136, 18ZDA061), Project of National Social Science
   Foundation of China (15BGL147, 14BGL196), and is sponsored by the
   Chinese Scholarship Council.
CR Buchert M, 2009, CRITICAL METALS FOR
   Camera shutter life expectancy database, 2017, CAMERA SHUTTER LIFE
   Castilloux R, 2014, EMERGING END USES OF
   Ciacci L, 2019, RESOUR CONSERV RECY, V142, P143, DOI 10.1016/j.resconrec.2018.11.024
   Cucchiella F, 2015, RENEW SUST ENERG REV, V51, P263, DOI 10.1016/j.rser.2015.06.010
   de Koning A, 2018, RESOUR CONSERV RECY, V129, P202, DOI 10.1016/j.resconrec.2017.10.040
   DoE US, 2010, CRITICAL MAT STRATEG, P14
   Du XY, 2011, J IND ECOL, V15, P836, DOI 10.1111/j.1530-9290.2011.00362.x
   European Commission, 2014, REPORT OF THE AD HOC
   Frenzel M, 2015, RESOUR POLICY, V46, P45, DOI 10.1016/j.resourpol.2015.08.002
   Gaustad G, 2018, RESOUR CONSERV RECY, V135, P24, DOI 10.1016/j.resconrec.2017.08.002
   Graedel TE, 2015, P NATL ACAD SCI USA, V112, P4257, DOI 10.1073/pnas.1500415112
   Graedel TE, 2012, ENVIRON SCI TECHNOL, V46, P1063, DOI 10.1021/es203534z
   Graedel TE, 2011, J IND ECOL, V15, P355, DOI 10.1111/j.1530-9290.2011.00342.x
   Harper EM, 2015, RESOUR CONSERV RECY, V95, P193, DOI 10.1016/j.resconrec.2014.12.009
   He PW, 2018, J CLEAN PROD, V192, P940, DOI 10.1016/j.jclepro.2018.04.222
   Helbig C, 2016, RESOUR POLICY, V48, P13, DOI 10.1016/j.resourpol.2016.02.003
   Isnard C. A, 1974, SOME MODELS FROM CAT
   Jaffe B, 2010, CRITICAL ELEMENTS FO
   Jody B. J., 2010, END OF LIFE VEHICLE
   Johnson J, 2008, ENERG POLICY, V36, P181, DOI 10.1016/j.enpol.2007.08.028
   Kim M, 2013, J ENVIRON MANAGE, V128, P941, DOI 10.1016/j.jenvman.2013.06.049
   Li B, 2015, WASTE MANAGE, V35, P247, DOI 10.1016/j.wasman.2014.09.008
   Martinez E, 2009, RENEW ENERG, V34, P667, DOI 10.1016/j.renene.2008.05.020
   Nassar NT, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1400180
   Nelen D, 2014, J CLEAN PROD, V83, P305, DOI 10.1016/j.jclepro.2014.06.094
   Nogueira C. A, 2012, TMS 2012 ANNUAL MEET
   Oguchi M, 2013, SCI TOTAL ENVIRON, V463, P1124, DOI 10.1016/j.scitotenv.2012.07.078
   Rodrigues LEOC, 2010, J POWER SOURCES, V195, P3735, DOI 10.1016/j.jpowsour.2009.12.071
   Petranikova M., 2011, ACTA METALLURGICA SL, V17, P106
   Rademaker JH, 2013, ENVIRON SCI TECHNOL, V47, P10129, DOI 10.1021/es305007w
   Richa K, 2014, RESOUR CONSERV RECY, V83, P63, DOI 10.1016/j.resconrec.2013.11.008
   Schiler M, 1992, SIMPLIFIED DESIGN OF
   Statista Inc, 2017, AVERAGE LIFESPAN REP
   Sun X, 2019, RESOUR CONSERV RECY, V149, P45, DOI 10.1016/j.resconrec.2019.05.009
   Sun Z, 2016, J CLEAN PROD, V112, P2977, DOI 10.1016/j.jclepro.2015.10.116
   Tremeac B, 2009, RENEW SUST ENERG REV, V13, P2104, DOI 10.1016/j.rser.2009.01.001
   UNEP, 2013, A REPORT OF THE WORK
   US Geological Survey, 2016, MIN COMM SUMM, DOI [10.3133/70170140, DOI 10.3133/70170140]
   [王昶 Wang Chang], 2016, [生态学报, Acta Ecologica Sinica], V36, P7346
   Wang C, 2013, T NONFERR METAL SOC, V23, P2465, DOI 10.1016/S1003-6326(13)62756-9
   Wen ZG, 2015, J IND ECOL, V19, P1091, DOI 10.1111/jiec.12271
   Wu YF, 2014, RESOUR CONSERV RECY, V88, P21, DOI 10.1016/j.resconrec.2014.04.007
   Yang D, 2014, CHINA POPUL ENV, V24, P230
   Zeeman E.C., 1977, CATASTROPHE THEORY S
   ZEEMAN EC, 1976, SCI AM, V234, P65, DOI 10.1038/scientificamerican0476-65
   Zhang LX, 2013, MATH COMPUT MODEL, V58, P862, DOI 10.1016/j.mcm.2012.12.014
   Zhang T J, 2009, MINING SCI TECHNOLOG, V19, P430, DOI DOI 10.1016/S1674-5264(09)60080-6
   Zhang WW, 2017, INT J DISAST RISK RE, V24, P361, DOI 10.1016/j.ijdrr.2017.06.022
   Zhang X, 2011, LAND RESOUR INFORM, P2
   Zuo LS, 2019, J CLEAN PROD, V208, P697, DOI 10.1016/j.jclepro.2018.10.030
NR 51
TC 1
Z9 1
U1 8
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 261
EP 274
DI 10.1016/j.resconrec.2019.06.003
PG 14
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300025
DA 2020-05-12
ER

PT J
AU Rajeev, A
   Pati, RK
   Padhi, SS
AF Rajeev, A.
   Pati, Rupesh K.
   Padhi, Sidhartha S.
TI Sustainable supply chain management in the chemical industry: Evolution,
   opportunities, and challenges
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Review
DE Sustainable supply chain; Chemical industry; SWOT; Literature review
ID CONCEPTUAL-FRAMEWORK; GREEN; PERFORMANCE; LOGISTICS
AB Chemical industries play a significant role in the global debate on reasons behind climate change and adverse social effect. It is necessary to understand as well as find ways to improve the sustainability aspects of the supply chain in the chemical industry. This study presents a systematic review through content analysis using "Five W" namely Why, When, Where, Who, and What; and "Two H" namely How and How much framework, to understand the evolution of sustainable supply chain in the chemical industry over past two decades. Using 145 selected articles, this study attempts to understand the research trend over journal outlets, preferred methodologies, mathematical tools, theoretical perspectives, and issues studied over various stages of growth across various economies. Finally, the SWOT framework has been used to understand the strength-weakness of Sustainable Supply Chain research in the chemical industry and map it to the opportunities-threat across multiple sub-industries. This framework is further used to develop the future scope of research by identifying theories, techniques/tool to overcome challenges across multiple issues in the Chemical industry's achievement of sustainability goal.
C1 [Rajeev, A.; Pati, Rupesh K.; Padhi, Sidhartha S.] Indian Inst Management Kozhikode, QMOM Grp, Kozhikode 673570, Kerala, India.
RP Padhi, SS (reprint author), Indian Inst Management Kozhikode, QMOM Grp, Kozhikode 673570, Kerala, India.
EM drpadhi@gmail.com
RI A, Rajeev/R-3143-2019; Pati, Rupesh Kumar/Z-2946-2019
OI A, Rajeev/0000-0001-8604-3113; Pati, Rupesh Kumar/0000-0001-9544-6053
CR Ahi P, 2015, J CLEAN PROD, V86, P360, DOI 10.1016/j.jclepro.2014.08.005
   Alexander A, 2014, SUPPLY CHAIN MANAG, V19, P504, DOI 10.1108/SCM-01-2014-0007
   [Anonymous], 2002, CREATINGMINDS
   Ashby A, 2012, SUPPLY CHAIN MANAG, V17, P497, DOI 10.1108/13598541211258573
   Barbosa-Povoa AP, 2018, EUR J OPER RES, V268, P399, DOI 10.1016/j.ejor.2017.10.036
   Bastas A, 2018, J CLEAN PROD, V181, P726, DOI 10.1016/j.jclepro.2018.01.110
   Beske P, 2014, INT J PROD ECON, V152, P131, DOI 10.1016/j.ijpe.2013.12.026
   Biloslavo R, 2009, MANAGE DECIS, V47, P1158, DOI 10.1108/00251740910978359
   Bollheimer Meredith, 2015, Journal of Business Strategy, V36, P3, DOI 10.1108/JBS-02-2014-0022
   Brandenburg M, 2014, EUR J OPER RES, V233, P299, DOI 10.1016/j.ejor.2013.09.032
   Bush SR, 2015, J CLEAN PROD, V107, P8, DOI 10.1016/j.jclepro.2014.10.019
   Carter CR, 2011, INT J PHYS DISTR LOG, V41, P46, DOI 10.1108/09600031111101420
   Carter CR, 2008, INT J PHYS DISTR LOG, V38, P360, DOI 10.1108/09600030810882816
   Chu WS, 2014, INT J PRECIS ENG MAN, V15, P973, DOI 10.1007/s12541-014-0424-8
   Dasgupta S, 2000, J ENVIRON ECON MANAG, V39, P39, DOI 10.1006/jeem.1999.1090
   Defee CC, 2010, INT J LOGIST MANAG, V21, P404, DOI 10.1108/09574091011089817
   Despeisse M, 2012, PROD PLAN CONTROL, V23, P354, DOI 10.1080/09537287.2011.555425
   Dunlap R.E., 2012, ENV PROBLEMS
   Gold S, 2010, CORP SOC RESP ENV MA, V17, P230, DOI 10.1002/csr.207
   Gosling J, 2016, J CLEAN PROD, V137, P1458, DOI 10.1016/j.jclepro.2014.10.029
   Govindan K, 2016, J CLEAN PROD, V112, P1813, DOI 10.1016/j.jclepro.2015.11.084
   Govindan K, 2015, EUR J OPER RES, V240, P603, DOI 10.1016/j.ejor.2014.07.012
   Grossmann IE, 2010, COMPUT CHEM ENG, V34, P1365, DOI 10.1016/j.compchemeng.2009.11.012
   Guillen-Gosalbez G, 2010, COMPUT CHEM ENG, V34, P42, DOI 10.1016/j.compchemeng.2009.09.003
   Helms MM, 2010, J STRATEGY MANAG, V3, P215, DOI 10.1108/17554251011064837
   Maditati DR, 2018, RESOUR CONSERV RECY, V139, P150, DOI 10.1016/j.resconrec.2018.08.004
   Meixell MJ, 2015, INT J PHYS DISTR LOG, V45, P69, DOI 10.1108/IJPDLM-05-2013-0155
   Nikolopoulou A, 2012, COMPUT CHEM ENG, V44, P94, DOI 10.1016/j.compchemeng.2012.05.006
   OECD, 2018, FUT ENV IMP CHEM IND
   Rajeev A, 2017, J CLEAN PROD, V162, P299, DOI 10.1016/j.jclepro.2017.05.026
   Seuring S, 2008, J CLEAN PROD, V16, P1699, DOI 10.1016/j.jclepro.2008.04.020
   Seuring S, 2013, DECIS SUPPORT SYST, V54, P1513, DOI 10.1016/j.dss.2012.05.053
   Taticchi P, 2013, INT J PRODUCT PERFOR, V62, P782, DOI 10.1108/IJPPM-03-2013-0037
   Thome AMT, 2016, PROD PLAN CONTROL, V27, P408, DOI 10.1080/09537287.2015.1129464
   Tranfield D, 2003, BRIT J MANAGE, V14, P207, DOI 10.1111/1467-8551.00375
   United Nations Framework Convention on Climate Change, 2005, KYOT PROT DOC
   Winter M, 2013, INT J PHYS DISTR LOG, V43, P18, DOI 10.1108/09600031311293237
   Zhang MM, 2018, IEEE ACCESS, V6, P18933, DOI 10.1109/ACCESS.2018.2819185
NR 38
TC 1
Z9 1
U1 7
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 275
EP 291
DI 10.1016/j.resconrec.2019.05.020
PG 17
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300026
DA 2020-05-12
ER

PT J
AU Mousavi, M
   Hosseinnezhad, S
   Kabir, SF
   Burnett, DJ
   Fini, EH
AF Mousavi, Masoumeh
   Hosseinnezhad, Shahrzad
   Kabir, Sk Faisal
   Burnett, Daniel J.
   Fini, Ellie H.
TI Reaction pathways for surface activated rubber particles
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Density functional theory (DFT); Surface activation; Crumb rubber; Phase
   separation; Asphalt-binder; Bio-modification
ID FREE-RADICAL REACTIONS; WASTE TIRE RUBBER; NATURAL-RUBBER; MODIFIED
   ASPHALT; MICROWAVE; STABILITY; PHOTOLYSIS
AB This paper studies molecular level interaction mechanisms involved in surface activation of rubber particles when exposed to a newly developed bio-modifier and microwave irradiation. It further examines how surface activation of rubber promotes its interaction with asphalt molecules to reduce phase separation in rubberized asphalt-binder. Using quantum-based calculations, chain reactions between an amide-rich bio-modifier and irradiated molecules of rubber is examined. The density functional theory (DFT)-based molecular modeling was performed on amide-type molecules as representatives for the bio-modifier. Comparing interactions of amidyl radical (RCO-N'H) of bio-modifier with sulfur-centered and carbon-centered radicals of rubber showed that amidyl radicals have higher affinity to bind to carbon-centered radicals than to sulfur-centered radicals. While the spine triplet state for -N center dot center dot center dot S- reaction coordinates encounters the obstacle of spin block and activation barrier, no spin block is observed on the -N center dot center dot center dot C- reaction pathway. The latter reaction was further observed via FTIR spectra where a new peak appeared at 1040 cm(-1) indicating formation of C-N bonds. Aforementioned reactions led to grafting highly polar molecules of bio-modifier onto the surface of rubber increasing rubber's surface polarity. This was evidenced by the increase in acid-base component of rubber's surface energy from 2.9 mJ/m(2) in control rubber to 14.6 mJ/m(2) in treated rubber. The increased polarity increased the interactions of rubber with asphalt molecules reducing the phase separation commonly known as segregation in rubberized asphalt. The latter was reflected in reduction of differences in complex modulus (G*) between top and bottom parts of rubberized asphalt specimens from 53.69% to 0.05%.
C1 [Mousavi, Masoumeh; Hosseinnezhad, Shahrzad] North Carolina A&T State Univ, 1601 E Market St, Greensboro, NC 27411 USA.
   [Kabir, Sk Faisal; Fini, Ellie H.] Arizona State Univ, 660 S Coll Ave, Tempe, AZ 85287 USA.
   [Burnett, Daniel J.] Surface Measurement Syst, 2125 28th St SW,Suite 1, Allentown, PA 18103 USA.
RP Fini, EH (reprint author), Arizona State Univ, 660 S Coll Ave, Tempe, AZ 85287 USA.
EM efini@asu.edu
FU National Cooperative Highway Research Program [NCHRP-IDEA 194]; National
   Science FoundationNational Science Foundation (NSF) [1546921]
FX This research is sponsored by the National Cooperative Highway Research
   Program (NCHRP-IDEA 194), and the National Science Foundation (Awards
   No: 1546921). The contents of this paper reflect the view of the
   authors, who are responsible for the facts and the accuracy of the data
   presented. This paper does not constitute a standard, specification, or
   regulation.
CR [Anonymous], 2012, AASHTOT315 DSR
   [Anonymous], 2014, ASTMD7173 ASTM INT
   Berry J, 2017, J CREATIVE INQUIRY, V1, P1
   Cai Y, 2015, ORG LETT, V17, P488, DOI 10.1021/ol5035047
   Cao XW, 2014, POLYM DEGRAD STABIL, V109, P1, DOI 10.1016/j.polymdegradstab.2014.06.014
   Cheng XW, 2017, APPL SURF SCI, V409, P325, DOI 10.1016/j.apsusc.2017.03.072
   de Sousa FDB, 2017, POLYM DEGRAD STABIL, V138, P169, DOI 10.1016/j.polymdegradstab.2017.03.008
   Ernzerhof M, 1999, J CHEM PHYS, V110, P5029, DOI 10.1063/1.478401
   Fabiula D., 2017, POLYM DEGRAD STAB
   Fini EH, 2011, J MATER CIVIL ENG, V23, P1506, DOI 10.1061/(ASCE)MT.1943-5533.0000237
   Frisch MJ, 2009, GAUSSIAN 09 REVISION
   Gawel I, 2006, IND ENG CHEM RES, V45, P3044, DOI 10.1021/ie050905r
   Gawel I, 2011, POLYMER MODIFIED BITUMEN: PROPERTIES AND CHARACTERISATION, P72
   Gehrke S, 2017, J CHEM PHYS, V147, DOI 10.1063/1.5001574
   Hanson DE, 2018, PHYS CHEM CHEM PHYS, V20, P8460, DOI 10.1039/c7cp06730e
   Hanson DE, 2013, J CHEM PHYS, V139, DOI 10.1063/1.4840096
   Hanson DE, 2011, J CHEM PHYS, V135, DOI 10.1063/1.3622487
   Hanson DE, 2009, J CHEM PHYS, V131, DOI 10.1063/1.3270166
   Hanson DE, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3071196
   Hill B, 2018, INT J PAVEMENT ENG, V19, P362, DOI 10.1080/10298436.2016.1175563
   Hioe J, 2015, ORG BIOMOL CHEM, V13, P157, DOI 10.1039/c4ob01656d
   Hirayama D, 2012, IND ENG CHEM RES, V51, P3975, DOI 10.1021/ie202077g
   Hosseinnezhad S., 2018, J CLEAN PROD
   Hosseinnezhad S, 2019, J CLEAN PROD, V225, P82, DOI 10.1016/j.jclepro.2019.03.219
   Hosseinnezhad S, 2015, RSC ADV, V5, P75519, DOI 10.1039/c5ra10267g
   Ibrahim MR, 2013, ADV MATER SCI ENG, V2013, DOI 10.1155/2013/415246
   Jana GK, 2005, MACROMOL RES, V13, P30, DOI 10.1007/BF03219012
   Karger-Kocsis J, 2013, J MATER SCI, V48, P1, DOI 10.1007/s10853-012-6564-2
   Kluppel M, 2001, MACROMOLECULES, V34, P8107, DOI 10.1021/ma010490v
   Kocevski S, 2012, CONSTR BUILD MATER, V34, P83, DOI 10.1016/j.conbuildmat.2012.02.040
   Liang M, 2017, MATER DESIGN, V127, P84, DOI 10.1016/j.matdes.2017.04.060
   Markey SJ, 2013, ORG LETT, V15, P6306, DOI 10.1021/ol403191k
   McBurney RT, 2012, RSC ADV, V2, P1264, DOI 10.1039/c1ra00909e
   Mohammadi-Jam S, 2014, ADV COLLOID INTERFAC, V212, P21, DOI 10.1016/j.cis.2014.07.002
   Muchall HM, 1999, J MOL STRUC-THEOCHEM, V469, P135, DOI 10.1016/S0166-1280(98)00574-0
   Navarro FJ, 2004, FUEL, V83, P2041, DOI 10.1016/j.fuel.2004.04.003
   Paje SE, 2010, APPL ACOUST, V71, P578, DOI 10.1016/j.apacoust.2009.12.003
   Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865
   Perez-Lepe A, 2007, J APPL POLYM SCI, V103, P1166, DOI 10.1002/app.25336
   Portela-Cubillo F, 2009, J ORG CHEM, V74, P4934, DOI 10.1021/jo900629g
   Rappoport D., 2008, COMPUT INORG BIOINOR, V594
   Romero-Sanchez MD, 2006, INT J ADHES ADHES, V26, P345, DOI 10.1016/j.ijadhadh.2005.05.002
   SCHAAFSMA Y, 1960, TETRAHEDRON, V10, P76, DOI 10.1016/0040-4020(60)85010-7
   SCHMIDT U, 1964, ANGEW CHEM INT EDIT, V3, P602, DOI 10.1002/anie.196406021
   Shu X, 2014, CONSTR BUILD MATER, V67, P217, DOI 10.1016/j.conbuildmat.2013.11.027
   Stockelhuber KW, 2011, MACROMOLECULES, V44, P4366, DOI 10.1021/ma1026077
   Treloar LRG, 1944, T FARADAY SOC, V40, P0059, DOI 10.1039/tf9444000059
   Tripathy AR, 2002, MACROMOLECULES, V35, P4616, DOI 10.1021/ma012110b
   Tyczkowski J, 2003, SURF COAT TECH, V174, P849, DOI 10.1016/S0257-8972(03)00419-5
   WALLING C, 1959, J AM CHEM SOC, V81, P1137, DOI 10.1021/ja01514a031
   Walton JC, 2014, ACCOUNTS CHEM RES, V47, P1406, DOI 10.1021/ar500017f
   Yu GX, 2011, PETROL SCI TECHNOL, V29, P411, DOI 10.1080/10916460903394102
   Yu J, 2017, IOP CONF SER-MAT SCI, V230, DOI 10.1088/1757-899X/230/1/012001
   Zhang XX, 2009, J POLYM RES, V16, P411, DOI 10.1007/s10965-008-9243-x
NR 54
TC 2
Z9 2
U1 15
U2 28
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 292
EP 300
DI 10.1016/j.resconrec.2019.05.041
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300027
DA 2020-05-12
ER

PT J
AU Aryapratama, R
   Pauliuk, S
AF Aryapratama, Rio
   Pauliuk, Stefan
TI Estimating in-use wood-based materials carbon stocks in Indonesia:
   Towards a contribution to the national climate mitigation effort
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Wood-based materials; In-use carbon stocks; Carbon sequestration;
   Material flow analysis; Dynamic stock modeling; Climate change
   mitigation
ID RESIDENTIAL BUILDINGS; ENERGY; FLOW; EMISSIONS; ECONOMY; STEEL;
   PRODUCTS; DYNAMICS; IMPACTS; JAKARTA
AB The carbon sequestered in harvested wood products (HWP) can contribute to climate change mitigation. As a fast-growing country with abundant forest resources, Indonesia potentially has vast HWP carbon stocks that need to be accurately assessed as a first step towards understanding the extent of their potential contribution in climate change mitigation. In this study, a dynamic materials stock and flow analysis for carbon in wood-based products in Indonesia was conducted, covering six end-use sectors. In general, only around 30.3% of the harvested wood (carbon mass) was converted into end-use materials in 2014, indicating a significantly low harvested wood conversion rate in Indonesia. There was a significant increase of wood-based products' carbon stocks in Indonesia from 1961 to 2016. There were 72 (-17/+15) Mt-C of wood stocks in Indonesian society in 2016, or equivalent to 0.28 t-C/capita. Buildings (42%) and infrastructure (31%) were the largest contributors to in-use carbon stocks. The product lifetime uncertainty had a significant influence on the estimate of total society's wood-based carbon stock. Indonesia's in-use stock of wood-based products in 2008 was below its stock level of steel (1.2 times smaller) and cement (5.3 times smaller). Both wood-steel and wood-cement stock ratios showed declining trends, indicating a shifting trend to non-renewable materials use over the past decades. This is the first study that accounts for the in-use wood-based carbon stocks in a developing country. Its results can facilitate further quantitative environmental assessments of non-renewable materials substitution and could help framing materials use policies for climate change mitigation.
C1 [Aryapratama, Rio; Pauliuk, Stefan] Univ Freiburg, Fac Environm & Nat Resources, Ind Ecol Res Grp, D-79106 Freiburg, Germany.
RP Aryapratama, R (reprint author), Univ Freiburg, Fac Environm & Nat Resources, Ind Ecol Res Grp, D-79106 Freiburg, Germany.
EM rio.aryapratama@indecol.uni-freiburg.de;
   stefan.pauliuk@indecol.uni-freiburg.de
FU Landesgraduiertenforderung LGF-BBW-8, Germany
FX This work by R.A. was supported by Landesgraduiertenforderung LGF-BBW-8,
   Germany, and is part of the bioeconomy graduate program BBW ForWerts.
CR Addinsyah A., 2017, J TEK ITS, V6, pD62 
   Almulqu A. A., 2017, DYNAMIC SIMULATION C
   Alongi DM, 2016, WETL ECOL MANAG, V24, P3, DOI 10.1007/s11273-015-9446-y
   Badan Pusat Statistik, 2016, IND KES RAK
   Badan Pusat Statistik, 2015, TAB INP OUTP IND 201
   Badan Pusat Statistik, 2010, IND KES RAK
   Bahtiar E. T., 2012, J ILMU DAN TEKNOL HA, V5, P15
   Bahtiar E. T., 2016, J FLMU TEKNOL KAYU T, V14, P62
   Balasbaneh AT, 2017, BUILD ENVIRON, V124, P357, DOI 10.1016/j.buildenv.2017.08.025
   Bedi AS, 2017, ENERG ECON, V68, P66, DOI 10.1016/j.eneco.2017.09.006
   Bin Marsono AK, 2015, CONSTR BUILD MATER, V85, P100, DOI 10.1016/j.conbuildmat.2015.03.083
   BIRU, 2018, ANN REP IND DOM BIOG
   Bosch M, 2015, RESOUR CONSERV RECY, V94, P99, DOI 10.1016/j.resconrec.2014.11.014
   Brunet-Navarro P, 2018, J CLEAN PROD, V170, P137, DOI 10.1016/j.jclepro.2017.09.135
   Brunet-Navarro P, 2017, MITIG ADAPT STRAT GL, V22, P1193, DOI 10.1007/s11027-016-9722-z
   Butarbutar T, 2016, CARBON BAL MANAGE, V11, DOI 10.1186/s13021-016-0046-9
   Cao Z, 2017, ENVIRON SCI TECHNOL, V51, P11468, DOI 10.1021/acs.est.7b03077
   Cao Z, 2017, RESOUR CONSERV RECY, V122, P21, DOI 10.1016/j.resconrec.2017.01.021
   Chen JX, 2008, CAN J FOREST RES, V38, P1947, DOI 10.1139/X08-046
   Chen WQ, 2015, ENVIRON SCI TECHNOL, V49, P3048, DOI 10.1021/es504353s
   Cote M, 2015, J IND ECOL, V19, P366, DOI 10.1111/jiec.12210
   Dalilla F., 2017, ESTIMASI KANDUNGAN D
   Dwiprabowo H., 2010, JURNAL ANALISIS KEBI, V7, P1
   Eggleston H.S., 2006, 2006 IPCC GUIDELINES
   Erawati E., 2018, 8 U RES C 2018 U MUH, P97
   FAO, 2015, FAO FOR PROD 2009 20
   FAO-RWEDP, 1999, IND WOOD EN SIT
   FAOSTAT, 2018, AGR FISH FOR NUTR
   Firman T, 2009, HABITAT INT, V33, P327, DOI 10.1016/j.habitatint.2008.08.005
   Frick H., 2007, DASAR DASAR ARSITEKT
   Furukawa T, 2015, GLOB ECOL CONSERV, V4, P150, DOI 10.1016/j.gecco.2015.06.011
   Gatto M, 2015, LAND USE POLICY, V46, P292, DOI 10.1016/j.landusepol.2015.03.001
   Gloser S, 2013, ENVIRON SCI TECHNOL, V47, P6564, DOI 10.1021/es400069b
   Graham V, 2017, ENVIRON RES LETT, V12, DOI 10.1088/1748-9326/aa6656
   Guest G, 2013, ENVIRON IMPACT ASSES, V43, P21, DOI 10.1016/j.eiar.2013.05.002
   Guillaume T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04755-y
   Gustavsson L, 2011, CLIMATIC CHANGE, V105, P129, DOI 10.1007/s10584-010-9876-8
   Hamilton SE, 2018, NAT CLIM CHANGE, V8, P240, DOI 10.1038/s41558-018-0090-4
   Harahap F, 2017, LAND USE POLICY, V61, P451, DOI 10.1016/j.landusepol.2016.11.033
   Hatayama H, 2010, ENVIRON SCI TECHNOL, V44, P6457, DOI 10.1021/es100044n
   Howard GS, 2000, AM PSYCHOL, V55, P509, DOI 10.1037/0003-066X.55.5.509
   Hu MM, 2010, RESOUR CONSERV RECY, V54, P591, DOI 10.1016/j.resconrec.2009.10.016
   Indonesia, 2012, AN KOM EKSP 2005 201
   Indonesia, 2006, AN KOM EKSP 1999 200
   Indonesia, 2017, PANDUAN PEMBANGUNAN
   Indonesia, 2018, AN KOM EKSP 2011 201
   Inventory NF, 2000, FOREST CARBON STOCK, DOI [10.1517/13543784.9.11.2663, DOI 10.1517/13543784.9.11.2663]
   Iordan CM, 2018, CARBON BAL MANAGE, V13, DOI 10.1186/s13021-018-0101-9
   IPCC, 2014, 2013 REV SUPPL METH
   IPCC, 2014, IPCC 2014 CLIM CHANG
   Ji CY, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13111132
   Kayo C, 2019, J IND ECOL, V23, P635, DOI 10.1111/jiec.12766
   Koh L. P., 2010, P NATL ACAD SCI USA, V107, DOI [10.1073/pnas.1012681107.E172-E172, DOI 10.1073/PNAS.1012681107.E172-E172]
   Koh LP, 2011, P NATL ACAD SCI USA, V108, P5127, DOI 10.1073/pnas.1018776108
   Koleangan H. S. J., 2008, CHEM PROG, V1, P43
   Larson C., 2012, MANAGING EST CARB, P1, DOI [10.1007/978-94-007-2232-3, DOI 10.1007/978-94-007-2232-3]
   Lasco RD, 2002, SCI CHINA SER C, V45, P55
   Lauk C, 2012, ENVIRON RES LETT, V7, DOI 10.1088/1748-9326/7/3/034023
   Liu G, 2013, ENVIRON SCI TECHNOL, V47, P4882, DOI 10.1021/es305108p
   Maddison Angus, 2010, STAT WORLD POPULATIO
   Martinico-Perez MFG, 2018, ECOL ECON, V147, P155, DOI 10.1016/j.ecolecon.2018.01.012
   Mitchard ETA, 2018, NATURE, V559, P527, DOI 10.1038/s41586-018-0300-2
   Muller DB, 2011, ENVIRON SCI TECHNOL, V45, P182, DOI 10.1021/es102273t
   Muller DB, 2013, ENVIRON SCI TECHNOL, V47, P11739, DOI 10.1021/es402618m
   Murdiyarso D., 2011, INDONESIAS FOREST MO
   Nakamura S, 2007, J IND ECOL, V11, P50, DOI 10.1162/jiec.2007.1290
   Ohno H, 2018, ENVIRON SCI TECHNOL, V52, P3899, DOI 10.1021/acs.est.7b06412
   Pablo S., 2018, MESKI MASUK ERA DIGI
   Partohardjono S., 2005, FOREST MARGINS SUMAT
   Pauliuk S, 2012, ENVIRON SCI TECHNOL, V46, P148, DOI 10.1021/es201904c
   Ramage MH, 2017, RENEW SUST ENERG REV, V68, P333, DOI 10.1016/j.rser.2016.09.107
   Roliadi H., 2005, J PENELIT HAS HUTAN, V23, P219
   Roubik H., 2018, Agronomy Research, V16, P1228, DOI 10.15159/AR.18.095
   Rozak AH, 2018, FOREST ECOL MANAG, V417, P154, DOI 10.1016/j.foreco.2018.03.007
   Sathre R, 2006, RESOUR CONSERV RECY, V47, P332, DOI 10.1016/j.resconrec.2005.12.008
   Schandl H, 2018, J IND ECOL, V22, P827, DOI 10.1111/jiec.12626
   Schandl H, 2010, GLOBAL ENVIRON CHANG, V20, P636, DOI 10.1016/j.gloenvcha.2010.06.003
   Setyawati D., 2003, FALSAFAT SAINS PROGA
   Sianipar T., 2015, JALAN JEMBATAN KAYO
   Simangunsong BCH, 2017, FOREST POLICY ECON, V81, P10, DOI 10.1016/j.forpol.2017.03.022
   Surahman U, 2017, J MATER CYCLES WASTE, V19, P657, DOI 10.1007/s10163-015-0460-1
   Sylviani Dwiprabowo H, 2013, J PENELIT SOS DAN EK, V10, P48
   Sylviani Suryandari E. Y, 2013, J PENELIT SOS DAN EK, V10, P235
   The World Bank, 2012, MEMP LAJ REV PERT SE
   Nguyen TC, 2019, J IND ECOL, V23, P663, DOI 10.1111/jiec.12773
   UNECE, 2010, 49 UNECE
   United Nations, 2015, TRANSF OUR WORLD 203, DOI [10.5363/tits.7.8_44, DOI 10.5363/TITS.7.8_44]
   Van Ewijk S, 2018, J IND ECOL, V22, P686, DOI 10.1111/jiec.12613
   Warren M, 2017, CARBON BAL MANAGE, V12, DOI 10.1186/s13021-017-0080-2
   Widi H., 2015, CENDANA NEWS
   Wiedenhofer D, 2019, ECOL ECON, V156, P121, DOI 10.1016/j.ecolecon.2018.09.010
   Wijaya SH, 2017, MOL INFORM, V36, DOI 10.1002/minf.201700050
   Wijedasa LS, 2018, GLOBAL CHANGE BIOL, V24, P4598, DOI 10.1111/gcb.14340
   Yang HQ, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8030216
   Zhang XB, 2018, FOREST POLICY ECON, V92, P181, DOI 10.1016/j.forpol.2018.05.005
   Zhu JM, 2015, LAND USE POLICY, V43, P63, DOI 10.1016/j.landusepol.2014.10.016
NR 96
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 301
EP 311
DI 10.1016/j.resconrec.2019.06.010
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300028
DA 2020-05-12
ER

PT J
AU Lin, SH
   Mao, JS
   Chen, WQ
   Shi, L
AF Lin, Shaohua
   Mao, Jiansu
   Chen, Weiqiang
   Shi, Lei
TI Indium in mainland China: Insights into use, trade, and efficiency from
   the substance flow analysis
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Indium; Substance flow analysis; Import/export trade; China
ID EUROPEAN COPPER CYCLE; GALLIUM
AB Based on the general framework of substance flow analysis, this paper quantifies the social economic metabolism of indium in China. The results show that in recent years, the output of indium primary products in China accounts for more than 50% of the worldwide production, but the domestic consumption is less than 20%. For the lack of key technologies for processing into indium tin oxide (ITO), more than 98% of the high quality ITO targets depend on imports. As the indium industry has been affected by policy, great changes have occurred in China's indium import/export trade, which has mainly focused on a few countries. There is a significant excess in indium primary products, which are mainly absorbed by national purchasing and the Pan Asian Nonferrous Metals Exchange. In the short-term this protects the development of China's primary indium industry, but in the long-term the development of indium still needs to rely on downstream industries. The quantitative analysis of indium flow can provide a quantitative scientific basis for adjusting the indium industrial structure, improving the indium industrial policy and realizing the sustainable development of the indium industry.
C1 [Lin, Shaohua; Shi, Lei] Tsinghua Univ, Sch Environm, State Key Lab Environm Protect & Ecol Ind, Beijing 100084, Peoples R China.
   [Mao, Jiansu] Beijing Normal Univ, Sch Environm, State Key Joint Lab Environm Simulat & Pollut Con, Beijing 100875, Peoples R China.
   [Chen, Weiqiang] Chinese Acad Sci, Inst Urban Environm, Key Lab Urban Environm & Hlth, Xiamen 361021, Fujian, Peoples R China.
RP Shi, L (reprint author), Tsinghua Univ, Sch Environm, State Key Lab Environm Protect & Ecol Ind, Beijing 100084, Peoples R China.
EM wqchen@iue.ac.cn; slone@tsinghua.edu.cn
RI CAS, KLUEH/T-5743-2019
FU National Key RD Project [2016YFF0201603]; National Key Joint Laboratory
   of environmental simulation and pollution control [14Y01ESPCT]; Major
   projects of the National Social Science Fund [11 ZD166]
FX The research was conducted with financial support from the National Key
   R&D Project (2016YFF0201603), the National Key Joint Laboratory of
   environmental simulation and pollution control (14Y01ESPCT) and the
   Major projects of the National Social Science Fund (11 &ZD166).
CR AM, 2016, DISTR PROD IND RES
   AM, 2016, US APPL IND
   AM, 2016, DISC IND ITS IND DEV
   [Anonymous], 2014, GEN ADM CUSTOMS PRC
   [Anonymous], 2015, INDIUM BISMUTH GERMA
   Cao Yongfeng, 2012, METROLOGY MEASUREMEN, V39, P55
   Chen W, 2016, RESOUR CONSERV RECY, V111, P67, DOI 10.1016/j.resconrec.2016.04.014
   China Nonferrous Metals Industry Association (CNMIA), 2015, YB NONF MET IND CHIN
   Choi CH, 2016, RESOUR CONSERV RECY, V114, P59, DOI 10.1016/j.resconrec.2016.04.012
   Deng Mengli, 2007, RAR MET CEM CARB, V02
   Ding N, 2016, J CLEAN PROD, V133, P1167, DOI 10.1016/j.jclepro.2016.05.129
   Du Yilun, 2014, J CHINA U MIN TECHNO, P11
   Graedel TE, 2002, ECOL ECON, V42, P9, DOI 10.1016/S0921-8009(02)00101-5
   Guo Peng, 2011, NEW MAT IND, P32
   Hong Tao, 2013, ENTERPRISE SCI TECHN, P22
   Huang Xiaoke, 2010, WORLD NONFERROUS MET, P34
   LI MC, 2008, CHIN ENG SCI, V5, DOI DOI 10.1115/1.2784284
   Liao Yaqin, 2014, DONGFANG ELECT REV, V28, P13
   Licht C, 2015, J IND ECOL, V19, P890, DOI 10.1111/jiec.12287
   Liu Qianbang, 2004, CHINA NONFERROUS MET, V04
   Lovik AN, 2015, ENVIRON SCI TECHNOL, V49, P5704, DOI 10.1021/acs.est.5b00320
   Lu Ting, 2015, J NAT RESOUR LIFE SC, P1008
   Nakajima K., 2007, MAT T, V72, P99
   National Bureau of Statistics of China, 2015, CHIN STAT YB
   Nong Jiantao, 2002, NONFERROUS METALL, P12
   Song Yu, 2008, SUBSTANCE FLOW ANAL
   Spatari S, 2002, ECOL ECON, V42, P27, DOI 10.1016/S0921-8009(02)00103-9
   Wang Ruixiang, 2008, NONFERROUS METALS, V01
   Wang Shukai, 2007, INDIUM METALLURGY
   Werner TT, 2015, T I MIN METALL B, V124, P213, DOI 10.1179/1743275815Y.0000000007
   Werner T, 2018, ROBOTICS, V7, DOI 10.3390/robotics7030033
   Wu Chengchun, 2002, J GUANGDONG NONFERRO
   Wu Mingming, 2014, CHINA LIGHT LIGHTING, V04, P1
   Wu Mingming, 2014, DATA DEV CHINAS SOLI
   Xie Keng, 2008, PROTECTION UHL MINER, V01
   Yoshimura A, 2013, MATER TRANS, V54, P102, DOI 10.2320/matertrans.M2012279
   YUAN TF, 2008, HUNAN NONFERROUS MET, V1, DOI DOI 10.1126/STKE.115JC1
   Yue WY, 2012, PROCEEDINGS OF THE 9TH CHINA NATIONAL CONVENTION ON SPORTS SCIENCE, VOL I: SPORTS PSYCHOLOGY AND PHYSICAL HEALTH, P118
   Zhang Wei, 2016, CHINAS NATL STRENGTH, P19
   Zhi Yan Consulting Group, 2016, REP IMP EXP SIT ZINC
NR 40
TC 1
Z9 1
U1 8
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 312
EP 321
DI 10.1016/j.resconrec.2019.05.028
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300029
DA 2020-05-12
ER

PT J
AU Zhang, BY
   Tong, YF
   Singh, S
   Cai, H
   Huang, JY
AF Zhang, Bruce Yizhe
   Tong, Yifan
   Singh, Soumya
   Cai, Hua
   Huang, Jen-Yi
TI Assessment of carbon footprint of nano-packaging considering potential
   food waste reduction due to shelf life extension
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Nano-packaging; Nanomaterial; Food waste; Food shelf life; Consumer
   behavior; Life cycle assessment
ID CYCLE ASSESSMENT; COLOR STABILITY; FRESH; NANOCOMPOSITES; POLYPROPYLENE;
   SYSTEMS; POLYETHYLENE; CONSUMPTION; STORAGE; IMPACT
AB Approximately 30 to 50% of food produced is wasted in industrialized countries, which has caused severe impacts both economically and environmentally. Recently, nano-packaging has been proved to be a promising technology to significantly prolong the shelf life of many food products, and thus a potential solution for source reduction of food waste. However, the production of nanomaterials requires extra input of resources and generates additional emissions and wastes. This study conducted a life cycle assessment to evaluate the net carbon footprint of nano-packaging from a systems perspective, considering its entire life cycle and ultimate application for food preservation. Based on the defined functional unit (Le., 1 kg of food product and the required amount of nano-packaging materials), the global warming potential (GWP) associated with the nano-packaging system was highly affected by the concentration of incorporated nanomaterials and the type of packaged food. Furthermore, the packaging-food ratio played an important role in the relative contributions of nanomaterial, polymer, and food to the GWP of a nano-packaging system. A consumer behavior study was also performed to more accurately correlate food shelf life extension with food waste reduction. The results indicated that even with less than 3 days of shelf life extension, there is a potential to gain a net beneficial effect of the use of nano-packaging on carbon footprint mitigation. This study developed a novel conceptual framework enabling a comparative assessment of direct life cycle impacts of nano-packaging in parallel to indirect benefits related to its use stage. The results are expected provide food manufacturers with the groundwork to make more informed decisions on nano-packaging applications.
C1 [Zhang, Bruce Yizhe; Singh, Soumya; Huang, Jen-Yi] Purdue Univ, Dept Food Sci, 745 Agr Mall Dr, W Lafayette, IN 47907 USA.
   [Tong, Yifan; Cai, Hua; Huang, Jen-Yi] Purdue Univ, Environm & Ecol Engn, 500 Cent Dr, W Lafayette, IN 47907 USA.
   [Cai, Hua] Purdue Univ, Sch Ind Engn, 315 N Grant St, W Lafayette, IN 47907 USA.
RP Huang, JY (reprint author), 745 Agr Mall Dr, W Lafayette, IN 47907 USA.
EM huang874@purdue.edu
RI Cai, Hua/B-2011-2014
OI Cai, Hua/0000-0002-5895-1664
FU Center for the Environment (C4E), Purdue University; USDA National
   Institute of Food and Agriculture, Hatch project [1014964]
FX This project was supported by the Center for the Environment (C4E),
   Purdue University, and the USDA National Institute of Food and
   Agriculture, Hatch project 1014964.
CR Biji KB, 2015, J FOOD SCI TECH MYS, V52, P6125, DOI 10.1007/s13197-015-1766-7
   Brodt S, 2013, FOOD POLICY, V42, P106, DOI 10.1016/j.foodpol.2013.07.004
   Bull M. K., 2004, Innovative Food Science & Emerging Technologies, V5, P135, DOI 10.1016/j.ifset.2003.11.005
   Caballero-Guzman A, 2015, WASTE MANAGE, V36, P33, DOI 10.1016/j.wasman.2014.11.006
   CEC, 2017, CHAR MAN FOOD LOSS W
   Conte A, 2015, FOOD RES INT, V78, P11, DOI 10.1016/j.foodres.2015.11.015
   Cushen M, 2012, TRENDS FOOD SCI TECH, V24, P30, DOI 10.1016/j.tifs.2011.10.006
   De Silva RT, 2017, CARBOHYD POLYM, V157, P739, DOI 10.1016/j.carbpol.2016.10.038
   Duncan TV, 2011, J COLLOID INTERF SCI, V363, P1, DOI 10.1016/j.jcis.2011.07.017
   Dwivedi P, 2012, AGR SYST, V108, P104, DOI 10.1016/j.agsy.2012.01.006
   Emamifar A, 2010, INNOV FOOD SCI EMERG, V11, P742, DOI 10.1016/j.ifset.2010.06.003
   EPA, 2018, ADV SUST MAT MAN 201
   Eriksson M, 2016, RESOUR CONSERV RECY, V107, P73, DOI 10.1016/j.resconrec.2015.11.022
   FAO, 2011, GLOBAL FOOD LOSSES F
   FELLERS PJ, 1988, J FOOD SCI, V53, P1699, DOI 10.1111/j.1365-2621.1988.tb07819.x
   Feraldi R, 2011, CRADLE TO GATE LIFE
   Garnett T, 2006, WORKING PAPER
   Geyer R, 2014, LIFE CYCLE ASSESSMEN
   Gunders, 2012, GUNDERS WASTED AM IS
   Gutierrez MM, 2017, FOOD RES INT, V91, P124, DOI 10.1016/j.foodres.2016.11.031
   Hall KD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007940
   Harding KG, 2007, J BIOTECHNOL, V130, P57, DOI 10.1016/j.jbiotec.2007.02.012
   Huang JY, 2017, INNOV FOOD SCI EMERG, V43, P216, DOI 10.1016/j.ifset.2017.08.012
   Khalaj MJ, 2016, TRENDS FOOD SCI TECH, V51, P41, DOI 10.1016/j.tifs.2016.03.007
   Lloret E, 2016, LWT-FOOD SCI TECHNOL, V66, P582, DOI 10.1016/j.lwt.2015.11.012
   Manfredi M, 2015, J CLEAN PROD, V95, P291, DOI 10.1016/j.jclepro.2015.02.048
   Manfredi M, 2015, J FOOD ENG, V147, P39, DOI 10.1016/j.jfoodeng.2014.09.018
   Middlemas S, 2015, J CLEAN PROD, V89, P137, DOI 10.1016/j.jclepro.2014.11.019
   Moller JKS, 2000, MEAT SCI, V54, P399, DOI 10.1016/S0309-1740(99)00116-3
   Osterwalder N, 2006, J NANOPART RES, V8, P1, DOI 10.1007/s11051-005-8384-7
   Pergola M, 2017, J CLEAN PROD, V142, P4059, DOI 10.1016/j.jclepro.2016.10.030
   Raccach M, 2007, J FOOD PROCESS PRES, V31, P129, DOI 10.1111/j.1745-4549.2007.00115.x
   Rajchl A, 2010, J FOOD ENG, V99, P465, DOI 10.1016/j.jfoodeng.2010.01.035
   Roes AL, 2007, J POLYM ENVIRON, V15, P212, DOI 10.1007/s10924-007-0064-5
   Roes AL, 2010, J NANOPART RES, V12, P2011, DOI 10.1007/s11051-009-9819-3
   Shen L, 2008, J POLYM ENVIRON, V16, P154, DOI 10.1007/s10924-008-0092-9
   Silvestre C, 2011, PROG POLYM SCI, V36, P1766, DOI 10.1016/j.progpolymsci.2011.02.003
   Sorrentino A, 2007, TRENDS FOOD SCI TECH, V18, P84, DOI 10.1016/j.tifs.2006.09.004
   Van Boxstael S, 2014, FOOD CONTROL, V37, P85, DOI 10.1016/j.foodcont.2013.08.043
   Venkat K., 2011, International Journal on Food System Dynamics, V2, P431
   Vilaplana F, 2010, POLYM DEGRAD STABIL, V95, P2147, DOI 10.1016/j.polymdegradstab.2010.07.016
   Villamonte G, 2014, P 9 INT C LIF CYCL A
   Vink ETH, 2003, POLYM DEGRAD STABIL, V80, P403, DOI 10.1016/S0141-3910(02)00372-5
   Vinyes E, 2017, J CLEAN PROD, V149, P313, DOI 10.1016/j.jclepro.2017.02.102
   Walser T, 2011, ENVIRON SCI TECHNOL, V45, P4570, DOI 10.1021/es2001248
   Wilson MD, 2019, CRIT REV FOOD SCI, V59, P411, DOI 10.1080/10408398.2017.1375892
   WRAP, 2011, NEW EST HOUS FOOD DR
   WRAP, 2017, EST FOOD SURPL WAST
   Zanoni B, 2005, J FOOD ENG, V70, P512, DOI 10.1016/j.jfoodeng.2004.10.019
   Zhang H, 2015, PACKAG TECHNOL SCI, V28, P761, DOI 10.1002/pts.2135
NR 50
TC 0
Z9 0
U1 12
U2 23
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 322
EP 331
DI 10.1016/j.resconrec.2019.05.030
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300030
DA 2020-05-12
ER

PT J
AU Ashraf, MS
   Ghouleh, Z
   Shao, YX
AF Ashraf, Muhammad Shoaib
   Ghouleh, Zaid
   Shao, Yixin
TI Production of eco-cement exclusively from municipal solid waste
   incineration residues
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Municipal solid waste incineration; MSWI residues; Eco-cement; Waste
   recycling; Resource conservation; Carbon sequestration
ID FLY-ASH; CARBONATION; MORTARS
AB Incineration is an effective way to reduce the volume of municipal solid waste (MSW) and recover energy as a co-benefit. The main challenge with this process lies in the management of the generated residues, namely, air pollution control (APC) lime, fly ash, and bottom ash. In this study, a novel approach is explored that could potentially allow using incineration energy and residues to produce an ecological cement (eco-cement) at a low synthesis temperature (1100 degrees C) with the ability to achieve structural binding strength when reacted with carbon dioxide. It was found that eco-cement made exclusively from residues (100%) had shown low early strength by carbonation activation and was more latent hydraulic. With 6% virgin additives, eco-cement could develop a strength of 55 MPa by 2 h carbonation, which was comparable to the performance of control ordinary Portland cement (OPC) hydrated for 28 days. Leaching tests validated the stability of the product, where concentrations of monitored heavy metals in the leachate solution were all well under regulatory limits. In the near future, eco-cement could possibly be produced within MSW incinerators by making use of abundantly generated heat for clinkering raw meals prepared from incineration residues. As a further step, concrete made from such cement could also be activated by carbon dioxide captured locally from emission stacks, thereby reducing an operation's carbon footprint and effectively diverting carbon emissions from the atmosphere.
C1 [Ashraf, Muhammad Shoaib; Ghouleh, Zaid; Shao, Yixin] McGill Univ, Dept Civil Engn, 817 Sherbrooke St West, Montreal, PQ H3A 2K6, Canada.
RP Shao, YX (reprint author), McGill Univ, Dept Civil Engn, 817 Sherbrooke St West, Montreal, PQ H3A 2K6, Canada.
EM yixin.shao@mcgill.ca
FU Natural Science and Engineering Research Council (NSERC) of
   CanadaNatural Sciences and Engineering Research Council of Canada;
   Emerald EFW Inc. in Brampton, Ontario, Canada
FX The authors gratefully acknowledge the support of the Natural Science
   and Engineering Research Council (NSERC) of Canada, and the Emerald EFW
   Inc. in Brampton, Ontario, Canada.
CR Aubert JE, 2004, CEMENT CONCRETE RES, V34, P957, DOI 10.1016/j.cemconres.2003.11.002
   Baciocchi R, 2009, WASTE MANAGE, V29, P2994, DOI 10.1016/j.wasman.2009.07.012
   Batchelor B, 2006, WASTE MANAGE, V26, P689, DOI 10.1016/j.wasman.2006.01.020
   BUKOWSKI JM, 1979, CEMENT CONCRETE RES, V9, P57, DOI 10.1016/0008-8846(79)90095-4
   El-Hassan H, 2013, ACI MATER J, V110, P441
   European Commission, 2015, 0702012014SI2697025E
   Fernandez Bertos M, 2004, J HAZARD MATER, V112, P193, DOI 10.1016/j.jhazmat.2004.04.019
   Ghouleh Z, 2018, J CLEAN PROD, V195, P268, DOI 10.1016/j.jclepro.2018.05.209
   Ghouleh Z, 2015, CONSTR BUILD MATER, V99, P175, DOI 10.1016/j.conbuildmat.2015.09.028
   Gunning PJ, 2009, WASTE MANAGE, V29, P2722, DOI 10.1016/j.wasman.2009.05.021
   Guo X., 2015, MATER STRUCT, V49, P2383
   Joseph AM, 2018, MATERIALS, V11, DOI 10.3390/ma11010141
   Kikuchi R, 2001, RESOUR CONSERV RECY, V31, P137, DOI 10.1016/S0921-3449(00)00077-X
   Lam C. H. K., 2010, SUSTAINABILITY, V2, P1
   Lange LC, 1996, WASTE MANAGE, V16, P749, DOI 10.1016/S0956-053X(97)00021-4
   Lee TC, 2009, CEMENT CONCRETE RES, V39, P651, DOI 10.1016/j.cemconres.2009.02.005
   Mindess S., 2002, CONCRETE
   Odler I., 2000, SPECIAL INORGANIC CE
   Rostami V, 2011, CONSTR BUILD MATER, V25, P3345, DOI 10.1016/j.conbuildmat.2011.03.025
   ROUSE RC, 1982, AM MINERAL, V67, P90
   Saikia N, 2007, WASTE MANAGE, V27, P1178, DOI 10.1016/j.wasman.2006.06.004
   Shao Y, 2013, MATER STRUCT, V48, P307
   Shi HS, 2009, J HAZARD MATER, V164, P750, DOI 10.1016/j.jhazmat.2008.08.077
   Shimoda T., 1999, P INT C CREAT CONCR, P17
   Siddique R, 2010, RESOUR CONSERV RECY, V54, P1037, DOI 10.1016/j.resconrec.2010.05.002
   United States Enviornment Protecting Agency, 2012, HAZ WAST
   Wieser T., 2014, P GEO C HELD ATL GEO, P234
   YOUNG JF, 1974, J AM CERAM SOC, V57, P394, DOI 10.1111/j.1151-2916.1974.tb11420.x
NR 28
TC 2
Z9 2
U1 18
U2 30
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 332
EP 342
DI 10.1016/j.resconrec.2019.06.018
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300031
DA 2020-05-12
ER

PT J
AU Xu, YF
   Wang, Z
   Jiang, Y
   Yang, YX
   Wang, F
AF Xu, Yifan
   Wang, Zheng
   Jiang, Ying
   Yang, Yanxia
   Wang, Fang
TI Small-world network analysis on fault propagation characteristics of
   water networks in eco-industrial parks
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Water network; Small-world network; Ant colony algorithm; Fault
   propagation
ID SYMBIOSIS NETWORKS; SYSTEM; METHODOLOGY; EVOLUTION; DESIGN; ULSAN
AB Water network failures in eco-industrial parks (EIPs) are often caused due to the spread of a fault from a small fault source. Therefore, it is necessary to investigate failure propagation characteristics to ensure the safety and stability of operations. This paper presents the fault propagation characteristics of water networks in EIPs. First, a water network model of an EIP is constructed based on the theory of small-world network. Second, the degree and betweenness centrality of nodes are used to identify the high-load nodes of water networks. The fault nodes are assumed to be the ones affecting the effluent-quality nodes. According to the ant colony algorithm, the failure propagation paths with the highest risk are found by fault attack and maximum load attack, respectively. The illustrated cases show that the proposed method can find weak links of water networks, which provides a basis for fault prevention, selection of key monitoring variables, and risk assessment.
C1 [Xu, Yifan; Wang, Zheng; Jiang, Ying; Yang, Yanxia] Qingdao Univ Sci & Technol, Coll Chem Engn, Qingdao 266042, Shandong, Peoples R China.
   [Wang, Fang] Qingdao Univ Sci & Technol, Coll Environm & Safety Engn, Qingdao 266042, Shandong, Peoples R China.
RP Wang, Z (reprint author), Qingdao Univ Sci & Technol, Coll Chem Engn, Qingdao 266042, Shandong, Peoples R China.
EM 1290983805@qq.com; wangzheng@qust.edu.cn; jyemily@163.com;
   287561676@qq.com; wangf@qust.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [41771575]
FX The authors thank the financial support provided by the National Natural
   Science Foundation of China (41771575).
CR Adler CO, 2014, PROCEDIA COMPUT SCI, V36, P345, DOI 10.1016/j.procs.2014.09.004
   Armando D. N., 2017, WATER SCI TECHNOL, V18, P767
   Bao ZJ, 2009, PHYSICA A, V388, P4491, DOI 10.1016/j.physa.2009.07.017
   Behera SK, 2012, J CLEAN PROD, V29-30, P103, DOI 10.1016/j.jclepro.2012.02.009
   Chae SH, 2010, APPL ENERG, V87, P1978, DOI 10.1016/j.apenergy.2009.12.003
   Chen WJ, 2018, RESOUR CONSERV RECY, V133, P438, DOI 10.1016/j.resconrec.2018.02.019
   Chertow MR, 2007, J IND ECOL, V11, P11, DOI 10.1162/jiec.2007.1110
   Cuguero-Escofet MA, 2016, CONTROL ENG PRACT, V49, P159, DOI 10.1016/j.conengprac.2015.11.005
   Dorigo M, 1996, IEEE T SYST MAN CY B, V26, P29, DOI 10.1109/3477.484436
   Eliades DG, 2010, IEEE T CONTR SYST T, V18, P1254, DOI 10.1109/TCST.2009.2035515
   Fan YP, 2017, RESOUR CONSERV RECY, V125, P9, DOI 10.1016/j.resconrec.2017.05.009
   Geng Y, 2010, J CLEAN PROD, V18, P993, DOI 10.1016/j.jclepro.2010.03.003
   Guo L, 2015, DESALIN WATER TREAT, V57, P1
   Halverson MJ, 2015, HYDROL EARTH SYST SC, V19, P3301, DOI 10.5194/hess-19-3301-2015
   Hao Q, 2017, RESOUR CONSERV RECY, V122, P106, DOI 10.1016/j.resconrec.2017.02.001
   KIM S, 2009, J ENVIRON MANAGE, V91, P690
   Kollat JB, 2011, WATER RESOUR RES, V47, DOI 10.1029/2010WR009194
   Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701
   Liu XF, 2014, PROCEDIA ENGINEER, V80, P506, DOI 10.1016/j.proeng.2014.09.108
   [刘忠华 Liu Zhonghua], 2014, [中国科学. 技术科学, Scientia Sinica Technologica], V44, P1280
   Lopez-Morales CA, 2019, RESOUR CONSERV RECY, V140, P1, DOI 10.1016/j.resconrec.2018.09.001
   Lovelady EM, 2009, ENVIRON PROG SUSTAIN, V28, P265, DOI 10.1002/ep.10326
   Gomez AMM, 2018, RESOUR CONSERV RECY, V135, P58, DOI 10.1016/j.resconrec.2017.08.007
   Martin M, 2018, RESOUR CONSERV RECY, V138, P246, DOI 10.1016/j.resconrec.2018.07.026
   Miciolino EE, 2017, IEEE DES TEST, V34, P44, DOI 10.1109/MDAT.2017.2682223
   Mirata M, 2005, J CLEAN PROD, V13, P993, DOI 10.1016/j.jclepro.2004.12.010
   Mirata M, 2004, J CLEAN PROD, V12, P967, DOI 10.1016/j.jclepro.2004.002.031
   Monfared MAS, 2014, PHYSICA A, V406, P24, DOI 10.1016/j.physa.2014.03.031
   Mukherjee R, 2017, COMPUT CHEM ENG, V103, P91, DOI 10.1016/j.compchemeng.2017.03.014
   Nazempour R, 2018, INT J DISAST RISK RE, V30, P225, DOI 10.1016/j.ijdrr.2018.04.029
   Pan M, 2016, APPL ENERG, V175, P305, DOI 10.1016/j.apenergy.2016.05.019
   Park HS, 2008, J ENVIRON MANAGE, V87, P1, DOI 10.1016/j.jenvman.2006.12.045
   Ragot J, 2006, J PROCESS CONTR, V16, P887, DOI 10.1016/j.jprocont.2006.06.005
   Rubio-Castro E, 2011, COMPUT CHEM ENG, V35, P1558, DOI 10.1016/j.compchemeng.2011.03.010
   Sun L., 2016, RESOURCES CONSERVATI, V119, P78
   Tiu BTC, 2017, RESOUR CONSERV RECY, V119, P89, DOI 10.1016/j.resconrec.2016.06.005
   Tunakova Y., 2017, BIONANOSCIENCE, V8, P1
   [王彤 Wang Tong], 2018, [中国给水排水, China Water & Wastewater], V34, P37
   [王政 Wang Zheng], 2017, [化工进展, Chemical Industry and Engineering Progress], V36, P1581
   Wu X., 2013, J WATER RESOURCES WA, V24, P145
   Xiao S., 2010, AS PAC POW EN ENG C, V1-4, P28
   Yazdani A, 2012, WATER RESOUR RES, V48, DOI 10.1029/2012WR011897
   Yazdani A, 2011, CHAOS, V21, DOI 10.1063/1.3540339
   Zhang C, 2016, APPL ENERG, V184, P88, DOI 10.1016/j.apenergy.2016.10.016
   Zhang Y, 2015, ECOL MODEL, V306, P174, DOI 10.1016/j.ecolmodel.2014.05.005
   Zhu Geng, 2005, Computer Measurement & Control, V13, P784
NR 46
TC 3
Z9 3
U1 7
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 343
EP 351
DI 10.1016/j.resconrec.2019.05.040
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300032
DA 2020-05-12
ER

PT J
AU Richter, A
   Ng, KTW
   Karimi, N
AF Richter, Amy
   Ng, Kelvin Tsun Wai
   Karimi, Nima
TI A data driven technique applying GIS, and remote sensing to rank
   locations for waste disposal site expansion
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Landfill expansion; Remote sensing imagery; GIS; Suitable waste site
   selection; Landfill regionalization; Thiessen polygons
ID LANDFILL; SELECTION; SYSTEMS; COVER; DUMPS; LIGHT; INDEX
AB Landfilling is the most common method for final treatment of municipal solid waste worldwide. Canadians generated 973 kg/cap of waste in 2016, and 73% of that was sent to landfills or incinerators. This study proposes a novel method which combines remote sensing and vector data to rank the suitability of current landfill sites and their area of influence for expansion in Saskatchewan, Canada; where there are currently more than 500 active landfills. This study found that using average normalized data, 55.3% of the land in the study area was suitable or moderately suitable for landfill expansion while 45% of the area was unsuitable for landfill expansion. Polygon 32, an area dominated by agriculture and pasture land, is the most suitable for landfill expansion based on the mean normalized rank and was ranked 9th (out of 39) in terms of standard deviation. Polygon 27 is the least suitable for landfill expansion, having the largest mean normalized rank, and was ranked 38th (out of 39) in terms of standard deviation. This method is advantageous compared to other decision-making tools which rely on expert opinion. This method relies solely on remote sensing and vector data; but is flexible enough that weighting of data sets can be applied by policy makers if so desired. Results show that using remote sensing data and vector data together are capable of capturing distinctly different aspects of the study area, and that vector data can be used as a proxy for imagery where cloud cover is present.
C1 [Richter, Amy; Ng, Kelvin Tsun Wai; Karimi, Nima] Univ Regina, Environm Syst Engn, Regina, SK S4S 0A2, Canada.
RP Ng, KTW (reprint author), Univ Regina, Environm Syst Engn, Regina, SK S4S 0A2, Canada.
EM kelvin.ng@uregina.ca
RI Ng, Kelvin Tsun Wai/H-6365-2019
OI Ng, Kelvin Tsun Wai/0000-0002-2045-9367
FU Natural Sciences and Engineering Research Council of CanadaNatural
   Sciences and Engineering Research Council of Canada [RGPIN-2019-06154];
   FEROF at the University of Regina
FX The research reported in this paper was supported by a grant from the
   Natural Sciences and Engineering Research Council of Canada
   (RGPIN-2019-06154) to the corresponding author, using computing
   equipment funded by FEROF at the University of Regina. The authors are
   grateful for their support. The views expressed herein are those of the
   writers and not necessarily those of our research and funding partners.
CR Agovino M, 2019, ECOL INDIC, V98, P297, DOI 10.1016/j.ecolind.2018.11.003
   Agovino M, 2018, ECOL INDIC, V89, P680, DOI 10.1016/j.ecolind.2018.02.045
   Agovino M, 2016, LAND USE POLICY, V57, P669, DOI 10.1016/j.landusepol.2016.06.027
   Agriculture and Agri-food Canada, 1998, GROUP
   Musse MA, 2018, INT J APPL EARTH OBS, V71, P95, DOI 10.1016/j.jag.2018.05.010
   Alexakis DD, 2014, ENVIRON EARTH SCI, V72, P467, DOI 10.1007/s12665-013-2966-y
   Bruce N, 2016, CAN J CIVIL ENG, V43, P351, DOI 10.1139/cjce-2015-0414
   CCEA 2017. Canadian Council on Ecological Areas, 2017, CONSERVATION AREAS R
   Chabuk AJ, 2017, ENVIRON EARTH SCI, V76, DOI 10.1007/s12665-017-6524-x
   Chen J, 2014, J DEPRESS ANXIETY, V3, P1, DOI DOI 10.1186/2193-2697-3-13
   Curtis FA, 1990, ENV IMPACT ASSES, V10, P285, DOI DOI 10.1016/0195-9255(90)90043-Y
   El Maguiri A, 2016, B ENG GEOL ENVIRON, V75, P1301, DOI 10.1007/s10064-016-0889-z
   Esri, 2017, ARCGIS DESKTOP RELEA
   Esri, 2018, CREATE THIESSEN POLY
   Esri Canada, 2014, CANADA POPULATED PLA
   Faisal K. S, 2011, THESIS
   Government of Alberta, 2018, LANDFILLS
   Government of Canada, 2011, LAKES AND RIVERS POL
   Government of Saskatchewan, 2018, LANDFILLS
   Government of Saskatchewan, 2017, SASKATCHEWAN SOLID W
   Hall DK, 2002, REMOTE SENS ENVIRON, V83, P181, DOI 10.1016/S0034-4257(02)00095-0
   Vu HL, 2017, WASTE MANAGE, V69, P315, DOI 10.1016/j.wasman.2017.08.028
   Ito M, 2009, B ENG GEOL ENVIRON, V68, P551, DOI 10.1007/s10064-009-0229-7
   Jin SM, 2005, REMOTE SENS ENVIRON, V94, P364, DOI 10.1016/j.rse.2004.10.012
   Keith S, 2015, SOLID WASTE MANAGEME
   Keske CMH, 2018, DETRITUS, V2, P63, DOI 10.31025/2611-4135/2018.13641
   Khan MMU, 2018, SCI TOTAL ENVIRON, V610, P1065, DOI 10.1016/j.scitotenv.2017.08.169
   Kontos TD, 2003, WASTE MANAGE RES, V21, P262, DOI 10.1177/0734242X0302100310
   Li KN, 2018, REMOTE SENS-BASEL, V10, DOI 10.3390/rs10020277
   Li X, 2017, INT J REMOTE SENS, V38, P5855, DOI 10.1080/01431161.2017.1351784
   Li XH, 2019, ISPRS J PHOTOGRAMM, V148, P103, DOI 10.1016/j.isprsjprs.2018.12.013
   Madi N, 2019, RESOUR CONSERV RECY, V141, P163, DOI 10.1016/j.resconrec.2018.10.018
   Mahmood K, 2017, ECOL INDIC, V82, P131, DOI 10.1016/j.ecolind.2017.06.042
   Mahmood K, 2016, WASTE MANAGE, V55, P118, DOI 10.1016/j.wasman.2016.04.020
   Manzo C, 2017, SCI TOTAL ENVIRON, V584, P1333, DOI 10.1016/j.scitotenv.2017.01.033
   Manzo C, 2016, J AFR EARTH SCI, V122, P63, DOI 10.1016/j.jafrearsci.2015.12.021
   Mu L, 2009, PRINT, P231
   NASA, 2018, GIBS AVAILABLE IMAGE
   NOM, 2014, VIIRS VISIBLE INFRAR
   Ouyang ZT, 2019, SCI TOTAL ENVIRON, V647, P1266, DOI 10.1016/j.scitotenv.2018.08.015
   Pan CL, 2019, J MATER CYCLES WASTE, V21, P478, DOI 10.1007/s10163-018-0809-3
   Pan CL, 2019, ENVIRON SCI POLLUT R, V26, P5724, DOI 10.1007/s11356-018-3967-x
   Pan CL, 2019, ENVIRON SCI POLLUT R, V26, P1821, DOI 10.1007/s11356-018-3751-y
   Powell JT, 2018, WASTE MANAGE, V80, P137, DOI 10.1016/j.wasman.2018.09.008
   QUATERNARY M, 2019, GEOLOGICAL SURVEY, V5, P17
   QUATERNARY M, 2016, GEOLOGICAL SURVEY, V101, P50, DOI DOI 10.1016/J.WASMAN.2007.09.032
   QUATERNARY M, GEOLOGICAL SURVEY
   Richter A, 2018, CAN SOC CIVIL ENG, V35, P18
   Richter A, 2019, SCIENTOMETRICS, V118, P1027, DOI 10.1007/s11192-019-03011-4
   Richter A, 2018, SUSTAIN CITIES SOC, V38, P420, DOI 10.1016/j.scs.2018.01.026
   Saskatchewan Ministry of the Economy, 2017, SURFICIAL GEOLOGY
   Siddiqui MZ, 1996, J ENVIRON ENG-ASCE, V122, P515, DOI 10.1061/(ASCE)0733-9372(1996)122:6(515)
   Simsek C, 2014, LANDSCAPE URBAN PLAN, V132, P1, DOI 10.1016/j.landurbplan.2014.08.007
   Spigolon LMG, 2018, WASTE MANAGE RES, V36, P606, DOI 10.1177/0734242X18773538
   STATISTICS C, 2018, CENS, V12, P3
   STATISTICS C, 2018, SOURCE, V150, P12, DOI DOI 10.1016/J.JAG.2016.04.004
   Sumathi VR, 2008, WASTE MANAGE, V28, P2146, DOI 10.1016/j.wasman.2007.09.032
   Urbanski JA, 2016, INT J APPL EARTH OBS, V51, P28, DOI 10.1016/j.jag.2016.04.004
   *USGS, 2018, UNITED STATES GEOLOG, V2018, P31, DOI DOI 10.1016/J.RSE.2014.10.009
   USGS, 2019, GEOLOGICAL SURVEY, P3, DOI DOI 10.1016/J.RESCONREC.2018.07.008
   USGS, 2018, SOURCE
   Wang Y, 2016, J MATER CYCLES WASTE, V18, P715, DOI 10.1007/s10163-015-0373-z
   Wang Y, 2018, RESOUR CONSERV RECY, V138, P40, DOI 10.1016/j.resconrec.2018.07.008
   Whitcraft AK, 2015, REMOTE SENS ENVIRON, V156, P438, DOI 10.1016/j.rse.2014.10.009
   Xiao HW, 2018, APPL ENERG, V231, P1070, DOI 10.1016/j.apenergy.2018.09.200
   YER AS, 2019, ENG GEOL, V3, P45, DOI DOI 10.1016/J.ENGGEO.2018.12.015
   Zha Y, 2003, INT J REMOTE SENS, V24, P583, DOI 10.1080/01431160304987
   Zhenyao S., 2012, J HYDROL, V472, P205, DOI DOI 10.1016/J.JHYDR0L.2012.09.019
NR 68
TC 1
Z9 1
U1 13
U2 23
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 352
EP 362
DI 10.1016/j.resconrec.2019.06.013
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300033
DA 2020-05-12
ER

PT J
AU Alaerts, L
   Van Acker, K
   Rousseau, S
   De Jaeger, S
   Moraga, G
   Dewulf, J
   De Meester, S
   Van Passel, S
   Compernolle, T
   Bachus, K
   Vrancken, K
   Eyckmans, J
AF Alaerts, Luc
   Van Acker, Karel
   Rousseau, Sandra
   De Jaeger, Simon
   Moraga, Gustavo
   Dewulf, Jo
   De Meester, Steven
   Van Passel, Steven
   Compernolle, Tine
   Bachus, Kris
   Vrancken, Karl
   Eyckmans, Johan
TI Towards a more direct policy feedback in circular economy monitoring via
   a societal needs perspective
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Monitoring framework; Meso indicators; Circular economy policy;
   Mobility; Consumption perspective; Circular business models
ID INDICATORS; FRAMEWORK
AB The increasing focus on circular economy at the level of governments and policy requires the development of appropriate indicators to effectively monitor the progress towards the circular economy. Currently two very different types of indicator areas are under development: (i) monitoring frameworks based on macro indicators that summarize the progress at (supra)national level, and (ii) micro indicators tailored towards assessing circularity at the level of products. It is not possible to obtain sufficiently direct feedback about the impact of policy interventions by either macro or micro indicators alone. In this paper, a conceptual approach is developed that aims to bridge the gap between the micro and macro level with meso level indicators, and thus ultimately deliver more direct feedback for policymakers, via the insertion of an extra level of meso indicators in between the macro and the micro level. These indicators have been extracted from a dedicated workshop that involved policy, sector and societal stakeholders. The aim of these indicators is to report on progress towards circular economy objectives based on the fulfillment of societal needs. In this way the consumption perspective is given a central position, and the role of circular business models is acknowledged. Following the development of the concept, the next steps towards tailored, flexible and agile monitoring frameworks for circular economy at (supra)national and regional level are outlined. The paper concludes with an illustrative example of the framework applied to the mobility system.
C1 [Alaerts, Luc; Van Acker, Karel] Katholieke Univ Leuven, Dept Mat Engn, Sustainabil Assessments Mat Life Cycles, Kasteelpk Arenberg 44, B-3001 Leuven, Belgium.
   [Van Acker, Karel; Rousseau, Sandra; De Jaeger, Simon; Eyckmans, Johan] Katholieke Univ Leuven, Ctr Econ & Corp Sustainabil CEDON, Warmoesberg 26, B-1000 Brussels, Belgium.
   [Moraga, Gustavo; Dewulf, Jo] Univ Ghent, Dept Green Chem & Technol, Coupure Links 653, B-9000 Ghent, Belgium.
   [De Meester, Steven] Univ Ghent, Dept Ind Biol Sci, Graaf Karel de Goedelaan 5, B-8500 Kortrijk, Belgium.
   [Van Passel, Steven] Univ Antwerp, Dept Engn Management, Prinsstr 13, B-2000 Antwerp, Belgium.
   [Compernolle, Tine] Univ Antwerp, Dept Econ, Prinsstr 13, B-2000 Antwerp, Belgium.
   [Bachus, Kris] Katholieke Univ Leuven, HIVA, Res Grp Sustainable Dev, Parkstr 47 Bus 5300, B-3000 Leuven, Belgium.
   [Vrancken, Karl] VITO Flemish Inst Technol Res, Boeretang 200, B-2400 Mol, Belgium.
   [Vrancken, Karl] Univ Antwerp, Dept Bioengn, Groenenborgerlaan 171, B-2020 Antwerp, Belgium.
RP Alaerts, L (reprint author), Katholieke Univ Leuven, Dept Mat Engn, Sustainabil Assessments Mat Life Cycles, Kasteelpk Arenberg 44, B-3001 Leuven, Belgium.
EM luc.alaerts@kuleuven.be
RI Rousseau, Sandra/C-8723-2011; Van Acker, Karel/E-6481-2011; Eyckmans,
   Johan/C-3754-2013
OI Rousseau, Sandra/0000-0001-8948-8644; Van Acker,
   Karel/0000-0002-5320-8839; Moraga, Gustavo/0000-0001-6775-1456;
   Eyckmans, Johan/0000-0002-2885-4740
FU Flemish administration via the Steunpunt Circulaire Economie (Policy
   Research Centre Circular Economy)
FX The authors are very grateful for financial support received from the
   Flemish administration via the Steunpunt Circulaire Economie (Policy
   Research Centre Circular Economy). This publication contains the
   opinions of the authors, not that of the Flemish administration. The
   Flemish administration will not carry any liability with respect to the
   use that can be made of the produced data or conclusions. The authors
   are also grateful to the numerous stakeholders for extended discussions
   and comments.
CR Alaerts L, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10051487
   [Anonymous], 2018, MAT EC
   Becker H, 2017, TRANSPORT RES A-POL, V97, P17, DOI 10.1016/j.tra.2017.01.004
   Blomsma F, 2017, J IND ECOL, V21, P603, DOI 10.1111/jiec.12603
   De Wit M., 2018, CIRCULARITY GAP REPO
   Di Maio F., 2015, J ENV PROT, V06, P1095, DOI DOI 10.4236/JEP.2015.610096
   Du XY, 2013, SCI TOTAL ENVIRON, V461, P781, DOI 10.1016/j.scitotenv.2013.02.099
   Dutch government, 2018, NAT AGR CIRC EC LETT
   EMF-Ellen MacArthur Foundation, 2015, METHODOLOGY, V23, DOI [10.1016/j.giq.2006.04.004, DOI 10.1016/J.GIQ.2006.04.004]
   European Commission, 2014, COM2014398 EUR COMM
   European Commission, 2018, MEAS PROGR CIRC EC E
   European Commission Closing the loop - an EU action plan for the cir- cular economy, 2015, COM2015614 EUR COMM
   Garcia-Barragan JF, 2019, ECOL ECON, V157, P369, DOI 10.1016/j.ecolecon.2018.12.003
   Geng Y, 2012, J CLEAN PROD, V23, P216, DOI 10.1016/j.jclepro.2011.07.005
   Ghisellini P, 2016, J CLEAN PROD, V114, P11, DOI 10.1016/j.jclepro.2015.09.007
   Giljum S, 2011, RESOUR CONSERV RECY, V55, P300, DOI 10.1016/j.resconrec.2010.09.009
   Hertwich E, 2003, P 1 INT WORKSH SUST
   Homrich AS, 2018, J CLEAN PROD, V175, P525, DOI 10.1016/j.jclepro.2017.11.064
   Jacobi N, 2018, RESOUR CONSERV RECY, V137, P156, DOI 10.1016/j.resconrec.2018.05.022
   Kirchherr J, 2017, RESOUR CONSERV RECY, V127, P221, DOI 10.1016/j.resconrec.2017.09.005
   Linder M, 2017, J IND ECOL, V21, P545, DOI 10.1111/jiec.12552
   Magnier C., 2017, 10 KEY INDICATORS M
   Maslow A.H., 1954, MOTIVATION PERSONALI
   Max-Neef M, 1992, REAL LIFE EC UNDERST, P197
   Mayer A, 2019, J IND ECOL, V23, P62, DOI 10.1111/jiec.12809
   McKinsey, 2015, GROWTH CIRC EC VIS C
   Moraga G, 2019, RESOUR CONSERV RECY, V146, P452, DOI 10.1016/j.resconrec.2019.03.045
   Moriguchi Y, 2007, J MATER CYCLES WASTE, V9, P112, DOI 10.1007/s10163-007-0182-0
   Nakanishi H., 2015, INT MANAG REV, V11, P89
   Nassar NT, 2015, J IND ECOL, V19, P1044, DOI 10.1111/jiec.12237
   Niero M, 2019, RESOUR CONSERV RECY, V140, P305, DOI 10.1016/j.resconrec.2018.10.002
   NOSS RF, 1990, CONSERV BIOL, V4, P355, DOI 10.1111/j.1523-1739.1990.tb00309.x
   Notarnicola B, 2017, J CLEAN PROD, V140, P753, DOI 10.1016/j.jclepro.2016.06.080
   OECD, 2018, AS PAC LOW CARB LIF
   Peterson EE, 2017, ECOL INDIC, V79, P265, DOI 10.1016/j.ecolind.2017.04.002
   Potting J, 2017, CIRCULAR EC MEASURIN
   Potting J., 2018, CIRCULAR EC WHAT WE
   Raworth K., 2017, DOUGHNUT EC 7 WAYS T
   Reichel A., 2016, 22016 EUR ENV AG
   Reike D, 2018, RESOUR CONSERV RECY, V135, P246, DOI 10.1016/j.resconrec.2017.08.027
   Saidani M, 2017, RECYCLING, V2, P6, DOI [10.3390/recycling2010006, DOI 10.3390/RECYCLING2010006]
   Schroeder P, 2019, J IND ECOL, V23, P77, DOI 10.1111/jiec.12732
   Smol M, 2017, CLEAN TECHNOL ENVIR, V19, P669, DOI 10.1007/s10098-016-1323-8
   Steffen W, 2015, SCIENCE, V347, DOI 10.1126/science.1259855
   Tukker A., 2006, NEW BUSINESS OLD EUR
   Vercalsteren A, 2018, INDICATORS CIRCULAR
NR 46
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 363
EP 371
DI 10.1016/j.resconrec.2019.06.004
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300034
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Zhou, HX
   Bhattarai, R
   Li, YK
   Li, SY
   Fan, YH
AF Zhou, Hongxu
   Bhattarai, Rabin
   Li, Yunkai
   Li, Shiyang
   Fan, Youheng
TI Utilization of coal fly and bottom ash pellet for phosphorus adsorption:
   Sustainable management and evaluation
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Coal ash reuse; Pelletized adsorbent; Foaming; Phosphate removal; Heavy
   metal leaching
ID WASTE-WATER; ISOTHERM MODELS; REMOVAL; PHOSPHATE; CARBONATION;
   POLLUTANTS; STABILIZATION; MECHANISMS; NUTRIENTS; HYDRATION
AB Recycling of coal combustion solids can have several environmental benefits. The objective of this study was to evaluate a sustainable approach to recycle coal fly ash and bottom ash as pelletized-adsorbents for dissolved phosphorus (P). Sodium Dodecyl Sulfate (SDS), a foaming agent, was added to enhance the phosphorus adsorption capacity of fly ash pellets (FAP) and bottom ash pellets (BAP) during the pellet fabrication. Ten types of fly ash pellets and bottom ash pellets with varying Sodium Dodecyl Sulfate proportions (FAP-0/BAP-0: 0% SDS; FAP-1/BAP-1: 2% SDS; FAP-2/BAP-2: 4% SDS; FAP-3/BAP-3: 6% SDS; FAP-4/BAP-4: 8% SDS by weight) were manufactured with a high temperature (700 degrees C) modification process. The results indicated that the bottom ash pellet was more suitable adsorbent than fly ash pellet due to the better phosphorus adsorption capacity and lower heavy metal leaching. After the addition of Sodium Dodecyl Sulfate, the volumetric porosity of fly ash pellets and bottom ash pellets increased by 45.5%-163.6%, 52.9%-76.5%, respectively. However, higher Sodium Dodecyl Sulfate fraction did not result in better pellet phosphorus removal, since FAP-2 and BAP-3 resulted in the highest phosphorus removal among the pellets tested in this study. The results from X-ray diffraction demonstrated that Calcium and Silica were the major phases in the pellets. This study provides a feasible approach to reuse fly ash and bottom ash as effective pelletized-adsorbents for water quality improvement. These pellets can be applied in edge-of-field and in-stream treatment to control P loss from the agricultural area.
C1 [Zhou, Hongxu; Bhattarai, Rabin; Fan, Youheng] Univ Illinois, Dept Agr & Biol Engn, Urbana, IL 61801 USA.
   [Zhou, Hongxu; Li, Yunkai] China Agr Univ, Coll Water Resources & Civil Engn, Beijing 100083, Peoples R China.
   [Li, Shiyang] Tongii Univ, Coll Environm Sci & Engn, Shanghai 200092, Peoples R China.
RP Bhattarai, R (reprint author), Univ Illinois, Dept Agr & Biol Engn, Urbana, IL 61801 USA.
EM rbhatta2@illinois.edu
OI Bhattarai, Rabin/0000-0002-3433-299X
FU USDA National Institute of Food and Agriculture, Hatch project
   [ILLU-741-379, 741119]; Student Sustainability Committee at the
   University of Illinois; China Scholarship CouncilChina Scholarship
   Council
FX This work was supported by the USDA National Institute of Food and
   Agriculture, Hatch project ILLU-741-379. We also acknowledge support
   provided by a grant (741119) from Student Sustainability Committee at
   the University of Illinois for the materials and sample analysis for
   this study. We appreciate the scholarship provided by China Scholarship
   Council to Honou Zhou to conduct this study. We are grateful to Dr.
   Kiran Subedi for his assistance in ICP-MS analysis.
CR Agriz C., 2018, J CLEAN PROD, V170, P25, DOI [10.1016/jidepro.2017.09.117, DOI 10.1016/JIDEPRO.2017.09.117]
   Ahmaruzzaman M, 2010, PROG ENERG COMBUST, V36, P327, DOI 10.1016/j.pecs.2009.11.003
   Allred BJ, 2010, T ASABE, V53, P39
   Asl SMH, 2019, J CLEAN PROD, V208, P1131, DOI 10.1016/j.jclepro.2018.10.186
   Asokbunyarat V, 2015, WATER AIR SOIL POLL, V226, DOI 10.1007/s11270-015-2415-5
   Badruzzaman M, 2004, WATER RES, V38, P4002, DOI 10.1016/j.watres.2004.07.007
   Chen J, 2013, NEUROLOGY, V80
   Chen M, 2007, J EUR CERAM SOC, V27, P1953, DOI 10.1016/j.jeurceramsoc.2006.05.101
   Chimenos JM, 1999, J HAZARD MATER, V64, P211, DOI 10.1016/S0304-3894(98)00246-5
   Chong MF, 2009, WATER RES, V43, P3326, DOI 10.1016/j.watres.2009.04.044
   Colangelo F, 2012, WASTE MANAGE, V32, P1179, DOI 10.1016/j.wasman.2011.12.013
   Conley DJ, 2009, SCIENCE, V323, P1014, DOI 10.1126/science.1167755
   Cui XQ, 2019, J CLEAN PROD, V207, P846, DOI 10.1016/j.jclepro.2018.10.027
   Dai LC, 2017, J ENVIRON MANAGE, V198, P70, DOI 10.1016/j.jenvman.2017.04.057
   Gan FQ, 2009, WATER RES, V43, P2907, DOI 10.1016/j.watres.2009.03.051
   Guo B, 2017, J ENVIRON MANAGE, V193, P410, DOI 10.1016/j.jenvman.2017.02.026
   Gustafsson JP, 2012, GEODERMA, V189, P304, DOI 10.1016/j.geoderma.2012.05.014
   Han Y, 2011, MATER CHARACT, V62, P817, DOI 10.1016/j.matchar.2011.05.014
   Hermassi M, 2017, J ENVIRON CHEM ENG, V5, P160, DOI 10.1016/j.jece.2016.11.027
   Huang WY, 2017, J ENVIRON MANAGE, V193, P470, DOI 10.1016/j.jenvman.2017.02.030
   Khelifi O, 2002, MAR POLLUT BULL, V45, P311, DOI 10.1016/S0025-326X(02)00107-8
   Koukouzas N, 2010, J HAZARD MATER, V173, P581, DOI 10.1016/j.jhazmat.2009.08.126
   Kundu S, 2006, CHEM ENG J, V122, P93, DOI 10.1016/j.cej.2006.06.002
   Lakshmi V, 2015, CERAM INT, V41, P14263, DOI 10.1016/j.ceramint.2015.07.056
   Lemly AD, 2015, ENVIRON POLLUT, V197, P55, DOI 10.1016/j.envpol.2014.11.027
   Li SY, 2018, J ENVIRON MANAGE, V207, P269, DOI 10.1016/j.jenvman.2017.11.040
   Li SY, 2017, J ENVIRON MANAGE, V189, P67, DOI 10.1016/j.jenvman.2016.12.042
   Lin CY, 2002, J ENVIRON SCI HEAL A, V37, P1509, DOI 10.1081/ESE-120013273
   Littler J, 2013, CHEMOSPHERE, V90, P1533, DOI 10.1016/j.chemosphere.2012.08.054
   Lu SG, 2009, J HAZARD MATER, V161, P95, DOI 10.1016/j.jhazmat.2008.02.123
   Lu XW, 2012, CHEMOSPHERE, V86, P817, DOI 10.1016/j.chemosphere.2011.11.043
   Mor S, 2016, J CLEAN PROD, V129, P673, DOI 10.1016/j.jclepro.2016.03.088
   National Primary Drinking Water Regulations (NPDWR), 2009, 816F09004 NPDWR EPA
   Papandreou AD, 2011, MINER ENG, V24, P1495, DOI 10.1016/j.mineng.2011.07.016
   Pengthamkeerati P, 2008, FUEL, V87, P2469, DOI 10.1016/j.fuel.2008.03.013
   Ragheb SM, 2013, HBRC J, V9, P270, DOI [10.1016/j.hbrcj.2013.08.005, DOI 10.1016/J.HBRCJ.2013.08.005]
   Rangabhashiyam S, 2014, J ENVIRON CHEM ENG, V2, P398, DOI 10.1016/j.jece.2014.01.014
   Ren XJ, 2019, J CLEAN PROD, V206, P374, DOI 10.1016/j.jclepro.2018.09.202
   Sabbas T, 2003, WASTE MANAGE, V23, P61, DOI 10.1016/S0956-053X(02)00161-7
   Singh N, 2019, RESOUR CONSERV RECY, V144, P240, DOI 10.1016/j.resconrec.2019.01.044
   SONG HS, 1990, CEMENT CONCRETE RES, V20, P815, DOI 10.1016/0008-8846(90)90015-P
   Su MH, 2015, ENVIRON SCI TECHNOL, V49, P14452, DOI 10.1021/acs.est.5b02072
   Sun WL, 2008, J HAZARD MATER, V154, P595, DOI 10.1016/j.jhazmat.2007.10.063
   U.S. Environmental Protection Agency (USEPA), 1993, METH DET IN SUBST EN
   USEPA, 1995, 841F95007 USEPA
   Van Gerven T, 2005, WASTE MANAGE, V25, P291, DOI 10.1016/j.wasman.2004.07.008
   Wang SB, 2006, J HAZARD MATER, V133, P243, DOI 10.1016/j.jhazmat.2005.10.034
   Wei XC, 2008, WATER RES, V42, P3275, DOI 10.1016/j.watres.2008.04.005
   Xu G, 2018, RESOUR CONSERV RECY, V136, P95, DOI 10.1016/j.resconrec.2018.04.010
   Xuan DX, 2018, J HAZARD MATER, V344, P73, DOI 10.1016/j.jhazmat.2017.10.002
   Yang J, 2009, J HAZARD MATER, V168, P331, DOI 10.1016/j.jhazmat.2009.02.024
   Zhang ZQ, 2018, J CLEAN PROD, V170, P379, DOI 10.1016/j.jclepro.2017.09.150
NR 52
TC 3
Z9 3
U1 18
U2 37
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 372
EP 380
DI 10.1016/j.resconrec.2019.06.017
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300035
DA 2020-05-12
ER

PT J
AU Liu, XG
   Wang, ZH
   Li, W
   Li, GM
   Zhang, YY
AF Liu, Xiaoguang
   Wang, Zhihao
   Li, Wei
   Li, Guomin
   Zhang, Yingyue
TI Mechanisms of public education influencing waste classification
   willingness of urban residents
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Public education; Theory of planned behavior; Conscientious personality;
   Classify household waste
ID PREDICTING RECYCLING BEHAVIOR; HOUSEHOLD HAZARDOUS-WASTE; 5
   PERSONALITY-TRAITS; PLANNED BEHAVIOR; SOURCE SEPARATION; POLICY;
   MANAGEMENT; CHINA; DETERMINANTS; GENERATION
AB On the basis of the theory of planned behavior, persuasion theory, and big five personality theory, this study constructed a mechanism model of the influence of public education on residents' willingness to classify household waste and analyzed the role of attitude, subjective norms, perceived behavior control, and conscientious personality. The model was validated using a questionnaire survey of 378 ordinary residents via hierarchical regression analysis. Results corroborate that attitude, subjective norms, and perceived behavior control partially mediate the relationship between public education and willingness to classify household waste. Conscientious personality moderates the relationship between public education and perceived behavioral control, but not the relationship of public education and attitude. In addition, the relationship between public education and subjective norms is not moderated by conscientious personality.
C1 [Liu, Xiaoguang; Wang, Zhihao; Li, Wei; Li, Guomin] Taiyuan Univ Technol, Sch Econ & Management, Taiyuan 030024, Shanxi, Peoples R China.
   [Zhang, Yingyue] Univ Elect Sci & Technol China, Chengdu 611731, Sichuan, Peoples R China.
RP Li, W (reprint author), Taiyuan Univ Technol, Sch Econ & Management, Taiyuan 030024, Shanxi, Peoples R China.
EM xinrongli@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [71602136, 71373170, 71774105, 41776199]; Shanxi
   Planning Office of Philosophy and Social Sciences [2018B024]
FX This research was supported by the National Natural Science Foundation
   of China (Grant Nos. 71602136, 71373170, 71774105, 41776199) and the
   Shanxi Planning Office of Philosophy and Social Sciences (Grant Nos.
   2018B024). The authors express their gratitude to the team members for
   their help in the data collection. Meanwhile, the authors would like to
   express their gratitude to the usable answers of survey respondents.
CR AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Ajzen I., 2005, HDB ATTITUDES
   Ajzen I, 1980, UNDERSTANDING ATTITU
   BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173
   BOLDERO J, 1995, J APPL SOC PSYCHOL, V25, P440, DOI 10.1111/j.1559-1816.1995.tb01598.x
   Botetzagias I, 2015, RESOUR CONSERV RECY, V95, P58, DOI 10.1016/j.resconrec.2014.12.004
   Busic-Sontic A, 2017, J ECON PSYCHOL, V62, P313, DOI 10.1016/j.joep.2017.06.012
   Calabro PS, 2009, WASTE MANAGE, V29, P2178, DOI 10.1016/j.wasman.2009.02.011
   Chan L, 2013, J ENVIRON PSYCHOL, V36, P96, DOI 10.1016/j.jenvp.2013.07.010
   Cheung SF, 1999, ENVIRON BEHAV, V31, P587, DOI 10.1177/00139169921972254
   Costa J. P. T., 1992, PERSONALITY INDIVIDU, V13, P653, DOI [DOI 10.1016/0191-8869(92)90236-I, 10.1016/0191-8869(92)90236-I]
   Davis G, 2008, AUST COMMUNITY PSYCH, V20, P105
   Ghani WAWA, 2013, WASTE MANAGE, V33, P1276, DOI 10.1016/j.wasman.2012.09.019
   Grazhdani D, 2016, WASTE MANAGE, V48, P3, DOI 10.1016/j.wasman.2015.09.028
   Grodzinska-Jurczak M, 2006, RESOUR CONSERV RECY, V46, P182, DOI 10.1016/j.resconrec.2005.06.010
   Gu BX, 2014, WASTE MANAGE, V34, P2414, DOI 10.1016/j.wasman.2014.06.002
   Guerrero LA, 2013, WASTE MANAGE, V33, P220, DOI 10.1016/j.wasman.2012.09.008
   Hovland CI, 1953, COMMUNICATION PERSUA
   Ittiravivongs A., 2012, ASIAN SOCIAL SCI, V8, P74, DOI DOI 10.5539/ASS.V8N6P74
   Jani D, 2015, INT J HOSP MANAG, V44, P48, DOI 10.1016/j.ijhm.2014.10.006
   JOHNSON JL, 1995, PERS INDIV DIFFER, V18, P127, DOI 10.1016/0191-8869(94)00109-6
   Judge TA, 2002, J APPL PSYCHOL, V87, P530, DOI 10.1037//0021-9010.87.3.530
   Kim Y, 2013, J COMMUN, V63, P498, DOI 10.1111/jcom.12034
   Knussen C, 2004, J ENVIRON PSYCHOL, V24, P237, DOI 10.1016/j.jenvp.2003.12.001
   Kvasova O, 2015, PERS INDIV DIFFER, V83, P111, DOI 10.1016/j.paid.2015.04.011
   Lapinski MK, 2005, COMMUN THEOR, V15, P127, DOI 10.1111/j.1468-2885.2005.tb00329.x
   Largo-Wight E, 2012, AM J HEALTH EDUC, V43, P66, DOI 10.1080/19325037.2012.10599221
   Lim-Wavde K, 2017, RESOUR CONSERV RECY, V120, P88, DOI 10.1016/j.resconrec.2016.10.007
   Liu TT, 2015, RESOUR CONSERV RECY, V104, P31, DOI 10.1016/j.resconrec.2015.09.004
   Liu WL, 2016, J CLEAN PROD, V134, P13, DOI 10.1016/j.jclepro.2015.10.124
   lyer E. S., 2007, J CONSUM BEHAV, V6, P32, DOI [DOI 10.1002/CB.206, 10.1002/cb]
   Mahmud SND, 2010, PROCD SOC BEHV, V9, DOI 10.1016/j.sbspro.2010.12.123
   Marquez MY, 2008, RESOUR CONSERV RECY, V52, P1299, DOI 10.1016/j.resconrec.2008.07.011
   Martin M, 2006, RESOUR CONSERV RECY, V48, P357, DOI 10.1016/j.resconrec.2005.09.005
   Matthies E, 2012, J ENVIRON PSYCHOL, V32, P277, DOI 10.1016/j.jenvp.2012.04.003
   Mee N, 2004, RESOUR CONSERV RECY, V42, P1, DOI 10.1016/j.resconrec.2003.12.003
   Milfont TL, 2012, J ENVIRON PSYCHOL, V32, P187, DOI 10.1016/j.jenvp.2011.12.006
   Moh YC, 2014, RESOUR CONSERV RECY, V82, P50, DOI 10.1016/j.resconrec.2013.11.004
   Murakami F, 2015, J CLEAN PROD, V96, P94, DOI 10.1016/j.jclepro.2014.03.083
   Oh J, 2015, J COMMUN, V65, P213, DOI 10.1111/jcom.12147
   Oztekin C, 2017, WASTE MANAGE, V62, P290, DOI 10.1016/j.wasman.2016.12.036
   Pakpour AH, 2014, WASTE MANAGE, V34, P980, DOI 10.1016/j.wasman.2013.10.028
   Poskus MS, 2017, J ENVIRON PSYCHOL, V54, P57, DOI 10.1016/j.jenvp.2017.10.003
   Preacher KJ, 2007, MULTIVAR BEHAV RES, V42, P185, DOI 10.1080/00273170701341316
   Qu Y, 2009, ECOL ENV, P135
   [曲英 Qu Ying], 2009, [管理评论, Management Review], V21, P108
   Ramayah T, 2012, J ENVIRON MANAGE, V102, P141, DOI 10.1016/j.jenvman.2012.02.025
   Ru XJ, 2018, RESOUR CONSERV RECY, V134, P91, DOI 10.1016/j.resconrec.2018.03.001
   Sakai S, 1996, WASTE MANAGE, V16, P395, DOI 10.1016/S0956-053X(96)00107-9
   SCHULTZ PW, 1995, J ENVIRON PSYCHOL, V15, P105, DOI 10.1016/0272-4944(95)90019-5
   Shalley CE, 2004, J MANAGE, V30, P933, DOI 10.1016/j.jm.2004.06.007
   Shao-Jun C, 2015, CHIN POPUL RESOURC E, DOI [10.3969/j.issn.1002-2104.2015.09.022, DOI 10.3969/J.ISSN.1002-2104.2015.09.022]
   Sidique SF, 2010, RESOUR CONSERV RECY, V54, P242, DOI 10.1016/j.resconrec.2009.08.006
   Sidique SF, 2010, RESOUR CONSERV RECY, V54, P163, DOI 10.1016/j.resconrec.2009.07.012
   Simmons D., 1990, J ENVIRON EDUC, V22, P13, DOI DOI 10.1080/00958964.1990.9943041
   Starr J, 2015, RESOUR CONSERV RECY, V99, P7, DOI 10.1016/j.resconrec.2015.03.009
   Stoeva K, 2017, WASTE MANAGE, V68, P732, DOI 10.1016/j.wasman.2017.06.005
   Struk M, 2017, RESOUR CONSERV RECY, V122, P155, DOI 10.1016/j.resconrec.2017.01.023
   Swami V, 2011, J ENVIRON PSYCHOL, V31, P21, DOI 10.1016/j.jenvp.2010.08.001
   Tonglet M, 2004, RESOUR CONSERV RECY, V42, P27, DOI 10.1016/j.resconrec.2004.02.001
   Tonglet M, 2004, RESOUR CONSERV RECY, V41, P191, DOI 10.1016/j.resconrec.2003.11.001
   Vicente P, 2008, WASTE MANAGE RES, V26, P140, DOI 10.1177/0734242X07077371
   Wadehra S, 2018, RESOUR CONSERV RECY, V134, P239, DOI 10.1016/j.resconrec.2018.03.013
   Wan C, 2014, RESOUR CONSERV RECY, V83, P141, DOI 10.1016/j.resconrec.2013.12.009
   Wan C, 2013, WASTE MANAGE, V33, P783, DOI 10.1016/j.wasman.2013.02.001
   Wang ZH, 2018, RESOUR CONSERV RECY, V133, P1, DOI 10.1016/j.resconrec.2018.01.014
   Wang ZH, 2018, J CLEAN PROD, V173, P256, DOI 10.1016/j.jclepro.2016.09.223
   Wang ZH, 2011, ENERG POLICY, V39, P3550, DOI 10.1016/j.enpol.2011.03.055
   Wang ZH, 2011, J CLEAN PROD, V19, P977, DOI 10.1016/j.jclepro.2010.09.016
   Wen XF, 2014, J MATER CYCLES WASTE, V16, P321, DOI 10.1007/s10163-013-0190-1
   [温忠麟 Wen Zhonglin], 2014, [心理科学进展, Advances in Psychological Science], V22, P731
   Xiao SJ, 2018, RESOUR CONSERV RECY, V134, P112, DOI 10.1016/j.resconrec.2018.02.032
   Xu L., 2017, J PUBLIC MANAG, V14, P142, DOI [10.16149/j.cnki.23-1523.2017.01.012, DOI 10.16149/J.CNKI.23-1523.2017.01.012]
   Xu L, 2018, RESOUR CONSERV RECY, V129, P219, DOI 10.1016/j.resconrec.2017.10.028
   Zhuang Y, 2008, WASTE MANAGE, V28, P2022, DOI 10.1016/j.wasman.2007.08.012
NR 75
TC 2
Z9 2
U1 38
U2 60
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 381
EP 390
DI 10.1016/j.resconrec.2019.06.001
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300036
DA 2020-05-12
ER

PT J
AU Ma, N
   Li, HJ
   Wang, YH
   Feng, SD
   Shi, JL
   Wang, K
AF Ma, Ning
   Li, Huajiao
   Wang, Yuhai
   Feng, Sida
   Shi, Jianglan
   Wang, Kai
TI Interaction pattern features and driving forces of intersectoral CO2
   emissions in China: A network motif analysis
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Network motif; Input-output; Complex network; Sector interaction
   pattern; CO2 emissions; China
ID CARBON-DIOXIDE EMISSIONS; INPUT-OUTPUT; DECOMPOSITION ANALYSIS;
   ENERGY-CONSUMPTION; BUILDING-BLOCKS; ECONOMIC-GROWTH; FOOTPRINTS;
   INTENSITY; INVENTORY; EVOLUTION
AB To identify the interaction pattern features and driving forces of intersectoral CO2 emissions, this paper studies the interaction pattern types, interaction linkage strengths and key interaction patterns of 28-sector CO2 emissions flow networks in China from 1997 to 2015 via network motif analysis. Network motif analysis is a useful tool for measuring interactions between agents and their function in networks. This paper extends network motif analysis by investigating the weighted edges of motifs to observe the function of motifs. The results show that in 1997-2002 and 2008-2015, the strongest carbon intensity sectors, including electricity production, metal smelting and gas production, were the greatest contributors to the increase in intersectoral CO2 emissions. From 2003 to 2007, the strongest energy intensity sectors, including electricity production and fuel processing, were the greatest contributors. In contrast, the strongest export intensity sectors, including other electronic equipment, leather manufacturing, instrumentation, and textile, were the largest contributors to the decrease in intersectoral CO2 emissions. Second, the strongest interaction linkages were between construction and nonmetallic products and metal smelting, machinery and construction and metal smelting, construction and nonmetallic products, construction and metal smelting. Third, the key interaction patterns for the increase in intersectoral CO2 emissions were patterns such as infrastructure-export, manufacturing intensive, energy consumption, and energy tracing, while the export-intensive pattern and high export pattern were the key interaction patterns for the decrease in intersectoral CO2 emissions. This paper is beneficial to the establishment of a coordinated emissions reduction mechanism across sectors.
C1 [Ma, Ning; Li, Huajiao; Feng, Sida; Shi, Jianglan] China Univ Geosci, Sch Econ & Management, Beijing 100083, Peoples R China.
   [Ma, Ning; Li, Huajiao; Feng, Sida; Shi, Jianglan] Minist Nat Resources, Key Lab Carrying Capac Assessment Resource & Envi, Beijing 100083, Peoples R China.
   [Ma, Ning; Li, Huajiao; Feng, Sida; Shi, Jianglan] Minist Nat Resources, Key Lab Strateg Studies, Beijing 100812, Peoples R China.
   [Wang, Yuhai] Beijing Normal Univ, Fac Geog Sci, Beijing 100875, Peoples R China.
   [Wang, Kai] China Mobile Commun Corp, Govt & Enterprise Serv Co, Dept Finance, Beijing 100053, Peoples R China.
RP Li, HJ (reprint author), China Univ Geosci, Sch Econ & Management, Beijing 100083, Peoples R China.; Li, HJ (reprint author), Minist Nat Resources, Key Lab Carrying Capac Assessment Resource & Envi, Beijing 100083, Peoples R China.; Li, HJ (reprint author), Minist Nat Resources, Key Lab Strateg Studies, Beijing 100812, Peoples R China.
EM hli@cugb.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [41701121, 41871202]; Beijing Youth Talents Funds
   [2017000020124G190]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
   [2-9-2017-041]; Graduate teaching reform program of China University of
   Geosciences, Beijing [YJG2019002]
FX This research is supported by grants from the National Natural Science
   Foundation of China (Grant No. 41701121 and No. 41871202), the Beijing
   Youth Talents Funds (2017000020124G190), the Fundamental Research Funds
   for the Central Universities (Grant No. 2-9-2017-041) and the Graduate
   teaching reform program of China University of Geosciences, Beijing
   (Grant No.YJG2019002).
CR Ahmad M, 2018, ENVIRON SCI POLLUT R, V25, P30617, DOI 10.1007/s11356-018-3054-3
   Antras P, 2012, AM ECON REV, V102, P412, DOI 10.1257/aer.102.3.412
   Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272
   Bergmann A, 2013, ENERG ENVIRON SCI, V6, P2745, DOI 10.1039/c3ee41194j
   [BP B. S. R. o. W], 2018, ENERGY
   Brown MT, 1996, ECOL ECON, V19, P219, DOI 10.1016/S0921-8009(96)00046-8
   BULLARD CW, 1975, ENERG POLICY, V3, P268, DOI 10.1016/0301-4215(75)90035-X
   Chen GQ, 2010, COMMUN NONLINEAR SCI, V15, P3647, DOI 10.1016/j.cnsns.2009.12.024
   Chen Shiyi, 2009, EC STUD J, V4, P41
   Chen ZM, 2013, COMMUN NONLINEAR SCI, V18, P1757, DOI 10.1016/j.cnsns.2012.11.004
   Cheng H, 2018, ENVIRON SCI TECHNOL, V52, P346, DOI 10.1021/acs.est.7b04608
   Conant GC, 2003, NAT GENET, V34, P264, DOI 10.1038/ng1181
   Du Q, 2018, ENVIRON SCI POLLUT R, V25, P24469, DOI 10.1007/s11356-018-2533-x
   Geard N, 2011, COMPLEXITY, V16, P48, DOI 10.1002/cplx.20341
   Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064
   Guan D, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2008GL036540
   Guan Q, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14141-1
   IEA, 2009, CO2 EM FUEL COMB HIG
   Jalil A, 2009, ENERG POLICY, V37, P5167, DOI 10.1016/j.enpol.2009.07.044
   Kashani ZRM, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-318
   Li F, 2011, ENERG POLICY, V39, P568, DOI 10.1016/j.enpol.2010.10.025
   Liao H, 2017, J CLEAN PROD, V166, P395, DOI 10.1016/j.jclepro.2017.08.033
   Lin BQ, 2013, RENEW SUST ENERG REV, V26, P389, DOI 10.1016/j.rser.2013.05.054
   Lin BQ, 2010, ENERG POLICY, V38, P613, DOI 10.1016/j.enpol.2009.10.014
   Liu HG, 2015, ENERG ECON, V50, P294, DOI 10.1016/j.eneco.2015.06.006
   [刘华军 Liu Huajun], 2016, [中国人口·资源与环境, China Population Resources and Environment], V26, P90
   Liu LC, 2007, ENERG POLICY, V35, P5892, DOI 10.1016/j.enpol.2007.07.010
   Liu LC, 2016, J CLEAN PROD, V133, P1053, DOI 10.1016/j.jclepro.2016.05.126
   [刘亮 Liu Liang], 2013, [系统工程理论与实践, Systems Engineering-Theory & Practice], V33, P1335
   Masoudi-Nejad A, 2012, IET SYST BIOL, V6, P164, DOI 10.1049/iet-syb.2011.0011
   Mazurie A, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-4-r35
   Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824
   Miu L., 2012, STUD SCI SCI, V30, P1468
   National Bureau of Statistics P. R. C, 2001, CHIN EN STAT YB 1997
   National Bureau of Statistics P. R. C, 2017, CHIN EN STAT YB 2017
   Ohnishi T, 2010, J ECON INTERACT COOR, V5, P171, DOI 10.1007/s11403-010-0066-6
   Onnela JP, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.065103
   Ouyang XL, 2015, RENEW SUST ENERG REV, V45, P838, DOI 10.1016/j.rser.2015.02.030
   Sarajlic A, 2016, SCI REP-UK, V6, DOI 10.1038/srep35098
   Shi JL, 2019, J CLEAN PROD, V226, P28, DOI 10.1016/j.jclepro.2019.04.015
   Sole RV, 2006, TRENDS ECOL EVOL, V21, P419, DOI 10.1016/j.tree.2006.05.013
   Squartini Tiziano, 2012, Self-Organizing Systems. 6th IFIP TC 6 International Workshop (IWSOS 2012). Proceedings, P24, DOI 10.1007/978-3-642-28583-7_3
   Su B, 2016, ENERG ECON, V59, P414, DOI 10.1016/j.eneco.2016.09.006
   Tian YH, 2013, ENERG POLICY, V56, P352, DOI 10.1016/j.enpol.2012.12.068
   Wang SJ, 2014, J GEOGR SCI, V24, P612, DOI 10.1007/s11442-014-1109-z
   Wang YL, 2013, J CLEAN PROD, V53, P252, DOI 10.1016/j.jclepro.2013.04.001
   Wang ZH, 2018, RENEW SUST ENERG REV, V82, P1068, DOI 10.1016/j.rser.2017.09.057
   Wang Z, 2018, J ENVIRON MANAGE, V226, P30, DOI 10.1016/j.jenvman.2018.08.018
   WBCSD WRI, 2009, GREENH GAS PROT CORP
   Wernicke S, 2006, BIOINFORMATICS, V22, P1152, DOI 10.1093/bioinformatics/btl038
   Wu SM, 2017, NAT HAZARDS, V85, P537, DOI 10.1007/s11069-016-2585-5
   Xie R, 2017, ENERG POLICY, V107, P688, DOI 10.1016/j.enpol.2017.04.021
   Yang J, 2014, RENEW SUST ENERG REV, V29, P499, DOI 10.1016/j.rser.2013.09.013
   Yang S., 2015, CHINA IND EC, V6, P55
   Zha DL, 2010, ENERG POLICY, V38, P3377, DOI 10.1016/j.enpol.2010.02.011
   Zhang M, 2009, ENERG POLICY, V37, P767, DOI 10.1016/j.enpol.2008.11.025
   Zhang Q, 2015, SUSTAINABILITY-BASEL, V7, P8223, DOI 10.3390/su7078223
   Zhang XP, 2009, ECOL ECON, V68, P2706, DOI 10.1016/j.ecolecon.2009.05.011
   Zhang YG, 2013, ENERG ECON, V40, P967, DOI 10.1016/j.eneco.2013.05.025
   Zhao Q.Z., 2017, SCI TECHNOL MANAG RE, V37, P233
   Zhao R, 2017, J CLEAN PROD, V142, P3083, DOI 10.1016/j.jclepro.2016.10.159
   Zhu BZ, 2018, APPL ENERG, V230, P1545, DOI 10.1016/j.apenergy.2018.09.026
NR 62
TC 3
Z9 3
U1 16
U2 29
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 391
EP 412
DI 10.1016/j.resconrec.2019.03.006
PG 22
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300037
DA 2020-05-12
ER

PT J
AU Teigiserova, DA
   Hamelin, L
   Thomsen, M
AF Teigiserova, Dominika Alexa
   Hamelin, Lorie
   Thomsen, Marianne
TI Review of high-value food waste and food residues biorefineries with
   focus on unavoidable wastes from processing
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Review
DE Food waste definition; Circular economy; Circular bioeconomy;
   Bioplastic; Platform chemicals; Enzyme
ID SOLID-STATE FERMENTATION; SUSTAINABLE CHEMISTRY; PLATFORM CHEMICALS;
   TOMATO PEEL; RECOVERY; PRODUCTS; LYCOPENE; VALORISATION; LEES;
   POLY-3-HYDROXYBUTYRATE
AB Processing of food is linked to unavoidable and inedible food waste that, despite efforts to minimize waste, will persevere. It nevertheless represents a stable feedstock for the future bioeconomy value chains and products. This study presents a systematic review of 149 examples from the scientific literature using inedible, unavoidable food residues and wastes for the production of value-added bio-based compounds that could substitute synthetic chemicals production. The main high-value products investigated are organic acids, bioplastics, colorants, enzymes and other platform chemicals. We found 44 examples of acid production with high variability in output (from 43 to 640 g kg(-1) waste), 9 examples of bioplastics (from 0.28 to 49 g L-1), 26 examples related to colorants (from 0.04 to more than 400 mg per 100 g), 22 cases of enzyme production (from 6000 Ug(-1)), 4 examples of protein (23.6 to 38.5 %wt. DM) and 44 cases of other high-value molecules such as pectin and single cell oils. Our findings highlight fermentation as a key technology for the valorization of the studied feedstock, with 76 examples out of the 149 reviewed. The review process also uncovered important limitations related to the lack of standardized food waste definitions, a barrier that is discussed and for which solutions are proposed. At the light of our findings, we further proposed guiding criteria towards the sustainable development of future biorefineries based on food waste. This work touches upon several Sustainable Development Goals, in particular goals 8.2, 9.5, and 12.3.
C1 [Teigiserova, Dominika Alexa; Thomsen, Marianne] Aarhus Univ, Dept Environm Sci, Res Grp EcoInd Syst Anal, Frederiksborgvej 399,Postboks 358, DK-4000 Roskilde, Denmark.
   [Hamelin, Lorie] Fed Univ Toulouse, Dept Engn Biol Syst & Proc LISBP, INSA, INRA,UMR792, 135 Ave Rangueil, F-31077 Toulouse, France.
   [Hamelin, Lorie] Fed Univ Toulouse, CNRS, UMR5504, 135 Ave Rangueil, F-31077 Toulouse, France.
RP Thomsen, M (reprint author), Aarhus Univ, Dept Environm Sci, Res Grp EcoInd Syst Anal, Frederiksborgvej 399,Postboks 358, DK-4000 Roskilde, Denmark.
EM hamelin@insa-toulouse.fr; mth@envs.au.dk
RI Hamelin, Lorie/I-2280-2018
OI Hamelin, Lorie/0000-0001-9092-1900; Thomsen,
   Marianne/0000-0003-2453-5141
FU Horizon 2020 project DECISIVE (Decentralised valorisation of biowaste)
   [689229]; Aarhus University Centre for Circular Bioeconomy; Aarhus
   University Graduate School of Science and Technology; Cambioscop project
   - French National Agency, Programme Investissement d'AvenirFrench
   National Research Agency (ANR) [ANR-17-MGPA-0006]
FX The research was performed as part of the Horizon 2020 project DECISIVE
   (Decentralised valorisation of biowaste) under grant agreement No
   689229. The work was further supported by Aarhus University Centre for
   Circular Bioeconomy and Aarhus University Graduate School of Science and
   Technology. The time used by L. Hamelin was funded by the Cambioscop
   project, supported by the French National Agency, Programme
   Investissement d'Avenir (ANR-17-MGPA-0006).
CR Abu Yazid N, 2017, THESIS
   Aggelopoulos T, 2014, FOOD CHEM, V145, P710, DOI 10.1016/j.foodchem.2013.07.105
   Alexandri M, 2017, CURR OPIN GREEN SUST, V8, P24, DOI 10.1016/j.cogsc.2017.09.003
   Allied market research, ACR AC MARK GLOB SIZ
   [Anonymous], 2018, BLOOMBERG MARKETS
   Arikan E.B., 2015, J CIV ENG ARCH, V9, P188, DOI [10.17265/1934-7359/2015.02.007, DOI 10.17265/1934-7359/2015.02.007]
   Bansal N, 2012, WASTE MANAGE, V32, P1341, DOI 10.1016/j.wasman.2012.03.006
   BCC Research, 2011, GLOB CAR MARK
   Bhatia Pankaj, 2011, PRODUCT LIFE CYCLE A
   Cavallo E, 2017, FEMS YEAST RES, V17, DOI 10.1093/femsyr/fox084
   Chaturvedi V, 2013, 3 BIOTECH, V3, P415, DOI 10.1007/s13205-013-0167-8
   Chavas JP, 2010, INT J PROD ECON, V126, P229, DOI 10.1016/j.ijpe.2010.03.010
   Cicala G, 2018, MATERIALS, V11, DOI 10.3390/ma11071191
   Ciesielski S, 2015, J CLEAN PROD, V106, P408, DOI 10.1016/j.jclepro.2014.09.040
   Cristobal J, 2018, BIORESOURCE TECHNOL, V259, P244, DOI 10.1016/j.biortech.2018.03.016
   De Corato U, 2018, RENEW SUST ENERG REV, V88, P326, DOI 10.1016/j.rser.2018.02.041
   De Moraes T., 2013, LWT-FOOD SCI TECHNOL, P1
   Dhillon GS, 2011, FOOD BIOPROCESS TECH, V4, P505, DOI 10.1007/s11947-010-0399-0
   Dimou C, 2016, BIOCHEM ENG J, V116, P157, DOI 10.1016/j.bej.2016.09.004
   Dimou C, 2015, FOOD RES INT, V73, P81, DOI 10.1016/j.foodres.2015.02.020
   dos Santos TC, 2012, FOOD CHEM, V133, P1299, DOI 10.1016/j.foodchem.2011.11.115
   Dutta D, 2005, AFR J BIOTECHNOL, V4, P1510
   EC, 2014, CIRC EC ZER WAST PRO
   EC, 2018, SUST BIOEC EUR STREN
   FAO, 2011, GLOBAL FOOD LOSSES F
   FAO, 2014, DEF FRAM FOOD LOSS
   Foley JA, 2011, NATURE, V478, P337, DOI 10.1038/nature10452
   Freitas A, 2015, J SCI FOOD AGR, V95, P44, DOI 10.1002/jsfa.6751
   Galanakis CM, 2012, TRENDS FOOD SCI TECH, V26, P68, DOI 10.1016/j.tifs.2012.03.003
   Gonzalez-Rivera J, 2016, GREEN CHEM, V18, P6482, DOI [10.1039/c6gc02200f, 10.1039/C6GC02200F]
   Guerin M, 2003, TRENDS BIOTECHNOL, V21, P210, DOI 10.1016/S0167-7799(03)00078-7
   Haddadi MH, 2018, INT J ENVIRON SCI TE, V15, P675, DOI 10.1007/s13762-017-1424-x
   Hartikainen H, 2018, WASTE MANAGE, V71, P502, DOI 10.1016/j.wasman.2017.10.026
   Henders S, 2015, ENVIRON RES LETT, V10, DOI 10.1088/1748-9326/10/12/125012
   Hic C, 2016, ENVIRON SCI TECHNOL, V50, P4269, DOI 10.1021/acs.est.5b05088
   IEA Bioenergy, 2012, BIOB CHEM VAL ADD PR
   Kallel F, 2017, ENVIRON PROG SUSTAIN, V36, P1765, DOI 10.1002/ep.12649
   Kandansamy K, 2012, INT J FOOD ENG, V8, DOI 10.1515/1556-3758.2647
   Kantifedaki A, 2018, J CLEAN PROD, V185, P882, DOI 10.1016/j.jclepro.2018.03.032
   Kaur G, 2018, CURR OPIN GREEN SUST, V9, P30, DOI 10.1016/j.cogsc.2017.11.003
   Kehili M, 2016, BIOTECHNOL BIOFUELS, V9, DOI 10.1186/s13068-016-0676-x
   Kiran EU, 2015, J CHEM TECHNOL BIOT, V90, P1364, DOI 10.1002/jctb.4551
   Le Quere C, 2018, EARTH SYST SCI DATA, V10, P405, DOI 10.5194/essd-10-405-2018
   Li C, 2018, J CLEAN PROD, V179, P151, DOI 10.1016/j.jclepro.2018.01.081
   Liu ZG, 2016, BIOTECHNOL BIOFUELS, V9, DOI 10.1186/s13068-016-0609-8
   Machmudah S, 2012, J FOOD ENG, V108, P290, DOI 10.1016/j.jfoodeng.2011.08.012
   Martins N, 2016, TRENDS FOOD SCI TECH, V52, P1, DOI 10.1016/j.tifs.2016.03.009
   Mika LT, 2018, CHEM REV, V118, P505, DOI 10.1021/acs.chemrev.7b00395
   Mirabella N, 2014, J CLEAN PROD, V65, P28, DOI 10.1016/j.jclepro.2013.10.051
   Monrad JK, 2010, J AGR FOOD CHEM, V58, P2862, DOI 10.1021/jf904087n
   Mushtaq Q, 2017, J FOOD PROCESS ENG, V40, DOI 10.1111/jfpe.12512
   Mustafa A, 2012, MOLECULES, V17, P1809, DOI 10.3390/molecules17021809
   Nguyen QA, 2017, BIORESOURCE TECHNOL, V244, P1039, DOI 10.1016/j.biortech.2017.07.169
   Obruca S, 2015, NEW BIOTECHNOL, V32, P569, DOI 10.1016/j.nbt.2015.02.008
   Osma JF, 2011, J ENVIRON MANAGE, V92, P2907, DOI 10.1016/j.jenvman.2011.06.052
   Ostergren K., 2014, FUSIONS DEFINITIONAL
   Pan YD, 2011, SCIENCE, V333, P988, DOI 10.1126/science.1201609
   Panda SK, 2016, ENVIRON RES, V146, P161, DOI 10.1016/j.envres.2015.12.035
   Panoutsou C, 2009, ENERG POLICY, V37, P5675, DOI 10.1016/j.enpol.2009.08.032
   Papaioannou EH, 2016, CRIT REV FOOD SCI, V56, P686, DOI 10.1080/10408398.2013.817381
   Papaioannou EH, 2012, ACTA BIOCHIM POL, V59, P71
   Parfitt J, 2010, PHILOS T R SOC B, V365, P3065, DOI 10.1098/rstb.2010.0126
   Patsalou M, 2017, J CLEAN PROD, V166, P706, DOI 10.1016/j.jclepro.2017.08.039
   Queiroz AUB, 2009, POLYM REV, V49, P65, DOI 10.1080/15583720902834759
   Ravindran R, 2016, TRENDS BIOTECHNOL, V34, P58, DOI 10.1016/j.tibtech.2015.10.008
   Ritala A, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02009
   Rivas B, 2006, J AGR FOOD CHEM, V54, P7904, DOI 10.1021/jf061617o
   Roland-Hoist D., 2013, BIOPLASTICS CALIFORN
   Ronzon T., 2017, BIOECONOMY REPORT 20, DOI [10.2760/20166, DOI 10.2760/20166]
   Sadh PK, 2018, BIORESOUR BIOPROCESS, V5, DOI 10.1186/s40643-017-0187-z
   Schieber A, 2017, ANNU REV FOOD SCI T, V8, P97, DOI 10.1146/annurev-food-030216-030135
   Sharma K, 2017, NUTRITION, V34, P29, DOI 10.1016/j.nut.2016.09.006
   Springmann M, 2018, NATURE, V562, P519, DOI 10.1038/s41586-018-0594-0
   Stenmarck A., 2016, ESTIMATES EUROPEAN F
   Stevenson DE, 2007, CELL MOL LIFE SCI, V64, P2900, DOI 10.1007/s00018-007-7237-1
   Strati IF, 2014, FOOD RES INT, V65, P311, DOI 10.1016/j.foodres.2014.09.032
   Takkellapati S, 2018, CLEAN TECHNOL ENVIR, V20, P1615, DOI 10.1007/s10098-018-1568-5
   Cesario MT, 2014, NEW BIOTECHNOL, V31, P104, DOI 10.1016/j.nbt.2013.10.004
   Tesfaye T, 2017, CLEAN TECHNOL ENVIR, V19, P2363, DOI 10.1007/s10098-017-1443-9
   Tonini D, 2016, GCB BIOENERGY, V8, P690, DOI 10.1111/gcbb.12290
   Tsiropoulos I, 2015, J CLEAN PROD, V90, P114, DOI 10.1016/j.jclepro.2014.11.071
   UN, 2016, GOAL 12 ENS SUST CON
   United Nations, 2017, TIER CLASS GLOB SDG
   United Nations, 2015, TRANSF OUR WORLD 203, DOI [10.1007/s13398-014-0173-7.2, DOI 10.1007/S13398-014-0173-7.2]
   Urbonaviciene D, 2012, J FOOD AGRIC ENVIRON, V10, P142
   Villa ALV, 2013, BMC BIOTECHNOL, V13, DOI 10.1186/1472-6750-13-15
   Vea E. B., 2018, PROCEDIA CIRP
   Verma N, 2011, BIORESOURCES, V6, P1505
   Vermeulen SJ, 2012, ANNU REV ENV RESOUR, V37, P195, DOI 10.1146/annurev-environ-020411-130608
   Waller JL, 2012, BIORESOURCE TECHNOL, V120, P285, DOI 10.1016/j.biortech.2012.06.024
   Wang LJ, 2013, T ASABE, V56, P217
   West PC, 2014, SCIENCE, V345, P325, DOI 10.1126/science.1246067
   World Resources Institute (WRI), 2016, FOOD LOSS WAST ACC R
   Xue L, 2017, ENVIRON SCI TECHNOL, V51, P6618, DOI 10.1021/acs.est.7b00401
   Yang XG, 2015, RENEW SUST ENERG REV, V49, P335, DOI 10.1016/j.rser.2015.04.114
   Zhu CJ, 2010, BIOTECHNOL PROGR, V26, P424, DOI 10.1002/btpr.355
   Zink T, 2017, J IND ECOL, V21, P593, DOI 10.1111/jiec.12545
   Zion Market Research, 2018, FREE AN BIOPL MARK
   Zion Market Research, 2017, GLOB REN CHEM MARK S
NR 99
TC 5
Z9 5
U1 19
U2 44
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 413
EP 426
DI 10.1016/j.resconrec.2019.05.003
PG 14
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300038
DA 2020-05-12
ER

PT J
AU Huang, YY
   Duan, HB
   Dong, D
   Song, QB
   Zuo, J
   Jiang, WP
AF Huang, Yuanyuan
   Duan, Huabo
   Dong, Dan
   Song, Qingbin
   Zuo, Jian
   Jiang, Weiping
TI How to evaluate the efforts on reducing CO2 emissions for megacities?
   Public building practices in Shenzhen city
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Energy-saving buildings; Life cycle assessment; Carbon dioxide
   emissions; Mitigation strategy; Shenzhen city
ID LIFE-CYCLE ASSESSMENT; GREENHOUSE-GAS EMISSIONS; ENVIRONMENTAL IMPACTS;
   MATERIAL EFFICIENCY; ASSESSMENT LCA; CONSTRUCTION; ENERGY; PERFORMANCE;
   DEMOLITION; STOCK
AB China' cities have made great efforts to seek effective measures to encourage and promote energy-saving building practices, for decades. Shenzhen, a fast-growing megacity in Southern China, has been one of the first practitioners to vigorously promote sustainable development in the building sector, for over 15 years. This study was therefore designed to employ the life cycle assessment approach to quantify the efforts of Shenzhen's public building practices, and evaluate its real 'achievement' by quantifying the CO2 emissions (CO(2)e) reduction over the past decades. The results show that the total CO(2)e from public buildings sectors in Shenzhen city have increased rapidly, from 15 Mt in 2005 to 22 Mt CO(2)e in 2016, because of the fast growth of public buildings' construction activities. However, current low-carbon' efforts have only reduced CO(2)e by approximately 0.5 Mt annually over the past decade, and thus could not offset the rapid growth arising from the increase in floor area. This is hardly enough to contribute proportionally to the city's overall reduction target. In addition, we conducted a scenario analysis to determine the optimal mitigation measures. The results imply that accelerating the energy-saving renovation of existing buildings is a promising approach and could meet the pressing mitigation needs. These findings could not only inform evidence-based policies to promote the adoption of energy-saving building technologies in Shenzhen, but also shed light on sustainable transition in other megacities.
C1 [Huang, Yuanyuan; Duan, Huabo; Dong, Dan; Jiang, Weiping] Shenzhen Univ, Coll Civil & Transportat Engn, Shenzhen 518060, Peoples R China.
   [Song, Qingbin] Macau Univ Sci & Technol, Macau Environm Res Inst, Macau, Peoples R China.
   [Zuo, Jian] Univ Adelaide, Sch Architecture & Built Environm, Adelaide, SA 5005, Australia.
RP Duan, HB (reprint author), Shenzhen Univ, Coll Civil & Transportat Engn, Shenzhen 518060, Peoples R China.
EM huabo@szu.edu.cn
OI Zuo, Jian/0000-0002-8279-9666
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [NSFC 51478267]; Natural Science Foundation of
   Guangdong ProvinceNational Natural Science Foundation of Guangdong
   Province [2017A030313438]
FX This work was financially supported by the National Natural Science
   Foundation of China (NSFC 51478267) and the Natural Science Foundation
   of Guangdong Province (2017A030313438).
CR Allwood JM, 2011, RESOUR CONSERV RECY, V55, P362, DOI 10.1016/j.resconrec.2010.11.002
   BG, 2017, INT MEAS MAN EN CONS
   BMCHURD, 2016, EN SAV DEV CIV BUILD
   BMCHURD, 2017, INT MEAS MAN DEM PRO
   Cabeza LF, 2014, RENEW SUST ENERG REV, V29, P394, DOI 10.1016/j.rser.2013.08.037
   CABR, 1995, 2695 CABR JGJ
   Chang Y, 2016, J CLEAN PROD, V113, P274, DOI 10.1016/j.jclepro.2015.11.014
   Chow L. C, 2007, ENERG POLICY, V29, P1099
   CHURDC, 2016, FUNDS MAN MEAS EN SA
   CHURDC, 2016, 13 5 YEAR PLAN BUILD
   Dong YH, 2015, BUILD ENVIRON, V89, P183, DOI 10.1016/j.buildenv.2015.02.020
   DRCSM, 2013, MED LONG TERM PLAN L
   Frischknecht R, 2007, OVERVIEW METHODOLOGY, P1
   Gonzalez AG, 2005, ACCREDIT QUAL ASSUR, V10, P324, DOI 10.1007/s00769-005-0934-2
   Herrmann IT, 2015, J CLEAN PROD, V86, P163, DOI 10.1016/j.jclepro.2014.08.004
   Hong JK, 2015, J CLEAN PROD, V103, P249, DOI 10.1016/j.jclepro.2014.11.023
   Hossain MU, 2019, RESOUR CONSERV RECY, V145, P160, DOI 10.1016/j.resconrec.2019.02.030
   Hossain MU, 2019, RESOUR CONSERV RECY, V142, P10, DOI 10.1016/j.resconrec.2018.11.010
   Hu S, 2016, ENERG POLICY, V92, P158, DOI 10.1016/j.enpol.2016.01.032
   Huang T, 2013, RESOUR CONSERV RECY, V72, P91, DOI 10.1016/j.resconrec.2012.12.013
   IEA, 2017, WORLD EN OUTL 2017 C
   IEA, 2017, TRACK PROGR BUILD
   Jiang P, 2014, URBAN CLIM, V10, P92, DOI 10.1016/j.uclim.2014.10.004
   Kajaste R, 2016, J CLEAN PROD, V112, P4041, DOI 10.1016/j.jclepro.2015.07.055
   Lamnatou C, 2019, SCI TOTAL ENVIRON, V660, P1576, DOI 10.1016/j.scitotenv.2018.12.461
   Lin JY, 2018, J CLEAN PROD, V171, P972, DOI 10.1016/j.jclepro.2017.10.040
   Liu G, 2013, NAT CLIM CHANGE, V3, P338, DOI [10.1038/nclimate1698, 10.1038/NCLIMATE1698]
   Ma JJ, 2017, BUILD ENVIRON, V117, P36, DOI 10.1016/j.buildenv.2017.03.005
   Ma MD, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9101744
   Ma X. W, 2017, HEATING VENTIL AIR C, V47, P15
   Mao C, 2013, ENERG BUILDINGS, V66, P165, DOI 10.1016/j.enbuild.2013.07.033
   Miatto A, 2017, RESOUR CONSERV RECY, V122, P143, DOI 10.1016/j.resconrec.2017.01.015
   Milford RL, 2013, ENVIRON SCI TECHNOL, V47, P3455, DOI 10.1021/es3031424
   Na W, 2009, ENERG POLICY, V37, P2087, DOI 10.1016/j.enpol.2008.12.032
   NDRC, 2016, CLEAN DEV MECH CHIN
   Rezaei F, 2019, BUILD ENVIRON, V153, P158, DOI 10.1016/j.buildenv.2019.01.034
   SCC, 2016, 13 5 YEAR CONTR PLAN
   SG, 2016, SPEC SUPP MEAS BUILD
   SG, 2017, 13 5 YEAR PLAN EN CO
   SGBA, 2015, GREEN BUILD DEM CAS
   SHCB, 2016, NOT FURTH PROM EN SA
   SHCB, 2015, 13 5 YEAR PLAN BUILD
   SHCB, 2018, MAN MEAS SPEC FUNDS
   Shi Q, 2017, J CLEAN PROD, V166, P615, DOI 10.1016/j.jclepro.2017.08.056
   Teixeira ER, 2016, J CLEAN PROD, V112, P2221, DOI 10.1016/j.jclepro.2015.09.124
   Trevisan L, 2016, J PHYS C SER, V733
   Wang T, 2016, RENEW SUST ENERG REV, V56, P484, DOI 10.1016/j.rser.2015.11.037
   Wang X, 2016, ADV MECH ENG, V8, DOI 10.1177/1687814016628395
   Yim SYC, 2018, BUILDINGS, V8, DOI 10.3390/buildings8110147
   Zgola M.L, 2011, TRIAGE APPROACH STRE, P64
   Zhang Y, 2015, RES POTENTIAL POLICY
NR 51
TC 2
Z9 2
U1 12
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 427
EP 434
DI 10.1016/j.resconrec.2019.06.015
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300039
DA 2020-05-12
ER

PT J
AU Kuo, TC
   Chiu, MC
   Chung, WH
   Yang, TI
AF Kuo, Tsai-Chi
   Chiu, Ming-Chuan
   Chung, Wu-Hsun
   Yang, Tzu-, I
TI The circular economy of LCD panel shipping in a packaging logistics
   system
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Circular economy; Reverse logistics; 3R; LCD panel; Product packaging
ID LIFE-CYCLE ASSESSMENT; WASTE MANAGEMENT
AB In a circular economy, an enterprise should pursue long-term business and economic opportunities for environmental and societal benefits. One of the critical issues in industries with a circular economy is the development of the reverse logistics system for semi-finished product packaging and shipping. There are several challenges while designing this system; for example, the use of reusable semi-finished product shipping boxes and a logistics system for shipping the products and returning these boxes. In this research, under the context of global manufacturing, a logistics system for reusable semi-finished product packaging in LCD panel industry is studied. The cost models of semi-finished product packaging in a traditional logistics mode and a green logistics mode are introduced. In the green logistics mode, the shipping boxes are redesigned to be reusable and capable of accommodating multiple various-sized panels simultaneously. The cost models involve material cost, shipping, and recycling cost. The economic performances of the traditional and green logistics modes at different package recycling levels are analyzed. The results show that the total cost of the green logistics mode is beneficial, always lower than that of the traditional logistics mode, even at a low recycling rate (30%). In addition, in the green mode, the material cost of shipping boxes is the most influential sector of the total cost.
C1 [Kuo, Tsai-Chi; Yang, Tzu-, I] Chung Yuan Christian Univ, Dept Ind & Syst Engn, Taoyuan, Taiwan.
   [Kuo, Tsai-Chi] Chung Yuan Christian Univ, R&D Ctr Membrane Technol, Taoyuan, Taiwan.
   [Chiu, Ming-Chuan] Natl Tsing Hua Univ, Dept Ind Engn & Engn Management, Hsinchu, Taiwan.
   [Chung, Wu-Hsun] Natl Taiwan Ocean Univ, Dept Transportat Sci, Keelung, Taiwan.
RP Chung, WH (reprint author), Natl Taiwan Ocean Univ, Dept Transportat Sci, Keelung, Taiwan.
EM wxc218@ntou.edu.tw
OI Kuo, Tsai Chi/0000-0002-4661-5276
FU Ministry of Science and Technology (MOST), Taiwan, R.O.C. [MOST
   105-2622-E-007-015-CC3, MOST 106-2621-M-033-002]
FX The study was supported by the Ministry of Science and Technology
   (MOST), Taiwan, R.O.C. under Grant MOST 105-2622-E-007-015-CC3 and MOST
   106-2621-M-033-002.
CR Albrecht S, 2013, INT J LIFE CYCLE ASS, V18, P1549, DOI 10.1007/s11367-013-0590-4
   Brouwer MT, 2018, WASTE MANAGE, V71, P62, DOI 10.1016/j.wasman.2017.10.034
   Cahill R, 2011, WASTE MANAGE RES, V29, P455, DOI 10.1177/0734242X10379455
   Chang Q., 2008, INT J BUS MANAG, V9, P96
   Chen M, 2006, THESIS
   Chung SH, 2018, RESOUR CONSERV RECY, V128, P259, DOI 10.1016/j.resconrec.2016.06.025
   da Cruz NF, 2012, J CLEAN PROD, V37, P8, DOI 10.1016/j.jclepro.2012.05.043
   Dahlbo H, 2018, WASTE MANAGE, V71, P52, DOI 10.1016/j.wasman.2017.10.033
   De Jaeger S, 2014, RESOUR CONSERV RECY, V85, P106, DOI 10.1016/j.resconrec.2013.08.006
   Doppner D. A., 2018, P 51 HAW INT C SYST
   Duan HB, 2019, RESOUR CONSERV RECY, V144, P137, DOI 10.1016/j.resconrec.2019.01.037
   Dubiel M, 1996, PACKAGING TECHNOLOGY, V9, P237
   EC, 2018, PACK PACK WAST
   EC, 2018, 2018 CIRC EC PACK
   FA, 2004, LIF CYCL INV PACK OP
   Ferreira S, 2017, J ENVIRON PLANN MAN, V60, P773, DOI 10.1080/09640568.2016.1181609
   Ferrer G, 2001, PROD OPER MANAG, V10, P112
   Gil MJA, 2001, OMEGA-INT J MANAGE S, V29, P457
   Guide VDR, 2000, J OPER MANAG, V18, P467, DOI 10.1016/S0272-6963(00)00034-6
   Hervani AA, 2005, BENCHMARKING, V12, P330, DOI 10.1108/14635770510609015
   Kim E, 2013, EUR J OPER RES, V231, P337, DOI 10.1016/j.ejor.2013.05.052
   Klaiman K, 2016, RESOUR CONSERV RECY, V115, P1, DOI 10.1016/j.resconrec.2016.08.021
   Kong DM, 2008, FRONT ECON CHINA, V3, P1, DOI 10.1007/s11459-008-0001-0
   Kuo TC, 2010, ROBOT CIM-INT MANUF, V26, P100, DOI 10.1016/j.rcim.2009.05.004
   Kuo TC, 2018, COMPUT ECON, V52, P1353, DOI 10.1007/s10614-017-9675-7
   Kuo TC, 2014, INT J COMPUT INTEG M, V27, P266, DOI 10.1080/0951192X.2013.814157
   Li L, 2014, TRANSPORT RES E-LOG, V70, P190, DOI 10.1016/j.tre.2014.06.018
   Lu HA, 2012, J MAR SCI TECH-TAIW, V20, P431, DOI 10.6119/JMST-011-0322-1
   Mitra S, 2007, OMEGA-INT J MANAGE S, V35, P553, DOI 10.1016/j.omega.2005.10.003
   Rao P, 2005, INT J OPER PROD MAN, V25, P898, DOI 10.1108/01443570510613956
   Reuters, 2017, AL SINGL DAY SAL SMA
   Rodrigue J., 2013, GREEN LOGISTICS
   Rosenau W. V., 1996, J BUSINESS LOGISTICS, V17, P139
   Song DP, 2009, MARIT POLICY MANAG, V36, P291, DOI 10.1080/03088830903056934
   Stock J. R., 1992, CISC VIS NETW IND GL
   Stock J. R., 2011, TRANSPORT LOGISTICS
   Telenko Cassandra, 2008, ASME 2008 INT DES EN
   Teunter R, 2004, COMPUT IND ENG, V46, P431, DOI 10.1016/j.cie.2004.01.006
   Tseng ML, 2018, RESOUR CONSERV RECY, V131, P146, DOI 10.1016/j.resconrec.2017.12.028
   Walker Helen, 2008, Journal of Purchasing and Supply Management, V14, P69, DOI 10.1016/j.pursup.2008.01.007
   Xie YY, 2017, EUR J OPER RES, V257, P223, DOI 10.1016/j.ejor.2016.07.053
   Yildiz-Geyhan E, 2019, RESOUR CONSERV RECY, V143, P119, DOI 10.1016/j.resconrec.2018.12.028
   Yildiz-Geyhan E, 2017, RESOUR CONSERV RECY, V124, P1, DOI 10.1016/j.resconrec.2017.04.003
   Zabaniotou A, 2003, J CLEAN PROD, V11, P549, DOI 10.1016/S0959-6526(02)00076-8
   Zhang QH, 2015, INT J PROD ECON, V168, P234, DOI 10.1016/j.ijpe.2015.07.002
NR 45
TC 0
Z9 0
U1 9
U2 22
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 435
EP 444
DI 10.1016/j.resconrec.2019.06.022
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300040
DA 2020-05-12
ER

PT J
AU Borsatto, JMLS
   Amui, LBL
AF Lima Silva Borsatto, Jaluza Maria
   Liboni Amui, Lara Bartocci
TI Green innovation: Unfolding the relation with environmental regulations
   and competitiveness
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Green innovation; Environmental regulations; Developed countries;
   Developing countries; Structural equation modeling
ID RESEARCH-AND-DEVELOPMENT; SUPPLY CHAIN MANAGEMENT; EMPIRICAL-EVIDENCE;
   ECO-INNOVATION; PRODUCT INNOVATION; INSTITUTIONAL PRESSURES;
   PERFORMANCE; CHINA; FIRMS; SUSTAINABILITY
AB The present study intends to analyze how the degree of severity of environmental regulations and the international competitiveness of the countries affects the efforts in Green Innovation (GI) of companies of the industrial sector of Developed Countries (MEDC) and developing countries (LEDC). The survey sample consisted of 186 industrial companies, which are listed in the Financial Times' top 500 companies by market value in 2015, of which 114 were MEDC and 72 were LEDC. For the analysis, we used Structural Equation Modeling to verify the relationship between the variables. The main results were, among the antecedents of the green innovation analyzed, the rigor of the environmental regulations of the countries and the size of the companies had a statistically significant positive impact of the industrial enterprises of the MEDC and LEDC only in the IV2 construct, composed of the variables Global Compact and environmental investments. The competitiveness of the countries did not have a positive influence on the GI effort of the companies, and the Degree of Internationalization of companies has not had a significant effect on any of the GI constructs. Moreover, the results also showed that the relationship between environmental regulation and GI is moderated positively by the size of the companies and moderated negatively by the degree of internationalization, and the relation between the competitiveness of the countries and GI is negatively moderated by the size of the companies and moderated positively by its degree of internationalization. Although there is a prevailing view that environmental regulations provide a greater effort on the part of companies with green innovation, in this study it was verified that this relation can be positive or negative, and can also be modified by external factors such as size and the degree of internationalization of companies.
C1 [Lima Silva Borsatto, Jaluza Maria] Univ Fed Uberlandia, FAGEN UFU Sch Management & Business, Av Joao Naves de Avila,2121 Bloco 1F Sala 216, BR-38400902 Uberlandia, MG, Brazil.
   [Lima Silva Borsatto, Jaluza Maria; Liboni Amui, Lara Bartocci] Univ Sao Paulo, FEA RP USP Sch Econ Business Adm & Accounting Rib, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
RP Borsatto, JMLS (reprint author), Univ Fed Uberlandia, FAGEN UFU Sch Management & Business, Av Joao Naves de Avila,2121 Bloco 1F Sala 216, BR-38400902 Uberlandia, MG, Brazil.
EM jaluza.silva@ufu.br; lara.liboni@gmail.com
RI Liboni, Lara/AAI-9237-2020
OI Liboni, Lara/0000-0002-4729-7943; Borsatto, Jaluza
   Maria/0000-0002-8852-4583
CR Aguilera-Caracuel J, 2013, ORGAN ENVIRON, V26, P365, DOI 10.1177/1086026613507931
   Aguilera-Caracuel J, 2012, INT BUS REV, V21, P847, DOI 10.1016/j.ibusrev.2011.09.009
   Akisik O., 2014, J MANAG CONTROL, V25, P259, DOI DOI 10.1007/S00187-014-0198-2
   Amores-Salvado J, 2015, TECHNOL FORECAST SOC, V96, P288, DOI 10.1016/j.techfore.2015.04.004
   Amores-Salvado J, 2014, J CLEAN PROD, V83, P356, DOI 10.1016/j.jclepro.2014.07.059
   Amran YHM, 2015, CONSTR BUILD MATER, V101, P990, DOI 10.1016/j.conbuildmat.2015.10.112
   Apak S, 2015, PROCD SOC BEHV, V181, P207, DOI 10.1016/j.sbspro.2015.04.882
   Aragon-Correa JA, 1998, ACAD MANAGE J, V41, P556, DOI 10.2307/256942
   Arenhardt DL, 2016, INT J INNOV MANAG, V20, DOI 10.1142/S1363919616500043
   Barla P, 2007, J ENVIRON ECON MANAG, V53, P291, DOI 10.1016/j.jeem.2006.10.004
   Barnett V, 1994, OUTLIERS STAT DATA
   Belin J., 2011, DETERMINANTS SPECIFI
   Bernauer T., 2007, POLIT VIERTELJAHR, V39, P323
   Brunnermeier SB, 2003, J ENVIRON ECON MANAG, V45, P278, DOI 10.1016/S0095-0696(02)00058-X
   Cai WG, 2014, J CLEAN PROD, V79, P239, DOI 10.1016/j.jclepro.2014.05.035
   Cai YY, 2017, ANN OPER RES, V255, P141, DOI 10.1007/s10479-015-1927-0
   Cainelli Giulio, 2011, International Journal of Technology, Policy and Management, V11, P328, DOI 10.1504/IJTPM.2011.042090
   Capar N, 2003, J INT BUS STUD, V34, P345, DOI 10.1057/palgrave.jibs.8400036
   Chen CF, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8020153
   Chen YS, 2006, J BUS ETHICS, V67, P331, DOI 10.1007/s10551-006-9025-5
   Chen YS, 2012, MANAGE DECIS, V50, P368, DOI 10.1108/00251741211216197
   Chiarvesio M., 2013, TRANSIT STUD REV, V20, P389, DOI [DOI 10.1007/s11300-013-0287-1, DOI 10.1007/S11300-013-0287-1]
   Dangelico RM, 2016, BUS STRATEG ENVIRON, V25, P560, DOI 10.1002/bse.1886
   Dangelico R, 2010, J BUS ETHICS, V95, P471, DOI 10.1007/s10551-010-0434-0
   DIMAGGIO PJ, 1983, AM SOCIOL REV, V48, P147, DOI 10.2307/2095101
   Doran J, 2012, EUR J INNOV MANAG, V15, P421, DOI 10.1108/14601061211272367
   Dubey R, 2017, INT J PROD ECON, V193, P63, DOI 10.1016/j.ijpe.2017.06.029
   Dubey R, 2016, RESOUR CONSERV RECY, V106, P78, DOI 10.1016/j.resconrec.2015.11.008
   Eiadat Y, 2008, J WORLD BUS, V43, P131, DOI 10.1016/j.jwb.2007.11.012
   Feldman I. R., 2012, ENV QUALITY MANAGEME, V10, P69
   Fernandez-Feijoo B, 2014, J BUS ETHICS, V122, P53, DOI 10.1007/s10551-013-1748-5
   Ferraz C., 2002, REGULACAO MERCADO PR
   Frondel M, 2008, ECOL ECON, V66, P153, DOI 10.1016/j.ecolecon.2007.08.016
   Gaur AS, 2009, BRIT J MANAGE, V20, P172, DOI 10.1111/j.1467-8551.2007.00558.x
   Ghisetti C, 2014, J CLEAN PROD, V75, P106, DOI 10.1016/j.jclepro.2014.03.097
   GRANT RM, 1987, J INT BUS STUD, V18, P79, DOI 10.1057/palgrave.jibs.8490413
   GREEN K, 1994, FUTURES, V26, P1047, DOI 10.1016/0016-3287(94)90072-8
   Hair Jr J. F., 2005, FUNDAMENTOS METODOS
   HAIR JR J. F., 2009, ANALISE MULTIVARIADA
   Hall J, 2000, J CLEAN PROD, V8, P455, DOI DOI 10.1016/S0959-6526(00)00013-5
   Handeman JM, 1999, J MARKETING, V63, P33, DOI 10.2307/1251774
   Hennart JF, 2011, GLOB STRATEG J, V1, P135, DOI 10.1002/gsj.8
   Horbach J, 2008, RES POLICY, V37, P163, DOI 10.1016/j.respol.2007.08.006
   Horbach J, 2012, ECOL ECON, V78, P112, DOI 10.1016/j.ecolecon.2012.04.005
   Huang XX, 2016, J CLEAN PROD, V112, P3423, DOI 10.1016/j.jclepro.2015.10.106
   Jakobsen S, 2016, J CLEAN PROD, V128, P131, DOI 10.1016/j.jclepro.2015.06.023
   Johnstone N, 2012, APPL ECON, V44, P2157, DOI 10.1080/00036846.2011.560110
   Kesidou E, 2012, RES POLICY, V41, P862, DOI 10.1016/j.respol.2012.01.005
   Kim Y, 2015, BUS STRATEG ENVIRON, V24, P58, DOI 10.1002/bse.1811
   Kostova T, 2002, ACAD MANAGE J, V45, P215, DOI 10.2307/3069293
   Kostova T, 1999, ACAD MANAGE REV, V24, P308, DOI 10.2307/259084
   Lakatos E. M., 2007, CACCI J, P7
   Lee KH, 2015, J CLEAN PROD, V108, P534, DOI 10.1016/j.jclepro.2015.05.114
   Lee KH, 2011, BUS STRATEG ENVIRON, V20, P527, DOI 10.1002/bse.714
   Leonidou CN, 2013, J ACAD MARKET SCI, V41, P151, DOI 10.1007/s11747-012-0317-2
   Li YN, 2014, J CLEAN PROD, V66, P450, DOI 10.1016/j.jclepro.2013.11.044
   Lin H, 2014, J CLEAN PROD, V64, P63, DOI 10.1016/j.jclepro.2013.07.046
   Liu Y, 2017, RESOUR CONSERV RECY, V121, P64, DOI 10.1016/j.resconrec.2015.12.005
   Jabbour ABLD, 2015, RESOUR CONSERV RECY, V104, P366, DOI 10.1016/j.resconrec.2015.07.017
   LUSTOSA M. C. J., 2011, POLITICA AMBIENTAL, V8, P111
   Lustosa M. C. J., 2002, THESIS
   Luthra S, 2018, RESOUR CONSERV RECY, V138, P194, DOI 10.1016/j.resconrec.2018.07.005
   Maroc J., 2010, ANALISE EQUACOES EST
   McFarland RG, 2008, J MARKETING, V72, P63, DOI 10.1509/jmkg.72.2.63
   Murphy J, 2000, GEOFORUM, V31, P33, DOI 10.1016/S0016-7185(99)00042-1
   Nidumolu R, 2009, HARVARD BUS REV, V87, P56
   Nill J, 2009, RES POLICY, V38, P668, DOI 10.1016/j.respol.2009.01.011
   Oltra V, 2009, TECHNOL FORECAST SOC, V76, P567, DOI 10.1016/j.techfore.2008.03.025
   Peng DX, 2012, J OPER MANAG, V30, P467, DOI 10.1016/j.jom.2012.06.002
   Podcameni MGVB, 2007, THESIS
   Porter M., 1995, DYNAMICS ECOEFFICIEN, P33
   Prange C., 2011, MULTINATIONAL BUSINE, V46, P123
   Qi GY, 2013, CORP SOC RESP ENV MA, V20, P1, DOI 10.1002/csr.283
   Ren SG, 2018, J CLEAN PROD, V173, P245, DOI 10.1016/j.jclepro.2016.08.113
   Rennings K, 2006, ECOL ECON, V57, P45, DOI 10.1016/j.ecolecon.2005.03.013
   Rentizelas A, 2018, ANN OPER RES, DOI [10.1007/s10479-018-2821-3, DOI 10.1007/S10479-018-2821-3]
   Seles BMRP, 2016, INT J PROD ECON, V182, P342, DOI 10.1016/j.ijpe.2016.08.033
   Rubashkina Y, 2015, ENERG POLICY, V83, P288, DOI 10.1016/j.enpol.2015.02.014
   Ruigrok W., 2003, MANAGE INT REV, V43, P63, DOI DOI 10.2307/40835634
   Sarkis J, 2010, J OPER MANAG, V28, P163, DOI 10.1016/j.jom.2009.10.001
   Sharma S, 1998, STRATEGIC MANAGE J, V19, P729, DOI 10.1002/(SICI)1097-0266(199808)19:8<729::AID-SMJ967>3.0.CO;2-4
   Singh RK, 2019, RESOUR CONSERV RECY, V147, P10, DOI 10.1016/j.resconrec.2019.04.014
   Song ML, 2018, MANAGE DECIS, V56, P188, DOI 10.1108/MD-04-2017-0375
   Song ML, 2015, ANN OPER RES, V228, P47, DOI 10.1007/s10479-013-1442-0
   Song ML, 2013, J CLEAN PROD, V42, P42, DOI 10.1016/j.jclepro.2012.11.010
   Souza T. R. D., 2016, REV REUNA, V21, P97
   Sueyoshi T, 2009, ENERG POLICY, V37, P4819, DOI 10.1016/j.enpol.2009.06.038
   Tang L, 2017, RESOUR CONSERV RECY, V117, P34, DOI 10.1016/j.resconrec.2015.08.016
   Tierney J. M., 2011, ENV QUAL MANAGE, V21, P23
   Triguero A, 2013, ECOL ECON, V92, P25, DOI 10.1016/j.ecolecon.2013.04.009
   van Hemel C, 2002, J CLEAN PROD, V10, P439, DOI 10.1016/S0959-6526(02)00013-6
   Colares ACV, 2015, SIST GEST, V10, P356, DOI 10.7177/sg.2015.v10.n3.a2
   Wang SH, 2017, SCI TOTAL ENVIRON, V595, P201, DOI 10.1016/j.scitotenv.2017.03.243
   Wang YF, 2017, RESOUR CONSERV RECY, V117, P66, DOI 10.1016/j.resconrec.2015.07.007
   Weng HH, 2015, SUSTAINABILITY-BASEL, V7, P4997, DOI 10.3390/su7054997
   Wong SKS, 2013, BUS STRATEG ENVIRON, V22, P321, DOI 10.1002/bse.1746
   Xielin Liu, 2011, International Journal of Technology and Globalisation, V5, P255, DOI 10.1504/IJTG.2011.039767
   Zailani S, 2015, J CLEAN PROD, V108, P1115, DOI 10.1016/j.jclepro.2015.06.039
   Zhu Q, 2007, INT J PROD RES, V45, P4333, DOI 10.1080/00207540701440345
   Zhu QH, 2013, J CLEAN PROD, V40, P6, DOI 10.1016/j.jclepro.2010.09.017
NR 100
TC 3
Z9 3
U1 42
U2 68
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 445
EP 454
DI 10.1016/j.resconrec.2019.06.005
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300041
DA 2020-05-12
ER

PT J
AU D'Adamo, I
   Ferella, F
   Gastaldi, M
   Maggiore, F
   Rosa, P
   Terzi, S
AF D'Adamo, Idiano
   Ferella, Francesco
   Gastaldi, Massimo
   Maggiore, Fabio
   Rosa, Paolo
   Terzi, Sergio
TI Towards sustainable recycling processes: Wasted printed circuit boards
   as a source of economic opportunities
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Circular economy; Economic analysis; Wasted printed circuit board;
   Recycling; Waste electrical and electronic equipment
ID MATERIAL FLOW-ANALYSIS; PRECIOUS METALS; ELECTRONIC EQUIPMENT; SELECTIVE
   RECOVERY; PERFORMANCE EVALUATION; VALUABLE CONTENT; WEEE; GOLD;
   MANAGEMENT; END
AB In modern society, use of natural resources poses a great challenge. However, the circular economy paradigm has defined a new concept of waste, proposing it as a business opportunity. Of particular interest in this paradigm is 'waste electrical and electronic equipment' (WEEE), given its high growth rate, and 'wasted printed circuit boards' (WPCBs), which are the most valuable component of WEEE. Although WPCB recycling is currently dominated by large firms, the present work evaluates the economic feasibility of hydrometallurgical processes, as used within small and medium enterprises (SMEs). Discounted cash flow (DCF) is used as a reference methodology and net present value (NPV) is used as an economic performance index. The analysis is conducted on three categories of WPCBs (low-, medium- and high-grade) and 15 categories of e-waste. The results underline the key role played by the market price of Au and Pd, plus the purchase cost of WPCBs. Accordingly, sensitivity, scenario and risk analyses are conducted on these variables and a break-even point (BEP) analysis is used to define the exact values for which economic feasibility is verified. NPV is shown to vary from 6.8 million E for medium-grade WPCBs to 63.0 million E for high-grade WPCBs in a baseline scenario, with a negative (unprofitable) result (NPV of -2.8 million E) for low-grade WPCBs.
C1 [D'Adamo, Idiano; Ferella, Francesco; Gastaldi, Massimo] Univ Aquila, Dept Ind & Informat Engn & Econ, Via G Gronchi 18, I-67100 Laquila, Italy.
   [D'Adamo, Idiano] Unitelma Sapienza Univ Rome, Dept Law & Econ, Virile Regina Elena 295, I-00161 Rome, Italy.
   [Ferella, Francesco] ORIM SpA, Via D Concordia 65, I-62100 Macerata, Italy.
   [Maggiore, Fabio] Hobre Instruments BV, Netwerk 4, NL-1446 WK Purmerend, Netherlands.
   [Rosa, Paolo; Terzi, Sergio] Politecn Milan, Dept Management Econ & Ind Engn, Piazza L da Vinci 32, I-20133 Milan, Italy.
RP Rosa, P (reprint author), Politecn Milan, Dept Management Econ & Ind Engn, Piazza L da Vinci 32, I-20133 Milan, Italy.
EM idiano.dadamo@univaq.it; francesco.ferella@univaq.it;
   massimo.gastaldi@univaq.it; maggioref@hobre.com; paolo1.rosa@polimi.it
RI Rosa, Paolo/N-2370-2019; D'Adamo, Idiano/P-8693-2016
OI Rosa, Paolo/0000-0003-3957-707X; D'Adamo, Idiano/0000-0003-1861-8813
CR Akcil A, 2015, WASTE MANAGE, V45, P258, DOI 10.1016/j.wasman.2015.01.017
   Arshadi M, 2018, RESOUR CONSERV RECY, V139, P298, DOI 10.1016/j.resconrec.2018.08.013
   Avarmaa K, 2019, MINER ENG, V133, P95, DOI 10.1016/j.mineng.2019.01.006
   Awasthi AK, 2018, SCI TOTAL ENVIRON, V613, P46, DOI 10.1016/j.scitotenv.2017.08.288
   Awasthi AK, 2017, WASTE MANAGE RES, V35, P346, DOI 10.1177/0734242X16682607
   Bahers JB, 2018, RESOUR CONSERV RECY, V129, P45, DOI 10.1016/j.resconrec.2017.10.016
   Balde C.P., 2017, GLOBAL E WASTE MONIT, DOI [10.1016/j.proci.2014.05.148., DOI 10.1016/J.PROCI.2014.05.148]
   Behnamfard A, 2013, WASTE MANAGE, V33, P2354, DOI 10.1016/j.wasman.2013.07.017
   Birloaga I, 2018, WOODH PUB SER ELECT, P95, DOI 10.1016/B978-0-08-102057-9.00004-4
   Birloaga I, 2016, J ENVIRON CHEM ENG, V4, P20, DOI 10.1016/j.jece.2015.11.021
   Birloaga I, 2014, WASTE MANAGE, V34, P2581, DOI 10.1016/j.wasman.2014.08.028
   Birloaga I, 2013, WASTE MANAGE, V33, P935, DOI 10.1016/j.wasman.2013.01.003
   Courtney H, 1997, HARV BUS REV
   Cucchiella F, 2016, RENEW SUST ENERG REV, V64, P749, DOI 10.1016/j.rser.2016.06.057
   Cucchiella F, 2015, RENEW SUST ENERG REV, V51, P263, DOI 10.1016/j.rser.2015.06.010
   D'Adamo I, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8070633
   De Almeida ST, 2019, RESOUR CONSERV RECY, V140, P189, DOI 10.1016/j.resconrec.2018.09.020
   De Clercq D, 2017, RESOUR CONSERV RECY, V116, P178, DOI 10.1016/j.resconrec.2016.09.031
   Degreif S, 2014, GLOBAL CIRCULAR EC S
   Doidge ED, 2016, ANGEW CHEM INT EDIT, V55, P12436, DOI 10.1002/anie.201606113
   European Commission, 2017, 2 YEARS PAR PROGR M
   Faircloth CC, 2019, RESOUR CONSERV RECY, V143, P260, DOI 10.1016/j.resconrec.2019.01.008
   Ferella F, 2016, RESOUR CONSERV RECY, V108, P10, DOI 10.1016/j.resconrec.2016.01.010
   Foley S, 2018, METHODS SELECTIVE LE
   Fujimori T, 2018, J HAZARD MATER, V341, P365, DOI 10.1016/j.jhazmat.2017.07.066
   Gaustad G, 2018, RESOUR CONSERV RECY, V135, P24, DOI 10.1016/j.resconrec.2017.08.002
   Ghodrat M, 2016, J CLEAN PROD, V126, P178, DOI 10.1016/j.jclepro.2016.03.033
   Tran HP, 2018, RESOUR CONSERV RECY, V139, P78, DOI 10.1016/j.resconrec.2018.07.031
   Hageluken, 2006, ACTA METALL SLOVACA, V12, P111
   Holgersson S, 2018, RESOUR CONSERV RECY, V133, P300, DOI 10.1016/j.resconrec.2017.02.011
   Imre-Lucaci A, 2017, CHEM ENG J, V309, P655, DOI 10.1016/j.cej.2016.10.045
   Innocenzi V, 2016, AD ENVIRON RES, V5, P125, DOI 10.12989/aer.2016.5.2.125
   Ip K, 2018, RESOUR CONSERV RECY, V131, P192, DOI 10.1016/j.resconrec.2017.11.021
   Isildar A, 2018, RESOUR CONSERV RECY, V135, P296, DOI 10.1016/j.resconrec.2017.07.031
   Jadhav U, 2015, SCI REP-UK, V5, DOI 10.1038/srep14574
   Ji L, 2018, RESOUR CONSERV RECY, V134, P34, DOI 10.1016/j.resconrec.2018.03.005
   Kim EY, 2011, J HAZARD MATER, V198, P206, DOI 10.1016/j.jhazmat.2011.10.034
   Kim S, 2013, WASTE MANAGE, V33, P474, DOI 10.1016/j.wasman.2012.07.011
   Kumar A, 2017, RESOUR CONSERV RECY, V122, P32, DOI 10.1016/j.resconrec.2017.01.018
   Li H, 2018, RESOUR CONSERV RECY, V139, P122, DOI 10.1016/j.resconrec.2018.08.007
   Li J, 2010, ENVIRON SCI TECHNOL, V44, P1418, DOI 10.1021/es903242t
   Lu Y, 2016, RESOUR CONSERV RECY, V113, P28, DOI 10.1016/j.resconrec.2016.05.007
   Oguchi M, 2013, SCI TOTAL ENVIRON, V463, P1124, DOI 10.1016/j.scitotenv.2012.07.078
   Oguchi M, 2011, WASTE MANAGE, V31, P2150, DOI 10.1016/j.wasman.2011.05.009
   Ogunniyi IO, 2009, MINER ENG, V22, P378, DOI 10.1016/j.mineng.2008.10.007
   Ongondo FO, 2011, WASTE MANAGE, V31, P1307, DOI 10.1016/j.wasman.2011.01.032
   Orgul S, 2002, HYDROMETALLURGY, V67, P71, DOI 10.1016/S0304-386X(02)00136-6
   Parga JR, 2007, JOM-US, V59, P43, DOI 10.1007/s11837-007-0130-4
   Park YJ, 2009, J HAZARD MATER, V164, P1152, DOI 10.1016/j.jhazmat.2008.09.043
   Pinho S, 2018, RESOUR CONSERV RECY, V132, P71, DOI 10.1016/j.resconrec.2018.01.022
   Reuter M. A., 2013, METAL RECYCLING OPPO
   Riedewald F, 2015, METHODSX, V2, P100, DOI 10.1016/j.mex.2015.02.010
   Rocchetti L, 2018, J CLEAN PROD, V178, P814, DOI 10.1016/j.jclepro.2018.01.076
   Rocchetti L, 2013, ENVIRON SCI TECHNOL, V47, P1581, DOI 10.1021/es302192t
   Rosa P, 2018, J CLEAN PROD, V184, P520, DOI 10.1016/j.jclepro.2018.02.264
   Song XL, 2018, RESOUR CONSERV RECY, V128, P470, DOI 10.1016/j.resconrec.2016.09.004
   Tazi N, 2019, RESOUR CONSERV RECY, V145, P199, DOI 10.1016/j.resconrec.2019.02.039
   Tian X, 2018, J CLEAN PROD, V198, P1559, DOI 10.1016/j.jclepro.2018.07.089
   Vinh HH, 2010, J HAZARD MATER, V178, P1115, DOI 10.1016/j.jhazmat.2010.01.099
   Wang HD, 2017, RESOUR CONSERV RECY, V126, P209, DOI 10.1016/j.resconrec.2017.08.001
   Wang ZH, 2016, J CLEAN PROD, V137, P850, DOI 10.1016/j.jclepro.2016.07.155
   Wang ZH, 2016, NATURE, V536, P23, DOI 10.1038/536023a
   Widmer R, 2015, ENVIRON SCI TECHNOL, V49, P4591, DOI 10.1021/es505415d
   Xia MC, 2018, RESOUR CONSERV RECY, V136, P267, DOI 10.1016/j.resconrec.2018.05.001
   Xiu FR, 2013, WASTE MANAGE, V33, P1251, DOI 10.1016/j.wasman.2013.01.023
   Xiu FR, 2010, J HAZARD MATER, V178, P628, DOI 10.1016/j.jhazmat.2010.01.131
   Yang JS, 2019, RESOUR CONSERV RECY, V146, P264, DOI 10.1016/j.resconrec.2019.03.008
   Yazici EY, 2015, INT J MINER PROCESS, V134, P89, DOI 10.1016/j.minpro.2014.10.012
   Yi QP, 2016, PROCEDIA ENVIRON SCI, V31, P185, DOI 10.1016/j.proenv.2016.02.025
   Yoshida A, 2016, RESOUR CONSERV RECY, V106, P48, DOI 10.1016/j.resconrec.2015.10.020
   Zeng XL, 2016, J CLEAN PROD, V131, P156, DOI 10.1016/j.jclepro.2016.05.055
   Zeng XL, 2016, ENVIRON SCI TECHNOL, V50, P1347, DOI 10.1021/acs.est.5b05446
   Zeng XL, 2015, J CLEAN PROD, V90, P55, DOI 10.1016/j.jclepro.2014.10.026
   Zhu P, 2013, ENVIRON SCI TECHNOL, V47, P2654, DOI 10.1021/es303264c
NR 74
TC 7
Z9 7
U1 17
U2 35
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 455
EP 467
DI 10.1016/j.resconrec.2019.06.012
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300042
DA 2020-05-12
ER

PT J
AU Ng, SL
AF Ng, Sai-Leung
TI Predicting multi-family dwelling recycling behaviors using structural
   equation modelling: A case study of Hong Kong
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Multi-family dwelling (MFD) recycling; Knowledge-attitude-practice
   (KAP); Convenience; Housing type; Property manager (PM) initiative;
   Structural Equation Modelling (SEM)
ID PRO-ENVIRONMENTAL BEHAVIORS; PLANNED BEHAVIOR; WASTE; ATTITUDES;
   KNOWLEDGE; DETERMINANTS; NEIGHBORHOOD; CONVENIENCE; PERCEPTIONS;
   MANAGEMENT
AB The problem of solid waste is acute in Hong Kong. Among various options for waste management, recycling attracts the most attention. Recycling minimizes the amount of waste that requires disposal and at the same time, it promotes the management of sustainable resources. Different from most Western cities, the recycling program of Hong Kong primarily targets multi-family dwellings (MFDs). Although the performance of the program is far from satisfactory, little is known about what factors and how they affect recycling behavior. With that in mind, this paper adopted a modified knowledge-attitude-practice (KAP) model by proposing three components (i.e., convenience, housing type and PM initiative) as the theoretical framework, to investigate how the MFD recycling behavior is shaped by environmental and psychological factors. A random telephone survey (N = 1016) was conducted in Hong Kong, then Structural Equation Modelling (SEM) was used to identify and outline the structures of the framework. The results indicated that housing type, property manager (PM) initiative, attitude, and convenience affected the recycling behavior of Hong Kong residents. In addition, PM initiative had a significant effect on attitude that further affected convenience. These findings not only can provide a reference for the improvement and implementation of the recycling program in Hong Kong but also supplement the existing literature.
C1 [Ng, Sai-Leung] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China.
RP Ng, SL (reprint author), Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China.
EM slng@cuhk.edu.hk
FU Environmental Protection Department (EPD), the Hong Kong Special
   Administrative Region Government [16-03823]
FX This study was supported by a research fund (Ref: 16-03823) from the
   Environmental Protection Department (EPD), the Hong Kong Special
   Administrative Region Government. The author is grateful to Ms. Joni
   F.M. Wong and Ms. Crystal P. Y. Chan who assisted in organizing the
   telephone survey. Thanks is given to The Centre for Communication and
   Public Opinion Survey (CCPOS) of The Chinese University of Hong Kong for
   the operation of the telephone survey. The English editing provided by
   Mr. Andrew Y.T. Ng is greatly appreciated.
CR Abhary K, 2009, PROCD SOC BEHV, V1, P1753, DOI 10.1016/j.sbspro.2009.01.310
   Acreman S., 2015, PLOS ONE, V10, P1, DOI [10.3886/E42859V1, DOI 10.3886/E42859V1]
   Ahmad J., 2015, PRACTICE COMMUNICATI, V11, P284, DOI DOI 10.5539/ASS.V11N16P284
   Ahuja A., 2010, INTERNATIONAL MONETA
   AJZEN I, 1977, PSYCHOL BULL, V84, P888, DOI 10.1037/0033-2909.84.5.888
   Ajzen I, 2011, BASIC APPL SOC PSYCH, V33, P101, DOI 10.1080/01973533.2011.568834
   Akpinar-Elci M., 2011, THE KNOWLEDGE ATTITU
   Allen K, 2018, SUICIDE LIFE-THREAT, V48, P677, DOI 10.1111/sltb.12391
   Ando AW, 2005, ECON INQ, V43, P426, DOI 10.1093/ei/cbi029
   [Anonymous], 2014, SOUTH CHINA MORNING
   ARCURY TA, 1990, HUM ORGAN, V49, P300, DOI 10.17730/humo.49.4.y6135676n433r880
   Babaei AA, 2015, RESOUR CONSERV RECY, V102, P94, DOI 10.1016/j.resconrec.2015.06.014
   Badran I. G., 1995, E MEDITERANIAN HLTH, V1, P8
   Baldwin G, 1994, PROPERTY MANAGEMENT, V12, P18
   Banga M., 2011, ZAMB SOC SCI J, V2, P27
   Barr S, 2003, LOCAL ENVIRON, V8, P407, DOI DOI 10.1080/13549830306667
   Bernstad A, 2014, WASTE MANAGE, V34, P1317, DOI 10.1016/j.wasman.2014.03.013
   Besar TA, 2013, PERTANIKA J SOC SCI, V21, P21
   Bhattacharyya K., 1997, ANTHR INFECT DIS INT, P211
   Census and Statistics Department, 2011, 2011 POPULATION CENS
   Chan EHW, 2002, HABITAT INT, V26, P159, DOI 10.1016/S0197-3975(01)00041-8
   Chan YK, 1999, SOC INDIC RES, V48, P103, DOI 10.1023/A:1006944807696
   Chen MF, 2010, ENVIRON BEHAV, V42, P824, DOI 10.1177/0013916509352833
   Cheung SF, 1999, ENVIRON BEHAV, V31, P587, DOI 10.1177/00139169921972254
   Chiu S. W. K., 2017, SOCIAL TRANSFORMATIO, V13, P2, DOI [10.1108/STICS-09-2016-0016, DOI 10.1108/STICS-09-2016-0016]
   Chung SS, 2007, ENVIRON MANAGE, V40, P603, DOI 10.1007/s00267-006-0363-y
   Chung SS, 2004, ENVIRON MANAGE, V33, P692, DOI 10.1007/s00267-004-0020-2
   CorralVerdugo V, 1997, J ENVIRON PSYCHOL, V17, P135, DOI 10.1006/jevp.1997.0048
   DAVIES J, 2002, MARKETING THEORY, V2, P29, DOI DOI 10.1177/1470593102002001645
   Delang CO, 2010, URBAN STUD, V47, P1391, DOI 10.1177/0042098009353623
   DEYOUNG R, 1995, POPUL ENVIRON, V16, P253, DOI 10.1007/BF02331920
   DiGiacomo A, 2018, J ENVIRON PLANN MAN, V61, P309, DOI 10.1080/09640568.2017.1305332
   Domina T, 2002, ENVIRON BEHAV, V34, P216, DOI 10.1177/0013916502034002004
   Eagly A. H., 1993, THE PSYCHOLOGY OF AT
   Eagly A.H., 1998, HDB SOCIAL PSYCHOL, Vone, P269
   Eagly AH, 2007, SOC COGNITION, V25, P582, DOI 10.1521/soco.2007.25.5.582
   Emanuel E., 2010, WASTEWATER MANAGEMEN
   Environmental Protection Department, 2017, LIST OF PARTICIPATIN
   Environmental Protection Department, 2010, ANNUAL UPDATE 2010 P
   Environmental Protection Department, 2006, PROGRAMME ON SOURCE
   Environmental Protection Department, 2018, PROGRESS OF THE PROG
   Environmental Protection Department, 2005, A POLICY FRAMEWORK F
   Environmental Protection Department, 2005, WASTE RECYCLING PROG
   Environmental Protection Department, 2016, MONITORING OF SOLID
   Ertz M, 2016, J BUS RES, V69, P3971, DOI 10.1016/j.jbusres.2016.06.010
   Esa N, 2010, INT RES GEOGR ENVIRO, V19, P39, DOI 10.1080/10382040903545534
   Fishbein M., 1975, BELIEF ATTITUDE INTE
   FISHER JD, 1992, PSYCHOL BULL, V111, P455, DOI 10.1037/0033-2909.111.3.455
   Forrest R, 2014, J SOC POLICY, V43, P135, DOI 10.1017/S0047279413000585
   GAMBA RJ, 1994, ENVIRON BEHAV, V26, P587, DOI 10.1177/0013916594265001
   Gou ZH, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15020219
   Grodzinska-Jurczak M, 2006, RESOUR CONSERV RECY, V46, P182, DOI 10.1016/j.resconrec.2005.06.010
   Halder P, 2013, INT J GREEN ENERGY, V10, P797, DOI 10.1080/15435075.2012.706244
   Ho SY, 2010, TOB CONTROL, V19, P129, DOI 10.1136/tc.2009.032003
   Hong Kong Housing Authority, 2019, GREEN DELIGHT IN EST
   Hong Kong Institute of Surveyors, 2015, GREEN PROPERTY MANAG
   Huddart E, 2009, HUM ECOL REV, V16, P151
   Jain S., 2016, INT DENT MED J ADV R, V2, P1, DOI [10.15713/ins.idmjar.39, DOI 10.15713/INS.IDMJAR.39]
   Jatau A. A, 2013, MEDITERRANEAN J SOCI, V4, P119, DOI [10.5901/mjss.2013.v4n5p119, DOI 10.5901/MJSS.2013.V4N5P119]
   Johnson PJ, 2008, ANN EPIDEMIOL, V18, P552, DOI 10.1016/j.annepidem.2008.02.007
   Karami S, 2017, INT J CLIM CHANG STR, V9, P402, DOI 10.1108/IJCCSM-04-2016-0043
   Kiran KG, 2015, NITTE UNIV J HEALTH, V5, P29
   Kollmuss A., 2002, ENVIRON EDUC RES, V8, P239, DOI DOI 10.1080/13504620220145401
   KRAUS SJ, 1995, PERS SOC PSYCHOL B, V21, P58, DOI 10.1177/0146167295211007
   KREJCIE RV, 1970, EDUC PSYCHOL MEAS, V30, P607, DOI 10.1177/001316447003000308
   Kuo YL, 2010, ENVIRON RESOUR ECON, V47, P423, DOI 10.1007/s10640-010-9386-1
   La Grange A, 2011, URBAN STUD, V48, P1181, DOI 10.1177/0042098010370628
   Lai JHK, 2011, HABITAT INT, V35, P391, DOI 10.1016/j.habitatint.2010.11.009
   Lai JHK, 2011, BUILD ENVIRON, V46, P165, DOI 10.1016/j.buildenv.2010.07.012
   Launiala A., 2009, ANTHR MATTERS, V11, P1
   Lee S, 2011, BUILD ENVIRON, V46, P1159, DOI 10.1016/j.buildenv.2010.12.005
   Lee S, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14020163
   Leeming F., 1993, J ENVIRON EDUC, V24, P8, DOI DOI 10.1080/00958964.1993.9943504
   Lei P.W., 2007, ED MEASUREMENT ISSUE, V26, P33, DOI [DOI 10.1111/J.1745-3992.2007.00099.X, 10.1111/j.1745-3992.2007.00099.x]
   Leung C. Y., 2013, THE 2013 POLICY ADDR, P22
   Liu A. M. M., 1999, Automation in Construction, V8, P511, DOI 10.1016/S0926-5805(98)00098-3
   Mak TMW, 2019, WASTE MANAGE, V83, P161, DOI 10.1016/j.wasman.2018.11.016
   Margai FL, 1997, ENVIRON BEHAV, V29, P769, DOI 10.1177/0013916597296003
   Meneses GD, 2005, ENVIRON BEHAV, V37, P837, DOI 10.1177/0013916505276742
   Metcalfe A, 2012, SOCIOL REV, V60, P135, DOI 10.1111/1467-954X.12042
   Miafodzyeva S, 2013, WASTE BIOMASS VALORI, V4, P221, DOI 10.1007/s12649-012-9144-4
   Mohd Isa N.K., 2016, MALAYSIAN J SOC SPAC, V12, P89
   Ng SL, 2018, ASIAN GEOGR, V35, P35, DOI 10.1080/10225706.2017.1406863
   Ng S. L., 2014, CONSULTANCY REPORT S
   Nguyan L. B. D., 2015, J EC DEV, V22, P124, DOI [10.24311/jed/2015.22.2.03, DOI 10.24311/JED/2015.22.2.03]
   Nixon H, 2009, J ENVIRON PLANN MAN, V52, P257, DOI 10.1080/09640560802666610
   Oakes J Michael, 2015, Curr Epidemiol Rep, V2, P80, DOI 10.1007/s40471-015-0035-7
   Oskamp S, 1995, J SOC ISSUES, V51, P157, DOI 10.1111/j.1540-4560.1995.tb01353.x
   PEDHAZUR EJ, 1982, MULTIPLE REGRESSION
   Ramayah T, 2012, J ENVIRON MANAGE, V102, P141, DOI 10.1016/j.jenvman.2012.02.025
   RAMSEY CE, 1976, J ENVIRON EDUC, V8, P10, DOI 10.1080/00958964.1976.9941552
   Rav-Marathe K., 2016, MED RES ARCH, V4, P1
   Rex J., 1967, RACE COMMUNITY AND C
   Sampson RJ, 2002, ANNU REV SOCIOL, V28, P443, DOI 10.1146/annurev.soc.28.110601.141114
   Saphores JDM, 2006, ENVIRON BEHAV, V38, P183, DOI 10.1177/0013916505279045
   Saylan C., 2007, FAILURE ENV ED WE CA, DOI [10.1371/journal.pbio.0050120, DOI 10.1371/JOURNAL.PBIO.0050120]
   SCHULTZ PW, 1995, J ENVIRON PSYCHOL, V15, P105, DOI 10.1016/0272-4944(95)90019-5
   SCHUMAN H, 1976, ANNU REV SOCIOL, V2, P161, DOI 10.1146/annurev.so.02.080176.001113
   Schwab N, 2014, ENVIRON BEHAV, V46, P403, DOI 10.1177/0013916512466093
   Scott D, 1999, ENVIRON BEHAV, V31, P267, DOI 10.1177/00139169921972100
   Sheeran P, 2003, BRIT J SOC PSYCHOL, V42, P393, DOI 10.1348/014466603322438224
   Sidique SF, 2010, RESOUR CONSERV RECY, V54, P163, DOI 10.1016/j.resconrec.2009.07.012
   Singhirunnusorn W., 2012, J ASIAN BEHAV STUDIE, V2, P35, DOI [DOI 10.1016/J.SBSPRO.2012.03.075, DOI 10.21834/JABS.V2I5.215]
   Siu KWM, 2016, APPL RES QUAL LIFE, V11, P1137, DOI 10.1007/s11482-015-9426-7
   Sivek D., 1990, J ENVIRON EDUC, V21, P35, DOI DOI 10.1080/00958964.1990.9941929
   Stoeva K, 2017, WASTE MANAGE, V68, P732, DOI 10.1016/j.wasman.2017.06.005
   STONE L, 1984, HUM ORGAN, V43, P27, DOI 10.17730/humo.43.1.6wl5k01724878166
   Tabernero C, 2015, J ENVIRON MANAGE, V159, P192, DOI 10.1016/j.jenvman.2015.05.024
   Thomas C, 2013, RESOUR CONSERV RECY, V79, P11, DOI 10.1016/j.resconrec.2013.04.010
   Tian YH, 2012, URBAN FOR URBAN GREE, V11, P223, DOI 10.1016/j.ufug.2012.03.003
   Tonglet M, 2004, RESOUR CONSERV RECY, V41, P191, DOI 10.1016/j.resconrec.2003.11.001
   Vassanadumrongdee S, 2018, SUSTAIN ENVIRON RES, V28, P90, DOI 10.1016/j.serj.2017.11.003
   VINING J, 1990, ENVIRON BEHAV, V22, P55, DOI 10.1177/0013916590221003
   Wan C, 2012, FACILITIES, V30, P630, DOI 10.1108/02632771211270595
   Wang HT, 2001, J AIR WASTE MANAGE, V51, P250, DOI 10.1080/10473289.2001.10464266
   Weinstein D., 2014, RESOURCE GUIDE FOR I
   Werner CM, 1998, J ENVIRON PSYCHOL, V18, P373, DOI 10.1006/jevp.1998.0114
   White KM, 2012, ENVIRON BEHAV, V44, P785, DOI 10.1177/0013916511408069
   WICKER AW, 1969, J SOC ISSUES, V25, P41, DOI 10.1111/j.1540-4560.1969.tb00619.x
   World Health Organization, 2008, ADVOCACY COMMUNICATI
   Yau Y, 2011, HOUSING STUD, V26, P701, DOI 10.1080/02673037.2011.581911
   Yau Y, 2012, SUSTAIN DEV, V20, P115, DOI 10.1002/sd.468
   Yau Y, 2010, WASTE MANAGE, V30, P2440, DOI 10.1016/j.wasman.2010.06.009
   Yip NM, 2007, FACILITIES, V25, P215, DOI 10.1108/02632770710742183
   Zhang SP, 2016, RESOUR CONSERV RECY, V109, P176, DOI 10.1016/j.resconrec.2016.02.008
NR 125
TC 0
Z9 0
U1 6
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 468
EP 478
DI 10.1016/j.resconrec.2019.06.007
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300043
DA 2020-05-12
ER

PT J
AU Caldeira, C
   De Laurentiis, V
   Corrado, S
   van Holsteijn, F
   Sala, S
AF Caldeira, Carla
   De Laurentiis, Valeria
   Corrado, Sara
   van Holsteijn, Freija
   Sala, Serenella
TI Quantification of food waste per product group along the food supply
   chain in the European Union: a mass flow analysis
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Food waste; Mass balance; Food groups; By-products; Systematic
   accounting; Food value chain
ID LOSSES
AB In 2015, the United Nations defined the Sustainable Development Goals (SDG), which include a target (12.3) on food waste. The target requires "by 2030, to halve per capita global food waste at the retail and consumer levels and to reduce food losses along production and supply chains, including post-harvest losses". The target has increased awareness about the food waste problem and boosted research in food waste quantification. Nevertheless, there is a lack of studies that adopt a systematic approach to account for food waste providing disaggregated values per food supply chain stage and per food groups. Such an approach could support policy makers in prioritizing interventions for food waste reduction. To fill this gap, this paper presents a high-level top down approach to food waste accounting in the European Union. The study aims to support the understanding of the mass flows associated with food production, consumption, and waste, addressing different food groups along the food supply chain. The method for accountin is the mass flow analysis. According to the results, cereals, fruit, and vegetables as the food groups are responsible for the highest amount of food waste, and the consumption stage to be responsible for the largest share of food waste for most food groups. This work highlights the need for further primary research on food waste generation in the EU. Ultimately, this would allow to robustly estimate the food waste generated at EU level, and establishing a more accurate baseline to track the progress towards SDG target 12.3.
C1 [Caldeira, Carla; De Laurentiis, Valeria; Corrado, Sara; Sala, Serenella] European Commiss Joint Res Ctr, Via Enrico Fermi 2749, I-21027 Ispra, VA, Italy.
   [van Holsteijn, Freija] VHK BV, Rotterdamseweg 386 B-18, NL-2629 HG Delft, Netherlands.
   [van Holsteijn, Freija] Blonk Consultants, Gravin Beatrixstr 34, NL-2805 PJ Gouda, Netherlands.
RP Sala, S (reprint author), European Commiss Joint Res Ctr, Via Enrico Fermi 2749, I-21027 Ispra, VA, Italy.
EM serenella.sala@ec.europa.eu
OI Sala, Serenella/0000-0003-1919-9948
CR Alexander P, 2017, AGR SYST, V153, P190, DOI 10.1016/j.agsy.2017.01.014
   Allesch A, 2015, J IND ECOL, V19, P753, DOI 10.1111/jiec.12354
   [Anonymous], 2016, ESTIMATES EUROPEAN F
   Beausang C, 2017, RESOUR CONSERV RECY, V126, P177, DOI 10.1016/j.resconrec.2017.07.042
   Beretta C, 2013, WASTE MANAGE, V33, P764, DOI 10.1016/j.wasman.2012.11.007
   Betz A, 2015, WASTE MANAGE, V35, P218, DOI 10.1016/j.wasman.2014.09.015
   Brautigam KR, 2014, WASTE MANAGE RES, V32, P683, DOI 10.1177/0734242X14545374
   Brunner PH, 2004, PRACTICAL HDB MAT FL
   Caldeira C, 2017, 28988 EUR EN, DOI [10.2760/54845.JRC109202, DOI 10.2760/54845.JRC109202]
   Corrado S, 2019, GLOB FOOD SECUR-AGR, V20, P93, DOI 10.1016/j.gfs.2019.01.002
   Corrado S, 2018, WASTE MANAGE, V79, P120, DOI 10.1016/j.wasman.2018.07.032
   Davies RWD, 2009, MAR POLICY, V33, P661, DOI 10.1016/j.marpol.2009.01.003
   De Laurentiis V, 2018, WASTE MANAGE, V77, P238, DOI 10.1016/j.wasman.2018.04.001
   EEA, 2017, 162017 EEA, DOI [10.2800/884986, DOI 10.2800/884986]
   EUROSTAT, 2017, FOOD WAST STAT
   FAO, 1990, HDB FISH STAT
   FAO, 2011, FAOSTAT TRAD STAT
   FAO, 2013, FOOD WAST FOOTPR IMP
   FAO, 2003, TECHN CONV FACT AGR
   FLW Protocol (Food Losses and Waste Protocol), 2016, FOOD LOSS WAST ACC R
   Foley JA, 2011, NATURE, V478, P337, DOI 10.1038/nature10452
   Foresight, 2011, FOR MIGR GLOB ENV CH
   Franke U, 2016, FOOD LOSSES WASTE PR, DOI [10.6027/TN2016-529, DOI 10.6027/TN2016-529]
   FUSIONS, 2014, DEF FRAM FOOD WAST F
   Godfray HCJ, 2010, SCIENCE, V327, P812, DOI 10.1126/science.1185383
   Gregory JR, 2013, INT J LIFE CYCLE ASS, V18, P1605, DOI 10.1007/s11367-013-0606-0
   Gustaysson J., 2011, GLOBAL FOOD LOSSES F
   HAMBY DM, 1994, ENVIRON MONIT ASSESS, V32, P135, DOI 10.1007/BF00547132
   Hartikainen H, 2018, WASTE MANAGE, V71, P502, DOI 10.1016/j.wasman.2017.10.026
   Jackson A., 2016, PROJECT MODEL USE FI
   Leclercq C, 2009, PUBLIC HEALTH NUTR, V12, P2504, DOI 10.1017/S1368980009005035
   Mena C, 2014, INT J PROD ECON, V152, P144, DOI 10.1016/j.ijpe.2014.03.012
   Monier V, 2010, REPORT EUROPEAN COMM
   Moriguchi Y., 2016, TAKING STOCK IND ECO
   Pearson A. M, 2013, INEDIBLE MEAT BY PRO
   Porter SD, 2016, SCI TOTAL ENVIRON, V571, P721, DOI 10.1016/j.scitotenv.2016.07.041
   Redlingshofer B, 2017, J CLEAN PROD, V164, P703, DOI 10.1016/j.jclepro.2017.06.173
   Rimestad A. H, 2017, NORWEGIAN FOOD COMPO
   Roels K, 2017, IMPACT COSMETIC QUAL
   Thyberg KL, 2016, RESOUR CONSERV RECY, V106, P110, DOI 10.1016/j.resconrec.2015.11.016
   Vanham D, 2015, ENVIRON RES LETT, V10, DOI 10.1088/1748-9326/10/8/084008
   Willersinn C, 2015, WASTE MANAGE, V46, P120, DOI 10.1016/j.wasman.2015.08.033
   WRAP, 2014, HOUS FOOD DRINK WAST
   WRAP, 2011, RES MAPS FRUIT VEG R
   WRAP (Waste and Resources Action Programme), 2009, HOUSEHOLD FOOD DRINK
   Xue L, 2017, ENVIRON SCI TECHNOL, V51, P6618, DOI 10.1021/acs.est.7b00401
NR 46
TC 1
Z9 1
U1 9
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 479
EP 488
DI 10.1016/j.resconrec.2019.06.011
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300044
PM 31582876
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Casadesus, M
   Alvarez, MD
   Garrido, N
   Molins, G
   Macanas, J
   Colom, X
   Canavate, J
   Carrillo, F
AF Casadesus, Marta
   Dolores Alvarez, Maria
   Garrido, Nuria
   Molins, Gemma
   Macanas, Jorge
   Colom, Xavier
   Canavate, Javier
   Carrillo, Fernando
TI Environmental impact assessment of sound absorbing nonwovens based on
   chicken feathers waste
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Chicken feathers; Keratin; Stone wool; Nonwoven; Acoustic properties;
   Life cycle assessment
ID CARDBOARD BASED PANELS; ACOUSTIC PERFORMANCE; RECYCLED MATERIALS;
   INSULATION MATERIALS; FIBERS; COMPOSITES; WOOL
AB Chicken feathers (CFs) are currently a biogenic solid waste generated on a large scale and around the world. Its valorization could provide a great opportunity to manufacture environmentally friendly materials and increase the profit of poultry processors. The aim of this study was to fabricate sound absorbing nonwoven materials using CFs wastes to evaluate both the environmental impact of their fabrication processes using Life Cycle Assessment (LCA) methodology and the acoustic performance and to compare the results with a conventional insulating material such as stone wool (SW). The study showed that it was possible to fabricate CFs-wool nonwovens incorporating up to 50% w/w of CFs. The new material showed similar acoustic properties to those of SW, even behaving better for frequencies below 2200 Hz. LCA study showed that the environmental impacts decrease when the amount of CFs increases in those nonwoven materials containing CFs-wool, except for abiotic depletion and eutrophication impact categories. However, despite the synthetic nature of the SW, SW only presented worse environmental performance than the CFs based nonwoven materials for few impact categories (depletion of abiotic resources, human toxicity and photo-oxidant formation) due to the negative contribution caused by the incorporation of wool (W) into the nonwoven materials.
C1 [Dolores Alvarez, Maria; Molins, Gemma; Macanas, Jorge; Colom, Xavier; Canavate, Javier; Carrillo, Fernando] Univ Politecn Cataluna, Dept Chem Engn, Colom 1, Terrassa 08222, Spain.
   [Casadesus, Marta; Dolores Alvarez, Maria; Macanas, Jorge; Carrillo, Fernando] Univ Politecn Cataluna, INTEXTER, Colom 15, Terrassa 08222, Spain.
   [Garrido, Nuria] Univ Politecn Cataluna, Dept Heat Engines, Colom 1, Terrassa 08222, Spain.
RP Carrillo, F (reprint author), Univ Politecn Cataluna, Colom 1, Terrassa 08222, Spain.
EM fernando.carrillo@upc.edu
RI Garrido Soriano, Nuria/L-4512-2014; Alvarez del Castillo/L-4913-2014
OI Garrido Soriano, Nuria/0000-0002-3606-3199; Alvarez del
   Castillo/0000-0001-9956-0523; Colom, Xavier/0000-0003-3511-852X;
   Casadesus Fuste, Marta/0000-0003-3131-4670
FU Ministerio de Economia, Industria y Competitividad
   [MAT2015-65392-C2-1-R]
FX Authors thank the financial support from Ministerio de Economia,
   Industria y Competitividad, project reference MAT2015-65392-C2-1-R
   (MINECO/FEDER). Also, authors acknowledge P. Picado and F. Cano for
   their technical support in the nonwoven preparation.
CR AENOR, 2002, 1053422002 AENOR UNE, P36
   AENOR, 2006, 140442006 AENOR ISO
   AENOR, 2006, 140402006 ISO
   AENOR, 1998, 121271998 AENOR UNEE, P10
   Althaus H. -J., 2017, SWISS CTR LIFE CYCLE
   Arrebola Molina F. A., 2018, CORDOBA VALERA MERCE
   Asdrubali F, 2015, ENRGY PROCED, V78, P321, DOI 10.1016/j.egypro.2015.11.652
   Asdrubali F, 2016, BUILD ENVIRON, V95, P145, DOI 10.1016/j.buildenv.2015.09.003
   Asdrubali F, 2012, BUILD ACOUST, V19, P283, DOI 10.1260/1351-010X.19.4.283
   Asdrubali F, 2015, SUSTAIN MATER TECHNO, V4, P1, DOI 10.1016/j.susmat.2015.05.002
   ASTM subcomitee, 2018, E3301ASTMC42317 ASTM, P11
   Barone JR, 2005, COMPOS SCI TECHNOL, V65, P683, DOI 10.1016/j.compscitech.2004.09.030
   Barone JR, 2005, COMPOS SCI TECHNOL, V65, P173, DOI 10.1016/j.compscitech.2004.06.011
   Berardi U, 2015, BUILD ENVIRON, V94, P840, DOI 10.1016/j.buildenv.2015.05.029
   Bessa J, 2017, PROCEDIA ENGINEER, V200, P472, DOI 10.1016/j.proeng.2017.07.066
   Buratti C, 2018, CONSTR BUILD MATER, V171, P338, DOI 10.1016/j.conbuildmat.2018.03.089
   Buratti C, 2016, ENRGY PROCED, V101, P972, DOI 10.1016/j.egypro.2016.11.123
   Carrillo F., 2012, 15TH EUR C COMPOS MA, P24
   Casadesus M, 2018, J COMPOS MATER, V52, P3637, DOI 10.1177/0021998318766652
   Colom X, 2016, J COMPOS MATER, V50, P1671
   Dieckmann E, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018.e00818
   Doka G., 2013, UPDATES LIFE CYCLE 2, P48
   Ecoinvent, 2019, ECOINVENT DATABASE
   European Commission-Joint Research Centre-Institute for Environment and Sustainability, 2010, INT REF LIF CYCL DAT, P417
   Fouladi M. H., 2013, UTILIZING MALAYSIAN, DOI [10.5772/53197, DOI 10.5772/53197]
   Fundacion Espafiola para el Desarrollo de la Nutricion Animal (FEDNA), 2012, FUND ESP DES NUTR AN
   George B. R., 2003, INT NONWOVENS J, P45
   Gobiemo de Espafia-Ministerio de Agricultura y Pesca Alimentacifin y Medio Ambiente, 2018, SANDACH SUBPR AN DES
   Heijungs R, 1992, ENV LIFE CYCLE ASS 1
   Huda S, 2008, COMPOS SCI TECHNOL, V68, P790, DOI 10.1016/j.compscitech.2007.08.015
   Huda S, 2009, J POLYM ENVIRON, V17, P131, DOI 10.1007/s10924-009-0130-2
   Institute Markin, 2009, ESTUDIO SUBPRODUCTOS
   Jayamani Elammaran, 2013, Advanced Materials Research, V701, P53, DOI 10.4028/www.scientific.net/AMR.701.53
   Jin XY, 2013, J ENG FIBER FABR, V8, P89
   John MJ, 2008, CARBOHYD POLYM, V71, P343, DOI 10.1016/j.carbpol.2007.05.040
   Kellenberger D., 2007, LIFE CYCLE INVENTORI, P7
   Kusno A., 2017, 24 INT C SOUND VIB I
   Kusno A, 2019, SUSTAINABILITY-BASEL, V11, DOI 10.3390/su11051476
   Liu DG, 2012, CELLULOSE, V19, P1449, DOI 10.1007/s10570-012-9741-1
   Marculescu C, 2011, ENRGY PROCED, V6, P550, DOI 10.1016/j.egypro.2011.05.063
   Molins G, 2018, J POLYM ENVIRON, V26, P873, DOI 10.1007/s10924-017-0982-9
   Murphy R. J., 2008, 11 INT C NONC MAT TE
   Patnaik A, 2015, ENERG BUILDINGS, V92, P161, DOI 10.1016/j.enbuild.2015.01.056
   Pedroso M, 2017, CONSTR BUILD MATER, V140, P221, DOI 10.1016/j.conbuildmat.2017.02.132
   PRe, 2018, SIM PROD MAN METH LI
   Reddy N., 2013, POLYM POLYM COMPOS, V21, P449
   Ricciardi P, 2017, CONSTR BUILD MATER, V147, P185, DOI 10.1016/j.conbuildmat.2017.04.114
   Ricciardi P, 2014, APPL ENERG, V134, P150, DOI 10.1016/j.apenergy.2014.07.112
   Rosa G., 2008, P WORLD ACAD SCI ENG, V2, P338
   Schmidt AC, 2004, INT J LIFE CYCLE ASS, V9, P53, DOI 10.1007/BF02978536
   Seddeq HS, 2009, AUST J BASIC APPL SC, V3, P4610
   Simpson W.S., 2002, WOOL SCI TECHNOLOGY
   Soheilmoghaddam M, 2017, MACROMOL MATER ENG, V302, DOI 10.1002/mame.201600260
   Staron P., 2011, CHEMIK, V65, P1019
   Ventura H, 2014, J TEXT I, V105, P1065, DOI 10.1080/00405000.2013.874628
   Wernet G, 2016, INT J LIFE CYCLE ASS, V21, P1218, DOI 10.1007/s11367-016-1087-8
   World Health Organization, 2016, WHO PUBL HLTH IMP CH
   Yalcin I, 2013, TEXT RES J, V83, P1551, DOI 10.1177/0040517512474366
   Yang WD, 2012, SCI CHINA TECHNOL SC, V55, P2278, DOI 10.1007/s11431-012-4943-1
   Zahn H, 1997, CHEM UNSERER ZEIT, V31, P280, DOI 10.1002/ciuz.19970310604
   Zhang YW, 2018, J APPL POLYM SCI, V135, DOI 10.1002/app.46332
NR 61
TC 1
Z9 1
U1 8
U2 20
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 489
EP 499
DI 10.1016/j.resconrec.2019.06.009
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300045
DA 2020-05-12
ER

PT J
AU Drabik, D
   de Gorter, H
   Reynolds, C
AF Drabik, Dusan
   de Gorter, Harry
   Reynolds, Christian
TI A conceptual and empirical framework to analyze the economics of
   consumer food waste
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Economic model; Food waste; Consumption; Consumer purchases; Effective
   consumption price; Downstream
ID BEHAVIOR; REDUCTION; COUNTRIES; ATTITUDES; BARRIERS; LOSSES; RETAIL;
   FRUIT
AB We develop a microeconomic model to understand food waste of consumers. We capture at-home and away-from home food consumption and distinguish between food purchases and food consumption. We allow the consumer to choose the rate of food waste at home optimally to maximize her utility. We show that consumer purchases can decline or increase with a cut in the rate of consumer waste, depending on the elasticity of food demand. Using the UK data for poultry in 2012, we also show a case where for a price elastic demand food consumption increases with a reduction in the food waste rate, but food purchases (retail sales) increase.
C1 [Drabik, Dusan] Wageningen Univ, Agr Econ & Rural Policy Grp, Wageningen, Netherlands.
   [de Gorter, Harry] Cornell Univ, Charles H Dyson Sch Appl Econ & Management, Ithaca, NY 14853 USA.
   [Reynolds, Christian] Univ Sheffield, Dept Geog, Sheffield, S Yorkshire, England.
   [Reynolds, Christian] WRAP, Banbury, Oxon, England.
RP Drabik, D (reprint author), Wageningen Univ, Agr Econ & Rural Policy Grp, Wageningen, Netherlands.
EM dusan.drabik@wur.nl
RI Reynolds, Christian/L-2760-2015
OI Reynolds, Christian/0000-0002-1073-7394
FU World Bank; HEFCE Catalyst-funded N8 AgriFood Resilience Programme; N8
   group of Universities; NERCNERC Natural Environment Research Council;
   Innovation Placement at the Waste and Resources Action Programme (WRAP)
   [NE/R007160/1]
FX This research was supported by funding from the World Bank. Christian
   Reynolds is supported from the HEFCE Catalyst-funded N8 AgriFood
   Resilience Programme and matched funding from the N8 group of
   Universities. Christian Reynolds has additional funding from NERC to
   support an Innovation Placement at the Waste and Resources Action
   Programme (WRAP) (Grant Ref: NE/R007160/1).
CR AHDB, 2012, POULTR POCK 2012
   AHDB, 2018, POULTR POCK 2018
   AHDB, 2014, POULTR POCK 2014
   AHDB, 2015, POULTR POCK 2013, DOI [10.1055/s-0034-1395665, DOI 10.1055/S-0034-1395665]
   AHDB, 2015, POULTR POCK 2015
   Aschemann-Witzel J, 2015, SUSTAINABILITY-BASEL, V7, P6457, DOI 10.3390/su7066457
   Bates B., 2014, PUBLIC HEAL ENGL, V4, P1, DOI DOI 10.1017/CB09781107415324.004
   Belavina E, 2016, SSRN ELECT J, P1, DOI [10.2139/ssm.2890962, DOI 10.2139/SSRN.2890962]
   Bellemare MF, 2017, AM J AGR ECON, V99, P1148, DOI 10.1093/ajae/aax034
   Bernstad A, 2011, WASTE MANAGE, V31, P1879, DOI 10.1016/j.wasman.2011.02.026
   Buzby J.C, 2014, EIB121 USDA EC RES S
   Buzby JC, 2015, AGRICULTURE-BASEL, V5, P626, DOI 10.3390/agriculture5030626
   Buzby JC, 2012, FOOD POLICY, V37, P561, DOI 10.1016/j.foodpol.2012.06.002
   Buzby JC, 2011, J CONSUM AFF, V45, P492, DOI 10.1111/j.1745-6606.2011.01214.x
   Canali M, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9010037
   CEC (Commission for Environmental Cooperation), 2018, CANADASECOND FOOD LO
   CHAMPIONS 12.3, 2018, BUSINESS CASE REDUCI
   Champions 12.3, 2017, BUSINESS CASE REDUCI
   Choi SC, 2006, J RETAILING, V82, P79, DOI 10.1016/j.jretai.2006.02.005
   de Gorter Harry, 2017, POLICY CONSIDERATION
   deGorter H, 2014, EC FOOD LOSSES WASTE
   Dou ZX, 2016, GLOB FOOD SECUR-AGR, V8, P19, DOI 10.1016/j.gfs.2016.02.001
   Dusoruth V, 2017, 2017 AGR APPL EC BEH
   EPA, 2014, FOOD WAST SCOP AN
   Eriksson M, 2015, J CLEAN PROD, V93, P115, DOI 10.1016/j.jclepro.2015.01.026
   FAO (Food and Agriculture Organization), 2011, GLOBAL FOOD LOSSES F
   G20, 2018, ARGENTINADECLARATION
   Galanakis C. M., 2015, FOOD WASTE RECOVERY
   Garrone P, 2014, FOOD POLICY, V46, P129, DOI 10.1016/j.foodpol.2014.03.014
   Graham-Rowe E, 2015, RESOUR CONSERV RECY, V101, P194, DOI 10.1016/j.resconrec.2015.05.020
   Graham-Rowe E, 2014, RESOUR CONSERV RECY, V84, P15, DOI 10.1016/j.resconrec.2013.12.005
   Gustaysson J., 2011, GLOBAL FOOD LOSSES F, DOI [10.1098/rstb.2010.0126, DOI 10.1098/RSTB.2010.0126]
   Hackner J, 2000, J ECON THEORY, V93, P233, DOI 10.1006/jeth.2000.2654
   Halloran A, 2014, FOOD POLICY, V49, P294, DOI 10.1016/j.foodpol.2014.09.005
   Hartikainen H, 2018, WASTE MANAGE, V71, P502, DOI 10.1016/j.wasman.2017.10.026
   Heller M, 2017, OPTIMIZING ENV PERFO
   Just DR, 2016, GLOB FOOD SECUR-AGR, V11, P26, DOI 10.1016/j.gfs.2016.05.006
   Just DR, 2016, AGR ECON-BLACKWELL, V47, P73, DOI 10.1111/agec.12302
   Just DR, 2016, FRONT ECON GLOBAL, V16, P215, DOI 10.1108/S1574-871520150000016009
   Katare B, 2017, AM J AGR ECON, V99, P499, DOI 10.1093/ajae/aaw114
   Koivupuro HK, 2012, INT J CONSUM STUD, V36, P183, DOI 10.1111/j.1470-6431.2011.01080.x
   Landry CE, 2017, SSRN ELECT J, DOI [10.2139/ssrn.3048544, DOI 10.2139/SSRN.3048544]
   Lipinski B., 2013, REDUCING FOOD LOSS W, P1, DOI DOI 10.2499/9780896295827_03
   Lorenz BA, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9050807
   Lusk JL, 2017, APPL ECON LETT, V24, P1199, DOI 10.1080/13504851.2016.1265070
   Moult JA, 2018, FOOD POLICY, V77, P50, DOI 10.1016/j.foodpol.2018.04.003
   Neff RA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127881
   Newsome R, 2014, COMPR REV FOOD SCI F, V13, P745, DOI 10.1111/1541-4337.12086
   O'Donnell T, 2016, FOOD TOO GOOD WASTE
   Parizeau K, 2015, WASTE MANAGE, V35, P207, DOI 10.1016/j.wasman.2014.09.019
   Parry A, 2015, OECD FOOD AGR FISHER, V76, DOI [10.1787/5js4w29cf0f7-en, DOI 10.1787/5JS4W29CF0F7-EN]
   Petit Olivia, 2017, 201714 WP
   Porat R, 2018, POSTHARVEST BIOL TEC, V139, P135, DOI 10.1016/j.postharvbio.2017.11.019
   Qi D, 2018, 3 ESSAYS EC FOOD WAS
   Qi DY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159250
   Quested TE, 2013, RESOUR CONSERV RECY, V79, P43, DOI 10.1016/j.resconrec.2013.04.011
   Quinn EL, 2018, PREV CHRONIC DIS, V15, DOI 10.5888/pcd15.170377
   Redlingshofer B, 2017, J CLEAN PROD, V164, P703, DOI 10.1016/j.jclepro.2017.06.173
   ReFED, 2016, ROADM RED US FOOD WA
   Refsgaard K, 2009, J ENVIRON MANAGE, V90, P760, DOI 10.1016/j.jenvman.2008.01.018
   Reynolds C, 2019, FOOD POLICY, V83, P7, DOI 10.1016/j.foodpol.2019.01.009
   Russell SV, 2017, RESOUR CONSERV RECY, V125, P107, DOI 10.1016/j.resconrec.2017.06.007
   Rutten M. M., 2013, AGR FOOD SECURITY, V2, P1, DOI DOI 10.1186/2048-7010-2-13
   Schott ABS, 2015, J ENVIRON MANAGE, V147, P219, DOI 10.1016/j.jenvman.2014.07.048
   Secondi L, 2015, FOOD POLICY, V56, P25, DOI 10.1016/j.foodpol.2015.07.007
   Segre I, 2014, SPINOZA: THE ETHICS OF AN OUTLAW, P1
   Stancu V, 2016, APPETITE, V96, P7, DOI 10.1016/j.appet.2015.08.025
   Stefan V, 2013, FOOD QUAL PREFER, V28, P375, DOI 10.1016/j.foodqual.2012.11.001
   Tatum M, 2018, GOVES 15M PILOT CAN
   Tesco P. L. C, 2018, UK FOOD WAST DAT 201
   Tesco PLC, 2018, UK FOOD WAST DAT 201, P5
   Thyberg KL, 2016, RESOUR CONSERV RECY, V106, P110, DOI 10.1016/j.resconrec.2015.11.016
   USDA, 2018, SEL NEW ONG USDA FOO
   Visschers VHM, 2016, J ENVIRON PSYCHOL, V45, P66, DOI 10.1016/j.jenvp.2015.11.007
   Vittuari M, 2015, REV EU LEGISLATION P, P54
   Waarts Y., 2011, 2011059 LEI
   Wansink B, 2018, J FOOD PROD MARK, V24, P500, DOI 10.1080/10454446.2018.1472694
   Williams H, 2012, J CLEAN PROD, V24, P141, DOI 10.1016/j.jclepro.2011.11.044
   Wilson NLW, 2017, FOOD QUAL PREFER, V55, P35, DOI 10.1016/j.foodqual.2016.08.004
   WRAP, 2013, UND OUT HOM CONS FOO
   WRAP, 2008, THE FOOD WE WAST
   WRAP, 2014, HOUS FOOD DRINK WAST
   WRAP, 2016, QUANT FOOD SURPL WAS
   WRAP, 2018, HOUS FOOD WAST REST
   WRAP, 2013, EST FOOD PACK WAST U
   WRAP, 2011, COMP WAST DISP UK HO
   WRAP, 2011, SYNTH FOOD WAST COMP
   WRAP, 2013, GAT FEES REP 2013 CO
   WRAP, 2018, RCY111002 WRAP
   Wrap, 2013, TRUE COST FOOD WAST
   WRAP, 2009, HOUS FOOD DRINK WAST, DOI [DOI 10.1111/J.1467-3010.2011.01924.X, 10.1111/j.1467-3010.2011.01924.x]
   WRAP, 2017, MAT PRIC REP
   WRAP, 2013, FOOD WAST AR UK HOSP
   WRAP, 2013, WAST UK HOSP FOOD SE
   WRAP, 2014, EC MOD HOUS FOOD WAS
   WRAP, 2012, GAT FEES REP 2012 CO
   WRAP (Waste and Resources Action Programme), 2009, HOUSEHOLD FOOD DRINK
NR 97
TC 1
Z9 1
U1 3
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 500
EP 509
DI 10.1016/j.resconrec.2019.06.008
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300046
OA Other Gold, Green Accepted
DA 2020-05-12
ER

PT J
AU Yousef, S
   Hamdy, M
   Tatariants, M
   Tuckute, S
   El-Abden, SZ
   Kliucininkas, L
   Baltusnikas, A
AF Yousef, Samy
   Hamdy, Mohamed
   Tatariants, Maksym
   Tuckute, Simona
   El-Abden, Samy Zein
   Kliucininkas, Linas
   Baltusnikas, Arunas
TI Sustainable industrial technology for recovery of cellulose from
   banknote production waste and reprocessing into cellulose nanocrystals
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Banknote; Banknote waste; Recycling; Cotton recovery; Cellulose
   nanocrystals; Sustainability
ID PAPER; CURRENCY; POLYMER; TEXTILE; STAMPS; ENGLAND; COSTS; PULP
AB Banknote printing is the industry that has a deep influence on financial operations on market, reflecting the economic performance of governments. Therefore, it is surrounded by a great secrecy even when dealing with production waste and end-of-life products, which are utilized very carefully by controlled combustion or incineration after crushing using special techniques designed to ensure that the waste does not come into possession by third parties. This waste contains significant amounts of cotton, percentage of which sometimes can reach up to 100% of the weight of banknote paper. It is clear that disposal of such waste by simply incinerating it is contrary to the principles of sustainability and preservation of resources. In order to achieve these principles, this research aims to develop a new strategy called "Banknote for Banknote (BFB)" to recover and refine cotton from Banknote waste and later reuse it in the production of banknote paper or reprocess it into cellulose nanocrystals suitable for use in many advanced applications through a sustainable technology. The experiments were performed only on the Banknote Production Waste (BPW) (which is estimated as "3% of the total volume of Banknote production) because the end-of-life banknotes are usually contaminated with many substances during the circulation. Some of them can become hazardous to the extent of being contaminated with drugs (e.g. cocaine, etc.); that requires many additional analyses and special treatment. In the developed technology BPW was treated by using five sequential processes that were selected based on the banknote design, structure, need to reach minimum gas emissions and high recovery rate. The technology began from crushing treatment at the Central Bank for safety reasons, then leaching process was used to dissolve the heavy metals from the ink layer (Al, Fe, Ni, etc.) and separate other pigment metal elements (Si, Ti, etc.) in the form of suspended particles, while the dissolution and bleaching stages were employed to dissolve the remaining organic components and purify the cotton substrate. Finally, acid hydrolysis was used to prepare Cellulose nanocrystals with average size 75 nm from the purified cotton. Although the experiments were conducted on Egyptian Banknote, the advanced technology is applicable to all types of cotton based-banknotes with high profitability.
C1 [Yousef, Samy] Kaunas Univ Technol, Dept Prod Engn, Fac Mech Engn & Design, LT-51424 Kaunas, Lithuania.
   [Hamdy, Mohamed; El-Abden, Samy Zein] Menia Univ, Fac Engn, Dept Prod Engn & Design, Al Minya, Egypt.
   [Tatariants, Maksym; Kliucininkas, Linas] Kaunas Univ Technol, Fac Chem Technol, Dept Environm Technol, LT-50254 Kaunas, Lithuania.
   [Tuckute, Simona; Baltusnikas, Arunas] Lithuanian Energy Inst, Breslaujos 3, LT-44403 Kaunas, Lithuania.
   [Yousef, Samy] Akhbar Elyom Acad 6th October, Dept Prod Engn & Printing Technol, 6th Of October City, Egypt.
RP Yousef, S (reprint author), Kaunas Univ Technol, Dept Prod Engn, Fac Mech Engn & Design, LT-51424 Kaunas, Lithuania.
EM ahmed.saed@ktu.lt
OI Yousef, Samy/0000-0002-4846-3202
CR Agarwal B, 2013, CUTTING COTTON CARBO
   Aitken CGG, 2017, FORENSIC SCI INT, V270, P261, DOI 10.1016/j.forsciint.2016.10.017
   Maciel MMAD, 2019, INT J BIOL MACROMOL, V126, P496, DOI 10.1016/j.ijbiomac.2018.12.202
   Badovinac IJ, 2010, NUCL INSTRUM METH A, V619, P487, DOI 10.1016/j.nima.2009.10.174
   Baek S, 2018, DIGIT SIGNAL PROCESS, V78, P294, DOI 10.1016/j.dsp.2018.03.015
   Bank of Thailand, 2015, BANKN PRINT PROC
   Bartzsch N, 2013, Q REV ECON FINANC, V53, P393, DOI 10.1016/j.qref.2013.05.008
   Bayer IS, 2014, MACROMOLECULES, V47, P5135, DOI 10.1021/ma5008557
   Borjesson M, 2015, CELLULOSE FUNDAMENTA, P159, DOI DOI 10.5772/61899
   Bouhdaoui Y, 2017, J MACROECON, V52, P252, DOI 10.1016/j.jmacro.2017.05.002
   Carter JF, 2003, FORENSIC SCI INT, V132, P106, DOI 10.1016/S0379-0738(03)00015-X
   Christopher M, 2017, BIORESOURCE TECHNOL, V242, P178, DOI 10.1016/j.biortech.2017.03.190
   Downham RP, 2017, FORENSIC SCI INT, V275, P30, DOI 10.1016/j.forsciint.2017.02.026
   EEA, 2014, EEA GREENH GAS DAT V
   Fan M, 2012, FOURIER TRANSFORM - MATERIALS ANALYSIS, P45
   Garcia-Lamont F, 2012, EXPERT SYST APPL, V39, P9651, DOI 10.1016/j.eswa.2012.02.132
   Gaspar D, 2014, NANOTECHNOLOGY, V25, DOI 10.1088/0957-4484/25/9/094008
   Gert EV, 2000, CELLULOSE, V7, P57, DOI 10.1023/A:1009206113613
   Gharfalkar M, 2015, WASTE MANAGE, V39, P305, DOI 10.1016/j.wasman.2015.02.007
   Goldberg D, 2009, J ECON HIST, V69, P1092, DOI 10.1017/S0022050709001399
   Aguayo MG, 2018, POLYMERS-BASEL, V10, DOI 10.3390/polym10101145
   Griffin PW, 2018, APPL THERM ENG, V134, P152, DOI 10.1016/j.applthermaleng.2018.01.126
   Hamawand I, 2016, RENEW SUST ENERG REV, V66, P435, DOI 10.1016/j.rser.2016.08.033
   Hardwick B, 2001, ADV MATER, V13, P980, DOI 10.1002/1521-4095(200107)13:12/13<980::AID-ADMA980>3.0.CO;2-F
   Hasanzadeh E, 2018, FUEL, V218, P41, DOI 10.1016/j.fuel.2018.01.035
   Itric K., 2017, TECH J
   Jeswani HK, 2016, WASTE MANAGE, V50, P346, DOI 10.1016/j.wasman.2016.02.010
   Kaufmann T, 2010, POLYM CHEM-UK, V1, P371, DOI 10.1039/b9py00281b
   Khanduja V, 2017, J INF SECUR APPL, V37, P38, DOI 10.1016/j.jisa.2017.10.001
   Kumar H, 2013, J NONLINEAR OPT PHYS, V22, DOI 10.1142/S021886351350001X
   Kyrychok T, 2014, MECHANIKA, P327, DOI 10.5755/j01.mech.20.3.7393
   Lim HT, 2017, OPT LASER ENG, V98, P168, DOI 10.1016/j.optlaseng.2017.06.022
   Liu WC, 2019, CARBOHYD POLYM, V206, P141, DOI 10.1016/j.carbpol.2018.10.046
   Lujan-Ornelas C, 2018, SCI TOTAL ENVIRON, V630, P409, DOI 10.1016/j.scitotenv.2018.02.177
   Menzies G., 2004, N AM J EC FINAN, DOI 10.1016/j.najef.2004.10.002
   Miranda R, 2007, J ANAL APPL PYROL, V80, P489, DOI 10.1016/j.jaap.2007.03.008
   Nathan VK, 2018, J CLEAN PROD, V203, P926, DOI 10.1016/j.jclepro.2018.08.335
   Petzold G, 2015, COLLOID SURFACE A, V480, P398, DOI 10.1016/j.colsurfa.2015.01.084
   Pires J. R. A., 2019, LECT NOTES ELECT ENG, DOI [10.1007/978-3-319-91334-698, DOI 10.1007/978-3-319-91334-698]
   Rehman A., 2019, J SAUDI SOC AGR SCI, V18, P49, DOI [10.1016/j.jssas.2016.12.005, DOI 10.1016/J.JSSAS.2016.12.005]
   Ruiz A, 2017, J COGN PSYCHOL, V29, P169, DOI 10.1080/20445911.2016.1237954
   Sadeghifar H, 2011, J MATER SCI, V46, P7344, DOI 10.1007/s10853-011-5696-0
   Saxena A, 2017, CRIT REV BIOTECHNOL, V37, P598, DOI 10.1080/07388551.2016.1207594
   Sebastian RM, 2019, RESOUR CONSERV RECY, V140, P286, DOI 10.1016/j.resconrec.2018.09.022
   Shiga TM, 2017, BIOTECHNOL BIOFUELS, V10, DOI 10.1186/s13068-017-0999-2
   Shukla SK, 2017, ACM T EMBED COMPUT S, V16, DOI 10.1145/3087913
   Sifat IM, 2018, INT J ETHICS SYST, V34, P2, DOI 10.1108/IJOES-06-2017-0090
   Soukup D, 2009, IMAGE VISION COMPUT, V27, P989, DOI 10.1016/j.imavis.2008.08.008
   Takalo J, 2014, FORENSIC SCI INT, V244, P252, DOI 10.1016/j.forsciint.2014.09.002
   Tatariants M, 2018, J CLEAN PROD, V203, P498, DOI 10.1016/j.jclepro.2018.08.283
   Tatariants M, 2018, J CLEAN PROD, V172, P2811, DOI 10.1016/j.jclepro.2017.11.132
   Turner DA, 2015, RESOUR CONSERV RECY, V105, P186, DOI 10.1016/j.resconrec.2015.10.026
   Van Hove L, 2015, ECON MODEL, V46, P238, DOI 10.1016/j.econmod.2014.12.006
   Varenberg M, 2014, J ADHES SCI TECHNOL, V28, P630, DOI 10.1080/01694243.2013.859063
   Vukoje M., 2019, ACTA GRAPH J PRINT S, V29, P27, DOI [10.25027/agj2017.28.v29i2.156, DOI 10.25027/AGJ2017.28.V29I2.156]
   Wang L, 2018, CARBOHYD POLYM, V197, P490, DOI 10.1016/j.carbpol.2018.05.084
   Willis M, 2009, J GLOB MARK, V22, P67
   Wulandari WT, 2016, IOP CONF SER-MAT SCI, V107, DOI 10.1088/1757-899X/107/1/012045
   Yehia A, 2018, SEP SCI TECHNOL, V53, P544, DOI 10.1080/01496395.2017.1395887
   Yousef S, 2019, RESOUR CONSERV RECY, V145, P359, DOI 10.1016/j.resconrec.2019.02.031
   Yousef S, 2019, SOL ENERG MAT SOL C, V191, P493, DOI 10.1016/j.solmat.2018.12.008
   Yousef S, 2018, J CLEAN PROD, V197, P379, DOI 10.1016/j.jclepro.2018.06.154
   Zarayneh S, 2018, INT J BIOL MACROMOL, V118, P1045, DOI 10.1016/j.ijbiomac.2018.06.160
   Zhang Y, 2016, FUEL, V184, P815, DOI 10.1016/j.fuel.2016.07.089
   Zhou JZ, 2015, FUEL, V158, P619, DOI 10.1016/j.fuel.2015.05.071
   Zhou X, 2016, ACS SUSTAIN CHEM ENG, V4, P5585, DOI 10.1021/acssuschemeng.6b01408
   Zhu YX, 2015, PROD OPER MANAG, V24, P1966, DOI 10.1111/poms.12378
NR 67
TC 0
Z9 0
U1 13
U2 25
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 510
EP 520
DI 10.1016/j.resconrec.2019.06.026
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300047
DA 2020-05-12
ER

PT J
AU Peng, ZW
   Tang, HM
   Augustine, R
   Le, J
   Tian, WG
   Chen, YH
   Gu, FQ
   Zhang, YB
   Li, GH
   Jiang, T
AF Peng, Zhiwei
   Tang, Huimin
   Augustine, Robin
   Le, Joonho
   Tian, Weiguang
   Chen, Yanhu
   Gu, Foquan
   Zhang, Yuanbo
   Li, Guanghui
   Jiang, Tao
TI From ferronickel slag to value-added refractory materials: A microwave
   sintering strategy
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Ferronickel slag; Refractory material; Microwave sintering; Phase
   transformation; Spinel
ID NICKEL SLAG; SELECTIVE RECOVERY; VALUABLE METALS; FLY-ASH;
   MICROSTRUCTURE; COPPER; MGO; DENSIFICATION; MGCRXFE2-XO4; FUNDAMENTALS
AB The present study proposes a novel strategy for preparation of refractory materials from potentially hazardous ferronickel slag by microwave sintering of the slag with addition of sintered magnesia in which a series of chemical reactions were involved. This strategy was developed based on examination of the phase transformations and microstructural changes of the slag during microwave sintering through X-ray diffraction (XRD) analysis and scanning electron microscopy-energy dispersive X-ray spectroscopy (SEM-EDS) analysis, which determined the properties of refractory materials derived from the slag. It was shown that under microwave irradiation there existed rapid transformation of the olivine phase in the slag to high-melting point phases, including forsterite and spinels (e.g., magnesium iron chromate spinel, magnesium chromate spinel, and magnesium iron aluminate spinel). As a result, a high-quality refractory material with refractoriness of 1730 degrees C, bulk density of 2.80 g/cm(3), apparent porosity of 1.6%, and compressive strength of 206.62 MPa was obtained by microwave sintering of the slag at 1350 degrees C for only 20 min with addition of 25 wt % sintered magnesia. Because the microwave sintering strategy not only elevated the refractoriness by 70 degrees C, but also reduced the heating duration required by the conventional approach by 6 times, it demonstrated apparent technological superiority and wide application prospect in preparing superior-quality refractory materials from ferronickel slag and relevant industrial waste, which contributed to conservation of resources and energy as well as environmental protection.
C1 [Peng, Zhiwei; Tang, Huimin; Gu, Foquan; Zhang, Yuanbo; Li, Guanghui; Jiang, Tao] Cent S Univ, Sch Minerals Proc & Bioengn, Changsha 410083, Hunan, Peoples R China.
   [Augustine, Robin] Uppsala Univ, Dept Engn Sci, SE-75121 Uppsala, Sweden.
   [Le, Joonho] Korea Univ, Dept Mat Sci & Engn, Seoul 02841, South Korea.
   [Tian, Weiguang; Chen, Yanhu] Guangdong Guangqing Met Technol Co Ltd, Yangjiang 529500, Guangdong, Peoples R China.
RP Peng, ZW (reprint author), Cent S Univ, Sch Minerals Proc & Bioengn, Changsha 410083, Hunan, Peoples R China.
EM zwpeng@csu.edu.cn
OI Li, Guanghui/0000-0001-8835-8346
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51774337, 51504297, 51811530108]; Key Laboratory
   for Solid Waste Management and Environment Safety (Tsinghua University)
   Open Fund [SWMES2017-04]; Project of State Key Laboratory Cultivation
   Base for Nonmetal Composites and Functional Materials [17kffK11];
   Fundamental Research Funds for the Central Universities of Central South
   University [2018zzts779, 2018zzts220]
FX This work was partially supported by the National Natural Science
   Foundation of China under Grants 51774337, 51504297 and 51811530108, the
   Key Laboratory for Solid Waste Management and Environment Safety
   (Tsinghua University) Open Fund under Grant SWMES2017-04, the Project of
   State Key Laboratory Cultivation Base for Nonmetal Composites and
   Functional Materials under Grant 17kffK11, and the Fundamental Research
   Funds for the Central Universities of Central South University under
   Grants 2018zzts779 and 2018zzts220.
CR Acevedo L, 2015, ENERGY, V80, P437, DOI 10.1016/j.energy.2014.11.085
   Balomenos E, 2013, P 3 INT SLAG VAL S B
   Banda W, 2002, MINER ENG, V15, P899, DOI 10.1016/S0892-6875(02)00090-0
   Bhattacharya M, 2016, ENERGY, V97, P306, DOI 10.1016/j.energy.2015.11.034
   Bhattacharya M, 2013, ENERGY, V55, P278, DOI 10.1016/j.energy.2013.03.016
   Choi YC, 2015, CONSTR BUILD MATER, V99, P279, DOI 10.1016/j.conbuildmat.2015.09.039
   Clark DE, 2000, MAT SCI ENG A-STRUCT, V287, P153, DOI 10.1016/S0921-5093(00)00768-1
   Ganesh I, 2004, J EUR CERAM SOC, V24, P201, DOI 10.1016/S0955-2219(03)00602-2
   Ganesh I, 2002, CERAM INT, V28, P245, DOI 10.1016/S0272-8842(01)00086-4
   Ganesh I, 2001, CERAM INT, V27, P773, DOI 10.1016/S0272-8842(01)00029-3
   Gu FQ, 2018, MINERAL MET MAT SER, P633, DOI 10.1007/978-3-319-72484-3_67
   Gu FQ, 2018, ACS SUSTAIN CHEM ENG, V6, P4880, DOI 10.1021/acssuschemeng.7b04336
   Guo M, 2009, J EUR CERAM SOC, V29, P1053, DOI 10.1016/j.jeurceramsoc.2008.07.063
   Han D, 2018, CERAM INT, V44, P11101, DOI 10.1016/j.ceramint.2018.03.109
   Huang FR, 2015, SEP PURIF TECHNOL, V156, P572, DOI 10.1016/j.seppur.2015.10.051
   Huang YD, 2017, CONSTR BUILD MATER, V156, P773, DOI 10.1016/j.conbuildmat.2017.09.038
   Jones DA, 2002, RESOUR CONSERV RECY, V34, P75, DOI 10.1016/S0921-3449(01)00088-X
   Jones PT, 2002, J EUR CERAM SOC, V22, P903, DOI 10.1016/S0955-2219(00)00343-5
   Karamanov A, 2017, J ENVIRON CHEM ENG, V5, P432, DOI 10.1016/j.jece.2016.12.020
   Katsiotis NS, 2015, WASTE BIOMASS VALORI, V6, P177, DOI 10.1007/s12649-015-9346-7
   Kirillidi Y, 2005, PROC INT CONF ENV SC, pA768
   Komnitsas K, 2007, J MATER SCI, V42, P3073, DOI 10.1007/s10853-006-0529-2
   Komnitsas K, 2013, APPL CLAY SCI, V73, P103, DOI 10.1016/j.clay.2012.09.018
   Koruderlieva SN, 2017, J ENVIRON PROT ECOL, V18, P978
   Lang L., 2019, BOILER MANUFACT, V273, P12
   Lemonis N, 2015, CONSTR BUILD MATER, V81, P130, DOI 10.1016/j.conbuildmat.2015.02.046
   Li Jing, 2009, J Environ Sci (China), V21 Suppl 1, pS92, DOI 10.1016/S1001-0742(09)60046-2
   Li YJ, 2008, J HAZARD MATER, V152, P607, DOI 10.1016/j.jhazmat.2007.07.052
   Li YJ, 2009, HYDROMETALLURGY, V97, P185, DOI 10.1016/j.hydromet.2009.03.007
   Ma GJ, 2010, ACTA METALL SIN-ENGL, V23, P267, DOI 10.11890/1006-7191-104-267
   Mushtaq F, 2014, RENEW SUST ENERG REV, V39, P555, DOI 10.1016/j.rser.2014.07.073
   Mustafa E, 2002, CERAM INT, V28, P663, DOI 10.1016/S0272-8842(02)00025-1
   Ni S., 2017, CERAM INT, V33, P83
   Oghbaei M, 2010, J ALLOY COMPD, V494, P175, DOI 10.1016/j.jallcom.2010.01.068
   Othman AGM, 2005, CERAM INT, V31, P1117, DOI 10.1016/j.ceramint.2004.11.011
   Pack A, 2005, GEOCHIM COSMOCHIM AC, V69, P3159, DOI 10.1016/j.gca.2005.01.013
   Pan J, 2013, T NONFERR METAL SOC, V23, P3421, DOI 10.1016/S1003-6326(13)62883-6
   Peng Z., 2016, CHARACTERIZATION MIN, P443
   Peng Z. W., 2013, MET MAT, V2013, P389
   Peng ZW, 2018, ACS SUSTAIN CHEM ENG, V6, P10536, DOI 10.1021/acssuschemeng.8b01882
   Peng Z, 2015, CERAM INT, V41, P3058, DOI 10.1016/j.ceramint.2014.10.145
   Peng ZW, 2015, INT MATER REV, V60, P30, DOI 10.1179/1743280414Y.0000000042
   Peng ZW, 2013, CERAM INT, V39, P6721, DOI 10.1016/j.ceramint.2013.01.114
   Peng ZW, 2011, METALL MATER TRANS A, V42A, P2259, DOI 10.1007/s11661-011-0652-9
   Peng ZW, 2010, ISIJ INT, V50, P1590, DOI 10.2355/isijinternational.50.1590
   Popescu S, 2008, RESOUR CONSERV RECY, V52, P671, DOI 10.1016/j.resconrec.2007.09.003
   Rahman MA, 2017, CONSTR BUILD MATER, V140, P194, DOI 10.1016/j.conbuildmat.2017.02.023
   Rudnik E, 2009, MINER ENG, V22, P88, DOI 10.1016/j.mineng.2008.04.016
   Rybakov KI, 2012, SCRIPTA MATER, V66, P1049, DOI 10.1016/j.scriptamat.2012.02.043
   Rybakov KI, 2013, J AM CERAM SOC, V96, P1003, DOI 10.1111/jace.12278
   Sabri K, 2016, PHYSICA B, V501, P38, DOI 10.1016/j.physb.2016.08.011
   Saha AK, 2018, RESOUR CONSERV RECY, V134, P10, DOI 10.1016/j.resconrec.2018.02.034
   Saha AK, 2017, J CLEAN PROD, V162, P438, DOI 10.1016/j.jclepro.2017.06.035
   Sahu N, 2016, MIN PROC EXT MET REV, V37, P255, DOI 10.1080/08827508.2016.1181630
   Sarkar R, 2002, J EUR CERAM SOC, V22, P1243, DOI 10.1016/S0955-2219(01)00446-0
   Schutz MB, 2018, INT MATER REV, V63, P341, DOI 10.1080/09506608.2017.1402158
   Tang HM, 2019, MINERAL MET MAT SER, P161, DOI 10.1007/978-3-030-05749-7_17
   Tavangarian F, 2011, CERAM INT, V37, P2543, DOI 10.1016/j.ceramint.2011.03.056
   Tavangarian F, 2010, POWDER TECHNOL, V198, P412, DOI 10.1016/j.powtec.2009.12.007
   Tripathi HS, 2010, CERAM INT, V36, P1189, DOI 10.1016/j.ceramint.2009.12.011
   Vargas E, 2016, MATER DESIGN, V90, P47, DOI 10.1016/j.matdes.2015.10.110
   Wang ZJ, 2011, INT J MIN MET MATER, V18, P455, DOI 10.1007/s12613-011-0462-5
   Wang ZM, 2011, J APPL MATHE COMPUT, V36, P507, DOI [10.1007/s12190-010-0416-5, 10.1016/j.jnoncrysol.2010.05.063]
   Xia BD, 2018, RESOUR CONSERV RECY, V139, P15, DOI 10.1016/j.resconrec.2018.08.002
   Xu P., 2017, RECYCL RESOUR CIRCUL, V8, P39
   Yang Cheng-wu, 2014, Chinese Journal of Nonferrous Metals, V24, P2145
   Yang T, 2017, CONSTR BUILD MATER, V155, P475, DOI 10.1016/j.conbuildmat.2017.08.081
   Yang T, 2014, CONSTR BUILD MATER, V59, P188, DOI 10.1016/j.conbuildmat.2014.01.038
   Yin XW, 2017, INT MATER REV, V62, P117, DOI 10.1080/09506608.2016.1213939
   Zaharaki D, 2012, FRESEN ENVIRON BULL, V21, P2436
   Zakaria AKM, 2015, J ALLOY COMPD, V633, P115, DOI 10.1016/j.jallcom.2015.01.179
   Zhang XF, 2016, J ALLOY COMPD, V686, P356, DOI 10.1016/j.jallcom.2016.06.038
   Zhang Y, 2010, HYDROMETALLURGY, V103, P25, DOI 10.1016/j.hydromet.2010.02.009
   Zuo F, 2015, J EUR CERAM SOC, V35, P959, DOI 10.1016/j.jeurceramsoc.2014.10.025
NR 74
TC 1
Z9 1
U1 12
U2 24
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 521
EP 531
DI 10.1016/j.resconrec.2019.06.019
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300048
DA 2020-05-12
ER

PT J
AU Nylen, EJA
   Salminen, JM
AF Nylen, Erkki-Jussi Antero
   Salminen, Jani Markus
TI How does the circular economy discourse affect policy-making? The case
   of streamlining waste utilisation in Finnish earthworks
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Circular economy; Policy formulation; Waste utilisation; Discursive
   space; Upcycling; Deregulation
ID CHINA; IDEAS; POWER
AB Since entering the waste policy debate in the 1980s, the sustainability discourse has sought to find alternatives to end-of-pipe solutions. The latest development on this path is the emergence of the circular economy, which aims to close the loop of the current linear economy. This case study analyses a substantial Finnish waste policy reform that has been underway since the late 1990s. The objective of the reform has been to create a decree that streamlines waste utilisation in earthworks. The decree was prepared between 2000 and 2006, and then reformed between 2015 and 2018. We analysed the discursive spaces of both phases and compared them to interpret the changes in the discourse of waste policy. The discursive space in the preparation phase was structured by the tension between the discourses of resource efficiency and precaution, but in the reform, the emergence of the circular economy diversified the discursive space. The thinking regarding the circular economy has added complexity, competition, and struggle to waste policy, but also enhanced the role of upcycling.
C1 [Nylen, Erkki-Jussi Antero] Tampere Univ, Fac Management & Business, Kanslerinrinne 1,Pinni A, Tampere 33014, Finland.
   [Salminen, Jani Markus] Finnish Environm Inst, Ctr Sustainable Consumpt & Prod, POB 140, FI-00251 Helsinki, Finland.
RP Nylen, EJA (reprint author), Tampere Univ, Fac Management & Business, Kanslerinrinne 1,Pinni A, Tampere 33014, Finland.
EM erkki-jussi.nylen@tuni.fi; jani.salminen@ymparisto.fi
OI Nylen, Erkki-Jussi/0000-0003-0693-0447
CR [Anonymous], 1993, ACT
   [Anonymous], 2006, BACKGROUND
   [Anonymous], 2009, ANNEXES
   [Anonymous], 2017, DG
   [Anonymous], 2006, SCHOOL OF ENGINEERIN
   [Anonymous], 2017, STUDIES
   [Anonymous], 2006, DG
   [Anonymous], 2017, STUDIES
   [Anonymous], 2017, ACT
   [Anonymous], 2018, GUIDE
   Ayres I., 1992, PRESS
   Blomsma F, 2017, J IND ECOL, V21, P603, DOI 10.1111/jiec.12603
   Bridgens B, 2018, J CLEAN PROD, V189, P145, DOI 10.1016/j.jclepro.2018.03.317
   Collier U., 1998, DEREGULATION IN THE
   de Jesus A, 2018, ECOL ECON, V145, P75, DOI 10.1016/j.ecolecon.2017.08.001
   Di Maria A, 2018, WASTE MANAGE, V75, P3, DOI 10.1016/j.wasman.2018.01.028
   Domenech T, 2019, ECOL ECON, V155, P7, DOI 10.1016/j.ecolecon.2017.11.001
   Elia V, 2017, J CLEAN PROD, V142, P2741, DOI 10.1016/j.jclepro.2016.10.196
   European Commission, 2015, CLOS LOOP EU ACT PLA
   Feindt Peter H., 2005, J ENVIRON POL PLAN, V7, P161, DOI DOI 10.1080/15239080500339638
   Finnish Transport Agency, 2015, LIIKENNEVIRASTON YMP
   FROSCH R, 1977, BIOSCIENCE, V27, P266
   Gregson N, 2015, ECON SOC, V44, P218, DOI 10.1080/03085147.2015.1013353
   Hajer M. A., 1995, POLITICS ENV DISCOUR
   Hajera M., 2005, J ENVIRON POL PLAN, V7, P175, DOI DOI 10.1080/15239080500339646
   Hill JE, 2015, PROC INST CIV ENG-WA, V168, P3, DOI 10.1680/warm.14.00003
   Howarth D., 2000, DISCOURSE THEORY POL
   Howlett M., 2013, ROUTLEDGE HDB PUBLIC
   Hultman J, 2012, ENVIRON PLANN A, V44, P2413, DOI 10.1068/a44668
   Iacovidou E, 2017, J CLEAN PROD, V168, P1279, DOI 10.1016/j.jclepro.2017.09.002
   Jokinen P, 2018, BIODIVERS CONSERV, V27, P1725, DOI 10.1007/s10531-016-1216-5
   Jurgilevich A, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8010069
   Kaufmann M, 2016, LAND USE POLICY, V57, P277, DOI 10.1016/j.landusepol.2016.05.033
   Kirchherr J, 2017, RESOUR CONSERV RECY, V127, P221, DOI 10.1016/j.resconrec.2017.09.005
   Korhonen J, 2018, J CLEAN PROD, V175, P544, DOI 10.1016/j.jclepro.2017.12.111
   Korhonen J, 2018, ECOL ECON, V143, P37, DOI 10.1016/j.ecolecon.2017.06.041
   Kronenberg J, 2009, ECOL ECON, V68, P3026, DOI 10.1016/j.ecolecon.2009.07.006
   Lazarevic D, 2017, ENERGY RES SOC SCI, V31, P60, DOI 10.1016/j.erss.2017.05.006
   Lidskog R., 2005, J ENVIRON POL PLAN, V7, P89, DOI [DOI 10.1080/15239080500338473, 10.1080/15239080500338473]
   Lincoln Y.S., 1985, NATURALISTIC INQUIRY, P289, DOI DOI 10.1016/0147-1767(85)90062-8
   McDonough W., 2008, VINTAGE
   McDowall W, 2017, J IND ECOL, V21, P651, DOI 10.1111/jiec.12597
   Meadowcroft J., 2017, MIT PRESS
   Milios L, 2018, SUSTAIN SCI, V13, P861, DOI 10.1007/s11625-017-0502-9
   Ministry of Finance, 2012, MAA AINESVERO
   Ministry of the Environment, 2016, MINISTRY
   Ministry of the Environment, 2017, ENVIRONMENT 2017
   Ministry of the Environment, 2006, MINISTRY
   Moore SA, 2012, PROG HUM GEOG, V36, P780, DOI 10.1177/0309132512437077
   Nylen E. -J., 2019, LEADING CHANGE IN A
   Paul KT, 2009, CRIT POLICY STUD, V3, P240, DOI 10.1080/19460170903385692
   Pol VG, 2010, ENVIRON SCI TECHNOL, V44, P4753, DOI 10.1021/es100243u
   Reno J, 2009, J MAT CULT, V14, P29, DOI DOI 10.1177/1359183508100007
   Schejter Laura, 2015, Revista de Investigacion y Desarrollo Pesquero, V26, P89
   Schmidt VA, 2008, ANNU REV POLIT SCI, V11, P303, DOI 10.1146/annurev.polisci.11.060606.135342
   Schmidt VA, 2017, CRIT REV, V29, P248, DOI 10.1080/08913811.2017.1366665
   Silva A, 2017, WASTE MANAGE, V61, P547, DOI 10.1016/j.wasman.2016.11.038
   Silva A, 2016, J CLEAN PROD, V115, P224, DOI 10.1016/j.jclepro.2015.12.069
   Sormunen L. A., 2017, RECOVERED MUNICIPAL
   Sorvari J, 2008, WASTE MANAGE, V28, P489, DOI 10.1016/j.wasman.2006.12.021
   Su B, 2013, J CLEAN PROD, V42, P215, DOI 10.1016/j.jclepro.2012.11.020
   Thomas G., 2017, THE ANATOMY OF THE C, DOI 10.4135/9781473920156
   Timmermans A, 2006, J EUR PUBLIC POLICY, V13, P1104, DOI 10.1080/13501760600924209
   Turnpenny J., 2015, THE TOOLS OF POLICY, DOI 10.4337/9781783477043
   Wilts H, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8070622
   BIOSCIENCE, P266
NR 66
TC 0
Z9 0
U1 3
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 532
EP 540
DI 10.1016/j.resconrec.2019.06.029
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300049
DA 2020-05-12
ER

PT J
AU Baker, GA
   Gray, LC
   Harwood, MJ
   Osland, TJ
   Tooley, JBC
AF Baker, Gregory A.
   Gray, Leslie C.
   Harwood, Michael J.
   Osland, Travis J.
   Tooley, Jean Baptiste C.
TI On-farm food loss in northern and central California: Results of field
   survey measurements
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Food loss; Food waste; Food recovery; Farm, gleaning; Primary production
ID WASTE
AB Prevailing estimates of food loss at the farm level are sparse and often reliant upon grower surveys. A more comprehensive review of food loss at the farm level using field surveys is required to gain an adequate understanding of the depth of this issue. This paper details the results of 123 in-field surveys and 18 in-depth interviews of 20 different, hand-harvested field crops performed largely on midsize to large conventional farms in northern and central California. We also provide estimates of the percentage of fields that go unharvested, commonly known as walk-by fields. The results show that food loss is highly variable and largely dependent upon the crop, variety, market price, labor costs, grower practices, buyer specifications, and environmental conditions. On average, we found 11,299 kg/ha of food loss at the farm level, which equates to 31.3% of the marketed yield. When walk-by losses are included, this figure rises to 33.7%. Our paper also demonstrates that grower estimates are typically very unreliable for estimating on-farm food losses. Actual, measured edible food loss exceeded growers' estimates by a median value of 157%. Strategies to utilize this lost produce could play a significant role in reducing the impact of agriculture on the environment and providing food for the rapidly growing population.
C1 [Baker, Gregory A.; Harwood, Michael J.; Osland, Travis J.; Tooley, Jean Baptiste C.] Santa Clara Univ, Ctr Food Innovat & Entrepreneurship, Santa Clara, CA 95053 USA.
   [Gray, Leslie C.] Santa Clara Univ, Dept Environm Studies & Sci, Santa Clara, CA 95053 USA.
RP Baker, GA (reprint author), Santa Clara Univ, Ctr Food Innovat & Entrepreneurship, Santa Clara, CA 95053 USA.
EM gbaker@scu.edu
FU World Wildlife Fund (from a grant from the Foundation for Food and
   Agriculture Research); Bank of America Charitable Foundation
FX We acknowledge the financial support received from the World Wildlife
   Fund (from a grant from the Foundation for Food and Agriculture
   Research) and the Bank of America Charitable Foundation. We extend our
   sincerest gratitude to the growers who cooperated so generously with us.
   We also acknowledge the staff and researchers who contributed to the
   research, without whom the project would not have been possible: Lauren
   Cloward, Lucy Diekmann, Erika French-Arnold, Carol Kelly, Thayne
   Kollmorgen, Nicholas Matera, Katelyn O'Neil, Leigh Pond, Katharine
   Rondthaler, Marisa Rudolph, Matthew Ryan, Thomas Vickers, and Michael
   Whalen.
CR Bacho L, 2017, MERCURY NEWS    1220
   Beausang C, 2017, RESOUR CONSERV RECY, V126, P177, DOI 10.1016/j.resconrec.2017.07.042
   Berkenkamp J., 2015, BEAUTY OPPORTUNITIES
   Bigelow D.P., 2017, MAJOR USES LAND US 2
   Buzby JC, 2012, FOOD POLICY, V37, P561, DOI 10.1016/j.foodpol.2012.06.002
   Carpenter SR, 1998, ECOL APPL, V8, P559, DOI 10.1890/1051-0761(1998)008[0559:NPOSWW]2.0.CO;2
   Davis J., 2011, EMISSIONS GREENHOUSE
   Foley JA, 2005, SCIENCE, V309, P570, DOI 10.1126/science.1111772
   Gustavsson J, 2013, METHODOLOGY FAO STUD
   Hartikainen H, 2018, WASTE MANAGE, V71, P502, DOI 10.1016/j.wasman.2017.10.026
   Hayward D. B., 2017, HUNGER SILICON VALLE
   Hodges RJ, 2011, J AGR SCI, V149, P37, DOI 10.1017/S0021859610000936
   Johnson LK, 2018, AGR SYST, V167, P136, DOI 10.1016/j.agsy.2018.09.008
   Johnson LK, 2018, RESOUR CONSERV RECY, V137, P243, DOI 10.1016/j.resconrec.2018.05.017
   Parfitt J, 2010, PHILOS T R SOC B, V365, P3065, DOI 10.1098/rstb.2010.0126
   ReFED, 2016, ROADM RED US FOOD WA
   Strid I., 2014, 9 INT C LCA AGR FOOD
   Stuart T., 2009, WASTE UNCOVERING GLO
   Tubiello FN, 2015, GLOBAL CHANGE BIOL, V21, P2655, DOI 10.1111/gcb.12865
   Vitousek PM, 1997, ECOL APPL, V7, P737, DOI 10.2307/2269431
   WRAP, 2017, FOOD WAST PRIM PROD
NR 21
TC 2
Z9 2
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 541
EP 549
DI 10.1016/j.resconrec.2019.03.022
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300050
OA Other Gold
DA 2020-05-12
ER

PT J
AU Ravandi, B
   Jovanovic, N
AF Ravandi, Babak
   Jovanovic, Nina
TI Impact of plate size on food waste: Agent-based simulation of food
   consumption
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Food waste; Food waste prevention; Plate size; All-you-can-eat
   operation; Food consumption modeling; Agent-based modeling
ID GENERATION; REDUCTION; HUNGER
AB Food waste is a substantial contributor to environmental change and it poses a threat to global sustainability. A significant portion of this waste accounts for plate waste and food surplus from food-service operations such as restaurants, workplace canteens, cafeterias, etc. In this work, we seek to identify potential strategies to optimize food consumption in all-you-can-eat food-service operations, in terms of minimizing food waste while ensuring quality of service (i.e., maintaining low wait-time, unsatisfied-hunger, and walk-out percentages). We treat these facilities as complex systems and propose an agent-based model to capture the dynamics between plate waste, food surplus, and the facility organization setup. Moreover, we measure the impact of plate size on food waste. The simulation results show reducing plate size from large to small decreases plate waste up to 30% while ensuring quality of service. However, total waste as the sum of food surplus and plate waste is lower with large plates. Our results indicate the need for optimizing food preparation along with designing choice environments that encourage guests to avoid taking more food than they need.
C1 [Ravandi, Babak] Purdue Univ, Dept Comp & Informat Technol, W Lafayette, IN 47906 USA.
   [Jovanovic, Nina] Purdue Univ, Dept Agr Econ, W Lafayette, IN 47906 USA.
RP Ravandi, B (reprint author), Purdue Univ, Dept Comp & Informat Technol, W Lafayette, IN 47906 USA.
EM bravandi@purdue.edu; njovano@purdue.edu
OI Jovanovic, Nina/0000-0002-1026-9981
FU Horizon 2020 Framework Program of the European Union
FX REFRESH (Resource Efficient Food and dRink for the Entire Supply cHain)
   is an EU research project funded by the Horizon 2020 Framework Program
   of the European Union that works toward Sustainable Development Goal
   12.3 to reduce food waste.
CR Axelrod R., 1997, COMPLEXITY COOPERATI, V3
   Bichraoui-Draper N, 2015, RESOUR CONSERV RECY, V103, P171, DOI 10.1016/j.resconrec.2015.08.003
   Boys K. A, 2019, CHOICES MAG, P34
   Buzby J. C, 2002, TECHNICAL REPORT
   Capps Jr.  O., 2019, CHOICES MAG, P34
   Carlson AJ, 1913, AM J PHYSIOL, V31, P175
   Derqui B, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8070693
   Filimonau V, 2019, TOURISM MANAGE, V71, P234, DOI 10.1016/j.tourman.2018.10.009
   Food and Agriculture Organization (FAO), 2015, TECHNICAL REPORT
   Grainger M, 2016, TECHNICAL REPORT, DOI [10.18174/399920, DOI 10.18174/399920]
   GROSSMAN MI, 1955, ANN NY ACAD SCI, V63, P76, DOI 10.1111/j.1749-6632.1955.tb36547.x
   Gunders D., 2012, WASTED AM IS LOSING, P26
   Gustaysson J, 2011, TECHNICAL REPORT
   Hall KD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007940
   Hansen P. G., 2015, J FOOD HOSPITALITY R, V4, P11
   Heckbert S, 2010, ANN NY ACAD SCI, V1185, P39, DOI 10.1111/j.1749-6632.2009.05286.x
   Heikkila L, 2016, WASTE MANAGE, V56, P446, DOI 10.1016/j.wasman.2016.06.019
   Hic C, 2016, ENVIRON SCI TECHNOL, V50, P4269, DOI 10.1021/acs.est.5b05088
   Just D., 2009, CHOICES, V24, P1
   Kallbekken S, 2013, ECON LETT, V119, P325, DOI 10.1016/j.econlet.2013.03.019
   Kummu M, 2012, SCI TOTAL ENVIRON, V438, P477, DOI 10.1016/j.scitotenv.2012.08.092
   Kuo ChenFeng, 2016, Journal of Foodservice Business Research, V19, P223
   Lam Y, 2010, WHY DO UC BERKELEY S
   Lowe MR, 2007, PHYSIOL BEHAV, V91, P432, DOI 10.1016/j.physbeh.2007.04.006
   Macal CM, 2010, J SIMUL, V4, P151, DOI 10.1057/jos.2010.3
   Martin Corby K, 2007, Eat Behav, V8, P148, DOI 10.1016/j.eatbeh.2006.03.003
   Meng XY, 2018, RESOUR CONSERV RECY, V128, P535, DOI 10.1016/j.resconrec.2016.09.033
   Mitchell M., 2009, COMPLEXITY GUIDED TO
   Nolan J, 2009, CAN J AGR ECON, V57, P417, DOI 10.1111/j.1744-7976.2009.01163.x
   Papargyropoulou E, 2016, WASTE MANAGE, V49, P326, DOI 10.1016/j.wasman.2016.01.017
   Piech RM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006581
   Pirani SI, 2016, J CLEAN PROD, V132, P129, DOI 10.1016/j.jclepro.2015.07.146
   Qi DY, 2017, AM J AGR ECON, V99, P1159, DOI 10.1093/ajae/aax050
   Ravandi B, 2019, J COMPUT SOC SCI, DOI [10.1007/s42001-019-00036-w, DOI 10.1007/S42001-019-00036-W]
   ReFED, 2016, ROADM RED US FOOD WA
   Searchinger T, 2013, TECHNICAL REPORT
   Stockli S, 2018, RESOUR CONSERV RECY, V136, P445, DOI 10.1016/j.resconrec.2018.03.029
   Thaler R. H., 2008, NUDGE IMPROVING DECI
   Thiagarajah K, 2013, J ACAD NUTR DIET, V113, P141, DOI 10.1016/j.jand.2012.07.004
   Thyberg KL, 2016, RESOUR CONSERV RECY, V106, P110, DOI 10.1016/j.resconrec.2015.11.016
   Tisue S., 2004, INT C COMPL SYST, V21, P16
   United Nations (UN), 2015, SUST DEV GOALS
   Venkat K., 2011, International Journal on Food System Dynamics, V2, P431
   Ward JA, 2016, ROY SOC OPEN SCI, V3, DOI 10.1098/rsos.150703
   Whitehair KJ, 2013, J ACAD NUTR DIET, V113, P63, DOI 10.1016/j.jand.2012.09.015
   Wilensky U, 2015, INTRO AGENT BASED MO
   Wolper C, 1995, MEASURING FOOD INTAK, P215
   WRAP, 2011, TECHNICAL REPORT
   WRAP, 2013, TECHNICAL REPORT
NR 49
TC 1
Z9 1
U1 17
U2 28
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 550
EP 565
DI 10.1016/j.resconrec.2019.05.033
PG 16
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300051
DA 2020-05-12
ER

PT J
AU Nogueira, A
   Ashton, WS
   Teixeira, C
AF Nogueira, Andre
   Ashton, Weslynne S.
   Teixeira, Carlos
TI Expanding perceptions of the circular economy through design: Eight
   capitals as innovation lenses
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Circular economy; Systems thinking; Community capitals; Design;
   Brownfields
ID INDUSTRIAL SYMBIOSIS; FRAMEWORK; TRANSITIONS; CHINA
AB We widely recognize that systems approaches are necessary to tackle the complex and urgent challenges of the unsustainability of human actions on the planet. However, how we perceive systems is largely framed by who is in included in the discussion and the experiences and interests that they bring to bear. Efforts to create the circular economy aim at closing material loops, but these efforts are limited because they only consider the flows of a few types of capital - natural, manufactured and financial, and are based on specific interests of a few actors. Other types of capital - human, social, political, cultural and digital - are often ignored, and as such the full scope of dynamics in a system is missed. Even though there will always be a discrepancy between what is perceived, and the actual system in operation, there are greater opportunities to expand such perception by drawing more deeply on systems thinking and the concept of capitals. This involves expanding not only the notion of the system itself, but also acknowledging different actors and their interests, types of capital in the system, and interactions between the actors and capital stocks and flows. We develop a systems thinking framework using eight capitals, and apply it in multi-level contexts in the Chicago region to demonstrate how they provide new insights and critical pathways for the transition to the circular economy.
C1 [Nogueira, Andre; Teixeira, Carlos] IIT, Inst Design, 3137 S Fed St, Chicago, IL 60616 USA.
   [Ashton, Weslynne S.] IIT, Stuart Sch Business, 565 W Adams St, Chicago, IL 60661 USA.
RP Nogueira, A (reprint author), IIT, Inst Design, 3137 S Fed St, Chicago, IL 60616 USA.
EM anogueira@id.iit.edu
FU Chicago Community Trust
FX The authors would like to acknowledge the time and input given by all
   the participants in this study, as well as the support and seed research
   funding from the Chicago Community Trust, and from the project partners.
CR Antikainen M, 2016, TECHNOL INNOV MANAG, V6, P5
   Ashton W., 2017, COLL INN NETW COINS
   Ashton WS, 2012, J IND ECOL, V16, P70, DOI 10.1111/j.1530-9290.2011.00453.x
   Babbitt CW, 2018, RESOUR CONSERV RECY, V135, P1, DOI 10.1016/j.resconrec.2018.04.012
   Barabasi A.-L., 2003, LINKED NEW SCI NETWO
   Bertola P., 2003, Design Studies, V24, P181, DOI 10.1016/S0142-694X(02)00036-4
   Bjorgvinsson Erling, 2010, P 11 BIENN PART DES, P41, DOI DOI 10.1145/1900441.1900448
   Bocken NMP, 2016, J IND PROD ENG, V33, P308, DOI 10.1080/21681015.2016.1172124
   Capra F, 1996, WEB LIFE, P153
   Chertow M, 2008, REG STUD, V42, P1299, DOI 10.1080/00343400701874123
   Chertow MR, 2000, ANNU REV ENERG ENV, V25, P313, DOI 10.1146/annurev.energy.25.1.313
   Cote M, 2012, PROG HUM GEOG, V36, P475, DOI 10.1177/0309132511425708
   Cross N., 1989, ENG DESIGN METHODS, V4
   Edwards PN, 2003, MODERNITY AND TECHNOLOGY, P185
   Emery M, 2006, COMMUNITY DEV, V37, P19, DOI 10.1080/15575330609490152
   EMF (Ellen MacArthur Foundation), 2017, WHAT IS CIRC EC FRAM
   Flora C.B., 2004, RURAL COMMUNITIES LE
   Galey A, 2010, LIT LINGUIST COMPUT, V25, P405, DOI 10.1093/llc/fqq021
   Gaziulusoy AI, 2015, J CLEAN PROD, V108, P558, DOI 10.1016/j.jclepro.2015.06.066
   Gaziulusoy AI, 2015, J CLEAN PROD, V107, P366, DOI 10.1016/j.jclepro.2015.01.012
   Geels FW, 2002, RES POLICY, V31, P1257, DOI 10.1016/S0048-7333(02)00062-8
   Geng Y, 2008, INT J SUST DEV WORLD, V15, P231, DOI 10.3843/SusDev.15.3:6
   Ghisellini P, 2016, J CLEAN PROD, V114, P11, DOI 10.1016/j.jclepro.2015.09.007
   Gregson N, 2015, ECON SOC, V44, P218, DOI 10.1080/03085147.2015.1013353
   Haas W, 2015, J IND ECOL, V19, P765, DOI 10.1111/jiec.12244
   Hodges A., 2018, WHATS NEXT FUTURE BR
   Joore Peter, 2015, Journal of Cleaner Production, V97, P92, DOI 10.1016/j.jclepro.2014.06.043
   Kalmykova Y, 2018, RESOUR CONSERV RECY, V135, P190, DOI 10.1016/j.resconrec.2017.10.034
   Karasti H., 2014, P 13 PART DES C PDC, V1, P141, DOI DOI 10.1145/2661435.2661450
   Kirchherr J, 2017, RESOUR CONSERV RECY, V127, P221, DOI 10.1016/j.resconrec.2017.09.005
   Kumar Vijay, 2012, 101 DESIGN METHODS S
   Lacy P., 2016, WASTE WEALTH CIRCULA
   Lewin K, 1946, J SOC ISSUES, V2, P34, DOI 10.1111/j.1540-4560.1946.tb02295.x
   McGinnis MD, 2014, ECOL SOC, V19, DOI 10.5751/ES-06387-190230
   Meadows D.H., 2008, THINKING SYSTEMS PRI
   Meadows DH, 1999, LEVERAGE POINTS PLAC
   Mulrow JS, 2017, J IND ECOL, V21, P559, DOI 10.1111/jiec.12592
   Murray A, 2017, J BUS ETHICS, V140, P369, DOI 10.1007/s10551-015-2693-2
   Nogueira A, 2018, FUTURE BROWNFIELDS C
   Nogueira A., 2018, BROWNFIELDS CRITICAL
   Nogueira A., 2018, INNOVATION LENSES SU
   Ostrom E, 2009, SCIENCE, V325, P419, DOI 10.1126/science.1172133
   Reese S., 2016, CENTURY HEAVY IND TR
   Reike D, 2018, RESOUR CONSERV RECY, V135, P246, DOI 10.1016/j.resconrec.2017.08.027
   Rockstrom J, 2009, ECOL SOC, V14
   Simon H. S., 1996, SCI ARTIFICIAL
   Su B, 2013, J CLEAN PROD, V42, P215, DOI 10.1016/j.jclepro.2012.11.020
   Swann C, 2002, DES ISSUES, V18, P49, DOI 10.1162/07479360252756287
   Teixeira C., 2017, SHE JI J DES EC INNO, V3, P1
   Teram E, 2005, QUAL HEALTH RES, V15, P1129, DOI 10.1177/1049732305275882
   VanAel K., 2018, CODIFYING SYSTEMIC D
   Whitney P., 2015, SHE JI J DES EC INNO, V1, P58
NR 52
TC 1
Z9 1
U1 2
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 566
EP 576
DI 10.1016/j.resconrec.2019.06.021
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300052
DA 2020-05-12
ER

PT J
AU Li, X
   Ren, Q
   You, XL
   Yang, YQ
   Shan, MW
   Wang, MX
AF Li, Xin
   Ren, Qiang
   You, Xiaoling
   Yang, Yunqi
   Shan, Mingwei
   Wang, Minxi
TI Material flow analysis of discarded refrigerators from households in
   urban and rural areas of China
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Material flow analysis; Obsolete refrigerators; Stock-driven; Waste
   management
ID ELECTRONIC EQUIPMENT WEEE; E-WASTE; RESOURCE CONSERVATION; TV SETS;
   MANAGEMENT; METALS; QUANTITIES; PREDICTION; APPLIANCES; RECOVERY
AB Waste electrical and electronic equipment (WEEE) is one of the fastest growing waste streams in China. How to quantify and systematically analyze the flow and materials is a problem. This paper provides a basis for managing refrigerators at both product and substance levels through developed dynamic material flow analysis model, bottom-up (refrigerators grouped by material modules), stock-driven combined with Weibull distribution function and refrigerator life cycle to predict the number of metals and plastics contained in obsolete refrigerators. We found that: (1) A gradual increase of obsolete refrigerators from 1990 to 2035. The total possession of refrigerators is from 417.6 million units in 2016 to 500.3 million units in 2035, with an average annual growth rate for the value 19.8%/20 (years). The total number of obsolete refrigerators is from 28.5 million units in 2016 to 45 million units in 2035, with an average annual growth rate for the value 57.9%/20 (years); a) the possession of refrigerators of urban is higher than the rural areas from 1990 to 2016, but the possession of refrigerators of urban and rural will be convergence in 2035; These growing obsolete refrigerators would mean there are potentially numerous recyclable materials. Such as most precious metals (i.e., Au, Ag), common metals (i.e., Fe, Al, Cu, Sn), toxic metals (i.e., Pb, Sb, Cd, Hg), plastics and gas will reach 0.0072 Gg, 1636.1 Gg, 0.2776 Gg, 930.1 Gg and 29.2 Gg in 2035, respectively. Because of a huge gap on the possession level of e-waste between urban and rural areas in China, this paper recommends that future national policies should focus on recycling and reusing of refrigerators in urban while also focusing on the increasing number of obsolete refrigerators in rural areas.
C1 [Li, Xin; Ren, Qiang; You, Xiaoling; Wang, Minxi] Chengdu Univ Technol, Coll Management Sci, Chengdu 610051, Sichuan, Peoples R China.
   [Yang, Yunqi] Sch Visual Arts, New York, NY 10003 USA.
   [Shan, Mingwei] Environm Def Fund Beijing Representat Off, Beijing 100007, Peoples R China.
RP Wang, MX (reprint author), Chengdu Univ Technol, Coll Management Sci, Chengdu 610051, Sichuan, Peoples R China.
EM lixin2012@cdut.cn; renyouyu128@163.com; sylviayyxl@163.com;
   yyang43@sva.edu; shanmingwei@cet.net.cn; wangminxi@mail.cdut.edu.cn
FU National Social Science Fund of China [17BGL147]
FX This research is supported by Projects of the National Social Science
   Fund of China (17BGL147).
CR Bakhiyi B, 2018, ENVIRON INT, V110, P173, DOI 10.1016/j.envint.2017.10.021
   Balde C.P., 2015, GLOBAL E WASTE MONIT
   Cayumil R, 2016, WASTE MANAGE, V57, P121, DOI 10.1016/j.wasman.2015.12.004
   Chen WQ, 2012, ENVIRON SCI TECHNOL, V46, P8574, DOI 10.1021/es3010333
   China Household Electric Appliance Research Institute, 1990, 11 INT C REC TECHN P
   Chinese Academy of Engineering, 2011, RES EN DEV STRAT CHI
   Chung SS, 2011, WASTE MANAGE, V31, P2638, DOI 10.1016/j.wasman.2011.07.010
   Cui JR, 2008, J HAZARD MATER, V158, P228, DOI 10.1016/j.jhazmat.2008.02.001
   Cui JR, 2003, J HAZARD MATER, V99, P243, DOI 10.1016/S0304-3894(03)00061-X
   Dwivedy M, 2012, J CLEAN PROD, V37, P229, DOI 10.1016/j.jclepro.2012.07.017
   GAC (General Administration of Custom of the People's Republic of China), 2016, CHIN CUST STAT YB 19
   Ghosh B, 2015, J CLEAN PROD, V94, P5, DOI 10.1016/j.jclepro.2015.02.024
   Habuer, 2014, WASTE MANAGE, V34, P489, DOI 10.1016/j.wasman.2013.11.004
   Hatayama H, 2014, RESOUR CONSERV RECY, V87, P65, DOI 10.1016/j.resconrec.2014.03.006
   Hatayama H, 2010, ENVIRON SCI TECHNOL, V44, P6457, DOI 10.1021/es100044n
   He WZ, 2006, J HAZARD MATER, V136, P502, DOI 10.1016/j.jhazmat.2006.04.060
   Holgersson S, 2018, RESOUR CONSERV RECY, V133, P300, DOI 10.1016/j.resconrec.2017.02.011
   Kida A., 2009, MAT CYCLES WASTE MAN, V20, P59
   Kiddee P, 2013, WASTE MANAGE, V33, P1237, DOI 10.1016/j.wasman.2013.01.006
   Kim S, 2013, WASTE MANAGE, V33, P474, DOI 10.1016/j.wasman.2012.07.011
   Lambert AJD, 2001, J CLEAN PROD, V9, P243
   Laner D, 2007, RESOUR CONSERV RECY, V52, P136, DOI 10.1016/j.resconrec.2007.03.004
   Liu XB, 2006, WASTE MANAGE RES, V24, P434, DOI 10.1177/0734242X06067449
   Martinho G, 2012, WASTE MANAGE, V32, P1213, DOI 10.1016/j.wasman.2012.02.010
   Menikpura SNM, 2014, J CLEAN PROD, V74, P183, DOI 10.1016/j.jclepro.2014.03.040
   NBSC (National Bureau of Statistics of the People's Republic of China), 2017, CHIN STAT YB 1990 20
   Nowakowski P, 2018, RESOUR CONSERV RECY, V135, P93, DOI 10.1016/j.resconrec.2017.12.016
   Oguchi M, 2008, RESOUR CONSERV RECY, V52, P463, DOI 10.1016/j.resconrec.2007.06.001
   Oguchi M, 2013, SCI TOTAL ENVIRON, V463, P1124, DOI 10.1016/j.scitotenv.2012.07.078
   Oguchi M, 2011, WASTE MANAGE, V31, P2150, DOI 10.1016/j.wasman.2011.05.009
   Parajuly K, 2017, RESOUR CONSERV RECY, V123, P85, DOI 10.1016/j.resconrec.2016.08.004
   Pauliuk S, 2013, RESOUR CONSERV RECY, V71, P22, DOI 10.1016/j.resconrec.2012.11.008
   Perkins DN, 2014, ANN GLOB HEALTH, V80, P286, DOI 10.1016/j.aogh.2014.10.001
   Petridis K, 2017, COMPUT IND ENG, V108, P15, DOI 10.1016/j.cie.2017.03.014
   Petridis NE, 2016, J CLEAN PROD, V112, P3072, DOI 10.1016/j.jclepro.2015.09.119
   Robinson BH, 2009, SCI TOTAL ENVIRON, V408, P183, DOI 10.1016/j.scitotenv.2009.09.044
   Ruan JJ, 2011, WASTE MANAGE, V31, P2319, DOI 10.1016/j.wasman.2011.06.004
   Salhofer S, 2016, WASTE MANAGE, V57, P27, DOI 10.1016/j.wasman.2015.11.014
   Schwarzer S, 2005, E WASTE HIDDEN SIDE
   Tasaki T, 2004, WASTE MANAGE, V24, P571, DOI 10.1016/j.wasman.2004.02.008
   Tasaki T., 2001, J JPN SOC WASTE MANA, V12, P49
   Tian H, 2012, PROCEDIA ENVIRON SCI, V16, P477, DOI 10.1016/j.proenv.2012.10.065
   Tong X, 2018, RESOUR CONSERV RECY, V135, P163, DOI 10.1016/j.resconrec.2017.10.039
   Truttmann N, 2006, RESOUR CONSERV RECY, V48, P249, DOI 10.1016/j.resconrec.2006.02.003
   Tsydenova O, 2011, WASTE MANAGE, V31, P45, DOI 10.1016/j.wasman.2010.08.014
   US Environmental Protection Agency (EPA), 2012, OZ SCI FACTS PHAS
   Van Eygen E, 2016, RESOUR CONSERV RECY, V107, P53, DOI 10.1016/j.resconrec.2015.10.032
   Vazquez YV, 2016, WASTE MANAGE, V53, P196, DOI 10.1016/j.wasman.2016.04.022
   Wang MX, 2018, J CLEAN PROD, V187, P730, DOI 10.1016/j.jclepro.2018.03.243
   Wang WH, 2017, J CLEAN PROD, V153, P299, DOI 10.1016/j.jclepro.2017.03.202
   Xiao RF, 2015, J CLEAN PROD, V95, P301, DOI 10.1016/j.jclepro.2015.02.031
   Yang JX, 2008, WASTE MANAGE, V28, P1589, DOI 10.1016/j.wasman.2007.08.019
   Yazici B, 2014, WASTE MANAGE, V34, P162, DOI 10.1016/j.wasman.2013.09.008
   Yin X., 2013, RESOUR POLICY, V48, P32
   Yu LL, 2014, WASTE MANAGE, V34, P1705, DOI 10.1016/j.wasman.2014.05.012
   Zeng XL, 2017, RENEW SUST ENERG REV, V72, P1076, DOI 10.1016/j.rser.2016.10.015
   Zhang L., 2012, WASTE MANAGE RES, P1
   Zhang L, 2011, RESOUR CONSERV RECY, V55, P1087, DOI 10.1016/j.resconrec.2011.06.003
   Zhang SG, 2017, WASTE MANAGE, V65, P113, DOI 10.1016/j.wasman.2017.04.003
   Zhang WH, 2012, PEDOSPHERE, V22, P434, DOI 10.1016/S1002-0160(12)60030-7
   Zhao M, 2016, PROCEDIA ENVIRON SCI, V31, P925, DOI 10.1016/j.proenv.2016.02.113
   Zhao XY, 2011, WASTE MANAGE, V31, P555, DOI 10.1016/j.wasman.2010.10.018
   Zhou N, 2011, ENERG POLICY, V39, P4541, DOI 10.1016/j.enpol.2011.04.027
NR 63
TC 0
Z9 0
U1 21
U2 34
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 577
EP 585
DI 10.1016/j.resconrec.2019.06.027
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300053
DA 2020-05-12
ER

PT J
AU Fujii, M
   Dou, Y
   Sun, L
   Ohnishi, S
   Maki, S
   Dong, HJ
   Dong, L
   Chandran, R
AF Fujii, Minoru
   Dou, Yi
   Sun, Lu
   Ohnishi, Satoshi
   Maki, Seiya
   Dong, Huijuan
   Dong, Liang
   Chandran, Remi
TI Contribution to a low-carbon society from improving exergy of
   waste-to-energy system by upgrading utilization of waste
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Energy recovery; Exergy; Life-cycle assessment; Burnable waste; Carbon
   dioxide
ID LIFE-CYCLE ASSESSMENT; CIRCULAR ECONOMY; INCINERATION; MANAGEMENT;
   INDUSTRIES; SYMBIOSIS; RECOVERY
AB Efficient energy recovery from burnable solid waste is considered an important component in a low-carbon society. Herein, we discuss the optimization of energy recovery from waste and how to reduce the environmental load of waste. First, we introduce the concept of upgrading waste-to-energy (WtE) processes to improve the exergy efficiency of society as a whole and provide guidance for selecting and combining the most appropriate technology for transforming waste-to-energy. We then propose a methodology called resource life-cycle assessment (LCA) that can be used to properly evaluate the effect of upgrading WtE processes and to optimize waste utilization not only within a given factory or municipality but also within society as a whole. Finally, we present two case studies with which we examine the direct and indirect upgrading of WtE processes and use resource LCA to quantitatively analyze the CO2 reduction achieved by upgrading WtE processes compared with that achieved by conventional WtE processes. The analysis of these case studies shows that upgrading WtE processes would result in approximately 50%-100% greater reduction in fossil fuel input compared with conventional waste power generation, which means that we expect a 50% to 100% greater reduction in CO2 emissions and the concomitant savings in fuel cost. The concept of upgrading WtE processes and resource LCA is useful for selecting a cost-effective option to improve the exergy efficiency both in developed countries and in developing countries, many of which need to contribute to their Nationally Determined Contribution under the Paris Agreement.
C1 [Fujii, Minoru; Sun, Lu; Maki, Seiya] NIES, Ctr Social & Environm Syst Res, 16-2 Onogawa, Tsukuba, Ibaraki 3058506, Japan.
   [Dou, Yi] Univ Tokyo, Presidential Endowed Chair Platinum Soc, Bunkyo Ku, 3-7-1 Hongo, Tokyo 1138656, Japan.
   [Ohnishi, Satoshi] Tokyo Univ Sci, Fac Sci & Engn, 2641 Yamazaki, Noda, Chiba 2788510, Japan.
   [Dong, Huijuan] Shanghai Jiao Tong Univ, Sch Environm Sci & Engn, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.
   [Dong, Liang] City Univ Hong Kong, Dept Publ & Social Adm, Kowloon Tong, 83 Tat Chee Ave, Hong Kong, Peoples R China.
   [Chandran, Remi] TOKYU REIT, Remote Sensing Technol Ctr Japan RESTEC, Minato Ku, Toranomon Bldg 3-17-1 Toranomon, Tokyo 1050001, Japan.
RP Fujii, M (reprint author), NIES, Ctr Social & Environm Syst Res, 16-2 Onogawa, Tsukuba, Ibaraki 3058506, Japan.
EM m-fujii@nies.go.jp
OI Dong, Liang/0000-0001-9747-5851; Dou, Yi/0000-0002-6665-1653
FU Environment Research and Technology Development Fund of the
   Environmental Restoration and Conservation Agency of Japan [3-1709,
   3K163001]; Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [71603165]
FX This research was supported by the Environment Research and Technology
   Development Fund (3-1709 and 3K163001) of the Environmental Restoration
   and Conservation Agency of Japan, and the Natural Science Foundation of
   China (Grant No. 71603165).
CR Ashina S, 2012, ENERG POLICY, V41, P584, DOI 10.1016/j.enpol.2011.11.020
   Behera SK, 2012, J CLEAN PROD, V29-30, P103, DOI 10.1016/j.jclepro.2012.02.009
   BoroumandJazi G, 2013, RENEW SUST ENERG REV, V27, P198, DOI 10.1016/j.rser.2013.06.054
   Chetal S. C., 2015, Proceedings of the Indian National Science Academy, V81, P739, DOI 10.16943/ptinsa/2015/v81i4/48294
   Dewulf JP, 2002, ENVIRON SCI TECHNOL, V36, P1130, DOI 10.1021/es010140o
   Dong J, 2018, J CLEAN PROD, V203, P287, DOI 10.1016/j.jclepro.2018.08.139
   Dou Y, 2018, J CLEAN PROD, V170, P548, DOI 10.1016/j.jclepro.2017.09.147
   Fruergaard T, 2011, WASTE MANAGE, V31, P572, DOI 10.1016/j.wasman.2010.09.009
   Fujii M, 2016, J CLEAN PROD, V114, P376, DOI 10.1016/j.jclepro.2015.04.027
   Fujii M, 2012, RESOUR CONSERV RECY, V63, P1, DOI 10.1016/j.resconrec.2012.03.002
   HPTCJ (Heat Pump & Thermal Storage Technology Center of Japan, 2012, HEAT PUMP STYL
   IEA (International Energy Agency), 2018, WORLD BAL 2015
   Ji LJ, 2016, WASTE MANAGE RES, V34, P280, DOI 10.1177/0734242X16633776
   Kumar A, 2017, WASTE MANAGE, V69, P407, DOI 10.1016/j.wasman.2017.08.046
   Lausselet C, 2017, RESOUR CONSERV RECY, V126, P50, DOI 10.1016/j.resconrec.2017.07.025
   Main A, 2010, PROCEEDINGS OF THE 18TH ANNUAL NORTH AMERICAN WASTE TO ENERGY CONFERENCE, P33
   Malinauskaite J, 2017, ENERGY, V141, P2013, DOI 10.1016/j.energy.2017.11.128
   Margallo M, 2014, RESOUR CONSERV RECY, V93, P144, DOI 10.1016/j.resconrec.2014.09.014
   MOEJ (Ministry of Environment Japan), 2018, FAC IMPR MAN HIGH EF
   MRI (Mitsubishi Research Institute Inc.), 2013, FISC YEAR 2012 REP P
   Nerini FF, 2018, NAT ENERGY, V3, P10, DOI 10.1038/s41560-017-0036-5
   Ogawa K., 2014, THERMAL NUCL POWER, V65, P46
   Paraskevas D, 2015, J CLEAN PROD, V105, P357, DOI 10.1016/j.jclepro.2014.09.102
   Peiro LT, 2008, ENVIRON SCI TECHNOL, V42, P4977, DOI 10.1021/es071972a
   Sun L, 2018, RESOUR CONSERV RECY, V136, P289, DOI 10.1016/j.resconrec.2018.05.005
   Suzuki H., 2017, EBARA ENG REV, V254, P1
   Tian HZ, 2012, ENVIRON SCI TECHNOL, V46, P10364, DOI 10.1021/es302343s
   Tonini D, 2013, ENVIRON SCI TECHNOL, V47, P8962, DOI 10.1021/es400998y
   UNFCCC, 2016, AGGR EFF INT NAT DET
   Zheng DX, 2009, ENERG FUEL, V23, P2613, DOI 10.1021/ef8011307
   Zhou ZZ, 2018, WASTE MANAGE RES, V36, P3, DOI [10.1177/0734242X17730137, 10.1177/0734242x17730137]
NR 31
TC 1
Z9 1
U1 13
U2 23
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 586
EP 594
DI 10.1016/j.resconrec.2019.06.038
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300054
DA 2020-05-12
ER

PT J
AU Ferreira, IA
   Barreiros, MS
   Carvalho, H
AF Ferreira, Ines A.
   Barreiros, Marta S.
   Carvalho, Helena
TI The industrial symbiosis network of the biomass fluidized bed boiler
   sand-Mapping its value network
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Circular economy; Industrial symbiosis; Pulp and paper industry; Use of
   by-products as raw materials
ID PERSPECTIVE; EXPERIENCES; WASTE; PAPER
AB The stakeholders engaged in industrial symbiosis network context expect to optimize resources to obtain a more significant mutual benefit. This paper intends to analyse the value network composed by the stakeholders and the respective flows involved in the symbiosis process. A real case study is developed in the Portuguese pulp and paper sector describing the value network inherent to the fluidized bed sands commercialization; this type of sands is a by-product produced in the fluidized bed biomass boilers used for energy generation located at the pulp and paper plants. The stakeholders, resources, and flows involved in the industrial symbiosis process are identified and the relative importance of value flows exchanged between them is quantified. The results show that the focal organization, sand producers, and end users of material mixtures containing fluidized bed sands are the entities most powerful in the symbiosis network.
C1 [Ferreira, Ines A.; Barreiros, Marta S.; Carvalho, Helena] UNIDEMI, Campus Caparica, P-2829516 Caparica, Portugal.
RP Carvalho, H (reprint author), UNIDEMI, Campus Caparica, P-2829516 Caparica, Portugal.
EM hmlc@fct.unl.pt
RI Ferreira, Ines/AAC-4365-2019; Remigio, Helena Maria Lourenco
   Carvalho/A-4160-2015
OI Ferreira, Ines/0000-0002-3096-2935; Remigio, Helena Maria Lourenco
   Carvalho/0000-0002-1588-0579
FU Fundacao para a Ciencia e TecnologiaPortuguese Foundation for Science
   and Technology [UID/EMS/00667/2019]
FX The authors would like to acknowledge financial support from Fundacao
   para a Ciencia e Tecnologia (reference UID/EMS/00667/2019).
CR Afshari H, 2018, RESOUR CONSERV RECY, V139, P315, DOI 10.1016/j.resconrec.2018.09.002
   Alvarez R, 2017, WASTE BIOMASS VALORI, V8, P1521, DOI 10.1007/s12649-016-9748-1
   APA Agencia Portuguesa do Ambiente, 2015, CRITERIOS GERAIS PAR
   APA Agencia Portuguesa do Ambiente, 2016, SUBPRODUTO
   Bauman Z., 2001, J CONSUM CULT, V1, P9, DOI DOI 10.1177/146954050100100102
   Bousios S, 2017, RESOUR CONSERV RECY, V125, P218, DOI 10.1016/j.resconrec.2017.06.020
   CELPA, 2016, BOLETIM ESTATISTICO
   Chertow MR, 2007, J IND ECOL, V11, P11, DOI 10.1162/jiec.2007.1110
   Costa I, 2010, J CLEAN PROD, V18, P984, DOI 10.1016/j.jclepro.2010.03.007
   Domenech T, 2019, RESOUR CONSERV RECY, V141, P76, DOI 10.1016/j.resconrec.2018.09.016
   Domenech T, 2011, PROCD SOC BEHV, V10, DOI 10.1016/j.sbspro.2011.01.011
   Elia V, 2017, J CLEAN PROD, V142, P2741, DOI 10.1016/j.jclepro.2016.10.196
   Feng W., 2013, ENGINEERING PROJECT, V356
   Fraccascia L, 2019, RESOUR CONSERV RECY, V146, P114, DOI 10.1016/j.resconrec.2019.03.016
   Fraccascia L, 2018, RESOUR CONSERV RECY, V136, P473, DOI 10.1016/j.resconrec.2018.03.009
   Freeman R. E., 1984, STRATEGIC MANAGEMENT, DOI [10.2139/ssrn.263511, DOI 10.2139/SSRN.263511]
   Frooman J, 1999, ACAD MANAGE REV, V24, P191
   Genovese A, 2017, OMEGA-INT J MANAGE S, V66, P344, DOI 10.1016/j.omega.2015.05.015
   Hein AM, 2017, J CLEAN PROD, V148, P923, DOI 10.1016/j.jclepro.2017.01.136
   Jensen PD, 2011, RESOUR CONSERV RECY, V55, P703, DOI 10.1016/j.resconrec.2011.02.003
   Jiao WT, 2014, J CLEAN PROD, V67, P14, DOI 10.1016/j.jclepro.2013.12.050
   Kalmykova Y, 2018, RESOUR CONSERV RECY, V135, P190, DOI 10.1016/j.resconrec.2017.10.034
   Martin M, 2018, RESOUR CONSERV RECY, V138, P246, DOI 10.1016/j.resconrec.2018.07.026
   Mirata M, 2004, J CLEAN PROD, V12, P967, DOI 10.1016/j.jclepro.2004.002.031
   Mitchell RK, 1997, ACAD MANAGE REV, V22, P853, DOI 10.2307/259247
   Modolo RCE, 2014, FUEL PROCESS TECHNOL, V125, P170, DOI 10.1016/j.fuproc.2014.03.040
   Pfeffer J., 2003, THE EXTERNAL CONTROL
   Raupp-Pereira F, 2007, CONSTR BUILD MATER, V21, P646, DOI 10.1016/j.conbuildmat.2005.12.005
   Richards D. J., 1997, THE INDUSTRIAL GREEN
   Rowley TJ, 1997, ACAD MANAGE REV, V22, P887, DOI 10.2307/259248
   de Abreu MCS, 2018, RESOUR CONSERV RECY, V138, P99, DOI 10.1016/j.resconrec.2018.07.001
   Song XQ, 2018, J CLEAN PROD, V193, P414, DOI 10.1016/j.jclepro.2018.05.058
   Tao Y, 2019, J CLEAN PROD, V213, P1172, DOI 10.1016/j.jclepro.2018.12.176
   Toppinen A, 2017, FUTURES, V88, P1, DOI 10.1016/j.futures.2017.02.002
   Valentine SV, 2016, J CLEAN PROD, V118, P65, DOI 10.1016/j.jclepro.2016.01.061
   van Ewijk S, 2018, RESOUR CONSERV RECY, V134, P48, DOI 10.1016/j.resconrec.2018.02.026
   Velenturf A. P. M, 2016, PEOPLE PLACE POLICY, V10, P146, DOI DOI 10.3351/PPP.0010.0002.0003
   Velenturf APM, 2016, J IND ECOL, V20, P700, DOI 10.1111/jiec.12315
   Voss C, 2002, INT J OPER PROD MAN, V22, P195, DOI 10.1108/01443570210414329
   Winans K, 2017, RENEW SUST ENERG REV, V68, P825, DOI 10.1016/j.rser.2016.09.123
   Xiang PC, 2019, RESOUR CONSERV RECY, V141, P273, DOI 10.1016/j.resconrec.2018.10.037
   Zhu QH, 2010, J ENVIRON MANAGE, V91, P1324, DOI 10.1016/j.jenvman.2010.02.013
NR 42
TC 1
Z9 1
U1 2
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 595
EP 604
DI 10.1016/j.resconrec.2019.06.024
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300055
DA 2020-05-12
ER

PT J
AU Schumacher, KA
   Agbemabiese, L
AF Schumacher, Kelsea A.
   Agbemabiese, Lawrence
TI Towards comprehensive e-waste legislation in the United States: Design
   considerations based on quantitative and qualitative assessments
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE E-waste; Environmental policy; Sustainable production and consumption;
   United States; Legislation
ID MANAGEMENT
AB Comprehensive electronic waste (e.-waste) legislation is necessary to simplify and unify e-waste management in the U.S. and ultimately to improve the collection and recycling of end-of-life electronics. In lieu of federal activity, 25 states have passed legislation promoting e-waste recycling and/or prohibiting e-waste landfilling or incineration. However, each of these state programs differs from the next, and this regulatory 'patchwork' is in fact impeding e-waste recycling. A more unified and comprehensive approach to e-waste legislation must utilize the experience of existing programs as well as the wisdom of industry and policy experts. We performed a two-part assessment of the current e-waste recycling industry: (1) a quantitative analysis of existing state programs to discern legislative components that have a statistically positive influence on e-waste collection rates, and (2) a qualitative assessment of stakeholder inputs on the design of effective legislation, using Delphi technique of engaging respondents in multiple rounds of interviews. Results of the two assessments inform our development of a comprehensive legislative framework which can be adopted at any level of U.S. policy to effectively manage e-waste. Our proposed framework includes recommendations for legislative components that promote increased collection rates, uphold socially and environmentally sound treatment standards throughout the vendor chain, shift the cost of e-waste management from public to private organizations, and distribute regulatory authority such that regulation can evolve with the industry.
C1 [Schumacher, Kelsea A.] Univ Delaware, Ctr Energy & Environm Policy, 278 Graham Hall, Newark, DE 19716 USA.
   [Agbemabiese, Lawrence] Univ Delaware, Energy & Environm Policy Program, 292 Graham Hall, Newark, DE 19716 USA.
RP Schumacher, KA (reprint author), Univ Delaware, Ctr Energy & Environm Policy, 278 Graham Hall, Newark, DE 19716 USA.
EM kschum@udel.edu; agbe@udel.edu
FU Delaware Environmental Institute
FX The authors would like to sincerely thank Barabara Kyle for her guidance
   in this study. We are also grateful to all of the participants of the
   Delphi study and the interviews. Additionally, the first author was
   supported by a fellowship from the Delaware Environmental Institute and
   she is most appreciative.
CR Campbell K, 2016, PBS NEWSHOUR
   Eifert V, 2009, PENN STATE ENV LAW R
   Hasson F, 2000, J ADV NURS, V32, P1008, DOI 10.1046/j.1365-2648.2000.01567.x
   Hickle GT, 2014, J CLEAN PROD, V64, P266, DOI 10.1016/j.jclepro.2013.08.013
   Hsu CC, 2007, PRACTICAL ASSESSMENT, V12, P10, DOI DOI 10.1145/1255456.1255458
   Kuntz M, 2015, COMMUNICATION
   Nnorom IC, 2008, RESOUR CONSERV RECY, V52, P843, DOI 10.1016/j.resconrec.2008.01.004
   Ongondo FO, 2011, WASTE MANAGE, V31, P714, DOI 10.1016/j.wasman.2010.10.023
   Osibanjo O, 2007, WASTE MANAGE RES, V25, P489, DOI 10.1177/0734242X07082028
   PSI, 2013, EL EPR CAS STUD STAT
   Puckett J, 2002, EXPORTING HARM HIGH
   Puckett J., 2004, DIGITAL DUMP EXPORTI
   Sachs Noah M., 2012, OUT SIGHT OUT MIND R
   Schmidt C. W, 2006, ENV HLTH PERSPECT, V114
   Schumacher K, 2016, ELECT WASTE MANAGEME
   StEP, 2015, WORLD E WAST MAP REV
   Stitt-Gohdes W. L., 2004, J CAREER TECHNICAL E, V20, P55, DOI DOI 10.21061/JCTE.V20I2.636
   Tojo N, 2011, LEGISLATIVE FRAMEWOR
   US EPA, 2016, EL PROD GEN REC
NR 19
TC 1
Z9 1
U1 2
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 605
EP 621
DI 10.1016/j.resconrec.2019.06.033
PG 17
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300056
DA 2020-05-12
ER

PT J
AU Akcil, A
   Agcasulu, I
   Swain, B
AF Akcil, Ata
   Agcasulu, Ismail
   Swain, Basudev
TI Valorization of waste LCD and recovery of critical raw material for
   circular economy: A review
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Review
DE Indium; LCD; Critical raw material; E-waste recycling; Circular economy
ID LIQUID-CRYSTAL-DISPLAY; WET CHEMICAL-REDUCTION; ETCHING WASTE; SELECTIVE
   RECOVERY; ELECTRONIC-WASTE; HEALTH CONSEQUENCES; RECYCLING INDIUM;
   METALS; GLASS; SCRAP
AB Waste an E-waste is a global environmental issue but potential resources for Indium through urban mining and recycling, which a critical raw material for the industry has been reviewed. In the e-waste, the computer followed by spent television scarp is the second highest by volume generation invariably contains the LCD panel. Indium-tin-oxide (ITO) layer in the LCD panel is an important resource for indium which has 90 wt% In2O3 and 10 wt% SnO2 is a potential resource for indium has been focused in the discussion. Challenges and opportunities associated with LCD recycling and indium recovery have been critically reviewed. Indium a critical metal; scarce in primary sources but abundant in e-waste, critical in supply chain but crucial to green energy, lacking in recycling rate but progressive EOL waste generation, poses a threat to ecosystem/habitat but potential to circularize the economy, primarily as a by-product but potential urban mine, both a challenge and an opportunity, concurrently. Cost effective industrial process development is essential for a circular economy and urban mining notion, which can address the challenge associated with environment and energy and create the opportunity for circularizing the metal economy.
C1 [Akcil, Ata; Agcasulu, Ismail] Suleyman Demirel Univ, Dept Min Engn, Mineral Proc Div, MMR&R Res Grp, TR-32260 Isparta, Turkey.
   [Swain, Basudev] IAE, Mat Sci & Chem Engn Ctr, Yongin 449863, Gyeonggi Do, South Korea.
RP Swain, B (reprint author), IAE, Mat Sci & Chem Engn Ctr, Yongin 449863, Gyeonggi Do, South Korea.
EM swain@iae.re.kr
RI Swain, Basudev/F-1230-2014
OI Swain, Basudev/0000-0003-2771-8058
FU SDU Project Coordination [YL02-19-7138]; TUBITAKTurkiye Bilimsel ve
   Teknolojik Arastirma Kurumu (TUBITAK) [119M010]; R&D Center for Valuable
   Recycling (Ministry of Environment) [GT-11-C-01-020-0]
FX Professor Ata Akcil as a coordinator is thankful to SDU Project
   Coordination (YL02-19-7138) and TUBITAK (Project No: 119M010) for
   awarding funding during the course of the investigation. Dr. Basudev
   Swain is thankful to the R&D Center for Valuable Recycling (Ministry of
   Environment, Project No. GT-11-C-01-020-0) for awarding funding during
   the course of the investigation.
CR Alfantazi AM, 2003, MINER ENG, V16, P687, DOI 10.1016/S0892-6875(03)00168-7
   Andarani P., 2012, International Journal of Environmental Science and Development, V3, P562
   Anderson P., 2005, JISC TECHNOLOGY STAN, P52
   Anvil Memon R. L. P., 2016, INT J CONSTR RES CIV, V2
   Arrobas D.L.P., 2017, GROWING ROLE MINERAL
   Ashiq A, 2019, ELECTRONIC WASTE MANAGEMENT AND TREATMENT TECHNOLOGY, P225, DOI 10.1016/B978-0-12-816190-6.00010-8
   Assefi M, 2018, J CLEAN PROD, V180, P814, DOI 10.1016/j.jclepro.2018.01.165
   Balde C.P., 2017, GLOBAL E WASTE MONIT
   Barceloux DG, 1999, J TOXICOL-CLIN TOXIC, V37, P231, DOI 10.1081/CLT-100102422
   Barceloux DG, 1999, J TOXICOL-CLIN TOXIC, V37, P217, DOI 10.1081/CLT-100102421
   Bolen W. P., 2015, 2013 MINERALS YB SAL
   Boundy T, 2017, J CLEAN PROD, V154, P436, DOI 10.1016/j.jclepro.2017.04.038
   Buchert M., 2012, RECYCLING CRITICAL R, V49, P30
   Canda L, 2016, IOP CONF SER-MAT SCI, V106, DOI 10.1088/1757-899X/106/1/012020
   Chen Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25400-0
   Choi D, 2014, RSC ADV, V4, P50975, DOI 10.1039/c4ra11085d
   Chonan T, 2007, EUR RESPIR J, V29, P317, DOI 10.1183/09030936.00020306
   Chou WS, 2016, ENVIRON PROG SUSTAIN, V35, P758, DOI 10.1002/ep.12304
   D'Adamo I., 2019, CURR OPIN GREEN SUST
   DEBNATH B, 2018, FRONT ENV SCI ENG, V12, DOI DOI 10.1007/s11783-018-1044-9
   Dodbiba G, 2012, WASTE MANAGE, V32, P1937, DOI 10.1016/j.wasman.2012.05.016
   Dodson JR, 2012, CHEM ENG PROCESS, V51, P69, DOI 10.1016/j.cep.2011.09.008
   Energy U. S. D. o, 2011, US DEP EN CRIT MET S
   European-Commission, 2017, STUDY ON THE REVIEW
   Fabian Blaser M. S., 2012, EC FEASIBILITY E WAS
   Ferella F, 2017, WASTE MANAGE, V60, P569, DOI 10.1016/j.wasman.2016.12.030
   Fisher M., 2004, SUSTAINABLE ELECT EL, P292
   Fontana D, 2015, WASTE MANAGE, V45, P325, DOI 10.1016/j.wasman.2015.07.043
   FOWLER BA, 1993, SCAND J WORK ENV HEA, V19, P101
   Goosey G. C. S. a. M., 2008, MAT USED MANUFACTURI, P40
   Graedel T.E., 2011, UNEP RECYCLING RATES
   Graedel T. E., 2011, INT RESOURCES PANEL
   Grant K, 2013, LANCET GLOB HEALTH, V1, pE350, DOI 10.1016/S2214-109X(13)70101-3
   Gu S, 2017, RSC ADV, V7, P52017, DOI 10.1039/c7ra11976c
   Gupta UC, 1998, COMMUN SOIL SCI PLAN, V29, P1491, DOI 10.1080/00103629809370045
   Hasegawa H, 2013, MICROCHEM J, V110, P133, DOI 10.1016/j.microc.2013.03.005
   Hasegawa H, 2013, MICROCHEM J, V106, P289, DOI 10.1016/j.microc.2012.08.010
   He YX, 2014, J HAZARD MATER, V268, P185, DOI 10.1016/j.jhazmat.2014.01.011
   Heacock M, 2016, ENVIRON HEALTH PERSP, V124, P550, DOI 10.1289/ehp.1509699
   Hischier R, 2015, INT J LIFE CYCLE ASS, V20, P61, DOI 10.1007/s11367-014-0806-2
   Hong HS, 2010, RES CHEM INTERMEDIAT, V36, P761, DOI 10.1007/s11164-010-0179-5
   Hsieh SJ, 2009, MATER SCI ENG B-ADV, V158, P82, DOI 10.1016/j.mseb.2009.01.019
   Ilyas S, 2013, MIN PROC EXT MET REV, V34, P185, DOI 10.1080/08827508.2011.623751
   Itoh S, 2011, HIGH TEMP MAT PR-ISR, V30, P317, DOI 10.1515/HTMP.2011.051
   Jaffe R, 2011, ENERGY CRITICAL ELEM
   Jowkar MJ, 2018, J CLEAN PROD, V180, P417, DOI 10.1016/j.jclepro.2018.01.136
   Kamberovic Z, 2018, METALS-BASEL, V8, DOI 10.3390/met8060441
   Kang HN, 2011, HYDROMETALLURGY, V110, P120, DOI 10.1016/j.hydromet.2011.09.009
   Kang HY, 2006, ENVIRON SCI TECHNOL, V40, P1672, DOI 10.1021/es0503783
   Kim DJ, 2010, HYDROMETALLURGY, V103, P136, DOI 10.1016/j.hydromet.2010.03.010
   Kumar A., 2016, TRANSPARENT CONDUCTI
   Lee CH, 2013, WASTE MANAGE, V33, P730, DOI 10.1016/j.wasman.2012.10.002
   Li JH, 2009, WASTE MANAGE, V29, P2033, DOI 10.1016/j.wasman.2008.12.013
   Li YH, 2011, HYDROMETALLURGY, V105, P207, DOI 10.1016/j.hydromet.2010.09.006
   Lin KL, 2009, J CLEAN PROD, V17, P1499, DOI 10.1016/j.jclepro.2009.05.012
   Liu HM, 2009, J HAZARD MATER, V172, P744, DOI 10.1016/j.jhazmat.2009.07.098
   Ma E, 2013, J HAZARD MATER, V263, P610, DOI 10.1016/j.jhazmat.2013.10.020
   Martin M, 2015, MINER ENG, V75, P94, DOI 10.1016/j.mineng.2014.11.015
   Mostafa T. M., 2018, EVERGREEN, V5, P26
   Noel-Brune M, 2013, LANCET GLOB HEALTH, V1, pE70, DOI 10.1016/S2214-109X(13)70020-2
   Nogami Hiroko, 2008, Nihon Kokyuki Gakkai Zasshi, V46, P60
   Panda S, 2015, BIORESOURCE TECHNOL, V196, P694, DOI 10.1016/j.biortech.2015.08.064
   Park JC, 2011, B KOREAN CHEM SOC, V32, P3796, DOI 10.5012/bkcs.2011.32.10.3796
   Pdrez C., 2014, TRANSL J NET     MAY
   Perkins DN, 2014, ANN GLOB HEALTH, V80, P286, DOI 10.1016/j.aogh.2014.10.001
   Pradhan D, 2018, MIN PROC EXT MET REV, V39, P167, DOI 10.1080/08827508.2017.1399887
   Pradhan D, 2010, J HAZARD MATER, V175, P267, DOI 10.1016/j.jhazmat.2009.09.159
   Quinet P, 2005, MINER METALL PROC, V22, P17, DOI 10.1007/BF03403191
   Radha R. C., 2014, IOSR J MECH CIV ENG, P41
   Rocchetti L, 2016, J CLEAN PROD, V116, P299, DOI 10.1016/j.jclepro.2015.12.080
   Rocchetti L, 2015, WASTE MANAGE, V42, P180, DOI 10.1016/j.wasman.2015.04.035
   Ruan JL, 2012, PROCEDIA ENVIRON SCI, V16, P545, DOI 10.1016/j.proenv.2012.10.075
   Sand W, 2001, HYDROMETALLURGY, V59, P159, DOI 10.1016/S0304-386X(00)00180-8
   Sethurajan M, 2019, CRIT REV ENV SCI TEC, V49, P212, DOI 10.1080/10643389.2018.1540760
   Silveira AVM, 2015, WASTE MANAGE, V45, P334, DOI 10.1016/j.wasman.2015.04.007
   Song QB, 2015, ENVIRON POLLUT, V196, P450, DOI 10.1016/j.envpol.2014.11.004
   Sun Z, 2017, ACS SUSTAIN CHEM ENG, V5, P21, DOI 10.1021/acssuschemeng.6b00841
   Survey U. S. G., 2018, MINERAL COMMODITY SU
   Susanne R. V., 2013, RECYCLING ORIENTED P, P192
   Swain B, 2019, WASTE MANAGE, V87, P597, DOI 10.1016/j.wasman.2019.02.042
   Swain B, 2018, METALS-BASEL, V8, DOI 10.3390/met8040235
   Swain B, 2016, WASTE MANAGE, V57, P207, DOI 10.1016/j.wasman.2016.02.019
   Swain B, 2016, ENVIRON RES, V147, P249, DOI 10.1016/j.envres.2016.01.032
   Swain B, 2015, GREEN CHEM, V17, P4418, DOI 10.1039/c5gc01244a
   Swain B, 2015, GREEN CHEM, V17, P3979, DOI [10.1039/C5GC00473J, 10.1039/c5gc00473j]
   Takahashi K, 2009, METALL MATER TRANS A, V40A, P891, DOI 10.1007/s11661-009-9786-4
   Tchounwou Paul B, 2012, Exp Suppl, V101, P133, DOI 10.1007/978-3-7643-8340-4_6
   Tolcin A. C., 2015, 2015 MINERAL YB
   Tsujiguchi M., 2012, DESIGN INNOVATIVE VA, P743
   Ueberschaar M., 2017, ASSESSING RECYCLING
   UNEP, 2017, MIN CONV MERC
   Veit H. M., 2015, ELECT WASTE RECYCLIN
   Virolainen S, 2011, HYDROMETALLURGY, V107, P56, DOI 10.1016/j.hydromet.2011.01.005
   Wang HY, 2009, WASTE MANAGE, V29, P335, DOI 10.1016/j.wasman.2008.03.005
   Wang J, 2015, J ENVIRON MANAGE, V159, P11, DOI 10.1016/j.jenvman.2015.05.013
   Werner TT, 2015, T I MIN METALL B, V124, P213, DOI 10.1179/1743275815Y.0000000007
   Wong MH, 2007, ENVIRON POLLUT, V149, P131, DOI 10.1016/j.envpol.2007.01.044
   Wrap, 2011, WEEE GUID COLL HANDL
   Yang J., 2015, PROCESS DEV EXTRACTI
   Yang JX, 2013, HYDROMETALLURGY, V137, P68, DOI 10.1016/j.hydromet.2013.05.008
   Yang YX, 2017, J SUSTAIN METALL, V3, P122, DOI 10.1007/s40831-016-0090-4
   Yen FC, 2016, SOLVENT EXTR RES DEV, V23, P63
   Yokel R. A., 2014, ENCY NEUROLOGICAL SC, P116
   Zeng XL, 2015, ACS SUSTAIN CHEM ENG, V3, P1306, DOI 10.1021/acssuschemeng.5b00020
   Zhang KH, 2017, WASTE MANAGE, V64, P236, DOI 10.1016/j.wasman.2017.03.031
   Zhang KH, 2015, RESOUR CONSERV RECY, V104, P276, DOI 10.1016/j.resconrec.2015.07.015
   Zhang LG, 2016, J CLEAN PROD, V127, P19, DOI 10.1016/j.jclepro.2016.04.004
   Zhuang X., 2016, INDIUM LEACHING WAST
   Zhuang XN, 2012, POL J ENVIRON STUD, V21, P1921
NR 109
TC 3
Z9 3
U1 28
U2 50
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 622
EP 637
DI 10.1016/j.resconrec.2019.06.031
PG 16
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300057
DA 2020-05-12
ER

PT J
AU Li, WB
   Long, RY
   Chen, H
   Yang, MY
   Chen, FY
   Zheng, X
   Li, CF
AF Li, Wenbo
   Long, Ruyin
   Chen, Hong
   Yang, Muyi
   Chen, Feiyu
   Zheng, Xiao
   Li, Cunfang
TI Would personal carbon trading enhance individual adopting intention of
   battery electric vehicles more effectively than a carbon tax?
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Adopting intention; Battery electric vehicles; Carbon tax; Personal
   carbon trading
ID WILLINGNESS-TO-PAY; CHOICE EXPERIMENT; CONSUMER PREFERENCES; ENERGY
   VEHICLES; CHINA; POLICY; EMISSIONS; INCENTIVES; JIANGSU; DECOMPOSITION
AB The implementation of carbon tax (CT) and personal carbon trading (PCT) to transport choices has recently been considered as an approach to draw individual attention to reduce carbon emissions. Since PCT can provide multi motivations, its effectiveness in changing individual adopting decision of battery electric vehicles (BEVs) was hypothesized higher than that of CT. By using the choice experiment method, potential effects of the two policy schemes have been explored and compared. The results showed evidence that both of them could effectively encourage the adoption of BEVs, and the effectiveness of PCT is relatively higher than that of CT. They were shown to be more effective than purchase tax exemption, no driving restriction, and charging discount, but less effective than no purchase restriction. In addition, barriers like purchase price, driving range, and charging time were proved to be less effective than CT, PCT, no purchase restriction, purchase tax exemption, no driving restriction and charging discount. These findings provide insight into further understanding the mechanism of CT and PCT, have important implications to their practical implementation in transport sector, and help perfecting the promotion strategies of BEVs in the future.
C1 [Li, Wenbo; Zheng, Xiao; Li, Cunfang] Jiangsu Normal Univ, Business Sch, 101 Shanghai Rd, Xuzhou 221116, Jiangsu, Peoples R China.
   [Long, Ruyin; Chen, Hong; Chen, Feiyu] China Univ Min & Technol, Sch Management, 1 Daxue Rd, Xuzhou 221116, Jiangsu, Peoples R China.
   [Yang, Muyi] Univ Technol Sydney, Ctr Energy Policy, POB 123,Broadway, Sydney, NSW 2007, Australia.
RP Li, WB (reprint author), Jiangsu Normal Univ, Business Sch, 101 Shanghai Rd, Xuzhou 221116, Jiangsu, Peoples R China.; Long, RY (reprint author), China Univ Min & Technol, Sch Management, 1 Daxue Rd, Xuzhou 221116, Jiangsu, Peoples R China.
EM liwenbo5498@126.com; longruyin@163.com
RI Yang, Muyi/G-9648-2018
OI Li, Wenbo/0000-0003-3599-3324; Gong, Likun/0000-0001-8821-641X; Yang,
   Muyi/0000-0003-4009-2002
FU Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [2017XKZD12]
FX This study was supported by grants from the Fundamental Research Funds
   for the Central Universities (No. 2017XKZD12). The authors would like to
   extend special thanks to the editor and anonymous reviewers for their
   constructive comments and suggestions for improving the quality of this
   study.
CR Beck MJ, 2017, TRANSPORTATION, V44, P753, DOI 10.1007/s11116-016-9675-9
   Bjerkan KY, 2016, TRANSPORT RES D-TR E, V43, P169, DOI 10.1016/j.trd.2015.12.002
   Bristow AL, 2010, ECOL ECON, V69, P1824, DOI 10.1016/j.ecolecon.2010.04.021
   Capstick S, 2009, PERSONAL CARBON ALLO, P88
   [China Automotive Technology and Research Center (CATARC) Nissan China investment Company limited (NCIC) Dongfeng Motor Company Limited (DFL)], 2017, BLUE BOOK NEW EN VEH
   Cui LB, 2018, WORLD DEV, V101, P173, DOI 10.1016/j.worlddev.2017.08.009
   Fan J, 2016, ECON MODEL, V59, P164, DOI 10.1016/j.econmod.2016.07.005
   Fan J, 2015, ENERGY, V82, P601, DOI 10.1016/j.energy.2015.01.069
   Fan J, 2015, NAT RESOUR MODEL, V28, P1, DOI 10.1111/nrm.12054
   Gong HM, 2013, MITIG ADAPT STRAT GL, V18, P207, DOI 10.1007/s11027-012-9358-6
   Hackbarth A, 2016, TRANSPORT RES A-POL, V85, P89, DOI 10.1016/j.tra.2015.12.005
   Han L, 2017, TRANSPORT RES A-POL, V103, P185, DOI 10.1016/j.tra.2017.05.033
   Helveston JP, 2015, TRANSPORT RES A-POL, V73, P96, DOI 10.1016/j.tra.2015.01.002
   Hidrue MK, 2015, APPL ENERG, V151, P67, DOI 10.1016/j.apenergy.2015.04.051
   Hidrue MK, 2011, RESOUR ENERGY ECON, V33, P686, DOI 10.1016/j.reseneeco.2011.02.002
   Hoen A, 2014, TRANSPORT RES A-POL, V61, P199, DOI 10.1016/j.tra.2014.01.008
   Huang YL, 2018, TRANSPORT RES D-TR E, V63, P482, DOI 10.1016/j.trd.2018.06.017
   Klockner CA, 2013, TRANSPORT RES D-TR E, V21, P32, DOI 10.1016/j.trd.2013.02.007
   Ko W, 2013, IEEE T SMART GRID, V4, P437, DOI 10.1109/TSG.2012.2234770
   Li WB, 2018, APPL ENERG, V209, P478, DOI 10.1016/j.apenergy.2017.10.119
   Li WB, 2017, RENEW SUST ENERG REV, V78, P318, DOI 10.1016/j.rser.2017.04.076
   Li WB, 2016, ENERG POLICY, V99, P33, DOI 10.1016/j.enpol.2016.09.050
   Ma SC, 2017, ENERG POLICY, V110, P609, DOI 10.1016/j.enpol.2017.07.057
   Mangham LJ, 2009, HEALTH POLICY PLANN, V24, P151, DOI 10.1093/heapol/czn047
   Parag Y, 2011, J POLICY ANAL MANAG, V30, P889, DOI 10.1002/pam.20610
   Parag Y, 2011, ENVIRONMENT, V53, P29, DOI 10.1080/00139157.2011.539945
   Parsons GR, 2014, ENERG ECON, V42, P313, DOI 10.1016/j.eneco.2013.12.018
   Raux C, 2015, TRANSPORT RES D-TR E, V35, P72, DOI 10.1016/j.trd.2014.11.008
   Sang YN, 2015, J CLEAN PROD, V92, P75, DOI 10.1016/j.jclepro.2014.12.045
   Song ML, 2016, COMPUT IND ENG, V101, P614, DOI 10.1016/j.cie.2016.05.035
   Wang N, 2017, TRANSPORT RES A-POL, V105, P210, DOI 10.1016/j.tra.2017.08.009
   Wang QW, 2017, APPL ENERG, V194, P679, DOI 10.1016/j.apenergy.2016.05.073
   Wang QW, 2015, ENERG ECON, V51, P252, DOI 10.1016/j.eneco.2015.07.009
   Wang QW, 2015, ECOL INDIC, V51, P151, DOI 10.1016/j.ecolind.2014.07.022
   Wang SY, 2019, HUM ECOL RISK ASSESS, V25, P1745, DOI 10.1080/10807039.2018.1471580
   Wang SY, 2016, TRANSPORTATION, V43, P123, DOI 10.1007/s11116-014-9567-9
   Zanni AM, 2013, J ENVIRON ECON POLIC, V2, P222, DOI 10.1080/21606544.2013.782471
   Zhang X, 2013, ENERG POLICY, V61, P382, DOI 10.1016/j.enpol.2013.06.114
   Zhang YJ, 2018, EMPIR ECON, V54, P1743, DOI 10.1007/s00181-017-1272-z
   Zhang YJ, 2017, APPL ENERG, V196, P132, DOI 10.1016/j.apenergy.2016.12.087
   Zhang YJ, 2017, ENERG POLICY, V100, P149, DOI 10.1016/j.enpol.2016.10.010
NR 41
TC 2
Z9 2
U1 17
U2 36
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 638
EP 645
DI 10.1016/j.resconrec.2019.06.035
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300058
DA 2020-05-12
ER

PT J
AU Zhang, CB
   Hu, MM
   Dong, L
   Gebremariam, A
   Miranda-Xicotencatl, B
   Di Maio, F
   Tukker, A
AF Zhang, Chunbo
   Hu, Mingming
   Dong, Liang
   Gebremariam, Abraham
   Miranda-Xicotencatl, Brenda
   Di Maio, Francesco
   Tukker, Arnold
TI Eco-efficiency assessment of technological innovations in high-grade
   concrete recycling
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Eco-efficiency assessment; Life cycle assessment; Life cycle costing;
   Concrete recycling; Construction and demolition waste; Technological
   innovation
ID LIFE-CYCLE ASSESSMENT; DATA ENVELOPMENT ANALYSIS; DEMOLITION WASTE;
   CONSTRUCTION; MANAGEMENT; SUSTAINABILITY; PERFORMANCE; FRAMEWORK;
   INDUSTRY; SYSTEMS
AB The increasing volume of Construction and demolition waste (CDW) associated with economic growth is posing challenges to the sustainable management of the built environment. The largest fraction of all the CDW generated in the member states of the European Union (EU) is End-of-life (EOL) concrete. The most widely applied method for EOL concrete recovery in Europe is road base backfilling, which is considered low-grade recovery. The common practice for high-grade recycling is wet process that processes and washes EOL concrete into clean coarse aggregate for concrete manufacturing. It is costly. As a result, a series of EU projects have been launched to advance the technologies for high value-added concrete recycling. A critical environmental and economic evaluation of such technological innovations is important to inform decision making, while there has been a lack of studies in this field. Hence the present study aimed to assess the efficiency of the technical innovations in high-grade concrete recycling, using an improved eco-efficiency analytical approach by integrating life cycle assessment (LCA) and life cycle costing (LCC). Four systems of high-grade concrete recycling were analyzed for comparison: (i) business-as-usual (BAU) stationary wet processing; (ii) stationary advanced dry recovery (ADR); (iii) mobile ADR; (iv) mobile ADR and Heating Air Classification (A&H). An overarching framework was proposed for LCA/LCC-type eco-efficiency assessment conforming to ISO standards, The study found that technological routes that recycle on-site and produce high-value secondary products are most advantageous. Accordingly, policy recommendations are proposed to support the technological innovations of CDW management.
C1 [Zhang, Chunbo; Hu, Mingming; Miranda-Xicotencatl, Brenda; Tukker, Arnold] Leiden Univ, Inst Environm Sci, NL-2300 RA Leiden, Netherlands.
   [Hu, Mingming] Chongqing Univ, Sch Construct Management & Real Estate, Chongqing 40045, Peoples R China.
   [Dong, Liang] City Univ Hong Kong, Dept Publ Policy, Kowloon, 83 Tat Chee Ave, Hong Kong, Peoples R China.
   [Gebremariam, Abraham; Di Maio, Francesco] Delft Univ Technol, Fac Civil Engn & Geosci, NL-2628 CN Delft, Netherlands.
   [Tukker, Arnold] TNO, Netherlands Org Appl Sci Res, NL-2595 DA The Hague, Netherlands.
RP Hu, MM (reprint author), Chongqing Univ, Sch Construct Management & Real Estate, Chongqing 40045, Peoples R China.; Dong, L (reprint author), City Univ Hong Kong, Dept Publ Policy, Kowloon, 83 Tat Chee Ave, Hong Kong, Peoples R China.
EM mingminghu@cqu.edu.cn; dong0926@163.com
RI Tukker, Arnold/M-4596-2013
OI Tukker, Arnold/0000-0002-8229-2929; Dong, Liang/0000-0001-9747-5851;
   Zhang, Chunbo/0000-0002-1729-8515; Di Maio,
   Francesco/0000-0001-6018-1227; Gebremariam, Abraham/0000-0001-9675-527X
FU EU's 7th Framework Project C2CA "Advanced Technologies for the
   Production of Cement and Clean Aggregates from Construction and
   Demolition Waste" [265189]; EU's Horizon 2020 Project HISER "Holistic
   Innovative Solutions for an Efficient Recycling and Recovery of Valuable
   Raw Materials from Complex Construction and Demolition Waste" [642085];
   EU's Horizon 2020 Project VEEP "Cost - Effective Recycling of C&DW in
   High Added Value Energy Efficient Prefabricated Concrete Components for
   Massive Retrofitting of our Built Environment" [723582]; China
   Scholarship CouncilChina Scholarship Council [201706050090]; National
   Science Foundation, China (NSFC)National Natural Science Foundation of
   China [41701636]
FX The authors thank the support of EU's 7th Framework Project C2CA
   "Advanced Technologies for the Production of Cement and Clean Aggregates
   from Construction and Demolition Waste" (No. 265189), EU's Horizon 2020
   Project HISER "Holistic Innovative Solutions for an Efficient Recycling
   and Recovery of Valuable Raw Materials from Complex Construction and
   Demolition Waste" (No. 642085), and EU's Horizon 2020 Project VEEP "Cost
   - Effective Recycling of C&DW in High Added Value Energy Efficient
   Prefabricated Concrete Components for Massive Retrofitting of our Built
   Environment" (No. 723582). The first author appreciates the support of
   the China Scholarship Council (No. 201706050090). Dr. L. Dong also
   appreciates the support of the National Science Foundation, China (NSFC,
   NO. 41701636). The authors thank Dr. Jeroen Guinee for his suggestions
   on flow diagram depiction and functional unit definition.
CR Afrane G, 2012, APPL ENERG, V98, P301, DOI 10.1016/j.apenergy.2012.03.041
   Almutairi K, 2015, ENERG BUILDINGS, V102, P370, DOI 10.1016/j.enbuild.2015.06.004
   Anastasiou E, 2014, CONSTR BUILD MATER, V50, P154, DOI 10.1016/j.conbuildmat.2013.09.037
   [Anonymous], 2009, EC IND MEAS RES US E
   [Anonymous], 2008, 15459 EN
   [Anonymous], 2006, 14040 ISO
   [Anonymous], 2012, 14045 ISO
   [Anonymous], 2006, 14044 ISO
   Atici KB, 2015, OMEGA-INT J MANAGE S, V54, P72, DOI 10.1016/j.omega.2015.01.015
   Auer J, 2017, J CLEAN PROD, V141, P99, DOI 10.1016/j.jclepro.2016.08.096
   BIO Intelligence Service, 2011, ENVG4FRA20080112 BIO
   Bohne RA, 2008, J IND ECOL, V12, P52, DOI 10.1111/j.1530-9290.2008.00013.x
   Burchart-Korol D, 2016, FUEL, V173, P239, DOI 10.1016/j.fuel.2016.01.019
   Chen L, 2017, J CLEAN PROD, V142, P846, DOI 10.1016/j.jclepro.2016.01.045
   EC-JRC, 2016, GUID IMPL EU PROD EN
   Ferrandez-Garcia A, 2016, J CLEAN PROD, V112, P649, DOI 10.1016/j.jclepro.2015.07.136
   Fuller S.K., 1995, NIST HDB, DOI [10.1108/eb006413, DOI 10.1108/EB006413]
   Galvez-Martos JL, 2018, RESOUR CONSERV RECY, V136, P166, DOI 10.1016/j.resconrec.2018.04.016
   Gerdessen JC, 2013, AGR SYST, V118, P78, DOI 10.1016/j.agsy.2013.03.004
   Guinee J. B., 2002, HDB LIFE CYCLE ASSES, DOI [10.1007/BF02978784, DOI 10.1007/BF02978784]
   Hincapie I, 2015, WASTE MANAGE, V43, P398, DOI 10.1016/j.wasman.2015.07.004
   Huang BJ, 2018, RESOUR CONSERV RECY, V129, P36, DOI 10.1016/j.resconrec.2017.09.029
   Huijbregts M.A.J, 2003, CODE OFLIFE CYCLE IN
   Hunkeler D, 2008, ENV LIFE CYCLE COSTI, DOI [10.1201/9781420054736, DOI 10.1201/9781420054736.CH3]
   Huppes G, 2005, J IND ECOL, V9, P25, DOI 10.1162/108819805775247882
   Ibbotson S, 2013, INT J LIFE CYCLE ASS, V18, P1137, DOI 10.1007/s11367-013-0547-7
   ISO, 2017, 156865 ISO
   KEFFER C, 1999, ECOEFFICIENCY INDICA
   Kicherer A, 2007, INT J LIFE CYCLE ASS, V12, P537, DOI 10.1065/lca2007.01.305
   Klostermann J. E. M., 1998, PRODUCT INNOVATION E
   Korhonen PJ, 2004, EUR J OPER RES, V154, P437, DOI 10.1016/S0377-2217(03)00180-2
   Koutamanis A, 2018, RESOUR CONSERV RECY, V138, P32, DOI 10.1016/j.resconrec.2018.06.024
   Lee JY, 2011, INT J HYDROGEN ENERG, V36, P1754, DOI 10.1016/j.ijhydene.2010.10.074
   Lorenzo-Toja Y, 2016, SCI TOTAL ENVIRON, V566, P468, DOI 10.1016/j.scitotenv.2016.05.110
   Lotfi S, 2014, RESOUR CONSERV RECY, V87, P117, DOI 10.1016/j.resconrec.2014.03.010
   Luo L, 2009, RENEW SUST ENERG REV, V13, P1613, DOI 10.1016/j.rser.2008.09.024
   Mardani A, 2017, RENEW SUST ENERG REV, V70, P1298, DOI 10.1016/j.rser.2016.12.030
   Menikpura SNM, 2016, RENEW ENERG, V86, P576, DOI 10.1016/j.renene.2015.08.054
   Miah JH, 2017, J CLEAN PROD, V168, P846, DOI 10.1016/j.jclepro.2017.08.187
   Minne E, 2015, INT J LIFE CYCLE ASS, V20, P36, DOI 10.1007/s11367-014-0809-z
   Pretel R, 2016, J ENVIRON MANAGE, V166, P45, DOI 10.1016/j.jenvman.2015.10.004
   Rodriguez G, 2007, RESOUR CONSERV RECY, V50, P334, DOI 10.1016/j.resconrec.2006.06.008
   Saling P, 2002, INT J LIFE CYCLE ASS, V7, P203, DOI 10.1007/BF02978875
   Seppala J, 2005, J IND ECOL, V9, P117, DOI 10.1162/108819805775247972
   Song ML, 2018, MANAGE DECIS, V56, P188, DOI 10.1108/MD-04-2017-0375
   Swarr TE, 2011, INT J LIFE CYCLE ASS, V16, P389, DOI 10.1007/s11367-011-0287-5
   Tajbakhsh A, 2015, J CLEAN PROD, V105, P74, DOI 10.1016/j.jclepro.2014.07.054
   Tam VWY, 2010, WASTE MANAGE, V30, P291, DOI 10.1016/j.wasman.2009.09.044
   Technalia, 2018, WP2 VEEP TECHN
   Vegas I, 2015, CONSTR BUILD MATER, V75, P121, DOI 10.1016/j.conbuildmat.2014.09.109
   Vercalsteren A, 2010, INT J LIFE CYCLE ASS, V15, P221, DOI 10.1007/s11367-009-0143-z
   Woon KS, 2016, RESOUR CONSERV RECY, V107, P104, DOI 10.1016/j.resconrec.2015.11.020
   Yang ZF, 2015, J CLEAN PROD, V104, P242, DOI 10.1016/j.jclepro.2014.09.091
   Yeheyis M, 2013, CLEAN TECHNOL ENVIR, V15, P81, DOI 10.1007/s10098-012-0481-6
   Zhang CB, 2018, J CLEAN PROD, V201, P481, DOI 10.1016/j.jclepro.2018.07.238
   Zhang Q, 2019, J CLEAN PROD, V210, P563, DOI 10.1016/j.jclepro.2018.11.050
   Zhao W, 2011, WASTE MANAGE, V31, P1407, DOI 10.1016/j.wasman.2011.01.013
NR 57
TC 2
Z9 2
U1 9
U2 21
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 649
EP 663
DI 10.1016/j.resconrec.2019.06.023
PG 15
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300060
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Ghorbani, S
   Sharifi, S
   Ghorbani, S
   Tam, VWY
   de Brito, J
   Kurda, R
AF Ghorbani, Saeid
   Sharifi, Sohrab
   Ghorbani, Sahar
   Tam, Vivian W. Y.
   de Brito, Jorge
   Kurda, Rawaz
TI Effect of crushed concrete waste's maximum size as partial replacement
   of natural coarse aggregate on the mechanical and durability properties
   of concrete
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Mechanical characteristics; Durability characteristics; Crushed concrete
   waste; Natural coarse aggregate; Statistical analysis
ID RECYCLED CONCRETE; DEMOLITION WASTE; FLY-ASH; CORROSION-RESISTANCE;
   COMPRESSIVE STRENGTH; STATISTICAL-ANALYSIS; STRUCTURAL CONCRETE;
   MAGNETIZED WATER; BINDER RATIO; STEEL REBARS
AB The purpose of this research is to investigate the effect of the incorporation ratio of various maximum sizes of crushed concrete waste (CCW) on the mechanical and durability characteristics of concrete mixes. CCW is undoubtedly one of the main focuses of researchers in the field of sustainable development. However, knowledge regarding the effect of its maximum size on concrete is very scarce. For that purpose, 10 concrete mixes with three different ranges of CCW sizes (5-25 mm), (5-20 mm) and (5-12.5 mm) and different ratios of CCW (0%, 25%, 50%, 75%, and 100%) as replacement of natural coarse aggregate (NCA) were prepared. In addition, compressive and splitting tensile strength, freeze-thaw, water absorption, and abrasion resistance tests were made with the concrete mixes. Since one of the most relevant parts of any experimental investigation is to produce a mathematical relationship between the parameters studied, a statistical analysis was performed, specifically to understand the global effect of the various maximum sizes of CCW as partial replacement of NCA on various characteristics of concrete. The results show that, by incorporating 25% of CCW, the strength of concrete mixes improved for all sizes of CCW. In most cases, for the same incorporation ratio of CCW, the strength and durability (except for abrasion) of concrete slightly improved by decreasing the maximum size of the aggregates. Additionally, the resistance to freeze-thaw cycles results revealed that using CCW instead of NCA can improve the durability characteristics of concrete.
C1 [Ghorbani, Saeid; Sharifi, Sohrab; Ghorbani, Sahar] Ferdowsi Univ Mashhad, Fac Engn, Civil Engn Dept, Mashhad 917751111, Razavi Khorasan, Iran.
   [Tam, Vivian W. Y.] Western Sydney Univ, Sch Comp Engn & Math, Penrith, NSW 2751, Australia.
   [de Brito, Jorge] Univ Lisbon, CERIS, Inst Super Tecn, Lisbon, Portugal.
   [Kurda, Rawaz] Univ Lisbon, Inst Super Tecn, Civil Engn Architecture & Georresources Dept, CERIS, Av Rovisco Pais, P-1049001 Lisbon, Portugal.
   [Kurda, Rawaz] Erbil Polytech Univ, Dept Civil Engn, Tech Engn Coll, Erbil, Kurdistan Regio, Iraq.
RP Ghorbani, S (reprint author), Ferdowsi Univ Mashhad, Fac Engn, Civil Engn Dept, Mashhad 917751111, Razavi Khorasan, Iran.; de Brito, J (reprint author), Univ Lisbon, CERIS, Inst Super Tecn, Lisbon, Portugal.
EM saeid.ghorbani@mail.um.ac.ir; jb@civil.utl.pt
RI de Brito, Jorge/A-4299-2008
OI de Brito, Jorge/0000-0001-6766-2736; Sharifi,
   Sohrab/0000-0002-7958-5405; Tam, Vivian/0000-0002-1074-8018; Ghorbani,
   Saeid/0000-0001-9296-4189
FU Faculty of Engineering at Ferdowsi University of Mashhad; Foundation for
   Science and TechnologyPortuguese Foundation for Science and Technology;
   CERIS research centre; Instituto Superior Tecnico
FX This research was partially supported by Faculty of Engineering at
   Ferdowsi University of Mashhad. The authors wish to acknowledge their
   gratitude for this support and express that the results and conclusions
   presented here are their own and do not represent the views of the
   sponsor. The support of the Foundation for Science and Technology, CERIS
   research centre and Instituto Superior Tecnico is also acknowledged.
CR Ahmed SFU, 2013, J MATER CIVIL ENG, V25, P1864, DOI 10.1061/(ASCE)MT.1943-5533.0000763
   Aldahdooh MAA, 2013, MATER DESIGN, V52, P957, DOI 10.1016/j.matdes.2013.06.034
   Alyamac KE, 2017, J CLEAN PROD, V144, P192, DOI 10.1016/j.jclepro.2016.12.156
   Arel HS, 2016, J CLEAN PROD, V131, P179, DOI 10.1016/j.jclepro.2016.05.052
   Barbudo A, 2013, J CLEAN PROD, V59, P93, DOI 10.1016/j.jclepro.2013.06.022
   Behera M, 2014, CONSTR BUILD MATER, V68, P501, DOI 10.1016/j.conbuildmat.2014.07.003
   Box GEP, 2007, RESPONSE SURFACES MI
   Bravo M, 2015, CONSTR BUILD MATER, V77, P357, DOI 10.1016/j.conbuildmat.2014.12.103
   Butler L, 2013, CONSTR BUILD MATER, V47, P1292, DOI 10.1016/j.conbuildmat.2013.05.074
   Cachim PB, 2009, CONSTR BUILD MATER, V23, P1292, DOI 10.1016/j.conbuildmat.2008.07.023
   de Brito J, 2010, INT J SUSTAIN ENG, V3, P58, DOI 10.1080/19397030903254710
   Evangelista L, 2010, CEMENT CONCRETE COMP, V32, P9, DOI 10.1016/j.cemconcomp.2009.09.005
   Fonseca N, 2011, CEMENT CONCRETE COMP, V33, P637, DOI 10.1016/j.cemconcomp.2011.04.002
   Ghorbani S, 2019, CONSTR BUILD MATER, V207, P28, DOI 10.1016/j.conbuildmat.2019.02.098
   Ghorbani S, 2019, CONSTR BUILD MATER, V197, P280, DOI 10.1016/j.conbuildmat.2018.11.160
   Ghorbani S, 2019, CONSTR BUILD MATER, V194, P143, DOI 10.1016/j.conbuildmat.2018.11.023
   Ghorbani S, 2018, CONSTR BUILD MATER, V185, P110, DOI 10.1016/j.conbuildmat.2018.07.066
   Ghorbani S, 2018, MATERIALS, V11, DOI 10.3390/ma11091647
   Grdic ZJ, 2010, CONSTR BUILD MATER, V24, P1129, DOI 10.1016/j.conbuildmat.2009.12.029
   Guneyisi E, 2014, COMPOS PART B-ENG, V60, P707, DOI 10.1016/j.compositesb.2014.01.017
   Katz A, 2003, CEMENT CONCRETE RES, V33, P703, DOI 10.1016/S0008-8846(02)01033-5
   Kou SC, 2012, CONSTR BUILD MATER, V28, P549, DOI 10.1016/j.conbuildmat.2011.08.027
   Kwan WH, 2012, CONSTR BUILD MATER, V26, P565, DOI 10.1016/j.conbuildmat.2011.06.059
   Lindquist W, 2015, CONSTR BUILD MATER, V74, P49, DOI 10.1016/j.conbuildmat.2014.10.027
   Manzi S, 2013, CEMENT CONCRETE COMP, V37, P312, DOI 10.1016/j.cemconcomp.2013.01.003
   Matias D, 2013, CONSTR BUILD MATER, V44, P101, DOI 10.1016/j.conbuildmat.2013.03.011
   Medina C, 2013, J CLEAN PROD, V40, P151, DOI 10.1016/j.jclepro.2012.08.042
   Nambiar EKK, 2006, CEMENT CONCRETE COMP, V28, P752, DOI 10.1016/j.cemconcomp.2006.06.001
   Newman K, 1959, MAGAZINE CONCRETE RE, V11, P135, DOI DOI 10.1680/MACR.1959.11.33.135
   Oikonomou ND, 2005, CEMENT CONCRETE COMP, V27, P315, DOI 10.1016/j.cemconcomp.2004.02.020
   Olorunsogo FT, 2002, CEMENT CONCRETE RES, V32, P179, DOI 10.1016/S0008-8846(01)00653-6
   Oltean M., 2003, COMPLEX SYSTEMS, V14, P285
   Poon CS, 2004, CONSTR BUILD MATER, V18, P461, DOI 10.1016/j.conbuildmat.2004.03.005
   Rao A, 2007, RESOUR CONSERV RECY, V50, P71, DOI 10.1016/j.resconrec.2006.05.010
   Rao MJ, 2016, CONSTR BUILD MATER, V115, P42, DOI 10.1016/j.conbuildmat.2016.03.172
   Shayan A, 2003, ACI MATER J, V100, P371
   Silva RV, 2014, CONSTR BUILD MATER, V65, P201, DOI 10.1016/j.conbuildmat.2014.04.117
   Soares D, 2014, CONSTR BUILD MATER, V71, P263, DOI 10.1016/j.conbuildmat.2014.08.034
   Somna R, 2012, J MATER CIVIL ENG, V24, P16, DOI 10.1061/(ASCE)MT.1943-5533.0000360
   Tabrizi MK, 2019, CONSTR BUILD MATER, V223, P106, DOI 10.1016/j.conbuildmat.2019.06.159
   Tabsh SW, 2009, CONSTR BUILD MATER, V23, P1163, DOI 10.1016/j.conbuildmat.2008.06.007
   Taji I, 2019, J CLEAN PROD, V210, P837, DOI 10.1016/j.jclepro.2018.11.091
   Tam VWY, 2006, HUM ECOL RISK ASSESS, V12, P277, DOI 10.1080/10807030500531653
   Topcu IB, 2004, CEMENT CONCRETE RES, V34, P1307, DOI 10.1016/j.cemconres.2003.12.019
   Wang GM, 2013, CONSTR BUILD MATER, V38, P1129, DOI 10.1016/j.conbuildmat.2012.09.027
   Wu K, 2016, CEMENT CONCRETE RES, V79, P243, DOI 10.1016/j.cemconres.2015.09.018
   Xu GL, 2018, CEMENT CONCRETE COMP, V93, P19, DOI 10.1016/j.cemconcomp.2018.06.013
   Yang K.-H., 2008, INFLUENCE TYPE REPLA
   Yong T.D, 2009, UNIMAS E J CIVIL ENG, V1, P1
NR 49
TC 6
Z9 6
U1 6
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 664
EP 673
DI 10.1016/j.resconrec.2019.06.030
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300061
DA 2020-05-12
ER

PT J
AU Madden, B
   Florin, N
   Mohr, S
   Giurco, D
AF Madden, Ben
   Florin, Nick
   Mohr, Steve
   Giurco, Damien
TI Using the waste Kuznet's curve to explore regional variation in the
   decoupling of waste generation and socioeconomic indicators
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Kuznets curve; Municipal solid waste; Decoupling; Geographically and
   temporally weighted regression
ID TEMPORALLY WEIGHTED REGRESSION; CIRCULAR ECONOMY; PREDICTION; IMPACT;
   MODEL; HETEROGENEITY; DYNAMICS; GROWTH
AB Decoupling of resource consumption from economic growth is a key principle in the transition towards a circular economy. This study explores regional variation in the decoupling of waste generation from mean income in the Australian state of New South Wales (NSW), following the Waste Kuznet's curve (WKC) hypothesis. The WKC hypothesis tests for the existence of a relationship between waste and economic indicators conforming to an inverted-U shape that may indicate decoupling. A geographically and temporally weighted regression (GTWR) model is used to test the WKC hypothesis for municipal waste from 2011 to 2015. We identify municipalities conforming to the WKC hypothesis, and examine the socioeconomic and urban morphological characteristics of these municipalities. Results show that waste policy must be targeted to consider local variability in socioeconomics. Municipalities across rural NSW were found to conform to the WKC over the time frame. WKC conforming municipalities had higher per-capita rates of waste generation, and lower mean incomes compared to non-conforming municipalities. Ratios of tipping point (global maximum) to mean income for WKC conforming municipalities were estimated between 0.8 and 2, indicating that these municipalities are in stages of relative, rather than absolute, decoupling. This study demonstrates the application of the WKC for examining decoupling, and highlights the importance of considering variations in regional characteristics when assessing the decoupling of waste generation from income. Findings also broadly suggest regionally specific policy making is required for circular economy transitions in NSW.
C1 [Madden, Ben; Florin, Nick; Mohr, Steve; Giurco, Damien] Univ Technol Sydney, Inst Sustainable Futures, Ultimo, NSW, Australia.
RP Madden, B (reprint author), Univ Technol Sydney, Inst Sustainable Futures, Ultimo, NSW, Australia.
EM benjamin.madden@uts.edu.au
OI Madden, Ben/0000-0001-9167-8535; Giurco, Damien/0000-0002-1707-9531
CR Australian Bureau of Statistics, 2018, DAT REG 2012 17
   Australian Bureau of Statistics, 2017, AUSTR STAT GEOGR STA
   Australian Bureau of Statistics, 2016, AUSTR STAT GEOGR STA, V3
   Barrens R., 1998, ECON LETT, V55, P435, DOI [10.1016/S0165-1765(97)00088-8, DOI 10.1016/S0165-1765(97)00088-8]
   Belsley D. A., 1980, REGRESSION DIAGNOSTI
   Bivand RS, 2008, USE R, P1
   Concu N., 2000, TIRANNIA TRADE SCONF
   Du ZH, 2018, ECOL INFORM, V43, P185, DOI 10.1016/j.ecoinf.2017.12.005
   Dyson B, 2005, WASTE MANAGE, V25, P669, DOI 10.1016/j.wasman.2004.10.005
   Ellen MacArthur Foundation, 2015, DEL CIRC EC TOOLK PO
   Ercolano S, 2018, ECOL INDIC, V93, P397, DOI 10.1016/j.ecolind.2018.05.021
   Fischer-Kowalski M, 2001, POPUL ENVIRON, V23, P7, DOI 10.1023/A:1017560208742
   Fletcher R, 2017, GLOBALIZATIONS, V14, P450, DOI 10.1080/14747731.2016.1263077
   Fotheringham AS, 2015, GEOGR ANAL, V47, P431, DOI 10.1111/gean.12071
   Fotheringham AS, 2002, GEOGRAPHICALLY WEIGH
   Gollini I, 2015, J STAT SOFTW, V63, P1
   GOODCHILD MF, 1992, INT J GEOGR INF SYST, V6, P31, DOI 10.1080/02693799208901893
   Huang B, 2010, INT J GEOGR INF SCI, V24, P383, DOI 10.1080/13658810802672469
   Ichinose D., 2011, 1107 GRIPS
   Jackson T., 2009, PROSPERITY GROWTH EC
   Jaligot R, 2018, RESOUR CONSERV RECY, V130, P260, DOI 10.1016/j.resconrec.2017.12.014
   Kannangara M, 2018, WASTE MANAGE, V74, P3, DOI 10.1016/j.wasman.2017.11.057
   Keser S, 2012, WASTE MANAGE, V32, P359, DOI 10.1016/j.wasman.2011.10.017
   Khan D, 2016, WASTE MANAGE, V49, P15, DOI 10.1016/j.wasman.2016.01.019
   Kim Y, 2018, STOCH ENV RES RISK A, V32, P2147, DOI 10.1007/s00477-017-1503-z
   Kirchherr J, 2017, RESOUR CONSERV RECY, V127, P221, DOI 10.1016/j.resconrec.2017.09.005
   Kolekar KA, 2016, PROCEDIA ENVIRON SCI, V35, P238, DOI 10.1016/j.proenv.2016.07.087
   Kumar A, 2017, WASTE MANAGE, V68, P3, DOI 10.1016/j.wasman.2017.07.034
   Kuznets S, 1955, AM ECON REV, V45, P1
   Lewandowska-Gwarda K, 2018, ISPRS INT J GEO-INF, V7, DOI 10.3390/ijgi7010017
   Ma XL, 2018, COMPUT ENVIRON URBAN, V70, P113, DOI 10.1016/j.compenvurbsys.2018.03.001
   Maddison D, 2006, J ENVIRON ECON MANAG, V51, P218, DOI 10.1016/j.jeem.2005.07.002
   Mazzanti M., 2008, J ENVIRON DEV, V17-1, P51, DOI DOI 10.1177/1070496507312575
   Mazzanti M, 2012, J ENVIRON PLANN MAN, V55, P563, DOI 10.1080/09640568.2011.616582
   Mazzanti M, 2009, ENVIRON RESOUR ECON, V44, P203, DOI 10.1007/s10640-009-9280-x
   Montello D, 2012, INTRO SCI RES METHOD
   Montevecchi F, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8050442
   NSW EPA State of Nsw, 2016, NSW LOC GOV WAST RES
   NSW Government, 2018, NSW GOVT TECHNICAL R
   OECD, 2018, OECD GLOB MAT RES OU
   Oribe-Garcia I, 2015, WASTE MANAGE, V39, P26, DOI 10.1016/j.wasman.2015.02.017
   Trang PTT, 2017, ENRGY PROCED, V107, P253, DOI 10.1016/j.egypro.2016.12.144
   Suarez-Eiroa B, 2019, J CLEAN PROD, V214, P952, DOI 10.1016/j.jclepro.2018.12.271
   Sun N, 2017, ENRGY PROCED, V138, P907, DOI 10.1016/j.egypro.2017.10.134
   Wang P, 1998, APPL ECON LETT, V5, P761, DOI 10.1080/135048598353970
   Ward J., 2016, PLOS ONE, V11, DOI [10.1371/joumal.pone.0164733, DOI 10.1371/JOUMAL.PONE.0164733]
   Wiedmann TO, 2015, P NATL ACAD SCI USA, V112, P6271, DOI 10.1073/pnas.1220362110
   World Trade Organization, 2017, 18 JUL 2017 COMM TEC
   Wu B, 2014, INT J GEOGR INF SCI, V28, P1186, DOI 10.1080/13658816.2013.878463
   Yu DL, 2006, ANN REGIONAL SCI, V40, P173, DOI 10.1007/s00168-005-0038-2
NR 50
TC 2
Z9 2
U1 5
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 674
EP 686
DI 10.1016/j.resconrec.2019.06.025
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300062
DA 2020-05-12
ER

PT J
AU Chin, HH
   Foo, DCY
   Lam, HL
AF Chin, Hon Huin
   Foo, Dominic C. Y.
   Lam, Hon Loong
TI Simultaneous water and energy integration with isothermal and
   non-isothermal mixing - A P-graph approach
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Direct reuse/recycle; Heat-integrated water network; NLP transformation;
   Non-isothermal mixing; P-graph; Regeneration
ID MATHEMATICAL-PROGRAMMING SYNTHESIS; HEAT-EXCHANGER NETWORKS;
   SIMULTANEOUS-OPTIMIZATION; ALLOCATION NETWORKS; SUPPLY CHAINS; THEORETIC
   APPROACH; DESIGN; SYSTEMS; SUPERSTRUCTURE; MINIMIZATION
AB Heat-integrated water network (HIWN) is an active area of research in the past decade. It focuses on simultaneous saving of energy and water, which are both important resources to enhance sustainability for the process plants. This problem has been previously approached using insight-based pinch analysis and mathematical programming techniques. In this work, an alternative optimization tool, process graph (P-graph) framework is utilized to solve for water and energy integration. P-graph is a graph-theoretic approach to process synthesis, for which the developed algorithms can reduce the complexity of the mathematical programming algorithms efficiently. P-graph methodology enables the effective generation of sub-optimal network structures that allow wider exploration of alternatives through network topology. This paper also introduces some transformation techniques to convert the non-linear programming (NLP) model in the non-isothermal HIWN problem into model which is solvable using P-graph. Two examples with different water recovery schemes are used to elucidate the proposed approach, covering both direct recycle/reuse and regeneration networks; for both cases, isothermal and non-isothermal mixing problems are solved.
C1 [Chin, Hon Huin; Foo, Dominic C. Y.; Lam, Hon Loong] Univ Nottingham, Dept Chem & Environm Engn, Malaysia Campus,Jalan Broga, Semenyih 43500, Selangor, Malaysia.
RP Lam, HL (reprint author), Univ Nottingham, Dept Chem & Environm Engn, Malaysia Campus,Jalan Broga, Semenyih 43500, Selangor, Malaysia.
EM Honhuinchin@gmail.com; Dominic.Foo@nottingham.edu.my;
   HonLoong.Lam@nottingham.edu.my
RI Chin, Huin/N-2395-2019; Lam, Hon Loong/H-1438-2016; Foo,
   Dominic/H-8541-2016
OI Lam, Hon Loong/0000-0003-1818-9078; Foo, Dominic/0000-0002-8185-255X
CR Ahmetovic E, 2015, COMPUT CHEM ENG, V82, P144, DOI 10.1016/j.compchemeng.2015.06.011
   Ahmetovic E, 2013, ENERGY, V57, P236, DOI 10.1016/j.energy.2013.02.061
   Ahmetovic E, 2011, AICHE J, V57, P434, DOI 10.1002/aic.12276
   Ahmetovic E, 2010, IND ENG CHEM RES, V49, P7972, DOI 10.1021/ie1000955
   Bagajewicz M, 2002, COMPUT CHEM ENG, V26, P59, DOI 10.1016/S0098-1354(01)00751-7
   Bagajewicz M, 2000, COMPUT CHEM ENG, V24, P2093, DOI 10.1016/S0098-1354(00)00579-2
   BAGAJEWICZ MJ, 1992, AICHE J, V38, P1769, DOI 10.1002/aic.690381110
   Bogataj M, 2008, COMPUT CHEM ENG, V32, P3130, DOI 10.1016/j.compchemeng.2008.05.006
   Cabezas H, 2018, ENVIRON PROG SUSTAIN, V37, P624, DOI 10.1002/ep.12887
   Cabezas H, 2015, CHEM ENG PROG, V111, P41
   Dong HG, 2008, CHEM ENG SCI, V63, P3664, DOI 10.1016/j.ces.2008.04.044
   Eles A., 2018, CHEM ENG T, V70, P1783
   Feng X, 2008, CHINESE J CHEM ENG, V16, P480, DOI 10.1016/S1004-9541(08)60109-3
   Foo D, 2012, PROCESS INTEGRATION, P323
   Foo DCY, 2009, IND ENG CHEM RES, V48, P5125, DOI 10.1021/ie801264c
   FRIEDLER F, 1992, COMPUT CHEM ENG, V16, pS313, DOI 10.1016/S0098-1354(09)80037-9
   FRIEDLER F, 1992, CHEM ENG SCI, V47, P1973, DOI 10.1016/0009-2509(92)80315-4
   FRIEDLER F, 1993, COMPUT CHEM ENG, V17, P929, DOI 10.1016/0098-1354(93)80074-W
   Friedler F, 1996, NONCON OPTIM ITS APP, V7, P609
   Furman KC, 2002, IND ENG CHEM RES, V41, P2335, DOI 10.1021/ie010389e
   George N, 2011, EUR J ORG CHEM, V2011, P3695, DOI 10.1002/ejoc.201100426
   Hong XD, 2018, IND ENG CHEM RES, V57, P9323, DOI 10.1021/acs.iecr.8b00978
   Hong XD, 2018, ACS SUSTAIN CHEM ENG, V6, P2704, DOI 10.1021/acssuschemeng.7b04315
   Hong XD, 2017, APPL ENERG, V197, P254, DOI 10.1016/j.apenergy.2017.04.003
   Hong XD, 2016, APPL ENERG, V169, P395, DOI 10.1016/j.apenergy.2016.01.059
   How BS, 2016, J CLEAN PROD, V130, P45, DOI 10.1016/j.jclepro.2015.12.021
   Ibric N, 2016, CLEAN TECHNOL ENVIR, V18, P1779, DOI 10.1007/s10098-016-1152-9
   Ibric N, 2014, J CLEAN PROD, V77, P116, DOI 10.1016/j.jclepro.2014.01.004
   Kamat S, 2018, CHEM ENG RES DES, V70, P307
   Kamat S, 2019, IND ENG CHEM RES, V58, P1310, DOI 10.1021/acs.iecr.8b04703
   Klemes JJ, 2015, CHEM ENGINEER TRANS, V45, P1333, DOI 10.3303/CET1545223
   Lam HL, 2013, IND ENG CHEM RES, V52, P172, DOI 10.1021/ie301184e
   Lam HL, 2010, COMPUT CHEM ENG, V34, P782, DOI 10.1016/j.compchemeng.2009.11.020
   Leewongtanawit B, 2008, CHEM ENG PROCESS, V47, P670, DOI 10.1016/j.cep.2006.12.018
   Leewongtanawit B, 2009, ENERGY, V34, P880, DOI 10.1016/j.energy.2009.03.004
   Liao ZW, 2016, AICHE J, V62, P670, DOI 10.1002/aic.15049
   Liao ZW, 2011, IND ENG CHEM RES, V50, P6713, DOI 10.1021/ie1016392
   Lim C. H., 2017, PROCESS INTEGRAT OPT, V1, P225
   Lim C. H., 2017, PROCESS INTEGRAT OPT, V1, P69
   Linnhoff B, 1982, USER GUIDE PROCESS I
   Luo YQ, 2014, COMPUT CHEM ENG, V61, P1, DOI 10.1016/j.compchemeng.2013.10.008
   Mesbah H, 2015, AM J ENERGY SCI, V2, P28
   PAPOULIAS SA, 1983, COMPUT CHEM ENG, V7, P707, DOI 10.1016/0098-1354(83)85023-6
   Savulescu L, 2005, CHEM ENG SCI, V60, P3279, DOI 10.1016/j.ces.2004.12.037
   Savulescu L, 2005, CHEM ENG SCI, V60, P3291, DOI 10.1016/j.ces.2004.12.036
   Savulescu L, 1998, AICHE ANN M
   Savulescu LE, 2002, APPL THERM ENG, V22, P981, DOI 10.1016/S1359-4311(02)00015-7
   Shen R, 2017, CHEM ENG T, V61, P571
   Shen R, 2018, PROCESS INTEGR OPTIM
   Sorin M, 1999, PROCESS SAF ENVIRON, V77, P305, DOI 10.1205/095758299530189
   Tan R. R., 2018, CHEM ENG T, V70, P91, DOI DOI 10.3303/CETI
   Varbanov P, 2008, APPL THERM ENG, V28, P2020, DOI 10.1016/j.applthermaleng.2008.02.007
   YEE TF, 1990, COMPUT CHEM ENG, V14, P1165, DOI 10.1016/0098-1354(90)85010-8
   Zhao HP, 2019, J CLEAN PROD, V211, P530, DOI 10.1016/j.jclepro.2018.11.210
   Zhou L, 2015, IND ENG CHEM RES, V54, P3355, DOI 10.1021/ie501960e
NR 55
TC 3
Z9 3
U1 1
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 687
EP 713
DI 10.1016/j.resconrec.2019.05.007
PG 27
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300063
DA 2020-05-12
ER

PT J
AU Li, FY
   Ou, R
   Xiao, XL
   Zhou, KL
   Xie, W
   Ma, DW
   Liu, KP
   Song, Z
AF Li, Fangyi
   Ou, Rui
   Xiao, Xilin
   Zhou, Kaile
   Xie, Wu
   Ma, Dawei
   Liu, Kunpeng
   Song, Zhuo
TI Regional comparison of electric vehicle adoption and emission reduction
   effects in China
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Electric vehicles; Air pollutants emissions; Well-to-wheel; Power
   structure; Regional differences
ID LIFE-CYCLE ASSESSMENT; GREENHOUSE-GAS EMISSIONS; TO-WHEELS ENERGY;
   PLUG-IN HYBRID; CO2 EMISSIONS; ENVIRONMENTAL ASSESSMENT; CONVENTIONAL
   VEHICLES; POLLUTANT EMISSIONS; AIR EMISSIONS; CONSUMPTION
AB There is a dispute regarding the environmental benefits of electric vehicle (EV) adoption in China because the power used by EVs is generated primarily by burning coal, which produces air pollutants, such as sulfur dioxide (SO2) and nitrogen oxides (NOx). However, it is difficult to resolve the dispute because its resolution varies across different provinces. In this study, the emission reduction effects of EV adoption are assessed by province to provide suggestions to provincial governments. A well-to-wheel model is employed to reveal the current situation of SO2 and NOx emissions reduction by using passenger EVs instead of internal combustion engine vehicles (ICEVs), and the marginal effects of adopting EVs are compared to demonstrate regional heterogeneity. The results showed that in 2017, the adoption of EVs in all regions can reduce NOx emission, but only in the region south of the Yangtze River can it reduce SO2 emission. SO2 emissions are even promoted by adopting EVs in some northern provinces, such as Shandong, Shanxi and Hebei. The marginal environmental effects revealed that the future potential for emission reduction is mainly from southern provinces, including Sichuan, Guangdong, Hubei and Yunnan, due to their large market potential and availability of clean power. Finally, provinces are classified into five types, and individual suggestions are proposed to improve emission reduction in different provinces.
C1 [Li, Fangyi; Ou, Rui; Xiao, Xilin; Zhou, Kaile; Xie, Wu] Hefei Univ Technol, Sch Management, Hefei 230009, Anhui, Peoples R China.
   [Li, Fangyi; Ou, Rui; Xiao, Xilin; Zhou, Kaile; Xie, Wu] Hefei Univ Technol, Minist Educ, Key Lab Proc Optimizat & Intelligent Decis Making, Hefei 230009, Anhui, Peoples R China.
   [Ma, Dawei] State Grid Anhui Elect Power Corp Res Inst, Hefei 230601, Anhui, Peoples R China.
   [Liu, Kunpeng] State Grid Anhui Elect Power Corp, Hefei 230061, Anhui, Peoples R China.
   [Song, Zhuo] State Grid Corp China, Beijing 10031, Peoples R China.
RP Li, FY (reprint author), Hefei Univ Technol, Sch Management, Hefei 230009, Anhui, Peoples R China.
EM fly-ustc@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [41401126]
FX This work is supported by the National Natural Science Foundation of
   China (41401126).
CR Alvarez R, 2015, ENERGY, V82, P996, DOI 10.1016/j.energy.2015.01.110
   Archsmith J, 2015, RES TRANSP ECON, V52, P72, DOI 10.1016/j.retrec.2015.10.007
   Bickert S, 2015, TRANSPORT RES D-TR E, V36, P138, DOI 10.1016/j.trd.2015.02.004
   China Electricity Council (CEC), 2017, NAT POW IND STAT EXP
   Clover D. G., 2013, MARKET ELECT VEHICLE
   de Souza LL, 2018, J CLEAN PROD, V203, P444, DOI 10.1016/j.jclepro.2018.08.236
   Dhar S, 2017, J CLEAN PROD, V146, P139, DOI 10.1016/j.jclepro.2016.05.111
   Ding N, 2017, RESOUR CONSERV RECY, V119, P47, DOI 10.1016/j.resconrec.2016.07.010
   Ding Ning, 2015, China Environmental Science, V35, P1592
   Franzo S., 2017, P 2017 12 INT C EC V, P1
   Fuchs D.I.S., 2014, ATZ WORLDWIDE, V116, P54
   Gebrehiwot M., 2015, IEEE AFRICON 2015
   General Office of State Council of China (GOSC), 2016, 13 5 YEAR PLAN EC PR
   General Office of State Council of China (GOSC), 2013, ACT PLAN AIR POLL CO
   Gopal AR, 2018, TRANSPORT RES D-TR E, V62, P362, DOI 10.1016/j.trd.2018.03.014
   Gulbe M, 2014, PROCD SOC BEHV, V109, P935, DOI 10.1016/j.sbspro.2013.12.567
   Hao H, 2017, TRANSPORT RES D-TR E, V56, P68, DOI 10.1016/j.trd.2017.07.025
   Hao H, 2017, RESOUR CONSERV RECY, V122, P114, DOI 10.1016/j.resconrec.2017.02.005
   Hawkins TR, 2013, J IND ECOL, V17, P53, DOI 10.1111/j.1530-9290.2012.00532.x
   Hawkins TR, 2012, INT J LIFE CYCLE ASS, V17, P997, DOI 10.1007/s11367-012-0440-9
   Hill J, 2009, P NATL ACAD SCI USA, V106, P2077, DOI 10.1073/pnas.0812835106
   Hofmann J, 2016, APPL ENERG, V184, P995, DOI 10.1016/j.apenergy.2016.06.042
   Hu ZY, 2004, APPL ENERG, V78, P247, DOI 10.1016/j.apenergy.2003.09.003
   Huo H, 2013, ENVIRON SCI TECHNOL, V47, P1711, DOI 10.1021/es303352x
   Huo H, 2009, ATMOS ENVIRON, V43, P1796, DOI 10.1016/j.atmosenv.2008.12.025
   IEA, 2018, GLOB EV OUTL
   Jochem P, 2016, TRANSPORT RES D-TR E, V42, P60, DOI 10.1016/j.trd.2015.09.022
   Jochem P, 2015, TRANSPORT RES A-POL, V78, P68, DOI 10.1016/j.tra.2015.05.007
   Ke WW, 2017, APPL ENERG, V188, P367, DOI 10.1016/j.apenergy.2016.12.011
   Lave L, 2000, ENVIRON SCI TECHNOL, V34, P3598, DOI 10.1021/es991322+
   Lewis AM, 2014, APPL ENERG, V126, P13, DOI 10.1016/j.apenergy.2014.03.023
   Li FY, 2018, J CLEAN PROD, V183, P56, DOI 10.1016/j.jclepro.2018.01.190
   Li ZJ, 2012, PROCEDIA ENVIRON SCI, V13, P550, DOI 10.1016/j.proenv.2012.01.045
   Lin Gao, 2012, ENERGIES, V5, P605
   Ma HR, 2012, ENERG POLICY, V44, P160, DOI 10.1016/j.enpol.2012.01.034
   Ma Y, 2017, J CLEAN PROD, V145, P395, DOI 10.1016/j.jclepro.2016.12.131
   Marshall BM, 2013, ENERG POLICY, V58, P358, DOI 10.1016/j.enpol.2013.03.037
   Michalek JJ, 2011, P NATL ACAD SCI USA, V108, P16554, DOI 10.1073/pnas.1104473108
   Ministry of Ecology and Environment of China (MEEC), 2013, LIM MEAS METH EM LIG
   Falcao EAM, 2017, APPL ENERG, V193, P297, DOI 10.1016/j.apenergy.2017.02.050
   Moro A, 2017, INT J LIFE CYCLE ASS, V22, P4, DOI 10.1007/s11367-015-0954-z
   Nanaki EA, 2013, J CLEAN PROD, V53, P261, DOI 10.1016/j.jclepro.2013.04.010
   National Bureau of Statistics of China (NBS), 2018, STAT B CHIN 2017 NAT
   National Ministry of Industry and Information Technology of China (NMIITC), 2016, TECHN ROADM EN CONS
   National Ministry of Public Security of China (NMPSC), 2018, AM VEH DRIV MAINT HI
   National Ministry of Public Security of China (NMPSC), 2019, AM SMALL VEH REACH 2
   NDRC (National Development and Reform Committee), 2016, 13 5 YEAR PLAN REN E
   Orsi F, 2016, APPL ENERG, V169, P197, DOI 10.1016/j.apenergy.2016.02.039
   [强明明 Qiang Mingming], 2016, [环境工程, Environment Engineering], V34, P166
   Qiao QY, 2017, APPL ENERG, V204, P1399, DOI 10.1016/j.apenergy.2017.05.041
   Qu S, 2017, APPL ENERG, V200, P249, DOI 10.1016/j.apenergy.2017.05.046
   Safari M, 2018, ENERG POLICY, V115, P54, DOI 10.1016/j.enpol.2017.12.053
   [沈万霞 Shen Wanxia], 2017, [环境科学学报, Acta Scientiae Circumstantiae], V37, P4409
   State Council of China (SCC), 2012, DEV PLAN EN CONS NEW
   Sun Y., 2017, DATA NEW ENERGY VEHI
   Tagliaferri C, 2016, CHEM ENG RES DES, V112, P298, DOI 10.1016/j.cherd.2016.07.003
   Tan RR, 2004, ENVIRON MODELL SOFTW, V19, P907, DOI 10.1016/j.envsoft.2003.10.004
   Tessum CW, 2014, P NATL ACAD SCI USA, V111, P18490, DOI 10.1073/pnas.1406853111
   Tong D., 2018, ENV SCI TECHNOL
   Van Mierlo J, 2017, TRANSP RES PROC, V25, P3439, DOI 10.1016/j.trpro.2017.05.244
   Wang M, 2002, J POWER SOURCES, V112, P307, DOI 10.1016/S0378-7753(02)00447-0
   Woo JR, 2017, TRANSPORT RES D-TR E, V51, P340, DOI 10.1016/j.trd.2017.01.005
   Wu G, 2015, ENERG POLICY, V80, P196, DOI 10.1016/j.enpol.2015.02.004
   Wu M, 2006, BIOTECHNOL PROGR, V22, P1012, DOI 10.1021/bp050371p
   Wu Y, 2017, TRANSPORT RES D-TR E, V51, P129, DOI 10.1016/j.trd.2016.12.007
   Wu Y, 2012, ENERG POLICY, V48, P537, DOI 10.1016/j.enpol.2012.05.060
   Wu ZX, 2018, J CLEAN PROD, V190, P462, DOI 10.1016/j.jclepro.2018.04.036
   Yuan XM, 2015, APPL ENERG, V157, P75, DOI 10.1016/j.apenergy.2015.08.001
   Zhang YP, 2017, J CLEAN PROD, V162, P71, DOI 10.1016/j.jclepro.2017.06.024
   Zhao Z., 2017, ADV ENERGY SYSTEMS E
NR 70
TC 3
Z9 3
U1 16
U2 39
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 714
EP 726
DI 10.1016/j.resconrec.2019.01.038
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300064
DA 2020-05-12
ER

PT J
AU Aydin, R
   Badurdeen, F
AF Aydin, Ridvan
   Badurdeen, Fazleena
TI Sustainable product line design considering a multi-lifecycle approach
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Product line design; Sustainability; Multiple lifecycles; Reuse;
   Remanufacturing
ID MODEL; CONFIGURATION; DECISION; PRICE; OPTIMIZATION; METHODOLOGY;
   UNCERTAINTY; NEWSVENDOR; DEMAND
AB Global awareness on product lifecycle issues and competitive advantages of implementing end-of-life (EoL) recovery strategies (i.e., reuse, remanufacturing, and recycling) have driven companies to develop more sustainable product designs. Designing a product line involves developing variants of a product to address needs of different market segments. Sharing of same types of components between variants when feasible can lead to lower product cost and improved manufacturing efficiency. Prior research has considered many aspects related to sustainable product line design. However, none of them have comprehensively addressed the consideration of multi-lifecycle, closed-loop material flow for sustainable product line design; studies that incorporate pricing decisions while simultaneously considering economic and environmental objectives are also lacking. In this study, a novel approach for sustainable product line design considering the multiple lifecycle approach and EoL recovery strategies is proposed. An optimization model with economic and environmental performance objectives is developed to determine the designs and selling prices of new and hybrid products. Dynamic demand models based on the diffusion function of time and price are developed to incorporate the price-sensitivity of demand multiple lifecycles. The application of the approach is demonstrated using an industrial case study to identify the sustainable product line design of toner cartridges. The Pareto optimal solutions obtained show that the proposed methodology can identify more sustainable product line designs. The new designs have much higher total lifecycle profit, energy use, and water use compared to baseline designs that do not follow a closed-loop, multi-lifecycle flow.
C1 [Aydin, Ridvan] Amer Univ Middle East, Coll Engn & Technol, Kuwait, Kuwait.
   [Badurdeen, Fazleena] Inst Sustainable Mfg, Lexington, KY 40506 USA.
   [Badurdeen, Fazleena] Univ Kentucky, Dept Mech Engn, Lexington, KY 40506 USA.
RP Aydin, R (reprint author), Amer Univ Middle East, Coll Engn & Technol, Kuwait, Kuwait.
EM ray223@uky.edu
FU Digital Manufacturing and Design Innovation Institute (DMDII) [15-05-08]
FX This work was supported by the Digital Manufacturing and Design
   Innovation Institute (DMDII) [grant number 15-05-08]. The authors would
   also like to acknowledge the support of industry partner for providing
   access to data and for their continuous support throughout the project.
CR Ahmad S, 2018, RESOUR CONSERV RECY, V132, P49, DOI 10.1016/j.resconrec.2018.01.020
   Ameli M, 2019, RESOUR CONSERV RECY, V140, P246, DOI 10.1016/j.resconrec.2018.02.031
   Ameli M, 2016, RESOUR CONSERV RECY, V109, P123, DOI 10.1016/j.resconrec.2016.01.011
   Aydin R, 2016, J CLEAN PROD, V114, P286, DOI 10.1016/j.jclepro.2015.05.116
   Aydin R, 2015, INT J PROD ECON, V169, P127, DOI 10.1016/j.ijpe.2015.07.022
   Aydin R, 2018, J MANUF SYST, V48, P3, DOI 10.1016/j.jmsy.2018.04.009
   Badurdeen F, 2018, J CLEAN PROD, V200, P756, DOI 10.1016/j.jclepro.2018.07.317
   BASS FM, 1969, MANAGE SCI, V15, P215, DOI 10.1287/mnsc.15.5.215
   Chang DN, 2014, J CLEAN PROD, V83, P48, DOI 10.1016/j.jclepro.2014.07.050
   Chang XY, 2015, INT J PROD ECON, V162, P160, DOI 10.1016/j.ijpe.2015.01.020
   Chen JM, 2013, INT J PROD ECON, V146, P153, DOI 10.1016/j.ijpe.2013.06.017
   Cui L, 2017, J CLEAN PROD, V161, P1308, DOI 10.1016/j.jclepro.2017.03.056
   Deb K, 2002, IEEE T EVOLUT COMPUT, V6, P182, DOI 10.1109/4235.996017
   Ghayebloo S, 2015, J MANUF SYST, V36, P76, DOI 10.1016/j.jmsy.2015.02.011
   Go TF, 2015, J CLEAN PROD, V95, P16, DOI 10.1016/j.jclepro.2015.02.065
   He B, 2019, J CLEAN PROD, V206, P238, DOI 10.1016/j.jclepro.2018.09.097
   Hu GP, 2009, INT J PROD ECON, V122, P366, DOI 10.1016/j.ijpe.2009.06.011
   JAIN DC, 1990, J BUS ECON STAT, V8, P163, DOI 10.2307/1391978
   Jawahir IS, 2016, PROC CIRP, V40, P103, DOI 10.1016/j.procir.2016.01.067
   Jawahir I.S., 2006, 10 INT RES EXP C BAR
   Jayal AD, 2010, CIRP J MANUF SCI TEC, V2, P144, DOI 10.1016/j.cirpj.2010.03.006
   Kalverkamp M, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9091540
   Kim S, 2017, J ENG DESIGN, V28, P731, DOI 10.1080/09544828.2017.1393657
   Kim S, 2017, J CLEAN PROD, V143, P567, DOI 10.1016/j.jclepro.2016.12.073
   Kocabiyikoglu A, 2011, OPER RES, V59, P301, DOI 10.1287/opre.1100.0890
   Kwak M, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10114283
   Kwak M, 2015, ENG OPTIMIZ, V47, P18, DOI 10.1080/0305215X.2013.868450
   Kwak M, 2011, ENG OPTIMIZ, V43, P233, DOI 10.1080/0305215X.2010.482990
   Ma J, 2016, INT J PRECIS ENG MAN, V17, P1229, DOI 10.1007/s12541-016-0148-z
   Ma J, 2014, J CLEAN PROD, V68, P189, DOI 10.1016/j.jclepro.2014.01.026
   MAHAJAN V, 1990, J MARKETING, V54, P1, DOI 10.2307/1252170
   Mangun D, 2002, IEEE T ENG MANAGE, V49, P479, DOI 10.1109/TEM.2002.807292
   O'Reilly CJ, 2016, J CLEAN PROD, V135, P750, DOI 10.1016/j.jclepro.2016.06.163
   Petruzzi NC, 1999, OPER RES, V47, P183, DOI 10.1287/opre.47.2.183
   ROBINSON B, 1975, MANAGE SCI B-APPL, V21, P1113, DOI 10.1287/mnsc.21.10.1113
   Romli A, 2015, INT J PROD RES, V53, P549, DOI 10.1080/00207543.2014.958593
   San Gan S, 2015, OPER RES PERSPECT, V2, P1, DOI 10.1016/j.orp.2014.11.001
   Schmitdein D.C., 1982, MARK SCI, V1, P57, DOI DOI 10.1287/mksc.1.1.57
   Srinivasan V., 1986, MARKET SCI, V5, P169, DOI DOI 10.1287/MKSC.5.2.169
   Wang Q, 2016, ROBOT CIM-INT MANUF, V41, P53, DOI 10.1016/j.rcim.2016.02.001
   Wu ZQ, 2016, INT J PROD RES, V54, P4689, DOI 10.1080/00207543.2015.1109154
   Zeballos LJ, 2014, COMPUT CHEM ENG, V66, P151, DOI 10.1016/j.compchemeng.2014.02.027
NR 42
TC 1
Z9 1
U1 11
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 727
EP 737
DI 10.1016/j.resconrec.2019.06.014
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300065
DA 2020-05-12
ER

PT J
AU Cao, WD
   Wang, AT
   Yu, DS
   Liu, ST
   Hou, W
AF Cao, Weidong
   Wang, Aitao
   Yu, Deshui
   Liu, Shutang
   Hou, Wei
TI Establishment and implementation of an asphalt pavement recycling
   decision system based on the analytic hierarchy process
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Asphalt pavement recycling; Recycling methods; Reclaimed asphalt
   pavement (RAP); Analytic hierarchy process (AHP); Economic evaluation;
   Decision system
ID MAINTENANCE; OPTIMIZATION; TREE
AB Asphalt pavement recycling technology is widely used in China and other countries due to its economic and environmental benefits. Pavement recycling methods can generally be divided into central plant hot recycling, hot in-place recycling, central plant cold recycling, and cold in-place recycling. However, no quantitative evaluation method and calculation program for selecting an optimal recycling method are available for existing asphalt pavements. In this study, a quantitative evaluation approach for recycling method selection was proposed in consideration of pavement performance and construction cost. An asphalt pavement recycling decision system was established, and a corresponding calculation program was developed based on the. Net platform. Case study showed that the asphalt pavement recycling decision system developed based on the analytic hierarchy process in this study is feasible and reasonable. The system can help pavement managers make efficient maintenance decisions in practical projects.
C1 [Cao, Weidong; Yu, Deshui; Liu, Shutang] Shandong Univ, Sch Qilu Transportat, Jinan 250002, Shandong, Peoples R China.
   [Wang, Aitao; Hou, Wei] Shandong Binlai Expressway Co Ltd, Jinan 250101, Shandong, Peoples R China.
RP Cao, WD; Liu, ST (reprint author), Shandong Univ, Sch Qilu Transportat, Jinan 250002, Shandong, Peoples R China.
EM cwd2001@sdu.edu.cn; gtreesl@sdu.edu.cn
FU Transportation Science and Technology Foundation of Qilu Transportation
   Development Group [2016B20]
FX This work was supported by Transportation Science and Technology
   Foundation of Qilu Transportation Development Group (No. 2016B20), and
   the authors would like to acknowledge their financial support.
CR Abo-Hashema MA, 2009, INT J PAVEMENT ENG, V10, P173, DOI 10.1080/10298430802169457
   Akhlaghi E, 2012, SMART INNOV SYST TEC, V15, P471
   Alkins AE, 2008, TRANSPORT RES REC, P100, DOI 10.3141/2084-11
   ARRA (Asphalt Recycling and Reclaiming Association, 1992, AN OVERVIEW OF RECYC
   Chen CT, 2015, J MAR SCI TECH-TAIW, V23, P302, DOI 10.6119/JMST-014-0327-5
   Chesner W. H., 1998, HIGHWAY
   Cross SA, 2011, TRANSPORT RES REC, P43, DOI 10.3141/2227-05
   Daniel R, 2018, THE ANALYTIC HIERARC
   de la Garza JM, 2011, ADV ENG INFORM, V25, P699, DOI 10.1016/j.aei.2011.08.002
   France-Mensah J, 2018, J MANAGE ENG, V34, DOI 10.1061/(ASCE)ME.1943-5479.0000599
   Gao SP, 2013, APPL MECH MATER, V405-408, P1820, DOI 10.4028/www.scientific.net/AMM.405-408.1820
   Govindan K, 2014, INT J PROD ECON, V147, P555, DOI 10.1016/j.ijpe.2013.08.018
   Hajek D. J., 2004, 2004 ANNUAL CONFEREN
   Harputlugil T., 2011, MANAGE INNOVATION
   HTTP, DG
   Lin X., 2010, THESIS
   Lin X, 2010, TECHNICAL GUIDELINES
   Liu X., 2013, THESIS
   Mangla SK, 2015, RESOUR CONSERV RECY, V104, P375, DOI 10.1016/j.resconrec.2015.01.001
   MARZOUK M, 2012, BALT J ROAD BRIDGE E, V7, P4, DOI DOI 10.1016/J.JCLEPRO.2015.04.110
   Mathiyazhagan K, 2015, J CLEAN PROD, V107, P229, DOI 10.1016/j.jclepro.2015.04.110
   *MOT, 2017, SPECIFICATIONS FOR D, DOI DOI 10.1016/J.RESCONREC.2015.01.001
   MOT (Ministry of Transport of the People's Republic of China, 2008, CONSTRUCTION MACHINE
   MOT (Ministry of Transport of the People's Republic of China, 2007, HIGHWAY PERFORMANCE
   MOT (Ministry of Transport of the People's Republic of China, 2017, TECHNICAL SPECIFICAT
   MOT (Ministry of Transport of the People's Republic of China, 2007, HIGHWAY ENGINEERING
   SAATY TL, 1988, BERLIN, DOI DOI 10.1080/15732479.2014.945095
   Santos J, 2015, STRUCT INFRASTRUCT E, V11, P1199, DOI 10.1080/15732479.2014.945095
   SULLIVAN J, 1996, PAVEMENT RECYCLING E
   Tack JN, 2002, TRANSPORT RES REC, P3, DOI 10.3141/1816-01
   [谭练武 Tan Lianwu], 2011, [安全与环境学报, Journal of Safety and Environment], V11, P126
   Wang F, 2003, TRANSPORT RES REC, P21
   Yepes V, 2016, J CIV ENG MANAG, V22, P540, DOI 10.3846/13923730.2015.1120770
   Yu B, 2015, TRANSPORT RES D-TR E, V41, P64, DOI 10.1016/j.trd.2015.09.016
   ZHANG X, 2012, THESIS, DOI DOI 10.1016/J.TRC.2011.10.007
   Zhang X, 2012, THESIS
   Zhou GQ, 2012, TRANSPORT RES C-EMER, V21, P287, DOI 10.1016/j.trc.2011.10.007
NR 37
TC 0
Z9 0
U1 9
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 738
EP 749
DI 10.1016/j.resconrec.2019.06.028
PG 12
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300066
DA 2020-05-12
ER

PT J
AU Farinha, CB
   de Brito, J
   Veiga, R
AF Farinha, Catarina Brazao
   de Brito, Jorge
   Veiga, Rosario
TI Influence of forest biomass bottom ashes on the fresh, water and
   mechanical behaviour of cement-based mortars
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Biomass ash; Mortar; Render; Eco-mortar; Industrial waste; Reuse;
   Sustainability
ID FLY-ASH; WASTE; REPLACEMENT; PERFORMANCE; SYSTEMS
AB Renewable energies' production is increasing globally over the years. Biomass is considered a renewable source of energy that can be produced by organic matter. The biomass energy production, although generating low CO2 emissions, creates wastes during the production process, namely ashes. The increase of renewable energies' production and the consequent biomass energy production is also responsible for a higher production of these ashes. Most of these ashes are sent to landfills. This should be avoided since it is responsible for several soil, air and human environmental impacts. The fine ashes particles can lead to respiratory human health problems, as well as contaminate the soils, ground water and the air. Therefore, it is necessary to find new applications for these ashes in order to reduce their deposition in landfills.
   In this research, an eco-solution is presented to reduce the cement content of the mortars and, at the same time, the biomass deposited in landfill by their incorporation in renders, replacing cement at 5%, 10% and 15%, by volume. The use of biomass ashes in cement-based mortars was investigated through their fresh, water and mechanical behaviour.
   It was possible to conclude that cement can be replaced up to 15% by a forest biomass ash waste in render applications, without compromising the global behaviour. The incorporation of the waste led to similar fresh and water behaviour to that of a reference mortar, better deformability and slightly lower mechanical strengths, which did not affect the scope of the mortars application, according to EN 998-1.
C1 [Farinha, Catarina Brazao; de Brito, Jorge] Univ Lisbon, Inst Super Tecn, CERIS, Av Rovisco Pais 1, P-1049001 Lisbon, Portugal.
   [Farinha, Catarina Brazao; Veiga, Rosario] Natl Lab Civil Engn, Av Brasil 101, P-1700066 Lisbon, Portugal.
RP Farinha, CB (reprint author), Univ Lisbon, Inst Super Tecn, CERIS, Av Rovisco Pais 1, P-1049001 Lisbon, Portugal.
EM catarina.brazao.farinha@ist.utl.pt; jb@civil.ist.utl.pt; rveiga@lnec.pt
RI de Brito, Jorge/A-4299-2008
OI de Brito, Jorge/0000-0001-6766-2736; Correia de Araujo Brazao Farinha,
   Catarina/0000-0002-9889-8503
FU REuSE project from National Laboratory for Civil Engineering of Portugal
   (LNEC); research unit CERIS from Instituto Superior Tecnico (IST),
   University of Lisbon; Portuguese Foundation for Science and
   TechnologyPortuguese Foundation for Science and Technology
   [PD/BD/113639/2015]
FX The authors would like to acknowledge the support of the REuSE project
   from National Laboratory for Civil Engineering of Portugal (LNEC) and
   the research unit CERIS from Instituto Superior Tecnico (IST),
   University of Lisbon. The authors would also like to acknowledge the
   support of the Portuguese Foundation for Science and Technology for the
   financial support of this research (PD/BD/113639/2015).
CR [Anonymous], 2013, 16322 EN
   [Anonymous], 1999, 10152 EN
   [Anonymous], 1999, 101511 EN
   [Anonymous], 1999, 10158 PREN
   [Anonymous], 1998, 10156 EN
   [Anonymous], 2004, 14146 EN
   [Anonymous], 2000, 101512 EN
   [Anonymous], 2010, 9981 EN
   [Anonymous], 2002, 101518 EN
   [Anonymous], 2010, 43 FE PA LNEC
   Ban CC, 2011, RESOUR CONSERV RECY, V55, P669, DOI 10.1016/j.resconrec.2011.02.002
   Barbosa R, 2013, CONSTR BUILD MATER, V48, P457, DOI 10.1016/j.conbuildmat.2013.07.031
   Coutinho de S., 1988, MANUFACTURE PROPERTI, VI
   Cuenca J, 2013, CONSTR BUILD MATER, V40, P702, DOI 10.1016/j.conbuildmat.2012.09.101
   Demirbas A, 2005, PROG ENERG COMBUST, V31, P171, DOI 10.1016/j.pecs.2005.02.002
   Demis S, 2014, CONSTR BUILD MATER, V68, P291, DOI 10.1016/j.conbuildmat.2014.06.071
   Elinwa AU, 2002, CEMENT CONCRETE COMP, V24, P219, DOI 10.1016/S0958-9465(01)00039-7
   EN (European Standards), 2004, 125044 EN
   European Cement Research Academy (ECRA), 2015, ENV PROD DECL REP PO
   Farinha C. B, 2018, J CLEAN PROD, V210
   Farinha CB, 2018, MATERIALS, V11, DOI 10.3390/ma11030453
   Garcia MD, 2013, CONSTR BUILD MATER, V41, P897, DOI 10.1016/j.conbuildmat.2012.11.081
   Gonzalez-Kunz RN, 2017, SUSTAIN CITIES SOC, V31, P151, DOI 10.1016/j.scs.2017.03.001
   Martinez-Lage I, 2016, J ENVIRON MANAGE, V181, P863, DOI 10.1016/j.jenvman.2016.06.052
   Modolo RCE, 2013, CONSTR BUILD MATER, V45, P275, DOI 10.1016/j.conbuildmat.2013.03.093
   Nunes LJR, 2016, RENEW SUST ENERG REV, V53, P235, DOI 10.1016/j.rser.2015.08.053
   Portuguese National Statistics Institute (INE), 2018, CONTR REN EN FIN CON
   Rajamma R, 2015, COMPOS PART B-ENG, V77, P1, DOI 10.1016/j.compositesb.2015.03.019
   Rajamma R, 2009, J HAZARD MATER, V172, P1049, DOI 10.1016/j.jhazmat.2009.07.109
   Raut AN, 2016, CONSTR BUILD MATER, V126, P476, DOI 10.1016/j.conbuildmat.2016.09.034
   Romero E, 2017, FUEL, V208, P1, DOI 10.1016/j.fuel.2017.06.133
   Rosales J, 2017, J CLEAN PROD, V154, P424, DOI 10.1016/j.jclepro.2017.04.024
   Sata V, 2012, CEMENT CONCRETE COMP, V34, P94, DOI 10.1016/j.cemconcomp.2011.09.003
   Sigvardsen NM, 2019, CEMENT CONCRETE COMP, V95, P25, DOI 10.1016/j.cemconcomp.2018.10.005
   Tosti L, 2018, RESOUR CONSERV RECY, V134, P25, DOI 10.1016/j.resconrec.2018.03.004
   van der Sloot HA, 2000, CEMENT CONCRETE RES, V30, P1079, DOI 10.1016/S0008-8846(00)00287-8
   Veiga MR, 2007, MATER STRUCT, V40, P1115, DOI 10.1617/s11527-006-9209-6
   Veiga R, 2005, 42705NRI LNEC
NR 38
TC 0
Z9 0
U1 2
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 750
EP 759
DI 10.1016/j.resconrec.2019.06.020
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300067
DA 2020-05-12
ER

PT J
AU Roman, A
   de Jalon, DG
   Alonso, C
AF Roman, Alfonso
   Garcia de Jalon, Diego
   Alonso, Carlos
TI Could future electric vehicle energy storage be used for hydropeaking
   mitigation? An eight-country viability analysis
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Water policy; hydropower; river ecology; renewable energy; PEV; V2G
ID RENEWABLE ENERGY; POWER-SYSTEMS; HYDROPOWER; HYBRID; IMPACT; BATTERY;
   TECHNOLOGIES; MANAGEMENT; REQUIREMENTS; INTEGRATION
AB Hydropower short-term response capability and operating flexibility are critical in some electricity systems, especially during peak demand periods. However, operational variability at hydro plants may originate relevant water flow fluctuations (i.e., hydropeaking) that cause severe alterations in stream ecosystem functionality. Such harmful consequences could be reduced if other energy storage were available.
   The increasing use of electric vehicles (EVs) has presented the application of their batteries for energy grid scale accumulation purposes. EV interaction with the grid and other renewable energy (RE) sources (primarily wind and solar) has been broadly studied. It seems, however, that EV energy storage allocation to mitigate hydropeaking impacts at regional or national scale remains unexplored. This article evaluates the possibility of using EV batteries to provide the system with additional storage capacity to support a more balanced hydropower operation.
   The analysis is performed for eight countries with diverse socioeconomic and technological environments. Initially, the coherency in the orders of magnitude between hydropower generation and energy storage capacity is evaluated by calculating the accumulation potential of the current passenger car pare in a hypothetical scenario in which the complete fleet is electrified and suited for vehicle-to-grid (V2G) interaction. After validating the feasibility of the proposal, a long-term analysis is performed using diverse energy, EV rates, and battery capacity forecasts gathered from reliable sources. The results indicate that a 50% PEV fleet using 300 Wh/kg batteries may provide stable storage capacity for average daily hydropower 2050 projections in China, Germany, Japan, Spain and the United States.
C1 [Roman, Alfonso; Garcia de Jalon, Diego; Alonso, Carlos] Tech Univ Madrid UPM, Dept Nat Syst & Resources, Ciudad Univ SN, Madrid 28040, Spain.
   [Roman, Alfonso] Tech Univ Madrid UPM, Transport Res Ctr TRANSyT, Ciudad Univ SN, Madrid 28040, Spain.
RP Roman, A (reprint author), Tech Univ Madrid UPM, Dept Nat Syst & Resources, Ciudad Univ SN, Madrid 28040, Spain.
EM alfonso.roman@upm.es; diego.gjalon@upm.es; carlos.alonso@upm.es
RI Roman, Alfonso/AAC-9378-2020; Alonso, Carlos/B-1253-2010
OI Alonso, Carlos/0000-0002-2395-4259; Roman, Alfonso/0000-0001-5210-3333
CR ALISE, 2017, EUROPEAN UNION HORIZ
   Bayindir KC, 2011, ENERG CONVERS MANAGE, V52, P1305, DOI 10.1016/j.enconman.2010.09.028
   BBC, 2017, BBC NEWS
   Bejarano MD, 2017, J HYDROL, V550, P186, DOI 10.1016/j.jhydrol.2017.04.023
   Belver M., 2016, EL MUNDO, V4
   Bieri M., 2016, HYDRO 2016
   Bishop JDK, 2013, APPL ENERG, V111, P206, DOI 10.1016/j.apenergy.2013.04.094
   Borba BSMC, 2012, ENERGY, V37, P469, DOI 10.1016/j.energy.2011.11.008
   Bradley TH, 2010, J POWER SOURCES, V195, P5399, DOI 10.1016/j.jpowsour.2010.02.082
   California Air Resources Board (CARB, 2018, 2018 ANNUAL EVALUATI
   Chalk SG, 2006, J POWER SOURCES, V159, P73, DOI 10.1016/j.jpowsour.2006.04.058
   Chan CC, 2007, P IEEE, V95, P704, DOI 10.1109/JPROC.2007.892489
   Cherif R., 2017, IMF WORKING PAPER WP
   ChinaAutoWeb, 2017, BEST SELLING CHINA M
   Cohen C, 2005, ENERG POLICY, V33, P555, DOI 10.1016/j.enpol.2003.08.021
   Coignard J, 2018, ENVIRON RES LETT, V13, DOI 10.1088/1748-9326/aabe97
   Cooper A., 2017, PLUG IN ELECTRIC VEH
   CUSHMAN R M, 1985, North American Journal of Fisheries Management, V5, P330, DOI 10.1577/1548-8659(1985)5<330:ROEEOR>2.0.CO;2
   DEJALON DG, 1994, REGUL RIVER, V9, P253, DOI 10.1002/rrr.3450090406
   EC European Commission, 2011, CISC VIS NETW IND GL
   Egbue O, 2012, ENERG POLICY, V48, P717, DOI 10.1016/j.enpol.2012.06.009
   Elkington J, 1998, J ENV QUAL MANAGE, V8, P37, DOI DOI 10.1002/TQEM.3310080106
   Empresa de Pesquisa Energdtica (EPE, 2016, NOTE TECNICA DEA 13
   European Automobile Manufacturers' Association (ACEA), 2013, NEW POWERTRAINS WILL
   European Commission (EC), 2016, EU REFERENCE SCENARI
   European Environment Agency (EEA), 2017, ELECTRIC VEHICLES AN
   Faggioli E, 1999, J POWER SOURCES, V84, P261, DOI 10.1016/S0378-7753(99)00326-2
   Forrest KE, 2016, J POWER SOURCES, V336, P63, DOI 10.1016/j.jpowsour.2016.10.048
   Garcia de Jalon S, 2017, 15TH INTERNATIONAL C
   Garfield L., 2018, BUSINESS INSIDER
   Gonder J, 2009, IEEE VEHICLE POWER, P570
   Gordijn J, 2007, ELECTR POW SYST RES, V77, P1178, DOI 10.1016/j.epsr.2006.08.008
   Greimel F, 2018, AQUAT ECOL SER, V8, P91, DOI 10.1007/978-3-319-73250-3_5
   Hadley S. W., 2009, ELECT J, V22, P56, DOI DOI 10.1016/J.TEJ.2009.10.011
   HARBY A, 2004, COST ACTION 626 REPO
   Harding R., 2017, FINANCIAL TIMES
   Harpman DA, 1999, LAND ECON, V75, P390, DOI 10.2307/3147185
   He G, 2017, RESOUR CONSERV RECY, V121, P3, DOI 10.1016/j.resconrec.2016.11.003
   Huo H, 2012, ENERG POLICY, V43, P6, DOI 10.1016/j.enpol.2011.09.019
   Ibusuki S., 2018, NIKKEI ASIAN REV, V6, P2018
   IEA, 2011, TECHNOLOGY ROADMAP E
   IEA, 2018, GLOBAL EV OUTLOOK 20
   Instituto Nacional de Estadistica (INE) Gobiemo de Espana, 2008, KM MEDIOS RECORRIDOS
   International Energy Agency (IEA), 2014, ELECTRIC AND PLUG IN
   International Energy Agency (IEA), 2018, ELECTRICITY GENERATI
   International Energy Agency (IEA), 2018, WORLD ELECTRICITY AN
   International Energy Agency (IEA), 2015, TECHNOLOGY ROADMAP H
   International Energy Agency (IEA), 2018, HYDROPOWER
   International Energy Agency (IEA), 2016, CHINA 13TH HYDROPOWE
   International Energy Agency (IEA), 2017, GLOBAL EV OUTLOOK 20
   Itazaki H., 1999, THE PRIUS THAT SHOOK, P387
   Kasten P., 2016, ASSESSING THE STATUS
   Kato Y, 2016, NAT ENERGY, V1, DOI 10.1038/NENERGY.2016.30
   Kaygusuz K, 2009, ENERG SOURCE PART B, V4, P365, DOI 10.1080/15567240701756889
   Kempton W, 2005, J POWER SOURCES, V144, P280, DOI 10.1016/j.jpowsour.2004.12.022
   Kempton W, 1997, TRANSPORT RES D-TR E, V2, P157, DOI 10.1016/S1361-9209(97)00001-1
   Kirsch D. A., 2000, THE ELECTRIC VEHICLE, P291
   Kiviluoma J, 2011, ENERGY, V36, P1758, DOI 10.1016/j.energy.2010.12.053
   Koch FH, 2002, ENERG POLICY, V30, P1207, DOI 10.1016/S0301-4215(02)00081-2
   Liu Z., 2013, D2 2 EV CHARGING ANA
   Lund H, 2008, ENERG POLICY, V36, P3578, DOI 10.1016/j.enpol.2008.06.007
   Lutsey N., 2015, CISC VIS NETW IND GL
   Matos M., 2010, 7 MED C EXH POW GEN, P126, DOI [DOI 10.1049/CP.2010.0866, 10.1049/cp.2010.0866]
   Ministerio de Agricultura Pesca Alimentacidn y Medio Ambiente (MAPAMA), 2017, INFORME RESUMEN DE S
   Monteiro V., 2011, IEEE 11 INT C EL POW, DOI [10.1109/EPQU.2011, DOI 10.1109/EPQU.2011]
   MOOG O, 1993, REGUL RIVER, V8, P5, DOI 10.1002/rrr.3450080105
   Mwasilu F, 2014, RENEW SUST ENERG REV, V34, P501, DOI 10.1016/j.rser.2014.03.031
   NEWBURY R, 1993, FRESHWATER BIOL, V29, P195, DOI 10.1111/j.1365-2427.1993.tb00757.x
   Olden JD, 2003, RIVER RES APPL, V19, P101, DOI 10.1002/rra.700
   Papadimitratos P, 2009, IEEE COMMUN MAG, V47, P84, DOI 10.1109/MCOM.2009.5307471
   Person E, 2014, ECOHYDROLOGY, V7, P580, DOI 10.1002/eco.1380
   Pham S., 2017, CHINA WANTS TO BAN G
   Poff NL, 2010, FRESHWATER BIOL, V55, P147, DOI 10.1111/j.1365-2427.2009.02204.x
   Poff NL, 1997, BIOSCIENCE, V47, P769, DOI 10.2307/1313099
   Pollet BG, 2012, ELECTROCHIM ACTA, V84, P235, DOI 10.1016/j.electacta.2012.03.172
   Puffer M, 2015, RIVER RES APPL, V31, P1101, DOI 10.1002/rra.2801
   Qian KJ, 2011, IEEE T POWER SYST, V26, P802, DOI 10.1109/TPWRS.2010.2057456
   Quinn C, 2010, J POWER SOURCES, V195, P1500, DOI 10.1016/j.jpowsour.2009.08.075
   Raab A. F., 2011, IEEE 16 INT C INT SY, DOI [10.1109/ISAP.2011.6082214, DOI 10.1109/ISAP.2011.6082214]
   RECHARGE. The European Association for Advanced Rechargeable Batteries, 2013, E MOBILITY ROADMAP F
   Research and Markets, 2018, GLOB HYDR FUEL CELL, P2017
   Reuters, 2016, AIR POLLUTION IN NOR
   Richter BD, 1996, CONSERV BIOL, V10, P1163, DOI 10.1046/j.1523-1739.1996.10041163.x
   Rissman J., 2017, ENERGY POST
   Schmitt B., 2017, FORBES
   Schmutz S, 2015, RIVER RES APPL, V31, P919, DOI 10.1002/rra.2795
   SEAR DA, 1995, REGUL RIVER, V10, P247, DOI 10.1002/rrr.3450100219
   Simon B, 2015, RESOUR CONSERV RECY, V104, P300, DOI 10.1016/j.resconrec.2015.07.011
   Smart J, 2014, SAE INT J ALTERN POW, V3, P30, DOI 10.4271/2014-01-1803
   Society of Automotive Engineers (SAE, 2010, UTILITY FACTOR DEFIN
   Sternberg R, 2010, RENEW SUST ENERG REV, V14, P713, DOI 10.1016/j.rser.2009.08.016
   Tarroja B, 2016, ENERGY, V106, P673, DOI 10.1016/j.energy.2016.03.094
   Tesla Inc, 2018, TESLA MODEL S SPECS
   United States Department of Energy (DOE), 2017, BATTERIES
   United States Department of Energy (DOE), 2017, DOE TECHNICAL TARGET
   United States Energy Information Administration (EIA, 2018, TABLE LIGHT DUTY VEH
   Walters J., 2001, 2001012501 SAE, DOI [10.4271/2001-01-2501, DOI 10.4271/2001-01-2501]
   Wang JH, 2011, ENERG POLICY, V39, P4016, DOI 10.1016/j.enpol.2011.01.042
   Wolinetz M, 2018, NAT ENERGY, V3, P132, DOI 10.1038/s41560-017-0077-9
   World Bank (WB), 2018, ACCESS TO ELECTRICIT
   Yang Z., 2017, LIGHT DUTY VEHICLE G
   Yilmaz M, 2013, IEEE T POWER ELECTR, V28, P5673, DOI 10.1109/TPEL.2012.2227500
   Yoo HD, 2014, MATER TODAY, V17, P110, DOI 10.1016/j.mattod.2014.02.014
   Yuksel I, 2010, RENEW SUST ENERG REV, V14, P462, DOI 10.1016/j.rser.2009.07.025
   Zimmerman JKH, 2010, RIVER RES APPL, V26, P1246, DOI 10.1002/rra.1324
   Zolezzi G, 2009, WATER RESOUR RES, V45, DOI 10.1029/2008WR007266
NR 106
TC 1
Z9 1
U1 9
U2 22
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 760
EP 777
DI 10.1016/j.resconrec.2019.04.032
PG 18
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300068
DA 2020-05-12
ER

PT J
AU Defraeye, T
   Tagliavini, G
   Wu, WT
   Prawiranto, K
   Schudel, S
   Kerisima, MA
   Verboven, P
   Buhlmann, A
AF Defraeye, Thijs
   Tagliavini, Giorgia
   Wu, Wentao
   Prawiranto, Kevin
   Schudel, Seraina
   Kerisima, Mekdim Assefa
   Verboven, Pieter
   Buhlmann, Andreas
TI Digital twins probe into food cooling and biochemical quality changes
   for reducing losses in refrigerated supply chains
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Thermophysical; Fruit simulator; Multiphysics; In-silico; Biophysical
   twin; Digital avatar
ID COMPUTATIONAL FLUID-DYNAMICS; HORTICULTURAL PRODUCE; CHILLING INJURY;
   CITRUS-FRUIT; TOMMY-ATKINS; FRESH FRUIT; MANGO; ATMOSPHERE; DESIGN;
   MODEL
AB Refrigerated transport and storage of mango fruit are essential to maintain quality, reduce food waste and the associated embodied energy losses. Refrigeration is also key to enable successful transcontinental export to distant markets. To minimize the environmental impact of the cold chain and to optimize logistics, a better knowledge of the fruit quality evolution within individual shipments would be extremely valueable. For this purpose, a digital fruit twin is developed, based on mechanistic modeling. This digital twin simulates the thermal behavior of mango fruit throughout the cold chain, based on the measured environmental temperature conditions, namely the air temperature in the vicinity of the fruit. At the same time, the evolution of associated quality attributes, due to enzymatically-driven, temperature-dependent biochemical degradation reactions, is quantified. Also, a biophysical counterpart of real mango fruit an innovative fruit simulator sensing device - was developed and used for model validation of fruit pulp temperatures. We identified - in-silico - the impact of the unique delivery air temperature history and cold chain length on fruit quality evolution for actual maritime vs. airfreight transport pathways. Digital twins were found to provide complementary insights in the thermophysical behavior of fruit, particularly in supply chains of very perishable species, and for storage at low airflow rates. Such mechanistic modeling enabled to understand, record, and predict where temperature-dependent fruit quality loss occurs in each supply chain. In that way, digital twins can help to improve refrigeration processes and logistics to reduce food losses, thereby making the refrigerated supply chain greener.
C1 [Defraeye, Thijs; Tagliavini, Giorgia; Prawiranto, Kevin; Schudel, Seraina] Empa, Swiss Fed Labs Mat Sci & Technol, Lab Biomimet Membranes & Text, Lerchenfeldstr 5, CH-9014 St Gallen, Switzerland.
   [Tagliavini, Giorgia; Wu, Wentao; Prawiranto, Kevin] Swiss Fed Inst Technol, Chair Bldg Phys, Stefano Franscini Pl 5, CH-8093 Zurich, Switzerland.
   [Wu, Wentao] Empa, Swiss Fed Labs Mat Sci & Technol, Multiscale Studies Bldg Phys, Uberlandstr 129, CH-8600 Dubendorf, Switzerland.
   [Wu, Wentao] Harvard Univ, Harvard Grad Sch Design, Harvard Ctr Green Bldg & Cities, Cambridge, MA 02138 USA.
   [Schudel, Seraina; Buhlmann, Andreas] Agroscope, Plants & Plant Prod Div, Muller Thurgau Str 29, CH-8820 Wadenswil, Switzerland.
   [Kerisima, Mekdim Assefa; Verboven, Pieter] Katholieke Univ Leuven, Dept Biosyst, MeBioS Postharvest Grp, Willem de Croylaan 42, B-3001 Heverlee, Belgium.
   [Kerisima, Mekdim Assefa] Addis Ababa Univ, Addis Ababa Inst Technol, King George VI St, Addis Ababa 1000, Ethiopia.
RP Defraeye, T (reprint author), Empa, Swiss Fed Labs Mat Sci & Technol, Lab Biomimet Membranes & Text, Lerchenfeldstr 5, CH-9014 St Gallen, Switzerland.
EM thijs.defraeye@empa.ch
RI Prawiranto, Kevin/O-4493-2018
OI Prawiranto, Kevin/0000-0002-0816-7142; Defraeye,
   Thijs/0000-0002-9835-5859; Schudel, Seraina/0000-0003-3999-843X
FU Swiss National Science Foundation SNSFSwiss National Science Foundation
   (SNSF) [200021_169372]; Commission for Technology and Innovation (CTI,
   Switzerland) [18155.2 PFLSLS, 26032.1 PFLS-LS]
FX We acknowledge the support of the Swiss National Science Foundation SNSF
   (project 200021_169372) and of the Commission for Technology and
   Innovation (CTI, Switzerland, projects 18155.2 PFLSLS, 26032.1 PFLS-LS).
CR Ambaw A, 2013, J FOOD ENG, V119, P13, DOI 10.1016/j.jfoodeng.2013.05.007
   ASHRAE, 2010, ASHRAE HDB REFR SYST
   Baldwin EA, 1999, POSTHARVEST BIOL TEC, V17, P215, DOI 10.1016/S0925-5214(99)00053-8
   Berry TM, 2016, FOOD BIOPROCESS TECH, V9, P1481, DOI 10.1007/s11947-016-1733-y
   Bon J, 2010, J FOOD ENG, V97, P563, DOI 10.1016/j.jfoodeng.2009.12.001
   Brecht JK, 2003, POSTHARVEST BIOL TEC, V27, P87, DOI 10.1016/S0925-5214(02)00185-0
   Brosnan T, 2001, INT J REFRIG, V24, P154, DOI 10.1016/S0140-7007(00)00017-7
   Cantre D, 2017, POSTHARVEST BIOL TEC, V125, P99, DOI 10.1016/j.postharvbio.2016.11.009
   Casado C, 2017, CHEM ENG J, V310, P368, DOI 10.1016/j.cej.2016.07.081
   Clary B. L., 1960, THESIS
   Copelli S, 2019, CHEM ENG J, V358, P1410, DOI 10.1016/j.cej.2018.10.055
   Datta A. K., 2002, BIOL BIOENVIRONMENTA, DOI [10.1201/9780203910184, DOI 10.1201/9780203910184]
   de Castro LR, 2004, J FOOD AGRIC ENVIRON, V2, P135
   Vasconcelos OCD, 2019, SCI HORTIC-AMSTERDAM, V244, P413, DOI 10.1016/j.scienta.2018.09.068
   Dea S, 2010, POSTHARVEST BIOL TEC, V57, P61, DOI 10.1016/j.postharvbio.2010.02.005
   DECASTRO LR, 2005, CANADIAN BIOSYSTEMS, V47, P1
   Defraeye T, 2017, J FOOD ENG, V215, P51, DOI 10.1016/j.jfoodeng.2017.07.012
   Defraeye T, 2015, POSTHARVEST BIOL TEC, V108, P91, DOI 10.1016/j.postharvbio.2015.06.004
   Defraeye T, 2015, TRENDS FOOD SCI TECH, V44, P201, DOI 10.1016/j.tifs.2015.04.008
   Defraeye T, 2015, BIOSYST ENG, V134, P20, DOI 10.1016/j.biosystemseng.2015.03.012
   Defraeye T, 2013, J FOOD ENG, V114, P495, DOI 10.1016/j.jfoodeng.2012.09.003
   Dehghannya J, 2010, FOOD ENG REV, V2, P227, DOI 10.1007/s12393-010-9027-z
   Delele MA, 2013, POSTHARVEST BIOL TEC, V86, P536, DOI 10.1016/j.postharvbio.2013.08.014
   Emongor V. E., 2015, American Journal of Experimental Agriculture, V5, P252, DOI 10.9734/AJEA/2015/12174
   Gartner, 2019, 5 TRENDS EM GARTN HY, P2018
   Gartner, 2019, PREP IMP DIG TWINS
   Gill PPS, 2017, J FOOD SCI TECH MYS, V54, P1964, DOI 10.1007/s13197-017-2632-6
   Gruyters W, 2018, FOOD BIOPROCESS TECH, V11, P2008, DOI 10.1007/s11947-018-2163-9
   Gustavsson J., 2011, GLOBAL FOOD LOSSES F
   Gwanpua SG, 2015, J FOOD ENG, V148, P2, DOI 10.1016/j.jfoodeng.2014.06.021
   Kader A., 1997, UC DAVIS COMMOD FACT
   Karithi Esther M, 2016, EVALUATION EFFICACY
   Marcelo D., 2018, DYNA, V7
   Mohammed M, 2002, SCI HORTIC-AMSTERDAM, V95, P297, DOI 10.1016/S0304-4238(02)00041-9
   Nakamura N, 2004, JARQ-JPN AGR RES Q, V38, P221, DOI 10.6090/jarq.38.221
   National Mango Board, 2010, NAT MANG BOARD SUST
   Ngamchuachit P, 2014, J FOOD SCI, V79, pC505, DOI 10.1111/1750-3841.12380
   Nordio M, 2019, CHEM ENG J, V369, P432, DOI 10.1016/j.cej.2019.03.106
   Norton T, 2013, CRIT REV FOOD SCI, V53, P251, DOI 10.1080/10408398.2010.518256
   Nunes MCN, 2007, J FOOD QUALITY, V30, P104, DOI 10.1111/j.1745-4557.2007.00109.x
   ORBEGOSO EMM, 2017, J SUSTAIN DEV ENERGY, V4, P219, DOI DOI 10.13044/J.SDEWES.D5.0145
   Pesis E, 2000, POSTHARVEST BIOL TEC, V19, P93, DOI 10.1016/S0925-5214(00)00080-6
   Radu AI, 2014, CHEM ENG J, V241, P77, DOI 10.1016/j.cej.2013.12.021
   Rao DVS, 2015, J FOOD SCI TECH MYS, V52, P4360, DOI 10.1007/s13197-014-1468-6
   Robertson GL, 2016, FOOD PACKAGING PRINC, DOI [10.1177/0340035206070163, DOI 10.1177/0340035206070163]
   Sitaraman H, 2015, CHEM ENG J, V268, P47, DOI 10.1016/j.cej.2015.01.020
   Sivakumar D, 2012, J SCI FOOD AGR, V92, P821, DOI 10.1002/jsfa.4653
   Slaughter D. C, 2009, METHODS MANAGEMENT R
   Stoessel F, 2012, ENVIRON SCI TECHNOL, V46, P3253, DOI 10.1021/es2030577
   Tagliavini G., 2019, MULTIPHYSICS M UNPUB
   Thompson, 2008, COMMERCIAL COOLING F
   Thompson J. F., 2004, USDA AGR HDB, V66, P1
   van Boekel MAJS, 2008, COMPR REV FOOD SCI F, V7, P144, DOI 10.1111/j.1541-4337.2007.00036.x
   WHITAKER S, 1972, AICHE J, V18, P361, DOI 10.1002/aic.690180219
   Wu WT, 2018, APPL THERM ENG, V133, P407, DOI 10.1016/j.applthermaleng.2017.11.049
   Wu WT, 2018, COMPUT ELECTRON AGR, V144, P199, DOI 10.1016/j.compag.2017.11.034
NR 56
TC 1
Z9 2
U1 27
U2 45
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD OCT
PY 2019
VL 149
BP 778
EP 794
DI 10.1016/j.resconrec.2019.06.002
PG 17
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IU2MK
UT WOS:000483414300069
DA 2020-05-12
ER

PT J
AU Ellsworth, SA
   Nystrom, GS
   Ward, MJ
   de Sousa, LAF
   Hogan, MP
   Rokyta, DR
AF Ellsworth, Schyler A.
   Nystrom, Gunnar S.
   Ward, Micaiah J.
   Freitas de Sousa, Luciana Aparecida
   Hogan, Micheal P.
   Rokyta, Darin R.
TI Convergent recruitment of adamalysin-like metalloproteases in the venom
   of the red bark centipede (Scolopocryptops sexspinosus)
SO TOXICON
LA English
DT Article
ID TOXIC ACTIVITIES; RNA; PROTEINS; SEQUENCE; DIVERSIFICATION; DIVERGENCE;
   PROTEOMICS; ALGORITHM; PROGRAM; FAMILY
AB Many venom proteins have presumably been convergently recruited by taxa from diverse venomous lineages. These toxic proteins have characteristics that allow them to remain stable in solution and have a high propensity for toxic effects on prey and/or potential predators. Despite this well-established convergent toxin recruitment, some toxins seem to be lineage specific. To further investigate the toxic proteins found throughout venomous lineages, venom proteomics and venom-gland transcriptomics were performed on two individual red bark centipedes (Scolopocryptops sexspinosus). Combining the protein phenotype with the transcript genotype resulted in the first in-depth venom characterization of S. sexspinosus, including 72 venom components that were identified in both the transcriptome and proteome and 1468 nontoxin transcripts identified in the transcriptome. Ten different toxin families were represented in the venom and venom gland with the majority of the toxins belonging to metalloproteases, CAPS (cysteine-rich secretory protein, antigen 5, and pathogenesis-related 1 proteins), and beta-pore-forming toxins. Nine of these toxin families shared a similar proteomic structure to venom proteins previously identified from other centipedes. However, the most highly expressed toxin family, the adamalysin-like metalloproteases, has until now only been observed in the venom of snakes. We confirmed adamalysin-like metalloprotease activity by means of in vivo functional assays. The recruitment of an adamalysin-like metalloprotease into centipede venom represents a striking case of convergent evolution.
C1 [Ellsworth, Schyler A.; Nystrom, Gunnar S.; Ward, Micaiah J.; Hogan, Micheal P.; Rokyta, Darin R.] Florida State Univ, Dept Biol Sci, 319 Stadium Dr, Tallahassee, FL 32306 USA.
   [Freitas de Sousa, Luciana Aparecida] Inst Butantan, Lab Imunopatol, Av Vital Brazil 1500, BR-05503900 Sao Paulo, SP, Brazil.
RP Rokyta, DR (reprint author), Florida State Univ, Dept Biol Sci, 319 Stadium Dr, Tallahassee, FL 32306 USA.
EM drokyta@bio.fsu.edu
RI Ellsworth, Schyler/AAH-8776-2019; Freitas-de-Sousa, Luciana
   A./U-1779-2017
OI Freitas-de-Sousa, Luciana A./0000-0002-4426-0731; Ward,
   Micaiah/0000-0001-9474-8615
FU National Science Foundation Graduate Research Fellowship ProgramNational
   Science Foundation (NSF) [1449440]; National Science FoundationNational
   Science Foundation (NSF) [NSF DEB-1145978, NSF DEB 1638902]; Florida
   State University Council on Research and Creativity
FX This material is based upon work supported by the National Science
   Foundation Graduate Research Fellowship Program under Grant No. 1449440.
   Any opinions, findings, and conclusions or recommendations expressed in
   this material are those of the authors and do not necessarily reflect
   the views of the National Science Foundation. Funding for this work was
   provided by the National Science Foundation (NSF DEB-1145978 and NSF DEB
   1638902) and the Florida State University Council on Research and
   Creativity. We thank Rakesh Singh of the Florida State University
   College of Medicine Translational Science Laboratory for advice and
   assistance with proteomic analyses, and Margaret Seavy of the Florida
   State Molecular Core Facility for her guidance on RP-HPLC parameters. We
   also thank Pierson Hill for his assistance in collecting specimens.
CR Aitchison J., 1986, STAT ANAL COMPOSITIO
   Ali A, 2014, EXP APPL ACAROL, V63, P559, DOI 10.1007/s10493-014-9796-9
   Baldo C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000727
   Bankevich A, 2012, J COMPUT BIOL, V19, P455, DOI 10.1089/cmb.2012.0021
   Bonato L., 2016, CHILOBASE 2 0 WORLD
   Camacho E, 2016, TOXINS, V8, DOI 10.3390/toxins8100292
   Casewell NR, 2013, TRENDS ECOL EVOL, V28, P219, DOI 10.1016/j.tree.2012.10.020
   Casewell NR, 2011, MOL BIOL EVOL, V28, P2637, DOI 10.1093/molbev/msr091
   Currier RB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041888
   Dal Peraro M, 2016, NAT REV MICROBIOL, V14, P77, DOI 10.1038/nrmicro.2015.3
   Doley R, 2009, CELL MOL LIFE SCI, V66, P2851, DOI 10.1007/s00018-009-0050-2
   Feitosa L, 1998, TOXICON, V36, P1039, DOI 10.1016/S0041-0101(97)00083-4
   Fox JW, 2008, PROTEOMICS, V8, P909, DOI 10.1002/pmic.200700777
   Fox JW, 2005, TOXICON, V45, P969, DOI 10.1016/j.toxicon.2005.02.012
   Freitas-de-Sousa LA, 2017, TOXINS, V9, DOI 10.3390/toxins9080239
   Fry BG, 2009, J MOL EVOL, V68, P311, DOI 10.1007/s00239-009-9223-8
   Fry BG, 2009, ANNU REV GENOM HUM G, V10, P483, DOI 10.1146/annurev.genom.9.081307.164356
   Gasteiger E., 2005, PROTEIN IDENTIFICATI
   Gibbs GM, 2008, ENDOCR REV, V29, P865, DOI 10.1210/er.2008-0032
   Girish KS, 2004, BIOCHIMIE, V86, P193, DOI 10.1016/j.biochi.2004.02.004
   Gonzalez-Morales L, 2014, J PROTEOMICS, V111, P224, DOI 10.1016/j.jprot.2014.04.033
   Gonzalez-Morales L, 2009, TOXICON, V54, P8, DOI 10.1016/j.toxicon.2009.03.003
   Grabherr MG, 2011, NAT BIOTECHNOL, V29, P644, DOI 10.1038/nbt.1883
   Gutierrez JM, 2005, TOXICON, V45, P997, DOI 10.1016/j.toxicon.2005.02.029
   Haas B, 2016, TRANSDECODER FIND CO
   Hakim MA, 2015, TOXINS, V7, P4832, DOI 10.3390/toxins7114832
   Heng Li., 2013, 13033997 ARXIV, V1303, P3997, DOI DOI 10.1093/BI0INF0RMATICS/BTP352
   Joshi J, 2011, MOL PHYLOGENET EVOL, V60, P287, DOI 10.1016/j.ympev.2011.04.024
   Jungo F, 2012, TOXICON, V60, P551, DOI 10.1016/j.toxicon.2012.03.010
   Kini RM, 2018, TOXICON, V148, P16, DOI 10.1016/j.toxicon.2018.04.005
   Knittel PS, 2016, TOXICON, V119, P1, DOI 10.1016/j.toxicon.2016.04.048
   Kondo H., 1960, Japanese Journal of Medical Science and Biology, V18, P43
   Krueger F, 2015, TRIM GALORE WRAPPER
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Li MY, 2011, SCIENCE, V333, P53, DOI 10.1126/science.1207018
   Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158
   Liu JT, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004772
   Liu ZC, 2012, J PROTEOME RES, V11, P6197, DOI 10.1021/pr300881d
   MacManes MD, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00013
   Malta MB, 2008, TOXICON, V52, P255, DOI 10.1016/j.toxicon.2008.05.012
   Marcais G, 2011, BIOINFORMATICS, V27, P764, DOI 10.1093/bioinformatics/btr011
   Margres MJ, 2016, TOXICON, V119, P28, DOI 10.1016/j.toxicon.2016.05.005
   Moran Y, 2012, MOL BIOL EVOL, V29, P2223, DOI 10.1093/molbev/mss089
   Morgenstern D, 2011, TOXICON, V57, P695, DOI 10.1016/j.toxicon.2011.02.001
   Moura-Da-Silva AM, 2007, CURR PHARM DESIGN, V13, P2893, DOI 10.2174/138161207782023711
   Paszkiewicz KH, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00157
   Petersen TN, 2011, NAT METHODS, V8, P785, DOI 10.1038/nmeth.1701
   Rates B, 2007, TOXICON, V49, P810, DOI 10.1016/j.toxicon.2006.12.001
   Rehm P, 2014, MOL PHYLOGENET EVOL, V77, P25, DOI 10.1016/j.ympev.2014.04.007
   de Oliveira-Mendes BBR, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007048
   Rice P, 2000, EMBOSS EUROPEAN MOL
   Rokyta DR, 2017, TOXICON, V128, P23, DOI 10.1016/j.toxicon.2017.01.014
   Rokyta DR, 2015, G3-GENES GENOM GENET, V5, P2375, DOI 10.1534/g3.115.020578
   Rokyta DR, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-312
   Rokyta DR, 2011, TOXICON, V57, P657, DOI 10.1016/j.toxicon.2011.01.008
   Rong MQ, 2015, J PROTEOMICS, V114, P28, DOI 10.1016/j.jprot.2014.10.014
   Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703
   SHANNON JD, 1989, J BIOL CHEM, V264, P11575
   Shelley R.M, 2002, SYNOPSIS N AM CENTIP
   Sher D, 2005, J BIOL CHEM, V280, P22847, DOI 10.1074/jbc.M503242200
   Smith JJ, 2018, TOXINS, V10, DOI 10.3390/toxins10030096
   Spivak M, 2009, J PROTEOME RES, V8, P3737, DOI 10.1021/pr801109k
   Takeda S, 2016, TOXINS, V8, DOI 10.3390/toxins8050155
   Undheim EAB, 2015, TOXINS, V7, P679, DOI 10.3390/toxins7030679
   Undheim EAB, 2014, MOL BIOL EVOL, V31, P2124, DOI 10.1093/molbev/msu162
   Undheim EAB, 2014, J PROTEOMICS, V102, P1, DOI 10.1016/j.jprot.2014.02.024
   Vizcaino JA, 2016, NUCLEIC ACIDS RES, V44, pD447, DOI 10.1093/nar/gkv1145
   Ward MJ, 2018, TOXICON, V152, P137, DOI 10.1016/j.toxicon.2018.07.026
   Ward MJ, 2018, TOXICON, V152, P121, DOI 10.1016/j.toxicon.2018.07.030
   Ward MJ, 2018, TOXICON, V142, P14, DOI 10.1016/j.toxicon.2017.12.042
   Xie YL, 2014, BIOINFORMATICS, V30, P1660, DOI 10.1093/bioinformatics/btu077
   Yang S, 2012, MOL CELL PROTEOMICS, V11, P640, DOI 10.1074/mcp.M112.018853
   Zhang JJ, 2014, BIOINFORMATICS, V30, P614, DOI 10.1093/bioinformatics/btt593
NR 73
TC 0
Z9 0
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT
PY 2019
VL 168
BP 1
EP 15
DI 10.1016/j.toxicon.2019.06.021
PG 15
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IW3JJ
UT WOS:000484876000001
PM 31229627
DA 2020-05-12
ER

PT J
AU Han, YY
   Lu, M
   Zhou, JS
AF Han, Yangyang
   Lu, Ming
   Zhou, Jinsong
TI Buforin IIb induces androgen-independent prostate cancer cells apoptosis
   though p53 pathway in vitro
SO TOXICON
LA English
DT Article
DE Buforin IIb; Prostate cancer cells; Apoptosis; P53; Peptides; Bcl-2
ID ANTICANCER ACTIVITY; MECHANISM; PEPTIDES
AB Prostate cancer (PCa) is one of the most common male cancer types, androgen-independent prostate cancer possesses poor prognosis. Buforin IIb, an attractive antibacterial peptide derived from histone H2A, showed selective cytotoxicity against most cancer cell lines. However, the molecular mechanism of buforin IIb on prostate cancer cell has still not been determined. In this study, we found buforin lIb significantly inhibited the prostate cancer cells proliferation, Furthermore, buforin IIb-induced cell apoptosis through downregulation of pro-caspase 3/8/9, poly (ADP-ribose) polymerase PARP and anti-apoptotic Bcl-2 and upregulation of proapoptotic Bax. In addition, buforin IIb increased the expression of tumor suppressor p53 and its target genes p21, fas, noxa and puma. The cytotoxicity of buforin IIb on PC-3 and Du-145 cells is decreased by p53 knockdown. In conclusion, our results indicated that buforin IIb induced PC-3 and Du-145 cell apoptosis and could be considered as a potential drug for prostate cancer.
C1 [Han, Yangyang; Lu, Ming; Zhou, Jinsong] Xi An Jiao Tong Univ, Sch Basic Med Sci, Dept Human Anat Histol & Embryol, Hlth Sci Ctr, Xian 710061, Shaanxi, Peoples R China.
RP Zhou, JS (reprint author), Xi An Jiao Tong Univ, Sch Basic Med Sci, Dept Human Anat Histol & Embryol, Hlth Sci Ctr, Xian 710061, Shaanxi, Peoples R China.
EM zjs301@mail.xjtu.edu.cn
FU China Postdoctoral Science FoundationChina Postdoctoral Science
   Foundation [2018M643676]; Shaanxi Province Postdoctoral Science
   Foundation
FX This work was supported by the China Postdoctoral Science Foundation
   (grant numbers 2018M643676) and Shaanxi Province Postdoctoral Science
   Foundation.
CR Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986
   Han YY, 2016, TOXICOL IN VITRO, V35, P112, DOI 10.1016/j.tiv.2016.05.019
   Han YY, 2013, BIOCHEM PHARMACOL, V86, P1254, DOI 10.1016/j.bcp.2013.08.008
   Jang JH, 2015, PEPTIDES, V69, P144, DOI 10.1016/j.peptides.2015.04.024
   Jang SA, 2012, PEPTIDES, V34, P283, DOI 10.1016/j.peptides.2012.01.015
   Jiang LL, 2017, PHARM BIOL, V55, P2259, DOI 10.1080/13880209.2017.1401647
   Junttila MR, 2009, NAT REV CANCER, V9, P821, DOI 10.1038/nrc2728
   Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054
   Lee HS, 2008, CANCER LETT, V271, P47, DOI 10.1016/j.canlet.2008.05.041
   Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1
   Lopes EA, 2019, CURR MED CHEM, V26, P7323, DOI 10.2174/0929867325666181116124308
   Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065
   Mantovani F, 2017, FEBS J, V284, P837, DOI 10.1111/febs.13948
   Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3
   Park CB, 2000, P NATL ACAD SCI USA, V97, P8245, DOI 10.1073/pnas.150518097
   Roca H, 2018, J CLIN INVEST, V128, P248, DOI 10.1172/JCI92466
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Tsoi KKF, 2017, BRIT MED BULL, V121, P83, DOI 10.1093/bmb/ldw050
   Verlekar D, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0964-4
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Wang LW, 2010, NAT STRUCT MOL BIOL, V17, P1324, DOI 10.1038/nsmb.1920
NR 21
TC 0
Z9 0
U1 1
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT
PY 2019
VL 168
BP 16
EP 21
DI 10.1016/j.toxicon.2019.06.016
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IW3JJ
UT WOS:000484876000002
PM 31229626
DA 2020-05-12
ER

PT J
AU Abdel-Ghani, LM
   Rahmy, TR
   Tawfik, MM
   Kaziri, I
   Al-Obaidi, A
   Rowan, EG
   Plevin, R
   Abdel-Rahman, MA
AF Abdel-Ghani, Lougin M.
   Rahmy, Tarek R.
   Tawfik, Mohamed M.
   Kaziri, Ibtisam
   Al-Obaidi, Ahlam
   Rowan, Edward G.
   Plevin, Robin
   Abdel-Rahman, Mohamed A.
TI Cytotoxicity of Nubein6.8 peptide isolated from the snake venom of Naja
   nubiae on melanoma and ovarian carcinoma cell lines
SO TOXICON
LA English
DT Article
DE Cancer therapy; Snake venom; Cardiotoxins; Malignant melanoma; Ovarian
   carcinoma; Cytotoxic potential; Cellular uptake; Apoptosis
ID III-INDUCED APOPTOSIS; AMINO-ACID OXIDASE; CARDIOTOXIN III; IN-VITRO;
   CANCER; PROLIFERATION; CYCLE
AB This study was conducted to examine the cytotoxic effects of Nubein6.8 isolated from the venom of the Egyptian Spitting Cobra Naja nubiae on melanoma (A375) and ovarian carcinoma cell lines and to reveal its mode of action. The size of Nubein6.8 (6801.8 Da) and its N-terminal sequence are similar to cytotoxins purified from the venom of other spitting cobras. Nubein6.8 showed a high significant cytotoxic effect on A375 cell line and moderate effect on A2780. A clonogenic assay showed that Nubein6.8 has a significant long-term potency on A375 cell survival when compared to A2780. The molecular intracellular signaling pathways of Nubein6.8 have been investigated using Western blotting analysis, flow cytometry, and microscale protein labeling. This data revealed that Nubein6.8 has DNA damaging effects and the ability to activate apoptosis in both tumor cell lines. Cellular uptake recordings revealed that the labeled-Nubein6.8 was intracellularly present in A375 cells while A2780 displayed resistance against it. SEM examination showed that Nubein6.8 was found to have high accessibility to malignant melanoma cells. The apoptotic effect of Nubein6.8 was confirmed by TEM examination that revealed many evident characteristics for Nubein6.8 apoptotic efficacy on A375 cell sections. Also, TEM reflected many resistant characteristics that faced Nubein6.8 acquisition through ovarian carcinoma cell sections. Accordingly, the snake venom peptide of Nubein6.8 is a promising template for developing potential cytotoxic agents targeting human melanoma and ovarian carcinoma.
C1 [Abdel-Ghani, Lougin M.; Rahmy, Tarek R.; Abdel-Rahman, Mohamed A.] Suez Canal Univ, Fac Sci, Zool Dept, Ismailia 41522, Egypt.
   [Tawfik, Mohamed M.] Port Said Univ, Zool Dept, Fac Sci, Port Said, Egypt.
   [Kaziri, Ibtisam; Al-Obaidi, Ahlam; Rowan, Edward G.; Plevin, Robin] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow G4 0RE, Lanark, Scotland.
   [Abdel-Rahman, Mohamed A.] Suez Canal Univ, Inst Biotechnol Grad Studies & Res, Ismailia 41522, Egypt.
RP Abdel-Rahman, MA (reprint author), Suez Canal Univ, Fac Sci, Zool Dept, Ismailia 41522, Egypt.
EM mohamed_hassanain@science.suez.edu.eg
RI ; Abdel-Rahman, Mohamed/L-8362-2013
OI Plevin, Robin/0000-0002-7849-1220; AbdelGhani,
   Lougin/0000-0001-7075-8077; Abdel-Rahman, Mohamed/0000-0003-3862-5535
FU Egyptian Ministry of Higher Education and Scientific Research
FX Lougin M. Abdel-Ghani acknowledges a Governmental PhD Scholarship
   (Channel Scheme between Suez Canal University, Egypt and University of
   Strathclyde, UK) supported by the Egyptian Ministry of Higher Education
   and Scientific Research to study at the Institute of Pharmacy and
   Biomedical Sciences, University of Strathclyde, Glasgow, UK.
CR Abdel-Rahman MA, 2015, J ARID ENVIRON, V112, P170, DOI 10.1016/j.jaridenv.2014.01.007
   Paiva RDA, 2011, BIOCHIMIE, V93, P941, DOI 10.1016/j.biochi.2011.01.009
   Beneteau M, 2012, P NATL ACAD SCI USA, V109, P20071, DOI 10.1073/pnas.1206360109
   Birsoy K, 2013, NAT GENET, V45, P104, DOI 10.1038/ng.2471
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Calderon LA, 2014, BIOMED RES INT, DOI 10.1155/2014/203639
   Calvete JJ, 2007, J MASS SPECTROM, V42, P1405, DOI 10.1002/jms.1242
   Chen Na, 2018, Biophys Rep, V4, P233, DOI 10.1007/s41048-018-0067-x
   Chien CM, 2008, CLIN EXP PHARMACOL P, V35, P1059, DOI 10.1111/j.1440-1681.2008.04968.x
   Chiu CC, 2008, ONCOL RES, V17, P311
   Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022
   Corzo G, 2001, FEBS LETT, V499, P256, DOI 10.1016/S0014-5793(01)02558-3
   Cron KR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073710
   da Silva CP, 2015, J VENOM ANIM TOXINS, V21, DOI 10.1186/s40409-015-0044-5
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Fry BG, 2003, J MOL EVOL, V57, P110, DOI 10.1007/s00239-003-2461-2
   Ganapathy-Kanniappan S, 2013, MOL CANCER, V12, P1
   Harvey AL, 2014, TOXICON, V92, P193, DOI 10.1016/j.toxicon.2014.10.020
   Khalid H., 2015, TOXINS J, P1
   Lai D, 2012, BIOSCIENCE REP, V32, P361, DOI 10.1042/BSR20110125
   Liu CC, 2014, ASIAN PAC J CANCER P, V15, P4753, DOI 10.7314/APJCP.2014.15.12.4753
   Liu TY, 2010, BIOL PHARM BULL, V33, P1740, DOI 10.1248/bpb.33.1740
   Ma R, 2017, ONCOTARGET, V8, P100908, DOI 10.18632/oncotarget.21740
   Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602
   Minea R, 2012, TOXICON, V59, P472, DOI 10.1016/j.toxicon.2011.02.020
   Munawar A, 2014, TOXINS, V6, P850, DOI 10.3390/toxins6030850
   Nakano A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027222
   Nurgali K, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00245
   Petras D, 2011, J PROTEOME RES, V10, P1266, DOI 10.1021/pr101040f
   Podhorecka M, 2010, J NUCLEIC ACIDS, DOI 10.4061/2010/920161
   Sanhajariya S, 2018, TOXINS, V10, DOI 10.3390/toxins10020073
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Tsai CH, 2006, CLIN EXP PHARMACOL P, V33, P177, DOI 10.1111/j.1440-1681.2006.04334.x
   Vonk FJ, 2011, BIOESSAYS, V33, P269, DOI 10.1002/bies.201000117
   Wang H, 2013, EUR J PHARMACOL, V707, P1, DOI 10.1016/j.ejphar.2013.03.028
   Wang JS, 2006, CELL MOL IMMUNOL, V3, P255
   Zhang L, 2008, NAT PROD RES, V22, P554, DOI 10.1080/14786410701592679
NR 37
TC 0
Z9 0
U1 19
U2 38
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT
PY 2019
VL 168
BP 22
EP 31
DI 10.1016/j.toxicon.2019.06.220
PG 10
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IW3JJ
UT WOS:000484876000003
PM 31233771
DA 2020-05-12
ER

PT J
AU Sanchez, EE
   Migl, C
   Suntravat, M
   Rodriguez-Acosta, A
   Galan, JA
   Salazar, E
AF Sanchez, Elda E.
   Migl, Chesney
   Suntravat, Montamas
   Rodriguez-Acosta, Alexis
   Galan, Jacob A.
   Salazar, Emelyn
TI The neutralization efficacy of expired polyvalent antivenoms: An
   alternative option
SO TOXICON
LA English
DT Article
DE Expired antivenom; Activated clot time; Clot rate; Platelet function;
   Wyeth; Antivipmyn (R); Biotecfar; South African institute for medical
   research (SAIMR); Crotalus atrox; Crotalus vegrandis; Bothrops
   colombiensis; Bitis gabonica; Echis carinatus; Sonoclot coagulation &
   platelet function analyzer
ID SNAKE-VENOMS; DISINTEGRINS; VARIABILITY; RATTLESNAKE; STABILITY;
   VIPERIDAE
AB The expense of production and distribution of snakebite antivenom, as well as its relatively infrequent use, has caused antivenom to be increasingly difficult to obtain and ultimately producing an alarming global shortage. Unused, expired antivenom may represent a significant, untapped resource to ameliorate this crisis. This study examines the efficacy of expired antivenom over time using in vitro, whole blood clotting, and platelet function statistics. Representatives from three years for four different global brands of polyvalent antivenom were chosen and tested against their corresponding venoms as well as other venoms that could display cross-reactivity. These antivenoms include Wyeth Polyvalent (U.S.; exp. 1997, 2001, 2003), Antivipmyn (R) (Mexico; exp. 2005, 2013, 2017), Biotecfars Polyvalent (Venezuela; exp. 2010, 2014, 2016), and SAIMR (South Africa; exp. 1997, 2005, 2017). Venoms of species tested were Crotalus atrox against Wyeth; C. atrox and Crotalus vegrandis against Antivipmyn (R) ; C. atrox, C. vegrandis and Bothrops colombiensis against Biotecfar; and Bids gabonica and Echis carinatus against South African Institute for Medical Research (SAIMR). Parameters recorded were activated clotting time (ACT), clotting rate (CR), and platelet function (PF). Preliminary results are encouraging as the antivenoms maintained significant efficacy even 20 y after their expiration date. We anticipate these results will motivate further studies and provide hope in the cases of snakebite emergencies when preferable treatments are unavailable.
C1 [Sanchez, Elda E.; Migl, Chesney; Suntravat, Montamas; Galan, Jacob A.; Salazar, Emelyn] Texas A&M Univ Kingsville, Natl Nat Toxins Res Ctr, Kingsville, TX 78363 USA.
   [Sanchez, Elda E.; Suntravat, Montamas; Galan, Jacob A.] Texas A&M Univ Kingsville, Dept Chem, MSC 161, Kingsville, TX 78363 USA.
   [Rodriguez-Acosta, Alexis] Univ Cent Venezuela, Inst Anat Jose Izquierdo, Lab Inmunoquim & Ultraestruct, Caracas, Venezuela.
RP Sanchez, EE (reprint author), Texas A&M Univ Kingsville, Natl Nat Toxins Res Ctr, Kingsville, TX 78363 USA.
EM elda.sanchez@tamuk.edu
FU NIH/ORIP, Viper Resource Grant (National Natural Toxins Research Center
   (NNTRC) [P400D01960-15]; Texas A&M University-Kingsville; Robert A.
   Welch FoundationThe Welch Foundation [AC-0006]
FX Funding for this project was provided by Grant from the NIH/ORIP, Viper
   Resource Grant #P400D01960-15 (National Natural Toxins Research Center
   (NNTRC), Texas A&M University-Kingsville, Dr. E.E. Sanchez), and the
   Robert A. Welch Foundation, grant #AC-0006 (TAMUK-Department of
   Chemistry). We also thank Mark Hockmuller and Juan Salinas, curator and
   animal room technician of the NNTRC and Nora Diaz De Leon for her
   administrative assistance.
CR Ainsworth S., 2018, COMM BIO, V34, P1
   Alirol E., 2015, PLOS NEGLECTED TROP, V9, P1
   Amer Coll Med Toxicology, 2015, J MED TOXICOL, V11, P144, DOI 10.1007/s13181-013-0372-1
   Calvete JJ, 2009, J PROTEOMICS, V72, P227, DOI 10.1016/j.jprot.2009.01.005
   Cantu E, 2017, COMP BIOCHEM PHYS C, V191, P168, DOI 10.1016/j.cbpc.2016.10.009
   Chippaux JP, 1998, B WORLD HEALTH ORGAN, V76, P515
   de Queiroz MR, 2017, TOXICON, V133, P33, DOI 10.1016/j.toxicon.2017.04.013
   Fuchs J, 2017, CLIN TOXICOL, V55, P613, DOI 10.1080/15563650.2017.1294694
   Giron ME, 2018, TOXICON, V144, P23, DOI 10.1016/j.toxicon.2018.01.020
   Gummin DD, 2017, CLIN TOXICOL, V55, P1072, DOI 10.1080/15563650.2017.1388087
   Gutierrez JM, 2017, NAT REV DIS PRIMERS, V3, DOI [10.1038/nrdp.2017.79, 10.1038/nrdp.2017.63]
   Gutierrez JM, 2012, TOXICON, V60, P676, DOI 10.1016/j.toxicon.2012.02.008
   Habib AG, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004088
   Harrison RA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005969
   Harrison RA, 2016, TOXINS, V8, DOI 10.3390/toxins8120351
   Harrison RA, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000569
   Hoffman RS, 2012, DISASTER MED PUBLIC, V6, P20, DOI 10.1001/dmp.2011.86
   Kasturiratne A, 2008, PLOS MED, V5, P1591, DOI 10.1371/journal.pmed.0050218
   Lyon RC, 2006, J PHARM SCI-US, V95, P1549, DOI 10.1002/jps.20636
   Gutierrez JM, 2019, TOXINS, V11, DOI 10.3390/toxins11010005
   Gutierrez JM, 2010, TOXICON, V56, P1223, DOI 10.1016/j.toxicon.2009.11.020
   Massey DJ, 2012, J PROTEOMICS, V75, P2576, DOI 10.1016/j.jprot.2012.02.035
   O'Leary MA, 2009, T ROY SOC TROP MED H, V103, P937, DOI 10.1016/j.trstmh.2008.11.011
   Rogalski A, 2017, TOXICOL LETT, V280, P159, DOI 10.1016/j.toxlet.2017.08.020
   Salazar A. M., 2009, COMP BIOCH PHYSL C, V149, P273
   Sanchez EE, 2009, ARCH TOXICOL, V83, P271, DOI 10.1007/s00204-008-0358-y
   Suntravat M, 2016, TOXICON, V122, P43, DOI 10.1016/j.toxicon.2016.09.007
   Suntravat M, 2016, BMC MOL BIOL, V17, DOI 10.1186/s12867-016-0059-7
   Suntravat M, 2010, TOXICON, V56, P544, DOI 10.1016/j.toxicon.2010.05.012
   Tan KY, 2019, TOXICON, V160, P55, DOI 10.1016/j.toxicon.2019.02.010
   Viala VL, 2015, TOXICON, V107, P234, DOI 10.1016/j.toxicon.2015.09.023
   Visser LE, 2008, T ROY SOC TROP MED H, V102, P445, DOI 10.1016/j.trstmh.2007.11.006
   Warrel D. A., 2008, T R SOC TROP MED HYG, V102, P607
   Wood A, 2013, CLIN TOXICOL, V51, P783, DOI 10.3109/15563650.2013.828841
   World Health Organization, 2019, NEGLECTED TROPICAL D
NR 35
TC 0
Z9 0
U1 2
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT
PY 2019
VL 168
BP 32
EP 39
DI 10.1016/j.toxicon.2019.06.216
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IW3JJ
UT WOS:000484876000004
PM 31229628
DA 2020-05-12
ER

PT J
AU Siqueira, RAGB
   Calabria, PAL
   Caporrino, MC
   Tavora, BCLF
   Barbaro, KC
   Faquim-Mauro, EL
   Della-Casa, MS
   Magalhaes, GS
AF Siqueira, Raquel A. G. B.
   Calabria, Paula A. L.
   Caporrino, Maria C.
   Tavora, Bianca C. L. F.
   Barbaro, Katia C.
   Faquim-Mauro, Eliana L.
   Della-Casa, Maisa S.
   Magalhaes, Geraldo S.
TI When spider and snake get along: Fusion of a snake disintegrin with a
   spider phospholipase D to explore their synergistic effects on a tumor
   cell
SO TOXICON
LA English
DT Article
ID CYCLIC PHOSPHATIDIC-ACID; LOXOSCELES-INTERMEDIA; PLATELET-AGGREGATION;
   DERMONECROTIC TOXIN; VENOM; ALPHA(V)BETA(3); PROLIFERATION;
   ANGIOGENESIS; METASTASIS; ECHISTATIN
AB Venoms of spiders and snakes contain toxins extremely active and, thus, provide a natural source for the development of new biotechnological tools. Among the diversity of toxins present in the venom of spiders from genus Loxosceles, the phospholipases D (PLDs) show high hydrolytic activity upon lysophosphatidylcholine (LPC) and sphingomyelin (SM), generating bioactive phospholipids such as cyclic phosphatidic acid (cPA). Since this mediator has been shown to play a major role in complex signaling pathways, including inhibition of tumor cells, the PLDs may hold the key to learn how toxins could be used for therapeutic purposes. However, the strong platelet aggregation of PLDs and their lack of selectivity impose a major limitation. On the other hand, disintegrins present in the venoms of Viperidae snakes are a potent inhibitor of platelet aggregation and possess high affinity and specificity to molecules called integrins that are highly expressed in some tumor cells, such as murine melanoma B16F10. Therefore, disintegrins might be suitable molecules to carry the PLDs to the malignant cells, so both toxins may work synergistically to eliminate these cells. Thus, in this work, a recombinant PLD from Loxosceles gaucho spider was recombinantly fused to a disintegrin from Echis carinatus snake to form a hybrid toxin called Rechistatin. This recombinant toxin was successfully expressed in bacteria, showed binding activity in B16F10 murine melanoma cells and exerted a synergistic cytotoxicity effect on these cells. Therefore, the approach presented in this work may represent a new strategy to explore new potential applications for spider PLDs.
C1 [Siqueira, Raquel A. G. B.; Calabria, Paula A. L.; Caporrino, Maria C.; Tavora, Bianca C. L. F.; Barbaro, Katia C.; Faquim-Mauro, Eliana L.; Della-Casa, Maisa S.; Magalhaes, Geraldo S.] Butantan Inst, Lab Immunopathol, Av Vital Brazil 1500, BR-05503900 Sao Paulo, SP, Brazil.
RP Magalhaes, GS (reprint author), Butantan Inst, Lab Immunopathol, Av Vital Brazil 1500, BR-05503900 Sao Paulo, SP, Brazil.
EM raquel.barbeto@gmail.com; pacalabria@hotmail.com;
   maria.caporrino@butantan.gov.br; bianca.tavora@butantan.gov.br;
   katia.barbaro@butantan.gov.br; eliana.faquim@butantan.gov.br;
   maisa.dellacasa@butantan.gov.br; geraldo.magalhaes@butantan.gov.br
RI ; Faquim-Mauro, Eliana/M-2489-2017
OI de Carvalho Lins Fernandes Tavora Bevilacqua,
   Bianca/0000-0001-5635-0745; Faquim-Mauro, Eliana/0000-0001-8083-4272
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - BrazilFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2017/16999-8,
   2014/23457-9]; Conselho Nacional de Desenvolvimento Cientffico e
   Tecnologico (CNPq) - BrazilNational Council for Scientific and
   Technological Development (CNPq) [312096/2018-6]
FX This work has received financial support from the Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo - Brazil (grants 2017/16999-8 and
   2014/23457-9). We also thank the Conselho Nacional de Desenvolvimento
   Cientffico e Tecnologico (CNPq) - Brazil for the grant to Eliana L.
   Faquim-Mauro (312096/2018-6).
CR Akbari B, 2017, INT REV IMMUNOL, V36, P207, DOI 10.1080/08830185.2017.1284211
   Arosio D, 2017, RECENT PAT ANTI-CANC, V12, P148, DOI 10.2174/1574892812666170203151930
   Barbaro KC, 2010, TOXICON, V56, P972, DOI 10.1016/j.toxicon.2010.06.022
   Barbaro KC, 1996, J PROTEIN CHEM, V15, P337, DOI 10.1007/BF01886859
   BEVIGLIA L, 1995, ONCOL RES, V7, P7
   Boger C, 2015, GASTRIC CANCER, V18, P784, DOI 10.1007/s10120-014-0435-2
   Calabria PAL, 2019, TOXINS, V11, DOI 10.3390/toxins11020108
   Calderon L. A., 2013, BIOMED RES INT, V1, P1
   Casewell NR, 2013, TRENDS ECOL EVOL, V28, P219, DOI 10.1016/j.tree.2012.10.020
   Chaim OM, 2011, BBA-MOL CELL BIOL L, V1811, P84, DOI 10.1016/j.bbalip.2010.11.005
   Chaim OM, 2011, TOXINS, V3, P309, DOI 10.3390/toxins3030309
   Chaisakul J, 2016, J CANCER, V7, P1571, DOI 10.7150/jca.15309
   Chaves-Moreira D., 2016, J CELL BIOCHEM, V1, P1
   Chaves-Moreira D, 2017, J VENOM ANIM TOXINS, V23, DOI 10.1186/s40409-017-0097-8
   Chaves-Moreira D, 2009, J CELL BIOCHEM, V107, P655, DOI 10.1002/jcb.22148
   Chen Na, 2018, Biophys Rep, V4, P233, DOI 10.1007/s41048-018-0067-x
   Correa MA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153090
   Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748
   Ellegala DB, 2003, CIRCULATION, V108, P336, DOI 10.1161/01.CIR.0000080326.15367.0C
   Fry BG, 2009, ANNU REV GENOM HUM G, V10, P483, DOI 10.1146/annurev.genom.9.081307.164356
   Fukuda D. A., 2017, TOXINS, V191, P1
   GAN ZR, 1988, J BIOL CHEM, V263, P19827
   Gremski LH, 2014, TOXICON, V83, P91, DOI 10.1016/j.toxicon.2014.02.023
   Grivicich I, 2007, REV BRAS CANCEROL, V53, P335, DOI DOI 10.1016/J.PESTBP.2010.12.005
   Heemskerk JWM, 2002, THROMB HAEMOSTASIS, V88, P186
   Hogan CJ, 2004, ANN EMERG MED, V44, P608, DOI 10.1016/j.annemergmed.2004.08.028
   Hu Q., 2016, PLOS ONE, V11, P1
   Huang TF, 2001, HAEMOSTASIS, V31, P192
   Ishihara R, 2004, INT J CANCER, V110, P188, DOI 10.1002/ijc.20069
   Janib SM, 2014, BIOMACROMOLECULES, V15, P2347, DOI 10.1021/bm401622y
   Karakecili AG, 2007, J BIOSCI BIOENG, V104, P69, DOI 10.1263/jbb.104.69
   Khew ST, 2007, BIOMACROMOLECULES, V8, P3153, DOI 10.1021/bm700587j
   Konakazawa M, 2015, BRAIN RES, V1614, P28, DOI 10.1016/j.brainres.2015.04.013
   Kren A, 2007, EMBO J, V26, P2832, DOI 10.1038/sj.emboj.7601738
   KURPIEWSKI G, 1981, BIOCHIM BIOPHYS ACTA, V678, P467, DOI 10.1016/0304-4165(81)90128-8
   Kwakwa KA, 2017, CANCERS, V9, DOI 10.3390/cancers9070084
   Lajoie DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072372
   Lee S, 2005, BIOCHEM J, V391, P317, DOI 10.1042/BJ20050043
   Liapis H, 1996, DIAGN MOL PATHOL, V5, P127, DOI 10.1097/00019606-199606000-00008
   Liu ZF, 2008, DRUG DEVELOP RES, V69, P329, DOI 10.1002/ddr.20265
   Lucena S, 2011, TOXICON, V57, P794, DOI 10.1016/j.toxicon.2011.02.014
   Luciano MN, 2004, J HISTOCHEM CYTOCHEM, V52, P455, DOI 10.1177/002215540405200404
   Magalhaes GS, 2013, BIOCHIMIE, V95, P1773, DOI 10.1016/j.biochi.2013.06.002
   Magalhaes GS, 2012, MOL BIOTECHNOL, V51, P119, DOI 10.1007/s12033-011-9444-0
   Marcinkiewicz C, 1996, BIOCHEM J, V317, P817, DOI 10.1042/bj3170817
   Mazor R, 2016, IMMUNOL REV, V270, P152, DOI 10.1111/imr.12390
   McLane MA, 2008, FRONT BIOSCI-LANDMRK, V13, P6617, DOI 10.2741/3177
   Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081
   Mukai M, 1999, INT J CANCER, V81, P918, DOI 10.1002/(SICI)1097-0215(19990611)81:6<918::AID-IJC13>3.0.CO;2-E
   Murakami-Murofushi K, 2002, BBA-MOL CELL BIOL L, V1582, P1, DOI 10.1016/S1388-1981(02)00131-2
   Ramos CRR, 2004, BRAZ J MED BIOL RES, V37, P1103, DOI 10.1590/S0100-879X2004000800001
   Ramos OHP, 2008, CLIN EXP METASTAS, V25, P53, DOI 10.1007/s10585-007-9101-y
   Sanchez A. M., 2006, DIANAS J, V1, P1
   Santoro ML, 2004, THROMB HAEMOSTASIS, V92, P369, DOI 10.1160/TH04-02-0120
   SAUDEK V, 1991, EUR J BIOCHEM, V202, P329, DOI 10.1111/j.1432-1033.1991.tb16380.x
   Shimokawa-Falcao LHAL, 2017, TOXINS, V9, DOI 10.3390/toxins9030082
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   Sun DJ, 2015, TOXINS, V7, P423, DOI 10.3390/toxins7020423
   Swenson S, 2004, MOL CANCER THER, V3, P499
   Swenson S, 2007, CURR PHARM DESIGN, V13, P2860, DOI 10.2174/138161207782023793
   Tambourgi DV, 1998, BIOCHEM BIOPH RES CO, V251, P366, DOI 10.1006/bbrc.1998.9474
   Tambourgi DV, 2005, J INVEST DERMATOL, V124, P725, DOI 10.1111/j.0022-202X.2005.23654.x
   Tambourgi DV, 2002, IMMUNOLOGY, V107, P93, DOI 10.1046/j.1365-2567.2002.01483.x
   Tang NH, 2014, EXP DERMATOL, V23, P512, DOI 10.1111/exd.12444
   Tavares FL, 2011, HUM EXP TOXICOL, V30, P1567, DOI 10.1177/0960327110393761
   Tsukahara T, 2015, CELL MOL BIOL LETT, V20, P38, DOI 10.2478/s11658-014-0224-2
   Tsukahara T, 2012, SCI REP-UK, V2, DOI 10.1038/srep00687
   Tsukahara T, 2010, PROSTAG OTH LIPID M, V93, P126, DOI 10.1016/j.prostaglandins.2010.09.002
   Uchiyama A, 2007, BBA-MOL CELL BIOL L, V1771, P103, DOI 10.1016/j.bbalip.2006.10.001
   Vyas Vivek Kumar, 2013, Asian Pacific Journal of Tropical Biomedicine, V3, P156, DOI 10.1016/S2221-1691(13)60042-8
   Wei JX, 2018, P NATL ACAD SCI USA, V115, pE3501, DOI 10.1073/pnas.1721780115
   Xiong SY, 2017, CELL SIGNAL, V34, P92, DOI 10.1016/j.cellsig.2017.03.010
   Yang RS, 2005, TOXICON, V45, P661, DOI 10.1016/j.toxicon.2005.01.013
NR 73
TC 0
Z9 0
U1 2
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT
PY 2019
VL 168
BP 40
EP 48
DI 10.1016/j.toxicon.2019.06.225
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IW3JJ
UT WOS:000484876000005
PM 31251993
DA 2020-05-12
ER

PT J
AU Xu, Y
   Ji, J
   Wu, H
   Pi, FW
   Blazenovic, I
   Zhang, YZ
   Sun, XL
AF Xu, Yun
   Ji, Jian
   Wu, Hao
   Pi, Fuwei
   Blazenovic, Ivana
   Zhang, Yinzhi
   Sun, Xiulan
TI Untargeted GC-TOFMS-based cellular metabolism analysis to evaluate ozone
   degradation effect of deoxynivalenol
SO TOXICON
LA English
DT Article
DE Ozone; Deoxynivalenol; Metabolomics; Degradation effect
ID MYCOTOXINS; CYTOTOXICITY; METABOLOMICS; INFLAMMATION; OZONOLYSIS;
   MECHANISMS; FOOD
AB Ozone plays an increasingly important role in food processing for its antimicrobial ability and degradation effects on mycotoxins. The mycotoxin deoxynivalenol (DON) was treated with saturated aqueous ozone for different amounts of time, and by-products were collected for compounds annotation and cytotoxicity evaluation. To investigate the cytotoxicity of ozone degradation by-products, untargeted GC-TOFMS-based metabolomics were utilized. Caco-2 cells were dosed with 0.1 mu g/mL DON and saturated aqueous ozone-treated DON (treatment time: 1 min, 3 min, 5 min) for 24 h followed by cytotoxicity tests (cell viability assay, ROS assay, and apoptosis assay), and intracellular metabolic analysis. Cytotoxicity test results revealed that ozone treatment could degrade DON structure; however, its degradation products and cellular toxicity existed under different treatment time of ozone. Metabolomics analysis indicated that ozone-treated DON degradation products weakened DON-induced metabolic disorder, such as purines-related nucleotide metabolism; Krebs cycle-related fuel and energy metabolism; and lipid, alkaloid and amino acid metabolism. By contrast, the catecholamine pathway, which is related to latent inflammation and oxidative stress effects, was unaltered in the ozone-treated DON group, indicating that the potential cytotoxicity still existed. These findings provide a comprehensive safety evaluation for ozone-treated DON in vitro and propose a new strategy for studying the effects of ozone-treated food.
C1 [Xu, Yun; Ji, Jian; Pi, Fuwei; Zhang, Yinzhi; Sun, Xiulan] Jiangnan Univ, Synerget Innovat Ctr Food Safety & Qual Control, Sch Food Sci & Technol, State Key Lab Food Sci & Technol, Wuxi 214122, Jiangsu, Peoples R China.
   [Wu, Hao] Guangzhou GRG Metrol & Test Co Ltd, Xiping Yun Rd 163,Whampoa Ave, Guangzhou 510630, Guangdong, Peoples R China.
   [Blazenovic, Ivana] Univ Calif Davis, West Coast Metabol Ctr, Davis, CA 95616 USA.
RP Sun, XL (reprint author), Jiangnan Univ, 1800 Lihu Ave, Wuxi 214122, Jiangsu, Peoples R China.
EM sxlzzz@jiangnan.edu.cn
RI Ji, Jian/AAC-4514-2019
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31772069]; National First-class Discipline Program
   of Food Science and Technology [JUFSTR 20180303]; Jiangsu Agricultural
   Science and Technology Independent Innovation Fund Project
   [CX(17)1003-2]; Synergetic Innovation Center of Food Safety and Quality
   Control; State Grain Administration [201513006-01-05]
FX This work was supported by the National Natural Science Foundation of
   China (No. 31772069), National First-class Discipline Program of Food
   Science and Technology (No. JUFSTR 20180303), Jiangsu Agricultural
   Science and Technology Independent Innovation Fund Project
   (CX(17)1003-2), the State Grain Administration (201513006-01-05) and
   Synergetic Innovation Center of Food Safety and Quality Control.
CR Boccard J, 2013, ANAL CHIM ACTA, V769, P30, DOI 10.1016/j.aca.2013.01.022
   Bony S, 2006, TOXICOL LETT, V166, P67, DOI 10.1016/j.toxlet.2006.04.010
   Broekaert N, 2016, FOOD CHEM TOXICOL, V95, P103, DOI 10.1016/j.fct.2016.06.012
   Buccafusco JJ, 2007, NEUROSCI LETT, V413, P68, DOI 10.1016/j.neulet.2006.11.028
   Chong J, 2018, NUCLEIC ACIDS RES, V46, pW486, DOI 10.1093/nar/gky310
   Cortese M, 2014, CELL METAB, V19, P737, DOI 10.1016/j.cmet.2014.04.012
   CRIEGEE R, 1975, ANGEW CHEM INT EDIT, V14, P745, DOI 10.1002/anie.197507451
   Cui FC, 2018, CHEM-BIOL INTERACT, V281, P81, DOI 10.1016/j.cbi.2017.12.008
   Diao EJ, 2013, FOOD CHEM TOXICOL, V55, P519, DOI 10.1016/j.fct.2013.01.038
   Fernandez-Blanco C, 2016, TOXICOL LETT, V241, P38, DOI 10.1016/j.toxlet.2015.11.005
   Fiehn O, 2002, PLANT MOL BIOL, V48, P155, DOI 10.1023/A:1013713905833
   Freitas-Silva O, 2010, DRUG METAB REV, V42, P612, DOI 10.3109/03602532.2010.484461
   Girardet C, 2011, TOXICOL SCI, V124, P179, DOI 10.1093/toxsci/kfr219
   Hassan YI, 2015, TOXINS, V7, P1989, DOI 10.3390/toxins7061989
   HIBERTY PC, 1976, J AM CHEM SOC, V98, P6088, DOI 10.1021/ja00436a002
   Ji J, 2017, CHEMOSPHERE, V180, P267, DOI 10.1016/j.chemosphere.2017.03.129
   Ji J, 2017, TOXINS, V9, DOI 10.3390/toxins9010028
   Kind T, 2009, ANAL CHEM, V81, P10038, DOI 10.1021/ac9019522
   Lin SH, 2010, TALANTA, V83, P262, DOI 10.1016/j.talanta.2010.09.019
   Liu KQ, 2017, J AGR FOOD CHEM, V65, P6070, DOI 10.1021/acs.jafc.7b01692
   Ma M, 2017, CHEMOSPHERE, V168, P223, DOI 10.1016/j.chemosphere.2016.10.004
   MacIver NJ, 2013, ANNU REV IMMUNOL, V31, P259, DOI 10.1146/annurev-immunol-032712-095956
   Maresca M, 2002, J NUTR, V132, P2723
   McKenzie KS, 1997, FOOD CHEM TOXICOL, V35, P807, DOI 10.1016/S0278-6915(97)00052-5
   Payros D, 2016, ARCH TOXICOL, V90, P2931, DOI 10.1007/s00204-016-1826-4
   Peng Z, 2017, J APPL TOXICOL, V37, P518, DOI 10.1002/jat.3428
   Pestka JJ, 2010, ARCH TOXICOL, V84, P663, DOI 10.1007/s00204-010-0579-8
   Pestka JJ, 2004, TOXICOL LETT, V153, P61, DOI 10.1016/j.toxlet.2004.04.023
   Prosperini A, 2013, TOXICOL LETT, V222, P204, DOI 10.1016/j.toxlet.2013.07.005
   Raiola A, 2015, FOOD CHEM TOXICOL, V84, P169, DOI 10.1016/j.fct.2015.08.023
   Sivamani RK, 2014, J INVEST DERMATOL, V134, P2258, DOI 10.1038/jid.2014.137
   Sun C, 2016, FOOD CONTROL, V69, P185, DOI 10.1016/j.foodcont.2016.04.041
   Trombete FM, 2017, J FOOD PROCESS PRES, V41, DOI 10.1111/jfpp.12927
   Tsugawa H, 2015, NAT METHODS, V12, P523, DOI 10.1038/nmeth.3393
   Vermeulen N, 2006, J AGR FOOD CHEM, V54, P3832, DOI 10.1021/jf052733e
   Wang L, 2017, FOOD ADDIT CONTAM A, V34, P103, DOI 10.1080/19440049.2016.1253112
   Wang L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157137
   Wang XC, 2016, ENVIRON TOXICOL PHAR, V43, P193, DOI 10.1016/j.etap.2016.03.016
   Wyss-Coray T, 2000, NAT MED, V6, P973, DOI 10.1038/79661
   Xu Y, 2019, FOOD ADDIT CONTAM A, V36, P163, DOI 10.1080/19440049.2018.1547425
   Yang H, 2018, ONCOGENE, V37, P3909, DOI 10.1038/s41388-018-0246-8
   Young JC, 2006, FOOD CHEM TOXICOL, V44, P417, DOI 10.1016/j.fct.2005.08.015
   Zhang XO, 2009, TOXICON, V54, P513, DOI 10.1016/j.toxicon.2009.05.021
   Zhang ZZ, 2016, DIFFER EQUAT APPL, V8, P1, DOI 10.7153/dea-08-01
NR 44
TC 0
Z9 0
U1 7
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT
PY 2019
VL 168
BP 49
EP 57
DI 10.1016/j.toxicon.2019.06.022
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IW3JJ
UT WOS:000484876000006
PM 31207350
DA 2020-05-12
ER

PT J
AU Combs, MD
   Hamlin, A
   Quinn, JC
AF Combs, M. D.
   Hamlin, A.
   Quinn, J. C.
TI A single exposure to the tremorgenic mycotoxin lolitrem B inhibits
   voluntary motor activity and spatial orientation but not spatial
   learning or memory in mice
SO TOXICON
LA English
DT Article
DE Lolitrem B; Paxilline; Tremor; Spatial learning; Memory; Paxilline;
   Voluntary movement; Coordination
ID HARMALINE-INDUCED TREMOR; PERENNIAL RYEGRASS TOXICOSIS; LOCATE FOOD
   PATCHES; BEHAVIORAL DESPAIR; GRAZING ANIMALS; SMOOTH-MUSCLE; MUTANT
   MICE; PENITREM; CHANNEL; MAZE
AB The indole diterpenoid toxin lolitrem B is a tremorgenic agent found in the common grass species, perennial ryegrass (Lolium perenne). The toxin is produced by a symbiotic fungus Epichloe festucae (var. lolii) and ingestion of infested grass with sufficient toxin levels causes a movement disorder in grazing herbivores known as 'ryegrass staggers'. Beside ataxia, lolitrem B intoxicated animals frequently show indicators of cognitive dysfunction or exhibition of erratic and unpredictable behaviours during handling. Evidence from field cases in livestock and controlled feeding studies in horses have indicated that intoxication with lolitrem B may affect higher cortical or subcortical functioning. In order to define the role of lolitrem B in voluntary motor control, spatial learning and memory under controlled conditions, mice were exposed to a known dose of purified lolitrem B toxin and tremor, coordination, voluntary motor activity and spatial learning and memory assessed. Motor activity, coordination and spatial memory were compared to tremor intensity using a novel quantitative piezo-electronic tremor analysis. Peak tremor was observed as frequencies between 15 and 25Hz compared to normal movement at approximately 1.4-10Hz. A single exposure to a known tremorgenic dose of lolitrem B (2 mg/kg IP) induced measureable tremor for up to 72 h in some animals. Initially, intoxication with lolitrem B significantly decreased voluntary movement. By 25 h post exposure a return to normal voluntary movement was observed in this group, despite continuing evidence of tremor. This effect was not observed in animals exposed to the short-acting tremorgenic toxin paxilline. Lolitrem B intoxicated mice demonstrated a random search pattern and delayed latency to escape a 3 h post intoxication, however by 27 h post exposure latency to escape matched controls and mice had returned to normal searching behavior indicating normal spatial learning and memory. Together these data indicate that the tremor exhibited by lolitrem B intoxicated mice does not directly impair spatial learning and memory but that exposure does reduce voluntary motor activity in intoxicated animals. Management of acutely affected livestock suffering toxicosis should be considered in the context of their ability to spatially orientate with severe toxicity.
C1 [Combs, M. D.; Quinn, J. C.] Charles Sturt Univ, Sch Anim & Vet Sci, Wagga Wagga, NSW 2560, Australia.
   [Combs, M. D.; Quinn, J. C.] NSW Dept Primary Ind, Graham Ctr Agr Innovat, Wagga Wagga, NSW 2560, Australia.
   [Combs, M. D.; Quinn, J. C.] Charles Sturt Univ, Wagga Wagga, NSW 2560, Australia.
   [Hamlin, A.] Univ New England, Sch Sci & Technol, Armidale, NSW 2351, Australia.
RP Quinn, JC (reprint author), Charles Sturt Univ, Sch Anim & Vet Sci, Wagga Wagga, NSW 2560, Australia.
EM jquinn@csu.edu.au
OI Combs, Martin/0000-0003-0606-7284; Quinn, Jane/0000-0002-9310-0291
FU Meat and Livestock AustraliaMeat and Livestock Australia; Graham Centre
   for Agricultural Innovation at Charles Sturt University
FX The authors wish to thank Sarah Finch at AgResearch, New Zealand for
   supply of lolitrem B toxin. They also acknowledge the assistance of Gill
   Rodgers and Kellie Munn for animal analysis and research facilities
   support. MAC was supported by a Post-Graduate Support Scholarship from
   Meat and Livestock Australia. JCQ was supported by a Research Fellowship
   from the Graham Centre for Agricultural Innovation at Charles Sturt
   University.
CR Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z
   Augustynek BS, 2014, BIOPHYS J, V106, p738A, DOI 10.1016/j.bpj.2013.11.4067
   Balaban CD, 2001, J ANXIETY DISORD, V15, P53, DOI 10.1016/S0887-6185(00)00042-6
   Baloh RW, 2003, NEW ENGL J MED, V348, P1027, DOI 10.1056/NEJMcp021154
   BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579
   BARNES CA, 1980, CAN J PSYCHOL, V34, P29, DOI 10.1037/h0081022
   BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1
   Berntsen HF, 2017, TOXICOLOGY, V392, P64, DOI 10.1016/j.tox.2017.10.008
   Berntsen HF, 2013, NEUROTOXICOLOGY, V35, P129, DOI 10.1016/j.neuro.2013.01.004
   Berta S., 2007, BARNES MAZE USEFUL T
   Brandt T, 2005, BRAIN, V128, P2732, DOI 10.1093/brain/awh617
   Brantberg K, 2005, ACTA OTO-LARYNGOL, V125, P276, DOI 10.1080/00016480510003165
   Breton P, 1998, TOXICON, V36, P645, DOI 10.1016/S0041-0101(97)00084-6
   Cavanagh JB, 1998, VET PATHOL, V35, P53, DOI 10.1177/030098589803500105
   Combs M., 2017, MODEL INVESTIGATION
   Combs M., 2018, NZ VET J, P1
   Combs MD, 2018, NEW ZEAL VET J, V66, P281, DOI 10.1080/00480169.2018.1492986
   Combs MDA, 2014, AUST VET J, V92, P107, DOI 10.1111/avj.12161
   CUNNINGHAM PJ, 1993, AGR ECOSYST ENVIRON, V44, P157, DOI 10.1016/0167-8809(93)90044-P
   DEMONTIGNY C, 1975, CAN J PHYSIOL PHARM, V53, P845, DOI 10.1139/y75-116
   Deuschl G, 1998, MOVEMENT DISORD, V13, P2, DOI 10.1002/mds.870131303
   Edwards GR, 1996, APPL ANIM BEHAV SCI, V50, P147, DOI 10.1016/0168-1591(96)01077-5
   Edwards GR, 1997, APPL ANIM BEHAV SCI, V51, P59, DOI 10.1016/S0168-1591(96)01095-7
   Edwards LE, 2011, APPL ANIM BEHAV SCI, V133, P169, DOI 10.1016/j.applanim.2011.05.014
   Finch S., 2007, P 6 INT S FUNG END G, P363
   Frick KM, 2003, BEHAV NEUROSCI, V117, P1283, DOI 10.1037/0735-7044.117.6.1283
   GALLAGHER RT, 1982, NEW ZEAL VET J, V30, P183, DOI 10.1080/00480169.1982.34936
   GOTHONI P, 1983, N-S ARCH PHARMACOL, V323, P205, DOI 10.1007/BF00497664
   Imlach WL, 2008, J PHARMACOL EXP THER, V327, P657, DOI 10.1124/jpet.108.143933
   Imlach WL, 2011, TOXICON, V57, P686, DOI 10.1016/j.toxicon.2011.01.013
   Imlach WL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008698
   Imlach WL, 2009, EUR J PHARMACOL, V605, P36, DOI 10.1016/j.ejphar.2008.12.031
   Johnstone LK, 2012, EQUINE VET J, V44, P304, DOI 10.1111/j.2042-3306.2011.00439.x
   Johnstone L. K., 2010, CLIN EXPRESSION PERE, P148
   Kamens HM, 2007, NAT PROTOC, V2, P277, DOI 10.1038/nprot.2007.19
   KNAUS HG, 1994, BIOCHEMISTRY-US, V33, P5819, DOI 10.1021/bi00185a021
   Lalonde R, 2003, CEREBELLUM, V2, P300, DOI 10.1080/14734220310017456
   Lee C, 2006, APPL ANIM BEHAV SCI, V96, P43, DOI 10.1016/j.applanim.2005.06.001
   LEHTINEN MS, 1985, IEEE T BIO-MED ENG, V32, P549, DOI 10.1109/TBME.1985.325478
   Mansur Paulo Henrique G., 2007, Critical Reviews in Biomedical Engineering, V35, P343
   Martin FC, 2005, MOVEMENT DISORD, V20, P298, DOI 10.1002/mds.20331
   Martin FC, 2006, MOVEMENT DISORD, V21, P1641, DOI 10.1002/mds.20940
   Matthews EA, 2009, LEARN MEMORY, V16, P106, DOI 10.1101/lm.1289809
   MILNER TE, 1995, J NEUROPHYSIOL, V73, P2568
   Mirkowski M. N., 2013, COGNITIVE FUNCTION B
   Miwa H, 2006, BRAIN RES, V1068, P94, DOI 10.1016/j.brainres.2005.11.036
   Miwa H, 2007, CEREBELLUM, V6, P66, DOI 10.1080/14734220601016080
   Nardi A, 2008, CURR MED CHEM, V15, P1126, DOI 10.2174/092986708784221412
   Oscar-Berman M, 2007, NEUROPSYCHOL REV, V17, P239, DOI 10.1007/s11065-007-9038-6
   Passot JB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032560
   Paterson NE, 2009, EUR J PHARMACOL, V616, P73, DOI 10.1016/j.ejphar.2009.05.031
   Petrosini L, 1996, EUR J NEUROSCI, V8, P1882, DOI 10.1111/j.1460-9568.1996.tb01332.x
   PORSOLT RD, 1978, EUR J PHARMACOL, V51, P291, DOI 10.1016/0014-2999(78)90414-4
   PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327
   Reed K., 2009, PERENNIAL RYEGRASS S
   Reed K., 2002, NEWSL GRASSLD SOC VI
   Reed KFM, 2011, ANIM PROD SCI, V51, P738, DOI 10.1071/AN11016
   Reed KFM, 2011, ANIM PROD SCI, V51, P225, DOI 10.1071/AN10090
   Smith BL, 1997, RES VET SCI, V62, P111, DOI 10.1016/S0034-5288(97)90130-2
   SOBOTKA TJ, 1978, PHARMACOLOGY, V16, P287, DOI 10.1159/000136781
   Typlt M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081270
   Zhou Y, 2014, J GEN PHYSIOL, V144, P415, DOI 10.1085/jgp.201411259
NR 62
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT
PY 2019
VL 168
BP 58
EP 66
DI 10.1016/j.toxicon.2019.06.228
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IW3JJ
UT WOS:000484876000007
PM 31254599
DA 2020-05-12
ER

PT J
AU Yao, JY
   Jin, W
   Li, DM
   Xu, DY
   Wen, SY
   Liu, RY
   Liang, YB
   Lu, SH
AF Yao, Jingyuan
   Jin, Wei
   Li, Dongmei
   Xu, Daoyan
   Wen, Shiyong
   Liu, Renyan
   Liang, Yubo
   Lu, Songhui
TI Geographical distribution and seasonal variation in paralytic shellfish
   toxins in the coastal water of the South China Sea
SO TOXICON
LA English
DT Article
DE Paralytic shellfish toxin; Geographical distribution; Seasonal
   variation; South China sea
ID POISONING TOXINS; BIOTRANSFORMATION; DEPURATION
AB Paralytic shellfish toxins (PSTs) are a group of the most harmful neurotoxins distributed worldwide. Marine organism samples, including mollusks, crustaceans and fish, collected from 11 sites around the coastal water of the South China Sea, were analyzed in terms of the PST and toxicity via high-performance liquid chromatography. The PST geographical distribution, detectable rate for PST and toxin content all increased slightly from 2006 to 2008 to 2015. High PST content with more than 2 nmol g(-1) appeared in Shantou (ST), Shanwei (SW), Zhanjiang (ZJ), Beihai (BH), Xuwen (XW), Haikou (HK), Dongfang (DF), Wanning (WN) and Sanya (SY). Low PST content with less than 2 nmol g(-1) appeared in Shenzhen (SZ) and Yangjiang (YJ). High PST toxicity over the safety limit 800 mu g STXeq/kg appeared in ST, SW, ZJ, BH, DF, SY and XW. PST has significant seasonal characteristics and was mostly detected in spring, early summer (March-June) and autumn (September-November) in the coastal water of the South China Sea. PST was usually detected in some specific species of scallop, mussel, bloody clam, hard clam, razor clam, oyster, crab, shrimp and fish. Toxin profile variation of marine organism samples was influenced greatly by species, sampling time and site.
C1 [Yao, Jingyuan; Jin, Wei; Lu, Songhui] Jinan Univ, Coll Life Sci & Technol, Guangzhou 510632, Guangdong, Peoples R China.
   [Yao, Jingyuan; Jin, Wei; Li, Dongmei; Xu, Daoyan; Wen, Shiyong; Liu, Renyan; Liang, Yubo] Minist Ecol & Environm, Natl Marine Environm Monitoring Ctr, Dalian 116023, Peoples R China.
   [Li, Dongmei; Xu, Daoyan; Wen, Shiyong; Liu, Renyan; Liang, Yubo] Dalian Municipal Phycotoxins Key Lab, Dalian 116023, Peoples R China.
RP Lu, SH (reprint author), Jinan Univ, Coll Life Sci & Technol, Guangzhou 510632, Guangdong, Peoples R China.; Liang, YB (reprint author), Minist Ecol & Environm, Natl Marine Environm Monitoring Ctr, Dalian 116023, Peoples R China.
EM ybliang@nmemc.org.cn; lusonghui1963@163.com
FU National Key Research and Development Program of China [2017YFC1404303,
   2016YFF0201104]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [41276099, 41576120]; National
   Marine Public Welfare Research Project of China [201305010-2]
FX This work was supported by the National Key Research and Development
   Program of China (Grant Nos. 2017YFC1404303 and 2016YFF0201104), the
   National Natural Science Foundation of China (Grant Nos. 41276099 and
   41576120), and the National Marine Public Welfare Research Project of
   China (Grant No. 201305010-2). We thank several anonymous referees for
   their professional comments on this manuscript.
CR Anderson DM, 1996, TOXICON, V34, P579, DOI 10.1016/0041-0101(95)00158-1
   Botana LM, 2017, TRENDS FOOD SCI TECH, V59, P15, DOI 10.1016/j.tifs.2016.09.015
   CEMBELLA AD, 1994, J EXP MAR BIOL ECOL, V180, P1, DOI 10.1016/0022-0981(94)90075-2
   Choi MC, 2003, MAR BIOL, V143, P927, DOI 10.1007/s00227-003-1148-y
   Costa ST, 2016, CHEMOSPHERE, V149, P351, DOI 10.1016/j.chemosphere.2016.01.105
   [杜克梅 Du Kemei], 2013, [暨南大学学报. 自然科学与医学版, Journal of Jinan University], V34, P343
   Jaime E, 2007, HARMFUL ALGAE, V6, P308, DOI 10.1016/j.hal.2006.04.003
   Jiang T., 2000, J JINAN U NATURAL SC, V21, P65
   Jiang T., 2000, CHINA ENV SCI, V20, P341
   Jiang T. J., 2000, MARINE ENV SCI, V19, P1
   Jiang T, 2010, J CENT SOUTH UNIV T, V17, P1190, DOI 10.1007/s11771-010-0617-y
   Jiang Tian-Jiu, 2000, Marine Environmental Science, V19, P16
   Jiang Tian-jiu, 2007, Oceanologia et Limnologia Sinica, V38, P36
   Jiang Tianjiu, 2003, Yingyong Shengtai Xuebao, V14, P1156
   [冷科明 Leng Keming], 2014, [海洋环境科学, Marine Environmental Science], V33, P666
   [冷科明 Leng Keming], 2013, [生态科学, Ecologic Science], V32, P558
   Li A, 2012, FOOD ADDIT CONTAM A, V29, P1455, DOI 10.1080/19440049.2012.699005
   Li Zheng-ju, 2016, Marine Environmental Science, V35, P168
   Lin Yan-tang, 2001, Journal of Fisheries of China, V25, P479
   Lin Yantang, 1999, Tropic Oceanology, V18, P90
   Lin Yantang, 1994, OCEANOLOGY LIMNOLOGY, V25, P220
   [卢楚谦 Lu Chuqian], 2005, [海洋环境科学, Marine Environmental Science], V24, P47
   Oikawa H, 2005, TOXICON, V45, P163, DOI 10.1016/j.toxicon.2004.10.004
   OSHIMA Y, 1982, B JPN SOC SCI FISH, V48, P525
   OSHIMA Y, 1995, J AOAC INT, V78, P528
   Oshima Yasukatsu, 1995, P475
   Shi-Wei W. U., 2008, J MAR SCI, V26, P49
   Shumway S. E., 2010, J WORLD AQUACULT SOC, V21, P65
   Wang DZ, 2006, TOXICON, V48, P138, DOI 10.1016/j.toxicon.2006.04.002
   Wang ZH, 2011, MAR ENVIRON RES, V72, P53, DOI 10.1016/j.marenvres.2011.04.007
   Wiese M, 2010, MAR DRUGS, V8, P2185, DOI 10.3390/md8072185
   [吴施卫 Wu Shiwei], 2005, [海洋通报, Marine Science Bulletin], V24, P48
   [吴施卫 Wu Shiwei], 2005, [海洋环境科学, Marine Environmental Science], V24, P40
   Yang M., 1999, J ZHEJIANG OCEAN U N, V19, P38
   Yang Mei-lan, 2002, Journal of Fishery Sciences of China, V9, P283
   [杨美兰 Yang Meilan], 2005, [海洋环境科学, Marine Environmental Science], V24, P48
   Zhou MJ, 1999, MAR POLLUT BULL, V39, P331, DOI 10.1016/S0025-326X(99)00026-0
NR 37
TC 0
Z9 0
U1 8
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT
PY 2019
VL 168
BP 67
EP 75
DI 10.1016/j.toxicon.2019.06.221
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IW3JJ
UT WOS:000484876000008
PM 31251991
DA 2020-05-12
ER

PT J
AU Fuchs, J
   Weiler, S
   Meier, J
AF Fuchs, Joan
   Weiler, Stefan
   Meier, Jurg
TI Envenomation by a western green mamba (Dendroaspis viridis) - A report
   of three episodes in Switzerland
SO TOXICON
LA English
DT Review
DE Dendroaspis viridis; Neurotoxic; Local symptoms; Fasciotomy; Antivenom
ID FASCIOTOMY; BITE; ANTIVENOM; VENOM
AB The African elapid snake genus Dendroaspis comprises four species, with D. polylepsis the most dangerous of them. D. viridis is believed to cause stronger neurotoxic symptoms than the potentially least toxic of the genus, D. angusticeps, but seems less toxic compared to either of the D. jamesoni species (D. j. jomesoni(TRAILL 1843) and D. j. kaimosae (Loveridge 1936)). We present three episodes of bites by D. viridis in the same patient, sustained on three different occasions, caused by three different and unrelated snakes. While the first bite remained oligosymptomatic with a slight tightness of the throat and speedy resolution of symptoms without specific therapy, episodes two and three resulted in the patient developing massive local swelling. However, the patient showed only minimal neurologic and systemic symptoms such as tightness of the throat and a tingling sensation of the body. Episode two resolved with fasciotomy after compartment syndrome was diagnosed with a measured intracompartmental pressure of 52 mmHg. In episode three, antivenom was administered with good resolution of symptoms.
   The clinical courses in this patient were remarkable as he displayed mainly local symptoms after three individual bites by a supposedly neurotoxic snake.
C1 [Fuchs, Joan; Weiler, Stefan] Univ Zurich, Associated Inst, Tox Info Suisse, Natl Poisons Informat Ctr, Zurich, Switzerland.
   [Weiler, Stefan] ETH, Dept Chem & Appl Biosci, Inst Pharmaceut Sci, Zurich, Switzerland.
   [Meier, Jurg] Univ Basel, Dept Environm Sci, Basel, Switzerland.
RP Fuchs, J (reprint author), Tox Info Suisse, Freiestr 16, CH-8032 Zurich, Switzerland.
EM joan.fuchs@toxinfo.ch
CR Ainsworth S, 2018, J PROTEOMICS, V172, P173, DOI 10.1016/j.jprot.2017.08.016
   Chippaux J.-P, 1977, Medecine trop, V37, P545
   Chippaux J. P., 2002, ANTIDOTES IMMUNOTHER, DOI [10.4000/books.irdeditions.10622, DOI 10.4000/BOOKS.IRDEDITIONS.10622]
   CHIPPAUX JP, 1991, B SOC PATHOL EXOT, V84, P286
   Cumpston KL, 2011, CLIN TOXICOL, V49, P351, DOI 10.3109/15563650.2011.597032
   Darracq MA, 2015, TOXICON, V101, P23, DOI 10.1016/j.toxicon.2015.04.014
   de Haro L, 2003, VET HUM TOXICOL, V45, P214
   FREYVOGEL THIERRY A., 1965, ACTA TROP, V22, P11
   Fulton J, 2005, ANN EMERG MED, V45, P338, DOI 10.1016/j.annemergmed.2004.08.049
   Gawarammana IB, 2004, MED J AUSTRALIA, V180, P20, DOI 10.5694/j.1326-5377.2004.tb05768.x
   Hsu CP, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0179-y
   Kanaan NC, 2015, WILD ENVIRON MED, V26, P472, DOI 10.1016/j.wem.2015.05.007
   Kim YH, 2019, ARCH PLAST SURG-APS, V46, P69, DOI 10.5999/aps.2018.00577
   Leclerc T, 2008, ANN FR ANESTH, V27, P323, DOI 10.1016/j.annfar.2007.10.040
   MacKay N., 1966, East African Medical Journal, V43, P454
   Mai J., 2014, ANAT PHYSL, V4, P161, DOI [10.4172/2161-0940, DOI 10.4172/2161-0940]
   MEIER J, 1986, TOXICON, V24, P41, DOI 10.1016/0041-0101(86)90164-9
   SENNWALD G, 1992, SCHWEIZ MED WSCHR, V122, P696
   Shirokawa M., 2011, JJAAM, V22, P777
   SLABBERT NP, 1979, J BONE JOINT SURG BR, V61, P259
   TAN NH, 1991, COMP BIOCHEM PHYS C, V99, P463, DOI 10.1016/0742-8413(91)90272-U
   TILBURY CR, 1982, S AFR MED J, V61, P308
   Warrell D. A., 1995, HDB CLIN TOXICOLOGY, V1995, P463
   Warrell DA, 2019, INFECT DIS CLIN N AM, V33, P17, DOI 10.1016/j.idc.2018.10.001
NR 24
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT
PY 2019
VL 168
BP 76
EP 82
DI 10.1016/j.toxicon.2019.06.223
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IW3JJ
UT WOS:000484876000009
PM 31254601
DA 2020-05-12
ER

PT J
AU Tilahun, S
   Kifle, D
   Zewde, TW
   Johansen, JA
   Demissie, TB
   Hansen, JH
AF Tilahun, Samson
   Kifle, Demeke
   Zewde, Tigist W.
   Johansen, Jostein A.
   Demissie, Taye B.
   Hansen, Jorn H.
TI Temporal dynamics of intra-and extra-cellular microcystins
   concentrations in Koka reservoir (Ethiopia): Implications for public
   health risk
SO TOXICON
LA English
DT Article
DE Cyanobacteria; Intra-cellular; Extra-cellular; Eutrophication;
   Microcystis, microcystin nitrogen; Tropical
ID CYANOBACTERIAL TOXINS; LAKE; BLOOMS; AERUGINOSA; SEDIMENTS
AB This study was carried out with a view of understanding the temporal dynamics of microcystin concentrations in both algal seston and water samples and the associated public health risk. All the major MC variants, namely MC-LR, MC-YR, and MC-RR, were detected in both the algal seston and water samples. In the majority of the samples, the most potent variant, MC-LR, constituted the greatest proportion of the total MC concentration suggesting extremely high potential public health risk. The exceptionally high concentrations (mu g L-1) of all the variants, MC-LR (815), MC-YR (466.6) and MC-RR (265.68), were observed in May. Although the extracellular MCs were relatively less concentrated and less frequently detected, concentrations (mu g L-1) of up to 20 of MC-LR, 6.13 of MC-YR, and 1.27 MC-RR were encountered. The strong and significant association between Microcystis abundance and concentration of nitrate (Spearman Rank Order Correlation r = 0.793, p < 0.001) may suggest that nitrate is the key dictating factor in the dynamics of Microcystis, and may have consequently influenced the MC levels in the reservoir.
C1 [Tilahun, Samson; Zewde, Tigist W.] Addis Ababa Univ, Ethiopian Inst Water Resources, POB 1176, Addis Ababa, Ethiopia.
   [Kifle, Demeke] Addis Ababa Univ, Dept Zool Sci, POB 1176, Addis Ababa, Ethiopia.
   [Johansen, Jostein A.; Hansen, Jorn H.] UiT Arctic Univ Norway, Dept Chem, Organ Chem Grp, N-9037 Tromso, Norway.
   [Demissie, Taye B.] Addis Ababa Univ, Dept Chem, Mat Sci Program, POB 1176, Addis Ababa, Ethiopia.
RP Tilahun, S (reprint author), Addis Ababa Univ, Ethiopian Inst Water Resources, POB 1176, Addis Ababa, Ethiopia.
EM samson.tilahun@aau.edu.et
FU USAID, Higher Education for Development (HED); Addis Ababa University;
   Swedish International Development Cooperation Agency (SIDA); Department
   of Chemistry at UiT The Arctic University of Norway
FX The authors greatly acknowledge the financial support provided by USAID,
   Higher Education for Development (HED) and Addis Ababa University.
   T.W.Z. acknowledges the support from Swedish International Development
   Cooperation Agency (SIDA); whereas T.B.D., J.A.J. and J.H.H. acknowledge
   the Department of Chemistry at UiT The Arctic University of Norway for
   financial and materials support.
CR Abebe M., 2001, P 4 INT C HYDR BERG, P345
   AMERICAN PUBLIC HEALTH ASSOCIATION (APHA), 1999, STANDARD METHODS EXA
   Amha B., 1982, SINET ETHIOP J SCI, V5, P1
   Backer LC, 2002, LAKE RESERV MANAGE, V18, P20, DOI 10.1080/07438140209353926
   Ballot A, 2003, LIMNOLOGICA, V33, P2, DOI 10.1016/S0075-9511(03)80003-8
   Carmichael WW, 1997, APPL ENVIRON MICROB, V63, P3104, DOI 10.1128/AEM.63.8.3104-3110.1997
   Chorus I, 2000, J TOXICOL ENV HEAL B, V3, P323, DOI 10.1080/109374000436364
   Cronberg G, 2004, NOVA HEDWIGIA, V78, P71, DOI 10.1127/0029-5035/2004/0078-0071
   Dai RH, 2008, TOXICON, V51, P649, DOI 10.1016/j.toxicon.2007.11.021
   Davis TW, 2009, HARMFUL ALGAE, V8, P715, DOI 10.1016/j.hal.2009.02.004
   de Figueiredo DR, 2004, ECOTOX ENVIRON SAFE, V59, P151, DOI 10.1016/j.ecoenv.2004.04.006
   Dittmann E, 2006, MOL NUTR FOOD RES, V50, P7, DOI 10.1002/mnfr.200500162
   Falconer Ian R, 2005, Int J Environ Res Public Health, V2, P43, DOI 10.3390/ijerph2005010043
   Fan JJ, 2014, J ENVIRON ENG, V140, DOI 10.1061/(ASCE)EE.1943-7870.0000852
   Fromme H, 2000, ENVIRON TOXICOL, V15, P120, DOI 10.1002/(SICI)1522-7278(2000)15:2<120::AID-TOX8>3.0.CO;2-X
   Halcrow W., 1989, ETHIOPIAN VALL UNPUB, P4
   Halinen K, 2007, APPL ENVIRON MICROB, V73, P6543, DOI 10.1128/AEM.01377-07
   HAWKINS PR, 1985, APPL ENVIRON MICROB, V50, P1292, DOI 10.1128/AEM.50.5.1292-1295.1985
   HOTZEL G, 1999, PHYTOPLANKTON METHOD
   Ibelings BW, 2007, ENVIRON POLLUT, V150, P177, DOI 10.1016/j.envpol.2007.04.012
   Jahnichen S, 2011, HARMFUL ALGAE, V12, P95, DOI 10.1016/j.hal.2011.09.002
   Jurczak T, 2005, WATER RES, V39, P2394, DOI 10.1016/j.watres.2005.04.031
   Kebede E., 1996, ACTA U UPSAL PHYTOPL
   Kebede Elizabeth, 1998, Archiv fuer Hydrobiologie Supplement, V124, P63
   KOMAREK J, 1991, ARCH HYDROBIOL, P21
   KOMAREK J, 2005, CYANOPROKARYOTA, V2, P759
   Kotak BG, 2007, LAKE RESERV MANAGE, V23, P109, DOI 10.1080/07438140709353915
   Krienitz L., 2002, CYANOTOXIN PRODUCING
   LAWTON LA, 1994, ANALYST, V119, P1525, DOI 10.1039/an9941901525
   Li ZL, 2010, HARMFUL ALGAE, V9, P481, DOI 10.1016/j.hal.2010.03.003
   MESFIN M, 1988, HYDROBIOLOGIA, V157, P47, DOI 10.1007/BF00008809
   Mwaura F, 2004, J WATER HEALTH, V2, P49
   O'Neil JM, 2012, HARMFUL ALGAE, V14, P313, DOI 10.1016/j.hal.2011.10.027
   PARK HD, 1993, ENVIRON TOXIC WATER, V8, P425, DOI 10.1002/tox.2530080407
   Park HD, 1998, ENVIRON TOXIC WATER, V13, P61, DOI 10.1002/(SICI)1098-2256(1998)13:1<61::AID-TOX4>3.0.CO;2-5
   Romo S, 2013, FRESHWATER BIOL, V58, P513, DOI 10.1111/j.1365-2427.2012.02734.x
   Rouhiainen L, 2004, APPL ENVIRON MICROB, V70, P686, DOI 10.1128/AEM.70.2.686-692.2004
   Roy-Lachapelle A, 2015, J AGR FOOD CHEM, V63, P7440, DOI 10.1021/acs.jafc.5b02318
   Rucker J, 2007, TOXICON, V50, P800, DOI 10.1016/j.toxicon.2007.06.019
   Semyalo R, 2011, LIMNOLOGICA, V41, P30, DOI 10.1016/j.limno.2010.04.002
   Shahis M., 1993, P YOK S 217 IAHS I H, P93
   Song HH, 2015, TOXINS, V7, P900, DOI 10.3390/toxins7030900
   Tilahun S, 2019, AQUAT ECOL, V53, P61, DOI 10.1007/s10452-019-09673-9
   TSUJI K, 1994, ENVIRON SCI TECHNOL, V28, P173, DOI 10.1021/es00050a024
   Tsuji K, 2001, TOXICON, V39, P687, DOI 10.1016/S0041-0101(00)00196-3
   Verspagen JMH, 2005, FRESHWATER BIOL, V50, P854, DOI 10.1111/j.1365-2427.2005.01368.x
   Wang Q, 2010, THESCIENTIFICWORLDJO, V10, P1795, DOI 10.1100/tsw.2010.172
   WATANABE MF, 1985, APPL ENVIRON MICROB, V49, P1342, DOI 10.1128/AEM.49.5.1342-1344.1985
   Weng D, 2007, TOXICOLOGY, V232, P15, DOI 10.1016/j.tox.2006.12.010
   Wetzel R., 2000, LIMNOLGICAL ANAL, P357
   Willen E, 2011, INLAND WATERS, V1, P81, DOI 10.5268/IW-1.2.391
   Wormer L, 2011, CHEMOSPHERE, V82, P1141, DOI 10.1016/j.chemosphere.2010.11.024
   World Health Organization (WHO), 1998, HLTH CRIT OTH SUPP I, V2
   Wu XQ, 2012, ANAL CHIM ACTA, V709, P66, DOI 10.1016/j.aca.2011.10.027
   Zewde T. W., 2018, CYANOBACTERIAL DEV L
   Zewde TW, 2018, TOXICON, V153, P85, DOI 10.1016/j.toxicon.2018.08.013
   Zhang M, 2012, WATER RES, V46, P442, DOI 10.1016/j.watres.2011.11.013
NR 57
TC 2
Z9 2
U1 3
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT
PY 2019
VL 168
BP 83
EP 92
DI 10.1016/j.toxicon.2019.06.217
PG 10
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IW3JJ
UT WOS:000484876000010
PM 31228479
DA 2020-05-12
ER

PT J
AU Codd, GA
   Nunn, PB
AF Codd, Geoffrey A.
   Nunn, Peter B.
TI Cyanotoxin production beyond the cyanobacteria
SO TOXICON
LA English
DT Letter
ID BIOSYNTHESIS
C1 [Codd, Geoffrey A.] Univ Dundee, Sch Life Sci, Dundee DD1 5EH, Scotland.
   [Codd, Geoffrey A.] Univ Stirling, Sch Nat Sci, Stirling FK9 4LA, Scotland.
   [Nunn, Peter B.] Univ Portsmouth, Sch Pharm & Biomed Sci, Portsmouth PO1 1DT, Hants, England.
RP Codd, GA (reprint author), Univ Dundee, Sch Life Sci, Dundee DD1 5EH, Scotland.
EM g.a.codd@stir.ac.uk
CR Ballot A., 2017, HDB CYANOBACTERIAL M, P148, DOI DOI 10.1002/9781119068761
   Buratti FM, 2017, ARCH TOXICOL, V91, P1049, DOI 10.1007/s00204-016-1913-6
   Jiang LY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084578
   Jiang Z, 2014, J CAUSAL INFERENCE, V2, P1, DOI 10.1515/jci-2012-0006
   Laczny CC, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00884
   Llewellyn L, 2006, TOXIN REV, V25, P159, DOI 10.1080/15569540600599217
   Meriluoto J., 2017, HDB CYANOBACTERIAL M
   Metcalf J.S., 2012, ECOLOGY CYANOBACTERI, p651?675
   Monchamp ME, 2019, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03344
   Monteiro S., 2017, HDB CYANOBACTERIAL M, P165
   Moss B. R., 2018, ECOLOGY FRESHWATERS
   Muller S, 2014, ANGEW CHEM INT EDIT, V53, P10821, DOI 10.1002/anie.201404572
   Nunn PB, 2017, PHYTOCHEMISTRY, V144, P271, DOI 10.1016/j.phytochem.2017.10.002
   Nunn PB, 2017, PHYTOCHEMISTRY, V144, P253, DOI 10.1016/j.phytochem.2017.09.015
   Pearson LA, 2016, HARMFUL ALGAE, V54, P98, DOI 10.1016/j.hal.2015.11.002
   Shih PM, 2017, GEOBIOLOGY, V15, P19, DOI 10.1111/gbi.12200
   SHOJI J, 1975, J ANTIBIOT, V28, P122, DOI 10.7164/antibiotics.28.122
   Svircev Z, 2017, ARCH TOXICOL, V91, P621, DOI 10.1007/s00204-016-1921-6
NR 18
TC 0
Z9 0
U1 4
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT
PY 2019
VL 168
BP 93
EP 94
DI 10.1016/j.toxicon.2019.06.226
PG 2
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IW3JJ
UT WOS:000484876000011
PM 31265845
DA 2020-05-12
ER

PT J
AU Lingam, TMC
   Tan, KY
   Tan, CH
AF Lingam, Thava Malar Changra
   Tan, Kae Yi
   Tan, Choo Hock
TI Thai Russell's viper monospecific antivenom is immunoreactive and
   effective in neutralizing the venom of Daboia siamensis from Java,
   Indonesia
SO TOXICON
LA English
DT Article
DE Daboia siamensis; Eastern Russell's viper; Antivenom; Neutralization
ID COMPLEX; COBRA; NAJA
AB Daboia siamensis monovalent antivenom (DSMAV, Thailand) exhibited comparable immunoreactivity toward the venoms of eastern Russell's vipers from Thailand and Indonesia. It also effectively neutralized the procoagulant and lethal effects of both venoms, showing high potency. The Indonesian heterologous trivalent antivenom SABU (Serum Anti Bisa Ular), however, has very weak immunoreactivity and it failed to neutralize the Russell's viper venoms. DSMAV appears to be the appropriate choice of antivenom to treat Russell's viper envenoming.
C1 [Lingam, Thava Malar Changra; Tan, Kae Yi] Univ Malaya, Fac Med, Dept Mol Med, Kuala Lumpur 50603, Malaysia.
   [Tan, Choo Hock] Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur 50603, Malaysia.
RP Tan, CH (reprint author), Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur 50603, Malaysia.
EM tanch@um.edu.my
RI TAN, KAE YI/D-7915-2017; TAN, KAE YI/H-6727-2017; Tan, Choo
   Hock/B-9905-2010
OI TAN, KAE YI/0000-0002-6938-7325; TAN, KAE YI/0000-0002-6938-7325; Tan,
   Choo Hock/0000-0003-1416-077X
FU Universiti MalayaUniversiti Malaya [RF007C-2018]
FX The work was supported by research grant RF007C-2018 from the Universiti
   Malaya. Authors would like to express gratitude to Dr Tri Maharani from
   the Ministry of Health, Indonesia for clinical inputs, and Queen
   Saovabha Memorial Institute (Bangkok, Thailand) and Biofarma (Java,
   Indonesia) for antivenom supply.
CR Adiwinata R, 2015, ACTA MED INDONES, V47, P358
   Belt PM A., 1997, VENOMOUS SNAKES ECOL, P207
   Faisal T, 2018, J PROTEOMICS, V183, P1, DOI 10.1016/j.jprot.2018.05.003
   Kularatne SAM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090198
   Mukherjee AK, 2016, J PROTEOMICS, V144, P73, DOI 10.1016/j.jprot.2016.06.001
   Print M, 2015, CIVIC POLIT EDUC, P1
   Sapsutthipas S, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003609
   Tan CH, 2019, TOXINS, V11, DOI 10.3390/toxins11020095
   Tan CH, 2017, TOXICON, V140, P32, DOI 10.1016/j.toxicon.2017.10.014
   Tan CH, 2016, SCI REP-UK, V6, DOI 10.1038/srep37299
   Tan KY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25955-y
   Tan NH, 2017, J PROTEOMICS, V157, P18, DOI 10.1016/j.jprot.2017.01.018
   THANTHAN, 1988, BRIT J HAEMATOL, V69, P513, DOI 10.1111/j.1365-2141.1988.tb02408.x
   Thorpe RS, 2007, HERPETOL J, V17, P209
   UETZ P, 2019, REPTILE DATABASE
   WHO, 2010, GUID PROD CONTR REG
   WHO, 2016, GUID MAN SNAK BIT
   Wong KY, 2016, AM J TROP MED HYG, V94, P1392, DOI 10.4269/ajtmh.15-0871
NR 18
TC 3
Z9 3
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT
PY 2019
VL 168
BP 95
EP 97
DI 10.1016/j.toxicon.2019.06.227
PG 3
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IW3JJ
UT WOS:000484876000012
PM 31254600
DA 2020-05-12
ER

PT J
AU Huicab-Uribe, MA
   Verdel-Aranda, K
   Martinez-Hernandez, A
   Zamudio, FZ
   Jimenez-Vargas, JM
   Lara-Reyna, J
AF Huicab-Uribe, M. A.
   Verdel-Aranda, K.
   Martinez-Hernandez, A.
   Zamudio, F. Z.
   Jimenez-Vargas, J. M.
   Lara-Reyna, J.
TI Molecular composition of the paralyzing venom of three solitary wasps
   (Hymenoptera: Pompilidae) collected in southeast Mexico
SO TOXICON
LA English
DT Article
DE Pompilidae; Venom composition; Solitary spider wasp; Peptide profile;
   Enzymatic activities
ID ANTIMICROBIAL PEPTIDE; PROTEINS; KININS; IDENTIFICATION; TRANSCRIPTOME;
   TRANSMISSION; NEUROTOXINS; MASTOPARAN; COMPONENTS; MORPHOLOGY
AB The chemical and biological characterization of peptide and protein components of the paralyzing venom from three Pompilidae solitary spider wasps (Pepsis mexicana, Pepsis terminata, and Anoplius nigritus) is described for the first time. The molecular masses of the most abundant peptides were determined. The N-terminal sequences of two cysteine-rich peptides were obtained from Pepsis. Metalloproteinase and hyaluronidase activities were identified in the venom of P. mexicana. A novel non-lethal method to collect venom is described.
C1 [Huicab-Uribe, M. A.; Martinez-Hernandez, A.; Lara-Reyna, J.] Colegio Postgrad, Campus Campeche, Champoton 24450, Campeche, Mexico.
   [Zamudio, F. Z.; Jimenez-Vargas, J. M.] Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Mol Med & Bioproc, Cuernavaca, Morelos, Mexico.
   [Verdel-Aranda, K.] CONACyT, Colegio Postgrad, Champoton 24450, Campeche, Mexico.
   [Jimenez-Vargas, J. M.] Univ Colima, CONACyT, Fac Ciencias Quim, Km 9 Carretera Coquimatlan, Coquimatlan 28400, Colima, Mexico.
RP Lara-Reyna, J (reprint author), Colegio Postgrad, Campus Campeche, Champoton 24450, Campeche, Mexico.
EM jlara@colpos.mx
RI Verdel-Aranda, Karina/N-8568-2017
OI Verdel-Aranda, Karina/0000-0002-7827-5464; Lara,
   Joel/0000-0003-2944-0328; Martinez-Hernandez, Aida/0000-0003-1784-670X
FU National Council for Science and Technology [453330]
FX The authors acknowledge the support received from Dr. Lourival D.
   Possani from the Institute of Biotechnology of the National Autonomous
   University of Mexico during the development of this work. H-U.M. thanks
   the master scholarship 453330 from the National Council for Science and
   Technology.
CR Baek JH, 2013, J ASIA-PAC ENTOMOL, V16, P497, DOI 10.1016/j.aspen.2013.08.003
   Baek JH, 2010, TOXICON, V56, P554, DOI 10.1016/j.toxicon.2010.05.014
   Bateman A, 2017, NUCLEIC ACIDS RES, V45, pD158, DOI 10.1093/nar/gkw1099
   Beleboni RD, 2004, EUR J PHARMACOL, V493, P1, DOI 10.1016/j.ejphar.2004.03.049
   Bordon KCF, 2015, J VENOM ANIM TOXINS, V21, DOI 10.1186/s40409-015-0042-7
   Cid-Uribe JI, 2018, TOXICON, V151, P47, DOI 10.1016/j.toxicon.2018.06.085
   Csoka TB, 1997, INVAS METAST, V17, P297
   ELDEFRAWI AT, 1988, P NATL ACAD SCI USA, V85, P4910, DOI 10.1073/pnas.85.13.4910
   EVANS HE, 1953, SYST ZOOL, V2, P155, DOI 10.2307/2411559
   EVANS HOWARD E., 1966, MEM AMER ENTOMOL SOC, V20, P1
   Girish KS, 2007, LIFE SCI, V80, P1921, DOI 10.1016/j.lfs.2007.02.037
   Goulet H, 1993, HYMENOPTERA WORLD ID
   Hisada M, 2005, BIOCHEM BIOPH RES CO, V330, P1048, DOI 10.1016/j.bbrc.2005.03.087
   Kall L, 2007, NUCLEIC ACIDS RES, V35, pW429, DOI 10.1093/nar/gkm256
   Konno K, 2000, TOXICON, V38, P1505, DOI 10.1016/S0041-0101(00)00083-0
   Konno K, 1997, NEUROSCI LETT, V238, P99, DOI 10.1016/S0304-3940(97)00849-5
   Konno K, 1998, BIOCHEM BIOPH RES CO, V250, P612, DOI 10.1006/bbrc.1998.9299
   Konno K, 2002, TOXICON, V40, P309, DOI 10.1016/S0041-0101(01)00230-6
   Konno K, 2001, BBA-PROTEIN STRUCT M, V1550, P70, DOI 10.1016/S0167-4838(01)00271-0
   Konno K, 2006, PEPTIDES, V27, P2624, DOI 10.1016/j.peptides.2006.04.013
   Konno K, 2016, TOXINS, V8, DOI 10.3390/toxins8040114
   Kumpanenko AS, 2018, ENTOMOL SCI, V21, P124, DOI 10.1111/ens.12288
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lee SH, 2016, TOXINS, V8, DOI 10.3390/toxins8020032
   Murata K, 2009, AMINO ACIDS, V37, P389, DOI 10.1007/s00726-008-0166-y
   Nolasco M, 2018, TOXICON, V150, P74, DOI 10.1016/j.toxicon.2018.04.023
   O'Neil K. M., 2001, SOLITARY WASPS BEHAV, P54
   Palma MS, 2006, HANDBOOK OF BIOLOGICALLY ACTIVE PEPTIDES, P389, DOI 10.1016/B978-012369442-3/50059-3
   Picolo G, 2010, BIOCHEM PHARMACOL, V79, P478, DOI 10.1016/j.bcp.2009.08.020
   PIEK T, 1988, INT CONGR SER, V832, P61
   PIEK T, 1991, TOXICON, V29, P139, DOI 10.1016/0041-0101(91)90098-C
   Piek T., 1986, P45
   Piek T, 2000, METH TOOLS BIOSCI ME, P99
   PIEK T, 1990, COMP BIOCHEM PHYS C, V96, P157, DOI 10.1016/0742-8413(90)90062-E
   Prado J. L., 1966, HYPOTENSIVE PEPTIDES, P93, DOI 10.1007/978-3-642-94965-4_11
   Price DRG, 2009, INSECT MOL BIOL, V18, P195, DOI 10.1111/j.1365-2583.2009.00864.x
   Punzo Fred, 1994, Psyche (Cambridge), V101, P243, DOI 10.1155/1994/27564
   Schoeters E, 1997, CAN J ZOOL, V75, P1014, DOI 10.1139/z97-122
   TOLKSDORF S, 1949, J LAB CLIN MED, V34, P74
   Townes H., 1957, Bulletin United States National Museum, V209, P1
   Ueberheide BM, 2009, P NATL ACAD SCI USA, V106, P6910, DOI 10.1073/pnas.0900745106
   Vardy C. R., 2002, ZOOL VERHANDEL, V135
   Vardy C. R., 2000, ZOOL VERHANDEL, V86
   Wasbauer M.S., 1985, Bulletin of the California Insect Survey, V26, P1
   YASUHARA T, 1987, TOXICON, V25, P527, DOI 10.1016/0041-0101(87)90288-1
   Zamyatnin AA, 2006, NUCLEIC ACIDS RES, V34, pD261, DOI 10.1093/nar/gkj008
NR 46
TC 0
Z9 0
U1 3
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT
PY 2019
VL 168
BP 98
EP 102
DI 10.1016/j.toxicon.2019.06.224
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IW3JJ
UT WOS:000484876000013
PM 31251992
DA 2020-05-12
ER

PT J
AU Keyler, DE
   Sanchez, EE
   Mackessy, SP
AF Keyler, Daniel E.
   Sanchez, Elda E.
   Mackessy, Stephen P.
TI Venom Week VI Texas A&M University, Kingsville, Texas, March 14-18, 2018
   North American Society of Toxinology
SO TOXICON
LA English
DT Editorial Material
C1 [Keyler, Daniel E.] Univ Minnesota, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA.
   [Sanchez, Elda E.] Texas A&M Univ, Natl Nat Toxins Res Ctr, Kingsville, TX 78363 USA.
   [Mackessy, Stephen P.] Univ Northern Colorado, Sch Biol Sci, Greeley, CO 80639 USA.
RP Keyler, DE (reprint author), Univ Minnesota, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA.
EM keyle001@umn.edu; elda.sanchez@tamuk.edu; stephen.mackessy@unco.edu
OI Mackessy, Stephen/0000-0003-4515-2545
NR 0
TC 0
Z9 0
U1 1
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT
PY 2019
VL 168
BP 103
EP 103
DI 10.1016/j.toxicon.2019.07.001
PG 1
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IW3JJ
UT WOS:000484876000014
PM 31278909
DA 2020-05-12
ER

PT J
AU Elnahriry, KA
   Wai, DCC
   Krishnarjuna, B
   Badawy, NN
   Chittoor, B
   MacRaild, CA
   Williams-Noonan, BJ
   Surm, JM
   Chalmers, DK
   Zhang, AH
   Peigneur, S
   Mobli, M
   Tytgat, J
   Prentis, P
   Norton, RS
AF Elnahriry, Khaled A.
   Wai, Dorothy C. C.
   Krishnarjuna, Bankala
   Badawy, Noha N.
   Chittoor, Balasubramanyam
   MacRaild, Christopher A.
   Williams-Noonan, Billy J.
   Surm, Joachim M.
   Chalmers, David K.
   Zhang, Alan H.
   Peigneur, Steve
   Mobli, Mehdi
   Tytgat, Jan
   Prentis, Peter
   Norton, Raymond S.
TI Structural and functional characterisation of a novel peptide from the
   Australian sea anemone Actinia tenebrosa
SO TOXICON
LA English
DT Article
DE Sea anemone; Cysteine-containing peptide; Structure; NMR spectroscopy;
   Lipid interactions
ID PERIODIC BOUNDARY-CONDITIONS; PARTICLE MESH EWALD; MOLECULAR-DYNAMICS;
   ELECTROSTATIC SYSTEMS; PROTEIN STRUCTURES; CONSTANT-PRESSURE; K+
   CHANNELS; NMR; TOXINS; DIFFUSION
AB Sea anemone venoms have long been recognised as a rich source of peptides with interesting pharmacological and structural properties. Our recent transcriptomic studies of the Australian sea anemone Actinia tenebrosa have identified a novel 13-residue peptide, U-AITx-Ate1. U-AITx-Ate1 contains a single disulfide bridge and bears no significant homology to previously reported amino acid sequences of peptides from sea anemones or other species. We have produced U-AITx-Ate1 using solid-phase peptide synthesis, followed by oxidative folding and purification of the folded peptide using reversed-phase high-performance liquid chromatography. The solution structure of U-AITx-Ate1 was determined based on two-dimensional nuclear magnetic resonance spectroscopic data. Diffusion-ordered NMR spectroscopy revealed that U-AITx-Ate1 was monomeric in solution. Perturbations in the 1D H-1 NMR spectrum of U-AITx-Ate1 in the presence of dodecylphosphocholine micelles together with molecular dynamics simulations indicated an interaction of U-AITx-Ate1 with lipid membranes, although no binding was detected to 100% POPC and 80% POPC: 20% POPG lipid nanodiscs by isothermal titration calorimetry. Functional assays were performed to explore the biological activity profile of U-AITx-Ate1. U-AITx-Ate1 showed no activity in voltage-clamp electrophysiology assays and no change in behaviour and mortality rates in crustacea. Moderate cytotoxic activity was observed against two breast cancer cell lines.
C1 [Elnahriry, Khaled A.; Wai, Dorothy C. C.; Krishnarjuna, Bankala; Badawy, Noha N.; Chittoor, Balasubramanyam; MacRaild, Christopher A.; Williams-Noonan, Billy J.; Chalmers, David K.; Norton, Raymond S.] Monash Univ, Monash Inst Pharmaceut Sci, Med Chem, 381 Royal Parade, Parkville, Vic 3052, Australia.
   [Surm, Joachim M.] Queensland Univ Technol, Fac Hlth, Sch Biomed Sci, Brisbane, Qld, Australia.
   [Surm, Joachim M.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Kelvin Grove, Australia.
   [Prentis, Peter] Queensland Univ Technol, Sci & Engn Fac, Sch Earth Environm & Biol Sci, Brisbane, Qld, Australia.
   [Prentis, Peter] Queensland Univ Technol, Inst Future Environm, Brisbane, Qld, Australia.
   [Zhang, Alan H.; Mobli, Mehdi] Univ Queensland, Ctr Adv Imaging, Brisbane, Qld 4072, Australia.
   [Peigneur, Steve; Tytgat, Jan] Univ Leuven, Toxicol & Pharmacol, O&N 2, B-3000 Leuven, Belgium.
   [Norton, Raymond S.] Monash Univ, ARC Ctr Fragment Based Design, Parkville, Vic 3052, Australia.
RP Norton, RS (reprint author), Monash Univ, Monash Inst Pharmaceut Sci, Med Chem, 381 Royal Parade, Parkville, Vic 3052, Australia.
EM ray.norton@monash.edu
RI Krishnarjuna, Bankala/H-4562-2013; Chalmers, David/L-8533-2013
OI Krishnarjuna, Bankala/0000-0002-4575-0011; Chalmers,
   David/0000-0003-2366-569X; Elnahriry, Khaled/0000-0002-4378-1228;
   Tytgat, Jan/0000-0003-1778-6022
FU Monash University scholarship (FPPS); Australian National Health and
   Medical Research CouncilNational Health and Medical Research Council of
   Australia; FWO-VlaanderenFWO [GOA4919N]; KU LeuvenKU Leuven
   [CELSA/17/047]
FX We thank Trayder Thomas for his help in setting up the lipid bilayer
   model and for advice on MD simulations. KE acknowledges support from a
   Monash University scholarship (FPPS). R.S.N acknowledges fellowship
   support from the Australian National Health and Medical Research
   Council. Some of the data reported here were obtained at the Central
   Analytical Research Facility operated by the Institute for Future
   Environments at QUT. JT was supported by grants GOA4919N from
   FWO-Vlaanderen and CELSA/17/047 from KU Leuven. We also thank an
   anonymous reviewer for helpful comments on the manuscript.
CR Agwa AJ, 2018, J BIOL CHEM, V293, P9041, DOI 10.1074/jbc.RA118.002553
   Ayala-Sumuano JT, 2017, GENOM DATA, V11, P92, DOI 10.1016/j.gdata.2016.11.022
   AYRE DJ, 1995, J ANIM ECOL, V64, P186, DOI 10.2307/5754
   AYRE DJ, 1982, MAR BIOL, V68, P199, DOI 10.1007/BF00397607
   Baxter NJ, 1997, J BIOMOL NMR, V9, P359, DOI 10.1023/A:1018334207887
   Beeton C, 2001, P NATL ACAD SCI USA, V98, P13942, DOI 10.1073/pnas.241497298
   Beeton C, 2006, P NATL ACAD SCI USA, V103, P17414, DOI 10.1073/pnas.0605136103
   Berendsen HJC, 1981, INTERMOLECULAR FORCE, V14, P331, DOI DOI 10.1007/978-94-015-7658-1_21
   BERESS L, 1982, PURE APPL CHEM, V54, P1981, DOI 10.1351/pac198254101981
   Beress L, 2000, METH TOOLS BIOSCI ME, P31
   Berger O, 1997, BIOPHYS J, V72, P2002, DOI 10.1016/S0006-3495(97)78845-3
   Berman H, 2003, NAT STRUCT BIOL, V10, P980, DOI 10.1038/nsb1203-980
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Chi V, 2012, TOXICON, V59, P529, DOI 10.1016/j.toxicon.2011.07.016
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6
   de Oliveira JS, 2006, BBA-GEN SUBJECTS, V1760, P453, DOI 10.1016/j.bbagen.2005.12.018
   DELEEUW SW, 1980, P ROY SOC LOND A MAT, V373, P57, DOI 10.1098/rspa.1980.0136
   DELEEUW SW, 1980, P ROY SOC LOND A MAT, V373, P27, DOI 10.1098/rspa.1980.0135
   Dominguez-Perez D, 2018, MAR DRUGS, V16, DOI 10.3390/md16020042
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Fautin DG, 2009, TOXICON, V54, P1054, DOI 10.1016/j.toxicon.2009.02.024
   FERRARIO M, 1985, MOL PHYS, V54, P587, DOI 10.1080/00268978500100451
   FLETCHER R, 1963, COMPUT J, V6, P163, DOI 10.1093/comjnl/6.2.163
   Frazao B, 2012, MAR DRUGS, V10, P1812, DOI 10.3390/md10081812
   Gershwin LA, 2006, ZOOTAXA, P1
   GIBBS SJ, 1991, J MAGN RESON, V93, P395, DOI 10.1016/0022-2364(91)90014-K
   Guntert Peter, 2004, Methods Mol Biol, V278, P353
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Honma T, 2006, MAR BIOTECHNOL, V8, P1, DOI 10.1007/s10126-005-5093-2
   Jones JA, 1997, J BIOMOL NMR, V10, P199, DOI 10.1023/A:1018304117895
   Jouiaei M, 2015, TOXINS, V7, P2251, DOI 10.3390/toxins7062251
   Kim CH, 2017, FEBS J, V284, P3320, DOI 10.1111/febs.14194
   King GF, 2011, EXPERT OPIN BIOL TH, V11, P1469, DOI 10.1517/14712598.2011.621940
   Kohda D, 2018, ADV EXP MED BIOL, V1104, P171, DOI 10.1007/978-981-13-2158-0_9
   Krishnarjuna B, 2018, TOXICON, V150, P50, DOI 10.1016/j.toxicon.2018.05.006
   Krishnarjuna B, 2018, PEPTIDES, V99, P169, DOI 10.1016/j.peptides.2017.10.001
   Lavergne V, 2015, RSC DRUG DISCOV, V42, P37
   Lee W, 2015, BIOINFORMATICS, V31, P1325, DOI 10.1093/bioinformatics/btu830
   Leffler AE, 2017, P NATL ACAD SCI USA, V114, pE8100, DOI 10.1073/pnas.1703952114
   Lemkul J., 2019, LIVING J COMP MOL SC, V1, P5068
   LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A
   Logashina YA, 2017, TOXINS, V9, DOI 10.3390/toxins9050154
   Logashina YA, 2017, J BIOL CHEM, V292, P2992, DOI 10.1074/jbc.M116.757369
   LOTAN A, 1995, NATURE, V375, P456, DOI 10.1038/375456a0
   Macrander J, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1417-4
   Madio B, 2018, CELL MOL LIFE SCI, V75, P4511, DOI 10.1007/s00018-018-2897-6
   Madio B, 2017, J PROTEOMICS, V166, P83, DOI 10.1016/j.jprot.2017.07.007
   Mitchell ML, 2017, AUST J CHEM, V70, P1235, DOI 10.1071/CH17228
   MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805
   Mouhat S, 2004, BIOCHEM J, V378, P717, DOI 10.1042/BJ20031860
   Norton R. S., 2013, HDB BIOL ACTIVE PEPT, P430, DOI DOI 10.1016/B978-0-12-385095-9.00060-9
   Norton RS, 2017, NEUROPHARMACOLOGY, V127, P124, DOI 10.1016/j.neuropharm.2017.07.002
   Norton RS, 2017, EXPERT OPIN DRUG DIS, V12, P611, DOI 10.1080/17460441.2017.1317243
   Norton RS, 2006, HANDBOOK OF BIOLOGICALLY ACTIVE PEPTIDES, P363, DOI 10.1016/B978-012369442-3/50056-8
   Oliveira JS, 2012, TOXICON, V60, P539, DOI 10.1016/j.toxicon.2012.05.020
   Omardien S, 2018, BBA-BIOMEMBRANES, V1860, P2416, DOI 10.1016/j.bbamem.2018.06.005
   Oostenbrink C, 2004, J COMPUT CHEM, V25, P1656, DOI 10.1002/jcc.20090
   Osmakov DI, 2013, J BIOL CHEM, V288, P23116, DOI 10.1074/jbc.M113.485516
   OTTAWAY JR, 1978, AUST J MAR FRESH RES, V29, P787
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Paterlini MG, 1998, CHEM PHYS, V236, P243, DOI 10.1016/S0301-0104(98)00214-6
   Peigneur S, 2011, BIOCHEM PHARMACOL, V82, P81, DOI 10.1016/j.bcp.2011.03.023
   Pennington MW, 2018, BIOORGAN MED CHEM, V26, P2738, DOI 10.1016/j.bmc.2017.09.029
   Prentis PJ, 2018, TOXINS, V10, DOI 10.3390/toxins10010036
   Rao SSC, 2014, CLIN GASTROENTEROL H, V12, P616, DOI 10.1016/j.cgh.2013.09.022
   Robinson SD, 2017, GEN COMP ENDOCR, V244, P11, DOI 10.1016/j.ygcen.2015.07.012
   Safavi-Hemami H, 2015, P NATL ACAD SCI USA, V112, P1743, DOI 10.1073/pnas.1423857112
   Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9
   Schmidtko A, 2010, LANCET, V375, P1569, DOI 10.1016/S0140-6736(10)60354-6
   Schubert M, 2002, J BIOMOL NMR, V24, P149, DOI 10.1023/A:1020997118364
   Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9
   Shiomi K, 2009, TOXICON, V54, P1112, DOI 10.1016/j.toxicon.2009.02.031
   Simakov O, 2013, NATURE, V493, P526, DOI 10.1038/nature11696
   SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Smith LJ, 1996, J MOL BIOL, V255, P494, DOI 10.1006/jmbi.1996.0041
   Stewart ZK, 2017, SCI REP-UK, V7, DOI 10.1038/srep41458
   Suchyna TM, 2004, NATURE, V430, P235, DOI 10.1038/nature02743
   SUNANDA P, 2018, J PEPT SCI, V110, DOI DOI 10.1002/PEP2.24073
   Surm JM, 2019, MOL ECOL, V28, P2272, DOI 10.1111/mec.15084
   Todaro D, 2012, BIOL OPEN, V1, P582, DOI 10.1242/bio.2012695
   Ulrich EL, 2008, NUCLEIC ACIDS RES, V36, pD402, DOI 10.1093/nar/gkm957
   Undheim EAB, 2015, P NATL ACAD SCI USA, V112, P4026, DOI 10.1073/pnas.1424068112
   Veale AJ, 2012, NEW ZEAL J MAR FRESH, V46, P523, DOI 10.1080/00288330.2012.730053
   WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4
   WATSON GM, 1989, SCIENCE, V243, P1589, DOI 10.1126/science.2564698
   Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q
   WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777
   WUTHRICH K, 1982, J MOL BIOL, V155, P311, DOI 10.1016/0022-2836(82)90007-9
   Yao SG, 2000, J BIOMOL NMR, V16, P109, DOI 10.1023/A:1008382624724
   Zambelli VO, 2016, PHARMACOL RES, V112, P30, DOI 10.1016/j.phrs.2016.01.009
   Zhang AH, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00238
   Zhang ZQ, 2011, ZOOTAXA, P7, DOI 10.11646/zootaxa.3703.1.1
NR 93
TC 0
Z9 0
U1 10
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT
PY 2019
VL 168
BP 104
EP 112
DI 10.1016/j.toxicon.2019.07.002
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IW3JJ
UT WOS:000484876000015
PM 31302115
DA 2020-05-12
ER

PT J
AU Bustillo, S
   Fernandez, J
   Chaves-Araya, S
   Angulo, Y
   Leiva, LC
   Lomonte, B
AF Bustillo, Soledad
   Fernandez, Julian
   Chaves-Araya, Stephanie
   Angulo, Yamileth
   Leiva, Laura C.
   Lomonte, Bruno
TI Isolation of two basic phospholipases A(2) from Bothrops diporus snake
   venom: Comparative characterization and synergism between Asp49 and
   Lys49 variants
SO TOXICON
LA English
DT Article
DE Snake venom; Bothrops diporus; Phospholipase A(2); Synergism;
   Myotoxicity; Cytotoxicity
ID NEUWIEDII YARARA CHICA; BA SPII RP4; FUNCTIONAL-CHARACTERIZATION;
   MYOTOXIN-II; ALTERNATUS VENOM; ASPER; METALLOPROTEINASE; HOMOLOG;
   A(2)-HOMOLOG; MECHANISMS
AB Bothrops diporus, previously considered a subspecies of the B. neuwiedi complex, is a medically relevant viperid in Northeastern Argentina. The venom of this species causes local tissue damage characterized by myonecrosis, hemorrhage, blistering, and edema. In the present study, two basic phospholipases A(2) (PLA(2)-I and PLA(2)-II) were isolated from this venom, and their pathological effects upon murine skeletal muscle and myogenic cells in culture were analyzed. Partial amino acid sequencing showed that PLA(2)-I and PLA(2)-II are Asp49 and Lys49 PLA(2)s, respectively. In agreement with this, PLA(2)-I showed PLA(2) activity, whereas PLA(2)-II did not. Functional assays revealed differences in their myotoxicity, cytotoxicity, and anti-adhesion activity, and in the ability to inhibit cell migration, all of which were greater for the Lys49 variant. Native electrophoresis showed that PLA(2)-I was less basic than PLA(2)-II. The two proteins act synergistically to affect the integrity of C2C12 myogenic cells, providing a further example of the concerted action of coexisting snake venom components. PLA(2)-I and PLA(2)-II, together with additional basic PLA(2)s revealed by RP-HPLC, probably play an important role in myonecrosis after envenomation by B. diporus.
C1 [Bustillo, Soledad; Leiva, Laura C.] Univ Nacl Nordeste UNNE, Corrientes, Argentina.
   [Fernandez, Julian; Chaves-Araya, Stephanie; Angulo, Yamileth; Lomonte, Bruno] Univ Costa Rica, Fac Microbiol, Inst Clodomiro Picado, San Jose 11501, Costa Rica.
RP Lomonte, B (reprint author), Univ Costa Rica, Fac Microbiol, Inst Clodomiro Picado, San Jose 11501, Costa Rica.
EM bruno.lomonte@ucr.ac.cr
RI ; Lomonte, Bruno/B-8862-2019
OI Bustillo, Soledad/0000-0002-1875-7664; Lomonte,
   Bruno/0000-0003-2419-6469
FU Vicerrectoria de Investigacion, Universidad de Costa Rica [VI-B-5602];
   Secretaria General de Ciencia y Tecnica, Universidad Nacional del
   Nordeste [PI 17F009]
FX We thank Vicerrectoria de Investigacion (grant VI-B-5602), Universidad
   de Costa Rica, and Secretaria General de Ciencia y Tecnica (PI 17F009),
   Universidad Nacional del Nordeste, for partial support of this study.
   The valuable help of Christian Vargas, Daniela Solano, and Rodrigo
   Chaves in laboratory support is gratefully acknowledged. The authors
   also thank 'Centro de Produccion de Sueros Antiofidicos' (CEPSAN,
   Corrientes, Argentina) providing the Bothrops diporus venom.
CR Angulo Y, 2000, INT J BIOCHEM CELL B, V32, P63, DOI 10.1016/S1357-2725(99)00099-0
   Bazaa A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010124
   Bazaa A, 2009, MATRIX BIOL, V28, P188, DOI 10.1016/j.matbio.2009.03.007
   Borges RJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15614-z
   Bustillo S, 2009, J VENOM ANIM TOXINS, V15, P28, DOI 10.1590/S1678-91992009000100004
   Bustillo S, 2017, APOPTOSIS, V22, P491, DOI 10.1007/s10495-017-1350-x
   Bustillo S, 2015, CHEM-BIOL INTERACT, V240, P30, DOI 10.1016/j.cbi.2015.08.002
   Bustillo S, 2012, TOXICON, V59, P338, DOI 10.1016/j.toxicon.2011.11.007
   Cedro RCA, 2018, J VENOM ANIM TOXINS, V24, DOI 10.1186/s40409-018-0170-y
   Cintra-Francischinelli M, 2009, CELL MOL LIFE SCI, V66, P1718, DOI 10.1007/s00018-009-9053-2
   da Silva Vinicius Xavier, 2008, Phyllomedusa, V7, P45
   DANIELE JJ, 1995, ARCH BIOCHEM BIOPHYS, V318, P65, DOI 10.1006/abbi.1995.1205
   Daniele JJ, 1997, TOXICON, V35, P1205, DOI 10.1016/S0041-0101(97)00023-8
   de Oliveira AHC, 2001, BIOCHEM BIOPH RES CO, V284, P1011, DOI 10.1006/bbrc.2001.5073
   De Perez OCA, 1998, TOXICON, V36, P1165, DOI 10.1016/S0041-0101(98)00007-5
   de Roodt A, 2018, TOXICON, V148, P143, DOI 10.1016/j.toxicon.2018.04.026
   dos Santos JI, 2011, PROTEINS, V79, P61, DOI 10.1002/prot.22858
   Fernandes CAH, 2014, BBA-PROTEINS PROTEOM, V1844, P2265, DOI 10.1016/j.bbapap.2014.09.015
   Fernandez J, 2013, FEBS J, V280, P3878, DOI 10.1111/febs.12386
   Fernandez J, 2010, BIOCHIMIE, V92, P273, DOI 10.1016/j.biochi.2009.12.006
   Denegri MEG, 2010, TOXICON, V56, P64, DOI 10.1016/j.toxicon.2010.02.031
   Gay C, 2016, TOXINS, V8, DOI 10.3390/toxins8010009
   Geoghegan P, 1999, TOXICON, V37, P1735, DOI 10.1016/S0041-0101(99)00115-4
   Giraudo Alejandro R., 2002, Smithsonian Herpetological Information Service, V132, P1
   GUTIERREZ JM, 1995, TOXICON, V33, P1405, DOI 10.1016/0041-0101(95)00085-Z
   GUTIERREZ JM, 1986, TOXICON, V24, P885, DOI 10.1016/0041-0101(86)90089-9
   Holzer M, 1996, TOXICON, V34, P1149, DOI 10.1016/0041-0101(96)00057-8
   Jimenez-Charris E, 2016, TOXICON, V119, P289, DOI 10.1016/j.toxicon.2016.07.006
   LOMONTE B, 1989, TOXICON, V27, P725, DOI 10.1016/0041-0101(89)90039-1
   LOMONTE B, 1994, J BIOL CHEM, V269, P29867
   Lomonte B, 1999, TOXICON, V37, P145, DOI 10.1016/S0041-0101(98)00171-8
   Lomonte B, 2017, J VENOM ANIM TOXINS, V23, DOI 10.1186/s40409-017-0117-8
   Lomonte B, 2015, TOXICON, V93, P144, DOI 10.1016/j.toxicon.2014.11.235
   Lomonte B, 2012, TOXICON, V60, P520, DOI 10.1016/j.toxicon.2012.02.007
   Lomonte B, 2011, ACTA CHIM SLOV, V58, P647
   Gutierrez JM, 2013, TOXICON, V62, P27, DOI 10.1016/j.toxicon.2012.09.006
   Massimino ML, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28846-4
   Montecucco C, 2008, CELL MOL LIFE SCI, V65, P2897, DOI 10.1007/s00018-008-8113-3
   Mora-Obando D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109846
   Mora-Obando D, 2014, PEERJ, V2, DOI 10.7717/peerj.569
   Nithez V., 2004, TOXICON, V44, P91
   Nunes DCO, 2011, COMP BIOCHEM PHYS C, V154, P226, DOI 10.1016/j.cbpc.2011.06.003
   Ponce-Soto LA, 2007, BBA-GEN SUBJECTS, V1770, P585, DOI 10.1016/j.bbagen.2006.11.015
   Arias SP, 2017, TOXINS, V9, DOI 10.3390/toxins9110342
   Randazzo-Moura P, 2008, PROTEIN J, V27, P355, DOI 10.1007/s10930-008-9144-1
   Salvador GHM, 2018, BBA-PROTEINS PROTEOM, V1866, P473, DOI 10.1016/j.bbapap.2017.12.008
   Santos NA, 2008, TOXICON, V52, P908, DOI 10.1016/j.toxicon.2008.08.020
   Soares AM, 2000, ARCH BIOCHEM BIOPHYS, V378, P201, DOI 10.1006/abbi.2000.1790
   Soares AM, 2004, CURR ORG CHEM, V8, P1677, DOI 10.2174/1385272043369610
   Teixeira CFP, 2003, TOXICON, V42, P947, DOI 10.1016/j.toxicon.2003.11.006
   Teixera LF, 2018, TOXICON, V141, P55, DOI 10.1016/j.toxicon.2017.11.007
   Van der Laat M, 2013, TOXICON, V73, P71, DOI 10.1016/j.toxicon.2013.07.008
   Ward RJ, 2002, BIOCHEM J, V362, P89, DOI 10.1042/0264-6021:3620089
   Quartino PJY, 2012, BIOCHEM BIOPH RES CO, V427, P321, DOI 10.1016/j.bbrc.2012.09.051
   Zouari-Kessentini R, 2009, TOXICON, V53, P444, DOI 10.1016/j.toxicon.2009.01.003
NR 55
TC 0
Z9 0
U1 1
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT
PY 2019
VL 168
BP 113
EP 121
DI 10.1016/j.toxicon.2019.07.004
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IW3JJ
UT WOS:000484876000016
PM 31326508
DA 2020-05-12
ER

PT J
AU Machado, M
   Miguel, MP
   Terra, JP
   Ferreira, JA
   Riet-Correa, F
   de Castro, MB
AF Machado, Mizael
   Miguel, Marina Pacheco
   Terra, Juliano Pereira
   Ferreira Jr, Jair Alves
   Riet-Correa, Franklin
   de Castro, Marcio Botelho
TI Acute fatal poisoning by spontaneous ingestion of Enterolobium
   contortisiliquum (Mimosidae) pods in horses
SO TOXICON
LA English
DT Review
DE Equine; Hepatic necrosis; Enterolobium contortisiliquum pods; Poisonous
   plants
ID HEPATOGENOUS PHOTOSENSITIZATION; RUMINANTS; LIVER; AFLATOXIN; PATHOLOGY;
   CATTLE; PLANTS
AB An outbreak of acute poisoning of horses by Enterolobium contortisiliquum pods is reported in the state of Goias, Brazil. Three horses presented apathy, hyporexia, prostration, jaundice, recumbency and died in 24-48 hours. The main pathological findings were a yellowish liver with an enhanced lobular pattern, multifocal hepatic necrosis mostly in the midzones of lobules and sometimes with a random distribution across the hepatic lobes and swelling of hepatocytes. E. contortisiliquum trees has a wide distribution in South America and cases of poisoning have not been reported in horses.
C1 [Machado, Mizael; Ferreira Jr, Jair Alves; de Castro, Marcio Botelho] Univ Brasilia, Vet Teaching Hosp, Vet Pathol Lab, Via L4 Norte SN,Campus Univ Darcy Ribeiro, BR-70636200 Brasilia, DF, Brazil.
   [Miguel, Marina Pacheco] Univ Fed Goias, Inst Patol Trop & Saude Publ, Rua 235 S-N, BR-74605050 Goiania, Go, Brazil.
   [Terra, Juliano Pereira] Inst Fed Catarinense, Campus Araquari,Rodovia BR 280 Km 27 Cx Postal 21, BR-89245000 Araquari, SC, Brazil.
   [Riet-Correa, Franklin] Inst Nacl Invest Agr, Estn Expt INIA La Estanzuela, Ruta 50 Km 11, Colonia Del Sacramento, Colonia, Uruguay.
RP de Castro, MB (reprint author), Univ Brasilia, Vet Teaching Hosp, Vet Pathol Lab, Via L4 Norte SN,Campus Univ Darcy Ribeiro, BR-70636200 Brasilia, DF, Brazil.
EM mbcastro@unb.br
RI de Castro, Marcio Botelho/AAB-9986-2020
OI de Castro, Marcio Botelho/0000-0002-3996-0856; Machado,
   Mizael/0000-0002-2029-884X
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil
   (CAPES)CAPES [001]
FX Special thanks to Rosana de Carvalho, DVM, Comigo Agricultural
   Cooperative of Serranopolis, Goias State and Sidney Aniceto Rezende
   Jimior, Lab Technician at the Veterinary Clinical Analysis Laboratory,
   Federal University of Jatai for the technical support and analysis of
   blood and biochemical samples. This study was financed in part by the
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil
   (CAPES) - Finance Code 001.
CR Bacha FB, 2017, PESQUI VET BRASIL, V37, P23, DOI 10.1590/s0100-736x2017000100004
   Bandarra PM, 2010, EQUINE VET J, V42, P456, DOI 10.1111/j.2042-3306.2010.00035.x
   Barbosa JD, 2006, PESQUI VET BRASIL, V26, P147, DOI 10.1590/S0100-736X2006000300003
   Benicio T. M. A., 2005, POISONOUS PLANTS GLO, P67
   Bonel-Raposo J, 2008, PESQUISA VET BRASIL, V28, P593, DOI 10.1590/S0100-736X2008001200005
   Brown DL, 2017, PATHOLOGIC BASIS VET, P412
   BULL LB, 1958, J PATHOL BACTERIOL, V75, P17, DOI 10.1002/path.1700750104
   Bezerra CWC, 2012, CIENC RURAL, V42, P1070, DOI 10.1590/S0103-84782012000600020
   Castro MB, 2011, POISONING BY PLANTS, MYCOTOXINS, AND RELATED TOXINS, P110, DOI 10.1079/9781845938338.0110
   Cullen J. M., 2016, PATHOLOGY DOMESTIC A, P258
   DENZ FA, 1961, J PATHOL BACTERIOL, V81, P91, DOI 10.1002/path.1700810111
   de Sant'Ana FJF, 2014, CIENC RURAL, V44, P865, DOI 10.1590/S0103-84782014000500018
   Furlan F. H., 2012, International Journal of Poisonous Plant Research, V2, P1
   Grecco FB, 2002, VET HUM TOXICOL, V44, P160
   Leal PV, 2017, TOXICON, V131, P6, DOI 10.1016/j.toxicon.2017.03.009
   Lorenzett MP, 2018, EQUINE VET J, V50, P192, DOI 10.1111/evj.12741
   Lorenzi H, 2008, ARVORES BRASILEIRAS
   MCDONOUGH SP, 1994, J VET DIAGN INVEST, V6, P392, DOI 10.1177/104063879400600324
   MCGAVIN MD, 1977, VET PATHOL, V14, P182, DOI 10.1177/030098587701400210
   Mimaki Y, 2003, BIOORG MED CHEM LETT, V13, P623, DOI 10.1016/S0960-894X(02)01044-2
   NEWBERNE PM, 1969, CANCER RES, V29, P236
   Nobre VMD, 2004, PESQUISA VET BRASIL, V24, P132, DOI 10.1590/S0100-736X2004000300004
   Olinda RG, 2015, PESQUI VET BRASIL, V35, P44, DOI 10.1590/S0100-736X2015000100010
   Oliveira JP, 2013, EQUINE VET J, V45, P240, DOI 10.1111/j.2042-3306.2012.00599.x
   Panziera W, 2017, PESQUI VET BRASIL, V37, P313, DOI [10.1590/s0100-736x2017000400003, 10.1590/S0100-736X2017000400003]
   Pupin RC, 2017, TOXICON, V126, P90, DOI 10.1016/j.toxicon.2016.12.015
   Santos JCA, 2008, PESQUI VET BRASIL, V28, P1, DOI 10.1590/S0100-736X2008000100001
   SEAWRIGHT AA, 1972, AUST VET J, V48, P323, DOI 10.1111/j.1751-0813.1972.tb02260.x
   TOKARNIA CARLOS HUBINGER, 1960, ARQ INST BIOL ANIMAL, V3, P73
   Tokarnia C. H., 2012, PLANTAS TOXICAS BRAS
NR 30
TC 0
Z9 0
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT
PY 2019
VL 168
BP 122
EP 125
DI 10.1016/j.toxicon.2019.07.006
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IW3JJ
UT WOS:000484876000017
PM 31330192
DA 2020-05-12
ER

PT J
AU Serodio, JJ
   Castro, LTS
   Morais, TL
   Cunha, RDD
   de Sant'Ana, FJF
   Juliano, RS
   Borges, JRJ
   Fioravanti, MCS
   da Cunha, PHJ
AF Serodio, Juliana J.
   Silva Castro, Luma T.
   Morais, Tabata L.
   da Silva Cunha, Roberta Dias
   Ferreira de Sant'Ana, Fabiano J.
   Juliano, Raquel Soares
   Junqueira Borges, Jose Renato
   Soares Fioravanti, Maria C.
   Jorge da Cunha, Paulo H.
TI Evaluation of the resistance of Nellore, Curraleiro Pe-duro and
   Pantaneiro cattle breeds by experimental intoxication of Palicourea
   marcgravii
SO TOXICON
LA English
DT Article
DE Bovine; Genetic susceptibility; Sodium monofluoroacetate; Sudden death;
   Toxic plants
ID SODIUM MONOFLUOROACETATE; AMORIMIA-SEPTENTRIONALIS; SUDDEN-DEATH;
   PLANTS; GOATS; BIGNONIACEAE; INOCULATION; ACETAMIDE
AB Palicourea marcgravii is the most important toxic plant in Brazil due to its acute toxicity (sudden death), palatability, cumulative effect and broad geographical distribution. The study aimed to evaluate the resistance between cattle of different breeds by experimental intoxication of Palicourea marcgravii. Eighteen males were randomly divided into three groups (Nellore, Curraleiro Pe-Duro and Pantaneiro), six animals in each group. All animals were experimentally intoxicated with P. marcgravii at 0.5 mg/kg of equivalent sodium monofluoracetate acid, receiving one single oral dose. All cattle presented symptoms and the toxic plant caused death in all cattle of the Nellore and Pantaneiro breeds and only three Curraleiro cattle. No changes were observed in the leukogram, fibrinogen, albumin, total protein and bilirubins. Hyperglycemia and increased of aspartate transaminase, creatinine kinase, urea and creatinine were detected in all breeds. Changes in the values of the gamma glutamyl transferase were individualized and did not follow a standard response. Fourteen cattle presented the histopathological findings of renal hydropic degeneration. The lower death rate of Curraleiro cattle indicates a higher resistance than cattle of the Nellore and Pantaneiro breeds.
C1 [Serodio, Juliana J.; Silva Castro, Luma T.; Morais, Tabata L.; da Silva Cunha, Roberta Dias; Soares Fioravanti, Maria C.; Jorge da Cunha, Paulo H.] Univ Fed Goias, Escola Vet & Zootecnia, Rodovia Goiania Nova Veneza,Km 8 Campus Samambaia, BR-74001970 Goiania, Go, Brazil.
   [Ferreira de Sant'Ana, Fabiano J.; Junqueira Borges, Jose Renato] Univ Brasilia UnB, Hosp Vet, Via L4 Norte,Cx Postal 4508, BR-70910970 Brasilia, DF, Brazil.
   [Juliano, Raquel Soares] Embrapa Pantanal, Corumba, MS, Brazil.
RP da Cunha, PHJ (reprint author), Univ Fed Goias, Escola Vet & Zootecnia, Rodovia Goiania Nova Veneza,Km 8 Campus Samambaia, BR-74001970 Goiania, Go, Brazil.
EM phjorgecunha@gmail.com
RI da Cunha, Paulo Henrique Jorge/E-7107-2019
OI da Cunha, Paulo Henrique Jorge/0000-0002-1478-3670
FU National Council for Scientific and Technological Development,
   BrazilNational Council for Scientific and Technological Development
   (CNPq) [564300/2010-1]; Fundacao de Apoio a Pesquisa do Estado de Goias,
   Brazil [201110267000129]
FX This work was financially supported by the National Council for
   Scientific and Technological Development, Brazil (number 564300/2010-1)
   and Fundacao de Apoio a Pesquisa do Estado de Goias, Brazil (number:
   201110267000129).
CR Afonso E., 2001, PLANTAS PANTANAL TEO
   da Silva LCA, 2015, CIENC RURAL, V45, P2218, DOI 10.1590/0103-8478cr20141231
   Barbosa JD, 2003, PESQUI VET BRASIL, V23, P167, DOI 10.1590/S0100-736X2003000400005
   Cook D, 2014, TOXICON, V80, P9, DOI 10.1016/j.toxicon.2013.12.003
   da Silva LCA, 2016, TOXICON, V111, P65, DOI 10.1016/j.toxicon.2015.12.016
   DANFAER A, 1995, COMP BIOCHEM PHYS B, V111, P201, DOI 10.1016/0305-0491(94)00242-M
   de Brito LB, 2016, CIENC RURAL, V46, P138, DOI 10.1590/0103-8478cr20150079
   Dirksen G., 1993, ROSENBERGER EXAME CL, P166
   Duarte AL, 2013, CIENC RURAL, V43, P1294, DOI 10.1590/S0103-84782013005000081
   Eisler R., 1995, 27 US NAT BIOL SERV
   Fioravanti M. C. S., 2010, INCT INFORM GENETICO
   Green B. T., 2014, Rangelands, V36, P10, DOI 10.2111/RANGELANDS-D-13-00031.1
   Helayel M. A., 2012, ARQ PESQUI ANIM, V1, P8
   Helayel MA, 2009, PESQUI VET BRASIL, V29, P498, DOI 10.1590/S0100-736X2009000700003
   Lee ST, 2014, J AGR FOOD CHEM, V62, P7345, DOI 10.1021/jf500563h
   Lee ST, 2012, TOXICON, V60, P791, DOI 10.1016/j.toxicon.2012.05.029
   MARRAZZI MA, 1981, BIOCHEM PHARMACOL, V30, P3231, DOI 10.1016/0006-2952(81)90523-2
   MCILROY JC, 1981, AUST WILDLIFE RES, V8, P385, DOI 10.1071/WR9810385
   McManus C., 2005, Archivos de Zootecnia, V54, P453
   Nascimento NCF, 2018, PESQUI VET BRASIL, V38, P1239, DOI [10.1590/1678-5150-pvb-5548, 10.1590/1678-5150-PVB-5548]
   Nogueira VA, 2010, PESQUI VET BRASIL, V30, P533, DOI 10.1590/S0100-736X2010000700004
   Nogueira VA, 2011, PESQUI VET BRASIL, V31, P823, DOI 10.1590/S0100-736X2011001000001
   Peixoto TC, 2012, PESQUI VET BRASIL, V32, P319, DOI 10.1590/S0100-736X2012000400008
   Peixoto TC, 2011, PESQUI VET BRASIL, V31, P938, DOI 10.1590/S0100-736X2011001100002
   Peixoto TC, 2010, PESQUI VET BRASIL, V30, P1021, DOI 10.1590/S0100-736X2010001200004
   Pellegrin A. O., 1997, COMUNICADO TECNICO E
   Pessoa DAN, 2018, PESQUI VET BRASIL, V38, P1913, DOI [10.1590/1678-5150-PVB-5840, 10.1590/1678-5150-pvb-5840]
   Pessoa DAN, 2015, PESQUI VET BRASIL, V35, P125, DOI 10.1590/S0100-736X2015000200005
   Russell KE, 2007, VET CLIN N AM-FOOD A, V23, P403, DOI 10.1016/j.cvfa.2007.07.003
   Sampaio I. B. M., 1998, ESTATISTICA APLICADA
   Santos S. A., 2005, Archivos de Zootecnia, V54, P501
   Shokry E, 2017, TOXICON, V137, P54, DOI 10.1016/j.toxicon.2017.07.014
   Stockham S. L., 2002, FUNDAMENTALS VET CLI, P279
   Tokarnia C. H., 2012, PLANTAS TERXICAS BRA
   TOKARNIA CH, 1983, PESQUISA VET BRASIL, V3, P75
   Tokarnia CH, 2004, PESQUISA VET BRASIL, V24, P74, DOI 10.1590/S0100-736X2004000200005
   Tokarnia CH, 2002, TOXICON, V40, P1635, DOI 10.1016/S0041-0101(02)00239-8
   TOKARNIA CH, 1990, PESQUISA VET BRASIL, V10, P1
   Weiss D. J., 2010, SCHALMS VET HEMATOLO
NR 39
TC 0
Z9 0
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT
PY 2019
VL 168
BP 126
EP 130
DI 10.1016/j.toxicon.2019.07.008
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IW3JJ
UT WOS:000484876000018
PM 31325459
DA 2020-05-12
ER

PT J
AU Downing, S
   Van Onselen, R
   Kemp, G
   Downing, TG
AF Downing, Simone
   Van Onselen, Rianita
   Kemp, Gabre
   Downing, Timothy Grant
TI Metabolism of the neurotoxic amino acid beta-N-methylamino-L-alanine in
   human cell culture models
SO TOXICON
LA English
DT Article
DE Cyanobacteria; beta-N-Methylamino-L-alanine; BMAA; Metabolism;
   Bioavailability; Oral toxicity; Oral exposure
ID CYANOBACTERIAL NEUROTOXIN; NEURODEGENERATIVE DISEASE; GLUTAMINE
   TRANSAMINASE; INTESTINAL BARRIER; BMAA; TRANSPORT; QUANTITATION;
   SPECIFICITY; BICARBONATE; ASPARAGINE
AB Human dietary exposure to the environmental neurotoxin beta-N-methylamino-L-alanine (BMAA) has been implicated in an increased risk of developing sporadic neurodegenerative diseases like Alzheimer's and amyotrophic lateral sclerosis. Evidence suggests that humans are exposed to BMAA globally, but very little is known about BMAA metabolism in mammalian systems, let alone in humans. The most plausible, evidence-based mechanisms of BMAA toxicity rely on the metabolic stability of the amino acid and that, following ingestion, it enters the circulatory system unmodified. BMAA crosses from the intestinal lumen into the circulatory system, and the small intestine and liver are the first sites for dietary amino acid metabolism. Both tissues have substantial amino acid metabolic needs, which are largely fulfilled by dietary amino acids. Metabolism of BMAA in these tissues has been largely overlooked, yet is important in gauging the true human exposure risk. Here we investigate the potential for BMAA metabolism by the human liver and small intestine, using in vitro cell systems. Data show that BMAA metabolism via common proteinogenic amino acid metabolic pathways is negligible, and that in the presence of other amino acids cellular uptake of BMAA is substantially reduced. These data suggest that the majority of ingested BMAA remains unmodified following passage through the small intestine and liver. This not only supports oral BMAA exposure as a plausible exposure route to toxic doses of BMAA, but also supports previous notions that protein deficient diets or malnutrition may increase an individual's susceptibility to BMAA absorption and subsequent toxicity.
C1 [Downing, Simone; Van Onselen, Rianita; Downing, Timothy Grant] Nelson Mandela Univ, Dept Biochem & Microbiol, POB 77 000, ZA-6031 Port Elizabeth, South Africa.
   [Kemp, Gabre] Univ Free State, Dept Microbial Biochem & Food Biotechnol, Bloemfontein, South Africa.
RP Downing, S (reprint author), Nelson Mandela Univ, Dept Biochem & Microbiol, POB 77 000, ZA-6031 Port Elizabeth, South Africa.
EM Simone.Downing@mandela.ac.za
FU Claude Leon Foundation, South Africa
FX S.D. acknowledges the Claude Leon Foundation, South Africa, for
   financial support.
CR Al-Sammak MA, 2014, TOXINS, V6, P488, DOI 10.3390/toxins6020488
   Alican I, 1996, AM J PHYSIOL-GASTR L, V270, pG225
   Andersson M, 2017, TOXICOL APPL PHARM, V320, P40, DOI 10.1016/j.taap.2017.02.004
   Andersson M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078133
   Armenta JM, 2010, ANAL CHEM, V82, P548, DOI 10.1021/ac901790q
   Banack SA, 2014, TOXICON, V90, P167, DOI 10.1016/j.toxicon.2014.07.018
   Beach DG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18392-w
   Berger V, 2000, J NUTR, V130, P2780
   Berntzon L, 2015, NEUROSCIENCE, V292, P137, DOI 10.1016/j.neuroscience.2015.02.032
   Botman D, 2014, J HISTOCHEM CYTOCHEM, V62, P802, DOI 10.1369/0022155414549071
   Brand LE, 2010, HARMFUL ALGAE, V9, P620, DOI 10.1016/j.hal.2010.05.002
   BRAUNSTEIN AE, 1960, BIOCHIM BIOPHYS ACTA, V44, P187, DOI 10.1016/0006-3002(60)91545-6
   Brosnan JT, 2000, J NUTR, V130, p988S, DOI 10.1093/jn/130.4.988S
   Brosnan ME, 2009, AM J CLIN NUTR, V90, p857S, DOI 10.3945/ajcn.2009.27462Z
   Burrin DG, 1997, CURR OPIN GASTROEN, V13, P165, DOI 10.1097/00001574-199703000-00015
   CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43
   Cooper AJL, 2008, ARCH BIOCHEM BIOPHYS, V474, P72, DOI 10.1016/j.abb.2008.02.038
   COPANI A, 1991, BRAIN RES, V558, P79, DOI 10.1016/0006-8993(91)90716-9
   Costa C, 2000, BBA-BIOMEMBRANES, V1509, P95, DOI 10.1016/S0005-2736(00)00281-9
   Cox PA, 2003, P NATL ACAD SCI USA, V100, P13380, DOI 10.1073/pnas.2235808100
   Cox PA, 2016, P ROY SOC B-BIOL SCI, V283, DOI 10.1098/rspb.2015.2397
   Cucchiaroni ML, 2010, J NEUROSCI, V30, P5176, DOI 10.1523/JNEUROSCI.5351-09.2010
   Downing S, 2018, TOXINS, V10, DOI 10.3390/toxins10010014
   Downing S, 2016, TOXICON, V115, P41, DOI 10.1016/j.toxicon.2016.03.005
   Downing S, 2014, ECOTOX ENVIRON SAFE, V101, P51, DOI 10.1016/j.ecoenv.2013.11.028
   DUNCAN MW, 1992, NEUROBIOL AGING, V13, P333, DOI 10.1016/0197-4580(92)90047-2
   DUNCAN MW, 1991, J PHARMACOL EXP THER, V258, P27
   Dunlop R. A., 2013, PLOS ONE, V25, P9, DOI [10.1371/journal.pone.0075376.e75376, DOI 10.1371/JOURNAL.PONE.0075376.E75376]
   Engskog MKR, 2013, TOXICOLOGY, V312, P6, DOI 10.1016/j.tox.2013.07.010
   Faassen EJ, 2016, MAR DRUGS, V14, DOI 10.3390/md14030045
   Field NC, 2013, TOXICON, V70, P179, DOI 10.1016/j.toxicon.2013.04.010
   Guo W, 2006, AM J PHYSIOL-GASTR L, V290, pG528, DOI 10.1152/ajpgi.00386.2005
   Gutierrez-Praena D, 2012, WATER RES, V46, P1566, DOI 10.1016/j.watres.2011.12.044
   JAVITT NB, 1990, FASEB J, V4, P161
   Jiang LY, 2014, SCI REP-UK, V4, DOI 10.1038/srep06931
   Jochems PGM, 2018, NUTRIENTS, V10, DOI 10.3390/nu10030322
   Jonasson S, 2010, P NATL ACAD SCI USA, V107, P9252, DOI 10.1073/pnas.0914417107
   Karlsson O, 2009, PIGM CELL MELANOMA R, V22, P120, DOI 10.1111/j.1755-148X.2008.00508.x
   Kisby G. E., 1992, Society for Neuroscience Abstracts, V18, P82
   Kisby GE, 2011, INT J ENV RES PUB HE, V8, P3889, DOI 10.3390/ijerph8103889
   Landowski CP, 2004, AAPS J, V6
   Liu XQ, 2009, EXP NEUROL, V217, P429, DOI 10.1016/j.expneurol.2009.04.002
   Lobner D, 2007, NEUROBIOL DIS, V25, P360, DOI 10.1016/j.nbd.2006.10.002
   LUK GD, 1980, SCIENCE, V210, P195, DOI 10.1126/science.6774420
   MAILLIARD ME, 1995, GASTROENTEROLOGY, V108, P888, DOI 10.1016/0016-5085(95)90466-2
   McMahon KW, 2016, ECOSPHERE, V7, DOI 10.1002/ecs2.1511
   Mordrelle A, 2000, AM J PHYSIOL-GASTR L, V279, pG366
   Murch SJ, 2004, ACTA NEUROL SCAND, V110, P267, DOI 10.1111/j.1600-0404.2004.00320.x
   MUSHAWAR IK, 1963, J BIOL CHEM, V238, P2460
   MYERS TG, 1990, J BIOL CHEM, V265, P10193
   Nunn PB, 2009, TOXICON, V54, P85, DOI 10.1016/j.toxicon.2009.03.008
   Okle O, 2013, TOXICOL SCI, V131, P217, DOI 10.1093/toxsci/kfs291
   Pablo J, 2009, ACTA NEUROL SCAND, V120, P216, DOI 10.1111/j.1600-0404.2008.01150.x
   Rao SD, 2006, EXP NEUROL, V201, P244, DOI 10.1016/j.expneurol.2006.04.017
   REECE DM, 1989, BIOCHEM SOC T, V17, P203, DOI 10.1042/bst0170203
   Reeds PJ, 1997, AM J PHYSIOL-ENDOC M, V273, pE408
   Reveillon D, 2015, MAR ENVIRON RES, V110, P8, DOI 10.1016/j.marenvres.2015.07.015
   RICHTER KE, 1989, BRAIN RES, V492, P385, DOI 10.1016/0006-8993(89)90925-6
   Roucher VF, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-622
   Sambuy Y, 2005, CELL BIOL TOXICOL, V21, P1, DOI 10.1007/s10565-005-0085-6
   Scott LL, 2018, TOXINS, V10, DOI 10.3390/toxins10010016
   Scott LL, 2018, TOXINS, V10, DOI 10.3390/toxins10010022
   Scott LL, 2018, NEUROTOX RES, V33, P6, DOI 10.1007/s12640-017-9742-9
   Shanks Niall, 2009, Philos Ethics Humanit Med, V4, P2, DOI 10.1186/1747-5341-4-2
   SMITH QR, 1992, J NEUROCHEM, V58, P1330, DOI 10.1111/j.1471-4159.1992.tb11346.x
   Donato MT, 2015, METHODS MOL BIOL, V1250, P77, DOI 10.1007/978-1-4939-2074-7_5
   van Onselen R, 2018, TOXICON, V143, P74, DOI 10.1016/j.toxicon.2018.01.011
   van Onselen R, 2018, NEUROTOX RES, V33, P15, DOI 10.1007/s12640-017-9743-8
   van Onselen R, 2017, TOXINS, V9, DOI 10.3390/toxins9120400
   van Onselen R, 2015, TOXICON, V102, P55, DOI 10.1016/j.toxicon.2015.05.014
   Waidyanatha S, 2018, TOXICOL APPL PHARM, V339, P151, DOI 10.1016/j.taap.2017.12.008
   WEISS JH, 1989, BRAIN RES, V497, P64, DOI 10.1016/0006-8993(89)90970-0
   WEISS JH, 1988, SCIENCE, V241, P973, DOI 10.1126/science.3136549
   WEISS PM, 1988, BIOCHEMISTRY-US, V27, P4814, DOI 10.1021/bi00413a035
   WINDMUELLER HG, 1982, ADV ENZYMOL RAMB, V53, P201
   WINDMUELLER HG, 1976, ARCH BIOCHEM BIOPHYS, V175, P670, DOI 10.1016/0003-9861(76)90558-0
   WINDMUELLER HG, 1975, ARCH BIOCHEM BIOPHYS, V171, P662, DOI 10.1016/0003-9861(75)90078-8
   Wisniewski JR, 2016, J PROTEOMICS, V136, P234, DOI 10.1016/j.jprot.2016.01.016
   Wu GY, 1998, J NUTR, V128, P1249
   Yarmush G, 2016, METABOLITES, V6, DOI 10.3390/metabo6010001
   YUDKOFF M, 1994, J NEUROCHEM, V62, P1192
NR 81
TC 1
Z9 1
U1 5
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT
PY 2019
VL 168
BP 131
EP 139
DI 10.1016/j.toxicon.2019.07.007
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IW3JJ
UT WOS:000484876000019
PM 31330193
DA 2020-05-12
ER

PT J
AU Li, C
   Chen, WY
   Zheng, LR
   Zhang, BY
   Yang, XQ
   Zhang, QP
   Wang, N
   Wang, Y
   Yang, JYQ
   Sha, JZ
   Zhou, Z
   Li, XH
   Li, YZ
   Shen, XL
AF Li, Chen
   Chen, Wenying
   Zheng, Lirong
   Zhang, Boyang
   Yang, Xuqin
   Zhang, Qipeng
   Wang, Ning
   Wang, Yan
   Yang, Jieyeqi
   Sha, Jingzhou
   Zhou, Zheng
   Li, Xiaohong
   Li, Yuzhe
   Shen, Xiao Li
TI Ameliorative effect of ursolic acid on ochratoxin A-induced renal
   cytotoxicity mediated by Lonp1/Aco2/Hsp75
SO TOXICON
LA English
DT Article
DE Ochratoxin A; Ursolic acid; Renal cytotoxicity; Lon protease 1;
   Heat-shock protein 75; Aconitase 2
ID PUBLIC-HEALTH PERSPECTIVES; OXIDATIVE STRESS; DNA-DAMAGE; MYCOTOXINS;
   NEPHROTOXICITY; INFLAMMATION; MECHANISMS; KIDNEY; CELLS; FOOD
AB Ochratoxin A (OTA) is a mycotoxin ubiquitous in feeds and foodstuffs. The water-insoluble pentacyclic triterpene bioactive compound, ursolic acid (UA), is widespread in various cuticular waxes of edible fruits, food materials, and medicinal plants. Although studies have reported that oxidative stress was involved in both the nephrotoxicity of OTA and the renoprotective function of UA, the role of stress-responsive Lon protease 1 (Lonp1) in the renoprotection of UA against OTA is still unknown. In this study, cell viability, reactive oxygen species (ROS) production, and several proteins' expressions of human embryonic kidney 293T (HEK293T) cells in response to UA, OTA, and/or Lonp1 inhibitor CDDO-me treatment were detected to reveal the protective mechanism of UA against OTA-induced renal cytotoxicity. Results indicated that a 2 h-treatment of 1 mu M UA could significantly alleviate the ROS production and cell death induced by a 24 h-treatment of 8 mu M OTA in HEK293T cells (P < 0.05). Compared with the control, the protein expressions of Lonp1, Aco2 and Hsp75 were significantly inhibited after 8 mu M OTA treating for 24 h (P < 0.05), which could be notably reversed by the pretreatment and post-treatment of 1 mu M UA (P < 0.05). The protein expressions of Lonp1, Aco2 and Hsp75 were inhibited by the addition of CDDO-me. The three protein expression trends were similar before and after the addition of CDDO-me. In conclusion, OTA could inhibit the expression of Lonp1, suppressing Aco2 and Hsp75 as a result, thereby activating ROS and inducing cell death in HEK293T cells, which could be alleviated by UA pre-treatment.
C1 [Li, Chen; Chen, Wenying; Yang, Xuqin; Zhang, Qipeng; Yang, Jieyeqi; Zhou, Zheng; Shen, Xiao Li] Zunyi Med Univ, Sch Publ Hlth, Zunyi 563000, Guizhou, Peoples R China.
   [Chen, Wenying; Zhou, Zheng; Shen, Xiao Li] Expt Teaching Demonstrat Ctr Prevent Med Guizhou, Zunyi 563000, Guizhou, Peoples R China.
   [Wang, Ning] Henan Univ Anim Husb & Econ, Coll Food & Biol Engn, Zhengzhou 450046, Henan, Peoples R China.
   [Wang, Yan] Zhejiang Univ Technol, Dept Food Sci & Technol, Hangzhou 310014, Zhejiang, Peoples R China.
   [Zheng, Lirong; Zhang, Boyang] China Agr Univ, Coll Food Sci & Nutr Engn, Beijing Adv Innovat Ctr Food Nutr & Human Hlth, Beijing 100083, Peoples R China.
   [Li, Xiaohong] Beijing Agr Vocat Coll, Dept Food & Bioengn, Beijing 102442, Peoples R China.
   [Li, Yuzhe] China Natl Ctr Food Safety Risk Assessment, 37 Guangqu Rd, Beijing 100022, Peoples R China.
   [Sha, Jingzhou] Sichuan Prov Dept Ecol & Environm, Chengdu 610000, Sichuan, Peoples R China.
   [Sha, Jingzhou] Solid Waste & Chem Management Ctr Sichuan Prov, Chengdu 610000, Sichuan, Peoples R China.
RP Shen, XL (reprint author), Zunyi Med Univ, Sch Publ Hlth, Dept Food Qual & Safety, Univ West Rd 6, Zunyi 563000, Guizhou, Peoples R China.
EM zylc666666@163.com; chenxiaomi1006@163.com; zlr941106@163.com;
   boyang0214@126.com; 1583411437@qq.com; zhangxia861012@163.com;
   wning_2017@126.com; wangyan062006@163.com; aurealways@126.com;
   524216057@qq.com; yy_185@126.com; lixiaohongXHL@163.com;
   liyuzhe@cfsa.net.cn; xiaolishen1983@163.com
RI Zhang, Boyang/AAG-4852-2020
FU District Program of National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [31460426]; Youth Program of
   National Natural Science Foundation of China [31601577]; Excellent Youth
   Talents of Zunyi Medical University [17zy-006]; projects of Guizhou
   Province [201710661034]; projects of Zunyi Medical University [20163753,
   F-968]
FX This work was supported by the District Program of National Natural
   Science Foundation of China (31460426), the Youth Program of National
   Natural Science Foundation of China (31601577), the Excellent Youth
   Talents of Zunyi Medical University (17zy-006), the projects of Guizhou
   Province (201710661034), and the projects of Zunyi Medical University
   (20163753 and F-968).
CR Bacanli M, 2018, TURK J PHARM SCI, V15, P166, DOI 10.4274/tjps.49469
   Bashir R, 2019, NUTRITION AND ENHANCED SPORTS PERFORMANCE: MUSCLE BUILDING, ENDURANCE, AND STRENGTH, 2ND EDITION, P707, DOI 10.1016/B978-0-12-813922-6.00061-8
   Bernstein SH, 2012, BLOOD, V119, P3321, DOI 10.1182/blood-2011-02-340075
   Bhat PV, 2018, NEUROCHEM INT, V118, P252, DOI 10.1016/j.neuint.2018.04.003
   Chen R, 2015, TOXICOL IN VITRO, V30, P264, DOI 10.1016/j.tiv.2015.10.011
   Chen WY, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01386
   Chen Y, 2018, ECOTOX ENVIRON SAFE, V166, P71, DOI 10.1016/j.ecoenv.2018.09.070
   Dai Q, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-333
   Di Stefano V., 2019, ENCY FOOD CHEM, P420
   Fan K, 2019, ENVIRON POLLUT, V248, P865, DOI 10.1016/j.envpol.2019.02.091
   Jackson LS, 2017, J AGR FOOD CHEM, V65, P7017, DOI 10.1021/acs.jafc.7b02909
   Lee HJ, 2018, FOOD CHEM TOXICOL, V122, P59, DOI 10.1016/j.fct.2018.10.004
   Lee HJ, 2017, J AGR FOOD CHEM, V65, P7034, DOI 10.1021/acs.jafc.6b04847
   Liang R, 2015, SCI REP-UK, V5, DOI 10.1038/srep08078
   Liew WPP, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00060
   Lopez-Hortas L, 2018, FOOD RES INT, V103, P130, DOI 10.1016/j.foodres.2017.10.028
   Ma JQ, 2014, INT IMMUNOPHARMACOL, V21, P389, DOI 10.1016/j.intimp.2014.05.022
   Marin DE, 2015, TOXIN REV, V34, P11, DOI 10.3109/15569543.2014.958757
   Masuda Y, 2004, J BIOL CHEM, V279, P42503, DOI 10.1074/jbc.M404256200
   Pfohl-Leszkowicz A, 2012, CHEM RES TOXICOL, V25, P252, DOI 10.1021/tx200430f
   Pinotti L, 2016, TOXINS, V8, DOI 10.3390/toxins8020045
   Qi XZ, 2018, FOOD CHEM TOXICOL, V121, P15, DOI 10.1016/j.fct.2018.08.026
   Raiola A, 2015, FOOD CHEM TOXICOL, V84, P169, DOI 10.1016/j.fct.2015.08.023
   Sajnani K, 2017, BIOCHIMIE, V135, P164, DOI 10.1016/j.biochi.2017.02.008
   Shen XL, 2014, FOOD CHEM TOXICOL, V69, P202, DOI 10.1016/j.fct.2014.04.017
   Shen XL, 2013, J PROTEOMICS, V78, P398, DOI 10.1016/j.jprot.2012.10.010
   Shen XL, 2010, FOOD HYDROCOLLOID, V24, P285, DOI 10.1016/j.foodhyd.2009.10.003
   Silva JP, 2018, TOXICOL LETT, V287, P59, DOI 10.1016/j.toxlet.2018.01.023
   Szakiel A, 2012, PHYTOCHEM REV, V11, P263, DOI 10.1007/s11101-012-9241-9
   Tao YF, 2018, FOOD CHEM TOXICOL, V112, P320, DOI 10.1016/j.fct.2018.01.002
   Ternette N, 2013, CELL REP, V3, P689, DOI 10.1016/j.celrep.2013.02.013
   Thakur R, 2018, BIOMED PHARMACOTHER, V101, P972, DOI 10.1016/j.biopha.2018.02.143
   Unusan N, 2019, FOOD CONTROL, V97, P1, DOI 10.1016/j.foodcont.2018.10.015
   Wang Y, 2017, TOXINS, V9, DOI 10.3390/toxins9050167
   Xu HL, 2018, BIOMED PHARMACOTHER, V105, P915, DOI 10.1016/j.biopha.2018.06.055
   Yang JQ, 2018, ARCH TOXICOL, V92, P1913, DOI 10.1007/s00204-018-2210-3
   YOUNG HS, 1994, BIOL PHARM BULL, V17, P990
   Zhang BY, 2014, J PROTEOMICS, V101, P154, DOI 10.1016/j.jprot.2014.02.017
   Zhang H, 2018, MOL THER-NUCL ACIDS, V12, P758, DOI 10.1016/j.omtn.2018.07.015
   Zhao T, 2017, TOXIN REV, V36, P39, DOI 10.1080/15569543.2016.1243560
   Zheng JJ, 2013, TOXICOL APPL PHARM, V268, P123, DOI 10.1016/j.taap.2013.01.021
NR 41
TC 0
Z9 0
U1 6
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT
PY 2019
VL 168
BP 141
EP 146
DI 10.1016/j.toxicon.2019.07.014
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IW3JJ
UT WOS:000484876000021
PM 31356822
DA 2020-05-12
ER

PT J
AU van Losenoord, W
   Krause, J
   Parker-Nance, S
   Krause, R
   Stoychev, S
   Frost, CL
AF van Losenoord, Wynand
   Krause, Jason
   Parker-Nance, Shirley
   Krause, Rui
   Stoychev, Stoyan
   Frost, Carminita Lara
TI Purification and biochemical characterisation of a putative sodium
   channel agonist secreted from the South African Knobbly sea anemone
   Bunodosoma capense
SO TOXICON
LA English
DT Article
DE Na-v channels; Artemia bioassay; Neurotoxin; Anthozoa; beta-defensin;
   Sea anemone
ID AMINO-ACID-SEQUENCE; GEL-ELECTROPHORESIS; THERAPEUTIC TARGETS; BLOCKING
   TOXINS; ION CHANNELS; VENOM; PEPTIDE; NEUROTOXINS; GRANULIFERA;
   ACTINIARIA
AB Voltage gated ion channels have become a subject of investigation as possible pharmaceutical targets. Research has linked the activity of ion channels directly to anti-inflammatory pathways, energy homeostasis, cancer proliferation and painful diabetic neuropathy. Sea anemones secrete a diverse array of bioactive compounds including potassium and sodium channel toxins. A putative novel sodium channel agonist (molecular mass of 4619.7 Da) with a predicted sequence: CLCNSDGPSV RGNTLSGILW LAGCPSGWHN CKKHKPTIGW CCK was isolated from Bunodosoma capense using a modified stimulation technique to induce the secretion of the neurotoxin rich mucus confirmed by an Artemia nauplii bio-assay. The peptide purification combined size-exclusion and reverse-phase high performance liquid chromatography. A thallium-based ion flux assay confirmed the presence of a sodium channel agonist/inhibitor and purity was determined using a modified tricine SDS-PAGE system. The peptide isolated indicated the presence of multiple disulfide bonds in a tight beta-defensin cystine conformation. An IC50 value of 26 nM was determined for total channel inhibition on MCF-7 cells. The unique putative sodium channel agonist initiating with a cystine bond indicates a divergent evolution to those previously isolated from Bunodosoma species.
C1 [van Losenoord, Wynand; Krause, Jason; Frost, Carminita Lara] Nelson Mandela Univ, Dept Biochem & Microbiol, POB 77000 6031, Port Elizabeth, South Africa.
   [Parker-Nance, Shirley] Nelson Mandela Univ, Dept Zool, Ocean Sci Campus, Port Elizabeth, South Africa.
   [Krause, Rui] Rhodes Univ, Dept Chem, Grahamstown, South Africa.
   [Stoychev, Stoyan] CSIR, Biomed Res Unit, Pretoria, South Africa.
   [Parker-Nance, Shirley] Nelson Mandela Univ, South African Environm Observat Network, Ocean Sci Campus, Elwandle Coastal Node, South Africa.
RP Frost, CL (reprint author), Nelson Mandela Univ, Dept Biochem & Microbiol, POB 77000 6031, Port Elizabeth, South Africa.
EM carminita.frost@mandela.ac.za
RI Parker-Nance, Shirley/C-8846-2013
OI Parker-Nance, Shirley/0000-0003-4231-6313; Stoychev,
   Stoyan/0000-0001-7504-4313
FU Nelson Mandela University, South Africa; National Research Fund, South
   Africa
FX The authors would like thank Nelson Mandela University, South Africa for
   funding and infrastructure support. The authors would also like to thank
   the National Research Fund, South Africa for financial support.
CR ANEIROS A, 1993, BIOCHIM BIOPHYS ACTA, V1157, P86, DOI 10.1016/0304-4165(93)90082-J
   Bosmans F, 2002, FEBS LETT, V532, P131, DOI 10.1016/S0014-5793(02)03653-0
   Bruhn T., 2001, ISOLATION CHARACTERI
   Candiano G, 2004, ELECTROPHORESIS, V25, P1327, DOI 10.1002/elps.200305844
   CASTANEDA O, 1995, TOXICON, V33, P603, DOI 10.1016/0041-0101(95)00013-C
   Chahine M, 1996, J MEMBRANE BIOL, V152, P39, DOI 10.1007/s002329900083
   Cotton J, 1997, EUR J BIOCHEM, V244, P192, DOI 10.1111/j.1432-1033.1997.00192.x
   Cusdin FS, 2008, TRAFFIC, V9, P17, DOI 10.1111/j.1600-0854.2007.00673.x
   Daly M., 2018, WORMS WORLD REGISTER
   Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302
   Dias T., 2007, PAN AM J AQUAT SCI, V2
   DORSEY JG, 1989, CHEM REV, V89, P331, DOI 10.1021/cr00092a005
   Du Y, 2015, ACS CHEM NEUROSCI, V6, P871, DOI 10.1021/acschemneuro.5b00004
   Frazao B, 2012, MAR DRUGS, V10, P1812, DOI 10.3390/md10081812
   Gondran M, 2002, TOXICON, V40, P1667, DOI 10.1016/S0041-0101(02)00181-2
   Gonzalez-Munoz Ricardo, 2016, Marine Biodiversity Records, V9, DOI 10.1186/s41200-016-0016-7
   GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017
   Gupta A, 2004, PROTEIN SCI, V13, P2045, DOI 10.1110/ps.04613004
   GUTTMAN A, 1993, ANAL CHEM, V65, P199, DOI 10.1021/ac00051a002
   Haider S. R., 2012, PROTEIN ELECTROPHORE, V869, DOI [10.1007/978-1-61779-821-4, DOI 10.1007/978-1-61779-821-4]
   HILLE B, 2001, ION CHANNELS EXCITAB
   Honma T, 2006, MAR BIOTECHNOL, V8, P1, DOI 10.1007/s10126-005-5093-2
   Invitrogen, 2017, FLUXOR 2 GREEN POT I
   JANATOVA J, 1986, BIOCHEM J, V233, P819, DOI 10.1042/bj2330819
   Jouiaei M, 2015, MOL BIOL EVOL, V32, P1598, DOI 10.1093/molbev/msv050
   Kaczorowski GJ, 2008, J GEN PHYSIOL, V131, P399, DOI 10.1085/jgp.200709946
   Kasianowicz JJ, 2012, CHEM REV, V112, P6215, DOI 10.1021/cr300444k
   Kass-Simon G, 2002, CAN J ZOOL, V80, P1772, DOI 10.1139/Z02-135
   Kharatmal SB, 2015, MINI-REV MED CHEM, V15, P1134, DOI 10.2174/1389557515666150722112621
   KUMAR TKS, 1993, ANAL BIOCHEM, V213, P226, DOI 10.1006/abio.1993.1413
   Laird MC, 2016, AFR INVERTEBR, V57, P15, DOI 10.3897/afrinvertebr.57.8459
   Libralato G, 2016, ECOL INDIC, V69, P35, DOI 10.1016/j.ecolind.2016.04.017
   Liu PR, 2010, J AM SOC MASS SPECTR, V21, P837, DOI 10.1016/j.jasms.2010.01.016
   LORET EP, 1994, J BIOL CHEM, V269, P16785
   Madio B, 2019, MAR DRUGS, V17, DOI 10.3390/md17060325
   MALPEZZI ELA, 1993, TOXICON, V31, P853, DOI 10.1016/0041-0101(93)90220-D
   Mantegazza M, 2010, LANCET NEUROL, V9, P413, DOI 10.1016/S1474-4422(10)70059-4
   MARSHALL DL, 1994, TOXICON, V32, P1433, DOI 10.1016/0041-0101(94)90415-4
   Miseta A, 2000, MOL BIOL EVOL, V17, P1232, DOI 10.1093/oxfordjournals.molbev.a026406
   Oliveira JS, 2006, BBA-PROTEINS PROTEOM, V1764, P1592, DOI 10.1016/j.bbapap.2006.08.010
   Oliveira JS, 2012, TOXICON, V60, P539, DOI 10.1016/j.toxicon.2012.05.020
   Oliveira JS, 2004, J BIOL CHEM, V279, P33323, DOI 10.1074/jbc.M404344200
   Orts DJB, 2013, MAR DRUGS, V11, P655, DOI 10.3390/md11030655
   Rachamim T, 2015, MOL BIOL EVOL, V32, P740, DOI 10.1093/molbev/msu335
   Rath A, 2009, P NATL ACAD SCI USA, V106, P1760, DOI 10.1073/pnas.0813167106
   Schagger H, 2006, NAT PROTOC, V1, P16, DOI 10.1038/nprot.2006.4
   Shiomi K, 1997, BBA-GEN SUBJECTS, V1335, P191, DOI 10.1016/S0304-4165(96)00137-7
   SMITH PK, 1987, ANAL BIOCHEM, V163, P279
   Standker L, 2006, TOXICON, V48, P211, DOI 10.1016/j.toxicon.2006.05.001
   TANAKA M, 1977, BIOCHEMISTRY-US, V16, P204, DOI 10.1021/bi00621a007
   Wang L, 2004, BIOCHEM BIOPH RES CO, V313, P163, DOI 10.1016/j.bbrc.2003.11.102
   Wang W, 2009, J VENOM ANIM TOXINS, V15, P268, DOI 10.1590/S1678-91992009000200009
   Wanke E, 2009, TOXICON, V54, P1102, DOI 10.1016/j.toxicon.2009.04.018
   Williams S, 2004, J CHROMATOGR A, V1052, P1, DOI 10.1016/j.chroma.2004.07.110
   Yu HB, 2016, ACTA PHARMACOL SIN, V37, P34, DOI 10.1038/aps.2015.108
   Zaharenko AJ, 2008, COMP BIOCHEM PHYS D, V3, P219, DOI 10.1016/j.cbd.2008.04.002
   Zaharenko AJ, 2008, TOXICON, V51, P1303, DOI 10.1016/j.toxicon.2008.01.011
NR 57
TC 0
Z9 0
U1 4
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT
PY 2019
VL 168
BP 147
EP 157
DI 10.1016/j.toxicon.2019.06.222
PG 11
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IW3JJ
UT WOS:000484876000022
PM 31330191
DA 2020-05-12
ER

PT J
AU Kutschenko, A
   Bigalke, H
   Wegner, F
   Wohlfarth, K
AF Kutschenko, Anna
   Bigalke, Hans
   Wegner, Florian
   Wohlfarth, Kai
TI The role of human serum albumin and neurotoxin associated proteins in
   the formulation of BoNT/A products
SO TOXICON
LA English
DT Article
DE Botulinum neurotoxin; Human serum albumin; Neurotoxin associated
   proteins; Mouse hemidiaphragm assay; Neutralizing antibodies
ID TOXIN TYPE-A; D BOTULINUM TOXIN; CLOSTRIDIUM-BOTULINUM; COMPLEXING
   PROTEINS; EPITHELIAL BARRIER; DOUBLE-BLIND; E-CADHERIN; THERAPY;
   INCOBOTULINUMTOXINA; IDENTIFICATION
AB Botulinum neurotoxin (BoNT) is synthesized as a progenitor toxin complex (PTC) by Clostridium botulinum. This PTC comprises, in addition to the neurotoxin itself, neurotoxin associated proteins (NAPs) which are composed of three hemagglutinins and one non-toxic, non-hemagglutinin protein. After oral ingestion, these NAPs protect the neurotoxin from the low pH and proteases in the gastrointestinal tract and play a role in the entry via the intestinal barrier. Two of the three therapeutically used botulinum neurotoxin serotype A (BoNT/A) products (onabotulinumtoxinA and abobotulinumtoxinA) contain different amounts of NAPs, while incobotulinumtoxinA, lacks these proteins. In addition, human serum albumin (HSA) that is supposed to stabilize BoNT/A is added at different concentrations. Up to now, the function of the NAPs and HSA after parenteral therapeutic application is not completely understood.
   To investigate the influence of NAPs and HSA on potency of BoNT/A, we used the ex vivo mouse phrenic nerve hemidiaphragm assay.
   Increasing doses of HSA resulted dose-dependently in a more pronounced effect of BoNT/A. Though, a plateau was reached with concentrations of 0.8 mg/ml HSA and higher, the accessory addition of NAPs in a relevant amount (4 ng/ml) did not further enhance the effect of BoNT/A.
   In conclusion, in our ex vivo assay an adequate concentration of HSA prevented BoNT/A from loss of effect and supplementary NAPs did not alter this effect. A confirmation of these data in an in vivo assay is still lacking. However, it might be supposed that even in clinically applied BoNT/A products an increase of HSA accompanied by the avoidance of NAPs could potentially reduce the injected dose and, thus, the risk of unwanted side effects, the treatment costs as well as the risk of a secondary therapy failure due to BoNT/A neutralizing antibodies.
C1 [Kutschenko, Anna; Wegner, Florian] Hannover Med Sch, Dept Neurol, Carl Neuberg Str 1, D-30625 Hannover, Germany.
   [Wohlfarth, Kai] BG Hosp Bergmannstrost, Dept Neurol, Halle, Saale, Germany.
   [Bigalke, Hans] Hannover Med Sch, Inst Toxicol, Hannover, Germany.
RP Kutschenko, A (reprint author), Hannover Med Sch, Dept Neurol, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM Kutschenko.Anna@mh-hannover.de
FU German Working Group Botulinum Toxin
FX The study was supported by a grant to KW of the "German Working Group
   Botulinum Toxin".
CR Albrecht P, 2019, NEUROLOGY, V92, pE48, DOI 10.1212/WNL.0000000000006688
   Benecke R, 2005, NEUROLOGY, V64, P1949, DOI 10.1212/01.WNL.0000163767.99354.C3
   Bigalke H, 2001, EXP NEUROL, V168, P162, DOI 10.1006/exnr.2000.7583
   Bigalke H, 2015, TOXINS, V7, P4895, DOI 10.3390/toxins7124855
   Brunt J, 2018, FEBS LETT, V592, P310, DOI 10.1002/1873-3468.12969
   Bryant AM, 2013, TOXICON, V72, P126, DOI 10.1016/j.toxicon.2013.06.011
   Chellappan G, 2014, PROTEIN J, V33, P557, DOI 10.1007/s10930-014-9588-4
   Chen F, 1998, INFECT IMMUN, V66, P2420, DOI 10.1128/IAI.66.6.2420-2425.1998
   Chen JJ, 2013, PHARMACOTHERAPY, V33, P304, DOI 10.1002/phar.1196
   Cheng LW, 2008, TOXICOLOGY, V249, P123, DOI 10.1016/j.tox.2008.04.018
   Collins MD, 1998, J APPL MICROBIOL, V84, P5, DOI 10.1046/j.1365-2672.1997.00313.x
   Connan C, 2017, CELL MICROBIOL, V19, DOI 10.1111/cmi.12738
   Dressler D, 2002, EUR NEUROL, V48, P26, DOI 10.1159/000064953
   Eisele KH, 2011, TOXICON, V57, P555, DOI 10.1016/j.toxicon.2010.12.019
   Frevert J, 2015, DRUGS R&D, V15, P1, DOI 10.1007/s40268-014-0077-1
   Frevert J, 2010, BIOL-TARGETS THER, V4, P325, DOI 10.2147/BTT.S14902
   Frevert J, 2010, DRUGS R&D, V10, P67, DOI 10.2165/11584780-000000000-00000
   Frevert J, 2009, TOXICON, V54, P697, DOI 10.1016/j.toxicon.2009.03.010
   Friday D., 2002, N-S ARCH PHARMACOL, V365, P175
   Fujinaga Y, 1997, MICROBIOL-UK, V143, P3841, DOI 10.1099/00221287-143-12-3841
   Fujinaga Y, 2009, TOXICON, V54, P583, DOI 10.1016/j.toxicon.2008.11.014
   GILL DM, 1982, MICROBIOL REV, V46, P86, DOI 10.1128/MMBR.46.1.86-94.1982
   GOODNOUGH MC, 1992, APPL ENVIRON MICROB, V58, P3426, DOI 10.1128/AEM.58.10.3426-3428.1992
   Goschel H, 1997, EXP NEUROL, V147, P96, DOI 10.1006/exnr.1997.6580
   Gu SY, 2013, CURR TOP MICROBIOL, V364, P21, DOI 10.1007/978-3-642-33570-9_2
   Gu SY, 2012, SCIENCE, V335, P977, DOI 10.1126/science.1214270
   Inoue K, 1996, INFECT IMMUN, V64, P1589, DOI 10.1128/IAI.64.5.1589-1594.1996
   Ito H, 2011, FEMS IMMUNOL MED MIC, V61, P323, DOI 10.1111/j.1574-695X.2011.00779.x
   Jankovic J, 2017, MOVEMENT DISORD, V32, P1131, DOI 10.1002/mds.27072
   Jost WH, 2015, DRUG DES DEV THER, V9, P1913, DOI 10.2147/DDDT.S79193
   Kukreja R, 2009, TOXICON, V53, P616, DOI 10.1016/j.toxicon.2009.01.017
   Kutschenko A, 2019, CLIN NEUROPHYSIOL, V130, P1066, DOI 10.1016/j.clinph.2019.02.007
   Kutschenko A, 2016, NEUROSCI LETT, V627, P216, DOI 10.1016/j.neulet.2016.06.001
   Lange O, 2009, CLIN NEUROPHARMACOL, V32, P213, DOI 10.1097/WNF.0b013e3181914d0a
   Lee JC, 2005, MICROBIOL-SGM, V151, P3739, DOI 10.1099/mic.0.28421-0
   Lee K, 2014, SCIENCE, V344, P1405, DOI 10.1126/science.1253823
   Mohammadi B, 2009, J NEURAL TRANSM, V116, P437, DOI 10.1007/s00702-009-0200-6
   Montecucco C, 1995, Q REV BIOPHYS, V28, P423, DOI 10.1017/S0033583500003292
   Niwa K, 2007, FEMS IMMUNOL MED MIC, V49, P346, DOI 10.1111/j.1574-695X.2006.00205.x
   Peck MW, 2017, TOXINS, V9, DOI 10.3390/toxins9010038
   Pickett A, 2007, EUR J NEUROL, V14, pE11, DOI 10.1111/j.1468-1331.2007.01683.x
   Pirazzini M, 2017, PHARMACOL REV, V69, P200, DOI 10.1124/pr.116.012658
   Rasetti-Escargueil C, 2011, TOXICON, V57, P1008, DOI 10.1016/j.toxicon.2011.04.003
   Roggenkamper P, 2006, J NEURAL TRANSM, V113, P303, DOI 10.1007/s00702-005-0323-3
   Rollnik JD, 2000, EUR NEUROL, V43, P9, DOI 10.1159/000008121
   Rosales RL, 2006, EUR J NEUROL, V13, P2, DOI 10.1111/j.1468-1331.2006.01438.x
   Rummel A, 2015, TOXICON, V107, P9, DOI 10.1016/j.toxicon.2015.09.009
   SCHANTZ EJ, 1990, LANCET, V335, P421, DOI 10.1016/0140-6736(90)90263-5
   SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0
   Sharma SK, 2003, TOXICON, V41, P321, DOI 10.1016/S0041-0101(02)00309-4
   Sibar S, 2017, ANN PLAS SURG, V78, P436, DOI 10.1097/SAP.0000000000000957
   Singh BR, 1996, TOXICON, V34, P267, DOI 10.1016/0041-0101(95)00113-1
   Sugawara Y, 2011, CELL ADHES MIGR, V5, P34, DOI 10.4161/cam.5.1.13574
   Sugawara Y, 2010, J CELL BIOL, V189, P691, DOI 10.1083/jcb.200910119
   Tang-Liu DDS, 2003, TOXICON, V42, P461, DOI 10.1016/S0041-0101(03)00196-X
   Wohlfarth K, 1997, N-S ARCH PHARMACOL, V355, P335, DOI 10.1007/PL00004951
   Wohlfarth K, 2007, CLIN NEUROPHARMACOL, V30, P86, DOI 10.1097/01.WNF.0000240951.18821.50
   Wohlfarth K, 2009, CURR MED RES OPIN, V25, P1573, DOI 10.1185/03007990903028203
   Wohlfarth K, 2008, J NEUROL, V255, P1932, DOI 10.1007/s00415-008-0031-7
   Zhang SC, 2018, CELL HOST MICROBE, V23, P169, DOI 10.1016/j.chom.2017.12.018
   Zhang SC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14130
NR 61
TC 0
Z9 0
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT
PY 2019
VL 168
BP 158
EP 163
DI 10.1016/j.toxicon.2019.07.005
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IW3JJ
UT WOS:000484876000023
PM 31323228
DA 2020-05-12
ER

PT J
AU Zhan, ZX
   Yan, X
   Nie, WG
   Ding, YN
   Xu, WD
   Huang, HY
AF Zhan, Zhixin
   Yan, Xu
   Nie, Weiguang
   Ding, Yaonan
   Xu, Weidong
   Huang, Haiyan
TI Neurofibroma and Meningioma within a Single Dumbbell-Shaped Tumor at the
   Same Cervical Level without Neurofibromatosis: A Case Report and
   Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Coexisting tumor; Concurrent tumor; Meningioma; Multiple spinal tumors;
   Neurinoma; Neurofibromatosis
ID SPINAL SCHWANNOMAS; MIMICKING; OUTCOMES
AB BACKGROUND: Cases of multiple intracranial tumors are common; however, cases of multiple intraspinal tumors are rare. Except for cases of neurofibromatosis, it is very rare for tumors of different pathological types to exist concurrently at the same spinal level. Only 9 cases have been reported to date, with meningioma found with schwannoma in 7 cases and with neurofibroma in 2 cases.
   CASE DESCRIPTION: We have reported another rare case in which neurofibroma and meningioma were identified within a single dumbbell-shaped tumor at the same cervical level without neurofibromatosis. The preoperative magnetic resonance imaging findings indicated a single extra- and intradural extramedullary dumbbell-shaped neurogenic tumor on the left ventral side of the cervical spine. Intraoperatively, we found that the mass consisted of 2 pathologically different tumors. The results of surgical resection were mostly satisfactory.
   CONCLUSIONS: To the best of our knowledge, the present case is the first reported case of intradural neurofibroma (not meningioma) and extradural meningioma growing mixed together at the same spinal level without neurofibromatosis. The precise mechanism underlying the formation of the tumor is unknown, and multidirectional differentiation of a common progenitor cell is one possibility. Intra- and extradural exploration and component biopsies are useful for treatment planning, especially when the magnetic resonance imaging is not sufficiently sensitive for the diagnosis of coexisting tumor types.
C1 [Zhan, Zhixin; Nie, Weiguang; Ding, Yaonan; Xu, Weidong; Huang, Haiyan] First Hosp Jilin Univ, Dept Neurosurg, Changchun, Jilin, Peoples R China.
   [Yan, Xu] First Hosp Jilin Univ, Pathlol Diagnost Ctr, Changchun, Jilin, Peoples R China.
RP Huang, HY (reprint author), First Hosp Jilin Univ, Dept Neurosurg, Changchun, Jilin, Peoples R China.
EM huanghy@jlu.edu.cn
CR Alorainy IA, 2006, EUR J RADIOL, V60, P387, DOI 10.1016/j.ejrad.2006.06.012
   Chen KY, 2014, J CHIN MED ASSOC, V77, P594, DOI 10.1016/j.jcma.2014.06.007
   Cihangiroglu M, 2002, AM J NEURORADIOL, V23, P1637
   Cofano F, 2019, NEUROSURG REV, V42, P297, DOI 10.1007/s10143-017-0939-4
   de Verdelhan O, 2005, J NEURORADIOLOGY, V32, P42, DOI 10.1016/S0150-9861(05)83021-4
   Emel E, 2017, TURK NEUROSURG, V27, P217, DOI 10.5137/1019-5149.JTN.15678-15.1
   Ferner RE, 2007, LANCET NEUROL, V6, P340, DOI 10.1016/S1474-4422(07)70075-3
   GEDDES JF, 1995, CLIN NEUROPATHOL, V14, P310
   Hokari M, 2002, NEUROL SURG TOKYO, V30, P953
   Lee JW, 2016, J NEURO-ONCOL, V129, P15, DOI 10.1007/s11060-016-2148-3
   Liebelt BD, 2016, WORLD NEUROSURG, V93, DOI 10.1016/j.wneu.2016.07.046
   Matsuda Shingo, 2018, NMC Case Rep J, V5, P105, DOI 10.2176/nmccrj.cr.2017-0207
   Nakamizo A, 2012, NEUROPATHOLOGY, V32, P190, DOI 10.1111/j.1440-1789.2011.01239.x
   Nakamura M, 2012, SPINE, V37, pE617, DOI 10.1097/BRS.0b013e31824167f1
   Ogihara S, 2003, J NEUROSURG, V98, P300, DOI 10.3171/spi.2003.98.3.0300
   Oichi T, 2015, J NEUROSURG-SPINE, V23, P784, DOI 10.3171/2015.3.SPINE141315
   Parry DM, 2006, J NEUROSURG-SPINE, V5, P179, DOI 10.3171/spi.2006.5.2.179
   Porcnik A, 2020, BRIT J NEUROSURG, V34, P104, DOI 10.1080/02688697.2017.1419162
   Schick U, 2001, NEUROSURG REV, V24, P20, DOI 10.1007/PL00011961
   Sevick RJ, 2015, CAN J NEUROL SCI, V22, P936
   SOLERO CL, 1989, NEUROSURGERY, V25, P153, DOI 10.1227/00006123-198908000-00001
NR 21
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 1
EP 6
DI 10.1016/j.wneu.2019.06.142
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200140
PM 31254713
DA 2020-05-12
ER

PT J
AU Avci, I
   Baskurt, O
   Seker, S
   Celik, SE
AF Avci, Idris
   Baskurt, Ozan
   Seker, Selim
   Celik, Suat Erol
TI Late-onset Metastasis of Intracranial Papillary Thyroid Carcinoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain metastasis; Papillary thyroid carcinoma; Thyroid
ID DISTANT METASTASES; SURGERY
AB BACKGROUND: Papillary thyroid carcinoma is the most common subtype of thyroid cancers, accounting for >90% of all thyroid carcinomas. Despite a favorable long-term survival rate of 94.4%, people with distant metastases show worse outcome. Cerebral metastases are slightly uncommon and stand for only 1%-3% of all metastases.
   CASE DESCRIPTION: We present a 56-year-old male patient complaining of serous headaches for >20 days. lie underwent thyroidectomy surgery 13 years ago due to papillary thyroid carcinoma and was reported "tumor free" on his follow-ups without any complaints. On his cranial magnetic resonance imaging scan a right temporal mass lesion was detected. During surgery, the tumor was removed and reported as papillary thyroid carcinoma metastasis.
   CONCLUSION: A case in which a patient with papillary thyroid carcinoma developed brain metastasis after such a long time was not reported in the literature before.
C1 [Avci, Idris; Baskurt, Ozan; Seker, Selim; Celik, Suat Erol] Univ Hlth Sci Okmeydani Training & Res Hosp, Dept Neurosurg, Istanbul, Turkey.
RP Avci, I (reprint author), Univ Hlth Sci Okmeydani Training & Res Hosp, Dept Neurosurg, Istanbul, Turkey.
EM mail.idrisavci@gmail.com
RI Baskurt, Ozan/AAH-3664-2020
OI Baskurt, Ozan/0000-0003-1021-6529
CR Chiu AC, 1997, J CLIN ENDOCR METAB, V82, P3637, DOI 10.1210/jc.82.11.3637
   Choi Won Ho, 2013, Brain Tumor Res Treat, V1, P99, DOI 10.14791/btrt.2013.1.2.99
   DELATTRE JY, 1988, ARCH NEUROL-CHICAGO, V45, P741, DOI 10.1001/archneur.1988.00520310047016
   DINNEEN SF, 1995, J CLIN ENDOCR METAB, V80, P2041, DOI 10.1210/jc.80.7.2041
   HOIE J, 1988, CANCER, V61, P1, DOI 10.1002/1097-0142(19880101)61:1<1::AID-CNCR2820610102>3.0.CO;2-R
   Hu MI, 2008, CANC MANAGEMENT MULT
   Jin J, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4371-0
   Kaal ECA, 2005, J NEURO-ONCOL, V75, P15, DOI 10.1007/s11060-004-8094-5
   Kim DY, 2018, ANN SURG TREAT RES, V94, P13, DOI 10.4174/astr.2018.94.1.13
   Nussbaum ES, 1996, CANCER-AM CANCER SOC, V78, P1781, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1781::AID-CNCR19>3.0.CO;2-U
   Owen S, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00248
   PATCHELL RA, 1990, NEW ENGL J MED, V322, P494, DOI 10.1056/NEJM199002223220802
   Song HJ, 2011, ENDOCR-RELAT CANCER, V18, pR165, DOI 10.1530/ERC-11-0068
   Tsuda K, 2013, MOL CLIN ONCOL, V1, P817, DOI 10.3892/mco.2013.139
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 7
EP 9
DI 10.1016/j.wneu.2019.06.164
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200141
PM 31260848
DA 2020-05-12
ER

PT J
AU Usher, I
   Flanagan, AM
   Choi, D
AF Usher, Inga
   Flanagan, Adrienne M.
   Choi, David
TI Systematic Review of Clinical, Radiologic, and Histologic Features of
   Benign Notochordal Cell Tumors: Implications for Patient Management
SO WORLD NEUROSURGERY
LA English
DT Review
DE Bone neoplasms; Chordoma; Notochord/pathology; Spinal
   neoplasms/pathology
ID ECCHORDOSIS-PHYSALIPHORA; CHORDOMA; DIAGNOSIS; SECONDARY; DISTINCT;
   LESIONS; ENTITY; REST; CT
AB BACKGROUND: There are no absolute defining criteria for benign notochordal cell tumors; the diagnosis is usually based on small size and the absence of aggressive features. Therefore, by definition, the diagnosis is subjective and usually determined by multidisciplinary consensus. A benign notochordal cell tumor should not grow during surveillance, and this may be used to confirm the diagnosis, but is a tautologic definition. Diagnostic ambiguity leads to uncertainty in management. If a tumor is a small chordoma then early surgery is likely to provide a better outcome. However, unnecessary treatment of a benign tumor may incur unjustified risk.
   OBJECTIVE: To propose dearer guidelines for the definition and management of benign notochordal tumors.
   METHODS: We performed a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) review of the reported definitions for benign notochordal tumors and their management.
   RESULTS: The accepted features of benign notochordal tumors vary considerably: a typical tumor may be diagnosed in the absence of neurology, radiologically well-corticated bony margins, size <35 mm, no enhancement with contrast, no soft tissue extension, no dural penetration, no progression on scans, histologic absence of extracellular myxoid matrix, and low Ki67 index. If these criteria are fulfilled, it is reasonable to use radiologic surveillance in the first instance. Biopsy may be offered depending on the relative risks of performing the biopsy, or if there are atypical features.
   CONCLUSIONS: We suggest a clearer definition for a benign notochordal tumor and a management algorithm that incorporates a level of diagnostic uncertainty.
C1 [Usher, Inga; Choi, David] Natl Hosp Neurol & Neurosurg, Victor Horsley Dept Neurosurg, Queen Sq, London, England.
   [Flanagan, Adrienne M.] Royal Natl Orthopaed Hosp, Dept Histopathol, Stanmore, Middx, England.
RP Usher, I (reprint author), Natl Hosp Neurol & Neurosurg, Victor Horsley Dept Neurosurg, Queen Sq, London, England.
EM Inga.usher@nhs.net
OI Flanagan, Adrienne/0000-0002-2832-1303
CR Alli A, 2008, SKULL BASE-INTERD AP, V18, P395, DOI 10.1055/s-0028-1087221
   Amer HZM, 2010, ARCH PATHOL LAB MED, V134, P283, DOI 10.1043/1543-2165-134.2.283
   Arain A, 2017, SKELETAL RADIOL, V46, P1745, DOI 10.1007/s00256-017-2727-1
   Carter JM, 2017, AM J SURG PATHOL, V41, P39, DOI 10.1097/PAS.0000000000000766
   Cha ST, 2002, MINIM INVAS NEUROSUR, V45, P36, DOI 10.1055/s-2002-23584
   Chauvel A, 2005, HISTOPATHOLOGY, V47, P646, DOI 10.1111/j.1365-2559.2005.02168.x
   Chihara C, 2013, EUR RADIOL, V23, P2854, DOI 10.1007/s00330-013-2888-9
   Chung M, 2011, EMERGING MRI TECHNOL
   CONGDON CC, 1952, AM J PATHOL, V28, P793
   Darby AJ, 1999, SKELETAL RADIOL, V28, P342, DOI 10.1007/s002560050528
   Deshpande V, 2007, AM J SURG PATHOL, V31, P1573, DOI 10.1097/PAS.0b013e31805c9967
   Du J, 2019, J CLIN PATHOL, V72, P66, DOI 10.1136/jclinpath-2018-205441
   Flanagan AM, 2013, WHO CLASSIFICATION T, P328
   Galloway L, 2019, BRIT J NEUROSURG, V33, P99, DOI 10.1080/02688697.2017.1297766
   George B, 2015, NEUROSURG CLIN N AM, V26, P437, DOI 10.1016/j.nec.2015.03.012
   Golden LD, 2014, J NEUROIMAGING, V24, P245, DOI 10.1111/jon.12013
   HO KL, 1985, CLIN NEUROPATHOL, V4, P77
   Inagawa S, 2013, NEURORADIOLOGY, V55, P1297
   Iorgulescu JB, 2013, NEUROSURGERY, V73, P411, DOI 10.1227/01.neu.0000431476.94783.c6
   Ishak SEA, 2012, LAB INVEST, V92, p14A
   Kreshak J, 2014, CANCER IMAGING, V14, DOI 10.1186/1470-7330-14-4
   Kyriakos M, 2003, AM J SURG PATHOL, V27, P396, DOI 10.1097/00000478-200303000-00015
   Kyriakos M, 2011, SKELETAL RADIOL, V40, P1141, DOI 10.1007/s00256-011-1167-6
   Lagman C, 2016, CUREUS, V8, DOI 10.7759/cureus.547
   Ling SS, 2007, OTOL NEUROTOL, V28, P931
   Ma XM, 2014, INT J CLIN EXP PATHO, V7, P3548
   MACDONALD RL, 1990, CAN J NEUROL SCI, V17, P420, DOI 10.1017/S0317167100031000
   MACDONALD RL, 1990, NEUROSURGERY, V26, P515
   Mirra JM, 2001, SKELETAL RADIOL, V30, P698, DOI 10.1007/s002560100422
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Ng SH, 1998, BRIT J RADIOL, V71, P329, DOI 10.1259/bjr.71.843.9616246
   Nishiguchi T, 2010, BRIT J RADIOL, V83, pE49, DOI 10.1259/bjr/63846600
   Nishiguchi T, 2011, AM J ROENTGENOL, V196, P644, DOI 10.2214/AJR.10.4460
   OECD, 2018, MAGN RES IM MRI EX I, DOI [10.1787/1D89353F-EN, DOI 10.1787/1D89353F-EN, 10.1787/1d89353f-en]
   Ozgur A, 2016, CLIN NEURORADIOL, V26, P347, DOI 10.1007/s00062-014-0361-z
   Pasalic Dario, 2013, Open Neuroimag J, V7, P36, DOI 10.2174/1874440001307010036
   Picci P, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.21503
   Santegoeds Rene G C, 2018, Curr Radiol Rep, V6, P16, DOI 10.1007/s40134-018-0275-7
   Souteyrand P, 2013, Diagn Interv Imaging, V94, P466, DOI 10.1016/j.diii.2013.01.008
   Stewart MJ, 1923, J NEUROL PSYCHOPATHO, V4, P218
   Terzi S, 2012, SPINE, V37, pE1356, DOI 10.1097/BRS.0b013e318266e7e6
   ULICH TR, 1982, CLIN ORTHOP RELAT R, P282
   Vujovic S, 2006, J PATHOL, V209, P157, DOI 10.1002/path.1969
   Wang L, 2014, WORLD NEUROSURG, V82, P791, DOI 10.1016/j.wneu.2012.12.037
   Yamaguchi T, 2005, MODERN PATHOL, V18, P1005, DOI 10.1038/modpathol.3800378
   Yamaguchi T, 2004, HISTOPATHOLOGY, V44, P597, DOI 10.1111/j.1365-2559.2004.01877.x
   Yamaguchi T, 2004, AM J SURG PATHOL, V28, P756, DOI 10.1097/01.pas.0000126058.18669.5d
   Yamaguchi T, 2002, SKELETAL RADIOL, V31, P413, DOI 10.1007/s00256-002-0514-z
   Yamaguchi T, 2008, SKELETAL RADIOL, V37, P291, DOI 10.1007/s00256-007-0435-y
NR 49
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 13
EP 23
DI 10.1016/j.wneu.2019.06.009
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200143
PM 31421435
DA 2020-05-12
ER

PT J
AU Scullen, T
   Hanna, J
   Carr, C
   Mathkour, M
   Aslam, R
   Amenta, P
   Dallapiazza, RF
AF Scullen, Tyler
   Hanna, Joshua
   Carr, Christopher
   Mathkour, Mansour
   Aslam, Rizwan
   Amenta, Peter
   Dallapiazza, Robert F.
TI Surgical Approaches in the Treatment of Intracranial Complications of
   Paranasal Sinus Disease: A Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Central nervous system infections; Endoscopic sinus surgery;
   Neurosurgical procedure; Otorhinolaryngology procedure; Paranasal sinus
   disease
ID SUBDURAL EMPYEMA; SUPPURATIVE COMPLICATIONS; MANAGEMENT; RARE
AB BACKGROUND: Intracranial extension of frontal or ethmoid sinusitis carries a high morbidity and mortality if not treated aggressively. With the emergence of endoscopic sinus surgery (ESS), we questioned whether these approaches have supplanted traditional transcranial procedures for intracranial extension of sinus disease, and whether ESS approaches had a difference in patient outcomes.
   METHODS: Studies reporting surgical management and outcomes of frontal sinus disease with intracranial extension were queried using the United States National Library of Medicine at the National Institutes of Health PubMed database. We also queried common Internet search engines. We included studies regarding sinogenic intracranial suppurative infections treated surgically with ESS and neurosurgical approaches. Studies with insufficient data regarding specific treatment methods and studies that included populations of medically treated infections were excluded.
   RESULTS: A total of 108 cases were identified in which patients with intracranial sinogenic disease were treated via ESS alone (morbidity: 43.5%, mortality: 0.9%), 47 cases via transcranial intervention alone (morbidity: 33.2%, mortality: 7.8%), and 43 cases via simultaneous neurosurgical and ESS approaches (morbidity: 16.3%, mortality: 6.4%). Complex sinus disease with posterior table compromise in the absence of intracranial extension treated via ESS alone was reported in 164 cases with a morbidity and mortality of 3.8% and 0%, respectively.
   CONCLUSIONS: Combined ESS and transcranial approaches achieve definitive control of sinogenic and intracranial disease, whereas either modality alone carries a potential risk for higher morbidity and mortality. The use of ESS alone may have use in the treatment of sinusitis with posterior table erosion prior to intracranial extension.
C1 [Scullen, Tyler; Hanna, Joshua; Carr, Christopher; Mathkour, Mansour; Amenta, Peter; Dallapiazza, Robert F.] Tulane Univ, Dept Neurol Surg, New Orleans, LA 70118 USA.
   [Aslam, Rizwan] Tulane Univ, Dept Otolaryngol, New Orleans, LA 70118 USA.
   [Scullen, Tyler; Hanna, Joshua; Carr, Christopher; Mathkour, Mansour; Amenta, Peter; Dallapiazza, Robert F.] Ochsner Med Ctr, Dept Neurol Surg, Jefferson, LA USA.
RP Dallapiazza, RF (reprint author), Tulane Univ, Dept Neurol Surg, New Orleans, LA 70118 USA.
EM rdallapiazza@tulane.edu
CR Brook I, 2017, J CLIN NEUROSCI, V38, P8, DOI 10.1016/j.jocn.2016.12.035
   Conger BT, 2014, OTOLARYNG HEAD NECK, V151, P159, DOI 10.1177/0194599814529078
   DelGaudio JM, 2010, AM J OTOLARYNG, V31, P25, DOI 10.1016/j.amjoto.2008.09.009
   DOLAN FW, 1995, J ORAL MAXIL SURG, V53, P1080, DOI 10.1016/0278-2391(95)90128-0
   Gallagher RM, 1998, LARYNGOSCOPE, V108, P1635, DOI 10.1097/00005537-199811000-00009
   Giannoni CM, 1997, LARYNGOSCOPE, V107, P863, DOI 10.1097/00005537-199707000-00005
   Gitomer SA, 2018, OTOLARYNG HEAD NECK, V159, P359, DOI 10.1177/0194599818765160
   Hurley DB, 2000, AM J RHINOL, V14, P113, DOI 10.2500/105065800781692840
   Kombogiorgas D, 2007, BRIT J NEUROSURG, V21, P603, DOI 10.1080/02688690701552856
   Kumar PS, 2013, CASE REP PEDIAT, DOI 10.1155/2013/153239
   MILLER ES, 1987, J NEUROL NEUROSUR PS, V50, P1415, DOI 10.1136/jnnp.50.11.1415
   Nica DA, 2011, CHIRURGIA-BUCHAREST, V106, P673
   Nicoli TK, 2016, SCAND J SURG, V105, P254, DOI 10.1177/1457496915622129
   Osborn MK, 2007, LANCET INFECT DIS, V7, P62, DOI 10.1016/S1473-3099(06)70688-0
   Piatt Joseph H Jr, 2011, J Neurosurg Pediatr, V7, P567, DOI 10.3171/2011.3.PEDS10504
   Pollock RA, 2013, ANN PLAS SURG, V71, P54, DOI 10.1097/SAP.0b013e3182468198
   Sade R, 2017, J CRANIOFAC SURG, V28, pE144, DOI 10.1097/SCS.0000000000003326
   Szyfter W, 2018, EUR ARCH OTO-RHINO-L, V275, P1165, DOI 10.1007/s00405-018-4932-5
   Visocchi M, 2012, ACTA NEUROL BELG, V112, P85, DOI 10.1007/s13760-012-0030-4
   Von Wihl S, 2016, J OTOL RHINOL, V5
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 24
EP 29
DI 10.1016/j.wneu.2019.06.135
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200144
PM 31254711
DA 2020-05-12
ER

PT J
AU Sangondimath, G
   Mallepally, AR
   Yelamarthy, PKK
   Chhabra, HS
AF Sangondimath, Gururaj
   Mallepally, Abhinandan Reddy
   Yelamarthy, P. K. Karthik
   Chhabra, Harvinder Singh
TI Severe Pott's Kyphosis in a 19-Month-Old Child: Case Report and Review
   of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Children; Kyphosis; Nonfusion; Pedicle screw; Pott's spine;
   Tuberculosis; VCR
ID VERTEBRAL COLUMN RESECTION; SPINAL TUBERCULOSIS; MANAGEMENT; DEFORMITY;
   DISEASE
AB BACKGROUND: Spinal osseous tuberculosis, or Pott's spine, although very common in endemic countries, has a lower incidence in very young children. However, the infection has the propensity to cause greater vertebral destruction in this age group, leading to severe structural kyphotic deformity and associated neurologic deficits. We report the case of a 19-month-old child with severe tubercular kyphotic deformity of the upper thoracic spine managed with posterior vertebral column resection (VCR) and nonfusion posterior pedicle screw instrumentation.
   CASE DESCRIPTION: This 19-month-old boy presented with 1-month history of spontaneous-onset, progressive, painful rigid kyphotic deformity of the upper back associated with spastic paraparesis with bowel and bladder incontinence. Magnetic resonance imaging showed severe destruction of bodies of D4-D7 vertebrae with cord edema and draping of the spinal cord over the internal gibbus at D4-D7 Surgery was performed with a restricted anterior fusion via single-stage posterior VCR at D4- D7 with nonfusion pedicle screw instrumentation from D1 to D9, with subsequent extension of instrumentation to D10 after 4 months.
   CONCLUSIONS: Multilevel posterior VCR with a restricted fusion and non-fusion pedicle screw instrumentation beyond the resection site can be safely done in young children (age <3 years) requiring rigid tubercular kyphotic deformity correction. However, these patients require regular follow-up and may need multiple surgeries.
C1 [Sangondimath, Gururaj; Mallepally, Abhinandan Reddy; Yelamarthy, P. K. Karthik; Chhabra, Harvinder Singh] Indian Spinal Injuries Ctr, Dept Spine Serv, New Delhi, India.
RP Mallepally, AR (reprint author), Indian Spinal Injuries Ctr, Dept Spine Serv, New Delhi, India.
EM mabhi28@gmail.com
OI mallepally, abhinandan reddy/0000-0001-8153-7499
CR Ahuja S R, 2003, J Postgrad Med, V49, P346
   Batirel A, 2015, CLIN MICROBIOL INFEC, V21, DOI 10.1016/j.cmi.2015.07.013
   Consigilieri G, 2011, NEUROSURGERY, V68, pE1485, DOI 10.1227/NEU.0b013e318210c81b
   Duarte RM, 2013, EUR SPINE J, V22, P2787, DOI 10.1007/s00586-013-2850-1
   Erdem MN, 2014, CASE REP ORTHOP, V2014
   Garg RK, 2011, J SPINAL CORD MED, V34, P440, DOI 10.1179/2045772311Y.0000000023
   Hidalgo JA, 2018, MEDSCAPE        0828
   Hristea A, 2008, INT J INFECT DIS, V12, P425, DOI 10.1016/j.ijid.2007.12.004
   Jain AK, 2014, INDIAN J ORTHOP, V48, P136, DOI 10.4103/0019-5413.128747
   Jeszenszky D, 2014, EUR SPINE J, V23, P198, DOI 10.1007/s00586-013-2924-0
   Kiymaz N, 2006, PEDIATR NEUROSURG, V42, P180, DOI 10.1159/000091864
   Kumar R, 2011, J PEDIATR NEUROSCI, V6, P101, DOI 10.4103/1817-1745.85726
   Laheri VJ, 2001, SPINAL CORD, V39, P429, DOI 10.1038/sj.sc.3101185
   Li J, 2013, J SPINAL DISORD TECH, V26, pE46, DOI 10.1097/BSD.0b013e31825d5c87
   Moon MS, 1997, INT ORTHOP, V21, P417
   Ohlin A, 2011, GROWING SPINE: MANAGEMENT OF SPINAL DISORDERS IN YOUNG CHILDREN, P317, DOI 10.1007/978-3-540-85207-0_24
   Osguthorpe RJ, 2001, CURR OPIN PEDIATR, V13, P598, DOI 10.1097/00008480-200112000-00019
   Panchmatia JR, 2015, J ORTHOP SURG-HONG K, V23, P391, DOI 10.1177/230949901502300328
   Rajasekaran S, 2002, CLIN ORTHOP RELAT R, P85
   Rajasekaran S, 2001, J BONE JOINT SURG BR, V83B, P954, DOI 10.1302/0301-620X.83B7.12170
   Rangel-Castilla L, 2012, J NEUROSURG-PEDIATR, V9, P447, DOI 10.3171/2011.12.PEDS11315
   Rasouli MR, 2012, ASIAN SPINE J, V6, P294, DOI 10.4184/asj.2012.6.4.294
   Saifi C, 2017, GLOB SPINE J, V7, P280, DOI 10.1177/2192568217699203
   Schulitz KP, 1997, SPINE, V22, P1150, DOI 10.1097/00007632-199705150-00016
   Shi T, 2016, ORTHOPEDICS, V39, pE838, DOI 10.3928/01477447-20160509-03
   Tufan K, 2005, J NEUROSURG, V102, P431, DOI 10.3171/ped.2005.102.4.0431
   Yazici M, 2011, NONIDIOPATHIC SPINE, P145
NR 27
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 30
EP 36
DI 10.1016/j.wneu.2019.06.097
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200145
PM 31252083
DA 2020-05-12
ER

PT J
AU Bresler, AY
   Mir, G
   Grube, J
   Hegazin, M
   Liu, JK
   Eloy, JA
   Paskhover, B
AF Bresler, Amishav Y.
   Mir, Ghayoour
   Grube, Jordon
   Hegazin, Michael
   Liu, James K.
   Eloy, Jean Anderson
   Paskhover, Boris
TI Endoscopic Paramedian Forehead Flap Reconstruction of the Anterior Skull
   Base for Recalcitrant Cerebrospinal Fluid Leaks: Minimally Invasive
   Adaptation of Ancient Flap
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior skull base defect; Local flaps; Paramedian forehead flap;
   Radiation
ID SECONDARY; OUTCOMES; DEFECTS
AB BACKGROUND: The anterior skull base (ASB) remains one of the greatest challenges for reconstructive surgeons. The current armamentarium includes endoscopic placement of free grafts, endonasal vascularized pedicled flaps, regional flaps, and microvascular free flaps. As the defect size increases, reconstruction complexity increases along with potential complications. Here, we report an endoscopic-assisted paramedian forehead flap, a novel adaptation of an age-old technique, for ASB reconstruction.
   CASE DESCRIPTION: A 66-year-old male underwent a dual bifrontal and transnasal endoscopic approach for the resection of a T4N0M0 sinonasal squamous cell carcinoma. The resulting ASB defect was repaired using simultaneous pericranial and nasoseptal flaps. Adjuvant radiation therapy resulted in delayed radiation necrosis in the right frontal lobe 3 years later requiring debridement via a supraorbital approach. Recovery from this operation was complicated by an ASB defect and cerebrospinal fluid (CSF) leak. The defect remained despite multiple attempts at endoscopic repairs. Due to multiple medical comorbidities, the patient was not a candidate for microvascular reconstruction. Prior surgeries had disrupted the traditional regional flaps (i.e., pericranial, nasoseptal, and temporoparietal fascia flaps) bilaterally. Therefore the novel endoscopic-assisted paramedian forehead flap was used to successfully repair the ASB defect. Postoperatively, the patient has done well with no recurrences in the CSF leak.
   CONCLUSIONS: The endoscopic-assisted paramedian forehead flap is a robust regional flap whose advantages include the utilization of muscle, low donor morbidity, and endoscopic placement with avoidance of craniotomies. Therefore it should be considered an important option for ASB reconstruction of recalcitrant CSF leaks when all other options are unavailable.
C1 [Bresler, Amishav Y.; Liu, James K.; Eloy, Jean Anderson; Paskhover, Boris] Rutgers New Jersey Med Sch, Dept Otolaryngol Head & Neck Surg, Newark, NJ 07103 USA.
   [Mir, Ghayoour; Grube, Jordon; Hegazin, Michael; Eloy, Jean Anderson; Paskhover, Boris] Robert Wood Johnson Barnabas Hlth, Dept Otolaryngol Facial Plast Surg, Livingston, NJ 07039 USA.
   [Liu, James K.; Eloy, Jean Anderson] Neurol Inst New Jersey, Tenter Skull Base & Pituitary Surg, Newark, NJ USA.
   [Liu, James K.] Rutgers New Jersey Med Sch, Dept Neurol Surg, Newark, NJ USA.
   [Eloy, Jean Anderson] Rutgers New Jersey Med Sch, Dept Ophthalmol & Visual Sci, Newark, NJ USA.
RP Paskhover, B (reprint author), Rutgers New Jersey Med Sch, Dept Otolaryngol Head & Neck Surg, Newark, NJ 07103 USA.; Paskhover, B (reprint author), Robert Wood Johnson Barnabas Hlth, Dept Otolaryngol Facial Plast Surg, Livingston, NJ 07039 USA.
EM borpas@njms.rutgers.edu
CR Bernal-Sprekelsen M, 2000, AM J RHINOL, V14, P257, DOI 10.2500/105065800779954473
   Casiano RR, 2001, AM J RHINOL, V15, P271, DOI 10.1177/194589240101500410
   Ciporen J, 2017, TURK NEUROSURG, DOI [10.5137/1019-5149.JTN.20662-17.1, DOI 10.5137/1019-5149.JTN.20662-17.1]
   Clavenna MJ, 2015, CURR OPIN OTOLARYNGO, V23, P71, DOI 10.1097/MOO.0000000000000115
   Faris C, 2015, JAMA FACIAL PLAST SU, V17, P16, DOI 10.1001/jamafacial.2014.738
   Fortes FSG, 2007, LARYNGOSCOPE, V117, P970, DOI 10.1097/MLG.0b013e3180471482
   Gil Z, 2007, SKULL BASE-INTERD AP, V17, P25, DOI 10.1055/s-2006-959333
   Griner D, 2014, ANN PLAS SURG, V72, pS121, DOI 10.1097/SAP.0000000000000105
   Harvey RJ, 2012, LARYNGOSCOPE, V122, P452, DOI 10.1002/lary.22475
   Kang S, 2018, J NEUROL SURG PART B, V79, P1
   Little SC, 2009, LARYNGOSCOPE, V119, P1093, DOI 10.1002/lary.20243
   Paddack AC, 2012, ARCH OTOLARYNGOL, V138, P367, DOI 10.1001/archoto.2012.69
   Patel MR, 2014, LARYNGOSCOPE, V124, P846, DOI 10.1002/lary.24319
   Pawar SS, 2013, CURR OPIN OTOLARYNGO, V21, P384, DOI 10.1097/MOO.0b013e328362ce42
   Reece EM, 2008, PLAST RECONSTR SURG, V121, P1956, DOI 10.1097/PRS.0b013e3181707109
   Rivera-Serrano CM, 2010, LARYNGOSCOPE, V120, P1922, DOI 10.1002/lary.21049
   SCHAEFER SD, 1986, ARCH OTOLARYNGOL, V112, P745
   Schmalbach CE, 2010, CURR OPIN OTOLARYNGO, V18, P238, DOI 10.1097/MOO.0b013e32833a4706
   Schmidt RF, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.5.FOCUS12129
   Soudry E, 2014, OTOLARYNG HEAD NECK, V150, P730, DOI 10.1177/0194599814520685
   Thorp BD, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14350
   Turri-Zanoni M, 2018, WORLD NEUROSURG, V116, pE436, DOI 10.1016/j.wneu.2018.04.225
   Zanation AM, 2009, LARYNGOSCOPE, V119, P13, DOI 10.1002/lary.20022
   Zanation AM, 2009, AM J RHINOL ALLERGY, V23, P518, DOI 10.2500/ajra.2009.23.3378
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 37
EP 41
DI 10.1016/j.wneu.2019.06.162
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200146
PM 31260852
DA 2020-05-12
ER

PT J
AU Scullen, T
   Mathkour, M
   Amenta, PS
   Dallapiazza, RF
AF Scullen, Tyler
   Mathkour, Mansour
   Amenta, Peter S.
   Dallapiazza, Robert F.
TI Arteriovenous Fistula of the Filum Terminale: A Case Report and Review
   of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Arteriovenous fistula; Endovascular; Microsurgery; Myelopathy; Spinal
   stenosis
AB BACKGROUND: Fistulas of the filum terminale are rare lesions that result from a fistulous connection between the artery and vein of the filum terminale. These lesions often present as progressive thoracic myelopathy secondary to venous hypertension that is transmitted to the corona! venous plexus of the spinal cord. Frequently, filum fistulas will be associated with lumbar stenosis and likely form as a result of chronic inflammation and compression. However, owing to the relative rarity of filum fistulas and the commonality of lumbar stenosis, the presence of a filum fistula could be overlooked or misdiagnosed.
   CASE DESCRIPTION: We have presented the case of a 62-year-old man with severe lumbar stenosis who had presented with progressive thoracic myelopathy. The evaluation, including spinal angiography, identified a low-flow arteriovenous fistula within the filum terminale that was successfully treated with microsurgical obliteration. The patient tolerated the procedure well, with good functional recovery within 1 month.
   CONCLUSION: Just as was the case with our patient, these lesions demonstrate a high association with lumbar stenosis and tethered or tight cord syndrome. We reviewed the clinical presentation, imaging findings, surgical management, and possible mechanisms of development for these rarely encountered fistulas.
C1 [Scullen, Tyler; Mathkour, Mansour; Amenta, Peter S.; Dallapiazza, Robert F.] Tulane Univ, Sch Med, Dept Neurol Surg, 1430 Tulane Ave, New Orleans, LA 70112 USA.
   [Scullen, Tyler; Mathkour, Mansour] Ochsner Med Ctr, Dept Neurol Surg, Jefferson, LA USA.
RP Dallapiazza, RF (reprint author), Tulane Univ, Sch Med, Dept Neurol Surg, 1430 Tulane Ave, New Orleans, LA 70112 USA.
EM tylerscullen@gmail.com
RI Mathkour, Mansour/N-7878-2015
OI Mathkour, Mansour/0000-0002-1913-3677
CR Chanthanaphak E, 2013, J NEUROSURG-SPINE, V19, P49, DOI 10.3171/2013.4.SPINE12685
   Ding D, 2016, J NEUROL SCI, V369, P276, DOI 10.1016/j.jns.2016.08.054
   EPSTEIN JA, 1978, J NEUROSURG, V48, P252, DOI 10.3171/jns.1978.48.2.0252
   Fabiano AJ, 2009, PEDIATR NEUROSURG, V45, P256, DOI 10.1159/000228983
   Finn MA, 2007, NEUROSURG FOCUS, V23, P1, DOI DOI 10.3171/FOC-07/08/E10
   Giordan E, 2019, J NEUROSURG SCI, V63, P237, DOI 10.23736/S0390-5616.17.04125-X
   Giordan E, 2018, J NEUROINTERV SURG, V10, P191, DOI 10.1136/neurintsurg-2017-013309
   Hong T, 2017, AM J NEURORADIOL, V38, P403, DOI 10.3174/ajnr.A5001
   Hong T, 2018, WORLD NEUROSURG, V118, P235, DOI 10.1016/j.wneu.2018.07.097
   Huang SL, 2015, SCI REP-UK, V5, DOI 10.1038/srep09116
   Jin YJ, 2010, NEUROSURGERY, V66, P219, DOI 10.1227/01.NEU.0000359529.40577.A1
   Krishnan P, 2013, ANN INDIAN ACAD NEUR, V16, P432, DOI 10.4103/0972-2327.116931
   Kumar Ashish, 2011, Surg Neurol Int, V2, P12, DOI 10.4103/2152-7806.76280
   Laitt R, 1996, BRIT J RADIOL, V69, P693, DOI 10.1259/0007-1285-69-824-693
   Lim SM, 2011, AM J NEURORADIOL, V32, P1846, DOI 10.3174/ajnr.A2612
   Macht S, 2012, NEURORADIOLOGY, V54, P517, DOI 10.1007/s00234-011-0899-2
   Meisel HJ, 1995, MINIM INVAS NEUROSUR, V38, P138, DOI 10.1055/s-2008-1053474
   Namba K, 2016, NEUROL MED-CHIR, V56, P310, DOI 10.2176/nmc.ra.2016-0006
   Patel M, 2018, CHILD NERV SYST, V34, P1767, DOI 10.1007/s00381-018-3837-3
   Sharma P, 2014, ASIAN SPINE J, V8, P365, DOI 10.4184/asj.2014.8.3.365
   Singh R, 2016, ANN VASC MED RES, V3, P1045
   Takai K, 2019, WORLD NEUROSURG, V122, pE795, DOI 10.1016/j.wneu.2018.10.149
   Takami T, 2012, SPINE, V37, pE1524, DOI 10.1097/BRS.0b013e31826f20c0
   Tanioka S, 2018, EUR SPINE J, V27, pS281, DOI 10.1007/s00586-017-5129-0
   Tehli O, 2011, PEDIATR NEUROSURG, V47, P412, DOI 10.1159/000338981
   Tender GC, 2005, J NEUROSURG-SPINE, V3, P488, DOI 10.3171/spi.2005.3.6.0488
   Trinh Victoria T, 2011, Surg Neurol Int, V2, P63, DOI 10.4103/2152-7806.81065
   Wajima D, 2017, INTERV NEURORADIOL, V23, P221, DOI 10.1177/1591019916687716
   Witiw CD, 2011, NEUROSURGERY, V69, pE780, DOI 10.1227/NEU.0b013e31821bc64c
NR 29
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 42
EP 49
DI 10.1016/j.wneu.2019.06.136
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200147
PM 31254689
DA 2020-05-12
ER

PT J
AU Xei, F
   Wang, T
   Hao, JQ
   Zhang, CW
   Richard, SA
   Liu, YH
AF Xei Fei
   Wang Ting
   Hao Jianqiang
   Zhang Changwei
   Richard, Seidu A.
   Liu Yanhui
TI Traumatic Arteriovenous Fistula Between Extracranial Middle Meningeal
   Artery and Petrosal Vein
SO WORLD NEUROSURGERY
LA English
DT Article
DE Coils; Extracranial; MMA; Petrosal vein; TAVF
ID SPONTANEOUS CLOSURE
AB BACKGROUND: The incidence of traumatic arteriovenous fistula (TAVF) between the middle meningeal artery (MMA) and the petrosal vein (PV) is rare. Although TAVF has been reported involving the MMA several sinus and veins, this is the first incidence of a fistula involving the extracranial MMA and PV.
   CASE DESCRIPTION: We present a 47-year-old male with sudden onset of weakness of his right limb and speech difficulty a few hours before admission to our facility. He had a 6-month history of mild traumatic head injury. Initial computed tomography revealed midbrain hemorrhage while digital subtraction angiography revealed a TAVF of the left MMA. Enhanced magnetic resonance imaging, however, revealed communication between the MMA and PV. We treated the patient with coil embolization via the transarterial route.
   CONCLUSIONS: This is the first incidence of a fistula connecting the extracranial and PV. We managed the patient with only coil embolization without any further neurologic deficits.
C1 [Xei Fei; Hao Jianqiang; Liu Yanhui] Ziyang First Peoples Hosp, Dept Neurosurg, Ziyang, Peoples R China.
   [Xei Fei; Wang Ting; Zhang Changwei; Richard, Seidu A.] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China.
   [Richard, Seidu A.] Princefield Univ, Dept Med, Accra, Ho Volta Region, Ghana.
RP Liu, YH (reprint author), Ziyang First Peoples Hosp, Dept Neurosurg, Ziyang, Peoples R China.
EM gbepoo@yandex.ru
RI A. Richard, Seidu/H-7590-2017
OI A. Richard, Seidu/0000-0003-3475-0363
CR Basheer N, 2008, NEUROL INDIA, V56, P207
   BITOH S, 1980, SURG NEUROL, V14, P355
   Chandrashekar HS, 2007, INTERV NEURORADIOL, V13, P173, DOI 10.1177/159101990701300208
   Chmielewski Przemyslaw, 2013, Folia Med Cracov, V53, P41
   FRECKMANN N, 1981, ACTA NEUROCHIR, V55, P273, DOI 10.1007/BF01808443
   Geibprasert S, 2009, AM J NEURORADIOL, V30, P1459, DOI 10.3174/ajnr.A1500
   HUANG YP, 1968, AMER J ROENTGENOL RA, V104, P36, DOI 10.2214/ajr.104.1.36
   Kornieieva M, 2015, J NEUROL SURG PART B, V76, P451, DOI 10.1055/s-0035-1554902
   Luciani A, 2001, AM J NEURORADIOL, V22, P992
   Mantini S., 2010, ITAL J ANAT EMBRYO S, V115, P101
   PADGET DORCAS H., 1957, CARNEGIE INST WASHINGTON PUBL 611 CONTR EMBRYOL, V36, P79
   PRITZ MB, 1992, SURG NEUROL, V37, P460, DOI 10.1016/0090-3019(92)90136-B
   Talib JA, 2009, MED J TIKRIT, V15, P38
   Tanriover N, 2007, J NEUROSURG, V106, P1041, DOI 10.3171/jns.2007.106.6.1041
   Unterhofer C, 2009, ACTA NEUROCHIR, V151, P1301, DOI 10.1007/s00701-009-0251-3
   Vassilyadi M, 2009, CAN J NEUROL SCI, V36, P751, DOI 10.1017/S0317167100008386
   Yu JL, 2017, INTERV NEURORADIOL, V23, P90, DOI 10.1177/1591019916673584
   Yu JL, 2016, INT J MED SCI, V13, P790, DOI 10.7150/ijms.16489
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 50
EP 53
DI 10.1016/j.wneu.2019.06.171
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200148
PM 31265928
DA 2020-05-12
ER

PT J
AU Otsuka, R
   Ikeda, H
   Tsujimoto, Y
   Kawauchi, T
   Torikoshi, S
   Sano, N
   Hayase, M
   Toda, H
AF Otsuka, Ryotaro
   Ikeda, Hiroyuki
   Tsujimoto, Yoshitaka
   Kawauchi, Takeshi
   Torikoshi, Sadaharu
   Sano, Noritaka
   Hayase, Makoto
   Toda, Hiroki
TI Breakage and Retrieval of an Aspiration Catheter Coil with a Stent
   Retriever During Mechanical Thrombectomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aspiration catheter; Device breakage; Ischemic stroke; Stent retriever;
   Thrombectomy; Winding coil
ID ACUTE STROKE; DETACHMENT; DEVICE
AB BACKGROUND: Some mechanical thrombectomy techniques for acute ischemic stroke use a combination of an aspiration catheter and stent retriever. We experienced a rare case of aspiration catheter coil breakage and subsequent retrieval using a stent retriever.
   CASE DESCRIPTION: A 79-year-old man suddenly developed somnolence, global aphasia, and right hemiplegia. Magnetic resonance imaging revealed acute infarction of the left frontal lobe and occlusion of the left common carotid artery. Thus, using an aspiration catheter and a stent retriever, mechanical thrombectomy was performed. The stent retriever was deployed from the middle cerebral artery to the internal carotid artery and retracted into the aspiration catheter placed in the internal carotid artery proximal to the thrombus. The catheter was bent during retraction of the stent retriever. After thrombus aspiration, the internal carotid and anterior and middle cerebral arteries were successfully reperfused; however, the stent retriever captured a broken section of the winding coil of the aspiration catheter. We suspected that an X-ray marker on the stent retriever broke the winding coil at the bent segment of the aspiration catheter and the stent captured the broken coil.
   CONCLUSIONS: The combined use of an aspiration catheter and a stent retriever may cause unexpected device breakage, especially when the catheter is bent.
C1 [Otsuka, Ryotaro; Ikeda, Hiroyuki; Tsujimoto, Yoshitaka; Kawauchi, Takeshi; Torikoshi, Sadaharu; Sano, Noritaka; Hayase, Makoto; Toda, Hiroki] Fukui Red Cross Hosp, Dept Neurosurg, Fukui, Japan.
RP Ikeda, H (reprint author), Fukui Red Cross Hosp, Dept Neurosurg, Fukui, Japan.
EM rocky@kuhp.kyoto-u.ac.jp
OI Ikeda, Hiroyuki/0000-0001-5710-7456; Toda, Hiroki/0000-0002-1596-4131
CR Akpinar S, 2015, CARDIOVASC INTER RAD, V38, P475, DOI 10.1007/s00270-014-1022-y
   Al-Schameri AR, 2019, INTERV NEURORADIOL, V25, P297, DOI 10.1177/1591019918814011
   Arai D, 2016, J NEUROINTERV SURG, V8, P992, DOI 10.1136/neurintsurg-2015-011968
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Castano C, 2016, J NEUROINTERV SURG, V8, P1226, DOI 10.1136/neurintsurg-2015-012156
   Delgado F, 2019, J NEUROINTERV SURG, V11, P147, DOI 10.1136/neurintsurg-2018-014163
   Goto S, 2018, WORLD NEUROSURG, V109, pE468, DOI 10.1016/j.wneu.2017.10.004
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Gurkas E, 2017, INTERV NEURORADIOL, V23, P166, DOI 10.1177/1591019916682358
   Jadhav AP, 2017, INTERV NEUROL, V6, P16, DOI 10.1159/000449321
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Kinariwala Jay P, 2018, Brain Circ, V4, P185, DOI 10.4103/bc.bc_12_18
   Kwon HJ, 2015, J NEUROINTERV SURG, V7, P114, DOI 10.1136/neurintsurg-2013-010942
   Lee MS, 2011, KOREAN J RADIOL, V12, P638, DOI 10.3348/kjr.2011.12.5.638
   Maegerlein C, 2018, J NEUROINTERV SURG, V10, P751, DOI 10.1136/neurintsurg-2017-013558
   Masoud H, 2015, INTERV NEUROL, V4, P75, DOI 10.1159/000441920
   Massari F, 2016, INTERV NEURORADIOL, V22, P325, DOI 10.1177/1591019916632369
   Maus V, 2018, CLIN NEURORADIOL, V28, P327, DOI 10.1007/s00062-017-0566-z
   McTaggart RA, 2017, J NEUROINTERV SURG, V9, P1154, DOI 10.1136/neurintsurg-2016-012838
   Moshayedi P, 2018, INTERV NEUROL, V7, P148, DOI 10.1159/000486245
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Spiotta AM, 2015, J NEUROINTERV SURG, V7, P2, DOI 10.1136/neurintsurg-2013-011022
   Tanriover N, 2017, WORLD NEUROSURG, V107, DOI 10.1016/j.wneu.2017.08.102
   Wei M, 2017, INTERV NEURORADIOL, V23, P285, DOI 10.1177/1591019916689053
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 54
EP 58
DI 10.1016/j.wneu.2019.06.175
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200149
PM 31265926
DA 2020-05-12
ER

PT J
AU Olijnyk, LD
   Patel, K
   Brandao, MR
   de Morais, ANL
   de Carvalho, RF
   Severino, AG
   Mayor, D
   da Silva, CE
   Stefani, MA
AF Olijnyk, Leonardo Desessards
   Patel, Krunal
   Brandao, Michel Rasche
   Lima de Morais, Artur Nobrega
   de Carvalho, Rodolfo Figueiredo
   Severino, Antonio Generoso
   Mayor, Diana
   da Silva, Carlos Eduardo
   Stefani, Marco Antonio
TI The Role of Low-Cost Microsurgical Training Models and Experience with
   Exercises Based on a Bovine Heart
SO WORLD NEUROSURGERY
LA English
DT Article
DE Laboratory training models; Low-cost model; Microsurgical training;
   Microvascular anastomosis
ID 10-0 NYLON; SIMULATION; SKILLS; PLACENTA
AB BACKGROUND: Microscopic training is essential for development of neurosurgical skills. A range of models is reported in the literature for this purpose, including live animals, exvivo, and synthetic material. Among the factors involved in selection and development of a training station, cost is a decisive one.
   METHODS: We present a low-cost model to practice microvascular anastomoses using a bovine heart and an artificial perfusion system. We also present a brief review of laboratory models for microsurgical training, focusing on the costs and reproducibility of the different options.
   RESULTS: Exvivo models are a great bridging point between nonbiologic and living animal training models. These models have major similarities to human vessels, such as lumen size and malleability of the arteries. The bovine heart model allowed the residents to gain confidence in handling vascular tissue in a microscopic environment.
   CONCLUSIONS: Although these models do not resemble anatomic landmarks in the human brain, the bovine heart model allowed the residents to gain confidence in handling vascular tissue in a microscopic environment.
C1 [Olijnyk, Leonardo Desessards; Brandao, Michel Rasche; Lima de Morais, Artur Nobrega; Severino, Antonio Generoso; Stefani, Marco Antonio] Univ Fed Rio Grande do Sul, Inst Basic Hlth Sci, Dept Morphol Sci, Porto Alegre, RS, Brazil.
   [Olijnyk, Leonardo Desessards; de Carvalho, Rodolfo Figueiredo; da Silva, Carlos Eduardo] Ernesto Dornelles Hosp, Neurosurg & Skull Base Surg, Porto Alegre, RS, Brazil.
   [Patel, Krunal] Toronto Western Hosp, Div Neurosurg, Toronto, ON, Canada.
   [Mayor, Diana] Univ Toronto, Dept Physiol, Toronto, ON, Canada.
RP Olijnyk, LD (reprint author), Univ Fed Rio Grande do Sul, Inst Basic Hlth Sci, Dept Morphol Sci, Porto Alegre, RS, Brazil.; Olijnyk, LD (reprint author), Ernesto Dornelles Hosp, Neurosurg & Skull Base Surg, Porto Alegre, RS, Brazil.
EM leonardo.olijnyk@gmail.com
RI Stefani, Marco/C-3993-2013
OI Stefani, Marco/0000-0002-4728-8764
CR Aboud E, 2002, J NEUROSURG, V97, P1367, DOI 10.3171/jns.2002.97.6.1367
   Aoun SG, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2012.05.024
   Atkins JL, 2005, MICROSURG, V25, P481, DOI 10.1002/micr.20150
   AYOUBI S, 1992, NEUROSURGERY, V30, P252, DOI 10.1227/00006123-199202000-00018
   Chan WY, 2007, MICROSURG, V27, P494, DOI 10.1002/micr.20393
   Colpan ME, 2008, NEUROSURGERY, V62, P407, DOI 10.1227/01.NEU.0000312345.06054.3e
   Crosby NL, 1995, MICROSURG, V16, P655, DOI 10.1002/micr.1920160913
   de Oliveira MMR, 2016, J NEUROSURG, V3, P846
   Evgeniou E, 2018, J SURG EDUC, V75, P171, DOI 10.1016/j.jsurg.2017.06.032
   Fanua SP, 2001, MICROSURG, V21, P379, DOI 10.1002/micr.21812
   Gasco J, 2013, NEUROSURGERY, V73, P39, DOI 10.1227/NEU.0000000000000102
   GOVILA A, 1981, BRIT J PLAST SURG, V34, P486, DOI 10.1016/0007-1226(81)90065-5
   Higurashi M, 2014, J CLIN NEUROSCI, V21, P554, DOI 10.1016/j.jocn.2013.07.029
   Hino A, 2003, NEUROSURGERY, V52, P1495, DOI 10.1227/01.NEU.0000065174.83840.62
   Indo M, 2011, WORLD NEUROSURG, V75, P87, DOI 10.1016/j.wneu.2010.07.030
   Inoue T, 2006, SURG NEUROL, V66, P183, DOI 10.1016/j.surneu.2005.11.064
   Kshettry Varun R, 2014, World Neurosurg, V82, P554, DOI 10.1016/j.wneu.2014.05.028
   Lahiri A, 2005, MICROSURG, V25, P21, DOI 10.1002/micr.20074
   Lannon DA, 2001, MICROSURG, V21, P389, DOI 10.1002/micr.21709
   MacDonald JD, 2005, SKULL BASE-INTERD AP, V15, P229, DOI 10.1055/s-2005-872598
   Matsumura N, 2009, SURG NEUROL, V71, P616, DOI 10.1016/j.surneu.2007.12.024
   Meybodi AT, 2019, OPER NEUROSURG, V16, P345, DOI 10.1093/ons/opy157
   Moulton CAE, 2006, ANN SURG, V244, P400, DOI 10.1097/01.sla.0000234808.85789.6a
   Okhah Z, 2013, J SURG RES, V185, P450, DOI 10.1016/j.jss.2013.04.090
   Olabe J, 2009, SURG NEUROL, V72, P700, DOI 10.1016/j.surneu.2009.02.028
   Olabe J, 2009, SURG NEUROL, V72, P695, DOI 10.1016/j.surneu.2008.12.008
   Oliveira MM, 2016, OPER NEUROSURG, V12, P61, DOI 10.1227/NEU.0000000000001030
   Reznick RK, 2006, NEW ENGL J MED, V355, P2664, DOI 10.1056/NEJMra054785
   Russin J, 2012, WORLD NEUROSURG, V2, P289
   Scholz M, 2006, MICROSURG, V26, P450, DOI 10.1002/micr.20269
   Sidhu RS, 2007, J VASC SURG, V45, P343, DOI 10.1016/j.jvs.2006.09.040
   Yen DM, 1995, MICROSURG, V16, P760, DOI 10.1002/micr.1920161112
   Yonekawa Y, 1999, OPERATIVE TECHNIQ NE, V2, P149
NR 33
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 59
EP 64
DI 10.1016/j.wneu.2019.06.089
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200150
PM 31238170
DA 2020-05-12
ER

PT J
AU Slade, SJ
   Bauer, EM
   Stone, VV
   Dave, AJ
AF Slade, Stephen J.
   Bauer, Erin M.
   Stone, Vivian V.
   Dave, Amish J.
TI Spinal IgG4-Related Hypertrophic Pachymeningitis with Spinal Cord
   Compression: Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE IgG4-related disease; Pachymeningitis; Spine
ID DISEASE; STATEMENT; FEATURES; IGG4
AB BACKGROUND: Back pain is a leading reason for patients to seek medical attention. Although musculoskeletal causes are common, patients can also present with rarer etiologies.
   CASE DESCRIPTION: A 50-year-old man presented with 2 months of isolated upper back pain initially suspected to be secondary to overuse muscular strain. During the next 3 months, his pain worsened, and he developed lower extremity dysesthesia and subjective weakness, despite normal neurological examination findings. Nonrevealing laboratory workup included normal muscle enzymes, C-reactive protein, urinalysis, and human leukocyte antigen B27. Magnetic resonance imaging revealed a normal brain but a hypointense C7-T5 epidural mass, prompting a neurosurgical recommendation for laminectomy with evacuation of the suspected hematoma. His symptoms fully and promptly resolved after a 5-day course of prednisone 40 mg. When his symptoms recurred within 2 months, he underwent T4-T5 laminectomy with biopsy of a mass confluent with the dura mater. Initial pathological examination revealed fibrotic tissue of unclear etiology with polyclonal lymphoid infiltrate but no malignant cells, vasculitis, or granulomas. After months of recurrent, steroid-responsive symptoms, he presented to the rheumatology clinic. Repeat spinal magnetic resonance imaging demonstrated progression of epidural thickening with suspected spinal cord compression. Previous biopsy samples were then immunostained for IgG4, revealing focally dense IgG4-positive plasma cells, up to 29 cells per high power field, consistent with spinal IgG4-related hypertrophic pachymeningitis. He began rituximab therapy with a prednisone taper and demonstrated symptomatic and neurologic improvement with successful withdrawal from corticosteroids.
   CONCLUSIONS: To the best of our knowledge, the present case represents the 12th reported case of spinal IgG4-related hypertrophic pachymeningitis. An early diagnosis and treatment could prevent progression to permanent neurological impairment and functional disability.
C1 [Slade, Stephen J.] Virginia Mason Med Ctr, Dept Grad Med Educ, Seattle, WA 98101 USA.
   [Bauer, Erin M.; Stone, Vivian V.; Dave, Amish J.] Virginia Mason Med Ctr, Sect Rheumatol, Seattle, WA 98101 USA.
RP Slade, SJ (reprint author), Virginia Mason Med Ctr, Dept Grad Med Educ, Seattle, WA 98101 USA.
EM stephen.j.slade@gmail.com
CR Carruthers MN, 2015, ANN RHEUM DIS, V74, P1171, DOI 10.1136/annrheumdis-2014-206605
   Carruthers MN, 2012, INT J RHEUMATOL, DOI 10.1155/2012/259408
   Chan SK, 2009, AM J SURG PATHOL, V33, P1249, DOI 10.1097/PAS.0b013e3181abdfc2
   Choi SH, 2010, NEUROLOGY, V75, P1388, DOI 10.1212/WNL.0b013e3181f73614
   Danlos FX, 2017, AUTOIMMUN REV, V16, P1036, DOI 10.1016/j.autrev.2017.07.020
   De Virgilio A, 2017, IMMUNOL RES, V65, P386, DOI 10.1007/s12026-016-8863-1
   Della Torre E, 2012, ANN INTERN MED, V156, P401, DOI 10.7326/0003-4819-156-5-201203060-00025
   Della-Torre E, 2014, J NEUROIMMUNOL, V266, P82, DOI 10.1016/j.jneuroim.2013.10.008
   Della-Torre E, 2013, J RHEUMATOL, V40, P1927, DOI 10.3899/jrheum.130678
   Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72
   Finley CR, 2018, CAN FAM PHYSICIAN, V64, P832
   Gu R, 2016, EUR SPINE J, V25, pS147, DOI 10.1007/s00586-015-4251-0
   Hamano H, 2001, NEW ENGL J MED, V344, P732, DOI 10.1056/NEJM200103083441005
   Hart PA, 2013, GUT, V62, P1607, DOI 10.1136/gutjnl-2012-302886
   Hoy D, 2010, BEST PRACT RES CL RH, V24, P769, DOI 10.1016/j.berh.2010.10.002
   Kamisawa T, 2003, GUT, V52, P683, DOI 10.1136/gut.52.5.683
   Khosroshahi A, 2015, ARTHRITIS RHEUMATOL, V67, P1688, DOI 10.1002/art.39132
   Lindstrom KM, 2010, ACTA NEUROPATHOL, V120, P765, DOI 10.1007/s00401-010-0746-2
   Lu LX, 2014, JAMA NEUROL, V71, P785, DOI 10.1001/jamaneurol.2014.243
   Lu Z, 2016, CLIN RHEUMATOL, V35, P1549, DOI 10.1007/s10067-015-3104-x
   Maher M, 2017, CLIN IMAG, V46, P108, DOI 10.1016/j.clinimag.2017.07.012
   Mito Y, 2012, CASE REP, V2012
   Niska R, 2007, NATL HLTH STAT REPOR, V2010, P1
   Okazaki K, 2017, CURR TOP MICROBIOL, V401, P1, DOI 10.1007/82_2016_47
   Popkirov S, 2015, J CLIN NEUROSCI, V22, P1038, DOI 10.1016/j.jocn.2014.12.020
   Radotra BD, 2016, J NEUROSURG-SPINE, V25, P790, DOI 10.3171/2016.4.SPINE1674
   Regev K, 2014, JAMA NEUROL, V71, P767, DOI 10.1001/jamaneurol.2014.40
   Sakai Toshiyuki, 2014, Rinsho Shinkeigaku, V54, P664
   Sato M, 2015, INTERNAL MED, V54, P2267, DOI 10.2169/internalmedicine.54.3230
   Stone JH, 2012, ARTHRITIS RHEUM-US, V64, P3061, DOI 10.1002/art.34593
   Stone JH, 2012, NEW ENGL J MED, V366, P539, DOI 10.1056/NEJMra1104650
   Takeuchi S, 2014, J KOREAN NEUROSURG S, V55, P300, DOI 10.3340/jkns.2014.55.5.300
   Umehara H, 2017, MOD RHEUMATOL, V27, P381, DOI 10.1080/14397595.2017.1290911
   Umehara H, 2012, MOD RHEUMATOL, V22, P1, DOI 10.1007/s10165-011-0508-6
   Wallace ZS, 2013, MEDICINE, V92, P206, DOI 10.1097/MD.0b013e31829cce35
NR 35
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 65
EP 70
DI 10.1016/j.wneu.2019.06.130
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200151
PM 31254697
DA 2020-05-12
ER

PT J
AU Watanabe, Y
   Higuchi, Y
   Sunaoka, H
   Yakufujiang, M
   Ikegami, S
   Iwadate, Y
AF Watanabe, Yousuke
   Higuchi, Yoshinori
   Sunaoka, Hirokazu
   Yakufujiang, Maidinamu
   Ikegami, Shiro
   Iwadate, Yasuo
TI Postoperative Cerebellar Cyst with Pseudomeningocele After Tumor Removal
   at the Craniovertebral Junction
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebellar cyst; Posterior fossa surgery; Pseudomeningocele
ID SURGERY; GRAFT
AB BACKGROUND: Cerebellar cyst formation after surgery is uncommon, and cases of this condition have been previously reported. These cases had an intraparenchymal cyst in the cerebellar hemisphere that required surgical fenestration of the cyst. We herein present a rare case of a postoperative cerebellar cyst with pseudomeningocele and magnetic resonance images indicating a fistula between the cyst and pseudomeningocele.
   CASE DESCRIPTION: A patient presented with an intraparenchymal cyst and aunding edema in the cerebellar hemisphere that developed after a C1 laminectomy and a small suboccipital craniectomy for the removal of an accessory nerve neurinoma at the craniovertebral junction. Fast imaging employing steady-state acquisition images identified the fistula connecting the cyst and extradural cerebrospinal fluid retention. Conservative management with administration of dexamethasone induced spontaneous regression of the cyst, and no recurrence had occurred by the 1-year follow-up.
   CONCLUSIONS: Watertight dural closure is important for the prevention of rare complication after posterior fossa surgery. However, an arachnoid tear on the cerebellar fissure and adjacent dural defect are necessary antecedents for this rare condition. High-resolution fast imaging employing steady-state acquisition images could provide additional information for the etiology of postoperative cerebellar cyst.
C1 [Watanabe, Yousuke; Higuchi, Yoshinori; Sunaoka, Hirokazu; Yakufujiang, Maidinamu; Ikegami, Shiro; Iwadate, Yasuo] Chiba Univ, Dept Neurol Surg, Grad Sch Med, Chiba, Japan.
RP Higuchi, Y (reprint author), Chiba Univ, Dept Neurol Surg, Grad Sch Med, Chiba, Japan.
EM yhiguchi@faculty.chiba-u.jp
OI Higuchi, Yoshinori/0000-0001-5689-3416
CR Chiang Jung-Ying, 2015, Surg Neurol Int, V6, pS101, DOI 10.4103/2152-7806.153645
   Danish SF, 2006, J NEUROSURG, V104, P16, DOI 10.3171/ped.2006.104.1.16
   de Jong L, 2012, BRIT J NEUROSURG, V26, P537, DOI 10.3109/02688697.2012.685786
   Dlouhy BJ, 2018, J NEUROSURG-PEDIATR, V22, P297, DOI 10.3171/2018.3.PEDS17550
   Kosnik EJ, 1998, J NEUROSURG, V89, P155, DOI 10.3171/jns.1998.89.1.0155
   Ling PY, 2014, ACTA NEUROCHIR, V156, P1879, DOI 10.1007/s00701-014-2190-x
   Mehendale NH, 2004, OTOLARYNG HEAD NECK, V131, P253, DOI 10.1016/j.otohns.2004.01.018
   Moskowitz SI, 2009, NEUROSURGERY, V64, pS28, DOI 10.1227/01.NEU.0000334414.79963.59
   Moskowitz SI, 2009, NEUROSURGERY, V64, pons33
   Rozenfeld M, 2015, AM J ROENTGENOL, V205, P1086, DOI 10.2214/AJR.15.14314
   Sharif R, 2016, J CLIN NEUROSCI, V34, P219, DOI 10.1016/j.jocn.2016.05.019
   Wait SD, 2006, BARROW Q, V22, P15
NR 12
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 71
EP 76
DI 10.1016/j.wneu.2019.06.197
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200152
PM 31279920
DA 2020-05-12
ER

PT J
AU Torres-Corzo, JG
   Islas-Aguilar, MA
   Cervantes, DS
   Chalita-Williams, JC
AF Gerardo Torres-Corzo, Jaime
   Alberto Islas-Aguilar, Mario
   Shelby Cervantes, Dominic
   Carlos Chalita-Williams, Juan
TI The Role of Flexible Neuroendoscopy in Spinal Neurocysticercosis:
   Technical Note and Report of 3 Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Flexible endoscopy; Neurocysticercosis; Spinal cord compression; Spinal
   endoscopy; Spinal neurocysticercosis
ID INTRADURAL NEUROCYSTICERCOSIS; CYSTICERCOSIS; THERAPY; CORD
AB BACKGROUND: Neurocysticercosis, caused by the larval form of the tapeworm Taenia solium, is the most common parasitic disease affecting the human central nervous system. The incidence of spinal neurocysticercosis in endemic regions ranges from 025% to 5.85%. Surgery is preferred when medical treatment fails to achieve control of the symptoms or when multiple cysts are present.
   METHODS: We describe the use of spinal flexible endoscopy for patients with spinal neurocysticercosis who failed to achieve control with standard treatment. Three patients with limb weakness and pain underwent a midline interspinous approach at the L5-S1 level to access the lumbar cistern. The flexible endoscope was introduced, the subarachnoid space was inspected, and the cysticerci were extracted. In 1 patient with cervical subarachnoid blockage, a 3-cm suboccipital craniotomy and removal of the posterior arch of C1 were performed to place a subarachnoid-to-subarachnoid catheter going from the craniocervical junction to the thoracic region.
   RESULTS: Removal of the cysticerci was possible in all No complications related to the surgery were observed. All patients received medical treatment for 2-3 months, and all symptoms were solved.
   CONCLUSIONS: Flexible spinal endoscopy is a feasible valuable tool in patients with spinal neurocysticercosis that do not respond adequately to standard treatment. It helps restore cerebrospinal fluid dynamics and can be used to place shunt catheters under guided vision. Longer endoscopes are needed to explore the entire spinal subarachnoid space with a single approach, and more research in this area is needed.
C1 [Gerardo Torres-Corzo, Jaime; Alberto Islas-Aguilar, Mario; Shelby Cervantes, Dominic; Carlos Chalita-Williams, Juan] Hosp Cent Dr Ignacio Morones Prieto, Dept Neurosurg, San Luis Potosi, Mexico.
RP Torres-Corzo, JG (reprint author), Hosp Cent Dr Ignacio Morones Prieto, Dept Neurosurg, San Luis Potosi, Mexico.
EM torrescjaime@yahoo.com.mx
CR Bakare AA, 2018, WORLD NEUROSURG, V110, P26, DOI 10.1016/j.wneu.2017.10.127
   Bazan R, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005115
   Bustos JA, 2016, EXPERT REV NEUROTHER, V16, P1079, DOI 10.1080/14737175.2016.1194757
   Callacondo D, 2012, NEUROLOGY, V78, P1394, DOI 10.1212/WNL.0b013e318253d641
   Mezo RC, 2015, ACTA TROP, V152, P60, DOI 10.1016/j.actatropica.2015.08.017
   Chaurasia RN, 2015, BMJ CASE REP, V2015
   Datta SGS, 2017, WORLD NEUROSURG, V105, DOI 10.1016/j.wneu.2017.05.168
   Del Brutto OH, 2014, EXPERT REV NEUROTHER, V14, P389, DOI 10.1586/14737175.2014.890892
   Del Brutto OH, 2013, J NEUROL SCI, V331, P114, DOI 10.1016/j.jns.2013.05.025
   Del Brutto OH, 2012, SCI WORLD J, DOI 10.1100/2012/159821
   Ganesan S, 2015, GLOB SPINE J, V5, pE1, DOI 10.1055/s-0034-1394125
   Garcia HH, 2014, LANCET NEUROL, V13, P1202, DOI 10.1016/S1474-4422(14)70094-8
   Govindappa SS, 2000, AM J NEURORADIOL, V21, P679
   Maste Praful Suresh, 2018, Asian J Neurosurg, V13, P154, DOI 10.4103/1793-5482.180894
   Muralidharan V, 2017, WORLD NEUROSURG, V106, DOI 10.1016/J.WNEU.2017.07.008
   Proano JV, 2009, CHILD NERV SYST, V25, P1467, DOI 10.1007/s00381-009-0933-4
   Raffa Giovanni, 2019, Acta Neurochir Suppl, V125, P133, DOI 10.1007/978-3-319-62515-7_19
   Shah A, 2017, WORLD NEUROSURG, V105, DOI 10.1016/j.wneu.2017.07.003
   Singh SK, 2017, EXP PARASITOL, V182, P1, DOI 10.1016/j.exppara.2017.08.009
   Torres-Corzo JG, 2010, CLIN NEUROL NEUROSUR, V112, P11, DOI 10.1016/j.clineuro.2009.08.022
   Torres-Corzo JG, 2016, NEUROENDOSCOPIC SURG, P196
   Wang DD, 2015, J CLIN NEUROSCI, V22, P1525, DOI 10.1016/j.jocn.2015.03.031
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   Yacoub Hussam A, 2017, Hosp Pract (1995), V45, P99, DOI 10.1080/21548331.2017.1325704
   Zhang SZ, 2017, EXP THER MED, V13, P3591, DOI 10.3892/etm.2017.4403
NR 25
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 77
EP 83
DI 10.1016/j.wneu.2019.06.194
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200153
PM 31279105
DA 2020-05-12
ER

PT J
AU Wu, WC
   Wang, SL
   Lin, JH
AF Wu, Wence
   Wang, Shenglin
   Lin, Jianhua
TI A 34-Year-Old Female Patient with Hirayama Disease Complicated by Severe
   Spinal Cord Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cervical corpectomy and fusion; Hirayama disease; Hoffmann
   sign; Spastic gait; Spinal cord injury
ID MUSCULAR-ATROPHY; FUSION
AB BACKGROUND: Hirayama disease (HD), characterized by insidiously progressive muscular atrophy of forearms and hands, is a self-limited cervical myelopathy that predominantly affects male adolescents, with female patients, especially middle-aged women, rarely affected. We present a rare case of HD with severe spinal cord injury in a 34-year-old woman.
   CASE DESCRIPTION: A 34-year-old woman presented with progressive weakness of both hands and forearms for a duration of 6 years and spastic gait for 1 year. The patient worked as a teacher and experienced long-term and repetitive neck flexion while writing at a desk, potentially causing cervical loading. Examination showed weakness and muscular atrophy of the bilateral upper limbs and pyramidal signs, including Hoffmann sign and hyperreflexia of the lower limbs. Radiologic studies revealed midcervical kyphosis and spinal cord compression by forward displacement of the dura mater with neck flexion. The clinical presentation and radiologic characteristics confirmed the diagnosis of HD. Anterior cervical corpectomy and fusion was performed owing to severe spinal cord injury, and the patient experienced satisfactory improvement.
   CONCLUSIONS: The present case clarified the potential involvement of cervical kyphosis and cervical loading-related exercise in the onset and progression of HD. Anterior cervical corpectomy and fusion could serve as a promising treatment of HD with severe spinal cord injury.
C1 [Wu, Wence; Wang, Shenglin; Lin, Jianhua] Fujian Med Univ, Dept Spinal Surg, Affiliated Hosp 1, Fuzhou, Fujian, Peoples R China.
RP Lin, JH (reprint author), Fujian Med Univ, Dept Spinal Surg, Affiliated Hosp 1, Fuzhou, Fujian, Peoples R China.
EM 710489558@qq.com
CR Agundez M, 2015, NEUROLOGIA, V30, P502, DOI 10.1016/j.nrl.2013.05.005
   Anuradha S, 2016, CASE REP NEUROL MED, DOI 10.1155/2016/5839761
   Brandicourt P, 2018, NEUROCHIRURGIE, V64, P303, DOI 10.1016/j.neuchi.2018.04.004
   Chen CJ, 1998, AM J NEURORADIOL, V19, P365
   Desai JA, 2011, NEUROLOGY, V77, pE73, DOI 10.1212/WNL.0b013e31822f02d0
   Fujimori Takahito, 2017, Spinal Cord Ser Cases, V3, P17016, DOI 10.1038/scsandc.2017.16
   Guo X, 2014, J SPINAL DISORD TECH, V27, pE241, DOI 10.1097/BSD.0000000000000098
   Hassan KM, 2012, ANN INDIAN ACAD NEUR, V15, P106, DOI 10.4103/0972-2327.94993
   Hirayama K, 2000, INTERNAL MED, V39, P283, DOI 10.2169/internalmedicine.39.283
   Kim J, 2016, J KOREAN MED SCI, V31, P1664, DOI 10.3346/jkms.2016.31.10.1664
   Kohno M, 1999, J NEUROSURG, V91, P33, DOI 10.3171/spi.1999.91.1.0033
   Kuo YH, 2019, NEUROSPINE, V16, P626, DOI 10.14245/ns.1836178.089
   Lehman VT, 2013, AM J NEURORADIOL, V34, P451, DOI 10.3174/ajnr.A3277
   Narayana Gowda B S, 2013, J Orthop Case Rep, V3, P11, DOI 10.13107/jocr.2250-0685.107
   Quarracino C, 2015, ASIAN SPINE J, V9, P794, DOI 10.4184/asj.2015.9.5.794
   Sim K, 2014, J CLIN NEUROSCI, V21, P487, DOI 10.1016/j.jocn.2013.06.028
   Song J, 2017, WORLD NEUROSURG, V105, P69, DOI 10.1016/j.wneu.2017.05.097
   Yokote A, 2019, CASE REP NEUROL, V11, P106, DOI 10.1159/000495606
   Zheng CJ, 2018, CLIN NEUROPHYSIOL, V129, P2341, DOI 10.1016/j.clinph.2018.08.024
   Zhou B, 2010, AMYOTROPH LATERAL SC, V11, P133, DOI 10.3109/17482960902912407
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 84
EP 88
DI 10.1016/j.wneu.2019.06.208
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200154
PM 31284057
DA 2020-05-12
ER

PT J
AU Jang, JH
   Cho, WS
   Kang, HS
   Kim, JE
AF Jang, Je Hun
   Cho, Won-Sang
   Kang, Hyun-Seung
   Kim, Jeong Eun
TI Surgical Obliteration of Anterior Cranial Fossa Dural Arteriovenous
   Fistulas via Unilateral High Frontal Craniotomv
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cranial fossa; Dural arteriovenous fistula; Frontal;
   Frontobasal; Surgical obliteration
ID INTERHEMISPHERIC APPROACH; NATURAL-HISTORY; MANAGEMENT; ARTERY;
   CLASSIFICATION; MALFORMATIONS; COMPLICATIONS
AB BACKGROUND: Surgical obliteration is generally recommended for anterior cranial fossa dural arteriovenous fistulas (ACF DAVFs) because of a high risk of bleeding and the difficulty of endovascular approaches. Surgical obliteration is generally performed via a frontobasal craniotomy; however, it is slightly excessive over the target fistula. Here, we present 2 cases of ACF DAVFs treated with small craniotomy without frontal sinus involvement and a review of the related literature.
   METHODS: We present 2 cases including a 63-year-old -aan who presented with a right-sided ACF DAVF that was fed by both ethmoidal arteries and drained into the right cortical veins (case 1) and a 59-year-old man with right-sided unruptured multiple aneurysms and a left-sided ACF DAVF that was fed by the right ethmoidal artery and drained into the left cortical veins (case 2).
   RESULTS: Case 1 underwent surgical obliteration via a right main frontal craniotomy. Case 2 was simultaneously treated with surgical clipping of the multiple aneurysms via a right lateral supraorbital craniotomy and surgical obliteration of the ACF DAVF via a left high frontal craniotomy. These 2 patients had no neurologic deficits, and complete obliteration of all the lesions was confirmed on cerebral angiography.
   CONCLUSIONS: Constructing a small corridor and a deep working distance in unilateral small high frontal craniotomy may be a slightly unusual approach; however, it is thought to provide sufficient space and a range of microscopic views that facilitate surgical manipulation without requiring extensive bone work.
C1 [Jang, Je Hun; Cho, Won-Sang; Kang, Hyun-Seung; Kim, Jeong Eun] Seoul Natl Univ Hosp, Dept Neurosurg, Seoul, South Korea.
RP Cho, WS (reprint author), Seoul Natl Univ Hosp, Dept Neurosurg, Seoul, South Korea.
EM nsdrcho@gmail.com
CR Abrahams JM, 2002, SURG NEUROL, V58, P410, DOI 10.1016/S0090-3019(02)00871-6
   Agid R, 2009, J NEUROSURG, V110, P79, DOI 10.3171/2008.6.17601
   BORDEN JA, 1995, J NEUROSURG, V82, P166, DOI 10.3171/jns.1995.82.2.0166
   Cannizzaro D, 2018, NEUROSURG REV, V41, P391, DOI 10.1007/s10143-016-0764-1
   Chen JC, 2003, TZU CHI MED J, V15, P199
   Chen Z, 2010, J NEUROIMAGING, V20, P382, DOI 10.1111/j.1552-6569.2009.00392.x
   Cho WS, 2017, J KOREAN NEUROSURG S, V60, P275, DOI 10.3340/jkns.2017.0101.002
   Choi HJ, 2010, J KOREAN NEUROSURG S, V47, P155, DOI 10.3340/jkns.2010.47.2.155
   Choi Su Yong, 2015, J Cerebrovasc Endovasc Neurosurg, V17, P263, DOI 10.7461/jcen.2015.17.3.263
   Cole Tyler S, 2019, Neurosurg Focus, V46, pV14, DOI 10.3171/2019.2.FocusVid.18702
   Davies MA, 1996, J NEUROSURG, V85, P830, DOI 10.3171/jns.1996.85.5.0830
   Ding DL, 2015, J CLIN NEUROSCI, V22, P1969, DOI 10.1016/j.jocn.2015.06.003
   Fiorella D, 2005, NEUROSURGERY, V57, P210, DOI 10.1227/01.NEU.0000163685.23846.DD
   HALBACH VV, 1990, NEUROSURGERY, V26, P816, DOI 10.1227/00006123-199005000-00014
   Hashimoto H, 1998, SURG NEUROL, V49, P47, DOI 10.1016/S0090-3019(97)98982-5
   Hoh BL, 1998, NEUROSURGERY, V42, P796, DOI 10.1097/00006123-199804000-00066
   Im SH, 2004, SURG NEUROL, V62, P72, DOI 10.1016/j.surneu.2003.07.018
   Kakarla UK, 2007, NEUROSURGERY, V61, P447, DOI 10.1227/01.NEU.0000290889.62201.7F
   Kohama M, 2010, NEUROL MED-CHIR, V50, P217, DOI 10.2176/nmc.50.217
   LASJAUNIAS P, 1977, J NEURORADIOLOGY, V4, P361
   Lawton MT, 1999, NEUROSURGERY, V45, P805, DOI 10.1097/00006123-199910000-00014
   Linzey JR, 2017, NEUROSURGERY, V81, P504, DOI 10.1093/neuros/nyx046
   Mack WJ, 2011, INTERV NEURORADIOL, V17, P93, DOI 10.1177/159101991101700115
   Magro Elsa, 2014, Surg Neurol Int, V5, P172, DOI 10.4103/2152-7806.146345
   Mayfrank L, 1996, MINIM INVAS NEUROSUR, V39, P74, DOI 10.1055/s-2008-1052221
   Meetze K, 2004, LARYNGOSCOPE, V114, P945, DOI 10.1097/00005537-200405000-00031
   Meneghelli P, 2017, ACTA NEUROCHIR, V159, P823, DOI 10.1007/s00701-017-3107-2
   Mielke D, 2014, ACTA NEUROCHIR, V156, P689, DOI 10.1007/s00701-013-1972-x
   O'Connor Kyle P, 2019, Neurosurg Focus, V46, pV3, DOI 10.3171/2019.2.FocusVid.18682
   de San Pedro JR, 2010, CLIN NEUROL NEUROSUR, V112, P903, DOI 10.1016/j.clineuro.2010.07.006
   Sato K, 2011, NEUROL MED-CHIR, V51, P40, DOI 10.2176/nmc.51.40
   Soderman M, 2008, STROKE, V39, P1735, DOI 10.1161/STROKEAHA.107.506485
   Tanei T, 2008, NEUROL MED-CHIR, V48, P560, DOI 10.2176/nmc.48.560
   Tsutsumi S, 2009, NEUROL MED-CHIR, V49, P407, DOI 10.2176/nmc.49.407
   Veeravagu A, 2013, INT J SURG CASE REP, V4, P656, DOI 10.1016/j.ijscr.2013.04.033
   Wicks Robert T, 2019, Neurosurg Focus, V46, pV9, DOI 10.3171/2019.2.FocusVid.18660
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 89
EP 94
DI 10.1016/j.wneu.2019.06.206
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200155
PM 31284056
DA 2020-05-12
ER

PT J
AU Dubuisson, A
   Lombard, A
   Otto, B
AF Dubuisson, Annie
   Lombard, Arnaud
   Otto, Bernard
TI Pseudomalignant Myositis Ossificans of the Neck in a Child: Case Report
   and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cervical spine; Children; Myositis ossificans; Myositis ossificans
   circumscripta; Nontraumatic ossificans; Pseudomalignant
ID CIRCUMSCRIPTA; PROGRESSIVA; MIMICKING; TRAUMATICA; HISTORY; SPORT
AB BACKGROUND: Myositis ossificans is a benign process of heterotopic bone formation developing in soft tissues that can mimic malignancy. Differential diagnosis can be difficult without a biopsy when it originates in atypical locations.
   CASE DESCRIPTION: A 5 1/2-year-old boy was admitted for a cervical tumor causing torticollis. The nodular tumor developed at the lateral border of the right C3-4 foramen, had calcification/ossification at its periphery, and was accompanied by a huge edematous reaction of the scalene muscles. The patient underwent an extensive work-up by pediatric oncologists. A biopsy was requested because of high suspicion of malignancy. At surgery, the lesion was benign on frozen sections and was completely resected, allowing the diagnosis of myositis ossificans. The patient made a rapid and complete recovery.
   CONCLUSIONS: Myositis ossificans circumscripta is rare in children, especially in the neck region. The diagnostic challenge is to differentiate it from bone and soft tissue malignancies. Appropriate management, including surgery if needed, leads to an excellent outcome. Another concern is to exclude fibro-dysplasia ossificans progressiva when atraumatic myositis ossificans develops in a young child in the neck or shoulder region.
C1 [Dubuisson, Annie; Lombard, Arnaud] Ctr Hosp Univ Liege, Dept Neurosurg, Liege, Belgium.
   [Otto, Bernard] Ctr Hosp Univ Liege, Dept Diagnost & Intervent Neuroradiol, Liege, Belgium.
RP Dubuisson, A (reprint author), Ctr Hosp Univ Liege, Dept Neurosurg, Liege, Belgium.
EM A.Dubuisson@chu.ulg.ac.be
CR BAREA FL, 1991, SKELETAL RADIOL, V20, P539, DOI 10.1007/BF00194255
   Beck TM, 2010, EUR J TRAUMA EMERG S, V36, P257, DOI 10.1007/s00068-009-8094-4
   BRONFEN C, 1993, REV CHIR ORTHOP, V79, P229
   Civan Melih, 2018, J Orthop Case Rep, V8, P36, DOI 10.13107/jocr.2250-0685.1200
   COHEN RB, 1993, J BONE JOINT SURG AM, V75A, P215, DOI 10.2106/00004623-199302000-00008
   Devilbiss Z, 2018, CURR SPORT MED REP, V17, P290, DOI 10.1249/JSR.0000000000000515
   DUCLOYER P, 1988, REV CHIR ORTHOP, V74, P659
   Dudkiewicz I, 2001, ARCH ORTHOP TRAUM SU, V121, P234, DOI 10.1007/s004020000219
   Findlay I, 2010, SPINE, V35, pE1525, DOI 10.1097/BRS.0b013e3181ec066b
   Garcia Callejo F J, 2000, Acta Otorrinolaringol Esp, V51, P646
   Gindele A, 2000, PEDIATR RADIOL, V30, P451, DOI 10.1007/s002479900168
   Jouve JL, 1997, J PEDIATR ORTHOP B, V6, P33, DOI 10.1097/01202412-199701000-00008
   Kaplan FS, 2008, PEDIATRICS, V121, pE1295, DOI 10.1542/peds.2007-1980
   Kartal-Kaess M, 2010, EUR J PEDIATR, V169, P1417, DOI 10.1007/s00431-010-1232-5
   Kokkosis AA, 2009, PEDIATR RADIOL, V39, P409, DOI 10.1007/s00247-009-1165-1
   Lakkireddy M, 2015, J CLIN DIAGN RES, V9, pRD1, DOI 10.7860/JCDR/2015/15160.6393
   Lasry F, 2005, JOINT BONE SPINE, V72, P335, DOI 10.1016/j.jbspin.2003.09.013
   Lau J, 2012, J PEDIATR SURG, V47, P1763, DOI 10.1016/j.jpedsurg.2012.05.009
   Lin TY, 2011, HEAD NECK-J SCI SPEC, V33, P753, DOI 10.1002/hed.21329
   Luczynska E, 2014, POL J RADIOL, V79, P228, DOI 10.12659/PJR.890209
   Man Sorin Claudiu, 2011, Maedica (Buchar), V6, P128
   Micheli A, 2009, EUR J PEDIATR, V168, P523, DOI 10.1007/s00431-008-0906-8
   Mortazavi H, 2013, IRAN J RADIOL, V10, P37, DOI 10.5812/iranjradiol.10302
   Onen MR, 2019, WORLD NEUROSURG, V123, P208, DOI 10.1016/j.wneu.2018.11.259
   Rashid U, 2016, JCPSP-J COLL PHYSICI, V26, P154, DOI 02.2016/JCPSP.154155
   Sarac S, 1999, EUR ARCH OTO-RHINO-L, V256, P199, DOI 10.1007/s004050050139
   Sferopoulos N K, 2017, Eur J Orthop Surg Traumatol, V27, P491, DOI 10.1007/s00590-017-1932-x
   Simmonds J, 2016, INT J PEDIATR OTORHI, V84, P116, DOI 10.1016/j.ijporl.2016.03.003
   Simon T, 2016, JOINT BONE SPINE, V83, P416, DOI 10.1016/j.jbspin.2015.07.013
   Turra C S, 1999, Chir Organi Mov, V84, P93
   Yazici M, 2002, J PEDIATR SURG, V37, P1621, DOI 10.1053/jpsu.2002.36196
NR 31
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 95
EP 97
DI 10.1016/j.wneu.2019.06.165
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200156
PM 31260851
DA 2020-05-12
ER

PT J
AU Dong, XW
   Zheng, JP
   Xiao, Q
   Huang, YY
   Liu, W
   Chen, GQ
AF Dong, Xuanwei
   Zheng, Jiaping
   Xiao, Qing
   Huang, Yiyang
   Liu, Wei
   Chen, Guoqiang
TI Surgical Techniques and Long-Term Outcomes of Flexible Neuroendoscopic
   Aqueductoplasty and Stenting in Infants with Obstructive Hydrocephalus:
   A Single-Center Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aqueductal membranous obstruction; Aqueductal stenosis; Infant;
   Neuroendoscopy; Stent; Treatment
ID ENDOSCOPIC 3RD VENTRICULOSTOMY; ISOLATED 4TH-VENTRICLE; PLACEMENT;
   CHILDREN; AGE
AB OBJECTIVE: To technically review and explore long-term follow-up results of aqueductoplasty and stenting under flexible neuroendoscopy in infantile obstructive hydrocephalus.
   METHODS: The clinical data, surgical techniques, and long-term effects in 14 infants with obstructive hydrocephalus treated by flexible neuroendoscopic aqueductoplasty and stenting between 2008 and 2010 were analyzed retrospectively.
   RESULTS: The 14 infants had a mean age of 5.71 +/- 3.10 (range, 2 -11 months) and a mean duration of follow-up of 62.64 +/- 34.52 months (range, 9-121 months). Subdural effusion was observed in 4 infants (28.6%) after surgery. There were no deaths or serious complications related to intracranial stent placement. Three infants (21.4%) failed, 2 due to proximal aqueduct occlusion from a short stent length and 1 due to intraluminal ependymal adhesion obstruction. One case was abandoned when a second surgical adjustment stent was unsuccessful, and the other 2 cases went to shunt surgery.
   CONCLUSIONS: Aqueductoplasty with stenting is a feasible and safe surgical procedure for treating infants with midbrain aqueduct stenosis or occlusion. However, the optimal stent material and definitive outcomes after this procedure require additional long-term follow-up studies in large numbers of infants.
C1 [Dong, Xuanwei; Liu, Wei] Weifang Med Univ, Dept Neurosurg, Weifang, Shandong, Peoples R China.
   [Zheng, Jiaping; Xiao, Qing; Huang, Yiyang; Chen, Guoqiang] Aviat Gen Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Chen, GQ (reprint author), Aviat Gen Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM guoqchen@mail.tsinghua.edu.cn
RI ZHENG, JIAPING/AAC-9008-2020
CR Adams-Chapman I, 2008, PEDIATRICS, V121, pE1167, DOI 10.1542/peds.2007-0423
   Antes S, 2016, CHILD NERV SYST, V32, P359, DOI 10.1007/s00381-015-2902-4
   Baldauf J, 2007, CHILD NERV SYST, V23, P623, DOI 10.1007/s00381-007-0335-4
   Chen GQ, 2013, EXP THER MED, V5, P1643, DOI 10.3892/etm.2013.1062
   Cinalli G, 2006, J NEUROSURG, V104, P21, DOI 10.3171/ped.2006.104.1.21
   da Silva LRF, 2007, CHILD NERV SYST, V23, P1263, DOI 10.1007/s00381-007-0393-7
   Deep NL, 2017, LARYNGOSCOPE, V127, P715, DOI 10.1002/lary.26126
   Ersahin Y, 2006, MINIM INVAS NEUROSUR, V49, P124, DOI 10.1055/s-2006-932182
   Ersahin Y, 2007, CHILD NERV SYST, V23, P143, DOI 10.1007/s00381-006-0227-z
   Fallah A, 2016, NEUROSURGERY, V78, P285, DOI 10.1227/NEU.0000000000001024
   Ferrer E, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2012.02.017
   Fritsch MJ, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2012.02.013
   Fritsch MJ, 2004, NEUROSURGERY, V55, P372, DOI 10.1227/01.NEU.0000130444.71677.BC
   Fritsch MJ, 2004, CHILD NERV SYST, V20, P137, DOI 10.1007/s00381-003-0860-8
   Gallo P, 2012, NEUROL INDIA, V60, P271, DOI 10.4103/0028-3886.98507
   Geng JF, 2015, WORLD NEUROSURG, V84, P1347, DOI 10.1016/j.wneu.2015.06.031
   Hayashi N, 2000, MINIM INVAS NEUROSUR, V43, P181, DOI 10.1055/s-2000-11377
   Hellwig D, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2012.02.006
   Hong S, 2019, J NEUROSURG-PEDIATR, V23, P104, DOI 10.3171/2018.7.PEDS18220
   Jiao YB, 2018, WORLD NEUROSURG, V110, pE1, DOI 10.1016/j.wneu.2017.09.138
   Koch D, 2004, CHILD NERV SYST, V20, P405, DOI 10.1007/s00381-004-0958-7
   Kulkarni AV, 2009, J PEDIATR-US, V155, P254, DOI 10.1016/j.jpeds.2009.02.048
   Marx S, 2019, NEUROSURGERY, V85, P91, DOI 10.1093/neuros/nyy219
   Marx S, 2016, J NEUROSURG, V125, P576, DOI 10.3171/2015.7.JNS151005
   Melot A, 2016, NEUROCHIRURGIE, V62, P94, DOI 10.1016/j.neuchi.2015.10.009
   Miki T, 2005, MINIM INVAS NEUROSUR, V48, P136, DOI 10.1055/s-2004-830265
   Mottolese C, 2007, J NEUROSURG, V106, P414, DOI 10.3171/ped.2007.106.5.414
   Peretta P, 2009, NEUROSURGERY, V65, P539, DOI 10.1227/01.NEU.0000350228.08523.D1
   Pitskhelauri DI, 2009, NEUROSURGERY, V64, P256, DOI 10.1227/01.NEU.0000338260.05545.84
   Sagan LM, 2006, J NEUROSURG, V105, P275, DOI 10.3171/ped.2006.105.4.275
   Schroeder HWS, 2004, CHILD NERV SYST, V20, P821, DOI 10.1007/s00381-004-0937-z
   Schroeder HWS, 2000, J NEUROSURG, V93, P237, DOI 10.3171/jns.2000.93.2.0237
   Schroeder HWS, 1999, NEUROSURGERY, V45, P508, DOI 10.1097/00006123-199909000-00020
   Schulz M, 2012, NEUROSURGERY, V70, P847, DOI 10.1227/NEU.0b013e318236717f
   Teo C, 1999, NEUROSURGERY, V44, P1257, DOI 10.1097/00006123-199906000-00049
   Teo C, 1999, NEUROSURGERY, V44, P1257
   van Aalst J, 2002, J NEUROSURG, V96, P597, DOI 10.3171/jns.2002.96.3.0597
   van Zanten SA, 2011, EUR J PAEDIATR NEURO, V15, P487, DOI 10.1016/j.ejpn.2011.04.011
NR 38
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 98
EP 105
DI 10.1016/j.wneu.2019.06.069
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200157
PM 31226461
DA 2020-05-12
ER

PT J
AU Yoshiura, T
   Wada, K
   Kumagai, K
   Takeuchi, S
   Toyooka, T
   Otani, N
   Mori, K
AF Yoshiura, Toru
   Wada, Kojiro
   Kumagai, Kosuke
   Takeuchi, Satoru
   Toyooka, Terushige
   Otani, Naoki
   Mori, Kentaro
TI Surgical Rescue Technique for Incomplete Burr Hole Using a Small Bone
   Piece and the Craniotome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Craniotomy; Neurosurgical technique; Osteoporosis
AB BACKGROUND: Incomplete penetration of a burr hole sometimes occurs when performing a craniotomy in elderly patients due to osteoporosis. Completion of the burr hole takes more time and may sometimes cause tearing of the dura mater. We have introduced a small bone piece method that can easily and reliably recover an incomplete burr hole safely.
   METHODS: 1) Cut out a small bone piece of the outer table of about 5-mm size using a rongeur. 2) Place the small bone piece in the center of the incomplete burr hole. 3) Push on the small bone piece with a craniotome after unlocking the safety stop mechanism. 4) Restart and complete the burr hole with the craniotome.
   RESULTS: We succeeded in 10 of 11 incomplete burr holes. One case that failed had osteoporosis. There were no complications.
   CONCLUSIONS: Application of the unlocked craniotome the small bone piece can easily complete the burr hole. Less bone deficit is caused compared with making a new burr hole. In addition, time is saved without changing the attachment, and the burr hole is completed safely. This small bone piece method is effective to recover an incomplete burr hole.
C1 [Yoshiura, Toru; Wada, Kojiro; Kumagai, Kosuke; Takeuchi, Satoru; Toyooka, Terushige; Otani, Naoki; Mori, Kentaro] Natl Def Med Coll, Dept Neurosurg, Saitama, Japan.
RP Yoshiura, T (reprint author), Natl Def Med Coll, Dept Neurosurg, Saitama, Japan.
EM torumiru.neurosurgery@gmail.com
CR Caird JD, 2003, BRIT J NEUROSURG, V17, P509, DOI 10.1080/02688690310001627722
   Ito M, 2001, J CLIN NEUROSCI, V8, P261, DOI 10.1054/jocn.1999.0733
   Menovsky T, 2014, J NEUROSURG, V120, P572, DOI 10.3171/2012.3.JNS112168
   Murai Y, 2017, OPER NEUROSURG, V13, P324, DOI 10.1093/ons/opw043
   Vogel TW, 2011, J NEUROSURG, V115, P570, DOI 10.3171/2011.3.JNS101310
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 106
EP 109
DI 10.1016/j.wneu.2019.06.080
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200158
PM 31247350
DA 2020-05-12
ER

PT J
AU Khan, AB
   Goethe, EA
   Hadley, CC
   Rouah, E
   North, R
   Srinivasan, VM
   Gallagher, KK
   Fuentes, A
   Vaz-Guimaraes, F
AF Khan, A. Basit
   Goethe, Eric A.
   Hadley, Caroline C.
   Rouah, Emilie
   North, Robert
   Srinivasan, Visish M.
   Gallagher, K. Kelly
   Fuentes, Alfonso
   Vaz-Guimaraes, Francisco
TI Infundibular Epidermoid Cyst: Case Report and Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cystic epithelial tumor; Intracranial epidermoid cyst; Pituitary tumor
ID PITUITARY; TUMORS
AB BACKGROUND: Intracranial epidermoid cysts are benign, congenital, keratinizing, squamous epithelial-lined cysts filled with keratin. They are uncommon and often pose a surgical challenge owing to the adherence to surrounding structures. They are typically found at the cerebellopontine angle or in the parasellar region, where they are associated with abnormal development of the Rathke pouch; involvement of the pituitary stalk is rare.
   CASE DESCRIPTION: The patient's electronic health record was queried for relevant data. A systematic review of the literature using dedicated search terms for cases of infundibular epidermoid cysts was conducted. We present a unique case of a 55-year-old male who presented with vision changes and was found to have a parasellar epidermoid cyst confined to the pituitary stalk. The patient underwent endoscopic transsphenoidal resection, and gross total resection was achieved. The patient's postoperative course was significant for possible chemical meningitis and the development of panhypopituitarism. The patient's vision subjectively improved after surgery.
   CONCLUSIONS: Although 3 other cases of epidermoid cysts involving the pituitary stalk were identified, our patient's tumor was unique in that it was confined to the stalk. Our patient's case highlights a surgical approach to parasellar epidermoid cysts and the possible complications associated therewith.
C1 [Khan, A. Basit; Goethe, Eric A.; Hadley, Caroline C.; North, Robert; Srinivasan, Visish M.; Fuentes, Alfonso; Vaz-Guimaraes, Francisco] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
   [Rouah, Emilie] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.
   [Gallagher, K. Kelly] Baylor Coll Med, Dept Otolaryngol Head & Neck Surg, Houston, TX 77030 USA.
RP Vaz-Guimaraes, F (reprint author), Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
EM francisc.vaz@bcm.edu
OI Vaz Guimaraes Filho, Francisco/0000-0003-4810-0847; Khan,
   Abdul/0000-0002-5450-930X
CR Akar Z, 2003, NEUROL MED-CHIR, V43, P275, DOI 10.2176/nmc.43.275
   ASA SL, 1983, VIRCHOWS ARCH A, V399, P49
   Cappello Zachary J, 2013, Eplasty, V13, pic44
   Costa F, 2013, NEUROSURG QUART, V23, P108, DOI 10.1097/WNQ.0b013e318266c267
   DUBOIS PM, 1995, TRENDS ENDOCRIN MET, V6, P1, DOI 10.1016/1043-2760(94)00090-Q
   Ellenbogen RG, 2018, PRINCIPLES NEUROLOGI
   Ezer H, 2011, SKULL BASE-INTERD AP, V21, P159, DOI 10.1055/s-0031-1275247
   Fatemi N, 2008, NEUROSURGERY, V63, P244, DOI 10.1227/01.NEU.0000327025.03975.BA
   GORMLEY WB, 1994, ACTA NEUROCHIR, V128, P115, DOI 10.1007/BF01400660
   HARRISON MJ, 1994, J NEUROSURG, V80, P1018, DOI 10.3171/jns.1994.80.6.1018
   INOUE T, 1988, NEUROSURGERY, V23, P576, DOI 10.1227/00006123-198811000-00006
   Javorsky BR, 2017, GREENSPANS BASIC CLI
   Kato Koichi, 2010, Asian J Neurosurg, V5, P32
   Kumari R, 2009, NEUROL INDIA, V57, P359, DOI 10.4103/0028-3886.53266
   Lynch Jose Carlos, 2014, Surg Neurol Int, V5, P163, DOI 10.4103/2152-7806.145764
   McCormack Erin P, 2018, Cureus, V10, pe3226, DOI 10.7759/cureus.3226
   Nakassa ACI, 2018, J NEUROSURG, V128, P437, DOI 10.3171/2016.11.JNS161605
   NETSKY MG, 1988, SURG NEUROL, V29, P477, DOI 10.1016/0090-3019(88)90144-9
   Osborn AG, 2006, RADIOLOGY, V239, P650, DOI 10.1148/radiol.2393050823
   Rehman L, 2018, TURK NEUROSURG, V28, P763, DOI 10.5137/1019-5149.JTN.21095-17.0
   Sadler T.W., 2019, LANGMANS MED EMBRYOL
   Saeger W, 2007, EUR J ENDOCRINOL, V156, P203, DOI 10.1530/eje.1.02326
   ULRICH J, 1964, J NEUROSURG, V21, P1051, DOI 10.3171/jns.1964.21.12.1051
   VANGILDER JC, 1973, J NEUROSURG, V38, P608, DOI 10.3171/jns.1973.38.5.0608
   Vaz-Guimaraes F, 2019, J NEUROSURG, V130, P368, DOI 10.3171/2017.7.JNS162783
   YASARGIL MG, 1989, NEUROSURGERY, V24, P561
   Zada G, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS09318
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 110
EP 114
DI 10.1016/j.wneu.2019.06.205
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200159
PM 31284058
DA 2020-05-12
ER

PT J
AU Alves, JL
   Rato, J
   Silva, V
AF Alves, Jose Luis
   Rato, Joana
   Silva, Vitor
TI Why Does Brain Trauma Research Fail?
SO WORLD NEUROSURGERY
LA English
DT Review
DE Animal models; Brain trauma; Clinical trials; Translational research
ID IN-VITRO MODELS; PLACEBO-CONTROLLED TRIAL; CLINICAL-TRIALS; NEUROTROPHIC
   FACTOR; ANIMAL-MODELS; INJURY; PROGESTERONE; NEUROPROTECTION;
   CHALLENGES; OUTCOMES
AB Traumatic brain injury (TBI) represents a major health care problem and a significant social and economic issue worldwide. Considering the generalized failure in introducing effective drugs and clinical protocols, there is an urgent need for efficient treatment modalities, able to improve devastating post-traumatic morbidity and mortality. In this work, the status of brain trauma research is analyzed in all its aspects, including basic and translational science and clinical trials. Implicit and explicit challenges to different lines of research are discussed and clinical trial structures and outcomes are scrutinized, along with possible explanations for systematic therapeutic failures and their implications for future development of drug and clinical trials. Despite significant advances in basic and clinical research in recent years, no specific therapeutic protocols for TBI have been shown to be effective. New potential therapeutic targets have been identified, following a better understanding of pathophysiologic mechanisms underlying TBI, although with disappointing results. Several reasons can be pinpointed at different levels, from inaccurate animal models of disease to faulty preclinical and clinical trials, with poor design and subjective outcome measures. Distinct strategies can be delineated to overcome specific shortcomings of research studies. Identifying and contextualizing the failures that have dominated TBI research is mandatory. This review analyzes current approaches and discusses possible strategies for improving outcomes.
C1 [Alves, Jose Luis; Rato, Joana; Silva, Vitor] Ctr Hosp & Univ Coimbra, Dept Neurosurg, Coimbra, Portugal.
RP Alves, JL (reprint author), Ctr Hosp & Univ Coimbra, Dept Neurosurg, Coimbra, Portugal.
EM jlmonteiroalves@gmail.com
CR Ahirrao M, 2017, DRUG DEV IND PHARM, V43, P1686, DOI 10.1080/03639045.2017.1338721
   Alali AS, 2015, J NEUROTRAUM, V32, P581, DOI 10.1089/neu.2014.3495
   ALOSCO M, 2017, ALZHEIMERS DEMENT, V10, P56
   Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300
   Barbosa RR, 2012, J TRAUMA ACUTE CARE, V73, pS307, DOI 10.1097/TA.0b013e3182701885
   Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp
   Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a
   Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411
   Bodanapally UK, 2015, RADIOL CLIN N AM, V53, P695, DOI 10.1016/j.rcl.2015.02.011
   Bonds B. W., 2015, J NEUROTRAUM, V2014, DOI [10.1089/neu.2014.3742, DOI 10.1089/NEU.2014.3742]
   Bouzat P, 2014, INTENS CARE MED, V40, P412, DOI 10.1007/s00134-013-3203-6
   Buki A, 2009, METHOD MOL BIOL, V556, P41
   Bullock M Ross, 2006, Neurosurgery, V58, pS7
   Cacialli P, 2018, NEURAL REGEN RES, V13, P941, DOI 10.4103/1673-5374.233430
   Carpenter KLH, 2017, CURR OPIN CRIT CARE, V23, P103, DOI 10.1097/MCC.0000000000000400
   Carteron L, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00601
   Cater HL, 2007, J NEUROCHEM, V101, P434, DOI 10.1111/j.1471-4159.2006.04379.x
   Chauny JM, 2016, J EMERG MED, V51, P519, DOI 10.1016/j.jemermed.2016.05.045
   Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363
   Currie S, 2016, POSTGRAD MED J, V92, P41, DOI 10.1136/postgradmedj-2014-133211
   Dekmak A, 2018, BEHAV BRAIN RES, V340, P49, DOI 10.1016/j.bbr.2016.12.039
   Denayer T, 2014, NEW HORIZ TRANSL MED, V2, P5, DOI 10.1016/j.nhtm.2014.08.001
   Depreitere B, 2012, Acta Neurochir Suppl, V114, P289, DOI 10.1007/978-3-7091-0956-4_56
   Dewan S, 2018, EXPERT OPIN BIOL TH, V18, P515, DOI 10.1080/14712598.2018.1439473
   Dorsett CR, 2017, J NEUROTRAUM, V34, P263, DOI 10.1089/neu.2015.4373
   Edwards P, 2005, LANCET, V365, P1957
   Ercole A, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0614-3
   Feldman AM, 2015, CTS-CLIN TRANSL SCI, V8, P171, DOI 10.1111/cts.12302
   Fernandez-Hernandez I, 2015, NEUROSCI BIOBEHAV R, V56, P62, DOI 10.1016/j.neubiorev.2015.06.021
   Fontana ACK, 2015, J NEUROCHEM, V134, P982, DOI 10.1111/jnc.13200
   Genet GF, 2017, J NEUROTRAUM, V34, P1054, DOI 10.1089/neu.2016.4574
   Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609
   Gold EM, 2018, ASN NEURO, V10, DOI 10.1177/1759091418781921
   Goodman S, 2013, R13EHC042EF37 AG HEA
   Gruenbaum SE, 2016, CNS DRUGS, V30, P791, DOI 10.1007/s40263-016-0355-2
   Guthrie RM, 2015, PHYSICIAN SPORTSMED, V43, P333, DOI 10.1080/00913847.2015.1081552
   Habtemariam S, 2018, NEURAL REGEN RES, V13, P983, DOI 10.4103/1673-5374.233438
   Hammond FM, 2018, J NEUROTRAUM, V35, P2298, DOI 10.1089/neu.2018.5767
   Harrison DA, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17230
   He W, 2014, PDL HANDB SER, P55, DOI 10.1016/B978-0-323-22805-3.00004-9
   Hillered L, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00245
   Hockey K S, 2013, Biomed Sci Instrum, V49, P134
   Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124
   Jalloh I, 2018, J NEUROTRAUM, V35, P2025, DOI 10.1089/neu.2017.5459
   Jickling GC, 2015, METAB BRAIN DIS, V30, P461, DOI 10.1007/s11011-014-9499-2
   Johnson Nicholas, 2009, Biomed Sci Instrum, V45, P125
   Joseph B, 2018, J NEUROSCI RES, V96, P589, DOI 10.1002/jnr.24132
   Karibe H, 2017, NEUROL MED-CHIR, V57, P418, DOI 10.2176/nmc.st.2017-0058
   Kaur P, 2018, CURR NEUROPHARMACOL, V16, P1224, DOI 10.2174/1570159X15666170613083606
   Khaitovich P, 2004, GENOME RES, V14, P1462, DOI 10.1101/gr.2538704
   Kreeger Karen, 2003, Nature, V424, P1090, DOI 10.1038/nj6952-1090a
   Kumaria A, 2008, BRIT J NEUROSURG, V22, P200, DOI 10.1080/02688690701772413
   Kumaria A, 2017, ATLA-ALTERN LAB ANIM, V45, P201, DOI 10.1177/026119291704500405
   Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001
   Lingsma HF, 2011, NEUROSURGERY, V68, P601, DOI 10.1227/NEU.0b013e318209333b
   Lochhead JJ, 2015, J CEREBR BLOOD F MET, V35, P371, DOI 10.1038/jcbfm.2014.215
   Losoi H, 2016, J NEUROTRAUM, V33, P766, DOI 10.1089/neu.2015.4070
   Lowenstein PR, 2009, CURR GENE THER, V9, P368, DOI 10.2174/156652309789753392
   Lu J, 2012, BRAIN INJURY, V26, P1523, DOI 10.3109/02699052.2012.722257
   Lyeth B., 2015, BRAIN NEUROTRAUMA MO, V38, P109
   Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753
   Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9
   Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X
   Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599
   Magruder KM, 2017, EUR J PSYCHOTRAUMATO, V8, DOI 10.1080/20008198.2017.1375338
   Margulies S, 2016, J NEUROTRAUM, V33, P101, DOI 10.1089/neu.2014.3855
   Marion DW, 2006, NEUROSURGERY, V58, P655
   Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431
   Martini AC, 2018, J ALZHEIMERS DIS, V64, pS365, DOI 10.3233/JAD-179917
   McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000
   McGonigle P, 2014, BIOCHEM PHARMACOL, V87, P162, DOI 10.1016/j.bcp.2013.08.006
   Medaglia J., 2017, FRONT NEUROL, V8, P57
   Menon DK, 2015, NAT REV NEUROL, V11, P71, DOI 10.1038/nrneurol.2014.261
   Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225
   Montenigro PH, 2015, ANNU REV CLIN PSYCHO, V11, P309, DOI 10.1146/annurev-clinpsy-032814-112814
   Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014
   Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706
   Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651
   Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511
   Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011
   Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037
   Nimer F., 2015, PLOS ONE, V10
   Norris J., 17M DOD AWARD AIMS I
   Nourallah B, 2018, ACTA NEUROCHIR, V160, P1315, DOI 10.1007/s00701-018-3555-3
   O'Leary RA, 2018, J NEUROSURG SCI, V62, P542, DOI 10.23736/S0390-5616.18.04501-0
   Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245
   Pardeshi C, 2013, EXPERT OPIN DRUG DEL, V10, P105
   Petraglia Anthony L, 2014, Neurosurgery, V75 Suppl 4, pS34, DOI 10.1227/NEU.0000000000000472
   Rao KVR, 2018, J NEUROTRAUM, V35, P2077, DOI 10.1089/neu.2017.5358
   Retzios AD, 2009, WHY DO SO MANY CLIN
   Rolfe A., 2015, BRAIN NEUROTRAUMA MO
   Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035
   Ruprecht R, 2019, J MAGN RESON IMAGING, V49, P212, DOI 10.1002/jmri.26162
   Rusnak M, 2013, NAT REV NEUROL, V9, P186, DOI 10.1038/nrneurol.2013.38
   Schwamm LH, 2014, NEW ENGL J MED, V371, P2522, DOI 10.1056/NEJMe1412951
   Shrirao AB, 2018, BIOTECHNOL BIOENG, V115, P815, DOI 10.1002/bit.26519
   Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090
   Stein D., WHY MOST TBI STUDIES
   Stein DG, 2015, BRAIN INJURY, V29, P1259, DOI 10.3109/02699052.2015.1065344
   Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206
   Sun D, 2014, NEURAL REGEN RES, V9, P688, DOI 10.4103/1673-5374.131567
   Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512
   Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5
   Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x
   Vespa PM, 2016, NEUROSURG CLIN N AM, V27, pXV, DOI 10.1016/j.nec.2016.08.008
   Vink R, 2004, J AM COLL NUTR, V23, p538S, DOI 10.1080/07315724.2004.10719398
   Walker WC, 2018, J NEUROTRAUM, V35, P1587, DOI 10.1089/neu.2017.5359
   Wilson M., 2014, SCAND J TRAUMA RE S1, V22, pA7, DOI [10.1186/1757-7241-22-S1-A7, DOI 10.1186/1757-7241-22-S1-A7]
   Wintermark M, 2015, AJNR Am J Neuroradiol, V36, pE1, DOI 10.3174/ajnr.A4181
   Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304
   Yi X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070306
   Yin G., 2012, CLIN TRIAL DESIGN BA, P71
   Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127
NR 113
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 115
EP 121
DI 10.1016/j.wneu.2019.06.212
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200160
PM 31284053
DA 2020-05-12
ER

PT J
AU Kaur, M
   Aggarwal, A
   Sharma, A
   Malik, A
AF Kaur, Maninder
   Aggarwal, Ankita
   Sharma, Anuradha
   Malik, Amita
TI Cervical Lipomyelocele with Congenital Inclusion Cyst
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical lipomyelocele; Congenital inclusion cyst; Dorsal dermal sinus;
   Spinal dysraphism
ID SPINE
AB BACKGROUND: Spinal dysraphism refers to a group of congenital malformations affecting the spine and the spinal cord. Although there are several varieties, all have one thing in common, i.e., faulty closure of midline structures at embryogenesis. Rarely, these anomalies are associated with spinal inclusion cysts. Lipomyelocele (LMC) is a type of spinal dysraphism wherein the neural elements along with fat herniate through a posterior defect in the spine. A vast majority of these anomalies are seen in the lumbosacral region, and their occurrence in the cervical region is extremely rare.
   CASE DESCRIPTION: A 45-year-old female patient presented with swelling over the nape of her neck since birth, with recent-onset paresthesia and unsteady gait. On local examination, a soft fluctuant swelling with blackish discoloration of skin was noted at the nape of the neck. Radiographs revealed congenital C4-C5 block vertebra with defect in posterior elements from C4 to C6. Magnetic resonance imaging revealed a cervical LMC with extramedullary intradural congenital inclusion cyst. Other notable findings were dorsal dermal sinus in cervical region, low lying tethered cord, and aberrant right subclavian artery. In our literature review, we could find only 1 case report of a cervical LMC and no cases reported of cervical LMC with congenital inclusion cyst.
   CONCLUSIONS: Herein, we report a case of a cervical LMC with a spinal inclusion cyst.
C1 [Kaur, Maninder; Aggarwal, Ankita; Sharma, Anuradha; Malik, Amita] VMMC & Safdarjung Hosp, Dept Rat Radiadiag, New Delhi, India.
RP Aggarwal, A (reprint author), VMMC & Safdarjung Hosp, Dept Rat Radiadiag, New Delhi, India.
EM dr.ankitaaggarwal@gmail.com
CR Archarya UV, 2017, INDIAN J RADIOL IMAG, V27, P417
   BARKOVICH AJ, 1991, AM J NEURORADIOL, V12, P123
   GUPTA S, 1993, CLIN RADIOL, V48, P405, DOI 10.1016/S0009-9260(05)81110-9
   Moore K., 2013, CAFFEYS PEDIAT DIAGN, P449
   Rossi A, 2004, EUR J RADIOL, V50, P177, DOI 10.1016/j.ejrad.2003.10.015
   Rufener SL, 2010, AM J ROENTGENOL, V194, pS26, DOI 10.2214/AJR.07.7141
   Shubha AM, 2010, INDIAN J PEDIATR, V77, P167, DOI 10.1007/s12098-009-0290-z
   Valeur Natalie S, 2016, Radiol Case Rep, V11, P266, DOI 10.1016/j.radcr.2016.04.008
NR 8
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 122
EP 128
DI 10.1016/j.wneu.2019.06.179
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200161
PM 31255725
DA 2020-05-12
ER

PT J
AU Li, M
   Gao, XG
   Rajah, GB
   Liang, JT
   Chen, J
   Yan, F
   Beo, YH
   Jiao, LQ
   Zhang, HQ
   Ding, YC
   Ji, XM
   Meng, R
AF Li, Min
   Gao, Xiaogang
   Rajah, Gary B.
   Liang, Jiantao
   Chen, Jian
   Yan, Feng
   Beo, Yuhai
   Jiao, Liqun
   Zhang, Hongqi
   Ding, Yuchuan
   Ji, Xunming
   Meng, Ran
TI Styloidectomy and Venous Stenting for Treatment of Styloid-Induced
   Internal Jugular Vein Stenosis: A Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Internal jugular vein stenosis; Intracranial hypertension; Jugular
   venous outflow disturbance; Stenting; Styloid compression; Styloidectomy
ID INTRACRANIAL HYPERTENSION; COMPRESSION; DIAGNOSIS
AB BACKGROUND: Internal jugular vein stenosis (IJVS) results in poor venous outflow and can result in intracranial hypertension. Venous stenting has become a debated topic for correction of this pathology.
   CASE DESCRIPTION: A 49-year-old male merchant with bilateral IJVS presented with headache, dizziness, and pulsatile tinnitus. He was found to have intracranial hypertension and left IJVS caused by styloid process compression and right IJVS caused by damage of the venous intima. His symptoms improved after undergoing styloidectomy followed by left intra-internal jugular vein (IJV) balloon. However, 1 year later, the prior symptoms reoccurred. At this time, the patient underwent right intra-IJV stenting. After treatment of the contralateral side, the symptoms resolved during the following 3 months.
   CONCLUSIONS: The clinical practice in this case indicated that in patients with bilateral IJVS, a 2-side intervention may be necessary when unilateral correction fails. We advise a staged approach to correction of bilateral IJVS. Styloid compression-induced IJVS should be corrected by styloidectomy in combination with balloon and/or stenting, whereas IJVS induced by venous wall issues needs only stenting.
C1 [Li, Min; Meng, Ran] Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing, Peoples R China.
   [Liang, Jiantao; Chen, Jian; Yan, Feng; Beo, Yuhai; Jiao, Liqun; Zhang, Hongqi; Ji, Xunming] Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Li, Min; Ji, Xunming; Meng, Ran] Beijing Inst Brain Disorders, Adv Ctr Stroke, Beijing, Peoples R China.
   [Gao, Xiaogang] Tianjin Huanhu Hosp, Dept Med, Tianjin Key Lab Cerebrovasc & Neurodegenerat Dis, Tianjin, Peoples R China.
   [Rajah, Gary B.; Ding, Yuchuan] Wayne State Univ, Sch Med, Dept Neurosurg, Detroit, MI USA.
RP Ji, XM (reprint author), Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.; Ji, XM (reprint author), Beijing Inst Brain Disorders, Adv Ctr Stroke, Beijing, Peoples R China.
EM jixm@ccmu.edu.cn
FU National Key RD Program [2017YFC1308401]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China
   [81371289]; Project of Beijing Municipal Top Talent of Healthy Work
   [2014-2-015]
FX This study was supported by the National Key R&D Program
   (2017YFC1308401), the National Natural Science Foundation of China
   (81371289), and the Project of Beijing Municipal Top Talent of Healthy
   Work (2014-2-015) of China.
CR Ahn SS, 2014, ANN VASC SURG, V28, P946, DOI 10.1016/j.avsg.2013.12.009
   Attanasio G, 2017, ACTA OTO-LARYNGOL, V137, P460, DOI 10.1080/00016489.2016.1252853
   Brinjikji W, 2017, J NEUROINTERV SURG, V9, pE28, DOI 10.1136/neurintsurg-2016-012827.rep
   Buch K, 2016, AM J ROENTGENOL, V206, P1082, DOI 10.2214/AJR.15.14689
   Dashti SR, 2012, NEUROSURGERY, V70, pE795, DOI 10.1227/NEU.0b013e3182333859
   Gianesini S, 2014, PHLEBOLOGY, V29, P632, DOI 10.1177/0268355513489549
   Higgins JN, 2017, J NEUROL SURG PART B, V78, P158, DOI 10.1055/s-0036-1594238
   Jayaraman MV, 2012, AM J NEURORADIOL, V33, P1247, DOI 10.3174/ajnr.A2953
   Martin TJ, 2008, ENT-EAR NOSE THROAT, V87, P399, DOI 10.1177/014556130808700714
   Ramina R, 2005, NEUROSURGERY, V57, P59, DOI 10.1227/01.NEU.0000163483.44754.47
   Uddin Muhammad Azeem, 2006, JPMA Journal of the Pakistan Medical Association, V56, P516
   Zhou D, 2018, EUR J NEUROL, V25, P365, DOI 10.1111/ene.13512
   Zhou D, 2019, THROMB HAEMOSTASIS, V119, P308, DOI 10.1055/s-0038-1676815
   Zhou D, 2018, CNS NEUROSCI THER, V24, P473, DOI 10.1111/cns.12859
NR 14
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 129
EP 132
DI 10.1016/j.wneu.2019.06.100
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200162
PM 31229748
DA 2020-05-12
ER

PT J
AU Casabella, AM
   Perry, A
   Graffeo, CS
   Marcellino, CR
   Carlstrom, LP
   Rabinstein, AA
AF Casabella, Amanda Munoz
   Perry, Avital
   Graffeo, Christopher S.
   Marcellino, Christopher R.
   Carlstrom, Lucas P.
   Rabinstein, Alejandro A.
TI Emergent Decompression of Intracranial Abscess in Eisenmenger Syndrome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain abscess; Cerebral abscess; CHD; Congenital heart disease;
   Eisenmenger syndrome; Ventricular septal defect; VSD
ID CONGENITAL HEART-DISEASE; BRAIN-ABSCESS; PULMONARY-HYPERTENSION;
   TASK-FORCE; THROMBOCYTOPENIA; MANAGEMENT; ASPIRATION; ADULTS
AB BACKGROUND: Eisenmenger syndrome is a rare sequela of uncorrected genital heart disease complicated by pulmonary hypertension, from which reversal of the pathologic left-to-right cardiovascular shunt and cyanosis follow. Right-to-left shunting can lead to paradoxical cerebral emboli-increasing the risk of spontaneous or iatrogenic stroke and cerebral abscess.
   CASE DESCRIPTION: A 38-year-old man presented with new focal seizures due to a brain abscess. Ventricular septa! defect and pulmonary hypertension were identified. Despite dexamethasone and broad-spectrum antibiotics, he developed hemiparesis and altered mental status and required emergent stereotactic abscess drainage. Despite the anesthetic hazards of Eisenmenger syndrome, the procedure was successful and the patient recovered completely.
   CONCLUSIONS: Noncardiac perioperative mortality in Eisenmenger syndrome is historically reported up to 19%, and risks are further increased with prolonged case duration or hypotension, mandating vigilant attention to volume status. Correspondingly, shorter- or lower-risk procedures such as stereotactic drainage are recommended. Procedures should be performed only at centers with expertise in management of Eisenmenger syndrome and cardiac-specialized anesthesiologists whenever possible. Although a conservative approach with early, aggressive medical management is preferred, operative intervention may be required in the setting of progressive deterioration and excellent postoperative outcomes are achievable.
C1 [Casabella, Amanda Munoz; Perry, Avital; Graffeo, Christopher S.; Marcellino, Christopher R.; Carlstrom, Lucas P.] Mayo Clin, Dept Neurol Surg, Rochester, MN USA.
   [Marcellino, Christopher R.; Rabinstein, Alejandro A.] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.
RP Rabinstein, AA (reprint author), Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.
EM rabinstein.alejandro@mayo.edu
CR Ammash NM, 1999, J AM COLL CARDIOL, V33, P222, DOI 10.1016/S0735-1097(98)00554-3
   Bansal Sumit, 2017, Asian J Neurosurg, V12, P220, DOI 10.4103/1793-5482.144171
   Carson JL, 2018, AM HEART J, V200, P96, DOI 10.1016/j.ahj.2018.04.007
   Cavusoglu H, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/6/E9
   Chau AMT, 2012, MED J AUSTRALIA, V196, P525, DOI 10.5694/mja11.10768
   Clave MM, 2017, PULM CIRC, V7, P635, DOI 10.1177/2045893217721928
   de Campos Fernando Peixoto Ferraz, 2017, Autops Case Rep, V7, P5, DOI 10.4322/acr.2017.006
   Dulac Y., 2009, PRESSE MED S1, V38
   Graham TP, 2005, J AM COLL CARDIOL, V45, P1326, DOI 10.1016/j.jacc.2005.02.009
   Granton John T., 2002, Cardiology Clinics, V20, P441, DOI 10.1016/S0733-8651(02)00017-6
   Greenberg MS, 2016, HDB NEUROSURGERY
   Horigome H, 2002, J AM COLL CARDIOL, V39, P1072, DOI 10.1016/S0735-1097(02)01718-7
   Kempny A, 2017, HEART, V103, P1313, DOI 10.1136/heartjnl-2017-311396
   Lill MC, 2006, AM J CARDIOL, V98, P254, DOI 10.1016/j.amjcard.2006.01.083
   Lumbiganon P, 2013, COCHRANE DB SYST REV, V3
   Martinez-Quintana E, 2015, PLATELETS, V26, P432, DOI 10.3109/09537104.2014.925104
   Muzumdar D, 2011, INT J SURG, V9, P136, DOI 10.1016/j.ijsu.2010.11.005
   Niwa K, 1999, J AM COLL CARDIOL, V34, P223, DOI 10.1016/S0735-1097(99)00153-9
   Oechslin E, 2010, CURR CARDIOL REV, V6, P363, DOI 10.2174/157340310793566127
   Ozsurekci Y, 2012, TURKISH J PEDIATR, V54, P144
   Quintana LM, 2011, WORLD NEUROSURG, V76, P388, DOI 10.1016/j.wneu.2011.04.012
   Ratnaike TE, 2011, WORLD NEUROSURG, V76, P431, DOI 10.1016/j.wneu.2011.03.048
   ROBINSON S, 1983, ANESTHESIOLOGY, V58, P588, DOI 10.1097/00000542-198306000-00031
   Roth TS, 2016, CARDIOL CLIN, V34, P391, DOI 10.1016/j.ccl.2016.04.002
   Srinivasaiah B, 2016, J NEUROSURG ANESTH, V28, P433, DOI 10.1097/ANA.0000000000000228
   STOUT KK, 2018, J AM COLL CARDIOL, V139, pE698
   Udayakumaran S, 2017, WORLD NEUROSURG, V107, P124, DOI [10.1016/j.wneu.2017.07.144, 10.1016/J.WNEU.2017.07.144]
   Valkovicova T, 2018, BRATISL MED J, V119, P321, DOI 10.4149/BLL_2018_060
   Vongpatanasin W, 1998, ANN INTERN MED, V128, P745, DOI 10.7326/0003-4819-128-9-199805010-00008
   Warnes CA, 2008, CIRCULATION, V118, pE714, DOI 10.1161/CIRCULATIONAHA.108.190690
   WOOD P, 1958, BRIT MED J, V2, P700
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 133
EP 137
DI 10.1016/j.wneu.2019.07.010
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200163
PM 31295595
DA 2020-05-12
ER

PT J
AU Miyaza, S
   Matsuda, R
   Nakamura, M
   Nakagawa, I
   Motoyama, Y
   Nakase, H
AF Miyaza, Shizuka
   Matsuda, Ryosuke
   Nakamura, Mitsutoshi
   Nakagawa, Ichiro
   Motoyama, Yasushi
   Nakase, Hiroyuki
TI Intracranial Methotrexate-Associated Lymphoproliferative Disorder in
   Rheumatoid Arthritis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Lymphoproliferative disorder; Methotrexate; Rheumatoid arthritis
AB BACKGROUND: Methotrexate (MTX) is widely used as an anchor drug for the treatment of rheumatoid arthritis (RA) because of its ability to control pain and inflammation. However, few studies have shown that long-term MTX use can lead to lymphoproliferative disorders (LPDs) in these patients. Here we describe a rare case of intracranial MTX-associated LPD in a patient with RA.
   CASE DESCRIPTION: A 68-year-old woman was admitted to our hospital because of progressive right limb palsy. She was diagnosed with RA 15 years ago and has been receiving MTX therapy for the past 5 years. Magnetic resonance imaging of the head revealed a ring-enhancing lesion in the left parietal lobe. Open biopsy was performed for making a definite diagnosis and planning treatment. Hematoxylin-eosin stain revealed dense proliferation of atypical lymphocytes in the perivascular lesion. Immunohistochemistry results were positive for CD20; this lesion was observed as a strong nuclear signal on in-situ hybridization for the Epstein-Barr virus-encoded RNA. Finally, the patient was diagnosed with MTX-associated LPD. We discontinued MTX administration and initiated steroid therapy for RA. The intracranial lesion reduced in size, and her symptoms resolved after MTX discontinuation; no recurrence has been observed at 3 years after MTX discontinuation.
   CONCLUSIONS: Intracranial MTX-associated LPD is extremely rare. Here we describe a particular case and review the literature pertaining to intracranial MTX-associated LPD. More attention should be paid to LPD in a patient receiving immunosuppressive treatment for RA.
C1 [Miyaza, Shizuka] Higashiosaka City Med Ctr, Dept Neurosurg, Higashiosaka, Osaka, Japan.
   [Matsuda, Ryosuke; Nakamura, Mitsutoshi; Nakagawa, Ichiro; Motoyama, Yasushi; Nakase, Hiroyuki] Nara Med Univ, Kashihara, Nara, Japan.
RP Matsuda, R (reprint author), Nara Med Univ, Kashihara, Nara, Japan.
EM cak93500@pop02.odn.ne.jp
CR Abbasi M, 2019, J CELL PHYSIOL, V234, P10018, DOI 10.1002/jcp.27860
   Harigai M, 2018, MOD RHEUMATOL, V28, P1, DOI 10.1080/14397595.2017.1352477
   Hoshida Y, 2007, J RHEUMATOL, V34, P322
   Kameda H, 2019, MOD RHEUMATOL, V29, P31, DOI 10.1080/14397595.2018.1472358
   Kleinschmidt-DeMasters BK, 2008, J NEUROPATH EXP NEUR, V67, P1103, DOI 10.1097/NEN.0b013e31818beaea
   Matsuda I, 2018, BRIT J HAEMATOL, V180, P628, DOI 10.1111/bjh.14978
   Migita K, 2013, MOD RHEUMATOL, V23, P832, DOI 10.1007/s10165-012-0717-7
   Rizzi R, 2009, MED ONCOL, V26, P1, DOI 10.1007/s12032-008-9069-8
   Shimada Hiromi, 2015, BMC Res Notes, V8, P88, DOI 10.1186/s13104-015-1040-0
   Smolen JS, 2014, ANN RHEUM DIS, V73, P492, DOI 10.1136/annrheumdis-2013-204573
   Weinblatt Michael E, 2013, Trans Am Clin Climatol Assoc, V124, P16
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 138
EP 141
DI 10.1016/j.wneu.2019.06.226
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200164
PM 31295614
DA 2020-05-12
ER

PT J
AU Lovato, RM
   Paiva, ALC
   Pesente, FS
   de Oliveira, JG
   Ferrarez, CE
   Araujo, JLV
   Veiga, JCE
AF Lovato, Renan Maximilian
   Campos Paiva, Aline Lariessy
   Pesente, Francisco Spessatto
   de Oliveira, Jean Goncalves
   Ferrarez, Carlos Eduardo
   Vitorino Araujo, Joao Luiz
   Esteves Veiga, Jose Carlos
TI An Affordable Stereomicroscope for Microsurgery Training with
   Fluorescence Mode
SO WORLD NEUROSURGERY
LA English
DT Article
DE Fluorescein; Fluorescence; ICG; Laboratory; Microsurgical training;
   Microvascular anastomosis; Neurosurgery
ID MICROVASCULAR SURGERY
AB BACKGROUND: Laboratory training is a very important step on the development of the skills necessary for a neurosurgeon. This can be achieved using animal models and surgical microscopes or stereomicroscopes. Methods, like the use of fluorescein, increase the lifelike situation and allow anyone to assess the patency of an anastomosis and improve the quality of this training.
   METHODS: We report the use of a stereomicroscope with white light and a fluorescence mode used to perform dissection of small arteries and anastomosis using a chicken wing model. Using an affordable device, we could perform fluorescein videoangiography to asses the patency of those anastomosis and improve the quality of the training skills in microsurgery.
   RESULTS: The stereomicroscope is a useful tool for laboratory training and can be used as a substitute of a surgical microscope for microsurgery training. The fluorescence mode allowed us to perform fluorescein videoangiography with very a good quality of image.
   CONCLUSIONS: Microsurgery training is important part in the life of any neurosurgeon. Using a stereomicroscope with a fluorescence mode is an affordable method that can be reproduced in any laboratory in the world.
C1 [Lovato, Renan Maximilian; Campos Paiva, Aline Lariessy; de Oliveira, Jean Goncalves; Vitorino Araujo, Joao Luiz; Esteves Veiga, Jose Carlos] Santa Casa Sao Paulo Sch Med Sci FCMSCSP, Div Neurosurg, Dept Surg, Sao Paulo, SP, Brazil.
   [Lovato, Renan Maximilian; Pesente, Francisco Spessatto] Univ Estadual Londrina, Dept Neurosurg, Univ Hosp, Londrina, PR, Brazil.
   [Campos Paiva, Aline Lariessy] HCOR, Sao Paulo, SP, Brazil.
   [de Oliveira, Jean Goncalves] ACCCC, Dept Neurosurg, Sao Paulo, SP, Brazil.
   [Ferrarez, Carlos Eduardo] Hosp Madre Teresa, Dept Neurosurg, Belo Horizonte, MG, Brazil.
   [Vitorino Araujo, Joao Luiz] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil.
   [Vitorino Araujo, Joao Luiz] Hosp Sirio Libanes, Sao Paulo, SP, Brazil.
RP Lovato, RM (reprint author), Santa Casa Sao Paulo Sch Med Sci FCMSCSP, Div Neurosurg, Dept Surg, Sao Paulo, SP, Brazil.; Lovato, RM (reprint author), Univ Estadual Londrina, Dept Neurosurg, Univ Hosp, Londrina, PR, Brazil.
EM renan_lovato@yahoo.com.br
RI de Oliveira, Jean G./H-2896-2012
OI de Oliveira, Jean G./0000-0002-7274-7715
CR Chung SB, 2017, WORLD NEUROSURG, V105, P369, DOI 10.1016/j.wneu.2017.05.174
   Colpan ME, 2008, NEUROSURGERY, V62, P407, DOI 10.1227/01.NEU.0000312345.06054.3e
   Couceiro J, 2015, JOVE-J VIS EXP, DOI 10.3791/52625
   FOX JL, 1974, STROKE, V5, P196, DOI 10.1161/01.STR.5.2.196
   Gasco J, 2014, MALAYS J MED SCI, V21, P1
   Gasco J, 2013, NEUROSURGERY, V73, P39, DOI 10.1227/NEU.0000000000000102
   Gelinas-Phaneuf N, 2013, NEUROSURGERY, V73, P30, DOI 10.1227/NEU.0000000000000115
   Hafez Ahmad, 2017, Surg Neurol Int, V8, P295, DOI 10.4103/sni.sni_322_17
   Higurashi M, 2014, J CLIN NEUROSCI, V21, P554, DOI 10.1016/j.jocn.2013.07.029
   Hino A, 2003, NEUROSURGERY, V52, P1495, DOI 10.1227/01.NEU.0000065174.83840.62
   Kim Byeong Jin, 2013, J Cerebrovasc Endovasc Neurosurg, V15, P20, DOI 10.7461/jcen.2013.15.1.20
   Manton RN, 2017, J PLAST RECONSTR AES, V70, P553, DOI 10.1016/j.bjps.2016.12.016
   Myers SR, 2013, ARCH PLAST SURG-APS, V40, P302, DOI 10.5999/aps.2013.40.4.302
   Narducci A, 2018, ACTA NEUROCHIR, V160, P767, DOI 10.1007/s00701-017-3453-0
   Olabe J, 2009, SURG NEUROL, V72, P695, DOI 10.1016/j.surneu.2008.12.008
   Oliveira MM, 2019, WORLD NEUROSURG, V130, pE112, DOI 10.1016/j.wneu.2019.05.262
   Oliveira MM, 2018, WORLD NEUROSURG, V119, pE694, DOI 10.1016/j.wneu.2018.07.246
   Yasargil MG, 1967, MICROVASCULAR SURG
   Yonekawa Y, 1999, OPERATIVE TECHNIQ NE, V2, P149
NR 19
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 142
EP 145
DI 10.1016/j.wneu.2019.06.199
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200165
PM 31279115
DA 2020-05-12
ER

PT J
AU Sato, H
   Shimokawa, N
   Matsumoto, H
   Takami, T
AF Sato, Hidetoshi
   Shimokawa, Nobuyuki
   Matsumoto, Hiroaki
   Takami, Toshihiro
TI Familial Os Odontoideum: Proatlas Segmentation Abnormality
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dystopic; Familial; Os odontoideum; Posterior fusion; Proatlas
AB BACKGROUND: Os odontoideum is a smooth, independent ossicle separated a from hypoplastic odontoid process located cranially in the expected position of the odontoid tip. The pathogenesis of os odontoideum remains controversial, and several etiological theories have been suggested for congenital, developmental, and traumatic origins.
   CASE DESCRIPTION: We have reported symptomatic familial cases of dystopic os odontoideum in 2 elderly sisters who denied any traumatic history of the head and neck. Both patients were treated surgically, with successful outcomes achieved.
   CONCLUSIONS: When examining the etiology of os odontoideum, checking for the existence of a traumatic history is important. However, a more important matter is to consider morphological segmentation abnormalities of the proatlas. Segmentation abnormalities of the proatlas could be closely connected to the development of familial os odontoideum.
C1 [Sato, Hidetoshi; Shimokawa, Nobuyuki; Matsumoto, Hiroaki] Tsukazaki Hosp, Dept Neurosurg, Himeji, Hyogo, Japan.
   [Takami, Toshihiro] Osaka City Univ, Dept Neurosurg, Grad Sch Med, Osaka, Japan.
RP Sato, H (reprint author), Tsukazaki Hosp, Dept Neurosurg, Himeji, Hyogo, Japan.
EM hidetoshi1028@gmail.com
RI Takami, Toshihiro/AAF-7239-2019
OI Sato, Hidetoshi/0000-0001-9224-5440
CR Arvin B, 2010, NEUROSURGERY, V66, pA22, DOI 10.1227/01.NEU.0000366113.15248.07
   Cunningham D J, 1886, J Anat Physiol, V20, P238
   GAN GULY D. N., 1964, ANAT ANZ, V114, P433
   Gladstone RJ, 1915, J ANAT PHYSIOL, V49, P190
   Jumah F, 2017, CUREUS, V9, DOI 10.7759/cureus.1551
   Kaissi AA, 2009, SKELETAL RADIOL, V38, P293, DOI 10.1007/s00256-008-0623-4
   KIRLEW KA, 1993, SKELETAL RADIOL, V22, P525
   Menezes AH, 2008, CHILD NERV SYST, V24, P1109, DOI 10.1007/s00381-008-0600-1
   MORGAN MK, 1989, J NEUROSURG, V70, P636, DOI 10.3171/jns.1989.70.4.0636
   Nishikawa M, 1997, J NEUROSURG, V86, P40, DOI 10.3171/jns.1997.86.1.0040
   Rozzelle CJ, 2013, NEUROSURGERY, V72, P159, DOI 10.1227/NEU.0b013e318276ee69
   Stevens CA, 2009, AM J MED GENET A, V149A, P1290, DOI 10.1002/ajmg.a.32860
   Straus David, 2014, Surg Neurol Int, V5, P37, DOI 10.4103/2152-7806.129259
   Tang XS, 2018, EUR SPINE J, V27, pS259, DOI 10.1007/s00586-017-5116-5
   Verska JM, 1997, SPINE, V22, P706, DOI 10.1097/00007632-199703150-00026
   Wang Shenglin, 2011, J Bone Joint Surg Am, V93, pe44, DOI 10.2106/JBJS.J.01018
   Wu XH, 2018, J NEUROSURG-SPINE, V28, P131, DOI 10.3171/2017.5.SPINE161211
NR 17
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 146
EP 149
DI 10.1016/j.wneu.2019.07.019
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200166
PM 31295610
DA 2020-05-12
ER

PT J
AU Maki, Y
   Kikuchi, T
   Komatsu, K
   Takagi, Y
   Miyamoto, S
AF Maki, Yoshinori
   Kikuchi, Takayuki
   Komatsu, Katsuya
   Takagi, Yasushi
   Miyamoto, Susumu
TI Rare Case of Concurrent Glossopharyngeal and Trigeminal Neuralgia, in
   Which Glossopharyngeal Neuralgia was Possibly Induced by Postoperative
   Changes Following Microvascular Decompression for Trigeminal Neuralgia
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arachnid membrane; Glossopharyngeal nerve; Glossopharyngeal neuralgia;
   Microvascular decompression; Posterior inferior cerebellar artery;
   Trigeminal neuralgia; Trigeminal nerve
ID HEMIFACIAL SPASM
AB BACKGROUND: Glossopharyngeal neuralgia (GPN) and trigeminal neuralgia (TN) can result from mechanical stimulation of the glossopharyngeal nerve (GPNv) and trigeminal nerve (TNv) by blood vessels. TN can cause severe pain in the orofacial region, whereas GPN manifests as pain in the tongue, throat, tonsil, and ear. Although these 2 neuralgias can occur concurrently, concurrence of recurrent TN and GPN that develops postoperatively has not been previously described.
   CASE DESCRIPTION: A 68-year-old male complained of right glossalgia and pain in the pharynx radiating to the right auricular area. The patient had previously undergone microvascular decompression (MVD) for right TN. Medication and intraoral xylocaine spray did not relieve the symptoms. An oral surgeon was unable to find any disease related to the glossalgia. The anesthesiologist pointed out that the symptoms could be from partial recurrence of the TN because the patient also complained of pain in the inferior alveolus. Magnetic resonance angiography indicated that the right GPNv seemed to be compressed by the right posterior inferior cerebellar artery (PICA); hence, MVD for both GPN and TN was performed. lntraoperatively, the right PICA was found to be adherent to the GPNv because of the thickened arachnoid membrane and was subsequently detached. The TNv was also examined, but only a Teflon ball was found, which was detached from the TNv. The GPN disappeared postoperatively, although TN persisted after the second operation.
   CONCLUSIONS: GPN can result from adhesions between the GPNv and arachnoid membrane following previous MVD.
C1 [Maki, Yoshinori; Kikuchi, Takayuki; Komatsu, Katsuya; Takagi, Yasushi; Miyamoto, Susumu] Kyoto Univ, Grad Sch Med, Dept Neurosurg, Sakyo Ku, Kyoto, Kyoto, Japan.
   [Takagi, Yasushi] Tokushima Univ, Grad Sch, Inst Biomed Sci, Dept Neurosurg, Tokushima, Tokushima, Japan.
   [Komatsu, Katsuya] Sapporo Med Univ, Dept Neurosurg, Chuo Ku, Sapporo, Hokkaido, Japan.
RP Kikuchi, T (reprint author), Kyoto Univ, Grad Sch Med, Dept Neurosurg, Sakyo Ku, Kyoto, Kyoto, Japan.
EM tkik@kuhp.kyoto-u.ac.jp
OI Komatsu, Katsuya/0000-0003-0567-818X
CR GARDNER WJ, 1962, J NEUROSURG, V19, P947, DOI 10.3171/jns.1962.19.11.0947
   Haller S, 2016, AM J NEURORADIOL, V37, P1384, DOI 10.3174/ajnr.A4683
   Katoh Masahito, 2012, No Shinkei Geka, V40, P533
   Khan M, 2017, PAIN RES MANAG, V2017, DOI 10.1155/2017/7438326
   Kobata H, 1998, NEUROSURGERY, V43, P1351, DOI 10.1097/00006123-199812000-00052
   Koopman JSHA, 2009, PAIN, V147, P122, DOI 10.1016/j.pain.2009.08.023
   LAHA RK, 1977, J NEUROSURG, V47, P316, DOI 10.3171/jns.1977.47.3.0316
   Papalexopoulou N, 2014, BRIT J NEUROSURG, P1
   Wang YN, 2014, ACTA NEUROCHIR, V156, P1167, DOI 10.1007/s00701-014-2034-8
   Warren HG, 2006, AM J NEURORADIOL, V27, P705
   YOSHIOKA J, 1985, SURG NEUROL, V24, P416, DOI 10.1016/0090-3019(85)90301-5
NR 11
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 150
EP 153
DI 10.1016/j.wneu.2019.06.216
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200167
PM 31295589
DA 2020-05-12
ER

PT J
AU Yokoyama, K
   Sugie, A
   Yamada, M
   Tanaka, H
   Ito, Y
   Yamashita, M
   Kawanishi, M
AF Yokoyama, Kunio
   Sugie, Akira
   Yamada, Makoto
   Tanaka, Hidekazu
   Ito, Yutaka
   Yamashita, Masashi
   Kawanishi, Masahiro
TI Formation of de Novo Symptomatic Premedullary Arachnoid Cyst in Adult
SO WORLD NEUROSURGERY
LA English
DT Article
DE De novo arachnoid cyst; Retroclival arachnoid cyst; Surgical strategy
AB BACKGROUND: Intracranial de novo arachnoid cysts in adults are rare, suggesting the involvement of head trauma and inflammatory diseases. We report a symptomatic adult case of nontraumatic de novo arachnoid cyst on the ventral medulla oblongata.
   CASE DESCRIPTION: A 56-year-old man came to our hospital complaining of dysphagia and writing difficult since 3 months ago. There was no history of head injury or inflammatory disease. A 25-mm cystic lesion was found on the ventral side of the medulla oblongata on brain magnetic resonance imaging, and the lower cranial nerve and medulla oblongata were highly compressed. The lesion did not exist on magnetic resonance imaging performed 9 years ago. Capsular resection was performed, and the histologic diagnosis was a typical arachnoid cyst. After the operation, all neurologic symptoms disappeared and no recurrence has been observed after 6 months.
   CONCLUSIONS: The pathophysiology of nontraumatic de novo arachnoid cysts has many unknown features, and it appears necessary to accumulate further case reports.
C1 [Yokoyama, Kunio; Sugie, Akira; Yamada, Makoto; Tanaka, Hidekazu; Ito, Yutaka; Yamashita, Masashi; Kawanishi, Masahiro] Takeda Gen Hosp, Dept Neurosurg, Kyoto, Japan.
RP Yokoyama, K (reprint author), Takeda Gen Hosp, Dept Neurosurg, Kyoto, Japan.
EM neu100@osaka-med.ac.jp
CR Al-Holou WN, 2013, J NEUROSURG, V118, P222, DOI 10.3171/2012.10.JNS12548
   Aoki H, 1997, JPN J NEUROSURG, V6, P44
   Brewington D, 2017, WORLD NEUROSURG, V98, DOI 10.1016/j.wneu.2016.11.124
   Clifton W, 2018, WORLD NEUROSURG, V116, P329, DOI 10.1016/j.wneu.2018.05.046
   Gangemi M, 2007, BRIT J NEUROSURG, V21, P276, DOI 10.1080/02688690701339197
   Goel A, 2007, NEUROL INDIA, V55, P388, DOI 10.4103/0028-3886.37097
   Ibrahim GM, 2017, NEUROLOGY, V88, P331, DOI 10.1212/WNL.0000000000003522
   Iglesias-Pais M, 2003, REV NEUROLOGIA, V36, P1149, DOI 10.33588/rn.3612.2003084
   Invergo D, 2012, PEDIATR NEUROSURG, V48, P199, DOI 10.1159/000345636
   Kukreja K, 2007, PEDIATR RADIOL, V37, P556, DOI 10.1007/s00247-007-0463-8
   Nonaka Masahiro, 2019, No Shinkei Geka, V47, P39, DOI 10.11477/mf.1436203894
   Ogiwara H, 2011, J NEUROSURG-PEDIATR, V8, P484, DOI 10.3171/2011.8.PEDS11226
   Sarica C, 2019, WORLD NEUROSURG, V121, pE898, DOI 10.1016/j.wneu.2018.10.006
   Struck AF, 2006, J NEUROSURG, V104, P426, DOI 10.3171/ped.2006.104.6.426
   Yokoyama Kunio, 2018, No Shinkei Geka, V46, P159, DOI 10.11477/mf.1436203693
NR 15
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 154
EP 156
DI 10.1016/j.wneu.2019.07.029
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200168
PM 31301440
DA 2020-05-12
ER

PT J
AU Han, KS
   Lee, KM
   Kim, BJ
   Kwun, BD
   Choi, SK
   Lee, SH
AF Han, Kwang Seok
   Lee, Kyung Mi
   Kim, Bum Joon
   Kwun, Byung Duk
   Choi, Seok Keun
   Lee, Sung Ho
TI Life-Threatening Hemothorax Caused by Spontaneous Extracranial Vertebral
   Aneurysm Rupture in Neurofibromatosis Type 1
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Coil embolization; Hemothorax; Neurofibromatosis; Vertebral
   artery
ID VON RECKLINGHAUSENS DISEASE; PATIENT
AB BACKGROUND: Although vascular abnormality is an uncommon comorbidity of neurofibromatosis type 1 (NF1), it is potentially fatal. We present spontaneous hemothorax caused by rupture of a vertebral artery (VA) aneurysm in a patient with NF1.
   CASE DESCRIPTION: A 36-year-old man with a history of NF1 was transferred to the emergency department with dyspnea. Chest computed tomography scan revealed hemothorax in the left lung field with mediastinal shifting and aneurysmal dilatation of the left VA at the C6 vertebra level. Immediate drainage of the hematoma by chest tube insertion was performed. Diagnostic angiogram showed a 3- to 4-cm fusiform aneurysm of the VA. After the angiogram, cardiopulmonary arrest occurred after a rebleed of the VA aneurysm. The aneurysmal segment of the VA was urgently occluded with detachable coils. Postoperatively, the patient was in intensive care for 1 month because of fulminant pneumonia After the patient regained consciousness, he was found to have right hemiparesis from a small infarction at the pons. The patient's function improved to near normal after 1 year of recovery.
   CONCLUSIONS: Hemothorax caused by VA rupture in a patient with NF1 is an extremely rare condition that can be fatal. Careful examination with suspicion for early detection and treatment is required for this urgent condition. Endovascular coiling was safe even for an unstable patient with massive bleeding.
C1 [Han, Kwang Seok; Kwun, Byung Duk; Choi, Seok Keun] Kyung Hee Univ, Coll Med, Dept Neurosurg, Seoul, South Korea.
   [Lee, Kyung Mi] Kyung Hee Univ, Coll Med, Dept Radiol, Seoul, South Korea.
   [Kim, Bum Joon] Kyung Hee Univ, Coll Med, Dept Neurol, Seoul, South Korea.
   [Lee, Sung Ho] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Neurosurg, Seoul, South Korea.
RP Lee, SH (reprint author), Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Neurosurg, Seoul, South Korea.
EM nooname79@gmail.com
RI Lee, Sung Ho/AAK-9066-2020
OI Lee, Sung Ho/0000-0002-0202-8969
CR [Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007
   Arai K, 2007, CARDIOVASC INTER RAD, V30, P477, DOI 10.1007/s00270-006-0056-1
   Degbelo FDA, 2019, AM J CASE REP, V20, P674, DOI 10.12659/AJCR.915810
   Fohrding LZ, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/s13019-014-0172-y
   Fusco MR, 2011, NEUROSURGERY, V68, P517, DOI 10.1227/NEU.0b013e3181fe2fda
   Jeong SC, 2018, J THORAC DIS, V10, pE203, DOI 10.21037/jtd.2018.01.170
   Misao T, 2012, GEN THORAC CARDIOVAS, V60, P179, DOI 10.1007/s11748-011-0806-0
   Miura H, 1997, THORAX, V52, P577, DOI 10.1136/thx.52.6.577
   Miura T, 2005, GEN THORAC CARDIOVAS, V53, P649, DOI 10.1007/BF02665078
   Miyazaki T, 2011, ANN THORAC CARDIOVAS, V17, P301, DOI 10.5761/atcs.cr.09.01517
   Morasch MD, 2013, ANN VASC SURG, V27, P418, DOI 10.1016/j.avsg.2012.08.002
   Mydin Muhammad Izanee Mohamed, 2015, Asian Cardiovasc Thorac Ann, V23, P573, DOI 10.1177/0218492314522636
   Nenadic D, 2018, EJVES Short Rep, V38, P12, DOI 10.1016/j.ejvssr.2018.01.001
   Nopajaroonsri C, 1996, HUM PATHOL, V27, P982, DOI 10.1016/S0046-8177(96)90229-4
   Oderich GS, 2007, J VASC SURG, V46, P475, DOI 10.1016/j.jvs.2007.03.055
NR 15
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 157
EP 159
DI 10.1016/j.wneu.2019.07.007
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200169
PM 31295587
DA 2020-05-12
ER

PT J
AU Zeng, S
   Yang, HJ
   Yang, DH
   Xu, LS
   Xu, MH
   Wang, H
AF Zeng, Shi
   Yang, Huajiang
   Yang, Donghong
   Xu, LunShan
   Xu, MinHui
   Wang, Hao
TI Case Report of Late Type IIIb Endoleak with Willis Covered Stent (WCS)
   and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Paraclinoid aneurysm; Type IIIb endoleak; Willis covered stent
ID ANEURYSM REPAIR; COMPLICATION; MANAGEMENT; SAC
AB OBJECTIVE: We report a case of late type IIIb endoleak with Willis covered stent (WCS) developed 14 months after endovascular paraclinoid aneurysm repair.
   METHODS: A 52-year-old woman presented with episodic headache, caused by a giant paraclinoid aneurysm. She underwent a successful 3.5 x 16mm WCS positioning to treat the aneurysm. Fourteen months later, the patient was admitted with the same symptoms. Digital subtraction angiography examination showed recurrence of the aneurysm, which was similar to the preoperative one. DynaCT (Siemens, Erlangen, Germany) indicated the intact of the metal structure of the stent without migration. Type IIIb endoleak (defect in the graft fabric) was confirmed with a whole aneurysm neck located in the middle part of the stent. The type IIIb endoleak was treated with another WCS (4.0 x 16mm). The immediate digital subtraction angiography imaging indicated that the endoleak disappeared and the aneurysm was completely occluded. Re-examination done 1 year after the second treatment showed a complete exclusion of the aneurysm sac.
   CONCLUSIONS: Type IIIb endoleaks can be safely treated by the endovascular positioning of another WCS. Continuous surveillance after endovascular paraclinoid aneurysm repair for intracranial aneurysms is warranted to make ensure the safety of WCS.
C1 [Zeng, Shi; Yang, Huajiang; Yang, Donghong; Xu, LunShan; Xu, MinHui; Wang, Hao] Army Med Univ, Daping Hosp, Inst Surg Res, Dept Neurosurg, Chongqing, Peoples R China.
RP Yang, DH (reprint author), Army Med Univ, Daping Hosp, Inst Surg Res, Dept Neurosurg, Chongqing, Peoples R China.
EM yang_donghong18@163.com
CR Baum RA, 2003, J VASC INTERV RADIOL, V14, P1111, DOI 10.1097/01.RVI.0000085773.71254.86
   Bucci F, 2011, G CHIR, V32, P329
   Lai XB, 2013, J CLIN NEUROSCI, V20, P122, DOI 10.1016/j.jocn.2012.01.051
   Li MH, 2008, AM J NEURORADIOL, V29, P1395, DOI 10.3174/ajnr.A1096
   Li MH, 2009, RADIOLOGY, V253, P470, DOI 10.1148/radiol.2532090037
   Liu LX, 2019, WORLD NEUROSURG, V123, pE652, DOI 10.1016/j.wneu.2018.11.245
   Murakami Y, 2018, INT J SURG CASE REP, V49, P215, DOI 10.1016/j.ijscr.2018.06.030
   Park Keun Young, 2016, Neurointervention, V11, P99, DOI 10.5469/neuroint.2016.11.2.99
   Shi WY, 2014, VASCULAR, V22, P432, DOI 10.1177/1708538113519443
   Stavropoulos SW, 2007, RADIOLOGY, V243, P641, DOI 10.1148/radiol.2433051649
   Tan HQ, 2011, CEREBROVASC DIS, V31, P154, DOI 10.1159/000321735
   White GH, 1997, J ENDOVASC SURG, V4, P152, DOI 10.1583/1074-6218(1997)004<0152:EAACOE>2.0.CO;2
   White GH, 1998, J ENDOVASC SURG, V5, P305, DOI 10.1583/1074-6218(1998)005<0305:TIATIE>2.0.CO;2
   Zhang YX, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00639
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 160
EP 164
DI 10.1016/j.wneu.2019.06.105
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200170
PM 31233925
DA 2020-05-12
ER

PT J
AU Liu, XH
   Zhou, J
   Shen, B
   Sun, DZ
   Zhang, ZY
   Li, HL
   Zhang, J
AF Liu, Xianghui
   Zhou, Jun
   Shen, Bin
   Sun, Dezhou
   Zhang, Zhiying
   Li, Honglei
   Zhang, Jian
TI Ossified Chronic Subdural Hematoma and Subsequent Epstein-Barr Virus-
   Positive Large B-Cell Lymphoma: Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE B-cell lymphoma; Chronic subdural hematoma; Epstein-Barr virus
ID CENTRAL-NERVOUS-SYSTEM; MALIGNANT-LYMPHOMA; CHRONIC INFLAMMATION
AB BACKGROUND: Ossified chronic subdural hematoma (CSH) associated with has rarely been reported in the literature. We describe a patient with ossified CSH and underlying large B-cell lymphoma and discuss the relationship between lymphoma and CSH, emphasizing clinical characteristics, tumorigenic mechanism, and histopathologic analysis.
   CASE DESCRIPTION: A 46-year-old man with a history of alcohol abuse and a frontotcmporoparietal and left frontal ossified CSH that was diagnosed 2 years previously presented with headache and memory loss over 6 days. The patient was being followed with serial imaging, which showed the static state of the mass and no other lesions 7 months before admission. He underwent right frontotemporoparietal craniectomy to remove the ossified CSH and tumor. When the bone was lifted and the thin dura was opened, a hard, thick, ossified capsule was observed. No apparent tumor invasion was noted in the skull or epidural space Despite refusing further chemotherapy and radiation therapy, the patient has been disease-free and working for 5 years.
   CONCLUSIONS: Based on reported cases and relevant literature, large B-cell -phoma limy be associated with ossified CSH.
C1 [Liu, Xianghui; Shen, Bin; Sun, Dezhou; Zhang, Zhiying; Zhang, Jian] Dezhou Peoples Hosp, Dept Neurosurg, Dezhou, Peoples R China.
   [Zhou, Jun] Dezhou Peoples Hosp, Dept Neurol, Dezhou, Peoples R China.
   [Li, Honglei] Dezhou Peoples Hosp, Dept Pathol, Dezhou, Peoples R China.
RP Zhang, J (reprint author), Dezhou Peoples Hosp, Dept Neurosurg, Dezhou, Peoples R China.
EM zhangjianceo@126.com
CR AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5
   Alimehmeti R, 2002, SURG NEUROL, V57, P179, DOI 10.1016/S0090-3019(01)00694-2
   [Anonymous], 2015, NCCN GUID NONH LYMPH
   Anuja K, 2017, INFLAMM RES, V66, P119, DOI 10.1007/s00011-016-0985-3
   Bataille B, 2000, J NEUROSURG, V92, P261, DOI 10.3171/jns.2000.92.2.0261
   Boroumand N, 2012, AM J SURG PATHOL, V36, P1074, DOI 10.1097/PAS.0b013e3182515fb5
   Boyer DF, 2017, AM J SURG PATHOL, V41, P299, DOI 10.1097/PAS.0000000000000775
   Cheuk W, 2005, AM J SURG PATHOL, V29, P832, DOI 10.1097/01.pas.0000157747.10967.f4
   Danbara M, 1998, ACTA HAEMATOL-BASEL, V99, P41, DOI 10.1159/000040715
   Gotoh M, 2001, NEUROL SURG TOKYO, V29, P259
   HELLE TL, 1984, J NEUROSURG, V60, P94, DOI 10.3171/jns.1984.60.1.0094
   Kameda K, 2015, PATHOL INT, V65, P138, DOI 10.1111/pin.12242
   Loong F, 2010, MODERN PATHOL, V23, P493, DOI 10.1038/modpathol.2009.168
   MACLEAN JA, 1955, NEUROLOGY, V5, P520, DOI 10.1212/WNL.5.7.520
   REYES MG, 1990, SURG NEUROL, V33, P35, DOI 10.1016/0090-3019(90)90222-B
   Sugita Y, 2012, PATHOL INT, V62, P412, DOI 10.1111/j.1440-1827.2012.02824.x
   Valli R, 2011, INT J SURG PATHOL, V19, P117, DOI 10.1177/1066896910391253
   Villa A, 2015, SCI REP-UK, V5, DOI 10.1038/srep15224
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 165
EP 169
DI 10.1016/j.wneu.2019.07.011
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200171
PM 31299306
DA 2020-05-12
ER

PT J
AU Ren, QQ
   Chen, HX
   Wang, YL
   Xu, JG
AF Ren, Qingqing
   Chen, Hongxu
   Wang, Yuelong
   Xu, Jianguo
TI Melanotic Neuroectodermal Tumor of Infancy Arising in the Skull and
   Brain: A Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Brain; Melanotic neuroectodermal tumor of infancy; Skull
ID HIGH URINARY-EXCRETION; RETINAL ANLAGE TUMOR; OCCIPITAL BONE; PROGONOMA;
   DIAGNOSIS; CT; MEDULLOBLASTOMA; ADAMANTINOMA; CHEMOTHERAPY; SURGERY
AB Melanotic neuroectodermal tumor of infancy (MNTI) is a rare pigmented craniofacial tumor of infants. This study aimed to analyze the literature on MNTI arising from the skull and brain. A systematic literature review was performed and 91 patients reported in 78 articles were identified from 1918 to 2019. MNTI of the skull and brain was slightly more prevalent among boys. The age at diagnosis of patients with intracranial MNTI was mainly >1 year, and most patients with skull MNTI were diagnosed within the first year of life (P< 0.001). MNTI of the skull mostly presented as a rapidly growing mass, whereas intracranial MNTI presented with increasing intracranial pressure and neurologic dysfunction. Surgical resection was the primary treatment, with an average follow-up of 25.6 months. Overall survival was related to age at diagnosis within 1 year (P = 0.001), tumor location (P < 0.001), tumor size (P = 0.010), treatment (P < 0.001), and metastasis (P < 0.001) and malignancy (P < 0.001), whereas recurrence rate was significantly associated with age (P < 0.001), tumor size (P = 0.010), complete surgical resection (P = 0.011), metastasis (P = 0.003), and malignant behavior (P = 0.001).
C1 [Ren, Qingqing; Chen, Hongxu; Wang, Yuelong; Xu, Jianguo] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
RP Xu, JG (reprint author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
EM Jianguo_1229@126.com
CR Al-Otaibi M, 2005, BRAIN PATHOL, V15, P171
   ALLEN MS, 1969, AM J CLIN PATHOL, V51, P309
   ANAGNOSTOPOULOS DI, 1972, J NEUROL NEUROSUR PS, V35, P88, DOI 10.1136/jnnp.35.1.88
   Antunes ACM, 2005, ARQ NEURO-PSIQUIAT, V63, P670, DOI 10.1590/S0004-282X2005000400022
   ASHLEY DJB, 1964, J PATHOL BACTERIOL, V87, P179, DOI 10.1002/path.1700870125
   ATKINSON GO, 1989, PEDIATR RADIOL, V20, P20, DOI 10.1007/BF02010627
   Batta N, 2017, DIAGN CYTOPATHOL, V45, P173, DOI 10.1002/dc.23624
   Bellarbi S, 2013, NEUROCHIRURGIE, V59, P138, DOI 10.1016/j.neuchi.2013.02.007
   BEST PV, 1972, J PATHOL, V107, P69, DOI 10.1002/path.1711070113
   BIGNOLD LP, 1980, PATHOLOGY, V12, P473, DOI 10.3109/00313028009077111
   BORELLO ED, 1966, CANCER-AM CANCER SOC, V19, P196
   Caird J, 2000, BRAIN PATHOL, V10, P317, DOI 10.1111/j.1750-3639.2000.tb00206.x
   CLARKE BE, 1951, CANCER, V4, P78, DOI 10.1002/1097-0142(195101)4:1<78::AID-CNCR2820040107>3.0.CO;2-9
   COHEN BH, 1988, NEUROLOGY, V38, P163, DOI 10.1212/WNL.38.1.163-a
   Pontes FSC, 2018, HEAD NECK-J SCI SPEC, V40, P2749, DOI 10.1002/hed.25514
   DAMMANN O, 1995, CHILD NERV SYST, V11, P186, DOI 10.1007/BF00570263
   Dashti SR, 1999, NEUROSURGERY, V45, P175, DOI 10.1097/00006123-199907000-00042
   DEPASCALIS C, 1977, TUMORI, V63, P373
   Di Rocco F, 2007, EUR J PEDIATR, V166, P739, DOI 10.1007/s00431-006-0297-7
   DOOLING EC, 1977, CANCER, V39, P1535, DOI 10.1002/1097-0142(197704)39:4<1535::AID-CNCR2820390426>3.0.CO;2-0
   Ellison DA, 2007, PEDIATR DEVEL PATHOL, V10, P157, DOI 10.2350/06-07-0138.1
   Foster KA, 2017, PEDIATR NEUROSURG, V52, P36, DOI 10.1159/000445954
   FOWLER M, 1962, J PATHOL BACTERIOL, V84, P307, DOI 10.1002/path.1700840205
   Furtado SV, 2012, J CRANIO MAXILL SURG, V40, pE170, DOI 10.1016/j.jcms.2011.08.010
   GEORGE JC, 1995, AM J NEURORADIOL, V16, P1273
   GILMOR RL, 1972, J NEUROSURG, V36, P507, DOI 10.3171/jns.1972.36.4.0507
   Gorhan C, 2001, NEURORADIOLOGY, V43, P944, DOI 10.1007/s002340100593
   GRAVE GF, 1972, J PEDIATR SURG, V7, P36, DOI 10.1016/0022-3468(72)90399-5
   Hadley C, 2015, J NEUROSURG-PEDIATR, V16, P46, DOI 10.3171/2014.12.PEDS14497
   HAHN JF, 1976, J NEUROPATH EXP NEUR, V35, P508, DOI 10.1097/00005072-197609000-00003
   Haider N, 2003, MED PEDIATR ONCOL, V41, P495, DOI 10.1002/mpo.10371
   Haque S, 2012, PEDIATR RADIOL, V42, P699, DOI 10.1007/s00247-011-2339-1
   HOSHINO S, 1994, J NEUROSURG, V80, P919, DOI 10.3171/jns.1994.80.5.0919
   HUPP JR, 1981, INT J ORAL MAXILLOF, V10, P432, DOI 10.1016/S0300-9785(81)80080-4
   Jeon H, 2008, CHILD NERV SYST, V24, P1489, DOI 10.1007/s00381-008-0671-z
   JOHNSON RE, 1982, MAYO CLIN PROC, V57, P719
   JONES HH, 1990, SKELETAL RADIOL, V19, P527
   KACKER A, 1993, J LARYNGOL OTOL, V107, P843, DOI 10.1017/S0022215100124594
   Kamgarpour A, 2013, PEDIATR NEUROSURG, V49, P254, DOI 10.1159/000363192
   Kantar M, 2008, CHILD NERV SYST, V24, P1371, DOI 10.1007/s00381-008-0664-y
   KAPADIA SB, 1993, AM J SURG PATHOL, V17, P566, DOI 10.1097/00000478-199306000-00004
   Khan MB, 2013, JCPSP-J COLL PHYSICI, V23, P367, DOI 05.2013/JCPSP.367369
   Klingenberg C, 1998, MED PEDIATR ONCOL, V31, P555, DOI 10.1002/(SICI)1096-911X(199812)31:6<555::AID-MPO25>3.0.CO;2-4
   Kocaoglu M, 2015, TURKISH J PEDIATR, V57, P183
   Koral K, 2010, CLIN IMAG, V34, P382, DOI 10.1016/j.clinimag.2009.11.006
   KOUDSTAAL J, 1968, CANCER-AM CANCER SOC, V22, P151, DOI 10.1002/1097-0142(196807)22:1<151::AID-CNCR2820220118>3.0.CO;2-3
   Kruse-Losler B, 2006, ORAL SURG ORAL MED O, V102, P204, DOI 10.1016/j.tripleo.2005.08.010
   Kumari TP, 2005, PEDIATR HEMAT ONCOL, V22, P199, DOI 10.1080/08880010590921450
   Lambropoulos V, 2010, ACTA NEUROCHIR, V152, P869, DOI 10.1007/s00701-009-0472-5
   LAMPING KA, 1985, OPHTHALMOLOGY, V92, P143
   Matsumoto M, 2005, SURG NEUROL, V63, P275, DOI 10.1016/j.surneu.2004.02.032
   MIRICH DR, 1991, AM J NEURORADIOL, V12, P689
   Moreau A, 2018, J CRANIO MAXILL SURG, V46, P201, DOI 10.1016/j.jcms.2017.12.001
   MOSBY EL, 1992, J ORAL MAXIL SURG, V50, P886, DOI 10.1016/0278-2391(92)90285-8
   Naidoo J, 2013, CHILD NERV SYST, V29, P167, DOI 10.1007/s00381-012-1940-4
   NEUSTEIN HB, 1967, EXP MOL PATHOL, V6, P131, DOI 10.1016/0014-4800(67)90011-1
   Neven J, 2008, ORAL SURG ORAL MED O, V106, P493, DOI 10.1016/j.tripleo.2008.02.001
   Nicosia G, 2017, J NEUROSURG-PEDIATR, V19, P538, DOI 10.3171/2016.11.PEDS16509
   Nishio S, 1999, NEURORADIOLOGY, V41, P202, DOI 10.1007/s002340050735
   NITTA T, 1995, J NEUROSURG, V83, P145, DOI 10.3171/jns.1995.83.1.0145
   OGATA A, 1989, ACTA NEUROPATHOL, V77, P654, DOI 10.1007/BF00687894
   Omodaka S, 2010, BRAIN TUMOR PATHOL, V27, P51, DOI 10.1007/s10014-010-0263-y
   Owen B, 2018, PEDIATR DERMATOL, V35, pE389, DOI 10.1111/pde.13601
   PARIZEK J, 1986, NEUROPEDIATRICS, V17, P115, DOI 10.1055/s-2008-1052511
   Patankar T, 1998, J Postgrad Med, V44, P73
   Paueksakon P, 2002, PEDIATR NEUROSURG, V36, P33, DOI 10.1159/000048346
   PETTINATO G, 1991, AM J SURG PATHOL, V15, P233, DOI 10.1097/00000478-199103000-00004
   PIERREKAHN A, 1992, PEDIATR NEUROSURG, V18, P6, DOI 10.1159/000120636
   Rachidi S, 2015, J ORAL MAXIL SURG, V73, P1946, DOI 10.1016/j.joms.2015.03.061
   Raila FA, 1997, J NEUROIMAGING, V7, P123, DOI 10.1111/jon199772123
   Rege JD, 1999, DIAGN CYTOPATHOL, V21, P280, DOI 10.1002/(SICI)1097-0339(199910)21:4<280::AID-DC10>3.0.CO;2-2
   Retna Kumari N, 2007, J Indian Soc Pedod Prev Dent, V25, P148
   REYES HA, 1964, J PEDIATR-US, V64, P268, DOI 10.1016/S0022-3476(64)80271-7
   Rickert CH, 1998, CHILD NERV SYST, V14, P389, DOI 10.1007/s003810050251
   RUBINSTEIN LJ, 1964, BRAIN, V87, P379, DOI 10.1093/brain/87.2.379
   Saleem S, 2010, PEDIATR RADIOL, V40, P159, DOI 10.1007/s00247-010-1747-y
   Sharma M C, 1996, J Assoc Physicians India, V44, P278
   Shuangshoti S, 2006, BRAIN PATHOL, V16, P333, DOI 10.1111/j.1750-3639.2006.00023_1.x
   Soles BS, 2018, ARCH PATHOL LAB MED, V142, P1358, DOI 10.5858/arpa.2018-0241-RA
   STIRLING RW, 1988, HISTOPATHOLOGY, V12, P425, DOI 10.1111/j.1365-2559.1988.tb01957.x
   STOWENS D, 1974, HUM PATHOL, V5, P105, DOI 10.1016/S0046-8177(74)80104-8
   SUNG JH, 1973, J NEUROPATH EXP NEUR, V32, P437, DOI 10.1097/00005072-197307000-00008
   Suzuki C, 2007, J NEURORADIOLOGY, V34, P212, DOI 10.1016/j.neurad.2007.04.006
   Tan AP, 2018, NEURORADIOL J, V31, P434, DOI 10.1177/1971400917741770
   Tandon PN, 2011, CONTEMP CLIN DENT, V2, P337, DOI 10.4103/0976-237X.91799
   WALSH JW, 1982, CHILD BRAIN, V9, P329
   Yoo IH, 2014, J PEDIAT HEMATOL ONC, V36, pE61, DOI 10.1097/MPH.0b013e31829dd114
   YU JS, 1992, SURG NEUROL, V37, P123, DOI 10.1016/0090-3019(92)90188-S
   Zhang JG, 2015, J CHILD NEUROL, V30, P631, DOI 10.1177/0883073813494477
   Zur KE., 1918, BEITR PATHOL ANAT AL, V64, P165
NR 90
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 170
EP 178
DI 10.1016/j.wneu.2019.07.017
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200172
PM 31295620
DA 2020-05-12
ER

PT J
AU Yang, JS
   Wang, XF
   Zhao, K
   Liu, P
   Liu, TJ
   Chen, CM
   Hao, DJ
   Chu, L
AF Yang, Jun-Song
   Wang, Xiang-Fu
   Zhao, Kai
   Liu, Peng
   Liu, Tuan-Jiang
   Chen, Chien-Min
   Hao, Ding-Jun
   Chu, Lei
TI Posterior Unlocking of Facet Joints Under Endoscopy Followed by Anterior
   Decompression, Reduction, and Fixation of Old Subaxial Cervical Facet
   Dislocations: A Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cervical fusion; Endoscope; Lower cervical spine; Old facet
   dislocations
ID SPINE; MANAGEMENT; INJURIES; DISC
AB OBJECTIVE: Besides the facet joints interlocking, the fibrous tissue or bony callus around the dislocated segments make the reduction for this kind of old injury to be more challenging and different from that of acute injuries. This study is aimed to present 4 cases of old subaxial cervical facet dislocations (SCFD) that were successfully treated with posterior unlocking under endoscopy followed by anterior decompression, reduction, and fixation.
   METHODS: Between January 2017 and December 2017, 4 dents with old SCFD who underwent posterior unlocking of facet joints under endoscopy followed by anterior decompression, reduction, and fixation were enrolled. A cervical collar was prescribed for 4 weeks postoperatively. Postoperative follow-up evaluations were conducted at 2, 6, and 12 months, including neck visual analogue scale score and neck disability index, radiography, and computed tomography.
   RESULTS: The operative time averaged 145 minutes (range, 130-155 minutes). No deterioration of neural function, major vessel rupture, or iatrogenic injury to esophagus occurred. Intraoperative blood loss averaged 45 mL (range, 40-50 mL). Hospital stay for all patients was only 4 days. The neck visual analogue scale score and neck disability index were improved at the final follow-up, and interbody fusion was satisfactory without any radiologic sign of instability or internal failure.
   CONCLUSIONS: For patients with old SCFD, the unlocking of facet joints via the posterior approach under endoscopy followed by anterior decompression, reduction, and fixation is an alternative technique.
C1 [Yang, Jun-Song; Liu, Peng; Liu, Tuan-Jiang; Hao, Ding-Jun] Xi An Jiao Tong Univ, Honghui Hosp, Dept Spine Surg, Xian, Shaanxi, Peoples R China.
   [Zhao, Kai; Chu, Lei] Xi An Jiao Tong Univ, Honghui Hosp, Dept Foot & Ankle Surg, Xian, Shaanxi, Peoples R China.
   [Wang, Xiang-Fu] Gansu Prov Hosp Tradit Chinese Med, Dept Spinal Minimally Invas Surg, Lanzhou, Gansu, Peoples R China.
   [Chen, Chien-Min] Changhua Christian Hosp, Dept Neurosurg, Changhua, Taiwan.
   [Chen, Chien-Min] Kaohsiung Med Univ, Sch Med, Kaohsiung, Taiwan.
   [Chen, Chien-Min] Dayeh Univ, Coll Nursing & Hlth Sci, Changhua, Taiwan.
RP Hao, DJ (reprint author), Xi An Jiao Tong Univ, Honghui Hosp, Dept Spine Surg, Xian, Shaanxi, Peoples R China.
EM dingjun.hao@qq.com
OI liu, peng/0000-0003-3453-2278
FU Chinese National Natural Science FoundationNational Natural Science
   Foundation of China [81830077]
FX The authors thank the Chinese National Natural Science Foundation (no.
   81830077 for Ding-Jun Hao) for providing the grant.
CR Allred CD, 2001, SPINE, V26, P1927, DOI 10.1097/00007632-200109010-00021
   Bartels RHMA, 2002, J NEUROSURG, V97, P362, DOI 10.3171/spi.2002.97.3.0362
   BEDBROOK GM, 1979, J BONE JOINT SURG BR, V61, P267
   BUCHOLZ RD, 1989, J NEUROSURG, V70, P884, DOI 10.3171/jns.1989.70.6.0884
   DAVIS JW, 1993, J TRAUMA, V34, P342, DOI 10.1097/00005373-199303000-00006
   Ding C, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008809
   DORR LD, 1982, SPINE, V7, P545, DOI 10.1097/00007632-198211000-00006
   Farooque K, 2015, TRAUMA MON, V20, DOI 10.5812/traumamon.18385
   Gelb DE, 2013, NEUROSURGERY, V72, P73, DOI 10.1227/NEU.0b013e318276ee02
   Hassan MG, 2002, INT ORTHOP, V26, P263, DOI 10.1007/s00264-002-0350-8
   Jain AK, 2010, J BONE JOINT SURG BR, V92B, P246, DOI 10.1302/0301-620X.92B2.22963
   Kim M, 2018, BIOMED RES INT, DOI 10.1155/2018/9073460
   Liu P, 2008, SPINE, V33, P1459, DOI 10.1097/BRS.0b013e318175c2fb
   Nakashima H, 2011, EUR SPINE J, V20, P387, DOI 10.1007/s00586-010-1589-1
   Park JH, 2015, J NEUROSURG-SPINE, V23, P35, DOI 10.3171/2014.11.SPINE14805
   Payer M, 2007, J CLIN NEUROSCI, V14, P782, DOI 10.1016/j.jocn.2006.04.021
   Theodotou CB, 2019, NEUROSURGERY, V84, P388, DOI 10.1093/neuros/nyy032
   Wang M, 2016, EUR SPINE J, V25, P2302, DOI 10.1007/s00586-016-4524-2
   Yang JS, 2019, WORLD NEUROSURG, V122, pE1472, DOI 10.1016/j.wneu.2018.11.087
   Yang JS, 2014, SPINE, V39, P1743, DOI 10.1097/BRS.0000000000000508
   Yang SC, 2014, EUR SPINE J, V23, P846, DOI 10.1007/s00586-013-3157-y
   Yu KX, 2019, CLIN SPINE SURG, V32, P10, DOI 10.1097/BSD.0000000000000680
   Zhang ZF, 2016, SPINE, V41, pE403, DOI 10.1097/BRS.0000000000001260
   Zheng CK, 2018, WORLD NEUROSURG, V120, pE63, DOI 10.1016/j.wneu.2018.07.141
NR 24
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 179
EP 186
DI 10.1016/j.wneu.2019.06.239
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200173
PM 31299305
DA 2020-05-12
ER

PT J
AU Oishi, T
   Sameshima, T
   Totsuka, T
   Yamasaki, T
   Koizumi, S
   Namba, H
AF Oishi, Tomoya
   Sameshima, Tetsuro
   Totsuka, Takeaki
   Yamasaki, Tomohiro
   Koizumi, Shinichiro
   Namba, Hiroki
TI Cosmetic and Neuroprotective Placement of Custom-Made
   Ultra-High-Molecular Weight Polyethylene Cranial Plate (SKULPIO) in
   Single-Step Surgery: Technical Note and Case Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cranioplasty; Custom-made cranial plate; Meningioma; Single-step surgery
ID CRANIOPLASTY; MENINGIOMAS; DESIGN
AB BACKGROUND: Cranioplasty is a common procedure in neurosurgery. However, cosmetic and neuroprotective reconstructions are necessary after cranioplasty. Treatment of patients with a meningioma with bone infiltration requires removal of the tumor-infiltrated bone and subsequent cranioplasty. We report an efficient technique for cosmetic and neuroprotective reconstructions using a custom-made ultra-high-molecular-weight polyethylene cranial plate (SKULPIO, Kyocera Medical, Kyoto, Japan) in a single-step surgery involving tumor removal and skull reconstruction.
   METHODS: We present 2 illustrative cases of a 49-year-old female with a right frontal convexity meningioma and 69-year-old male with a bilateral parasagittal atypical meningioma, both involving extensive skull invasion. We preoperatively planned craniotomy size to facilitate the removal of the tumor-infiltrated skull bone using the patients' 3-dimensional cranial models followed by the construction of a custom-made cranial plate. After tumor removal, we drilled out the outer table and the diploe of the cranial edge until the custom-made bone plate accurately fit the bone defect. Finally, the cranial plate was fixed using titanium plates and screws.
   RESULTS: Postoperative magnetic resonance imaging for each case revealed total meningioma removal and an aesthetically reconstructed skull. Using this technique, precise adjustment of the cranial edge to the plate contributes to a gapless and aesthetic reconstruction. Furthermore, the intact inner table of the skull firmly supports the custom-made bone plate.
   CONCLUSIONS: This technique involving the placement of a custom-made cranial plate during a single-step surgery was found to be efficient for cosmetic and neuroprotective reconstructions.
C1 [Oishi, Tomoya; Sameshima, Tetsuro; Totsuka, Takeaki; Yamasaki, Tomohiro; Koizumi, Shinichiro; Namba, Hiroki] Hamamatsu Univ, Sch Med, Dept Neurosurg, Hamamatsu, Shizuoka, Japan.
RP Sameshima, T (reprint author), Hamamatsu Univ, Sch Med, Dept Neurosurg, Hamamatsu, Shizuoka, Japan.
EM tetsurosameshima@gmail.com
CR Bloch O, 2011, CAN J NEUROL SCI, V38, P59, DOI 10.1017/S0317167100011082
   Bonda DJ, 2015, NEUROSURGERY, V77, P814, DOI 10.1227/NEU.0000000000000899
   Broeckx CE, 2017, WORLD NEUROSURG, V108, P225, DOI 10.1016/j.wneu.2017.08.177
   Cabraja M, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS091
   Fathi AR, 2008, J CRANIOFAC SURG, V19, P777, DOI 10.1097/SCS.0b013e31816b1b2a
   Guerrini F, 2017, WORLD NEUROSURG, V107, DOI 10.1016/j.wneu.2017.08.111
   Mohammad K, 2019, TURK NEUROSURG, V29, P148, DOI 10.5137/1019-5149.JTN.19895-17.1
   Mukherjee S, 2014, ACTA NEUROCHIR, V156, P989, DOI 10.1007/s00701-014-2024-x
   Nout E, 2018, ORAL MAXILLOFAC SURG, V22, P65, DOI 10.1007/s10006-017-0668-4
   Oya S, 2012, J NEUROSURG, V117, P121, DOI 10.3171/2012.3.JNS111945
   Velnar T, 2011, RADIOL ONCOL, V45, P304, DOI 10.2478/v10019-011-0036-1
   Zanotti B, 2016, J CRANIOFAC SURG, V27, P2061, DOI 10.1097/SCS.0000000000003025
NR 12
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 187
EP 191
DI 10.1016/j.wneu.2019.07.026
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200174
PM 31299307
DA 2020-05-12
ER

PT J
AU Silva, NA
   Vaz, HHS
   Ribeiro, AF
   Sule, H
   Sifri, ZC
   Nanda, A
   Sknoes, ELJ
AF Silva, Nicole A.
   Silva Vaz, Herison Harrider
   Ribeiro, Adriele Feitosa
   Sule, Harsh
   Sifri, Ziad C.
   Nanda, Anil
   Jennings Sknoes, Erik Leonardo
TI Neurosurgery in the Brazilian Amazon: Is It Possible?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brazilian neurosurgery; Global health; Global neurosurgery; Global
   surgery; Low to middle income countries; Public health; Sustainable
   development goals
ID GLOBAL HEALTH; SURGERY
AB BACKGROUND: The need for neurosurgical care across the globe remains a public health issue. The creation of sustainable neurological surgery departments and training programs will be indispensable in alleviating the burden of neurological disease in low to middle income countries (LMICs).
   METHODS: We reviewed the history of the neurological surgery department and residency program of Santarem in the state of Para, Brazil, from 1999 to the present. We have described the epidemiology unique to the region and provided evidence of a sustainable practice in a LMIC. The challenges, limitations, and resources were explored.
   RESULTS: We have provided a historical vignette of the evolution of neurological surgery in the Brazilian Amazon, including the creation of a sustainable neurological surgery practice and accredited residency program. In addition, we assessed the neurological surgery burden and epidemiology unique to the region, with an emphasis on the community and indigenous health in this remote area. We also explored the future directions of this example, which could affect the international neurological surgery community.
   CONCLUSION: A sustainable neurosurgery practice and training program is possible in a LMIC. Training neurosurgeons in developing regions of LMICs is a sustainable method to decrease the morbidity and mortality of neurological diseases and prevent the misdistribution of physicians in a country. We encourage adaptation of sustainable neurological surgery practices in similar regions across the world to increase access to necessary neurosurgical care.
C1 [Silva, Nicole A.; Nanda, Anil] Rutgers New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07103 USA.
   [Sule, Harsh] Rutgers New Jersey Med Sch, Dept Emergency Med, Newark, NJ 07103 USA.
   [Sifri, Ziad C.] Rutgers New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA.
   [Silva, Nicole A.; Sule, Harsh; Sifri, Ziad C.] Rutgers New Jersey Med Sch, Off Global Hlth, Newark, NJ 07103 USA.
   [Silva Vaz, Herison Harrider; Ribeiro, Adriele Feitosa; Jennings Sknoes, Erik Leonardo] State Univ Para, Dept Neurol Surg, Santarem, Brazil.
RP Sknoes, ELJ (reprint author), State Univ Para, Dept Neurol Surg, Santarem, Brazil.
EM erik@paju.net.br
CR Andrews RJ, 2016, WORLD NEUROSURG, V85, P22, DOI 10.1016/j.wneu.2015.08.002
   Barthelemy EJ, 2018, WORLD NEUROSURG, V120, P143, DOI 10.1016/j.wneu.2018.08.070
   Corley JA, 2016, NEUROSURGERY, V79, pE544, DOI 10.1227/NEU.0000000000001351
   Dewan MC, 2019, J NEUROSURG, V130, P1098, DOI 10.3171/2017.10.JNS17347
   Dewan MC, 2019, J NEUROSURG, V130, P1080, DOI 10.3171/2017.10.JNS17352
   Dewan MC, 2019, J NEUROSURG, V130, P1055, DOI 10.3171/2017.11.JNS171500
   Farmer PE, 2008, WORLD J SURG, V32, P533, DOI 10.1007/s00268-008-9525-9
   Hsiao M, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002621
   Hughes JD, 2018, WORLD NEUROSURG, V115, P430, DOI 10.1016/j.wneu.2018.03.220
   Meara JG, 2015, SURGERY, V157, P834, DOI 10.1016/j.surg.2015.02.009
   Meara JG, 2014, LANCET, V383, P12, DOI 10.1016/S0140-6736(13)62345-4
   Park KB, 2016, WORLD NEUROSURG, V88, P32, DOI 10.1016/j.wneu.2015.12.048
   Punchak M, 2018, WORLD NEUROSURG, V112, pE240, DOI 10.1016/j.wneu.2018.01.029
   Rocque BG, 2014, NEUROL RES, V36, P903, DOI 10.1179/1743132814Y.0000000379
   de Almeida CER, 2016, WORLD NEUROSURG, V87, P540, DOI 10.1016/j.wneu.2015.10.020
   Rubiano AM, 2019, WORLD NEUROSURG, V125, pE82, DOI 10.1016/j.wneu.2019.01.005
   Rudolfson N, 2019, J NEUROSURG, V130, P1149, DOI 10.3171/2017.12.JNS17281
   Starke RM, 2015, J NEUROSURG, V122, P237, DOI 10.3171/2014.9.JNS142171
   Teixeira MJ, 2014, ARQ NEURO-PSIQUIAT, V72, P251, DOI 10.1590/0004-282X20130245
NR 19
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 192
EP 200
DI 10.1016/j.wneu.2019.07.015
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200175
PM 31295601
DA 2020-05-12
ER

PT J
AU Zanaty, M
   Roa, JA
   Dandapat, S
   Samaniego, EA
   Jabbour, P
   Hasan, D
AF Zanaty, Mario
   Roa, Jorge A.
   Dandapat, Sudeepta
   Samaniego, Edgar A.
   Jabbour, Pascal
   Hasan, David
TI Diverse Use of the WEB Device: A Technical Note on WEB Stenting and WEB
   Coiling of Complex Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Coiling; Embolization; Flow-diversion; Intracranial aneurysm; Stenting;
   WEB device; Wide-neck
ID ENDOVASCULAR TREATMENT; FLOW-DISRUPTION
AB The Woven EndoBridge (WEB) device, an intrasaccular flow-diverter that does not require long-term antiplatelet use, has recently emerged as an alternative to embolize complex intracranial aneurysms; however, there are limitations to the WEB device. First, it does not immediately secure the aneurysm in most subarachnoid hemorrhage cases. Second, it may not be suitable for embolization of wide-neck aneurysms with an unfavorable aspect ratio. To overcome these limitations, we have used the WEB device in conjunction with stenting and/or coiling. Here, we present a technical note with an illustrated case series and provide a detailed step-by-step description on how the WEB device can be used in adjunct to coiling and/or stenting to achieve successful angiographic results. Accurate sizing of the WEB device before deployment is critical. Larger case series are required to further assess the safety and success of these combined techniques.
C1 [Zanaty, Mario; Samaniego, Edgar A.; Hasan, David] Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.
   [Roa, Jorge A.] Univ Iowa Hosp & Clin, Dept Neurol & Neurosurg, Iowa City, IA 52242 USA.
   [Dandapat, Sudeepta; Samaniego, Edgar A.] Univ Iowa Hosp & Clin, Dept Neurol, Iowa City, IA 52242 USA.
   [Dandapat, Sudeepta] Univ Iowa Hosp & Clin, Dept Neurol Neurosurg & Radiol, Iowa City, IA 52242 USA.
   [Samaniego, Edgar A.] Univ Iowa Hosp & Clin, Dept Radiol, Iowa City, IA 52242 USA.
   [Jabbour, Pascal] Thomas Jefferson Univ Hosp, Dept Neurol Surg, Philadelphia, PA 19107 USA.
RP Hasan, D (reprint author), Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.
EM david-hasan@uiowa.edu
OI Roa, Jorge/0000-0003-4987-8853; Dandapat, Sudeepta/0000-0003-3744-7845
CR Cagnazzo Federico, 2019, J Neuroradiol, DOI 10.1016/j.neurad.2019.03.011
   Caroff J, 2014, NEURORADIOLOGY, V56, P755, DOI 10.1007/s00234-014-1390-7
   Chalouhi N, 2016, NEUROSURGERY, V78, P670, DOI 10.1227/NEU.0000000000001071
   Cognard C, 2011, NEUROSURGERY, V69, P837, DOI 10.1227/NEU.0b013e3182257b30
   Hudson JS, 2019, NEUROSURGERY, V84, P479, DOI 10.1093/neuros/nyy127
   Hudson JS, 2018, J NEUROSURG, V129, P916, DOI 10.3171/2017.5.JNS17642
   Lawson A, 2018, J NEUROSURG, V128, P144, DOI 10.3171/2016.9.JNS152849
   Leyon JJ, 2016, J NEUROINTERV SURG, V8, DOI 10.1136/neurintsurg-2015-011649.rep
   Lubicz B, 2014, AM J NEURORADIOL, V35, P432, DOI 10.3174/ajnr.A3869
   Mihalea C, 2019, J NEUROINTERV SURG, V11, P386, DOI 10.1136/neurintsurg-2018-014104
   Nagahama Y, 2018, J NEUROSURG, V129, P702, DOI 10.3171/2017.5.JNS17831
   Papagiannaki C, 2014, AM J NEURORADIOL, V35, P2106, DOI 10.3174/ajnr.A4028
   Pierot L, 2012, AM J NEURORADIOL, V33, P1232, DOI 10.3174/ajnr.A3191
   Pierot L, 2012, AM J NEURORADIOL, V33, P469, DOI 10.3174/ajnr.A2771
   Pierot L, 2008, STROKE, V39, P2497, DOI 10.1161/STROKEAHA.107.512756
   Pierot L, 2018, J NEUROINTERV SURG, V10, P553, DOI 10.1136/neurintsurg-2017-013448
   Pierot L, 2013, STROKE, V44, P2046, DOI 10.1161/STROKEAHA.113.000733
   Pierot L, 2013, NEUROSURGERY, V73, P27, DOI 10.1227/01.neu.0000429860.04276.c1
   Samaniego EA, 2019, STROKE VASC NEUROL, V4, P36, DOI 10.1136/svn-2018-000192
NR 19
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 201
EP 205
DI 10.1016/j.wneu.2019.07.027
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200176
PM 31301439
DA 2020-05-12
ER

PT J
AU Gupta, S
   Mehrotra, A
   Attri, G
   Pal, L
   Jaiswal, AK
   Kumar, R
AF Gupta, Shruti
   Mehrotra, Anant
   Attri, Gagandeep
   Pal, Lily
   Jaiswal, Awadhesh Kumar
   Kumar, Raj
TI Isolated Intraventricular Chronic Mucormycosis in an Immunocompetent
   Infant: A Rare Case with Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Immunocompetent; Intraventricular; Mucormycosis
ID ISOLATED CEREBRAL MUCORMYCOSIS; INTRACRANIAL MUCORMYCOSIS
AB BACKGROUND: Mucormycosis of the central nervous system is an uncommon infection caused by saprophytic or parasitic fungi of the subphylum Mucormycotina and order Mucorales viz. Rhizopus, Mucor, and Rhizomucoz Isolated, chronic involvement of the central nervous system is a rare occurrence. To the best of our knowledge, isolated chronic ventricular involvement in an infant has not been reported previously. Isolated intracerebral mucormycosis is a disease of the immunocompromised patient, and to date only 6 cases have been reported in immunocompetent patients, including 2 pediatric cases.
   CASE DESCRIPTION: We present the case of an immunocompetent infant presenting with features of increased intracranial tension. He underwent cerebrospinal fluid diversion and was found to harbor mucormycosis on histopathologic examination of intraventricular debris. We also present a brief review of the relevant literature.
   CONCLUSIONS: Although mucormycosis is an acute fulminant infection, chronic isolated cerebral cases are known in the immunocompetent patient. Patients also may present with isolated hydrocephalus, and hence fungal infection must be ruled out in all, especially if a shunt is warranted.
C1 [Gupta, Shruti; Mehrotra, Anant; Attri, Gagandeep; Jaiswal, Awadhesh Kumar; Kumar, Raj] Sanjay Gandhi Postgrad Inst Med Sci, Dept Neurosurg, Lucknow, Uttar Pradesh, India.
   [Pal, Lily] Sanjay Gandhi Postgrad Inst Med Sci, Dept Pathol, Lucknow, Uttar Pradesh, India.
RP Mehrotra, A (reprint author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Neurosurg, Lucknow, Uttar Pradesh, India.
EM dranantmehrotra@gmail.com
CR Air Ellen L, 2010, Surg Neurol Int, V1, P81, DOI 10.4103/2152-7806.73800
   Al Barbarawi MM, 2014, PEDIATR NEUROSURG, V50, P165, DOI 10.1159/000381750
   BICHILE L, 1985, J NEUROL NEUROSUR PS, V48, P1188, DOI 10.1136/jnnp.48.11.1188
   Dhakar MB, 2015, AM J MED, V128, P1296, DOI 10.1016/j.amjmed.2015.08.033
   GINSBERG F, 1987, AM J NEURORADIOL, V8, P558
   Han SR, 2007, J KOREAN NEUROSURG S, V42, P400, DOI 10.3340/jkns.2007.42.5.400
   Herrera DA, 2009, SKULL BASE-INTERD AP, V19, P117, DOI 10.1055/s-0028-1096209
   Kulendra K, 2010, J LARYNGOL OTOL, V124, P1314, DOI 10.1017/S0022215110000678
   Ma JJ, 2015, J GLOB INFECT DIS, V7, P143, DOI 10.4103/0974-777X.170497
   Malik Athar N, 2014, Clin Neurol Neurosurg, V124, P102, DOI 10.1016/j.clineuro.2014.06.022
   Rumboldt Z, 2002, AM J NEURORADIOL, V23, P932
   Tsung Lilian L. Y., 2010, Hong Kong Medical Journal, V16, P137
   Verma A, 2006, J NEUROL SCI, V240, P65, DOI 10.1016/j.jns.2005.09.010
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 206
EP 210
DI 10.1016/j.wneu.2019.06.190
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200177
PM 31279104
DA 2020-05-12
ER

PT J
AU Deora, H
   Das, KK
   Jaiswal, S
   Jaiswal, AK
   Behari, S
AF Deora, Harsh
   Das, Kuntal Kanti
   Jaiswal, Sushila
   Jaiswal, Awadesh K.
   Behari, Sanjay
TI Meningioma in a Postrenal Transplant Case: More than Meets the Eye
SO WORLD NEUROSURGERY
LA English
DT Article
DE Calcineurin inhibitors; Dural lesion; Meningioma; MRI; Renal transplant
AB BACKGROUND: Patients with a renal transplant are an ever-increasing demographic. Their life expectancy is also on the rise and thus malignancies or tumors in these cases are more frequent. These patients are often on immunosuppressive drugs that are known to cause changes in the microvasculature, especially of the deep white matter. However, benign dural-based lesions are a rarity in these cases with very few (<5) ever being reported. Imaging findings in such cases are altered, which leads to an altered set of differential diagnosis.
   CASE DESCRIPTION: We present a case of a right parasagittal lesion in case of postrenal transplant with imaging findings suggestive of an inflammatory lesion. The lesion was excised and histopathology was that of a fibrous meningioma. Pathological basis of altered imaging is discussed and potential causes elaborated along with a thorough review of similar cases and their findings.
   CONCLUSIONS: Renal transplants and long-term survival are now a reality; calcineurin inhibitors are a staple for these cases. The drugs alter imaging findings and hence cases need to be carefully evaluated with a host of differential diagnosis. Knowledge of these changes is now necessary for these new spectra of cases.
C1 [Deora, Harsh] Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neurosurg, Bangalore, Karnataka, India.
   [Das, Kuntal Kanti; Jaiswal, Awadesh K.; Behari, Sanjay] Sanjay Gandhi Postgrad Inst Med Sci, Lucknow, Uttar Pradesh, India.
   [Jaiswal, Sushila] Sanjay Gandhi Postgrad Inst Med Sci, Dept Pathol, Lucknow, Uttar Pradesh, India.
RP Das, KK (reprint author), Sanjay Gandhi Postgrad Inst Med Sci, Lucknow, Uttar Pradesh, India.
EM kkdas@sgpgi.ac.in
RI DEORA, HARSH/A-5817-2019
OI DEORA, HARSH/0000-0003-3247-1117
CR Besenski N, 2005, AM J NEURORADIOL, V26, P2282
   Das KK, 2017, WORLD NEUROSURG, V104, P248, DOI 10.1016/j.wneu.2017.04.159
   Deora H, 2018, J NEUROSCI RURAL PRA, V9, P258, DOI 10.4103/jnrp.jnrp_469_17
   Kute V B, 2013, Indian J Nephrol, V23, P393, DOI 10.4103/0971-4065.116338
   Patel U, 2019, SAUDI J KIDNEY DIS T, V28, P28921
   Rossetto A, 2015, TRANSPL P, V47, P2116, DOI 10.1016/j.transproceed.2015.01.029
   Srinivas D, 2019, NEUROL INDIA, V67, P142, DOI 10.4103/0028-3886.253609
   Zevgaridis D, 2009, ACTA NEUROCHIR, V151, P1705, DOI 10.1007/s00701-009-0307-4
NR 8
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 211
EP 215
DI 10.1016/j.wneu.2019.07.056
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200178
PM 31302277
DA 2020-05-12
ER

PT J
AU Vinnakota, A
   Wright, JM
   Tomei, KL
AF Vinnakota, Anirudh
   Wright, James M.
   Tomei, Krystal L.
TI A Precursor to Multiloculated Hydrocephalus: Case Report and Review of
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Endoscopic fenestration; Hydrocephalus; Multiloculated
ID VENTRICLES; FENESTRATION; CRANIOTOMY
AB BACKGROUND: Multiloculated hydrocephalus (MH) is a challenging pathology for pediatric neurosurgeons, arising from various etiologies including intraventricular hemorrhage, infection, and overshunting. Although previous publications have discussed the potential etiology of this pathological process, including fibroglial webbing, no clear precursor has been proven. We present a case of MH developing after both intraventricular hemorrhage and intraventricular infection, with visualization of the precursor via endoscopy and a confirmed glial scar on pathological examination.
   CASE DESCRIPTION: Our patient is an preterm-born (at 24 weeks of gestation) male with a grade III intraventricular hemorrhage treated with reservoir placement and serial taps. He did not develop posthemorrhagic hydrocephalus but presented back at approximately 4 months of age with Escherichia coli meningitis that necessitated multiple interventions for intraventricular abscesses, including an endoscopic exploration. He ultimately developed MH requiring placement of a ventriculoperitoneal shunt.
   CONCLUSIONS: MH is a complex pathology with multiple risk factors. To only theories regarding the etiology have been proposed. Our case represents the first known direct visualization of intraventricular fibroglial webbing with magnetic resonance imaging correlation. Improved understanding of the pathophysiology of this entity may improve our ability to treat this pathology before loculations develop.
C1 [Vinnakota, Anirudh; Wright, James M.; Tomei, Krystal L.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH 44106 USA.
   [Tomei, Krystal L.] Rainbow Babies & Childrens Hosp, Dept Neurosurg, 2101 Adelbert Rd, Cleveland, OH 44106 USA.
RP Tomei, KL (reprint author), Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH 44106 USA.; Tomei, KL (reprint author), Rainbow Babies & Childrens Hosp, Dept Neurosurg, 2101 Adelbert Rd, Cleveland, OH 44106 USA.
EM krystal.tomei@uhhospitals.org
CR ELLER TW, 1985, J NEUROSURG, V62, P357, DOI 10.3171/jns.1985.62.3.0357
   Gabriel C, 1996, PHYS MED BIOL, V41, P2231, DOI 10.1088/0031-9155/41/11/001
   Gabriel S, 1996, PHYS MED BIOL, V41, P2251, DOI 10.1088/0031-9155/41/11/002
   HANDLER LC, 1978, NEURORADIOLOGY, V16, P31, DOI 10.1007/BF00395195
   Jamjoom AB, 1996, ACTA NEUROCHIR, V138, P714, DOI 10.1007/BF01411477
   KALSBECK JE, 1980, J NEUROSURG, V52, P547, DOI 10.3171/jns.1980.52.4.0547
   Keen WW, 1908, SURG ITS PRINCIPLES, V3
   NIDA TY, 1993, J NEUROSURG, V78, P70, DOI 10.3171/jns.1993.78.1.0070
   Oi SZ, 2004, NEUROSURG CLIN N AM, V15, P77, DOI 10.1016/S1042-3680(03)00072-X
   Pastel DA, 2009, J NEUROS-PEDIATR, V4, P81, DOI 10.3171/2008.5.17681
   Sandberg DI, 2005, NEUROSURGERY, V57, P100, DOI 10.1227/01.NEU.0000163489.75279.8C
   SCHULTZ P, 1973, J NEUROSURG, V38, P620, DOI 10.3171/jns.1973.38.5.0620
   Stucht D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133921
   Valenzuela S, 1999, CHILD NERV SYST, V15, P457, DOI 10.1007/s003810050439
   Wood R, 2012, CADTH Technol Overv, V2, pe2201
NR 15
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 216
EP 221
DI 10.1016/j.wneu.2019.07.051
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200179
PM 31302268
DA 2020-05-12
ER

PT J
AU Hironaka, K
   Tateyama, K
   Tsukiyama, A
   Adachi, K
   Morita, A
AF Hironaka, Kohei
   Tateyama, Kojiro
   Tsukiyama, Atsushi
   Adachi, Koji
   Morita, Akio
TI Hydrocephalus Secondary to Intradural Extramedullary Malignant Melanoma
   of Spinal Cord
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hydrocephalus; Intradural extramedullary spinal tumor; Malignant
   melanoma; Peritoneal metastasis; Ventriculoperitoneal shunt
ID CENTRAL-NERVOUS-SYSTEM
AB BACKGROUND: Hydrocephalus secondary to spinal cord tumors is rare.
   CASE DESCRIPTION: We present a 39-year-old male with gradual-onset headache whose initial diagnosis was cerebral aneurysm and communicating hydrocephalus. The correct diagnosis was primary intradural extramedullary malignant melanoma of the spinal cord. Initial brain magnetic resonance imaging demonstrated slight dilation of cerebral ventricles and a 3-mm unruptured anterior communicating artery aneurysm. He was placed under observation therapy. Two months later he was seen again due to severe headache. There was no intracranial hemorrhage on brain computed tomography scans. As we suspected rupture of the aneurysm, we operated on him for surgical clipping; however, there was no aneurysmal rupture. We found no lesions responsible for hydrocephalus, so we placed a ventriculoperitoneal shunt. His headache subsequently resolved. Nine months later he developed gait disturbance; a large volume of ascites was observed. Gadolinium-enhanced lumbar magnetic resonance imaging revealed an intradural extramedullary mass at the L-1 to S-5 level. Cytology and immunohistochemistry of the cerebrospinal fluid and ascites identified a few atypical cells positive for HMB-45, S-100 protein, and Melan-A. Whole-body examinations detected no primary lesions outside the central nervous system. Our final diagnosis was primary intradural extramedullary malignant melanoma of the spinal cord with cerebrospinal fluid dissemination.
   CONCLUSIONS: Our findings indicate that communicating hydrocephalus may be due to primary malignant melanoma of the spinal cord.
C1 [Hironaka, Kohei; Tateyama, Kojiro; Adachi, Koji] Nippon Med Sch Masashi Kosugi Hosp, Dept Neurol Surg, Kawasaki, Kanagawa, Japan.
   [Tsukiyama, Atsushi; Morita, Akio] Nippon Med Coll Hosp, Kawasaki, Kanagawa, Japan.
RP Hironaka, K (reprint author), Nippon Med Sch Masashi Kosugi Hosp, Dept Neurol Surg, Kawasaki, Kanagawa, Japan.
EM s9080@nms.ac.jp
RI Hironaka, Kohei/J-2723-2016
OI Hironaka, Kohei/0000-0003-1412-6037
CR Celli P, 2001, J Neurosurg Sci, V45, P235
   Fujimori K, 2018, NEUROSURG REV, V41, P333, DOI 10.1007/s10143-017-0914-0
   GATTUSO P, 1995, DIAGN CYTOPATHOL, V13, P257, DOI 10.1002/dc.2840130314
   HAYWARD RD, 1976, J NEUROL NEUROSUR PS, V39, P526, DOI 10.1136/jnnp.39.6.526
   Hering K, 2016, CASE REP ONCOL MED, DOI 10.1155/2016/3815280
   Horikoshi M, 2000, J JPN SOC CLIN CYTOL, V39, P359
   Iga Takahito, 2018, Spinal Cord Ser Cases, V4, P24, DOI 10.1038/s41394-018-0063-x
   Jeong Dong Hwan, 2013, Brain Tumor Res Treat, V1, P116, DOI 10.14791/btrt.2013.1.2.116
   Kanatas AN, 2007, BRIT J NEUROSURG, V21, P39, DOI 10.1080/02688690701242235
   Kawanabe Yoshifumi, 2014, NMC Case Rep J, V1, P24, DOI 10.2176/nmccrj.2013-0337
   Kim MS, 2010, J KOREAN NEUROSURG S, V48, P157, DOI 10.3340/jkns.2010.48.2.157
   Lee CH, 2010, SPINE, V35, pE303, DOI 10.1097/BRS.0b013e3181ccb1b3
   Liu Q-Y, 2015, Spinal Cord Ser Cases, V1, P15003, DOI 10.1038/scsandc.2015.3
   Mallick S, 2015, J CANCER RES THER, V11, DOI 10.4103/0973-1482.151416
   Matsuno A, 1992, No To Shinkei, V44, P935
   Mirone G, 2011, CHILD NERV SYST, V27, P1741, DOI 10.1007/s00381-011-1543-5
   Omar AT, 2018, WORLD NEUROSURG, V120, P583, DOI 10.1016/j.wneu.2018.09.002
   TANAKA Y, 1985, Neurologia Medico-Chirurgica, V25, P1029, DOI 10.2176/nmc.25.1029
   Tosaka M, 2001, J NEUROSURG, V94, P528, DOI 10.3171/jns.2001.94.3.0528
   Wang YB, 2016, SPINE J, V16, pE59, DOI 10.1016/j.spinee.2015.09.036
   Wu L, 2017, J NEURO-ONCOL, V135, P513, DOI 10.1007/s11060-017-2593-7
   Zhang MZ, 2018, WORLD NEUROSURG, V114, P408, DOI 10.1016/j.wneu.2018.03.169
NR 22
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 222
EP 226
DI 10.1016/j.wneu.2019.07.046
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200180
PM 31302270
DA 2020-05-12
ER

PT J
AU Kotsugi, M
   Nakagawa, I
   Takamura, Y
   Wada, T
   Kichikawa, K
   Nakase, H
AF Kotsugi, Masashi
   Nakagawa, Ichiro
   Takamura, Yoshiaki
   Wada, Takeshi
   Kichikawa, Kimihiko
   Nakase, Hiroyuki
TI Transarterial Embolization of Dural Arteriovenous Fistula in Superior
   Sagittal Sinus Under Bilateral External Carotid Artery Flow Control:
   Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Balloon; Fistula; Liquid embolic material
ID ENDOVASCULAR TREATMENT
AB BACKGROUND: Transarterial embolization (TAE) using liquid embolic material is a standard treatment for non-sinus-type dural arteriovenous fistula (DAVF). However, to reach embolic material over a shunt point for complete obliteration of DAVF is often difficult. We present a technical case report of the efficacy of bilateral external carotid artery (ECA) flow control for the TAE of superior sagittal sinus DAVF.
   CASE DESCRIPTION: A 64-year-old man presented with dizziness and left hemiparesis. Computed tomography imaging showed right parietal subcortical hemorrhage, and cerebral angiography revealed a DAVF in the superior sagittal sinus fed by bilateral occipital artery, bilateral superficial temporal artery and bilateral middle meningeal artery (MMA), with cortical venous reflux and without connection to the superior sagittal sinus. We therefore planned TAE using glue via MMA under bilateral ECA flow control. A 7-Fr balloon guide catheter was positioned in the bilateral ECA origins, and a microcatheter was introduced distal to the MMA. Heated 20% n-butyl-2-cyanoacrylate was slowly injected via the left MMA under bilateral ECA origin flow control. The n-butyl-2-cyanoacrylate reached the shunt point and obliterated the shunt in a single session. The patient was discharged without neurological symptoms.
   CONCLUSIONS: Bilateral ECA flow control using balloon guide catheter is safe and effective for a DAVF in the superior sagittal sinus with multiple and tortuous scalp feeders.
C1 [Kotsugi, Masashi; Nakagawa, Ichiro; Takamura, Yoshiaki; Nakase, Hiroyuki] Nara Med Univ, Dept Neurosurg, Nara, Japan.
   [Wada, Takeshi; Kichikawa, Kimihiko] Nara Med Univ, Dept Radiol, Nara, Japan.
RP Nakagawa, I (reprint author), Nara Med Univ, Dept Neurosurg, Nara, Japan.
EM nakagawa@naramed-u.ac.jp
CR Andreou A, 2008, NEURORADIOLOGY, V50, P267, DOI 10.1007/s00234-007-0322-1
   Baum Griffin R, 2016, Surg Neurol Int, V7, pS223, DOI 10.4103/2152-7806.179577
   Cognard C, 2008, AM J NEURORADIOL, V29, P235, DOI 10.3174/ajnr.A0817
   Fukai J, 2001, SURG NEUROL, V55, P353, DOI 10.1016/S0090-3019(01)00469-4
   Geibprasert S, 2009, AM J NEURORADIOL, V30, P1459, DOI 10.3174/ajnr.A1500
   Guo F, 2018, WORLD NEUROSURG, V116, pE203, DOI 10.1016/j.wneu.2018.04.163
   HALBACH VV, 1988, AM J NEURORADIOL, V9, P337
   Hiramatsu M, 2014, NEUROL MED-CHIR, V54, P63, DOI 10.2176/nmc.st.2013-0172
   Hou K, 2019, WORLD NEUROSURG, V122, P133, DOI 10.1016/j.wneu.2018.10.145
   Kiyosue H, 2013, AM J NEURORADIOL, V34, P1612, DOI 10.3174/ajnr.A3428
   Lin Ning, 2015, J Neurointerv Surg, V7, pe24, DOI 10.1136/neurintsurg-2014-011256.rep
   Nakamura M, 1997, Interv Neuroradiol, V3 Suppl 2, P97
   Nelson PK, 2003, J NEUROSURG, V98, P498, DOI 10.3171/jns.2003.98.3.0498
   Ohnishi H, 2017, NEUROL MED-CHIR, V57, P44, DOI 10.2176/nmc.tn.2016-0144
   Piske RL, 2005, AM J NEURORADIOL, V26, P1715
   Shi ZS, 2013, J NEUROINTERV SURG, V5, P311, DOI 10.1136/neurintsurg-2012-010303
   Song WZ, 2017, NEUROLOGIST, V22, P186, DOI 10.1097/NRL.0000000000000137
   Tao YH, 2016, NEUROSCIENCES, V21, P158, DOI 10.17712/nsj.2016.2.20150331
   van Dijk JMC, 2002, STROKE, V33, P1233, DOI 10.1161/01.STR.0000014772.02908.44
   Yamauchi S, 2014, INTERV NEURORADIOL, V20, P91, DOI 10.15274/INR-2014-10013
   Ye M, 2018, WORLD NEUROSURG, V115, pE761, DOI 10.1016/j.wneu.2018.04.171
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 227
EP 230
DI 10.1016/j.wneu.2019.07.012
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200181
PM 31295596
DA 2020-05-12
ER

PT J
AU Basil, GW
   Kolcun, JPG
   Wang, MY
AF Basil, Gregory W.
   Kolcun, John Paul G.
   Wang, Michael Y.
TI Modularized Implant Assembly for Spinal Fusion-Means for Managing
   Adjacent Level Disease: Technical Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adjacent segment disease; Minimally invasive spine surgery; Modularized
   spine surgery; Revision surgery
ID SEGMENT DEGENERATION; ARTIFICIAL DISC; FOLLOW-UP; LUMBAR
AB BACKGROUND: The occurrence of adjacent-level disease in spinal fusion is a complex and contentious issue. Through the years, surgeons have developed various approaches to address this problem. While some have avoided fusion altogether, others have advocated for large, multilevel fusion constructs. With the advent of minimally invasive spine surgery, there are now novel approaches to the spine which allow for less onerous and morbid revision surgeries. In this paper, we present the case of a woman who previously underwent a posterior cervical fusion and presented with adjacent-level disease.
   CASE DESCRIPTION: A 63-year-old female who had previously undergone a cervical 5 to thoracic 1 posterior instrumented fusion presented with axial neck pain, hand numbness, and imbalance. Imaging demonstrated adjacent-level disease with anterolisthesis of cervical 4 on cervical 5. Rather than exposing her entire fusion construct, we used a new technique to link her old hardware to new instrumentation.
   CONCLUSIONS: We believe that our case is demonstrative of a new, modularized approach to spinal fusion and suggest a way forward in the treatment of adjacent-level disease.
C1 [Basil, Gregory W.; Kolcun, John Paul G.; Wang, Michael Y.] Univ Miami, Dept Neurol Surg, Miami, FL 33136 USA.
RP Basil, GW (reprint author), Univ Miami, Dept Neurol Surg, Miami, FL 33136 USA.
EM gregory.basil@jhsmiami.org
CR Chang PY, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.2.FocusVid.1694
   David T, 2007, SPINE, V32, P661, DOI 10.1097/01.brs.0000257554.67505.45
   Davis RJ, 2015, J NEUROSURG-SPINE, V22, P15, DOI 10.3171/2014.7.SPINE13953
   Foley KT, 2003, SPINE, V28, pS26, DOI 10.1097/00007632-200308011-00006
   Goffin J, 2002, NEUROSURGERY, V51, P840, DOI 10.1227/01.NEU.0000026100.14273.B3
   Harrop JS, 2008, SPINE, V33, P1701, DOI 10.1097/BRS.0b013e31817bb956
   Helgeson MD, 2013, SPINE J, V13, P342, DOI 10.1016/j.spinee.2012.12.009
   Hilibrand Alan S, 2004, Spine J, V4, p190S, DOI 10.1016/j.spinee.2004.07.007
   Hilibrand AS, 1999, J BONE JOINT SURG AM, V81A, P519, DOI 10.2106/00004623-199904000-00009
   Hoy D, 2014, ANN RHEUM DIS, V73, P968, DOI 10.1136/annrheumdis-2013-204428
   Kolcun JPG, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2018.12.FOCUS18701
   Ozgur Burak M, 2006, Spine J, V6, P435, DOI 10.1016/j.spinee.2005.08.012
   Park P, 2004, SPINE, V29, P1938, DOI 10.1097/01.brs.0000137069.88904.03
NR 13
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 231
EP 234
DI 10.1016/j.wneu.2019.07.028
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200182
PM 31301444
DA 2020-05-12
ER

PT J
AU Li, ZF
   Lv, ZR
   Li, JM
AF Li, Zhenfeng
   Lv, Zhaorui
   Li, Jianmin
TI Total En Bloc Spondylectomy for the Fifth Lumbar Solitary Metastasis by
   a Posterior-Only Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE Fifth lumbar; Posterior-only approach; Solitary metastasis; Total en
   bloc spondylectomy
ID SURGICAL-TECHNIQUES; VASCULAR ANATOMY; SCORING SYSTEM; SPINAL TUMORS;
   RECONSTRUCTION; RESECTION
AB BACKGROUND: Relatively few cases of total en bloc spondylectomy (TES) for L5 tumors have been reported. TES in the lower lumbar region is usually performed through a combined anterior and posterior approach. TES for L5 tumors by a posterior-only approach is technically challenging.
   CASE DESCRIPTION: A 62-year-old woman with persistent pain in her lumbosacral area and lower extremities and numbness of her lateral left lower extremity for 2 months came to our department. She had undergone radical mastectomy 4 years earlier. X-ray and magnetic resonance imaging (MRI) showed that the tumor had destroyed the vertebral body of L5. No other lesions were revealed by emission computed tomography (ECT) or positron emission tomography/computed tomography (PET/CT). With a diagnosis of breast cancer and a solitary metastasis to L5, the patient was treated with posterior-only TES of the L5 tumor and reconstruction The whole procedure took 10 hours, and her intraoperative blood loss was 9000 mL. The lumbar and leg pain of the patient disappeared postoperatively without serious complications. She started walking 4 weeks after surgery and resumed her daily life. New multiple metastases developed 6 months after surgery, with no sign of local recurrence. Despite active treatment, she died 18 months after surgery.
   CONCLUSION: TES of the L5 tumor can be achieved by a posterior-only approach, with good results and limited complications.
C1 [Li, Zhenfeng; Lv, Zhaorui; Li, Jianmin] Shandong Univ, Qilu Hosp, Dept Orthoped, Jinan, Shandong, Peoples R China.
   [Lv, Zhaorui] Shandong Univ, Cheeloo Coll Med, Jinan, Shandong, Peoples R China.
RP Li, JM (reprint author), Shandong Univ, Qilu Hosp, Dept Orthoped, Jinan, Shandong, Peoples R China.
EM qilubonetumor@foxmail.com
CR Abe E, 2001, J SPINAL DISORD, V14, P237, DOI 10.1097/00002517-200106000-00009
   Abe E, 2000, SPINAL CORD, V38, P146, DOI 10.1038/sj.sc.3100968
   Barrey C, 2013, WORLD NEUROSURG, V79, P784, DOI 10.1016/j.wneu.2012.03.019
   Boriani Stefano, 2018, J Spine Surg, V4, P668, DOI 10.21037/jss.2018.09.02
   Dai T, 2019, J BONE ONCOL, V14, DOI 10.1016/j.jbo.2018.10.003
   Detwiler P W, 1999, Neurosurg Focus, V7, pe3
   Gallia GL, 2007, J NEUROSURG-SPINE, V7, P103, DOI 10.3171/SPI-07/07/103
   Heary RF, 1998, SURG NEUROL, V50, P548, DOI 10.1016/S0090-3019(98)00078-0
   Kawahara N, 1996, SPINE, V21, P1401, DOI 10.1097/00007632-199606150-00001
   Kawahara N, 2011, SPINE, V36, P74, DOI 10.1097/BRS.0b013e3181cded6c
   Kawahara N, 2009, ORTHOP CLIN N AM, V40, P47, DOI 10.1016/j.ocl.2008.09.004
   Laufer I, 2013, J NEUROSURG-SPINE, V18, P207, DOI 10.3171/2012.11.SPINE12111
   Marmor E, 2001, J NEUROSURG, V95, P264, DOI 10.3171/spi.2001.95.2.0264
   Mesfin A, 2015, ORTHOPEDICS, V38, pE995, DOI 10.3928/01477447-20151020-08
   Shimada Y, 2007, SPINE J, V7, P499, DOI 10.1016/j.spinee.2006.01.016
   Tokuhashi Y, 2014, WORLD J ORTHOP, V5, P262, DOI 10.5312/wjo.v5.i3.262
   Tokuhashi Y, 2009, SPINE, V34, P69, DOI 10.1097/BRS.0b013e3181913f19
   Tomita K, 2006, J ORTHOP SCI, V11, P3, DOI 10.1007/s00776-005-0964-y
   Wenger M, 2006, ACTA ORTHOP, V77, P825, DOI 10.1080/17453670610013060
   Yamazaki T, 2009, SPINE, V34, pS31, DOI 10.1097/BRS.0b013e3181b8b796
   Yang XH, 2019, SPINE, V44, P896, DOI 10.1097/BRS.0000000000003003
   Zhang YD, 2018, CLIN ORTHOP RELAT R, V476, P490, DOI 10.1007/s11999.0000000000000053
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 235
EP 239
DI 10.1016/j.wneu.2019.07.054
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200183
PM 31302271
DA 2020-05-12
ER

PT J
AU Gurjar, HK
   Mishra, S
   Garg, K
AF Gurjar, Hitesh Kumar
   Mishra, Shashwat
   Garg, Kanwaljeet
TI Incipient Transcalvarial Cerebral Herniation: Underrecognized
   Complication of Elective Craniotomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adult; latrogenic; Incipient; Transcalvarial herniation
ID GROWING SKULL FRACTURE
AB BACKGROUND: Herniation of the brain through an osseodural defect has been well described in small children as an uncommon occurrence after closed head injury. Pressure from the growing brain has been implicated in progressive enlargement and reshaping of the fracture line. An analogous phenomenon in adults has been observed in the described cases where neurosurgical intervention led to a persistent dural defect. Transcalvarial herniation of the brain through the dural defect resulted in characteristic neurologic and imaging findings producing symptoms disproportionately greater than expected from the extent of the affected brain, accompanied by enlargement of the underlying ventricle and elevation of the bone flap. Disruption of the axonal conduction due to distortion of the axons in the herniated brain is probably responsible for these observations.
   CASE DESCRIPTION: A series of 3 cases is described. In all cases, the dural reconstitution at the conclusion of surgery was incomplete. Brain herniation was evident in the postoperative scan. The transcalvarial herniation of the brain was precipitated by either a seizure and resultant brain swelling or persistently raised intracranial tension from a tumor residual. In 2 cases, surgical reexploration resulted in improvement in the neurologic symptoms.
   CONCLUSIONS: In symptomatic patients with transcalvarial herniation of the brain, identified on imaging, the neurologic syndrome is quite characteristic. Recognition of this condition and prompt treatment lead to lasting neurologic improvement.
C1 [Gurjar, Hitesh Kumar; Mishra, Shashwat; Garg, Kanwaljeet] All India Inst Med Sci, Dept Neurosurg, New Delhi, India.
RP Mishra, S (reprint author), All India Inst Med Sci, Dept Neurosurg, New Delhi, India.
EM smishra@aiims.edu
OI MISHRA, SHASHWAT/0000-0003-4227-0562
CR ITO H, 1977, CHILD BRAIN, V3, P116
   Kutlay M, 1998, NEUROSURGERY, V43, P72, DOI 10.1097/00006123-199807000-00045
   Leung GKK, 2011, J CLIN NEUROSCI, V18, P855, DOI 10.1016/j.jocn.2010.09.020
   Li XG, 2013, J CLIN NEUROSCI, V20, P509, DOI 10.1016/j.jocn.2012.04.019
   MUHONEN MG, 1995, SURG NEUROL, V43, P367, DOI 10.1016/0090-3019(95)80066-P
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 240
EP 243
DI 10.1016/j.wneu.2019.07.009
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200184
PM 31295622
DA 2020-05-12
ER

PT J
AU Fiorenza, V
   Ascanio, F
AF Fiorenza, Vito
   Ascanio, Francesco
TI Percutaneous Endoscopic Transforaminal Outside-In Outside Technique for
   Foraminal and Extraforaminal Lumbar Disc Herniations-Operative Technique
SO WORLD NEUROSURGERY
LA English
DT Article
DE Extraforaminal lumbar disc herniation; Foraminal lumbar disc herniation;
   Lumbar spine; Minimally invasive spine surgery; Percutaneous endoscopic
   lumbar discectomy
ID SURGICAL TECHNIQUE; NERVE ROOTS; DISKECTOMY; PAIN; CLASSIFICATION;
   COMPLICATIONS; SURGERY; L5-S1
AB BACKGROUND: Different transforaminal endoscopic r eroaches have been developed for the surgical treatment of lumbar disc herniation: Kambin (intradiscal), Yeung (intraforaminal intradiscal), Ruetten (extreme lateral), transforaminal endoscopic surgical system (intraforaminal extradiscal) approach, and modifications. The operative technique for the treatment of foraminal and extraforaminal lumbar disc herniation through these surgical approaches has not been well described in reported studies. Moreover, each of these surgical approaches has limitations in the removal of migrated intra- or extraforaminal disc herniation. We have described, step by step, the operative technique of a modified percutaneous endoscopic transforaminal approach we have termed the "percutaneous endoscopic intra- and extraforaminal extradiscal approach or transforaminal outside-in outside [TOIO] approach" for the treatment of foraminal and extraforaminal lumbar disc herniation.
   METHODS: From 2012 to 2018, 48 patients had undergone the percutaneous endoscopic TOIO approach for symptomatic foraminal and extraforaminal lumbar disc herniation. The inclusion criteria were the same as the microdiscectomy criteria. The exclusion criteria included patients with severe foraminal stenosis and disc degeneration, listhesis, and scoliosis. The pre- and postoperative clinical data, radiographic findings, and surgical technique were investigated.
   RESULTS: No intraoperative complications developed. the patients showed progressive improvement of initial neurological deficits with complete recovery of motor weakness and L4, L5 hypoesthesia at 1 month postoperatively. One patient experienced persistent postoperative dysesthesia on the affected leg for similar to 1 month.
   CONCLUSION: The percutaneous endoscopic TOIO approach is a minimally invasive, safe, and efficacious surgical procedure for the treatment of lumbar foraminal and extraforaminal disc herniation. Proper patient selection is mandatory to ensure a satisfactory outcome.
C1 [Fiorenza, Vito; Ascanio, Francesco] ARNAS Civ Cristina Benfratelli Hosp, Dept Neurosurg, Palermo, Italy.
RP Fiorenza, V (reprint author), ARNAS Civ Cristina Benfratelli Hosp, Dept Neurosurg, Palermo, Italy.
EM vito.fiorenza1@gmail.com
OI Fiorenza, Vito/0000-0002-0981-4639
CR Akdemir G, 2010, J NEUROSURG-SPINE, V13, P351, DOI 10.3171/2010.3.SPINE09799
   Choi G, 2007, SPINE, V32, pE93, DOI 10.1097/01.brs.0000252093.31632.54
   Chun EH, 2016, KOREAN J PAIN, V29, P57, DOI 10.3344/kjp.2016.29.1.57
   Doi T, 2011, J ORTHOP SURG RES, V26, P6
   Ebraheim NA, 1997, CLIN ORTHOP RELAT R, P230
   Gambardella G, 2005, ACT NEUR S, V92, P151
   Gerszten PC, 2000, NEUROSURGERY, V46, P1478, DOI 10.1097/00006123-200006000-00033
   Gu X, 2013, CLIN ANAT, V26, P728, DOI 10.1002/ca.22286
   Jang JS, 2006, J SPINAL DISORD TECH, V19, P338, DOI 10.1097/01.bsd.0000204500.14719.2e
   Kambin P, 1996, J NEUROSURG, V84, P462, DOI 10.3171/jns.1996.84.3.0462
   Kambin P, 1998, CLIN ORTHOP RELAT R, P150
   KAMBIN P, 1983, CLIN ORTHOP RELAT R, P127
   Lee S, 2007, EUR SPINE J, V16, P431, DOI 10.1007/s00586-006-0219-4
   Lee S, 2010, AM J ROENTGENOL, V194, P1095, DOI 10.2214/AJR.09.2772
   Lew SM, 2001, J NEUROSURG, V94, P216, DOI 10.3171/spi.2001.94.2.0216
   Lewandrowski KU, 2014, INT J SPINE SURG, V8, DOI 10.14444/1026
   Lubbers T, 2012, ACTA NEUROCHIR, V154, P1789, DOI 10.1007/s00701-012-1432-z
   Ma L, 2016, INT J CLIN EXP MED, V9, P5023
   MAYER HM, 1993, J NEUROSURG, V78, P216, DOI 10.3171/jns.1993.78.2.0216
   NEIDRE A, 1983, SPINE, V8, P294, DOI 10.1097/00007632-198304000-00010
   O'Toole JE, 2007, SPINE J, V7, P414, DOI 10.1016/j.spinee.2006.07.008
   Pfirrmann CWA, 2001, SPINE, V26, P1873, DOI 10.1097/00007632-200109010-00011
   Ruetten S, 2005, SPINE, V30, P2570, DOI 10.1097/01.brs.0000186327.21435.cc
   Shaikh S, 2003, CAN J ANAESTH, V50, P514, DOI 10.1007/BF03021067
   STRIFFELER H, 1991, ACTA NEUROCHIR, V112, P62, DOI 10.1007/BF01402455
   Swartz Karin R, 2003, Neurosurg Focus, V15, pE10, DOI 10.3171/foc.2003.15.3.10
   Vogelsang JP, 1999, EUR SPINE J, V8, P475, DOI 10.1007/s005860050208
   Yeung A T, 1999, Surg Technol Int, V8, P267
   Yeung AT, 2002, SPINE, V27, P722, DOI 10.1097/00007632-200204010-00009
NR 29
TC 3
Z9 3
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 244
EP 253
DI 10.1016/j.wneu.2019.07.005
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200185
PM 31299304
DA 2020-05-12
ER

PT J
AU Gao, P
   Li, XY
   Li, GL
AF Gao, Peng
   Li, Xiaoyu
   Li, Guilin
TI Retrograde Cannulation of the Draining Vein for Embolization of Filum
   Terminale Arteriovenous Fistula in the Lower Sacral Region
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous fistula; Draining vein; Filum terminale; Hybrid treatment;
   Lower sacral region; Retrograde cannulation
ID DIAGNOSIS
AB BACKGROUND: Filum terminale arteriovenous fistulae (FTAVFs) are rare entities. For those with the fistulous point located in the lower sacral region (below S2), neither surgical nor endovascular strategies are the optimal treatment.
   CASE DESCRIPTION: We describe 2 FTAVF cases with the fistulous point below S2: one had the anterior spinal artery (ASA) as a single feeder with a long distance to the fistula and the other developed an inaccessible feeder after the initial non-ASA feeder embolization. In a hybrid operating room, through an L4 laminectomy, we surgically exposed and cannulated the cephalad draining vein, other than the feeding arteries, to retrograde occlude the proximal draining vein along with the fistulous point and feeders using Onyx. All shunt points were obliterated with the help of intraoperative digital subtraction angiography.
   CONCLUSIONS: Retrograde embolization of the draining vein to obliterate FTAVFs in the lower sacral region is feasible and complete. This technique may provide a new treatment option for FTAVFs.
C1 [Gao, Peng] Capital Med Univ, Xuanwu Hosp, Dept Intervent Neuroradiol, Beijing, Peoples R China.
   [Li, Xiaoyu; Li, Guilin] Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Li, GL (reprint author), Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM lgl723@sina.com
CR Chanthanaphak E, 2013, J NEUROSURG-SPINE, V19, P49, DOI 10.3171/2013.4.SPINE12685
   DJINDJIAN M, 1977, SURG NEUROL, V8, P85
   Fischer S, 2013, CLIN NEURORADIOL, V23, P309, DOI 10.1007/s00062-012-0188-4
   Giordan E, 2018, J NEUROINTERV SURG, V10, P191, DOI 10.1136/neurintsurg-2017-013309
   Haddad S, 2012, J NEURORADIOLOGY, V39, P368, DOI 10.1016/j.neurad.2012.05.004
   Hong T, 2017, AM J NEURORADIOL, V38, P403, DOI 10.3174/ajnr.A5001
   Kim DJ, 2010, AM J NEURORADIOL, V31, P1512, DOI 10.3174/ajnr.A2109
   Lim SM, 2011, AM J NEURORADIOL, V32, P1846, DOI 10.3174/ajnr.A2612
   Macht S, 2012, NEURORADIOLOGY, V54, P517, DOI 10.1007/s00234-011-0899-2
   Mitra AP, 2006, J NEUROSURG-SPINE, V5, P447
   Saito Hisayasu, 2011, No Shinkei Geka, V39, P375
   Wajima D, 2017, INTERV NEURORADIOL, V23, P221, DOI 10.1177/1591019916687716
   Witiw CD, 2011, NEUROSURGERY, V69, pE780, DOI 10.1227/NEU.0b013e31821bc64c
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 254
EP 258
DI 10.1016/j.wneu.2019.06.236
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200186
PM 31299309
DA 2020-05-12
ER

PT J
AU Esquenazi, Y
   Zeineddine, HA
   Reimer, E
   Stackowicz, D
   Demian, N
AF Esquenazi, Yoshua
   Zeineddine, Hussein A.
   Reimer, Eric
   Stackowicz, Daniel
   Demian, Nagi
TI Intracranial Approach for Retrieval of the Condylar Head After Avulsion
   into the Middle Cranial Fossa
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intracranial approach; Mandibular condylar fracture; Middle cranial
   fossa; Trauma
ID INTACT MANDIBULAR CONDYLE; TRAUMATIC DISLOCATION; RECONSTRUCTION;
   ANKYLOSIS
AB BACKGROUND: Dislocation of the mandibular condyle into the middle cranial fossa is a rare injury that can be seen after facial trauma. Early identification of condyle dislocation into the middle cranial fossa was difficult until the development of computed tomography, and diagnosis was often significantly delayed after the initial trauma.
   CASE DESCRIPTION: We present a rare case of a young woman who presents after a mechanical fall resulting in facial trauma with an avulsion condyle fracture with dislocation of the mandibular condyle into the middle cranial fossa.
   CONCLUSIONS: To our knowledge, this complete avulsion of the condyle into the middle cranial fossa requiring an intracranial approach for condylectomy is extremely rare. We discuss the surgical management options for reduction and fixation accomplished in a multidisciplinary approach involving neurosurgery and oral maxillofacial surgery.
C1 [Esquenazi, Yoshua; Zeineddine, Hussein A.] McGovern Med Sch, Vivian L Smith Dept Neurosurg, Houston, TX 77030 USA.
   [Reimer, Eric; Stackowicz, Daniel; Demian, Nagi] Univ Texas Hlth Sci Ctr Houston, Oral & Maxillofacial Surg, Houston, TX 77030 USA.
RP Esquenazi, Y (reprint author), McGovern Med Sch, Vivian L Smith Dept Neurosurg, Houston, TX 77030 USA.
EM Yoshua.EsquenaziLevy@uth.tmc.edu
CR Arya V, 2016, J ORAL MAXIL SURG, V74, P569, DOI 10.1016/j.joms.2015.09.033
   Clauser L, 2006, J CRANIOFAC SURG, V17, P590, DOI 10.1097/00001665-200605000-00036
   De Mol A, 2017, J SURG CASE REP, DOI 10.1093/jscr/rjx149
   He Y, 2015, INT J ORAL MAX SURG, V44, P864, DOI 10.1016/j.ijom.2014.12.016
   Kanno C, 2016, J ORAL MAX SURG MED, V28, P541, DOI 10.1016/j.ajoms.2016.07.003
   Lindell B, 2017, CRANIOMAX TRAUM REC, V10, P60, DOI 10.1055/s-0036-1572493
   Lloyd TE, 2010, BRIT J ORAL MAX SURG, V48, P176, DOI 10.1016/j.bjoms.2009.08.031
   Magge SN, 2007, J NEUROSURG, V107, P75, DOI 10.3171/PED-07/07/075
   Man C, 2011, INT J ORAL MAX SURG, V40, P118, DOI 10.1016/j.ijom.2010.02.028
   Monteiro JLGC, 2019, J ORAL MAXILLOFAC SU, V77
   Oberman B, 2014, AM J OTOLARYNG, V35, P251, DOI 10.1016/j.amjoto.2013.11.004
   Ozalp B, 2014, J CRANIOFAC SURG, V25, pE382, DOI 10.1097/SCS.0000000000000965
   Rikhotso ER, 2016, J ORAL MAXILLOFAC SU, V74, P2378
   Rosa Vera L M, 2006, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, V102, pe4, DOI 10.1016/j.tripleo.2006.02.004
   Scafati CT, 2008, CHILD NERV SYST, V24, P1067, DOI 10.1007/s00381-008-0659-8
   Struewer J, 2012, J CRANIO MAXILL SURG, V40, P396, DOI 10.1016/j.jcms.2011.07.006
   Temiz G, 2015, J ORAL MAXIL SURG, V73, DOI 10.1016/j.joms.2015.04.010
   Tutela JP, 2013, J CRANIOFAC SURG, V24, P1703, DOI 10.1097/SCS.0b013e31828a76b1
   Vaezi T, 2014, ORAL MAXILLOFAC SURG, V18, P69, DOI 10.1007/s10006-013-0395-4
   Zamorano GM, 2016, REV STOMATOL CHIR, V117, P351, DOI 10.1016/j.revsto.2016.06.001
   Zhang M, 2016, WORLD NEUROSURG, V86, DOI 10.1016/j.wneu.2015.09.007
   Zhang SL, 2014, CRANIO, V32, P63, DOI 10.1179/0886963413Z.0000000007
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 259
EP 263
DI 10.1016/j.wneu.2019.07.008
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200187
PM 31295609
DA 2020-05-12
ER

PT J
AU Tao, Y
   Yagi, K
   Nishimura, H
   Hara, K
   Matsubara, S
   Uno, M
AF Tao, Yoshifumi
   Yagi, Kenji
   Nishimura, Hirotake
   Hara, Keijirou
   Matsubara, Shunji
   Uno, Masaaki
TI Orbitotemporal Bone Cyst of Metastatic Breast Cancer: Case Report and
   Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Aneurysmal bone cyst; Bone metastasis; Breast cancer; Cystic bone
   lesion; Recurrence of cancer
AB BACKGROUND: Metastatic breast cancer in the bone rarely has a cystic appearance, and while it is common in the orbit, its metastasis to the orbitotemporal skull is rare. Consequently, it is difficult to diagnose it. We report and discuss a rare case of metastatic breast cancer with simple cyst appearance in the orbitotemporal region of the skull.
   CASE DESCRIPTION: A 63-year-old woman presented with mild double vision only on left gaze that lasted for 2 months. Ten and a half years ago, the patient underwent surgery for tumor resection of a stage 3 breast adenocarcinoma, followed by radiotherapy and administration of anticancer therapy. Thereafter, she continued hormonal therapy with antiestrogen drugs, which was discontinued a half year ago because there was no recurrence during treatment.
   On admission, magnetic resonance imaging (MRI) showed a single and simple cystic lesion in the orbitotemporal region of the skull. The cyst was filled with fluid of different intensity, indicative of a hemorrhagic component. Additional gadolinium-contrasted MRI showed no enhancing effects in the lesion. The cyst was totally removed by surgery, and the histologic examination confirmed the diagnosis of breast adenocarcinoma. Intensity-modulated radiotherapy was then administered, and the patient started follow-up hormonal therapy with antiestrogen agents. No recurrence in the orbitotemporal region of the skull occurred during 6 months after the surgery.
   CONCLUSIONS: Metastatic breast cancer should be considered in the differential diagnosis even if it appears as a simple cyst in the orbitotemporal bone after long-term remission.
C1 [Tao, Yoshifumi; Yagi, Kenji; Hara, Keijirou; Matsubara, Shunji; Uno, Masaaki] Kawasaki Med Sch, Dept Neurosurg, Kurashiki, Okayama, Japan.
   [Nishimura, Hirotake] Kawasaki Med Sch, Dept Pathol, Kurashiki, Okayama, Japan.
RP Yagi, K (reprint author), Kawasaki Med Sch, Dept Neurosurg, Kurashiki, Okayama, Japan.
EM kenji-yagi@mail.goo.ne.jp
CR Colleoni M, 2016, J CLIN ONCOL, V34, P927, DOI 10.1200/JCO.2015.62.3504
   Frenzel L, 2010, JOINT BONE SPINE, V77, P171, DOI 10.1016/j.jbspin.2010.01.006
   Gundogdu F, 2016, SPINE J, V16, pE303, DOI 10.1016/j.spinee.2015.11.026
   Ito K, 2010, NEUROL MED-CHIR, V50, P417, DOI 10.2176/nmc.50.417
   Karadeniz E, 2013, ACTA ORTHOP TRAUMATO, V47, P366, DOI 10.3944/AOTT.2013.2729
   KITNEYHAYES KA, 2014, BMJ CASE REP, V140
   Mankin HJ, 2005, J CLIN ONCOL, V23, P6756, DOI 10.1200/JCO.2005.15.255
   Mitsuya K, 2011, J NEURO-ONCOL, V104, P239, DOI 10.1007/s11060-010-0465-5
   Noordin S, 2018, ANN MED SURG, V34, P43, DOI 10.1016/j.amsu.2018.06.005
   Shields JA, 2004, OPHTHALMOLOGY, V111, P997, DOI 10.1016/j.ophtha.2003.01.002
NR 10
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 267
EP 270
DI 10.1016/j.wneu.2019.07.076
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200189
PM 31319189
DA 2020-05-12
ER

PT J
AU Kwon, SM
   Kim, JH
   Byun, J
   Kim, YH
   Hong, SH
   Cho, YH
   Kim, CJ
AF Kwon, Sae Min
   Kim, Jeong Hoon
   Byun, Joonho
   Kim, Young-Hoon
   Hong, Seok Ho
   Cho, Young Hyun
   Kim, Chang Jin
TI Malignant Transformation of a Rosette-Forming Glioneuronal Tumor to
   Glioblastoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Glioblastoma; Malignant transformation; Rosette-forming glioneuronal
   tumor
ID PILOCYTIC ASTROCYTOMA; NERVOUS-SYSTEM; CLASSIFICATION; 4TH-VENTRICLE;
   FEATURES
AB BACKGROUND: A rosette-forming glioneuronal tumor (RGNT), a rare brain tumor, presents as a benign feature with a favorable outcome. To date, a few cases with aggressive behaviors, such as recurrence or dissemination, but none with malignant transformation, have been reported. We describe 1 case that recurred as glioblastoma after complete resection of the benign RGNT.
   CASE DESCRIPTION: A man aged 58 years presented with headache and dizziness without neurologic symptoms. Magnetic resonance imaging showed a 4 x 2.5 cm, well-demarcated mass in the left cerebellar hemisphere. The patient underwent gross total resection of the tumor and a diagnosis of RGNT was made. There was no evidence of recurrence on serial follow-up. However, a recurrent heterogeneous enhancing mass in the previous surgical cavity was observed on a 7-year postoperative magnetic resonance imaging scan. Reoperation was performed and a histopathological study revealed a glioblastoma.
   CONCLUSIONS: To the best of our knowledge, this is the first case of spontaneous malignant transformation of an RGNT. Our case may be helpful in better understanding the biological behavior and clinical outcome of RGNT. We emphasize the malignant potential of this rare tumor and the necessity of future large-scaled research for most appropriate therapeutic strategies.
C1 [Kwon, Sae Min] Keimyung Univ, Dongsan Med Ctr, Dept Neurosurg, Sch Med, Daegu, South Korea.
   [Kim, Jeong Hoon; Byun, Joonho; Kim, Young-Hoon; Hong, Seok Ho; Cho, Young Hyun; Kim, Chang Jin] Univ Ulsan, Asan Med Ctr, Dept Neurol Surg, Coll Med, Seoul, South Korea.
RP Kim, JH (reprint author), Univ Ulsan, Asan Med Ctr, Dept Neurol Surg, Coll Med, Seoul, South Korea.
EM jhkim1@amc.seoul.kr
OI Cho, Young Hyun/0000-0002-3274-5096; Kim,
   Young-Hoon/0000-0002-8852-6503; Byun, Joonho/0000-0003-0687-3286; Kwon,
   Sae Min/0000-0001-9720-6037
CR Allinson KSJ, 2015, CLIN NEUROPATHOL, V34, P64, DOI 10.5414/NP300682
   Bidinotto LT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137690
   COELHO J, 2015, CHILD NEUROL OPEN, V2
   DIRKS PB, 1994, NEUROSURGERY, V34, P68
   Garcia E, 2015, INT J INF LEARN TECH, V32, P124, DOI 10.1108/IJILT-01-2015-0001
   Komori T, 2002, AM J SURG PATHOL, V26, P582, DOI 10.1097/00000478-200205000-00004
   KUCHELMEISTER K, 1995, ACTA NEUROPATHOL, V89, P385
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Matyja E, 2011, NEUROPATHOLOGY, V31, P427, DOI 10.1111/j.1440-1789.2010.01168.x
   Medhi G, 2016, EUR RADIOL, V26, P262, DOI 10.1007/s00330-015-3808-y
   Privett BJ, 2011, J CLIN NEUROSCI, V18, P705, DOI 10.1016/j.jocn.2010.09.005
   Rosenblum MK, 2007, BRAIN PATHOL, V17, P308, DOI 10.1111/j.1750-3639.2007.00079.x
   Scheithauer BW, 2009, NEUROSURGERY, V64, P771, DOI 10.1227/01.NEU.0000340979.81362.F3
   Shibahara I, 2011, NEUROL MED-CHIR, V51, P144, DOI 10.2176/nmc.51.144
   Solis OE, 2011, J NEURO-ONCOL, V102, P477, DOI 10.1007/s11060-010-0335-1
   Tan CC, 2008, NEUROSURGERY, V63, P175, DOI [10.1227/01.NEU.0000319638.62586.52, 10.1227/01.NEU.0000335085.00718.92]
   van der Wal EPJ, 2003, PEDIATR RADIOL, V33, P207, DOI 10.1007/s00247-002-0828-y
   Wang Y, 2009, ACTA NEUROPATHOL, V118, P813, DOI 10.1007/s00401-009-0569-1
   Xiong J, 2012, NEUROPATHOLOGY, V32, P301, DOI 10.1111/j.1440-1789.2011.01261.x
   Yang C, 2017, ONCOTARGET, V8
   Zhang J, 2013, J CLIN NEUROSCI, V20, P335, DOI 10.1016/j.jocn.2012.09.003
   Zoeller GK, 2010, J NEUROSURG-PEDIATR, V5, P507, DOI 10.3171/2009.12.PEDS09173
NR 22
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 271
EP 275
DI 10.1016/j.wneu.2019.06.042
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200190
PM 31203071
DA 2020-05-12
ER

PT J
AU Texakalidis, P
   Sweid, A
   Mouchtouris, N
   Peterson, EC
   Sioka, C
   Rangel-Castilla, L
   Reavey-Cantwell, J
   Jabbour, P
AF Texakalidis, Pavlos
   Sweid, Ahmad
   Mouchtouris, Nikolaos
   Peterson, Eric C.
   Sioka, Chrissa
   Rangel-Castilla, Leonardo
   Reavey-Cantwell, John
   Jabbour, Pascal
TI Aneurysm Formation, Growth, and Rupture: The Biology and Physics of
   Cerebral Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cerebral aneurysms; Flow dynamics; Inflammation; Intracranial aneurysms;
   Wall shear stress
ID UNRUPTURED INTRACRANIAL ANEURYSMS; SMOOTH-MUSCLE-CELLS; WALL
   SHEAR-STRESS; SUBARACHNOID HEMORRHAGE; RISK-FACTORS; SACCULAR ANEURYSMS;
   OXIDATIVE STRESS; PARENT VESSEL; ASPECT RATIO; SIZE RATIO
AB Cerebral aneurysms (CAs) are characterized by a pathological wall structure with internal elastic lamina and media disruption, which leads to focal weak-ened pouches of the arterial wall. The prevalence of unruptured CAs has been estimated to be 2%-5% in the general population. During the past few decades, the pathophysiological mechanisms behind the formation, growth, and rupture of CAs have been the focus of numerous research studies. In the present review, we have summarized the inflammatory pathways, genetics, and risk factors for the formation, growth, and rupture of CAs. In addition, we have discussed the concepts of geometric indexes, flow patterns, and fluid dynamics that govern CA development.
C1 [Texakalidis, Pavlos] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA 30322 USA.
   [Sweid, Ahmad; Mouchtouris, Nikolaos; Jabbour, Pascal] Thomas Jefferson Univ Hosp, Dept Neurosurg, Philadelphia, PA 19107 USA.
   [Peterson, Eric C.] Univ Miami, Sch Med, Dept Neurosurg, Miami, FL USA.
   [Sioka, Chrissa] Univ Ioannina, Sch Med, Dept Nucl Med, Ioannina, Greece.
   [Rangel-Castilla, Leonardo] Mayo Clin, Dept Neurosurg, Rochester, MN USA.
   [Reavey-Cantwell, John] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA.
RP Jabbour, P (reprint author), Thomas Jefferson Univ Hosp, Dept Neurosurg, Philadelphia, PA 19107 USA.
EM pascal.jabbour@jefferson.edu
RI Sioka, Chrissa/J-3381-2019
OI Sioka, Chrissa/0000-0002-2184-4945; Mouchtouris,
   Nikolaos/0000-0001-9495-9391; Sweid, Ahmad/0000-0002-2652-2451
CR Ali MS, 2013, J CEREBR BLOOD F MET, V33, P1564, DOI 10.1038/jcbfm.2013.109
   Aoki T, 2007, STROKE, V38, P162, DOI 10.1161/01.STR.0000252129.18605.c8
   Aoki T, 2017, J STROKE CEREBROVASC, V26, P2055, DOI 10.1016/j.jstrokecerebrovasdis.2016.10.026
   Aoki T, 2009, LAB INVEST, V89, P730, DOI 10.1038/labinvest.2009.36
   Aoki T, 2009, STROKE, V40, P942, DOI 10.1161/STROKEAHA.108.532556
   Asano H, 2012, J PHARMACOL SCI, V118, P275, DOI 10.1254/jphs.11166FP
   Baharoglu MI, 2012, J NEUROSURG, V116, P871, DOI 10.3171/2011.11.JNS11311
   Beck J, 2006, SURG NEUROL, V65, P18, DOI 10.1016/j.surneu.2005.05.019
   Bederson JB, 2000, STROKE, V31, P2742, DOI 10.1161/01.STR.31.11.2742
   Bilguvar K, 2008, NAT GENET, V40, P1472, DOI 10.1038/ng.240
   Bor ASE, 2008, BRAIN, V131, P2662, DOI 10.1093/brain/awn187
   Brinjikji W, 2016, AM J NEURORADIOL, V37, P1479, DOI 10.3174/ajnr.A4762
   Brisman JL, 2006, NEW ENGL J MED, V355, P928, DOI 10.1056/NEJMra052760
   Bromberg JEC, 1995, ANN NEUROL, V38, P929, DOI 10.1002/ana.410380614
   Brown LC, 1999, ANN SURG, V230, P289, DOI 10.1097/00000658-199909000-00002
   Cagnazzo F, 2017, ACTA NEUROCHIR, V159, P811, DOI 10.1007/s00701-017-3142-z
   Caranci F, 2013, EUR J RADIOL, V82, P1598, DOI 10.1016/j.ejrad.2012.12.026
   Brandao RACS, 2009, SURG NEUROL, V72, P296, DOI 10.1016/j.surneu.2008.03.044
   Cebral JR, 2011, AM J NEURORADIOL, V32, P145, DOI 10.3174/ajnr.A2419
   Chalouhi Nohra, 2016, Hypertension, V68, P411, DOI 10.1161/HYPERTENSIONAHA.116.07515
   Chalouhi N, 2014, STROKE, V45, P54, DOI 10.1161/STROKEAHA.113.003038
   Chalouhi N, 2013, STROKE, V44, P3613, DOI 10.1161/STROKEAHA.113.002390
   Chalouhi N, 2012, J CEREBR BLOOD F MET, V32, P1659, DOI 10.1038/jcbfm.2012.84
   Chalouhi N, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11210
   Chien S, 1998, HYPERTENSION, V31, P162, DOI 10.1161/01.HYP.31.1.162
   Conway JE, 1999, STROKE, V30, P1632, DOI 10.1161/01.STR.30.8.1632
   Conway JE, 2001, STROKE, V32, P2481, DOI 10.1161/hs1101.098329
   Davies PF, 2009, NAT CLIN PRACT CARD, V6, P16, DOI 10.1038/ncpcardio1397
   Doddasomayajula R, 2017, AM J NEURORADIOL, V38, P2301, DOI 10.3174/ajnr.A5397
   Etminan N, 2015, NEUROLOGY, V85, P881, DOI 10.1212/WNL.0000000000001891
   Etminan N, 2014, TRANSL STROKE RES, V5, P167, DOI 10.1007/s12975-013-0294-x
   Forget TR, 2001, NEUROSURGERY, V49, P1322, DOI 10.1097/00006123-200112000-00006
   Fukuda S, 2000, CIRCULATION, V101, P2532, DOI 10.1161/01.CIR.101.21.2532
   Gieteling EW, 2003, J NEUROL, V250, P418, DOI 10.1007/s00415-003-0997-0
   GOBIN YP, 1994, NEURORADIOLOGY, V36, P530, DOI 10.1007/BF00593516
   Greving JP, 2014, LANCET NEUROL, V13, P59, DOI 10.1016/S1474-4422(13)70263-1
   Grobelny TJ, 2011, DM-DIS MON, V57, P647, DOI 10.1016/j.disamonth.2011.08.022
   Guo FY, 2007, J CLIN NEUROSCI, V14, P550, DOI 10.1016/j.jocn.2005.11.018
   Hademenos GJ, 1998, NEURORADIOLOGY, V40, P755, DOI 10.1007/s002340050679
   Hasan D, 2012, STROKE, V43, P3258, DOI 10.1161/STROKEAHA.112.673400
   Hasan D, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-222
   Hasan DM, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.112.000019
   Hasan DM, 2012, ARTERIOSCL THROM VAS, V32, P1032, DOI 10.1161/ATVBAHA.111.239871
   Hasan DM, 2011, STROKE, V42, P3156, DOI 10.1161/STROKEAHA.111.619411
   Hassan T, 2005, J NEUROSURG, V103, P662, DOI 10.3171/jns.2005.103.4.0662
   Huang ZQ, 2016, AM J NEURORADIOL, V37, P1413, DOI 10.3174/ajnr.A4764
   Irazabal MV, 2011, CLIN J AM SOC NEPHRO, V6, P1274, DOI 10.2215/CJN.09731110
   JAKUBOWSKI J, 1978, J NEUROL NEUROSUR PS, V41, P972, DOI 10.1136/jnnp.41.11.972
   Kadirvel R, 2007, NEURORADIOLOGY, V49, P1041, DOI 10.1007/s00234-007-0295-0
   Kanematsu Y, 2011, STROKE, V42, P173, DOI 10.1161/STROKEAHA.110.590976
   Kashiwazaki D, 2013, STROKE, V44, P2169, DOI 10.1161/STROKEAHA.113.001138
   Killer-Oberpfalzer M, 2012, CARDIOVASC PATHOL, V21, P299, DOI 10.1016/j.carpath.2011.09.010
   Kim ST, 2016, AM J NEURORADIOL, V37, P1422, DOI 10.3174/ajnr.A4718
   Kleinloog R, 2018, NEUROSURGERY, V82, P431, DOI 10.1093/neuros/nyx238
   Korja M, 2017, J NEUROSURG, V127, P748, DOI 10.3171/2016.9.JNS161085
   KOSIERKIEWICZ TA, 1994, J NEUROPATH EXP NEUR, V53, P399, DOI 10.1097/00005072-199407000-00012
   Krischek B, 2008, ADV TECH STAND NEURO, V33, P131, DOI 10.1007/978-3-211-72283-1_3
   Krischek B, 2006, J HUM GENET, V51, P587, DOI 10.1007/s10038-006-0407-4
   Kulcsar Z, 2011, AM J NEURORADIOL, V32, P587, DOI 10.3174/ajnr.A2339
   Lee JS, 2008, J KOREAN NEUROSURG S, V44, P136, DOI 10.3340/jkns.2008.44.3.136
   Lieber BB, 1997, ANN BIOMED ENG, V25, P460, DOI 10.1007/BF02684187
   Loeys BL, 2006, NEW ENGL J MED, V355, P788, DOI 10.1056/NEJMoa055695
   LOW M, 1993, BIORHEOLOGY, V30, P287
   LOZANO AM, 1987, J NEUROSURG, V66, P522, DOI 10.3171/jns.1987.66.4.0522
   Ma BS, 2004, ANN BIOMED ENG, V32, P264, DOI 10.1023/B:ABME.0000012746.31343.92
   Machi P, 2019, CLIN NEURORADIOL, V29, P285, DOI 10.1007/s00062-017-0640-6
   Meng H, 2014, AM J NEURORADIOL, V35, P1254, DOI 10.3174/ajnr.A3558
   Meng H, 2007, STROKE, V38, P1924, DOI 10.1161/STROKEAHA.106.481234
   Miura Y, 2013, STROKE, V44, P519, DOI 10.1161/STROKEAHA.112.675306
   Montezano AC, 2012, BASIC CLIN PHARMACOL, V110, P87, DOI 10.1111/j.1742-7843.2011.00785.x
   Murayama Y, 2016, STROKE, V47, P365, DOI 10.1161/STROKEAHA.115.010698
   Nader-Sepahi A, 2004, NEUROSURGERY, V54, P1343, DOI 10.1227/01.NEU.0000124482.03676.8B
   Nakajima N, 2000, ACTA NEUROPATHOL, V100, P475, DOI 10.1007/s004010000220
   NUSSEL F, 1993, ACTA NEUROCHIR, V120, P1, DOI 10.1007/BF02001461
   Onda H, 2001, AM J HUM GENET, V69, P804, DOI 10.1086/323614
   Papaharalambus CA, 2007, TRENDS CARDIOVAS MED, V17, P48, DOI 10.1016/j.tcm.2006.11.005
   PERKTOLD K, 1984, BASIC RES CARDIOL, V79, P253, DOI 10.1007/BF01908024
   PERKTOLD K, 1988, BASIC RES CARDIOL, V83, P24, DOI 10.1007/BF01907101
   Perrone RD, 2015, NAT REV NEPHROL, V11, P589, DOI 10.1038/nrneph.2015.128
   Preul M, 1998, NEUROSURGERY, V42, P971, DOI 10.1097/00006123-199805000-00007
   Qin LY, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-5
   Raghavan ML, 2005, J NEUROSURG, V102, P355, DOI 10.3171/jns.2005.102.2.0355
   Rahman M, 2010, STROKE, V41, P916, DOI 10.1161/STROKEAHA.109.574244
   Rincon F, 2013, NEUROSURGERY, V73, P217, DOI 10.1227/01.neu.0000430290.93304.33
   Ruigrok YM, 2004, NEUROLOGY, V62, P891, DOI 10.1212/01.WNL.0000115104.19787.8E
   Ruigrok YM, 2008, STROKE, V39, P1049, DOI 10.1161/STROKEAHA.107.497305
   Ruiz DS, 2006, AM J NEURORADIOL, V27, P504
   Sadasivan C, 2013, ANN BIOMED ENG, V41, P1347, DOI 10.1007/s10439-013-0800-z
   Sforza DM, 2016, J NEUROINTERV SURG, V8, P407, DOI 10.1136/neurintsurg-2014-011339
   Shojima M, 2004, STROKE, V35, P2500, DOI 10.1161/01.STR.0000144648.89172.0f
   Starke RM, 2013, CURR NEUROVASC RES, V10, P247, DOI 10.2174/15672026113109990003
   STEIGER H J, 1987, Heart and Vessels, V3, P55, DOI 10.1007/BF02058520
   STROTHER CM, 1992, AM J NEURORADIOL, V13, P1089
   Takaki A, 2011, J ATHEROSCLER THROMB, V18, P857, DOI 10.5551/jat.7260
   Texakalidis P, 2018, WORLD NEUROSURG, V117, P453, DOI 10.1016/j.wneu.2018.06.008
   Texakalidis P, 2017, CLIN NEUROL NEUROSUR, V161, P78, DOI 10.1016/j.clineuro.2017.08.003
   Theodotou Christian B, 2017, Asian J Neurosurg, V12, P374, DOI 10.4103/1793-5482.180972
   Tremmel M, 2009, NEUROSURGERY, V64, P622, DOI 10.1227/01.NEU.0000341529.11231.69
   Ujiie H, 2001, NEUROSURGERY, V48, P495, DOI 10.1097/00006123-200103000-00007
   Ujiie H, 1999, NEUROSURGERY, V45, P119, DOI 10.1097/00006123-199907000-00028
   Vernooij MW, 2007, NEW ENGL J MED, V357, P1821, DOI 10.1056/NEJMoa070972
   Vlak MHM, 2013, STROKE, V44, P984, DOI 10.1161/STROKEAHA.111.000329
   Vlak MHM, 2011, LANCET NEUROL, V10, P626, DOI 10.1016/S1474-4422(11)70109-0
   Wang GX, 2018, J NEUROINTERV SURG, V10, P566, DOI 10.1136/neurintsurg-2017-013308
   Wang ZJ, 2009, NEUROSURGERY, V65, P169, DOI 10.1227/01.NEU.0000343541.85713.01
   Williams Lindsy N, 2013, Neurol Clin Pract, V3, P99
   Xu HW, 2011, STROKE, V42, P204, DOI 10.1161/STROKEAHA.110.578740
   Yoneyama T, 2004, STROKE, V35, P443, DOI 10.1161/01.STR.0000110788.45858.DC
NR 108
TC 2
Z9 2
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 277
EP 284
DI 10.1016/j.wneu.2019.07.093
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200191
PM 31323409
DA 2020-05-12
ER

PT J
AU Pennington, Z
   Ahmed, AK
   Goodwin, CR
   Westbroek, EM
   Sciubba, DM
AF Pennington, Zach
   Ahmed, A. Karim
   Goodwin, C. Rory
   Westbroek, Erick M.
   Sciubba, Daniel M.
TI The Use of Sacral Osteotomy in the Correction of Spinal Deformity:
   Technical Report and Systematic Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE 3-column osteotomy; Failed back syndrome; Flat back syndrome; Osteotomy;
   Spinopelvic deformity
ID PROXIMAL JUNCTIONAL KYPHOSIS; PARAMETERS; FUSION; SPONDYLOLISTHESIS;
   RECONSTRUCTION; CONTINENCE; IMBALANCE; ALIGNMENT; BLADDER; BOWEL
AB BACKGROUND: Flat back deformity is a disabling adverse outcome following instrumented lumbar fusion. As patients are often fused in this non-physiologic alignment, correction is complex and has conventionally required fracture of the preexisting fusion mass. Sacral osteotomy may be one effective means of correcting the positive sagittal balance in these patients. Here we report a case of flat back deformity corrected using a 3-column sacral osteotomy, and systematically review the available literature on the effectiveness of 3-column sacral osteotomy for correcting flat back deformity.
   METHODS: A systematic review was performed using results of a search of the PubMed, EMBASE, Web of Science, and Cochrane databases according to PRISMA guidelines. We also include our patient as an example of the technique.
   RESULTS: Eight studies-all case reports or small case series-were identified describing 37 patients, including our case example. The variety of techniques was too heterogeneous for meta-analysis, but all studies reported good correction of sagittal deformity. Transient L5 palsy was the most common side effect of this technique, being reported in 21 patients (56.8%) across all studies.
   CONCLUSIONS: Sacral osteotomy is potentially an effective means of correcting positive sagittal balance in patients with flat back deformity secondary to high pelvic incidence.
C1 [Pennington, Zach; Ahmed, A. Karim; Westbroek, Erick M.; Sciubba, Daniel M.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
   [Goodwin, C. Rory] Duke Univ, Sch Med, Dept Neurosurg, Durham, NC USA.
RP Sciubba, DM (reprint author), Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
EM dsciubb1@jhmi.edu
OI Pennington, Zachary/0000-0001-8012-860X
CR Ames CP, 2012, J NEUROSURG-SPINE, V16, P547, DOI 10.3171/2012.2.SPINE11320
   Bianco K, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS1422
   Bodin A, 2015, EUR SPINE J, V24, pS72, DOI 10.1007/s00586-014-3651-x
   BRIDWELL KH, 2006, SPINE S, V31, pS17
   Chang TL, 2009, SPINE, V34, P436, DOI 10.1097/BRS.0b013e318194128c
   Crandall DG, 2013, SPINE J, V13, pS108
   Czyz M, 2017, EUR SPINE J, V26, P2204, DOI 10.1007/s00586-017-5205-5
   Fabris DA, 1996, SPINE, V21, P728, DOI 10.1097/00007632-199603150-00014
   Farid YR, 2010, CLIN ORTHOP RELAT R, V468, P1362, DOI 10.1007/s11999-009-1031-3
   Geiger EV, 2007, INT ORTHOP, V31, P253, DOI 10.1007/s00264-006-0157-0
   GENNARI L, 1987, J BONE JOINT SURG BR, V69, P565
   Gokaslan ZL, 1997, J NEUROSURG, V87, P781, DOI 10.3171/jns.1997.87.5.0781
   Guo Y, 2005, J NEUROSURG-SPINE, V3, P106, DOI 10.3171/spi.2005.3.2.0106
   Hsieh PC, 2007, J NEUROSURG-SPINE, V6, P368, DOI 10.3171/spi.2007.6.4.15
   Husmann DA, 2001, J UROLOGY, V165, P922, DOI 10.1016/S0022-5347(05)66575-5
   Hyun SJ, 2016, SPINE J, V16, P1095, DOI 10.1016/j.spinee.2016.05.008
   Iyer S, 2018, JBJS REV, V6, DOI 10.2106/JBJS.RVW.17.00117
   Katsuura Y, 2018, SURG RADIOL ANAT, V40, P521, DOI 10.1007/s00276-017-1955-3
   Kim DK, 2017, J KOREAN NEUROSURG S, V60, P174, DOI 10.3340/jkns.2016.0707.014
   Kim JE, 2015, J NEUROSURG-SPINE, V22, P571, DOI 10.3171/2014.10.SPINE14114
   La Marca F, 2008, NEUROSURGERY, V63, pA163, DOI 10.1227/01.NEU.0000320428.67620.4F
   LAGRONE MO, 1988, J BONE JOINT SURG AM, V70A, P569, DOI 10.2106/00004623-198870040-00014
   Legaye J, 1998, Eur Spine J, V7, P99, DOI 10.1007/s005860050038
   Lindsey C, 2006, SPINE, V31, P1680, DOI 10.1097/01.brs.0000224177.97846.00
   Min Kan, 2012, Eur Spine J, V21 Suppl 6, pS785, DOI 10.1007/s00586-011-1949-5
   Moran D, 2015, SPINE J, V15, P222, DOI 10.1016/j.spinee.2014.08.445
   Moshirfar A, 2007, SPINE J, V7, P100, DOI 10.1016/j.spinee.2006.04.002
   Ozturk AK, 2018, J NEUROSURG-SPINE, V28, P532, DOI 10.3171/2017.8.SPINE17550
   Roussouly P, 2005, SPINE, V30, P346, DOI 10.1097/01.brs.0000152379.54463.65
   Schwab F, 2014, NEUROSURGERY, V74, P112, DOI 10.1227/NEU.0000000000000182o
   Schwab F, 2010, SPINE, V35, P2224, DOI 10.1097/BRS.0b013e3181ee6bd4
   Schwab FJ, 2013, SPINE, V38, pE803, DOI 10.1097/BRS.0b013e318292b7b9
   Tang JA, 2013, NEUROSURGERY, V72, P276, DOI 10.1227/NEU.0b013e31827ba066
   Vialle R, 2007, EUR SPINE J, V16, P1641, DOI 10.1007/s00586-007-0348-4
   Zileli Mehmet, 2003, Neurosurg Focus, V15, pE9
NR 35
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 285
EP 292
DI 10.1016/j.wneu.2019.07.083
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200192
PM 31323414
DA 2020-05-12
ER

PT J
AU Williams, JR
   Buckley, R
   Oushy, S
   Ruzevick, J
   Chesnut, RM
AF Williams, John R.
   Buckley, Robert
   Oushy, Soliman
   Ruzevick, Jacob
   Chesnut, Randall M.
TI Reversible, Position-Dependent Midbrain Compression in a Patient with
   Spontaneous Intracranial Hypotension
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hemorrhage; Intracranial hypotension; Spontaneous; Subdural
ID SPONTANEOUS CSF LEAKS; EPIDURAL BLOOD PATCH; SUBDURAL-HEMATOMA;
   HEADACHES; PRESSURE
AB BACKGROUND: Intracranial hypotension is an underrecognized cause of spontaneous subdural hematoma. Failure to identify this entity and treat the underlying etiology can result in profoundly dangerous clinical consequences, prolonged and costly hospitalization, and caregiver fatigue, as seen in the case presented here.
   CASE DESCRIPTION: We present a case of intracranial hypotension associated with a spontaneous cerebrospinal fluid (CSF) leak in the cervical spine leading to consistently reproducible herniation syndrome with head of bed elevation, and bilateral subdural hematomas as a result of a pressure gradient favoring downward migration of intracranial contents resulting in traction on bridging veins. This gradient promoted transtentorial herniation with resultant brainstem compression, leading to a prolonged intensive care unit stay, recurrent respiratory failure, and severe deconditioning. An exhaustive diagnostic workup uncovered a cervical root CSF leak with a nuclear medicine CSF flow study, which was successfully treated with nerve root ligation and dural closure. The patient recovered well postprocedurally and was able to return to baseline level of function.
   CONCLUSIONS: This case demonstrates the importance of considering intracranial hypotension in cases of positional herniation syndrome and the necessity for early and aggressive attempts at identifying and treating the underlying cause to prevent unnecessary neurologic dysfunction and protracted medical care.
C1 [Williams, John R.; Buckley, Robert; Ruzevick, Jacob; Chesnut, Randall M.] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA.
   [Oushy, Soliman] Mayo Clin, Dept Neurosurg, Rochester, MN USA.
   [Chesnut, Randall M.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA.
   [Chesnut, Randall M.] Univ Washington, Sch Med, Seattle, WA USA.
   [Chesnut, Randall M.] Univ Washington, Sch Global Hlth, Seattle, WA 98195 USA.
RP Williams, JR (reprint author), Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA.
EM jrwneur0@uw.edu
OI Oushy, Soliman/0000-0001-6343-6950
CR Atkinson JLD, 1998, J NEUROSURG, V88, P237, DOI 10.3171/jns.1998.88.2.0237
   Beck J, 2016, NEUROLOGY, V87, P1220, DOI 10.1212/WNL.0000000000003122
   Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658
   Chung SJ, 2006, NEUROLOGY, V67, P1088, DOI 10.1212/01.wnl.0000237338.44702.61
   Davidson B, 2017, WORLD NEUROSURG, V101, P343, DOI 10.1016/j.wneu.2017.01.123
   de Noronha RJ, 2003, J NEUROL NEUROSUR PS, V74, P752, DOI 10.1136/jnnp.74.6.752
   Farb RI, 2019, AM J NEURORADIOL, V40, P745, DOI 10.3174/ajnr.A6016
   Ferrante E, 2004, HEADACHE, V44, P615, DOI 10.1111/j.1526-4610.2004.446012.x
   Garcia-Morales I, 2001, CEPHALALGIA, V21, P703, DOI 10.1046/j.1468-2982.2001.00226.x
   Ghavanini AA, 2013, CEPHALALGIA, V33, P43, DOI 10.1177/0333102412466963
   Ishii T, 2004, NEUROL SURG TOKYO, V32, P1239
   Kim BW, 2011, J KOREAN NEUROSURG S, V50, P274, DOI 10.3340/jkns.2011.50.3.274
   LASATER G M, 1970, Headache, V10, P63, DOI 10.1111/j.1526-4610.1970.hed1002063.x
   Mokri B, 1997, MAYO CLIN PROC, V72, P400, DOI 10.4065/72.5.400
   Mokri B, 2002, NEUROLOGY, V58, P814, DOI 10.1212/WNL.58.5.814
   Mokri B, 2014, HEADACHE, V54, P1358, DOI 10.1111/head.12421
   Mokri B, 2013, HEADACHE, V53, P1034, DOI 10.1111/head.12149
   Monteith TS, 2016, CEPHALALGIA, V36, P1291, DOI 10.1177/0333102416628467
   Sato Y, 1998, CEPHALALGIA, V18, P60, DOI 10.1046/j.1468-2982.1998.1801060.x
   Schievink WI, 2006, JAMA-J AM MED ASSOC, V295, P2286, DOI 10.1001/jama.295.19.2286
   Schievink WI, 1998, J NEUROSURG, V88, P243, DOI 10.3171/jns.1998.88.2.0243
   Sencakova D, 2001, NEUROLOGY, V57, P1921, DOI 10.1212/WNL.57.10.1921
   Taylor WR, 2003, J NEUROSURG, V98, P205, DOI 10.3171/jns.2003.98.1.0205
   Watanabe A, 2009, AM J NEURORADIOL, V30, P147, DOI 10.3174/ajnr.A1277
   Wu JW, 2017, BRAIN, V140, P344, DOI 10.1093/brain/aww328
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 293
EP 297
DI 10.1016/j.wneu.2019.07.088
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200193
PM 31323415
DA 2020-05-12
ER

PT J
AU Kang, MG
   Kim, KH
   Park, JY
   Koo, SW
   Chin, DK
   Kim, KS
   Cho, YE
AF Kang, Min Gyu
   Kim, Kyung Hyun
   Park, Jeong Yoon
   Koo, Seong Wook
   Chin, Dong Kyu
   Kim, Keun Su
   Cho, Yong Eun
TI Intramedullary Cavernous Hemangioma with Calcification of Spinal Cord
SO WORLD NEUROSURGERY
LA English
DT Article
DE Calcification; Hemangioma calcificans; Intramedullary cavernous
   hemangioma; Spinal cord
ID VENOUS MALFORMATION; PHLEBOLITHS; MRI
AB BACKGROUND: A 61-year-old man was admitted complaining of myelopathy and back for 3 months.
   CASE DESCRIPTION: A 15-mm hemangioma with calcification was noted on magnetic resonance imaging and computed tomography. Intraoperatively, the mass was hard with ill-defined demarcation. The cranial portion of the mass was brown and dark gray on the dorsal cord. During surgery, motor evoked potentials transiently decreased, but they fully recovered at the end of surgery. After surgery, the patient's symptoms recovered without severe neurologic deficit.
   CONCLUSIONS: Hemangioma calcificans, a variant of cavernous hemangioma with full calcification and ossification, is an extremely rare disease in the spine and brain. Here we report a rare case of intramedullary cavernous hemangioma with calcification of the spinal cord.
C1 [Kang, Min Gyu; Kim, Kyung Hyun; Park, Jeong Yoon; Koo, Seong Wook; Chin, Dong Kyu; Kim, Keun Su; Cho, Yong Eun] Yonsei Univ, Gangnam Severance Hosp, Dept Neurosurg, Sch Med, Seoul, South Korea.
RP Cho, YE (reprint author), Yonsei Univ, Gangnam Severance Hosp, Dept Neurosurg, Sch Med, Seoul, South Korea.
EM YECHO@yuhs.ac
CR Badhiwala JH, 2014, J NEUROSURG-SPINE, V21, P662, DOI 10.3171/2014.6.SPINE13949
   Choi HJ, 2013, J CRANIOFAC SURG, V24, pE621, DOI 10.1097/SCS.0b013e3182a2d87b
   DITULLIO MV, 1979, J NEUROSURG, V50, P110, DOI 10.3171/jns.1979.50.1.0110
   Fujioka M, 1997, J CLIN NEUROSCI, V4, P234, DOI 10.1016/S0967-5868(97)90078-3
   Ghogawala Z, 1999, NEUROSURG CLIN N AM, V10, P101, DOI 10.1016/S1042-3680(18)30213-4
   Ghosh Prithwijit, 2013, South Asian J Cancer, V2, P231, DOI 10.4103/2278-330X.119931
   Gooi Z, 2014, LARYNGOSCOPE, V124, P2826, DOI 10.1002/lary.24758
   Goyal A, 2019, J NEUROL NEUROSUR PS, V90, P695, DOI 10.1136/jnnp-2018-319553
   Gross BA, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.6.FOCUS10144
   HARBAUGH RE, 1984, J NEUROSURG, V60, P417, DOI 10.3171/jns.1984.60.2.0417
   Hessel AC, 1999, OTOLARYNG HEAD NECK, V120, P545
   Jallo George I, 2006, Neurosurg Focus, V21, pe10
   Jellinger K., 1978, SPINAL ANGIOMAS, P18
   KOBAYASHI H, 1984, NEUROSURGERY, V14, P737, DOI 10.1227/00006123-198406000-00016
   Merli G A, 1981, Riv Patol Nerv Ment, V102, P78
   Naim-Ur-Rahman, 1998, BRIT J NEUROSURG, V12, P267
   OCCHIOGROSSO M, 1983, J NEUROSURG, V59, P150, DOI 10.3171/jns.1983.59.1.0150
   OGILVY CS, 1992, NEUROSURGERY, V31, P219, DOI 10.1227/00006123-199208000-00007
   Reitz M, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.5.FOCUS15153
   Ren D, 2019, J NEUROSURG-SPINE, V31, P123, DOI 10.3171/2018.12.SPINE181263
   SHIMOJI T, 1984, NEUROSURGERY, V14, P346, DOI 10.1227/00006123-198403000-00017
   Shukla D, 2003, BRIT J NEUROSURG, V17, P561, DOI 10.1080/02688690310001627812
   TURJMAN F, 1995, NEURORADIOLOGY, V37, P297, DOI 10.1007/s002340050094
   TYNDEL FJ, 1985, CAN J NEUROL SCI, V12, P321, DOI 10.1017/S0317167100035423
   Uzun C, 2017, QUINTESSENCE INT, V48, P51, DOI 10.3290/j.qi.a37018
   Weinzierl MR, 2004, NEURORADIOLOGY, V46, P65, DOI 10.1007/s00234-003-1072-3
   Zevgaridis D, 1999, ACTA NEUROCHIR, V141, P237, DOI 10.1007/s007010050293
NR 27
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 298
EP 303
DI 10.1016/j.wneu.2019.07.061
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200194
PM 31306838
DA 2020-05-12
ER

PT J
AU Fu, ZY
   Feng, Y
   Ma, C
   Chen, JC
   Krings, T
   Zhao, WY
AF Fu, Zheng-Yi
   Feng, Yu
   Ma, Chao
   Chen, Jin-cao
   Krings, Timo
   Zhao, Wen-yuan
TI Endovascular Treatment of Cavernous Sinus Dural Arteriovenous Fistulas
   via Direct Transorbital Puncture Using Cone-Beam Computed Tomography
   Image Guidance: Report of 3 Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cavernous sinus DAVFs; Cone-beam CT; Image guidance; Transorbital
   puncture
ID TRANSVENOUS EMBOLIZATION; ONYX EMBOLIZATION
AB BACKGROUND: Certain cavernous sinus (CS) dural arteriovenous fistulas (DAVFs) are difficult to access through transarterial or transvenous routes and may necessitate access through direct transorbital puncture of the superior ophthalmic vein (SOV) or the CS. However, to be successful, the accurate design of the puncture route and guidance are crucial. This study aimed to report our preliminary clinical experience using cone-beam computed tomography (CT) with real-time fluoroscopic overlays for image guidance during transorbital needle puncture.
   METHODS: Between December 2017 and July 2018, 3 patients with CS DAVFs were treated via a transorbital puncture to establish access to the CS under the guidance of XperGuide planning software either via direct CS puncture or through the SOV. The guidance trajectory was superimposed onto the real-time fluoroscopic image during needle puncture. Once access was established, the CS DAVFs were treated with a combination of liquid embolic materials and coils.
   RESULTS: Image guidance aided to avoid at-risk structures and treatment resulted in all cases in complete obliteration of the CS DAVFs as verified by control angiography without peri- or postprocedural complications.
   CONCLUSIONS: Endovascular embolization of CS DAVFs direct transorbital puncture aided by image guidance provided an alternative option when more conventional approaches are deemed not possible.
C1 [Fu, Zheng-Yi; Feng, Yu; Ma, Chao; Chen, Jin-cao; Zhao, Wen-yuan] Univ Wuhan, Zhongnan Hosp, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
   [Krings, Timo] Univ Toronto, Toronto Western Hosp, Div Neuroradiol, UHN, Toronto, ON, Canada.
RP Zhao, WY (reprint author), Univ Wuhan, Zhongnan Hosp, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
EM doczhaowy@163.com
OI Krings, Timo/0000-0001-6321-5787; Xu, Shuangxiang/0000-0001-8864-9653
CR Amiridze N, 2009, INTERV NEURORADIOL, V15, P179, DOI 10.1177/159101990901500207
   BARROW DL, 1985, J NEUROSURG, V62, P248, DOI 10.3171/jns.1985.62.2.0248
   Benndorf G, 2001, NEURORADIOLOGY, V43, P499, DOI 10.1007/s002340000508
   Dashti SR, 2011, NEUROSURGERY, V68, DOI 10.1227/NEU.0b013e3182073cc5
   Elhammady MS, 2011, J NEUROSURG, V114, P129, DOI 10.3171/2010.1.JNS091433
   Gil A, 2013, J NEUROSURG, V119, P247, DOI 10.3171/2013.4.JNS121504
   Kim DJ, 2006, AM J NEURORADIOL, V27, P2078
   Kim DJ, 2010, STROKE, V41, P1489, DOI 10.1161/STROKEAHA.110.581462
   Kiyosue H, 2004, RADIOGRAPHICS, V24, P1637, DOI 10.1148/rg.246045026
   Lee JW, 2008, ACTA NEUROCHIR, V150, P557, DOI 10.1007/s00701-008-1573-2
   Liu AH, 2014, ACTA NEUROCHIR, V156, P897, DOI 10.1007/s00701-014-2037-5
   Luo CB, 2015, J CHIN MED ASSOC, V78, P526, DOI 10.1016/j.jcma.2015.05.008
   Puffer RC, 2014, OPER NEUROSURG, V10, pE370, DOI 10.1227/NEU.0000000000000316
   Racadio JM, 2007, AM J ROENTGENOL, V189, pW357, DOI 10.2214/AJR.07.2469
   Rhim JK, 2015, NEUROSURGERY, V77, P192, DOI 10.1227/NEU.0000000000000751
   SASAKI H, 1988, ACTA NEUROCHIR, V90, P117, DOI 10.1007/BF01560564
   Trivelato FP, 2018, CLIN NEURORADIOL, V28, P55, DOI 10.1007/s00062-016-0534-z
   Zhang J, 2010, INTERV NEURORADIOL, V16, P269, DOI 10.1177/159101991001600307
   Zhang P, 2007, CHIN J CEREBROVASE D, V4, P529
NR 19
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 306
EP 312
DI 10.1016/j.wneu.2019.01.002
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200196
PM 31299303
DA 2020-05-12
ER

PT J
AU Zaidman, N
   Merve, A
   Russo, V
AF Zaidman, Nathalie
   Merve, Ashirwad
   Russo, Vittorio
TI Intraosseous Thoracic Schwannoma: Case Report and Review of the
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Intraosseous schwannoma; Thoracic spine
ID VERTEBRAL BODY; CERVICAL-SPINE
AB BACKGROUND: Intraosseous locations are extremely rare when it comes to schwannomas and account for 0.2% of primary bone tumors. The most common intraosseous locations include the mandible and sacrum, while cervical, thoracic, and lumbar spine lesions are even more uncommon.
   CASE DESCRIPTION: We describe a 56-year-old female patient with incidental finding of an intraosseous lytic lesion within the vertebral body of T1. Complete surgical excision was performed with instrumented fusion. Histopathology results confirmed a World Health Organization grade I schwannoma.
   CONCLUSIONS: Our case is the fourth case of purely intraosseous schwannoma described in the mobile spine in the literature, with good results both clinically and radiologically after complete surgical resection.
C1 [Zaidman, Nathalie; Russo, Vittorio] Natl Hosp Neurol & Neurosurg, Dept Neurosurg, Queen Sq, London, England.
   [Merve, Ashirwad] Natl Hosp Neurol & Neurosurg, Dept Neuropathol, Queen Sq, London, England.
RP Zaidman, N (reprint author), Natl Hosp Neurol & Neurosurg, Dept Neurosurg, Queen Sq, London, England.
EM Nathalie.zaidman@gmail.com
RI Merve, Ashirwad/AAC-9166-2020
FU Medical Research CouncilMedical Research Council UK (MRC) [G0902001]
CR Boriani S, 1997, SPINE, V22, P1036, DOI 10.1097/00007632-199705010-00020
   Cetinkal A, 2009, EUR SPINE J, V18, pS236, DOI 10.1007/s00586-009-0922-z
   Chang CJ, 1998, NEUROSURGERY, V43, P1219, DOI 10.1097/00006123-199811000-00120
   Choudry Q, 2007, EUR SPINE J, V16, pS283, DOI 10.1007/s00586-006-0247-0
   DICKSON JH, 1971, J BONE JOINT SURG AM, VA 53, P349, DOI 10.2106/00004623-197153020-00016
   Gupta S P, 2005, Indian J Pathol Microbiol, V48, P367
   Inaoka T, 2001, SKELETAL RADIOL, V30, P286, DOI 10.1007/s002560100327
   Jia SJ, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014153
   Kojima M, 2011, EUR SPINE J, V20, pS153, DOI 10.1007/s00586-010-1456-0
   Mizutani A, 2010, BRIT J NEUROSURG, V24, P604, DOI 10.3109/02688697.2010.495168
   Mohanty CB, 2012, PEDIATR NEUROSURG, V48, P364, DOI 10.1159/000351734
   Mutlu A, 2016, SPINE J, V16, pE407, DOI 10.1016/j.spinee.2015.12.028
   NAIDU MRC, 1988, CLIN NEUROL NEUROSUR, V90, P257, DOI 10.1016/0303-8467(88)90033-9
   Nannapaneni R, 2005, BRIT J NEUROSURG, V19, P244, DOI 10.1080/02688690500207546
   Nayal B, 2015, J INTERDISC HISTOPAT, V3, P74
   Nooraie H, 1997, ARCH ORTHOP TRAUM SU, V116, P440
   Park SC, 2009, J KOREAN NEUROSURG S, V46, P403, DOI 10.3340/jkns.2009.46.4.403
   Peng XS, 2011, INT SURG, V96, P337, DOI 10.9738/CC42.1
   Ramasamy P, 2000, Sarcoma, V4, P185, DOI 10.1080/13577140020025922
   Schreuder H W, 2001, Sarcoma, V5, P101, DOI 10.1155/S1357714X01000196
   Singrakhia MD, 2006, SURG NEUROL, V66, P192, DOI 10.1016/j.surneu.2005.11.057
   Wang YQ, 2018, EUR SPINE J, V27, P3092, DOI 10.1007/s00586-018-5766-y
   Youn B, 2012, BRIT J NEUROSURG, V26, P561, DOI 10.3109/02688697.2012.671974
   Zainab Hina, 2012, J Oral Maxillofac Pathol, V16, P294, DOI 10.4103/0973-029X.99094
   Zhang F, 2015, J KOREAN NEUROSURG S, V57, P478, DOI 10.3340/jkns.2015.57.6.478
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 313
EP 316
DI 10.1016/j.wneu.2019.06.222
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200197
PM 31295618
DA 2020-05-12
ER

PT J
AU Liu, XW
   Li, TF
   Shi, L
   Luo, YB
   Chen, DY
   Xu, B
   Chen, Y
AF Liu, Xiaowei
   Li, Tiefeng
   Shi, Lei
   Luo, Yibin
   Chen, Deyu
   Xu, Bin
   Chen, Yu
TI Extended Laminoplasty for Ossification of Posterior Longitudinal
   Ligament Involving the C2 Segment
SO WORLD NEUROSURGERY
LA English
DT Article
DE C2 segment; Laminoplasty; Ossification of posterior longitudinal
   ligament
ID CERVICAL MYELOPATHY; SURGICAL-TREATMENT; ANTERIOR DECOMPRESSION;
   RISK-FACTORS; FUSION; SURGERY; ALIGNMENT; OUTCOMES; MUSCLES
AB BACKGROUND: To evaluate effectiveness and safety of extended laminoplasty for the treatment of ossification of posterior longitudinal ligament (OPLL) involving the C2 segment.
   METHODS: A total of 132 cases who accepted laminoplasty for treating the OPLL from 2010 to 2015 were included and divided into Group A (n = 26, with C2 OPLL and C2-C7 laminoplasty), Group B (n = 29, with C2 OPLL and C3-C7 laminoplasty), and Group C (n = 77, without C2 OPLL and had C3-C7 laminoplasty). Clinical and radiologic outcomes were compared among the 3 groups.
   RESULTS: At the final visit, significant improvements in japanese Orthopedic Association score, Neck Disability Index, Health-Related Quality-of-Life Short Form 36 Physical Component Summary, and Visual Analog Scale score in neck were observed in all 3 groups. However, all the C2-C7 Cobb angle, C2-C3 Cobb angle, sagittal vertical axis, and number of cases with cervical or segmental kyphosis in the 3 groups were not significantly changed. Although total blood loss, operation time, maximum Visual Analog Scale score in neck, incidence of axial pain, change of C2-C7, or sagittal vertical axis in Group A were all significantly larger than that in Group B or Group C, differences in neurologic recovery rate, Neck Disability Index, Health-Related Quality-of-Life Short Form 36 Physical Component Summary, change of the C2-C3 Cobb angle, and incidence of cervical or segmental malalignment among the 3 groups were not significant at the final visit.
   CONCLUSIONS: If decompression indication for cases with OPLL involving the C2 segment was appropriate, extended laminoplasty up to the C2 segment could provide satisfactory neurologic recovery and would not accelerate cervical or segmental malalignment progression.
C1 [Liu, Xiaowei; Xu, Bin] Nanjing Univ, Jinling Hosp, Med Coll, Dept Orthopaed, Nanjing, Jiangsu, Peoples R China.
   [Li, Tiefeng; Shi, Lei; Luo, Yibin; Chen, Deyu; Chen, Yu] Naval Mil Med Univ, Changzheng Hosp, Dept Spine Surg, Shanghai, Peoples R China.
RP Chen, Y (reprint author), Naval Mil Med Univ, Changzheng Hosp, Dept Spine Surg, Shanghai, Peoples R China.
EM cyspine@smmu.edu.cn
CR Blood AG, 2017, SURG INFECT, V18, P234, DOI 10.1089/sur.2016.183
   Carr FA, 2011, J NEUROSURG-SPINE, V15, P486, DOI 10.3171/2011.6.SPINE11114
   Chen Y, 2009, INT ORTHOP, V33, P1075, DOI 10.1007/s00264-008-0609-9
   Choi BW, 2015, CLIN ORTHOP SURG, V7, P465, DOI 10.4055/cios.2015.7.4.465
   Fargen KM, 2012, J NEUROSURG-SPINE, V17, P512, DOI 10.3171/2012.9.SPINE12548
   Feng F, 2016, INT J SURG, V27, P26, DOI 10.1016/j.ijsu.2016.01.038
   Goel Atul, 2019, Acta Neurochir Suppl, V125, P63, DOI 10.1007/978-3-319-62515-7_10
   Goel A, 2016, J CRANIOVERTEBRAL JU, V7, P20, DOI 10.4103/0974-8237.176613
   Goel A, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.05.017
   Kato M, 2008, SPINE, V33, pE455, DOI 10.1097/BRS.0b013e318178e607
   Kimura H, 2014, EUR SPINE J, V23, P1491, DOI 10.1007/s00586-014-3253-7
   Lee CK, 2016, J NEUROSURG-SPINE, V24, P100, DOI 10.3171/2015.4.SPINE141004
   Lee CH, 2017, SPINE, V42, P887, DOI 10.1097/BRS.0000000000001933
   Lee DH, 2017, J NEUROSURG-SPINE, V26, P325, DOI 10.3171/2016.8.SPINE16542
   Lee JJ, 2018, SPINE J, V18, P1779, DOI 10.1016/j.spinee.2018.03.002
   Lee SE, 2016, WORLD NEUROSURG, V90, P51, DOI 10.1016/j.wneu.2015.11.074
   Matsumoto M, 2012, SPINE, V37, pE303, DOI 10.1097/BRS.0b013e318239cca0
   Matsunaga S, 2008, SPINE, V33, P2648, DOI 10.1097/BRS.0b013e31817f988c
   MATSUZAKI H, 1989, SPINE, V14, P1198, DOI 10.1097/00007632-198911000-00011
   Odate S, 2017, J NEUROSURG-SPINE, V26, P466, DOI 10.3171/2016.9.SPINE16430
   Park SH, 2007, SURG NEUROL, V68, P519, DOI 10.1016/j.surneu.2006.11.070
   Passias PG, 2013, EUR SPINE J, V22, pS478, DOI 10.1007/s00586-012-2654-8
   Resnick DN, 2005, J CHIROPR MED, V4, P113, DOI 10.1016/S0899-3467(07)60121-9
   Saetia K, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2010.11.FOCUS10276
   Sakai K, 2012, SPINE, V37, P367, DOI 10.1097/BRS.0b013e31821f4a51
   Scheer JK, 2013, J NEUROSURG-SPINE, V19, P141, DOI 10.3171/2013.4.SPINE12838
   Sebastian A, 2016, SPINE J, V16, P504, DOI 10.1016/j.spinee.2015.12.009
   Shou FY, 2015, EUR SPINE J, V24, P2724, DOI 10.1007/s00586-015-4186-5
   Stapleton CJ, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2010.12.FOCUS10271
   Umeda M, 2013, J NEUROSURG-SPINE, V18, P545, DOI 10.3171/2013.2.SPINE12468
   Vender JR, 2000, J NEUROSURG, V92, P24, DOI 10.3171/spi.2000.92.1.0024
   Wang L, 2019, SPINE, V44, pE150, DOI 10.1097/BRS.0000000000002807
   Wang SJ, 2011, EUR SPINE J, V20, P185, DOI 10.1007/s00586-010-1600-x
NR 33
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 317
EP 323
DI 10.1016/j.wneu.2019.07.086
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200198
PM 31323405
DA 2020-05-12
ER

PT J
AU Ahmetspahic, A
   Burazerovic, E
   Omerhodzic, I
   Gulmez, MA
   Sefo, H
   Yamada, Y
   Arnautovic, K
   Kato, Y
AF Ahmetspahic, Adi
   Burazerovic, Eldin
   Omerhodzic, Ibrahim
   Gulmez, Muhammed Abdullah
   Sefo, Haso
   Yamada, Yasuhiro
   Arnautovic, Kenan
   Kato, Yoko
TI Current Management of Mirror Distal Anterior Cerebral Artery Aneurysms
   in Association with Multiple Aneurysms: Case Report with Literature
   Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Computational flow dynamic (CFD); Distal anterior cerebral artery
   (DACA); Kissing; Mirror; Multiple aneurysms; Pericallosal
ID INTRACRANIAL ANEURYSMS; KISSING ANEURYSMS; RISK-FACTORS; PERICALLOSAL
   ARTERY; RUPTURE
AB BACKGROUND: Mirror aneurysms represent 2 adjacent arterial protrusions. Although the size is considered a major risk factor in terms of rupture, sometimes it is the smaller aneurysm that ruptures. Here, we present the contemporary management of mirror distal anterior cerebral artery (DACA) aneurysms associated with multiple aneurysms. Computational fluid dynamic (CFD) analysis was performed when assessing multiple aneurysms using Hemoscope, version 2015.
   CASE DESCRIPTION: Among multiple aneurysms, a mirror A2/A3 DACA aneurysm was found in a single patient. Surgical treatment was provided for all aneurysms through a single-stage procedure. The left ruptured A2/A3 aneurysm was smaller compared with the right (7.5 x 3.5 mm/10.8 x 3.2 mm). CFD showed greater wall pressure (WP) in the left ruptured A2/A3 aneurysm (left A2/A3 WP 84,000-84,402 Inst. mm Hg/right A2/3 WP 84,224-84,315). WP in the left middle cerebral artery and anterior communicating artery aneurysms showed lesser values compared with the ruptured aneurysm (WP upper values 84,361 and 84,367, respectively). Wall shear stress showed low values for all aneurysms with the lowest flow rate values in the left A2/A3 aneurysm.
   CONCLUSIONS: In cases of ruptured mirror aneurysms followed by the presence of intracerebral hematoma, surgery is considered the primary option with the best results. A one-stage dual craniotomy procedure was found safe in the associated treatment of other multiple aneurysms. At present, the size of the aneurysm, the hemodynamic influence, and the local configuration are all considerations during the preoperative assessment of multiple aneurysm cases. According to our knowledge, this article presents the first CFD analysis of mirror DACA aneurysms associated with aneurysm multiplicity.
C1 [Ahmetspahic, Adi; Burazerovic, Eldin; Omerhodzic, Ibrahim; Sefo, Haso] Clin Ctr Univ Sarajevo, Dept Neurosurg, Sarajevo, Bosnia & Herceg.
   [Ahmetspahic, Adi; Omerhodzic, Ibrahim; Gulmez, Muhammed Abdullah] Sarajevo Sch Sci & Technol, Dept Neurosci, Sarajevo, Bosnia & Herceg.
   [Arnautovic, Kenan] Univ Tennessee, Hlth Sci Ctr, Coll Med, Semmes Murphey Clin, Memphis, TN USA.
   [Arnautovic, Kenan] Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Neurosurg, Memphis, TN USA.
   [Ahmetspahic, Adi; Yamada, Yasuhiro; Kato, Yoko] Bantane Hosp, Fujita Hlth Univ Ctr, Dept Neurosurg, Nagoya, Aichi, Japan.
RP Ahmetspahic, A (reprint author), Clin Ctr Univ Sarajevo, Dept Neurosurg, Sarajevo, Bosnia & Herceg.; Ahmetspahic, A (reprint author), Sarajevo Sch Sci & Technol, Dept Neurosci, Sarajevo, Bosnia & Herceg.; Ahmetspahic, A (reprint author), Bantane Hosp, Fujita Hlth Univ Ctr, Dept Neurosurg, Nagoya, Aichi, Japan.
EM adi85@live.com
RI Omerhodzic, Ibrahim/AAL-7976-2020; Arnautovic, Kenan/AAI-6898-2020
OI Arnautovic, Kenan/0000-0003-3745-288X
CR Ahn Hyeong-Jun, 2006, [Journal of Korean Neurosurgical Society, 대한신경외과학회지], V39, P238
   Alimohammadi M, 2010, NEUROSURG QUART, V20, P308, DOI 10.1097/WNQ.0b013e31820113fe
   ANDREWS RJ, 1977, NEW ENGL J MED, V297, P115
   Baccin CE, 2006, ACTA NEUROCHIR, V148, P1091, DOI 10.1007/s00701-006-0860-z
   Casimiro MV, 2004, SURG NEUROL, V61, P541
   Choi CY, 2011, J CLIN NEUROSCI, V18, P260, DOI 10.1016/j.jocn.2010.04.032
   Choque-Velasquez Joham, 2018, Surg Neurol Int, V9, P141, DOI 10.4103/sni.sni_163_18
   Dinc C, 2006, NEUROL MED-CHIR, V46, P438, DOI 10.2176/nmc.46.438
   Doddasomayajula R, 2017, AM J NEURORADIOL, V38, P2301, DOI 10.3174/ajnr.A5397
   Enesi E, 2013, INTERV NEURORADIOL, V19, P49, DOI 10.1177/159101991301900107
   Fu CY, 2018, EXP THER MED, V15, P3471, DOI 10.3892/etm.2018.5854
   Giordan E, 2018, ACTA NEUROCHIR, V160, P2419, DOI 10.1007/s00701-018-3729-z
   Grochowski C, 2018, J CLIN NEUROSCI, V48, P181, DOI 10.1016/j.jocn.2017.10.064
   Gupta Pankaj, 2018, Asian J Neurosurg, V13, P814, DOI 10.4103/ajns.AJNS_252_16
   Harada K, 2004, NEUROL SURG TOKYO, V32, P513
   Huang ZQ, 2017, EUR J RADIOL, V96, P80, DOI 10.1016/j.ejrad.2017.09.015
   Inagawa T, 1996, ACTA NEUROCHIR WIEN, V106, P119
   Kadoya Chitoshi, 1994, Neurologia Medico-Chirurgica, V34, P35, DOI 10.2176/nmc.34.35
   Kawamata T, 1999, NEUROL SURG TOKYO, V27, P341
   Keston P, 2004, J NEURORADIOLOGY, V31, P384, DOI 10.1016/S0150-9861(04)97021-6
   Komiyama Masaki, 1994, Neurologia Medico-Chirurgica, V34, P360, DOI 10.2176/nmc.34.360
   Kozyrev Danil A, 2017, Surg Neurol Int, V8, P62, DOI 10.4103/sni.sni_394_16
   Kuroiwa Toshihiko, 1992, Neurological Surgery, V20, P905
   LAITINEN L, 1960, J NEUROSURG, V17, P447, DOI 10.3171/jns.1960.17.3.0447
   Lehecka M, 2010, ACTA NEUROCHIR SUPPL, V107, P15, DOI 10.1007/978-3-211-99373-6_3
   Liu J, 2010, J INVEST MED, V58, P225
   Thenier-Villa JL, 2018, WORLD NEUROSURG, V118, DOI 10.1016/j.wneu.2018.07.009
   Matsumoto H, 2005, J ENDOVASC THER, V12, P750, DOI 10.1583/05-1637R.1
   MEGELE R, 1988, NEUROCHIRURGIA, V31, P154
   Mehrotra A, 2016, WORLD NEUROSURG, V92, P126, DOI 10.1016/j.wneu.2016.04.124
   Meissner I, 2012, J NEUROSURG, V116, P1238, DOI 10.3171/2012.1.JNS11779
   Meng H, 2014, AM J NEURORADIOL, V35, P1254, DOI 10.3174/ajnr.A3558
   Mizunari T, 2011, J NIPPON MED SCH, V78, P178, DOI 10.1272/jnms.78.178
   MORI T, 1995, SURG NEUROL, V43, P497, DOI 10.1016/0090-3019(95)80097-Z
   NIIJIMA K H, 1989, Neurological Surgery, V17, P779
   OSTERGAARD JR, 1985, J NEUROSURG, V63, P49, DOI 10.3171/jns.1985.63.1.0049
   Otani N, 2009, J CLIN NEUROSCI, V16, P802, DOI 10.1016/j.jocn.2008.09.012
   Qureshi AI, 1998, NEUROSURGERY, V43, P22, DOI 10.1097/00006123-199807000-00013
   RINNE J, 1994, NEUROSURGERY, V35, P803, DOI 10.1227/00006123-199411000-00001
   Rinne J, 1996, NEUROSURGERY, V38, P2, DOI 10.1097/00006123-199601000-00002
   Singh Saraj K, 2018, Surg Neurol Int, V9, P80, DOI 10.4103/sni.sni_478_17
   Sousa J, 2002, ACTA NEUROCHIR, V144, P933, DOI 10.1007/s00701-002-0986-6
   Sun Zheng-hui, 2013, Zhonghua Wai Ke Za Zhi, V51, P912
   Tian ZB, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00219
   Wang HW, 2017, BRIT J NEUROSURG, V31, P96, DOI 10.1080/02688697.2016.1226255
   Wang WX, 2017, WORLD NEUROSURG, V100, P450, DOI 10.1016/j.wneu.2017.01.049
   WEIL SM, 1988, ACTA NEUROCHIR, V95, P121, DOI 10.1007/BF01790772
   Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401
   WISOFF JH, 1987, NEUROSURGERY, V20, P735, DOI 10.1227/00006123-198705000-00011
   Yamada K, 2000, SURG NEUROL, V54, P361, DOI 10.1016/S0090-3019(00)00304-9
   YASARGIL MG, 1974, J NEUROSURG, V40, P218
   Yasargil MG., 1984, MICRONEUROSURGERY, VII, P33
   Zhang Y, 2014, BMC NEUROL, V14, DOI 10.1186/s12883-014-0253-5
NR 53
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 324
EP 334
DI 10.1016/j.wneu.2019.07.084
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200199
PM 31323413
DA 2020-05-12
ER

PT J
AU Suzuki, Y
   Shiba, M
   Wada, H
   Yasuda, R
   Toma, N
   Suzuki, H
AF Suzuki, Yume
   Shiba, Masato
   Wada, Hideo
   Yasuda, Ryuta
   Toma, Naoki
   Suzuki, Hidenori
TI Case of Hemorrhagic Moyamoya Disease Associated with Von Willebrand
   Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Coagulation factor; Hemorrhagic moyamoya disease; Von Willebrand disease
ID BYPASS
AB BACKGROUND: Association of moyamoya disease (MMD) with von Wille-brand disease (vWD) is extremely rare.
   CASE DESCRIPTION: We first report a 27-year-old female case of MMD concurrent with vWD type 1, which presented as hemorrhagic stroke. The patient underwent a revascularization surgery with perioperative replacement therapy of von Willebrand factor and coagulation factor VIII. No hemorrhagic complications occurred.
   CONCLUSIONS: The patient overcame postoperative transient neurological events and fully recovered. We discuss appropriate perioperative supplementation of coagulation factors for a revascularization surgery for MMD with vWD.
C1 [Suzuki, Yume; Shiba, Masato; Yasuda, Ryuta; Toma, Naoki; Suzuki, Hidenori] Mie Univ, Grad Sch Med, Dept Neurosurg, Tsu, Mie, Japan.
   [Wada, Hideo] Mie Univ, Grad Sch Med, Dept Hematol, Tsu, Mie, Japan.
RP Suzuki, Y (reprint author), Mie Univ, Grad Sch Med, Dept Neurosurg, Tsu, Mie, Japan.
EM box_308044@yahoo.co.jp
OI Suzuki, Hidenori/0000-0002-8555-5448
CR Burke GM, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.1.FOCUS08310
   Kuroda S, 2010, NEUROSURGERY, V66, P1093, DOI 10.1227/01.NEU.0000369606.00861.91
   Miesbach W, 2017, EUR J HAEMATOL, V98, P121, DOI 10.1111/ejh.12809
   Miki K, 2017, WORLD NEUROSURG, V991, pe17
   Miyamoto S, 2014, STROKE, V45, P1415, DOI 10.1161/STROKEAHA.113.004386
   Nakau R, 2005, NEUROL MED-CHIR, V45, P631, DOI 10.2176/nmc.45.631
   Nishino M, 1999, JPN J PEDIAT HEMATOL, V13, P410
   Tominaga T, 2018, SURG CEREB STROKE, V46, P1
NR 8
TC 0
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 335
EP 338
DI 10.1016/j.wneu.2019.07.106
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200200
PM 31326638
DA 2020-05-12
ER

PT J
AU Lewis, W
   Saber, H
   Sadeghi, M
   Rajah, G
   Narayanan, S
AF Lewis, Whitfield
   Saber, Hamidreza
   Sadeghi, Mahsa
   Rajah, Gary
   Narayanan, Sandra
TI Transvenous Endovascular Recanalization for Cerebral Venous Thrombosis:
   A Systematic Review and Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cerebral venous thrombosis; Endovascular; Interventional neurology;
   Recanalization; Stroke; Thrombectomy; Thrombolysis
ID SINGLE-CENTER EXPERIENCE; SINUS THROMBOSIS; MECHANICAL THROMBECTOMY;
   INTRASINUS THROMBOLYSIS; VEIN; ANTICOAGULATION
AB BACKGROUND: In patients who have failed systemic anticoagulation therapy, various endovascular approaches may assist in emergent recanalization.
   METHODS: We searched the PubMed database from January 1999 to August 2018 for studies that reported endovascular treatment modalities and associated clinical outcomes including recanalization, functional independence, mortality, or intracranial complications. Random-effect models were used to pool estimates across studies using R software.
   RESULTS: Overall, 393 patients with cerebral venous thrombosis from 21 studies were included in the study. Transvenous local chemolysis treatment results were as follows: good outcome rate. 0.88 (95% confidence interval [CI], 0.80-0.93), mortality, 0.08 (95% CI, 0.04-0.16), postprocedural hemorrhagic rate, 0.11 (95% CI, 0.06-0.19), and complete recanalization rate, 0.59 (95% CI, 0.48-0.70). Transvenous mechanical thrombectomy results were as follows: good outcome rate, 0.66 (95% CI, 0.41-0.84), mortality, 0.09 (95% CI, 0.03-0.26), postprocedural hemorrhagic rate, 0.03 (95% CI, 0-0.16), and complete recanalization rate, 0.60 (95% CI, 0.35-0.80). Combined approach treatment results were as follows: good outcome rate, 0.80 (95% CI, 0.70-0.87), mortality, 0.10 (0.04-0.22), postprocedural hemorrhagic rate, 0.17 (95% CI, 0.10-0.27), and complete recanalization rate, 0.75 (95% CI, 0.64-0.84). Mixed approach to treatment results were as follows: good outcome rate, 0.61 (95% CI, 0.51-0.70), mortality, 0.23 (95% CI, 0.16-0.32), postprocedural hemorrhagic rate, 0.46 (95% CI, 0.33-0.59), and complete recanalization rate, 0.48 (95% CI, 0.37-0.58).
   CONCLUSIONS: The combination approach treatment tended to have better outcomes, although this meta-analysis did not achieve statistical significance in all outcome parameters. Future studies are needed to establish the best treatment options with tailoring to specific clinical or angiographic scenarios.
C1 [Lewis, Whitfield; Sadeghi, Mahsa; Narayanan, Sandra] Wayne State Univ, Detroit Med Ctr, Dept Neurol, Detroit, MI 48202 USA.
   [Narayanan, Sandra] Wayne State Univ, Detroit Med Ctr, Dept Neurosurg, Detroit, MI USA.
   [Saber, Hamidreza] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
   [Rajah, Gary] Univ Buffalo State Univ New York, Jacobs Sch Med & Biomed Sci, Dept Neurosurg, Buffalo, NY USA.
RP Lewis, W (reprint author), Wayne State Univ, Detroit Med Ctr, Dept Neurol, Detroit, MI 48202 USA.
EM whitfield.lewis@wayne.edu
RI Narayanan, Sandra/AAC-9810-2019
CR Agnelli Giancarlo, 2008, Front Neurol Neurosci, V23, P16
   Baker MD, 2001, NEUROSURGERY, V48, P487, DOI 10.1097/00006123-200103000-00005
   Bousser MG, 2007, LANCET NEUROL, V6, P162, DOI 10.1016/S1474-4422(07)70029-7
   Coutinho JM, 2015, J THROMB HAEMOST, V13, pS238, DOI 10.1111/jth.12945
   Coutinho JM, 2013, INT J STROKE, V8, P135, DOI 10.1111/j.1747-4949.2011.00753.x
   Dashti SR, 2013, J NEUROINTERV SURG, V5, P49, DOI 10.1136/neurintsurg-2011-010112
   Sousa DA, 2018, STROKE, V49, P1828, DOI 10.1161/STROKEAHA.118.022129
   Ferro JM, 2005, CEREBROVASC DIS, V19, P152, DOI 10.1159/000083248
   Ferro JM, 2004, STROKE, V35, P664, DOI 10.1161/01.STR.0000117571.76197.26
   Ferro JM, 2017, EUR STROKE J, V2, P195, DOI 10.1177/2396987317719364
   Ferro JM, 2009, CEREBROVASC DIS, V28, P39, DOI 10.1159/000215942
   Filippidis A, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.8.FOCUS09167
   Frey JL, 1999, STROKE, V30, P489, DOI 10.1161/01.STR.30.3.489
   Guo XB, 2012, AM J NEURORADIOL, V33, P1187, DOI 10.3174/ajnr.A2932
   Ilyas A, 2017, J NEUROINTERV SURG, V9, P1086, DOI 10.1136/neurintsurg-2016-012938
   Jankowitz BT, 2013, J NEUROINTERV SURG, V5, P534, DOI 10.1136/neurintsurg-2012-010476
   Kumar S, 2010, NEUROL INDIA, V58, P225, DOI 10.4103/0028-3886.63800
   Lee SK, 2018, J NEUROINTERV SURG, V10, P803, DOI 10.1136/neurintsurg-2018-013973
   Li GW, 2013, NEUROSURGERY, V72, P730, DOI 10.1227/NEU.0b013e318285c1d3
   Li K, 2019, J NEUROINTERV SURG, V11, P307, DOI 10.1136/neurintsurg-2018-014328
   Mohammadian R, 2012, INTERV NEURORADIOL, V18, P89, DOI 10.1177/159101991201800112
   Mokin M, 2015, INTERV NEURORADIOL, V21, P520, DOI 10.1177/1591019915583015
   Nyberg EM, 2017, J STROKE CEREBROVASC, V26, P2240, DOI 10.1016/j.jstrokecerebrovasdis.2017.05.006
   Peng Y, 2009, INTERV NEURORADIOL, V15, P407, DOI 10.1177/159101990901500405
   Pfefferkorn T, 2009, J NEUROL, V256, P1839, DOI 10.1007/s00415-009-5206-3
   Philips MF, 1999, J NEUROSURG, V90, P65, DOI 10.3171/jns.1999.90.1.0065
   Renowden S, 2004, EUR RADIOL, V14, P215, DOI 10.1007/s00330-003-2021-6
   Saposnik G, 2011, STROKE, V42, P1158, DOI 10.1161/STR.0b013e31820a8364
   Shui SF, 2014, NEUROL INDIA, V62, P371, DOI 10.4103/0028-3886.141241
   Siddiqui FM, 2015, STROKE, V46, P1263, DOI 10.1161/STROKEAHA.114.007465
   Siddiqui FM, 2014, INTERV NEURORADIOL, V20, P336, DOI 10.15274/NRJ-2014-10032
   Stam J, 2008, STROKE, V39, P1487, DOI 10.1161/STROKEAHA.107.502658
   Tsai FY, 2007, CARDIOVASC INTER RAD, V30, P675, DOI 10.1007/s00270-007-9046-1
   van den Bergh WM, 2005, NEUROLOGY, V65, P192, DOI 10.1212/01.wnl.0000179677.84785.63
   Wang JZ, 2007, BRAIN RES, V1181, P118, DOI 10.1016/j.brainres.2007.08.070
   Wasay M, 2001, STROKE, V32, P2310, DOI 10.1161/hs1001.096192
   Wetzel SG, 1999, AM J NEURORADIOL, V20, P249
   Yue XY, 2010, J THROMB THROMBOLYS, V29, P361, DOI 10.1007/s11239-009-0386-3
   Zhang A, 2008, NEUROCRIT CARE, V9, P17, DOI 10.1007/s12028-008-9058-y
   Zhen Y, 2015, EXP THER MED, V9, P1080, DOI 10.3892/etm.2015.2198
NR 40
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 341
EP 350
DI 10.1016/j.wneu.2019.06.211
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200202
PM 31284054
DA 2020-05-12
ER

PT J
AU Bernstock, JD
   Shafaat, O
   Hardigan, A
   Fox, BM
   Moore, LS
   Chagoya, G
   Elsayed, G
   Gessler, F
   Ilyas, A
   Yamashita, D
   McGrew, B
   Fisher, WS
   Hackney, J
   Sotoudeh, H
AF Bernstock, Joshua D.
   Shafaat, Omid
   Hardigan, Andrew
   Fox, Brandon M.
   Moore, Lindsay S.
   Chagoya, Gustavo
   Elsayed, Galal
   Gessler, Florian
   Ilyas, Adeel
   Yamashita, Daisuke
   McGrew, Benjamin
   Fisher, Winfield S., III
   Hackney, James
   Sotoudeh, Houman
TI Angiosarcoma of the Temporal Bone: Case Report and Review of the
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Angiosarcoma; Lateral skull base; Temporal bone
ID HEMANGIOENDOTHELIOMA ANGIOSARCOMA; PATHOLOGY; OUTCOMES; SKULL; HEAD
AB BACKGROUND: Angiosarcomas are rare malignant tumors of endothelial origin. Nearly one half of all angiosarcomas occur in the head and neck. Temporal bone angiosarcomas are extremely uncommon. We present a case of temporal bone angiosarcoma and a review of the relevant data.
   CASE DESCRIPTION: We present the case of a 20-year-old man with a painful right postauricular mass after a closed head injury. Radiologic studies demonstrated a large right osteolytic and heterogeneously enhancing mass. The patient underwent right transpetrosal craniectomy for resection. Histologic studies confirmed high-grade sarcoma. Immunohistochemical staining demonstrated a uniformly positive ERG endothelial marker, CD31 staining with cytoplasmic and membranous patterns of immunopositivity, positive nuclear staining for FLI-1, positive cytoplasmic and membranous staining for CD99 and STATE, and negative smooth muscle actin stains in the neoplastic cells. Ki-67 staining showed similar to 94% positivity in the neoplastic cell nuclei. Postoperative follow-up imaging studies demonstrated evidence of metastatic right cervical lymphadenopathy.
   CONCLUSIONS: Angiosarcoma of the temporal bone is extremely uncommon. In the present case report, we explored a relationship between trauma and angiosarcoma of the temporal bone. We reviewed the reported data regarding the pathogenesis, diagnosis, treatment, radiologic findings, and histologic characteristics of angiosarcoma of the temporal bone.
C1 [Bernstock, Joshua D.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
   [Shafaat, Omid] Isfahan Univ Med Sci, Dept Radiol & Intervent Neuroradiol, Esfahan, Iran.
   [Hardigan, Andrew; Fox, Brandon M.; Chagoya, Gustavo; Elsayed, Galal; Ilyas, Adeel; Yamashita, Daisuke; Fisher, Winfield S., III] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL USA.
   [Moore, Lindsay S.; McGrew, Benjamin] Univ Alabama Birmingham, Dept Otolaryngol, Birmingham, AL USA.
   [Hackney, James] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Sotoudeh, Houman] Univ Alabama Birmingham, Dept Neuroradiol, Birmingham, AL 35294 USA.
   [Gessler, Florian] Goethe Univ Hosp, Dept Neurosurg, Frankfurt, Germany.
RP Sotoudeh, H (reprint author), Univ Alabama Birmingham, Dept Neuroradiol, Birmingham, AL 35294 USA.
EM hsotoudeh@uabmc.edu
RI Chagoya, Gustavo/S-8172-2019
OI Chagoya, Gustavo/0000-0002-8337-4467; Elsayed,
   Galal/0000-0002-0894-9486; Yamashita, Daisuke/0000-0002-5829-7287; Fox,
   Brandon/0000-0003-2242-2477; Shafaat, Omid/0000-0001-8793-7901
CR Abraham JA, 2007, ANN SURG ONCOL, V14, P1953, DOI 10.1245/s10434-006-9335-y
   Ai Di, 2018, Proc (Bayl Univ Med Cent), V31, P84, DOI 10.1080/08998280.2017.1390339
   Bourekas EC, 1996, AM J NEURORADIOL, V17, P1946
   Bridge J, 2013, WHO CLASSIFICATION T, P137
   Buehler D, 2014, AM J CLIN ONCOL-CANC, V37, P473, DOI 10.1097/COC.0b013e31827e4e7b
   CAMPANACCI M, 1980, CANCER, V46, P804, DOI 10.1002/1097-0142(19800815)46:4<804::AID-CNCR2820460427>3.0.CO;2-1
   Cao Ying, 2012, Proc (Bayl Univ Med Cent), V25, P70
   Chou YC, 2004, SURG NEUROL, V61, P575, DOI 10.1016/j.surneu.2003.07.002
   Chugh Ashish P, 2014, Surg Neurol Int, V5, P92, DOI 10.4103/2152-7806.134365
   D'Angelo SP, 2015, ONCOLOGY-BASEL, V89, P205, DOI 10.1159/000381917
   Durbec M, 2014, EUR ANN OTORHINOLARY, V131, P375, DOI 10.1016/j.anorl.2014.06.002
   Fedok FG, 1999, AM J OTOLARYNG, V20, P223, DOI 10.1016/S0196-0709(99)90004-2
   Fomete B, 2015, J KOR ASSOC ORAL MAX, V41, P273, DOI 10.5125/jkaoms.2015.41.5.273
   Fury MG, 2005, CANCER J, V11, P241, DOI 10.1097/00130404-200505000-00011
   Hammon RJ, 2011, ARCH OTOLARYNGOL, V137, P197
   Hart J, 2008, ARCH PATHOL LAB MED, V135, P1
   KINKADE JM, 1948, ANN OTO RHINOL LARYN, V57, P235
   La Corte E, 2015, NEUROPATHOLOGY, V35, P184, DOI 10.1111/neup.12178
   Lopes M, 1999, NEUROSURGERY, V44, P405, DOI 10.1097/00006123-199902000-00102
   O'Neill JP, 2013, NEUROSURG CLIN N AM, V24, P67, DOI 10.1016/j.nec.2012.08.010
   Reichardt P, 2014, FUTURE ONCOL, V10, DOI [10.2217/FON.14.116, 10.2217/fon.14.116]
   Renukaswamy GM, 2009, INT J PEDIATR OTORHI, V73, P1598, DOI 10.1016/j.ijporl.2009.07.025
   Samadian M, 2012, TURK NEUROSURG, V22, P113, DOI 10.5137/1019-5149.JTN.3148-10.1
   Sasaki R, 2002, INT J RADIAT ONCOL, V52, P1032, DOI 10.1016/S0360-3016(01)02753-5
   Scholsem M, 2005, J NEURO-ONCOL, V75, P121, DOI 10.1007/s11060-005-0375-0
   Selim A, 2005, CUTIS, V76, P313
   SHUANGSHOTI S, 1988, BRIT J OPHTHALMOL, V72, P713, DOI 10.1136/bjo.72.9.713
   Sullivan HC, 2015, J CLIN PATHOL, V68, P44, DOI 10.1136/jclinpath-2014-202629
   Verbeke SLJ, 2011, INT J CLIN EXP PATHO, V4, P541
   VOLPE R, 1982, CANCER-AM CANCER SOC, V49, P727, DOI 10.1002/1097-0142(19820215)49:4<727::AID-CNCR2820490422>3.0.CO;2-V
   Yamada Y, 2013, HEAD NECK PATHOL, V7, P159, DOI 10.1007/s12105-012-0389-9
   Young RJ, 2015, LANCET ONCOL, V11, P507
   Young RJ, 2017, MEMO-MAG EUR MED ONC, V10, P190, DOI 10.1007/s12254-017-0365-x
NR 33
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 351
EP 357
DI 10.1016/j.wneu.2019.07.107
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200203
PM 31330332
DA 2020-05-12
ER

PT J
AU Kondo, H
   Kiura, Y
   Takeshita, S
   Magaki, T
   Sakoguchi, T
   Mukai, T
   Maeda, Y
   Tominaga, A
   Kurisu, K
AF Kondo, Hiroshi
   Kiura, Yoshihiro
   Takeshita, Shinichiro
   Magaki, Takuro
   Sakoguchi, Tetsuhiko
   Mukai, Tomoya
   Maeda, Yuyo
   Tominaga, Atsushi
   Kurisu, Kaoru
TI Angioscopic Findings in 3 Patients Who Required Retreatment After
   Carotid Artery Stenting
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angioscopy; Carotid artery stenting; Neointima; Restenosis; Retreatment;
   Stent lumen
ID RESTENOSIS; PLAQUE
AB BACKGROUND: Use of angioscopy to directly observe the stent lumen in the phase after carotid artery stenting (CAS) has not been reported to date. Here we report 3 patients in whom angioscopy helped confirm the stent lumen during retreatment after CAS.
   CASE DESCRIPTION: Case 1 required retreatment for stent shortening that occurred 1 month after the first CAS. Preprocedure angioscopy showed the presence of neointima, which could not be revealed by intravascular ultrasound (IVUS). In case 2, which required repeat CAS for distal progressive stenosis of the internal carotid artery, the neointima was observed on the stent surface and was more pronounced on the distal side. In case 3, retreatment was necessary for recurrent ischemic stroke caused by stent restenosis; preprocedure angioscopy showed an unstable plaque, which was not detected as vulnerable by IVUS, protruding into the stent lumen, with partial ulceration and bleeding.
   CONCLUSIONS: Compared with IVUS, angioscopy enables a more detailed observation of the stent lumen. Although angioscopy is relatively invasive, its use in evaluating changes in the stent lumen after CAS should be clarified by accumulation of reported cases.
C1 [Kondo, Hiroshi; Kiura, Yoshihiro; Takeshita, Shinichiro; Magaki, Takuro; Sakoguchi, Tetsuhiko; Maeda, Yuyo; Tominaga, Atsushi] Hiroshima Prefectural Hosp, Dept Neurosurg & Neuroendovasc Therapy, Hiroshima, Hiroshima, Japan.
   [Kondo, Hiroshi; Kiura, Yoshihiro; Kurisu, Kaoru] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Hiroshima, Japan.
   [Mukai, Tomoya] Hiroshima Prefectural Hosp, Dept Neurol, Hiroshima, Hiroshima, Japan.
RP Kondo, H (reprint author), Hiroshima Prefectural Hosp, Dept Neurosurg & Neuroendovasc Therapy, Hiroshima, Hiroshima, Japan.; Kondo, H (reprint author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Hiroshima, Japan.
EM springhascome0224@gmail.com
OI Kondo, Hiroshi/0000-0003-3981-3052
CR Arquizan C, 2011, STROKE, V42, P1015, DOI 10.1161/STROKEAHA.110.589309
   Asakura M, 1998, CIRCULATION, V97, P2003, DOI 10.1161/01.CIR.97.20.2003
   Clark DJ, 2006, J AM COLL CARDIOL, V47, P2390, DOI 10.1016/j.jacc.2006.01.076
   Inoue K, 2008, J JPN CORON ASS, V14, P36
   Kazuoki D, 2013, J CARDIOL, V61, P22
   Kimura S, 2016, INT J CARDIOVAS IMAG, V32, P1483, DOI 10.1007/s10554-016-0941-x
   Komatsu R, 1998, CIRCULATION, V98, P224, DOI 10.1161/01.CIR.98.3.224
   Kondo H, 2019, WORLD NEUROSURG, V125, pE448, DOI 10.1016/j.wneu.2019.01.102
   Lal BK, 2012, LANCET NEUROL, V11, P755, DOI 10.1016/S1474-4422(12)70159-X
   Matsuo K, 2013, EUROINTERVENTION, V9, P235, DOI 10.4244/EIJV9I2A39
   Miyata H, 2015, J NEUROENDOVASC THER, V9, P245
   Tamakawa N, 2008, J NEUROENDOVASCULAR, V2, P193
   Tanemura H, 2005, AM J NEURORADIOL, V26, P1943
   Toma N, 2003, J NEUROSURG, V98, P199, DOI 10.3171/jns.2003.98.1.0199
   Uchida Y, 2019, ANGIOSCOPE, V5, P1
   Uchida Y, 2011, J CARDIOL, V57, P18, DOI 10.1016/j.jjcc.2010.11.001
   Ueda Y, 2004, AM HEART J, V148, P333, DOI 10.1016/j.ahj.2004.03.047
   Yoshimura S, OPTICAL COHERENCE TO
   Younis G, 2005, ENDOVASC TODAY, V1, P18
NR 19
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 358
EP 363
DI 10.1016/j.wneu.2019.06.191
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200204
PM 31279107
DA 2020-05-12
ER

PT J
AU Gravbrot, N
   Brasiliense, LBC
   Alswied, A
   Sun, B
   Lemole, GM
AF Gravbrot, Nicholas
   Brasiliense, Leonardo B. C.
   Alswied, Abdullah
   Sun, Belinda
   Lemole, G. Michael, Jr.
TI Multiple Extraaxial Cavernous Hemanpiomas: Rare Entity
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cavernous hemangioma; Dural sinus; Extraaxial; Vascular disorder; Venous
   malformation
ID HEMANGIOMA; ANGIOMA
AB BACKGROUND: Cavernous hemangiomas arising in the extraaxial space are rarely encountered, often mimicking other more common pathologies. Furthermore, multiple coexisting lesions and posterior fossa involvement are scarcely reported. Herein, we present the case of a patient with concurrent frontal bone and posterior fossa extraaxial cavernous hemangiomas. We also review the challenges associated with the diagnosis and management of these entities.
   CASE DESCRIPTION: An otherwise healthy 41-year-old gentleman presented with a 7-month history of a progressive right forehead mass. Imaging demonstrated a right frontal bone mass and an incidentally noted transverse sinus- based mass. The patient opted for surgical resection of both lesions. A right frontal craniotomy was performed to remove the bony lesion, followed by a suboccipital approach for the dural-based mass. There were no significant complications intraoperatively, and gross total resection was achieved for both lesions. Final pathology for each was consistent with cavernous hemangioma.
   CONCLUSIONS: Extraaxial cavernous hemangiomas are uncommon clinical entities that are challenging to distinguish from other diseases. If intraoperative complications can be avoided, treatment with surgical resection often offers excellent patient outcomes.
C1 [Gravbrot, Nicholas; Brasiliense, Leonardo B. C.; Lemole, G. Michael, Jr.] Univ Arizona, Dept Surg, Div Neurosurg, Tucson, AZ 85721 USA.
   [Alswied, Abdullah; Sun, Belinda] Univ Arizona, Dept Pathol, Tucson, AZ USA.
RP Lemole, GM (reprint author), Univ Arizona, Dept Surg, Div Neurosurg, Tucson, AZ 85721 USA.
EM mlemole@surgery.arizona.edu
OI Gravbrot, Nicholas/0000-0003-2024-6481
CR Abou-Al-Shaar Hussam, 2016, Surg Neurol Int, V7, pS523, DOI 10.4103/2152-7806.187495
   Albanese A, 2009, NEUROSURGERY, V64, pS135, DOI 10.1227/01.NEU.0000335654.56346.B6
   Amenta P, 2011, JHN J, V6, P5
   Bansal S, 2014, J CLIN NEUROSCI, V21, P968, DOI 10.1016/j.jocn.2013.09.008
   Barnabas O, 2013, J GERIATR CARDIOL, V10, P377, DOI 10.3969/j.issn.1671-5411.2013.04.008
   Dorner L, 2005, ACTA NEUROCHIR, V147, P1091, DOI 10.1007/s00701-005-0567-6
   Ghanta Rajesh K, 2013, J Neurosci Rural Pract, V4, P210, DOI 10.4103/0976-3147.112772
   Gonzalez L Fernando, 2006, Neurosurg Focus, V21, pe6
   Hasiloglu ZI, 2013, CLIN IMAG, V37, P744, DOI 10.1016/j.clinimag.2013.01.018
   Jagannatha AT, 2017, CHILD NERV SYST, V33, P691, DOI 10.1007/s00381-016-3307-8
   Kim Jung-Hoon, 2018, Asian J Neurosurg, V13, P499, DOI 10.4103/ajns.AJNS_166_16
   KRIEF O, 1991, AM J NEURORADIOL, V12, P988
   Lan ZG, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013098
   LASJAUNIAS P, 1989, NEUROCHIRURGIE, V35, P132
   Li ZZ, 2018, J CLIN NEUROSCI, V58, P218, DOI 10.1016/j.jocn.2018.10.015
   Mansour TR, 2017, WORLD NEUROSURG, V100, DOI 10.1016/j.wneu.2017.02.029
   NAMBA S, 1983, SURG NEUROL, V19, P379, DOI 10.1016/0090-3019(83)90249-5
   Ooi KH, 2018, CUREUS, V10, DOI 10.7759/cureus.2285
   Ryu HS, 2018, WORLD NEUROSURG, V110, P39, DOI 10.1016/j.wneu.2017.10.148
   Shah Roban, 2015, Radiol Case Rep, V10, P1013, DOI 10.2484/rcr.v10i1.1013
   Shi JX, 1999, NEUROSURGERY, V45, P1308, DOI 10.1097/00006123-199912000-00006
   SIMARD JM, 1986, NEUROSURGERY, V18, P162
   Simonin A, 2019, NEUROSURGERY, V84, pE211, DOI 10.1093/neuros/nyy080
   Sohn CH, 2003, AM J NEURORADIOL, V24, P1148
   Yadav RR, 2012, NEURORADIOL J, V25, P515, DOI 10.1177/197140091202500503
   Yang CY, 2010, BRAIN DEV-JPN, V32, P883, DOI 10.1016/j.braindev.2010.02.006
   Yin YH, 2013, J CLIN NEUROSCI, V20, P128, DOI 10.1016/j.jocn.2012.01.050
   Yoshimura J, 2014, J NEUROSURG-PEDIATR, V14, P43, DOI 10.3171/2014.4.PEDS13628
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 364
EP 368
DI 10.1016/j.wneu.2019.07.104
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200205
PM 31326639
DA 2020-05-12
ER

PT J
AU Almeida, ND
   Klein, AL
   Hogan, EA
   Terhaar, SJ
   Kedda, J
   Uppal, P
   Sack, K
   Keidar, M
   Sherman, JH
AF Almeida, Neil D.
   Klein, Andrea L.
   Hogan, Elizabeth A.
   Terhaar, Samantha J.
   Kedda, Jayanidhi
   Uppal, Prayerna
   Sack, Kenneth
   Keidar, Michael
   Sherman, Jonathan H.
TI Cold Atmospheric Plasma as an Adjunct to Immunotherapy for Glioblastoma
   Multiforme
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cold atmospheric plasma; Glioblastoma multiforme; Immunotherapy
ID MESENCHYMAL STEM-CELLS; HLA-DR EXPRESSION; TUMOR MICROENVIRONMENT;
   SIGNALING PATHWAYS; CANCER; INDUCTION; MONOCYTES; CARCINOMA; MOLECULE;
   MAPK
AB Glioblastoma multiforme (GBM) is the most common and aggressive form of brain cancer in adults. GBM carries a dismal prognosis because of its proliferative, invasive, and angiogenic capabilities and because of its ability to downregulate the immune system. Immune-based therapies under investigation for GBM have been unsuccessful in vivo because of this downregulation. Cold atmospheric plasma (CAP) is a high-energy state of matter that can be applied directly or indirectly to tumor tissue to serve as an adjunct to immunotherapy in the treatment of GBM because it upregulates the immune system by the induction of reactive oxygen species. CAP has the potential to improve the efficacy of existing and investigative immunotherapies for GBM.
C1 [Almeida, Neil D.; Klein, Andrea L.; Terhaar, Samantha J.; Kedda, Jayanidhi; Uppal, Prayerna] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA.
   [Klein, Andrea L.; Hogan, Elizabeth A.; Sack, Kenneth; Keidar, Michael; Sherman, Jonathan H.] George Washington Univ, Dept Neurosurg, Washington, DC 20052 USA.
   [Klein, Andrea L.; Keidar, Michael] George Washington Univ, Dept Mech & Aerosp Engn, Washington, DC 20052 USA.
RP Hogan, EA (reprint author), George Washington Univ, Dept Neurosurg, Washington, DC 20052 USA.
EM eahogan13@gmail.com
OI Hogan, Elizabeth/0000-0002-1754-5643
CR Anderton MJ, 2011, TOXICOL PATHOL, V39, P916, DOI 10.1177/0192623311416259
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Bernd HW, 2009, HAEMATOL-HEMATOL J, V94, P1569, DOI 10.3324/haematol.2009.008862
   Bundscherer L, 2013, IMMUNOBIOLOGY, V218, P1248, DOI 10.1016/j.imbio.2013.04.015
   CHEADLE WG, 1991, AM J SURG, V161, P639, DOI 10.1016/0002-9610(91)91247-G
   Cheema TA, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27218
   Cheng XQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098652
   Cuoco JA, 2018, WORLD NEUROSURG, V120, P302, DOI 10.1016/j.wneu.2018.08.202
   Dix AR, 1999, J NEUROIMMUNOL, V100, P216, DOI 10.1016/S0165-5728(99)00203-9
   Dubuc A, 2018, THER ADV MED ONCOL, V10, P1, DOI 10.1177/1758835918786475
   Gustafson MP, 2010, NEURO-ONCOLOGY, V12, P631, DOI 10.1093/neuonc/noq001
   Hirst AM, 2016, TUMOR BIOL, V37, P7021, DOI 10.1007/s13277-016-4911-7
   Hudson AL, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00314
   Johnson LA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4963
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Kerrigan BCP, 2017, CYTOTHERAPY, V19, P445, DOI 10.1016/j.jcyt.2017.02.002
   Kore RA, 2014, BIOCHEM BIOPH RES CO, V453, P326, DOI 10.1016/j.bbrc.2014.09.068
   Kream RM, 2007, MED SCI MONITOR, V13, pBR25
   Lacerda L, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0549-4
   Lang FM, 2018, NEURO-ONCOLOGY, V20, P380, DOI 10.1093/neuonc/nox152
   Lee JC, 2004, J IMMUNOL, V172, P7335, DOI 10.4049/jimmunol.172.12.7335
   Lei SG, 2012, STEM CELLS, V30, P2810, DOI 10.1002/stem.1251
   Lekkou A, 2004, CLIN DIAGN LAB IMMUN, V11, P161, DOI 10.1128/CDLI.11.1.161-167.2004
   Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027
   Li LL, 2011, ACS NANO, V5, P7462, DOI 10.1021/nn202399w
   Li M, 2018, LIFE SCI, V201, P37, DOI 10.1016/j.lfs.2018.03.044
   Li MH, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/2051-1426-2-21
   Lin A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050966
   Lin A, 2015, PLASMA PROCESS POLYM, V12, P1392, DOI 10.1002/ppap.201500139
   LOS M, 1995, EUR J IMMUNOL, V25, P159, DOI 10.1002/eji.1830250127
   Mishra PJ, 2008, CANCER RES, V68, P4331, DOI 10.1158/0008-5472.CAN-08-0943
   Murakami T, 2018, ANTICANCER RES, V38, P5049, DOI 10.21873/anticanres.12824
   Nakano O, 2001, CANCER RES, V61, P5132
   Otsu K, 2009, BLOOD, V113, P4197, DOI 10.1182/blood-2008-09-176198
   Park J, 2016, SCI REP-UK, V6, DOI 10.1038/srep39298
   Park J, 2015, NEUROSCI LETT, V584, P191, DOI 10.1016/j.neulet.2014.10.016
   Rahman M, 2018, J NEURO-ONCOL, V137, P249, DOI 10.1007/s11060-017-2732-1
   Reardon DA, 2014, NEURO-ONCOLOGY, V16, P1441, DOI 10.1093/neuonc/nou212
   Ridge SM, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0597-8
   Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082
   Robert E, 2013, CLIN PLASMA MED, V1, P8, DOI 10.1016/j.cpme.2013.10.002
   Rodon J, 2015, CLIN CANCER RES, V21, P553, DOI 10.1158/1078-0432.CCR-14-1380
   Sahin A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199414
   Sayegh ET, 2014, J NEURO-ONCOL, V119, P531, DOI 10.1007/s11060-014-1502-6
   Schumacher T, 2014, NATURE, V512, P324, DOI 10.1038/nature13387
   Spaeth EL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004992
   Stevens RD, 2015, NEUROCRIT CARE, V23, pS76, DOI 10.1007/s12028-015-0168-z
   Tamura R, 2018, WORLD NEUROSURG, V120, pE601, DOI 10.1016/j.wneu.2018.08.133
   Tseng CY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131911
   Wang C, 2016, BIOMATERIALS, V79, P88, DOI 10.1016/j.biomaterials.2015.11.040
   Wang HCR, 2011, NAT REV UROL, V8, P608, DOI 10.1038/nrurol.2011.135
   Wang MN, 2017, J CANCER, V8, P761, DOI 10.7150/jca.17648
   Waziri A, 2010, NEUROSURG CLIN N AM, V21, P31, DOI 10.1016/j.nec.2009.08.005
   Weiss T, 2015, CURR OPIN NEUROL, V28, P639, DOI 10.1097/WCO.0000000000000249
   Wen PY, 2014, J CLIN ONCOL S, V32
   Xu D, 2015, BIOCHEM BIOPH RES CO, V473, P1125
   Yan DY, 2017, ONCOTARGET, V8, P15977, DOI 10.18632/oncotarget.13304
   Ye HM, 2012, CANCER INVEST, V30, P513, DOI 10.3109/07357907.2012.692171
   Youn GS, 2016, FREE RADICAL BIO MED, V97, P14, DOI 10.1016/j.freeradbiomed.2016.05.014
   Zhang Q, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0977-z
   Zhou Y, 2018, CANCER MED-US, V7, P4012, DOI 10.1002/cam4.1670
NR 61
TC 0
Z9 0
U1 4
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 369
EP 376
DI 10.1016/j.wneu.2019.06.209
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200206
PM 31284051
DA 2020-05-12
ER

PT J
AU Rafiq, R
   Sharma, R
   Borkar, SA
AF Rafiq, Rahil
   Sharma, Ravi
   Borkar, Sachin A.
TI Giant Sporadic Unilateral Vestibular Schwannoma in Child: Can It Get
   Bigger Than This?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acoustic schwannoma; Cerebellopontine angle; Giant; Pediatric vestibular
   schwannoma; Vestibular schwannoma
ID NEUROFIBROMATOSIS
AB Vestibular schwannomas (VSs) are rare in children and, when present, are usually part of neurofibromatosis 2 and bilateral. Sporadic unilateral VSs in the pediatric age group itself are rare in medical literature and giant sporadic unilateral pediatric VSs (>4 cm) are extremely rare. Herein, we describe the largest reported case of giant sporadic left-sided VS in a 10-year-old boy.
C1 [Rafiq, Rahil; Sharma, Ravi; Borkar, Sachin A.] All India Inst Med Sci, Dept Neurosurg, New Delhi, India.
RP Borkar, SA (reprint author), All India Inst Med Sci, Dept Neurosurg, New Delhi, India.
EM sachin.aiims@gmail.com
CR Bull JG, 2006, PEDIATR NEUROSURG, V42, P338, DOI 10.1159/000094076
   Choi JW, 2014, J NEUROSURG-PEDIATR, V13, P650, DOI 10.3171/2014.3.PEDS13455
   Garg P, 2007, J PEDIATR NEUROSCI, V2, P58, DOI 10.4103/1817-1745.36764
   HERNANZSCHULMAN M, 1986, AM J NEURORADIOL, V7, P519
   KANTER WR, 1980, NEUROLOGY, V30, P851, DOI 10.1212/WNL.30.8.851
   Pothula VB, 2001, OTOL NEUROTOL, V22, P903, DOI 10.1097/00129492-200111000-00032
   REVILLA AG, 1947, B JOHNS HOPKINS HOSP, V80, P254
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 378
EP 379
DI 10.1016/j.wneu.2019.07.064
PG 2
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200208
PM 31306840
DA 2020-05-12
ER

PT J
AU Baltus, C
   Toffoli, S
   London, F
   Delree, P
   Gilliard, C
   Gustin, T
AF Baltus, Cedric
   Toffoli, Sebastien
   London, Frederic
   Delree, Paul
   Gilliard, Claude
   Gustin, Thierry
TI Chromothripsis in an Early Recurrent Chordoid Meningioma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chordoid meningioma; Chromothripsis; Recurrence
ID CLASSIFICATION; MUTATIONS; SYSTEM; AKT1; REARRANGEMENTS; MECHANISMS; SMO
AB BACKGROUND: Chromothripsis is characterized by a multitude of chromosomal rearrangements during a unique cataclysmic event in a cell life. Disintegration of one or several chromosomes is followed by a chaotic rearrangement of generated fragments. It might play a role in oncogenesis and tumor progression. It is observed in 2%-3% of cancers and is rarely reported in benign tumors. We report a case of massive chromothripsis in a fast growing chordoid meningioma.
   CASE DESCRIPTION: A 55-year-old woman was admitted for a meningeal mass developing in the right parietal parasagittal area. She underwent subtotal resection of the tumor. Histologic analysis revealed a chordoid meningioma (World Health Organization grade II). Six months later, magnetic resonance imaging showed a large bilateral tumor recurrence. After a second surgery, the patient received radiotherapy. Thereafter, the clinical course was uneventful. Comparative genomic hybridization showed only a monosomy X in the primary tumor. In the recurrent meningioma, this anomaly was associated with a massive chromothripsis including more than 370 chromosomal abnormalities affecting chromosomes 1-22.
   CONCLUSIONS: Chromothripsis is rarely described in benign tumors and especially in meningiomas. In the presented case, the high number of chromosomal rearrangements and the onset of this phenomenon at a later stage of tumor progression are very unusual. The role of surgical stress on the emergence of chromothripsis and its relation with tumor aggressiveness are discussed.
C1 [Baltus, Cedric; Gilliard, Claude; Gustin, Thierry] CHU UcL Namur, Dept Neurosurg, Yvoir, Belgium.
   [London, Frederic] CHU UcL Namur, Dept Neurol, Yvoir, Belgium.
   [Toffoli, Sebastien; Delree, Paul] Pathol & Genet Inst, Gosselies, Belgium.
RP Baltus, C (reprint author), CHU UcL Namur, Dept Neurosurg, Yvoir, Belgium.
EM cedricbaltus.pro@gmail.com
CR Abedalthagafi M, 2016, NEURO-ONCOLOGY, V18, P649, DOI 10.1093/neuonc/nov316
   Aizer AA, 2016, NEURO-ONCOLOGY, V18, P269, DOI 10.1093/neuonc/nov177
   Brastianos PK, 2013, NAT GENET, V45, P285, DOI 10.1038/ng.2526
   Clark VE, 2013, SCIENCE, V339, P1077, DOI 10.1126/science.1233009
   DeVitis LR, 1996, HUM GENET, V97, P632
   Furgason John M, 2015, Oncoscience, V2, P618
   Holland AJ, 2012, NAT MED, V18, P1630, DOI 10.1038/nm.2988
   Kloosterman WP, 2011, HUM MOL GENET, V20, P1916, DOI 10.1093/hmg/ddr073
   Koltsova AS, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00393
   Korbel JO, 2013, CELL, V152, P1226, DOI 10.1016/j.cell.2013.02.023
   Liu PF, 2011, CELL, V146, P888, DOI 10.1016/j.cell.2011.07.042
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Luijten MNH, 2018, MUTAT RES-REV MUTAT, V777, P29, DOI 10.1016/j.mrrev.2018.06.004
   Ly P, 2017, TRENDS CELL BIOL, V27, P917, DOI 10.1016/j.tcb.2017.08.005
   Maher CA, 2012, CELL, V148, P29, DOI 10.1016/j.cell.2012.01.006
   Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910
   Rausch T, 2012, CELL, V148, P59, DOI 10.1016/j.cell.2011.12.013
   Rennert RC, 2017, J NEUROSURG, V126, P1472, DOI 10.3171/2016.4.JNS153052
   Riemenschneider MJ, 2006, LANCET NEUROL, V5, P1045, DOI 10.1016/S1474-4422(06)70625-1
   Rode A, 2016, INT J CANCER, V138, P2322, DOI 10.1002/ijc.29888
   Sahm F, 2017, LANCET ONCOL, V18, P682, DOI 10.1016/S1470-2045(17)30155-9
   Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055
   Stevens JB, 2010, MOL CYTOGENET, V3, DOI 10.1186/1755-8166-3-20
   Wyatt AW, 2013, J PATHOL, V231, P1, DOI 10.1002/path.4220
   Zhang CZ, 2013, GENE DEV, V27, P2513, DOI 10.1101/gad.229559.113
NR 25
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 380
EP 385
DI 10.1016/j.wneu.2019.07.003
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200209
PM 31295612
DA 2020-05-12
ER

PT J
AU Dadhich, H
   Sharma, R
   Borkar, SA
   Dash, A
   Mahajan, S
   Sharma, MC
AF Dadhich, Hrishikesh
   Sharma, Ravi
   Borkar, Sachin Anil
   Dash, Atmanranjan
   Mahajan, Swati
   Sharma, Mehar Chand
TI Solitary Extra-axial Intracranial Primary Meningeal Pleomorphic
   Xanthoastrocytoma: An Extremely Rare Case
SO WORLD NEUROSURGERY
LA English
DT Article
DE Falcotentorial mass lesion; Glioma; Pleomorphic xanthoastrocytoma;
   Primary meningeal glioma
ID PRIMARY LEPTOMENINGEAL ASTROCYTOMA; GLIOMA; MR; GLIOBLASTOMA; MIMICKING;
   DIAGNOSIS; OUTCOMES; TUMOR; CT
AB BACKGROUND: Pleomorphic xanthoastrocytomas (PXAs) are a rare type of astrocytoma, which, similar to other gliomas, can rarely arise from glial nests in the meninges, manifesting as an extra-axial mass. We describe a solitary extraaxial intracranial primary meningeal PXA in the pediatric age group, which was masquerading as a tentorial meningioma.
   CASE DESCRIPTION: A 9-year-old girl presented with features of raised intracranial pressure. Imaging revealed a dural-based mass in the tentorial region suggestive of a meningioma. This suspicion was further strengthened by intraoperative visualization of an extra-axial tumor with wide tentorial attachment. Near-total excision was achieved. Histopathologic examination established the diagnosis of PXA. Given the tumor's apparent meningeal origin and lack of connection with brain parenchyma in imaging and intraoperative findings, primary meningeal PXA was diagnosed. The absence of coexisting tumor foci on spinal magnetic resonance imaging further refined the diagnosis as solitary extra-axial intracranial primary meningeal PXA. The patient received radiotherapy for the residual tumor and was doing well at 6 months after presentation; however, she was lost to follow-up after that.
   CONCLUSIONS: Solitary extra-axial intracranial primary meningeal PXA is an extremely rare entity with only 3 reported cases in the literature including the present case. This is the first report of such a tumor in a pediatric patient. This report also highlights that primary meningeal PXA can manifest as an extra-axial mass lesion and may warrant inclusion in the differential diagnosis of extraaxial mass lesions.
C1 [Dadhich, Hrishikesh; Sharma, Ravi; Borkar, Sachin Anil; Dash, Atmanranjan] All India Inst Med Sci, Dept Neurosurg, New Delhi, India.
   [Mahajan, Swati; Sharma, Mehar Chand] All India Inst Med Sci, Dept Pathol, New Delhi, India.
RP Borkar, SA (reprint author), All India Inst Med Sci, Dept Neurosurg, New Delhi, India.
EM sachin.aiims@gmail.com
CR Abbott KH, 1955, EXCERPTA MED, P786
   BAILEY P, 1985, CAN J NEUROL SCI, V12, P278, DOI 10.1017/S031716710004717X
   Bathla G, 2015, CLIN IMAG, V39, P672, DOI 10.1016/j.clinimag.2015.03.013
   Chamberlain MC, 2013, J NEURO-ONCOL, V114, P237, DOI 10.1007/s11060-013-1176-5
   Cirak B, 2000, PEDIATR INT, V42, P389, DOI 10.1046/j.1442-200x.2000.01237.x
   COOPER IS, 1951, J NEUROPATH EXP NEUR, V10, P16
   Crespo-Rodriguez AM, 2007, NEURORADIOLOGY, V49, P307, DOI 10.1007/s00234-006-0191-z
   De Tommasi Antonio, 2007, World J Surg Oncol, V5, P72, DOI 10.1186/1477-7819-5-72
   Giannini C, 1999, CANCER, V85, P2033, DOI 10.1002/(SICI)1097-0142(19990501)85:9<2033::AID-CNCR22>3.0.CO;2-Z
   Haddix T, 2007, BRAIN PATHOL, V17, P331, DOI 10.1111/j.1750-3639.2007.00076_3.x
   Hayashi Ken, 1994, Neurologia Medico-Chirurgica, V34, P295, DOI 10.2176/nmc.34.295
   HOROUPIAN DS, 1979, ARCH PATHOL LAB MED, V103, P676
   Ideguchi M, 1998, NEUROL MED-CHIR, V38, P283, DOI 10.2176/nmc.38.283
   KAKITA A, 1992, ACTA NEUROPATHOL, V83, P538, DOI 10.1007/BF00310033
   Karsy M, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0722-5
   Katsuhara T, 2016, NEURO-ONCOLOGY, V18, P43
   Katsuhara T, 2018, MOL CLIN ONCOL, V8, P466, DOI 10.3892/mco.2018.1561
   KEPES JJ, 1993, BRAIN PATHOL, V3, P269, DOI 10.1111/j.1750-3639.1993.tb00753.x
   Kim Young Goo, 2013, Brain Tumor Res Treat, V1, P36, DOI 10.14791/btrt.2013.1.1.36
   KRIEF O, 1994, AM J NEURORADIOL, V15, P1782
   Lee EQ, 2016, J CLIN ONCOL, V34, pE87, DOI 10.1200/JCO.2013.51.1766
   Lim S, 2013, J KOREAN NEUROSURG S, V53, P281, DOI 10.3340/jkns.2013.53.5.281
   LIPPER MH, 1993, AM J NEURORADIOL, V14, P1397
   MACAULAY RJB, 1993, J NEUROSURG, V79, P761, DOI 10.3171/jns.1993.79.5.0761
   MACKENZIE JM, 1987, NEUROPATH APPL NEURO, V13, P481, DOI 10.1111/j.1365-2990.1987.tb00076.x
   MALEKI M, 1983, SURG NEUROL, V20, P235, DOI 10.1016/0090-3019(83)90059-9
   Menendez R, 2014, TURK NEUROSURG, V24, P987, DOI 10.5137/1019-5149.JTN.10063-13.1
   Moore W, 2014, AM J NEURORADIOL, V35, P2192, DOI 10.3174/ajnr.A4011
   Narayan V, 2018, WORLD NEUROSURG, V116, P163, DOI 10.1016/j.wneu.2018.04.080
   Ng HK, 1998, J NEUROSURG, V88, P586, DOI 10.3171/jns.1998.88.3.0586
   Oka H, 1994, Noshuyo Byori, V11, P193
   OPESKIN K, 1994, PATHOLOGY, V26, P72, DOI 10.1080/00313029400169181
   Pahapill PA, 1996, NEUROSURGERY, V38, P822, DOI 10.1227/00006123-199604000-00038
   Perkins SM, 2012, J NEURO-ONCOL, V110, P99, DOI 10.1007/s11060-012-0939-8
   Pierallini A, 1999, NEURORADIOLOGY, V41, P30, DOI 10.1007/s002340050700
   Raz E, 2010, BRAIN PATHOL, V20, P987, DOI 10.1111/j.1750-3639.2010.00422.x
   RIPPE DJ, 1992, J COMPUT ASSIST TOMO, V16, P856, DOI 10.1097/00004728-199211000-00004
   SCEATS DJ, 1986, NEUROSURGERY, V19, P649, DOI 10.1227/00006123-198610000-00027
   Sharma R, 2017, NEUROL INDIA, V65, P898, DOI 10.4103/neuroindia.NI_260_17
   SHUANGSHOTI S, 1984, J NEUROSURG, V61, P777, DOI 10.3171/jns.1984.61.4.0777
   Stavrinou P, 2010, CENT EUR NEUROSURG, V71, P46, DOI 10.1055/s-0029-1225652
   SUMI SM, 1968, J NEUROL NEUROSUR PS, V31, P190, DOI 10.1136/jnnp.31.2.190
   Taraszewska A, 2013, CLIN NEUROPATHOL, V32, P58, DOI 10.5414/NP300510
   TIEN RD, 1992, AM J ROENTGENOL, V159, P1287, DOI 10.2214/ajr.159.6.1442403
   Usubalieva A, 2015, J NEUROPATH EXP NEUR, V74, P960, DOI 10.1097/NEN.0000000000000240
   Wakabayashi K, 2002, CLIN NEUROPATHOL, V21, P206
   WHITTLE IR, 1989, J NEUROSURG, V70, P463, DOI 10.3171/jns.1989.70.3.0463
   YOSHINO MT, 1992, AM J NEURORADIOL, V13, P1330
   Yu SP, 2011, ACTA RADIOL, V52, P223, DOI 10.1258/ar.2010.100221
   Zarate JO, 1999, AM J SURG PATHOL, V23, P79, DOI 10.1097/00000478-199901000-00008
   ZENTNER J, 1988, NEUROCHIRURGIA, V31, P101
   Zhao XT, 2015, INT J CLIN EXP PATHO, V8, P1036
NR 52
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 386
EP 390
DI 10.1016/j.wneu.2019.06.218
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200210
PM 31295593
DA 2020-05-12
ER

PT J
AU Kammoun, B
   Belmabrouk, H
   Kolsi, F
   Kammoun, O
   Kallel, R
   Ammar, M
   Kallel, M
   Mseddi, MA
   Boudawara, MZ
AF Kammoun, Brahim
   Belmabrouk, Houda
   Kolsi, Fatma
   Kammoun, Omar
   Kallel, Rim
   Ammar, Mouna
   Kallel, Mouna
   Mseddi, Mohamed Amine
   Boudawara, Mohamed Zaher
TI Brain Metastasis of Pheochromocytoma: Diagnostic and Therapeutic
   Challenge
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumor; Metastasis; Pheochromocytoma; Surgery
ID MALIGNANT PHEOCHROMOCYTOMA; PATIENT; DISEASE; GENE
AB BACKGROUND: Pheochromocytoma brain metastasis is extremely rare. Few cases have been reported in the literature. Therefore, diagnosis and effective treatment of these lesions are difficult.
   CASE DESCRIPTION: Here, we report the case of 29-year-old woman, who was operated on for a right adrenal pheochromocytoma. Fourteen months later, a posterior fossa tumor was diagnosed. Radiologic findings mimicked an extra-axial lesion. The radiologic differential diagnosis was difficult even using magnetic resonance imaging spectroscopy. The patient was operated on through a retrosigmoid approach. Local recurrence occurred 6 months after first surgery. The patient died 1 month later, despite a second operation.
   CONCLUSIONS: Although the occurrence of brain metastases in pheochromocytoma is not prevalent, patients presenting with suggestive features need to be carefully considered. Magnetic resonance imaging can help in differential diagnosis with a primary brain tumor. There are no established guidelines for the treatment of pheochromocytoma brain metastasis, for which the prognosis remains dismal, despite effective surgery.
C1 [Kammoun, Brahim; Belmabrouk, Houda; Kolsi, Fatma; Boudawara, Mohamed Zaher] Sfax Univ, Habib Bourguiba Univ Hosp, Dept Neurosurg, Sfax, Tunisia.
   [Kammoun, Omar] Sfax Univ, Habib Bourguiba Univ Hosp, Dept Radiol, Sfax, Tunisia.
   [Kallel, Rim] Sfax Univ, Habib Bourguiba Univ Hosp, Dept Pathol, Sfax, Tunisia.
   [Kallel, Mouna] Sfax Univ, Habib Bourguiba Univ Hosp, Dept Radiotherapy, Sfax, Tunisia.
   [Mseddi, Mohamed Amine] Sfax Univ, Habib Bourguiba Univ Hosp, Dept Urol, Sfax, Tunisia.
   [Ammar, Mouna] Sfax Univ, Hedi Chaker Univ Hosp, Dept Endocrinol, Sfax, Tunisia.
RP Kammoun, B (reprint author), Sfax Univ, Habib Bourguiba Univ Hosp, Dept Neurosurg, Sfax, Tunisia.
EM kammoun.brahim28@gmail.com
CR Adler JT, 2008, ONCOLOGIST, V13, P779, DOI 10.1634/theoncologist.2008-0043
   Barba I, 2001, J NEUROSURG, V94, P55, DOI 10.3171/jns.2001.94.1.0055
   BEARD CM, 1983, MAYO CLIN PROC, V58, P802
   Boettcher LB, 2018, WORLD NEUROSURG, V114, P235, DOI [10.1016/J.WNEU.2018.03.126, 10.1016/j.wneu.2018.03.126]
   BRAVO EL, 1993, ENDOCRIN METAB CLIN, V22, P329, DOI 10.1016/S0889-8529(18)30169-5
   Cheikhrouhou H, 2006, ANN ENDOCRINOL-PARIS, V67, P238, DOI 10.1016/S0003-4266(06)72592-6
   Chen MY, 2001, J NEUROSURG, V94, P138, DOI 10.3171/jns.2001.94.1.0138
   Cho YD, 2003, MAGN RESON IMAGING, V21, P663, DOI 10.1016/S0730-725X(03)00097-3
   Cho Yun Seong, 2018, Brain Tumor Res Treat, V6, P101, DOI 10.14791/btrt.2018.6.e18
   Eisenhofer G, 2004, ENDOCR-RELAT CANCER, V11, P423, DOI 10.1677/erc.1.00829
   Eisenhofer G, 2004, FRONT HORM RES, V31, P76
   Ferrari G, 1979, Pathologica, V71, P703
   Galanaud D, 2007, J RADIOL, V88, P483, DOI 10.1016/S0221-0363(07)89848-9
   Gentile S, 2001, PANMINERVA MED, V43, P305
   Gimenez-Roqueplo AP, 2003, CANCER RES, V63, P5615
   GRABEL JC, 1990, NEUROSURGERY, V27, P134, DOI 10.1227/00006123-199007000-00021
   Hanna NN, 2001, SURG TREATMENT EVIDE
   Johnson MH, 2014, UROL CASE REP, V2, P139, DOI 10.1016/j.eucr.2014.05.001
   Kowalska A, 2009, END ABSTR, V20, P316
   Maher ER, 2002, HUM MOL GENET, V11, P2347, DOI 10.1093/hmg/11.20.2347
   Manger WM, 2004, CURR HYPERTENS REP, V6, P477, DOI 10.1007/s11906-004-0044-2
   Manger WM, 2003, J CLIN ENDOCR METAB, V88, P4080, DOI 10.1210/jc.2003-031234
   Mannelli M, 2012, BEST PRACT RES CL EN, V26, P507, DOI 10.1016/j.beem.2011.10.008
   MELICOW MM, 1977, CANCER, V40, P1987, DOI 10.1002/1097-0142(197711)40:5<1987::AID-CNCR2820400502>3.0.CO;2-R
   Mercuri S, 2005, J NEURO-ONCOL, V73, P169, DOI 10.1007/s11060-004-4595-5
   Miyahara M, 2017, INTERDISCIP NEUROSUR, V10, P130, DOI 10.1016/j.inat.2017.08.003
   MORNEX R, 1992, J ENDOCRINOL INVEST, V15, P643, DOI 10.1007/BF03345808
   Schaefer IM, 2010, CANCER GENET CYTOGEN, V200, P194, DOI 10.1016/j.cancergencyto.2010.04.013
   SCOTT HW, 1976, ANN SURG, V183, P587, DOI 10.1097/00000658-197605000-00016
   Sisson JC, 2006, ANN NY ACAD SCI, V1073, P505, DOI 10.1196/annals.1353.053
   SPATT SD, 1948, AM J MED SCI, V216, P39, DOI 10.1097/00000441-194807000-00007
   STENSTROM G, 1986, ACTA MED SCAND, V220, P225
   Thouennon E, 2007, J CLIN ENDOCR METAB, V92, P4865, DOI 10.1210/jc.2007-1253
   Vassilopoulou-Sellin R, 1998, ENDOCR-RELAT CANCER, V5, P59, DOI 10.1677/erc.0.0050059
   WHALEN RK, 1992, J UROLOGY, V147, P1, DOI 10.1016/S0022-5347(17)37119-7
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 391
EP 399
DI 10.1016/j.wneu.2019.06.163
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200211
PM 31260853
DA 2020-05-12
ER

PT J
AU Yamaguchi, J
   Motomura, K
   Ohka, F
   Aoki, K
   Tanahashi, K
   Hirano, M
   Nishikawa, T
   Shimizu, H
   Wakabayashi, T
   Natsume, A
AF Yamaguchi, Junya
   Motomura, Kazuya
   Ohka, Fumiharu
   Aoki, Kosuke
   Tanahashi, Kuniaki
   Hirano, Masaki
   Nishikawa, Tomohide
   Shimizu, Hiroyuki
   Wakabayashi, Toshihiko
   Natsume, Atsushi
TI Spontaneous Tumor Regression of Intracranial Solitary Fibrous Tumor
   Originating From the Medulla Oblongata: A Case Report and Literature
   Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Case report; Intracranial solitary fibrous tumor; Medulla oblongata;
   Tumor regression
ID CENTRAL-NERVOUS-SYSTEM; EXPRESSION; GERMINOMA; LOCATION; FUSION; CD34
AB BACKGROUND: Intracranial solitary fibrous tumor (SFT) is a rare occurrence and involvement of the fourth ventricle rarely reported. Because of its rarity, some characteristics of intracranial SFT seem to still remain uncertain.
   CASE DESCRIPTION: This study describes a very rare case of intracranial SFT in a 55-year-old woman who presented with gait disturbance and numbness in bilateral upper limbs from 3 months before visiting the hospital. Head magnetic resonance imaging scan revealed a homogeneously enhancing mass lesion located primarily in the fourth ventricle extending into the spinal canal and left foramen of Luschka, with a maximum diameter of 60 mm. Notably, this tumor presented spontaneous partial regression during waiting planned surgery without therapy, including chemotherapy and radiotherapy. This patient underwent a midline suboccipital craniotomy and resection of the tumor. Interestingly, there was no attachment to the dura mater of the posterior cranial fossa and the lesion was only attached to the dorsal part of the medulla oblongata.
   CONCLUSIONS: Although the location of the SFT in the fourth ventricle is rare, SFT should be considered as 1 of the differential diagnosis of fourth ventricle tumors. In addition, this case indicates that SFT in the fourth ventricle may regress on occasion spontaneously without a precisely known cause for this spontaneous partial regression.
C1 [Yamaguchi, Junya; Motomura, Kazuya; Ohka, Fumiharu; Aoki, Kosuke; Tanahashi, Kuniaki; Hirano, Masaki; Nishikawa, Tomohide; Shimizu, Hiroyuki; Wakabayashi, Toshihiko; Natsume, Atsushi] Nagoya Univ, Dept Neurosurg, Sch Med, Nagoya, Aichi, Japan.
RP Motomura, K (reprint author), Nagoya Univ, Dept Neurosurg, Sch Med, Nagoya, Aichi, Japan.
EM kmotomura@med.nagoya-u.ac.jp
OI Ohka, Fumiharu/0000-0002-5569-5626
CR Barron J, 2001, BRAIN PATHOL, V11, P485, DOI 10.1111/j.1750-3639.2001.tb01091.x
   Bisceglia M, 2011, ADV ANAT PATHOL, V18, P356, DOI 10.1097/PAP.0b013e318229c004
   Carneiro SS, 1996, AM J CLIN PATHOL, V106, P217, DOI 10.1093/ajcp/106.2.217
   Chmielecki J, 2013, NAT GENET, V45, P131, DOI 10.1038/ng.2522
   Clarencon F, 2006, J NEURORADIOLOGY, V33, P279, DOI 10.1016/S0150-9861(06)77281-9
   Cummings TJ, 2001, ACTA NEUROPATHOL, V102, P349
   D'Angelo F, 2019, NAT MED, V25, P176, DOI 10.1038/s41591-018-0263-8
   Gessi M, 2006, J NEURO-ONCOL, V80, P109, DOI 10.1007/s11060-006-9154-9
   Ide M, 1997, CANCER, V79, P558, DOI 10.1002/(SICI)1097-0142(19970201)79:3<558::AID-CNCR19>3.0.CO;2-2
   Jiang N, 2017, WORLD NEUROSURG, V99, P584, DOI 10.1016/j.wneu.2016.12.057
   KALARIA RN, 1992, ACTA NEUROPATHOL, V84, P606
   Kim KA, 2004, NEUROSURGERY, V54, P1004, DOI 10.1227/01.NEU.0000115675.74366.87
   Klemperer P, 1931, ARCH PATHOL, V11, P387
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Mohajeri A, 2013, GENE CHROMOSOME CANC, V52, P873, DOI 10.1002/gcc.22083
   Montano N, 2010, BRIT J NEUROSURG, V24, P495, DOI 10.3109/02688691003675226
   Murai Y, 2000, J NEUROSURG, V93, P884, DOI 10.3171/jns.2000.93.5.0884
   Sawauchi S, 2003, NEUROL SURG TOKYO, V31, P551
   Surendrababu NRS, 2006, AM J NEURORADIOL, V27, P2135
   Vassal F, 2011, ACTA NEUROCHIR, V153, P377, DOI 10.1007/s00701-010-0866-4
   Wang Congli, 2012, J Med Case Rep, V6, P205, DOI 10.1186/1752-1947-6-205
   Yamamoto J, 2014, ONCOL LETT, V7, P1835, DOI 10.3892/ol.2014.2033
NR 22
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 400
EP 404
DI 10.1016/j.wneu.2019.07.052
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200212
PM 31326640
DA 2020-05-12
ER

PT J
AU Deniel, A
   Marguet, F
   Beaussire, L
   Tobenas-Dujardin, AC
   Peillon, C
   Gambirasio, MA
   Veresezan, O
   Magne, N
   Di Fiore, F
   Laquerriere, A
   Sarafan-Vasseur, N
   Fontanilles, M
AF Deniel, Anne
   Marguet, Florent
   Beaussire, Ludivine
   Tobenas-Dujardin, Anne-Claire
   Peillon, Christophe
   Gambirasio, Marco-Achille
   Veresezan, Ovidiu
   Magne, Nicolas
   Di Fiore, Frederic
   Laquerriere, Annie
   Sarafan-Vasseur, Nasrin
   Fontanilles, Maxime
TI TERTp Mutation Detection in Plasma by Droplet-Digital Polymerase Chain
   Reaction in Spinal Myxopapillary Ependymoma with Lung Metastases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Circulating tumor DNA; Droplet digital PCR; Liquid biopsy; Metastasis;
   Spinal myxopapillary ependymoma; TERT promoter mutation
ID CLASSIFICATION; TUMORS
AB BACKGROUND: Spinal myxopapillary ependymoma (SP-MPE) is a subgroup of ependymomas in which after initial gross tumor resection, recurrences occur in more than half of the patients. Anaplastic transformation may also occur and contributes to intraneural and extraneural metastatic dissemination. Extraneural metastases from SP-MPE are rare and worsen the prognosis. In this situation, the noninvasive detection of recurrent somatic mutations in the circulating tumor DNA (ctDNA) from plasma is challenging. Telomerase-reverse transcriptase gene promoter (TERTp) mutation has been identified in a subset of ependymomas with aggressive behavior.
   CASE DESCRIPTION: We report on a patient with TERTp mutated SP-MPE presenting with an extraneural anaplastic metastatic dissemination after iterative local recurrences. From the initial SP-MPE to pleural anaplastic lesion, TERTp C228T mutation was present with allele frequency varying from 33% to 39%. Interestingly, TERTp mutation was also detected by droplet digital polymerase chain reaction in the plasma with a frequency of 2.1% at the time of pleural metastases, highlighting that ctDNA is released in plasma of patients suffering from SP-MPE with extraneural metastatic dissemination.
   CONCLUSIONS: Despite the rarity of this evolution, plasmatic liquid biopsy appears d useful diagnostic and follow-up tool in a subset of primary brain tumors.
C1 [Deniel, Anne; Di Fiore, Frederic; Fontanilles, Maxime] Canc Ctr Henri Becquerel, Dept Med Oncol, Rouen, France.
   [Veresezan, Ovidiu] Canc Ctr Henri Becquerel, Dept Radiat Oncol & Med Phys, Rouen, France.
   [Marguet, Florent; Laquerriere, Annie] Normandie Univ, Normandy Ctr Genom & Personalized Med, UNIROUEN, Dept Pathol, Rouen, France.
   [Beaussire, Ludivine; Di Fiore, Frederic; Sarafan-Vasseur, Nasrin; Fontanilles, Maxime] Normandie Univ, Normandy Ctr Genom & Personalized Med, UNIROUEN, IRON Grp, Rouen, France.
   [Tobenas-Dujardin, Anne-Claire] Rouen Univ Hosp, Dept Neurosurg, Rouen, France.
   [Peillon, Christophe] Rouen Univ Hosp, Dept Thorac Surg, Rouen, France.
   [Gambirasio, Marco-Achille] Rouen Univ Hosp, Dept Palliat Care, Rouen, France.
   [Magne, Nicolas] Rouen Univ Hosp, Dept Radiol, Rouen, France.
RP Fontanilles, M (reprint author), Canc Ctr Henri Becquerel, Dept Med Oncol, Rouen, France.; Fontanilles, M (reprint author), Normandie Univ, Normandy Ctr Genom & Personalized Med, UNIROUEN, IRON Grp, Rouen, France.
EM maxime.fontanilles@chb.unicancer.fr
FU Institute of Research and Innovation in Biomedicine of Normandy (IRIB,
   INSERM U1245, Rouen, Normandie, France)
FX This project was supported by the Institute of Research and Innovation
   in Biomedicine of Normandy (IRIB, INSERM U1245, Rouen, Normandie,
   France).
CR Beauchesne Patrick, 2011, Cancers (Basel), V3, P461, DOI 10.3390/cancers3010461
   Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094
   Brugger F, 2017, J NEUROPATH EXP NEUR, V76, P61, DOI 10.1093/jnen/nlw106
   Chiu A, 2017, BIOINFORMATICS, V33, P2743, DOI 10.1093/bioinformatics/btx308
   Connolly ID, 2017, J NEURO-ONCOL, V135, P29, DOI 10.1007/s11060-017-2557-y
   Figarella-Branger D, 2016, NEURO-ONCOLOGY, V18, P919, DOI 10.1093/neuonc/now025
   Fouladi M, 2013, J NEURO-ONCOL, V114, P173, DOI 10.1007/s11060-013-1166-7
   Gessi M, 2019, AM J SURG PATHOL, V43, P56, DOI 10.1097/PAS.0000000000000979
   Juratli TA, 2018, CLIN CANCER RES, V24, P5282, DOI 10.1158/1078-0432.CCR-17-3717
   Kraetzig T, 2018, J NEUROSURG-SPINE, V28, P201, DOI 10.3171/2017.5.SPINE161164
   Lee JC, 2019, BRAIN PATHOL, V29, P75, DOI 10.1111/bpa.12673
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Milbury Coren A, 2014, Biomol Detect Quantif, V1, P8
   Pajtler KW, 2015, CANCER CELL, V27, P728, DOI 10.1016/j.ccell.2015.04.002
   Payet M, 2012, CHILD NERV SYST, V28, P739, DOI 10.1007/s00381-011-1656-x
   Rousseau E, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-47
   Vinagre J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3185
NR 17
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 405
EP 409
DI 10.1016/j.wneu.2019.07.111
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200213
PM 31330336
DA 2020-05-12
ER

PT J
AU Han, MS
   Jung, S
   Kim, IY
   Moon, KS
   Jung, TY
   Jang, WY
AF Han, Moon-Soo
   Jung, Shin
   Kim, In-Young
   Moon, Kyung-Sub
   Jung, Tae-Young
   Jang, Woo-Youl
TI Hemifacial Spasm Caused by Small Epidermoid Tumor, Misinterpreted as
   Delayed Secondary Hemifacial Spasm Caused by Vestibular Schwannoma
   Treated with Gamma Knife Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Epidermoid cyst; Hemifacial spasm; Secondary hemifacial spasm;
   Vestibular schwannoma
ID CEREBELLOPONTINE ANGLE; NERVE; CYST
AB BACKGROUND: Hemifacial spasm (HFS), one of the most common hyperactive cranial rhizopathies, is a disorder characterized by spontaneous, intermittent, and repetitive contraction of unilateral facial muscle. The most common cause of HFS is a mechanical compression of the facial nerve at the root exit zone (REZ) by blood vessels located in the brainstem. The incidence of cerebellopontine angle (CPA) tumor-induced HFS ranges from 0.3% - 2.5% of all patients with HFS, and the incidence of epidermoid cyst among such tumors is extremely rare (0.2% to 0.25%). We present a patient manifesting HFS induced by a small epidermoid cyst who underwent Gamma Knife surgery (GKS) for ipsilateral vestibular schwannoma (VS) more than 10 years ago.
   CLINICAL DESCRIPTION: A 59-year-old female was admitted to our hospital with HFS. Ten years before admission, the patient underwent GKS for ipsilateral VS. Enhanced brain magnetic resonance imaging demonstrated that the volume of VS was not increased. Also, no definitive mechanical compression of the facial nerve REZ by blood vessels was detected. We concluded that HFS was secondary to the VS treatment by GKS and decided to operate to remove the tumor and identify REZ. A standardized lateral suboccipital retrosigmoid approach was performed. The cochlear nerve was encased by a tumor mass, and the posterior inferior cerebellar artery (PICA) was displaced by the mass. During tumor excision, we ensured that the VS and displaced PICA did not directly compress the REZ. Interestingly, an unexpected lesion was found with a yellowish viscous mass located between the sixth nerve and ventral side of the seventh nerve REZ. After the tumor removal, a small piece of Teflon was inserted between the PICA and REZ of the facial nerve. Postoperatively, the patient experienced no HFS or facial nerve dysfunction. Histopathologic examination of the lesion revealed an epidermoid cyst.
   CONCLUSIONS: We should consider various possibilities for the cause of HFS and review brain imaging meticulously if patients were treated for CPA tumor with GKS a long time ago and the delayed HFS occurred without changes in tumor volume. HFS induced by epidermoid cyst is rare. Therefore it is critical for the neurosurgeon to ensure the absence of any abnormal contact with the REZ of the facial nerve during surgery for HFS induced by CPA tumors.
C1 [Jung, Shin] Chonnam Natl Univ, Hwasun Hosp & Med Sch, Brain Tumor Clin, Dept Neurosurg,Res Inst Med Sci, Hwasun, Jeollanam Do, South Korea.
   Chonnam Natl Univ, Hwasun Hosp & Med Sch, Gamma Knife Ctr, Dept Neurosurg,Res Inst Med Sci, Hwasun, Jeollanam Do, South Korea.
RP Jung, S (reprint author), Chonnam Natl Univ, Hwasun Hosp & Med Sch, Brain Tumor Clin, Dept Neurosurg,Res Inst Med Sci, Hwasun, Jeollanam Do, South Korea.
EM sjung@chonnam.ac.kr
CR Berrettini S, 1996, J NEUROL SCI, V144, P24, DOI 10.1016/S0022-510X(96)00174-8
   Cancelli I, 2005, NEUROL SCI, V26, P46, DOI 10.1007/s10072-005-0382-0
   Choi SK, 2009, J KOREAN NEUROSURG S, V45, P196, DOI 10.3340/jkns.2009.45.3.196
   Chung SS, 2000, ACTA NEUROCHIR, V142, P901, DOI 10.1007/s007010070076
   GORMLEY WB, 1994, ACTA NEUROCHIR, V128, P115, DOI 10.1007/BF01400660
   Han HY, 2010, NEUROSURG REV, V33, P335, DOI 10.1007/s10143-010-0250-0
   Harada A, 2002, J NEUROSURG, V97, P482, DOI 10.3171/jns.2002.97.2.0482
   HIGASHI S, 1992, SURG NEUROL, V37, P289, DOI 10.1016/0090-3019(92)90155-G
   Iwai Y, 2001, NEUROL MED-CHIR, V41, P87, DOI 10.2176/nmc.41.87
   JANNETTA PJ, 1977, J NEUROSURG, V47, P321, DOI 10.3171/jns.1977.47.3.0321
   Kobata H, 2002, NEUROSURGERY, V50, P276, DOI 10.1097/00006123-200202000-00008
   Lee SH, 2010, ACTA NEUROCHIR, V152, P1901, DOI 10.1007/s00701-010-0796-1
   Miyazaki S, 1983, No To Shinkei, V35, P951
   NAGATA S, 1992, SURG NEUROL, V38, P204, DOI 10.1016/0090-3019(92)90170-R
   Sandberg DI, 1999, PEDIATR NEUROL, V21, P754, DOI 10.1016/S0887-8994(99)00077-6
   SPRIK C, 1988, OPHTHALMOLOGY, V95, P1042
   Zhang X, 2019, WORLD NEUROSURG, V125, pE10, DOI 10.1016/j.wneu.2018.12.035
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 410
EP 414
DI 10.1016/j.wneu.2019.07.119
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200214
PM 31349082
DA 2020-05-12
ER

PT J
AU Dietz, N
   Sharma, M
   Adams, S
   Alhourani, A
   Ugiliweneza, B
   Wang, DZ
   Nuno, M
   Drazin, D
   Boakye, M
AF Dietz, Nicholas
   Sharma, Mayur
   Adams, Shawn
   Alhourani, Ahmad
   Ugiliweneza, Beatrice
   Wang, Dengzhi
   Nuno, Miriam
   Drazin, Doniel
   Boakye, Maxwell
TI Enhanced Recovery After Surgery (ERAS) for Spine Surgery: A Systematic
   Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE ERAS; Enhanced recovery after surgery; Fast-track recovery; Laminectomy;
   Spine surgery
ID REPORTED OUTCOME MEASURES; LUMBAR INTERBODY FUSION; COLORECTAL SURGERY;
   PATIENT; PROGRAM; CARE; IMPLEMENTATION; COMPLICATIONS; LENGTH; STAY
AB BACKGROUND: Enhanced recovery after surgery (ERAS) represents an evidence-based multidisciplinary approach to perioperative management after major surgery that decreases complications and readmissions and improves functional recovery. Spine surgery is a traditionally invasive intervention with an extended recovery phase and may benefit from ERAS protocol integration.
   METHODS: We analyzed the use of ERAS in spine surgery by completing a search using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and the PICOS (Participants, Intervention, Comparison, Outcomes, Study Design) model through PubMed and Ovid databases to identify studies that fit our search criteria. We assess the outcomes and ERAS elements selected across protocols as well as the study design and internal validation methods.
   RESULTS: A total of 19 studies met the inclusion criteria and were used in our analysis. Patient populations differed significantly across all 4 studies. Reduction in length of stay was reported in 7 studies using the ERAS protocol. Comparative studies between ERAS and non-ERAS show improved pain scores and reduced opioid consumption postoperatively, but no differences in complications or readmissions between groups. Complication rates under ERAS protocols ranged from 2.0% to 31.7%. Significant pain reduction in visual analog scale scores was observed with 3 ERAS protocols. Direct, indirect, and total cost decreases were also observed with implementation of ERAS protocols.
   CONCLUSIONS: A limited cohort of studies with significant variability in patient population and ERAS protocol implementation have evaluated the integration of ERAS within spine surgery. ERAS in spine surgery may provide reductions in complications, readmissions, length of stay, and opioid use, in combination with improvements in patient-reported outcomes and functional recovery.
C1 [Dietz, Nicholas; Sharma, Mayur; Adams, Shawn; Alhourani, Ahmad; Ugiliweneza, Beatrice; Wang, Dengzhi; Boakye, Maxwell] Univ Louisville, Dept Neurosurg, Louisville, KY 40292 USA.
   [Dietz, Nicholas] Georgetown Univ, Sch Med, Washington, DC USA.
   [Nuno, Miriam] Univ Calif Davis, Dept Publ Hlth Sci, Div Biostat, Davis, CA 95616 USA.
   [Drazin, Doniel] Pacific Northwest Univ Hlth Sci, Coll Med, Yakima, WA USA.
RP Boakye, M (reprint author), Univ Louisville, Dept Neurosurg, Louisville, KY 40292 USA.
EM Maxwell.boakye@ulp.org
RI Adams, Shawn/AAK-3854-2020; Sharma, Mayur/B-3228-2018
OI Sharma, Mayur/0000-0001-6481-7819; Dietz, Nicholas/0000-0001-5822-1680
CR Ackerman RS, 2019, WORLD J SURG, V43, P839, DOI 10.1007/s00268-018-4850-0
   Ali ZS, 2019, J NEUROSURG-SPINE, V30, P532, DOI 10.3171/2018.9.SPINE18681
   Ali ZS, 2018, CLIN NEUROL NEUROSUR, V164, P142, DOI 10.1016/j.clineuro.2017.12.003
   Angus Michelle, 2019, J Spine Surg, V5, P116, DOI 10.21037/jss.2019.01.07
   Basques BA, 2014, SPINE, V39, P833, DOI 10.1097/BRS.0000000000000276
   Brusko GD, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2019.1.FOCUS18692
   Carr DA, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2019.1.FOCUS18630
   Carreon LY, 2003, J BONE JOINT SURG AM, V85A, P2089, DOI 10.2106/00004623-200311000-00004
   Chahar Praveen, 2012, J Pain Res, V5, P257, DOI 10.2147/JPR.S27894
   Chakravarthy VB, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2019.1.FOCUS18696
   Chang PY, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.2.FocusVid.1694
   Chin KR, 2015, SPINE, V40, pE36, DOI 10.1097/BRS.0000000000000604
   Chin KR, 2012, J NEUROSURG-SPINE, V17, P194, DOI 10.3171/2012.5.SPINE111112
   Dagal A, 2019, SPINE, V44, P959, DOI 10.1097/BRS.0000000000002968
   Debono B, 2017, WORLD NEUROSURG, V106, P891, DOI 10.1016/j.wneu.2017.07.065
   Dietz N, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.8.FOCUS18331
   Eckman WW, 2014, CLIN ORTHOP RELAT R, V472, P1806, DOI 10.1007/s11999-013-3366-z
   Eskicioglu C, 2009, J GASTROINTEST SURG, V13, P2321, DOI 10.1007/s11605-009-0927-2
   Feng CC, 2019, WORLD NEUROSURG, V129, pE317, DOI 10.1016/j.wneu.2019.05.139
   Grasu RM, 2018, J NEUROSURG-SPINE, V29, P588, DOI 10.3171/2018.4.SPINE171317
   Graves C, 2018, NEUROSURGERY, V82, P136, DOI 10.1093/neuros/nyx476
   Kehlet H, 1997, BRIT J ANAESTH, V78, P606
   Khor S, 2018, JAMA SURG, V153, P634, DOI 10.1001/jamasurg.2018.0072
   Kim J, 2016, WORLD NEUROSURG, V91, P460, DOI 10.1016/j.wneu.2016.04.058
   Koenig L, 2013, AM J GASTROENTEROL, V108, P10, DOI 10.1038/ajg.2012.183
   Lam KKY, 2016, HONG KONG MED J, V22, P428, DOI 10.12809/hkmj154769
   Lee TG, 2011, DIS COLON RECTUM, V54, P21, DOI 10.1007/DCR.0b013e3181fcdb3e
   Lemanu DP, 2014, COLORECTAL DIS, V16, P338, DOI 10.1111/codi.12505
   Li J, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013195
   Liu VX, 2017, JAMA SURG, V152, DOI 10.1001/jamasurg.2017.1032
   Ljungqvist O, 2017, JAMA SURG, V152, P292, DOI 10.1001/jamasurg.2016.4952
   Martini ML, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2019.1.FOCUS18652
   Mathiesen O, 2013, EUR SPINE J, V22, P2089, DOI 10.1007/s00586-013-2826-1
   McCormick JD, 2013, J AM ACAD ORTHOP SUR, V21, P99, DOI 10.5435/JAAOS-21-02-99
   Melnyk M, 2011, CUAJ-CAN UROL ASSOC, V5, P342, DOI 10.5489/cuaj.11002
   Miller TE, 2014, ANESTH ANALG, V118, P1052, DOI 10.1213/ANE.0000000000000206
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Nasser R, 2010, J NEUROSURG-SPINE, V13, P144, DOI 10.3171/2010.3.SPINE09369
   Ni TG, 2015, WORLD J GASTROENTERO, V21, P9209, DOI 10.3748/wjg.v21.i30.9209
   Oresanya LB, 2014, JAMA-J AM MED ASSOC, V311, P2110, DOI 10.1001/jama.2014.4573
   Sandrucci S, 2018, EJSO-EUR J SURG ONC, V44, P509, DOI 10.1016/j.ejso.2017.12.010
   Sarin A, 2016, BMC ANESTHESIOL, V16, DOI 10.1186/s12871-016-0223-0
   Schifftner TL, 2007, J AM COLL SURGEONS, V204, P1166, DOI 10.1016/j.jamcollsurg.2007.03.023
   Smith J, 2019, PERIOPER MED-LONDON, V8, DOI 10.1186/s13741-019-0114-2
   Soffin EM, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2019.1.FOCUS18643
   Soffin EM, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2019.1.FOCUS18645
   Soffin EM, 2019, SPINE, V44, pE561, DOI 10.1097/BRS.0000000000002905
   Spanjersberg WR, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007635.pub2
   Staartjes VE, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2019.1.FOCUS18646
   Tatsui CE, 2015, J NEUROSURG-SPINE, V23, P400, DOI 10.3171/2015.2.SPINE141185
   Thanh NX, 2016, CAN J SURG, V59, P415, DOI 10.1503/cjs.006716
   Venkata HK, 2018, J NEUROSURG SCI, V62, P245, DOI 10.23736/S0390-5616.16.03695-X
   Visioni A, 2018, ANN SURG, V267, P57, DOI 10.1097/SLA.0000000000002267
   Wainwright TW, 2016, BEST PRACT RES-CLIN, V30, P91, DOI 10.1016/j.bpa.2015.11.001
   Weldring T, 2013, HEALTH SERV INSIGHTS, V6, P61, DOI 10.4137/HSI.S11093
   Yadla S, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.12.FOCUS09254
NR 56
TC 4
Z9 5
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 415
EP 426
DI 10.1016/j.wneu.2019.06.181
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200215
PM 31276851
DA 2020-05-12
ER

PT J
AU Sharma, SB
   Lin, GX
   Kim, JS
AF Sharma, Sagar B.
   Lin, Guang-Xun
   Kim, Jin-Sung
TI Full-Endoscopic Resection of Ligamentum Flavum Cyst in Lumbar Spine
SO WORLD NEUROSURGERY
LA English
DT Article
DE Degenerative spine; Endoscopic spine surgery; Interlaminar approach;
   Ligamentum flavum cyst; Lumbar spine; Minimally invasive spine surgery
AB BACKGROUND: Cysts of the ligamentum flavum (IF) are rare occurrences, with only a few cases reported in literature. They are a result of age-related degenerative changes in the IF. The cyst compresses the neural elements and causes neurogenic symptoms. Endoscopic resection of the LF cyst has not been described in literature. In this report, we describe our experience with endoscopic resection of an LF cyst in the 13-14 region.
   CASE DESCRIPTION: A 54-year-old female patient presented with claudication in both lower limbs and evidence on magnetic resonance imaging of a LF cyst in the L3-L4 region compressing the neural elements. The patient underwent full endoscopic resection of the LF cyst through the interlaminar approach from the left side with preservation of facet joints. The postoperative clinical outcomes improved significantly, and postoperative magnetic resonance imaging revealed a complete removal of the cyst.
   CONCLUSIONS: Full-endoscopic resection may be considered as a viable option for treatment of IF cyst in the lumbar region.
C1 [Sharma, Sagar B.; Lin, Guang-Xun; Kim, Jin-Sung] Catholic Univ Korea, Seoul St Marys Hosp, Dept Neurosurg, Seoul, South Korea.
RP Kim, JS (reprint author), Catholic Univ Korea, Seoul St Marys Hosp, Dept Neurosurg, Seoul, South Korea.
EM mdlukekim@gmail.com
RI Kim, Jin-Sung/Y-2904-2019; Sharma, Sagar/AAG-5911-2020
OI Kim, Jin-Sung/0000-0001-5086-0875; Sharma, Sagar/0000-0002-2559-6010
CR ABDULLAH AF, 1984, J NEUROSURG, V60, P617, DOI 10.3171/jns.1984.60.3.0617
   BAKER JK, 1994, SPINE, V19, P1092, DOI 10.1097/00007632-199405000-00019
   Bruder M, 2017, J NEUROSURG-SPINE, V27, P256, DOI 10.3171/2016.12.SPINE16756
   Cakir E, 2004, J CLIN NEUROSCI, V11, P67, DOI 10.1016/j.jocn.2003.02.008
   Choi KC, 2018, WORLD NEUROSURG, V116, pE750, DOI 10.1016/j.wneu.2018.05.085
   HAASE J, 1972, ACTA ORTHOP SCAND, V43, P32, DOI 10.3109/17453677208988661
   Mahallati H, 1999, AM J NEURORADIOL, V20, P1166
   Okuda T, 2004, SPINE, V29, P1689, DOI 10.1097/01.BRS.0000132510.25378.8C
   Seo Dong-Ho, 2014, Korean J Spine, V11, P18, DOI 10.14245/kjs.2014.11.1.18
   Shah K, 2018, WORLD NEUROSURG, V110, P284, DOI 10.1016/j.wneu.2017.11.075
   Taha H, 2010, J ORTHOP TRAUMATOL, V11, P117, DOI 10.1007/s10195-010-0094-y
   Terada H, 2001, NEURORADIOLOGY, V43, P49, DOI 10.1007/s002340000387
   VERNET O, 1991, NEUROSURGERY, V29, P277, DOI 10.1227/00006123-199108000-00021
   Wildi LM, 2004, J SPINAL DISORD TECH, V17, P395, DOI 10.1097/01.bsd.0000109837.59382.0e
NR 14
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 427
EP 431
DI 10.1016/j.wneu.2019.07.120
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200216
PM 31349083
DA 2020-05-12
ER

PT J
AU Yuan, CH
   Yao, QY
   Zhang, C
   Jian, FZ
AF Yuan, Chenghua
   Yao, Qingyu
   Zhang, Can
   Jian, Fengzeng
TI Spontaneous Resolution of Syringomyelia with a 16-Year Serial Magnetic
   Resonance Imaging Follow-Up: A Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Adult; Chiari malformation; Spontaneous resolution; Syringomyelia
ID CHIARI-I MALFORMATION; REVERSIBLE TONSILLAR PROLAPSE; SPONTANEOUS
   REGRESSION; NONOPERATIVE OUTCOMES; SPONTANEOUS DRAINAGE; CEREBELLAR
   TONSILS; PATHOPHYSIOLOGY; MANAGEMENT; PATIENT; AGE
AB BACKGROUND: The natural course of syringomyelia is unpredictable. Only a few cases of adults with spontaneous resolution of syringomyelia associated with Chiari malformation type I (CM-I) have been reported. The timing of surgical intervention for syringomyelia remains controversial. The present report has documented a case with the longest medical history of syringomyelia reported, the associated imaging findings over 16 years, the mild symptom progression after the spontaneous resolution of syringomyelia, and a review of the relevant reported data. The natural history of our patient provides a unique view regarding the factors that might lead to the development and spontaneous resolution of syringomyelia.
   CASE DESCRIPTION: We present the case of a 36-year-old woman who had been monitored for 16 years for mild symptomatic CM-I and syringomyelia. After regular follow-up examinations for the initial 10 years, magnetic resonance imaging revealed partial spontaneous resolution of the syringomyelia and unchanged symptoms. However, after 6 additional years of follow-up examinations, her symptoms had mildly progressed, and the size of the syringomyelia had obviously decreased.
   CONCLUSIONS: The findings from our patient suggest that the natural course of mild symptomatic CM-I in adult patients will be benign and nonprogressive. Patients will commonly present with very few or mild symptoms, despite the presence of a large syrinx. It would be reasonable to observe patients with similar mild symptoms and syringomyelia. Surgery will be indicated by the type, severity, and duration of symptoms at the first clinical visit. Periodic follow-up examinations are also essential after spontaneous resolution because the pathophysiology of syringomyelia is incompletely understood and recurrence possible.
C1 [Yuan, Chenghua; Yao, Qingyu; Zhang, Can; Jian, Fengzeng] Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Jian, FZ (reprint author), Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM fengzengjian@hotmail.com
CR Attal N, 2004, J NEUROL NEUROSUR PS, V75, P1025, DOI 10.1136/jnnp.2003.026674
   BINDAL AK, 1995, NEUROSURGERY, V37, P1069, DOI 10.1227/00006123-199512000-00005
   BIRBAMER G, 1993, EUR NEUROL, V33, P378, DOI 10.1159/000116975
   Bogdanov EI, 2000, NEURORADIOLOGY, V42, P676, DOI 10.1007/s002340000358
   Caranci F, 2012, NEURORADIOL J, V25, P739, DOI 10.1177/197140091202500613
   Chavez A, 2014, J CLIN NEUROSCI, V21, P2201, DOI 10.1016/j.jocn.2014.06.009
   Coppa ND, 2006, J NEUROSURG, V105, P769, DOI 10.3171/jns.2006.105.5.769
   Deniz FE, 2009, TURK NEUROSURG, V19, P96
   DYSTE GN, 1989, J NEUROSURG, V71, P159, DOI 10.3171/jns.1989.71.2.0159
   Fukutake T, 1998, J NEUROL NEUROSUR PS, V65, P606, DOI 10.1136/jnnp.65.4.606
   GARDNER WJ, 1965, J NEUROL NEUROSUR PS, V28, P247, DOI 10.1136/jnnp.28.3.247
   GIRARD N, 1994, CHILD NERV SYST, V10, P141, DOI 10.1007/BF00301078
   Itoyama Y, 2001, NEUROL SURG TOKYO, V29, P321
   JACK CR, 1991, J NEUROSURG, V74, P283, DOI 10.3171/jns.1991.74.2.0283
   Jain PK, 2017, NEUROL INDIA, V65, P1187, DOI 10.4103/neuroindia.NI_899_16
   Killeen A, 2015, J CLIN NEUROSCI, V22, P133, DOI 10.1016/j.jocn.2014.06.008
   Killeen T, 2016, NEUROLOGY, V87, P1299, DOI 10.1212/WNL.0000000000003130
   Klekamp J, 1996, ACTA NEUROCHIR, V138, P788, DOI 10.1007/BF01411256
   Klekamp J, 2002, ACTA NEUROCHIR, V144, P649, DOI 10.1007/s00701-002-0944-3
   Klekamp J, 2001, NEUROSURGERY, V48, P664, DOI 10.1097/00006123-200103000-00044
   Kyoshima K, 2003, NEUROSURGERY, V53, P762, DOI 10.1227/01.NEU.0000079629.05048.A2
   MIKULIS DJ, 1992, RADIOLOGY, V183, P725, DOI 10.1148/radiology.183.3.1584927
   Milhorat TH, 1999, NEUROSURGERY, V44, P1005, DOI 10.1097/00006123-199905000-00042
   MILHORAT TH, 1995, J NEUROSURG, V82, P802, DOI 10.3171/jns.1995.82.5.0802
   MILHORAT TH, 1995, NEUROSURGERY, V37, P206, DOI 10.1227/00006123-199508000-00003
   Mizuno J, 2003, J NEUROSURG, V99, P162, DOI 10.3171/spi.2003.99.2.0162
   Muthukumar N, 2013, ACTA NEUROCHIR, V155, P817, DOI 10.1007/s00701-013-1620-5
   Nishizawa S, 2001, NEUROSURGERY, V49, P637, DOI 10.1097/00006123-200109000-00018
   OLDFIELD EH, 1994, J NEUROSURG, V80, P3, DOI 10.3171/jns.1994.80.1.0003
   Perrini P, 2012, NEUROL SCI, V33, P1463, DOI 10.1007/s10072-012-0946-8
   Pierallini A, 1997, Radiol Med, V93, P621
   Raz N, 2001, AM J NEURORADIOL, V22, P1161
   RIEDEL A, 1989, BRAIN RES, V499, P333, DOI 10.1016/0006-8993(89)90782-8
   Rodesch G, 2007, J NEUROSURG, V107, P412, DOI 10.3171/JNS-07/08/0412
   SANTORO A, 1993, J NEUROSURG, V79, P132, DOI 10.3171/jns.1993.79.1.0132
   Singhal A, 2018, CHILD NERV SYST, V34, P1177, DOI 10.1007/s00381-018-3741-x
   Sudo K, 1998, ACTA NEUROL BELG, V98, P342
   Sun JCL, 2000, J NEUROSURG, V92, P207, DOI 10.3171/spi.2000.92.2.0207
   Sung WS, 2008, J CLIN NEUROSCI, V15, P1185, DOI 10.1016/j.jocn.2007.08.017
   TACHIBANA S, 1992, J NEUROSURG, V76, P67, DOI 10.3171/jns.1992.76.1.0067
   TACHIBANA S, 1994, SPINE, V19, P2174, DOI 10.1097/00007632-199410000-00008
   Tachibana S, 1994, SPINE, V19, P8
   Vaquero J, 2012, NEUROL SCI, V33, P339, DOI 10.1007/s10072-011-0670-9
   WILLIAMS B, 1980, J ROY SOC MED, V73, P798
NR 44
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 432
EP 438
DI 10.1016/j.wneu.2019.07.138
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200217
PM 31351204
DA 2020-05-12
ER

PT J
AU Yamashita, S
   Kimura, H
   Kohta, M
   Fujita, A
   Kohmura, E
AF Yamashita, Shunsuke
   Kimura, Hidehito
   Kohta, Masaaki
   Fujita, Atsushi
   Kohmura, Eiji
TI Thrombosed Middle Meningeal Artery Aneurysms Mimicking Aneurysmal Bone
   Cysts in a Patient with Fibrous Dysplasia
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysmal bone cyst; Endovascular treatment; Fibrous dysplasia;
   Thrombosed middle meningeal artery aneurysm
ID RUPTURE
AB BACKGROUND: The aneurysmal bone cyst (ABC) is a rare osteolytic lesion that is associated with osseous disease such as fibrous dysplasia (FD).
   CASE DESCRIPTION: A 66-year-old woman previously diagnosed with FD presented with suddenly reduced visual acuity. Computed tomography and magnetic resonance imaging revealed a large osteolytic lesion in the middle cranial fossa that had invaded the left orbit. Although its radiological findings were compatible with an ABC, rotational digital subtraction angiography revealed that this osteolytic lesion was a large middle meningeal artery (MAA) aneurysm. To release the compression force on the optic nerve and confirm the diagnosis, we performed endovascular embolization, followed by surgical removal of the lesion. Histologic examination revealed that the resected lesion met the requirements of a thrombosed aneurysm. No new neurologic deficits appeared after the surgery, and no symptomatic recurrence have been noted during the 6-month follow-up.
   CONCLUSIONS: This is the first case report to show that ABC-like lesions patients with FD could be thrombosed MMA aneurysms. It is thus possible that some lesions previously diagnosed as ABCs were thrombosed MMA aneurysms or included a thrombosed MMA aneurysm. It is therefore important to rule out the presence of a MMA aneurysm when we encounter what appears to be an ABC in the presence of FD.
C1 [Yamashita, Shunsuke; Kimura, Hidehito; Kohta, Masaaki; Fujita, Atsushi; Kohmura, Eiji] Kobe Univ, Dept Neurosurg, Grad Sch Med, Kobe, Hyogo, Japan.
RP Yamashita, S (reprint author), Kobe Univ, Dept Neurosurg, Grad Sch Med, Kobe, Hyogo, Japan.
EM yamashun@med.kobe-ac.jp
OI Kohta, Masaaki/0000-0001-5936-7163; Fujita, Atsushi/0000-0003-1294-6584
CR Diah E, 2007, J NEUROSURG, V107, P504, DOI 10.3171/JNS-07/09/0504
   Gang YC, 2007, J NEUROSURG, V106, P401, DOI 10.3171/ped.2007.106.5.401
   Garber ST, 2015, J NEUROSURG-PEDIATR, V15, P272, DOI 10.3171/2014.9.PEDS14224
   Itshayek E, 2002, NEUROSURGERY, V51, P815, DOI 10.1097/00006123-200209000-00040
   Kpelao E, 2017, Surg Neurol Int, V8, P172, DOI 10.4103/sni.sni_159_17
   Lee JW, 2010, J KOREAN NEUROSURG S, V48, P551, DOI 10.3340/jkns.2010.48.6.551
   MARTINEZ V, 1988, CANCER, V61, P2291, DOI 10.1002/1097-0142(19880601)61:11<2291::AID-CNCR2820611125>3.0.CO;2-V
   Sandin JA, 1999, J NEUROSURG, V90, P951, DOI 10.3171/jns.1999.90.5.0951
   Settecase F, 2016, J NEUROSURG-PEDIATR, V17, P324, DOI 10.3171/2015.9.PEDS15267
   Teng MMH, 2003, J CLIN NEUROSCI, V10, P460, DOI 10.1016/S0967-5868(03)00092-4
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 439
EP 443
DI 10.1016/j.wneu.2019.07.062
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200218
PM 31306839
DA 2020-05-12
ER

PT J
AU Khoo, J
   Khoo, B
   Alalade, AF
   Webster, J
AF Khoo, Jolyn
   Khoo, Boyuan
   Alalade, Andrew F.
   Webster, Jefferson
TI Case of Recurrent Artery of Heubner Aneurysm Masquerading as Partially
   Thrombosed A1 Aneurysm Radiologically
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Angiogram; Recurrent artery of Heubner; Subarachnoid
   hemorrhage
ID DIGITAL-SUBTRACTION-ANGIOGRAPHY; SUBARACHNOID HEMORRHAGE; DISSECTING
   ANEURYSM; PATIENT
AB BACKGROUND: Recurrent artery of Heubner (RAH) aneurysms are rare, with only 7 reported cases in the literature to date. In evaluating cerebral aneurysms, cerebral digital subtraction angiogram (DSA) is considered the gold standard and demonstrated the RAH aneurysms in previous case reports. We present a case of spontaneous subarachnoid hemorrhage secondary to RAH aneurysmal rupture, with initial DSA misleading, suggesting minor aneurysmal filling of a presumed thrombosed A1 segment aneurysm instead.
   CASE DESCRIPTION: A 71-year-old female presented with sudden-onset severe headache, nausea, and vomiting. Computed tomography along with computed tomography angiogram revealed a left-sided subarachnoid hemorrhage and a 5-mm aneurysm arising from either the left A1 or distal internal carotid artery. In addition, complex anterior cerebral artery anatomy with trifurcation was noted. This along with partial aneurysmal thrombosis made identification of the anatomy difficult on subsequent DSA, though a residual neck was still suggested to be arising from A1. Intraoperatively, the aneurysm was found to be arising from the RAH instead and was successfully secured by clipping.
   CONCLUSIONS: This case highlights the risk of RAH aneurysms masquerading as emanating from the A1 segment on DSA. Case particularities of complex anatomy and aneurysmal thrombosis were contributory. Other factors such as severe vasospasm, microaneurysms, and aneurysmal compression by overlying hematoma or brain parenchymal swelling could also distort DSA interpretation. These are important considerations in treatment planning by neurovascular surgeons and endovascular neuroradiologists.
C1 [Khoo, Jolyn; Khoo, Boyuan; Alalade, Andrew F.; Webster, Jefferson] Princess Alexandra Hosp, Dept Neurosurg, Brisbane, Qld, Australia.
RP Khoo, J (reprint author), Princess Alexandra Hosp, Dept Neurosurg, Brisbane, Qld, Australia.
EM jolyn.khoo@uqconnect.edu.au
CR Bakker NA, 2014, J NEUROSURG, V120, P99, DOI 10.3171/2013.9.JNS131337
   Bechan RS, 2014, INTERV NEURORADIOL, V20, P791, DOI 10.15274/INR-2014-10071
   Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395
   El Falougy H, 2013, BIOMED RES INT, DOI 10.1155/2013/873434
   Hakim A, 2018, J NEUROIMAGING, V28, P14, DOI 10.1111/jon.12475
   Mansfield K, 2015, CAN J NEUROL SCI, V42, P461, DOI 10.1017/cjn.2015.295
   Ogata A, 2017, NEUROL INDIA, V65, P623, DOI 10.4103/neuroindia.NI_1034_16
   van Rooij WJ, 2008, AM J NEURORADIOL, V29, P976, DOI 10.3174/ajnr.A0964
   Vellore Yagnesh, 2014, Asian J Neurosurg, V9, P244, DOI 10.4103/1793-5482.146658
   Wang F, 2015, BIOMED RES-INDIA, V26, P543
   Wanibuchi M, 2001, SURG NEUROL, V55, P148, DOI 10.1016/S0090-3019(01)00396-2
NR 11
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 444
EP 449
DI 10.1016/j.wneu.2019.07.118
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200219
PM 31349077
DA 2020-05-12
ER

PT J
AU Chang, DG
   Park, JB
AF Chang, Dong-Gune
   Park, Jong-Beom
TI Osteochondroma Arising from the Transverse Process of the Lower Cervical
   Spine in an Elderly Patient
SO WORLD NEUROSURGERY
LA English
DT Article
DE Elderly; Lower cervical spine; Osteochondroma
ID SOLITARY OSTEOCHONDROMA
AB BACKGROUND: Osteochondroma rarely occurs in the lower cervical spine in elderly patients, because it usually develops during skeletal growth and because of the limited mobility and lower stress in the lower cervical spine.
   CASE DESCRIPTION: A 63-year-old man complained of 3-month history of neck pain and a hard, palpable mass in the lower cervical spine. Plain radiography, computed tomography (CT) scan, and magnetic resonance imaging (MRI) revealed a bony mass arising from the left C5 transverse process with a medullary continuation and calcification and soft tissue displacement at the C4-C6 level. After the operation, the biopsy finding was consistent with osteochondroma, without malignant degeneration. We performed en bloc resection of the tumor, including the cartilaginous cap. The patient's symptoms improved after resection of the osteochondroma and demonstrated no recurrence of tumor at a 1-year follow-up.
   CONCLUSIONS: This patient had a rare involvement of the transverse process without neurologic symptoms. Multiple imaging modalities, including plain radiography, CT, and MRI, play important roles in the diagnosis of osteochondroma. Complete surgical excision, including the cartilaginous cap, achieved a satisfactory surgical outcome and prevented possible recurrence.
C1 [Chang, Dong-Gune] Inje Univ, Sanggye Paik Hosp, Dept Orthoped Surg, Seoul, South Korea.
   [Park, Jong-Beom] Catholic Univ Korea, Uijeongbu St Marys Hosp, Coll Med, Dept Orthoped Surg, Seoul, South Korea.
RP Park, JB (reprint author), Catholic Univ Korea, Uijeongbu St Marys Hosp, Coll Med, Dept Orthoped Surg, Seoul, South Korea.
EM spinepjb@catholic.ac.kr
OI Chang, Dong-Gune/0000-0001-6731-1063
CR ALBRECHT S, 1992, J NEUROSURG, V77, P247, DOI 10.3171/jns.1992.77.2.0247
   Arasil E, 1996, SPINE, V21, P516, DOI 10.1097/00007632-199602150-00021
   Bernard SA, 2010, RADIOLOGY, V255, P857, DOI 10.1148/radiol.10082120
   Bonic EE, 2012, SPINE, V37, pE69, DOI 10.1097/BRS.0b013e31821fcfde
   Chin KR, 2010, SPINE J, V10, P136, DOI [10.1016/j.spinee.2009.10.007, 10.1016/j.spinee.2010.02.018]
   Eap C, 2011, ORTHOP TRAUMATOL-SUR, V97, P94, DOI 10.1016/j.otsr.2010.06.013
   Gille O, 2005, SPINE, V30, pE13, DOI 10.1097/01.brs.0000148047.31164.f1
   Grivas TB, 2005, EUR SPINE J, V14, P795, DOI 10.1007/s00586-005-0890-x
   Huda N, 2014, J CLIN DIAGN RES, V8, pLD1, DOI 10.7860/JCDR/2014/7906.4333
   INGLIS AE, 1977, CLIN ORTHOP RELAT R, P127
   Kaneko K, 2000, Bull Hosp Jt Dis, V59, P106
   Rao H, 2009, J PEDIATR ORTHOP B, V18, P103, DOI 10.1097/BPB.0b013e328329431c
   Reckelhoff KE, 2010, J MANIP PHYSIOL THER, V33, P711, DOI 10.1016/j.jmpt.2010.08.021
   Sakai Daisuke, 2002, Spine (Phila Pa 1976), V27, pE503, DOI 10.1097/00007632-200212010-00017
   Schomacher M, 2009, ACTA NEUROCHIR, V151, P629, DOI 10.1007/s00701-009-0235-3
   Sekharappa V, 2014, ASIAN SPINE J, V8, P84, DOI 10.4184/asj.2014.8.1.84
   Singh R, 2006, J Orthop Surg (Hong Kong), V14, P192
   Yagi M, 2009, J NEUROSURG-SPINE, V11, P64, DOI 10.3171/2009.3.SPINE0912
NR 18
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 450
EP 453
DI 10.1016/j.wneu.2019.07.143
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200220
PM 31356982
DA 2020-05-12
ER

PT J
AU Whaley, CC
   Young, MM
   Gaynor, BG
AF Whaley, Calvin C.
   Young, Michael M.
   Gaynor, Brandon G.
TI Very High Blood Alcohol Concentration and Fatal Hemorrhage in Acute
   Subdural Hematoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Alcohol; Coagulopathy; Subdural hematoma; Traumatic brain injury
ID TRAUMATIC BRAIN-INJURY; SERUM ETHANOL LEVELS; TIME-COURSE; COAGULOPATHY;
   INTOXICATION; COAGULATION; PREDICTOR; SURVIVAL
AB INTRODUCTION: Alcohol intoxication is often present concurrently with traumatic brain injury (TBI). Recent studies have looked at the effect alcohol has on TBI and on coagulopathy. Typically, cases reviewed in the current literature report only on the effects of modest alcohol intoxication.
   CASE DESCRIPTION: A 43-year-old male presented to the trauma center after a fall, with rapidly deteriorating mental status. Computed tomography of the head demonstrated a 1.9-cm acute subdural hematoma. Of note, classical coagulation studies were normal, hut blood ethanol level was high, 436 mg/dL. Post-operatively, the patient suffered an intracerebral hemorrhage requiring emergent return to the operating room, where a large volume of unclotted blood and clinical coagulopathy was encountered.
   DISCUSSION: We review the literature pertaining to coagulopathy in the context of TBI and ethanol intoxication. This case is a cautionary tale of a phenomenon of unmeasured coagulopathy in the face of severe alcohol intoxication manifested by intraoperative coagulopathy with new postoperative hemorrhage. Although routine preoperative testing indicated normal clotting function, a thromboelastogram demonstrated delayed clot formation. The protective effects of alcohol are well described; however, we believe that there is a population of patients with severe acute intoxication who have coagulopathy that may go undetected by routine preoperative screening.
   CONCLUSIONS: Caution should be exercised when taking care of patients with very high levels of alcohol because physiologic derangements may be unpredictable. Additional research is needed for patients with very high levels of alcohol intoxication and the effect it may have on coagulation.
C1 [Whaley, Calvin C.; Young, Michael M.; Gaynor, Brandon G.] Advocate Christ Med Ctr, Sect Neurosurg, Oak Lawn, IL 60453 USA.
RP Whaley, CC (reprint author), Advocate Christ Med Ctr, Sect Neurosurg, Oak Lawn, IL 60453 USA.
EM calvinwhaley@gmail.com
OI Young, Michael/0000-0002-9771-0572
CR Berry C, 2010, AM SURGEON, V76, P1067
   Brennan JH, 2015, J CLIN NEUROSCI, V22, P1375, DOI 10.1016/j.jocn.2015.02.030
   Centers for Disease Control and Prevention, 2015, C TRAUM BRAIN INJ US
   Centers for Disease Control and Prevention, 2016, EARL REL SEL EST BAS
   Folkerson LE, 2018, AM J EMERG MED, V36, P38, DOI 10.1016/j.ajem.2017.06.057
   Folkerson LE, 2015, SURGERY, V158, P655, DOI 10.1016/j.surg.2015.02.029
   Franschman G, 2012, J NEUROTRAUM, V29, P128, DOI 10.1089/neu.2011.2044
   Howard BM, 2014, J TRAUMA ACUTE CARE, V77, P865, DOI 10.1097/TA.0000000000000357
   Joseph B, 2015, J TRAUMA ACUTE CARE, V78, P403, DOI 10.1097/TA.0000000000000504
   Lange RT, 2014, ARCH CLIN NEUROPSYCH, V29, P478, DOI 10.1093/arclin/acu027
   Lindblad C, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00015
   Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019
   Martin G, 2018, NEUROCRIT CARE, V28, P330, DOI 10.1007/s12028-017-0485-5
   Nakae R, 2016, J NEUROTRAUM, V33, P688, DOI 10.1089/neu.2015.4039
   Pandit V, 2014, J SURG RES, V190, P634, DOI 10.1016/j.jss.2014.04.039
   Rao AJ, 2018, WORLD NEUROSURG, V112, pE216, DOI 10.1016/j.wneu.2018.01.025
   Salim A, 2009, J TRAUMA, V67, P697, DOI 10.1097/TA.0b013e3181b5dcf2
   Shrestha Ajit, 2017, Asian J Neurosurg, V12, P648, DOI 10.4103/ajns.AJNS_192_14
   Spoerke N, 2010, J TRAUMA, V68, P1106, DOI 10.1097/TA.0b013e3181d86860
   Talving P, 2010, J TRAUMA, V68, P357, DOI 10.1097/TA.0b013e3181bb80bf
   Yuan Q, 2018, SCAND J TRAUMA RESUS, V26, DOI 10.1186/s13049-017-0471-0
   Zhang JN, 2018, BLOOD, V131, P2001, DOI 10.1182/blood-2017-11-784108
   Zhou Y, 2018, BLOOD, V131, P563, DOI 10.1182/blood-2017-08-801738
NR 23
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 454
EP 458
DI 10.1016/j.wneu.2019.06.124
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200221
PM 31252079
DA 2020-05-12
ER

PT J
AU Liu, WJ
   Zhang, S
   Liu, JX
   Shao, ZW
AF Liu, Weijian
   Zhang, Shuo
   Liu, Jianxiang
   Shao, Zengwu
TI Intraosseous Malignant Peripheral Nerve Sheath Tumor of 2 Consecutive
   Lumbar Vertebrae: A Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Intraosseous; Kyphosis; Low grade; Malignant peripheral nerve sheath
   tumor; Spondylectomy
ID EN-BLOC SPONDYLECTOMY; SPINAL-CORD; DIFFERENTIATION; SCHWANNOMA;
   FEATURES; INSTITUTION; SURVIVAL; SERIES
AB BACKGROUND: Malignant peripheral nerve sheath tumor (MPNST), which refers to any malignant tumor that originates from peripheral nerve sheath cells, is rarely found in the spine. Primary intraosseous spinal MPNSTs are extremely uncommon; in fact, such an occurrence has been reported in a very limited number of cases hitherto. We report here one case of low-grade intraosseous MPNST in the lumbar vertebrae and review clinical research related to this rare tumor and modus operandi to its treatment.
   CASE DESCRIPTION: A 51-year-old man suffering from lower back pain was initially diagnosed with lumbar tuberculosis. The intraoperative histopathologic examination, however, revealed that the occupying lesion was synovial sarcoma when surgeons intended to perform a debridement surgery of what was thought to be tuberculosis. The operation was therefore suspended. Two months later, the patient was referred to our institution. The pathologic sections were reexamined. Its results refuted the earlier thought of being synovial sarcoma, and a final diagnosis of MPNST was made. In addition, preoperative examination revealed that the tumor had advanced rapidly to the adjacent inferior vena cava and pedicle, which ruled out the possibility of performing a total en bloc spondylectomy. Therefore, a marginal resection for 2-level consecutive lumbar vertebrae was performed successfully via an anterior-posterior combined approach. No serious complications were detected at 18-month follow-up.
   CONCLUSIONS: Preoperative biopsy is of great importance for the diagnosis of spinal tumors. Marginal resection of a complicated intraosseous spine MPNST via an anterior-posterior combined approach, despite being technically challenging, resulted in good survival and functional outcomes.
C1 [Liu, Weijian; Zhang, Shuo; Liu, Jianxiang; Shao, Zengwu] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthopaed, Wuhan, Hubei, Peoples R China.
RP Shao, ZW (reprint author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthopaed, Wuhan, Hubei, Peoples R China.
EM szwpro@163.com
FU National Key Research and Development Program of China [2016YFC1100100];
   Natural Science Foundation of Hubei Province, ChinaNatural Science
   Foundation of Hubei Province [2018CFB118]
FX This study was supported by grants from the National Key Research and
   Development Program of China (2016YFC1100100) and the Natural Science
   Foundation of Hubei Province, China (2018CFB118).
CR Anghileri M, 2006, CANCER-AM CANCER SOC, V107, P1065, DOI 10.1002/cncr.22098
   Casanova M, 1999, J PEDIAT HEMATOL ONC, V21, P509, DOI 10.1097/00043426-199911000-00012
   Disch AC, 2008, EUR SPINE J, V17, P715, DOI 10.1007/s00586-008-0588-y
   DUCATMAN BS, 1986, CANCER-AM CANCER SOC, V57, P2006, DOI 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6
   Gnanalingham K, 2004, SPINE, V29, pE402, DOI 10.1097/01.brs.0000138410.28657.ee
   Guo AT, 2012, J CANCER, V3, P303, DOI 10.7150/jca.4179
   Guo CA, 2011, EUR SPINE J, V20, P655, DOI 10.1007/s00586-010-1618-0
   Huang L, 2013, EUR SPINE J, V22, P556, DOI 10.1007/s00586-012-2460-3
   Kar Madhabananda, 2006, World J Surg Oncol, V4, P55, DOI 10.1186/1477-7819-4-55
   Kato S, 2012, J SPINAL DISORD TECH, V25, pE183, DOI 10.1097/BSD.0b013e31825dd964
   Kawahara N, 2005, SPINE, V30, P613, DOI 10.1097/01.brs.0000155407.87439.a2
   Kawahara N, 2009, J ORTHOP SCI, V14, P830, DOI 10.1007/s00776-009-1389-9
   Khan M, 2018, AM J NEURORADIOL, V39, P1576, DOI 10.3174/ajnr.A5671
   Khan RJK, 1998, PATHOLOGY, V30, P237, DOI 10.1080/00313029800169376
   Kim AeRang, 2017, Sarcoma, V2017, P7429697, DOI 10.1155/2017/7429697
   Liang J, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0203-1
   Liljenqvist U, 2008, EUR SPINE J, V17, P600, DOI 10.1007/s00586-008-0599-8
   Luzzati AD, 2015, CLIN ORTHOP RELAT R, V473, P858, DOI 10.1007/s11999-014-3578-x
   Miyakoshi N, 2007, NEUROL INDIA, V55, P64, DOI 10.4103/0028-3886.30431
   Mizutani A, 2010, BRIT J NEUROSURG, V24, P604, DOI 10.3109/02688697.2010.495168
   Moon SJ, 2008, SPINE, V33, pE712, DOI 10.1097/BRS.0b013e31817e6995
   Nannapaneni R, 2005, BRIT J NEUROSURG, V19, P244, DOI 10.1080/02688690500207546
   Olsen SH, 2006, MODERN PATHOL, V19, P659, DOI 10.1038/modpathol.3800569
   Patnaik Ashis, 2012, Surg Neurol Int, V3, P157, DOI 10.4103/2152-7806.105096
   Rekhi B, 2008, ANN DIAGN PATHOL, V12, P90, DOI 10.1016/j.anndiagpath.2007.04.010
   Shimada S, 2007, PATHOL INT, V57, P60, DOI 10.1111/j.1440-1827.2006.02059.x
   SORDILLO PP, 1981, CANCER-AM CANCER SOC, V47, P2503, DOI 10.1002/1097-0142(19810515)47:10<2503::AID-CNCR2820471033>3.0.CO;2-3
   STENER B, 1971, Journal of Bone and Joint Surgery British Volume, V53, P288
   Suzuki K, 2014, ONCOL LETT, V7, P1965, DOI 10.3892/ol.2014.1987
   Thway K, 2015, INT J SURG PATHOL, V23, P377, DOI 10.1177/1066896915583996
   TOMITA K, 1994, INT ORTHOP, V18, P291
   WICK MR, 1987, AM J CLIN PATHOL, V87, P425, DOI 10.1093/ajcp/87.4.425
   Wong WW, 1998, INT J RADIAT ONCOL, V42, P351, DOI 10.1016/S0360-3016(98)00223-5
   Yao Kevin C, 2003, Neurosurg Focus, V15, pE6
   Yoshioka K, 2013, SPINE, V38, pE1511, DOI 10.1097/BRS.0b013e3182a6427a
   Zhu B, 2012, EUR SPINE J, V21, P897, DOI 10.1007/s00586-011-2093-y
NR 36
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 459
EP 466
DI 10.1016/j.wneu.2019.07.117
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200222
PM 31349078
DA 2020-05-12
ER

PT J
AU John, S
   Navarro, R
   Hussain, SI
   Zahra, K
   Elhammady, MS
AF John, Seby
   Navarro, Ramon
   Hussain, Syed Irteza
   Zahra, Khalil
   Elhammady, Mohammed Samy
TI Rescue Maneuver for Dislocated Woven EndoBridge Device in Middle
   Cerebral Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dislocation; MCA aneurysm; Repositioning; WEB device
AB BACKGROUND: Intrasaccular flow disruption has emerged as a useful modality for treatment of wide-necked saccular aneurysm at vessel bifurcations. The Woven EndoBridge (WEB) device is one such device that has been evaluated in several series with excellent safety and good midterm efficacy. Bailout techniques to retrieve or reposition a dislocated WEB device are sparse and associated with significant risks. We describe a case of a dislocated WEB device that was repositioned with a microcatheter alone.
   METHODS: We describe a case of a WEB device that inadvertently detached in the parent vessel and the technique we used to reposition it. A number of bailout techniques are discussed with pros and cons associated with each maneuver.
   RESULTS: An unruptured middle cerebral artery (MCA) aneurysm was treated by endovascular embolization with a WEB device. The WEB was deployed within the aneurysm without incident. However, the device failed to detach. While attempting to resheath the device, it extruded out of the aneurysm and then inadvertently detached in the MCA. After many options were considered, a microcatheter alone was used to push the device back into the aneurysm.
   CONCLUSION: Caution should be exercised, especially when detaching the WEB device. Microcatheter repositioning by pushing the dislocated device may be attempted, especially if part of the device is within the aneurysm. This is the first description of the described microcatheter repositioning rescue maneuver.
C1 [John, Seby; Hussain, Syed Irteza] Cleveland Clin Abu Dhabi, Neurol Inst, Dept Neurol, Abu Dhabi, U Arab Emirates.
   [John, Seby; Navarro, Ramon; Hussain, Syed Irteza; Zahra, Khalil; Elhammady, Mohammed Samy] Cleveland Clin Abu Dhabi, Neurol Inst, Dept Neurointervent Surg, Abu Dhabi, U Arab Emirates.
   [Navarro, Ramon; Elhammady, Mohammed Samy] Cleveland Clin Abu Dhabi, Neurol Inst, Dept Neurosurg, Abu Dhabi, U Arab Emirates.
   [Zahra, Khalil] Cleveland Clin Abu Dhabi, Neurol Inst, Dept Neuroradiol, Abu Dhabi, U Arab Emirates.
RP John, S (reprint author), Cleveland Clin Abu Dhabi, Neurol Inst, Dept Neurol, Abu Dhabi, U Arab Emirates.; John, S (reprint author), Cleveland Clin Abu Dhabi, Neurol Inst, Dept Neurointervent Surg, Abu Dhabi, U Arab Emirates.
EM johns5@clevelandclinicabudhabi.ae
CR Konig I, 2019, CLIN NEURORADIOL, V29, P361, DOI 10.1007/s00062-018-0685-1
   LINNC, BALL REM ASS WEB TRE
   Pierot L, 2018, J NEUROINTERV SURG, V10, P553, DOI 10.1136/neurintsurg-2017-013448
NR 3
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 467
EP 469
DI 10.1016/j.wneu.2019.06.160
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200223
PM 31254706
DA 2020-05-12
ER

PT J
AU Sahin, A
   Dalgic, N
AF Sahin, Ayse
   Dalgic, Nazan
TI Intraventricular Plus Intravenous Tigecycline for the Treatment of
   Daptomycin Nonsusceptible Vancomycin-Resistant Enterococci in an Infant
   with Ventriculoperitoneal Shunt Infection
SO WORLD NEUROSURGERY
LA English
DT Article
DE Infant; Intraventricular; Shunt infections; Tigecycline
ID MENINGITIS
AB BACKGROUND: Ventriculoperitoneal (VP) shunt infection, which is 1 of the most important complications of VP shunt is observed at a rate of 4%-17%. Staphylococcus epidermtdis is the most common causative agent. Vancomycin-resistant Enterococcus (VRE) is an increasingly common nosocomial pathogen that rarely causes central nervous system infections globally. Current treatment options that have shown appreciable activity against various VRE infections include daptomycin, linezolid, inquinupristin/dalfopristin, and tigecycline. Daptomycin has a particular mode of action and a potent bactericidal activity, making it a useful addition to the clinician's antibiotic collection. Global surveillance data indicate <1.0% rates of daptomycin resistance in enterococci.
   CASE DESCRIPTION: Here, we describe, to the best of our knowledge, the first case of successful Intraventricular plus intravenous use of tigecycline to treat VP shunt infections caused by daptomycin resistant VRE faecium.
   CONCLUSION: Tigecycline is a life-saving option in the treatment of resistant nosocomial infections but it has not yet been approved for use and there are not enough data in terms of dose and side effects associated with its use in children.
C1 [Sahin, Ayse; Dalgic, Nazan] Univ Hlth Sci, Sisli Hamidiye Etfal Res & Educ Hosp, Dept Pediat Infect Dis, Istanbul, Turkey.
RP Sahin, A (reprint author), Univ Hlth Sci, Sisli Hamidiye Etfal Res & Educ Hosp, Dept Pediat Infect Dis, Istanbul, Turkey.
EM ayseturgutsahin@gmail.com
CR Adams DJ, 2014, CURR INFECT DIS REP, V16, DOI 10.1007/s11908-014-0427-8
   Bender JK, 2018, DRUG RESIST UPDATE, V40, P25, DOI 10.1016/j.drup.2018.10.002
   Curebal B, 2018, J NEUROSURG PEDIAT, V23, P1
   Emiroglu M, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-0963
   European Committee on Antimicrobial Susceptibility Testing [EUCAST], 2019, BREAKP TABL INT MICS
   Fang YQ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007703
   Jaspan HB, 2010, PEDIATR INFECT DIS J, V29, P379, DOI 10.1097/INF.0b013e3181c806d8
   Kelesidis T, 2012, ANTIMICROB AGENTS CH, V56, P2150, DOI 10.1128/AAC.05918-11
   Knoll BM, 2013, SCAND J INFECT DIS, V45, P131, DOI 10.3109/00365548.2012.717711
   Lauretti L, 2017, J NEUROSURG, V127, P370, DOI 10.3171/2016.6.JNS16352
   Lewin JJ, 2019, NEUROCRIT CARE, V30, P609, DOI 10.1007/s12028-018-0647-0
   Mastrolia MV, 2017, EXPERT REV ANTI-INFE, V15, P605, DOI 10.1080/14787210.2017.1318064
   Miller WR, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026997
   Mueller Scott W, 2012, Ann Pharmacother, V46, pe35, DOI 10.1345/aph.1R412
   O'Driscoll T, 2015, INFECT DRUG RESIST, V8, P217, DOI 10.2147/IDR.S54125
   Pallotto C, 2014, SCAND J INFECT DIS, V46, P69, DOI 10.3109/00365548.2013.837957
   Sahin A, 2019, WORLD NEUROSURG, V124, P328, DOI 10.1016/j.wneu.2019.01.065
   Seidelman J, 2018, INFECT DIS CLIN N AM, V32, P861, DOI 10.1016/j.idc.2018.06.006
   STONE EM, 2011, BMJ CASE REP, V2011
   Summers NA, 2019, JMM CASE REP, V6
   Tsolaki V, 2018, J CRIT CARE, V47, P338, DOI 10.1016/j.jcrc.2018.07.025
   Tunkel AR, 2017, CLIN INFECT DIS, V64, pE34, DOI 10.1093/cid/ciw861
   Wang GQ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209785
   Wang LJ, 2017, EUR J HOSP PHARM-S P, V24, P182, DOI 10.1136/ejhpharm-2016-000972
   Wu YX, 2018, J CHEMOTHERAPY, V30, P49, DOI 10.1080/1120009X.2017.1338846
NR 25
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 470
EP 473
DI 10.1016/j.wneu.2019.07.045
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200224
PM 31302272
DA 2020-05-12
ER

PT J
AU Goethe, EA
   Srinivasan, VM
   Khan, AB
   LoPresti, MA
   Kan, P
   Burkhardt, JK
AF Goethe, Eric A.
   Srinivasan, Visish M.
   Khan, A. Basit
   LoPresti, Melissa A.
   Kan, Peter
   Burkhardt, Jan-Karl
TI Endovascular "Boost": External Carotid Angioplasty to Augment Flow
   Before Superficial Temporal-Middle Cerebral Artery Bypass
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angioplasty; Bilateral carotid occlusion; Ischemic stroke; STA-MCA
   bypass
AB BACKGROUND: Superficial temporal artery-middle cerebral artery (STA-MCA) bypass may be used to augment cerebral blood flow in patients with select cerebrovascular pathologies or after failed attempts at revascularization. In this article we describe the use of balloon angioplasty to boost the flow of the external carotid artery (ECA) including the STA to be later used as a donor artery for a STA-MCA bypass procedure.
   CASE DESCRIPTION: A 67-year-old male with bilateral carotid artery stenosis presented 2 days after a right middle cerebral artery (MCA) stroke and was admitted for medical management. Over the next 4 days his examination worsened; magnetic resonance imaging and computed tomography perfusion confirmed a right MCA stroke with penumbra and angiography revealed complete occlusion of the right internal carotid artery within a prior carotid stent. There was also a right ECA stenosis at its origin, thus limiting options for traditional extracranial-intracranial bypass. Therefore the patient underwent balloon angioplasty of the right ECA by traversing the carotid stent followed by right STA-MCA bypass, resulting in increased flow, clinical stability, and improved cerebral perfusion.
   CONCLUSIONS: This case highlights a unique strategy for the management of internal carotid artery occlusion in combination with an ipsilateral ECA stenosis. We also demonstrate the utility of endovascular adjuncts to open vascular surgery when complex patterns of stenosis or occlusion exist.
C1 [Goethe, Eric A.; Srinivasan, Visish M.; Khan, A. Basit; LoPresti, Melissa A.; Kan, Peter; Burkhardt, Jan-Karl] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
RP Burkhardt, JK (reprint author), Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
EM jan-karl.burkhardt@bcm.edu
OI Khan, Abdul/0000-0002-5450-930X
CR AbuRahma AF, 1998, CARDIOVASC SURG, V6, P579, DOI 10.1016/S0967-2109(98)00072-6
   Burkhardt JK, 2018, WORLD NEUROSURG, V109, pE476, DOI 10.1016/j.wneu.2017.10.005
   Cherian J, 2018, OPER NEUROSURG, V14, P288, DOI 10.1093/ons/opx119
   Choi Yun-Hee, 2018, J Cerebrovasc Endovasc Neurosurg, V20, P127, DOI 10.7461/jcen.2018.20.2.127
   LoPresti M, J NEUROSURG PEDIAT
   Maltezos Chrisostomos, 2018, Vasc Specialist Int, V34, P31, DOI 10.5758/vsi.2018.34.2.31
   Nico L, 2017, J NEUROINTERV SURG, V9, DOI 10.1136/neurintsurg-2016-012722.rep
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 474
EP 478
DI 10.1016/j.wneu.2019.06.065
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200225
PM 31226451
DA 2020-05-12
ER

PT J
AU Bhatt, AS
   Muthusubramanian, V
   Kondappan, A
   Mahadevan, A
AF Bhatt, Anusha S.
   Muthusubramanian, Vikram
   Kondappan, Asokan
   Mahadevan, Anita
TI Intradural Hemangioendothelioma of Lumbar Spine: Dilemmas and
   Differentials in Diagnosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hemangioendothelioma; Immunohistochemistry; Intradural; Spine
ID EPITHELIOID HEMANGIOENDOTHELIOMA; NERVE ROOT; CORD; PARAGANGLIOMAS;
   MENINGIOMA
AB BACKGROUND: Vascular tumors of the spine range from benign hemangiomas to malignant angiosarcomas. Hemangioendotheliomas of spine are tumors of intermediate-grade malignancy with rare occurrence in the intradural location. The imaging and histopathologic features may mimic other common lesions occurring at this location.
   CASE DESCRIPTION: A 70-year-old woman presented with lower limb weakness and sensory impairment along the L5-S1 dermatome. A radiologic diagnosis of neurofibroma at the intradural location of the L4-L5 level was made, and total excision of the space-occupying lesion was done. Histopatho logic examination, however, revealed a vascular tumor consistent with hemangioendothelioma, which was confirmed by immunohistochemical analysis. We present this case discussing the dilemmas and difficulties in arriving at the diagnosis, highlighting the role of immunohistochemical aid.
   CONCLUSION: Histomorphology, aided by ancillar tests like immunohistochemistry, remains the criterion for the definitive diagnosis of such rare lesions, and pathologists need to be aware of these lesions occurring in uncommon locations.
C1 [Bhatt, Anusha S.; Mahadevan, Anita] Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Bengaluru, India.
   [Muthusubramanian, Vikram] Sri Ramakrishna Hosp, Dept Minimally Invas Brain & Spine Surg, Coimbatore, Tamil Nadu, India.
   [Kondappan, Asokan] Sri Ramakrishna Hosp, Dept Neurol, Coimbatore, Tamil Nadu, India.
RP Mahadevan, A (reprint author), Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Bengaluru, India.
EM mahadevananita@gmail.com
OI Bhatt, Anusha S/0000-0003-2153-9390
CR Abuzallouf S, 2005, MED PRIN PRACT, V14, P354, DOI 10.1159/000086935
   Aquilina K, 2005, J NEUROSURG-SPINE, V3, P393, DOI 10.3171/spi.2005.3.5.0393
   Duffau H, 2000, SPINE, V25, P1993, DOI 10.1097/00007632-200008010-00021
   FELDENZER JA, 1990, J NEUROSURG, V72, P951, DOI 10.3171/jns.1990.72.6.0951
   Fletchers CDM, 2013, DIAGNOSTIC HISTOPATH, P2040
   Gokhan GA, 2006, WIEN KLIN WOCHENSCHR, V118, P358, DOI 10.1007/s00508-006-0582-5
   Goldblum JR, 2014, ENZINGER WIESSS SOFT, P682
   Kopniczky Z, 2008, BRIT J NEUROSURG, V22, P793, DOI 10.1080/02688690802158694
   Louis DN, 2016, WHO CLASSIFICATION T, P232
   Mahdavi Z, 1996, J NEURO-ONCOL, V27, P231, DOI 10.1007/BF00165479
   Marucci G, 2006, INT J SURG PATHOL, V14, P340, DOI 10.1177/1066896906292451
   Mataliotakis G, 2014, SPINE J, V14, pE1, DOI 10.1016/j.spinee.2014.08.447
   NG THK, 1989, J NEUROSURG, V70, P646, DOI 10.3171/jns.1989.70.4.0646
   Panero I, 2017, WORLD NEUROSURG, V108, DOI 10.1016/j.wneu.2017.08.030
   PERRIN RG, 1982, J NEUROSURG, V56, P835, DOI 10.3171/jns.1982.56.6.0835
   Roncaroli F, 2001, J NEUROSURG, V95, P93, DOI 10.3171/spi.2001.95.1.0093
   Sardaro A, 2014, ONCOL REV, V8, P82, DOI 10.4081/oncol.2014.259
   Scheithauer BW, 2007, WHO CLASSIFICATION T, P117
   Schick U, 2001, NEUROSURG REV, V24, P1, DOI 10.1007/PL00011959
   Simsek M, 2015, TURK NEUROSURG, V25, P162, DOI 10.5137/1019-5149.JTN.9303-13.4
   WEST CGH, 1979, J NEUROSURG, V51, P251, DOI 10.3171/jns.1979.51.2.0251
   Yang SY, 2005, J NEURO-ONCOL, V72, P49, DOI 10.1007/s11060-004-2159-3
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 479
EP 483
DI 10.1016/j.wneu.2019.06.172
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200226
PM 31295588
DA 2020-05-12
ER

PT J
AU Jha, DK
   Khera, P
   Bhasker, S
   Garg, M
AF Jha, Deepak K.
   Khera, Puspinder
   Bhasker, Suryanarayanan
   Garg, Mayank
TI Three-Dimensional Volume Rendering: An Underutilized Tool in
   Neurosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Computed tomography; Magnetic resonance imaging; Neurosurgery; Three
   dimensional; Volume rendering
ID SURGICAL APPROACH
AB OBJECTIVE: Two-dimensional radiologic images of computed tomography (CT) and magnetic resonance imaging (MRI) examinations are insufficient to provide three-dimensional conception of intracranial or spinal lesions, especially for an inexperienced neurosurgeon. We share our experience of applications of volume rendering (VR) images of CT and MRI studies of brain and spine for the purpose of training and surgical planning in neurosurgery.
   METHODS: Digital Imaging and Communications in Medicine viewer software was used on a personal computer/laptop to view CT and MRI examinations of various lesions of brain, spine, and spinal cord. Various user-friendly applications of the software enable users to edit the images acquired.
   RESULTS: Imaging technique (CT and MRI) incorporating continuous or overlapping slice with slice thickness of 1 mm with zero gap provides adequate three-dimensional image quality on personal computer/laptop acquired by VR. It was especially helpful for assessment of lesions of the skull base, intracranial vessels (aneurysm and arteriovenous malformation), craniovertebral junction and contrast-enhancing lesions of the brain. Displaying VR images in the operating room as per the patient's head position orients the surgeon to identify various structures in the surgical field.
   CONCLUSIONS: VR is underused in neurosurgery. It enables inexperienced neurosurgeons to understand morphologic details of a lesion and important osteoneurovascular structures around it. It is also helpful for training and preoperative planning in selected patients in neurosurgery.
C1 [Jha, Deepak K.; Bhasker, Suryanarayanan; Garg, Mayank] All India Inst Med Sci, Dept Neurosurg, Jodhpur, Rajasthan, India.
   [Khera, Puspinder] All India Inst Med Sci, Dept Diagnost & Intervent Radiol, Jodhpur, Rajasthan, India.
RP Jha, DK (reprint author), All India Inst Med Sci, Dept Neurosurg, Jodhpur, Rajasthan, India.
EM drdeepakjha@gmail.com
CR Arenson RL, 2003, J DIGIT IMAGING, V16, P142, DOI 10.1007/s10278-002-6004-y
   Aydin K, 2006, MINIM INVAS NEUROSUR, V49, P189, DOI 10.1055/s-2006-948300
   Santos BFD, 2018, WORLD NEUROSURG, V110, pE864, DOI 10.1016/j.wneu.2017.11.123
   Debnam JM, 2014, SCOLIOSIS SPINAL DIS, V9, DOI 10.1186/1748-7161-9-15
   Jia LP, 2012, J CRANIOFAC SURG, V23, P1893, DOI 10.1097/SCS.0b013e31827105d9
   Kuruoglu E, 2015, TURK NEUROSURG, V25, P914, DOI 10.5137/1019-5149.JTN.11473-14.1
   Liu XL, 2016, J CRANIOFAC SURG, V27, pE691, DOI 10.1097/SCS.0000000000002965
   Qu Y, 2016, J CRANIOFAC SURG, V27, P177, DOI 10.1097/SCS.0000000000002340
   Randazzo Michael, 2016, Surg Neurol Int, V7, pS801
   Sun W, 2014, J CRANIOFAC SURG, V25, P611, DOI 10.1097/SCS.0000000000000444
   Turner PJ, 2011, BRIT J RADIOL, V84, P1061, DOI 10.1259/bjr/99730184
   Willemse RB, 2011, BRIT J NEUROSURG, V25, P210, DOI 10.3109/02688697.2010.522742
NR 12
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 485
EP 492
DI 10.1016/j.wneu.2019.07.065
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200227
PM 31306842
DA 2020-05-12
ER

PT J
AU Mencser, Z
   Kopniczky, Z
   Kis, D
   Barzo, P
AF Mencser, Zoltan
   Kopniczky, Zsolt
   Kis, David
   Barzo, Pal
TI Slit Ventricle as a Neurosurgical Emergency: Case Report and Review of
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Hydrocephalus; Raised ICP; Shunt failure; Slit ventricle
ID IDIOPATHIC INTRACRANIAL HYPERTENSION; CEREBROSPINAL-FLUID; CHILDHOOD
   HYDROCEPHALUS; PSEUDOTUMOR CEREBRI; PRESSURE; CHILDREN; OBSTRUCTION;
   MANAGEMENT; RESISTANCE; SECONDARY
AB BACKGROUND: Symptomatic slit ventricle is one of the most challenging complications of shunt surgery in children. Clinical signs and symptoms may appear with a wide range of intracranial pressure (ICP) values. We report the case of a 10-year-old girl, who did not present the classic clinical features of extremely elevated ICP, which was proven by multiple invasive ICP recordings, performed during shunt revisions.
   CASE DESCRIPTION: At the age of 6 months, the patient presented squeal for many hours, accompanied with sunset eyes, bulging anterior fontanel, and dilated ventricles of all 4 ventricles on computed tomography scan. Acute ventriculoperitoneal shunt insertion was performed with adjustable valve. During the following 9 years, she was regularly seen and medically treated for intermittent headache, with nausea and vomiting. From 9 years of age, she was hospitalized for severe (10/10 on the visual analog scale), unbearable headache, agitation, and screaming on multiple occasions. Altogether, we had to revise the shunt system 5 times throughout 1 year. Radiologic imaging always showed narrow ventricles. Ophthalmologic examination of the fundus never revealed signs of raised ICP. Perioperative monitoring of the ICP with intraparenchymal sensor showed unexpected high values of 40-45 mm Hy. However, repetitive shunt revisions were successful only temporarily because the symptoms always returned. Only bilateral shunting of the ventricular system was able to eliminate the symptoms permanently.
   CONCLUSIONS: Images of slit ventricle can be associated either with low or extremely high ICP needing urgent surgical consideration, including ICP monitoring. Bilateral shunt insertion can be effective treatment for slit ventricle syndrome.
C1 [Mencser, Zoltan; Kopniczky, Zsolt; Kis, David; Barzo, Pal] Univ Szeged, Fac Med, Albert Szent Gyorgyi Clin Ctr, Dept Neurosurg, Szeged, Hungary.
   [Kopniczky, Zsolt] Peterfy Hosp, Dept Neurotraumatol, Natl Inst Traumatol, Budapest, Hungary.
RP Mencser, Z (reprint author), Univ Szeged, Fac Med, Albert Szent Gyorgyi Clin Ctr, Dept Neurosurg, Szeged, Hungary.
EM mencser67@gmail.com
CR Adams H, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002353
   Albright AL, 2001, NEUROSURGERY, V48, P764, DOI 10.1097/00006123-200104000-00013
   Bateman GA, 2007, J NEUROSURG, V107, P439, DOI 10.3171/PED-07/12/439
   Bateman GA, 2017, FLUIDS BARRIERS CNS, V14, DOI 10.1186/s12987-017-0066-1
   Bateman GA, 2013, J NEUROSURG, V119, P1503, DOI 10.3171/2013.7.JNS13390
   Buxton N, 1999, NEUROSURGERY, V44, P513, DOI 10.1097/00006123-199903000-00045
   Chernov MF, 2005, J NEUROSURG, V102, P260, DOI 10.3171/ped.2005.102.3.0260
   Czosnyka M, 2017, ACTA NEUROCHIR, V159, P1387, DOI 10.1007/s00701-017-3251-8
   Di Rocco C, 2006, CHILD NERV SYST, V22, P1573, DOI 10.1007/s00381-006-0194-4
   Dwyer CM, 2013, J NEUROSURG-PEDIATR, V11, P144, DOI 10.3171/2012.10.PEDS1299
   Eide PK, 2010, NEUROSURGERY, V66, P80, DOI 10.1227/01.NEU.0000363408.69856.B8
   Eide PK, 2003, J NEUROL NEUROSUR PS, V74, P231, DOI 10.1136/jnnp.74.2.231
   ENGEL M, 1979, NEUROSURGERY, V5, P549, DOI 10.1227/00006123-197911000-00001
   EPSTEIN FJ, 1974, J NEUROSURG, V41, P29, DOI 10.3171/jns.1974.41.1.0029
   FRIED A, 1986, J NEUROSURG, V65, P211, DOI 10.3171/jns.1986.65.2.0211
   Haubrich C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158506
   Jang M, 2013, MED HYPOTHESES, V81, P199, DOI 10.1016/j.mehy.2013.05.003
   Karahalios DG, 1996, NEUROLOGY, V46, P198, DOI 10.1212/WNL.46.1.198
   Le H, 2002, PEDIATR NEUROSURG, V36, P178, DOI 10.1159/000056054
   LINDER M, 1981, J NEUROSURG, V55, P183, DOI 10.3171/jns.1981.55.2.0183
   MARMAROU A, 1975, J NEUROSURG, V43, P523, DOI 10.3171/jns.1975.43.5.0523
   OBANA WG, 1990, NEUROSURGERY, V27, P760, DOI 10.1227/00006123-199011000-00014
   Pickard JD, 2008, ACTA NEUROCHIR SUPPL, V102, P283, DOI 10.1007/978-3-211-85578-2_53
   Preuss M, 2013, CHILD NERV SYST, V29, P1263, DOI 10.1007/s00381-013-2159-8
   Rekate HL, 2008, CHILD NERV SYST, V24, P423, DOI 10.1007/s00381-008-0579-7
   Rekate HL, 2006, J NEUROSURG, V104, P240, DOI 10.3171/ped.2006.104.4.240
   REKATE HL, 1988, PEDIATR NEUROSCI, V14, P85, DOI 10.1159/000120368
   REKATE HL, 1993, PEDIATR NEUROSURG, V19, P15, DOI 10.1159/000120694
   Ros B, 2018, NEUROSURG REV, V41, P969, DOI 10.1007/s10143-017-0849-5
   Saehle T, 2015, J NEUROSURG, V122, P1076, DOI 10.3171/2014.12.JNS141029
   SAINTEROSE C, 1984, J NEUROSURG, V60, P727, DOI 10.3171/jns.1984.60.4.0727
   SHAPIRO K, 1986, J NEUROSURG, V64, P390, DOI 10.3171/jns.1986.64.3.0390
   SHAPIRO K, 1985, J NEUROSURG, V63, P69, DOI 10.3171/jns.1985.63.1.0069
   Szczepanski TA, 2012, ADV CLIN EXP MED, V21, P55
NR 34
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 493
EP 498
DI 10.1016/j.wneu.2019.07.006
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200228
PM 31295607
DA 2020-05-12
ER

PT J
AU Pacca, P
   Marengo, N
   Di Perna, G
   Penner, F
   Ajello, M
   Garbossa, D
   Zenga, F
AF Pacca, Paolo
   Marengo, Nicola
   Di Perna, Giuseppe
   Penner, Federica
   Ajello, Marco
   Garbossa, Diego
   Zenga, Francesco
TI Endoscopic Endonasal Approach for Urgent Decompression of
   Craniovertebral Junction in Syringobulbia
SO WORLD NEUROSURGERY
LA English
DT Article
DE CVJ stability; Endonasal approach; Endoscopic; Odontoidectomy;
   Syringobulbia
ID C1 ARCH PRESERVATION; FORAMEN MAGNUM; ODONTOIDECTOMY
AB BACKGROUND: Syringobulbia is an uncommon lesion that occurs in the central nervous system; it is often defined as a pathologic cavitation in the brainstem. The cases with partial blockage of the cerebrospinal fluid pathways at the level of the foramen magnum are more common and the most important group. The most common treatment of syringobulbia is craniovertebral decompression.
   CASE DESCRIPTION: This paper reports a case of a symptomatic syringobulbia in which an urgent endoscopic endonasal approach to the craniovertebral junction (CVJ) was done to limit bulbo-medullary compression and rapid neurologic deterioration. A 69-year-old man was admitted to the hospital because of acute onset of dysphonia, dysphagia, imbalance, and vomiting. Magnetic resonance imaging revealed a cystic lesion in the brainstem, suggestive of a syringobulbia in Klippel Feil syndrome with CVJ stenosis.
   CONCLUSIONS: This case report details the successful use of endoscopic endonasal anterior decompression to treat syringobulbia, and adds to the growing literature in support of the endonasal endoscopic approach as a safe and feasible means for decompressing the craniocervical junction, even in the setting of urgency. However, prudent patient selection, combined with sound clinical judgment, access to instrumentation, and intraoperative imaging cannot be overemphasized.
C1 [Pacca, Paolo; Marengo, Nicola; Di Perna, Giuseppe; Penner, Federica; Ajello, Marco; Garbossa, Diego; Zenga, Francesco] Univ Turin, Div Neurosurg, Dept Neurosci, Turin, Italy.
RP Di Perna, G (reprint author), Univ Turin, Div Neurosurg, Dept Neurosci, Turin, Italy.
EM dr.giuseppediperna@gmail.com
RI Garbossa, Diego/AAC-8888-2019; Ajello, Marco/AAC-9910-2019
OI Penner, Federica/0000-0002-4491-1725
CR Baird CJ, 2009, NEUROSURGERY, V65, P158, DOI 10.1227/01.NEU.0000345641.97181.ED
   Burns TC, 2015, J NEUROL SURG REP, V76, P37, DOI 10.1055/s-0034-1395492
   CROCKARD HA, 1985, ANN ROY COLL SURG, V67, P321
   de Almeida JR, 2009, LARYNGOSCOPE, V119, P239, DOI 10.1002/lary.20108
   Dubey SP, 2014, INDIAN J OTOLARYNGOL, V66, P287, DOI 10.1007/s12070-014-0703-9
   Iacoangeli M, 2017, WORLD NEUROSURG, V107, P820, DOI 10.1016/j.wneu.2017.08.063
   Iacoangeli M, 2016, OPER NEUROSURG, V12, P222, DOI 10.1227/NEU.0000000000001330
   Iacoangeli M, 2013, SPINE J, V13, P542, DOI 10.1016/j.spinee.2013.01.043
   Kassam AB, 2005, NEUROSURGERY, V57, P213, DOI 10.1227/01.NEU.0000163687.64774.E4
   Klekamp J, 2002, J NEUROSURG, V97, P317, DOI 10.3171/spi.2002.97.3.0317
   La Corte E, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.1.FOCUS14777
   Levine DN, 2004, J NEUROL SCI, V220, P3, DOI 10.1016/j.jns.2004.01.014
   Messina A, 2007, NEUROSURG REV, V30, P189, DOI 10.1007/s10143-007-0084-6
   MORGAN D, 1992, J NEUROL NEUROSUR PS, V55, P1132, DOI 10.1136/jnnp.55.12.1132
   Mummaneni PV, 2005, NEUROSURGERY, V56, P1045, DOI 10.1227/01.NEU.0000158202.60442.FA
   Pacca Paolo, 2017, Oper Neurosurg (Hagerstown), V13, P732, DOI 10.1093/ons/opx035
   Re M, 2016, ACTA OTORHINOLARYNGO, V36, P107, DOI 10.14639/0392-100X-647
   Williams B, 1993, Acta Neurochir (Wien), V123, P190
   Zenga F, 2016, WORLD NEUROSURG, V89, P394, DOI 10.1016/j.wneu.2016.02.011
   Zenga Francesco, 2015, Surg Neurol Int, V6, P192, DOI 10.4103/2152-7806.172696
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 499
EP 505
DI 10.1016/j.wneu.2019.07.004
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200229
PM 31295597
DA 2020-05-12
ER

PT J
AU Altieri, R
   Morrone, A
   Certo, F
   Parisi, G
   Buscema, G
   Broggi, G
   Magro, G
   Barbagallo, GM
AF Altieri, Roberto
   Morrone, Antonio
   Certo, Francesco
   Parisi, Giuseppe
   Buscema, Giovanni
   Broggi, Giuseppe
   Magro, Gaetano
   Barbagallo, Giuseppe M.
TI Tentorial Angioleiomyoma: A Rare Neurosurgical Entity. Case Report and
   Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Arteriovenous malformations; Brain tumor; Diagnostic pitfall;
   Hemangiopericytoma; Intracranial angioleiomyoma; Meningioma; Posterior
   fossa tumor
ID CAVERNOUS SINUS ANGIOLEIOMYOMA; INFRATENTORIAL ANGIOLEIOMYOMA;
   REAPPRAISAL; DIAGNOSIS
AB BACKGROUND: Angioleiomyoma (ALM) is a soft tissue neoplasm rarely described in the intracranial site. Because of their uncommon presentation, atypical neuroradiologic and pathologic features, ALMs are often misdiagnosed.
   CASE DESCRIPTION: We describe the neuroradiologic, clinical, and pathologic data of a 37-year-old male patient suffering from a tentorial ALM. He was admitted at our hospital because of a posterior cranial fossa mass. Magnetic resonance imaging (MRI) showed a left tentorial tumor, hypointense on T1-weighted sequences, with heterogeneous contrast enhancement after gadolinium injection ("salt-and-pepper" fashion) and slightly hyperintense signal on T2-weighted sequence. After surgery, pathological examination showed a tumor composed of several thick-walled blood vessels mixed with a population of deeply eosinophilic spindle-shaped smooth muscle cells arranged in bundles. Necrosis was absent. Neither cellular pleomorphism nor mitoses were detected. lmmuno-histochemical analysis confirmed the smooth muscle phenotype of the spindle cell component: diffuse and strong positivity for alpha-smooth muscle actin, desmin, and h-caldesmon. Based on both morphologic and immunohistochemical findings, a diagnosis of primary intracranial ALM was rendered.
   CONCLUSIONS: We add to the literature the tenth case of this exceedingly rare tumor and submit that ALM should be suspected when a tentorial mass with a "flame-like" time-dependent pattern of contrast enhancement on MRI, a "salt-and-pepper" post-contrast appearance on MRI T1-weighted sequences, and a relation with large intracranial feeding vessels are present.
C1 [Altieri, Roberto; Morrone, Antonio; Certo, Francesco; Parisi, Giuseppe; Barbagallo, Giuseppe M.] Univ Hosp, Dept Neurosci, Div Neurosurg, Policlin G Rodolico, Catania, Italy.
   [Certo, Francesco; Barbagallo, Giuseppe M.] Univ Catania, Multidisciplinary Res Ctr Brain Tumors Diag & Tre, Catania, Italy.
   [Buscema, Giovanni] Univ Catania, Dept Anaesthesiol, Catania, Italy.
   [Broggi, Giuseppe; Magro, Gaetano] Univ Catania, Dept Med Surg Sci & Adv Technol & Biotechnol Sci, Anat Pathol, Catania, Italy.
   [Altieri, Roberto] Univ Turin, Neurosurg Unit, Dept Neurosci, Turin, Italy.
RP Altieri, R (reprint author), Univ Hosp, Dept Neurosci, Div Neurosurg, Policlin G Rodolico, Catania, Italy.; Altieri, R (reprint author), Univ Turin, Neurosurg Unit, Dept Neurosci, Turin, Italy.
EM roberto.altieri.87@gmail.com
RI Certo, Francesco/AAC-1855-2019
OI Broggi, Giuseppe/0000-0003-2576-6523; Altieri,
   Roberto/0000-0003-2671-4944
CR Calle S, 2016, J RADIOL CASE REP, V10, P8, DOI 10.3941/jrcr.v10i4.2713
   Campbell PG, 2010, NEUROSURG FOCUS, V29, P1
   Colnat-Coulbois Sophie, 2008, Neurosurgery, V62, pE257, DOI 10.1227/01.NEU.0000311086.81142.CD
   Conner TM, 2012, AM J SURG PATHOL, V36, P526, DOI 10.1097/PAS.0b013e31823def98
   Delgado-Fernandez J, 2016, REV NEUROLOGIA, V62, P68, DOI 10.33588/rn.6202.2015374
   Figueiredo EG, 2005, NEUROSURGERY, V56, P411, DOI 10.1227/01.NEU.0000148003.42589.83
   FOX SB, 1990, HISTOPATHOLOGY, V16, P495
   Gasco J, 2009, J NEUROSURG, V110, P670, DOI 10.3171/2008.8.17645
   HACHISUGA T, 1984, CANCER, V54, P126, DOI 10.1002/1097-0142(19840701)54:1<126::AID-CNCR2820540125>3.0.CO;2-F
   Hashimoto H, 2016, WHO CLASSIFICATION T
   He KM, 2014, JPN J CLIN ONCOL, V44, P1052, DOI 10.1093/jjco/hyu138
   Karagama Yakubu G, 2005, Ear Nose Throat J, V84, P218
   Kohan D, 1997, AM J OTOL, V18, P386
   LACH B, 1994, CANCER, V74, P1915, DOI 10.1002/1097-0142(19941001)74:7<1915::AID-CNCR2820740715>3.0.CO;2-1
   Lescher S, 2014, J NEUROL SURG PART A, V75, P403, DOI 10.1055/s-0034-1368688
   Li CB, 2018, WORLD NEUROSURG, V113, P1, DOI 10.1016/j.wneu.2018.01.207
   Li D, 2014, BRAIN TUMOR PATHOL, V31, P101, DOI 10.1007/s10014-013-0150-4
   Lim C. C. T., 2003, SMJ Singapore Medical Journal, V44, P526
   Louis DN, 2016, WHO CLASSIFICATION T
   Ma C, 2014, ONCOL LETT, V8, P2140, DOI 10.3892/ol.2014.2503
   Matsuyama A, 2007, HUM PATHOL, V38, P645, DOI 10.1016/j.humpath.2006.10.012
   Nayak L, 2009, CANCER-AM CANCER SOC, V115, P1947, DOI 10.1002/cncr.24203
   O'Leary S, 2007, CLIN RADIOL, V62, P10, DOI 10.1016/j.crad.2006.09.009
   Pepper JP, 2010, OTOL NEUROTOL, V31, P1451, DOI 10.1097/MAO.0b013e3181f1ce20
   Ramesh P, 2004, INT J CLIN PRACT, V58, P587, DOI 10.1111/j.1368-5031.2004.00085.x
   Scherer K, 2009, J RADIOL CASE REP, V3, P1, DOI 10.3941/jrcr.v3i11.189
   Shinde SV, 2012, NEUROL INDIA, V60, P123, DOI 10.4103/0028-3886.93613
   Skolnik AD, 2016, RADIOGRAPHICS, V36, P1463, DOI 10.1148/rg.2016150199
   Sun LJ, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-217
   Teranishi Y, 2014, J NEUROL SURG REP, V75, pE122, DOI 10.1055/s-0034-1376425
   Vecchio GM, 2011, PATHOL RES PRACT, V207, P322, DOI 10.1016/j.prp.2011.01.009
   Vijayasaradhi M, 2008, J NEUROSURG-PEDIATR, V2, P266, DOI 10.3171/PED.2008.2.10.266
   Watts J, 2014, INSIGHTS IMAGING, V5, P113, DOI 10.1007/s13244-013-0302-4
   Xiaofeng L, 2016, WORLD NEUROSURG, V87
NR 34
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 506
EP 511
DI 10.1016/j.wneu.2019.07.129
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200230
PM 31349075
DA 2020-05-12
ER

PT J
AU Campbell, JI
   Mural, M
   Rubino, F
   Lopez, ES
   Cervio, A
   Olvi, L
AF Iaconis Campbell, Juan
   Mural, Miguel
   Rubino, Franco
   Sales Lopez, Eduardo
   Cervio, Andres
   Olvi, Liliana
TI Clivus Hemangioma in a Pediatric Patient: Case Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clival hemangioma; Endoscopy; Pediatrics; Radiotherapy; Skull base
ID CAVERNOUS HEMANGIOMA; INTRAOSSEOUS HEMANGIOMA; SKULL
AB BACKGROUND: Hemangiomas are benign blood vessels tumors that represent less than 1% of all the bone neoplasms. Calvarial hemangiomas are mainly solitary lesions commonly located in the frontal and parietal bone; however, they may occur in any skull region. These tumors increase in size over a period of months to years before they start showing their first symptoms such as headache, bone deformity, and pathological fractures. Differential diagnosis with osteosarcoma should be considered. Surgical resection with a safety margin is a standard treatment of the cranial hemangioma. Furthermore, radiotherapy has proven to stop the tumor's growth but not its size.
   CASE DESCRIPTION: We treated an 11-year-old male who had a rare case of a capillary hemangioma located in the clivus bone. The patient underwent 2 endoscopic endonasal resection because of tumor recurrence. Surgical safety margins are highly recommended, but this procedure could not he performed because of the tumor's location. After the second relapse, the oncology team decided to initiate radiotherapy. At 6-month follow-up, the tumor reduced its size and remained unchanged.
   CONCLUSIONS: Surgical safety margins are highly important to prevent recurrence in this type of bone tumors. Skull base hemangiomas are a big challenge when you want to achieve these safety margins. We believe that a combined treatment of surgery and radiotherapy should be considered as the main treatment.
C1 [Iaconis Campbell, Juan; Mural, Miguel; Rubino, Franco; Sales Lopez, Eduardo] Hosp Nacl Prof Alejandro Posadas, Dept Neurosurg, Buenos Aires, DF, Argentina.
   [Cervio, Andres] FLENI, Dept Neurosurg, Buenos Aires, DF, Argentina.
   [Olvi, Liliana] Orthoped Pathol Inst, Buenos Aires, DF, Argentina.
RP Campbell, JI (reprint author), Hosp Nacl Prof Alejandro Posadas, Dept Neurosurg, Buenos Aires, DF, Argentina.
EM Juaniaconiscampbell@hotmail.com
OI Iaconis Campbell, Juan/0000-0001-5482-322X
CR BASTUG D, 1995, AM J ROENTGENOL, V164, P683, DOI 10.2214/ajr.164.3.7863894
   CLAUSER L, 1991, J CRANIO MAXILL SURG, V19, P353, DOI 10.1016/S1010-5182(05)80278-1
   Fechner RE, 1993, ATLAS TUMOR PATHOL, P129
   Gologorsky Y, 2013, J NEUROL SURG REP, V74, P17, DOI 10.1055/s-0033-1346980
   HOFFMANN DF, 1990, HEAD NECK-J SCI SPEC, V12, P160, DOI 10.1002/hed.2880120212
   HOOK SR, 1987, AM J OPHTHALMOL, V103, P824, DOI 10.1016/S0002-9394(14)74401-0
   Khanam H, 2001, SURG NEUROL, V55, P63, DOI 10.1016/S0090-3019(00)00268-8
   Kumar NAM, 1996, NEURORADIOLOGY, V38, pS83, DOI 10.1007/s002340050927
   Liu JK, 2003, SKULL BASE-INTERD AP, V13, P219, DOI 10.1055/s-2004-817698
   Moravan MJ, 2012, J NEUROSURG SCI, V56, P255
   Naama O, 2008, SURG NEUROL, V70, P654, DOI 10.1016/j.surneu.2007.05.052
   PETERSON DL, 1992, NEUROSURGERY, V30, P778
   Serrano Lucas, 2015, Surg Neurol Int, V6, pS117, DOI 10.4103/2152-7806.155695
   Singh Urvashi, 2019, World Neurosurg X, V3, P100030, DOI 10.1016/j.wnsx.2019.100030
   Sweet C, 1997, AM J NEURORADIOL, V18, P379
   TASHIRO T, 1991, AM J NEURORADIOL, V12, P1193
   Vanhoenacker FM, 2011, SKELETAL RADIOL, V40, P223, DOI 10.1007/s00256-010-0981-6
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 512
EP 515
DI 10.1016/j.wneu.2019.06.192
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200231
PM 31279922
DA 2020-05-12
ER

PT J
AU Ngaage, LM
   Harris, C
   Gao, C
   Puthumana, J
   Crabill, GA
   Baglien, B
   Wu, YL
   Rosen, C
   Rada, EM
   Groves, M
   Sansur, CA
   Rasko, YM
AF Ngaage, Ledibabari M.
   Harris, Chelsea
   Gao, Cynthia
   Puthumana, Joseph
   Crabill, George A.
   Baglien, Brigit
   Wu, Yinglun
   Rosen, Carly
   Rada, Erin M.
   Groves, Mari
   Sansur, Charles A.
   Rasko, Yvonne M.
TI Investigating the Gender Pay Gap in Industry Contributions to Academic
   Neurosurgeons
SO WORLD NEUROSURGERY
LA English
DT Article
DE Academic success; Faculty; Gender; Industry funding; Neurosurgery
ID SUNSHINE ACT; PAYMENTS
AB BACKGROUND: A large gender gap exists in industry funding for academic neurosurgeons. Selection criteria for funding distribution remain unclear. However, academic rank, scholarly productivity, and experience have been suggested as determining factors.
   METHODS: We conducted a cross-sectional study of industry payments to US academic neurosurgeons. We used online faculty listings to determine academic rank and gender, then used the Center for Medicare and Medicaid Services Open Payment Database to identify industry contributions. Details were collected on H-index and length of time in practice was used as a proxy for experience.
   RESULTS: Of the 1481 academic neurosurgeons included, men were in the majority (91% vs. 9%, P = 0.0001). Relative to their male colleagues, female assistant and associate professors received fewer payments (4 vs. 8, P = 0.0040; 2 vs. 7, P = 0.0067) at lower median values ($409 vs. $437, P = 0.0490; $163 vs. $260, P = 0.0089). H-index was more strongly associated with general payment receipt for women academic neurosurgeons (r = 0.20, P = 0.0201) than men academic neurosurgeons (r = 0.06, P = 0.0301). Experience trended toward a significant association with industry funding in men (r = 0.05, P = 0.0601). After adjustment for scholarly productivity and experience, gender-based funding inequalities became insignificant.
   CONCLUSIONS: In academic neurosurgery, substantial gender disparities exist in industry payments and metrics of academic success. There may be an industry selection bias toward recruitment of key opinion and thought leaders, as identified by scholarly productivity and experience. Despite the objective gender inequalities, industry funding to academic neurosurgeons appears to be equitable when metrics of academic success are considered.
C1 [Ngaage, Ledibabari M.; Rada, Erin M.; Rasko, Yvonne M.] Univ Maryland, Med Ctr, Div Plast Surg, Baltimore, MD 21201 USA.
   [Ngaage, Ledibabari M.; Harris, Chelsea; Rada, Erin M.; Rasko, Yvonne M.] Univ Maryland, Med Ctr, Dept Surg, Baltimore, MD 21201 USA.
   [Groves, Mari; Sansur, Charles A.] Univ Maryland, Med Ctr, Dept Neurosurg, Baltimore, MD 21201 USA.
   [Gao, Cynthia; Puthumana, Joseph; Crabill, George A.; Baglien, Brigit; Wu, Yinglun; Rosen, Carly] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
RP Rasko, YM (reprint author), Univ Maryland, Med Ctr, Div Plast Surg, Baltimore, MD 21201 USA.; Rasko, YM (reprint author), Univ Maryland, Med Ctr, Dept Surg, Baltimore, MD 21201 USA.
EM yrasko@som.umaryland.edu
OI Ngaage, Ledibabari/0000-0001-5802-779X
CR Agrawal S, 2013, NEW ENGL J MED, V368, P2054, DOI 10.1056/NEJMp1303523
   Baldwin C, 2011, TEACH LEARN MED, V23, P285, DOI 10.1080/10401334.2011.586936
   Buerba RA, 2018, J BONE JOINT SURG AM, V100, DOI 10.2106/JBJS.17.00838
   Centers for Medicare & Medicaid Services, OP PAYM DAT
   Chao AH, 2016, PLAST RECONSTR SURG, V138, p341E, DOI 10.1097/PRS.0000000000002404
   de Lotbiniere-Bassett MP, 2018, WORLD NEUROSURG, V114, pE920, DOI 10.1016/j.wneu.2018.03.116
   Eloy JA, 2017, WORLD NEUROSURG, V103, P517, DOI 10.1016/j.wneu.2017.03.110
   Eloy JA, 2013, OTOLARYNG HEAD NECK, V148, P215, DOI 10.1177/0194599812466055
   Fox CW, 2018, ECOL EVOL, V8, P11492, DOI 10.1002/ece3.4584
   Grissom RJ, 2012, EFFECT SIZES RES UNI
   Hirsch JE, 2005, P NATL ACAD SCI USA, V102, P16569, DOI 10.1073/pnas.0507655102
   Jagsi R, 2012, JAMA-J AM MED ASSOC, V307, P2410, DOI 10.1001/jama.2012.6183
   Jena AB, 2016, JAMA INTERN MED, V176, P1294, DOI 10.1001/jamainternmed.2016.3284
   King MM, 2017, SOCIUS, V3
   Lopez J, 2015, PLAST RECONSTR SURG, V136, p690E, DOI 10.1097/PRS.0000000000001718
   Ngaage LM, 2019, ANN PLAST SURG
   Oliveira DFM, 2019, JAMA-J AM MED ASSOC, V321, P898, DOI 10.1001/jama.2018.21944
   Renfrow JJ, 2018, NEUROSURGERY, V82, P576, DOI 10.1093/neuros/nyx251
   Ruan QZ, 2018, ANN PLAS SURG, V80, pS214, DOI 10.1097/SAP.0000000000001309
   Ruel E, 2013, DEMOGRAPHY, V50, P1155, DOI 10.1007/s13524-012-0182-0
   Shaikh AT, 2019, WORLD NEUROSURG, V123, P95, DOI 10.1016/j.wneu.2018.11.145
   Sismondo S, 2013, J LAW MED ETHICS, V41, P635, DOI 10.1111/jlme.12073
   Sugimoto C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121124
   Tringale KR, 2017, JAMA-J AM MED ASSOC, V317, P1774, DOI 10.1001/jama.2017.3091
   Wietsma AC, 2014, J COMMUNITY HOSP INT, V4, DOI 10.3402/jchimp.v4.24665
NR 25
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 516
EP +
DI 10.1016/j.wneu.2019.06.145
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200232
PM 31254703
DA 2020-05-12
ER

PT J
AU Agnoletto, GJ
   Meyers, PM
   Coon, A
   Kan, PTM
   Wakhloo, AK
   Hanel, RA
AF Agnoletto, Guilherme J.
   Meyers, Philip M.
   Coon, Alexander
   Kan, Peter Tze Man
   Wakhloo, Ajay K.
   Hanel, Ricardo A.
TI A Contemporary Review of Endovascular Treatment of Wide-Neck Large and
   Giant Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cerebrovascular; Coil embolization; Endovascular treatment; Intracranial
   aneurysm
ID PIPELINE EMBOLIZATION DEVICE; OPHTHALMIC SEGMENT ANEURYSMS;
   STENT-ASSISTED EMBOLIZATION; SINGLE-CENTER EXPERIENCE; CEREBRAL
   ANEURYSMS; COIL EMBOLIZATION; FLOW DIVERSION; INTRACRANIAL ANEURYSMS;
   FOLLOW-UP; CAROTID ANEURYSMS
AB BACKGROUND: Despite widespread use of flow diverters, wide-necked large and giant aneurysms are still treated with other techniques as well. A contemporary review of results from different endovascular treatments is timely.
   METHODS: A literature review of the English language literature since 2011 was conducted using PubMed and Science Direct. Keywords and Medical Subheadings included large and giant aneurysms, ruptured aneurysms, aneurysms located in posterior circulation, and aneurysm occlusion status. Case reports were excluded. A combined model was built including both flow diverter and coil treatments in addition to separate models. Efficacy and safety were pooled using random effects analysis and regression.
   RESULTS: The review comprised 29 studies. For coiling techniques, complete occlusion was 40.2%-82.8%, and adjusted regression resulted in 53% (95% confidence interval [CI] 22%-81%). Flow diverter complete occlusion rate was 40.5%-87.8%, and adjusted regression resulted in 87% (95% CI 76%-93%). Overall occlusion rate for both techniques combined was 62%-75%, and adjusted regression resulted in 81% (95% CI 68%-89%). Overall stroke and death regression rate was 5% (95% CI 3%-10%); flow diverters showed slightly higher rates than coiling (6% vs. 3%).
   CONCLUSIONS: All current treatments of large and giant wide-necked aneurysms have comparable safety and efficacy with a trend of superiority of efficacy toward flow diverters. Results of future treatment options and devices can be compared with current technology to evaluate feasibility.
C1 [Agnoletto, Guilherme J.; Hanel, Ricardo A.] Baptist Hlth, Baptist Neurol Inst Lyerly Neurosurg, Jacksonville, FL 32207 USA.
   [Meyers, Philip M.] Columbia Presbyterian Med Ctr, Dept Neurointervent Surg, New York, NY USA.
   [Coon, Alexander] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
   [Kan, Peter Tze Man] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
   [Wakhloo, Ajay K.] Tufts Med Ctr, Dept Neurointervent Radiol, Boston, MA 02111 USA.
RP Hanel, RA (reprint author), Baptist Hlth, Baptist Neurol Inst Lyerly Neurosurg, Jacksonville, FL 32207 USA.
EM rhanel@lyerlyneuro.com
CR Adeeb N, 2017, WORLD NEUROSURG, V105, P206, DOI 10.1016/j.wneu.2017.05.104
   Almandoz DJ, 2017, J NEUROINTERV SUR S1, V9, pA72
   Becske T, 2017, NEUROSURGERY, V80, P40, DOI 10.1093/neuros/nyw014
   Becske T, 2013, RADIOLOGY, V267, P858, DOI 10.1148/radiol.13120099
   Burrows AM, 2015, J NEUROINTERV SURG, V7, P646, DOI 10.1136/neurintsurg-2014-011184
   Cekirge HS, 2016, AM J NEURORADIOL, V37, P19, DOI 10.3174/ajnr.A4489
   Chalouhi N, 2014, AM J NEURORADIOL, V35, P546, DOI 10.3174/ajnr.A3696
   Chalouhi N, 2014, STROKE, V45, P54, DOI 10.1161/STROKEAHA.113.003038
   Chalouhi N, 2013, STROKE, V44, P2150, DOI 10.1161/STROKEAHA.113.001785
   Cinar C, 2013, DIAGN INTERV RADIOL, V19, P154, DOI 10.4261/1305-3825.DIR.6111-12.1
   D'Souza S, 2015, J NEUROSURG ANESTH, V27, P222, DOI 10.1097/ANA.0000000000000130
   Damiano RJ, 2015, J BIOMECH, V48, P3332, DOI 10.1016/j.jbiomech.2015.06.018
   Fennell VS, 2016, J NEUROSURG, V124, P13, DOI 10.3171/2014.11.JNS141030
   Gu DQ, 2013, J CLIN NEUROSCI, V20, P238, DOI 10.1016/j.jocn.2012.01.053
   Guan N, 2016, J STROKE CEREBROVASC, V25, P1929, DOI 10.1016/j.jstrokecerebrovasdis.2016.04.012
   Kallmes DF, 2017, J NEUROSURG, V127, P775, DOI 10.3171/2016.8.JNS16467
   Kallmes DF, 2016, INTERV NEUROL, V5, P89, DOI 10.1159/000446503
   Kono K, 2014, NEUROL MED-CHIR, V54, P126, DOI 10.2176/nmc.oa2013-0013
   Linzey JR, 2017, J NEUROINTERV SURG, V9, P1081, DOI 10.1136/neurintsurg-2016-012704
   Liu YQ, 2014, J CLIN NEUROSCI, V21, P2140, DOI 10.1016/j.jocn.2014.03.033
   Lopes DK, 2014, NEUROSURGERY, V74, P286, DOI 10.1227/NEU.0000000000000263
   Mascitelli JR, 2015, J CLIN NEUROSCI, V22, P1275, DOI 10.1016/j.jocn.2015.03.002
   McDonald RJ, 2015, INTERV NEURORADIOL, V21, P6, DOI 10.1177/1591019915576289
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   O'Kelly CJ, 2013, AM J NEURORADIOL, V34, P381, DOI 10.3174/ajnr.A3224
   Peker A, 2017, TURK NEUROSURG, V27, P863, DOI 10.5137/1019-5149.JTN.17426-16.0
   Peschillo S, 2017, OPER NEUROSURG, V13, P492, DOI 10.1093/ons/opx032
   Piano M, 2013, J NEUROSURG, V118, P408, DOI 10.3171/2012.10.JNS112222
   Qu RB, 2016, TURK NEUROSURG, V26, P223, DOI 10.5137/1019-5149.JTN.7710-12.1
   Raychev R, 2016, INTERV NEURORADIOL, V22, P34, DOI 10.1177/1591019915609125
   Raymond J, 2017, J NEUROSURG, V127, P454, DOI 10.3171/2016.4.JNS152662
   Rezek I, 2013, AM J NEURORADIOL, V34, P1380, DOI 10.3174/ajnr.A3398
   Shankar JJS, 2016, J NEUROINTERV SURG, V8, P273, DOI 10.1136/neurintsurg-2015-011708
   Shrier I, 2007, AM J EPIDEMIOL, V166, P1203, DOI 10.1093/aje/kwm189
   Song J, 2015, CLIN NEUROL NEUROSUR, V135, P73, DOI 10.1016/j.clineuro.2015.05.013
   Starke RM, 2014, J CLIN NEUROSCI, V21, P40, DOI 10.1016/j.jocn.2013.03.003
   Sterne JAC, 2008, SYSTEMATIC REV HLTH, P347, DOI DOI 10.1002/9780470693926.CH18
   Suzuki K, 2017, NEUROL MED-CHIR, V57, P231, DOI 10.2176/nmc.oa.2016-0176
   Thompson BG, 2015, STROKE, V46, P2368, DOI 10.1161/STR.0000000000000070
   Toma AK, 2013, BRIT J NEUROSURG, V27, P622, DOI 10.3109/02688697.2013.793292
   Velioglu M, 2012, NEURORADIOLOGY, V54, P1355, DOI 10.1007/s00234-012-1051-7
   Wang B, 2015, ACTA RADIOL, V56, P105, DOI 10.1177/0284185113520312
NR 42
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 523
EP +
DI 10.1016/j.wneu.2019.06.201
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200233
PM 31279111
DA 2020-05-12
ER

PT J
AU Montano, N
   Ricciardi, L
   Olivi, A
AF Montano, Nicola
   Ricciardi, Luca
   Olivi, Alessandro
TI Comparison of Anterior Cervical Decompression and Fusion versus
   Laminoplasty in the Treatment of Multilevel Cervical Spondylotic
   Myelopathy: A Meta-Analysis of Clinical and Radiological Outcomes
SO WORLD NEUROSURGERY
LA English
DT Review
DE ACDF; Anterior versus posterior approach; Cervical spondylotic
   myelopathy; Laminoplasty; Meta-analysis; Spine surgery
ID POSTERIOR LAMINOPLASTY; LAMINECTOMY; DISKECTOMY; SURGERY; DEFORMITY;
   SERIES
AB OBJECTIVE: Spondylotic cervical myelopathy is a severe condition commonly affecting aging people. Although many investigations have been conducted, a consensus on the best surgical management is still missing. The aim of our study was to systematically review the pertinent literature and carry out a meta-analysis to compare the clinical and radiological outcome of the anterior cervical decompression and fusion (ACDF) and the posterior laminoplasty.
   METHODS: This study was conducted in agreement with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines statement. Different medical database (PubMed, Embase, Scopus) were screened for eligible scientific reports. The key words "cervical," "spondylosis," "myelopathy," "laminoplasty," "ACDF" (MeSH) have been used in any possible combination. As outcome variables, the Japanese Orthopedic Association score, operation time, blood loss, cervical lordosis, range of motion and, complications were evaluated.
   RESULTS: A total of 626 articles were screened and 5 finally included in the meta-analysis. Comparing the anterior cervical decompression and fusion (ACDF) and laminoplasty groups, no differences were found in Japanese Orthopedic Association score, operation time, and complication rate. The ACDF was associated with lower intraoperative blood loss and better cervical lordosis preservation, whereas the laminoplasty was associated with a wider cervical range of motion.
   CONCLUSIONS: The results of this meta-analysis seem to suggest that ACDF should be preferred to the laminoplasty for the treatment of multilevel cervical myelopathy, although proper designed randomized controlled clinical trials are needed to further investigate this relevant ongoing issue.
C1 [Montano, Nicola; Ricciardi, Luca; Olivi, Alessandro] Catholic Univ, Fdn Policlin Univ A Gemelli IRCCS, Inst Neurosurg, Rome, Italy.
RP Montano, N (reprint author), Catholic Univ, Fdn Policlin Univ A Gemelli IRCCS, Inst Neurosurg, Rome, Italy.
EM nicolamontanomd@yahoo.it
RI Montano, Nicola/M-4565-2016; Ricciardi, Luca/L-5405-2019
OI Montano, Nicola/0000-0002-4965-1950; Ricciardi, Luca/0000-0001-5110-8386
CR Asher AL, 2019, NEUROSURGERY, V84, P919, DOI 10.1093/neuros/nyy144
   Chaudhary SK, 2017, J ORTHOP SURG-HONG K, V25, DOI 10.1177/2309499017731446
   Chen QX, 2019, WORLD NEUROSURG, V125, pE341, DOI 10.1016/j.wneu.2019.01.075
   Di Martino A, 2015, EUR SPINE J, V24, pS810, DOI 10.1007/s00586-015-4258-6
   Edwards Charles C 2nd, 2003, Spine J, V3, P68, DOI 10.1016/S1529-9430(02)00566-1
   Fang Z, 2016, CLIN SPINE SURG, V29, pE21, DOI 10.1097/BSD.0000000000000074
   Fouyas IP, 2002, SPINE, V27, P736, DOI 10.1097/00007632-200204010-00011
   GOEL VK, 1988, J ORTHOPAED RES, V6, P611, DOI 10.1002/jor.1100060419
   Goldschmidt Ezequiel, 2020, Neurosurgery, V86, P446, DOI 10.1093/neuros/nyz088
   Hida T, 2017, SPINE, V42, pE253, DOI 10.1097/BRS.0000000000001994
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Huang YM, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891-018-2378-y
   Kaptain GJ, 2000, J NEUROSURG, V93, P199, DOI 10.3171/spi.2000.93.2.0199
   Kim BJ, 2019, WORLD NEUROSURG, V126, pE1228, DOI 10.1016/j.wneu.2019.02.233
   Lao LF, 2013, J ORTHOP SURG RES, V8, DOI 10.1186/1749-799X-8-45
   Lee CH, 2015, J NEUROSURG-SPINE, V22, P589, DOI 10.3171/2014.10.SPINE1498
   Lin BJ, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013111
   Lin X, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014651
   Liu T, 2011, J SPINAL DISORD TECH, V24, P213, DOI 10.1097/BSD.0b013e3181e9f294
   Liu WJ, 2016, THER CLIN RISK MANAG, V12, P675, DOI 10.2147/TCRM.S100046
   Liu XZ, 2014, ORTHOPEDICS, V37, pE117, DOI 10.3928/01477447-20140124-12
   Liu XZ, 2014, EUR SPINE J, V23, P362, DOI 10.1007/s00586-013-3043-7
   Luo JQ, 2015, EUR SPINE J, V24, P1621, DOI 10.1007/s00586-015-3911-4
   Luo WQ, 2018, WORLD NEUROSURG, V120, P296, DOI 10.1016/j.wneu.2018.08.231
   Luo WQ, 2018, WORLD NEUROSURG, V117, P129, DOI 10.1016/j.wneu.2018.06.026
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Montano N, 2014, CLIN NEUROL NEUROSUR, V125, P69, DOI 10.1016/j.clineuro.2014.07.024
   Nikolaidis I, 2010, COCHRANE DB SYST REV, V1
   Papacci F, 2016, J CLIN NEUROSCI, V33, P159, DOI 10.1016/j.jocn.2016.03.036
   Ren H, 2017, CLIN SPINE SURG, V30, pE1104, DOI 10.1097/BSD.0000000000000396
   Rhee J, 2017, GLOB SPINE J, V7, p35S, DOI 10.1177/2192568217703083
   Ricciardi L, 2019, WORLD NEUROSURG, V122, pE1041, DOI 10.1016/j.wneu.2018.10.208
   Sun YF, 2015, CLIN NEUROL NEUROSUR, V134, P28, DOI 10.1016/j.clineuro.2015.04.011
   Tetreault L, 2018, NEUROSURG CLIN N AM, V29, P115, DOI 10.1016/j.nec.2017.09.020
   Tetreault LA, 2017, GLOB SPINE J, V7, p28S, DOI 10.1177/2192568217700396
   Wang T, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005437
   Witwer BP, 2007, NEUROSURGERY, V60, P130, DOI 10.1227/01.NEU.0000215351.32372.CE
   Xu LP, 2017, INT J SURG, V48, P247, DOI 10.1016/j.ijsu.2017.06.030
   Youssef JA, 2019, SPINE J, V19, P1714, DOI 10.1016/j.spinee.2019.04.019
   Yuan XJ, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014971
   Zhang JX, 2019, WORLD NEUROSURG, V121, pE917, DOI 10.1016/j.wneu.2018.10.016
   Zhang L, 2019, ARCH ORTHOP TRAUM SU, V139, P735, DOI 10.1007/s00402-018-03102-6
   Zhu B, 2013, EUR SPINE J, V22, P1583, DOI 10.1007/s00586-013-2817-2
NR 43
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 530
EP +
DI 10.1016/j.wneu.2019.06.144
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200234
PM 31254693
DA 2020-05-12
ER

PT J
AU Lu, VM
   Wahood, W
   Akinduro, OO
   Parney, IF
   Quinones-Hinojosa, A
   Chaichana, KL
AF Lu, Victor M.
   Wahood, Waseem
   Akinduro, Oluwaseun O.
   Parney, Ian F.
   Quinones-Hinojosa, Alfredo
   Chaichana, Kaisom L.
TI Four Independent Predictors of Postoperative Seizures After Meningioma
   Surgery: A Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Meningioma; Non-skull base; Postoperative; Predictors; Seizure; Surgery
ID QUALITY-OF-LIFE; SUPRATENTORIAL MENINGIOMA; INTRACRANIAL MENINGIOMAS;
   CONVEXITY MENINGIOMAS; UNITED-STATES; PRIMARY BRAIN; RISK-FACTORS;
   EPILEPSY; RESECTION; TUMORS
AB BACKGROUND: Postoperative seizures after surgical resection of intracranial meningiomas will negatively affect the quality of life of patients. The aim of the present meta-analysis was to pool the current data and identify the independent predictors of postoperative seizures to better guide postoperative surveillance.
   METHODS: Searches of 4 electronic databases from inception to February 2019 were conducted using the preferred reporting items for systematic reviews and meta-analyses guidelines. We identified 430 reports for screening. The hazard ratios (HRs) of the preoperative and postoperative parameters from Z3 separate multivariate regression analyses were pooled using a meta-analysis of the proportions.
   RESULTS: Of the 430 reports, 12 satisfied the criteria for inclusion in the present study. The pooled population of 5681 patients with meningioma had a median age of 56 years (range, 50-61) and a median proportion of World Health Organization grade I of 91% (range, 66-100). From these data, 4 statistically significant, independent predictors of postoperative seizures were identified: 1) preoperative seizure history (HR, 3.53; P< 0.01), 2) non-skull base location (HR, 2.35; P< 0.01), 3) postoperative complications (HR, 3.95; P < 0.01), and 4) meningioma recurrence (HR, 3.69; P < 0.01). However, the certainty of these results ranged from low to moderate.
   CONCLUSIONS: We identified 4 significant independent predictors of postoperative seizures after meningioma resection. These parameters should be considered in the follow-up of these patients to ensure optimal seizure surveillance, although ultimate validation by prospective studies is still required.
C1 [Lu, Victor M.; Wahood, Waseem; Parney, Ian F.] Mayo Clin, Dept Neurosurg, Rochester, MN 55904 USA.
   [Akinduro, Oluwaseun O.; Quinones-Hinojosa, Alfredo; Chaichana, Kaisom L.] Mayo Clin, Dept Neurosurg, Jacksonville, FL 32224 USA.
RP Lu, VM (reprint author), Mayo Clin, Dept Neurosurg, Rochester, MN 55904 USA.
EM lu.victor@mayo.edu
OI Wahood, Waseem/0000-0002-2963-4096
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01CA183827,
   R01CA195503, R01CA216855, R01CA200399, R43CA221490]; Florida State
   Department of Health Research; William J. and Charles H. Mayo
   Professorship; Mayo Clinic
FX A.Q.H. is funded by the National Institutes of Health (grants
   R01CA183827, R01CA195503, R01CA216855, R01CA200399, and R43CA221490),
   Florida State Department of Health Research, William J. and Charles H.
   Mayo Professorship, and Mayo Clinic Clinician Investigator. The
   remaining authors declare that the article content was composed in the
   absence of any commercial or financial relationships that could be
   construed as a potential conflict of interest.
CR Alvernia JE, 2011, J NEUROSURG, V115, P491, DOI 10.3171/2011.4.JNS101922
   Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
   Baumgarten P, 2018, EPILEPSY BEHAV, V88, P146, DOI 10.1016/j.yebeh.2018.09.002
   Beaumont A, 2000, ACTA NEUROCHIR, V142, P1, DOI 10.1007/s007010050001
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benz LS, 2018, CANCER-AM CANCER SOC, V124, P161, DOI 10.1002/cncr.30975
   Chaichana KL, 2013, WORLD NEUROSURG, V79, P515, DOI 10.1016/j.wneu.2012.02.051
   CHAN RC, 1984, J NEUROSURG, V60, P52, DOI 10.3171/jns.1984.60.1.0052
   Chen WC, 2017, NEUROSURGERY, V81, P297, DOI 10.1093/neuros/nyx001
   Chen WC, 2014, EPILEPSY BEHAV, V30, P50, DOI 10.1016/j.yebeh.2013.09.024
   Chozick BS, 1996, J NEUROSURG, V84, P382, DOI 10.3171/jns.1996.84.3.0382
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ehresman JS, 2019, J NEUROL SURG PART B, V80, P59, DOI 10.1055/s-0038-1667066
   Englot DJ, 2016, J NEUROSURG, V124, P1552, DOI 10.3171/2015.4.JNS142742
   Gilliam F, 1997, EPILEPSIA, V38, P233, DOI 10.1111/j.1528-1157.1997.tb01102.x
   Harden CL, 2002, CNS DRUGS, V16, P291, DOI 10.2165/00023210-200216050-00002
   Hasseleid BF, 2012, J NEUROSURG, V117, P999, DOI 10.3171/2012.9.JNS12294
   Hess K, 2019, J NEUROSURG, V130, P789, DOI 10.3171/2017.11.JNS172265
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13
   Hwang WL, 2016, NEURO-ONCOLOGY, V18, P863, DOI 10.1093/neuonc/nov285
   Islim AI, 2018, J NEURO-ONCOL, V140, P123, DOI 10.1007/s11060-018-2941-2
   Karamitopoulou E, 1998, HUM PATHOL, V29, P140, DOI 10.1016/S0046-8177(98)90224-6
   Li Xiangrong, 2020, Neurosurg Rev, V43, P597, DOI 10.1007/s10143-019-01085-5
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Lieu AS, 2000, EPILEPSY RES, V38, P45
   McGovern SL, 2010, J NEUROSURG, V112, P925, DOI 10.3171/2009.9.JNS09617
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI 10.1093/neuonc/nov189
   Porter KR, 2010, NEURO-ONCOLOGY, V12, P520, DOI 10.1093/neuonc/nop066
   Rogers L, 2015, J NEUROSURG, V122, P4, DOI 10.3171/2014.7.JNS131644
   Sanai N, 2010, J NEUROSURG, V112, P913, DOI 10.3171/2009.6.JNS081490
   Seyedi JF, 2018, CLIN NEUROL NEUROSUR, V165, P60, DOI 10.1016/j.clineuro.2018.01.002
   Shamji MF, 2009, NEUROSURG REV, V32, P275, DOI 10.1007/s10143-009-0191-7
   Skardelly M, 2017, WORLD NEUROSURG, V97, P538, DOI 10.1016/j.wneu.2016.10.062
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Sughrue ME, 2011, J NEUROSURG, V114, P705, DOI 10.3171/2010.5.JNS091972
   Wan X, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-135
   Wang X, 2018, WORLD NEUROSURG, V117, pE362, DOI 10.1016/j.wneu.2018.06.037
   Wirsching HG, 2016, NEURO-ONCOLOGY, V18, P1002, DOI 10.1093/neuonc/nov303
   Xue H, 2018, ACTA NEUROCHIR, V160, P589, DOI 10.1007/s00701-017-3434-3
   Zhang B, 2011, J INT MED RES, V39, P1728, DOI 10.1177/147323001103900515
   Zheng Z, 2013, J NEURO-ONCOL, V114, P101, DOI 10.1007/s11060-013-1156-9
NR 44
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 537
EP +
DI 10.1016/j.wneu.2019.06.063
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200235
PM 31226449
DA 2020-05-12
ER

PT J
AU Shin, Y
   Lee, KM
   San Lee, J
   Kim, EJ
   Kim, HG
   Yeon, EK
AF Shin, Yeji
   Lee, Kyung Mi
   San Lee, Jin
   Kim, Eui Jong
   Kim, Hyug-Gi
   Yeon, Eung Koo
TI Isolated Trochlear Nerve Palsy it a Patient with Superior Cerebellar
   Rete Mirabile
SO WORLD NEUROSURGERY
LA English
DT Article
DE Rete mirabile; Superior cerebellar artery; Trochlear nerve palsy
ID ARTERY; 4TH; ETIOLOGY
AB BACKGROUND: Rete mirabile is a very rare vascular malformation and superior cerebellar artery (SCA) rete mirabile is not reported previously. We report a new case of rete mirabile of SCA initially detected by magnetic resonance imaging and transfemoral cerebral angiography.
   CASE DESCRIPTION: This report illustrates the case of a 58-year-old man who presented with vertical diplopia. Brain magnetic resonance angiography and transfemoral cerebral angiography revealed a rete mirabile of SCA and 3-dimensional volume isotropic turbo spin echo acquisition, brain magnetic resonance imaging sequence, demonstrated that the cisternal segment of the ipsilateral trochlear nerve was compressed by this vascular malformation. We assumed that his cranial nerve palsy was caused by the rete mirabile of the right SCA. During the 8 weeks presence of diplopia, the patient was observed and the symptom was relieved spontaneously.
   CONCLUSIONS: We provide a first report in the literature of rete mirabile involving the SCA and suggest a descriptive knowledge of rete mirabile for clinicians during decision-making of treatment.
C1 [Shin, Yeji] Kyung Hee Univ, Coll Med, Dept Radiol, Kyung Hee Univ Hosp Gangdong, Seoul, South Korea.
   [Lee, Kyung Mi; Kim, Eui Jong; Kim, Hyug-Gi; Yeon, Eung Koo] Kyung Hee Univ, Kyung Hee Univ Hosp, Coll Med, Dept Radiol, Seoul, South Korea.
   [San Lee, Jin] Kyung Hee Univ, Kyung Hee Univ Hosp, Coll Med, Dept Neurol, Seoul, South Korea.
RP Lee, KM (reprint author), Kyung Hee Univ, Kyung Hee Univ Hosp, Coll Med, Dept Radiol, Seoul, South Korea.
EM bandilee@khu.ac.kr
OI YEON, EUNG KOO/0000-0001-7965-0118
FU Basic Science Research Program through the Ministry of Education of the
   Republic of Korea [NRF-2016R1D1A1B03933173]
FX The research was supported by a grant of the Basic Science Research
   Program through the Ministry of Education of the Republic of Korea
   (NRF-2016R1D1A1B03933173).
CR Aydin ME, 2011, ANAT CELL BIOL, V44, P164, DOI 10.5115/acb.2011.44.2.164
   COLLINS TE, 1992, NEUROSURGERY, V30, P258, DOI 10.1227/00006123-199202000-00020
   Dosunmu EO, 2018, AM J OPHTHALMOL, V185, P110, DOI 10.1016/j.ajo.2017.10.019
   Giragani S, 2018, INTERV NEURORADIOL, V24, P662, DOI 10.1177/1591019918782147
   HARDY DG, 1980, NEUROSURGERY, V6, P10, DOI 10.1227/00006123-198001000-00002
   Keane JR, 2004, ARCH NEUROL-CHICAGO, V61, P280, DOI 10.1001/archneur.61.2.280
   Lee SY, 2011, KOREAN J RADIOL, V12, P740, DOI 10.3348/kjr.2011.12.6.740
   Lin E, 2013, INTERV NEURORADIOL, V19, P73, DOI 10.1177/159101991301900111
   Makki AA, 2005, NEUROLOGY, V65, P1989, DOI 10.1212/01.wnl.0000188882.80729.79
   MARGOLIS MT, 1969, RADIOLOGY, V93, P834, DOI 10.1148/93.4.834
   Mollan SP, 2009, EYE, V23, P640, DOI 10.1038/eye.2008.24
   Tamhankar MA, 2013, OPHTHALMOLOGY, V120, P2264, DOI 10.1016/j.ophtha.2013.04.009
   Tubbs RS, 2015, NERVES NERVE INJURIE
   Uchino Akira, 2003, Radiat Med, V21, P235
   Verma A, 2018, INTERV NEURORADIOL, V24, DOI 10.1177/1591019918772054
   Zheng L, 2008, INTERV NEURORADIOL, V14, P195, DOI 10.1177/159101990801400212
NR 16
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 546
EP 549
DI 10.1016/j.wneu.2019.05.244
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200236
PM 31181360
DA 2020-05-12
ER

PT J
AU Primalani, NK
   Quek, TJ
   Low, DCY
   Low, SYY
AF Primalani, Nishal K.
   Quek, Terence J.
   Low, David C. Y.
   Low, Sharon Y. Y.
TI Spontaneous Intracranial Hypotension Presenting As Cervicogenic
   Headache: Case Report and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Headache; Spontaneous intracranial hypotension
ID CEREBROSPINAL-FLUID LEAKS; MISDIAGNOSIS; FEATURES
AB BACKGROUND: Spontaneous intracranial hypotension is uncommon. There is lack of understanding of its exact pathophysiology along with significant variability in its clinical management.
   CASE DESCRIPTION: The authors report the case of a previously well man cervicogenic headache associated with magnetic resonance imaging features of intracranial hypotension. The salient features of this case include the details of various treatments prescribed for his condition and the therapeutic difficulties encountered.
   CONCLUSION: Owing to the infrequency of the diagnosis, the challenges of clinical management for this patient are discussed in relationship to current literature. Next, the highlights of this unusual case in an individual add to the growing body of literature reports for better understanding of this disease.
C1 [Primalani, Nishal K.] Tan Tock Seng Hosp, Dept Neurosurg, Natl Neurosci Inst, Singapore, Singapore.
   [Quek, Terence J.] Tan Tock Seng Hosp, Anaesthesiol Intens Care & Pain Med Dept, Singapore, Singapore.
   [Low, David C. Y.; Low, Sharon Y. Y.] Natl Neurosci Inst, SingHlth Duke NUS Neurosci Acad Clin Program, Dept Neurosurg, Singapore, Singapore.
RP Low, SYY (reprint author), Natl Neurosci Inst, SingHlth Duke NUS Neurosci Acad Clin Program, Dept Neurosurg, Singapore, Singapore.
EM sharon.low.y.y@singhealth.com.sg
OI LOW, SHARON/0000-0001-7317-670X
CR Acosta Jr FL, 2003, NEUROSURG FOCUS, V15, P15
   Caspar W, 2003, SURG NEUROL, V59, P101, DOI 10.1016/S0090-3019(02)00981-3
   Costa P, 2012, HEADACHE, V52, P1592, DOI 10.1111/j.1526-4610.2012.02261.x
   Dillo W, 2002, J NEUROL, V249, P224, DOI 10.1007/PL00007870
   Ferrante E, 2004, HEADACHE, V44, P615, DOI 10.1111/j.1526-4610.2004.446012.x
   Franzini A, 2010, ACTA NEUROCHIR, V152, P1997, DOI 10.1007/s00701-010-0783-6
   Inenaga C, 2001, J NEUROSURG, V94, P642, DOI 10.3171/jns.2001.94.4.0642
   Kim YJ, 2017, HEADACHE, V57, P1593, DOI 10.1111/head.13132
   Kong WK, 2011, J KOREAN NEUROSURG S, V50, P123, DOI 10.3340/jkns.2011.50.2.123
   Kranz PG, 2017, CURR PAIN HEADACHE R, V21, DOI 10.1007/s11916-017-0639-3
   Langdown AJ, 2005, J SPINAL DISORD TECH, V18, P29, DOI 10.1097/01.bsd.0000133495.78245.71
   MARCELIS J, 1990, HEADACHE, V30, P192, DOI 10.1111/j.1526-4610.1990.hed3004192.x
   Michali-Stolarska M, 2017, POL J RADIOL, V82, P842, DOI 10.12659/PJR.904433
   Mokri B, 1999, MAYO CLIN PROC, V74, P1113, DOI 10.4065/74.11.1113
   NOSIK WA, 1955, JAMA-J AM MED ASSOC, V157, P1110, DOI 10.1001/jama.1955.02950300038008
   Rahman M, 2011, NEUROSURGERY, V69, P4, DOI 10.1227/NEU.0b013e3182134399
   Riva-Amarante E, 2006, NEUROLOGIA, V21, P209
   Schievink WI, 2003, ARCH NEUROL-CHICAGO, V60, P1713, DOI 10.1001/archneur.60.12.1713
   Schievink WI, 1996, J NEUROSURG, V84, P598, DOI 10.3171/jns.1996.84.4.0598
   Schievink WI, 2009, J NEUROSURG, V110, P521, DOI 10.3171/2008.9.JNS08670
   Spelle L, 2001, NEURORADIOLOGY, V43, P622, DOI 10.1007/s002340000529
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 550
EP 554
DI 10.1016/j.wneu.2019.05.107
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200237
PM 31125776
DA 2020-05-12
ER

PT J
AU Knisely, JPS
   Apuzzo, MLJ
AF Knisely, Jonathan P. S.
   Apuzzo, Michael L. J.
TI Historical Aspects of Stereotactic Radiosurgery: Concepts, People, and
   Devices
SO WORLD NEUROSURGERY
LA English
DT Article
DE Interdisciplinary; Multidisciplinary; Radiation; Radiosurgery;
   Stereotactic history; Stereotaxis; Technology
ID LINEAR-ACCELERATOR; BRAIN METASTASES; SINGLE; BEAM; IRRADIATION; SYSTEM
AB Stereotactic radiosurgery is a modern discipline that emerged after World War II. It represents a synthesis of an approach to patient care that was not immediately embraced by either neurosurgeons or radiation oncologists, but which has been shown, time and again, to be advantageous for the treatment of intracranial pathology. Indeed, stereotactic radiosurgical techniques are now being rapidly adapted and adopted for the treatment of extracranial malignant and benign disease. Any examination of the individuals, devices, and technological advances that permitted stereotactic radiosurgery to become a preferred approach for patient care cannot be absolutely comprehensive but can provide insights into the evolution of the specialty and potential future prospects for further improvements in patient care. As Shakespeare wrote in The Tempest, "What's past is prologue."
C1 [Knisely, Jonathan P. S.] Weill Cornell Med, Dept Radiat Oncol, New York, NY 10065 USA.
   [Apuzzo, Michael L. J.] Weill Cornell Med, Dept Neurol Surg, New York, NY USA.
RP Knisely, JPS (reprint author), Weill Cornell Med, Dept Radiat Oncol, New York, NY 10065 USA.
EM jok9121@med.cornell.edu
CR Adler JR, 2017, CUREUS, V9, DOI 10.7759/cureus.1663
   ADLER JRA, 2009, CUREUS, V1, pE1, DOI DOI 10.7759/CUREUS.1
   [Anonymous], 1906, BRIT MED J, V1906, P1799
   [Anonymous], 2003, COMMUNICATION   0505
   Arle J., 2009, TXB STEREOTACTIC FUN, p[453, 1]
   BETTI O, 1983, NEUROCHIRURGIE, V29, P295
   BETTI OO, 1989, NEUROSURGERY, V24, P311, DOI 10.1227/00006123-198903000-00001
   Chung H, 2007, IFMBE P, V14
   Clark GM, 2012, PRACT RADIAT ONCOL, V2, P306, DOI 10.1016/j.prro.2011.12.003
   Clarke RH, 1920, J HOPK HOSP REP, P1
   COLOMBO F, 1985, NEUROSURGERY, V16, P154, DOI 10.1227/00006123-198502000-00005
   Cushing H., 1912, PITUITARY BODY ITS D
   FRIEDMAN WA, 1989, SURG NEUROL, V32, P334, DOI 10.1016/0090-3019(89)90135-3
   HAKANSON S, 1981, NEUROSURGERY, V9, P638, DOI 10.1227/00006123-198112000-00005
   HAYNE RA, 1949, ELECTROEN CLIN NEURO, V1, P437, DOI 10.1016/0013-4694(49)90215-1
   Hill DLG, 2001, MED IMAGE REGISTRATI, P40
   Horsley V, 1908, BRAIN, V31, P45, DOI 10.1093/brain/31.1.45
   Jaffray DA, 1999, INT J RADIAT ONCOL, V45, P773, DOI 10.1016/S0360-3016(99)00118-2
   Jang SY, 2016, J APPL CLIN MED PHYS, V17, P184, DOI 10.1120/jacmp.v17i5.6260
   JONES D, 1993, BRIT J RADIOL, V66, P1142, DOI 10.1259/0007-1285-66-792-1142
   Knisely JP, 2000, J NEUROSURG, V93, P208, DOI 10.3171/jns.2000.93.supplement_3.0208
   LARSSON B, 1958, NATURE, V182, P1222, DOI 10.1038/1821222a0
   LEAVITT DD, 1991, INT J RADIAT ONCOL, V21, P1247, DOI 10.1016/0360-3016(91)90283-A
   Leksell D, 2016, INTRACRANIAL STEREOT, P2
   LEKSELL L, 1971, ACTA CHIR SCAND, V137, P311
   LEKSELL L, 1951, ACTA CHIR SCAND, V102, P316
   LEKSELL L, 1960, ACTA RADIOL, V54, P251, DOI 10.3109/00016926009172547
   LEKSELL L, 1949, ACTA CHIR SCAND, V98, P270
   LINDQUIST C, 1989, NEUROSURGERY, V25, P802, DOI 10.1227/00006123-198911000-00018
   LOEFFLER JS, 1990, J CLIN ONCOL, V8, P576, DOI 10.1200/JCO.1990.8.4.576
   Meyer J, 2007, BIOINSPIRATION ROBOT
   Mozdy M., 2017, INVENTING N LOCALIZE
   OLIVIER A, 1985, APPL NEUROPHYSIOL, V48, P94
   PETERS TM, 1987, APPL NEUROPHYSIOL, V50, P33
   PIKE B, 1987, MED PHYS, V14, P780, DOI 10.1118/1.596003
   PODGORSAK EB, 1988, INT J RADIAT ONCOL, V14, P115, DOI 10.1016/0360-3016(88)90059-4
   PODGORSAK EB, 1987, APPL NEUROPHYSIOL, V50, P263
   SALORIO JLB, 1985, APPL NEUROPHYSIOL, V48, P400
   SCHLEGEL W, 1992, INT J RADIAT ONCOL, V24, P781, DOI 10.1016/0360-3016(92)90729-2
   Schonberg RG, HIST PORTABLE LINEAR
   Shiu AS, 1997, INT J RADIAT ONCOL, V37, P679, DOI 10.1016/S0360-3016(96)00507-X
   SPIEGEL EA, 1947, SCIENCE, V106, P349, DOI 10.1126/science.106.2754.349
   SPIEGEL EA, 1951, J NEUROSURG, V8, P452, DOI 10.3171/jns.1951.8.4.0452
   STEINER L, 1972, ACTA CHIR SCAND, V138, P459
   STURM V, 1987, INT J RADIAT ONCOL, V13, P279, DOI 10.1016/0360-3016(87)90140-4
   TALAIRACH J, 1952, PRESSE MED, V60, P605
   TALAIRACH J, 1950, PRESSE MED, V58, P697
   Tondreau R L, 1985, Radiographics, V5, P994
   WINSTON KR, 1988, NEUROSURGERY, V22, P454, DOI 10.1227/00006123-198803000-00002
   Yuan Y, 2018, J RADIOSURGERY SBRT, V5, P131
   2007, PRIV PENS VERS SOC, P1
NR 51
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 593
EP 607
DI 10.1016/j.wneu.2019.04.030
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200260
PM 31581409
DA 2020-05-12
ER

PT J
AU Pannullo, SC
   Julie, DAR
   Chidambaram, S
   Balogun, OD
   Formenti, SC
   Apuzzo, MLJ
   Knisely, JPS
AF Pannullo, Susan C.
   Julie, Diana A. R.
   Chidambaram, Swathi
   Balogun, Onyinye D.
   Formenti, Silvia Chiara
   Apuzzo, Michael L. J.
   Knisely, Jonathan P. S.
TI Worldwide Access to Stereotactic Radiosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Access; Cost-effectiveness; CyberKnife; Device costs; Gamma Knife;
   Global health; Novalis; Stereotactic radiosurgery
ID GAMMA-KNIFE RADIOSURGERY; OPEN SURGERY; COSTS; MICROSURGERY;
   NEUROSURGERY; EXPERIENCE; AFRICA; SYSTEM
AB Stereotactic radiosurgery is a safe and effective technology that can address a variety of neurosurgical conditions, but in many parts of the world, access remains an issue. Although the technology is increasingly available in the United States, Canada, Europe, and parts of Asia, poor access to central nervous system (CNS) imaging and inadequate treatment equipment in other parts of the world limit the availability of radiosurgery as a treatment option. In addition, epidemiologic data about cancer and CNS metastases in low-income countries are sparse and much less complete than in more developed countries, and the need for radiosurgery may be underestimated as a result , Current radiosurgical platforms can be expensive to install and require a substantial amount of personnel training for safe operation. Socioeconomic and political forces are relevant to limitations to and opportunities for improving access to care. Here we examine the current barriers to access and propose areas for future efforts to improve global availability of radiosurgery for neurosurgical conditions.
C1 [Pannullo, Susan C.; Chidambaram, Swathi; Apuzzo, Michael L. J.] Weill Cornell Med, Dept Neurol Surg, New York, NY 10065 USA.
   [Julie, Diana A. R.; Balogun, Onyinye D.; Formenti, Silvia Chiara; Knisely, Jonathan P. S.] Weill Cornell Med, Dept Radiat Oncol, New York, NY USA.
RP Pannullo, SC (reprint author), Weill Cornell Med, Dept Neurol Surg, New York, NY 10065 USA.
EM scp2002@med.cornell.edu
CR Abdel-Wahab M, 2013, LANCET ONCOL, V14, pE168, DOI 10.1016/S1470-2045(12)70532-6
   Abdel-Wahab M, 2011, J AM COLL RADIOL, V8, P789, DOI 10.1016/j.jacr.2011.07.014
   Abou-Al-Shaar H, 2018, WORLD NEUROSURG, V119, pE357, DOI 10.1016/j.wneu.2018.07.161
   ALEXANDER E, 1995, JNCI-J NATL CANCER I, V87, P34, DOI 10.1093/jnci/87.1.34
   Andrews DW, 2006, SURG NEUROL, V66, P559, DOI 10.1016/j.surneu.2006.08.002
   Brainlab, FIND EXP
   Breneman JC, 2009, INT J RADIAT ONCOL, V74, P702, DOI 10.1016/j.ijrobp.2008.11.015
   Canadian Agency for Drugs and Technologies in Health (CADTH), 2010, CADTH TECHNOL OVERV, V1, pe0119
   Caruso JP, 2015, J CLIN NEUROSCI, V22, P184, DOI 10.1016/j.jocn.2014.08.012
   Cho DY, 2006, NEUROSURGERY, V58, P866, DOI 10.1227/01.NEU.0000209892.42585.9B
   Datta NR, 2004, LANCET ONCOL, V5, P695, DOI 10.1016/S1470-2045(04)01613-4
   Eich HT, 2004, INT J RADIAT ONCOL, V58, P805, DOI 10.1016/S0360-3016(03)01565-7
   El Khamlichi A, 2001, NEUROSURGERY, V48, P1344, DOI 10.1097/00006123-200106000-00034
   EPSTEIN ME, 1993, STEREOT FUNCT NEUROS, V61, P6, DOI 10.1159/000100652
   Fezeu F, 2014, CUREUS, V6, pe157
   Griffiths A, 2007, INT J TECHNOL ASSESS, V23, P488, DOI 10.1017/S0266462307070584
   Kamath R, 2005, INT J RADIAT ONCOL, V61, P1467, DOI 10.1016/j.ijrobp.2004.08.021
   Kuo JS, 2008, NEUROSURGERY, V62, P785, DOI [10.1227/01.NIEU.0000089485.47590.05, 10.1227/01.neu.0000316282.07124.31]
   Levin CV, 1999, RADIOTHER ONCOL, V52, P79, DOI 10.1016/S0167-8140(99)00069-9
   Lievens Y, 2015, ACTA ONCOL, V54, P1275, DOI 10.3109/0284186X.2015.1066932
   Minniti G, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-158
   Muller-Riemenschneider Falk, 2009, GMS Health Technol Assess, V5, pDoc03, DOI 10.3205/hta000065
   Nath SK, 2010, INT J RADIAT ONCOL, V78, P91, DOI 10.1016/j.ijrobp.2009.07.1726
   Olsen DR, 2000, RADIOTHER ONCOL, V54, P255, DOI 10.1016/S0167-8140(99)00185-1
   Ott K., 2006, STEREOT FUNCT NEUROS, V66, P357
   Pistenmaa DA, 2018, RADIOTHER ONCOL, V128, P393, DOI 10.1016/j.radonc.2018.05.025
   POLLOCK BE, 1995, NEUROSURGERY, V36, P215, DOI 10.1227/00006123-199501000-00036
   Reith A, 2008, STUD HEALTH TECHNOL, V134, P209
   van der Giessen PH, 2004, RADIOTHER ONCOL, V71, P347, DOI 10.1016/j.radonc.2004.02.021
   vanRoijen L, 1997, ACTA NEUROCHIR, V139, P942, DOI 10.1007/BF01411303
NR 30
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 608
EP 614
DI 10.1016/j.wneu.2019.04.031
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200261
PM 31581410
DA 2020-05-12
ER

PT J
AU Ramakrishna, R
   Formenti, S
AF Ramakrishna, Rohan
   Formenti, Silvia
TI Radiosurgery and Immunotherapy in the Treatment of Brain Metastases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain metastasis; Gamma Knife; Immunotherapy; Radiation necrosis;
   Stereotactic radiosurgery
ID CELL LUNG-CANCER; CD8(+) T-CELLS; MHC CLASS-I; STEREOTACTIC
   RADIOSURGERY; RADIATION-THERAPY; CLINICAL-OUTCOMES; TGF-BETA; COLORECTAL
   TUMORS; MELANOMA; IPILIMUMAB
AB Radiation therapy represents a mainstay of treatment for patients with brain metastases. Recently, the widespread adoption of immune checkpoint blockade has led to keen interest in treating cancers with checkpoint inhibitors in place of, or as an adjunct to, traditional chemotherapy. However, with the exception of melanoma, immune checkpoint blockade in solid tumors has failed to achieve significant brain control in patients with brain metastases. The possibility of combining immune checkpoint blockade with radiation for the treatment of brain and other metastases represents an exciting new strategy that is in its early stages of investigation. Success with this combinatorial strategy has the potential to result in enhanced rates of brain control, less brain exposure to radiation, and improved cognitive outcomes. In this review, we discuss the mechanisms behind this synergy, describe its limitations, and suggest ways to move the field forward.
C1 [Ramakrishna, Rohan] Weill Cornell Med, New York Presbyterian Hosp New York, Dept Neurol Surg, New York, NY 10065 USA.
   [Formenti, Silvia] Weill Cornell Med, New York Presbyterian Hosp New York, Dept Radiat Oncol, New York, NY USA.
RP Ramakrishna, R (reprint author), Weill Cornell Med, New York Presbyterian Hosp New York, Dept Neurol Surg, New York, NY 10065 USA.
EM Ror9068@med.cornell.edu
CR Acharya S, 2017, ADV RAD ONCOL, V2, P572, DOI DOI 10.1016/j.adro.2017.07.003
   Ahmed KA, 2016, ANN ONCOL, V27, P2288, DOI 10.1093/annonc/mdw417
   Ahmed KA, 2016, ANN ONCOL, V27, P434, DOI 10.1093/annonc/mdv622
   An Y, 2017, RADIOTHER ONCOL, V125, P80, DOI 10.1016/j.radonc.2017.08.009
   Anderson ES, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0282-x
   Anitei MG, 2014, CLIN CANCER RES, V20, P1891, DOI 10.1158/1078-0432.CCR-13-2830
   Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937
   Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622
   Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643
   Bowden G, 2019, WORLD NEUROSURG, V126, pE989, DOI 10.1016/j.wneu.2019.03.019
   Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627
   Brahmer Julie R, 2012, Clin Adv Hematol Oncol, V10, P674
   Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694
   Brown PD, 2016, JAMA-J AM MED ASSOC, V316, P401, DOI 10.1001/jama.2016.9839
   Brown PD, 2013, NEURO-ONCOLOGY, V15, P1429, DOI 10.1093/neuonc/not114
   Cabrera CM, 2003, TISSUE ANTIGENS, V61, P211, DOI 10.1034/j.1399-0039.2003.00020.x
   Chakraborty M, 2004, CANCER RES, V64, P4328, DOI 10.1158/0008-5472.CAN-04-0073
   Chandra RA, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1046028
   Chang EL, 2009, LANCET ONCOL, V10, P1037, DOI 10.1016/S1470-2045(09)70263-3
   Characiejus D, 2011, ANTICANCER RES, V31, P699
   Characiejus D, 2011, ANTICANCER RES, V31, P639
   Cohen JV, 2016, PIGM CELL MELANOMA R, V29, P627, DOI 10.1111/pcmr.12538
   Cohen-Inbar O, 2017, J NEUROSURG, V127, P1007, DOI 10.3171/2016.9.JNS161585
   Demaria S, 2005, CLIN CANCER RES, V11, P728
   Demaria S, 2004, INT J RADIAT ONCOL, V58, P862, DOI 10.1016/j.ijrobp.2003.09.012
   Demaria S, 2016, TRENDS CANCER, V2, P286, DOI 10.1016/j.trecan.2016.05.002
   Dewan MZ, 2009, CLIN CANCER RES, V15, P5379, DOI 10.1158/1078-0432.CCR-09-0265
   Diamond MS, 2011, J EXP MED, V208, P1989, DOI 10.1084/jem.20101158
   Diao K, 2018, J NEUROSURG, V129, P1397, DOI 10.3171/2017.7.JNS171286
   Duan F, 2014, J EXP MED, V211, P2231, DOI 10.1084/jem.20141308
   Dudley ME, 1996, J EXP MED, V184, P441, DOI 10.1084/jem.184.2.441
   DuPage M, 2012, NATURE, V482, P405, DOI 10.1038/nature10803
   Dushyanthen S, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0431-3
   Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245
   Fuertes MB, 2011, J EXP MED, V208, P2005, DOI 10.1084/jem.20101159
   Gajewski TF, 2013, CURR OPIN IMMUNOL, V25, P268, DOI 10.1016/j.coi.2013.02.009
   Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
   Garnett CT, 2004, CANCER RES, V64, P7985, DOI 10.1158/0008-5472.CAN-04-1525
   Gaudy-Marqueste C, 2017, EUR J CANCER, V84, P44, DOI 10.1016/j.ejca.2017.07.017
   Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028
   Goldberg SB, 2016, LANCET ONCOL, V17, P976, DOI 10.1016/S1470-2045(16)30053-5
   Golden EB, 2015, LANCET ONCOL, V16, P795, DOI 10.1016/S1470-2045(15)00054-6
   Golden EB, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28518
   Golden EB, 2013, CANCER IMMUNOL RES, V1, P365, DOI 10.1158/2326-6066.CIR-13-0115
   Grandhi R, 2012, J NEUROSURG, V117, P237, DOI 10.3171/2012.4.JNS11870
   Grimaldi AM, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28780
   Hamanishi J, 2016, INT J CLIN ONCOL, V21, P462, DOI 10.1007/s10147-016-0959-z
   Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133
   Hernandez C, 2016, ONCOGENE, V35, P5931, DOI 10.1038/onc.2016.104
   Hiniker SM, 2012, NEW ENGL J MED, V366, P2035, DOI 10.1056/NEJMc1203984
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
   Horvat TZ, 2015, J CLIN ONCOL, V33, P3193, DOI 10.1200/JCO.2015.60.8448
   Hughes RT, 2019, NEUROSURGERY, V85, P257, DOI 10.1093/neuros/nyy276
   Iorgulescu JB, 2018, CANCER IMMUNOL RES, V6, P1039, DOI 10.1158/2326-6066.CIR-18-0067
   Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467
   Johnson AG, 2015, ONCOTARGET, V6, P18945, DOI 10.18632/oncotarget.4153
   Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204
   Kang J, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0156-7
   Kiess AP, 2015, INT J RADIAT ONCOL, V92, P368, DOI 10.1016/j.ijrobp.2015.01.004
   Knisely JPS, 2012, J NEUROSURG, V117, P227, DOI 10.3171/2012.5.JNS111929
   Koller KM, 2017, CANCER BIOL THER, V18, P36, DOI 10.1080/15384047.2016.1264543
   Kotecha R, 2018, J NEUROSURG, V129, P50, DOI 10.3171/2017.1.JNS162797
   Liu SZ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3148
   Long GV, 2018, LANCET ONCOL, V19, P672, DOI 10.1016/S1470-2045(18)30139-6
   Mahajan A, 2017, LANCET ONCOL, V18, P1040, DOI 10.1016/S1470-2045(17)30414-X
   Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501
   Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755
   Mills CD, 2012, CRIT REV IMMUNOL, V32, P463, DOI 10.1615/CritRevImmunol.v32.i6.10
   Mirzaei HR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01850
   Mulvenna P, 2016, LANCET, V388, P2004, DOI 10.1016/S0140-6736(16)30825-X
   Naito Y, 1998, CANCER RES, V58, P3491
   Ngwa W, 2018, NAT REV CANCER, V18, P313, DOI 10.1038/nrc.2018.6
   Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523
   Park SS, 2015, CANCER IMMUNOL RES, V3, P610, DOI 10.1158/2326-6066.CIR-14-0138
   Patel KR, 2017, AM J CLIN ONCOL-CANC, V40, P444, DOI 10.1097/COC.0000000000000199
   Patel KR, 2015, NEURO-ONCOLOGY, V17, P1312, DOI 10.1093/neuonc/nov093
   Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428
   Postow MA, 2012, NEW ENGL J MED, V366, P925, DOI 10.1056/NEJMoa1112824
   Reits EA, 2006, J EXP MED, V203, P1259, DOI 10.1084/jem.20052494
   Ribas A, 2012, NEW ENGL J MED, V366, P2517, DOI 10.1056/NEJMe1205943
   Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082
   Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033
   Rosenberg SA, 2005, J IMMUNOL, V175, P6169, DOI 10.4049/jimmunol.175.9.6169
   Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643
   Schoenfeld JD, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0095-8
   Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486
   Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971
   Sharabi AB, 2015, CANCER IMMUNOL RES, V3, P345, DOI 10.1158/2326-6066.CIR-14-0196
   Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004
   Silk AW, 2013, CANCER MED-US, V2, P899, DOI 10.1002/cam4.140
   Skrepnik T, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1283461
   Stamell EF, 2013, INT J RADIAT ONCOL, V85, P293, DOI 10.1016/j.ijrobp.2012.03.017
   Sui XB, 2015, ONCOTARGET, V6, P19393, DOI 10.18632/oncotarget.5107
   Tang C, 2014, CANCER IMMUNOL RES, V2, P831, DOI 10.1158/2326-6066.CIR-14-0069
   Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492
   Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   Vanpouille-Box C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15618
   Vanpouille-Box C, 2015, CANCER RES, V75, P2232, DOI 10.1158/0008-5472.CAN-14-3511
   Wefel Jeffrey S, 2018, Handb Clin Neurol, V149, P155, DOI 10.1016/B978-0-12-811161-1.00012-8
   Weichselbaum RR, 2017, NAT REV CLIN ONCOL, V14, P365, DOI 10.1038/nrclinonc.2016.211
   Yamamoto M, 2014, J NEUROSURG, V121, P16, DOI 10.3171/2014.8.GKS141421
   Yamamoto M, 2013, J NEUROSURG, V118, P1258, DOI 10.3171/2013.3.JNS121900
   Yang H, 2017, P NATL ACAD SCI USA, V114, pE4612, DOI 10.1073/pnas.1705499114
   Zeng J, 2013, INT J RADIAT ONCOL, V86, P343, DOI 10.1016/j.ijrobp.2012.12.025
NR 105
TC 0
Z9 0
U1 3
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP 615
EP 622
DI 10.1016/j.wneu.2019.04.032
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200262
PM 31581411
DA 2020-05-12
ER

PT J
AU Ahn, JS
   Lee, HJ
   Park, EJ
   Kim, SB
   Choi, DJ
   Kwon, YS
   Chung, HJ
AF Ahn, Jae-Sung
   Lee, Ho-Jin
   Park, Eugene J.
   Kim, Sang Bum
   Choi, Dae-Jung
   Kwon, Youk-Sang
   Chung, Hyung-Jin
TI Multifidus Muscle Changes After Biportal Endoscopic Spinal Surgery:
   Magnetic Resonance Imaging Evaluation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biportal endoscopic spinal surgery; Lumbar vertebrae; Magnetic resonance
   imaging; Minimally invasive spine surgery; Multifidus muscles
ID LUMBAR INTERBODY FUSION; MICROENDOSCOPIC DISKECTOMY; SURGICAL TECHNIQUE;
   DISC HERNIATIONS; LEARNING-CURVE; MINI-OPEN; DECOMPRESSION;
   COMPLICATIONS; INJURY; SPECTROSCOPY
AB OBJECTIVE: We used magnetic resonance imaging (MRI) to assess the radiological status of the multifidus muscles (MFMs) after biportal endoscopic spinal surgery (BESS) and evaluated the extent of MFM injury and atrophy.
   METHODS: A total of 88 patients who had met the inclusion and exclusion criteria were enrolled in the present study. T2-weighted signal intensity MRI was performed 3 times: preoperatively, immediately postoperatively, and at the final follow-up examination. We measured the cross-sectional area of the MFM on both sides (ipsilaterally and contralaterally) and recorded the operative times. The association between the interval from surgery to the final follow-up MRI and changes in the MFMs and between the operative time and changes in the MFMs were analyzed. For the group comparisons, the patients were divided into 3 groups according to the follow-up interval. Group 1 was followed up within 2 weeks, group 2 within 2-4 weeks, and group 3 after 4 weeks. The MFM changes were recorded.
   RESULTS: The operative time correlated significantly with the percentage of change in the T2-weighted signal intensity ratio (SIR) for both sides (P < 0.01). At the final follow-up examination, the SIR of the ipsilateral side had decreased in group 3 (P = 0.002). The percentage of change in the SIR was smallest in group 3 (P = 0.004).
   CONCLUSIONS: The MFM change on MRI after BESS became significant on both sides as the operative time increased. However, the change showed a tendency to reverse within several months, and no substantial change in the MFM cross-sectional area was found. We have concluded that MFM changes after BESS might correlate with an increased operative time but will resolve over time.
C1 [Ahn, Jae-Sung; Lee, Ho-Jin; Park, Eugene J.; Kim, Sang Bum; Chung, Hyung-Jin] Chungnam Natl Univ, Dept Orthopaed Surg, Sch Med, Daejeon, South Korea.
   [Choi, Dae-Jung] Himnaera Hosp, Dept Orthopaed Surg, Busan, South Korea.
   [Kwon, Youk-Sang] Daejeon Centum Hosp, Dept Orthoped Surg, Daejeon, South Korea.
RP Lee, HJ (reprint author), Chungnam Natl Univ, Dept Orthopaed Surg, Sch Med, Daejeon, South Korea.
EM leeleo98@gmail.com
CR Ahn JS, 2018, J NEUROSURG-SPINE, V28, P492, DOI 10.3171/2017.8.SPINE17771
   Birkenmaier C, 2013, PAIN PHYSICIAN, V16, P335
   Choi DJ, 2016, ASIAN SPINE J, V10, P624, DOI 10.4184/asj.2016.10.4.624
   Choi I, 2013, EUR SPINE J, V22, P2481, DOI 10.1007/s00586-013-2849-7
   Choi KC, 2018, WORLD NEUROSURG, V116, pE750, DOI 10.1016/j.wneu.2018.05.085
   DeAntoni DJ, 1996, ARTHROSCOPY, V12, P330, DOI 10.1016/S0749-8063(96)90069-9
   Dhall SS, 2008, J NEUROSURG-SPINE, V9, P560, DOI 10.3171/SPI.2008.9.08142
   Eum JH, 2016, J NEUROSURG-SPINE, V24, P602, DOI 10.3171/2015.7.SPINE15304
   Fan SW, 2010, EUR SPINE J, V19, P316, DOI 10.1007/s00586-009-1191-6
   Gejo R, 1999, SPINE, V24, P1023, DOI 10.1097/00007632-199905150-00017
   Gejo R, 2000, SPINE, V25, P941, DOI 10.1097/00007632-200004150-00008
   Gille O, 2007, SPINE, V32, P1236, DOI 10.1097/BRS.0b013e31805471fe
   Gold Garry E, 2003, Semin Musculoskelet Radiol, V7, P245
   Greenough CG, 1998, SPINE, V23, P479, DOI 10.1097/00007632-199802150-00015
   Harrington JF, 2008, MINIM INVAS NEUROSUR, V51, P30, DOI 10.1055/s-2007-1004543
   Heo DH, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.5.FOCUS17146
   Kafadar A, 2006, MINIM INVAS NEUROSUR, V49, P74, DOI 10.1055/s-2006-932184
   Kambin P, 2004, SPINE, V29, P598, DOI 10.1097/01.BRS.0000112066.78935.74
   Kikuchi Y, 2003, RADIOLOGY, V229, P861, DOI 10.1148/radiol.2293020904
   Kim DY, 2005, SPINE, V30, P123, DOI 10.1097/01.brs.0000148999.21492.53
   Mobbs RJ, 2014, J NEUROSURG-SPINE, V21, P179, DOI 10.3171/2014.4.SPINE13420
   Nakagawa H, 2003, J CLIN NEUROSCI, V10, P231, DOI 10.1016/S0967-5868(02)00337-5
   Nowitzke AM, 2005, NEUROSURGERY, V56, P755, DOI 10.1227/01.NEU.0000156470.79032.7B
   Panjabi M., 1990, CLIN BIOMECHANICS SP
   Papavero L, 2009, NEUROSURGERY, V65, P182, DOI 10.1227/01.NEU.0000341906.65696.08
   Park JH, 2017, ORTHOPEDICS, V40, pE779, DOI 10.3928/01477447-20170531-02
   PARK JH, 1990, RADIOLOGY, V177, P473, DOI 10.1148/radiology.177.2.2217788
   PARK JH, 1994, ARTHRITIS RHEUM, V37, P736, DOI 10.1002/art.1780370519
   Park Y, 2007, SPINE, V32, P537, DOI 10.1097/01.brs.0000256473.49791.f4
   Patten Carolynn, 2003, Semin Musculoskelet Radiol, V7, P297
   Peng Chan Wearn Benedict, 2009, Spine (Phila Pa 1976), V34, P1385, DOI 10.1097/BRS.0b013e3181a4e3be
   POLETTI CE, 1995, NEUROSURGERY, V37, P343, DOI 10.1227/00006123-199508000-00025
   Ruetten S, 2007, J NEUROSURG-SPINE, V6, P521, DOI 10.3171/spi.2007.6.6.521
   Sairyo K, 2010, MINIM INVAS NEUROSUR, V53, P175, DOI 10.1055/s-0030-1262814
   Soliman HM, 2016, SPINE J, V16, P1276, DOI 10.1016/j.spinee.2016.06.009
   Soliman HM, 2015, SPINE J, V15, P2282, DOI 10.1016/j.spinee.2015.07.009
   Soliman HM, 2013, EUR SPINE J, V22, P1037, DOI 10.1007/s00586-013-2701-0
   Tonomura H, 2017, CLIN SPINE SURG, V30, pE76, DOI 10.1097/BSD.0b013e31829eb9de
   Torudom Y, 2016, ASIAN SPINE J, V10, P335, DOI 10.4184/asj.2016.10.2.335
   Tsutsumimoto T, 2009, SPINE, V34, P1923, DOI 10.1097/BRS.0b013e3181a9d28e
   Wu XT, 2006, SPINE, V31, P2689, DOI 10.1097/01.brs.0000244615.43199.07
   Yeung AT, 2002, SPINE, V27, P722, DOI 10.1097/00007632-200204010-00009
   Zhi-Jun H, 2014, SPINE, V39, pE623, DOI 10.1097/BRS.0000000000000286
NR 43
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E525
EP E534
DI 10.1016/j.wneu.2019.06.148
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200065
PM 31254694
DA 2020-05-12
ER

PT J
AU Ahn, Y
   Keum, HJ
   Son, S
AF Ahn, Yong
   Keum, Han Joong
   Son, Seong
TI Percutaneous Endoscopic Lumbar Foraminotomy for Foraminal Stenosis with
   Postlaminectomy Syndrome in Geriatric Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic; Foraminotomy; Geriatric; Lumbar foraminal stenosis;
   Percutaneous; Post-laminectomy syndrome
ID SPINAL DEFORMITY SURGERY; ADJACENT SEGMENT DISEASE; AGED 80 YEARS;
   GENERAL-ANESTHESIA; ELDERLY-PATIENTS; JAPAN ASSOCIATION; INTERBODY
   FUSION; FOLLOW-UP; COMPLICATIONS; RISK
AB INTRODUCTION: Postlaminectomy syndrome (PLS) or failed back surgery syndrome is a condition characterized by persistent pain following a back surgery. Degenerative processes may result in foramina' stenosis development over time, even after a successful surgery. Percutaneous endoscopic lumbar foraminotomy (PELF) offers a minimally invasive means of treating foraminal stenosis after a back surgery. The objective of this study was to evaluate the outcomes of PELF for foraminal stenosis with PLS in geriatric patients.
   METHODS: Two-year follow-up data were collected from 21 consecutive patients aged 65 years or older (mean age, 72.4 years) who underwent PELF for foraminal stenosis with PLS. Transforaminal endoscopic foraminal decompression was performed under local anesthesia. Outcomes were assessed using visual analog scale pain score, Oswestry Disability Index, and modified Macnab criteria.
   RESULTS: Mean visual analog scale for leg pain improved from 8.48 at baseline to 3.33 at 6 weeks, 2.10 at 1 year, and 2.19 at 2 years after PELF (P < 0.01). Mean Oswestry Disability Index Unproved from 67.29 at baseline to 30.69 at 6 weeks, 22.50 at 1 year, and 20.81 at 2 years after PELF (P < 0.01). Based on the modified Macnab criteria, excellent or good results were obtained in 81.0% of patients and symptomatic improvements were obtained in 95.2% of patients.
   CONCLUSIONS: The transforaminal endoscopic approach can provide a better access angle to achieve a sophisticated foraminal decompression with less facet and dural injury. Therefore, PELF under local anesthesia can be useful for PLS or postoperative foraminal stenosis in elderly patients.
C1 [Ahn, Yong; Son, Seong] Gachon Univ, Gil Med Ctr, Dept Neurosurg, Coll Med, Incheon, South Korea.
   [Keum, Han Joong] Wooridul Spine Hosp, Dept Neurosurg, Seoul, South Korea.
RP Ahn, Y (reprint author), Gachon Univ, Gil Med Ctr, Dept Neurosurg, Coll Med, Incheon, South Korea.
EM ns-ay@hanmail.net
OI Son, Seong/0000-0002-2815-9908
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute - Ministry of Health & Welfare, Republic of Korea
   [HI16C2319]
FX This research was supported by a grant of the Korea Health Technology
   R&D Project through the Korea Health Industry Development Institute,
   funded by the Ministry of Health & Welfare, Republic of Korea (grant
   number: HI16C2319).
CR Acosta FL, 2011, J NEUROSURG-SPINE, V15, P667, DOI 10.3171/2011.7.SPINE10640
   Ahn Y, 2003, J NEUROSURG, V99, P320, DOI 10.3171/spi.2003.99.3.0320
   Ahn Y, 2014, NEUROSURGERY, V75, P124, DOI 10.1227/NEU.0000000000000361
   Brotchi L, 1999, NEUROL RES, V21, pS47, DOI 10.1080/01616412.1999.11741027
   Cammisa FP, 2000, SPINE, V25, P2663, DOI 10.1097/00007632-200010150-00019
   Chen W J, 2001, Spine (Phila Pa 1976), V26, pE519, DOI 10.1097/00007632-200111150-00024
   Choi JM, 2017, J KOREAN NEUROSURG S, V60, P684, DOI 10.3340/jkns.2017.0203
   Cloyd JM, 2008, J AM GERIATR SOC, V56, P1318, DOI 10.1111/j.1532-5415.2008.01771.x
   Daubs MD, 2007, SPINE, V32, P2238, DOI 10.1097/BRS.0b013e31814cf24a
   DEKUTOSKI MB, 1994, SPINE, V19, P1745, DOI 10.1097/00007632-199408000-00015
   Eichholz Kurt M, 2003, Neurosurg Focus, V15, pE1
   Finsterwald M, 2018, J CLIN ANESTH, V46, P3, DOI 10.1016/j.jclinane.2018.01.004
   Fritsch EW, 1996, SPINE, V21, P626, DOI 10.1097/00007632-199603010-00017
   Gu GF, 2018, WORLD NEUROSURG, V112, pE830, DOI 10.1016/j.wneu.2018.01.170
   Hussain M, 2014, CLIN INTERV AGING, V9, P1619, DOI 10.2147/CIA.S49680
   JONES AAM, 1989, SPINE, V14, P443, DOI 10.1097/00007632-198904000-00021
   Kim CT, 2018, J ALZHEIMERS DIS, V63, P395, DOI 10.3233/JAD-170951
   Kim DY, 2005, SPINE, V30, pE123, DOI 10.1097/01.brs.0000157172.00635.3a
   Knight MTN, 2014, INT J SPINE SURG, V8, DOI 10.14444/1021
   Kobayashi K, 2017, GLOB SPINE J, V7, P636, DOI 10.1177/2192568217716144
   Kobayashi K, 2017, GLOB SPINE J, V7, P560, DOI 10.1177/2192568217700115
   Long D M, 1991, Neurosurg Clin N Am, V2, P899
   MACNAB I, 1971, J BONE JOINT SURG AM, VA 53, P891, DOI 10.2106/00004623-197153050-00004
   Miwa T, 2013, EUR SPINE J, V22, P2864, DOI 10.1007/s00586-013-2863-9
   Ng LCL, 2007, EUR SPINE J, V16, P199, DOI 10.1007/s00586-006-0078-z
   Ostelo RWJG, 2008, SPINE, V33, P90, DOI 10.1097/BRS.0b013e31815e3a10
   Tsou Paul Moody, 2002, Spine J, V2, P41, DOI 10.1016/S1529-9430(01)00153-X
   Wang JC, 1998, J BONE JOINT SURG AM, V80A, P1728, DOI 10.2106/00004623-199812000-00002
   Yeung A, 2014, INT J SPINE SURG, V8, DOI 10.14444/1022
   Zorrilla-Vaca A, 2017, J NEUROSURG ANESTH, V29, P415, DOI 10.1097/ANA.0000000000000362
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E1070
EP E1076
DI 10.1016/j.wneu.2019.07.087
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200132
PM 31323406
DA 2020-05-12
ER

PT J
AU Akgun, MY
   Kemerdere, R
   Ulu, MO
   Alizada, O
   Isler, C
   Kizilkilic, O
   Islak, C
   Hanci, M
AF Akgun, Mehmet Yigit
   Kemerdere, Rahsan
   Ulu, Mustafa Onur
   Alizada, Orkhan
   Isler, Cihan
   Kizilkilic, Osman
   Islak, Civan
   Hanci, Murat
TI Spinal Vascular Malformations: Treatment and Outcome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous fistula; Outcome; Spinal; Treatment; Vascular
   malformations
ID DURAL ARTERIOVENOUS-FISTULAS; CLINICAL-FEATURES; SURGICAL-TREATMENT
AB BACKGROUND: Vascular malformations of the spinal cord are a rare and complex clinical entity and can lead to severe morbidity with progressive spinal cord symptoms if not treated properly. In early stages, the disease is characterized by slowly progressive, nonspecific symptoms, such as gait disturbance, paresthesia, diffuse sensory symptoms, and radicular pain; in the late stages, bowel and bladder incontinence, erectile dysfunction, and urinary retention may develop. In recent decades, understanding and treatment of spinal vascular malformations have improved with the evolution of diagnostic tools and treatment modalities; however, it is still difficult to manage these cases because of the complexity of the pathology. The aims of this study were to present the long-term outcomes of our patients and to discuss the optimal management strategies.
   METHODS: We reviewed the records of 78 patients with spinal vascular malformations and performed a retrospective, single-center case series evaluating initial occlusion, recanalization, retreatment, and neurologic status of patients with dural arteriovenous fistulas, perimedullary arteriovenous fistulas, arteriovenous malformations, and extradural arteriovenous fistulas who had undergone embolization and/or surgery.
   RESULTS: No mortality was observed. Complete obliteration was achieved in 76 patients (97.4%).
   CONCLUSIONS: Both endovascular and surgical treatment of spinal vascular malformations resulted in significant long-term recovery from myelopathic symptoms and improvement in quality of life for most patients.
C1 [Akgun, Mehmet Yigit; Kemerdere, Rahsan; Ulu, Mustafa Onur; Alizada, Orkhan; Isler, Cihan; Hanci, Murat] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Neurosurg, Istanbul, Turkey.
   [Kizilkilic, Osman; Islak, Civan] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Radiol, Istanbul, Turkey.
RP Akgun, MY (reprint author), Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Neurosurg, Istanbul, Turkey.
EM myigitakgun@gmail.com
RI Kemerdere, Rahsan/D-6667-2019; Alizada, Orkhan/E-1210-2019; HANCI,
   MURAT/A-7976-2016; ISLER, CIHAN/D-6443-2019; islak, civan/AAH-3857-2019;
   Akgun, Mehmet Yigit/AAA-2136-2020
OI Kemerdere, Rahsan/0000-0002-9947-3486; Alizada,
   Orkhan/0000-0003-0942-9906; HANCI, MURAT/0000-0001-9261-6686; ISLER,
   CIHAN/0000-0001-8365-3338; Akgun, Mehmet Yigit/0000-0003-1342-7663
CR AMINOFF MJ, 1974, BRAIN, V97, P197, DOI 10.1093/brain/97.1.197
   AMINOFF MJ, 1974, BRAIN, V97, P211, DOI 10.1093/brain/97.1.211
   Bao YH, 1997, NEUROSURGERY, V40, P75, DOI 10.1097/00006123-199701000-00017
   Bretonnier M, 2019, WORLD NEUROSURG, V127, pE943, DOI 10.1016/j.wneu.2019.04.005
   Cenzato M, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.2.FOCUS1218
   Cho KT, 2005, NEUROSURGERY, V56, P232, DOI 10.1227/01.neu.0000147974.79671.83
   da Costa L, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/FOC.2009.26.1.E6
   Durnford AJ, 2017, WORLD NEUROSURG, V107, P488, DOI 10.1016/j.wneu.2017.07.140
   Endo T, 2018, WORLD NEUROSURG, V110, pE383, DOI 10.1016/j.wneu.2017.11.002
   Fiaschi P, 2019, WORLD NEUROSURG, V122, pE270, DOI 10.1016/j.wneu.2018.10.019
   Flores BC, 2017, NEUROSURG REV, V40, P15, DOI 10.1007/s10143-016-0713-z
   Gemmete JJ, 2013, AM J NEURORADIOL, V34, P1974, DOI 10.3174/ajnr.A3522
   Gokhale Sankalp, 2014, Surg Neurol Int, V5, P7, DOI 10.4103/2152-7806.125628
   Gross BA, 2017, J NEUROINTERV SURG, V9, P102, DOI 10.1136/neurintsurg-2016-012333
   Hida K, 1999, J NEUROSURG, V90, P198, DOI 10.3171/spi.1999.90.2.0198
   Jellema K, 2003, J NEUROL NEUROSUR PS, V74, P1438, DOI 10.1136/jnnp.74.10.1438
   JELLINGER K, 1986, NEUROSURG REV, V9, P177, DOI 10.1007/BF01743136
   Kang MS, 2019, WORLD NEUROSURG, V122, pE1519, DOI 10.1016/j.wneu.2018.11.093
   KENDALL BE, 1977, NEURORADIOLOGY, V13, P181, DOI 10.1007/BF00344211
   Liu A-H, 2003, OPER TECH NEUROSURG, V6, P163
   Marcus J, 2013, CURR ATHEROSCLER REP, V15, DOI 10.1007/s11883-013-0335-7
   Narvid J, 2008, NEUROSURGERY, V62, P159, DOI 10.1227/01.NEU.0000311073.71733.C4
   Park JE, 2018, CLIN NEURORADIOL, V28, P39, DOI 10.1007/s00062-016-0541-0
   Rangel-Castilla L, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14236
   Sanborn Matthew R, 2014, Neurosurgery, V61 Suppl 1, P6, DOI 10.1227/NEU.0000000000000386
   Schuss P, 2015, WORLD NEUROSURG, V83, P1002, DOI 10.1016/j.wneu.2015.02.026
   Takai K, 2018, WORLD NEUROSURG, V111, pE819, DOI 10.1016/j.wneu.2017.12.162
   Takai K, 2017, NEUROL MED-CHIR, V57, P356, DOI 10.2176/nmc.ra.2016-0316
NR 28
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E953
EP E960
DI 10.1016/j.wneu.2019.07.043
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200119
PM 31302279
DA 2020-05-12
ER

PT J
AU Akins, PT
   Guppy, KH
AF Akins, Paul T.
   Guppy, Kern H.
TI Are Hygromas and Hydrocephalus After Decompressive Craniectomy Caused by
   Impaired Brain Pulsatility, Cerebrospinal Fluid Hydrodynamics, and
   Glymphatic Drainage? Literature Overview and Illustrative Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebrospinal fluid; Craniectomy; Cranioplasty; Decompressive
   craniectomy article; Glymphatic; Hydrocephalus; Hygroma; Review
ID CONTRALATERAL SUBDURAL EFFUSION; INTERHEMISPHERIC HYGROMA; MOVEMENT;
   FEATURES
AB BACKGROUND: Poorly understood cranial fluid accumulations are frequently observed after decompressive craniectomy and often termed "external hydrocephalus." These findings are difficult to explain using traditional models of hydrocephalus.
   METHODS: Representative cases, clinical management, and literature overview are presented.
   RESULTS: We present a hypothesis that abnormal cranial fluid accumulations develop after decompressive craniectomy in a vulnerable subset of patients as a result of 1) the large compliant cranial defect with durotomy causing reduced internal brain expansion, ventricular squeezing, and pulsatile cerebrospinal fluid (CSF) circulation; 2) impaired pulsatile CSF flow along major cerebral arteries and the adjoining perivascular spaces (Virchow-Robin spaces); 3) reduced clearance of interstitial fluid by the glymphatic system; and 4) redistribution of CSF from the subarachnoid space into the subdural and subgaleal compartments and the ventricles.
   CONCLUSION: Closure of the cranial defect with cranioplasty improves cerebral blood flow and CSF pulsatile circulation and is frequently sufficient to resolve the external hydrocephalus.
C1 [Akins, Paul T.; Guppy, Kern H.] Kaiser Sacramento Med Ctr, Permanente Med Grp, Dept Neurosurg, Sacramento, CA 95825 USA.
RP Akins, PT (reprint author), Kaiser Sacramento Med Ctr, Permanente Med Grp, Dept Neurosurg, Sacramento, CA 95825 USA.
EM paul.t.akins@kp.org
CR Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469
   Abbott NJ, 2018, ACTA NEUROPATHOL, V135, P387, DOI 10.1007/s00401-018-1812-4
   Akins PT, 2008, NEUROCRIT CARE, V9, P269, DOI 10.1007/s12028-007-9033-z
   Cai RY, 2019, NAT NEUROSCI, V22, P317, DOI 10.1038/s41593-018-0301-3
   DANDY WE, 1946, ARCH SURG-CHICAGO, V52, P421, DOI 10.1001/archsurg.1946.01230050428003
   Dandy WE, 1919, ANN SURG, V70, P129, DOI 10.1097/00000658-191908000-00001
   Dandy WE, 1938, ANN SURG, V108, P194, DOI 10.1097/00000658-193808000-00004
   Dandy WE, 1925, ANN SURG, V82, P199, DOI 10.1097/00000658-192508000-00002
   De Bonis P, 2013, CLIN NEUROL NEUROSUR, V115, P1308, DOI 10.1016/j.clineuro.2012.12.011
   Fattahian Reza, 2018, Med Arch, V72, P214, DOI 10.5455/medarh.2018.72.214-219
   FRENCH BN, 1978, SURG NEUROL, V9, P145
   GREITZ D, 1992, NEURORADIOLOGY, V34, P370, DOI 10.1007/BF00596493
   Halani SH, 2017, NEUROSURGERY, V81, P204, DOI 10.1093/neuros/nyx054
   Hamilton RB, 2019, FLUIDS BARRIERS CNS, V16, DOI 10.1186/s12987-019-0122-0
   Herisson F, 2018, NAT NEUROSCI, V21, P1209, DOI 10.1038/s41593-018-0213-2
   Iliff JJ, 2013, J NEUROSCI, V33, P18190, DOI 10.1523/JNEUROSCI.1592-13.2013
   Johnston M., 2004, CEREBROSPINAL FLUID, V1, P2, DOI DOI 10.1186/1743-8454-1-2
   Kaen A, 2010, J NEUROSURG, V113, P1287, DOI 10.3171/2010.4.JNS10132
   Kilincer C, 2005, CLIN NEUROL NEUROSUR, V107, P412, DOI 10.1016/j.clineuro.2004.09.018
   Kiviniemi V, 2016, J CEREBR BLOOD F MET, V36, P1033, DOI 10.1177/0271678X15622047
   Kurland DB, 2015, NEUROCRIT CARE, V23, P292, DOI 10.1007/s12028-015-0144-7
   Kutty RK, 2018, J NEUROSCI RURAL PRA, V9, P232, DOI 10.4103/jnrp.jnrp_395_17
   Leinonen V, 2018, HAND CLINIC, V145, P39, DOI 10.1016/B978-0-12-802395-2.00005-5
   Linninger AA, 2009, ANN BIOMED ENG, V37, P1434, DOI 10.1007/s10439-009-9691-4
   Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432
   Mori K, 2000, SURG NEUROL, V53, P303, DOI 10.1016/S0090-3019(00)00199-3
   NAFFZIGER HC, 1924, JAMA-J AM MED ASSOC, V82, P1751
   Nakada T, 2019, NEUROSCIENTIST, V25, P155, DOI 10.1177/1073858418775027
   Nakada T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081798
   Nalbach SV, 2012, J CLIN NEUROSCI, V19, P1222, DOI 10.1016/j.jocn.2012.01.016
   Nasi D, 2018, ACTA NEUROCHIR, V160, P1691, DOI 10.1007/s00701-018-3639-0
   Oreskovic D, 2017, PEDIATR NEUROSURG, V52, P417, DOI 10.1159/000452169
   Perlmutter I, 1953, AMA ARCH SURG, V4, P398
   Rasmussen MK, 2018, LANCET NEUROL, V17, P1016, DOI 10.1016/S1474-4422(18)30318-1
   Rekate HL, 2011, CHILD NERV SYST, V27, P1535, DOI 10.1007/s00381-011-1558-y
   Ringstad G, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121537
   Robin C., 1859, J PHYSL HOMME ANIMAU, V2, P537
   Salunke P, 2015, J NEUROSURG, V122, P602, DOI 10.3171/2014.10.JNS14780
   SCHURR PH, 1953, J NEUROSURG, V10, P515, DOI 10.3171/jns.1953.10.5.0515
   Scollato A, 2015, BRIT J NEUROSURG, V29, P440, DOI 10.3109/02688697.2014.997671
   Sokolowski W, 2018, BIOLOGIA, V73, P563, DOI 10.2478/s11756-018-0074-x
   Su TM, 2011, J TRAUMA, V71, P833, DOI 10.1097/TA.0b013e31821b092a
   Tait MJ, 2010, NEUROSCIENCE, V167, P60, DOI 10.1016/j.neuroscience.2010.01.053
   Vedantam A, 2018, J NEUROSURG, V128, P1547, DOI 10.3171/2017.1.JNS162721
   Virchow R., 1851, ARCH PATH ANAT, V3, P427
   WINESTOCK DP, 1975, RADIOLOGY, V115, P373, DOI 10.1148/115.2.373
   WYCIS HT, 1945, J NEUROSURG, V2, P340, DOI 10.3171/jns.1945.2.4.0340
   Yang Xue-Jun, 2003, Chin J Traumatol, V6, P99
NR 48
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E941
EP E952
DI 10.1016/j.wneu.2019.07.041
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200118
PM 31302278
DA 2020-05-12
ER

PT J
AU AlBayar, A
   Sullivan, PZ
   Blue, R
   Leonard, J
   Kung, DK
   Ozturk, AK
   Chen, HI
   Schuster, JM
AF AlBayar, Ahmed
   Sullivan, Patricia Zadnik
   Blue, Rachel
   Leonard, Jennifer
   Kung, David K.
   Ozturk, Ali K.
   Chen, H. Isaac
   Schuster, James M.
TI Risk of Vertebral Artery Injury and Stroke Following Blunt and
   Penetrating Cervical Spine Trauma: A Retrospective Review of 729
   Patients
SO WORLD NEUROSURGERY
LA English
DT Review
DE Gunshot wound; Spinal cord Injury; Stroke; Surgery; Traumatic spinal
   cord injury; Vertebral artery
ID ANTIPLATELET TREATMENT; SCREENING CRITERIA; ANTICOAGULATION; DISSECTION;
   CENTER.
AB BACKGROUND: Cervical spine trauma (CST) may result in vertebral artery injury (VAI), increasing the risk of developing stroke. Stroke risk following CST is poorly reported.
   METHODS: In total, 729 patients with CST were retrospectively analyzed, including rates of VAI, age at injury, cause of injury, cardiovascular history, smoking history, substance abuse history, embolization therapy, and antiplatelet or anticoagulant therapy prior or after injury. VAIs were identified and graded following the Modified Denver Criteria for Blunt Cerebrovascular Injury using magnetic resonance angiography and computed tomography angiography. Brain scans were reviewed for stroke rates and statistically significant variations.
   RESULTS: Thirty-three patients suffered penetrating trauma, whereas 696 patients experienced blunt trauma. In total, 81 patients met the criteria for analysis with confirmed VAI. VAI was more common in penetrating injury group compared with blunt injury group (64% vs. 9%, P < 0.0005). However, low-grade VAI (less than grade III) was more common in blunt injury group versus penetrating group (37% vs. 14%, P < 0.05). The frequency of posterior circulation strokes did not vary significantly between groups (26.3% vs. 13.8%, P = 0.21). Cardiovascular comorbidities were significantly more common in the blunt group (50%, P = 0.0001) compared with the penetrating group (0%).
   CONCLUSIONS: VAI occurs with a high incidence in penetrating CST. Although stroke risk following penetrating and blunt CST did not vary significantly, they resulted in serious complications in a group of patients. Further study of this patient population is required to provide high-level, evidence-based preventions for VAI complications.
C1 [AlBayar, Ahmed; Kung, David K.] Hosp Univ Penn, Dept Neurosurg, 3400 Spruce St, Philadelphia, PA 19104 USA.
   [Sullivan, Patricia Zadnik; Blue, Rachel; Chen, H. Isaac; Schuster, James M.] Penn Presbyterian Med Ctr, Dept Neurosurg, Philadelphia, PA USA.
   [Leonard, Jennifer] Penn Presbyterian Med Ctr, Div Traumatol Surg Crit Care & Emergency Surg, Philadelphia, PA USA.
   [Ozturk, Ali K.] Univ Pennsivania Hlth Syst, Dept Neurosurg, Penn Hosp, Philadelphia, PA USA.
   [Chen, H. Isaac] Corporal Michael J Crescenz Vet Affairs Med Ctr, Dept Neurosurg, Philadelphia, PA USA.
RP AlBayar, A (reprint author), Hosp Univ Penn, Dept Neurosurg, 3400 Spruce St, Philadelphia, PA 19104 USA.
EM Ahmed.albayar@pennmedicine.upenn.edu
OI Blue, Rachel/0000-0001-6419-7373
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [NIHT32 NS043126-16];
   Neurosurgery Resident Research Fund at the University of Pennsylvania
FX This work was supported by the National Institutes of Health (NIHT32
   NS0431-6-16). The Neurosurgery Resident Research Fund at the University
   of Pennsylvania provided additional funding for this study.
CR Amenta Peter S, 2012, Surg Neurol Int, V3, P160, DOI 10.4103/2152-7806.105099
   Burlew CC, 2012, J TRAUMA ACUTE CARE, V72, P330, DOI 10.1097/TA.0b013e31823de8a0
   Daou B, 2017, NEUROSURGERY, V80, P368, DOI 10.1093/neuros/nyw086
   deSouza RM, 2011, EUR SPINE J, V20, P1405, DOI 10.1007/s00586-011-1862-y
   Leiderman DBD, 2017, ANN VASC SURG, V45, DOI 10.1016/j.avsg.2017.06.145
   Esnault P, 2017, J NEUROSURG, V127, P16, DOI 10.3171/2016.4.JNS152600
   Franz RW, 2012, J AM COLL SURGEONS, V214, P313, DOI 10.1016/j.jamcollsurg.2011.11.012
   Fumihiro A, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005764
   Khanzada T W, 2002, J Pak Med Assoc, V52, P185
   Lauerman MH, 2015, J TRAUMA ACUTE CARE, V78, P1071, DOI 10.1097/TA.0000000000000654
   Markus HS, 2015, LANCET NEUROL, V14, P361, DOI 10.1016/S1474-4422(15)70018-9
   Moerman JR, 2011, J TRAUMA, V70, P1485, DOI 10.1097/TA.0b013e3182185509
   Morton RP, 2014, J NEUROSURG, V120, P1446, DOI 10.3171/2014.2.JNS131658
   Nagata K, 2017, ACTA MED OKAYAMA, V71, P427, DOI 10.18926/AMO/55441
   Sarkari Avijit, 2016, Asian J Neurosurg, V11, P317, DOI 10.4103/1793-5482.144192
   Scott WW, 2015, J NEUROSURG, V122, P1196, DOI 10.3171/2015.1.JNS14642
   Scott WW, 2015, J NEUROSURG, V122, P610, DOI 10.3171/2014.10.JNS14875
   Shahan CP, 2017, J AM COLL SURGEONS, V224, P595, DOI 10.1016/j.jamcollsurg.2016.12.008
   Sinnathamby M, 2017, INJURY, V48, P1917, DOI 10.1016/j.injury.2017.06.006
   Tannoury C, 2015, CASE REP NEUROL MED, V2015, P1
   Weber CD, 2018, WORLD J SURG, V42, P2043, DOI 10.1007/s00268-017-4408-6
NR 21
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E672
EP E679
DI 10.1016/j.wneu.2019.06.187
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200085
PM 31279109
DA 2020-05-12
ER

PT J
AU Alvi, MA
   Zreik, J
   Wahood, W
   Goyal, A
   Freedman, BA
   Sebastian, AS
   Bydon, M
AF Alvi, Mohammed Ali
   Zreik, Jad
   Wahood, Waseem
   Goyal, Anshit
   Freedman, Brett A.
   Sebastian, Arjun S.
   Bydon, Mohamad
TI Impact of Dialysis on 30-Day Outcomes After Spinal Fusion Surgery for
   Pathologic Fractures: Insights from a National Quality Registry
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical; Dialysis; Fusion; Lumbar; NSQIP; Spine; Surgery
ID DEPENDENT PATIENTS; MORTALITY; COMPLICATIONS; MORBIDITY; DISEASE
AB BACKGROUND: Patients with chronic renal failure undergoing hemodialysis have been shown to have poor overall health, osteoporosis, and altered bone metabolism. However, the impact of hemodialysis on patient outcomes after spinal fusion remains unknown. We sought to assess the effect of dialysis on 30-day perioperative and postoperative outcomes after cervical and lumbar fusion for pathologic compression fractures.
   METHODS: We queried the National Surgical Quality Improvement Program from 2009 to 2016 for patients undergoing cervical or lumbar fusion for compression fractures. Three-to-one propensity score matching using sex, age, body mass index, and number of operated levels was used to match patients not undergoing dialysis with those undergoing dialysis. Multivariable conditional regression was used to identify the association between dialysis and 30-day clinical outcomes, after adjusting for confounders.
   RESULTS: A total of 48,492 patients undergoing cervical fusion were identified; 156 (0.32%) of these were on dialysis. On multivariable regression, dialysis dependency was associated with increased operative time (regression coefficient [coef.], 15.93; 95% CI, 0.4-31.5; P = 0.045), length of stay (coef. 6.06; 95% CI, 4.64-7.48; P < 0.001), 30-day readmissions (odds ratio [OR], 1.07; 95% CI, 1.02-1.12; P = 0.009), any complications (OR 1.08; 95% CI, 1.03-1.13; P = 0.002), and serious complications (OR, 1.08; 95% CI, 1.02-1.14; P = 0.012). A total of 25,417 patients undergoing lumbar fusion were identified; 51 of these (0.2%) were on dialysis. On multivariable regression, dialysis dependency was associated with significantly higher length of stay (coef. 2.98; 95% CI, 1.28-468; P < 0.001).
   CONCLUSIONS: Our analyses indicated that dialysis dependency is associated with poor perioperative and postoperative outcomes after cervical/lumbar fusion for pathologic compression fractures.
C1 [Alvi, Mohammed Ali; Zreik, Jad; Wahood, Waseem; Goyal, Anshit; Bydon, Mohamad] Mayo Clin, Neuroinformat Lab, Rochester, MN 55904 USA.
   [Alvi, Mohammed Ali; Zreik, Jad; Wahood, Waseem; Goyal, Anshit; Bydon, Mohamad] Mayo Clin, Dept Neurol Surg, Rochester, MN 55904 USA.
   [Freedman, Brett A.; Sebastian, Arjun S.] Mayo Clin, Dept Orthoped Surg, Rochester, MN USA.
RP Bydon, M (reprint author), Mayo Clin, Neuroinformat Lab, Rochester, MN 55904 USA.; Bydon, M (reprint author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55904 USA.
EM bydon.mohamad@mayo.edu
RI Alvi, Mohammed Ali/AAE-1490-2019
OI Alvi, Mohammed Ali/0000-0002-7131-079X
CR American College of Surgeons National Surgical Quality Improvement Program, 2019, ACS NSQIP PART US DA
   Austin PC, 2011, STAT MED, V30, P1292, DOI 10.1002/sim.4200
   BRESLOW NE, 1978, AM J EPIDEMIOL, V108, P299, DOI 10.1093/oxfordjournals.aje.a112623
   Chikawa T, 2013, J SPINAL DISORD TECH, V26, P321, DOI 10.1097/BSD.0b013e318246af73
   Chikuda H, 2012, J BONE JOINT SURG AM, V94A, P433, DOI 10.2106/JBJS.K.00183
   Chung AS, 2017, SPINE, V42, P1494, DOI 10.1097/BRS.0000000000002122
   D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B
   Drazin D, 2016, BIOMED RES INT, DOI 10.1155/2016/3623875
   Feng R, 2018, SPINE, V43, pE601, DOI 10.1097/BRS.0000000000002438
   Hartman C, 2019, WORLD NEUROSURG, V122, pE1037, DOI 10.1016/j.wneu.2018.10.207
   Hickson LJ, 2018, KIDNEY INT REP, V3, P1294, DOI 10.1016/j.ekir.2018.07.001
   Inoue T, 2018, SPINE, V43, P1169, DOI 10.1097/BRS.0000000000002577
   Kazberouk A, 2016, SPINE, V41, P344, DOI 10.1097/BRS.0000000000001212
   Kerezoudis P, 2016, CLIN NEUROL NEUROSUR, V149, P75, DOI 10.1016/j.clineuro.2016.07.027
   Locatelli F, 2001, J AM SOC NEPHROL, V12, P2411
   Manchikanti L, 2011, PAIN PHYSICIAN, V14, pE35
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   National Kidney Foundation, 2016, END STAG REN DIS US
   R Core Team, 2018, R LANG ENV STAT COMP
   Rajaee SS, 2012, SPINE, V37, P67, DOI 10.1097/BRS.0b013e31820cccfb
   Rodriguez-Garcia M, 2009, NEPHROL DIAL TRANSPL, V24, P239, DOI 10.1093/ndt/gfn466
   Sebastian A, 2019, WORLD NEUROSURG, V126, pE323, DOI 10.1016/j.wneu.2019.02.049
   Sidibe Aboubacar, 2019, JBMR Plus, V3, P45, DOI 10.1002/jbm4.10067
   Trombetti A, 2013, OSTEOPOROSIS INT, V24, P1721, DOI 10.1007/s00198-012-2133-4
   Ugiliweneza B, 2014, SPINE, V39, P1235, DOI 10.1097/BRS.0000000000000378
   Wahood W, 2019, CLIN NEUROL NEUROSUR, V180, P79, DOI 10.1016/j.clineuro.2019.03.021
   Whitmore RG, 2012, SPINE, V37, P1065, DOI 10.1097/BRS.0b013e31823da22d
NR 27
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E862
EP E873
DI 10.1016/j.wneu.2019.07.021
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200109
PM 31295605
DA 2020-05-12
ER

PT J
AU Amano, Y
   Kuroda, N
   Uchida, D
   Sakakura, Y
   Nakatogawa, H
   Ando, N
   Nakayama, T
   Sato, H
   Masui, T
   Sameshima, T
   Tanaka, T
AF Amano, Yuki
   Kuroda, Naoto
   Uchida, Daiki
   Sakakura, Yuya
   Nakatogawa, Hirokazu
   Ando, Naoto
   Nakayama, Teiji
   Sato, Haruhiko
   Masui, Takayuki
   Sameshima, Tetsuro
   Tanaka, Tokutaro
TI Unexpectedly Smaller Artifacts of 3.0-T Magnetic Resonance Imaging than
   1.5 T: Recommendation of 3.0-T Scanners for Patients with
   Magnet-Resistant Adjustable Ventriculoperitoneal Shunt Devices
SO WORLD NEUROSURGERY
LA English
DT Article
DE Artifact; Hydrocephalus; Magnetic resonance angiography; Magnetic
   resonance imaging; Stroke; Ventriculoperitoneal shunt
ID SUSCEPTIBILITY ARTIFACTS
AB BACKGROUND: Magnetic resonance imaging (MRI) artifacts of adjustable shunt devices are thought to be similar to metal clip artifacts, in that they are larger with higher field strength scanners. We have published several reports about the artifacts of new MRI-resistant adjustable shunt devices, and we found a case in which a 3.0-T scanner showed smaller artifacts than the 1.5-T scanner. We aimed to clarify whether this claim is true or not.
   METHODS: Under permission of our institutional Ethical Committee, 2 volunteers underwent imaging studies using 3.0-T and 1.5-T scanners from GE, Siemens, and Philips. Four MRI-resistant adjustable shunt devices-proGAV2.0 (Miethke), Codman Certas Plus (Johnson & Johnson), Polaris (Sophysa), and Strata MR valve (Medtronic)-were fixed on the left temporal scalp. Routine MRI images, including T1-and T2-weighted imaging, fluid-attenuated inversion recovery, diffusion-weighted imaging (DWI), and magnetic resonance angiography (MRA), were obtained. We also compared artifacts between a 3.0-T scanner and a-1.5 T scanner in 4 patients.
   RESULTS: The 3.0 T-scanners showed smaller artifacts than the 1.5-T scanners on DWI and MRA images for all shunt devices and scanners. In the other sequences, the results depended on the MRI scanner manufacturer; however, the GE 3.0-T scanner showed smaller artifacts in every sequence. This was also true in the 4 clinical cases.
   CONCLUSIONS: A 3.0-T scanner is recommended over a 1.5-T scanner for patients with MRI-resistant adjustable shunt devices in the diagnosis of acute ischemic condition or when using GE scanners.
C1 [Amano, Yuki; Kuroda, Naoto; Uchida, Daiki; Nakatogawa, Hirokazu; Tanaka, Tokutaro] Seirei Hamamatsu Gen Hosp, Dept Neurosurg, Hamamatsu, Shizuoka, Japan.
   [Masui, Takayuki] Seirei Hamamatsu Gen Hosp, Dept Radiol, Hamamatsu, Shizuoka, Japan.
   [Sakakura, Yuya] Natl Ctr Global Hlth & Med, Dept Neurosurg, Ctr Hosp, Tokyo, Japan.
   [Ando, Naoto] Seirei Numazu Gen Hosp, Dept Neurosurg, Numazu, Japan.
   [Nakayama, Teiji] Hamamatsu Med Ctr, Dept Neurosurg, Hamamatsu, Shizuoka, Japan.
   [Sato, Haruhiko] Seirei Mikatahara Gen Hosp, Dept Neurosurg, Hamamatsu, Shizuoka, Japan.
   [Sameshima, Tetsuro] Hamamatsu Univ Sch Med, Dept Neurosurg, Hamamatsu, Shizuoka, Japan.
RP Tanaka, T (reprint author), Seirei Hamamatsu Gen Hosp, Dept Neurosurg, Hamamatsu, Shizuoka, Japan.
EM tokutarotanaka@sis.seirei.or.jp
RI Masui, takayuki/AAE-6830-2019
OI Kuroda, Naoto/0000-0003-1977-4893
CR Amano Y, 2018, JPN J NEUROSURG TOKY, V27, P463
   Hargreaves BA, 2011, AM J ROENTGENOL, V197, P547, DOI 10.2214/AJR.11.7364
   Lifshutz JI, 2001, NEUROSURG FOCUS, V11, pE1, DOI DOI 10.3171/F0C.2001.11.2.2
   Matsuura H, 2005, NEUROL MED-CHIR, V45, P395, DOI 10.2176/nmc.45.395
   Miyake H, 2016, NEUROL MED-CHIR, V56, P274, DOI 10.2176/nmc.ra.2015-0282
   Nakazawa Hisato, 2014, Nihon Hoshasen Gijutsu Gakkai Zasshi, V70, P534
   Port JD, 2000, J COMPUT ASSIST TOMO, V24, P958, DOI 10.1097/00004728-200011000-00024
   Shellock FG, 2011, AM J ROENTGENOL, V197, P202, DOI 10.2214/AJR.10.5915
   Toma AK, 2010, J NEUROSURG, V113, P74, DOI 10.3171/2009.9.JNS09171
   Uchida D, 2017, JPN J NEUROSURG TOKY, V26, P523
   Uchida D, 2019, J NEUROSURG, V130, P1260, DOI 10.3171/2017.12.JNS171533
   Zabramski Joseph M, 2012, Surg Neurol Int, V3, P81, DOI 10.4103/2152-7806.99171
   Zemack G, 2003, J NEUROSURG, V98, P471, DOI 10.3171/jns.2003.98.3.0471
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E393
EP E399
DI 10.1016/j.wneu.2019.06.095
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200048
PM 31260847
DA 2020-05-12
ER

PT J
AU Anand, N
   Alayan, A
   Agrawal, A
   Kahwaty, S
   Nomoto, E
   Khandehroo, B
AF Anand, Neel
   Alayan, Alisa
   Agrawal, Aniruddh
   Kahwaty, Sheila
   Nomoto, Edward
   Khandehroo, Babak
TI Analysis of Spino-Pelvic Parameters and Segmental Lordosis with L5-S1
   Oblique Lateral Interbody Fusion at the Bottom of a Long Construct in
   Circumferential Minimally Invasive Surgical Correction of Adult Spinal
   Deformity
SO WORLD NEUROSURGERY
LA English
DT Article
DE ASD; Deformity correction; Minimally invasive surgery; OLIF; OLIF 5-1
ID PERIOPERATIVE COMPLICATIONS; SURGERY; SCOLIOSIS; DISKECTOMY; OUTCOMES;
   INJURY; RISK; TLIF
AB BACKGROUND: Lateral interbody fusion (LW) is an effective adjuvant for circumferential minimally invasive surgery (CMIS) treatment of adult spinal deformity (ASD). Accessing L5-S1 via an oblique LIF (OLIF) approach (OLIF 5-1) allows for anterior LIF (ALIF) at the lumbosacral junction without repositioning the patient. We review the early outcomes and complications of OLIF 5-1 at the bottom of a long construct for an MIS approach to treat ASD.
   METHODS: We queried a prospectively collected registry of 111 consecutive patients with ASD (Cobb angle >20 degrees, sagittal vertical alignment [SVA] >50, or pelvic inci- dence [PO-lumbar lordosis [LL] mismatch>10) patients who underwent CMIS correction between January 2015 and January 2019. Sixty patients had >= 4 levels fused and OLIF 5-1. Multilevel pre-psoas LIF + OLIF 5-1 were performed in the first stage. Three days later, stage 2 involved MIS installation of pedicle screws with aggressive rod contouring and derotation/translation.
   RESULTS: The mean patient age was 66.8 years (range, 48-79 years), and the mean duration of follow-up was 24 months (range, 3-60 months). A mean of 7 levels were fused (range, 4-9). Significant improvements in L5-S1 segmental lordosis (SL), LL, SVA, PI-LL mismatch, and pelvic tilt were seen following the first stage (P < 0.05). There was no intraoperative vascular, ureteral, or sympathetic chain injury, and no transient or permanent lumbar plexopathy. In 2 patients, OLIF 5-1 was abandoned due to difficult access, and transforaminal LIF was done at L5-S1 at the second stage. Five patients required intraoperative transfusion. No patient experienced postoperative ileus or L5-S1 pseudarthrosis. Significant improvements in visual analog scale pain score, Oswestry Disability Index, 36-Item Short Form Health Survey, and Scoliosis Research Society Outcomes Questionnaire were found.
   CONCLUSIONS: A single-position MIS OLIF 5-1 at the bottom of a long construct in conjunction with multilevel pre-psoas LIF seems to be a safe and effective technique for improving SL, global LL, and SVA with a low risk of perioperative and postoperative complications.
C1 [Anand, Neel; Alayan, Alisa; Kahwaty, Sheila; Nomoto, Edward; Khandehroo, Babak] Cedars Sinai Med Ctr, Spine Ctr, Los Angeles, CA 90048 USA.
   [Agrawal, Aniruddh] Topiwalla Natl Med Coll, Mumbai, Maharashtra, India.
RP Alayan, A (reprint author), Cedars Sinai Med Ctr, Spine Ctr, Los Angeles, CA 90048 USA.
EM alisa.alayan@gmail.com
OI Agrawal, Aniruddh/0000-0003-2737-9607
CR Abe K, 2017, SPINE, V42, P55, DOI 10.1097/BRS.0000000000001650
   Anand N, 2017, SPINE DEFORM, V5, P213
   Anand N, 2008, J SPINAL DISORD TECH, V21, P459, DOI 10.1097/BSD.0b013e318167b06b
   Anand N, 2006, SPINE, V31, pE748, DOI 10.1097/01.brs.0000240211.23617.ae
   Anand N, 2018, JAAOS GLOB RES REV, V2, DOI 10.5435/JAAOSGlobal-D-18-00067
   Anand N, 2017, NEUROSURGERY, V81, P733, DOI 10.1093/neuros/nyx353
   Anand N, 2012, ADV ORTHOP, V2012, DOI 10.1155/2012/218385
   Anand N, 2014, CLIN ORTHOP RELAT R, V472, P1762, DOI 10.1007/s11999-014-3565-2
   Anand N, 2014, NEUROSURG CLIN N AM, V25, P361, DOI 10.1016/j.nec.2013.12.014
   Anand N, 2014, CLIN ORTHOP RELAT R, V472, P1769, DOI 10.1007/s11999-013-3335-6
   Anand N, 2013, SPINE, V38, P1566, DOI 10.1097/BRS.0b013e31829cb67a
   Anand Neel, 2008, SAS J, V2, P40, DOI 10.1016/SASJ-2007-0120-MIS
   Anand N, 2013, EUR SPINE J, V22, pS232, DOI 10.1007/s00586-012-2344-6
   Anand N, 2013, J NEUROSURG-SPINE, V18, P18, DOI 10.3171/2012.9.SPINE12659
   Anand Neel, 2007, SAS J, V1, P93, DOI 10.1016/SASJ-2007-0101-RR
   Anand N, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09278
   Bateman DK, 2015, SPINE J, V15, P1118, DOI 10.1016/j.spinee.2015.02.040
   Chastain CA, 2007, ORTHOPEDICS, V30, P389, DOI 10.3928/01477447-20070501-18
   GILL K, 1993, ACTA ORTHOP SCAND, V64, P108, DOI 10.3109/17453679309160137
   Glassman SD, 2007, SPINE, V32, P2764, DOI 10.1097/BRS.0b013e31815a7644
   Haque RM, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.3.FOCUS1424
   Mayer HM, 1997, SPINE, V22, P691, DOI 10.1097/00007632-199703150-00023
   Mehren C, 2016, CLIN ORTHOP RELAT R, V474, P2020, DOI 10.1007/s11999-016-4883-3
   Melgar MA, 2014, INT J SPINE SURG, V8, DOI 10.14444/1010
   Mobbs Ralph J, 2015, J Spine Surg, V1, P2, DOI 10.3978/j.issn.2414-469X.2015.10.05
   Mundis G, 2015, NEUROSURGERY, V62, P222
   Orita S, 2017, SPINE, V42, P135, DOI 10.1097/BRS.0000000000001700
   Phan K, 2016, J CLIN NEUROSCI, V31, P23, DOI 10.1016/j.jocn.2016.02.030
   Quillo-Olvera J, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.01.22
   Schroeder GD, 2016, CLIN SPINE SURG, V29, P150, DOI 10.1097/BSD.0000000000000356
   Sharma AK, 2011, J SPINAL DISORD TECH, V24, P242, DOI 10.1097/BSD.0b013e3181ecf995
   Silvestre C, 2012, ASIAN SPINE J, V6, P89, DOI 10.4184/asj.2012.6.2.89
   Smith JS, 2011, SPINE, V36, P817, DOI 10.1097/BRS.0b013e3181e21783
   TAKAHASHI K, 1990, SPINE, V15, P1211, DOI 10.1097/00007632-199011010-00022
   Woods KRM, 2017, SPINE J, V17, P545, DOI 10.1016/j.spinee.2016.10.026
   Xu DS, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.03.24
   Zairi F, 2017, ORTHOP TRAUMATOL-SUR, V103, P295, DOI 10.1016/j.otsr.2016.11.016
   Zhang C, 2019, WORLD NEUROSURG, V124, pE17, DOI 10.1016/j.wneu.2018.11.139
   Zhu GD, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012680
NR 39
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E1077
EP E1083
DI 10.1016/j.wneu.2019.07.091
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200133
PM 31323412
DA 2020-05-12
ER

PT J
AU Aydin, S
   Comunoglu, N
   Ahmedov, ML
   Korkmaz, OP
   Oz, B
   Kadioglu, P
   Gazioglu, N
   Tanriover, N
AF Aydin, Seckin
   Comunoglu, Nil
   Ahmedov, Merdin Lyutviev
   Korkmaz, Ozge Polat
   Oz, Buge
   Kadioglu, Pinar
   Gazioglu, Nurperi
   Tanriover, Necmettin
TI Clinicopathologic Characteristics and Surgical Treatment of
   Plurihormonal Pituitary Adenomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE PIT-1-positive plurihormonal pituitary adenomas; Plurihormonal adenomas
   with unusual immunohistochemical combinations; Plurihormonal pituitary
   adenomas; WHO 2017 classification of tumors of endocrine organs
ID CUSHINGS-SYNDROME; GROWTH-HORMONE; CLASSIFICATION; DIAGNOSIS; SILENT;
   INVASION; PIT-1; ACTH
AB OBJECTIVE: Plurihormonal pituitary adenomas (PPAs) have recently been divided into 2 subtypes: pituitary specific transcription factor 1-positive plurihormonal pituitary adenomas (PIT-1 + PPAs) and plurihormonal adenomas with unusual immunohistochemical combinations (PAwUIC). The purpose of this study was to review patients with PPAs, elucidate their clinicopathologic characteristics, and present the surgical results.
   METHODS: Records were analyzed for 665 patients who underwent endoscopic endonasal transsphenoidal surgery for pituitary adenomas between 2007 and 2018. Data were reviewed for 27 patients who met the definition of PPAs and delineated regarding clinical, radiologic, pathologic features, and surgical outcomes.
   RESULTS: Of the 27 patients, 18 had PAwUIC, and 9 patients were diagnosed with PIT-1 + PPAs. Twenty-four patients (88.8%) had macroadenomas, including 6 giant adenomas (>= 4 cm) (22.2%). Cavernous sinus invasion was found in 12 patients (44.4%). Pathologic examinations showed high aggressivity in nearly half of the patients. Most patients with PAwUIC (77.8%) had features of nonfunctioning pituitary adenomas, and only 4 had features of hormone-secreting pituitary adenomas. Gross total resection rates were 57.1% for PAwUIC and 771% for PIT-1 + PPAs. The remission rate for hormone-secreting pituitary adenomas was 100% in this case series. Mean follow-up was 74.4 +/- 33 months (range, 6-121 months) for overall groups.
   CONCLUSIONS: To our knowledge, this is the first study to describe the clinicopathologic features of newly classified PPAs, which are characterized by aggressive behavior with higher values of percentage of cavernous sinus invasion. Relevant pathologic diagnosis of PPAs is crucial for appropriate management and follow-up.
C1 [Aydin, Seckin] Univ Hlth Sci, Okmeydani Training & Res Hosp, Dept Neurosurg, Istanbul, Turkey.
   [Comunoglu, Nil; Oz, Buge] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Pathol, Istanbul, Turkey.
   [Ahmedov, Merdin Lyutviev; Tanriover, Necmettin] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Neurosurg, Istanbul, Turkey.
   [Korkmaz, Ozge Polat; Kadioglu, Pinar] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Endoctinol & Metab, Istanbul, Turkey.
   [Gazioglu, Nurperi] Demiroglu Bilim Univ, Dept Neurosurg, Sch Med, Istanbul, Turkey.
RP Tanriover, N (reprint author), Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Neurosurg, Istanbul, Turkey.
EM nctan27@yahoo.com
RI aydin, seckin/F-8538-2015; , nil/AAA-6280-2020; Tanriover,
   Necmettin/AAD-3212-2020; Kadioglu, Pinar/AAM-9935-2020; Oz,
   Buge/AAH-6542-2019
OI Tanriover, Necmettin/0000-0001-7628-9443; 
FU Turkish Neurosurgical Society
FX Preparation for publication of this article was partly supported by the
   Turkish Neurosurgical Society.
CR Arnaldi G, 2003, J CLIN ENDOCR METAB, V88, P5593, DOI 10.1210/jc.2003-030871
   Asa S L, 1999, Pituitary, V1, P159, DOI 10.1023/A:1009948813587
   Asa SL., 2011, 4 SERIES FASCICLE 15
   Asa SL, 2018, HISTOPATHOLOGY, V72, P133, DOI 10.1111/his.13295
   Biller BMK, 2008, J CLIN ENDOCR METAB, V93, P2454, DOI 10.1210/jc.2007-2734
   Carmichael JD, 2009, J CLIN ENDOCR METAB, V94, P523, DOI 10.1210/jc.2008-1371
   Ceylan S, 2011, TURK NEUROSURG, V21, P330, DOI 10.5137/1019-5149.JTN.4149-11.0
   Erickson D, 2009, CLIN ENDOCRINOL, V71, P92, DOI 10.1111/j.1365-2265.2008.03514.x
   FELIX I, 1994, ARCH PATHOL LAB MED, V118, P66
   Hardy J, 1976, Adv Neurol, V15, P261
   Ho DMT, 2001, HISTOPATHOLOGY, V39, P310, DOI 10.1046/j.1365-2559.2001.01204.x
   Horvath E, 2005, ULTRASTRUCT PATHOL, V29, P511, DOI 10.1080/01913120500323514
   HORVATH E, 1983, ULTRASTRUCT PATHOL, V5, P171, DOI 10.3109/01913128309141837
   Hovarth E, 2004, WHO CLASSIFICATION T, P35
   Inoshita N, 2018, BRAIN TUMOR PATHOL, V35, P51, DOI 10.1007/s10014-018-0314-3
   Jastania RA, 2005, ENDOCR PATHOL, V16, P187, DOI 10.1385/EP:16:3:187
   Jiang ZQ, 2012, J NEURO-ONCOL, V108, P341, DOI 10.1007/s11060-011-0792-1
   KAMEYA T, 1991, PATHOL RES PRACT, V187, P574, DOI 10.1016/S0344-0338(11)80147-0
   Kannan S, 2012, CASE REP ENDOCRINOL, DOI 10.1155/2012/529730
   Katznelson L, 2014, J CLIN ENDOCR METAB, V99, P3933, DOI 10.1210/jc.2014-2700
   KNOSP E, 1993, NEUROSURGERY, V33, P610, DOI 10.1227/00006123-199310000-00008
   Kontogeorgos G, 2017, WHO CLASSIFICATION T, P39
   KOVACS K, 1989, TRENDS ENDOCRIN MET, V1, P104, DOI 10.1016/1043-2760(89)90012-X
   LABATMOLEUR F, 1991, PATHOL RES PRACT, V187, P534, DOI 10.1016/S0344-0338(11)80136-6
   Lopes MBS, 2017, ACTA NEUROPATHOL, V134, P521, DOI 10.1007/s00401-017-1769-8
   Mazarakis N, 2001, Pituitary, V4, P215, DOI 10.1023/A:1020764013137
   Meij B P, 2000, Pituitary, V3, P159, DOI 10.1023/A:1011499609096
   Mete O, 2017, ENDOCR PATHOL, V28, P228, DOI 10.1007/s12022-017-9498-z
   Mete O, 2016, MODERN PATHOL, V29, P131, DOI 10.1038/modpathol.2015.151
   Mete O, 2012, BRAIN PATHOL, V22, P443, DOI 10.1111/j.1750-3639.2012.00599.x
   Miermeister CP, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0229-8
   Nakao N, 2011, J CLIN NEUROSCI, V18, P71, DOI 10.1016/j.jocn.2010.04.049
   Nieman LK, 2008, J CLIN ENDOCR METAB, V93, P1526, DOI 10.1210/jc.2008-0125
   Paluzzi A, 2014, PITUITARY, V17, P307, DOI 10.1007/s11102-013-0502-4
   Rasul FT, 2014, ACTA NEUROCHIR, V156, P141, DOI 10.1007/s00701-013-1890-y
   Rick J, 2019, J NEUROSURG, V131, P147, DOI 10.3171/2018.4.JNS18230
   Roca E, 2018, WORLD NEUROSURG, V114, pE158, DOI 10.1016/j.wneu.2018.02.120
   Rotondo F, 2011, PATHOL INT, V61, P42, DOI 10.1111/j.1440-1827.2010.02613.x
   SANO T, 1990, VIRCHOWS ARCH A, V417, P361, DOI 10.1007/BF01605790
   SCHEITHAUER BW, 1986, SEMIN DIAGN PATHOL, V3, P69
   Solari D, 2012, PANMINERVA MED, V54, P271
   Villa A, 2014, ACTA NEUROCHIR, V156, P1389, DOI 10.1007/s00701-014-2027-7
   Wang AJ, 2016, J NEUROSURG SCI, V60, P441
NR 43
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E765
EP E774
DI 10.1016/j.wneu.2019.06.217
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200098
PM 31295602
DA 2020-05-12
ER

PT J
AU Bae, HJ
   Choi, JH
   Kim, BS
   Lee, KS
   Shin, YS
AF Bae, Hong-Ju
   Choi, Jai Ho
   Kim, Bum Soo
   Lee, Kwan-Sung
   Shin, Yong Sam
TI Predictors of Atherosclerotic Change in Unruptured Intracranial
   Aneurysms and Parent Arteries During Clipping
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Atherosclerotic change; Clipping aneurysm; Parent artery
ID FRAMINGHAM RISK SCORE; NATURAL-HISTORY; CLASSIFICATION; EPIDEMIOLOGY;
   MANAGEMENT; STENOSIS; MRI
AB OBJECTIVES: To identify predictors of atherosclerotic change in aneurysms and parent arteries, and to retrospectively analyze outcomes from clipped aneurysms that showed atherosclerotic changes.
   METHODS: Between May 2017 and April 2018, we collected a total of 151 clipping cases and reviewed records of operation videos to classify atherosclerosis by location (dome, neck of aneurysm, or parent artery). To identify predictors of atherosclerotic change in aneurysms, we analyzed baseline demographic characteristics, preoperative images, and Framingham Risk Scores (FRS). We also analyzed incomplete clipping cases according to atherosclerosis presence and location.
   RESULT: This study cohort included 110 women (mean age, 59.3 +/- 7.1 years) and 41 men (mean age, 55.9 +/- 9.6 years). Atherosclerotic change was seen in 77 cases. FRS, diabetes mellitus, and aneurysm size were identified as independent risk factors for atherosclerotic change in multivariate logistic regression analysis. There were 11 incomplete clipping cases (7.2%). Among the 30 cases with atherosclerotic change in the neck were 10 cases of incomplete clipping (P < 0.001).
   CONCLUSIONS: FRS, diabetes mellitus, and aneurysm size as predictors of atherosclerosis in patients undergoing aneurysm surgery can help guide surgical decisions and performance.
C1 [Bae, Hong-Ju; Choi, Jai Ho; Lee, Kwan-Sung; Shin, Yong Sam] Catholic Univ Korea, Dept Neurosurg, Seoul St Marys Hosp, Coll Med, Seoul, South Korea.
   [Kim, Bum Soo] Catholic Univ Korea, Dept Radiol, Seoul St Marys Hosp, Coll Med, Seoul, South Korea.
RP Shin, YS (reprint author), Catholic Univ Korea, Dept Neurosurg, Seoul St Marys Hosp, Coll Med, Seoul, South Korea.
EM nsshin@gmail.com
RI KIM, Bum-soo/F-3086-2018
OI KIM, Bum-soo/0000-0002-3870-6813
CR Aboyans V, 2007, PROG CARDIOVASC DIS, V50, P112, DOI 10.1016/j.pcad.2007.04.001
   ASARI S, 1994, ACTA MED OKAYAMA, V48, P257
   Bae Hong-Ju, 2014, J Cerebrovasc Endovasc Neurosurg, V16, P200, DOI 10.7461/jcen.2014.16.3.200
   Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570
   Brown RD, 2014, LANCET NEUROL, V13, P393, DOI 10.1016/S1474-4422(14)70015-8
   Chung J, 2015, WORLD NEUROSURG, V83, P666, DOI 10.1016/j.wneu.2015.01.023
   DRAKE CG, 1984, J NEUROSURG, V61, P848, DOI 10.3171/jns.1984.61.5.0848
   Insull W, 2009, AM J MED, V122, pS3, DOI 10.1016/j.amjmed.2008.10.013
   Intarakhao P, 2018, J NEUROSURG, V129, P684, DOI 10.3171/2017.5.JNS162469
   Kim JH, 2018, CLIN NEUROL NEUROSUR, V173, P110, DOI 10.1016/j.clineuro.2018.08.011
   Lloyd-Jones DM, 2004, AM J CARDIOL, V94, P20, DOI 10.1016/j.amjcard.2004.03.023
   Majidi S, 2013, AM J NEURORADIOL, V34, P2259, DOI 10.3174/ajnr.A3631
   Molyneux Andrew, 2002, J Stroke Cerebrovasc Dis, V11, P304, DOI 10.1053/jscd.2002.130390
   Park Chang Kyu, 2014, J Cerebrovasc Endovasc Neurosurg, V16, P247, DOI 10.7461/jcen.2014.16.3.247
   Qiao Y, 2011, J MAGN RESON IMAGING, V34, P22, DOI 10.1002/jmri.22592
   Sangiorgi G, 1998, J AM COLL CARDIOL, V31, P126, DOI 10.1016/S0735-1097(97)00443-9
   Sindou R, 1998, ACTA NEUROCHIR, V140, P1153, DOI 10.1007/s007010050230
   Song J, 2015, ACTA NEUROCHIR, V157, P1303, DOI 10.1007/s00701-015-2460-2
   STARY HC, 1995, CIRCULATION, V92, P1355, DOI 10.1161/01.CIR.92.5.1355
   STEIGER H J, 1989, Heart and Vessels, V5, P41, DOI 10.1007/BF02058357
   Sughrue ME, 2011, NEUROSURGERY, V69, P1261, DOI 10.1227/NEU.0b013e31822bb8a6
   Szelenyi A, 2011, CLIN NEUROL NEUROSUR, V113, P129, DOI 10.1016/j.clineuro.2010.10.012
   Tateshima S, 2008, SURG NEUROL, V70, P454, DOI 10.1016/j.surneu.2008.03.035
   Ueda Y, 2003, HERZ, V28, P501, DOI 10.1007/s00059-003-2486-8
   Wannamethee SG, 2005, ARCH INTERN MED, V165, P2644, DOI 10.1001/archinte.165.22.2644
   Watanabe Y, 2009, EUR RADIOL, V19, P1019, DOI 10.1007/s00330-008-1213-5
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
NR 27
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E338
EP E343
DI 10.1016/j.wneu.2019.06.084
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200040
PM 31228701
DA 2020-05-12
ER

PT J
AU Bailey, RL
   Quattrone, F
   Curtin, C
   Frangos, S
   Maloney-Wilensky, E
   Levine, JM
   LeRoux, PD
AF Bailey, Robert L.
   Quattrone, Francis
   Curtin, Colin
   Frangos, Suzanne
   Maloney-Wilensky, Eileen
   Levine, Joshua M.
   LeRoux, Peter D.
TI The Safety of Multimodality Monitoring Using Triple-Lumen Bolt in Severe
   Acute Brain Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain oxygen; Intracranial hemorrhage; Intracranial pressure;
   Intraventricular hemorrhage; Multimodality monitoring; Neuromonitoring;
   Subarachnoid hemorrhage; Traumatic brain injury
ID INTRACRANIAL-PRESSURE MONITORS; TISSUE OXYGEN; CLINICAL-PRACTICE;
   MANAGEMENT; COMPLICATIONS; VENTRICULITIS; RELIABILITY; HEMORRHAGE;
   PLACEMENT; DRAINS
AB BACKGROUND: Multimodality monitoring is used frequently to guide care of patients with severe acute brain injury. The aim of this study was to examine the safety and reliability of multimodality monitoring.
   METHODS: From a prospective observational database at a Level I trauma center, 501 patients, including 300 men and 201 women (mean age 58 +/- 39 years) were identified retrospectively. Each patient received a triple-lumen bolt and 3 monitors: intracranial pressure, brain temperature, and brain oxygen. Intensive care unit and hospital records were examined to identify complications, reasons for device replacement, malfunction and infection. Head computed tomography (CT) scans performed before and after the monitors were inserted were examined for evidence of monitor-related adverse effects.
   RESULTS: A total of 696 triple-lumen bolts were placed. Median duration of monitoring was 78.88 hours (interquartile range, 33.0-133.2 hours). Bilateral monitors were inserted in 22 (3.16%) patients. Ten (1.43%) monitors were replaced to allow magnetic resonance imaging, and 40 (5.74%) monitors were replaced to facilitate additional cranial surgery. Of 35 (5.02%) monitors that were replaced because they were thought to not be functioning properly, 19 (54.29%) were subsequently found to be functioning normally. Follow-up CT scans were compared with CT scans obtained before insertion of monitors; 9 (2.13%) small contusions and 10 (2.36%) extra-axial hematomas associated with the devices were identified. Based on the CT findings, the hematomas were thought to be associated with the insertion technique rather than the device; 4 hematomas required treatment. Twenty-two (3.16%) devices were incorrectly placed (e.g., the probe was in an infarct or an already existing contusion). Only 1 associated infection was identified.
   CONCLUSIONS: Placement of intracranial monitors for multimodality neuromonitoring using a triple-lumen bolt appears to be safe. The complication rate is similar to published complication rates for single-lumen bolts and single monitors.
C1 [Bailey, Robert L.; LeRoux, Peter D.] Main Line Hlth, Div Neurosurg, Wynnewood, PA 19096 USA.
   [LeRoux, Peter D.] Lankenau Inst Med Res, Wynnewood, PA 19096 USA.
   [Quattrone, Francis; Curtin, Colin; Frangos, Suzanne; Maloney-Wilensky, Eileen; Levine, Joshua M.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.
   [Levine, Joshua M.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
   [Levine, Joshua M.] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA.
RP LeRoux, PD (reprint author), Main Line Hlth, Div Neurosurg, Wynnewood, PA 19096 USA.; LeRoux, PD (reprint author), Lankenau Inst Med Res, Wynnewood, PA 19096 USA.
EM lerouxpeterd@gmail.com
CR Anderson RCE, 2004, J NEUROSURG, V101, P53, DOI 10.3171/ped.2004.101.2.0053
   Antes S, 2014, ACTA NEUROCHIR, V156, P1009, DOI 10.1007/s00701-013-1991-7
   Barber MA, 2012, J TRAUMA ACUTE CARE, V73, P558, DOI 10.1097/TA.0b013e318265cb75
   Bardt TF, 1998, ACT NEUR S, V71, P153
   Baum GR, 2017, J NEUROSURG, V127, P1190, DOI 10.3171/2016.9.JNS16367
   Bohman LE, 2011, NEUROCRIT CARE, V14, P361, DOI 10.1007/s12028-011-9526-7
   Brain Trauma Foundation, 2007, GUID MAN SEV TRAUM B
   Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998
   Camacho EF, 2011, INFECTION, V39, P47, DOI 10.1007/s15010-010-0073-5
   Chesnut R, 2014, NEUROCRIT CARE, V21, P64, DOI 10.1007/s12028-014-0048-y
   CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045
   Dings J, 1997, NEUROL RES, V19, P241, DOI 10.1080/01616412.1997.11740806
   Diringer MN, 2011, NEUROCRIT CARE, V15, P211, DOI 10.1007/s12028-011-9605-9
   Doerfler S, 2018, WORLD NEUROSURG, V114, pE483, DOI 10.1016/j.wneu.2018.02.195
   Foreman B, 2018, NEUROCRIT CARE, V29, P469, DOI 10.1007/s12028-018-0551-7
   Fried HI, 2016, NEUROCRIT CARE, V24, P61, DOI 10.1007/s12028-015-0224-8
   Gelabert-Gonzalez M, 2006, ACTA NEUROCHIR, V148, P435, DOI 10.1007/s00701-005-0683-3
   Guyot LL, 1998, ACT NEUR S, V71, P47
   Harrop JS, 2010, NEUROSURGERY, V67, P187, DOI 10.1227/01.NEU.0000370247.11479.B6
   Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069
   Honda H, 2010, INFECT CONT HOSP EP, V31, P1078, DOI 10.1086/656377
   Le Roux P, 2016, TRANSLATIONAL RES TR, P315
   Le Roux P, 2015, FRONT NEUROSCI, V57, P315
   Le Roux P, 2014, NEUROCRIT CARE, V21, P1, DOI 10.1007/s12028-014-0041-5
   Le Roux P, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-012-0331-2
   Leverstein-van Hall MA, 2010, J NEUROSURG, V112, P345, DOI 10.3171/2009.6.JNS09223
   Lozier AP, 2002, NEUROSURGERY, V51, P170, DOI 10.1097/00006123-200207000-00024
   Maloney-Wilensky E, 2009, CRIT CARE MED, V37, P2057, DOI 10.1097/CCM.0b013e3181a009f8
   Manoel ALD, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1193-9
   McKhann GM, 2004, MANAGEMENT CEREBRAL, P431
   Merck LH, 2019, CRIT CARE MED, V47, P623, DOI 10.1097/CCM.0000000000003680
   Morton R, 2012, NEUROSURGERY, V71, pE193, DOI 10.1227/NEU.0b013e318232e250
   Munch E, 1998, ACTA NEUROCHIR, V140, P1113, DOI 10.1007/s007010050224
   Nangunoori R, 2012, NEUROCRIT CARE, V17, P131, DOI 10.1007/s12028-011-9621-9
   National Institute for Health and Clinical Excellence, 2011, NIC GUID HEAD INJ
   NORTH B, 1986, NEUROSURGERY, V18, P730, DOI 10.1227/00006123-198606000-00009
   Oddo M, 2014, NEUROCRIT CARE, V21, P103, DOI 10.1007/s12028-014-0024-6
   Okonkwo DO, 2017, CRIT CARE MED, V45, P1907, DOI 10.1097/CCM.0000000000002619
   Pascual JL, 2011, J TRAUMA, V70, P535, DOI 10.1097/TA.0b013e31820b59de
   Sadaka F, 2013, BRAIN INJURY, V27, P600, DOI 10.3109/02699052.2013.772238
   Scheithauer S, 2009, J NEUROL NEUROSUR PS, V80, P1381, DOI 10.1136/jnnp.2008.165357
   Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506
   Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738
   Stocchetti N, 2014, ACTA NEUROCHIR, V156, P1615, DOI 10.1007/s00701-014-2127-4
   Swadron SP, 2012, NEUROCRIT CARE, V17, P112, DOI 10.1007/s12028-012-9760-7
   TEASDALE G, 1974, LANCET, V2, P81
   van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018
   vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007
   Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35
   Whitmore RG, 2012, J NEUROSURG, V116, P1106, DOI 10.3171/2012.1.JNS11962
   Wiesmann M, 2001, J CLIN NEUROSCI, V8, P126, DOI 10.1054/jocn.2000.0749
   Williams TA, 2011, J NEUROSURG, V115, P1040, DOI 10.3171/2011.6.JNS11167
NR 54
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E62
EP E67
DI 10.1016/j.wneu.2019.05.195
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200008
PM 31195129
DA 2020-05-12
ER

PT J
AU Baldoncini, M
   Campero, A
   Moran, G
   Avendano, M
   Hinojosa-Martinez, P
   Cimmino, M
   Buosi, P
   Forlizzi, V
   Chuang, J
   Gargurevich, B
AF Baldoncini, Matias
   Campero, Alvaro
   Moran, Gabriel
   Avendano, Maximiliano
   Hinojosa-Martinez, Pablo
   Cimmino, Marcela
   Buosi, Pablo
   Forlizzi, Valeria
   Chuang, Joaquin
   Gargurevich, Brian
TI Microsurgical Anatomy of the Central Retinal Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Central retinal artery; Central retinal artery area; Microsurgical
   retina anatomy; Retina
ID OPTIC-NERVE; OPHTHALMIC ARTERY; VASCULAR ANATOMY; OCCLUSION; PART
AB BACKGROUND: The central retinal artery (CRA) has -on described as one of the first branches of the ophthalmic artery. It arises medial to the ciliary ganglion and after a sinuous path within the orbital cavity it penetrates the lower surface of the dura mater that covers the optic nerve, approximately 1 cm behind the eyeball. However, the numerous anatomic descriptions that were made of the CRA have been insufficient or unclear in relation to certain characteristics that are analyzed in the present study.
   METHODS: An electronic literature search was made in the PubMed database and a cadaver dissection was performed on 11 orbits fixed in formaldehyde.
   RESULTS: Results were obtained regarding the source, collateral branches, curves, direction, length of the optic nerve, dural perforation site, distance, path and relations, diameter, and area of the central artery of the retina.
   CONCLUSIONS: Our anatomic study innovates in 2 as-pects of the CRA: area and curves. Not only was there a simple count of the number of curves, but it also analyzed the angle presented by each of the curves based on photos obtained in high definition, with a digital program to reduce the margin of error. These curvatures of the CRA were classified according to their spatial disposition within the orbital cavity based on a pattern that was easy to understand, Data were obtained from the area of the CRA on the penetration of the CRA into the dural sheath of the optic nerve.
C1 [Baldoncini, Matias; Moran, Gabriel; Avendano, Maximiliano; Hinojosa-Martinez, Pablo; Cimmino, Marcela; Buosi, Pablo; Forlizzi, Valeria; Chuang, Joaquin; Gargurevich, Brian] Univ Buenos Aires, Sch Med, Div Anat 2, Microsurg Neuroanat Lab LaNeMic, Buenos Aires, DF, Argentina.
   [Baldoncini, Matias; Campero, Alvaro] San Fernando Hosp, Dept Neurol Surg, Buenos Aires, DF, Argentina.
   [Campero, Alvaro] Padilla Hosp, Dept Neurol Surg, San Miguel De Tucuman, Argentina.
RP Baldoncini, M (reprint author), Univ Buenos Aires, Sch Med, Div Anat 2, Microsurg Neuroanat Lab LaNeMic, Buenos Aires, DF, Argentina.; Baldoncini, M (reprint author), San Fernando Hosp, Dept Neurol Surg, Buenos Aires, DF, Argentina.
EM drbaldoncinimatias@gmail.com
OI Baldoncini, Matias/0000-0001-9323-8306
CR [Anonymous], 2001, SOC ANATOMICA ESPANO
   Aviv RI, 2005, CLIN RADIOL, V60, P279, DOI 10.1016/j.crad.2004.05.017
   Bertelli E, 2017, SURG RADIOL ANAT, V39, P485, DOI 10.1007/s00276-016-1776-9
   BLUNT MJ, 1956, P ROY SOC MED, V49, P433, DOI 10.1177/003591575604900712
   Dutton J., 2011, ATLAS CLIN SURG ORBI, P51
   Erdogmus S, 2007, MINIM INVAS NEUROSUR, V50, P202, DOI 10.1055/s-2007-985862
   Erdogmus S, 2006, ACTA OPHTHALMOL SCAN, V84, P642, DOI 10.1111/j.1600-0420.2006.00673.x
   ERICKSON SJ, 1989, RADIOLOGY, V173, P511, DOI 10.1148/radiology.173.2.2678264
   Ettl A, 1997, OPHTHALMOLOGY, V104, P869, DOI 10.1016/S0161-6420(97)30219-X
   Ettl A, 1998, RADIOL CLIN N AM, V36, P1021, DOI 10.1016/S0033-8389(05)70229-3
   Francois J, 1963, Br J Ophthalmol, V47, P21, DOI 10.1136/bjo.47.1.21
   FRANCOIS J, 1954, BRIT J OPHTHALMOL, V38, P472, DOI 10.1136/bjo.38.8.472
   FRANCOIS J, 1955, Br J Ophthalmol, V39, P220, DOI 10.1136/bjo.39.4.220
   Hayek GE, ANATOMY ORBIT ITS SU
   Hayreh SS, 2006, EYE, V20, P1130, DOI 10.1038/sj.eye.6702377
   HAYREH S S, 1963, Br J Ophthalmol, V47, P651, DOI 10.1136/bjo.47.11.651
   Hayreh SS, 2011, PROG RETIN EYE RES, V30, P359, DOI 10.1016/j.preteyeres.2011.05.001
   Hayreh SS, 2004, EXP EYE RES, V78, P723, DOI 10.1016/S0014-4835(03)00214-8
   HAYREH SS, 1995, EXP EYE RES, V61, P259, DOI 10.1016/S0014-4835(05)80121-6
   Hendrix P, 2014, CLIN ANAT, V27, P1159, DOI 10.1002/ca.22415
   HUGHES B, 1958, Br J Ophthalmol, V42, P106, DOI 10.1136/bjo.42.2.106
   Kiel JW, 2010, OCULAR CIRCULATION
   Kocabiyik N, 2005, OPHTHAL PHYSL OPT, V25, P375, DOI 10.1111/j.1475-1313.2005.00286.x
   Liesegang T, 2007, BASIC CLIN SCI COURS, P11
   MANGAT HS, 1995, SURV OPHTHALMOL, V40, P145, DOI 10.1016/S0039-6257(95)80004-2
   Martins Carolina, 2011, Anat Res Int, V2011, P468727, DOI 10.1155/2011/468727
   Michalinos A, 2015, ANAT RES INT, V2015, P1
   Miller NR, 2004, EYE, V18, P1026, DOI 10.1038/sj.eye.6701592
   ONDA E, 1995, AM J OPHTHALMOL, V120, P92, DOI 10.1016/S0002-9394(14)73763-8
   Perrini P, 2007, J NEUROSURG, V106, P142, DOI 10.3171/jns.2007.106.1.142
   Pro E., 2014, ANATOMIA CLIN
   Rene C, 2006, EYE, V20, P1119, DOI 10.1038/sj.eye.6702376
   Rhoton Jr AL, 2003, RHOTONS CRANIAL ANAT
   Sehi M., 2009, ACTA OPHTHALMOL, V89, pe1
   Singh J, 2007, ARCH OPHTHALMOL-CHIC, V125, P1430, DOI 10.1001/archopht.125.10.1430
   SINGH S, 1960, Br J Ophthalmol, V44, P280, DOI 10.1136/bjo.44.5.280
   SINGH S, 1960, Br J Ophthalmol, V44, P193, DOI 10.1136/bjo.44.4.193
   STEELE EJ, 1956, J ANAT, V90, P486
   SUDAKEVITCH T, 1947, BRIT J OPHTHALMOL, V31, P738, DOI 10.1136/bjo.31.12.738
   Testut L, 1984, TRATADO ANATOMIA HUM, P249
   Testut L, 1964, TRATADO ANATOMIA TOP, P463
   Testut L, 1984, TRATADO ANATOMIA HUM, P616
   Tsutsumi S, 2006, NEUROSURGERY, V59, P870, DOI 10.1227/01.NEU.0000232654.15306.4A
   van Overbeeke J, 2003, Orbit, V22, P81
   Varma DD, 2013, EYE, V27, P688, DOI 10.1038/eye.2013.25
   VIGNAUD J, 1974, RADIOLOGY, V111, P617, DOI 10.1148/111.3.617
   WYBAR K C, 1956, Br J Ophthalmol, V40, P65, DOI 10.1136/bjo.40.2.65
NR 47
TC 0
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E172
EP E187
DI 10.1016/j.wneu.2019.06.026
PG 16
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200023
PM 31252082
DA 2020-05-12
ER

PT J
AU Barbagallo, GMV
   Certo, F
AF Barbagallo, Giuseppe M. V.
   Certo, Francesco
TI Three-Dimensional, High-Definition Exoscopic Anterior Cervical
   Discectomy and Fusion: A Valid Alternative to Microscope-Assisted
   Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D surgery; ACDF; Disc hernia; Exoscope; Spondylosis; Vitom
ID OPERATING MICROSCOPE; VITOM; EXPERIENCE; GUIDANCE; REMOVAL; SYSTEM
AB BACKGROUND: Anterior cervical discectomy and fusion (ACDF) remains one of the most commonly taught procedures during residency and one of the most frequently performed by neurosurgeons. Neurosurgeons use microscopes to perform surgery and to train other surgeons. Although the microscope provides excellent illumination and magnification, its use will be limited to 2 people: the surgeon and the assistant. Consequently, the scrub nurse and residents watching 2-dimensional images on monitors will have a reduced perception of the surgical field depth and anatomical details. The exoscope has been introduced as an alternative to microscopes and endoscopes. We used a 3-dimensional (3D), high-definition exoscope (30 Vitom [Karl Storz, Tuttlingen, Germany]) in 2 patients undergoing 2-level ACDF for cervical myeloradiculopathy.
   METHODS: The exoscope was used during soft tissue dissection, discectomy, osteophytectomy, and cage insertion. Microsurgical drilling of the posterior osteophytes, which will usually require adequate magnification and proper microscope angulation, was also performed using the exoscope.
   RESULTS: The exoscope provided a 3D view of the surgical field similar to that provided by a microscope and allowed us to effectively and safely perform the required surgical steps. The main advantage of 3D exoscopeassisted surgery, compared with microscope-assisted surgery, is the possibility to generate videos with a similar view and image quality as perceived by the surgeon. Therefore, the didactic capabilities of exoscopic videos are greater than those provided by microscopic videos. Exoscopes are also smaller compared with microscopes, allowing for comfortable use from the early surgical steps to device implantation.
   CONCLUSION: We believe that exoscope-assisted surgery could become a safe and effective alternative to microscope-assisted surgery in ACDF.
C1 [Barbagallo, Giuseppe M. V.; Certo, Francesco] Policlin G Rodolico Univ Hosp, Dept Neurol Surg, Catania, Italy.
RP Certo, F (reprint author), Policlin G Rodolico Univ Hosp, Dept Neurol Surg, Catania, Italy.
EM francesco.certomd@gmail.com
RI Certo, Francesco/AAC-1855-2019
CR Adogwa Owoicho, 2016, J Spine Surg, V2, P25, DOI 10.21037/jss.2016.01.04
   Albanese V, 2017, WORLD NEUROSURG, V106, P724, DOI 10.1016/j.wneu.2017.06.051
   Barbagallo GMV, 2013, EUR SPINE J, V22, pS868, DOI 10.1007/s00586-013-3005-0
   Beez T, 2018, CUREUS, V10, DOI 10.7759/cureus.2108
   Birch K, 2014, J CLIN NEUROSCI, V21, P1245, DOI 10.1016/j.jocn.2013.10.026
   CLOWARD RB, 1958, J NEUROSURG, V15, P602, DOI 10.3171/jns.1958.15.6.0602
   Frykman PK, 2013, J LAPAROENDOSC ADV S, V23, P639, DOI 10.1089/lap.2013.0125
   GILDENBERG PL, 1994, STEREOT FUNCT NEUROS, V63, P23, DOI 10.1159/000100285
   Gildenberg PL, 1997, STEREOT FUNCT NEUROS, V68, P64, DOI 10.1159/000099905
   HANKINSON HL, 1975, J NEUROSURG, V43, P452, DOI 10.3171/jns.1975.43.4.0452
   Krishnan KG, 2017, WORLD NEUROSURG, V97, P652, DOI 10.1016/j.wneu.2016.09.037
   Kwan K, 2019, OPER NEUROSURG, V16, P619, DOI 10.1093/ons/opy196
   Mamelak AN, 2012, J CLIN NEUROSCI, V19, P306, DOI 10.1016/j.jocn.2011.07.014
   MAYFIELD FH, 1965, POSTGRAD MED, V38, P345, DOI 10.1080/00325481.1965.11696804
   Oertel JM, 2017, WORLD NEUROSURG, V105, P153, DOI 10.1016/j.wneu.2017.05.109
   ROBINSON RA, 1959, J BONE JOINT SURG AM, V41, P1
   Rossini Z, 2017, WORLD NEUROSURG, V107, P663, DOI 10.1016/j.wneu.2017.08.083
   SCOVILLE WB, 1966, J AMER MED ASSOC, V196, P479, DOI 10.1001/jama.196.6.479
   Shirzadi A, 2012, SPINE, V37, pE1517, DOI 10.1097/BRS.0b013e3182709cef
   SMITH GW, 1958, J BONE JOINT SURG AM, V40, P607, DOI 10.2106/00004623-195840030-00009
   Vercellino GF, 2012, GEBURTSH FRAUENHEILK, V72, P945, DOI 10.1055/s-0032-1327779
   Vercellino GF, 2011, J LOW GENIT TRACT DI, V15, P292, DOI 10.1097/LGT.0b013e3182102891
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E244
EP E250
DI 10.1016/j.wneu.2019.06.049
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200031
PM 31207374
DA 2020-05-12
ER

PT J
AU Bassaganyas-Vancells, C
   Roldan, P
   Gonzalez, JJ
   Ferres, A
   Garcia, S
   Culebras, D
   Hoyos, J
   Reyes, L
   Torales, J
   Ensenat, J
AF Bassaganyas-Vancells, Clara
   Roldan, Pedro
   Jose Gonzalez, Juan
   Ferres, Abel
   Garcia, Sergio
   Culebras, Diego
   Hoyos, Jhon
   Reyes, Luis
   Torales, Jorge
   Ensenat, Joaquim
TI Combined Use of 5-Aminolevulinic Acid and Intraoperative Low-Field
   Magnetic Resonance Imaging in High-Grade Glioma Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE 5-amino-levulinic acid; Extent of resection; Gross total resection;
   High-grade glioma; Intraoperative magnetic resonance
ID MAXIMUM-SAFE-RESECTION; GLIOBLASTOMA-MULTIFORME; GUIDED SURGERY; EXTENT;
   SURVIVAL; FLUORESCENCE; TEMOZOLOMIDE; IMPACT; EXPERIENCE; GUIDANCE
AB OBJECTIVE: We sought to assess the impact of 5-aminolevulinic acid (5-ALA) and low-field intraoperative magnetic resonance imaging (iMRI) on the extent of resection of high-grade gliomas (HGGs). Results are compared with those obtained when using 5-ALA and iMRI separately.
   METHODS: We retrospectively included patients with an HGG eligible for gross total resection (GTR) from January 2013 to January 2018. Patients were included according to 5-ALA surgical guidance (5A-group), iMRI (iMRI-group), or both (5A-iMRI-group). Surgical variables were registered, and presurgical and postsurgical radiologic and clinical variables were analyzed. Extent of resection >= 90%, complications, and new permanent neurologic deficit were compared using the chi-squared and analysis of variance tests. Other variables studied were mortality, average hospital stay, surgical time, and Karnofsky Performance Scale status before and after surgery.
   RESULTS: Most of the 118 procedures carried out were in men (59.2%). The mean age was 58 years. Sixty patients (50.8%) were operated on using exclusively 5-ALA assistance (5A-group), 19 (16.1%) using iMRI (iMRI-group), and 39 (33%) combining both techniques (5A-IMRI-group). There were no statistically significant differences among 3 groups regarding extent of resection 90 >= (73% 5A, 73.7% iMRI, 71.8% 5A-iMRI, P = 0.94); complication rates (18.3% 5A, 5.3% iMRI, 7.7% 5A-iMRI, P = 0.17); new or worsening of preexisting neurologic deficit at 1-month follow-up (13.3% 5A, 10.5% iMRI, 15.4% 5A-iMRI, P = 0.26); average hospital stay in days (9.5 5A, 6.4 iMRI, 7.6 5A-iMRI, P = 0.18); Karnofsky Performance Scale; nor surgical time in minutes (212.4 5A, 187.9 iMRI, 201.4 5A-iMRI, P = 0.13).
   CONCLUSIONS: In our experience, combined use of iMRI and 5-ALA does not improve the studied variables when compared with those technologies when used separately, even though a slight tendency of a superior effectiveness is observed when using iMRI individually.
C1 [Bassaganyas-Vancells, Clara; Roldan, Pedro; Jose Gonzalez, Juan; Ferres, Abel; Garcia, Sergio; Culebras, Diego; Hoyos, Jhon; Reyes, Luis; Torales, Jorge; Ensenat, Joaquim] Hosp Clin Barcelona, Dept Neurosurg, Barcelona, Spain.
RP Roldan, P (reprint author), Hosp Clin Barcelona, Dept Neurosurg, Barcelona, Spain.
EM pedro.roldanramos@gmail.com
OI Garcia Garcia, Sergio/0000-0003-2356-5306
CR BURGER PC, 1987, CANCER, V59, P1617, DOI 10.1002/1097-0142(19870501)59:9<1617::AID-CNCR2820590916>3.0.CO;2-X
   Chaichana KL, 2014, NEURO-ONCOLOGY, V16, P113, DOI 10.1093/neuonc/not137
   Coburger J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131872
   Valle RD, 2014, NEUROLOGIA, V29, P131, DOI 10.1016/j.nrl.2013.05.004
   Eljamel MS, 2016, PHOTODIAGN PHOTODYN, V16, P35, DOI 10.1016/j.pdpdt.2016.07.012
   Garcia S, 2017, WORLD NEUROSURG, V102, P102, DOI 10.1016/j.wneu.2017.02.094
   Gehan E A, 1977, Natl Cancer Inst Monogr, V46, P189
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Jenkinson MD, 2018, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD012788
   Keles GE, 1999, SURG NEUROL, V52, P371, DOI 10.1016/S0090-3019(99)00103-2
   Kuhnt D, 2011, NEURO-ONCOLOGY, V13, P1339, DOI 10.1093/neuonc/nor133
   Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190
   Lacroix M, 2014, J CLIN ONCOL, V32, P727, DOI 10.1200/JCO.2013.53.2788
   Lau D, 2016, J NEUROSURG, V124, P1300, DOI 10.3171/2015.5.JNS1577
   Lewin JS, 2000, J MAGN RESON IMAGING, V12, P512, DOI 10.1002/1522-2586(200010)12:4<512::AID-JMRI2>3.3.CO;2-V
   Livne O, 2014, WORLD NEUROSURG, V82, P770, DOI 10.1016/j.wneu.2014.02.004
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Gil-Salu JL, 2013, NEUROCIRUGIA, V24, P163, DOI 10.1016/j.neucir.2013.01.004
   Marko NF, 2014, J CLIN ONCOL, V32, P774, DOI 10.1200/JCO.2013.51.8886
   Roldan P, 2017, NEUROCIRUGIA, V28, P103, DOI 10.1016/j.neucir.2016.08.001
   Sanai N, 2008, NEUROSURGERY, V62, P753, DOI 10.1227/01.neu.0000318159.21731.cf
   Sanai N, 2011, J NEUROSURG, V115, P3, DOI 10.3171/2011.2.JNS10998
   Sanai N, 2010, J NEUROSURG, V112, P1, DOI 10.3171/2009.6.JNS0952
   Senft C, 2011, LANCET ONCOL, V12, P997, DOI 10.1016/S1470-2045(11)70196-6
   Stark AM, 2005, SURG NEUROL, V63, P162, DOI 10.1016/j.surneu.2004.01.028
   Stummer W, 2006, LANCET ONCOL, V7, P392, DOI 10.1016/S1470-2045(06)70665-9
   Stummer W, 2008, NEUROSURGERY, V62, P564, DOI [10.1227/01.NEU.0000297118.47076.5F, 10.1227/01.neu.0000317304.31579.17, 10.1227/01.NEU.0000346230.80425.3A]
   Stummer W, 2011, J NEUROSURG, V114, P613, DOI 10.3171/2010.3.JNS097
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Tsugu A, 2011, WORLD NEUROSURG, V76, P120, DOI 10.1016/j.wneu.2011.02.005
   van den Bent MJ, 2005, EJC SUPPL, V3, P134
   Wen PY, 2010, J CLIN ONCOL, V28, P1963, DOI 10.1200/JCO.2009.26.3541
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E206
EP E212
DI 10.1016/j.wneu.2019.06.029
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200026
PM 31203073
DA 2020-05-12
ER

PT J
AU Benko, MJ
   Abdulla, SG
   Cuoco, JA
   Dhiman, N
   Klein, BJ
   Guilliams, EL
   Marvin, EA
   Howes, GA
   Collier, BR
   Hamill, ME
AF Benko, Michael J.
   Abdulla, Sarah G.
   Cuoco, Joshua A.
   Dhiman, Nitasha
   Klein, Brendan J.
   Guilliams, Evin L.
   Marvin, Eric A.
   Howes, Gregory A.
   Collier, Bryan R.
   Hamill, Mark E.
TI Short- and Long-Term Geriatric Mortality After Acute Traumatic Subdural
   Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Closed head injury; Elderly; Geriatric; Subdural hematoma; Subdural
   hemorrhage; Trauma; Traumatic brain injury
ID SEVERE HEAD-INJURY; BRAIN-INJURY; PROGNOSTIC-FACTORS; PATIENTS OLDER;
   HEMATOMA; AGE; MORBIDITY; OUTCOMES; LESION; RISK
AB BACKGROUND: Acute subdural hemorrhage often occurs in those >= 65 years of age after trauma and tends to yield poor clinical outcomes. Previous studies have demonstrated a propensity toward high in-hospital mortality rates in this population; however, postdischarge mortality data are limited. The objective of the present study was to analyze short- and long-term mortality data after acute traumatic subdural hemorrhage in the geriatric population as well as review the impact of associated clinical variables including mechanism of injury, pre-morbid antithrombotic use, and need for surgical decompression on mortality rates.
   METHODS: We retrospectively reviewed 455 patients who presented with an isolated traumatic acute subdural hemorrhage to our level-1 trauma center over a 5 year period using our data registry. Patients were then cross-referenced in the National Social Security Death Index for postdischarge mortality rates. United States life tables were used for peer-controlled actuarial comparisons.
   RESULTS: Acute traumatic subdural hemorrhage is often a fatal injury in the geriatric population, especially if taking antithrombotics or requiring surgical decompression. Specifically, they have greater in-hospital mortality rates than adults with similar injuries and have significantly lower survival rates for several years following discharge compared with their peer-matched controls.
   CONCLUSIONS: Here, we found that age is a significant predictor of both short- and long-term survival after acute traumatic subdural hemorrhage. Moreover, the present study corroborates that the need for surgical decompression or the use of pre-morbid antithrombotic medications is associated with increased overall mortality.
C1 [Benko, Michael J.; Cuoco, Joshua A.; Klein, Brendan J.; Guilliams, Evin L.; Marvin, Eric A.; Howes, Gregory A.] Carilion Clin, Div Neurosurg, Roanoke, VA 24014 USA.
   [Collier, Bryan R.; Hamill, Mark E.] Carilion Clin, Div Trauma Surg, Roanoke, VA 24014 USA.
   [Benko, Michael J.; Cuoco, Joshua A.; Klein, Brendan J.; Guilliams, Evin L.; Marvin, Eric A.; Howes, Gregory A.] Virginia Tech, Sch Neurosci, Blacksburg, VA 24061 USA.
   [Benko, Michael J.; Cuoco, Joshua A.; Klein, Brendan J.; Guilliams, Evin L.; Marvin, Eric A.; Howes, Gregory A.] Virginia Tech, Carilion Sch Med, Roanoke, VA USA.
   [Benko, Michael J.; Cuoco, Joshua A.; Klein, Brendan J.; Guilliams, Evin L.; Marvin, Eric A.; Howes, Gregory A.] Edward Via Coll Osteopath Med, Blacksburg, VA USA.
   [Abdulla, Sarah G.] Harbor Univ Calif Los Angeles, Torrance, CA USA.
   [Dhiman, Nitasha] Columbia Univ, Dept Radiol, New York, NY USA.
RP Benko, MJ (reprint author), Carilion Clin, Div Neurosurg, Roanoke, VA 24014 USA.; Benko, MJ (reprint author), Virginia Tech, Sch Neurosci, Blacksburg, VA 24061 USA.; Benko, MJ (reprint author), Virginia Tech, Carilion Sch Med, Roanoke, VA USA.; Benko, MJ (reprint author), Edward Via Coll Osteopath Med, Blacksburg, VA USA.
EM mjbenko@carilionclinic.org
OI Hamill, Mark/0000-0001-9566-0009
CR AMACHER AL, 1987, NEUROSURGERY, V20, P954
   Bajsarowicz P, 2015, J NEUROSURG, V123, P1176, DOI 10.3171/2014.10.JNS141728
   Baraniskin A, 2014, J NEUROL SURG PART A, V75, P31, DOI 10.1055/s-0032-1325629
   Bershad EM, 2008, J NEUROSURG, V109, P664, DOI 10.3171/JNS/2008/109/10/0664
   CAGETTI B, 1992, BRIT J NEUROSURG, V6, P227, DOI 10.3109/02688699209002930
   DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005
   Domenicucci M, 1998, NEUROSURGERY, V42, P51, DOI 10.1097/00006123-199801000-00010
   El-Fiki M, 2012, WORLD NEUROSURG, V78, P228, DOI 10.1016/j.wneu.2012.02.049
   FELL DA, 1975, J NEUROSURG, V42, P37, DOI 10.3171/jns.1975.42.1.0037
   Frontera JA, 2011, NEUROCRIT CARE, V14, P260, DOI 10.1007/s12028-010-9418-2
   GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005
   GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026
   HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858
   Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666
   Kalanithi P, 2011, J NEUROSURG, V115, P1013, DOI 10.3171/2011.6.JNS101989
   Lee JJ, 2018, J NEUROSURG, V128, P236, DOI 10.3171/2016.5.JNS16255
   Leitgeb J, 2012, J NEUROSURG, V117, P324, DOI 10.3171/2012.4.JNS111448
   LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762
   LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409
   Lukasiewicz AM, 2016, J NEUROSURG, V124, P760, DOI 10.3171/2015.2.JNS142721
   Mak CHK, 2012, CURR GERIATR REP, V1, P171, DOI 10.1007/s13670-012-0017-2
   Marion DW, 2006, NEUROSURGERY, V58, P655
   Maurice-Williams RS, 1999, BRIT J NEUROSURG, V13, P5, DOI 10.1080/02688699944104
   Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015
   Panczykowski DM, 2011, J NEUROSURG, V114, P47, DOI 10.3171/2010.7.JNS10446
   Petridis AK, 2009, CENT EUR NEUROSURG, V70, P73, DOI 10.1055/s-0029-1224096
   Prasad GL, 2018, WORLD NEUROSURG, V111, pE221, DOI 10.1016/j.wneu.2017.12.034
   Prevention C. F. D. C. a., 2019, TRAUM BRAIN INJ CONC
   Raj R, 2016, WORLD NEUROSURG, V88, P592, DOI 10.1016/j.wneu.2015.10.095
   SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503
   Servadei E, 2000, BRIT J NEUROSURG, V14, P110
   Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021
   Shimoda K, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.08.014
   Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004
   Tallon JM, 2008, CAN J SURG, V51, P339
   Taussky P, 2008, SWISS MED WKLY, V138, P281, DOI 2008/19/smw-12056
   Taussky P, 2012, WORLD NEUROSURG, V78, P306, DOI 10.1016/j.wneu.2011.10.030
   Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577
   VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37
   Whitehouse KJ, 2016, WORLD NEUROSURG, V94, P493, DOI 10.1016/j.wneu.2016.07.057
   WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212
   World Health Organization, 1998, 50 FACTS GLOB HLTH S
   Yokobori S, 2016, WORLD NEUROSURG, V86, P127, DOI 10.1016/j.wneu.2015.09.105
   Zumkeller M, 1996, NEUROSURGERY, V39, P708, DOI 10.1097/00006123-199610000-00011
NR 44
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E350
EP E355
DI 10.1016/j.wneu.2019.06.086
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200042
PM 31229743
DA 2020-05-12
ER

PT J
AU Bolognese, PA
   Brodbelt, A
   Bloom, AB
   Kula, RW
AF Bolognese, Paolo A.
   Brodbelt, Andrew
   Bloom, Alexander B.
   Kula, Roger W.
TI Chiari I Malformation: Opinions on Diagnostic Trends and Controversies
   from a Panel of 63 International Experts
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chiari I malformation; Questionnaire; Syringomyelia
ID TETHERED CORD SYNDROME; SURGICAL DECOMPRESSION; CERVICAL SYRINGOMYELIA;
   TONSILLAR HERNIATION; CHILDREN; MANIFESTATIONS; ASSOCIATION;
   PATHOGENESIS; MORPHOLOGY; PHYSIOLOGY
AB BACKGROUND: Chiari I malformation (CMI) and the topics concerning it have been the subject of numerous discussions and polarizing controversies over the course of the last 20 years.
   METHODS: The opinions of 63 recognized international CMI experts from 4 continents, with a collective surgical experience of >15,000 CMI cases, were gathered through a detailed questionnaire.
   RESULTS: Three facts emerged from the analysis of the results.
   1) Most of the replies showed a high level of consensus on most CMI-related topics.
   2) Several topics, which had been considered controversial as recently as 10 years ago, are now more widely accepted.
   3) The so-called 5-mm rule was rejected by 88.5% of the CMI experts who responded to the questionnaire.
   CONCLUSIONS: Sixty three recognized international CMI experts from 4 continents, with a collective surgical experience of >15,000 CMI cases were polled about a number of CMI topics. The results showed a high level of consensus, as well as a paradigm shift.
C1 [Bolognese, Paolo A.; Bloom, Alexander B.; Kula, Roger W.] Chiari Neurosurg Ctr, Lake Success, NY 11042 USA.
   [Brodbelt, Andrew] Walton Ctr NHS Fdn Trust, Liverpool, Merseyside, England.
RP Bolognese, PA (reprint author), Chiari Neurosurg Ctr, Lake Success, NY 11042 USA.
EM pbolognese@chiarinsc.com
CR Abel TJ, 2008, J NEUROSURG PEDIAT S, V105, P329
   Abla AA, 2010, J CRANIOVERTEBRAL JU, V1, P29, DOI 10.4103/0974-8237.65479
   ABOULEZZ AO, 1985, J COMPUT ASSIST TOMO, V9, P1033, DOI 10.1097/00004728-198511000-00005
   Addo NK, 2013, J NEUROSURG-PEDIATR, V11, P296, DOI 10.3171/2012.11.PEDS12297
   Ahmmed AU, 1996, J LARYNGOL OTOL, V110, P1060, DOI 10.1017/S0022215100135753
   ALBERS FWJ, 1993, J LARYNGOL OTOL, V107, P441, DOI 10.1017/S0022215100123370
   Alperin N, 2014, NEUROSURGERY, V75, P515, DOI 10.1227/NEU.0000000000000507
   Baisden Jamie, 2012, Surg Neurol Int, V3, pS232, DOI 10.4103/2152-7806.98580
   BARKOVICH AJ, 1986, AM J NEURORADIOL, V7, P795
   Bejjani GK, 2003, MED HYPOTHESES, V60, P859, DOI 10.1016/S0306-9877(03)00064-1
   Bollo RJ, 2012, J NEUROSURG-PEDIATR, V10, P134, DOI 10.3171/2012.3.PEDS11340
   Bolognese Paolo A, 2017, Surg Neurol Int, V8, P12, DOI 10.4103/2152-7806.198739
   Brockmeyer D, 2003, SPINE, V28, P2505, DOI 10.1097/01.BRS.0000092381.05229.87
   Brockmeyer DL, 2015, NEUROSURG CLIN N AM, V26, P555, DOI 10.1016/j.nec.2015.06.002
   Bunc G, 2001, J NEUROTRAUM, V18, P645, DOI 10.1089/089771501750291882
   Canpolat A, 2014, J NEUROSCI RURAL PRA, V5, P81, DOI 10.4103/0976-3147.127885
   CASTILLO M, 1995, AM J NEURORADIOL, V16, P1158
   Chern JJ, 2011, J NEUROSURG-PEDIATR, V8, P1, DOI 10.3171/2011.4.PEDS10528
   Chu D, 2009, P 17 SCI M INT SOC M
   Dagtekin A, 2011, CLIN NEUROL NEUROSUR, V113, P399, DOI 10.1016/j.clineuro.2010.12.020
   Di Rocco C, 2011, CHILD NERV SYST, V27, P1653, DOI 10.1007/s00381-011-1545-3
   Fox B, 2005, SKULL BASE-INTERD AP, V15, P89, DOI 10.1055/s-2005-868168
   Furtado SV, 2009, J CLIN NEUROSCI, V16, P1449, DOI 10.1016/j.jocn.2009.04.005
   Glenn C, 2015, J CLIN NEUROSCI, V22, P1749, DOI 10.1016/j.jocn.2015.05.023
   Goel A, 2005, J CLIN NEUROSCI, V12, P608, DOI 10.1016/j.jocn.2004.06.019
   Heiss JD, 2012, J NEUROSURG, V117, P942, DOI 10.3171/2012.8.JNS111476
   Henderson FC, 2017, AM J MED GENET C, V175, P195, DOI 10.1002/ajmg.c.31549
   Janjua MB, 2017, WORLD NEUROSURG, V104, DOI 10.1016/j.wneu.2017.05.089
   Krishna V, 2016, J NEUROSURG, V125, P1112, DOI 10.3171/2015.9.JNS151196
   Kumar A, 2002, OTOL NEUROTOL, V23, P727, DOI 10.1097/00129492-200209000-00021
   Lacy M, 2008, NEUROSURGERY, V62, P1415, DOI 10.1227/01.neu.0000333499.42980.fb
   Lacy M, 2019, WORLD NEUROSURG, V126, pE641, DOI 10.1016/j.wneu.2019.02.105
   Lacy M, 2018, PEDIATR NEUROSURG, V53, P371, DOI 10.1159/000488460
   LEIGH RJ, 1994, ANN NEUROL, V36, P129, DOI 10.1002/ana.410360204
   Markunas CA, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-39
   Markunas CA, 2012, J NEUROSURG-PEDIATR, V9, P372, DOI 10.3171/2011.12.PEDS11113
   McGirt MJ, 2008, CHILD NERV SYST, V24, P833, DOI 10.1007/s00381-007-0569-1
   Meadows J, 2000, J NEUROSURG, V92, P920, DOI 10.3171/jns.2000.92.6.0920
   Meager MR, 2012, ABSTR INT B
   Milhorat TH, 1999, NEUROSURGERY, V44, P1005, DOI 10.1097/00006123-199905000-00042
   Milhorat TH, 2007, J NEUROSURG-SPINE, V7, P601, DOI 10.3171/SPI-07/12/601
   Milhorat TH, 2010, ACTA NEUROCHIR, V152, P1117, DOI 10.1007/s00701-010-0636-3
   Milhorat TH, 2009, SURG NEUROL, V72, P20, DOI 10.1016/j.surneu.2009.03.008
   Mueller DM, 2005, AM J PERINAT, V22, P67, DOI 10.1055/s-2005-837271
   Muraszko Karin M, 2004, Clin Neurosurg, V51, P241
   Muzumdar D, 2006, CHILD NERV SYST, V22, P454, DOI 10.1007/s00381-005-0027-x
   Nishikawa M, 1997, J NEUROSURG, V86, P40, DOI 10.3171/jns.1997.86.1.0040
   Novegno F, 2008, J NEUROSURG-PEDIATR, V2, P179, DOI 10.3171/PED/2008/2/9/179
   Pearce JMS, 2000, J NEUROL NEUROSUR PS, V68, P13, DOI 10.1136/jnnp.68.1.13
   Platt SR, 2009, J SMALL ANIM PRACT, V50, P383, DOI 10.1111/j.1748-5827.2009.00804.x
   Prilipko O, 2005, J NEUROL NEUROSUR PS, V76, P1034, DOI 10.1136/jnnp.2004.048330
   Samii C, 1999, J NEUROL, V246, P162, DOI 10.1007/s004150050327
   Schijman E, 2004, CHILD NERV SYST, V20, P341, DOI 10.1007/s00381-003-0882-2
   Simons JP, 2008, ANN OTO RHINOL LARYN, V117, P443, DOI 10.1177/000348940811700607
   Speer M C, 2000, Neurosurg Focus, V8, pE12
   Speer Marcy C, 2003, J Genet Couns, V12, P297, DOI 10.1023/A:1023948921381
   Sporns PB, 2015, SPINE J, V15, pE13, DOI 10.1016/j.spinee.2015.04.025
   STOVNER LJ, 1993, NEURORADIOLOGY, V35, P113, DOI 10.1007/BF00593966
   Straus D, 2009, PEDIATR NEUROSURG, V45, P384, DOI 10.1159/000260909
   Szewka AJ, 2006, PEDIATR NEUROL, V34, P481, DOI 10.1016/j.pediatrneurol.2005.09.008
   Taylor Frederick R, 2002, Curr Pain Headache Rep, V6, P331, DOI 10.1007/s11916-002-0056-z
   Thimineur M, 2002, CLIN J PAIN, V18, P171, DOI 10.1097/00002508-200205000-00006
   Toldo I, 2014, HEADACHE, V54, P899, DOI 10.1111/head.12341
   Trigylidas T, 2008, CHILD NERV SYST, V24, P329, DOI 10.1007/s00381-007-0432-4
   Tubbs RS, 2010, J NEUROL, V257, P1218, DOI 10.1007/s00415-010-5529-0
   Tubbs RS, 2004, J NEUROSURG, V101, P179, DOI 10.3171/ped.2004.101.2.0179
   Wan MJ, 2008, NEUROSURGERY, V63, P748, DOI 10.1227/01.NEU.0000325498.04975.C0
   Yglesias A, 1996, DEV MED CHILD NEUROL, V38, P1126
NR 68
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E9
EP E16
DI 10.1016/j.wneu.2019.05.098
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200003
PM 31121369
DA 2020-05-12
ER

PT J
AU Briggs, RG
   Nix, CE
   Conner, AK
   Palejwala, AH
   Smitherman, AD
   Teo, C
   Sughrue, ME
AF Briggs, Robert G.
   Nix, Cameron E.
   Conner, Andrew K.
   Palejwala, Ali H.
   Smitherman, Adam D.
   Teo, Charles
   Sughrue, Michael E.
TI An Awake Contralateral, Transcallosal Approach for Deep-Seated Gliomas
   of the Basal Ganglia
SO WORLD NEUROSURGERY
LA English
DT Article
DE Basal ganglia; Glioma; Neurosurgery; Resection
ID SURGICAL RESECTION; THALAMIC TUMORS; NATURAL-HISTORY; SURGERY;
   MANAGEMENT; SURVIVAL; EXTENT
AB BACKGROUND: it basal ganglia and thalamus are uncommon locations for infiltrating gliomas. Tumors here are usually managed with biopsy and adjuvant therapy, with relatively poor results. Rarely do patients undergo extensive surgical intervention. It seems reasonable to suggest that successful cytoreduction may help these patients. However, this hypothesis has not been studied because of the general view that it is not possible to remove deep-seated brain tumors with acceptable outcomes.
   METHODS: Through retrospective data collection, we describe a small case series of patients undergoing awake contralateral, transcallosal surgery for deep-seated brain tumors affecting the basal ganglia. We describe our patient cohort, report on patient outcomes, and describe our surgical technique.
   RESULTS: Four patients underwent awake contralateral, transcallosal surgery for glioblastoma invading the basal ganglia. All 4 patients demonstrated hemibody weakness contralateral to the side of their tumors, with 3 patients confined to wheelchairs at presentation. Their ages ranged from 25 to 64 years. Tumor volumes ranged from 14 to 93 cm(3). More than 50% resection of each tumor was achieved during surgery. In 2 cases, approximately 90% resection was achieved. Motor strength improved in 1 patient who presented with hemiplegia. Two patients required ventriculoperitoneal shunting for complications related to hydrocephalus. At the writing of this article, 2 of our patients were still alive, functional, and free of tumor progression.
   CONCLUSIONS: We present the results of our attempts to resect large gliomas infiltrating the basal ganglia in 4 patients. Our technique combined a contralateral, transcallosal approach with awake neuromonitoring. Our results suggest it is possible to remove these tumors with reasonable outcomes.
C1 [Briggs, Robert G.; Nix, Cameron E.; Conner, Andrew K.; Palejwala, Ali H.; Smitherman, Adam D.] Univ Oklahoma, Hlth Sci Ctr, Dept Neurosurg, Oklahoma City, OK USA.
   [Teo, Charles; Sughrue, Michael E.] Prince Wales Private Hosp, Ctr Minimally Invas Neurosurg, Sydney, NSW, Australia.
RP Sughrue, ME (reprint author), Prince Wales Private Hosp, Ctr Minimally Invas Neurosurg, Sydney, NSW, Australia.
EM sughruevs@gmail.com
CR Aghi MK, 2015, J NEURO-ONCOL, V125, P503, DOI 10.1007/s11060-015-1867-1
   ARSENI C, 1958, ARCH NEURO PSYCHIATR, V80, P18, DOI 10.1001/archneurpsyc.1958.02340070036003
   Ashby Lynn S, 2006, Neurosurg Focus, V20, pE3, DOI 10.3171/foc.2006.20.4.3
   Berger M S, 1995, Clin Neurosurg, V42, P437
   BERNSTEIN M, 1984, J NEUROSURG, V61, P649, DOI 10.3171/jns.1984.61.4.0649
   Chang EF, 2011, J NEUROSURG, V114, P566, DOI 10.3171/2010.6.JNS091246
   CHEEK WR, 1966, J NEUROSURG, V24, P505, DOI 10.3171/jns.1966.24.2.0505
   Conner AK, 2018, JAMA ONCOL, V4, P884, DOI 10.1001/jamaoncol.2018.0001
   Duffau H, 2000, SURG NEUROL, V53, P250, DOI 10.1016/S0090-3019(00)00183-X
   FRANZINI A, 1994, NEUROSURGERY, V35, P817, DOI 10.1227/00006123-199411000-00003
   Greenwood J Jr, 1973, Surg Neurol, V1, P29
   HIROSE G, 1975, ARCH NEUROL-CHICAGO, V32, P740, DOI 10.1001/archneur.1975.00490530062005
   Kilic T, 2002, J CLIN NEUROSCI, V9, P549, DOI 10.1054/jocn.2002.1136
   Kowalczuk A, 1997, NEUROSURGERY, V41, P1028, DOI 10.1097/00006123-199711000-00004
   KRAUSS JK, 1992, J NEUROL NEUROSUR PS, V55, P1162, DOI 10.1136/jnnp.55.12.1162
   Louis DN, 2007, WHO CLASSIFICATION T
   Mandonnet E, 2017, NEUROSURG REV, V40, P29, DOI 10.1007/s10143-016-0723-x
   McCarter MD, 2001, ANN SURG ONCOL, V8, P38, DOI 10.1245/aso.2001.8.1.38
   MCKISSOCK W, 1958, BRAIN, V81, P41, DOI 10.1093/brain/81.1.41
   Olar A, 2012, CURR TREAT OPTION ON, V13, P417, DOI 10.1007/s11864-012-0210-8
   Oya S, 2011, J NEUROSURG, V114, P1250, DOI 10.3171/2010.12.JNS101623
   QUIGLEY MR, 1991, NEUROSURGERY, V29, P385, DOI 10.1227/00006123-199109000-00008
   Rezvan A, 2009, ACTA NEUROCHIR, V151, P1359, DOI 10.1007/s00701-009-0435-x
   ROSTOMILY RC, 1994, NEUROSURGERY, V35, P378, DOI 10.1227/00006123-199409000-00004
   Sala F, 2015, J NEUROSURG SCI, V59, P373
   Sala F, 2002, CHILD NERV SYST, V18, P264, DOI 10.1007/s00381-002-0582-3
   Sanai N, 2010, J NEUROSURG, V112, P1, DOI 10.3171/2009.6.JNS0952
   Sills Allen K Jr, 2004, Curr Treat Options Oncol, V5, P491, DOI 10.1007/s11864-004-0037-z
   Smyth GE, 1938, BRAIN, V61, P339, DOI 10.1093/brain/61.4.339
   Souweidane MM, 1996, J NEURO-ONCOL, V28, P157
   Stummer W, 2009, CURR OPIN NEUROL, V22, P645, DOI 10.1097/WCO.0b013e3283320165
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Vuorinen V, 2003, ACTA NEUROCHIR, V145, P5, DOI 10.1007/s00701-002-1030-6
NR 33
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E880
EP E887
DI 10.1016/j.wneu.2019.07.031
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200111
PM 31301441
DA 2020-05-12
ER

PT J
AU Brunozzi, D
   Theiss, P
   Amin-Hanjani, S
   Charbel, FT
   Mohammaden, M
   Andrews, A
   Linninger, A
   Alaraj, A
AF Brunozzi, Denise
   Theiss, Peter
   Amin-Hanjani, Sepideh
   Charbel, Fady T.
   Mohammaden, Mahmoud
   Andrews, Amanda
   Linninger, Andreas
   Alaraj, Ali
TI Ratio of Arteriovenous Malformation Draining Vein to Adjacent Venous
   Sinus Diameter Is Associated with Increased Risk of Venous Stenosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE AVM; Draining vein; Flow turbulence; Hemodynamics; Venous sinus; Venous
   stenosis
ID DRAINAGE SYSTEM; HEMORRHAGE; ANGIOARCHITECTURE; HEMODYNAMICS; FLOW
AB BACKGROUND: The development of venous outflow stenosis in cerebral arteriovenous malformation (AVM) is poorly understood. The location of stenosis within the AVM draining vein in relation to the adjacent venous sinus and the hypothesis that the ratio of draining vein to adjacent sinus diameter might predict the development of venous stenosis were explored.
   METHODS: Patients with supratentorial AVMs (1997-2018) were reviewed (N = 290). AVM draining vein and adjacent venous sinus diameters, degree of draining vein stenosis, and distance from the maximal stenotic point to the junction of the adjacent draining sinus were recorded. Correlation between percentage of AVM draining vein stenosis and the ratio of AVM draining vein to venous sinus diameters was analyzed.
   RESULTS: A total of 360 draining veins in 243 AVMs with complete angiographic data were measured. Venous stenosis (in 131 draining veins) was observed within 20 mm of the junction to the adjacent draining sinus in 85% of our sample. The ratio of draining vein to adjacent sinus diameter correlated positively with the percentage of venous stenosis (P < 0.01, r = 0.21). The ratio between 0.51-1.0 and >1.0 showed significant tighter stenosis compared with the ratio <= 0.5 (25.9% and 28.9% vs. 10.0%, respectively; P < 0.01).
   CONCLUSIONS: AVM venous outflow stenosis is observed close to the adjacent venous sinus junction. The degree of venous stenosis is greater when the ratio of AVM draining vein/adjacent venous sinus diameter is >0.5. This may be related to more turbulent flow at the junction of the draining vein and venous sinus, especially in larger draining veins, which causes venous stenosis to develop over time.
C1 [Brunozzi, Denise; Theiss, Peter; Amin-Hanjani, Sepideh; Charbel, Fady T.; Mohammaden, Mahmoud; Andrews, Amanda; Linninger, Andreas; Alaraj, Ali] Univ Illinois, Dept Neurosurg, Chicago, IL 60607 USA.
   [Linninger, Andreas; Alaraj, Ali] Univ Illinois, Dept Bioengn, Chicago, IL 60607 USA.
RP Alaraj, A (reprint author), Univ Illinois, Dept Neurosurg, Chicago, IL 60607 USA.; Alaraj, A (reprint author), Univ Illinois, Dept Bioengn, Chicago, IL 60607 USA.
EM alaraj@uic.edu
OI Amin-Hanjani, Sepideh/0000-0002-1289-4596
FU National Institute of Neurological Disorders and StrokeUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [1R21NS099896-01A1]; National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA
FX This work was supported by the National Institute of Neurological
   Disorders and Stroke (1R21NS099896-01A1). A. Alaraj has received a
   research grant from the National Institutes of Health and is a
   consultant for Cerenovus. A. Linninger has received a research grant
   from the National Institutes of Health.
CR Abecassis IJ, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.6.FOCUS14250
   Alaraj A, 2015, STROKE, V46, P942, DOI 10.1161/STROKEAHA.114.008569
   ALBERT P, 1990, ACTA NEUROCHIR, V103, P30, DOI 10.1007/BF01420189
   Fleetwood IG, 2002, LANCET, V359, P863, DOI 10.1016/S0140-6736(02)07946-1
   FRY DL, 1968, CIRC RES, V22, P165, DOI 10.1161/01.RES.22.2.165
   Hademenos GJ, 1996, STROKE, V27, P1072, DOI 10.1161/01.STR.27.6.1072
   Hetts SW, 2014, AM J NEURORADIOL, V35, P1376, DOI 10.3174/ajnr.A3886
   Hirai S, 1998, NEUROL MED-CHIR, V38, P165, DOI 10.2176/nmc.38.suppl_165
   Massoud TF, 2000, AM J NEURORADIOL, V21, P1268
   Mendoza-Elias N, 2018, J NEUROINTERV SURG, V10, P788, DOI 10.1136/neurintsurg-2017-013580
   MIYASAKA Y, 1994, STROKE, V25, P504, DOI 10.1161/01.STR.25.2.504
   MIYASAKA Y, 1992, J NEUROSURG, V76, P239, DOI 10.3171/jns.1992.76.2.0239
   Moftakhar P, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS09317
   MONACO RG, 1990, NEURORADIOLOGY, V31, P471, DOI 10.1007/BF00340124
   Nataf F, 1997, NEURORADIOLOGY, V39, P52, DOI 10.1007/s002340050367
   NORNES H, 1980, J NEUROSURG, V53, P456, DOI 10.3171/jns.1980.53.4.0456
   PILESPELLMAN JMD, 1986, AM J NEURORADIOL, V7, P811
   QUISLING RG, 1989, AM J NEURORADIOL, V10, P411
   Sahlein DH, 2014, STROKE, V45, P1964, DOI 10.1161/STROKEAHA.114.005170
   Shakur SF, 2018, WORLD NEUROSURG, V113, pE654, DOI 10.1016/j.wneu.2018.02.116
   Shakur SF, 2018, J NEUROINTERV SURG, V10, P156, DOI 10.1136/neurintsurg-2017-012991
   Shakur SF, 2017, STROKE, V48, P1088, DOI 10.1161/STROKEAHA.116.015666
   Takagi Y, 2006, NEUROSURGERY, V58, P740, DOI 10.1227/01.NEU.0000192167.54627.3A
   VINUELA F, 1985, J NEUROSURG, V63, P180, DOI 10.3171/jns.1985.63.2.0180
   WILLINSKY R, 1988, J NEURORADIOLOGY, V15, P225
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E1111
EP E1115
DI 10.1016/j.wneu.2019.07.100
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200138
PM 31323417
DA 2020-05-12
ER

PT J
AU Byun, YH
   Phi, JH
   Lee, JY
   Ha, EJ
   Kim, KH
   Yang, J
   Kim, HS
   Ryu, SK
   Choi, JW
   Cho, BK
   Kim, SK
AF Byun, Yoon Hwan
   Phi, Ji Hoon
   Lee, Ji Yeoun
   Ha, Eun Jin
   Kim, Kyung Hyun
   Yang, Jeyul
   Kim, Hee-Soo
   Ryu, Seul Ki
   Choi, Jung Won
   Cho, Byung-Kyu
   Kim, Seung-Ki
TI Preservation of the Arachnoid Membrane During
   Encephaloduroarteriosynangiosis Reduces Postoperative Complications
   without Undermining the Surgical Outcome in Pediatric Moyamoya Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arachnoid; Cerebral revascularization; Dissection; Hemorrhage;
   Infarction; Moyamoya disease
ID BIFRONTAL ENCEPHALOGALEO(PERIOSTEAL)SYNANGIOSIS; STROKE;
   REVASCULARIZATION; SYNANGIOSIS; CHILDREN; PATIENT
AB BACKGROUND: Encephaloduroarteriosynangiosis (EDAS) is a commonly used indirect revascularization operation method to treat pediatric patients with Moyamoya disease (MMD). Arachnoid dissection frequently has been performed during the EDAS operation to promote better revascularization. However, no studies have yet proven its surgical benefits. In this study, we investigated the impact of arachnoid preservation on the surgical outcome and postoperative complication by comparing pediatric patients with MMD who had the arachnoid membrane preserved during EDAS operation with those who had it dissected.
   METHODS: This was a retrospective cohort study based on a single surgeon's experience at a single institution. A total of 206 pediatric patients with MMD who underwent EDAS operation at Seoul National University Children's Hospital were recruited for the study. We compared the surgical outcome and the postoperation complication rate of these 2 groups. Furthermore, risk factors for postoperative complication were analyzed.
   RESULTS: The overall clinical outcome (P = 0.342) and the extent of revascularization of middle cerebral artery territories (P = 0.736) were not different between the arachnoid dissection group and the arachnoid preservation group. However, the postoperative infarction/hemorrhage rate was significantly greater in the arachnoid dissection group (P = 0.005). Arachnoid dissection (P = 0.011) and young age (<3 years old, P = 0.012) were significantly associated with increased risk of postoperative complications.
   CONCLUSIONS: Arachnoid preservation may help to reduce postoperative complications without decreasing the surgical outcome of EDAS. Furthermore, factors such as the patient's age should be taken into account when treating pediatric patients with MMD.
C1 [Byun, Yoon Hwan; Phi, Ji Hoon; Lee, Ji Yeoun; Ha, Eun Jin; Kim, Kyung Hyun; Yang, Jeyul; Ryu, Seul Ki; Kim, Seung-Ki] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Neurosurg, Seoul, South Korea.
   [Phi, Ji Hoon; Lee, Ji Yeoun; Kim, Kyung Hyun; Yang, Jeyul; Ryu, Seul Ki; Kim, Seung-Ki] Seoul Natl Univ, Childrens Hosp, Div Pediat Neurosurg, Seoul, South Korea.
   [Lee, Ji Yeoun] Seoul Natl Univ, Dept Anat, Coll Med, Seoul, South Korea.
   [Ha, Eun Jin] Seoul Natl Univ Hosp, Crit Care Ctr, Seoul, South Korea.
   [Kim, Hee-Soo] Seoul Natl Univ Hosp, Dept Anesthesiol & Pain Med, Seoul, South Korea.
   [Choi, Jung Won] Sungkyunkwan Univ, Samsung Med Ctr, Dept Neurosurg, Sch Med, Seoul, South Korea.
   [Cho, Byung-Kyu] Armed Forces Capital Hosp, Dept Neurosurg, Seongnam, South Korea.
RP Kim, SK (reprint author), Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Neurosurg, Seoul, South Korea.; Kim, SK (reprint author), Seoul Natl Univ, Childrens Hosp, Div Pediat Neurosurg, Seoul, South Korea.
EM nsthomas@snu.ac.kr
OI Kim, Kyung Hyun/0000-0002-8238-2043
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI) - Ministry of Health and Welfare, Republic
   of Korea [HI12C0066]
FX This research was supported by a grant of the Korea Health Technology
   R&D Project through the Korea Health Industry Development Institute
   (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea
   (grant number: HI12C0066).
CR Budohoski KP, 2014, J NEUROL NEUROSUR PS, V85, P1343, DOI 10.1136/jnnp-2014-307711
   Byung-Kyu Cho TT, 2010, MOYAMOYA DIS UPDATE
   Choi H, 2013, J NEUROSURG-PEDIATR, V12, P181, DOI 10.3171/2013.4.PEDS12505
   Kazumata K, 2014, J NEUROSURG, V121, P432, DOI 10.3171/2014.1.JNS13946
   Kim CY, 2003, CHILD NERV SYST, V19, P316, DOI 10.1007/s00381-003-0742-0
   Kim SK, 2008, NEUROSURGERY, V62, P1456, DOI 10.1227/01.neu.0000333810.49283.39
   Kim SK, 2010, ANN NEUROL, V68, P92, DOI 10.1002/ana.21981
   Kim SK, 2004, NEUROSURGERY, V54, P840, DOI 10.1227/01.NEU.0000114140.41509.14
   Kim SK, 2003, PEDIATR NEUROSURG, V38, P68, DOI 10.1159/000068050
   Kim T, 2015, J KOREAN NEUROSURG S, V57, P390, DOI 10.3340/jkns.2015.57.6.390
   Kuriyama S, 2008, STROKE, V39, P42, DOI 10.1161/STROKEAHA.107.490714
   Lee JY, 2014, J NEUROL, V261, P2305, DOI 10.1007/s00415-014-7484-7
   Mangla R, 2011, RADIOGRAPHICS, V31, P1201, DOI 10.1148/rg.315105014
   MATSUSHIMA T, 1992, NEUROSURGERY, V31, P401, DOI 10.1227/00006123-199209000-00003
   MATSUSHIMA Y, 1981, SURG NEUROL, V15, P313, DOI 10.1016/S0090-3019(81)80017-1
   Muraoka S, 2018, WORLD NEUROSURG, V113, pE190, DOI 10.1016/j.wneu.2018.01.212
   Ogiwara H, 2012, J NEUROSURG-PEDIATR, V10, P246, DOI 10.3171/2012.6.PEDS11483
   Park JH, 2007, J NEUROSURG, V106, P237, DOI 10.3171/ped.2007.106.3.237
   Provenzale JM, 2003, RADIOLOGY, V229, P347, DOI 10.1148/radiol.2292020402
   Samanta D, 2017, PEDIATR NEUROL, V71, P82, DOI 10.1016/j.pediatrneurol.2017.03.009
   Sasaki T, 2013, ACTA NEUROCHIR SUPPL, V115, P53, DOI 10.1007/978-3-7091-1192-5_12
   Scott RM, 2009, NEW ENGL J MED, V360, P1226, DOI 10.1056/NEJMra0804622
   Seol HJ, 2006, CHILD NERV SYST, V22, P145, DOI 10.1007/s00381-005-1234-1
   Smith ER, 2005, SKULL BASE-INTERD AP, V15, P15, DOI 10.1055/s-2005-868160
   SUZUKI J, 1983, STROKE, V14, P104, DOI 10.1161/01.STR.14.1.104
   Zhao X, 2015, BRIT J NEUROSURG, V29, P811, DOI 10.3109/02688697.2015.1071318
NR 26
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E406
EP E416
DI 10.1016/j.wneu.2019.06.103
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200050
PM 31233923
DA 2020-05-12
ER

PT J
AU Chang, CW
   Fu, TS
   Lin, DY
   Lai, PL
   Chiu, PY
   Kao, FC
   Tsai, TT
   Hsieh, MK
AF Chang, Chia-Wei
   Fu, Tsai-Sheng
   Lin, Dong-Yi
   Lai, Po-Liang
   Chiu, Ping-Yeh
   Kao, Fu-Cheng
   Tsai, Tsung-Ting
   Hsieh, Ming-Kai
TI Percutaneous Balloon Kyphoplasty and Short Instrumentation Compared with
   Traditional Long Instrumentation for Thoracolumbar Metastatic Spinal
   Cord Compression
SO WORLD NEUROSURGERY
LA English
DT Article
DE Kyphoplasty; Metastatic spinal cord compression; Spinal metastasis;
   Tumor
ID POSTERIOR DECOMPRESSION; INTRAOPERATIVE RADIOTHERAPY; BONE-CEMENT;
   VERTEBROPLASTY; STABILIZATION; FRACTURES; SURGERY; TUMORS; PMMA
AB BACKGROUND: A considerable propotion of patients with cancer got thoracolumbar vertebral metastatic epidural spinal cord compression, which affected their quality of life. Traditional surgical management involves early decompression with concomitant spine stabilization with long instrumentation. However, complications are caused by massive blood loss and long operation time. This study aimed to compare the safety and efficacy of short posterior instrumentation with kyphoplasty and the traditional method for thoracolumbar metastatic epidural spinal cord compression.
   METHODS: Between January 2004 and December 2015, a retrospective study was conducted on 120 patients with metastatic epidural spinal cord compression from T6 to L5 and divided into 2 groups: short posterior instrumentation with the balloon kyphoplasty group (group I, n = 50) and the long posterior instrumentation group (group II, n = 70). The clinical and radiographic parameters of patients in the 2 groups were compared with a nonrandomized cohort method. Patients were followed up from 3 to 40 months after surgery according to survival time.
   RESULTS: In group I, the surgery had a mean blood loss of 650 mL and a survival time of 19.1 months. In group II, the surgery had a mean blood loss of 2100 mL and a survival time of 14.14 months. A significant difference in blood loss amount (P = 0.002) was observed. Complications, including deep wound infection, durotomy, and uncontrolled bleeding, were observed in both groups. No postoperative cement-induced neurologic deterioration, implant failure occurred.
   CONCLUSIONS: Kyphoplasty with short posterior instrumentation is a novel technique that can be performed safely and effectively for the treatment of thoracolumbar metastatic epidural spinal cord compression. Rigid stability, reduced blood loss, and short fixation decrease surgical morbidity of spinal metastasis.
C1 [Chang, Chia-Wei; Fu, Tsai-Sheng; Lin, Dong-Yi] Chang Gung Mem Hosp, Dept Orthopaed Surg, Keelung Branch, Keelung, Taiwan.
   [Lai, Po-Liang; Chiu, Ping-Yeh; Kao, Fu-Cheng; Tsai, Tsung-Ting; Hsieh, Ming-Kai] Chang Gung Mem Hosp, Bone & Joint Res Ctr, Linkou, Taiwan.
   [Lai, Po-Liang; Chiu, Ping-Yeh; Kao, Fu-Cheng; Tsai, Tsung-Ting; Hsieh, Ming-Kai] Chang Gung Mem Hosp, Dept Orthoped Surg, Taoyuan, Taiwan.
   [Lai, Po-Liang; Chiu, Ping-Yeh; Kao, Fu-Cheng; Tsai, Tsung-Ting; Hsieh, Ming-Kai] Chang Gung Univ, Taoyuan, Taiwan.
RP Hsieh, MK (reprint author), Chang Gung Mem Hosp, Bone & Joint Res Ctr, Linkou, Taiwan.; Hsieh, MK (reprint author), Chang Gung Mem Hosp, Dept Orthoped Surg, Taoyuan, Taiwan.; Hsieh, MK (reprint author), Chang Gung Univ, Taoyuan, Taiwan.
EM stock-best@yahoo.com.tw
OI Hsieh, Ming-kai/0000-0002-9154-8850; Tsai,
   Tsung-Ting/0000-0002-7776-7627
CR Bai M, 2017, REGEN BIOMATER, V4, P251, DOI 10.1093/rb/rbx019
   Barzilai O, 2018, NEUROSURGERY, V82, P757, DOI 10.1093/neuros/nyx567
   Berenson J, 2011, LANCET ONCOL, V12, P225, DOI 10.1016/S1470-2045(11)70008-0
   Chen LH, 2012, ARCH ORTHOP TRAUM SU, V132, P759, DOI 10.1007/s00402-012-1474-y
   Cho DC, 2009, SURG NEUROL, V71, P424, DOI 10.1016/j.surneu.2008.02.049
   Clausen C, 2017, DAN MED J, V64
   Corcos G, 2014, SPINE, V39, pE332, DOI 10.1097/BRS.0000000000000134
   Coumans JVCE, 2003, J NEUROSURG, V99, P44, DOI 10.3171/spi.2003.99.1.0044
   Gangi Afshin, 2010, Semin Intervent Radiol, V27, P124, DOI 10.1055/s-0030-1253511
   Heini PF, 2004, EUR SPINE J, V13, P184, DOI 10.1007/s00586-003-0654-4
   Hong CG, 2017, WORLD J SURG ONCOL, V15, P1, DOI 10.1186/s12957-017-1118-3
   Jha RM, 2010, J NEUROINTERV SURG, V2, P221, DOI 10.1136/jnis.2010.002675
   Kim JM, 2012, SPINE, V37, P78, DOI 10.1097/BRS.0b013e318223b9b6
   Kondo T, 2008, SPINE, V33, P1898, DOI 10.1097/BRS.0b013e31817c0410
   Lei M, 2015, EJSO-EUR J SURG ONC, V41, P1691, DOI 10.1016/j.ejso.2015.09.025
   Lei MX, 2016, SPINE, V41, P1469, DOI 10.1097/BRS.0000000000001538
   Lo WY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0190342
   Mendel E, 2009, SPINE, V34, pS93, DOI 10.1097/BRS.0b013e3181b77895
   Molina C, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.5.FOCUS16129
   Muhlbauer M, 2000, ACTA NEUROCHIR, V142, P1219, DOI 10.1007/s007010070018
   Papanastassiou ID, 2014, CANCER CONTROL, V21, P151, DOI 10.1177/107327481402100208
   Quraishi NA, 2010, J BONE JOINT SURG BR, V92B, P1054, DOI 10.1302/0301-620X.92B8.22296
   Roedel B, 2015, J NEURORADIOLOGY, V42, P222, DOI 10.1016/j.neurad.2014.02.004
   Sadeghi-Naini M, 2018, CLIN SPINE SURG, V31, P203, DOI 10.1097/BSD.0000000000000601
   Saito T, 2006, EUR SPINE J, V15, P216, DOI 10.1007/s00586-005-0979-2
   Salem KMI, 2016, EUR SPINE J, V25, P3916, DOI 10.1007/s00586-015-4154-0
   Schmidt Meic H, 2005, J Natl Compr Canc Netw, V3, P711
   SHIMIZU K, 1992, SPINE, V17, P1400, DOI 10.1097/00007632-199211000-00022
   Tsai PJ, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1753-4
   Wang H, 2015, PAIN PHYSICIAN, V18, P209
   Wang Li-jun, 2012, Orthop Surg, V4, P182, DOI 10.1111/j.1757-7861.2012.00193.x
   Webb JCJ, 2007, J BONE JOINT SURG BR, V89B, P851, DOI 10.1302/0301-620X.89B7.19148
   Yu CW, 2014, BMC SURG, V14, DOI 10.1186/1471-2482-14-3
NR 33
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E640
EP E647
DI 10.1016/j.wneu.2019.06.182
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200081
PM 31276852
DA 2020-05-12
ER

PT J
AU Chen, JW
   Hou, CX
   Zheng, ZT
   Lin, H
   Lv, GZ
   Zhou, D
AF Chen, Jiawei
   Hou, Chongxian
   Zheng, Zongtai
   Lin, Han
   Lv, Guangzhao
   Zhou, Dong
TI Identification of Secreted Phosphoprotein 1 (SPP1) as a Prognostic
   Factor in Lower-Grade Gliomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Lower-grade glioma; Prognostic factor; SPP1
ID EPITHELIAL-MESENCHYMAL TRANSITION; PROLIFERATOR-ACTIVATED RECEPTORS;
   PROMOTES TUMOR-GROWTH; PPAR-GAMMA; OSTEOPONTIN; CANCER; EXPRESSION;
   APOPTOSIS; PATHWAY; HEALTH
AB OBJECTIVE: Secreted phosphoprotein 1 (SPP1) is an important extracellular glycoprotein that is associated with immune regulation, tumorigenesis, and cell signaling. However, the prognostic value of SPP1 in patients with glioma has not yet been clarified, especially in lower-grade gliomas. The objective of this study is to evaluate the prognostic merit of SPP1 in lower-grade gliomas.
   METHODS: The messenger RNA (mRNA) expression of SPP1 in about 1000 cancer cell lines was explored by using the data from the Cancer Cell Line Encyclopedia database. The Oncomine database was mined to evaluate the mRNA expression of SPP1 in lower-grade glioma, glioblastoma, and normal brain tissues. The correlation between SPP1 mRNA expression and overall survival of patients with glioma from The Cancer Genome Atlas database was analyzed.
   RESULTS: SPP1 mRNA expression of glioma was ranked as the eighth highest of all cancer cell lines in the Cancer Cell Line Encyclopedia database. The data from the Oncomine database suggested that SPP1 expression was significantly high in glioblastoma compared with normal brain tissues but was not significantly high in lower-grade glioma compared with normal brain tissue. Analysis of the RNA-Seq data from The Cancer Genome Atlas database showed that the increased SPP1 mRNA expression in lower-grade glioma was significantly associated with poor survival outcomes in patients with lower-grade glioma. Multivariate Cox regression analysis showed that SPP1 might be considered as an independent prognostic factor in lower-grade gliomas.
   CONCLUSIONS: The present study showed that SPP1 overexpression is related to worse overall survival in patients with lower-grade glioma. Moreover, SPP1 could be considered as an independent factor in lower-grade gliomas.
C1 [Chen, Jiawei; Lin, Han; Lv, Guangzhao] Shantou Univ, Med Coll, Shantou, Peoples R China.
   [Chen, Jiawei; Zheng, Zongtai; Lin, Han; Lv, Guangzhao; Zhou, Dong] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China.
   [Hou, Chongxian] Hokkaido Univ, Dept Neurosurg, Fac Med, Sapporo, Hokkaido, Japan.
RP Zhou, D (reprint author), Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China.
EM zhoudong5413@163.com
OI Chen, Jiawei/0000-0001-5383-1359
CR Akopova O V, 2011, Ukr Biokhim Zh (1999), V83, P46
   Behera R, 2010, CARCINOGENESIS, V31, P192, DOI 10.1093/carcin/bgp289
   Bhattacharya SD, 2012, ANN SURG, V255, P319, DOI 10.1097/SLA.0b013e31823e3a1c
   Borbath I, 2008, PPAR RES, V2008, DOI 10.1155/2008/209520
   Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58
   Chaffer CL, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-53
   Chakraborty G, 2008, CANCER RES, V68, P152, DOI 10.1158/0008-5472.CAN-07-2126
   Chaudhry A, 2017, PULM CIRC, V7, P98, DOI 10.1086/689749
   Chearwae W, 2008, BRIT J CANCER, V99, P2044, DOI 10.1038/sj.bjc.6604786
   Choi SH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07470-w
   Dajon M, 2017, IMMUNOBIOLOGY, V222, P89, DOI 10.1016/j.imbio.2016.06.009
   Deng SL, 2014, PROTEIN CELL, V5, P899, DOI 10.1007/s13238-014-0112-6
   El-Tanani MK, 2008, FRONT BIOSCI, V13, P4276, DOI 10.2741/3004
   Elrod HA, 2008, PPAR RES, V2008, DOI 10.1155/2008/704165
   Erpolat OP, 2013, STRAHLENTHER ONKOL, V189, P147, DOI 10.1007/s00066-012-0262-5
   Guttler A, 2013, RADIOTHER ONCOL, V108, P535, DOI 10.1016/j.radonc.2013.06.036
   Gupta G, 2013, CNS NEUROSCI THER, V19, P724, DOI 10.1111/cns.12137
   Halon A, 2012, POSTEP HIG MED DOSW, V66, P158, DOI 10.5604/17322693.987628
   Henry A, 2016, ONCOTARGET, V7, P63708, DOI 10.18632/oncotarget.11483
   Huang B, 2007, CANCER RES, V67, P4346, DOI 10.1158/0008-5472.CAN-06-4067
   Ito K, 2009, MATRIX BIOL, V28, P11, DOI 10.1016/j.matbio.2008.10.002
   Iwatsuki M, 2010, CANCER SCI, V101, P293, DOI 10.1111/j.1349-7006.2009.01419.x
   Jan HJ, 2010, NEURO-ONCOLOGY, V12, P58, DOI 10.1093/neuonc/nop013
   Kahlert UD, 2013, CANCER LETT, V331, P131, DOI 10.1016/j.canlet.2012.12.010
   Kothari AN, 2016, J CLIN MED, V5, DOI 10.3390/jcm5040039
   Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007
   Lamkanfi M, 2012, ANNU REV CELL DEV BI, V28, P137, DOI 10.1146/annurev-cellbio-101011-155745
   Li CL, 2019, GENE, V700, P52, DOI 10.1016/j.gene.2019.02.084
   Li MY, 2006, CRIT REV CL LAB SCI, V43, P183, DOI 10.1080/10408360600552587
   Li NY, 2013, J AM COLL SURGEONS, V217, P17, DOI 10.1016/j.jamcollsurg.2013.02.025
   Ling GQ, 2016, INT J ONCOL, V49, P2387, DOI 10.3892/ijo.2016.3724
   Liu H, 2019, PATHOL ONCOL RES, V25, P1487, DOI 10.1007/s12253-018-0504-7
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Lu DY, 2012, NEURO-ONCOLOGY, V14, P1367, DOI 10.1093/neuonc/nos262
   Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9
   Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254
   Moon SH, 2013, INT J ONCOL, V42, P921, DOI 10.3892/ijo.2013.1765
   Morosetti R, 2004, INT J ONCOL, V25, P493
   Mueller S, 2012, NEURO-ONCOLOGY, V14, P1146, DOI 10.1093/neuonc/nos140
   Nikitakis NG, 2002, BRIT J CANCER, V87, P1396, DOI 10.1038/sj.bjc.6600618
   O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev-med-051113-024537
   Ostrom QT, 2018, NEURO-ONCOLOGY, V20, P1, DOI 10.1093/neuonc/noy131
   Pietras A, 2014, CELL STEM CELL, V14, P357, DOI 10.1016/j.stem.2014.01.005
   Rabjerg M, 2016, APMIS, V124, P372, DOI 10.1111/apm.12519
   Ramchandani D, 2013, ONCOL REP, V30, P1860, DOI 10.3892/or.2013.2632
   Riccardo F, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-S3-S1
   Salvi V, 2013, J LEUKOCYTE BIOL, V94, P147, DOI 10.1189/jlb.0412194
   Senft C, 2011, J NEURO-ONCOL, V101, P393, DOI 10.1007/s11060-010-0273-y
   Shen XY, 2019, J CELL PHYSIOL, V234, P22311, DOI 10.1002/jcp.28797
   Shi WN, 2014, TUMOR BIOL, V35, P9627, DOI 10.1007/s13277-014-2268-3
   Song H., 2016, INT J MOL SCI, V17
   Sreekanthreddy P, 2010, CANCER EPIDEM BIOMAR, V19, P1409, DOI 10.1158/1055-9965.EPI-09-1077
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tachibana K, 2008, PPAR RES, V2008, DOI 10.1155/2008/102737
   Takano S, 2000, BRIT J CANCER, V82, P1967
   Tarassishin L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103432
   Tsai WC, 2012, HISTOPATHOLOGY, V61, P844, DOI 10.1111/j.1365-2559.2012.04277.x
   Tu YY, 2011, MED ONCOL, V28, P15, DOI 10.1007/s12032-010-9435-1
   Tyagi S, 2011, J ADV PHARM TECHNOL, V2, P236, DOI 10.4103/2231-4040.90879
   Wang C, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-415
   Xu CH, 2019, J CELL PHYSIOL, V234, P22272, DOI 10.1002/jcp.28794
   Xu J, 2015, MOL MED REP, V12, P4708, DOI 10.3892/mmr.2015.3975
   Yamada D, 2018, NEUROCHEM RES, V43, P2047, DOI 10.1007/s11064-018-2626-4
   Yang XY, 2008, PPAR RES, V2008, DOI 10.1155/2008/961753
   Yin XF, 2018, INT J ONCOL, V53, P973, DOI 10.3892/ijo.2018.4480
   Youssef J, 2011, BRIT J PHARMACOL, V164, P68, DOI 10.1111/j.1476-5381.2011.01383.x
   Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818
   Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734
   Zheng XG, 2012, MOL CARCINOGEN, V51, P150, DOI 10.1002/mc.20772
   Zheng X, 2009, CANCER BIOL THER, V8, P1045, DOI 10.4161/cbt.8.11.8539
   Zhuo CJ, 2016, CELL PHYSIOL BIOCHEM, V40, P1316, DOI 10.1159/000453184
NR 71
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E775
EP E785
DI 10.1016/j.wneu.2019.06.219
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200099
PM 31295606
DA 2020-05-12
ER

PT J
AU Cheung, ZB
   Selverian, S
   Cho, BH
   Ball, CJ
   Cho, SKW
AF Cheung, Zoe B.
   Selverian, Stephen
   Cho, Brian H.
   Ball, Christopher J.
   Cho, Samuel Kang-Wook
TI Idiopathic Scoliosis in Children and Adolescents: Emerging Techniques in
   Surgical Treatment
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adolescent idiopathic scoliosis; Fusionless; Growth-modulating;
   Growth-modulation; Pediatric spine
ID PEDICLE SCREW PLACEMENT; EARLY-ONSET SCOLIOSIS; DEFORMITY CORRECTION;
   POLYESTER BANDS; THORACIC SPINE; DRILL GUIDE; GROWTH RODS; NAVIGATION;
   ACCURACY; FIXATION
AB BACKGROUND: Idiopathic scoliosis is the most common spinal disorder in the pediatric population. The goals of treatment for pediatric idiopathic scoliosis are to correct deformity, prevent curve progression, restore trunk symmetry and balance, and minimize pain and morbidity. Surgical treatment has advanced significantly, from the advent of segmental pedicle screw instrumentation several decades ago to the recent development of robotic-assisted surgery and growth-modulating fusionless surgery. The objective of the present study was to review the reported data on emerging techniques in the surgical treatment of idiopathic scoliosis in children and adolescents.
   METHODS: The PubMed and Google Scholar electronic databases were used to identify studies that had examined new emerging techniques in the surgical treatment of idiopathic scoliosis in children and adolescents.
   RESULTS: Major developments in the surgical techniques for pediatric idiopathic scoliosis have included robotic-assisted pedicle screw placement, vertebral body stapling, vertebral body tethering, magnetically controlled growing rods, ApiFix (not currently approved for use in the United States by the Food and Drug Administration), and sublaminar polyester bands. Such growth-modulating fusionless surgical techniques have received increasing attention in recent years, especially for the younger pediatric scoliosis population with significant growth potential remaining.
   CONCLUSIONS: Various emerging techniques in the surgical treatment of idiopathic scoliosis in children and adolescents have demonstrated promising results in the reported data thus far. However, longer term prospective studies with larger cohorts are necessary to better evaluate their safety and efficacy.
C1 [Cheung, Zoe B.; Selverian, Stephen; Cho, Brian H.; Ball, Christopher J.; Cho, Samuel Kang-Wook] Icahn Sch Med Mt Sinai, Dept Orthopaed Surg, New York, NY 10029 USA.
RP Cho, SKW (reprint author), Icahn Sch Med Mt Sinai, Dept Orthopaed Surg, New York, NY 10029 USA.
EM samuel.cho@mountsinai.org
RI Cheung, Zoe/AAG-4511-2020
OI Cheung, Zoe/0000-0002-0189-5390; Cho, Brian/0000-0002-8763-8992
CR Abul-Kasim K, 2011, ACTA ORTHOP, V82, P50, DOI 10.3109/17453674.2010.548032
   Abul-Kasim K, 2009, EUR RADIOL, V19, P610, DOI 10.1007/s00330-008-1178-4
   Bettany-Saltikov J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010663.pub2
   Betz RR, 2003, SPINE, V28, pS255, DOI 10.1097/01.BRS.0000092484.31316.32
   Braun JT, 2006, SPINE, V31, P1776, DOI 10.1097/01.brs.0000227263.43060.50
   Carlioz H, 1995, CHIRURGIE, V120, P1994
   Charroin C, 2014, ORTHOP TRAUMATOL-SUR, V100, P469, DOI 10.1016/j.otsr.2014.05.006
   Cheng I, 2005, SPINE, V30, P2104, DOI 10.1097/01.brs.0000179261.70845.b7
   Cheung KMC, 2012, LANCET, V379, P1967, DOI 10.1016/S0140-6736(12)60112-3
   Clement JL, 2011, EUR SPINE J, V20, P1149, DOI 10.1007/s00586-011-1779-5
   de Gauzy JS, 2011, J CHILD ORTHOP, V5, P273, DOI 10.1007/s11832-011-0357-z
   Dinesh SK, 2012, BRIT J NEUROSURG, V26, P838, DOI 10.3109/02688697.2012.690917
   Floman Y, 2015, SCOLIOSIS SPINAL DIS, V10, DOI 10.1186/s13013-015-0028-9
   Gaines RW, 2000, J BONE JOINT SURG AM, V82A, P1458, DOI 10.2106/00004623-200010000-00013
   Gao ST, 2018, EUR SPINE J, V27, P921, DOI 10.1007/s00586-017-5333-y
   Ghasem A, 2018, SPINE, V43, P1670, DOI 10.1097/BRS.0000000000002695
   Grass PJ, 1997, SPINE, V22, P1922, DOI 10.1097/00007632-199708150-00022
   Guo F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171509
   Hamilton-Bennett SE, 2018, VET SURG, V47, P236, DOI 10.1111/vsu.12734
   Hickey B A, 2014, Eur Spine J, V23 Suppl 1, pS61, DOI 10.1007/s00586-013-3163-0
   Hicks JM, 2010, SPINE, V35, pE465, DOI 10.1097/BRS.0b013e3181d1021a
   Hirsch C, 2014, ORTHOP TRAUMATOL-SUR, V100, P791, DOI 10.1016/j.otsr.2014.07.019
   HOFFMAN DA, 1989, J NATL CANCER I, V81, P1307, DOI 10.1093/jnci/81.17.1307
   Hongo M, 2009, EUR SPINE J, V18, P1213, DOI 10.1007/s00586-009-0999-4
   Hresko MT, 2013, NEW ENGL J MED, V368, P834, DOI 10.1056/NEJMcp1209063
   Hu XB, 2013, EUR SPINE J, V22, P661, DOI 10.1007/s00586-012-2499-1
   Hunt KJ, 2010, SPINE, V35, P371, DOI 10.1097/BRS.0b013e3181b962a4
   Ilharreborde B, 2010, SPINE, V35, P306, DOI 10.1097/BRS.0b013e3181b7c7c4
   Izatt MT, 2010, SPINE, V35, pE1577, DOI 10.1097/BRS.0b013e3181d12627
   JOHNSTON CE, 1986, J BONE JOINT SURG AM, V68A, P556, DOI 10.2106/00004623-198668040-00012
   Kuklo TR, 2005, SPINE, V30, P2113, DOI 10.1097/01.brs.0000179260.73267.f4
   Labelle H, 2011, J PEDIATR ORTHOPED, V31, pS37, DOI 10.1097/BPO.0b013e3181fd8801
   Laituri CA, 2012, J LAPAROENDOSC ADV S, V22, P830, DOI 10.1089/lap.2011.0289
   Liljenqvist UR, 1997, SPINE, V22, P2239, DOI 10.1097/00007632-199710010-00008
   Liu K, 2017, EUR SPINE J, V26, P1684, DOI 10.1007/s00586-016-4926-1
   Lonstein JE, 2006, CLIN ORTHOP RELAT R, P248, DOI 10.1097/01.blo.0000198725.54891.73
   Lubicky JP, 2011, SPINE, V36, P1692, DOI 10.1097/BRS.0b013e3182102c6a
   Macke JJ, 2016, J ROBOT SURG, V10, P145, DOI 10.1007/s11701-016-0587-7
   Matsumoto M, 2014, J ORTHOP SCI, V19, P6, DOI 10.1007/s00776-013-0474-2
   Mazda K, 2009, EUR SPINE J, V18, P158, DOI 10.1007/s00586-008-0839-y
   Meng XT, 2016, NEUROSURG REV, V39, P385, DOI 10.1007/s10143-015-0679-2
   Menger RP, 2018, NEUROSPINE, V15, P216, DOI 10.14245/ns.1836082.041
   Miyanji Firoz, 2018, Spine Deform, V6, P820, DOI 10.1016/j.jspd.2018.09.062
   Negrini S, 2012, SCOLIOSIS SPINAL DIS, V7, DOI 10.1186/1748-7161-7-3
   Newton PO, 2008, SPINE, V33, P724, DOI 10.1097/BRS.0b013e31816950a0
   Park HJ, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0788-z
   Roach JW, 1999, ORTHOP CLIN N AM, V30, P353, DOI 10.1016/S0030-5898(05)70092-4
   Rolton D, 2015, EUR SPINE J, V24, P1457, DOI 10.1007/s00586-014-3699-7
   Samdani AF, 2015, EUR SPINE J, V24, P1533, DOI 10.1007/s00586-014-3706-z
   Samdani AF, 2014, SPINE, V39, P1688, DOI 10.1097/BRS.0000000000000472
   Samdani AF, 2010, CLIN ORTHOP RELAT R, V468, P700, DOI 10.1007/s11999-009-0886-7
   Silbermann J, 2011, EUR SPINE J, V20, P875, DOI 10.1007/s00586-010-1683-4
   Smith Jason R, 2008, JAAPA, V21, P40
   Su AW, 2015, SPINE, V40, P1851, DOI 10.1097/BRS.0000000000001077
   Tan Lee A, 2018, J Spine Surg, V4, P319, DOI 10.21037/jss.2018.05.16
   Teoh KH, 2016, SPINE J, V16, pS40, DOI 10.1016/j.spinee.2015.12.099
   Trobisch PD, 2011, OPER ORTHOP TRAUMATO, V23, P227, DOI 10.1007/s00064-011-0032-z
   Urbanski W, 2018, CLIN ORTHOP RELAT R, V476, P1020, DOI 10.1007/s11999.0000000000000204
   Viswanathan A, 2010, NEUROSURGERY, V66, P862, DOI 10.1227/01.NEU.0000368106.34969.FA
   Watanabe K, 2010, SPINE, V35, P1836, DOI 10.1097/BRS.0b013e3181d3cfde
   Wood MJ, 2014, INT J SPINE SURG, V8, DOI 10.14444/1027
   Xu W, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1703-1
   Yazici M, 2009, SPINE, V34, P1800, DOI 10.1097/BRS.0b013e3181978ec9
   Youkilis AS, 2001, NEUROSURGERY, V48, P771, DOI 10.1097/00006123-200104000-00015
   Yu ZX, 2017, EUR SPINE J, V26, P2348, DOI 10.1007/s00586-017-5118-3
NR 65
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E737
EP E742
DI 10.1016/j.wneu.2019.06.207
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200094
PM 31284059
DA 2020-05-12
ER

PT J
AU Chikani, MC
   Mesi, M
   Okwunodulu, O
   Mezue, W
   Ohaegbulam, S
   Ndubuisi, C
   Iroegbu, L
   Nkwerem, S
AF Chikani, Mark C.
   Mesi, Mathew
   Okwunodulu, Okwuoma
   Mezue, Wilfred
   Ohaegbulam, Samuel
   Ndubuisi, Chika
   Iroegbu, Linda
   Nkwerem, Sunday
TI Changing Trends and Challenges of Spine Surgery in a Developing Country
SO WORLD NEUROSURGERY
LA English
DT Article
DE Developing country; Spine surgery; Trends
ID SUB-SAHARAN AFRICA; CORD-INJURY; NEUROSURGERY; DISEASE
AB BACKGROUND: Spine conditions are common and the surgery is evolving even in developed economies. This study aims to review the changing trends and challenges of spine surgery, particularly from a low-income country.
   METHODS: This is a retrospective study of patients who were surgically treated for spine conditions in Enugu, Nigeria. Patient records from 2006 to 2016 were reviewed. Relevant clinical information was extracted from the operation theater logbooks and patient case files.
   RESULTS: A total of 463 spine surgical procedures were carried out on the same number of patients. The number of treated patients has been on the increase and shows a male predominance. Pediatric spine cases accounted for 1.5%, adult/middle aged patients accounted for 77.8%. Degenerative conditions, trauma, and neoplasms were the most frequent indications for operation, accounting for 52.3%, 30.5%, and 11.4%, respectively. The most commonly operated region was cervical and lumbar regions among male (49.3%) and female (51.8%) patients, respectively. Spine fixation was required in 137 patients (29.6%). A paradigm shift from trauma to degenerative conditions among patients was noted after 2010. Prior to 2009, spine wiring techniques were the most common spine stabilizing method, but from 2011 to 2013 anterior cervical discectomy and anterior cervical discectomy and fusion predominated, and thereafter pedicle screws predominated. Cost implications, lack of trained personnel, and lack of and basic equipment pose significant challenges to spine care.
   CONCLUSIONS: The trend in spinal surgery has improved rapidly and consistently in Nigeria over the 10 years of the study and is related to increasing expertise, more available facilities, and implant availability.
C1 [Chikani, Mark C.; Mesi, Mathew; Mezue, Wilfred] Univ Nigeria, Teaching Hosp, Dept Surg, Neurosurg Unit, Enugu, Nigeria.
   [Chikani, Mark C.; Okwunodulu, Okwuoma; Ohaegbulam, Samuel; Ndubuisi, Chika; Iroegbu, Linda; Nkwerem, Sunday] Memfys Hosp Neurosurg, Dept Neurosurg, Enugu, Nigeria.
RP Chikani, MC (reprint author), Univ Nigeria, Teaching Hosp, Dept Surg, Neurosurg Unit, Enugu, Nigeria.; Chikani, MC (reprint author), Memfys Hosp Neurosurg, Dept Neurosurg, Enugu, Nigeria.
EM markochikani@yahoo.com
CR Adeolu AA, 2014, NIGER J CLIN PRACT, V17, P51, DOI 10.4103/1119-3077.122838
   Aregbeshola BS, 2016, LANCET, V387, P2506, DOI 10.1016/S0140-6736(16)30798-X
   Bean JR, 2017, WORLD NEUROSURG, V101, P768, DOI 10.1016/j.wneu.2017.02.049
   Bundepuun OM, 2018, J SURG, V6, P97
   Chikani MC, 2018, J NEUROSCI RURAL PRA, V9, P137, DOI 10.4103/jnrp.jnrp_391_17
   Emejulu JKC, 2009, AFR J NEUROL SCI, V28, P11
   Ernst & Young Global Limited, GLOB AN HLTH INS SUB
   Idowu O E, 2012, Niger Med J, V53, P42, DOI 10.4103/0300-1652.99832
   Ilesanmi OS, 2014, PAN AFR MED J, V18, P1
   John J, 2018, J CLIN NEUROSCI, V51, P80, DOI 10.1016/j.jocn.2018.02.013
   Kigera JWM, 2010, E AFRICAN ORTHOP J, V4, P19
   Mooney MA, 2019, NEUROSURGERY, V84, P1280, DOI 10.1093/neuros/nyy185
   Nanda A, 2017, WORLD NEUROSURG, V101, P752, DOI 10.1016/j.wneu.2017.03.018
   Nnamdi Ibe Michael Onwuzuruike, 2013, Niger Med J, V54, P339, DOI 10.4103/0300-1652.122363
   Nwankwo OE, 2013, SPINAL CORD, V51, P448, DOI 10.1038/sc.2013.10
   Ohaegbulam Samuel C, 2018, Niger J Surg, V24, P1, DOI 10.4103/njs.NJS_12_17
   Ojo OA, 2017, NIGER J CLIN PRACT, V20, P1455, DOI 10.4103/njcp.njcp_303_16
   Otsyeno FMT, 2018, E AFRICAN ORTHOP J, V12, P46
   Park BE, 2016, WORLD NEUROSURG, V87, P417, DOI 10.1016/j.wneu.2015.11.077
   Park KB, 2016, WORLD NEUROSURG, V88, P32, DOI 10.1016/j.wneu.2015.12.048
   PharmAccess Group, 2016, CLOS LOOK HLTH SYST
   Punchak M, 2018, WORLD NEUROSURG, V112, pE240, DOI 10.1016/j.wneu.2018.01.029
   Qureshi MM, 2010, WORLD NEUROSURG, V73, P261, DOI 10.1016/j.wneu.2010.02.014
   Rabiu TB, 2016, J NEUROSCI RURAL PRA, V7, P485, DOI 10.4103/0976-3147.188624
   Solagberu Babatunde A, 2002, West Afr J Med, V21, P230
   Udoh D. O., 2012, Journal of Medicine and Biomedical Research, V11, P46
NR 26
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E815
EP E821
DI 10.1016/j.wneu.2019.06.229
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200103
PM 31295594
DA 2020-05-12
ER

PT J
AU Choi, DH
   Yoo, CJ
   Park, CW
   Kim, MJ
AF Choi, Dae Han
   Yoo, Chan Jong
   Park, Cheol Wan
   Kim, Myeong Jin
TI Practical Dose Parameter Values for the Prediction of the Adverse Effect
   of Neurointerventional Radiation: Relationship Between the Dose
   Parameters and Temporary Alopecia After Intracranial Coil Embolization
SO WORLD NEUROSURGERY
LA English
DT Article
DE Alopecia; Dose; Embolization; Fluoroscopy; Radiation
ID AREA PRODUCT; INTERVENTIONAL NEURORADIOLOGY; AIR KERMA;
   CEREBRAL-ANGIOGRAPHY; SKIN; PATIENT; EXPOSURE; FLUOROSCOPY
AB OBJECTIVE: To present values for the dose parameters predictive of alopecia as an adverse effect induced by neuroembolization using a biplane fluoroscopy.
   METHODS: This study included a total of 151 patients (52 men, mean age of 55.1 +/- 12.2 years) treated for intracranial neuroembolization between 2014 to 2018 with the following criteria: 1) obtainable dose report with digital subtraction angiographic image records, 2) no history of radiation exposure 6 months prior to the first procedure, and 3) and clinical follow-up performed through 12 months following the procedure. Patients were divided into 2 groups according to their presentation of alopecia during the follow-up period.
   RESULTS: Eighteen (11.9%) patients developed alopecia 10 to 30 days after the procedure (average: 18.5 +/- 5.3 days). Sixteen (88.9%) patients in the alopecia group were affected by projection of the A-plane fluoroscopy. Area under the receiver operating characteristic analysis curves of 0.865 (P = 0.000) and 0.831 (P = 0.000) were used to compute the optimal A-plane dose area product (255.4 Gy-cm(2); sensitivity: 0.875; specificity: 0.805; Youden J = 0.682) and cumulative dose (4437.5 mGy; sensitivity, 0.750; specificity, 0.805; Youden J = 0.556) cutoff values, respectively, capable of distinguishing patients with alopecia (n = 16) from subtotal patients (n = 149).
   CONCLUSIONS: The dose area product and the cumulative dose may be useful, intuitive factors for predicting the adverse effects of the neurointerventional radiation. Further multicenter research should be performed to confirm the efficacy and utility of the reference values of dose area product and cumulative dose for preventing excessive irradiation during neurointerventional procedures.
C1 [Choi, Dae Han; Yoo, Chan Jong; Park, Cheol Wan; Kim, Myeong Jin] Gachon Univ, Coll Med, Gil Med Ctr, Dept Neurosurg, Incheon, South Korea.
RP Kim, MJ (reprint author), Gachon Univ, Coll Med, Gil Med Ctr, Dept Neurosurg, Incheon, South Korea.
EM skymedi@gachon.ac.kr
OI Kim, Myeong Jin/0000-0001-5855-5533
CR Alexander MD, 2010, J NEUROINTERV SURG, V2, P6, DOI 10.1136/jnis.2009.000802
   Aroua A, 2007, EUR RADIOL, V17, P1621, DOI 10.1007/s00330-006-0463-3
   Bogaert E, 2009, BRIT J RADIOL, V82, P303, DOI 10.1259/bjr/29449648
   Bor D, 2004, BRIT J RADIOL, V77, P315, DOI 10.1259/bjr/29942833
   Chida K, 2006, AM J ROENTGENOL, V186, P774, DOI 10.2214/AJR.04.1653
   Chu RYL, 2006, HEALTH PHYS, V91, P41, DOI 10.1097/01.HP.0000198784.94210.1f
   Chun CW, 2014, KOREAN J RADIOL, V15, P844, DOI 10.3348/kjr.2014.15.6.844
   D'Ercole L, 2007, AM J NEURORADIOL, V28, P503
   D'Ercole L, 2012, PHYS MEDICA, V28, P61, DOI 10.1016/j.ejmp.2010.10.008
   Domienik J, 2008, RADIAT PROT DOSIM, V132, P18, DOI 10.1093/rpd/ncn247
   Fletcher DW, 2002, J VASC INTERV RADIOL, V13, P391, DOI 10.1016/S1051-0443(07)61742-4
   Hansson B, 2000, RADIAT PROT DOSIM, V90, P141, DOI 10.1093/oxfordjournals.rpd.a033104
   Ihn Yon Kwon, 2016, Neurointervention, V11, P78, DOI 10.5469/neuroint.2016.11.2.78
   Jung Yeun-Ho, 2005, [Journal of Korean Neurosurgical Society, 대한신경외과학회지], V38, P190
   Karambatsakidou A, 2005, BRIT J RADIOL, V78, P803, DOI 10.1259/bjr/14000648
   Kwon D, 2011, MED PHYS, V38, P4196, DOI 10.1118/1.3590358
   LEHERON JC, 1992, PHYS MED BIOL, V37, P2117, DOI 10.1088/0031-9155/37/11/008
   Livingstone RS, 2003, J RADIOL PROT, V23, P327, DOI 10.1088/0952-4746/23/3/308
   Magrassi L, 2012, ACTA NEUROCHIR, V154, P33, DOI 10.1007/s00701-011-1209-9
   Mahesh M, 2001, RADIOGRAPHICS, V21, P1033, DOI 10.1148/radiographics.21.4.g01jl271033
   Miller DL, 2012, J VASC INTERV RADIOL, V23, P11, DOI 10.1016/j.jvir.2011.09.004
   Neil S, 2010, J RADIOL PROT, V30, P659, DOI 10.1088/0952-4746/30/4/002
   Norbash AM, 1996, AM J NEURORADIOL, V17, P41
   Pearl MS, 2015, J NEUROINTERV SURG, V7, P141, DOI 10.1136/neurintsurg-2013-010982
   Perkins NJ, 2006, AM J EPIDEMIOL, V163, P670, DOI 10.1093/aje/kwj063
   Schneider T, 2017, J NEUROINTERV SURG, V9, P384, DOI 10.1136/neurintsurg-2015-012204
   Suzuki S, 2008, AM J NEURORADIOL, V29, P1076, DOI 10.3174/ajnr.A1045
   Suzuki S, 2006, CIRC J, V70, P44, DOI 10.1253/circj.70.44
   Tosti A, 1999, ARCH DERMATOL, V135, P1555, DOI 10.1001/archderm.135.12.1555
   Valentin J, 2000, Ann ICRP, V30, P7, DOI 10.1016/S0146-6453(00)00026-9
   Vano E, 2001, BRIT J RADIOL, V74, P48, DOI 10.1259/bjr.74.877.740048
   Yi HJ, 2017, WORLD NEUROSURG, V100, P216, DOI 10.1016/j.wneu.2017.01.004
NR 32
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E222
EP E229
DI 10.1016/j.wneu.2019.06.039
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200028
PM 31203064
DA 2020-05-12
ER

PT J
AU Dawes, BH
   Lloyd, RA
   Rogers, JM
   Magnussen, JS
   Bilston, LE
   Stoodley, MA
AF Dawes, Bryden H.
   Lloyd, Robert A.
   Rogers, Jeffrey M.
   Magnussen, John S.
   Bilston, Lynne E.
   Stoodley, Marcus A.
TI Cerebellar Tissue Strain in Chiari Malformation with Headache
SO WORLD NEUROSURGERY
LA English
DT Article
DE Balanced fast-field echo; Cerebellar tonsils; Chiari malformation; Cine
   magnetic resonance imaging; Craniocervical junction
ID COUGH-ASSOCIATED CHANGES; CEREBROSPINAL-FLUID; I MALFORMATION;
   SPINAL-CORD; BRAIN-STEM; CSF FLOW; MOTION; PRESSURE; PATHOPHYSIOLOGY;
   DYNAMICS
AB OBJECTIVE: The pathogenesis of Chiari malformation type 1 (CM-1)-associated Valsalva headache is unknown, but it may be caused by abnormal cerebellar tonsil tissue strain. Advances in cardiac-gated magnetic resonance imaging (MRI) techniques such as balanced fast-field echo (bFFE) allow quantification of the motion of anatomic structures and can be used to measure tissue strain. The current study investigated the relationship between Valsalva heachache and tonsillar motion in patients with CM-1.
   METHODS: A retrospective review of patients with CM-1 who had undergone cardiac-gated bFFE MRI was performed. Headache symptoms were retrieved from the medical records. Anatomic landmarks were manually selected on the tine bFFE, and a validated motion-tracking software was used to assess motion over the cardiac cycle in patients at rest. For each patient, displacement, strain, and strain rate were calculated for 3 anatomic segments. Patients undergoing surgery were examined before and after surgery.
   RESULTS: From 88 patients, a total of 108 bFFE sequences were analyzed. Valsalva headache was present in 50% of patients. Cerebellar tonsil displacement (P = 0.003), strain (P = 0.012), and maximum strain rate (P = 0.04) were reduced after surgery (n = 20). There was no statistically significant association between tissue motion and headache symptoms.
   CONCLUSION: The results of this study do not support a relationship between cardiac cycle cerebellar strain and Valsalva headache in patients with CM-1. It is possible that cerebellar strain related to respiratory maneuvers is associated with headache in Chiari patients. Further investigation of tissue strain is warranted because it represents a potential biomarker for outcomes after surgery.
C1 [Dawes, Bryden H.; Rogers, Jeffrey M.; Magnussen, John S.; Stoodley, Marcus A.] Macquarie Univ, Dept Clin Med, Sydney, NSW, Australia.
   [Lloyd, Robert A.; Bilston, Lynne E.] Univ New South Wales, Neurosci Res Australia, Sydney, NSW, Australia.
   [Lloyd, Robert A.; Bilston, Lynne E.] Univ New South Wales, Prince Wales Clin Sch, Sydney, NSW, Australia.
   [Rogers, Jeffrey M.] Univ Sydney, Fac Hlth Sci, Sydney, NSW, Australia.
RP Stoodley, MA (reprint author), Macquarie Univ, Dept Clin Med, Sydney, NSW, Australia.
EM marcus.stoodley@mq.edu.au
OI Rogers, Jeffrey M/0000-0002-0320-969X; Stoodley,
   Marcus/0000-0002-4207-8493; Lloyd, Robert/0000-0002-8149-7949
FU Column of Hope
FX The study was supported by a grant from the Column of Hope.
CR Alexander AL, 2011, BRAIN CONNECT, V1, P423, DOI 10.1089/brain.2011.0071
   Alperin N, 2005, J NEUROSURG, V103, P46, DOI 10.3171/jns.2005.103.1.0046
   Alperin N, 2017, J NEUROSURG-SPINE, V26, P28, DOI 10.3171/2016.5.SPINE1621
   Alperin N, 2014, NEUROSURGERY, V75, P515, DOI 10.1227/NEU.0000000000000507
   BARKOVICH AJ, 1986, AM J NEURORADIOL, V7, P795
   Bejjani G K, 2001, Neurosurg Focus, V11, pE1
   Bezuidenhout AF, 2018, AM J NEURORADIOL, V39, P1267, DOI 10.3174/ajnr.A5670
   Bhadelia RA, 2016, AM J NEURORADIOL, V37, P825, DOI 10.3174/ajnr.A4629
   Clarke EC, 2013, J BIOMECH, V46, P1801, DOI 10.1016/j.jbiomech.2013.05.013
   Clarke EC, 2013, J NEUROSURG, V118, P1135, DOI 10.3171/2013.2.JNS12759
   Cousins J, 2009, AM J NEURORADIOL, V30, P1587, DOI 10.3174/ajnr.A1507
   EDMEADS J, 1988, NEUROLOGY, V38, P1874, DOI 10.1212/WNL.38.12.1874
   ELSTER AD, 1992, RADIOLOGY, V183, P347, DOI 10.1148/radiology.183.2.1561334
   Eshetu T, 2014, DEV MED CHILD NEUROL, V56, P742, DOI 10.1111/dmcn.12494
   Hofmann E, 2000, AM J NEURORADIOL, V21, P151
   JOKICH PM, 1984, J NEUROSURG, V60, P707, DOI 10.3171/jns.1984.60.4.0707
   Krishna V, 2016, J NEUROSURG, V125, P1112, DOI 10.3171/2015.9.JNS151196
   Kumar M, 2011, WORLD NEUROSURG, V76, P189, DOI 10.1016/j.wneu.2011.02.022
   Kurtcan S, 2018, ACTA NEUROL BELG, V118, P39, DOI 10.1007/s13760-017-0792-9
   Lawrence BJ, 2018, WORLD NEUROSURG, V116, pE298, DOI 10.1016/j.wneu.2018.04.191
   Leung V, 2016, J NEUROSURG-SPINE, V24, P546, DOI 10.3171/2015.8.SPINE15325
   Li AE, 2015, CLIN NEURORADIOL, V25, P349, DOI 10.1007/s00062-015-0383-1
   Lin M, 2016, MAGN RESON MED, V76, P290, DOI 10.1002/mrm.25816
   Lloyd RA, 2017, J BIOMECH, V65, P185, DOI 10.1016/j.jbiomech.2017.10.007
   Meadows J, 2000, J NEUROSURG, V92, P920, DOI 10.3171/jns.2000.92.6.0920
   Milhorat TH, 1999, NEUROSURGERY, V44, P1005, DOI 10.1097/00006123-199905000-00042
   OLDFIELD EH, 1994, J NEUROSURG, V80, P3, DOI 10.3171/jns.1994.80.1.0003
   Oshinski J, 2018, MOTION CEREBELLUM PA
   Pahlavian SH, 2018, J BIOMECH ENG-T ASME, V140, DOI 10.1115/1.4040227
   Pahlavian SH, 2015, ANN BIOMED ENG, V43, P2911, DOI 10.1007/s10439-015-1355-y
   PASCUAL J, 1992, NEUROLOGY, V42, P1519, DOI 10.1212/WNL.42.8.1519
   PUJOL J, 1995, NEUROLOGY, V45, P1746, DOI 10.1212/WNL.45.9.1746
   Radmanesh A, 2015, NEURORADIOLOGY, V57, P387, DOI 10.1007/s00234-014-1481-5
   Sansur CA, 2003, J NEUROSURG, V98, P453, DOI 10.3171/jns.2003.98.3.0453
   Sekula Jr. R.F., 2005, CEREBROSPINAL FLUID, V2, P11, DOI [DOI 10.1186/1743-8454-2-11, 10.1186/1743-8454-2-11]
   Sharma A, 2012, NEURORADIOLOGY, V54, P133, DOI 10.1007/s00234-011-0861-3
   Smith BW, 2013, J NEUROSURG, V119, P812, DOI 10.3171/2013.5.JNS121825
   STEVENS JM, 1993, J NEUROL NEUROSUR PS, V56, P1072, DOI 10.1136/jnnp.56.10.1072
   STOVNER LJ, 1993, HEADACHE, V33, P175, DOI 10.1111/j.1526-4610.1993.hed33040175.x
   WILLIAMS B, 1980, ARCH NEUROL-CHICAGO, V37, P226, DOI 10.1001/archneur.1980.00500530064010
   WILLIAMS B, 1981, ACTA NEUROCHIR, V59, P123, DOI 10.1007/BF01411198
   Yiallourou TI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052284
NR 42
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E74
EP E81
DI 10.1016/j.wneu.2019.05.211
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200010
PM 31158545
DA 2020-05-12
ER

PT J
AU Dong, JW
   Meng, XQ
   Li, SY
   Chen, Q
   Shi, L
   Jiang, CL
   Cai, JQ
AF Dong, Jiawei
   Meng, Xiangqi
   Li, Siyi
   Chen, Qun
   Shi, Lei
   Jiang, Chuanlu
   Cai, Jinquan
TI Risk of Adverse Vascular Events in Patients with Malignant Glioma
   Treated with Bevacizumab Plus Irinotecan: A Systematic Review and
   Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Adverse vascular events; Bevacizumab; Irinotecan; Malignant glioma
ID NEWLY-DIAGNOSED GLIOBLASTOMA; TEMOZOLOMIDE; RECURRENT; TRIAL; BRAIN;
   GRADE; HYPERTENSION; RADIOTHERAPY; CONCOMITANT; THERAPY
AB BACKGROUND: Bevacizumab plus irinotecan is a new beneficial chemotherapy strategy for patients with malignant glioma. The purpose of this systematic review and meta-analysis was to comprehensively assess the risk of adverse vascular events in adults with malignant glioma treated with bevacizumab plus irinotecan.
   METHODS: The Cochrane Library, Embase and PubMed were searched, and relevant trials were identified up to June 2018. Two investigators screened all titles and abstracts for possible inclusion and extracted data independently. Six studies were included, and 5 of them in the control group using bevacizumab alone or bevacizumab with temozolomide. Three systems were used to assess the quality of evidence and the level of recommendation. The Oxford Centre for Evidence-Based Medicine Levels of Evidence (2009) system was used to classify the evidence into 5 levels (classes I-V). The star system from the Newcastle-Ottawa Scale was used to assess methodological quality. The GRADE profiler was used to evaluate the overall body of evidence.
   RESULTS: Our data show that bevacizumab plus irinotecan therapy does not significantly affect the risk of systemic adverse events (odds ratio [OR] 1.17; 95% confidence interval [CI], 0.43-3.18). Patients treated with bevacizumab plus irinotecan had a similar risk of hematotoxicity (OR, 1.06; 95% CI, 0.26-4.38), thrombocytopenia (OR, 1.07; 95% CI, 0.25-4.63), and hypertension (OR, 1.34; 95% CI, 0.28-6.36) compared with the control group (those treated without irinotecan). Thrombosis occurred more frequently in patients treated with bevacizumab plus irinotecan compared with the control group (OR, 3.23; 95% CI, 1.47-7.12).
   CONCLUSIONS: The risk of systemic adverse events was not significantly different between patients with malignant glioma treated with bevacizumab plus irinotecan and the control group. The risks of hematotoxicity, thrombocytopenia, and hypertension were similar in the 2 groups. The risk of thrombosis was higher in patients treated with bevacizumab plus irinotecan. Monitoring for thrombosis and administering anticoagulant therapy as necessary merit promotion for patients with malignant glioma receiving treatment with bevacizumab plus irinotecan.
C1 [Dong, Jiawei; Meng, Xiangqi; Jiang, Chuanlu; Cai, Jinquan] Harbin Med Univ, Affiliated Hosp 2, Heilongjiang Acad Med Sci, Dept Neurosurg,Neurosci Inst, Harbin, Heilongjiang, Peoples R China.
   [Li, Siyi] McGill Univ, Dept Min & Mat Engn, Montreal, PQ, Canada.
   [Chen, Qun] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Neurosurg, Hangzhou, Zhejiang, Peoples R China.
   [Shi, Lei] Harbin Med Univ, Sch Publ Hlth, Dept Hlth Management, Harbin, Heilongjiang, Peoples R China.
RP Cai, JQ (reprint author), Harbin Med Univ, Affiliated Hosp 2, Heilongjiang Acad Med Sci, Dept Neurosurg,Neurosci Inst, Harbin, Heilongjiang, Peoples R China.
EM caijinquan666777@126.com
OI Shi, Lei/0000-0002-8924-0734
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81702972, 81874204, 81572701, 81772666]; China
   Postdoctoral Science FoundationChina Postdoctoral Science Foundation
   [2018M640305]; Heilongjiang Postdoctoral Science Foundation [LBH-Z18103]
FX This study was supported by the National Natural Science Foundation of
   China (No. 81702972, No. 81874204, No. 81572701, and No. 81772666), the
   China Postdoctoral Science Foundation (2018M640305), and the
   Heilongjiang Postdoctoral Science Foundation (LBH-Z18103).
CR Ameratunga M, 2018, COCHRANE DB SYST REV, V11
   Bhandari M, 2017, J CLIN DIAGN RES, V11, DOI 10.7860/JCDR/2017/27611.9945
   Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12
   Buckner JC, 2003, SEMIN ONCOL, V30, P10, DOI 10.1053/j.seminoncol.2003.11.031
   Chen Q, 2019, INT J CANCER, V145, P517, DOI 10.1002/ijc.32102
   Chinot OL, 2011, ADV THER, V28, P334, DOI 10.1007/s12325-011-0007-3
   Cohen MH, 2009, ONCOLOGIST, V14, P1131, DOI 10.1634/theoncologist.2009-0121
   DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Friedman HS, 2009, J CLIN ONCOL, V27, P4733, DOI 10.1200/JCO.2008.19.8721
   Furuta T, 2014, BRAIN TUMOR PATHOL, V31, P32, DOI 10.1007/s10014-013-0142-4
   Gallego O, 2015, CURR ONCOL, V22, pE273, DOI 10.3747/co.22.2436
   Gatson NN, 2012, NEUROSCI LETT, V527, P62, DOI 10.1016/j.neulet.2012.08.001
   Gilbert MR, 2017, J NEURO-ONCOL, V131, P193, DOI 10.1007/s11060-016-2288-5
   Gilbert MR, 2013, J CLIN ONCOL, V31, P4085, DOI 10.1200/JCO.2013.49.6968
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Han B, 2018, CANCER LETT, V419, P280, DOI 10.1016/j.canlet.2018.01.056
   Herrlinger U, 2016, J CLIN ONCOL, V34, P1611, DOI 10.1200/JCO.2015.63.4691
   Higgins J, 2011, COCHRANE COLLAB, V5, P1, DOI DOI 10.1002/9780470712184
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hofland KF, 2014, ACTA ONCOL, V53, P939, DOI 10.3109/0284186X.2013.879607
   Erices JI, 2018, PHYTOTHER RES, V32, P2191, DOI 10.1002/ptr.6170
   Iwamoto FM, 2010, ARCH NEUROL-CHICAGO, V67, P285, DOI 10.1001/archneurol.2010.11
   Jeck J, 2018, THER ADV NEUROL DISO, V11, DOI 10.1177/1756285617753597
   Jhaveri N, 2016, CANCER LETT, V380, P545, DOI 10.1016/j.canlet.2014.12.028
   Jiang JJ, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2912-z
   Jiang T, 2016, CANCER LETT, V375, P263, DOI 10.1016/j.canlet.2016.01.024
   Leal T, 2010, CANCER CHEMOTH PHARM, V65, P399, DOI 10.1007/s00280-009-1118-2
   Li XB, 2015, SCI REP-UK, V5, DOI 10.1038/srep10848
   Lin L, 2017, CURR MED CHEM, V24, P1365, DOI 10.2174/0929867323666161223150242
   Martin RCG, 2015, CANCER-AM CANCER SOC, V121, P3649, DOI 10.1002/cncr.29534
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Morris SB, 2002, PSYCHOL METHODS, V7, P105, DOI 10.1037//1082-989X.7.1.105
   Niewald M, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-141
   Oki E, 2018, CLIN COLORECTAL CANC, V17, P147, DOI 10.1016/j.clcc.2018.01.011
   Ostrom QT, 2013, NEURO-ONCOLOGY, V15, P1, DOI 10.1093/neuonc/not151
   Perry JR, 2012, NEURO-ONCOLOGY, V14, P73, DOI 10.1093/neuonc/nos197
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Peters KB, 2015, ONCOLOGIST, V20, P727, DOI 10.1634/theoncologist.2015-0135
   Platten M, 2001, MICROSC RES TECHNIQ, V52, P401, DOI 10.1002/1097-0029(20010215)52:4<401::AID-JEMT1025>3.0.CO;2-C
   Prados MD, 2006, NEURO-ONCOLOGY, V8, P189, DOI 10.1215/15228517-2005-010
   Ranpura V, 2011, JAMA-J AM MED ASSOC, V305, P487, DOI 10.1001/jama.2011.51
   Reardon David A, 2003, Oncology (Williston Park), V17, P9
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Scholz A, 2016, EMBO MOL MED, V8, P39, DOI 10.15252/emmm.201505505
   Seystahl K, 2013, EUR NEUROL, V69, P95, DOI 10.1159/000343811
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Syrigos KN, 2011, BIODRUGS, V25, P159, DOI 10.2165/11590180-000000000-00000
   Takano S, 2010, J NEURO-ONCOL, V99, P177, DOI 10.1007/s11060-010-0118-8
   Tanaka H, 2018, BIOL PHARM BULL, V41, P644, DOI 10.1248/bpb.b17-00605
   Turkowski K, 2018, GLIA, V66, P161, DOI 10.1002/glia.23234
   Ullrich RT, 2009, J NUCL MED, V50, P1962, DOI 10.2967/jnumed.109.065904
   Ursu R, 2017, EUR J CANCER, V73, P30, DOI 10.1016/j.ejca.2016.12.003
   von Baumgarten L, 2011, CLIN CANCER RES, V17, P6192, DOI 10.1158/1078-0432.CCR-10-1868
   Vredenburgh JJ, 2007, J CLIN ONCOL, V25, P4722, DOI 10.1200/JCO.2007.12.2440
   Wick W, 2018, THER ADV NEUROL DISO, V11, DOI 10.1177/1756286418790452
   Wick W, 2016, NEURO-ONCOLOGY, V18, P315, DOI 10.1093/neuonc/nov180
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
NR 58
TC 2
Z9 2
U1 6
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E236
EP E243
DI 10.1016/j.wneu.2019.06.043
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200030
PM 31203059
DA 2020-05-12
ER

PT J
AU Donnally, CJ
   Sheu, JI
   Bondar, KJ
   Mouhanna, JN
   Li, DJ
   Butler, AJ
   Rush, AJ
   Gjolaj, JP
AF Donnally, Chester J., III
   Sheu, Jonathan I.
   Bondar, Kevin J.
   Mouhanna, Joelle N.
   Li, Deborah J.
   Butler, Alexander J.
   Rush, Augustus J., III
   Gjolaj, Joseph P.
TI Is There a Correlation Between Preoperative or Postoperative Vitamin D
   Levels with Pseudarthrosis, Hardware Failure, and Revisions After Lumbar
   Spine Fusion?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hardware failure; Outcomes; Pseudoarthrosis; Spine fusion; Spine
   surgery; Vitamin D
ID CERVICAL PLATE FIXATION; SCREW PULLOUT STRENGTH; HYPOVITAMINOSIS D; D
   DEFICIENCY; RISK-FACTORS; BONE LOSS; SURGERY; PREVALENCE;
   INSTRUMENTATION; OSTEOPOROSIS
AB BACKGROUND: Vitamin D deficiency is a well-known cause of postoperative complications in patients undergoing orthopedic surgery. Orthopedic complications seen in vitamin D deficiency include nonunion, pseudarthrosis, and hardware failure. We seek to investigate the relationship between vitamin D deficiency and outcomes after lumbar spinal fusions.
   METHODS: A retrospective patient chart review was conducted at a single center for all patients who underwent lumbar spinal fusions from January 2015 to September 2017 with preoperative or postoperative vitamin D laboratory values. We recorded demographics, social history, medications, pre-existing medical conditions, bone density (dual-energy x-ray absorptiometry) T-scores, procedural details, 1-year postoperative Visual Analog Score (VAS), documented pseudarthrosis, revisions, and hardware failure. A total of 150 patients were initially included in the cohort for analysis.
   RESULTS: Overall, preoperative and postoperative vitamin D levels were not significantly associated with a vast majority of the patient characteristics studied, including comorbidities, medications, or surgical diagnoses (P> 0.05). Age at surgery was significantly associated with vitamin D levels; older patients had higher serum levels of vitamin D both preoperatively (P = 0.03) and postoperatively (P = 0.01). Those with a higher average body mass index had lower vitamin D in both groups (P = 0.02). Vitamin D levels were not significantly associated with rates of postoperative pseudarthrosis, revision, or hardware complications (P> 0.05). VAS pain score at 1 year and smoking status preoperatively or postoperatively were not associated with vitamin D levels (P> 0.05).
   CONCLUSIONS: Both preoperative and postoperative vitamin D levels were not significantly associated with an increased or decreased risk of pseudarthrosis, revision surgery, hardware failure, or 1-year VAS pain score after lumbar spine fusion surgery.
C1 [Donnally, Chester J., III; Butler, Alexander J.; Rush, Augustus J., III; Gjolaj, Joseph P.] Univ Miami Hosp, Dept Orthoped Surg, Miami, FL 33136 USA.
   [Sheu, Jonathan I.; Bondar, Kevin J.; Mouhanna, Joelle N.; Li, Deborah J.] Univ Miami, Dept Educ, Leonard M Miller Sch Med, Miami, FL USA.
RP Donnally, CJ (reprint author), Univ Miami Hosp, Dept Orthoped Surg, Miami, FL 33136 USA.
EM Chester.Donnally@jhsmiami.org
OI Donnally III, Chester/0000-0002-1701-0745; Butler,
   Alexander/0000-0003-4135-7391
CR Amankulor NM, 2014, SPINE J, V14, P1850, DOI 10.1016/j.spinee.2013.10.028
   Aydogan Nevres Hurriyet, 2016, J Clin Orthop Trauma, V7, P90, DOI 10.1016/j.jcot.2016.01.003
   Bee CR, 2013, J ORTHOP TRAUMA, V27, pE103, DOI 10.1097/BOT.0b013e31825cf8fb
   Bogunovic L, 2010, J BONE JOINT SURG AM, V92A, P2300, DOI 10.2106/JBJS.I.01231
   Bouquegneau A, 2016, CLIN J AM SOC NEPHRO, V11, P1282, DOI 10.2215/CJN.11371015
   Chun DS, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS15292
   Cohen A, 2004, J BONE MINER RES, V19, P1919, DOI 10.1359/JBMR.040912
   DiPaola CP, 2008, J AM ACAD ORTHOP SUR, V16, P130, DOI 10.5435/00124635-200803000-00004
   Dvorak MF, 2005, SPINE, V30, P294, DOI 10.1097/01.brs.0000152154.57171.92
   Etebar S, 1999, J NEUROSURG, V90, P163, DOI 10.3171/spi.1999.90.2.0163
   Freedman BA, 2007, CLIN ORTHOP RELAT R, P202, DOI 10.1097/01.blo.0000238866.15228.c4
   Gorter E A, 2017, J Clin Orthop Trauma, V8, P34, DOI 10.1016/j.jcot.2016.09.003
   Hegde V, 2018, ORTHOPEDICS, V41, pE489, DOI 10.3928/01477447-20180424-04
   Kerezoudis P, 2016, WORLD NEUROSURG, V95, P71, DOI 10.1016/j.wneu.2016.07.074
   KING D, 1948, J BONE JOINT SURG AM, V30-A, P560, DOI 10.2106/00004623-194830030-00003
   Kocjan T, 2006, INT J VITAM NUTR RES, V76, P307, DOI 10.1024/0300-9831.76.5.307
   Lee HJ, 2013, J HAND SURG-AM, V38A, P519, DOI 10.1016/j.jhsa.2012.12.002
   Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477
   Lips P, 2011, BEST PRACT RES CL EN, V25, P585, DOI 10.1016/j.beem.2011.05.002
   Lowery GL, 1998, SPINE, V23, P181, DOI 10.1097/00007632-199801150-00006
   MACLAUGHLIN J, 1985, J CLIN INVEST, V76, P1536, DOI 10.1172/JCI112134
   Maier GS, 2015, BONE JOINT J, V97B, P89, DOI 10.1302/0301-620X.97B1.34558
   Moore KR, 2017, J FOOT ANKLE SURG, V56, P457, DOI 10.1053/j.jfas.2017.01.011
   Oh JH, 2009, J BONE JOINT SURG BR, V91B, P1587, DOI 10.1302/0301-620X.91B12.22481
   Patton CM, 2012, J AM ACAD ORTHOP SUR, V20, P123, DOI 10.5435/JAAOS-20-03-123
   Raizman NM, 2009, J AM ACAD ORTHOP SUR, V17, P494, DOI 10.5435/00124635-200908000-00003
   Ravindra VM, 2015, SPINE, V40, P1536, DOI 10.1097/BRS.0000000000001041
   Reitman CA, 2004, J SPINAL DISORD TECH, V17, P306, DOI 10.1097/01.bsd.0000090575.08296.9d
   Seller K, 2007, EUR SPINE J, V16, P1047, DOI 10.1007/s00586-007-0307-0
   Sprague S, 2016, J ORTHOP TRAUMA, V30, P53, DOI 10.1097/BOT.0000000000000455
   von Domarus C, 2011, CLIN ORTHOP RELAT R, V469, P3127, DOI 10.1007/s11999-011-1880-4
   Wat WZM, 2007, ANN NUTR METAB, V51, P59, DOI 10.1159/000100822
   Wetzel FT, 1999, SPINE, V24, P1138, DOI 10.1097/00007632-199906010-00014
   YAMAGATA M, 1992, SPINE, V17, pS51
   Zafeiris CP, 2012, SPINE J, V12, P304, DOI 10.1016/j.spinee.2012.02.016
   ZDEBLICK TA, 1993, SPINE, V18, P1673, DOI 10.1097/00007632-199309000-00016
NR 36
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E431
EP E437
DI 10.1016/j.wneu.2019.06.109
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200053
PM 31238168
DA 2020-05-12
ER

PT J
AU dos Santos, AG
   Solla, DJF
   Moscardi, R
   Neville, IS
   Weltman, E
   Teixeira, MJ
   Paiva, WS
AF dos Santos, Alexandra Gomes
   Solla, Davi J. Fontoura
   Moscardi, Ricardo
   Neville, Iuri Santana
   Weltman, Eduardo
   Teixeira, Manoel Jacobsen
   Paiva, Wellingson Silva
TI Adjuvant Radiotherapy Did Not Reduce Recurrence of World Health
   Organization Grade I Meningiomas with Venous Sinus Involvement: A
   Propensity Score Adjusted Analysis and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Central nervous system neoplasm; Meningioma; Radiation therapy;
   Recurrence
ID INTRACRANIAL MENINGIOMAS; RADIATION-THERAPY; IRRADIATION; MANAGEMENT;
   SURGERY
AB BACKGROUND: Most meningiomas are classified as World Health Organization (WHO) grade I. Adjuvant radiation therapy (RT) is commonly recommended for subtotal resections with documented progressive regrowth of lesions with venous sinus involvement. We investigated if recurrence of WHO grade I meningiomas was influenced by adjuvant RT.
   METHODS: From 2000 to 2014, patients with grade I meningiomas with at least one venous sinus involvement and at least 4 years of follow-up were included. Demographics, venous sinus involvement, histology, and extent of resection (EOR) were characterized. Because patients undergoing RT tend to differ from those for whom adjuvant therapy was not prescribed, we used propensity scores to adjust for confounding variables.
   RESULTS: Sixty-two patients were included; of these, 18 (29.0%) had recurrences. The mean age was 52.8 +/- 12.3 years, and 79.0% were women. A total of 34 cases (54.8%) were submitted to adjuvant RT. Adjuvant RT was more frequent in those who had tumor recurrence (77.8% vs. 45.5%, P = 0.020). RT was more frequent in superior sagittal sinus (SSS) invasion (76.5% vs. 50.0%, P = 0.030) and less prevalent after gross total resection (GTR) (32.4% vs. 67.9%, P = 0.005). Propensity score adjusted analysis suggested no adjuvant RT benefit (odds ratio [OR], 2.51; 95% confidence interval [CI], 0.68-9.28; P = 0.167), independent of the EOR. SSS involvement increased recurrence risk (OR, 12.69; 95% CI, 1.46-110.27; P = 0.021), whereas GTR tended to decrease it (OR, 0.26; 95% CI, 0.06-1.09; P = 0.065).
   CONCLUSIONS: Adjuvant RT does not seem to be a pivotal criterion to reduce the recurrence rate in patients with grade I meningioma, even when venous sinuses are involved.
C1 [Solla, Davi J. Fontoura; Moscardi, Ricardo; Neville, Iuri Santana; Teixeira, Manoel Jacobsen; Paiva, Wellingson Silva] Hosp Clin HCFMUSP, Div Neurosurg, Sao Paulo, Brazil.
   [Neville, Iuri Santana] Inst Canc Sao Paulo, Sao Paulo, Brazil.
   [Weltman, Eduardo] Discipline Radiat Oncol, Sao Paulo, Brazil.
   [dos Santos, Alexandra Gomes; Weltman, Eduardo; Teixeira, Manoel Jacobsen] Univ Sao Paulo, Med Sch, Sao Paulo, Brazil.
   [Weltman, Eduardo] Hosp Israelita Albert Einstein, Dept Radiat Oncol, Sao Paulo, Brazil.
RP dos Santos, AG (reprint author), Univ Sao Paulo, Med Sch, Sao Paulo, Brazil.
EM alexandra.santos@usp.br
CR ADEGBITE AB, 1983, J NEUROSURG, V58, P51, DOI 10.3171/jns.1983.58.1.0051
   ARMSTRONG C, 1995, J CLIN ONCOL, V13, P2263, DOI 10.1200/JCO.1995.13.9.2263
   Armstrong CL, 2000, NEUROPSY NEUROPSY BE, V13, P101
   BARBARO NM, 1987, NEUROSURGERY, V20, P525, DOI 10.1227/00006123-198704000-00003
   CARELLA RJ, 1982, NEUROSURGERY, V10, P332, DOI 10.1227/00006123-198203000-00006
   CHAN RC, 1984, J NEUROSURG, V60, P52, DOI 10.3171/jns.1984.60.1.0052
   Cheung VLS, 2018, J NEURO-ONCOL, V136, P351, DOI 10.1007/s11060-017-2659-6
   Condra KS, 1997, INT J RADIAT ONCOL, V39, P427, DOI 10.1016/S0360-3016(97)00317-9
   Fathi AR, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0337-4
   Jereczek-Fossa BA, 2003, CANCER TREAT REV, V29, P417, DOI 10.1016/S0305-7372(03)00066-5
   Kondziolka D, 2009, NEUROSURGERY, V64, P463, DOI 10.1227/01.NEU.0000336765.85922.D9
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Maclean J, 2014, CLIN ONCOL-UK, V26, P51, DOI 10.1016/j.clon.2013.10.001
   MIRALBELL R, 1992, J NEURO-ONCOL, V13, P157, DOI 10.1007/BF00172765
   Ohba S, 2011, J NEUROSURG, V114, P1278, DOI 10.3171/2010.11.JNS10701
   Ostrom QT, 2018, NEURO-ONCOLOGY, V20, P1, DOI 10.1093/neuonc/noy131
   Peele KA, 1996, OPHTHALMOLOGY, V103, P1761, DOI 10.1016/S0161-6420(96)30430-2
   Pessina F, 2019, WORLD NEUROSURG, V123, pE273, DOI 10.1016/j.wneu.2018.11.150
   Pourel N, 2001, RADIOTHER ONCOL, V61, P65, DOI 10.1016/S0167-8140(01)00391-7
   ROGERS L, 2007, [No title captured], V23, pE4, DOI DOI 10.3171/FOC-07/10/E4
   Ruben JD, 2006, INT J RADIAT ONCOL, V65, P499, DOI 10.1016/j.ijrobp.2005.12.002
   Sainani KL, 2012, PM&R, V4, P693, DOI 10.1016/j.pmrj.2012.07.002
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   Soyuer S, 2004, RADIOTHER ONCOL, V71, P85, DOI 10.1016/j.radonc.2004.01.006
   TAYLOR BW, 1988, INT J RADIAT ONCOL, V15, P299, DOI 10.1016/S0360-3016(98)90008-6
   Winther TL, 2017, WORLD NEUROSURG, V99, P104, DOI 10.1016/j.wneu.2016.11.034
NR 26
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E1015
EP E1019
DI 10.1016/j.wneu.2019.07.068
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200125
PM 31306847
DA 2020-05-12
ER

PT J
AU Erwood, MS
   Walters, BC
   Connolly, TM
   Carroll, WR
   Trahan, DV
   Graves, AW
   Agee, BS
   Hadley, MN
AF Erwood, Matthew S.
   Walters, Beverly C.
   Connolly, Timothy M.
   Carroll, William R.
   Trahan, Duane V.
   Graves, Abby W.
   Agee, Bonita S.
   Hadley, Mark N.
TI Assessment of the Reliability of the Fiberoptic Endoscopic Evaluation of
   Swallowing as an Outcome Measure in Patients Undergoing Revision
   Anterior Cervical Discectomy and Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dysphagia; Fiberoptic endoscopic evaluation of swallowing; Reliability;
   Reoperative ACDF surgery
ID PENETRATION-ASPIRATION SCALE; LARYNGEAL NERVE INJURY; NECK-CANCER;
   DYSPHAGIA; AGREEMENT; HEAD; STATISTICS; VALIDATION; SURGERY; KAPPA
AB BACKGROUND: Dysphagia is one of the most common complications of anterior cervical spine surgery, and there is a need to establish that the means of testing for it are reliable and valid. The objective of this study was to measure observer variability of the fiberoptic endoscopic evaluation of swallowing (FEES) test, specifically when used for evaluation of dysphagia in patients undergoing revisionary anterior cervical decompression and fusion (ACDF).
   METHODS: Images from patients undergoing revision ACDF at a single institution were collected from May 1, 2010, through July 1, 2014. Two senior certified speech pathologists independently evaluated the swallowing function of patients preoperatively and at 2 weeks postoperatively. Their numeric evaluations of the Rosenbeck Penetration-Aspiration Scale and the Swallowing Performance Scale during the FEES were then compared for interrater reliability.
   RESULTS: Positive agreement between raters was 94% for the preoperative Penetration-Aspiration Scale (prevalence-adjusted bias-adjusted kappa, 0.77). The postoperative Penetration-Aspiration Scale showed reliability coefficients for kappa, Kendall's W, and intraclass correlation coefficient (ICC) of 0.34 (fair agreement), 0.70 (extremely strong agreement), and 0.35 (poor agreement), respectively. The preoperative Swallowing Performance Scale showed strong agreement, with a Kendall's W coefficient of 0.68, and fair reliability, with an ICC of 0.40. The postoperative Swallowing Performance Scale indicated extremely strong agreement between raters, with a Kendall's W of 0.82, and good agreement, with an ICC of 0.53.
   CONCLUSIONS: The FEES test appears to be a reliable assessor of dysphagia in patients undergoing ACDF and may be a useful measure for exploring outcomes in this population.
C1 [Erwood, Matthew S.; Walters, Beverly C.; Agee, Bonita S.; Hadley, Mark N.] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35294 USA.
   [Carroll, William R.] Univ Alabama Birmingham, Dept Surg, Div Otolaryngol, Birmingham, AL 35294 USA.
   [Trahan, Duane V.; Graves, Abby W.] Univ Alabama Birmingham, Dept Speech Pathol, Birmingham, AL USA.
   [Connolly, Timothy M.] Univ Hosp Geelong, Dept Surg, Geelong, Vic, Australia.
RP Erwood, MS (reprint author), Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35294 USA.
EM merwood@uabmc.edu
CR Bader CA, 2008, HNO, V56, P397, DOI 10.1007/s00106-007-1625-6
   Beutler WJ, 2001, SPINE, V26, P1337, DOI 10.1097/00007632-200106150-00014
   Butler SG, 2015, ANN OTO RHINOL LARYN, V124, P480, DOI 10.1177/0003489414566267
   BYRT T, 1993, J CLIN EPIDEMIOL, V46, P423, DOI 10.1016/0895-4356(93)90018-V
   Carlsson S, 2012, DYSPHAGIA, V27, P361, DOI 10.1007/s00455-011-9375-8
   Chen AY, 2001, ARCH OTOLARYNGOL, V127, P870
   Chen B, 2005, P 30 SAS US GROUP IN
   Cho SK, 2013, BONE JOINT J, V95B, P868, DOI 10.1302/0301-620X.95B7.31029
   Chotai S, 2015, NEUROSURGERY, V77, P157, DOI 10.1227/NEU.0000000000000768
   Erwood MS, 2018, J NEUROSURG-SPINE, V28, P140, DOI 10.3171/2017.5.SPINE161104
   Erwood MS, 2016, J NEUROSURG-SPINE, V25, P198, DOI 10.3171/2015.9.SPINE15187
   Fattori B, 2017, AURIS NASUS LARYNX, V44, P306, DOI 10.1016/j.anl.2016.07.002
   FEINSTEIN AR, 1990, J CLIN EPIDEMIOL, V43, P543, DOI 10.1016/0895-4356(90)90158-L
   Gerek Mustafa, 2005, Kulak Burun Bogaz Ihtis Derg, V15, P103
   Hey C, 2014, HNO, V62, P276, DOI 10.1007/s00106-013-2815-z
   Hey C, 2015, DYSPHAGIA, V30, P418, DOI 10.1007/s00455-015-9616-3
   Hiss SG, 2003, LARYNGOSCOPE, V113, P1386, DOI 10.1097/00005537-200308000-00023
   Karanicolas PJ, 2009, J BONE JOINT SURG AM, V91A, P99, DOI 10.2106/JBJS.H.01624
   Kendall M.G., 1990, RANK CORRELATION MET
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Leder SB, 1999, J HEAD TRAUMA REHAB, V14, P448, DOI 10.1097/00001199-199910000-00005
   Leder SB, 2000, LARYNGOSCOPE, V110, P1132, DOI 10.1097/00005537-200007000-00012
   Leder SB, 1998, ARCH PHYS MED REHAB, V79, P1264, DOI 10.1016/S0003-9993(98)90273-8
   McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.1.30
   McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031
   Mukherjee R, 2014, HNO, V62, P575, DOI 10.1007/s00106-014-2877-6
   Nienstedt JC, 2017, DYSPHAGIA, V32, P443, DOI 10.1007/s00455-017-9784-4
   Paniello RC, 2008, ANN OTO RHINOL LARYN, V117, P594, DOI 10.1177/000348940811700808
   Robbins J, 1999, DYSPHAGIA, V14, P228, DOI 10.1007/PL00009610
   Rosenbek JC, 1996, DYSPHAGIA, V11, P93, DOI 10.1007/BF00417897
   Salama JK, 2008, ARCH OTOLARYNGOL, V134, P1060, DOI 10.1001/archotol.134.10.1060
   Schindler A, 2008, Rev Laryngol Otol Rhinol (Bord), V129, P97
   SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420
   Stenson KM, 2000, ARCH OTOLARYNGOL, V126, P371, DOI 10.1001/archotol.126.3.371
   ten Cate DF, 2010, ARTHRIT CARE RES, V62, P1357, DOI 10.1002/acr.20255
   Thomas RL, 2015, PEDIATR RADIOL, V45, P146, DOI 10.1007/s00247-014-2882-7
   Walter SD, 1998, STAT MED, V17, P101, DOI 10.1002/(SICI)1097-0258(19980115)17:1<101::AID-SIM727>3.3.CO;2-5
   Zidan M, 2015, PEDIATR RADIOL, V45, P317, DOI 10.1007/s00247-014-2944-x
NR 38
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E199
EP E205
DI 10.1016/j.wneu.2019.06.028
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200025
PM 31203083
DA 2020-05-12
ER

PT J
AU Faheem, N
   Gattozzi, DA
   Madarang, EJ
   Camarata, PJ
   Gronseth, GS
AF Faheem, Nida
   Gattozzi, Domenico A.
   Madarang, Ernest J.
   Camarata, Paul J.
   Gronseth, Gary S.
TI Case-Control Study of Cephalometrics in Patients with Moyamoya
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid canal; Cephalometric; Ischemic stroke; Moyamoya; Skull
ID DOWN-SYNDROME; DISEASE; MORPHOLOGY; HEMODYNAMICS; BASE
AB OBJECTIVE: To determine whether cranial metrics consistently differed between patients with moyamoya and age-, sex-, and race-matched controls.
   METHODS: Patients diagnosed with moyamoya disease by cerebral angiogram were obtained from a prospectively collected database through the Department of Neurosurgery at the University of Kansas Medical Center. Control patients matched by decade of age, sex, and race were collected through a deidentified hospital database by International Classification of Diseases-9 and 10 codes for ischemic stroke to identify patients with computed tomography angiograms. Imaging studies for both groups were analyzed to obtain 6 skull metrics: maximum anterior to posterior distance, maximum biparietal distance, bregma to occiput distance, right carotid canal diameter (CCD), left CCD, and cephalic index.
   RESULTS: Forty-five patients were identified in each cohort. Measurements of mean anterior to posterior skull diameter, mean biparietal skull diameter, bregma to occiput distances, and calculated cephalic index did not demonstrate a statistically significant difference between patients with moyamoya and control patients. Right carotid canal mean diameter was 4.8 mm for the moyamoya group and 5.4 mm for the control group, with a significant raw mean difference of -0.61 mm (95% confidence interval, -0.95 to -0.27). Left CCD was 4.7 mm for the moyamoya group and 5.5 mm for the control group, resulting in a significant raw mean difference of -0.76 mm (95% confidence interval, -1.09 to -0.43).
   CONCLUSIONS: This study identified 2 skull parameters as statistically different in patients with moyamoya compared with a matched control group of patients with ischemic stroke: right CCD and left CCD.
C1 [Faheem, Nida; Gronseth, Gary S.] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA.
   [Gattozzi, Domenico A.; Camarata, Paul J.] Univ Kansas, Med Ctr, Dept Neurosurg, Kansas City, KS 66103 USA.
   [Madarang, Ernest J.] Univ Kansas, Med Ctr, Dept Radiol, Kansas City, KS 66103 USA.
RP Gattozzi, DA (reprint author), Univ Kansas, Med Ctr, Dept Neurosurg, Kansas City, KS 66103 USA.
EM dgattozzi@kumc.edu
FU NREF (Neurosurgery Research and Education Foundation)
FX Dr. Gattozzi is a recipient of an NREF (Neurosurgery Research and
   Education Foundation) grant to study adult stem cell transplantation in
   a rodent model of cerebral ischemia. Dr. Gronseth is an editor for the
   journal Neurology and is the methodologist for the AAN (American Academy
   of Neurology).
CR Ball R, 2010, APPL ERGON, V41, P832, DOI 10.1016/j.apergo.2010.02.002
   Graham JM, 2005, J PEDIATR-US, V146, P253, DOI 10.1016/j.jpeds.2004.10.017
   Hwang SW, 2013, CLIN PEDIATR, V52, P845, DOI 10.1177/0009922813491311
   Iwama T, 1997, CLIN NEUROL NEUROSUR, V99, pS187, DOI 10.1016/S0303-8467(97)00081-4
   Kainth DS, 2013, NEUROSURGERY, V72, P210, DOI 10.1227/NEU.0b013e31827b9beb
   KASAI K, 1993, HUM BIOL, V65, P821
   Kim T, 2015, ACTA NEUROCHIR, V157, P755, DOI 10.1007/s00701-015-2367-y
   Li S, 2017, NEURORADIOL J, V30, DOI 10.1177/1971400917692162
   Moate S J, 2002, Aust Orthod J, V18, P19
   Motoshima Shigenobu, 2012, Fukuoka Acta Medica, V103, P206
   OKA K, 1981, VIRCHOWS ARCH A, V392, P247, DOI 10.1007/BF02155663
   Quintanilla JS, 2002, PEDIATR RADIOL, V32, P635, DOI 10.1007/s00247-002-0703-x
   Qureshi Adnan I, 2014, J Vasc Interv Neurol, V7, P13
   Ryoo S, 2014, STROKE, V45, P2457, DOI 10.1161/STROKEAHA.114.004761
   Seol HJ, 2010, J NEUROSURG-PEDIATR, V5, P297, DOI 10.3171/2009.10.PEDS09452
   Suri S, 2010, ANGLE ORTHOD, V80, P861, DOI 10.2319/111709-650.1
   SUZUKI J, 1969, ARCH NEUROL-CHICAGO, V20, P288, DOI 10.1001/archneur.1969.00480090076012
   Takeuchi K, 1957, BRAIN NERVE, V9, P37
   Uchino K, 2005, NEUROLOGY, V65, P956, DOI 10.1212/01.wnl.0000176066.33797.82
   Wakai K, 1997, CLIN NEUROL NEUROSUR, V99, pS1, DOI 10.1016/S0303-8467(97)00031-0
   Watanabe A, 2010, J NEUROSURG-PEDIATR, V5, P591, DOI 10.3171/2010.3.PEDS09417
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E831
EP E838
DI 10.1016/j.wneu.2019.06.233
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200105
PM 31295617
DA 2020-05-12
ER

PT J
AU Feng, MT
   Zhang, HJ
   Zhang, YX
   Xing, PF
   Zhang, L
   Zhang, YW
   Li, ZF
   Xu, Y
   Hong, B
   Huang, QH
   Yang, PF
   Liu, JM
AF Feng, Ming-tao
   Zhang, Hong-jian
   Zhang, Yong-xin
   Xing, Peng-fei
   Zhang, Lei
   Zhang, Yong-wei
   Li, Zi-fu
   Xu, Yi
   Hong, Bo
   Huang, Qing-hai
   Yang, Peng-fei
   Liu, Jian-min
TI Stent Angioplasty for Acute Intracranial Atherosclerotic Occlusion After
   Failed Thrombectomy: A Single-Institution Series of 55 Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute stroke; Atherosclerotic stenosis; Efficacy analysis; Endovascular
   treatment
ID ACUTE ISCHEMIC-STROKE; VASCULAR RECONSTRUCTION DEVICE; MECHANICAL
   THROMBECTOMY; ENDOVASCULAR TREATMENT; THERAPY; RECANALIZATION; FAILURE;
   SAFETY
AB INTRODUCTION: Analysis of safety and effectiveness of stent angioplasty for failure of thrombectomy in patients with acute intracranial atherosclerotic occlusion.
   METHODS: Retrospective continuous analysis of the clinical data of 458 patients with acute stroke undergoing endovascular artery thrombectomy in Changhai Hospital of Second Military Medical University from May 2013 to February 2018. Patients with acute intracranial atherosclerotic occlusion treating with stent implantation were included and the safety and effectiveness of stent angioplasty was evaluated.
   RESULTS: There was successful stent release in 55 patients. There were 36 cases (65.5%) with occlusion located in the anterior circulation and 19 cases (34.5%) in the posterior circulation. Twenty patients underwent intravenous thrombolysis before surgery, and the time of admission to intravenous thrombolysis was (39.9 +/- 13.2) minutes. Fifty-four patients (98.2%) achieved modified thrombolysis in cerebral infarction 2b-3 recanalization. The National Institutes of Health Stroke Scale score 2.0 (0.0,6.0) 7 days after surgery was significantly improved compared with the preoperative National Institutes of Health Stroke Scale score 12.5 (6.0-20.0) (Z = -4.073, P < 0.05). Intracranial hemorrhage occurred in 7 patients (12.7%) after surgery, among them, symptomatic intracranial hemorrhage occurred in 2 cases (3.6%). CTP examination of the skull 3-5 days after operation showed: Among 39 cases (70.9%): 33 cases (84.6%) were patency, 4 cases (10.3%) were occlusion, 2 cases (5.1%) were moderate stenosis, and 16 cases (29.1%) were not examined by computed tomography perfusion. Ninety-day follow-up showed that a total of 43 cases were followed up, and 12 cases were lost to followup. Thirty-four patients (79.1%) had a good prognosis 90 days after surgery (modified Rankin scale score 0-2) and 9 patients died (20.9%).
   CONCLUSION: When thrombectomy in patients with acute intracranial atherosclerotic occlusion fails, stent angioplasty is safe and effective; however, short-term stent reocclusion after surgery cannot be ignored. Because of the small sample size, larger multicenter clinical studies are needed to confirm this result.
C1 [Feng, Ming-tao; Zhang, Hong-jian; Zhang, Yong-xin; Xing, Peng-fei; Zhang, Lei; Zhang, Yong-wei; Li, Zi-fu; Xu, Yi; Hong, Bo; Huang, Qing-hai; Yang, Peng-fei; Liu, Jian-min] Second Mil Med Univ, Dept Neurosurg, Changhai Hosp, Shanghai, Peoples R China.
RP Yang, PF (reprint author), Second Mil Med Univ, Dept Neurosurg, Changhai Hosp, Shanghai, Peoples R China.
EM 15921196312@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81501008]
FX This work was supported by National Natural Science Foundation of China
   (81501008).
CR Albuquerque FC, 2008, NEUROSURGERY, V63, P23, DOI 10.1227/01.NEU.0000335067.53190.A2
   Baek JH, 2017, STROKE, V48, P2746, DOI 10.1161/STROKEAHA.117.018096
   Baek JH, 2016, NEUROLOGY, V87, P1542, DOI 10.1212/WNL.0000000000003202
   Baek JH, 2016, STROKE, V47, P2360, DOI 10.1161/STROKEAHA.116.014073
   Baracchini C, 2017, WORLD NEUROSURG, V103, P57, DOI 10.1016/j.wneu.2017.03.070
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Brekenfeld C, 2009, STROKE, V40, P847, DOI 10.1161/STROKEAHA.108.533810
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Chang Y, 2018, STROKE, V49, P958, DOI 10.1161/STROKEAHA.117.020072
   Ding D, 2015, J STROKE, V17, P123, DOI 10.5853/jos.2015.17.2.123
   Dumont TM, 2014, J NEUROINTERV SURG, V6, P363, DOI 10.1136/neurintsurg-2013-010794
   Fiorella DJ, 2009, STROKE, V40, P106, DOI 10.1161/STROKEAHA.108.525774
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Hong KS, 2015, J STROKE, V17, P268, DOI 10.5853/jos.2015.17.3.268
   Jia BX, 2018, J NEUROINTERV SURG, V10, P746, DOI 10.1136/neurintsurg-2017-013489
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Kim BM, 2017, J STROKE, V19, P131, DOI 10.5853/jos.2017.00283
   Levy EI, 2007, AM J NEURORADIOL, V28, P816
   Levy EI, 2009, STROKE, V40, P3552, DOI 10.1161/STROKEAHA.109.561274
   Linfante I, 2011, STROKE, V42, P2636, DOI 10.1161/STROKEAHA.111.618389
   Mocco J, 2010, J NEUROSURG, V112, P557, DOI 10.3171/2009.8.JNS09231
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Song Dongbeum, 2015, Neurointervention, V10, P51, DOI 10.5469/neuroint.2015.10.2.51
   Sugiura Y, 2016, J STROKE CEREBROVASC, V26
   Zaidat OO, 2008, STROKE, V39, P2392, DOI 10.1161/STROKEAHA.107.510966
   Zi WJ, 2017, CEREBROVASC DIS, V44, P248, DOI 10.1159/000478667
NR 26
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E444
EP E448
DI 10.1016/j.wneu.2019.06.112
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200055
PM 31252077
DA 2020-05-12
ER

PT J
AU Franca, C
   Barbosa, ER
   Iglesio, R
   Teixeira, MJ
   Cury, RG
AF Franca, Carina
   Barbosa, Egberto Reis
   Iglesio, Ricardo
   Teixeira, Manoel Jacobsen
   Cury, Rubens Gisbert
TI Interleaving Stimulation in Parkinson Disease: Interesting to Whom?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Deep brain stimulation; Interleaving; Parkinson disease
ID DEEP BRAIN-STIMULATION; SUBTHALAMIC NUCLEUS; MOVEMENT-DISORDERS; INDUCED
   DYSKINESIA; MANAGEMENT; MECHANISMS; DYSTONIA; OUTCOMES; PATIENT; AREA
AB BACKGROUND: Interleaving stimulation (ILS) is a stim-ulation strategy that can help the physician manage more challenging cases of patients with deep brain stimulation (DBS) for Parkinson disease (PD). It consists of altering 2 different programs on the electrode with the same frequency.
   OBJECTIVES: Our objective was to overview our patients experience with ILS and explore clinical scenarios in which ILS should be considered when programming DBS in patients with PD.
   METHODS: We retrospectively reviewed medical charts from 120 patients with PD treated with DBS between 2011 and 2018.
   RESULTS: Eighteen patients received ILS. One was excluded because of the medical chart was incomplete. The remaining 17 patients had subthalamic nucleus DBS (n = 14) and globus pallidus internus DBS (n = 3). Eight patients (47%) received ILS to improve rigidity and bradykinesia, 4 to improve dyskinesias, 4 because of refractory tremor, and 1 for gait management. Until the end of data collection, 13 of 17 patients (70%) were still on ILS, with a mean duration time of 28.8 months (range, 2-44 months) Four patients reported no benefit from ILS and had their program changed.
   CONCLUSIONS: Overall, ILS is useful 1) to use 2 contacts optimally improve 2 specific symptoms but have different therapeutic windows; 2) to avoid side effects related to current spreading to nearby areas; 3) to increase frequency in a small region; or 4) to stimulate a larger target area.
C1 [Franca, Carina; Barbosa, Egberto Reis; Cury, Rubens Gisbert] Univ Sao Paulo, Movement Disorders Ctr, Sao Paulo, Brazil.
   [Iglesio, Ricardo; Teixeira, Manoel Jacobsen] Univ Sao Paulo, Div Funct Neurosurg, Dept Neurol, Sch Med, Sao Paulo, Brazil.
RP Cury, RG (reprint author), Univ Sao Paulo, Movement Disorders Ctr, Sao Paulo, Brazil.
EM rubens_cury@usp.br
CR Barbe MT, 2014, NEUROLOGY, V82, P614, DOI 10.1212/WNL.0000000000000127
   Baumann CR, 2012, MOVEMENT DISORD, V27, P1700, DOI 10.1002/mds.25221
   Birdno MJ, 2008, NEUROTHERAPEUTICS, V5, P14, DOI 10.1016/j.nurt.2007.10.067
   Blomstedt P, 2018, J NEUROL NEUROSUR PS, V89, P710, DOI 10.1136/jnnp-2017-317219
   Brosius SN, 2015, PARKINSONISM RELAT D, V21, P1469, DOI 10.1016/j.parkreldis.2015.09.047
   Ferraye MU, 2010, BRAIN, V133, P205, DOI 10.1093/brain/awp229
   Guridi J, 2008, NEUROSURGERY, V62, P311, DOI 10.1227/01.neu.0000315998.58022.55
   Herzog J, 2007, MOVEMENT DISORD, V22, P679, DOI 10.1002/mds.21387
   JACCARD P, 1912, NEW PHYTOL, V11, P37, DOI DOI 10.1111/J.1469-8137.1912.TB05611.X
   Kern DS, 2018, STEREOT FUNCT NEUROS, V96, P379, DOI 10.1159/000494983
   Kovacs N, 2012, MOVEMENT DISORD, V27, P163, DOI 10.1002/mds.23962
   Krack P, 1999, BRAIN, V122, P1133, DOI 10.1093/brain/122.6.1133
   Maks CB, 2009, J NEUROL NEUROSUR PS, V80, P659, DOI 10.1136/jnnp.2007.126219
   Miocinovic S, 2014, PARKINSONISM RELAT D, V20, P1434, DOI 10.1016/j.parkreldis.2014.10.011
   Moro E, 2002, NEUROLOGY, V59, P706, DOI 10.1212/WNL.59.5.706
   Moro E, 2010, BRAIN, V133, P215, DOI 10.1093/brain/awp261
   Nishikawa Y, 2010, NEUROL MED-CHIR, V50, P257, DOI 10.2176/nmc.50.257
   Okun MS, 2005, ARCH NEUROL-CHICAGO, V62, P1250, DOI 10.1001/archneur.62.8.noc40425
   Peppe A, 2004, J NEUROSURG, V101, P195, DOI 10.3171/jns.2004.101.2.0195
   Picillo M, 2016, BRAIN STIMUL, V9, P425, DOI 10.1016/j.brs.2016.02.004
   Ramirez-Zamora A, 2015, J NEUROL, V262, P578, DOI 10.1007/s00415-014-7605-3
   Rodriguez-Oroz MC, 2012, MOVEMENT DISORD, V27, P1718, DOI 10.1002/mds.25214
   Tsukada R, 2017, NEUROL CLIN NEUROSCI, V5, P32, DOI 10.1111/ncn3.12085
   Volkmann J, 2006, MOVEMENT DISORD, V21, pS284, DOI 10.1002/mds.20961
   Wagle Shukla Aparna, 2016, IEEE Rev Biomed Eng, V9, P219, DOI 10.1109/RBME.2016.2588399
   Weiss D, 2013, BRAIN, V136, P2098, DOI 10.1093/brain/awt122
   Weiss D, 2011, J NEUROL, V258, P1183, DOI 10.1007/s00415-011-5906-3
   Wojtecki L, 2011, PARKINSONISM RELAT D, V17, P293, DOI 10.1016/j.parkreldis.2010.12.005
   ZHANG SZ, 2016, MEDICINE, V95, DOI DOI 10.1097/MD.0000000000005575
NR 29
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E786
EP E793
DI 10.1016/j.wneu.2019.06.223
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200100
PM 31295615
DA 2020-05-12
ER

PT J
AU Fu, CY
   Chen, SJ
   Cai, NH
   Liu, ZH
   Wang, PC
   Zhao, JN
AF Fu, Chuanyi
   Chen, Shuijie
   Cai, Nanhua
   Liu, Zhaohui
   Wang, Pengcheng
   Zhao, Jiannong
TI Potential Neuroprotective Effect of miR-451 Against Cerebral
   Ischemia/Reperfusion Injury in Stroke Patients and a Mouse Model
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain ischemia; miR-451; MCAO; Stroke
ID ISCHEMIA-REPERFUSION INJURY; INDUCED CELL-DEATH; MICRORNA-451 PROTECTS;
   THERAPEUTIC TARGET; BIOMARKERS; COUNCIL; INFARCT; NEURONS; DISEASE;
   UPDATE
AB OBJECTIVE: Recently, microRNAs (miRs) have been reported to be novel regulators in ischemic stroke. In this study, we investigated the pattern of miR-451 expression along with its clinical application in human ischemic stroke and in an in vivo mouse model.
   METHODS: The level of miR-451 was evaluated in patients and mice after ischemic stroke. National Institute of Health Stroke Scale scores and brain infarct volume were analyzed to the correlation of miR-451 expression and clinical information. In addition, blood samples and brain tissues were collected from an established middle cerebral artery occlusion model consisting of 12 adult male mice at 24 hours after the middle cerebral artery occlusion.
   RESULTS: The results showed that miR-451 levels in the circulating blood of ischemic stroke patients were greatly decreased compared with the control. Further correlation analysis revealed a negative association between miR-451 and National Institute of Health Stroke Scale scores (r = -0.6104, P < 0.001) and infarct volume (r = -0.5442, P < 0.001). Moreover, miR-451 was downregulated in response to middle cerebral artery occlusion in vivo, along with a negative correlation between miR-451 in brain and blood (r = 0.9240, P < 0.01). In addition, forced expression of miR-451 weakened ischemic brain infarction and apoptosis levels in focal ischemia-stroked mice, while downregulation of miR-451 significantly augmented ischemic injury.
   CONCLUSIONS: In conclusion, miR-451 displays the neuroprotective effect in ischemic stroke and might serve as a novel therapeutic target of ischemic stroke.
C1 [Fu, Chuanyi; Chen, Shuijie; Cai, Nanhua; Liu, Zhaohui; Wang, Pengcheng; Zhao, Jiannong] Hainan Gen Hosp, Hainan Clin Med Res Inst, Natl Key Clin Specialty, Dept Neurosurg, Haikou, Hainan, Peoples R China.
RP Zhao, JN (reprint author), Hainan Gen Hosp, Hainan Clin Med Res Inst, Natl Key Clin Specialty, Dept Neurosurg, Haikou, Hainan, Peoples R China.
EM zhaojiannong421@126.com
FU Natural Science Foundation of Hainan Province [817308]
FX This study was supported by grant from the Natural Science Foundation of
   Hainan Province (817308).
CR ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35
   Baczynska Dagmara, 2013, Przegl Lek, V70, P135
   Broderick J, 2007, CIRCULATION, V116, pE391, DOI 10.1161/CIRCULATIONAHA.107.183689
   Chen BL, 2015, BIOMED RES INT, DOI 10.1155/2015/895284
   Chi W, 2014, NEUROSCIENCE, V277, P111, DOI 10.1016/j.neuroscience.2014.06.062
   Ebert MS, 2012, CELL, V149, P515, DOI 10.1016/j.cell.2012.04.005
   FENG XY, 2014, BMC NEUROL, V14, DOI DOI 10.1186/1471-2229-14-187
   Goldstein LB, 2001, STROKE, V32, P280, DOI 10.1161/01.STR.32.1.280
   Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267
   Li YY, 2015, AM J TRANSL RES, V7, P2775
   Liu KH, 2019, J CELL BIOCHEM, V120, P12074, DOI 10.1002/jcb.26657
   Liu Q, 2018, NEUROPSYCH DIS TREAT, V14, P2773, DOI 10.2147/NDT.S173632
   Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106
   Long GW, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-178
   Mahlamaki EH, 2002, GENE CHROMOSOME CANC, V35, P353, DOI 10.1002/gcc.10122
   Min XL, 2015, NEURAL REGEN RES, V10, P1799, DOI 10.4103/1673-5374.170302
   Prugger C, 2013, ARTERIOSCL THROM VAS, V33, P659, DOI 10.1161/ATVBAHA.112.300109
   Sepramaniam S, 2010, J BIOL CHEM, V285, P29223, DOI 10.1074/jbc.M110.144576
   Sims JR, 2009, NEUROLOGY, V72, P2104, DOI 10.1212/WNL.0b013e3181aa5329
   Sun XJ, 2018, CELL TISSUE RES, V374, P487, DOI 10.1007/s00441-018-2898-7
   Taj SH, 2016, BIOMATERIALS, V91, P151, DOI 10.1016/j.biomaterials.2016.03.025
   Tan KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007689
   Tan MS, 2014, J ALZHEIMERS DIS, V38, P633, DOI 10.3233/JAD-131148
   Tang XJ, 2016, EXP THER MED, V11, P1045, DOI 10.3892/etm.2016.3021
   Tao Z, 2015, J NEUROL SCI, V355, P113, DOI 10.1016/j.jns.2015.05.036
   Thom T, 2006, CIRCULATION, V113, pE85, DOI 10.1161/CIRCULATIONAHA.105.171600
   Truettner JS, 2013, BRAIN RES, V1533, P122, DOI 10.1016/j.brainres.2013.08.011
   Tsai PC, 2013, J VASC RES, V50, P346, DOI 10.1159/000351767
   Villela D, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/2584940
   Wang J, 2017, AGING DIS, V8, P71, DOI 10.14336/AD.2016.0530
   Wang P, 2015, J NEUROSCI RES, V93, P1756, DOI 10.1002/jnr.23637
   Wang XH, 2012, CARDIOVASC RES, V94, P379, DOI 10.1093/cvr/cvs096
   WHISNANT JP, 1990, STROKE, V21, P707, DOI 10.1161/01.STR.21.5.707
   Xie J, 2016, MOL MED REP, V13, P5335, DOI 10.3892/mmr.2016.5192
   YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165
   Yin KJ, 2010, NEUROBIOL DIS, V38, P17, DOI 10.1016/j.nbd.2009.12.021
   Yoo AJ, 2012, STROKE, V43, P1323, DOI 10.1161/STROKEAHA.111.639401
   Zampetaki A, 2010, CIRC RES, V107, P810, DOI 10.1161/CIRCRESAHA.110.226357
   Zhang XW, 2010, J MOL CELL CARDIOL, V49, P841, DOI 10.1016/j.yjmcc.2010.08.007
NR 39
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E54
EP E61
DI 10.1016/j.wneu.2019.05.194
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200007
PM 31150847
DA 2020-05-12
ER

PT J
AU Fujio, S
   Takajo, T
   Kinoshita, Y
   Hanaya, R
   Arimura, H
   Sugata, J
   Sugata, S
   Bohara, M
   Hiraki, T
   Yoshimoto, K
   Arita, K
AF Fujio, Shingo
   Takajo, Tomoko
   Kinoshita, Yasuyuki
   Hanaya, Ryosuke
   Arimura, Hiroshi
   Sugata, Jun
   Sugata, Sei
   Bohara, Manoj
   Hiraki, Tsubasa
   Yoshimoto, Koji
   Arita, Kazunori
TI Sellar Xanthogranuloma: A Quest Based on Nine Cases Assessed with an
   Anterior Pituitary Provocation Test
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cholesterol crystal; Chronic inflammation; Hypopituitarism; Rathke cleft
   cyst; Xanthogranuloma
ID RATHKES CLEFT CYST; SUPRASELLAR REGION; HYPOPHYSITIS; FEATURES;
   CRANIOPHARYNGIOMA; LESIONS; ENTITY; MR
AB BACKGROUND: Xanthogranuloma is a chronic inflammatory mass characterized by cholesterol crystal deposition, which is rarely seen in the sellar region. The objective of this study is to identify the clinical features and cause of sellar xanthogranulomas.
   METHODS: We retrospectively analyzed manifestation, radiographic, and endocrinologic presentation in 9 patients (7 women and 2 men) whom we had previously treated.
   RESULTS: The patients were between 26 and 73 years of age (median, 56 years). The chief symptoms were visual symptoms in 3, polyuria in 3, headache in 4, and tiredness in 4 patients. Perimetry found visual field deficit in 6 patients. Anterior pituitary provocation tests disclosed impairment of >= 1 hormone in all patients: growth hormone in 8 patients and adrenocorticotropic hormone-cortisol axis in 8 patients. The lesions were suprasellar in 2 patients, intrasellar in 2 patients, and intrasuprasellar region in 5 patients. Three of the lesions were solid and 6 were single cystic to multicystic. Very low intensity area on T2-weighted magnetic resonance imaging was observed in 4 lesions. Postcontrast study performed in 7 lesions showed enhancement in solid parts or cyst walls. Surgical decompression improved visual disturbance in half of the patients but rarely improved hormonal deficits. Follow-up (median, 47 months) found no recurrence of the lesion. In addition to these 9 cases, we found 2 xanthogranulomatous lesions pathologically associated with ciliated epithelia, which also presented with severe hypopituitarism.
   CONCLUSIONS: Xanthogranuloma seems to be the last stage of the chronic inflammation affecting Rathke cleft cyst or craniopharyngioma presenting with severe anterior pituitary insufficiency.
C1 [Fujio, Shingo; Takajo, Tomoko; Hanaya, Ryosuke; Sugata, Jun; Sugata, Sei; Bohara, Manoj; Yoshimoto, Koji; Arita, Kazunori] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurosurg, Kagoshima, Japan.
   [Arimura, Hiroshi] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Diabet Metab & Endocrinol, Kagoshima, Japan.
   [Hiraki, Tsubasa] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Pathol, Kagoshima, Japan.
   [Fujio, Shingo; Arimura, Hiroshi; Yoshimoto, Koji] Kagoshima Univ Hosp, Pituitary Disorders Ctr, Kagoshima, Japan.
   [Kinoshita, Yasuyuki] Hiroshima Univ, Grad Sch Biomed Sci, Dept Neurosurg, Hiroshima, Japan.
   [Sugata, Jun; Arita, Kazunori] Izumi Reg Med Ctr, Dept Neurosurg, Akune, Japan.
RP Arita, K (reprint author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurosurg, Kagoshima, Japan.; Arita, K (reprint author), Izumi Reg Med Ctr, Dept Neurosurg, Akune, Japan.
EM karita@m2.kufm.kagoshima-u.ac.jp
FU Health and Labor Sciences Research Grant on "Research on Intractable
   Diseases in Japan: Hypothalamo-Pituitary Dysfunction" from the Ministry
   of Education, Culture, Sports, Science, and Technology of Japan
FX This study was partly financed by Health and Labor Sciences Research
   Grant on "Research on Intractable Diseases in Japan:
   Hypothalamo-Pituitary Dysfunction" from the Ministry of Education,
   Culture, Sports, Science, and Technology of Japan. We declare that each
   of us participated sufficiently in the work to take public
   responsibility for the content of this article. Moreover, we declare
   that there is no conflict of interest that could be perceived as
   prejudicing the impartiality of the study reported. Case 2 (Figure 5)
   was previously published by us in Neurologia Medico-Chirurgica (Tokyo) 7
   and is republished here with the permission of the editorial office.
CR Amano K, 2013, BRAIN TUMOR PATHOL, V30, P233, DOI 10.1007/s10014-012-0130-0
   Burger PC, 1991, SURG PATHOLOGY NERVO, P537
   Burt Morton G, 2003, Pituitary, V6, P161, DOI 10.1023/B:PITU.0000011177.43408.56
   Buslei R, 2007, IARC WHO CLASSIFICAT, P324
   Cho Sung Min, 2018, Brain Tumor Res Treat, V6, P82, DOI 10.14791/btrt.2018.6.e10
   Duan K, 2017, ENDOCR PATHOL, V28, P83, DOI 10.1007/s12022-017-9471-x
   Hama S, 2002, J NEUROSURG, V96, P209, DOI 10.3171/jns.2002.96.2.0209
   Hama S, 1999, ENDOCR J, V46, P187, DOI 10.1507/endocrj.46.187
   Hernandez-Estrada RA, 2017, PITUITARY, V20, P325, DOI 10.1007/s11102-016-0775-5
   Kleinschmidt-DeMasters BK, 2017, BRAIN PATHOL, V27, P377, DOI 10.1111/bpa.12498
   Komatsu F, 2010, ACTA NEUROCHIR, V152, P1673, DOI 10.1007/s00701-010-0687-5
   Kunii N, 2007, ACTA NEUROCHIR, V149, P759, DOI 10.1007/s00701-007-1234-x
   Le BH, 2007, ENDOCR PATHOL, V18, P23, DOI 10.1007/s12022-007-0011-y
   Macaulay RJB, 1997, CLIN NEUROPATHOL, V16, P98
   Melmed S, 2008, WILLIAMS TXB ENDOCRI, P241
   Nishioka H, 2006, CLIN ENDOCRINOL, V64, P184, DOI 10.1111/j.1365-2265.2006.02446.x
   Nishioka H, 2010, NEURORADIOLOGY, V52, P997, DOI 10.1007/s00234-010-0675-8
   Nishiuchi Takamasa, 2012, J Med Case Rep, V6, P119, DOI 10.1186/1752-1947-6-119
   Paulus W, 1999, ACTA NEUROPATHOL, V97, P377, DOI 10.1007/s004010051001
   Petrakakis I, 2016, CLIN NEUROL NEUROSUR, V149, P154, DOI 10.1016/j.clineuro.2016.08.011
   Rahmani R, 2015, J NEUROSURG, V122, P812, DOI 10.3171/2014.12.JNS14542
   Roncaroli F, 1998, NEUROSURGERY, V43, P146, DOI 10.1097/00006123-199807000-00092
   Schwartz KM, 2006, NEURORADIOLOGY, V48, P143, DOI 10.1007/s00234-005-0024-5
   Shirataki K, 1988, No To Shinkei, V40, P133
   Sugata S, 2009, NEUROL MED-CHIR, V49, P124, DOI 10.2176/nmc.49.124
   SUMIDA M, 1994, AM J NEURORADIOL, V15, P525
   Ved R, 2018, PITUITARY, V21, P256, DOI 10.1007/s11102-017-0859-x
   Wearne MJ, 1995, BRIT J NEUROSURG, V9, P799, DOI 10.1080/02688699550040800
   Yang B, 2017, WORLD NEUROSURG, V99, P439, DOI 10.1016/j.wneu.2016.12.017
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E150
EP E159
DI 10.1016/j.wneu.2019.06.021
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200020
PM 31203060
DA 2020-05-12
ER

PT J
AU Godzik, J
   Haglin, JM
   Alan, N
   Hlubek, RJ
   Walker, CT
   Bach, K
   Mundis, GM
   Turner, JD
   Kanter, AS
   Okonwko, DO
   Uribe, JS
AF Godzik, Jakub
   Haglin, Jack M.
   Alan, Nima
   Hlubek, Randall J.
   Walker, Corey T.
   Bach, Konrad
   Mundis, Gregory M., Jr.
   Turner, Jay D.
   Kanter, Adam S.
   Okonwko, David O.
   Uribe, Juan S.
TI Retrospective Multicenter Assessment of Rod Fracture After Anterior
   Column Realignment in Minimally Invasive Adult Spinal Deformity
   Correction
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior column realignment; Coronal Cobb angle; Fusion; Lumbar
   lordosis; Minimally invasive spine surgery; Pelvic incidence; Pelvic
   tilt; Sagittal vertical axis; Thoracic kyphosis; Three-column
   osteotomies
ID PEDICLE SUBTRACTION OSTEOTOMY; LATERAL TRANSPSOAS APPROACH;
   RISK-FACTORS; SURGICAL STRATEGIES; SAGITTAL BALANCE; SURGERY;
   COMPLICATIONS; IMPACT; CONSTRUCTS; PARAMETERS
AB BACKGROUND: Anterior column realignment (ACR) was developed as a minimally invasive method for treating sagittal imbalance. However, rod fracture (RF) rates associated with ACR are not known. Our objective was to assess the rate of and risk factors for RF following ACR in deformity correction surgery.
   METHODS: We conducted a retrospective multicenter review of patients with adult spinal deformity (ASD) who underwent ACR for deformity correction. ASD was defined as coronal Cobb angle >= 20 degrees, pelvic incidence-lumbar lordosis >10 degrees, sagittal vertical axis >= 5 cm, pelvic tilt >= 25 degrees, or thoracic kyphosis . Inclusion criteria were ASD, age >18 years, use of ACR, and development of RF or full radiographs obtained at least 1 year after surgery that did not demonstrate RF.
   RESULTS: Ninety patients were identified, with mean follow-up of 2.3 +/- 1.4 years (age, 64.1 +/- 9.4; 54 [60%] women). The most common ACR location was L3/4 (42 cases; 47%). Mean fusion length was 7.5 +/- 3.6 levels. Four (4.4%) of 90 patients developed RF within 12 months of surgery. RF occurred adjacent to ACR in all cases; RF was not associated with focal correction (P = 0.49), rod material (P = 0.8), degree of correction (P> 0.07), or interbody at L5/S1 (P = 0.06). RF was associated with longer fusion constructs in univariate (P = 0.002) and multivariate (P = 0.03) analyses.
   CONCLUSIONS: RF occurred in 4.4% of patients with ASD who underwent ACR with a minimum of 1-year follow-up. RF was not associated with focal correction but appears to be associated with global correction and extent of fixation.
C1 [Godzik, Jakub; Hlubek, Randall J.; Walker, Corey T.; Turner, Jay D.; Uribe, Juan S.] St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
   [Haglin, Jack M.] Mayo Clin, Sch Med, Scottsdale, AZ USA.
   [Alan, Nima; Kanter, Adam S.; Okonwko, David O.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA.
   [Bach, Konrad] Univ S Florida, Tampa, FL USA.
   [Mundis, Gregory M., Jr.] Scripps Clin, San Diego Spine Fdn, Div Orthoped Surg, La Jolla, CA 92037 USA.
RP Uribe, JS (reprint author), St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
EM Neuropub@barrowneuro.org
CR Akbarnia BA, 2014, J SPINAL DISORD TECH, V27, P29, DOI 10.1097/BSD.0b013e318287bdc1
   Bach K, 2014, CLIN ORTHOP RELAT R, V472, P1749, DOI 10.1007/s11999-013-3441-5
   Bae J, 2018, J NEUROSURG-SPINE, V28, P40, DOI 10.3171/2017.5.SPINE161370
   Barton C, 2015, SCOLIOSIS SPINAL DIS, V10, DOI 10.1186/s13013-015-0056-5
   Bess S, 2016, SPINE, V41, P224, DOI 10.1097/BRS.0000000000001202
   Bess S, 2013, NEUROSURG CLIN N AM, V24, P185, DOI 10.1016/j.nec.2012.12.008
   Castro C, 2014, CLIN ORTHOP RELAT R, V472, P1776, DOI 10.1007/s11999-013-3263-5
   Cho KJ, 2005, SPINE, V30, P2030, DOI 10.1097/01.brs.0000179085.92998.ee
   Choy W, 2018, NEUROSURG CLIN N AM, V29, P399, DOI 10.1016/j.nec.2018.03.007
   Costanzo G, 2014, EUR SPINE J, V23, pS699, DOI 10.1007/s00586-014-3561-y
   Deukmedjian AR, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.5.FOCUS13173
   Eastlack RK, 2017, GLOB SPINE J, V7, P703, DOI 10.1177/2192568217716151
   Glassman SD, 2005, SPINE, V30, P2024, DOI 10.1097/01.brs.0000179086.30449.96
   Godzik J, 2018, 11 ANN M SOC LAT ACC
   Januszewski Jacob, 2017, Surg Neurol Int, V8, P207, DOI 10.4103/sni.sni_44_17
   Lafage V, 2009, SPINE, V34, pE599, DOI 10.1097/BRS.0b013e3181aad219
   Le TV, 2012, J NEUROSURG-SPINE, V16, P302, DOI 10.3171/2011.11.SPINE11653
   Lertudomphonwanit T, 2018, SPINE J, V18, P1612, DOI 10.1016/j.spinee.2018.02.008
   Manwaring JC, 2014, J NEUROSURG-SPINE, V20, P515, DOI 10.3171/2014.2.SPINE1347
   Merrill RK, 2017, GLOB SPINE J, V7, P514, DOI 10.1177/2192568217699392
   Min Zhong-han, 2015, Zhongguo Gu Shang, V28, P643
   Mummaneni PV, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.3.FOCUS1413
   Mundis GM, 2017, WORLD NEUROSURG, V105, P249, DOI 10.1016/j.wneu.2017.05.122
   Passias PG, 2016, J BONE JOINT SURG AM, V98, P536, DOI 10.2106/JBJS.14.01126
   Saigal R, 2016, SPINE, V41, pS66, DOI 10.1097/BRS.0000000000001483
   Scheer JK, 2011, NEUROSURGERY, V69, P164, DOI 10.1227/NEU.0b013e31820f362a
   Schwab FJ, 2013, SPINE, V38, pE803, DOI 10.1097/BRS.0b013e318292b7b9
   Schwab FJ, 2012, EUR SPINE J, V21, P2603, DOI 10.1007/s00586-012-2370-4
   Smith JS, 2016, NEUROSURGERY, V78, P851, DOI 10.1227/NEU.0000000000001116
   Smith JS, 2014, J NEUROSURG-SPINE, V21, P994, DOI 10.3171/2014.9.SPINE131176
   Smith JS, 2012, NEUROSURGERY, V71, P862, DOI 10.1227/NEU.0b013e3182672aab
   Soroceanu A, 2016, SPINE, V41, P1718, DOI 10.1097/BRS.0000000000001636
   Tang JA, 2013, NEUROSURGERY, V72, P276, DOI 10.1227/NEU.0b013e31827ba066
   Uribe JS, 2017, NEUROSURGERY, V80, P489, DOI 10.1093/neuros/nyw072
   Uribe JS, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.3.FOCUS13534
   Wang MY, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09286
NR 36
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E400
EP E405
DI 10.1016/j.wneu.2019.06.096
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200049
PM 31229745
DA 2020-05-12
ER

PT J
AU Gopalakrishna, KN
   Chakrabarti, D
   Sadashiva, N
   Bharadwaj, S
   Bhat, R
   Sudhir, V
AF Gopalakrishna, Kadarapura Nanjundaiah
   Chakrabarti, Dhritiman
   Sadashiva, Nishanth
   Bharadwaj, Suparna
   Bhat, Ravitej
   Sudhir, Venkataramaiah
TI Perioperative Factors Affecting Neurologic Outcome in Infants Undergoing
   Surgery for Intracranial Lesion: A Retrospective Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anesthesia; Infant; Neurosurgery; Neurologic deficits; Outcomes; Tumor
ID CENTRAL-NERVOUS-SYSTEM; 1ST YEAR; BRAIN-TUMORS; PEDIATRIC ANESTHESIA;
   NEOPLASMS; COMPLICATIONS; MORBIDITY; CHILDREN; TRANSFUSION; EXPERIENCE
AB BACKGROUND: The short-term neurologic outcome of infants undergoing brain tumor surgery depends on various perioperative factors. This study was undertaken to analyze the effects of perioperative variables on the postoperative neurologic outcome in infants undergoing brain tumor surgery.
   METHODS: We retrospectively reviewed the chart of infants undergoing craniotomy for brain tumor removal from 2000 to 2017. The data related to preoperative variables, intraoperative management details, and postoperative factors were collected and analyzed. The primary outcome measure was occurrence of new postoperative neurologic deficit (POND) and the secondary outcome measure was length of hospital stay (LOHS).
   RESULTS: Complete data were available for 40 infants undergoing craniotomy for excision of intracranial tumor. New-onset POND was found in 14 infants (35%). Based on logistic regression analysis, POND was associated with use of mannitol and massive blood transfusion (MBT) trended toward significance. Based on linear regression analysis, the risk factor associated with prolonged LOHS was reintubation and POND trended toward significance.
   CONCLUSIONS: In this study, factors associated with new POND were mannitol use and to a certain extent MBT. The variables associated with prolonged LOHS were reintubation and to a certain extent POND. The anesthetic technique, location of tumor, tumor histology, and extent of tumor resection did not influence the occurrence of new POND or prolonged LOHS in infantile intracranial tumor surgery. Further prospective studies with larger samples are required for confirmation of these findings and identification of new perioperative risk factors.
C1 [Gopalakrishna, Kadarapura Nanjundaiah; Chakrabarti, Dhritiman; Bharadwaj, Suparna; Sudhir, Venkataramaiah] NIMHANS, Dept Neuroanaesthesia & Neurocrit Care, Bangalore, Karnataka, India.
   [Sadashiva, Nishanth] NIMHANS, Dept Neurosurg, Bangalore, Karnataka, India.
   [Bhat, Ravitej] Kasturba Med Coll & Hosp, Manipal, Karnataka, India.
RP Gopalakrishna, KN (reprint author), NIMHANS, Dept Neuroanaesthesia & Neurocrit Care, Bangalore, Karnataka, India.
EM gops868@gmail.com
RI Sadashiva, Nishanth/J-9587-2015
OI Sadashiva, Nishanth/0000-0003-0509-4993
CR Aleksic V, 2009, PEDIATR ANESTH, V19, P879, DOI 10.1111/j.1460-9592.2009.03096.x
   ASAI A, 1989, CHILD NERV SYST, V5, P230, DOI 10.1007/BF00271024
   Auroy Y, 1997, ANESTH ANALG, V84, P234, DOI 10.1097/00000539-199701000-00060
   Bhananker SM, 2007, ANESTH ANALG, V105, P344, DOI 10.1213/01.ane.0000268712.00756.dd
   Bognar L, 1997, ANN NY ACAD SCI, V824, P148, DOI 10.1111/j.1749-6632.1997.tb46217.x
   Brown K, 1997, PEDIATR NEUROSURG, V26, P25, DOI 10.1159/000121157
   Chumas P, 2011, ACTA NEUROCHIR, V153, P1231, DOI 10.1007/s00701-011-0970-0
   Cinotti R, 2018, ANESTHESIOLOGY, V129, P1111, DOI 10.1097/ALN.0000000000002426
   COCHRANE DD, 1994, PEDIATR NEUROSURG, V20, P19, DOI 10.1159/000120761
   COHEN MM, 1990, ANESTH ANALG, V70, P160
   El-Gaidi MA, 2010, PEDIATR NEUROSURG, V46, P272, DOI 10.1159/000321540
   Ghodsi SM, 2015, J PEDIATR NEUROSCI, V10, P335, DOI 10.4103/1817-1745.174454
   Glance LG, 2011, ANESTHESIOLOGY, V114, P283, DOI 10.1097/ALN.0b013e3182054d06
   Iwama T, 1996, NEUROSURGERY, V38, P1120, DOI 10.1097/00006123-199606000-00011
   Jagdevan S, 2015, NEUROL INDIA, V63, P702, DOI 10.4103/0028-3886.166575
   Jaing TH, 2011, CHILD NERV SYST, V27, P415, DOI 10.1007/s00381-010-1298-4
   JOOMA R, 1984, NEUROSURGERY, V14, P31, DOI 10.1227/00006123-198401000-00008
   Kane PJ, 1999, BRIT J NEUROSURG, V13, P294
   Kneyber MCJ, 2007, INTENS CARE MED, V33, P1414, DOI 10.1007/s00134-007-0741-9
   Larouche V, 2007, PEDIATR BLOOD CANCER, V49, P1074, DOI 10.1002/pbc.21351
   McCann ME, 2012, BRIT J ANAESTH, V109, pI60, DOI 10.1093/bja/aes424
   McCann ME, 2014, PEDIATR ANESTH, V24, P68, DOI 10.1111/pan.12310
   McClain CD, 2011, CORE TOPICS NEUROANA, P205
   McClain CD, 2014, CURR OPIN ANESTHESIO, V27, P465, DOI 10.1097/ACO.0000000000000112
   Mehrotra N, 2009, CHILD NERV SYST, V25, P1563, DOI 10.1007/s00381-009-0936-1
   Mekitarian E, 2011, PEDIATR NEUROSURG, V47, P423, DOI 10.1159/000339312
   Mekitarian E, 2012, REV ASSOC MED BRAS, V58, P388, DOI 10.1590/S0104-42302012000300022
   Mohanty CB, 2013, PEDIATR NEUROSURG, V49, P145, DOI 10.1159/000358308
   Phi JH, 2014, PEDIATR ANESTH, V24, P791, DOI 10.1111/pan.12447
   Piastra M, 2008, J NEURO-ONCOL, V90, P191, DOI 10.1007/s11060-008-9643-0
   R Core Team, 2014, R LANG ENV STAT COMP
   Rickert CH, 1997, CHILD NERV SYST, V13, P507, DOI 10.1007/s003810050127
   Soriano SG, 2017, COTTRELL PATELS NEUR, P337
   TODD MM, 1993, ANESTHESIOLOGY, V78, P1005, DOI 10.1097/00000542-199306000-00002
   Young HK, 2004, J CHILD NEUROL, V19, P424, DOI 10.1177/088307380401900605
NR 35
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E702
EP E708
DI 10.1016/j.wneu.2019.06.196
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200089
PM 31279108
DA 2020-05-12
ER

PT J
AU Griffin, A
   Reese, V
   Huseyinoglu, Z
   Niedzwiecki, D
   Yang, LX
   Cutler, A
   Gonzalez, LF
   Zomorodi, A
   Smith, T
   Hauck, EF
AF Griffin, Andrew
   Reese, Vanessa
   Huseyinoglu, Zeynep
   Niedzwiecki, Donna
   Yang, Lexie
   Cutler, Andrew
   Gonzalez, L. Fernando
   Zomorodi, Ali
   Smith, Tony
   Hauck, Erik F.
TI Predictors of Clinical Outcome After Treatment of Intracranial Aneurysms
   with the Pipeline Embolization Device
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Pipeline embolization device; Stent
ID CEREBRAL ANEURYSMS; MULTICENTER; COMPLICATIONS
AB BACKGROUND: Flow-diverting stents have revolutionized the endovascular treatment of intracranial aneurysms. The purpose of this study is to identify predictors of adverse outcomes associated with the pipeline embolization device (PED).
   METHODS: A retrospective analysis of all patients treated with PED at a single high-volume center from January 2014 to September 2018. Patient outcomes, neurologic morbidity/mortality, and other clinical variables were analyzed.
   RESULTS: We treated 204 aneurysms in 170 patients with PED. Mean length of follow-up was 11 months. Most (181) aneurysms (89%) were located in the anterior circulation, and 23 (11%) were found in the posterior circulation. Most aneurysms were saccular (82%), followed by fusiform (11%), blister (4%), and dissecting pseudoaneurysms (3%). Mean aneurysm size was 8.2 + 5.7 mm with 145 (71%) small aneurysms (<= 10 mm), 53 (26%) large aneurysms (between 10 and 25 mm), and 6 (3%) giant aneurysms (>= 25 mm). Ninety-two percent of aneurysms were unruptured, and 8% were ruptured. The overall major neurologic morbidity/mortality was 4.7% and 1.8%, respectively. The all-cause mortality was 2.9%. Predictors of neurologic morbidity/mortality included the baseline modified Rankin Scale (P = 0.001), aneurysm neck size (P = 0.003), aneurysm size (P = 0.006), anterior versus posterior location (P = 0.02), and rupture at presentation (0.006). The P2Y12 Reactivity Unit, parent vessel diameter, and patient age did not correlate with adverse events.
   CONCLUSIONS: The PED has a satisfactory safety profile in both on- and off-label indications. A poor clinical patient baseline, wider aneurysm neck or larger size, and rupture predict an increased risk of an unfavorable outcome.
C1 [Griffin, Andrew; Reese, Vanessa; Huseyinoglu, Zeynep; Cutler, Andrew; Gonzalez, L. Fernando; Zomorodi, Ali; Smith, Tony; Hauck, Erik F.] Duke Univ, Med Ctr, Dept Neurosurg, Durham, NC 27710 USA.
   [Niedzwiecki, Donna; Yang, Lexie] Duke Univ, Med Ctr, Dept Biostat, Durham, NC USA.
RP Griffin, A (reprint author), Duke Univ, Med Ctr, Dept Neurosurg, Durham, NC 27710 USA.
EM asg32@duke.edu
OI Niedzwiecki, Donna/0000-0002-3566-0450; Griffin,
   Andrew/0000-0003-3266-1359; Cutler, Andrew/0000-0003-4064-1139
CR Adeeb N, 2017, WORLD NEUROSURG, V105, P232, DOI 10.1016/j.wneu.2017.05.128
   Adeeb N, 2017, STROKE, V48, P1322, DOI 10.1161/STROKEAHA.116.015308
   Almandoz JED, 2014, AM J NEURORADIOL, V35, P128, DOI 10.3174/ajnr.A3621
   Almandoz JED, 2013, J NEUROINTERV SURG, V5, pIII3, DOI 10.1136/neurintsurg-2012-010582
   Becske T, 2013, RADIOLOGY, V267, P858, DOI 10.1148/radiol.13120099
   Bender MT, 2019, NEUROSURGERY, V84, P206, DOI 10.1093/neuros/nyy076
   Bender MT, 2017, J NEUROINTERV SURG, V9, P978, DOI 10.1136/neurintsurg-2016-012618
   Brinjikji W, 2015, AM J NEURORADIOL, V36, P2090, DOI 10.3174/ajnr.A4411
   Brinjikji W, 2013, STROKE, V44, P442, DOI 10.1161/STROKEAHA.112.678151
   Chalouhi N, 2015, NEUROSURGERY, V76, P165, DOI 10.1227/NEU.0000000000000586
   Griessenauer CJ, 2019, J NEUROSURG, V130, P923, DOI 10.3171/2017.9.JNS171376
   Hanel R., 2017, INT STROK C FEBR 22
   Kallmes DF, 2015, AM J NEURORADIOL, V36, P108, DOI 10.3174/ajnr.A4111
   Kallmes DF, 2017, J NEUROSURG, V127, P775, DOI 10.3171/2016.8.JNS16467
   Kallmes DF, 2016, INTERV NEUROL, V5, P89, DOI 10.1159/000446503
   Lin N, 2015, J NEUROINTERV SURG, V7, P808, DOI 10.1136/neurintsurg-2014-011320
   Lopes DK, 2018, NEUROSURGERY, V83, P488, DOI 10.1093/neuros/nyx467
   Miyachi Shigeru, 2017, Neurointervention, V12, P83, DOI 10.5469/neuroint.2017.12.2.83
   Nelson PK, 2011, AM J NEURORADIOL, V32, P34, DOI 10.3174/ajnr.A2421
   Park MS, 2016, AM J NEURORADIOL, V37, P1127, DOI 10.3174/ajnr.A4678
   Patel PD, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1742
   Skukalek SL, 2016, J NEUROINTERV SURG, V8, P58, DOI 10.1136/neurintsurg-2014-011145
   Tan LA, 2015, J NEUROINTERV SURG, V7, P217, DOI 10.1136/neurintsurg-2014-011111
   Taylor LI, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1746
   Zammar SG, 2018, WORLD NEUROSURG, V115, pE200, DOI 10.1016/j.wneu.2018.04.012
NR 25
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E666
EP E671
DI 10.1016/j.wneu.2019.06.185
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200084
PM 31276854
DA 2020-05-12
ER

PT J
AU Herguido, NG
   Fuentes, ED
   Venegas-Moreno, E
   Maorad, LB
   Flores-Martinez, A
   Ruiz, PR
   Duenas, MC
   Roldan, F
   Fajardo, E
   Ruiz-Valdepenas, EC
   Kaen, A
   Schrader, IM
   Cano, DA
   Soto-Moreno, A
AF Gros Herguido, Noelia
   Dios Fuentes, Elena
   Venegas-Moreno, Eva
   Borau Maorad, Laura
   Flores-Martinez, Alvaro
   Remon Ruiz, Pablo
   Cozar Duenas, Miriam
   Roldan, Florinda
   Fajardo, Elena
   Cardenas Ruiz-Valdepenas, Eugenio
   Kaen, Ariel
   Martin Schrader, Ignacio
   Cano, David A.
   Soto-Moreno, Alfonso
TI Surgical Outcome and Treatment of Thyrotropin-Secreting Pituitary Tumors
   in a Tertiary Referral Center
SO WORLD NEUROSURGERY
LA English
DT Article
DE Somatostatin receptors; SSTRs; TSH-Secreting pituitary tumors
ID SOMATOSTATIN ANALOGS; SINGLE-CENTER; ADENOMAS; ASSOCIATION; DIAGNOSIS
AB OBJECTIVE: Thyrotropin (TSH)-secreting pituitary tumors are rare and typically present with hyperthyroidism. Here we report the diagnosis, treatment, and surgical outcomes in a series of patients with TSH-secreting pituitary tumors in a tertiary referral center.
   METHODS: Descriptive retrospective study that included all patients with TSH-secreting pituitary tumors who underwent transsphenoidal surgery in the endocrinology and nutrition unit of the Virgen del Rocio University Hospital (Seville, Spain) between 2004 and 2016.
   RESULTS: The mean age at diagnosis was 42.8 +/- 17 years. The mean time from onset of symptoms to diagnosis was 13 +/- 10 months. Four patients displayed symptoms indicating hyperthyroidism (1 suffered from tachycardia); 3 patients showed symptoms because of mass effect (visual impairment and headache) and 3 patients were diagnosed based on incidental findings after routine blood tests (high free thyroxine levels). Eight patients had macroadenomas, and 2 patients had microadenomas. Five patients underwent conventional pituitary surgery, and 5 patients underwent expanded endoscopic transsphenoidal surgery. Six patients achieved cure after surgery. The other patients received radiotherapy and/or treatment with somatostatin analogs. Analysis of somatostatin receptor (SSTR) expression by immunohistochemistry could be performed in 6 tumors.
   CONCLUSIONS: Our results confirm the clinical and hormonal heterogeneity caused by TSH-secreting pituitary adenomas. Surgery is considered the first choice of treatment for these tumors. We observed surgical cure rates similar to those reported in recent published series. SSTR2 and SSTR3 are highly expressed in TSH-secreting pituitary adenomas. Our results suggest that somatostatin analog treatment may be also helpful in the treatment of TSH-secreting pituitary adenomas.
C1 [Gros Herguido, Noelia; Dios Fuentes, Elena; Venegas-Moreno, Eva; Borau Maorad, Laura; Flores-Martinez, Alvaro; Remon Ruiz, Pablo; Cozar Duenas, Miriam; Cano, David A.; Soto-Moreno, Alfonso] Univ Seville, Unidad Gest Endocrinol & Nutr, Inst Biomed Sevilla, Hosp Univ Virgen del Rocio,CSIC, Seville, Spain.
   [Roldan, Florinda; Fajardo, Elena] Hosp Univ Virgen del Rocio, Radiol, Seville, Spain.
   [Cardenas Ruiz-Valdepenas, Eugenio; Kaen, Ariel; Martin Schrader, Ignacio] Hosp Univ Virgen del Rocio, Neurocirugia, Seville, Spain.
RP Soto-Moreno, A (reprint author), Univ Seville, Unidad Gest Endocrinol & Nutr, Inst Biomed Sevilla, Hosp Univ Virgen del Rocio,CSIC, Seville, Spain.
EM alfonsom.soto.sspa@juntadeandalucia.es
RI kaen, ariel/G-3786-2015; Martinez, Alvaro Flores/N-6406-2017; Cano,
   David/B-8013-2015
OI Martinez, Alvaro Flores/0000-0002-4926-3288; Cano,
   David/0000-0001-6264-3288; Remon-Ruiz, Pablo/0000-0002-4551-8159
FU ISCIII-Subdireccion General de Evaluacion y Fomento de la Investigacion;
   Fondos FEDEREuropean Union (EU) [PI16/00175]; Sistema Andaluz de Salud
   [A-0003 2016, A-0006 2017, C-0015 2014, RC-0006-2018]
FX This work was supported by grants from the ISCIII-Subdireccion General
   de Evaluacion y Fomento de la Investigacion cofunded with Fondos FEDER
   (PI16/00175 to A. Soto-Moreno and D. A. Cano) and the Sistema Andaluz de
   Salud (A-0003 2016 and A-0006 2017 to A. Soto-Moreno, C-0015 2014 and
   RC-0006-2018 to D. A. Cano.).
CR Azzalin A, 2016, PITUITARY, V19, P183, DOI 10.1007/s11102-015-0697-7
   Beck-Peccoz P, 2013, EUR THYROID J, V2, P76, DOI 10.1159/000351007
   Beck-Peccoz P, 2009, BEST PRACT RES CL EN, V23, P597, DOI 10.1016/j.beem.2009.05.006
   BECKPECCOZ P, 1994, EUR J ENDOCRINOL, V131, P331, DOI 10.1530/eje.0.1310331
   Brucker-Davis F, 1999, J CLIN ENDOCR METAB, V84, P476, DOI 10.1210/jc.84.2.476
   Cossu G, 2019, PITUITARY, V22, P79, DOI 10.1007/s11102-018-0921-3
   Gatto F, 2015, PITUITARY, V18, P583, DOI 10.1007/s11102-014-0611-8
   Gatto F, 2011, PITUITARY, V14, P141, DOI 10.1007/s11102-010-0271-2
   Kirkman MA, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.03.031
   Malchiodi E, 2014, J CLIN ENDOCR METAB, V99, P2069, DOI 10.1210/jc.2013-4376
   Nazato DM, 2018, J ENDOCRINOL INVEST, V41, P447, DOI 10.1007/s40618-017-0770-3
   Onnestam L, 2013, J CLIN ENDOCR METAB, V98, P626, DOI 10.1210/jc.2012-3362
   Rimareix F, 2015, THYROID, V25, P877, DOI 10.1089/thy.2015.0041
   Rotermund R, 2017, ACTA NEUROCHIR, V159, P1219, DOI 10.1007/s00701-017-3105-4
   Sapkota S, 2017, J CLIN ENDOCR METAB, V102, P566, DOI 10.1210/jc.2016-2261
   Tjornstrand A, 2017, EUR J ENDOCRINOL, V177, pR183, DOI 10.1530/EJE-16-1029
   van Varsseveld NC, 2014, CLIN ENDOCRINOL, V80, P395, DOI 10.1111/cen.12290
   Venegas-Moreno E, 2018, J CELL MOL MED, V22, P1640, DOI 10.1111/jcmm.13440
   Yamada S, 2014, J NEUROSURG, V121, P1462, DOI 10.3171/2014.7.JNS1471
NR 19
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E634
EP E639
DI 10.1016/j.wneu.2019.06.180
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200080
PM 31276853
DA 2020-05-12
ER

PT J
AU Gross, BA
   Jadhav, AP
   Jovin, TG
   Jankowitz, BT
AF Gross, Bradley A.
   Jadhav, Ashutosh P.
   Jovin, Tudor G.
   Jankowitz, Brian T.
TI Clinical Comparison of New Generation 0.071-inch and 0.072-inch
   Aspiration Catheters
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aspiration; Catheter; Stroke; Thrombectomy
AB INTRODUCTION: Three new 0.071-inch and 0.072-inch aspiration catheters have been introduced for stroke thrombectomy. Their comparative efficacy has not been clinically evaluated.
   METHODS: We reviewed a prospectively maintained thrombectomy database for cases using 1 of these 3 catheters for proximal large vessel occlusion from September 2018 to February 2019. Clinical and angiographic information was extracted.
   RESULTS: Of 145 thrombectomies performed over the time period, 49 utilized 1 of the 3 new large-bore catheters (React 71, n = 21; Vecta 71, n = 19; Jet 7, n = 9) on the first pass. Mean patient age was 73 years (SD: 15). Mean presenting National Institute of Health Stroke Scale score was 19 (SD: 6, range: 5-33). Clot location was middle cerebral artery first segment in 59% of cases, internal carotid artery in 31%, and basilar in 10%. With or without a stentriever, clot access with the initially selected aspiration catheter was achieved in 47 of 49 (96%) cases. Excluding empiric stentriever usage, the aspiration catheter could be delivered to the clot without needing a stentriever in 87% of cases: 100% with React 71, 93% with Vecta 71, and 43% with Jet 7 (P = 0.002). Final Thrombolysis in Cerebral Infarction score 2b/3 was achieved in 92% of cases overall: 95% with React 71, 89% with Jet 7, and 89% with Vecta 71. Median procedure time was 28 minutes; mean total number of passes was 2.4 (SD: 1.6) with 39% of cases being single-pass cases. These rates did not significantly differ between aspiration catheters.
   CONCLUSIONS: In comparing the newest large bore aspiration catheters, similar angiographic efficacy is achieved.
C1 [Gross, Bradley A.; Jankowitz, Brian T.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15213 USA.
   [Jadhav, Ashutosh P.] Univ Pittsburgh, Dept Neurol, Med Ctr, Pittsburgh, PA 15260 USA.
   [Gross, Bradley A.; Jadhav, Ashutosh P.; Jankowitz, Brian T.] Univ Pittsburgh, Stroke Inst, Med Ctr, Pittsburgh, PA 15213 USA.
   [Jovin, Tudor G.] Cooper Hlth Syst, Dept Neurol, Camden, NJ USA.
RP Gross, BA (reprint author), Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15213 USA.; Gross, BA (reprint author), Univ Pittsburgh, Stroke Inst, Med Ctr, Pittsburgh, PA 15213 USA.
EM Grossb2@upmc.edu
CR Alawieh Ali, 2020, Neurosurgery, V86, P61, DOI 10.1093/neuros/nyy444
   Delgado F, 2019, J NEUROINTERV SURG, V11, P147, DOI 10.1136/neurintsurg-2018-014163
   Lapergue B, 2017, JAMA-J AM MED ASSOC, V318, P443, DOI 10.1001/jama.2017.9644
   Nikoubashman O, 2017, AM J NEURORADIOL, V38, P2277, DOI 10.3174/ajnr.A5401
   Tonetti DA, 2019, J NEUROINTERV SURG, V11, P637, DOI 10.1136/neurintsurg-2018-014633
   Vargas J, 2017, J NEUROINTERV SURG, V9, P437, DOI 10.1136/neurintsurg-2015-012211
NR 6
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E463
EP E466
DI 10.1016/j.wneu.2019.06.120
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200058
PM 31247355
DA 2020-05-12
ER

PT J
AU Guo, MC
   Kong, C
   Sun, SY
   Sun, XY
   Li, XY
   Lu, SB
AF Guo, Machao
   Kong, Chao
   Sun, Siyuan
   Sun, Xiangyao
   Li, Xiangyu
   Lu, Shibao
TI Predictors of L4-L5 Degenerative Lumbar Spondylolisthesis: L4
   Inclination Angle and Facet Joint Angle
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atrophy paraspinal muscle; Degenerative lumbar spondylolisthesis; Facet
   joint angle; Facet joint degeneration; L4 inclination angle
ID BACK MUSCLES; BIOMECHANICS
AB OBJECTIVE: To evaluate the relationship between degenerative lumbar spondylolisthesis (DLS) and the L4 inclination angle (IA) and evaluate the risk factors of DLS.
   METHODS: Ninety patients with L4- L5 DLS and 90 with L4- L5 lumbar disc herniation or spinal stenosis (control group) were compared. Parameters including L4 IA, facet joint angle (FJA), cross-sectional area of paraspinal muscle, Pfirrmann grading of intervertebral disc, and degeneration grading of facet joint (FJ) were evaluated. The Student t tests and logistic regression analysis were used to analyze the risk factors of DLS.
   RESULTS: Statistical differences were found in L4 IA, -ass-sectional area of multifidus muscle, FJA, and degeneration grading of FJ between 2 groups (P < 0.001, P = 0.07, P < 0.001, and P < 0.001, respectively). The logistic regression analysis demonstrated that greater L4 IA (beta: -0.186, P < 0.001), more sagittal FJ (beta: -0.117, P < 0.001), and more severe degeneration of FJ (beta: -1.033, P < 0.001) were both significant predictors of DLS.
   CONCLUSIONS: Patients with L4 IA greater than 11.15 degrees greater than 60.19 degrees are more likely to occur DLS.
C1 [Guo, Machao; Kong, Chao; Sun, Siyuan; Sun, Xiangyao; Li, Xiangyu; Lu, Shibao] Capital Med Univ, Xuanwu Hosp, Dept Orthoped, Beijing, Peoples R China.
RP Lu, SB (reprint author), Capital Med Univ, Xuanwu Hosp, Dept Orthoped, Beijing, Peoples R China.
EM 13167513099@163.com
OI Sun, Xiangyao/0000-0001-9385-2402
CR Aono K, 2010, SPINE, V35, P887, DOI 10.1097/BRS.0b013e3181cdd1aa
   Berlemann U, 1998, Eur Spine J, V7, P376, DOI 10.1007/s005860050093
   BUTLER D, 1990, SPINE, V15, P111, DOI 10.1097/00007632-199002000-00012
   Danneels LA, 2001, SPINE, V26, pE114, DOI 10.1097/00007632-200103150-00003
   Degulmadi D, 2019, ASIAN SPINE J, V13, P22, DOI 10.31616/asj.2018.0116
   Ghogawala Z, 2016, NEW ENGL J MED, V374, P1424, DOI 10.1056/NEJMoa1508788
   GROBLER JL, 1993, SPINE, V18, P80
   Hansen L, 2006, SPINE, V31, P1888, DOI 10.1097/01.brs.0000229232.66090.58
   Izzo R, 2013, EUR J RADIOL, V82, P118, DOI 10.1016/j.ejrad.2012.07.024
   Jacobsen S, 2007, SPINE, V32, P120, DOI 10.1097/01.brs.0000250979.12398.96
   Kalichman L, 2009, SPINE, V34, pE579, DOI 10.1097/BRS.0b013e3181aa2acb
   Kalpakcioglu B, 2009, J BACK MUSCULOSKELET, V22, P27, DOI 10.3233/BMR-2009-0212
   Kamaz M, 2007, DIAGN INTERV RADIOL, V13, P144
   Lai Q, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891-018-2073-z
   LORENZ M, 1983, SPINE, V8, P122, DOI 10.1097/00007632-198303000-00002
   Pfirrmann CWA, 2001, SPINE, V26, P1873, DOI 10.1097/00007632-200109010-00011
   Roussouly Pierre, 2011, Eur Spine J, V20 Suppl 5, P609, DOI 10.1007/s00586-011-1928-x
   Schmidt H, 2008, SPINE, V33, P2741, DOI 10.1097/BRS.0b013e31817c4319
   Sengupta DK, 2005, SPINE, V30, pS71, DOI 10.1097/01.brs.0000155579.88537.8e
   STOKES IAF, 1995, SPINE, V20, P2168, DOI 10.1097/00007632-199510000-00018
   Wang GL, 2015, J BACK MUSCULOSKELET, V28, P277, DOI 10.3233/BMR-140515
NR 21
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E680
EP E686
DI 10.1016/j.wneu.2019.06.188
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200086
PM 31279114
DA 2020-05-12
ER

PT J
AU Gurung, P
   Motoyama, Y
   Takatani, T
   Takamura, Y
   Takeshima, Y
   Matsuda, R
   Tamura, K
   Yamada, S
   Nishimura, F
   Nakagawa, I
   Park, YS
   Kawaguchi, M
   Ohnishi, H
   Nakase, H
AF Gurung, Pritam
   Motoyama, Yasushi
   Takatani, Tsunenori
   Takamura, Yoshiaki
   Takeshima, Yasuhiro
   Matsuda, Ryosuke
   Tamura, Kentaro
   Yamada, Shuichi
   Nishimura, Fumihiko
   Nakagawa, Ichiro
   Park, Young-Su
   Kawaguchi, Masahiko
   Ohnishi, Hideyuki
   Nakase, Hiroyuki
TI Transient Augmentation of Intraoperative Motor Evoked Potentials During
   Middle Cerebral Artery Aneurysm Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Augmentation of evoked potential; Middle cerebral artery aneurysm; Motor
   evoked potential; Temporary clipping
ID BLOOD-FLOW INSUFFICIENCY; ANOXIA
AB OBJECTIVE: To study clinical significance of augmentation of intraoperative motor evoked potentials (MVPs) during direct open surgery for middle cerebral artery (MCA) aneurysms.
   METHODS: Between 2009 and 2017, 134 MCA aneurysm surgeries were performed with intraoperative MEP monitoring. The frequency and cause of augmentation with >50% increase of MEP amplitude from baseline were studied. Factors associated with MEP augmentation were investigated.
   RESULTS: MEP augmentation was demonstrated in 9 patients. All 9 events were observed just after application of the temporary clip to the parent artery. The ratio of the maximum amplitude to baseline was 2.6 +/- 1.1 at an mean of 2.4 +/- 1.1 minutes after parent artery occlusion. Ten patients who did not show MEP augmentation after parent artery occlusion were compared with the patients showing MEP augmentation. The distance of the temporary clip point from the midline was smaller in patients with MEP augmentation compared with patients without MEP augmentation (P = 0.033).
   CONCLUSIONS: MEP augmentation was thought to be an early ischumic sign preceding a significant decrease in MEPs during MCA aneurysm surgery. Transient augmentation of MEPs was more frequently observed in cases with a temporary clip applied to the more proximal part of the MCA.
C1 [Gurung, Pritam; Motoyama, Yasushi; Takamura, Yoshiaki; Takeshima, Yasuhiro; Matsuda, Ryosuke; Tamura, Kentaro; Yamada, Shuichi; Nishimura, Fumihiko; Nakagawa, Ichiro; Park, Young-Su; Nakase, Hiroyuki] Nara Med Univ, Dept Neurosurg, Kashihara, Nara, Japan.
   [Takatani, Tsunenori] Nara Med Univ, Dept Cent Lab, Kashihara, Nara, Japan.
   [Kawaguchi, Masahiko] Nara Med Univ, Dept Anesthesiol, Kashihara, Nara, Japan.
   [Gurung, Pritam; Ohnishi, Hideyuki] Ohnishi Neurol Ctr, Dept Neurosurg, Akashi, Hyogo, Japan.
RP Motoyama, Y (reprint author), Nara Med Univ, Dept Neurosurg, Kashihara, Nara, Japan.
EM myasushi@naramed-u.ac.jp
OI yamada, shuichi/0000-0002-7278-3978
FU Ministry of Education, Culture, Sports, Science, and Technology of
   JapanMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT) [17K10904]
FX This work was supported by a Grant-in-Aid for Scientific Research from
   the Ministry of Education, Culture, Sports, Science, and Technology of
   Japan (Grant No. 17K10904).
CR Bolay H, 2000, BRAIN RES, V873, P26, DOI 10.1016/S0006-8993(00)02466-5
   Chung J, 2019, J NEUROSURG, V130, P936, DOI 10.3171/2017.8.JNS17791
   Fujii M, 2008, SURG CEREB STROKE, V36, P373
   Fujioka M, 1999, STROKE, V30, P1043, DOI 10.1161/01.STR.30.5.1043
   Hofmeijer J, 2012, STROKE, V43, P607, DOI 10.1161/STROKEAHA.111.632943
   Horiuchi K, 2005, J NEUROSURG, V103, P275, DOI 10.3171/jns.2005.103.2.0275
   Iizuka T, 1982, Nihon Seikeigeka Gakkai Zasshi, V56, P163
   KHAZIPOV R, 1995, J NEUROPHYSIOL, V74, P2138
   Motoyama Y, 2011, NEUROL MED-CHIR, V51, P15, DOI 10.2176/nmc.51.15
   Suzuki K, 2003, J NEUROSURG, V98, P507, DOI 10.3171/jns.2003.98.3.0507
   Szelenyi A, 2006, J NEUROSURG, V105, P675, DOI 10.3171/jns.2006.105.5.675
   ZHU PJ, 1994, NEUROSCI LETT, V166, P27, DOI 10.1016/0304-3940(94)90832-X
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E127
EP E132
DI 10.1016/j.wneu.2019.06.004
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200017
PM 31201943
DA 2020-05-12
ER

PT J
AU Hajimohammadebrahim-Ketabforoush, M
   Shahmohammadi, M
   Khoundabi, B
   Shariatpanahi, ZV
AF Hajimohammadebrahim-Ketabforoush, Melika
   Shahmohammadi, Mohammadreza
   Khoundabi, Batoul
   Shariatpanahi, Zahra Vahdat
TI Effect of Vitamin D Supplementation on Postcraniotomy Pain After Brain
   Tumor Surgery: A Randomized Clinical Trial
SO WORLD NEUROSURGERY
LA English
DT Article
DE 25(OH) D; Analgesics; Brain tumor surgery; Visual analogue scale
ID QUALITY-OF-LIFE; D DEFICIENCY; POSTOPERATIVE PAIN; MUSCULOSKELETAL PAIN;
   CRANIOTOMY; CHOLECALCIFEROL; REQUIREMENTS; HEADACHE
AB OBJECTIVE: To determine the effect of vitamin D supplementation on postoperative pain and analgesic requirement in brain tumor surgery.
   METHODS: A total of 60 patients with vitamin D serum levels <= 20 ng/dL were randomly assigned to 2 groups equally. The study group (n = 30) received intramuscular injection of 300,000 IU vitamin D before surgery.
   RESULTS: Preoperative serum level of vitamin D was 15.9 +/- ng/dL and 14.5 +/- 3.6 ng/dL in the study and control groups, respectively (P = 0.13). Serum level of vitamin D on day 5 of surgery was 22.5 +/- 4.3 and 13.7 +/- 3.8 in the study and control groups, respectively (P < 0.001). A percentage of 50% had pain scores >4 on the first postoperative day, which decreased with time. The median (interquartile range) of the visual analogue scale score during the 3 postoperative days was 3(5), 3(5), 1(3), and 5(7), 2(5), 1(3) in the study and control groups, respectively, with no significant difference. There was no difference in analgesic consumption between the 2 groups. Analysis through the generalized estimating equation model indicated that patients who had received vitamin D for a longer time before the operative time had an insignificantly less pain score.
   CONCLUSIONS: On the basis of the study results, one of our patients reported moderate-to-severe pain scores on the first day after surgery. The pain in the study group was insignificantly less than that in the control group, but it seems that chronic high level of vitamin D may lead to promising results.
C1 [Hajimohammadebrahim-Ketabforoush, Melika] Shahid Beheshti Univ Med Sci, Natl Nutr & Food Technol Res Inst, Fac Nutr Sci & Food Technol, Student Res Comm,Dept Clin Nutr & Dietet, Tehran, Iran.
   [Shahmohammadi, Mohammadreza] Shahid Beheshti Univ Med Sci, Shohada Tajrish Hosp, Dept Neurosurg, Tehran, Iran.
   [Khoundabi, Batoul] Red Crescent Soc Iran, Helal E Iran Appl Sci Higher Educ Inst, Tehran, Iran.
   [Shariatpanahi, Zahra Vahdat] Shahid Beheshti Univ Med Sci, Natl Nutr & Food Technol Res Inst, Fac Nutr Sci & Food Technol, Dept Clin Nutr & Dietet, Tehran, Iran.
RP Shariatpanahi, ZV (reprint author), Shahid Beheshti Univ Med Sci, Natl Nutr & Food Technol Res Inst, Fac Nutr Sci & Food Technol, Dept Clin Nutr & Dietet, Tehran, Iran.
EM nutritiondata@yahoo.com
OI khoundabi, batoul/0000-0001-8558-4735; Vahdat Shariatpanahi,
   Zahra/0000-0002-8008-2493
FU Shahid Beheshti University of Medical Sciences, Tehran, Iran
FX This study is financially supported by Shahid Beheshti University of
   Medical Sciences, Tehran, Iran.
CR Al Faraj S, 2003, SPINE, V28, P177, DOI 10.1097/00007632-200301150-00015
   Ardehali SH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21177-4
   Badsha H, 2009, CLIN RHEUMATOL, V28, P971, DOI 10.1007/s10067-009-1146-7
   Bose S, 2015, CAN J ANESTH, V62, P770, DOI 10.1007/s12630-015-0357-4
   Chowdhury T, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00023
   de la Jara GD, 2004, BMJ-BRIT MED J, V329, P156
   de Torrente de la Jara G, 2006, BMC Fam Pract, V7, P4, DOI 10.1186/1471-2296-7-4
   DeBenedittis G, 1996, NEUROSURGERY, V38, P466, DOI 10.1097/00006123-199603000-00008
   Dunbar PJ, 1999, ANESTH ANALG, V88, P335, DOI 10.1097/00000539-199902000-00021
   GLOTH FM, 1991, ARCH INTERN MED, V151, P1662, DOI 10.1001/archinte.151.8.1662
   Gottschalk A, 2007, J NEUROSURG, V106, P210, DOI 10.3171/jns.2007.106.2.210
   HANSEN MS, 2013, DAN MED J, V60
   Huang W, 2013, CLIN J PAIN, V29, P341, DOI 10.1097/AJP.0b013e318255655d
   Iwamoto Jun, 2003, J Orthop Sci, V8, P532, DOI 10.1007/s00776-003-0655-5
   Lee A, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001812
   Lee P, 2008, ARCH INTERN MED, V168, P771, DOI 10.1001/archinte.168.7.771
   Leslie K, 2003, ANESTHESIOLOGY, V99, P1158, DOI 10.1097/00000542-200311000-00024
   Lotfi A, 2007, CLIN RHEUMATOL, V26, P1895, DOI 10.1007/s10067-007-0603-4
   Mordhorst C, 2010, J NEUROSURG ANESTH, V22, P202, DOI 10.1097/ANA.0b013e3181df0600
   Nair P, 2015, CRIT CARE MED, V43, P2313, DOI 10.1097/CCM.0000000000001201
   Plotnikoff GA, 2003, MAYO CLIN PROC, V78, P1463, DOI 10.4065/78.12.1463
   Prakash S, 2013, ANN INDIAN ACAD NEUR, V16, P650, DOI 10.4103/0972-2327.120487
   Quraishi SA, 2015, CRIT CARE MED, V43, P1928, DOI 10.1097/CCM.0000000000001148
   Rocha PAS, 2008, CEPHALALGIA, V28, P41, DOI 10.1111/j.1468-2982.2007.01465.x
   Shams Tarek, 2014, J Anaesthesiol Clin Pharmacol, V30, P20, DOI 10.4103/0970-9185.125692
   Shipton EA, 2015, PAIN RES TREAT, V2015, DOI 10.1155/2015/904967
   Suksompong Sirilak, 2016, Journal of the Medical Association of Thailand, V99, P539
   Van Veldhuizen PJ, 2000, J UROLOGY, V163, P187, DOI 10.1016/S0022-5347(05)68001-9
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E105
EP E111
DI 10.1016/j.wneu.2019.05.250
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200014
PM 31181357
DA 2020-05-12
ER

PT J
AU Hasegawa, M
   Hatayama, T
   Kondo, A
   Nagahiro, S
   Fujimaki, T
   Amagasaki, K
   Arita, K
   Date, I
   Fujii, Y
   Goto, T
   Hanaya, R
   Higuchi, Y
   Hongo, K
   Inoue, T
   Kasuya, H
   Kayama, T
   Kawashima, M
   Kohmura, E
   Maehara, T
   Matsushima, T
   Mizobuchi, Y
   Morita, A
   Nishizawa, S
   Noro, S
   Saito, S
   Shimano, H
   Shirane, R
   Takeshima, H
   Tanaka, Y
   Tanabe, H
   Toda, H
   Yamakami, I
   Nishiyama, Y
   Ohba, S
   Hirose, Y
   Suzuki, T
AF Hasegawa, Mitsuhiro
   Hatayama, Toru
   Kondo, Akinori
   Nagahiro, Shinji
   Fujimaki, Takamitsu
   Amagasaki, Kenichi
   Arita, Kazunori
   Date, Isao
   Fujii, Yukihiko
   Goto, Takeo
   Hanaya, Ryosuke
   Higuchi, Yoshinori
   Hongo, Kazuhiro
   Inoue, Toru
   Kasuya, Hidetoshi
   Kayama, Takamasa
   Kawashima, Masatou
   Kohmura, Eiji
   Maehara, Taketoshi
   Matsushima, Toshio
   Mizobuchi, Yoshihumi
   Morita, Akio
   Nishizawa, Shigeru
   Noro, Shusaku
   Saito, Shinjiro
   Shimano, Hirofumi
   Shirane, Reizo
   Takeshima, Hideo
   Tanaka, Yuichiro
   Tanabe, Hidenori
   Toda, Hiroki
   Yamakami, Iwao
   Nishiyama, Yuya
   Ohba, Shigeo
   Hirose, Yuichi
   Suzuki, Takeya
TI Prosthesis Used in Microvascular Decompressions: A Multicenter Survey in
   Japan Focusing on Adverse Events
SO WORLD NEUROSURGERY
LA English
DT Article
DE Absorbable material; Adverse event; Microvascular decompression;
   Non-absorbable material; Prosthesis; Surgical technique
ID RECURRENT TRIGEMINAL NEURALGIA; GIANT-CELL REACTION; HEMIFACIAL SPASM;
   TEFLON GRANULOMA; POSTERIOR-FOSSA; NEUROVASCULAR COMPRESSION; VASCULAR
   TRANSPOSITION; ETHYL 2-CYANOACRYLATE; VERTEBRAL ARTERY; CRANIAL NERVES
AB OBJECTIVE: To investigate the characteristics of materials used as prostheses for microvascular decompression surgery (MVDs) in Japan and their possible adverse events (AEs) to determine preferable materials for MVDs.
   METHODS: A questionnaire was sent to all members of the Japanese Society for MVDs, and answers were obtained from 59 institutions.
   RESULTS: Among a total of 2789 MVDs, 1088 operations for trigeminal neuralgia, 1670 for hemifacial spasm, and 31 others, including 117 reoperations, were performed between April 2011 and March 2014. Nonabsorbable material was used in 96.5% of MVDs, including polytetrafluoroethylene (PTFE) (80.5%), polyurethane (11.9%), expanded PTFE (21%), and silk thread (t47%). The use of absorbable materials, including fibrin glue (87.5%), cellulose (13.5%), gelatin (4,77%), and collagen (136%), was reported. The major combinations were PTFE with fibrin glue (58.7%) followed by PTFE alone (7.60%). Eighty-eight AEs in 85 (32%) cases were reported among 2672 first operations. AEs included 51 central nervous system dysfunctions, 15 wound infections/dehiscence, and 10 others, which were presumed to be related to the intraoperative procedure. Among relatively high-, moderate-, and low-volume centers, there were no significant differences in the frequency of AEs (P = 0.077). Tissue-prosthesis adhesion and/or granuloma formation were reported in 13 cases of 117 reoperations. The incidence of adhesion-related recurrence was 11.1% of all reoperations.
   CONCLUSIONS: The number of AEs was quite low in this survey, and intradural use of any prosthesis reported in this paper might be justified; however, further development of easily handled and less-adhesive prosthesis materials is awaited.
C1 [Hasegawa, Mitsuhiro; Nishiyama, Yuya; Ohba, Shigeo; Hirose, Yuichi; Suzuki, Takeya] Fujita Hlth Univ, Sch Med, Toyoake, Aichi, Japan.
   [Hatayama, Toru] Mito Brain Heart Ctr, Mito, Ibaraki, Japan.
   [Kondo, Akinori; Shimano, Hirofumi] Shiroyama Hosp, Brain & Spine Surg Ctr, Osaka, Japan.
   [Nagahiro, Shinji; Mizobuchi, Yoshihumi] Tokushima Univ, Grad Sch, Inst Biomed Sci, Tokushima, Japan.
   [Fujimaki, Takamitsu] Saitama Med Univ Hosp, Saitama, Japan.
   [Amagasaki, Kenichi] Mitsui Mem Hosp, Tokyo, Japan.
   [Arita, Kazunori; Hanaya, Ryosuke] Kagoshima Univ, Grad Sch Med & Dent Sci, Kagoshima, Japan.
   [Date, Isao] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan.
   [Fujii, Yukihiko] Niigata Univ, Niigata, Japan.
   [Goto, Takeo] Osaka City Univ, Grad Sch Med, Osaka, Japan.
   [Higuchi, Yoshinori] Chiba Univ, Grad Sch Med, Chiba, Japan.
   [Hongo, Kazuhiro] Shinshu Univ, Matsumoto, Nagano, Japan.
   [Hongo, Kazuhiro] Shinshu Univ, Sch Med, Matsumoto, Nagano, Japan.
   [Inoue, Toru] Fukuoka Univ, Sch Med Sci, Fukuoka, Fukuoka, Japan.
   [Kasuya, Hidetoshi] Tokyo Womens Med Univ, Med Ctr East, Tokyo, Japan.
   [Kayama, Takamasa] Yamagata Univ, Yamagata, Japan.
   [Kawashima, Masatou] Int Univ Hlth & Welf, Chiba, Japan.
   [Kohmura, Eiji] Kobe Univ, Grad Sch Med, Kobe, Hyogo, Japan.
   [Maehara, Taketoshi] Tokyo Med & Dent Univ, Tokyo, Japan.
   [Matsushima, Toshio] Fukuoka Sanno Hosp, Fukuoka, Fukuoka, Japan.
   [Morita, Akio] Nippon Med Sch, Tokyo, Japan.
   [Nishizawa, Shigeru] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka, Japan.
   [Noro, Shusaku] Nakamura Mem Hosp, Sapporo, Hokkaido, Japan.
   [Saito, Shinjiro] Saiseikan Hosp, Yamagata, Japan.
   [Shirane, Reizo] Miyagi Childrens Hosp, Dept Neurosurg, Sendai, Miyagi, Japan.
   [Takeshima, Hideo] Univ Miyazaki, Fac Med, Miyazaki, Japan.
   [Tanaka, Yuichiro] St Marianna Univ, Sch Med, Kawasaki, Kanagawa, Japan.
   [Tanabe, Hidenori] Tanabe Neurosurg Hosp, Fujiidera, Japan.
   [Toda, Hiroki] Fukui Red Cross Hosp, Fukui, Japan.
   [Yamakami, Iwao] Seikei Kai Chiba Med Ctr, Chiba, Japan.
RP Hasegawa, M (reprint author), Fujita Hlth Univ, Sch Med, Toyoake, Aichi, Japan.
EM mhasegawah@yahoo.co.jp
CR Amador N, 2008, J NEUROSURG, V108, P916, DOI 10.3171/JNS/2008/108/5/0916
   Apfelbaum R I, 1983, Clin Neurosurg, V31, P351
   Au WL, 2004, ANN ACAD MED SINGAP, V33, P324
   Banczerowski P, 2014, J NEUROSURG, V121, P1492, DOI 10.3171/2014.8.JNS132445
   BARKER FG, 1995, J NEUROSURG, V82, P201, DOI 10.3171/jns.1995.82.2.0201
   Barker FG, 1997, NEUROSURGERY, V40, P39, DOI 10.1097/00006123-199701000-00008
   Bejjani GK, 1997, J NEUROSURG, V86, P728, DOI 10.3171/jns.1997.86.4.0728
   Capelle HH, 2010, J HEADACHE PAIN, V11, P339, DOI 10.1007/s10194-010-0213-4
   Chen JF, 2000, SURG NEUROL, V53, P281, DOI 10.1016/S0090-3019(00)00169-5
   CHO DY, 1994, NEUROSURGERY, V35, P665, DOI 10.1227/00006123-199410000-00012
   Chou S N, 1977, J Neurosurg, V46, P266
   CHUONG R, 1993, ORAL SURG ORAL MED O, V76, P16, DOI 10.1016/0030-4220(93)90286-D
   DANDY WE, 1934, AM J SURG, V24, P447, DOI DOI 10.1016/S0002-9610(34)90403-7
   Deep NL, 2017, LARYNGOSCOPE, V127, P715, DOI 10.1002/lary.26126
   Fukushima T, 1984, FACIAL N RES JPN, V4, P9
   GARDNER WJ, 1962, J NEUROSURG, V19, P947, DOI 10.3171/jns.1962.19.11.0947
   GARDNER WJ, 1959, JAMA-J AM MED ASSOC, V170, P1773, DOI 10.1001/jama.1959.03010150017004
   Gheorghiu D, 2010, ACTA ORTHOP BELG, V76, P129
   GOYA T, 1990, Neurologia Medico-Chirurgica, V30, P462, DOI 10.2176/nmc.30.462
   Jannetta P J, 1997, Clin Neurosurg, V44, P331
   Jannetta P J, 1985, Clin Neurosurg, V32, P334
   JANNETTA PJ, 1977, J NEUROSURG, V47, P321, DOI 10.3171/jns.1977.47.3.0321
   JANNETTA PJ, 1980, ANN SURG, V192, P518, DOI 10.1097/00000658-198010000-00010
   JANNETTA PJ, 1967, J NEUROSURG, V26, P159, DOI 10.3171/jns.1967.26.1part2.0159
   Kalkanis SN, 2003, NEUROSURGERY, V52, P1251, DOI 10.1227/01.NEU.0000065129.25359.EE
   Kawamura S, 1998, NEUROL MED-CHIR, V38, P12, DOI 10.2176/nmc.38.12
   Kobata H, 1998, NEUROSURGERY, V43, P1351, DOI 10.1097/00006123-199812000-00052
   Kondo A, 1979, No Shinkei Geka, V7, P677
   Kondo Akihide, 2018, Surg Neurol Int, V9, P187, DOI 10.4103/sni.sni_146_18
   Kudo T, 2006, INTERV NEURORADIOL, V12, P145, DOI 10.1177/15910199060120S124
   Kureshi SA, 1998, NEUROSURGERY, V43, P1111, DOI 10.1097/00006123-199811000-00061
   LAWS ER, 1986, J NEUROSURG, V64, P679, DOI 10.3171/jns.1986.64.4.0679
   LINSKEY ME, 1994, J NEUROSURG, V81, P1, DOI 10.3171/jns.1994.81.1.0001
   Lypka M, 2007, J ORAL MAXIL SURG, V65, P1680, DOI 10.1016/j.joms.2006.09.030
   Matsushima T, 2000, ACTA NEUROCHIR, V142, P557, DOI 10.1007/s007010050469
   MEGERIAN CA, 1995, AM J OTOL, V16, P783
   Miller LE, 2012, BRIT J NEUROSURG, V26, P438, DOI 10.3109/02688697.2011.641613
   Mitsos AP, 2008, NEUROSURG REV, V31, P327, DOI 10.1007/s10143-008-0144-6
   Mizobuchi Y, 2018, NEUROL MED-CHIR, V58, P10, DOI 10.2176/nmc.oa.2017-0100
   Mizobuchi Y, 2017, NEUROL MED-CHIR, V57, P184, DOI 10.2176/nmc.oa.2016-0237
   NAGATA K, 1986, J NEUROSURG, V65, P564, DOI 10.3171/jns.1986.65.4.0564
   Nakajima N, 2004, SURG NEUROL, V62, P346, DOI 10.1016/j.surneu.2003.10.046
   Oda K, 2017, NEUROSURG REV, V40, P513, DOI 10.1007/s10143-017-0865-5
   Oiwa Y, 2004, NEUROL MED-CHIR, V44, P94, DOI 10.2176/nmc.44.94
   Premsagar IC, 1997, J NEUROSURG, V87, P454, DOI 10.3171/jns.1997.87.3.0454
   Rath SA, 1996, NEUROSURGERY, V39, P933, DOI 10.1097/00006123-199611000-00010
   Rawlinson J N, 1988, Br J Neurosurg, V2, P173, DOI 10.3109/02688698808992667
   Rzaev D A, 2016, Zh Vopr Neirokhir Im N N Burdenko, V80, P78, DOI 10.17116/neiro201680278-83
   Shigeno T, 2002, NEUROL MED-CHIR, V42, P184, DOI 10.2176/nmc.42.184
   Sindou M, 2018, NEUROCHIRURGIE, V64, P106, DOI 10.1016/j.neuchi.2018.01.001
   SINDOU M, 1990, NEUROCHIRURGIE, V36, P16
   Sindou M, 2008, NEUROSURGERY, V63, P341, DOI 10.1227/01.NEU.0000327022.79171.D6
   Sindou MP, 2005, ACTA NEUROCHIR, V147, P1019, DOI 10.1007/s00701-005-0583-6
   Soose RJ, 2007, SKULL BASE-INTERD AP, V17, P247, DOI 10.1055/s-2007-984492
   Tanaka Y, 2014, NEUROL MED-CHIR, V54, P483, DOI 10.2176/nmc.tn2012-0296
   Tate JR, 2007, ENT-EAR NOSE THROAT, V86, P134, DOI 10.1177/014556130708600304
   Tatli M, 2008, ACTA NEUROCHIR, V150, P243, DOI 10.1007/s00701-007-1488-3
   Tokuda Y, 1998, NEUROSURGERY, V43, P626, DOI 10.1097/00006123-199809000-00136
   Toth G, 2007, NEUROSURGERY, V61, P875
   Udeshi M, 2006, Australas Radiol, V50, P233, DOI 10.1111/j.1440-1673.2006.01568.x
   Ueki T, 1992, Rinsho Shinkeigaku, V32, P1028
   Vitali AM, 2007, ACTA NEUROCHIR, V149, P719, DOI 10.1007/s00701-007-1174-5
   Yamagata Sen, 1993, Neurologia Medico-Chirurgica, V33, P582, DOI 10.2176/nmc.33.582
   YAMAKI T, 1992, ACTA NEUROCHIR, V115, P1, DOI 10.1007/BF01400583
NR 64
TC 1
Z9 1
U1 4
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E251
EP E258
DI 10.1016/j.wneu.2019.06.053
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200032
PM 31207376
DA 2020-05-12
ER

PT J
AU He, YS
   Zheng, T
   Wu, B
   Wang, JY
AF He, Yunsen
   Zheng, Tao
   Wu, Bo
   Wang, Jiyang
TI Significance of Modified Clivoaxial Angles in the Treatment of Adult
   Chiari Malformation Type I
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chicago Chiari outcome scale; Chiari malformation type I; Classification
   system; Modified clivoaxial angles; Surgical procedures; Ventral
   compression
ID POSTERIOR-FOSSA DECOMPRESSION; SURGICAL-TREATMENT; DURAPLASTY;
   INCLINATION; OUTCOMES; SYSTEM; LINE
AB OBJECTIVE: To investigate the influence of modified clivoaxial angle (MCAA) on the surgical planning and outcome in adult patients with Chiari malformation type I.
   METHODS: Clinical data of 268 adult patients undergoing posterior fossa decompression without (PFD) or with duraplasty (PFDD) or with resection of tonsils (RT) for Chiari malformation type I over 10 years were reviewed retrospectively, with outcome evaluated by Chicago Chiari Outcome Scale (CCOS) score. By means of receiver operating characteristic curve, the threshold of MCAA was calculated to stratify the patients.
   RESULTS: MCAA was positively correlated with CCOS score. In the MCAA <= 127 degrees group (n = 57) with severe ventral cervicomedullary compression (VCMC), CCOS score of PFD, PFDD, and RT was 11.00, 11.06, and 12.42 (P < 0.05), respectively. In the 127 degrees < MCAA <= 138 degrees group (n = 87) with moderate VCMC, CCOS score of PFD, PFDD, and RT was 11.71, 12.72, and 13.00 (P < 0.01), respectively. In the MCAA > 138 degrees group (n = 124) with mild or no VCMC, CCOS score of PFD, PFDD, and RT was 13.19, 13.90, and 13.67 (P < 0.05), respectively. The mean MCAA increased by 4.4 degrees postoperatively (P < 0.05), which was positively associated with syringomyelia shrinkage.
   CONCLUSIONS: MCAA may play a role in guiding the surgical treatment and predicting the prognosis in adult CMI patients. The larger the MCAA, the less invasive surgery is preferred with higher CCOS. PFDD should be the first choice in patients with mild or no VCMC (MCAA >138 degrees) and RT in patients with moderate VCMC (127 < MCAA <= 138 degrees). For patients with severe VCMC (MCAA <= 127 degrees), RT could be considered as the primary surgery with awareness of the possible insufficiency of posterior decompression alone.
C1 [He, Yunsen; Zheng, Tao; Wu, Bo] Sichuan Acad Med Sci, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
   [He, Yunsen; Zheng, Tao; Wu, Bo] Sichuan Prov Peoples Hosp, Chengdu, Sichuan, Peoples R China.
   [Wang, Jiyang] Southwest Med Univ, Dept Neurosurg, Affiliated Hosp, Luzhou, Sichuan, Peoples R China.
RP Wu, B (reprint author), Sichuan Acad Med Sci, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.; Wu, B (reprint author), Sichuan Prov Peoples Hosp, Chengdu, Sichuan, Peoples R China.
EM wuboscph@sina.com
CR Aliaga L, 2012, NEUROSURGERY, V70, P656, DOI 10.1227/NEU.0b013e31823200a6
   Batzdorf U, 2013, J NEUROSURG, V118, P232, DOI 10.3171/2012.10.JNS12305
   Batzdorf U, 2011, WORLD NEUROSURG, V75, P222, DOI 10.1016/j.wneu.2010.10.058
   Besachio DA, 2015, J NEUROSURG-SPINE, V23, P701, DOI 10.3171/2015.3.SPINE14926
   BINDAL AK, 1995, NEUROSURGERY, V37, P1069, DOI 10.1227/00006123-199512000-00005
   Bollo RJ, 2012, J NEUROSURG-PEDIATR, V10, P134, DOI 10.3171/2012.3.PEDS11340
   Chotai S, 2014, CLIN NEUROL NEUROSUR, V125, P182, DOI 10.1016/j.clineuro.2014.07.027
   Fernandes YB, 2016, ARQ NEURO-PSIQUIAT, V74, P405, DOI 10.1590/0004-282X20160041
   GARDNER W J, 1958, Clin Neurosurg, V6, P131
   Grabb PA, 1999, NEUROSURGERY, V44, P520, DOI 10.1097/00006123-199903000-00050
   Greenberg JK, 2015, NEUROSURGERY, V76, P279, DOI 10.1227/NEU.0000000000000608
   Hankinson TC, 2017, J NEUROSURG-PEDIATR, V20, P170, DOI 10.3171/2017.3.PEDS16604
   Hayashi Y, 2018, WORLD NEUROSURG, V116, pE1129, DOI 10.1016/j.wneu.2018.05.186
   Henderson FC, 2018, NEUROSURG REV, V41, P149, DOI 10.1007/s10143-017-0830-3
   Houston JR, 2018, J NEURORADIOLOGY, V45, P23, DOI 10.1016/j.neurad.2017.06.006
   Khaleel ZL, 2014, J NEUROSURG-SPINE, V20, P172, DOI 10.3171/2013.10.SPINE13405
   Lei ZW, 2018, CURR MED SCI, V38, P289, DOI 10.1007/s11596-018-1877-2
   Limonadi FM, 2004, J NEUROSURG, V101, P184, DOI 10.3171/ped.2004.101.2.0184
   Lin WW, 2018, WORLD NEUROSURG, V110, P460, DOI 10.1016/j.wneu.2017.10.161
   Munshi I, 2000, NEUROSURGERY, V46, P1384, DOI 10.1097/00006123-200006000-00018
   Nagashima C, 1983, Neurosurg Rev, V6, P187, DOI 10.1007/BF01743100
   Navarro R, 2004, CHILD NERV SYST, V20, P349, DOI 10.1007/s00381-003-0883-1
   Salunke P, 2012, ACTA NEUROCHIR, V154, P147, DOI 10.1007/s00701-011-1215-y
   Sanders FH, 2017, CHILD NERV SYST, V33, P1415, DOI 10.1007/s00381-017-3459-1
   Shweikeh Faris, 2015, Pediatr Neurosurg, V50, P31, DOI 10.1159/000371659
   Smoker WRK, 2008, CHILD NERV SYST, V24, P1123, DOI 10.1007/s00381-008-0601-0
   Sousa UD, 2018, NEUROSURG REV, V41, P311, DOI 10.1007/s10143-017-0857-5
   Tanaka S, 2010, J CLIN NEUROSCI, V17, P649, DOI 10.1016/j.jocn.2009.07.116
   Thakar S, 2018, J NEUROSURG-SPINE, V28, P23, DOI 10.3171/2017.5.SPINE17264
   Wang X, 2019, WORLD NEUROSURG, V122, pE443, DOI 10.1016/j.wneu.2018.10.068
   Zhao JL, 2016, WORLD NEUROSURG, V88, P7, DOI 10.1016/j.wneu.2015.11.087
NR 31
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E1004
EP E1014
DI 10.1016/j.wneu.2019.07.060
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200124
PM 31306845
DA 2020-05-12
ER

PT J
AU Henaux, PL
   Jannin, P
   Riffaud, L
AF Henaux, Pierre-Louis
   Jannin, Pierre
   Riffaud, Laurent
TI Nontechnical Skills in Neurosurgery: A Systematic Review of the
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cognitive skills; Interpersonal skills; Neurosurgery; Nontechnical
   skills; Patient safety
ID OBSERVATIONAL TEAMWORK ASSESSMENT; SURGICAL SAFETY CHECKLIST;
   OPERATING-ROOM; SURGEONS LEADERSHIP; DECISION-MAKING; REALITY
   SIMULATION; NEEDS-ASSESSMENT; RATING SYSTEM; RESIDENCY; EDUCATION
AB BACKGROUND: Undesirable events in the neurosurgery operating theater have less often been the result of a technical error than of a dysfunction linked to nontechnical skills (NTSs). The essential aim of our study was to perform a systematic review of the reported data on NTS in neurosurgery. Our secondary objective was to identify the NTSs more specific to neurosurgery to define the training needs of neurosurgery trainees.
   METHODS: The MEDLINE and Cochrane Database of Systematic Reviews were searched according to the PRISMA (preferred reporting items for systematic reviews and meta-analysis) guidelines. The search initially identified 2132 reports, of which 21 were eligible for systematic study. Data were extracted from the report regarding study design, sample size, NTSs assessed, and assessment tools, and the key results were collected.
   RESULTS: Interpersonal skills (communication, teamwork), cognitive skills (decision making, situational awareness), and personal resource factors (coping with stress or fatigue) were specifically identified. No study had used assessment tools such as NOTECHS (nontechnical skills), NOTSS (nontechnical skills for surgeons), or OTAS (observational teamwork assessment for surgery). They were performed in a real environment in 11 cases, in a simulated environment in 9, and during theoretical teaching in 1 case.
   CONCLUSIONS: Very few studies have been performed concerning neurosurgical NTSs, despite the increasing the number of studies during the past few years on NTSs in other domains of surgery. Society has been concentrating more and more on the quality and safety of medical care. The development and application of NTS assessment tools is, therefore, essential to provide assistance in the training of future neurosurgeons.
C1 [Henaux, Pierre-Louis; Riffaud, Laurent] Rennes Univ Hosp, Dept Neurosurg, Rennes, France.
   [Henaux, Pierre-Louis; Jannin, Pierre; Riffaud, Laurent] Rennes 1 Univ, INSERM MediCIS, Unit LTSI U1099, Fac Med, Rennes, France.
RP Henaux, PL (reprint author), Rennes Univ Hosp, Dept Neurosurg, Rennes, France.
EM pierre-louis.henaux@etudiant.univ-rennes1.fr
RI Jannin, Pierre/P-9958-2019
OI Jannin, Pierre/0000-0002-7415-071X
CR Ajlan AM, 2015, WORLD NEUROSURG, V83, P46, DOI 10.1016/j.wneu.2013.08.039
   Alaraj A, 2013, NEUROSURGERY, V72, pA115, DOI 10.1227/NEU.0b013e3182753093
   Arora S, 2012, ANN SURG, V256, P982, DOI 10.1097/SLA.0b013e3182610c91
   Arora S, 2011, AM J SURG, V202, P500, DOI 10.1016/j.amjsurg.2011.01.024
   Arora S, 2010, AM J SURG, V199, P60, DOI 10.1016/j.amjsurg.2009.07.036
   Brandman DM, 2015, CAN J NEUROL SCI, V42, P17, DOI 10.1017/cjn.2014.123
   Chan S, 2013, NEUROSURGERY, V72, pA154, DOI 10.1227/NEU.0b013e3182750d26
   Ciporen J, 2018, J NEUROSURG ANESTH, V30, P65, DOI 10.1097/ANA.0000000000000401
   Couat JF, 2013, NEUROCHIRURGIE, V59, P142, DOI 10.1016/j.neuchi.2013.05.001
   Cusimano MD, 1999, ACAD MED, V74, P925, DOI 10.1097/00001888-199908000-00019
   Da Silva-Freitas R, 2012, NEUROCIRUGIA, V23, P60, DOI 10.1016/j.neucir.2012.04.006
   de Ribaupierre S, 2012, COMPUT BIOL MED, V42, P692, DOI 10.1016/j.compbiomed.2012.03.005
   Dedy NJ, 2013, SURGERY, V154, P1000, DOI 10.1016/j.surg.2013.04.034
   Dumont TM, 2012, J SURG EDUC, V69, P407, DOI 10.1016/j.jsurg.2011.09.011
   Fallah A, 2014, WORLD NEUROSURG, V81, pE21, DOI 10.1016/j.wneu.2010.12.058
   Fallah A, 2010, CAN J NEUROL SCI, V37, P855, DOI 10.1017/S0317167100051568
   Fargen KM, 2013, J NEUROINTERV SURG, V5, P497, DOI 10.1136/neurintsurg-2012-010430
   Fargen KM, 2012, J NEUROINTERV SURG, V4, P438, DOI 10.1136/neurintsurg-2011-010128
   Fernando N, 2007, MED EDUC, V41, P968, DOI 10.1111/j.1365-2923.2007.02839.x
   Ferroli P, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12252
   Filho Francisco Vaz Guimaraes, 2011, Neurosurg Focus, V30, pE17, DOI 10.3171/2011.2.FOCUS10321
   Flin R, 2007, SURG-J R COLL SURG E, V5, P86, DOI 10.1016/S1479-666X(07)80059-X
   Flin R, 2007, QUAL SAF HEALTH CARE, V16, P235, DOI 10.1136/qshc.2006.020743
   Ganju A, 2012, J NEUROSURG, V116, P478, DOI 10.3171/2011.9.JNS101406
   Haase J, 2009, SURG NEUROL, V72, P89, DOI 10.1016/j.surneu.2009.02.005
   Haji FA, 2015, CAN J NEUROL SCI, V42, P25, DOI 10.1017/cjn.2014.124
   Haji FA, 2013, J NEUROSURG, V118, P250, DOI 10.3171/2012.10.JNS12767
   Harnof S, 2013, ISR MED ASSOC J, V15, P489
   Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119
   Heros RC, 2003, J NEUROSURG, V99, P623, DOI 10.3171/jns.2003.99.4.0623
   Hull L, 2013, ANN SURG, V258, P370, DOI 10.1097/SLA.0b013e318279560b
   Hull L, 2012, INT J SURG, V10, P493, DOI 10.1016/j.ijsu.2012.07.005
   Hull L, 2012, J AM COLL SURGEONS, V214, P214, DOI 10.1016/j.jamcollsurg.2011.10.016
   Hull L, 2011, J AM COLL SURGEONS, V212, P234, DOI 10.1016/j.jamcollsurg.2010.11.001
   Hull L, 2011, AM J SURG, V201, P24, DOI 10.1016/j.amjsurg.2010.07.039
   Hunt MA, 2017, NEUROSURGERY, V80, pE201, DOI 10.1093/neuros/nyw093
   Kabwama S, 2011, BRIT J NEUROSURG, V25, P783, DOI 10.3109/02688697.2011.621998
   KAUFMAN HH, 1987, ACTA NEUROCHIR, V87, P1, DOI 10.1007/BF02076007
   Khan A, 2018, WORLD NEUROSURG, V120, pE227, DOI 10.1016/j.wneu.2018.08.036
   Ladak A, 2014, WORLD NEUROSURG, V81, pE33, DOI 10.1016/j.wneu.2013.02.055
   Lane-Fall MB, 2018, ACAD MED, V93, P904, DOI 10.1097/ACM.0000000000002039
   Lau CY, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12244
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Long DM, 2000, ACAD MED, V75, P1178, DOI 10.1097/00001888-200012000-00009
   Malone HR, 2010, NEUROSURGERY, V67, P1105, DOI 10.1227/NEU.0b013e3181ee46d0
   Marcus H, 2013, NEUROSURGERY, V72, pA124, DOI 10.1227/NEU.0b013e318270d010
   Mazzola CA, 2010, NEUROSURGERY, V67, P225, DOI 10.1227/01.NEU.0000372206.41812.23
   McConnell Douglas J, 2012, Surg Neurol Int, V3, P2, DOI 10.4103/2152-7806.92163
   McLaughlin N, 2014, WORLD NEUROSURG, V82, P567, DOI 10.1016/j.wneu.2013.07.074
   Michinov E, 2014, J EVAL CLIN PRACT, V20, P582, DOI 10.1111/jep.12152
   Mitchell L, 2013, J EVAL CLIN PRACT, V19, P317, DOI 10.1111/j.1365-2753.2012.01825.x
   Mitchell L, 2012, INT J NURS STUD, V49, P201, DOI 10.1016/j.ijnurstu.2011.08.012
   Mitchell P, 2006, ACTA NEUROCHIR, V148, P1289, DOI 10.1007/s00701-006-1041-9
   Morineau T, 2009, HUM FACTORS, V51, P67, DOI 10.1177/0018720809332847
   Muzumdar Dattatraya, 2007, Int J Surg, V5, P286, DOI 10.1016/j.ijsu.2006.03.013
   Nathoo N, 2003, SURG CLIN N AM, V83, P1339, DOI 10.1016/S0039-6109(03)00157-9
   Neil-Dwyer G, 2001, ACT NEUR S, V78, P135
   Oszvald A, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.8.FOCUS12261
   Parker SH, 2013, AM J SURG, V205, P745, DOI 10.1016/j.amjsurg.2012.02.020
   Parker SH, 2012, AM J SURG, V204, P347, DOI 10.1016/j.amjsurg.2011.03.009
   Parker SH, 2011, BMJ QUAL SAF, V20, P570, DOI 10.1136/bmjqs.2010.040295
   Pathak A, 2000, NEUROL INDIA, V48, P216
   Pauley K, 2011, AM J SURG, V202, P375, DOI 10.1016/j.amjsurg.2010.11.009
   Pettit JE, 2011, NEUROSURGERY, V68, P546, DOI 10.1227/NEU.0b013e318201c2ac
   Rahmathulla G, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12260
   Russ S, 2013, J AM COLL SURGEONS, V216, P472, DOI 10.1016/j.jamcollsurg.2012.12.013
   Russ S, 2012, ANN SURG, V255, P804, DOI 10.1097/SLA.0b013e31824a9a02
   Sakamoto Y, 2018, WORLD NEUROSURG, V118, pE818, DOI 10.1016/j.wneu.2018.07.061
   Sekhar LN, 2015, WORLD NEUROSURG, V83, P41, DOI 10.1016/j.wneu.2013.08.052
   Selden NR, 2012, NEUROSURGERY, V70, P971, DOI 10.1227/NEU.0b013e31823d7a45
   Sharma B, 2011, SURG ONCOL, V20, P169, DOI 10.1016/j.suronc.2010.10.001
   Tanweer O, 2015, J NEUROSURG, V122, P678, DOI 10.3171/2014.11.JNS14400
   Walcott BP, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.8.FOCUS12245
   Wong JM, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.7.FOCUS12179
   Wong JM, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.7.FOCUS12180
   Wong JM, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12184
   Wong JM, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.7.FOCUS12181
   Wong JM, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.7.FOCUS12183
   Yule S, 2006, MED EDUC, V40, P1098, DOI 10.1111/j.1365-2929.2006.02610.x
   Yule S, 2006, SURGERY, V139, P140, DOI 10.1016/j.surg.2005.06.017
   Yule S, 2008, WORLD J SURG, V32, P548, DOI 10.1007/s00268-007-9320-z
   Yule S, 2012, SURG CLIN N AM, V92, P37, DOI 10.1016/j.suc.2011.11.004
   Zuckerman SL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12257
   Zuckerman SL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.8.FOCUS12248
NR 84
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E726
EP E736
DI 10.1016/j.wneu.2019.06.204
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200093
PM 31284064
DA 2020-05-12
ER

PT J
AU Hong, EP
   Kim, BJ
   Jeon, JP
   Yang, JS
   Choi, HJ
   Kang, SH
   Cho, YJ
AF Hong, Eun Pyo
   Kim, Bong Jun
   Jeon, Jin Pyeong
   Yang, Jin Seo
   Choi, Hyuk Jai
   Kang, Suk Hyung
   Cho, Yong Jun
TI Association of Endothelin Receptor Type A with intracranial Aneurysm in
   20,609 East Asians: An Updated Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE East-Asian meta-analysis; EDNRA; Intracranial aneurysm; Subarachnoid
   hemorrhage
ID GENE; JAPANESE; VARIANT
AB INTRODUCTION: Genome-wide association studies have reported an association between the EDNRA gene and intracranial aneurysm (IA) in European and Japanese populations; however, there is no study on this polymorphism in other Asian populations. Therefore, we performed an extensive large-scale meta-analysis for association of the rs6841581 variant of EDNRA with IA susceptibility in East Asian population.
   METHODS: We conducted a systemic review via electronic search for papers published between January 2002 and February 2019. We used fixed and random effect models and applied the inverse variance method. The statistical power of the result was estimated in the genome-wide significant threshold under an additive inheritance model.
   RESULTS: Our meta-analysis included 5873 patients with IA and 14,736 non-IA controls from 6 independent populations: 4 Japanese, 1 Chinese, and 1 Korean. The risk (major) G allele of rs6841581 showed the highest significant association with the increased risk of IA under the fixed effect model in the East-Asian population (odds ratio = 1.244, 95% confidence interval: 1,174-1.318, P = 1.36E-13). The rs6841581 variant showed sufficient statistical power (80.3%) in this meta-analysis under the additive model. In subsequent analysis, the frequencies of the risk G allele showed similar pattern in all of the Japanese, Chinese, and Korean populations (69%, 80%, and 78%, respectively). In the in silico functional analysis, none of the functional variants was correlated with rs6841581.
   CONCLUSIONS: The genetic variant of EDNRA, rs6841581, was significantly associated with increased risk of IA. Our findings indicate that it could be used as an IA-predicting variant in East Asian populations.
C1 [Hong, Eun Pyo] Massachusetts Gen Hosp, Ctr Genom Med, Mol Neurogenet Unit, Boston, MA 02114 USA.
   [Hong, Eun Pyo; Kim, Bong Jun; Jeon, Jin Pyeong] Hallym Univ, Coll Med, Inst New Frontier Stroke Res, Chunchon, South Korea.
   [Jeon, Jin Pyeong; Yang, Jin Seo; Choi, Hyuk Jai; Kang, Suk Hyung; Cho, Yong Jun] Hallym Univ, Coll Med, Dept Neurosurg, Chunchon, South Korea.
   [Jeon, Jin Pyeong] Genet & Res, Chunchon, South Korea.
RP Jeon, JP (reprint author), Hallym Univ, Coll Med, Inst New Frontier Stroke Res, Chunchon, South Korea.; Jeon, JP (reprint author), Hallym Univ, Coll Med, Dept Neurosurg, Chunchon, South Korea.; Jeon, JP (reprint author), Genet & Res, Chunchon, South Korea.
EM jjs6553@daum.net
FU National IT Industry Promotion Agency [R-20190315-004075]
FX This research was supported by the National IT Industry Promotion Agency
   (R-20190315-004075).
CR Alg VS, 2013, NEUROLOGY, V80, P2154, DOI 10.1212/WNL.0b013e318295d751
   Cook-Mills JM, 2005, J LEUKOCYTE BIOL, V77, P487, DOI 10.1189/jlb.0904554
   Frosen J, 2004, STROKE, V35, P2287, DOI 10.1161/01.STR.0000140636.30204.da
   Gallek M, 2013, BIOL RES NURS, V15, P390, DOI 10.1177/1099800412459674
   Griessenauer CJ, 2018, J NEUROSURG, V128, P1311, DOI 10.3171/2016.12.JNS162594
   Hashimoto T, 2006, NEUROL RES, V28, P372, DOI 10.1179/016164106X14973
   Hong EP, 2019, J CLIN MED, V8
   Huang T, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-2328-0
   Inci S, 2000, SURG NEUROL, V53, P530, DOI 10.1016/S0090-3019(00)00244-5
   Katati MJ, 2007, CEREBROVASC DIS, V24, P66, DOI 10.1159/000103118
   KOSIERKIEWICZ TA, 1994, J NEUROPATH EXP NEUR, V53, P399, DOI 10.1097/00005072-199407000-00012
   Lim Kyoung Ah, 2010, Korean Circ J, V40, P459, DOI 10.4070/kcj.2010.40.9.459
   Liu Li, 2014, Nan Fang Yi Ke Da Xue Xue Bao, V34, P60
   Low SK, 2012, HUM MOL GENET, V21, P2102, DOI 10.1093/hmg/dds020
   Machiela MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/bioinformatics/btv402
   Magi R, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-288
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   Theodotou Christian B, 2017, Asian J Neurosurg, V12, P374, DOI 10.4103/1793-5482.180972
   Tromp G, 2014, ANN MED, V46, P597, DOI 10.3109/07853890.2014.949299
   van't Hof FNG, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002603
   Vlak MHM, 2011, LANCET NEUROL, V10, P626, DOI 10.1016/S1474-4422(11)70109-0
   Wang YC, 2018, HEREDITAS, V155, DOI 10.1186/s41065-018-0057-5
   Xu ZL, 2009, NUCLEIC ACIDS RES, V37, pW600, DOI 10.1093/nar/gkp290
   Yasuno K, 2011, P NATL ACAD SCI USA, V108, P19707, DOI 10.1073/pnas.1117137108
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E804
EP E814
DI 10.1016/j.wneu.2019.06.228
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200102
PM 31295611
DA 2020-05-12
ER

PT J
AU Iwata, T
AF Iwata, Tomonori
TI Initial Experience of a Novel Sheath Guide Specifically Designed for
   Transradial Approach for Carotid Artery Stenting
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid artery stenting (CAS); Sheath guide; Transradial
ID SAFETY; ACCESS
AB BACKGROUND: The transfemoral approach is a common technique for carotid artery stenting (CAS) but is sometimes limited by aortic or peripheral arterial conditions. The purpose of this study is to report the initial experiences with CAS using a novel sheath guide for transradial carotid cannulation.
   METHODS: A sheath guide designed specifically for transradial carotid cannulation was developed. The transradial approach for CAS was started in April 2016, and data were collected prospectively. Patients who underwent transradial elective CAS from April 2016 to June 2018 were included in the analysis. Every CAS procedure was started through the right radial route with a 6-French (internal diameter) sheath guide specifically designed for the radial approach under local anesthesia. Technical success, periprocedural complications, and 30-day major vascular events (stroke, myocardial infarction, and/or death) were investigated.
   RESULTS: Twenty-six patients underwent transradial CAS. Procedures performed via the radial route were successful in every case. A periprocedural complication (transient ischemic attack after CAS) occurred in 1 patient. The patient returned to the preoperative state within a few days and had no neurologic deficits. No access site-related complications occurred. Patients who underwent transradial CAS could walk immediately after CAS, even during hemostasis. No major cardiovascular events occurred within 30 days after CAS.
   CONCLUSIONS: The herein-described sheath guide specifically designed for transradial carotid cannulation was useful for CAS.
C1 [Iwata, Tomonori] Tokai Univ, Dept Neurol, Isehara, Kanagawa, Japan.
RP Iwata, T (reprint author), Tokai Univ, Dept Neurol, Isehara, Kanagawa, Japan.
EM toiwata-ths@tsc.u-tokai.ac.jp
CR Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321
   Chang FC, 2009, J NEUROSURG, V110, P437, DOI 10.3171/2008.7.17627
   Etxegoien N, 2012, CATHETER CARDIO INTE, V80, P1081, DOI 10.1002/ccd.24503
   Fang HY, 2010, ANN VASC SURG, V24, P670, DOI 10.1016/j.avsg.2009.12.001
   Iwata T, 2013, J NEUROINTERV SURG, V5, P77, DOI 10.1136/neurintsurg-2012-010506
   Iwata T, 2013, J NEUROINTERV SURG, V5, P40, DOI 10.1136/neurintsurg-2011-010147
   Iwata T, 2012, NEUROSURGERY, V70, P82, DOI 10.1227/NEU.0b013e31822e074c
   Iwata T, 2011, NEUROSURGERY, V68, P649, DOI 10.1227/NEU.0b013e3182077ed8
   Kiemeneij F, 1997, J AM COLL CARDIOL, V29, P1269, DOI 10.1016/S0735-1097(97)00064-8
   Lee WC, 2016, J ENDOVASC THER, V23, P516, DOI 10.1177/1526602816640291
   Mendiz OA, 2016, J INTERV CARDIOL, V29, P588, DOI 10.1111/joic.12342
   Mendiz OA, 2011, VASC ENDOVASC SURG, V45, P499, DOI 10.1177/1538574411405547
   Montorsi P, 2016, J ENDOVASC THER, V23, P549, DOI 10.1177/1526602816651424
   Patel T, 2010, CATHETER CARDIO INTE, V75, P268, DOI 10.1002/ccd.22159
   Rashid M, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002686
   Ruzsa Z, 2014, EUROINTERVENTION, V10, P381, DOI 10.4244/EIJV10I3A64
   Trani C, 2009, CATHETER CARDIO INTE, V74, P267, DOI 10.1002/ccd.22014
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E760
EP E764
DI 10.1016/j.wneu.2019.06.215
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200097
PM 31284065
DA 2020-05-12
ER

PT J
AU Jin, ZR
   Li, L
   Yu, P
   Bao, Y
   Wang, Y
   Li, ZP
   Wang, YB
AF Jin, Zhuoru
   Li, Long
   Yu, Peng
   Bao, Yue
   Wang, Yong
   Li, Zhipeng
   Wang, Yibao
TI The Degree of Middle and Lower Clivus Invasion by Chordoma is Linked to
   Patient Prognosis Via Ki-67 Value
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chordoma; Clivus; Craniocerebral magnetic resonance imaging; Ki-67;
   Skull-based 3D-CT
ID GROWTH-FACTOR RECEPTOR; SKULL BASE CHORDOMAS; TERM-FOLLOW-UP; CHONDROID
   CHORDOMA; PROLIFERATION; KI67
AB OBJECTIVE: The aim of this study was to discuss the relationship between Ki-67 values and the degree to which chordoma invade the clivus and to certify that the prognosis of chordoma is worse when it invades the middle and lower clivus than when it does not.
   METHODS: We collected 56 cases of first-time chordoma illness in which patients received no treatment before surgery. Patients underwent craniocerebral magnetic resonance imaging and skull-base 3-dimensional computed tomography scans before the operation. We divided patients into 2 groups depending on the extent to which the middle and lower clivus were invaded. We classified patients with chordoma that did not significantly invade the middle and lower clivuses into a noninvasive" group and the others into an "invasive" group. Ki-67 values were extracted from the pathological report after surgery. We use an independent chi(2) test to indicate that Ki-67 values for the invasive group were higher than those for the noninvasive group.
   RESULTS: We grouped the data and did a statistical analysis. We found that the Ki-67 values are >5% for most patients in whom chordoma have eroded the middle-lower clivus, whereas it is <= 5% for patients in whom the middle-lower clivus region has not been invaded. Therefore, there is a correlation between Ki-67 value and the region of chordoma invading the clivus.
   CONCLUSIONS: Statistical analysis revealed that Ki-67 values when the chordoma invaded the middle and lower clivus were significantly higher than when it did not. Thus, we can conclude that the prognosis is worse when chordoma invade the middle and lower clivus.
C1 [Jin, Zhuoru; Li, Long; Yu, Peng; Bao, Yue; Wang, Yong; Li, Zhipeng; Wang, Yibao] China Med Univ, Affiliated Hosp 1, Dept Neurosurg, Shenyang, Liaoning, Peoples R China.
RP Wang, YB (reprint author), China Med Univ, Affiliated Hosp 1, Dept Neurosurg, Shenyang, Liaoning, Peoples R China.
EM cmuwyb@hotmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31540077]
FX This study was supported by grants from the National Natural Science
   Foundation of China (No. 31540077 to Yi.W.).
CR Agrawal P P, 2006, Australas Radiol, V50, P201, DOI 10.1111/j.1440-1673.2006.01562.x
   Ashwood N, 1994, Clin Oncol (R Coll Radiol), V6, P341, DOI 10.1016/S0936-6555(05)80279-1
   Boari N, 2016, J NEUROSURG, V125, P450, DOI 10.3171/2015.6.JNS142370
   Catton C, 1996, RADIOTHER ONCOL, V41, P67, DOI 10.1016/S0167-8140(96)91805-8
   Chadha M, 2005, EUR SPINE J, V14, P803, DOI 10.1007/s00586-005-0906-6
   Chugh R, 2007, ONCOLOGIST, V12, P1344, DOI 10.1634/theoncologist.12-11-1344
   Di Maio S, 2015, THER CLIN RISK MANAG, V11, DOI 10.2147/TCRM.S50526
   Erazo Ibeth S, 2018, Cureus, V10, pe3381, DOI 10.7759/cureus.3381
   Funaki T, 2013, NEUROSURGERY, V73, P155, DOI 10.1227/01.neu.0000431469.82215.93
   GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104
   Holton JL, 2000, NEUROPATH APPL NEURO, V26, P497, DOI 10.1046/j.1365-2990.2000.00280.x
   Horbinski C, 2010, ARCH PATHOL LAB MED, V134, P1170, DOI 10.1043/2009-0380-OA.1
   Jian BJ, 2010, J NEURO-ONCOL, V98, P101, DOI 10.1007/s11060-009-0068-1
   Komotar RJ, 2011, WORLD NEUROSURG, V76, P318, DOI 10.1016/j.wneu.2011.02.026
   Naka T, 2003, CANCER, V98, P1934, DOI 10.1002/cncr.11756
   Naka T, 1996, HUM PATHOL, V27, P381, DOI 10.1016/S0046-8177(96)90112-4
   Romero Q, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-341
   Samii A, 2007, J NEUROSURG, V107, P319, DOI 10.3171/JNS-07/08/0319
   Santegoeds Rene G C, 2018, Curr Radiol Rep, V6, P16, DOI 10.1007/s40134-018-0275-7
   VOLPE R, 1983, AM J SURG PATHOL, V7, P161, DOI 10.1097/00000478-198303000-00006
   Wu Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119523
   Wu Z, 2010, NEUROSURG REV, V33, P451, DOI 10.1007/s10143-010-0273-6
   Yerushalmi R, 2010, LANCET ONCOL, V11, P174, DOI 10.1016/S1470-2045(09)70262-1
   Zhai YX, 2017, WORLD NEUROSURG, V98, P288, DOI 10.1016/j.wneu.2016.07.096
NR 24
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E620
EP E626
DI 10.1016/j.wneu.2019.06.173
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200078
PM 31265927
DA 2020-05-12
ER

PT J
AU Johnson, A
   Rice, AN
   Titch, JF
   Gupta, DK
AF Johnson, Abigail
   Rice, Andi N.
   Titch, J. Frank
   Gupta, Dhanesh K.
TI Identifying Components Necessary for an Enhanced Recovery After Surgery
   Pathway for Elective Intracranial Surgery: An Improvement Project Using
   the Quality of Recovery-15 Score
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acetaminophen; Analgesia; Craniotomy; Enhanced recovery after surgery;
   Intracranial surgery
ID BRAIN-TUMOR SURGERY; INTRAVENOUS ACETAMINOPHEN; POSTOPERATIVE QUALITY;
   CRANIOTOMY; PAIN; PHARMACOKINETICS; PARACETAMOL; PLASMA; ANALGESIA
AB OBJECTIVE: To identify the domains of recovery, as determined by the Quality of Recovery-15 (QoR-15) score, that needed improvement to develop initial interventions for an enhanced recovery after surgery protocol for patients undergoing elective intracranial surgery under general anesthesia.
   METHODS: A paired-availability design was used to assess 2 groups of 41 patients undergoing elective intracranial surgery. The baseline QoR-15 score and scores 0, 6, 12, and 24 hours after arrival in the intensive care unit characterized the postoperative recovery trajectory. The lowest scoring domains of the QoR-15 score were identified in the preimplementation group, and pharmacologic interventions were initiated in the postimplementation group.
   RESULTS: Postoperative analgesia and postoperative nausea and vomiting were identified as the lowest scoring domains. The pharmacologic interventions implemented were chosen because they produced minimal sedation and were easy to administer-1 40-mg oral preoperative dose of aprepitant to target postoperative nausea and vomiting and 2 perioperative 1-g doses of intravenous acetaminophen to improve analgesia. We observed a clinically significant as well as statistically significant improvement in analgesia on arrival in the intensive care unit and at the 6-hour postoperative time point. The total QoR-15 score was improved through the 12-hour time point.
   CONCLUSIONS: In this quality improvement project, the QoR-15 score allowed us to identify domains that slowed the recovery course in this patient population. Two 1-g doses of intravenous acetaminophen improved patients' well-being and analgesia after elective intracranial surgery.
C1 [Johnson, Abigail; Rice, Andi N.; Titch, J. Frank] Duke Univ, Sch Nursing, Div Certified Nurse Anesthesia, Durham, NC USA.
   [Gupta, Dhanesh K.] Duke Univ, Sch Med, Dept Anesthesiol, Durham, NC 27708 USA.
RP Gupta, DK (reprint author), Duke Univ, Sch Med, Dept Anesthesiol, Durham, NC 27708 USA.
EM dhanesh.gupta@duke.edu
CR Aarts MA, 2018, ANN SURG, V267, P992, DOI 10.1097/SLA.0000000000002632
   Akcil EF, 2017, CLIN NEUROL NEUROSUR, V154, P98, DOI 10.1016/j.clineuro.2017.01.018
   Allegaert K, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-77
   Artime CA, 2018, J NEUROSURG ANESTH, V30, P231, DOI 10.1097/ANA.0000000000000461
   Au K, 2016, J NEUROSURG, V125, P1130, DOI 10.3171/2015.11.JNS152151
   BANNWARTH B, 1992, BRIT J CLIN PHARMACO, V34, P79, DOI 10.1111/j.1365-2125.1992.tb04112.x
   Boulton M, 2008, J NEUROSURG, V108, P649, DOI 10.3171/JNS/2008/108/4/0649
   Goettel N, 2014, J NEUROSURG ANESTH, V26, P60, DOI 10.1097/ANA.0b013e3182991d8b
   Greenberg S, 2018, WORLD NEUROSURG, V109, pE554, DOI 10.1016/j.wneu.2017.10.021
   Gupta DK, 2012, CLIN PHARMACOL THER, V91, P339, DOI 10.1038/clpt.2011.307
   Habib AS, 2011, ANESTH ANALG, V112, P813, DOI 10.1213/ANE.0b013e3181ff47e2
   Hagan KB, 2016, J CLIN NEUROSCI, V24, P10, DOI 10.1016/j.jocn.2015.08.013
   Hansen MS, 2011, EUR J ANAESTH, V28, P821, DOI 10.1097/EJA.0b013e32834a0255
   Jibril Farah, 2015, Can J Hosp Pharm, V68, P238
   Kehlet H, 1996, REGION ANESTH, V21, P149
   Kehlet H, 2018, ANN SURG, V267, P998, DOI 10.1097/SLA.0000000000002720
   Klimek M, 2006, J NEUROSURG, V104, P350, DOI 10.3171/jns.2006.104.3.350
   Kotak D, 2009, BRIT J NEUROSURG, V23, P538, DOI 10.1080/02688690903100595
   Langford RA, 2016, ANESTH ANALG, V123, P610, DOI 10.1213/ANE.0000000000001463
   Leslie K, 2003, ANESTHESIOLOGY, V99, P1158, DOI 10.1097/00000542-200311000-00024
   Miller TE, 2014, PERIOPER MED, V3, DOI 10.1186/2047-0525-3-4
   Mordhorst C, 2010, J NEUROSURG ANESTH, V22, P202, DOI 10.1097/ANA.0b013e3181df0600
   Myles PS, 2016, ANESTHESIOLOGY, V125, P39, DOI 10.1097/ALN.0000000000001158
   Myles PS, 2000, BRIT J ANAESTH, V84, P11
   Nair S, 2011, BRIT J NEUROSURG, V25, P100, DOI 10.3109/02688697.2010.534199
   Owens KH, 2014, J PHARMACOKINET PHAR, V41, P211, DOI 10.1007/s10928-014-9358-0
   Peng YM, 2016, J NEUROSURG ANESTH, V28, P309, DOI 10.1097/ANA.0000000000000230
   Purzner T, 2011, NEUROSURGERY, V69, P119, DOI 10.1227/NEU.0b013e318215a270
   Raffa RB, 2018, CLIN DRUG INVEST, V38, P259, DOI 10.1007/s40261-017-0610-4
   Scott Michael J, 2015, Anesthesiol Clin, V33, P79, DOI 10.1016/j.anclin.2014.11.006
   Singla NK, 2012, PAIN PRACT, V12, P523, DOI 10.1111/j.1533-2500.2012.00556.x
   Sivakumar W, 2019, J NEUROSURG, V130, P766, DOI 10.3171/2017.10.JNS171464
   Song J, 2016, J NEUROSURG ANESTH, V28, P14, DOI 10.1097/ANA.0000000000000190
   Stark PA, 2013, ANESTHESIOLOGY, V118, P1332, DOI 10.1097/ALN.0b013e318289b84b
   Vincent WR, 2018, AM J HEALTH-SYST PH, V75, P548, DOI 10.2146/ajhp170054
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E423
EP E430
DI 10.1016/j.wneu.2019.06.108
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200052
PM 31279110
DA 2020-05-12
ER

PT J
AU Jung, YJ
   Chang, CH
   Kim, JH
AF Jung, Young-Jin
   Chang, Chul-Hoon
   Kim, Jong-Hoon
TI Advantages of Coil Embolization Performed Immediately After Diagnostic
   Cerebral Digital Subtraction Angiography in Unruptured Intracranial
   Aneurysms: Patients' Perspective
SO WORLD NEUROSURGERY
LA English
DT Article
DE Coil embolization; Hospital costs; Unruptured intracranial aneurysm
ID ENDOVASCULAR TREATMENT; COMPLICATIONS; MANAGEMENT; MORTALITY; MORBIDITY
AB BACKGROUND: We are inevitably faced with the need to perform coil embolization immediately after diagnostic cerebral digital subtraction angiography (DSA) for economic reasons, patient convenience, fear of rupture, and other reasons. Here we report the advantages of coil embolization performed immediately after diagnostic cerebral DSA for unruptured intracranial aneurysms (UIAs) from the patients' perspective.
   METHODS: Between January 2017 and October 2018, 145 patients were treated for UIAs with endovascular coil embolization at the Yeungnam University Medical Center. There were 87 patients in the group in which coil embolization was to be performed at least 1 week after diagnostic cerebral DSA (regular [R] group) and 58 patients in the group in which coil embolization was to be performed immediately after diagnostic cerebral DSA (immediate [I] group).
   RESULTS: There were no statistically significant between group differences in any factor analyzed expect for medical expenses (out-of-pocket costs), 2,218,416 KRW (1963 USD) for the R group and 1,128,906 KRW (999 USD) for the I group (P < 0.001). There were no statistically significant differences in the rate of complications between the 2 groups, with 4 minor complications and 1 death in the R group and 3 minor complications and 1 death in the I group.
   CONCLUSIONS: Our findings indicate that coil embolization performed immediately after diagnostic cerebral DSA can be a relatively safe alternative approach to treating patients with UIAs.
C1 [Jung, Young-Jin; Chang, Chul-Hoon; Kim, Jong-Hoon] Yeungnam Univ, Dept Neurosurg, Coll Med, Daegu, South Korea.
RP Kim, JH (reprint author), Yeungnam Univ, Dept Neurosurg, Coll Med, Daegu, South Korea.
EM kjhns@yu.ac.kr
FU Yeungnam University
FX This work was supported by a 2019 Yeungnam University Research Grant.
CR Brinjikji W, 2013, STROKE, V44, P1343, DOI 10.1161/STROKEAHA.111.000628
   Brown RD, 2014, LANCET NEUROL, V13, P393, DOI 10.1016/S1474-4422(14)70015-8
   Hoh BL, 2009, NEUROSURGERY, V64, P614, DOI 10.1227/01.NEU.0000340784.75352.A4
   Ji WJ, 2016, STROKE, V47, P971, DOI 10.1161/STROKEAHA.115.012097
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Park HK, 2005, AM J NEURORADIOL, V26, P506
   Pierot L, 2008, STROKE, V39, P2497, DOI 10.1161/STROKEAHA.107.512756
   Ross IB, 2005, SURG NEUROL, V64, P12, DOI 10.1016/j.surneu.2004.09.045
   Thompson BG, 2015, STROKE, V46, P2368, DOI 10.1161/STR.0000000000000070
   van Rooij WJ, 2006, AM J NEURORADIOL, V27, P1678
NR 10
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E573
EP E576
DI 10.1016/j.wneu.2019.06.154
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200071
PM 31254708
DA 2020-05-12
ER

PT J
AU Kang, T
   Park, SY
   Nam, JJ
   Lee, SH
   Park, JH
   Suh, SW
AF Kang, Taewook
   Park, Si Young
   Nam, Jae Jun
   Lee, Soon Hyuck
   Park, Jong Hoon
   Suh, Seung Woo
TI Patient Mood Management During Lumbar Spinal Fusion Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anemia; Lumbar spinal fusion; Patient blood management; Transfusion
ID ALLOGENEIC BLOOD-TRANSFUSION; PREOPERATIVE ANEMIA; TRANEXAMIC ACID;
   INTRAVENOUS IRON; KNEE ARTHROPLASTY; UNITED-STATES; HIP FRACTURE;
   EFFICACY; PREDICTORS; THERAPY
AB OBJECTIVE: Patient blood management (PBM) is defined as treatment of a patient who is at risk of transfusion to minimize the need for transfusion and improve the probability of an optimal clinical outcome. We performed the present study to examine the effects of PBM in spinal fusion surgery.
   METHODS: A total of 154 patients who had undergone 1-and 2-level posterior lumbar interbody fusion for degenerative lumbar disease were included. We retrospectively reviewed the data from 101 patients from 2012 to 2016 as the pre-PBM group. We recruited 53 patients from 2017 to 2018 for the post-PBM group. Intravenous iron was administered 2-4 weeks before surgery, and intravenous tranexamic acid was administered intraoperatively in the post-PBM group. The primary outcome was the reduction of hemoglobin (Fib). The secondary outcomes included perioperative blood loss, Hemovac drain output, postoperative transfusion, complications, and length of hospital stay.
   RESULTS: Intravenous iron was administered 17.4 days before surgery in the post-PBM group. The reduction in Fib was not significantly different statistically between the 2 groups (3.06 vs. 3.33 g/dL; P > 0.05). Of the 101 patients in the pre-PBM group, 24 (24%) underwent transfusion. In contrast, no patient in the post-PBM group had required a transfusion (P < 0.001). The average hospital stay was 10.15 days in the pre-PBM group and 8.33 days in the post-PBM group (P = 0.02). The average operative time was 146 minutes in the pre-PBM group and 133 minutes in the post-PBM group (P = 0.03). The Fib decrease and total Hemovac drain output did not differ significantly between the 2 groups.
   CONCLUSIONS: Implementation of PBM is an effective strategy for reducing the rate of transfusion in patients undergoing lumbar spinal fusion surgery without significant complications.
C1 [Kang, Taewook; Park, Si Young; Nam, Jae Jun; Lee, Soon Hyuck; Park, Jong Hoon; Suh, Seung Woo] Korea Univ, Coll Med, Anam Hosp, Dept Orthopaed, Seoul, South Korea.
RP Park, SY (reprint author), Korea Univ, Coll Med, Anam Hosp, Dept Orthopaed, Seoul, South Korea.
EM drspine90@kumc.or.kr
CR Serrano-Trenas JA, 2011, TRANSFUSION, V51, P97, DOI 10.1111/j.1537-2995.2010.02769.x
   Berenholtz SM, 2002, TRANSFUSION, V42, P183, DOI 10.1046/j.1537-2995.2002.00034.x
   Bisbe E, 2011, BRIT J ANAESTH, V107, P477, DOI 10.1093/bja/aer242
   Cuenca Jorge, 2007, Int J Surg, V5, P89, DOI 10.1016/j.ijsu.2006.02.003
   Dunne JR, 2002, J SURG RES, V102, P237, DOI 10.1006/jsre.2001.6330
   Elwatidy S, 2008, SPINE, V33, P2577, DOI 10.1097/BRS.0b013e318188b9c5
   Garcia-Erce JA, 2005, VOX SANG, V88, P235, DOI 10.1111/j.1423-0410.2005.00627.x
   Gill JB, 2008, J BONE JOINT SURG AM, V90A, P2399, DOI 10.2106/JBJS.G.01179
   Goodnough LT, 2011, BRIT J ANAESTH, V106, P13, DOI 10.1093/bja/aeq361
   Guralnik JM, 2004, BLOOD, V104, P2263, DOI 10.1182/blood-2004-05-1812
   Hegde C, 2013, J ARTHROPLASTY, V28, P1888, DOI 10.1016/j.arth.2013.03.018
   Karkouti K, 2008, CIRCULATION, V117, P478, DOI 10.1161/CIRCULATIONAHA.107.718353
   Kim KT, 2017, EUR SPINE J, V26, P2851, DOI 10.1007/s00586-017-5230-4
   Kotze A, 2012, BRIT J ANAESTH, V108, P943, DOI 10.1093/bja/aes135
   Kulier A, 2007, CIRCULATION, V116, P471, DOI 10.1161/CIRCULATIONAHA.106.653501
   Li ZJ, 2013, EUR SPINE J, V22, P1950, DOI 10.1007/s00586-013-2774-9
   Mannucci PM, 1998, NEW ENGL J MED, V339, P245, DOI 10.1056/NEJM199807233390407
   Munoz M, 2012, BLOOD TRANSFUS-ITALY, V10, P8, DOI 10.2450/2011.0061-11
   Munoz M, 2011, J CLIN PATHOL, V64, P287, DOI 10.1136/jcp.2010.086991
   Pape A, 2007, BEST PRACT RES-CLIN, V21, P221, DOI 10.1016/j.bpa.2007.02.004
   Shander A, 2010, TRANSFUSION, V50, P753, DOI 10.1111/j.1537-2995.2009.02518.x
   Spahn DR, 2010, ANESTHESIOLOGY, V113, P482, DOI 10.1097/ALN.0b013e3181e08e97
   Spahn DR, 2008, ANESTHESIOLOGY, V109, P951, DOI 10.1097/ALN.0b013e31818e3d75
   Tengborn L, 2015, THROMB RES, V135, P231, DOI 10.1016/j.thromres.2014.11.012
   Theusinger OM, 2007, ANESTHESIOLOGY, V107, P923, DOI 10.1097/01.anes.0000291441.10704.82
   Yang BH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055436
   Yoshihara H, 2014, SPINE, V39, P304, DOI 10.1097/BRS.0000000000000123
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E566
EP E572
DI 10.1016/j.wneu.2019.06.153
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200070
PM 31254701
DA 2020-05-12
ER

PT J
AU Kelly, PD
   Voce, DJ
   Sivaganesan, A
   Wellons, JC
AF Kelly, Patrick David
   Voce, David James
   Sivaganesan, Ahilan
   Wellons, John Clifton, III
TI The Legacy of a Neurosurgeon: A US-Based Obituary Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Legacy; Memoriam; Obituary; Text analysis
ID PRESTIGE; VALUES; LIFE
AB BACKGROUND: Textual analysis of obituaries provides insight into the shared values of a profession or community. Neurosurgeon obituaries are frequently published in both the medical literature and the lay press, but the content of these works has never been analyzed.
   METHODS: Using obituary pieces from Neurosurgery, Journal of Neurosurgery, and the New York Times, frequent terms were quantified through preliminary text analysis to derive the relative importance of concepts such as innovation, research, training and family. The sentiment of these obituaries was qualitatively reviewed to approximate perceptions of neurosurgical legacy within the profession and the general public.
   RESULTS: Thirty relevant obituaries with full text available were identified in the Journal of Neurosurgery, 14 were identified in Neurosurgery, and 23 were identified in the New York Times. Both neurosurgical journals and lay press articles relied on linear narratives, with greater emphasis on professional leadership and residency training in neurosurgical journals and proportionally greater mention of family in the lay press.
   CONCLUSIONS: Our preliminary text analysis of neurosurgeon obituaries suggest what values are shared among the professional community and general public regarding the legacy of a neurosurgeon.
C1 [Kelly, Patrick David; Voce, David James; Sivaganesan, Ahilan; Wellons, John Clifton, III] Vanderbilt Univ, Med Ctr, Dept Neurosurg, Nashville, TN 37212 USA.
RP Kelly, PD (reprint author), Vanderbilt Univ, Med Ctr, Dept Neurosurg, Nashville, TN 37212 USA.
EM Patrick.d.kelly@vumc.org
OI Kelly, Patrick/0000-0003-4911-4239
FU National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [T32CA106183, 1F32CA232643-01A1]
FX Patrick David Kelly is supported by National Cancer Institute Grant
   T32CA106183, and David J. Voce is supported by National Cancer Institute
   Grant 1F32CA232643-01A1, although no funding from this grant was used in
   this study. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the National Cancer
   Institute or National Institutes of Health.
CR Abosch A, 2018, J NEUROSURG, V129, P277, DOI 10.3171/2018.4.JNS172878
   Album D, 2008, SOC SCI MED, V66, P182, DOI 10.1016/j.socscimed.2007.07.003
   Alfano M, 2018, J VALUE INQUIRY, V52, P59, DOI 10.1007/s10790-017-9602-0
   American Medical Association, 1985, PHYS CHAR DISTR US 1
   Association of American Medical Colleges, 2018, PHYS SPEC DAT REP
   Bernard F, 2018, WORLD NEUROSURG, V119, P66, DOI 10.1016/j.wneu.2018.07.169
   Bourdieu P, 1986, ACTES RECHERCHE SCI, V62, P6972, DOI DOI 10.3406/ARSS.1986.2317
   Creed PA, 2010, SOC SCI MED, V71, P1084, DOI 10.1016/j.socscimed.2010.06.027
   Dilevko J, 2004, LIBR QUART, V74, P152, DOI 10.1086/382845
   Feinerer I, 2008, J STAT SOFTW, V25, P1
   Fowler B, 2005, THEOR CULT SOC, V22, P53, DOI 10.1177/0263276405059414
   Fowler B., 2007, OBITUARY COLLECTIVE
   Fowler B, 2007, SOCIOL REV, V55, P203, DOI 10.1111/j.1467-954X.2007.00702.x
   Fowler B, 2004, SOC REV MON, P148
   George LS, 2016, REV GEN PSYCHOL, V20, P205, DOI 10.1037/gpr0000077
   Gould V, 2016, OBIT
   Johannessen LEF, 2014, SOC SCI MED, V120, P85, DOI 10.1016/j.socscimed.2014.09.013
   Kelly PJ, POINT RETIREMENT MYT
   KINNIER RT, 1994, CURR PSYCHOL, V13, P88, DOI 10.1007/BF02686860
   Lollis SS, 2010, J NEUROSURG, V113, P474, DOI 10.3171/2010.1.JNS091740
   Menchik DA, 2010, J HEALTH SOC BEHAV, V51, P137, DOI 10.1177/0022146510372231
   R Development Core Team, R LANG ENV STAT COMP
   ROSOFF SM, 1991, SOC SCI MED, V32, P321, DOI 10.1016/0277-9536(91)90110-X
   SCHWARTZBAUM AM, 1973, SOC SCI MED, V7, P365, DOI 10.1016/0037-7856(73)90045-0
   StataCorp, 2017, STAT STAT SOFTW REL
   Wright DJM, 1996, BRIT MED J, V313, P1581, DOI 10.1136/bmj.313.7072.1581
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E908
EP E914
DI 10.1016/j.wneu.2019.07.034
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200114
PM 31299311
DA 2020-05-12
ER

PT J
AU Kessler, RA
   Shrivastaya, RK
   Chen, SL
   Loewenstern, J
   Kohli, KM
   Yaeger, K
   Hadjipanayis, C
   Bederson, J
   Benzil, DL
AF Kessler, Remi A.
   Shrivastaya, Raj K.
   Chen, Sabrina L.
   Loewenstern, Joshua
   Kohli, Karan M.
   Yaeger, Kurt
   Hadjipanayis, Constantinos
   Bederson, Joshua
   Benzil, Deborah L.
TI Snapshot: Socioeconomic Competence in US Neurosurgery Residents
SO WORLD NEUROSURGERY
LA English
DT Article
DE ABNS; ACGME; Education; Residency; Socioeconomic
ID PRACTICE MANAGEMENT EDUCATION; INFORMED-CONSENT; SURGERY; CURRICULUM
AB INTRODUCTION: Socioeconomic topics such as federal mandates/regulations, conflict of interest, and practice management have become increasingly important for all neurosurgeons. Graduating residents immediately need a host of skills to successfully navigate neurosurgical practice. Surgical and medical skills are closely evaluated through the American Board of Neurological Surgery, and a formal socioeconomic curriculum has been developed with defined milestones. Nevertheless, little has been done to evaluate neurosurgery resident competence in socioeconomic and medicolegal principles. The purpose of this study was to assess the competence of Accreditation Council for Graduate Medical Education neurosurgical residents in socioeconomic knowledge.
   METHODS: Neurosurgery resident members of the American Association of Neurological Surgeons (N = 1385) were sent a Survey Monkey of 10 questions. The survey covered the most basic of socioeconomic principles. Initial survey responses were collected across a 1-month period from April to May 2018.
   RESULTS: The response rate was 14% (194/1385). Overall, neurosurgery residents would have received a grade of D, with an average score of 67% on the survey. For 7 of the 10 questions, the majority (>50%) of neurosurgery residents answered correctly. Furthermore, for 3 questions, more than 90% of residents selected the correct answer. However, for one-half of all questions, residents averaged a score of less than 65%. Residents tended to answer questions correctly for physician compensation and compensation models, but incorrectly for topics of informed consent, Controlled Substances Act, and conflicts of interest.
   CONCLUSION: With the increasing complexity of neurosurgery practice, solid knowledge of socioeconomic topics is essential. The study confirms suspected deficiencies in socioeconomic proficiency among neurosurgery residents, despite the availability of a validated curriculum. This knowledge gap will likely affect career success and satisfaction. Nevertheless, this survey had a significantly low response rate, and it may be an incomplete representation of the neurosurgical resident mind. Focused educational initiatives through the neurosurgical Residency Review Committee and individual training programs must facilitate an action plan that ensures the effective implementation of socioeconomic curricula.
C1 [Kessler, Remi A.; Shrivastaya, Raj K.; Loewenstern, Joshua; Kohli, Karan M.; Yaeger, Kurt; Hadjipanayis, Constantinos; Bederson, Joshua] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
   [Chen, Sabrina L.] Johns Hopkins Univ, Kreiger Sch Arts & Sci, Baltimore, MD USA.
   [Benzil, Deborah L.] Cleveland Clin Fdn, Dept Neurosurg, Cleveland, OH 44195 USA.
RP Kessler, RA (reprint author), Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
EM remi.kessler@icahn.mssm.edu
OI Kohli, Karan/0000-0001-6248-1880
CR Angelos Peter, 2002, Curr Surg, V59, P115, DOI 10.1016/S0149-7944(01)00591-8
   Armstrong AP, 1997, BRIT J PLAST SURG, V50, P637, DOI 10.1016/S0007-1226(97)90510-5
   Bernat JL, 2006, ARCH SURG-CHICAGO, V141, P86, DOI 10.1001/archsurg.141.1.86
   Hashmi Asra, 2017, BMC Res Notes, V10, P234, DOI 10.1186/s13104-017-2561-5
   Hicks Caitlin W, 2017, J Vasc Surg Venous Lymphat Disord, V5, P897, DOI 10.1016/j.jvsv.2017.06.014
   Issa MM, 2006, J UROLOGY, V176, P694, DOI 10.1016/j.juro.2006.03.037
   Jimenez DF, 1998, SURG NEUROL, V50, P179, DOI 10.1016/S0090-3019(97)00240-1
   Jones K, 2008, AM J SURG, V196, P878, DOI 10.1016/j.amjsurg.2008.08.008
   Kash KM, 2009, NEUROLOGY, V72, P893, DOI 10.1212/01.wnl.0000344164.98457.bf
   Leeper-Majors Kristine, 2003, Curr Surg, V60, P615, DOI 10.1016/S0149-7944(03)00157-0
   Lusco VC, 2005, AM J SURG, V189, P11, DOI 10.1016/j.amjsurg.2004.05.002
   Nexon D, 2010, HEALTH AFFAIR, V29, P1325, DOI 10.1377/hlthaff.2010.0436
   Pesudovs K, 2006, J LAW MED, V13, P496
   Pleat JM, 2004, BRIT J SURG, V91, P1377, DOI 10.1002/bjs.4590
   Sachdeva AK, 2007, SURGERY, V141, P427, DOI 10.1016/j.surg.2006.12.009
   Thompson J, 2008, AM J SURG, V196, P881
   Wayne DB, 2006, J GEN INTERN MED, V21, P251, DOI 10.1111/j.1525-1497.2006.00341.x
   Youngerman BE, 2016, NEUROSURGERY, V79, P492, DOI 10.1227/NEU.0000000000001126
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E874
EP E879
DI 10.1016/j.wneu.2019.07.030
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200110
PM 31301446
DA 2020-05-12
ER

PT J
AU Kim, BJ
   Kim, Y
   Hong, EP
   Jeon, JP
   Yang, JS
   Choi, HJ
   Kang, SH
   Cho, YJ
AF Kim, Bong Jun
   Kim, Youngmi
   Hong, Eun Pyo
   Jeon, Jin Pyeong
   Yang, Jin Seo
   Choi, Hyuk Jai
   Kang, Suk Hyung
   Cho, Yong Jun
TI Correlation Between Altered DNA Methylation of Intergenic Regions of
   ITPR3 and Development of Delayed Cerebral lschemia in Patients with
   Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Delayed cerebral ischemia; Methylation; Subarachnoid hemorrhage
ID INTRACRANIAL ANEURYSM; CA2+ SENSITIZATION; GENE; POLYMORPHISM;
   VASOSPASM; ASSOCIATION; MECHANISMS; STROKE; RISK
AB BACKGROUND: Delayed cerebral ischemia (DCI) is related to the major causes of morbidity and mortality in patients following subarachnoid hemorrhage (SAH); however, little is known about the role of epigenetics in the pathogenesis of DCI. We investigated the specific DNA methylation profile that may affect the expression of inositol 1-,4-,5-trisphosphate receptor (ITPR3) responsible for cerebral vasospasm following SAH.
   METHODS: We prospectively studied patients with SAH between March 2015 and October 2018. The degree of methylation in the distal intergenic region (IGR) located on ITPR3 and gene expression were measured using methylation-specific polymerase chain reaction (MSP) and quantitative real-time polymerase chain reaction (qPCR). To investigate the regulatory mechanims of DNA hypermethylation, we further analyzed the mRNA expression of DNA methyltransferase (DNMT1) and ten-eleven translocation enzymes (TET1, TET2, and TET3).
   RESULTS: A total of 42 patients were included in our analysis. Patients with SAH and DCI had significantly higher levels of methylation intensity of distal IGR upstream of ITPR3 than those without DCI (median, 0.941 [interquartile range (IQR), 0.857-0.984] versus (0.670 [IQR, 0.543-0.761]; P < 0.001). In addition, patients with DCI showed decreased mRNA expression of ITPR3 compared with patients without DCI (median, 0.039 [IQR, 0.0300.045] vs. 0.047 [IQR, 0.038-0.064]; P = 0.0328). Patients with DCI had higher DNMT1 expression (P < 0.001) and lower TET1 expression (P = 0.040) than those without DCI; however, differences in TET2 and TET3 levels between the 2 groups were not statistically significant.
   CONCLUSIONS: Hypermethylation of the distal IGR located upstream of ITPR3 is related to greater DCI development in patients with SAH. Further studies of the precise mechanisms of methylation degree and DCI development using in vitro and in vivo models are needed.
C1 [Kim, Bong Jun; Kim, Youngmi; Hong, Eun Pyo; Jeon, Jin Pyeong] Hallym Univ, Coll Med, Inst New Frontier Stroke Res, Chunchon, South Korea.
   [Hong, Eun Pyo] Massachusetts Gen Hosp, Mol Neurogenet Unit, Ctr Genom Med, Boston, MA 02114 USA.
   [Jeon, Jin Pyeong; Yang, Jin Seo; Choi, Hyuk Jai; Kang, Suk Hyung; Cho, Yong Jun] Hallym Univ, Coll Med, Dept Neurosurg, Chunchon, South Korea.
   [Jeon, Jin Pyeong] Genet & Res Inc, Chunchon, South Korea.
RP Jeon, JP (reprint author), Hallym Univ, Coll Med, Inst New Frontier Stroke Res, Chunchon, South Korea.; Jeon, JP (reprint author), Hallym Univ, Coll Med, Dept Neurosurg, Chunchon, South Korea.; Jeon, JP (reprint author), Genet & Res Inc, Chunchon, South Korea.
EM jjs6553@daum.net
FU National IT Industry Promotion Agency [R-20190315-004075]; Hallym
   University Research Fund
FX This research was supported by the National IT Industry Promotion Agency
   (R-20190315-004075) and the Hallym University Research Fund.
CR Bellapart J, 2014, NEUROCRIT CARE, V20, P77, DOI 10.1007/s12028-013-9887-1
   Bevan S, 2012, STROKE, V43, P3161, DOI 10.1161/STROKEAHA.112.665760
   Bocklandt S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014821
   Cho SS, 2019, WORLD NEUROSURG, V123, P418, DOI 10.1016/j.wneu.2018.10.213
   Cho YD, 2018, J KOREAN NEUROSURG S, V61, P458, DOI 10.3340/jkns.2017.0202.001
   Dorningues-Montanari S, 2008, EXPERT REV MOL DIAGN, V8, P495, DOI 10.1586/14737159.8.4.495
   Duan WY, 2018, NEUROEPIDEMIOLOGY, V50, P128, DOI 10.1159/000487325
   Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909
   Edvinsson L, 2013, INT J PHYS MED REHAB, V1, P162
   Geraghty JR, 2017, CURR ATHEROSCLER REP, V19, DOI 10.1007/s11883-017-0690-x
   Han H, 2011, HUM MOL GENET, V20, P4299, DOI 10.1093/hmg/ddr356
   Hendrix P, 2017, WORLD NEUROSURG, V101, P514, DOI 10.1016/j.wneu.2017.02.062
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hirano K, 2007, J PHARMACOL SCI, V104, P109, DOI 10.1254/jphs.CP0070027
   Hong EP, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020275
   Hong EP, 2018, WORLD NEUROSURG, V110, pE823, DOI 10.1016/j.wneu.2017.11.108
   Hong EP, 2017, YONSEI MED J, V58, P1006, DOI 10.3349/ymj.2017.58.5.1006
   Hu X, 2018, WORLD NEUROSURG, V118, DOI 10.1016/j.wneu.2018.07.019
   Huang YC, 2010, INT J IMMUNOGENET, V37, P439, DOI 10.1111/j.1744-313X.2010.00943.x
   Jeon JS, 2012, J KOREAN NEUROSURG S, V52, P75, DOI 10.3340/jkns.2012.52.2.75
   Katati MJ, 2007, CEREBROVASC DIS, V24, P66, DOI 10.1159/000103118
   Kawasaki Eiji, 2014, Clin Pediatr Endocrinol, V23, P99, DOI 10.1297/cpe.23.99
   Kikkawa Y, 2012, J CEREBR BLOOD F MET, V32, P341, DOI 10.1038/jcbfm.2011.132
   Kim BJ, 2018, WORLD NEUROSURG, V117, pE221, DOI 10.1016/j.wneu.2018.06.003
   Kim CH, 2018, J KOREAN NEUROSURG S, V61, P467, DOI 10.3340/jkns.2017.0505.006
   Kim H, 2013, INT J STROKE, V8, P620, DOI 10.1111/j.1747-4949.2012.00823.x
   Kim M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009692
   Krupinski J, 2018, COMPUT STRUCT BIOTEC, V16, P1, DOI 10.1016/j.csbj.2017.12.001
   Li H, 2013, STROKE, V44, P29, DOI 10.1161/STROKEAHA.112.663559
   Lin QS, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89402
   MAYBERG MR, 1994, STROKE, V25, P2315, DOI 10.1161/01.STR.25.11.2315
   Mazzuca MQ, 2012, BIOCHEM PHARMACOL, V84, P147, DOI 10.1016/j.bcp.2012.03.020
   Nahed BV, 2007, NEUROSURGERY, V60, P213, DOI 10.1227/01.NEU.0000249270.18698.BB
   Roach JC, 2006, AM J HUM GENET, V79, P614, DOI 10.1086/507876
   Sarrafzadeh A, 2011, STROKE, V42, P53, DOI 10.1161/STROKEAHA.110.594705
   Sarrafzadeh AS, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00134
   Soriano-Tarraga C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096543
   Wu H, 2014, CELL, V156, P45, DOI 10.1016/j.cell.2013.12.019
   Yegnasubramanian S, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-313
   Yu LB, 2017, WORLD NEUROSURG, V105, P28, DOI 10.1016/j.wneu.2017.04.064
   Zaina S, 2014, CIRC-CARDIOVASC GENE, V7, P692, DOI 10.1161/CIRCGENETICS.113.000441
NR 41
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E449
EP E456
DI 10.1016/j.wneu.2019.06.113
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200056
PM 31247352
DA 2020-05-12
ER

PT J
AU Kim, BS
   Kim, KH
   Lee, MH
   Lee, JI
AF Kim, Byung Sup
   Kim, Kyung Hwan
   Lee, Min Ho
   Lee, Jung-Il
TI Stereotactic Radiosurgery for Brainstem Cavernous Malformations: An
   Updated Systematic Review and Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Adverse radiation effect; Brainstem; Cavernous malformation; Hemorrhage;
   SRS
ID GAMMA-KNIFE RADIOSURGERY; NATURAL-HISTORY; MANAGEMENT
AB OBJECTIVE: This study was conducted to achieve more conclusive evidence for the efficacy of stereotactic radiosurgery (SRS) for brainstem cavernous malformations (BSCMs).
   METHODS: A literature search of PubMed, EMBASE, and Web of Science was performed and studies reporting the outcomes of SRS for BSCMs were included. The primary outcome was the pre-SRS and post-SRS hemorrhage rates; the pooled incidence rate ratio (IRR) with 95% confidence interval was chosen as effect size. Lesion control, symptom change, and radiation-related complications were evaluated.
   RESULTS: A total of 576 patients across 14 studies were included in this meta-analysis. The post-SRS hemorrhage rate was significantly decreased compared with the pre-SRS rate (IRR, 0.123; P < 0.001), and the hemorrhage rate 2 years after SRS was significantly lower than that within 2 years after SRS (IRR, 0.317; P< 0.001). Ten among 14 studies have shown that the symptoms were improved or stationary after SRS. Lesion volume was reduced in 47.3% of the patients and was stationary in 49.4% on the last follow-up images. Symptomatic adverse radiation effects (AREs) developed in 7.3% and permanent AREs were observed in 2.2%. In subgroup analysis, studies having mean marginal dose of <= 13 Gy showed statistically significantly lower development of symptomatic AREs than those having mean marginal dose of >13Gy (2.0% vs. 10.8%; P = 0.008).
   CONCLUSIONS: SRS using a relatively low marginal dose can be a safe and effective treatment for BSCM. Further prospective studies are necessary to confirm the optimal radiation dose and efficacy of SRS for BSCMs.
C1 [Kim, Byung Sup] Kosin Univ, Gospel Hosp, Dept Neurosurg, Coll Med, Busan, South Korea.
   [Kim, Kyung Hwan] Chungnam Natl Univ, Chungnam Natl Univ Hosp, Sch Med, Dept Neurosurg, Daejeon, South Korea.
   [Lee, Min Ho] Catholic Univ Korea, Dept Neurosurg, Uijeongbu St Marys Hosp, Coll Med, Uijongbu, South Korea.
   [Lee, Jung-Il] Sungkyunkwan Univ, Samsung Med Ctr, Dept Neurosurg, Sch Med, Seoul, South Korea.
RP Kim, BS (reprint author), Kosin Univ, Gospel Hosp, Dept Neurosurg, Coll Med, Busan, South Korea.
EM skysareblue@gmail.com
OI Kim, Kyung Hwan/0000-0003-1244-6969; Lee, Min Ho/0000-0001-6174-7579;
   Kim, Byung Sup/0000-0001-6814-6194
CR Aboukais R, 2016, STEREOT FUNCT NEUROS, V94, P397, DOI 10.1159/000452844
   Acciarri N, 2009, PEDIATR NEUROSURG, V45, P81, DOI 10.1159/000209283
   Barker FG, 2001, NEUROSURGERY, V49, P15, DOI 10.1097/00006123-200107000-00002
   Bertalanffy H, 2002, NEUROSURG REV, V25, P1, DOI 10.1007/s101430100179
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   DELCURLING O, 1991, J NEUROSURG, V75, P702, DOI 10.3171/jns.1991.75.5.0702
   Duckworth EAM, 2010, NEUROL CLIN, V28, P887, DOI 10.1016/j.ncl.2010.03.018
   Flemming KD, 2012, NEUROLOGY, V78, P632, DOI 10.1212/WNL.0b013e318248de9b
   Frischer JM, 2014, WORLD NEUROSURG, V81, P520, DOI 10.1016/j.wneu.2014.01.004
   FRITSCHI JA, 1994, ACTA NEUROCHIR, V130, P35, DOI 10.1007/BF01405501
   Fuetsch M, 2012, STRAHLENTHER ONKOL, V188, P311, DOI 10.1007/s00066-011-0050-7
   Gross BA, 2009, NEUROSURGERY, V64, P805, DOI [10.1227/01.NEU.0000343667.14177.72, 10.1227/01.NEU.0000343668.44288.18]
   Hasegawa T, 2002, NEUROSURGERY, V50, P1190, DOI 10.1097/00006123-200206000-00003
   Hauck EF, 2009, NEUROSURGERY, V64, P61, DOI 10.1227/01.NEU.0000335158.11692.53
   Horne MA, 2016, LANCET NEUROL, V15, P166, DOI 10.1016/S1474-4422(15)00303-8
   Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13
   Jacobs R, 2019, WORLD NEUROSURG, V124, pE58, DOI 10.1016/j.wneu.2018.11.226
   KASHIWAGI S, 1990, J NEUROSURG, V72, P27, DOI 10.3171/jns.1990.72.1.0027
   Kim BS, 2014, CLIN NEUROL NEUROSUR, V126, P110, DOI 10.1016/j.clineuro.2014.08.028
   Kim DG, 2002, ACTA NEUROCHIR, V144, P869, DOI 10.1007/s00701-002-0983-9
   Lee CC, 2012, J NEUROSURG, V117, P164, DOI 10.3171/2012.8.GKS121066
   Lee SH, 2014, ACTA NEUROCHIR, V156, P1937, DOI 10.1007/s00701-014-2155-0
   Li D, 2014, J NEUROSURG, V121, P32, DOI 10.3171/2014.3.JNS132537
   Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006
   Liscak R, 2000, MINIM INVAS NEUROSUR, V43, P201, DOI 10.1055/s-2000-11378
   Liu HB, 2016, CLIN NEUROL NEUROSUR, V151, P55, DOI 10.1016/j.clineuro.2016.09.018
   Lu XY, 2014, J NEUROSURG, V120, P982, DOI 10.3171/2013.12.JNS13990
   Monaco EA, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.7.FOCUS10151
   Park K, 2018, WORLD NEUROSURG, V116, pE1054, DOI 10.1016/j.wneu.2018.05.164
   Park SH, 2013, WORLD NEUROSURG, V80, pE261, DOI 10.1016/j.wneu.2012.09.013
   Porter PJ, 1997, J NEUROSURG, V87, P190, DOI 10.3171/jns.1997.87.2.0190
   Porter RW, 1999, J NEUROSURG, V90, P50, DOI 10.3171/jns.1999.90.1.0050
   ROBINSON JR, 1991, J NEUROSURG, V75, P709, DOI 10.3171/jns.1991.75.5.0709
   Ucuncu Kefeli A, 2019, TURK NEUROSURG, V29, P14, DOI 10.5137/1019-5149.JTN.21690-17.1
   Wang CC, 2003, SURG NEUROL, V59, P444, DOI 10.1016/S0090-3019(03)00187-3
NR 35
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E648
EP E659
DI 10.1016/j.wneu.2019.06.183
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200082
PM 31276856
DA 2020-05-12
ER

PT J
AU Kim, S
   Alan, N
   Sansosti, A
   Agarwal, N
   Wecht, DA
AF Kim, Song
   Alan, Nima
   Sansosti, Alexandra
   Agarwal, Nitin
   Wecht, Daniel A.
TI Complications After 3-and 4-Level Anterior Cervical Diskectomy and
   Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE ACDF; Cervical spine; Complications; Fusion; Multilevel
ID FOLLOW-UP; INTERBODY FUSION; PLATE FIXATION; SPINE SURGERY;
   RADICULOPATHY; DYSPHAGIA
AB BACKGROUND: Anterior cervical diskectomy and fusion(ACDF) is a standard surgical procedure used widely in the treatment of degenerative cervical spine conditions. Although the safety and effectiveness of single-level ACDF is well supported in the literature, reports of multilevel ACDF are sparse and present mixed results. There is concern for greater complications with increasing levels of fusion given the increased complexity, procedure duration, and invasiveness of multilevel ACDF.
   METHODS: In this retrospective review, we report complications data for 105 adult neurosurgical patients who underwent elective multilevel ACDF at a single institution by a single surgeon between 2004 and 2016.
   RESULTS: Fifty-four patients underwent 3-level ACDF Di patients underwent 4-level ACDF with a mean follow-up of 2.7 +/- 1.9 years. Although patients with 4-level fusion were more likely than those with 3-level fusion to have estimated blood loss >= 100 mL (P = 0.04), we found no significant differences in other peri- and postoperative complications, need for revision, and presence of symptoms at the time of last follow-up between groups.
   CONCLUSIONS: This study suggests that 4-level ACDF is necessarily associated with a greater number of or more severe complications than 3-level ACDF.
C1 [Kim, Song; Sansosti, Alexandra] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA.
   [Alan, Nima; Agarwal, Nitin; Wecht, Daniel A.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA.
RP Kim, S (reprint author), Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA.
EM sok50@pitt.edu
OI Agarwal, Nitin/0000-0003-0256-3897; Kim, Song/0000-0002-3400-3176
CR Bazaz R, 2002, SPINE, V27, P2453, DOI 10.1097/00007632-200211150-00007
   BOHLMAN HH, 1993, J BONE JOINT SURG AM, V75A, P1298, DOI 10.2106/00004623-199309000-00005
   Bolesta MJ, 2000, SPINE, V25, P2040, DOI 10.1097/00007632-200008150-00007
   Cauthen JC, 1998, SPINE, V23, P188, DOI 10.1097/00007632-199801150-00008
   Chang SW, 2010, NEUROSURGERY, V66, P639, DOI 10.1227/01.NEU.0000367449.60796.94
   CLOWARD RB, 1958, J NEUROSURG, V15, P602, DOI 10.3171/jns.1958.15.6.0602
   Daniels AH, 2008, J AM ACAD ORTHOP SUR, V16, P729, DOI 10.5435/00124635-200812000-00005
   De la Garza-Ramos R, 2016, J NEUROSURG-SPINE, V24, P885, DOI 10.3171/2015.10.SPINE15795
   Emery SE, 1997, SPINE, V22, P2622, DOI 10.1097/00007632-199711150-00008
   Fehlings MG, 2012, J NEUROSURG-SPINE, V16, P425, DOI 10.3171/2012.1.SPINE11467
   Fountas KN, 2007, SPINE, V32, P2310, DOI 10.1097/BRS.0b013e318154c57e
   Fraser JF, 2007, J NEUROSURG-SPINE, V6, P298, DOI 10.3171/spi.2007.6.4.298
   Garringer SM, 2010, J SPINAL DISORD TECH, V23, P439, DOI 10.1097/BSD.0b013e3181bd0419
   Gore DR, 1998, SPINE, V23, P2047, DOI 10.1097/00007632-199810010-00002
   Kalb S, 2012, WORLD NEUROSURG, V77, P183, DOI 10.1016/j.wneu.2011.07.004
   Klein GR, 2000, SPINE, V25, P801, DOI 10.1097/00007632-200004010-00007
   Miller LE, 2011, SPINE, V36, P2045, DOI 10.1097/BRS.0b013e3181ff37eb
   Mullins J, 2018, J NEUROSURG-SPINE, V28, P630, DOI [10.3171/2017.10.SPINE17938, 10.1080/08952841.2018.1529474]
   Nanda A, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2013.09.022
   Palit M, 1999, SPINE, V24, P2224, DOI 10.1097/00007632-199911010-00009
   RILEY LH, 1969, J NEUROSURG, V30, P127, DOI 10.3171/jns.1969.30.2.0127
   Veeravagu A, 2014, SPINE J, V14, P1125, DOI 10.1016/j.spinee.2013.07.474
   Wang SJ, 2016, J ORTHOP SURG-HONG K, V24, P338, DOI 10.1177/1602400313
   Yang Sei-Youn, 2015, Korean J Neurotrauma, V11, P191, DOI 10.13004/kjnt.2015.11.2.191
   Yu SZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091329
   Zigler JE, 2016, SPINE, V41, P463, DOI 10.1097/BRS.0000000000001263
NR 26
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E1105
EP E1110
DI 10.1016/j.wneu.2019.07.099
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200137
PM 31323419
DA 2020-05-12
ER

PT J
AU Klassen, PD
   Lesage, G
   Miller, LE
   Hes, R
   Wolfs, JFC
   Eustacchio, S
   Vajkoczy, P
AF Klassen, Peter D.
   Lesage, Geoffrey
   Miller, Larry E.
   Hes, Robert
   Wolfs, Jasper F. C.
   Eustacchio, Sandro
   Vajkoczy, Peter
TI Reoperation After Primary Lumbar Discectomy with or without Implantation
   of a Bone-Anchored Annular Closure Device: Surgical Strategies and
   Clinical Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Annulus fibrosus; Discectomy; Fusion; Revision; Sciatica
ID DISC HERNIATION; RISK-FACTORS; RECURRENT; SURGERY
AB OBJECTIVE: To determine whether presence of a honeanchored annular closure device (ACD) impacts reoperation strategies and subsequent outcomes.
   METHODS: Patients with large annular defects after single-level limited lumbar discectomy were randomly allocated to receive an ACD or discectomy alone (controls) and were followed for at least 3 years.
   RESULTS: Among 550 patients, reoperation risk was lower with ACD (11.0% vs. 19.3%). The types of reoperations and operative time were similar in each group, and the ACD did not interfere with surgical planning or operative technique. Fusion success was 87% with ACD versus 85% for controls. Perioperative complications occurred in 22% and 19% of reoperations, respectively. Leg pain and back function were improved with ACD versus controls after fusion procedures, and no group differences were observed after non-fusion reoperations.
   CONCLUSIONS: In patients undergoing post- discectomy reoperation, patients with an ACD were treated with similar operative techniques, were not exposed to additional surgical risks, and reported comparable clinical outcomes versus those without an ACD.
C1 [Klassen, Peter D.] Bonifatius Hosp, Dept Neurosurg, Lingen, Germany.
   [Lesage, Geoffrey] Onze Lieve Vrouw Hosp, Dept Neurosurg, Aalst, Belgium.
   [Miller, Larry E.] Miller Sci Consulting Inc, Asheville, NC USA.
   [Hes, Robert] AZ Klina, Dept Neurosurg, Brasschaat, Belgium.
   [Wolfs, Jasper F. C.] Haaglanden Med Ctr Westeinde Antoniushove, Dept Neurosurg, Leidschendam, Netherlands.
   [Eustacchio, Sandro] Med Univ Graz, Dept Neurosurg, Graz, Austria.
   [Vajkoczy, Peter] Charite, Dept Neurosurg, Berlin, Germany.
RP Klassen, PD (reprint author), Bonifatius Hosp, Dept Neurosurg, Lingen, Germany.
EM PeterDouglas.Klassen@hospital-lingen.de
OI Miller, Larry/0000-0003-1594-1885
FU Intrinsic Therapeutics (Woburn, Massachusetts, USA)
FX This work was supported by Intrinsic Therapeutics (Woburn,
   Massachusetts, USA). P.D. Klassen, L.E. Miller, and J.F.C. Wolfs
   disclose consultancy with Intrinsic Therapeutics. The remaining authors
   have no conflicts to report.
CR Abdu RW, 2017, SPINE, V42, P1106, DOI 10.1097/BRS.0000000000002088
   Ambrossi GLG, 2009, NEUROSURGERY, V65, P574, DOI 10.1227/01.NEU.0000350224.36213.F9
   Ament J, 2019, SPINE, V44, P5, DOI 10.1097/BRS.0000000000002746
   Ebenbichler GR, 2016, AM J PHYS MED REHAB, V95, P871, DOI 10.1097/PHM.0000000000000522
   Fritzell P, 2015, CLIN ORTHOP RELAT R, V473, P1978, DOI 10.1007/s11999-014-3596-8
   Fu TS, 2005, SPINE, V30, P2830, DOI 10.1097/01.brs.0000190393.15369.94
   Gray DT, 2006, SPINE, V31, P1957, DOI 10.1097/01.brs.0000229148.63418.c1
   Guan J, 2017, J NEUROSURG-SPINE, V26, P39, DOI 10.3171/2016.5.SPINE1616
   Guterl CC, 2013, EUR CELLS MATER, V25, P1
   Kim CH, 2013, SPINE, V38, P581, DOI 10.1097/BRS.0b013e318274f9a7
   Kim KT, 2015, J SPINAL DISORD TECH, V28, pE571, DOI 10.1097/BSD.0000000000000041
   Klassen PD, 2016, INT J CLIN TRIALS, V3, P120, DOI DOI 10.18203/2349-3259.ijct20162794
   Miller LE, 2018, SPINE, V43, pE308, DOI 10.1097/BRS.0000000000002501
   Mroz TE, 2014, SPINE J, V14, P2334, DOI 10.1016/j.spinee.2014.01.037
   Peul WC, 2007, NEW ENGL J MED, V356, P2245, DOI 10.1056/NEJMoa064039
   Suk KS, 2001, SPINE, V26, P672, DOI 10.1097/00007632-200103150-00024
   Thome C, 2018, SPINE J, V18, P2278, DOI 10.1016/j.spinee.2018.05.003
   Weinstein JN, 2006, JAMA-J AM MED ASSOC, V296, P2441, DOI 10.1001/jama.296.20.2441
NR 18
TC 2
Z9 2
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E926
EP E932
DI 10.1016/j.wneu.2019.07.038
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200116
PM 31301442
DA 2020-05-12
ER

PT J
AU Kumar, A
   Kutty, RK
   Yamada, Y
   Tanaka, R
   Ravisankar, V
   Musara, A
   Miyatani, K
   Higashiguchi, S
   Kawase, T
   Takizawa, K
   Kato, Y
AF Kumar, Ambuj
   Kutty, Raja K.
   Yamada, Yashuhiro
   Tanaka, Riki
   Ravisankar, Vigeshwar
   Musara, Aaron
   Miyatani, Kyosuke
   Higashiguchi, Saeko
   Kawase, Tsukasa
   Takizawa, Katsumi
   Kato, Yoko
TI A Retrospective Analysis of Treatment Outcomes of 40 Incidental
   Cavernous Carotid Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cavernous carotid aneurysm; Endovascular; High-flow bypass; Incidental
ID BALLOON TEST OCCLUSION; INTRACRANIAL ANEURYSMS; ARTERY ANEURYSM;
   NATURAL-HISTORY; ENDOVASCULAR TREATMENT; PIPELINE EMBOLIZATION;
   FOLLOW-UP; BYPASS
AB BACKGROUND: Hie management of cavernous carotid aneurysms (CCAs) poses a significant dilemma to the treating surgeon. Asymptomatic CCAs usually are managed conservatively with clinical and radiologic follow-up. Large size, intradural extension, sphenoid bone erosion, and increasing size on follow-up are usual indications for treating asymptomatic CCAs. However, there are no clear-cut guidelines in literature. We share our experience of 40 asymptomatic CCAs treated by endovascular and surgical methods.
   METHODS: All the asymptomatic CCAs treated between January 2014 and December 2018 were analyzed retrospectively. Patient demographics, aneurysm characteristics, postprocedural complications, and clinical and radiologic follow-up data were obtained from records. Outcome was evaluated in terms of aneurysm obliteration and maintained cerebral perfusion, postoperative complications, recurrence, and clinically significant complications during follow-up.
   RESULTS: Endovascular coiling, balloon-assisted coiling, and stent-assisted coiling were performed in 27 (75%), 5 (13.9%), and 4 (11.1%), respectively. Raymond-Roy occlusion classification grade I occlusion was achieved in 88.9% of cases. No immediate or delayed complications were noted. Coil compaction was seen in 4 (11.1%) patients. In the surgery group, all patient underwent high-flow bypass with radial artery graft. Aneurysm exclusion with good graft patency was achieved in all 4 cases without any permanent morbidity or mortality.
   CONCLUSIONS: The current study demonstrates excellent outcomes of asymptomatic CCAs after treatment. In view of the technical advancements of both surgical and endovascular methods, consideration for treatment should be given to asymptomatic CCAs. Each aneurysm should be individually assessed by experts for choosing the best endovascular or surgical treatment option.
C1 [Kumar, Ambuj] NSCB Med Coll, Dept Neurosurg, Jabalpur, India.
   [Kutty, Raja K.] Govt Med Coll, Dept Neurosurg, Trivandrum, Kerala, India.
   [Yamada, Yashuhiro; Tanaka, Riki; Miyatani, Kyosuke; Higashiguchi, Saeko; Kawase, Tsukasa; Kato, Yoko] Fujita Hlth Univ, Banbuntane Hotokukai Hosp, Dept Neurosurg, Nagoya, Aichi, Japan.
   [Ravisankar, Vigeshwar] MGM Hosp, Dept Neurosurg, Chennai, Tamil Nadu, India.
   [Musara, Aaron] Coll Hlth Sci, Dept Neurosurg, Harare, Zimbabwe.
   [Takizawa, Katsumi] Japanese Red Cross Asahikawa Hosp, Dept Neurosurg, Sapporo, Hokkaido, Japan.
RP Kumar, A (reprint author), NSCB Med Coll, Dept Neurosurg, Jabalpur, India.
EM drambuj21@gmail.com
CR Ambekar S, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.03.042
   Bavinzski G, 1998, AM J NEURORADIOL, V19, P559
   Choulakian A, 2010, J NEUROINTERV SURG, V2, P359, DOI 10.1136/jnis.2010.003137
   Dare AO, 1998, SURG NEUROL, V50, P147, DOI 10.1016/S0090-3019(97)00444-8
   Eddleman CS, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS0920
   Guan N, 2016, J STROKE CEREBROVASC, V25, P1929, DOI 10.1016/j.jstrokecerebrovasdis.2016.04.012
   Hahn CD, 2000, J NEURO-OPHTHALMOL, V20, P253, DOI 10.1097/00041327-200020040-00010
   HARDY WG, 1958, J NEUROSURG, V15, P281, DOI 10.3171/jns.1958.15.3.0281
   Hongo K, 2003, NEUROSURGERY, V52, P597, DOI 10.1227/01.NEU.0000047892.12003.58
   Ishishita Y, 2014, WORLD NEUROSURG, V82, P130, DOI 10.1016/j.wneu.2013.02.063
   Kai Y, 2007, SURG NEUROL, V67, P148, DOI 10.1016/j.surneu.2006.03.037
   Kasliwal MK, 2008, PEDIATR NEUROSURG, V44, P329, DOI 10.1159/000134926
   Koffijberg H, 2008, J NEUROSURG, V109, P176, DOI 10.3171/JNS/2008/109/8/0176
   Lee AG, 1996, NEUROSURGERY, V38, P596, DOI 10.1097/00006123-199603000-00038
   Leung GKK, 2012, CLIN NEURORADIOL, V22, P295, DOI 10.1007/s00062-012-0178-6
   LINSKEY ME, 1990, NEUROSURGERY, V26, P933, DOI 10.1227/00006123-199006000-00002
   LINSKEY ME, 1994, AM J NEURORADIOL, V15, P829
   lshikawa T, 2005, SURG NEUROL, V63, P490
   Lye R H, 1989, Br J Neurosurg, V3, P181, DOI 10.3109/02688698909002793
   Meng H, 2006, AM J NEURORADIOL, V27, P1861
   MOUNT LA, 1959, J NEUROSURG, V16, P611, DOI 10.3171/jns.1959.16.6.0611
   Murai Y, 2011, NEUROL INDIA, V59, P48, DOI 10.4103/0028-3886.84333
   Oishi H, 2018, NEUROL MED-CHIR, V58, P461, DOI 10.2176/nmc.oa.2018-0148
   Patel HC, 2010, BRIT J NEUROSURG, V24, P173, DOI 10.3109/02688690903531075
   Raymond J, 2003, STROKE, V34, P1398, DOI 10.1161/01.STR.0000073841.88563.E9
   Shimizu H, 2010, CLIN NEUROL NEUROSUR, V112, P32, DOI 10.1016/j.clineuro.2009.10.002
   Siddiqui AH, 2012, NEUROSURGERY, V71, pE509, DOI 10.1227/NEU.0b013e318258e1f8
   Stiebel-Kalish H, 2005, NEUROSURGERY, V57, P850, DOI 10.1227/01.NEU.0000179922.48165.42
   Wanke I, 2001, J NEUROL NEUROSUR PS, V71, P784, DOI 10.1136/jnnp.71.6.784
   Welch BG, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.06.029
   White JA, 1999, SURG NEUROL, V52, P607, DOI 10.1016/S0090-3019(99)00136-6
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
NR 32
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E1034
EP E1040
DI 10.1016/j.wneu.2019.07.071
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200128
PM 31306843
DA 2020-05-12
ER

PT J
AU Kuroda, N
   Fujimoto, A
   Okanishi, T
   Sato, K
   Itamura, S
   Baba, S
   Nishimura, M
   Ichikawa, N
   Enoki, H
AF Kuroda, Naoto
   Fujimoto, Ayataka
   Okanishi, Tohru
   Sato, Keishiro
   Itamura, Shinji
   Baba, Shimpei
   Nishimura, Mitsuyo
   Ichikawa, Naoki
   Enoki, Hideo
TI Low Body Mass Index and Low Intelligence Quotient Are Infection Risk
   Factors in Vagus Nerve Stimulation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Body mass index (BMI); Infection risk factor; Intelligence quotient
   (IQ); Surgical site infection; Vagus nerve stimulation (VNS)
ID SURGICAL SITE INFECTIONS; DEEP BRAIN-STIMULATION; TOTAL
   HIP-ARTHROPLASTY; QUALITY-OF-LIFE; INTELLECTUAL DISABILITY; ILAE
   COMMISSION; POSITION PAPER; VENOUS ACCESS; COMPLICATIONS; EPILEPSY
AB BACKGROUND: Risk factors for infection after vagus nerve stimulation (VNS) device implantation represent an important issue but remain unclear. We hypothesized that specific risk factors for infection would be associated with VNS device implantation. This study reviewed patients with epilepsy who underwent VNS device implantation and undertook a statistical analysis of risk factors for surgical site infection (SSI).
   METHODS: We reviewed all medical records for patients who underwent VNS therapy in our facility between August 2011 and May 2018. Age, sex, height, body weight, body mass index (BMI), intelligence quotient (IQ), surgical incision opening time, blood loss, epilepsy classification, activities of daily living, and generator replacement were statistically compared between cases with and without SSI.
   RESULTS: We performed 208 VNS device implantation surgeries at our facility during the study period. Among these, 150 patients underwent initial implantation, 56 patients underwent first generator replacement, and 2 patients underwent second replacement. Six patients (2.7%) with initial implantation and 3 patients (5.4%) with first replacement showed SSI. Low BMI was a risk factor for infection at initial implantation (P < 0.0012) using a BMI within 1.78 kg/m(2) of the cutoff for being underweight (100% sensitivity, 25% specificity). Low IQ (P = 0.0015) was also a risk factor for SSI.
   CONCLUSIONS: This study identified low BMI and low IQ at initial implantation as risk factors for infection.
C1 [Kuroda, Naoto; Fujimoto, Ayataka; Okanishi, Tohru; Sato, Keishiro; Itamura, Shinji; Baba, Shimpei; Nishimura, Mitsuyo; Ichikawa, Naoki; Enoki, Hideo] Seirei Hamamatsu Gen Hosp, Comprehens Epilepsy Ctr, Shizuoka, Japan.
RP Fujimoto, A (reprint author), Seirei Hamamatsu Gen Hosp, Comprehens Epilepsy Ctr, Shizuoka, Japan.
EM afujimotoscienceacademy@gmail.com
OI Kuroda, Naoto/0000-0003-1977-4893
CR Aalbers MW, 2015, ACTA NEUROCHIR, V157, P1917, DOI 10.1007/s00701-015-2547-9
   Armenteros-Yeguas V, 2017, J CLIN NURS, V26, P4267, DOI 10.1111/jocn.13750
   Arocho-Quinones EV, 2019, WORLD NEUROSURG, V128, pE87, DOI 10.1016/j.wneu.2019.04.003
   Barr SP, 2016, EJSO-EUR J SURG ONC, V42, P591, DOI 10.1016/j.ejso.2016.02.240
   Ben Abdelaziz R, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0965-y
   Bjerknes S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105288
   Bozic KJ, 2014, J ARTHROPLASTY, V29, P154, DOI 10.1016/j.arth.2013.04.015
   Cederholm T, 2015, CLIN NUTR, V34, P335, DOI 10.1016/j.clnu.2015.03.001
   Chen J, 2013, ARCH ORTHOP TRAUM SU, V133, P675, DOI 10.1007/s00402-013-1723-8
   Cortes-Barberena E, 2008, CLIN EXP IMMUNOL, V152, P585, DOI 10.1111/j.1365-2249.2008.03649.x
   Couch JD, 2016, NEUROSURGERY, V78, P42, DOI 10.1227/NEU.0000000000000985
   Dewey KG, 2011, MATERN CHILD NUTR, V7, P129, DOI 10.1111/j.1740-8709.2011.00357.x
   Dlouhy BJ, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.1.FOCUS11333
   Douglas A, 2011, ANTIMICROB AGENTS CH, V55, P5238, DOI 10.1128/AAC.05033-11
   Emil A, 2015, INFECT DIS-NOR, V47, P761, DOI 10.3109/23744235.2015.1055587
   Fisher RS, 2017, EPILEPSIA, V58, P522, DOI 10.1111/epi.13670
   Franca TGD, 2009, J VENOM ANIM TOXINS, V15, P374, DOI 10.1590/S1678-91992009000300003
   Fujimoto A, 2018, NEUROL ASIA, V23, P1
   Giordano F, 2017, EPILEPSIA, V58, P85, DOI 10.1111/epi.13678
   Hafez S, 2012, AM J INFECT CONTROL, V40, P426, DOI 10.1016/j.ajic.2011.07.001
   Hall PA, 2018, ANN NY ACAD SCI, V1428, P240, DOI 10.1111/nyas.13868
   Hamed SA, 2015, EXPERT REV CLIN PHAR, V8, P103, DOI 10.1586/17512433.2015.991716
   Hirao M, 2013, GASTRIC CANCER, V16, P239, DOI 10.1007/s10120-012-0174-1
   HONDA M, 1995, PEDIATR NEPHROL, V9, P543, DOI 10.1007/BF00860924
   Horowitz G, 2013, EUR ARCH OTO-RHINO-L, V270, P355, DOI 10.1007/s00405-012-2118-0
   Iwaki H, 2018, EPILEPSY BEHAV, V83, P87, DOI 10.1016/j.yebeh.2018.03.010
   Kahlow H, 2013, SEIZURE-EUR J EPILEP, V22, P827, DOI 10.1016/j.seizure.2013.06.011
   Kao AM, 2019, J PEDIATR SURG, V54, P2300, DOI 10.1016/j.jpedsurg.2019.04.020
   Krawinkel MB, 2012, ANN NUTR METAB, V61, P39, DOI 10.1159/000345162
   MAKI DG, 1991, ANN INTERN MED, V114, P845, DOI 10.7326/0003-4819-114-10-845
   Manrique Jorge, 2017, Arthroplast Today, V3, P57, DOI 10.1016/j.artd.2016.03.005
   Mattie H, 2005, J ANTIMICROB CHEMOTH, V56, P154, DOI 10.1093/jac/dki176
   Roca GM, 2012, MED CLIN-BARCELONA, V139, P185, DOI 10.1016/j.medcli.2011.12.021
   Oyama G, 2014, NEUROMODULATION, V17, P126, DOI 10.1111/ner.12097
   Parodi D, 2012, ARTHROSCOPY, V28, P924, DOI 10.1016/j.arthro.2011.12.012
   Patel NC, 2004, PEDIATR INFECT DIS J, V23, P681, DOI 10.1097/01.inf.0000131632.25375.c7
   PETRO TM, 1994, IMMUNOL INVEST, V23, P143, DOI 10.3109/08820139409087795
   Polyzos KA, 2015, EUROPACE, V17, P767, DOI 10.1093/europace/euv053
   Rayner CR, 1998, ANTIMICROB AGENTS CH, V42, P1370, DOI 10.1128/AAC.42.6.1370
   REDMOND HP, 1991, SURGERY, V110, P311
   Reunes S, 2011, EUR J INTERN MED, V22, pE39, DOI 10.1016/j.ejim.2011.02.004
   Revesz D, 2016, J NEUROSURG-PEDIATR, V18, P97, DOI 10.3171/2016.1.PEDS15534
   Rodriguez L, 2005, CLIN DIAGN LAB IMMUN, V12, P502, DOI 10.1128/CDLI.12.4.502-507.2005
   Savage JW, 2013, SPINE J, V13, P1017, DOI 10.1016/j.spinee.2013.03.051
   Savino W, 2002, EUR J CLIN NUTR, V56, pS46, DOI 10.1038/sj.ejcn.1601485
   Scheffer IE, 2017, EPILEPSIA, V58, P512, DOI 10.1111/epi.13709
   Sebbane M, 2013, J EMERG MED, V44, P299, DOI 10.1016/j.jemermed.2012.07.051
   Selber JC, 2015, PLAST RECONSTR SURG, V136, P10, DOI 10.1097/PRS.0000000000001327
   Shean KE, 2018, ANN VASC SURG, V49, P17, DOI 10.1016/j.avsg.2017.10.030
   Skeie E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197344
   Tanamachi Y, 2015, NEUROPSYCH DIS TREAT, V11, P1007, DOI 10.2147/NDT.S80898
   Tolleson C, 2014, STEREOT FUNCT NEUROS, V92, P227, DOI 10.1159/000362934
   van Kasteren MEE, 2007, CLIN INFECT DIS, V44, P921, DOI 10.1086/512192
   Weimann A, 2017, CLIN NUTR, V36, P623, DOI 10.1016/j.clnu.2017.02.013
   Yusuf E, 2017, NEUROMODULATION, V20, P563, DOI 10.1111/ner.12555
NR 55
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E839
EP E845
DI 10.1016/j.wneu.2019.06.235
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200106
PM 31295613
DA 2020-05-12
ER

PT J
AU Lai, PMR
   Gormley, WB
   Patel, N
   Frerichs, KU
   Aziz-Sultan, MA
   Du, R
AF Lai, Pui Man Rosalind
   Gormley, William B.
   Patel, Nirav
   Frerichs, Kai U.
   Aziz-Sultan, M. Ali
   Du, Rose
TI Age-Dependent Radiographic Vasospasm and Delayed Cerebral Ischemia in
   Women After Aneurysmal Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral infarction; Delayed cerebral ischemia; Delayed ischemic
   neurological deficit; Sex; Subarachnoid hemorrhage; Vasospasm
ID SYMPTOMATIC VASOSPASM; 17-BETA-ESTRADIOL; EPIDEMIOLOGY; PREDICTORS;
   MENOPAUSE; RISK
AB OBJECTIVE: Recent literature suggests there are sex differences in delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (aSAH). Our study serves to compare sex differences in radiographic vasospasm, DCI, and clinical outcome after aSAH, and to determine whether there are age-dependent differences.
   METHODS: A total of 328 patients with ruptured cerebral aneurysms were evaluated for radiographic vasospasm, clinical deterioration, cerebral infarction, and modified Rankin Scale-determined clinical outcome at 6 months to 1 year after rupture. Multivariate regression analyses were performed to evaluate the associations between these outcome measures and sex, adjusting for age, hypertension, aneurysm location, admission Hunt and Hess grade, and modified Fisher grade.
   RESULTS: After multivariate adjustment, women had higher rates of radiographic vasospasm (beta= 0.35; 95% confidence interval [CI], 0.068-0.63; P = 0.015), clinical deterioration (odds ratio [OR], 2.8; 95% CI, 1.3-6.0; P = 0.008) and cerebral infarction (OR, 2.4; 95% CI, 1.0-5.5; P = 0.039), but no difference was observed in follow-up modified Rankin Scale (mRS) outcome score at 6 months to 1 year (P = 0.96). Older women (age >55 years) have a higher rate of clinical deterioration than men in the same age group (OR, 3.5; 95% CI, 1.0-12; P = 0.043). In contrast, younger women (age <= 55 years) had increased radiographic vasospasm (beta = 0.55; 95% CI, 0.17-0.93; P = 0.005) and worse mRS outcome score (beta = 0.042; 95% CI, -0.021 to 1.1; P = 0.042) compared with men.
   CONCLUSIONS: Female sex is associated with a higher risk of radiographic vasospasm, clinical deterioration, and cerebral infarction. Furthermore, this association appears to be age-dependent. This study further supports the unique role of sex, and highlights the need to better understand the possible role of female hormones in the development of complications of subarachnoid hemorrhage.
C1 [Du, Rose] Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.
   Harvard Med Sch, Boston, MA 02115 USA.
RP Du, R (reprint author), Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.
EM rdu@bwh.harvard.edu
RI Du, Rose/AAJ-2873-2020; Du, Rose/I-5402-2012
OI Du, Rose/0000-0003-2641-6496
CR Carr KR, 2013, NEUROL RES INT, V2013, DOI 10.1155/2013/506584
   Charpentier C, 1999, STROKE, V30, P1402, DOI 10.1161/01.STR.30.7.1402
   Duan WY, 2018, NEUROEPIDEMIOLOGY, V50, P128, DOI 10.1159/000487325
   Frontera JA, 2006, NEUROSURGERY, V59, P21, DOI 10.1227/01.NEU.0000218821.34014.1B
   Germans MR, 2018, J NEUROSURG, V129, P458, DOI 10.3171/2017.3.JNS162808
   Harrod CG, 2006, MED HYPOTHESES, V66, P736, DOI 10.1016/j.mehy.2005.09.051
   Kale SP, 2013, J STROKE CEREBROVASC, V22, P22, DOI 10.1016/j.jstrokecerebrovasdis.2011.05.024
   King JT, 1997, NEUROIMAG CLIN N AM, V7, P659
   Koivisto T, 2000, STROKE, V31, P2369, DOI 10.1161/01.STR.31.10.2369
   Kongable GL, 1996, J NEUROSURG, V84, P43, DOI 10.3171/jns.1996.84.1.0043
   Kozak N, 2016, TURK NEUROSURG, V26, P545, DOI 10.5137/1019-5149.JTN.14408-15.1
   Lin CL, 2006, EXP BIOL MED, V231, P1054
   Lin CL, 2006, J NEUROSURG, V104, P298, DOI 10.3171/jns.2006.104.2.298
   LONGSTRETH WT, 1985, STROKE, V16, P377, DOI 10.1161/01.STR.16.3.377
   McKinlay SM, 2008, MATURITAS, V61, P4, DOI 10.1016/j.maturitas.2008.09.005
   Oppong MD, 2018, ACTA NEUROCHIR, V160, P1393, DOI 10.1007/s00701-018-3549-1
   Rivero-Arias Oliver, 2010, Cost Eff Resour Alloc, V8, P6, DOI 10.1186/1478-7547-8-6
   Smith ML, 2005, SURG NEUROL, V63, P229, DOI 10.1016/j.surneu.2004.06.017
   Tabuchi S, 2015, BEHAV NEUROL, DOI 10.1155/2015/720141
   TREVOUX R, 1986, MATURITAS, V8, P309, DOI 10.1016/0378-5122(86)90039-3
   Tu J, 2013, BIOMED RES INT, DOI 10.1155/2013/524324
   Vergouwen MDI, 2008, J CEREBR BLOOD F MET, V28, P1761, DOI 10.1038/jcbfm.2008.74
   Vergouwen MDI, 2010, STROKE, V41, P2391, DOI 10.1161/STROKEAHA.110.589275
   Woitzik J, 2012, J CEREBR BLOOD F MET, V32, P203, DOI 10.1038/jcbfm.2011.169
   Zacharia BE, 2010, NEUROSURG CLIN N AM, V21, P221, DOI 10.1016/j.nec.2009.10.002
NR 25
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E230
EP E235
DI 10.1016/j.wneu.2019.06.040
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200029
PM 31203057
DA 2020-05-12
ER

PT J
AU Lauridsen, SV
   Hvas, CL
   Sandgaard, E
   Gyldenholm, T
   Mikkelsen, R
   Obbekjaer, T
   Sunde, N
   Tonnesen, EK
   Hvas, AM
AF Lauridsen, Signe Voigt
   Hvas, Christine Lodberg
   Sandgaard, Emilie
   Gyldenholm, Tua
   Mikkelsen, Ronni
   Obbekjaer, Tina
   Sunde, Niels
   Tonnesen, Else Kirstine
   Hvas, Anne-Mette
TI Thromboelastometry Shows Early Hypercoagulation in Patients with
   Spontaneous Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Blood coagulation tests; Factor XIII; Platelets; Subarachnoid
   hemorrhage; Thromboelastography
ID DELAYED CEREBRAL-ISCHEMIA; THROMBOXANE RELEASE; FIBRINOLYTIC SYSTEM;
   PLATELET ACTIVATION; THROMBIN GENERATION; BLOOD-COAGULATION; PROGNOSTIC
   VALUE; BRAIN-INJURY; HEMOSTASIS; GRADE
AB BACKGROUND: The ability to achieve hemostasis after spontaneous subarachnoid hemorrhage (SAH) plays a pivotal role in outcome. Changes in coagulation in the early hours after SAH have been only sparsely investigated.
   OBJECTIVE: To investigate changes in coagulation after SAH and illuminate underlying mechanisms.
   METHODS: We enrolled 46 patients with spontaneous aneurysmal SAH. Blood samples were collected at admission and 24 hours after symptom onset. Thromboelastometry (ROTEM) was performed using the standard assays EXTEM, INTEM, and FIBTEM. Platelet maximum clot elasticity was calculated based on ROTEM results. Thrombin generation, levels of thrombin-antithrombin complex, fibrinogen, and coagulation factor XIII were measured. All data were compared with a gender-matched healthy control group.
   RESULTS: At admission (median, 3 hours 39 minutes from symptom onset), maximum clot firmness (EXTEM, P < 0.0001; INTEM, P = 0.08; FIBTEM, P < 0.0001) and platelet maximum clot elasticity (P < 0.0001) were higher in patients with SAH than in healthy controls. Thrombin generation showed higher, although nonsignificant, endogenous thrombin potential in patients with SAH than in healthy controls (P = 0.06), and thrombin-antithrombin complex levels were above the reference interval. Median fibrinogen and coagulation factor XIII levels were both within the reference parameters and remained increased 24 hours after symptom onset, whereas endogenous thrombin potential (P = 0.01) and thrombin-antithrombin complex levels decreased (P < 0.0001).
   CONCLUSIONS: Patients with SAH were in a hypercoagulable state at admission and remained so 24 hours after SAH. Increased clot firmness could be caused by increased platelet function, because platelet maximum clot elasticity was increased despite normal fibrinogen and coagulation factor XIII levels.
C1 [Lauridsen, Signe Voigt; Hvas, Christine Lodberg; Tonnesen, Else Kirstine] Aarhus Univ Hosp, Dept Intens Care, Aarhus, Denmark.
   [Lauridsen, Signe Voigt; Sandgaard, Emilie; Gyldenholm, Tua; Hvas, Anne-Mette] Aarhus Univ Hosp, Dept Clin Biochem, Aarhus, Denmark.
   [Lauridsen, Signe Voigt] Aarhus Univ Hosp, Dept Anaesthesiol, Aarhus, Denmark.
   [Mikkelsen, Ronni] Aarhus Univ Hosp, Dept Neuroradiol, Aarhus, Denmark.
   [Obbekjaer, Tina; Sunde, Niels] Aarhus Univ Hosp, Dept Neurosurg, Aarhus, Denmark.
   [Hvas, Anne-Mette] Aarhus Univ, Dept Clin Med, Aarhus, Denmark.
RP Lauridsen, SV (reprint author), Aarhus Univ Hosp, Dept Intens Care, Aarhus, Denmark.; Lauridsen, SV (reprint author), Aarhus Univ Hosp, Dept Clin Biochem, Aarhus, Denmark.; Lauridsen, SV (reprint author), Aarhus Univ Hosp, Dept Anaesthesiol, Aarhus, Denmark.
EM sivl@clin.au.dk
OI Lauridsen, Signe Voigt/0000-0002-3584-2270; Hvas, Christine
   Lodberg/0000-0003-0826-4126
FU Aarhus University; Director Werner Richter & Wife Foundation, Doctor
   Sofus Carl Emil Friis & Wife Olga Doris Friis Foundation [1.6.1978];
   Letterstedtske Foundation; Lippman Foundation; Emil & Wife Inger Hertz
   Foundation; Aase & Ejnar Danielsens Foundation; Danish Society of
   Anaesthesiology and Intensive Care Foundation; CLS Behring; Octapharma
FX We thank Mai Sternulm Veirup and Vivi Bo Mogensen for support in the
   laboratory. Also, a special thanks to doctors, nurses, and health care
   personnel at the Department of Neurosurgery and Department of Intensive
   Care, Section of Neurointensive Care, Aarhus University Hospital,
   Denmark, for cooperation and help during enrollment. We thank Aarhus
   University, Director Werner Richter & Wife Foundation, Doctor Sofus Carl
   Emil Friis & Wife Olga Doris Friis Foundation, Lily Benthine Lunds
   Foundation of 1.6.1978, The Letterstedtske Foundation, The Lippman
   Foundation, Emil & Wife Inger Hertz Foundation, Aase & Ejnar Danielsens
   Foundation, Holger & Ruth Hesses Memorial Foundation, and Danish Society
   of Anaesthesiology and Intensive Care Foundation (DASAIM), CLS Behring,
   and Octapharma for financial research support. None of our research
   supports had any influence on the design, analysis, interpretation of
   results, or manuscript writing. Author contributions: S.V.L., A.M.H.,
   C.L.H., and E.T. designed the study, interpreted the results, performed
   the statistical analysis, wrote the manuscript, and critically revised
   the manuscript. E.S., T.G., R.M., T.O., and N.S. were involved in
   designing the project, interpretation of the results, and revising the
   manuscript.
CR Abboud T, 2017, WORLD NEUROSURG, V108, P669, DOI 10.1016/j.wneu.2017.09.074
   Andersen MG, 2014, ACTA ANAESTH SCAND, V58, P525, DOI 10.1111/aas.12290
   Anker-Moller T, 2017, SEMIN THROMB HEMOST, V43, P750, DOI 10.1055/s-0037-1604089
   Antovic J, 2002, SCAND J CLIN LAB INV, V62, P195, DOI 10.1080/003655102317475452
   Cha KC, 2010, J KOREAN NEUROSURG S, V47, P119, DOI 10.3340/jkns.2010.47.2.119
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   Ebihara T, 2006, ACTA NEUROCHIR SUPPL, V96, P69
   ETTINGER M G, 1970, Stroke, V1, P139
   Frijns CJM, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.081539
   Frontera JA, 2012, J THROMB HAEMOST, V10, P711, DOI 10.1111/j.1538-7836.2012.04651.x
   Frontera JA, 2017, NEUROCRIT CARE, V26, P48, DOI 10.1007/s12028-016-0292-4
   Fujii Y, 1997, J NEUROSURG, V86, P594, DOI 10.3171/jns.1997.86.4.0594
   FUJII Y, 1995, NEUROSURGERY, V37, P226, DOI 10.1227/00006123-199508000-00006
   Ganter MT, 2008, ANESTH ANALG, V106, P1366, DOI 10.1213/ane.0b013e318168b367
   Hemker HC, 2006, THROMB HAEMOSTASIS, V96, P553, DOI 10.1160/TH06-07-0408
   Hirashima Y, 1997, NEUROCHEM RES, V22, P1249, DOI 10.1023/A:1021985030331
   Ilveskero S, 2005, NEUROSURGERY, V57, P16, DOI 10.1227/01.NEU.0000163085.48999.D6
   Ji Y, 2014, NEUROL MED-CHIR, V54, P457, DOI 10.2176/nmc.oa2013-0006
   Juvela S, 2006, STROKE, V37, P1451, DOI 10.1161/01.STR.0000221710.55467.33
   JUVELA S, 1991, J NEUROSURG, V74, P21, DOI 10.3171/jns.1991.74.1.0021
   JUVELA S, 1991, J NEUROSURG, V74, P386, DOI 10.3171/jns.1991.74.3.0386
   Larsen CC, 2012, THROMB RES, V129, pE229, DOI 10.1016/j.thromres.2012.01.016
   Macdonald RL, 2017, LANCET, V389, P655, DOI 10.1016/S0140-6736(16)30668-7
   Morga R, 2007, NEUROL NEUROCHIR POL, V41, P296
   Moritz S, 2010, J NEUROSURG ANESTH, V22, P21, DOI 10.1097/ANA.0b013e3181bdf50d
   Nieuwkamp DJ, 2009, LANCET NEUROL, V8, P635, DOI 10.1016/S1474-4422(09)70126-7
   Nina P, 2001, SURG NEUROL, V55, P197, DOI 10.1016/S0090-3019(01)00402-5
   Nissen JJ, 2001, J NEUROL NEUROSUR PS, V71, P329, DOI 10.1136/jnnp.71.3.329
   OHKUMA H, 1991, STROKE, V22, P854, DOI 10.1161/01.STR.22.7.854
   Passier PECA, 2010, CEREBROVASC DIS, V29, P557, DOI 10.1159/000306642
   Peltonen S, 1997, J NEUROSURG, V87, P207, DOI 10.3171/jns.1997.87.2.0207
   Pereira AR, 2007, NEUROCRIT CARE, V7, P18, DOI 10.1007/s12028-007-0053-5
   Prodan CI, 2013, J NEUROL SCI, V334, P126, DOI 10.1016/j.jns.2013.08.008
   Ramchand P, 2016, WORLD NEUROSURG, V96, P215, DOI 10.1016/j.wneu.2016.04.002
   Ray B, 2018, TRANSL STROKE RES, V9, P459, DOI 10.1007/s12975-017-0594-7
   Sanchez-Pena P, 2008, CRIT CARE MED, V36, P2267, DOI 10.1097/CCM.0b013e3181809750
   Sandgaard E, 2019, MOL NEUROBIOL, V56, P78, DOI 10.1007/s12035-018-1066-0
   Schneider T, 2015, HAMOSTASEOLOGIE, V35, P181, DOI 10.5482/HAMO-14-08-0033
   Solomon C, 2015, ANESTH ANALG, V121, P868, DOI 10.1213/ANE.0000000000000859
   Steiner T, 2013, CEREBROVASC DIS, V35, P93, DOI 10.1159/000346087
   Vahtera AS, 2019, WORLD NEUROSURG, V122, pE334, DOI 10.1016/j.wneu.2018.10.035
   van Gijn J, 2007, LANCET, V369, P306, DOI 10.1016/S0140-6736(07)60153-6
   Vibede E, 2017, ACTA ANAESTH SCAND, V61, P492, DOI 10.1111/aas.12885
   von Elm E, 2007, EPIDEMIOLOGY, V18, P800, DOI 10.1097/EDE.0b013e3181577654
   Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35
NR 45
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E140
EP E149
DI 10.1016/j.wneu.2019.06.019
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200019
PM 31327692
DA 2020-05-12
ER

PT J
AU Lee, HS
   Ahn, JS
   Park, JC
   Lee, S
   Kim, M
   Park, W
AF Lee, Heui Seung
   Ahn, Jae Sung
   Park, Jung Cheol
   Lee, Seungjoo
   Kim, Moinay
   Park, Wonhyoung
TI Dominance of the Anterior Cerebral Artery as a Predictor of
   Vasospasm-Related Cerebral Infarction After Surgical Treatment of
   Ruptured Blood Blister-Like Aneurysm in the Internal Carotid Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cerebral artery; Blister-like aneurysm; Internal carotid
   artery; Infarction; Vasospasm
ID HIGH-FLOW BYPASS; SUBARACHNOID HEMORRHAGE; INTRACRANIAL BYPASS;
   TREATMENT STRATEGY; SAPHENOUS-VEIN; MANAGEMENT; GRAFTS; OCCLUSION;
   ISCHEMIA; PUNCTURE
AB OBJECTIVE: Vasospasm (VSP)-related ischemic complications have been associated with poor outcomes in patients with subarachnoid hemorrhage due to ruptured blood blister-like aneurysms (BBAs) in the communicating segment of the internal carotid artery (ICA). The purpose of the present study was to investigate the incidence of, and factors related to, VSP-related cerebral infarction (VSP-CI) in patients with surgically treated BBAs in the communicating segment of the ICA.
   METHODS: The medical records of 25 consecutive patients with surgically treated BBAs in the communicating segment of the ICA were reviewed. The preoperative angiographic findings, surgical methods, and patient outcomes, including VSP-CI, were evaluated.
   RESULTS: Of the 25 patients, 10 had undergone extracranial-intracranial (EC-IC) bypass with trapping and 15 had undergone clipping surgery. VSP-CI occurred in the ipsilateral hemisphere to the aneurysm in 4 patients with EC-IC bypass with trapping and in 6 patients who had undergone received clipping. Positive balloon test occlusion findings did not affect the occurrence of VSP-CI in the EC-IC bypass and trapping group. The occurrence of VSP-CI was significantly greater in the patients with a dominant anterior cerebral artery ipsilateral to the aneurysm on preoperative angiogram (P = 0.023), with a hazard ratio of 14.14 (95% confidence interval, 1.57-127.68).
   CONCLUSIONS: The results of preoperative balloon test occlusion were less reliable for predicting postoperative ischemic complications of EC-IC bypass with trapping in patients with ruptured BBAs in the communicating segment of the ICA. However, anterior cerebral artery dominance ipsilateral to the ruptured aneurysm could be predictive for postoperative VSP-CI.
C1 [Lee, Heui Seung; Ahn, Jae Sung; Park, Jung Cheol; Lee, Seungjoo; Kim, Moinay; Park, Wonhyoung] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Neurosurg, Seoul, South Korea.
RP Park, W (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Neurosurg, Seoul, South Korea.
EM elevenes@gmail.com
OI Park, Jung Cheol/0000-0001-6677-455X
CR Abud DG, 2005, AM J NEURORADIOL, V26, P2602
   Alaraj A, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/2/E7
   BARNETT DW, 1994, NEUROSURGERY, V35, P92, DOI 10.1227/00006123-199407000-00014
   Bouthillier A, 1996, NEUROSURGERY, V38, P425, DOI 10.1097/00006123-199603000-00001
   Dabus G, 2013, INTERV NEUROL, V2, P30, DOI 10.1159/000354755
   Fiorella D, 2005, NEUROSURGERY, V57, P210, DOI 10.1227/01.NEU.0000163685.23846.DD
   FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001
   Goldman S, 2004, J AM COLL CARDIOL, V44, P2149, DOI 10.1016/j.jacc.2004.08.064
   Horiuchi T, 2011, NEUROSURG REV, V34, P49, DOI 10.1007/s10143-010-0272-7
   Hui C, 2005, CLIN RADIOL, V60, P1030, DOI 10.1016/j.crad.2005.04.004
   Hyun SJ, 2007, ACTA NEUROCHIR, V149, P1049, DOI 10.1007/s00701-007-1281-3
   Ishikawa T, 2009, NEUROL MED-CHIR, V49, P553, DOI 10.2176/nmc.49.553
   IWATA Y, 1988, Microsurgery, V9, P14, DOI 10.1002/micr.1920090105
   Kai Y, 2007, SURG NEUROL, V67, P148, DOI 10.1016/j.surneu.2006.03.037
   Kazumata K, 2014, OPER NEUROSURG, V10, P66, DOI 10.1227/NEU.0000000000000076
   Kikkawa Y, 2017, WORLD NEUROSURG, V105, P470, DOI 10.1016/j.wneu.2017.06.033
   Kim BC, 2014, NEURORADIOLOGY, V56, P211, DOI 10.1007/s00234-014-1317-3
   Kim JH, 2006, SURG NEUROL, V66, P441, DOI 10.1016/j.surneu.2005.12.030
   Kubo Y, 2006, J NEUROSURG, V105, P785, DOI 10.3171/jns.2006.105.5.785
   Kumar G, 2015, J ULTRAS MED, V34, P1345, DOI 10.7863/ultra.34.8.1345
   LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268
   Liu Z, 2017, WORLD NEUROSURG, V108, P618, DOI 10.1016/j.wneu.2017.09.080
   Maselli Giuliano, 2011, Surg Neurol Int, V2, P46, DOI 10.4103/2152-7806.79764
   Matsubara N, 2011, ACTA NEUROCHIR, V153, P287, DOI 10.1007/s00701-010-0898-9
   Matsuzaki H, 2017, WORLD NEUROSURG, V104, P45, DOI 10.1016/j.wneu.2017.04.173
   McLaughlin N, 2012, NEUROCHIRURGIE, V58, P170, DOI 10.1016/j.neuchi.2012.02.025
   McLaughlin N, 2010, WORLD NEUROSURG, V74, P483, DOI 10.1016/j.wneu.2010.06.039
   Meling TR, 2008, J NEUROSURG, V108, P662, DOI 10.3171/JNS/2008/108/4/0662
   Meling TR, 2017, NEUROSURG REV, V40, P587, DOI 10.1007/s10143-017-0893-1
   Mohit AA, 2007, NEUROSURGERY, V60, P105, DOI 10.1227/01.NEU.0000249243.25429.EE
   Murai Y, 2012, WORLD NEUROSURG, V77, P166, DOI 10.1016/j.wneu.2011.05.020
   O'Kelly CJ, 2009, J NEUROSURG, V111, P1029, DOI 10.3171/2008.9.JNS08881
   Owen CM, 2017, NEUROSURGERY, V80, P235, DOI 10.1227/NEU.0000000000001259
   PERLMUTTER D, 1978, J NEUROSURG, V49, P204, DOI 10.3171/jns.1978.49.2.0204
   Powers WJ, 2015, STROKE, V46, P3020, DOI 10.1161/STR.0000000000000074
   Regelsberger J, 2011, NEUROSURG REV, V34, P409, DOI 10.1007/s10143-011-0313-x
   REGLI L, 1995, J NEUROSURG, V83, P806, DOI 10.3171/jns.1995.83.5.0806
   Reilly C, 2004, J NEUROSURG, V101, P255, DOI 10.3171/jns.2004.101.2.0255
   Sanelli PC, 2014, AM J NEURORADIOL, V35, P2209, DOI 10.3174/ajnr.A3782
   Shimizu H, 2010, CLIN NEUROL NEUROSUR, V112, P32, DOI 10.1016/j.clineuro.2009.10.002
   Shin HS, 2003, YONSEI MED J, V44, P210, DOI 10.3349/ymj.2003.44.2.210
   Tarulli E, 2010, AM J NEURORADIOL, V31, P1186, DOI 10.3174/ajnr.A2065
   Vergouwen MDI, 2011, NEUROCRIT CARE, V15, P308, DOI 10.1007/s12028-011-9586-8
   Winship IR, 2015, MICROCIRCULATION, V22, P228, DOI 10.1111/micc.12177
   Yang K, 2015, WORLD NEUROSURG, V83, P197, DOI 10.1016/j.wneu.2014.06.008
   Yu ZT, 2017, BRIT J NEUROSURG, V31, P668, DOI 10.1080/02688697.2017.1327015
NR 46
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E513
EP E524
DI 10.1016/j.wneu.2019.06.143
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200064
PM 31254698
DA 2020-05-12
ER

PT J
AU Lee, S
   Park, SK
   Joo, BE
   Lee, JA
   Park, K
AF Lee, Seunghoon
   Park, Sang-Ku
   Joo, Byung-Euk
   Lee, Jeong-A.
   Park, Kwan
TI Vascular Complications in Microvascular Decompression: A Survey of 4000
   Operations
SO WORLD NEUROSURGERY
LA English
DT Article
DE Microvascular decompression; Neurovascular compression syndrome;
   Vascular complication
ID TRIGEMINAL NEURALGIA; HEMIFACIAL SPASM; SURGERY; SACRIFICE; LESSONS
AB BACKGROUND: Vascular complications in posterior fossa surgery, even in microvascular decompression (MVD) involving a small cranial opening, can have catastrophic consequences. We analyzed these complications to determine the incidence, risk factors, prognosis, and preventive measures involved.
   METHODS: Between April 1997 and March 2018, 4000 consecutive patients with neurovascular compression syndrome were admitted and underwent MVD. We reviewed the medical records of patients who developed vascular complications after MVD, focusing on their past medical history, perioperative laboratory findings and images, surgical findings, and postoperative progress.
   RESULTS: Vascular complications developed in 28 patients (0.7%), including 24 with hemifacial spasm and 4 with trigeminal neuralgia. Twenty-two hemorrhagic (78.6%) and 6 ischemic (21.4%) complications occurred, with epidural hematoma the most frequent type identified. Ten patients (35.7%) patients were asymptomatic and 18 (64.3%) were symptomatic. Six patients (21.4%) underwent revision surgery, such as hematoma removal, craniectomy, or extraventricular drainage insertion. At the last follow-up, dizziness was the most commonly reported sequela from vascular complications. No deaths had occurred.
   CONCLUSIONS: Vascular complications are rare, but can be the most devastating adverse outcome of MVD surgery. Unusual signs and symptoms after MVD should prompt special attention to early management and patient safety.
C1 [Lee, Seunghoon; Lee, Jeong-A.; Park, Kwan] Sungkyunkwan Univ, Sch Med, Dept Neurosurg, Samsung Med Ctr, Seoul, South Korea.
   [Park, Sang-Ku] Sungkyunkwan Univ, Sch Med, Dept Neurol, Samsung Med Ctr, Seoul, South Korea.
   [Joo, Byung-Euk] Myongji Hosp, Dept Neurol, Goyang, South Korea.
RP Park, K (reprint author), Sungkyunkwan Univ, Sch Med, Dept Neurosurg, Samsung Med Ctr, Seoul, South Korea.
EM kwanpark@skku.edu
OI Park, Sang-Ku/0000-0002-0546-9014
CR Dumot C, 2018, WORLD NEUROSURG, V117, P422, DOI 10.1016/j.wneu.2018.06.160
   Hyun SJ, 2010, NEUROSURG REV, V33, P325, DOI 10.1007/s10143-010-0254-9
   KALFAS IH, 1988, NEUROSURGERY, V23, P343, DOI 10.1227/00006123-198809000-00010
   Lee MH, 2016, NEUROSURG REV, V39, P151, DOI 10.1007/s10143-015-0666-7
   Lee S, 2018, J CLIN NEUROSCI, V52, P156, DOI 10.1016/j.jocn.2018.03.013
   Liebelt BD, 2017, WORLD NEUROSURG, V104, P788, DOI 10.1016/j.wneu.2017.05.098
   Masuoka J, 2009, J CLIN NEUROSCI, V16, P1342, DOI 10.1016/j.jocn.2008.12.024
   McLaughlin MR, 1999, J NEUROSURG, V90, P1, DOI 10.3171/jns.1999.90.1.0001
   Olson S, 2005, J CLIN NEUROSCI, V12, P787, DOI 10.1016/j.jocn.2005.08.001
   Sade B, 2006, J NEUROSURG, V105, P200, DOI 10.3171/jns.2006.105.2.200
   Sekula RF, 2013, MUSCLE NERVE, V48, P770, DOI 10.1002/mus.23800
   Sindou M, 2018, NEUROCHIRURGIE, V64, P106, DOI 10.1016/j.neuchi.2018.01.001
   Xia L, 2017, NEUROSURG REV, V40, P389, DOI 10.1007/s10143-016-0791-y
   Xia L, 2014, J CRANIOFAC SURG, V25, P1413, DOI 10.1097/SCS.0000000000000984
NR 14
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E577
EP E582
DI 10.1016/j.wneu.2019.06.155
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200072
PM 31254687
DA 2020-05-12
ER

PT J
AU Lin, FX
   Wu, J
   Jiao, YM
   Cai, JW
   Cao, Y
   Wang, S
   Lin, YX
AF Lin, Fuxin
   Wu, Jun
   Jiao, Yuming
   Cai, Jiawei
   Cao, Yong
   Wang, Shuo
   Lin, Yuanxiang
TI One-Stage Surgical Resection of Giant Intracranial Arteriovenous
   Malformations in Selected Patients: A Novel Diffusion Tenser Imaging
   Score
SO WORLD NEUROSURGERY
LA English
DT Article
DE Diffusion tensor imaging; Functional magnetic resonance imaging; Giant
   cerebral arteriovenous malformations; Surgical outcomes
ID SINGLE-CENTER EXPERIENCE; CORTICOSPINAL TRACT; MULTIMODALITY TREATMENT;
   PREDICTIVE-VALUE; NATURAL-HISTORY; BRAIN; OUTCOMES; REORGANIZATION;
   EMBOLIZATION; RISK
AB OBJECTIVE: The effective treatment of giant cerebral arteriovenous malformations (gAVMs) is challenging. The aim of this study was to determine the risk factors for 1-stage resection of gAVM and develop a reliable indicator for patient selection.
   METHODS: A prospectively maintained database of patients with AVM in our hospital was reviewed. The neuroradiological findings and clinical characteristics of the patients and lesions were analyzed with respect to postoperative functional deficits (FD). A novel blood oxygen level-dependent functional magnetic resonance imaging score and a diffusion tensor imaging (DTI) score were created to predict surgical outcomes. Furthermore, the long-term outcomes of gAVMs treated by other methods in the literature were reviewed.
   RESULTS: A total of 35 patients with 35 gAVMs were included. The mean diameter of the gAVMs was 64.8 +/- 4.9 mm. In the univariate analysis, the functional magnetic resonance imaging score (P = 0.022) and DTI score (P = 0.003) were both significantly associated with longterm FD. The Spetzler-Martin score (P = 0.092) trended toward significance. Multivariate analysis revealed that a high DTI score (odds ratio, 2.19; 95% confidence interval, 1.08-4.46; P = 0.030) was the only independent risk factor that was correlated with long-term FD. The predictive effect of the DTI score (area under the curve = 0.822) is superior to that of the Spetzler-Martin score (area under the curve = 0.640) according to the receiver operating characteristic analysis, and the cutoff point was 2.5 (sensitivity = 0.860 and specificity = 0.867).
   CONCLUSIONS: One-stage surgical resection of gAVMs in patients with a low DTI score (0-2) seems to be feasible. The DTI score could be a reliable indicator for patient selection.
C1 [Lin, Fuxin; Cai, Jiawei; Lin, Yuanxiang] Fujian Med Univ, Affiliated Hosp 1, Dept Neurosurg, Fuzhou, Fujian, Peoples R China.
   [Wu, Jun; Jiao, Yuming; Cao, Yong; Wang, Shuo] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Lin, YX (reprint author), Fujian Med Univ, Affiliated Hosp 1, Dept Neurosurg, Fuzhou, Fujian, Peoples R China.
EM lyx99070@126.com
FU National Natural Science Youth Fund grant from the National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [81801302]; Fujian Provincial Health and Family Planning Scientific
   Research Personnel Training Project grant from the Health and Family
   Planning Commission of Fujian Province [2018-ZQN-43]; National Science
   and Technology Support Plan, a grant from the Ministry of Health of
   China [2011BAI08B08]
FX This study was supported by a National Natural Science Youth Fund (No.
   81801302, principal investigator: Fuxin Lin) grant from the National
   Natural Science Foundation of China, and funded by the Fujian Provincial
   Health and Family Planning Scientific Research Personnel Training
   Project (No. 2018-ZQN-43, principal investigator: Fuxin Lin) grant from
   the Health and Family Planning Commission of Fujian Province. This study
   was also supported by a National Science and Technology Support Plan
   (No. 2011BAI08B08, principal investigator: Shuo Wang), a grant from the
   Ministry of Health of China.
CR Chang SD, 2003, NEUROSURGERY, V53, P1
   Chun DH, 2016, TURK NEUROSURG, V26, P709, DOI 10.5137/1019-5149.JTN.13280-14.5
   CRAWFORD PM, 1986, J NEUROL NEUROSUR PS, V49, P1, DOI 10.1136/jnnp.49.1.1
   Gallagher TA, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2013.2.FOCUS12417
   GRAF CJ, 1983, J NEUROSURG, V58, P331, DOI 10.3171/jns.1983.58.3.0331
   Hernesniemi JA, 2008, NEUROSURGERY, V63, P823, DOI 10.1227/01.NEU.0000330401.82582.5E
   Lawton MT, 2010, NEUROSURGERY, V66, P702, DOI 10.1227/01.NEU.0000367555.16733.E1
   Lehericy S, 2002, RADIOLOGY, V223, P672, DOI 10.1148/radiol.2233010792
   Lin FX, 2017, J NEUROSURG, V126, P1863, DOI 10.3171/2016.4.JNS1616
   Lin FX, 2016, J NEUROSURG, V125, P289, DOI 10.3171/2015.6.JNS15969
   Lin FX, 2016, WORLD NEUROSURG, V88, P538, DOI 10.1016/j.wneu.2015.10.074
   Lin FX, 2016, WORLD NEUROSURG, V85, P273, DOI 10.1016/j.wneu.2015.10.002
   Lin YX, 2018, J NEUROSURG, V128, P541, DOI 10.3171/2016.10.JNS161179
   Natarajan SK, 2008, NEUROSURGERY, V62, P1213, DOI 10.1227/01.neu.0000333293.74986.e5
   Niizuma K, 2006, J CLIN NEUROSCI, V13, P1028, DOI 10.1016/j.jocn.2004.11.025
   Okada T, 2007, AM J NEURORADIOL, V28, P1107, DOI 10.3174/ajnr.A0493
   Reinard KA, 2015, WORLD NEUROSURG, V84, P1765, DOI 10.1016/j.wneu.2015.07.051
   Richling B, 2006, NEUROSURGERY S3, V59, pS3
   Richling Bernd, 2006, Neurosurgery, V59, pS148
   SPETZLER RF, 1986, J NEUROSURG, V65, P476, DOI 10.3171/jns.1986.65.4.0476
   Ulmer JL, 2004, NEUROSURGERY, V55, P569, DOI 10.1227/01.NEU.0000134384.94749.B2
   Ulmer JL, 2003, AM J NEURORADIOL, V24, P213
   van Beijnum J, 2011, JAMA-J AM MED ASSOC, V306, P2011, DOI 10.1001/jama.2011.1632
   Wang Huan-Chih, 2012, Surg Neurol Int, V3, pS105, DOI 10.4103/2152-7806.95421
   Xiao FR, 2010, NEUROSURGERY, V67, P1253, DOI 10.1227/NEU.0b013e3181efbaef
   Yang WY, 2016, NEUROSURGERY, V79, P116, DOI 10.1227/NEU.0000000000001189
   Yasargil MG, 1999, NEW ENGL J MED, V340, P1812
   Zhao B, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006618
   Zhao JZ, 2010, NEUROSURGERY, V67, P1359, DOI 10.1227/NEU.0b013e3181eda216
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E1041
EP E1050
DI 10.1016/j.wneu.2019.07.075
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200129
PM 31323399
DA 2020-05-12
ER

PT J
AU Liu, D
   Shi, B
   Shi, BL
   Li, Y
   Xia, SQ
   Liu, Z
   Zhu, ZZ
   Qiu, Y
AF Liu, Dun
   Shi, Bo
   Shi, Benlong
   Li, Yang
   Xia, Sanqiang
   Liu, Zhen
   Zhu, Zezhang
   Qiu, Yong
TI Partial Hemivertebra Resection (Grade 4 Osteotomy) for Congenital
   Scoliosis: A Comparison with Radical Hemivertebra resection
SO WORLD NEUROSURGERY
LA English
DT Article
DE Congenital scoliosis; Grade 4 osteotomy; Hemi-vertebra; Partial HV
   resection
ID FIXATION; FUSION
AB INTRODUCTION: To compare radiological and clinical outcomes between partial and radical hemivertebra (HV) resection in congenital scoliosis (CS) patients with single nonincarcerated HV.
   METHODS: CS patients with single HV undergoing partial HV resection from February 2011 to May 2016 were retrospectively reviewed and included in the P group; those undergoing radical HV resection were included in the R group. Patients in R group were age-, sex-, curve magnitude-, and apex location-matched with those in P group. Comparisons were performed in terms of radiological results, clinical outcomes, and complications pre-operation, postoperation, and at the last follow-up between the P and R groups.
   RESULTS: Both P and R groups included 25 CS patients, and the mean age at surgery was 10.1 +/- 5.2 years. Compared with the R group, the P group had a similar correction of the Cobb angle at postoperation (38.6 +/- 6.7 degrees vs. 35.2 +/- 5.6 degrees, P = 0.057) and at the last follow-up (38.4 +/- 7.0 degrees vs. 34.7 +/- 6.7 degrees, P = 0.062). The estimated blood loss was 690.9 +/- 291.3 mL in the R group and 502.2 +/- 223.8 ml in the P group (P = 0.023), and the operating time was 259.4 +/- 70.2 minutes in the R group and 206.9 +/- 61.2 minutes in the P group (P = 0.007). During followup, no significant correction loss and major complication were observed in the P group, whereas 1 patient in the R group had rod breakage with pseudarthrosis at 24-month follow-up.
   CONCLUSIONS: Partial HV resection is a safe, effective, and less invasive procedure and achieved comparable correction with radical HV resection in the treatment of CS patients with single nonincarcerated HV.
C1 [Liu, Dun; Shi, Bo; Shi, Benlong; Li, Yang; Xia, Sanqiang; Liu, Zhen; Zhu, Zezhang; Qiu, Yong] Nanjing Univ, Affiliated Drum Tower Hosp, Spine Surg, Med Sch, Nanjing, Jiangsu, Peoples R China.
RP Zhu, ZZ (reprint author), Nanjing Univ, Affiliated Drum Tower Hosp, Spine Surg, Med Sch, Nanjing, Jiangsu, Peoples R China.
EM zhuzezhang@126.com
FU Natural Science Foundation of Youth Fund Projects of Jiangsu Province
   [BK20170126]; Funding for the Postdoctoral Science Foundation of China
   [2017M610323]; Jiangsu Postdoctoral Research Funding Program [1701018C]
FX Natural Science Foundation of Youth Fund Projects of Jiangsu Province
   (BK20170126) and Funding for the Postdoctoral Science Foundation of
   China (2017M610323) and Jiangsu Postdoctoral Research Funding Program
   (1701018C) were received in support of this work.
CR Chang DG, 2015, SPINE, V40, pE484, DOI 10.1097/BRS.0000000000000809
   Demirkiran G, 2015, J SPINAL DISORD TECH, V30, P285
   Gao R, 2015, SPINE J, V15, P2009, DOI 10.1016/j.spinee.2015.04.047
   Geck MJ, 2009, SPINE, V34, P1942, DOI 10.1097/BRS.0b013e3181a3c777
   Hedequist D, 2007, J PEDIATR ORTHOPED, V27, P106, DOI 10.1097/BPO.0b013e31802b4993
   Hengwei F, 2017, WORLD NEUROSURG, V116, pe1
   Hu WH, 2016, J ORTHOP SURG RES, V11, DOI 10.1186/s13018-016-0447-1
   KUHNS JG, 1952, AMA ARCH SURG, V65, P250, DOI 10.1001/archsurg.1952.01260020263007
   MCMASTER MJ, 1982, J BONE JOINT SURG AM, V64, P1128, DOI 10.2106/00004623-198264080-00003
   NASCA RJ, 1975, J BONE JOINT SURG AM, VA 57, P456, DOI 10.2106/00004623-197557040-00003
   Papadopoulos EC, 2015, SPINE J, V15, P983, DOI 10.1016/j.spinee.2013.03.023
   Schwab F, 2014, NEUROSURGERY, V74, P112, DOI 10.1227/NEU.0000000000000182o
   Shi BL, 2018, SPINE J, V18, P2059, DOI 10.1016/j.spinee.2018.04.011
   Wang S, 2015, EUR SPINE J, V26, P1817
   Wang SR, 2017, SPINE, V42, P1687, DOI 10.1097/BRS.0000000000002197
   WINTER RB, 1968, J BONE JOINT SURG AM, VA 50, P1
NR 16
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E1028
EP E1033
DI 10.1016/j.wneu.2019.07.070
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200127
PM 31306841
DA 2020-05-12
ER

PT J
AU Lu, C
   White, SJ
   Ye, IB
   Mikhail, CM
   Cheung, ZB
   Cho, SK
AF Lu, Charles
   White, Samuel J.
   Ye, Ivan B.
   Mikhail, Christopher M.
   Cheung, Zoe B.
   Cho, Samuel K.
TI The Effects of Liver Disease on Surgical Outcomes Following Adult Spinal
   Deformity Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE ACS-NSQIP; Adult spinal deformity; ASD; Complications; Hepatic
   dysfunction; Liver disease; MELD-Na
ID QUALITY IMPROVEMENT PROGRAM; SHORT-TERM OUTCOMES; KNEE ARTHROPLASTY;
   AMERICAN-COLLEGE; UNITED-STATES; POSTOPERATIVE MORTALITY;
   CIRRHOTIC-PATIENTS; HEPATITIS-C; MELD SCORE; MODEL
AB BACKGROUND: As the prevalence of chronic liver disease continues to rise in the United States, understanding the effects of liver dysfunction on surgical outcomes has become increasingly important. The objective of this study was to assess the effects of chronic liver disease on 30-day complications following adult spinal deformity (ASD) surgery.
   METHODS: We performed a retrospective cohort study of 2337 patients in the 2008-2015 American College of Surgeons National Surgical Quality Improvement Program database who underwent corrective ASD surgery. Patients with liver disease were identified based on a Model for End-Stage Liver Disease-Na score >= 10. A univariate analysis was performed to compare 30-day postoperative complications between patients with and without liver disease. A multivariate regression analysis adjusting for differences in baseline patient characteristics was performed to identify complications that were associated with liver disease.
   RESULTS: Patients with liver disease had a significantly greater incidence of postoperative pulmonary complications (6.3% vs. 2.9%; P< 0.001), blood transfusion (34.6% vs. 24.0%; P < 0.001), sepsis (2.2% vs. 0.9%; P = 0.011), prolonged hospitalization (19.0% vs. 8.0%; P < 0.001), as well as any 30-day complication (45.4% vs. 29.4%; P < 0.001). The multivariate regression analysis identified liver disease as a risk factor for prolonged hospitalization (odds ratio [OR] 216; 95% confidence interval [CI] 1.64-2.84; P < 0.001), pulmonary complications (OR 1.78; 95% CI 1.16-2.74; P = 0.009), blood transfusion (OR 1.67; 95% CI 1.36-2.05; P < 0.001), and any 30-day complication (OR 1.43; 95% CI 1.15-137; P = 0.001).
   CONCLUSIONS: The multisystem pathophysiology of liver dysfunction predisposes patients to postoperative complications following ASD surgery. A multidisciplinary approach in surgical planning and preoperative optimization is needed to minimize liver disease-related complications and improve patient outcomes.
C1 [Lu, Charles] New York Inst Technol Coll Osteopath Med, Glen Head, NY USA.
   [White, Samuel J.; Ye, Ivan B.; Mikhail, Christopher M.; Cheung, Zoe B.; Cho, Samuel K.] Icahn Sch Med Mt Sinai, Dept Orthopaed Surg, New York, NY 10029 USA.
RP Cho, SK (reprint author), Icahn Sch Med Mt Sinai, Dept Orthopaed Surg, New York, NY 10029 USA.
EM samuel.cho@mountsinai.org
RI Cheung, Zoe/AAG-4511-2020
OI Cheung, Zoe/0000-0002-0189-5390
CR Bell BP, 2008, AM J GASTROENTEROL, V103, P2727, DOI 10.1111/j.1572-0241.2008.02071.x
   Best MJ, 2015, J ARTHROPLASTY, V30, P663, DOI 10.1016/j.arth.2014.11.013
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Causey MW, 2014, AM J SURG, V207, P520, DOI 10.1016/j.amjsurg.2013.06.008
   Corey KE, 2014, CLIN LIVER DIS, V18, P1, DOI 10.1016/j.cld.2013.09.019
   Cramer JD, 2017, LARYNGOSCOPE, V127, P102, DOI 10.1002/lary.26044
   Elnahas A, 2014, SURG ENDOSC, V28, P2708, DOI 10.1007/s00464-014-3532-8
   Farrell GC, 2006, HEPATOLOGY, V43, pS99, DOI 10.1002/hep.20973
   Findlay JY, 2011, LIVER TRANSPLANT, V17, P496, DOI 10.1002/lt.22269
   Friedman Lawrence S, 2010, Trans Am Clin Climatol Assoc, V121, P192
   Friedman LS, 1999, HEPATOLOGY, V29, P1617, DOI 10.1002/hep.510290639
   Funk GC, 2007, LIVER INT, V27, P901, DOI 10.1111/j.1478-3231.2007.01510.x
   Goel NJ, 2018, WORLD NEUROSURG, V115, pE85, DOI 10.1016/j.wneu.2018.03.183
   Hedrick TL, 2013, AM SURGEON, V79, P347
   Hsieh PH, 2003, J BONE JOINT SURG BR, V85B, P818, DOI 10.1302/0301-620X.85B6.14278
   Issa K, 2015, J BONE JOINT SURG AM, V97A, P1952, DOI 10.2106/JBJS.O.00183
   Khuri SF, 2008, ANN SURG, V248, P329, DOI 10.1097/SLA.0b013e3181823485
   Kim HJ, 2013, CLIN MOL HEPATOL, V19, P105, DOI 10.3350/cmh.2013.19.2.105
   KIM S, 1992, HEPATOLOGY, V15, P357, DOI 10.1002/hep.1840150231
   Kim Y, 2014, CANCER-AM CANCER SOC, V120, P3058, DOI 10.1002/cncr.28843
   Ko CY, 2015, JT COMM J QUAL PATIE, V41, P199, DOI 10.1016/S1553-7250(15)41026-8
   Koch DG, 2014, CLIN LIVER DIS, V18, P407, DOI 10.1016/j.cld.2014.01.003
   Krafcik BM, 2016, J VASC SURG, V64, P124, DOI 10.1016/j.jvs.2016.01.033
   Lange EO, 2015, DIS COLON RECTUM, V58, P494, DOI 10.1097/DCR.0000000000000358
   Liao JC, 2013, SPINE J, V13, P908, DOI 10.1016/j.spinee.2013.02.028
   Lin BC, 2012, INJURY, V43, P1457, DOI 10.1016/j.injury.2011.03.057
   Lisman T, 2010, J HEPATOL, V53, P362, DOI 10.1016/j.jhep.2010.01.042
   Mabee CL, 1998, J CLIN GASTROENTEROL, V26, P44, DOI 10.1097/00004836-199801000-00012
   Machicao VI, 2014, HEPATOLOGY, V59, P1627, DOI 10.1002/hep.26745
   Mahmoud AM, 2015, TEX HEART I J, V42, P414, DOI 10.14503/THIJ-14-4976
   Mannucci PM, 2013, BLOOD TRANSFUS-ITALY, V11, P32, DOI 10.2450/2012.0151-12
   Mansour J, 2012, ORTHOPEDICS, V35, P1053, DOI 10.3928/01477447-20121120-09
   Mucino-Bermejo J, 2013, ANN HEPATOL, V12, P713, DOI 10.1016/S1665-2681(19)31312-2
   Murata M, 2016, INT J CARDIOL, V203, P682, DOI 10.1016/j.ijcard.2015.10.181
   Northup PG, 2005, ANN SURG, V242, P244, DOI 10.1097/01.sla.0000171327.29262.e0
   Nyberg EM, 2016, J CLIN TRANSL HEPATO, V4, P83, DOI 10.14218/JCTH.2015.00049
   Peck-Radosavljevic M, 2017, LIVER INT, V37, P778, DOI 10.1111/liv.13317
   Petrucci N, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003844.pub4
   Porres-Aguilar M, 2013, REV GASTROENTEROL ME, V78, P35, DOI 10.1016/j.rgmx.2012.10.004
   Pour AE, 2011, J BONE JOINT SURG AM, V93A, P1448, DOI 10.2106/JBJS.J.00219
   Rai R, 2012, J CLIN EXP HEPATOL, V2, P238, DOI 10.1016/j.jceh.2012.05.003
   Ramalingam VS, 2016, CRIT CARE CLIN, V32, P357, DOI 10.1016/j.ccc.2016.03.002
   Roberts LN, 2010, BRIT J HAEMATOL, V148, P507, DOI 10.1111/j.1365-2141.2009.08021.x
   Rodriguez-Roisin R, 2004, EUR RESPIR J, V24, P861, DOI 10.1183/09031936.04.00010904
   Ross SW, 2016, SURGERY, V159, P777, DOI 10.1016/j.surg.2015.08.021
   Scaglione S, 2015, J CLIN GASTROENTEROL, V49, P690, DOI 10.1097/MCG.0000000000000208
   Sellers MM, 2013, J AM COLL SURGEONS, V216, P420, DOI 10.1016/j.jamcollsurg.2012.11.013
   Shih LY, 2004, J BONE JOINT SURG AM, V86A, P335, DOI 10.2106/00004623-200402000-00017
   Sureka B, 2015, GASTROENTEROL REP, V3, P194, DOI 10.1093/gastro/gov017
   Tiberi JV, 2014, CLIN ORTHOP RELAT R, V472, P2774, DOI 10.1007/s11999-014-3681-z
   Tossios P, 2013, INTERACT CARDIOV TH, V16, P338, DOI 10.1093/icvts/ivt024
   Tumgor G, 2014, WORLD J GASTROENTERO, V20, P2586, DOI 10.3748/wjg.v20.i10.2586
   Udompap P, 2015, CLIN GASTROENTEROL H, V13, P2031, DOI 10.1016/j.cgh.2015.08.015
   Umemura T, 2015, HEPATOL RES, V45, P739, DOI 10.1111/hepr.12412
   Viasus D, 2011, MEDICINE, V90, P110, DOI 10.1097/MD.0b013e318210504c
   Zielsdorf SM, 2015, AM SURGEON, V81, P755
   Ziser A, 1999, ANESTHESIOLOGY, V90, P42, DOI 10.1097/00000542-199901000-00008
NR 57
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E498
EP E504
DI 10.1016/j.wneu.2019.06.137
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200062
PM 31254688
DA 2020-05-12
ER

PT J
AU Malik, AT
   Yu, E
   Kim, J
   Khan, SN
AF Malik, Azeem Tariq
   Yu, Elizabeth
   Kim, Jeffery
   Khan, Safdar N.
TI Understanding Costs in a 90-Day Episode of Care Following Posterior
   Spinal Fusions for Adolescent Idiopathic Scoliosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adolescent idiopathic scoliosis; Bundled payment; Costs; Pediatric;
   Posterior spinal fusion
ID EARLY DISCHARGE; PAYMENT; CHARGES
AB OBJECTIVE: To understand cost distribution in a 90-day episode of care following posterior spinal fusions (PSFs) for adolescent idiopathic scoliosis (AIS).
   METHODS: The 2007-2016 Humana PearlDiver dataset was queried using Current Procedural Terminology codes (22800, 22802, 22804, 22842, 22843, and 22844) to identify patients with AIS, aged 10-19 years, receiving PSFs. The following categories were used to define distribution in 90-day costs: 1) facility costs, 2) surgeon costs, 3) anesthesia costs, 4) intraoperative neuromonitoring, 5) hospital services and investigations, 6) intensive care unit stay, 7) radiology, 8) physical therapy/rehabilitation, 9) office visits, and 10) readmissions.
   RESULTS: A total of 455 patients with AIS received PSFs, of whom 381 (83.7%) were commercial insurance beneficiaries and 74 (16.3%) were Medicaid beneficiaries. The overall average 90-day cost of surgery was $124,360 with the 90-day stipulated bundled prices being $136,302 and $62,871 for commercial and Medicaid beneficiaries, respectively. Facility costs comprised 85% - 92% of the 90-day cost, followed by surgeon costs (5.2% - 5.7%). Post-acute care (physical therapy/rehab and office visits) was not a major driver of the 90-day cost (0.2% - 0.3%). Significant independent predictors of increased 90-day costs were-increased co-morbidity burden (+$11,284), >= 7 levels fusion (+$65,330), and length of stay (+$5298/day). Medicaid (-$81,957) payer type was associated with lower 90-day costs.
   CONCLUSIONS: Facility costs are a major determinant of overall 90-day costs following PSFs in AIS. Providers should aim at optimizing the co-morbidity burden and constructing accelerated care-pathways to decrease the length of stay and reduce the cost of the entire episode of care.
C1 [Malik, Azeem Tariq; Yu, Elizabeth; Kim, Jeffery; Khan, Safdar N.] Ohio State Univ, Wexner Med Ctr, Dept Orthopaed, Columbia, OH 43210 USA.
RP Khan, SN (reprint author), Ohio State Univ, Wexner Med Ctr, Dept Orthopaed, Columbia, OH 43210 USA.
EM Safdar.Khan@osumc.edu
CR Berry JG, 2017, PEDIATRICS, P140
   Cairns MA, 2018, J BONE JOINT SURG AM, V100, P269, DOI 10.2106/JBJS.17.00327
   Daffner SD, 2010, SPINE, V35, P1165, DOI 10.1097/BRS.0b013e3181d88e78
   de Brantes F, 2009, NEW ENGL J MED, V361, P1033, DOI 10.1056/NEJMp0906121
   Fletcher ND, 2017, J PEDIATR ORTHOPED, V37, P92, DOI 10.1097/BPO.0000000000000601
   Fletcher ND, 2014, J CHILD ORTHOP, V8, P257, DOI 10.1007/s11832-014-0587-y
   Friedberg Mark W, 2015, Rand Health Q, V5, P8
   Godfrey JM, 2019, J PEDIATR ORTHOPED, V39, pE216, DOI 10.1097/BPO.0000000000001286
   Gray Chancellor F, 2018, Arthroplast Today, V4, P221, DOI 10.1016/j.artd.2018.02.002
   Greene Jan, 2017, Manag Care, V26, P22
   Jain N, 2018, CLIN SPINE SURG, V31, pE197, DOI 10.1097/BSD.0000000000000612
   Jain N, 2018, SPINE, V43, P193, DOI 10.1097/BRS.0000000000002283
   Kapoor Deepak A, 2017, Rev Urol, V19, P198, DOI 10.3909/riu193NewsinUro
   Keren R, 2012, ARCH PEDIAT ADOL MED, V166, P1155, DOI 10.1001/archpediatrics.2012.1266
   Malik AT, 2019, SPINE, V44, P558, DOI 10.1097/BRS.0000000000002886
   Martin AB, 2016, HEALTH AFFAIR, V35, P150, DOI 10.1377/hlthaff.2015.1194
   Martin BI, 2018, SPINE, V43, P705, DOI 10.1097/BRS.0000000000002404
   Martin CT, 2014, SPINE, V39, P1676, DOI 10.1097/BRS.0000000000000501
   Nussbaum S, 2018, JAMA-J AM MED ASSOC, V319, P653, DOI 10.1001/jama.2017.20226
   Obremskey WT, 2012, CLIN ORTHOP RELAT R, V470, P1054, DOI 10.1007/s11999-011-2147-9
   Patel K, 2016, CLIN GASTROENTEROL H, V14, P497, DOI 10.1016/j.cgh.2015.06.025
   Sanders AE, 2017, SPINE, V42, P92, DOI 10.1097/BRS.0000000000001666
   Shaughnessy Erin E, 2017, Pediatr Qual Saf, V2, pe028, DOI 10.1097/pq9.0000000000000028
   Sullivan R, 2017, CURR REV MUSCULOSKE, V10, P218, DOI 10.1007/s12178-017-9405-8
   Workman JK, 2018, J PEDIATR-US, V195, P213, DOI 10.1016/j.jpeds.2017.12.031
NR 25
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E535
EP E541
DI 10.1016/j.wneu.2019.06.149
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200066
PM 31279112
DA 2020-05-12
ER

PT J
AU Marengo, N
   Matsukawa, K
   Monticelli, M
   Ajello, M
   Pacca, P
   Cofano, F
   Penner, F
   Zenga, F
   Ducati, A
   Garbossa, D
AF Marengo, Nicola
   Matsukawa, Keitaro
   Monticelli, Matteo
   Ajello, Marco
   Pacca, Paolo
   Cofano, Fabio
   Penner, Federica
   Zenga, Francesco
   Ducati, Alessandro
   Garbossa, Diego
TI Cortical Bone Trajectory Screw Placement Accuracy with a Patient-Matched
   3-Dimensional Printed Guide in Lumbar Spinal Surgery: A Clinical Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D patient-matched guides; CBT screws; Lumbar spinal surgery; Minimally
   invasive spinal surgery; Navigation system; Screws placement accuracy
ID PEDICLE SCREWS; BIOMECHANICAL EVALUATION; FIXATION STRENGTH; TEMPLATE
AB BACKGROUND: Cortical bone trajectory (CBT) screw is an attractive technique in terms of fixation strength and less invasiveness. However, the insertion of a pedicle screw penetrating cortical bone on the ideal trajectory is technically demanding. The use of 3-dimensional (3D) patient-matched guides may facilitate the use of this technique. In this technical note and case series, the use of a patient-matched 3D targeting guide for a circumferential fixation with CBT screws is described.
   METHODS: Eleven patients with a mean age of 49 years were treated. The MySpine MC (Medacta International SA, Castel San Pietro, Switzerland) technology was used to place CBT screws. A computed tomography (CT) scan- derived 3D model of the patient vertebra was created after the surgeons planned the best custom CBT screw trajectory. Then, scaffolds were printed and used during surgery to guide the screw through the patient pedicle. An intersomatic arthrodesis was also performed.
   RESULTS: The images of the planned trajectory were superimposed on the postoperative CT scan, confirming the accuracy of the trajectory. The mean deviation from the planned pedicle midpoint was 0.91 mm; 85.2% of the screws were placed within 2 degrees from the planned trajectory. There were 2 grade A (<2 mm) and no grade B or C perforations. The actual entry point was always within 2 mm from the planned entry point.
   CONCLUSIONS: This technical note and case series is the first clinical description on the use of a patient-matched guide for posterior CBT screw placement. The use of these devices could also improve placement accuracy and decrease the risk of nerve damage.
C1 [Marengo, Nicola; Monticelli, Matteo; Ajello, Marco; Pacca, Paolo; Cofano, Fabio; Penner, Federica; Zenga, Francesco; Ducati, Alessandro; Garbossa, Diego] AOU Citta Salute & Sci, Neurosurg Div, Dept Neurosci, Turin, Italy.
   [Matsukawa, Keitaro] Natl Def Med Coll, Dept Orthopaed Surg, Tokorozawa, Saitama, Japan.
RP Monticelli, M (reprint author), AOU Citta Salute & Sci, Neurosurg Div, Dept Neurosci, Turin, Italy.
EM mmonticelli89@gmail.com
RI Garbossa, Diego/AAC-8888-2019; Ajello, Marco/AAC-9910-2019
OI Monticelli, Matteo/0000-0002-3738-5106; Penner,
   Federica/0000-0002-4491-1725
CR Ahn Y, 2013, SPINE, V38, P617, DOI 10.1097/BRS.0b013e318275ca58
   Aichmair A, 2017, EUR SPINE J, V26, P2865, DOI 10.1007/s00586-017-5025-7
   Al-Khouja Lutfi, 2015, Surg Neurol Int, V6, pS323, DOI 10.4103/2152-7806.159381
   Aoude AA, 2015, EUR SPINE J, V24, P990, DOI 10.1007/s00586-015-3853-x
   Baluch DA, 2014, SPINE, V39, pE1297, DOI 10.1097/BRS.0000000000000553
   Calvert GC, 2015, J NEUROSURG-SPINE, V22, P166, DOI 10.3171/2014.10.SPINE14371
   Cofano F, 2019, NEUROSURG REV, V42, P297, DOI 10.1007/s10143-017-0939-4
   Costa F, 2014, SPINE J, V14, P1790, DOI 10.1016/j.spinee.2013.10.019
   Dea N, 2016, SPINE J, V16, P23, DOI 10.1016/j.spinee.2015.09.062
   Farshad M, 2017, EUR SPINE J, V26, P738, DOI 10.1007/s00586-016-4728-5
   Gautschi OP, 2017, J NEUROSURG SCI, V61, P335, DOI 10.23736/S0390-5616.16.03230-6
   GERTZBEIN SD, 1990, SPINE, V15, P11, DOI 10.1097/00007632-199001000-00004
   Hartl R, 2013, WORLD NEUROSURG, V79, P162, DOI 10.1016/j.wneu.2012.03.011
   Hu Y, 2016, EUR SPINE J, V25, P1706, DOI 10.1007/s00586-016-4540-2
   Kaito T, 2018, J ORTHOP SCI, V23, P865, DOI 10.1016/j.jos.2018.06.005
   Lamartina C, 2014, EUR SPINE J, V23, P2765, DOI 10.1007/s00586-014-3645-8
   Lamartina C, 2015, EUR SPINE J, V24, pS937, DOI 10.1007/s00586-015-4261-y
   Li Xin, 2014, Zhonghua Yi Xue Za Zhi, V94, P840
   Luther N, 2015, J SPINAL DISORD TECH, V28, pE298, DOI 10.1097/BSD.0b013e31828af33e
   Marengo N, 2018, BIOMED RES INT, V2018, P7
   Marengo N, 2018, EUR SPINE J, V27, P213, DOI 10.1007/s00586-018-5599-8
   Matsukawa K, 2017, CLIN SPINE SURG, V30, P301, DOI 10.1097/BSD.0000000000000258
   Matsukawa K, 2017, CLIN SPINE SURG, V30, pE497, DOI 10.1097/BSD.0000000000000130
   Matsukawa K, 2016, SPINE, V41, pE851, DOI 10.1097/BRS.0000000000001459
   Matsukawa K, 2016, ACTA NEUROCHIR, V158, P465, DOI 10.1007/s00701-016-2705-8
   Matsukawa K, 2015, J NEUROSURG-SPINE, V23, P471, DOI 10.3171/2015.1.SPINE141103
   Matsukawa K, 2014, J NEUROSURG-SPINE, V21, P203, DOI 10.3171/2014.3.SPINE13665
   Matsukawa K, 2014, SPINE, V39, pE240, DOI 10.1097/BRS.0000000000000116
   Matsukawa K, 2013, J SPINAL DISORD TECH, V26, pE248, DOI 10.1097/BSD.0b013e318288ac39
   Merc M, 2014, CHIN J TRAUMATOL, V17, P261, DOI 10.3760/cma.j.issn.1008-1275.2014.05.003
   Penner F, 2019, WORLD NEUROSURG, V126, pE1468, DOI 10.1016/j.wneu.2019.03.121
   Perez-Orribo L, 2013, SPINE, V38, P635, DOI 10.1097/BRS.0b013e318279a95e
   Putzier M, 2017, CLIN SPINE SURG, V30, pE430, DOI 10.1097/BSD.0000000000000220
   Radermacher K, 1998, CLIN ORTHOP RELAT R, P28
   Rao G, 2003, SPINE, V28, P2527, DOI 10.1097/01.BRS.0000092341.56793.F1
   Santoni BG, 2009, SPINE J, V9, P366, DOI 10.1016/j.spinee.2008.07.008
   Takemoto M, 2016, EUR SPINE J, V25, P1698, DOI 10.1007/s00586-015-3908-z
   Watkins Robert Green, 2010, Open Orthop J, V4, P228, DOI 10.2174/1874325001004010228
   Zhao X, 2016, BIOMED RES INT, V2016
NR 39
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E98
EP E104
DI 10.1016/j.wneu.2019.05.241
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200013
PM 31307931
OA Green Published
DA 2020-05-12
ER

PT J
AU Maslink, C
   Cheng, K
   Smith, TR
   Das, S
AF Maslink, Colin
   Cheng, Kathleen
   Smith, Timothy R.
   Das, Sunit
TI Advanced Age Is Not a Universal Predictor of Poorer Outcome in Patients
   Undergoing Neurosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Age; Morbidity; Mortality; Neurosurgery
ID NATIONWIDE INPATIENT SAMPLE; ANTERIOR CERVICAL DISKECTOMY;
   SUBDURAL-HEMATOMA; ELDERLY-PATIENTS; UNITED-STATES; PERIOPERATIVE
   COMPLICATIONS; FUNCTIONAL OUTCOMES; LUMBAR LAMINECTOMY; 30-DAY
   MORBIDITY; BRAIN-TUMORS
AB BACKGROUND: Advances in medical care and technology have dramatically improved outcomes in patients undergoing neurosurgical intervention; however, certain patient subgroups (e.g., older adults) may encounter greater rates of morbidity and mortality in the perioperative period. The objective of this study was to determine the effects of patient and hospital characteristics, including age, on in-hospital mortality, and complication rates of 3 routine neurosurgical operations: subdural hematoma evacuation, brain tumor resection, and degenerative spine procedures.
   METHODS: A retrospective multivariable analysis of the 2014 National Inpatient Sample was performed. The setting was a national sample of hospitalized inpatient stays occurring in 2014 in the United States. Patients (N = 48,963) included those undergoing subdural hematoma evacuation, brain tumor resection, or degenerative spine procedures, stratified according to age group (<65, 65-74, 75-84, 85+ years). Mortality and complication rate were measured.
   RESULTS: Age >= 85 years was found to increase the odds of mortality (odds ratio 11.32) and complications (odds ratio 2.64) in patients undergoing degenerative spine procedures, whereas age had no significant effect on mortality and complication rate in subdural hematoma evacuation and brain tumor resection. Multiple comorbidities and nonelective status were predictors of increased mortality and complication rate in all procedure groups.
   CONCLUSIONS: Overall, our data would suggest that increased age does not universally predict worse outcome and that, for many procedures, surgical decision-making in older patients should instead consider other pertinent factors, such as comorbidities and elective status.
C1 [Maslink, Colin; Cheng, Kathleen; Das, Sunit] Univ Toronto, Div Neurosurg, Toronto, ON, Canada.
   [Smith, Timothy R.] Harvard Med Sch, Dept Neurosurg, Computat Neurosci Outcomes Ctr, Boston, MA 02115 USA.
   [Das, Sunit] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.
RP Das, S (reprint author), Univ Toronto, Div Neurosurg, Toronto, ON, Canada.; Das, S (reprint author), St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.
EM sunit.das@utoronto.ca
RI Das, Sunit/J-3903-2015
OI Das, Sunit/0000-0002-2146-4168
CR Ambekar S, 2013, J NEURO-ONCOL, V114, P299, DOI 10.1007/s11060-013-1183-6
   Barker FG, 2004, CANCER-AM CANCER SOC, V100, P999, DOI 10.1002/cncr.20058
   Bohl DD, 2014, J BONE JOINT SURG AM, V96A, DOI 10.2106/JBJS.M.01490
   Chang SM, 2003, J NEUROSURG, V98, P1175, DOI 10.3171/jns.2003.98.6.1175
   Chibbaro S, 2011, NEUROSURG REV, V34, P229, DOI 10.1007/s10143-010-0301-6
   Curry WT, 2005, J NEUROSURG, V102, P977, DOI 10.3171/jns.2005.102.6.0977
   Di Capua J, 2017, GLOB SPINE J, V7, P425, DOI 10.1177/2192568217699383
   Grossman R, 2010, CLIN ENDOCRINOL, V73, P361, DOI 10.1111/j.1365-2265.2010.03813.x
   Iwamoto FM, 2009, CANCER-AM CANCER SOC, V115, P5534, DOI 10.1002/cncr.24612
   Kalanithi P, 2011, J NEUROSURG, V115, P1013, DOI 10.3171/2011.6.JNS101989
   Karhade AV, 2018, NEUROSURGERY, V83, P333, DOI 10.1093/neuros/nyx408
   Konglund A, 2013, ACTA NEUROL SCAND, V127, P161, DOI 10.1111/j.1600-0404.2012.01692.x
   Lee L, 2016, J NEUROSURG, V124, P546, DOI 10.3171/2014.12.JNS142053
   Leroy HA, 2015, J CLIN NEUROSCI, V22, P1895, DOI 10.1016/j.jocn.2015.03.064
   Li G, 2008, SPINE, V33, P1250, DOI 10.1097/BRS.0b013e3181714a44
   Liu CY, 2017, SPINE, V42, pE906, DOI 10.1097/BRS.0000000000001999
   Liu JF, 2015, J AM GERIATR SOC, V63, P1924, DOI 10.1111/jgs.13590
   Lo WL, 2013, FORMOS J SURG, V46, P10, DOI 10.1016/j.fjs.2012.10.005
   Lukasiewicz AM, 2016, J NEUROSURG, V124, P760, DOI 10.3171/2015.2.JNS142721
   Martin CT, 2014, J BONE JOINT SURG AM, V96A, P1288, DOI 10.2106/JBJS.M.00767
   McClelland S, 2017, J CLIN NEUROSCI, V39, P133, DOI 10.1016/j.jocn.2016.12.027
   Mulligan P, 2013, J NEUROSCI RURAL PRA, V4, P250, DOI 10.4103/0976-3147.118760
   Nagashima H, 2011, EUR SPINE J, V20, P240, DOI 10.1007/s00586-010-1672-7
   Nie H, 2013, J SPINAL DISORD TECH, V26, P74, DOI 10.1097/BSD.0b013e318236b92d
   Passias PG, 2017, SPINE J, V17, P1633, DOI 10.1016/j.spinee.2017.05.018
   Poon MTC, 2013, J NEURO-ONCOL, V114, P219, DOI 10.1007/s11060-013-1173-8
   Raj R, 2016, WORLD NEUROSURG, V88, P592, DOI 10.1016/j.wneu.2015.10.095
   Seicean A, 2013, CANCER-AM CANCER SOC, V119, P1058, DOI 10.1002/cncr.27851
   Shen Y, 2009, J NEUROSURG ANESTH, V21, P21, DOI 10.1097/ANA.0b013e31818b47e9
   Stark AM, 2005, NEUROSURG REV, V28, P115, DOI 10.1007/s10143-004-0364-3
   Stovell MG, 2014, BRIT J NEUROSURG, V28, P611, DOI 10.3109/02688697.2014.889809
   Tabuchi Sadaharu, 2014, J Clin Med Res, V6, P379, DOI 10.14740/jocmr1907w
   Taussky P, 2012, WORLD NEUROSURG, V78, P306, DOI 10.1016/j.wneu.2011.10.030
   United Nations Department of Economic and Social Affairs, 2015, ESAPWP2 UN DEP EC SO
   Wang MC, 2007, SPINE, V32, P342, DOI 10.1097/01.brs.0000254120.25411.ae
   Watt J, 2018, BMC MED, V16, DOI 10.1186/s12916-017-0986-2
   Zoia C, 2014, AUSTIN NEUROSURG OPE, V1, P12
   Zygourakis CC, 2017, NEUROSURGERY, V81, P331, DOI 10.1093/neuros/nyx047
NR 38
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E375
EP E382
DI 10.1016/j.wneu.2019.06.093
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200046
PM 31229751
DA 2020-05-12
ER

PT J
AU Matsumoto, A
   Kawai, N
   Yabuno, S
   Hirashita, K
   Yunoki, M
   Yoshino, K
AF Matsumoto, Atsushi
   Kawai, Nobuhiko
   Yabuno, Satoru
   Hirashita, Koji
   Yunoki, Masatoshi
   Yoshino, Kimihiro
TI Treatment Strategy for Progressive Cervical Internal Carotid Artery
   Stenosis Under Restriction of the Use of Antiplatelet Drugs
SO WORLD NEUROSURGERY
LA English
DT Article
DE Antiplatelet drugs; Emergency carotid artery stenting; Progressive
   cervical internal carotid artery stenosis; Staged angioplasty; Tissue
   plasminogen activator
ID CEREBRAL HYPERPERFUSION SYNDROME; ENDARTERECTOMY; ANGIOPLASTY
AB BACKGROUND: Acute ischemic stroke caused by cervical internal carotid artery stenosis (ICS) with altered consciousness and progressive paralysis leads to a poor neurologic prognosis. When such a patient is brought to the hospital in the hyperacute phase, intravenous tissue plasminogen activator is first administered. However, when an indwelling carotid artery stent is required after administration, physicians often hesitate to use antithrombotic drugs. In this report, we propose performing staged angioplasty (SAP) for such cases.
   METHODS: Four patients were retrospectively investigated. In all 4 patients, we immediately performed only percutaneous transluminal angioplasty (PTA) without antiplatelet drugs. If both cerebral perfusion on angiography and neurologic findings improved, no additional treatment was provided; otherwise, emergency carotid artery stenting (eCAS) was performed. In PTA-successful cases, eCAS or carotid endarterectomy (CEA) was performed with single or dual antiplatelet drugs at a later date.
   RESULTS: The success rate of PTA was 50% (2 of 4), and the overall treatment success rate was 100% (4 of 4). Three patients had favorable outcomes (modified Rankin Scale [mRS] score 0-2), but unfortunately, 1 patient had severe disability (mRS score >3) on discharge. The PTA-successful patients had no perioperative complications. On the other hand, 1 of the 2 patients who underwent eCAS experienced embolic complications, including distal embolization.
   CONCLUSIONS: In this investigation, both eCAS and SAP could be performed safety. However, performing SAP first without antiplatelet drugs to avoid hemorrhagic complications and cerebral hyperperfusion syndrome appears to have considerable validity.
C1 [Matsumoto, Atsushi; Kawai, Nobuhiko; Yabuno, Satoru; Hirashita, Koji; Yunoki, Masatoshi; Yoshino, Kimihiro] Kagawa Rosai Hosp, Dept Neurol Surg, Marugame, Kagawa, Japan.
RP Matsumoto, A (reprint author), Kagawa Rosai Hosp, Dept Neurol Surg, Marugame, Kagawa, Japan.
EM a_met@med.kagawa-u.ac.jp
CR Coutts SB, 2003, NEUROSURGERY, V53, P1053, DOI 10.1227/01.NEU.0000088738.80838.74
   Dalyai RT, 2013, WORLD NEUROSURG, V79, P143, DOI 10.1016/j.wneu.2012.08.017
   Fargen KM, 2013, WORLD NEUROSURG, V79, P66, DOI 10.1016/j.wneu.2012.10.040
   GERTLER JP, 1994, J VASC SURG, V19, P32, DOI 10.1016/S0741-5214(94)70118-0
   Golledge J, 1996, J VASC SURG, V24, P120, DOI 10.1016/S0741-5214(96)70152-0
   Grunwald IQ, 2009, NEURORADIOLOGY, V51, P169, DOI 10.1007/s00234-008-0483-6
   Hwang SB, 2013, J NEUROINTERV SURG, V5, P426, DOI 10.1136/neurintsurg-2012-010274
   Imai K, 2005, AM J NEURORADIOL, V26, P1249
   Inoue S, 2017, J NEUROENDOVASC THER, V11, P260
   Lieb M, 2012, CARDIOL REV, V20, P84, DOI 10.1097/CRD.0b013e318237eef8
   Mo DP, 2016, STROKE VASC NEUROL, V1, P147, DOI 10.1136/svn-2016-000024
   Ogasawara K, 2007, J NEUROSURG, V107, P1130, DOI 10.3171/JNS-07/12/1130
   Villwock Mark R, 2015, J Vasc Interv Neurol, V8, P11
   Xu GL, 2015, INTERV NEUROL, V4, P38, DOI 10.1159/000438777
   Yamaguchi S, 2014, J NEUROENDOVASC THER, V8, P231
   Yoshimura S, 2009, NEUROSURGERY, V64, pS122, DOI 10.1227/01.NEU.0000334046.41985.BB
   Zinkstok SM, 2012, LANCET, V380, P731, DOI 10.1016/S0140-6736(12)60949-0
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E438
EP E443
DI 10.1016/j.wneu.2019.06.111
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200054
PM 31247349
DA 2020-05-12
ER

PT J
AU Min, LZ
   Liu, MX
   Zhang, WB
   Tao, BB
   Sun, QY
   Li, ST
   Wang, XQ
AF Min, Lingzhao
   Liu, Mingxing
   Zhang, Wenbo
   Tao, Bangbao
   Sun, Qiuyang
   Li, Shiting
   Wang, Xiaoqiang
TI Outcomes and Safety of Overlapping Surgery in Patients Undergoing
   Microvascular Decompression for Hemifacial Spasm and Trigeminal
   Neuralgia
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hemifacial spasm; Microvascular decompression; Overlapping surgery;
   Trigeminal neuralgia
ID EXPERIENCE; OPERATIONS; SERIES; HEAD
AB OBJECTIVE: Overlapping surgery, performed by the same primary attending surgeon asynchronously, has gained significant attention from the government and media as potentially harmful to patients. Therefore, the goal of this study was to evaluate the outcomes and safety of overlapping versus nonoverlapping microvascular decompression (MVD) operations.
   METHODS: Patients who underwent MVD operations were retrospectively reviewed: 1153 with hemifacial spasm (HFS), 694 (60.2%) of whom underwent overlapping procedures, and 935 with trigeminal neuralgia (TN), 612 (65.5%) of whom underwent overlapping procedures. Collected variables included patient age, sex, side, disease duration, clinical characteristic, comorbidity, affected vessel, intraoperative neuroelectrophysiology, operation time under microscope, total surgical procedure times, mean length of stay (LOS), efficacy (at discharge, 6 months, 1 year), short-term complications, and long-term complications. chi(2) and t tests were performed to compare overlapping versus nonoverlapping cases, and then multivariate analysis were conducted to adjust for patient demographics, clinical characteristics, and comorbidity between the 2 groups.
   RESULTS: Patient variables (age, sex, side, disease duration, clinical characteristic, and comorbidity), affected vessel, and intraoperative neuroelectrophysiology were similar between the 2 groups. After adjustment for patient demographics, clinical characteristics, and comorbidity, overlapping surgeries had longer total surgical procedure times (HFS: standardized coefficient = 0.066, P < 0.05; TN: standardized coefficient = 0.086, P < 0.05). Overlapping surgery was not associated with a significant difference in operation time under microscope, mean LOS, efficacy (at discharge, 6 months, 1 year), short-term complications, and long-term complications.
   CONCLUSIONS: Overlapping MVD operations may be performed safely at our institution. Further prospective studies are needed to understand the association of overlapping surgery among MVD operations.
C1 [Min, Lingzhao; Liu, Mingxing; Zhang, Wenbo; Tao, Bangbao; Sun, Qiuyang; Li, Shiting; Wang, Xiaoqiang] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Neurosurg Dept, Shanghai, Peoples R China.
RP Wang, XQ (reprint author), Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Neurosurg Dept, Shanghai, Peoples R China.
EM wangxiaoqiang@xinhuamed.com.cn
FU Science and Technology Committee of Shanghai MunicipalScience &
   Technology Commission of Shanghai Municipality (STCSM) [13ZR1426800]
FX Supported by the Science and Technology Committee of Shanghai Municipal
   (13ZR1426800).
CR Abelson J., 2015, CLASH NAME CARE
   Aquina CT, 2016, SURGERY, V159, P736, DOI 10.1016/j.surg.2015.09.021
   Beasley GM, 2015, ANN SURG, V261, P1044, DOI 10.1097/SLA.0000000000001208
   Corbitt C, 2014, HEAD NECK-J SCI SPEC, V36, P1440, DOI 10.1002/hed.23471
   Guan J, 2017, J NEUROSURG, V127, P1096, DOI 10.3171/2016.8.JNS161226
   Howard BM, 2018, JAMA SURG, V153, P313, DOI 10.1001/jamasurg.2017.4502
   Kim HR, 2009, J KOREAN NEUROSURG S, V45, P336, DOI 10.3340/jkns.2009.45.6.336
   Kondo A, 2012, ACTA NEUROCHIR, V154, P773, DOI 10.1007/s00701-012-1277-5
   Lee MH, 2016, NEUROSURG REV, V39, P151, DOI 10.1007/s10143-015-0666-7
   Liu LX, 2018, WORLD NEUROSURG, V118, pE557, DOI 10.1016/j.wneu.2018.06.238
   Polo G, 2004, NEUROSURGERY, V54, P97, DOI 10.1227/01.NEU.0000097268.90620.07
   Rogers CL, 2000, INT J RADIAT ONCOL, V47, P1013, DOI 10.1016/S0360-3016(00)00513-7
   Sweeny L, 2017, OTOLARYNG HEAD NECK, V156, P627, DOI 10.1177/0194599817691746
   Vrabec JT, 2009, OTOLARYNG HEAD NECK, V140, P445, DOI 10.1016/j.otohns.2008.12.031
   Yeo HL, 2017, ANN SURG, V265, P151, DOI 10.1097/SLA.0000000000001672
   Zhang X, 2017, WORLD NEUROSURG, V101, P93, DOI 10.1016/j.wneu.2017.01.074
   Zygourakis CC, 2017, J NEUROSURG, V127, P1089, DOI 10.3171/2016.6.JNS16822
   Zygourakis CC, 2017, NEUROSURGERY, V80, P257, DOI 10.1093/neuros/nyw067
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E1084
EP E1090
DI 10.1016/j.wneu.2019.07.092
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200134
PM 31323398
DA 2020-05-12
ER

PT J
AU Motoyama, Y
   Takamura, Y
   Park, HS
   Miyasaka, T
   Wada, T
   Yamada, S
   Saito, K
   Nakagawa, I
   Park, YS
   Sugie, K
   Nakase, H
AF Motoyama, Yasushi
   Takamura, Yoshiaki
   Park, Hun Soo
   Miyasaka, Toshiteru
   Wada, Takeshi
   Yamada, Shuichi
   Saito, Kozue
   Nakagawa, Ichiro
   Park, Young-Su
   Sugie, Kazuma
   Nakase, Hiroyuki
TI Appropriate Flow Reduction for Unilateral Ruptured Vertebral Artery
   Dissection by Proximal Clipping to Prevent Rebleeding and Medullary
   Infarction
SO WORLD NEUROSURGERY
LA English
DT Article
DE Medullary infarction; Perforating artery; Proximal clipping; Ruptured
   vertebral artery dissection
ID ENDOVASCULAR TREATMENT; ANEURYSMS
AB BACKGROUND: Medullary infarction (MI) occasionally _urs after treatment of ruptured vertebral artery dissection (VAD). The aim of this study was to validate whether flow reduction for ruptured unilateral VAD by proximal clipping prevents rebleeding and MI in comparison with trapping.
   METHODS: Thirty-one patients who underwent direct surgery or endovascular procedures for unilateral ruptured VAD and postoperative magnetic resonance imaging (MRI), including 9 patients treated with trapping and 22 patients treated with proximal clipping, were enrolled. For posterior inferior cerebellar artery (PICA) -involved type VAD, occipital artery to PICA anastomosis was added as needed to isolate the rupture point. The rate of rebleeding and the occurrence of MI on MRI were compared between the 2 groups.
   RESULTS: There was no rebleeding after treatment in all 31 patients. However, 5 patients had MI on postoperative MRI (16.1%, kappa = 0.903). In 5 of the 9 patients treated with trapping, MI was seen on MRI after treatment (55.6%). On the other hand, 0 of the 22 patients treated with proximal clipping developed MI (P < 0.01).
   CONCLUSIONS: Appropriate flow reduction for ruptured unilateral VAD by proximal clipping is thought to be effective for preventing rebleeding and avoiding MI.
C1 [Motoyama, Yasushi; Takamura, Yoshiaki; Park, Hun Soo; Yamada, Shuichi; Nakagawa, Ichiro; Park, Young-Su; Nakase, Hiroyuki] Nara Med Univ, Dept Neurosurg, Kashihara, Nara, Japan.
   [Miyasaka, Toshiteru; Wada, Takeshi] Nara Med Univ, Dept Radiol, Kashihara, Nara, Japan.
   [Saito, Kozue; Sugie, Kazuma] Nara Med Univ, Dept Neurol, Kashihara, Nara, Japan.
   [Motoyama, Yasushi; Takamura, Yoshiaki; Park, Hun Soo; Wada, Takeshi; Yamada, Shuichi; Saito, Kozue; Nakagawa, Ichiro; Sugie, Kazuma; Nakase, Hiroyuki] Nara Med Univ, Stroke Ctr, Kashihara, Nara, Japan.
RP Motoyama, Y (reprint author), Nara Med Univ, Dept Neurosurg, Kashihara, Nara, Japan.; Motoyama, Y (reprint author), Nara Med Univ, Stroke Ctr, Kashihara, Nara, Japan.
EM myasushi@naramed-u.ac.jp
OI yamada, shuichi/0000-0002-7278-3978
CR Aihara M, 2018, J NEUROSURG, V129, P107, DOI 10.3171/2017.2.JNS162916
   Endo H, 2013, J NEUROSURG, V118, P131, DOI 10.3171/2012.9.JNS12566
   FRIEDMAN AH, 1984, J NEUROSURG, V60, P325, DOI 10.3171/jns.1984.60.2.0325
   Guan J, 2017, J NEUROINTERV SURG, V9, P558, DOI 10.1136/neurintsurg-2016-012309
   Iihara K, 2002, J NEUROSURG, V97, P259, DOI 10.3171/jns.2002.97.2.0259
   Ikeda H, 2016, INTERV NEURORADIOL, V22, P67, DOI 10.1177/1591019915609127
   Jin SC, 2009, AM J NEURORADIOL, V30, P1518, DOI 10.3174/ajnr.A1621
   Kanematsu Y, 2018, NEUROL MED-CHIR, V58, P341, DOI 10.2176/nmc.oa.2018-0076
   Kim BM, 2011, STROKE, V42, P2425, DOI 10.1161/STROKEAHA.111.617381
   KITANAKA C, 1992, J NEUROSURG, V77, P466, DOI 10.3171/jns.1992.77.3.0466
   Marinkovic S, 2004, SURG NEUROL, V61, P190, DOI 10.1016/S0090-3019(03)00577-9
   Mercier P, 2008, INTERV NEURORADIOL, V14, P49, DOI 10.1177/159101990801400107
   Tsuruta W, 2018, OPER NEUROSURG, V15, P701, DOI 10.1093/ons/opy026
   Yasui T, 2000, NEUROL SURG TOKYO, V28, P345
NR 14
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E627
EP E633
DI 10.1016/j.wneu.2019.06.174
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200079
PM 31265925
DA 2020-05-12
ER

PT J
AU Mouchtouris, N
   Turpin, J
   Chalouhi, N
   Al Saiegh, F
   Theofanis, T
   Das, S
   Shah, SO
   Jallo, J
AF Mouchtouris, Nikolaos
   Turpin, Justin
   Chalouhi, Nohra
   Al Saiegh, Fadi
   Theofanis, Thana
   Das, Somnath
   Shah, Syed Omar
   Jallo, Jack
TI Statewide Trends in Intracranial Pressure Monitor Use in 36,915 Patients
   with Severe Traumatic Brain Injury in a Mature Trauma System over the
   Past 18 Years
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intracranial pressure monitoring; Neurocritical care; Trauma; Traumatic
   brain injury
ID MANAGEMENT; GUIDELINES; OUTCOMES; IMPACT; CARE
AB OBJECTIVE: Intracranial pressure (ICP)-guided therapy has been the mainstay of treatment of patients with severe traumatic brain injury (TBI), but recent data have questioned its efficacy. The aim of this study was to demonstrate trends in compliance to TBI guidelines and use of ICP-guided care in a mature trauma system.
   METHODS: A retrospective analysis was conducted of 36,915 patients with severe TBI collected by the Pennsylvania Trauma Systems Foundation. The registry includes all patients >18 years old with a diagnosis of TBI with a Glasgow Coma Scale score <= 8 who were admitted from January 2000 to December 2017.
   RESULTS: Of 36,915 patients, 73.6% were men with a median age of 43.0 +/- 21.3 years. An ICP monitor was placed in 16.3% of all patients. The rate of ICP monitoring ranged from 17.8% of patients in 2000-2004 to 16.7% in 2005-2009, 16.4% in 2010-2014, and 12.8% in 2015-2017 (P< 0.001). The most statistically significant decrease was noted from 2014 (16.4%) to 2015 (14.1%, P = 0.042). The percent decrease in ICP monitoring from 2000-2014 to 2015-2017 was equivalent for patients with Glasgow Coma Scale scores of 3-5 ( - 4.0%) and 6-8 ( - 4.5%).
   CONCLUSIONS: As studies emerged that demonstrated unclear benefit of ICP monitoring in improving care in patients with severe TBI, there was a significant statewide decline in the use of ICP monitoring after 2014 among all TBI subpopulations despite noteworthy limitations in the aforementioned studies and clear recommendations recommendations from the Brain Trauma Foundation guidelines.
C1 [Jallo, Jack] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA.
   Jefferson Hosp Neurosci, Philadelphia, PA USA.
RP Jallo, J (reprint author), Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA.
EM Jack.Jallo@jefferson.edu
RI ; Shah, Syed/E-4083-2013
OI Mouchtouris, Nikolaos/0000-0001-9495-9391; Jallo,
   Jack/0000-0002-5512-1729; Shah, Syed/0000-0003-4760-5229
CR Agrawal D, 2016, J NEUROTRAUM, V33, P853, DOI 10.1089/neu.2015.4015
   Alali AS, 2013, J NEUROTRAUM, V30, P1737, DOI 10.1089/neu.2012.2802
   Alice P, 2017, INJURY, V48, P1944, DOI 10.1016/j.injury.2017.04.033
   Biersteker HAR, 2012, CRIT CARE MED, V40, P1914, DOI 10.1097/CCM.0b013e3182474bde
   Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998
   Bullock MR, 1996, J NEUROTRAUM, V13, P643
   Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432
   Centers for Disease Control and Prevention, 2014, TRAUM BRAIN INJ US F
   Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363
   Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5
   Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816
   Faul M. M., 2010, TRAUMATIC BRAIN INJU
   Gerber LM, 2013, J NEUROSURG, V119, P1583, DOI 10.3171/2013.8.JNS13276
   GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023
   Hyder AA, 2007, NEUROREHABILITATION, V22, P341
   Khormi YH, 2018, J NEUROTRAUM, V35, P1407, DOI 10.1089/neu.2017.5345
   LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1
   Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7
   MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503
   Sahjpaul R, 2000, CAN J NEUROL SCI, V27, P143
   Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2
   Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017
   Suehiro E, 2017, J NEUROTRAUM, V34, P2230, DOI 10.1089/neu.2016.4948
   Suehiro E, 2011, WORLD NEUROSURG, V75, P563, DOI 10.1016/j.wneu.2010.09.013
   Talving P, 2013, J NEUROSURG, V119, P1248, DOI 10.3171/2013.7.JNS122255
NR 25
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E166
EP E171
DI 10.1016/j.wneu.2019.06.025
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200022
PM 31203067
DA 2020-05-12
ER

PT J
AU Mushlin, H
   Kole, MJ
   Chryssikos, T
   Cannarsa, G
   Schwartzbauer, G
   Aarabi, B
AF Mushlin, Harry
   Kole, Matthew J.
   Chryssikos, Timothy
   Cannarsa, Gregory
   Schwartzbauer, Gary
   Aarabi, Bizhan
TI AOSpine Subaxial Cervical Spine Injury Classification System: The
   Relationship Between Injury Morphology, Admission Injury Severity, and
   Long-Term Neurologic Outcome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angioplasty; Aortic arch reconstruction; Stroke
ID DISLOCATIONS; FRACTURES
AB OBJECTIVE: The AOSpine Subaxial Cervical Spine Injury Classification System was introduced to improve communication, clinical management, and research. Here, the system was studied in relation to injury severity along with admission and long term neurologic follow-up.
   METHODS: A retrospective study was performed in subaxial cervical spine injury patients. Morphology was classified using the AOSpine Subaxial Cervical Spine Injury Classification System. Six major morphology subtypes were selected for analysis. The American Spinal Injury Association (ASIA) motor and Abbreviated Injury Severity (AIS) scores were recorded at admission and at follow-up >6 months. Admission intramedullary lesion length (IMLL) on MRI was recorded.
   RESULTS: In all, 82 patients met criteria for analysis. The mean follow-up time was 11 months (range, 6-33 months). The were 36 patients with morphology subtypes A0, 4 with A1/A2, 9 with A3/A4, 8 with B2, 11 with B3, and 14 with C. The A1/2 subtype had the least severe injuries on admission. The C and A3/A4 subtypes had the most severe injuries. The subtype C had the lowest ASIA Motor Score (AMS) and second highest percentage of complete injuries. A3/A4 patients had the highest percentage of complete injuries on admission. At follow-up, A3/A4 patients had the lowest AMS, and 33% of patients continued to have complete injuries. C subtype injuries all converted to AIS incomplete injuries on follow-up (P = 0.04). IMLL was found to be significantly different compared across multiple morphologic subtypes. Surgical management for each morphology subtype was reported.
   CONCLUSION: The AOSpine Subaxial Cervical Spine Injury Classification System successfully associated injury morphology with IMLL along with admission and long-term neurologic function and recovery.
C1 [Mushlin, Harry; Kole, Matthew J.; Chryssikos, Timothy; Cannarsa, Gregory; Schwartzbauer, Gary; Aarabi, Bizhan] Univ Maryland, Med Ctr, Dept Neurosurg, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA.
   [Schwartzbauer, Gary; Aarabi, Bizhan] Univ Maryland, Med Ctr, Dept Trauma Crit Care, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA.
RP Mushlin, H (reprint author), Univ Maryland, Med Ctr, Dept Neurosurg, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA.
EM hmushlin@som.umaryland.edu
CR Aarabi B, 2017, J ORTHOP TRAUMA, V31, pS24, DOI 10.1097/BOT.0000000000000944
   Aarabi B, 2017, NEUROSURGERY, V80, P610, DOI 10.1093/neuros/nyw053
   Aarabi B, 2013, NEUROSURGERY, V72, P170, DOI 10.1227/NEU.0b013e31828341c5
   ALLEN BL, 1982, SPINE, V7, P1, DOI 10.1097/00007632-198200710-00001
   HARRIS JH, 1986, ORTHOP CLIN N AM, V17, P15
   HOLDSWORTH F, 1970, J BONE JOINT SURG AM, VA 52, P1534, DOI 10.2106/00004623-197052080-00002
   Le E, 2015, J NEUROSURG-SPINE, V22, P611, DOI 10.3171/2014.10.SPINE14576
   NICOLL EA, 1949, J BONE JOINT SURG BR, V31, P376
   Stevenson CM, 2016, SPINAL CORD, V54, P1010, DOI 10.1038/sc.2016.34
   Vaccaro AR, 2007, SPINE, V32, P2365, DOI 10.1097/BRS.0b013e3181557b92
   Vaccaro AR, 2016, EUR SPINE J, V25, P2173, DOI 10.1007/s00586-015-3831-3
NR 11
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E368
EP E374
DI 10.1016/j.wneu.2019.06.092
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200045
PM 31229750
DA 2020-05-12
ER

PT J
AU Nam, KH
   Song, Y
   Kim, DH
   Choi, HJ
   Lee, IS
   Lee, JI
   Choi, BK
   Han, IH
AF Nam, Kyoung Hyup
   Song, Youseon
   Kim, Dong Hwan
   Choi, Hyuk Jin
   Lee, In Sook
   Lee, Jae Il
   Choi, Byung Kwan
   Han, In Ho
TI Symptomatic Pneumocephalus After Spinal Intradural-Extramedullary Tumor
   Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Headache; Pneumocephalus; Spinal IDEM tumor
ID TENSION PNEUMOCEPHALUS; DIFFUSE PNEUMOCEPHALUS; RARE COMPLICATION;
   POSITION
AB OBJECTIVE: Durotomy is a necessary procedure for resection of spinal intradural-extramedullary (IDEM) tumor. The purpose of this study was to investigate the prevalence and clinical implications of pneumocephalus after spinal IDEM tumor surgery and also the association between pneumocephalus and postoperative headache.
   METHODS: This prospective study was conducted in a cohort of 20 patients who were diagnosed with a spinal IDEM tumor and underwent surgical resection. The mean patient age was 53.6 years (range, 29-75 years). Histological findings revealed schwannoma in 16 cases (80.0%) and meningioma in 4 cases (20.0%). Brain computed tomography scan was performed immediately after surgery. The prevalence and severity were analyzed based on the classification into 4 groups according to the extension of pneumocephalus: absence, mild, moderate, and severe. A visual analog scale (VAS; range 0-10) for headache was reported daily for the first postoperative week. Headache-related pneumocephalus was defined as a VAS score of >= 5 points at least once in that 1-week period.
   RESULTS: The prevalence of pneumocephalus was 90.0% (18 patients). Five patients (25.0%) had severe pneumocephalus extending to the extra-axial space. Seven of the 20 patients (38.9%) complained of significant headache. Five of these patients had severe pneumocephalus, 1 patient had moderate pneumocephalus, and 1 patient had moderate pneumocephalus. A statistically significant association was observed between the severity of pneumocephalus and headache (P = 0.001).
   CONCLUSIONS: Pneumocephalus is a common complication after spinal IDEM tumor surgery. This report is the first study to investigate the prevalence of pneumocephalus and analyze its association with headache after spine surgery. The severity of pneumocephalus was significantly related to postoperative headache.
C1 [Nam, Kyoung Hyup; Kim, Dong Hwan; Choi, Hyuk Jin; Lee, Jae Il; Choi, Byung Kwan; Han, In Ho] Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Dept Neurosurg,Biomed Res Inst, Busan, South Korea.
   [Song, Youseon; Lee, In Sook] Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Dept Radiol,Biomed Res Inst, Busan, South Korea.
RP Han, IH (reprint author), Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Dept Neurosurg,Biomed Res Inst, Busan, South Korea.
EM farlateral@hanmail.net
FU Biomedical Research Institute Grant [2016-13]
FX This study was supported by a Biomedical Research Institute Grant
   (2016-13) to Pusan National University Hospital.
CR ARBIT E, 1991, J NEUROSURG, V74, P139, DOI 10.3171/jns.1991.74.1.0139
   Ayberk G, 2010, J CLIN NEUROSCI, V17, P934, DOI 10.1016/j.jocn.2009.10.033
   DelGaudio JM, 2010, AM J OTOLARYNG, V31, P226, DOI 10.1016/j.amjoto.2009.02.012
   Dhamija B, 2011, J ROY SOC MED, V104, P81, DOI 10.1258/jrsm.2010.100311
   Gauthe R, 2016, ORTHOP TRAUMATOL-SUR, V102, P251, DOI 10.1016/j.otsr.2015.12.006
   Karavelioglu E, 2014, NEUROL MED-CHIR, V54, P405, DOI 10.2176/nmc.cr2013-0118
   Lam KK, 2014, CAN J ANESTH, V61, P969, DOI 10.1007/s12630-014-0214-x
   LUNSFORD LD, 1979, J NEUROSURG, V50, P525, DOI 10.3171/jns.1979.50.4.0525
   Markham J W, 1967, Acta Neurochir (Wien), V16, P1
   McMurtrie R, 2002, J CLIN ANESTH, V14, P539, DOI 10.1016/S0952-8180(02)00426-9
   Nowak R, 2011, J PEDIATR ORTHOP B, V20, P41, DOI 10.1097/BPB.0b013e32833f33d1
   OSBORN AG, 1978, J NEUROSURG, V48, P355, DOI 10.3171/jns.1978.48.3.0355
   Ozturk E, 2006, ACTA RADIOL, V47, P497, DOI 10.1080/02841850600644766
   Pirris SM, 2013, CASE REP NEUROL MED, DOI 10.1155/2013/792168
   Schirmer CM, 2010, NEUROCRIT CARE, V13, P152, DOI 10.1007/s12028-010-9363-0
   Sprague A, 1999, J CLIN NEUROSCI, V6, P418, DOI 10.1016/S0967-5868(99)90040-1
   STANDEFER M, 1984, NEUROSURGERY, V14, P649, DOI 10.1227/00006123-198406000-00001
   TOUNG TJK, 1986, ANESTH ANALG, V65, P65
   Turgut M, 2007, J CLIN NEUROSCI, V14, P666, DOI 10.1016/j.jocn.2006.02.021
   Uemura K, 1997, BRIT J NEUROSURG, V11, P253, DOI 10.1080/02688699746366
   Yun JH, 2010, J KOREAN NEUROSURG S, V48, P288, DOI 10.3340/jkns.2010.48.3.288
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E344
EP E349
DI 10.1016/j.wneu.2019.06.085
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200041
PM 31229753
DA 2020-05-12
ER

PT J
AU Natarajan, SK
   Zeeshan, Q
   Ghodke, BV
   Sekhar, LN
AF Natarajan, Sabareesh K.
   Zeeshan, Qazi
   Ghodke, Basavaraj V.
   Sekhar, Laligam N.
TI Brain Bypass Surgery for Complex Middle Cerebral Artery Aneurysms:
   Evolving Techniques, Results, and Lessons Learned
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral revascularization; Endovascular management; Graft occlusion;
   High flow bypass; Middle cerebral artery aneurysms; Radial artery graft;
   Saphenous vein graft
ID SUPERFICIAL TEMPORAL ARTERY; BIFURCATION ANEURYSMS; MANAGEMENT; OUTCOMES
AB OBJECTIVE: To analyze a consecutive series of patients with middle cerebral artery (MCA) aneurysms who needed an adjunctive cerebral revascularization procedure to achieve aneurysm occlusion with preservation of flow through all MCA branches.
   METHODS: A total of 42 patients with 43 MCA aneurysms underwent 52 bypass procedures over 13 years. The location of the aneurysm were M1 trunk, M1 bifurcation, M2 and beyond. The bypasses performed included intracranial bypasses (resection with end to end anastomosis, end to side implantation, side to side anastomosis, and short interposition graft), extraintracranial bypasses (superficial temporal to middle cerebral artery anastomosis, and radial artery bypass graft, or saphenous vein graft), double bypasses, Y-grafts, and combined techniques.
   RESULTS: Forty-two of 43 aneurysms (98%) had patent bypasses at long-term follow-up. All 43 aneurysms were completely occluded at last follow-up. Six patients (14%) developed strokes related to the surgical treatment. At last follow-up, 36 patients had a modified Rankin score of 0-2, 5 patients had modified Rankin score 3-5, and 1 died. In this series, 31 (73.8%) patients improved, 8 (19%) patients had same functional status, and 3 (7.2%) patients deteriorated, including 1 patient who expired due to sepsis. The mean clinical follow-up duration was 39.3 months (0.4-124 months) and the mean radiological follow-up was 37 months (0.4-134 months).
   CONCLUSIONS: Cerebral revascularization is an important adjunct for treating MCA aneurysms and can be done safely. The article provides the insights we gained by rising through the learning curve.
C1 [Natarajan, Sabareesh K.] Univ Massachusetts, Dept Neurosurg, Sch Med, Amherst, MA 01003 USA.
   [Zeeshan, Qazi; Sekhar, Laligam N.] Univ Washington, Dept Neurosurg, Seattle, WA 98195 USA.
   [Ghodke, Basavaraj V.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA.
RP Sekhar, LN (reprint author), Univ Washington, Dept Neurosurg, Seattle, WA 98195 USA.
EM lsekhar@uw.edu
CR Alaraj A, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/2/E7
   Cay F, 2018, INTERV NEURORADIOL, V24, P263, DOI 10.1177/1591019917753710
   Gory B, 2014, AM J NEURORADIOL, V35, P715, DOI 10.3174/ajnr.A3781
   Iosif C, 2017, AM J NEURORADIOL, V38, P310, DOI 10.3174/ajnr.A5022
   Kim FY, 2013, CARDIOL REV, V21, P101, DOI 10.1097/CRD.0b013e3182736190
   Kivipelto L, 2014, J NEUROSURG, V120, P398, DOI 10.3171/2013.10.JNS13738
   Machi P, 2013, EUR J RADIOL, V82, P1646, DOI 10.1016/j.ejrad.2013.01.034
   Martinez-Galdamez M, 2017, J NEUROINTERV SURG, V9, P772, DOI 10.1136/neurintsurg-2016-012896
   Matano F, 2013, CLIN NEUROL NEUROSUR, V115, P718, DOI 10.1016/j.clineuro.2012.08.007
   Meybodi AT, 2017, J NEUROSURG, V127, P463, DOI 10.3171/2016.7.JNS16772
   Meybodi AT, 2016, WORLD NEUROSURG, V93, P67, DOI 10.1016/j.wneu.2016.05.050
   Pierot L, 2016, J NEURORADIOLOGY, V43, P167, DOI 10.1016/j.neurad.2016.02.001
   Pierot L, 2016, J NEUROSURG, V124, P1250, DOI 10.3171/2015.2.JNS142634
   Ramanathan D, 2013, WORLD NEUROSURG, V80, P322, DOI 10.1016/j.wneu.2012.01.035
   Safavi-Abbasi S, 2017, J NEUROSURG, V127, P1353, DOI 10.3171/2016.9.JNS161165
   Sekhar LN, 2008, NEUROSURGERY, V62, P1373, DOI [10.1227/01.NEU.0000315873.41953.74, 10.1227/01.neu.0000333803.97703.c6]
   Sekhar LN, 2008, NEUROSURGERY, V62, P1440
   van Doormaal TPC, 2008, NEUROSURGERY, V63, P12, DOI 10.1227/01.NEU.0000335066.45566.D1
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E272
EP E293
DI 10.1016/j.wneu.2019.06.059
PG 22
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200034
PM 31207370
DA 2020-05-12
ER

PT J
AU Niu, ZF
   Xia, HC
   Zhao, ZJ
   Xu, HY
   Fei, Z
AF Niu Zhanfeng
   Xia Hechun
   Zhao Zhijun
   Xu Hongyu
   Fei Zhou
TI Regulation of Circadian Clock Genes on Sleep Disorders in Traumatic
   Brain Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Circadian rhythm; Sleep disorder; TBI
ID INJURY; MELATONIN; CONSEQUENCES; DISTURBANCE; PREVALENCE; EXPRESSION;
   RHYTHMS; CORTISOL; HEALTH
AB BACKGROUND: In patients with traumatic brain injury (TBI), whether sleep disorder is associated with disturbances in molecular rhythmicity is unclear. This study aimed to investigate the relationship between abnormal sleep and regulation by circadian rhythms in patients with TBI.
   METHODS: We sampled buccal cells and human blood samples from patients with TBI diagnosed with sleep disorders and those with normal sleep and investigated differences in the expression levels of Clock, Per2, and Bmal1 between the 2 groups.
   RESULTS: The expression peaks of Clock, Per2, and Bmal1 were at 12:00. There was a statistically significant difference between the sleep disorder group and the normal sleep group in the level of Clock mRNA expression (P = 0.0003 in oral mucosa and P < 0.0001 in mononuclear cells). There was no significant between-group difference in Small mRNA expression level (P = 0.1187 in oral mucosa and P = 0.2094 in mononuclear cells). There were significant between-group differences in Per2 mRNA expression levels at 12:00 (P = 0.0102 in oral mucosa and P = 0.0006 in mononuclear cells) and 18:00 (P = 0.0004 in oral mucosa and P = 0.0015 in mononuclear cells) but no significant difference at 24:00 (P = 0.7838 in oral mucosa and P = 0.2808 in mononuclear cells).
   CONCLUSIONS: Abnormal expression levels of Per2, Clock, and Bmal1 were detected in patients with TBI-related sleep disorders. These novel findings demonstrate disturbances in the molecular clock in TBI patients and have important implications for our understanding of the aberrant rhythms reported in this disease.
C1 [Niu Zhanfeng; Fei Zhou] Air Force Med Univ, Dept Neurosurg, Xijing Hosp, Xian, Shaanxi, Peoples R China.
   [Niu Zhanfeng; Xia Hechun] Ningxia Med Univ, Dept Neurosurg, Gen Hosp, Yinchuan, Peoples R China.
   [Zhao Zhijun] Ningxia Med Univ, Clin Lab Ctr, Gen Hosp, Yinchuan, Peoples R China.
   [Xu Hongyu] Air Force Med Univ, Xian, Shaanxi, Peoples R China.
RP Fei, Z (reprint author), Air Force Med Univ, Dept Neurosurg, Xijing Hosp, Xian, Shaanxi, Peoples R China.
EM feizhou@fmmu.edu.cn
FU Ningxia Key Research and Development program [2018YBZD0027]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [8166100258, 81430043]; First-Class Discipline Construction
   Founded Project of Ningxia Medical University; School of Clinical
   Medicine [NXYLXK2017A05]
FX This work was supported by the Ningxia Key Research and Development
   program (2018YBZD0027), the National Natural Science Foundation of China
   (8166100258, 81430043), and the First-Class Discipline Construction
   Founded Project of Ningxia Medical University and the School of Clinical
   Medicine (NXYLXK2017A05).
CR Ackermann K, 2013, CHRONOBIOL INT, V30, P901, DOI 10.3109/07420528.2013.784773
   Llompart-Pou JA, 2010, NEUROCRIT CARE, V13, P211, DOI 10.1007/s12028-010-9399-1
   Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30
   Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109
   Boivin DB, 2003, BLOOD, V102, P4143, DOI 10.1182/blood-2003-03-0779
   Breen DP, 2014, JAMA NEUROL, V71, P589, DOI 10.1001/jamaneurol.2014.65
   Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349
   Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000
   Colantonio A, 2004, INT J REHABIL RES, V27, P209, DOI 10.1097/00004356-200409000-00006
   Dibner C, 2010, ANNU REV PHYSIOL, V72, P517, DOI 10.1146/annurev-physiol-021909-135821
   Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8
   Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940
   Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635
   HAIMOV I, 1995, SLEEP, V18, P598, DOI 10.1093/sleep/18.7.598
   Hastings MH, 2003, NAT REV NEUROSCI, V4, P649, DOI 10.1038/nrn1177
   James FO, 2007, CHRONOBIOL INT, V24, P1009, DOI 10.1080/07420520701800736
   Johansson AS, 2016, SCHIZOPHR RES, V174, P17, DOI 10.1016/j.schres.2016.04.029
   Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815
   Lustenberger C, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fneur.2012.00077
   Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598
   Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006
   Meerlo P, 2009, SLEEP MED REV, V13, P187, DOI 10.1016/j.smrv.2008.07.004
   Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057
   Paul T, 2007, CHRONOBIOL INT, V24, P45, DOI 10.1080/07420520601142569
   Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647
   Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b
   Shimoda K, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.08.014
   VandenHeuvel CJ, 1997, PHYSIOL BEHAV, V61, P795, DOI 10.1016/S0031-9384(96)00534-3
   Voultsios A, 1997, J BIOL RHYTHM, V12, P457, DOI 10.1177/074873049701200507
   Zeitzer JM, 2000, J CLIN ENDOCR METAB, V85, P2189, DOI 10.1210/jc.85.6.2189
NR 30
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E475
EP E486
DI 10.1016/j.wneu.2019.06.122
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200060
DA 2020-05-12
ER

PT J
AU O'Connor, KP
   Algan, O
   Vesely, SK
   Palejwala, AH
   Briggs, RG
   Conner, AK
   Cornwell, BO
   Andrews, B
   Sughrue, ME
   Glenn, CA
AF O'Connor, Kyle P.
   Algan, Ozer
   Vesely, Sara K.
   Palejwala, Ali H.
   Briggs, Robert G.
   Conner, Andrew K.
   Cornwell, Benjamin O.
   Andrews, Bethany
   Sughrue, Michael E.
   Glenn, Chad A.
TI Factors Associated with Treatment Failure and Radiosurgery-Related Edema
   in WHO Grade 1 and 2 Meningioma Patients Receiving Gamma Knife
   Radiosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Edema; Gamma knife; Local failure; Meningioma; Predictive factors
ID STEREOTACTIC RADIOSURGERY; PERITUMORAL EDEMA; TUMOR-CONTROL; PREDICTORS
AB BACKGROUND: Before the advent of radiosurgery, neurosurgical treatment of meningiomas typically involved gross total resection of the mass whenever surgery was deemed possible. Over the past 4 decades, though, Gamma Knife radiosurgery (GKRS) has proved to be an effective, minimally invasive means to control the growth of these tumors. However, the variables associated with treatment failure (regrowth or clinical progression) after GKRS and GKRS-related complications, such as cerebral edema, are less well understood.
   METHODS: We retrospectively collected data between 2009 and 2018 for patients who underwent GKRS for meningiomas. After data collection, we performed univariate and multivariable modeling of the factors that predict treatment failure and cerebral edema after GKRS. Hazard ratios (HR) and P values were determined for these variables.
   RESULTS: Fifty-two patients were included our analysis. The majority of patients were female (38/52,73%), and nearly all patients presented with a suspected or confirmed World Health Organization grade 1 meningioma (48/52, 92%). The median tumor volume was 3.49 cc (range, 0.22-20.11 cc). Evidence of meningioma progression after treatment developed in 5 patients (10%), with a median time to continued tumor growth of 5.9 months (range, 2.7-18.3 months). In multivariable analysis, patients in whom treatment failed were more likely to be male (HR = 8.42, P = 0.045) and to present with larger tumor volumes (HR = 1.27, P = 0.011). In addition, 5 patients (10%) experienced treatment-related cerebral edema. On univariate analysis, patients who experienced cerebral edema were more likely present with larger tumors (HR = 1.16, P = 0.028).
   CONCLUSIONS: Increasing meningioma size and male gender predispose to meningioma progression after treatment with GKRS. Increasing tumor size also predicts the development of postradiosurgery cerebral edema.
C1 [O'Connor, Kyle P.; Palejwala, Ali H.; Briggs, Robert G.; Andrews, Bethany; Glenn, Chad A.] Univ Oklahoma, Hlth Sci Ctr, Dept Neurosurg, Oklahoma City, OK 73104 USA.
   [Algan, Ozer] Univ Oklahoma, Hlth Sci Ctr, Dept Radiat Oncol, Oklahoma City, OK USA.
   [Vesely, Sara K.] Univ Oklahoma, Hlth Sci Ctr, Dept Biostat & Epidemiol, Oklahoma City, OK USA.
   [Cornwell, Benjamin O.] Univ Oklahoma, Hlth Sci Ctr, Dept Neuroradiol, Oklahoma City, OK USA.
   [Sughrue, Michael E.] Prince Wales Private Hosp, Dept Neurosurg, Randwick, NSW, Australia.
   [Conner, Andrew K.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Glenn, CA (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Neurosurg, Oklahoma City, OK 73104 USA.
EM chad-glenn@ouhsc.edu
OI O'Connor, Kyle/0000-0003-0168-3379
CR Aboukais R, 2015, J NEUROSURG, V122, P1157, DOI 10.3171/2014.9.JNS14233
   Chen CH, 2007, STEREOT FUNCT NEUROS, V85, P292, DOI 10.1159/000107362
   Chen WC, 2018, J NEURO-ONCOL, V138, P425, DOI 10.1007/s11060-018-2813-9
   DiBiase SJ, 2004, INT J RADIAT ONCOL, V60, P1515, DOI 10.1016/j.ijrobp.2004.05.073
   Hwang K, 2019, WORLD NEUROSURG, V123, pE549, DOI 10.1016/j.wneu.2018.11.211
   Iplikcioglu AC, 2014, CLIN NEUROL NEUROSUR, V124, P119, DOI 10.1016/j.clineuro.2014.06.015
   Kaprealian T, 2016, J NEURO-ONCOL, V128, P357, DOI 10.1007/s11060-016-2121-1
   Kim JW, 2017, STEREOT FUNCT NEUROS, V95, P209, DOI 10.1159/000475763
   Kondziolka D, 2008, NEUROSURGERY, V62, P53, DOI 10.1227/01.NEU.0000311061.72626.0D
   Kondziolka D, 2016, AM J CLIN ONCOL-CANC, V39, P453, DOI 10.1097/COC.0000000000000080
   Kuroi Y, 2018, WORLD NEUROSURG, V118, pE918, DOI 10.1016/j.wneu.2018.07.100
   Lee JYK, 2002, J NEUROSURG, V97, P65, DOI 10.3171/jns.2002.97.1.0065
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Mansouri A, 2015, J NEUROSURG, V123, P1294, DOI 10.3171/2014.12.JNS141687
   Mitrasinovic S, 2019, J CLIN NEUROSCI, V59, P12, DOI 10.1016/j.jocn.2018.09.029
   Nundkumar N, 2013, J CLIN NEUROSCI, V20, P616, DOI 10.1016/j.jocn.2012.03.041
   Park KJ, 2019, J NEUROSURG, V130, P1799, DOI 10.3171/2018.2.JNS172361
   Pinzi V, 2017, CRIT REV ONCOL HEMAT, V113, P122, DOI 10.1016/j.critrevonc.2017.03.005
   Przybylowski CJ, 2015, J CLIN NEUROSCI, V22, P161, DOI 10.1016/j.jocn.2014.07.028
   Rojas-Villabona A, 2016, J APPL CLIN MED PHYS, V17, P217, DOI 10.1120/jacmp.v17i6.6347
   Sethi RA, 2015, AM J CLIN ONCOL-CANC, V38, P600, DOI 10.1097/COC.0000000000000008
   Sheehan JP, 2015, J NEUROSURG, V123, P1287, DOI 10.3171/2014.12.JNS142159
   Sheehan JP, 2015, J NEURO-ONCOL, V125, P317, DOI 10.1007/s11060-015-1911-1
   Sheehan JP, 2015, J NEUROSURG, V122, P1479, DOI 10.3171/2014.10.JNS14139
   Varlotto J, 2015, ONCOTARGET, V6, P38421, DOI 10.18632/oncotarget.5376
NR 25
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E558
EP E565
DI 10.1016/j.wneu.2019.06.152
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200069
PM 31299310
DA 2020-05-12
ER

PT J
AU Ohba, S
   Murayama, K
   Nishiyama, Y
   Adachi, K
   Yamada, S
   Abe, M
   Hasegawa, M
   Hirose, Y
AF Ohba, Shigeo
   Murayama, Kazuhiro
   Nishiyama, Yuya
   Adachi, Kazuhide
   Yamada, Seiji
   Abe, Masato
   Hasegawa, Mitsuhiro
   Hirose, Yuichi
TI Clinical and Radiographic Features for Differentiating Solitary Fibrous
   Tumor/Hemangiopericvtoma From Meningioma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Meningioma; MRS; Myo-inositol; Perfusion MRI; Solitary fibrous
   tumor/hemangiopericytoma
ID CENTRAL-NERVOUS-SYSTEM; MAGNETIC-RESONANCE-SPECTROSCOPY; INTRACRANIAL
   HEMANGIOPERICYTOMA; MR SPECTROSCOPY; PERFUSION MRI; MYOINOSITOL; H-1-MRS
AB OBJECTIVE: Solitary fibrous tumor/hemangiopericytoma (SFT/HPC) and meningioma exhibit similar radiographic features; however, they differ in their prognoses. Preoperative differentiation between them is important for determining the treatment and follow-up plan. The aim of this study was to determine the factors that can be used to differentiate SFT/HPC from meningioma and World Health Organization (WHO) grade I from grade II meningioma.
   METHODS: The analysis included 84 cases: 5 of SFT/HPC, 72 of WHO grade I meningioma, and 7 of WHO grade II meningioma. Clinical characteristics and conventional magnetic resonance imaging, perfusion magnetic resonance imaging, and magnetic resonance spectroscopy (MRS) LCModel parameters were evaluated via multivariate logistic regression analysis to identify the factors that distinguish SFT/HPC from meningioma.
   RESULTS: Patients with SFT/HPC were mostly men and were younger than those with meningioma. The percentage of T2-weighted images in meningioma was greater than that in SFT/HPC. There were significant differences between SFT/HPC and meningioma in levels of glutamate, phosphocholine, myo-inositol, or glycerophosphocholine + phosphocholine derived from long echo-time MRS, and myoinositol derived from short echo-time MRS. Stepwise logistic regression analysis revealed that the age of <45 years and myo-inositol in short echo-time MRS of >= 6.347 were associated with a diagnosis of SFT/HPC with high sensitivity and specificity. However, no factors were found that differentiated WHO grade I meningioma from WHO grade II meningioma.
   CONCLUSIONS: Age and myo-inositol level calculated from MRS are useful factors for distinguishing SFT/HPC from meningioma preoperatively.
C1 [Ohba, Shigeo; Nishiyama, Yuya; Adachi, Kazuhide; Hasegawa, Mitsuhiro; Hirose, Yuichi] Fujita Hlth Univ, Dept Neurosurg, Toyoake, Aichi, Japan.
   [Murayama, Kazuhiro] Fujita Hlth Univ, Dept Radiol, Toyoake, Aichi, Japan.
   [Yamada, Seiji; Abe, Masato] Fujita Hlth Univ, Dept Pathol, Toyoake, Aichi, Japan.
RP Ohba, S (reprint author), Fujita Hlth Univ, Dept Neurosurg, Toyoake, Aichi, Japan.
EM shigeo.ohba@gmail.com
OI ADACHI, KAZUHIDE/0000-0002-5275-8572
CR Barba I, 2001, J NEUROSURG, V94, P55, DOI 10.3171/jns.2001.94.1.0055
   Chernov MF, 2011, CLIN NEUROL NEUROSUR, V113, P202, DOI 10.1016/j.clineuro.2010.11.008
   Chiechi MV, 1996, AM J NEURORADIOL, V17, P1365
   Cho YD, 2003, MAGN RESON IMAGING, V21, P663, DOI 10.1016/S0730-725X(03)00097-3
   Demir MK, 2006, EUR J RADIOL, V60, P48, DOI 10.1016/j.ejrad.2006.06.002
   Ginat DT, 2012, ACAD RADIOL, V19, P986, DOI 10.1016/j.acra.2012.04.006
   GUTHRIE BL, 1989, NEUROSURGERY, V25, P514, DOI 10.1227/00006123-198910000-00003
   Hattingen E, 2003, NEURORADIOLOGY, V45, P386, DOI 10.1007/s00234-003-0992-2
   Hattingen E, 2008, NMR BIOMED, V21, P233, DOI 10.1002/nbm.1186
   Huang RY, 2019, NEURO-ONCOLOGY, V21, pI44, DOI 10.1093/neuonc/noy143
   Jaskolski DJ, 2013, NEUROL NEUROCHIR POL, V47, P249, DOI 10.5114/ninp.2013.32998
   Kanazawa T, 2018, WORLD NEUROSURG, V120, pE1208, DOI 10.1016/j.wneu.2018.09.044
   Koc AM, 2016, TURK NEUROSURG, V26, P173, DOI 10.5137/1019-5149.JTN.8374-14.1
   Lin MC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207612
   Liu G, 2013, J MAGN RESON IMAGING, V38, P1146, DOI 10.1002/jmri.24075
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Magill ST, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.1.FOCUS17752
   Mama N, 2014, J NEURORADIOLOGY, V41, P296, DOI 10.1016/j.neurad.2013.10.007
   Mora P, 2014, EUR RADIOL, V24, P2895, DOI 10.1007/s00330-014-3308-5
   Nagashima H, 2018, J NEURO-ONCOL, V136, P317, DOI 10.1007/s11060-017-2655-x
   Ostrom QT, 2018, NEURO-ONCOLOGY, V20, P1, DOI 10.1093/neuonc/noy131
   Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698
   Qiao XJ, 2017, EUR J RADIOL, V97, P31, DOI 10.1016/j.ejrad.2017.10.005
   Shah T, 2011, J MAGN RESON IMAGING, V34, P1053, DOI 10.1002/jmri.22711
   Shi RH, 2016, J BUON, V21, P709
   Shiino A, 1999, J NEUROSURG, V91, P928, DOI 10.3171/jns.1999.91.6.0928
   Violaris Konstantinos, 2013, Neurosci J, V2013, P706481, DOI 10.1155/2013/706481
   Yu M, 2015, CLIN NEUROL NEUROSUR, V138, P78, DOI 10.1016/j.clineuro.2015.08.005
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E383
EP E392
DI 10.1016/j.wneu.2019.06.094
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200047
PM 31233926
DA 2020-05-12
ER

PT J
AU Oliveira, MM
   Ferrarez, CE
   Lovato, R
   Costa, PV
   Malheiros, JA
   Avellar, L
   Granja, M
   Sauvageau, E
   Machado, C
   Hanel, R
AF Oliveira, Marcelo Magaldi
   Ferrarez, Carlos Eduardo
   Lovato, Renan
   Costa, Pollyana Vieira
   Malheiros, Jose Augusto
   Avellar, Leonardo
   Granja, Manuel
   Sauvageau, Eric
   Machado, Carla
   Hanel, Ricardo
TI Quality Assurance During Brain Aneurysm Microsurgery-Operative Error
   Teaching
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain aneurysm; Fluorescein; Human placenta; Microsurgery; Neurosurgical
   education; Neurosurgical simulation
ID HUMAN PLACENTA; SURGERY; COMPLICATIONS; MODEL
AB INTRODUCTION: Quality assurance (QA) is a way to prevent mistakes in advance. Although it has been previously reported for surgical setup, there is no effective approach for minimizing microsurgical technical errors before an operation is done. Neurosurgery resident operative errors during brain aneurysm surgery could be foreseen by practicing in an ex vivo hybrid simulator with microscopic fluorescein vessel flow image.
   METHODS: Five vascular neurosurgeons and 8 junior/senior neurosurgical residents voluntarily joined this research initiative. The following methodology was adopted: 1) Identification of the 7 most-common resident operative performance errors during brain aneurysm surgery; 2) Design of exercises to prevent common mistakes in brain aneurysm microsurgery using a placenta simulator; and 3) Blinded staff neurosurgeon evaluation of resident performance during real brain aneurysm microsurgery.
   RESULTS: All key steps to perform such intervention were accomplished with a simulator that uses 2 placentas, a synthetic cranium, and microscopic fluorescein vessel flow image. Neurosurgery residents trained in this model had better surgical performance with fewer perioperative mistakes (P < 0.05). Fine microsurgical dissection of the arachnoid membrane and aneurysm sac were the most commonly improved tasks among the 7 common operative mistakes. Brain parenchyma traction with secondary bleeding was the only error not prevented after previous simulator training.
   CONCLUSIONS: There was a left-shift on the quality assurance line with residents who practiced brain aneurysm microsurgical errors in an ex vivo model. A multicentric prospective study is necessary to confirm the hypothesis that real operative error could be reduced after training in a realistic simulator.
C1 [Oliveira, Marcelo Magaldi; Ferrarez, Carlos Eduardo; Costa, Pollyana Vieira; Malheiros, Jose Augusto; Avellar, Leonardo] Placentarium, Dept Neurosurg, Belo Horizonte, MG, Brazil.
   [Lovato, Renan] Santa Casa Sao Paulo Sch Med Sci, Dept Neurosurg, Sao Paulo, Brazil.
   [Oliveira, Marcelo Magaldi; Sauvageau, Eric; Hanel, Ricardo] Baptist Med Ctr, Neurosurg Simulat Lab, Dept Neurosurg, Jacksonville, FL 32207 USA.
   [Granja, Manuel; Machado, Carla] Univ Fed Minas Gerais, Prevent & Social Med Dept, Belo Horizonte, MG, Brazil.
RP Oliveira, MM (reprint author), Placentarium, Dept Neurosurg, Belo Horizonte, MG, Brazil.; Oliveira, MM (reprint author), Baptist Med Ctr, Neurosurg Simulat Lab, Dept Neurosurg, Jacksonville, FL 32207 USA.
EM mmagaldi@hotmail.com
OI Lovato, Renan/0000-0002-9239-008X
CR Algra AM, 2018, JAMA NEUROL, V5, P41
   Bydon M, 2015, J NEUROSURG, V122, P955, DOI 10.3171/2014.11.JNS14890
   Dumont TM, 2012, J NEUROSURG, V116, P483, DOI 10.3171/2011.9.JNS116
   Gozal YM, 2020, J NEUROSURG, V132, P272, DOI 10.3171/2018.9.JNS181004
   Gupta R, 2018, WORLD NEUROSURG, V109, pE563, DOI 10.1016/j.wneu.2017.10.022
   Lovato RM, 2017, WORLD NEUROSURG, V104, P61, DOI 10.1016/j.wneu.2017.04.169
   Magaldi MO, 2014, OPER NEUROSURG, V10, P592, DOI 10.1227/NEU.0000000000000553
   Oppong MD, 2020, J NEUROSURG, V132, P79, DOI 10.3171/2018.9.JNS182105
   Rhoton AL, 2002, NEUROSURGERY, V51, pS121, DOI 10.1227/01.NEU.0000028227.73143.A7
   Ribeiro de Oliveira Marcelo Magaldi, 2019, J Neurosurg, P1, DOI 10.3171/2018.7.JNS173007
   de Oliveira MMR, 2018, J NEUROSURG, V128, P846, DOI 10.3171/2016.10.JNS162083
   de Oliveira MMR, 2016, J NEUROSURG, V124, P1238, DOI 10.3171/2015.1.JNS141583
   Savardekar AR, 2018, WORLD NEUROSURG, V119, P294, DOI 10.1016/j.wneu.2018.06.231
   Sorenson T, 2016, J NEUROSURG SCI, V60, P22
   Sorenson T, 2016, J NEUROSURG SCI, V60, P116
   Stebbing L, 1993, QUALITY ASSURANCE RO, P300
   Vasella F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37533-3
NR 17
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E112
EP E116
DI 10.1016/j.wneu.2019.05.262
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200015
PM 31176838
DA 2020-05-12
ER

PT J
AU Oravec, CS
   Frey, CD
   Berwick, BW
   Vilella, L
   Aschenbrenner, CA
   Wolfe, SQ
   Fargen, KM
AF Oravec, Chesney S.
   Frey, Casey D.
   Berwick, Benjamin W.
   Vilella, Lukas
   Aschenbrenner, Carol A.
   Wolfe, Stacey Q.
   Fargen, Kyle M.
TI Predictors of Citations in Neurosurgical Research
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bibliometrics; Citation rate; Collaboration; Level of evidence;
   Neurosurgery; Publications
ID BIBLIOMETRIC ANALYSIS; MAJOR RADIOLOGY; COUNT DATA; COLLABORATION;
   RATES; PUBLICATION; IMPACT; LEVEL
AB OBJECTIVE: The number of citations an article receives is an important measure of impact for published research. There are limited published data on predictors of citations in neurosurgery research. We aimed to analyze predictors of citations for neurosurgical articles.
   METHODS: All articles published in 14 neurosurgical journals in the year 2015 were examined and data collected about their features. The number of citations for each article was tallied using both Web of Science (WoS) and Google Scholar (GS) 2.5 years after their publication in print. Negative binomial regression was then performed to determine the relationship between article features and citation counts for scientific articles.
   RESULTS: A total of 3923 articles were analyzed, comprising 2867 scientific articles (72.6%) and 1056 nonscientific (editorial, commentary, etc.) articles (27.4%). At 2.5 years, scientific articles had a median [interquartile range] number of citations per article of 3.0 [6.0] and 7.0 [9.0] found in WoS and GS, respectively; nonscientific articles had accumulated median 0.0 [2.0] in both WOS and GS. Articles with the study topic "Spine" had the highest citation count at 4.0 [5.0] and 8.0 [10.0] in WoS and GS, respectively. Significant predictors of citation count in scientific articles were level of evidence, number of centers, number of authors, and impact factor.
   CONCLUSIONS: This is the largest investigation analyzing predictors of citations in the neurosurgical literature. Factors found to be most influential on citation rates in scientific articles included the study's level of evidence, number of participating centers, number of authors, and the publishing journal's impact factor.
C1 [Oravec, Chesney S.; Wolfe, Stacey Q.; Fargen, Kyle M.] Wake Forest Baptist Med Ctr, Dept Neurosurg, Winston Salem, NC 27157 USA.
   [Aschenbrenner, Carol A.] Wake Forest Baptist Med Ctr, Dept Biostat & Data Sci, Winston Salem, NC USA.
   [Frey, Casey D.; Berwick, Benjamin W.; Vilella, Lukas] Wake Forest Sch Med, Winston Salem, NC USA.
RP Oravec, CS (reprint author), Wake Forest Baptist Med Ctr, Dept Neurosurg, Winston Salem, NC 27157 USA.
EM coravec@wakehealth.edu
CR Bhandari M, 2007, CAN J SURG, V50, P119
   Callaham M, 2002, JAMA-J AM MED ASSOC, V287, P2847, DOI 10.1001/jama.287.21.2847
   Cheng KL, 2017, J ORAL MAXIL SURG, V75, P1313, DOI 10.1016/j.joms.2017.03.043
   Chokshi FH, 2016, CURR PROBL DIAGN RAD, V45, P356, DOI 10.1067/j.cpradiol.2016.03.002
   Fargen KM, 2017, J NEUROINTERV SURG, V9, P694, DOI 10.1136/neurintsurg-2016-012504
   Figg WD, 2006, PHARMACOTHERAPY, V26, P759, DOI 10.1592/phco.26.6.759
   Frey CD, 2017, WORLD NEUROSURG, V108, P901, DOI 10.1016/j.wneu.2017.09.011
   Garner RM, 2018, J NEUROINTERV SURG, V10, P102, DOI 10.1136/neurintsurg-2017-013265
   Kleiber C, 2016, AM STAT, V70, P296, DOI 10.1080/00031305.2016.1173590
   Kossmeier M, 2019, TRANSPL INT, V32, P6, DOI 10.1111/tri.13292
   Kulkarni AV, 2009, JAMA-J AM MED ASSOC, V302, P1092, DOI 10.1001/jama.2009.1307
   Lopez J, 2017, J SURG EDUC, V74, P191, DOI 10.1016/j.jsurg.2016.08.005
   Minasny B, 2013, PEERJ, V1, DOI 10.7717/peerj.183
   Okike K, 2011, J CLIN EPIDEMIOL, V64, P331, DOI 10.1016/j.jclinepi.2010.03.019
   Rosenkrantz AB, 2018, J AM COLL RADIOL, V15, P258, DOI 10.1016/j.jacr.2017.09.030
   Ruano-Ravina A, 2012, ANN EPIDEMIOL, V22, P649, DOI 10.1016/j.annepidem.2012.06.104
   Shekhani HN, 2017, AM J ROENTGENOL, V209, P1191, DOI 10.2214/AJR.17.18077
   Susarla SM, 2018, INT J ORAL MAX SURG, V47, P1411, DOI 10.1016/j.ijom.2018.04.016
   Willis DL, 2011, BJU INT, V107, P1876, DOI 10.1111/j.1464-410X.2010.10028.x
   Winnik S, 2012, EUR HEART J, V33, P3034, DOI 10.1093/eurheartj/ehs113
   Zeileis A, 2008, J STAT SOFTW, V27, P1, DOI 10.18637/jss.v027.i08
NR 21
TC 0
Z9 0
U1 4
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E82
EP E89
DI 10.1016/j.wneu.2019.05.226
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200011
PM 31158543
DA 2020-05-12
ER

PT J
AU Oushy, S
   Peris-Celda, M
   Van Gompel, JJ
AF Oushy, Soliman
   Peris-Celda, Maria
   Van Gompel, Jamie J.
TI Skull Base Enchondroma and Chondrosarcoma in Oilier Disease and Maffucci
   Syndrome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chondrosarcoma; Enchondroma; Maffucci; Oilier; Skull base;
   Transformation
ID OF-THE-LITERATURE; OLLIERS-DISEASE; EMPHASIS; PATIENT; BRAIN; BONE;
   RADIOLOGY; GLIOMAS; TUMORS; ABC/2
AB BACKGROUND: Maffucci syndrome (MS) and Oilier disease (OD) are rare diseases characterized by multiple benign enchondromas. The incidence of skull base (SB) enchondromas and the risk of malignant transformation remain unknown. Most SB lesions are asymptomatic, and surgical resection carries significant morbidity. Observation may be a reasonable strategy. We report our experience with observation of probable SB enchondromas in MS/OD patients.
   METHODS: Retrospective review of OD/MS patients with cranial imaging between 1995 and 2018 at 1 institution.
   RESULTS: 14 patients were included: 3 with MS (21.4%) and 11 with OD (78.6%). The median age was 28 years (range, 11-74 years) and 57.1% were female. Extracranial chondrosarcoma was reported in 3 (21.4%) patients. Seven (50%) patients with SB enchondroma or chondrosarcoma were identified on initial imaging. In patients with SB lesions, the indications for imaging were headache (n =3), seizure (n =1), and diplopia (n =1); 2 cases were incidental findings. The most commonly involved structures were petroclival fissure (86%) and clivus (71%). Treatment included observation (6/7) and resection (1/7). Follow-up imaging was available for all SB lesions, with a mean interval of 50.7 months (range, 5-225 months) and was negative for progression in all patients.
   CONCLUSIONS: Primary SB lesions in OD/MS patients frequently present in the petroclival junction. Cranial screening and close observation should be considered in MS/OD patients, given the increased risk of intra-axial intracranial tumors, de novo chondrosarcomas, or malignant degeneration of previously known lesions. In asymptomatic patients, observation appears to be a safe strategy in this cohort. Further case accumulation and follow-up are required to better understand the long-term outcomes.
C1 [Oushy, Soliman; Van Gompel, Jamie J.] Mayo Clin, Dept Neurosurg, Rochester, MN 55905 USA.
   [Peris-Celda, Maria] Albany Med Coll, Dept Neurosurg, Albany, NY 12208 USA.
RP Van Gompel, JJ (reprint author), Mayo Clin, Dept Neurosurg, Rochester, MN 55905 USA.
EM VanGompel.Jamie@mayo.edu
OI Oushy, Soliman/0000-0001-6343-6950
CR Ahmed SK, 1999, J LARYNGOL OTOL, V113, P861, DOI 10.1017/S0022215100145438
   ALBREGTS AE, 1995, DERMATOL CLIN, V13, P73, DOI 10.1016/S0733-8635(18)30109-8
   Altay M, 2007, J ORTHOP SCI, V12, P415, DOI 10.1007/s00776-007-1152-z
   Balcer LJ, 1999, J NEURO-OPHTHALMOL, V19, P62
   Bathla G, 2017, OTOL NEUROTOL, V38, P889, DOI 10.1097/MAO.0000000000001423
   Brackmann DE, 2006, OTOL NEUROTOL, V27, P981, DOI 10.1097/01.mao.0000233812.48800.b4
   Brien EW, 1997, SKELETAL RADIOL, V26, P325, DOI 10.1007/s002560050246
   CHANG S, 1994, NEUROSURGERY, V34, P903, DOI 10.1227/00006123-199405000-00018
   Choi BB, 2013, CLIN IMAG, V37, P542, DOI 10.1016/j.clinimag.2012.08.006
   Dini LI, 2007, ARQ NEURO-PSIQUIAT, V65, P816, DOI 10.1590/S0004-282X2007000500016
   Fridirici ZC, 2018, OTOL NEUROTOL, V39, pE52, DOI 10.1097/MAO.0000000000001651
   Gajavelli Srikanth, 2016, Surg Neurol Int, V7, pS607, DOI 10.4103/2152-7806.189731
   GOTO H, 1987, Neurological Surgery, V15, P971
   Herget GW, 2014, NEOPLASMA, V61, P365, DOI 10.4149/neo_2014_046
   Hofman S, 1998, SKELETAL RADIOL, V27, P688, DOI 10.1007/s002560050460
   JIRARATTANAPHOCHAI K, 1990, Journal of the Medical Association of Thailand, V73, P288
   Kurian S, 2004, SKELETAL RADIOL, V33, P609, DOI 10.1007/s00256-004-0802-x
   LIU J, 1987, CANCER, V59, P1376, DOI 10.1002/1097-0142(19870401)59:7<1376::AID-CNCR2820590725>3.0.CO;2-F
   Maffucci A, 1881, MOV MED CHIR NAP, V3, P565
   Mahafza WS, 2004, SAUDI MED J, V25, P1261
   Mandonnet E, 2017, CLIN NEUROL NEUROSUR, V160, P147, DOI 10.1016/j.clineuro.2017.07.011
   MIKI K, 1987, ACTA NEUROCHIR, V87, P79, DOI 10.1007/BF02076022
   Mosier SM, 2012, J RADIOL CASE REP, V6, P32, DOI 10.3941/jrcr.v6i12.1241
   Nengsu A, 2002, Ann Otolaryngol Chir Cervicofac, V119, P287
   Nishio S, 1997, ACTA NEUROCHIR, V139, P336, DOI 10.1007/BF01808830
   Ollier M., 1899, B SOC CHIR LYON, V3, P22
   PATT S, 1990, NEUROSURGERY, V27, P487, DOI 10.1227/00006123-199009000-00029
   Ranger A, 2009, NEUROSURGERY, V65, P1106, DOI 10.1227/01.NEU.0000356984.92242.D5
   Rapidis AD, 1997, J CRANIO MAXILL SURG, V25, P322, DOI 10.1016/S1010-5182(97)80034-0
   Rosenberg AE, 1999, AM J SURG PATHOL, V23, P1370, DOI 10.1097/00000478-199911000-00007
   SCHWARTZ HS, 1987, J BONE JOINT SURG AM, V69A, P269, DOI 10.2106/00004623-198769020-00016
   Silve C, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-37
   SUN TC, 1985, J BONE JOINT SURG AM, V67A, P1214, DOI 10.2106/00004623-198567080-00011
   van Nielen KMB, 1999, CLIN NEUROL NEUROSUR, V101, P106, DOI 10.1016/S0303-8467(98)00072-9
   Verdegaal SHM, 2011, ONCOLOGIST, V16, P1771, DOI 10.1634/theoncologist.2011-0200
   Walid MS, 2008, J NEURO-ONCOL, V89, P59, DOI 10.1007/s11060-008-9583-8
   Yu YL, 2013, CLIN NEUROL NEUROSUR, V115, P1371, DOI 10.1016/j.clineuro.2012.12.029
NR 37
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E356
EP E361
DI 10.1016/j.wneu.2019.06.087
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200043
PM 31233929
DA 2020-05-12
ER

PT J
AU Almeida, JP
   Sanchez, MM
   Karekezi, C
   Warsi, N
   Fernandez-Gajardo, R
   Panwar, J
   Mansouri, A
   Suppiah, S
   Nassiri, F
   Nejad, R
   Kucharczyk, W
   Ridout, R
   Joaquim, AF
   Gentili, F
   Zadeh, G
AF Paulo Almeida, Joao
   Marigil Sanchez, Miguel
   Karekezi, Claire
   Warsi, Nebras
   Fernandez-Gajardo, Rodrigo
   Panwar, Jyoti
   Mansouri, Alireza
   Suppiah, Suganth
   Nassiri, Farshad
   Nejad, Romina
   Kucharczyk, Walter
   Ridout, Rowena
   Joaquim, Andrei F.
   Gentili, Fred
   Zadeh, Gelareh
TI Pituitary Apoplexy: Results of Surgical and Conservative Management
   Clinical Series and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Apoplexy; Conservative; Endoscopy; Pituitary tumor; Transsphenoidal
ID TRANSSPHENOIDAL SURGERY; SPONTANEOUS REMISSION; EXPERIENCE; ADENOMAS;
   OUTCOMES
AB OBJECTIVE: Pituitary apoplexy is associated with visual, cranial nerve, and endocrine dysfunction. In this article, the results of surgical and conservative management of pituitary apoplexy in a single center are evaluated and a review of the literature is presented.
   METHODS: A retrospective analysis was made of patients with pituitary apoplexy who underwent surgery or conservative management at our center between January 2007 and June 2017. Surgery was typically selected for patients who presented with acute deterioration of visual status and/or level of consciousness. Patients with no visual field deficit and those who had medical contraindications to undergo a surgical procedure because of previous comorbidities typically had conservative treatment. Baseline characteristics and clinical and radiologic outcomes were reviewed. A review of the literature (1990-2018) was performed according to PRISMA guidelines. Studies comparing the results of conservative and surgical management were identified. Visual, cranial nerve, and endocrine outcomes and tumor recurrence were analyzed.
   RESULTS: Forty-nine patients (73.1%) were managed surgically and 18 (26.9%) conservatively. After careful case selection, patients underwent surgical or conservative treatment. Patients who underwent conservative treatment had fewer visual deficits. At diagnosis, visual deficit (38.8% vs. 75.5%; P = 0.008) and cranial nerve palsy (27.7% vs. 51%; P = 0.058) were less common in the conservative group. Conservative and surgical treatments had similar visual and cranial nerve improvement rates (75% vs. 58.3%, P = 0.63 and 75% vs. 692%, P = 1.0, respectively). In the conservative group, tumor shrinkage was observed in 76.4% of cases. The systematic review retrieved 11 studies. No significant difference between conservative and surgical treatment for clinical outcomes (visual field recovery, odds ratio [OR], 1.45; 95% confidence interval [CI], 0.72-2.92; cranial nerve recovery, OR, 2.30; 95% CI, 0.93-5.65; and hypopituitarism, OR, 1.05; 95% CI, 0.64-1.74) or tumor recurrence (OR, 0.68; 95% CI, 0.20-2.34) was observed.
   CONCLUSIONS: A tailored approach to pituitary apoplexy, one that does not include an absolute need for surgery, is appropriate. Conservative management is appropriate in selected patients presenting without visual deficits.
C1 [Paulo Almeida, Joao; Marigil Sanchez, Miguel; Karekezi, Claire; Warsi, Nebras; Mansouri, Alireza; Suppiah, Suganth; Nassiri, Farshad; Nejad, Romina; Gentili, Fred; Zadeh, Gelareh] Univ Toronto, Toronto Western Hosp, Div Neurosurg, Toronto, ON, Canada.
   [Ridout, Rowena] Univ Toronto, Toronto Western Hosp, Dept Endocrinol, Toronto, ON, Canada.
   [Panwar, Jyoti; Kucharczyk, Walter] Univ Toronto, Dept Radiol, Toronto, ON, Canada.
   [Paulo Almeida, Joao; Joaquim, Andrei F.] State Univ Campinas UNICAMP, Dept Neurol, Div Neurosurg, Campinas, SP, Brazil.
   [Fernandez-Gajardo, Rodrigo] Univ Chile, Dept Neurol Sci, Santiago, Chile.
RP Almeida, JP (reprint author), Univ Toronto, Toronto Western Hosp, Div Neurosurg, Toronto, ON, Canada.; Almeida, JP (reprint author), State Univ Campinas UNICAMP, Dept Neurol, Div Neurosurg, Campinas, SP, Brazil.
EM jpaulocavalcante@yahoo.com.br
OI Mansouri, Alireza/0000-0002-7442-7539
CR Abbott J, 2004, BRIT MED J, V329, P218, DOI 10.1136/bmj.329.7459.218
   Abdulbaki Arif, 2017, Surg Neurol Int, V8, P16, DOI 10.4103/2152-7806.199557
   Ayuk J, 2004, CLIN ENDOCRINOL, V61, P747, DOI 10.1111/j.1365-2265.2004.02162.x
   Bi WL, 2015, ENDOCRINE, V48, P69, DOI 10.1007/s12020-014-0359-y
   BILLS DC, 1993, NEUROSURGERY, V33, P602, DOI 10.1227/00006123-199310000-00007
   BONICKI W, 1993, ACTA NEUROCHIR, V120, P118, DOI 10.1007/BF02112028
   Briet C, 2015, ENDOCR REV, V36, P622, DOI 10.1210/er.2015-1042
   Briet C, 2015, ENDOCRIN METAB CLIN, V44, P199, DOI 10.1016/j.ecl.2014.10.016
   Bujawansa S, 2014, CLIN ENDOCRINOL, V80, P419, DOI 10.1111/cen.12307
   Capatina C, 2015, EUR J ENDOCRINOL, V172, pR179, DOI 10.1530/EJE-14-0794
   Chuang CC, 2006, J NEURO-ONCOL, V80, P39, DOI 10.1007/s11060-006-9148-7
   Dehdashti AR, 2008, NEUROSURGERY, V62, P1006, DOI 10.1227/01.neu.0000325862.83961.12
   Fraser LA, 2009, ENDOCR PRACT, V15, P725, DOI 10.4158/EP09126.CRR
   Giritharan S, 2016, CLIN ENDOCRINOL, V85, P415, DOI 10.1111/cen.13075
   Glezer A, 2015, ARCH ENDOCRIN METAB, V59, P259, DOI 10.1590/2359-3997000000047
   Gondim JA, 2017, WORLD NEUROSURG, V108, P137, DOI 10.1016/j.wneu.2017.08.131
   Gruber A, 2006, BRIT J NEUROSURG, V20, P379, DOI 10.1080/02688690601046678
   Leyer C, 2011, J ENDOCRINOL INVEST, V34, P502, DOI 10.3275/7241
   Lubina A, 2005, ACTA NEUROCHIR, V147, P151, DOI 10.1007/s00701-004-0413-2
   MACCAGNAN P, 1995, J CLIN ENDOCR METAB, V80, P2190, DOI 10.1210/jc.80.7.2190
   MCFADZEAN RM, 1991, NEUROSURGERY, V29, P669, DOI 10.1227/00006123-199111000-00005
   Micko ASG, 2015, J NEUROSURG, V122, P803, DOI 10.3171/2014.12.JNS141083
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Nawar Rita N, 2008, J Intensive Care Med, V23, P75, DOI 10.1177/0885066607312992
   Nishioka H, 2005, ENDOCR J, V52, P117, DOI 10.1507/endocrj.52.117
   ONESTI ST, 1990, NEUROSURGERY, V26, P980, DOI 10.1227/00006123-199006000-00010
   PETER M, 1995, BRIT J NEUROSURG, V9, P151, DOI 10.1080/02688699550041485
   Rajasekaran S, 2011, CLIN ENDOCRINOL, V74, P9, DOI 10.1111/j.1365-2265.2010.03913.x
   Randeva HS, 1999, CLIN ENDOCRINOL, V51, P181, DOI 10.1046/j.1365-2265.1999.00754.x
   Rutkowski MJ, 2018, J NEUROSURG, V129, P417, DOI 10.3171/2017.2.JNS1784
   Seuk JW, 2011, J KOREAN NEUROSURG S, V49, P339, DOI 10.3340/jkns.2011.49.6.339
   Sibal Latika, 2004, Pituitary, V7, P157, DOI 10.1007/s11102-005-1050-3
   Singh TD, 2015, J NEUROSURG, V122, P1450, DOI 10.3171/2014.10.JNS141204
   TAMASAWA N, 1988, J ENDOCRINOL INVEST, V11, P429, DOI 10.1007/BF03349076
   Teixeira JC, 2018, WORLD NEUROSURG, V111, pE495, DOI 10.1016/j.wneu.2017.12.103
   Woo HJ, 2010, J KOREAN NEUROSURG S, V48, P213, DOI 10.3340/jkns.2010.48.3.213
   Yang T, 2015, CUREUS, V7, DOI 10.7759/cureus.357
   Zaidi HA, 2017, NEUROSURGERY, V81, P659, DOI 10.1093/neuros/nyx073
   Zaidi HA, 2016, WORLD NEUROSURG, V96, P434, DOI 10.1016/j.wneu.2016.09.052
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E988
EP E999
DI 10.1016/j.wneu.2019.01.055
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200122
PM 31302273
DA 2020-05-12
ER

PT J
AU Pennington, Z
   Lubelski, D
   Molina, C
   Westbroek, EM
   Ahmed, AK
   Sciubba, DM
AF Pennington, Zach
   Lubelski, Daniel
   Molina, Camilo
   Westbroek, Erick M.
   Ahmed, A. Karim
   Sciubba, Daniel M.
TI Prolonged Post-surgical Drain Retention Increases Risk for Deep Wound
   Infection After Spine Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Revision surgery; Surgical drain; Surgical site infection; Wound
   infection
ID SURGICAL SITE INFECTION; IDIOPATHIC SCOLIOSIS PATIENTS; CLOSED-SUCTION
   DRAINAGE; FUSION; ASSOCIATION; PREVENTION; GUIDELINE; OUTCOMES; THERAPY
AB OBJECTIVE: Surgical site infections (SSIs) complicate 1% to 9% of elective spine surgeries. Previously identified risk factors include diabetes mellitus type 2, obesity, and chronic kidney disease. We sought to determine whether the use of postoperative surgical site drains is associated with deep SSIs.
   METHODS: We retrospectively identified patients operated for deep SSIs after surgery for degenerative spine pathologies between July 2016 and December 2018. Patients were excluded if the reason for operation was other than deep SSI or if their primary operation was for infection or tumor. Using their index procedure and the electronic medical record, patients were matched to controls based on age, surgical invasiveness, International Classification of Diseases, Tenth Revision, Clinical Modification code, race, and sex. Our main outcome of interest was whether drain retention time, total output, or daily output differed significantly between cases and controls.
   RESULTS: We identified 38 patients who met inclusion criteria. Infected patients had a higher body mass index (34.2 vs. 29.9 kg/m(2); P = 0.001), higher odds of having diabetes mellitus type 2 (55.3% vs. 18.4%; P = 0.002), longer drain retention time (5.5 vs. 3.5 days; P = 0.02), and longer inpatient stay (9.5 vs. 4.3 days; P = 0.005). Multivariable logistic regression demonstrated that even after controlling for the other risk factors, drain retention time independently predicted postoperative surgical site infection (odds ratio: 1.36; P = 0.02).
   CONCLUSIONS: Prolonged surgical drain retention correlates with risk of deep SSI after surgery for degenerative spine disease independent of surgical invasiveness, diabetes mellitus type 2 status, and total drain output. Our data suggest early postoperative drain removal may potentially decrease the risk of SSI and shorten duration of hospital stay.
C1 [Pennington, Zach; Lubelski, Daniel; Molina, Camilo; Westbroek, Erick M.; Ahmed, A. Karim; Sciubba, Daniel M.] Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
RP Sciubba, DM (reprint author), Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
EM dsciubb1@jhmi.edu
OI Pennington, Zachary/0000-0001-8012-860X
CR Adogwa Owoicho, 2018, J Spine Surg, V4, P220, DOI 10.21037/jss.2018.05.09
   Adogwa Owoicho, 2018, J Spine Surg, V4, P227, DOI 10.21037/jss.2018.05.10
   Anderson PA, 2017, NEUROSURGERY, V80, pS114, DOI 10.1093/neuros/nyw066
   Badia JM, 2017, J HOSP INFECT, V96, P1, DOI 10.1016/j.jhin.2017.03.004
   Barker FG, 2002, NEUROSURGERY, V51, P391, DOI 10.1097/00006123-200208000-00017
   Berrios SI, 2017, JAMA SURG, V152, P784, DOI 10.1001/jamasurg.2017.0904
   Casper DS, 2018, SPINE, V43, P223, DOI 10.1097/BRS.0000000000002277
   CERISE EJ, 1970, ANN SURG, V171, P764, DOI 10.1097/00000658-197005000-00016
   Chen CF, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005605
   Chen Zhao-Yu, 2014, Eur J Orthop Surg Traumatol, V24, P939, DOI 10.1007/s00590-013-1284-0
   Chimenti P, 2013, J SPINAL CORD MED, V36, P213, DOI 10.1179/2045772312Y.0000000070
   Diab M, 2012, SPINE, V37, P966, DOI 10.1097/BRS.0b013e31823bbf0b
   Felippe WAB, 2007, WORLD J SURG, V31, P2293, DOI 10.1007/s00268-007-9248-3
   Glennie RA, 2015, J CLIN NEUROSCI, V22, P1081, DOI 10.1016/j.jocn.2015.01.009
   He XQ, 2019, CLIN SPINE SURG, V32, P150, DOI 10.1097/BSD.0000000000000778
   Henry J., 2016, HOSP ADJUSTED EXPENS
   Herrick DB, 2018, J NEUROSURG-SPINE, V29, P628, DOI 10.3171/2018.5.SPINE171313
   Kamath VHD, 2016, EUR SPINE J, V25, P3242, DOI 10.1007/s00586-016-4491-7
   Kanayama M, 2010, CLIN ORTHOP RELAT R, V468, P2690, DOI 10.1007/s11999-010-1235-6
   Kobayashi K, 2017, CLIN SPINE SURG, V30, P356, DOI 10.1097/BSD.0000000000000326
   Kuhns BD, 2015, J NEUROSURG-SPINE, V22, P381, DOI 10.3171/2014.10.SPINE14228
   Lee JJ, 2019, WORLD NEUROSURG, V126, pE196, DOI 10.1016/j.wneu.2019.01.293
   Liu YC, 2016, J ORTHOP SURG RES, V11, DOI 10.1186/s13018-016-0351-8
   Macki M, 2017, J CLIN NEUROSCI, V40, P44, DOI 10.1016/j.jocn.2016.12.008
   Mangram AJ, 1999, AM J INFECT CONTROL, V27, P97, DOI 10.1016/S0196-6553(99)70088-X
   McGirt MJ, 2011, J NEUROSURG-SPINE, V14, P771, DOI 10.3171/2011.1.SPINE10571
   Mehta AI, 2012, SPINE, V37, P1652, DOI 10.1097/BRS.0b013e318241b186
   Mehta AI, 2013, J BONE JOINT SURG AM, V95A, P323, DOI 10.2106/JBJS.L.00225
   Meng F, 2015, J CLIN NEUROSCI, V22, P1862, DOI 10.1016/j.jocn.2015.03.065
   Neuman BJ, 2018, NEUROSURGERY, V82, P847, DOI 10.1093/neuros/nyx303
   Park P, 2018, NEUROSURGERY, P1
   Pawar AY, 2016, ASIAN SPINE J, V10, P176, DOI 10.4184/asj.2016.10.1.176
   Ramo BA, 2014, J BONE JOINT SURG AM, V96A, P2038, DOI 10.2106/JBJS.N.00277
   Ranson WA, 2018, GLOB SPINE J, V8, P834, DOI 10.1177/2192568218775960
   RAVES JJ, 1984, AM J SURG, V148, P618, DOI 10.1016/0002-9610(84)90336-2
   Reiffel AJ, 2013, SURG INFECT, V14, P244, DOI 10.1089/sur.2011.126
   Saleh K, 2002, J ORTHOPAED RES, V20, P506, DOI 10.1016/S0736-0266(01)00153-X
   Savage JW, 2013, SPINE J, V13, P1017, DOI 10.1016/j.spinee.2013.03.051
   Smith JS, 2011, SPINE, V36, P556, DOI 10.1097/BRS.0b013e3181eadd41
   SORENSEN AI, 1991, ACTA ORTHOP SCAND, V62, P451, DOI 10.3109/17453679108996642
   Steiner CA, 2014, SURG HOSP BASED AMBU
   Wang LL, 2017, J ORTHOP SCI, V22, P254, DOI 10.1016/j.jos.2016.12.006
   Yao R, 2018, GLOB SPINE J, V8, p5S, DOI 10.1177/2192568218799056
   Zhang QD, 2011, J ARTHROPLASTY, V26, P1265, DOI 10.1016/j.arth.2011.02.005
NR 44
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E846
EP E853
DI 10.1016/j.wneu.2019.07.013
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200107
PM 31295586
DA 2020-05-12
ER

PT J
AU Peshes-Yeloz, N
   Ungar, L
   Wohl, A
   Jacoby, E
   Fisher, T
   Leitner, M
   Nass, D
   Rubinek, T
   Wolf, I
   Cohen, ZR
AF Peshes-Yeloz, Naama
   Ungar, Lior
   Wohl, Anton
   Jacoby, Elad
   Fisher, Tamar
   Leitner, Moshe
   Nass, Dvora
   Rubinek, Tamar
   Wolf, Ido
   Cohen, Zvi R.
TI Role of Klotho Protein in Tumor Genesis, Cancer Progression, and
   Prognosis in Patients with High-Grade Glioma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Glioblastoma; Klotho
ID SUPPRESSOR; GLIOBLASTOMA; APOPTOSIS; MUTATION; HORMONE; GROWTH; BRAIN;
   CELLS; RISK; MICE
AB BACKGROUND: Klotho, a single-pass transmembrane protein associated with premature aging, acts as a tumor suppressor gene by inhibiting insulin/insulin-like growth factor-1 and fibroblast growth factor pathways. Downregulated Klotho expression is reported in melanoma, mesothelioma, bladder, breast, gastric, cervix, lung, and kidney cancers and is associated with a poor prognosis. Klotho expression and Klotho promoter hypermethylation are predictive factors for patient prognosis.
   METHODS: To investigate the potential role of Klotho in glioblastoma-multiforme (GBM), 22 GBM samples were collected from the Sheba Tumor Bank and examined.
   RESULTS: We found that increased Klotho messenger ribonucleic acid (RNA) expression predicted longer survival (P = 0.03) of GBM patients. Methylation analysis was performed on bisulfite-treated deoxyribonucleic acid from the GBM patient samples using ionization time-of-flight mass spectrometry according to the Sequenom EpiTYPER protocols. Klotho promoter hypermethylation was detected in 65% of the GBM samples and correlated significantly with improved survival (P < 0.04). We found 3 major Klotho promotor hypermethylation sites located 585-579 bp, 540-533 bp, and 537-534 bp upstream of the transcription start site. Methylated deoxyribonucleic acid immunoprecipitation studies confirmed these results. Notably, the messenger RNA expression in these GBM samples revealed an unexpected linear correlation with methylation of these 3 hypermethylation sites identified in the Klotho promotor. Thus Klotho expression and methylation could predict prognosis in patients with GBM.
   CONCLUSIONS: Epigenetic regulation in GBM appears to be complicated. Specific CpG islands affect genes or micro RNAs that interact to control Klotho expression. The diverse effects of these islands may be due to unique factors of GBM.
C1 [Peshes-Yeloz, Naama; Ungar, Lior; Wohl, Anton; Cohen, Zvi R.] Sheba Med Ctr, Dept Neurosurg, Ramat Gan, Israel.
   [Peshes-Yeloz, Naama; Ungar, Lior; Wohl, Anton; Jacoby, Elad; Fisher, Tamar; Leitner, Moshe; Nass, Dvora; Rubinek, Tamar; Wolf, Ido; Cohen, Zvi R.] Sackler Sch Med, Tel Aviv, Israel.
   [Jacoby, Elad; Fisher, Tamar; Leitner, Moshe] Sheba Med Ctr, Canc Res Ctr, Ramat Gan, Israel.
   [Nass, Dvora] Sheba Med Ctr, Inst Pathol, Ramat Gan, Israel.
   [Rubinek, Tamar; Wolf, Ido] Tel Aviv Med Ctr & Sch Med, Inst Oncol, Tel Aviv, Israel.
RP Cohen, ZR (reprint author), Sheba Med Ctr, Dept Neurosurg, Ramat Gan, Israel.; Cohen, ZR (reprint author), Sackler Sch Med, Tel Aviv, Israel.
EM zvi.cohen@sheba.health.gov.il
FU Sackler School of Medicine, Tel Aviv University
FX This research was supported by internal research funding of the Sackler
   School of Medicine, Tel Aviv University.
CR Abramovitz L, 2011, CLIN CANCER RES, V17, P4254, DOI 10.1158/1078-0432.CCR-10-2749
   Baluchnejadmojarad T, 2017, EXP GERONTOL, V100, P70, DOI 10.1016/j.exger.2017.10.023
   Bezecny P, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0985-5
   Bier A, 2013, ONCOTARGET, V4, P665, DOI 10.18632/oncotarget.928
   Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034
   Chang B, 2012, ONCOL REP, V28, P1022, DOI 10.3892/or.2012.1865
   Chen B, 2012, CANCER BIOL THER, V13, P1221, DOI 10.4161/cbt.21420
   Chen B, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-99
   Chen CD, 2015, J MOL NEUROSCI, V55, P76, DOI 10.1007/s12031-014-0336-1
   Chen CD, 2013, J NEUROSCI, V33, P1927, DOI 10.1523/JNEUROSCI.2080-12.2013
   Chen TH, 2013, EUR J PHARMACOL, V698, P67, DOI 10.1016/j.ejphar.2012.09.032
   Gan Li-hong, 2011, Zhejiang Da Xue Xue Bao Yi Xue Ban, V40, P309
   Jiang B, 2014, CANCER INVEST, V32, P218, DOI 10.3109/07357907.2014.905586
   Kim HJ, 2014, MOL BIOL REP, V41, P7595, DOI 10.1007/s11033-014-3647-y
   Kroeger KM, 2010, DISCOV MED, V10, P293
   Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285
   Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766
   Le Mercier M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045475
   Li SA, 2004, CELL STRUCT FUNCT, V29, P91, DOI 10.1247/csf.29.91
   Martinez R, 2010, NEUROBIOL DIS, V39, P40, DOI 10.1016/j.nbd.2009.12.030
   Mehi SJ, 2014, AGE, V36, P141, DOI 10.1007/s11357-013-9555-6
   Nagai T, 2002, FASEB J, V16, P50, DOI 10.1096/fj.02-0448fje
   Nagarajan RP, 2009, SEMIN CANCER BIOL, V19, P188, DOI 10.1016/j.semcancer.2009.02.005
   Neidert MC, 2013, EUR J ENDOCRINOL, V168, P575, DOI 10.1530/EJE-12-1045
   Polivka J, 2012, ANTICANCER RES, V32, P2935
   Rubinek T, 2012, BREAST CANCER RES TR, V133, P649, DOI 10.1007/s10549-011-1824-4
   Schmid C, 2013, J ENDOCRINOL, V219, pR37, DOI 10.1530/JOE-13-0285
   Shiozaki M, 2008, NEUROSCIENCE, V152, P924, DOI 10.1016/j.neuroscience.2008.01.032
   Shu GS, 2013, CELL ONCOL, V36, P121, DOI 10.1007/s13402-012-0118-0
   Vitucci M, 2011, BRIT J CANCER, V104, P545, DOI 10.1038/sj.bjc.6606031
   Wang LJ, 2011, AM J CANCER RES, V1, P111
   Wolf I, 2010, ONCOGENE, V29, P26, DOI 10.1038/onc.2009.301
   Wolf I, 2008, ONCOGENE, V27, P7094, DOI 10.1038/onc.2008.292
   Wong ET, 1999, J CLIN ONCOL, V17, P2572, DOI 10.1200/JCO.1999.17.8.2572
   Xie B, 2013, PATHOL ONCOL RES, V19, P611, DOI 10.1007/s12253-013-9663-8
   Xie BA, 2013, HUM PATHOL, V44, P795, DOI 10.1016/j.humpath.2012.07.023
   Zhou X, 2014, J CANCER RES CLIN, V141, P961
   Zhu Y, 2013, CANCER SCI, V104, P663, DOI 10.1111/cas.12134
NR 38
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E324
EP E332
DI 10.1016/j.wneu.2019.06.082
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200038
PM 31228703
DA 2020-05-12
ER

PT J
AU Phang, I
   Leach, J
   Leggate, JRS
   Karabatsou, K
   Coope, D
   D'Urso, PI
AF Phang, Isaac
   Leach, John
   Leggate, James R. S.
   Karabatsou, Konstantina
   Coope, David
   D'Urso, Pietro I.
TI Minimally Invasive Resection of Brain Metastases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain metastasis; Minimally invasive
ID RANDOMIZED-TRIAL; SINGLE; SURGERY
AB BACKGROUND: Minimally invasive resection of brain metastases aims to maximize resection while minimizing brain trauma.
   METHODS: Patients with 1 or more metastases that underwent resection following neuro-oncology multidisciplinary meeting discussion from September 2014 to October 2018, with pre- and postoperative magnetic resonance imaging, were included. All patients including posterior fossa metastases or multiple metastases were positioned supine. Hair was not shaved. Volumetric post-contrast T1 magnetic resonance imaging was used for incision planning and neuronavigation. The craniotomy site was tailored to tumor depth according to keyhole principles and ranged between 2 and 5 cm. Intraoperative monitoring and awake mapping were carried out in selected cases.
   RESULTS: Out of 320 consecutive patients with brain metastases, 44 patients were identified as suitable for minimally invasive resection. Nine patients had no postoperative imaging and were excluded. There were 38 metastases in 35 patients. There were 18 cerebellar metastases, 10 frontal, 3 parietal, 3 occipital, 2 temporal, 1 intraventricular, and 1 basal ganglia. Median length of stay was 3 days (range, 1-24). Average tumor volume was 54.7 cm(3) (range, 10-240 cm(3)). Endoscopic assistance was used in 4 patients. Median performance status improved from 2 to 1 (range, preoperative: 0-4; postoperative: 0-2). Median survival was 14.7 months.
   CONCLUSIONS: Minimally invasive resection of brain metastasis is safe and effective, and in selected cases confers advantages compared with standard techniques.
C1 [Phang, Isaac; Leach, John; Leggate, James R. S.; Karabatsou, Konstantina; Coope, David; D'Urso, Pietro I.] Salford Royal NHS Fdn Trust, Dept Neurosurg, Stott Lane, Salford, Lancs, England.
RP D'Urso, PI (reprint author), Salford Royal NHS Fdn Trust, Dept Neurosurg, Stott Lane, Salford, Lancs, England.
EM pietro.durso@srft.nhs.uk
RI D'Urso, Pietro/AAL-8919-2020
OI D'Urso, Pietro Ivo/0000-0002-8823-3938; Coope, David/0000-0003-2110-8670
CR Baker CM, 2017, WORLD NEUROSURG, V106, P359, DOI [10.1016/J.WNEU.2017.06.118, 10.1016/j.wneu.2017.06.118]
   Fischer G, 2011, NEUROSURGERY, V68, DOI 10.1227/NEU.0b013e31820934ca
   Gazzeri R, 2014, CLIN NEUROL NEUROSUR, V123, P117, DOI 10.1016/j.clineuro.2014.05.010
   Hardesty DA, 2015, WORLD NEUROSURG, V83, P479, DOI 10.1016/j.wneu.2014.08.056
   Ma RC, 2018, WORLD NEUROSURG, V117, pE238, DOI 10.1016/j.wneu.2018.06.006
   Marcus HJ, 2014, BRIT J NEUROSURG, V28, P606, DOI 10.3109/02688697.2014.887654
   Mintz AH, 1996, CANCER, V78, P1470, DOI 10.1002/(SICI)1097-0142(19961001)78:7<1470::AID-CNCR14>3.0.CO;2-X
   PATCHELL RA, 1990, NEW ENGL J MED, V322, P494, DOI 10.1056/NEJM199002223220802
   Plaha P, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.07.034
   Teo C, 2015, PRINCIPLES PRACTICE
   Wilson DA, 2014, WORLD NEUROSURG, V82, pE243, DOI 10.1016/j.wneu.2013.02.002
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E362
EP E367
DI 10.1016/j.wneu.2019.06.091
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200044
PM 31233927
DA 2020-05-12
ER

PT J
AU Puyana, C
   Denyer, S
   Burch, T
   Bhimani, AD
   McGuire, LS
   Patel, AS
   Mehta, AI
AF Puyana, Carolina
   Denyer, Steven
   Burch, Taylor
   Bhimani, Abhiraj D.
   McGuire, Laura S.
   Patel, Akash S.
   Mehta, Ankit, I
TI Primary Malignant Melanoma of the Brain: A Population-Based Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chemotherapy; CNS melanoma; Malignant melanoma; Melanoma survival;
   Radiotherapy; SEER
ID CENTRAL-NERVOUS-SYSTEM; INTRACRANIAL MELANOMA; METASTASES
AB BACKGROUND: Primary melanocytic neoplasms of the central nervous system (CNS) are rare and account for 1% of all melanomas. This study used the Surveillance, Epidemiology, and End Results (SEER) database to evaluate the epidemiology of primary CNS melanoma and further characterize their treatment.
   METHODS: Data from the National Cancer Institute SEER program, collected from 1973-2015, were retrospectively analyzed. A total of 86 records of malignant melanoma cases with CNS as the primary site were identified, and 54 patients were studied based on the inclusion criteria. Demographic, tumor, and treatment regimen effectiveness were studied.
   RESULTS: A total of 54 patients were included in this study. Tumors were distributed evenly in size and localized primarily to the cerebral meninges and spinal cord. A total of 13% of patients underwent biopsy, 40.7% gross total resection (GTR), 7.4% subtotal resection (STR), 46.3% radiation therapy (RT), and 27.3% chemotherapy (CT) in a variety of treatment combinations. GTR alone and STR + RT resulted in increased disease-specific survival compared to biopsy alone, but no survival benefit was found with biopsy with RT and/or CT as well as STR alone.
   CONCLUSIONS: To our knowledge, this is the largest single database study completed for primary malignant melanoma of the CNS. The study identified the need for tumor resection for the proper treatment of these lesions, particularly GTR. GTR could be paired with adjuvant RT or RT + CT providing survival benefit as well. In cases when GTR is unable to be completed, STR + RT provides significant improvement in survival compared to biopsy alone.
C1 [Puyana, Carolina; Denyer, Steven; Burch, Taylor; Bhimani, Abhiraj D.; McGuire, Laura S.; Patel, Akash S.; Mehta, Ankit, I] Univ Illinois, Dept Neurosurg, Chicago, IL 60607 USA.
   [Bhimani, Abhiraj D.] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
RP Mehta, AI (reprint author), Univ Illinois, Dept Neurosurg, Chicago, IL 60607 USA.
EM ankitm@uic.edu
RI Mehta, Ankit/AAL-3851-2020
OI Denyer, Steven/0000-0001-5631-8788; Puyana, Carolina/0000-0002-9601-1120
CR BAENA RRY, 1992, SURG NEUROL, V38, P26, DOI 10.1016/0090-3019(92)90208-5
   Balakrishnan R, 2015, CASE REP ONCOL MED, DOI 10.1155/2015/293802
   Bhandari L, 2012, TURK NEUROSURG, V22, P469, DOI 10.5137/1019-5149.JTN.3632-10.2
   Brat DJ, 1999, AM J SURG PATHOL, V23, P745, DOI 10.1097/00000478-199907000-00001
   Crasto SG, 2001, SURG NEUROL, V55, P163, DOI 10.1016/S0090-3019(01)00348-2
   Doll KM, 2018, JAMA SURG, V153, P588, DOI 10.1001/jamasurg.2018.0501
   Farrokh D, 2001, AM J NEURORADIOL, V22, P1864
   Fujimori K, 2018, NEUROSURG REV, V41, P333, DOI 10.1007/s10143-017-0914-0
   Gempt J, 2011, J NEURO-ONCOL, V102, P323, DOI 10.1007/s11060-010-0311-9
   GIBSON JB, 1957, J PATHOL BACTERIOL, V74, P419, DOI 10.1002/path.1700740220
   Han CH, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00230
   HAYWARD RD, 1976, J NEUROL NEUROSUR PS, V39, P526, DOI 10.1136/jnnp.39.6.526
   Jaiswal S, 2011, NEUROL INDIA, V59, P413, DOI 10.4103/0028-3886.82758
   Kim MS, 2010, J KOREAN NEUROSURG S, V48, P157, DOI 10.3340/jkns.2010.48.2.157
   Kusters-Vandevelde HVN, 2015, BRAIN PATHOL, V25, P209, DOI 10.1111/bpa.12241
   LARSON TC, 1987, J NEUROSURG, V66, P47, DOI 10.3171/jns.1987.66.1.0047
   Liubinas SV, 2010, J CLIN NEUROSCI, V17, P1227, DOI 10.1016/j.jocn.2010.01.017
   Ma YF, 2015, ONCOL LETT, V10, P2171, DOI 10.3892/ol.2015.3537
   Nishihara M, 2009, NEUROL MED-CHIR, V49, P546, DOI 10.2176/nmc.49.546
   OZDEN B, 1984, NEUROSURGERY, V15, P104
   Pan ZY, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-265
   Salpietro FM, 1998, J NEUROSURG, V89, P659, DOI 10.3171/jns.1998.89.4.0659
   Smith AB, 2009, RADIOGRAPHICS, V29, P1503, DOI 10.1148/rg.295095109
   Troya-Castilla M, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0965-7
   Virchow R, 1859, ARCH PATHOL ANAT, V16, P180, DOI DOI 10.1007/BF01945262
   Wang J, 2014, EJSO-EUR J SURG ONC, V40, P1062, DOI 10.1016/j.ejso.2013.11.024
   YAMASAKI T, 1989, NEUROSURGERY, V25, P117, DOI 10.1227/00006123-198907000-00023
   Young GJ, 2017, ONCOTARGET, V8, P89326, DOI 10.18632/oncotarget.19223
   Yu J, 2012, J INT MED RES, V40, P1207, DOI 10.1177/147323001204000341
NR 29
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E1091
EP E1097
DI 10.1016/j.wneu.2019.07.095
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200135
PM 31323401
DA 2020-05-12
ER

PT J
AU Ramos, CL
   Williams, JE
   Bababekov, YJ
   Chang, DC
   Carter, BS
   Jones, PS
AF Ramos, Christian Lopez
   Williams, Jonathan E.
   Bababekov, Yanik J.
   Chang, David C.
   Carter, Bob S.
   Jones, Pamela S.
TI Assessing the Understandability and Actionability of Online
   Neurosurgical Patient Education Materials
SO WORLD NEUROSURGERY
LA English
DT Article
DE CCI; Health literacy; Neurosurgery; Patient education materials; PEMAT
ID MATERIALS ASSESSMENT-TOOL; HEALTH LITERACY; READABILITY ASSESSMENT;
   INTERNET INFORMATION; OUTCOMES; OTOLARYNGOLOGY; QUALITY; HEAD
AB BACKGROUND: Most Americans consult the Internet to address their health concerns. Limited health literacy among the public highlights the need for patient education Web sites to deliver understandable health information. We assessed the understandability and actionability of online neurosurgical patient education materials (PEMs) provided by the American Association of Neurological Surgeons (AANS) and MedlinePlus.
   METHODS: Articles on neurosurgical conditions and treatments listed on both the AANS site and MedlinePlus were analyzed. Two reviewers scored articles using 2 validated health literacy tools, the Centers for Disease Control and Prevention Clear Communication Index (CCI) and the Agency for Healthcare Research and Quality (AHRQ) Patient Education Materials Assessment Tool (PEMAT). These tools evaluate the quality of written health information and assess for content, organization, and actionability of PEMs.
   RESULTS: One hundred and thirty-eight articles were evaluated from the AANS (n = 61) and MedlinePlus (n = 77). The median CCI score for MedlinePlus and AANS articles was 68.9 {interquartile range [IQR], 62.5-81.3) and 56.3 [IQR, 46.7-73.7], respectively (P < 0.001). Only 1 article scored >= 90%, which is the CCI threshold for PEMs to be considered easy to read. Although the AANS and Medline performed similarly on the understandability component of the PEMAT (66.7 [IQR, 53.8-69.2] vs. 69.2 [IQR, 66.7-83.3], respectively; P < 0.001), significant differences were observed for the actionability section of the PEMAT (Medline 60 [IQR, 60-60] vs. AANS 0 [IQR, 0-60]; P < 0.001). Less than 13% of articles provided summaries, visual aids, and tangible tools to aid patient action.
   CONCLUSIONS: Neurosurgical online PEMs may be difficult to understand and potentially act as barriers for patients' engagement with health systems. There is a need to deliver patient-centered health information that effectively informs patients, aiding in meaningful health decision making.
C1 [Ramos, Christian Lopez] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA.
   [Williams, Jonathan E.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
   [Bababekov, Yanik J.; Chang, David C.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
   [Carter, Bob S.; Jones, Pamela S.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
   [Bababekov, Yanik J.; Chang, David C.] Massachusetts Gen Hosp, Codman Ctr Surg & Outcomes Res, Boston, MA 02114 USA.
RP Jones, PS (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
EM psjones@partners.org
CR Agarwal N, 2017, J NEUROSURG, V126, P1263, DOI 10.3171/2015.12.JNS151102
   Agarwal N, 2015, WORLD NEUROSURG, V84, P1223, DOI 10.1016/j.wneu.2015.06.024
   Agarwal N, 2013, J CLIN NEUROSCI, V20, P1357, DOI 10.1016/j.jocn.2012.10.047
   Agency for Healthcare Research and Quality, 2017, PAT ED MAT ASS TOOL
   American Association of Neurological Surgeons, 2017, NEUR COND TREAT
   Bababekov YJ, 2019, TRANSPLANTATION, V103, P522, DOI 10.1097/TP.0000000000002536
   Baker DW, 2008, J GEN INTERN MED, V23, P723, DOI 10.1007/s11606-008-0566-4
   Balakrishnan V, 2016, OTOLARYNG HEAD NECK, V154, P460, DOI 10.1177/0194599815626146
   Baur C, 2014, HEALTH PROMOT PRACT, V15, P629, DOI 10.1177/1524839914538969
   Berkman ND, 2011, ANN INTERN MED, V155, P97, DOI 10.7326/0003-4819-155-2-201107190-00005
   Centers for Disease Control and Prevention, 2014, CLEAR COMM IND US GU
   Colaco M, 2013, J UROLOGY, V189, P1048, DOI 10.1016/j.juro.2012.08.255
   Edmunds MR, 2013, JAMA OPHTHALMOL, V131, P1610, DOI 10.1001/jamaophthalmol.2013.5521
   Fox S, 2013, HLTH ONLINE 2013
   Greywoode J, 2009, OTOLARYNG HEAD NECK, V141, P555, DOI 10.1016/j.otohns.2009.08.004
   Grubbs V, 2009, CLIN J AM SOC NEPHRO, V4, P195, DOI 10.2215/CJN.03290708
   Gupta R, 2017, J NEUROSURG, V127, P278, DOI 10.3171/2016.5.JNS16793
   Haas K, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6278-8
   Huang G, 2015, JAMA OPHTHALMOL, V133, P449, DOI 10.1001/jamaophthalmol.2014.6104
   Kutner M., 2006, HLTH LITERACY AM ADU
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Maciolek KA, 2017, UROLOGY, V109, P101, DOI 10.1016/j.urology.2017.07.037
   McClure E, 2016, PREV CHRONIC DIS, V13, DOI 10.5888/pcd13.150478
   National Institutes of Health, 2017, MEDLINEPLUS
   Nielsen-Bohlman L., 2004, HLTH LITERACY PRESCR
   Perks A, 2009, J NEUROSURG ANESTH, V21, P127, DOI 10.1097/ANA.0b013e31819a6ca3
   Peterson PN, 2011, JAMA-J AM MED ASSOC, V305, P1695, DOI 10.1001/jama.2011.512
   Ramos RD, 2017, NEUROSURGERY, V81, P422, DOI 10.1093/neuros/nyx055
   Ryu JH, 2016, SPINE, V41, pE561, DOI 10.1097/BRS.0000000000001321
   Saeed F, 2017, WORLD NEUROSURG, V97, P312, DOI 10.1016/j.wneu.2016.10.001
   Schmitt Paul J, 2013, World Neurosurg, V80, pe33, DOI 10.1016/j.wneu.2011.09.007
   Shoemaker SJ, 2014, PATIENT EDUC COUNS, V96, P395, DOI 10.1016/j.pec.2014.05.027
   Storino A, 2016, JAMA SURG, V151, P831, DOI 10.1001/jamasurg.2016.0730
   Stossel LM, 2012, J GEN INTERN MED, V27, P1165, DOI 10.1007/s11606-012-2046-0
   Svider PF, 2013, AM J OTOLARYNG, V34, P31, DOI 10.1016/j.amjoto.2012.08.001
   Tran BNN, 2018, CANCER-AM CANCER SOC, V124, P769, DOI 10.1002/cncr.31113
   U.S. Department of Health and Human Services, 2010, NAT ACT PLAN IMPR HL
   Volsky PG, 2012, INT J PEDIATR OTORHI, V76, P1312, DOI 10.1016/j.ijporl.2012.05.026
   Wong K, 2017, HEAD NECK-J SCI SPEC, V39, P2256, DOI 10.1002/hed.24891
   Wright JP, 2018, JAMA SURG, V153, P137, DOI 10.1001/jamasurg.2017.3832
   Wu DTY, 2016, J AM MED INFORM ASSN, V23, P269, DOI 10.1093/jamia/ocv062
NR 41
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E588
EP E597
DI 10.1016/j.wneu.2019.06.166
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200074
PM 31260846
DA 2020-05-12
ER

PT J
AU Rao, HM
   Huang, YM
   Lan, ZB
   Xu, ZQ
   Li, GS
   Xu, WH
AF Rao, Hongming
   Huang, Yuming
   Lan, Zhibin
   Xu, Zhengquan
   Li, Guishuang
   Xu, Weihong
TI Does Preoperative T1 Slope and Cervical Lordosis Mismatching Affect
   Surgical Outcomes After Laminoplasty in Patients with Cervical
   Spondylotic Myelopathy?
SO WORLD NEUROSURGERY
LA English
DT Article
DE C2-C7 lordosis; Cervical spondylotic myelopathy; Kyphotic alignment
   change; Laminoplasty; Sagittal alignment; T1 slope
ID OPEN-DOOR LAMINOPLASTY; SAGITTAL BALANCE; FOLLOW-UP; ALIGNMENT;
   CURVATURE; PREDICTOR; DEFORMITY; SPINE
AB OBJECTIVE: To assess whether preoperative T1 slope and cervical lordosis mismatching affect the surgical outcomes of patients with cervical spondylotic myelopathy (CSM) after laminoplasty.
   METHODS: A total of 85 patients with CSM who underwent unilateral open-door laminoplasty between January 2013 and May 2017 were retrospectively reviewed. Based on preoperative T1 slope and C2-C7 lordosis matching, the patients were divided into 2 groups: the match group and the mismatch group. The T1 slope minus C2-C7 lordosis (T1S-CL) <20 was defined as matching. Radiographic parameters included T1 slope, C2-C7 lordosis, C2-C7 sagittal vertical axis (SVA), and T1S-CL. Clinical outcomes were based on the Neck Disability Index (NDI) and Japanese Orthopedic Association (JOA) scores.
   RESULTS: The preoperative T1S-CL had significant correlation with T1 slope (r = 0.283), C2-C7 lordosis (r = -0.611), and C2-C7 SVA (r = 0.331). At the final follow-up, patients in the mismatch group had a higher incidence of postoperative cervical kyphosis (P = 0.007) and C2-C7 SVA >40 mm (P = 0.043). The mismatch group also had greater Delta C2-C7 lordosis (P = 0.028), Delta C2-C7 SVA (P = 0.042), and Delta T1S-CL = 0.044). Comparison of clinical outcomes revealed that patients in the match group had better NDI and JOA recovery (P < 0.05).
   CONCLUSIONS: T1S-CL is a clinically relevant parameter for surgical decision making because patients with T1S-CL mismatching are more likely to have postoperative kyphotic alignment changes and cervical sagittal imbalance. Laminoplasty might not be a suitable option for patients with T1S-CL mismatching.
C1 [Rao, Hongming; Lan, Zhibin; Xu, Zhengquan; Li, Guishuang; Xu, Weihong] Fujian Med Univ, Affiliated Hosp 1, Dept Spine Surg, Fuzhou, Fujian, Peoples R China.
   [Huang, Yuming] Xiamen Univ, Fuzhou Hosp 2, Orthoped Dept, Fuzhou, Fujian, Peoples R China.
RP Xu, WH (reprint author), Fujian Med Univ, Affiliated Hosp 1, Dept Spine Surg, Fuzhou, Fujian, Peoples R China.
EM xwhfygk@163.com
OI Lan, Zhibin/0000-0001-8610-7244; Huang, Yuming/0000-0002-7693-6417
CR Aita I, 2000, J BONE JOINT SURG AM, V82A, P1743, DOI 10.2106/00004623-200012000-00008
   Ames CP, 2015, J NEUROSURG-SPINE, V23, P673, DOI 10.3171/2014.12.SPINE14780
   Chavanne A, 2011, SPINE, V36, P1619, DOI 10.1097/BRS.0b013e3181fc17b0
   Chiba K, 2006, SPINE, V31, P2998, DOI 10.1097/01.brs.0000250307.78987.6b
   Cho JH, 2014, SPINE, V39, pE1575, DOI 10.1097/BRS.0000000000000614
   Du W, 2013, EUR SPINE J, V22, P1594, DOI 10.1007/s00586-013-2741-5
   HIRABAYASHI K, 1981, SPINE, V6, P354, DOI 10.1097/00007632-198107000-00005
   HIRABAYASHI K, 1983, SPINE, V8, P693, DOI 10.1097/00007632-198310000-00003
   Huang YM, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891-018-2378-y
   Hyun SJ, 2019, OPER NEUROSURG, V16, P20, DOI 10.1093/ons/opy055
   Hyun SJ, 2017, SPINE, V42, P1859, DOI 10.1097/BRS.0000000000002250
   Kawaguchi Y, 2016, SPINE, V41, P1570, DOI 10.1097/BRS.0000000000001579
   Kim TH, 2013, SPINE, V38, pE992, DOI 10.1097/BRS.0b013e3182972e1b
   Kwon WK, 2017, SPINE, V42, P318, DOI 10.1097/BRS.0000000000001776
   Lan ZB, 2019, WORLD NEUROSURG, V122, pE1195, DOI 10.1016/j.wneu.2018.11.016
   Lee HD, 2017, SPINE, V42, P1901, DOI 10.1097/BRS.0000000000002256
   Lee SH, 2012, J SPINAL DISORD TECH, V25, pE41, DOI 10.1097/BSD.0b013e3182396301
   Lin SR, 2015, EUR SPINE J, V24, P127, DOI 10.1007/s00586-014-3605-3
   Protopsaltis TS, 2018, SPINE, V43, pE773, DOI 10.1097/BRS.0000000000002524
   Sakai K, 2016, SPINE, V41, P299, DOI 10.1097/BRS.0000000000001206
   Smith JS, 2013, SPINE, V38, pS161, DOI 10.1097/BRS.0b013e3182a7eb9e
   Suda K, 2003, SPINE, V28, P1258, DOI 10.1097/00007632-200306150-00008
   Tang Jessica A, 2015, Neurosurgery, V76 Suppl 1, pS14, DOI 10.1227/01.neu.0000462074.66077.2b
   Villavicencio AT, 2011, NEUROSURGERY, V68, P1309, DOI 10.1227/NEU.0b013e31820b51f3
   Zhang JT, 2017, EUR SPINE J, V26, P1205, DOI 10.1007/s00586-017-4971-4
NR 25
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E687
EP E693
DI 10.1016/j.wneu.2019.06.193
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200087
PM 31279919
DA 2020-05-12
ER

PT J
AU Ravina, K
   Rennert, RC
   Kim, PE
   Strickland, B
   Chun, A
   Russin, JJ
AF Ravina, Kristine
   Rennert, Robert C.
   Kim, Paul E.
   Strickland, Ben A.
   Chun, Alice
   Russin, Jonathan J.
TI Orphaned Middle Cerebral Artery Side-to-Side In Situ Bypass as a
   Favorable Alternative Approach for Complex Middle Cerebral Artery
   Aneurysm Treatment: A Case Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Cerebral revascularization; In situ bypass;
   Intracranial-to-intracranial bypass; Middle cerebral artery
ID MICRONEUROSURGICAL MANAGEMENT; SURGICAL-MANAGEMENT; ANASTOMOSIS;
   OCCLUSION; SURGERY
AB OBJECTIVE: Middle cerebral artery (MCA) aneurysms have continued to be primarily managed microsurgically. In cases of complex MCA aneurysms, revascularization could facilitate effective aneurysm treatment. The MCA candelabra provides excellent candidates for in situ side-to-side bypass. In the present case series, we have described applications of MCA in situ side-to-side bypass for the management of complex MCA aneurysms, along with a review of the pertinent data.
   METHODS: A retrospective review of a prospectively maintained neurosurgical patient database was performed to identify all patients treated with MCA side-to-side in situ bypass. Six consecutive patients were identified and included in the present series, representing a single-surgeon experience from February 2016 to November 2018.
   RESULTS: Of the 6 complex MCA aneurysms, all were unruptured, and one half had been treated via a minipterional approach that also allowed for simultaneous anterior communicating artery aneurysm clipping in 1 case. The median temporary occlusion time for anastomosis was 33 minutes (interquartile range [IQR], 30.3-35 minutes). Bypass patency was confirmed in all cases both intraoperatively and postoperatively. The median hospitalization time was 4.5 days (IQR, 2-8 days). The median follow-up period was 5.5 months (IQR, 2.8-22.3 months). All patients had achieved excellent or good (<= 1) modified Rankin scale scores at discharge and during the follow-up period. No mortalities occurred, and no technical, bypass-related, or ischemic morbidities had developed.
   CONCLUSIONS: Our experience with MCA side-to-side in situ bypass has demonstrated its safety and utility in complex MCA aneurysm management. The favorable anatomy of the MCA branches allows for minimally invasive revascularization and clipping that can potentially reduce the hospitalization time and incidence of perioperative morbidity.
C1 [Ravina, Kristine; Chun, Alice; Russin, Jonathan J.] Univ Southern Calif, Keck Sch Med, Neurorestorat Ctr, Los Angeles, CA 90007 USA.
   [Kim, Paul E.] Univ Southern Calif, Keck Sch Med, Dept Radiol, Los Angeles, CA 90007 USA.
   [Strickland, Ben A.; Russin, Jonathan J.] Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, Los Angeles, CA 90007 USA.
   [Rennert, Robert C.] Univ Calif San Diego, Sch Med, Dept Neurosurg, San Diego, CA 92103 USA.
RP Russin, JJ (reprint author), Univ Southern Calif, Keck Sch Med, Neurorestorat Ctr, Los Angeles, CA 90007 USA.; Russin, JJ (reprint author), Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, Los Angeles, CA 90007 USA.
EM jonathan.russin@med.usc.edu
OI Ravina, Kristine/0000-0002-0927-5719
CR ARTERO JC, 1985, SURG NEUROL, V24, P5, DOI 10.1016/0090-3019(85)90054-0
   Blackburn SL, 2014, STROKE RES TREAT, V2014, DOI 10.1155/2014/348147
   Dashti R, 2007, SURG NEUROL, V67, P553, DOI 10.1016/j.surneu.2007.03.023
   Dashti R, 2007, SURG NEUROL, V67, P441, DOI 10.1016/j.surneu.2006.11.056
   Davies JM, 2014, NEUROSURGERY, V74, pS7, DOI 10.1227/NEU.0000000000000193
   Diaz FG, 1998, NEUROL MED-CHIR, V38, P50, DOI 10.2176/nmc.38.suppl_50
   Elsharkawy A, 2013, NEUROSURGERY, V73, P94, DOI 10.1227/01.neu.0000429842.61213.d5
   Esposito G, 2019, WORLD NEUROSURG, V122, pE349, DOI 10.1016/j.wneu.2018.09.238
   Heros RC, 2001, NEUROSURGERY, V48, P780, DOI 10.1097/00006123-200104000-00017
   Kalani MYS, 2013, NEUROSURGERY, V72, P428, DOI 10.1227/NEU.0b013e3182804381
   Kato N, 2013, ACTA NEUROCHIR, V155, P261, DOI 10.1007/s00701-012-1538-3
   Korja M, 2010, NEUROSURGERY, V67, DOI 10.1227/NEU.0b013e3181f7420e
   Meybodi AT, 2017, J NEUROSURG, V127, P463, DOI 10.3171/2016.7.JNS16772
   Michelozzi C, 2019, J NEUROSURG, V131, P1751, DOI 10.3171/2018.7.JNS18654
   Mori T, 2018, PROCEEDINGS OF 2018 INTERNATIONAL SYMPOSIUM ON INFORMATION THEORY AND ITS APPLICATIONS (ISITA2018), P1, DOI 10.23919/ISITA.2018.8664349
   Nussbaum ES, 2019, J NEUROSURG, V131, P1297, DOI 10.3171/2018.4.JNS172752
   Nussbaum ES, 2019, J NEUROSURG, V130, P1498, DOI 10.3171/2018.1.JNS172466
   Quinones-Hinojosa Alfredo, 2008, Neurosurgery, V62, P1442, DOI 10.1227/01.neu.0000333808.64530.dd
   Ramanathan D, 2012, NEUROSURGERY, V70, P1442, DOI 10.1227/NEU.0b013e31824c046f
   Ramanathan D, 2010, WORLD NEUROSURG, V73, P317, DOI 10.1016/j.wneu.2010.01.025
   Rinne J, 1996, NEUROSURGERY, V38, P2, DOI 10.1097/00006123-199601000-00002
   Rodriguez-Hernandez A, 2013, WORLD NEUROSURG, V80, P103, DOI 10.1016/j.wneu.2012.09.010
   Rodriguez-Hernandez A, 2013, NEUROSURGERY, V72, P415, DOI 10.1227/NEU.0b013e3182804aa2
   Russin JJ, 2017, J CLIN NEUROSCI, V39, P209, DOI 10.1016/j.jocn.2017.01.026
   Sanai N, 2009, NEUROSURGERY, V65, P670, DOI 10.1227/01.NEU.0000348557.11968.F1
   Smith TR, 2015, WORLD NEUROSURG, V84, P942, DOI 10.1016/j.wneu.2015.05.073
   Steiger HJ, 2001, NEUROSURGERY, V49, P743
   Straus DC, 2017, NEUROSURGERY, V80, P759, DOI 10.1093/neuros/nyx064
   van Dijk JMC, 2011, ACTA NEUROCHIR, V153, P2111, DOI 10.1007/s00701-011-1139-6
   Wang L, 2018, WORLD NEUROSURG, V115, P357, DOI 10.1016/j.wneu.2018.04.173
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E971
EP E987
DI 10.1016/j.wneu.2019.07.053
PG 17
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200121
PM 31302280
DA 2020-05-12
ER

PT J
AU Saadeh, YS
   Elswick, CM
   Fateh, JA
   Smith, BW
   Joseph, JR
   Spratt, DE
   Oppenlander, ME
   Park, P
   Szerlip, NJ
AF Saadeh, Yamaan S.
   Elswick, Clay M.
   Fateh, Jibran A.
   Smith, Brandon W.
   Joseph, Jacob R.
   Spratt, Daniel E.
   Oppenlander, Mark E.
   Park, Paul
   Szerlip, Nicholas J.
TI Analysis of Outcomes Between Traditional Open versus Mini-Open Approach
   in Surgical Treatment of Spinal Metastasis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hybrid open approach; Metastatic spinal cord compression; Minimally
   invasive transpedicular technique; Spine oncology
ID EXPANDABLE CAGE RECONSTRUCTION; TRANSPEDICULAR APPROACH; MANAGEMENT;
   DISEASE; DECOMPRESSION; COMPLICATIONS; VERTEBRECTOMY; INSERTION;
   RESECTION; SYSTEM
AB OBJECTIVE: The treatment of spinal metastasis carries significant surgical morbidity, and decompression and stabilization are often necessary. Less invasive techniques may reduce risks and postoperative pain. This study describes the differences between a mini-open (MO) procedure and a traditional open surgery (OS) for symptomatic spinal metastasis, and reports differences in outcome for similar patients undergoing each procedure.
   METHODS: We describe a MO technique and retrospective analysis of 20 OS patients who were matched to 20 MO patients by histology, spinal region, and levels instrumented. MO surgery combined a traditional midline exposure for tumor resection with transfascial pedicle screw fixation. Outcome measures included estimated blood loss (EBL), operative time (OT), length of stay (LOS), transfusion rate, complication rate, ASIA Impairment Scale motor score (AMS), and pain scores. Statistical analysis used unpaired t tests and Fisher exact test.
   RESULTS: Average age of the patients was 58.3 years. Forty-eight percent of patients were women. Average number of levels treated was 5.9. Both groups had similar LOS (P = 0.98), OT (P = 0.30), perioperative complication rates (P = 0.51), transfusion rates (P = 0.33), and AMS (P = 0.17). EBL was found to be significantly lower in the MO group than the open group (805 +/- 138 mL vs. 1732 +/- 359 mL, respectively; P = 0.019). The MO group had a significant reduction in postoperative pain (-1.71 +/- 0.5 vs. 0.33 +/- 0.7, P = 0.018).
   CONCLUSIONS: Although further studies are needed, the MO approach appears to result in decreased blood loss and postoperative pain, without compromising neural element decompression or spinal stability. These findings are consistent with the use of muscle sparing, minimally invasive pedicle screw fixation.
C1 [Saadeh, Yamaan S.; Elswick, Clay M.; Smith, Brandon W.; Joseph, Jacob R.; Oppenlander, Mark E.; Park, Paul; Szerlip, Nicholas J.] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA.
   [Fateh, Jibran A.] Univ Michigan, Sch Med, Ann Arbor, MI USA.
   [Spratt, Daniel E.] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA.
RP Szerlip, NJ (reprint author), Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA.
EM nszerlip@med.umich.edu
RI Spratt, Daniel/AAM-4612-2020
CR Soriano-Sanchez JA, 2015, INT J SPINE SURG, V9, DOI 10.14444/2054
   Bakar D, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.6.FOCUS16166
   Bilsky MH, 2000, SPINE, V25, P2240, DOI 10.1097/00007632-200009010-00016
   BOLAND PJ, 1982, CLIN ORTHOP RELAT R, P95
   BRIDWELL KH, 1988, SPINE, V13, P1383, DOI 10.1097/00007632-198812000-00010
   Brodowicz T, 2012, ANN ONCOL, V23, P2215, DOI 10.1093/annonc/mds009
   Chang CC, 2015, J ORTHOP SURG RES, V10, DOI 10.1186/s13018-015-0255-z
   Chen YJ, 2007, SPINE, V32, pE413, DOI 10.1097/BRS.0b013e318074d6c7
   Cho DC, 2009, SURG NEUROL, V71, P424, DOI 10.1016/j.surneu.2008.02.049
   Choi D, 2017, NEUROSURGERY, V80, pS131, DOI 10.1093/neuros/nyw084
   Chou DA, 2011, J NEUROSURG-SPINE, V14, P71, DOI 10.3171/2010.10.SPINE091009
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931
   Dunning EC, 2012, WORLD J ORTHOP, V3, P114, DOI 10.5312/wjo.v3.i8.114
   Elsamadicy Aladine A, 2018, J Spine Surg, V4, P304, DOI 10.21037/jss.2018.05.14
   Fisher CG, 2010, SPINE, V35, pE1221, DOI 10.1097/BRS.0b013e3181e16ae2
   Gerszten PC, 2000, ONCOLOGY-NY, V14, P1013
   Gokaslan ZL, 1998, J NEUROSURG, V89, P599, DOI 10.3171/jns.1998.89.4.0599
   Jandial Rahul, 2012, Surg Neurol Int, V3, pS362, DOI 10.4103/2152-7806.103869
   Jandial R, 2013, J NEUROSURG-SPINE, V19, P27, DOI 10.3171/2013.4.SPINE12344
   Kendrick DB, 2005, AM J EMERG MED, V23, P828, DOI 10.1016/j.ajem.2005.07.009
   Kienstra GEM, 2000, ARCH NEUROL-CHICAGO, V57, P690, DOI 10.1001/archneur.57.5.690
   Klimo P, 2004, ONCOLOGIST, V9, P188, DOI 10.1634/theoncologist.9-2-188
   Klimo Paul Jr, 2003, Neurosurg Focus, V15, pE1
   Laufer I, 2013, ONCOLOGIST, V18, P744, DOI 10.1634/theoncologist.2012-0293
   Li Shuling, 2012, Clin Epidemiol, V4, P87, DOI 10.2147/CLEP.S28339
   Ling JM, 2014, J CLIN NEUROSCI, V21, P493, DOI 10.1016/j.jocn.2013.02.034
   Mehra R, 2011, CLIN CANCER RES, V17, P3924, DOI 10.1158/1078-0432.CCR-10-3120
   Metcalfe S, 2012, SPINE, V37, P1375, DOI 10.1097/BRS.0b013e318250a172
   Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140-6736(05)66954-1
   Rao PJ, 2014, ORTHOP SURG, V6, P187, DOI 10.1111/os.12114
   Schuchert MJ, 2014, ANN THORAC SURG, V97, P1750, DOI 10.1016/j.athoracsur.2013.09.085
   Sebaaly A, 2018, SPINE J, V18, P1382, DOI 10.1016/j.spinee.2018.01.002
   Spratt DE, 2017, LANCET ONCOL, V18, pE720, DOI 10.1016/S1470-2045(17)30612-5
   Walter J, 2012, J CANCER RES CLIN, V138, P301, DOI 10.1007/s00432-011-1100-3
   Wang JC, 2004, J NEUROSURG-SPINE, V1, P287, DOI 10.3171/spi.2004.1.3.0287
   Wiesner L, 1999, SPINE, V24, P1599, DOI 10.1097/00007632-199908010-00015
   Wiggins G C, 2001, Neurosurg Focus, V11, pe4
NR 38
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E467
EP E474
DI 10.1016/j.wneu.2019.06.121
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200059
PM 31247354
DA 2020-05-12
ER

PT J
AU Schmitt, PJ
   Altafulla, JJ
   Kikuta, S
   Dupont, G
   Iwanaga, J
   Monteith, S
   Litvack, Z
   Dumont, AS
   Tubbs, RS
AF Schmitt, Paul J.
   Altafulla, Juan J.
   Kikuta, Shogo
   Dupont, Graham
   Iwanaga, Joe
   Monteith, Stephen
   Litvack, Zachary
   Dumont, Aaron S.
   Tubbs, R. Shane
TI Internal Thoracic Artery to Vertebral Artery Bypass Surgery: A Cadaveric
   Feasibility Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Internal mammary artery; Revascularization; Transposition; Vascular; V1
   segment
ID POSTERIOR CIRCULATION; MEDICAL-TREATMENT; ORIGIN STENOSIS;
   REVASCULARIZATION; ANGIOPLASTY; RECONSTRUCTION; TRANSPOSITION
AB OBJECTIVE: Posterior circulation strokes account for over one quarter of all ischemic strokes. The frequency of vertebral artery origin stenosis (VAOS) in patients with vertebrobasilar insufficiency (VBI) has been estimated to be as high 26%-32%, and VAOS is the direct cause of posterior circulation strokes in 9% of patients. This association could have a significant genetic component. This study examines the feasibility of the internal thoracic artery (ITA) as a donor vessel for revascularization in patients with VACS.
   METHODS: Ten sides from 5 fresh-frozen white cadaveric necks derived from 3 women and 2 men were used in this study. The mean age of the cadavers at death was 77.2 years (range, 68-88 years). The subclavian artery, vertebral artery, and ITA were dissected. The length and diameter (proximal and distal) of the V1 segment and the length and diameter of the ITA were recorded. Finally, the ITA was transposed to the V1 segment of the vertebral artery (VA1).
   RESULTS: The mean length of the VA1 and its diameter at the proximal and distal parts were 35.51 and 3.69 mm, respectively. The mean length and diameter of the ITA were 26.53 and 3.27 mm, respectively. Rerouting the ITA to the VA1 was feasible without tension on all sides.
   CONCLUSIONS: This study indicates that the ITA is anatomically and hemodynamically an excellent option for bypass surgery in a VACS scenario. We present convincing and reproducible data to aid neurosurgeons in choosing the procedure best suited to their patients.
C1 [Schmitt, Paul J.; Altafulla, Juan J.; Monteith, Stephen; Litvack, Zachary] Swedish Med Ctr, Swedish Neurosci Inst, Seattle, WA USA.
   [Altafulla, Juan J.; Kikuta, Shogo; Dupont, Graham; Iwanaga, Joe; Tubbs, R. Shane] Seattle Sci Fdn, Seattle, WA 98122 USA.
   [Altafulla, Juan J.] St Georges Univ, Dept Anat Sci, St Georges, Grenada.
   [Iwanaga, Joe] Tulane Univ, Dept Neurosurg, New Orleans, LA 70118 USA.
   [Dumont, Aaron S.] Kurume Univ, Dept Anat, Div Gross & Clin Anat, Sch Med, Kurume, Fukuoka, Japan.
   [Tubbs, R. Shane] Hosp Santo Tomas, Neurosurg Dept, Panama City, Panama.
RP Iwanaga, J (reprint author), Seattle Sci Fdn, Seattle, WA 98122 USA.; Iwanaga, J (reprint author), Tulane Univ, Dept Neurosurg, New Orleans, LA 70118 USA.
EM joei@seattlesciencefoundation.org
OI Kikuta, Shogo/0000-0002-2236-2884; Altafulla, Juan/0000-0002-2110-8665
CR Al-Ali F, 2011, STROKE, V42, P2544, DOI 10.1161/STROKEAHA.110.610451
   Albuquerque FC, 2003, NEUROSURGERY, V53, P607, DOI 10.1227/01.NEU.0000079494.87390.28
   BERGUER R, 1981, ANN SURG, V193, P441, DOI 10.1097/00000658-198104000-00008
   BOHMFALK GL, 1979, J NEUROSURG, V51, P628, DOI 10.3171/jns.1979.51.5.0628
   Brasiliense LBC, 2014, NEUROSURGERY, V74, pS102, DOI 10.1227/NEU.0000000000000218
   Compter A, 2015, LANCET NEUROL, V14, P606, DOI 10.1016/S1474-4422(15)00017-4
   Coward LJ, 2007, STROKE, V38, P1526, DOI 10.1161/STROKEAHA.106.471862
   DIAZ FG, 1984, J NEUROSURG, V61, P874, DOI 10.3171/jns.1984.61.5.0874
   Haghighi AB, 2011, J STROKE CEREBROVASC, V20, P369, DOI 10.1016/j.jstrokecerebrovasdis.2011.05.007
   Hanel RA, 2009, NEUROSURGERY, V64, P1043, DOI 10.1227/01.NEU.0000347099.17437.64
   Lutsep HL, 2004, STROKE, V35, P1388, DOI 10.1161/01.STR.0000128708.86762.d6
   Otsuka F, 2013, ANN CARDIOTHORAC SUR, V2, P519, DOI 10.3978/j.issn.2225-319X.2013.07.06
   Perue GLG, 2015, INT J STROKE, V10, P185, DOI 10.1111/ijs.12321
   Rangel-Castilla L, 2015, J NEUROSURG, V122, P671, DOI 10.3171/2014.9.JNS14194
   Sajja Lokeswara Rao, 2015, Asian Cardiovasc Thorac Ann, V23, P88, DOI 10.1177/0218492314523629
   Sarkar S, 2007, MED BIOL ENG COMPUT, V45, P327, DOI 10.1007/s11517-007-0176-z
   Stayman AN, 2011, STROKE, V42, P2212, DOI 10.1161/STROKEAHA.110.611459
   Sun X, 2015, J NEUROINTERV SURG, V7, P888, DOI 10.1136/neurintsurg-2014-011356
   Thompson MC, 2014, J STROKE CEREBROVASC, V23, pE1, DOI 10.1016/j.jstrokecerebrovasdis.2012.12.004
   Ziyal IM, 1999, ACTA NEUROCHIR, V141, P655, DOI 10.1007/s007010050356
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E722
EP E725
DI 10.1016/j.wneu.2019.06.203
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200092
PM 31284060
DA 2020-05-12
ER

PT J
AU Schucht, P
   Zubak, I
   Kuhlen, D
   Abu-Isa, J
   Murek, M
   Raabe, A
   Soe, ZW
   Aung, K
   Myint, ATS
   Thu, M
AF Schucht, Philippe
   Zubak, Irena
   Kuhlen, Dominique
   Abu-Isa, Janine
   Murek, Michael
   Raabe, Andreas
   Soe, Zaw Wai
   Aung, Kyawzwa
   Myint, Aung Thu Soe
   Thu, Myat
TI Assisted Education for Specialized Medicine: A Sustainable Development
   Plan for Neurosurgery in Myanmar
SO WORLD NEUROSURGERY
LA English
DT Article
DE Developmental help; Myanmar; Neurosurgical education
ID TANZANIA; SURGERY
AB BACKGROUND: With only 4 active certified neurosurgeons for a population of 50 million, neurosurgical care was seriously underdeveloped in Myanmar in 2012. Together with the local neurosurgical community, Swiss Neurosurgeons International started a program of assisted education with the aim of increasing the neurosurgical capacity to 60 active neurosurgeons by 2023.
   METHODS: Our program included a fully sponsored fellowship at an academic hospital in Switzerland for every Myanmar neurosurgeon in training to observe contemporary neurosurgery and the organization of regular workshops, lectures, and educational surgeries in Myanmar. Halfway through the program, we performed a survey to assess its benefits and shortcomings.
   RESULTS: In 2019, the number of active neurosurgeons in Myanmar had increased to 20, with 50 more in training. Intracranial pressure monitoring, cervical spine surgery, transsphenoidal surgery, and intraoperative electrophysiology have become established procedures. Our survey showed an increased interest by the residents in tumor and vascular surgery and a new interest in spinal surgery. The overall rating of the fellowship was "very good," with language barriers, cultural differences, and coping with inclement weather reported as the greatest difficulties.
   CONCLUSIONS: Since the start of our project in 2013, a series of contemporary neurosurgical technologies and procedures have been introduced to Myanmar with the help of Swiss Neurosurgeons International. Our survey results have shown the strong points of the ongoing educational program and the weaknesses to be addressed. Midway through our 10-year project, with an expanded and improved education program, our goal of 60 active neurosurgeons in Myanmar by 2023 seems well within reach.
C1 [Schucht, Philippe; Zubak, Irena; Abu-Isa, Janine; Murek, Michael; Raabe, Andreas] Univ Hosp Bern, Dept Neurosurg, Bern, Switzerland.
   [Kuhlen, Dominique] Hosp Cantonale, Dept Neurosurg, Lugano, Switzerland.
   [Soe, Zaw Wai] Univ Med 1, Yangon, Myanmar.
   [Aung, Kyawzwa] Univ Med, Dept Neurosurg, Mandalay, Myanmar.
   [Myint, Aung Thu Soe] Naypyitaw Gen Hosp, Dept Neurosurg, Naypyitaw, Myanmar.
   [Thu, Myat] Yangon Gen Hosp, Dept Neurosurg, Yangon, Myanmar.
RP Schucht, P (reprint author), Univ Hosp Bern, Dept Neurosurg, Bern, Switzerland.
EM philippe.schucht@insel.ch
OI Zubak, Irena/0000-0001-8474-6421
CR Alkire BC, 2015, LANCET GLOB HEALTH, V3, pE316, DOI 10.1016/S2214-109X(15)70115-4
   [Anonymous], 2015, GLOB STAT REP ROAD S
   Carlson L, 2015, WORLD J SURG, V39, P813, DOI 10.1007/s00268-014-2938-8
   Dempsey RJ, 2018, WORLD NEUROSURG, V112, P325, DOI 10.1016/j.wneu.2018.02.099
   Dempsey RJ, 2013, NEUROSURGERY, V73, P1070, DOI 10.1227/NEU.0000000000000136
   El Khamlichi Abdeslam, 2005, Clin Neurosurg, V52, P214
   Fuller Anthony, 2016, eNeurologicalSci, V3, P1, DOI 10.1016/j.ensci.2015.10.003
   Heidektueger PI, 2017, J NEUROSURG-PEDIATR, V20, P334, DOI 10.3171/2017.5.PEDS1762
   Kahamba JF, 2013, WORLD NEUROSURG, V80, P255, DOI 10.1016/j.wneu.2011.07.021
   Lund-Johansen M, 2017, WORLD NEUROSURG, V99, P403, DOI 10.1016/j.wneu.2016.12.051
   Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442
   Meara JG, 2014, LANCET, V383, P12, DOI 10.1016/S0140-6736(13)62345-4
   Murek M, CLIN TRANSL NEUROSCI, DOI [10.1177/2514183X18782467, DOI 10.1177/2514183X18782467]
   Park KB, 2016, WORLD NEUROSURG, V88, P32, DOI 10.1016/j.wneu.2015.12.048
   Prinja S, 2015, ESSENTIAL SURG DIS C, V1, P317, DOI DOI 10.1596/978-1-4648-0346-8_
   Reulen H-J, 2009, DTSCH ARZTEBL INT, V106, P2364
   Rock J, 2018, WORLD NEUROSURG, V113, pE239, DOI 10.1016/j.wneu.2018.02.001
   Servadei F, 2018, WORLD NEUROSURG, V112, P315, DOI 10.1016/j.wneu.2018.01.047
   Shawar YR, 2015, LANCET GLOB HEALTH, V3, pE487, DOI 10.1016/S2214-109X(15)00098-4
   Winkler AS, 2010, WORLD NEUROSURG, V73, P264, DOI 10.1016/j.wneu.2010.03.037
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E854
EP E861
DI 10.1016/j.wneu.2019.07.018
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200108
PM 31295600
DA 2020-05-12
ER

PT J
AU Schunemann, V
   Wang, JHL
   Dornbos, D
   Youssef, PP
   Sribnick, E
   Leonard, J
   Nimjee, SM
AF Schunemann, Victoria
   Wang, Joshua L.
   Dornbos, David, III
   Youssef, Patrick P.
   Sribnick, Eric
   Leonard, Jeffrey
   Nimjee, Shahid M.
TI One and Done: Multimodal Treatment of Pediatric Cerbral Arteriovenous
   Malformations in a Single Anesthesia Event
SO WORLD NEUROSURGERY
LA English
DT Article
DE Pediatric arteriovenous malformations; Single anesthesia; Symptomatic
   arteriovenous malformations; Treatment of arteriovenous malformations
ID NATURAL-HISTORY; PREOPERATIVE EMBOLIZATION; BRAIN; OUTCOMES; CHILDREN;
   EXPERIENCE; RESECTION; MICROSURGERY; MANAGEMENT; INCREASE
AB BACKGROUND: Brain arteriovenous malformations (AVMs) are complex vascular lesions composed of abnormal arteries directly connected to veins without the typical intervening angioarchitecture. Rupture rates range from 2% to 4%, with that risk increasing to 4.5% per year for those presenting with hemorrhage. Mortality ranges from 12% to 66.7% after rupture, and up to 40% of survivors suffer from permanent neurologic sequelae. Treatment commonly includes a multimodality approach consisting of a combination of microsurgery, embolization, and radiosurgery. Typically, preoperative embolization is undertaken in a staged manner several days to weeks prior to microsurgical resection.
   METHODS: We describe a series of 5 pediatric patients harboring intracranial AVMs who underwent embolization and resection in the same anesthetic event, an approach that has not yet been described in the literature.
   RESULTS: Three patients presented symptomatically, whereas 2 AVMs were discovered incidentally, and average Spetzler -Martin grade was 1.6. Average anesthesia length was 580.8 minutes, and intraoperative angiography revealed complete resection in all cases. All patients were extubated at the end of the case and were discharged and followed up with a modified Rankin Scale score of 0.
   CONCLUSIONS: We describe a novel approach to treatment of pediatric intracranial AVMs that is shown to be safe and feasible. A single anesthesia event allows for aggressive preoperative embolization without increasing the risk of hemorrhage in the waiting period until resection. A single anesthesia event also prevents the patients from undergoing another intubation and anesthesia and decreases the risk associated with another anesthesia in a relatively short time frame.
C1 [Schunemann, Victoria; Wang, Joshua L.; Dornbos, David, III; Youssef, Patrick P.; Sribnick, Eric; Leonard, Jeffrey; Nimjee, Shahid M.] Ohio State Univ, Dept Neurosurg, Wexner Med Ctr, Columbus, OH 43210 USA.
   [Youssef, Patrick P.; Sribnick, Eric; Leonard, Jeffrey; Nimjee, Shahid M.] Nationwide Childrens Hosp, Div Pediat Neurosurg, Columbus, OH 43205 USA.
RP Nimjee, SM (reprint author), Ohio State Univ, Dept Neurosurg, Wexner Med Ctr, Columbus, OH 43210 USA.; Nimjee, SM (reprint author), Nationwide Childrens Hosp, Div Pediat Neurosurg, Columbus, OH 43205 USA.
EM shahid.nimjee@osumc.edu
RI Sribnick, Eric/AAH-6693-2020; Dornbos, David/AAF-5091-2019
CR Abecassis IJ, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.6.FOCUS14250
   Andreou A, 2008, J NEUROSURG, V109, P1091, DOI 10.3171/JNS.2008.109.12.1091
   Baharvandat H, 2019, AM J NEURORADIOL, V40, P668, DOI 10.3174/ajnr.A5988
   Berman MF, 2000, NEUROSURGERY, V47, P389, DOI 10.1097/00006123-200008000-00023
   Blauwblomme T, 2014, STROKE, V45, P1664, DOI 10.1161/STROKEAHA.113.004292
   BROWN RD, 1988, J NEUROSURG, V68, P352, DOI 10.3171/jns.1988.68.3.0352
   Conger Jordan R, 2016, J Cerebrovasc Endovasc Neurosurg, V18, P90, DOI 10.7461/jcen.2016.18.2.90
   CRAWFORD PM, 1986, J NEUROL NEUROSUR PS, V49, P1, DOI 10.1136/jnnp.49.1.1
   Crowley RW, 2014, NEUROSURGERY, V74, pS74, DOI 10.1227/NEU.0000000000000176
   Darsaut TE, 2011, NEUROSURGERY, V69, P540, DOI 10.1227/NEU.0b013e3182181c00
   Di Rocco C, 2000, ACTA NEUROCHIR, V142, P145, DOI 10.1007/s007010050017
   Gaballah M, 2014, J NEUROSURG-PEDIATR, V13, P222, DOI 10.3171/2013.10.PEDS13291
   Gross BA, 2015, J NEUROSURG-PEDIATR, V15, P71, DOI 10.3171/2014.9.PEDS146
   Gross BA, 2013, J NEUROSURG, V118, P437, DOI 10.3171/2012.10.JNS121280
   Heros RC, 2004, J NEUROSURG, V100, P807, DOI 10.3171/jns.2004.100.5.0807
   Iosif C, 2019, J NEUROINTERV SURG, V11, P699, DOI 10.1136/neurintsurg-2018-014390
   Ivanov AA, 2016, NEUROSURGERY, V78, P562, DOI 10.1227/NEU.0000000000001191
   Mast H, 1997, LANCET, V350, P1065, DOI 10.1016/S0140-6736(97)05390-7
   Munting KE, 2015, CAN J ANESTH, V62, P1248, DOI 10.1007/s12630-015-0492-y
   Murat I, 2004, PAEDIATR ANAESTH, V14, P158, DOI 10.1111/j.1460-9592.2004.01167.x
   Nataraj A, 2014, WORLD NEUROSURG, V82, P149, DOI 10.1016/j.wneu.2013.02.064
   Natarajan SK, 2008, NEUROSURGERY, V62, P1213, DOI 10.1227/01.neu.0000333293.74986.e5
   Nerva JD, 2016, NEUROSURGERY, V78, P695, DOI 10.1227/NEU.0000000000001076
   ONDRA SL, 1990, J NEUROSURG, V73, P387, DOI 10.3171/jns.1990.73.3.0387
   Oofuvong M, 2015, ANESTH ANALG, V120, P411, DOI 10.1213/ANE.0000000000000557
   Potts MB, 2015, J NEUROSURG, V122, P912, DOI 10.3171/2014.12.JNS14938
   Reig AS, 2010, J NEUROINTERV SURG, V2, P202, DOI 10.1136/jnis.2009.001636
   Saatci I, 2011, J NEUROSURG, V115, P78, DOI 10.3171/2011.2.JNS09830
   Sanchez-Mejia RO, 2006, J NEUROSURG, V105, P82, DOI 10.3171/ped.2006.105.2.82
   Schramm J, 2017, J NEUROSURG, V126, P1056, DOI 10.3171/2016.4.JNS153017
   Shtaya A, 2017, CHILD NERV SYST, V33, P573, DOI 10.1007/s00381-017-3383-4
   Soltanolkotabi M, 2013, J NEUROSURG-PEDIATR, V11, P431, DOI 10.3171/2013.1.PEDS12286
   SPETZLER RF, 1986, J NEUROSURG, V65, P476, DOI 10.3171/jns.1986.65.4.0476
   Weber W, 2007, NEUROSURGERY, V61, P244, DOI 10.1227/01.NEU.0000255473.60505.84
   Williams GD, 2017, ANESTH ANALG, V125, P1515, DOI 10.1213/ANE.0000000000002208
NR 35
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E715
EP E721
DI 10.1016/j.wneu.2019.06.200
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200091
PM 31279921
DA 2020-05-12
ER

PT J
AU Servadei, F
   Tropeano, MP
   Spaggiari, R
   Cannizzaro, D
   Al Fauzi, A
   Bajamal, AH
   Khan, T
   Kolias, AG
   Hutchinson, PJ
AF Servadei, Franco
   Tropeano, Maria Pia
   Spaggiari, Riccardo
   Cannizzaro, Delia
   Al Fauzi, Asra
   Bajamal, Abdul Hafid
   Khan, Tarik
   Kolias, Angelos G.
   Hutchinson, Peter J.
TI Footprint of Reports From Low- and Low- to Middle-Income Countries in
   the Neurosurgical Data: A Study From 2015 to 2017
SO WORLD NEUROSURGERY
LA English
DT Article
DE Developing countries; Education; Global neurosurgery; Literature; World
   health
ID TRAUMATIC BRAIN-INJURY; HEALTH; EPIDEMIOLOGY; JOURNALS
AB OBJECTIVE: In 2015, the Lancet Commission on Global Surgery highlighted the disparities in surgical care worldwide. The aim of the present study was to investigate the research productivity of low-income countries (LICs) and low- to middle-income countries (LMICs) in selected journals representing the worldwide neurosurgical data and their ability to report and communicate globally the existing differences between high-income countries (HICs) and LMICs.
   METHODS: We performed a retrospective bibliometric analysis using PubMed and Scopus databases to record all the reports from 2015 to 2017 by investigators affiliated with neurosurgical departments in LICs and LMICs.
   RESULTS: A total of 8459 reports by investigators self-identified as members of neurosurgery departments worldwide were identified. Of these, 6708 reports were included in accordance with our method in the final analysis. The systematic search resulted in 459 studies reported by LICs and LMICs. Of these, 334 reports were included for the full text evaluation. Of the 6708 reports, 303 (4.52%) had been reported with an LMIC affiliation and only 31 (0.46%) with an LIC. The leading countries were India with 182 (54.5% among LMICs and LICs; 2.71% overall), followed by Egypt at 66 (19.76% among the LMICs and LICs; 0.98% overall), with a large difference compared with other countries such as Uganda at 9 (2.69% among the LMICs and LICs) and Tunisia and Pakistan at 8 each (2.4% among the LMICs and LICs). A few reports studies had been generated by collaboration with HIC neurosurgeons.
   CONCLUSIONS: Our results have shown that research studies from LMICs are underrepresented. Understanding and discussing the reasons for this underrepresentation are necessary to start addressing the disparities in neurosurgical research and care capacity. Future engagements from international journals, more partnership collaboration from HICs, and tailored funding to support investigators, collaborations, and networks could be of help.
C1 [Servadei, Franco; Tropeano, Maria Pia; Spaggiari, Riccardo; Cannizzaro, Delia] Humanitas Clin & Res Hosp, Dept Neurosurg, Milan, Italy.
   [Servadei, Franco; Tropeano, Maria Pia; Spaggiari, Riccardo; Cannizzaro, Delia] Humanitas Univ, Milan, Italy.
   [Tropeano, Maria Pia; Kolias, Angelos G.; Hutchinson, Peter J.] Univ Cambridge, Natl Inst Hlth Res Global Hlth Res Grp Neurotraum, Cambridge, England.
   [Al Fauzi, Asra; Bajamal, Abdul Hafid] Univ Airlangga, Dr Soetomo Acad Med Ctr Hosp, Dept Neurosurg, Surabaya, Indonesia.
   [Khan, Tarik] North Western Gen & Res Hosp, Dept Neurosurg, Peshawar, Pakistan.
   [Kolias, Angelos G.; Hutchinson, Peter J.] Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge, England.
   [Kolias, Angelos G.; Hutchinson, Peter J.] Univ Cambridge, Cambridge, England.
RP Tropeano, MP (reprint author), Humanitas Clin & Res Hosp, Dept Neurosurg, Milan, Italy.; Tropeano, MP (reprint author), Humanitas Univ, Milan, Italy.; Tropeano, MP (reprint author), Univ Cambridge, Natl Inst Hlth Res Global Hlth Res Grp Neurotraum, Cambridge, England.
EM mariapia.tropeano@libero.it
RI Cannizzaro, Delia/K-7197-2016
OI Cannizzaro, Delia/0000-0002-1611-0840; Al Fauzi,
   Asra/0000-0002-5155-2476
FU National Institute for Health Research (NIHR) Cambridge Biomedical
   Research CentreNational Institute for Health Research (NIHR); NIHR
   Global Health Research Group on Neurotrauma; NIHR Research
   Professorship; United Kingdom NIHR [16/137/105]
FX Angelos Kolias and Peter Hutchinson are supported by the National
   Institute for Health Research (NIHR) Cambridge Biomedical Research
   Centre and the NIHR Global Health Research Group on Neurotrauma. Peter
   Hutchinson is also supported by a NIHR Research Professorship. The NIHR
   Global Health Research Group on Neurotrauma was commissioned by the
   United Kingdom NIHR using Official Development Assistance funding
   (project no. 16/137/105). The views expressed in this manuscript are
   those of the authors and are not necessarily those of the United Kingdom
   National Health Service, NIHR, or the Department of Health. The
   remaining authors declare that the article content was composed in the
   absence of any commercial or financial relationships that could be
   construed as a potential conflict of interest.
CR Adeleye AO, 2012, WORLD NEUROSURG, V78, DOI [10.1016/J.WNEU.2011.07.015, 10.1016/j.wneu.2011.07.015]
   Adeleye AO, 2016, J CRANIOFAC SURG, V27, P1302, DOI 10.1097/SCS.0000000000002791
   Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432
   Chow DS, 2010, RADIOLOGY, V257, P410, DOI 10.1148/radiol.10100070
   Chua MH, 2018, WORLD NEUROSURG, V114, P375, DOI 10.1016/j.wneu.2018.03.057
   Cruccu G, 2018, EUR J NEUROL, V25, P1128, DOI 10.1111/ene.13666
   Dewan MC, 2019, J NEUROSURG, V130, P1055, DOI 10.3171/2017.11.JNS171500
   Goel A, 2013, WORLD NEUROSURG, V79, P632, DOI 10.1016/j.wneu.2013.03.009
   Haglund MM, 2017, NEUROSURGERY, V80, P656, DOI 10.1093/neuros/nyw159
   Hauptman JS, 2011, J NEUROSURG, V115, P1262, DOI 10.3171/2011.8.JNS11857
   Helal AE, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.7.FOCUS18258
   Horton R, 2003, LANCET, V361, P712, DOI 10.1016/S0140-6736(03)12665-7
   King DA, 2004, NATURE, V430, P311, DOI 10.1038/430311a
   Kolias AG, 2019, LANCET NEUROL, V18, P136, DOI 10.1016/S1474-4422(18)30494-0
   Kulkarni AV, 2017, NEW ENGL J MED, V377, P2456, DOI 10.1056/NEJMoa1707568
   Langer A, 2004, B WORLD HEALTH ORGAN, V82, P802
   Lund-Johansen M, 2017, WORLD NEUROSURG, V99, P403, DOI 10.1016/j.wneu.2016.12.051
   Meara JG, 2014, LANCET, V383, P12, DOI 10.1016/S0140-6736(13)62345-4
   Morimoto T, 2003, INT J HEMATOL, V77, P192, DOI 10.1007/BF02983221
   Park KB, 2016, WORLD NEUROSURG, V88, P32, DOI 10.1016/j.wneu.2015.12.048
   Patel V, 2001, BRIT J PSYCHIAT, V178, P406, DOI 10.1192/bjp.178.5.406
   Patel V, 2007, BRIT J PSYCHIAT, V190, P77, DOI 10.1192/bjp.bp.106.025692
   Peeters S, 2017, WORLD NEUROSURG, V97, P580, DOI 10.1016/j.wneu.2016.09.127
   Saxena S, 2006, BRIT J PSYCHIAT, V188, P81, DOI 10.1192/bjp.bp.105.011221
   Servadei F, 2018, WORLD NEUROSURG, V112, P315, DOI 10.1016/j.wneu.2018.01.047
   Smart LR, 2017, WORLD NEUROSURG, V105, P238, DOI 10.1016/j.wneu.2017.05.101
   Spanu F, 2018, WORLD NEUROSURG, V111, P326, DOI 10.1016/j.wneu.2017.12.146
   Sumathipala Athula, 2004, BMC Med Ethics, V5, pE5
   Twitchell S, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.1.FOCUS17775
   Uthman OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078517
   Vaca SD, 2019, NEUROSURGERY, V84, P95, DOI 10.1093/neuros/nyy004
   Walcott BP, 2016, JAMA NEUROL, V73, P1002, DOI 10.1001/jamaneurol.2016.0609
   Yang Xiang, 2018, J Spine Surg, V4, P490, DOI 10.21037/jss.2018.06.11
NR 33
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E822
EP E830
DI 10.1016/j.wneu.2019.06.230
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200104
PM 31295603
DA 2020-05-12
ER

PT J
AU Shen, J
   Gao, YL
   Li, QF
   Ge, RX
   Wang, QF
   Jiang, XC
   Shao, XF
AF Shen, Jun
   Gao, YaLong
   Li, Qifeng
   Ge, Ruixiang
   Wang, Qifu
   Jiang, XiaoChun
   Shao, Xuefei
TI Risk Factors Predicting Recurrence of Bilateral Chronic Subdural
   Hematomas after Initial Bilateral Evacuation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain atrophy; Chronic subdural hematoma; Grading system; Recurrence
   rate
ID INDEPENDENT PREDICTORS; MANAGEMENT; REOPERATION; SURGERY
AB BACKGROUND: Most patients with bilateral chronic subdural hematomas (bCSDH) undergo initial bilateral evacuation. Risk factors associated with the recurrence of bCSDH after initial bilateral evacuation have not been published to date. In this study, we aimed to identify risk factors related to recurrence of bCSDH after initial bilateral evacuation, and to develop a prognostic grading system for clinical reference.
   METHODS: This study included 102 patients with bCSDH who underwent initial bilateral evacuation. Predictors of recurrence were identified via univariate analysis and multivariate logistic regression analysis. A prognostic grading system was created based on the independent predictors combined with a cutoff value. All cases were scored according to the prognostic grading system, and the recurrence rates of the different scores were reanalyzed.
   RESULTS: Anticoagulant use (odds ratio [OR], 84.266; 95% confidence interval [Cl], 13.113-541.522; P < 0.001), severe brain atrophy (OR, 11.551; 95% CI, 2.558-52.163; P = 0.001), and postoperative pneumocephalus volume (PostPV) (OR, 0.978; 95% CI, 0.957-1.000; P = 0.049) were independent risk factors for the recurrence of bCSDH after initial bilateral evacuation. The cutoff value of PostPV was >20.9484 cm(3). A prognostic grading system was then developed, and the recurrence rates based on score were determined. Rates were 2.8% for a score of 0-1, 28.1% for a score of 2-3, and 100% for a score of 4-5, showing a significant increase in risk with increasing score (P < 0.001).
   CONCLUSIONS: Anticoagulant use, severe brain atrophy, and PostPV were identified as independent risk factors for recurrence of bCSDH after initial bilateral evacuation. The prognostic grading system for recurrence of bCSDH after initial bilateral evacuation is reliable and applicable for clinical reference.
C1 [Shen, Jun; Ge, Ruixiang; Wang, Qifu; Jiang, XiaoChun; Shao, Xuefei] Wannan Med Coll, Yijishan Hosp, Dept Neurosurg, Wuhu, Peoples R China.
   [Gao, YaLong; Li, Qifeng] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China.
RP Shao, XF (reprint author), Wannan Med Coll, Yijishan Hosp, Dept Neurosurg, Wuhu, Peoples R China.
EM drshao@163.com
FU Collegiate Major Natural Science Research Projects (Anhui Province,
   China) [KJ2017A267, KJ2018ZD027]
FX This study was supported by grants from Collegiate Major Natural Science
   Research Projects (Grants KJ2017A267 and KJ2018ZD027, Anhui Province,
   China).
CR Bartek J, 2017, WORLD NEUROSURG, V106, P609, DOI 10.1016/j.wneu.2017.07.044
   Chon KH, 2012, ACTA NEUROCHIR, V154, P1541, DOI 10.1007/s00701-012-1399-9
   Ducruet AF, 2012, NEUROSURG REV, V35, P155, DOI 10.1007/s10143-011-0349-y
   Bae ME, 2011, ACTA NEUROCHIR, V153, P1097, DOI 10.1007/s00701-010-0903-3
   Fujitani S, 2017, J NEUROSURG, V126, P755, DOI 10.3171/2016.1.JNS152655
   Guha D, 2016, J NEUROSURG, V124, P750, DOI 10.3171/2015.2.JNS141889
   Jack A, 2015, CAN J NEUROL SCI, V42, P34, DOI 10.1017/cjn.2014.122
   Kolias AG, 2014, NAT REV NEUROL, V10, P570, DOI 10.1038/nrneurol.2014.163
   Kung WM, 2012, INJURY, V43, P598, DOI 10.1016/j.injury.2010.07.240
   Leroy HA, 2015, J CLIN NEUROSCI, V22, P1895, DOI 10.1016/j.jocn.2015.03.064
   Motiei-Langroudi R, 2019, NEUROSURGERY, V85, P648, DOI 10.1093/neuros/nyy432
   Nathan S, 2017, NEUROLOGY, V88, P1889, DOI 10.1212/WNL.0000000000003918
   Okano A, 2014, BRIT J NEUROSURG, V28, P204, DOI 10.3109/02688697.2013.829563
   Rauhala M, 2020, J NEUROSURG, V132, P1147, DOI 10.3171/2018.12.JNS183035
   Schwarz F, 2015, CLIN NEUROL NEUROSUR, V138, P66, DOI 10.1016/j.clineuro.2015.08.002
   Shen J, 2019, WORLD NEUROSURG, V126, pE773, DOI 10.1016/j.wneu.2019.02.148
   Stanisic M, 2017, NEUROSURGERY, V81, P752, DOI 10.1093/neuros/nyx090
   Torihashi K, 2008, NEUROSURGERY, V63, P1125, DOI 10.1227/01.NEU.0000335782.60059.17
   Wada M, 2014, CLIN NEUROL NEUROSUR, V120, P49, DOI 10.1016/j.clineuro.2014.02.007
   You CG, 2018, CLIN NEUROL NEUROSUR, V166, P56, DOI 10.1016/j.clineuro.2018.01.029
   You WD, 2018, ACTA NEUROCHIR, V160, P893, DOI 10.1007/s00701-018-3513-0
NR 21
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E133
EP E139
DI 10.1016/j.wneu.2019.06.016
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200018
PM 31203079
DA 2020-05-12
ER

PT J
AU Shen, XL
   Wu, HQ
   Shi, CG
   Liu, Y
   Tian, Y
   Wu, XD
   Cao, P
   Wang, XW
   Chen, HJ
   Yuan, W
AF Shen, Xiaolong
   Wu, Huiqiao
   Shi, Changgui
   Liu, Yang
   Tian, Ye
   Wu, Xiaodong
   Cao, Peng
   Wang, Xinwei
   Chen, Huajiang
   Yuan, Wen
TI Preoperative and Intraoperative Skull Traction Combined with
   Anterior-Only Cervical Operation in the Treatment of Severe Cervical
   Kyphosis (> 50 Degrees)
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior; Cervical spine; Cobb angle; Decompression; Kyphosis; Operation
ID TITANIUM MESH CAGES; NEUROFIBROMATOSIS TYPE-1; SURGICAL-TREATMENT;
   ALIGNMENT; DECOMPRESSION; FUSION
AB OBJECTIVE: To evaluate the clinical and radiographic outcomes of an anterior-only approach for the correction of severe cervical kyphotic deformities.
   METHODS: We performed a retrospective study of 33 consecutive patients with severe cervical kyphosis treated with an anterior cervical operation and preoperative and intraoperative skull traction. Cobb angle, kyphosis index (KI), kyphosis level, C2-7 sagittal vertical axis (SVA), and T1 slope were measured. The preoperative and postoperative Japanese Orthopedic Association (JOA) scores, visual analog scale (VAS) score for neck pain, Neck Disability Index (NDI) scores, and cervical alignment were compared.
   RESULTS: The mean angle of the kyphosis was 83.2 +/- 20 degrees. The mean Cobb angle of the operative region was 71.7 +/- 18.5 degrees preoperation, which was reduced to 10.6 +/- 5.7 degrees postoperation (mean correction, 85.2%). The mean KI was 75.1 +/- 18.2 preoperation, which was reduced to 14.4 +/- 9.1 postoperation (mean correction, 80.8%). The preoperative and postoperative mean C2-7 Cobb angle was 53.8 +/- 16.5 degrees and 14.7 +/- 7.6 degrees, respectively. The preoperative and postoperative mean C2-7 SVA was 3.9 + 14.5 mm and 12.8 +/- 7.3 mm, respectively. The preoperative and postoperative mean T1 slope was -9.4 +/- 15.7 degrees and 7.31 +/- 13.1 degrees, respectively. The average postoperative C2-7 Cobb angle, Cobb angle of the operative region, KI, C2-7 SVA, and T1 slope changed significantly compared with preoperative values (P < 0.05). The average postoperative JOA, VAS, and NDI scores improved significantly compared with preoperative scores (P < 0.05).
   CONCLUSIONS: Preoperative and intraoperative skull traction combined with anterior-only cervical operation may be a safe and effective technique for treating severe cervical kyphosis. If the postoperative correction is >80%, sufficient decompression could be achieved.
C1 [Shen, Xiaolong; Wu, Huiqiao; Shi, Changgui; Liu, Yang; Tian, Ye; Wu, Xiaodong; Cao, Peng; Wang, Xinwei; Chen, Huajiang; Yuan, Wen] Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Surg, Shanghai, Peoples R China.
RP Yuan, W (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Surg, Shanghai, Peoples R China.
EM spine_yuanwen@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81601928]; Shanghai Sailing Program [18YF1423100]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81601928, to Xiaolong Shen) and Shanghai Sailing
   Program (18YF1423100, to Changgui Shi).
CR Cho JH, 2014, SPINE, V39, pE1575, DOI 10.1097/BRS.0000000000000614
   Daubs MD, 2005, SPINE, V30, P1402, DOI 10.1097/01.brs.0000166526.78058.3c
   Eck KR, 2000, SPINE, V25, P2407, DOI 10.1097/00007632-200009150-00023
   Ferch RD, 2004, J NEUROSURG, V100, P13, DOI 10.3171/spi.2004.100.1.0013
   Han K, 2011, EUR SPINE J, V20, P523, DOI 10.1007/s00586-010-1602-8
   Helenius IJ, 2016, J BONE JOINT SURG AM, V98, DOI 10.2106/JBJS.16.00096
   Hey HWD, 2017, SPINE, V42, P1614, DOI 10.1097/BRS.0000000000002160
   Iwasaki M, 2002, SPINE, V27, P1419, DOI 10.1097/00007632-200207010-00009
   Kawabata S, 2013, J NEUROSURG-SPINE, V18, P274, DOI 10.3171/2012.11.SPINE12417
   Knott PT, 2010, SPINE J, V10, P994, DOI 10.1016/j.spinee.2010.08.031
   Lau D, 2015, J NEUROSURG-SPINE, V23, P263, DOI 10.3171/2014.12.SPINE14178
   Lin QS, 2012, EUR SPINE J, V21, P474, DOI 10.1007/s00586-011-1961-9
   Liu Y, 2012, EUR SPINE J, V21, P2428, DOI 10.1007/s00586-012-2323-y
   Ma JM, 2011, J NEUROSURG-SPINE, V14, P93, DOI 10.3171/2010.9.SPINE091015
   Machino M, 2012, SPINE, V37, pE1243, DOI 10.1097/BRS.0b013e3182659d3e
   Mummaneni PV, 2008, J NEUROSURG-SPINE, V9, P515, DOI 10.3171/SPI.2008.10.08226
   O'Shaughnessy BA, 2008, SPINE, V33, P771, DOI 10.1097/BRS.0b013e3181695082
   Okawa A, 2011, SPINE, V36, pE582, DOI 10.1097/BRS.0b013e3181e0f06a
   Papadopoulos EC, 2006, SPINE, V31, P897, DOI 10.1097/01.brs.0000209348.17377.be
   Park Y, 2010, SPINE J, V10, P380, DOI 10.1016/j.spinee.2010.02.006
   Parker SL, 2015, EUR SPINE J, V24, pS544, DOI 10.1007/s00586-014-3682-3
   Schultz KD, 2000, J NEUROSURG, V93, P214, DOI 10.3171/spi.2000.93.2.0214
   Shen XL, 2017, CLIN SPINE SURG, V30, pE560, DOI 10.1097/BSD.0000000000000257
   Singh Sunil Kumar, 2015, Asian J Neurosurg, V10, P32, DOI 10.4103/1793-5482.151506
   Stewart Todd J, 2005, Neurosurgery, V56, P191
   Thalgott John S, 2003, Spine J, V3, P294, DOI 10.1016/S1529-9430(02)00588-0
   Wang SJ, 2011, EUR SPINE J, V20, P185, DOI 10.1007/s00586-010-1600-x
NR 27
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E915
EP E925
DI 10.1016/j.wneu.2019.07.035
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200115
PM 31301447
DA 2020-05-12
ER

PT J
AU Shibahara, I
   Hanihara, M
   Miyasaka, K
   Sato, S
   Hide, T
   Kumabe, T
AF Shibahara, Ichiyo
   Hanihara, Mitsuto
   Miyasaka, Kazuhiro
   Sato, Sumito
   Hide, Takuichiro
   Kumabe, Toshihiro
TI Temporal Glioblastoma Mimicking Basal Ganglia Invasion: Distinguishing
   Removable and Unremovable Tumors
SO WORLD NEUROSURGERY
LA English
DT Article
DE Basal ganglia; Extent of resection; Medial temporal lobe; Schramm type;
   Temporal glioblastoma
ID MICROSURGICAL ANATOMY; SURGICAL RESECTION; SURVIVAL; LOCATION; GRADE;
   MULTIFORME; PROPOSAL; EXTENT; LOBE
AB OBJECTIVE: Maximal safe resection prolongs the survival of patients with glioblastoma (GB). However, whether total resection of the enhanced lesion is pursued or abandoned depends on preoperative judgments based on the findings of magnetic resonance imaging (MRI). Anatomically, medial temporal tumor tends to invade toward the temporal stem, insula, and basal ganglia, representing tumor with high surgical risk. In the present study, we describe the key radiologic features of medial temporal GB to achieve extent of resection.
   METHODS: We reviewed all GB cases located in the temporal lobe (tGB) treated between April 2013 and March 2018 at Kitasato University Hospital. On the basis of MRI, tGB was simply classified into 3 groups: medial tGB and nonmedial tGB, and medial tGB was further subdivided into invading type and mimicking type. We focused on the resectability of medial tGB.
   RESULTS: Twenty-seven patients with tGB were identified. Twenty were included in the nonmedial tGB, and 7 were in the medial tGB. All medial tGB seemed to invade into the basal ganglia and/or the lenticulostriate arteries, but detailed examination revealed 2 types of tumor, invading type (3 cases) and mimicking type (4 cases). The invading type had true involvement of the basal ganglia and/or lenticulostriate arteries, whereas the mimicking type had no involvement of these structures. This new classification is highly effective, as the former is unresectable, but the latter is totally resectable.
   CONCLUSIONS: Medial tGB is a challenging tumor for maximal safe resection, so our classification will help to identify cases of removable medial tGB.
C1 [Shibahara, Ichiyo; Hanihara, Mitsuto; Miyasaka, Kazuhiro; Sato, Sumito; Hide, Takuichiro; Kumabe, Toshihiro] Kitasato Univ, Sch Med, Dept Neurosurg, Sagamihara, Kanagawa, Japan.
RP Shibahara, I (reprint author), Kitasato Univ, Sch Med, Dept Neurosurg, Sagamihara, Kanagawa, Japan.
EM shibahar@med.kitasato-u.ac.jp
FU KAKENHIMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for
   Scientific Research (KAKENHI) [18K16569]; Ichiro Kanehara Foundation
FX This work was supported in part by KAKENHI (Grants-in-Aid for Scientific
   Research), grant Number 18K16569 and Ichiro Kanehara Foundation.
CR Carroll KT, 2018, WORLD NEUROSURG, V111, pE790, DOI 10.1016/j.wneu.2017.12.165
   Chaichana KL, 2014, WORLD NEUROSURG, V82, pE257, DOI 10.1016/j.wneu.2014.01.019
   Chaichana KL, 2014, NEURO-ONCOLOGY, V16, P113, DOI 10.1093/neuonc/not137
   Duffau H, 2002, J NEUROSURG, V97, P363, DOI 10.3171/jns.2002.97.2.0363
   Faust K, 2014, ACTA NEUROCHIR, V156, P409, DOI 10.1007/s00701-013-1917-4
   FUJIMURA M, 1995, TOHOKU J EXP MED, V175, P211, DOI 10.1620/tjem.175.211
   Glenn CA, 2018, WORLD NEUROSURG, V114, pE747, DOI 10.1016/j.wneu.2018.03.072
   Hansen S, 2018, J NEURO-ONCOL, V139, P479, DOI 10.1007/s11060-018-2892-7
   Kamada K, 2009, J NEUROSURG, V111, P785, DOI 10.3171/2008.9.JNS08414
   Kim Seung Hwan, 2015, J Cerebrovasc Endovasc Neurosurg, V17, P85, DOI 10.7461/jcen.2015.17.2.85
   Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190
   Li HY, 2018, WORLD NEUROSURG, V112, pE407, DOI 10.1016/j.wneu.2018.01.055
   Morshed RA, 2019, J NEUROSURG, V131, P467, DOI 10.3171/2018.4.JNS18375
   Peters O, 2004, PEDIATR BLOOD CANCER, V43, P250, DOI 10.1002/pbc.20111
   Phi JH, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.5.FOCUS09106
   Potts MB, 2012, NEUROSURGERY, V70, P824, DOI 10.1227/NEU.0b013e318236760d
   Saito R, 2009, J NEUROSURG, V111, P278, DOI 10.3171/2008.11.JNS08858
   Sanai N, 2011, J NEUROSURG, V115, P3, DOI 10.3171/2011.2.JNS10998
   Schramm J, 2008, ACTA NEUROCHIR, V150, P857, DOI 10.1007/s00701-008-0013-7
   Shibahara I, 2018, J NEURO-ONCOL, V137, P417, DOI 10.1007/s11060-017-2733-0
   SIMPSON JR, 1993, INT J RADIAT ONCOL, V26, P239, DOI 10.1016/0360-3016(93)90203-8
   Talos IF, 2006, RADIOLOGY, V239, P506, DOI 10.1148/radiol.2392050661
   Tanriover N, 2014, J NEUROSURG, V120, P1217, DOI 10.3171/2014.1.JNS131325
   Wen HT, 1999, NEUROSURGERY, V45, P549, DOI 10.1097/00006123-199909000-00028
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E213
EP E221
DI 10.1016/j.wneu.2019.06.035
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200027
PM 31252080
DA 2020-05-12
ER

PT J
AU Siddiqui, MI
   Wallace, DJ
   Salazar, LM
   Vardiman, AB
AF Siddiqui, Mehdi I.
   Wallace, David J.
   Salazar, Luis M.
   Vardiman, Arnold B.
TI Robot-Assisted Pedicle Screw Placement: Learning Curve Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Learning curve; Residency training; Robot-assisted spine surgery; Spinal
   navigation
AB OBJECTIVES: To describe the learning curve of pedicle screw placement using robot-assisted spine surgery of an experienced neurosurgeon and 2 supervised neurosurgical fellows.
   METHODS: The first 120 cases of robot-assisted spine surgery at our institution were assessed. Patient variables included age, body mass index, and indication for surgery. lntraoperative variables included the vertebral level of screw placement, number of screws placed by each operator, intraoperative blood loss, and operative time. Postoperative variables included length of stay, discharge disposition, 30-day readmissions, wound complications, and hardware revisions. Screw accuracy was determined with image overlay analysis comparing planned screw trajectory on the navigation software with the intraoperative computed tomography scan with final screw placement. Two-dimensional accuracy was determined for the tip of the screw, tail of the screw, and angle at the screw was placed. The supervising physician and first fellow began utilizing the robot concurrently upon its arrival, and the second fellow began using the robot after the system had been in place for 7 months.
   RESULTS: Both experienced surgeon and first fellow displayed a learning curve and achieved statistically significant improvement of accuracy after 30 screws. The second fellow had significantly better accuracy than the experienced surgeon in his first 30 screws. There were no complications from hardware placement in either group. There were no returns to the operating room for hardware issues.
   CONCLUSIONS: Robot-assisted spine surgery is a safe, accurate method of pedicle screw instrumentation. Our data show similar learning adaptation rates for the first fellow and the experienced surgeon. Techniques learned by the attending surgeon were immediately transferable to a new learner, who was able to achieve a faster learning curve than both the first fellow and the experienced surgeon.
C1 [Siddiqui, Mehdi I.; Salazar, Luis M.] Univ Texas Hlth Sci Ctr San Antonio, Long Sch Med, San Antonio, TX 78229 USA.
   [Wallace, David J.; Vardiman, Arnold B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurosurg, San Antonio, TX 78229 USA.
RP Wallace, DJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Neurosurg, San Antonio, TX 78229 USA.
EM davidwallace.md@gmail.com
CR Allen J, 2015, INT J SPINE SURG, V9, DOI 10.14444/2023
   Bergeson RK, 2008, SPINE, V33, pE501, DOI 10.1097/BRS.0b013e31817b61af
   Burstrom G, 2019, SPINE, V44, P1097, DOI 10.1097/BRS.0000000000003006
   FAN Y, 2018, MEDICINE, V97
   Feng S, 2019, WORLD NEUROSURG, V125, pE1057, DOI 10.1016/j.wneu.2019.01.243
   Fujishiro T, 2015, SPINE, V40, P1882, DOI 10.1097/BRS.0000000000001099
   Gasco J, 2014, NEUROL RES, V36, P968, DOI 10.1179/1743132814Y.0000000388
   Green CA, 2019, ACAD MED, V94, P1532, DOI 10.1097/ACM.0000000000002751
   Hu XB, 2014, CLIN ORTHOP RELAT R, V472, P1839, DOI 10.1007/s11999-013-3291-1
   Hyun SJ, 2017, SPINE, V42, P353, DOI 10.1097/BRS.0000000000001778
   Jagannathan J, 2009, J NEUROSURG, V110, P820, DOI 10.3171/2009.2.JNS081446
   Joseph JR, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.2.FOCUS16544
   Lenihan JP, 2008, J MINIM INVAS GYN, V15, P589, DOI 10.1016/j.jmig.2008.06.015
   Ryang YM, 2015, SPINE J, V15, P467, DOI 10.1016/j.spinee.2014.10.003
   Srinivasan D, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.07.041
   Sundar SJ, 2016, J NEUROSURG-SPINE, V24, P850, DOI 10.3171/2015.8.SPINE15119
   Tian W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086346
   Vidovszky TJ, 2006, J SURG RES, V136, P172, DOI 10.1016/j.jss.2006.03.021
   West JL, 2019, NEUROSURGERY, V84, pE279, DOI 10.1093/neuros/nyz015
   Yohannes P, 2002, UROLOGY, V60, P39, DOI 10.1016/S0090-4295(02)01717-X
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E417
EP E422
DI 10.1016/j.wneu.2019.06.107
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200051
PM 31247356
DA 2020-05-12
ER

PT J
AU Starnoni, D
   Maduri, R
   Hajdu, SD
   Pierzchala, K
   Giammattei, L
   Rocca, A
   Grosfilley, SB
   Saliou, G
   Messerer, M
   Daniel, RT
AF Starnoni, Daniels
   Maduri, Rodolfo
   Hajdu, Steven David
   Pierzchala, Katarzyna
   Giammattei, Lorenzo
   Rocca, Aida
   Grosfilley, Sarah Beatrice
   Saliou, Guillaume
   Messerer, Mahmoud
   Daniel, Roy Thomas
TI Early Perfusion Computed Tomography Scan for Prediction of Vasospasm and
   Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysmal subarachnoid hemorrhage; Brain imaging; Cerebral infarction;
   Cerebrovascular-circulation; Computed tomography; Intracranial aneurysm;
   Intracranial vasospasm
ID CT PERFUSION; TRANSCRANIAL DOPPLER; RISK; HYPOPERFUSION; ANGIOGRAPHY;
   SAH
AB OBJECTIVE: We investigated the ability of early alteration of cerebral perfusion-computed tomography (PCT) parameters to predict the risk of vasospasm, delayed cerebral ischemia (DCI), and clinical outcome in patients with aneurysmal subarachnoid hemorrhage (aSAH).
   METHODS: A retrospective cohort study of 38 aSAH patients investigated with PCT within 48 hours after hemorrhage. Cerebral blood flow (CBF), cerebral blood volume, and mean transit time (MIT) values were recorded. Mean values were compared with clinical data. Vasospasm and DCI were determined by imaging and clinical criteria. Neurologic outcome was assessed by the modified Rankin Scale at discharge and 1-year follow-up visit.
   RESULTS: More than a third (39.5%) of patients developed DCI, of whom 86.7% presented moderate-severe vasospasm. There was a significant correlation between perfusion parameters in the early phase and occurrence of DCI and vasospasm. The occurrence of DCI and vasospasm correlated significantly with lower mean early PCT values. DCI was correlated with lower mean early CBF values (P = 0.049) and vasospasm with lower mean CBF (P = 0.01) and MTT (P< 0.00001) values. MIT values of 5.5s were shown to have 94% specificity and 100% sensitivity for predicting the risk of developing vasospasm.
   The severity of the SAH according to the Barrow Neurological Institute scale correlated significantly with the risk of developing DCI and vasospasm, both significantly associated with unfavorable neurologic outcome (modified Rankin Scale score 3-6) (P = 0.0002 and P = 0.02, respectively).
   CONCLUSIONS: Early alterations in PCT parameters and high Barrow Neurological Institute grade may identify a subgroup of patients at high risk of developing DCI and vasospasm after aSAH, thus prompting more robust preventative measures and treatment in this subgroup.
C1 [Starnoni, Daniels; Maduri, Rodolfo; Giammattei, Lorenzo; Rocca, Aida; Messerer, Mahmoud; Daniel, Roy Thomas] Univ Hosp Lausanne CHUV, Dept Clin Neurosci, Serv Neurosurg, Lausanne, Switzerland.
   [Hajdu, Steven David; Grosfilley, Sarah Beatrice; Saliou, Guillaume] Univ Hosp Lausanne CHUV, Diagnost & Intervent Radiol, Lausanne, Switzerland.
   [Pierzchala, Katarzyna] EPFL SB CIBM AIT LIFMET, Ctr Imagerie BioMed, Lausanne, Switzerland.
   [Saliou, Guillaume; Messerer, Mahmoud; Daniel, Roy Thomas] Univ Lausanne UniL, Fac Biol & Med, Lausanne, Switzerland.
RP Maduri, R (reprint author), Univ Hosp Lausanne CHUV, Dept Clin Neurosci, Serv Neurosurg, Lausanne, Switzerland.
EM rodolfo.maduri@gmail.com
RI MADURI, Rodolfo/A-7297-2019
OI MADURI, Rodolfo/0000-0001-6649-5585
CR Binaghi S, 2007, AM J NEURORADIOL, V28, P750
   Bouzat P, 2015, CRIT CARE MED, V43, P445, DOI 10.1097/CCM.0000000000000720
   Claassen J, 2001, STROKE, V32, P2012, DOI 10.1161/hs0901.095677
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   Dankbaar JW, 2009, NEURORADIOLOGY, V51, P813, DOI 10.1007/s00234-009-0575-y
   Dengler NF, 2017, NEUROSURGERY, V81, P341, DOI 10.1093/neuros/nyw141
   Etminan N, 2013, STROKE, V44, P1260, DOI 10.1161/STROKEAHA.111.675975
   FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001
   Foreman B, 2016, J CLIN NEUROPHYSIOL, V33, P174, DOI 10.1097/WNP.0000000000000273
   Friedrich B, 2012, J CEREBR BLOOD F MET, V32, P447, DOI 10.1038/jcbfm.2011.154
   Inagawa T, 2016, WORLD NEUROSURG, V85, P56, DOI 10.1016/j.wneu.2015.08.052
   Jabbarli R, 2013, J STROKE CEREBROVASC, V22, P1332, DOI 10.1016/j.jstrokecerebrovasdis.2013.01.006
   Kamp Marcel A, 2012, Acta Neurochir Suppl, V114, P329, DOI 10.1007/978-3-7091-0956-4_63
   Killeen RP, 2014, AM J NEURORADIOL, V35, P459, DOI 10.3174/ajnr.A3767
   Klimo Paul Jr, 2006, Neurosurg Focus, V21, pE5
   Kumar G, 2015, J ULTRAS MED, V34, P1345, DOI 10.7863/ultra.34.8.1345
   Kunze E, 2012, RADIOL RES PRACT, V2012, DOI 10.1155/2012/231206
   Lagares A, 2012, ACTA NEUROCHIR, V154, P405, DOI 10.1007/s00701-011-1267-z
   Laslo AM, 2008, AM J NEURORADIOL, V29, P79, DOI 10.3174/ajnr.A0747
   Lefournier V, 2010, J NEURORADIOLOGY, V37, P284, DOI 10.1016/j.neurad.2010.03.003
   Maduri R, 2019, ACTA NEUROCHIR, V161, P769, DOI 10.1007/s00701-019-03812-9
   Malinova V, 2016, J NEUROSURG, V125, P128, DOI 10.3171/2015.6.JNS15720
   Mascia L, 2009, F1000 MED REP, VI
   Miranda P, 2006, SURG NEUROL, V65, P247, DOI 10.1016/j.surneu.2005.06.042
   Neidert MC, 2018, NEUROSURGERY, V83, P1286, DOI 10.1093/neuros/nyx609
   Riordan AJ, 2013, AM J NEURORADIOL, V34, P1353, DOI 10.3174/ajnr.A3397
   Rodriguez-Regent C, 2016, EUR RADIOL, V26, P2956, DOI 10.1007/s00330-015-4135-z
   Rowland MJ, 2012, BRIT J ANAESTH, V109, P315, DOI 10.1093/bja/aes264
   Rubbert C, 2017, J NEURORADIOLOGY, V44, P371, DOI 10.1016/j.neurad.2017.06.001
   Sanelli PC, 2011, NEURORADIOLOGY, V53, P425, DOI 10.1007/s00234-010-0752-z
   Schubert GA, 2011, ACTA NEUROCHIR SUPPL, V110, P35, DOI 10.1007/978-3-7091-0353-1_6
   Schubert GA, 2009, J NEUROTRAUM, V26, P2225, DOI 10.1089/neu.2009.0924
   Stienen MN, 2014, WORLD NEUROSURG, V82, pE599, DOI 10.1016/j.wneu.2014.05.011
   Stienen MN, 2018, STROKE, V49, P333, DOI 10.1161/STROKEAHA.117.019328
   Takahashi Y, 2017, ACTA NEUROCHIR, V159, P2319, DOI 10.1007/s00701-017-3362-2
   TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457
   Vergouwen MDI, 2010, STROKE, V41, P2391, DOI 10.1161/STROKEAHA.110.589275
   Wintermark M, 2006, AM J NEURORADIOL, V27, P26
NR 38
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E743
EP E752
DI 10.1016/j.wneu.2019.06.213
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200095
PM 31284055
DA 2020-05-12
ER

PT J
AU Sun, HB
   Jing, XS
   Zhang, GQ
   Hai, Y
   Liu, YZ
   Wang, DC
AF Sun, Hai-Bo
   Jing, Xiao-Shan
   Zhang, Guo-Qiang
   Hai, Yong
   Liu, Yu-Zeng
   Wang, De-Cheng
TI Preliminary Study of Obese Patients with Chronic Obstructive Pulmonary
   Disease Suffering from Painful Osteoporotic Vertebral Compression
   Fracture Treated by Percutaneous Vertebroplasty in Improved Prone
   Position and Right Lateral Position
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chronic obstructive pulmonary disease; Obese patients; Osteoporotic
   vertebral compression fracture; Percutaneous vertebroplasty
ID BILATERAL PUNCTURE TECHNIQUES; TRANSVERSE PROCESS-PEDICLE; CEMENT
   LEAKAGE; RISK-FACTORS; BALLOON KYPHOPLASTY; IDENTIFICATION
AB OBJECTIVE: To assess outcomes in obese patients with chronic obstructive pulmonary disease (COPD) who sustained an osteoporotic vertebral compression fracture (OVCF) treated by percutaneous vertebroplasty (PVP) in the improved prone position and right lateral position.
   METHODS: Between January 2015 and May 2016, a total of 60 patients were enrolled in this randomized controlled study. Patients in group A were placed in the improved prone position for a bilateral transpedicular technique, and those in group B were placed in the right lateral position for a left transverse process-pedicle approach. Clinical and radiologic outcomes were assessed and compared between the 2 groups during the 12-month follow-up period.
   RESULTS: All operations were successfully completed without any serious sequelae. The operation time, fluoroscopic time, scores for respiratory condition during the operation, intravertebral cement volume, and incidence of cement leakage were significantly greater in group A compared with group B (P < 0.01). During the follow-up period, all patients in both groups experienced significant improvement in pain relief. Satisfactory functional improvement was obtained at 3 months postoperatively.
   CONCLUSIONS: Treatment of obese patients with COPD suffering from painful OVCF by PUP in both the improved prone position with a bilateral technique and the right lateral position with a unilateral technique was relatively safe and effective. However, unilateral PVP in the right lateral position was associated with a shorter operation time, limited fluoroscopic time, and minimal cement leakage.
C1 [Sun, Hai-Bo; Zhang, Guo-Qiang] Capital Med Univ, Beijing Friendship Hosp, Dept Orthoped, Beijing, Peoples R China.
   [Jing, Xiao-Shan] Capital Med Univ, Beijing Friendship Hosp, Dept Emergency, Beijing, Peoples R China.
   [Hai, Yong; Liu, Yu-Zeng] Capital Med Univ, Beijing Chaoyang Hosp, Dept Orthoped, Beijing, Peoples R China.
   [Wang, De-Cheng] Beijing Tongzhou Hosp Integrated Chinese & Wester, Dept Orthoped, Beijing, Peoples R China.
RP Sun, HB (reprint author), Capital Med Univ, Beijing Friendship Hosp, Dept Orthoped, Beijing, Peoples R China.
EM spinesurgeon_sun@163.com
RI Hai, Yong/L-6987-2019
OI Hai, Yong/0000-0002-7206-325X
CR Alexandru Daniela, 2012, Perm J, V16, P46
   Barakat AS, 2018, EUR SPINE J, V27, P2584, DOI 10.1007/s00586-017-5267-4
   Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658
   Chen LH, 2011, ARCH ORTHOP TRAUM SU, V131, P927, DOI 10.1007/s00402-010-1236-7
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   Groen RJM, 2004, SPINE, V29, P1465, DOI 10.1097/01.BRS.0000128758.64381.75
   Jin YJ, 2011, SPINE, V36, pE761, DOI 10.1097/BRS.0b013e3181fc914e
   Kim YJ, 2009, RADIOLOGY, V251, P250, DOI 10.1148/radiol.2511080854
   Limthongkul W, 2010, SPINE J, V10, P153, DOI 10.1016/j.spinee.2009.11.018
   Lin J, 2013, PAIN PHYSICIAN, V16, P447
   Ma XL, 2012, EUR SPINE J, V21, P1844, DOI 10.1007/s00586-012-2441-6
   Mattie R, 2016, J BONE JOINT SURG AM, V98, P1041, DOI 10.2106/JBJS.15.00425
   Nieuwenhuijse MJ, 2011, SPINE J, V11, P839, DOI 10.1016/j.spinee.2011.07.027
   Nooh A, 2015, CASE REP ORTHOP, V2015
   Ren HL, 2015, EUR SPINE J, V24, P750, DOI 10.1007/s00586-015-3786-4
   Rousing R, 2010, SPINE, V35, P478, DOI 10.1097/BRS.0b013e3181b71bd1
   Si L, 2015, OSTEOPOROSIS INT, V26, P1929, DOI 10.1007/s00198-015-3093-2
   Sun G, 2014, J SURG ONCOL, V110, P123, DOI 10.1002/jso.23608
   Sun HL, 2016, J ORTHOP SURG RES, V11, DOI 10.1186/s13018-016-0479-6
   Tome-Bermejo F, 2014, SPINE, V39, pE693, DOI 10.1097/BRS.0000000000000294
   Wang BA, 2016, EUR SPINE J, V25, P3486, DOI 10.1007/s00586-016-4425-4
   Yan L, 2016, OSTEOPOROSIS INT, V27, P1849, DOI 10.1007/s00198-015-3430-5
   Yan L, 2014, SPINE, V39, pB19, DOI 10.1097/BRS.0000000000000493
   Yang SF, 2016, INT J SURG, V36, P138, DOI 10.1016/j.ijsu.2016.10.030
   Yeom JS, 2003, J BONE JOINT SURG BR, V85B, P83, DOI 10.1302/0301-620X.85B1.13026
   Yi HJ, 2016, PAIN PHYSICIAN, V19, pE743
   Zhai WF, 2015, INT J CLIN EXP MED, V8, P20861
   Zhong BY, 2017, PAIN PHYSICIAN, V20, pE513
NR 28
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E933
EP E940
DI 10.1016/j.wneu.2019.07.040
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200117
PM 31302276
DA 2020-05-12
ER

PT J
AU Sun, YJ
   Su, YY
   Chen, ZY
   He, YB
   Zhang, YB
   Chen, HB
AF Sun, Yijia
   Su, Yingying
   Chen, Zhongyun
   He, Yanbo
   Zhang, Yingbo
   Chen, Hongbo
TI Contrast Extravasation After Endovascular Treatment in Posterior
   Circulation Stroke
SO WORLD NEUROSURGERY
LA English
DT Article
DE Contrast extravasation; Dual-energy computed tomography; Endovascular
   treatment; Intracranial hemorrhage; Stroke
ID ACUTE ISCHEMIC-STROKE; DUAL-ENERGY CT; HEMORRHAGE; OUTCOMES; OCCLUSION;
   THERAPY; REVASCULARIZATION; THROMBOLYSIS; THROMBECTOMY; PREDICTORS
AB OBJECTIVE: Endovascular treatment (EVT) is a promising clinical technology. However, some patients with posterior circulation stroke might not experience neurological function recovery after EVT. We reviewed the recent experience with EVT to clarify the clinical and radiographic factors that contribute to optimal neurological outcomes.
   METHODS: We analyzed the data from 108 consecutive patients with acute posterior circulation stroke who had undergone EVT from January 2016 to December 2018. A favorable outcome was defined as a modified Rankin scale score of 0-3 at 3 months. We evaluated the association and predictive value of the clinical and radiographic factors that contribute to good neurological outcomes.
   RESULTS: Of the 108 included patients, 43 had a favorable clinical outcome at day 90. Univariate analysis revealed a significant association between the 90-day favorable outcome and the baseline values of systolic blood pressure, time of stroke onset, contrast extravasation, symptomatic intracranial hemorrhage, general anesthesia, Alberta stroke program early computed tomography score for the posterior circulation, and the National Institutes of Health stroke scale (NIHSS) score. Contrast extravasation (odds ratio [OR], 5.094; 95% confidence interval [CI], 1.22-21.261), symptomatic intracranial hemorrhage (OR, 11.24; 95% CI, 1.309-96.517), general anesthesia (OR, 5.094; 95% CI, 1.22-21.26), and baseline NIHSS score (OR, 1.087; 95% CI, 1.023-1.309) were found to be independent predictors of a favorable outcome at day 90. Contrast extravasation alone predicted for unfavorable clinical outcomes and mortality with high specificity.
   CONCLUSION: In the present retrospective case series, contrast extravasation, symptomatic intracranial hemorrhage, the use of general anesthesia, and baseline NIHSS score were related to a favorable prognosis for patients with posterior circulation stroke after EVT. Contrast extravasation was an independent and strong predictor of unfavorable clinical outcomes.
C1 [Sun, Yijia; Su, Yingying; Chen, Zhongyun] Capital Med Univ, Xuan Wu Hosp, Dept Neurol, Beijing, Peoples R China.
   [He, Yanbo] Beijing Moslem People Hosp, Dept Neurol, Beijing, Peoples R China.
   [Zhang, Yingbo] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Dept Neurol, Beijing, Peoples R China.
   [Chen, Hongbo] Liangxiang Hosp Beijing, Dept Neurol, Beijing, Peoples R China.
RP Su, YY (reprint author), Capital Med Univ, Xuan Wu Hosp, Dept Neurol, Beijing, Peoples R China.
EM suyingyingxwy@126.com
CR Bouslama M, 2017, STROKE, V48, P3252, DOI 10.1161/STROKEAHA.117.018270
   Brinjikji W, 2017, STROKE, V48, P2784, DOI 10.1161/STROKEAHA.117.017786
   Gory B, 2018, CEREBROVASC DIS, V45, P61, DOI 10.1159/000486690
   Gory B, 2018, J NEUROSURG, V129, P1482, DOI 10.3171/2017.7.JNS171043
   Gupta R, 2010, RADIOLOGY, V257, P205, DOI 10.1148/radiol.10091806
   Kang DH, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009419
   Khatri R, 2010, J NEUROINTERV SURG, V2, P115, DOI 10.1136/jnis.2009.000794
   Krueger M, 2017, J CEREBR BLOOD F MET, V37, P2539, DOI 10.1177/0271678X16670922
   Lin SF, 2018, J NEUROL, V265, P926, DOI 10.1007/s00415-018-8746-6
   Nikoubashman O, 2014, NEURORADIOLOGY, V56, P1087, DOI 10.1007/s00234-014-1424-1
   Payabvash S, 2014, NEURORADIOLOGY, V56, P737, DOI 10.1007/s00234-014-1381-8
   Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158
   Sajobi TT, 2017, STROKE, V48, P105, DOI 10.1161/STROKEAHA.116.014456
   Schneck MJ, 2018, STROKE, V49, P2565, DOI 10.1161/STROKEAHA.118.023201
   Schonewille WJ, 2005, J NEUROL NEUROSUR PS, V76, P1238, DOI 10.1136/jnnp.2004.049924
   Shireman TI, 2017, STROKE, V48, P379, DOI 10.1161/STROKEAHA.116.014735
   Simonsen CZ, 2018, JAMA NEUROL, V75, P470, DOI 10.1001/jamaneurol.2017.4474
   Talke PO, 2014, STROKE, V45, pE138, DOI 10.1161/STROKEAHA.113.003412
   Tijssen MPM, 2014, EUR RADIOL, V24, P834, DOI 10.1007/s00330-013-3073-x
   van den Berg LA, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1669-6
   Vanacker P, 2016, CRIT CARE MED, V44, pE336, DOI 10.1097/CCM.0000000000001630
   Yang Y, 2017, INT J SURG, V39, P197, DOI 10.1016/j.ijsu.2017.02.002
   Yoon W, 2004, STROKE, V35, P876, DOI 10.1161/01.STR.0000120726.69501.74
   Zhang YB, 2018, CHINESE MED J-PEKING, V131, P137, DOI 10.4103/0366-6999.222343
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E583
EP E587
DI 10.1016/j.wneu.2019.06.156
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200073
PM 31254696
DA 2020-05-12
ER

PT J
AU Suya, D
   Shao, LW
   Gu, R
   Xu, QL
   Luo, WQ
AF Suya, Danny
   Shao, Liwei
   Gu, Rui
   Xu, Qinli
   Luo, Wenqi
TI Could Nonstructural Interbody Fusion Be an Alternative Surgical
   Technique for Treatment of Single Segment Thoracic and Lumbar Spinal
   Tuberculosis via a Posterior- Only Approach?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Interbody fusion; Nonstructural; Posterior approach only; Structural;
   Thoracic and lumbar spinal tuberculosis
ID ANTERIOR; BONE; INSTRUMENTATION; RECONSTRUCTION; DEBRIDEMENT; KYPHOSIS;
   OUTCOMES; DORSAL; GRAFT; CAGES
AB OBJECTIVE: To compare and evaluate the efficacy and safety of nonstructural versus structural interbody fusion, using a combination of autograft and allograft bone for treatment of single segment thoracic and lumbar spinal tuberculosis (TB) via a posterior-only approach.
   METHODS: We retrospectively analyzed 37 patients who were surgically treated in our department for thoracic and lumbar spinal TB between March 2015 and March 2018 and met our inclusion criteria. Eighteen of these 37 patients underwent nonstructural interbody fusion (group A), whereas the other 19 underwent structural interbody fusion with the aid of titanium mesh cages (group B). We compared and analyzed visual analog scale scores, erythrocyte sedimentation rate, blood loss, operation time, bone fusion rates, and correction angles.
   RESULTS: The average duration of follow-up was 20.33 +/- 4.73 months (range, 12-26 months) in group A and 19.63 +/- 4.63 months (range, 12-26 months), in group B. All patients showed significant improvement in neurologic function by 1 or 2 grades. Bone fusion was achieved in all patients, with no statistically significant difference between the 2 groups (P > 0.05). However, there were significant between-group differences in operation time (mean, 196.28 +/- 43.49 minutes [range, 128-300 minutes] in group A vs. 223.26 +/- 46.34 minutes [range, 150-300 minutes] in group B; P < 0.05) and estimated blood loss (mean, 474.44 +/- 224.37 mL [range, 200-900 mL] in group A vs. 585.79 +/- 378.82 mL [range, 200-1500] in group B; P < 0.05).
   CONCLUSION: The 2 surgical techniques may well have achieved similar results in terms of decreasing bone fusion time, improving neurologic function, and correcting kyphotic angles. However, the nonstructural interbody fusion technique exhibited less blood loss and faster operation time, and thus could serve as an alternative surgical technique for treatment of single-segment thoracic and lumbar spinal TB.
C1 [Suya, Danny; Shao, Liwei; Gu, Rui; Xu, Qinli; Luo, Wenqi] Jilin Univ, Dept Orthoped Surg, China Japan Union Hosp, Changchun, Jilin, Peoples R China.
RP Gu, R (reprint author), Jilin Univ, Dept Orthoped Surg, China Japan Union Hosp, Changchun, Jilin, Peoples R China.
EM 1317057649@qq.com
RI shao, liwei/AAF-6934-2019
OI Suya, Danny/0000-0002-6131-1254
FU Jilin Province Department of Finance [3D517N903430]
FX This study was funded by the Jilin Province Department of Finance
   (3D517N903430, to R. Gu).
CR Assaghir YM, 2016, EUR SPINE J, V25, P3884, DOI 10.1007/s00586-016-4516-2
   Darbyshire J, 1998, J BONE JOINT SURG BR, V80B, P456
   Du X, 2019, INT J SURG, V65, P134, DOI 10.1016/j.ijsu.2019.04.002
   Dunn RN, 2018, BONE JOINT J, V100B, P425, DOI 10.1302/0301-620X.100B4.BJJ-2017-1040.R1
   Dvorak MF, 2003, SPINE, V28, P902, DOI 10.1097/00007632-200305010-00012
   Fayazi Amir H, 2004, Spine J, V4, P388, DOI 10.1016/j.spinee.2004.01.004
   Gao YJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175567
   Grob D, 2005, EUR SPINE J, V14, P211, DOI 10.1007/s00586-004-0748-7
   HODGSON AR, 1960, BRIT J SURG, V48, P172, DOI 10.1002/bjs.18004820819
   Huang YP, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0994-8
   LEE CK, 1995, SPINE, V20, P356, DOI 10.1097/00007632-199502000-00018
   Liu JM, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004677
   Liu Z, 2018, INT ORTHOP, V42, P1883, DOI 10.1007/s00264-018-3807-0
   Liu ZL, 2014, ARCH ORTHOP TRAUM SU, V134, P1051, DOI 10.1007/s00402-014-2016-6
   MOON MS, 1995, SPINE, V20, P1910, DOI 10.1097/00007632-199509000-00013
   RAJASEKARAN S, 1989, J BONE JOINT SURG AM, V71A, P1314, DOI 10.2106/00004623-198971090-00006
   Rajasekaran S, 2012, INT ORTHOP, V36, P359, DOI 10.1007/s00264-011-1469-2
   Rexiti P, 2018, WORLD NEUROSURG, V120, pE392, DOI 10.1016/j.wneu.2018.08.081
   Sundararaj GD, 2011, ASIAN SPINE J, V5, P155, DOI 10.4184/asj.2011.5.3.155
   Ukunda UNE, 2018, BONE JOINT J, V100B, P1208, DOI 10.1302/0301-620X.100B9.BJJ-2017-1326.R2
   van der Donk S, 2003, CLIN ORTHOP RELAT R, P302, DOI 10.1097/01.blo.0000038051-29678.37
   WEINSTEIN JN, 1992, CLIN ORTHOP RELAT R, P34
   WHO, GLOB TUB REP 2018
   Wu WJ, 2018, WORLD NEUROSURG, V110, pE842, DOI 10.1016/j.wneu.2017.11.126
   Zhang HQ, 2018, J ORTHOP SURG-HONG K, V26, DOI 10.1177/2309499018806684
   Zhang HQ, 2015, J ORTHOP SURG RES, V10, DOI 10.1186/s13018-015-0292-7
   Zhang PH, 2016, BRIT J NEUROSURG, V30, P666, DOI 10.1080/02688697.2016.1206182
NR 27
TC 0
Z9 0
U1 4
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E316
EP E323
DI 10.1016/j.wneu.2019.06.072
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200037
PM 31226454
DA 2020-05-12
ER

PT J
AU Sweid, A
   Rahm, SP
   Das, S
   Baldassari, MP
   Jabbour, P
   Alexander, TD
   Velagapudi, L
   Chalouhi, N
   Gooch, MR
   Herial, N
   Rosenwasser, RH
   Tjoumakaris, S
AF Sweid, Ahmad
   Rahm, Sage P.
   Das, Somnath
   Baldassari, Michael P.
   Jabbour, Pascal
   Alexander, Tyler D.
   Velagapudi, Lohit
   Chalouhi, Nohra
   Gooch, Michael R.
   Herial, Nabeel
   Rosenwasser, Robert H.
   Tjoumakaris, Stavropoula
TI Safety and Efficacy of Bilateral Flow Diversion for Treatment of
   Anterior Circulation Cerebral Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysms; Bilateral aneurysms; Embolization; Endovascular; Flow
   diversion; Two-stage approach
ID MULTIPLE INTRACRANIAL ANEURYSMS; PIPELINE EMBOLIZATION DEVICE; ARTERY
   ANEURYSMS; ENDOVASCULAR TREATMENT; COIL EMBOLIZATION; RECONSTRUCTION;
   HEMORRHAGE; EXPERIENCE; OUTCOMES
AB BACKGROUND: Nearly 20% of individuals with an aneurysm will have multiple aneurysms-these individuals are at increased risk of subarachnoid hemorrhage. Treatment of bilateral aneurysms with flow diverters (FDs), or Pipeline embolization device, has not yet been established as an effective therapy. We evaluated the safety and efficacy of a 2-stage treatment of bilateral aneurysms with Pipeline embolization devices placed 6 months apart.
   METHODS: We performed a retrospective review to analyze the clinical and angiographic outcomes of 16 individuals with bilateral aneurysms treated with 2-stage flow diversion at a tertiary referral center from January 2010 to July 2018.
   RESULTS: Of the 16 patients with 33 aneurysms treated with bilateral flow diversion, 1 had 2 aneurysms treated with a single FD on the contralateral side. The aneurysms treated were ophthalmic, superior hypophyseal, posterior communicating, or cavernous segment aneurysms, with an average size of 6.5 mm. No major complications, such as in-stent stenosis, thromboembolic events, distal intraparenchymal hemorrhage, rerupture, stent migration, or neurological death, were recorded. All the patients had good functional outcomes. At the 24-month follow-up examination, 81% of aneurysms showed complete occlusion. No aneurysm required repeat treatment.
   CONCLUSIONS: The results from the present study have demonstrated that 2-stage treatment of bilateral aneurysms with FDs is both safe and efficacious. The timing of contralateral FD stent placement is critical. We found that 6 months allows for adequate neurological recovery and stent endothelialization.
C1 [Tjoumakaris, Stavropoula] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA.
   Jefferson Hosp Neurosci, Philadelphia, PA USA.
RP Tjoumakaris, S (reprint author), Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA.
EM Stavropoula.tjoumakaris@jefferson.edu
OI Herial, Nabeel/0000-0002-5790-783X; Sweid, Ahmad/0000-0002-2652-2451
CR Acik V, 2017, WORLD NEUROSURG, V108, P774, DOI 10.1016/j.wneu.2017.09.078
   Andic C, 2017, J NEUROINTERV SURG, V9, P1069, DOI 10.1136/neurintsurg-2016-012745
   Andrade-Barazarte H, 2015, NEUROSURGERY, V77, P916, DOI 10.1227/NEU.0000000000000930
   Becske T, 2017, J NEUROSURG, V127, P81, DOI 10.3171/2015.6.JNS15311
   Becske T, 2017, NEUROSURGERY, V80, P40, DOI 10.1093/neuros/nyw014
   Becske T, 2013, RADIOLOGY, V267, P858, DOI 10.1148/radiol.13120099
   Beydoun HA, 2018, WORLD NEUROSURG, V114, pE938, DOI 10.1016/j.wneu.2018.03.120
   Campi A, 2007, STROKE, V38, P1538, DOI 10.1161/STROKEAHA.106.466987
   Chalouhi N, 2013, STROKE, V44, P2150, DOI 10.1161/STROKEAHA.113.001785
   Chalouhi N, 2013, NEUROSURGERY, V72, P390, DOI 10.1227/NEU.0b013e31828046a6
   Cho MJ, 2017, WORLD NEUROSURG, V108, P627, DOI 10.1016/j.wneu.2017.08.175
   Cho YD, 2016, CLIN NEURORADIOL, V26, P285, DOI 10.1007/s00062-014-0367-6
   Choi CY, 2011, J CLIN NEUROSCI, V18, P260, DOI 10.1016/j.jocn.2010.04.032
   Colby GP, 2018, J NEUROSURG, V129, P1475, DOI 10.3171/2017.7.JNS171289
   Dinc C, 2006, NEUROL MED-CHIR, V46, P438, DOI 10.2176/nmc.46.438
   Giorgianni A, 2015, INTERV NEURORADIOL, V21, P23, DOI [10.11771591019915575441, 10.1177/1591019915575441]
   Hong T, 2009, SURG NEUROL, V72, pS23, DOI 10.1016/j.surneu.2007.12.031
   Hong Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082311
   Hopf NJ, 2009, MINIM INVAS NEUROSUR, V52, P126, DOI 10.1055/s-0029-1225618
   Hughes JD, 2018, WORLD NEUROSURG, V115, P430, DOI 10.1016/j.wneu.2018.03.220
   Inci S, 2012, NEUROSURG REV, V35, P505, DOI 10.1007/s10143-012-0392-3
   Jeon P, 2014, AM J NEURORADIOL, V35, P1170, DOI 10.3174/ajnr.A3821
   Kallmes DF, 2015, AM J NEURORADIOL, V36, P108, DOI 10.3174/ajnr.A4111
   Kallmes DF, 2016, INTERV NEUROL, V5, P89, DOI 10.1159/000446503
   Kelkar PS, 2014, NEUROSURGERY, V74, pE226, DOI 10.1227/NEU.0000000000000127
   Kuhn AL, 2019, INTERV NEURORADIOL, V25, P4, DOI 10.1177/1591019918792536
   Lu HT, 2013, CLIN NEUROL NEUROSUR, V115, P690, DOI 10.1016/j.clineuro.2012.08.011
   Lv XL, 2016, NEURORADIOL J, V29, P66, DOI 10.1177/1971400915621321
   Lylyk P, 2009, NEUROSURGERY, V64, P632, DOI 10.1227/01.NEU.0000339109.98070.65
   Mitchell Bartley, 2014, J Vasc Interv Neurol, V7, P5
   Molyneux Andrew, 2002, J Stroke Cerebrovasc Dis, V11, P304, DOI 10.1053/jscd.2002.130390
   Murayama Y, 2003, J NEUROSURG, V98, P959, DOI 10.3171/jns.2003.98.5.0959
   Murrone D, 2018, INT J SURG CASE REP, V42, P191, DOI 10.1016/j.ijscr.2017.12.011
   O'Kelly CJ, 2010, INTERV NEURORADIOL, V16, P133, DOI 10.1177/159101991001600204
   Oh Keun, 2013, J Cerebrovasc Endovasc Neurosurg, V15, P184, DOI 10.7461/jcen.2013.15.3.184
   Puffer RC, 2014, AM J NEURORADIOL, V35, P948, DOI 10.3174/ajnr.A3826
   Raymond J, 2003, STROKE, V34, P1398, DOI 10.1161/01.STR.0000073841.88563.E9
   Roka YB, 2013, NEPAL J NEUROSCI, V10, P86
   Salunke P, 2010, BRIT J NEUROSURG, V24, P686, DOI 10.3109/02688697.2010.515320
   Shin BG, 2005, ACTA NEUROCHIR, V147, P33, DOI 10.1007/s00701-004-0411-4
   Singh Saraj K, 2018, Surg Neurol Int, V9, P80, DOI 10.4103/sni.sni_478_17
   Solander S, 1999, J NEUROSURG, V90, P857, DOI 10.3171/jns.1999.90.5.0857
   Szikora I, 2010, AM J NEURORADIOL, V31, P1139, DOI 10.3174/ajnr.A2023
   Tsang ACO, 2016, CLIN NEURORADIOL, V26, P477, DOI 10.1007/s00062-016-0499-y
   VAJDA J, 1992, ACTA NEUROCHIR, V118, P59, DOI 10.1007/BF01400727
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   WINN HR, 1983, J NEUROSURG, V59, P642, DOI 10.3171/jns.1983.59.4.0642
   Yasui N, 1996, NEUROSURGERY, V39, P1096, DOI 10.1097/00006123-199612000-00004
NR 48
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E1116
EP E1121
DI 10.1016/j.wneu.2019.07.115
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200139
PM 31330338
DA 2020-05-12
ER

PT J
AU Sweid, A
   Head, J
   Tjoumakaris, S
   Xu, V
   Shivashankar, K
   Alexander, TD
   Dougherty, JA
   Gooch, MR
   Herial, N
   Hasan, D
   DePrince, M
   Rosenwasser, RH
   Jabbour, P
AF Sweid, Ahmad
   Head, Jeffery
   Tjoumakaris, Stavropoula
   Xu, Vivian
   Shivashankar, Kavya
   Alexander, Tyler D.
   Dougherty, Jaime A.
   Gooch, Michael R.
   Herial, Nabeel
   Hasan, David
   DePrince, Maureen
   Rosenwasser, Robert H.
   Jabbour, Pascal
TI Mechanical Thrombectomy in Distal Vessels: Revascularization Rates,
   Complications, and Functional Outcome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute ischemic stroke; Distal thrombectomy; Mechanical thrombectomy
ID ENDOVASCULAR TREATMENT; M2 OCCLUSIONS; ISCHEMIC-STROKE; THERAPY
AB INTRODUCTION: Pivotal trials have shown the tremendous efficacy of mechanical thrombectomy in proximal occlusions. However distal occlusions involving second-order branches of the middle cerebral artery and beyond, anterior cerebral and posterior cerebral arteries were not represented. In this study, we investigated the feasibility and safety of distal circulation mechanical thrombectomy.
   METHODS: A retrospective review of patients presenting with distal circulation acute ischemic stroke who underwent mechanical thrombectomy 2010 and 2018.
   RESULTS: Of 453 patients who underwent mechanical thrombectomy for acute ischemic stroke, 76 had a distal occlusion. The mean National Institute Health Stroke Scale on admission was 12. Vessels involved included second-order branches of the middle cerebral artery (89%), third-and fourth-order branches of the middle cerebral artery (5%), second-order branch of the anterior cerebral artery (3%), and posterior cerebral artery (3%). Most procedures required 1 pass to recanalize the vessel (55%, n = 42). Thrombolysis in Cerebral Infarction score >= Ilb was achieved in 89% of subjects. Mortality rate was 8% and independent functional outcome of m Rankin score <= 2 at 3 months was seen in 643% with clinical follow-up. On multivariate analysis, distal circulation had a significantly shorter length of stay by about 2 days, compared with proximal circulation. Subjects with proximal occlusion were more than 5 times more likely to have a good Thrombolysis in Cerebral Infarction score compared with the distal group. There was no significant difference in periprocedural and postprocedural complications, good functional outcome at 3 months, and mortality between both groups.
   CONCLUSIONS: Mechanical thrombectomy procedure for distal circulation strokes is as effective and safe as a proximal group. Though distal vessels supply smaller brain area; however, when symptoms are pronounced, the benefit of the procedure outweighs the risks.
C1 [Sweid, Ahmad; Head, Jeffery; Tjoumakaris, Stavropoula; Xu, Vivian; Shivashankar, Kavya; Alexander, Tyler D.; Dougherty, Jaime A.; Gooch, Michael R.; Herial, Nabeel; DePrince, Maureen; Rosenwasser, Robert H.; Jabbour, Pascal] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA.
   [Sweid, Ahmad; Head, Jeffery; Tjoumakaris, Stavropoula; Xu, Vivian; Shivashankar, Kavya; Alexander, Tyler D.; Dougherty, Jaime A.; Gooch, Michael R.; Herial, Nabeel; DePrince, Maureen; Rosenwasser, Robert H.; Jabbour, Pascal] Jefferson Hosp Neurosci, Philadelphia, PA 19107 USA.
   [Hasan, David] Univ Iowa, Dept Neurosurg, Iowa City, IA USA.
RP Jabbour, P (reprint author), Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA.; Jabbour, P (reprint author), Jefferson Hosp Neurosci, Philadelphia, PA 19107 USA.
EM pascal.jabbour@jefferson.edu
OI Sweid, Ahmad/0000-0002-2652-2451; Herial, Nabeel/0000-0002-5790-783X
CR AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45
   Barber PA, 2000, LANCET, V355, P1670, DOI 10.1016/S0140-6736(00)02237-6
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Campbell BCV, 2016, STROKE VASC NEUROL, V1, P16, DOI 10.1136/svn-2015-000004
   Coutinho JM, 2016, AM J NEURORADIOL, V37, P667, DOI 10.3174/ajnr.A4591
   Dorn F, 2015, J STROKE CEREBROVASC, V24, P1465, DOI 10.1016/j.jstrokecerebrovasdis.2015.04.013
   Flores A, 2015, J NEUROINTERV SURG, V7, P234, DOI 10.1136/neurintsurg-2014-011100
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Haussen DC, 2016, J NEUROINTERV SURG, V8, P295, DOI 10.1136/neurintsurg-2014-011613
   JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Kim Y-W, 2017, J NEUROINTERV SURG, V9, P353
   Lima FO, 2014, JAMA NEUROL, V71, P151, DOI 10.1001/jamaneurol.2013.5007
   Powers WJ, 2015, STROKE, V46, P3020, DOI 10.1161/STR.0000000000000074
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Sheth SA, 2015, J NEUROINTERV SURG, V7, P478, DOI 10.1136/neurintsurg-2014-011232
NR 17
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E1098
EP E1104
DI 10.1016/j.wneu.2019.07.098
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200136
PM 31323418
DA 2020-05-12
ER

PT J
AU Tanaka, J
   Hosoda, K
   Matsuo, K
   Kyotani, K
   Takemoto, Y
   Yamamoto, Y
   Fujita, A
   Kohta, M
   Kimura, H
   Sasayama, T
   Kohmura, E
AF Tanaka, Jun
   Hosoda, Kohkichi
   Matsuo, Kazuya
   Kyotani, Katsusuke
   Takemoto, Youta
   Yamamoto, Yusuke
   Fujita, Atsushi
   Kohta, Masaaki
   Kimura, Hidehito
   Sasayama, Takashi
   Kohmura, Eiji
TI Pencil Beam Presaturation Magnetic Resonance Imaging Helps to Identify
   Patients at Risk for Intolerance to Temporary Internal Carotid Artery
   Occlusion During Carotid Endarterectomy and Carotid Artery Stenting
SO WORLD NEUROSURGERY
LA English
DT Article
DE BeamSAT; CAS; CEA; ICA-selective MRA; Intolerance
ID BLOOD-FLOW; WILLIS; CIRCLE; PREDICTION; AGREEMENT; ISCHEMIA
AB BACKGROUND: There has been no effective method to predict ischemic intolerance to temporary internal carotid artery (ICA) occlusion during carotid artery reconstruction. Pencil beam presaturation (BeamSAT) pulse suppresses the flow signal of the target vessel in magnetic resonance angiography (MRA). Applying this method, we constructed ICA-selective MRA images. The aim of this study was to identify patients at risk for ischemic intolerance by ICA-selective MRA.
   METHODS: By evaluating flow of anterior communicating artery (Acom) and A1 portion of anterior cerebral artery with ICA-selective MRA and posterior communicating artery (Pcom) with conventional MRA, we investigated associations of these collateral flow patterns with ischemic intolerance and decrease of regional cerebral oxygen saturation.
   RESULTS: The study included 58 patients who underwent carotid endarterectomy or carotid artery stenting. Six of 7 patients without Acorn flow and Pcom flow demonstrated ischemic intolerance, whereas all patients (n = 51) with Acom and/or Pcom flow demonstrated tolerance. The accuracy of this prediction model according to Acom and Pcom flow patterns for ischemic intolerance was 0.98 (P = 0.01, binomial test). Regional cerebral oxygen saturation decrease after ICA occlusion was significantly larger in patients without Acom flow and Pcom flow (12.0% +/- 6.0%) than in patients with Acom flow and Pcom flow (3.0% +/- 3.1%, P< 0.01) and in patients with Acorn flow but no Pcom flow (2.4% +/- 5.2%, P< 0.01).
   CONCLUSIONS: These findings support the importance of Acorn flow as a collateral route. ICA-selective MRA enables prediction of ischemic intolerance to temporary ICA occlusion during carotid endarterectomy or carotid artery stenting. This method provides valuable information regarding probability of an ischemic complication.
C1 [Tanaka, Jun; Matsuo, Kazuya; Yamamoto, Yusuke; Fujita, Atsushi; Kohta, Masaaki; Kimura, Hidehito; Sasayama, Takashi; Kohmura, Eiji] Kobe Univ, Grad Sch Med, Dept Neurosurg, Kobe, Hyogo, Japan.
   [Hosoda, Kohkichi] Kobe City Nishi Kobe Med Ctr, Dept Neurosurg, Kobe, Hyogo, Japan.
   [Kyotani, Katsusuke; Takemoto, Youta] Kobe Univ Hosp, Ctr Radiol & Radiat Oncol, Kobe, Hyogo, Japan.
RP Hosoda, K (reprint author), Kobe City Nishi Kobe Med Ctr, Dept Neurosurg, Kobe, Hyogo, Japan.
EM khosoda@med.kobe-u.ac.jp
RI Fujita, Atsushi/Q-6619-2019; Hosoda, Kohkichi/AAF-1949-2020
OI Fujita, Atsushi/0000-0003-1294-6584; Kohta, Masaaki/0000-0001-5936-7163;
   Sasayama, Takashi/0000-0002-5593-9045; Hosoda,
   Kohkichi/0000-0002-0419-9497; Matsuo, Kazuya/0000-0001-6721-1353
FU Japan Society for the Promotion of ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [15K10302, 18K08994]
FX K. Hosoda is supported in part by the Japan Society for the Promotion of
   Science Grant-in-Aid for Scientific Research (KAKENHI) Number 15K10302
   and 18K08994.
CR Akutsu N, 2012, AM J NEURORADIOL, V33, P1557, DOI 10.3174/ajnr.A3002
   ALPERS BJ, 1959, ARCH NEURO PSYCHIATR, V81, P409, DOI 10.1001/archneurpsyc.1959.02340160007002
   Bianchi PG, 2012, INT ANGIOL, V31, P22
   Chaer RA, 2006, J VASC SURG, V43, P946, DOI 10.1016/j.jvs.2006.01.007
   Chuang YM, 2007, EUR NEUROL, V57, P208, DOI 10.1159/000099160
   COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104
   Doblar DD, 1998, STROKE, V29, P2038, DOI 10.1161/01.STR.29.10.2038
   Halliday A, 2004, LANCET, V363, P1491
   Hans SS, 2015, J VASC SURG, V61, P915, DOI 10.1016/j.jvs.2014.11.046
   Imahori T, 2016, J STROKE CEREBROVASC, V25, P360, DOI 10.1016/j.jstrokecerebrovasdis.2015.10.007
   Ito K, 2014, J STROKE CEREBROVASC, V23, P1019, DOI 10.1016/j.jstrokecerebrovasdis.2013.08.018
   Kardile PB, 2013, J CLIN DIAGN RES, V7, P386, DOI [10.7860/JCDR/2013/6664.3725, 10.7860/JCDR/2013/5304.2778, 10.7860/JCOR/2013/6664.3725]
   Komiyama M., 2007, FUNCTIONAL ANATOMY B
   Krabbe-Hartkamp MJ, 1998, RADIOLOGY, V207, P103, DOI 10.1148/radiology.207.1.9530305
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lee JH, 2004, AM J NEURORADIOL, V25, P558
   Montisci R, 2013, EUR J VASC ENDOVASC, V45, P107, DOI 10.1016/j.ejvs.2012.11.012
   Murkin J M, 2009, Br J Anaesth, V103 Suppl 1, pi3, DOI 10.1093/bja/aep299
   Pennekamp CWA, 2013, EUR J VASC ENDOVASC, V46, P631, DOI 10.1016/j.ejvs.2013.09.007
   PUCHADESORTS A, 1976, ANAT REC, V185, P119, DOI 10.1002/ar.1091850112
   Shahidi S, 2017, J CARDIOVASC SURG, V58, P431, DOI 10.23736/S0021-9509.16.08173-8
   Shin S, 2013, WORLD J SURG, V37, P663, DOI 10.1007/s00268-012-1851-2
   Spacek M, 2015, INT J ANGIOL, V24, P236, DOI 10.1055/s-0034-1370889
   Sussman ES, 2014, J NEUROSURG, V121, P593, DOI 10.3171/2014.5.JNS131736
   TAYLOR DW, 1991, NEW ENGL J MED, V325, P445
   Uchihashi Y, 2011, AM J NEURORADIOL, V32, P1545, DOI 10.3174/ajnr.A2525
   WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035
   Woodworth GF, 2007, NEUROSURGERY, V61, P1170, DOI 10.1227/01.neu.0000306094.15270.40
   Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127
   Yamamoto D, 2017, WORLD NEUROSURG, V102, P477, DOI 10.1016/j.wneu.2017.03.037
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E899
EP E907
DI 10.1016/j.wneu.2019.07.033
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200113
PM 31301443
DA 2020-05-12
ER

PT J
AU Tang, AM
   Bakhsheshian, J
   Ding, L
   Jarvis, CA
   Yuan, E
   Strickland, B
   Giannotta, SL
   Amar, A
   Attenello, FJ
   Mack, WJ
AF Tang, Austin M.
   Bakhsheshian, Joshua
   Ding, Li
   Jarvis, Casey A.
   Yuan, Edith
   Strickland, Ben
   Giannotta, Steven L.
   Amar, Arun
   Attenello, Frank J.
   Mack, William J.
TI Nonindex Readmission After Ruptured Brain Aneurysm Treatment Is
   Associated with Higher Morbidity and Repeat Readmission
SO WORLD NEUROSURGERY
LA English
DT Article
DE Care fragmentation; Cerebral aneurysm; Continuity of care; Nonindex
   readmission; Quality improvement; Subarachnoid hemorrhage
ID LENGTH-OF-STAY; SUBARACHNOID HEMORRHAGE; HOSPITAL READMISSIONS;
   MEDICATION ADHERENCE; ADMINISTRATIVE DATA; STROKE COUNCIL; OUTCOMES;
   CARE; GUIDELINES; CONTINUITY
AB BACKGROUND: Aneurysmal subarachnoid hemorrhage (aSAH) requires complex multidisciplinary care. After initial treatment (index hospital), readmission to a different hospital (nonindex) can compromise quality of care, resulting in increased morbidity. We aimed to evaluate factors associated with nonindex readmission and evaluate association of nonindex hospital readmission on outcomes in patients with ruptured aneurysm.
   METHODS: Readmissions within 90 days after aSAH treatment were identified in the 2010-2014 Nationwide Readmissions Database. Multivariable logistic regression identified patient and hospital characteristics associated with nonindex readmission. Separate multivariable models determined increased morbidity or risk of second readmission for nonindex readmissions.
   RESULTS: A total of 9254 patients who underwent treatment of ruptured aneurysms from 2010 to 2014 were identified. Of these, 1985 (21.5%) were readmitted within 90 days. Three hundred and fifty-five of these readmissions (17.9%) occurred to nonindex hospitals. Patients that were discharged to a skilled nursing or other facility (odds ratio [OR] 1.70; 95% confidence interval [CI], 1.27-2.28]) had higher odds of nonindex readmission, whereas patients with private insurance were associated with lower odds of nonindex readmission (OR, 0.65; 95% CI, 0.46-0.92). Patients readmitted to a nonindex (vs. index) hospital were associated with increased likelihood of major complications (OR, 1.71; 95% CI, 1.18-2.48) and second readmissions (OR, 1.51; 95% CI, 1.17-1.96).
   CONCLUSIONS: After treatment of a ruptured cerebral aneurysm, 17.9% of readmissions occurred at a nonindex hospital. These patients were at increased risk for major complications or subsequent readmissions, which may be because of care fragmentation. Interventions aimed at improving continuity of care may reduce higher morbidity associated with nonindex readmission.
C1 [Bakhsheshian, Joshua; Strickland, Ben; Giannotta, Steven L.; Amar, Arun; Attenello, Frank J.; Mack, William J.] Univ Southern Calif, Dept Neurol Surg, Los Angeles, CA USA.
   [Ding, Li] Univ Southern Calif, Dept Prevent Med, Los Angeles, CA USA.
   [Tang, Austin M.; Jarvis, Casey A.; Yuan, Edith] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA.
RP Tang, AM (reprint author), Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA.
EM austint@usc.edu
OI Jarvis, Casey/0000-0001-9598-6615
FU National Institutes of Health Southern Clinical and Translational
   Science Institute KL2 Research Scholar AwardUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [5KL2TR001854-03]
FX W. J. Mack reports the following: consultant to Rebound Therapeutics,
   Viseon TSP, Medtronic, Penumbra, and Stream Biomedical; and investor
   with Cerebrotech, Endostream, Viseon, and Rebound. This work was
   supported by the National Institutes of Health Southern Clinical and
   Translational Science Institute KL2 Research Scholar Award to F. J.
   Attenello (grant number 5KL2TR001854-03).
CR Alaraj A, 2017, J CLIN NEUROSCI, V42, P66, DOI 10.1016/j.jocn.2017.03.049
   Anderson SW, 2006, ANN NEUROL, V60, P518, DOI 10.1002/ana.21018
   Averill R, 2012, ALL PATIENT REFINED
   Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395
   Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689
   Bulyez S, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2016-015280corr1
   Burke RE, 2018, MED CARE, V56, P85, DOI 10.1097/MLR.0000000000000829
   Cabana MD, 2004, J FAM PRACTICE, V53, P974
   Chappidi MR, 2017, J UROLOGY, V197, P296, DOI 10.1016/j.juro.2016.08.082
   Chappidi MR, 2017, J UROLOGY, V197, P235, DOI 10.1016/j.juro.2016.07.078
   Chen CC, 2016, AM J MANAG CARE, V22, P136
   Chen CC, 2013, MED CARE, V51, P231, DOI 10.1097/MLR.0b013e31827da5b9
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   DOLINSKAS CA, 1977, AM J ROENTGENOL, V129, P681, DOI 10.2214/ajr.129.4.681
   Glebova NO, 2014, J VASC SURG, V60, P1429, DOI 10.1016/j.jvs.2014.08.092
   Greenberg JK, 2016, J NEUROSURG, V124, P743, DOI 10.3171/2015.2.JNS142771
   HASAN D, 1990, ANN NEUROL, V27, P106, DOI 10.1002/ana.410270118
   Hillis AE, 2000, J NEUROL NEUROSUR PS, V69, P608, DOI 10.1136/jnnp.69.5.608
   Hoffman H, 2018, WORLD NEUROSURG, V110, pE621, DOI 10.1016/j.wneu.2017.11.058
   Johnson EK, 2013, J UROLOGY, V190, P17, DOI 10.1016/j.juro.2013.04.048
   Kelley KA, 2018, J SURG RES, V227, P220, DOI 10.1016/j.jss.2018.02.022
   Lammers EJ, 2014, MED CARE, V52, P227, DOI 10.1097/MLR.0000000000000067
   Liang JW, 2018, NEUROCRIT CARE, V29, P336, DOI 10.1007/s12028-018-0557-1
   Lichtman JH, 2011, STROKE, V42, P3387, DOI 10.1161/STROKEAHA.111.622613
   Mascia L, 2009, F1000 MED REP, V1, P33
   McClelland S, 2016, J RADIOSURGERY SBRT, V4, P177
   McClelland S, 2011, ARCH NEUROL-CHICAGO, V68, P725, DOI 10.1001/archneurol.2011.7
   Nina P, 2001, SURG NEUROL, V55, P197, DOI 10.1016/S0090-3019(01)00402-5
   Nuno M, 2012, NEUROCRIT CARE, V17, P312, DOI 10.1007/s12028-012-9740-y
   Parikh NS, 2018, STROKE, V49, P370, DOI 10.1161/STROKEAHA.117.018166
   Patel MS, 2018, ANN VASC SURG, V50, P186, DOI 10.1016/j.avsg.2017.12.012
   Peltonen S, 1997, J NEUROSURG, V87, P207, DOI 10.3171/jns.1997.87.2.0207
   Rournie CL, 2008, PHARMACOEPIDEM DR S, V17, P20, DOI 10.1002/pds.1518
   Rumalla K, 2018, WORLD NEUROSURG, V110, pE100, DOI 10.1016/j.wneu.2017.10.089
   Smith AB, 2018, UROL ONCOL-SEMIN ORI, V36, DOI 10.1016/j.urolonc.2018.03.005
   Southern DA, 2010, CAN J PUBLIC HEALTH, V101, P61, DOI 10.1007/BF03405564
   Tirschwell DL, 2002, STROKE, V33, P2465, DOI 10.1161/01.STR.0000032240.28636.BD
   von Elm E, 2007, EPIDEMIOLOGY, V18, P800, DOI 10.1097/EDE.0b013e3181577654
   Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35
   Weber SM, 2014, SURGERY, V156, P1066, DOI 10.1016/j.surg.2014.05.024
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Zacharia BE, 2010, NEUROSURG CLIN N AM, V21, P221, DOI 10.1016/j.nec.2009.10.002
   Zafar SN, 2018, JAMA SURG, V11, pE2
   Zheng CY, 2016, J AM COLL SURGEONS, V222, P780, DOI 10.1016/j.jamcollsurg.2016.01.052
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E753
EP E759
DI 10.1016/j.wneu.2019.06.214
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200096
PM 31284063
DA 2020-05-12
ER

PT J
AU Tang, HX
   Zhu, DL
   Zhang, GZ
   Luo, XL
   Xie, W
AF Tang, HengXin
   Zhu, Delong
   Zhang, Guozhi
   Luo, Xiaoli
   Xie, Wei
TI AFAP1-AS1 Promotes Proliferation of Pituitary Adenoma Cells through
   miR-103a-3p to Activate PI3K/AKT Signaling Pathway
SO WORLD NEUROSURGERY
LA English
DT Article
DE AFAP1-AS1; AKT; miR-103a-3p; Pituitary adenoma; PI3K
ID GROWTH; CANCER; MANAGEMENT; INHIBITOR; CARCINOMA; INVASION
AB BACKGROUND: We previously found that AFAP1-AS1 regulates the cell growth of pituitary tumor cells; however, the mechanism still remains unclear. Here, we investigated whether AFAP1-AS1 acts as a competing endogenous RNA of miR-103a-3p to regulate pituitary adenoma growth via the PI3K/AKT pathway.
   METHODS: The bind between AFAP1-AS1 and rno-miR-103a-3p was measured by luciferase reporter assay, and rno-miR-103a-3p expression was measured by quantitative reverse transcription polymerase chain reaction. Proliferation, cell cycle, and apoptosis were measured by cell counting kit 8 and flow cytometry. Rat growth hormone (GH) and prolactin (PRL) levels in culture supernatant of GH3 and MMQ cells were measured by enzyme-linked immunosorbent assay.
   RESULTS: AFAP1-AS1 binds to rno-miR-103a-3p in rat pituitary adenoma cells. Additionally, rno-miR-103a-3p overexpression suppressed rat pituitary adenoma cell proliferation, induced cell apoptosis, arrested cell cycle in the G/S phase, reduced GH and PLR secretion, and inhibited the PI3K/AKT signaling pathway. Activated PI3K/AKT signaling pathway revised the effect of rno-miR-103a-3p overexpression on proliferation and GH and PLR secretion. Coexpression of both si-AFAP1-AS1 and rno-miR-103a-3p inhibitor promoted cell proliferation and cell cycle progression, reduced cell apoptosis, enhanced GH and PLR secretion, and activated the PI3K/AKT signaling pathway in rat pituitary adenoma cells.
   CONCLUSION: We found that AFAP1-AS1 and miR-103a-3p could be a potential therapeutic target for pituitary adenoma.
C1 [Tang, HengXin; Zhu, Delong; Zhang, Guozhi; Luo, Xiaoli; Xie, Wei] South China Univ Technol, Dept Neurosurg, Sch Med, Guangzhou Peoples Hosp 1, Guangzhou, Guangdong, Peoples R China.
RP Tang, HX (reprint author), South China Univ Technol, Dept Neurosurg, Sch Med, Guangzhou Peoples Hosp 1, Guangzhou, Guangdong, Peoples R China.
EM thx201978@126.com
CR Brachmann SM, 2012, MOL CANCER THER, V11, P1747, DOI 10.1158/1535-7163.MCT-11-1021
   Chen B, 2018, CELL CYCLE, V17, P1949, DOI 10.1080/15384101.2018.1496741
   Cheng SQ, 2016, J HUAZHONG U SCI-MED, V36, P558, DOI 10.1007/s11596-016-1625-4
   De Santis MC, 2019, BBA-REV CANCER, V1871, P361, DOI 10.1016/j.bbcan.2019.03.003
   Di Pasquale C, 2018, ENDOCRINE, V60, P308, DOI 10.1007/s12020-017-1432-0
   Day PF, 2016, ARCH ENDOCRIN METAB, V60, P554, DOI 10.1590/2359-3997000000195
   Feng YJ, 2018, HORM METAB RES, V50, P179, DOI 10.1055/s-0043-123763
   Hashemzadeh Kamelia, 2019, Middle East J Dig Dis, V11, P5, DOI 10.15171/mejdd.2018.122
   He QR, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-0990-1
   Hu XY, 2018, MOL CELLS, V41, P390, DOI 10.14348/molcells.2018.2078
   Inoshita N, 2018, BRAIN TUMOR PATHOL, V35, P51, DOI 10.1007/s10014-018-0314-3
   Kalinin P L, 2017, Zh Vopr Neirokhir Im N N Burdenko, V81, P95, DOI 10.17116/neiro201780795-107
   Lian Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0918-9
   Lu X, 2017, CELL PHYSIOL BIOCHEM, V42, P222, DOI 10.1159/000477319
   Luo HL, 2016, CANCER MED-US, V5, P2879, DOI 10.1002/cam4.848
   Markham A, 2017, DRUGS, V77, P1247, DOI 10.1007/s40265-017-0771-8
   Mehta GU, 2017, NEURO-ONCOLOGY, V19, P762, DOI 10.1093/neuonc/now130
   Mello-Grand M, 2019, CARCINOGENESIS, V40, P246, DOI 10.1093/carcin/bgy167
   Rosignolo F, 2017, J ENDOCR SOC, V1, P3, DOI 10.1210/js.2016-1032
   Tampourlou M, 2017, J CLIN ENDOCR METAB, V102, P1889, DOI 10.1210/jc.2016-4061
   Tang HX, 2018, INT J CLIN EXP PATHO, V11, P1238
   Weber DG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114483
   Yang C, 2016, ONCOTARGET, V7, P13479, DOI 10.18632/oncotarget.7266
   Yang QS, 2015, CLIN CANCER RES, V21, P1537, DOI 10.1158/1078-0432.CCR-14-2034
   Yu MJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0677-9
   Yuan ZN, 2018, J CELL MOL MED, V22, P4253, DOI 10.1111/jcmm.13707
   Zhan XQ, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00054
   Zhang H, 2019, GENE, V687, P246, DOI 10.1016/j.gene.2018.11.055
   Zhang Y, 2015, TUMOR BIOL, V36, P2277, DOI 10.1007/s13277-014-2835-7
   Zheng ZM, 2017, MED SCI MONITOR, V23, P1277, DOI 10.12659/MSM.900092
   Zhong ZY, 2016, SCI REP-UK, V6, DOI 10.1038/srep30919
NR 31
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E888
EP E898
DI 10.1016/j.wneu.2019.07.032
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200112
PM 31299308
DA 2020-05-12
ER

EF